Gene	O
expression	O
studies	O
in	O
isolated	O
mitochondria	O
:	O
Solanum	B-Species
tuberosum	I-Species
rps10	O
is	O
recognized	O
by	O
cognate	O
potato	B-Species
but	O
not	O
by	O
the	O
transcription	O
,	O
splicing	O
and	O
editing	O
machinery	O
of	O
wheat	B-Species
mitochondria	O

Abstract	O
<EOS>	B-X
Abstract	B-X
writing	B-X
.	B-X
The	B-X
informative	B-X
abstract	B-X
.	B-X
Crafting	B-X
a	B-X
compelling	B-X
abstract	B-X
.	B-X
Why	B-X
the	B-X
structured	B-X
abstract	B-X
?	B-X

The	O
complex	O
gene	O
expression	O
mechanisms	O
that	O
occur	O
in	O
plant	O
mitochondria	O
,	O
such	O
as	O
RNA	O
editing	O
and	O
splicing	O
,	O
are	O
not	O
yet	O
well	O
understood	O
.	O
<EOS>	B-X
Higher	B-X
plant	B-X
mitochondria	B-X
contain	B-X
a	B-X
genetic	B-X
system	B-X
with	B-X
a	B-X
genome	B-X
,	B-X
transcription	B-X
and	B-X
translation	B-X
processes	B-X
,	B-X
which	B-X
have	B-X
to	B-X
be	B-X
logistically	B-X
integrated	B-X
with	B-X
the	B-X
two	B-X
other	B-X
genomes	B-X
in	B-X
the	B-X
nucleus	B-X
and	B-X
the	B-X
plastid	B-X
.	B-X
In	B-X
plant	B-X
mitochondria	B-X
,	B-X
after	B-X
transcripts	B-X
have	B-X
been	B-X
synthesised	B-X
,	B-X
at	B-X
least	B-X
in	B-X
some	B-X
cases	B-X
by	B-X
a	B-X
phage-type	B-X
RNA	B-X
polymerase	B-X
,	B-X
they	B-X
have	B-X
to	B-X
go	B-X
through	B-X
a	B-X
complex	B-X
processing	B-X
apparatus	B-X
,	B-X
which	B-X
depends	B-X
on	B-X
protein	B-X
factors	B-X
imported	B-X
from	B-X
the	B-X
cytosol	B-X
.	B-X
Processing	B-X
involves	B-X
cis-	B-X
and	B-X
trans-splicing	B-X
,	B-X
internal	B-X
RNA	B-X
editing	B-X
and	B-X
maturation	B-X
at	B-X
the	B-X
transcript	B-X
termini	B-X
,	B-X
these	B-X
steps	B-X
often	B-X
occurring	B-X
in	B-X
parallel	B-X
.	B-X
Transcript	B-X
life	B-X
is	B-X
terminated	B-X
by	B-X
RNA	B-X
degradation	B-X
mechanisms	B-X
,	B-X
one	B-X
of	B-X
which	B-X
involves	B-X
polyadenylation	B-X
.	B-X
RNA	B-X
metabolism	B-X
seems	B-X
to	B-X
be	B-X
a	B-X
key	B-X
element	B-X
of	B-X
the	B-X
regulation	B-X
of	B-X
gene	B-X
expression	B-X
in	B-X
higher	B-X
plant	B-X
mitochondria	B-X
.	B-X

RNA	O
editing	O
in	O
higher	O
plant	O
mitochondria	O
is	O
a	O
highly	O
specific	O
process	O
which	O
modifies	O
mRNA	O
sequences	O
by	O
C	O
-	O
to	O
-	O
U	O
conversions	O
.	O

It	O
has	O
been	O
suggested	O
that	O
in	O
some	O
cases	O
this	O
process	O
is	O
required	O
for	O
splicing	O
.	O
<EOS>	B-X
Hereditary	B-X
PCC	B-X
accounts	B-X
for	B-X
~35	B-X
%	B-X
of	B-X
cases	B-X
and	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
germline	B-X
mutations	B-X
in	B-X
several	B-X
cancer	B-X
susceptibility	B-X
genes	B-X
(	B-X
e.g.	B-X
,	B-X
KIF1B	B-X
,	B-X
SDHB	B-X
,	B-X
VHL	B-X
,	B-X
SDHD	B-X
,	B-X
RET	B-X
)	B-X
.	B-X
We	B-X
performed	B-X
whole-exome	B-X
sequencing	B-X
in	B-X
a	B-X
family	B-X
with	B-X
four	B-X
PCC-affected	B-X
patients	B-X
in	B-X
two	B-X
consecutive	B-X
generations	B-X
and	B-X
identified	B-X
a	B-X
potential	B-X
novel	B-X
candidate	B-X
pathogenic	B-X
variant	B-X
in	B-X
the	B-X
REXO2	B-X
gene	B-X
that	B-X
affects	B-X
splicing	B-X
(	B-X
c.531-1G	B-X
>	B-X
T	B-X
(	B-X
NM	B-X
015523.3	B-X
)	B-X
)	B-X
,	B-X
which	B-X
co-segregated	B-X
with	B-X
the	B-X
phenotype	B-X
in	B-X
the	B-X
family	B-X
.	B-X
REXO2	B-X
protein	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
DNA	B-X
repair	B-X
,	B-X
replication	B-X
and	B-X
recombination	B-X
processes	B-X
and	B-X
thus	B-X
its	B-X
inactivation	B-X
may	B-X
contribute	B-X
to	B-X
tumorigenesis	B-X
.	B-X
While	B-X
the	B-X
study	B-X
suggests	B-X
that	B-X
this	B-X
novel	B-X
REXO2	B-X
gene	B-X
variant	B-X
underlies	B-X
PCC	B-X
in	B-X
this	B-X
family	B-X
,	B-X
additional	B-X
functional	B-X
studies	B-X
are	B-X
required	B-X
in	B-X
order	B-X
to	B-X
establish	B-X
the	B-X
putative	B-X
role	B-X
of	B-X
the	B-X
REXO2	B-X
gene	B-X
in	B-X
PCC	B-X
predisposition	B-X
.	B-X

Here	O
,	O
we	O
use	O
an	O
experimental	O
model	O
based	O
on	O
the	O
introduction	O
of	O
DNA	O
into	O
isolated	O
mitochondria	O
by	O
electroporation	O
to	O
study	O
organellar	O
gene	O
expression	O
events	O
.	O
<EOS>	B-X
The	B-X
complex	B-X
gene	B-X
expression	B-X
mechanisms	B-X
that	B-X
occur	B-X
in	B-X
plant	B-X
mitochondria	B-X
,	B-X
such	B-X
as	B-X
RNA	B-X
editing	B-X
and	B-X
splicing	B-X
,	B-X
are	B-X
not	B-X
yet	B-X
well	B-X
understood	B-X
.	B-X
RNA	B-X
editing	B-X
in	B-X
higher	B-X
plant	B-X
mitochondria	B-X
is	B-X
a	B-X
highly	B-X
specific	B-X
process	B-X
which	B-X
modifies	B-X
mRNA	B-X
sequences	B-X
by	B-X
C-to-U	B-X
conversions	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
use	B-X
an	B-X
experimental	B-X
model	B-X
based	B-X
on	B-X
the	B-X
introduction	B-X
of	B-X
DNA	B-X
into	B-X
isolated	B-X
mitochondria	B-X
by	B-X
electroporation	B-X
to	B-X
study	B-X
organellar	B-X
gene	B-X
expression	B-X
events	B-X
.	B-X
Our	B-X
aim	B-X
was	B-X
to	B-X
compare	B-X
processing	B-X
and	B-X
editing	B-X
of	B-X
potato	B-X
small	B-X
ribosomal	B-X
protein	B-X
10	B-X
gene	B-X
(	B-X
rps10	B-X
)	B-X
transcripts	B-X
in	B-X
heterologous	B-X
(	B-X
wheat	B-X
mitochondria	B-X
)	B-X
and	B-X
homologous	B-X
(	B-X
potato	B-X
mitochondria	B-X
)	B-X
contexts	B-X
.	B-X
rps10	B-X
is	B-X
a	B-X
suitable	B-X
model	B-X
because	B-X
it	B-X
contains	B-X
a	B-X
group	B-X
II	B-X
intron	B-X
,	B-X
is	B-X
absent	B-X
in	B-X
wheat	B-X
mitochondria	B-X
but	B-X
is	B-X
actively	B-X
expressed	B-X
in	B-X
potato	B-X
mitochondria	B-X
,	B-X
where	B-X
transcripts	B-X
are	B-X
spliced	B-X
and	B-X
undergo	B-X
five	B-X
C-to-U	B-X
editing	B-X
events	B-X
.	B-X
For	B-X
this	B-X
purpose	B-X
,	B-X
conditions	B-X
for	B-X
electroporating	B-X
isolated	B-X
potato	B-X
mitochondria	B-X
were	B-X
established	B-X
.	B-X
In	B-X
wheat	B-X
mitochondria	B-X
,	B-X
rps10	B-X
transcripts	B-X
were	B-X
neither	B-X
spliced	B-X
nor	B-X
edited	B-X
while	B-X
they	B-X
are	B-X
correctly	B-X
processed	B-X
in	B-X
potato	B-X
mitochondria	B-X
.	B-X
Interestingly	B-X
,	B-X
a	B-X
wheat	B-X
editing	B-X
site	B-X
grafted	B-X
into	B-X
rps10	B-X
was	B-X
not	B-X
recognized	B-X
by	B-X
wheat	B-X
mitochondria	B-X
but	B-X
was	B-X
correctly	B-X
edited	B-X
in	B-X
potato	B-X
mitochondria	B-X
.	B-X

Our	O
aim	O
was	O
to	O
compare	O
processing	O
and	O
editing	O
of	O
potato	B-Species
small	O
ribosomal	O
protein	O
10	O
gene	O
(	O
rps10	O
)	O
transcripts	O
in	O
heterologous	O
(	O
wheat	B-Species
mitochondria	O
)	O
and	O
homologous	O
(	O
potato	B-Species
mitochondria	O
)	O
contexts	O
.	O
<EOS>	B-X
The	B-X
complex	B-X
gene	B-X
expression	B-X
mechanisms	B-X
that	B-X
occur	B-X
in	B-X
plant	B-X
mitochondria	B-X
,	B-X
such	B-X
as	B-X
RNA	B-X
editing	B-X
and	B-X
splicing	B-X
,	B-X
are	B-X
not	B-X
yet	B-X
well	B-X
understood	B-X
.	B-X
RNA	B-X
editing	B-X
in	B-X
higher	B-X
plant	B-X
mitochondria	B-X
is	B-X
a	B-X
highly	B-X
specific	B-X
process	B-X
which	B-X
modifies	B-X
mRNA	B-X
sequences	B-X
by	B-X
C-to-U	B-X
conversions	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
use	B-X
an	B-X
experimental	B-X
model	B-X
based	B-X
on	B-X
the	B-X
introduction	B-X
of	B-X
DNA	B-X
into	B-X
isolated	B-X
mitochondria	B-X
by	B-X
electroporation	B-X
to	B-X
study	B-X
organellar	B-X
gene	B-X
expression	B-X
events	B-X
.	B-X
Our	B-X
aim	B-X
was	B-X
to	B-X
compare	B-X
processing	B-X
and	B-X
editing	B-X
of	B-X
potato	B-X
small	B-X
ribosomal	B-X
protein	B-X
10	B-X
gene	B-X
(	B-X
rps10	B-X
)	B-X
transcripts	B-X
in	B-X
heterologous	B-X
(	B-X
wheat	B-X
mitochondria	B-X
)	B-X
and	B-X
homologous	B-X
(	B-X
potato	B-X
mitochondria	B-X
)	B-X
contexts	B-X
.	B-X
rps10	B-X
is	B-X
a	B-X
suitable	B-X
model	B-X
because	B-X
it	B-X
contains	B-X
a	B-X
group	B-X
II	B-X
intron	B-X
,	B-X
is	B-X
absent	B-X
in	B-X
wheat	B-X
mitochondria	B-X
but	B-X
is	B-X
actively	B-X
expressed	B-X
in	B-X
potato	B-X
mitochondria	B-X
,	B-X
where	B-X
transcripts	B-X
are	B-X
spliced	B-X
and	B-X
undergo	B-X
five	B-X
C-to-U	B-X
editing	B-X
events	B-X
.	B-X
For	B-X
this	B-X
purpose	B-X
,	B-X
conditions	B-X
for	B-X
electroporating	B-X
isolated	B-X
potato	B-X
mitochondria	B-X
were	B-X
established	B-X
.	B-X
rps10	B-X
was	B-X
placed	B-X
under	B-X
the	B-X
control	B-X
of	B-X
either	B-X
potato	B-X
or	B-X
wheat	B-X
cox2	B-X
promoters	B-X
.	B-X
We	B-X
found	B-X
that	B-X
rps10	B-X
was	B-X
only	B-X
transcribed	B-X
under	B-X
the	B-X
control	B-X
of	B-X
a	B-X
cognate	B-X
promoter	B-X
.	B-X
In	B-X
wheat	B-X
mitochondria	B-X
,	B-X
rps10	B-X
transcripts	B-X
were	B-X
neither	B-X
spliced	B-X
nor	B-X
edited	B-X
while	B-X
they	B-X
are	B-X
correctly	B-X
processed	B-X
in	B-X
potato	B-X
mitochondria	B-X
.	B-X
Interestingly	B-X
,	B-X
a	B-X
wheat	B-X
editing	B-X
site	B-X
grafted	B-X
into	B-X
rps10	B-X
was	B-X
not	B-X
recognized	B-X
by	B-X
wheat	B-X
mitochondria	B-X
but	B-X
was	B-X
correctly	B-X
edited	B-X
in	B-X
potato	B-X
mitochondria	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
editing	B-X
might	B-X
occur	B-X
only	B-X
when	B-X
the	B-X
transcripts	B-X
are	B-X
engaged	B-X
in	B-X
processing	B-X
and	B-X
that	B-X
they	B-X
would	B-X
not	B-X
be	B-X
available	B-X
to	B-X
editing	B-X
factors	B-X
outside	B-X
of	B-X
a	B-X
putative	B-X
RNA	B-X
maturation	B-X
machinery	B-X
complex	B-X
.	B-X

rps10	O
is	O
a	O
suitable	O
model	O
because	O
it	O
contains	O
a	O
group	O
II	O
intron	O
,	O
is	O
absent	O
in	O
wheat	B-Species
mitochondria	O
but	O
is	O
actively	O
expressed	O
in	O
potato	B-Species
mitochondria	O
,	O
where	O
transcripts	O
are	O
spliced	O
and	O
undergo	O
five	O
C	O
-	O
to	O
-	O
U	O
editing	O
events	O
.	O

For	O
this	O
purpose	O
,	O
conditions	O
for	O
electroporating	O
isolated	O
potato	B-Species
mitochondria	O
were	O
established	O
.	O
<EOS>	B-X
The	B-X
complex	B-X
gene	B-X
expression	B-X
mechanisms	B-X
that	B-X
occur	B-X
in	B-X
plant	B-X
mitochondria	B-X
,	B-X
such	B-X
as	B-X
RNA	B-X
editing	B-X
and	B-X
splicing	B-X
,	B-X
are	B-X
not	B-X
yet	B-X
well	B-X
understood	B-X
.	B-X
RNA	B-X
editing	B-X
in	B-X
higher	B-X
plant	B-X
mitochondria	B-X
is	B-X
a	B-X
highly	B-X
specific	B-X
process	B-X
which	B-X
modifies	B-X
mRNA	B-X
sequences	B-X
by	B-X
C-to-U	B-X
conversions	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
use	B-X
an	B-X
experimental	B-X
model	B-X
based	B-X
on	B-X
the	B-X
introduction	B-X
of	B-X
DNA	B-X
into	B-X
isolated	B-X
mitochondria	B-X
by	B-X
electroporation	B-X
to	B-X
study	B-X
organellar	B-X
gene	B-X
expression	B-X
events	B-X
.	B-X
Our	B-X
aim	B-X
was	B-X
to	B-X
compare	B-X
processing	B-X
and	B-X
editing	B-X
of	B-X
potato	B-X
small	B-X
ribosomal	B-X
protein	B-X
10	B-X
gene	B-X
(	B-X
rps10	B-X
)	B-X
transcripts	B-X
in	B-X
heterologous	B-X
(	B-X
wheat	B-X
mitochondria	B-X
)	B-X
and	B-X
homologous	B-X
(	B-X
potato	B-X
mitochondria	B-X
)	B-X
contexts	B-X
.	B-X
rps10	B-X
is	B-X
a	B-X
suitable	B-X
model	B-X
because	B-X
it	B-X
contains	B-X
a	B-X
group	B-X
II	B-X
intron	B-X
,	B-X
is	B-X
absent	B-X
in	B-X
wheat	B-X
mitochondria	B-X
but	B-X
is	B-X
actively	B-X
expressed	B-X
in	B-X
potato	B-X
mitochondria	B-X
,	B-X
where	B-X
transcripts	B-X
are	B-X
spliced	B-X
and	B-X
undergo	B-X
five	B-X
C-to-U	B-X
editing	B-X
events	B-X
.	B-X
For	B-X
this	B-X
purpose	B-X
,	B-X
conditions	B-X
for	B-X
electroporating	B-X
isolated	B-X
potato	B-X
mitochondria	B-X
were	B-X
established	B-X
.	B-X
rps10	B-X
was	B-X
placed	B-X
under	B-X
the	B-X
control	B-X
of	B-X
either	B-X
potato	B-X
or	B-X
wheat	B-X
cox2	B-X
promoters	B-X
.	B-X
In	B-X
wheat	B-X
mitochondria	B-X
,	B-X
rps10	B-X
transcripts	B-X
were	B-X
neither	B-X
spliced	B-X
nor	B-X
edited	B-X
while	B-X
they	B-X
are	B-X
correctly	B-X
processed	B-X
in	B-X
potato	B-X
mitochondria	B-X
.	B-X
Interestingly	B-X
,	B-X
a	B-X
wheat	B-X
editing	B-X
site	B-X
grafted	B-X
into	B-X
rps10	B-X
was	B-X
not	B-X
recognized	B-X
by	B-X
wheat	B-X
mitochondria	B-X
but	B-X
was	B-X
correctly	B-X
edited	B-X
in	B-X
potato	B-X
mitochondria	B-X
.	B-X

rps10	O
was	O
placed	O
under	O
the	O
control	O
of	O
either	O
potato	B-Species
or	O
wheat	B-Species
cox2	O
promoters	O
.	O
<EOS>	B-X
Our	B-X
aim	B-X
was	B-X
to	B-X
compare	B-X
processing	B-X
and	B-X
editing	B-X
of	B-X
potato	B-X
small	B-X
ribosomal	B-X
protein	B-X
10	B-X
gene	B-X
(	B-X
rps10	B-X
)	B-X
transcripts	B-X
in	B-X
heterologous	B-X
(	B-X
wheat	B-X
mitochondria	B-X
)	B-X
and	B-X
homologous	B-X
(	B-X
potato	B-X
mitochondria	B-X
)	B-X
contexts	B-X
.	B-X
rps10	B-X
is	B-X
a	B-X
suitable	B-X
model	B-X
because	B-X
it	B-X
contains	B-X
a	B-X
group	B-X
II	B-X
intron	B-X
,	B-X
is	B-X
absent	B-X
in	B-X
wheat	B-X
mitochondria	B-X
but	B-X
is	B-X
actively	B-X
expressed	B-X
in	B-X
potato	B-X
mitochondria	B-X
,	B-X
where	B-X
transcripts	B-X
are	B-X
spliced	B-X
and	B-X
undergo	B-X
five	B-X
C-to-U	B-X
editing	B-X
events	B-X
.	B-X
For	B-X
this	B-X
purpose	B-X
,	B-X
conditions	B-X
for	B-X
electroporating	B-X
isolated	B-X
potato	B-X
mitochondria	B-X
were	B-X
established	B-X
.	B-X
rps10	B-X
was	B-X
placed	B-X
under	B-X
the	B-X
control	B-X
of	B-X
either	B-X
potato	B-X
or	B-X
wheat	B-X
cox2	B-X
promoters	B-X
.	B-X
We	B-X
found	B-X
that	B-X
rps10	B-X
was	B-X
only	B-X
transcribed	B-X
under	B-X
the	B-X
control	B-X
of	B-X
a	B-X
cognate	B-X
promoter	B-X
.	B-X
In	B-X
wheat	B-X
mitochondria	B-X
,	B-X
rps10	B-X
transcripts	B-X
were	B-X
neither	B-X
spliced	B-X
nor	B-X
edited	B-X
while	B-X
they	B-X
are	B-X
correctly	B-X
processed	B-X
in	B-X
potato	B-X
mitochondria	B-X
.	B-X
Interestingly	B-X
,	B-X
a	B-X
wheat	B-X
editing	B-X
site	B-X
grafted	B-X
into	B-X
rps10	B-X
was	B-X
not	B-X
recognized	B-X
by	B-X
wheat	B-X
mitochondria	B-X
but	B-X
was	B-X
correctly	B-X
edited	B-X
in	B-X
potato	B-X
mitochondria	B-X
.	B-X

We	O
found	O
that	O
rps10	O
was	O
only	O
transcribed	O
under	O
the	O
control	O
of	O
a	O
cognate	O
promoter	O
.	O
<EOS>	B-X
Our	B-X
aim	B-X
was	B-X
to	B-X
compare	B-X
processing	B-X
and	B-X
editing	B-X
of	B-X
potato	B-X
small	B-X
ribosomal	B-X
protein	B-X
10	B-X
gene	B-X
(	B-X
rps10	B-X
)	B-X
transcripts	B-X
in	B-X
heterologous	B-X
(	B-X
wheat	B-X
mitochondria	B-X
)	B-X
and	B-X
homologous	B-X
(	B-X
potato	B-X
mitochondria	B-X
)	B-X
contexts	B-X
.	B-X
rps10	B-X
is	B-X
a	B-X
suitable	B-X
model	B-X
because	B-X
it	B-X
contains	B-X
a	B-X
group	B-X
II	B-X
intron	B-X
,	B-X
is	B-X
absent	B-X
in	B-X
wheat	B-X
mitochondria	B-X
but	B-X
is	B-X
actively	B-X
expressed	B-X
in	B-X
potato	B-X
mitochondria	B-X
,	B-X
where	B-X
transcripts	B-X
are	B-X
spliced	B-X
and	B-X
undergo	B-X
five	B-X
C-to-U	B-X
editing	B-X
events	B-X
.	B-X
rps10	B-X
was	B-X
placed	B-X
under	B-X
the	B-X
control	B-X
of	B-X
either	B-X
potato	B-X
or	B-X
wheat	B-X
cox2	B-X
promoters	B-X
.	B-X
We	B-X
found	B-X
that	B-X
rps10	B-X
was	B-X
only	B-X
transcribed	B-X
under	B-X
the	B-X
control	B-X
of	B-X
a	B-X
cognate	B-X
promoter	B-X
.	B-X
In	B-X
wheat	B-X
mitochondria	B-X
,	B-X
rps10	B-X
transcripts	B-X
were	B-X
neither	B-X
spliced	B-X
nor	B-X
edited	B-X
while	B-X
they	B-X
are	B-X
correctly	B-X
processed	B-X
in	B-X
potato	B-X
mitochondria	B-X
.	B-X
Interestingly	B-X
,	B-X
a	B-X
wheat	B-X
editing	B-X
site	B-X
grafted	B-X
into	B-X
rps10	B-X
was	B-X
not	B-X
recognized	B-X
by	B-X
wheat	B-X
mitochondria	B-X
but	B-X
was	B-X
correctly	B-X
edited	B-X
in	B-X
potato	B-X
mitochondria	B-X
.	B-X

In	O
wheat	B-Species
mitochondria	O
,	O
rps10	O
transcripts	O
were	O
neither	O
spliced	O
nor	O
edited	O
while	O
they	O
are	O
correctly	O
processed	O
in	O
potato	B-Species
mitochondria	O
.	O
<EOS>	B-X
The	B-X
complex	B-X
gene	B-X
expression	B-X
mechanisms	B-X
that	B-X
occur	B-X
in	B-X
plant	B-X
mitochondria	B-X
,	B-X
such	B-X
as	B-X
RNA	B-X
editing	B-X
and	B-X
splicing	B-X
,	B-X
are	B-X
not	B-X
yet	B-X
well	B-X
understood	B-X
.	B-X
RNA	B-X
editing	B-X
in	B-X
higher	B-X
plant	B-X
mitochondria	B-X
is	B-X
a	B-X
highly	B-X
specific	B-X
process	B-X
which	B-X
modifies	B-X
mRNA	B-X
sequences	B-X
by	B-X
C-to-U	B-X
conversions	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
use	B-X
an	B-X
experimental	B-X
model	B-X
based	B-X
on	B-X
the	B-X
introduction	B-X
of	B-X
DNA	B-X
into	B-X
isolated	B-X
mitochondria	B-X
by	B-X
electroporation	B-X
to	B-X
study	B-X
organellar	B-X
gene	B-X
expression	B-X
events	B-X
.	B-X
Our	B-X
aim	B-X
was	B-X
to	B-X
compare	B-X
processing	B-X
and	B-X
editing	B-X
of	B-X
potato	B-X
small	B-X
ribosomal	B-X
protein	B-X
10	B-X
gene	B-X
(	B-X
rps10	B-X
)	B-X
transcripts	B-X
in	B-X
heterologous	B-X
(	B-X
wheat	B-X
mitochondria	B-X
)	B-X
and	B-X
homologous	B-X
(	B-X
potato	B-X
mitochondria	B-X
)	B-X
contexts	B-X
.	B-X
rps10	B-X
is	B-X
a	B-X
suitable	B-X
model	B-X
because	B-X
it	B-X
contains	B-X
a	B-X
group	B-X
II	B-X
intron	B-X
,	B-X
is	B-X
absent	B-X
in	B-X
wheat	B-X
mitochondria	B-X
but	B-X
is	B-X
actively	B-X
expressed	B-X
in	B-X
potato	B-X
mitochondria	B-X
,	B-X
where	B-X
transcripts	B-X
are	B-X
spliced	B-X
and	B-X
undergo	B-X
five	B-X
C-to-U	B-X
editing	B-X
events	B-X
.	B-X
For	B-X
this	B-X
purpose	B-X
,	B-X
conditions	B-X
for	B-X
electroporating	B-X
isolated	B-X
potato	B-X
mitochondria	B-X
were	B-X
established	B-X
.	B-X
rps10	B-X
was	B-X
placed	B-X
under	B-X
the	B-X
control	B-X
of	B-X
either	B-X
potato	B-X
or	B-X
wheat	B-X
cox2	B-X
promoters	B-X
.	B-X
We	B-X
found	B-X
that	B-X
rps10	B-X
was	B-X
only	B-X
transcribed	B-X
under	B-X
the	B-X
control	B-X
of	B-X
a	B-X
cognate	B-X
promoter	B-X
.	B-X
In	B-X
wheat	B-X
mitochondria	B-X
,	B-X
rps10	B-X
transcripts	B-X
were	B-X
neither	B-X
spliced	B-X
nor	B-X
edited	B-X
while	B-X
they	B-X
are	B-X
correctly	B-X
processed	B-X
in	B-X
potato	B-X
mitochondria	B-X
.	B-X
Interestingly	B-X
,	B-X
a	B-X
wheat	B-X
editing	B-X
site	B-X
grafted	B-X
into	B-X
rps10	B-X
was	B-X
not	B-X
recognized	B-X
by	B-X
wheat	B-X
mitochondria	B-X
but	B-X
was	B-X
correctly	B-X
edited	B-X
in	B-X
potato	B-X
mitochondria	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
editing	B-X
might	B-X
occur	B-X
only	B-X
when	B-X
the	B-X
transcripts	B-X
are	B-X
engaged	B-X
in	B-X
processing	B-X
and	B-X
that	B-X
they	B-X
would	B-X
not	B-X
be	B-X
available	B-X
to	B-X
editing	B-X
factors	B-X
outside	B-X
of	B-X
a	B-X
putative	B-X
RNA	B-X
maturation	B-X
machinery	B-X
complex	B-X
.	B-X

Interestingly	O
,	O
a	O
wheat	B-Species
editing	O
site	O
grafted	O
into	O
rps10	O
was	O
not	O
recognized	O
by	O
wheat	B-Species
mitochondria	O
but	O
was	O
correctly	O
edited	O
in	O
potato	B-Species
mitochondria	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
editing	O
might	O
occur	O
only	O
when	O
the	O
transcripts	O
are	O
engaged	O
in	O
processing	O
and	O
that	O
they	O
would	O
not	O
be	O
available	O
to	O
editing	O
factors	O
outside	O
of	O
a	O
putative	O
RNA	O
maturation	O
machinery	O
complex	O
.	O

INTRODUCTION	O

Gene	O
expression	O
in	O
plant	O
mitochondria	O
is	O
a	O
complex	O
process	O
involving	O
multiple	O
steps	O
such	O
as	O
transcription	O
,	O
cis	O
-	O
and	O
trans	O
-	O
splicing	O
,	O
RNA	O
trimming	O
and	O
RNA	O
editing	O
on	O
the	O
way	O
to	O
translation	O
(	O
1	O
)	O
.	O

RNA	O
editing	O
has	O
been	O
found	O
in	O
a	O
variety	O
of	O
organisms	O
and	O
occurs	O
through	O
different	O
mechanisms	O
such	O
as	O
insertion	O
or	O
deletion	O
of	O
nucleotides	O
,	O
or	O
base	O
conversions	O
[	O
for	O
details	O
see	O
reference	O
(	O
2	O
)	O
]	O
.	O
<EOS>	B-X
A	B-X
major	B-X
contribution	B-X
to	B-X
the	B-X
genome	B-X
variability	B-X
among	B-X
individuals	B-X
comes	B-X
from	B-X
deletions	B-X
and	B-X
duplications	B-X
-	B-X
collectively	B-X
termed	B-X
copy	B-X
number	B-X
variations	B-X
(	B-X
CNVs	B-X
)	B-X
-	B-X
which	B-X
alter	B-X
the	B-X
diploid	B-X
status	B-X
of	B-X
DNA	B-X
.	B-X
Depending	B-X
on	B-X
the	B-X
level	B-X
of	B-X
stringency	B-X
of	B-X
the	B-X
map	B-X
,	B-X
we	B-X
estimated	B-X
that	B-X
4.8-9.5	B-X
%	B-X
of	B-X
the	B-X
genome	B-X
contributes	B-X
to	B-X
CNV	B-X
and	B-X
found	B-X
approximately	B-X
100	B-X
genes	B-X
that	B-X
can	B-X
be	B-X
completely	B-X
deleted	B-X
without	B-X
producing	B-X
apparent	B-X
phenotypic	B-X
consequences	B-X
.	B-X
An	B-X
important	B-X
recent	B-X
advance	B-X
in	B-X
the	B-X
functional	B-X
analysis	B-X
of	B-X
Saccharomyces	B-X
cerevisiae	B-X
genes	B-X
is	B-X
the	B-X
development	B-X
of	B-X
the	B-X
one-step	B-X
PCR-mediated	B-X
technique	B-X
for	B-X
deletion	B-X
and	B-X
modification	B-X
of	B-X
chromosomal	B-X
genes	B-X
.	B-X
We	B-X
describe	B-X
here	B-X
a	B-X
new	B-X
set	B-X
of	B-X
plasmids	B-X
that	B-X
serve	B-X
as	B-X
templates	B-X
for	B-X
the	B-X
PCR	B-X
synthesis	B-X
of	B-X
fragments	B-X
that	B-X
allow	B-X
a	B-X
variety	B-X
of	B-X
gene	B-X
modifications	B-X
.	B-X
Using	B-X
as	B-X
selectable	B-X
marker	B-X
the	B-X
S.	B-X
cerevisiae	B-X
TRP1	B-X
gene	B-X
or	B-X
modules	B-X
containing	B-X
the	B-X
heterologous	B-X
Schizosaccharomyces	B-X
pombe	B-X
his5+	B-X
or	B-X
Escherichia	B-X
coli	B-X
kan	B-X
(	B-X
r	B-X
)	B-X
gene	B-X
,	B-X
these	B-X
plasmids	B-X
allow	B-X
gene	B-X
deletion	B-X
,	B-X
gene	B-X
overexpression	B-X
(	B-X
using	B-X
the	B-X
regulatable	B-X
GAL1	B-X
promoter	B-X
)	B-X
,	B-X
C-	B-X
or	B-X
N-terminal	B-X
protein	B-X
tagging	B-X
[	B-X
with	B-X
GFP	B-X
(	B-X
S65T	B-X
)	B-X
,	B-X
GST	B-X
,	B-X
or	B-X
the	B-X
3HA	B-X
or	B-X
13Myc	B-X
epitope	B-X
]	B-X
,	B-X
and	B-X
partial	B-X
N-	B-X
or	B-X
C-terminal	B-X
deletions	B-X
(	B-X
with	B-X
or	B-X
without	B-X
concomitant	B-X
protein	B-X
tagging	B-X
)	B-X
.	B-X
Because	B-X
of	B-X
the	B-X
modular	B-X
nature	B-X
of	B-X
the	B-X
plasmids	B-X
,	B-X
they	B-X
allow	B-X
efficient	B-X
and	B-X
economical	B-X
use	B-X
of	B-X
a	B-X
small	B-X
number	B-X
of	B-X
PCR	B-X
primers	B-X
for	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
gene	B-X
manipulations	B-X
.	B-X

In	O
higher	O
plant	O
organelles	O
,	O
RNA	O
editing	O
is	O
an	O
important	O
post	O
-	O
transcriptional	O
event	O
characterized	O
by	O
C	O
-	O
to	O
-	O
U	O
changes	O
via	O
a	O
deamination	O
mechanism	O
(	O
3	O
-	O
5	O
)	O
.	O

In	O
Arabidopsis	B-Species
thaliana	I-Species
456	O
C	O
-	O
to	O
-	O
U	O
editing	O
events	O
have	O
been	O
described	O
(	O
6	O
)	O
.	O

RNA	O
editing	O
occurs	O
mostly	O
in	O
the	O
coding	O
regions	O
which	O
alter	O
the	O
identity	O
of	O
the	O
encoded	O
amino	O
acid	O
,	O
but	O
some	O
editing	O
events	O
occur	O
in	O
highly	O
structured	O
regions	O
of	O
introns	O
(	O
7	O
,	O
8	O
)	O
.	O

Like	O
other	O
maturation	O
processes	O
,	O
RNA	O
editing	O
is	O
an	O
essential	O
post	O
-	O
transcriptional	O
event	O
in	O
plant	O
mitochondrial	O
gene	O
expression	O
(	O
9	O
-	O
11	O
)	O
required	O
for	O
the	O
synthesis	O
of	O
functional	O
proteins	O
(	O
12	O
,	O
13	O
)	O
.	O

The	O
introduction	O
of	O
foreign	O
DNA	O
into	O
isolated	O
mitochondria	O
is	O
a	O
novel	O
experimental	O
model	O
which	O
has	O
provided	O
important	O
information	O
on	O
RNA	O
editing	O
and	O
RNA	O
splicing	O
enabling	O
the	O
use	O
of	O
a	O
site	O
-	O
directed	O
mutagenesis	O
approach	O
(	O
14	O
,	O
15	O
)	O
.	O

Using	O
a	O
cognate	O
cox2	O
chimeric	O
gene	O
construct	O
,	O
the	O
cis	O
-	O
recognition	O
elements	O
required	O
for	O
plant	O
mitochondria	O
RNA	O
editing	O
have	O
been	O
determined	O
(	O
16	O
,	O
17	O
)	O
.	O

Using	O
the	O
same	O
approach	O
,	O
Staudinger	O
and	O
Kempken	O
(	O
18	O
)	O
have	O
reported	O
that	O
transcripts	O
from	O
A	B-Species
.	I-Species
thaliana	I-Species
cox2	O
,	O
but	O
not	O
Sorghum	B-Species
bicolor	I-Species
atp6	O
,	O
are	O
edited	O
when	O
the	O
genes	O
are	O
introduced	O
into	O
maize	B-Species
mitochondria	O
.	O

Interestingly	O
,	O
higher	O
plant	O
mitochondrial	O
genomes	O
differ	O
in	O
their	O
gene	O
contents	O
due	O
to	O
an	O
evolutionary	O
information	O
transfer	O
from	O
the	O
organelle	O
to	O
the	O
nucleus	O
(	O
19	O
)	O
.	O

Of	O
particular	O
interest	O
is	O
the	O
situation	O
of	O
the	O
small	O
ribosomal	O
protein	O
10	O
gene	O
(	O
rps10	O
)	O
,	O
a	O
group	O
II	O
intron	O
-	O
bearing	O
gene	O
which	O
is	O
encoded	O
in	O
Solanum	B-Species
tuberosum	I-Species
mitochondrial	O
DNA	O
but	O
is	O
absent	O
from	O
the	O
wheat	B-Species
mitochondrial	O
genome	O
(	O
20	O
)	O
.	O

Higher	O
plant	O
mitochondria	O
contain	O
group	O
II	O
introns	O
either	O
in	O
cis	O
-	O
or	O
trans	O
-	O
configuration	O
(	O
1	O
)	O
which	O
can	O
be	O
folded	O
in	O
a	O
characteristic	O
secondary	O
structure	O
(	O
21	O
)	O
.	O

Intron	O
removal	O
in	O
plant	O
mitochondrial	O
mRNAs	O
is	O
not	O
well	O
documented	O
because	O
such	O
introns	O
are	O
unable	O
to	O
self	O
-	O
splice	O
.	O
<EOS>	B-X
During	B-X
the	B-X
evolution	B-X
of	B-X
eukaryotic	B-X
genomes	B-X
,	B-X
many	B-X
genes	B-X
have	B-X
been	B-X
interrupted	B-X
by	B-X
intervening	B-X
sequences	B-X
(	B-X
introns	B-X
)	B-X
that	B-X
must	B-X
be	B-X
removed	B-X
post-transcriptionally	B-X
from	B-X
RNA	B-X
precursors	B-X
to	B-X
form	B-X
mRNAs	B-X
ready	B-X
for	B-X
translation	B-X
.	B-X
The	B-X
origin	B-X
of	B-X
nuclear	B-X
introns	B-X
is	B-X
still	B-X
under	B-X
debate	B-X
,	B-X
but	B-X
one	B-X
hypothesis	B-X
is	B-X
that	B-X
the	B-X
spliceosome	B-X
and	B-X
the	B-X
intron-exon	B-X
structure	B-X
of	B-X
genes	B-X
have	B-X
evolved	B-X
from	B-X
bacterial-type	B-X
group	B-X
II	B-X
introns	B-X
that	B-X
invaded	B-X
the	B-X
eukaryotic	B-X
genomes	B-X
.	B-X
The	B-X
group	B-X
II	B-X
introns	B-X
were	B-X
most	B-X
likely	B-X
introduced	B-X
into	B-X
the	B-X
eukaryotic	B-X
genome	B-X
from	B-X
an	B-X
Î±-proteobacterial	B-X
predecessor	B-X
of	B-X
mitochondria	B-X
early	B-X
during	B-X
the	B-X
endosymbiosis	B-X
event	B-X
.	B-X
These	B-X
self-splicing	B-X
and	B-X
mobile	B-X
introns	B-X
spread	B-X
through	B-X
the	B-X
eukaryotic	B-X
genome	B-X
and	B-X
later	B-X
degenerated	B-X
.	B-X
Pieces	B-X
of	B-X
introns	B-X
became	B-X
part	B-X
of	B-X
the	B-X
general	B-X
splicing	B-X
machinery	B-X
we	B-X
know	B-X
today	B-X
as	B-X
the	B-X
spliceosome	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
group	B-X
II	B-X
introns	B-X
likely	B-X
brought	B-X
intron	B-X
maturases	B-X
with	B-X
them	B-X
to	B-X
the	B-X
nucleus	B-X
.	B-X
Maturases	B-X
are	B-X
found	B-X
in	B-X
most	B-X
bacterial	B-X
introns	B-X
,	B-X
where	B-X
they	B-X
act	B-X
as	B-X
highly	B-X
specific	B-X
splicing	B-X
factors	B-X
for	B-X
group	B-X
II	B-X
introns	B-X
.	B-X
In	B-X
the	B-X
spliceosome	B-X
,	B-X
the	B-X
core	B-X
protein	B-X
Prp8	B-X
shows	B-X
homology	B-X
to	B-X
group	B-X
II	B-X
intron-encoded	B-X
maturases	B-X
.	B-X
While	B-X
maturases	B-X
are	B-X
entirely	B-X
intron	B-X
specific	B-X
,	B-X
their	B-X
descendant	B-X
of	B-X
the	B-X
spliceosomal	B-X
machinery	B-X
,	B-X
the	B-X
Prp8	B-X
protein	B-X
,	B-X
is	B-X
an	B-X
extremely	B-X
versatile	B-X
splicing	B-X
factor	B-X
with	B-X
multiple	B-X
interacting	B-X
proteins	B-X
and	B-X
RNAs	B-X
.	B-X
How	B-X
could	B-X
such	B-X
a	B-X
general	B-X
player	B-X
in	B-X
spliceosomal	B-X
splicing	B-X
evolve	B-X
from	B-X
the	B-X
monospecific	B-X
bacterial	B-X
maturases	B-X
?	B-X
Analysis	B-X
of	B-X
the	B-X
organellar	B-X
splicing	B-X
machinery	B-X
in	B-X
plants	B-X
may	B-X
give	B-X
clues	B-X
on	B-X
the	B-X
evolution	B-X
of	B-X
nuclear	B-X
splicing	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
several	B-X
maturase	B-X
genes	B-X
have	B-X
been	B-X
found	B-X
in	B-X
the	B-X
nucleus	B-X
as	B-X
well	B-X
,	B-X
which	B-X
are	B-X
acting	B-X
on	B-X
mitochondrial	B-X
pre-RNAs	B-X
.	B-X
All	B-X
plant	B-X
maturases	B-X
show	B-X
sequence	B-X
deviation	B-X
from	B-X
their	B-X
progenitor	B-X
bacterial	B-X
maturases	B-X
,	B-X
and	B-X
interestingly	B-X
are	B-X
all	B-X
acting	B-X
on	B-X
multiple	B-X
organellar	B-X
group	B-X
II	B-X
intron	B-X
targets	B-X
.	B-X
Moreover	B-X
,	B-X
they	B-X
seem	B-X
to	B-X
function	B-X
in	B-X
the	B-X
splicing	B-X
of	B-X
group	B-X
II	B-X
introns	B-X
together	B-X
with	B-X
a	B-X
number	B-X
of	B-X
additional	B-X
nuclear-encoded	B-X
splicing	B-X
factors	B-X
,	B-X
possibly	B-X
acting	B-X
as	B-X
an	B-X
organellar	B-X
proto-spliceosome	B-X
.	B-X
Together	B-X
,	B-X
this	B-X
makes	B-X
them	B-X
interesting	B-X
models	B-X
for	B-X
the	B-X
early	B-X
evolution	B-X
of	B-X
nuclear	B-X
spliceosomal	B-X
splicing	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
summarize	B-X
recent	B-X
advances	B-X
in	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
role	B-X
of	B-X
plant	B-X
maturases	B-X
and	B-X
their	B-X
accessory	B-X
factors	B-X
in	B-X
plants	B-X
.	B-X

Previously	O
,	O
we	O
described	O
that	O
electroporated	O
cox2	O
constructs	O
were	O
a	O
good	O
model	O
for	O
the	O
study	O
of	O
the	O
splicing	O
process	O
.	O

Using	O
this	O
model	O
,	O
we	O
found	O
that	O
editing	O
and	O
splicing	O
of	O
cox2	O
transcripts	O
were	O
not	O
linked	O
in	O
wheat	B-Species
mitochondria	O
(	O
15	O
)	O
.	O
<EOS>	B-X
The	B-X
complex	B-X
gene	B-X
expression	B-X
mechanisms	B-X
that	B-X
occur	B-X
in	B-X
plant	B-X
mitochondria	B-X
,	B-X
such	B-X
as	B-X
RNA	B-X
editing	B-X
and	B-X
splicing	B-X
,	B-X
are	B-X
not	B-X
yet	B-X
well	B-X
understood	B-X
.	B-X
RNA	B-X
editing	B-X
in	B-X
higher	B-X
plant	B-X
mitochondria	B-X
is	B-X
a	B-X
highly	B-X
specific	B-X
process	B-X
which	B-X
modifies	B-X
mRNA	B-X
sequences	B-X
by	B-X
C-to-U	B-X
conversions	B-X
.	B-X
It	B-X
has	B-X
been	B-X
suggested	B-X
that	B-X
in	B-X
some	B-X
cases	B-X
this	B-X
process	B-X
is	B-X
required	B-X
for	B-X
splicing	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
use	B-X
an	B-X
experimental	B-X
model	B-X
based	B-X
on	B-X
the	B-X
introduction	B-X
of	B-X
DNA	B-X
into	B-X
isolated	B-X
mitochondria	B-X
by	B-X
electroporation	B-X
to	B-X
study	B-X
organellar	B-X
gene	B-X
expression	B-X
events	B-X
.	B-X
Our	B-X
aim	B-X
was	B-X
to	B-X
compare	B-X
processing	B-X
and	B-X
editing	B-X
of	B-X
potato	B-X
small	B-X
ribosomal	B-X
protein	B-X
10	B-X
gene	B-X
(	B-X
rps10	B-X
)	B-X
transcripts	B-X
in	B-X
heterologous	B-X
(	B-X
wheat	B-X
mitochondria	B-X
)	B-X
and	B-X
homologous	B-X
(	B-X
potato	B-X
mitochondria	B-X
)	B-X
contexts	B-X
.	B-X
rps10	B-X
is	B-X
a	B-X
suitable	B-X
model	B-X
because	B-X
it	B-X
contains	B-X
a	B-X
group	B-X
II	B-X
intron	B-X
,	B-X
is	B-X
absent	B-X
in	B-X
wheat	B-X
mitochondria	B-X
but	B-X
is	B-X
actively	B-X
expressed	B-X
in	B-X
potato	B-X
mitochondria	B-X
,	B-X
where	B-X
transcripts	B-X
are	B-X
spliced	B-X
and	B-X
undergo	B-X
five	B-X
C-to-U	B-X
editing	B-X
events	B-X
.	B-X
For	B-X
this	B-X
purpose	B-X
,	B-X
conditions	B-X
for	B-X
electroporating	B-X
isolated	B-X
potato	B-X
mitochondria	B-X
were	B-X
established	B-X
.	B-X
rps10	B-X
was	B-X
placed	B-X
under	B-X
the	B-X
control	B-X
of	B-X
either	B-X
potato	B-X
or	B-X
wheat	B-X
cox2	B-X
promoters	B-X
.	B-X
We	B-X
found	B-X
that	B-X
rps10	B-X
was	B-X
only	B-X
transcribed	B-X
under	B-X
the	B-X
control	B-X
of	B-X
a	B-X
cognate	B-X
promoter	B-X
.	B-X
In	B-X
wheat	B-X
mitochondria	B-X
,	B-X
rps10	B-X
transcripts	B-X
were	B-X
neither	B-X
spliced	B-X
nor	B-X
edited	B-X
while	B-X
they	B-X
are	B-X
correctly	B-X
processed	B-X
in	B-X
potato	B-X
mitochondria	B-X
.	B-X
Interestingly	B-X
,	B-X
a	B-X
wheat	B-X
editing	B-X
site	B-X
grafted	B-X
into	B-X
rps10	B-X
was	B-X
not	B-X
recognized	B-X
by	B-X
wheat	B-X
mitochondria	B-X
but	B-X
was	B-X
correctly	B-X
edited	B-X
in	B-X
potato	B-X
mitochondria	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
editing	B-X
might	B-X
occur	B-X
only	B-X
when	B-X
the	B-X
transcripts	B-X
are	B-X
engaged	B-X
in	B-X
processing	B-X
and	B-X
that	B-X
they	B-X
would	B-X
not	B-X
be	B-X
available	B-X
to	B-X
editing	B-X
factors	B-X
outside	B-X
of	B-X
a	B-X
putative	B-X
RNA	B-X
maturation	B-X
machinery	B-X
complex	B-X
.	B-X

To	O
challenge	O
the	O
ability	O
of	O
mitochondrial	O
gene	O
expression	O
machinery	O
to	O
recognize	O
genetic	O
information	O
which	O
has	O
been	O
lost	O
during	O
evolution	O
,	O
we	O
decided	O
to	O
introduce	O
the	O
S	B-Species
.	I-Species
tuberosum	I-Species
non	O
-	O
cognate	O
rps10	O
gene	O
into	O
wheat	B-Species
mitochondria	O
.	O

Five	O
C	O
residues	O
are	O
changed	O
to	O
U	O
in	O
potato	B-Species
mitochondria	O
rps10	O
transcripts	O
by	O
editing	O
.	O

Two	O
of	O
them	O
have	O
been	O
postulated	O
as	O
being	O
necessary	O
for	O
acquisition	O
of	O
a	O
proper	O
secondary	O
and	O
/	O
or	O
tertiary	O
structure	O
for	O
splicing	O
.	O
<EOS>	B-X
Pre-mRNA	B-X
splicing	B-X
is	B-X
catalyzed	B-X
by	B-X
the	B-X
spliceosome	B-X
,	B-X
a	B-X
multimegadalton	B-X
ribonucleoprotein	B-X
(	B-X
RNP	B-X
)	B-X
complex	B-X
comprised	B-X
of	B-X
five	B-X
snRNPs	B-X
and	B-X
numerous	B-X
proteins	B-X
.	B-X
Both	B-X
the	B-X
conformation	B-X
and	B-X
composition	B-X
of	B-X
the	B-X
spliceosome	B-X
are	B-X
highly	B-X
dynamic	B-X
,	B-X
affording	B-X
the	B-X
splicing	B-X
machinery	B-X
its	B-X
accuracy	B-X
and	B-X
flexibility	B-X
,	B-X
and	B-X
these	B-X
remarkable	B-X
dynamics	B-X
are	B-X
largely	B-X
conserved	B-X
between	B-X
yeast	B-X
and	B-X
metazoans	B-X
.	B-X
X-ray	B-X
and	B-X
NMR	B-X
studies	B-X
have	B-X
provided	B-X
high	B-X
resolution	B-X
structure	B-X
information	B-X
about	B-X
spliceosomal	B-X
proteins	B-X
alone	B-X
or	B-X
complexed	B-X
with	B-X
one	B-X
or	B-X
more	B-X
binding	B-X
partners	B-X
.	B-X
The	B-X
extensive	B-X
interplay	B-X
of	B-X
RNA	B-X
and	B-X
proteins	B-X
in	B-X
aligning	B-X
the	B-X
pre-mRNA	B-X
's	B-X
reactive	B-X
groups	B-X
,	B-X
and	B-X
the	B-X
presence	B-X
of	B-X
both	B-X
RNA	B-X
and	B-X
protein	B-X
at	B-X
the	B-X
core	B-X
of	B-X
the	B-X
splicing	B-X
machinery	B-X
,	B-X
suggest	B-X
that	B-X
the	B-X
spliceosome	B-X
is	B-X
an	B-X
RNP	B-X
enzyme	B-X
.	B-X
However	B-X
,	B-X
elucidation	B-X
of	B-X
the	B-X
precise	B-X
nature	B-X
of	B-X
the	B-X
spliceosome	B-X
's	B-X
active	B-X
site	B-X
,	B-X
awaits	B-X
the	B-X
generation	B-X
of	B-X
a	B-X
high-resolution	B-X
structure	B-X
of	B-X
its	B-X
RNP	B-X
core	B-X
.	B-X

To	O
test	O
this	O
hypothesis	O
,	O
it	O
was	O
necessary	O
to	O
set	O
up	O
the	O
conditions	O
for	O
electroporation	O
of	O
foreign	O
DNA	O
into	O
S	B-Species
.	I-Species
tuberosum	I-Species
mitochondria	O
.	O

Here	O
,	O
we	O
show	O
that	O
a	O
potato	B-Species
rps10	O
construct	O
is	O
transcribed	O
when	O
introduced	O
into	O
wheat	B-Species
mitochondria	O
,	O
but	O
transcripts	O
are	O
not	O
recognized	O
by	O
the	O
post	O
-	O
transcriptional	O
processing	O
machinery	O
.	O

In	O
contrast	O
,	O
a	O
rps10	O
construct	O
is	O
correctly	O
expressed	O
and	O
processed	O
in	O
cognate	O
potato	B-Species
mitochondria	O
.	O

Moreover	O
,	O
we	O
present	O
evidence	O
that	O
transcript	O
editing	O
might	O
be	O
linked	O
to	O
overall	O
RNA	O
processing	O
.	O

This	O
is	O
the	O
first	O
report	O
on	O
DNA	O
electroporation	O
into	O
potato	B-Species
mitochondria	O
.	O

MATERIALS	O
AND	O
METHODS	O

Plasmids	O
<EOS>	B-X
Plasmids	B-X
mediate	B-X
the	B-X
horizontal	B-X
transmission	B-X
of	B-X
genetic	B-X
information	B-X
between	B-X
bacteria	B-X
,	B-X
facilitating	B-X
their	B-X
adaptation	B-X
to	B-X
multiple	B-X
environmental	B-X
conditions	B-X
.	B-X
Plasmids	B-X
provide	B-X
bacteria	B-X
with	B-X
new	B-X
adaptive	B-X
tools	B-X
,	B-X
but	B-X
they	B-X
also	B-X
entail	B-X
a	B-X
metabolic	B-X
burden	B-X
that	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
selection	B-X
for	B-X
plasmid-encoded	B-X
traits	B-X
,	B-X
reduces	B-X
the	B-X
competitiveness	B-X
of	B-X
the	B-X
plasmid-carrying	B-X
clone	B-X
.	B-X
Plasmids	B-X
are	B-X
important	B-X
vehicles	B-X
for	B-X
rapid	B-X
adaptation	B-X
of	B-X
bacterial	B-X
populations	B-X
to	B-X
changing	B-X
environmental	B-X
conditions	B-X
.	B-X
Plasmids	B-X
provide	B-X
various	B-X
accessory	B-X
traits	B-X
which	B-X
might	B-X
be	B-X
beneficial	B-X
under	B-X
particular	B-X
conditions	B-X
.	B-X

All	O
plasmids	O
used	O
in	O
this	O
study	O
are	O
based	O
on	O
the	O
previously	O
described	O
pCOXII	O
vector	O
(	O
14	O
)	O
.	O

An	O
NsiI	O
restriction	O
site	O
was	O
introduced	O
at	O
the	O
initiation	O
codon	O
of	O
the	O
wheat	B-Species
cox2	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
.	O

Then	O
,	O
NsiI	O
was	O
used	O
in	O
combination	O
with	O
a	O
SpeI	O
restriction	O
site	O
present	O
in	O
the	O
original	O
vector	O
after	O
the	O
stop	O
codon	O
,	O
to	O
produce	O
the	O
chimeric	O
vectors	O
.	O

S	B-Species
.	I-Species
tuberosum	I-Species
cox2	O
gene	O
,	O
including	O
a	O
727	O
bp	O
non	O
-	O
coding	O
upstream	O
region	O
,	O
was	O
isolated	O
by	O
PCR	O
from	O
total	O
DNA	O
using	O
the	O
primer	O
A	O
designed	O
from	O
partial	O
sequences	O
reported	O
by	O
L	O
o	O
essl	O
et	O
al	O
.	O

(	O
22	O
)	O
,	O
accession	O
no	O
.	O
<EOS>	B-X
Methods	B-X
141:22	B-X
,	B-X
2007	B-X
.	B-X
The	B-X
complete	B-X
mitochondrial	B-X
genome	B-X
of	B-X
MicroRNAs	B-X
(	B-X
miRNAs	B-X
)	B-X
are	B-X
short	B-X
non-coding	B-X
single-stranded	B-X
RNAs	B-X
with	B-X
approximately	B-X
22	B-X
nucleotides	B-X
in	B-X
length	B-X
that	B-X
negatively	B-X
regulate	B-X
the	B-X
mRNA	B-X
translation	B-X
of	B-X
a	B-X
target	B-X
gene	B-X
.	B-X
Morphological	B-X
and	B-X
pomological	B-X
diversity	B-X
among	B-X
81	B-X
accessions	B-X
of	B-X
P.	B-X
microcarpa	B-X
species	B-X
selected	B-X
from	B-X
natural	B-X
habitats	B-X
was	B-X
assessed	B-X
.	B-X

AF096321	O
,	O
containing	O
the	O
KpnI	O
restriction	O
sequence	O
,	O
and	O
primer	O
B	O
derived	O
from	O
Triticum	B-Species
timopheevi	I-Species
cox2	O
(	O
AF336134	O
)	O
.	O

A	O
fragment	O
of	O
2888	O
bp	O
was	O
obtained	O
and	O
cloned	O
on	O
pGEM	O
-	O
T	O
vector	O
.	O

The	O
complete	O
sequence	O
of	O
the	O
S	B-Species
.	I-Species
tuberosum	I-Species
cox2	O
was	O
determined	O
(	O
accession	O
no	O
.	O
DQ18064	O
)	O
.	O

To	O
generate	O
the	O
plasmid	O
pCOXIISt	O
containing	O
the	O
S	B-Species
.	I-Species
tuberosum	I-Species
cox2	O
gene	O
,	O
a	O
KpnI	O
/	O
SpeI	O
fragment	O
containing	O
the	O
727	O
bp	O
upstream	O
region	O
and	O
the	O
complete	O
coding	O
region	O
was	O
used	O
to	O
replace	O
the	O
wheat	B-Species
gene	O
from	O
pCOXII	O
.	O

As	O
for	O
pCOXII	O
,	O
a	O
NsiI	O
site	O
was	O
inserted	O
at	O
the	O
ATG	O
start	O
codon	O
and	O
a	O
23	O
bp	O
fragment	O
was	O
inserted	O
at	O
position	O
-	O
20	O
.	O

This	O
23	O
bp	O
insertion	O
provides	O
a	O
specific	O
sequence	O
allowing	O
isolation	O
of	O
potato	B-Species
cox2	O
transcripts	O
originating	O
from	O
the	O
introduced	O
DNA	O
by	O
RT	O
-	O
PCR	O
.	O

The	O
chimeric	O
wheat	B-Species
/	O
potato	B-Species
cox2	O
gene	O
was	O
constructed	O
by	O
replacing	O
727	O
bp	O
KpnI	O
/	O
NsiI	O
promoter	O
sequence	O
from	O
pCOXIISt	O
with	O
the	O
880	O
bp	O
wheat	B-Species
upstream	O
region	O
from	O
pCOXII	O
.	O

The	O
vectors	O
pRPS10W	O
and	O
the	O
pRPS10St	O
derivative	O
,	O
containing	O
wheat	B-Species
and	O
potato	B-Species
cox2	O
promoters	O
,	O
respectively	O
,	O
were	O
constructed	O
by	O
inserting	O
the	O
1178	O
bp	O
rps10	O
sequence	O
containing	O
two	O
exons	O
separated	O
by	O
a	O
777	O
bp	O
intronic	O
sequence	O
[	O
(	O
23	O
)	O
,	O
accession	O
no	O
.	O
X74826	O
]	O
.	O

The	O
coding	O
region	O
was	O
isolated	O
from	O
total	O
S	B-Species
.	I-Species
tuberosum	I-Species
DNA	O
by	O
PCR	O
using	O
primers	O
D1	O
and	O
D2	O
containing	O
the	O
restriction	O
sites	O
NsiI	O
and	O
SpeI	O
,	O
respectively	O
.	O

The	O
fragment	O
NsiI	O
/	O
SpeI	O
was	O
purified	O
and	O
cloned	O
into	O
pCOXII	O
and	O
pCOXIISt	O
,	O
replacing	O
the	O
respective	O
cox2	O
coding	O
regions	O
.	O

Since	O
all	O
vectors	O
used	O
here	O
were	O
based	O
on	O
pCOXII	O
,	O
they	O
contain	O
the	O
downstream	O
region	O
from	O
the	O
wheat	B-Species
cob	O
gene	O
(	O
Ir	O
-	O
cob	O
)	O
(	O
accession	O
no	O
.	O
AF337547	O
)	O
(	O
14	O
)	O
.	O

This	O
sequence	O
,	O
combined	O
with	O
the	O
23	O
bp	O
upstream	O
insert	O
sequence	O
served	O
to	O
distinguish	O
,	O
using	O
primers	O
1a	O
and	O
1b	O
,	O
foreign	O
from	O
endogenous	O
transcripts	O
.	O

All	O
mutants	O
were	O
obtained	O
using	O
QuickChange	O
(R)	O
Site	O
-	O
Directed	O
Mutagenesis	O
kit	O
(	O
Stratagene	O
)	O
.	O

PCR	O
product	O
purifications	O
were	O
carried	O
out	O
with	O
the	O
Wizard	O
(R)	O
Clean	O
-	O
Up	O
System	O
(	O
Promega	O
)	O
.	O

PCR	O
primers	O
used	O
<EOS>	B-X
Nested	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
is	B-X
used	B-X
in	B-X
situations	B-X
in	B-X
which	B-X
it	B-X
is	B-X
necessary	B-X
to	B-X
increase	B-X
the	B-X
sensitivity	B-X
and/or	B-X
specificity	B-X
of	B-X
PCR	B-X
,	B-X
for	B-X
example	B-X
,	B-X
when	B-X
amplifying	B-X
a	B-X
particular	B-X
member	B-X
of	B-X
a	B-X
polymorphic	B-X
gene	B-X
family	B-X
or	B-X
when	B-X
amplifying	B-X
a	B-X
cDNA	B-X
copy	B-X
of	B-X
an	B-X
mRNA	B-X
present	B-X
at	B-X
very	B-X
low	B-X
abundance	B-X
in	B-X
a	B-X
clinical	B-X
specimen	B-X
containing	B-X
a	B-X
heterogeneous	B-X
population	B-X
of	B-X
cell	B-X
types	B-X
.	B-X
Nested	B-X
PCR	B-X
usually	B-X
involves	B-X
two	B-X
sequential	B-X
amplification	B-X
reactions	B-X
,	B-X
each	B-X
of	B-X
which	B-X
uses	B-X
a	B-X
different	B-X
pair	B-X
of	B-X
primers	B-X
.	B-X
The	B-X
product	B-X
of	B-X
the	B-X
first	B-X
amplification	B-X
reaction	B-X
is	B-X
used	B-X
as	B-X
the	B-X
template	B-X
for	B-X
the	B-X
second	B-X
PCR	B-X
,	B-X
which	B-X
is	B-X
primed	B-X
by	B-X
oligonucleotides	B-X
that	B-X
are	B-X
placed	B-X
internal	B-X
to	B-X
the	B-X
first	B-X
primer	B-X
pair	B-X
.	B-X
The	B-X
use	B-X
of	B-X
two	B-X
pairs	B-X
of	B-X
oligonucleotides	B-X
allows	B-X
a	B-X
higher	B-X
number	B-X
of	B-X
cycles	B-X
to	B-X
be	B-X
performed	B-X
,	B-X
thereby	B-X
increasing	B-X
the	B-X
sensitivity	B-X
of	B-X
the	B-X
PCR	B-X
.	B-X
The	B-X
improved	B-X
specificity	B-X
of	B-X
the	B-X
reaction	B-X
derives	B-X
from	B-X
the	B-X
binding	B-X
of	B-X
two	B-X
separate	B-X
sets	B-X
of	B-X
primers	B-X
to	B-X
the	B-X
same	B-X
target	B-X
template	B-X
.	B-X
Nested	B-X
PCR	B-X
is	B-X
an	B-X
efficient	B-X
method	B-X
to	B-X
amplify	B-X
segments	B-X
of	B-X
long	B-X
templates	B-X
but	B-X
requires	B-X
knowledge	B-X
of	B-X
the	B-X
sequence	B-X
of	B-X
the	B-X
target	B-X
.	B-X

Oligonucleotides	O
sequences	O
are	O
in	O
5	O
'	O
to	O
3	O
'	O
orientation	O
.	O
<EOS>	B-X
After	B-X
candidate	B-X
selection	B-X
,	B-X
further	B-X
optimizations	B-X
such	B-X
as	B-X
shortening	B-X
and	B-X
modifying	B-X
candidate	B-X
sequences	B-X
are	B-X
performed	B-X
.	B-X
In	B-X
this	B-X
article	B-X
,	B-X
we	B-X
review	B-X
existing	B-X
in	B-X
silico	B-X
approaches	B-X
to	B-X
RNA	B-X
aptamer	B-X
development	B-X
,	B-X
including	B-X
a	B-X
method	B-X
for	B-X
ranking	B-X
the	B-X
candidates	B-X
of	B-X
RNA	B-X
aptamers	B-X
from	B-X
HT-SELEX	B-X
data	B-X
,	B-X
clustering	B-X
a	B-X
huge	B-X
number	B-X
of	B-X
aptamer	B-X
sequences	B-X
,	B-X
and	B-X
finding	B-X
motifs	B-X
amidst	B-X
a	B-X
set	B-X
of	B-X
significant	B-X
RNA	B-X
aptamers	B-X
.	B-X
The	B-X
conformation	B-X
of	B-X
the	B-X
crotonaldehyde-derived	B-X
N	B-X
(	B-X
2	B-X
)	B-X
-	B-X
[	B-X
3-oxo-1	B-X
(	B-X
S	B-X
)	B-X
-methyl-propyl	B-X
]	B-X
-dG	B-X
adduct	B-X
in	B-X
the	B-X
oligodeoxynucleotide	B-X
5'-d	B-X
(	B-X
G	B-X
(	B-X
1	B-X
)	B-X
C	B-X
(	B-X
2	B-X
)	B-X
T	B-X
(	B-X
3	B-X
)	B-X
A	B-X
(	B-X
4	B-X
)	B-X
G	B-X
(	B-X
5	B-X
)	B-X
C	B-X
(	B-X
6	B-X
)	B-X
X	B-X
(	B-X
7	B-X
)	B-X
A	B-X
(	B-X
8	B-X
)	B-X
G	B-X
(	B-X
9	B-X
)	B-X
T	B-X
(	B-X
10	B-X
)	B-X
C	B-X
(	B-X
11	B-X
)	B-X
C	B-X
(	B-X
12	B-X
)	B-X
)	B-X
-3'.5'-d	B-X
(	B-X
G	B-X
(	B-X
13	B-X
)	B-X
G	B-X
(	B-X
14	B-X
)	B-X
A	B-X
(	B-X
15	B-X
)	B-X
C	B-X
(	B-X
16	B-X
)	B-X
T	B-X
(	B-X
17	B-X
)	B-X
C	B-X
(	B-X
18	B-X
)	B-X
G	B-X
(	B-X
19	B-X
)	B-X
C	B-X
(	B-X
20	B-X
)	B-X
T	B-X
(	B-X
21	B-X
)	B-X
A	B-X
(	B-X
22	B-X
)	B-X
G	B-X
(	B-X
23	B-X
)	B-X
C	B-X
(	B-X
2	B-X
)	B-X
(	B-X
4	B-X
)	B-X
)	B-X
-3	B-X
'	B-X
,	B-X
where	B-X
X	B-X
=	B-X
N	B-X
(	B-X
2	B-X
)	B-X
-	B-X
[	B-X
3-oxo-1	B-X
(	B-X
S	B-X
)	B-X
-methyl-propyl	B-X
]	B-X
-dG	B-X
,	B-X
is	B-X
reported	B-X
.	B-X
This	B-X
adduct	B-X
arises	B-X
from	B-X
opening	B-X
of	B-X
the	B-X
cyclic	B-X
N	B-X
(	B-X
2	B-X
)	B-X
-	B-X
(	B-X
S-alpha-CH	B-X
(	B-X
3	B-X
)	B-X
-gamma-OH-1	B-X
,	B-X
N	B-X
(	B-X
2	B-X
)	B-X
-propano-2	B-X
'	B-X
)	B-X
-dG	B-X
adduct	B-X
when	B-X
placed	B-X
opposite	B-X
dC	B-X
in	B-X
duplex	B-X
DNA	B-X
.	B-X
This	B-X
oligodeoxynucleotide	B-X
contains	B-X
the	B-X
5'-CpG-3	B-X
'	B-X
sequence	B-X
in	B-X
which	B-X
the	B-X
N	B-X
(	B-X
2	B-X
)	B-X
-	B-X
(	B-X
R-alpha-CH	B-X
(	B-X
3	B-X
)	B-X
-gamma-OH-1	B-X
,	B-X
N	B-X
(	B-X
2	B-X
)	B-X
-propano-2	B-X
'	B-X
)	B-X
-dG	B-X
but	B-X
not	B-X
the	B-X
N	B-X
(	B-X
2	B-X
)	B-X
-	B-X
(	B-X
S-alpha-CH	B-X
(	B-X
3	B-X
)	B-X
-gamma-OH-1	B-X
,	B-X
N	B-X
(	B-X
2	B-X
)	B-X
-propano-2	B-X
'	B-X
)	B-X
-dG	B-X
adduct	B-X
preferentially	B-X
formed	B-X
an	B-X
interstrand	B-X
carbinolamine	B-X
cross-link	B-X
[	B-X
Kozekov	B-X
,	B-X
I.	B-X
D.	B-X
,	B-X
Nechev	B-X
,	B-X
L.	B-X
V.	B-X
,	B-X
Moseley	B-X
,	B-X
M.	B-X
S.	B-X
,	B-X
Harris	B-X
,	B-X
C.	B-X
M.	B-X
,	B-X
Rizzo	B-X
,	B-X
C.	B-X
J.	B-X
,	B-X
Stone	B-X
,	B-X
M.	B-X
P.	B-X
,	B-X
and	B-X
Harris	B-X
,	B-X
T.	B-X
M.	B-X
(	B-X
2003	B-X
)	B-X
J	B-X
.	B-X
125	B-X
,	B-X
50-61	B-X
;	B-X
Cho	B-X
,	B-X
Y.-J.	B-X
,	B-X
Wang	B-X
,	B-X
H.	B-X
,	B-X
Kozekov	B-X
,	B-X
I.	B-X
D.	B-X
,	B-X
Kurtz	B-X
,	B-X
A.	B-X
J.	B-X
,	B-X
Jacob	B-X
,	B-X
J.	B-X
,	B-X
Voehler	B-X
,	B-X
M.	B-X
,	B-X
Smith	B-X
,	B-X
J.	B-X
,	B-X
Harris	B-X
,	B-X
T.	B-X
M.	B-X
,	B-X
Lloyd	B-X
,	B-X
R.	B-X
S.	B-X
,	B-X
Rizzo	B-X
,	B-X
C.	B-X
J.	B-X
,	B-X
and	B-X
Stone	B-X
,	B-X
M.	B-X
P.	B-X
(	B-X
2006	B-X
)	B-X
Chem	B-X
.	B-X
19	B-X
,	B-X
195-208	B-X
]	B-X
.	B-X
Analysis	B-X
of	B-X
(	B-X
1	B-X
)	B-X
H	B-X
NOE	B-X
data	B-X
,	B-X
chemical	B-X
shift	B-X
perturbations	B-X
,	B-X
and	B-X
deoxyribose	B-X
pseudorotations	B-X
and	B-X
backbone	B-X
torsion	B-X
angles	B-X
suggested	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
stable	B-X
and	B-X
ordered	B-X
DNA	B-X
conformation	B-X
at	B-X
pH	B-X
9.3	B-X
and	B-X
30	B-X
degrees	B-X
C	B-X
,	B-X
with	B-X
minimal	B-X
conformational	B-X
perturbation	B-X
.	B-X
The	B-X
crotonaldehydic-derived	B-X
methyl	B-X
protons	B-X
showed	B-X
NOEs	B-X
in	B-X
the	B-X
5'-direction	B-X
to	B-X
C	B-X
(	B-X
18	B-X
)	B-X
H1	B-X
'	B-X
,	B-X
G	B-X
(	B-X
19	B-X
)	B-X
H1	B-X
'	B-X
,	B-X
and	B-X
G	B-X
(	B-X
19	B-X
)	B-X
H4	B-X
'	B-X
in	B-X
the	B-X
complementary	B-X
strand	B-X
of	B-X
the	B-X
duplex	B-X
.	B-X
The	B-X
aldehyde	B-X
proton	B-X
of	B-X
the	B-X
adduct	B-X
exhibited	B-X
NOEs	B-X
in	B-X
the	B-X
3'-direction	B-X
to	B-X
A	B-X
(	B-X
8	B-X
)	B-X
H1	B-X
'	B-X
and	B-X
A	B-X
(	B-X
8	B-X
)	B-X
H4	B-X
'	B-X
in	B-X
the	B-X
modified	B-X
strand	B-X
.	B-X
Molecular	B-X
dynamics	B-X
calculations	B-X
,	B-X
restrained	B-X
by	B-X
distances	B-X
and	B-X
torsion	B-X
angles	B-X
derived	B-X
from	B-X
the	B-X
NMR	B-X
data	B-X
,	B-X
revealed	B-X
that	B-X
within	B-X
the	B-X
minor	B-X
groove	B-X
,	B-X
the	B-X
aldehyde	B-X
of	B-X
the	B-X
N	B-X
(	B-X
2	B-X
)	B-X
-	B-X
[	B-X
3-oxo-1	B-X
(	B-X
S	B-X
)	B-X
-methyl-propyl	B-X
]	B-X
-dG	B-X
adduct	B-X
oriented	B-X
in	B-X
the	B-X
3'-direction	B-X
,	B-X
while	B-X
the	B-X
1	B-X
(	B-X
S	B-X
)	B-X
methyl	B-X
group	B-X
oriented	B-X
in	B-X
the	B-X
5'-direction	B-X
.	B-X
This	B-X
positioned	B-X
the	B-X
aldehyde	B-X
distal	B-X
to	B-X
the	B-X
G	B-X
(	B-X
19	B-X
)	B-X
exocyclic	B-X
amine	B-X
and	B-X
provided	B-X
a	B-X
rationale	B-X
as	B-X
to	B-X
why	B-X
the	B-X
N	B-X
(	B-X
2	B-X
)	B-X
-	B-X
(	B-X
S-alpha-CH	B-X
(	B-X
3	B-X
)	B-X
-gamma-OH-1	B-X
,	B-X
N	B-X
(	B-X
2	B-X
)	B-X
-propano-2	B-X
'	B-X
)	B-X
-dG	B-X
adduct	B-X
generated	B-X
interstrand	B-X
cross-links	B-X
less	B-X
efficiently	B-X
than	B-X
did	B-X
the	B-X
N	B-X
(	B-X
2	B-X
)	B-X
-	B-X
(	B-X
R-alpha-CH	B-X
(	B-X
3	B-X
)	B-X
-gamma-OH-1	B-X
,	B-X
N	B-X
(	B-X
2	B-X
)	B-X
-propano-2	B-X
'	B-X
)	B-X
-dG	B-X
adduct	B-X
.	B-X

(	O
1a	O
)	O
,	O
GCGGTGCAGTCATACAGATCTGC	O
;	O
(	O
1b	O
)	O
,	O
TATCCAGATTTGGTACCAAAC	O
;	O
(	O
2a	O
)	O
,	O
GCAGTCATACAGATCTGCCAAAG	O
;	O
(	O
2b	O
)	O
,	O
AGATTTGGTACCAAACCCGGG	O
;	O
(	O
A	O
)	O
,	O
TATAGGTACCTCTCAGGTGTCAAAGTGTGGATTT	O
;	O
(	O
B	O
)	O
,	O
TATAACTAGTTTAAGCTTCCCCG	O
;	O
(	O
D1	O
)	O
,	O
TATAATGCATAGACAAAGGAGAGCACTTA	O
;	O
(	O
D2	O
)	O
,	O
TATAACTAGTTCAGGAAAGGGTCAACGCAA	O
.	O
<EOS>	B-X
This	B-X
article	B-X
discusses	B-X
the	B-X
prevention	B-X
of	B-X
venous	B-X
thromboembolism	B-X
(	B-X
VTE	B-X
)	B-X
and	B-X
is	B-X
part	B-X
of	B-X
the	B-X
Antithrombotic	B-X
and	B-X
Thrombolytic	B-X
Therapy	B-X
:	B-X
American	B-X
College	B-X
of	B-X
Chest	B-X
Physicians	B-X
Evidence-Based	B-X
Clinical	B-X
Practice	B-X
Guidelines	B-X
(	B-X
8th	B-X
Edition	B-X
)	B-X
.	B-X
For	B-X
patients	B-X
undergoing	B-X
hip	B-X
fracture	B-X
surgery	B-X
(	B-X
HFS	B-X
)	B-X
,	B-X
we	B-X
recommend	B-X
the	B-X
routine	B-X
use	B-X
of	B-X
fondaparinux	B-X
(	B-X
Grade	B-X
1A	B-X
)	B-X
,	B-X
LMWH	B-X
(	B-X
Grade	B-X
1B	B-X
)	B-X
,	B-X
a	B-X
VKA	B-X
(	B-X
target	B-X
INR	B-X
,	B-X
2.5	B-X
;	B-X
range	B-X
,	B-X
2.0	B-X
to	B-X
3.0	B-X
)	B-X
[	B-X
Grade	B-X
1B	B-X
]	B-X
,	B-X
or	B-X
LDUH	B-X
(	B-X
Grade	B-X
1B	B-X
)	B-X
.	B-X
Toxigenic	B-X
Properties	B-X
of	B-X
This	B-X
article	B-X
discusses	B-X
the	B-X
prevention	B-X
of	B-X
venous	B-X
thromboembolism	B-X
(	B-X
VTE	B-X
)	B-X
and	B-X
is	B-X
part	B-X
of	B-X
the	B-X
Seventh	B-X
American	B-X
College	B-X
of	B-X
Chest	B-X
Physicians	B-X
Conference	B-X
on	B-X
Antithrombotic	B-X
and	B-X
Thrombolytic	B-X
Therapy	B-X
:	B-X
Evidence-Based	B-X
Guidelines	B-X
.	B-X
For	B-X
patients	B-X
undergoing	B-X
hip	B-X
fracture	B-X
surgery	B-X
(	B-X
HFS	B-X
)	B-X
,	B-X
we	B-X
recommend	B-X
the	B-X
routine	B-X
use	B-X
of	B-X
fondaparinux	B-X
(	B-X
Grade	B-X
1A	B-X
)	B-X
,	B-X
LMWH	B-X
(	B-X
Grade	B-X
1C+	B-X
)	B-X
,	B-X
VKA	B-X
(	B-X
target	B-X
INR	B-X
,	B-X
2.5	B-X
;	B-X
range	B-X
,	B-X
2.0	B-X
to	B-X
3.0	B-X
)	B-X
[	B-X
Grade	B-X
2B	B-X
]	B-X
,	B-X
or	B-X
LDUH	B-X
(	B-X
Grade	B-X
1B	B-X
)	B-X
.	B-X

Restriction	O
sites	O
are	O
underlined	O
.	O
<EOS>	B-X
Nutritional	B-X
factors	B-X
(	B-X
diet	B-X
,	B-X
weight	B-X
,	B-X
alcohol	B-X
,	B-X
physical	B-X
activity	B-X
)	B-X
are	B-X
identified	B-X
as	B-X
factors	B-X
having	B-X
an	B-X
impact	B-X
on	B-X
the	B-X
onset	B-X
of	B-X
several	B-X
cancer	B-X
sites	B-X
.	B-X
Human	B-X
placenta	B-X
,	B-X
decidua	B-X
,	B-X
and	B-X
fetal	B-X
membranes	B-X
are	B-X
the	B-X
major	B-X
sites	B-X
of	B-X
production	B-X
and	B-X
secretion	B-X
of	B-X
inhibin	B-X
A	B-X
and	B-X
activin	B-X
A	B-X
in	B-X
maternal	B-X
serum	B-X
,	B-X
amniotic	B-X
fluid	B-X
,	B-X
and	B-X
umbilical	B-X
cord	B-X
blood	B-X
.	B-X
The	B-X
interactions	B-X
of	B-X
the	B-X
Ephs	B-X
with	B-X
their	B-X
ephrin	B-X
ligands	B-X
are	B-X
restricted	B-X
to	B-X
the	B-X
sites	B-X
of	B-X
cell-cell	B-X
contact	B-X
since	B-X
both	B-X
molecules	B-X
are	B-X
membrane	B-X
attached	B-X
.	B-X
Recent	B-X
developments	B-X
in	B-X
applying	B-X
fluorescence	B-X
(	B-X
steady-state	B-X
,	B-X
time-resolved	B-X
,	B-X
synchronous	B-X
techniques	B-X
)	B-X
,	B-X
circular	B-X
dichroism	B-X
and	B-X
vibrational	B-X
(	B-X
FTIR	B-X
and	B-X
Raman	B-X
)	B-X
spectroscopies	B-X
for	B-X
obtaining	B-X
relevant	B-X
parameters	B-X
(	B-X
binding	B-X
constant	B-X
,	B-X
K	B-X
,	B-X
number	B-X
of	B-X
binding	B-X
sites	B-X
,	B-X
thermodynamic	B-X
effects	B-X
)	B-X
are	B-X
presented	B-X
.	B-X

Mutagenesis	O
primers	O
(	O
only	O
sense	O
primers	O
in	O
5	O
'	O
-	O
3	O
'	O
orientation	O
are	O
indicated	O
)	O

Single	O
C2	O
,	O
C3	O
and	O
C2	O
+	O
C3	O
double	O
mutant	O
plasmids	O
were	O
constructed	O
with	O
primers	O
(	O
C2	O
)	O
AAGAAGTTCTTTTGGTTAAAACGCC	O
and	O
(	O
C3	O
)	O
CGCCGTGCGACTTGGAGGACATAAG	O
.	O

NsiI	O
-	O
pCOXII	O
:	O
GGAAATCCAATGCATCTTCGTTCATT	O
and	O
NsiI	O
-	O
pCOXIISt	O
:	O
CCAAACCAAATGCATGTTCTAGAATG	O
.	O

Construct	O
pCOXIISt	O
containing	O
a	O
23	O
nt	O
insertion	O
in	O
the	O
promoter	O
region	O
,	O
was	O
carried	O
out	O
into	O
two	O
consecutive	O
insertions	O
using	O
primers	O
:	O
TGGGGGGAGCAGAGCAGTGCGGTGCAGTCACAAAGAATGAACCAAACC	O
and	O
GCAGTGCGGTGCAGTCATACAGATCTGCCAAAGAATGAACCAAACC	O
.	O

For	O
constructs	O
MA	O
and	O
MAB	O
containing	O
the	O
wheat	B-Species
cox2	O
C259	O
editing	O
site	O
,	O
two	O
consecutive	O
insertions	O
were	O
carried	O
out	O
using	O
primers	O
:	O
GGAAGATTGGATTACTATCGAAATTGCCCTGAATCA	O
and	O
TACTATCGAAATTATTCGGACCATGCCCTGAATCA	O
.	O

For	O
ME6	O
and	O
ME6b	O
constructs	O
,	O
primers	O
CCGCGAGGAATCAACTACTATCGAAATTATTGCCGGTGCTGAC	O
and	O
CAACTACTATCGAAATTATTCGGACCATATTGCCGGTGCTGAC	O
were	O
used	O
.	O

Inserted	O
nucleotides	O
are	O
underlined	O
and	O
the	O
modified	O
residues	O
are	O
indicated	O
in	O
bold	O
.	O

Mitochondria	O
purification	O
<EOS>	B-X
Cell-Specific	B-X
Mitochondria	B-X
Affinity	B-X
Purification	B-X
(	B-X
CS-MAP	B-X
)	B-X
enables	B-X
isolation	B-X
and	B-X
purification	B-X
of	B-X
intact	B-X
mitochondria	B-X
from	B-X
individual	B-X
cell	B-X
types	B-X
of	B-X
Purification	B-X
and	B-X
subfractionation	B-X
of	B-X
mitochondria	B-X
from	B-X
the	B-X
yeast	B-X
Saccharomyces	B-X
cerevisiae	B-X
.	B-X
Mitochondria	B-X
are	B-X
the	B-X
main	B-X
site	B-X
of	B-X
ATP	B-X
production	B-X
during	B-X
aerobic	B-X
metabolism	B-X
in	B-X
eukaryotic	B-X
non-photosynthetic	B-X
cells	B-X
.	B-X
Here	B-X
we	B-X
present	B-X
a	B-X
detailed	B-X
description	B-X
of	B-X
a	B-X
rapid	B-X
and	B-X
effective	B-X
method	B-X
for	B-X
purification	B-X
of	B-X
yeast	B-X
mitochondria	B-X
.	B-X
This	B-X
method	B-X
enables	B-X
the	B-X
isolation	B-X
of	B-X
highly	B-X
pure	B-X
mitochondria	B-X
that	B-X
are	B-X
essentially	B-X
free	B-X
of	B-X
contamination	B-X
by	B-X
other	B-X
organelles	B-X
and	B-X
retain	B-X
their	B-X
structural	B-X
and	B-X
functional	B-X
integrity	B-X
after	B-X
their	B-X
purification	B-X
.	B-X
Mitochondria	B-X
purified	B-X
by	B-X
this	B-X
method	B-X
are	B-X
suitable	B-X
for	B-X
cell-free	B-X
reconstitution	B-X
of	B-X
essential	B-X
mitochondrial	B-X
processes	B-X
and	B-X
can	B-X
be	B-X
used	B-X
for	B-X
the	B-X
analysis	B-X
of	B-X
mitochondrial	B-X
structure	B-X
and	B-X
functions	B-X
,	B-X
mitochondrial	B-X
proteome	B-X
and	B-X
lipidome	B-X
,	B-X
and	B-X
mitochondrial	B-X
DNA	B-X
.	B-X

S	B-Species
.	I-Species
tuberosum	I-Species
cv	O
.	O
<EOS>	B-X
Evidence	B-X
for	B-X
Cardiac	B-X
Glycosides	B-X
in	B-X
Foliage	B-X
of	B-X
Colorado	B-X
Potato	B-X
Beetle-Resistant	B-X
Solanum	B-X
tuberosum	B-X
L.	B-X
cv	B-X
Jayoung	B-X
(	B-X
JY	B-X
)	B-X
is	B-X
a	B-X
potato	B-X
with	B-X
dark	B-X
purple	B-X
flesh	B-X
and	B-X
contains	B-X
substantial	B-X
amounts	B-X
of	B-X
polyphenols	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
therapeutic	B-X
effects	B-X
of	B-X
S.	B-X
tuberosum	B-X
L.	B-X
cv	B-X
JY	B-X
in	B-X
a	B-X
mouse	B-X
model	B-X
of	B-X
Dermatophagoides	B-X
farinae	B-X
body	B-X
(	B-X
Dfb	B-X
)	B-X
-induced	B-X
atopic	B-X
dermatitis	B-X
(	B-X
AD	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
four	B-X
new	B-X
full-length	B-X
cDNA	B-X
of	B-X
SADs	B-X
(	B-X
ScoSAD	B-X
,	B-X
SaSAD	B-X
,	B-X
ScaSAD	B-X
and	B-X
StSAD	B-X
)	B-X
were	B-X
cloned	B-X
from	B-X
four	B-X
Solanum	B-X
species	B-X
,	B-X
Solanum	B-X
commersonii	B-X
,	B-X
S.	B-X
acaule	B-X
,	B-X
S.	B-X
cardiophyllum	B-X
and	B-X
S.	B-X
tuberosum	B-X
,	B-X
respectively	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
sequence	B-X
alignments	B-X
between	B-X
StSAD	B-X
and	B-X
ScoSAD	B-X
indicated	B-X
that	B-X
only	B-X
7	B-X
different	B-X
amino	B-X
acids	B-X
at	B-X
residues	B-X
were	B-X
found	B-X
in	B-X
SAD	B-X
of	B-X
S.	B-X
tuberosum	B-X
(	B-X
Zhongshu8	B-X
)	B-X
against	B-X
the	B-X
protein	B-X
sequence	B-X
of	B-X
ScoSAD	B-X
.	B-X
A	B-X
phylogenetic	B-X
analysis	B-X
showed	B-X
the	B-X
three	B-X
wild	B-X
potato	B-X
species	B-X
had	B-X
the	B-X
closest	B-X
genetic	B-X
relationship	B-X
with	B-X
the	B-X
SAD	B-X
of	B-X
S.	B-X
lycopersicum	B-X
and	B-X
Nicotiana	B-X
tomentosiformis	B-X
but	B-X
not	B-X
S.	B-X
tuberosum	B-X
.	B-X
A	B-X
freeze	B-X
tolerance	B-X
analysis	B-X
showed	B-X
overexpression	B-X
of	B-X
the	B-X
ScoSAD	B-X
gene	B-X
in	B-X
transgenic	B-X
plants	B-X
significantly	B-X
enhanced	B-X
freeze	B-X
tolerance	B-X
in	B-X
cv	B-X
.	B-X

Rosevalt	O
tubers	O
and	O
T	B-Species
.	I-Species
aestivum	I-Species
var	I-Species
Fortal	I-Species
seeds	O
were	O
used	O
.	O

Potato	B-Species
mitochondria	O
were	O
prepared	O
from	O
2	O
kg	O
of	O
tubers	O
in	O
batches	O
of	O
200	O
g	O
with	O
200	O
ml	O
of	O
a	O
homogenization	O
buffer	O
containing	O
0	O
.	O
4	O
M	O
mannitol	O
,	O
25	O
mM	O
MOPS	O
(	O
pH	O
7	O
.	O
8	O
)	O
,	O
1	O
mM	O
EGTA	O
,	O
8	O
mM	O
cysteine	O
and	O
1	O
mg	O
/	O
ml	O
fatty	O
acid	O
-	O
free	O
BSA	O
.	O

Homogenization	O
was	O
carried	O
out	O
for	O
15	O
s	O
in	O
a	O
Waring	O
blendor	O
at	O
full	O
speed	O
.	O

Homogenate	O
was	O
centrifuged	O
in	O
a	O
Sorvall	O
GSA	O
rotor	O
at	O
1500	O
g	O
for	O
10	O
min	O
at	O
4	O
degrees	O
C	O
.	O

Supernatant	O
was	O
centrifuged	O
in	O
a	O
GSA	O
rotor	O
at	O
12	O
000	O
g	O
for	O
15	O
min	O
.	O

The	O
mitochondrial	O
pellet	O
was	O
resuspended	O
in	O
50	O
ml	O
of	O
homogenization	O
buffer	O
and	O
centrifuged	O
at	O
1500	O
g	O
.	O

The	O
supernatant	O
was	O
centrifuged	O
in	O
a	O
Sorvall	O
SS	O
-	O
34	O
rotor	O
at	O
15	O
000	O
g	O
for	O
10	O
min	O
,	O
the	O
pellet	O
was	O
resuspended	O
in	O
12	O
ml	O
of	O
homogenization	O
buffer	O
and	O
mitochondria	O
were	O
purified	O
by	O
centrifugation	O
on	O
a	O
sucrose	O
gradient	O
essentially	O
as	O
described	O
for	O
wheat	B-Species
embryo	O
mitochondria	O
(	O
14	O
)	O
.	O

Electroporation	O
<EOS>	B-X
Electroporation	B-X
is	B-X
a	B-X
process	B-X
in	B-X
which	B-X
brief	B-X
electrical	B-X
pulses	B-X
create	B-X
transient	B-X
pores	B-X
in	B-X
the	B-X
plasma	B-X
membrane	B-X
that	B-X
allow	B-X
nucleic	B-X
acids	B-X
to	B-X
enter	B-X
the	B-X
cellular	B-X
cytoplasm	B-X
.	B-X
Electroporation	B-X
can	B-X
be	B-X
reversible	B-X
and	B-X
is	B-X
used	B-X
in	B-X
gene	B-X
transfer	B-X
and	B-X
enhanced	B-X
drug	B-X
delivery	B-X
but	B-X
can	B-X
also	B-X
lead	B-X
to	B-X
cell	B-X
death	B-X
.	B-X
Electroporation	B-X
resulting	B-X
in	B-X
cell	B-X
death	B-X
(	B-X
termed	B-X
as	B-X
irreversible	B-X
electroporation	B-X
)	B-X
has	B-X
been	B-X
successfully	B-X
used	B-X
as	B-X
a	B-X
new	B-X
non-thermal	B-X
ablation	B-X
method	B-X
of	B-X
soft	B-X
tissue	B-X
such	B-X
as	B-X
tumours	B-X
or	B-X
arrhythmogenic	B-X
heart	B-X
tissue	B-X
.	B-X
Electroporation	B-X
is	B-X
a	B-X
method	B-X
to	B-X
permeabilise	B-X
cell	B-X
membranes	B-X
.	B-X

Electrotransfer	O
experiments	O
were	O
carried	O
out	O
with	O
1	O
mg	O
of	O
purified	O
wheat	B-Species
embryo	O
or	O
potato	B-Species
tuber	O
mitochondria	O
in	O
50	O
micro	O
l	O
of	O
0	O
.	O
33	O
M	O
sucrose	O
and	O
1	O
micro	O
g	O
of	O
recombinant	O
plasmid	O
as	O
described	O
(	O
14	O
)	O
.	O

The	O
electroporated	O
mitochondria	O
were	O
incubated	O
for	O
18	O
h	O
at	O
25	O
degrees	O
C	O
,	O
then	O
recovered	O
by	O
centrifugation	O
in	O
a	O
Sigma	O
N	O
degrees	O
12024	O
rotor	O
(	O
Sigma	O
1K15	O
refrigerated	O
centrifuge	O
)	O
at	O
15	O
000	O
g	O
for	O
15	O
min	O
at	O
4	O
degrees	O
C	O
.	O

In	O
the	O
case	O
of	O
potato	B-Species
mitochondria	O
the	O
incubation	O
mixture	O
was	O
supplemented	O
with	O
1	O
mg	O
/	O
ml	O
of	O
fatty	O
acid	O
-	O
free	O
BSA	O
.	O

RNA	O
was	O
purified	O
with	O
200	O
micro	O
l	O
of	O
TRIzol	O
(TM)	O
reagent	O
(	O
Gibco	O
-	O
BRL	O
)	O
according	O
to	O
the	O
supplier	O
'	O
s	O
protocol	O
.	O

DNAse	O
I	O
protection	O
assay	O
and	O
DNA	O
purification	O
<EOS>	B-X
MutS-DNA	B-X
interactions	B-X
and	B-X
DNase	B-X
protection	B-X
analysis	B-X
with	B-X
surface	B-X
plasmon	B-X
resonance	B-X
.	B-X
Several	B-X
basic	B-X
methods	B-X
for	B-X
Nrf2	B-X
evaluation	B-X
with	B-X
exposure	B-X
to	B-X
nanoparticles	B-X
are	B-X
described	B-X
in	B-X
this	B-X
chapter	B-X
including	B-X
real-time	B-X
reverse	B-X
transcription-polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT-PCR	B-X
)	B-X
,	B-X
western	B-X
blotting	B-X
,	B-X
immunofluorescence	B-X
staining	B-X
,	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
,	B-X
DNase	B-X
I	B-X
footprinting	B-X
,	B-X
dimethylsulfate	B-X
footprinting	B-X
,	B-X
protein	B-X
pulse-chase	B-X
analysis	B-X
,	B-X
and	B-X
tert-butylhydroquinone	B-X
treatment	B-X
.	B-X
Using	B-X
oligonucleotide	B-X
affinity	B-X
chromatography	B-X
with	B-X
DNase	B-X
I	B-X
footprinting	B-X
as	B-X
an	B-X
assay	B-X
we	B-X
have	B-X
looked	B-X
for	B-X
proteins	B-X
that	B-X
interact	B-X
with	B-X
sequence	B-X
elements	B-X
within	B-X
the	B-X
yeast	B-X
origin	B-X
of	B-X
replication	B-X
,	B-X
autonomously	B-X
replicating	B-X
sequence	B-X
1	B-X
(	B-X
ARS1	B-X
)	B-X
.	B-X
In	B-X
this	B-X
work	B-X
we	B-X
describe	B-X
a	B-X
protein	B-X
that	B-X
binds	B-X
with	B-X
high	B-X
affinity	B-X
to	B-X
DNA	B-X
but	B-X
displays	B-X
only	B-X
moderate	B-X
sequence	B-X
specificity	B-X
.	B-X
Footprinting	B-X
analysis	B-X
on	B-X
ARS1	B-X
at	B-X
a	B-X
high	B-X
protein	B-X
concentration	B-X
revealed	B-X
at	B-X
least	B-X
three	B-X
sites	B-X
of	B-X
protection	B-X
flanking	B-X
element	B-X
A	B-X
and	B-X
its	B-X
repeats	B-X
.	B-X
This	B-X
pattern	B-X
is	B-X
also	B-X
observed	B-X
for	B-X
the	B-X
H4	B-X
and	B-X
HMR-E	B-X
ARSs	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
protein	B-X
alters	B-X
the	B-X
DNA	B-X
conformation	B-X
at	B-X
element	B-X
A	B-X
and	B-X
its	B-X
repeats	B-X
.	B-X
Highly	B-X
purified	B-X
preparations	B-X
of	B-X
the	B-X
protein	B-X
are	B-X
enriched	B-X
in	B-X
an	B-X
18-kDa	B-X
polypeptide	B-X
which	B-X
can	B-X
be	B-X
renatured	B-X
from	B-X
a	B-X
denaturing	B-X
gel	B-X
and	B-X
shown	B-X
to	B-X
bind	B-X
ARS1	B-X
DNA	B-X
.	B-X
We	B-X
have	B-X
designated	B-X
this	B-X
protein	B-X
DBF-A	B-X
,	B-X
DNA-binding	B-X
factor	B-X
A	B-X
.	B-X

After	O
electroporation	O
and	O
centrifugation	O
,	O
the	O
mitochondrial	O
pellet	O
was	O
resuspended	O
in	O
100	O
micro	O
l	O
of	O
buffer	O
[	O
10	O
mM	O
Tris	O
-	O
HCl	O
(	O
pH	O
7	O
.	O
5	O
)	O
,	O
2	O
mM	O
magnesium	O
acetate	O
and	O
0	O
.	O
33	O
M	O
sucrose	O
]	O
containing	O
60	O
U	O
of	O
DNase	O
I	O
(	O
Gibco	O
-	O
BRL	O
)	O
and	O
incubated	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

The	O
DNase	O
reaction	O
was	O
stopped	O
by	O
adding	O
4	O
micro	O
l	O
of	O
0	O
.	O
5	O
M	O
EDTA	O
and	O
then	O
heating	O
for	O
10	O
min	O
at	O
65	O
degrees	O
C	O
.	O

Mitochondria	O
were	O
incubated	O
with	O
100	O
micro	O
g	O
of	O
Proteinase	O
K	O
(	O
Merck	O
)	O
for	O
4	O
h	O
at	O
37	O
degrees	O
C	O
.	O

One	O
microliter	O
of	O
20	O
%	O
SDS	O
was	O
added	O
to	O
achieve	O
mitochondrial	O
lysis	O
and	O
the	O
DNA	O
was	O
extracted	O
with	O
phenol	O
/	O
chloroform	O
,	O
precipitated	O
with	O
0	O
.	O
1	O
vol	O
of	O
3	O
M	O
Sodium	O
Acetate	O
(	O
pH	O
5	O
.	O
2	O
)	O
,	O
3	O
vol	O
of	O
100	O
%	O
ethanol	O
and	O
100	O
ng	O
of	O
carrier	O
yeast	B-Species
tRNA	O
and	O
left	O
overnight	O
at	O
-	O
20	O
degrees	O
C	O
.	O

After	O
centrifugation	O
,	O
the	O
DNA	O
pellet	O
was	O
resuspended	O
in	O
TE	O
buffer	O
[	O
10	O
mM	O
Tris	O
-	O
HCl	O
(	O
pH	O
8	O
)	O
and	O
1	O
mM	O
EDTA	O
]	O
.	O

RT	O
-	O
PCR	O
<EOS>	B-X
RT-PCR	B-X
is	B-X
commonly	B-X
used	B-X
to	B-X
test	B-X
for	B-X
genetic	B-X
diseases	B-X
and	B-X
to	B-X
characterize	B-X
gene	B-X
expression	B-X
in	B-X
various	B-X
tissue	B-X
types	B-X
,	B-X
cell	B-X
types	B-X
,	B-X
and	B-X
over	B-X
developmental	B-X
time	B-X
courses	B-X
.	B-X
RT-PCR	B-X
is	B-X
also	B-X
commonly	B-X
used	B-X
to	B-X
clone	B-X
cDNAs	B-X
for	B-X
further	B-X
use	B-X
with	B-X
other	B-X
molecular	B-X
biology	B-X
techniques	B-X
(	B-X
e.g.	B-X
,	B-X
see	B-X
Oligo	B-X
(	B-X
dT	B-X
)	B-X
-primed	B-X
RT-PCR	B-X
isolation	B-X
of	B-X
polyadenylated	B-X
RNA	B-X
degradation	B-X
intermediates	B-X
and	B-X
Circularized	B-X
RT-PCR	B-X
(	B-X
cRT-PCR	B-X
)	B-X
:	B-X
analysis	B-X
of	B-X
RNA	B-X
5	B-X
'	B-X
ends	B-X
,	B-X
3	B-X
'	B-X
ends	B-X
,	B-X
and	B-X
poly	B-X
(	B-X
A	B-X
)	B-X
tails	B-X
)	B-X
.	B-X
The	B-X
real-time	B-X
reverse	B-X
transcription	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT-PCR	B-X
)	B-X
uses	B-X
fluorescent	B-X
reporter	B-X
molecules	B-X
to	B-X
monitor	B-X
the	B-X
production	B-X
of	B-X
amplification	B-X
products	B-X
during	B-X
each	B-X
cycle	B-X
of	B-X
the	B-X
PCR	B-X
reaction	B-X
.	B-X
Its	B-X
simplicity	B-X
,	B-X
specificity	B-X
and	B-X
sensitivity	B-X
,	B-X
together	B-X
with	B-X
its	B-X
potential	B-X
for	B-X
high	B-X
throughput	B-X
and	B-X
the	B-X
ongoing	B-X
introduction	B-X
of	B-X
new	B-X
chemistries	B-X
,	B-X
more	B-X
reliable	B-X
instrumentation	B-X
and	B-X
improved	B-X
protocols	B-X
,	B-X
has	B-X
made	B-X
real-time	B-X
RT-PCR	B-X
the	B-X
benchmark	B-X
technology	B-X
for	B-X
the	B-X
detection	B-X
and/or	B-X
comparison	B-X
of	B-X
RNA	B-X
levels	B-X
.	B-X

RNA	O
(	O
1	O
micro	O
g	O
)	O
was	O
treated	O
with	O
2	O
U	O
of	O
Amplification	O
grade	O
DNase	O
I	O
(	O
Promega	O
)	O
.	O

cDNA	O
synthesis	O
was	O
performed	O
with	O
200	O
U	O
of	O
Superscript	O
II	O
RT	O
using	O
100	O
ng	O
of	O
random	O
hexamers	O
.	O

The	O
PCR	O
were	O
performed	O
with	O
primers	O
1a	O
and	O
1b	O
using	O
Advantage	O
(R)	O
2	O
Polymerase	O
Mix	O
(	O
Clontech	O
)	O
as	O
follows	O
:	O
95	O
degrees	O
C	O
,	O
1	O
min	O
;	O
5	O
cycles	O
at	O
95	O
degrees	O
C	O
for	O
30	O
s	O
and	O
68	O
degrees	O
C	O
for	O
1	O
min	O
;	O
30	O
cycles	O
at	O
95	O
degrees	O
C	O
for	O
30	O
s	O
,	O
58	O
degrees	O
C	O
for	O
30	O
s	O
and	O
68	O
degrees	O
C	O
for	O
30	O
s	O
,	O
and	O
finally	O
68	O
degrees	O
C	O
for	O
1	O
min	O
.	O

Primers	O
2a	O
and	O
2b	O
were	O
used	O
for	O
nested	O
PCR	O
from	O
1	O
micro	O
l	O
of	O
the	O
first	O
PCR	O
.	O

No	O
RT	O
-	O
PCR	O
amplification	O
products	O
were	O
obtained	O
with	O
RNA	O
from	O
non	O
-	O
electroporated	O
mitochondria	O
.	O

DNA	O
sequencing	O
<EOS>	B-X
Recent	B-X
scientific	B-X
discoveries	B-X
that	B-X
resulted	B-X
from	B-X
the	B-X
application	B-X
of	B-X
next-generation	B-X
DNA	B-X
sequencing	B-X
technologies	B-X
highlight	B-X
the	B-X
striking	B-X
impact	B-X
of	B-X
these	B-X
massively	B-X
parallel	B-X
platforms	B-X
on	B-X
genetics	B-X
.	B-X
These	B-X
new	B-X
methods	B-X
have	B-X
expanded	B-X
previously	B-X
focused	B-X
readouts	B-X
from	B-X
a	B-X
variety	B-X
of	B-X
DNA	B-X
preparation	B-X
protocols	B-X
to	B-X
a	B-X
genome-wide	B-X
scale	B-X
and	B-X
have	B-X
fine-tuned	B-X
their	B-X
resolution	B-X
to	B-X
single	B-X
base	B-X
precision	B-X
.	B-X
The	B-X
sequencing	B-X
of	B-X
RNA	B-X
also	B-X
has	B-X
transitioned	B-X
and	B-X
now	B-X
includes	B-X
full-length	B-X
cDNA	B-X
analyses	B-X
,	B-X
serial	B-X
analysis	B-X
of	B-X
gene	B-X
expression	B-X
(	B-X
SAGE	B-X
)	B-X
-based	B-X
methods	B-X
,	B-X
and	B-X
noncoding	B-X
RNA	B-X
discovery	B-X
.	B-X
Next-generation	B-X
sequencing	B-X
has	B-X
also	B-X
enabled	B-X
novel	B-X
applications	B-X
such	B-X
as	B-X
the	B-X
sequencing	B-X
of	B-X
ancient	B-X
DNA	B-X
samples	B-X
,	B-X
and	B-X
has	B-X
substantially	B-X
widened	B-X
the	B-X
scope	B-X
of	B-X
metagenomic	B-X
analysis	B-X
of	B-X
environmentally	B-X
derived	B-X
samples	B-X
.	B-X

Sequence	O
analyses	O
were	O
performed	O
directly	O
on	O
the	O
RT	O
-	O
PCR	O
product	O
using	O
an	O
automatic	O
DNA	O
sequencing	O
equipment	O
with	O
the	O
BigDye	O
(R)	O
Terminator	O
Cycle	O
Sequencing	O
Kit	O
(	O
Applied	O
Biosystem	O
)	O
.	O

RESULTS	O

S	B-Species
.	I-Species
tuberosum	I-Species
rps10	O
transcripts	O
are	O
not	O
processed	O
in	O
wheat	B-Species
mitochondria	O

The	O
S	B-Species
.	I-Species
tuberosum	I-Species
rps10	O
construct	O
under	O
control	O
of	O
a	O
wheat	B-Species
cox2	O
promoter	O
(	O
Figure	O
1A	O
)	O
was	O
incorporated	O
into	O
purified	O
wheat	B-Species
mitochondria	O
by	O
electroporation	O
as	O
indicated	O
in	O
Materials	O
and	O
Methods	O
.	O

After	O
electroporation	O
and	O
incubation	O
in	O
expression	O
medium	O
,	O
mitochondrial	O
RNA	O
was	O
extracted	O
and	O
analysed	O
by	O
RT	O
-	O
PCR	O
.	O

The	O
primers	O
used	O
allowed	O
detection	O
of	O
the	O
transcripts	O
generated	O
by	O
the	O
constructs	O
introduced	O
and	O
excluded	O
any	O
product	O
from	O
endogenous	O
cox2	O
(	O
or	O
rps10	O
in	O
the	O
potato	B-Species
system	O
)	O
.	O

Two	O
bands	O
of	O
1204	O
and	O
427	O
bp	O
were	O
expected	O
from	O
precursor	O
and	O
mature	O
rps10	O
mRNAs	O
,	O
respectively	O
.	O

Only	O
precursor	O
rps10	O
molecules	O
were	O
detected	O
(	O
Figure	O
1B	O
)	O
.	O

As	O
a	O
control	O
,	O
a	O
cognate	O
cox2	O
construct	O
(	O
16	O
)	O
was	O
used	O
.	O

In	O
this	O
case	O
,	O
the	O
2048	O
and	O
827	O
bp	O
RT	O
-	O
PCR	O
bands	O
representing	O
the	O
precursor	O
and	O
spliced	O
cox2	O
products	O
,	O
respectively	O
were	O
observed	O
(	O
Figure	O
1B	O
)	O
.	O

In	O
all	O
cases	O
,	O
the	O
PCR	O
bands	O
actually	O
represent	O
transcription	O
products	O
since	O
when	O
PCR	O
was	O
performed	O
without	O
the	O
RT	O
step	O
we	O
observed	O
no	O
amplification	O
products	O
.	O

Previously	O
,	O
five	O
C	O
residues	O
,	O
two	O
in	O
exon	O
1	O
,	O
one	O
in	O
the	O
intron	O
and	O
two	O
in	O
exon	O
2	O
have	O
been	O
reported	O
to	O
be	O
changed	O
to	O
U	O
by	O
editing	O
in	O
potato	B-Species
mitochondria	O
(	O
23	O
)	O
.	O

To	O
determine	O
if	O
the	O
non	O
-	O
cognate	O
transcript	O
could	O
be	O
recognized	O
by	O
the	O
wheat	B-Species
RNA	O
editing	O
machinery	O
,	O
the	O
1204	O
bp	O
RT	O
-	O
PCR	O
product	O
was	O
sequenced	O
.	O

While	O
wheat	B-Species
cox2	O
editing	O
sites	O
were	O
correctly	O
edited	O
in	O
control	O
as	O
expected	O
(	O
Figure	O
1C	O
,	O
only	O
site	O
C77	O
is	O
shown	O
)	O
,	O
all	O
five	O
editable	O
residues	O
in	O
potato	B-Species
rps10	O
transcript	O
remain	O
unchanged	O
.	O

cox2	O
C77	O
editing	O
sites	O
are	O
identical	O
in	O
potato	B-Species
and	O
wheat	B-Species
.	O

Failure	O
of	O
rps10	O
transcript	O
splicing	O
in	O
wheat	B-Species
mitochondria	O
is	O
not	O
linked	O
to	O
the	O
absence	O
of	O
editing	O

It	O
has	O
been	O
suggested	O
that	O
residues	O
C2	O
and	O
C3	O
participate	O
in	O
the	O
secondary	O
structure	O
of	O
the	O
intron	O
necessary	O
for	O
splicing	O
(	O
23	O
)	O
.	O

A	O
possible	O
explanation	O
to	O
the	O
failure	O
observed	O
in	O
precursor	O
rps10	O
splicing	O
could	O
be	O
that	O
the	O
absence	O
of	O
edition	O
of	O
C2	O
and	O
C3	O
prevent	O
the	O
intron	O
from	O
organizing	O
itself	O
in	O
a	O
catalytically	O
competent	O
conformation	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
single	O
C2	O
and	O
C3	O
mutants	O
and	O
a	O
C2	O
+	O
C3	O
double	O
mutant	O
were	O
constructed	O
by	O
changing	O
the	O
C	O
residues	O
to	O
T	O
.	O

Neither	O
single	O
nor	O
double	O
mutants	O
were	O
able	O
to	O
undergo	O
splicing	O
(	O
Figure	O
2	O
)	O
.	O

Electroporation	O
of	O
S	B-Species
.	I-Species
tuberosum	I-Species
mitochondria	O

Since	O
two	O
important	O
post	O
-	O
transcriptional	O
processes	O
,	O
RNA	O
editing	O
and	O
splicing	O
,	O
were	O
inoperative	O
when	O
S	B-Species
.	I-Species
tuberosum	I-Species
rps10	O
was	O
expressed	O
in	O
wheat	B-Species
mitochondria	O
,	O
we	O
decided	O
to	O
verify	O
whether	O
the	O
negative	O
results	O
were	O
inherent	O
to	O
the	O
rps10	O
chimeric	O
constructs	O
or	O
due	O
to	O
the	O
lack	O
of	O
trans	O
-	O
recognition	O
elements	O
in	O
wheat	B-Species
mitochondria	O
.	O

For	O
this	O
purpose	O
,	O
it	O
was	O
necessary	O
to	O
set	O
up	O
an	O
electroporation	O
protocol	O
adapted	O
to	O
S	B-Species
.	I-Species
tuberosum	I-Species
mitochondria	O
.	O

Purified	O
organelles	O
were	O
prepared	O
from	O
potato	B-Species
tubers	O
as	O
indicated	O
in	O
Materials	O
and	O
Methods	O
.	O

Electric	O
pulses	O
in	O
the	O
range	O
between	O
8	O
and	O
20	O
kV	O
were	O
performed	O
.	O
<EOS>	B-X
However	B-X
,	B-X
electrochemotherapy	B-X
is	B-X
associated	B-X
with	B-X
microsecond	B-X
range	B-X
of	B-X
electrical	B-X
pulses	B-X
,	B-X
while	B-X
nanosecond	B-X
range	B-X
electrochemotherapy	B-X
is	B-X
almost	B-X
non-existent	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
feasibility	B-X
of	B-X
nanosecond	B-X
range	B-X
pulse	B-X
bursts	B-X
for	B-X
successful	B-X
doxorubicin-based	B-X
electrochemotherapy	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
conventional	B-X
microsecond	B-X
(	B-X
1.4	B-X
kV/cm	B-X
Ã	B-X
100	B-X
Âµs	B-X
Ã	B-X
8	B-X
)	B-X
procedure	B-X
was	B-X
compared	B-X
to	B-X
the	B-X
nanosecond	B-X
(	B-X
3.5	B-X
kV/cm	B-X
Ã	B-X
800	B-X
ns	B-X
Ã	B-X
250	B-X
)	B-X
non-thermal	B-X
PEF-based	B-X
treatment	B-X
.	B-X
Additionally	B-X
,	B-X
basic	B-X
current	B-X
and	B-X
voltage	B-X
measurements	B-X
were	B-X
performed	B-X
to	B-X
detect	B-X
the	B-X
characteristic	B-X
conductivity-dependent	B-X
patterns	B-X
and	B-X
to	B-X
serve	B-X
as	B-X
an	B-X
indicator	B-X
of	B-X
successful	B-X
tumor	B-X
permeabilization	B-X
both	B-X
in	B-X
the	B-X
nano	B-X
and	B-X
microsecond	B-X
pulse	B-X
range	B-X
.	B-X

Internalization	O
of	O
exogenous	O
DNA	O
was	O
measured	O
by	O
DNAse	O
protection	O
assays	O
(	O
14	O
)	O
.	O

Potato	B-Species
mitochondria	O
show	O
a	O
broad	O
range	O
response	O
with	O
a	O
maximum	O
around	O
13	O
kV	O
(	O
Figure	O
3	O
)	O
.	O

This	O
voltage	O
setting	O
was	O
therefore	O
used	O
for	O
further	O
experiments	O
.	O
<EOS>	B-X
With	B-X
the	B-X
recent	B-X
increase	B-X
in	B-X
the	B-X
use	B-X
of	B-X
augmented	B-X
reality	B-X
(	B-X
AR	B-X
)	B-X
in	B-X
educational	B-X
laboratory	B-X
settings	B-X
,	B-X
there	B-X
is	B-X
a	B-X
need	B-X
for	B-X
new	B-X
intelligent	B-X
sensor	B-X
systems	B-X
capturing	B-X
all	B-X
aspects	B-X
of	B-X
the	B-X
real	B-X
environment	B-X
.	B-X
We	B-X
present	B-X
a	B-X
smart	B-X
sensor	B-X
system	B-X
meeting	B-X
these	B-X
requirements	B-X
for	B-X
STEM	B-X
(	B-X
science	B-X
,	B-X
technology	B-X
,	B-X
engineering	B-X
,	B-X
and	B-X
mathematics	B-X
)	B-X
experiments	B-X
in	B-X
electrical	B-X
circuits	B-X
.	B-X
The	B-X
boxes	B-X
combine	B-X
sensors	B-X
for	B-X
measuring	B-X
the	B-X
electrical	B-X
voltage	B-X
and	B-X
current	B-X
at	B-X
the	B-X
integrated	B-X
electrical	B-X
components	B-X
as	B-X
well	B-X
as	B-X
a	B-X
reconstruction	B-X
of	B-X
the	B-X
currently	B-X
constructed	B-X
electrical	B-X
circuit	B-X
and	B-X
the	B-X
position	B-X
of	B-X
the	B-X
sensor	B-X
box	B-X
on	B-X
a	B-X
table	B-X
.	B-X
One	B-X
of	B-X
the	B-X
industrial	B-X
products	B-X
is	B-X
also	B-X
optical	B-X
devices	B-X
used	B-X
for	B-X
testing	B-X
cars	B-X
.	B-X
For	B-X
this	B-X
reason	B-X
,	B-X
this	B-X
study	B-X
was	B-X
performed	B-X
,	B-X
which	B-X
focused	B-X
on	B-X
the	B-X
production	B-X
of	B-X
a	B-X
precise	B-X
slot	B-X
measuring	B-X
5000	B-X
Ã	B-X
170	B-X
Âµm	B-X
in	B-X
a	B-X
copper	B-X
foil	B-X
with	B-X
a	B-X
thickness	B-X
of	B-X
125	B-X
Âµm	B-X
.	B-X
The	B-X
same	B-X
copper	B-X
foil	B-X
was	B-X
used	B-X
as	B-X
a	B-X
tool	B-X
,	B-X
which	B-X
represents	B-X
an	B-X
advance	B-X
in	B-X
the	B-X
production	B-X
of	B-X
micro-parts.The	B-X
use	B-X
of	B-X
the	B-X
same	B-X
semi-product	B-X
for	B-X
the	B-X
production	B-X
of	B-X
the	B-X
slit	B-X
as	B-X
well	B-X
as	B-X
the	B-X
tool	B-X
itself	B-X
has	B-X
not	B-X
yet	B-X
been	B-X
presented	B-X
in	B-X
any	B-X
similar	B-X
study	B-X
.	B-X
A	B-X
design	B-X
of	B-X
experiment	B-X
Box	B-X
and	B-X
Behnken	B-X
Response	B-X
Surface	B-X
Design	B-X
was	B-X
performed	B-X
for	B-X
a	B-X
total	B-X
of	B-X
15	B-X
rounds	B-X
,	B-X
monitoring	B-X
the	B-X
effect	B-X
of	B-X
machine	B-X
setting	B-X
parameters	B-X
(	B-X
Pulse	B-X
current	B-X
,	B-X
Pulse	B-X
on	B-X
time	B-X
and	B-X
Voltage	B-X
)	B-X
on	B-X
responses	B-X
in	B-X
the	B-X
form	B-X
of	B-X
Erosion	B-X
rate	B-X
,	B-X
corner	B-X
radius	B-X
,	B-X
slot	B-X
length	B-X
and	B-X
width	B-X
.	B-X
Using	B-X
multi-criteria	B-X
optimization	B-X
,	B-X
the	B-X
optimal	B-X
setting	B-X
of	B-X
the	B-X
machine	B-X
parameters	B-X
for	B-X
the	B-X
production	B-X
of	B-X
a	B-X
given	B-X
slit	B-X
was	B-X
determined	B-X
,	B-X
which	B-X
is	B-X
Pulse	B-X
current	B-X
=	B-X
2.1	B-X
A	B-X
,	B-X
Pulse	B-X
on	B-X
time	B-X
=	B-X
40	B-X
Âµs	B-X
and	B-X
Voltage	B-X
=	B-X
238.8	B-X
V.	B-X
Micro-EDM	B-X
technology	B-X
has	B-X
been	B-X
found	B-X
to	B-X
be	B-X
suitable	B-X
for	B-X
the	B-X
production	B-X
of	B-X
miniaturized	B-X
slits	B-X
.	B-X

S	B-Species
.	I-Species
tuberosum	I-Species
mitochondria	O
does	O
not	O
recognize	O
the	O
wheat	B-Species
cox2	O
promoter	O
<EOS>	B-X
Pesticides	B-X
can	B-X
seriously	B-X
affect	B-X
the	B-X
respiratory	B-X
chain	B-X
of	B-X
the	B-X
mitochondria	B-X
of	B-X
many	B-X
crops	B-X
,	B-X
reducing	B-X
the	B-X
intensity	B-X
of	B-X
plant	B-X
growth	B-X
and	B-X
its	B-X
yield	B-X
.	B-X
Studying	B-X
the	B-X
effect	B-X
of	B-X
pesticides	B-X
on	B-X
the	B-X
bioenergetic	B-X
parameters	B-X
of	B-X
intact	B-X
plant	B-X
mitochondria	B-X
is	B-X
a	B-X
promising	B-X
approach	B-X
for	B-X
assessing	B-X
their	B-X
toxicity	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
some	B-X
pesticides	B-X
on	B-X
isolated	B-X
potato	B-X
mitochondria	B-X
,	B-X
which	B-X
used	B-X
exogenous	B-X
NADH	B-X
as	B-X
a	B-X
substrate	B-X
for	B-X
respiration	B-X
.	B-X
We	B-X
showed	B-X
that	B-X
succinate	B-X
is	B-X
the	B-X
most	B-X
preferred	B-X
substrate	B-X
for	B-X
phosphorylating	B-X
respiration	B-X
of	B-X
intact	B-X
potato	B-X
tubers	B-X
mitochondria	B-X
.	B-X
Potato	B-X
mitochondria	B-X
poorly	B-X
oxidize	B-X
exogenous	B-X
NADH	B-X
,	B-X
despite	B-X
of	B-X
the	B-X
presence	B-X
of	B-X
external	B-X
NADH	B-X
dehydrogenases	B-X
.	B-X
Permeabilization	B-X
of	B-X
the	B-X
mitochondrial	B-X
membrane	B-X
with	B-X
alamethicin	B-X
increased	B-X
the	B-X
availability	B-X
of	B-X
exogenous	B-X
NADH	B-X
to	B-X
complex	B-X
I	B-X
.	B-X
However	B-X
,	B-X
the	B-X
pathway	B-X
of	B-X
electrons	B-X
through	B-X
complex	B-X
I	B-X
to	B-X
complex	B-X
IV	B-X
makes	B-X
intact	B-X
potato	B-X
mitochondria	B-X
susceptible	B-X
to	B-X
a	B-X
number	B-X
of	B-X
pesticides	B-X
such	B-X
as	B-X
difenoconazole	B-X
,	B-X
fenazaquin	B-X
,	B-X
pyridaben	B-X
and	B-X
tolfenpyrad	B-X
,	B-X
which	B-X
strongly	B-X
inhibit	B-X
the	B-X
rate	B-X
of	B-X
mitochondrial	B-X
respiration	B-X
.	B-X
Dithianon	B-X
,	B-X
the	B-X
inhibitor	B-X
of	B-X
Complex	B-X
II	B-X
,	B-X
is	B-X
the	B-X
only	B-X
pesticide	B-X
which	B-X
significantly	B-X
increased	B-X
the	B-X
respiratory	B-X
rate	B-X
of	B-X
NADH-supported	B-X
respiration	B-X
of	B-X
permeabilized	B-X
mitochondria	B-X
of	B-X
potato	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
can	B-X
be	B-X
assumed	B-X
that	B-X
the	B-X
alternative	B-X
NADH	B-X
dehydrogenases	B-X
for	B-X
electron	B-X
flow	B-X
represent	B-X
a	B-X
factor	B-X
responsible	B-X
for	B-X
plant	B-X
resistance	B-X
to	B-X
xenobiotics	B-X
,	B-X
such	B-X
as	B-X
mitochondria-targeted	B-X
pesticides	B-X
.	B-X

To	O
ascertain	O
the	O
ability	O
of	O
electroporated	O
mitochondria	O
to	O
perform	O
expression	O
of	O
the	O
exogenous	O
gene	O
construct	O
,	O
we	O
used	O
a	O
plasmid	O
containing	O
the	O
potato	B-Species
cox2	O
gene	O
controlled	O
either	O
by	O
T	B-Species
.	I-Species
aestivum	I-Species
or	O
S	B-Species
.	I-Species
tuberosum	I-Species
promoters	O
.	O
<EOS>	B-X
GIGANTEA	B-X
(	B-X
GI	B-X
)	B-X
genes	B-X
are	B-X
ubiquitous	B-X
in	B-X
the	B-X
plant	B-X
kingdom	B-X
and	B-X
are	B-X
involved	B-X
in	B-X
diverse	B-X
processes	B-X
from	B-X
flowering	B-X
during	B-X
stress	B-X
responses	B-X
to	B-X
tuberization	B-X
;	B-X
the	B-X
latter	B-X
occurs	B-X
in	B-X
potato	B-X
(	B-X
Solanum	B-X
tuberosum	B-X
L.	B-X
)	B-X
.	B-X
GI	B-X
genes	B-X
have	B-X
a	B-X
diurnal	B-X
cycle	B-X
of	B-X
expression	B-X
;	B-X
however	B-X
,	B-X
no	B-X
details	B-X
on	B-X
the	B-X
regulation	B-X
of	B-X
GI	B-X
gene	B-X
expression	B-X
in	B-X
potato	B-X
have	B-X
been	B-X
reported	B-X
thus	B-X
far	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
our	B-X
work	B-X
was	B-X
the	B-X
analysis	B-X
of	B-X
the	B-X
GI	B-X
promoter	B-X
sequence	B-X
and	B-X
studying	B-X
GI	B-X
expression	B-X
in	B-X
different	B-X
organs	B-X
and	B-X
under	B-X
abiotic	B-X
stress	B-X
conditions	B-X
in	B-X
potato	B-X
.	B-X
Two	B-X
GI	B-X
genes	B-X
homologous	B-X
to	B-X
Arabidopsis	B-X
GI	B-X
located	B-X
on	B-X
chromosomes	B-X
4	B-X
and	B-X
12	B-X
(	B-X
StGI.04	B-X
and	B-X
StGI.12	B-X
)	B-X
were	B-X
identified	B-X
in	B-X
the	B-X
genome-sequenced	B-X
potato	B-X
S.	B-X
phureja	B-X
.	B-X
The	B-X
GI	B-X
promoter	B-X
regions	B-X
of	B-X
the	B-X
commercial	B-X
potato	B-X
cultivar	B-X
'DÃ©sirÃ©e	B-X
'	B-X
were	B-X
cloned	B-X
and	B-X
found	B-X
to	B-X
be	B-X
almost	B-X
identical	B-X
to	B-X
the	B-X
S.	B-X
phureja	B-X
GI	B-X
promoter	B-X
sequence	B-X
.	B-X
More	B-X
than	B-X
ten	B-X
TF	B-X
families	B-X
binding	B-X
to	B-X
the	B-X
GI	B-X
promoters	B-X
were	B-X
predicted	B-X
.	B-X
EVENING	B-X
ELEMENT	B-X
and	B-X
ABSCISIC	B-X
ACID	B-X
RESPONSE	B-X
ELEMENT	B-X
LIKE	B-X
elements	B-X
related	B-X
to	B-X
circadian	B-X
regulation	B-X
and	B-X
a	B-X
binding	B-X
site	B-X
for	B-X
POTATO	B-X
HOMEOBOX	B-X
20	B-X
presumably	B-X
involved	B-X
in	B-X
tuber	B-X
initiation	B-X
were	B-X
detected	B-X
in	B-X
both	B-X
GI	B-X
promoters	B-X
.	B-X
However	B-X
,	B-X
the	B-X
locations	B-X
of	B-X
these	B-X
elements	B-X
and	B-X
several	B-X
other	B-X
cis-acting	B-X
regulatory	B-X
elements	B-X
as	B-X
well	B-X
as	B-X
the	B-X
organ-specific	B-X
expression	B-X
and	B-X
responses	B-X
of	B-X
the	B-X
genes	B-X
to	B-X
abiotic	B-X
stresses	B-X
and	B-X
abscisic	B-X
acid	B-X
were	B-X
different	B-X
.	B-X
This	B-X
study	B-X
lays	B-X
foundation	B-X
for	B-X
further	B-X
investigation	B-X
of	B-X
the	B-X
roles	B-X
of	B-X
GI	B-X
genes	B-X
in	B-X
potato	B-X
.	B-X

As	O
shown	O
in	O
Figure	O
4	O
,	O
the	O
construct	O
containing	O
the	O
wheat	B-Species
or	O
potato	B-Species
promoters	O
was	O
transcribed	O
only	O
in	O
cognate	O
mitochondria	O
.	O
<EOS>	B-X
The	B-X
complex	B-X
gene	B-X
expression	B-X
mechanisms	B-X
that	B-X
occur	B-X
in	B-X
plant	B-X
mitochondria	B-X
,	B-X
such	B-X
as	B-X
RNA	B-X
editing	B-X
and	B-X
splicing	B-X
,	B-X
are	B-X
not	B-X
yet	B-X
well	B-X
understood	B-X
.	B-X
RNA	B-X
editing	B-X
in	B-X
higher	B-X
plant	B-X
mitochondria	B-X
is	B-X
a	B-X
highly	B-X
specific	B-X
process	B-X
which	B-X
modifies	B-X
mRNA	B-X
sequences	B-X
by	B-X
C-to-U	B-X
conversions	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
use	B-X
an	B-X
experimental	B-X
model	B-X
based	B-X
on	B-X
the	B-X
introduction	B-X
of	B-X
DNA	B-X
into	B-X
isolated	B-X
mitochondria	B-X
by	B-X
electroporation	B-X
to	B-X
study	B-X
organellar	B-X
gene	B-X
expression	B-X
events	B-X
.	B-X
Our	B-X
aim	B-X
was	B-X
to	B-X
compare	B-X
processing	B-X
and	B-X
editing	B-X
of	B-X
potato	B-X
small	B-X
ribosomal	B-X
protein	B-X
10	B-X
gene	B-X
(	B-X
rps10	B-X
)	B-X
transcripts	B-X
in	B-X
heterologous	B-X
(	B-X
wheat	B-X
mitochondria	B-X
)	B-X
and	B-X
homologous	B-X
(	B-X
potato	B-X
mitochondria	B-X
)	B-X
contexts	B-X
.	B-X
rps10	B-X
is	B-X
a	B-X
suitable	B-X
model	B-X
because	B-X
it	B-X
contains	B-X
a	B-X
group	B-X
II	B-X
intron	B-X
,	B-X
is	B-X
absent	B-X
in	B-X
wheat	B-X
mitochondria	B-X
but	B-X
is	B-X
actively	B-X
expressed	B-X
in	B-X
potato	B-X
mitochondria	B-X
,	B-X
where	B-X
transcripts	B-X
are	B-X
spliced	B-X
and	B-X
undergo	B-X
five	B-X
C-to-U	B-X
editing	B-X
events	B-X
.	B-X
For	B-X
this	B-X
purpose	B-X
,	B-X
conditions	B-X
for	B-X
electroporating	B-X
isolated	B-X
potato	B-X
mitochondria	B-X
were	B-X
established	B-X
.	B-X
rps10	B-X
was	B-X
placed	B-X
under	B-X
the	B-X
control	B-X
of	B-X
either	B-X
potato	B-X
or	B-X
wheat	B-X
cox2	B-X
promoters	B-X
.	B-X
We	B-X
found	B-X
that	B-X
rps10	B-X
was	B-X
only	B-X
transcribed	B-X
under	B-X
the	B-X
control	B-X
of	B-X
a	B-X
cognate	B-X
promoter	B-X
.	B-X
In	B-X
wheat	B-X
mitochondria	B-X
,	B-X
rps10	B-X
transcripts	B-X
were	B-X
neither	B-X
spliced	B-X
nor	B-X
edited	B-X
while	B-X
they	B-X
are	B-X
correctly	B-X
processed	B-X
in	B-X
potato	B-X
mitochondria	B-X
.	B-X
Interestingly	B-X
,	B-X
a	B-X
wheat	B-X
editing	B-X
site	B-X
grafted	B-X
into	B-X
rps10	B-X
was	B-X
not	B-X
recognized	B-X
by	B-X
wheat	B-X
mitochondria	B-X
but	B-X
was	B-X
correctly	B-X
edited	B-X
in	B-X
potato	B-X
mitochondria	B-X
.	B-X

In	O
potato	B-Species
,	O
the	O
mature	O
product	O
is	O
barely	O
detectable	O
.	O

In	O
contrast	O
to	O
wheat	B-Species
mitochondria	O
,	O
the	O
821	O
nt	O
mature	O
transcript	O
was	O
only	O
detected	O
when	O
the	O
electroporated	O
potato	B-Species
mitochondria	O
were	O
incubated	O
in	O
the	O
presence	O
of	O
fatty	O
acid	O
-	O
free	O
BSA	O
.	O

A	O
cognate	O
rps10	O
construct	O
is	O
correctly	O
expressed	O
,	O
edited	O
and	O
processed	O
in	O
potato	B-Species
mitochondria	O

The	O
construct	O
expressing	O
potato	B-Species
rps10	O
under	O
the	O
control	O
of	O
potato	B-Species
cox2	O
promoter	O
was	O
introduced	O
into	O
S	B-Species
.	I-Species
tuberosum	I-Species
isolated	O
mitochondria	O
.	O

After	O
incubation	O
,	O
the	O
precursor	O
and	O
mature	O
transcripts	O
were	O
amplified	O
by	O
RT	O
-	O
PCR	O
(	O
Figure	O
5A	O
)	O
and	O
sequenced	O
.	O

As	O
shown	O
in	O
Figure	O
5B	O
,	O
the	O
four	O
editing	O
sites	O
C1	O
,	O
C2	O
,	O
C4	O
and	O
C5	O
,	O
described	O
previously	O
in	O
endogenous	O
transcripts	O
,	O
were	O
found	O
edited	O
in	O
mature	O
mRNA	O
.	O

The	O
presence	O
of	O
spliced	O
molecules	O
containing	O
unedited	O
residues	O
(	O
Figure	O
5B	O
)	O
indicates	O
that	O
rps10	O
transcripts	O
could	O
be	O
spliced	O
before	O
editing	O
.	O

To	O
confirm	O
this	O
observation	O
,	O
the	O
PCR	O
product	O
was	O
cloned	O
and	O
sequenced	O
.	O
<EOS>	B-X
Therefore	B-X
,	B-X
the	B-X
nested	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
for	B-X
target	B-X
region	B-X
of	B-X
GGTA1	B-X
was	B-X
performed	B-X
.	B-X
Next	B-X
,	B-X
the	B-X
PCR	B-X
products	B-X
from	B-X
each	B-X
group	B-X
were	B-X
checked	B-X
in	B-X
blotting	B-X
,	B-X
and	B-X
the	B-X
products	B-X
were	B-X
placed	B-X
into	B-X
the	B-X
cloning	B-X
sit	B-X
of	B-X
TOPO	B-X
vector	B-X
and	B-X
transformed	B-X
into	B-X
Escherichia	B-X
coli	B-X
.	B-X
Sixteen	B-X
colonies	B-X
of	B-X
each	B-X
group	B-X
were	B-X
checked	B-X
by	B-X
PCR	B-X
,	B-X
and	B-X
clones	B-X
containing	B-X
PCR	B-X
product	B-X
with	B-X
slightly	B-X
varying	B-X
length	B-X
were	B-X
evaluated	B-X
.	B-X
The	B-X
direct	B-X
sequence	B-X
of	B-X
these	B-X
PCR	B-X
changes	B-X
were	B-X
demonstrated	B-X
as	B-X
294	B-X
to	B-X
754	B-X
bp	B-X
deletions	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
we	B-X
confirmed	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
CRISPR/Cas3	B-X
system	B-X
on	B-X
pig	B-X
cell	B-X
,	B-X
especially	B-X
in	B-X
xenotransplantation	B-X
.	B-X

One	O
half	O
of	O
the	O
individual	O
clones	O
were	O
found	O
edited	O
at	O
sites	O
C1	O
and	O
C2	O
;	O
65	O
%	O
were	O
edited	O
at	O
site	O
C4	O
and	O
25	O
%	O
were	O
edited	O
at	O
site	O
C5	O
.	O

A	O
cognate	O
editing	O
site	O
in	O
a	O
non	O
-	O
native	O
context	O
is	O
not	O
recognized	O
by	O
wheat	B-Species
mitochondria	O
but	O
is	O
recognized	O
in	O
heterologous	O
mitochondria	O

To	O
test	O
whether	O
wheat	B-Species
mitochondria	O
are	O
able	O
to	O
edit	O
a	O
cognate	O
site	O
when	O
placed	O
in	O
the	O
context	O
of	O
a	O
potato	B-Species
transcript	O
,	O
we	O
introduced	O
the	O
C259	O
-	O
16	O
/	O
+	O
6	O
region	O
from	O
wheat	B-Species
cox2	O
into	O
potato	B-Species
rps10	O
exon	O
1	O
or	O
intron	O
(	O
Figure	O
6A	O
,	O
construct	O
MA	O
and	O
ME6	O
,	O
respectively	O
)	O
.	O

As	O
reported	O
previously	O
,	O
the	O
23	O
nt	O
region	O
forming	O
the	O
C259	O
editing	O
site	O
from	O
wheat	B-Species
cox2	O
was	O
efficiently	O
edited	O
when	O
grafted	O
into	O
a	O
different	O
context	O
in	O
a	O
wheat	B-Species
transcript	O
(	O
17	O
)	O
.	O

Wild	O
-	O
type	O
rps10	O
(	O
pRPS10W	O
)	O
and	O
the	O
MA	O
and	O
ME6	O
mutants	O
were	O
expressed	O
in	O
wheat	B-Species
mitochondria	O
but	O
no	O
splicing	O
was	O
observed	O
(	O
Figure	O
6B	O
)	O
.	O

Unexpectedly	O
,	O
wheat	B-Species
mitochondria	O
appear	O
to	O
be	O
unable	O
to	O
edit	O
the	O
cognate	O
C259	O
site	O
when	O
the	O
-	O
16	O
/	O
+	O
6	O
region	O
is	O
located	O
on	O
a	O
potato	B-Species
rps10	O
precursor	O
.	O

The	O
control	O
CM	O
construct	O
,	O
containing	O
the	O
C259	O
site	O
grafted	O
in	O
a	O
different	O
context	O
but	O
in	O
its	O
own	O
cox2	O
gene	O
,	O
was	O
expressed	O
,	O
spliced	O
and	O
edited	O
as	O
expected	O
[	O
(	O
17	O
)	O
,	O
Figure	O
6B	O
and	O
D	O
]	O
.	O

To	O
compare	O
the	O
editing	O
status	O
of	O
RNAs	O
at	O
the	O
same	O
stage	O
of	O
processing	O
,	O
the	O
editing	O
status	O
of	O
the	O
inserted	O
C259	O
site	O
in	O
precursor	O
cox2	O
transcripts	O
is	O
shown	O
(	O
Figure	O
6D	O
)	O
.	O

The	O
analogous	O
MAb	O
and	O
ME6b	O
constructs	O
,	O
containing	O
the	O
S	B-Species
.	I-Species
tuberosum	I-Species
cox2	O
promoter	O
and	O
the	O
C259	O
region	O
inserted	O
into	O
rps10	O
exon	O
1	O
and	O
intron	O
were	O
used	O
to	O
electroporate	O
potato	B-Species
mitochondria	O
.	O

As	O
shown	O
in	O
Figure	O
6C	O
,	O
MAb	O
and	O
ME6b	O
were	O
expressed	O
and	O
spliced	O
at	O
the	O
same	O
level	O
as	O
the	O
control	O
in	O
the	O
homologous	O
context	O
,	O
indicating	O
that	O
insertion	O
does	O
not	O
affect	O
the	O
splicing	O
process	O
.	O

Interestingly	O
,	O
while	O
C259	O
insertion	O
was	O
not	O
recognized	O
in	O
wheat	B-Species
mitochondria	O
(	O
Figure	O
6D	O
)	O
,	O
the	O
potato	B-Species
RNA	O
editing	O
machinery	O
edited	O
the	O
inserted	O
C259	O
region	O
(	O
Figure	O
6E	O
)	O
.	O

The	O
C259	O
region	O
inserted	O
in	O
the	O
rps10	O
intron	O
(	O
construct	O
ME6b	O
)	O
was	O
also	O
edited	O
,	O
although	O
at	O
a	O
very	O
low	O
level	O
,	O
showing	O
that	O
editing	O
may	O
precede	O
intron	O
removal	O
(	O
not	O
shown	O
)	O
.	O

DISCUSSION	O

Plant	O
mitochondria	O
undergo	O
complex	O
expression	O
mechanisms	O
which	O
are	O
poorly	O
understood	O
.	O
<EOS>	B-X
In	B-X
insects	B-X
,	B-X
the	B-X
loss	B-X
of	B-X
flight	B-X
typically	B-X
involves	B-X
a	B-X
dispersal-reproduction	B-X
transition	B-X
,	B-X
but	B-X
the	B-X
underlying	B-X
molecular	B-X
mechanisms	B-X
remain	B-X
poorly	B-X
understood	B-X
.	B-X
In	B-X
the	B-X
parthenogenetic	B-X
pea	B-X
aphid	B-X
Acyrthosiphon	B-X
pisum	B-X
,	B-X
winged	B-X
females	B-X
undergo	B-X
flight-muscle	B-X
degeneration	B-X
after	B-X
flight	B-X
and	B-X
feeding	B-X
on	B-X
new	B-X
host	B-X
plants	B-X
.	B-X
We	B-X
found	B-X
that	B-X
feeding	B-X
preferentially	B-X
upregulated	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
JH	B-X
receptor	B-X
gene	B-X
Met	B-X
and	B-X
a	B-X
JH-inducible	B-X
gene	B-X
,	B-X
Kr-h1	B-X
,	B-X
in	B-X
the	B-X
flight	B-X
muscles	B-X
,	B-X
and	B-X
,	B-X
thus	B-X
,	B-X
enhanced	B-X
tissue-specific	B-X
JH	B-X
sensitivity	B-X
and	B-X
signaling	B-X
.	B-X
Likewise	B-X
,	B-X
blocking	B-X
nutritional	B-X
signals	B-X
by	B-X
pharmacological	B-X
inhibition	B-X
of	B-X
the	B-X
target	B-X
of	B-X
rapamycin	B-X
complex	B-X
1	B-X
(	B-X
TORC1	B-X
)	B-X
impaired	B-X
JH	B-X
sensitivity	B-X
of	B-X
the	B-X
flight	B-X
muscles	B-X
in	B-X
feeding	B-X
aphids	B-X
and	B-X
subsequently	B-X
delayed	B-X
muscle	B-X
degeneration	B-X
.	B-X
RNA-sequencing	B-X
analysis	B-X
revealed	B-X
that	B-X
enhanced	B-X
JH	B-X
signaling	B-X
inhibited	B-X
the	B-X
transcription	B-X
of	B-X
genes	B-X
involved	B-X
in	B-X
the	B-X
tricarboxylic	B-X
acid	B-X
cycle	B-X
,	B-X
likely	B-X
resulting	B-X
in	B-X
reduction	B-X
of	B-X
the	B-X
energy	B-X
supply	B-X
,	B-X
mitochondrial	B-X
dysfunction	B-X
and	B-X
muscle-fiber	B-X
breakdown	B-X
.	B-X

Most	O
studies	O
are	O
based	O
on	O
analysis	O
of	O
in	O
vivo	O
mature	O
or	O
intermediate	O
gene	O
products	O
giving	O
clues	O
on	O
possible	O
mechanisms	O
and	O
suggesting	O
pathways	O
operating	O
in	O
gene	O
expression	O
.	O
<EOS>	B-X
In	B-X
parallel	B-X
,	B-X
advances	B-X
in	B-X
single-cell	B-X
RNA	B-X
sequencing	B-X
have	B-X
led	B-X
to	B-X
identification	B-X
of	B-X
a	B-X
variety	B-X
of	B-X
cell	B-X
types	B-X
in	B-X
the	B-X
organoids	B-X
,	B-X
and	B-X
have	B-X
shown	B-X
these	B-X
to	B-X
be	B-X
similar	B-X
to	B-X
,	B-X
but	B-X
more	B-X
immature	B-X
than	B-X
,	B-X
human	B-X
kidney	B-X
cells	B-X
in	B-X
vivo	B-X
.	B-X
Although	B-X
most	B-X
current	B-X
organoids	B-X
are	B-X
based	B-X
on	B-X
the	B-X
induction	B-X
of	B-X
NPCs	B-X
,	B-X
an	B-X
induction	B-X
protocol	B-X
for	B-X
ureteric	B-X
buds	B-X
(	B-X
collecting	B-X
duct	B-X
precursors	B-X
)	B-X
has	B-X
also	B-X
been	B-X
developed	B-X
,	B-X
and	B-X
approaches	B-X
to	B-X
generate	B-X
more	B-X
complex	B-X
kidney	B-X
structures	B-X
may	B-X
soon	B-X
be	B-X
possible	B-X
.	B-X
Maturation	B-X
of	B-X
organoids	B-X
is	B-X
a	B-X
major	B-X
challenge	B-X
,	B-X
and	B-X
more	B-X
detailed	B-X
analysis	B-X
of	B-X
the	B-X
developing	B-X
kidney	B-X
at	B-X
a	B-X
single	B-X
cell	B-X
level	B-X
is	B-X
needed	B-X
.	B-X
Eventually	B-X
,	B-X
organotypic	B-X
kidney	B-X
structures	B-X
equipped	B-X
with	B-X
nephrons	B-X
,	B-X
collecting	B-X
ducts	B-X
,	B-X
ureters	B-X
,	B-X
stroma	B-X
and	B-X
vascular	B-X
flow	B-X
are	B-X
required	B-X
to	B-X
generate	B-X
transplantable	B-X
kidneys	B-X
;	B-X
such	B-X
attempts	B-X
are	B-X
in	B-X
progress	B-X
.	B-X

Direct	O
tests	O
using	O
in	O
vitro	O
approaches	O
have	O
been	O
fruitful	O
(	O
4	O
,	O
5	O
,	O
24	O
)	O
,	O
but	O
are	O
hampered	O
by	O
the	O
difficulty	O
of	O
obtaining	O
active	O
mitochondrial	O
extracts	O
.	O

Previously	O
,	O
we	O
devised	O
an	O
experimental	O
model	O
based	O
on	O
electroporation	O
of	O
isolated	O
mitochondria	O
that	O
allows	O
us	O
to	O
test	O
gene	O
expression	O
of	O
wild	O
-	O
type	O
and	O
mutant	O
genes	O
.	O

This	O
approach	O
has	O
been	O
very	O
useful	O
in	O
elucidating	O
the	O
process	O
of	O
RNA	O
maturation	O
in	O
plant	O
mitochondria	O
,	O
in	O
particular	O
splicing	O
and	O
editing	O
(	O
14	O
,	O
15	O
)	O
.	O

The	O
aim	O
of	O
this	O
work	O
was	O
to	O
analyse	O
different	O
gene	O
expression	O
events	O
when	O
a	O
foreign	O
gene	O
was	O
expressed	O
in	O
a	O
heterologous	O
context	O
.	O

rps10	O
was	O
chosen	O
precisely	O
because	O
this	O
genetic	O
information	O
is	O
lacking	O
in	O
wheat	B-Species
mitochondria	O
but	O
is	O
active	O
in	O
potato	B-Species
mitochondria	O
(	O
20	O
,	O
23	O
,	O
25	O
)	O
.	O

Moreover	O
,	O
rps10	O
transcripts	O
undergo	O
five	O
C	O
-	O
to	O
-	O
U	O
editing	O
events	O
in	O
potato	B-Species
mitochondria	O
and	O
rps10	O
contains	O
an	O
intron	O
,	O
thus	O
facilitating	O
the	O
analysis	O
of	O
post	O
-	O
transcriptional	O
processing	O
.	O

To	O
best	O
evaluate	O
the	O
expression	O
of	O
rps10	O
in	O
the	O
non	O
-	O
cognate	O
mitochondria	O
,	O
it	O
was	O
necessary	O
to	O
set	O
up	O
electroporation	O
conditions	O
for	O
introducing	O
foreign	O
DNA	O
into	O
S	B-Species
.	I-Species
tuberosum	I-Species
mitochondria	O
.	O

Potato	B-Species
tuber	O
mitochondria	O
were	O
able	O
to	O
incorporate	O
DNA	O
essentially	O
under	O
the	O
same	O
conditions	O
described	O
for	O
wheat	B-Species
embryo	O
organelles	O
(	O
14	O
)	O
,	O
except	O
that	O
the	O
optimal	O
voltage	O
range	O
was	O
larger	O
.	O

A	O
major	O
difference	O
to	O
wheat	B-Species
was	O
that	O
isolated	O
potato	B-Species
mitochondria	O
were	O
viable	O
for	O
3	O
-	O
4	O
h	O
as	O
measured	O
by	O
oxygen	O
consumption	O
(	O
data	O
not	O
shown	O
)	O
.	O

Thus	O
,	O
to	O
observe	O
transcript	O
maturation	O
after	O
electroporation	O
the	O
incubation	O
mixture	O
needed	O
to	O
be	O
supplemented	O
with	O
fatty	O
acid	O
-	O
free	O
BSA	O
(	O
see	O
Figure	O
4	O
)	O
.	O

This	O
behaviour	O
probably	O
reflects	O
the	O
uncoupling	O
of	O
oxidative	O
phosphorylation	O
by	O
fatty	O
acids	O
during	O
incubation	O
of	O
potato	B-Species
mitochondria	O
(	O
26	O
)	O
.	O

In	O
fact	O
,	O
previously	O
we	O
found	O
that	O
proper	O
gene	O
expression	O
in	O
isolated	O
mitochondria	O
requires	O
a	O
functional	O
organelle	O
able	O
to	O
generate	O
ATP	O
from	O
ADP	O
and	O
succinate	O
(	O
14	O
)	O
.	O

An	O
interesting	O
observation	O
was	O
that	O
neither	O
the	O
wheat	B-Species
nor	O
the	O
potato	B-Species
cox2	O
promoters	O
were	O
recognized	O
in	O
a	O
heterologous	O
context	O
(	O
Figure	O
4A	O
and	O
B	O
)	O
.	O

This	O
situation	O
might	O
by	O
explained	O
by	O
the	O
fact	O
that	O
potato	B-Species
and	O
wheat	B-Species
promoter	O
sequences	O
have	O
no	O
recognizable	O
homologous	O
motifs	O
.	O

Plant	O
mitochondria	O
promoters	O
are	O
characterized	O
by	O
a	O
conserved	O
core	O
CRTA	O
sequence	O
with	O
differences	O
in	O
the	O
extent	O
and	O
the	O
composition	O
of	O
sequences	O
around	O
the	O
consensus	O
motif	O
(	O
27	O
,	O
28	O
)	O
.	O

While	O
the	O
transcription	O
initiation	O
site	O
in	O
wheat	B-Species
mitochondria	O
is	O
located	O
at	O
position	O
-	O
170	O
(	O
29	O
)	O
,	O
the	O
potato	B-Species
promoter	O
has	O
not	O
yet	O
been	O
described	O
.	O

Transcription	O
may	O
be	O
initiated	O
at	O
numerous	O
sites	O
suggesting	O
a	O
relaxed	O
promoter	O
recognition	O
by	O
the	O
transcription	O
machinery	O
(	O
28	O
)	O
.	O

However	O
,	O
the	O
lack	O
of	O
crossed	O
recognition	O
of	O
cox2	O
promoters	O
in	O
wheat	B-Species
and	O
potato	B-Species
is	O
not	O
a	O
general	O
situation	O
since	O
the	O
A	B-Species
.	I-Species
thaliana	I-Species
cox2	O
gene	O
is	O
expressed	O
and	O
spliced	O
when	O
introduced	O
into	O
maize	B-Species
mitochondria	O
,	O
indicating	O
that	O
the	O
Arabidopsis	B-Species
gene	O
shares	O
some	O
signals	O
with	O
maize	B-Species
cox2	O
promoter	O
that	O
are	O
sufficient	O
for	O
transcription	O
(	O
18	O
)	O
.	O

The	O
sites	O
required	O
for	O
transcript	O
initiation	O
have	O
been	O
recently	O
described	O
in	O
A	B-Species
.	I-Species
thaliana	I-Species
mitochondrial	O
genes	O
(	O
28	O
)	O
.	O

Three	O
regions	O
were	O
described	O
as	O
important	O
for	O
transcription	O
initiation	O
.	O
<EOS>	B-X
We	B-X
and	B-X
others	B-X
have	B-X
demonstrated	B-X
strong	B-X
enrichment	B-X
of	B-X
such	B-X
single	B-X
nucleotide	B-X
polymorphisms	B-X
(	B-X
SNPs	B-X
)	B-X
for	B-X
expression	B-X
quantitative	B-X
trait	B-X
loci	B-X
(	B-X
eQTLs	B-X
)	B-X
,	B-X
supporting	B-X
an	B-X
important	B-X
role	B-X
for	B-X
regulatory	B-X
genetic	B-X
variation	B-X
in	B-X
complex	B-X
disease	B-X
pathogenesis	B-X
.	B-X
The	B-X
complete	B-X
model	B-X
revealed	B-X
independent	B-X
contributions	B-X
of	B-X
specific	B-X
annotations	B-X
as	B-X
strong	B-X
predictors	B-X
,	B-X
including	B-X
evidence	B-X
for	B-X
an	B-X
eQTL	B-X
(	B-X
odds	B-X
ratio	B-X
(	B-X
OR	B-X
)	B-X
=	B-X
1.2-2.0	B-X
,	B-X
P	B-X
<	B-X
10	B-X
(	B-X
-11	B-X
)	B-X
)	B-X
and	B-X
the	B-X
chromatin	B-X
states	B-X
of	B-X
active	B-X
promoters	B-X
,	B-X
different	B-X
classes	B-X
of	B-X
strong	B-X
or	B-X
weak	B-X
enhancers	B-X
,	B-X
or	B-X
transcriptionally	B-X
active	B-X
regions	B-X
(	B-X
OR	B-X
=	B-X
1.5-2.3	B-X
,	B-X
P	B-X
<	B-X
10	B-X
(	B-X
-11	B-X
)	B-X
)	B-X
.	B-X
Histone	B-X
modifications	B-X
show	B-X
important	B-X
roles	B-X
in	B-X
both	B-X
transcription	B-X
initiation	B-X
and	B-X
mRNA	B-X
splicing	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
intended	B-X
to	B-X
find	B-X
the	B-X
link	B-X
between	B-X
AS	B-X
and	B-X
histone	B-X
modifications	B-X
in	B-X
flanking	B-X
regions	B-X
through	B-X
analyzing	B-X
publicly	B-X
available	B-X
data	B-X
in	B-X
two	B-X
human	B-X
cell	B-X
lines	B-X
,	B-X
GM12878	B-X
and	B-X
K562	B-X
cell	B-X
lines	B-X
.	B-X

We	O
found	O
no	O
such	O
homologous	O
sequences	O
in	O
the	O
potato	B-Species
cox2	O
upstream	O
region	O
indicating	O
that	O
the	O
two	O
dicot	O
promoters	O
do	O
not	O
have	O
the	O
same	O
origin	O
.	O

This	O
in	O
turn	O
may	O
reflect	O
the	O
natural	O
history	O
of	O
this	O
particular	O
mitochondrial	O
gene	O
evolving	O
in	O
its	O
own	O
context	O
.	O

It	O
should	O
be	O
mentioned	O
that	O
the	O
presence	O
of	O
a	O
conserved	O
sequence	O
is	O
not	O
sufficient	O
for	O
expression	O
since	O
a	O
region	O
that	O
acts	O
as	O
promoter	O
in	O
Arabidopsis	B-Species
,	O
potato	B-Species
and	O
Oenothera	O
is	O
inactive	O
in	O
vivo	O
in	O
pea	B-Species
(	O
30	O
)	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
shown	B-X
that	B-X
the	B-X
DDC	B-X
amino	B-X
acid	B-X
sequence	B-X
is	B-X
highly	B-X
evolutionarily	B-X
conserved	B-X
across	B-X
many	B-X
species	B-X
.	B-X
A	B-X
single	B-X
gene	B-X
codes	B-X
for	B-X
DDC	B-X
both	B-X
in	B-X
neuronal	B-X
and	B-X
non-neuronal	B-X
tissue	B-X
,	B-X
but	B-X
synthesized	B-X
isoforms	B-X
of	B-X
mRNA	B-X
differ	B-X
in	B-X
the	B-X
5	B-X
'	B-X
UTR	B-X
and	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
alternative	B-X
exons	B-X
.	B-X
Tissue-specific	B-X
expression	B-X
of	B-X
the	B-X
DDC	B-X
gene	B-X
is	B-X
controlled	B-X
by	B-X
two	B-X
spatially	B-X
distinct	B-X
promoters	B-X
-	B-X
neuronal	B-X
and	B-X
non-neuronal	B-X
.	B-X
Several	B-X
consensus	B-X
sequences	B-X
recognized	B-X
by	B-X
the	B-X
HNF	B-X
and	B-X
POU	B-X
family	B-X
proteins	B-X
have	B-X
been	B-X
mapped	B-X
in	B-X
the	B-X
neuronal	B-X
DDC	B-X
promoter	B-X
.	B-X
Since	B-X
DDC	B-X
is	B-X
located	B-X
close	B-X
to	B-X
the	B-X
imprinted	B-X
gene	B-X
cluster	B-X
,	B-X
its	B-X
expression	B-X
can	B-X
be	B-X
subjected	B-X
to	B-X
tightly	B-X
controlled	B-X
epigenetic	B-X
regulation	B-X
.	B-X
Perturbations	B-X
in	B-X
DDC	B-X
expression	B-X
result	B-X
in	B-X
a	B-X
range	B-X
of	B-X
neurodegenerative	B-X
and	B-X
psychiatric	B-X
disorders	B-X
and	B-X
correlate	B-X
with	B-X
neoplasia	B-X
.	B-X
Moreover	B-X
,	B-X
novel	B-X
and	B-X
prospective	B-X
clinical	B-X
treatments	B-X
based	B-X
on	B-X
gene	B-X
therapy	B-X
and	B-X
stem	B-X
cells	B-X
for	B-X
the	B-X
diseases	B-X
mentioned	B-X
above	B-X
are	B-X
described	B-X
.	B-X

Further	O
studies	O
will	O
be	O
required	O
to	O
understand	O
the	O
transcriptional	O
events	O
in	O
plant	O
mitochondria	O
.	O

Electroporation	O
of	O
foreign	O
DNA	O
into	O
isolated	O
mitochondria	O
provides	O
an	O
interesting	O
functional	O
model	O
,	O
complementary	O
to	O
in	O
vitro	O
transcription	O
assay	O
,	O
for	O
answering	O
these	O
questions	O
.	O

The	O
potato	B-Species
rps10	O
gene	O
controlled	O
by	O
a	O
T	B-Species
.	I-Species
aestivum	I-Species
promoter	O
(	O
Figure	O
1A	O
)	O
was	O
transcribed	O
as	O
a	O
1204	O
nt	O
precursor	O
in	O
wheat	B-Species
mitochondria	O
,	O
but	O
no	O
traces	O
of	O
mature	O
RNA	O
were	O
observed	O
.	O

Moreover	O
,	O
the	O
five	O
C	O
residues	O
reported	O
as	O
RNA	O
editing	O
targets	O
in	O
vivo	O
(	O
23	O
)	O
remain	O
unchanged	O
,	O
indicating	O
that	O
rps10	O
transcript	O
was	O
not	O
recognized	O
by	O
the	O
wheat	B-Species
splicing	O
and	O
editing	O
machinery	O
.	O

A	O
control	O
using	O
the	O
cognate	O
cox2	O
construct	O
demonstrates	O
that	O
electroporated	O
organelles	O
were	O
competent	O
for	O
splicing	O
and	O
editing	O
(	O
Figure	O
1B	O
and	O
C	O
)	O
.	O

Some	O
editing	O
events	O
occur	O
in	O
highly	O
structured	O
domains	O
of	O
introns	O
.	O

Because	O
in	O
some	O
cases	O
,	O
editing	O
corrects	O
A	O
-	O
C	O
mispairing	O
improving	O
conformation	O
of	O
the	O
intron	O
,	O
it	O
has	O
been	O
proposed	O
that	O
the	O
C	O
-	O
to	O
-	O
U	O
change	O
might	O
be	O
necessary	O
for	O
efficient	O
splicing	O
(	O
8	O
,	O
9	O
,	O
23	O
,	O
31	O
)	O
.	O

Based	O
on	O
the	O
canonical	O
structure	O
of	O
group	O
II	O
mitochondrial	O
introns	O
(	O
21	O
)	O
,	O
two	O
editing	O
sites	O
,	O
C2	O
located	O
at	O
the	O
Intron	O
Binding	O
Site	O
2	O
(	O
IBS2	O
)	O
and	O
C3	O
located	O
in	O
the	O
intron	O
,	O
nine	O
residues	O
downstream	O
from	O
the	O
end	O
of	O
exon	O
1	O
in	O
S	B-Species
.	I-Species
tuberosum	I-Species
rps10	O
are	O
of	O
particular	O
interest	O
.	O

It	O
has	O
been	O
predicted	O
that	O
both	O
edited	O
residues	O
participate	O
in	O
base	O
-	O
pair	O
interactions	O
in	O
the	O
putative	O
secondary	O
structure	O
.	O

Of	O
particular	O
interest	O
is	O
the	O
site	O
C3	O
located	O
in	O
intron	O
domain	O
I	O
(	O
23	O
)	O
.	O

This	O
position	O
may	O
be	O
crucial	O
for	O
splicing	O
as	O
inferred	O
from	O
mutants	O
of	O
a	O
yeast	B-Species
mitochondrial	O
intron	O
(	O
32	O
)	O
.	O

We	O
addressed	O
this	O
question	O
by	O
introducing	O
rps10	O
mutant	O
genes	O
presenting	O
C2	O
,	O
C3	O
or	O
both	O
positions	O
in	O
the	O
edited	O
form	O
into	O
mitochondria	O
.	O
<EOS>	B-X
Emerging	B-X
evidence	B-X
suggests	B-X
that	B-X
mitochondria	B-X
provide	B-X
a	B-X
platform	B-X
for	B-X
signaling	B-X
pathways	B-X
involved	B-X
in	B-X
innate	B-X
immune	B-X
response	B-X
.	B-X
Mitochondrial	B-X
ROS	B-X
(	B-X
mtROS	B-X
)	B-X
production	B-X
,	B-X
mitochondrial	B-X
DNA	B-X
(	B-X
mtDNA	B-X
)	B-X
release	B-X
,	B-X
mitochondrial	B-X
antiviral	B-X
signaling	B-X
protein	B-X
(	B-X
MAVS	B-X
)	B-X
are	B-X
key	B-X
triggers	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
innate	B-X
immune	B-X
response	B-X
following	B-X
variety	B-X
of	B-X
stress	B-X
signals	B-X
that	B-X
include	B-X
infection	B-X
,	B-X
tissue	B-X
damage	B-X
and	B-X
metabolic	B-X
dysregulation	B-X
.	B-X
These	B-X
signals	B-X
converge	B-X
to	B-X
form	B-X
a	B-X
multiprotein	B-X
complex	B-X
called	B-X
inflammasome	B-X
that	B-X
leads	B-X
to	B-X
caspase-1	B-X
activation	B-X
to	B-X
promote	B-X
processing	B-X
of	B-X
precursor	B-X
cytokines	B-X
(	B-X
pro-IL1Î²	B-X
and	B-X
pro-IL-18	B-X
)	B-X
to	B-X
active	B-X
cytokines	B-X
(	B-X
IL-1Î²	B-X
and	B-X
IL-18	B-X
)	B-X
.	B-X
It	B-X
appears	B-X
that	B-X
mitochondria	B-X
induced	B-X
inflammasome	B-X
activation	B-X
contributes	B-X
to	B-X
inflammatory	B-X
process	B-X
in	B-X
many	B-X
diverse	B-X
disorders	B-X
.	B-X
Therefore	B-X
,	B-X
strategies	B-X
aimed	B-X
at	B-X
modulating	B-X
mitochondria	B-X
mediated	B-X
inflammasome	B-X
activation	B-X
might	B-X
be	B-X
beneficial	B-X
in	B-X
many	B-X
pathophysiological	B-X
conditions	B-X
.	B-X
This	B-X
article	B-X
is	B-X
part	B-X
of	B-X
a	B-X
Special	B-X
Issue	B-X
entitled	B-X
:	B-X
Oxidative	B-X
Stress	B-X
and	B-X
Mitochondrial	B-X
Quality	B-X
in	B-X
Diabetes/Obesity	B-X
and	B-X
Critical	B-X
Illness	B-X
Spectrum	B-X
of	B-X
Diseases	B-X
-	B-X
edited	B-X
by	B-X
P.	B-X
Hemachandra	B-X
Reddy	B-X
.	B-X

As	O
shown	O
in	O
Figure	O
2	O
,	O
transcription	O
was	O
as	O
efficient	O
as	O
for	O
the	O
cognate	O
cox2	O
construct	O
but	O
neither	O
wild	O
-	O
type	O
rps10	O
nor	O
the	O
C	O
-	O
U	O
mutants	O
underwent	O
splicing	O
.	O

These	O
results	O
clearly	O
demonstrate	O
that	O
C2	O
and	O
C3	O
editing	O
is	O
not	O
sufficient	O
for	O
splicing	O
of	O
rps10	O
precursor	O
in	O
wheat	B-Species
mitochondria	O
and	O
lead	O
us	O
to	O
conclude	O
that	O
splicing	O
failure	O
is	O
probably	O
linked	O
to	O
the	O
lack	O
of	O
trans	O
-	O
recognition	O
elements	O
.	O

One	O
may	O
speculate	O
that	O
these	O
trans	O
-	O
acting	O
factors	O
,	O
for	O
instance	O
nuclear	O
-	O
encoded	O
maturases	O
,	O
were	O
lost	O
after	O
rps10	O
was	O
transferred	O
to	O
the	O
nucleus	O
in	O
monocots	O
(	O
20	O
,	O
25	O
)	O
.	O

The	O
C	O
-	O
to	O
-	O
U	O
mutants	O
were	O
also	O
tested	O
in	O
potato	B-Species
mitochondria	O
;	O
no	O
significant	O
differences	O
were	O
detected	O
in	O
splicing	O
efficiency	O
when	O
compared	O
to	O
the	O
unedited	O
construct	O
(	O
D	O
.	O
Choury	O
,	O
unpublished	O
data	O
)	O
.	O

It	O
should	O
be	O
noted	O
that	O
the	O
lack	O
of	O
splicing	O
in	O
wheat	B-Species
mitochondria	O
is	O
not	O
a	O
general	O
feature	O
of	O
potato	B-Species
introns	O
,	O
since	O
the	O
potato	B-Species
cox2	O
intron	O
is	O
removed	O
efficiently	O
(	O
Figure	O
4B	O
)	O
.	O

This	O
is	O
consistent	O
with	O
the	O
hypothesis	O
that	O
potato	B-Species
and	O
wheat	B-Species
mitochondria	O
have	O
similar	O
trans	O
-	O
acting	O
factors	O
for	O
cox2	O
intron	O
removal	O
.	O

A	O
possible	O
link	O
between	O
intron	O
removal	O
and	O
editing	O
has	O
been	O
proposed	O
for	O
splicing	O
of	O
nad1e	O
and	O
nad5III	O
trans	O
-	O
introns	O
where	O
domain	O
six	O
may	O
require	O
editing	O
to	O
be	O
structured	O
in	O
a	O
catalytic	O
competent	O
secondary	O
conformation	O
(	O
8	O
)	O
.	O

In	O
rice	B-Species
,	O
failure	O
of	O
RNA	O
maturation	O
and	O
editing	O
has	O
been	O
correlated	O
with	O
cytoplasmic	O
male	O
sterile	O
phenotype	O
.	O

In	O
this	O
model	O
,	O
the	O
absence	O
of	O
the	O
nuclear	O
gene	O
Rf	O
-	O
1	O
affects	O
B	O
-	O
atp6	O
RNA	O
cleavage	O
and	O
editing	O
(	O
33	O
)	O
.	O

In	O
organello	O
studies	O
have	O
shown	O
that	O
S	B-Species
.	I-Species
bicolor	I-Species
atp6	O
-	O
1	O
gene	O
was	O
transcribed	O
but	O
not	O
edited	O
when	O
introduced	O
into	O
maize	B-Species
mitochondria	O
(	O
18	O
)	O
.	O

However	O
,	O
partially	O
edited	O
molecules	O
were	O
detected	O
in	O
sorghum	B-Species
-	O
maize	B-Species
atp6	O
chimeric	O
transcripts	O
when	O
they	O
included	O
the	O
maize	B-Species
atp6	O
5	O
'	O
-	O
untranslated	O
sequence	O
,	O
suggesting	O
that	O
the	O
5	O
'	O
non	O
-	O
coding	O
region	O
provides	O
a	O
structural	O
motif	O
or	O
binding	O
site	O
for	O
a	O
transcript	O
-	O
specific	O
editing	O
factor	O
(	O
34	O
)	O
.	O
<EOS>	B-X
The	B-X
exact	B-X
downstream	B-X
signaling	B-X
mechanism	B-X
by	B-X
which	B-X
caspase-2	B-X
accomplishes	B-X
its	B-X
specific	B-X
tumor	B-X
suppressor	B-X
functions	B-X
is	B-X
not	B-X
clear	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
identify	B-X
a	B-X
nuclear	B-X
caspase-2	B-X
specific	B-X
substrate	B-X
,	B-X
p54nrb	B-X
,	B-X
which	B-X
is	B-X
selectively	B-X
cleaved	B-X
by	B-X
caspase-2	B-X
at	B-X
D422	B-X
,	B-X
leading	B-X
to	B-X
disruption	B-X
of	B-X
the	B-X
C-terminal	B-X
site	B-X
,	B-X
the	B-X
putative	B-X
DNA	B-X
binding	B-X
region	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
P54nrb	B-X
is	B-X
an	B-X
RNA	B-X
and	B-X
DNA	B-X
binding	B-X
protein	B-X
,	B-X
which	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
RNA	B-X
editing	B-X
,	B-X
transport	B-X
,	B-X
and	B-X
transcriptional	B-X
regulation	B-X
of	B-X
genes	B-X
.	B-X
Overexpression	B-X
of	B-X
p54nrb	B-X
is	B-X
observed	B-X
in	B-X
several	B-X
human	B-X
tumor	B-X
types	B-X
,	B-X
such	B-X
as	B-X
cervix	B-X
adenocarcinoma	B-X
,	B-X
melanoma	B-X
,	B-X
and	B-X
colon	B-X
carcinoma	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
loss	B-X
of	B-X
p54nrb	B-X
in	B-X
tumor	B-X
cell	B-X
lines	B-X
leads	B-X
to	B-X
increased	B-X
cell	B-X
death	B-X
susceptibility	B-X
and	B-X
striking	B-X
decrease	B-X
in	B-X
tumorigenic	B-X
potential	B-X
.	B-X
By	B-X
employing	B-X
high	B-X
resolution	B-X
quantitative	B-X
proteomics	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
loss/cleavage	B-X
of	B-X
p54nrb	B-X
results	B-X
in	B-X
altered	B-X
expression	B-X
of	B-X
oncogenic	B-X
genes	B-X
,	B-X
among	B-X
which	B-X
the	B-X
downregulation	B-X
of	B-X
the	B-X
tumorigenic	B-X
protease	B-X
cathepsin-Z	B-X
and	B-X
the	B-X
anti-apoptotic	B-X
gelsolin	B-X
can	B-X
be	B-X
detected	B-X
universally	B-X
across	B-X
three	B-X
tumor	B-X
cell	B-X
types	B-X
,	B-X
including	B-X
adenocarcinoma	B-X
,	B-X
melanoma	B-X
and	B-X
colon	B-X
carcinoma	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
p54nrb	B-X
interacts	B-X
with	B-X
cathepsin-Z	B-X
and	B-X
gelsolin	B-X
DNA	B-X
,	B-X
but	B-X
not	B-X
RNA	B-X
.	B-X

Unfortunately	O
,	O
no	O
data	O
on	O
atp6	O
processing	O
was	O
reported	O
to	O
determine	O
whether	O
this	O
region	O
is	O
directly	O
involved	O
in	O
editing	O
or	O
some	O
other	O
maturation	O
event	O
.	O
<EOS>	B-X
On	B-X
July	B-X
25	B-X
,	B-X
1978	B-X
,	B-X
the	B-X
first	B-X
human	B-X
was	B-X
born	B-X
following	B-X
extracorporeal	B-X
fertilization	B-X
,	B-X
an	B-X
event	B-X
that	B-X
opened	B-X
up	B-X
a	B-X
new	B-X
medical	B-X
science	B-X
:	B-X
expanding	B-X
our	B-X
knowledge	B-X
of	B-X
and	B-X
developing	B-X
novel	B-X
treatments	B-X
for	B-X
infertility	B-X
,	B-X
radically	B-X
changing	B-X
the	B-X
opportunities	B-X
for	B-X
families	B-X
with	B-X
inherited	B-X
monogenic	B-X
disorders	B-X
,	B-X
generating	B-X
the	B-X
new	B-X
discipline	B-X
of	B-X
clinical	B-X
embryology	B-X
,	B-X
and	B-X
paving	B-X
the	B-X
way	B-X
for	B-X
studies	B-X
into	B-X
stem	B-X
cell	B-X
biology	B-X
.	B-X
The	B-X
first	B-X
step	B-X
in	B-X
the	B-X
biogenesis	B-X
of	B-X
microRNAs	B-X
is	B-X
the	B-X
processing	B-X
of	B-X
primary	B-X
microRNAs	B-X
(	B-X
pri-miRNAs	B-X
)	B-X
by	B-X
the	B-X
microprocessor	B-X
complex	B-X
,	B-X
composed	B-X
of	B-X
the	B-X
RNA-binding	B-X
protein	B-X
DGCR8	B-X
and	B-X
the	B-X
type	B-X
III	B-X
RNase	B-X
DROSHA	B-X
.	B-X
This	B-X
initial	B-X
event	B-X
requires	B-X
recognition	B-X
of	B-X
the	B-X
junction	B-X
between	B-X
the	B-X
stem	B-X
and	B-X
the	B-X
flanking	B-X
single-stranded	B-X
RNA	B-X
of	B-X
the	B-X
pri-miRNA	B-X
hairpin	B-X
by	B-X
DGCR8	B-X
followed	B-X
by	B-X
recruitment	B-X
of	B-X
DROSHA	B-X
,	B-X
which	B-X
cleaves	B-X
the	B-X
RNA	B-X
duplex	B-X
to	B-X
yield	B-X
the	B-X
pre-miRNA	B-X
product	B-X
.	B-X
While	B-X
the	B-X
mechanisms	B-X
underlying	B-X
pri-miRNA	B-X
processing	B-X
have	B-X
been	B-X
determined	B-X
,	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
DGCR8	B-X
recognizes	B-X
and	B-X
binds	B-X
pri-miRNAs	B-X
,	B-X
as	B-X
opposed	B-X
to	B-X
other	B-X
secondary	B-X
structures	B-X
present	B-X
in	B-X
transcripts	B-X
,	B-X
is	B-X
not	B-X
understood	B-X
.	B-X
Here	B-X
we	B-X
find	B-X
in	B-X
mammalian	B-X
cells	B-X
that	B-X
methyltransferase-like	B-X
3	B-X
(	B-X
METTL3	B-X
)	B-X
methylates	B-X
pri-miRNAs	B-X
,	B-X
marking	B-X
them	B-X
for	B-X
recognition	B-X
and	B-X
processing	B-X
by	B-X
DGCR8	B-X
.	B-X
In	B-X
vitro	B-X
processing	B-X
reactions	B-X
confirmed	B-X
the	B-X
sufficiency	B-X
of	B-X
the	B-X
N	B-X
(	B-X
6	B-X
)	B-X
-methyladenosine	B-X
(	B-X
m	B-X
(	B-X
6	B-X
)	B-X
A	B-X
)	B-X
mark	B-X
in	B-X
promoting	B-X
pri-miRNA	B-X
processing	B-X
.	B-X
Finally	B-X
,	B-X
gain-of-function	B-X
experiments	B-X
revealed	B-X
that	B-X
METTL3	B-X
is	B-X
sufficient	B-X
to	B-X
enhance	B-X
miRNA	B-X
maturation	B-X
in	B-X
a	B-X
global	B-X
and	B-X
non-cell-type-specific	B-X
manner	B-X
.	B-X

Since	O
wheat	B-Species
mitochondria	O
do	O
not	O
have	O
rps10	O
encoded	O
in	O
the	O
mitochondrial	O
genome	O
(	O
20	O
)	O
,	O
it	O
was	O
interesting	O
to	O
test	O
whether	O
wheat	B-Species
mitochondria	O
were	O
able	O
to	O
recognize	O
editing	O
sites	O
which	O
had	O
been	O
lost	O
during	O
evolution	O
.	O
<EOS>	B-X
The	B-X
polyamine	B-X
pathway	B-X
is	B-X
highly	B-X
conserved	B-X
from	B-X
bacteria	B-X
to	B-X
mammals	B-X
and	B-X
spermidine	B-X
(	B-X
prominently	B-X
found	B-X
in	B-X
some	B-X
kinds	B-X
of	B-X
aged	B-X
cheese	B-X
,	B-X
wheat	B-X
germs	B-X
,	B-X
nuts	B-X
,	B-X
soybeans	B-X
,	B-X
and	B-X
fermented	B-X
products	B-X
thereof	B-X
,	B-X
among	B-X
others	B-X
)	B-X
is	B-X
an	B-X
intrinsic	B-X
part	B-X
of	B-X
the	B-X
human	B-X
diet	B-X
.	B-X
Apart	B-X
from	B-X
nutrition	B-X
,	B-X
spermidine	B-X
is	B-X
available	B-X
to	B-X
mammalian	B-X
organisms	B-X
from	B-X
intracellular	B-X
biosynthesis	B-X
and	B-X
microbial	B-X
production	B-X
in	B-X
the	B-X
gut	B-X
.	B-X
Importantly	B-X
,	B-X
externally	B-X
supplied	B-X
spermidine	B-X
(	B-X
via	B-X
drinking	B-X
water	B-X
or	B-X
food	B-X
)	B-X
prolongs	B-X
lifespan	B-X
,	B-X
activates	B-X
autophagy	B-X
,	B-X
improves	B-X
mitochondrial	B-X
function	B-X
,	B-X
and	B-X
refills	B-X
polyamine	B-X
pools	B-X
that	B-X
decline	B-X
during	B-X
aging	B-X
in	B-X
various	B-X
tissues	B-X
of	B-X
model	B-X
organisms	B-X
,	B-X
including	B-X
mice	B-X
.	B-X
In	B-X
two	B-X
adjacent	B-X
studies	B-X
,	B-X
we	B-X
explored	B-X
how	B-X
dietary	B-X
spermidine	B-X
supplementation	B-X
enhances	B-X
eEF5/EIF5A	B-X
hypusination	B-X
,	B-X
cerebral	B-X
mitochondrial	B-X
function	B-X
and	B-X
cognition	B-X
in	B-X
aging	B-X

In	O
other	O
words	O
,	O
whether	O
the	O
mitochondrial	O
trans	O
-	O
recognition	O
elements	O
are	O
specific	O
for	O
each	O
site	O
or	O
whether	O
they	O
are	O
operating	O
on	O
a	O
subset	O
of	O
editing	O
sites	O
.	O

This	O
question	O
is	O
important	O
since	O
to	O
date	O
the	O
factors	O
responsible	O
for	O
RNA	O
editing	O
in	O
plant	O
mitochondria	O
remain	O
unknown	O
.	O

Solving	O
this	O
issue	O
may	O
provide	O
clues	O
to	O
uncover	O
such	O
factors	O
.	O

As	O
described	O
above	O
,	O
the	O
rps10	O
transcript	O
was	O
not	O
processed	O
in	O
wheat	B-Species
but	O
it	O
was	O
correctly	O
spliced	O
in	O
cognate	O
mitochondria	O
(	O
Figure	O
5A	O
)	O
.	O

Indeed	O
,	O
the	O
mature	O
transcript	O
had	O
identical	O
exon1	O
and	O
exon2	O
junction	O
as	O
found	O
in	O
endogenous	O
rps10	O
mRNA	O
(	O
data	O
not	O
shown	O
)	O
.	O

More	O
importantly	O
,	O
all	O
editing	O
sites	O
,	O
C1	O
,	O
C2	O
,	O
C4	O
and	O
C5	O
were	O
significantly	O
converted	O
to	O
Us	O
(	O
Figure	O
5B	O
)	O
.	O

The	O
fact	O
that	O
the	O
four	O
editing	O
sites	O
were	O
found	O
either	O
edited	O
or	O
unedited	O
in	O
spliced	O
rps10	O
mRNA	O
is	O
an	O
indication	O
that	O
editing	O
does	O
not	O
precede	O
splicing	O
as	O
was	O
previously	O
found	O
for	O
cox2	O
in	O
wheat	B-Species
(	O
15	O
)	O
.	O
<EOS>	B-X
Because	B-X
of	B-X
its	B-X
adaptability	B-X
to	B-X
sites	B-X
polluted	B-X
with	B-X
toxic	B-X
chemicals	B-X
,	B-X
the	B-X
model	B-X
soil	B-X
bacterium	B-X
Pseudomonas	B-X
putida	B-X
is	B-X
naturally	B-X
endowed	B-X
with	B-X
a	B-X
number	B-X
of	B-X
metabolic	B-X
and	B-X
stress-endurance	B-X
qualities	B-X
which	B-X
have	B-X
considerable	B-X
value	B-X
for	B-X
hosting	B-X
energy-demanding	B-X
and	B-X
redox	B-X
reactions	B-X
thereof	B-X
.	B-X
The	B-X
growing	B-X
body	B-X
of	B-X
knowledge	B-X
on	B-X
P.	B-X
putida	B-X
strain	B-X
KT2440	B-X
has	B-X
been	B-X
exploited	B-X
for	B-X
the	B-X
rational	B-X
design	B-X
of	B-X
a	B-X
derivative	B-X
strain	B-X
in	B-X
which	B-X
the	B-X
genome	B-X
has	B-X
been	B-X
heavily	B-X
edited	B-X
in	B-X
order	B-X
to	B-X
construct	B-X
a	B-X
robust	B-X
microbial	B-X
cell	B-X
factory	B-X
.	B-X
Despite	B-X
the	B-X
major	B-X
role	B-X
of	B-X
chitin	B-X
biosynthesis	B-X
inhibitors	B-X
such	B-X
as	B-X
benzoylureas	B-X
(	B-X
BPUs	B-X
)	B-X
in	B-X
the	B-X
control	B-X
of	B-X
pests	B-X
in	B-X
agricultural	B-X
and	B-X
public	B-X
health	B-X
for	B-X
almost	B-X
four	B-X
decades	B-X
,	B-X
their	B-X
molecular	B-X
mode	B-X
of	B-X
action	B-X
(	B-X
MoA	B-X
)	B-X
has	B-X
in	B-X
most	B-X
cases	B-X
remained	B-X
elusive	B-X
.	B-X
Using	B-X
a	B-X
genome-editing	B-X
CRISPR/Cas9	B-X
approach	B-X
coupled	B-X
with	B-X
homology-directed	B-X
repair	B-X
(	B-X
HDR	B-X
)	B-X
in	B-X
Drosophila	B-X
melanogaster	B-X
,	B-X
we	B-X
introduced	B-X
both	B-X
substitutions	B-X
(	B-X
I1056M/F	B-X
)	B-X
in	B-X
the	B-X
corresponding	B-X
fly	B-X
CHS1	B-X
gene	B-X
(	B-X
kkv	B-X
)	B-X
.	B-X
Homozygous	B-X
lines	B-X
bearing	B-X
either	B-X
of	B-X
these	B-X
mutations	B-X
were	B-X
highly	B-X
resistant	B-X
to	B-X
etoxazole	B-X
and	B-X
all	B-X
tested	B-X
BPUs	B-X
,	B-X
as	B-X
well	B-X
as	B-X
buprofezin-an	B-X
important	B-X
hemipteran	B-X
chitin	B-X
biosynthesis	B-X
inhibitor	B-X
.	B-X
This	B-X
provides	B-X
compelling	B-X
evidence	B-X
that	B-X
BPUs	B-X
,	B-X
etoxazole	B-X
,	B-X
and	B-X
buprofezin	B-X
share	B-X
in	B-X
fact	B-X
the	B-X
same	B-X
molecular	B-X
MoA	B-X
and	B-X
directly	B-X
interact	B-X
with	B-X
CHS	B-X
.	B-X
The	B-X
study	B-X
elaborates	B-X
on	B-X
how	B-X
genome	B-X
editing	B-X
can	B-X
directly	B-X
,	B-X
rapidly	B-X
,	B-X
and	B-X
convincingly	B-X
elucidate	B-X
the	B-X
MoA	B-X
of	B-X
bioactive	B-X
molecules	B-X
,	B-X
especially	B-X
when	B-X
target	B-X
sites	B-X
are	B-X
complex	B-X
and	B-X
hard	B-X
to	B-X
reconstitute	B-X
in	B-X
vitro	B-X
.	B-X

It	O
may	O
be	O
argued	O
that	O
the	O
absence	O
of	O
splicing	O
precluded	O
editing	O
.	O

This	O
possibility	O
can	O
be	O
discarded	O
since	O
potato	B-Species
rps10	O
precursor	O
mRNA	O
was	O
found	O
to	O
be	O
edited	O
in	O
vivo	O
(	O
23	O
)	O
.	O

These	O
data	O
clearly	O
show	O
that	O
splicing	O
is	O
not	O
required	O
for	O
rps10	O
editing	O
,	O
similar	O
to	O
previous	O
findings	O
for	O
cox2	O
mRNA	O
and	O
also	O
in	O
cox2	O
mutant	O
derivatives	O
unable	O
to	O
remove	O
the	O
intron	O
(	O
15	O
)	O
.	O
<EOS>	B-X
Very	B-X
few	B-X
risk	B-X
factors	B-X
have	B-X
been	B-X
clearly	B-X
identified	B-X
but	B-X
many	B-X
epidemiological	B-X
studies	B-X
have	B-X
reported	B-X
a	B-X
higher	B-X
incidence	B-X
in	B-X
men	B-X
than	B-X
women	B-X
with	B-X
a	B-X
sex	B-X
ratio	B-X
of	B-X
1:4	B-X
.	B-X
The	B-X
study	B-X
of	B-X
these	B-X
receptors	B-X
is	B-X
even	B-X
more	B-X
complex	B-X
since	B-X
many	B-X
isoforms	B-X
are	B-X
produced	B-X
from	B-X
each	B-X
estrogen	B-X
receptor	B-X
encoding	B-X
gene	B-X
through	B-X
alternative	B-X
promoter	B-X
usage	B-X
or	B-X
splicing	B-X
,	B-X
with	B-X
each	B-X
of	B-X
them	B-X
potentially	B-X
having	B-X
a	B-X
specific	B-X
role	B-X
in	B-X
the	B-X
cell	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
review	B-X
is	B-X
to	B-X
discuss	B-X
recent	B-X
data	B-X
supporting	B-X
the	B-X
involvement	B-X
of	B-X
steroids	B-X
during	B-X
gliomagenesis	B-X
and	B-X
to	B-X
focus	B-X
on	B-X
the	B-X
potential	B-X
neuroprotective	B-X
role	B-X
as	B-X
well	B-X
as	B-X
the	B-X
mechanisms	B-X
of	B-X
action	B-X
of	B-X
estrogens	B-X
in	B-X
gliomas	B-X
.	B-X
Due	B-X
to	B-X
the	B-X
complexity	B-X
of	B-X
these	B-X
diseases	B-X
,	B-X
their	B-X
molecular	B-X
mechanisms	B-X
have	B-X
not	B-X
been	B-X
revealed	B-X
clearly	B-X
.	B-X
We	B-X
obtained	B-X
EAC-	B-X
and	B-X
BE-associated	B-X
microarray	B-X
datasets	B-X
GSE26886	B-X
,	B-X
GSE1420	B-X
,	B-X
GSE37200	B-X
,	B-X
and	B-X
GSE37203	B-X
from	B-X
the	B-X
Gene	B-X
Expression	B-X
Omnibus	B-X
and	B-X
ArrayExpress	B-X
using	B-X
systematic	B-X
meta-analysis	B-X
.	B-X
These	B-X
data	B-X
were	B-X
accompanied	B-X
by	B-X
clinical	B-X
data	B-X
and	B-X
RNAseq	B-X
data	B-X
from	B-X
The	B-X
Cancer	B-X
Genome	B-X
Atlas	B-X
(	B-X
TCGA	B-X
)	B-X
.	B-X
Furthermore	B-X
,	B-X
five	B-X
shared	B-X
hub	B-X
gene	B-X
signatures	B-X
(	B-X
SHGS	B-X
)	B-X
,	B-X
namely	B-X
,	B-X
pre-mRNA	B-X
processing	B-X
factor	B-X
4	B-X
(	B-X
PRPF4	B-X
)	B-X
,	B-X
serine	B-X
and	B-X
arginine-rich	B-X
splicing	B-X
factor	B-X
1	B-X
(	B-X
SRSF1	B-X
)	B-X
,	B-X
heterogeneous	B-X
nuclear	B-X
ribonucleoprotein	B-X
M	B-X
(	B-X
HNRNPM	B-X
)	B-X
,	B-X
DExH-Box	B-X
Helicase	B-X
9	B-X
(	B-X
DHX9	B-X
)	B-X
,	B-X
and	B-X
origin	B-X
recognition	B-X
complex	B-X
subunit	B-X
2	B-X
(	B-X
ORC2	B-X
)	B-X
,	B-X
were	B-X
identified	B-X
between	B-X
BE	B-X
and	B-X
EAC	B-X
.	B-X

This	O
led	O
us	O
to	O
postulate	O
that	O
the	O
inability	O
of	O
wheat	B-Species
mitochondria	O
to	O
recognize	O
rps10	O
editing	O
sites	O
is	O
likely	O
due	O
to	O
the	O
fact	O
that	O
wheat	B-Species
mitochondria	O
have	O
lost	O
the	O
editing	O
trans	O
-	O
recognition	O
elements	O
which	O
become	O
dispensable	O
after	O
transfer	O
of	O
rps10	O
to	O
the	O
nucleus	O
.	O

To	O
test	O
this	O
possibility	O
,	O
rps10	O
chimeric	O
plasmids	O
containing	O
editing	O
site	O
C259	O
from	O
wheat	B-Species
cox2	O
inserted	O
either	O
in	O
exon1	O
or	O
the	O
intron	O
were	O
constructed	O
.	O
<EOS>	B-X
The	B-X
exon/intron	B-X
structure	B-X
,	B-X
which	B-X
is	B-X
computed	B-X
as	B-X
part	B-X
of	B-X
spliced	B-X
alignment	B-X
procedures	B-X
,	B-X
often	B-X
conveys	B-X
important	B-X
information	B-X
for	B-X
the	B-X
distinguishing	B-X
paralogous	B-X
members	B-X
of	B-X
gene	B-X
families	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
simple	B-X
,	B-X
blat-based	B-X
approach	B-X
has	B-X
advantages	B-X
over	B-X
established	B-X
tools	B-X
in	B-X
particular	B-X
for	B-X
genes	B-X
with	B-X
very	B-X
large	B-X
introns	B-X
and	B-X
applications	B-X
to	B-X
fragmented	B-X
genome	B-X
assemblies	B-X
.	B-X
Investigation	B-X
of	B-X
exon-intron	B-X
gene	B-X
structures	B-X
is	B-X
a	B-X
non-trivial	B-X
task	B-X
due	B-X
to	B-X
enormous	B-X
expansions	B-X
of	B-X
the	B-X
eukaryotic	B-X
genomes	B-X
,	B-X
great	B-X
variety	B-X
of	B-X
gene	B-X
forms	B-X
,	B-X
and	B-X
the	B-X
imperfectness	B-X
in	B-X
sequence	B-X
data	B-X
.	B-X
Among	B-X
them	B-X
,	B-X
the	B-X
Exon-Intron	B-X
Database	B-X
(	B-X
EID	B-X
)	B-X
is	B-X
a	B-X
good	B-X
choice	B-X
for	B-X
large-scale	B-X
computational	B-X
examination	B-X
of	B-X
exon/intron	B-X
structure	B-X
and	B-X
splicing	B-X
.	B-X
The	B-X
collection	B-X
of	B-X
exons	B-X
and	B-X
introns	B-X
has	B-X
been	B-X
extended	B-X
beyond	B-X
coding	B-X
regions	B-X
and	B-X
current	B-X
versions	B-X
of	B-X
EID	B-X
contain	B-X
data	B-X
on	B-X
untranslated	B-X
regions	B-X
of	B-X
gene	B-X
sequences	B-X
as	B-X
well	B-X
.	B-X
A	B-X
novel	B-X
Mammalian	B-X
Orthologous	B-X
Intron	B-X
Database	B-X
(	B-X
MOID	B-X
)	B-X
has	B-X
been	B-X
introduced	B-X
which	B-X
includes	B-X
the	B-X
full	B-X
set	B-X
of	B-X
introns	B-X
that	B-X
come	B-X
from	B-X
orthologous	B-X
genes	B-X
that	B-X
have	B-X
the	B-X
same	B-X
positions	B-X
relative	B-X
to	B-X
the	B-X
reading	B-X
frames	B-X
.	B-X
We	B-X
present	B-X
the	B-X
latest	B-X
data	B-X
on	B-X
our	B-X
comparison	B-X
of	B-X
intron	B-X
positions	B-X
in	B-X
11,025	B-X
orthologous	B-X
genes	B-X
of	B-X
human	B-X
,	B-X
mouse	B-X
and	B-X
rat	B-X
,	B-X
and	B-X
find	B-X
no	B-X
convincing	B-X
cases	B-X
of	B-X
intron	B-X
gain	B-X
.	B-X

Site	O
C259	O
is	O
formed	O
by	O
23	O
nt	O
corresponding	O
to	O
the	O
-	O
16	O
/	O
+	O
6	O
sequence	O
embedding	O
the	O
target	O
C	O
.	O

Previously	O
we	O
found	O
that	O
this	O
small	O
region	O
could	O
be	O
recognized	O
by	O
the	O
RNA	O
editing	O
machinery	O
when	O
placed	O
outside	O
of	O
its	O
natural	O
context	O
(	O
16	O
,	O
17	O
)	O
.	O

The	O
wheat	B-Species
C259	O
editing	O
site	O
in	O
the	O
chimeric	O
construct	O
was	O
correctly	O
edited	O
by	O
potato	B-Species
mitochondria	O
.	O

This	O
result	O
is	O
not	O
unexpected	O
since	O
the	O
corresponding	O
region	O
in	O
endogenous	O
potato	B-Species
cox2	O
mRNA	O
,	O
which	O
presents	O
two	O
differences	O
at	O
positions	O
-	O
3	O
(	O
C	O
instead	O
of	O
A	O
)	O
and	O
-	O
7	O
(	O
G	O
instead	O
of	O
A	O
)	O
,	O
is	O
edited	O
.	O
<EOS>	B-X
TYK2	B-X
belongs	B-X
to	B-X
the	B-X
JAK	B-X
protein	B-X
tyrosine	B-X
kinase	B-X
family	B-X
and	B-X
mediates	B-X
signaling	B-X
of	B-X
numerous	B-X
antiviral	B-X
and	B-X
immunoregulatory	B-X
cytokines	B-X
(	B-X
type	B-X
I	B-X
and	B-X
type	B-X
III	B-X
IFNs	B-X
,	B-X
IL-10	B-X
,	B-X
IL-12	B-X
,	B-X
IL-22	B-X
,	B-X
IL-23	B-X
)	B-X
in	B-X
immune	B-X
and	B-X
non-immune	B-X
cells	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
have	B-X
studied	B-X
two	B-X
AID-associated	B-X
common	B-X
TYK2	B-X
variants	B-X
:	B-X
rs12720270	B-X
located	B-X
in	B-X
intron	B-X
7	B-X
and	B-X
rs2304256	B-X
,	B-X
a	B-X
non-synonymous	B-X
variant	B-X
in	B-X
exon	B-X
8	B-X
that	B-X
causes	B-X
a	B-X
valine	B-X
to	B-X
phenylalanine	B-X
substitution	B-X
(	B-X
c.1084	B-X
G	B-X
>	B-X
T	B-X
,	B-X
Val362Phe	B-X
)	B-X
.	B-X
Based	B-X
on	B-X
in	B-X
silico	B-X
predictions	B-X
that	B-X
these	B-X
variants	B-X
may	B-X
impact	B-X
splicing	B-X
of	B-X
exon	B-X
8	B-X
,	B-X
we	B-X
:	B-X
i	B-X
)	B-X
analyzed	B-X
TYK2	B-X
transcripts	B-X
in	B-X
genotyped	B-X
EBV-B	B-X
cells	B-X
and	B-X
in	B-X
CRISPR/Cas9-edited	B-X
cells	B-X
,	B-X
ii	B-X
)	B-X
measured	B-X
splicing	B-X
using	B-X
minigene	B-X
assays	B-X
,	B-X
and	B-X
iii	B-X
)	B-X
performed	B-X
eQTL	B-X
(	B-X
expression	B-X
quantitative	B-X
trait	B-X
locus	B-X
)	B-X
analysis	B-X
of	B-X
TYK2	B-X
transcripts	B-X
in	B-X
primary	B-X
monocytes	B-X
and	B-X
whole	B-X
blood	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
reveal	B-X
that	B-X
the	B-X
two	B-X
variants	B-X
promote	B-X
the	B-X
inclusion	B-X
of	B-X
exon	B-X
8	B-X
,	B-X
which	B-X
,	B-X
we	B-X
demonstrate	B-X
,	B-X
is	B-X
essential	B-X
for	B-X
TYK2	B-X
binding	B-X
to	B-X
cognate	B-X
receptors	B-X
.	B-X
In	B-X
addition	B-X
and	B-X
in	B-X
line	B-X
with	B-X
GTEx	B-X
(	B-X
Genetic	B-X
Tissue	B-X
Expression	B-X
)	B-X
data	B-X
,	B-X
our	B-X
eQTL	B-X
results	B-X
show	B-X
that	B-X
rs2304256	B-X
mildly	B-X
enhances	B-X
TYK2	B-X
expression	B-X
in	B-X
whole	B-X
blood	B-X
.	B-X
In	B-X
all	B-X
,	B-X
these	B-X
findings	B-X
suggest	B-X
that	B-X
these	B-X
TYK2	B-X
variants	B-X
are	B-X
not	B-X
neutral	B-X
but	B-X
instead	B-X
have	B-X
a	B-X
potential	B-X
impact	B-X
in	B-X
AID	B-X
.	B-X

Furthermore	O
,	O
these	O
positions	O
were	O
not	O
crucial	O
for	O
editing	O
of	O
C259	O
(	O
17	O
)	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
use	B-X
of	B-X
electrical	B-X
activity	B-X
of	B-X
the	B-X
diaphragm	B-X
(	B-X
EADi	B-X
)	B-X
-driven	B-X
ventilation	B-X
has	B-X
been	B-X
demonstrated	B-X
to	B-X
improve	B-X
patient	B-X
comfort	B-X
when	B-X
compared	B-X
to	B-X
PSV	B-X
,	B-X
while	B-X
reducing	B-X
neural	B-X
drive	B-X
and	B-X
effort	B-X
.	B-X
Furthermore	B-X
,	B-X
aspects	B-X
of	B-X
delineation	B-X
of	B-X
organs	B-X
at	B-X
risk	B-X
and	B-X
of	B-X
dose	B-X
constraints	B-X
are	B-X
described	B-X
in	B-X
both	B-X
,	B-X
standard	B-X
and	B-X
hypofractionated	B-X
,	B-X
settings	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
ability	B-X
to	B-X
incorporate	B-X
soft-tissue	B-X
laxity	B-X
data	B-X
into	B-X
the	B-X
plan	B-X
prior	B-X
to	B-X
bone	B-X
resection	B-X
should	B-X
reduce	B-X
variability	B-X
between	B-X
the	B-X
planned	B-X
polyethylene	B-X
thickness	B-X
and	B-X
the	B-X
final	B-X
implanted	B-X
polyethylene	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
diagnosis	B-X
of	B-X
acute	B-X
high-grade	B-X
PLC	B-X
injuries	B-X
is	B-X
critical	B-X
because	B-X
early	B-X
and	B-X
aggressive	B-X
treatment	B-X
,	B-X
for	B-X
which	B-X
surgical	B-X
reconstruction	B-X
is	B-X
often	B-X
required	B-X
,	B-X
leads	B-X
to	B-X
improved	B-X
long-term	B-X
outcomes	B-X
and	B-X
the	B-X
prevention	B-X
of	B-X
persistent	B-X
instability	B-X
that	B-X
would	B-X
otherwise	B-X
result	B-X
in	B-X
varus	B-X
thrust	B-X
gait	B-X
,	B-X
chronic	B-X
pain	B-X
,	B-X
and	B-X
accelerated	B-X
cartilage	B-X
damage	B-X
.	B-X

Surprisingly	O
,	O
the	O
C259	O
editing	O
site	O
grafted	O
in	O
rps10	O
was	O
not	O
recognized	O
by	O
the	O
wheat	B-Species
editing	O
machinery	O
.	O

We	O
cannot	O
exclude	O
the	O
possibility	O
that	O
editing	O
efficiency	O
in	O
precursor	O
molecules	O
is	O
very	O
low	O
and	O
so	O
is	O
undetectable	O
when	O
sequencing	O
RT	O
-	O
PCR	O
products	O
representing	O
a	O
pool	O
of	O
transcripts	O
.	O

However	O
,	O
analysis	O
of	O
the	O
same	O
region	O
in	O
cox2	O
precursors	O
indicates	O
that	O
this	O
was	O
not	O
the	O
case	O
since	O
significant	O
C	O
-	O
to	O
-	O
U	O
conversion	O
was	O
observed	O
(	O
Figure	O
6D	O
)	O
.	O

These	O
observations	O
lead	O
us	O
to	O
postulate	O
that	O
editing	O
is	O
occurring	O
only	O
when	O
the	O
transcript	O
is	O
engaged	O
in	O
post	O
-	O
transcriptional	O
processing	O
,	O
suggesting	O
that	O
rps10	O
transcripts	O
are	O
not	O
available	O
to	O
editing	O
factors	O
independently	O
of	O
the	O
RNA	O
maturation	O
machinery	O
.	O

The	O
fact	O
that	O
the	O
wheat	B-Species
editing	O
site	O
C259	O
inserted	O
in	O
chimeric	O
rps10	O
transcripts	O
was	O
not	O
recognized	O
by	O
wheat	B-Species
mitochondria	O
is	O
a	O
strong	O
argument	O
for	O
this	O
hypothesis	O
.	O

One	O
might	O
speculate	O
that	O
in	O
plant	O
mitochondria	O
,	O
transcripts	O
have	O
to	O
be	O
engaged	O
in	O
a	O
kind	O
of	O
multiprotein	O
processing	O
complex	O
.	O

A	O
failure	O
to	O
be	O
recognized	O
at	O
some	O
early	O
stage	O
will	O
lead	O
to	O
their	O
accumulation	O
as	O
unmodified	O
precursors	O
.	O

Rap1p	O
and	O
other	O
transcriptional	O
regulators	O
can	O
function	O
in	O
defining	O
distinct	O
domains	O
of	O
gene	O
expression	O
<EOS>	B-X
Barrier	B-X
elements	B-X
that	B-X
are	B-X
able	B-X
to	B-X
block	B-X
the	B-X
propagation	B-X
of	B-X
transcriptional	B-X
silencing	B-X
in	B-X
yeast	B-X
are	B-X
functionally	B-X
similar	B-X
to	B-X
chromatin	B-X
boundary/insulator	B-X
elements	B-X
in	B-X
metazoans	B-X
that	B-X
delimit	B-X
functional	B-X
chromosomal	B-X
domains	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
upstream	B-X
activating	B-X
sequences	B-X
of	B-X
many	B-X
highly	B-X
expressed	B-X
ribosome	B-X
protein	B-X
genes	B-X
and	B-X
glycolytic	B-X
genes	B-X
exhibit	B-X
barrier	B-X
activity	B-X
.	B-X
Analyses	B-X
of	B-X
these	B-X
barriers	B-X
indicate	B-X
that	B-X
binding	B-X
sites	B-X
for	B-X
transcriptional	B-X
regulators	B-X
Rap1p	B-X
,	B-X
Abf1p	B-X
,	B-X
Reb1p	B-X
,	B-X
Adr1p	B-X
and	B-X
Gcn4p	B-X
may	B-X
participate	B-X
in	B-X
barrier	B-X
function	B-X
.	B-X
We	B-X
also	B-X
present	B-X
evidence	B-X
suggesting	B-X
that	B-X
Rap1p	B-X
is	B-X
directly	B-X
involved	B-X
in	B-X
barrier	B-X
activity	B-X
,	B-X
and	B-X
its	B-X
barrier	B-X
function	B-X
correlates	B-X
with	B-X
local	B-X
changes	B-X
in	B-X
chromatin	B-X
structure	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
tethering	B-X
the	B-X
transcriptional	B-X
activation	B-X
domain	B-X
of	B-X
Rap1p	B-X
to	B-X
DNA	B-X
is	B-X
sufficient	B-X
to	B-X
recapitulate	B-X
barrier	B-X
activity	B-X
.	B-X
These	B-X
results	B-X
support	B-X
the	B-X
notion	B-X
that	B-X
transcriptional	B-X
regulators	B-X
could	B-X
also	B-X
participate	B-X
in	B-X
delimiting	B-X
functional	B-X
domains	B-X
in	B-X
the	B-X
genome	B-X
.	B-X

Abstract	O
<EOS>	B-X
Abstract	B-X
writing	B-X
.	B-X
The	B-X
informative	B-X
abstract	B-X
.	B-X
Crafting	B-X
a	B-X
compelling	B-X
abstract	B-X
.	B-X
Why	B-X
the	B-X
structured	B-X
abstract	B-X
?	B-X

Barrier	O
elements	O
that	O
are	O
able	O
to	O
block	O
the	O
propagation	O
of	O
transcriptional	O
silencing	O
in	O
yeast	B-Species
are	O
functionally	O
similar	O
to	O
chromatin	O
boundary	O
/	O
insulator	O
elements	O
in	O
metazoans	O
that	O
delimit	O
functional	O
chromosomal	O
domains	O
.	O
<EOS>	B-X
Barrier	B-X
elements	B-X
that	B-X
are	B-X
able	B-X
to	B-X
block	B-X
the	B-X
propagation	B-X
of	B-X
transcriptional	B-X
silencing	B-X
in	B-X
yeast	B-X
are	B-X
functionally	B-X
similar	B-X
to	B-X
chromatin	B-X
boundary/insulator	B-X
elements	B-X
in	B-X
metazoans	B-X
that	B-X
delimit	B-X
functional	B-X
chromosomal	B-X
domains	B-X
.	B-X
Analyses	B-X
of	B-X
these	B-X
barriers	B-X
indicate	B-X
that	B-X
binding	B-X
sites	B-X
for	B-X
transcriptional	B-X
regulators	B-X
Rap1p	B-X
,	B-X
Abf1p	B-X
,	B-X
Reb1p	B-X
,	B-X
Adr1p	B-X
and	B-X
Gcn4p	B-X
may	B-X
participate	B-X
in	B-X
barrier	B-X
function	B-X
.	B-X
We	B-X
also	B-X
present	B-X
evidence	B-X
suggesting	B-X
that	B-X
Rap1p	B-X
is	B-X
directly	B-X
involved	B-X
in	B-X
barrier	B-X
activity	B-X
,	B-X
and	B-X
its	B-X
barrier	B-X
function	B-X
correlates	B-X
with	B-X
local	B-X
changes	B-X
in	B-X
chromatin	B-X
structure	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
tethering	B-X
the	B-X
transcriptional	B-X
activation	B-X
domain	B-X
of	B-X
Rap1p	B-X
to	B-X
DNA	B-X
is	B-X
sufficient	B-X
to	B-X
recapitulate	B-X
barrier	B-X
activity	B-X
.	B-X
Moreover	B-X
,	B-X
targeting	B-X
the	B-X
activation	B-X
domain	B-X
of	B-X
Adr1p	B-X
or	B-X
Gcn4p	B-X
also	B-X
establishes	B-X
a	B-X
barrier	B-X
to	B-X
silencing	B-X
.	B-X
These	B-X
results	B-X
support	B-X
the	B-X
notion	B-X
that	B-X
transcriptional	B-X
regulators	B-X
could	B-X
also	B-X
participate	B-X
in	B-X
delimiting	B-X
functional	B-X
domains	B-X
in	B-X
the	B-X
genome	B-X
.	B-X

We	O
show	O
that	O
the	O
upstream	O
activating	O
sequences	O
of	O
many	O
highly	O
expressed	O
ribosome	O
protein	O
genes	O
and	O
glycolytic	O
genes	O
exhibit	O
barrier	O
activity	O
.	O
<EOS>	B-X
We	B-X
show	B-X
that	B-X
the	B-X
upstream	B-X
activating	B-X
sequences	B-X
of	B-X
many	B-X
highly	B-X
expressed	B-X
ribosome	B-X
protein	B-X
genes	B-X
and	B-X
glycolytic	B-X
genes	B-X
exhibit	B-X
barrier	B-X
activity	B-X
.	B-X
Analyses	B-X
of	B-X
these	B-X
barriers	B-X
indicate	B-X
that	B-X
binding	B-X
sites	B-X
for	B-X
transcriptional	B-X
regulators	B-X
Rap1p	B-X
,	B-X
Abf1p	B-X
,	B-X
Reb1p	B-X
,	B-X
Adr1p	B-X
and	B-X
Gcn4p	B-X
may	B-X
participate	B-X
in	B-X
barrier	B-X
function	B-X
.	B-X
We	B-X
also	B-X
present	B-X
evidence	B-X
suggesting	B-X
that	B-X
Rap1p	B-X
is	B-X
directly	B-X
involved	B-X
in	B-X
barrier	B-X
activity	B-X
,	B-X
and	B-X
its	B-X
barrier	B-X
function	B-X
correlates	B-X
with	B-X
local	B-X
changes	B-X
in	B-X
chromatin	B-X
structure	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
tethering	B-X
the	B-X
transcriptional	B-X
activation	B-X
domain	B-X
of	B-X
Rap1p	B-X
to	B-X
DNA	B-X
is	B-X
sufficient	B-X
to	B-X
recapitulate	B-X
barrier	B-X
activity	B-X
.	B-X
Moreover	B-X
,	B-X
targeting	B-X
the	B-X
activation	B-X
domain	B-X
of	B-X
Adr1p	B-X
or	B-X
Gcn4p	B-X
also	B-X
establishes	B-X
a	B-X
barrier	B-X
to	B-X
silencing	B-X
.	B-X

Analyses	O
of	O
these	O
barriers	O
indicate	O
that	O
binding	O
sites	O
for	O
transcriptional	O
regulators	O
Rap1p	O
,	O
Abf1p	O
,	O
Reb1p	O
,	O
Adr1p	O
and	O
Gcn4p	O
may	O
participate	O
in	O
barrier	O
function	O
.	O
<EOS>	B-X
Barrier	B-X
elements	B-X
that	B-X
are	B-X
able	B-X
to	B-X
block	B-X
the	B-X
propagation	B-X
of	B-X
transcriptional	B-X
silencing	B-X
in	B-X
yeast	B-X
are	B-X
functionally	B-X
similar	B-X
to	B-X
chromatin	B-X
boundary/insulator	B-X
elements	B-X
in	B-X
metazoans	B-X
that	B-X
delimit	B-X
functional	B-X
chromosomal	B-X
domains	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
upstream	B-X
activating	B-X
sequences	B-X
of	B-X
many	B-X
highly	B-X
expressed	B-X
ribosome	B-X
protein	B-X
genes	B-X
and	B-X
glycolytic	B-X
genes	B-X
exhibit	B-X
barrier	B-X
activity	B-X
.	B-X
Analyses	B-X
of	B-X
these	B-X
barriers	B-X
indicate	B-X
that	B-X
binding	B-X
sites	B-X
for	B-X
transcriptional	B-X
regulators	B-X
Rap1p	B-X
,	B-X
Abf1p	B-X
,	B-X
Reb1p	B-X
,	B-X
Adr1p	B-X
and	B-X
Gcn4p	B-X
may	B-X
participate	B-X
in	B-X
barrier	B-X
function	B-X
.	B-X
We	B-X
also	B-X
present	B-X
evidence	B-X
suggesting	B-X
that	B-X
Rap1p	B-X
is	B-X
directly	B-X
involved	B-X
in	B-X
barrier	B-X
activity	B-X
,	B-X
and	B-X
its	B-X
barrier	B-X
function	B-X
correlates	B-X
with	B-X
local	B-X
changes	B-X
in	B-X
chromatin	B-X
structure	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
tethering	B-X
the	B-X
transcriptional	B-X
activation	B-X
domain	B-X
of	B-X
Rap1p	B-X
to	B-X
DNA	B-X
is	B-X
sufficient	B-X
to	B-X
recapitulate	B-X
barrier	B-X
activity	B-X
.	B-X
Moreover	B-X
,	B-X
targeting	B-X
the	B-X
activation	B-X
domain	B-X
of	B-X
Adr1p	B-X
or	B-X
Gcn4p	B-X
also	B-X
establishes	B-X
a	B-X
barrier	B-X
to	B-X
silencing	B-X
.	B-X
These	B-X
results	B-X
support	B-X
the	B-X
notion	B-X
that	B-X
transcriptional	B-X
regulators	B-X
could	B-X
also	B-X
participate	B-X
in	B-X
delimiting	B-X
functional	B-X
domains	B-X
in	B-X
the	B-X
genome	B-X
.	B-X

We	O
also	O
present	O
evidence	O
suggesting	O
that	O
Rap1p	O
is	O
directly	O
involved	O
in	O
barrier	O
activity	O
,	O
and	O
its	O
barrier	O
function	O
correlates	O
with	O
local	O
changes	O
in	O
chromatin	O
structure	O
.	O
<EOS>	B-X
Barrier	B-X
elements	B-X
that	B-X
are	B-X
able	B-X
to	B-X
block	B-X
the	B-X
propagation	B-X
of	B-X
transcriptional	B-X
silencing	B-X
in	B-X
yeast	B-X
are	B-X
functionally	B-X
similar	B-X
to	B-X
chromatin	B-X
boundary/insulator	B-X
elements	B-X
in	B-X
metazoans	B-X
that	B-X
delimit	B-X
functional	B-X
chromosomal	B-X
domains	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
upstream	B-X
activating	B-X
sequences	B-X
of	B-X
many	B-X
highly	B-X
expressed	B-X
ribosome	B-X
protein	B-X
genes	B-X
and	B-X
glycolytic	B-X
genes	B-X
exhibit	B-X
barrier	B-X
activity	B-X
.	B-X
Analyses	B-X
of	B-X
these	B-X
barriers	B-X
indicate	B-X
that	B-X
binding	B-X
sites	B-X
for	B-X
transcriptional	B-X
regulators	B-X
Rap1p	B-X
,	B-X
Abf1p	B-X
,	B-X
Reb1p	B-X
,	B-X
Adr1p	B-X
and	B-X
Gcn4p	B-X
may	B-X
participate	B-X
in	B-X
barrier	B-X
function	B-X
.	B-X
We	B-X
also	B-X
present	B-X
evidence	B-X
suggesting	B-X
that	B-X
Rap1p	B-X
is	B-X
directly	B-X
involved	B-X
in	B-X
barrier	B-X
activity	B-X
,	B-X
and	B-X
its	B-X
barrier	B-X
function	B-X
correlates	B-X
with	B-X
local	B-X
changes	B-X
in	B-X
chromatin	B-X
structure	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
tethering	B-X
the	B-X
transcriptional	B-X
activation	B-X
domain	B-X
of	B-X
Rap1p	B-X
to	B-X
DNA	B-X
is	B-X
sufficient	B-X
to	B-X
recapitulate	B-X
barrier	B-X
activity	B-X
.	B-X
Moreover	B-X
,	B-X
targeting	B-X
the	B-X
activation	B-X
domain	B-X
of	B-X
Adr1p	B-X
or	B-X
Gcn4p	B-X
also	B-X
establishes	B-X
a	B-X
barrier	B-X
to	B-X
silencing	B-X
.	B-X
These	B-X
results	B-X
support	B-X
the	B-X
notion	B-X
that	B-X
transcriptional	B-X
regulators	B-X
could	B-X
also	B-X
participate	B-X
in	B-X
delimiting	B-X
functional	B-X
domains	B-X
in	B-X
the	B-X
genome	B-X
.	B-X

We	O
further	O
demonstrate	O
that	O
tethering	O
the	O
transcriptional	O
activation	O
domain	O
of	O
Rap1p	O
to	O
DNA	O
is	O
sufficient	O
to	O
recapitulate	O
barrier	O
activity	O
.	O
<EOS>	B-X
Barrier	B-X
elements	B-X
that	B-X
are	B-X
able	B-X
to	B-X
block	B-X
the	B-X
propagation	B-X
of	B-X
transcriptional	B-X
silencing	B-X
in	B-X
yeast	B-X
are	B-X
functionally	B-X
similar	B-X
to	B-X
chromatin	B-X
boundary/insulator	B-X
elements	B-X
in	B-X
metazoans	B-X
that	B-X
delimit	B-X
functional	B-X
chromosomal	B-X
domains	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
upstream	B-X
activating	B-X
sequences	B-X
of	B-X
many	B-X
highly	B-X
expressed	B-X
ribosome	B-X
protein	B-X
genes	B-X
and	B-X
glycolytic	B-X
genes	B-X
exhibit	B-X
barrier	B-X
activity	B-X
.	B-X
Analyses	B-X
of	B-X
these	B-X
barriers	B-X
indicate	B-X
that	B-X
binding	B-X
sites	B-X
for	B-X
transcriptional	B-X
regulators	B-X
Rap1p	B-X
,	B-X
Abf1p	B-X
,	B-X
Reb1p	B-X
,	B-X
Adr1p	B-X
and	B-X
Gcn4p	B-X
may	B-X
participate	B-X
in	B-X
barrier	B-X
function	B-X
.	B-X
We	B-X
also	B-X
present	B-X
evidence	B-X
suggesting	B-X
that	B-X
Rap1p	B-X
is	B-X
directly	B-X
involved	B-X
in	B-X
barrier	B-X
activity	B-X
,	B-X
and	B-X
its	B-X
barrier	B-X
function	B-X
correlates	B-X
with	B-X
local	B-X
changes	B-X
in	B-X
chromatin	B-X
structure	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
tethering	B-X
the	B-X
transcriptional	B-X
activation	B-X
domain	B-X
of	B-X
Rap1p	B-X
to	B-X
DNA	B-X
is	B-X
sufficient	B-X
to	B-X
recapitulate	B-X
barrier	B-X
activity	B-X
.	B-X
Moreover	B-X
,	B-X
targeting	B-X
the	B-X
activation	B-X
domain	B-X
of	B-X
Adr1p	B-X
or	B-X
Gcn4p	B-X
also	B-X
establishes	B-X
a	B-X
barrier	B-X
to	B-X
silencing	B-X
.	B-X
These	B-X
results	B-X
support	B-X
the	B-X
notion	B-X
that	B-X
transcriptional	B-X
regulators	B-X
could	B-X
also	B-X
participate	B-X
in	B-X
delimiting	B-X
functional	B-X
domains	B-X
in	B-X
the	B-X
genome	B-X
.	B-X

Moreover	O
,	O
targeting	O
the	O
activation	O
domain	O
of	O
Adr1p	O
or	O
Gcn4p	O
also	O
establishes	O
a	O
barrier	O
to	O
silencing	O
.	O
<EOS>	B-X
Barrier	B-X
elements	B-X
that	B-X
are	B-X
able	B-X
to	B-X
block	B-X
the	B-X
propagation	B-X
of	B-X
transcriptional	B-X
silencing	B-X
in	B-X
yeast	B-X
are	B-X
functionally	B-X
similar	B-X
to	B-X
chromatin	B-X
boundary/insulator	B-X
elements	B-X
in	B-X
metazoans	B-X
that	B-X
delimit	B-X
functional	B-X
chromosomal	B-X
domains	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
upstream	B-X
activating	B-X
sequences	B-X
of	B-X
many	B-X
highly	B-X
expressed	B-X
ribosome	B-X
protein	B-X
genes	B-X
and	B-X
glycolytic	B-X
genes	B-X
exhibit	B-X
barrier	B-X
activity	B-X
.	B-X
Analyses	B-X
of	B-X
these	B-X
barriers	B-X
indicate	B-X
that	B-X
binding	B-X
sites	B-X
for	B-X
transcriptional	B-X
regulators	B-X
Rap1p	B-X
,	B-X
Abf1p	B-X
,	B-X
Reb1p	B-X
,	B-X
Adr1p	B-X
and	B-X
Gcn4p	B-X
may	B-X
participate	B-X
in	B-X
barrier	B-X
function	B-X
.	B-X
We	B-X
also	B-X
present	B-X
evidence	B-X
suggesting	B-X
that	B-X
Rap1p	B-X
is	B-X
directly	B-X
involved	B-X
in	B-X
barrier	B-X
activity	B-X
,	B-X
and	B-X
its	B-X
barrier	B-X
function	B-X
correlates	B-X
with	B-X
local	B-X
changes	B-X
in	B-X
chromatin	B-X
structure	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
tethering	B-X
the	B-X
transcriptional	B-X
activation	B-X
domain	B-X
of	B-X
Rap1p	B-X
to	B-X
DNA	B-X
is	B-X
sufficient	B-X
to	B-X
recapitulate	B-X
barrier	B-X
activity	B-X
.	B-X
Moreover	B-X
,	B-X
targeting	B-X
the	B-X
activation	B-X
domain	B-X
of	B-X
Adr1p	B-X
or	B-X
Gcn4p	B-X
also	B-X
establishes	B-X
a	B-X
barrier	B-X
to	B-X
silencing	B-X
.	B-X
These	B-X
results	B-X
support	B-X
the	B-X
notion	B-X
that	B-X
transcriptional	B-X
regulators	B-X
could	B-X
also	B-X
participate	B-X
in	B-X
delimiting	B-X
functional	B-X
domains	B-X
in	B-X
the	B-X
genome	B-X
.	B-X

These	O
results	O
support	O
the	O
notion	O
that	O
transcriptional	O
regulators	O
could	O
also	O
participate	O
in	O
delimiting	O
functional	O
domains	O
in	O
the	O
genome	O
.	O
<EOS>	B-X
Barrier	B-X
elements	B-X
that	B-X
are	B-X
able	B-X
to	B-X
block	B-X
the	B-X
propagation	B-X
of	B-X
transcriptional	B-X
silencing	B-X
in	B-X
yeast	B-X
are	B-X
functionally	B-X
similar	B-X
to	B-X
chromatin	B-X
boundary/insulator	B-X
elements	B-X
in	B-X
metazoans	B-X
that	B-X
delimit	B-X
functional	B-X
chromosomal	B-X
domains	B-X
.	B-X
Analyses	B-X
of	B-X
these	B-X
barriers	B-X
indicate	B-X
that	B-X
binding	B-X
sites	B-X
for	B-X
transcriptional	B-X
regulators	B-X
Rap1p	B-X
,	B-X
Abf1p	B-X
,	B-X
Reb1p	B-X
,	B-X
Adr1p	B-X
and	B-X
Gcn4p	B-X
may	B-X
participate	B-X
in	B-X
barrier	B-X
function	B-X
.	B-X
We	B-X
also	B-X
present	B-X
evidence	B-X
suggesting	B-X
that	B-X
Rap1p	B-X
is	B-X
directly	B-X
involved	B-X
in	B-X
barrier	B-X
activity	B-X
,	B-X
and	B-X
its	B-X
barrier	B-X
function	B-X
correlates	B-X
with	B-X
local	B-X
changes	B-X
in	B-X
chromatin	B-X
structure	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
tethering	B-X
the	B-X
transcriptional	B-X
activation	B-X
domain	B-X
of	B-X
Rap1p	B-X
to	B-X
DNA	B-X
is	B-X
sufficient	B-X
to	B-X
recapitulate	B-X
barrier	B-X
activity	B-X
.	B-X
Moreover	B-X
,	B-X
targeting	B-X
the	B-X
activation	B-X
domain	B-X
of	B-X
Adr1p	B-X
or	B-X
Gcn4p	B-X
also	B-X
establishes	B-X
a	B-X
barrier	B-X
to	B-X
silencing	B-X
.	B-X
These	B-X
results	B-X
support	B-X
the	B-X
notion	B-X
that	B-X
transcriptional	B-X
regulators	B-X
could	B-X
also	B-X
participate	B-X
in	B-X
delimiting	B-X
functional	B-X
domains	B-X
in	B-X
the	B-X
genome	B-X
.	B-X

INTRODUCTION	O

The	O
eukaryotic	O
genome	O
is	O
organized	O
into	O
discrete	O
functional	O
domains	O
in	O
which	O
gene	O
expression	O
is	O
either	O
permitted	O
or	O
repressed	O
.	O
<EOS>	B-X
This	B-X
long-standing	B-X
question	B-X
about	B-X
the	B-X
existence	B-X
of	B-X
repressed	B-X
memories	B-X
has	B-X
been	B-X
at	B-X
the	B-X
heart	B-X
of	B-X
one	B-X
of	B-X
the	B-X
most	B-X
heated	B-X
debates	B-X
in	B-X
modern	B-X
psychology	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
this	B-X
assumption	B-X
is	B-X
incorrect	B-X
and	B-X
that	B-X
the	B-X
controversial	B-X
issue	B-X
of	B-X
repressed	B-X
memories	B-X
is	B-X
alive	B-X
and	B-X
well	B-X
and	B-X
may	B-X
even	B-X
be	B-X
on	B-X
the	B-X
rise	B-X
.	B-X
We	B-X
review	B-X
converging	B-X
research	B-X
and	B-X
data	B-X
from	B-X
legal	B-X
cases	B-X
indicating	B-X
that	B-X
the	B-X
topic	B-X
of	B-X
repressed	B-X
memories	B-X
remains	B-X
active	B-X
in	B-X
clinical	B-X
,	B-X
legal	B-X
,	B-X
and	B-X
academic	B-X
settings	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
belief	B-X
in	B-X
repressed	B-X
memories	B-X
occurs	B-X
on	B-X
a	B-X
nontrivial	B-X
scale	B-X
(	B-X
58	B-X
%	B-X
)	B-X
and	B-X
appears	B-X
to	B-X
have	B-X
increased	B-X
among	B-X
clinical	B-X
psychologists	B-X
since	B-X
the	B-X
1990s	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
review	B-X
work	B-X
on	B-X
the	B-X
adverse	B-X
side	B-X
effects	B-X
of	B-X
certain	B-X
psychotherapeutic	B-X
techniques	B-X
,	B-X
some	B-X
of	B-X
which	B-X
may	B-X
be	B-X
linked	B-X
to	B-X
the	B-X
recovery	B-X
of	B-X
repressed	B-X
memories	B-X
.	B-X

Domains	O
permissive	O
for	O
gene	O
expression	O
are	O
usually	O
defined	O
as	O
euchromatin	O
or	O
active	O
chromatin	O
,	O
and	O
domains	O
that	O
repress	O
gene	O
expression	O
heterochromatin	O
or	O
silent	O
chromatin	O
.	O
<EOS>	B-X
Chromatin	B-X
,	B-X
the	B-X
physiological	B-X
template	B-X
of	B-X
all	B-X
eukaryotic	B-X
genetic	B-X
information	B-X
,	B-X
is	B-X
subject	B-X
to	B-X
a	B-X
diverse	B-X
array	B-X
of	B-X
posttranslational	B-X
modifications	B-X
that	B-X
largely	B-X
impinge	B-X
on	B-X
histone	B-X
amino	B-X
termini	B-X
,	B-X
thereby	B-X
regulating	B-X
access	B-X
to	B-X
the	B-X
underlying	B-X
DNA	B-X
.	B-X
Distinct	B-X
histone	B-X
amino-terminal	B-X
modifications	B-X
can	B-X
generate	B-X
synergistic	B-X
or	B-X
antagonistic	B-X
interaction	B-X
affinities	B-X
for	B-X
chromatin-associated	B-X
proteins	B-X
,	B-X
which	B-X
in	B-X
turn	B-X
dictate	B-X
dynamic	B-X
transitions	B-X
between	B-X
transcriptionally	B-X
active	B-X
or	B-X
transcriptionally	B-X
silent	B-X
chromatin	B-X
states	B-X
.	B-X
The	B-X
combinatorial	B-X
nature	B-X
of	B-X
histone	B-X
amino-terminal	B-X
modifications	B-X
thus	B-X
reveals	B-X
a	B-X
``	B-X
histone	B-X
code	B-X
''	B-X
that	B-X
considerably	B-X
extends	B-X
the	B-X
information	B-X
potential	B-X
of	B-X
the	B-X
genetic	B-X
code	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
this	B-X
epigenetic	B-X
marking	B-X
system	B-X
represents	B-X
a	B-X
fundamental	B-X
regulatory	B-X
mechanism	B-X
that	B-X
has	B-X
an	B-X
impact	B-X
on	B-X
most	B-X
,	B-X
if	B-X
not	B-X
all	B-X
,	B-X
chromatin-templated	B-X
processes	B-X
,	B-X
with	B-X
far-reaching	B-X
consequences	B-X
for	B-X
cell	B-X
fate	B-X
decisions	B-X
and	B-X
both	B-X
normal	B-X
and	B-X
pathological	B-X
development	B-X
.	B-X

The	O
HML	O
and	O
HMR	O
loci	O
in	O
Saccharomyces	B-Species
cerevisiae	I-Species
are	O
silent	O
chromatin	O
domains	O
(	O
1	O
)	O
.	O
<EOS>	B-X
In	B-X
the	B-X
budding	B-X
yeast	B-X
Saccharomyces	B-X
cerevisiae	B-X
,	B-X
heterochromatic	B-X
gene	B-X
silencing	B-X
has	B-X
been	B-X
found	B-X
within	B-X
HMR	B-X
and	B-X
HML	B-X
silent	B-X
mating	B-X
type	B-X
loci	B-X
,	B-X
the	B-X
telomeres	B-X
,	B-X
and	B-X
the	B-X
rRNA-encoding	B-X
DNA	B-X
.	B-X
There	B-X
may	B-X
be	B-X
boundary	B-X
elements	B-X
that	B-X
regulate	B-X
the	B-X
spread	B-X
of	B-X
silencing	B-X
to	B-X
protect	B-X
genes	B-X
adjacent	B-X
to	B-X
silenced	B-X
domains	B-X
from	B-X
this	B-X
epigenetic	B-X
repressive	B-X
effect	B-X
.	B-X
Here	B-X
,	B-X
the	B-X
characteristics	B-X
and	B-X
functions	B-X
of	B-X
boundaries	B-X
at	B-X
silenced	B-X
domains	B-X
in	B-X
S.	B-X
cerevisiae	B-X
are	B-X
discussed	B-X
.	B-X
Saccharomyces	B-X
cerevisiae	B-X
Esc2p	B-X
is	B-X
a	B-X
member	B-X
of	B-X
a	B-X
conserved	B-X
family	B-X
of	B-X
proteins	B-X
that	B-X
contain	B-X
small	B-X
ubiquitin-like	B-X
modifier	B-X
(	B-X
SUMO	B-X
)	B-X
-like	B-X
domains	B-X
.	B-X
However	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
how	B-X
Esc2p	B-X
regulates	B-X
the	B-X
structure	B-X
of	B-X
silent	B-X
chromatin	B-X
.	B-X
We	B-X
demonstrate	B-X
here	B-X
that	B-X
ESC2	B-X
differentially	B-X
regulates	B-X
silent	B-X
chromatin	B-X
at	B-X
telomeric	B-X
,	B-X
rDNA	B-X
,	B-X
and	B-X
HM	B-X
loci	B-X
.	B-X
Specifically	B-X
,	B-X
ESC2	B-X
is	B-X
required	B-X
for	B-X
efficient	B-X
telomeric	B-X
silencing	B-X
and	B-X
Sir2p	B-X
association	B-X
with	B-X
telomeric	B-X
silent	B-X
chromatin	B-X
and	B-X
for	B-X
silencing	B-X
and	B-X
maintenance	B-X
of	B-X
silent	B-X
chromatin	B-X
structure	B-X
at	B-X
rDNA	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
ESC2	B-X
negatively	B-X
regulates	B-X
silencing	B-X
at	B-X
HML	B-X
and	B-X
HMR	B-X
and	B-X
destabilizes	B-X
HML	B-X
silent	B-X
chromatin	B-X
without	B-X
affecting	B-X
Sir2p	B-X
association	B-X
with	B-X
chromatin	B-X
.	B-X
We	B-X
present	B-X
evidence	B-X
that	B-X
Esc2p	B-X
is	B-X
associated	B-X
with	B-X
both	B-X
transcriptionally	B-X
silent	B-X
and	B-X
active	B-X
loci	B-X
in	B-X
the	B-X
genome	B-X
,	B-X
and	B-X
the	B-X
abundance	B-X
of	B-X
Esc2p	B-X
is	B-X
not	B-X
correlated	B-X
with	B-X
the	B-X
chromatin	B-X
state	B-X
at	B-X
a	B-X
particular	B-X
locus	B-X
.	B-X

Compared	O
to	O
active	O
chromatin	O
,	O
silent	O
chromatin	O
is	O
more	O
compact	O
and	O
its	O
histone	O
components	O
are	O
hypoacetylated	O
(	O
2	O
)	O
.	O

The	O
SIR	O
complex	O
consisting	O
of	O
Sir2p	O
through	O
Sir4p	O
is	O
an	O
integral	O
part	O
of	O
yeast	B-Species
silent	O
chromatin	O
.	O

Sir3p	O
and	O
Sir4p	O
interact	O
with	O
the	O
N	O
-	O
terminal	O
tails	O
of	O
histones	O
H3	O
and	O
H4	O
providing	O
the	O
structural	O
basis	O
of	O
silent	O
chromatin	O
(	O
1	O
)	O
.	O

Sir2p	O
was	O
recently	O
found	O
to	O
be	O
an	O
NAD	O
-	O
dependent	O
histone	O
deacetylase	O
and	O
was	O
suggested	O
to	O
be	O
responsible	O
for	O
histone	O
hypoacetylation	O
in	O
silent	O
chromatin	O
(	O
3	O
)	O
.	O

Silent	O
chromatin	O
is	O
initiated	O
at	O
small	O
cis	O
-	O
acting	O
DNA	O
elements	O
known	O
as	O
the	O
E	O
and	O
I	O
silencers	O
flanking	O
each	O
of	O
the	O
HM	O
loci	O
(	O
4	O
)	O
.	O

Increasing	O
evidence	O
indicates	O
that	O
histone	O
deacetylation	O
is	O
key	O
to	O
the	O
propagation	O
of	O
silent	O
chromatin	O
(	O
4	O
)	O
.	O

In	O
vertebrates	O
and	O
fission	O
yeast	B-Species
,	O
spread	O
of	O
silent	O
chromatin	O
involves	O
a	O
chain	O
of	O
events	O
of	O
histone	O
H3	O
deacetylation	O
-->	O
H3	O
methylation	O
-->	O
binding	O
of	O
methylated	O
H3	O
by	O
HP1	O
(	O
heterochromatin	O
protein	O
1	O
)	O
or	O
swi6	O
(	O
4	O
)	O
.	O

In	O
S	B-Species
.	I-Species
cerevisiae	I-Species
,	O
there	O
is	O
evidence	O
that	O
Sir3p	O
(	O
hence	O
the	O
SIR	O
complex	O
)	O
has	O
much	O
higher	O
affinity	O
to	O
unacetylated	O
histone	O
H4	O
than	O
acetylated	O
H4	O
(	O
5	O
)	O
.	O

Based	O
on	O
this	O
and	O
the	O
fact	O
that	O
Sir2p	O
is	O
a	O
histone	O
deacetylase	O
,	O
a	O
refined	O
model	O
for	O
the	O
propagation	O
of	O
silent	O
chromatin	O
can	O
be	O
proposed	O
.	O

In	O
this	O
model	O
,	O
Sir2p	O
recruited	O
to	O
the	O
silencer	O
deacetylates	O
histones	O
in	O
an	O
adjacent	O
nucleosome	O
enabling	O
it	O
to	O
bind	O
another	O
SIR	O
complex	O
with	O
high	O
affinity	O
.	O

The	O
nucleosome	O
-	O
bound	O
SIR	O
complex	O
in	O
turn	O
deacetylates	O
the	O
neighboring	O
nucleosome	O
allowing	O
it	O
to	O
recruit	O
a	O
new	O
SIR	O
complex	O
.	O

In	O
this	O
manner	O
,	O
the	O
SIR	O
complex	O
promotes	O
its	O
own	O
propagation	O
along	O
an	O
array	O
of	O
nucleosomes	O
(	O
4	O
)	O
.	O

The	O
fact	O
that	O
transcriptionally	O
silent	O
chromatin	O
can	O
encroach	O
upon	O
active	O
chromatin	O
poses	O
the	O
question	O
of	O
how	O
interspersed	O
domains	O
of	O
silent	O
and	O
active	O
chromatin	O
are	O
demarcated	O
.	O

Studies	O
of	O
the	O
Drosophila	O
and	O
vertebrate	O
genomes	O
demonstrated	O
that	O
some	O
domains	O
are	O
delimited	O
by	O
boundary	O
or	O
insulator	O
elements	O
(	O
6	O
)	O
.	O
<EOS>	B-X
Chromatin	B-X
insulators	B-X
are	B-X
factors	B-X
involved	B-X
in	B-X
higher-order	B-X
,	B-X
genome-wide	B-X
organization	B-X
of	B-X
chromatin	B-X
,	B-X
and	B-X
play	B-X
key	B-X
roles	B-X
in	B-X
regulating	B-X
transcriptional	B-X
programs	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
recent	B-X
studies	B-X
on	B-X
the	B-X
diverse	B-X
composition	B-X
of	B-X
insulator	B-X
complexes	B-X
,	B-X
and	B-X
on	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
they	B-X
establish	B-X
long-range	B-X
DNA	B-X
interactions	B-X
.	B-X
As	B-X
an	B-X
alternative	B-X
,	B-X
several	B-X
groups	B-X
have	B-X
been	B-X
investigating	B-X
a	B-X
class	B-X
of	B-X
DNA	B-X
regulatory	B-X
elements	B-X
known	B-X
as	B-X
chromatin	B-X
insulators	B-X
.	B-X
These	B-X
elements	B-X
provide	B-X
a	B-X
means	B-X
of	B-X
blocking	B-X
the	B-X
interaction	B-X
between	B-X
an	B-X
integrating	B-X
vector	B-X
and	B-X
the	B-X
target	B-X
cell	B-X
genome	B-X
in	B-X
a	B-X
manner	B-X
that	B-X
is	B-X
independent	B-X
of	B-X
the	B-X
vector	B-X
transgene	B-X
,	B-X
regulatory	B-X
elements	B-X
,	B-X
or	B-X
virus	B-X
of	B-X
origin	B-X
.	B-X
This	B-X
review	B-X
outlines	B-X
the	B-X
background	B-X
,	B-X
rationale	B-X
,	B-X
and	B-X
evidence	B-X
for	B-X
using	B-X
chromatin	B-X
insulators	B-X
to	B-X
improve	B-X
the	B-X
expression	B-X
and	B-X
safety	B-X
of	B-X
gene	B-X
transfer	B-X
vectors	B-X
.	B-X
Also	B-X
reviewed	B-X
are	B-X
topological	B-X
factors	B-X
that	B-X
constrain	B-X
the	B-X
use	B-X
of	B-X
insulators	B-X
in	B-X
integrating	B-X
gene	B-X
transfer	B-X
vectors	B-X
,	B-X
alternative	B-X
sources	B-X
of	B-X
insulators	B-X
,	B-X
and	B-X
the	B-X
role	B-X
of	B-X
chromatin	B-X
insulators	B-X
as	B-X
one	B-X
of	B-X
several	B-X
components	B-X
for	B-X
optimal	B-X
vector	B-X
design	B-X
.	B-X

These	O
elements	O
are	O
specialized	O
DNA	O
sequences	O
that	O
act	O
as	O
barriers	O
to	O
enhancers	O
and	O
/	O
or	O
silent	O
chromatin	O
.	O
<EOS>	B-X
Chromatin	B-X
,	B-X
the	B-X
physiological	B-X
template	B-X
of	B-X
all	B-X
eukaryotic	B-X
genetic	B-X
information	B-X
,	B-X
is	B-X
subject	B-X
to	B-X
a	B-X
diverse	B-X
array	B-X
of	B-X
posttranslational	B-X
modifications	B-X
that	B-X
largely	B-X
impinge	B-X
on	B-X
histone	B-X
amino	B-X
termini	B-X
,	B-X
thereby	B-X
regulating	B-X
access	B-X
to	B-X
the	B-X
underlying	B-X
DNA	B-X
.	B-X
Distinct	B-X
histone	B-X
amino-terminal	B-X
modifications	B-X
can	B-X
generate	B-X
synergistic	B-X
or	B-X
antagonistic	B-X
interaction	B-X
affinities	B-X
for	B-X
chromatin-associated	B-X
proteins	B-X
,	B-X
which	B-X
in	B-X
turn	B-X
dictate	B-X
dynamic	B-X
transitions	B-X
between	B-X
transcriptionally	B-X
active	B-X
or	B-X
transcriptionally	B-X
silent	B-X
chromatin	B-X
states	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
this	B-X
epigenetic	B-X
marking	B-X
system	B-X
represents	B-X
a	B-X
fundamental	B-X
regulatory	B-X
mechanism	B-X
that	B-X
has	B-X
an	B-X
impact	B-X
on	B-X
most	B-X
,	B-X
if	B-X
not	B-X
all	B-X
,	B-X
chromatin-templated	B-X
processes	B-X
,	B-X
with	B-X
far-reaching	B-X
consequences	B-X
for	B-X
cell	B-X
fate	B-X
decisions	B-X
and	B-X
both	B-X
normal	B-X
and	B-X
pathological	B-X
development	B-X
.	B-X
Pioneer	B-X
transcription	B-X
factors	B-X
have	B-X
the	B-X
intrinsic	B-X
biochemical	B-X
ability	B-X
to	B-X
scan	B-X
partial	B-X
DNA	B-X
sequence	B-X
motifs	B-X
that	B-X
are	B-X
exposed	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
a	B-X
nucleosome	B-X
and	B-X
thus	B-X
access	B-X
silent	B-X
genes	B-X
that	B-X
are	B-X
inaccessible	B-X
to	B-X
other	B-X
transcription	B-X
factors	B-X
.	B-X
Pioneer	B-X
factors	B-X
subsequently	B-X
enable	B-X
other	B-X
transcription	B-X
factors	B-X
,	B-X
nucleosome	B-X
remodeling	B-X
complexes	B-X
,	B-X
and	B-X
histone	B-X
modifiers	B-X
to	B-X
engage	B-X
chromatin	B-X
,	B-X
thereby	B-X
initiating	B-X
the	B-X
formation	B-X
of	B-X
an	B-X
activating	B-X
or	B-X
repressive	B-X
regulatory	B-X
sequence	B-X
.	B-X
Thus	B-X
,	B-X
pioneer	B-X
factors	B-X
endow	B-X
the	B-X
competence	B-X
for	B-X
fate	B-X
changes	B-X
in	B-X
embryonic	B-X
development	B-X
,	B-X
are	B-X
essential	B-X
for	B-X
cellular	B-X
reprogramming	B-X
,	B-X
and	B-X
rewire	B-X
gene	B-X
networks	B-X
in	B-X
cancer	B-X
cells	B-X
.	B-X
Recent	B-X
studies	B-X
with	B-X
reconstituted	B-X
nucleosomes	B-X
in	B-X
vitro	B-X
and	B-X
chromatin	B-X
binding	B-X
in	B-X
vivo	B-X
reveal	B-X
that	B-X
pioneer	B-X
factors	B-X
can	B-X
directly	B-X
perturb	B-X
nucleosome	B-X
structure	B-X
and	B-X
chromatin	B-X
accessibility	B-X
in	B-X
different	B-X
ways	B-X
.	B-X
This	B-X
review	B-X
focuses	B-X
on	B-X
our	B-X
current	B-X
understanding	B-X
of	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
pioneer	B-X
factors	B-X
initiate	B-X
gene	B-X
network	B-X
changes	B-X
and	B-X
will	B-X
ultimately	B-X
contribute	B-X
to	B-X
our	B-X
ability	B-X
to	B-X
control	B-X
cell	B-X
fates	B-X
at	B-X
will	B-X
.	B-X

One	O
of	O
the	O
best	O
characterized	O
insulators	O
is	O
the	O
chicken	B-Species
HS4	O
insulator	O
at	O
the	O
beta	O
-	O
globin	O
locus	O
.	O

Histones	O
surrounding	O
this	O
insulator	O
are	O
hyperacetylated	O
indicating	O
the	O
presence	O
of	O
histone	O
acetyltransferase	O
(	O
HAT	O
)	O
activity	O
at	O
the	O
insulator	O
(	O
6	O
)	O
.	O

Recently	O
,	O
sequences	O
that	O
could	O
block	O
the	O
spread	O
of	O
silent	O
chromatin	O
have	O
been	O
discovered	O
in	O
S	B-Species
.	I-Species
cerevisiae	I-Species
(	O
7	O
,	O
8	O
)	O
.	O

These	O
sequences	O
(	O
referred	O
to	O
as	O
silent	O
chromatin	O
barriers	O
)	O
include	O
sub	O
-	O
telomeric	O
anti	O
-	O
silencing	O
regions	O
(	O
STARs	O
)	O
,	O
the	O
right	O
boundary	O
of	O
HMR	O
,	O
and	O
the	O
upstream	O
activating	O
sequence	O
(	O
UAS	O
)	O
of	O
the	O
highly	O
expressed	O
TEF2	O
gene	O
(	O
9	O
-	O
11	O
)	O
.	O

The	O
mechanisms	O
underlying	O
barrier	O
functions	O
in	O
yeast	B-Species
are	O
not	O
known	O
.	O
<EOS>	B-X
It	B-X
exists	B-X
as	B-X
a	B-X
commensal	B-X
in	B-X
the	B-X
oral	B-X
cavity	B-X
,	B-X
gut	B-X
or	B-X
genital	B-X
tract	B-X
of	B-X
most	B-X
individuals	B-X
,	B-X
constrained	B-X
by	B-X
the	B-X
local	B-X
microbiota	B-X
,	B-X
epithelial	B-X
barriers	B-X
and	B-X
immune	B-X
defences	B-X
.	B-X
Due	B-X
to	B-X
its	B-X
nature	B-X
as	B-X
a	B-X
structural	B-X
pigment	B-X
,	B-X
higher	B-X
lutein	B-X
content	B-X
might	B-X
interfere	B-X
with	B-X
the	B-X
LHC	B-X
in	B-X
fulfilling	B-X
photosynthetic	B-X
functions	B-X
.	B-X
Storing	B-X
lutein	B-X
in	B-X
a	B-X
lipophilic	B-X
environment	B-X
is	B-X
a	B-X
mechanism	B-X
for	B-X
achieving	B-X
high	B-X
lutein	B-X
content	B-X
but	B-X
several	B-X
critical	B-X
barriers	B-X
must	B-X
be	B-X
overcome	B-X
such	B-X
as	B-X
lutein	B-X
degradation	B-X
and	B-X
access	B-X
to	B-X
lipid	B-X
droplet	B-X
to	B-X
be	B-X
stored	B-X
through	B-X
esterification	B-X
.	B-X
Understanding	B-X
the	B-X
mechanisms	B-X
underlying	B-X
lipid	B-X
droplet	B-X
biogenesis	B-X
in	B-X
chloroplasts	B-X
,	B-X
as	B-X
well	B-X
as	B-X
carotenoid	B-X
trafficking	B-X
through	B-X
chloroplast	B-X
membranes	B-X
and	B-X
carotenoid	B-X
esterification	B-X
,	B-X
may	B-X
provide	B-X
insight	B-X
for	B-X
new	B-X
approaches	B-X
to	B-X
achieve	B-X
high	B-X
lutein	B-X
contents	B-X
in	B-X
algae	B-X
.	B-X
In	B-X
the	B-X
meantime	B-X
,	B-X
building	B-X
the	B-X
machinery	B-X
for	B-X
esterification	B-X
and	B-X
sequestration	B-X
of	B-X
lutein	B-X
and	B-X
other	B-X
hydroxyl-carotenoids	B-X
in	B-X
model	B-X
microorganisms	B-X
,	B-X
such	B-X
as	B-X
yeast	B-X
,	B-X
with	B-X
synthetic	B-X
biology	B-X
technology	B-X
provides	B-X
a	B-X
promising	B-X
option	B-X
.	B-X

TEF2	O
-	O
UAS	O
contains	O
three	O
tandem	O
repressor	O
activator	O
protein	O
1	O
(	O
Rap1p	O
)	O
-	O
binding	O
sites	O
that	O
are	O
necessary	O
and	O
sufficient	O
for	O
its	O
barrier	O
function	O
(	O
11	O
)	O
.	O

Rap1p	O
is	O
an	O
abundant	O
sequence	O
-	O
specific	O
DNA	O
-	O
binding	O
protein	O
(	O
12	O
)	O
.	O

Variants	O
of	O
the	O
13	O
bp	O
consensus	O
sequence	O
for	O
Rap1p	O
binding	O
(	O
ACACC	O
CRYACAYM	O
)	O
(	O
13	O
)	O
lie	O
not	O
only	O
in	O
the	O
UASs	O
of	O
numerous	O
genes	O
but	O
also	O
in	O
the	O
silencers	O
of	O
the	O
HM	O
loci	O
and	O
in	O
telomeric	O
C1	O
-	O
3A	O
repeats	O
.	O

Accordingly	O
,	O
Rap1p	O
functions	O
as	O
a	O
global	O
regulator	O
of	O
transcriptional	O
activation	O
and	O
repression	O
,	O
silencing	O
,	O
as	O
well	O
as	O
telomere	O
length	O
(	O
12	O
)	O
.	O

Rap1p	O
performs	O
these	O
diverse	O
functions	O
by	O
interacting	O
with	O
different	O
factors	O
in	O
respective	O
contexts	O
.	O

As	O
an	O
activator	O
,	O
Rap1p	O
binds	O
to	O
the	O
promoters	O
of	O
362	O
ORFs	O
(	O
13	O
)	O
and	O
can	O
function	O
via	O
at	O
least	O
three	O
mechanisms	O
.	O

First	O
,	O
Rap1p	O
binding	O
can	O
'	O
open	O
up	O
'	O
local	O
chromatin	O
structure	O
at	O
a	O
promoter	O
to	O
help	O
another	O
activator	O
to	O
bind	O
(	O
14	O
)	O
.	O

Secondly	O
,	O
Rap1p	O
bound	O
to	O
DNA	O
can	O
help	O
Gcr1p	O
bind	O
to	O
an	O
adjacent	O
site	O
in	O
the	O
promoter	O
through	O
physical	O
interaction	O
(	O
15	O
)	O
.	O

Thirdly	O
,	O
Rap1p	O
is	O
involved	O
in	O
the	O
recruitment	O
of	O
the	O
NuA4	O
HAT	O
complex	O
and	O
TFIID	O
to	O
ribosome	O
protein	O
genes	O
(	O
RPGs	O
)	O
(	O
16	O
,	O
17	O
)	O
.	O

As	O
a	O
silencing	O
factor	O
,	O
Rap1p	O
binds	O
to	O
silencers	O
or	O
telomeric	O
repeats	O
and	O
recruits	O
Sir3p	O
/	O
Sir4p	O
through	O
direct	O
interactions	O
(	O
18	O
)	O
.	O
<EOS>	B-X
The	B-X
DNA-binding	B-X
protein	B-X
Rap1p	B-X
fulfills	B-X
many	B-X
different	B-X
functions	B-X
in	B-X
the	B-X
yeast	B-X
cell	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
Rap1p	B-X
is	B-X
an	B-X
essential	B-X
structural	B-X
component	B-X
of	B-X
yeast	B-X
telomeres	B-X
,	B-X
where	B-X
it	B-X
contributes	B-X
to	B-X
telomeric	B-X
silencing	B-X
.	B-X
Here	B-X
we	B-X
review	B-X
the	B-X
evidence	B-X
indicating	B-X
that	B-X
Rap1p	B-X
function	B-X
is	B-X
modulated	B-X
by	B-X
the	B-X
precise	B-X
architecture	B-X
of	B-X
the	B-X
its	B-X
binding	B-X
site	B-X
and	B-X
its	B-X
surroundings	B-X
:	B-X
long	B-X
tracts	B-X
of	B-X
telomeric	B-X
repeats	B-X
for	B-X
telomeric	B-X
functions	B-X
,	B-X
specific	B-X
sequences	B-X
and	B-X
orientation	B-X
for	B-X
maximal	B-X
transcriptional	B-X
activation	B-X
,	B-X
and	B-X
specific	B-X
DNA	B-X
recognition	B-X
sequences	B-X
for	B-X
complementary	B-X
factors	B-X
in	B-X
other	B-X
cases	B-X
.	B-X
Many	B-X
of	B-X
these	B-X
functions	B-X
are	B-X
probably	B-X
related	B-X
to	B-X
chromatin	B-X
organization	B-X
around	B-X
Rap1p	B-X
DNA	B-X
binding	B-X
sites	B-X
,	B-X
resulting	B-X
from	B-X
the	B-X
very	B-X
tight	B-X
binding	B-X
of	B-X
Rap1p	B-X
to	B-X
DNA	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
Rap1p	B-X
alters	B-X
its	B-X
structure	B-X
to	B-X
bind	B-X
to	B-X
different	B-X
versions	B-X
of	B-X
its	B-X
DNA	B-X
binding	B-X
sequence	B-X
.	B-X
These	B-X
structural	B-X
changes	B-X
may	B-X
modulate	B-X
the	B-X
function	B-X
of	B-X
Rap1p	B-X
domains	B-X
,	B-X
providing	B-X
different	B-X
interacting	B-X
surfaces	B-X
for	B-X
binding	B-X
to	B-X
specific	B-X
co-operating	B-X
factors	B-X
,	B-X
and	B-X
thus	B-X
contributing	B-X
to	B-X
the	B-X
diversity	B-X
of	B-X
Rap1p	B-X
function	B-X
.	B-X

Rap1p	O
also	O
interacts	O
with	O
telomere	O
-	O
specific	O
proteins	O
in	O
executing	O
its	O
role	O
in	O
regulating	O
telomere	O
length	O
(	O
19	O
)	O
.	O

It	O
is	O
puzzling	O
that	O
a	O
protein	O
that	O
helps	O
establish	O
silent	O
chromatin	O
could	O
also	O
act	O
as	O
a	O
barrier	O
to	O
its	O
propagation	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
in	O
addition	O
to	O
TEF2	O
-	O
UAS	O
,	O
UASs	O
of	O
many	O
yeast	B-Species
genes	O
exhibit	O
barrier	O
activity	O
.	O

Analyses	O
of	O
these	O
UASs	O
indicate	O
that	O
binding	O
sites	O
for	O
transcriptional	O
regulators	O
Abf1p	O
,	O
Reb1p	O
,	O
Adr1p	O
,	O
Gcn4p	O
,	O
as	O
well	O
as	O
Rap1p	O
,	O
may	O
participate	O
in	O
barrier	O
function	O
.	O

These	O
UASs	O
are	O
dispersed	O
across	O
the	O
genome	O
and	O
might	O
play	O
a	O
role	O
in	O
defining	O
functional	O
chromosomal	O
domains	O
.	O

Moreover	O
,	O
we	O
demonstrated	O
that	O
targeting	O
the	O
activation	O
domain	O
of	O
Rap1p	O
,	O
Adr1p	O
or	O
Gcn4p	O
alone	O
,	O
led	O
to	O
barrier	O
function	O
.	O
<EOS>	B-X
Barrier	B-X
elements	B-X
that	B-X
are	B-X
able	B-X
to	B-X
block	B-X
the	B-X
propagation	B-X
of	B-X
transcriptional	B-X
silencing	B-X
in	B-X
yeast	B-X
are	B-X
functionally	B-X
similar	B-X
to	B-X
chromatin	B-X
boundary/insulator	B-X
elements	B-X
in	B-X
metazoans	B-X
that	B-X
delimit	B-X
functional	B-X
chromosomal	B-X
domains	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
upstream	B-X
activating	B-X
sequences	B-X
of	B-X
many	B-X
highly	B-X
expressed	B-X
ribosome	B-X
protein	B-X
genes	B-X
and	B-X
glycolytic	B-X
genes	B-X
exhibit	B-X
barrier	B-X
activity	B-X
.	B-X
Analyses	B-X
of	B-X
these	B-X
barriers	B-X
indicate	B-X
that	B-X
binding	B-X
sites	B-X
for	B-X
transcriptional	B-X
regulators	B-X
Rap1p	B-X
,	B-X
Abf1p	B-X
,	B-X
Reb1p	B-X
,	B-X
Adr1p	B-X
and	B-X
Gcn4p	B-X
may	B-X
participate	B-X
in	B-X
barrier	B-X
function	B-X
.	B-X
We	B-X
also	B-X
present	B-X
evidence	B-X
suggesting	B-X
that	B-X
Rap1p	B-X
is	B-X
directly	B-X
involved	B-X
in	B-X
barrier	B-X
activity	B-X
,	B-X
and	B-X
its	B-X
barrier	B-X
function	B-X
correlates	B-X
with	B-X
local	B-X
changes	B-X
in	B-X
chromatin	B-X
structure	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
tethering	B-X
the	B-X
transcriptional	B-X
activation	B-X
domain	B-X
of	B-X
Rap1p	B-X
to	B-X
DNA	B-X
is	B-X
sufficient	B-X
to	B-X
recapitulate	B-X
barrier	B-X
activity	B-X
.	B-X
Moreover	B-X
,	B-X
targeting	B-X
the	B-X
activation	B-X
domain	B-X
of	B-X
Adr1p	B-X
or	B-X
Gcn4p	B-X
also	B-X
establishes	B-X
a	B-X
barrier	B-X
to	B-X
silencing	B-X
.	B-X
These	B-X
results	B-X
support	B-X
the	B-X
notion	B-X
that	B-X
transcriptional	B-X
regulators	B-X
could	B-X
also	B-X
participate	B-X
in	B-X
delimiting	B-X
functional	B-X
domains	B-X
in	B-X
the	B-X
genome	B-X
.	B-X

Since	O
the	O
activation	O
domain	O
of	O
an	O
activator	O
was	O
usually	O
involved	O
in	O
interacting	O
with	O
co	O
-	O
activators	O
and	O
/	O
or	O
components	O
of	O
the	O
transcriptional	O
machinery	O
,	O
these	O
data	O
indicated	O
that	O
other	O
factors	O
might	O
also	O
be	O
involved	O
in	O
barrier	O
function	O
.	O
<EOS>	B-X
TP53	B-X
functions	B-X
as	B-X
a	B-X
transcription	B-X
factor	B-X
that	B-X
directly	B-X
regulates	B-X
the	B-X
expression	B-X
of	B-X
~500	B-X
genes	B-X
,	B-X
some	B-X
of	B-X
them	B-X
involved	B-X
in	B-X
cell	B-X
cycle	B-X
arrest/cell	B-X
senescence	B-X
,	B-X
apoptotic	B-X
cell	B-X
death	B-X
or	B-X
DNA	B-X
damage	B-X
repair	B-X
,	B-X
i.e	B-X
.	B-X
Defects	B-X
in	B-X
TP53	B-X
function	B-X
not	B-X
only	B-X
cause	B-X
tumour	B-X
development	B-X
but	B-X
also	B-X
impair	B-X
the	B-X
response	B-X
of	B-X
malignant	B-X
cells	B-X
to	B-X
anti-cancer	B-X
drugs	B-X
,	B-X
particularly	B-X
those	B-X
that	B-X
induce	B-X
DNA	B-X
damage	B-X
[	B-X
1-6	B-X
]	B-X
.	B-X
Most	B-X
mutations	B-X
in	B-X
TP53	B-X
in	B-X
human	B-X
cancers	B-X
cause	B-X
a	B-X
single	B-X
amino	B-X
acid	B-X
substitution	B-X
,	B-X
usually	B-X
within	B-X
the	B-X
DNA	B-X
binding	B-X
domain	B-X
of	B-X
the	B-X
TP53	B-X
protein	B-X
.	B-X
Three	B-X
cancer	B-X
causing	B-X
attributes	B-X
have	B-X
been	B-X
postulated	B-X
for	B-X
mutant	B-X
TP53	B-X
proteins	B-X
:	B-X
the	B-X
inability	B-X
to	B-X
activate	B-X
target	B-X
genes	B-X
controlled	B-X
by	B-X
wt	B-X
TP53	B-X
(	B-X
loss-of-function	B-X
,	B-X
LOF	B-X
)	B-X
that	B-X
are	B-X
critical	B-X
for	B-X
tumour	B-X
suppression	B-X
,	B-X
dominant	B-X
negative	B-X
effects	B-X
(	B-X
DNE	B-X
)	B-X
,	B-X
i.e	B-X
.	B-X
blocking	B-X
the	B-X
function	B-X
of	B-X
wt	B-X
TP53	B-X
in	B-X
cells	B-X
during	B-X
early	B-X
stages	B-X
of	B-X
transformation	B-X
when	B-X
mutant	B-X
and	B-X
wt	B-X
TP53	B-X
proteins	B-X
are	B-X
co-expressed	B-X
,	B-X
and	B-X
gain-of-function	B-X
(	B-X
GOF	B-X
)	B-X
effects	B-X
whereby	B-X
mutant	B-X
TP53	B-X
impacts	B-X
diverse	B-X
cellular	B-X
pathways	B-X
by	B-X
interacting	B-X
with	B-X
proteins	B-X
that	B-X
are	B-X
not	B-X
normally	B-X
engaged	B-X
by	B-X
wt	B-X
TP53	B-X
[	B-X
1-6	B-X
]	B-X
.	B-X

MATERIALS	O
AND	O
METHODS	O

Plasmids	O
and	O
strains	O
<EOS>	B-X
A	B-X
set	B-X
of	B-X
yeast	B-X
strains	B-X
based	B-X
on	B-X
Saccharomyces	B-X
cerevisiae	B-X
S288C	B-X
in	B-X
which	B-X
commonly	B-X
used	B-X
selectable	B-X
marker	B-X
genes	B-X
are	B-X
deleted	B-X
by	B-X
design	B-X
based	B-X
on	B-X
the	B-X
yeast	B-X
genome	B-X
sequence	B-X
has	B-X
been	B-X
constructed	B-X
and	B-X
analysed	B-X
.	B-X
These	B-X
strains	B-X
minimize	B-X
or	B-X
eliminate	B-X
the	B-X
homology	B-X
to	B-X
the	B-X
corresponding	B-X
marker	B-X
genes	B-X
in	B-X
commonly	B-X
used	B-X
vectors	B-X
without	B-X
significantly	B-X
affecting	B-X
adjacent	B-X
gene	B-X
expression	B-X
.	B-X
Because	B-X
the	B-X
homology	B-X
between	B-X
commonly	B-X
used	B-X
auxotrophic	B-X
marker	B-X
gene	B-X
segments	B-X
and	B-X
genomic	B-X
sequences	B-X
has	B-X
been	B-X
largely	B-X
or	B-X
completely	B-X
abolished	B-X
,	B-X
these	B-X
strains	B-X
will	B-X
also	B-X
reduce	B-X
plasmid	B-X
integration	B-X
events	B-X
which	B-X
can	B-X
interfere	B-X
with	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
molecular	B-X
genetic	B-X
applications	B-X
.	B-X
A	B-X
recent	B-X
occurrence	B-X
of	B-X
carbapenemase-producing	B-X
Acinetobacter	B-X
ursingii	B-X
was	B-X
reported	B-X
in	B-X
the	B-X
Netherlands	B-X
and	B-X
comprised	B-X
three	B-X
unrelated	B-X
strains	B-X
carrying	B-X
the	B-X
bla	B-X

Plasmids	O
1	O
-	O
53	O
were	O
used	O
to	O
make	O
strains	O
1	O
-	O
53	O
,	O
respectively	O
(	O
see	O
Figs	O
1	O
-	O
6	O
)	O
.	O

Plasmid	O
1	O
was	O
previously	O
named	O
pMB22	O
-	O
a	O
that	O
contained	O
a	O
HindIII	O
-	O
BamHI	O
fragment	O
of	O
chromosome	O
III	O
(	O
coordinates	O
14838	O
-	O
16263	O
)	O
with	O
a	O
URA3	O
gene	O
inserted	O
at	O
its	O
EcoRV	O
site	O
(	O
20	O
)	O
.	O

Plasmid	O
2	O
was	O
derived	O
from	O
1	O
by	O
inserting	O
TEF2	O
-	O
UAS	O
(	O
-	O
511	O
to	O
-	O
407	O
bp	O
relative	O
to	O
the	O
translation	O
start	O
codon	O
)	O
at	O
the	O
SnaBI	O
site	O
.	O

Plasmids	O
3	O
-	O
38	O
were	O
identical	O
to	O
2	O
except	O
that	O
different	O
fragments	O
from	O
various	O
promoters	O
(	O
see	O
Figs	O
1	O
and	O
2	O
)	O
were	O
inserted	O
at	O
the	O
SnaBI	O
site	O
.	O

Plasmid	O
29	O
had	O
a	O
sequence	O
of	O
chromosome	O
III	O
(	O
295327	O
-	O
295713	O
)	O
containing	O
the	O
HMR	O
-	O
tRNA	O
gene	O
(	O
21	O
)	O
inserted	O
at	O
the	O
SnaBI	O
site	O
of	O
plasmid	O
1	O
.	O

Plasmids	O
39	O
and	O
40	O
were	O
previously	O
named	O
pYXB26	O
and	O
pYXB59	O
,	O
respectively	O
(	O
11	O
)	O
.	O

Plasmid	O
41	O
was	O
identical	O
to	O
pYXB59	O
except	O
bearing	O
mutations	O
illustrated	O
in	O
Figure	O
3A	O
.	O

Plasmids	O
42	O
-	O
48	O
were	O
previously	O
described	O
as	O
pYXB29	O
,	O
48	O
,	O
28	O
,	O
27	O
,	O
59	O
,	O
31	O
and	O
37	O
,	O
respectively	O
(	O
11	O
)	O
.	O

Plasmid	O
50	O
was	O
derived	O
from	O
plasmid	O
1	O
by	O
inserting	O
two	O
copies	O
of	O
a	O
sequence	O
bearing	O
the	O
consensus	O
binding	O
sequence	O
of	O
LexA	O
(	O
bold	O
)	O
(	O
22	O
)	O
,	O
GGGGTACGTACTGTATGTACATACAGGATATCGGGG	O
,	O
at	O
the	O
SnaBI	O
site	O
.	O

Plasmid	O
51	O
was	O
identical	O
to	O
50	O
except	O
having	O
only	O
one	O
copy	O
of	O
the	O
LexA	O
-	O
binding	O
sequence	O
.	O

Plasmid	O
52	O
was	O
derived	O
from	O
pYXB26	O
(	O
11	O
)	O
by	O
inserting	O
a	O
SpeI	O
-	O
ADE2	O
-	O
AvrII	O
sequence	O
at	O
the	O
SpeI	O
site	O
.	O

Plasmid	O
53	O
was	O
derived	O
from	O
plasmid	O
52	O
by	O
inserting	O
TEF2	O
-	O
UAS	O
(	O
-	O
511	O
to	O
-	O
407	O
bp	O
relative	O
to	O
the	O
translation	O
start	O
codon	O
)	O
at	O
the	O
SpeI	O
site	O
.	O

Plasmid	O
L1	O
(	O
see	O
Fig	O
.	O
5A	O
)	O
was	O
made	O
by	O
inserting	O
LEU2	O
into	O
pBTM116	O
(	O
23	O
)	O
carrying	O
the	O
LexA	O
gene	O
flanked	O
by	O
the	O
promoter	O
and	O
terminator	O
of	O
ADH1	O
.	O

L2	O
through	O
L8	O
were	O
derived	O
from	O
L1	O
by	O
fusing	O
various	O
sequences	O
to	O
LexA	O
(	O
see	O
Fig	O
.	O
5A	O
and	O
B	O
)	O
.	O

Plasmid	O
pRS425	O
(	O
24	O
)	O
carried	O
the	O
2	O
micro	O
m	O
origin	O
and	O
LEU2	O
.	O

Strain	O
YXB76	O
was	O
MATa	O
ura3	O
-	O
52	O
leu2	O
-	O
3	O
,	O
112	O
ade2	O
-	O
1	O
lys1	O
-	O
1	O
his5	O
-	O
2	O
can1	O
-	O
100	O
,	O
E	O
-	O
HML	O
alpha	O
-	O
Iinverted	O
(	O
20	O
)	O
.	O

Y2047b	O
was	O
MATa	O
HMRa	O
HML	O
alpha	O
E	O
Delta	O
79	O
-	O
113	O
:	O
:	O
SUP4	O
-	O
o	O
I	O
Delta	O
242	O
LEU2	O
-	O
GAL10	O
-	O
FLP1	O
ura3	O
-	O
52	O
ade2	O
-	O
1	O
lys1	O
-	O
1	O
his5	O
-	O
1	O
can1	O
-	O
100	O
[	O
cir0	O
]	O
(	O
25	O
)	O
.	O

Strain	O
1	O
was	O
made	O
by	O
transforming	O
YXB76	O
to	O
Ura	O
+	O
with	O
HindIII	O
+	O
BamHI	O
digested	O
plasmid	O
1	O
.	O

Strains	O
2	O
-	O
38	O
,	O
50	O
and	O
51	O
were	O
similarly	O
made	O
with	O
corresponding	O
plasmids	O
,	O
respectively	O
(	O
e	O
.	O
g	O
.	O
strain	O
2	O
was	O
made	O
with	O
plasmid	O
2	O
)	O
.	O

Strains	O
39	O
,	O
40	O
and	O
42	O
-	O
48	O
were	O
previously	O
described	O
as	O
YXB26	O
,	O
48	O
,	O
29	O
,	O
48	O
,	O
28	O
,	O
27	O
,	O
59	O
,	O
31	O
and	O
37	O
,	O
respectively	O
(	O
11	O
)	O
.	O

Strains	O
41	O
,	O
52	O
and	O
53	O
(	O
see	O
Figs	O
3C	O
and	O
6	O
)	O
were	O
made	O
by	O
transforming	O
Y2047b	O
to	O
canavanine	O
-	O
resistant	O
by	O
BamHI	O
-	O
digested	O
plasmids	O
41	O
,	O
52	O
and	O
53	O
,	O
respectively	O
.	O

Strains	O
40	O
'	O
-	O
48	O
'	O
were	O
sir3	O
:	O
:	O
URA3	O
derivatives	O
of	O
strains	O
40	O
-	O
48	O
,	O
respectively	O
.	O

The	O
relevant	O
genotypes	O
of	O
all	O
the	O
strains	O
were	O
confirmed	O
by	O
Southern	O
blotting	O
.	O
<EOS>	B-X
A	B-X
single	B-X
HAV	B-X
serotype	B-X
has	B-X
been	B-X
described	B-X
,	B-X
although	B-X
seven	B-X
genotypes	B-X
have	B-X
been	B-X
defined	B-X
.	B-X
However	B-X
,	B-X
even	B-X
with	B-X
the	B-X
adoption	B-X
of	B-X
these	B-X
techniques	B-X
,	B-X
the	B-X
choice	B-X
of	B-X
the	B-X
most	B-X
adequate	B-X
target	B-X
is	B-X
of	B-X
relevant	B-X
importance	B-X
.	B-X
For	B-X
this	B-X
reason	B-X
it	B-X
is	B-X
extremely	B-X
important	B-X
to	B-X
include	B-X
a	B-X
confirmative	B-X
method	B-X
such	B-X
as	B-X
Southern	B-X
blot	B-X
hybridization	B-X
with	B-X
an	B-X
internal	B-X
probe	B-X
from	B-X
a	B-X
region	B-X
not	B-X
affected	B-X
by	B-X
the	B-X
insertions/deletions	B-X
.	B-X
Southern	B-X
blotting	B-X
of	B-X
the	B-X
nucH	B-X
gene	B-X
against	B-X
chromosomal	B-X
DNA	B-X
of	B-X
JMP636	B-X
confirmed	B-X
that	B-X
it	B-X
had	B-X
originated	B-X
from	B-X
this	B-X
strain	B-X
and	B-X
demonstrated	B-X
that	B-X
it	B-X
was	B-X
present	B-X
in	B-X
a	B-X
single	B-X
copy	B-X
,	B-X
although	B-X
additional	B-X
faint	B-X
bands	B-X
were	B-X
also	B-X
detected	B-X
.	B-X
Comparison	B-X
of	B-X
the	B-X
deduced	B-X
nucleotide	B-X
sequence	B-X
and	B-X
the	B-X
NucH	B-X
predicted	B-X
protein	B-X
sequence	B-X
with	B-X
relevant	B-X
databases	B-X
indicated	B-X
that	B-X
no	B-X
known	B-X
homologs	B-X
have	B-X
previously	B-X
been	B-X
identified	B-X
.	B-X

Quantitative	O
mating	O
assay	O
<EOS>	B-X
C-terminal	B-X
fusion	B-X
to	B-X
the	B-X
Aga2p	B-X
mating	B-X
adhesion	B-X
receptor	B-X
of	B-X
Saccharomyces	B-X
cerevisiae	B-X
has	B-X
been	B-X
used	B-X
for	B-X
the	B-X
selection	B-X
of	B-X
scFv	B-X
antibody	B-X
fragments	B-X
with	B-X
threefold	B-X
decreased	B-X
antigen	B-X
dissociation	B-X
rate	B-X
from	B-X
a	B-X
randomly	B-X
mutated	B-X
library	B-X
.	B-X
Quantitative	B-X
flow	B-X
cytometric	B-X
analysis	B-X
enables	B-X
fine	B-X
discrimination	B-X
of	B-X
kinetic	B-X
parameters	B-X
for	B-X
protein	B-X
binding	B-X
to	B-X
soluble	B-X
ligands	B-X
.	B-X
Using	B-X
formal	B-X
phylogenetic	B-X
meta-analysis	B-X
and	B-X
meta-regression	B-X
techniques	B-X
,	B-X
we	B-X
quantitatively	B-X
review	B-X
the	B-X
existing	B-X
literature	B-X
on	B-X
MHC-dependent	B-X
mating	B-X
preferences	B-X
in	B-X
nonhuman	B-X
vertebrates	B-X
with	B-X
a	B-X
focus	B-X
on	B-X
the	B-X
role	B-X
of	B-X
MHC	B-X
diversity	B-X
and	B-X
dissimilarity	B-X
.	B-X
Genes	B-X
involved	B-X
in	B-X
mating	B-X
type	B-X
determination	B-X
and	B-X
recognition	B-X
were	B-X
examined	B-X
in	B-X
Metschnikowia	B-X
and	B-X
related	B-X
species	B-X
,	B-X
to	B-X
gather	B-X
insights	B-X
on	B-X
factors	B-X
affecting	B-X
mating	B-X
compatibility	B-X
patterns	B-X
among	B-X
haplontic	B-X
,	B-X
heterothallic	B-X
yeast	B-X
species	B-X
of	B-X
the	B-X
genus	B-X
.	B-X
We	B-X
confirmed	B-X
the	B-X
universality	B-X
of	B-X
the	B-X
special	B-X
mating	B-X
locus	B-X
organisation	B-X
found	B-X
in	B-X
Clavispora	B-X
lusitaniae	B-X
across	B-X
and	B-X
exclusive	B-X
to	B-X
the	B-X
family	B-X
Metschnikowiaceae	B-X
(	B-X
i.e.	B-X
,	B-X
Metschnikowia	B-X
and	B-X
Clavispora	B-X
)	B-X
.	B-X
The	B-X
sequence	B-X
of	B-X
the	B-X
a	B-X
mating	B-X
pheromone	B-X
is	B-X
highly	B-X
conserved	B-X
within	B-X
the	B-X
large-spored	B-X
Metschnikowia	B-X
species	B-X
,	B-X
including	B-X
Metschnikowia	B-X
orientalis	B-X
and	B-X
Metschnikowia	B-X
hawaiiana	B-X
,	B-X
but	B-X
not	B-X
Metschnikowia	B-X
drosophilae	B-X
or	B-X
Metschnikowia	B-X
torresii	B-X
,	B-X
which	B-X
have	B-X
a	B-X
pattern	B-X
of	B-X
their	B-X
own	B-X
,	B-X
as	B-X
do	B-X
other	B-X
clades	B-X
in	B-X
the	B-X
genus	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
variation	B-X
in	B-X
Î±	B-X
pheromones	B-X
shows	B-X
a	B-X
more	B-X
continuous	B-X
,	B-X
although	B-X
imperfect	B-X
correlation	B-X
with	B-X
phylogenetic	B-X
distance	B-X
as	B-X
well	B-X
as	B-X
with	B-X
in	B-X
vivo	B-X
mating	B-X
compatibility	B-X
.	B-X

Quantitative	O
mating	O
was	O
performed	O
as	O
described	O
(	O
11	O
)	O
.	O
<EOS>	B-X
To	B-X
describe	B-X
the	B-X
reproductive	B-X
performance	B-X
of	B-X
beef	B-X
cow	B-X
herds	B-X
in	B-X
New	B-X
Zealand	B-X
and	B-X
to	B-X
develop	B-X
reference	B-X
ranges	B-X
for	B-X
assessing	B-X
the	B-X
reproductive	B-X
performance	B-X
of	B-X
individual	B-X
herds	B-X
from	B-X
in-calf	B-X
rates	B-X
,	B-X
that	B-X
take	B-X
into	B-X
account	B-X
variation	B-X
in	B-X
the	B-X
length	B-X
of	B-X
mating	B-X
periods	B-X
.	B-X
Here	B-X
we	B-X
describe	B-X
the	B-X
Green	B-X
Monster	B-X
method	B-X
for	B-X
routinely	B-X
engineering	B-X
multiple	B-X
deletions	B-X
in	B-X
yeast	B-X
(	B-X
11	B-X
)	B-X
.	B-X
Repeated	B-X
rounds	B-X
of	B-X
assortment	B-X
of	B-X
GFP-marked	B-X
deletions	B-X
via	B-X
yeast	B-X
mating	B-X
and	B-X
meiosis	B-X
coupled	B-X
with	B-X
flow-cytometric	B-X
enrichment	B-X
of	B-X
strains	B-X
carrying	B-X
more	B-X
of	B-X
these	B-X
deletions	B-X
lead	B-X
to	B-X
the	B-X
accumulation	B-X
of	B-X
deletions	B-X
in	B-X
strains	B-X
(	B-X
Figure	B-X
2	B-X
)	B-X
.	B-X
Each	B-X
GMToolkit	B-X
contains	B-X
:	B-X
either	B-X
the	B-X
a-	B-X
or	B-X
Î±-mating-type-specific	B-X
haploid	B-X
selection	B-X
marker	B-X
(	B-X
1	B-X
)	B-X
and	B-X
exactly	B-X
one	B-X
of	B-X
the	B-X
two	B-X
markers	B-X
that	B-X
,	B-X
when	B-X
both	B-X
GMToolkits	B-X
are	B-X
present	B-X
,	B-X
collectively	B-X
allow	B-X
for	B-X
selection	B-X
of	B-X
diploids	B-X
.	B-X
The	B-X
second	B-X
step	B-X
is	B-X
to	B-X
carry	B-X
out	B-X
the	B-X
sexual	B-X
cycling	B-X
through	B-X
which	B-X
deletion	B-X
loci	B-X
can	B-X
be	B-X
combined	B-X
within	B-X
a	B-X
single	B-X
cell	B-X
by	B-X
the	B-X
random	B-X
assortment	B-X
and/or	B-X
meiotic	B-X
recombination	B-X
that	B-X
accompanies	B-X
each	B-X
cycle	B-X
of	B-X
mating	B-X
and	B-X
sporulation	B-X
.	B-X

Electrophoresis	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
<EOS>	B-X
The	B-X
gel	B-X
electrophoresis	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
is	B-X
used	B-X
to	B-X
detect	B-X
protein	B-X
complexes	B-X
with	B-X
nucleic	B-X
acids	B-X
.	B-X
In	B-X
the	B-X
classical	B-X
assay	B-X
,	B-X
solutions	B-X
of	B-X
protein	B-X
and	B-X
nucleic	B-X
acid	B-X
are	B-X
combined	B-X
and	B-X
the	B-X
resulting	B-X
mixtures	B-X
are	B-X
subjected	B-X
to	B-X
electrophoresis	B-X
under	B-X
native	B-X
conditions	B-X
through	B-X
polyacrylamide	B-X
or	B-X
agarose	B-X
gel	B-X
.	B-X
In	B-X
this	B-X
protocol	B-X
,	B-X
we	B-X
identify	B-X
the	B-X
most	B-X
important	B-X
factors	B-X
that	B-X
determine	B-X
the	B-X
stabilities	B-X
and	B-X
electrophoretic	B-X
mobilities	B-X
of	B-X
complexes	B-X
under	B-X
assay	B-X
conditions	B-X
.	B-X
The	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
is	B-X
a	B-X
well-established	B-X
method	B-X
to	B-X
detect	B-X
formation	B-X
of	B-X
complexes	B-X
between	B-X
proteins	B-X
and	B-X
nucleic	B-X
acids	B-X
and	B-X
to	B-X
determine	B-X
,	B-X
among	B-X
other	B-X
parameters	B-X
,	B-X
equilibrium	B-X
constants	B-X
for	B-X
the	B-X
interaction	B-X
.	B-X

Rap1p	O
was	O
expressed	O
in	O
Escherichia	B-Species
coli	I-Species
BL21	I-Species
(	I-Species
DE3	I-Species
)	I-Species
from	O
pL3S5	O
,	O
a	O
pET	O
vector	O
carrying	O
the	O
RAP1	O
gene	O
downstream	O
of	O
a	O
T7	O
promoter	O
(	O
26	O
)	O
.	O

Crude	O
protein	O
extracts	O
were	O
prepared	O
from	O
40	O
ml	O
cultures	O
harvested	O
after	O
3	O
h	O
of	O
IPTG	O
induction	O
and	O
resuspended	O
in	O
1	O
ml	O
of	O
lysis	O
buffer	O
(	O
50	O
mM	O
NaH2PO4	O
,	O
300	O
mM	O
NaCl	O
,	O
pH	O
8	O
.	O
0	O
)	O
.	O

A	O
control	O
extract	O
was	O
prepared	O
from	O
a	O
culture	O
without	O
IPTG	O
induction	O
.	O
<EOS>	B-X
The	B-X
transfected	B-X
cells	B-X
expressed	B-X
high	B-X
levels	B-X
of	B-X
the	B-X
fusion	B-X
protein	B-X
(	B-X
FLAG-CNTF	B-X
)	B-X
following	B-X
induction	B-X
by	B-X
isopropyl	B-X
beta-D-thiogalactoside	B-X
(	B-X
IPTG	B-X
)	B-X
.	B-X
FLAG-CNTF	B-X
is	B-X
expressed	B-X
as	B-X
insoluble	B-X
material	B-X
that	B-X
was	B-X
resolubilized	B-X
by	B-X
extraction	B-X
with	B-X
guanidine	B-X
hydrochloride	B-X
and	B-X
purified	B-X
by	B-X
immuno-affinity	B-X
chromatography	B-X
.	B-X
Treatment	B-X
of	B-X
IMR-32	B-X
cells	B-X
with	B-X
FLAG-CNTF	B-X
increased	B-X
the	B-X
level	B-X
of	B-X
choline	B-X
acetyltransferase	B-X
(	B-X
ChAT	B-X
)	B-X
in	B-X
these	B-X
cells	B-X
2-3-fold	B-X
over	B-X
that	B-X
of	B-X
control	B-X
cells	B-X
in	B-X
a	B-X
dose	B-X
dependent	B-X
manner	B-X
.	B-X

Western	O
blotting	O
revealed	O
that	O
Rap1p	O
protein	O
was	O
present	O
in	O
the	O
induced	O
extract	O
but	O
not	O
the	O
uninduced	O
one	O
(	O
data	O
not	O
shown	O
)	O
.	O

DNA	O
fragments	O
of	O
26	O
bp	O
in	O
length	O
(	O
see	O
Fig	O
.	O
3A	O
)	O
were	O
end	O
-	O
labeled	O
with	O
32P	O
-	O
phosphate	O
.	O

Fifteen	O
microliter	O
binding	O
reactions	O
were	O
prepared	O
,	O
each	O
consisting	O
of	O
20	O
000	O
c	O
.	O
p	O
.	O
m	O
.	O
radiolabeled	O
DNA	O
probe	O
,	O
5	O
micro	O
g	O
of	O
crude	O
protein	O
extract	O
,	O
non	O
-	O
specific	O
competitor	O
DNAs	O
(	O
0	O
.	O
3	O
micro	O
g	O
of	O
yeast	B-Species
tRNA	O
,	O
0	O
.	O
3	O
micro	O
g	O
of	O
salmon	B-Species
sperm	O
DNA	O
and	O
0	O
.	O
5	O
micro	O
g	O
of	O
E	B-Species
.	I-Species
coli	I-Species
DNA	O
)	O
,	O
10	O
micro	O
g	O
of	O
BSA	O
,	O
10	O
mM	O
Tris	O
-	O
HCl	O
(	O
pH	O
8	O
.	O
0	O
)	O
,	O
10	O
mM	O
MgCl2	O
and	O
8	O
%	O
glycerol	O
.	O

The	O
reactions	O
were	O
incubated	O
at	O
25	O
degrees	O
C	O
for	O
20	O
min	O
and	O
loaded	O
onto	O
non	O
-	O
denaturing	O
polyacrylamide	O
gels	O
(	O
4	O
-	O
5	O
%	O
)	O
.	O

Gels	O
were	O
run	O
at	O
40	O
mA	O
for	O
1	O
h	O
in	O
0	O
.	O
5	O
x	O
TBE	O
buffer	O
.	O

Analysis	O
of	O
the	O
supercoiling	O
of	O
DNA	O
circles	O
<EOS>	B-X
Single-strand	B-X
DNA	B-X
binding	B-X
protein	B-X
did	B-X
not	B-X
affect	B-X
PcrA	B-X
translocation	B-X
velocity	B-X
but	B-X
slightly	B-X
increased	B-X
its	B-X
processivity	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
degree	B-X
of	B-X
DNA	B-X
supercoiling	B-X
required	B-X
for	B-X
RepC	B-X
nicking	B-X
,	B-X
and	B-X
the	B-X
time	B-X
between	B-X
RepC	B-X
nicking	B-X
and	B-X
DNA	B-X
unwinding	B-X
,	B-X
suggests	B-X
that	B-X
RepC	B-X
and	B-X
PcrA	B-X
form	B-X
a	B-X
protein	B-X
complex	B-X
on	B-X
the	B-X
DNA	B-X
binding	B-X
site	B-X
before	B-X
nicking	B-X
.	B-X
We	B-X
analyzed	B-X
the	B-X
structure	B-X
of	B-X
open-circular	B-X
and	B-X
supercoiled	B-X
dimeric	B-X
DNA	B-X
catenanes	B-X
generated	B-X
by	B-X
site-specific	B-X
recombination	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
relationships	B-X
are	B-X
similar	B-X
to	B-X
those	B-X
observed	B-X
with	B-X
supercoiled	B-X
DNA	B-X
.	B-X
Statistical	B-X
analyses	B-X
reveal	B-X
,	B-X
however	B-X
,	B-X
that	B-X
the	B-X
conformations	B-X
of	B-X
the	B-X
individual	B-X
rings	B-X
of	B-X
the	B-X
catenanes	B-X
are	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
unlinked	B-X
circles	B-X
.	B-X
The	B-X
observations	B-X
suggest	B-X
that	B-X
chain	B-X
entropy	B-X
is	B-X
a	B-X
major	B-X
factor	B-X
determining	B-X
the	B-X
conformation	B-X
of	B-X
DNA	B-X
catenanes	B-X
.	B-X

Cells	O
were	O
grown	O
in	O
YPR	O
(	O
yeast	B-Species
extract	O
+	O
bacto	O
peptone	O
+	O
2	O
%	O
raffinose	O
)	O
to	O
early	O
log	O
phase	O
.	O

Galactose	O
(	O
2	O
%	O
)	O
was	O
then	O
added	O
to	O
the	O
culture	O
to	O
induce	O
the	O
expression	O
of	O
FLP1	O
.	O

After	O
2	O
.	O
5	O
h	O
of	O
incubation	O
,	O
nucleic	O
acid	O
was	O
isolated	O
using	O
the	O
glass	O
bead	O
method	O
and	O
fractionated	O
on	O
agarose	O
gels	O
with	O
30	O
micro	O
g	O
/	O
ml	O
chloroquine	O
.	O

DNA	O
circles	O
were	O
detected	O
by	O
Southern	O
blotting	O
.	O
<EOS>	B-X
We	B-X
described	B-X
previously	B-X
a	B-X
novel	B-X
DNA	B-X
amplification	B-X
technique	B-X
,	B-X
termed	B-X
ramification	B-X
amplification	B-X
(	B-X
RAM	B-X
)	B-X
(	B-X
Zhang	B-X
et	B-X
al.	B-X
,	B-X
Gene	B-X
211	B-X
(	B-X
1998	B-X
)	B-X
277	B-X
)	B-X
.	B-X
This	B-X
method	B-X
was	B-X
designed	B-X
to	B-X
utilize	B-X
a	B-X
circular	B-X
probe	B-X
(	B-X
C-probe	B-X
)	B-X
that	B-X
is	B-X
covalently	B-X
linked	B-X
by	B-X
a	B-X
DNA	B-X
ligase	B-X
when	B-X
it	B-X
hybridizes	B-X
to	B-X
a	B-X
target	B-X
.	B-X
Then	B-X
,	B-X
a	B-X
DNA	B-X
polymerase	B-X
extends	B-X
the	B-X
bound	B-X
forward	B-X
primer	B-X
along	B-X
the	B-X
C-probe	B-X
and	B-X
continuously	B-X
displaces	B-X
a	B-X
downstream	B-X
strand	B-X
,	B-X
generating	B-X
a	B-X
multimeric	B-X
single-stranded	B-X
DNA	B-X
(	B-X
ssDNA	B-X
)	B-X
,	B-X
analogous	B-X
to	B-X
in	B-X
vivo	B-X
'rolling	B-X
circle	B-X
'	B-X
replication	B-X
of	B-X
bacteriophage	B-X
.	B-X
This	B-X
multimeric	B-X
ssDNA	B-X
then	B-X
serves	B-X
as	B-X
a	B-X
template	B-X
for	B-X
multiple	B-X
reverse	B-X
primers	B-X
to	B-X
hybridize	B-X
,	B-X
extend	B-X
,	B-X
and	B-X
displace	B-X
downstream	B-X
DNA	B-X
,	B-X
generating	B-X
a	B-X
large	B-X
ramified	B-X
(	B-X
branching	B-X
)	B-X
DNA	B-X
complex	B-X
,	B-X
and	B-X
resulting	B-X
in	B-X
an	B-X
exponential	B-X
amplification	B-X
.	B-X
Previously	B-X
,	B-X
we	B-X
were	B-X
able	B-X
to	B-X
achieve	B-X
a	B-X
significant	B-X
amplification	B-X
using	B-X
phi29	B-X
DNA	B-X
polymerase	B-X
that	B-X
has	B-X
a	B-X
high	B-X
processivity	B-X
and	B-X
strong	B-X
displacement	B-X
activity	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
tested	B-X
several	B-X
DNA	B-X
polymerases	B-X
and	B-X
found	B-X
that	B-X
exo	B-X
(	B-X
-	B-X
)	B-X
Bst	B-X
DNA	B-X
polymerase	B-X
meets	B-X
the	B-X
requirement	B-X
for	B-X
high	B-X
sensitivity	B-X
.	B-X

RESULTS	O

UASs	O
of	O
many	O
highly	O
expressed	O
genes	O
can	O
function	O
as	O
barriers	O
to	O
the	O
spread	O
of	O
silencing	O

We	O
have	O
previously	O
shown	O
that	O
TEF2	O
-	O
UAS	O
was	O
able	O
to	O
block	O
the	O
spread	O
of	O
silencing	O
in	O
a	O
silencer	O
-	O
blocking	O
assay	O
(	O
11	O
)	O
.	O

Such	O
an	O
assay	O
tested	O
if	O
a	O
sequence	O
had	O
the	O
ability	O
to	O
prevent	O
a	O
silencer	O
from	O
silencing	O
a	O
reporter	O
gene	O
when	O
it	O
was	O
positioned	O
between	O
the	O
silencer	O
and	O
the	O
reporter	O
.	O

In	O
this	O
report	O
we	O
used	O
a	O
new	O
silencer	O
-	O
blocking	O
assay	O
to	O
identify	O
more	O
barrier	O
elements	O
.	O

This	O
assay	O
employed	O
the	O
URA3	O
gene	O
and	O
an	O
inverted	O
HML	O
-	O
I	O
that	O
could	O
silence	O
sequences	O
to	O
the	O
right	O
of	O
HML	O
(	O
20	O
)	O
(	O
Fig	O
.	O
1	O
,	O
strain	O
1	O
)	O
.	O

URA3	O
expression	O
makes	O
cells	O
sensitive	O
to	O
5	O
-	O
fluoroorotic	O
acid	O
(	O
FOA	O
)	O
thus	O
URA3	O
silencing	O
could	O
be	O
measured	O
by	O
cell	O
growth	O
on	O
FOA	O
medium	O
(	O
Fig	O
.	O
1	O
,	O
strain	O
1	O
)	O
.	O

As	O
expected	O
,	O
TEF2	O
-	O
UAS	O
and	O
another	O
known	O
barrier	O
element	O
,	O
HMR	O
-	O
tRNA	O
gene	O
(	O
21	O
)	O
exhibited	O
barrier	O
activity	O
in	O
this	O
assay	O
as	O
indicated	O
by	O
the	O
lack	O
of	O
silencing	O
of	O
URA3	O
in	O
strains	O
2	O
and	O
29	O
(	O
Fig	O
.	O
1	O
)	O
.	O

TEF2	O
encoding	O
translation	O
elongation	O
factor	O
1	O
alpha	O
is	O
one	O
of	O
the	O
most	O
highly	O
expressed	O
genes	O
in	O
yeast	B-Species
(	O
27	O
)	O
.	O

Other	O
highly	O
expressed	O
genes	O
include	O
ribosome	O
protein	O
genes	O
(	O
RPGs	O
)	O
and	O
genes	O
coding	O
for	O
glycolytic	O
enzymes	O
(	O
27	O
)	O
.	O

The	O
coordinated	O
regulation	O
of	O
most	O
of	O
these	O
genes	O
requires	O
the	O
so	O
-	O
called	O
general	O
regulatory	O
factors	O
Rap1p	O
,	O
Abf1p	O
and	O
Reb1p	O
(	O
28	O
,	O
29	O
)	O
.	O

Using	O
the	O
above	O
silencer	O
-	O
blocking	O
assay	O
,	O
we	O
tested	O
if	O
the	O
UASs	O
of	O
other	O
highly	O
expressed	O
genes	O
could	O
also	O
block	O
URA3	O
silencing	O
(	O
Fig	O
.	O
1	O
)	O
.	O

Seventeen	O
new	O
barrier	O
elements	O
were	O
identified	O
from	O
a	O
total	O
of	O
26	O
UASs	O
tested	O
.	O

These	O
17	O
elements	O
were	O
UASs	O
of	O
eight	O
RPGs	O
(	O
see	O
Fig	O
.	O
1	O
,	O
strains	O
3	O
-	O
10	O
)	O
,	O
eight	O
glycolytic	O
genes	O
(	O
strains	O
18	O
-	O
25	O
)	O
and	O
the	O
HIS3	O
gene	O
(	O
strain	O
26	O
)	O
.	O

All	O
17	O
elements	O
except	O
ADH2	O
-	O
UAS	O
and	O
HIS3	O
-	O
UAS	O
exhibited	O
very	O
strong	O
barrier	O
activity	O
as	O
evidenced	O
by	O
the	O
absence	O
of	O
URA3	O
-	O
silencing	O
in	O
strains	O
3	O
-	O
10	O
and	O
18	O
-	O
24	O
(	O
Fig	O
.	O
1	O
)	O
.	O

Seven	O
of	O
the	O
eight	O
RPG	O
-	O
UASs	O
that	O
had	O
barrier	O
activity	O
,	O
contained	O
a	O
single	O
or	O
a	O
pair	O
of	O
tandem	O
Rap1p	O
-	O
binding	O
sites	O
(	O
Fig	O
.	O
1	O
,	O
strains	O
3	O
-	O
9	O
)	O
.	O

Three	O
of	O
them	O
also	O
contained	O
an	O
Abf1p	O
or	O
Reb1p	O
site	O
(	O
strains	O
6	O
,	O
8	O
and	O
9	O
)	O
.	O
<EOS>	B-X
One	B-X
of	B-X
the	B-X
auxiliary	B-X
elements	B-X
identified	B-X
at	B-X
several	B-X
origins	B-X
is	B-X
a	B-X
DNA	B-X
replication	B-X
enhancer	B-X
that	B-X
binds	B-X
the	B-X
Abf1p	B-X
protein	B-X
.	B-X
We	B-X
have	B-X
isolated	B-X
an	B-X
ARS	B-X
sequence	B-X
from	B-X
Saccharomyces	B-X
cerevisiae	B-X
based	B-X
on	B-X
its	B-X
ability	B-X
to	B-X
bind	B-X
Abf1p	B-X
.	B-X
Mutagenesis	B-X
of	B-X
the	B-X
Abf1p	B-X
DNA-binding	B-X
sites	B-X
revealed	B-X
that	B-X
these	B-X
sequences	B-X
did	B-X
not	B-X
contribute	B-X
significantly	B-X
to	B-X
ARS	B-X
function	B-X
.	B-X
These	B-X
include	B-X
the	B-X
ARS	B-X
essential	B-X
sequences	B-X
and	B-X
the	B-X
Abf1p	B-X
and	B-X
Rap1p	B-X
DNA-binding	B-X
sites	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
function	B-X
of	B-X
REN1501	B-X
at	B-X
the	B-X
origin	B-X
can	B-X
not	B-X
be	B-X
replaced	B-X
by	B-X
a	B-X
Rap1p	B-X
DNA-binding	B-X
site	B-X
or	B-X
a	B-X
site	B-X
that	B-X
binds	B-X
the	B-X
transcriptional	B-X
factor	B-X
Gal4p	B-X
and	B-X
can	B-X
only	B-X
be	B-X
partially	B-X
substituted	B-X
for	B-X
by	B-X
an	B-X
Abf1p	B-X
recognition	B-X
sequence	B-X
.	B-X

One	O
barrier	O
RPG	O
-	O
UAS	O
(	O
strain	O
10	O
)	O
had	O
only	O
a	O
predicted	O
Abf1p	O
site	O
.	O

Of	O
the	O
seven	O
RPG	O
-	O
UASs	O
that	O
had	O
no	O
barrier	O
activity	O
(	O
Fig	O
.	O
1	O
,	O
11	O
-	O
17	O
)	O
,	O
only	O
two	O
bore	O
no	O
site	O
for	O
Rap1p	O
,	O
Abf1p	O
or	O
Reb1p	O
(	O
11	O
and	O
12	O
)	O
.	O

The	O
remaining	O
five	O
each	O
contained	O
one	O
to	O
three	O
Rap1p	O
sites	O
(	O
strains	O
13	O
-	O
17	O
)	O
.	O

RPL15A	O
-	O
UAS	O
(	O
17	O
)	O
also	O
contained	O
an	O
Abf1p	O
site	O
.	O

For	O
most	O
of	O
the	O
15	O
RPG	O
-	O
UASs	O
tested	O
(	O
3	O
-	O
17	O
)	O
,	O
the	O
presence	O
or	O
absence	O
of	O
predicted	O
Rap1p	O
sites	O
correlated	O
with	O
the	O
presence	O
or	O
absence	O
of	O
Rap1p	O
association	O
in	O
vivo	O
as	O
previously	O
examined	O
by	O
chromatin	O
immunoprecipitation	O
assays	O
(	O
13	O
)	O
.	O

Exceptions	O
were	O
the	O
UASs	O
of	O
RPS24B	O
,	O
RPS28A	O
and	O
RPL15A	O
(	O
13	O
)	O
.	O

Of	O
the	O
eight	O
UASs	O
of	O
glycolytic	O
genes	O
tested	O
(	O
Fig	O
.	O
1	O
,	O
strains	O
18	O
-	O
25	O
)	O
,	O
seven	O
exhibited	O
strong	O
barrier	O
activity	O
(	O
18	O
-	O
24	O
)	O
and	O
one	O
had	O
weaker	O
but	O
detectable	O
barrier	O
activity	O
(	O
strain	O
25	O
)	O
.	O

Glycolytic	O
genes	O
are	O
among	O
the	O
most	O
highly	O
expressed	O
genes	O
and	O
their	O
high	O
expression	O
depends	O
on	O
the	O
functions	O
of	O
Rap1p	O
,	O
Abf1p	O
or	O
Reb1p	O
as	O
well	O
as	O
Gcr1p	O
(	O
29	O
,	O
30	O
)	O
.	O

The	O
seven	O
strong	O
glycolytic	O
barriers	O
all	O
consist	O
of	O
one	O
or	O
two	O
Rap1p	O
sites	O
plus	O
one	O
or	O
two	O
Reb1p	O
or	O
Abf1p	O
sites	O
(	O
Fig	O
.	O
1	O
,	O
strains	O
18	O
-	O
24	O
)	O
.	O
<EOS>	B-X
Most	B-X
yeast	B-X
rp-genes	B-X
are	B-X
under	B-X
transcriptional	B-X
control	B-X
of	B-X
Rap1p	B-X
(	B-X
repressor-activator	B-X
protein	B-X
)	B-X
,	B-X
while	B-X
a	B-X
small	B-X
subset	B-X
of	B-X
rp-genes	B-X
is	B-X
activated	B-X
through	B-X
Abf1p	B-X
(	B-X
ARS	B-X
binding	B-X
factor	B-X
)	B-X
.	B-X
The	B-X
third	B-X
protein	B-X
,	B-X
designated	B-X
Reb1p	B-X
(	B-X
rRNA	B-X
enhancer	B-X
binding	B-X
protein	B-X
)	B-X
,	B-X
which	B-X
binds	B-X
strongly	B-X
to	B-X
two	B-X
sites	B-X
located	B-X
upstream	B-X
of	B-X
the	B-X
enhancer	B-X
and	B-X
the	B-X
promoter	B-X
of	B-X
the	B-X
rRNA	B-X
operon	B-X
,	B-X
respectively	B-X
,	B-X
appears	B-X
to	B-X
play	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
efficient	B-X
transcription	B-X
of	B-X
the	B-X
chromosomal	B-X
rDNA	B-X
.	B-X
All	B-X
three	B-X
proteins	B-X
,	B-X
however	B-X
,	B-X
have	B-X
many	B-X
target	B-X
sites	B-X
on	B-X
the	B-X
yeast	B-X
genome	B-X
,	B-X
in	B-X
particular	B-X
,	B-X
in	B-X
the	B-X
upstream	B-X
regions	B-X
of	B-X
several	B-X
Pol	B-X
II	B-X
transcribed	B-X
genes	B-X
,	B-X
suggesting	B-X
that	B-X
they	B-X
play	B-X
a	B-X
much	B-X
more	B-X
general	B-X
role	B-X
than	B-X
solely	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
ribosome	B-X
biosynthesis	B-X
.	B-X
Furthermore	B-X
,	B-X
some	B-X
evidence	B-X
has	B-X
been	B-X
obtained	B-X
suggesting	B-X
that	B-X
these	B-X
factors	B-X
influence	B-X
the	B-X
chromatin	B-X
structure	B-X
and	B-X
creat	B-X
a	B-X
nucleosome-free	B-X
region	B-X
surrounding	B-X
their	B-X
binding	B-X
sites	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
Abf1p	B-X
,	B-X
Rap1p	B-X
,	B-X
and	B-X
Reb1p	B-X
are	B-X
primary	B-X
DNA-binding	B-X
proteins	B-X
that	B-X
serve	B-X
to	B-X
render	B-X
adjacent	B-X
cis-acting	B-X
elements	B-X
accessible	B-X
to	B-X
specific	B-X
trans-acting	B-X
factors	B-X
.	B-X

In	O
addition	O
,	O
one	O
or	O
more	O
Gcr1p	O
-	O
binding	O
sites	O
are	O
found	O
adjacent	O
to	O
each	O
Rap1p	O
site	O
.	O
<EOS>	B-X
Why	B-X
is	B-X
the	B-X
multiple	B-X
stressor	B-X
concept	B-X
of	B-X
relevance	B-X
to	B-X
radioecology	B-X
?	B-X
Due	B-X
to	B-X
the	B-X
ability	B-X
to	B-X
create	B-X
structures	B-X
with	B-X
complex	B-X
geometry	B-X
at	B-X
micro-	B-X
and	B-X
nanoscales	B-X
,	B-X
modern	B-X
additive	B-X
technologies	B-X
make	B-X
it	B-X
possible	B-X
to	B-X
produce	B-X
artificial	B-X
materials	B-X
(	B-X
metamaterials	B-X
)	B-X
with	B-X
properties	B-X
different	B-X
from	B-X
those	B-X
of	B-X
conventional	B-X
materials	B-X
found	B-X
in	B-X
nature	B-X
.	B-X
The	B-X
wide	B-X
interest	B-X
in	B-X
the	B-X
hierarchical	B-X
subclass	B-X
of	B-X
auxetics	B-X
is	B-X
explained	B-X
by	B-X
the	B-X
additional	B-X
advantages	B-X
of	B-X
structures	B-X
,	B-X
such	B-X
as	B-X
more	B-X
flexible	B-X
adjustment	B-X
of	B-X
the	B-X
desired	B-X
mechanical	B-X
characteristics	B-X
(	B-X
the	B-X
porosity	B-X
,	B-X
stiffness	B-X
,	B-X
specific	B-X
energy	B-X
absorption	B-X
,	B-X
degree	B-X
of	B-X
material	B-X
release	B-X
,	B-X
etc.	B-X
)	B-X
.	B-X
Microbial	B-X
activity	B-X
is	B-X
one	B-X
of	B-X
the	B-X
effective	B-X
ways	B-X
of	B-X
detoxifying	B-X
various	B-X
compounds	B-X
as	B-X
microorganisms	B-X
can	B-X
adapt	B-X
in	B-X
an	B-X
environment	B-X
with	B-X
high	B-X
prevalence	B-X
of	B-X
pollutants	B-X
.	B-X

It	O
was	O
proposed	O
that	O
the	O
function	O
of	O
Rap1p	O
was	O
to	O
facilitate	O
the	O
binding	O
of	O
Gcr1p	O
to	O
the	O
UAS	O
(	O
15	O
)	O
.	O

Abf1p	O
or	O
Reb1p	O
was	O
shown	O
to	O
play	O
a	O
role	O
similar	O
to	O
that	O
of	O
Rap1p	O
in	O
activating	O
glycolytic	O
genes	O
(	O
31	O
-	O
33	O
)	O
.	O
<EOS>	B-X
Three	B-X
abundant	B-X
ubiquitous	B-X
DNA-binding	B-X
protein	B-X
factors	B-X
appear	B-X
to	B-X
play	B-X
a	B-X
major	B-X
role	B-X
in	B-X
the	B-X
control	B-X
of	B-X
ribosome	B-X
biosynthesis	B-X
in	B-X
yeast	B-X
.	B-X
Two	B-X
of	B-X
these	B-X
factors	B-X
mediate	B-X
the	B-X
regulation	B-X
of	B-X
transcription	B-X
of	B-X
ribosomal	B-X
protein	B-X
genes	B-X
(	B-X
rp-genes	B-X
)	B-X
in	B-X
yeasts	B-X
.	B-X
Most	B-X
yeast	B-X
rp-genes	B-X
are	B-X
under	B-X
transcriptional	B-X
control	B-X
of	B-X
Rap1p	B-X
(	B-X
repressor-activator	B-X
protein	B-X
)	B-X
,	B-X
while	B-X
a	B-X
small	B-X
subset	B-X
of	B-X
rp-genes	B-X
is	B-X
activated	B-X
through	B-X
Abf1p	B-X
(	B-X
ARS	B-X
binding	B-X
factor	B-X
)	B-X
.	B-X
The	B-X
third	B-X
protein	B-X
,	B-X
designated	B-X
Reb1p	B-X
(	B-X
rRNA	B-X
enhancer	B-X
binding	B-X
protein	B-X
)	B-X
,	B-X
which	B-X
binds	B-X
strongly	B-X
to	B-X
two	B-X
sites	B-X
located	B-X
upstream	B-X
of	B-X
the	B-X
enhancer	B-X
and	B-X
the	B-X
promoter	B-X
of	B-X
the	B-X
rRNA	B-X
operon	B-X
,	B-X
respectively	B-X
,	B-X
appears	B-X
to	B-X
play	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
efficient	B-X
transcription	B-X
of	B-X
the	B-X
chromosomal	B-X
rDNA	B-X
.	B-X
All	B-X
three	B-X
proteins	B-X
,	B-X
however	B-X
,	B-X
have	B-X
many	B-X
target	B-X
sites	B-X
on	B-X
the	B-X
yeast	B-X
genome	B-X
,	B-X
in	B-X
particular	B-X
,	B-X
in	B-X
the	B-X
upstream	B-X
regions	B-X
of	B-X
several	B-X
Pol	B-X
II	B-X
transcribed	B-X
genes	B-X
,	B-X
suggesting	B-X
that	B-X
they	B-X
play	B-X
a	B-X
much	B-X
more	B-X
general	B-X
role	B-X
than	B-X
solely	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
ribosome	B-X
biosynthesis	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
Abf1p	B-X
,	B-X
Rap1p	B-X
,	B-X
and	B-X
Reb1p	B-X
are	B-X
primary	B-X
DNA-binding	B-X
proteins	B-X
that	B-X
serve	B-X
to	B-X
render	B-X
adjacent	B-X
cis-acting	B-X
elements	B-X
accessible	B-X
to	B-X
specific	B-X
trans-acting	B-X
factors	B-X
.	B-X

Although	O
the	O
above	O
data	O
reinforced	O
the	O
notion	O
that	O
certain	O
Rap1p	O
-	O
binding	O
UASs	O
could	O
serve	O
as	O
barriers	O
to	O
silencing	O
,	O
they	O
raised	O
new	O
questions	O
about	O
the	O
essential	O
components	O
of	O
a	O
barrier	O
element	O
.	O

For	O
example	O
,	O
some	O
of	O
the	O
UASs	O
that	O
contained	O
only	O
a	O
single	O
Rap1p	O
site	O
had	O
barrier	O
activity	O
(	O
e	O
.	O
g	O
.	O
RPL19B	O
-	O
UAS	O
,	O
strain	O
3	O
)	O
whereas	O
others	O
that	O
contained	O
two	O
or	O
three	O
sites	O
had	O
no	O
activity	O
(	O
e	O
.	O
g	O
.	O
RPL39	O
,	O
strain	O
16	O
)	O
.	O

One	O
explanation	O
was	O
that	O
sequences	O
flanking	O
the	O
Rap1p	O
site	O
(	O
s	O
)	O
in	O
a	O
particular	O
UAS	O
could	O
positively	O
or	O
negatively	O
influence	O
barrier	O
function	O
.	O
<EOS>	B-X
As	B-X
determined	B-X
,	B-X
the	B-X
microbiota	B-X
influences	B-X
the	B-X
shaping	B-X
and	B-X
modulation	B-X
of	B-X
the	B-X
functioning	B-X
of	B-X
the	B-X
gut-brain	B-X
axis	B-X
.	B-X
Additionally	B-X
,	B-X
it	B-X
is	B-X
known	B-X
that	B-X
,	B-X
in	B-X
periods	B-X
of	B-X
excessive	B-X
activation	B-X
of	B-X
stress	B-X
reactions	B-X
,	B-X
the	B-X
immune	B-X
system	B-X
also	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
,	B-X
negatively	B-X
affecting	B-X
the	B-X
tightness	B-X
of	B-X
the	B-X
intestinal	B-X
barrier	B-X
and	B-X
intestinal	B-X
microflora	B-X
.	B-X
We	B-X
also	B-X
describe	B-X
abnormalities	B-X
in	B-X
the	B-X
functioning	B-X
of	B-X
the	B-X
intestinal	B-X
barrier	B-X
caused	B-X
by	B-X
increased	B-X
activity	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
in	B-X
response	B-X
to	B-X
stressors	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
presented	B-X
study	B-X
discusses	B-X
the	B-X
role	B-X
of	B-X
psychobiotics	B-X
in	B-X
the	B-X
prevention	B-X
and	B-X
treatment	B-X
of	B-X
depression	B-X
through	B-X
their	B-X
influence	B-X
on	B-X
the	B-X
intestinal	B-X
barrier	B-X
,	B-X
immune	B-X
processes	B-X
,	B-X
and	B-X
functioning	B-X
of	B-X
the	B-X
nervous	B-X
system	B-X
.	B-X

Moreover	O
,	O
the	O
presence	O
of	O
Abf1p	O
or	O
Reb1p	O
sites	O
in	O
11	O
of	O
the	O
17	O
new	O
barriers	O
made	O
us	O
wonder	O
if	O
they	O
also	O
participated	O
in	O
barrier	O
function	O
.	O

We	O
began	O
to	O
address	O
these	O
issues	O
by	O
analyzing	O
three	O
new	O
barrier	O
elements	O
(	O
Fig	O
.	O
2	O
)	O
.	O

RPS10A	O
-	O
UAS	O
containing	O
an	O
Abf1p	O
-	O
binding	O
site	O
and	O
a	O
pair	O
of	O
Rap1p	O
sites	O
was	O
divided	O
into	O
three	O
fragments	O
that	O
were	O
tested	O
in	O
a	O
silencer	O
-	O
blocking	O
assay	O
(	O
Fig	O
.	O
2	O
,	O
strains	O
30	O
-	O
32	O
)	O
.	O

It	O
was	O
clear	O
that	O
only	O
the	O
fragment	O
containing	O
Rap1p	O
sites	O
functioned	O
as	O
a	O
barrier	O
(	O
strain	O
31	O
)	O
.	O

TPI1	O
-	O
UAS	O
bearing	O
a	O
Reb1p	O
site	O
and	O
a	O
Rap1p	O
site	O
was	O
divided	O
into	O
two	O
parts	O
with	O
one	O
containing	O
the	O
Rap1p	O
site	O
(	O
Fig	O
.	O
2	O
,	O
strain	O
34	O
)	O
and	O
the	O
other	O
Reb1p	O
site	O
(	O
strain	O
33	O
)	O
.	O

Neither	O
of	O
these	O
fragments	O
alone	O
retained	O
barrier	O
activity	O
indicating	O
that	O
concerted	O
action	O
of	O
Reb1p	O
and	O
Rap1p	O
was	O
required	O
for	O
barrier	O
activity	O
.	O

Duplicating	O
the	O
Reb1p	O
-	O
bearing	O
part	O
of	O
TPI1	O
-	O
UAS	O
didn	O
'	O
t	O
restore	O
barrier	O
activity	O
(	O
strain	O
35	O
)	O
.	O

However	O
,	O
triplicating	O
the	O
Rap1p	O
-	O
containing	O
part	O
did	O
re	O
-	O
create	O
barrier	O
function	O
(	O
strain	O
36	O
)	O
.	O

RPS28A	O
-	O
UAS	O
bore	O
,	O
in	O
addition	O
to	O
a	O
Rap1p	O
site	O
,	O
an	O
Abf1p	O
site	O
and	O
an	O
adjacent	O
T	O
-	O
rich	O
region	O
that	O
are	O
required	O
for	O
efficient	O
transcription	O
of	O
RPS28A	O
(	O
34	O
)	O
.	O

A	O
sequence	O
of	O
RPS28A	O
-	O
UAS	O
deleted	O
for	O
a	O
fragment	O
bearing	O
the	O
Rap1p	O
site	O
lost	O
the	O
barrier	O
activity	O
(	O
Fig	O
.	O
2	O
,	O
strain	O
37	O
)	O
.	O

However	O
,	O
duplicating	O
this	O
sequence	O
restored	O
barrier	O
activity	O
(	O
strain	O
38	O
)	O
.	O

The	O
above	O
results	O
indicated	O
again	O
that	O
Rap1p	O
sites	O
could	O
form	O
barriers	O
(	O
strains	O
31	O
and	O
36	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
they	O
also	O
suggested	O
that	O
synergistic	O
actions	O
of	O
Abf1p	O
sites	O
(	O
strain	O
38	O
)	O
,	O
Reb1p	O
site	O
+	O
Rap1p	O
site	O
(	O
strain	O
18	O
)	O
,	O
or	O
Abf1p	O
site	O
+	O
Rap1p	O
site	O
(	O
strain	O
16	O
)	O
could	O
all	O
lead	O
to	O
barrier	O
function	O
.	O

This	O
was	O
not	O
very	O
surprising	O
since	O
Rap1p	O
,	O
Abf1p	O
and	O
Reb1p	O
could	O
perform	O
similar	O
and	O
sometimes	O
interchangeable	O
functions	O
in	O
gene	O
regulation	O
(	O
16	O
,	O
35	O
,	O
36	O
)	O
.	O

Note	O
,	O
however	O
,	O
we	O
haven	O
'	O
t	O
ruled	O
out	O
the	O
possibility	O
that	O
other	O
factors	O
(	O
e	O
.	O
g	O
.	O
Gcr1p	O
)	O
or	O
structure	O
features	O
of	O
DNA	O
(	O
e	O
.	O
g	O
.	O
T	O
-	O
tracks	O
)	O
were	O
also	O
involved	O
in	O
barrier	O
function	O
.	O

It	O
was	O
interesting	O
that	O
ADH2	O
-	O
UAS	O
and	O
HIS3	O
-	O
UAS	O
bearing	O
no	O
site	O
for	O
Rap1p	O
,	O
Abf1p	O
or	O
Reb1p	O
exhibited	O
detectable	O
barrier	O
activity	O
(	O
Fig	O
.	O
1	O
,	O
strains	O
25	O
and	O
26	O
)	O
.	O

However	O
,	O
binding	O
sites	O
for	O
other	O
transcriptional	O
activators	O
existed	O
in	O
these	O
UASs	O
.	O

The	O
major	O
regulator	O
that	O
binds	O
to	O
ADH2	O
-	O
UAS	O
is	O
Adr1p	O
(	O
37	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
Gcn4p	O
binds	O
to	O
multiple	O
sites	O
in	O
HIS3	O
-	O
UAS	O
and	O
activates	O
HIS3	O
transcription	O
(	O
38	O
)	O
.	O

The	O
possible	O
involvement	O
of	O
Adr1p	O
or	O
Gcn4p	O
in	O
barrier	O
function	O
was	O
examined	O
below	O
.	O

Note	O
Adr1p	O
function	O
was	O
subject	O
to	O
glucose	O
repression	O
(	O
37	O
)	O
,	O
which	O
might	O
explain	O
why	O
ADH2	O
-	O
UAS	O
only	O
exhibited	O
limited	O
barrier	O
activity	O
since	O
glucose	O
was	O
used	O
in	O
the	O
media	O
used	O
in	O
our	O
assay	O
.	O

Effect	O
of	O
mutating	O
Rap1p	O
-	O
binding	O
sites	O
in	O
TEF2	O
-	O
UAS	O
on	O
barrier	O
function	O

Although	O
we	O
had	O
shown	O
that	O
the	O
three	O
Rap1p	O
-	O
binding	O
sites	O
in	O
TEF2	O
-	O
UAS	O
were	O
necessary	O
and	O
sufficient	O
for	O
its	O
barrier	O
activity	O
(	O
11	O
)	O
,	O
we	O
had	O
not	O
shown	O
if	O
binding	O
of	O
Rap1p	O
to	O
these	O
sites	O
was	O
required	O
.	O

To	O
address	O
this	O
we	O
performed	O
mutational	O
analysis	O
of	O
TEF2	O
-	O
UAS	O
.	O

As	O
shown	O
in	O
Figure	O
3A	O
and	O
B	O
,	O
the	O
three	O
Rap1p	O
-	O
binding	O
sites	O
in	O
TEF2	O
-	O
UAS	O
(	O
designated	O
as	O
R1	O
,	O
R2	O
and	O
R3	O
)	O
were	O
all	O
able	O
to	O
bind	O
Rap1p	O
in	O
an	O
EMSA	O
(	O
Fig	O
.	O
3B	O
)	O
.	O

Single	O
or	O
double	O
C	O
-->	O
A	O
mutations	O
were	O
introduced	O
into	O
R1	O
,	O
R2	O
and	O
R3	O
resulting	O
in	O
m1	O
,	O
m2	O
and	O
m3	O
,	O
respectively	O
(	O
Fig	O
.	O
3A	O
)	O
.	O
<EOS>	B-X
China	B-X
has	B-X
the	B-X
highest	B-X
excess	B-X
of	B-X
male	B-X
births	B-X
in	B-X
the	B-X
world	B-X
at	B-X
118	B-X
to	B-X
every	B-X
100	B-X
female	B-X
,	B-X
with	B-X
a	B-X
current	B-X
excess	B-X
of	B-X
20	B-X
million	B-X
men	B-X
of	B-X
reproductive	B-X
age	B-X
.	B-X
Searching	B-X
Ovid	B-X
MEDLINE	B-X
,	B-X
PsycINFO	B-X
,	B-X
CINAHL	B-X
,	B-X
Web	B-X
of	B-X
Science	B-X
,	B-X
Scopus	B-X
,	B-X
ProQuest	B-X
and	B-X
Google	B-X
Scholar	B-X
,	B-X
2949	B-X
papers	B-X
were	B-X
found	B-X
,	B-X
but	B-X
only	B-X
457	B-X
discussed	B-X
any	B-X
element	B-X
of	B-X
the	B-X
research	B-X
questions	B-X
.	B-X
Constant	B-X
comparative	B-X
analyses	B-X
were	B-X
used	B-X
to	B-X
develop	B-X
the	B-X
findings	B-X
.	B-X
China	B-X
has	B-X
an	B-X
ageing	B-X
population	B-X
with	B-X
the	B-X
number	B-X
of	B-X
older	B-X
people	B-X
living	B-X
alone	B-X
increasing	B-X
.	B-X
Living	B-X
alone	B-X
may	B-X
increase	B-X
the	B-X
risk	B-X
of	B-X
loneliness	B-X
of	B-X
older	B-X
people	B-X
,	B-X
especially	B-X
for	B-X
those	B-X
in	B-X
China	B-X
where	B-X
collectivism	B-X
and	B-X
filial	B-X
piety	B-X
are	B-X
emphasised	B-X
.	B-X
However	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
loneliness	B-X
and	B-X
social	B-X
support	B-X
of	B-X
older	B-X
people	B-X
living	B-X
alone	B-X
in	B-X
China	B-X
.	B-X
The	B-X
instruments	B-X
used	B-X
included	B-X
the	B-X
UCLA	B-X
Loneliness	B-X
Scale	B-X
version	B-X
3	B-X
and	B-X
the	B-X
Social	B-X
Support	B-X
Rate	B-X
Scale	B-X
.	B-X
Their	B-X
overall	B-X
social	B-X
support	B-X
level	B-X
was	B-X
low	B-X
compared	B-X
with	B-X
the	B-X
Chinese	B-X
norm	B-X
.	B-X
Children	B-X
were	B-X
the	B-X
major	B-X
source	B-X
of	B-X
objective	B-X
and	B-X
subjective	B-X
support	B-X
.	B-X

The	O
m2	O
and	O
m3	O
sites	O
had	O
both	O
lost	O
the	O
ability	O
to	O
bind	O
Rap1p	O
,	O
whereas	O
m1	O
still	O
bound	O
Rap1p	O
(	O
Fig	O
.	O
3B	O
)	O
,	O
which	O
could	O
be	O
predicted	O
from	O
the	O
specific	O
mutations	O
in	O
each	O
site	O
(	O
Fig	O
.	O
3A	O
,	O
compare	O
m1	O
,	O
m2	O
and	O
m3	O
to	O
the	O
consensus	O
sequence	O
)	O
.	O

We	O
then	O
tested	O
a	O
mutated	O
TEF2	O
-	O
UAS	O
containing	O
m1	O
,	O
m2	O
and	O
m3	O
in	O
a	O
silencer	O
-	O
blocking	O
assay	O
using	O
the	O
HML	O
-	O
E	O
silencer	O
and	O
the	O
HML	O
alpha	O
genes	O
(	O
Fig	O
.	O
3C	O
)	O
.	O

In	O
this	O
assay	O
,	O
the	O
HML	O
-	O
I	O
silencer	O
was	O
deleted	O
but	O
the	O
HML	O
-	O
E	O
silencer	O
was	O
sufficient	O
to	O
silence	O
the	O
HML	O
alpha	O
genes	O
(	O
Fig	O
.	O
3C	O
,	O
strain	O
39	O
)	O
(	O
11	O
)	O
.	O

Silencing	O
in	O
strain	O
39	O
(	O
a	O
-	O
type	O
)	O
was	O
measured	O
by	O
its	O
ability	O
to	O
mate	O
with	O
an	O
alpha	O
-	O
type	O
strain	O
(	O
Fig	O
.	O
3C	O
)	O
.	O

As	O
predicted	O
,	O
the	O
wild	O
-	O
type	O
TEF2	O
-	O
UAS	O
blocked	O
HML	O
alpha	O
silencing	O
(	O
11	O
)	O
(	O
Fig	O
.	O
3C	O
,	O
strain	O
40	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
mutated	O
TEF2	O
-	O
UAS	O
containing	O
m1	O
,	O
m2	O
and	O
m3	O
had	O
lost	O
barrier	O
activity	O
(	O
Fig	O
.	O
3C	O
,	O
compare	O
the	O
mating	O
efficiencies	O
of	O
strains	O
41	O
and	O
40	O
)	O
.	O

Therefore	O
,	O
mutations	O
that	O
prevented	O
Rap1p	O
from	O
binding	O
two	O
of	O
the	O
three	O
sites	O
in	O
TEF2	O
-	O
UAS	O
abolished	O
its	O
barrier	O
activity	O
,	O
indicating	O
that	O
association	O
of	O
Rap1p	O
with	O
TEF2	O
-	O
UAS	O
at	O
more	O
than	O
one	O
site	O
was	O
required	O
for	O
barrier	O
function	O
.	O

The	O
barrier	O
TEF2	O
-	O
UAS	O
alters	O
local	O
chromatin	O
structure	O

In	O
eukaryotic	O
cells	O
,	O
the	O
topology	O
of	O
local	O
DNA	O
reflects	O
the	O
chromatin	O
structure	O
in	O
which	O
it	O
resides	O
.	O
<EOS>	B-X
The	B-X
interphase	B-X
nucleus	B-X
structure	B-X
is	B-X
radially	B-X
organised	B-X
into	B-X
three-dimensional	B-X
discrete	B-X
chromosome	B-X
territories	B-X
or	B-X
domains	B-X
(	B-X
CTs	B-X
)	B-X
surrounded	B-X
by	B-X
a	B-X
channel	B-X
network	B-X
named	B-X
the	B-X
interchromatin	B-X
compartment	B-X
(	B-X
IC	B-X
)	B-X
which	B-X
harbours	B-X
factors	B-X
involved	B-X
in	B-X
DNA	B-X
replication	B-X
or	B-X
repair	B-X
as	B-X
well	B-X
as	B-X
RNA	B-X
transcription	B-X
and	B-X
processing	B-X
.	B-X
Replication	B-X
timing	B-X
and	B-X
topology	B-X
as	B-X
well	B-X
as	B-X
active	B-X
or	B-X
inactive	B-X
chromatin	B-X
residence	B-X
are	B-X
highly	B-X
regulated	B-X
in	B-X
eukaryotic	B-X
cells	B-X
.	B-X
Early	B-X
replicating	B-X
euchromatin	B-X
,	B-X
high	B-X
transcription	B-X
levels	B-X
and	B-X
histone	B-X
H4	B-X
hyperacetylation	B-X
(	B-X
H4+a	B-X
)	B-X
characterise	B-X
the	B-X
nuclear	B-X
interior	B-X
while	B-X
late	B-X
replicating	B-X
heterochromatin	B-X
,	B-X
poor	B-X
transcription	B-X
rates	B-X
and	B-X
underacetylated	B-X
histone	B-X
H4	B-X
distinguish	B-X
the	B-X
nuclear	B-X
periphery	B-X
.	B-X
Active	B-X
chromatin	B-X
loops	B-X
mostly	B-X
map	B-X
to	B-X
the	B-X
surface	B-X
of	B-X
CTs	B-X
and	B-X
protrude	B-X
into	B-X
the	B-X
IC	B-X
whereas	B-X
inactive	B-X
loops	B-X
mainly	B-X
reside	B-X
in	B-X
the	B-X
CTs	B-X
core	B-X
.	B-X
Chromatin	B-X
remodeling	B-X
associated	B-X
to	B-X
DNA	B-X
synthesis	B-X
,	B-X
CTs	B-X
relative	B-X
positioning	B-X
,	B-X
loci	B-X
spatial	B-X
proximity	B-X
,	B-X
intermingling	B-X
of	B-X
chromatin	B-X
loops	B-X
and	B-X
transcriptional	B-X
activity	B-X
could	B-X
be	B-X
critical	B-X
to	B-X
determine	B-X
chromosome	B-X
damage	B-X
localisation	B-X
,	B-X
genomic	B-X
instability	B-X
and	B-X
cancer-prone	B-X
translocation	B-X
frequencies	B-X
.	B-X

We	O
had	O
previously	O
developed	O
a	O
DNA	O
topology	O
-	O
based	O
assay	O
to	O
examine	O
chromatin	O
structure	O
in	O
vivo	O
,	O
which	O
involved	O
excising	O
a	O
chromosomal	O
region	O
of	O
interest	O
from	O
its	O
genomic	O
location	O
as	O
a	O
circle	O
using	O
site	O
-	O
specific	O
recombination	O
(	O
39	O
)	O
.	O

Using	O
this	O
strategy	O
,	O
we	O
demonstrated	O
that	O
DNA	O
in	O
silenced	O
chromatin	O
was	O
more	O
negatively	O
supercoiled	O
than	O
that	O
in	O
active	O
chromatin	O
(	O
39	O
)	O
.	O

In	O
this	O
report	O
we	O
used	O
the	O
topology	O
assay	O
to	O
address	O
if	O
barrier	O
elements	O
altered	O
local	O
chromatin	O
structure	O
as	O
Drosophila	B-Species
or	O
chicken	B-Species
insulators	O
did	O
(	O
40	O
,	O
41	O
)	O
.	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
compare	B-X
lead	B-X
damage	B-X
from	B-X
an	B-X
insulated	B-X
cautery	B-X
blade	B-X
when	B-X
used	B-X
with	B-X
several	B-X
different	B-X
techniques	B-X
that	B-X
included	B-X
coagulation	B-X
(	B-X
COAG	B-X
)	B-X
versus	B-X
cutting	B-X
(	B-X
CUT	B-X
)	B-X
mode	B-X
,	B-X
perpendicular	B-X
active	B-X
edge	B-X
(	B-X
active	B-X
)	B-X
versus	B-X
parallel	B-X
flat	B-X
blade	B-X
(	B-X
flat	B-X
)	B-X
orientation	B-X
(	B-X
phase	B-X
1	B-X
)	B-X
,	B-X
and	B-X
using	B-X
one	B-X
commercially	B-X
available	B-X
blade	B-X
(	B-X
PhotonBlade	B-X
)	B-X
versus	B-X
another	B-X
(	B-X
PlasmaBlade	B-X
)	B-X
(	B-X
phase	B-X
2	B-X
)	B-X
.	B-X

Various	O
sequences	O
(	O
designated	O
X	O
)	O
from	O
UASs	O
of	O
TEF2	O
,	O
AgTEF	O
(	O
TEF	O
gene	O
from	O
Ashbya	B-Species
gossypii	I-Species
)	O
and	O
ADE2	O
were	O
inserted	O
between	O
HML	O
-	O
E	O
and	O
HML	O
alpha	O
at	O
HML	O
Delta	O
I	O
(	O
HML	O
locus	O
deleted	O
for	O
the	O
I	O
silencer	O
)	O
flanked	O
by	O
the	O
FRT	O
sites	O
for	O
the	O
Flp1p	O
site	O
-	O
specific	O
recombinase	O
(	O
Fig	O
.	O
4A	O
and	O
B	O
)	O
.	O

The	O
FLP1	O
gene	O
was	O
under	O
the	O
control	O
of	O
the	O
inducible	O
GAL10	O
promoter	O
(	O
39	O
)	O
.	O

The	O
mating	O
efficiency	O
of	O
each	O
strain	O
measured	O
silencing	O
of	O
HML	O
alpha	O
(	O
Fig	O
.	O
4C	O
)	O
.	O

In	O
strains	O
40	O
,	O
42	O
,	O
44	O
and	O
47	O
,	O
silencing	O
was	O
restricted	O
to	O
the	O
left	O
of	O
the	O
X	O
insertions	O
and	O
HML	O
alpha	O
was	O
derepressed	O
(	O
Fig	O
.	O
4C	O
)	O
.	O

Consistently	O
,	O
the	O
proportion	O
of	O
silent	O
chromatin	O
in	O
the	O
region	O
flanked	O
by	O
the	O
FRT	O
sites	O
in	O
each	O
of	O
these	O
strains	O
was	O
decreased	O
,	O
as	O
indicated	O
by	O
the	O
reduced	O
negative	O
supercoiling	O
of	O
the	O
excised	O
circle	O
(	O
11	O
)	O
(	O
data	O
not	O
shown	O
)	O
.	O

Note	O
that	O
the	O
above	O
effect	O
of	O
a	O
barrier	O
on	O
HML	O
chromatin	O
reflected	O
both	O
change	O
in	O
the	O
scope	O
of	O
silencing	O
caused	O
by	O
the	O
barrier	O
activity	O
and	O
alteration	O
(	O
if	O
any	O
)	O
in	O
chromatin	O
structure	O
at	O
the	O
barrier	O
independent	O
of	O
the	O
silencing	O
state	O
of	O
the	O
locus	O
.	O

To	O
exclusively	O
examine	O
the	O
latter	O
,	O
we	O
analyzed	O
the	O
topology	O
of	O
HML	O
DNA	O
in	O
a	O
silencing	O
-	O
deficient	O
background	O
.	O

The	O
SIR3	O
gene	O
in	O
strains	O
described	O
in	O
Figure	O
4B	O
was	O
disrupted	O
rendering	O
them	O
defective	O
in	O
silencing	O
(	O
strains	O
40	O
'	O
-	O
48	O
'	O
in	O
Fig	O
.	O
4D	O
)	O
.	O

Recombination	O
mediated	O
by	O
Flp1p	O
in	O
these	O
strains	O
led	O
to	O
the	O
excision	O
of	O
a	O
group	O
of	O
chromosomal	O
circles	O
that	O
differed	O
only	O
in	O
the	O
X	O
insertion	O
.	O

The	O
supercoiling	O
of	O
these	O
circles	O
was	O
analyzed	O
as	O
a	O
function	O
of	O
the	O
length	O
of	O
the	O
insertion	O
(	O
Fig	O
.	O
4D	O
)	O
.	O

If	O
an	O
insertion	O
simply	O
lengthened	O
a	O
circle	O
without	O
causing	O
abnormal	O
changes	O
in	O
nucleosomal	O
structure	O
and	O
/	O
or	O
density	O
,	O
the	O
topoisomers	O
of	O
this	O
circle	O
would	O
migrate	O
slower	O
relative	O
to	O
those	O
of	O
a	O
similar	O
circle	O
with	O
a	O
smaller	O
size	O
.	O

Otherwise	O
,	O
migration	O
of	O
the	O
topoisomers	O
would	O
deviate	O
from	O
that	O
predicted	O
based	O
on	O
the	O
size	O
of	O
the	O
circle	O
.	O

As	O
shown	O
in	O
Figure	O
4D	O
,	O
the	O
circle	O
from	O
strain	O
40	O
'	O
bearing	O
a	O
104	O
bp	O
barrier	O
element	O
migrated	O
faster	O
rather	O
than	O
slower	O
than	O
the	O
circle	O
from	O
strain	O
46	O
'	O
bearing	O
a	O
91	O
bp	O
non	O
-	O
barrier	O
element	O
.	O

Circles	O
bearing	O
other	O
barrier	O
elements	O
also	O
exhibited	O
unexpected	O
faster	O
migration	O
(	O
compare	O
strains	O
44	O
'	O
to	O
45	O
'	O
,	O
47	O
'	O
to	O
43	O
'	O
,	O
42	O
'	O
to	O
48	O
'	O
,	O
respectively	O
)	O
.	O

Therefore	O
,	O
these	O
data	O
indicated	O
that	O
barrier	O
function	O
correlated	O
with	O
altered	O
topology	O
of	O
local	O
DNA	O
.	O

This	O
was	O
further	O
demonstrated	O
by	O
that	O
mutations	O
in	O
TEF2	O
-	O
UAS	O
that	O
abolished	O
its	O
barrier	O
activity	O
also	O
abolished	O
its	O
effect	O
on	O
DNA	O
topology	O
(	O
Fig	O
.	O
4D	O
,	O
compare	O
41	O
'	O
to	O
40	O
'	O
;	O
note	O
that	O
circles	O
from	O
both	O
strains	O
had	O
the	O
same	O
size	O
)	O
.	O

Since	O
in	O
our	O
gel	O
assay	O
more	O
negatively	O
supercoiled	O
DNA	O
migrate	O
slower	O
,	O
we	O
concluded	O
that	O
every	O
fragment	O
with	O
barrier	O
activity	O
caused	O
a	O
reduction	O
in	O
negative	O
supercoiling	O
of	O
approximately	O
one	O
to	O
two	O
turns	O
in	O
HML	O
Delta	O
I	O
DNA	O
(	O
Fig	O
.	O
4D	O
,	O
compare	O
the	O
centers	O
of	O
distributions	O
of	O
topoisomers	O
in	O
pairs	O
of	O
lanes	O
,	O
e	O
.	O
g	O
.	O
40	O
'	O
and	O
41	O
'	O
)	O
.	O

The	O
topology	O
of	O
eukaryotic	O
DNA	O
reflects	O
mainly	O
the	O
wrapping	O
of	O
DNA	O
into	O
nucleosomes	O
(	O
approximately	O
one	O
negative	O
superhelical	O
turn	O
is	O
associated	O
with	O
each	O
nucleosome	O
)	O
(	O
42	O
)	O
.	O

Therefore	O
,	O
removal	O
of	O
one	O
nucleosome	O
would	O
eliminate	O
approximately	O
one	O
turn	O
.	O

On	O
the	O
other	O
hand	O
,	O
histone	O
acetylation	O
can	O
reduce	O
negative	O
supercoiling	O
associated	O
with	O
a	O
nucleosome	O
by	O
approximately	O
0	O
.	O
2	O
turns	O
(	O
43	O
)	O
.	O

Therefore	O
,	O
acetylating	O
five	O
nucleosomes	O
would	O
reduce	O
negative	O
supercoiling	O
by	O
approximately	O
one	O
turn	O
.	O

Consequently	O
,	O
the	O
linking	O
number	O
change	O
of	O
one	O
to	O
two	O
brought	O
about	O
by	O
TEF2	O
-	O
UAS	O
can	O
be	O
accounted	O
for	O
by	O
either	O
the	O
loss	O
of	O
one	O
to	O
two	O
nucleosomes	O
or	O
acetylation	O
of	O
five	O
to	O
10	O
nucleosomes	O
.	O
<EOS>	B-X
The	B-X
progesterone	B-X
receptor	B-X
(	B-X
PR	B-X
)	B-X
binds	B-X
to	B-X
a	B-X
cluster	B-X
of	B-X
five	B-X
hormone	B-X
responsive	B-X
elements	B-X
(	B-X
HREs	B-X
)	B-X
and	B-X
activates	B-X
the	B-X
promoter	B-X
by	B-X
synergistic	B-X
interactions	B-X
with	B-X
the	B-X
ubiquitous	B-X
transcription	B-X
factor	B-X
,	B-X
nuclear	B-X
factor	B-X
1	B-X
(	B-X
NF1	B-X
)	B-X
.	B-X
Progesterone	B-X
treatment	B-X
of	B-X
cells	B-X
in	B-X
culture	B-X
leads	B-X
to	B-X
activation	B-X
of	B-X
the	B-X
Src/Ras/Erk/Msk1	B-X
cascade	B-X
.	B-X
A	B-X
complex	B-X
of	B-X
activated	B-X
PR	B-X
,	B-X
Erk	B-X
and	B-X
Msk1	B-X
is	B-X
recruited	B-X
to	B-X
promoter	B-X
after	B-X
5	B-X
min	B-X
of	B-X
hormone	B-X
treatment	B-X
and	B-X
phosphorylates	B-X
histone	B-X
H3	B-X
at	B-X
serine	B-X
10	B-X
.	B-X
Progestin	B-X
treatment	B-X
leads	B-X
to	B-X
the	B-X
recruitment	B-X
of	B-X
the	B-X
BAF	B-X
complex	B-X
,	B-X
which	B-X
selectively	B-X
displaces	B-X
histones	B-X
H2A	B-X
and	B-X
H2B	B-X
from	B-X
the	B-X
nucleosome	B-X
containing	B-X
the	B-X
HREs	B-X
.	B-X
The	B-X
acetyltransferase	B-X
PCAF	B-X
is	B-X
also	B-X
required	B-X
for	B-X
induction	B-X
of	B-X
progesterone	B-X
target	B-X
genes	B-X
and	B-X
acetylates	B-X
histone	B-X
H3	B-X
at	B-X
K14	B-X
,	B-X
an	B-X
epigenetic	B-X
mark	B-X
,	B-X
which	B-X
interacts	B-X
with	B-X
Brg1	B-X
and	B-X
Brm	B-X
,	B-X
anchoring	B-X
the	B-X
BAF	B-X
complex	B-X
to	B-X
chromatin	B-X
.	B-X
In	B-X
nucleosomes	B-X
assembled	B-X
on	B-X
either	B-X
MMTV	B-X
or	B-X
mouse	B-X
rDNA	B-X
promoter	B-X
sequences	B-X
,	B-X
SWI/SNF	B-X
displaces	B-X
histones	B-X
H2A	B-X
and	B-X
H2B	B-X
from	B-X
MMTV	B-X
,	B-X
but	B-X
not	B-X
from	B-X
the	B-X
rDNA	B-X
nucleosome	B-X
.	B-X
Thus	B-X
,	B-X
initial	B-X
activation	B-X
of	B-X
the	B-X
MMTV	B-X
promoter	B-X
requires	B-X
activation	B-X
of	B-X
several	B-X
kinases	B-X
and	B-X
PCAF	B-X
leading	B-X
to	B-X
phosphoacetylation	B-X
of	B-X
H3	B-X
,	B-X
and	B-X
recruitment	B-X
of	B-X
BAF	B-X
with	B-X
subsequent	B-X
removal	B-X
of	B-X
H2A/H2B	B-X
.	B-X

Further	O
experiments	O
are	O
under	O
way	O
to	O
clarify	O
the	O
nature	O
of	O
change	O
in	O
chromatin	O
induced	O
by	O
a	O
barrier	O
.	O

Targeting	O
the	O
transcription	O
activation	O
domain	O
of	O
Rap1p	O
recapitulates	O
its	O
barrier	O
activity	O
<EOS>	B-X
Barrier	B-X
elements	B-X
that	B-X
are	B-X
able	B-X
to	B-X
block	B-X
the	B-X
propagation	B-X
of	B-X
transcriptional	B-X
silencing	B-X
in	B-X
yeast	B-X
are	B-X
functionally	B-X
similar	B-X
to	B-X
chromatin	B-X
boundary/insulator	B-X
elements	B-X
in	B-X
metazoans	B-X
that	B-X
delimit	B-X
functional	B-X
chromosomal	B-X
domains	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
upstream	B-X
activating	B-X
sequences	B-X
of	B-X
many	B-X
highly	B-X
expressed	B-X
ribosome	B-X
protein	B-X
genes	B-X
and	B-X
glycolytic	B-X
genes	B-X
exhibit	B-X
barrier	B-X
activity	B-X
.	B-X
Analyses	B-X
of	B-X
these	B-X
barriers	B-X
indicate	B-X
that	B-X
binding	B-X
sites	B-X
for	B-X
transcriptional	B-X
regulators	B-X
Rap1p	B-X
,	B-X
Abf1p	B-X
,	B-X
Reb1p	B-X
,	B-X
Adr1p	B-X
and	B-X
Gcn4p	B-X
may	B-X
participate	B-X
in	B-X
barrier	B-X
function	B-X
.	B-X
We	B-X
also	B-X
present	B-X
evidence	B-X
suggesting	B-X
that	B-X
Rap1p	B-X
is	B-X
directly	B-X
involved	B-X
in	B-X
barrier	B-X
activity	B-X
,	B-X
and	B-X
its	B-X
barrier	B-X
function	B-X
correlates	B-X
with	B-X
local	B-X
changes	B-X
in	B-X
chromatin	B-X
structure	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
tethering	B-X
the	B-X
transcriptional	B-X
activation	B-X
domain	B-X
of	B-X
Rap1p	B-X
to	B-X
DNA	B-X
is	B-X
sufficient	B-X
to	B-X
recapitulate	B-X
barrier	B-X
activity	B-X
.	B-X
Moreover	B-X
,	B-X
targeting	B-X
the	B-X
activation	B-X
domain	B-X
of	B-X
Adr1p	B-X
or	B-X
Gcn4p	B-X
also	B-X
establishes	B-X
a	B-X
barrier	B-X
to	B-X
silencing	B-X
.	B-X
These	B-X
results	B-X
support	B-X
the	B-X
notion	B-X
that	B-X
transcriptional	B-X
regulators	B-X
could	B-X
also	B-X
participate	B-X
in	B-X
delimiting	B-X
functional	B-X
domains	B-X
in	B-X
the	B-X
genome	B-X
.	B-X

The	O
multifunctional	O
Rap1p	O
can	O
be	O
divided	O
into	O
at	O
least	O
four	O
functional	O
domains	O
(	O
Fig	O
.	O
5A	O
)	O
(	O
12	O
)	O
.	O

We	O
were	O
interested	O
in	O
defining	O
which	O
of	O
these	O
domains	O
might	O
be	O
involved	O
in	O
the	O
barrier	O
activity	O
of	O
Rap1p	O
.	O

To	O
this	O
end	O
,	O
we	O
fused	O
various	O
parts	O
of	O
Rap1p	O
to	O
the	O
bacterial	O
LexA	O
protein	O
and	O
tested	O
if	O
targeting	O
any	O
of	O
the	O
fusion	O
proteins	O
to	O
LexA	O
-	O
binding	O
sites	O
could	O
re	O
-	O
create	O
a	O
barrier	O
to	O
silencing	O
(	O
Fig	O
.	O
5A	O
)	O
.	O

The	O
LexA	O
-	O
RAP1	O
fusion	O
genes	O
were	O
carried	O
on	O
2	O
micro	O
m	O
based	O
plasmids	O
marked	O
by	O
LEU2	O
(	O
designated	O
L1	O
-	O
L6	O
,	O
Fig	O
.	O
5A	O
)	O
.	O

When	O
introduced	O
into	O
strain	O
50	O
in	O
which	O
two	O
LexA	O
-	O
binding	O
sites	O
had	O
been	O
inserted	O
between	O
the	O
inverted	O
HML	O
-	O
I	O
and	O
URA3	O
,	O
LexA	O
alone	O
had	O
no	O
effect	O
on	O
URA3	O
silencing	O
(	O
Fig	O
.	O
5A	O
,	O
plasmid	O
L1	O
)	O
.	O

Targeting	O
the	O
DNA	O
binding	O
domain	O
,	O
DNA	O
bending	O
domain	O
,	O
silencing	O
domain	O
,	O
or	O
the	O
activating	O
+	O
silencing	O
domain	O
of	O
Rap1p	O
also	O
did	O
not	O
affect	O
URA3	O
silencing	O
(	O
L2	O
-	O
L5	O
)	O
.	O
<EOS>	B-X
The	B-X
DNA-binding	B-X
protein	B-X
Rap1p	B-X
fulfills	B-X
many	B-X
different	B-X
functions	B-X
in	B-X
the	B-X
yeast	B-X
cell	B-X
.	B-X
It	B-X
targets	B-X
5	B-X
%	B-X
of	B-X
the	B-X
promoters	B-X
,	B-X
acting	B-X
both	B-X
as	B-X
a	B-X
transcriptional	B-X
activator	B-X
and	B-X
as	B-X
a	B-X
repressor	B-X
,	B-X
depending	B-X
on	B-X
the	B-X
DNA	B-X
sequence	B-X
context	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
Rap1p	B-X
is	B-X
an	B-X
essential	B-X
structural	B-X
component	B-X
of	B-X
yeast	B-X
telomeres	B-X
,	B-X
where	B-X
it	B-X
contributes	B-X
to	B-X
telomeric	B-X
silencing	B-X
.	B-X
Here	B-X
we	B-X
review	B-X
the	B-X
evidence	B-X
indicating	B-X
that	B-X
Rap1p	B-X
function	B-X
is	B-X
modulated	B-X
by	B-X
the	B-X
precise	B-X
architecture	B-X
of	B-X
the	B-X
its	B-X
binding	B-X
site	B-X
and	B-X
its	B-X
surroundings	B-X
:	B-X
long	B-X
tracts	B-X
of	B-X
telomeric	B-X
repeats	B-X
for	B-X
telomeric	B-X
functions	B-X
,	B-X
specific	B-X
sequences	B-X
and	B-X
orientation	B-X
for	B-X
maximal	B-X
transcriptional	B-X
activation	B-X
,	B-X
and	B-X
specific	B-X
DNA	B-X
recognition	B-X
sequences	B-X
for	B-X
complementary	B-X
factors	B-X
in	B-X
other	B-X
cases	B-X
.	B-X
Many	B-X
of	B-X
these	B-X
functions	B-X
are	B-X
probably	B-X
related	B-X
to	B-X
chromatin	B-X
organization	B-X
around	B-X
Rap1p	B-X
DNA	B-X
binding	B-X
sites	B-X
,	B-X
resulting	B-X
from	B-X
the	B-X
very	B-X
tight	B-X
binding	B-X
of	B-X
Rap1p	B-X
to	B-X
DNA	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
Rap1p	B-X
alters	B-X
its	B-X
structure	B-X
to	B-X
bind	B-X
to	B-X
different	B-X
versions	B-X
of	B-X
its	B-X
DNA	B-X
binding	B-X
sequence	B-X
.	B-X
These	B-X
structural	B-X
changes	B-X
may	B-X
modulate	B-X
the	B-X
function	B-X
of	B-X
Rap1p	B-X
domains	B-X
,	B-X
providing	B-X
different	B-X
interacting	B-X
surfaces	B-X
for	B-X
binding	B-X
to	B-X
specific	B-X
co-operating	B-X
factors	B-X
,	B-X
and	B-X
thus	B-X
contributing	B-X
to	B-X
the	B-X
diversity	B-X
of	B-X
Rap1p	B-X
function	B-X
.	B-X

On	O
the	O
other	O
hand	O
,	O
targeting	O
the	O
activation	O
domain	O
alone	O
recapitulated	O
the	O
barrier	O
activity	O
of	O
Rap1p	O
(	O
L6	O
)	O
.	O

These	O
results	O
indicated	O
that	O
the	O
activation	O
domain	O
of	O
Rap1p	O
was	O
involved	O
in	O
barrier	O
activity	O
.	O
<EOS>	B-X
Barrier	B-X
elements	B-X
that	B-X
are	B-X
able	B-X
to	B-X
block	B-X
the	B-X
propagation	B-X
of	B-X
transcriptional	B-X
silencing	B-X
in	B-X
yeast	B-X
are	B-X
functionally	B-X
similar	B-X
to	B-X
chromatin	B-X
boundary/insulator	B-X
elements	B-X
in	B-X
metazoans	B-X
that	B-X
delimit	B-X
functional	B-X
chromosomal	B-X
domains	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
upstream	B-X
activating	B-X
sequences	B-X
of	B-X
many	B-X
highly	B-X
expressed	B-X
ribosome	B-X
protein	B-X
genes	B-X
and	B-X
glycolytic	B-X
genes	B-X
exhibit	B-X
barrier	B-X
activity	B-X
.	B-X
Analyses	B-X
of	B-X
these	B-X
barriers	B-X
indicate	B-X
that	B-X
binding	B-X
sites	B-X
for	B-X
transcriptional	B-X
regulators	B-X
Rap1p	B-X
,	B-X
Abf1p	B-X
,	B-X
Reb1p	B-X
,	B-X
Adr1p	B-X
and	B-X
Gcn4p	B-X
may	B-X
participate	B-X
in	B-X
barrier	B-X
function	B-X
.	B-X
We	B-X
also	B-X
present	B-X
evidence	B-X
suggesting	B-X
that	B-X
Rap1p	B-X
is	B-X
directly	B-X
involved	B-X
in	B-X
barrier	B-X
activity	B-X
,	B-X
and	B-X
its	B-X
barrier	B-X
function	B-X
correlates	B-X
with	B-X
local	B-X
changes	B-X
in	B-X
chromatin	B-X
structure	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
tethering	B-X
the	B-X
transcriptional	B-X
activation	B-X
domain	B-X
of	B-X
Rap1p	B-X
to	B-X
DNA	B-X
is	B-X
sufficient	B-X
to	B-X
recapitulate	B-X
barrier	B-X
activity	B-X
.	B-X
Moreover	B-X
,	B-X
targeting	B-X
the	B-X
activation	B-X
domain	B-X
of	B-X
Adr1p	B-X
or	B-X
Gcn4p	B-X
also	B-X
establishes	B-X
a	B-X
barrier	B-X
to	B-X
silencing	B-X
.	B-X
These	B-X
results	B-X
support	B-X
the	B-X
notion	B-X
that	B-X
transcriptional	B-X
regulators	B-X
could	B-X
also	B-X
participate	B-X
in	B-X
delimiting	B-X
functional	B-X
domains	B-X
in	B-X
the	B-X
genome	B-X
.	B-X

The	O
inability	O
of	O
the	O
Rap1p	O
-	O
silencing	O
domain	O
to	O
block	O
URA3	O
silencing	O
in	O
our	O
assay	O
did	O
not	O
necessarily	O
mean	O
that	O
this	O
domain	O
had	O
no	O
barrier	O
function	O
,	O
since	O
such	O
a	O
function	O
might	O
be	O
suppressed	O
by	O
much	O
stronger	O
silencing	O
activity	O
associated	O
with	O
the	O
silencing	O
domain	O
.	O

Was	O
the	O
lack	O
of	O
barrier	O
function	O
of	O
fusion	O
constructs	O
L2	O
-	O
L5	O
due	O
to	O
a	O
lack	O
of	O
expression	O
of	O
these	O
proteins	O
?	O

To	O
address	O
this	O
possibility	O
,	O
we	O
examined	O
the	O
levels	O
of	O
L1	O
-	O
L6	O
proteins	O
as	O
well	O
as	O
L7	O
and	O
L8	O
proteins	O
described	O
in	O
Figure	O
5B	O
by	O
western	O
blotting	O
using	O
an	O
antibody	O
against	O
LexA	O
.	O

As	O
shown	O
in	O
Figure	O
5C	O
,	O
L5	O
was	O
expressed	O
at	O
a	O
level	O
comparable	O
to	O
L6	O
,	O
and	O
L4	O
was	O
expressed	O
at	O
a	O
higher	O
level	O
than	O
L6	O
.	O

Therefore	O
,	O
the	O
lack	O
of	O
barrier	O
function	O
of	O
L4	O
and	O
L6	O
was	O
not	O
the	O
result	O
of	O
their	O
lack	O
of	O
expression	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
level	O
of	O
L2	O
or	O
L3	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
L6	O
,	O
hence	O
the	O
lack	O
of	O
barrier	O
function	O
of	O
L2	O
and	O
L3	O
might	O
be	O
due	O
to	O
their	O
insufficient	O
expression	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
report	B-X
that	B-X
ATII	B-X
cells	B-X
in	B-X
IPF	B-X
lungs	B-X
express	B-X
higher	B-X
levels	B-X
of	B-X
serpine	B-X
1	B-X
,	B-X
also	B-X
known	B-X
as	B-X
plasminogen	B-X
activator	B-X
inhibitor	B-X
1	B-X
(	B-X
PAI-1	B-X
)	B-X
,	B-X
and	B-X
cell	B-X
senescence	B-X
markers	B-X
p21	B-X
and	B-X
p16	B-X
,	B-X
compared	B-X
to	B-X
ATII	B-X
cells	B-X
in	B-X
control	B-X
lungs	B-X
.	B-X
Silencing	B-X
PAI-1	B-X
or	B-X
inhibition	B-X
of	B-X
PAI-1	B-X
activity	B-X
in	B-X
cultured	B-X
rat	B-X
ATII	B-X
(	B-X
L2	B-X
)	B-X
cells	B-X
leads	B-X
to	B-X
decreases	B-X
in	B-X
p53	B-X
serine	B-X
18	B-X
phosphorylation	B-X
(	B-X
p53	B-X
Lately	B-X
,	B-X
their	B-X
soluble	B-X
counterparts	B-X
,	B-X
sPD-1	B-X
and	B-X
sPD-L1	B-X
,	B-X
have	B-X
been	B-X
detected	B-X
in	B-X
plasma	B-X
,	B-X
and	B-X
elevated	B-X
levels	B-X
have	B-X
been	B-X
associated	B-X
with	B-X
advanced	B-X
disease	B-X
,	B-X
clinical	B-X
stages	B-X
,	B-X
and	B-X
worst	B-X
prognosis	B-X
for	B-X
cancer	B-X
patients	B-X
.	B-X
Elevated	B-X
plasma	B-X
levels	B-X
of	B-X
sPD-L1	B-X
have	B-X
been	B-X
correlated	B-X
with	B-X
worst	B-X
prognosis	B-X
in	B-X
several	B-X
studies	B-X
and	B-X
has	B-X
displayed	B-X
a	B-X
persistent	B-X
outlook	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
sPD-1	B-X
levels	B-X
have	B-X
been	B-X
inconsistent	B-X
in	B-X
their	B-X
predictive	B-X
and	B-X
prognostic	B-X
ability	B-X
.	B-X
Pretherapeutic	B-X
higher	B-X
sPD-1	B-X
plasma	B-X
levels	B-X
have	B-X
shown	B-X
to	B-X
predict	B-X
advanced	B-X
disease	B-X
state	B-X
and	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
worst	B-X
prognosis	B-X
.	B-X
Any	B-X
increase	B-X
in	B-X
sPD-1	B-X
plasma	B-X
level	B-X
post	B-X
therapeutically	B-X
have	B-X
been	B-X
correlated	B-X
with	B-X
improved	B-X
survival	B-X
for	B-X
various	B-X
cancers	B-X
.	B-X

As	O
an	O
important	O
control	O
for	O
the	O
above	O
targeting	O
experiments	O
,	O
we	O
showed	O
that	O
plasmids	O
L1	O
-	O
L6	O
(	O
Fig	O
.	O
5A	O
)	O
as	O
well	O
as	O
L7	O
and	O
L8	O
(	O
Fig	O
.	O
5B	O
)	O
bearing	O
LexA	O
-	O
fusion	O
genes	O
had	O
no	O
effect	O
on	O
URA3	O
silencing	O
in	O
strain	O
1	O
(	O
Fig	O
.	O
1	O
)	O
in	O
which	O
there	O
was	O
no	O
binding	O
site	O
for	O
LexA	O
present	O
between	O
HML	O
-	O
I	O
and	O
URA3	O
(	O
data	O
not	O
shown	O
)	O
.	O

Hence	O
,	O
the	O
effect	O
of	O
the	O
fusion	O
proteins	O
on	O
URA3	O
silencing	O
was	O
the	O
result	O
of	O
their	O
targeting	O
to	O
specific	O
loci	O
,	O
not	O
the	O
consequence	O
of	O
non	O
-	O
specific	O
,	O
indirect	O
functions	O
(	O
if	O
any	O
)	O
of	O
these	O
proteins	O
.	O

Targeted	O
activation	O
domain	O
of	O
Adr1p	O
or	O
Gcn4p	O
can	O
also	O
act	O
as	O
a	O
barrier	O
factor	O
<EOS>	B-X
Barrier	B-X
elements	B-X
that	B-X
are	B-X
able	B-X
to	B-X
block	B-X
the	B-X
propagation	B-X
of	B-X
transcriptional	B-X
silencing	B-X
in	B-X
yeast	B-X
are	B-X
functionally	B-X
similar	B-X
to	B-X
chromatin	B-X
boundary/insulator	B-X
elements	B-X
in	B-X
metazoans	B-X
that	B-X
delimit	B-X
functional	B-X
chromosomal	B-X
domains	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
upstream	B-X
activating	B-X
sequences	B-X
of	B-X
many	B-X
highly	B-X
expressed	B-X
ribosome	B-X
protein	B-X
genes	B-X
and	B-X
glycolytic	B-X
genes	B-X
exhibit	B-X
barrier	B-X
activity	B-X
.	B-X
Analyses	B-X
of	B-X
these	B-X
barriers	B-X
indicate	B-X
that	B-X
binding	B-X
sites	B-X
for	B-X
transcriptional	B-X
regulators	B-X
Rap1p	B-X
,	B-X
Abf1p	B-X
,	B-X
Reb1p	B-X
,	B-X
Adr1p	B-X
and	B-X
Gcn4p	B-X
may	B-X
participate	B-X
in	B-X
barrier	B-X
function	B-X
.	B-X
We	B-X
also	B-X
present	B-X
evidence	B-X
suggesting	B-X
that	B-X
Rap1p	B-X
is	B-X
directly	B-X
involved	B-X
in	B-X
barrier	B-X
activity	B-X
,	B-X
and	B-X
its	B-X
barrier	B-X
function	B-X
correlates	B-X
with	B-X
local	B-X
changes	B-X
in	B-X
chromatin	B-X
structure	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
tethering	B-X
the	B-X
transcriptional	B-X
activation	B-X
domain	B-X
of	B-X
Rap1p	B-X
to	B-X
DNA	B-X
is	B-X
sufficient	B-X
to	B-X
recapitulate	B-X
barrier	B-X
activity	B-X
.	B-X
Moreover	B-X
,	B-X
targeting	B-X
the	B-X
activation	B-X
domain	B-X
of	B-X
Adr1p	B-X
or	B-X
Gcn4p	B-X
also	B-X
establishes	B-X
a	B-X
barrier	B-X
to	B-X
silencing	B-X
.	B-X
These	B-X
results	B-X
support	B-X
the	B-X
notion	B-X
that	B-X
transcriptional	B-X
regulators	B-X
could	B-X
also	B-X
participate	B-X
in	B-X
delimiting	B-X
functional	B-X
domains	B-X
in	B-X
the	B-X
genome	B-X
.	B-X

We	O
have	O
shown	O
above	O
that	O
ADH2	O
-	O
UAS	O
bearing	O
Adr1p	O
-	O
binding	O
sites	O
and	O
HIS3	O
-	O
UAS	O
bearing	O
Gcn4p	O
sites	O
both	O
had	O
detectable	O
barrier	O
activity	O
(	O
Fig	O
.	O
1	O
,	O
strains	O
25	O
and	O
26	O
)	O
.	O

Given	O
that	O
tethering	O
the	O
activation	O
domain	O
of	O
Rap1p	O
is	O
sufficient	O
for	O
barrier	O
function	O
,	O
we	O
tested	O
if	O
targeting	O
the	O
activation	O
domain	O
of	O
Adr1p	O
or	O
Gcn4p	O
could	O
also	O
establish	O
a	O
barrier	O
.	O
<EOS>	B-X
Barrier	B-X
elements	B-X
that	B-X
are	B-X
able	B-X
to	B-X
block	B-X
the	B-X
propagation	B-X
of	B-X
transcriptional	B-X
silencing	B-X
in	B-X
yeast	B-X
are	B-X
functionally	B-X
similar	B-X
to	B-X
chromatin	B-X
boundary/insulator	B-X
elements	B-X
in	B-X
metazoans	B-X
that	B-X
delimit	B-X
functional	B-X
chromosomal	B-X
domains	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
upstream	B-X
activating	B-X
sequences	B-X
of	B-X
many	B-X
highly	B-X
expressed	B-X
ribosome	B-X
protein	B-X
genes	B-X
and	B-X
glycolytic	B-X
genes	B-X
exhibit	B-X
barrier	B-X
activity	B-X
.	B-X
Analyses	B-X
of	B-X
these	B-X
barriers	B-X
indicate	B-X
that	B-X
binding	B-X
sites	B-X
for	B-X
transcriptional	B-X
regulators	B-X
Rap1p	B-X
,	B-X
Abf1p	B-X
,	B-X
Reb1p	B-X
,	B-X
Adr1p	B-X
and	B-X
Gcn4p	B-X
may	B-X
participate	B-X
in	B-X
barrier	B-X
function	B-X
.	B-X
We	B-X
also	B-X
present	B-X
evidence	B-X
suggesting	B-X
that	B-X
Rap1p	B-X
is	B-X
directly	B-X
involved	B-X
in	B-X
barrier	B-X
activity	B-X
,	B-X
and	B-X
its	B-X
barrier	B-X
function	B-X
correlates	B-X
with	B-X
local	B-X
changes	B-X
in	B-X
chromatin	B-X
structure	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
tethering	B-X
the	B-X
transcriptional	B-X
activation	B-X
domain	B-X
of	B-X
Rap1p	B-X
to	B-X
DNA	B-X
is	B-X
sufficient	B-X
to	B-X
recapitulate	B-X
barrier	B-X
activity	B-X
.	B-X
Moreover	B-X
,	B-X
targeting	B-X
the	B-X
activation	B-X
domain	B-X
of	B-X
Adr1p	B-X
or	B-X
Gcn4p	B-X
also	B-X
establishes	B-X
a	B-X
barrier	B-X
to	B-X
silencing	B-X
.	B-X
These	B-X
results	B-X
support	B-X
the	B-X
notion	B-X
that	B-X
transcriptional	B-X
regulators	B-X
could	B-X
also	B-X
participate	B-X
in	B-X
delimiting	B-X
functional	B-X
domains	B-X
in	B-X
the	B-X
genome	B-X
.	B-X

Adr1p	O
contains	O
four	O
separate	O
activation	O
domains	O
(	O
TADI	O
-	O
TADIV	O
)	O
that	O
can	O
contact	O
Ada2p	O
,	O
Gcn5p	O
and	O
/	O
or	O
TFIIB	O
(	O
45	O
)	O
.	O

TAD	O
III	O
(	O
415	O
-	O
467	O
)	O
interacts	O
with	O
only	O
Gcn5p	O
but	O
not	O
Ada2p	O
or	O
TFIIB	O
.	O
<EOS>	B-X
Known	B-X
components	B-X
of	B-X
heterochromatin	B-X
such	B-X
as	B-X
nucleosomes	B-X
and	B-X
DNA	B-X
preferentially	B-X
partition	B-X
into	B-X
the	B-X
HP1Î±	B-X
droplets	B-X
,	B-X
but	B-X
molecules	B-X
such	B-X
as	B-X
the	B-X
transcription	B-X
factor	B-X
TFIIB	B-X
show	B-X
no	B-X
preference	B-X
.	B-X
The	B-X
role	B-X
of	B-X
general	B-X
transcription	B-X
factor	B-X
TFIIB	B-X
in	B-X
transcription	B-X
extends	B-X
well	B-X
beyond	B-X
its	B-X
evolutionarily	B-X
conserved	B-X
function	B-X
in	B-X
initiation	B-X
.	B-X
Chromatin	B-X
localization	B-X
studies	B-X
demonstrating	B-X
binding	B-X
of	B-X
TFIIB	B-X
to	B-X
both	B-X
the	B-X
5	B-X
'	B-X
and	B-X
3	B-X
'	B-X
ends	B-X
of	B-X
genes	B-X
in	B-X
a	B-X
diverse	B-X
set	B-X
of	B-X
eukaryotes	B-X
strongly	B-X
suggested	B-X
a	B-X
rather	B-X
unexpected	B-X
role	B-X
of	B-X
the	B-X
factor	B-X
in	B-X
termination	B-X
.	B-X
TFIIB	B-X
indeed	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
termination	B-X
of	B-X
transcription	B-X
.	B-X
TFIIB	B-X
occupancy	B-X
of	B-X
the	B-X
3	B-X
'	B-X
end	B-X
is	B-X
possibly	B-X
due	B-X
to	B-X
its	B-X
interaction	B-X
with	B-X
the	B-X
termination	B-X
factors	B-X
residing	B-X
there	B-X
.	B-X
Interaction	B-X
of	B-X
the	B-X
promoter-bound	B-X
TFIIB	B-X
with	B-X
factors	B-X
occupying	B-X
the	B-X
3	B-X
'	B-X
end	B-X
of	B-X
a	B-X
gene	B-X
may	B-X
be	B-X
the	B-X
basis	B-X
of	B-X
transcription-dependent	B-X
gene	B-X
looping	B-X
.	B-X
TFIIB	B-X
,	B-X
therefore	B-X
,	B-X
is	B-X
emerging	B-X
as	B-X
a	B-X
factor	B-X
with	B-X
pleiotropic	B-X
roles	B-X
in	B-X
the	B-X
transcription	B-X
cycle	B-X
.	B-X
This	B-X
could	B-X
be	B-X
the	B-X
reason	B-X
for	B-X
preferential	B-X
targeting	B-X
of	B-X
TFIIB	B-X
by	B-X
viruses	B-X
.	B-X
Further	B-X
studies	B-X
are	B-X
needed	B-X
to	B-X
understand	B-X
the	B-X
critical	B-X
role	B-X
of	B-X
TFIIB	B-X
in	B-X
viral	B-X
pathogenesis	B-X
in	B-X
the	B-X
context	B-X
of	B-X
its	B-X
newly	B-X
identified	B-X
roles	B-X
in	B-X
termination	B-X
,	B-X
gene	B-X
looping	B-X
and	B-X
promoter	B-X
directionality	B-X
.	B-X

We	O
fused	O
this	O
domain	O
of	O
Adr1p	O
and	O
the	O
activation	O
domain	O
of	O
Gcn4p	O
(	O
102	O
-	O
149	O
)	O
to	O
LexA	O
,	O
respectively	O
(	O
Fig	O
.	O
5B	O
,	O
L7	O
and	O
L8	O
)	O
.	O

Targeting	O
these	O
fusion	O
proteins	O
to	O
two	O
LexA	O
-	O
binding	O
sites	O
between	O
HML	O
-	O
I	O
and	O
URA3	O
in	O
strain	O
50	O
dramatically	O
reduced	O
URA3	O
silencing	O
(	O
Fig	O
.	O
5B	O
,	O
compare	O
L7	O
and	O
L8	O
to	O
L1	O
)	O
.	O

Therefore	O
,	O
like	O
LexA	O
-	O
Rap1p	O
(	O
627	O
-	O
695	O
)	O
,	O
both	O
LexA	O
-	O
Adr1p	O
(	O
415	O
-	O
467	O
)	O
and	O
LexA	O
-	O
Gcn4p	O
(	O
102	O
-	O
149	O
)	O
also	O
had	O
barrier	O
activity	O
.	O

Barrier	O
function	O
of	O
these	O
fusion	O
proteins	O
was	O
significantly	O
decreased	O
in	O
strain	O
51	O
in	O
which	O
only	O
one	O
LexA	O
site	O
was	O
inserted	O
between	O
HML	O
-	O
I	O
and	O
URA3	O
(	O
compare	O
strains	O
50	O
and	O
51	O
carrying	O
plasmid	O
L7	O
)	O
,	O
indicating	O
that	O
the	O
potency	O
of	O
such	O
barriers	O
was	O
dependent	O
on	O
the	O
amount	O
of	O
tethered	O
fusion	O
proteins	O
.	O

DISCUSSION	O

We	O
have	O
shown	O
in	O
this	O
report	O
that	O
UASs	O
of	O
many	O
highly	O
expressed	O
genes	O
could	O
function	O
as	O
barriers	O
to	O
the	O
spread	O
of	O
transcriptional	O
silencing	O
.	O

These	O
newly	O
identified	O
barrier	O
elements	O
together	O
with	O
previously	O
described	O
barrier	O
elements	O
(	O
STARs	O
,	O
HMR	O
-	O
tRNA	O
gene	O
,	O
TEF2	O
-	O
UAS	O
and	O
CHA1	O
-	O
UAS	O
)	O
(	O
9	O
-	O
11	O
,	O
21	O
)	O
are	O
scattered	O
across	O
the	O
yeast	B-Species
genome	O
and	O
may	O
play	O
a	O
role	O
in	O
dividing	O
the	O
genome	O
into	O
functional	O
domains	O
.	O

Analyses	O
of	O
the	O
barrier	O
UASs	O
suggest	O
that	O
binding	O
sites	O
for	O
transcriptional	O
regulators	O
Rap1p	O
,	O
Abf1p	O
,	O
Reb1p	O
,	O
Adr1p	O
and	O
Gcn4p	O
can	O
participate	O
in	O
barrier	O
function	O
.	O

Barrier	O
activity	O
often	O
requires	O
concerted	O
actions	O
of	O
more	O
than	O
one	O
factor	O
-	O
binding	O
site	O
.	O

Our	O
mutational	O
analysis	O
of	O
TEF2	O
-	O
UAS	O
suggests	O
a	O
direct	O
involvement	O
of	O
Rap1p	O
in	O
its	O
barrier	O
function	O
.	O

It	O
is	O
noteworthy	O
that	O
not	O
all	O
UASs	O
of	O
highly	O
expressed	O
genes	O
have	O
barrier	O
activity	O
.	O
<EOS>	B-X
It	B-X
also	B-X
reviews	B-X
the	B-X
methods	B-X
for	B-X
diagnosis	B-X
and	B-X
treatment	B-X
of	B-X
CI	B-X
to	B-X
better	B-X
understand	B-X
this	B-X
noteworthy	B-X
disease	B-X
,	B-X
as	B-X
well	B-X
as	B-X
presents	B-X
the	B-X
related	B-X
consensus	B-X
and	B-X
controversies	B-X
according	B-X
to	B-X
the	B-X
newly	B-X
updated	B-X
guidelines	B-X
,	B-X
which	B-X
has	B-X
practical	B-X
significance	B-X
for	B-X
conducting	B-X
more	B-X
in-depth	B-X
investigations	B-X
in	B-X
the	B-X
future	B-X
.	B-X
What	B-X
is	B-X
new	B-X
and	B-X
noteworthy	B-X
?	B-X
It	B-X
presents	B-X
noteworthy	B-X
advances	B-X
in	B-X
research	B-X
and	B-X
industry	B-X
experiences	B-X
selected	B-X
from	B-X
major	B-X
literature	B-X
sources	B-X
.	B-X
These	B-X
novel	B-X
agents	B-X
demonstrate	B-X
substantial	B-X
activity	B-X
either	B-X
alone	B-X
or	B-X
as	B-X
part	B-X
of	B-X
a	B-X
range	B-X
of	B-X
combination	B-X
regimens	B-X
.	B-X
Thalidomide	B-X
reduces	B-X
bone	B-X
resorption	B-X
,	B-X
lenalidomide	B-X
and	B-X
bortezomib	B-X
inhibit	B-X
osteoclast	B-X
growth	B-X
and	B-X
survival	B-X
,	B-X
and	B-X
specifically	B-X
target	B-X
key	B-X
factors	B-X
in	B-X
osteoclastogenesis	B-X
,	B-X
preventing	B-X
development	B-X
of	B-X
osteolytic	B-X
lesions	B-X
.	B-X

Many	O
non	O
-	O
barrier	O
UASs	O
also	O
consist	O
of	O
multiple	O
regulator	O
binding	O
sites	O
,	O
therefore	O
other	O
unknown	O
factors	O
might	O
determine	O
whether	O
a	O
UAS	O
could	O
act	O
as	O
a	O
barrier	O
.	O

How	O
Rap1p	O
and	O
the	O
other	O
transcriptional	O
regulators	O
act	O
to	O
block	O
silencing	O
is	O
not	O
clear	O
.	O

Since	O
they	O
can	O
all	O
act	O
as	O
transcriptional	O
activators	O
,	O
one	O
natural	O
explanation	O
is	O
that	O
they	O
may	O
overcome	O
the	O
silencing	O
effect	O
of	O
a	O
silencer	O
and	O
directly	O
activate	O
the	O
reporter	O
gene	O
.	O

However	O
,	O
it	O
has	O
been	O
well	O
documented	O
that	O
Rap1p	O
and	O
the	O
other	O
transcriptional	O
regulators	O
usually	O
act	O
at	O
relatively	O
short	O
distances	O
(	O
less	O
than	O
~	O
600	O
bp	O
upstream	O
of	O
the	O
translation	O
start	O
codon	O
)	O
(	O
28	O
,	O
29	O
,	O
46	O
)	O
,	O
but	O
the	O
binding	O
sites	O
for	O
these	O
regulators	O
were	O
>	O
800	O
bp	O
from	O
the	O
translation	O
start	O
codon	O
in	O
most	O
of	O
the	O
silencing	O
-	O
blocking	O
tests	O
in	O
this	O
report	O
(	O
Figs	O
1	O
and	O
2	O
)	O
.	O

In	O
the	O
test	O
shown	O
in	O
Figure	O
6	O
,	O
TEF2	O
-	O
UAS	O
blocked	O
ADE2	O
silencing	O
when	O
it	O
was	O
~	O
2	O
kb	O
downstream	O
from	O
the	O
translation	O
start	O
codon	O
of	O
the	O
gene	O
.	O

Moreover	O
,	O
Fourel	O
et	O
al	O
.	O

(	O
44	O
)	O
demonstrated	O
that	O
the	O
barrier	O
function	O
(	O
or	O
anti	O
-	O
silencing	O
function	O
)	O
of	O
an	O
activator	O
was	O
independent	O
of	O
its	O
role	O
in	O
activating	O
transcription	O
.	O

Therefore	O
,	O
it	O
is	O
unlikely	O
that	O
the	O
ability	O
of	O
a	O
UAS	O
to	O
prevent	O
gene	O
silencing	O
is	O
due	O
to	O
its	O
direct	O
activation	O
of	O
the	O
gene	O
.	O

In	O
light	O
of	O
this	O
,	O
our	O
results	O
are	O
in	O
agreement	O
with	O
the	O
notion	O
that	O
transcriptional	O
regulators	O
can	O
also	O
participate	O
in	O
defining	O
the	O
boundaries	O
of	O
functional	O
chromosomal	O
domains	O
.	O

A	O
few	O
models	O
have	O
been	O
proposed	O
for	O
the	O
barrier	O
functions	O
of	O
transcriptional	O
regulators	O
.	O
<EOS>	B-X
Work	B-X
with	B-X
infectious	B-X
Ebola	B-X
viruses	B-X
is	B-X
restricted	B-X
to	B-X
biosafety	B-X
level	B-X
4	B-X
(	B-X
BSL4	B-X
)	B-X
laboratories	B-X
,	B-X
presenting	B-X
a	B-X
significant	B-X
barrier	B-X
for	B-X
studying	B-X
these	B-X
viruses	B-X
.	B-X

One	O
model	O
proposed	O
that	O
binding	O
of	O
a	O
regulator	O
to	O
a	O
barrier	O
led	O
to	O
the	O
formation	O
of	O
a	O
nucleosome	O
-	O
free	O
region	O
thereby	O
disrupting	O
a	O
continuous	O
nucleosome	O
array	O
(	O
11	O
)	O
.	O

Since	O
the	O
SIR	O
complexes	O
spread	O
by	O
self	O
-	O
interaction	O
and	O
interacting	O
with	O
adjacent	O
nucleosmes	O
in	O
a	O
stepwise	O
fashion	O
(	O
4	O
)	O
,	O
a	O
nucleosome	O
-	O
free	O
gap	O
could	O
present	O
a	O
barrier	O
to	O
the	O
spreading	O
SIR	O
complex	O
.	O

This	O
'	O
nucleosome	O
gap	O
'	O
hypothesis	O
is	O
consistent	O
with	O
that	O
certain	O
barrier	O
factors	O
such	O
as	O
Rap1p	O
and	O
Reb1p	O
could	O
indeed	O
prevent	O
nucleosome	O
formation	O
around	O
their	O
binding	O
sites	O
(	O
14	O
)	O
and	O
the	O
barrier	O
function	O
of	O
TEF2	O
-	O
UAS	O
correlated	O
with	O
its	O
ability	O
to	O
alter	O
local	O
chromatin	O
structure	O
(	O
this	O
report	O
)	O
.	O

In	O
fact	O
,	O
many	O
insulator	O
/	O
boundary	O
elements	O
in	O
higher	O
organisms	O
have	O
also	O
been	O
shown	O
to	O
alter	O
local	O
chromatin	O
structure	O
.	O

For	O
instance	O
,	O
the	O
chicken	B-Species
beta	O
-	O
globin	O
insulator	O
was	O
linked	O
to	O
changes	O
in	O
nucleosome	O
positioning	O
,	O
and	O
the	O
Drosophila	B-Species
scs	O
and	O
scs	O
'	O
boundary	O
elements	O
are	O
associated	O
with	O
unusual	O
chromatin	O
structures	O
that	O
are	O
hypersensitive	O
to	O
nucleases	O
(	O
40	O
,	O
41	O
)	O
.	O

However	O
,	O
it	O
is	O
not	O
clear	O
whether	O
any	O
chromatin	O
change	O
associated	O
with	O
barrier	O
function	O
in	O
yeast	B-Species
or	O
insulator	O
function	O
in	O
higher	O
cells	O
is	O
the	O
cause	O
or	O
effect	O
of	O
the	O
function	O
.	O
<EOS>	B-X
All	B-X
people	B-X
want	B-X
to	B-X
age	B-X
``	B-X
successfully	B-X
,	B-X
''	B-X
maintaining	B-X
functional	B-X
capacity	B-X
and	B-X
quality	B-X
of	B-X
life	B-X
as	B-X
they	B-X
reach	B-X
advanced	B-X
age	B-X
.	B-X
Achieving	B-X
this	B-X
goal	B-X
depends	B-X
on	B-X
preserving	B-X
optimal	B-X
cognitive	B-X
and	B-X
brain	B-X
functioning	B-X
.	B-X
Others	B-X
experience	B-X
declines	B-X
in	B-X
cognitive	B-X
and	B-X
functional	B-X
capacity	B-X
that	B-X
range	B-X
from	B-X
mild	B-X
decrements	B-X
in	B-X
certain	B-X
cognitive	B-X
functions	B-X
over	B-X
time	B-X
to	B-X
severe	B-X
dementia	B-X
among	B-X
those	B-X
with	B-X
neurodegenerative	B-X
diseases	B-X
.	B-X
Even	B-X
among	B-X
relatively	B-X
healthy	B-X
``	B-X
successful	B-X
agers	B-X
,	B-X
''	B-X
certain	B-X
cognitive	B-X
functions	B-X
are	B-X
reduced	B-X
from	B-X
earlier	B-X
levels	B-X
.	B-X
This	B-X
is	B-X
particularly	B-X
true	B-X
for	B-X
cognitive	B-X
functions	B-X
that	B-X
are	B-X
dependent	B-X
on	B-X
cognitive	B-X
processing	B-X
speed	B-X
and	B-X
efficiency	B-X
.	B-X
Working	B-X
memory	B-X
and	B-X
executive	B-X
and	B-X
attentional	B-X
functions	B-X
tend	B-X
to	B-X
be	B-X
most	B-X
vulnerable	B-X
.	B-X
Learning	B-X
and	B-X
memory	B-X
functions	B-X
are	B-X
also	B-X
usually	B-X
reduced	B-X
,	B-X
although	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
neurodegenerative	B-X
disease	B-X
learning	B-X
and	B-X
retrieval	B-X
efficiency	B-X
rather	B-X
than	B-X
memory	B-X
storage	B-X
are	B-X
affected	B-X
.	B-X
Other	B-X
functions	B-X
,	B-X
such	B-X
as	B-X
visual	B-X
perception	B-X
,	B-X
language	B-X
,	B-X
semantics	B-X
,	B-X
and	B-X
knowledge	B-X
,	B-X
are	B-X
often	B-X
well	B-X
preserved	B-X
.	B-X
Structural	B-X
,	B-X
functional	B-X
,	B-X
and	B-X
physiologic/metabolic	B-X
brain	B-X
changes	B-X
correspond	B-X
with	B-X
age-associated	B-X
cognitive	B-X
decline	B-X
.	B-X
Physiologic	B-X
and	B-X
metabolic	B-X
mechanisms	B-X
,	B-X
such	B-X
as	B-X
oxidative	B-X
stress	B-X
and	B-X
neuroinflammation	B-X
,	B-X
may	B-X
contribute	B-X
to	B-X
these	B-X
changes	B-X
,	B-X
along	B-X
with	B-X
the	B-X
contribution	B-X
of	B-X
comorbidities	B-X
that	B-X
secondarily	B-X
affect	B-X
the	B-X
brain	B-X
of	B-X
older	B-X
adults	B-X
.	B-X
Neuropsychologic	B-X
assessment	B-X
provides	B-X
a	B-X
way	B-X
of	B-X
measuring	B-X
the	B-X
cognitive	B-X
and	B-X
functional	B-X
status	B-X
of	B-X
older	B-X
adults	B-X
,	B-X
which	B-X
is	B-X
useful	B-X
for	B-X
monitoring	B-X
changes	B-X
that	B-X
may	B-X
be	B-X
occurring	B-X
.	B-X
Neuroimaging	B-X
is	B-X
also	B-X
useful	B-X
for	B-X
characterizing	B-X
age-associated	B-X
structural	B-X
,	B-X
functional	B-X
,	B-X
physiologic	B-X
,	B-X
and	B-X
metabolic	B-X
brain	B-X
changes	B-X
,	B-X
including	B-X
alterations	B-X
in	B-X
cerebral	B-X
blood	B-X
flow	B-X
and	B-X
metabolite	B-X
concentrations	B-X
.	B-X
Some	B-X
interventions	B-X
that	B-X
may	B-X
enhance	B-X
cognitive	B-X
function	B-X
,	B-X
such	B-X
as	B-X
cognitive	B-X
training	B-X
,	B-X
neuromodulation	B-X
,	B-X
and	B-X
pharmacologic	B-X
approaches	B-X
,	B-X
exist	B-X
or	B-X
are	B-X
being	B-X
developed	B-X
.	B-X
Yet	B-X
,	B-X
preventing	B-X
,	B-X
slowing	B-X
,	B-X
and	B-X
reversing	B-X
the	B-X
adverse	B-X
effects	B-X
of	B-X
cognitive	B-X
aging	B-X
remains	B-X
a	B-X
challenge	B-X
.	B-X

Another	O
model	O
for	O
barrier	O
action	O
proposed	O
by	O
R	O
.	O

Kamakaka	O
and	O
colleagues	O
(	O
21	O
)	O
proposed	O
that	O
barrier	O
factors	O
recruit	O
chromatin	O
modifying	O
and	O
/	O
or	O
remodeling	O
complexes	O
to	O
counteract	O
the	O
more	O
compact	O
,	O
hypoacetylated	O
silent	O
chromatin	O
.	O

In	O
agreement	O
with	O
this	O
hypothesis	O
,	O
targeted	O
HATs	O
SAS2	O
,	O
GCN5	O
and	O
ESA1	O
all	O
had	O
barrier	O
activity	O
(	O
21	O
;	O
Y	O
.	O
-	O
H	O
.	O
Chiu	O
,	O
Q	O
.	O
Yu	O
and	O
X	O
.	O
Bi	O
,	O
unpublished	O
results	O
)	O
.	O

Interestingly	O
,	O
Rap1p	O
,	O
Adr1p	O
,	O
Gcn4p	O
and	O
Abf1p	O
share	O
the	O
ability	O
to	O
recruit	O
HAT	O
complexes	O
NuA4	O
and	O
/	O
or	O
SAGA	O
to	O
target	O
genes	O
(	O
16	O
,	O
45	O
,	O
47	O
-	O
49	O
)	O
.	O

Therefore	O
,	O
these	O
factors	O
that	O
are	O
capable	O
of	O
binding	O
to	O
the	O
newly	O
identified	O
barriers	O
may	O
function	O
as	O
barrier	O
factors	O
by	O
recruiting	O
HAT	O
complexes	O
.	O

In	O
fact	O
,	O
recruitment	O
of	O
HAT	O
activity	O
has	O
also	O
been	O
suggested	O
to	O
be	O
the	O
mechanism	O
underlying	O
the	O
function	O
of	O
the	O
chicken	B-Species
beta	O
-	O
globin	O
insulator	O
(	O
6	O
)	O
,	O
although	O
it	O
was	O
not	O
known	O
what	O
HAT	O
might	O
be	O
involved	O
.	O

Our	O
demonstration	O
that	O
tethering	O
the	O
activation	O
domain	O
of	O
Rap1p	O
,	O
Adr1p	O
or	O
Gcn4p	O
alone	O
recapitulates	O
barrier	O
activity	O
is	O
consistent	O
with	O
the	O
above	O
HAT	O
model	O
for	O
barrier	O
function	O
,	O
since	O
at	O
least	O
the	O
activation	O
domain	O
of	O
Adr1p	O
has	O
been	O
shown	O
to	O
directly	O
interact	O
with	O
HAT	O
complexes	O
(	O
45	O
)	O
.	O
<EOS>	B-X
Barrier	B-X
elements	B-X
that	B-X
are	B-X
able	B-X
to	B-X
block	B-X
the	B-X
propagation	B-X
of	B-X
transcriptional	B-X
silencing	B-X
in	B-X
yeast	B-X
are	B-X
functionally	B-X
similar	B-X
to	B-X
chromatin	B-X
boundary/insulator	B-X
elements	B-X
in	B-X
metazoans	B-X
that	B-X
delimit	B-X
functional	B-X
chromosomal	B-X
domains	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
upstream	B-X
activating	B-X
sequences	B-X
of	B-X
many	B-X
highly	B-X
expressed	B-X
ribosome	B-X
protein	B-X
genes	B-X
and	B-X
glycolytic	B-X
genes	B-X
exhibit	B-X
barrier	B-X
activity	B-X
.	B-X
Analyses	B-X
of	B-X
these	B-X
barriers	B-X
indicate	B-X
that	B-X
binding	B-X
sites	B-X
for	B-X
transcriptional	B-X
regulators	B-X
Rap1p	B-X
,	B-X
Abf1p	B-X
,	B-X
Reb1p	B-X
,	B-X
Adr1p	B-X
and	B-X
Gcn4p	B-X
may	B-X
participate	B-X
in	B-X
barrier	B-X
function	B-X
.	B-X
We	B-X
also	B-X
present	B-X
evidence	B-X
suggesting	B-X
that	B-X
Rap1p	B-X
is	B-X
directly	B-X
involved	B-X
in	B-X
barrier	B-X
activity	B-X
,	B-X
and	B-X
its	B-X
barrier	B-X
function	B-X
correlates	B-X
with	B-X
local	B-X
changes	B-X
in	B-X
chromatin	B-X
structure	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
tethering	B-X
the	B-X
transcriptional	B-X
activation	B-X
domain	B-X
of	B-X
Rap1p	B-X
to	B-X
DNA	B-X
is	B-X
sufficient	B-X
to	B-X
recapitulate	B-X
barrier	B-X
activity	B-X
.	B-X
Moreover	B-X
,	B-X
targeting	B-X
the	B-X
activation	B-X
domain	B-X
of	B-X
Adr1p	B-X
or	B-X
Gcn4p	B-X
also	B-X
establishes	B-X
a	B-X
barrier	B-X
to	B-X
silencing	B-X
.	B-X
These	B-X
results	B-X
support	B-X
the	B-X
notion	B-X
that	B-X
transcriptional	B-X
regulators	B-X
could	B-X
also	B-X
participate	B-X
in	B-X
delimiting	B-X
functional	B-X
domains	B-X
in	B-X
the	B-X
genome	B-X
.	B-X

However	O
,	O
we	O
haven	O
'	O
t	O
ruled	O
out	O
the	O
possibility	O
that	O
the	O
barrier	O
function	O
of	O
the	O
targeted	O
activation	O
domain	O
of	O
Rap1p	O
,	O
Adr1p	O
or	O
Gcn4p	O
is	O
not	O
related	O
to	O
the	O
barrier	O
function	O
of	O
the	O
native	O
protein	O
.	O
<EOS>	B-X
The	B-X
thermotolerance	B-X
section	B-X
focuses	B-X
on	B-X
five	B-X
genes	B-X
related	B-X
with	B-X
the	B-X
capacity	B-X
of	B-X
the	B-X
fungus	B-X
to	B-X
grow	B-X
at	B-X
temperatures	B-X
above	B-X
30Â°C	B-X
(	B-X
thtA	B-X
,	B-X
cgrA	B-X
,	B-X
afpmt1	B-X
,	B-X
kre2/afmnt1	B-X
,	B-X
and	B-X
hsp1/asp	B-X
f	B-X
12	B-X
)	B-X
.	B-X
The	B-X
following	B-X
sections	B-X
discuss	B-X
molecules	B-X
and	B-X
genes	B-X
related	B-X
to	B-X
interaction	B-X
with	B-X
the	B-X
host	B-X
and	B-X
with	B-X
the	B-X
immune	B-X
responses	B-X
.	B-X
These	B-X
sections	B-X
include	B-X
Î²-glucan	B-X
,	B-X
Î±-glucan	B-X
,	B-X
chitin	B-X
,	B-X
galactomannan	B-X
,	B-X
galactomannoproteins	B-X
(	B-X
afmp1/asp	B-X
f	B-X
17	B-X
and	B-X
afmp2	B-X
)	B-X
,	B-X
hydrophobins	B-X
(	B-X
rodA/hyp1	B-X
and	B-X
rodB	B-X
)	B-X
,	B-X
DHN-melanin	B-X
,	B-X
their	B-X
respective	B-X
synthases	B-X
(	B-X
fks1	B-X
,	B-X
rho1-4	B-X
,	B-X
ags1-3	B-X
,	B-X
chsA-G	B-X
,	B-X
och1-4	B-X
,	B-X
mnn9	B-X
,	B-X
van1	B-X
,	B-X
anp1	B-X
,	B-X
glfA	B-X
,	B-X
pksP/alb1	B-X
,	B-X
arp1	B-X
,	B-X
arp2	B-X
,	B-X
abr1	B-X
,	B-X
abr2	B-X
,	B-X
and	B-X
ayg1	B-X
)	B-X
,	B-X
and	B-X
modifying	B-X
enzymes	B-X
(	B-X
gel1-7	B-X
,	B-X
bgt1	B-X
,	B-X
eng1	B-X
,	B-X
ecm33	B-X
,	B-X
afpigA	B-X
,	B-X
afpmt1-2	B-X
,	B-X
afpmt4	B-X
,	B-X
kre2/afmnt1	B-X
,	B-X
afmnt2-3	B-X
,	B-X
afcwh41	B-X
and	B-X
pmi	B-X
)	B-X
;	B-X
several	B-X
enzymes	B-X
related	B-X
to	B-X
oxidative	B-X
stress	B-X
protection	B-X
such	B-X
as	B-X
catalases	B-X
(	B-X
catA	B-X
,	B-X
cat1/catB	B-X
,	B-X
cat2/katG	B-X
,	B-X
catC	B-X
,	B-X
and	B-X
catE	B-X
)	B-X
,	B-X
superoxide	B-X
dismutases	B-X
(	B-X
sod1	B-X
,	B-X
sod2	B-X
,	B-X
sod3/asp	B-X
f	B-X
6	B-X
,	B-X
and	B-X
sod4	B-X
)	B-X
,	B-X
fatty	B-X
acid	B-X
oxygenases	B-X
(	B-X
ppoA-C	B-X
)	B-X
,	B-X
glutathione	B-X
tranferases	B-X
(	B-X
gstA-E	B-X
)	B-X
,	B-X
and	B-X
others	B-X
(	B-X
afyap1	B-X
,	B-X
skn7	B-X
,	B-X
and	B-X
pes1	B-X
)	B-X
;	B-X
and	B-X
efflux	B-X
transporters	B-X
(	B-X
mdr1-4	B-X
,	B-X
atrF	B-X
,	B-X
abcA-E	B-X
,	B-X
and	B-X
msfA-E	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
this	B-X
review	B-X
considers	B-X
toxins	B-X
and	B-X
related	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
a	B-X
diffusible	B-X
toxic	B-X
substance	B-X
from	B-X
conidia	B-X
,	B-X
gliotoxin	B-X
(	B-X
gliP	B-X
and	B-X
gliZ	B-X
)	B-X
,	B-X
mitogillin	B-X
(	B-X
res/mitF/asp	B-X
f	B-X
1	B-X
)	B-X
,	B-X
hemolysin	B-X
(	B-X
aspHS	B-X
)	B-X
,	B-X
festuclavine	B-X
and	B-X
fumigaclavine	B-X
A-C	B-X
,	B-X
fumitremorgin	B-X
A-C	B-X
,	B-X
verruculogen	B-X
,	B-X
fumagillin	B-X
,	B-X
helvolic	B-X
acid	B-X
,	B-X
aflatoxin	B-X
B1	B-X
and	B-X
G1	B-X
,	B-X
and	B-X
laeA	B-X
.	B-X
Two	B-X
sections	B-X
cover	B-X
genes	B-X
and	B-X
molecules	B-X
related	B-X
with	B-X
nutrient	B-X
uptake	B-X
,	B-X
signaling	B-X
and	B-X
metabolic	B-X
regulations	B-X
involved	B-X
in	B-X
virulence	B-X
,	B-X
including	B-X
enzymes	B-X
,	B-X
such	B-X
as	B-X
serine	B-X
proteases	B-X
(	B-X
alp/asp	B-X
f	B-X
13	B-X
,	B-X
alp2	B-X
,	B-X
and	B-X
asp	B-X
f	B-X
18	B-X
)	B-X
,	B-X
metalloproteases	B-X
(	B-X
mep/asp	B-X
f	B-X
5	B-X
,	B-X
mepB	B-X
,	B-X
and	B-X
mep20	B-X
)	B-X
,	B-X
aspartic	B-X
proteases	B-X
(	B-X
pep/asp	B-X
f	B-X
10	B-X
,	B-X
pep2	B-X
,	B-X
and	B-X
ctsD	B-X
)	B-X
,	B-X
dipeptidylpeptidases	B-X
(	B-X
dppIV	B-X
and	B-X
dppV	B-X
)	B-X
,	B-X
and	B-X
phospholipases	B-X
(	B-X
plb1-3	B-X
and	B-X
phospholipase	B-X
C	B-X
)	B-X
;	B-X
siderophores	B-X
and	B-X
iron	B-X
acquisition	B-X
(	B-X
sidA-G	B-X
,	B-X
sreA	B-X
,	B-X
ftrA	B-X
,	B-X
fetC	B-X
,	B-X
mirB-C	B-X
,	B-X
and	B-X
amcA	B-X
)	B-X
;	B-X
zinc	B-X
acquisition	B-X
(	B-X
zrfA-H	B-X
,	B-X
zafA	B-X
,	B-X
and	B-X
pacC	B-X
)	B-X
;	B-X
amino	B-X
acid	B-X
biosynthesis	B-X
,	B-X
nitrogen	B-X
uptake	B-X
,	B-X
and	B-X
cross-pathways	B-X
control	B-X
(	B-X
areA	B-X
,	B-X
rhbA	B-X
,	B-X
mcsA	B-X
,	B-X
lysF	B-X
,	B-X
cpcA/gcn4p	B-X
,	B-X
and	B-X
cpcC/gcn2p	B-X
)	B-X
;	B-X
general	B-X
biosynthetic	B-X
pathway	B-X
(	B-X
pyrG	B-X
,	B-X
hcsA	B-X
,	B-X
and	B-X
pabaA	B-X
)	B-X
,	B-X
trehalose	B-X
biosynthesis	B-X
(	B-X
tpsA	B-X
and	B-X
tpsB	B-X
)	B-X
,	B-X
and	B-X
other	B-X
regulation	B-X
pathways	B-X
such	B-X
as	B-X
those	B-X
of	B-X
the	B-X
MAP	B-X
kinases	B-X
(	B-X
sakA/hogA	B-X
,	B-X
mpkA-C	B-X
,	B-X
ste7	B-X
,	B-X
pbs2	B-X
,	B-X
mkk2	B-X
,	B-X
steC/ste11	B-X
,	B-X
bck1	B-X
,	B-X
ssk2	B-X
,	B-X
and	B-X
sho1	B-X
)	B-X
,	B-X
G-proteins	B-X
(	B-X
gpaA	B-X
,	B-X
sfaD	B-X
,	B-X
and	B-X
cpgA	B-X
)	B-X
,	B-X
cAMP-PKA	B-X
signaling	B-X
(	B-X
acyA	B-X
,	B-X
gpaB	B-X
,	B-X
pkaC1	B-X
,	B-X
and	B-X
pkaR	B-X
)	B-X
,	B-X
His	B-X
kinases	B-X
(	B-X
fos1	B-X
and	B-X
tcsB	B-X
)	B-X
,	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
signaling	B-X
(	B-X
calA/cnaA	B-X
,	B-X
crzA	B-X
,	B-X
gprC	B-X
and	B-X
gprD	B-X
)	B-X
,	B-X
and	B-X
Ras	B-X
family	B-X
(	B-X
rasA	B-X
,	B-X
rasB	B-X
,	B-X
and	B-X
rhbA	B-X
)	B-X
,	B-X
and	B-X
others	B-X
(	B-X
ace2	B-X
,	B-X
medA	B-X
,	B-X
and	B-X
srbA	B-X
)	B-X
.	B-X

Note	O
that	O
the	O
'	O
nucleosome	O
gap	O
'	O
model	O
and	O
the	O
HAT	O
model	O
are	O
not	O
mutually	O
exclusive	O
since	O
the	O
nucleosome	O
gap	O
could	O
result	O
from	O
destabilization	O
of	O
nucelosomes	O
caused	O
by	O
HAT	O
function	O
.	O

A	O
recent	O
intriguing	O
study	O
showed	O
that	O
targeting	O
proteins	O
of	O
the	O
nuclear	O
pore	O
complex	O
(	O
NPC	O
)	O
could	O
also	O
establish	O
a	O
boundary	O
for	O
silent	O
chromatin	O
,	O
and	O
that	O
tethering	O
to	O
NPC	O
was	O
required	O
for	O
boundary	O
activity	O
(	O
50	O
)	O
.	O

This	O
led	O
to	O
a	O
revisit	O
to	O
the	O
looping	O
model	O
for	O
the	O
function	O
of	O
boundary	O
/	O
insulator	O
elements	O
(	O
51	O
)	O
.	O

However	O
,	O
an	O
alternative	O
explanation	O
was	O
that	O
the	O
NPC	O
compartment	O
could	O
simply	O
be	O
rich	O
in	O
transcriptional	O
activating	O
factors	O
or	O
poor	O
in	O
silencing	O
factors	O
like	O
the	O
SIR	O
proteins	O
(	O
50	O
)	O
.	O

In	O
summary	O
,	O
results	O
from	O
this	O
and	O
other	O
studies	O
indicate	O
that	O
factors	O
previously	O
identified	O
as	O
positive	O
and	O
/	O
or	O
negative	O
regulators	O
of	O
gene	O
activation	O
could	O
also	O
function	O
in	O
demarcating	O
distinct	O
domains	O
of	O
gene	O
activity	O
.	O
<EOS>	B-X
Neuromuscular	B-X
disorders	B-X
are	B-X
a	B-X
heterogeneous	B-X
group	B-X
of	B-X
acquired	B-X
or	B-X
hereditary	B-X
conditions	B-X
that	B-X
affect	B-X
striated	B-X
muscle	B-X
function	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
directly	B-X
affecting	B-X
skeletal	B-X
muscle	B-X
,	B-X
pathogenesis	B-X
can	B-X
also	B-X
arise	B-X
from	B-X
dysfunctional	B-X
crosstalk	B-X
between	B-X
nerves	B-X
and	B-X
muscles	B-X
,	B-X
and	B-X
may	B-X
include	B-X
cardiac	B-X
impairment	B-X
.	B-X
Muscular	B-X
weakness	B-X
is	B-X
often	B-X
progressive	B-X
and	B-X
paralleled	B-X
by	B-X
continuous	B-X
decline	B-X
in	B-X
the	B-X
ability	B-X
of	B-X
skeletal	B-X
muscle	B-X
to	B-X
functionally	B-X
adapt	B-X
and	B-X
regenerate	B-X
.	B-X
Normally	B-X
,	B-X
the	B-X
skeletal	B-X
muscle	B-X
resident	B-X
stem	B-X
cells	B-X
,	B-X
named	B-X
satellite	B-X
cells	B-X
,	B-X
ensure	B-X
tissue	B-X
homeostasis	B-X
by	B-X
providing	B-X
myoblasts	B-X
for	B-X
growth	B-X
,	B-X
maintenance	B-X
,	B-X
repair	B-X
and	B-X
regeneration	B-X
.	B-X
We	B-X
recently	B-X
defined	B-X
'Satellite	B-X
Cell-opathies	B-X
'	B-X
as	B-X
those	B-X
inherited	B-X
neuromuscular	B-X
conditions	B-X
presenting	B-X
satellite	B-X
cell	B-X
dysfunction	B-X
in	B-X
muscular	B-X
dystrophies	B-X
and	B-X
myopathies	B-X
(	B-X
doi:10.1016/j.yexcr.2021.112906	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
expand	B-X
the	B-X
portfolio	B-X
of	B-X
Satellite	B-X
Cell-opathies	B-X
by	B-X
evaluating	B-X
the	B-X
potential	B-X
impairment	B-X
of	B-X
satellite	B-X
cell	B-X
function	B-X
across	B-X
all	B-X
16	B-X
categories	B-X
of	B-X
neuromuscular	B-X
disorders	B-X
,	B-X
including	B-X
those	B-X
with	B-X
mainly	B-X
neurogenic	B-X
and	B-X
cardiac	B-X
involvement	B-X
.	B-X
We	B-X
explore	B-X
the	B-X
expression	B-X
dynamics	B-X
of	B-X
myopathogenes	B-X
,	B-X
genes	B-X
whose	B-X
mutation	B-X
leads	B-X
to	B-X
skeletal	B-X
muscle	B-X
pathogenesis	B-X
,	B-X
using	B-X
transcriptomic	B-X
analysis	B-X
.	B-X
This	B-X
revealed	B-X
that	B-X
45	B-X
%	B-X
of	B-X
myopathogenes	B-X
are	B-X
differentially	B-X
expressed	B-X
during	B-X
early	B-X
satellite	B-X
cell	B-X
activation	B-X
(	B-X
0	B-X
-	B-X
5	B-X
hours	B-X
)	B-X
.	B-X
Of	B-X
these	B-X
271	B-X
myopathogenes	B-X
,	B-X
83	B-X
respond	B-X
to	B-X
Pax7	B-X
,	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
satellite	B-X
cells	B-X
.	B-X
Our	B-X
analysis	B-X
suggests	B-X
possible	B-X
perturbation	B-X
of	B-X
satellite	B-X
cell	B-X
function	B-X
in	B-X
many	B-X
neuromuscular	B-X
disorders	B-X
across	B-X
all	B-X
categories	B-X
,	B-X
including	B-X
those	B-X
where	B-X
skeletal	B-X
muscle	B-X
pathology	B-X
is	B-X
not	B-X
predominant	B-X
.	B-X

How	O
these	O
factors	O
carry	O
out	O
their	O
boundary	O
function	O
is	O
not	O
resolved	O
but	O
recruitment	O
of	O
other	O
factors	O
(	O
e	O
.	O
g	O
.	O
chromatin	O
modifying	O
complexes	O
)	O
is	O
likely	O
to	O
be	O
involved	O
.	O
<EOS>	B-X
Activation	B-X
of	B-X
the	B-X
phosphatidylinositol-3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
pathway	B-X
via	B-X
PIK3CA	B-X
mutations	B-X
occurs	B-X
in	B-X
28	B-X
%	B-X
-46	B-X
%	B-X
of	B-X
hormone	B-X
receptor-positive	B-X
(	B-X
HR+	B-X
)	B-X
,	B-X
human	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor-2-negative	B-X
(	B-X
HER2-	B-X
)	B-X
advanced	B-X
breast	B-X
cancers	B-X
(	B-X
ABCs	B-X
)	B-X
and	B-X
is	B-X
associated	B-X
with	B-X
poor	B-X
prognosis	B-X
.	B-X
The	B-X
SOLAR-1	B-X
trial	B-X
showed	B-X
that	B-X
the	B-X
addition	B-X
of	B-X
alpelisib	B-X
to	B-X
fulvestrant	B-X
treatment	B-X
provided	B-X
statistically	B-X
significant	B-X
and	B-X
clinically	B-X
meaningful	B-X
progression-free	B-X
survival	B-X
(	B-X
PFS	B-X
)	B-X
benefit	B-X
in	B-X
PIK3CA-mutated	B-X
,	B-X
HR+	B-X
,	B-X
HER2-	B-X
ABC	B-X
.	B-X
Aim	B-X
of	B-X
this	B-X
paper	B-X
is	B-X
to	B-X
allows	B-X
to	B-X
analyze	B-X
a	B-X
topic	B-X
of	B-X
great	B-X
relevance	B-X
and	B-X
media	B-X
interest	B-X
such	B-X
as	B-X
the	B-X
role	B-X
of	B-X
prophylactic	B-X
mastectomy	B-X
in	B-X
healthy	B-X
women	B-X
with	B-X
BRCA	B-X
mutation	B-X
proposing	B-X
to	B-X
the	B-X
surgeons	B-X
some	B-X
useful	B-X
informations	B-X
for	B-X
decision-making	B-X
.	B-X
Less	B-X
than	B-X
15	B-X
%	B-X
of	B-X
all	B-X
breast	B-X
cancers	B-X
are	B-X
associated	B-X
with	B-X
germline	B-X
genetic	B-X
mutations	B-X
.	B-X
The	B-X
majority	B-X
of	B-X
hereditary	B-X
breast	B-X
tumors	B-X
are	B-X
due	B-X
to	B-X
mutations	B-X
in	B-X
BRCA1	B-X
and	B-X
BRCA2	B-X
genes	B-X
that	B-X
are	B-X
responsible	B-X
for	B-X
only	B-X
one	B-X
third	B-X
of	B-X
hereditary	B-X
cases	B-X
.	B-X
The	B-X
risk	B-X
estimates	B-X
are	B-X
extremely	B-X
heterogeneous	B-X
with	B-X
a	B-X
mean	B-X
cumulative	B-X
lifetime	B-X
breast	B-X
cancer	B-X
risk	B-X
of	B-X
approximately	B-X
72	B-X
%	B-X
in	B-X
BRCA1	B-X
and	B-X
69	B-X
%	B-X
in	B-X
BRCA2	B-X
by	B-X
age	B-X
80	B-X
.	B-X
The	B-X
breast	B-X
cancer	B-X
is	B-X
often	B-X
bilateral	B-X
and	B-X
multicentric	B-X
in	B-X
BRCA	B-X
mutation	B-X
carriers	B-X
.	B-X
BRCA1	B-X
carriers	B-X
have	B-X
earlier-onset	B-X
disease	B-X
,	B-X
particularly	B-X
before	B-X
age	B-X
50	B-X
and	B-X
are	B-X
more	B-X
likely	B-X
to	B-X
develop	B-X
aggressive	B-X
triple-negative	B-X
breast	B-X
cancer	B-X
than	B-X
BRCA2	B-X
carriers	B-X
or	B-X
those	B-X
who	B-X
are	B-X
BRCA	B-X
mutation	B-X
negative	B-X
1	B-X
.	B-X
Multiple	B-X
strategies	B-X
are	B-X
effective	B-X
in	B-X
managing	B-X
the	B-X
risk	B-X
of	B-X
breast	B-X
cancer	B-X
in	B-X
these	B-X
women	B-X
,	B-X
including	B-X
surveillance	B-X
,	B-X
chemoprevention	B-X
,	B-X
bilateral	B-X
salpingo-oophorectomy	B-X
and	B-X
risk-reducing	B-X
mastectomy	B-X
.	B-X
More	B-X
intensive	B-X
surveillance	B-X
,	B-X
including	B-X
annual	B-X
mammography	B-X
and	B-X
breast	B-X
magnetic	B-X
resonance	B-X
imaging	B-X
screening	B-X
(	B-X
commonly	B-X
alternated	B-X
every	B-X
six	B-X
months	B-X
)	B-X
beginning	B-X
at	B-X
age	B-X
25	B-X
or	B-X
individualized	B-X
based	B-X
upon	B-X
the	B-X
earliest	B-X
age	B-X
of	B-X
onset	B-X
in	B-X
the	B-X
family	B-X
,	B-X
have	B-X
significantly	B-X
improved	B-X
early	B-X
detection	B-X
of	B-X
breast	B-X
cancer	B-X
among	B-X
patients	B-X
with	B-X
deleterious	B-X
BRCA	B-X
mutations	B-X
1	B-X
.	B-X
The	B-X
risk-reducing	B-X
benefit	B-X
of	B-X
chemoprevention	B-X
is	B-X
not	B-X
as	B-X
well	B-X
defined	B-X
;	B-X
chemopreventive	B-X
strategies	B-X
to	B-X
reduce	B-X
the	B-X
risk	B-X
of	B-X
breast	B-X
cancer	B-X
have	B-X
focused	B-X
exclusively	B-X
on	B-X
prevention	B-X
in	B-X
high-risk	B-X
women	B-X
and	B-X
involve	B-X
the	B-X
use	B-X
of	B-X
selective	B-X
estrogen	B-X
receptor	B-X
modulators	B-X
(	B-X
SERMs	B-X
)	B-X
and	B-X
aromatase	B-X
inhibitors	B-X
for	B-X
breast	B-X
cancer	B-X
prevention	B-X
.	B-X
Only	B-X
limited	B-X
data	B-X
are	B-X
available	B-X
regarding	B-X
the	B-X
preventive	B-X
benefit	B-X
of	B-X
tamoxifene	B-X
in	B-X
BRCA	B-X
mutations	B-X
carriers	B-X
1	B-X
.	B-X
Risk-reducing	B-X
bilateral	B-X
salpingo-oophorectomy	B-X
is	B-X
recommended	B-X
for	B-X
BRCA	B-X
mutation	B-X
carriers	B-X
by	B-X
35	B-X
to	B-X
40	B-X
or	B-X
when	B-X
childbearing	B-X
is	B-X
completed	B-X
,	B-X
or	B-X
individualized	B-X
based	B-X
on	B-X
age	B-X
of	B-X
onset	B-X
of	B-X
ovarian	B-X
cancer	B-X
in	B-X
the	B-X
family	B-X
;	B-X
bilateral	B-X
salpingo-oophorectomy	B-X
decreases	B-X
the	B-X
risk	B-X
of	B-X
both	B-X
breast	B-X
cancer	B-X
and	B-X
ovarian	B-X
cancer	B-X
in	B-X
BRCA1	B-X
and	B-X
BRCA2	B-X
mutation	B-X
carriers	B-X
and	B-X
has	B-X
also	B-X
been	B-X
associated	B-X
with	B-X
reduced	B-X
all	B-X
cause	B-X
,	B-X
breast	B-X
cancer-specific	B-X
,	B-X
and	B-X
ovarian	B-X
cancer-	B-X
specific	B-X
mortality	B-X
;	B-X
risk-reducing	B-X
bilateral	B-X
salpingooophorectomy	B-X
seems	B-X
to	B-X
offer	B-X
an	B-X
approximate	B-X
50	B-X
%	B-X
relative	B-X
reduction	B-X
in	B-X
breast	B-X
cancer	B-X
risk	B-X
1	B-X
.	B-X
Prophylactic	B-X
mastectomy	B-X
provides	B-X
the	B-X
greatest	B-X
reduction	B-X
in	B-X
risk	B-X
of	B-X
breast	B-X
cancer	B-X
development	B-X
.	B-X
In	B-X
both	B-X
retrospective	B-X
and	B-X
prospective	B-X
observational	B-X
studies	B-X
,	B-X
bilateral	B-X
prophylactic	B-X
mastectomy	B-X
decreases	B-X
the	B-X
incidence	B-X
of	B-X
breast	B-X
cancer	B-X
by	B-X
90	B-X
percent	B-X
or	B-X
more	B-X
in	B-X
patients	B-X
with	B-X
BRCA	B-X
mutation	B-X
;	B-X
it	B-X
also	B-X
is	B-X
able	B-X
to	B-X
determine	B-X
a	B-X
variable	B-X
gain	B-X
in	B-X
life	B-X
expectancy	B-X
compared	B-X
to	B-X
radiological	B-X
surveillance	B-X
;	B-X
besides	B-X
risk-reducing	B-X
mastectomy	B-X
allows	B-X
to	B-X
contain	B-X
the	B-X
strong	B-X
anxiety	B-X
and	B-X
the	B-X
fear	B-X
of	B-X
getting	B-X
sick	B-X
that	B-X
often	B-X
compromise	B-X
the	B-X
quality	B-X
of	B-X
life	B-X
of	B-X
BRCA	B-X
mutation	B-X
carriers	B-X
2	B-X
.	B-X
Prophylactic	B-X
mastectomy	B-X
could	B-X
be	B-X
technically	B-X
performed	B-X
in	B-X
different	B-X
ways	B-X
.	B-X
However	B-X
,	B-X
regarding	B-X
the	B-X
surgical	B-X
technique	B-X
,	B-X
on	B-X
the	B-X
basis	B-X
of	B-X
current	B-X
evidence	B-X
,	B-X
the	B-X
gold	B-X
standard	B-X
seems	B-X
to	B-X
be	B-X
represented	B-X
by	B-X
nipple-sparing	B-X
mastectomy	B-X
which	B-X
,	B-X
thanks	B-X
to	B-X
the	B-X
preservation	B-X
of	B-X
the	B-X
skin	B-X
envelope	B-X
and	B-X
the	B-X
nipple-areola	B-X
complex	B-X
,	B-X
is	B-X
able	B-X
to	B-X
optimize	B-X
the	B-X
oncological	B-X
and	B-X
aesthetic	B-X
results	B-X
.	B-X
Nipple-sparing	B-X
mastectomy	B-X
provides	B-X
superior	B-X
cosmetic	B-X
results	B-X
.	B-X
This	B-X
procedure	B-X
is	B-X
usually	B-X
performed	B-X
through	B-X
an	B-X
inframmamary	B-X
or	B-X
radial	B-X
or	B-X
axillary	B-X
incision	B-X
where	B-X
the	B-X
skin	B-X
is	B-X
carefully	B-X
dissected	B-X
off	B-X
the	B-X
breast	B-X
until	B-X
all	B-X
anatomic	B-X
boundaries	B-X
of	B-X
the	B-X
breast	B-X
are	B-X
reached	B-X
and	B-X
the	B-X
gland	B-X
in	B-X
its	B-X
entirety	B-X
is	B-X
excised	B-X
.	B-X
This	B-X
technique	B-X
does	B-X
not	B-X
seem	B-X
to	B-X
compromise	B-X
the	B-X
oncological/preventive	B-X
efficacy	B-X
compared	B-X
to	B-X
other	B-X
types	B-X
of	B-X
mastectomy	B-X
.	B-X
In	B-X
a	B-X
multi-institution	B-X
review	B-X
of	B-X
prophylactic	B-X
346	B-X
BRCA	B-X
carriers	B-X
undergoing	B-X
either	B-X
bilateral	B-X
mastectomy	B-X
or	B-X
contralateral	B-X
mastectomy	B-X
with	B-X
nipple-	B-X
areola	B-X
sparing	B-X
there	B-X
were	B-X
no	B-X
cases	B-X
of	B-X
breast	B-X
cancer	B-X
,	B-X
whereas	B-X
,	B-X
based	B-X
on	B-X
models	B-X
,	B-X
22	B-X
would	B-X
have	B-X
been	B-X
expected	B-X
3	B-X
.	B-X
However	B-X
nipple-sparing	B-X
mastectomy	B-X
must	B-X
be	B-X
carried	B-X
out	B-X
with	B-X
technical	B-X
skill	B-X
and	B-X
maximum	B-X
attention	B-X
not	B-X
to	B-X
leave	B-X
macroscopic	B-X
residues	B-X
of	B-X
mammary	B-X
gland	B-X
in	B-X
particular	B-X
in	B-X
the	B-X
axillary	B-X
extension	B-X
,	B-X
peripheral	B-X
extremities	B-X
of	B-X
the	B-X
gland	B-X
and	B-X
the	B-X
nipple-areola	B-X
complex	B-X
;	B-X
it	B-X
is	B-X
necessary	B-X
to	B-X
perform	B-X
an	B-X
accurate	B-X
dissection	B-X
and	B-X
a	B-X
meticulous	B-X
preparation	B-X
of	B-X
the	B-X
skin	B-X
flaps	B-X
and	B-X
of	B-X
the	B-X
areola-nipple	B-X
complex	B-X
which	B-X
must	B-X
be	B-X
reasonably	B-X
thin	B-X
without	B-X
however	B-X
compromising	B-X
its	B-X
vitality	B-X
.	B-X
Whenever	B-X
the	B-X
patients	B-X
opt	B-X
to	B-X
proceed	B-X
with	B-X
bilateral	B-X
prophylactic	B-X
mastectomy	B-X
,	B-X
an	B-X
accurate	B-X
preoperative	B-X
radiological	B-X
study	B-X
should	B-X
always	B-X
be	B-X
performed	B-X
with	B-X
mammography	B-X
,	B-X
ultrasound	B-X
and	B-X
magnetic	B-X
resonance	B-X
imaging	B-X
to	B-X
rule	B-X
out	B-X
the	B-X
presence	B-X
of	B-X
suspicious	B-X
breast	B-X
lesions	B-X
and	B-X
minimize	B-X
the	B-X
risk	B-X
of	B-X
occult	B-X
carcinomas	B-X
by	B-X
definitive	B-X
histological	B-X
examination	B-X
.	B-X
In	B-X
the	B-X
absence	B-X
of	B-X
contraindications	B-X
,	B-X
all	B-X
patients	B-X
should	B-X
be	B-X
candidates	B-X
for	B-X
breast	B-X
reconstruction	B-X
in	B-X
order	B-X
to	B-X
minimize	B-X
the	B-X
negative	B-X
physical	B-X
and	B-X
psychological	B-X
impact	B-X
of	B-X
the	B-X
mastectomy	B-X
;	B-X
the	B-X
breast	B-X
reconstruction	B-X
should	B-X
preferably	B-X
be	B-X
immediate	B-X
,	B-X
performed	B-X
at	B-X
the	B-X
same	B-X
time	B-X
of	B-X
the	B-X
prophylactic	B-X
mastectomy	B-X
,	B-X
by	B-X
a	B-X
team	B-X
of	B-X
dedicated	B-X
plastic	B-X
surgeons	B-X
,	B-X
or	B-X
with	B-X
permanent	B-X
prosthesis	B-X
or	B-X
autologous	B-X
tissues	B-X
;	B-X
the	B-X
choice	B-X
of	B-X
the	B-X
most	B-X
appropriate	B-X
reconstructive	B-X
technique	B-X
depends	B-X
on	B-X
various	B-X
factors	B-X
such	B-X
as	B-X
the	B-X
physical/anatomical	B-X
structure	B-X
of	B-X
the	B-X
woman	B-X
,	B-X
the	B-X
morphology/	B-X
degree	B-X
of	B-X
breast	B-X
ptosis	B-X
,	B-X
the	B-X
comorbidities	B-X
but	B-X
also	B-X
the	B-X
patient	B-X
's	B-X
wishes	B-X
and	B-X
preferences	B-X
1	B-X
.	B-X
However	B-X
,	B-X
in	B-X
the	B-X
discussion	B-X
on	B-X
the	B-X
possibility	B-X
of	B-X
carrying	B-X
out	B-X
a	B-X
prophylactic	B-X
mastectomy	B-X
,	B-X
it	B-X
is	B-X
always	B-X
necessary	B-X
to	B-X
consider	B-X
a	B-X
series	B-X
of	B-X
issues	B-X
related	B-X
to	B-X
this	B-X
procedure	B-X
:	B-X
-	B-X
the	B-X
possible	B-X
oncological	B-X
failure	B-X
because	B-X
risk-reducing	B-X
mastectomy	B-X
does	B-X
not	B-X
completely	B-X
eliminate	B-X
the	B-X
risk	B-X
of	B-X
developing	B-X
breast	B-X
cancer	B-X
;	B-X
there	B-X
is	B-X
always	B-X
a	B-X
residual	B-X
risk	B-X
of	B-X
about	B-X
5	B-X
%	B-X
to	B-X
be	B-X
related	B-X
to	B-X
the	B-X
possible	B-X
presence	B-X
of	B-X
residual	B-X
glandular	B-X
tissue	B-X
or	B-X
ectopic	B-X
breast	B-X
tissue	B-X
2	B-X
;	B-X
-	B-X
the	B-X
surgical	B-X
morbidity	B-X
with	B-X
overall	B-X
complication	B-X
rates	B-X
of	B-X
15-20	B-X
%	B-X
such	B-X
as	B-X
ischemia	B-X
of	B-X
the	B-X
skin	B-X
and/or	B-X
of	B-X
the	B-X
areola-nipple	B-X
complex	B-X
,	B-X
haematomas	B-X
,	B-X
infections	B-X
,	B-X
implant	B-X
failure	B-X
,	B-X
partial/total	B-X
autologous	B-X
flap	B-X
loss	B-X
;	B-X
in	B-X
a	B-X
considerable	B-X
percentage	B-X
of	B-X
cases	B-X
there	B-X
is	B-X
also	B-X
the	B-X
need	B-X
to	B-X
resort	B-X
after	B-X
the	B-X
prophylactic	B-X
mastectomy	B-X
to	B-X
further	B-X
aesthetic/	B-X
plastic	B-X
procedures	B-X
to	B-X
correct	B-X
some	B-X
imperfections	B-X
or	B-X
repair	B-X
surgical	B-X
complications	B-X
3-5	B-X
;	B-X
-	B-X
the	B-X
presence	B-X
of	B-X
sequelae	B-X
such	B-X
as	B-X
the	B-X
loss	B-X
of	B-X
sensitivity	B-X
of	B-X
the	B-X
areola-nipple	B-X
complex	B-X
,	B-X
possible	B-X
paresthesias	B-X
,	B-X
painful	B-X
sensations	B-X
and	B-X
the	B-X
need	B-X
for	B-X
re-adaptation	B-X
to	B-X
a	B-X
different	B-X
body	B-X
image	B-X
2	B-X
;	B-X
-	B-X
the	B-X
possible	B-X
body	B-X
image	B-X
issues	B-X
due	B-X
to	B-X
many	B-X
factors	B-X
,	B-X
such	B-X
as	B-X
self-consciousness	B-X
,	B-X
feeling	B-X
less	B-X
sexually	B-X
attractive	B-X
and	B-X
dissatisfaction	B-X
with	B-X
the	B-X
scars	B-X
2,3	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
these	B-X
issues	B-X
we	B-X
must	B-X
add	B-X
that	B-X
most	B-X
of	B-X
the	B-X
studies	B-X
that	B-X
show	B-X
a	B-X
gain	B-X
in	B-X
life	B-X
expectancy	B-X
thanks	B-X
to	B-X
prophylactic	B-X
mastectomy	B-X
,	B-X
are	B-X
based	B-X
only	B-X
on	B-X
mathematical	B-X
models	B-X
and	B-X
that	B-X
the	B-X
few	B-X
prospective	B-X
cohort	B-X
studies	B-X
often	B-X
do	B-X
not	B-X
show	B-X
a	B-X
statistically	B-X
significant	B-X
improvement	B-X
in	B-X
terms	B-X
of	B-X
survival	B-X
among	B-X
women	B-X
undergoing	B-X
MP	B-X
and	B-X
intensive	B-X
radiological	B-X
surveillance	B-X
1,2	B-X
.	B-X
Therefore	B-X
in	B-X
consideration	B-X
of	B-X
the	B-X
benefits	B-X
but	B-X
also	B-X
of	B-X
the	B-X
problems	B-X
that	B-X
the	B-X
prophylactic	B-X
mastectomy	B-X
involves	B-X
,	B-X
all	B-X
the	B-X
international	B-X
guidelines	B-X
highlight	B-X
that	B-X
this	B-X
procedure	B-X
must	B-X
be	B-X
considered	B-X
,	B-X
must	B-X
be	B-X
discussed	B-X
with	B-X
healthy	B-X
BRCA	B-X
women	B-X
,	B-X
however	B-X
without	B-X
giving	B-X
an	B-X
absolute	B-X
recommendation	B-X
to	B-X
perform	B-X
it	B-X
1	B-X
.	B-X
This	B-X
discussion	B-X
must	B-X
take	B-X
place	B-X
,	B-X
case	B-X
by	B-X
case	B-X
,	B-X
in	B-X
specialized	B-X
breast	B-X
centers	B-X
with	B-X
a	B-X
dedicated	B-X
risk	B-X
team	B-X
.	B-X
A	B-X
personalized	B-X
multidisciplinary	B-X
path	B-X
should	B-X
guarantee	B-X
an	B-X
accurate	B-X
genetic	B-X
and	B-X
clinical	B-X
counselling	B-X
,	B-X
adequate	B-X
psychological	B-X
support	B-X
and	B-X
detailed	B-X
information	B-X
about	B-X
all	B-X
alternative	B-X
risk	B-X
management	B-X
strategies	B-X
.	B-X
Clinical	B-X
decision-making	B-X
about	B-X
strategies	B-X
to	B-X
pursue	B-X
for	B-X
breast	B-X
cancer	B-X
risk	B-X
reduction	B-X
should	B-X
involve	B-X
a	B-X
tradeoff	B-X
between	B-X
life	B-X
expectancy	B-X
and	B-X
quality	B-X
of	B-X
life	B-X
.	B-X
However	B-X
if	B-X
the	B-X
patient	B-X
and	B-X
the	B-X
medical	B-X
team	B-X
opt	B-X
to	B-X
proceed	B-X
with	B-X
prophylactic	B-X
surgery	B-X
,	B-X
the	B-X
cumulative	B-X
evidence	B-X
to	B-X
date	B-X
supports	B-X
nipple	B-X
sparing	B-X
mastectomy	B-X
with	B-X
immediate	B-X
reconstruction	B-X
as	B-X
an	B-X
appropriate	B-X
risk-reducing	B-X
procedure	B-X
to	B-X
optimize	B-X
the	B-X
oncological	B-X
and	B-X
aesthetic	B-X
results	B-X
and	B-X
improve	B-X
quality	B-X
of	B-X
life	B-X
.	B-X

NOTE	O
ADDED	O
IN	O
PROOF	O
<EOS>	B-X
Note	B-X
added	B-X
in	B-X
proof	B-X
.	B-X
Note	B-X
added	B-X
in	B-X
proof	B-X
.	B-X
Note	B-X
added	B-X
in	B-X
proof	B-X
.	B-X
Note	B-X
added	B-X
in	B-X
proof	B-X
.	B-X

After	O
this	O
work	O
was	O
completed	O
and	O
submitted	O
for	O
publication	O
the	O
first	O
time	O
,	O
Fourel	O
et	O
al	O
.	O

(	O
52	O
)	O
reported	O
that	O
targeted	O
activation	O
domains	O
of	O
Rap1p	O
and	O
Abf1p	O
had	O
insulating	O
capacity	O
.	O

Comparison	O
of	O
age	O
-	O
specific	O
cataract	O
prevalence	O
in	O
two	O
population	O
-	O
based	O
surveys	O
6	O
years	O
apart	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
compare	B-X
age-specific	B-X
cortical	B-X
,	B-X
nuclear	B-X
and	B-X
posterior	B-X
subcapsular	B-X
(	B-X
PSC	B-X
)	B-X
cataract	B-X
prevalence	B-X
in	B-X
two	B-X
surveys	B-X
6	B-X
years	B-X
apart	B-X
.	B-X

Abstract	O
<EOS>	B-X
Abstract	B-X
writing	B-X
.	B-X
The	B-X
informative	B-X
abstract	B-X
.	B-X
Crafting	B-X
a	B-X
compelling	B-X
abstract	B-X
.	B-X
Why	B-X
the	B-X
structured	B-X
abstract	B-X
?	B-X

Background	O
<EOS>	B-X
Background	B-X
matching	B-X
is	B-X
the	B-X
most	B-X
familiar	B-X
and	B-X
widespread	B-X
camouflage	B-X
strategy	B-X
:	B-X
avoiding	B-X
detection	B-X
by	B-X
having	B-X
a	B-X
similar	B-X
colour	B-X
and	B-X
pattern	B-X
to	B-X
the	B-X
background	B-X
.	B-X
Background	B-X
is	B-X
thus	B-X
a	B-X
relatively	B-X
modest	B-X
correction	B-X
for	B-X
all	B-X
Z	B-X
opacity	B-X
data	B-X
published	B-X
to	B-X
date	B-X
.	B-X
Background	B-X
estimation	B-X
and	B-X
foreground	B-X
segmentation	B-X
are	B-X
important	B-X
steps	B-X
in	B-X
many	B-X
high-level	B-X
vision	B-X
tasks	B-X
.	B-X
Patient	B-X
Preference	B-X
for	B-X
Telehealth	B-X
Background	B-X
Shapes	B-X
Impressions	B-X
of	B-X
Physicians	B-X
and	B-X
Information	B-X
Recall	B-X
:	B-X
A	B-X
Randomized	B-X
Experiment	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
compare	O
age	O
-	O
specific	O
cortical	O
,	O
nuclear	O
and	O
posterior	O
subcapsular	O
(	O
PSC	O
)	O
cataract	O
prevalence	O
in	O
two	O
surveys	O
6	O
years	O
apart	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
compare	B-X
age-specific	B-X
cortical	B-X
,	B-X
nuclear	B-X
and	B-X
posterior	B-X
subcapsular	B-X
(	B-X
PSC	B-X
)	B-X
cataract	B-X
prevalence	B-X
in	B-X
two	B-X
surveys	B-X
6	B-X
years	B-X
apart	B-X
.	B-X

Methods	O
<EOS>	B-X
Methods	B-X
to	B-X
calculate	B-X
the	B-X
sample	B-X
size	B-X
are	B-X
explained	B-X
in	B-X
statistical	B-X
textbooks	B-X
,	B-X
but	B-X
because	B-X
there	B-X
are	B-X
many	B-X
different	B-X
formulas	B-X
available	B-X
,	B-X
it	B-X
can	B-X
be	B-X
difficult	B-X
for	B-X
investigators	B-X
to	B-X
decide	B-X
which	B-X
method	B-X
to	B-X
use	B-X
.	B-X

The	O
Blue	O
Mountains	O
Eye	O
Study	O
examined	O
3654	O
participants	B-Species
(	O
82	O
.	O
4	O
%	O
of	O
those	O
eligible	O
)	O
in	O
cross	O
-	O
section	O
I	O
(	O
1992	O
-	O
4	O
)	O
and	O
3509	O
participants	B-Species
(	O
75	O
.	O
1	O
%	O
of	O
survivors	O
and	O
85	O
.	O
2	O
%	O
of	O
newly	O
eligible	O
)	O
in	O
cross	O
-	O
section	O
II	O
(	O
1997	O
-	O
2000	O
,	O
66	O
.	O
5	O
%	O
overlap	O
with	O
cross	O
-	O
section	O
I	O
)	O
.	O

Cataract	O
was	O
assessed	O
from	O
lens	O
photographs	O
following	O
the	O
Wisconsin	O
Cataract	O
Grading	O
System	O
.	O
<EOS>	B-X
Cataract	B-X
surgery	B-X
is	B-X
the	B-X
most	B-X
frequently	B-X
performed	B-X
ophthalmic	B-X
procedure	B-X
worldwide	B-X
.	B-X

Cortical	O
cataract	O
was	O
defined	O
if	O
cortical	O
opacity	O
comprised	O
>=	O
5	O
%	O
of	O
lens	O
area	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
compare	B-X
age-specific	B-X
cortical	B-X
,	B-X
nuclear	B-X
and	B-X
posterior	B-X
subcapsular	B-X
(	B-X
PSC	B-X
)	B-X
cataract	B-X
prevalence	B-X
in	B-X
two	B-X
surveys	B-X
6	B-X
years	B-X
apart	B-X
.	B-X
To	B-X
identify	B-X
sociodemographic	B-X
and	B-X
biological	B-X
risk	B-X
factors	B-X
associated	B-X
with	B-X
the	B-X
4-year	B-X
incidence	B-X
of	B-X
nuclear	B-X
,	B-X
cortical	B-X
,	B-X
posterior	B-X
subcapsular	B-X
(	B-X
PSC	B-X
)	B-X
,	B-X
and	B-X
mixed	B-X
lens	B-X
opacities	B-X
.	B-X

Nuclear	O
cataract	O
was	O
defined	O
if	O
nuclear	O
opacity	O
>=	O
Wisconsin	O
standard	O
4	O
.	O
<EOS>	B-X
Nuclear	B-X
cataract	B-X
is	B-X
thought	B-X
to	B-X
cause	B-X
a	B-X
myopic	B-X
shift	B-X
in	B-X
refraction	B-X
in	B-X
older	B-X
persons	B-X
.	B-X
The	B-X
authors	B-X
tested	B-X
this	B-X
hypothesis	B-X
by	B-X
assessing	B-X
the	B-X
correlation	B-X
of	B-X
nuclear	B-X
opacity	B-X
with	B-X
spherical	B-X
equivalent	B-X
refraction	B-X
(	B-X
SER	B-X
)	B-X
in	B-X
an	B-X
older	B-X
population	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
compare	B-X
age-specific	B-X
cortical	B-X
,	B-X
nuclear	B-X
and	B-X
posterior	B-X
subcapsular	B-X
(	B-X
PSC	B-X
)	B-X
cataract	B-X
prevalence	B-X
in	B-X
two	B-X
surveys	B-X
6	B-X
years	B-X
apart	B-X
.	B-X
This	B-X
study	B-X
compares	B-X
age-related	B-X
cataract	B-X
prevalence	B-X
derived	B-X
from	B-X
two	B-X
commonly	B-X
used	B-X
methods	B-X
:	B-X
clinical	B-X
assessment	B-X
using	B-X
the	B-X
Lens	B-X
Opacity	B-X
Classification	B-X
System	B-X
(	B-X
LOCS	B-X
III	B-X
)	B-X
and	B-X
photographic	B-X
grading	B-X
using	B-X
the	B-X
Wisconsin	B-X
Cataract	B-X
Grading	B-X
System	B-X
(	B-X
Wisconsin	B-X
System	B-X
)	B-X
.	B-X

PSC	O
was	O
defined	O
if	O
any	O
present	O
.	O
<EOS>	B-X
Sclerosing	B-X
cholangitis	B-X
(	B-X
SC	B-X
)	B-X
is	B-X
defined	B-X
as	B-X
a	B-X
condition	B-X
with	B-X
progressive	B-X
stenosis	B-X
and	B-X
destruction	B-X
of	B-X
the	B-X
bile	B-X
ducts	B-X
due	B-X
to	B-X
diffuse	B-X
inflammation	B-X
and	B-X
fibrosis	B-X
and	B-X
currently	B-X
includes	B-X
three	B-X
categories	B-X
:	B-X
primary	B-X
sclerosing	B-X
cholangitis	B-X
(	B-X
PSC	B-X
)	B-X
,	B-X
secondary	B-X
cholangitis	B-X
,	B-X
and	B-X
IgG4-related	B-X
sclerosing	B-X
cholangitis	B-X
(	B-X
IgG4-SC	B-X
)	B-X
.	B-X
Patients	B-X
with	B-X
SC	B-X
present	B-X
with	B-X
cholestatic	B-X
symptoms	B-X
,	B-X
including	B-X
jaundice	B-X
and	B-X
pruritus	B-X
,	B-X
and	B-X
blood	B-X
tests	B-X
reveal	B-X
elevation	B-X
of	B-X
cholestatic	B-X
enzymes	B-X
.	B-X
Although	B-X
the	B-X
presentation	B-X
of	B-X
IgG4-SC	B-X
and	B-X
PSC	B-X
are	B-X
similar	B-X
,	B-X
the	B-X
comorbidities	B-X
,	B-X
treatment	B-X
response	B-X
,	B-X
and	B-X
outcomes	B-X
differ	B-X
significantly	B-X
,	B-X
and	B-X
therefore	B-X
,	B-X
it	B-X
is	B-X
strongly	B-X
advisable	B-X
to	B-X
be	B-X
familiar	B-X
with	B-X
these	B-X
two	B-X
diseases	B-X
to	B-X
make	B-X
a	B-X
correct	B-X
diagnosis	B-X
.	B-X
Differentiation	B-X
of	B-X
cholangiocarcinoma	B-X
from	B-X
IgG4-SC	B-X
and	B-X
PSC	B-X
is	B-X
also	B-X
extremely	B-X
important	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
the	B-X
clinical	B-X
characteristics	B-X
,	B-X
comorbidities	B-X
,	B-X
treatment	B-X
and	B-X
outcomes	B-X
of	B-X
IgG4-SC	B-X
and	B-X
PSC	B-X
will	B-X
be	B-X
outlined	B-X
based	B-X
on	B-X
experience	B-X
mainly	B-X
from	B-X
Japan	B-X
.	B-X

Any	O
cataract	O
was	O
defined	O
to	O
include	O
persons	B-Species
who	O
had	O
previous	O
cataract	O
surgery	O
.	O
<EOS>	B-X
Previous	B-X
trials	B-X
have	B-X
shown	B-X
that	B-X
the	B-X
use	B-X
of	B-X
statins	B-X
to	B-X
lower	B-X
cholesterol	B-X
reduces	B-X
the	B-X
risk	B-X
of	B-X
cardiovascular	B-X
events	B-X
among	B-X
persons	B-X
without	B-X
cardiovascular	B-X
disease	B-X
.	B-X
Those	B-X
trials	B-X
have	B-X
involved	B-X
persons	B-X
with	B-X
elevated	B-X
lipid	B-X
levels	B-X
or	B-X
inflammatory	B-X
markers	B-X
and	B-X
involved	B-X
mainly	B-X
white	B-X
persons	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
develop	B-X
a	B-X
risk	B-X
model	B-X
for	B-X
intraoperative	B-X
complication	B-X
(	B-X
IC	B-X
)	B-X
during	B-X
cataract	B-X
surgery	B-X
,	B-X
defined	B-X
as	B-X
posterior	B-X
capsule	B-X
rupture	B-X
and/or	B-X
zonular	B-X
dehiscence	B-X
,	B-X
and	B-X
to	B-X
include	B-X
previous	B-X
intravitreal	B-X
therapy	B-X
(	B-X
pIVT	B-X
)	B-X
in	B-X
the	B-X
model	B-X
.	B-X
To	B-X
describe	B-X
the	B-X
3-year	B-X
outcomes	B-X
of	B-X
combined	B-X
cataract	B-X
surgery	B-X
and	B-X
360-degree	B-X
endocyclophotocoagulation	B-X
(	B-X
ECP	B-X
)	B-X
in	B-X
eyes	B-X
with	B-X
uncontrolled	B-X
glaucoma	B-X
and	B-X
no	B-X
previous	B-X
glaucoma	B-X
drainage	B-X
surgery	B-X
.	B-X

Weighted	O
kappa	O
for	O
inter	O
-	O
grader	O
reliability	O
was	O
0	O
.	O
82	O
,	O
0	O
.	O
55	O
and	O
0	O
.	O
82	O
for	O
cortical	O
,	O
nuclear	O
and	O
PSC	O
cataract	O
,	O
respectively	O
.	O

We	O
assessed	O
age	O
-	O
specific	O
prevalence	O
using	O
an	O
interval	O
of	O
5	O
years	O
,	O
so	O
that	O
participants	B-Species
within	O
each	O
age	O
group	O
were	O
independent	O
between	O
the	O
two	O
surveys	O
.	O
<EOS>	B-X
However	B-X
,	B-X
the	B-X
relative	B-X
benefit	B-X
of	B-X
these	B-X
treatments	B-X
remains	B-X
unclear	B-X
due	B-X
to	B-X
the	B-X
limited	B-X
number	B-X
of	B-X
trials	B-X
comparing	B-X
them	B-X
directly	B-X
head-to-head	B-X
,	B-X
which	B-X
is	B-X
why	B-X
we	B-X
chose	B-X
to	B-X
conduct	B-X
a	B-X
network	B-X
meta-analysis	B-X
.	B-X
The	B-X
World	B-X
Health	B-X
Organization	B-X
(	B-X
WHO	B-X
)	B-X
and	B-X
the	B-X
International	B-X
Labour	B-X
Organization	B-X
(	B-X
ILO	B-X
)	B-X
are	B-X
developing	B-X
joint	B-X
estimates	B-X
of	B-X
the	B-X
work-related	B-X
burden	B-X
of	B-X
disease	B-X
and	B-X
injury	B-X
(	B-X
WHO/ILO	B-X
Joint	B-X
Estimates	B-X
)	B-X
,	B-X
with	B-X
contributions	B-X
from	B-X
a	B-X
large	B-X
network	B-X
of	B-X
experts	B-X
.	B-X
In	B-X
this	B-X
paper	B-X
,	B-X
we	B-X
present	B-X
a	B-X
systematic	B-X
review	B-X
and	B-X
meta-analysis	B-X
of	B-X
the	B-X
prevalence	B-X
of	B-X
occupational	B-X
exposure	B-X
to	B-X
physical	B-X
ergonomic	B-X
risk	B-X
factors	B-X
for	B-X
estimating	B-X
the	B-X
number	B-X
of	B-X
disability-adjusted	B-X
life	B-X
years	B-X
from	B-X
these	B-X
diseases	B-X
that	B-X
are	B-X
attributable	B-X
to	B-X
exposure	B-X
to	B-X
this	B-X
risk	B-X
factor	B-X
,	B-X
for	B-X
the	B-X
development	B-X
of	B-X
the	B-X
WHO/ILO	B-X
Joint	B-X
Estimates	B-X
.	B-X
The	B-X
global	B-X
burden	B-X
of	B-X
lower	B-X
respiratory	B-X
infections	B-X
(	B-X
LRIs	B-X
)	B-X
and	B-X
corresponding	B-X
risk	B-X
factors	B-X
in	B-X
children	B-X
older	B-X
than	B-X
5	B-X
years	B-X
and	B-X
adults	B-X
has	B-X
not	B-X
been	B-X
studied	B-X
as	B-X
comprehensively	B-X
as	B-X
it	B-X
has	B-X
been	B-X
in	B-X
children	B-X
younger	B-X
than	B-X
5	B-X
years	B-X
.	B-X
We	B-X
assessed	B-X
the	B-X
burden	B-X
and	B-X
trends	B-X
of	B-X
LRIs	B-X
and	B-X
risk	B-X
factors	B-X
across	B-X
all	B-X
age	B-X
groups	B-X
by	B-X
sex	B-X
,	B-X
for	B-X
204	B-X
countries	B-X
and	B-X
territories	B-X
.	B-X

Results	O

Age	O
and	O
gender	O
distributions	O
were	O
similar	O
between	O
the	O
two	O
populations	O
.	O
<EOS>	B-X
Lungworms	B-X
(	B-X
Network	B-X
Scale-up	B-X
(	B-X
NSU	B-X
)	B-X
method	B-X
is	B-X
an	B-X
indirect	B-X
method	B-X
for	B-X
the	B-X
estimation	B-X
of	B-X
hidden	B-X
behaviors	B-X
.	B-X
In	B-X
NSU	B-X
,	B-X
respondents	B-X
are	B-X
asked	B-X
about	B-X
the	B-X
number	B-X
of	B-X
members	B-X
they	B-X
know	B-X
from	B-X
a	B-X
subpopulation	B-X
of	B-X
interest	B-X
(	B-X
e.g.	B-X
,	B-X
injecting	B-X
drug	B-X
user	B-X
)	B-X
and	B-X
assume	B-X
that	B-X
the	B-X
prevalence	B-X
of	B-X
risky	B-X
behavior	B-X
in	B-X
the	B-X
networks	B-X
of	B-X
a	B-X
random	B-X
sample	B-X
of	B-X
respondents	B-X
is	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
the	B-X
population	B-X
.	B-X
However	B-X
,	B-X
first	B-X
,	B-X
we	B-X
need	B-X
to	B-X
identify	B-X
the	B-X
total	B-X
number	B-X
of	B-X
people	B-X
each	B-X
respondent	B-X
knows	B-X
[	B-X
the	B-X
social	B-X
network	B-X
size	B-X
(	B-X
C	B-X
)	B-X
]	B-X
;	B-X
Moreover	B-X
,	B-X
certain	B-X
risky	B-X
behaviors	B-X
happen	B-X
in	B-X
particular	B-X
age	B-X
and	B-X
gender	B-X
groups	B-X
.	B-X
Our	B-X
aim	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
size	B-X
and	B-X
age-gender	B-X
distribution	B-X
of	B-X
female	B-X
networks	B-X
.	B-X

The	O
age	O
-	O
specific	O
prevalence	O
of	O
cortical	O
(	O
23	O
.	O
8	O
%	O
in	O
1st	O
,	O
23	O
.	O
7	O
%	O
in	O
2nd	O
)	O
and	O
PSC	O
cataract	O
(	O
6	O
.	O
3	O
%	O
,	O
6	O
.	O
0	O
%	O
)	O
was	O
similar	O
.	O

The	O
prevalence	O
of	O
nuclear	O
cataract	O
increased	O
slightly	O
from	O
18	O
.	O
7	O
%	O
to	O
23	O
.	O
9	O
%	O
.	O
<EOS>	B-X
To	B-X
describe	B-X
the	B-X
prevalence	B-X
of	B-X
cataract	B-X
in	B-X
older	B-X
people	B-X
in	B-X
2	B-X
areas	B-X
of	B-X
north	B-X
and	B-X
south	B-X
India	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
compare	B-X
age-specific	B-X
cortical	B-X
,	B-X
nuclear	B-X
and	B-X
posterior	B-X
subcapsular	B-X
(	B-X
PSC	B-X
)	B-X
cataract	B-X
prevalence	B-X
in	B-X
two	B-X
surveys	B-X
6	B-X
years	B-X
apart	B-X
.	B-X

After	O
age	O
standardization	O
,	O
the	O
similar	O
prevalence	O
of	O
cortical	O
(	O
23	O
.	O
8	O
%	O
,	O
23	O
.	O
5	O
%	O
)	O
and	O
PSC	O
cataract	O
(	O
6	O
.	O
3	O
%	O
,	O
5	O
.	O
9	O
%	O
)	O
,	O
and	O
the	O
increased	O
prevalence	O
of	O
nuclear	O
cataract	O
(	O
18	O
.	O
7	O
%	O
,	O
24	O
.	O
2	O
%	O
)	O
remained	O
.	O

Conclusion	O
<EOS>	B-X
Conclusion	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X

In	O
two	O
surveys	O
of	O
two	O
population	O
-	O
based	O
samples	O
with	O
similar	O
age	O
and	O
gender	O
distributions	O
,	O
we	O
found	O
a	O
relatively	O
stable	O
cortical	O
and	O
PSC	O
cataract	O
prevalence	O
over	O
a	O
6	O
-	O
year	O
period	O
.	O

The	O
increased	O
prevalence	O
of	O
nuclear	O
cataract	O
deserves	O
further	O
study	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
compare	B-X
age-specific	B-X
cortical	B-X
,	B-X
nuclear	B-X
and	B-X
posterior	B-X
subcapsular	B-X
(	B-X
PSC	B-X
)	B-X
cataract	B-X
prevalence	B-X
in	B-X
two	B-X
surveys	B-X
6	B-X
years	B-X
apart	B-X
.	B-X

Background	O
<EOS>	B-X
Background	B-X
matching	B-X
is	B-X
the	B-X
most	B-X
familiar	B-X
and	B-X
widespread	B-X
camouflage	B-X
strategy	B-X
:	B-X
avoiding	B-X
detection	B-X
by	B-X
having	B-X
a	B-X
similar	B-X
colour	B-X
and	B-X
pattern	B-X
to	B-X
the	B-X
background	B-X
.	B-X
Background	B-X
is	B-X
thus	B-X
a	B-X
relatively	B-X
modest	B-X
correction	B-X
for	B-X
all	B-X
Z	B-X
opacity	B-X
data	B-X
published	B-X
to	B-X
date	B-X
.	B-X
Background	B-X
estimation	B-X
and	B-X
foreground	B-X
segmentation	B-X
are	B-X
important	B-X
steps	B-X
in	B-X
many	B-X
high-level	B-X
vision	B-X
tasks	B-X
.	B-X
Patient	B-X
Preference	B-X
for	B-X
Telehealth	B-X
Background	B-X
Shapes	B-X
Impressions	B-X
of	B-X
Physicians	B-X
and	B-X
Information	B-X
Recall	B-X
:	B-X
A	B-X
Randomized	B-X
Experiment	B-X
.	B-X

Age	O
-	O
related	O
cataract	O
is	O
the	O
leading	O
cause	O
of	O
reversible	O
visual	O
impairment	O
in	O
older	O
persons	B-Species
[	O
1	O
-	O
6	O
]	O
.	O
<EOS>	B-X
Bilateral	B-X
blindness	B-X
unrelated	B-X
to	B-X
simple	B-X
refractive	B-X
error	B-X
is	B-X
twice	B-X
as	B-X
prevalent	B-X
among	B-X
blacks	B-X
as	B-X
among	B-X
whites	B-X
,	B-X
although	B-X
the	B-X
difference	B-X
narrows	B-X
among	B-X
the	B-X
elderly	B-X
.	B-X
The	B-X
reasons	B-X
for	B-X
this	B-X
race-	B-X
and	B-X
age-related	B-X
pattern	B-X
are	B-X
uncertain	B-X
.	B-X
In	B-X
human	B-X
diabetes	B-X
,	B-X
the	B-X
deleterious	B-X
effects	B-X
of	B-X
chronic	B-X
hyperglycemia	B-X
are	B-X
the	B-X
result	B-X
of	B-X
excessive	B-X
nonenzymatic	B-X
modification	B-X
of	B-X
proteins	B-X
and	B-X
phospholipids	B-X
by	B-X
glucose	B-X
and	B-X
its	B-X
by-products	B-X
leading	B-X
to	B-X
the	B-X
formation	B-X
of	B-X
irreversible	B-X
oxidized	B-X
,	B-X
aromatic	B-X
,	B-X
and	B-X
fluorescent	B-X
ligands	B-X
known	B-X
as	B-X
advanced	B-X
glycation	B-X
end	B-X
products	B-X
.	B-X
The	B-X
present	B-X
invention	B-X
provides	B-X
the	B-X
potent	B-X
inhibitors	B-X
of	B-X
protein	B-X
glycation	B-X
and	B-X
AGEs	B-X
formation	B-X
,	B-X
which	B-X
are	B-X
particularly	B-X
advantageous	B-X
for	B-X
eyedrop	B-X
delivery	B-X
in	B-X
the	B-X
prevention	B-X
and	B-X
treatment	B-X
of	B-X
diabetes-	B-X
and	B-X
age-related	B-X
pathologies	B-X
.	B-X

In	O
Australia	O
,	O
it	O
is	O
estimated	O
that	O
by	O
the	O
year	O
2021	O
,	O
the	O
number	O
of	O
people	B-Species
affected	O
by	O
cataract	O
will	O
increase	O
by	O
63	O
%	O
,	O
due	O
to	O
population	O
aging	O
[	O
7	O
]	O
.	O

Surgical	O
intervention	O
is	O
an	O
effective	O
treatment	O
for	O
cataract	O
and	O
normal	O
vision	O
(	O
>	O
20	O
/	O
40	O
)	O
can	O
usually	O
be	O
restored	O
with	O
intraocular	O
lens	O
(	O
IOL	O
)	O
implantation	O
.	O

Cataract	O
surgery	O
with	O
IOL	O
implantation	O
is	O
currently	O
the	O
most	O
commonly	O
performed	O
,	O
and	O
is	O
,	O
arguably	O
,	O
the	O
most	O
cost	O
effective	O
surgical	O
procedure	O
worldwide	O
.	O

Performance	O
of	O
this	O
surgical	O
procedure	O
has	O
been	O
continuously	O
increasing	O
in	O
the	O
last	O
two	O
decades	O
.	O
<EOS>	B-X
During	B-X
the	B-X
last	B-X
decade	B-X
,	B-X
significant	B-X
technological	B-X
progress	B-X
has	B-X
taken	B-X
place	B-X
in	B-X
the	B-X
pediatric	B-X
cardiac	B-X
catheterization	B-X
laboratory	B-X
.	B-X
Improved	B-X
noninvasive	B-X
diagnostic	B-X
techniques	B-X
have	B-X
narrowed	B-X
down	B-X
the	B-X
indications	B-X
for	B-X
diagnostic	B-X
cardiac	B-X
catheterization	B-X
,	B-X
and	B-X
these	B-X
techniques	B-X
are	B-X
now	B-X
increasingly	B-X
being	B-X
applied	B-X
to	B-X
therapeutic	B-X
procedures	B-X
.	B-X
These	B-X
procedures	B-X
should	B-X
only	B-X
be	B-X
performed	B-X
in	B-X
institutions	B-X
equipped	B-X
with	B-X
appropriate	B-X
facilities	B-X
,	B-X
personnel	B-X
,	B-X
and	B-X
programs	B-X
.	B-X
These	B-X
considerations	B-X
,	B-X
combined	B-X
with	B-X
the	B-X
rapid	B-X
increase	B-X
in	B-X
the	B-X
number	B-X
of	B-X
laboratories	B-X
and	B-X
cardiologists	B-X
performing	B-X
therapeutic	B-X
catheterization	B-X
procedures	B-X
,	B-X
raises	B-X
concern	B-X
about	B-X
the	B-X
safety	B-X
of	B-X
patients	B-X
and	B-X
human	B-X
subjects	B-X
as	B-X
well	B-X
as	B-X
credentials	B-X
of	B-X
hospital	B-X
and	B-X
level	B-X
of	B-X
training	B-X
and	B-X
skill	B-X
of	B-X
physician	B-X
involved	B-X
.	B-X
Due	B-X
to	B-X
the	B-X
complexity	B-X
and	B-X
potential	B-X
risks	B-X
of	B-X
these	B-X
procedures	B-X
,	B-X
specific	B-X
skill	B-X
and	B-X
competency	B-X
benchmark	B-X
should	B-X
be	B-X
developed	B-X
for	B-X
personnel	B-X
undergoing	B-X
training	B-X
in	B-X
therapeutic	B-X
catheterization	B-X
as	B-X
well	B-X
as	B-X
for	B-X
those	B-X
who	B-X
continue	B-X
to	B-X
perform	B-X
various	B-X
procedures	B-X
.	B-X
Pediatric	B-X
cardiology	B-X
fellows	B-X
should	B-X
receive	B-X
therapeutic	B-X
catheterization	B-X
training	B-X
in	B-X
one	B-X
or	B-X
more	B-X
centers	B-X
that	B-X
specializes	B-X
in	B-X
angioplasties	B-X
,	B-X
valvuloplasties	B-X
,	B-X
and/or	B-X
vascular	B-X
occlusion	B-X
procedures	B-X
.	B-X
Before	B-X
performing	B-X
a	B-X
therapeutic	B-X
catheterization	B-X
as	B-X
the	B-X
primary	B-X
operator	B-X
,	B-X
the	B-X
fellow	B-X
or	B-X
practicing	B-X
pediatric	B-X
cardiologist	B-X
should	B-X
be	B-X
required	B-X
to	B-X
receive	B-X
procedure-specific	B-X
training	B-X
under	B-X
the	B-X
supervision	B-X
of	B-X
a	B-X
qualified	B-X
individual	B-X
.	B-X
Credential	B-X
should	B-X
be	B-X
procedure	B-X
specific	B-X
.	B-X
Interventional	B-X
pediatric	B-X
cardiology	B-X
has	B-X
grown	B-X
remarkably	B-X
over	B-X
the	B-X
last	B-X
two	B-X
decades	B-X
.	B-X
Catheter	B-X
based	B-X
interventional	B-X
procedures	B-X
have	B-X
become	B-X
the	B-X
treatment	B-X
of	B-X
choice	B-X
for	B-X
many	B-X
cardiac	B-X
lesions	B-X
,	B-X
and	B-X
these	B-X
procedures	B-X
serve	B-X
as	B-X
alternatives	B-X
or	B-X
adjuncts	B-X
to	B-X
surgical	B-X
treatment	B-X
for	B-X
many	B-X
other	B-X
relevant	B-X
conditions	B-X
.	B-X
Keeping	B-X
with	B-X
the	B-X
pace	B-X
of	B-X
development	B-X
worldwide	B-X
,	B-X
catheter	B-X
based	B-X
interventional	B-X
procedures	B-X
are	B-X
making	B-X
good	B-X
progress	B-X
in	B-X
Bangladesh	B-X
as	B-X
well	B-X
.	B-X

Data	O
from	O
the	O
Australian	O
Health	O
Insurance	O
Commission	O
has	O
shown	O
a	O
steady	O
increase	O
in	O
Medicare	O
claims	O
for	O
cataract	O
surgery	O
[	O
8	O
]	O
.	O

A	O
2	O
.	O
6	O
-	O
fold	O
increase	O
in	O
the	O
total	O
number	O
of	O
cataract	O
procedures	O
from	O
1985	O
to	O
1994	O
has	O
been	O
documented	O
in	O
Australia	O
[	O
9	O
]	O
.	O

The	O
rate	O
of	O
cataract	O
surgery	O
per	O
thousand	O
persons	B-Species
aged	O
65	O
years	O
or	O
older	O
has	O
doubled	O
in	O
the	O
last	O
20	O
years	O
[	O
8	O
,	O
9	O
]	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
efficacy	B-X
and	B-X
safety	B-X
of	B-X
dalteparin	B-X
postoperative	B-X
bridging	B-X
treatment	B-X
versus	B-X
placebo	B-X
for	B-X
patients	B-X
with	B-X
atrial	B-X
fibrillation	B-X
or	B-X
mechanical	B-X
heart	B-X
valves	B-X
when	B-X
warfarin	B-X
is	B-X
temporarily	B-X
interrupted	B-X
for	B-X
a	B-X
planned	B-X
procedure	B-X
.	B-X
Post-traumatic	B-X
stress	B-X
disorder	B-X
(	B-X
PTSD	B-X
)	B-X
is	B-X
prevalent	B-X
in	B-X
military	B-X
personnel	B-X
and	B-X
first	B-X
responders	B-X
,	B-X
many	B-X
of	B-X
whom	B-X
do	B-X
not	B-X
respond	B-X
to	B-X
currently	B-X
available	B-X
treatments	B-X
.	B-X
This	B-X
review	B-X
is	B-X
an	B-X
update	B-X
of	B-X
``	B-X
Single	B-X
dose	B-X
oral	B-X
ketoprofen	B-X
and	B-X
dexketoprofen	B-X
for	B-X
acute	B-X
postoperative	B-X
pain	B-X
in	B-X
adults	B-X
''	B-X
last	B-X
updated	B-X
in	B-X
Issue	B-X
4	B-X
,	B-X
2009	B-X
.	B-X
This	B-X
review	B-X
is	B-X
one	B-X
of	B-X
a	B-X
series	B-X
on	B-X
oral	B-X
analgesics	B-X
for	B-X
acute	B-X
postoperative	B-X
pain	B-X
.	B-X

In	O
the	O
Blue	O
Mountains	O
Eye	O
Study	O
population	O
,	O
we	O
observed	O
a	O
one	O
-	O
third	O
increase	O
in	O
cataract	O
surgery	O
prevalence	O
over	O
a	O
mean	O
6	O
-	O
year	O
interval	O
,	O
from	O
6	O
%	O
to	O
nearly	O
8	O
%	O
in	O
two	O
cross	O
-	O
sectional	O
population	O
-	O
based	O
samples	O
with	O
a	O
similar	O
age	O
range	O
[	O
10	O
]	O
.	O

Further	O
increases	O
in	O
cataract	O
surgery	O
performance	O
would	O
be	O
expected	O
as	O
a	O
result	O
of	O
improved	O
surgical	O
skills	O
and	O
technique	O
,	O
together	O
with	O
extending	O
cataract	O
surgical	O
benefits	O
to	O
a	O
greater	O
number	O
of	O
older	O
people	B-Species
and	O
an	O
increased	O
number	O
of	O
persons	B-Species
with	O
surgery	O
performed	O
on	O
both	O
eyes	O
.	O

Both	O
the	O
prevalence	O
and	O
incidence	O
of	O
age	O
-	O
related	O
cataract	O
link	O
directly	O
to	O
the	O
demand	O
for	O
,	O
and	O
the	O
outcome	O
of	O
,	O
cataract	O
surgery	O
and	O
eye	O
health	O
care	O
provision	O
.	O

This	O
report	O
aimed	O
to	O
assess	O
temporal	O
changes	O
in	O
the	O
prevalence	O
of	O
cortical	O
and	O
nuclear	O
cataract	O
and	O
posterior	O
subcapsular	O
cataract	O
(	O
PSC	O
)	O
in	O
two	O
cross	O
-	O
sectional	O
population	O
-	O
based	O
surveys	O
6	O
years	O
apart	O
.	O

Methods	O
<EOS>	B-X
Methods	B-X
to	B-X
calculate	B-X
the	B-X
sample	B-X
size	B-X
are	B-X
explained	B-X
in	B-X
statistical	B-X
textbooks	B-X
,	B-X
but	B-X
because	B-X
there	B-X
are	B-X
many	B-X
different	B-X
formulas	B-X
available	B-X
,	B-X
it	B-X
can	B-X
be	B-X
difficult	B-X
for	B-X
investigators	B-X
to	B-X
decide	B-X
which	B-X
method	B-X
to	B-X
use	B-X
.	B-X

The	O
Blue	O
Mountains	O
Eye	O
Study	O
(	O
BMES	O
)	O
is	O
a	O
population	O
-	O
based	O
cohort	O
study	O
of	O
common	O
eye	O
diseases	O
and	O
other	O
health	O
outcomes	O
.	O

The	O
study	O
involved	O
eligible	O
permanent	O
residents	O
aged	O
49	O
years	O
and	O
older	O
,	O
living	O
in	O
two	O
postcode	O
areas	O
in	O
the	O
Blue	O
Mountains	O
,	O
west	O
of	O
Sydney	O
,	O
Australia	O
.	O

Participants	B-Species
were	O
identified	O
through	O
a	O
census	O
and	O
were	O
invited	O
to	O
participate	O
.	O
<EOS>	B-X
The	B-X
PHM	B-X
approach	B-X
included	B-X
an	B-X
electronic	B-X
health	B-X
record	B-X
(	B-X
EHR	B-X
)	B-X
query	B-X
,	B-X
physician	B-X
review	B-X
of	B-X
identified	B-X
patients	B-X
,	B-X
letter	B-X
invitation	B-X
,	B-X
and	B-X
telephone	B-X
follow-up	B-X
.	B-X
The	B-X
PHM	B-X
approach	B-X
identified	B-X
10,177	B-X
potential	B-X
participants	B-X
to	B-X
receive	B-X
a	B-X
physician	B-X
letter	B-X
invitation	B-X
,	B-X
60	B-X
%	B-X
were	B-X
contacted	B-X
by	B-X
telephone	B-X
,	B-X
2,796	B-X
(	B-X
46	B-X
%	B-X
)	B-X
completed	B-X
telephone	B-X
screening	B-X
,	B-X
1,961	B-X
were	B-X
eligible	B-X
from	B-X
telephone	B-X
screen	B-X
,	B-X
and	B-X
599	B-X
were	B-X
enrolled	B-X
in	B-X
15	B-X
months	B-X
.	B-X
Relative	B-X
to	B-X
census	B-X
data	B-X
,	B-X
study	B-X
participants	B-X
were	B-X
more	B-X
likely	B-X
to	B-X
be	B-X
obese	B-X
,	B-X
female	B-X
,	B-X
older	B-X
,	B-X
and	B-X
Caucasian	B-X
.	B-X
Focussing	B-X
on	B-X
a	B-X
Swedish	B-X
1942	B-X
birth	B-X
cohort	B-X
and	B-X
guided	B-X
by	B-X
Andersen	B-X
's	B-X
Behavioral	B-X
Model	B-X
,	B-X
this	B-X
study	B-X
assessed	B-X
dental	B-X
hygienist	B-X
attendance	B-X
from	B-X
age	B-X
50	B-X
to	B-X
age	B-X
70	B-X
and	B-X
identified	B-X
covariates	B-X
at	B-X
the	B-X
population-averaged	B-X
and	B-X
person-specific	B-X
levels	B-X
.	B-X
In	B-X
1992	B-X
,	B-X
a	B-X
census	B-X
of	B-X
50-yr-old	B-X
subjects	B-X
was	B-X
invited	B-X
to	B-X
participate	B-X
in	B-X
a	B-X
questionnaire	B-X
survey	B-X
.	B-X

The	O
study	O
was	O
approved	O
at	O
each	O
stage	O
of	O
the	O
data	O
collection	O
by	O
the	O
Human	B-Species
Ethics	O
Committees	O
of	O
the	O
University	O
of	O
Sydney	O
and	O
the	O
Western	O
Sydney	O
Area	O
Health	O
Service	O
and	O
adhered	O
to	O
the	O
recommendations	O
of	O
the	O
Declaration	O
of	O
Helsinki	O
.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
each	O
participant	B-Species
.	O
<EOS>	B-X
Interventions	B-X
to	B-X
Improve	B-X
Patient	B-X
Comprehension	B-X
in	B-X
Informed	B-X
Consent	B-X
for	B-X
Medical	B-X
and	B-X
Surgical	B-X
Procedures	B-X
:	B-X
An	B-X
Updated	B-X
Systematic	B-X
Review	B-X
.	B-X
There	B-X
is	B-X
considerable	B-X
variability	B-X
in	B-X
surgeons	B-X
'	B-X
approach	B-X
to	B-X
write	B-X
and	B-X
obtain	B-X
informed	B-X
consent	B-X
for	B-X
surgery	B-X
,	B-X
particularly	B-X
among	B-X
resident	B-X
trainees	B-X
.	B-X
We	B-X
analyzed	B-X
differences	B-X
in	B-X
procedures	B-X
and	B-X
complications	B-X
described	B-X
in	B-X
documented	B-X
surgical	B-X
consents	B-X
for	B-X
cholecystectomy	B-X
between	B-X
residents	B-X
and	B-X
attendings	B-X
.	B-X
We	B-X
hypothesized	B-X
that	B-X
attending	B-X
consents	B-X
would	B-X
describe	B-X
more	B-X
comprehensive	B-X
procedures	B-X
and	B-X
complications	B-X
than	B-X
those	B-X
done	B-X
by	B-X
residents	B-X
.	B-X

Details	O
of	O
the	O
methods	O
used	O
in	O
this	O
study	O
have	O
been	O
described	O
previously	O
[	O
11	O
]	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
work	B-X
is	B-X
to	B-X
develop	B-X
similar	B-X
terminology	B-X
to	B-X
that	B-X
used	B-X
in	B-X
cognitive	B-X
classifications	B-X
of	B-X
the	B-X
general	B-X
population	B-X
for	B-X
use	B-X
in	B-X
investigations	B-X
of	B-X
cognitive	B-X
changes	B-X
after	B-X
anaesthesia	B-X
and	B-X
surgery	B-X
.	B-X
Two	B-X
major	B-X
classification	B-X
guidelines	B-X
[	B-X
Diagnostic	B-X
and	B-X
Statistical	B-X
Manual	B-X
for	B-X
Mental	B-X
Disorders	B-X
,	B-X
fifth	B-X
edition	B-X
(	B-X
DSM-5	B-X
)	B-X
and	B-X
National	B-X
Institute	B-X
for	B-X
Aging	B-X
and	B-X
the	B-X
Alzheimer	B-X
Association	B-X
(	B-X
NIA-AA	B-X
)	B-X
]	B-X
are	B-X
used	B-X
outside	B-X
of	B-X
anaesthesia	B-X
and	B-X
surgery	B-X
,	B-X
and	B-X
may	B-X
be	B-X
useful	B-X
for	B-X
inclusion	B-X
of	B-X
biomarkers	B-X
in	B-X
research	B-X
.	B-X
The	B-X
working	B-X
group	B-X
recommends	B-X
that	B-X
'perioperative	B-X
neurocognitive	B-X
disorders	B-X
'	B-X
be	B-X
used	B-X
as	B-X
an	B-X
overarching	B-X
term	B-X
for	B-X
cognitive	B-X
impairment	B-X
identified	B-X
in	B-X
the	B-X
preoperative	B-X
or	B-X
postoperative	B-X
period	B-X
.	B-X
This	B-X
includes	B-X
cognitive	B-X
decline	B-X
diagnosed	B-X
before	B-X
operation	B-X
(	B-X
described	B-X
as	B-X
neurocognitive	B-X
disorder	B-X
)	B-X
;	B-X
any	B-X
form	B-X
of	B-X
acute	B-X
event	B-X
(	B-X
postoperative	B-X
delirium	B-X
)	B-X
and	B-X
cognitive	B-X
decline	B-X
diagnosed	B-X
up	B-X
to	B-X
30	B-X
days	B-X
after	B-X
the	B-X
procedure	B-X
(	B-X
delayed	B-X
neurocognitive	B-X
recovery	B-X
)	B-X
and	B-X
up	B-X
to	B-X
12	B-X
months	B-X
(	B-X
postoperative	B-X
neurocognitive	B-X
disorder	B-X
)	B-X
.	B-X

The	O
baseline	O
examinations	O
(	O
BMES	O
cross	O
-	O
section	O
I	O
)	O
were	O
conducted	O
during	O
1992	O
-	O
1994	O
and	O
included	O
3654	O
(	O
82	O
.	O
4	O
%	O
)	O
of	O
4433	O
eligible	O
residents	O
.	O

Follow	O
-	O
up	O
examinations	O
(	O
BMES	O
IIA	O
)	O
were	O
conducted	O
during	O
1997	O
-	O
1999	O
,	O
with	O
2335	O
(	O
75	O
.	O
0	O
%	O
of	O
BMES	O
cross	O
section	O
I	O
survivors	O
)	O
participating	O
.	O

A	O
repeat	O
census	O
of	O
the	O
same	O
area	O
was	O
performed	O
in	O
1999	O
and	O
identified	O
1378	O
newly	O
eligible	O
residents	O
who	O
moved	O
into	O
the	O
area	O
or	O
the	O
eligible	O
age	O
group	O
.	O
<EOS>	B-X
People	B-X
with	B-X
mild	B-X
cognitive	B-X
impairment	B-X
and	B-X
dementia	B-X
are	B-X
a	B-X
frequent	B-X
and	B-X
continuously	B-X
increasing	B-X
patient	B-X
group	B-X
in	B-X
practically	B-X
all	B-X
fields	B-X
of	B-X
medicine	B-X
.	B-X
The	B-X
associated	B-X
challenges	B-X
involve	B-X
nearly	B-X
all	B-X
areas	B-X
of	B-X
life	B-X
in	B-X
addition	B-X
to	B-X
the	B-X
direct	B-X
medical	B-X
treatment	B-X
.	B-X
Because	B-X
age	B-X
is	B-X
a	B-X
substantial	B-X
risk	B-X
factor	B-X
for	B-X
the	B-X
development	B-X
of	B-X
cognitive	B-X
disorders	B-X
,	B-X
the	B-X
question	B-X
of	B-X
the	B-X
ability	B-X
to	B-X
drive	B-X
is	B-X
affected	B-X
not	B-X
only	B-X
by	B-X
neuropsychiatric	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
mild	B-X
cognitive	B-X
disorders	B-X
or	B-X
dementia	B-X
but	B-X
also	B-X
the	B-X
frequently	B-X
occurring	B-X
somatic	B-X
comorbidities	B-X
.	B-X
A	B-X
key	B-X
policy	B-X
question	B-X
is	B-X
whether	B-X
continued	B-X
expansion	B-X
of	B-X
university	B-X
education	B-X
is	B-X
beneficial	B-X
for	B-X
the	B-X
marginally	B-X
eligible	B-X
student	B-X
.	B-X
2SLS	B-X
estimates	B-X
find	B-X
that	B-X
a	B-X
10	B-X
%	B-X
point	B-X
increase	B-X
in	B-X
university	B-X
attendance	B-X
causes	B-X
a	B-X
roughly	B-X
one	B-X
percentage	B-X
point	B-X
increase	B-X
in	B-X
hospital	B-X
admissions	B-X
due	B-X
to	B-X
mental	B-X
ill	B-X
health	B-X
for	B-X
males	B-X
,	B-X
almost	B-X
exclusively	B-X
related	B-X
to	B-X
alcohol	B-X
and	B-X
narcotics	B-X
.	B-X
The	B-X
results	B-X
for	B-X
males	B-X
sit	B-X
in	B-X
contrast	B-X
to	B-X
results	B-X
from	B-X
previous	B-X
studies	B-X
,	B-X
and	B-X
suggest	B-X
that	B-X
the	B-X
effect	B-X
of	B-X
university	B-X
education	B-X
on	B-X
health	B-X
for	B-X
the	B-X
male	B-X
student	B-X
at	B-X
the	B-X
margin	B-X
of	B-X
eligibility	B-X
is	B-X
different	B-X
to	B-X
that	B-X
of	B-X
the	B-X
average	B-X
student	B-X
.	B-X

During	O
1999	O
-	O
2000	O
,	O
1174	O
(	O
85	O
.	O
2	O
%	O
)	O
of	O
this	O
group	O
participated	O
in	O
an	O
extension	O
study	O
(	O
BMES	O
IIB	O
)	O
.	O

BMES	O
cross	O
-	O
section	O
II	O
thus	O
includes	O
BMES	O
IIA	O
(	O
66	O
.	O
5	O
%	O
)	O
and	O
BMES	O
IIB	O
(	O
33	O
.	O
5	O
%	O
)	O
participants	B-Species
(	O
n	O
=	O
3509	O
)	O
.	O

Similar	O
procedures	O
were	O
used	O
for	O
all	O
stages	O
of	O
data	O
collection	O
at	O
both	O
surveys	O
.	O
<EOS>	B-X
However	B-X
,	B-X
studies	B-X
have	B-X
predominantly	B-X
focused	B-X
on	B-X
patients	B-X
with	B-X
advanced	B-X
disease	B-X
,	B-X
whose	B-X
experiences	B-X
may	B-X
differ	B-X
from	B-X
patients	B-X
with	B-X
earlier	B-X
stage	B-X
,	B-X
surgically	B-X
resectable	B-X
lung	B-X
cancer	B-X
and	B-X
an	B-X
improved	B-X
prognosis	B-X
.	B-X
Benson	B-X
and	B-X
Hartz	B-X
(	B-X
2000	B-X
)	B-X
conducted	B-X
a	B-X
study	B-X
in	B-X
which	B-X
they	B-X
focused	B-X
only	B-X
on	B-X
studies	B-X
reported	B-X
after	B-X
1985	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
136	B-X
reports	B-X
of	B-X
19	B-X
diverse	B-X
treatments	B-X
,	B-X
Benson	B-X
and	B-X
Hartz	B-X
concluded	B-X
that	B-X
in	B-X
only	B-X
2	B-X
of	B-X
the	B-X
19	B-X
analyses	B-X
did	B-X
the	B-X
combined	B-X
data	B-X
from	B-X
the	B-X
observational	B-X
studies	B-X
lie	B-X
outside	B-X
the	B-X
95	B-X
%	B-X
confidence	B-X
interval	B-X
for	B-X
the	B-X
combined	B-X
data	B-X
from	B-X
the	B-X
randomized	B-X
trials	B-X
.	B-X
A	B-X
similar	B-X
study	B-X
drew	B-X
only	B-X
on	B-X
data	B-X
reported	B-X
from	B-X
1991	B-X
to	B-X
1995	B-X
,	B-X
which	B-X
showed	B-X
remarkably	B-X
similar	B-X
results	B-X
among	B-X
observational	B-X
studies	B-X
and	B-X
randomized	B-X
,	B-X
controlled	B-X
trials	B-X
(	B-X
Concato	B-X
et	B-X
al.	B-X
,	B-X
2000	B-X
)	B-X
.	B-X
These	B-X
more	B-X
recent	B-X
data	B-X
suggest	B-X
that	B-X
advancing	B-X
the	B-X
study	B-X
design	B-X
and	B-X
analytic	B-X
methods	B-X
may	B-X
reduce	B-X
bias	B-X
in	B-X
some	B-X
evaluations	B-X
of	B-X
medical	B-X
and	B-X
public	B-X
health	B-X
interventions	B-X
.	B-X
By	B-X
focusing	B-X
attention	B-X
on	B-X
thorough	B-X
data	B-X
analysis	B-X
,	B-X
design	B-X
issues	B-X
can	B-X
be	B-X
understood	B-X
and	B-X
their	B-X
impact	B-X
or	B-X
bias	B-X
can	B-X
be	B-X
estimated	B-X
,	B-X
on	B-X
average	B-X
,	B-X
and	B-X
then	B-X
ideally	B-X
accounted	B-X
for	B-X
in	B-X
the	B-X
interpretation	B-X
of	B-X
data	B-X
.	B-X
Before	B-X
discussing	B-X
dietary	B-X
data	B-X
,	B-X
let	B-X
us	B-X
first	B-X
consider	B-X
some	B-X
of	B-X
the	B-X
more	B-X
clearly	B-X
delineated	B-X
preventive	B-X
exposures	B-X
.	B-X
Continuing	B-X
with	B-X
the	B-X
mammography	B-X
example	B-X
,	B-X
a	B-X
detailed	B-X
study	B-X
by	B-X
Demissie	B-X
and	B-X
colleagues	B-X
(	B-X
1998	B-X
)	B-X
combined	B-X
data	B-X
from	B-X
seven	B-X
randomized	B-X
trials	B-X
and	B-X
six	B-X
case-control	B-X
studies	B-X
that	B-X
investigated	B-X
the	B-X
association	B-X
between	B-X
participation	B-X
in	B-X
breast	B-X
cancer	B-X
screening	B-X
programs	B-X
and	B-X
breast	B-X
cancer	B-X
mortality	B-X
.	B-X
(	B-X
2004	B-X
)	B-X
conducted	B-X
a	B-X
combined	B-X
analysis	B-X
of	B-X
prospective	B-X
dietary	B-X
studies	B-X
of	B-X
calcium	B-X
and	B-X
vitamin	B-X
D	B-X
intake	B-X
data	B-X
from	B-X
10	B-X
cohorts	B-X
.	B-X
Similar	B-X
findings	B-X
apply	B-X
to	B-X
the	B-X
interpretation	B-X
of	B-X
the	B-X
vitamin	B-X
D	B-X
intervention	B-X
and	B-X
highlight	B-X
the	B-X
role	B-X
of	B-X
dietary	B-X
intake	B-X
at	B-X
randomization	B-X
when	B-X
evaluating	B-X
dietary	B-X
components	B-X
.	B-X

A	O
questionnaire	O
was	O
administered	O
including	O
demographic	O
,	O
family	O
and	O
medical	O
history	O
.	O
<EOS>	B-X
Therefore	B-X
,	B-X
this	B-X
study	B-X
examined	B-X
whether	B-X
there	B-X
is	B-X
an	B-X
association	B-X
between	B-X
a	B-X
family	B-X
history	B-X
of	B-X
hypertension	B-X
and	B-X
pubertal	B-X
growth	B-X
.	B-X
An	B-X
MDHAQ/RAPID3	B-X
(	B-X
multidimensional	B-X
health	B-X
assessment	B-X
questionnaire/routine	B-X
assessment	B-X
of	B-X
patient	B-X
index	B-X
data	B-X
)	B-X
was	B-X
developed	B-X
from	B-X
the	B-X
HAQ	B-X
over	B-X
25	B-X
years	B-X
,	B-X
based	B-X
on	B-X
observations	B-X
made	B-X
from	B-X
completion	B-X
by	B-X
every	B-X
patient	B-X
(	B-X
with	B-X
all	B-X
diagnoses	B-X
)	B-X
at	B-X
every	B-X
routine	B-X
rheumatology	B-X
visit	B-X
since	B-X
1980	B-X
.	B-X
A	B-X
longer	B-X
``	B-X
intake	B-X
''	B-X
MDHAQ	B-X
was	B-X
introduced	B-X
for	B-X
new	B-X
patients	B-X
to	B-X
record	B-X
a	B-X
complete	B-X
past	B-X
medical	B-X
history	B-X
-	B-X
illnesses	B-X
,	B-X
hospitalisations	B-X
,	B-X
surgeries	B-X
,	B-X
allergies	B-X
,	B-X
family	B-X
history	B-X
,	B-X
social	B-X
history	B-X
and	B-X
medications	B-X
.	B-X
MDHAQ	B-X
scales	B-X
not	B-X
found	B-X
on	B-X
the	B-X
HAQ	B-X
record	B-X
complex	B-X
activities	B-X
,	B-X
sleep	B-X
quality	B-X
,	B-X
anxiety	B-X
,	B-X
depression	B-X
,	B-X
self-report	B-X
joint	B-X
count	B-X
,	B-X
fatigue	B-X
,	B-X
symptom	B-X
checklist	B-X
,	B-X
morning	B-X
stiffness	B-X
,	B-X
exercise	B-X
status	B-X
,	B-X
recent	B-X
medical	B-X
history	B-X
,	B-X
social	B-X
history	B-X
and	B-X
demographic	B-X
data	B-X
within	B-X
2	B-X
pages	B-X
on	B-X
one	B-X
sheet	B-X
of	B-X
paper	B-X
.	B-X
A	B-X
patient	B-X
may	B-X
be	B-X
offered	B-X
a	B-X
patient-administered	B-X
,	B-X
password-protected	B-X
,	B-X
secure	B-X
,	B-X
web	B-X
site	B-X
,	B-X
to	B-X
store	B-X
the	B-X
medical	B-X
history	B-X
completed	B-X
on	B-X
the	B-X
eMDHAQ	B-X
.	B-X
This	B-X
eMDHAQ	B-X
would	B-X
allow	B-X
a	B-X
patient	B-X
to	B-X
complete	B-X
a	B-X
single	B-X
general	B-X
medical	B-X
history	B-X
questionnaire	B-X
rather	B-X
than	B-X
different	B-X
intake	B-X
questionnaires	B-X
in	B-X
different	B-X
medical	B-X
settings	B-X
.	B-X
The	B-X
eMDHAQ	B-X
would	B-X
be	B-X
available	B-X
for	B-X
updates	B-X
and	B-X
correction	B-X
by	B-X
the	B-X
patient	B-X
for	B-X
future	B-X
visits	B-X
,	B-X
regardless	B-X
of	B-X
electronic	B-X
medical	B-X
record	B-X
(	B-X
EMR	B-X
)	B-X
.	B-X
Advanced	B-X
features	B-X
include	B-X
reports	B-X
for	B-X
the	B-X
physician	B-X
formatted	B-X
as	B-X
a	B-X
medical	B-X
record	B-X
note	B-X
of	B-X
past	B-X
medical	B-X
history	B-X
for	B-X
entry	B-X
into	B-X
any	B-X
EMR	B-X
without	B-X
typing	B-X
or	B-X
dictation	B-X
,	B-X
and	B-X
a	B-X
periodic	B-X
``	B-X
tickler	B-X
''	B-X
function	B-X
to	B-X
monitor	B-X
long-term	B-X
outcomes	B-X
with	B-X
minimal	B-X
effort	B-X
of	B-X
the	B-X
physician	B-X
and	B-X
staff	B-X
.	B-X

A	O
detailed	O
eye	O
examination	O
included	O
subjective	O
refraction	O
,	O
slit	O
-	O
lamp	O
(	O
Topcon	O
SL	O
-	O
7e	O
camera	O
,	O
Topcon	O
Optical	O
Co	O
,	O
Tokyo	O
,	O
Japan	O
)	O
and	O
retroillumination	O
(	O
Neitz	O
CT	O
-	O
R	O
camera	O
,	O
Neitz	O
Instrument	O
Co	O
,	O
Tokyo	O
,	O
Japan	O
)	O
photography	O
of	O
the	O
lens	O
.	O

Grading	O
of	O
lens	O
photographs	O
in	O
the	O
BMES	O
has	O
been	O
previously	O
described	O
[	O
12	O
]	O
.	O

Briefly	O
,	O
masked	O
grading	O
was	O
performed	O
on	O
the	O
lens	O
photographs	O
using	O
the	O
Wisconsin	O
Cataract	O
Grading	O
System	O
[	O
13	O
]	O
.	O

Cortical	O
cataract	O
and	O
PSC	O
were	O
assessed	O
from	O
the	O
retroillumination	O
photographs	O
by	O
estimating	O
the	O
percentage	O
of	O
the	O
circular	O
grid	O
involved	O
.	O

Cortical	O
cataract	O
was	O
defined	O
when	O
cortical	O
opacity	O
involved	O
at	O
least	O
5	O
%	O
of	O
the	O
total	O
lens	O
area	O
.	O

PSC	O
was	O
defined	O
when	O
opacity	O
comprised	O
at	O
least	O
1	O
%	O
of	O
the	O
total	O
lens	O
area	O
.	O

Slit	O
-	O
lamp	O
photographs	O
were	O
used	O
to	O
assess	O
nuclear	O
cataract	O
using	O
the	O
Wisconsin	O
standard	O
set	O
of	O
four	O
lens	O
photographs	O
[	O
13	O
]	O
.	O

Nuclear	O
cataract	O
was	O
defined	O
when	O
nuclear	O
opacity	O
was	O
at	O
least	O
as	O
great	O
as	O
the	O
standard	O
4	O
photograph	O
.	O

Any	O
cataract	O
was	O
defined	O
to	O
include	O
persons	B-Species
who	O
had	O
previous	O
cataract	O
surgery	O
as	O
well	O
as	O
those	O
with	O
any	O
of	O
three	O
cataract	O
types	O
.	O

Inter	O
-	O
grader	O
reliability	O
was	O
high	O
,	O
with	O
weighted	O
kappa	O
0	O
.	O
82	O
for	O
cortical	O
cataract	O
,	O
0	O
.	O
55	O
(	O
simple	O
kappa	O
0	O
.	O
75	O
)	O
for	O
nuclear	O
cataract	O
and	O
0	O
.	O
82	O
for	O
PSC	O
grading	O
.	O

The	O
intra	O
-	O
grader	O
reliability	O
for	O
nuclear	O
cataract	O
was	O
assessed	O
with	O
simple	O
kappa	O
0	O
.	O
83	O
for	O
the	O
senior	O
grader	O
who	O
graded	O
nuclear	O
cataract	O
at	O
both	O
surveys	O
.	O

All	O
PSC	O
cases	O
were	O
confirmed	O
by	O
an	O
ophthalmologist	O
(	O
PM	O
)	O
.	O

In	O
cross	O
-	O
section	O
I	O
,	O
219	O
persons	B-Species
(	O
6	O
.	O
0	O
%	O
)	O
had	O
missing	O
or	O
ungradable	O
Neitz	O
photographs	O
,	O
leaving	O
3435	O
with	O
photographs	O
available	O
for	O
cortical	O
cataract	O
and	O
PSC	O
assessment	O
,	O
while	O
1153	O
(	O
31	O
.	O
6	O
%	O
)	O
had	O
randomly	O
missing	O
or	O
ungradable	O
Topcon	O
photographs	O
due	O
to	O
a	O
camera	O
malfunction	O
,	O
leaving	O
2501	O
with	O
photographs	O
available	O
for	O
nuclear	O
cataract	O
assessment	O
.	O

Comparison	O
of	O
characteristics	O
between	O
participants	B-Species
with	O
and	O
without	O
Neitz	O
or	O
Topcon	O
photographs	O
in	O
cross	O
-	O
section	O
I	O
showed	O
no	O
statistically	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
,	O
as	O
reported	O
previously	O
[	O
12	O
]	O
.	O

In	O
cross	O
-	O
section	O
II	O
,	O
441	O
persons	B-Species
(	O
12	O
.	O
5	O
%	O
)	O
had	O
missing	O
or	O
ungradable	O
Neitz	O
photographs	O
,	O
leaving	O
3068	O
for	O
cortical	O
cataract	O
and	O
PSC	O
assessment	O
,	O
and	O
648	O
(	O
18	O
.	O
5	O
%	O
)	O
had	O
missing	O
or	O
ungradable	O
Topcon	O
photographs	O
,	O
leaving	O
2860	O
for	O
nuclear	O
cataract	O
assessment	O
.	O

Data	O
analysis	O
was	O
performed	O
using	O
the	O
Statistical	O
Analysis	O
System	O
(	O
SAS	O
,	O
SAS	O
Institute	O
,	O
Cary	O
,	O
NC	O
,	O
USA	O
)	O
.	O

Age	O
-	O
adjusted	O
prevalence	O
was	O
calculated	O
using	O
direct	O
standardization	O
of	O
the	O
cross	O
-	O
section	O
II	O
population	O
to	O
the	O
cross	O
-	O
section	O
I	O
population	O
.	O

We	O
assessed	O
age	O
-	O
specific	O
prevalence	O
using	O
an	O
interval	O
of	O
5	O
years	O
,	O
so	O
that	O
participants	B-Species
within	O
each	O
age	O
group	O
were	O
independent	O
between	O
the	O
two	O
cross	O
-	O
sectional	O
surveys	O
.	O
<EOS>	B-X
In	B-X
recent	B-X
years	B-X
,	B-X
especially	B-X
following	B-X
publication	B-X
of	B-X
the	B-X
Diagnostic	B-X
and	B-X
Statistical	B-X
Manual	B-X
of	B-X
Mental	B-X
Disorders	B-X
-	B-X
Fifth	B-X
Edition	B-X
(	B-X
DSM-5	B-X
;	B-X
APA	B-X
2013	B-X
)	B-X
,	B-X
children	B-X
are	B-X
given	B-X
the	B-X
diagnosis	B-X
of	B-X
ASD	B-X
,	B-X
rather	B-X
than	B-X
subclassifications	B-X
of	B-X
the	B-X
spectrum	B-X
such	B-X
as	B-X
autistic	B-X
disorder	B-X
,	B-X
Asperger	B-X
syndrome	B-X
,	B-X
or	B-X
pervasive	B-X
developmental	B-X
disorder	B-X
-	B-X
not	B-X
otherwise	B-X
specified	B-X
.	B-X
Tests	B-X
to	B-X
diagnose	B-X
ASD	B-X
have	B-X
been	B-X
developed	B-X
using	B-X
parent	B-X
or	B-X
carer	B-X
interview	B-X
,	B-X
child	B-X
observation	B-X
,	B-X
or	B-X
a	B-X
combination	B-X
of	B-X
both	B-X
.	B-X
The	B-X
World	B-X
Health	B-X
Organization	B-X
(	B-X
WHO	B-X
)	B-X
and	B-X
the	B-X
International	B-X
Labour	B-X
Organization	B-X
(	B-X
ILO	B-X
)	B-X
are	B-X
developing	B-X
joint	B-X
estimates	B-X
of	B-X
the	B-X
work-related	B-X
burden	B-X
of	B-X
disease	B-X
and	B-X
injury	B-X
(	B-X
WHO/ILO	B-X
Joint	B-X
Estimates	B-X
)	B-X
,	B-X
with	B-X
contributions	B-X
from	B-X
a	B-X
large	B-X
network	B-X
of	B-X
experts	B-X
.	B-X
In	B-X
this	B-X
paper	B-X
,	B-X
we	B-X
present	B-X
a	B-X
systematic	B-X
review	B-X
and	B-X
meta-analysis	B-X
of	B-X
the	B-X
prevalence	B-X
of	B-X
occupational	B-X
exposure	B-X
to	B-X
physical	B-X
ergonomic	B-X
risk	B-X
factors	B-X
for	B-X
estimating	B-X
the	B-X
number	B-X
of	B-X
disability-adjusted	B-X
life	B-X
years	B-X
from	B-X
these	B-X
diseases	B-X
that	B-X
are	B-X
attributable	B-X
to	B-X
exposure	B-X
to	B-X
this	B-X
risk	B-X
factor	B-X
,	B-X
for	B-X
the	B-X
development	B-X
of	B-X
the	B-X
WHO/ILO	B-X
Joint	B-X
Estimates	B-X
.	B-X

Results	O

Characteristics	O
of	O
the	O
two	O
survey	O
populations	O
have	O
been	O
previously	O
compared	O
[	O
14	O
]	O
and	O
showed	O
that	O
age	O
and	O
sex	O
distributions	O
were	O
similar	O
.	O
<EOS>	B-X
Of	B-X
the	B-X
316	B-X
patients	B-X
,	B-X
there	B-X
were	B-X
184	B-X
adults	B-X
(	B-X
age	B-X
17	B-X
years	B-X
and	B-X
above	B-X
)	B-X
and	B-X
132	B-X
children	B-X
(	B-X
age	B-X
0-6	B-X
years	B-X
)	B-X
.	B-X
This	B-X
report	B-X
presents	B-X
national	B-X
statistics	B-X
on	B-X
hospital	B-X
use	B-X
from	B-X
the	B-X
U.S.	B-X
National	B-X
Hospital	B-X
Discharge	B-X
Survey	B-X
conducted	B-X
by	B-X
the	B-X
National	B-X
Center	B-X
for	B-X
Health	B-X
Statistics	B-X
and	B-X
the	B-X
national	B-X
survey	B-X
of	B-X
hospitalization	B-X
conducted	B-X
by	B-X
CREDES	B-X
,	B-X
Centre	B-X
de	B-X
Recherche	B-X
d'Etude	B-X
et	B-X
de	B-X
Documentation	B-X
en	B-X
Economie	B-X
de	B-X
la	B-X
SantÃ©	B-X
,	B-X
previously	B-X
the	B-X
Medical	B-X
Economics	B-X
Division	B-X
of	B-X
CREDOC	B-X
.	B-X
The	B-X
use	B-X
statistics	B-X
compared	B-X
between	B-X
the	B-X
two	B-X
countries	B-X
include	B-X
rates	B-X
and	B-X
percent	B-X
distributions	B-X
of	B-X
discharges	B-X
and	B-X
days	B-X
of	B-X
care	B-X
and	B-X
average	B-X
lengths	B-X
of	B-X
stay	B-X
.	B-X
These	B-X
statistics	B-X
are	B-X
shown	B-X
by	B-X
sex	B-X
,	B-X
age	B-X
,	B-X
diagnostic	B-X
category	B-X
,	B-X
and	B-X
other	B-X
hospital	B-X
and	B-X
patient	B-X
characteristics	B-X
.	B-X
The	B-X
similarities	B-X
and	B-X
differences	B-X
between	B-X
the	B-X
two	B-X
countries	B-X
in	B-X
population	B-X
characteristics	B-X
,	B-X
causes	B-X
of	B-X
death	B-X
,	B-X
health	B-X
care	B-X
systems	B-X
,	B-X
and	B-X
hospital	B-X
systems	B-X
are	B-X
also	B-X
described	B-X
.	B-X

Table	O
1	O
compares	O
participant	B-Species
characteristics	O
between	O
the	O
two	O
cross	O
-	O
sections	O
.	O
<EOS>	B-X
This	B-X
is	B-X
an	B-X
update	B-X
of	B-X
a	B-X
review	B-X
previously	B-X
published	B-X
in	B-X
2009	B-X
and	B-X
2015	B-X
.	B-X
The	B-X
World	B-X
Health	B-X
Organization	B-X
(	B-X
WHO	B-X
)	B-X
estimated	B-X
that	B-X
,	B-X
in	B-X
2019	B-X
,	B-X
approximately	B-X
229	B-X
million	B-X
cases	B-X
of	B-X
malaria	B-X
occurred	B-X
worldwide	B-X
,	B-X
with	B-X
94	B-X
%	B-X
occurring	B-X
in	B-X
the	B-X
WHO	B-X
's	B-X
African	B-X
region	B-X
(	B-X
WHO	B-X
2020	B-X
)	B-X
.	B-X
Sulfadoxine/pyrimethamine	B-X
(	B-X
SP	B-X
)	B-X
,	B-X
an	B-X
antifolate	B-X
antimalarial	B-X
,	B-X
has	B-X
been	B-X
widely	B-X
used	B-X
across	B-X
sub-Saharan	B-X
Africa	B-X
as	B-X
the	B-X
first-line	B-X
treatment	B-X
for	B-X
uncomplicated	B-X
malaria	B-X
since	B-X
it	B-X
was	B-X
first	B-X
introduced	B-X
in	B-X
Malawi	B-X
in	B-X
1993	B-X
(	B-X
Filler	B-X
2006	B-X
)	B-X
.	B-X
Due	B-X
to	B-X
increasing	B-X
resistance	B-X
to	B-X
SP	B-X
,	B-X
in	B-X
2000	B-X
the	B-X
WHO	B-X
recommended	B-X
that	B-X
one	B-X
of	B-X
several	B-X
artemisinin-based	B-X
combination	B-X
therapies	B-X
(	B-X
ACTs	B-X
)	B-X
be	B-X
used	B-X
instead	B-X
of	B-X
SP	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
uncomplicated	B-X
malaria	B-X
caused	B-X
by	B-X
Plasmodium	B-X
falciparum	B-X
(	B-X
Global	B-X
Partnership	B-X
to	B-X
Roll	B-X
Back	B-X
Malaria	B-X
2001	B-X
)	B-X
.	B-X
However	B-X
,	B-X
despite	B-X
these	B-X
recommendations	B-X
,	B-X
SP	B-X
continues	B-X
to	B-X
be	B-X
advised	B-X
for	B-X
intermittent	B-X
preventive	B-X
treatment	B-X
in	B-X
pregnancy	B-X
(	B-X
IPTp	B-X
)	B-X
and	B-X
intermittent	B-X
preventive	B-X
treatment	B-X
in	B-X
infants	B-X
(	B-X
IPTi	B-X
)	B-X
,	B-X
whether	B-X
the	B-X
person	B-X
has	B-X
malaria	B-X
or	B-X
not	B-X
(	B-X
WHO	B-X
2013	B-X
)	B-X
.	B-X
red	B-X
blood	B-X
cell	B-X
(	B-X
RBC	B-X
)	B-X
folate	B-X
concentrations	B-X
of	B-X
less	B-X
than	B-X
305	B-X
nanomoles	B-X
per	B-X
litre	B-X
(	B-X
nmol/L	B-X
)	B-X
;	B-X
serum	B-X
or	B-X
plasma	B-X
concentrations	B-X
of	B-X
less	B-X
than	B-X
7	B-X
nmol/L	B-X
)	B-X
is	B-X
common	B-X
in	B-X
many	B-X
parts	B-X
of	B-X
the	B-X
world	B-X
and	B-X
often	B-X
presents	B-X
as	B-X
megaloblastic	B-X
anaemia	B-X
,	B-X
resulting	B-X
from	B-X
inadequate	B-X
intake	B-X
,	B-X
increased	B-X
requirements	B-X
,	B-X
reduced	B-X
absorption	B-X
,	B-X
or	B-X
abnormal	B-X
metabolism	B-X
of	B-X
folate	B-X
(	B-X
Bailey	B-X
2015	B-X
;	B-X
WHO	B-X
2015a	B-X
)	B-X
.	B-X
Pregnant	B-X
women	B-X
have	B-X
greater	B-X
folate	B-X
requirements	B-X
;	B-X
inadequate	B-X
folate	B-X
intake	B-X
(	B-X
evidenced	B-X
by	B-X
RBC	B-X
folate	B-X
concentrations	B-X
of	B-X
less	B-X
than	B-X
400	B-X
nanograms	B-X
per	B-X
millilitre	B-X
(	B-X
ng/mL	B-X
)	B-X
,	B-X
or	B-X
906	B-X
nmol/L	B-X
)	B-X
prior	B-X
to	B-X
and	B-X
during	B-X
the	B-X
first	B-X
month	B-X
of	B-X
pregnancy	B-X
increases	B-X
the	B-X
risk	B-X
of	B-X
neural	B-X
tube	B-X
defects	B-X
,	B-X
preterm	B-X
delivery	B-X
,	B-X
low	B-X
birthweight	B-X
,	B-X
and	B-X
fetal	B-X
growth	B-X
restriction	B-X
(	B-X
Bourassa	B-X
2019	B-X
)	B-X
.	B-X
The	B-X
WHO	B-X
recommends	B-X
that	B-X
all	B-X
women	B-X
who	B-X
are	B-X
trying	B-X
to	B-X
conceive	B-X
consume	B-X
400	B-X
micrograms	B-X
(	B-X
Âµg	B-X
)	B-X
of	B-X
folic	B-X
acid	B-X
daily	B-X
from	B-X
the	B-X
time	B-X
they	B-X
begin	B-X
trying	B-X
to	B-X
conceive	B-X
through	B-X
to	B-X
12	B-X
weeks	B-X
of	B-X
gestation	B-X
(	B-X
WHO	B-X
2017	B-X
)	B-X
.	B-X
In	B-X
2015	B-X
,	B-X
the	B-X
WHO	B-X
added	B-X
the	B-X
dosage	B-X
of	B-X
0.4	B-X
mg	B-X
of	B-X
folic	B-X
acid	B-X
to	B-X
the	B-X
essential	B-X
drug	B-X
list	B-X
(	B-X
WHO	B-X
2015c	B-X
)	B-X
.	B-X
where	B-X
at	B-X
least	B-X
40	B-X
%	B-X
of	B-X
pregnant	B-X
women	B-X
have	B-X
a	B-X
blood	B-X
haemoglobin	B-X
(	B-X
Hb	B-X
)	B-X
concentration	B-X
of	B-X
less	B-X
than	B-X
110	B-X
g/L	B-X
)	B-X
.	B-X
A	B-X
study	B-X
in	B-X
Nigeria	B-X
found	B-X
that	B-X
children	B-X
with	B-X
malaria	B-X
infection	B-X
had	B-X
significantly	B-X
higher	B-X
RBC	B-X
folate	B-X
concentrations	B-X
compared	B-X
to	B-X
children	B-X
without	B-X
malaria	B-X
infection	B-X
,	B-X
but	B-X
plasma	B-X
folate	B-X
levels	B-X
were	B-X
similar	B-X
(	B-X
Bradley-Moore	B-X
1985	B-X
)	B-X
.	B-X
The	B-X
WHO	B-X
has	B-X
highlighted	B-X
the	B-X
limited	B-X
evidence	B-X
available	B-X
and	B-X
has	B-X
indicated	B-X
the	B-X
need	B-X
for	B-X
further	B-X
research	B-X
on	B-X
biomarkers	B-X
of	B-X
folate	B-X
status	B-X
,	B-X
particularly	B-X
interactions	B-X
between	B-X
RBC	B-X
folate	B-X
concentrations	B-X
and	B-X
tuberculosis	B-X
,	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
(	B-X
HIV	B-X
)	B-X
,	B-X
and	B-X
antifolate	B-X
antimalarial	B-X
drugs	B-X
(	B-X
WHO	B-X
2015b	B-X
)	B-X
.	B-X
An	B-X
earlier	B-X
Cochrane	B-X
Review	B-X
assessed	B-X
the	B-X
effects	B-X
and	B-X
safety	B-X
of	B-X
iron	B-X
supplementation	B-X
,	B-X
with	B-X
or	B-X
without	B-X
folic	B-X
acid	B-X
,	B-X
in	B-X
children	B-X
living	B-X
in	B-X
hyperendemic	B-X
or	B-X
holoendemic	B-X
malaria	B-X
areas	B-X
;	B-X
it	B-X
demonstrated	B-X
that	B-X
iron	B-X
supplementation	B-X
did	B-X
not	B-X
increase	B-X
the	B-X
risk	B-X
of	B-X
malaria	B-X
,	B-X
as	B-X
indicated	B-X
by	B-X
fever	B-X
and	B-X
the	B-X
presence	B-X
of	B-X
parasites	B-X
in	B-X
the	B-X
blood	B-X
(	B-X
Neuberger	B-X
2016	B-X
)	B-X
.	B-X
Additionally	B-X
,	B-X
it	B-X
will	B-X
contribute	B-X
to	B-X
achieving	B-X
both	B-X
the	B-X
WHO	B-X
Global	B-X
Technical	B-X
Strategy	B-X
for	B-X
Malaria	B-X
2016-2030	B-X
(	B-X
WHO	B-X
2015d	B-X
)	B-X
,	B-X
and	B-X
United	B-X
Nations	B-X
Sustainable	B-X
Development	B-X
Goal	B-X
3	B-X
(	B-X
to	B-X
ensure	B-X
healthy	B-X
lives	B-X
and	B-X
to	B-X
promote	B-X
well-being	B-X
for	B-X
all	B-X
of	B-X
all	B-X
ages	B-X
)	B-X
(	B-X
United	B-X
Nations	B-X
2021	B-X
)	B-X
,	B-X
and	B-X
evaluating	B-X
whether	B-X
the	B-X
potential	B-X
effects	B-X
of	B-X
folic	B-X
acid	B-X
supplementation	B-X
,	B-X
at	B-X
different	B-X
doses	B-X
(	B-X
e.g	B-X
.	B-X
0.4	B-X
mg	B-X
,	B-X
1	B-X
mg	B-X
,	B-X
5	B-X
mg	B-X
daily	B-X
)	B-X
,	B-X
interferes	B-X
with	B-X
the	B-X
effect	B-X
of	B-X
drugs	B-X
used	B-X
for	B-X
prevention	B-X
or	B-X
treatment	B-X
of	B-X
malaria	B-X
.	B-X

Cross	O
-	O
section	O
II	O
participants	B-Species
generally	O
had	O
higher	O
rates	O
of	O
diabetes	O
,	O
hypertension	O
,	O
myopia	O
and	O
more	O
users	O
of	O
inhaled	O
steroids	O
.	O

Cataract	O
prevalence	O
rates	O
in	O
cross	O
-	O
sections	O
I	O
and	O
II	O
are	O
shown	O
in	O
Figure	O
1	O
.	O

The	O
overall	O
prevalence	O
of	O
cortical	O
cataract	O
was	O
23	O
.	O
8	O
%	O
and	O
23	O
.	O
7	O
%	O
in	O
cross	O
-	O
sections	O
I	O
and	O
II	O
,	O
respectively	O
(	O
age	O
-	O
sex	O
adjusted	O
P	O
=	O
0	O
.	O
81	O
)	O
.	O

Corresponding	O
prevalence	O
of	O
PSC	O
was	O
6	O
.	O
3	O
%	O
and	O
6	O
.	O
0	O
%	O
for	O
the	O
two	O
cross	O
-	O
sections	O
(	O
age	O
-	O
sex	O
adjusted	O
P	O
=	O
0	O
.	O
60	O
)	O
.	O

There	O
was	O
an	O
increased	O
prevalence	O
of	O
nuclear	O
cataract	O
,	O
from	O
18	O
.	O
7	O
%	O
in	O
cross	O
-	O
section	O
I	O
to	O
23	O
.	O
9	O
%	O
in	O
cross	O
-	O
section	O
II	O
over	O
the	O
6	O
-	O
year	O
period	O
(	O
age	O
-	O
sex	O
adjusted	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Prevalence	O
of	O
any	O
cataract	O
(	O
including	O
persons	B-Species
who	O
had	O
cataract	O
surgery	O
)	O
,	O
however	O
,	O
was	O
relatively	O
stable	O
(	O
46	O
.	O
9	O
%	O
and	O
46	O
.	O
8	O
%	O
in	O
cross	O
-	O
sections	O
I	O
and	O
II	O
,	O
respectively	O
)	O
.	O

After	O
age	O
-	O
standardization	O
,	O
these	O
prevalence	O
rates	O
remained	O
stable	O
for	O
cortical	O
cataract	O
(	O
23	O
.	O
8	O
%	O
and	O
23	O
.	O
5	O
%	O
in	O
the	O
two	O
surveys	O
)	O
and	O
PSC	O
(	O
6	O
.	O
3	O
%	O
and	O
5	O
.	O
9	O
%	O
)	O
.	O

The	O
slightly	O
increased	O
prevalence	O
of	O
nuclear	O
cataract	O
(	O
from	O
18	O
.	O
7	O
%	O
to	O
24	O
.	O
2	O
%	O
)	O
was	O
not	O
altered	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
compare	B-X
age-specific	B-X
cortical	B-X
,	B-X
nuclear	B-X
and	B-X
posterior	B-X
subcapsular	B-X
(	B-X
PSC	B-X
)	B-X
cataract	B-X
prevalence	B-X
in	B-X
two	B-X
surveys	B-X
6	B-X
years	B-X
apart	B-X
.	B-X

Table	O
2	O
shows	O
the	O
age	O
-	O
specific	O
prevalence	O
rates	O
for	O
cortical	O
cataract	O
,	O
PSC	O
and	O
nuclear	O
cataract	O
in	O
cross	O
-	O
sections	O
I	O
and	O
II	O
.	O

A	O
similar	O
trend	O
of	O
increasing	O
cataract	O
prevalence	O
with	O
increasing	O
age	O
was	O
evident	O
for	O
all	O
three	O
types	O
of	O
cataract	O
in	O
both	O
surveys	O
.	O

Comparing	O
the	O
age	O
-	O
specific	O
prevalence	O
between	O
the	O
two	O
surveys	O
,	O
a	O
reduction	O
in	O
PSC	O
prevalence	O
in	O
cross	O
-	O
section	O
II	O
was	O
observed	O
in	O
the	O
older	O
age	O
groups	O
(	O
>=	O
75	O
years	O
)	O
.	O

In	O
contrast	O
,	O
increased	O
nuclear	O
cataract	O
prevalence	O
in	O
cross	O
-	O
section	O
II	O
was	O
observed	O
in	O
the	O
older	O
age	O
groups	O
(	O
>=	O
70	O
years	O
)	O
.	O

Age	O
-	O
specific	O
cortical	O
cataract	O
prevalence	O
was	O
relatively	O
consistent	O
between	O
the	O
two	O
surveys	O
,	O
except	O
for	O
a	O
reduction	O
in	O
prevalence	O
observed	O
in	O
the	O
80	O
-	O
84	O
age	O
group	O
and	O
an	O
increasing	O
prevalence	O
in	O
the	O
older	O
age	O
groups	O
(	O
>=	O
85	O
years	O
)	O
.	O

Similar	O
gender	O
differences	O
in	O
cataract	O
prevalence	O
were	O
observed	O
in	O
both	O
surveys	O
(	O
Table	O
3	O
)	O
.	O

Higher	O
prevalence	O
of	O
cortical	O
and	O
nuclear	O
cataract	O
in	O
women	B-Species
than	O
men	B-Species
was	O
evident	O
but	O
the	O
difference	O
was	O
only	O
significant	O
for	O
cortical	O
cataract	O
(	O
age	O
-	O
adjusted	O
odds	O
ratio	O
,	O
OR	O
,	O
for	O
women	B-Species
1	O
.	O
3	O
,	O
95	O
%	O
confidence	O
intervals	O
,	O
CI	O
,	O
1	O
.	O
1	O
-	O
1	O
.	O
5	O
in	O
cross	O
-	O
section	O
I	O
and	O
OR	O
1	O
.	O
4	O
,	O
95	O
%	O
CI	O
1	O
.	O
1	O
-	O
1	O
.	O
6	O
in	O
cross	O
-	O
section	O
II	O
)	O
.	O

In	O
contrast	O
,	O
men	B-Species
had	O
slightly	O
higher	O
PSC	O
prevalence	O
than	O
women	B-Species
in	O
both	O
cross	O
-	O
sections	O
but	O
the	O
difference	O
was	O
not	O
significant	O
(	O
OR	O
1	O
.	O
1	O
,	O
95	O
%	O
CI	O
0	O
.	O
8	O
-	O
1	O
.	O
4	O
for	O
men	B-Species
in	O
cross	O
-	O
section	O
I	O
and	O
OR	O
1	O
.	O
2	O
,	O
95	O
%	O
0	O
.	O
9	O
-	O
1	O
.	O
6	O
in	O
cross	O
-	O
section	O
II	O
)	O
.	O

Discussion	O
<EOS>	B-X
Discussion	B-X
structures	B-X
are	B-X
argumentation-theoretical	B-X
tools	B-X
that	B-X
can	B-X
be	B-X
employed	B-X
to	B-X
tackle	B-X
three	B-X
barriers	B-X
that	B-X
separate	B-X
lay	B-X
stakeholders	B-X
from	B-X
policy	B-X
debates	B-X
:	B-X
difficulty	B-X
,	B-X
magnitude	B-X
,	B-X
and	B-X
complexity	B-X
.	B-X
Discussions	B-X
about	B-X
preventive	B-X
behaviors	B-X
were	B-X
assessed	B-X
before	B-X
testing	B-X
and	B-X
1	B-X
and	B-X
6	B-X
months	B-X
post-testing	B-X
.	B-X
Discussion	B-X
of	B-X
preventive	B-X
behaviors	B-X
declined	B-X
following	B-X
test	B-X
reporting	B-X
,	B-X
with	B-X
more	B-X
rapid	B-X
decline	B-X
reported	B-X
by	B-X
noncarriers	B-X
.	B-X
Discussions	B-X
are	B-X
an	B-X
important	B-X
part	B-X
of	B-X
medical	B-X
education	B-X
research	B-X
papers	B-X
,	B-X
but	B-X
there	B-X
is	B-X
little	B-X
guidance	B-X
on	B-X
how	B-X
to	B-X
write	B-X
up	B-X
the	B-X
discussion	B-X
section	B-X
.	B-X

Findings	O
from	O
two	O
surveys	O
of	O
BMES	O
cross	O
-	O
sectional	O
populations	O
with	O
similar	O
age	O
and	O
gender	O
distribution	O
showed	O
that	O
the	O
prevalence	O
of	O
cortical	O
cataract	O
and	O
PSC	O
remained	O
stable	O
,	O
while	O
the	O
prevalence	O
of	O
nuclear	O
cataract	O
appeared	O
to	O
have	O
increased	O
.	O

Comparison	O
of	O
age	O
-	O
specific	O
prevalence	O
,	O
with	O
totally	O
independent	O
samples	O
within	O
each	O
age	O
group	O
,	O
confirmed	O
the	O
robustness	O
of	O
our	O
findings	O
from	O
the	O
two	O
survey	O
samples	O
.	O
<EOS>	B-X
Our	B-X
paper	B-X
had	B-X
the	B-X
objective	B-X
of	B-X
providing	B-X
a	B-X
pooled	B-X
effect	B-X
size	B-X
of	B-X
suicide	B-X
for	B-X
this	B-X
occupational	B-X
group	B-X
.	B-X
No	B-X
review	B-X
,	B-X
whether	B-X
searching	B-X
one	B-X
or	B-X
more	B-X
databases	B-X
,	B-X
can	B-X
expect	B-X
to	B-X
be	B-X
totally	B-X
exhaustive	B-X
.	B-X
Second	B-X
,	B-X
as	B-X
suggested	B-X
by	B-X
Rothman	B-X
et	B-X
al	B-X
(	B-X
7	B-X
)	B-X
,	B-X
quality	B-X
assessment	B-X
was	B-X
replaced	B-X
by	B-X
regression	B-X
analyses	B-X
of	B-X
the	B-X
effect	B-X
of	B-X
each	B-X
quality	B-X
item	B-X
(	B-X
study	B-X
characteristics	B-X
,	B-X
ie	B-X
,	B-X
study	B-X
design	B-X
,	B-X
effect	B-X
measure	B-X
,	B-X
reference	B-X
group	B-X
,	B-X
and	B-X
adjustment	B-X
)	B-X
.	B-X
Consequently	B-X
,	B-X
many	B-X
of	B-X
the	B-X
items	B-X
related	B-X
to	B-X
quality	B-X
were	B-X
not	B-X
pertinent	B-X
,	B-X
such	B-X
as	B-X
response	B-X
and	B-X
follow-up	B-X
rates	B-X
,	B-X
coverage	B-X
and	B-X
representativeness	B-X
of	B-X
the	B-X
sample	B-X
,	B-X
selection	B-X
,	B-X
etc	B-X
.	B-X
For	B-X
example	B-X
,	B-X
we	B-X
excluded	B-X
five	B-X
studies	B-X
including	B-X
three	B-X
prospective	B-X
and	B-X
case-control	B-X
studies	B-X
in	B-X
the	B-X
sensibility	B-X
analysis	B-X
because	B-X
the	B-X
group	B-X
of	B-X
interest	B-X
was	B-X
defined	B-X
on	B-X
the	B-X
basis	B-X
of	B-X
the	B-X
exposure	B-X
to	B-X
chemicals	B-X
(	B-X
pesticides	B-X
)	B-X
rather	B-X
than	B-X
job	B-X
title	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
as	B-X
the	B-X
objective	B-X
was	B-X
above	B-X
all	B-X
descriptive	B-X
and	B-X
not	B-X
etiological	B-X
or	B-X
explanatory	B-X
,	B-X
and	B-X
as	B-X
it	B-X
is	B-X
the	B-X
norm	B-X
in	B-X
the	B-X
exploration	B-X
of	B-X
social	B-X
inequalities	B-X
in	B-X
health	B-X
(	B-X
8	B-X
)	B-X
,	B-X
the	B-X
results	B-X
from	B-X
the	B-X
least	B-X
(	B-X
gender-	B-X
and	B-X
age-	B-X
)	B-X
adjusted	B-X
models	B-X
were	B-X
in	B-X
line	B-X
with	B-X
the	B-X
objective	B-X
.	B-X
Indeed	B-X
,	B-X
the	B-X
study	B-X
of	B-X
the	B-X
contribution	B-X
of	B-X
underlying	B-X
factors	B-X
in	B-X
explaining	B-X
social	B-X
inequalities	B-X
in	B-X
health	B-X
outcomes	B-X
is	B-X
a	B-X
fully-fledged	B-X
topic	B-X
of	B-X
research	B-X
(	B-X
12-15	B-X
)	B-X
,	B-X
but	B-X
this	B-X
is	B-X
relevant	B-X
research	B-X
to	B-X
conduct	B-X
after	B-X
demonstrating	B-X
that	B-X
inequalities	B-X
exist	B-X
between	B-X
social	B-X
or	B-X
occupational	B-X
groups	B-X
.	B-X
Second	B-X
,	B-X
our	B-X
subgroup	B-X
comparison	B-X
was	B-X
based	B-X
on	B-X
subsamples	B-X
that	B-X
were	B-X
independent	B-X
.	B-X
As	B-X
not	B-X
all	B-X
studies	B-X
provided	B-X
information	B-X
for	B-X
these	B-X
subgroups	B-X
,	B-X
each	B-X
subgroup	B-X
was	B-X
treated	B-X
as	B-X
a	B-X
unit	B-X
of	B-X
analysis	B-X
.	B-X
This	B-X
strategy	B-X
allows	B-X
the	B-X
use	B-X
of	B-X
all	B-X
relevant	B-X
subgroups	B-X
and	B-X
comparisons	B-X
between	B-X
them	B-X
(	B-X
16	B-X
)	B-X
.	B-X
We	B-X
also	B-X
assumed	B-X
differences	B-X
in	B-X
effect	B-X
size	B-X
between	B-X
studies	B-X
and	B-X
between	B-X
subgroups	B-X
,	B-X
and	B-X
the	B-X
use	B-X
of	B-X
random-effects	B-X
models	B-X
was	B-X
consistent	B-X
with	B-X
such	B-X
an	B-X
assumption	B-X
.	B-X
One	B-X
of	B-X
Shiri	B-X
's	B-X
comments	B-X
related	B-X
to	B-X
the	B-X
reference	B-X
group	B-X
used	B-X
in	B-X
the	B-X
studies	B-X
for	B-X
the	B-X
comparison	B-X
of	B-X
agricultural	B-X
,	B-X
forestry	B-X
,	B-X
and	B-X
fishery	B-X
workers	B-X
.	B-X
Although	B-X
we	B-X
reported	B-X
that	B-X
the	B-X
studies	B-X
using	B-X
a	B-X
specific	B-X
occupational	B-X
group	B-X
as	B-X
reference	B-X
group	B-X
provided	B-X
a	B-X
higher	B-X
effect	B-X
size	B-X
than	B-X
the	B-X
studies	B-X
using	B-X
other	B-X
reference	B-X
groups	B-X
,	B-X
we	B-X
did	B-X
not	B-X
explicitly	B-X
recognize	B-X
and	B-X
state	B-X
in	B-X
the	B-X
paper	B-X
that	B-X
the	B-X
results	B-X
for	B-X
Japan	B-X
were	B-X
based	B-X
on	B-X
two	B-X
studies	B-X
using	B-X
a	B-X
specific	B-X
occupational	B-X
group	B-X
as	B-X
reference	B-X
;	B-X
we	B-X
concede	B-X
that	B-X
this	B-X
may	B-X
explain	B-X
why	B-X
we	B-X
found	B-X
a	B-X
much	B-X
more	B-X
elevated	B-X
effect	B-X
size	B-X
for	B-X
Japan	B-X
.	B-X
Shiri	B-X
's	B-X
results	B-X
(	B-X
1	B-X
)	B-X
allow	B-X
to	B-X
conclude	B-X
that	B-X
the	B-X
difference	B-X
between	B-X
Japan	B-X
and	B-X
the	B-X
other	B-X
geographic	B-X
areas	B-X
could	B-X
be	B-X
explained	B-X
by	B-X
the	B-X
choice	B-X
of	B-X
reference	B-X
group-we	B-X
are	B-X
grateful	B-X
to	B-X
him	B-X
for	B-X
raising	B-X
this	B-X
point	B-X
.	B-X
However	B-X
,	B-X
we	B-X
would	B-X
note	B-X
that	B-X
the	B-X
effect	B-X
size	B-X
of	B-X
suicide	B-X
was	B-X
still	B-X
elevated	B-X
and	B-X
significant	B-X
for	B-X
agricultural	B-X
,	B-X
forestry	B-X
,	B-X
and	B-X
fishery	B-X
workers	B-X
even	B-X
after	B-X
this	B-X
change	B-X
in	B-X
the	B-X
reference	B-X
group	B-X
for	B-X
these	B-X
two	B-X
studies	B-X
.	B-X
Nevertheless	B-X
,	B-X
the	B-X
choice	B-X
of	B-X
the	B-X
optimal	B-X
reference	B-X
group	B-X
is	B-X
not	B-X
obvious	B-X
.	B-X
If	B-X
we	B-X
consider	B-X
the	B-X
general	B-X
population	B-X
as	B-X
the	B-X
reference	B-X
group	B-X
,	B-X
as	B-X
unemployed	B-X
people	B-X
and	B-X
economically	B-X
inactive	B-X
people	B-X
(	B-X
including	B-X
people	B-X
who	B-X
may	B-X
not	B-X
be	B-X
working	B-X
due	B-X
to	B-X
illness	B-X
or	B-X
disability	B-X
)	B-X
are	B-X
part	B-X
of	B-X
it	B-X
and	B-X
have	B-X
a	B-X
higher	B-X
risk	B-X
of	B-X
suicide	B-X
than	B-X
employed	B-X
people	B-X
,	B-X
the	B-X
effect	B-X
size	B-X
provided	B-X
by	B-X
the	B-X
nine	B-X
studies	B-X
using	B-X
the	B-X
general	B-X
population	B-X
as	B-X
the	B-X
reference	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
underestimated	B-X
,	B-X
which	B-X
may	B-X
contribute	B-X
to	B-X
an	B-X
underestimation	B-X
of	B-X
the	B-X
observed	B-X
effect	B-X
size	B-X
of	B-X
suicide	B-X
among	B-X
agricultural	B-X
,	B-X
forestry	B-X
,	B-X
and	B-X
fishery	B-X
workers	B-X
in	B-X
our	B-X
study	B-X
.	B-X
The	B-X
comparison	B-X
was	B-X
made	B-X
in	B-X
our	B-X
paper	B-X
with	B-X
the	B-X
other	B-X
occupational	B-X
groups	B-X
(	B-X
ie	B-X
,	B-X
the	B-X
working	B-X
population	B-X
except	B-X
the	B-X
group	B-X
of	B-X
interest	B-X
)	B-X
as	B-X
the	B-X
reference	B-X
,	B-X
which	B-X
was	B-X
used	B-X
by	B-X
nine	B-X
other	B-X
studies	B-X
,	B-X
but	B-X
this	B-X
did	B-X
not	B-X
allow	B-X
to	B-X
determine	B-X
the	B-X
exact	B-X
rank	B-X
of	B-X
the	B-X
group	B-X
of	B-X
interest	B-X
in	B-X
the	B-X
occupational	B-X
hierarchy	B-X
.	B-X
Another	B-X
relevant	B-X
choice	B-X
would	B-X
have	B-X
been	B-X
to	B-X
retain	B-X
the	B-X
group	B-X
with	B-X
the	B-X
lowest	B-X
suicide	B-X
risk	B-X
(	B-X
for	B-X
example	B-X
,	B-X
the	B-X
high-skilled	B-X
occupational	B-X
group	B-X
)	B-X
as	B-X
the	B-X
reference	B-X
,	B-X
which	B-X
would	B-X
have	B-X
led	B-X
to	B-X
a	B-X
much	B-X
higher	B-X
effect	B-X
size	B-X
of	B-X
suicide	B-X
for	B-X
agricultural	B-X
,	B-X
forestry	B-X
,	B-X
and	B-X
fishery	B-X
workers	B-X
.	B-X
To	B-X
conclude	B-X
,	B-X
as	B-X
statistical	B-X
power	B-X
in	B-X
detecting	B-X
differences	B-X
between	B-X
subgroups	B-X
may	B-X
be	B-X
low	B-X
in	B-X
subgroup	B-X
analyses	B-X
and	B-X
meta-regression	B-X
,	B-X
the	B-X
absence	B-X
of	B-X
significant	B-X
results	B-X
according	B-X
to	B-X
subgroups	B-X
found	B-X
in	B-X
our	B-X
results	B-X
can	B-X
not	B-X
be	B-X
interpreted	B-X
as	B-X
evidence	B-X
that	B-X
the	B-X
effect	B-X
size	B-X
is	B-X
the	B-X
same	B-X
across	B-X
subgroups	B-X
.	B-X
Consequently	B-X
,	B-X
our	B-X
meta-analysis	B-X
reporting	B-X
a	B-X
significant	B-X
excess	B-X
of	B-X
risk	B-X
of	B-X
suicide	B-X
among	B-X
agricultural	B-X
,	B-X
forestry	B-X
,	B-X
and	B-X
fishery	B-X
workers	B-X
may	B-X
also	B-X
be	B-X
a	B-X
good	B-X
incentive	B-X
for	B-X
more	B-X
research	B-X
among	B-X
this	B-X
group	B-X
of	B-X
workers	B-X
to	B-X
(	B-X
i	B-X
)	B-X
confirm	B-X
this	B-X
observed	B-X
excess	B-X
of	B-X
risk	B-X
using	B-X
differing	B-X
methodological	B-X
approaches	B-X
to	B-X
meta-analysis	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
explore	B-X
the	B-X
potential	B-X
differences	B-X
within	B-X
this	B-X
group	B-X
and	B-X
the	B-X
underlying	B-X
factors	B-X
that	B-X
may	B-X
explain	B-X
this	B-X
excess	B-X
of	B-X
risk	B-X
.	B-X
Milner	B-X
A	B-X
,	B-X
Page	B-X
A	B-X
,	B-X
LaMontagne	B-X
AD	B-X
.	B-X
Economically	B-X
inactive	B-X
,	B-X
unemployed	B-X
and	B-X
employed	B-X
suicides	B-X
in	B-X
Australia	B-X
by	B-X
age	B-X
and	B-X
sex	B-X
over	B-X
a	B-X
10-year	B-X
period	B-X
:	B-X
what	B-X
was	B-X
the	B-X
impact	B-X
of	B-X
the	B-X
2007	B-X
economic	B-X
recession	B-X
?	B-X
Niedhammer	B-X
I	B-X
,	B-X
Chastang	B-X
JF	B-X
,	B-X
David	B-X
S	B-X
,	B-X
Kelleher	B-X
C.	B-X
The	B-X
contribution	B-X
of	B-X
occupational	B-X
factors	B-X
to	B-X
social	B-X
inequalities	B-X
in	B-X
health	B-X
:	B-X
findings	B-X
from	B-X
the	B-X
national	B-X
French	B-X
SUMER	B-X
survey	B-X
.	B-X
Contribution	B-X
of	B-X
working	B-X
conditions	B-X
to	B-X
occupational	B-X
inequalities	B-X
in	B-X
depressive	B-X
symptoms	B-X
:	B-X
results	B-X
from	B-X
the	B-X
national	B-X
French	B-X
SUMER	B-X
survey	B-X
.	B-X

Although	O
lens	O
photographs	O
taken	O
from	O
the	O
two	O
surveys	O
were	O
graded	O
for	O
nuclear	O
cataract	O
by	O
the	O
same	O
graders	O
,	O
who	O
documented	O
a	O
high	O
inter	O
-	O
and	O
intra	O
-	O
grader	O
reliability	O
,	O
we	O
cannot	O
exclude	O
the	O
possibility	O
that	O
variations	O
in	O
photography	O
,	O
performed	O
by	O
different	O
photographers	O
,	O
may	O
have	O
contributed	O
to	O
the	O
observed	O
difference	O
in	O
nuclear	O
cataract	O
prevalence	O
.	O

However	O
,	O
the	O
overall	O
prevalence	O
of	O
any	O
cataract	O
(	O
including	O
cataract	O
surgery	O
)	O
was	O
relatively	O
stable	O
over	O
the	O
6	O
-	O
year	O
period	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
compare	B-X
age-specific	B-X
cortical	B-X
,	B-X
nuclear	B-X
and	B-X
posterior	B-X
subcapsular	B-X
(	B-X
PSC	B-X
)	B-X
cataract	B-X
prevalence	B-X
in	B-X
two	B-X
surveys	B-X
6	B-X
years	B-X
apart	B-X
.	B-X

Although	O
different	O
population	O
-	O
based	O
studies	O
used	O
different	O
grading	O
systems	O
to	O
assess	O
cataract	O
[	O
15	O
]	O
,	O
the	O
overall	O
prevalence	O
of	O
the	O
three	O
cataract	O
types	O
were	O
similar	O
across	O
different	O
study	O
populations	O
[	O
12	O
,	O
16	O
-	O
23	O
]	O
.	O

Most	O
studies	O
have	O
suggested	O
that	O
nuclear	O
cataract	O
is	O
the	O
most	O
prevalent	O
type	O
of	O
cataract	O
,	O
followed	O
by	O
cortical	O
cataract	O
[	O
16	O
-	O
20	O
]	O
.	O
<EOS>	B-X
To	B-X
evaluate	B-X
the	B-X
most	B-X
common	B-X
lens	B-X
opacities	B-X
in	B-X
Valencia	B-X
(	B-X
Spain	B-X
)	B-X
,	B-X
analyzed	B-X
by	B-X
gender	B-X
,	B-X
grade	B-X
,	B-X
and	B-X
type	B-X
of	B-X
cataracts	B-X
.	B-X
The	B-X
results	B-X
are	B-X
compared	B-X
with	B-X
other	B-X
studies	B-X
performed	B-X
at	B-X
other	B-X
geographical	B-X
latitudes	B-X
and	B-X
on	B-X
different	B-X
races	B-X
.	B-X
This	B-X
study	B-X
is	B-X
the	B-X
first	B-X
to	B-X
report	B-X
cataract	B-X
type	B-X
specific	B-X
risks	B-X
in	B-X
a	B-X
cohort	B-X
of	B-X
Russian	B-X
Mayak	B-X
Production	B-X
Association	B-X
workers	B-X
following	B-X
chronic	B-X
occupational	B-X
exposure	B-X
to	B-X
ionizing	B-X
radiation	B-X
.	B-X
In	B-X
this	B-X
retrospective	B-X
cohort	B-X
study	B-X
,	B-X
22,377	B-X
workers	B-X
(	B-X
females	B-X
25.4	B-X
%	B-X
)	B-X
first	B-X
employed	B-X
in	B-X
1948-1982	B-X
were	B-X
followed	B-X
up	B-X
till	B-X
the	B-X
end	B-X
of	B-X
2008	B-X
.	B-X
All	B-X
cataract	B-X
subtypes	B-X
were	B-X
significantly	B-X
dependent	B-X
on	B-X
sex	B-X
,	B-X
attained	B-X
age	B-X
,	B-X
diabetes	B-X
mellitus	B-X
,	B-X
myopia	B-X
and	B-X
glaucoma	B-X
.	B-X
For	B-X
each	B-X
of	B-X
posterior	B-X
subcapsular	B-X
(	B-X
PSC	B-X
)	B-X
,	B-X
cortical	B-X
and	B-X
nuclear	B-X
cataracts	B-X
,	B-X
the	B-X
risk	B-X
of	B-X
cataract	B-X
incidence	B-X
significantly	B-X
linearly	B-X
increased	B-X
with	B-X
increasing	B-X
radiation	B-X
dose	B-X
.	B-X
Excess	B-X
relative	B-X
risk	B-X
per	B-X
unit	B-X
effective	B-X
dose	B-X
(	B-X
ERR/Sv	B-X
)	B-X
from	B-X
external	B-X
Î³-rays	B-X
based	B-X
on	B-X
the	B-X
linear	B-X
model	B-X
was	B-X
0.91	B-X
[	B-X
95	B-X
%	B-X
confidence	B-X
intervals	B-X
(	B-X
CIs	B-X
)	B-X
0.67	B-X
,	B-X
1.20	B-X
]	B-X
for	B-X
PSC	B-X
,	B-X
0.63	B-X
(	B-X
95	B-X
%	B-X
CIs	B-X
0.49	B-X
,	B-X
0.76	B-X
)	B-X
for	B-X
cortical	B-X
,	B-X
and	B-X
0.47	B-X
(	B-X
95	B-X
%	B-X
CIs	B-X
0.35	B-X
,	B-X
0.60	B-X
)	B-X
for	B-X
nuclear	B-X
cataracts	B-X
.	B-X
For	B-X
all	B-X
three	B-X
types	B-X
of	B-X
cataracts	B-X
,	B-X
exclusion	B-X
of	B-X
an	B-X
adjustment	B-X
for	B-X
neutron	B-X
dose	B-X
as	B-X
well	B-X
as	B-X
inclusion	B-X
of	B-X
additional	B-X
adjustments	B-X
for	B-X
body	B-X
mass	B-X
index	B-X
and	B-X
smoking	B-X
index	B-X
decreased	B-X
ERR/Sv	B-X
of	B-X
external	B-X
Î³-rays	B-X
.	B-X
Inclusion	B-X
of	B-X
an	B-X
additional	B-X
adjustment	B-X
for	B-X
glaucoma	B-X
,	B-X
however	B-X
,	B-X
modestly	B-X
increased	B-X
incidence	B-X
risks	B-X
for	B-X
cortical	B-X
and	B-X
nuclear	B-X
cataracts	B-X
,	B-X
but	B-X
not	B-X
PSC	B-X
cataracts	B-X
.	B-X
Both	B-X
males	B-X
and	B-X
females	B-X
had	B-X
increased	B-X
risks	B-X
for	B-X
all	B-X
three	B-X
types	B-X
of	B-X
cataracts	B-X
,	B-X
but	B-X
ERR/Sv	B-X
was	B-X
significantly	B-X
higher	B-X
in	B-X
females	B-X
than	B-X
in	B-X
males	B-X
(	B-X
p	B-X
<	B-X
0.001	B-X
)	B-X
,	B-X
particularly	B-X
for	B-X
PSC	B-X
cataracts	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
chronic	B-X
occupational	B-X
radiation	B-X
exposure	B-X
significantly	B-X
increases	B-X
risks	B-X
of	B-X
PSC	B-X
,	B-X
cortical	B-X
and	B-X
nuclear	B-X
cataracts	B-X
,	B-X
and	B-X
that	B-X
such	B-X
risks	B-X
are	B-X
higher	B-X
in	B-X
females	B-X
than	B-X
in	B-X
males	B-X
.	B-X

Ours	O
and	O
other	O
studies	O
reported	O
that	O
cortical	O
cataract	O
was	O
the	O
most	O
prevalent	O
type	O
[	O
12	O
,	O
21	O
-	O
23	O
]	O
.	O

Our	O
age	O
-	O
specific	O
prevalence	O
data	O
show	O
a	O
reduction	O
of	O
15	O
.	O
9	O
%	O
in	O
cortical	O
cataract	O
prevalence	O
for	O
the	O
80	O
-	O
84	O
year	O
age	O
group	O
,	O
concordant	O
with	O
an	O
increase	O
in	O
cataract	O
surgery	O
prevalence	O
by	O
9	O
%	O
in	O
those	O
aged	O
80	O
+	O
years	O
observed	O
in	O
the	O
same	O
study	O
population	O
[	O
10	O
]	O
.	O

Although	O
cortical	O
cataract	O
is	O
thought	O
to	O
be	O
the	O
least	O
likely	O
cataract	O
type	O
leading	O
to	O
a	O
cataract	O
surgery	O
,	O
this	O
may	O
not	O
be	O
the	O
case	O
in	O
all	O
older	O
persons	B-Species
.	O

A	O
relatively	O
stable	O
cortical	O
cataract	O
and	O
PSC	O
prevalence	O
over	O
the	O
6	O
-	O
year	O
period	O
is	O
expected	O
.	O

We	O
cannot	O
offer	O
a	O
definitive	O
explanation	O
for	O
the	O
increase	O
in	O
nuclear	O
cataract	O
prevalence	O
.	O

A	O
possible	O
explanation	O
could	O
be	O
that	O
a	O
moderate	O
level	O
of	O
nuclear	O
cataract	O
causes	O
less	O
visual	O
disturbance	O
than	O
the	O
other	O
two	O
types	O
of	O
cataract	O
,	O
thus	O
for	O
the	O
oldest	O
age	O
groups	O
,	O
persons	B-Species
with	O
nuclear	O
cataract	O
could	O
have	O
been	O
less	O
likely	O
to	O
have	O
surgery	O
unless	O
it	O
is	O
very	O
dense	O
or	O
co	O
-	O
existing	O
with	O
cortical	O
cataract	O
or	O
PSC	O
.	O
<EOS>	B-X
The	B-X
current	B-X
knowledge	B-X
about	B-X
patient	B-X
safety	B-X
culture	B-X
(	B-X
PSC	B-X
)	B-X
in	B-X
the	B-X
healthcare	B-X
industry	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
research	B-X
tools	B-X
that	B-X
have	B-X
been	B-X
used	B-X
to	B-X
evaluate	B-X
PSC	B-X
in	B-X
hospitals	B-X
,	B-X
is	B-X
limited	B-X
.	B-X
This	B-X
study	B-X
provides	B-X
a	B-X
systematic	B-X
review	B-X
of	B-X
published	B-X
research	B-X
on	B-X
the	B-X
perception	B-X
of	B-X
PSC	B-X
in	B-X
hospitals	B-X
.	B-X
The	B-X
research	B-X
methods	B-X
used	B-X
to	B-X
survey	B-X
and	B-X
evaluate	B-X
PSC	B-X
in	B-X
healthcare	B-X
settings	B-X
are	B-X
also	B-X
explored	B-X
.	B-X
A	B-X
list	B-X
of	B-X
academic	B-X
databases	B-X
was	B-X
searched	B-X
from	B-X
2006	B-X
to	B-X
2020	B-X
to	B-X
form	B-X
a	B-X
comprehensive	B-X
view	B-X
of	B-X
PSC	B-X
's	B-X
current	B-X
applications	B-X
.	B-X
The	B-X
following	B-X
research	B-X
instruments	B-X
have	B-X
been	B-X
applied	B-X
in	B-X
the	B-X
past	B-X
to	B-X
assess	B-X
PSC	B-X
:	B-X
the	B-X
Hospital	B-X
Survey	B-X
on	B-X
Patient	B-X
Safety	B-X
Culture	B-X
(	B-X
HSPSC	B-X
)	B-X
,	B-X
the	B-X
Safety	B-X
Attitudes	B-X
Questionnaire	B-X
(	B-X
SAQ	B-X
)	B-X
,	B-X
the	B-X
Patient	B-X
Safety	B-X
Climate	B-X
in	B-X
Health	B-X
Care	B-X
Organizations	B-X
(	B-X
PSCHO	B-X
)	B-X
,	B-X
the	B-X
Modified	B-X
Stanford	B-X
Instrument	B-X
(	B-X
MSI-2006	B-X
)	B-X
,	B-X
and	B-X
the	B-X
Scottish	B-X
Hospital	B-X
Safety	B-X
Questionnaire	B-X
(	B-X
SHSQ	B-X
)	B-X
.	B-X
Some	B-X
of	B-X
the	B-X
most	B-X
critical	B-X
factors	B-X
that	B-X
impact	B-X
the	B-X
PSC	B-X
are	B-X
teamwork	B-X
and	B-X
organizational	B-X
and	B-X
behavioral	B-X
learning	B-X
.	B-X
Reporting	B-X
errors	B-X
and	B-X
safety	B-X
awareness	B-X
,	B-X
gender	B-X
and	B-X
demographics	B-X
,	B-X
work	B-X
experience	B-X
,	B-X
and	B-X
staffing	B-X
levels	B-X
have	B-X
also	B-X
been	B-X
identified	B-X
as	B-X
essential	B-X
factors	B-X
.	B-X
Therefore	B-X
,	B-X
these	B-X
factors	B-X
will	B-X
need	B-X
to	B-X
be	B-X
considered	B-X
in	B-X
future	B-X
work	B-X
to	B-X
improve	B-X
PSC	B-X
.	B-X

Previous	O
studies	O
have	O
shown	O
that	O
functional	O
vision	O
and	O
reading	O
performance	O
were	O
high	O
in	O
patients	B-Species
undergoing	O
cataract	O
surgery	O
who	O
had	O
nuclear	O
cataract	O
only	O
compared	O
to	O
those	O
with	O
mixed	O
type	O
of	O
cataract	O
(	O
nuclear	O
and	O
cortical	O
)	O
or	O
PSC	O
[	O
24	O
,	O
25	O
]	O
.	O
<EOS>	B-X
The	B-X
current	B-X
knowledge	B-X
about	B-X
patient	B-X
safety	B-X
culture	B-X
(	B-X
PSC	B-X
)	B-X
in	B-X
the	B-X
healthcare	B-X
industry	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
research	B-X
tools	B-X
that	B-X
have	B-X
been	B-X
used	B-X
to	B-X
evaluate	B-X
PSC	B-X
in	B-X
hospitals	B-X
,	B-X
is	B-X
limited	B-X
.	B-X
This	B-X
study	B-X
provides	B-X
a	B-X
systematic	B-X
review	B-X
of	B-X
published	B-X
research	B-X
on	B-X
the	B-X
perception	B-X
of	B-X
PSC	B-X
in	B-X
hospitals	B-X
.	B-X
The	B-X
research	B-X
methods	B-X
used	B-X
to	B-X
survey	B-X
and	B-X
evaluate	B-X
PSC	B-X
in	B-X
healthcare	B-X
settings	B-X
are	B-X
also	B-X
explored	B-X
.	B-X
A	B-X
list	B-X
of	B-X
academic	B-X
databases	B-X
was	B-X
searched	B-X
from	B-X
2006	B-X
to	B-X
2020	B-X
to	B-X
form	B-X
a	B-X
comprehensive	B-X
view	B-X
of	B-X
PSC	B-X
's	B-X
current	B-X
applications	B-X
.	B-X
The	B-X
following	B-X
research	B-X
instruments	B-X
have	B-X
been	B-X
applied	B-X
in	B-X
the	B-X
past	B-X
to	B-X
assess	B-X
PSC	B-X
:	B-X
the	B-X
Hospital	B-X
Survey	B-X
on	B-X
Patient	B-X
Safety	B-X
Culture	B-X
(	B-X
HSPSC	B-X
)	B-X
,	B-X
the	B-X
Safety	B-X
Attitudes	B-X
Questionnaire	B-X
(	B-X
SAQ	B-X
)	B-X
,	B-X
the	B-X
Patient	B-X
Safety	B-X
Climate	B-X
in	B-X
Health	B-X
Care	B-X
Organizations	B-X
(	B-X
PSCHO	B-X
)	B-X
,	B-X
the	B-X
Modified	B-X
Stanford	B-X
Instrument	B-X
(	B-X
MSI-2006	B-X
)	B-X
,	B-X
and	B-X
the	B-X
Scottish	B-X
Hospital	B-X
Safety	B-X
Questionnaire	B-X
(	B-X
SHSQ	B-X
)	B-X
.	B-X
Some	B-X
of	B-X
the	B-X
most	B-X
critical	B-X
factors	B-X
that	B-X
impact	B-X
the	B-X
PSC	B-X
are	B-X
teamwork	B-X
and	B-X
organizational	B-X
and	B-X
behavioral	B-X
learning	B-X
.	B-X
Therefore	B-X
,	B-X
these	B-X
factors	B-X
will	B-X
need	B-X
to	B-X
be	B-X
considered	B-X
in	B-X
future	B-X
work	B-X
to	B-X
improve	B-X
PSC	B-X
.	B-X

In	O
addition	O
,	O
the	O
overall	O
prevalence	O
of	O
any	O
cataract	O
(	O
including	O
cataract	O
surgery	O
)	O
was	O
similar	O
in	O
the	O
two	O
cross	O
-	O
sections	O
,	O
which	O
appears	O
to	O
support	O
our	O
speculation	O
that	O
in	O
the	O
oldest	O
age	O
group	O
,	O
nuclear	O
cataract	O
may	O
have	O
been	O
less	O
likely	O
to	O
be	O
operated	O
than	O
the	O
other	O
two	O
types	O
of	O
cataract	O
.	O

This	O
could	O
have	O
resulted	O
in	O
an	O
increased	O
nuclear	O
cataract	O
prevalence	O
(	O
due	O
to	O
less	O
being	O
operated	O
)	O
,	O
compensated	O
by	O
the	O
decreased	O
prevalence	O
of	O
cortical	O
cataract	O
and	O
PSC	O
(	O
due	O
to	O
these	O
being	O
more	O
likely	O
to	O
be	O
operated	O
)	O
,	O
leading	O
to	O
stable	O
overall	O
prevalence	O
of	O
any	O
cataract	O
.	O

Possible	O
selection	O
bias	O
arising	O
from	O
selective	O
survival	O
among	O
persons	B-Species
without	O
cataract	O
could	O
have	O
led	O
to	O
underestimation	O
of	O
cataract	O
prevalence	O
in	O
both	O
surveys	O
.	O

We	O
assume	O
that	O
such	O
an	O
underestimation	O
occurred	O
equally	O
in	O
both	O
surveys	O
,	O
and	O
thus	O
should	O
not	O
have	O
influenced	O
our	O
assessment	O
of	O
temporal	O
changes	O
.	O

Measurement	O
error	O
could	O
also	O
have	O
partially	O
contributed	O
to	O
the	O
observed	O
difference	O
in	O
nuclear	O
cataract	O
prevalence	O
.	O

Assessment	O
of	O
nuclear	O
cataract	O
from	O
photographs	O
is	O
a	O
potentially	O
subjective	O
process	O
that	O
can	O
be	O
influenced	O
by	O
variations	O
in	O
photography	O
(	O
light	O
exposure	O
,	O
focus	O
and	O
the	O
slit	O
-	O
lamp	O
angle	O
when	O
the	O
photograph	O
was	O
taken	O
)	O
and	O
grading	O
.	O

Although	O
we	O
used	O
the	O
same	O
Topcon	O
slit	O
-	O
lamp	O
camera	O
and	O
the	O
same	O
two	O
graders	O
who	O
graded	O
photos	O
from	O
both	O
surveys	O
,	O
we	O
are	O
still	O
not	O
able	O
to	O
exclude	O
the	O
possibility	O
of	O
a	O
partial	O
influence	O
from	O
photographic	O
variation	O
on	O
this	O
result	O
.	O

A	O
similar	O
gender	O
difference	O
(	O
women	B-Species
having	O
a	O
higher	O
rate	O
than	O
men	B-Species
)	O
in	O
cortical	O
cataract	O
prevalence	O
was	O
observed	O
in	O
both	O
surveys	O
.	O

Our	O
findings	O
are	O
in	O
keeping	O
with	O
observations	O
from	O
the	O
Beaver	O
Dam	O
Eye	O
Study	O
[	O
18	O
]	O
,	O
the	O
Barbados	O
Eye	O
Study	O
[	O
22	O
]	O
and	O
the	O
Lens	O
Opacities	O
Case	O
-	O
Control	O
Group	O
[	O
26	O
]	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
difference	O
could	O
be	O
related	O
to	O
hormonal	O
factors	O
[	O
18	O
,	O
22	O
]	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
ageing-induced	B-X
effects	B-X
are	B-X
difficult	B-X
to	B-X
disentangle	B-X
from	B-X
the	B-X
influence	B-X
of	B-X
other	B-X
factors	B-X
that	B-X
are	B-X
common	B-X
in	B-X
older	B-X
people	B-X
,	B-X
such	B-X
as	B-X
chronic	B-X
diseases	B-X
,	B-X
inflammation	B-X
,	B-X
and	B-X
low	B-X
nutritional	B-X
status	B-X
,	B-X
all	B-X
of	B-X
which	B-X
can	B-X
also	B-X
affect	B-X
endocrine	B-X
systems	B-X
.	B-X
Traditionally	B-X
,	B-X
the	B-X
decrease	B-X
in	B-X
hormone	B-X
activity	B-X
during	B-X
the	B-X
ageing	B-X
process	B-X
has	B-X
been	B-X
considered	B-X
to	B-X
be	B-X
detrimental	B-X
because	B-X
of	B-X
the	B-X
related	B-X
decline	B-X
in	B-X
bodily	B-X
functions	B-X
.	B-X
The	B-X
concept	B-X
of	B-X
hormone	B-X
replacement	B-X
therapy	B-X
was	B-X
suggested	B-X
as	B-X
a	B-X
therapeutic	B-X
intervention	B-X
to	B-X
stop	B-X
or	B-X
reverse	B-X
this	B-X
decline	B-X
.	B-X
However	B-X
,	B-X
clearly	B-X
some	B-X
of	B-X
these	B-X
changes	B-X
are	B-X
a	B-X
beneficial	B-X
adaptation	B-X
to	B-X
ageing	B-X
,	B-X
whereas	B-X
hormonal	B-X
intervention	B-X
often	B-X
causes	B-X
important	B-X
adverse	B-X
effects	B-X
.	B-X
In	B-X
this	B-X
paper	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
effects	B-X
of	B-X
age	B-X
on	B-X
the	B-X
different	B-X
hypothalamic-pituitary-hormonal	B-X
organ	B-X
axes	B-X
,	B-X
as	B-X
well	B-X
as	B-X
age-related	B-X
changes	B-X
in	B-X
calcium	B-X
and	B-X
bone	B-X
metabolism	B-X
and	B-X
glucose	B-X
homoeostasis	B-X
.	B-X

A	O
previous	O
study	O
on	O
biochemical	O
factors	O
and	O
cataract	O
showed	O
that	O
a	O
lower	O
level	O
of	O
iron	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
cortical	O
cataract	O
[	O
27	O
]	O
.	O

No	O
interaction	O
between	O
sex	O
and	O
biochemical	O
factors	O
were	O
detected	O
and	O
no	O
gender	O
difference	O
was	O
assessed	O
in	O
this	O
study	O
[	O
27	O
]	O
.	O
<EOS>	B-X
However	B-X
,	B-X
the	B-X
underlying	B-X
morphological	B-X
and	B-X
biochemical	B-X
brain	B-X
alterations	B-X
due	B-X
to	B-X
these	B-X
risk	B-X
factors	B-X
as	B-X
well	B-X
as	B-X
the	B-X
effects	B-X
of	B-X
gene-environmental	B-X
interaction	B-X
are	B-X
still	B-X
unclear	B-X
.	B-X
In	B-X
this	B-X
magnetic	B-X
resonance	B-X
imaging	B-X
(	B-X
MRI	B-X
)	B-X
study	B-X
in	B-X
47	B-X
first-episode	B-X
schizophrenia	B-X
patients	B-X
and	B-X
30	B-X
healthy	B-X
control	B-X
subjects	B-X
,	B-X
we	B-X
investigated	B-X
effects	B-X
of	B-X
previous	B-X
cannabis	B-X
abuse	B-X
and	B-X
increased	B-X
familial	B-X
risk	B-X
on	B-X
subcortical	B-X
brain	B-X
regions	B-X
such	B-X
as	B-X
hippocampus	B-X
,	B-X
amygdala	B-X
,	B-X
caudate	B-X
nucleus	B-X
,	B-X
putamen	B-X
,	B-X
thalamus	B-X
and	B-X
subsegments	B-X
of	B-X
the	B-X
corpus	B-X
callosum	B-X
(	B-X
CC	B-X
)	B-X
.	B-X
In	B-X
a	B-X
subsequent	B-X
single-volume	B-X
(	B-X
1	B-X
)	B-X
H-magnetic	B-X
resonance	B-X
spectroscopy	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
spectra	B-X
in	B-X
the	B-X
left	B-X
hippocampus	B-X
and	B-X
putamen	B-X
to	B-X
detect	B-X
metabolic	B-X
alterations	B-X
.	B-X
Patients	B-X
with	B-X
a	B-X
family	B-X
history	B-X
of	B-X
schizophrenia	B-X
combined	B-X
with	B-X
previous	B-X
cannabis	B-X
abuse	B-X
showed	B-X
lower	B-X
volumes	B-X
of	B-X
the	B-X
bilateral	B-X
caudate	B-X
nucleus	B-X
compared	B-X
to	B-X
all	B-X
other	B-X
patients	B-X
,	B-X
implicating	B-X
an	B-X
interaction	B-X
between	B-X
the	B-X
genetic	B-X
background	B-X
and	B-X
cannabis	B-X
abuse	B-X
as	B-X
environmental	B-X
factor	B-X
.	B-X
However	B-X
,	B-X
antipsychotic	B-X
medication	B-X
prior	B-X
to	B-X
MRI	B-X
acquisition	B-X
and	B-X
gender	B-X
effects	B-X
may	B-X
have	B-X
influenced	B-X
our	B-X
results	B-X
.	B-X

The	O
gender	O
difference	O
seen	O
in	O
cortical	O
cataract	O
could	O
be	O
related	O
to	O
relatively	O
low	O
iron	O
levels	O
and	O
low	O
hemoglobin	O
concentration	O
usually	O
seen	O
in	O
women	B-Species
[	O
28	O
]	O
.	O

Diabetes	O
is	O
a	O
known	O
risk	O
factor	O
for	O
cortical	O
cataract	O
but	O
in	O
this	O
particular	O
population	O
diabetes	O
is	O
more	O
prevalent	O
in	O
men	B-Species
than	O
women	B-Species
in	O
all	O
age	O
groups	O
[	O
29	O
]	O
.	O

Differential	O
exposures	O
to	O
cataract	O
risk	O
factors	O
or	O
different	O
dietary	O
or	O
lifestyle	O
patterns	O
between	O
men	B-Species
and	O
women	B-Species
may	O
also	O
be	O
related	O
to	O
these	O
observations	O
and	O
warrant	O
further	O
study	O
.	O
<EOS>	B-X
The	B-X
Dietary	B-X
Approaches	B-X
to	B-X
Stop	B-X
Hypertension	B-X
(	B-X
DASH	B-X
)	B-X
diet	B-X
is	B-X
recognized	B-X
as	B-X
an	B-X
effective	B-X
dietary	B-X
intervention	B-X
to	B-X
reduce	B-X
blood	B-X
pressure	B-X
(	B-X
BP	B-X
)	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
comprehensively	B-X
assess	B-X
the	B-X
DASH	B-X
diet	B-X
effect	B-X
on	B-X
BP	B-X
in	B-X
adults	B-X
with	B-X
and	B-X
without	B-X
hypertension	B-X
,	B-X
accounting	B-X
for	B-X
underlying	B-X
methodological	B-X
and	B-X
clinical	B-X
confounders	B-X
.	B-X
Subgroup	B-X
and	B-X
meta-regression	B-X
analyses	B-X
were	B-X
also	B-X
conducted	B-X
.	B-X
The	B-X
quality	B-X
of	B-X
evidence	B-X
was	B-X
rated	B-X
as	B-X
moderate	B-X
for	B-X
both	B-X
outcomes	B-X
according	B-X
to	B-X
the	B-X
Grading	B-X
of	B-X
Recommendations	B-X
,	B-X
Assessment	B-X
,	B-X
Development	B-X
,	B-X
and	B-X
Evaluation	B-X
approach	B-X
.	B-X

Conclusion	O
<EOS>	B-X
Conclusion	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X

In	O
summary	O
,	O
in	O
two	O
population	O
-	O
based	O
surveys	O
6	O
years	O
apart	O
,	O
we	O
have	O
documented	O
a	O
relatively	O
stable	O
prevalence	O
of	O
cortical	O
cataract	O
and	O
PSC	O
over	O
the	O
period	O
.	O

The	O
observed	O
overall	O
increased	O
nuclear	O
cataract	O
prevalence	O
by	O
5	O
%	O
over	O
a	O
6	O
-	O
year	O
period	O
needs	O
confirmation	O
by	O
future	O
studies	O
,	O
and	O
reasons	O
for	O
such	O
an	O
increase	O
deserve	O
further	O
study	O
.	O

Competing	O
interests	O
<EOS>	B-X
Elective	B-X
ventilation	B-X
and	B-X
interests	B-X
.	B-X
An	B-X
examination	B-X
of	B-X
the	B-X
principle	B-X
of	B-X
precedent	B-X
autonomy	B-X
reveals	B-X
that	B-X
a	B-X
future-binding	B-X
research	B-X
decision	B-X
is	B-X
within	B-X
the	B-X
scope	B-X
of	B-X
a	B-X
competent	B-X
person	B-X
's	B-X
critical	B-X
interests	B-X
,	B-X
if	B-X
the	B-X
decision	B-X
is	B-X
consistent	B-X
with	B-X
what	B-X
the	B-X
person	B-X
believes	B-X
gives	B-X
her	B-X
life	B-X
intrinsic	B-X
value	B-X
.	B-X
Safety	B-X
of	B-X
young	B-X
drivers	B-X
.	B-X
In	B-X
this	B-X
article	B-X
I	B-X
will	B-X
show	B-X
that	B-X
'best	B-X
interests	B-X
'	B-X
is	B-X
a	B-X
concept	B-X
that	B-X
fits	B-X
nicely	B-X
with	B-X
many	B-X
of	B-X
the	B-X
features	B-X
of	B-X
pragmatism	B-X
--	B-X
Holm	B-X
and	B-X
Edgar	B-X
's	B-X
rejection	B-X
of	B-X
the	B-X
principle	B-X
in	B-X
favour	B-X
of	B-X
pragmatism	B-X
it	B-X
will	B-X
be	B-X
suggested	B-X
is	B-X
misplaced	B-X
.	B-X
'Best	B-X
interests	B-X
'	B-X
as	B-X
a	B-X
principle	B-X
may	B-X
be	B-X
considered	B-X
an	B-X
embodiment	B-X
of	B-X
the	B-X
ideals	B-X
of	B-X
pragmatic	B-X
adjudication	B-X
.	B-X
The	B-X
paper	B-X
starts	B-X
by	B-X
briefly	B-X
introducing	B-X
the	B-X
concept	B-X
of	B-X
'best	B-X
interests	B-X
'	B-X
and	B-X
theories	B-X
of	B-X
judicial	B-X
and	B-X
legal	B-X
'pragmatism	B-X
'	B-X
.	B-X
The	B-X
paper	B-X
concludes	B-X
by	B-X
suggesting	B-X
how	B-X
we	B-X
view	B-X
the	B-X
relationship	B-X
between	B-X
'best	B-X
interests	B-X
'	B-X
and	B-X
'pragmatism	B-X
'	B-X
.	B-X

The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O
<EOS>	B-X
In	B-X
this	B-X
letter	B-X
,	B-X
I	B-X
argue	B-X
that	B-X
in	B-X
reality	B-X
and	B-X
in	B-X
practice	B-X
,	B-X
authorship	B-X
delimitations	B-X
are	B-X
not	B-X
that	B-X
clear-cut	B-X
,	B-X
nor	B-X
are	B-X
all	B-X
contributions	B-X
equal	B-X
or	B-X
equally	B-X
weighted	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
contributions	B-X
of	B-X
each	B-X
author	B-X
to	B-X
multiauthored	B-X
biomedical	B-X
research	B-X
papers	B-X
.	B-X
Much	B-X
research	B-X
on	B-X
APP	B-X
focusses	B-X
on	B-X
potential	B-X
contributions	B-X
to	B-X
neurodegeneration	B-X
,	B-X
mostly	B-X
based	B-X
on	B-X
mouse	B-X
models	B-X
with	B-X
altered	B-X
expression	B-X
or	B-X
mutated	B-X
forms	B-X
of	B-X
APP	B-X
.	B-X
For	B-X
papers	B-X
in	B-X
which	B-X
the	B-X
first	B-X
and	B-X
second	B-X
authors	B-X
made	B-X
equal	B-X
contributions	B-X
,	B-X
mixed-gender	B-X
combinations	B-X
were	B-X
most	B-X
frequent	B-X
,	B-X
followed	B-X
by	B-X
male-male	B-X
and	B-X
then	B-X
female-female	B-X
author	B-X
combinations	B-X
.	B-X
For	B-X
papers	B-X
in	B-X
which	B-X
three	B-X
or	B-X
more	B-X
authors	B-X
made	B-X
equal	B-X
contributions	B-X
,	B-X
there	B-X
were	B-X
more	B-X
male	B-X
authors	B-X
than	B-X
female	B-X
authors	B-X
in	B-X
the	B-X
first	B-X
position	B-X
and	B-X
more	B-X
all-male	B-X
than	B-X
all-female	B-X
author	B-X
combinations	B-X
.	B-X
The	B-X
gender	B-X
inequalities	B-X
observed	B-X
among	B-X
authors	B-X
who	B-X
made	B-X
equal	B-X
contributions	B-X
are	B-X
not	B-X
consistent	B-X
with	B-X
random	B-X
or	B-X
alphabetical	B-X
ordering	B-X
of	B-X
authors	B-X
.	B-X

AGT	O
graded	O
the	O
photographs	O
,	O
performed	O
literature	O
search	O
and	O
wrote	O
the	O
first	O
draft	O
of	O
the	O
manuscript	O
.	O

JJW	O
graded	O
the	O
photographs	O
,	O
critically	O
reviewed	O
and	O
modified	O
the	O
manuscript	O
.	O

ER	O
performed	O
the	O
statistical	O
analysis	O
and	O
critically	O
reviewed	O
the	O
manuscript	O
.	O

PM	O
designed	O
and	O
directed	O
the	O
study	O
,	O
adjudicated	O
cataract	O
cases	O
and	O
critically	O
reviewed	O
and	O
modified	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O
<EOS>	B-X
As	B-X
a	B-X
Generally	B-X
Recognized	B-X
As	B-X
Safe	B-X
(	B-X
GRAS	B-X
)	B-X
approved	B-X
substance	B-X
,	B-X
MSM	B-X
is	B-X
well-tolerated	B-X
by	B-X
most	B-X
individuals	B-X
at	B-X
dosages	B-X
of	B-X
up	B-X
to	B-X
four	B-X
grams	B-X
daily	B-X
,	B-X
with	B-X
few	B-X
known	B-X
and	B-X
mild	B-X
side	B-X
effects	B-X
.	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
manuscript	B-X
is	B-X
to	B-X
provide	B-X
a	B-X
description	B-X
of	B-X
the	B-X
epidemiology	B-X
and	B-X
presentation	B-X
of	B-X
piriformis	B-X
as	B-X
well	B-X
as	B-X
both	B-X
non-operative	B-X
and	B-X
operative	B-X
treatment	B-X
options	B-X
.	B-X
Due	B-X
to	B-X
the	B-X
widespread	B-X
use	B-X
of	B-X
landfilling	B-X
,	B-X
even	B-X
as	B-X
of	B-X
today	B-X
,	B-X
it	B-X
is	B-X
imperative	B-X
to	B-X
examine	B-X
any	B-X
environmental-	B-X
and/or	B-X
health-related	B-X
issues	B-X
that	B-X
have	B-X
emerged	B-X
.	B-X

Pre	O
-	O
publication	O
history	O
<EOS>	B-X
The	B-X
choice	B-X
of	B-X
Sydney	B-X
Brenner	B-X
to	B-X
adopt	B-X
this	B-X
species	B-X
in	B-X
the	B-X
mid-1960s	B-X
and	B-X
the	B-X
success	B-X
of	B-X
his	B-X
team	B-X
in	B-X
raising	B-X
it	B-X
to	B-X
a	B-X
model	B-X
organism	B-X
status	B-X
have	B-X
been	B-X
told	B-X
(	B-X
http	B-X
:	B-X
//www.wormbook.org/toc_wormhistory.html	B-X
;	B-X
Brenner	B-X
,	B-X
2001	B-X
;	B-X
Ankeny	B-X
,	B-X
2001	B-X
)	B-X
.	B-X
Here	B-X
we	B-X
review	B-X
the	B-X
pre-Brenner	B-X
history	B-X
of	B-X
the	B-X
use	B-X
of	B-X
free-living	B-X
nematodes	B-X
as	B-X
models	B-X
for	B-X
general	B-X
questions	B-X
in	B-X
biology	B-X
.	B-X
We	B-X
focus	B-X
on	B-X
the	B-X
period	B-X
that	B-X
started	B-X
in	B-X
1899	B-X
with	B-X
the	B-X
first	B-X
publication	B-X
of	B-X
Emile	B-X
Maupas	B-X
mentioning	B-X
Rhabditis	B-X
elegans	B-X
and	B-X
ended	B-X
in	B-X
1974	B-X
with	B-X
the	B-X
first	B-X
publications	B-X
by	B-X
Brenner	B-X
.	B-X
Oral	B-X
Cancer	B-X
:	B-X
A	B-X
Historical	B-X
Review	B-X
.	B-X

The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O
<EOS>	B-X
Humans	B-X
'	B-X
great	B-X
and	B-X
quick	B-X
technological	B-X
breakthroughs	B-X
in	B-X
the	B-X
previous	B-X
decade	B-X
have	B-X
undoubtedly	B-X
influenced	B-X
how	B-X
surgical	B-X
procedures	B-X
are	B-X
executed	B-X
in	B-X
the	B-X
operating	B-X
room	B-X
.	B-X
AI	B-X
is	B-X
becoming	B-X
incredibly	B-X
influential	B-X
for	B-X
surgical	B-X
decision-making	B-X
to	B-X
help	B-X
surgeons	B-X
make	B-X
better	B-X
projections	B-X
about	B-X
the	B-X
implications	B-X
of	B-X
surgical	B-X
operations	B-X
by	B-X
considering	B-X
different	B-X
sources	B-X
of	B-X
data	B-X
such	B-X
as	B-X
patient	B-X
health	B-X
conditions	B-X
,	B-X
disease	B-X
natural	B-X
history	B-X
,	B-X
patient	B-X
values	B-X
,	B-X
and	B-X
finance	B-X
.	B-X
By	B-X
leveraging	B-X
techniques	B-X
such	B-X
as	B-X
machine	B-X
learning	B-X
,	B-X
computer	B-X
vision	B-X
,	B-X
and	B-X
robotics	B-X
,	B-X
AI	B-X
may	B-X
play	B-X
a	B-X
key	B-X
role	B-X
in	B-X
diagnostic	B-X
augmentation	B-X
,	B-X
operative	B-X
management	B-X
,	B-X
pre-and	B-X
post-surgical	B-X
patient	B-X
management	B-X
,	B-X
and	B-X
upholding	B-X
safety	B-X
standards	B-X
.	B-X
In	B-X
this	B-X
paper	B-X
,	B-X
we	B-X
present	B-X
an	B-X
overview	B-X
of	B-X
AI	B-X
applications	B-X
in	B-X
thoracic	B-X
surgery	B-X
and	B-X
its	B-X
related	B-X
components	B-X
,	B-X
including	B-X
contemporary	B-X
projects	B-X
and	B-X
technology	B-X
that	B-X
use	B-X
AI	B-X
in	B-X
cardiothoracic	B-X
surgery	B-X
and	B-X
general	B-X
care	B-X
.	B-X

QGRS	O
Mapper	O
:	O
a	O
web	O
-	O
based	O
server	O
for	O
predicting	O
G	O
-	O
quadruplexes	O
in	O
nucleotide	O
sequences	O
<EOS>	B-X
The	B-X
quadruplex	B-X
structures	B-X
formed	B-X
by	B-X
guanine-rich	B-X
nucleic	B-X
acid	B-X
sequences	B-X
have	B-X
received	B-X
significant	B-X
attention	B-X
recently	B-X
because	B-X
of	B-X
growing	B-X
evidence	B-X
for	B-X
their	B-X
role	B-X
in	B-X
important	B-X
biological	B-X
processes	B-X
and	B-X
as	B-X
therapeutic	B-X
targets	B-X
.	B-X
G-quadruplex	B-X
DNA	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
regulate	B-X
DNA	B-X
replication	B-X
and	B-X
may	B-X
control	B-X
cellular	B-X
proliferation	B-X
.	B-X
Sequences	B-X
capable	B-X
of	B-X
forming	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
RNA	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
significant	B-X
roles	B-X
in	B-X
regulation	B-X
of	B-X
polyadenylation	B-X
and	B-X
splicing	B-X
events	B-X
in	B-X
mammalian	B-X
transcripts	B-X
.	B-X
Computational	B-X
approaches	B-X
to	B-X
study	B-X
G-quadruplexes	B-X
allow	B-X
detailed	B-X
analysis	B-X
of	B-X
mammalian	B-X
genomes	B-X
.	B-X
There	B-X
are	B-X
no	B-X
known	B-X
easily	B-X
accessible	B-X
user-friendly	B-X
tools	B-X
that	B-X
can	B-X
compute	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
nucleotide	B-X
sequences	B-X
.	B-X
We	B-X
have	B-X
developed	B-X
a	B-X
web-based	B-X
server	B-X
,	B-X
QGRS	B-X
Mapper	B-X
,	B-X
that	B-X
predicts	B-X
quadruplex	B-X
forming	B-X
G-rich	B-X
sequences	B-X
(	B-X
QGRS	B-X
)	B-X
in	B-X
nucleotide	B-X
sequences	B-X
.	B-X
It	B-X
is	B-X
a	B-X
user-friendly	B-X
application	B-X
that	B-X
provides	B-X
many	B-X
options	B-X
for	B-X
defining	B-X
and	B-X
studying	B-X
G-quadruplexes	B-X
.	B-X
It	B-X
performs	B-X
analysis	B-X
of	B-X
the	B-X
user	B-X
provided	B-X
genomic	B-X
sequences	B-X
,	B-X
e.g	B-X
.	B-X
promoter	B-X
and	B-X
telomeric	B-X
regions	B-X
,	B-X
as	B-X
well	B-X
as	B-X
RNA	B-X
sequences	B-X
.	B-X
It	B-X
is	B-X
also	B-X
useful	B-X
for	B-X
predicting	B-X
G-quadruplex	B-X
structures	B-X
in	B-X
oligonucleotides	B-X
.	B-X
The	B-X
program	B-X
provides	B-X
options	B-X
to	B-X
search	B-X
and	B-X
retrieve	B-X
desired	B-X
gene/nucleotide	B-X
sequence	B-X
entries	B-X
from	B-X
NCBI	B-X
databases	B-X
for	B-X
mapping	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
context	B-X
of	B-X
RNA	B-X
processing	B-X
sites	B-X
.	B-X
This	B-X
feature	B-X
is	B-X
very	B-X
useful	B-X
for	B-X
investigating	B-X
the	B-X
functional	B-X
relevance	B-X
of	B-X
G-quadruplex	B-X
structure	B-X
,	B-X
in	B-X
particular	B-X
its	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
gene	B-X
expression	B-X
by	B-X
alternative	B-X
processing	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
providing	B-X
data	B-X
on	B-X
composition	B-X
and	B-X
locations	B-X
of	B-X
QGRS	B-X
relative	B-X
to	B-X
the	B-X
processing	B-X
sites	B-X
in	B-X
the	B-X
pre-mRNA	B-X
sequence	B-X
,	B-X
QGRS	B-X
Mapper	B-X
features	B-X
interactive	B-X
graphic	B-X
representation	B-X
of	B-X
the	B-X
data	B-X
.	B-X
The	B-X
user	B-X
can	B-X
also	B-X
use	B-X
the	B-X
graphics	B-X
module	B-X
to	B-X
visualize	B-X
QGRS	B-X
distribution	B-X
patterns	B-X
among	B-X
all	B-X
the	B-X
alternative	B-X
RNA	B-X
products	B-X
of	B-X
a	B-X
gene	B-X
simultaneously	B-X
on	B-X
a	B-X
single	B-X
screen	B-X
.	B-X
QGRS	B-X
Mapper	B-X
can	B-X
be	B-X
accessed	B-X
at	B-X
http	B-X
:	B-X
//bioinformatics.ramapo.edu/QGRS/	B-X
.	B-X

Abstract	O
<EOS>	B-X
Abstract	B-X
writing	B-X
.	B-X
The	B-X
informative	B-X
abstract	B-X
.	B-X
Crafting	B-X
a	B-X
compelling	B-X
abstract	B-X
.	B-X
Why	B-X
the	B-X
structured	B-X
abstract	B-X
?	B-X

The	O
quadruplex	O
structures	O
formed	O
by	O
guanine	O
-	O
rich	O
nucleic	O
acid	O
sequences	O
have	O
received	O
significant	O
attention	O
recently	O
because	O
of	O
growing	O
evidence	O
for	O
their	O
role	O
in	O
important	O
biological	O
processes	O
and	O
as	O
therapeutic	O
targets	O
.	O
<EOS>	B-X
The	B-X
quadruplex	B-X
structures	B-X
formed	B-X
by	B-X
guanine-rich	B-X
nucleic	B-X
acid	B-X
sequences	B-X
have	B-X
received	B-X
significant	B-X
attention	B-X
recently	B-X
because	B-X
of	B-X
growing	B-X
evidence	B-X
for	B-X
their	B-X
role	B-X
in	B-X
important	B-X
biological	B-X
processes	B-X
and	B-X
as	B-X
therapeutic	B-X
targets	B-X
.	B-X
G-quadruplex	B-X
DNA	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
regulate	B-X
DNA	B-X
replication	B-X
and	B-X
may	B-X
control	B-X
cellular	B-X
proliferation	B-X
.	B-X
Sequences	B-X
capable	B-X
of	B-X
forming	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
RNA	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
significant	B-X
roles	B-X
in	B-X
regulation	B-X
of	B-X
polyadenylation	B-X
and	B-X
splicing	B-X
events	B-X
in	B-X
mammalian	B-X
transcripts	B-X
.	B-X
Whether	B-X
quadruplex	B-X
structure	B-X
directly	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
RNA	B-X
processing	B-X
requires	B-X
investigation	B-X
.	B-X
Computational	B-X
approaches	B-X
to	B-X
study	B-X
G-quadruplexes	B-X
allow	B-X
detailed	B-X
analysis	B-X
of	B-X
mammalian	B-X
genomes	B-X
.	B-X
There	B-X
are	B-X
no	B-X
known	B-X
easily	B-X
accessible	B-X
user-friendly	B-X
tools	B-X
that	B-X
can	B-X
compute	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
nucleotide	B-X
sequences	B-X
.	B-X
We	B-X
have	B-X
developed	B-X
a	B-X
web-based	B-X
server	B-X
,	B-X
QGRS	B-X
Mapper	B-X
,	B-X
that	B-X
predicts	B-X
quadruplex	B-X
forming	B-X
G-rich	B-X
sequences	B-X
(	B-X
QGRS	B-X
)	B-X
in	B-X
nucleotide	B-X
sequences	B-X
.	B-X
It	B-X
is	B-X
a	B-X
user-friendly	B-X
application	B-X
that	B-X
provides	B-X
many	B-X
options	B-X
for	B-X
defining	B-X
and	B-X
studying	B-X
G-quadruplexes	B-X
.	B-X
It	B-X
performs	B-X
analysis	B-X
of	B-X
the	B-X
user	B-X
provided	B-X
genomic	B-X
sequences	B-X
,	B-X
e.g	B-X
.	B-X
promoter	B-X
and	B-X
telomeric	B-X
regions	B-X
,	B-X
as	B-X
well	B-X
as	B-X
RNA	B-X
sequences	B-X
.	B-X
It	B-X
is	B-X
also	B-X
useful	B-X
for	B-X
predicting	B-X
G-quadruplex	B-X
structures	B-X
in	B-X
oligonucleotides	B-X
.	B-X
The	B-X
program	B-X
provides	B-X
options	B-X
to	B-X
search	B-X
and	B-X
retrieve	B-X
desired	B-X
gene/nucleotide	B-X
sequence	B-X
entries	B-X
from	B-X
NCBI	B-X
databases	B-X
for	B-X
mapping	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
context	B-X
of	B-X
RNA	B-X
processing	B-X
sites	B-X
.	B-X
This	B-X
feature	B-X
is	B-X
very	B-X
useful	B-X
for	B-X
investigating	B-X
the	B-X
functional	B-X
relevance	B-X
of	B-X
G-quadruplex	B-X
structure	B-X
,	B-X
in	B-X
particular	B-X
its	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
gene	B-X
expression	B-X
by	B-X
alternative	B-X
processing	B-X
.	B-X

G	O
-	O
quadruplex	O
DNA	O
has	O
been	O
suggested	O
to	O
regulate	O
DNA	O
replication	O
and	O
may	O
control	O
cellular	O
proliferation	O
.	O
<EOS>	B-X
Glioblastoma	B-X
is	B-X
the	B-X
most	B-X
aggressive	B-X
and	B-X
most	B-X
lethal	B-X
primary	B-X
brain	B-X
tumor	B-X
in	B-X
the	B-X
adulthood	B-X
.	B-X
Present	B-X
knowledge	B-X
suggests	B-X
that	B-X
the	B-X
continued	B-X
glioblastoma	B-X
growth	B-X
and	B-X
recurrence	B-X
is	B-X
determined	B-X
by	B-X
glioblastoma	B-X
stem-like	B-X
cells	B-X
(	B-X
GSCs	B-X
)	B-X
,	B-X
which	B-X
display	B-X
self-renewal	B-X
,	B-X
tumorigenic	B-X
potential	B-X
,	B-X
and	B-X
increased	B-X
radio-	B-X
and	B-X
chemo-resistance	B-X
.	B-X
The	B-X
G-quadruplex	B-X
ligand	B-X
RHPS4	B-X
displays	B-X
in	B-X
vitro	B-X
radiosensitizing	B-X
effect	B-X
in	B-X
GBM	B-X
radioresistant	B-X
cells	B-X
through	B-X
the	B-X
targeting	B-X
and	B-X
dysfunctionalization	B-X
of	B-X
telomeres	B-X
but	B-X
RHPS4	B-X
and	B-X
Ionizing	B-X
Radiation	B-X
(	B-X
IR	B-X
)	B-X
combined	B-X
treatment	B-X
efficacy	B-X
in	B-X
vivo	B-X
has	B-X
not	B-X
been	B-X
explored	B-X
so	B-X
far	B-X
.	B-X
The	B-X
quadruplex	B-X
structures	B-X
formed	B-X
by	B-X
guanine-rich	B-X
nucleic	B-X
acid	B-X
sequences	B-X
have	B-X
received	B-X
significant	B-X
attention	B-X
recently	B-X
because	B-X
of	B-X
growing	B-X
evidence	B-X
for	B-X
their	B-X
role	B-X
in	B-X
important	B-X
biological	B-X
processes	B-X
and	B-X
as	B-X
therapeutic	B-X
targets	B-X
.	B-X
G-quadruplex	B-X
DNA	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
regulate	B-X
DNA	B-X
replication	B-X
and	B-X
may	B-X
control	B-X
cellular	B-X
proliferation	B-X
.	B-X
Sequences	B-X
capable	B-X
of	B-X
forming	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
RNA	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
significant	B-X
roles	B-X
in	B-X
regulation	B-X
of	B-X
polyadenylation	B-X
and	B-X
splicing	B-X
events	B-X
in	B-X
mammalian	B-X
transcripts	B-X
.	B-X
Whether	B-X
quadruplex	B-X
structure	B-X
directly	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
RNA	B-X
processing	B-X
requires	B-X
investigation	B-X
.	B-X
Computational	B-X
approaches	B-X
to	B-X
study	B-X
G-quadruplexes	B-X
allow	B-X
detailed	B-X
analysis	B-X
of	B-X
mammalian	B-X
genomes	B-X
.	B-X
There	B-X
are	B-X
no	B-X
known	B-X
easily	B-X
accessible	B-X
user-friendly	B-X
tools	B-X
that	B-X
can	B-X
compute	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
nucleotide	B-X
sequences	B-X
.	B-X
We	B-X
have	B-X
developed	B-X
a	B-X
web-based	B-X
server	B-X
,	B-X
QGRS	B-X
Mapper	B-X
,	B-X
that	B-X
predicts	B-X
quadruplex	B-X
forming	B-X
G-rich	B-X
sequences	B-X
(	B-X
QGRS	B-X
)	B-X
in	B-X
nucleotide	B-X
sequences	B-X
.	B-X
It	B-X
is	B-X
a	B-X
user-friendly	B-X
application	B-X
that	B-X
provides	B-X
many	B-X
options	B-X
for	B-X
defining	B-X
and	B-X
studying	B-X
G-quadruplexes	B-X
.	B-X
It	B-X
is	B-X
also	B-X
useful	B-X
for	B-X
predicting	B-X
G-quadruplex	B-X
structures	B-X
in	B-X
oligonucleotides	B-X
.	B-X
The	B-X
program	B-X
provides	B-X
options	B-X
to	B-X
search	B-X
and	B-X
retrieve	B-X
desired	B-X
gene/nucleotide	B-X
sequence	B-X
entries	B-X
from	B-X
NCBI	B-X
databases	B-X
for	B-X
mapping	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
context	B-X
of	B-X
RNA	B-X
processing	B-X
sites	B-X
.	B-X
This	B-X
feature	B-X
is	B-X
very	B-X
useful	B-X
for	B-X
investigating	B-X
the	B-X
functional	B-X
relevance	B-X
of	B-X
G-quadruplex	B-X
structure	B-X
,	B-X
in	B-X
particular	B-X
its	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
gene	B-X
expression	B-X
by	B-X
alternative	B-X
processing	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
providing	B-X
data	B-X
on	B-X
composition	B-X
and	B-X
locations	B-X
of	B-X
QGRS	B-X
relative	B-X
to	B-X
the	B-X
processing	B-X
sites	B-X
in	B-X
the	B-X
pre-mRNA	B-X
sequence	B-X
,	B-X
QGRS	B-X
Mapper	B-X
features	B-X
interactive	B-X
graphic	B-X
representation	B-X
of	B-X
the	B-X
data	B-X
.	B-X
The	B-X
user	B-X
can	B-X
also	B-X
use	B-X
the	B-X
graphics	B-X
module	B-X
to	B-X
visualize	B-X
QGRS	B-X
distribution	B-X
patterns	B-X
among	B-X
all	B-X
the	B-X
alternative	B-X
RNA	B-X
products	B-X
of	B-X
a	B-X
gene	B-X
simultaneously	B-X
on	B-X
a	B-X
single	B-X
screen	B-X
.	B-X
QGRS	B-X
Mapper	B-X
can	B-X
be	B-X
accessed	B-X
at	B-X
http	B-X
:	B-X
//bioinformatics.ramapo.edu/QGRS/	B-X
.	B-X

Sequences	O
capable	O
of	O
forming	O
G	O
-	O
quadruplexes	O
in	O
the	O
RNA	O
have	O
been	O
shown	O
to	O
play	O
significant	O
roles	O
in	O
regulation	O
of	O
polyadenylation	O
and	O
splicing	O
events	O
in	O
mammalian	O
transcripts	O
.	O
<EOS>	B-X
G-quadruplex	B-X
motifs	B-X
in	B-X
the	B-X
RNA	B-X
play	B-X
significant	B-X
roles	B-X
in	B-X
key	B-X
cellular	B-X
processes	B-X
and	B-X
human	B-X
disease	B-X
.	B-X
While	B-X
sequences	B-X
capable	B-X
of	B-X
forming	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
pre-mRNA	B-X
are	B-X
involved	B-X
in	B-X
regulation	B-X
of	B-X
polyadenylation	B-X
and	B-X
splicing	B-X
events	B-X
in	B-X
mammalian	B-X
transcripts	B-X
,	B-X
the	B-X
G-quadruplex	B-X
motifs	B-X
in	B-X
the	B-X
UTRs	B-X
may	B-X
help	B-X
regulate	B-X
mRNA	B-X
expression	B-X
.	B-X
GRSDB2	B-X
is	B-X
a	B-X
second-generation	B-X
database	B-X
containing	B-X
information	B-X
on	B-X
the	B-X
composition	B-X
and	B-X
distribution	B-X
of	B-X
putative	B-X
Quadruplex-forming	B-X
G-Rich	B-X
Sequences	B-X
(	B-X
QGRS	B-X
)	B-X
mapped	B-X
in	B-X
approximately	B-X
29	B-X
000	B-X
eukaryotic	B-X
pre-mRNA	B-X
sequences	B-X
,	B-X
many	B-X
of	B-X
which	B-X
are	B-X
alternatively	B-X
processed	B-X
.	B-X
The	B-X
data	B-X
stored	B-X
in	B-X
the	B-X
GRSDB2	B-X
is	B-X
based	B-X
on	B-X
computational	B-X
analysis	B-X
of	B-X
NCBI	B-X
Entrez	B-X
Gene	B-X
entries	B-X
with	B-X
the	B-X
help	B-X
of	B-X
an	B-X
improved	B-X
version	B-X
of	B-X
the	B-X
QGRS	B-X
Mapper	B-X
program	B-X
.	B-X
The	B-X
database	B-X
allows	B-X
complex	B-X
queries	B-X
with	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
parameters	B-X
,	B-X
including	B-X
Gene	B-X
Ontology	B-X
terms	B-X
.	B-X
The	B-X
data	B-X
is	B-X
displayed	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
formats	B-X
with	B-X
several	B-X
additional	B-X
computational	B-X
capabilities	B-X
.	B-X
We	B-X
have	B-X
also	B-X
developed	B-X
a	B-X
new	B-X
database	B-X
,	B-X
GRS_UTRdb	B-X
,	B-X
containing	B-X
information	B-X
on	B-X
the	B-X
composition	B-X
and	B-X
distribution	B-X
patterns	B-X
of	B-X
putative	B-X
QGRS	B-X
in	B-X
the	B-X
5'-	B-X
and	B-X
3'-UTRs	B-X
of	B-X
eukaryotic	B-X
mRNA	B-X
sequences	B-X
.	B-X
The	B-X
goal	B-X
of	B-X
these	B-X
experiments	B-X
has	B-X
been	B-X
to	B-X
build	B-X
freely	B-X
accessible	B-X
resources	B-X
for	B-X
exploring	B-X
the	B-X
role	B-X
of	B-X
G-quadruplex	B-X
structure	B-X
in	B-X
regulation	B-X
of	B-X
gene	B-X
expression	B-X
at	B-X
post-transcriptional	B-X
level	B-X
.	B-X
The	B-X
databases	B-X
can	B-X
be	B-X
accessed	B-X
at	B-X
the	B-X
G-Quadruplex	B-X
Resource	B-X
Site	B-X
at	B-X
:	B-X
http	B-X
:	B-X
//bioinformatics.ramapo.edu/GQRS/	B-X
.	B-X

Whether	O
quadruplex	O
structure	O
directly	O
plays	O
a	O
role	O
in	O
regulating	O
RNA	O
processing	O
requires	O
investigation	O
.	O

Computational	O
approaches	O
to	O
study	O
G	O
-	O
quadruplexes	O
allow	O
detailed	O
analysis	O
of	O
mammalian	O
genomes	O
.	O
<EOS>	B-X
G-quadruplex	B-X
DNA	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
regulate	B-X
DNA	B-X
replication	B-X
and	B-X
may	B-X
control	B-X
cellular	B-X
proliferation	B-X
.	B-X
Sequences	B-X
capable	B-X
of	B-X
forming	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
RNA	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
significant	B-X
roles	B-X
in	B-X
regulation	B-X
of	B-X
polyadenylation	B-X
and	B-X
splicing	B-X
events	B-X
in	B-X
mammalian	B-X
transcripts	B-X
.	B-X
Computational	B-X
approaches	B-X
to	B-X
study	B-X
G-quadruplexes	B-X
allow	B-X
detailed	B-X
analysis	B-X
of	B-X
mammalian	B-X
genomes	B-X
.	B-X
There	B-X
are	B-X
no	B-X
known	B-X
easily	B-X
accessible	B-X
user-friendly	B-X
tools	B-X
that	B-X
can	B-X
compute	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
nucleotide	B-X
sequences	B-X
.	B-X
We	B-X
have	B-X
developed	B-X
a	B-X
web-based	B-X
server	B-X
,	B-X
QGRS	B-X
Mapper	B-X
,	B-X
that	B-X
predicts	B-X
quadruplex	B-X
forming	B-X
G-rich	B-X
sequences	B-X
(	B-X
QGRS	B-X
)	B-X
in	B-X
nucleotide	B-X
sequences	B-X
.	B-X
It	B-X
is	B-X
a	B-X
user-friendly	B-X
application	B-X
that	B-X
provides	B-X
many	B-X
options	B-X
for	B-X
defining	B-X
and	B-X
studying	B-X
G-quadruplexes	B-X
.	B-X
It	B-X
performs	B-X
analysis	B-X
of	B-X
the	B-X
user	B-X
provided	B-X
genomic	B-X
sequences	B-X
,	B-X
e.g	B-X
.	B-X
It	B-X
is	B-X
also	B-X
useful	B-X
for	B-X
predicting	B-X
G-quadruplex	B-X
structures	B-X
in	B-X
oligonucleotides	B-X
.	B-X
The	B-X
program	B-X
provides	B-X
options	B-X
to	B-X
search	B-X
and	B-X
retrieve	B-X
desired	B-X
gene/nucleotide	B-X
sequence	B-X
entries	B-X
from	B-X
NCBI	B-X
databases	B-X
for	B-X
mapping	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
context	B-X
of	B-X
RNA	B-X
processing	B-X
sites	B-X
.	B-X
This	B-X
feature	B-X
is	B-X
very	B-X
useful	B-X
for	B-X
investigating	B-X
the	B-X
functional	B-X
relevance	B-X
of	B-X
G-quadruplex	B-X
structure	B-X
,	B-X
in	B-X
particular	B-X
its	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
gene	B-X
expression	B-X
by	B-X
alternative	B-X
processing	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
providing	B-X
data	B-X
on	B-X
composition	B-X
and	B-X
locations	B-X
of	B-X
QGRS	B-X
relative	B-X
to	B-X
the	B-X
processing	B-X
sites	B-X
in	B-X
the	B-X
pre-mRNA	B-X
sequence	B-X
,	B-X
QGRS	B-X
Mapper	B-X
features	B-X
interactive	B-X
graphic	B-X
representation	B-X
of	B-X
the	B-X
data	B-X
.	B-X
The	B-X
user	B-X
can	B-X
also	B-X
use	B-X
the	B-X
graphics	B-X
module	B-X
to	B-X
visualize	B-X
QGRS	B-X
distribution	B-X
patterns	B-X
among	B-X
all	B-X
the	B-X
alternative	B-X
RNA	B-X
products	B-X
of	B-X
a	B-X
gene	B-X
simultaneously	B-X
on	B-X
a	B-X
single	B-X
screen	B-X
.	B-X
QGRS	B-X
Mapper	B-X
can	B-X
be	B-X
accessed	B-X
at	B-X
http	B-X
:	B-X
//bioinformatics.ramapo.edu/QGRS/	B-X
.	B-X

There	O
are	O
no	O
known	O
easily	O
accessible	O
user	O
-	O
friendly	O
tools	O
that	O
can	O
compute	O
G	O
-	O
quadruplexes	O
in	O
the	O
nucleotide	O
sequences	O
.	O
<EOS>	B-X
The	B-X
quadruplex	B-X
structures	B-X
formed	B-X
by	B-X
guanine-rich	B-X
nucleic	B-X
acid	B-X
sequences	B-X
have	B-X
received	B-X
significant	B-X
attention	B-X
recently	B-X
because	B-X
of	B-X
growing	B-X
evidence	B-X
for	B-X
their	B-X
role	B-X
in	B-X
important	B-X
biological	B-X
processes	B-X
and	B-X
as	B-X
therapeutic	B-X
targets	B-X
.	B-X
G-quadruplex	B-X
DNA	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
regulate	B-X
DNA	B-X
replication	B-X
and	B-X
may	B-X
control	B-X
cellular	B-X
proliferation	B-X
.	B-X
Sequences	B-X
capable	B-X
of	B-X
forming	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
RNA	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
significant	B-X
roles	B-X
in	B-X
regulation	B-X
of	B-X
polyadenylation	B-X
and	B-X
splicing	B-X
events	B-X
in	B-X
mammalian	B-X
transcripts	B-X
.	B-X
Computational	B-X
approaches	B-X
to	B-X
study	B-X
G-quadruplexes	B-X
allow	B-X
detailed	B-X
analysis	B-X
of	B-X
mammalian	B-X
genomes	B-X
.	B-X
There	B-X
are	B-X
no	B-X
known	B-X
easily	B-X
accessible	B-X
user-friendly	B-X
tools	B-X
that	B-X
can	B-X
compute	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
nucleotide	B-X
sequences	B-X
.	B-X
We	B-X
have	B-X
developed	B-X
a	B-X
web-based	B-X
server	B-X
,	B-X
QGRS	B-X
Mapper	B-X
,	B-X
that	B-X
predicts	B-X
quadruplex	B-X
forming	B-X
G-rich	B-X
sequences	B-X
(	B-X
QGRS	B-X
)	B-X
in	B-X
nucleotide	B-X
sequences	B-X
.	B-X
It	B-X
is	B-X
a	B-X
user-friendly	B-X
application	B-X
that	B-X
provides	B-X
many	B-X
options	B-X
for	B-X
defining	B-X
and	B-X
studying	B-X
G-quadruplexes	B-X
.	B-X
It	B-X
performs	B-X
analysis	B-X
of	B-X
the	B-X
user	B-X
provided	B-X
genomic	B-X
sequences	B-X
,	B-X
e.g	B-X
.	B-X
promoter	B-X
and	B-X
telomeric	B-X
regions	B-X
,	B-X
as	B-X
well	B-X
as	B-X
RNA	B-X
sequences	B-X
.	B-X
It	B-X
is	B-X
also	B-X
useful	B-X
for	B-X
predicting	B-X
G-quadruplex	B-X
structures	B-X
in	B-X
oligonucleotides	B-X
.	B-X
The	B-X
program	B-X
provides	B-X
options	B-X
to	B-X
search	B-X
and	B-X
retrieve	B-X
desired	B-X
gene/nucleotide	B-X
sequence	B-X
entries	B-X
from	B-X
NCBI	B-X
databases	B-X
for	B-X
mapping	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
context	B-X
of	B-X
RNA	B-X
processing	B-X
sites	B-X
.	B-X
This	B-X
feature	B-X
is	B-X
very	B-X
useful	B-X
for	B-X
investigating	B-X
the	B-X
functional	B-X
relevance	B-X
of	B-X
G-quadruplex	B-X
structure	B-X
,	B-X
in	B-X
particular	B-X
its	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
gene	B-X
expression	B-X
by	B-X
alternative	B-X
processing	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
providing	B-X
data	B-X
on	B-X
composition	B-X
and	B-X
locations	B-X
of	B-X
QGRS	B-X
relative	B-X
to	B-X
the	B-X
processing	B-X
sites	B-X
in	B-X
the	B-X
pre-mRNA	B-X
sequence	B-X
,	B-X
QGRS	B-X
Mapper	B-X
features	B-X
interactive	B-X
graphic	B-X
representation	B-X
of	B-X
the	B-X
data	B-X
.	B-X
The	B-X
user	B-X
can	B-X
also	B-X
use	B-X
the	B-X
graphics	B-X
module	B-X
to	B-X
visualize	B-X
QGRS	B-X
distribution	B-X
patterns	B-X
among	B-X
all	B-X
the	B-X
alternative	B-X
RNA	B-X
products	B-X
of	B-X
a	B-X
gene	B-X
simultaneously	B-X
on	B-X
a	B-X
single	B-X
screen	B-X
.	B-X
QGRS	B-X
Mapper	B-X
can	B-X
be	B-X
accessed	B-X
at	B-X
http	B-X
:	B-X
//bioinformatics.ramapo.edu/QGRS/	B-X
.	B-X

We	O
have	O
developed	O
a	O
web	O
-	O
based	O
server	O
,	O
QGRS	O
Mapper	O
,	O
that	O
predicts	O
quadruplex	O
forming	O
G	O
-	O
rich	O
sequences	O
(	O
QGRS	O
)	O
in	O
nucleotide	O
sequences	O
.	O

It	O
is	O
a	O
user	O
-	O
friendly	O
application	O
that	O
provides	O
many	O
options	O
for	O
defining	O
and	O
studying	O
G	O
-	O
quadruplexes	O
.	O
<EOS>	B-X
G-quadruplex	B-X
DNA	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
regulate	B-X
DNA	B-X
replication	B-X
and	B-X
may	B-X
control	B-X
cellular	B-X
proliferation	B-X
.	B-X
Sequences	B-X
capable	B-X
of	B-X
forming	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
RNA	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
significant	B-X
roles	B-X
in	B-X
regulation	B-X
of	B-X
polyadenylation	B-X
and	B-X
splicing	B-X
events	B-X
in	B-X
mammalian	B-X
transcripts	B-X
.	B-X
Computational	B-X
approaches	B-X
to	B-X
study	B-X
G-quadruplexes	B-X
allow	B-X
detailed	B-X
analysis	B-X
of	B-X
mammalian	B-X
genomes	B-X
.	B-X
There	B-X
are	B-X
no	B-X
known	B-X
easily	B-X
accessible	B-X
user-friendly	B-X
tools	B-X
that	B-X
can	B-X
compute	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
nucleotide	B-X
sequences	B-X
.	B-X
We	B-X
have	B-X
developed	B-X
a	B-X
web-based	B-X
server	B-X
,	B-X
QGRS	B-X
Mapper	B-X
,	B-X
that	B-X
predicts	B-X
quadruplex	B-X
forming	B-X
G-rich	B-X
sequences	B-X
(	B-X
QGRS	B-X
)	B-X
in	B-X
nucleotide	B-X
sequences	B-X
.	B-X
It	B-X
is	B-X
a	B-X
user-friendly	B-X
application	B-X
that	B-X
provides	B-X
many	B-X
options	B-X
for	B-X
defining	B-X
and	B-X
studying	B-X
G-quadruplexes	B-X
.	B-X
It	B-X
performs	B-X
analysis	B-X
of	B-X
the	B-X
user	B-X
provided	B-X
genomic	B-X
sequences	B-X
,	B-X
e.g	B-X
.	B-X
It	B-X
is	B-X
also	B-X
useful	B-X
for	B-X
predicting	B-X
G-quadruplex	B-X
structures	B-X
in	B-X
oligonucleotides	B-X
.	B-X
The	B-X
program	B-X
provides	B-X
options	B-X
to	B-X
search	B-X
and	B-X
retrieve	B-X
desired	B-X
gene/nucleotide	B-X
sequence	B-X
entries	B-X
from	B-X
NCBI	B-X
databases	B-X
for	B-X
mapping	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
context	B-X
of	B-X
RNA	B-X
processing	B-X
sites	B-X
.	B-X
This	B-X
feature	B-X
is	B-X
very	B-X
useful	B-X
for	B-X
investigating	B-X
the	B-X
functional	B-X
relevance	B-X
of	B-X
G-quadruplex	B-X
structure	B-X
,	B-X
in	B-X
particular	B-X
its	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
gene	B-X
expression	B-X
by	B-X
alternative	B-X
processing	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
providing	B-X
data	B-X
on	B-X
composition	B-X
and	B-X
locations	B-X
of	B-X
QGRS	B-X
relative	B-X
to	B-X
the	B-X
processing	B-X
sites	B-X
in	B-X
the	B-X
pre-mRNA	B-X
sequence	B-X
,	B-X
QGRS	B-X
Mapper	B-X
features	B-X
interactive	B-X
graphic	B-X
representation	B-X
of	B-X
the	B-X
data	B-X
.	B-X
The	B-X
user	B-X
can	B-X
also	B-X
use	B-X
the	B-X
graphics	B-X
module	B-X
to	B-X
visualize	B-X
QGRS	B-X
distribution	B-X
patterns	B-X
among	B-X
all	B-X
the	B-X
alternative	B-X
RNA	B-X
products	B-X
of	B-X
a	B-X
gene	B-X
simultaneously	B-X
on	B-X
a	B-X
single	B-X
screen	B-X
.	B-X
QGRS	B-X
Mapper	B-X
can	B-X
be	B-X
accessed	B-X
at	B-X
http	B-X
:	B-X
//bioinformatics.ramapo.edu/QGRS/	B-X
.	B-X

It	O
performs	O
analysis	O
of	O
the	O
user	O
provided	O
genomic	O
sequences	O
,	O
e	O
.	O
g	O
.	O
promoter	O
and	O
telomeric	O
regions	O
,	O
as	O
well	O
as	O
RNA	O
sequences	O
.	O

It	O
is	O
also	O
useful	O
for	O
predicting	O
G	O
-	O
quadruplex	O
structures	O
in	O
oligonucleotides	O
.	O
<EOS>	B-X
The	B-X
quadruplex	B-X
structures	B-X
formed	B-X
by	B-X
guanine-rich	B-X
nucleic	B-X
acid	B-X
sequences	B-X
have	B-X
received	B-X
significant	B-X
attention	B-X
recently	B-X
because	B-X
of	B-X
growing	B-X
evidence	B-X
for	B-X
their	B-X
role	B-X
in	B-X
important	B-X
biological	B-X
processes	B-X
and	B-X
as	B-X
therapeutic	B-X
targets	B-X
.	B-X
G-quadruplex	B-X
DNA	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
regulate	B-X
DNA	B-X
replication	B-X
and	B-X
may	B-X
control	B-X
cellular	B-X
proliferation	B-X
.	B-X
Sequences	B-X
capable	B-X
of	B-X
forming	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
RNA	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
significant	B-X
roles	B-X
in	B-X
regulation	B-X
of	B-X
polyadenylation	B-X
and	B-X
splicing	B-X
events	B-X
in	B-X
mammalian	B-X
transcripts	B-X
.	B-X
Whether	B-X
quadruplex	B-X
structure	B-X
directly	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
RNA	B-X
processing	B-X
requires	B-X
investigation	B-X
.	B-X
Computational	B-X
approaches	B-X
to	B-X
study	B-X
G-quadruplexes	B-X
allow	B-X
detailed	B-X
analysis	B-X
of	B-X
mammalian	B-X
genomes	B-X
.	B-X
There	B-X
are	B-X
no	B-X
known	B-X
easily	B-X
accessible	B-X
user-friendly	B-X
tools	B-X
that	B-X
can	B-X
compute	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
nucleotide	B-X
sequences	B-X
.	B-X
We	B-X
have	B-X
developed	B-X
a	B-X
web-based	B-X
server	B-X
,	B-X
QGRS	B-X
Mapper	B-X
,	B-X
that	B-X
predicts	B-X
quadruplex	B-X
forming	B-X
G-rich	B-X
sequences	B-X
(	B-X
QGRS	B-X
)	B-X
in	B-X
nucleotide	B-X
sequences	B-X
.	B-X
It	B-X
is	B-X
a	B-X
user-friendly	B-X
application	B-X
that	B-X
provides	B-X
many	B-X
options	B-X
for	B-X
defining	B-X
and	B-X
studying	B-X
G-quadruplexes	B-X
.	B-X
It	B-X
is	B-X
also	B-X
useful	B-X
for	B-X
predicting	B-X
G-quadruplex	B-X
structures	B-X
in	B-X
oligonucleotides	B-X
.	B-X
The	B-X
program	B-X
provides	B-X
options	B-X
to	B-X
search	B-X
and	B-X
retrieve	B-X
desired	B-X
gene/nucleotide	B-X
sequence	B-X
entries	B-X
from	B-X
NCBI	B-X
databases	B-X
for	B-X
mapping	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
context	B-X
of	B-X
RNA	B-X
processing	B-X
sites	B-X
.	B-X
This	B-X
feature	B-X
is	B-X
very	B-X
useful	B-X
for	B-X
investigating	B-X
the	B-X
functional	B-X
relevance	B-X
of	B-X
G-quadruplex	B-X
structure	B-X
,	B-X
in	B-X
particular	B-X
its	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
gene	B-X
expression	B-X
by	B-X
alternative	B-X
processing	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
providing	B-X
data	B-X
on	B-X
composition	B-X
and	B-X
locations	B-X
of	B-X
QGRS	B-X
relative	B-X
to	B-X
the	B-X
processing	B-X
sites	B-X
in	B-X
the	B-X
pre-mRNA	B-X
sequence	B-X
,	B-X
QGRS	B-X
Mapper	B-X
features	B-X
interactive	B-X
graphic	B-X
representation	B-X
of	B-X
the	B-X
data	B-X
.	B-X
The	B-X
user	B-X
can	B-X
also	B-X
use	B-X
the	B-X
graphics	B-X
module	B-X
to	B-X
visualize	B-X
QGRS	B-X
distribution	B-X
patterns	B-X
among	B-X
all	B-X
the	B-X
alternative	B-X
RNA	B-X
products	B-X
of	B-X
a	B-X
gene	B-X
simultaneously	B-X
on	B-X
a	B-X
single	B-X
screen	B-X
.	B-X
QGRS	B-X
Mapper	B-X
can	B-X
be	B-X
accessed	B-X
at	B-X
http	B-X
:	B-X
//bioinformatics.ramapo.edu/QGRS/	B-X
.	B-X

The	O
program	O
provides	O
options	O
to	O
search	O
and	O
retrieve	O
desired	O
gene	O
/	O
nucleotide	O
sequence	O
entries	O
from	O
NCBI	O
databases	O
for	O
mapping	O
G	O
-	O
quadruplexes	O
in	O
the	O
context	O
of	O
RNA	O
processing	O
sites	O
.	O
<EOS>	B-X
The	B-X
quadruplex	B-X
structures	B-X
formed	B-X
by	B-X
guanine-rich	B-X
nucleic	B-X
acid	B-X
sequences	B-X
have	B-X
received	B-X
significant	B-X
attention	B-X
recently	B-X
because	B-X
of	B-X
growing	B-X
evidence	B-X
for	B-X
their	B-X
role	B-X
in	B-X
important	B-X
biological	B-X
processes	B-X
and	B-X
as	B-X
therapeutic	B-X
targets	B-X
.	B-X
G-quadruplex	B-X
DNA	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
regulate	B-X
DNA	B-X
replication	B-X
and	B-X
may	B-X
control	B-X
cellular	B-X
proliferation	B-X
.	B-X
Sequences	B-X
capable	B-X
of	B-X
forming	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
RNA	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
significant	B-X
roles	B-X
in	B-X
regulation	B-X
of	B-X
polyadenylation	B-X
and	B-X
splicing	B-X
events	B-X
in	B-X
mammalian	B-X
transcripts	B-X
.	B-X
Whether	B-X
quadruplex	B-X
structure	B-X
directly	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
RNA	B-X
processing	B-X
requires	B-X
investigation	B-X
.	B-X
Computational	B-X
approaches	B-X
to	B-X
study	B-X
G-quadruplexes	B-X
allow	B-X
detailed	B-X
analysis	B-X
of	B-X
mammalian	B-X
genomes	B-X
.	B-X
There	B-X
are	B-X
no	B-X
known	B-X
easily	B-X
accessible	B-X
user-friendly	B-X
tools	B-X
that	B-X
can	B-X
compute	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
nucleotide	B-X
sequences	B-X
.	B-X
We	B-X
have	B-X
developed	B-X
a	B-X
web-based	B-X
server	B-X
,	B-X
QGRS	B-X
Mapper	B-X
,	B-X
that	B-X
predicts	B-X
quadruplex	B-X
forming	B-X
G-rich	B-X
sequences	B-X
(	B-X
QGRS	B-X
)	B-X
in	B-X
nucleotide	B-X
sequences	B-X
.	B-X
It	B-X
is	B-X
a	B-X
user-friendly	B-X
application	B-X
that	B-X
provides	B-X
many	B-X
options	B-X
for	B-X
defining	B-X
and	B-X
studying	B-X
G-quadruplexes	B-X
.	B-X
It	B-X
performs	B-X
analysis	B-X
of	B-X
the	B-X
user	B-X
provided	B-X
genomic	B-X
sequences	B-X
,	B-X
e.g	B-X
.	B-X
promoter	B-X
and	B-X
telomeric	B-X
regions	B-X
,	B-X
as	B-X
well	B-X
as	B-X
RNA	B-X
sequences	B-X
.	B-X
It	B-X
is	B-X
also	B-X
useful	B-X
for	B-X
predicting	B-X
G-quadruplex	B-X
structures	B-X
in	B-X
oligonucleotides	B-X
.	B-X
The	B-X
program	B-X
provides	B-X
options	B-X
to	B-X
search	B-X
and	B-X
retrieve	B-X
desired	B-X
gene/nucleotide	B-X
sequence	B-X
entries	B-X
from	B-X
NCBI	B-X
databases	B-X
for	B-X
mapping	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
context	B-X
of	B-X
RNA	B-X
processing	B-X
sites	B-X
.	B-X
This	B-X
feature	B-X
is	B-X
very	B-X
useful	B-X
for	B-X
investigating	B-X
the	B-X
functional	B-X
relevance	B-X
of	B-X
G-quadruplex	B-X
structure	B-X
,	B-X
in	B-X
particular	B-X
its	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
gene	B-X
expression	B-X
by	B-X
alternative	B-X
processing	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
providing	B-X
data	B-X
on	B-X
composition	B-X
and	B-X
locations	B-X
of	B-X
QGRS	B-X
relative	B-X
to	B-X
the	B-X
processing	B-X
sites	B-X
in	B-X
the	B-X
pre-mRNA	B-X
sequence	B-X
,	B-X
QGRS	B-X
Mapper	B-X
features	B-X
interactive	B-X
graphic	B-X
representation	B-X
of	B-X
the	B-X
data	B-X
.	B-X
The	B-X
user	B-X
can	B-X
also	B-X
use	B-X
the	B-X
graphics	B-X
module	B-X
to	B-X
visualize	B-X
QGRS	B-X
distribution	B-X
patterns	B-X
among	B-X
all	B-X
the	B-X
alternative	B-X
RNA	B-X
products	B-X
of	B-X
a	B-X
gene	B-X
simultaneously	B-X
on	B-X
a	B-X
single	B-X
screen	B-X
.	B-X
QGRS	B-X
Mapper	B-X
can	B-X
be	B-X
accessed	B-X
at	B-X
http	B-X
:	B-X
//bioinformatics.ramapo.edu/QGRS/	B-X
.	B-X

This	O
feature	O
is	O
very	O
useful	O
for	O
investigating	O
the	O
functional	O
relevance	O
of	O
G	O
-	O
quadruplex	O
structure	O
,	O
in	O
particular	O
its	O
role	O
in	O
regulating	O
the	O
gene	O
expression	O
by	O
alternative	O
processing	O
.	O
<EOS>	B-X
The	B-X
quadruplex	B-X
structures	B-X
formed	B-X
by	B-X
guanine-rich	B-X
nucleic	B-X
acid	B-X
sequences	B-X
have	B-X
received	B-X
significant	B-X
attention	B-X
recently	B-X
because	B-X
of	B-X
growing	B-X
evidence	B-X
for	B-X
their	B-X
role	B-X
in	B-X
important	B-X
biological	B-X
processes	B-X
and	B-X
as	B-X
therapeutic	B-X
targets	B-X
.	B-X
G-quadruplex	B-X
DNA	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
regulate	B-X
DNA	B-X
replication	B-X
and	B-X
may	B-X
control	B-X
cellular	B-X
proliferation	B-X
.	B-X
Sequences	B-X
capable	B-X
of	B-X
forming	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
RNA	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
significant	B-X
roles	B-X
in	B-X
regulation	B-X
of	B-X
polyadenylation	B-X
and	B-X
splicing	B-X
events	B-X
in	B-X
mammalian	B-X
transcripts	B-X
.	B-X
Whether	B-X
quadruplex	B-X
structure	B-X
directly	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
RNA	B-X
processing	B-X
requires	B-X
investigation	B-X
.	B-X
Computational	B-X
approaches	B-X
to	B-X
study	B-X
G-quadruplexes	B-X
allow	B-X
detailed	B-X
analysis	B-X
of	B-X
mammalian	B-X
genomes	B-X
.	B-X
There	B-X
are	B-X
no	B-X
known	B-X
easily	B-X
accessible	B-X
user-friendly	B-X
tools	B-X
that	B-X
can	B-X
compute	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
nucleotide	B-X
sequences	B-X
.	B-X
We	B-X
have	B-X
developed	B-X
a	B-X
web-based	B-X
server	B-X
,	B-X
QGRS	B-X
Mapper	B-X
,	B-X
that	B-X
predicts	B-X
quadruplex	B-X
forming	B-X
G-rich	B-X
sequences	B-X
(	B-X
QGRS	B-X
)	B-X
in	B-X
nucleotide	B-X
sequences	B-X
.	B-X
It	B-X
is	B-X
a	B-X
user-friendly	B-X
application	B-X
that	B-X
provides	B-X
many	B-X
options	B-X
for	B-X
defining	B-X
and	B-X
studying	B-X
G-quadruplexes	B-X
.	B-X
It	B-X
is	B-X
also	B-X
useful	B-X
for	B-X
predicting	B-X
G-quadruplex	B-X
structures	B-X
in	B-X
oligonucleotides	B-X
.	B-X
The	B-X
program	B-X
provides	B-X
options	B-X
to	B-X
search	B-X
and	B-X
retrieve	B-X
desired	B-X
gene/nucleotide	B-X
sequence	B-X
entries	B-X
from	B-X
NCBI	B-X
databases	B-X
for	B-X
mapping	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
context	B-X
of	B-X
RNA	B-X
processing	B-X
sites	B-X
.	B-X
This	B-X
feature	B-X
is	B-X
very	B-X
useful	B-X
for	B-X
investigating	B-X
the	B-X
functional	B-X
relevance	B-X
of	B-X
G-quadruplex	B-X
structure	B-X
,	B-X
in	B-X
particular	B-X
its	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
gene	B-X
expression	B-X
by	B-X
alternative	B-X
processing	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
providing	B-X
data	B-X
on	B-X
composition	B-X
and	B-X
locations	B-X
of	B-X
QGRS	B-X
relative	B-X
to	B-X
the	B-X
processing	B-X
sites	B-X
in	B-X
the	B-X
pre-mRNA	B-X
sequence	B-X
,	B-X
QGRS	B-X
Mapper	B-X
features	B-X
interactive	B-X
graphic	B-X
representation	B-X
of	B-X
the	B-X
data	B-X
.	B-X
The	B-X
user	B-X
can	B-X
also	B-X
use	B-X
the	B-X
graphics	B-X
module	B-X
to	B-X
visualize	B-X
QGRS	B-X
distribution	B-X
patterns	B-X
among	B-X
all	B-X
the	B-X
alternative	B-X
RNA	B-X
products	B-X
of	B-X
a	B-X
gene	B-X
simultaneously	B-X
on	B-X
a	B-X
single	B-X
screen	B-X
.	B-X
QGRS	B-X
Mapper	B-X
can	B-X
be	B-X
accessed	B-X
at	B-X
http	B-X
:	B-X
//bioinformatics.ramapo.edu/QGRS/	B-X
.	B-X

In	O
addition	O
to	O
providing	O
data	O
on	O
composition	O
and	O
locations	O
of	O
QGRS	O
relative	O
to	O
the	O
processing	O
sites	O
in	O
the	O
pre	O
-	O
mRNA	O
sequence	O
,	O
QGRS	O
Mapper	O
features	O
interactive	O
graphic	O
representation	O
of	O
the	O
data	O
.	O

The	O
user	O
can	O
also	O
use	O
the	O
graphics	O
module	O
to	O
visualize	O
QGRS	O
distribution	O
patterns	O
among	O
all	O
the	O
alternative	O
RNA	O
products	O
of	O
a	O
gene	O
simultaneously	O
on	O
a	O
single	O
screen	O
.	O
<EOS>	B-X
The	B-X
quadruplex	B-X
structures	B-X
formed	B-X
by	B-X
guanine-rich	B-X
nucleic	B-X
acid	B-X
sequences	B-X
have	B-X
received	B-X
significant	B-X
attention	B-X
recently	B-X
because	B-X
of	B-X
growing	B-X
evidence	B-X
for	B-X
their	B-X
role	B-X
in	B-X
important	B-X
biological	B-X
processes	B-X
and	B-X
as	B-X
therapeutic	B-X
targets	B-X
.	B-X
Sequences	B-X
capable	B-X
of	B-X
forming	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
RNA	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
significant	B-X
roles	B-X
in	B-X
regulation	B-X
of	B-X
polyadenylation	B-X
and	B-X
splicing	B-X
events	B-X
in	B-X
mammalian	B-X
transcripts	B-X
.	B-X
Whether	B-X
quadruplex	B-X
structure	B-X
directly	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
RNA	B-X
processing	B-X
requires	B-X
investigation	B-X
.	B-X
There	B-X
are	B-X
no	B-X
known	B-X
easily	B-X
accessible	B-X
user-friendly	B-X
tools	B-X
that	B-X
can	B-X
compute	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
nucleotide	B-X
sequences	B-X
.	B-X
We	B-X
have	B-X
developed	B-X
a	B-X
web-based	B-X
server	B-X
,	B-X
QGRS	B-X
Mapper	B-X
,	B-X
that	B-X
predicts	B-X
quadruplex	B-X
forming	B-X
G-rich	B-X
sequences	B-X
(	B-X
QGRS	B-X
)	B-X
in	B-X
nucleotide	B-X
sequences	B-X
.	B-X
It	B-X
is	B-X
a	B-X
user-friendly	B-X
application	B-X
that	B-X
provides	B-X
many	B-X
options	B-X
for	B-X
defining	B-X
and	B-X
studying	B-X
G-quadruplexes	B-X
.	B-X
It	B-X
performs	B-X
analysis	B-X
of	B-X
the	B-X
user	B-X
provided	B-X
genomic	B-X
sequences	B-X
,	B-X
e.g	B-X
.	B-X
promoter	B-X
and	B-X
telomeric	B-X
regions	B-X
,	B-X
as	B-X
well	B-X
as	B-X
RNA	B-X
sequences	B-X
.	B-X
It	B-X
is	B-X
also	B-X
useful	B-X
for	B-X
predicting	B-X
G-quadruplex	B-X
structures	B-X
in	B-X
oligonucleotides	B-X
.	B-X
The	B-X
program	B-X
provides	B-X
options	B-X
to	B-X
search	B-X
and	B-X
retrieve	B-X
desired	B-X
gene/nucleotide	B-X
sequence	B-X
entries	B-X
from	B-X
NCBI	B-X
databases	B-X
for	B-X
mapping	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
context	B-X
of	B-X
RNA	B-X
processing	B-X
sites	B-X
.	B-X
This	B-X
feature	B-X
is	B-X
very	B-X
useful	B-X
for	B-X
investigating	B-X
the	B-X
functional	B-X
relevance	B-X
of	B-X
G-quadruplex	B-X
structure	B-X
,	B-X
in	B-X
particular	B-X
its	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
gene	B-X
expression	B-X
by	B-X
alternative	B-X
processing	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
providing	B-X
data	B-X
on	B-X
composition	B-X
and	B-X
locations	B-X
of	B-X
QGRS	B-X
relative	B-X
to	B-X
the	B-X
processing	B-X
sites	B-X
in	B-X
the	B-X
pre-mRNA	B-X
sequence	B-X
,	B-X
QGRS	B-X
Mapper	B-X
features	B-X
interactive	B-X
graphic	B-X
representation	B-X
of	B-X
the	B-X
data	B-X
.	B-X
The	B-X
user	B-X
can	B-X
also	B-X
use	B-X
the	B-X
graphics	B-X
module	B-X
to	B-X
visualize	B-X
QGRS	B-X
distribution	B-X
patterns	B-X
among	B-X
all	B-X
the	B-X
alternative	B-X
RNA	B-X
products	B-X
of	B-X
a	B-X
gene	B-X
simultaneously	B-X
on	B-X
a	B-X
single	B-X
screen	B-X
.	B-X
QGRS	B-X
Mapper	B-X
can	B-X
be	B-X
accessed	B-X
at	B-X
http	B-X
:	B-X
//bioinformatics.ramapo.edu/QGRS/	B-X
.	B-X

QGRS	O
Mapper	O
can	O
be	O
accessed	O
at	O
.	O
<EOS>	B-X
We	B-X
have	B-X
developed	B-X
a	B-X
web-based	B-X
server	B-X
,	B-X
QGRS	B-X
Mapper	B-X
,	B-X
that	B-X
predicts	B-X
quadruplex	B-X
forming	B-X
G-rich	B-X
sequences	B-X
(	B-X
QGRS	B-X
)	B-X
in	B-X
nucleotide	B-X
sequences	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
providing	B-X
data	B-X
on	B-X
composition	B-X
and	B-X
locations	B-X
of	B-X
QGRS	B-X
relative	B-X
to	B-X
the	B-X
processing	B-X
sites	B-X
in	B-X
the	B-X
pre-mRNA	B-X
sequence	B-X
,	B-X
QGRS	B-X
Mapper	B-X
features	B-X
interactive	B-X
graphic	B-X
representation	B-X
of	B-X
the	B-X
data	B-X
.	B-X
The	B-X
user	B-X
can	B-X
also	B-X
use	B-X
the	B-X
graphics	B-X
module	B-X
to	B-X
visualize	B-X
QGRS	B-X
distribution	B-X
patterns	B-X
among	B-X
all	B-X
the	B-X
alternative	B-X
RNA	B-X
products	B-X
of	B-X
a	B-X
gene	B-X
simultaneously	B-X
on	B-X
a	B-X
single	B-X
screen	B-X
.	B-X
QGRS	B-X
Mapper	B-X
can	B-X
be	B-X
accessed	B-X
at	B-X
http	B-X
:	B-X
//bioinformatics.ramapo.edu/QGRS/	B-X
.	B-X

INTRODUCTION	O

The	O
quadruplex	O
structures	O
formed	O
by	O
guanine	O
-	O
rich	O
nucleic	O
acid	O
sequences	O
have	O
received	O
significant	O
attention	O
recently	O
because	O
of	O
increasing	O
evidence	O
for	O
their	O
role	O
in	O
important	O
biological	O
processes	O
and	O
as	O
therapeutic	O
targets	O
(	O
1	O
-	O
5	O
)	O
.	O

The	O
G	O
-	O
quadruplex	O
structure	O
,	O
also	O
known	O
as	O
a	O
G	O
-	O
quartet	O
,	O
is	O
formed	O
by	O
repeated	O
folding	O
of	O
either	O
the	O
single	O
polynucleotide	O
molecule	O
or	O
by	O
association	O
of	O
two	O
or	O
four	O
molecules	O
.	O
<EOS>	B-X
The	B-X
implicit	B-X
association	B-X
test	B-X
enables	B-X
measurement	B-X
of	B-X
implicit	B-X
bias	B-X
via	B-X
tests	B-X
of	B-X
automatic	B-X
associations	B-X
between	B-X
concepts	B-X
.	B-X
Fourteen	B-X
studies	B-X
examined	B-X
the	B-X
association	B-X
between	B-X
implicit	B-X
bias	B-X
and	B-X
healthcare	B-X
outcomes	B-X
using	B-X
clinical	B-X
vignettes	B-X
or	B-X
simulated	B-X
patients	B-X
.	B-X
Eight	B-X
found	B-X
no	B-X
statistically	B-X
significant	B-X
association	B-X
between	B-X
implicit	B-X
bias	B-X
and	B-X
patient	B-X
care	B-X
while	B-X
six	B-X
studies	B-X
found	B-X
that	B-X
higher	B-X
implicit	B-X
bias	B-X
was	B-X
associated	B-X
with	B-X
disparities	B-X
in	B-X
treatment	B-X
recommendations	B-X
,	B-X
expectations	B-X
of	B-X
therapeutic	B-X
bonds	B-X
,	B-X
pain	B-X
management	B-X
,	B-X
and	B-X
empathy	B-X
.	B-X
One	B-X
found	B-X
an	B-X
association	B-X
and	B-X
the	B-X
other	B-X
did	B-X
not	B-X
.	B-X

The	O
structure	O
consists	O
of	O
stacked	O
G	O
-	O
tetrads	O
,	O
which	O
are	O
square	O
co	O
-	O
planar	O
arrays	O
of	O
four	O
guanine	O
bases	O
each	O
(	O
6	O
)	O
.	O

G	O
-	O
quadruplex	O
is	O
stabilized	O
with	O
cyclic	O
Hoogsteen	O
hydrogen	O
bonding	O
between	O
the	O
four	O
guanines	O
within	O
each	O
tetrad	O
.	O
<EOS>	B-X
G-quadruplexes	B-X
are	B-X
formed	B-X
by	B-X
the	B-X
association	B-X
of	B-X
four	B-X
guanine	B-X
bases	B-X
through	B-X
Hoogsteen	B-X
hydrogen	B-X
bonding	B-X
in	B-X
guanine-rich	B-X
sequences	B-X
of	B-X
DNA	B-X
and	B-X
exist	B-X
in	B-X
the	B-X
telomere	B-X
as	B-X
well	B-X
as	B-X
in	B-X
promoter	B-X
regions	B-X
of	B-X
certain	B-X
oncogenes	B-X
.	B-X
The	B-X
sequences	B-X
of	B-X
G-quadruplex-DNA	B-X
are	B-X
targets	B-X
for	B-X
the	B-X
design	B-X
of	B-X
molecules	B-X
that	B-X
can	B-X
bind	B-X
and	B-X
can	B-X
be	B-X
developed	B-X
as	B-X
anti-cancer	B-X
drugs	B-X
.	B-X
The	B-X
linear	B-X
and	B-X
cyclic	B-X
protonated	B-X
diamines	B-X
have	B-X
been	B-X
explored	B-X
to	B-X
bind	B-X
to	B-X
G-quadruplex-DNA	B-X
through	B-X
hydrogen	B-X
bonding	B-X
interactions	B-X
.	B-X
The	B-X
quadruplex-DNA	B-X
binders	B-X
exploit	B-X
Ï-stacking	B-X
and	B-X
hydrogen	B-X
bonding	B-X
interactions	B-X
with	B-X
the	B-X
phosphate	B-X
backbone	B-X
of	B-X
loops	B-X
and	B-X
grooves	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
linear	B-X
and	B-X
cyclic	B-X
protonated	B-X
diamines	B-X
showed	B-X
remarkable	B-X
binding	B-X
affinity	B-X
for	B-X
G-tetrads	B-X
using	B-X
hydrogen	B-X
bonding	B-X
interactions	B-X
.	B-X
The	B-X
DFT	B-X
M06-2X/6-31G	B-X
(	B-X
d	B-X
)	B-X
//B3LYP/6-31+G	B-X
(	B-X
d	B-X
)	B-X
level	B-X
of	B-X
theory	B-X
showed	B-X
that	B-X
the	B-X
cyclic	B-X
ee-1,2-CHDA	B-X
(	B-X
equatorial-equatorial	B-X
form	B-X
of	B-X
1,2-disubstituted	B-X
cyclohexadiamine	B-X
di-cation	B-X
)	B-X
binds	B-X
to	B-X
the	B-X
G-tetrads	B-X
very	B-X
strongly	B-X
(	B-X
â¼70.0	B-X
kcal	B-X
mol	B-X

The	O
present	O
work	O
focuses	O
only	O
on	O
the	O
unimolecular	O
quadruplexes	O
,	O
since	O
it	O
is	O
more	O
likely	O
to	O
be	O
encountered	O
in	O
physiological	O
conditions	O
(	O
7	O
,	O
8	O
)	O
.	O

Guanine	O
-	O
rich	O
sequences	O
capable	O
of	O
forming	O
G	O
-	O
quadruplexes	O
are	O
found	O
in	O
telomeres	O
,	O
promoter	O
regions	O
,	O
transcribed	O
and	O
other	O
biologically	O
important	O
regions	O
of	O
the	O
mammalian	O
genomes	O
.	O

G	O
-	O
quadruplex	O
DNA	O
has	O
been	O
suggested	O
to	O
regulate	O
DNA	O
replication	O
in	O
retinoblastoma	O
susceptibility	O
gene	O
(	O
Rb	O
)	O
region	O
(	O
9	O
)	O
.	O

This	O
structure	O
may	O
control	O
cellular	O
proliferation	O
at	O
telomeric	O
level	O
and	O
by	O
transcriptional	O
regulation	O
of	O
oncogenes	O
like	O
c	O
-	O
myc	O
(	O
2	O
,	O
10	O
,	O
11	O
)	O
and	O
c	O
-	O
kit	O
(	O
12	O
)	O
.	O

Formation	O
of	O
G	O
-	O
quadruplex	O
seems	O
to	O
be	O
regulated	O
through	O
interactions	O
with	O
cellular	O
proteins	O
.	O
<EOS>	B-X
These	B-X
characteristics	B-X
allow	B-X
us	B-X
to	B-X
further	B-X
investigate	B-X
the	B-X
interactions	B-X
of	B-X
challenging	B-X
proteins	B-X
like	B-X
Rap1-interacting	B-X
factor	B-X
1	B-X
(	B-X
Rif1	B-X
)	B-X
.	B-X
Rif1	B-X
is	B-X
a	B-X
crucial	B-X
protein	B-X
responsible	B-X
for	B-X
regulating	B-X
different	B-X
cellular	B-X
processes	B-X
including	B-X
DNA	B-X
replication	B-X
,	B-X
repair	B-X
,	B-X
and	B-X
transcription	B-X
.	B-X

While	O
some	O
proteins	O
help	O
stabilize	O
the	O
structure	O
(	O
13	O
)	O
,	O
others	O
are	O
known	O
to	O
resolve	O
it	O
(	O
1	O
,	O
4	O
,	O
14	O
,	O
15	O
)	O
.	O

Proteins	O
and	O
chemicals	O
that	O
stabilize	O
the	O
G	O
-	O
quadruplex	O
structure	O
can	O
inhibit	O
telomerase	O
action	O
and	O
,	O
therefore	O
,	O
are	O
being	O
evaluated	O
as	O
anticancer	O
therapeutic	O
agents	O
(	O
16	O
-	O
20	O
)	O
.	O

Chemical	O
compounds	O
that	O
inhibit	O
G	O
-	O
quadruplex	O
helicase	O
activity	O
may	O
also	O
be	O
capable	O
of	O
regulating	O
cellular	O
proliferation	O
(	O
4	O
)	O
.	O

G	O
-	O
quadruplexes	O
are	O
also	O
being	O
eyed	O
as	O
potential	O
antimicrobial	O
agents	O
due	O
to	O
their	O
ability	O
to	O
transport	O
monovalent	O
anions	O
(	O
21	O
)	O
.	O

G	O
-	O
quadruplex	O
motifs	O
in	O
the	O
RNA	O
have	O
been	O
shown	O
to	O
play	O
significant	O
roles	O
in	O
mRNA	O
turnover	O
(	O
1	O
)	O
,	O
FMRP	O
binding	O
(	O
22	O
)	O
,	O
translation	O
initiation	O
(	O
23	O
)	O
as	O
well	O
as	O
repression	O
(	O
24	O
)	O
.	O

We	O
have	O
shown	O
previously	O
that	O
a	O
G	O
-	O
rich	O
sequence	O
(	O
GRS	O
)	O
can	O
mediate	O
3	O
'	O
end	O
processing	O
of	O
mammalian	O
pre	O
-	O
mRNAs	O
by	O
interacting	O
with	O
DSEF	O
-	O
1	O
/	O
hnRNPH	O
/	O
H	O
'	O
protein	O
(	O
25	O
-	O
27	O
)	O
.	O

Members	O
of	O
the	O
hnRNP	O
H	O
protein	O
family	O
recognize	O
G	O
-	O
rich	O
motifs	O
capable	O
of	O
forming	O
G	O
-	O
quadruplexes	O
and	O
are	O
known	O
to	O
regulate	O
polyadenylation	O
and	O
splicing	O
events	O
in	O
mammalian	O
transcripts	O
(	O
28	O
-	O
30	O
)	O
.	O

Regulated	O
RNA	O
processing	O
is	O
an	O
essential	O
component	O
of	O
differential	O
gene	O
expression	O
which	O
is	O
central	O
to	O
many	O
important	O
biologically	O
processes	O
.	O

More	O
than	O
half	O
of	O
human	B-Species
genes	O
are	O
known	O
to	O
have	O
alternative	O
polyadenylation	O
(	O
31	O
)	O
.	O

Over	O
two	O
-	O
thirds	O
of	O
human	B-Species
genes	O
are	O
thought	O
to	O
undergo	O
alternative	O
splicing	O
(	O
32	O
)	O
.	O

Sequences	O
capable	O
of	O
forming	O
G	O
-	O
quadruplexes	O
found	O
in	O
the	O
vicinity	O
of	O
polyadenylation	O
and	O
splice	O
sites	O
act	O
as	O
regulators	O
by	O
interacting	O
with	O
hnRNP	O
F	O
and	O
H	O
proteins	O
(	O
25	O
-	O
27	O
,	O
30	O
,	O
33	O
)	O
.	O

Whether	O
quadruplex	O
structure	O
directly	O
plays	O
a	O
role	O
in	O
regulating	O
RNA	O
processing	O
events	O
requires	O
investigation	O
.	O

Computational	O
approaches	O
to	O
study	O
G	O
-	O
quadruplexes	O
in	O
the	O
mammalian	O
genomes	O
allow	O
large	O
-	O
scale	O
and	O
detailed	O
analysis	O
of	O
mammalian	O
genes	O
.	O

Although	O
,	O
G	O
-	O
quadruplexes	O
have	O
been	O
surveyed	O
in	O
the	O
human	B-Species
genome	O
with	O
such	O
techniques	O
(	O
34	O
,	O
35	O
)	O
,	O
there	O
are	O
no	O
known	O
user	O
-	O
friendly	O
computational	O
tools	O
easily	O
accessible	O
to	O
the	O
public	O
.	O

We	O
had	O
previously	O
built	O
a	O
database	O
of	O
mapped	O
G	O
-	O
quadruplex	O
sequences	O
in	O
selected	O
alternatively	O
processed	O
human	B-Species
and	O
mouse	B-Species
genes	O
(	O
36	O
)	O
.	O

Our	O
preliminary	O
analysis	O
of	O
the	O
database	O
suggests	O
prevalence	O
of	O
such	O
motifs	O
near	O
alternative	O
splice	O
and	O
poly	O
(	O
A	O
)	O
sites	O
.	O

We	O
have	O
now	O
developed	O
a	O
web	O
-	O
based	O
server	O
,	O
QGRS	O
Mapper	O
,	O
that	O
generates	O
detailed	O
information	O
on	O
composition	O
and	O
distribution	O
of	O
putative	O
quadruplex	O
forming	O
G	O
-	O
rich	O
sequences	O
(	O
QGRS	O
)	O
in	O
any	O
NCBI	O
nucleotide	O
sequence	O
identified	O
or	O
provided	O
by	O
the	O
user	O
.	O
<EOS>	B-X
Data	B-X
aggregated	B-X
by	B-X
variant	B-X
are	B-X
accessible	B-X
on	B-X
the	B-X
website	B-X
,	B-X
in	B-X
an	B-X
improved	B-X
set	B-X
of	B-X
variant	B-X
call	B-X
format	B-X
files	B-X
and	B-X
as	B-X
a	B-X
new	B-X
comprehensive	B-X
XML	B-X
report	B-X
.	B-X
ClinVar	B-X
recently	B-X
started	B-X
accepting	B-X
submissions	B-X
that	B-X
are	B-X
focused	B-X
primarily	B-X
on	B-X
providing	B-X
phenotypic	B-X
information	B-X
for	B-X
individuals	B-X
who	B-X
have	B-X
had	B-X
genetic	B-X
testing	B-X
.	B-X
Submissions	B-X
may	B-X
come	B-X
from	B-X
clinical	B-X
providers	B-X
providing	B-X
their	B-X
own	B-X
interpretation	B-X
of	B-X
the	B-X
variant	B-X
(	B-X
'provider	B-X
interpretation	B-X
'	B-X
)	B-X
or	B-X
from	B-X
groups	B-X
such	B-X
as	B-X
patient	B-X
registries	B-X
that	B-X
primarily	B-X
provide	B-X
phenotypic	B-X
information	B-X
from	B-X
patients	B-X
(	B-X
'phenotyping	B-X
only	B-X
'	B-X
)	B-X
.	B-X
Several	B-X
new	B-X
fields	B-X
are	B-X
now	B-X
indexed	B-X
for	B-X
more	B-X
precise	B-X
searching	B-X
,	B-X
and	B-X
filters	B-X
allow	B-X
the	B-X
user	B-X
to	B-X
narrow	B-X
down	B-X
a	B-X
large	B-X
set	B-X
of	B-X
search	B-X
results	B-X
.	B-X

The	O
program	O
is	O
also	O
designed	O
to	O
handle	O
the	O
analysis	O
of	O
mammalian	O
pre	O
-	O
mRNA	O
sequences	O
,	O
including	O
those	O
that	O
are	O
alternatively	O
processed	O
(	O
alternatively	O
spliced	O
or	O
alternatively	O
polyadenylated	O
)	O
.	O

Researchers	O
interested	O
in	O
predicting	O
the	O
ability	O
of	O
a	O
nucleotide	O
sequence	O
to	O
form	O
G	O
-	O
quadruplex	O
structure	O
will	O
find	O
QGRS	O
Mapper	O
to	O
be	O
a	O
user	O
-	O
friendly	O
application	O
that	O
provides	O
many	O
options	O
for	O
analysis	O
.	O

The	O
user	O
can	O
define	O
the	O
minimum	O
number	O
of	O
tetrads	O
,	O
maximum	O
length	O
of	O
the	O
G	O
-	O
quadruplex	O
motif	O
,	O
and	O
size	O
as	O
well	O
as	O
composition	O
of	O
the	O
loops	O
.	O

The	O
program	O
can	O
map	O
unimolecular	O
QGRS	O
in	O
the	O
entire	O
nucleotide	O
sequence	O
provided	O
in	O
the	O
raw	O
or	O
FASTA	O
format	O
by	O
the	O
user	O
.	O
<EOS>	B-X
The	B-X
DOE	B-X
Joint	B-X
Genome	B-X
Institute	B-X
(	B-X
JGI	B-X
)	B-X
Metagenome	B-X
Workflow	B-X
performs	B-X
metagenome	B-X
data	B-X
processing	B-X
,	B-X
including	B-X
assembly	B-X
;	B-X
structural	B-X
,	B-X
functional	B-X
,	B-X
and	B-X
taxonomic	B-X
annotation	B-X
;	B-X
and	B-X
binning	B-X
of	B-X
metagenomic	B-X
data	B-X
sets	B-X
that	B-X
are	B-X
subsequently	B-X
included	B-X
into	B-X
the	B-X
Integrated	B-X
Microbial	B-X
Genomes	B-X
and	B-X
Microbiomes	B-X
(	B-X
IMG/M	B-X
)	B-X
(	B-X
I.-M.	B-X
A.	B-X
Chen	B-X
,	B-X
K.	B-X
Chu	B-X
,	B-X
K.	B-X
Palaniappan	B-X
,	B-X
A.	B-X
Ratner	B-X
,	B-X
et	B-X
al.	B-X
,	B-X
Nucleic	B-X
Acids	B-X
Res	B-X
,	B-X
49	B-X
:	B-X
D751-D763	B-X
,	B-X
2021	B-X
,	B-X
https	B-X
:	B-X
//doi.org/10.1093/nar/gkaa939	B-X
)	B-X
comparative	B-X
analysis	B-X
system	B-X
and	B-X
provided	B-X
for	B-X
download	B-X
via	B-X
the	B-X
JGI	B-X
data	B-X
portal	B-X
(	B-X
https	B-X
:	B-X
//genome.jgi.doe.gov/portal/	B-X
)	B-X
.	B-X
The	B-X
workflow	B-X
modules	B-X
for	B-X
annotation	B-X
and	B-X
binning	B-X
are	B-X
provided	B-X
as	B-X
a	B-X
service	B-X
to	B-X
the	B-X
user	B-X
community	B-X
at	B-X
https	B-X
:	B-X
//img.jgi.doe.gov/submit	B-X
and	B-X
require	B-X
filling	B-X
out	B-X
the	B-X
project	B-X
and	B-X
associated	B-X
metadata	B-X
descriptions	B-X
in	B-X
the	B-X
Genomes	B-X
OnLine	B-X
Database	B-X
(	B-X
GOLD	B-X
)	B-X
(	B-X
S.	B-X
Mukherjee	B-X
,	B-X
D.	B-X
Stamatis	B-X
,	B-X
J.	B-X
Bertsch	B-X
,	B-X
G.	B-X
Ovchinnikova	B-X
,	B-X
et	B-X
al.	B-X
,	B-X
Nucleic	B-X
Acids	B-X
Res	B-X
,	B-X
49	B-X
:	B-X
D723-D733	B-X
,	B-X
2021	B-X
,	B-X
https	B-X
:	B-X
//doi.org/10.1093/nar/gkaa983	B-X
)	B-X
.	B-X
The	B-X
continuous	B-X
growth	B-X
of	B-X
generated	B-X
sequencing	B-X
data	B-X
leads	B-X
to	B-X
the	B-X
development	B-X
of	B-X
a	B-X
variety	B-X
of	B-X
associated	B-X
bioinformatics	B-X
tools	B-X
.	B-X
It	B-X
can	B-X
efficiently	B-X
read	B-X
FASTA	B-X
and	B-X
FASTQ	B-X
files	B-X
by	B-X
combining	B-X
a	B-X
lightweight	B-X
parsing	B-X
method	B-X
by	B-X
means	B-X
of	B-X
an	B-X
optimized	B-X
formatting	B-X
implementation	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
provide	B-X
user-friendly	B-X
and	B-X
modularized	B-X
C++	B-X
APIs	B-X
that	B-X
can	B-X
be	B-X
easily	B-X
integrated	B-X
into	B-X
applications	B-X
in	B-X
order	B-X
to	B-X
increase	B-X
their	B-X
file	B-X
parsing	B-X
speed	B-X
.	B-X

This	O
method	O
can	O
be	O
used	O
for	O
the	O
analysis	O
of	O
genomic	O
sequences	O
,	O
e	O
.	O
g	O
.	O
promoter	O
and	O
telomeric	O
regions	O
,	O
as	O
well	O
as	O
RNA	O
sequences	O
.	O

It	O
is	O
also	O
useful	O
for	O
predicting	O
G	O
-	O
quadruplex	O
structures	O
in	O
oligonucleotides	O
.	O
<EOS>	B-X
The	B-X
quadruplex	B-X
structures	B-X
formed	B-X
by	B-X
guanine-rich	B-X
nucleic	B-X
acid	B-X
sequences	B-X
have	B-X
received	B-X
significant	B-X
attention	B-X
recently	B-X
because	B-X
of	B-X
growing	B-X
evidence	B-X
for	B-X
their	B-X
role	B-X
in	B-X
important	B-X
biological	B-X
processes	B-X
and	B-X
as	B-X
therapeutic	B-X
targets	B-X
.	B-X
G-quadruplex	B-X
DNA	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
regulate	B-X
DNA	B-X
replication	B-X
and	B-X
may	B-X
control	B-X
cellular	B-X
proliferation	B-X
.	B-X
Sequences	B-X
capable	B-X
of	B-X
forming	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
RNA	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
significant	B-X
roles	B-X
in	B-X
regulation	B-X
of	B-X
polyadenylation	B-X
and	B-X
splicing	B-X
events	B-X
in	B-X
mammalian	B-X
transcripts	B-X
.	B-X
Whether	B-X
quadruplex	B-X
structure	B-X
directly	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
RNA	B-X
processing	B-X
requires	B-X
investigation	B-X
.	B-X
Computational	B-X
approaches	B-X
to	B-X
study	B-X
G-quadruplexes	B-X
allow	B-X
detailed	B-X
analysis	B-X
of	B-X
mammalian	B-X
genomes	B-X
.	B-X
There	B-X
are	B-X
no	B-X
known	B-X
easily	B-X
accessible	B-X
user-friendly	B-X
tools	B-X
that	B-X
can	B-X
compute	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
nucleotide	B-X
sequences	B-X
.	B-X
We	B-X
have	B-X
developed	B-X
a	B-X
web-based	B-X
server	B-X
,	B-X
QGRS	B-X
Mapper	B-X
,	B-X
that	B-X
predicts	B-X
quadruplex	B-X
forming	B-X
G-rich	B-X
sequences	B-X
(	B-X
QGRS	B-X
)	B-X
in	B-X
nucleotide	B-X
sequences	B-X
.	B-X
It	B-X
is	B-X
a	B-X
user-friendly	B-X
application	B-X
that	B-X
provides	B-X
many	B-X
options	B-X
for	B-X
defining	B-X
and	B-X
studying	B-X
G-quadruplexes	B-X
.	B-X
It	B-X
is	B-X
also	B-X
useful	B-X
for	B-X
predicting	B-X
G-quadruplex	B-X
structures	B-X
in	B-X
oligonucleotides	B-X
.	B-X
The	B-X
program	B-X
provides	B-X
options	B-X
to	B-X
search	B-X
and	B-X
retrieve	B-X
desired	B-X
gene/nucleotide	B-X
sequence	B-X
entries	B-X
from	B-X
NCBI	B-X
databases	B-X
for	B-X
mapping	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
context	B-X
of	B-X
RNA	B-X
processing	B-X
sites	B-X
.	B-X
This	B-X
feature	B-X
is	B-X
very	B-X
useful	B-X
for	B-X
investigating	B-X
the	B-X
functional	B-X
relevance	B-X
of	B-X
G-quadruplex	B-X
structure	B-X
,	B-X
in	B-X
particular	B-X
its	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
gene	B-X
expression	B-X
by	B-X
alternative	B-X
processing	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
providing	B-X
data	B-X
on	B-X
composition	B-X
and	B-X
locations	B-X
of	B-X
QGRS	B-X
relative	B-X
to	B-X
the	B-X
processing	B-X
sites	B-X
in	B-X
the	B-X
pre-mRNA	B-X
sequence	B-X
,	B-X
QGRS	B-X
Mapper	B-X
features	B-X
interactive	B-X
graphic	B-X
representation	B-X
of	B-X
the	B-X
data	B-X
.	B-X
The	B-X
user	B-X
can	B-X
also	B-X
use	B-X
the	B-X
graphics	B-X
module	B-X
to	B-X
visualize	B-X
QGRS	B-X
distribution	B-X
patterns	B-X
among	B-X
all	B-X
the	B-X
alternative	B-X
RNA	B-X
products	B-X
of	B-X
a	B-X
gene	B-X
simultaneously	B-X
on	B-X
a	B-X
single	B-X
screen	B-X
.	B-X
QGRS	B-X
Mapper	B-X
can	B-X
be	B-X
accessed	B-X
at	B-X
http	B-X
:	B-X
//bioinformatics.ramapo.edu/QGRS/	B-X
.	B-X

Alternatively	O
,	O
the	O
program	O
provides	O
options	O
to	O
search	O
the	O
entire	O
NCBI	O
Gene	O
Entrez	O
,	O
RefSeq	O
and	O
GenBank	O
databases	O
in	O
order	O
to	O
retrieve	O
the	O
desired	O
gene	O
/	O
nucleotide	O
sequence	O
entries	O
for	O
analysis	O
of	O
their	O
transcribed	O
regions	O
.	O

Furthermore	O
,	O
QGRS	O
Mapper	O
is	O
a	O
unique	O
tool	O
for	O
mapping	O
G	O
-	O
quadruplex	O
forming	O
sequences	O
in	O
the	O
context	O
of	O
RNA	O
processing	O
sites	O
.	O

This	O
feature	O
is	O
very	O
useful	O
for	O
investigating	O
the	O
functional	O
relevance	O
of	O
G	O
-	O
quadruplex	O
structure	O
,	O
in	O
particular	O
its	O
role	O
in	O
regulating	O
the	O
gene	O
expression	O
by	O
alternative	O
processing	O
.	O
<EOS>	B-X
The	B-X
quadruplex	B-X
structures	B-X
formed	B-X
by	B-X
guanine-rich	B-X
nucleic	B-X
acid	B-X
sequences	B-X
have	B-X
received	B-X
significant	B-X
attention	B-X
recently	B-X
because	B-X
of	B-X
growing	B-X
evidence	B-X
for	B-X
their	B-X
role	B-X
in	B-X
important	B-X
biological	B-X
processes	B-X
and	B-X
as	B-X
therapeutic	B-X
targets	B-X
.	B-X
G-quadruplex	B-X
DNA	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
regulate	B-X
DNA	B-X
replication	B-X
and	B-X
may	B-X
control	B-X
cellular	B-X
proliferation	B-X
.	B-X
Sequences	B-X
capable	B-X
of	B-X
forming	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
RNA	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
significant	B-X
roles	B-X
in	B-X
regulation	B-X
of	B-X
polyadenylation	B-X
and	B-X
splicing	B-X
events	B-X
in	B-X
mammalian	B-X
transcripts	B-X
.	B-X
Whether	B-X
quadruplex	B-X
structure	B-X
directly	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
RNA	B-X
processing	B-X
requires	B-X
investigation	B-X
.	B-X
Computational	B-X
approaches	B-X
to	B-X
study	B-X
G-quadruplexes	B-X
allow	B-X
detailed	B-X
analysis	B-X
of	B-X
mammalian	B-X
genomes	B-X
.	B-X
There	B-X
are	B-X
no	B-X
known	B-X
easily	B-X
accessible	B-X
user-friendly	B-X
tools	B-X
that	B-X
can	B-X
compute	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
nucleotide	B-X
sequences	B-X
.	B-X
We	B-X
have	B-X
developed	B-X
a	B-X
web-based	B-X
server	B-X
,	B-X
QGRS	B-X
Mapper	B-X
,	B-X
that	B-X
predicts	B-X
quadruplex	B-X
forming	B-X
G-rich	B-X
sequences	B-X
(	B-X
QGRS	B-X
)	B-X
in	B-X
nucleotide	B-X
sequences	B-X
.	B-X
It	B-X
is	B-X
a	B-X
user-friendly	B-X
application	B-X
that	B-X
provides	B-X
many	B-X
options	B-X
for	B-X
defining	B-X
and	B-X
studying	B-X
G-quadruplexes	B-X
.	B-X
It	B-X
is	B-X
also	B-X
useful	B-X
for	B-X
predicting	B-X
G-quadruplex	B-X
structures	B-X
in	B-X
oligonucleotides	B-X
.	B-X
The	B-X
program	B-X
provides	B-X
options	B-X
to	B-X
search	B-X
and	B-X
retrieve	B-X
desired	B-X
gene/nucleotide	B-X
sequence	B-X
entries	B-X
from	B-X
NCBI	B-X
databases	B-X
for	B-X
mapping	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
context	B-X
of	B-X
RNA	B-X
processing	B-X
sites	B-X
.	B-X
This	B-X
feature	B-X
is	B-X
very	B-X
useful	B-X
for	B-X
investigating	B-X
the	B-X
functional	B-X
relevance	B-X
of	B-X
G-quadruplex	B-X
structure	B-X
,	B-X
in	B-X
particular	B-X
its	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
gene	B-X
expression	B-X
by	B-X
alternative	B-X
processing	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
providing	B-X
data	B-X
on	B-X
composition	B-X
and	B-X
locations	B-X
of	B-X
QGRS	B-X
relative	B-X
to	B-X
the	B-X
processing	B-X
sites	B-X
in	B-X
the	B-X
pre-mRNA	B-X
sequence	B-X
,	B-X
QGRS	B-X
Mapper	B-X
features	B-X
interactive	B-X
graphic	B-X
representation	B-X
of	B-X
the	B-X
data	B-X
.	B-X
The	B-X
user	B-X
can	B-X
also	B-X
use	B-X
the	B-X
graphics	B-X
module	B-X
to	B-X
visualize	B-X
QGRS	B-X
distribution	B-X
patterns	B-X
among	B-X
all	B-X
the	B-X
alternative	B-X
RNA	B-X
products	B-X
of	B-X
a	B-X
gene	B-X
simultaneously	B-X
on	B-X
a	B-X
single	B-X
screen	B-X
.	B-X
QGRS	B-X
Mapper	B-X
can	B-X
be	B-X
accessed	B-X
at	B-X
http	B-X
:	B-X
//bioinformatics.ramapo.edu/QGRS/	B-X
.	B-X

In	O
addition	O
to	O
providing	O
data	O
on	O
composition	O
and	O
locations	O
of	O
QGRS	O
relative	O
to	O
the	O
processing	O
sites	O
in	O
the	O
pre	O
-	O
mRNA	O
sequence	O
,	O
QGRS	O
Mapper	O
offers	O
interactive	O
graphic	O
representation	O
of	O
the	O
data	O
.	O

The	O
user	O
can	O
also	O
use	O
a	O
graphics	O
module	O
to	O
visualize	O
QGRS	O
distribution	O
patterns	O
among	O
all	O
the	O
alternative	O
RNA	O
products	O
of	O
a	O
gene	O
simultaneously	O
on	O
a	O
single	O
screen	O
.	O
<EOS>	B-X
The	B-X
quadruplex	B-X
structures	B-X
formed	B-X
by	B-X
guanine-rich	B-X
nucleic	B-X
acid	B-X
sequences	B-X
have	B-X
received	B-X
significant	B-X
attention	B-X
recently	B-X
because	B-X
of	B-X
growing	B-X
evidence	B-X
for	B-X
their	B-X
role	B-X
in	B-X
important	B-X
biological	B-X
processes	B-X
and	B-X
as	B-X
therapeutic	B-X
targets	B-X
.	B-X
Sequences	B-X
capable	B-X
of	B-X
forming	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
RNA	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
significant	B-X
roles	B-X
in	B-X
regulation	B-X
of	B-X
polyadenylation	B-X
and	B-X
splicing	B-X
events	B-X
in	B-X
mammalian	B-X
transcripts	B-X
.	B-X
Whether	B-X
quadruplex	B-X
structure	B-X
directly	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
RNA	B-X
processing	B-X
requires	B-X
investigation	B-X
.	B-X
There	B-X
are	B-X
no	B-X
known	B-X
easily	B-X
accessible	B-X
user-friendly	B-X
tools	B-X
that	B-X
can	B-X
compute	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
nucleotide	B-X
sequences	B-X
.	B-X
We	B-X
have	B-X
developed	B-X
a	B-X
web-based	B-X
server	B-X
,	B-X
QGRS	B-X
Mapper	B-X
,	B-X
that	B-X
predicts	B-X
quadruplex	B-X
forming	B-X
G-rich	B-X
sequences	B-X
(	B-X
QGRS	B-X
)	B-X
in	B-X
nucleotide	B-X
sequences	B-X
.	B-X
It	B-X
is	B-X
a	B-X
user-friendly	B-X
application	B-X
that	B-X
provides	B-X
many	B-X
options	B-X
for	B-X
defining	B-X
and	B-X
studying	B-X
G-quadruplexes	B-X
.	B-X
It	B-X
performs	B-X
analysis	B-X
of	B-X
the	B-X
user	B-X
provided	B-X
genomic	B-X
sequences	B-X
,	B-X
e.g	B-X
.	B-X
promoter	B-X
and	B-X
telomeric	B-X
regions	B-X
,	B-X
as	B-X
well	B-X
as	B-X
RNA	B-X
sequences	B-X
.	B-X
It	B-X
is	B-X
also	B-X
useful	B-X
for	B-X
predicting	B-X
G-quadruplex	B-X
structures	B-X
in	B-X
oligonucleotides	B-X
.	B-X
The	B-X
program	B-X
provides	B-X
options	B-X
to	B-X
search	B-X
and	B-X
retrieve	B-X
desired	B-X
gene/nucleotide	B-X
sequence	B-X
entries	B-X
from	B-X
NCBI	B-X
databases	B-X
for	B-X
mapping	B-X
G-quadruplexes	B-X
in	B-X
the	B-X
context	B-X
of	B-X
RNA	B-X
processing	B-X
sites	B-X
.	B-X
This	B-X
feature	B-X
is	B-X
very	B-X
useful	B-X
for	B-X
investigating	B-X
the	B-X
functional	B-X
relevance	B-X
of	B-X
G-quadruplex	B-X
structure	B-X
,	B-X
in	B-X
particular	B-X
its	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
gene	B-X
expression	B-X
by	B-X
alternative	B-X
processing	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
providing	B-X
data	B-X
on	B-X
composition	B-X
and	B-X
locations	B-X
of	B-X
QGRS	B-X
relative	B-X
to	B-X
the	B-X
processing	B-X
sites	B-X
in	B-X
the	B-X
pre-mRNA	B-X
sequence	B-X
,	B-X
QGRS	B-X
Mapper	B-X
features	B-X
interactive	B-X
graphic	B-X
representation	B-X
of	B-X
the	B-X
data	B-X
.	B-X
The	B-X
user	B-X
can	B-X
also	B-X
use	B-X
the	B-X
graphics	B-X
module	B-X
to	B-X
visualize	B-X
QGRS	B-X
distribution	B-X
patterns	B-X
among	B-X
all	B-X
the	B-X
alternative	B-X
RNA	B-X
products	B-X
of	B-X
a	B-X
gene	B-X
simultaneously	B-X
on	B-X
a	B-X
single	B-X
screen	B-X
.	B-X
QGRS	B-X
Mapper	B-X
can	B-X
be	B-X
accessed	B-X
at	B-X
http	B-X
:	B-X
//bioinformatics.ramapo.edu/QGRS/	B-X
.	B-X

METHODS	O

QGRS	O
definition	O

The	O
main	O
goal	O
of	O
the	O
QGRS	O
Mapper	O
program	O
is	O
to	O
predict	O
the	O
presence	O
of	O
QGRS	O
in	O
nucleotide	O
entries	O
.	O

These	O
putative	O
G	O
-	O
quadruplexes	O
are	O
identified	O
using	O
the	O
following	O
motif	O
.	O
<EOS>	B-X
Quadruplexes	B-X
(	B-X
G4s	B-X
)	B-X
are	B-X
of	B-X
interest	B-X
,	B-X
which	B-X
increases	B-X
with	B-X
the	B-X
number	B-X
of	B-X
identified	B-X
G4	B-X
structures	B-X
and	B-X
knowledge	B-X
about	B-X
their	B-X
biomedical	B-X
potential	B-X
.	B-X
These	B-X
unique	B-X
motifs	B-X
form	B-X
in	B-X
many	B-X
organisms	B-X
,	B-X
including	B-X
humans	B-X
,	B-X
where	B-X
their	B-X
appearance	B-X
correlates	B-X
with	B-X
various	B-X
diseases	B-X
.	B-X
Scientists	B-X
store	B-X
and	B-X
analyze	B-X
quadruplexes	B-X
using	B-X
recently	B-X
developed	B-X
bioinformatic	B-X
tools-many	B-X
of	B-X
them	B-X
focused	B-X
on	B-X
DNA	B-X
structures	B-X
.	B-X
With	B-X
an	B-X
expanding	B-X
collection	B-X
of	B-X
G4	B-X
RNAs	B-X
,	B-X
we	B-X
check	B-X
how	B-X
existing	B-X
tools	B-X
deal	B-X
with	B-X
them	B-X
.	B-X
We	B-X
review	B-X
all	B-X
available	B-X
bioinformatics	B-X
resources	B-X
dedicated	B-X
to	B-X
quadruplexes	B-X
and	B-X
examine	B-X
their	B-X
usefulness	B-X
in	B-X
G4	B-X
RNA	B-X
analysis	B-X
.	B-X
We	B-X
distinguish	B-X
the	B-X
following	B-X
subsets	B-X
of	B-X
resources	B-X
:	B-X
databases	B-X
,	B-X
tools	B-X
to	B-X
predict	B-X
putative	B-X
quadruplex	B-X
sequences	B-X
,	B-X
tools	B-X
to	B-X
predict	B-X
secondary	B-X
structure	B-X
with	B-X
quadruplexes	B-X
and	B-X
tools	B-X
to	B-X
analyze	B-X
and	B-X
visualize	B-X
quadruplex	B-X
structures	B-X
.	B-X

GxNy1GxNy2GxNy3Gx	O

Here	O
x	O
=	O
number	O
of	O
guanine	O
tetrads	O
in	O
the	O
G	O
-	O
quadruplex	O
and	O
y1	O
,	O
y2	O
,	O
y3	O
=	O
length	O
of	O
gaps	O
(	O
i	O
.	O
e	O
.	O
the	O
length	O
of	O
the	O
loops	O
connecting	O
the	O
guanine	O
tetrads	O
)	O
.	O

The	O
motif	O
consists	O
of	O
four	O
equal	O
length	O
sets	O
of	O
guanines	O
(	O
which	O
we	O
call	O
G	O
-	O
groups	O
)	O
,	O
separated	O
by	O
arbitrary	O
nucleotide	O
sequences	O
,	O
with	O
the	O
following	O
restrictions	O
.	O

The	O
sequence	O
must	O
contain	O
at	O
least	O
two	O
tetrads	O
(	O
i	O
.	O
e	O
.	O
x	O
>=	O
2	O
)	O
.	O

Although	O
structures	O
with	O
three	O
or	O
more	O
G	O
-	O
tetrads	O
are	O
considered	O
to	O
be	O
more	O
stable	O
,	O
many	O
nucleotide	O
sequences	O
are	O
known	O
to	O
form	O
quadruplexes	O
with	O
two	O
G	O
-	O
tetrads	O
(	O
37	O
,	O
38	O
)	O
.	O
<EOS>	B-X
The	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
(	B-X
HIV	B-X
)	B-X
genome	B-X
encodes	B-X
a	B-X
total	B-X
of	B-X
three	B-X
structural	B-X
proteins	B-X
,	B-X
two	B-X
envelope	B-X
proteins	B-X
,	B-X
three	B-X
enzymes	B-X
,	B-X
and	B-X
six	B-X
accessory	B-X
proteins	B-X
.	B-X
Studies	B-X
over	B-X
the	B-X
past	B-X
ten	B-X
years	B-X
have	B-X
provided	B-X
high-resolution	B-X
three-dimensional	B-X
structural	B-X
information	B-X
for	B-X
all	B-X
of	B-X
the	B-X
viral	B-X
enzymes	B-X
,	B-X
structural	B-X
proteins	B-X
and	B-X
envelope	B-X
proteins	B-X
,	B-X
as	B-X
well	B-X
as	B-X
for	B-X
three	B-X
of	B-X
the	B-X
accessory	B-X
proteins	B-X
.	B-X
In	B-X
some	B-X
cases	B-X
it	B-X
has	B-X
been	B-X
possible	B-X
to	B-X
solve	B-X
the	B-X
structures	B-X
of	B-X
the	B-X
intact	B-X
,	B-X
native	B-X
proteins	B-X
,	B-X
but	B-X
in	B-X
most	B-X
cases	B-X
structural	B-X
data	B-X
were	B-X
obtained	B-X
for	B-X
isolated	B-X
protein	B-X
domains	B-X
,	B-X
peptidic	B-X
fragments	B-X
,	B-X
or	B-X
mutants	B-X
.	B-X
Peptide	B-X
complexes	B-X
with	B-X
two	B-X
regulatory	B-X
RNA	B-X
fragments	B-X
and	B-X
a	B-X
protein	B-X
complex	B-X
with	B-X
an	B-X
RNA	B-X
recognition/encapsidation	B-X
element	B-X
have	B-X
also	B-X
been	B-X
structurally	B-X
characterized	B-X
.	B-X
This	B-X
article	B-X
summarizes	B-X
the	B-X
high-resolution	B-X
structural	B-X
information	B-X
that	B-X
is	B-X
currently	B-X
available	B-X
for	B-X
HIV	B-X
proteins	B-X
and	B-X
reviews	B-X
current	B-X
structure-function	B-X
and	B-X
structure-biological	B-X
relationships	B-X
.	B-X

QGRS	O
Mapper	O
is	O
meant	O
to	O
be	O
a	O
flexible	O
and	O
comprehensive	O
tool	O
for	O
investigating	O
G	O
-	O
quadruplexes	O
;	O
hence	O
it	O
considers	O
sequences	O
with	O
two	O
tetrads	O
.	O
By	O
default	O
,	O
only	O
QGRS	O
of	O
maximum	O
length	O
of	O
30	O
bases	O
are	O
considered	O
.	O

However	O
,	O
the	O
program	O
gives	O
the	O
user	O
the	O
option	O
to	O
search	O
for	O
sequences	O
up	O
to	O
45	O
bases	O
.	O

This	O
restriction	O
on	O
the	O
length	O
of	O
the	O
sequences	O
being	O
considered	O
is	O
in	O
agreement	O
with	O
recent	O
literature	O
(	O
34	O
,	O
35	O
)	O
.	O

The	O
maximum	O
length	O
of	O
30	O
bases	O
restricts	O
G	O
-	O
groups	O
to	O
a	O
maximum	O
size	O
of	O
6	O
.	O
The	O
gaps	O
or	O
loops	O
between	O
the	O
G	O
-	O
groups	O
may	O
be	O
arbitrary	O
in	O
composition	O
or	O
length	O
(	O
within	O
the	O
overall	O
restrictions	O
on	O
the	O
length	O
of	O
QGRS	O
)	O
.	O

The	O
program	O
gives	O
the	O
user	O
the	O
option	O
to	O
search	O
for	O
QGRS	O
having	O
loops	O
with	O
a	O
specified	O
length	O
range	O
(	O
e	O
.	O
g	O
.	O
the	O
user	O
can	O
search	O
for	O
QGRS	O
with	O
loops	O
of	O
lengths	O
between	O
1	O
and	O
4	O
)	O
.	O

The	O
user	O
can	O
also	O
specify	O
a	O
string	O
that	O
one	O
or	O
more	O
loops	O
of	O
each	O
QGRS	O
must	O
contain	O
.	O
<EOS>	B-X
The	B-X
rapid	B-X
growth	B-X
of	B-X
scientific	B-X
literature	B-X
has	B-X
rendered	B-X
the	B-X
task	B-X
of	B-X
finding	B-X
relevant	B-X
information	B-X
one	B-X
of	B-X
the	B-X
critical	B-X
problems	B-X
in	B-X
almost	B-X
any	B-X
research	B-X
.	B-X
Previously	B-X
,	B-X
we	B-X
developed	B-X
the	B-X
Associative	B-X
Network	B-X
Discovery	B-X
System	B-X
(	B-X
ANDSystem	B-X
)	B-X
,	B-X
which	B-X
also	B-X
implements	B-X
such	B-X
a	B-X
cycle	B-X
.	B-X
However	B-X
,	B-X
the	B-X
drawback	B-X
of	B-X
these	B-X
systems	B-X
is	B-X
dependence	B-X
on	B-X
the	B-X
employed	B-X
ontologies	B-X
describing	B-X
the	B-X
subject	B-X
area	B-X
,	B-X
which	B-X
limits	B-X
their	B-X
functionality	B-X
in	B-X
searching	B-X
information	B-X
based	B-X
on	B-X
user-specified	B-X
queries	B-X
.	B-X
PDB2ENTROPY	B-X
takes	B-X
in	B-X
input	B-X
two	B-X
files	B-X
containing	B-X
the	B-X
following	B-X
:	B-X
(	B-X
1	B-X
)	B-X
conformational	B-X
ensembles	B-X
of	B-X
the	B-X
same	B-X
molecule	B-X
(	B-X
s	B-X
)	B-X
in	B-X
PDB	B-X
format	B-X
and	B-X
(	B-X
2	B-X
)	B-X
definitions	B-X
of	B-X
torsion	B-X
angles	B-X
(	B-X
a	B-X
default	B-X
file	B-X
is	B-X
provided	B-X
where	B-X
additional	B-X
user	B-X
definitions	B-X
can	B-X
be	B-X
easily	B-X
implemented	B-X
)	B-X
.	B-X
PDB2TRENT	B-X
takes	B-X
in	B-X
a	B-X
file	B-X
containing	B-X
samples	B-X
of	B-X
the	B-X
complexed	B-X
molecules	B-X
,	B-X
a	B-X
string	B-X
specifying	B-X
atoms	B-X
providing	B-X
the	B-X
reference	B-X
framework	B-X
to	B-X
superimpose	B-X
samples	B-X
,	B-X
and	B-X
a	B-X
string	B-X
specifying	B-X
atoms	B-X
used	B-X
to	B-X
compute	B-X
rotation	B-X
and	B-X
translation	B-X
of	B-X
one	B-X
molecule	B-X
with	B-X
respect	B-X
to	B-X
the	B-X
other	B-X
.	B-X

This	O
string	O
can	O
be	O
given	O
as	O
a	O
regular	O
expression	O
.	O
<EOS>	B-X
Glycans	B-X
can	B-X
be	B-X
imported	B-X
in	B-X
GlycoCT	B-X
condensed	B-X
format	B-X
,	B-X
or	B-X
else	B-X
as	B-X
IUPAC	B-X
condensed	B-X
names	B-X
,	B-X
and	B-X
passed	B-X
as	B-X
substrates	B-X
to	B-X
the	B-X
enzymes	B-X
,	B-X
which	B-X
are	B-X
modeled	B-X
as	B-X
regular-expression-based	B-X
substitutions	B-X
on	B-X
strings	B-X
.	B-X
A	B-X
method	B-X
is	B-X
provided	B-X
for	B-X
predicting	B-X
the	B-X
enzymes	B-X
required	B-X
to	B-X
produce	B-X
a	B-X
given	B-X
substrate	B-X
,	B-X
using	B-X
an	B-X
O-glycan	B-X
from	B-X
human	B-X
gastric	B-X
mucin	B-X
as	B-X
an	B-X
example	B-X
.	B-X
A	B-X
method	B-X
is	B-X
presented	B-X
for	B-X
determining	B-X
within	B-X
strict	B-X
bounds	B-X
the	B-X
probability	B-X
of	B-X
matching	B-X
a	B-X
regular	B-X
expression	B-X
with	B-X
a	B-X
match	B-X
start	B-X
point	B-X
in	B-X
a	B-X
given	B-X
section	B-X
of	B-X
a	B-X
random	B-X
data	B-X
string	B-X
.	B-X
The	B-X
method	B-X
in	B-X
general	B-X
requires	B-X
time	B-X
and	B-X
space	B-X
exponential	B-X
in	B-X
the	B-X
number	B-X
of	B-X
optional	B-X
characters	B-X
in	B-X
the	B-X
regular	B-X
expression	B-X
,	B-X
but	B-X
in	B-X
practice	B-X
was	B-X
used	B-X
to	B-X
determine	B-X
bounds	B-X
for	B-X
probabilities	B-X
of	B-X
matching	B-X
all	B-X
the	B-X
ProSite	B-X
patterns	B-X
without	B-X
difficulty	B-X
.	B-X

For	O
example	O
,	O
entering	O
the	O
regular	O
expression	O
'	O
T	O
{	O
3	O
,	O
5	O
}	O
'	O
will	O
search	O
for	O
QGRS	O
having	O
one	O
or	O
more	O
loops	O
that	O
contain	O
three	O
to	O
five	O
consecutive	O
T	O
'	O
s	O
.	O
Also	O
,	O
at	O
most	O
one	O
of	O
the	O
gaps	O
is	O
allowed	O
to	O
be	O
of	O
zero	O
length	O

Table	O
1	O
shows	O
some	O
examples	O
of	O
valid	O
QGRS	O
.	O

The	O
guanine	O
groups	O
which	O
form	O
the	O
tetrads	O
are	O
underlined	O
.	O

The	O
first	O
sequence	O
has	O
four	O
tetrads	O
and	O
equal	O
length	O
gaps	O
.	O

This	O
would	O
seem	O
to	O
provide	O
a	O
G	O
-	O
quadruplex	O
that	O
is	O
the	O
most	O
stable	O
of	O
the	O
three	O
sequences	O
.	O

The	O
second	O
sequence	O
is	O
notable	O
for	O
the	O
significant	O
differences	O
in	O
the	O
size	O
of	O
its	O
loops	O
.	O

The	O
third	O
sequence	O
has	O
two	O
tetrads	O
,	O
even	O
though	O
three	O
of	O
the	O
G	O
-	O
groups	O
could	O
have	O
included	O
another	O
G	O
(	O
since	O
all	O
G	O
-	O
groups	O
must	O
be	O
equal	O
in	O
size	O
)	O
.	O

G	O
-	O
scores	O
<EOS>	B-X
DIAAS	B-X
scores	B-X
reflect	B-X
the	B-X
true	B-X
ileal	B-X
digestibility	B-X
of	B-X
the	B-X
indispensable	B-X
amino	B-X
acids	B-X
that	B-X
are	B-X
present	B-X
in	B-X
food	B-X
items	B-X
,	B-X
and	B-X
these	B-X
scores	B-X
can	B-X
be	B-X
used	B-X
to	B-X
compute	B-X
the	B-X
available	B-X
protein	B-X
in	B-X
diet	B-X
plans	B-X
.	B-X
Thirty-eight	B-X
omnivores	B-X
and	B-X
22	B-X
vegetarians	B-X
submitted	B-X
seven-day	B-X
food	B-X
records	B-X
that	B-X
were	B-X
analyzed	B-X
for	B-X
nutrient	B-X
content	B-X
,	B-X
and	B-X
DIAAS	B-X
scores	B-X
were	B-X
computed	B-X
by	B-X
diet	B-X
group	B-X
.	B-X
DIAAS	B-X
scores	B-X
and	B-X
available	B-X
protein	B-X
were	B-X
higher	B-X
for	B-X
omnivorous	B-X
versus	B-X
vegetarian	B-X
athletes	B-X
(	B-X
+11	B-X
%	B-X
and	B-X
+43	B-X
%	B-X
,	B-X
respectively	B-X
,	B-X
A	B-X
secondary	B-X
aim	B-X
is	B-X
to	B-X
establish	B-X
the	B-X
validity	B-X
and	B-X
applicability	B-X
of	B-X
these	B-X
scores	B-X
to	B-X
find	B-X
a	B-X
comprehensive	B-X
and	B-X
validated	B-X
histological	B-X
scoring	B-X
system	B-X
for	B-X
the	B-X
evaluation	B-X
of	B-X
tendon-enthesis	B-X
tissue	B-X
.	B-X

We	O
have	O
devised	O
a	O
scoring	O
system	O
that	O
evaluates	O
a	O
QGRS	O
for	O
its	O
likelihood	O
to	O
form	O
a	O
stable	O
G	O
-	O
quadruplex	O
.	O

Higher	O
scoring	O
sequences	O
will	O
make	O
better	O
candidates	O
for	O
G	O
-	O
quadruplexes	O
.	O

The	O
scoring	O
method	O
uses	O
the	O
following	O
principles	O
which	O
are	O
based	O
on	O
previous	O
studies	O
(	O
34	O
,	O
35	O
,	O
39	O
-	O
42	O
)	O
.	O

Shorter	O
loops	O
are	O
more	O
common	O
than	O
longer	O
loops	O
.	O
G	O
-	O
quadruplexes	O
tend	O
to	O
have	O
loops	O
roughly	O
equal	O
in	O
size	O
.	O
The	O
greater	O
the	O
number	O
of	O
guanine	O
tetrads	O
,	O
the	O
more	O
stable	O
the	O
quadruplex	O
.	O

The	O
computed	O
G	O
-	O
scores	O
are	O
dependent	O
on	O
the	O
user	O
selected	O
maximum	O
QGRS	O
length	O
.	O

The	O
highest	O
possible	O
G	O
-	O
score	O
,	O
using	O
the	O
default	O
maximum	O
QGRS	O
length	O
of	O
30	O
,	O
is	O
105	O
.	O

Here	O
is	O
a	O
sequence	O
attaining	O
that	O
score	O
:	O
<EOS>	B-X
Multi-ancestry	B-X
GWAS	B-X
meta-analysis	B-X
identified	B-X
237	B-X
loci	B-X
attaining	B-X
stringent	B-X
genome-wide	B-X
significance	B-X
(	B-X
P	B-X
<	B-X
5	B-X
Ã	B-X
10	B-X
A	B-X
joint	B-X
(	B-X
multi-phenotype	B-X
)	B-X
analysis	B-X
of	B-X
educational	B-X
attainment	B-X
and	B-X
three	B-X
related	B-X
cognitive	B-X
phenotypes	B-X
generates	B-X
polygenic	B-X
scores	B-X
that	B-X
explain	B-X
11-13	B-X
%	B-X
of	B-X
the	B-X
variance	B-X
in	B-X
educational	B-X
attainment	B-X
and	B-X
7-10	B-X
%	B-X
of	B-X
the	B-X
variance	B-X
in	B-X
cognitive	B-X
performance	B-X
.	B-X
This	B-X
prediction	B-X
accuracy	B-X
substantially	B-X
increases	B-X
the	B-X
utility	B-X
of	B-X
polygenic	B-X
scores	B-X
as	B-X
tools	B-X
in	B-X
research	B-X
.	B-X
To	B-X
enable	B-X
this	B-X
analysis	B-X
,	B-X
we	B-X
introduce	B-X
a	B-X
new	B-X
method	B-X
,	B-X
stratified	B-X
LD	B-X
score	B-X
regression	B-X
,	B-X
for	B-X
partitioning	B-X
heritability	B-X
from	B-X
GWAS	B-X
summary	B-X
statistics	B-X
while	B-X
accounting	B-X
for	B-X
linked	B-X
markers	B-X
.	B-X

GGGGGGTGGGGGGTGGGGGGTGGGGGG	O
.	O

Eliminating	O
QGRS	O
overlaps	O

Two	O
QGRS	O
are	O
said	O
to	O
overlap	O
if	O
their	O
positions	O
in	O
the	O
nucleotide	O
sequence	O
overlap	O
.	O

QGRS	O
Mapper	O
will	O
start	O
with	O
a	O
nucleotide	O
sequence	O
,	O
find	O
all	O
QGRS	O
occurring	O
in	O
the	O
sequence	O
and	O
then	O
produce	O
a	O
non	O
-	O
overlapping	O
set	O
of	O
QGRS	O
.	O

Overlaps	O
are	O
eliminated	O
by	O
selecting	O
the	O
higher	O
scoring	O
QGRS	O
.	O

In	O
the	O
non	O
-	O
overlapping	O
view	O
,	O
only	O
this	O
sequence	O
will	O
be	O
displayed	O
,	O
although	O
the	O
user	O
can	O
request	O
that	O
all	O
overlapping	O
sequences	O
be	O
displayed	O
.	O

Please	O
see	O
supplementary	O
materials	O
at	O
NAR	O
online	O
for	O
more	O
details	O
on	O
the	O
elimination	O
of	O
overlapping	O
QGRS	O
.	O

FEATURES	O

Design	O
and	O
implementation	O
<EOS>	B-X
Furthermore	B-X
,	B-X
we	B-X
will	B-X
discuss	B-X
the	B-X
current	B-X
practice	B-X
of	B-X
adaptive	B-X
design	B-X
implementation	B-X
by	B-X
demonstrating	B-X
a	B-X
complex	B-X
oncology	B-X
seamless	B-X
phase	B-X
2/3	B-X
adaptive	B-X
design	B-X
case	B-X
study	B-X
.	B-X
These	B-X
programs	B-X
are	B-X
complex	B-X
,	B-X
maintain	B-X
diverse	B-X
implementation	B-X
typologies	B-X
and	B-X
involve	B-X
many	B-X
components	B-X
that	B-X
can	B-X
influence	B-X
the	B-X
potential	B-X
success	B-X
of	B-X
a	B-X
program	B-X
or	B-X
its	B-X
ability	B-X
to	B-X
effectively	B-X
perform	B-X
at	B-X
scale	B-X
.	B-X
While	B-X
tools	B-X
and	B-X
methods	B-X
exist	B-X
to	B-X
support	B-X
the	B-X
design	B-X
and	B-X
implementation	B-X
of	B-X
iCCM	B-X
and	B-X
measure	B-X
its	B-X
progress	B-X
,	B-X
these	B-X
may	B-X
not	B-X
holistically	B-X
consider	B-X
some	B-X
of	B-X
its	B-X
key	B-X
components	B-X
,	B-X
which	B-X
can	B-X
include	B-X
program	B-X
structure	B-X
,	B-X
setting	B-X
context	B-X
and	B-X
the	B-X
interplay	B-X
between	B-X
community	B-X
,	B-X
human	B-X
resources	B-X
,	B-X
program	B-X
inputs	B-X
and	B-X
health	B-X
system	B-X
processes	B-X
.	B-X
More	B-X
and	B-X
more	B-X
literature	B-X
describes	B-X
how	B-X
to	B-X
overcome	B-X
challenges	B-X
in	B-X
the	B-X
implementation	B-X
of	B-X
adaptive	B-X
designs	B-X
for	B-X
trials	B-X
for	B-X
drug	B-X
approval	B-X
process	B-X
.	B-X

QGRS	O
Mapper	O
is	O
a	O
web	O
-	O
based	O
program	O
,	O
written	O
in	O
PHP	O
,	O
with	O
Java	O
being	O
used	O
for	O
some	O
of	O
its	O
graphics	O
.	O

The	O
program	O
takes	O
a	O
nucleotide	O
sequence	O
from	O
NCBI	O
(	O
or	O
as	O
provided	O
by	O
the	O
user	O
)	O
and	O
analyzes	O
it	O
for	O
the	O
presence	O
of	O
putative	O
G	O
-	O
quadruplexes	O
.	O

The	O
structure	O
of	O
QGRS	O
Mapper	O
is	O
summarized	O
in	O
Table	O
2	O
.	O

Search	O
and	O
analysis	O
<EOS>	B-X
We	B-X
demonstrate	B-X
how	B-X
PTM-Shepherd	B-X
improves	B-X
the	B-X
analysis	B-X
of	B-X
data	B-X
from	B-X
formalin-fixed	B-X
and	B-X
paraffin-embedded	B-X
samples	B-X
,	B-X
detects	B-X
extreme	B-X
underalkylation	B-X
of	B-X
cysteine	B-X
in	B-X
some	B-X
data	B-X
sets	B-X
,	B-X
discovers	B-X
an	B-X
artifactual	B-X
modification	B-X
introduced	B-X
during	B-X
peptide	B-X
synthesis	B-X
,	B-X
and	B-X
uncovers	B-X
site-specific	B-X
biases	B-X
in	B-X
sample	B-X
preparation	B-X
artifacts	B-X
in	B-X
a	B-X
multicenter	B-X
proteomics	B-X
profiling	B-X
study	B-X
.	B-X
Tandem	B-X
mass	B-X
spectrometry	B-X
(	B-X
MS/MS	B-X
)	B-X
is	B-X
widely	B-X
employed	B-X
for	B-X
the	B-X
analysis	B-X
of	B-X
complex	B-X
proteomic	B-X
samples	B-X
.	B-X
Search	B-X
data	B-X
for	B-X
ENDS	B-X
were	B-X
analyzed	B-X
against	B-X
relevant	B-X
traits	B-X
including	B-X
state	B-X
longitude	B-X
,	B-X
tobacco	B-X
tax	B-X
rate	B-X
and	B-X
national	B-X
tobacco	B-X
program	B-X
funding	B-X
.	B-X
Searches	B-X
increased	B-X
88	B-X
%	B-X
(	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
70-100	B-X
)	B-X
over	B-X
the	B-X
last	B-X
5	B-X
years	B-X
and	B-X
peaked	B-X
on	B-X
8	B-X
September	B-X
2019	B-X
,	B-X
after	B-X
the	B-X
CDC	B-X
issued	B-X
a	B-X
warning	B-X
about	B-X
the	B-X
link	B-X
between	B-X
ENDS	B-X
and	B-X
high-profile	B-X
lung	B-X
damage	B-X
cases	B-X
.	B-X
Searches	B-X
aimed	B-X
at	B-X
buying	B-X
ENDS	B-X
subsequently	B-X
dropped	B-X
25	B-X
%	B-X
(	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
20.1-29.6	B-X
)	B-X
,	B-X
while	B-X
health-related	B-X
ENDS	B-X
searches	B-X
spiked	B-X
to	B-X
their	B-X
all-time	B-X
high	B-X
,	B-X
increasing	B-X
22	B-X
%	B-X
(	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
-6	B-X
to	B-X
55	B-X
)	B-X
compared	B-X
with	B-X
the	B-X
first	B-X
half	B-X
of	B-X
2019	B-X
.	B-X

QGRS	O
Mapper	O
allows	O
the	O
user	O
to	O
search	O
for	O
putative	O
G	O
-	O
quadruplexes	O
in	O
a	O
variety	O
of	O
ways	O
.	O

It	O
is	O
possible	O
to	O
enter	O
a	O
nucleotide	O
sequence	O
in	O
raw	O
or	O
FASTA	O
format	O
for	O
analysis	O
.	O
<EOS>	B-X
Mass-spectrometry-based	B-X
proteomics	B-X
enables	B-X
the	B-X
high-throughput	B-X
identification	B-X
and	B-X
quantification	B-X
of	B-X
proteins	B-X
,	B-X
including	B-X
sequence	B-X
variants	B-X
and	B-X
post-translational	B-X
modifications	B-X
(	B-X
PTMs	B-X
)	B-X
in	B-X
biological	B-X
samples	B-X
.	B-X
However	B-X
,	B-X
most	B-X
workflows	B-X
require	B-X
that	B-X
such	B-X
variations	B-X
be	B-X
included	B-X
in	B-X
the	B-X
search	B-X
space	B-X
used	B-X
to	B-X
analyze	B-X
the	B-X
data	B-X
,	B-X
and	B-X
doing	B-X
so	B-X
remains	B-X
challenging	B-X
with	B-X
most	B-X
analysis	B-X
tools	B-X
.	B-X
In	B-X
order	B-X
to	B-X
facilitate	B-X
the	B-X
search	B-X
for	B-X
known	B-X
sequence	B-X
variants	B-X
and	B-X
PTMs	B-X
,	B-X
the	B-X
Proteomics	B-X
Standards	B-X
Initiative	B-X
(	B-X
PSI	B-X
)	B-X
has	B-X
designed	B-X
and	B-X
implemented	B-X
the	B-X
PSI	B-X
extended	B-X
FASTA	B-X
format	B-X
(	B-X
PEFF	B-X
)	B-X
.	B-X
PEFF	B-X
is	B-X
based	B-X
on	B-X
the	B-X
very	B-X
popular	B-X
FASTA	B-X
format	B-X
but	B-X
adds	B-X
a	B-X
uniform	B-X
mechanism	B-X
for	B-X
encoding	B-X
substantially	B-X
more	B-X
metadata	B-X
about	B-X
the	B-X
sequence	B-X
collection	B-X
as	B-X
well	B-X
as	B-X
individual	B-X
entries	B-X
,	B-X
including	B-X
support	B-X
for	B-X
encoding	B-X
known	B-X
sequence	B-X
variants	B-X
,	B-X
PTMs	B-X
,	B-X
and	B-X
proteoforms	B-X
.	B-X
The	B-X
format	B-X
is	B-X
very	B-X
nearly	B-X
backward	B-X
compatible	B-X
,	B-X
and	B-X
as	B-X
such	B-X
,	B-X
existing	B-X
FASTA	B-X
parsers	B-X
will	B-X
require	B-X
little	B-X
or	B-X
no	B-X
changes	B-X
to	B-X
be	B-X
able	B-X
to	B-X
read	B-X
PEFF	B-X
files	B-X
as	B-X
FASTA	B-X
files	B-X
,	B-X
although	B-X
without	B-X
supporting	B-X
any	B-X
of	B-X
the	B-X
extra	B-X
capabilities	B-X
of	B-X
PEFF	B-X
.	B-X
Popular	B-X
software	B-X
and	B-X
resources	B-X
are	B-X
starting	B-X
to	B-X
support	B-X
PEFF	B-X
,	B-X
including	B-X
the	B-X
sequence	B-X
search	B-X
engine	B-X
Comet	B-X
and	B-X
the	B-X
knowledge	B-X
bases	B-X
neXtProt	B-X
and	B-X
UniProtKB	B-X
.	B-X
Widespread	B-X
implementation	B-X
of	B-X
PEFF	B-X
is	B-X
expected	B-X
to	B-X
further	B-X
enable	B-X
proteogenomics	B-X
and	B-X
top-down	B-X
proteomics	B-X
applications	B-X
by	B-X
providing	B-X
a	B-X
standardized	B-X
mechanism	B-X
for	B-X
encoding	B-X
protein	B-X
sequences	B-X
and	B-X
their	B-X
known	B-X
variations	B-X
.	B-X
All	B-X
the	B-X
related	B-X
documentation	B-X
,	B-X
including	B-X
the	B-X
detailed	B-X
file	B-X
format	B-X
specification	B-X
and	B-X
example	B-X
files	B-X
,	B-X
are	B-X
available	B-X
at	B-X
http	B-X
:	B-X
//www.psidev.info/peff	B-X
.	B-X

One	O
can	O
search	O
and	O
analyze	O
gene	O
sequences	O
by	O
Gene	O
ID	O
,	O
Gene	O
name	O
or	O
symbol	O
,	O
accession	O
number	O
or	O
GI	O
number	O
for	O
an	O
NCBI	O
nucleotide	O
sequence	O
entry	O
.	O
<EOS>	B-X
We	B-X
provide	B-X
here	B-X
a	B-X
list	B-X
of	B-X
481	B-X
P450	B-X
genes	B-X
and	B-X
22	B-X
pseudogenes	B-X
,	B-X
plus	B-X
all	B-X
accession	B-X
numbers	B-X
that	B-X
have	B-X
been	B-X
reported	B-X
as	B-X
of	B-X
October	B-X
18	B-X
,	B-X
1995	B-X
.	B-X
These	B-X
genes	B-X
have	B-X
been	B-X
described	B-X
in	B-X
85	B-X
eukaryote	B-X
(	B-X
including	B-X
vertebrates	B-X
,	B-X
invertebrates	B-X
,	B-X
fungi	B-X
,	B-X
and	B-X
plants	B-X
)	B-X
and	B-X
20	B-X
prokaryote	B-X
species	B-X
.	B-X
Of	B-X
74	B-X
gene	B-X
families	B-X
so	B-X
far	B-X
described	B-X
,	B-X
14	B-X
families	B-X
exist	B-X
in	B-X
all	B-X
mammals	B-X
examined	B-X
to	B-X
date	B-X
.	B-X
Each	B-X
subfamily	B-X
usually	B-X
represents	B-X
a	B-X
cluster	B-X
of	B-X
tightly	B-X
linked	B-X
genes	B-X
widely	B-X
scattered	B-X
throughout	B-X
the	B-X
genome	B-X
,	B-X
but	B-X
there	B-X
are	B-X
exceptions	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
CYP51	B-X
family	B-X
has	B-X
been	B-X
found	B-X
in	B-X
mammals	B-X
,	B-X
filamentous	B-X
fungi	B-X
and	B-X
yeast	B-X
,	B-X
and	B-X
plants-attesting	B-X
to	B-X
the	B-X
fact	B-X
that	B-X
this	B-X
P450	B-X
gene	B-X
family	B-X
is	B-X
very	B-X
ancient	B-X
.	B-X
One	B-X
functional	B-X
CYP51	B-X
gene	B-X
and	B-X
two	B-X
processed	B-X
pseudogenes	B-X
,	B-X
which	B-X
are	B-X
the	B-X
first	B-X
examples	B-X
of	B-X
intronless	B-X
pseudogenes	B-X
within	B-X
the	B-X
P450	B-X
superfamily	B-X
,	B-X
have	B-X
been	B-X
mapped	B-X
to	B-X
three	B-X
different	B-X
human	B-X
chromosomes	B-X
.	B-X
For	B-X
the	B-X
gene	B-X
,	B-X
we	B-X
recommend	B-X
that	B-X
the	B-X
italicized	B-X
root	B-X
symbol	B-X
``	B-X
CYP	B-X
'	B-X
for	B-X
human	B-X
(	B-X
``	B-X
Cyp	B-X
'	B-X
for	B-X
mouse	B-X
and	B-X
Drosophila	B-X
)	B-X
,	B-X
representing	B-X
``	B-X
cytochrome	B-X
P450	B-X
'	B-X
,	B-X
be	B-X
followed	B-X
by	B-X
an	B-X
Arabic	B-X
number	B-X
denoting	B-X
the	B-X
family	B-X
,	B-X
a	B-X
letter	B-X
designating	B-X
the	B-X
subfamily	B-X
(	B-X
when	B-X
two	B-X
or	B-X
more	B-X
exist	B-X
)	B-X
,	B-X
and	B-X
an	B-X
Arabic	B-X
numeral	B-X
representing	B-X
the	B-X
individual	B-X
gene	B-X
within	B-X
the	B-X
subfamily	B-X
.	B-X
A	B-X
hyphen	B-X
is	B-X
no	B-X
longer	B-X
recommended	B-X
in	B-X
mouse	B-X
gene	B-X
nomenclature	B-X
.	B-X
``	B-X
P	B-X
'	B-X
(	B-X
``	B-X
ps	B-X
'	B-X
in	B-X
mouse	B-X
and	B-X
Drosophila	B-X
)	B-X
after	B-X
the	B-X
gene	B-X
number	B-X
denotes	B-X
a	B-X
pseudogene	B-X
;	B-X
``	B-X
X	B-X
'	B-X
after	B-X
the	B-X
gene	B-X
number	B-X
means	B-X
its	B-X
use	B-X
has	B-X
been	B-X
discontinued	B-X
.	B-X
If	B-X
a	B-X
gene	B-X
is	B-X
the	B-X
sole	B-X
member	B-X
of	B-X
a	B-X
family	B-X
,	B-X
the	B-X
subfamily	B-X
letter	B-X
and	B-X
gene	B-X
number	B-X
would	B-X
be	B-X
helpful	B-X
but	B-X
need	B-X
not	B-X
be	B-X
included	B-X
.	B-X

The	O
user	O
can	O
opt	O
to	O
change	O
the	O
maximum	O
length	O
of	O
QGRS	O
that	O
will	O
be	O
searched	O
for	O
(	O
the	O
default	O
maximum	O
length	O
being	O
30	O
)	O
and	O
change	O
the	O
minimum	O
sized	O
G	O
-	O
group	O
(	O
which	O
is	O
two	O
by	O
default	O
)	O
.	O

Also	O
,	O
the	O
user	O
can	O
specify	O
that	O
the	O
loops	O
in	O
the	O
QGRS	O
fall	O
within	O
a	O
given	O
size	O
range	O
and	O
that	O
one	O
or	O
more	O
loops	O
of	O
the	O
QGRS	O
contain	O
a	O
given	O
string	O
(	O
for	O
which	O
the	O
user	O
may	O
enter	O
a	O
regular	O
expression	O
)	O
.	O

The	O
web	O
page	O
for	O
QGRS	O
analysis	O
can	O
be	O
seen	O
in	O
Figure	O
1	O
.	O

After	O
entering	O
a	O
sequence	O
in	O
raw	O
or	O
FASTA	O
format	O
,	O
QGRS	O
Mapper	O
will	O
search	O
the	O
sequence	O
for	O
occurrences	O
of	O
QGRS	O
.	O
<EOS>	B-X
Currently	B-X
,	B-X
the	B-X
bacterial	B-X
composition	B-X
of	B-X
raw	B-X
milk	B-X
in	B-X
tanker	B-X
trucks	B-X
and	B-X
the	B-X
outcomes	B-X
of	B-X
transfer	B-X
and	B-X
storage	B-X
of	B-X
that	B-X
milk	B-X
at	B-X
commercial	B-X
processing	B-X
facilities	B-X
are	B-X
not	B-X
well	B-X
understood	B-X
.	B-X
We	B-X
set	B-X
out	B-X
to	B-X
identify	B-X
the	B-X
bacteria	B-X
in	B-X
raw	B-X
milk	B-X
collected	B-X
for	B-X
large-scale	B-X
dairy	B-X
product	B-X
manufacturing	B-X
.	B-X
Anaerobic	B-X
ammonia	B-X
oxidation	B-X
(	B-X
Anammox	B-X
)	B-X
is	B-X
a	B-X
highly	B-X
productive	B-X
research	B-X
area	B-X
in	B-X
municipal	B-X
wastewater	B-X
treatment	B-X
.	B-X
After	B-X
enhancing	B-X
and	B-X
stabilizing	B-X
the	B-X
PD/A	B-X
process	B-X
,	B-X
PN/A	B-X
effluent	B-X
entered	B-X
the	B-X
PD/A-USB	B-X
along	B-X
with	B-X
raw	B-X
municipal	B-X
wastewater	B-X
at	B-X
a	B-X
ratio	B-X
of	B-X
4:1	B-X
and	B-X
the	B-X
combined	B-X
system	B-X
was	B-X
established	B-X
.	B-X

The	O
user	O
may	O
enter	O
any	O
combination	O
of	O
the	O
letters	O
A	O
,	O
C	O
,	O
T	O
,	O
G	O
,	O
U	O
,	O
N	O
.	O

The	O
Gene	O
ID	O
field	O
allows	O
the	O
user	O
to	O
search	O
the	O
NCBI	O
Entrez	O
Gene	O
database	O
.	O

QGRS	O
Mapper	O
will	O
connect	O
to	O
NCBI	O
,	O
download	O
and	O
parse	O
the	O
gene	O
entry	O
,	O
and	O
then	O
analyze	O
the	O
transcribed	O
region	O
of	O
its	O
nucleotide	O
sequence	O
for	O
the	O
presence	O
of	O
QGRS	O
.	O

For	O
example	O
,	O
entering	O
the	O
gene	O
ID	O
403437	O
results	O
in	O
downloading	O
the	O
Brca1	O
gene	O
sequence	O
for	O
Canis	B-Species
familiaris	I-Species
.	O

Using	O
the	O
default	O
QGRS	O
search	O
parameters	O
,	O
QGRS	O
Mapper	O
finds	O
156	O
non	O
-	O
overlapping	O
QGRS	O
and	O
3394	O
overlapping	O
QGRS	O
in	O
the	O
transcribed	O
region	O
of	O
this	O
gene	O
.	O

The	O
Gene	O
Name	O
or	O
Gene	O
Symbol	O
field	O
also	O
allows	O
the	O
user	O
to	O
search	O
the	O
NCBI	O
databases	O
for	O
all	O
such	O
genes	O
.	O
<EOS>	B-X
It	B-X
may	B-X
also	B-X
reduce	B-X
plasma	B-X
oxidation	B-X
,	B-X
and	B-X
it	B-X
may	B-X
also	B-X
affect	B-X
drug	B-X
metabolism	B-X
.	B-X
Lentiviral	B-X
vectors	B-X
are	B-X
often	B-X
used	B-X
to	B-X
introduce	B-X
protein	B-X
encoding	B-X
cDNAs	B-X
,	B-X
such	B-X
as	B-X
reporter	B-X
genes	B-X
,	B-X
or	B-X
for	B-X
noncoding	B-X
sequences	B-X
,	B-X
such	B-X
as	B-X
mediators	B-X
of	B-X
RNA	B-X
interference	B-X
or	B-X
genome	B-X
editing	B-X
,	B-X
including	B-X
shRNA	B-X
or	B-X
gRNA	B-X
,	B-X
respectively	B-X
.	B-X
From	B-X
1979	B-X
,	B-X
cellular	B-X
ras	B-X
sequences	B-X
with	B-X
transforming	B-X
properties	B-X
were	B-X
identified	B-X
by	B-X
transfection	B-X
of	B-X
tumor	B-X
DNA	B-X
initially	B-X
by	B-X
Robert	B-X
Weinberg	B-X
from	B-X
rodent	B-X
tumors	B-X
,	B-X
and	B-X
the	B-X
isolation	B-X
of	B-X
homologous	B-X
oncogenes	B-X
from	B-X
human	B-X
tumors	B-X
soon	B-X
followed	B-X
,	B-X
including	B-X
HRAS	B-X
and	B-X
KRAS	B-X
,	B-X
and	B-X
a	B-X
new	B-X
member	B-X
of	B-X
the	B-X
family	B-X
named	B-X
NRAS	B-X
.	B-X
I	B-X
review	B-X
these	B-X
discoveries	B-X
,	B-X
placing	B-X
emphasis	B-X
on	B-X
the	B-X
pioneering	B-X
research	B-X
of	B-X
Christopher	B-X
Marshall	B-X
and	B-X
Alan	B-X
Hall	B-X
,	B-X
who	B-X
subsequently	B-X
made	B-X
immense	B-X
contributions	B-X
to	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
functions	B-X
of	B-X
RAS	B-X
and	B-X
related	B-X
small	B-X
GTPases	B-X
to	B-X
signal	B-X
transduction	B-X
pathways	B-X
,	B-X
cell	B-X
structure	B-X
,	B-X
and	B-X
the	B-X
behavior	B-X
of	B-X
normal	B-X
and	B-X
malignant	B-X
cells	B-X
.	B-X

Entering	O
the	O
gene	O
name	O
Bcl2	O
results	O
in	O
nine	O
different	O
hits	O
which	O
are	O
displayed	O
in	O
Table	O
3	O
.	O

All	O
nine	O
of	O
these	O
entries	O
can	O
be	O
analyzed	O
for	O
the	O
occurrence	O
of	O
QGRS	O
.	O

Clicking	O
on	O
the	O
Gene	O
ID	O
takes	O
the	O
user	O
to	O
the	O
respective	O
Entrez	O
Gene	O
entry	O
.	O

Clicking	O
on	O
the	O
last	O
column	O
initiates	O
analysis	O
of	O
the	O
selection	O
by	O
QGRS	O
Mapper	O
.	O

Similarly	O
,	O
the	O
user	O
can	O
also	O
enter	O
an	O
NCBI	O
accession	O
number	O
to	O
search	O
for	O
gene	O
sequences	O
.	O

For	O
example	O
,	O
searching	O
the	O
accession	O
number	O
AF312033	O
results	O
in	O
12	O
hits	O
being	O
displayed	O
for	O
this	O
GenBank	O
nucleotide	O
sequence	O
entry	O
.	O

The	O
search	O
phase	O
of	O
the	O
program	O
is	O
followed	O
by	O
an	O
analysis	O
of	O
the	O
QGRS	O
contained	O
in	O
the	O
query	O
sequence	O
.	O

In	O
this	O
phase	O
of	O
QGRS	O
Mapper	O
,	O
the	O
sequence	O
data	O
downloaded	O
previously	O
is	O
analyzed	O
to	O
identify	O
and	O
map	O
all	O
QGRS	O
relative	O
to	O
locations	O
such	O
as	O
splice	O
sites	O
in	O
exons	O
/	O
introns	O
,	O
and	O
poly	O
(	O
A	O
)	O
site	O
(	O
if	O
these	O
locations	O
are	O
known	O
)	O
.	O

Furthermore	O
the	O
QGRS	O
are	O
scored	O
by	O
the	O
method	O
described	O
above	O
.	O

The	O
computed	O
G	O
-	O
score	O
is	O
used	O
to	O
eliminate	O
overlapping	O
QGRS	O
.	O

At	O
times	O
,	O
QGRS	O
Mapper	O
must	O
analyze	O
a	O
considerable	O
amount	O
of	O
data	O
.	O

For	O
example	O
,	O
the	O
mouse	B-Species
version	O
of	O
the	O
gene	O
PTPRU	O
,	O
which	O
is	O
69822	O
bases	O
long	O
,	O
contains	O
94681	O
QGRS	O
of	O
length	O
up	O
to	O
45	O
bases	O
.	O

QGRS	O
Mapper	O
will	O
find	O
,	O
analyze	O
and	O
map	O
all	O
of	O
these	O
sequences	O
.	O

During	O
this	O
analysis	O
a	O
message	O
is	O
displayed	O
indicating	O
the	O
estimated	O
time	O
left	O
to	O
completion	O
.	O

QGRS	O
Mapper	O
output	O

After	O
the	O
analysis	O
of	O
overlaps	O
is	O
completed	O
,	O
QGRS	O
Mapper	O
displays	O
a	O
summary	O
of	O
its	O
findings	O
,	O
in	O
the	O
Gene	O
View	O
.	O

This	O
summary	O
includes	O
basic	O
gene	O
information	O
such	O
as	O
the	O
gene	O
ID	O
,	O
gene	O
symbol	O
,	O
gene	O
name	O
,	O
a	O
link	O
to	O
the	O
NCBI	O
entry	O
,	O
organism	O
name	O
,	O
chromosome	O
number	O
and	O
number	O
of	O
products	O
and	O
poly	O
(	O
A	O
)	O
signals	O
.	O

Information	O
is	O
also	O
given	O
for	O
each	O
product	O
,	O
such	O
as	O
the	O
number	O
of	O
exons	O
and	O
introns	O
,	O
number	O
of	O
QGRS	O
(	O
non	O
-	O
overlapping	O
and	O
overlapping	O
)	O
,	O
number	O
of	O
QGRS	O
found	O
near	O
RNA	O
processing	O
sites	O
,	O
and	O
a	O
visual	O
map	O
of	O
the	O
product	O
.	O

As	O
an	O
example	O
,	O
the	O
Gene	O
View	O
for	O
the	O
human	B-Species
GREB1	O
is	O
displayed	O
in	O
Figure	O
2	O
,	O
showing	O
the	O
table	O
of	O
gene	O
information	O
and	O
product	O
information	O
for	O
the	O
first	O
product	O
(	O
the	O
output	O
for	O
all	O
products	O
may	O
be	O
seen	O
in	O
the	O
supplementary	O
material	O
)	O
.	O

At	O
this	O
stage	O
in	O
the	O
analysis	O
the	O
user	O
can	O
choose	O
among	O
three	O
further	O
displays	O
:	O
'	O
Data	O
View	O
'	O
,	O
'	O
Data	O
View	O
(	O
with	O
overlaps	O
)	O
'	O
and	O
'	O
Graphics	O
View	O
'	O
.	O

This	O
can	O
be	O
done	O
for	O
the	O
entire	O
gene	O
or	O
for	O
any	O
particular	O
product	O
.	O
<EOS>	B-X
In	B-X
particular	B-X
,	B-X
we	B-X
highlight	B-X
recent	B-X
studies	B-X
that	B-X
have	B-X
explored	B-X
the	B-X
lean	B-X
six	B-X
sigma	B-X
healthcare	B-X
approach	B-X
.	B-X
This	B-X
phenomenon	B-X
is	B-X
discussed	B-X
in	B-X
several	B-X
aspects	B-X
:	B-X
health	B-X
,	B-X
social	B-X
or	B-X
labor	B-X
productivity	B-X
.	B-X
In	B-X
his	B-X
article	B-X
the	B-X
analysis	B-X
of	B-X
the	B-X
literature	B-X
concerning	B-X
the	B-X
problem	B-X
of	B-X
non-effective	B-X
presence	B-X
at	B-X
work	B-X
is	B-X
presented	B-X
,	B-X
paying	B-X
particular	B-X
attention	B-X
to	B-X
the	B-X
definition	B-X
of	B-X
presenteeism	B-X
,	B-X
the	B-X
reasons	B-X
for	B-X
it	B-X
is	B-X
creation	B-X
,	B-X
as	B-X
well	B-X
as	B-X
its	B-X
relationship	B-X
with	B-X
sickness	B-X
absence	B-X
and	B-X
the	B-X
prevalence	B-X
of	B-X
such	B-X
diseases	B-X
as	B-X
allergy	B-X
,	B-X
depression	B-X
,	B-X
migraine/headaches	B-X
,	B-X
arthritis	B-X
or	B-X
gastrointestinal	B-X
disorders	B-X
and	B-X
work	B-X
environment	B-X
.	B-X
Bearing	B-X
in	B-X
mind	B-X
that	B-X
presenteeism	B-X
is	B-X
one	B-X
of	B-X
the	B-X
biggest	B-X
financial	B-X
and	B-X
social	B-X
burden	B-X
,	B-X
in	B-X
the	B-X
final	B-X
part	B-X
of	B-X
this	B-X
article	B-X
an	B-X
attempt	B-X
was	B-X
made	B-X
to	B-X
estimate	B-X
economical	B-X
costs	B-X
generated	B-X
by	B-X
this	B-X
phenomenon	B-X
.	B-X

In	O
the	O
Data	O
View	O
,	O
a	O
table	O
is	O
displayed	O
showing	O
information	O
for	O
each	O
of	O
the	O
set	O
of	O
non	O
-	O
overlapping	O
QGRS	O
.	O

This	O
table	O
displays	O
the	O
position	O
of	O
the	O
QGRS	O
,	O
which	O
exon	O
/	O
intron	O
it	O
appears	O
in	O
,	O
its	O
distance	O
from	O
3	O
'	O
and	O
5	O
'	O
splice	O
sites	O
,	O
the	O
QGRS	O
sequence	O
(	O
with	O
each	O
G	O
-	O
group	O
underlined	O
)	O
and	O
the	O
corresponding	O
G	O
-	O
score	O
.	O

Similar	O
display	O
is	O
also	O
shown	O
for	O
each	O
QGRS	O
mapped	O
to	O
poly	O
(	O
A	O
)	O
region	O
in	O
the	O
product	O
.	O

If	O
the	O
user	O
requests	O
the	O
Data	O
View	O
for	O
the	O
entire	O
gene	O
,	O
then	O
the	O
QGRS	O
information	O
is	O
shown	O
for	O
each	O
product	O
.	O

The	O
'	O
Data	O
View	O
(	O
with	O
overlaps	O
)	O
'	O
gives	O
the	O
same	O
information	O
but	O
shows	O
the	O
locations	O
of	O
all	O
QGRS	O
.	O

Figure	O
3	O
shows	O
the	O
Data	O
View	O
for	O
product	O
1	O
of	O
the	O
GREB1	O
gene	O
.	O

The	O
user	O
can	O
also	O
choose	O
the	O
Graphics	O
View	O
to	O
give	O
a	O
visual	O
display	O
of	O
the	O
location	O
of	O
QGRS	O
.	O

This	O
allows	O
the	O
user	O
to	O
see	O
the	O
location	O
of	O
QGRS	O
relative	O
to	O
exons	O
and	O
introns	O
(	O
if	O
that	O
information	O
is	O
available	O
)	O
.	O

The	O
Graphics	O
View	O
has	O
the	O
following	O
components	O
.	O
<EOS>	B-X
The	B-X
development	B-X
and	B-X
testing	B-X
of	B-X
a	B-X
SparseCT	B-X
prototype	B-X
with	B-X
the	B-X
designed	B-X
MSC	B-X
will	B-X
be	B-X
described	B-X
in	B-X
a	B-X
following	B-X
paper	B-X
.	B-X
Introduction	B-X
:	B-X
The	B-X
human	B-X
prostate	B-X
gland	B-X
is	B-X
a	B-X
complex	B-X
organ	B-X
that	B-X
consists	B-X
of	B-X
two	B-X
main	B-X
components	B-X
-	B-X
glandular	B-X
and	B-X
non-glandular	B-X
.	B-X
The	B-X
first	B-X
of	B-X
them	B-X
represents	B-X
a	B-X
compound	B-X
of	B-X
components	B-X
of	B-X
different	B-X
origin	B-X
,	B-X
structure	B-X
,	B-X
location	B-X
,	B-X
and	B-X
complexity	B-X
of	B-X
spatial	B-X
organization	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
view	B-X
here	B-X
is	B-X
that	B-X
probability	B-X
theory	B-X
is	B-X
a	B-X
desirable	B-X
and	B-X
sufficient	B-X
basis	B-X
for	B-X
many	B-X
topics	B-X
in	B-X
causal	B-X
inference	B-X
for	B-X
the	B-X
following	B-X
two	B-X
reasons	B-X
.	B-X

A	O
graphic	O
display	O
of	O
the	O
entire	O
gene	O
(	O
showing	O
the	O
location	O
of	O
the	O
exons	O
)	O
.	O

This	O
display	O
includes	O
a	O
sliding	O
window	O
that	O
can	O
be	O
used	O
to	O
focus	O
on	O
any	O
particular	O
segment	O
of	O
the	O
gene	O
.	O

This	O
window	O
may	O
be	O
dragged	O
to	O
the	O
left	O
or	O
right	O
to	O
change	O
position	O
within	O
the	O
gene	O
.	O
A	O
magnified	O
view	O
of	O
the	O
fragment	O
of	O
the	O
gene	O
within	O
the	O
sliding	O
window	O
.	O
A	O
graph	O
showing	O
the	O
location	O
of	O
QGRS	O
within	O
the	O
fragment	O
,	O
with	O
each	O
QGRS	O
being	O
displayed	O
by	O
a	O
bar	O
whose	O
height	O
represents	O
its	O
G	O
-	O
score	O
.	O
A	O
vertical	O
slider	O
that	O
allows	O
the	O
user	O
to	O
change	O
the	O
size	O
of	O
the	O
window	O
.	O

This	O
allows	O
the	O
user	O
to	O
zoom	O
in	O
or	O
out	O
on	O
any	O
part	O
of	O
the	O
gene	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
present	B-X
a	B-X
complementary	B-X
approach	B-X
to	B-X
this	B-X
problem	B-X
:	B-X
the	B-X
design	B-X
and	B-X
construction	B-X
of	B-X
a	B-X
synthetic	B-X
network	B-X
to	B-X
implement	B-X
a	B-X
particular	B-X
function	B-X
.	B-X
We	B-X
used	B-X
three	B-X
transcriptional	B-X
repressor	B-X
systems	B-X
that	B-X
are	B-X
not	B-X
part	B-X
of	B-X
any	B-X
natural	B-X
biological	B-X
clock	B-X
to	B-X
build	B-X
an	B-X
oscillating	B-X
network	B-X
,	B-X
termed	B-X
the	B-X
repressilator	B-X
,	B-X
in	B-X
Escherichia	B-X
coli	B-X
.	B-X
The	B-X
resulting	B-X
oscillations	B-X
,	B-X
with	B-X
typical	B-X
periods	B-X
of	B-X
hours	B-X
,	B-X
are	B-X
slower	B-X
than	B-X
the	B-X
cell-division	B-X
cycle	B-X
,	B-X
so	B-X
the	B-X
state	B-X
of	B-X
the	B-X
oscillator	B-X
has	B-X
to	B-X
be	B-X
transmitted	B-X
from	B-X
generation	B-X
to	B-X
generation	B-X
.	B-X
Hundreds	B-X
,	B-X
perhaps	B-X
thousands	B-X
of	B-X
previously	B-X
unidentified	B-X
functional	B-X
small	B-X
peptides	B-X
could	B-X
exist	B-X
in	B-X
most	B-X
genomes	B-X
,	B-X
but	B-X
these	B-X
sequences	B-X
have	B-X
been	B-X
generally	B-X
overlooked	B-X
.	B-X
The	B-X
discovery	B-X
of	B-X
genes	B-X
encoding	B-X
small	B-X
peptides	B-X
with	B-X
important	B-X
functions	B-X
in	B-X
different	B-X
organisms	B-X
has	B-X
ignited	B-X
the	B-X
interest	B-X
in	B-X
these	B-X
sequences	B-X
and	B-X
led	B-X
to	B-X
an	B-X
increasing	B-X
amount	B-X
of	B-X
effort	B-X
towards	B-X
their	B-X
identification	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
the	B-X
advances	B-X
,	B-X
both	B-X
computational	B-X
and	B-X
biochemical	B-X
,	B-X
that	B-X
are	B-X
leading	B-X
the	B-X
way	B-X
in	B-X
the	B-X
discovery	B-X
of	B-X
putatively	B-X
functional	B-X
small	B-X
open	B-X
reading	B-X
frame	B-X
genes	B-X
(	B-X
smORFs	B-X
)	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
functional	B-X
studies	B-X
that	B-X
have	B-X
been	B-X
carried	B-X
out	B-X
as	B-X
a	B-X
consequence	B-X
of	B-X
these	B-X
searches	B-X
.	B-X
The	B-X
evidence	B-X
suggests	B-X
that	B-X
smORFs	B-X
form	B-X
a	B-X
substantial	B-X
part	B-X
of	B-X
our	B-X
genomes	B-X
,	B-X
and	B-X
that	B-X
their	B-X
encoded	B-X
peptides	B-X
could	B-X
have	B-X
a	B-X
variety	B-X
of	B-X
important	B-X
cellular	B-X
functions	B-X
.	B-X

The	O
sliding	O
window	O
on	O
the	O
gene	O
expands	O
or	O
contracts	O
as	O
one	O
zooms	O
in	O
or	O
out	O
.	O
<EOS>	B-X
Studies	B-X
using	B-X
the	B-X
intergroup	B-X
prisoner	B-X
's	B-X
dilemma-maximizing	B-X
difference	B-X
game	B-X
to	B-X
test	B-X
the	B-X
model	B-X
have	B-X
repeatedly	B-X
shown	B-X
that	B-X
people	B-X
do	B-X
not	B-X
exhibit	B-X
out-group	B-X
aggression	B-X
,	B-X
possibly	B-X
because	B-X
of	B-X
an	B-X
inappropriate	B-X
operationalization	B-X
and	B-X
framing	B-X
of	B-X
out-group	B-X
aggression	B-X
.	B-X
Results	B-X
of	B-X
two	B-X
laboratory	B-X
experiments	B-X
with	B-X
176	B-X
Japanese	B-X
university	B-X
students	B-X
in	B-X
total	B-X
showed	B-X
that	B-X
such	B-X
a	B-X
framing	B-X
did	B-X
not	B-X
promote	B-X
out-group	B-X
aggression	B-X
and	B-X
individuals	B-X
invested	B-X
more	B-X
money	B-X
to	B-X
cooperate	B-X
with	B-X
in-group	B-X
members	B-X
only	B-X
,	B-X
avoiding	B-X
the	B-X
strategy	B-X
of	B-X
cooperating	B-X
with	B-X
in-group	B-X
members	B-X
to	B-X
harm	B-X
out-group	B-X
members	B-X
.	B-X
Despite	B-X
the	B-X
risks	B-X
of	B-X
rejection	B-X
and	B-X
discrimination	B-X
,	B-X
``	B-X
coming	B-X
out	B-X
''	B-X
can	B-X
be	B-X
an	B-X
important	B-X
psychological	B-X
milestone	B-X
for	B-X
transgender	B-X
(	B-X
trans	B-X
)	B-X
and	B-X
gender	B-X
diverse	B-X
people	B-X
(	B-X
TGD	B-X
)	B-X
.	B-X
Doubly	B-X
uniparental	B-X
inheritance	B-X
(	B-X
DUI	B-X
)	B-X
of	B-X
mitochondrial	B-X
DNA	B-X
(	B-X
mtDNA	B-X
)	B-X
in	B-X
bivalve	B-X
mollusks	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
notable	B-X
departures	B-X
from	B-X
the	B-X
paradigm	B-X
of	B-X
strict	B-X
maternal	B-X
inheritance	B-X
of	B-X
mtDNA	B-X
among	B-X
metazoans	B-X
.	B-X

It	O
is	O
possible	O
to	O
see	O
the	O
nucleotide	O
sequence	O
of	O
the	O
product	O
at	O
maximum	O
zoom	O
levels	O
.	O

The	O
Graphics	O
View	O
for	O
the	O
entire	O
gene	O
shows	O
the	O
G	O
-	O
score	O
graph	O
together	O
with	O
an	O
exon	O
/	O
intron	O
map	O
for	O
each	O
product	O
.	O

This	O
allows	O
the	O
user	O
to	O
visually	O
compare	O
the	O
location	O
of	O
QGRS	O
for	O
each	O
product	O
relative	O
to	O
that	O
of	O
splice	O
sites	O
.	O

The	O
Graphics	O
View	O
for	O
the	O
first	O
product	O
of	O
the	O
GREB1	O
gene	O
is	O
represented	O
in	O
Figure	O
4	O
.	O

The	O
Graphics	O
View	O
for	O
the	O
entire	O
GREB1	O
gene	O
may	O
be	O
seen	O
in	O
the	O
Supplementary	O
Data	O
.	O

CONCLUSIONS	O
<EOS>	B-X
[	B-X
Conclusions	B-X
of	B-X
the	B-X
First	B-X
Workshop	B-X
of	B-X
the	B-X
oncology	B-X
societies	B-X
AIOM	B-X
,	B-X
AIRO	B-X
and	B-X
SICO	B-X
about	B-X
pancreatic	B-X
cancer	B-X
]	B-X
.	B-X

QGRS	O
Mapper	O
is	O
a	O
user	O
-	O
friendly	O
web	O
-	O
based	O
server	O
that	O
provides	O
computational	O
tools	O
for	O
prediction	O
of	O
Quadruplex	O
forming	O
G	O
-	O
rich	O
sequences	O
in	O
the	O
nucleotide	O
sequences	O
identified	O
or	O
provided	O
by	O
the	O
user	O
.	O
<EOS>	B-X
Data	B-X
aggregated	B-X
by	B-X
variant	B-X
are	B-X
accessible	B-X
on	B-X
the	B-X
website	B-X
,	B-X
in	B-X
an	B-X
improved	B-X
set	B-X
of	B-X
variant	B-X
call	B-X
format	B-X
files	B-X
and	B-X
as	B-X
a	B-X
new	B-X
comprehensive	B-X
XML	B-X
report	B-X
.	B-X
Several	B-X
new	B-X
fields	B-X
are	B-X
now	B-X
indexed	B-X
for	B-X
more	B-X
precise	B-X
searching	B-X
,	B-X
and	B-X
filters	B-X
allow	B-X
the	B-X
user	B-X
to	B-X
narrow	B-X
down	B-X
a	B-X
large	B-X
set	B-X
of	B-X
search	B-X
results	B-X
.	B-X
Activity-based	B-X
costing	B-X
(	B-X
ABC	B-X
)	B-X
is	B-X
an	B-X
accounting	B-X
tool	B-X
that	B-X
allocates	B-X
costs	B-X
incurred	B-X
through	B-X
a	B-X
company	B-X
's	B-X
practice	B-X
of	B-X
providing	B-X
goods	B-X
and	B-X
services	B-X
to	B-X
the	B-X
consumer	B-X
.	B-X
This	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
can	B-X
drive	B-X
services	B-X
provided	B-X
toward	B-X
generating	B-X
more	B-X
value	B-X
for	B-X
the	B-X
hospital	B-X
system	B-X
.	B-X
With	B-X
time-driven	B-X
ABC	B-X
(	B-X
Td-ABC	B-X
)	B-X
,	B-X
we	B-X
look	B-X
to	B-X
use	B-X
the	B-X
advantages	B-X
of	B-X
both	B-X
the	B-X
fee-for-service	B-X
and	B-X
capitation	B-X
model	B-X
to	B-X
transition	B-X
to	B-X
a	B-X
value-based	B-X
system	B-X
.	B-X
Providers	B-X
are	B-X
rewarded	B-X
based	B-X
on	B-X
efficiencies	B-X
and	B-X
successful	B-X
outcomes	B-X
in	B-X
patient	B-X
care	B-X
while	B-X
disincentivizing	B-X
poor	B-X
outcomes	B-X
and	B-X
superfluous	B-X
volume/expenditures	B-X
.	B-X
ABC	B-X
,	B-X
however	B-X
,	B-X
does	B-X
not	B-X
come	B-X
without	B-X
its	B-X
own	B-X
risks	B-X
and	B-X
disadvantages	B-X
,	B-X
and	B-X
the	B-X
user	B-X
must	B-X
exercise	B-X
caution	B-X
in	B-X
applying	B-X
this	B-X
cost-allocating	B-X
tool	B-X
to	B-X
avoid	B-X
detriment	B-X
to	B-X
its	B-X
practice	B-X
.	B-X

The	O
program	O
offers	O
many	O
options	O
,	O
including	O
user	O
-	O
defined	O
composition	O
of	O
the	O
quadruplex	O
.	O

It	O
can	O
analyze	O
DNA	O
or	O
RNA	O
sequence	O
provided	O
by	O
the	O
user	O
in	O
the	O
raw	O
or	O
FASTA	O
format	O
.	O
<EOS>	B-X
RNA-binding	B-X
proteins	B-X
(	B-X
RBPs	B-X
)	B-X
comprise	B-X
a	B-X
large	B-X
class	B-X
of	B-X
over	B-X
2,000	B-X
proteins	B-X
that	B-X
interact	B-X
with	B-X
transcripts	B-X
in	B-X
all	B-X
manner	B-X
of	B-X
RNA-driven	B-X
processes	B-X
.	B-X
The	B-X
structures	B-X
and	B-X
mechanisms	B-X
that	B-X
RBPs	B-X
use	B-X
to	B-X
bind	B-X
and	B-X
regulate	B-X
RNA	B-X
are	B-X
incredibly	B-X
diverse	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
take	B-X
a	B-X
look	B-X
at	B-X
the	B-X
components	B-X
of	B-X
protein-RNA	B-X
interaction	B-X
,	B-X
from	B-X
the	B-X
molecular	B-X
level	B-X
to	B-X
multi-component	B-X
interaction	B-X
.	B-X
We	B-X
first	B-X
summarize	B-X
what	B-X
is	B-X
known	B-X
about	B-X
protein-RNA	B-X
molecular	B-X
interactions	B-X
based	B-X
on	B-X
analyses	B-X
of	B-X
solved	B-X
structures	B-X
.	B-X
We	B-X
additionally	B-X
describe	B-X
software	B-X
currently	B-X
available	B-X
for	B-X
predicting	B-X
protein-RNA	B-X
interaction	B-X
and	B-X
other	B-X
resources	B-X
useful	B-X
for	B-X
the	B-X
study	B-X
of	B-X
RBPs	B-X
.	B-X
We	B-X
then	B-X
review	B-X
the	B-X
structure	B-X
and	B-X
function	B-X
of	B-X
seventeen	B-X
known	B-X
RNA-binding	B-X
domains	B-X
and	B-X
analyze	B-X
the	B-X
hydrogen	B-X
bonds	B-X
adopted	B-X
by	B-X
protein-RNA	B-X
structures	B-X
on	B-X
a	B-X
domain-by-domain	B-X
basis	B-X
.	B-X
We	B-X
conclude	B-X
with	B-X
a	B-X
summary	B-X
of	B-X
the	B-X
higher-level	B-X
mechanisms	B-X
that	B-X
regulate	B-X
protein-RNA	B-X
interactions	B-X
.	B-X

The	O
application	O
also	O
provides	O
tools	O
for	O
searching	O
and	O
retrieving	O
gene	O
/	O
nucleotide	O
entries	O
from	O
a	O
variety	O
of	O
NCBI	O
databases	O
.	O

There	O
are	O
several	O
options	O
for	O
data	O
output	O
format	O
,	O
including	O
an	O
interactive	O
graphic	O
module	O
.	O
<EOS>	B-X
It	B-X
provides	B-X
summaries	B-X
and	B-X
graphical	B-X
distributions	B-X
for	B-X
many	B-X
descriptive	B-X
statistics	B-X
about	B-X
any	B-X
set	B-X
of	B-X
annotations	B-X
,	B-X
regardless	B-X
of	B-X
their	B-X
source	B-X
.	B-X
Eval	B-X
can	B-X
be	B-X
run	B-X
interactively	B-X
or	B-X
via	B-X
the	B-X
command	B-X
line	B-X
,	B-X
in	B-X
which	B-X
case	B-X
output	B-X
options	B-X
include	B-X
easily	B-X
parsable	B-X
tab-delimited	B-X
files	B-X
.	B-X

Researchers	O
interested	O
in	O
evaluating	O
the	O
ability	O
of	O
nucleotide	O
sequences	O
to	O
form	O
unimolecular	O
G	O
-	O
quadruplexes	O
will	O
find	O
QGRS	O
Mapper	O
to	O
be	O
very	O
useful	O
.	O

Owing	O
to	O
the	O
flexible	O
and	O
comprehensive	O
nature	O
of	O
the	O
design	O
,	O
it	O
is	O
expected	O
to	O
serve	O
a	O
variety	O
of	O
scientists	O
.	O

The	O
application	O
will	O
be	O
especially	O
attractive	O
to	O
individuals	O
interested	O
in	O
exploring	O
the	O
role	O
of	O
G	O
-	O
quadruplexes	O
in	O
regulated	O
RNA	O
processing	O
.	O

We	O
are	O
using	O
the	O
server	O
to	O
perform	O
a	O
large	O
-	O
scale	O
analysis	O
of	O
alternatively	O
processed	O
mammalian	O
transcripts	O
.	O

We	O
are	O
particularly	O
interested	O
in	O
studying	O
the	O
composition	O
and	O
distribution	O
patterns	O
of	O
G	O
-	O
quadruplexes	O
in	O
the	O
transcribed	O
regions	O
of	O
mammalian	O
genes	O
.	O

SUPPLEMENTARY	O
DATA	O
<EOS>	B-X
Moderating	B-X
supplementary	B-X
data	B-X
.	B-X
[	B-X
Supplementary	B-X
Data	B-X
]	B-X
.	B-X

Supplementary	O
Data	O
are	O
available	O
at	O
NAR	O
online	O
.	O
<EOS>	B-X
This	B-X
article	B-X
defines	B-X
the	B-X
FASTQ	B-X
format	B-X
,	B-X
covering	B-X
the	B-X
original	B-X
Sanger	B-X
standard	B-X
,	B-X
the	B-X
Solexa/Illumina	B-X
variants	B-X
and	B-X
conversion	B-X
between	B-X
them	B-X
,	B-X
based	B-X
on	B-X
publicly	B-X
available	B-X
information	B-X
such	B-X
as	B-X
the	B-X
MAQ	B-X
documentation	B-X
and	B-X
conventions	B-X
recently	B-X
agreed	B-X
by	B-X
the	B-X
Open	B-X
Bioinformatics	B-X
Foundation	B-X
projects	B-X
Biopython	B-X
,	B-X
BioPerl	B-X
,	B-X
BioRuby	B-X
,	B-X
BioJava	B-X
and	B-X
EMBOSS	B-X
.	B-X
Being	B-X
an	B-X
open	B-X
access	B-X
publication	B-X
,	B-X
it	B-X
is	B-X
hoped	B-X
that	B-X
this	B-X
description	B-X
,	B-X
with	B-X
the	B-X
example	B-X
files	B-X
provided	B-X
as	B-X
Supplementary	B-X
Data	B-X
,	B-X
will	B-X
serve	B-X
in	B-X
future	B-X
as	B-X
a	B-X
reference	B-X
for	B-X
this	B-X
important	B-X
file	B-X
format	B-X
.	B-X
WACA	B-X
and	B-X
associated	B-X
files	B-X
are	B-X
freely	B-X
available	B-X
as	B-X
Supplementary	B-X
Data	B-X
.	B-X
edu/pir/	B-X
)	B-X
supports	B-X
research	B-X
on	B-X
molecular	B-X
evolution	B-X
,	B-X
functional	B-X
genomics	B-X
,	B-X
and	B-X
computational	B-X
biology	B-X
by	B-X
maintaining	B-X
a	B-X
comprehensive	B-X
,	B-X
non-redundant	B-X
,	B-X
well-organized	B-X
and	B-X
freely	B-X
available	B-X
protein	B-X
sequence	B-X
database	B-X
.	B-X
The	B-X
PIR	B-X
Protein	B-X
Sequence	B-X
Database	B-X
entries	B-X
are	B-X
classified	B-X
into	B-X
superfamilies	B-X
,	B-X
families	B-X
and	B-X
homology	B-X
domains	B-X
,	B-X
for	B-X
which	B-X
sequence	B-X
alignments	B-X
are	B-X
available	B-X
.	B-X
The	B-X
PIR	B-X
WWW	B-X
server	B-X
supports	B-X
direct	B-X
on-line	B-X
sequence	B-X
similarity	B-X
searches	B-X
,	B-X
information	B-X
retrieval	B-X
,	B-X
and	B-X
knowledge	B-X
discovery	B-X
by	B-X
providing	B-X
the	B-X
Protein	B-X
Sequence	B-X
Database	B-X
and	B-X
other	B-X
supplementary	B-X
databases	B-X
.	B-X
The	B-X
weekly	B-X
release	B-X
of	B-X
the	B-X
Protein	B-X
Sequence	B-X
Database	B-X
can	B-X
be	B-X
accessed	B-X
through	B-X
the	B-X
PIR	B-X
Web	B-X
site	B-X
.	B-X
The	B-X
quarterly	B-X
release	B-X
of	B-X
the	B-X
database	B-X
is	B-X
freely	B-X
available	B-X
from	B-X
our	B-X
anonymous	B-X
FTP	B-X
server	B-X
and	B-X
is	B-X
also	B-X
available	B-X
on	B-X
CD-ROM	B-X
with	B-X
the	B-X
accompanying	B-X
ATLAS	B-X
database	B-X
search	B-X
program	B-X
.	B-X

Drug	O
information	O
resources	O
used	O
by	O
nurse	O
practitioners	O
and	O
collaborating	O
physicians	O
at	O
the	O
point	O
of	O
care	O
in	O
Nova	O
Scotia	O
,	O
Canada	O
:	O
a	O
survey	O
and	O
review	O
of	O
the	O
literature	O

Abstract	O
<EOS>	B-X
Abstract	B-X
writing	B-X
.	B-X
The	B-X
informative	B-X
abstract	B-X
.	B-X
Crafting	B-X
a	B-X
compelling	B-X
abstract	B-X
.	B-X
Why	B-X
the	B-X
structured	B-X
abstract	B-X
?	B-X

Background	O
<EOS>	B-X
Background	B-X
matching	B-X
is	B-X
the	B-X
most	B-X
familiar	B-X
and	B-X
widespread	B-X
camouflage	B-X
strategy	B-X
:	B-X
avoiding	B-X
detection	B-X
by	B-X
having	B-X
a	B-X
similar	B-X
colour	B-X
and	B-X
pattern	B-X
to	B-X
the	B-X
background	B-X
.	B-X
Background	B-X
is	B-X
thus	B-X
a	B-X
relatively	B-X
modest	B-X
correction	B-X
for	B-X
all	B-X
Z	B-X
opacity	B-X
data	B-X
published	B-X
to	B-X
date	B-X
.	B-X
Background	B-X
estimation	B-X
and	B-X
foreground	B-X
segmentation	B-X
are	B-X
important	B-X
steps	B-X
in	B-X
many	B-X
high-level	B-X
vision	B-X
tasks	B-X
.	B-X
Patient	B-X
Preference	B-X
for	B-X
Telehealth	B-X
Background	B-X
Shapes	B-X
Impressions	B-X
of	B-X
Physicians	B-X
and	B-X
Information	B-X
Recall	B-X
:	B-X
A	B-X
Randomized	B-X
Experiment	B-X
.	B-X

Keeping	O
current	O
with	O
drug	O
therapy	O
information	O
is	O
challenging	O
for	O
health	O
care	O
practitioners	O
.	O
<EOS>	B-X
Keeping	B-X
current	B-X
with	B-X
drug	B-X
therapy	B-X
information	B-X
is	B-X
challenging	B-X
for	B-X
health	B-X
care	B-X
practitioners	B-X
.	B-X
Technologies	B-X
are	B-X
often	B-X
implemented	B-X
to	B-X
facilitate	B-X
access	B-X
to	B-X
current	B-X
and	B-X
credible	B-X
drug	B-X
information	B-X
sources	B-X
.	B-X
In	B-X
the	B-X
Canadian	B-X
province	B-X
of	B-X
Nova	B-X
Scotia	B-X
,	B-X
legislation	B-X
was	B-X
passed	B-X
in	B-X
2002	B-X
to	B-X
allow	B-X
nurse	B-X
practitioners	B-X
(	B-X
NPs	B-X
)	B-X
to	B-X
practice	B-X
collaboratively	B-X
with	B-X
physician	B-X
partners	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
current	B-X
utilization	B-X
patterns	B-X
of	B-X
information	B-X
technologies	B-X
by	B-X
these	B-X
groups	B-X
of	B-X
practitioners	B-X
.	B-X

Technologies	O
are	O
often	O
implemented	O
to	O
facilitate	O
access	O
to	O
current	O
and	O
credible	O
drug	O
information	O
sources	O
.	O
<EOS>	B-X
Keeping	B-X
current	B-X
with	B-X
drug	B-X
therapy	B-X
information	B-X
is	B-X
challenging	B-X
for	B-X
health	B-X
care	B-X
practitioners	B-X
.	B-X
Technologies	B-X
are	B-X
often	B-X
implemented	B-X
to	B-X
facilitate	B-X
access	B-X
to	B-X
current	B-X
and	B-X
credible	B-X
drug	B-X
information	B-X
sources	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
current	B-X
utilization	B-X
patterns	B-X
of	B-X
information	B-X
technologies	B-X
by	B-X
these	B-X
groups	B-X
of	B-X
practitioners	B-X
.	B-X

In	O
the	O
Canadian	O
province	O
of	O
Nova	O
Scotia	O
,	O
legislation	O
was	O
passed	O
in	O
2002	O
to	O
allow	O
nurse	O
practitioners	O
(	O
NPs	O
)	O
to	O
practice	O
collaboratively	O
with	O
physician	O
partners	O
.	O
<EOS>	B-X
Keeping	B-X
current	B-X
with	B-X
drug	B-X
therapy	B-X
information	B-X
is	B-X
challenging	B-X
for	B-X
health	B-X
care	B-X
practitioners	B-X
.	B-X
In	B-X
the	B-X
Canadian	B-X
province	B-X
of	B-X
Nova	B-X
Scotia	B-X
,	B-X
legislation	B-X
was	B-X
passed	B-X
in	B-X
2002	B-X
to	B-X
allow	B-X
nurse	B-X
practitioners	B-X
(	B-X
NPs	B-X
)	B-X
to	B-X
practice	B-X
collaboratively	B-X
with	B-X
physician	B-X
partners	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
current	B-X
utilization	B-X
patterns	B-X
of	B-X
information	B-X
technologies	B-X
by	B-X
these	B-X
groups	B-X
of	B-X
practitioners	B-X
.	B-X

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
current	O
utilization	O
patterns	O
of	O
information	O
technologies	O
by	O
these	O
groups	O
of	O
practitioners	O
.	O
<EOS>	B-X
Keeping	B-X
current	B-X
with	B-X
drug	B-X
therapy	B-X
information	B-X
is	B-X
challenging	B-X
for	B-X
health	B-X
care	B-X
practitioners	B-X
.	B-X
Technologies	B-X
are	B-X
often	B-X
implemented	B-X
to	B-X
facilitate	B-X
access	B-X
to	B-X
current	B-X
and	B-X
credible	B-X
drug	B-X
information	B-X
sources	B-X
.	B-X
In	B-X
the	B-X
Canadian	B-X
province	B-X
of	B-X
Nova	B-X
Scotia	B-X
,	B-X
legislation	B-X
was	B-X
passed	B-X
in	B-X
2002	B-X
to	B-X
allow	B-X
nurse	B-X
practitioners	B-X
(	B-X
NPs	B-X
)	B-X
to	B-X
practice	B-X
collaboratively	B-X
with	B-X
physician	B-X
partners	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
current	B-X
utilization	B-X
patterns	B-X
of	B-X
information	B-X
technologies	B-X
by	B-X
these	B-X
groups	B-X
of	B-X
practitioners	B-X
.	B-X

Methods	O
<EOS>	B-X
Methods	B-X
to	B-X
calculate	B-X
the	B-X
sample	B-X
size	B-X
are	B-X
explained	B-X
in	B-X
statistical	B-X
textbooks	B-X
,	B-X
but	B-X
because	B-X
there	B-X
are	B-X
many	B-X
different	B-X
formulas	B-X
available	B-X
,	B-X
it	B-X
can	B-X
be	B-X
difficult	B-X
for	B-X
investigators	B-X
to	B-X
decide	B-X
which	B-X
method	B-X
to	B-X
use	B-X
.	B-X

Nurse	O
practitioners	O
and	O
their	O
collaborating	O
physician	O
partners	O
in	O
Nova	O
Scotia	O
were	O
sent	O
a	O
survey	O
in	O
February	O
2005	O
to	O
determine	O
the	O
frequency	O
of	O
use	O
,	O
usefulness	O
,	O
accessibility	O
,	O
credibility	O
,	O
and	O
current	O
/	O
timeliness	O
of	O
personal	O
digital	O
assistant	O
(	O
PDA	O
)	O
,	O
computer	O
,	O
and	O
print	O
drug	O
information	O
resources	O
.	O
<EOS>	B-X
Keeping	B-X
current	B-X
with	B-X
drug	B-X
therapy	B-X
information	B-X
is	B-X
challenging	B-X
for	B-X
health	B-X
care	B-X
practitioners	B-X
.	B-X
Technologies	B-X
are	B-X
often	B-X
implemented	B-X
to	B-X
facilitate	B-X
access	B-X
to	B-X
current	B-X
and	B-X
credible	B-X
drug	B-X
information	B-X
sources	B-X
.	B-X
In	B-X
the	B-X
Canadian	B-X
province	B-X
of	B-X
Nova	B-X
Scotia	B-X
,	B-X
legislation	B-X
was	B-X
passed	B-X
in	B-X
2002	B-X
to	B-X
allow	B-X
nurse	B-X
practitioners	B-X
(	B-X
NPs	B-X
)	B-X
to	B-X
practice	B-X
collaboratively	B-X
with	B-X
physician	B-X
partners	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
current	B-X
utilization	B-X
patterns	B-X
of	B-X
information	B-X
technologies	B-X
by	B-X
these	B-X
groups	B-X
of	B-X
practitioners	B-X
.	B-X

Two	O
surveys	O
were	O
developed	O
(	O
one	O
for	O
PDA	O
users	O
and	O
one	O
for	O
computer	O
users	O
)	O
and	O
revised	O
based	O
on	O
a	O
literature	O
search	O
,	O
stakeholder	O
consultation	O
,	O
and	O
pilot	O
-	O
testing	O
results	O
.	O
<EOS>	B-X
Keeping	B-X
current	B-X
with	B-X
drug	B-X
therapy	B-X
information	B-X
is	B-X
challenging	B-X
for	B-X
health	B-X
care	B-X
practitioners	B-X
.	B-X
In	B-X
the	B-X
Canadian	B-X
province	B-X
of	B-X
Nova	B-X
Scotia	B-X
,	B-X
legislation	B-X
was	B-X
passed	B-X
in	B-X
2002	B-X
to	B-X
allow	B-X
nurse	B-X
practitioners	B-X
(	B-X
NPs	B-X
)	B-X
to	B-X
practice	B-X
collaboratively	B-X
with	B-X
physician	B-X
partners	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
current	B-X
utilization	B-X
patterns	B-X
of	B-X
information	B-X
technologies	B-X
by	B-X
these	B-X
groups	B-X
of	B-X
practitioners	B-X
.	B-X

A	O
second	O
distribution	O
to	O
nonresponders	O
occurred	O
two	O
weeks	O
following	O
the	O
first	O
.	O

Data	O
were	O
entered	O
and	O
analysed	O
with	O
SPSS	O
.	O
<EOS>	B-X
Data	B-X
were	B-X
collected	B-X
and	B-X
recorded	B-X
using	B-X
Microsoft	B-X
Excel	B-X
.	B-X
We	B-X
used	B-X
SPSS	B-X
Statistics	B-X
for	B-X
Windows	B-X
,	B-X
Version	B-X
20.0	B-X
.	B-X
Demographic	B-X
data	B-X
plus	B-X
pre	B-X
and	B-X
post-op	B-X
calcium	B-X
and	B-X
parathyroid	B-X
Hormone	B-X
(	B-X
PTH	B-X
)	B-X
levels	B-X
were	B-X
analysed	B-X
.	B-X
Data	B-X
were	B-X
coded	B-X
and	B-X
entered	B-X
into	B-X
SPSS	B-X
24	B-X
statistical	B-X
software	B-X
package	B-X
for	B-X
analysis	B-X
.	B-X

Results	O

Twenty	O
-	O
seven	O
(	O
14	O
NPs	O
and	O
13	O
physicians	O
)	O
of	O
36	O
(	O
75	O
%	O
)	O
recipients	O
responded	O
.	O

22	O
%	O
(	O
6	O
)	O
returned	O
personal	O
digital	O
assistant	O
(	O
PDA	O
)	O
surveys	O
.	O

Respondents	O
reported	O
print	O
,	O
health	O
professionals	O
,	O
and	O
online	O
/	O
electronic	O
resources	O
as	O
the	O
most	O
to	O
least	O
preferred	O
means	O
to	O
access	O
drug	O
information	O
,	O
respectively	O
.	O
<EOS>	B-X
Keeping	B-X
current	B-X
with	B-X
drug	B-X
therapy	B-X
information	B-X
is	B-X
challenging	B-X
for	B-X
health	B-X
care	B-X
practitioners	B-X
.	B-X
Technologies	B-X
are	B-X
often	B-X
implemented	B-X
to	B-X
facilitate	B-X
access	B-X
to	B-X
current	B-X
and	B-X
credible	B-X
drug	B-X
information	B-X
sources	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
current	B-X
utilization	B-X
patterns	B-X
of	B-X
information	B-X
technologies	B-X
by	B-X
these	B-X
groups	B-X
of	B-X
practitioners	B-X
.	B-X

37	O
%	O
and	O
35	O
%	O
of	O
respondents	O
reported	O
using	O
"	O
both	O
print	O
and	O
electronic	O
but	O
print	O
more	O
than	O
electronic	O
"	O
and	O
"	O
print	O
only	O
"	O
,	O
respectively	O
,	O
to	O
search	O
monograph	O
-	O
related	O
drug	O
information	O
queries	O
whereas	O
4	O
%	O
reported	O
using	O
"	O
PDA	O
only	O
"	O
.	O
<EOS>	B-X
Keeping	B-X
current	B-X
with	B-X
drug	B-X
therapy	B-X
information	B-X
is	B-X
challenging	B-X
for	B-X
health	B-X
care	B-X
practitioners	B-X
.	B-X
Technologies	B-X
are	B-X
often	B-X
implemented	B-X
to	B-X
facilitate	B-X
access	B-X
to	B-X
current	B-X
and	B-X
credible	B-X
drug	B-X
information	B-X
sources	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
current	B-X
utilization	B-X
patterns	B-X
of	B-X
information	B-X
technologies	B-X
by	B-X
these	B-X
groups	B-X
of	B-X
practitioners	B-X
.	B-X

Analysis	O
of	O
respondent	O
ratings	O
for	O
all	O
resources	O
in	O
the	O
categories	O
print	O
,	O
health	O
professionals	O
and	O
other	O
,	O
and	O
online	O
/	O
electronic	O
resources	O
,	O
indicated	O
that	O
the	O
Compendium	O
of	O
Pharmaceuticals	O
and	O
Specialties	O
and	O
pharmacists	O
ranked	O
highly	O
for	O
frequency	O
of	O
use	O
,	O
usefulness	O
,	O
accessibility	O
,	O
credibility	O
,	O
and	O
current	O
/	O
timeliness	O
by	O
both	O
groups	O
of	O
practitioners	O
.	O
<EOS>	B-X
Keeping	B-X
current	B-X
with	B-X
drug	B-X
therapy	B-X
information	B-X
is	B-X
challenging	B-X
for	B-X
health	B-X
care	B-X
practitioners	B-X
.	B-X
Technologies	B-X
are	B-X
often	B-X
implemented	B-X
to	B-X
facilitate	B-X
access	B-X
to	B-X
current	B-X
and	B-X
credible	B-X
drug	B-X
information	B-X
sources	B-X
.	B-X
In	B-X
the	B-X
Canadian	B-X
province	B-X
of	B-X
Nova	B-X
Scotia	B-X
,	B-X
legislation	B-X
was	B-X
passed	B-X
in	B-X
2002	B-X
to	B-X
allow	B-X
nurse	B-X
practitioners	B-X
(	B-X
NPs	B-X
)	B-X
to	B-X
practice	B-X
collaboratively	B-X
with	B-X
physician	B-X
partners	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
current	B-X
utilization	B-X
patterns	B-X
of	B-X
information	B-X
technologies	B-X
by	B-X
these	B-X
groups	B-X
of	B-X
practitioners	B-X
.	B-X

Respondents	O
'	O
preferences	O
and	O
resource	O
ratings	O
were	O
consistent	O
with	O
self	O
-	O
reported	O
methods	O
for	O
conducting	O
drug	O
information	O
queries	O
.	O
<EOS>	B-X
Keeping	B-X
current	B-X
with	B-X
drug	B-X
therapy	B-X
information	B-X
is	B-X
challenging	B-X
for	B-X
health	B-X
care	B-X
practitioners	B-X
.	B-X
Technologies	B-X
are	B-X
often	B-X
implemented	B-X
to	B-X
facilitate	B-X
access	B-X
to	B-X
current	B-X
and	B-X
credible	B-X
drug	B-X
information	B-X
sources	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
current	B-X
utilization	B-X
patterns	B-X
of	B-X
information	B-X
technologies	B-X
by	B-X
these	B-X
groups	B-X
of	B-X
practitioners	B-X
.	B-X

Few	O
differences	O
existed	O
between	O
NP	O
and	O
physician	O
rankings	O
of	O
resources	O
.	O
<EOS>	B-X
In	B-X
the	B-X
Canadian	B-X
province	B-X
of	B-X
Nova	B-X
Scotia	B-X
,	B-X
legislation	B-X
was	B-X
passed	B-X
in	B-X
2002	B-X
to	B-X
allow	B-X
nurse	B-X
practitioners	B-X
(	B-X
NPs	B-X
)	B-X
to	B-X
practice	B-X
collaboratively	B-X
with	B-X
physician	B-X
partners	B-X
.	B-X

Conclusion	O
<EOS>	B-X
Conclusion	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X

The	O
use	O
of	O
computers	O
and	O
PDAs	O
remains	O
limited	O
,	O
which	O
is	O
also	O
consistent	O
with	O
preferred	O
and	O
frequent	O
use	O
of	O
print	O
resources	O
.	O

Education	O
for	O
these	O
practitioners	O
regarding	O
available	O
electronic	O
drug	O
information	O
resources	O
may	O
facilitate	O
future	O
computer	O
and	O
PDA	O
use	O
.	O
<EOS>	B-X
Keeping	B-X
current	B-X
with	B-X
drug	B-X
therapy	B-X
information	B-X
is	B-X
challenging	B-X
for	B-X
health	B-X
care	B-X
practitioners	B-X
.	B-X
Technologies	B-X
are	B-X
often	B-X
implemented	B-X
to	B-X
facilitate	B-X
access	B-X
to	B-X
current	B-X
and	B-X
credible	B-X
drug	B-X
information	B-X
sources	B-X
.	B-X
In	B-X
the	B-X
Canadian	B-X
province	B-X
of	B-X
Nova	B-X
Scotia	B-X
,	B-X
legislation	B-X
was	B-X
passed	B-X
in	B-X
2002	B-X
to	B-X
allow	B-X
nurse	B-X
practitioners	B-X
(	B-X
NPs	B-X
)	B-X
to	B-X
practice	B-X
collaboratively	B-X
with	B-X
physician	B-X
partners	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
current	B-X
utilization	B-X
patterns	B-X
of	B-X
information	B-X
technologies	B-X
by	B-X
these	B-X
groups	B-X
of	B-X
practitioners	B-X
.	B-X

Further	O
research	O
is	O
needed	O
to	O
determine	O
methods	O
to	O
increase	O
computer	O
and	O
PDA	O
use	O
and	O
whether	O
these	O
technologies	O
affect	O
prescribing	O
and	O
patient	B-Species
outcomes	O
.	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
current	B-X
utilization	B-X
patterns	B-X
of	B-X
information	B-X
technologies	B-X
by	B-X
these	B-X
groups	B-X
of	B-X
practitioners	B-X
.	B-X

Background	O
<EOS>	B-X
Background	B-X
matching	B-X
is	B-X
the	B-X
most	B-X
familiar	B-X
and	B-X
widespread	B-X
camouflage	B-X
strategy	B-X
:	B-X
avoiding	B-X
detection	B-X
by	B-X
having	B-X
a	B-X
similar	B-X
colour	B-X
and	B-X
pattern	B-X
to	B-X
the	B-X
background	B-X
.	B-X
Background	B-X
is	B-X
thus	B-X
a	B-X
relatively	B-X
modest	B-X
correction	B-X
for	B-X
all	B-X
Z	B-X
opacity	B-X
data	B-X
published	B-X
to	B-X
date	B-X
.	B-X
Background	B-X
estimation	B-X
and	B-X
foreground	B-X
segmentation	B-X
are	B-X
important	B-X
steps	B-X
in	B-X
many	B-X
high-level	B-X
vision	B-X
tasks	B-X
.	B-X
Patient	B-X
Preference	B-X
for	B-X
Telehealth	B-X
Background	B-X
Shapes	B-X
Impressions	B-X
of	B-X
Physicians	B-X
and	B-X
Information	B-X
Recall	B-X
:	B-X
A	B-X
Randomized	B-X
Experiment	B-X
.	B-X

Challenges	O
with	O
knowledge	O
management	O
for	O
health	O
care	O
professionals	O
<EOS>	B-X
The	B-X
pandemic	B-X
of	B-X
COVID-19	B-X
is	B-X
the	B-X
biggest	B-X
public	B-X
health	B-X
crisis	B-X
in	B-X
21	B-X
Preparedness	B-X
for	B-X
practice	B-X
has	B-X
become	B-X
an	B-X
international	B-X
theme	B-X
within	B-X
Medical	B-X
Education	B-X
:	B-X
for	B-X
healthcare	B-X
systems	B-X
to	B-X
maintain	B-X
their	B-X
highest	B-X
clinical	B-X
standards	B-X
,	B-X
junior	B-X
doctors	B-X
must	B-X
``	B-X
hit	B-X
the	B-X
ground	B-X
running	B-X
''	B-X
on	B-X
beginning	B-X
work	B-X
.	B-X
Despite	B-X
demonstrating	B-X
logical	B-X
,	B-X
structured	B-X
assessment	B-X
and	B-X
management	B-X
plans	B-X
during	B-X
their	B-X
undergraduate	B-X
examinations	B-X
,	B-X
many	B-X
newly	B-X
qualified	B-X
doctors	B-X
report	B-X
difficulty	B-X
in	B-X
translating	B-X
this	B-X
theoretical	B-X
knowledge	B-X
into	B-X
the	B-X
real	B-X
clinical	B-X
environment	B-X
.	B-X
``	B-X
Preparedness	B-X
''	B-X
must	B-X
constitute	B-X
more	B-X
than	B-X
the	B-X
knowledge	B-X
and	B-X
skills	B-X
acquired	B-X
during	B-X
medical	B-X
school	B-X
.	B-X
Complexities	B-X
of	B-X
the	B-X
clinical	B-X
environment	B-X
overwhelm	B-X
some	B-X
junior	B-X
doctors	B-X
,	B-X
who	B-X
acknowledge	B-X
that	B-X
they	B-X
lack	B-X
strategies	B-X
to	B-X
manage	B-X
their	B-X
anxieties	B-X
,	B-X
under-confidence	B-X
and	B-X
low	B-X
self-efficacy	B-X
.	B-X
The	B-X
latter	B-X
promotes	B-X
management	B-X
of	B-X
negative	B-X
emotions	B-X
,	B-X
distractions	B-X
and	B-X
under-confidence	B-X
,	B-X
thus	B-X
optimizing	B-X
performance	B-X
despite	B-X
immense	B-X
pressures	B-X
of	B-X
career-defining	B-X
moments	B-X
.	B-X
Similar	B-X
techniques	B-X
might	B-X
allow	B-X
junior	B-X
doctors	B-X
to	B-X
optimize	B-X
patient	B-X
care	B-X
,	B-X
especially	B-X
within	B-X
stressful	B-X
situations	B-X
.	B-X
This	B-X
model	B-X
could	B-X
potentially	B-X
equip	B-X
junior	B-X
doctors	B-X
,	B-X
and	B-X
other	B-X
healthcare	B-X
professionals	B-X
facing	B-X
similar	B-X
challenges	B-X
,	B-X
with	B-X
strategies	B-X
to	B-X
optimize	B-X
clinical	B-X
care	B-X
under	B-X
the	B-X
most	B-X
difficult	B-X
circumstances	B-X
.	B-X

In	O
1986	O
,	O
Haynes	O
et	O
al	O
.	O
published	O
a	O
series	O
of	O
6	O
articles	O
entitled	O
"	O
how	O
to	O
keep	O
up	O
with	O
the	O
medical	O
literature	O
"	O
in	O
an	O
effort	O
to	O
help	O
clinicians	O
with	O
information	O
management	O
,	O
but	O
this	O
challenge	O
has	O
not	O
decreased	O
in	O
last	O
two	O
decades	O
[	O
1	O
-	O
6	O
]	O
.	O

Alper	O
et	O
al	O
.	O
suggest	O
that	O
maintaining	O
currency	O
with	O
relevant	O
literature	O
in	O
primary	O
care	O
would	O
"	O
require	O
627	O
.	O
5	O
hours	O
per	O
month	O
,	O
or	O
about	O
29	O
hours	O
per	O
weekday	O
,	O
or	O
3	O
.	O
6	O
full	O
-	O
time	O
equivalents	O
of	O
physician	O
effort	O
"	O
[	O
7	O
]	O
.	O

The	O
volume	O
of	O
information	O
associated	O
with	O
keeping	O
up	O
to	O
date	O
is	O
frequently	O
cited	O
as	O
a	O
barrier	O
[	O
8	O
]	O
.	O

It	O
is	O
estimated	O
that	O
annually	O
there	O
are	O
approximately	O
10	O
,	O
000	O
new	O
randomized	O
trials	O
in	O
MEDLINE	O
and	O
over	O
450	O
,	O
000	O
clinical	O
trials	O
identified	O
by	O
the	O
Cochrane	O
Collaboration	O
[	O
9	O
,	O
10	O
]	O
.	O

Keeping	O
up	O
to	O
date	O
has	O
been	O
described	O
with	O
several	O
analogies	O
including	O
clinicians	O
attempting	O
to	O
drink	O
water	O
from	O
a	O
fire	O
hose	O
and	O
swimming	O
in	O
rivers	O
of	O
clinical	O
research	O
with	O
unprecedented	O
depth	O
,	O
velocity	O
,	O
and	O
turbulence	O
[	O
11	O
,	O
12	O
]	O
.	O

Difficulties	O
with	O
dissemination	O
of	O
research	O
evidence	O
and	O
keeping	O
up	O
to	O
date	O
on	O
pharmacotherapeutic	O
interventions	O
are	O
reported	O
despite	O
the	O
development	O
of	O
tools	O
such	O
as	O
clinical	O
practice	O
guidelines	O
and	O
systematic	O
reviews	O
that	O
are	O
intended	O
to	O
reduce	O
the	O
need	O
for	O
practitioners	O
to	O
evaluate	O
original	O
research	O
[	O
13	O
]	O
.	O

To	O
complicate	O
matters	O
further	O
,	O
there	O
are	O
often	O
issues	O
of	O
credibility	O
,	O
timeliness	O
,	O
and	O
volume	O
of	O
clinical	O
practice	O
guidelines	O
and	O
reviews	O
.	O

Many	O
guidelines	O
are	O
criticized	O
for	O
their	O
methodological	O
development	O
.	O
<EOS>	B-X
Today	B-X
,	B-X
mindfulness	B-X
is	B-X
omnipresent	B-X
in	B-X
modern	B-X
societies	B-X
but	B-X
has	B-X
suffered	B-X
from	B-X
merchandising	B-X
and	B-X
banalization	B-X
,	B-X
which	B-X
has	B-X
been	B-X
strongly	B-X
criticized	B-X
.	B-X
Despite	B-X
some	B-X
limitations	B-X
regarding	B-X
methodological	B-X
aspects	B-X
of	B-X
mindfulness	B-X
research	B-X
,	B-X
it	B-X
is	B-X
considered	B-X
effective	B-X
for	B-X
treating	B-X
many	B-X
physical	B-X
and	B-X
psychological	B-X
disorders	B-X
,	B-X
and	B-X
even	B-X
it	B-X
is	B-X
recommended	B-X
in	B-X
clinical	B-X
guidelines	B-X
such	B-X
the	B-X
British	B-X
National	B-X
Institute	B-X
for	B-X
Health	B-X
and	B-X
Care	B-X
Excellence	B-X
.	B-X
However	B-X
,	B-X
the	B-X
traditional	B-X
format	B-X
of	B-X
case-control	B-X
studies	B-X
may	B-X
be	B-X
improved	B-X
by	B-X
incorporating	B-X
methodological	B-X
refinements	B-X
developed	B-X
over	B-X
the	B-X
past	B-X
30	B-X
years	B-X
in	B-X
environmental	B-X
epidemiology	B-X
.	B-X
The	B-X
present	B-X
chapter	B-X
attempts	B-X
to	B-X
outline	B-X
these	B-X
issues	B-X
and	B-X
to	B-X
provide	B-X
guidelines	B-X
for	B-X
the	B-X
selection	B-X
of	B-X
cases	B-X
and	B-X
controls	B-X
and	B-X
for	B-X
the	B-X
analysis	B-X
of	B-X
genetic	B-X
data	B-X
from	B-X
case-control	B-X
studies	B-X
.	B-X

Shaneyfelt	O
et	O
al	O
.	O
reviewed	O
279	O
guidelines	O
for	O
methodological	O
standards	O
from	O
peer	O
reviewed	O
medical	O
literature	O
[	O
14	O
]	O
.	O

These	O
authors	O
found	O
that	O
only	O
51	O
%	O
,	O
33	O
.	O
6	O
%	O
,	O
and	O
46	O
%	O
adhered	O
to	O
standards	O
on	O
guideline	O
development	O
and	O
format	O
,	O
evidence	O
identification	O
and	O
summary	O
,	O
and	O
formulation	O
of	O
recommendations	O
,	O
respectively	O
[	O
14	O
]	O
.	O

A	O
Canadian	O
review	O
on	O
drug	O
therapy	O
guidelines	O
found	O
significant	O
variation	O
in	O
quality	O
depending	O
on	O
the	O
developer	O
[	O
13	O
]	O
.	O

Approximately	O
25	O
%	O
of	O
guidelines	O
were	O
not	O
recommended	O
for	O
use	O
in	O
practice	O
by	O
the	O
appraisers	O
'	O
criteria	O
[	O
13	O
]	O
.	O
<EOS>	B-X
Kawasaki	B-X
disease	B-X
is	B-X
an	B-X
acute	B-X
vasculitis	B-X
of	B-X
childhood	B-X
that	B-X
leads	B-X
to	B-X
coronary	B-X
artery	B-X
aneurysms	B-X
in	B-X
â25	B-X
%	B-X
of	B-X
untreated	B-X
cases	B-X
.	B-X
It	B-X
has	B-X
been	B-X
reported	B-X
worldwide	B-X
and	B-X
is	B-X
the	B-X
leading	B-X
cause	B-X
of	B-X
acquired	B-X
heart	B-X
disease	B-X
in	B-X
children	B-X
in	B-X
developed	B-X
countries	B-X
.	B-X
For	B-X
many	B-X
women	B-X
,	B-X
it	B-X
can	B-X
cause	B-X
vaginal	B-X
bulge	B-X
and	B-X
pressure	B-X
,	B-X
voiding	B-X
dysfunction	B-X
,	B-X
defecatory	B-X
dysfunction	B-X
,	B-X
and	B-X
sexual	B-X
dysfunction	B-X
,	B-X
which	B-X
may	B-X
adversely	B-X
affect	B-X
quality	B-X
of	B-X
life	B-X
.	B-X
Women	B-X
in	B-X
the	B-X
United	B-X
States	B-X
have	B-X
a	B-X
13	B-X
%	B-X
lifetime	B-X
risk	B-X
of	B-X
undergoing	B-X
surgery	B-X
for	B-X
POP	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
joint	B-X
document	B-X
of	B-X
the	B-X
American	B-X
College	B-X
of	B-X
Obstetricians	B-X
and	B-X
Gynecologists	B-X
and	B-X
the	B-X
American	B-X
Urogynecologic	B-X
Society	B-X
is	B-X
to	B-X
review	B-X
information	B-X
on	B-X
the	B-X
current	B-X
understanding	B-X
of	B-X
POP	B-X
in	B-X
women	B-X
and	B-X
to	B-X
outline	B-X
guidelines	B-X
for	B-X
diagnosis	B-X
and	B-X
management	B-X
that	B-X
are	B-X
consistent	B-X
with	B-X
the	B-X
best	B-X
available	B-X
scientific	B-X
evidence	B-X
.	B-X

As	O
an	O
example	O
of	O
the	O
volume	O
of	O
clinical	O
practice	O
guidelines	O
available	O
,	O
eleven	O
recent	O
guidelines	O
on	O
community	O
acquired	O
pneumonia	O
exist	O
[	O
15	O
]	O
.	O

To	O
add	O
to	O
the	O
complexities	O
involved	O
with	O
keeping	O
current	O
with	O
pharmacotherapeutic	O
management	O
strategies	O
,	O
as	O
of	O
2000	O
,	O
there	O
were	O
over	O
22	O
,	O
000	O
drug	O
products	O
approved	O
for	O
sale	O
in	O
Canada	O
for	O
human	B-Species
use	O
[	O
16	O
]	O
.	O

There	O
is	O
also	O
considerable	O
debate	O
regarding	O
what	O
constitutes	O
"	O
evidence	O
"	O
in	O
practice	O
,	O
which	O
contributes	O
to	O
confusion	O
for	O
clinicians	O
[	O
17	O
,	O
18	O
]	O
.	O

Sim	O
et	O
al	O
.	O
succinctly	O
describe	O
the	O
gap	O
between	O
evidence	O
and	O
action	O
as	O
difficulties	O
with	O
obtaining	O
,	O
systematically	O
reviewing	O
,	O
applying	O
in	O
context	O
,	O
and	O
measuring	O
the	O
outcome	O
following	O
application	O
of	O
evidence	O
[	O
19	O
]	O
.	O

Maintaining	O
competence	O
-	O
nurse	O
practitioners	O
as	O
a	O
new	O
group	O
of	O
prescribers	O
<EOS>	B-X
For	B-X
the	B-X
GP	B-X
,	B-X
it	B-X
is	B-X
time	B-X
and	B-X
competence	B-X
and	B-X
for	B-X
the	B-X
patient	B-X
,	B-X
it	B-X
is	B-X
their	B-X
ability	B-X
to	B-X
recognise	B-X
inhaler	B-X
technique	B-X
as	B-X
an	B-X
issue	B-X
and	B-X
their	B-X
ability	B-X
to	B-X
maintain	B-X
correct	B-X
inhaler	B-X
technique	B-X
over	B-X
time	B-X
.	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
determine	B-X
GPs	B-X
'	B-X
experience	B-X
,	B-X
skills	B-X
and	B-X
priority	B-X
placed	B-X
on	B-X
inhaler	B-X
technique	B-X
and	B-X
to	B-X
identify	B-X
factor	B-X
(	B-X
s	B-X
)	B-X
associated	B-X
with	B-X
inhaler	B-X
technique	B-X
competence	B-X
.	B-X
UK	B-X
,	B-X
home-based	B-X
patients	B-X
with	B-X
COPD	B-X
receive	B-X
specialist	B-X
care	B-X
from	B-X
respiratory	B-X
physicians	B-X
,	B-X
nurses	B-X
,	B-X
and	B-X
general	B-X
practitioners	B-X
(	B-X
GPs	B-X
)	B-X
,	B-X
but	B-X
increasing	B-X
complexity	B-X
of	B-X
therapeutic	B-X
options	B-X
and	B-X
a	B-X
GP/Nurse	B-X
workforce	B-X
crisis	B-X
suggests	B-X
merit	B-X
in	B-X
testing	B-X
the	B-X
role	B-X
of	B-X
home	B-X
visits	B-X
by	B-X
a	B-X
clinical	B-X
pharmacist	B-X
.	B-X
We	B-X
conducted	B-X
a	B-X
non-randomised	B-X
intervention	B-X
study	B-X
with	B-X
a	B-X
contemporaneous	B-X
comparator	B-X
group	B-X
,	B-X
in	B-X
Glasgow	B-X
(	B-X
Scotland	B-X
)	B-X
.	B-X
Comparator	B-X
group-patients	B-X
were	B-X
drawn	B-X
from	B-X
another	B-X
hospital	B-X
out-patient	B-X
clinic	B-X
.	B-X
In	B-X
the	B-X
intervention	B-X
group	B-X
,	B-X
86	B-X
patients	B-X
received	B-X
a	B-X
median	B-X
of	B-X
three	B-X
home	B-X
visits	B-X
;	B-X
87	B-X
received	B-X
usual	B-X
care	B-X
(	B-X
UC	B-X
)	B-X
.	B-X
At	B-X
baseline	B-X
,	B-X
patients	B-X
in	B-X
the	B-X
intervention	B-X
group	B-X
were	B-X
similar	B-X
to	B-X
those	B-X
in	B-X
UC	B-X
in	B-X
terms	B-X
of	B-X
respiratory	B-X
hospitalisations	B-X
although	B-X
slightly	B-X
younger	B-X
,	B-X
more	B-X
likely	B-X
to	B-X
receive	B-X
specific	B-X
maintenance	B-X
antibiotics/Prednisolone	B-X
and	B-X
to	B-X
have	B-X
had	B-X
exacerbations	B-X
.	B-X
Sixty-two	B-X
(	B-X
72.1	B-X
%	B-X
)	B-X
of	B-X
the	B-X
intervention	B-X
group	B-X
received	B-X
dose	B-X
changes	B-X
;	B-X
45	B-X
(	B-X
52.3	B-X
%	B-X
)	B-X
had	B-X
medicines	B-X
stopped/started	B-X
and	B-X
21	B-X
(	B-X
24.4	B-X
%	B-X
)	B-X
received	B-X
an	B-X
expedited	B-X
review	B-X
at	B-X
the	B-X
specialist	B-X
respiratory	B-X
consultant	B-X
clinic	B-X
;	B-X
46	B-X
(	B-X
53.5	B-X
%	B-X
)	B-X
were	B-X
referred	B-X
to	B-X
other	B-X
healthcare	B-X
services	B-X
.	B-X
At	B-X
follow-up	B-X
,	B-X
54	B-X
(	B-X
63.5	B-X
%	B-X
)	B-X
of	B-X
intervention	B-X
group	B-X
participants	B-X
had	B-X
an	B-X
exacerbation	B-X
compared	B-X
with	B-X
75	B-X
(	B-X
86.2	B-X
%	B-X
)	B-X
in	B-X
the	B-X
UC	B-X
group	B-X
(	B-X
p	B-X
=	B-X
0.001	B-X
)	B-X
;	B-X
fewer	B-X
had	B-X
respiratory	B-X
hospitalisations	B-X
(	B-X
39	B-X
(	B-X
45.3	B-X
%	B-X
)	B-X
vs.	B-X
66	B-X
(	B-X
76.7	B-X
%	B-X
)	B-X
;	B-X
p	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
Hospitalisations	B-X
were	B-X
shorter	B-X
in	B-X
the	B-X
intervention	B-X
group	B-X
.	B-X

Competencies	O
for	O
nurse	O
practitioners	O
(	O
NPs	O
)	O
on	O
a	O
local	O
and	O
international	O
level	O
include	O
critically	O
appraising	O
and	O
applying	O
literature	O
and	O
research	O
findings	O
in	O
practice	O
[	O
20	O
-	O
23	O
]	O
.	O

The	O
Canadian	O
Nurses	O
Association	O
(	O
CNA	O
)	O
has	O
developed	O
the	O
Canadian	O
Nurse	O
Practitioner	O
Core	O
Competency	O
Framework	O
that	O
describes	O
the	O
knowledge	O
,	O
skills	O
,	O
judgment	O
,	O
and	O
attributes	O
required	O
for	O
practice	O
.	O

Evidence	O
based	O
practice	O
is	O
integral	O
to	O
pharmacotherapeutic	O
interventions	O
and	O
prescribing	O
competencies	O
[	O
23	O
]	O
.	O
<EOS>	B-X
While	B-X
both	B-X
pharmacological	B-X
and	B-X
psychological	B-X
interventions	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
effective	B-X
,	B-X
there	B-X
is	B-X
still	B-X
uncertainty	B-X
about	B-X
the	B-X
balance	B-X
between	B-X
these	B-X
and	B-X
what	B-X
treatment	B-X
strategy	B-X
should	B-X
be	B-X
preferred	B-X
in	B-X
clinical	B-X
practice	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
aim	B-X
to	B-X
compare	B-X
and	B-X
rank	B-X
in	B-X
a	B-X
network	B-X
meta-analysis	B-X
(	B-X
NMA	B-X
)	B-X
the	B-X
commonly	B-X
used	B-X
psychological	B-X
,	B-X
pharmacological	B-X
and	B-X
combined	B-X
interventions	B-X
for	B-X
depressive	B-X
disorder	B-X
in	B-X
children	B-X
and	B-X
adolescents	B-X
.	B-X
As	B-X
there	B-X
are	B-X
only	B-X
a	B-X
few	B-X
effective	B-X
therapies	B-X
for	B-X
people	B-X
with	B-X
COVID-19	B-X
in	B-X
the	B-X
community	B-X
,	B-X
a	B-X
thorough	B-X
understanding	B-X
of	B-X
the	B-X
current	B-X
evidence	B-X
regarding	B-X
the	B-X
efficacy	B-X
and	B-X
safety	B-X
of	B-X
fluvoxamine	B-X
as	B-X
an	B-X
anti-inflammatory	B-X
and	B-X
possible	B-X
anti-viral	B-X
treatment	B-X
for	B-X
COVID-19	B-X
,	B-X
based	B-X
on	B-X
randomised	B-X
controlled	B-X
trials	B-X
(	B-X
RCTs	B-X
)	B-X
,	B-X
is	B-X
needed	B-X
.	B-X
For	B-X
the	B-X
prompt	B-X
and	B-X
effective	B-X
management	B-X
of	B-X
malaria	B-X
cases	B-X
(	B-X
a	B-X
key	B-X
strategy	B-X
for	B-X
reducing	B-X
the	B-X
enormous	B-X
burden	B-X
of	B-X
the	B-X
disease	B-X
)	B-X
,	B-X
healthworkers	B-X
must	B-X
prescribe	B-X
antimalarial	B-X
drugs	B-X
according	B-X
to	B-X
evidence-based	B-X
guidelines	B-X
.	B-X
The	B-X
results	B-X
of	B-X
five	B-X
methodologically	B-X
comparable	B-X
studies	B-X
were	B-X
also	B-X
used	B-X
to	B-X
explore	B-X
the	B-X
determinants	B-X
of	B-X
malaria-treatment	B-X
practices	B-X
.	B-X
Although	B-X
interventions	B-X
such	B-X
as	B-X
the	B-X
Integrated	B-X
Management	B-X
of	B-X
Childhood	B-X
Illness	B-X
(	B-X
IMCI	B-X
)	B-X
strategy	B-X
can	B-X
lead	B-X
to	B-X
improvements	B-X
,	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
the	B-X
practices	B-X
of	B-X
the	B-X
healthworkers	B-X
responsible	B-X
for	B-X
treating	B-X
febrile	B-X
children	B-X
will	B-X
be	B-X
needed	B-X
before	B-X
treatment	B-X
is	B-X
made	B-X
much	B-X
better	B-X
.	B-X
The	B-X
failure	B-X
to	B-X
provide	B-X
treatment	B-X
of	B-X
good	B-X
quality	B-X
will	B-X
become	B-X
an	B-X
increasingly	B-X
important	B-X
problem	B-X
as	B-X
antimalarial	B-X
policies	B-X
involving	B-X
drugs	B-X
with	B-X
more	B-X
complex	B-X
dosing	B-X
regimens	B-X
,	B-X
such	B-X
as	B-X
artemisinin-based	B-X
combination	B-X
therapies	B-X
(	B-X
ACT	B-X
)	B-X
,	B-X
are	B-X
implemented	B-X
.	B-X
If	B-X
the	B-X
malaria	B-X
burden	B-X
in	B-X
Africa	B-X
is	B-X
to	B-X
be	B-X
greatly	B-X
reduced	B-X
,	B-X
the	B-X
deployment	B-X
of	B-X
ACT	B-X
must	B-X
be	B-X
accompanied	B-X
by	B-X
interventions	B-X
to	B-X
ensure	B-X
the	B-X
correct	B-X
treatment	B-X
of	B-X
children	B-X
at	B-X
the	B-X
point	B-X
of	B-X
care	B-X
.	B-X
Some	B-X
interventions	B-X
,	B-X
such	B-X
as	B-X
IMCI	B-X
,	B-X
can	B-X
improve	B-X
the	B-X
treatment	B-X
of	B-X
not	B-X
only	B-X
malaria	B-X
but	B-X
also	B-X
other	B-X
potentially	B-X
life-threatening	B-X
illnesses	B-X
.	B-X

The	O
National	O
Prescribing	O
Centre	O
,	O
an	O
organization	O
of	O
the	O
National	O
Health	O
Service	O
in	O
the	O
UK	O
,	O
describes	O
several	O
competencies	O
around	O
information	O
needs	O
relevant	O
to	O
prescribing	O
and	O
emphasis	O
is	O
placed	O
on	O
using	O
relevant	O
and	O
up	O
to	O
date	O
information	O
in	O
various	O
formats	O
(	O
e	O
.	O
g	O
.	O
print	O
,	O
electronic	O
,	O
verbal	O
)	O
.	O

Several	O
related	O
competencies	O
include	O
understanding	O
advantages	O
and	O
disadvantages	O
of	O
information	O
sources	O
and	O
the	O
currency	O
of	O
resources	O
[	O
21	O
]	O
.	O

Researchers	O
in	O
the	O
US	O
developed	O
NP	O
informatics	O
competencies	O
for	O
integration	O
into	O
advanced	O
nursing	O
practice	O
curricula	O
[	O
24	O
]	O
.	O

Competencies	O
related	O
to	O
informatics	O
knowledge	O
include	O
critical	O
analysis	O
of	O
data	O
and	O
information	O
for	O
use	O
in	O
evidence	O
based	O
practice	O
,	O
evaluating	O
and	O
applying	O
relevant	O
information	O
,	O
synthesizing	O
best	O
evidence	O
,	O
and	O
using	O
optimal	O
search	O
strategies	O
to	O
locate	O
clinically	O
sound	O
and	O
useful	O
studies	O
from	O
information	O
resources	O
[	O
24	O
]	O
.	O

Achieving	O
and	O
maintaining	O
competence	O
in	O
these	O
domains	O
as	O
well	O
as	O
a	O
solid	O
foundation	O
in	O
pharmacology	O
is	O
necessary	O
to	O
support	O
NPs	O
in	O
their	O
relatively	O
new	O
role	O
as	O
a	O
prescriber	O
[	O
25	O
-	O
27	O
]	O
.	O

Knowledge	O
management	O
and	O
information	O
seeking	O
behaviours	O
among	O
nurse	O
practitioners	O
and	O
physicians	O
<EOS>	B-X
We	B-X
characterized	B-X
6	B-X
clinicians	B-X
'	B-X
patterns	B-X
of	B-X
information-gathering	B-X
using	B-X
a	B-X
sequential	B-X
process-mining	B-X
approach	B-X
.	B-X

Information	O
seeking	O
behaviours	O
of	O
physicians	O
are	O
better	O
documented	O
than	O
NPs	O
[	O
11	O
]	O
.	O

Information	O
related	O
to	O
diagnosis	O
is	O
important	O
to	O
both	O
groups	O
but	O
drug	O
therapy	O
queries	O
may	O
occur	O
more	O
frequently	O
with	O
NPs	O
[	O
28	O
-	O
33	O
]	O
.	O

Research	O
on	O
nurses	O
'	O
behaviours	O
related	O
to	O
information	O
seeking	O
is	O
available	O
from	O
the	O
hospital	O
setting	O
[	O
33	O
-	O
35	O
]	O
but	O
the	O
generalizability	O
of	O
these	O
behaviours	O
to	O
NPs	O
with	O
a	O
prescribing	O
role	O
is	O
unclear	O
.	O

Differences	O
in	O
nursing	O
roles	O
,	O
responsibilities	O
,	O
and	O
legislation	O
,	O
including	O
prescriptive	O
authority	O
,	O
exist	O
depending	O
on	O
the	O
country	O
of	O
practice	O
.	O

Nurse	O
practitioners	O
and	O
their	O
collaborating	O
physician	O
partners	O
in	O
Nova	O
Scotia	O
<EOS>	B-X
Keeping	B-X
current	B-X
with	B-X
drug	B-X
therapy	B-X
information	B-X
is	B-X
challenging	B-X
for	B-X
health	B-X
care	B-X
practitioners	B-X
.	B-X
In	B-X
the	B-X
Canadian	B-X
province	B-X
of	B-X
Nova	B-X
Scotia	B-X
,	B-X
legislation	B-X
was	B-X
passed	B-X
in	B-X
2002	B-X
to	B-X
allow	B-X
nurse	B-X
practitioners	B-X
(	B-X
NPs	B-X
)	B-X
to	B-X
practice	B-X
collaboratively	B-X
with	B-X
physician	B-X
partners	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
current	B-X
utilization	B-X
patterns	B-X
of	B-X
information	B-X
technologies	B-X
by	B-X
these	B-X
groups	B-X
of	B-X
practitioners	B-X
.	B-X

Nova	O
Scotia	O
is	O
a	O
Canadian	O
province	O
with	O
a	O
population	O
of	O
approximately	O
942	O
,	O
000	O
[	O
36	O
]	O
.	O

The	O
province	O
is	O
divided	O
into	O
six	O
health	O
zones	O
that	O
include	O
nine	O
district	O
health	O
authorities	O
,	O
one	O
of	O
which	O
includes	O
the	O
provincial	O
capital	O
and	O
is	O
considered	O
to	O
be	O
urban	O
[	O
37	O
,	O
38	O
]	O
.	O

Health	O
care	O
service	O
delivery	O
is	O
challenging	O
due	O
to	O
many	O
factors	O
including	O
the	O
rural	O
nature	O
of	O
the	O
province	O
,	O
which	O
is	O
estimated	O
to	O
be	O
60	O
%	O
of	O
population	O
[	O
37	O
,	O
39	O
]	O
.	O

Starting	O
in	O
1998	O
,	O
the	O
Nova	O
Scotia	O
Department	O
of	O
Health	O
led	O
an	O
initiative	O
to	O
explore	O
different	O
methods	O
of	O
delivering	O
,	O
managing	O
,	O
and	O
funding	O
primary	O
care	O
services	O
.	O

The	O
Strengthening	O
Primary	O
Care	O
in	O
Nova	O
Scotia	O
Communities	O
Initiative	O
(	O
SPCI	O
)	O
was	O
established	O
with	O
the	O
selection	O
of	O
four	O
primary	O
care	O
demonstration	O
sites	O
where	O
a	O
primary	O
health	O
care	O
NP	O
was	O
hired	O
to	O
practice	O
collaboratively	O
with	O
one	O
or	O
more	O
family	O
/	O
general	O
physicians	O
and	O
other	O
members	O
of	O
an	O
interdisciplinary	O
team	O
.	O
<EOS>	B-X
Finally	B-X
,	B-X
several	B-X
core	B-X
components	B-X
of	B-X
the	B-X
autophagy	B-X
machinery	B-X
have	B-X
been	B-X
implicated	B-X
in	B-X
distinct	B-X
autophagic	B-X
processes	B-X
(	B-X
canonical	B-X
and	B-X
noncanonical	B-X
autophagy	B-X
)	B-X
,	B-X
implying	B-X
that	B-X
genetic	B-X
approaches	B-X
to	B-X
block	B-X
autophagy	B-X
should	B-X
rely	B-X
on	B-X
targeting	B-X
two	B-X
or	B-X
more	B-X
autophagy-related	B-X
genes	B-X
that	B-X
ideally	B-X
participate	B-X
in	B-X
distinct	B-X
steps	B-X
of	B-X
the	B-X
pathway	B-X
.	B-X
Complexity	B-X
science	B-X
has	B-X
been	B-X
introduced	B-X
in	B-X
healthcare	B-X
as	B-X
a	B-X
theoretical	B-X
framework	B-X
to	B-X
better	B-X
understand	B-X
complex	B-X
situations	B-X
.	B-X
Interdisciplinary	B-X
healthcare	B-X
teams	B-X
can	B-X
be	B-X
viewed	B-X
as	B-X
Complex	B-X
Adaptive	B-X
Systems	B-X
(	B-X
CAS	B-X
)	B-X
by	B-X
focusing	B-X
more	B-X
on	B-X
the	B-X
team	B-X
members	B-X
'	B-X
interaction	B-X
with	B-X
each	B-X
other	B-X
than	B-X
on	B-X
the	B-X
characteristics	B-X
of	B-X
individual	B-X
team	B-X
members	B-X
.	B-X
Viewing	B-X
teams	B-X
in	B-X
this	B-X
way	B-X
can	B-X
provide	B-X
us	B-X
with	B-X
insights	B-X
into	B-X
the	B-X
origins	B-X
of	B-X
team	B-X
behaviour	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
is	B-X
to	B-X
describe	B-X
the	B-X
functioning	B-X
of	B-X
a	B-X
healthcare	B-X
team	B-X
as	B-X
it	B-X
originates	B-X
from	B-X
the	B-X
members	B-X
'	B-X
interactions	B-X
using	B-X
the	B-X
CAS	B-X
principles	B-X
as	B-X
a	B-X
framework	B-X
and	B-X
to	B-X
explore	B-X
factors	B-X
influencing	B-X
workplace	B-X
learning	B-X
as	B-X
emergent	B-X
behaviour	B-X
.	B-X

Each	O
demonstration	O
site	O
adopted	O
alternative	O
(	O
non	O
fee	O
-	O
for	O
-	O
service	O
)	O
physician	O
payment	O
mechanisms	O
and	O
used	O
electronic	O
patient	B-Species
records	O
(	O
EPRs	O
)	O
to	O
support	O
service	O
delivery	O
[	O
41	O
]	O
.	O

Demonstration	O
sites	O
participated	O
in	O
project	O
evaluation	O
components	O
that	O
included	O
,	O
but	O
were	O
not	O
limited	O
to	O
,	O
NP	O
roles	O
,	O
alternative	O
fee	O
structures	O
,	O
consumer	O
satisfaction	O
,	O
and	O
implementation	O
and	O
integration	O
of	O
EPRs	O
[	O
41	O
,	O
42	O
]	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
is	B-X
to	B-X
evaluate	B-X
the	B-X
implementation	B-X
of	B-X
a	B-X
cluster	B-X
randomised	B-X
controlled	B-X
trial	B-X
of	B-X
a	B-X
group-based	B-X
,	B-X
peer	B-X
support	B-X
program	B-X
to	B-X
improve	B-X
diabetes	B-X
self-management	B-X
and	B-X
thereby	B-X
,	B-X
diabetes	B-X
control	B-X
in	B-X
people	B-X
with	B-X
Type	B-X
2	B-X
Diabetes	B-X
in	B-X
Victoria	B-X
,	B-X
Australia	B-X
.	B-X
Cross-Site	B-X
Process	B-X
Evaluation	B-X
Results	B-X
for	B-X
the	B-X
Early	B-X
Childhood	B-X
Education	B-X
Center	B-X
Setting	B-X
:	B-X
CORD	B-X
Study	B-X
.	B-X
We	B-X
examine	B-X
quality	B-X
improvement	B-X
(	B-X
QI	B-X
)	B-X
collaboratives	B-X
underway	B-X
in	B-X
9	B-X
states	B-X
participating	B-X
in	B-X
the	B-X
Children	B-X
's	B-X
Health	B-X
Insurance	B-X
Program	B-X
Reauthorization	B-X
Act	B-X
(	B-X
CHIPRA	B-X
)	B-X
Quality	B-X
Demonstration	B-X
Grant	B-X
Program	B-X
.	B-X
We	B-X
conducted	B-X
256	B-X
semistructured	B-X
interviews	B-X
with	B-X
key	B-X
stakeholders	B-X
from	B-X
March	B-X
to	B-X
August	B-X
2012-2	B-X
years	B-X
into	B-X
the	B-X
5-year	B-X
demonstration	B-X
projects-and	B-X
analyzed	B-X
states	B-X
'	B-X
grant	B-X
applications	B-X
,	B-X
operating	B-X
plans	B-X
,	B-X
and	B-X
progress	B-X
reports	B-X
.	B-X
Practice	B-X
staff	B-X
highly	B-X
valued	B-X
aspects	B-X
of	B-X
the	B-X
collaboratives	B-X
and	B-X
supplemental	B-X
strategies	B-X
,	B-X
including	B-X
the	B-X
opportunity	B-X
to	B-X
work	B-X
with	B-X
experts	B-X
and	B-X
other	B-X
child-serving	B-X
practices	B-X
;	B-X
states	B-X
'	B-X
efforts	B-X
to	B-X
provide	B-X
stipends	B-X
and	B-X
align	B-X
demonstration	B-X
efforts	B-X
with	B-X
other	B-X
professional	B-X
requirements	B-X
or	B-X
programs	B-X
;	B-X
receipt	B-X
of	B-X
relevant	B-X
,	B-X
customized	B-X
QI	B-X
materials	B-X
;	B-X
opportunities	B-X
to	B-X
learn	B-X
how	B-X
care	B-X
coordinators	B-X
or	B-X
QI	B-X
specialists	B-X
might	B-X
work	B-X
in	B-X
their	B-X
practice	B-X
without	B-X
the	B-X
risk	B-X
of	B-X
hiring	B-X
them	B-X
;	B-X
and	B-X
satisfaction	B-X
from	B-X
learning	B-X
more	B-X
about	B-X
quality	B-X
measures	B-X
,	B-X
QI	B-X
concepts	B-X
and	B-X
techniques	B-X
,	B-X
critical	B-X
medical	B-X
home	B-X
components	B-X
,	B-X
and	B-X
how	B-X
to	B-X
identify	B-X
PCMH	B-X
capacity	B-X
and	B-X
performance	B-X
gaps	B-X
.	B-X
However	B-X
,	B-X
practice	B-X
staff	B-X
also	B-X
reported	B-X
a	B-X
variety	B-X
of	B-X
challenges	B-X
,	B-X
including	B-X
difficulty	B-X
learning	B-X
from	B-X
other	B-X
practices	B-X
that	B-X
have	B-X
very	B-X
different	B-X
preexisting	B-X
QI	B-X
and	B-X
PCMH	B-X
capacity	B-X
and	B-X
patient	B-X
populations	B-X
,	B-X
or	B-X
that	B-X
are	B-X
working	B-X
on	B-X
different	B-X
topic	B-X
areas	B-X
and	B-X
measures	B-X
;	B-X
a	B-X
sometimes	B-X
overwhelming	B-X
amount	B-X
of	B-X
materials	B-X
and	B-X
ideas	B-X
covered	B-X
during	B-X
in-person	B-X
meetings	B-X
;	B-X
difficulty	B-X
keeping	B-X
up	B-X
with	B-X
Webinars	B-X
,	B-X
calls	B-X
,	B-X
and	B-X
Web	B-X
sites/blogs	B-X
;	B-X
and	B-X
trouble	B-X
motivating	B-X
and	B-X
sharing	B-X
information	B-X
with	B-X
other	B-X
practice	B-X
staff	B-X
not	B-X
attending	B-X
collaborative	B-X
activities	B-X
.	B-X
As	B-X
the	B-X
demonstration	B-X
projects	B-X
continue	B-X
,	B-X
states	B-X
and	B-X
the	B-X
national	B-X
evaluation	B-X
team	B-X
will	B-X
learn	B-X
more	B-X
about	B-X
how	B-X
best	B-X
to	B-X
use	B-X
collaboratives	B-X
and	B-X
complementary	B-X
strategies	B-X
to	B-X
support	B-X
child-serving	B-X
practices	B-X
in	B-X
QI	B-X
and	B-X
PCMH	B-X
development	B-X
.	B-X

Legislation	O
to	O
allow	O
NPs	O
to	O
practice	O
collaboratively	O
with	O
physicians	O
in	O
Nova	O
Scotia	O
was	O
passed	O
in	O
2002	O
,	O
part	O
way	O
through	O
the	O
SPCI	O
project	O
[	O
39	O
]	O
.	O

Prescriptive	O
authority	O
granted	O
through	O
legislation	O
authorizes	O
NPs	O
to	O
prescribe	O
from	O
a	O
schedule	O
of	O
drugs	O
[	O
43	O
,	O
44	O
]	O
.	O

At	O
the	O
time	O
of	O
conducting	O
this	O
research	O
project	O
,	O
16	O
primary	O
health	O
care	O
NPs	O
were	O
in	O
active	O
practice	O
[	O
43	O
]	O
.	O

The	O
EPR	O
component	O
of	O
the	O
SPCI	O
project	O
evaluation	O
provided	O
information	O
on	O
the	O
use	O
of	O
technologies	O
in	O
the	O
community	O
context	O
.	O

Results	O
from	O
the	O
implementation	O
process	O
indicated	O
that	O
considerable	O
attention	O
is	O
required	O
for	O
technology	O
literacy	O
,	O
time	O
for	O
training	O
,	O
and	O
selection	O
of	O
software	O
for	O
EPRs	O
[	O
41	O
]	O
.	O

Although	O
the	O
majority	O
of	O
community	O
-	O
based	O
,	O
non	O
-	O
institutional	O
clinical	O
practice	O
settings	O
in	O
Nova	O
Scotia	O
primarily	O
operate	O
with	O
paper	O
-	O
based	O
charting	O
systems	O
,	O
there	O
is	O
a	O
movement	O
toward	O
integrating	O
electronic	O
technologies	O
,	O
including	O
the	O
EPR	O
,	O
in	O
practice	O
among	O
health	O
care	O
providers	O
,	O
administrators	O
,	O
and	O
the	O
provincial	O
government	O
.	O

In	O
addition	O
to	O
recording	O
patient	B-Species
visit	O
information	O
,	O
a	O
component	O
of	O
the	O
EPR	O
package	O
serves	O
to	O
provide	O
drug	O
information	O
resources	O
.	O

Drug	O
therapy	O
information	O
resources	O
for	O
NPs	O
and	O
nurse	O
prescribers	O
have	O
frequently	O
been	O
described	O
as	O
essential	O
in	O
supporting	O
practice	O
[	O
25	O
,	O
28	O
,	O
29	O
]	O
.	O

The	O
role	O
of	O
NPs	O
is	O
relatively	O
new	O
in	O
Canada	O
[	O
39	O
]	O
and	O
there	O
is	O
limited	O
information	O
available	O
to	O
indicate	O
the	O
type	O
of	O
resources	O
(	O
e	O
.	O
g	O
.	O
print	O
,	O
electronic	O
,	O
EPR	O
based	O
)	O
these	O
prescribers	O
use	O
for	O
drug	O
and	O
therapeutic	O
information	O
queries	O
at	O
the	O
point	O
of	O
care	O
.	O

It	O
is	O
unknown	O
as	O
to	O
whether	O
differences	O
exist	O
regarding	O
types	O
of	O
resources	O
used	O
,	O
drug	O
information	O
needs	O
,	O
and	O
utilization	O
patterns	O
among	O
NPs	O
and	O
collaborating	O
physician	O
partners	O
.	O

Some	O
research	O
has	O
suggested	O
that	O
the	O
degree	O
of	O
multidisciplinary	O
team	O
functioning	O
relates	O
to	O
the	O
adoption	O
of	O
technology	O
or	O
innovations	O
in	O
practice	O
but	O
more	O
research	O
is	O
required	O
to	O
determine	O
the	O
extent	O
of	O
these	O
relationships	O
[	O
45	O
,	O
46	O
]	O
.	O

The	O
use	O
of	O
EPR	O
technology	O
is	O
increasing	O
in	O
Nova	O
Scotia	O
but	O
little	O
information	O
is	O
available	O
regarding	O
the	O
readiness	O
of	O
practitioners	O
for	O
use	O
of	O
specific	O
features	O
such	O
as	O
drug	O
information	O
resources	O
.	O

Based	O
on	O
the	O
EPR	O
related	O
results	O
of	O
the	O
SPCI	O
evaluation	O
,	O
use	O
of	O
these	O
functions	O
could	O
be	O
challenging	O
without	O
proper	O
facilitation	O
.	O

The	O
purpose	O
of	O
the	O
survey	O
for	O
this	O
research	O
was	O
to	O
describe	O
drug	O
information	O
resources	O
used	O
by	O
NPs	O
and	O
their	O
collaborating	O
physician	O
partners	O
at	O
the	O
point	O
of	O
care	O
.	O

The	O
results	O
of	O
the	O
survey	O
will	O
be	O
used	O
to	O
guide	O
further	O
technology	O
implementation	O
strategies	O
and	O
stimulate	O
further	O
discussion	O
around	O
drug	O
information	O
resource	O
usage	O
at	O
the	O
point	O
of	O
care	O
.	O

Methods	O
<EOS>	B-X
Methods	B-X
to	B-X
calculate	B-X
the	B-X
sample	B-X
size	B-X
are	B-X
explained	B-X
in	B-X
statistical	B-X
textbooks	B-X
,	B-X
but	B-X
because	B-X
there	B-X
are	B-X
many	B-X
different	B-X
formulas	B-X
available	B-X
,	B-X
it	B-X
can	B-X
be	B-X
difficult	B-X
for	B-X
investigators	B-X
to	B-X
decide	B-X
which	B-X
method	B-X
to	B-X
use	B-X
.	B-X

Survey	O
development	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
review	B-X
is	B-X
to	B-X
provide	B-X
guidance	B-X
on	B-X
the	B-X
development	B-X
,	B-X
validation	B-X
and	B-X
use	B-X
of	B-X
food-frequency	B-X
questionnaires	B-X
(	B-X
FFQs	B-X
)	B-X
for	B-X
different	B-X
study	B-X
designs	B-X
.	B-X
Evaluating	B-X
continuing	B-X
professional	B-X
development	B-X
(	B-X
CPD	B-X
)	B-X
programs	B-X
is	B-X
essential	B-X
to	B-X
demonstrate	B-X
their	B-X
value	B-X
to	B-X
participants	B-X
and	B-X
their	B-X
institutions	B-X
,	B-X
and	B-X
to	B-X
inform	B-X
the	B-X
improvement	B-X
and	B-X
quality	B-X
of	B-X
CPD	B-X
programs	B-X
.	B-X
We	B-X
conducted	B-X
a	B-X
national	B-X
survey	B-X
of	B-X
methods	B-X
used	B-X
by	B-X
Chinese	B-X
CG	B-X
developers	B-X
for	B-X
CG	B-X
development	B-X
,	B-X
adaptation	B-X
,	B-X
and	B-X
updating	B-X
.	B-X
It	B-X
remains	B-X
true	B-X
that	B-X
the	B-X
primary	B-X
goal	B-X
of	B-X
scale	B-X
development	B-X
is	B-X
to	B-X
create	B-X
valid	B-X
measures	B-X
of	B-X
underlying	B-X
constructs	B-X
and	B-X
that	B-X
Loevinger	B-X
's	B-X
theoretical	B-X
scheme	B-X
provides	B-X
a	B-X
powerful	B-X
model	B-X
for	B-X
scale	B-X
development	B-X
.	B-X
We	B-X
have	B-X
added	B-X
(	B-X
g	B-X
)	B-X
consideration	B-X
of	B-X
the	B-X
hierarchical	B-X
structures	B-X
of	B-X
personality	B-X
and	B-X
psychopathology	B-X
in	B-X
scale	B-X
development	B-X
,	B-X
discussion	B-X
of	B-X
(	B-X
h	B-X
)	B-X
codeveloping	B-X
scales	B-X
in	B-X
the	B-X
context	B-X
of	B-X
these	B-X
structures	B-X
,	B-X
(	B-X
i	B-X
)	B-X
``	B-X
orphan	B-X
,	B-X
''	B-X
and	B-X
``	B-X
interstitial	B-X
''	B-X
constructs	B-X
,	B-X
which	B-X
do	B-X
not	B-X
fit	B-X
neatly	B-X
within	B-X
these	B-X
structures	B-X
,	B-X
(	B-X
j	B-X
)	B-X
problems	B-X
with	B-X
``	B-X
conglomerate	B-X
''	B-X
constructs	B-X
,	B-X
and	B-X
(	B-X
k	B-X
)	B-X
developing	B-X
alternative	B-X
versions	B-X
of	B-X
measures	B-X
,	B-X
including	B-X
short	B-X
forms	B-X
,	B-X
translations	B-X
,	B-X
informant	B-X
versions	B-X
,	B-X
and	B-X
age-based	B-X
adaptations	B-X
.	B-X

Survey	O
development	O
involved	O
three	O
stages	O
including	O
identification	O
of	O
important	O
content	O
areas	O
,	O
development	O
of	O
draft	O
questions	O
,	O
and	O
survey	O
refinement	O
.	O

Identifying	O
important	O
content	O
areas	O
for	O
inclusion	O
in	O
the	O
survey	O
involved	O
conducting	O
a	O
comprehensive	O
English	O
language	O
literature	O
search	O
,	O
consultation	O
with	O
relevant	O
stakeholders	O
(	O
e	O
.	O
g	O
.	O
members	O
of	O
the	O
Nova	O
Scotia	O
Department	O
of	O
Health	O
)	O
,	O
and	O
input	O
from	O
subject	O
matter	O
experts	O
at	O
Dalhousie	O
University	O
.	O

The	O
literature	O
review	O
was	O
conducted	O
using	O
the	O
following	O
bibliographic	O
databases	O
:	O
PubMed	O
,	O
Cumulative	O
Index	O
to	O
Nursing	O
and	O
Allied	O
Health	O
Literature	O
(	O
CINAHL	O
)	O
,	O
International	O
Pharmaceutical	O
Abstracts	O
(	O
IPA	O
)	O
,	O
and	O
Web	O
of	O
Science	O
Citation	O
Databases	O
.	O

Hand	O
and	O
electronic	O
searching	O
of	O
relevant	O
journals	O
was	O
also	O
conducted	O
.	O
<EOS>	B-X
We	B-X
report	B-X
in	B-X
detail	B-X
the	B-X
methodology	B-X
of	B-X
our	B-X
scoping	B-X
review	B-X
used	B-X
to	B-X
identify	B-X
these	B-X
theories	B-X
including	B-X
which	B-X
involved	B-X
a	B-X
systematic	B-X
search	B-X
of	B-X
electronic	B-X
databases	B-X
,	B-X
consultation	B-X
with	B-X
a	B-X
multidisciplinary	B-X
advisory	B-X
group	B-X
,	B-X
web	B-X
searching	B-X
,	B-X
searching	B-X
of	B-X
reference	B-X
lists	B-X
and	B-X
hand	B-X
searching	B-X
of	B-X
key	B-X
behavioural	B-X
science	B-X
journals	B-X
.	B-X
The	B-X
literature	B-X
on	B-X
health	B-X
aspects	B-X
of	B-X
Ramadan	B-X
fasting	B-X
is	B-X
widely	B-X
spread	B-X
in	B-X
many	B-X
journals	B-X
making	B-X
it	B-X
not	B-X
readily	B-X
available	B-X
to	B-X
those	B-X
interested	B-X
in	B-X
the	B-X
subject	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
CIMT	B-X
's	B-X
studies	B-X
conducted	B-X
in	B-X
Iran	B-X
,	B-X
and	B-X
indicated	B-X
the	B-X
effectiveness	B-X
of	B-X
CIMT	B-X
on	B-X
duration	B-X
and	B-X
children	B-X
age	B-X
?	B-X
A	B-X
systematic	B-X
review	B-X
and	B-X
meta-analysis	B-X
was	B-X
conducted	B-X
to	B-X
determine	B-X
the	B-X
outcome	B-X
of	B-X
resin-based	B-X
endodontic	B-X
surgery	B-X
(	B-X
RES	B-X
,	B-X
the	B-X
use	B-X
of	B-X
high-magnification	B-X
preparation	B-X
of	B-X
a	B-X
shallow	B-X
and	B-X
concave	B-X
root-end	B-X
cavity	B-X
and	B-X
bonded	B-X
resin-based	B-X
root-end	B-X
filling	B-X
material	B-X
)	B-X
versus	B-X
endodontic	B-X
microsurgery	B-X
(	B-X
EMS	B-X
,	B-X
the	B-X
use	B-X
of	B-X
high-magnification	B-X
ultrasonic	B-X
root-end	B-X
preparation	B-X
and	B-X
root-end	B-X
filling	B-X
with	B-X
SuperEBA	B-X
[	B-X
Keystone	B-X
Industries	B-X
,	B-X
Gibbstown	B-X
,	B-X
NJ	B-X
]	B-X
,	B-X
IRM	B-X
[	B-X
Dentsply	B-X
Sirona	B-X
,	B-X
York	B-X
,	B-X
PA	B-X
]	B-X
,	B-X
mineral	B-X
trioxide	B-X
aggregate	B-X
[	B-X
MTA	B-X
]	B-X
,	B-X
or	B-X
other	B-X
calcium	B-X
silicate	B-X
cements	B-X
)	B-X
.	B-X

Broad	O
search	O
terms	O
were	O
used	O
without	O
limits	O
on	O
publication	O
date	O
or	O
place	O
as	O
nurse	O
practitioner	O
titles	O
,	O
roles	O
and	O
scopes	O
of	O
practice	O
,	O
and	O
terminology	O
regarding	O
technology	O
vary	O
nationally	O
and	O
internationally	O
.	O
<EOS>	B-X
Notwithstanding	B-X
,	B-X
the	B-X
conduct	B-X
and	B-X
application	B-X
of	B-X
research	B-X
in	B-X
CAM	B-X
faces	B-X
a	B-X
number	B-X
of	B-X
obstacles	B-X
.	B-X
No	B-X
systematic	B-X
review	B-X
has	B-X
mapped	B-X
these	B-X
barriers	B-X
to	B-X
date	B-X
.	B-X
Therefore	B-X
,	B-X
this	B-X
systematic	B-X
literature	B-X
review	B-X
aimed	B-X
to	B-X
explore	B-X
,	B-X
identify	B-X
and	B-X
map	B-X
the	B-X
barriers	B-X
to	B-X
the	B-X
conduct	B-X
and	B-X
application	B-X
of	B-X
research	B-X
in	B-X
CAM	B-X
.	B-X
It	B-X
is	B-X
timely	B-X
to	B-X
look	B-X
more	B-X
closely	B-X
at	B-X
the	B-X
published	B-X
empirical	B-X
research	B-X
and	B-X
to	B-X
ask	B-X
the	B-X
question	B-X
,	B-X
Where	B-X
are	B-X
we	B-X
now	B-X
?	B-X

Some	O
examples	O
of	O
terms	O
used	O
included	O
nurse	O
practitioner	O
,	O
nurse	O
prescriber	O
,	O
nurse	O
clinicians	O
,	O
district	O
nurse	O
,	O
health	O
visitor	O
,	O
drug	O
information	O
resources	O
,	O
drug	O
information	O
services	O
,	O
information	O
needs	O
,	O
and	O
information	O
technology	O
.	O

The	O
draft	O
survey	O
was	O
reviewed	O
by	O
the	O
research	O
team	O
to	O
reduce	O
the	O
number	O
of	O
items	O
and	O
improve	O
clarity	O
.	O

The	O
layout	O
of	O
the	O
questionnaire	O
was	O
carefully	O
examined	O
to	O
ensure	O
that	O
it	O
was	O
easy	O
to	O
follow	O
and	O
complete	O
.	O

Research	O
results	O
from	O
a	O
previous	O
investigation	O
of	O
Nova	O
Scotian	O
physicians	O
'	O
behaviours	O
regarding	O
drug	O
information	O
were	O
also	O
used	O
to	O
further	O
revise	O
the	O
survey	O
[	O
47	O
]	O
.	O

This	O
draft	O
questionnaire	O
was	O
pilot	O
tested	O
by	O
two	O
out	O
of	O
province	O
NPs	O
and	O
one	O
physician	O
.	O

The	O
results	O
of	O
the	O
pilot	O
were	O
used	O
to	O
make	O
final	O
revisions	O
to	O
the	O
survey	O
.	O

Based	O
on	O
pilot	O
-	O
testing	O
feedback	O
and	O
investigator	O
consensus	O
,	O
the	O
final	O
survey	O
was	O
divided	O
into	O
2	O
versions	O
,	O
one	O
for	O
personal	O
digital	O
assistant	O
(	O
PDA	O
)	O
users	O
and	O
one	O
for	O
computer	O
users	O
.	O

The	O
10	O
page	O
surveys	O
for	O
PDA	O
and	O
computer	O
users	O
had	O
5	O
or	O
6	O
sections	O
,	O
respectively	O
,	O
and	O
37	O
questions	O
,	O
many	O
with	O
multiple	O
parts	O
.	O

The	O
survey	O
content	O
included	O
demographics	O
,	O
computer	O
or	O
PDA	O
use	O
and	O
experience	O
,	O
drug	O
and	O
therapeutic	O
resource	O
use	O
and	O
preferences	O
,	O
PDA	O
future	O
use	O
,	O
perceived	O
barriers	O
and	O
facilitators	O
to	O
PDA	O
use	O
,	O
and	O
technology	O
training	O
preferences	O
.	O
<EOS>	B-X
Although	B-X
the	B-X
diagnostic	B-X
and	B-X
severity	B-X
grading	B-X
criteria	B-X
on	B-X
the	B-X
2013	B-X
Tokyo	B-X
Guidelines	B-X
(	B-X
TG13	B-X
)	B-X
are	B-X
used	B-X
worldwide	B-X
as	B-X
the	B-X
primary	B-X
standard	B-X
for	B-X
management	B-X
of	B-X
acute	B-X
cholangitis	B-X
(	B-X
AC	B-X
)	B-X
,	B-X
they	B-X
need	B-X
to	B-X
be	B-X
validated	B-X
through	B-X
implementation	B-X
and	B-X
assessment	B-X
in	B-X
actual	B-X
clinical	B-X
practice	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
the	B-X
TG13	B-X
severity	B-X
grading	B-X
criteria	B-X
can	B-X
be	B-X
used	B-X
to	B-X
identify	B-X
Grade	B-X
II	B-X
patients	B-X
whose	B-X
prognoses	B-X
may	B-X
be	B-X
improved	B-X
through	B-X
biliary	B-X
drainage	B-X
.	B-X
The	B-X
TG13	B-X
severity	B-X
grading	B-X
criteria	B-X
may	B-X
therefore	B-X
be	B-X
useful	B-X
as	B-X
an	B-X
indicator	B-X
for	B-X
biliary	B-X
drainage	B-X
as	B-X
well	B-X
as	B-X
a	B-X
predictive	B-X
factor	B-X
when	B-X
assessing	B-X
the	B-X
patient	B-X
's	B-X
prognosis	B-X
.	B-X
We	B-X
recommend	B-X
that	B-X
the	B-X
TG13	B-X
criteria	B-X
be	B-X
adopted	B-X
in	B-X
the	B-X
TG18	B-X
guidelines	B-X
and	B-X
used	B-X
as	B-X
standard	B-X
practice	B-X
in	B-X
the	B-X
clinical	B-X
setting	B-X
.	B-X
Free	B-X
full	B-X
articles	B-X
and	B-X
mobile	B-X
app	B-X
of	B-X
TG18	B-X
are	B-X
available	B-X
at	B-X
:	B-X
http	B-X
:	B-X
//www.jshbps.jp/modules/en/index.php	B-X
?	B-X
content_id=47	B-X
.	B-X
Related	B-X
clinical	B-X
questions	B-X
and	B-X
references	B-X
are	B-X
also	B-X
included	B-X
.	B-X

Section	O
one	O
contained	O
demographic	O
questions	O
such	O
as	O
gender	O
,	O
age	O
,	O
job	O
title	O
,	O
volume	O
of	O
patients	B-Species
,	O
and	O
EPR	O
availability	O
in	O
the	O
practice	O
setting	O
.	O

Section	O
two	O
was	O
designed	O
to	O
determine	O
PDA	O
or	O
computer	O
use	O
and	O
experience	O
in	O
the	O
practice	O
setting	O
with	O
questions	O
regarding	O
length	O
of	O
use	O
,	O
costs	O
,	O
and	O
work	O
versus	O
home	O
usage	O
.	O
<EOS>	B-X
Delayed	B-X
thyrotropin	B-X
(	B-X
TSH	B-X
)	B-X
elevation	B-X
(	B-X
dTSH	B-X
)	B-X
is	B-X
defined	B-X
as	B-X
elevated	B-X
TSH	B-X
at	B-X
the	B-X
second	B-X
neonatal	B-X
screening	B-X
(	B-X
after	B-X
normal	B-X
TSH	B-X
levels	B-X
at	B-X
the	B-X
initial	B-X
screening	B-X
)	B-X
in	B-X
premature	B-X
,	B-X
low-birth-weight	B-X
,	B-X
and	B-X
ill	B-X
newborns	B-X
,	B-X
mostly	B-X
in	B-X
the	B-X
neonatal	B-X
intensive	B-X
care	B-X
unit	B-X
(	B-X
NICU	B-X
)	B-X
setting	B-X
.	B-X
A	B-X
clinically	B-X
significant	B-X
patent	B-X
ductus	B-X
arteriosus	B-X
(	B-X
PDA	B-X
)	B-X
is	B-X
associated	B-X
with	B-X
significant	B-X
morbidity	B-X
and	B-X
mortality	B-X
in	B-X
premature	B-X
newborns	B-X
.	B-X
Symptomatic	B-X
PDAs	B-X
are	B-X
often	B-X
treated	B-X
with	B-X
prostaglandin	B-X
synthesis	B-X
inhibitors	B-X
(	B-X
PSI	B-X
)	B-X
,	B-X
but	B-X
controversy	B-X
remains	B-X
if	B-X
PSIs	B-X
should	B-X
also	B-X
be	B-X
used	B-X
to	B-X
manage	B-X
early	B-X
,	B-X
asymptomatic	B-X
PDAs	B-X
.	B-X
In	B-X
a	B-X
project	B-X
designed	B-X
to	B-X
investigate	B-X
the	B-X
specific	B-X
and	B-X
infraspecific	B-X
taxa	B-X
of	B-X

This	O
section	O
also	O
addressed	O
usage	O
and	O
rating	O
of	O
different	O
drug	O
information	O
resources	O
.	O

Resource	O
ratings	O
were	O
based	O
on	O
the	O
frequency	O
of	O
usage	O
,	O
usefulness	O
,	O
accessibility	O
,	O
credibility	O
,	O
and	O
current	O
/	O
timeliness	O
.	O

Resources	O
were	O
grouped	O
as	O
print	O
(	O
i	O
.	O
e	O
.	O
books	O
,	O
journals	O
,	O
and	O
clinical	O
practice	O
guidelines	O
)	O
,	O
online	O
/	O
electronic	O
resources	O
,	O
and	O
health	O
professionals	O
and	O
other	O
.	O

Respondents	O
used	O
5	O
-	O
point	O
Likert	O
scales	O
(	O
strongly	O
agree	O
to	O
strongly	O
disagree	O
)	O
for	O
rating	O
opinions	O
related	O
to	O
resources	O
.	O

A	O
rating	O
of	O
6	O
(	O
not	O
applicable	O
,	O
I	O
do	O
not	O
use	O
this	O
resource	O
)	O
was	O
also	O
included	O
for	O
respondents	O
who	O
did	O
not	O
use	O
a	O
particular	O
resource	O
.	O

Frequency	O
of	O
searching	O
for	O
specific	O
information	O
was	O
rated	O
on	O
a	O
3	O
-	O
point	O
Likert	O
scale	O
(	O
frequently	O
to	O
never	O
)	O
.	O

The	O
final	O
sections	O
of	O
the	O
survey	O
included	O
categorical	O
,	O
open	O
-	O
ended	O
,	O
and	O
Likert	O
scale	O
questions	O
regarding	O
preferred	O
resources	O
,	O
technology	O
barriers	O
,	O
PDA	O
future	O
use	O
,	O
and	O
technology	O
training	O
preferences	O
.	O

Copies	O
of	O
the	O
surveys	O
are	O
attached	O
as	O
an	O
appendix	O
in	O
PDF	O
format	O
[	O
see	O
additional	O
file	O
1	O
and	O
2	O
]	O
or	O
can	O
also	O
be	O
accessed	O
from	O
the	O
Initiative	O
for	O
Medication	O
Management	O
,	O
Policy	O
Analysis	O
,	O
Research	O
&	O
Training	O
(	O
IMPART	O
)	O
website	O
[	O
48	O
]	O
.	O

Ethics	O
approval	O
for	O
the	O
survey	O
was	O
granted	O
through	O
Dalhousie	O
University	O
Research	O
Ethics	O
Board	O
on	O
February	O
3	O
,	O
2005	O
.	O

Survey	O
population	O
<EOS>	B-X
A	B-X
systematic	B-X
review	B-X
identified	B-X
population-based	B-X
surveys	B-X
with	B-X
estimates	B-X
of	B-X
childhood	B-X
myopia	B-X
prevalence	B-X
published	B-X
by	B-X
February	B-X
2015	B-X
.	B-X
Multilevel	B-X
binomial	B-X
logistic	B-X
regression	B-X
of	B-X
log	B-X
odds	B-X
of	B-X
myopia	B-X
was	B-X
used	B-X
to	B-X
examine	B-X
the	B-X
association	B-X
with	B-X
age	B-X
,	B-X
gender	B-X
,	B-X
urban	B-X
versus	B-X
rural	B-X
setting	B-X
and	B-X
survey	B-X
year	B-X
,	B-X
among	B-X
populations	B-X
of	B-X
different	B-X
ethnic	B-X
origins	B-X
,	B-X
adjusting	B-X
for	B-X
study	B-X
design	B-X
factors	B-X
.	B-X
The	B-X
second	B-X
clinical	B-X
survey	B-X
of	B-X
the	B-X
population-based	B-X
study	B-X
on	B-X
health	B-X
and	B-X
living	B-X
conditions	B-X
in	B-X
regions	B-X
with	B-X
Sami	B-X
and	B-X
Norwegian	B-X
populations	B-X
-	B-X
the	B-X
SAMINOR	B-X
2	B-X
Clinical	B-X
Survey	B-X
:	B-X
Performing	B-X
indigenous	B-X
health	B-X
research	B-X
in	B-X
a	B-X
multiethnic	B-X
landscape	B-X
.	B-X
Surveying	B-X
Hard-to-Survey	B-X
Populations	B-X
Despite	B-X
the	B-X
Unfavorable	B-X
Environment	B-X
.	B-X

Licensed	O
,	O
actively	O
practicing	O
,	O
primary	O
health	O
care	O
NPs	O
(	O
n	O
=	O
16	O
)	O
and	O
their	O
collaborating	O
physician	O
partners	O
(	O
n	O
=	O
21	O
)	O
were	O
eligible	O
to	O
participate	O
.	O

Survey	O
procedures	O
<EOS>	B-X
Surveys	B-X
provide	B-X
evidence	B-X
on	B-X
practice	B-X
,	B-X
attitudes	B-X
,	B-X
and	B-X
knowledge	B-X
.	B-X
Surveys	B-X
are	B-X
a	B-X
common	B-X
method	B-X
for	B-X
assessing	B-X
patient	B-X
and	B-X
clinician	B-X
perceptions	B-X
,	B-X
attitudes	B-X
and	B-X
outcomes	B-X
of	B-X
telehealth	B-X
.	B-X
Surveys	B-X
are	B-X
one	B-X
of	B-X
the	B-X
most	B-X
frequently	B-X
employed	B-X
study	B-X
designs	B-X
in	B-X
healthcare	B-X
epidemiology	B-X
research	B-X
.	B-X
Publishing	B-X
survey	B-X
research	B-X
.	B-X

The	O
survey	O
recruitment	O
procedures	O
were	O
based	O
on	O
the	O
methods	O
of	O
Dillman	O
[	O
49	O
]	O
and	O
Salant	O
and	O
Dillman	O
[	O
50	O
]	O
.	O

Survey	O
packages	O
contained	O
a	O
cover	O
letter	O
,	O
separate	O
surveys	O
for	O
PDA	O
and	O
computer	O
users	O
,	O
and	O
a	O
return	O
self	O
-	O
addressed	O
stamped	O
envelope	O
.	O

The	O
covering	O
letter	O
instructed	O
respondents	O
to	O
self	O
-	O
select	O
the	O
appropriate	O
survey	O
(	O
either	O
PDA	O
or	O
computer	O
)	O
based	O
on	O
their	O
drug	O
information	O
seeking	O
behaviours	O
.	O

Participants	B-Species
who	O
had	O
used	O
a	O
PDA	O
at	O
any	O
time	O
were	O
instructed	O
to	O
complete	O
the	O
PDA	O
version	O
of	O
the	O
survey	O
.	O

Those	O
who	O
had	O
never	O
used	O
a	O
PDA	O
for	O
drug	O
information	O
were	O
instructed	O
to	O
complete	O
the	O
computer	O
version	O
of	O
the	O
survey	O
.	O

Several	O
strategies	O
were	O
used	O
to	O
optimize	O
response	O
rate	O
and	O
included	O
:	O
personalized	O
cover	O
letters	O
,	O
coloured	O
paper	O
for	O
surveys	O
,	O
stamped	O
return	O
envelopes	O
,	O
follow	O
-	O
up	O
mailing	O
,	O
and	O
a	O
priority	O
post	O
mailing	O
[	O
51	O
]	O
.	O

The	O
covering	O
letter	O
included	O
coloured	O
logos	O
of	O
Dalhousie	O
University	O
and	O
the	O
Nova	O
Scotia	O
Department	O
of	O
Health	O
representing	O
the	O
investigator	O
affiliations	O
and	O
endorsement	O
of	O
the	O
project	O
.	O

A	O
master	O
mailing	O
list	O
with	O
names	O
and	O
addresses	O
of	O
NPs	O
and	O
their	O
collaborating	O
physician	O
partners	O
was	O
created	O
.	O

To	O
maintain	O
confidentiality	O
of	O
respondents	O
,	O
a	O
number	O
placed	O
on	O
the	O
bottom	O
right	O
corner	O
of	O
each	O
survey	O
corresponded	O
to	O
a	O
name	O
on	O
the	O
confidential	O
master	O
mailing	O
sheet	O
.	O

The	O
postage	O
paid	O
return	O
envelopes	O
were	O
addressed	O
to	O
the	O
research	O
coordinator	O
at	O
the	O
School	O
of	O
Nursing	O
,	O
Dalhousie	O
University	O
,	O
who	O
matched	O
respondents	O
to	O
the	O
mailing	O
list	O
from	O
the	O
first	O
distribution	O
.	O

The	O
cross	O
-	O
referenced	O
mailing	O
list	O
was	O
not	O
accessible	O
to	O
those	O
entering	O
or	O
analysing	O
data	O
.	O
<EOS>	B-X
limma	B-X
is	B-X
an	B-X
R/Bioconductor	B-X
software	B-X
package	B-X
that	B-X
provides	B-X
an	B-X
integrated	B-X
solution	B-X
for	B-X
analysing	B-X
data	B-X
from	B-X
gene	B-X
expression	B-X
experiments	B-X
.	B-X
Over	B-X
the	B-X
past	B-X
decade	B-X
,	B-X
limma	B-X
has	B-X
been	B-X
a	B-X
popular	B-X
choice	B-X
for	B-X
gene	B-X
discovery	B-X
through	B-X
differential	B-X
expression	B-X
analyses	B-X
of	B-X
microarray	B-X
and	B-X
high-throughput	B-X
PCR	B-X
data	B-X
.	B-X
The	B-X
package	B-X
contains	B-X
particularly	B-X
strong	B-X
facilities	B-X
for	B-X
reading	B-X
,	B-X
normalizing	B-X
and	B-X
exploring	B-X
such	B-X
data	B-X
.	B-X
First	B-X
,	B-X
the	B-X
package	B-X
can	B-X
now	B-X
perform	B-X
both	B-X
differential	B-X
expression	B-X
and	B-X
differential	B-X
splicing	B-X
analyses	B-X
of	B-X
RNA	B-X
sequencing	B-X
(	B-X
RNA-seq	B-X
)	B-X
data	B-X
.	B-X
All	B-X
the	B-X
downstream	B-X
analysis	B-X
tools	B-X
previously	B-X
restricted	B-X
to	B-X
microarray	B-X
data	B-X
are	B-X
now	B-X
available	B-X
for	B-X
RNA-seq	B-X
as	B-X
well	B-X
.	B-X
These	B-X
capabilities	B-X
allow	B-X
users	B-X
to	B-X
analyse	B-X
both	B-X
RNA-seq	B-X
and	B-X
microarray	B-X
data	B-X
with	B-X
very	B-X
similar	B-X
pipelines	B-X
.	B-X
Second	B-X
,	B-X
the	B-X
package	B-X
is	B-X
now	B-X
able	B-X
to	B-X
go	B-X
past	B-X
the	B-X
traditional	B-X
gene-wise	B-X
expression	B-X
analyses	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
ways	B-X
,	B-X
analysing	B-X
expression	B-X
profiles	B-X
in	B-X
terms	B-X
of	B-X
co-regulated	B-X
sets	B-X
of	B-X
genes	B-X
or	B-X
in	B-X
terms	B-X
of	B-X
higher-order	B-X
expression	B-X
signatures	B-X
.	B-X

The	O
research	O
coordinator	O
sent	O
the	O
second	O
distribution	O
to	O
those	O
who	O
had	O
not	O
initially	O
responded	O
.	O
<EOS>	B-X
Few	B-X
studies	B-X
have	B-X
documented	B-X
the	B-X
value	B-X
of	B-X
mentoring	B-X
for	B-X
medical	B-X
students	B-X
,	B-X
and	B-X
research	B-X
has	B-X
been	B-X
limited	B-X
to	B-X
more	B-X
subjective	B-X
(	B-X
e.g.	B-X
,	B-X
job	B-X
satisfaction	B-X
,	B-X
perceived	B-X
career	B-X
preparation	B-X
)	B-X
rather	B-X
than	B-X
objective	B-X
outcomes	B-X
.	B-X

A	O
fluorescent	O
coloured	O
page	O
was	O
included	O
in	O
the	O
second	O
mailing	O
to	O
notify	O
recipients	O
of	O
the	O
second	O
and	O
final	O
mailing	O
status	O
.	O

The	O
second	O
mailing	O
followed	O
2	O
weeks	O
after	O
the	O
initial	O
mailing	O
(	O
February	O
2005	O
)	O
.	O

The	O
surveys	O
were	O
sent	O
via	O
Xpresspost	O
(TM)	O
through	O
Canada	O
Post	O
.	O

Data	O
analyses	O
<EOS>	B-X
This	B-X
methodology	B-X
review	B-X
will	B-X
outline	B-X
how	B-X
to	B-X
perform	B-X
rigorous	B-X
thematic	B-X
analyses	B-X
on	B-X
qualitative	B-X
data	B-X
to	B-X
draw	B-X
interpretations	B-X
from	B-X
the	B-X
data	B-X
.	B-X
Unfortunately	B-X
,	B-X
results	B-X
from	B-X
these	B-X
analyses	B-X
are	B-X
often	B-X
misinterpreted	B-X
and	B-X
not	B-X
presented	B-X
in	B-X
a	B-X
clinically	B-X
tangible	B-X
manner	B-X
.	B-X
In	B-X
the	B-X
data	B-X
pipeline	B-X
from	B-X
the	B-X
data	B-X
collection	B-X
process	B-X
to	B-X
the	B-X
planned	B-X
statistical	B-X
analyses	B-X
,	B-X
initial	B-X
data	B-X
analysis	B-X
(	B-X
IDA	B-X
)	B-X
typically	B-X
takes	B-X
place	B-X
between	B-X
the	B-X
end	B-X
of	B-X
the	B-X
data	B-X
collection	B-X
and	B-X
do	B-X
not	B-X
touch	B-X
the	B-X
research	B-X
questions	B-X
.	B-X
Initial	B-X
data	B-X
analyses	B-X
can	B-X
provide	B-X
valuable	B-X
insights	B-X
into	B-X
the	B-X
suitability	B-X
of	B-X
a	B-X
data	B-X
set	B-X
for	B-X
a	B-X
future	B-X
research	B-X
study	B-X
.	B-X
Our	B-X
aim	B-X
was	B-X
to	B-X
describe	B-X
the	B-X
practice	B-X
of	B-X
reporting	B-X
of	B-X
initial	B-X
data	B-X
analyses	B-X
in	B-X
observational	B-X
studies	B-X
in	B-X
five	B-X
highly	B-X
ranked	B-X
medical	B-X
journals	B-X
with	B-X
focus	B-X
on	B-X
data	B-X
cleaning	B-X
,	B-X
screening	B-X
,	B-X
and	B-X
reporting	B-X
of	B-X
findings	B-X
which	B-X
led	B-X
to	B-X
a	B-X
potential	B-X
change	B-X
in	B-X
the	B-X
analysis	B-X
plan	B-X
.	B-X

Quantitative	O
<EOS>	B-X
Quantitative	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
qPCR	B-X
)	B-X
is	B-X
a	B-X
routinely	B-X
used	B-X
method	B-X
for	B-X
the	B-X
detection	B-X
and	B-X
quantitation	B-X
of	B-X
gene	B-X
expression	B-X
in	B-X
real	B-X
time	B-X
.	B-X
Quantitative	B-X
anatomical	B-X
studies	B-X
are	B-X
numerous	B-X
,	B-X
whereas	B-X
quantitations	B-X
of	B-X
pathological	B-X
conditions	B-X
are	B-X
relatively	B-X
few	B-X
.	B-X
Quantitative	B-X
proteomics	B-X
has	B-X
evolved	B-X
considerably	B-X
over	B-X
the	B-X
last	B-X
decade	B-X
with	B-X
the	B-X
advent	B-X
of	B-X
higher	B-X
order	B-X
multiplexing	B-X
(	B-X
HOM	B-X
)	B-X
techniques	B-X
.	B-X
Quantitative	B-X
fluorescence	B-X
microscopy	B-X
is	B-X
a	B-X
powerful	B-X
and	B-X
important	B-X
tool	B-X
in	B-X
biological	B-X
research	B-X
but	B-X
is	B-X
also	B-X
an	B-X
error-prone	B-X
technique	B-X
that	B-X
requires	B-X
careful	B-X
attention	B-X
to	B-X
detail	B-X
.	B-X

Data	O
were	O
entered	O
and	O
analysed	O
in	O
Statistical	O
Package	O
for	O
Social	O
Sciences	O
(	O
SPSS	O
)	O
(	O
version	O
11	O
.	O
5	O
for	O
Windows	O
)	O
.	O

Five	O
surveys	O
were	O
randomly	O
selected	O
as	O
a	O
check	O
for	O
accuracy	O
of	O
data	O
entry	O
.	O

Descriptive	O
statistics	O
were	O
used	O
to	O
describe	O
resource	O
usage	O
by	O
practitioners	O
.	O

Chi	O
Square	O
(	O
Fisher	O
'	O
s	O
Exact	O
when	O
cell	O
count	O
less	O
than	O
5	O
)	O
analyses	O
were	O
used	O
to	O
determine	O
differences	O
in	O
computer	O
or	O
PDA	O
use	O
based	O
on	O
predetermined	O
variables	O
(	O
e	O
.	O
g	O
.	O
high	O
speed	O
Internet	O
connection	O
,	O
number	O
of	O
patients	B-Species
per	O
day	O
)	O
.	O

Mann	O
Whitney	O
U	O
tests	O
were	O
used	O
to	O
compare	O
physician	O
and	O
NPs	O
Likert	O
scale	O
ratings	O
(	O
1	O
=	O
strongly	O
agree	O
to	O
5	O
=	O
strongly	O
disagree	O
)	O
of	O
resource	O
use	O
.	O

Physician	O
and	O
NP	O
rankings	O
of	O
all	O
resources	O
(	O
print	O
,	O
online	O
/	O
electronic	O
,	O
and	O
health	O
professionals	O
and	O
other	O
)	O
were	O
determined	O
from	O
means	O
of	O
Likert	O
scale	O
ratings	O
(	O
1	O
=	O
strongly	O
agree	O
,	O
5	O
=	O
strongly	O
disagree	O
)	O
for	O
each	O
of	O
the	O
pre	O
-	O
specified	O
characteristics	O
(	O
e	O
.	O
g	O
.	O
frequency	O
of	O
use	O
,	O
accessibility	O
,	O
etc	O
.	O
)	O
and	O
the	O
frequency	O
of	O
use	O
of	O
the	O
resources	O
.	O

The	O
best	O
rankings	O
were	O
assigned	O
for	O
the	O
lowest	O
mean	O
scores	O
and	O
the	O
largest	O
number	O
of	O
the	O
sample	O
using	O
a	O
resource	O
.	O

These	O
rankings	O
(	O
ranks	O
based	O
on	O
mean	O
and	O
ranks	O
based	O
on	O
sample	O
)	O
were	O
then	O
entered	O
into	O
a	O
formula	O
to	O
calculate	O
an	O
overall	O
rank	O
.	O

The	O
formula	O
includes	O
:	O
rank	O
=	O
[	O
(	O
rank	O
according	O
to	O
%	O
of	O
sample	O
using	O
the	O
resource	O
+	O
rank	O
based	O
on	O
mean	O
score	O
)	O
/	O
2	O
]	O
.	O

This	O
formula	O
was	O
used	O
to	O
account	O
for	O
mean	O
scores	O
based	O
on	O
small	O
samples	O
as	O
these	O
numbers	O
could	O
potentially	O
over	O
or	O
underestimate	O
the	O
value	O
of	O
a	O
resource	O
.	O
<EOS>	B-X
Community-based	B-X
studies	B-X
have	B-X
consistently	B-X
shown	B-X
a	B-X
sex	B-X
ratio	B-X
heavily	B-X
skewed	B-X
towards	B-X
males	B-X
in	B-X
autism	B-X
spectrum	B-X
disorders	B-X
(	B-X
ASD	B-X
)	B-X
.	B-X
The	B-X
factors	B-X
underlying	B-X
this	B-X
predominance	B-X
of	B-X
males	B-X
are	B-X
largely	B-X
unknown	B-X
,	B-X
but	B-X
the	B-X
way	B-X
girls	B-X
score	B-X
on	B-X
standardized	B-X
categorical	B-X
diagnostic	B-X
tools	B-X
might	B-X
account	B-X
for	B-X
the	B-X
underrecognition	B-X
of	B-X
ASD	B-X
in	B-X
girls	B-X
.	B-X
Despite	B-X
the	B-X
existence	B-X
of	B-X
different	B-X
norms	B-X
for	B-X
boys	B-X
and	B-X
girls	B-X
with	B-X
ASD	B-X
on	B-X
several	B-X
major	B-X
screening	B-X
tests	B-X
,	B-X
the	B-X
algorithm	B-X
of	B-X
the	B-X
Autism	B-X
Diagnosis	B-X
Interview-Revised	B-X
(	B-X
ADI-R	B-X
)	B-X
has	B-X
not	B-X
been	B-X
reformulated	B-X
.	B-X
Entering	B-X
the	B-X
raw	B-X
scores	B-X
for	B-X
all	B-X
ADI-R	B-X
items	B-X
as	B-X
independent	B-X
variables	B-X
,	B-X
the	B-X
DA	B-X
correctly	B-X
classified	B-X
78.9	B-X
%	B-X
of	B-X
males	B-X
and	B-X
72.9	B-X
%	B-X
of	B-X
females	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
in	B-X
the	B-X
PARIS	B-X
cohort	B-X
,	B-X
and	B-X
72.2	B-X
%	B-X
of	B-X
males	B-X
and	B-X
68.3	B-X
%	B-X
of	B-X
females	B-X
(	B-X
P	B-X
<	B-X
0.0001	B-X
)	B-X
in	B-X
the	B-X
AGRE	B-X
cohort	B-X
.	B-X
Among	B-X
the	B-X
items	B-X
extracted	B-X
by	B-X
the	B-X
stepwise	B-X
DA	B-X
,	B-X
four	B-X
belonged	B-X
to	B-X
the	B-X
ADI-R	B-X
algorithm	B-X
used	B-X
for	B-X
the	B-X
final	B-X
diagnosis	B-X
of	B-X
ASD	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
several	B-X
items	B-X
of	B-X
the	B-X
ADI-R	B-X
that	B-X
are	B-X
taken	B-X
into	B-X
account	B-X
in	B-X
the	B-X
diagnosis	B-X
of	B-X
autism	B-X
significantly	B-X
differentiates	B-X
between	B-X
males	B-X
and	B-X
females	B-X
.	B-X

Ratings	O
of	O
6	O
(	O
i	O
.	O
e	O
.	O
not	O
applicable	O
,	O
I	O
do	O
not	O
use	O
this	O
resource	O
)	O
were	O
excluded	O
from	O
the	O
analyses	O
.	O

Qualitative	O
<EOS>	B-X
Qualitative	B-X
research	B-X
is	B-X
marked	B-X
by	B-X
context	B-X
sensitivity	B-X
with	B-X
an	B-X
inclusion	B-X
of	B-X
the	B-X
participants	B-X
'	B-X
points	B-X
of	B-X
view	B-X
and	B-X
setting	B-X
,	B-X
how	B-X
they	B-X
can	B-X
affect	B-X
how	B-X
participants	B-X
feel	B-X
and	B-X
how	B-X
this	B-X
feeling	B-X
is	B-X
captured	B-X
and	B-X
interpreted	B-X
by	B-X
researchers	B-X
(	B-X
Yardley	B-X
,	B-X
2017	B-X
)	B-X
.	B-X
Qualitative	B-X
research	B-X
(	B-X
QR	B-X
)	B-X
take	B-X
advantage	B-X
of	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
methods	B-X
and	B-X
theoretical	B-X
frameworks	B-X
to	B-X
explore	B-X
people	B-X
's	B-X
beliefs	B-X
,	B-X
perspectives	B-X
,	B-X
experiences	B-X
,	B-X
and	B-X
behaviours	B-X
and	B-X
has	B-X
been	B-X
applied	B-X
to	B-X
many	B-X
areas	B-X
of	B-X
healthcare	B-X
.	B-X
[	B-X
Qualitative	B-X
methods	B-X
]	B-X
.	B-X
Qualitatively	B-X
,	B-X
the	B-X
albumin	B-X
region	B-X
presented	B-X
different	B-X
shapes	B-X
:	B-X
a	B-X
simple	B-X
thickening	B-X
of	B-X
the	B-X
base	B-X
,	B-X
a	B-X
shoulder	B-X
to	B-X
the	B-X
right	B-X
or	B-X
to	B-X
the	B-X
left	B-X
of	B-X
the	B-X
peak	B-X
,	B-X
one	B-X
or	B-X
more	B-X
distinct	B-X
additional	B-X
peaks	B-X
.	B-X

Comments	O
were	O
entered	O
in	O
a	O
word	O
-	O
processing	O
program	O
and	O
organized	O
by	O
type	O
of	O
respondent	O
(	O
PDA	O
versus	O
computer	O
)	O
and	O
question	O
number	O
.	O

The	O
coded	O
survey	O
number	O
and	O
respondent	O
type	O
(	O
NP	O
or	O
physician	O
)	O
were	O
also	O
included	O
next	O
to	O
comments	O
.	O

Investigators	O
determined	O
themes	O
and	O
categorized	O
comments	O
based	O
on	O
previous	O
experience	O
,	O
knowledge	O
,	O
and	O
familiarity	O
with	O
the	O
topic	O
.	O

Results	O

Surveys	O
were	O
completed	O
and	O
returned	O
by	O
75	O
%	O
of	O
eligible	O
participants	B-Species
(	O
27	O
of	O
36	O
)	O
.	O
<EOS>	B-X
Outcome	B-X
measures	B-X
included	B-X
the	B-X
Short	B-X
Form-36	B-X
(	B-X
SF-36	B-X
)	B-X
,	B-X
the	B-X
General	B-X
Health	B-X
Questionnaire-12	B-X
(	B-X
GHQ-12	B-X
)	B-X
and	B-X
the	B-X
Barthel	B-X
Index	B-X
(	B-X
postal	B-X
version	B-X
)	B-X
,	B-X
along	B-X
with	B-X
questions	B-X
relating	B-X
to	B-X
chronic	B-X
illness	B-X
.	B-X
Out	B-X
of	B-X
233	B-X
elderly	B-X
people	B-X
sent	B-X
questionnaires	B-X
,	B-X
77	B-X
(	B-X
33	B-X
%	B-X
)	B-X
returned	B-X
a	B-X
completed	B-X
baseline	B-X
questionnaire	B-X
.	B-X
Between	B-X
baseline	B-X
and	B-X
follow-up	B-X
,	B-X
8	B-X
(	B-X
10	B-X
%	B-X
)	B-X
of	B-X
the	B-X
77	B-X
respondents	B-X
died	B-X
;	B-X
52	B-X
of	B-X
the	B-X
69	B-X
(	B-X
75	B-X
%	B-X
)	B-X
remaining	B-X
participants	B-X
completed	B-X
follow-up	B-X
questionnaires	B-X
.	B-X
Baseline	B-X
SF-36	B-X
scores	B-X
were	B-X
extremely	B-X
low	B-X
and	B-X
remained	B-X
largely	B-X
unchanged	B-X
at	B-X
follow-up	B-X
;	B-X
however	B-X
,	B-X
there	B-X
were	B-X
significant	B-X
improvements	B-X
in	B-X
GHQ-12	B-X
scores	B-X
(	B-X
mean	B-X
difference	B-X
=	B-X
-1.45	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
=	B-X
-2.63	B-X
to	B-X
-0.27	B-X
,	B-X
P	B-X
=	B-X
0.017	B-X
)	B-X
.	B-X
Significant	B-X
increases	B-X
in	B-X
benefit	B-X
income	B-X
were	B-X
identified	B-X
in	B-X
65	B-X
%	B-X
of	B-X
respondents	B-X
with	B-X
complete	B-X
financial	B-X
data	B-X
sets	B-X
(	B-X
mean	B-X
increase	B-X
=	B-X
pound14.73	B-X
per	B-X
week	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
=	B-X
5.27-24.18	B-X
,	B-X
d.f	B-X
.	B-X

One	O
physician	O
survey	O
was	O
undeliverable	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
factors	B-X
that	B-X
encourage	B-X
physicians	B-X
to	B-X
establish	B-X
collaborative	B-X
practice	B-X
agreements	B-X
with	B-X
community	B-X
pharmacists	B-X
.	B-X
This	B-X
study	B-X
sought	B-X
to	B-X
assess	B-X
factors	B-X
motivating	B-X
emergency	B-X
physicians	B-X
to	B-X
pursue	B-X
an	B-X
US	B-X
fellowship	B-X
and	B-X
to	B-X
characterize	B-X
their	B-X
employment	B-X
and	B-X
job	B-X
satisfaction	B-X
after	B-X
graduation	B-X
.	B-X
In	B-X
Anchorage	B-X
,	B-X
where	B-X
more	B-X
than	B-X
87,000	B-X
doses	B-X
were	B-X
given	B-X
,	B-X
a	B-X
survey	B-X
was	B-X
conducted	B-X
to	B-X
determine	B-X
the	B-X
frequency	B-X
of	B-X
side	B-X
effects	B-X
.	B-X
Postcard	B-X
questionnaires	B-X
were	B-X
mailed	B-X
to	B-X
2,000	B-X
randomly	B-X
selected	B-X
Anchorage	B-X
residents	B-X
;	B-X
467	B-X
questionnaires	B-X
were	B-X
returned	B-X
by	B-X
the	B-X
post	B-X
office	B-X
as	B-X
undeliverable	B-X
,	B-X
and	B-X
697	B-X
questionnaires	B-X
were	B-X
completed	B-X
and	B-X
returned	B-X
.	B-X
A	B-X
follow-up	B-X
survey	B-X
was	B-X
done	B-X
of	B-X
a	B-X
random	B-X
sample	B-X
of	B-X
the	B-X
836	B-X
non-responders	B-X
.	B-X
Of	B-X
those	B-X
vaccinated	B-X
,	B-X
0.5	B-X
per	B-X
cent	B-X
saw	B-X
a	B-X
physician	B-X
.	B-X

The	O
response	O
rates	O
from	O
within	O
the	O
NP	O
and	O
physician	O
samples	O
were	O
88	O
%	O
and	O
65	O
%	O
,	O
respectively	O
.	O

Complete	O
demographic	O
information	O
is	O
available	O
in	O
Table	O
1	O
.	O
<EOS>	B-X
All	B-X
available	B-X
information	B-X
has	B-X
always	B-X
been	B-X
presented	B-X
in	B-X
the	B-X
form	B-X
of	B-X
static	B-X
world	B-X
maps	B-X
or	B-X
large	B-X
dimension	B-X
tables	B-X
,	B-X
so	B-X
that	B-X
it	B-X
would	B-X
benefit	B-X
from	B-X
the	B-X
newly	B-X
available	B-X
visualization	B-X
tools	B-X
,	B-X
such	B-X
as	B-X
interactive	B-X
world	B-X
maps	B-X
.	B-X
Taking	B-X
all	B-X
this	B-X
into	B-X
consideration	B-X
,	B-X
the	B-X
aims	B-X
of	B-X
the	B-X
present	B-X
review	B-X
were	B-X
:	B-X
(	B-X
1	B-X
)	B-X
to	B-X
gather	B-X
and	B-X
summarize	B-X
all	B-X
available	B-X
information	B-X
on	B-X
LNP	B-X
and	B-X
LP	B-X
genetic	B-X
mechanisms	B-X
and	B-X
evolutionary	B-X
adaptation	B-X
theories	B-X
,	B-X
and	B-X
(	B-X
2	B-X
)	B-X
to	B-X
create	B-X
online	B-X
interactive	B-X
world	B-X
maps	B-X
,	B-X
including	B-X
all	B-X
LP	B-X
phenotype	B-X
and	B-X
genotype	B-X
frequency	B-X
data	B-X
reported	B-X
to	B-X
date	B-X
.	B-X
The	B-X
Statistical	B-X
Update	B-X
is	B-X
a	B-X
valuable	B-X
resource	B-X
for	B-X
researchers	B-X
,	B-X
clinicians	B-X
,	B-X
healthcare	B-X
policy	B-X
makers	B-X
,	B-X
media	B-X
professionals	B-X
,	B-X
the	B-X
lay	B-X
public	B-X
,	B-X
and	B-X
many	B-X
others	B-X
who	B-X
seek	B-X
the	B-X
best	B-X
national	B-X
data	B-X
available	B-X
on	B-X
disease	B-X
morbidity	B-X
and	B-X
mortality	B-X
and	B-X
the	B-X
risks	B-X
,	B-X
quality	B-X
of	B-X
care	B-X
,	B-X
medical	B-X
procedures	B-X
and	B-X
operations	B-X
,	B-X
and	B-X
costs	B-X
associated	B-X
with	B-X
the	B-X
management	B-X
of	B-X
these	B-X
diseases	B-X
in	B-X
a	B-X
single	B-X
document	B-X
.	B-X
Indeed	B-X
,	B-X
since	B-X
1999	B-X
,	B-X
the	B-X
Statistical	B-X
Update	B-X
has	B-X
been	B-X
cited	B-X
more	B-X
than	B-X
8700	B-X
times	B-X
in	B-X
the	B-X
literature	B-X
(	B-X
including	B-X
citations	B-X
of	B-X
all	B-X
annual	B-X
versions	B-X
)	B-X
.	B-X
In	B-X
2009	B-X
alone	B-X
,	B-X
the	B-X
various	B-X
Statistical	B-X
Updates	B-X
were	B-X
cited	B-X
â1600	B-X
times	B-X
(	B-X
data	B-X
from	B-X
ISI	B-X
Web	B-X
of	B-X
Science	B-X
)	B-X
.	B-X
Also	B-X
,	B-X
the	B-X
2011	B-X
Statistical	B-X
Update	B-X
is	B-X
a	B-X
major	B-X
source	B-X
for	B-X
monitoring	B-X
both	B-X
cardiovascular	B-X
health	B-X
and	B-X
disease	B-X
in	B-X
the	B-X
population	B-X
,	B-X
with	B-X
a	B-X
focus	B-X
on	B-X
progress	B-X
toward	B-X
achievement	B-X
of	B-X
the	B-X
AHA	B-X
â	B-X
s	B-X
2020	B-X
Impact	B-X
Goals	B-X
.	B-X

Methods	O
for	O
accessing	O
resources	O
and	O
self	O
-	O
reported	O
resource	O
use	O
<EOS>	B-X
Because	B-X
standard	B-X
questions	B-X
are	B-X
rare	B-X
,	B-X
patterns	B-X
of	B-X
patient-reported	B-X
access	B-X
are	B-X
unknown	B-X
.	B-X
In	B-X
general	B-X
,	B-X
the	B-X
use	B-X
of	B-X
technology	B-X
resources	B-X
or	B-X
electronic	B-X
health	B-X
(	B-X
e-health	B-X
)	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
have	B-X
beneficial	B-X
effects	B-X
on	B-X
patients	B-X
with	B-X
asthma	B-X
.	B-X
Web-based	B-X
asthma	B-X
self-management	B-X
systems	B-X
have	B-X
been	B-X
found	B-X
to	B-X
improve	B-X
quality	B-X
of	B-X
life	B-X
,	B-X
self-reported	B-X
asthma	B-X
symptoms	B-X
,	B-X
lung	B-X
function	B-X
,	B-X
reduction	B-X
in	B-X
asthma	B-X
symptoms/exacerbations	B-X
,	B-X
and	B-X
self-reported	B-X
adherence	B-X
for	B-X
adults	B-X
.	B-X
Social	B-X
media	B-X
is	B-X
commonly	B-X
being	B-X
used	B-X
as	B-X
a	B-X
platform	B-X
to	B-X
disseminate	B-X
information	B-X
on	B-X
asthma	B-X
to	B-X
increase	B-X
public	B-X
awareness	B-X
.	B-X
It	B-X
can	B-X
facilitate	B-X
asthma	B-X
self-management	B-X
in	B-X
a	B-X
patient	B-X
friendly	B-X
manner	B-X
and	B-X
has	B-X
shown	B-X
to	B-X
improve	B-X
asthma	B-X
control	B-X
test	B-X
scores	B-X
as	B-X
well	B-X
as	B-X
self-esteem	B-X
.	B-X
Mobile	B-X
health	B-X
applications	B-X
can	B-X
support	B-X
asthma	B-X
self-management	B-X
,	B-X
improve	B-X
a	B-X
patient	B-X
's	B-X
quality	B-X
of	B-X
life	B-X
,	B-X
promote	B-X
medication	B-X
adherence	B-X
,	B-X
and	B-X
potentially	B-X
reduce	B-X
the	B-X
overall	B-X
costs	B-X
for	B-X
asthma	B-X
care	B-X
.	B-X
Other	B-X
limitations	B-X
of	B-X
using	B-X
technology	B-X
resources	B-X
in	B-X
health	B-X
care	B-X
are	B-X
related	B-X
to	B-X
liability	B-X
,	B-X
professionalism	B-X
,	B-X
and	B-X
ethical	B-X
issues	B-X
such	B-X
as	B-X
breach	B-X
of	B-X
patient	B-X
confidentiality	B-X
and	B-X
privacy	B-X
.	B-X
Additionally	B-X
,	B-X
there	B-X
may	B-X
be	B-X
less	B-X
face-to-face	B-X
interaction	B-X
and	B-X
care	B-X
of	B-X
the	B-X
patient	B-X
when	B-X
e-health	B-X
is	B-X
used	B-X
.	B-X

Resource	O
use	O
was	O
similar	O
amongst	O
practitioners	O
.	O
<EOS>	B-X
While	B-X
challenges	B-X
facing	B-X
community	B-X
and	B-X
acute	B-X
care	B-X
practitioners	B-X
have	B-X
been	B-X
studied	B-X
elsewhere	B-X
,	B-X
this	B-X
is	B-X
not	B-X
the	B-X
case	B-X
for	B-X
respiratory	B-X
therapists	B-X
(	B-X
RTs	B-X
)	B-X
.	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
examine	B-X
attitudinal	B-X
differences	B-X
amongst	B-X
RTs	B-X
in	B-X
British	B-X
Columbia	B-X
regarding	B-X
challenges	B-X
faced	B-X
by	B-X
acute	B-X
and	B-X
community	B-X
settings	B-X
.	B-X
The	B-X
present	B-X
study	B-X
utilizes	B-X
REALISEâ¢	B-X
data	B-X
to	B-X
understand	B-X
resource	B-X
use	B-X
and	B-X
absenteeism	B-X
in	B-X
asthma	B-X
.	B-X
It	B-X
is	B-X
essential	B-X
for	B-X
practitioners	B-X
caring	B-X
for	B-X
patients	B-X
who	B-X
have	B-X
experienced	B-X
an	B-X
ischemic	B-X
stroke	B-X
to	B-X
be	B-X
familiar	B-X
with	B-X
the	B-X
literature	B-X
supporting	B-X
both	B-X
acute	B-X
management	B-X
as	B-X
well	B-X
as	B-X
secondary	B-X
preventive	B-X
strategies	B-X
.	B-X
Due	B-X
to	B-X
the	B-X
large	B-X
amount	B-X
of	B-X
literature	B-X
available	B-X
on	B-X
this	B-X
topic	B-X
,	B-X
this	B-X
bibliography	B-X
(	B-X
the	B-X
second	B-X
of	B-X
a	B-X
two-part	B-X
series	B-X
)	B-X
aims	B-X
to	B-X
provide	B-X
a	B-X
comprehensive	B-X
resource	B-X
for	B-X
medical	B-X
practitioners	B-X
charged	B-X
with	B-X
caring	B-X
for	B-X
this	B-X
population	B-X
.	B-X
Secondary	B-X
prevention	B-X
strategies	B-X
,	B-X
similar	B-X
to	B-X
primary	B-X
prevention	B-X
,	B-X
focus	B-X
on	B-X
modulation	B-X
of	B-X
various	B-X
risk	B-X
factors	B-X
including	B-X
antiplatelet	B-X
treatments	B-X
and	B-X
control	B-X
of	B-X
blood	B-X
pressure	B-X
,	B-X
and	B-X
lipid	B-X
levels	B-X
,	B-X
amongst	B-X
others	B-X
.	B-X

Respondents	O
indicated	O
that	O
print	O
resources	O
(	O
mean	O
4	O
.	O
56	O
,	O
SD	O
0	O
.	O
80	O
)	O
,	O
health	O
professionals	O
(	O
mean	O
3	O
.	O
26	O
,	O
SD	O
0	O
.	O
90	O
)	O
,	O
and	O
online	O
/	O
electronic	O
resources	O
(	O
mean	O
2	O
.	O
70	O
,	O
SD	O
1	O
.	O
20	O
)	O
were	O
the	O
preferred	O
method	O
(	O
1	O
=	O
least	O
preferred	O
to	O
5	O
=	O
most	O
preferred	O
)	O
for	O
accessing	O
drug	O
information	O
.	O

Thirty	O
-	O
seven	O
percent	O
of	O
respondents	O
reported	O
that	O
searching	O
for	O
specific	O
questions	O
related	O
to	O
drug	O
information	O
(	O
e	O
.	O
g	O
.	O
usual	O
dosage	O
,	O
duration	O
of	O
therapy	O
)	O
was	O
conducted	O
using	O
both	O
print	O
and	O
electronic	O
resources	O
(	O
but	O
print	O
use	O
greater	O
than	O
electronic	O
)	O
(	O
Table	O
2	O
)	O
.	O

The	O
preferred	O
means	O
(	O
i	O
.	O
e	O
.	O
print	O
)	O
to	O
access	O
resources	O
was	O
consistent	O
with	O
the	O
most	O
common	O
means	O
of	O
conducting	O
searches	O
for	O
specific	O
drug	O
information	O
queries	O
.	O

Respondents	O
'	O
ratings	O
for	O
pre	O
-	O
specified	O
print	O
,	O
online	O
/	O
electronic	O
,	O
and	O
professional	O
resources	O
and	O
other	O
,	O
based	O
on	O
means	O
from	O
Likert	O
scales	O
and	O
number	O
of	O
respondents	O
using	O
the	O
resources	O
,	O
are	O
presented	O
in	O
Tables	O
3	O
,	O
4	O
,	O
and	O
5	O
.	O

Of	O
all	O
resources	O
within	O
the	O
print	O
,	O
online	O
/	O
electronic	O
,	O
and	O
health	O
professionals	O
or	O
other	O
categories	O
,	O
NPs	O
and	O
physicians	O
rated	O
the	O
Compendium	O
of	O
Pharmaceuticals	O
and	O
Specialties	O
(	O
CPS	O
)	O
[	O
52	O
]	O
and	O
pharmacists	O
as	O
the	O
top	O
two	O
most	O
frequently	O
used	O
resources	O
for	O
providing	O
drug	O
and	O
therapeutic	O
information	O
.	O
<EOS>	B-X
There	B-X
are	B-X
a	B-X
variety	B-X
of	B-X
resources	B-X
to	B-X
obtain	B-X
health	B-X
information	B-X
,	B-X
but	B-X
few	B-X
studies	B-X
have	B-X
examined	B-X
if	B-X
main	B-X
and	B-X
allied	B-X
health	B-X
professionals	B-X
prefer	B-X
different	B-X
methods	B-X
.	B-X
The	B-X
current	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
their	B-X
information-searching	B-X
behaviours	B-X
.	B-X
The	B-X
research	B-X
assesses	B-X
the	B-X
impact	B-X
of	B-X
online	B-X
journals	B-X
on	B-X
citation	B-X
patterns	B-X
by	B-X
examining	B-X
whether	B-X
researchers	B-X
were	B-X
more	B-X
likely	B-X
to	B-X
limit	B-X
the	B-X
resources	B-X
they	B-X
cited	B-X
to	B-X
those	B-X
journals	B-X
available	B-X
online	B-X
rather	B-X
than	B-X
those	B-X
only	B-X
in	B-X
print	B-X
.	B-X
Understanding	B-X
health	B-X
information	B-X
needs	B-X
and	B-X
health-seeking	B-X
behavior	B-X
is	B-X
a	B-X
prerequisite	B-X
for	B-X
developing	B-X
an	B-X
electronic	B-X
health	B-X
information	B-X
literacy	B-X
(	B-X
EHIL	B-X
)	B-X
or	B-X
eHealth	B-X
literacy	B-X
program	B-X
for	B-X
nondegree	B-X
health	B-X
sciences	B-X
students	B-X
.	B-X
At	B-X
present	B-X
,	B-X
interest	B-X
in	B-X
researching	B-X
health	B-X
information	B-X
needs	B-X
and	B-X
reliable	B-X
sources	B-X
paradigms	B-X
has	B-X
gained	B-X
momentum	B-X
in	B-X
many	B-X
countries	B-X
.	B-X
However	B-X
,	B-X
most	B-X
studies	B-X
focus	B-X
on	B-X
health	B-X
professionals	B-X
and	B-X
students	B-X
in	B-X
higher	B-X
education	B-X
institutions	B-X
.	B-X

Physicians	O
rated	O
other	O
physicians	O
as	O
the	O
third	O
most	O
frequently	O
used	O
resource	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
extent	B-X
to	B-X
which	B-X
sports	B-X
medicine	B-X
physicians	B-X
encounter	B-X
and	B-X
discuss	B-X
psychological	B-X
issues	B-X
among	B-X
athletes	B-X
they	B-X
treat	B-X
and	B-X
to	B-X
evaluate	B-X
physicians	B-X
'	B-X
perceptions	B-X
of	B-X
the	B-X
availability	B-X
and	B-X
efficacy	B-X
of	B-X
sport	B-X
psychologists	B-X
and	B-X
other	B-X
mental	B-X
health	B-X
resources	B-X
.	B-X
Implementation	B-X
of	B-X
a	B-X
Low-Carbohydrate	B-X
Diet	B-X
Improves	B-X
the	B-X
Quality	B-X
of	B-X
Life	B-X
of	B-X
Cancer	B-X
Patients	B-X
-	B-X
An	B-X
Online	B-X
Survey	B-X
.	B-X
A	B-X
very	B-X
high	B-X
proportion	B-X
of	B-X
respondents	B-X
from	B-X
both	B-X
countries	B-X
identified	B-X
external	B-X
factors-such	B-X
as	B-X
governmental	B-X
budget	B-X
cuts	B-X
,	B-X
pressure	B-X
from	B-X
third	B-X
parties	B-X
to	B-X
increase	B-X
physicians	B-X
'	B-X
workload	B-X
,	B-X
and	B-X
the	B-X
turbulence	B-X
of	B-X
the	B-X
policy	B-X
environment-as	B-X
important	B-X
barriers	B-X
to	B-X
improving	B-X
doctor-manager	B-X
relationships	B-X
.	B-X
Other	B-X
common	B-X
sources	B-X
of	B-X
strain	B-X
were	B-X
concerns	B-X
over	B-X
resource	B-X
availability	B-X
and	B-X
the	B-X
relative	B-X
power	B-X
of	B-X
doctors	B-X
and	B-X
managers	B-X
.	B-X
Managers	B-X
can	B-X
implement	B-X
several	B-X
strategies	B-X
to	B-X
improve	B-X
doctor-manager	B-X
relationships	B-X
,	B-X
including	B-X
greater	B-X
organizational	B-X
transparency	B-X
in	B-X
decision	B-X
making	B-X
;	B-X
more	B-X
frequent	B-X
communication	B-X
between	B-X
managers	B-X
and	B-X
doctors	B-X
;	B-X
and	B-X
more	B-X
physician	B-X
involvement	B-X
in	B-X
decision	B-X
making	B-X
,	B-X
especially	B-X
with	B-X
regard	B-X
to	B-X
important	B-X
resource-related	B-X
decisions	B-X
,	B-X
and	B-X
in	B-X
organizational	B-X
governance	B-X
.	B-X

The	O
book	O
Therapeutic	O
Choices	O
[	O
53	O
]	O
ranked	O
third	O
for	O
NPs	O
.	O

Based	O
on	O
written	O
feedback	O
,	O
physicians	O
and	O
NPs	O
consulted	O
pharmacists	O
and	O
other	O
physicians	O
most	O
frequently	O
.	O

The	O
CPS	O
and	O
pharmacists	O
were	O
also	O
ranked	O
as	O
the	O
top	O
two	O
resources	O
overall	O
in	O
terms	O
of	O
usefulness	O
,	O
accessibility	O
,	O
credibility	O
,	O
and	O
current	O
/	O
timeliness	O
for	O
physicians	O
.	O

Rankings	O
by	O
NPs	O
were	O
similar	O
for	O
usefulness	O
,	O
accessibility	O
,	O
and	O
credibility	O
.	O

NPs	O
ranked	O
pharmacists	O
,	O
Therapeutic	O
Choices	O
,	O
and	O
academic	O
detailing	O
first	O
and	O
the	O
CPS	O
as	O
second	O
for	O
current	O
/	O
timeliness	O
.	O

Within	O
the	O
online	O
/	O
electronic	O
category	O
,	O
electronic	O
clinical	O
practice	O
guidelines	O
(	O
eCPGs	O
)	O
were	O
rated	O
the	O
highest	O
for	O
all	O
characteristics	O
(	O
e	O
.	O
g	O
.	O
usefulness	O
,	O
credibility	O
)	O
.	O

Although	O
eCPGs	O
were	O
highly	O
ranked	O
,	O
approximately	O
30	O
%	O
of	O
the	O
sample	O
reported	O
not	O
using	O
this	O
resource	O
.	O

Other	O
resources	O
in	O
this	O
category	O
were	O
infrequently	O
used	O
based	O
on	O
respondents	O
'	O
self	O
-	O
reports	O
.	O

Pharmaceutical	O
industry	O
representatives	O
were	O
used	O
as	O
a	O
source	O
of	O
drug	O
information	O
by	O
85	O
%	O
and	O
86	O
%	O
of	O
physicians	O
and	O
NPs	O
,	O
respectively	O
(	O
Table	O
5	O
)	O
.	O

This	O
was	O
higher	O
than	O
regional	O
drug	O
information	O
services	O
(	O
used	O
by	O
23	O
%	O
of	O
physicians	O
and	O
50	O
%	O
of	O
NPs	O
)	O
.	O

After	O
exclusion	O
of	O
traditional	O
health	O
professionals	O
(	O
i	O
.	O
e	O
.	O
physicians	O
,	O
nurses	O
,	O
pharmacists	O
,	O
allied	O
health	O
)	O
in	O
the	O
health	O
professionals	O
and	O
other	O
category	O
,	O
pharmaceutical	O
industry	O
representatives	O
received	O
rankings	O
for	O
second	O
or	O
third	O
for	O
frequency	O
of	O
use	O
,	O
usefulness	O
,	O
accessibility	O
,	O
credibility	O
,	O
and	O
current	O
/	O
timeliness	O
,	O
based	O
on	O
means	O
and	O
number	O
of	O
respondents	O
using	O
this	O
resource	O
(	O
data	O
not	O
shown	O
)	O
.	O

Differences	O
between	O
nurse	O
practitioners	O
and	O
physicians	O
<EOS>	B-X
To	B-X
examine	B-X
whether	B-X
nurse	B-X
practitioner	B-X
(	B-X
NP	B-X
)	B-X
-assigned	B-X
patients	B-X
exhibited	B-X
differences	B-X
in	B-X
utilization	B-X
,	B-X
costs	B-X
,	B-X
and	B-X
clinical	B-X
outcomes	B-X
compared	B-X
to	B-X
medical	B-X
doctor	B-X
(	B-X
MD	B-X
)	B-X
-assigned	B-X
patients	B-X
.	B-X
In	B-X
the	B-X
United	B-X
States	B-X
health	B-X
care	B-X
system	B-X
,	B-X
nurse	B-X
practitioners	B-X
(	B-X
NPs	B-X
)	B-X
and	B-X
physicians	B-X
work	B-X
very	B-X
closely	B-X
in	B-X
the	B-X
delivery	B-X
of	B-X
high-quality	B-X
patient	B-X
care	B-X
across	B-X
lifespans	B-X
and	B-X
acuities	B-X
.	B-X
In	B-X
fact	B-X
,	B-X
advanced	B-X
practice	B-X
nurses	B-X
work	B-X
closer	B-X
with	B-X
physicians	B-X
in	B-X
their	B-X
day-to-day	B-X
care	B-X
delivery	B-X
than	B-X
with	B-X
any	B-X
other	B-X
group	B-X
of	B-X
professionals	B-X
.	B-X
Because	B-X
of	B-X
the	B-X
significant	B-X
relationships	B-X
between	B-X
physicians	B-X
and	B-X
NPs	B-X
,	B-X
assessment	B-X
of	B-X
how	B-X
these	B-X
professionals	B-X
resolve	B-X
conflict	B-X
is	B-X
essential	B-X
.	B-X

A	O
series	O
of	O
Mann	O
Whitney	O
U	O
tests	O
were	O
used	O
to	O
compare	O
the	O
responses	O
of	O
NPs	O
and	O
physicians	O
on	O
their	O
use	O
of	O
print	O
,	O
online	O
/	O
electronic	O
,	O
and	O
health	O
professional	O
resources	O
.	O

In	O
total	O
95	O
statistical	O
tests	O
were	O
conducted	O
.	O
<EOS>	B-X
Excessive	B-X
screen	B-X
time	B-X
is	B-X
associated	B-X
with	B-X
delays	B-X
in	B-X
development	B-X
;	B-X
however	B-X
,	B-X
it	B-X
is	B-X
unclear	B-X
if	B-X
greater	B-X
screen	B-X
time	B-X
predicts	B-X
lower	B-X
performance	B-X
scores	B-X
on	B-X
developmental	B-X
screening	B-X
tests	B-X
or	B-X
if	B-X
children	B-X
with	B-X
poor	B-X
developmental	B-X
performance	B-X
receive	B-X
added	B-X
screen	B-X
time	B-X
as	B-X
a	B-X
way	B-X
to	B-X
modulate	B-X
challenging	B-X
behavior	B-X
.	B-X
No	B-X
comprehensive	B-X
study	B-X
has	B-X
been	B-X
conducted	B-X
to	B-X
collect	B-X
all	B-X
the	B-X
evidence	B-X
to	B-X
provide	B-X
estimates	B-X
of	B-X
psychological	B-X
and	B-X
social	B-X
risk	B-X
factors	B-X
in	B-X
China	B-X
.	B-X
Inter-rater	B-X
reliability	B-X
for	B-X
total	B-X
score	B-X
on	B-X
the	B-X
rating	B-X
scale	B-X
was	B-X
0.93	B-X
,	B-X
and	B-X
mean	B-X
agreement	B-X
of	B-X
items	B-X
was	B-X
88.2	B-X
%	B-X
(	B-X
SD	B-X
9.9	B-X
)	B-X
.	B-X
Inter-rater	B-X
reliability	B-X
for	B-X
total	B-X
score	B-X
on	B-X
the	B-X
screening	B-X
instrument	B-X
was	B-X
0.95	B-X
,	B-X
and	B-X
mean	B-X
agreement	B-X
of	B-X
items	B-X
was	B-X
92.7	B-X
%	B-X
(	B-X
SD	B-X
4.9	B-X
)	B-X
.	B-X

The	O
large	O
number	O
of	O
tests	O
increases	O
the	O
likelihood	O
of	O
a	O
type	O
I	O
error	O
as	O
five	O
significant	O
differences	O
would	O
be	O
expected	O
by	O
chance	O
alone	O
at	O
an	O
alpha	O
threshold	O
of	O
0	O
.	O
05	O
.	O

It	O
is	O
therefore	O
important	O
to	O
treat	O
these	O
results	O
with	O
caution	O
.	O
<EOS>	B-X
For	B-X
many	B-X
years	B-X
,	B-X
nutritional	B-X
intervention	B-X
studies	B-X
have	B-X
been	B-X
focused	B-X
on	B-X
reducing	B-X
dietary	B-X
fat	B-X
with	B-X
little	B-X
positive	B-X
results	B-X
over	B-X
the	B-X
long-term	B-X
.	B-X
This	B-X
review	B-X
discusses	B-X
the	B-X
physiological	B-X
basis	B-X
of	B-X
ketogenic	B-X
diets	B-X
and	B-X
the	B-X
rationale	B-X
for	B-X
their	B-X
use	B-X
in	B-X
obesity	B-X
,	B-X
discussing	B-X
the	B-X
strengths	B-X
and	B-X
the	B-X
weaknesses	B-X
of	B-X
these	B-X
diets	B-X
together	B-X
with	B-X
cautions	B-X
that	B-X
should	B-X
be	B-X
used	B-X
in	B-X
obese	B-X
patients	B-X
.	B-X
A	B-X
single	B-X
or	B-X
brief	B-X
series	B-X
of	B-X
sessions	B-X
often	B-X
results	B-X
in	B-X
substantial	B-X
and	B-X
sustained	B-X
improvement	B-X
among	B-X
people	B-X
with	B-X
treatment-resistant	B-X
depression	B-X
and	B-X
anxiety	B-X
,	B-X
including	B-X
those	B-X
with	B-X
serious	B-X
medical	B-X
conditions	B-X
.	B-X
Need	B-X
and	B-X
Clinical	B-X
Considerations	B-X
:	B-X
Palliative	B-X
care	B-X
clinicians	B-X
occasionally	B-X
encounter	B-X
patients	B-X
with	B-X
emotional	B-X
,	B-X
existential	B-X
,	B-X
or	B-X
spiritual	B-X
suffering	B-X
,	B-X
which	B-X
persists	B-X
despite	B-X
optimal	B-X
existing	B-X
treatments	B-X
.	B-X
Clinical	B-X
cautions	B-X
,	B-X
adverse	B-X
reactions	B-X
,	B-X
and	B-X
important	B-X
steps	B-X
related	B-X
to	B-X
safe	B-X
administration	B-X
of	B-X
psychedelics	B-X
are	B-X
presented	B-X
,	B-X
emphasizing	B-X
careful	B-X
patient	B-X
screening	B-X
,	B-X
preparation	B-X
,	B-X
setting	B-X
and	B-X
supervision	B-X
.	B-X

A	O
limited	O
number	O
of	O
statistically	O
significant	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
differences	O
were	O
identified	O
between	O
physicians	O
and	O
NPs	O
and	O
are	O
reported	O
in	O
Table	O
6	O
.	O

Therapeutic	O
Choices	O
differed	O
significantly	O
for	O
frequency	O
of	O
use	O
with	O
more	O
NPs	O
making	O
use	O
of	O
this	O
resource	O
.	O

Allied	O
health	O
professionals	O
significantly	O
differed	O
between	O
NPs	O
and	O
physicians	O
for	O
accessibility	O
and	O
current	O
/	O
timeliness	O
while	O
NPs	O
were	O
more	O
in	O
agreement	O
with	O
these	O
characteristics	O
of	O
the	O
resource	O
.	O

Nurse	O
colleague	O
credibility	O
and	O
current	O
/	O
timeliness	O
was	O
rated	O
significantly	O
higher	O
by	O
NPs	O
versus	O
physicians	O
.	O

Factors	O
influencing	O
electronic	O
technology	O
use	O
at	O
the	O
point	O
of	O
care	O
<EOS>	B-X
Health	B-X
care	B-X
leaders	B-X
have	B-X
recommended	B-X
the	B-X
use	B-X
of	B-X
health	B-X
information	B-X
technology	B-X
to	B-X
improve	B-X
the	B-X
quality	B-X
of	B-X
patient	B-X
care	B-X
.	B-X
In	B-X
athletic	B-X
training	B-X
,	B-X
using	B-X
informatics	B-X
,	B-X
such	B-X
as	B-X
electronic	B-X
medical	B-X
records	B-X
(	B-X
EMRs	B-X
)	B-X
,	B-X
would	B-X
support	B-X
practice-based	B-X
decisions	B-X
about	B-X
patient	B-X
care	B-X
.	B-X
However	B-X
,	B-X
athletic	B-X
trainers	B-X
(	B-X
ATs	B-X
)	B-X
may	B-X
lack	B-X
the	B-X
knowledge	B-X
to	B-X
effectively	B-X
participate	B-X
in	B-X
point-of-care	B-X
clinical	B-X
research	B-X
using	B-X
EMRs	B-X
.	B-X
Targeted	B-X
therapy	B-X
of	B-X
treating	B-X
patients	B-X
with	B-X
specific	B-X
tyrosine	B-X
kinase	B-X
inhibitors	B-X
(	B-X
TKIs	B-X
)	B-X
is	B-X
currently	B-X
the	B-X
standard	B-X
care	B-X
for	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
(	B-X
EGFR	B-X
)	B-X
mutant	B-X
non-small	B-X
cell	B-X
lung	B-X
cancer	B-X
.	B-X
Proteolysis	B-X
targeting	B-X
chimera	B-X
(	B-X
PROTAC	B-X
)	B-X
is	B-X
a	B-X
lately-developed	B-X
technology	B-X
to	B-X
target	B-X
point	B-X
of	B-X
interest	B-X
proteins	B-X
for	B-X
degradation	B-X
.	B-X
Because	B-X
EGFR-mutant	B-X
lung	B-X
cancers	B-X
are	B-X
highly	B-X
dependent	B-X
on	B-X
EGFR	B-X
proteins	B-X
,	B-X
designing	B-X
specific	B-X
PROTAC	B-X
molecules	B-X
to	B-X
degrade	B-X
EGFR	B-X
proteins	B-X
from	B-X
cancer	B-X
cells	B-X
provides	B-X
a	B-X
very	B-X
promising	B-X
strategy	B-X
to	B-X
treat	B-X
such	B-X
patients	B-X
and	B-X
eradicate	B-X
drug	B-X
resistance	B-X
.	B-X

Factors	O
such	O
as	O
gender	O
,	O
age	O
,	O
practitioner	O
type	O
(	O
NP	O
vs	O
physician	O
)	O
,	O
accessibility	O
,	O
technical	O
support	O
,	O
Internet	O
connection	O
speed	O
,	O
patient	B-Species
volume	O
,	O
presence	O
of	O
an	O
EPR	O
,	O
and	O
home	O
computer	O
use	O
were	O
examined	O
to	O
determine	O
if	O
they	O
were	O
associated	O
with	O
the	O
use	O
of	O
a	O
work	O
computer	O
to	O
search	O
for	O
drug	O
information	O
at	O
the	O
point	O
of	O
care	O
.	O

No	O
statistically	O
significant	O
associations	O
were	O
found	O
(	O
Fisher	O
'	O
s	O
Exact	O
)	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
tested	B-X
17	B-X
of	B-X
the	B-X
most	B-X
significantly	B-X
associated	B-X
single	B-X
nucleotide	B-X
polymorphisms	B-X
(	B-X
SNPs	B-X
)	B-X
from	B-X
these	B-X
GWAS	B-X
studies	B-X
(	B-X
P	B-X
<	B-X
10	B-X
(	B-X
-6	B-X
)	B-X
in	B-X
the	B-X
original	B-X
studies	B-X
)	B-X
in	B-X
a	B-X
new	B-X
independent	B-X
population	B-X
dataset	B-X
from	B-X
the	B-X
Netherlands	B-X
:	B-X
known	B-X
as	B-X
Familial	B-X
Influences	B-X
on	B-X
Literacy	B-X
Abilities	B-X
.	B-X
Two	B-X
SNPs	B-X
(	B-X
rs12636438	B-X
and	B-X
rs7187223	B-X
)	B-X
were	B-X
associated	B-X
with	B-X
performance	B-X
in	B-X
multivariate	B-X
and	B-X
univariate	B-X
testing	B-X
,	B-X
but	B-X
these	B-X
did	B-X
not	B-X
remain	B-X
significant	B-X
after	B-X
correction	B-X
for	B-X
multiple	B-X
testing	B-X
.	B-X
Alternatively	B-X
,	B-X
most	B-X
of	B-X
the	B-X
prior	B-X
reported	B-X
associations	B-X
may	B-X
have	B-X
been	B-X
false	B-X
positives	B-X
.	B-X

Additional	O
resources	O
from	O
respondent	O
comments	O
<EOS>	B-X
ALPHA	B-X
form	B-X
:	B-X
additional	B-X
resources	B-X
.	B-X
In	B-X
most	B-X
countries	B-X
,	B-X
the	B-X
allocation	B-X
of	B-X
financial	B-X
resources	B-X
for	B-X
cancer	B-X
prevention	B-X
,	B-X
early	B-X
detection	B-X
,	B-X
and	B-X
treatment	B-X
come	B-X
from	B-X
different	B-X
nonrelated	B-X
``	B-X
silos	B-X
.	B-X
''	B-X
We	B-X
found	B-X
that	B-X
dietary	B-X
guidelines	B-X
commonly	B-X
advocate	B-X
the	B-X
consumption	B-X
of	B-X
yoghurt	B-X
or	B-X
similar	B-X
products	B-X
,	B-X
but	B-X
specific	B-X
comments	B-X
on	B-X
probiotics	B-X
are	B-X
rare	B-X
.	B-X
Additional	B-X
research	B-X
to	B-X
support	B-X
future	B-X
dietary	B-X
recommendations	B-X
should	B-X
focus	B-X
on	B-X
determining	B-X
effect	B-X
size	B-X
,	B-X
identifying	B-X
responders	B-X
and	B-X
non-responders	B-X
,	B-X
clarifying	B-X
strain-specificity	B-X
of	B-X
effects	B-X
and	B-X
confirming	B-X
mechanisms	B-X
.	B-X

Respondents	O
indicated	O
other	O
resources	O
and	O
programs	O
,	O
such	O
as	O
clinical	O
calculators	O
,	O
that	O
they	O
would	O
like	O
to	O
access	O
from	O
their	O
computer	O
or	O
PDA	O
.	O
<EOS>	B-X
The	B-X
ductus	B-X
arteriosus	B-X
is	B-X
likely	B-X
to	B-X
close	B-X
without	B-X
treatment	B-X
in	B-X
most	B-X
infants	B-X
born	B-X
at	B-X
gestational	B-X
age	B-X
(	B-X
GA	B-X
)	B-X
>	B-X
28	B-X
weeks	B-X
(	B-X
73	B-X
%	B-X
)	B-X
,	B-X
and	B-X
those	B-X
with	B-X
birth	B-X
weight	B-X
>	B-X
1000	B-X
g	B-X
(	B-X
94	B-X
%	B-X
)	B-X
.	B-X
These	B-X
serious	B-X
hemorrhagic	B-X
complications	B-X
may	B-X
be	B-X
closely	B-X
related	B-X
to	B-X
hemodynamic	B-X
changes	B-X
caused	B-X
by	B-X
a	B-X
hemodynamically	B-X
significant	B-X
patent	B-X
ductus	B-X
arteriosus	B-X
(	B-X
hs-PDA	B-X
)	B-X
.	B-X
While	B-X
prophylactic	B-X
indomethacin	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
reduce	B-X
the	B-X
rates	B-X
of	B-X
PDA	B-X
,	B-X
PDA	B-X
ligation	B-X
,	B-X
severe	B-X
IVH	B-X
and	B-X
early	B-X
pulmonary	B-X
hemorrhage	B-X
,	B-X
the	B-X
available	B-X
evidence	B-X
does	B-X
not	B-X
support	B-X
its	B-X
prophylactic	B-X
use	B-X
in	B-X
preterm	B-X
infants	B-X
.	B-X
Symptomatic	B-X
or	B-X
late	B-X
treatment	B-X
is	B-X
associated	B-X
with	B-X
lower	B-X
success	B-X
rate	B-X
,	B-X
and	B-X
increased	B-X
complications	B-X
of	B-X
a	B-X
hs-PDA	B-X
.	B-X
The	B-X
issue	B-X
of	B-X
``	B-X
to	B-X
treat	B-X
or	B-X
not	B-X
to	B-X
treat	B-X
a	B-X
PDA	B-X
''	B-X
is	B-X
controversial	B-X
.	B-X
Considering	B-X
the	B-X
relationship	B-X
between	B-X
the	B-X
effectiveness	B-X
and	B-X
timing	B-X
of	B-X
pharmacological	B-X
treatment	B-X
,	B-X
early	B-X
targeted	B-X
treatment	B-X
may	B-X
be	B-X
an	B-X
alternative	B-X
approach	B-X
for	B-X
the	B-X
early	B-X
identification	B-X
of	B-X
a	B-X
hs-PDA	B-X
in	B-X
specific	B-X
high-risk	B-X
patient	B-X
population	B-X
,	B-X
especially	B-X
infants	B-X
<	B-X
26	B-X
weeks	B-X
GA	B-X
who	B-X
are	B-X
at	B-X
the	B-X
highest	B-X
risk	B-X
of	B-X
severe	B-X
IVH	B-X
or	B-X
pulmonary	B-X
hemorrhage	B-X
.	B-X
Serial	B-X
echocardiographic	B-X
studies	B-X
can	B-X
be	B-X
used	B-X
to	B-X
select	B-X
patients	B-X
who	B-X
are	B-X
candidates	B-X
for	B-X
early	B-X
targeted	B-X
medical	B-X
treatment	B-X
of	B-X
hs-PDA	B-X
.	B-X
Surgical	B-X
ligation	B-X
of	B-X
PDA	B-X
,	B-X
and	B-X
transcatheter	B-X
closure	B-X
if	B-X
proven	B-X
to	B-X
be	B-X
safe	B-X
,	B-X
can	B-X
be	B-X
used	B-X
as	B-X
back-up	B-X
therapy	B-X
for	B-X
patients	B-X
who	B-X
fail	B-X
medical	B-X
treatment	B-X
and	B-X
continue	B-X
to	B-X
have	B-X
cardiopulmonary	B-X
compromise	B-X
.	B-X

The	O
top	O
three	O
resources	O
that	O
were	O
desired	O
included	O
Canadian	O
clinical	O
practice	O
guidelines	O
,	O
patient	B-Species
education	O
information	O
,	O
and	O
ability	O
to	O
track	O
clinical	O
activities	O
/	O
statistics	O
.	O

Further	O
comments	O
from	O
two	O
NP	O
computer	O
survey	O
respondents	O
revealed	O
that	O
a	O
resource	O
on	O
drug	O
interactions	O
and	O
dosages	O
would	O
be	O
desired	O
.	O

One	O
other	O
NP	O
also	O
indicated	O
"	O
up	O
to	O
date	O
info	O
[	O
sic	O
]	O
on	O
drugs	O
to	O
treat	O
various	O
illnesses	O
ie	O
doseage	O
[	O
sic	O
]	O
,	O
length	O
of	O
use	O
etc	O
.	O
"	O

Computer	O
or	O
personal	O
digital	O
assistant	O
use	O
in	O
practice	O
<EOS>	B-X
As	B-X
the	B-X
use	B-X
of	B-X
personal	B-X
digital	B-X
assistants	B-X
(	B-X
PDAs	B-X
)	B-X
grows	B-X
,	B-X
the	B-X
value	B-X
of	B-X
reflection	B-X
of	B-X
learning	B-X
and	B-X
practice	B-X
draws	B-X
increased	B-X
attention	B-X
from	B-X
policymakers	B-X
and	B-X
evaluators	B-X
.	B-X
To	B-X
learn	B-X
more	B-X
about	B-X
the	B-X
use	B-X
of	B-X
PDAs	B-X
in	B-X
practice	B-X
and	B-X
learning	B-X
,	B-X
the	B-X
present	B-X
study	B-X
describes	B-X
use	B-X
of	B-X
(	B-X
1	B-X
)	B-X
PDAs	B-X
in	B-X
patient	B-X
care	B-X
and	B-X
(	B-X
2	B-X
)	B-X
a	B-X
PDA	B-X
version	B-X
of	B-X
the	B-X
Virginia	B-X
Board	B-X
of	B-X
Medicine	B-X
Continuing	B-X
Competency	B-X
and	B-X
Assessment	B-X
Form	B-X
(	B-X
CCAF	B-X
)	B-X
,	B-X
a	B-X
learning	B-X
portfolio	B-X
intended	B-X
to	B-X
encourage	B-X
documentation	B-X
of	B-X
reflection	B-X
on	B-X
practice	B-X
and	B-X
medical	B-X
education	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
describe	B-X
one	B-X
nurse	B-X
's	B-X
experience	B-X
of	B-X
using	B-X
a	B-X
personal	B-X
digital	B-X
assistant	B-X
(	B-X
PDA	B-X
)	B-X
in	B-X
nursing	B-X
practice	B-X
.	B-X
Molecular	B-X
computing	B-X
is	B-X
a	B-X
branch	B-X
of	B-X
computing	B-X
that	B-X
uses	B-X
DNA	B-X
,	B-X
biochemistry	B-X
,	B-X
and	B-X
molecular	B-X
biology	B-X
hardware	B-X
,	B-X
instead	B-X
of	B-X
traditional	B-X
silicon-based	B-X
computer	B-X
technologies	B-X
.	B-X

Approximately	O
50	O
%	O
of	O
computer	O
survey	O
respondents	O
reported	O
using	O
their	O
work	O
computers	O
for	O
searching	O
drug	O
or	O
therapeutic	O
information	O
related	O
to	O
patient	B-Species
care	O
.	O
<EOS>	B-X
Hospice	B-X
care	B-X
adds	B-X
to	B-X
the	B-X
quality	B-X
of	B-X
care	B-X
and	B-X
these	B-X
patient-centered	B-X
priorities	B-X
for	B-X
people	B-X
with	B-X
cancer	B-X
and	B-X
their	B-X
families	B-X
in	B-X
the	B-X
last	B-X
weeks	B-X
and	B-X
days	B-X
of	B-X
life	B-X
.	B-X
Evidence	B-X
from	B-X
large	B-X
observational	B-X
studies	B-X
demonstrate	B-X
that	B-X
hospice	B-X
care	B-X
can	B-X
improve	B-X
outcomes	B-X
directly	B-X
and	B-X
support	B-X
better	B-X
and	B-X
more	B-X
appropriate	B-X
health	B-X
care	B-X
use	B-X
for	B-X
people	B-X
in	B-X
the	B-X
last	B-X
stages	B-X
of	B-X
cancer.Team-based	B-X
community	B-X
hospice	B-X
care	B-X
has	B-X
measurable	B-X
benefits	B-X
for	B-X
patients	B-X
,	B-X
their	B-X
family	B-X
caregivers	B-X
,	B-X
and	B-X
health	B-X
services	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
improved	B-X
symptom	B-X
control	B-X
for	B-X
patients	B-X
and	B-X
a	B-X
greater	B-X
likelihood	B-X
of	B-X
time	B-X
spent	B-X
at	B-X
home	B-X
,	B-X
caregiver	B-X
outcomes	B-X
are	B-X
better	B-X
when	B-X
hospice	B-X
care	B-X
is	B-X
accessed	B-X
:	B-X
informational	B-X
needs	B-X
are	B-X
better	B-X
met	B-X
,	B-X
and	B-X
caregivers	B-X
have	B-X
an	B-X
improved	B-X
ability	B-X
to	B-X
move	B-X
on	B-X
with	B-X
life	B-X
after	B-X
the	B-X
patient	B-X
's	B-X
death	B-X
compared	B-X
with	B-X
people	B-X
who	B-X
did	B-X
not	B-X
have	B-X
access	B-X
to	B-X
these	B-X
services.Hospice	B-X
care	B-X
continues	B-X
to	B-X
evolve	B-X
as	B-X
its	B-X
reach	B-X
expands	B-X
and	B-X
the	B-X
needs	B-X
of	B-X
patients	B-X
continue	B-X
to	B-X
broaden	B-X
.	B-X
This	B-X
is	B-X
reflected	B-X
in	B-X
the	B-X
transition	B-X
from	B-X
hospice	B-X
being	B-X
based	B-X
on	B-X
excellence	B-X
in	B-X
nursing	B-X
to	B-X
teams	B-X
with	B-X
a	B-X
broad	B-X
range	B-X
of	B-X
health	B-X
professionals	B-X
to	B-X
meet	B-X
the	B-X
complex	B-X
and	B-X
changing	B-X
needs	B-X
of	B-X
patients	B-X
and	B-X
their	B-X
families	B-X
.	B-X
Additional	B-X
integration	B-X
of	B-X
cancer	B-X
services	B-X
with	B-X
hospice	B-X
care	B-X
will	B-X
help	B-X
to	B-X
provide	B-X
more	B-X
seamless	B-X
care	B-X
for	B-X
patients	B-X
and	B-X
supporting	B-X
family	B-X
caregivers	B-X
during	B-X
their	B-X
caregiving	B-X
and	B-X
after	B-X
the	B-X
death	B-X
of	B-X
the	B-X
patient	B-X
.	B-X

Of	O
those	O
respondents	O
,	O
just	O
over	O
half	O
(	O
54	O
%	O
)	O
also	O
reported	O
using	O
their	O
home	O
computer	O
for	O
this	O
purpose	O
.	O

Sixty	O
-	O
seven	O
and	O
17	O
%	O
of	O
PDA	O
survey	O
respondents	O
reported	O
using	O
their	O
PDA	O
for	O
searching	O
drug	O
or	O
therapeutic	O
information	O
related	O
to	O
patient	B-Species
care	O
at	O
work	O
and	O
home	O
,	O
respectively	O
.	O
<EOS>	B-X
Pressure	B-X
ulcers	B-X
can	B-X
be	B-X
painful	B-X
and	B-X
negatively	B-X
affect	B-X
health-related	B-X
quality	B-X
of	B-X
life	B-X
and	B-X
healthcare	B-X
costs	B-X
.	B-X
Many	B-X
people	B-X
living	B-X
in	B-X
nursing	B-X
homes	B-X
are	B-X
at	B-X
risk	B-X
of	B-X
developing	B-X
a	B-X
pressure	B-X
ulcer	B-X
.	B-X
Nursing	B-X
home	B-X
staff	B-X
,	B-X
tissue	B-X
viability	B-X
nurses	B-X
and	B-X
researchers	B-X
have	B-X
co-designed	B-X
the	B-X
first	B-X
theory	B-X
and	B-X
evidence-informed	B-X
care	B-X
bundle	B-X
specifically	B-X
for	B-X
nursing	B-X
homes	B-X
,	B-X
which	B-X
consists	B-X
of	B-X
three	B-X
prevention	B-X
practices	B-X
(	B-X
skin	B-X
inspection	B-X
,	B-X
support	B-X
surfaces	B-X
,	B-X
repositioning	B-X
)	B-X
and	B-X
a	B-X
range	B-X
of	B-X
behaviour	B-X
change	B-X
techniques	B-X
to	B-X
promote	B-X
these	B-X
practices	B-X
.	B-X
We	B-X
conducted	B-X
a	B-X
mixed	B-X
methods	B-X
feasibility	B-X
study	B-X
of	B-X
the	B-X
use	B-X
of	B-X
this	B-X
care	B-X
bundle	B-X
in	B-X
one	B-X
nursing	B-X
home	B-X
in	B-X
the	B-X
North	B-X
of	B-X
England	B-X
using	B-X
an	B-X
uncontrolled	B-X
,	B-X
before-and-after	B-X
study	B-X
design	B-X
.	B-X
We	B-X
collected	B-X
quantitative	B-X
data	B-X
on	B-X
pressure	B-X
ulcer	B-X
prevention	B-X
behaviours	B-X
of	B-X
the	B-X
nursing	B-X
home	B-X
staff	B-X
and	B-X
pressure	B-X
ulcer	B-X
incidence	B-X
rates	B-X
for	B-X
5	B-X
weeks	B-X
prior	B-X
to	B-X
implementing	B-X
the	B-X
bundle	B-X
.	B-X
We	B-X
explored	B-X
adherence	B-X
to	B-X
the	B-X
bundle	B-X
and	B-X
participants	B-X
'	B-X
experiences	B-X
of	B-X
using	B-X
it	B-X
.	B-X
The	B-X
Conceptual	B-X
Framework	B-X
for	B-X
Implementation	B-X
Fidelity	B-X
and	B-X
the	B-X
Theoretical	B-X
Domains	B-X
Framework	B-X
informed	B-X
the	B-X
semi-structured	B-X
interviews	B-X
.	B-X
Quantitative	B-X
and	B-X
qualitative	B-X
data	B-X
were	B-X
analysed	B-X
using	B-X
descriptive	B-X
statistics	B-X
and	B-X
deductive	B-X
framework	B-X
analysis	B-X
respectively	B-X
.	B-X
Participants	B-X
reported	B-X
that	B-X
the	B-X
bundle	B-X
enhanced	B-X
the	B-X
care	B-X
they	B-X
delivered	B-X
and	B-X
offered	B-X
suggestions	B-X
for	B-X
future	B-X
improvements	B-X
.	B-X
A	B-X
pressure	B-X
ulcer	B-X
prevention	B-X
bundle	B-X
specifically	B-X
designed	B-X
for	B-X
nursing	B-X
homes	B-X
was	B-X
acceptable	B-X
.	B-X
The	B-X
feasibility	B-X
work	B-X
has	B-X
highlighted	B-X
the	B-X
potential	B-X
for	B-X
the	B-X
intervention	B-X
and	B-X
the	B-X
areas	B-X
that	B-X
require	B-X
development	B-X
and	B-X
refinement	B-X
.	B-X

Searching	O
on	O
a	O
weekly	O
basis	O
for	O
specific	O
information	O
related	O
to	O
drugs	O

Of	O
the	O
24	O
specified	O
categories	O
of	O
drug	O
information	O
included	O
in	O
the	O
survey	O
,	O
the	O
majority	O
were	O
reported	O
as	O
infrequently	O
searched	O
and	O
a	O
smaller	O
percentage	O
as	O
never	O
searched	O
by	O
respondents	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
top	O
three	O
categories	O
rated	O
as	O
frequently	O
searched	O
were	O
side	O
effects	O
,	O
adult	O
or	O
usual	O
drug	O
dosage	O
,	O
and	O
most	O
appropriate	O
drug	O
for	O
an	O
indication	O
.	O
<EOS>	B-X
Chloroquine	B-X
(	B-X
CQ	B-X
)	B-X
and	B-X
hydroxychloroquine	B-X
(	B-X
HCQ	B-X
)	B-X
have	B-X
been	B-X
largely	B-X
adopted	B-X
in	B-X
the	B-X
clinical	B-X
setting	B-X
for	B-X
the	B-X
management	B-X
of	B-X
SARS-CoV-2	B-X
infection	B-X
;	B-X
however	B-X
,	B-X
their	B-X
known	B-X
retinal	B-X
toxicity	B-X
has	B-X
raised	B-X
some	B-X
safety	B-X
concerns	B-X
,	B-X
especially	B-X
considering	B-X
the	B-X
higher-dosage	B-X
employed	B-X
for	B-X
COVID-19	B-X
patients	B-X
as	B-X
compared	B-X
with	B-X
their	B-X
suggested	B-X
posology	B-X
for	B-X
their	B-X
usual	B-X
indications	B-X
,	B-X
including	B-X
systemic	B-X
lupus	B-X
erythematosus	B-X
and	B-X
other	B-X
rheumatic	B-X
diseases	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
will	B-X
discuss	B-X
the	B-X
optimal	B-X
dosages	B-X
recommended	B-X
for	B-X
COVID-19	B-X
patients	B-X
when	B-X
treated	B-X
with	B-X
HCQ	B-X
and	B-X
CQ	B-X
.	B-X
These	B-X
products	B-X
for	B-X
these	B-X
indications	B-X
,	B-X
however	B-X
,	B-X
are	B-X
deemed	B-X
human	B-X
cells	B-X
,	B-X
tissues	B-X
,	B-X
or	B-X
cellular	B-X
or	B-X
tissue-based	B-X
products	B-X
(	B-X
otherwise	B-X
known	B-X
as	B-X
HCTPs	B-X
)	B-X
in	B-X
the	B-X
``	B-X
351	B-X
''	B-X
category	B-X
,	B-X
meaning	B-X
that	B-X
they	B-X
need	B-X
to	B-X
have	B-X
a	B-X
biologic	B-X
license	B-X
to	B-X
be	B-X
marketed	B-X
and	B-X
sold	B-X
in	B-X
the	B-X
United	B-X
States	B-X
,	B-X
and	B-X
to	B-X
gain	B-X
this	B-X
license	B-X
,	B-X
one	B-X
needs	B-X
to	B-X
go	B-X
through	B-X
the	B-X
usual	B-X
rigor	B-X
of	B-X
investigational	B-X
new	B-X
drug	B-X
filing	B-X
and	B-X
phase	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
trials	B-X
to	B-X
prove	B-X
safety	B-X
and	B-X
efficacy	B-X
.	B-X
Appropriate	B-X
caution	B-X
by	B-X
the	B-X
Food	B-X
and	B-X
Drug	B-X
Administration	B-X
in	B-X
granting	B-X
licenses	B-X
for	B-X
these	B-X
indications	B-X
should	B-X
not	B-X
dissuade	B-X
basic	B-X
scientists	B-X
and	B-X
physicians	B-X
from	B-X
pursuing	B-X
further	B-X
research	B-X
into	B-X
these	B-X
interesting	B-X
products	B-X
.	B-X

(	O
Table	O
7	O
)	O
<EOS>	B-X
As	B-X
demonstrated	B-X
by	B-X
the	B-X
data	B-X
in	B-X
Tables	B-X
2	B-X
and	B-X
3	B-X
,	B-X
high-fidelity	B-X
DNA	B-X
amplification	B-X
will	B-X
be	B-X
best	B-X
achieved	B-X
by	B-X
using	B-X
a	B-X
polymerase	B-X
with	B-X
an	B-X
active	B-X
3	B-X
'	B-X
--	B-X
>	B-X
5	B-X
'	B-X
proofreading	B-X
exonuclease	B-X
activity	B-X
(	B-X
Fig	B-X
.	B-X
To	B-X
perform	B-X
high-fidelity	B-X
PCR	B-X
with	B-X
Taq	B-X
polymerase	B-X
,	B-X
reactions	B-X
should	B-X
contain	B-X
a	B-X
low	B-X
MgCl2	B-X
concentration	B-X
,	B-X
not	B-X
in	B-X
large	B-X
excess	B-X
over	B-X
the	B-X
total	B-X
concentration	B-X
of	B-X
dNTP	B-X
substrates	B-X
,	B-X
and	B-X
be	B-X
buffered	B-X
to	B-X
approximately	B-X
pH	B-X
6	B-X
(	B-X
70	B-X
degrees	B-X
C	B-X
)	B-X
using	B-X
Bis-Tris	B-X
Propane	B-X
or	B-X
PIPES	B-X
(	B-X
Table	B-X
2	B-X
)	B-X
.	B-X
These	B-X
buffers	B-X
have	B-X
a	B-X
pKa	B-X
between	B-X
pH	B-X
6	B-X
and	B-X
pH	B-X
7	B-X
and	B-X
a	B-X
small	B-X
temperature	B-X
coefficient	B-X
(	B-X
delta	B-X
pKa/degree	B-X
C	B-X
)	B-X
,	B-X
allowing	B-X
the	B-X
pH	B-X
to	B-X
be	B-X
maintained	B-X
stably	B-X
throughout	B-X
the	B-X
PCR	B-X
cycle	B-X
.	B-X
Table	B-X
1	B-X
,	B-X
Total	B-X
punches	B-X
,	B-X
Round	B-X
1	B-X
winners	B-X
should	B-X
be	B-X
20.7	B-X
not	B-X
2.7	B-X
,	B-X
and	B-X
Round	B-X
3	B-X
winners	B-X
should	B-X
be	B-X
20.3	B-X
not	B-X
2.3	B-X
.	B-X
Table	B-X
2	B-X
,	B-X
Air	B-X
punches	B-X
,	B-X
Round	B-X
1	B-X
winners	B-X
should	B-X
be	B-X
10.1	B-X
not	B-X
1.1	B-X
,	B-X
and	B-X
Round	B-X
3	B-X
losers	B-X
should	B-X
be	B-X
10.6	B-X
not	B-X
1.6	B-X
.	B-X
Table	B-X
2	B-X
,	B-X
Punches/min	B-X
,	B-X
Round	B-X
2	B-X
should	B-X
be	B-X
20.2	B-X
not	B-X
2.2	B-X
,	B-X
and	B-X
Round	B-X
1	B-X
losers	B-X
should	B-X
be	B-X
20.2	B-X
not	B-X
2.2	B-X
.	B-X
Table	B-X
4	B-X
,	B-X
2-punch-combinations	B-X
,	B-X
Round	B-X
2	B-X
winners	B-X
should	B-X
be	B-X
10.4	B-X
not	B-X
1.4	B-X
,	B-X
and	B-X
Round	B-X
3	B-X
winners	B-X
should	B-X
be	B-X
10.2	B-X
not	B-X
1.2	B-X
.	B-X

Issues	O
related	O
to	O
personal	O
digital	O
assistants	O
<EOS>	B-X
Mobile-	B-X
and	B-X
Internet-delivered	B-X
(	B-X
collectively	B-X
,	B-X
digital	B-X
)	B-X
interventions	B-X
are	B-X
widely	B-X
used	B-X
by	B-X
persons	B-X
with	B-X
diabetes	B-X
(	B-X
PWD	B-X
)	B-X
to	B-X
assist	B-X
with	B-X
self-management	B-X
and	B-X
improve/maintain	B-X
glycemic	B-X
control	B-X
(	B-X
hemoglobin	B-X
A1c	B-X
[	B-X
A1c	B-X
]	B-X
)	B-X
.	B-X
``	B-X
Computer	B-X
vision	B-X
syndrome	B-X
''	B-X
originally	B-X
related	B-X
to	B-X
the	B-X
few	B-X
professionals	B-X
exposed	B-X
to	B-X
long	B-X
hours	B-X
of	B-X
work	B-X
in	B-X
front	B-X
of	B-X
a	B-X
computer	B-X
screen	B-X
.	B-X
The	B-X
widespread	B-X
use	B-X
of	B-X
digital	B-X
screens	B-X
in	B-X
devices	B-X
used	B-X
throughout	B-X
the	B-X
day	B-X
have	B-X
led	B-X
to	B-X
the	B-X
emergence	B-X
of	B-X
``	B-X
digital	B-X
eye	B-X
strain	B-X
''	B-X
as	B-X
a	B-X
new	B-X
clinical	B-X
syndrome	B-X
that	B-X
affects	B-X
every	B-X
individual	B-X
who	B-X
spends	B-X
a	B-X
large	B-X
period	B-X
of	B-X
time	B-X
fixated	B-X
on	B-X
multiple	B-X
screens	B-X
,	B-X
for	B-X
work	B-X
or	B-X
leisure	B-X
.	B-X
A	B-X
new	B-X
subcategory	B-X
,	B-X
``	B-X
video	B-X
game	B-X
vision	B-X
''	B-X
has	B-X
been	B-X
proposed	B-X
to	B-X
specifically	B-X
address	B-X
vision	B-X
issues	B-X
related	B-X
to	B-X
large	B-X
periods	B-X
of	B-X
continuous	B-X
use	B-X
of	B-X
screen	B-X
enabled	B-X
devices	B-X
in	B-X
order	B-X
to	B-X
play	B-X
video	B-X
games	B-X
.	B-X
This	B-X
article	B-X
reviews	B-X
the	B-X
latest	B-X
research	B-X
studies	B-X
on	B-X
the	B-X
impact	B-X
of	B-X
digital	B-X
screen	B-X
enabled	B-X
devices	B-X
on	B-X
adolescent	B-X
vision	B-X
in	B-X
light	B-X
of	B-X
the	B-X
increasing	B-X
reports	B-X
of	B-X
internet	B-X
addiction	B-X
and	B-X
gaming	B-X
disorder	B-X
while	B-X
referencing	B-X
positive	B-X
findings	B-X
of	B-X
videogaming	B-X
on	B-X
vision	B-X
in	B-X
order	B-X
to	B-X
provide	B-X
a	B-X
balanced	B-X
approach	B-X
and	B-X
assist	B-X
with	B-X
classification	B-X
,	B-X
diagnosis	B-X
and	B-X
treatment	B-X
,	B-X
while	B-X
providing	B-X
directions	B-X
for	B-X
future	B-X
research	B-X
.	B-X

Respondents	O
reported	O
their	O
level	O
of	O
agreement	O
with	O
statements	O
related	O
to	O
how	O
PDAs	O
may	O
influence	O
their	O
practice	O
.	O

The	O
statements	O
included	O
aspects	O
of	O
workload	O
(	O
organization	O
and	O
paper	O
work	O
)	O
,	O
convenience	O
,	O
and	O
improving	O
quality	O
of	O
care	O
and	O
patient	B-Species
outcomes	O
.	O

(	O
Table	O
8	O
)	O
Respondents	O
agreed	O
that	O
PDAs	O
are	O
a	O
convenient	O
resource	O
but	O
indicated	O
that	O
PDAs	O
would	O
not	O
decrease	O
paperwork	O
or	O
improve	O
patient	B-Species
health	O
outcomes	O
.	O
<EOS>	B-X
In	B-X
the	B-X
interest	B-X
of	B-X
enhancing	B-X
patient	B-X
outcomes	B-X
,	B-X
numerous	B-X
perioperative	B-X
interventions	B-X
have	B-X
been	B-X
studied	B-X
,	B-X
including	B-X
preoperative	B-X
education	B-X
,	B-X
preoperative	B-X
rehabilitation	B-X
,	B-X
postoperative	B-X
inpatient	B-X
rehabilitation	B-X
,	B-X
continuous	B-X
passive	B-X
motion	B-X
,	B-X
postoperative	B-X
outpatient	B-X
rehabilitation	B-X
,	B-X
unsupervised	B-X
in-home	B-X
exercises	B-X
,	B-X
telerehabilitation	B-X
,	B-X
and	B-X
various	B-X
combinations	B-X
of	B-X
these	B-X
.	B-X
This	B-X
comprehensive	B-X
review	B-X
analyzes	B-X
the	B-X
existing	B-X
body	B-X
of	B-X
evidence	B-X
on	B-X
these	B-X
perioperative	B-X
interventions	B-X
and	B-X
examines	B-X
some	B-X
burgeoning	B-X
opportunities	B-X
in	B-X
rehabilitation	B-X
after	B-X
total	B-X
knee	B-X
arthroplasty	B-X
in	B-X
the	B-X
interest	B-X
of	B-X
improving	B-X
patient	B-X
outcomes	B-X
and	B-X
ensuring	B-X
sustainable	B-X
health	B-X
care	B-X
utilization	B-X
for	B-X
the	B-X
future	B-X
of	B-X
total	B-X
knee	B-X
arthroplasty	B-X
.	B-X
The	B-X
health	B-X
care	B-X
industry	B-X
is	B-X
undergoing	B-X
a	B-X
rapid	B-X
transformation	B-X
to	B-X
meet	B-X
the	B-X
ever-increasing	B-X
needs	B-X
and	B-X
demands	B-X
of	B-X
its	B-X
patient	B-X
population	B-X
.	B-X
Level	B-X
of	B-X
patients	B-X
'	B-X
satisfaction	B-X
is	B-X
an	B-X
important	B-X
health	B-X
outcome	B-X
,	B-X
which	B-X
is	B-X
regarded	B-X
as	B-X
a	B-X
determinant	B-X
measure	B-X
for	B-X
quality	B-X
of	B-X
care	B-X
.	B-X
This	B-X
study	B-X
was	B-X
performed	B-X
with	B-X
the	B-X
aim	B-X
of	B-X
assessing	B-X
the	B-X
level	B-X
of	B-X
patient	B-X
satisfaction	B-X
with	B-X
inpatient	B-X
services	B-X
and	B-X
its	B-X
determinants	B-X
in	B-X
Black	B-X
Lion	B-X
Specialized	B-X
Hospital	B-X
,	B-X
Addis	B-X
Ababa	B-X
,	B-X
Ethiopia	B-X
.	B-X

Barriers	O
and	O
facilitators	O
to	O
personal	O
digital	O
assistants	O
:	O
themes	O
from	O
written	O
comments	O

Peer	O
support	O
from	O
colleagues	O
,	O
convenience	O
,	O
standardized	O
usage	O
,	O
and	O
financial	O
and	O
technical	O
support	O
were	O
the	O
main	O
perceived	O
facilitators	O
to	O
PDA	O
use	O
reported	O
by	O
respondents	O
.	O

The	O
main	O
perceived	O
barrier	O
to	O
PDA	O
use	O
reported	O
by	O
respondents	O
(	O
n	O
=	O
10	O
)	O
included	O
cost	O
.	O

Other	O
factors	O
such	O
as	O
technology	O
literacy	O
,	O
time	O
,	O
lack	O
of	O
peer	O
support	O
,	O
no	O
high	O
speed	O
internet	O
for	O
downloads	O
,	O
lack	O
of	O
needed	O
resources	O
,	O
keeping	O
up	O
to	O
date	O
on	O
resources	O
,	O
and	O
searching	O
speed	O
were	O
also	O
reported	O
.	O

Future	O
use	O
of	O
personal	O
digital	O
assistants	O
<EOS>	B-X
During	B-X
the	B-X
past	B-X
decade	B-X
,	B-X
vision	B-X
problems	B-X
that	B-X
were	B-X
attributed	B-X
to	B-X
the	B-X
use	B-X
of	B-X
electronic	B-X
screens	B-X
have	B-X
gradually	B-X
shifted	B-X
from	B-X
being	B-X
a	B-X
workplace	B-X
health	B-X
issue	B-X
to	B-X
a	B-X
wider	B-X
public	B-X
health	B-X
issue	B-X
.	B-X
The	B-X
widespread	B-X
use	B-X
of	B-X
digital	B-X
screens	B-X
in	B-X
devices	B-X
used	B-X
throughout	B-X
the	B-X
day	B-X
have	B-X
led	B-X
to	B-X
the	B-X
emergence	B-X
of	B-X
``	B-X
digital	B-X
eye	B-X
strain	B-X
''	B-X
as	B-X
a	B-X
new	B-X
clinical	B-X
syndrome	B-X
that	B-X
affects	B-X
every	B-X
individual	B-X
who	B-X
spends	B-X
a	B-X
large	B-X
period	B-X
of	B-X
time	B-X
fixated	B-X
on	B-X
multiple	B-X
screens	B-X
,	B-X
for	B-X
work	B-X
or	B-X
leisure	B-X
.	B-X
A	B-X
new	B-X
subcategory	B-X
,	B-X
``	B-X
video	B-X
game	B-X
vision	B-X
''	B-X
has	B-X
been	B-X
proposed	B-X
to	B-X
specifically	B-X
address	B-X
vision	B-X
issues	B-X
related	B-X
to	B-X
large	B-X
periods	B-X
of	B-X
continuous	B-X
use	B-X
of	B-X
screen	B-X
enabled	B-X
devices	B-X
in	B-X
order	B-X
to	B-X
play	B-X
video	B-X
games	B-X
.	B-X
This	B-X
article	B-X
reviews	B-X
the	B-X
latest	B-X
research	B-X
studies	B-X
on	B-X
the	B-X
impact	B-X
of	B-X
digital	B-X
screen	B-X
enabled	B-X
devices	B-X
on	B-X
adolescent	B-X
vision	B-X
in	B-X
light	B-X
of	B-X
the	B-X
increasing	B-X
reports	B-X
of	B-X
internet	B-X
addiction	B-X
and	B-X
gaming	B-X
disorder	B-X
while	B-X
referencing	B-X
positive	B-X
findings	B-X
of	B-X
videogaming	B-X
on	B-X
vision	B-X
in	B-X
order	B-X
to	B-X
provide	B-X
a	B-X
balanced	B-X
approach	B-X
and	B-X
assist	B-X
with	B-X
classification	B-X
,	B-X
diagnosis	B-X
and	B-X
treatment	B-X
,	B-X
while	B-X
providing	B-X
directions	B-X
for	B-X
future	B-X
research	B-X
.	B-X

Fifty	O
-	O
two	O
percent	O
,	O
including	O
current	O
PDA	O
users	O
,	O
reported	O
that	O
they	O
would	O
use	O
a	O
PDA	O
in	O
the	O
future	O
.	O

Twenty	O
two	O
percent	O
were	O
uncertain	O
and	O
19	O
%	O
reported	O
that	O
they	O
would	O
not	O
use	O
a	O
PDA	O
in	O
the	O
future	O
.	O

Two	O
people	B-Species
did	O
not	O
respond	O
.	O
<EOS>	B-X
To	B-X
explore	B-X
older	B-X
people	B-X
's	B-X
initial	B-X
experience	B-X
of	B-X
household	B-X
isolation	B-X
,	B-X
social	B-X
distancing	B-X
and	B-X
shielding	B-X
,	B-X
and	B-X
the	B-X
plans	B-X
they	B-X
constructed	B-X
to	B-X
support	B-X
them	B-X
through	B-X
the	B-X
COVID-19	B-X
pandemic	B-X
.	B-X
Holistic	B-X
Health	B-X
of	B-X
Two	B-X
Spirit	B-X
People	B-X
in	B-X
Canada	B-X
:	B-X
A	B-X
Call	B-X
for	B-X
Nursing	B-X
Action	B-X
.	B-X
This	B-X
commentary	B-X
explores	B-X
the	B-X
sometimes	B-X
uncomfortable	B-X
ambivalence	B-X
that	B-X
colors	B-X
most	B-X
people	B-X
's	B-X
experience	B-X
of	B-X
disability	B-X
,	B-X
either	B-X
as	B-X
an	B-X
aspect	B-X
of	B-X
a	B-X
person	B-X
's	B-X
own	B-X
identity	B-X
,	B-X
or	B-X
as	B-X
an	B-X
aspect	B-X
of	B-X
a	B-X
person	B-X
's	B-X
interactions	B-X
with	B-X
a	B-X
person	B-X
with	B-X
a	B-X
disability	B-X
.	B-X
The	B-X
framework	B-X
provided	B-X
by	B-X
these	B-X
scholars	B-X
illuminates	B-X
ways	B-X
in	B-X
which	B-X
ambivalence	B-X
about	B-X
the	B-X
experience	B-X
of	B-X
disability	B-X
is	B-X
revealed	B-X
by	B-X
many	B-X
of	B-X
the	B-X
contributors	B-X
to	B-X
this	B-X
collection	B-X
of	B-X
essays	B-X
,	B-X
and	B-X
suggests	B-X
that	B-X
an	B-X
open	B-X
confrontation	B-X
with	B-X
this	B-X
ambivalence	B-X
may	B-X
facilitate	B-X
more	B-X
satisfactory	B-X
relationships	B-X
between	B-X
people	B-X
with	B-X
and	B-X
people	B-X
without	B-X
disabilities	B-X
.	B-X

Confidentiality	O
<EOS>	B-X
Confidentiality	B-X
.	B-X
Confidentiality	B-X
is	B-X
one	B-X
of	B-X
the	B-X
cornerstones	B-X
of	B-X
the	B-X
physician-patient	B-X
relationship	B-X
.	B-X
Confidentiality	B-X
.	B-X
Genomic	B-X
databases	B-X
,	B-X
subpoenas	B-X
,	B-X
and	B-X
Certificates	B-X
of	B-X
Confidentiality	B-X
.	B-X

Fifty	O
two	O
percent	O
of	O
respondents	O
indicated	O
that	O
patient	B-Species
confidentiality	O
with	O
PDAs	O
was	O
no	O
more	O
concerning	O
compared	O
to	O
use	O
of	O
other	O
technologies	O
.	O

Forty	O
-	O
four	O
percent	O
did	O
not	O
know	O
if	O
they	O
had	O
a	O
policy	O
on	O
patient	B-Species
confidentiality	O
with	O
regard	O
to	O
technologies	O
.	O
<EOS>	B-X
Surgical	B-X
flow	B-X
disruptions	B-X
(	B-X
SFD	B-X
)	B-X
are	B-X
deviations	B-X
from	B-X
the	B-X
progression	B-X
of	B-X
a	B-X
procedure	B-X
which	B-X
can	B-X
be	B-X
potentially	B-X
compromising	B-X
to	B-X
the	B-X
safety	B-X
of	B-X
the	B-X
patient	B-X
.	B-X
Forty-five	B-X
percent	B-X
of	B-X
faculty	B-X
physicians	B-X
felt	B-X
confident	B-X
that	B-X
they	B-X
could	B-X
use	B-X
the	B-X
EHR	B-X
in	B-X
a	B-X
time-efficient	B-X
manner	B-X
and	B-X
52	B-X
%	B-X
felt	B-X
could	B-X
keep	B-X
up	B-X
with	B-X
advances	B-X
but	B-X
16	B-X
%	B-X
felt	B-X
apprehensive	B-X
about	B-X
using	B-X
the	B-X
EHR	B-X
.	B-X
Ninety-four	B-X
percent	B-X
of	B-X
faculty	B-X
would	B-X
welcome	B-X
opportunities	B-X
to	B-X
learn	B-X
more	B-X
.	B-X
Forty-five	B-X
percent	B-X
of	B-X
the	B-X
publications	B-X
contained	B-X
no	B-X
explicit	B-X
research	B-X
question	B-X
.	B-X
Forty	B-X
percent	B-X
of	B-X
the	B-X
statements	B-X
made	B-X
were	B-X
about	B-X
``	B-X
teaching	B-X
methods	B-X
''	B-X
and	B-X
17	B-X
%	B-X
about	B-X
``	B-X
teaching	B-X
content	B-X
,	B-X
''	B-X
8	B-X
%	B-X
referred	B-X
to	B-X
``	B-X
practical	B-X
value	B-X
,	B-X
''	B-X
and	B-X
10	B-X
%	B-X
to	B-X
``	B-X
side	B-X
effects	B-X
''	B-X
of	B-X
anatomy	B-X
education	B-X
.	B-X
Ten	B-X
percent	B-X
of	B-X
the	B-X
statements	B-X
were	B-X
``	B-X
positional	B-X
,	B-X
''	B-X
five	B-X
percent	B-X
``	B-X
traditional	B-X
,	B-X
''	B-X
four	B-X
percent	B-X
``	B-X
self-evident	B-X
,	B-X
''	B-X
and	B-X
two	B-X
percent	B-X
referred	B-X
to	B-X
``	B-X
quality	B-X
of	B-X
care	B-X
.	B-X
''	B-X
Fifty-six	B-X
percent	B-X
of	B-X
the	B-X
statements	B-X
had	B-X
no	B-X
foundation	B-X
,	B-X
17	B-X
%	B-X
were	B-X
founded	B-X
on	B-X
empirical	B-X
data	B-X
,	B-X
and	B-X
27	B-X
%	B-X
by	B-X
references	B-X
.	B-X

Technology	O
training	O
and	O
reimbursement	O
<EOS>	B-X
The	B-X
study	B-X
identified	B-X
the	B-X
issues	B-X
with	B-X
technically	B-X
challenged	B-X
staff	B-X
(	B-X
11	B-X
%	B-X
)	B-X
,	B-X
followed	B-X
by	B-X
resistance	B-X
to	B-X
change	B-X
(	B-X
8	B-X
%	B-X
)	B-X
,	B-X
cost	B-X
(	B-X
8	B-X
%	B-X
)	B-X
,	B-X
reimbursement	B-X
(	B-X
5	B-X
%	B-X
)	B-X
,	B-X
age	B-X
of	B-X
patient	B-X
(	B-X
5	B-X
%	B-X
)	B-X
,	B-X
and	B-X
level	B-X
of	B-X
education	B-X
of	B-X
patient	B-X
(	B-X
5	B-X
%	B-X
)	B-X
.	B-X
The	B-X
top	B-X
barriers	B-X
are	B-X
technology-specific	B-X
and	B-X
could	B-X
be	B-X
overcome	B-X
through	B-X
training	B-X
,	B-X
change-management	B-X
techniques	B-X
,	B-X
and	B-X
alternating	B-X
delivery	B-X
by	B-X
telemedicine	B-X
and	B-X
personal	B-X
patient-to-provider	B-X
interaction	B-X
.	B-X
Telemedicine	B-X
training	B-X
is	B-X
essential	B-X
to	B-X
facilitate	B-X
rapport	B-X
,	B-X
maximize	B-X
engagement	B-X
,	B-X
and	B-X
conduct	B-X
an	B-X
accurate	B-X
virtual	B-X
exam	B-X
.	B-X
The	B-X
national	B-X
telehealth	B-X
resource	B-X
centers	B-X
can	B-X
provide	B-X
interested	B-X
clinicians	B-X
with	B-X
the	B-X
latest	B-X
information	B-X
on	B-X
telemedicine	B-X
reimbursement	B-X
,	B-X
parity	B-X
,	B-X
and	B-X
practice	B-X
.	B-X
To	B-X
experience	B-X
the	B-X
gains	B-X
of	B-X
teleoncology	B-X
,	B-X
appropriate	B-X
training	B-X
,	B-X
education	B-X
,	B-X
as	B-X
well	B-X
as	B-X
paying	B-X
close	B-X
attention	B-X
to	B-X
gaps	B-X
,	B-X
such	B-X
as	B-X
those	B-X
inherent	B-X
in	B-X
the	B-X
digital	B-X
divide	B-X
,	B-X
are	B-X
essential	B-X
.	B-X

Respondents	O
rated	O
(	O
1	O
=	O
least	O
preferred	O
to	O
5	O
=	O
most	O
preferred	O
)	O
one	O
on	O
one	O
instruction	O
and	O
group	O
learning	O
led	O
by	O
an	O
expert	O
facilitator	O
as	O
the	O
most	O
preferred	O
(	O
mean	O
4	O
.	O
32	O
,	O
SD	O
0	O
.	O
99	O
)	O
means	O
by	O
which	O
to	O
receive	O
instruction	O
on	O
a	O
new	O
technology	O
.	O

Least	O
preferred	O
methods	O
included	O
online	O
discussions	O
/	O
chatrooms	O
(	O
mean	O
1	O
.	O
52	O
,	O
SD	O
1	O
.	O
04	O
)	O
,	O
internet	O
videos	O
(	O
live	O
:	O
mean	O
1	O
.	O
70	O
,	O
SD	O
1	O
.	O
10	O
,	O
or	O
static	O
:	O
mean	O
1	O
.	O
87	O
,	O
SD	O
1	O
.	O
14	O
)	O
,	O
video	O
cassettes	O
(	O
mean	O
2	O
.	O
30	O
,	O
SD	O
1	O
.	O
55	O
)	O
,	O
trial	O
and	O
error	O
learning	O
(	O
mean	O
2	O
.	O
32	O
,	O
SD	O
1	O
.	O
28	O
)	O
,	O
and	O
written	O
manuals	O
(	O
mean	O
2	O
.	O
92	O
,	O
SD	O
1	O
.	O
44	O
)	O
.	O

Paid	O
leave	O
for	O
attendance	O
at	O
technology	O
training	O
sessions	O
was	O
the	O
preferred	O
means	O
(	O
mean	O
1	O
.	O
77	O
,	O
SD	O
0	O
.	O
86	O
;	O
1	O
=	O
strongly	O
agree	O
to	O
5	O
=	O
strongly	O
disagree	O
)	O
of	O
remuneration	O
for	O
respondents	O
.	O

Respondents	O
also	O
indicated	O
that	O
if	O
financial	O
remuneration	O
was	O
to	O
occur	O
,	O
it	O
should	O
correspond	O
to	O
the	O
amount	O
of	O
time	O
for	O
training	O
that	O
is	O
required	O
(	O
versus	O
a	O
flat	O
rate	O
)	O
(	O
mean	O
1	O
.	O
96	O
,	O
SD	O
1	O
.	O
08	O
)	O
.	O

Continuing	O
education	O
credits	O
were	O
not	O
viewed	O
as	O
an	O
incentive	O
(	O
mean	O
2	O
.	O
69	O
,	O
SD	O
1	O
.	O
44	O
)	O
.	O
<EOS>	B-X
The	B-X
Accreditation	B-X
Council	B-X
for	B-X
Pharmacy	B-X
Education	B-X
(	B-X
ACPE	B-X
)	B-X
Continuing	B-X
Pharmacy	B-X
Education	B-X
(	B-X
CPE	B-X
)	B-X
Provider	B-X
Accreditation	B-X
Program	B-X
has	B-X
been	B-X
in	B-X
existence	B-X
for	B-X
40	B-X
years	B-X
.	B-X
This	B-X
paper	B-X
explains	B-X
the	B-X
evolution	B-X
of	B-X
the	B-X
CPE	B-X
Provider	B-X
Accreditation	B-X
Program	B-X
,	B-X
including	B-X
the	B-X
Definition	B-X
of	B-X
Continuing	B-X
Education	B-X
for	B-X
the	B-X
Profession	B-X
of	B-X
Pharmacy	B-X
,	B-X
its	B-X
standards	B-X
,	B-X
types	B-X
of	B-X
activities	B-X
(	B-X
knowledge	B-X
,	B-X
application	B-X
,	B-X
and	B-X
practice	B-X
)	B-X
,	B-X
CPE	B-X
Monitor	B-X
,	B-X
Joint	B-X
Accreditation	B-X
for	B-X
Interprofessional	B-X
Continuing	B-X
Education	B-X
,	B-X
and	B-X
Continuing	B-X
Professional	B-X
Development	B-X
(	B-X
CPD	B-X
)	B-X
.	B-X
In	B-X
2015	B-X
,	B-X
accreditation	B-X
system	B-X
for	B-X
Japanese	B-X
midwives	B-X
was	B-X
started	B-X
by	B-X
Japan	B-X
Institute	B-X
of	B-X
Midwifery	B-X
Evaluation	B-X
.	B-X
To	B-X
be	B-X
linked	B-X
to	B-X
this	B-X
,	B-X
designation	B-X
rules	B-X
of	B-X
midwifery	B-X
education	B-X
was	B-X
changed	B-X
by	B-X
Ministry	B-X
of	B-X
Health	B-X
,	B-X
Labor	B-X
and	B-X
Welfare	B-X
.	B-X
It	B-X
increases	B-X
from	B-X
28	B-X
credits	B-X
to	B-X
31	B-X
credits	B-X
,	B-X
and	B-X
applied	B-X
from	B-X
2022	B-X
.	B-X
Then	B-X
,	B-X
we	B-X
reviewed	B-X
our	B-X
midwifery	B-X
program	B-X
and	B-X
created	B-X
core	B-X
curriculum	B-X
in	B-X
preferred	B-X
midwifery	B-X
education	B-X
by	B-X
Japan	B-X
Society	B-X
Midwifery	B-X
Education	B-X
.	B-X

Discussion	O
<EOS>	B-X
Discussion	B-X
structures	B-X
are	B-X
argumentation-theoretical	B-X
tools	B-X
that	B-X
can	B-X
be	B-X
employed	B-X
to	B-X
tackle	B-X
three	B-X
barriers	B-X
that	B-X
separate	B-X
lay	B-X
stakeholders	B-X
from	B-X
policy	B-X
debates	B-X
:	B-X
difficulty	B-X
,	B-X
magnitude	B-X
,	B-X
and	B-X
complexity	B-X
.	B-X
Discussions	B-X
about	B-X
preventive	B-X
behaviors	B-X
were	B-X
assessed	B-X
before	B-X
testing	B-X
and	B-X
1	B-X
and	B-X
6	B-X
months	B-X
post-testing	B-X
.	B-X
Discussion	B-X
of	B-X
preventive	B-X
behaviors	B-X
declined	B-X
following	B-X
test	B-X
reporting	B-X
,	B-X
with	B-X
more	B-X
rapid	B-X
decline	B-X
reported	B-X
by	B-X
noncarriers	B-X
.	B-X
Discussions	B-X
are	B-X
an	B-X
important	B-X
part	B-X
of	B-X
medical	B-X
education	B-X
research	B-X
papers	B-X
,	B-X
but	B-X
there	B-X
is	B-X
little	B-X
guidance	B-X
on	B-X
how	B-X
to	B-X
write	B-X
up	B-X
the	B-X
discussion	B-X
section	B-X
.	B-X

Preferred	O
resources	O
<EOS>	B-X
Some	B-X
topics	B-X
were	B-X
more	B-X
deeply	B-X
documented	B-X
than	B-X
others-there	B-X
is	B-X
,	B-X
for	B-X
example	B-X
,	B-X
a	B-X
large	B-X
number	B-X
of	B-X
studies	B-X
on	B-X
human	B-X
resources	B-X
for	B-X
health	B-X
(	B-X
HRH	B-X
)	B-X
planning	B-X
,	B-X
educational	B-X
interventions	B-X
,	B-X
and	B-X
policies	B-X
to	B-X
reduce	B-X
in-migration	B-X
,	B-X
but	B-X
much	B-X
less	B-X
on	B-X
topics	B-X
such	B-X
as	B-X
HRH	B-X
financing	B-X
and	B-X
task	B-X
shifting	B-X
.	B-X
This	B-X
study	B-X
examined	B-X
whether	B-X
variables	B-X
related	B-X
to	B-X
unequal	B-X
access	B-X
to	B-X
mental	B-X
health	B-X
resources	B-X
(	B-X
including	B-X
Black	B-X
and	B-X
Latinx	B-X
racial-ethnic	B-X
group	B-X
membership	B-X
,	B-X
lower	B-X
education	B-X
level	B-X
,	B-X
and	B-X
lower	B-X
number	B-X
of	B-X
community-level	B-X
treatment	B-X
providers	B-X
,	B-X
and	B-X
facilities	B-X
)	B-X
were	B-X
associated	B-X
with	B-X
current	B-X
mental	B-X
health	B-X
treatment	B-X
use	B-X
;	B-X
and	B-X
,	B-X
whether	B-X
these	B-X
variables	B-X
moderated	B-X
the	B-X
likelihood	B-X
that	B-X
individuals	B-X
would	B-X
receive	B-X
their	B-X
preferred	B-X
effective	B-X
treatment	B-X
.	B-X
The	B-X
survey	B-X
revealed	B-X
that	B-X
community	B-X
members	B-X
preferred	B-X
to	B-X
receive	B-X
information	B-X
on	B-X
health	B-X
resources	B-X
from	B-X
the	B-X
Internet	B-X
(	B-X
28.3	B-X
%	B-X
)	B-X
,	B-X
newspaper	B-X
(	B-X
26.4	B-X
%	B-X
)	B-X
,	B-X
or	B-X
mail	B-X
(	B-X
22.3	B-X
%	B-X
)	B-X
.	B-X
Ideally	B-X
,	B-X
if	B-X
health	B-X
resources	B-X
are	B-X
intended	B-X
for	B-X
adult	B-X
audiences	B-X
,	B-X
a	B-X
campaign	B-X
that	B-X
would	B-X
include	B-X
communication	B-X
through	B-X
newspaper	B-X
(	B-X
targeting	B-X
older	B-X
adults	B-X
)	B-X
,	B-X
mailing	B-X
(	B-X
targeting	B-X
obese	B-X
adults	B-X
)	B-X
,	B-X
and	B-X
Web	B-X
sites	B-X
(	B-X
targeting	B-X
younger	B-X
adults	B-X
)	B-X
would	B-X
be	B-X
the	B-X
most	B-X
effective	B-X
approach	B-X
.	B-X

In	O
our	O
study	O
,	O
printed	O
materials	O
(	O
e	O
.	O
g	O
.	O
compendia	O
,	O
journals	O
,	O
textbook	O
resources	O
)	O
and	O
professionals	O
(	O
e	O
.	O
g	O
.	O
pharmacists	O
)	O
were	O
the	O
most	O
preferred	O
and	O
frequently	O
used	O
means	O
to	O
access	O
information	O
.	O

Physician	O
reliance	O
on	O
text	O
and	O
compendia	O
relative	O
to	O
online	O
/	O
electronic	O
resources	O
has	O
been	O
frequently	O
reported	O
[	O
11	O
]	O
.	O

In	O
a	O
study	O
examining	O
family	O
doctors	O
'	O
use	O
of	O
information	O
sources	O
to	O
answer	O
clinical	O
questions	O
,	O
human	B-Species
resources	O
(	O
e	O
.	O
g	O
.	O
doctor	O
,	O
pharmacist	O
)	O
,	O
non	O
-	O
prescribing	O
print	O
information	O
(	O
e	O
.	O
g	O
.	O
textbooks	O
and	O
journal	O
articles	O
)	O
,	O
and	O
prescribing	O
texts	O
were	O
used	O
36	O
%	O
,	O
32	O
%	O
,	O
and	O
25	O
%	O
of	O
the	O
time	O
,	O
respectively	O
[	O
54	O
]	O
.	O

Books	O
from	O
the	O
workplace	O
were	O
reported	O
by	O
approximately	O
79	O
%	O
of	O
UK	O
primary	O
care	O
nurses	O
as	O
a	O
commonly	O
used	O
source	O
of	O
knowledge	O
and	O
information	O
used	O
to	O
support	O
practice	O
[	O
55	O
]	O
.	O

Fewer	O
than	O
one	O
-	O
third	O
(	O
31	O
%	O
)	O
reported	O
using	O
electronic	O
resources	O
(	O
e	O
.	O
g	O
.	O
Internet	O
,	O
electronic	O
journals	O
)	O
for	O
this	O
purpose	O
[	O
55	O
]	O
.	O

Results	O
of	O
a	O
postal	O
questionnaire	O
to	O
NPs	O
demonstrated	O
that	O
61	O
%	O
and	O
51	O
%	O
of	O
respondents	O
reported	O
using	O
drug	O
reference	O
manuals	O
and	O
textbooks	O
,	O
respectively	O
,	O
a	O
few	O
times	O
a	O
week	O
or	O
more	O
[	O
29	O
]	O
.	O
<EOS>	B-X
Lurbinectedin	B-X
.	B-X
Seventy-seven	B-X
undergraduates	B-X
and	B-X
70	B-X
demographically	B-X
diverse	B-X
members	B-X
of	B-X
the	B-X
community	B-X
completed	B-X
12	B-X
individual	B-X
differences	B-X
measures	B-X
hypothesized	B-X
to	B-X
predict	B-X
lie-telling	B-X
in	B-X
everyday	B-X
life	B-X
and	B-X
then	B-X
kept	B-X
a	B-X
diary	B-X
every	B-X
day	B-X
for	B-X
a	B-X
week	B-X
of	B-X
all	B-X
of	B-X
their	B-X
social	B-X
interactions	B-X
and	B-X
all	B-X
of	B-X
the	B-X
lies	B-X
that	B-X
they	B-X
told	B-X
during	B-X
those	B-X
interactions	B-X
.	B-X
People	B-X
who	B-X
told	B-X
fewer	B-X
lies	B-X
were	B-X
more	B-X
highly	B-X
socialized	B-X
and	B-X
reported	B-X
higher	B-X
quality	B-X
same-sex	B-X
relationships	B-X
.	B-X
IBS	B-X
is	B-X
1.5	B-X
times	B-X
more	B-X
common	B-X
in	B-X
women	B-X
than	B-X
in	B-X
men	B-X
,	B-X
more	B-X
common	B-X
in	B-X
lower	B-X
socioeconomic	B-X
groups	B-X
,	B-X
and	B-X
more	B-X
commonly	B-X
diagnosed	B-X
in	B-X
patients	B-X
younger	B-X
than	B-X
50	B-X
years	B-X
of	B-X
age	B-X
.	B-X

These	O
frequencies	O
were	O
second	O
and	O
third	O
only	O
to	O
consulting	O
with	O
their	O
physician	O
supervisor	O
(	O
63	O
%	O
)	O
.	O

Data	O
from	O
structured	O
interviews	O
of	O
a	O
sample	O
of	O
22	O
community	O
nurse	O
prescribers	O
reported	O
by	O
Hall	O
et	O
al	O
.	O
revealed	O
that	O
the	O
majority	O
relied	O
on	O
print	O
materials	O
to	O
access	O
information	O
,	O
namely	O
the	O
British	O
National	O
Formulary	O
[	O
32	O
]	O
.	O

A	O
survey	O
of	O
a	O
primary	O
care	O
practice	O
-	O
based	O
research	O
network	O
in	O
the	O
US	O
that	O
included	O
physicians	O
,	O
physician	O
assistants	O
,	O
and	O
nurse	O
practitioners	O
,	O
revealed	O
that	O
interpersonal	O
and	O
rapidly	O
accessed	O
print	O
resources	O
were	O
preferred	O
.	O

Sixty	O
-	O
one	O
and	O
58	O
%	O
of	O
respondents	O
reported	O
using	O
drug	O
reference	O
sources	O
such	O
as	O
the	O
Physician	O
'	O
s	O
Desk	O
Reference	O
(	O
PDR	O
)	O
and	O
medical	O
textbooks	O
,	O
respectively	O
,	O
a	O
few	O
times	O
a	O
day	O
or	O
daily	O
[	O
56	O
]	O
.	O
<EOS>	B-X
This	B-X
review	B-X
aimed	B-X
to	B-X
assess	B-X
the	B-X
efficacy	B-X
and	B-X
safety	B-X
of	B-X
once-	B-X
versus	B-X
twice-daily	B-X
administration	B-X
of	B-X
angiotensin-converting	B-X
enzyme	B-X
(	B-X
ACE	B-X
)	B-X
inhibitors	B-X
for	B-X
the	B-X
management	B-X
of	B-X
hypertension	B-X
.	B-X
A	B-X
literature	B-X
search	B-X
on	B-X
PubMed	B-X
and	B-X
Google	B-X
Scholar	B-X
was	B-X
performed	B-X
(	B-X
January	B-X
1980	B-X
to	B-X
June	B-X
2020	B-X
)	B-X
using	B-X
the	B-X
following	B-X
search	B-X
terms	B-X
:	B-X
ACE	B-X
inhibitors	B-X
,	B-X
lisinopril	B-X
,	B-X
enalapril	B-X
,	B-X
fosinopril	B-X
,	B-X
trandolapril	B-X
,	B-X
ramipril	B-X
,	B-X
perindopril	B-X
,	B-X
captopril	B-X
,	B-X
benazepril	B-X
,	B-X
ambulatory	B-X
blood	B-X
pressure	B-X
,	B-X
hypertension	B-X
,	B-X
twice-daily	B-X
dosing	B-X
,	B-X
once-daily	B-X
dosing	B-X
.	B-X
Reference	B-X
lists	B-X
from	B-X
retrieved	B-X
articles	B-X
were	B-X
examined	B-X
for	B-X
additional	B-X
reports	B-X
.	B-X
Overall	B-X
,	B-X
six	B-X
studies	B-X
were	B-X
included	B-X
that	B-X
compared	B-X
the	B-X
efficacy	B-X
of	B-X
once-daily	B-X
to	B-X
twice-daily	B-X
dosing	B-X
of	B-X
ACE	B-X
inhibitors	B-X
.	B-X
Similar	B-X
blood	B-X
pressure-lowering	B-X
effects	B-X
,	B-X
and	B-X
,	B-X
in	B-X
some	B-X
studies	B-X
,	B-X
greater	B-X
blood	B-X
pressure	B-X
lowering	B-X
has	B-X
been	B-X
noted	B-X
in	B-X
the	B-X
twice-daily	B-X
administration	B-X
arm	B-X
than	B-X
once-daily	B-X
administration	B-X
of	B-X
ACE	B-X
inhibitors	B-X
.	B-X
It	B-X
is	B-X
noteworthy	B-X
that	B-X
adherence	B-X
issues	B-X
may	B-X
arise	B-X
when	B-X
transitioning	B-X
from	B-X
a	B-X
once-daily	B-X
regimen	B-X
to	B-X
a	B-X
twice-daily	B-X
regimen	B-X
.	B-X
There	B-X
appear	B-X
to	B-X
be	B-X
no	B-X
added	B-X
safety	B-X
concerns	B-X
between	B-X
twice-daily	B-X
and	B-X
once-daily	B-X
administration	B-X
of	B-X
ACE	B-X
inhibitors	B-X
regarding	B-X
safety	B-X
outcomes	B-X
.	B-X
After	B-X
reviewing	B-X
the	B-X
available	B-X
literature	B-X
,	B-X
twice-daily	B-X
dosing	B-X
of	B-X
ACE	B-X
inhibitors	B-X
may	B-X
promote	B-X
added	B-X
blood	B-X
pressure-lowering	B-X
effects	B-X
,	B-X
with	B-X
the	B-X
advantages	B-X
of	B-X
reducing	B-X
cost	B-X
,	B-X
reducing	B-X
the	B-X
risk	B-X
of	B-X
drug-drug	B-X
interactions	B-X
,	B-X
reducing	B-X
polypharmacy	B-X
,	B-X
and	B-X
reducing	B-X
patient	B-X
confusion	B-X
about	B-X
their	B-X
medications	B-X
.	B-X
Recommendations	B-X
for	B-X
twice-daily	B-X
administration	B-X
of	B-X
ACE	B-X
-inhibitors	B-X
should	B-X
be	B-X
made	B-X
via	B-X
shared	B-X
decision-making	B-X
with	B-X
the	B-X
patient	B-X
,	B-X
and	B-X
clinician	B-X
judgment	B-X
,	B-X
to	B-X
drive	B-X
treatment	B-X
selection	B-X
.	B-X

The	O
clinicians	O
in	O
our	O
sample	O
perceived	O
the	O
Canadian	O
compendium	O
,	O
the	O
CPS	O
,	O
to	O
be	O
useful	O
,	O
accessible	O
,	O
credible	O
,	O
and	O
current	O
/	O
timely	O
.	O

The	O
CPS	O
,	O
is	O
described	O
as	O
"	O
the	O
Canadian	O
drug	O
reference	O
for	O
health	O
professionals	O
"	O
and	O
is	O
intended	O
to	O
provide	O
a	O
central	O
source	O
of	O
drug	O
information	O
on	O
drug	O
products	O
available	O
in	O
Canada	O
[	O
52	O
]	O
.	O

It	O
is	O
available	O
in	O
print	O
(	O
English	O
and	O
French	O
)	O
and	O
became	O
available	O
online	O
in	O
June	O
2004	O
.	O

The	O
CPS	O
includes	O
drug	O
monographs	O
for	O
commonly	O
used	O
products	O
approved	O
for	O
use	O
in	O
Canada	O
,	O
but	O
it	O
does	O
not	O
include	O
all	O
drugs	O
available	O
on	O
the	O
Canadian	O
market	O
[	O
57	O
]	O
.	O

The	O
majority	O
of	O
these	O
product	O
monographs	O
are	O
based	O
on	O
monographs	O
submitted	O
by	O
pharmaceutical	O
manufacturers	O
and	O
approved	O
by	O
Health	O
Canada	O
.	O

Some	O
of	O
the	O
monographs	O
are	O
written	O
by	O
the	O
Canadian	O
Pharmacists	O
Association	O
and	O
are	O
described	O
as	O
being	O
evidence	O
-	O
based	O
[	O
52	O
]	O
.	O

The	O
CPS	O
also	O
includes	O
more	O
than	O
100	O
pages	O
of	O
clinical	O
tools	O
[	O
52	O
]	O
.	O

The	O
CPS	O
has	O
been	O
criticized	O
for	O
including	O
pharmaceutical	O
company	O
advertising	O
and	O
requiring	O
manufacturer	O
payment	O
for	O
inclusion	O
of	O
product	O
monographs	O
[	O
58	O
]	O
.	O

The	O
accuracy	O
of	O
particular	O
components	O
of	O
CPS	O
monographs	O
has	O
also	O
been	O
investigated	O
.	O

A	O
review	O
of	O
overdose	O
management	O
in	O
119	O
monographs	O
from	O
the	O
2001	O
CPS	O
revealed	O
considerable	O
variability	O
in	O
the	O
utility	O
of	O
information	O
with	O
50	O
%	O
of	O
the	O
monographs	O
containing	O
misleading	O
or	O
dangerous	O
advice	O
[	O
59	O
]	O
.	O
<EOS>	B-X
Potential	B-X
risks	B-X
of	B-X
self-medication	B-X
practices	B-X
include	B-X
:	B-X
incorrect	B-X
self-diagnosis	B-X
,	B-X
delays	B-X
in	B-X
seeking	B-X
medical	B-X
advice	B-X
when	B-X
needed	B-X
,	B-X
infrequent	B-X
but	B-X
severe	B-X
adverse	B-X
reactions	B-X
,	B-X
dangerous	B-X
drug	B-X
interactions	B-X
,	B-X
incorrect	B-X
manner	B-X
of	B-X
administration	B-X
,	B-X
incorrect	B-X
dosage	B-X
,	B-X
incorrect	B-X
choice	B-X
of	B-X
therapy	B-X
,	B-X
masking	B-X
of	B-X
a	B-X
severe	B-X
disease	B-X
and	B-X
risk	B-X
of	B-X
dependence	B-X
and	B-X
abuse	B-X
.	B-X
In	B-X
this	B-X
short	B-X
review	B-X
the	B-X
author	B-X
analyzes	B-X
recent	B-X
literature	B-X
on	B-X
some	B-X
of	B-X
the	B-X
most	B-X
important	B-X
dangers	B-X
related	B-X
to	B-X
self-medication	B-X
practices	B-X
,	B-X
particularly	B-X
:	B-X
polypharmacy	B-X
and	B-X
drug	B-X
interactions	B-X
,	B-X
medications	B-X
abuse	B-X
or	B-X
dependence	B-X
,	B-X
misdiagnosis	B-X
and	B-X
incorrect	B-X
choice	B-X
of	B-X
treatment	B-X
.	B-X
Future	B-X
research	B-X
is	B-X
warranted	B-X
to	B-X
identify	B-X
the	B-X
clinical	B-X
and	B-X
subclinical	B-X
harm	B-X
associated	B-X
with	B-X
individual	B-X
practices	B-X
and	B-X
combinations	B-X
to	B-X
enable	B-X
appropriate	B-X
and	B-X
timely	B-X
advice	B-X
.	B-X
In	B-X
this	B-X
context	B-X
,	B-X
advice	B-X
on	B-X
continued	B-X
breastfeeding	B-X
must	B-X
consider	B-X
both	B-X
the	B-X
benefits	B-X
of	B-X
breastfeeding	B-X
and	B-X
the	B-X
possible	B-X
disadvantages	B-X
of	B-X
the	B-X
jaundice	B-X
.	B-X

Since	O
2004	O
,	O
the	O
CPS	O
has	O
included	O
an	O
alert	O
box	O
in	O
the	O
overdose	O
section	O
of	O
monographs	O
notifying	O
users	O
to	O
contact	O
Poison	O
Control	O
Centres	O
for	O
overdose	O
management	O
information	O
.	O

Some	O
authors	O
have	O
criticized	O
references	O
that	O
are	O
similar	O
to	O
the	O
CPS	O
as	O
being	O
inadequate	O
with	O
regard	O
to	O
inclusion	O
of	O
evidence	O
based	O
information	O
[	O
60	O
]	O
.	O

The	O
NPs	O
in	O
our	O
sample	O
also	O
rated	O
Therapeutic	O
Choices	O
highly	O
for	O
all	O
characteristics	O
.	O

This	O
finding	O
is	O
most	O
likely	O
attributable	O
to	O
the	O
fact	O
that	O
it	O
is	O
a	O
recommended	O
resource	O
for	O
coursework	O
associated	O
with	O
the	O
Dalhousie	O
NP	O
university	O
program	O
curriculum	O
.	O

Therapeutic	O
Choices	O
is	O
a	O
concise	O
therapeutics	O
reference	O
text	O
published	O
by	O
the	O
Canadian	O
Pharmacists	O
Association	O
.	O

The	O
text	O
contains	O
approximately	O
120	O
extensively	O
referenced	O
chapters	O
with	O
a	O
disease	O
management	O
approach	O
including	O
easy	O
to	O
use	O
algorithms	O
and	O
tables	O
.	O

An	O
editorial	O
board	O
is	O
responsible	O
for	O
extensively	O
reviewing	O
the	O
content	O
to	O
ensure	O
unbiased	O
and	O
objective	O
information	O
is	O
presented	O
[	O
53	O
]	O
.	O

Health	O
professionals	O
<EOS>	B-X
The	B-X
use	B-X
of	B-X
e-learning	B-X
,	B-X
defined	B-X
as	B-X
any	B-X
educational	B-X
intervention	B-X
mediated	B-X
electronically	B-X
via	B-X
the	B-X
Internet	B-X
,	B-X
has	B-X
steadily	B-X
increased	B-X
among	B-X
health	B-X
professionals	B-X
worldwide	B-X
.	B-X
Healthcare	B-X
professionals	B-X
are	B-X
crucial	B-X
in	B-X
the	B-X
identification	B-X
and	B-X
accessibility	B-X
to	B-X
treatment	B-X
for	B-X
people	B-X
with	B-X
substance	B-X
use	B-X
disorders	B-X
.	B-X
Our	B-X
objective	B-X
was	B-X
to	B-X
assess	B-X
health	B-X
professionals	B-X
'	B-X
attitudes	B-X
towards	B-X
patients	B-X
with	B-X
substance	B-X
use	B-X
disorders	B-X
and	B-X
examine	B-X
the	B-X
consequences	B-X
of	B-X
these	B-X
attitudes	B-X
on	B-X
healthcare	B-X
delivery	B-X
for	B-X
these	B-X
patients	B-X
in	B-X
Western	B-X
countries	B-X
.	B-X
It	B-X
is	B-X
unfortunate	B-X
that	B-X
so	B-X
little	B-X
educational	B-X
time	B-X
and	B-X
effort	B-X
are	B-X
devoted	B-X
to	B-X
train	B-X
future	B-X
health	B-X
professionals	B-X
on	B-X
how	B-X
to	B-X
practice	B-X
Healthy	B-X
Living	B-X
Medicine	B-X
(	B-X
HLM	B-X
)	B-X
and	B-X
,	B-X
deliver	B-X
healthy	B-X
living	B-X
(	B-X
HL	B-X
)	B-X
interventions	B-X
.	B-X
The	B-X
current	B-X
review	B-X
describes	B-X
current	B-X
trends	B-X
in	B-X
training	B-X
health	B-X
professionals	B-X
in	B-X
HLM	B-X
and	B-X
the	B-X
delivery	B-X
of	B-X
HL	B-X
interventions	B-X
.	B-X

Reliance	O
on	O
other	O
health	O
professionals	O
,	O
especially	O
pharmacists	O
and	O
physicians	O
,	O
as	O
a	O
resource	O
for	O
information	O
was	O
evident	O
from	O
our	O
study	O
and	O
concurs	O
with	O
the	O
findings	O
of	O
others	O
[	O
28	O
,	O
32	O
,	O
55	O
,	O
61	O
]	O
.	O

Nurse	O
practitioners	O
have	O
reported	O
that	O
collaborative	O
relationships	O
with	O
pharmacists	O
increase	O
NP	O
role	O
satisfaction	O
[	O
61	O
]	O
.	O

NPs	O
frequently	O
consult	O
with	O
allied	O
health	O
care	O
professionals	O
in	O
their	O
primary	O
health	O
care	O
provider	O
role	O
and	O
this	O
is	O
supported	O
by	O
written	O
feedback	O
from	O
our	O
sample	O
regarding	O
frequently	O
consulted	O
health	O
professionals	O
.	O

Nursing	O
colleagues	O
are	O
also	O
likely	O
to	O
be	O
rated	O
highly	O
by	O
NPs	O
due	O
to	O
their	O
affiliation	O
with	O
peers	O
from	O
the	O
same	O
profession	O
.	O

Some	O
investigators	O
have	O
shown	O
that	O
non	O
-	O
human	B-Species
references	O
(	O
e	O
.	O
g	O
.	O
textbook	O
)	O
are	O
sought	O
for	O
more	O
technical	O
aspects	O
of	O
prescribing	O
(	O
e	O
.	O
g	O
.	O
dose	O
)	O
,	O
whereas	O
guidance	O
regarding	O
selection	O
of	O
agents	O
(	O
i	O
.	O
e	O
.	O
right	O
drug	O
for	O
an	O
indication	O
)	O
is	O
sought	O
from	O
human	B-Species
resources	O
(	O
e	O
.	O
g	O
.	O
pharmacists	O
or	O
physicians	O
)	O
[	O
62	O
]	O
.	O

We	O
were	O
unable	O
to	O
determine	O
what	O
kinds	O
of	O
resources	O
were	O
used	O
for	O
specific	O
purposes	O
from	O
our	O
study	O
.	O

Online	O
and	O
electronic	O
resources	O
,	O
computers	O
,	O
and	O
personal	O
digital	O
assistants	O
<EOS>	B-X
The	B-X
sustained	B-X
interest	B-X
in	B-X
electronic	B-X
assistive	B-X
technology	B-X
in	B-X
dementia	B-X
care	B-X
has	B-X
been	B-X
fuelled	B-X
by	B-X
the	B-X
urgent	B-X
need	B-X
to	B-X
develop	B-X
useful	B-X
approaches	B-X
to	B-X
help	B-X
support	B-X
people	B-X
with	B-X
dementia	B-X
at	B-X
home	B-X
.	B-X
Also	B-X
the	B-X
low	B-X
costs	B-X
and	B-X
wide	B-X
availability	B-X
of	B-X
electronic	B-X
devices	B-X
make	B-X
it	B-X
more	B-X
feasible	B-X
to	B-X
use	B-X
electronic	B-X
devices	B-X
for	B-X
the	B-X
benefit	B-X
of	B-X
disabled	B-X
persons	B-X
.	B-X
By	B-X
using	B-X
AT	B-X
in	B-X
this	B-X
review	B-X
we	B-X
refer	B-X
to	B-X
electronic	B-X
assistive	B-X
devices	B-X
.	B-X
A	B-X
range	B-X
of	B-X
AT	B-X
devices	B-X
has	B-X
been	B-X
developed	B-X
to	B-X
support	B-X
people	B-X
with	B-X
dementia	B-X
and	B-X
their	B-X
carers	B-X
to	B-X
manage	B-X
their	B-X
daily	B-X
activities	B-X
and	B-X
to	B-X
enhance	B-X
safety	B-X
,	B-X
for	B-X
example	B-X
electronic	B-X
pill	B-X
boxes	B-X
,	B-X
picture	B-X
phones	B-X
,	B-X
or	B-X
mobile	B-X
tracking	B-X
devices	B-X
.	B-X
Although	B-X
reviews	B-X
of	B-X
(	B-X
electronic	B-X
)	B-X
memory	B-X
aids	B-X
do	B-X
exist	B-X
,	B-X
a	B-X
systematic	B-X
review	B-X
of	B-X
studies	B-X
focusing	B-X
on	B-X
the	B-X
efficacy	B-X
of	B-X
AT	B-X
for	B-X
memory	B-X
support	B-X
in	B-X
people	B-X
with	B-X
dementia	B-X
is	B-X
lacking	B-X
.	B-X

From	O
our	O
study	O
,	O
computer	O
survey	O
respondents	O
ranked	O
online	O
/	O
electronic	O
resources	O
third	O
in	O
preference	O
following	O
print	O
and	O
health	O
professionals	O
.	O

Various	O
barriers	O
and	O
facilitators	O
to	O
accessing	O
information	O
online	O
/	O
electronically	O
or	O
via	O
the	O
Internet	O
have	O
been	O
described	O
in	O
the	O
literature	O
[	O
55	O
,	O
63	O
-	O
66	O
]	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
UniProt	B-X
Knowledgebase	B-X
is	B-X
to	B-X
provide	B-X
users	B-X
with	B-X
a	B-X
comprehensive	B-X
,	B-X
high-quality	B-X
and	B-X
freely	B-X
accessible	B-X
set	B-X
of	B-X
protein	B-X
sequences	B-X
annotated	B-X
with	B-X
functional	B-X
information	B-X
.	B-X
We	B-X
continue	B-X
to	B-X
extract	B-X
detailed	B-X
annotations	B-X
from	B-X
the	B-X
literature	B-X
to	B-X
add	B-X
to	B-X
reviewed	B-X
entries	B-X
and	B-X
supplement	B-X
these	B-X
in	B-X
unreviewed	B-X
entries	B-X
with	B-X
annotations	B-X
provided	B-X
by	B-X
automated	B-X
systems	B-X
such	B-X
as	B-X
the	B-X
newly	B-X
implemented	B-X
Association-Rule-Based	B-X
Annotator	B-X
(	B-X
ARBA	B-X
)	B-X
.	B-X
UniProt	B-X
resources	B-X
are	B-X
available	B-X
under	B-X
a	B-X
CC-BY	B-X
(	B-X
4.0	B-X
)	B-X
license	B-X
via	B-X
the	B-X
web	B-X
at	B-X
https	B-X
:	B-X
//www.uniprot.org/	B-X
.	B-X
GenBankÂ®	B-X
(	B-X
http	B-X
:	B-X
//www.ncbi.nlm.nih.gov	B-X
)	B-X
is	B-X
a	B-X
comprehensive	B-X
database	B-X
that	B-X
contains	B-X
publicly	B-X
available	B-X
nucleotide	B-X
sequences	B-X
for	B-X
almost	B-X
260	B-X
000	B-X
formally	B-X
described	B-X
species	B-X
.	B-X
GenBank	B-X
is	B-X
accessible	B-X
through	B-X
the	B-X
NCBI	B-X
Entrez	B-X
retrieval	B-X
system	B-X
,	B-X
which	B-X
integrates	B-X
data	B-X
from	B-X
the	B-X
major	B-X
DNA	B-X
and	B-X
protein	B-X
sequence	B-X
databases	B-X
along	B-X
with	B-X
taxonomy	B-X
,	B-X
genome	B-X
,	B-X
mapping	B-X
,	B-X
protein	B-X
structure	B-X
and	B-X
domain	B-X
information	B-X
,	B-X
and	B-X
the	B-X
biomedical	B-X
journal	B-X
literature	B-X
via	B-X
PubMed	B-X
.	B-X

Variables	O
that	O
have	O
been	O
described	O
by	O
others	O
as	O
barriers	O
such	O
as	O
accessibility	O
,	O
high	O
speed	O
internet	O
access	O
,	O
patient	B-Species
volume	O
,	O
age	O
,	O
practitioner	O
type	O
,	O
and	O
technology	O
support	O
did	O
not	O
appear	O
to	O
influence	O
computer	O
searching	O
for	O
information	O
on	O
drugs	O
or	O
therapeutics	O
related	O
to	O
patient	B-Species
care	O
in	O
our	O
results	O
.	O
<EOS>	B-X
Hematologic	B-X
malignancies	B-X
are	B-X
a	B-X
heterogeneous	B-X
group	B-X
of	B-X
diseases	B-X
with	B-X
unique	B-X
illness	B-X
trajectories	B-X
,	B-X
treatment	B-X
paradigms	B-X
,	B-X
and	B-X
potential	B-X
for	B-X
curability	B-X
,	B-X
which	B-X
affect	B-X
patients	B-X
'	B-X
palliative	B-X
and	B-X
end-of-life	B-X
care	B-X
needs	B-X
.	B-X
Compared	B-X
with	B-X
patients	B-X
with	B-X
solid	B-X
tumors	B-X
,	B-X
those	B-X
with	B-X
hematologic	B-X
malignancies	B-X
also	B-X
experience	B-X
high	B-X
rates	B-X
of	B-X
hospitalizations	B-X
,	B-X
intensive	B-X
care	B-X
unit	B-X
admissions	B-X
,	B-X
and	B-X
in-hospital	B-X
deaths	B-X
and	B-X
low	B-X
rates	B-X
of	B-X
referral	B-X
to	B-X
hospice	B-X
as	B-X
well	B-X
as	B-X
shorter	B-X
hospice	B-X
length	B-X
of	B-X
stay	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
patients	B-X
with	B-X
hematologic	B-X
malignancies	B-X
harbor	B-X
substantial	B-X
misperceptions	B-X
about	B-X
treatment	B-X
risks	B-X
and	B-X
benefits	B-X
and	B-X
frequently	B-X
overestimate	B-X
their	B-X
prognosis	B-X
.	B-X
Despite	B-X
these	B-X
substantial	B-X
unmet	B-X
needs	B-X
,	B-X
specialty	B-X
palliative	B-X
care	B-X
services	B-X
are	B-X
infrequently	B-X
consulted	B-X
for	B-X
the	B-X
care	B-X
of	B-X
patients	B-X
with	B-X
hematologic	B-X
malignancies	B-X
.	B-X
Several	B-X
illness-specific	B-X
,	B-X
cultural	B-X
,	B-X
and	B-X
system-based	B-X
barriers	B-X
to	B-X
palliative	B-X
care	B-X
integration	B-X
and	B-X
optimal	B-X
end-of-life	B-X
care	B-X
exist	B-X
in	B-X
this	B-X
population	B-X
.	B-X
However	B-X
,	B-X
recent	B-X
evidence	B-X
has	B-X
demonstrated	B-X
the	B-X
feasibility	B-X
,	B-X
acceptability	B-X
,	B-X
and	B-X
efficacy	B-X
of	B-X
integrating	B-X
palliative	B-X
care	B-X
to	B-X
improve	B-X
the	B-X
quality	B-X
of	B-X
life	B-X
and	B-X
care	B-X
of	B-X
patients	B-X
with	B-X
hematologic	B-X
malignancies	B-X
and	B-X
their	B-X
caregivers	B-X
.	B-X
More	B-X
research	B-X
is	B-X
needed	B-X
to	B-X
develop	B-X
and	B-X
test	B-X
population-specific	B-X
palliative	B-X
and	B-X
supportive	B-X
care	B-X
interventions	B-X
to	B-X
ensure	B-X
generalizability	B-X
and	B-X
to	B-X
define	B-X
a	B-X
sustainable	B-X
clinical	B-X
delivery	B-X
model	B-X
.	B-X
Future	B-X
work	B-X
also	B-X
should	B-X
focus	B-X
on	B-X
identifying	B-X
moderators	B-X
and	B-X
mediators	B-X
of	B-X
the	B-X
effect	B-X
of	B-X
integrated	B-X
palliative	B-X
care	B-X
models	B-X
on	B-X
patient-reported	B-X
outcomes	B-X
and	B-X
on	B-X
developing	B-X
less	B-X
resource-intensive	B-X
integrated	B-X
care	B-X
models	B-X
to	B-X
address	B-X
the	B-X
diverse	B-X
needs	B-X
of	B-X
this	B-X
population	B-X
.	B-X

Some	O
qualitative	O
feedback	O
does	O
however	O
support	O
this	O
notion	O
.	O
<EOS>	B-X
Qualitative	B-X
reviews	B-X
of	B-X
studies	B-X
suggested	B-X
that	B-X
the	B-X
forced	B-X
confabulation	B-X
effect	B-X
is	B-X
enhanced	B-X
after	B-X
receiving	B-X
confirmatory	B-X
feedback	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
meta-analysis	B-X
supports	B-X
the	B-X
notion	B-X
that	B-X
forcing	B-X
participants	B-X
to	B-X
confabulate	B-X
can	B-X
lead	B-X
them	B-X
to	B-X
later	B-X
report	B-X
such	B-X
confabulations	B-X
as	B-X
part	B-X
of	B-X
the	B-X
truth	B-X
.	B-X
This	B-X
study	B-X
challenges	B-X
the	B-X
notion	B-X
that	B-X
people	B-X
living	B-X
with	B-X
dementia	B-X
are	B-X
unable	B-X
to	B-X
achieve	B-X
novel	B-X
learning	B-X
without	B-X
focussed	B-X
intervention	B-X
techniques	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
is	B-X
to	B-X
explore	B-X
how	B-X
a	B-X
woman	B-X
living	B-X
with	B-X
dementia	B-X
(	B-X
Alzheimer	B-X
's	B-X
disease	B-X
)	B-X
learns	B-X
to	B-X
use	B-X
a	B-X
tablet	B-X
computer	B-X
with	B-X
support	B-X
from	B-X
communicative	B-X
partners	B-X
.	B-X

As	O
an	O
example	O
,	O
in	O
response	O
to	O
a	O
request	O
for	O
a	O
rationale	O
for	O
not	O
using	O
computers	O
one	O
physician	O
commented	O
:	O
"	O
Retro	O
tech	O
[	O
sic	O
]	O
/	O
old	O
fashion	O
.	O
<EOS>	B-X
Dysfunction	B-X
of	B-X
lipid	B-X
metabolism	B-X
in	B-X
white	B-X
adipose	B-X
tissue	B-X
can	B-X
substantially	B-X
interfere	B-X
with	B-X
health	B-X
and	B-X
quality	B-X
of	B-X
life	B-X
,	B-X
for	B-X
example	B-X
in	B-X
obesity	B-X
and	B-X
associated	B-X
metabolic	B-X
diseases	B-X
.	B-X
Components	B-X
of	B-X
the	B-X
Janus	B-X
kinase	B-X
(	B-X
JAK	B-X
)	B-X
-signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
(	B-X
STAT	B-X
)	B-X
pathway	B-X
are	B-X
involved	B-X
in	B-X
adipocyte	B-X
physiology	B-X
and	B-X
pathophysiology	B-X
.	B-X
Nonetheless	B-X
,	B-X
he	B-X
apparently	B-X
died	B-X
peacefully	B-X
in	B-X
his	B-X
sleep	B-X
from	B-X
a	B-X
cardiac	B-X
arrest	B-X
one	B-X
night	B-X
and	B-X
was	B-X
found	B-X
the	B-X
next	B-X
day	B-X
by	B-X
a	B-X
concerned	B-X
neighbor	B-X
.	B-X
In	B-X
our	B-X
absence	B-X
,	B-X
after	B-X
Mr.	B-X
B.	B-X
expired	B-X
,	B-X
his	B-X
death	B-X
certificate	B-X
was	B-X
filled	B-X
out	B-X
by	B-X
a	B-X
physician	B-X
who	B-X
did	B-X
n't	B-X
know	B-X
him	B-X
in	B-X
detail	B-X
,	B-X
but	B-X
did	B-X
know	B-X
why	B-X
he	B-X
recently	B-X
was	B-X
treated	B-X
in	B-X
our	B-X
department	B-X
.	B-X
It	B-X
was	B-X
n't	B-X
long	B-X
after	B-X
his	B-X
death	B-X
before	B-X
we	B-X
began	B-X
to	B-X
receive	B-X
those	B-X
notorious	B-X
``	B-X
requests	B-X
for	B-X
additional	B-X
information	B-X
,	B-X
''	B-X
letters	B-X
from	B-X
the	B-X
statistical	B-X
office	B-X
of	B-X
a	B-X
well-known	B-X
cooperative	B-X
group	B-X
.	B-X
Perhaps	B-X
this	B-X
very	B-X
large	B-X
cancer	B-X
had	B-X
been	B-X
controlled	B-X
and	B-X
Mr.	B-X
B.	B-X
succumbed	B-X
to	B-X
old	B-X
age	B-X
(	B-X
helped	B-X
along	B-X
by	B-X
the	B-X
tobacco	B-X
industry	B-X
)	B-X
.	B-X
The	B-X
forms	B-X
and	B-X
requests	B-X
were	B-X
completed	B-X
with	B-X
a	B-X
succinct	B-X
``	B-X
cause	B-X
of	B-X
death	B-X
uncertain	B-X
,	B-X
''	B-X
adding	B-X
,	B-X
``	B-X
please	B-X
have	B-X
the	B-X
Study	B-X
Chairs	B-X
call	B-X
to	B-X
discuss	B-X
this	B-X
difficult	B-X
case	B-X
.	B-X
''	B-X
Obviously	B-X
,	B-X
for	B-X
any	B-X
OS	B-X
curve	B-X
,	B-X
if	B-X
one	B-X
waits	B-X
long	B-X
enough	B-X
it	B-X
will	B-X
ultimately	B-X
come	B-X
to	B-X
zero	B-X
.	B-X
There	B-X
is	B-X
thus	B-X
a	B-X
very	B-X
logical	B-X
rationale	B-X
for	B-X
reporting	B-X
the	B-X
DSS	B-X
separately	B-X
,	B-X
particularly	B-X
in	B-X
diseases	B-X
where	B-X
death	B-X
from	B-X
intercurrent	B-X
disease	B-X
is	B-X
expected	B-X
to	B-X
be	B-X
common	B-X
.	B-X
Given	B-X
the	B-X
same	B-X
biologic	B-X
disease	B-X
and	B-X
the	B-X
same	B-X
treatment	B-X
,	B-X
the	B-X
DSS	B-X
as	B-X
calculated	B-X
in	B-X
an	B-X
old	B-X
,	B-X
sick	B-X
population	B-X
at	B-X
high	B-X
risk	B-X
of	B-X
intercurrent	B-X
death	B-X
will	B-X
be	B-X
better	B-X
than	B-X
the	B-X
DSS	B-X
in	B-X
a	B-X
younger	B-X
,	B-X
healthier	B-X
population	B-X
whose	B-X
major	B-X
risk	B-X
is	B-X
from	B-X
their	B-X
cancer	B-X
.	B-X
All	B-X
statistical	B-X
endpoints	B-X
(	B-X
e.g.	B-X
,	B-X
response	B-X
rates	B-X
,	B-X
local-regional	B-X
control	B-X
,	B-X
freedom	B-X
from	B-X
brain	B-X
metastases	B-X
)	B-X
,	B-X
except	B-X
OS	B-X
,	B-X
are	B-X
known	B-X
to	B-X
depend	B-X
heavily	B-X
on	B-X
the	B-X
methods	B-X
used	B-X
to	B-X
define	B-X
the	B-X
endpoint	B-X
and	B-X
are	B-X
often	B-X
subject	B-X
to	B-X
significant	B-X
interobserver	B-X
variability	B-X
.	B-X
In	B-X
many	B-X
oncologic	B-X
situations-for	B-X
example	B-X
,	B-X
metastatic	B-X
lung	B-X
cancer-this	B-X
form	B-X
of	B-X
bias	B-X
does	B-X
not	B-X
exist	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
is	B-X
implied	B-X
that	B-X
many	B-X
prostate	B-X
cancer	B-X
metastases	B-X
are	B-X
usually	B-X
not	B-X
of	B-X
themselves	B-X
lethal	B-X
,	B-X
which	B-X
is	B-X
a	B-X
misconception	B-X
to	B-X
anyone	B-X
experienced	B-X
in	B-X
taking	B-X
care	B-X
of	B-X
prostate	B-X
cancer	B-X
patients	B-X
.	B-X
Studies	B-X
of	B-X
autopsies	B-X
,	B-X
which	B-X
are	B-X
now	B-X
rarely	B-X
done	B-X
in	B-X
the	B-X
U.S.	B-X
,	B-X
have	B-X
shown	B-X
that	B-X
fatal	B-X
malignant	B-X
tumors	B-X
were	B-X
occasionally	B-X
missed	B-X
by	B-X
clinicians	B-X
and-even	B-X
more	B-X
sobering-an	B-X
occasional	B-X
patient	B-X
thought	B-X
to	B-X
have	B-X
died	B-X
from	B-X
metastatic	B-X
cancer	B-X
is	B-X
found	B-X
to	B-X
have	B-X
no	B-X
tumor	B-X
but	B-X
to	B-X
have	B-X
died	B-X
from	B-X
a	B-X
``	B-X
benign	B-X
''	B-X
cause	B-X
such	B-X
as	B-X
TB	B-X
.	B-X
If	B-X
the	B-X
DSS	B-X
is	B-X
far	B-X
superior	B-X
to	B-X
the	B-X
OS	B-X
,	B-X
the	B-X
population	B-X
being	B-X
studied	B-X
may	B-X
be	B-X
unusually	B-X
sick	B-X
(	B-X
and	B-X
thus	B-X
unrealistic	B-X
)	B-X
,	B-X
or	B-X
there	B-X
may	B-X
be	B-X
a	B-X
bias	B-X
in	B-X
classifying	B-X
the	B-X
causes	B-X
of	B-X
death	B-X
.	B-X
We	B-X
honestly	B-X
think	B-X
that	B-X
everybody	B-X
has	B-X
a	B-X
few	B-X
patients	B-X
like	B-X
Mr.	B-X
B	B-X
.	B-X

I	O
still	O
like	O
to	O
use	O
my	O
mind	O
and	O
have	O
always	O
been	O
a	O
fan	O
of	O
pen	O
and	O
paper	O
"	O
.	O

Barriers	O
that	O
were	O
identified	O
with	O
our	O
sample	O
regarding	O
the	O
use	O
of	O
handheld	O
technologies	O
such	O
as	O
PDAs	O
included	O
cost	O
,	O
time	O
,	O
and	O
issues	O
related	O
to	O
technology	O
literacy	O
.	O

Several	O
people	B-Species
questioned	O
the	O
value	O
of	O
PDAs	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
if	B-X
using	B-X
personal	B-X
digital	B-X
assistants	B-X
(	B-X
PDAs	B-X
)	B-X
increased	B-X
accuracy	B-X
and	B-X
efficiency	B-X
of	B-X
clinical	B-X
decisions	B-X
made	B-X
by	B-X
novice	B-X
nurse	B-X
practitioners	B-X
(	B-X
NPs	B-X
)	B-X
.	B-X
This	B-X
study	B-X
reports	B-X
on	B-X
personal	B-X
digital	B-X
assistants	B-X
(	B-X
PDAs	B-X
)	B-X
as	B-X
a	B-X
means	B-X
to	B-X
prepare	B-X
nurse	B-X
professionals	B-X
who	B-X
value	B-X
and	B-X
seek	B-X
current	B-X
information	B-X
.	B-X
A	B-X
pre-post	B-X
and	B-X
comparative	B-X
group	B-X
design	B-X
of	B-X
second-degree	B-X
students	B-X
in	B-X
the	B-X
accelerated	B-X
and	B-X
traditional	B-X
baccalaureate	B-X
nursing	B-X
degree	B-X
(	B-X
BSN	B-X
)	B-X
options	B-X
was	B-X
used	B-X
to	B-X
examine	B-X
students	B-X
'	B-X
information-seeking	B-X
behaviors	B-X
,	B-X
and	B-X
the	B-X
effectiveness	B-X
and	B-X
cost	B-X
of	B-X
innovation	B-X
strategies	B-X
associated	B-X
with	B-X
incorporation	B-X
of	B-X
PDAs	B-X
into	B-X
students	B-X
'	B-X
clinical	B-X
practice	B-X
.	B-X
Results	B-X
of	B-X
this	B-X
study	B-X
support	B-X
PDAs	B-X
as	B-X
an	B-X
effective	B-X
student	B-X
learning	B-X
resource	B-X
,	B-X
especially	B-X
for	B-X
reference	B-X
materials	B-X
.	B-X
The	B-X
student	B-X
group	B-X
with	B-X
PDAs	B-X
had	B-X
increasing	B-X
numbers	B-X
of	B-X
questions	B-X
associated	B-X
with	B-X
clinical	B-X
situations	B-X
and	B-X
a	B-X
greater	B-X
recognition	B-X
of	B-X
the	B-X
need	B-X
to	B-X
use	B-X
current	B-X
resources	B-X
.	B-X
Students	B-X
made	B-X
substantial	B-X
use	B-X
of	B-X
their	B-X
PDAs	B-X
and	B-X
health	B-X
team	B-X
members	B-X
,	B-X
while	B-X
decreasing	B-X
reliance	B-X
on	B-X
textbooks	B-X
and	B-X
clinical	B-X
faculty	B-X
.	B-X
Providing	B-X
faculty	B-X
with	B-X
PDAs	B-X
is	B-X
recommended	B-X
to	B-X
enhance	B-X
their	B-X
comfort	B-X
with	B-X
and	B-X
incorporation	B-X
of	B-X
PDAs	B-X
into	B-X
clinical	B-X
teaching	B-X
.	B-X

One	O
GP	O
stated	O
when	O
referring	O
to	O
a	O
PDA	O
:	O
"	O
So	O
far	O
I	O
have	O
not	O
discovered	O
a	O
use	O
for	O
one	O
"	O
.	O
<EOS>	B-X
Fusarium	B-X
isolates	B-X
were	B-X
recovered	B-X
from	B-X
surface-sterilized	B-X
root	B-X
tissue	B-X
on	B-X
peptone	B-X
PCNB	B-X
agar	B-X
(	B-X
2	B-X
)	B-X
.	B-X
Single-spore	B-X
isolates	B-X
were	B-X
transferred	B-X
to	B-X
synthetic	B-X
low	B-X
nutrient	B-X
agar	B-X
(	B-X
SNA	B-X
)	B-X
overlain	B-X
with	B-X
pieces	B-X
(	B-X
1	B-X
Ã	B-X
2	B-X
cm	B-X
)	B-X
of	B-X
sterile	B-X
filter	B-X
paper	B-X
,	B-X
and	B-X
to	B-X
potato	B-X
dextrose	B-X
agar	B-X
(	B-X
PDA	B-X
)	B-X
,	B-X
and	B-X
placed	B-X
in	B-X
the	B-X
dark	B-X
for	B-X
10	B-X
to	B-X
14	B-X
days	B-X
for	B-X
morphological	B-X
identification	B-X
(	B-X
4	B-X
)	B-X
.	B-X
Colonies	B-X
on	B-X
PDA	B-X
had	B-X
white	B-X
,	B-X
fluffy	B-X
,	B-X
aerial	B-X
mycelium	B-X
with	B-X
magenta	B-X
to	B-X
violet	B-X
pigmentation	B-X
in	B-X
the	B-X
medium	B-X
.	B-X
AG2403	B-X
)	B-X
in	B-X
a	B-X
greenhouse	B-X
,	B-X
in	B-X
water	B-X
baths	B-X
set	B-X
at	B-X
18Â°C	B-X
,	B-X
using	B-X
autoclaved	B-X
soil	B-X
mixed	B-X
with	B-X
infested	B-X
sand-cornmeal	B-X
inoculum	B-X
(	B-X
3	B-X
)	B-X
.	B-X
The	B-X
experiment	B-X
entailed	B-X
a	B-X
completely	B-X
randomized	B-X
design	B-X
(	B-X
CRD	B-X
)	B-X
with	B-X
five	B-X
replications	B-X
(	B-X
single	B-X
plant/150	B-X
ml	B-X
cone	B-X
)	B-X
per	B-X
treatment	B-X
,	B-X
and	B-X
was	B-X
conducted	B-X
three	B-X
times	B-X
.	B-X
There	B-X
was	B-X
a	B-X
significant	B-X
difference	B-X
between	B-X
isolates	B-X
in	B-X
the	B-X
petri	B-X
dish	B-X
assay	B-X
(	B-X
P	B-X
=	B-X
0.0030	B-X
)	B-X
;	B-X
one	B-X
isolate	B-X
was	B-X
less	B-X
aggressive	B-X
,	B-X
but	B-X
both	B-X
isolates	B-X
resulted	B-X
in	B-X
significantly	B-X
more	B-X
disease	B-X
than	B-X
on	B-X
the	B-X
non-inoculated	B-X
control	B-X
plants	B-X
,	B-X
which	B-X
had	B-X
100	B-X
%	B-X
germination	B-X
and	B-X
no	B-X
symptoms	B-X
(	B-X
P	B-X
<	B-X
0.0001	B-X
)	B-X
.	B-X

Other	O
respondents	O
reinforced	O
their	O
preferences	O
for	O
other	O
resources	O
(	O
e	O
.	O
g	O
.	O
books	O
)	O
and	O
resistance	O
to	O
technology	O
.	O

When	O
responding	O
to	O
barriers	O
for	O
the	O
use	O
of	O
PDAs	O
,	O
one	O
NP	O
commented	O
,	O
"	O
My	O
huge	O
dislike	O
for	O
machinery	O
that	O
frequently	O
requires	O
updating	O
and	O
patience	O
"	O
.	O

A	O
physician	O
responded	O
,	O
"	O
as	O
stated	O
,	O
I	O
like	O
to	O
use	O
my	O
own	O
mind	O
,	O
and	O
can	O
get	O
all	O
the	O
info	O
I	O
need	O
from	O
books	O
relatively	O
quickly	O
"	O
.	O

Facilitators	O
to	O
the	O
use	O
of	O
PDAs	O
mainly	O
included	O
convenience	O
factors	O
such	O
as	O
having	O
resources	O
all	O
in	O
one	O
place	O
,	O
faster	O
means	O
to	O
get	O
information	O
,	O
and	O
portability	O
.	O

Our	O
sample	O
was	O
not	O
in	O
agreement	O
with	O
some	O
convenience	O
factors	O
in	O
that	O
they	O
did	O
not	O
feel	O
that	O
PDAs	O
would	O
decrease	O
paperwork	O
.	O
<EOS>	B-X
femoral	B-X
,	B-X
ideally	B-X
after	B-X
proximal	B-X
ligation	B-X
)	B-X
before	B-X
opening	B-X
the	B-X
body	B-X
,	B-X
minimises	B-X
the	B-X
risk	B-X
of	B-X
sample	B-X
contamination	B-X
with	B-X
,	B-X
for	B-X
example	B-X
,	B-X
gut	B-X
contents	B-X
or	B-X
urine	B-X
.	B-X
Appropriate	B-X
sample	B-X
preservation	B-X
,	B-X
transport	B-X
,	B-X
and	B-X
storage	B-X
are	B-X
mandatory	B-X
.	B-X
Interpretation	B-X
of	B-X
post-mortem	B-X
toxicology	B-X
must	B-X
take	B-X
into	B-X
account	B-X
what	B-X
is	B-X
known	B-X
of	B-X
the	B-X
clinical	B-X
pharmacology	B-X
,	B-X
including	B-X
pharmacokinetics	B-X
,	B-X
and	B-X
toxicology	B-X
of	B-X
the	B-X
agent	B-X
(	B-X
s	B-X
)	B-X
in	B-X
question	B-X
,	B-X
the	B-X
circumstances	B-X
under	B-X
which	B-X
death	B-X
occurred	B-X
including	B-X
the	B-X
possible	B-X
mechanism	B-X
(	B-X
s	B-X
)	B-X
of	B-X
exposure	B-X
,	B-X
and	B-X
other	B-X
factors	B-X
such	B-X
as	B-X
the	B-X
sample	B-X
(	B-X
s	B-X
)	B-X
analysed	B-X
and	B-X
the	B-X
analytical	B-X
methods	B-X
used	B-X
.	B-X
Branded	B-X
drug	B-X
samples	B-X
are	B-X
one	B-X
of	B-X
the	B-X
most	B-X
important	B-X
promotional	B-X
tools	B-X
that	B-X
pharmaceutical	B-X
manufactures	B-X
employ	B-X
.	B-X
Pharmaceutical	B-X
sales	B-X
representatives	B-X
(	B-X
``	B-X
drug	B-X
reps	B-X
''	B-X
)	B-X
use	B-X
samples	B-X
to	B-X
gain	B-X
access	B-X
to	B-X
physicians	B-X
and	B-X
other	B-X
prescribers	B-X
.	B-X
Only	B-X
drugs	B-X
with	B-X
the	B-X
highest	B-X
profit	B-X
margins	B-X
are	B-X
sampled	B-X
.	B-X
Although	B-X
physicians	B-X
believe	B-X
that	B-X
samples	B-X
save	B-X
patients	B-X
money	B-X
,	B-X
patients	B-X
who	B-X
receive	B-X
samples	B-X
have	B-X
higher	B-X
overall	B-X
out-of-pocket	B-X
costs	B-X
.	B-X
Most	B-X
studies	B-X
have	B-X
found	B-X
that	B-X
patients	B-X
in	B-X
financial	B-X
need	B-X
are	B-X
least	B-X
likely	B-X
to	B-X
receive	B-X
samples	B-X
.	B-X
Pharmaceutical	B-X
marketers	B-X
pitch	B-X
samples	B-X
as	B-X
a	B-X
low-risk	B-X
way	B-X
to	B-X
deal	B-X
with	B-X
diagnostic	B-X
uncertainty	B-X
.	B-X
In	B-X
fact	B-X
,	B-X
there	B-X
is	B-X
no	B-X
evidence	B-X
that	B-X
samples	B-X
aid	B-X
diagnosis	B-X
.	B-X
Although	B-X
physicians	B-X
believe	B-X
that	B-X
samples	B-X
improve	B-X
adherence	B-X
for	B-X
low-income	B-X
patients	B-X
,	B-X
branded	B-X
samples	B-X
do	B-X
not	B-X
improve	B-X
access	B-X
or	B-X
adherence	B-X
Samples	B-X
are	B-X
not	B-X
a	B-X
charitable	B-X
activity	B-X
,	B-X
but	B-X
are	B-X
instead	B-X
a	B-X
highly	B-X
effective	B-X
form	B-X
of	B-X
drug	B-X
marketing	B-X
.	B-X
Evidence	B-X
supports	B-X
a	B-X
ban	B-X
on	B-X
sample	B-X
distribution	B-X
of	B-X
branded	B-X
products	B-X
.	B-X

Practitioners	O
from	O
our	O
sample	O
felt	O
relatively	O
neutral	O
about	O
PDAs	O
improving	O
patient	B-Species
'	O
s	O
health	O
outcomes	O
with	O
41	O
%	O
responding	O
in	O
this	O
manner	O
.	O

Results	O
from	O
a	O
sample	O
of	O
primary	O
care	O
practitioners	O
in	O
the	O
US	O
revealed	O
that	O
76	O
%	O
agreed	O
that	O
the	O
use	O
of	O
handheld	O
devices	O
for	O
electronic	O
prescribing	O
would	O
substantially	O
reduce	O
medical	O
errors	O
and	O
improve	O
the	O
quality	O
of	O
health	O
care	O
[	O
67	O
]	O
.	O

Our	O
study	O
also	O
suggests	O
that	O
resources	O
such	O
as	O
the	O
Cochrane	O
Library	O
and	O
its	O
Database	O
of	O
Systematic	O
Reviews	O
were	O
not	O
frequently	O
used	O
.	O
<EOS>	B-X
However	B-X
,	B-X
the	B-X
therapeutic	B-X
effects	B-X
of	B-X
early	B-X
mobilization	B-X
have	B-X
been	B-X
difficult	B-X
to	B-X
interpret	B-X
due	B-X
to	B-X
variations	B-X
in	B-X
study	B-X
populations	B-X
,	B-X
interventions	B-X
,	B-X
and	B-X
outcome	B-X
measures	B-X
.	B-X
There	B-X
is	B-X
a	B-X
need	B-X
for	B-X
clarity	B-X
on	B-X
the	B-X
effectiveness	B-X
and	B-X
optimal	B-X
models	B-X
of	B-X
HSPC	B-X
,	B-X
given	B-X
that	B-X
most	B-X
people	B-X
still	B-X
die	B-X
in	B-X
hospital	B-X
and	B-X
also	B-X
to	B-X
allocate	B-X
scarce	B-X
resources	B-X
judiciously	B-X
.	B-X
The	B-X
need	B-X
for	B-X
an	B-X
electricity	B-X
supply	B-X
,	B-X
expensive	B-X
handpieces	B-X
and	B-X
highly	B-X
trained	B-X
dental	B-X
health	B-X
personnel	B-X
may	B-X
limit	B-X
access	B-X
to	B-X
dental	B-X
treatment	B-X
,	B-X
especially	B-X
in	B-X
underdeveloped	B-X
regions.To	B-X
overcome	B-X
the	B-X
limitations	B-X
of	B-X
conventional	B-X
restorative	B-X
treatment	B-X
,	B-X
the	B-X
Atraumatic	B-X
Restorative	B-X
Treatment	B-X
(	B-X
ART	B-X
)	B-X
was	B-X
developed	B-X
,	B-X
mainly	B-X
for	B-X
treating	B-X
caries	B-X
in	B-X
children	B-X
living	B-X
in	B-X
under-served	B-X
areas	B-X
of	B-X
the	B-X
world	B-X
where	B-X
resources	B-X
and	B-X
facilities	B-X
such	B-X
as	B-X
electricity	B-X
and	B-X
trained	B-X
manpower	B-X
are	B-X
limited	B-X
.	B-X
This	B-X
is	B-X
an	B-X
update	B-X
of	B-X
a	B-X
Cochrane	B-X
Review	B-X
first	B-X
published	B-X
in	B-X
2008	B-X
,	B-X
which	B-X
suggested	B-X
that	B-X
probiotics	B-X
may	B-X
not	B-X
be	B-X
an	B-X
effective	B-X
treatment	B-X
for	B-X
eczema	B-X
but	B-X
identified	B-X
areas	B-X
in	B-X
which	B-X
evidence	B-X
was	B-X
lacking	B-X
.	B-X

This	O
finding	O
is	O
similar	O
to	O
that	O
of	O
other	O
investigators	O
[	O
30	O
,	O
35	O
,	O
64	O
]	O
.	O
<EOS>	B-X
We	B-X
conclude	B-X
that	B-X
there	B-X
is	B-X
evidence	B-X
to	B-X
suggest	B-X
that	B-X
,	B-X
for	B-X
some	B-X
individuals	B-X
,	B-X
food	B-X
can	B-X
induce	B-X
addictive-type	B-X
behaviours	B-X
similar	B-X
to	B-X
those	B-X
seen	B-X
with	B-X
other	B-X
addictive	B-X
substances	B-X
.	B-X
Understanding	B-X
the	B-X
similarities	B-X
and	B-X
differences	B-X
between	B-X
the	B-X
addictive	B-X
characteristics	B-X
of	B-X
food	B-X
and	B-X
illicit	B-X
substances	B-X
should	B-X
prove	B-X
fruitful	B-X
in	B-X
further	B-X
developing	B-X
these	B-X
interventions	B-X
.	B-X
Stargardt	B-X
disease	B-X
is	B-X
the	B-X
most	B-X
common	B-X
inherited	B-X
macular	B-X
dystrophy	B-X
but	B-X
has	B-X
a	B-X
wide	B-X
clinical	B-X
spectrum	B-X
,	B-X
and	B-X
several	B-X
inherited	B-X
macular	B-X
dystrophies	B-X
have	B-X
phenotypic	B-X
similarities	B-X
that	B-X
can	B-X
make	B-X
clinical	B-X
diagnosis	B-X
challenging	B-X
.	B-X
Although	B-X
many	B-X
trials	B-X
have	B-X
similar	B-X
type	B-X
of	B-X
interventions	B-X
,	B-X
methodological	B-X
heterogeneity	B-X
may	B-X
challenge	B-X
study	B-X
comparisons	B-X
,	B-X
and	B-X
future	B-X
meta-analyses	B-X
aiming	B-X
to	B-X
provide	B-X
evidence-based	B-X
recommendations	B-X
.	B-X

Despite	O
the	O
desire	O
of	O
some	O
clinicians	O
to	O
use	O
these	O
resources	O
,	O
lack	O
of	O
confidence	O
and	O
ability	O
to	O
use	O
them	O
appropriately	O
has	O
been	O
found	O
[	O
30	O
,	O
64	O
,	O
68	O
,	O
69	O
]	O
.	O

Our	O
study	O
suggests	O
that	O
although	O
this	O
resource	O
is	O
perceived	O
as	O
credible	O
,	O
current	O
/	O
timely	O
,	O
and	O
useful	O
,	O
it	O
is	O
also	O
perceived	O
to	O
be	O
somewhat	O
inaccessible	O
.	O

The	O
Cochrane	O
Library	O
is	O
available	O
to	O
the	O
health	O
professionals	O
(	O
e	O
.	O
g	O
.	O
nurses	O
,	O
physicians	O
,	O
pharmacists	O
,	O
occupational	O
therapists	O
,	O
physiotherapists	O
,	O
etc	O
.	O
)	O
in	O
our	O
sample	O
through	O
professional	O
bodies	O
via	O
the	O
Atlantic	O
Health	O
Knowledge	O
Partnership	O
[	O
70	O
]	O
.	O

Technology	O
training	O
:	O
preferences	O
and	O
incentives	O
<EOS>	B-X
Food	B-X
choices	B-X
must	B-X
be	B-X
strongly	B-X
supported	B-X
by	B-X
clinical	B-X
behavior	B-X
change	B-X
efforts	B-X
,	B-X
health	B-X
systems	B-X
reforms	B-X
,	B-X
novel	B-X
technologies	B-X
,	B-X
and	B-X
robust	B-X
policy	B-X
strategies	B-X
targeting	B-X
economic	B-X
incentives	B-X
,	B-X
schools	B-X
and	B-X
workplaces	B-X
,	B-X
neighborhood	B-X
environments	B-X
,	B-X
and	B-X
the	B-X
food	B-X
system	B-X
.	B-X
Isabel	B-X
Barroso	B-X
,	B-X
Leila	B-X
Lapa	B-X
,	B-X
Cristina	B-X
Antunes	B-X
O72	B-X
Labour	B-X
stress	B-X
in	B-X
nursing	B-X
Ana	B-X
GonÃ§alves	B-X
,	B-X
Ana	B-X
GalvÃ£o	B-X
,	B-X
MÂª	B-X
JosÃ©	B-X
Gomes	B-X
,	B-X
Susana	B-X
R.	B-X
Escanciano	B-X
O73	B-X
The	B-X
influence	B-X
of	B-X
safe	B-X
staff	B-X
nursing	B-X
in	B-X
patient	B-X
satisfaction	B-X
with	B-X
nursing	B-X
care	B-X
Maria	B-X
Freitas	B-X
,	B-X
Pedro	B-X
Parreira	B-X
,	B-X
JoÃ£o	B-X
MarÃ´co	B-X
O74	B-X
Intention	B-X
to	B-X
use	B-X
eHealth	B-X
strategies	B-X
with	B-X
nursing	B-X
students	B-X
Ana	B-X
R.	B-X
Fernandes	B-X
,	B-X
Cremilde	B-X
Cabral	B-X
,	B-X
Samuel	B-X
Alves	B-X
,	B-X
Pedro	B-X
Sousa	B-X
O75	B-X
Community	B-X
Based	B-X
Mental	B-X
Health	B-X
:	B-X
contributions	B-X
of	B-X
an	B-X
interdisciplinary	B-X
international	B-X
program	B-X
for	B-X
students	B-X
in	B-X
higher	B-X
health	B-X
education	B-X
AntÃ³nio	B-X
Ferreira	B-X
,	B-X
Fernanda	B-X
PrÃ­ncipe	B-X
,	B-X
Ulla-Maija	B-X
SeppÃ¤nen	B-X
,	B-X
Margarida	B-X
Ferreira	B-X
,	B-X
Maribel	B-X
Carvalhais	B-X
,	B-X
Marilene	B-X
Silva	B-X
O76	B-X
Study	B-X
of	B-X
satisfaction	B-X
at	B-X
work	B-X
of	B-X
graduates	B-X
in	B-X
nursing	B-X
:	B-X
2002-2014	B-X
Manuela	B-X
Ferreira	B-X
,	B-X
Joana	B-X
Silva	B-X
,	B-X
JÃ©ssica	B-X
Neves	B-X
,	B-X
Diana	B-X
Costa	B-X
,	B-X
Bruno	B-X
Santos	B-X
,	B-X
Soraia	B-X
Duarte	B-X
O77	B-X
Health	B-X
professionals	B-X
â	B-X
attitudes	B-X
towards	B-X
breastfeeding	B-X
SÃ­lvia	B-X
Marques	B-X
,	B-X
SÃ³nia	B-X
Ramalho	B-X
,	B-X
Isabel	B-X
Mendes	B-X
O78	B-X
Continuity	B-X
of	B-X
nursing	B-X
care	B-X
to	B-X
person	B-X
with	B-X
type	B-X
2	B-X
diabetes	B-X
Clarisse	B-X
Louro	B-X
,	B-X
Eva	B-X
Menino	B-X
,	B-X
Maria	B-X
Dixe	B-X
,	B-X
Sara	B-X
S.	B-X
Dias	B-X
O79	B-X
Stigma	B-X
toward	B-X
mental	B-X
illness	B-X
among	B-X
future	B-X
health	B-X
professionals	B-X
Marina	B-X
Cordeiro	B-X
,	B-X
Catarina	B-X
TomÃ¡s	B-X
,	B-X
Ana	B-X
Querido	B-X
,	B-X
Daniel	B-X
Carvalho	B-X
,	B-X
JoÃ£o	B-X
Gomes	B-X
O80	B-X
Working	B-X
with	B-X
fears	B-X
and	B-X
anxieties	B-X
of	B-X
medical	B-X
students	B-X
in	B-X
search	B-X
of	B-X
a	B-X
humanized	B-X
care	B-X
Frederico	B-X
C.	B-X
Valim	B-X
,	B-X
Joyce	B-X
O.	B-X
Costa	B-X
,	B-X
LÃºcia	B-X
G.	B-X
Bernardes	B-X
P16	B-X
Surgical	B-X
paediatrics	B-X
patients	B-X
â	B-X
psycho	B-X
prophylaxis	B-X
at	B-X
a	B-X
teaching	B-X
hospital	B-X
Helena	B-X
Prebianchi	B-X
P17	B-X
Patient-perceived	B-X
outcomes	B-X
in	B-X
physiotherapy	B-X
â	B-X
a	B-X
pilot	B-X
study	B-X
Marlene	B-X
Cristina	B-X
Rosa	B-X
P18	B-X
Building	B-X
competencies	B-X
for	B-X
managers	B-X
in	B-X
nursing	B-X
Narcisa	B-X
GonÃ§alves	B-X
,	B-X
Maria	B-X
M.	B-X
Martins	B-X
,	B-X
Paulina	B-X
Kurcgant	B-X
P19	B-X
Theoretical	B-X
basis	B-X
underlying	B-X
physiotherapy	B-X
practice	B-X
in	B-X
stroke	B-X
rehabilitation	B-X
AndrÃ©	B-X
Vieira	B-X
P20	B-X
When	B-X
the	B-X
life-cycle	B-X
ends	B-X
:	B-X
the	B-X
nurse	B-X
â	B-X
s	B-X
confrontation	B-X
with	B-X
death	B-X
Sandrina	B-X
Bento	B-X
,	B-X
SÃ©rgio	B-X
Deodato	B-X
,	B-X
Isabel	B-X
Rabiais	B-X
P21	B-X
Nursing	B-X
students	B-X
â	B-X
opinion	B-X
about	B-X
the	B-X
supervision	B-X
relationship	B-X
during	B-X
their	B-X
first	B-X
clinical	B-X
experience	B-X
Laura	B-X
Reis	B-X
P22	B-X
Nursing	B-X
Relational	B-X
Laboratory	B-X
:	B-X
Pedagogical	B-X
,	B-X
dialogic	B-X
and	B-X
critical	B-X
project	B-X
Ana	B-X
Torres	B-X
,	B-X
SÃ©rgio	B-X
Soares	B-X
,	B-X
Margarida	B-X
Ferreira	B-X
,	B-X
Pedro	B-X
GraÃ§a	B-X
P23	B-X
Job	B-X
satisfaction	B-X
of	B-X
bioscientists	B-X
at	B-X
a	B-X
Lisbon	B-X
hospital	B-X
CÃ©u	B-X
LeitÃ£o	B-X
,	B-X
Renato	B-X
Abreu	B-X
,	B-X
Fernando	B-X
BellÃ©m	B-X
,	B-X
Ana	B-X
Almeida	B-X
,	B-X
Edna	B-X
Ribeiro-Varandas	B-X
,	B-X
Ana	B-X
Tavares	B-X
P24	B-X
Sociodemographic	B-X
and	B-X
professional	B-X
profile	B-X
of	B-X
nurses	B-X
and	B-X
its	B-X
relation	B-X
with	B-X
the	B-X
importance	B-X
of	B-X
family	B-X
in	B-X
nursing	B-X
practices	B-X
JoÃ£o	B-X
G.	B-X
Frade	B-X
,	B-X
Carolina	B-X
Henriques	B-X
,	B-X
Eva	B-X
Menino	B-X
,	B-X
Clarisse	B-X
Louro	B-X
,	B-X
CÃ©lia	B-X
JordÃ£o	B-X
P25	B-X
Professional	B-X
satisfaction	B-X
of	B-X
rehabilitation	B-X
nurses	B-X
Sofia	B-X
Neco	B-X
,	B-X
Carminda	B-X
Morais	B-X
,	B-X
Pedro	B-X
Ferreira	B-X
P26	B-X
The	B-X
person	B-X
living	B-X
with	B-X
a	B-X
stoma	B-X
:	B-X
the	B-X
formalization	B-X
of	B-X
knowledge	B-X
in	B-X
nursing	B-X
Carla	B-X
R.	B-X
Silva	B-X
,	B-X
Alice	B-X
Brito	B-X
,	B-X
AntÃ³nia	B-X
Silva	B-X
P27	B-X
Validation	B-X
of	B-X
the	B-X
Portuguese	B-X
versions	B-X
of	B-X
the	B-X
nursing	B-X
students	B-X
â	B-X
perceptions	B-X
of	B-X
learning	B-X
and	B-X
learner	B-X
satisfaction	B-X
with	B-X
simulation	B-X
tool	B-X
Hugo	B-X
Duarte	B-X
,	B-X
Maria	B-X
Dos	B-X
Anjos	B-X
Dixe	B-X
,	B-X
Pedro	B-X
Sousa	B-X
P28	B-X
Physiotherapists	B-X
â	B-X
perceived	B-X
knowledge	B-X
on	B-X
technologies	B-X
for	B-X
electronic	B-X
health	B-X
records	B-X
for	B-X
physiotherapy	B-X
Gabriela	B-X
Postolache	B-X
,	B-X
Raul	B-X
Oliveira	B-X
,	B-X
Isabel	B-X
Moreira	B-X
,	B-X
LuÃ­sa	B-X
Pedro	B-X
,	B-X
SÃ³nia	B-X
Vicente	B-X
,	B-X
Samuel	B-X
Domingos	B-X
,	B-X
Octavian	B-X
Postolache	B-X
P29	B-X
Quality	B-X
of	B-X
life	B-X
and	B-X
physical	B-X
activity	B-X
of	B-X
medicine	B-X
undergraduate	B-X
students	B-X
in	B-X
the	B-X
University	B-X
of	B-X
Southern	B-X
Santa	B-X
Catarina	B-X
,	B-X
Brazil	B-X
Darlen	B-X
Silva	B-X
,	B-X
JoÃ£o	B-X
G.	B-X
Filho	B-X
,	B-X
Nazare	B-X
Nazario	B-X
,	B-X
Marcia	B-X
Kretzer	B-X
,	B-X
Dulcineia	B-X
Schneider	B-X
P30	B-X
The	B-X
curricular	B-X
skills	B-X
for	B-X
decision	B-X
making	B-X
education	B-X
in	B-X
a	B-X
Nursing	B-X
Degree	B-X
FÃ¡tima	B-X
M.	B-X
Marques	B-X
P31	B-X
Effect	B-X
of	B-X
nurses	B-X
â	B-X
mobilization	B-X
in	B-X
satisfaction	B-X
at	B-X
work	B-X
and	B-X
turnover	B-X
:	B-X
An	B-X
empirical	B-X
study	B-X
in	B-X
the	B-X
hospital	B-X
setting	B-X
Pedro	B-X
Parreira	B-X
,	B-X
Carla	B-X
Carvalho	B-X
,	B-X
Lisete	B-X
M.	B-X
MÃ³nico	B-X
,	B-X
Carlos	B-X
Pinto	B-X
,	B-X
Sara	B-X
Vicente	B-X
,	B-X
SÃ£o	B-X
JoÃ£o	B-X
Breda	B-X
P32	B-X
Entrepreneurial	B-X
skills	B-X
of	B-X
students	B-X
of	B-X
polytechnic	B-X
higher	B-X
education	B-X
in	B-X
Portugal	B-X
:	B-X
Business	B-X
influences	B-X
JosÃ©	B-X
H.	B-X
Gomes	B-X
,	B-X
Rosa	B-X
Melo	B-X
,	B-X
Pedro	B-X
Parreira	B-X
,	B-X
Anabela	B-X
Salgueiro	B-X
,	B-X
JoÃ£o	B-X
Graveto	B-X
,	B-X
Marina	B-X
Vaquinhas	B-X
,	B-X
AmÃ©lia	B-X
Castilho	B-X
P33	B-X
Design	B-X
and	B-X
assessment	B-X
of	B-X
e-learning	B-X
modules	B-X
for	B-X
Pharmacology	B-X
Ãngelo	B-X
Jesus	B-X
,	B-X
Nuno	B-X
Duarte	B-X
,	B-X
JosÃ©	B-X
C.	B-X
Lopes	B-X
,	B-X
HÃ©lder	B-X
Nunes	B-X
,	B-X
Agostinho	B-X
Cruz	B-X
P34	B-X
Perspective	B-X
of	B-X
nurses	B-X
involved	B-X
in	B-X
an	B-X
action-research	B-X
study	B-X
on	B-X
the	B-X
changes	B-X
observed	B-X
in	B-X
care	B-X
provision	B-X
:	B-X
results	B-X
from	B-X
a	B-X
focus	B-X
group	B-X
Anabela	B-X
Salgueiro-Oliveira	B-X
,	B-X
Pedro	B-X
Parreira	B-X
,	B-X
Marta	B-X
L.	B-X
Basto	B-X
,	B-X
Luciene	B-X
M.	B-X
Braga	B-X
P35	B-X
Use	B-X
of	B-X
peer	B-X
feedback	B-X
by	B-X
nursing	B-X
students	B-X
during	B-X
clinical	B-X
training	B-X
:	B-X
teacher	B-X
â	B-X
s	B-X
perception	B-X
AntÃ³nio	B-X
Ferreira	B-X
,	B-X
Beatriz	B-X
AraÃºjo	B-X
,	B-X
JosÃ©	B-X
M.	B-X
Alves	B-X
,	B-X
Margarida	B-X
Ferreira	B-X
,	B-X
Maribel	B-X
Carvalhais	B-X
,	B-X
Marilene	B-X
Silva	B-X
,	B-X
SÃ³nia	B-X
Novais	B-X
P36	B-X
What	B-X
â	B-X
s	B-X
new	B-X
on	B-X
endotracheal	B-X
suctioning	B-X
recommendations	B-X
Ana	B-X
S.	B-X
Sousa	B-X
,	B-X
CÃ¢ndida	B-X
Ferrito	B-X
P37	B-X
Assessment	B-X
of	B-X
the	B-X
nurses	B-X
satisfaction	B-X
on	B-X
the	B-X
Central	B-X
Region	B-X
of	B-X
Portugal	B-X
Pedro	B-X
L.	B-X
Ferreira	B-X
,	B-X
Alexandre	B-X
Rodrigues	B-X
,	B-X
Margarida	B-X
Ferreira	B-X
,	B-X
Isabel	B-X
Oliveira	B-X
P38	B-X
Study	B-X
of	B-X
graduate	B-X
â	B-X
s	B-X
satisfaction	B-X
with	B-X
the	B-X
school	B-X
of	B-X
nursing	B-X
Manuela	B-X
Ferreira	B-X
,	B-X
JÃ©ssica	B-X
Neves	B-X
,	B-X
Diana	B-X
Costa	B-X
,	B-X
Soraia	B-X
Duarte	B-X
,	B-X
Joana	B-X
Silva	B-X
,	B-X
Bruno	B-X
Santos	B-X
P39	B-X
Partnership	B-X
between	B-X
the	B-X
school	B-X
of	B-X
nursing	B-X
and	B-X
the	B-X
hospital	B-X
:	B-X
SupervisorsÂ´	B-X
perspectives	B-X
Cristina	B-X
Martins	B-X
,	B-X
Ana	B-X
P.	B-X
Macedo	B-X
,	B-X
Odete	B-X
AraÃºjo	B-X
,	B-X
ClÃ¡udia	B-X
Augusto	B-X
,	B-X
FÃ¡tima	B-X
Braga	B-X
,	B-X
Lisa	B-X
Gomes	B-X
,	B-X
Maria	B-X
A.	B-X
Silva	B-X
,	B-X
Rafaela	B-X
RosÃ¡rio	B-X
P40	B-X
Coping	B-X
strategies	B-X
of	B-X
college	B-X
students	B-X
LuÃ­s	B-X
Pimenta	B-X
,	B-X
Diana	B-X
Carreira	B-X
,	B-X
PatrÃ­cia	B-X
Teles	B-X
,	B-X
Teresa	B-X
Barros	B-X
P41	B-X
Emotional	B-X
intelligence	B-X
and	B-X
mental	B-X
health	B-X
stigma	B-X
in	B-X
health	B-X
students	B-X
Catarina	B-X
TomÃ¡s	B-X
,	B-X
Ana	B-X
Querido	B-X
,	B-X
Daniel	B-X
Carvalho	B-X
,	B-X
JoÃ£o	B-X
Gomes	B-X
,	B-X
Marina	B-X
Cordeiro	B-X
P42	B-X
Stigma	B-X
of	B-X
mental	B-X
health	B-X
assessment	B-X
:	B-X
Comparison	B-X
between	B-X
health	B-X
courses	B-X
Daniel	B-X
Carvalho	B-X
,	B-X
Ana	B-X
Querido	B-X
,	B-X
Catarina	B-X
TomÃ¡s	B-X
,	B-X
JoÃ£o	B-X
Gomes	B-X
,	B-X
Marina	B-X
Cordeiro	B-X
O81	B-X
Short-	B-X
and	B-X
long-term	B-X
effects	B-X
of	B-X
pulmonary	B-X
rehabilitation	B-X
in	B-X
mild	B-X
COPD	B-X
Cristina	B-X
JÃ¡come	B-X
,	B-X
Alda	B-X
Marques	B-X
O82	B-X
Phonological	B-X
awareness	B-X
programme	B-X
for	B-X
preschool	B-X
children	B-X
Sylvie	B-X
Capelas	B-X
,	B-X
Andreia	B-X
Hall	B-X
,	B-X
Dina	B-X
Alves	B-X
,	B-X
Marisa	B-X
Lousada	B-X
O83	B-X
REforma	B-X
ATIVA	B-X
:	B-X
An	B-X
efficient	B-X
health	B-X
promotion	B-X
program	B-X
to	B-X
be	B-X
implemented	B-X
during	B-X
retirement	B-X
MÂª	B-X
Helena	B-X
Loureiro	B-X
,	B-X
Ana	B-X
Camarneiro	B-X
,	B-X
Margarida	B-X
Silva	B-X
,	B-X
Aida	B-X
Mendes	B-X
,	B-X
Ana	B-X
Pedreiro	B-X
O84	B-X
Intervention	B-X
for	B-X
men	B-X
who	B-X
batter	B-X
women	B-X
,	B-X
a	B-X
case	B-X
report	B-X
Anne	B-X
G.Silva	B-X
,	B-X
Elza	B-X
S.	B-X
Coelho	B-X
O85	B-X
Immediate	B-X
effects	B-X
of	B-X
Bowen	B-X
Therapy	B-X
on	B-X
muscle	B-X
tone	B-X
and	B-X
flexibility	B-X
FlÃ¡vio	B-X
Melo	B-X
,	B-X
Fernando	B-X
Ribeiro	B-X
,	B-X
Rui	B-X
Torres	B-X
,	B-X
Rui	B-X
Costa	B-X
O86	B-X
Predictive	B-X
equation	B-X
for	B-X
incremental	B-X
shuttle	B-X
walk	B-X
test	B-X
in	B-X
adolescents	B-X
TÃ¢nia	B-X
Pinho	B-X
,	B-X
Cristina	B-X
JÃ¡come	B-X
,	B-X
Alda	B-X
Marques	B-X
O87	B-X
Life	B-X
satisfaction	B-X
and	B-X
psychopathology	B-X
in	B-X
institutionalized	B-X
elderly	B-X
people	B-X
:	B-X
The	B-X
results	B-X
of	B-X
an	B-X
adapted	B-X
Mindfulness-Based	B-X
Stress	B-X
Reduction	B-X
program	B-X
BÃ¡rbara	B-X
Cruz	B-X
,	B-X
Daniel	B-X
Seabra	B-X
,	B-X
Diogo	B-X
Carreira	B-X
,	B-X
Maria	B-X
Ventura	B-X
O88	B-X
Outcome	B-X
changes	B-X
in	B-X
COPD	B-X
rehabilitation	B-X
:	B-X
exploring	B-X
the	B-X
relationship	B-X
between	B-X
physical	B-X
activity	B-X
and	B-X
health-related	B-X
outcomes	B-X
Joana	B-X
Cruz	B-X
,	B-X
Dina	B-X
Brooks	B-X
,	B-X
Alda	B-X
Marques	B-X
O89	B-X
Assessing	B-X
the	B-X
effectiveness	B-X
of	B-X
a	B-X
Complex	B-X
Nursing	B-X
Intervention	B-X
M	B-X
RosÃ¡rio	B-X
Pinto	B-X
,	B-X
Pedro	B-X
Parreira	B-X
,	B-X
Marta	B-X
Lima-Basto	B-X
,	B-X
Miguel	B-X
Neves	B-X
,	B-X
Lisete	B-X
M.	B-X
MÃ³nico	B-X
O90	B-X
Psychotherapeutic	B-X
intervention	B-X
in	B-X
addiction	B-X
disorders	B-X
:	B-X
Change	B-X
in	B-X
psychopathological	B-X
symptoms	B-X
and	B-X
emotional	B-X
states	B-X
Carla	B-X
Bizarro	B-X
,	B-X
Marina	B-X
Cunha	B-X
,	B-X
Ana	B-X
Galhardo	B-X
,	B-X
Couto	B-X
Margarida	B-X
,	B-X
Ana	B-X
P.	B-X
Amorim	B-X
,	B-X
Eduardo	B-X
Silva	B-X
O91	B-X
Economic	B-X
impact	B-X
of	B-X
a	B-X
nursing	B-X
intervention	B-X
program	B-X
to	B-X
promote	B-X
self-management	B-X
in	B-X
COPD	B-X
Susana	B-X
Cruz	B-X
,	B-X
JosÃ©	B-X
M.	B-X
Padilha	B-X
,	B-X
Jorge	B-X
Valente	B-X
O92	B-X
Multimodal	B-X
acute	B-X
pain	B-X
management	B-X
during	B-X
uterine	B-X
artery	B-X
embolization	B-X
in	B-X
treatment	B-X
of	B-X
uterine	B-X
myomas	B-X
JosÃ©	B-X
T.	B-X
Guerrero	B-X
,	B-X
Francisco	B-X
P.	B-X
Caballero	B-X
,	B-X
Rafael	B-X
B.	B-X
Santos	B-X
,	B-X
Estefania	B-X
P.	B-X
Gonzalez	B-X
,	B-X
FÃ¡tima	B-X
M.	B-X
Monago	B-X
,	B-X
Lierni	B-X
U.	B-X
Ugalde	B-X
,	B-X
Marta	B-X
M.	B-X
VÃ©lez	B-X
,	B-X
Maria	B-X
J.	B-X
Tena	B-X
O93	B-X
Fluid	B-X
administration	B-X
strategies	B-X
in	B-X
major	B-X
surgery	B-X
:	B-X
Goal-directed	B-X
therapy	B-X
JosÃ©	B-X
T.	B-X
Guerrero	B-X
,	B-X
Rafael	B-X
Bravo	B-X
,	B-X
Francisco	B-X
L.	B-X
PÃ©rez-Caballero	B-X
,	B-X
Isabel	B-X
A.	B-X
Becerra	B-X
,	B-X
MÂª	B-X
Elizabeth	B-X
Agudelo	B-X
,	B-X
Guadalupe	B-X
Acedo	B-X
,	B-X
Roberto	B-X
Bajo	B-X
O94	B-X
Development	B-X
and	B-X
implementation	B-X
of	B-X
a	B-X
self-management	B-X
educational	B-X
programme	B-X
using	B-X
lay-led	B-X
â	B-X
s	B-X
in	B-X
adolescents	B-X
Spina	B-X
Bifida	B-X
:	B-X
A	B-X
pilot	B-X
study	B-X
Isabel	B-X
Malheiro	B-X
,	B-X
Filomena	B-X
Gaspar	B-X
,	B-X
LuÃ­sa	B-X
Barros	B-X
O95	B-X
Influence	B-X
of	B-X
chair-based	B-X
yoga	B-X
exercises	B-X
on	B-X
salivary	B-X
anti-microbial	B-X
proteins	B-X
in	B-X
institutionalized	B-X
frail-elderly	B-X
women	B-X
:	B-X
a	B-X
preliminary	B-X
study	B-X
Guilherme	B-X
Furtado	B-X
,	B-X
Mateus	B-X
Uba-Chupel	B-X
,	B-X
Mariana	B-X
Marques	B-X
,	B-X
LuÃ­s	B-X
Rama	B-X
,	B-X
Margarida	B-X
Braga	B-X
,	B-X
JosÃ©	B-X
P.	B-X
Ferreira	B-X
,	B-X
Ana	B-X
MÂª	B-X
Teixeira	B-X
O96	B-X
High	B-X
intensity	B-X
interval	B-X
training	B-X
vs	B-X
moderate	B-X
intensity	B-X
continuous	B-X
training	B-X
impact	B-X
on	B-X
diabetes	B-X
2	B-X
JoÃ£o	B-X
Cruz	B-X
,	B-X
Tiago	B-X
Barbosa	B-X
,	B-X
Ãngela	B-X
SimÃµes	B-X
,	B-X
LuÃ­s	B-X
Coelho	B-X
O97	B-X
Family	B-X
caregiver	B-X
of	B-X
people	B-X
with	B-X
pressure	B-X
ulcer	B-X
:	B-X
Nursing	B-X
intervention	B-X
plan	B-X
Alexandre	B-X
Rodrigues	B-X
,	B-X
Juan-Fernando	B-X
JimÃ©nez-DÃ­az	B-X
,	B-X
Francisco	B-X
Martinez-HernÃ¡ndez	B-X
,	B-X
Bienvenida	B-X
Rodriguez-De-Vera	B-X
,	B-X
Pedro	B-X
Ferreira	B-X
,	B-X
Alexandrina	B-X
Rodrigues	B-X
O98	B-X
Chronic	B-X
effects	B-X
of	B-X
exercise	B-X
on	B-X
motor	B-X
memory	B-X
consolidation	B-X
in	B-X
elderly	B-X
people	B-X
AndrÃ©	B-X
Ramalho	B-X
,	B-X
JoÃ£o	B-X
Petrica	B-X
,	B-X
Pedro	B-X
Mendes	B-X
,	B-X
JoÃ£o	B-X
Serrano	B-X
,	B-X
InÃªs	B-X
Santo	B-X
,	B-X
AntÃ³nio	B-X
Rosado	B-X
O99	B-X
Impression	B-X
cytology	B-X
of	B-X
the	B-X
ocular	B-X
surface	B-X
:	B-X
Collection	B-X
technique	B-X
and	B-X
sample	B-X
processing	B-X
Paula	B-X
MendonÃ§a	B-X
,	B-X
KÃ¡tia	B-X
Freitas	B-X
O100	B-X
Does	B-X
sport	B-X
practice	B-X
affect	B-X
the	B-X
reaction	B-X
time	B-X
in	B-X
neuromuscular	B-X
activity	B-X
?	B-X
Paula	B-X
A.	B-X
Silva	B-X
,	B-X
Lisete	B-X
M.	B-X
MÃ³nico	B-X
,	B-X
Pedro	B-X
M.	B-X
Parreira	B-X
,	B-X
Carla	B-X
Carvalho	B-X
O243	B-X
Work-life	B-X
balance	B-X
in	B-X
health	B-X
professionals	B-X
and	B-X
professors	B-X
:	B-X
comparative	B-X
study	B-X
of	B-X
workers	B-X
with	B-X
shift	B-X
work	B-X
and	B-X
fixed	B-X
schedule	B-X
Carla	B-X
Carvalho	B-X
,	B-X
Pedro	B-X
M.	B-X
Parreira	B-X
,	B-X
Lisete	B-X
M.	B-X
MÃ³nico	B-X
,	B-X
Joana	B-X
Ruivo	B-X
O244	B-X
Technology	B-X
literacy	B-X
in	B-X
self-management	B-X
of	B-X
diabetes	B-X
VÃ¢nia	B-X
Silva	B-X
,	B-X
Paulino	B-X
Sousa	B-X
,	B-X
JosÃ©	B-X
M.	B-X
Padilha	B-X
O245	B-X
Satisfaction	B-X
with	B-X
therapeutic	B-X
education	B-X
and	B-X
its	B-X
relationship	B-X
with	B-X
clinical	B-X
variables	B-X
in	B-X
children	B-X
with	B-X
type	B-X
1	B-X
diabetes	B-X
Vera	B-X
Ferraz	B-X
,	B-X
GraÃ§a	B-X
AparÃ­cio	B-X
,	B-X
JoÃ£o	B-X
Duarte	B-X
O246	B-X
Nutrition-related	B-X
knowledge	B-X
in	B-X
middle-age	B-X
and	B-X
older	B-X
patients	B-X
with	B-X
type	B-X
2	B-X
diabetes	B-X
Carlos	B-X
Vasconcelos	B-X
,	B-X
AntÃ³nio	B-X
Almeida	B-X
,	B-X
Joel	B-X
Neves	B-X
,	B-X
Telma	B-X
Correia	B-X
,	B-X
Helena	B-X
Amorim	B-X
,	B-X
Romeu	B-X
Mendes	B-X
O247	B-X
Validating	B-X
the	B-X
HLS-EU-	B-X
(	B-X
PT	B-X
)	B-X
questionnaire	B-X
to	B-X
measure	B-X
health	B-X
literacy	B-X
in	B-X
adolescents	B-X
(	B-X
CrAdLiSa	B-X
project	B-X
:	B-X
HLS-EU-PT	B-X
)	B-X
LuÃ­s	B-X
Saboga-Nunes	B-X
,	B-X
Madalena	B-X
Cunha	B-X
,	B-X
Carlos	B-X
Albuquerque	B-X
O248	B-X
Health	B-X
education	B-X
in	B-X
people	B-X
with	B-X
coronary	B-X
heart	B-X
disease	B-X
:	B-X
Experience	B-X
of	B-X
the	B-X
cardiology	B-X
department	B-X
of	B-X
a	B-X
hospital	B-X
on	B-X
the	B-X
outskirts	B-X
of	B-X
Lisbon	B-X
Elsa	B-X
S.	B-X
Pereira	B-X
,	B-X
Leonino	B-X
S.	B-X
Santos	B-X
,	B-X
Ana	B-X
S.	B-X
Reis	B-X
,	B-X
Helena	B-X
R.	B-X
Silva	B-X
,	B-X
JoÃ£o	B-X
Rombo	B-X
,	B-X
Jorge	B-X
C.	B-X
Fernandes	B-X
,	B-X
PatrÃ­cia	B-X
Fernandes	B-X
O249	B-X
Information	B-X
and	B-X
training	B-X
needs	B-X
of	B-X
informal	B-X
caregivers	B-X
of	B-X
individuals	B-X
with	B-X
stroke	B-X
sequelae	B-X
:	B-X
a	B-X
qualitative	B-X
survey	B-X
Jaime	B-X
Ribeiro	B-X
,	B-X
Catarina	B-X
Mangas	B-X
,	B-X
Ana	B-X
Freire	B-X
O250	B-X
Prevention	B-X
of	B-X
psychoactive	B-X
substances	B-X
consumption	B-X
in	B-X
students	B-X
from	B-X
6th	B-X
grade	B-X
of	B-X
Albergaria-a-VelhaÂ´s	B-X
School	B-X
Group	B-X
Sara	B-X
Silva	B-X
,	B-X
Irene	B-X
Francisco	B-X
,	B-X
Ana	B-X
Oliveira	B-X
O251	B-X
Promoting	B-X
healthy	B-X
sexuality	B-X
:	B-X
shared	B-X
responsibility	B-X
for	B-X
family	B-X
,	B-X
youth	B-X
and	B-X
educators	B-X
Helena	B-X
Catarino	B-X
,	B-X
MÂª	B-X
Anjos	B-X
Dixe	B-X
,	B-X
MÂª	B-X
Clarisse	B-X
Louro	B-X
O252	B-X
Sexual	B-X
risk	B-X
behaviour	B-X
in	B-X
adolescents	B-X
and	B-X
young	B-X
people	B-X
Saudade	B-X
Lopes	B-X
,	B-X
Anjos	B-X
Dixe	B-X
O253	B-X
Knowledge	B-X
of	B-X
school	B-X
staff	B-X
on	B-X
type	B-X
1	B-X
diabetes	B-X
MÂª	B-X
Anjos	B-X
Dixe	B-X
,	B-X
Eva	B-X
Menino	B-X
,	B-X
Helena	B-X
Catarino	B-X
,	B-X
FÃ¡tima	B-X
Soares	B-X
,	B-X
Ana	B-X
P.	B-X
Oliveira	B-X
,	B-X
Sara	B-X
Gordo	B-X
,	B-X
Teresa	B-X
Kraus	B-X
O254	B-X
Sexual	B-X
health	B-X
in	B-X
adolescents	B-X
:	B-X
the	B-X
impact	B-X
of	B-X
information	B-X
search	B-X
in	B-X
literacy	B-X
Catarina	B-X
TomÃ¡s	B-X
,	B-X
Paulo	B-X
QueirÃ³s	B-X
,	B-X
Teresa	B-X
Rodrigues	B-X
P123	B-X
Improving	B-X
basic	B-X
life	B-X
support	B-X
skills	B-X
in	B-X
adolescents	B-X
through	B-X
a	B-X
training	B-X
programme	B-X
Pedro	B-X
Sousa	B-X
,	B-X
JoÃ£o	B-X
G.	B-X
Frade	B-X
,	B-X
Catarina	B-X
LobÃ£o	B-X
P124	B-X
Difficulties	B-X
in	B-X
sexual	B-X
education	B-X
reported	B-X
by	B-X
basic	B-X
education	B-X
teachers	B-X
in	B-X
the	B-X
city	B-X
of	B-X
Foz	B-X
do	B-X
IguaÃ§u	B-X
-	B-X
Brazil	B-X
Cynthia	B-X
B.	B-X
Moura	B-X
,	B-X
Laysa	B-X
C.	B-X
Dreyer	B-X
,	B-X
Vanize	B-X
Meneghetti	B-X
,	B-X
Priscila	B-X
P.	B-X
Cabral	B-X
P125	B-X
Breast	B-X
cancer	B-X
survivors	B-X
:	B-X
subjects	B-X
and	B-X
resources	B-X
for	B-X
information	B-X
.	B-X
To	B-X
offer	B-X
technology	B-X
supported	B-X
rehabilitation	B-X
matching	B-X
patient	B-X
's	B-X
goals	B-X
,	B-X
training	B-X
preferences	B-X
for	B-X
rehabilitation	B-X
and	B-X
technology	B-X
familiarity	B-X
need	B-X
to	B-X
be	B-X
known	B-X
.	B-X

With	O
regard	O
to	O
receiving	O
training	O
for	O
a	O
new	O
technology	O
,	O
our	O
study	O
demonstrates	O
that	O
in	O
person	B-Species
conferences	O
or	O
one	O
on	O
one	O
training	O
sessions	O
are	O
the	O
preferred	O
means	O
to	O
receive	O
continuing	O
education	O
.	O
<EOS>	B-X
While	B-X
some	B-X
governments	B-X
have	B-X
implemented	B-X
restrictions	B-X
to	B-X
limit	B-X
young	B-X
people	B-X
's	B-X
exposure	B-X
to	B-X
gambling	B-X
advertising	B-X
,	B-X
few	B-X
studies	B-X
have	B-X
investigated	B-X
where	B-X
young	B-X
people	B-X
recall	B-X
seeing	B-X
gambling	B-X
advertising	B-X
,	B-X
and	B-X
whether	B-X
they	B-X
perceive	B-X
that	B-X
advertising	B-X
restrictions	B-X
have	B-X
gone	B-X
far	B-X
enough	B-X
in	B-X
reducing	B-X
exposure	B-X
to	B-X
these	B-X
promotions	B-X
.	B-X

Person	B-Species
to	O
person	B-Species
interaction	O
has	O
been	O
reported	O
as	O
the	O
preferred	O
and	O
most	O
frequently	O
used	O
means	O
to	O
access	O
continuing	O
education	O
or	O
training	O
by	O
other	O
investigators	O
[	O
55	O
,	O
71	O
]	O
.	O
<EOS>	B-X
The	B-X
medical	B-X
education	B-X
system	B-X
based	B-X
on	B-X
principles	B-X
advocated	B-X
by	B-X
Flexner	B-X
and	B-X
Osler	B-X
has	B-X
produced	B-X
generations	B-X
of	B-X
scientifically	B-X
grounded	B-X
and	B-X
clinically	B-X
skilled	B-X
physicians	B-X
whose	B-X
collective	B-X
experiences	B-X
and	B-X
contributions	B-X
have	B-X
served	B-X
medicine	B-X
and	B-X
patients	B-X
well	B-X
.	B-X
Yet	B-X
sweeping	B-X
changes	B-X
launched	B-X
around	B-X
the	B-X
turn	B-X
of	B-X
the	B-X
millennium	B-X
have	B-X
constituted	B-X
a	B-X
revolution	B-X
in	B-X
medical	B-X
education	B-X
.	B-X
In	B-X
this	B-X
article	B-X
,	B-X
a	B-X
critique	B-X
is	B-X
presented	B-X
of	B-X
the	B-X
new	B-X
undergraduate	B-X
medical	B-X
education	B-X
(	B-X
UME	B-X
)	B-X
curricula	B-X
in	B-X
relationship	B-X
to	B-X
graduate	B-X
medical	B-X
education	B-X
(	B-X
GME	B-X
)	B-X
and	B-X
clinical	B-X
practice	B-X
.	B-X
Finally	B-X
,	B-X
I	B-X
offer	B-X
the	B-X
belief	B-X
that	B-X
an	B-X
emphasis	B-X
on	B-X
enhancing	B-X
critical	B-X
thinking	B-X
skills	B-X
at	B-X
all	B-X
levels	B-X
of	B-X
education	B-X
offers	B-X
the	B-X
best	B-X
hope	B-X
for	B-X
the	B-X
future	B-X
.	B-X

Our	O
study	O
also	O
indicates	O
that	O
this	O
group	O
of	O
practitioners	O
may	O
benefit	O
from	O
accessing	O
resources	O
[	O
72	O
-	O
80	O
]	O
that	O
provide	O
guidance	O
on	O
useful	O
drug	O
information	O
resources	O
available	O
for	O
devices	O
such	O
as	O
PDAs	O
.	O

This	O
is	O
exemplified	O
by	O
one	O
respondent	O
'	O
s	O
statement	O
"	O
knowledge	O
regarding	O
good	O
software	O
programs	O
"	O
as	O
a	O
barrier	O
to	O
the	O
use	O
of	O
PDAs	O
.	O

Pharmaceutical	O
industry	O
<EOS>	B-X
The	B-X
pharmaceutical	B-X
industry	B-X
is	B-X
under	B-X
growing	B-X
pressure	B-X
from	B-X
a	B-X
range	B-X
of	B-X
environmental	B-X
issues	B-X
,	B-X
including	B-X
major	B-X
losses	B-X
of	B-X
revenue	B-X
owing	B-X
to	B-X
patent	B-X
expirations	B-X
,	B-X
increasingly	B-X
cost-constrained	B-X
healthcare	B-X
systems	B-X
and	B-X
more	B-X
demanding	B-X
regulatory	B-X
requirements	B-X
.	B-X
In	B-X
our	B-X
view	B-X
,	B-X
the	B-X
key	B-X
to	B-X
tackling	B-X
the	B-X
challenges	B-X
such	B-X
issues	B-X
pose	B-X
to	B-X
both	B-X
the	B-X
future	B-X
viability	B-X
of	B-X
the	B-X
pharmaceutical	B-X
industry	B-X
and	B-X
advances	B-X
in	B-X
healthcare	B-X
is	B-X
to	B-X
substantially	B-X
increase	B-X
the	B-X
number	B-X
and	B-X
quality	B-X
of	B-X
innovative	B-X
,	B-X
cost-effective	B-X
new	B-X
medicines	B-X
,	B-X
without	B-X
incurring	B-X
unsustainable	B-X
R	B-X
&	B-X
D	B-X
costs	B-X
.	B-X
However	B-X
,	B-X
it	B-X
is	B-X
widely	B-X
acknowledged	B-X
that	B-X
trends	B-X
in	B-X
industry	B-X
R	B-X
&	B-X
D	B-X
productivity	B-X
have	B-X
been	B-X
moving	B-X
in	B-X
the	B-X
opposite	B-X
direction	B-X
for	B-X
a	B-X
number	B-X
of	B-X
years	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
present	B-X
a	B-X
detailed	B-X
analysis	B-X
based	B-X
on	B-X
comprehensive	B-X
,	B-X
recent	B-X
,	B-X
industry-wide	B-X
data	B-X
to	B-X
identify	B-X
the	B-X
relative	B-X
contributions	B-X
of	B-X
each	B-X
of	B-X
the	B-X
steps	B-X
in	B-X
the	B-X
drug	B-X
discovery	B-X
and	B-X
development	B-X
process	B-X
to	B-X
overall	B-X
R	B-X
&	B-X
D	B-X
productivity	B-X
.	B-X

The	O
influence	O
of	O
the	O
pharmaceutical	O
industry	O
on	O
physician	O
prescribing	O
and	O
research	O
outcomes	O
has	O
been	O
documented	O
[	O
81	O
,	O
82	O
]	O
.	O
<EOS>	B-X
To	B-X
systematically	B-X
review	B-X
the	B-X
evidence	B-X
on	B-X
the	B-X
knowledge	B-X
,	B-X
beliefs	B-X
,	B-X
and	B-X
attitudes	B-X
of	B-X
patients	B-X
and	B-X
the	B-X
general	B-X
public	B-X
towards	B-X
the	B-X
interactions	B-X
of	B-X
physicians	B-X
with	B-X
the	B-X
pharmaceutical	B-X
and	B-X
the	B-X
device	B-X
industry	B-X
.	B-X

Although	O
NP	O
use	O
of	O
industry	O
representatives	O
as	O
a	O
source	O
of	O
pharmacological	O
information	O
has	O
been	O
documented	O
,	O
the	O
influence	O
on	O
prescribing	O
is	O
largely	O
uninvestigated	O
[	O
32	O
,	O
61	O
,	O
83	O
-	O
85	O
]	O
.	O

The	O
CNA	O
competency	O
framework	O
includes	O
a	O
statement	O
regarding	O
prescribing	O
and	O
industry	O
relations	O
[	O
23	O
]	O
.	O

In	O
our	O
study	O
,	O
the	O
physician	O
and	O
NP	O
rankings	O
of	O
industry	O
representatives	O
were	O
similar	O
.	O

Within	O
the	O
health	O
professionals	O
and	O
other	O
category	O
,	O
pharmaceutical	O
representatives	O
were	O
used	O
as	O
a	O
resource	O
by	O
more	O
of	O
the	O
sample	O
than	O
regional	O
drug	O
information	O
services	O
and	O
comparably	O
to	O
academic	O
detailing	O
services	O
.	O

Academic	O
detailing	O
is	O
a	O
form	O
of	O
continuing	O
medical	O
education	O
where	O
a	O
trained	O
health	O
professional	O
visits	O
prescribers	O
for	O
a	O
fifteen	O
to	O
twenty	O
minute	O
session	O
to	O
provide	O
objective	O
information	O
regarding	O
a	O
therapeutic	O
topic	O
based	O
on	O
best	O
available	O
evidence	O
[	O
86	O
,	O
87	O
]	O
.	O

Following	O
academic	O
detailing	O
,	O
physician	O
and	O
NP	O
rankings	O
of	O
pharmaceutical	O
industry	O
representatives	O
were	O
second	O
or	O
third	O
for	O
frequency	O
of	O
use	O
,	O
usefulness	O
,	O
accessibility	O
,	O
credibility	O
,	O
and	O
current	O
/	O
timeliness	O
.	O

Limitations	O
<EOS>	B-X
Limitations	B-X
in	B-X
the	B-X
floc	B-X
formation	B-X
process	B-X
commonly	B-X
emerge	B-X
in	B-X
HRAS	B-X
systems	B-X
,	B-X
with	B-X
detrimental	B-X
consequences	B-X
for	B-X
the	B-X
capture	B-X
of	B-X
organics	B-X
.	B-X

We	O
do	O
not	O
have	O
demographics	O
or	O
information	O
regarding	O
the	O
reasons	O
why	O
survey	O
recipients	O
did	O
not	O
respond	O
.	O
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
compare	B-X
the	B-X
actual	B-X
donation	B-X
intention	B-X
rate	B-X
with	B-X
the	B-X
effective	B-X
donation	B-X
figures	B-X
,	B-X
and	B-X
analyze	B-X
the	B-X
main	B-X
reasons	B-X
why	B-X
families	B-X
decline	B-X
organ	B-X
donation	B-X
.	B-X
To	B-X
estimate	B-X
the	B-X
current	B-X
donation	B-X
intention	B-X
,	B-X
we	B-X
conducted	B-X
1065	B-X
surveys	B-X
in	B-X
March	B-X
2019	B-X
,	B-X
and	B-X
to	B-X
calculate	B-X
effective	B-X
donation	B-X
figures	B-X
in	B-X
our	B-X
hospital	B-X
,	B-X
we	B-X
analyzed	B-X
1158	B-X
interviews	B-X
conducted	B-X
with	B-X
relatives	B-X
of	B-X
potential	B-X
organ	B-X
donors	B-X
between	B-X
1996	B-X
and	B-X
2018	B-X
.	B-X
Regarding	B-X
the	B-X
surveys	B-X
to	B-X
estimate	B-X
donation	B-X
intention	B-X
,	B-X
the	B-X
mean	B-X
(	B-X
standard	B-X
deviation	B-X
)	B-X
age	B-X
was	B-X
51.6	B-X
(	B-X
17-91	B-X
)	B-X
years	B-X
.	B-X
A	B-X
total	B-X
of	B-X
58	B-X
%	B-X
were	B-X
women	B-X
,	B-X
26	B-X
%	B-X
were	B-X
health	B-X
care	B-X
professionals	B-X
,	B-X
and	B-X
5.1	B-X
%	B-X
were	B-X
transplant	B-X
recipients	B-X
;	B-X
89.4	B-X
%	B-X
would	B-X
donate	B-X
their	B-X
organs	B-X
.	B-X
However	B-X
,	B-X
only	B-X
one-half	B-X
of	B-X
those	B-X
surveyed	B-X
expressed	B-X
the	B-X
wish	B-X
to	B-X
be	B-X
a	B-X
donor	B-X
to	B-X
their	B-X
relatives	B-X
.	B-X
It	B-X
is	B-X
our	B-X
responsibility	B-X
to	B-X
improve	B-X
transplantation	B-X
rates	B-X
because	B-X
our	B-X
model	B-X
has	B-X
shown	B-X
to	B-X
save	B-X
lives	B-X
and	B-X
it	B-X
is	B-X
a	B-X
role	B-X
model	B-X
for	B-X
other	B-X
nations	B-X
,	B-X
promoting	B-X
information	B-X
activities	B-X
that	B-X
encourage	B-X
greater	B-X
discussion	B-X
of	B-X
organ	B-X
donation	B-X
within	B-X
families	B-X
.	B-X

As	O
per	O
ethical	O
requirements	O
to	O
maintain	O
confidentiality	O
of	O
respondents	O
,	O
we	O
were	O
not	O
able	O
to	O
match	O
respondents	O
from	O
their	O
respective	O
place	O
of	O
practice	O
and	O
therefore	O
cannot	O
conclude	O
whether	O
the	O
practitioners	O
within	O
a	O
practice	O
setting	O
influenced	O
the	O
others	O
'	O
responses	O
.	O
<EOS>	B-X
Using	B-X
Bangladesh	B-X
's	B-X
two	B-X
decades	B-X
of	B-X
experience	B-X
with	B-X
contracting	B-X
out	B-X
Urban	B-X
Primary	B-X
Health	B-X
Care	B-X
(	B-X
UPHC	B-X
)	B-X
,	B-X
this	B-X
paper	B-X
identifies	B-X
contextual	B-X
,	B-X
contractual	B-X
,	B-X
and	B-X
actor-related	B-X
factors	B-X
that	B-X
require	B-X
consideration	B-X
when	B-X
implementing	B-X
CO	B-X
in	B-X
Low-	B-X
and	B-X
Middle-	B-X
Income	B-X
Countries	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
identify	B-X
and	B-X
develop	B-X
outcome	B-X
measures	B-X
for	B-X
oral	B-X
health	B-X
and	B-X
explore	B-X
their	B-X
performance	B-X
using	B-X
health	B-X
insurance	B-X
claims	B-X
records	B-X
and	B-X
clinical	B-X
data	B-X
from	B-X
general	B-X
dental	B-X
practices	B-X
.	B-X
In	B-X
the	B-X
last	B-X
few	B-X
years	B-X
,	B-X
medical	B-X
personnel	B-X
have	B-X
emphasised	B-X
their	B-X
stand	B-X
against	B-X
the	B-X
practice	B-X
of	B-X
torture	B-X
.	B-X
However	B-X
,	B-X
more	B-X
than	B-X
37	B-X
per	B-X
cent	B-X
of	B-X
students	B-X
were	B-X
in	B-X
favour	B-X
of	B-X
beating	B-X
in	B-X
custody	B-X
.	B-X
Torture	B-X
could	B-X
be	B-X
reduced	B-X
if	B-X
the	B-X
medical	B-X
profession	B-X
maintains	B-X
high	B-X
standards	B-X
of	B-X
practice	B-X
and	B-X
ethics	B-X
.	B-X

The	O
sample	O
size	O
of	O
the	O
survey	O
is	O
small	O
although	O
it	O
includes	O
88	O
%	O
response	O
from	O
community	O
based	O
NPs	O
in	O
Nova	O
Scotia	O
.	O

The	O
generalizability	O
of	O
the	O
results	O
is	O
limited	O
due	O
to	O
the	O
variations	O
in	O
NP	O
scopes	O
of	O
practice	O
nationally	O
and	O
internationally	O
.	O

It	O
is	O
unknown	O
whether	O
the	O
findings	O
are	O
generalizable	O
to	O
nonresponding	O
physicians	O
within	O
Nova	O
Scotia	O
collaborating	O
with	O
NPs	O
or	O
to	O
physicians	O
not	O
in	O
collaborative	O
practices	O
with	O
NPs	O
as	O
they	O
were	O
not	O
included	O
as	O
a	O
part	O
of	O
the	O
sample	O
.	O
<EOS>	B-X
The	B-X
target	B-X
population	B-X
was	B-X
patients	B-X
from	B-X
the	B-X
out-patient	B-X
department	B-X
(	B-X
OPD	B-X
)	B-X
of	B-X
three	B-X
public	B-X
hospitals	B-X
from	B-X
Pakistan	B-X
.	B-X
By	B-X
using	B-X
the	B-X
convenient	B-X
sampling	B-X
technique	B-X
,	B-X
290	B-X
sample	B-X
participants	B-X
were	B-X
selected	B-X
from	B-X
the	B-X
target	B-X
population	B-X
.	B-X
The	B-X
findings	B-X
of	B-X
the	B-X
study	B-X
are	B-X
gleaned	B-X
by	B-X
using	B-X
regression	B-X
to	B-X
explore	B-X
patient	B-X
satisfaction	B-X
with	B-X
the	B-X
health	B-X
care	B-X
services	B-X
,	B-X
and	B-X
whether	B-X
or	B-X
not	B-X
the	B-X
physician	B-X
's	B-X
behavior	B-X
moderates	B-X
the	B-X
link	B-X
of	B-X
patient	B-X
satisfaction	B-X
and	B-X
healthcare	B-X
services	B-X
.	B-X
Cultural	B-X
portrayals	B-X
of	B-X
physicians	B-X
suggest	B-X
an	B-X
unclear	B-X
and	B-X
even	B-X
contradictory	B-X
role	B-X
for	B-X
humility	B-X
in	B-X
the	B-X
physician-patient	B-X
relationship	B-X
.	B-X
Despite	B-X
the	B-X
social	B-X
importance	B-X
of	B-X
humility	B-X
,	B-X
however	B-X
,	B-X
little	B-X
empirical	B-X
research	B-X
has	B-X
linked	B-X
humility	B-X
in	B-X
physicians	B-X
with	B-X
patient	B-X
outcomes	B-X
or	B-X
the	B-X
characteristics	B-X
of	B-X
the	B-X
doctor-patient	B-X
visit	B-X
.	B-X

Due	O
to	O
multiple	O
statistical	O
comparisons	O
(	O
Mann	O
Whitney	O
U	O
)	O
,	O
the	O
results	O
comparing	O
NP	O
and	O
physician	O
ratings	O
of	O
results	O
should	O
be	O
interpreted	O
with	O
caution	O
.	O

Conclusion	O
<EOS>	B-X
Conclusion	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X

Respondent	O
ratings	O
of	O
resources	O
and	O
preferences	O
for	O
resource	O
use	O
were	O
consistent	O
with	O
self	O
-	O
reported	O
means	O
of	O
conducting	O
searches	O
for	O
specific	O
drug	O
information	O
queries	O
.	O

The	O
use	O
of	O
computers	O
and	O
PDAs	O
remains	O
limited	O
and	O
also	O
matches	O
preferences	O
and	O
resource	O
ratings	O
.	O

Education	O
to	O
this	O
group	O
of	O
practitioners	O
regarding	O
available	O
drug	O
information	O
resources	O
may	O
facilitate	O
use	O
of	O
computer	O
and	O
PDA	O
resources	O
.	O
<EOS>	B-X
Keeping	B-X
current	B-X
with	B-X
drug	B-X
therapy	B-X
information	B-X
is	B-X
challenging	B-X
for	B-X
health	B-X
care	B-X
practitioners	B-X
.	B-X
Technologies	B-X
are	B-X
often	B-X
implemented	B-X
to	B-X
facilitate	B-X
access	B-X
to	B-X
current	B-X
and	B-X
credible	B-X
drug	B-X
information	B-X
sources	B-X
.	B-X
In	B-X
the	B-X
Canadian	B-X
province	B-X
of	B-X
Nova	B-X
Scotia	B-X
,	B-X
legislation	B-X
was	B-X
passed	B-X
in	B-X
2002	B-X
to	B-X
allow	B-X
nurse	B-X
practitioners	B-X
(	B-X
NPs	B-X
)	B-X
to	B-X
practice	B-X
collaboratively	B-X
with	B-X
physician	B-X
partners	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
current	B-X
utilization	B-X
patterns	B-X
of	B-X
information	B-X
technologies	B-X
by	B-X
these	B-X
groups	B-X
of	B-X
practitioners	B-X
.	B-X

Further	O
research	O
is	O
needed	O
to	O
determine	O
methods	O
to	O
increase	O
the	O
use	O
of	O
computers	O
and	O
PDAs	O
and	O
if	O
use	O
of	O
these	O
technologies	O
affects	O
prescribing	O
and	O
patient	B-Species
outcomes	O
.	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
current	B-X
utilization	B-X
patterns	B-X
of	B-X
information	B-X
technologies	B-X
by	B-X
these	B-X
groups	B-X
of	B-X
practitioners	B-X
.	B-X

Competing	O
interests	O
<EOS>	B-X
Elective	B-X
ventilation	B-X
and	B-X
interests	B-X
.	B-X
An	B-X
examination	B-X
of	B-X
the	B-X
principle	B-X
of	B-X
precedent	B-X
autonomy	B-X
reveals	B-X
that	B-X
a	B-X
future-binding	B-X
research	B-X
decision	B-X
is	B-X
within	B-X
the	B-X
scope	B-X
of	B-X
a	B-X
competent	B-X
person	B-X
's	B-X
critical	B-X
interests	B-X
,	B-X
if	B-X
the	B-X
decision	B-X
is	B-X
consistent	B-X
with	B-X
what	B-X
the	B-X
person	B-X
believes	B-X
gives	B-X
her	B-X
life	B-X
intrinsic	B-X
value	B-X
.	B-X
Safety	B-X
of	B-X
young	B-X
drivers	B-X
.	B-X
In	B-X
this	B-X
article	B-X
I	B-X
will	B-X
show	B-X
that	B-X
'best	B-X
interests	B-X
'	B-X
is	B-X
a	B-X
concept	B-X
that	B-X
fits	B-X
nicely	B-X
with	B-X
many	B-X
of	B-X
the	B-X
features	B-X
of	B-X
pragmatism	B-X
--	B-X
Holm	B-X
and	B-X
Edgar	B-X
's	B-X
rejection	B-X
of	B-X
the	B-X
principle	B-X
in	B-X
favour	B-X
of	B-X
pragmatism	B-X
it	B-X
will	B-X
be	B-X
suggested	B-X
is	B-X
misplaced	B-X
.	B-X
'Best	B-X
interests	B-X
'	B-X
as	B-X
a	B-X
principle	B-X
may	B-X
be	B-X
considered	B-X
an	B-X
embodiment	B-X
of	B-X
the	B-X
ideals	B-X
of	B-X
pragmatic	B-X
adjudication	B-X
.	B-X
The	B-X
paper	B-X
starts	B-X
by	B-X
briefly	B-X
introducing	B-X
the	B-X
concept	B-X
of	B-X
'best	B-X
interests	B-X
'	B-X
and	B-X
theories	B-X
of	B-X
judicial	B-X
and	B-X
legal	B-X
'pragmatism	B-X
'	B-X
.	B-X
The	B-X
paper	B-X
concludes	B-X
by	B-X
suggesting	B-X
how	B-X
we	B-X
view	B-X
the	B-X
relationship	B-X
between	B-X
'best	B-X
interests	B-X
'	B-X
and	B-X
'pragmatism	B-X
'	B-X
.	B-X

Ingrid	O
Sketris	O
holds	O
a	O
Chair	O
from	O
Canadian	O
Institutes	O
of	O
Health	O
Research	O
(	O
CIHR	O
)	O
,	O
Canadian	O
Health	O
Services	O
Research	O
Foundation	O
(	O
CHSRF	O
)	O
co	O
-	O
sponsored	O
by	O
the	O
Nova	O
Scotia	O
Health	O
Research	O
Foundation	O
(	O
NSHRF	O
)	O
.	O

Andrea	O
Murphy	O
received	O
salary	O
support	O
through	O
this	O
Chair	O
as	O
a	O
research	O
fellow	O
at	O
the	O
time	O
of	O
conducting	O
this	O
research	O
.	O

The	O
survey	O
was	O
performed	O
in	O
fulfillment	O
of	O
the	O
requirements	O
for	O
the	O
Drug	O
Use	O
Management	O
and	O
Policy	O
Residency	O
that	O
Murphy	O
participated	O
in	O
as	O
a	O
part	O
of	O
her	O
fellowship	O
.	O

The	O
residency	O
was	O
conducted	O
with	O
a	O
decision	O
making	O
partner	O
from	O
the	O
Nova	O
Scotia	O
Department	O
of	O
Health	O
.	O

The	O
opinions	O
expressed	O
in	O
this	O
paper	O
are	O
those	O
of	O
the	O
authors	O
and	O
do	O
not	O
represent	O
the	O
opinions	O
of	O
the	O
Nova	O
Scotia	O
Department	O
of	O
Health	O
,	O
CIHR	O
/	O
CHSRF	O
or	O
NSHRF	O
.	O

MF	O
,	O
MM	O
,	O
RMM	O
,	O
and	O
DG	O
have	O
no	O
competing	O
interests	O
to	O
declare	O
.	O

Authors	O
'	O
contributions	O
<EOS>	B-X
In	B-X
this	B-X
letter	B-X
,	B-X
I	B-X
argue	B-X
that	B-X
in	B-X
reality	B-X
and	B-X
in	B-X
practice	B-X
,	B-X
authorship	B-X
delimitations	B-X
are	B-X
not	B-X
that	B-X
clear-cut	B-X
,	B-X
nor	B-X
are	B-X
all	B-X
contributions	B-X
equal	B-X
or	B-X
equally	B-X
weighted	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
contributions	B-X
of	B-X
each	B-X
author	B-X
to	B-X
multiauthored	B-X
biomedical	B-X
research	B-X
papers	B-X
.	B-X
Much	B-X
research	B-X
on	B-X
APP	B-X
focusses	B-X
on	B-X
potential	B-X
contributions	B-X
to	B-X
neurodegeneration	B-X
,	B-X
mostly	B-X
based	B-X
on	B-X
mouse	B-X
models	B-X
with	B-X
altered	B-X
expression	B-X
or	B-X
mutated	B-X
forms	B-X
of	B-X
APP	B-X
.	B-X
For	B-X
papers	B-X
in	B-X
which	B-X
the	B-X
first	B-X
and	B-X
second	B-X
authors	B-X
made	B-X
equal	B-X
contributions	B-X
,	B-X
mixed-gender	B-X
combinations	B-X
were	B-X
most	B-X
frequent	B-X
,	B-X
followed	B-X
by	B-X
male-male	B-X
and	B-X
then	B-X
female-female	B-X
author	B-X
combinations	B-X
.	B-X
For	B-X
papers	B-X
in	B-X
which	B-X
three	B-X
or	B-X
more	B-X
authors	B-X
made	B-X
equal	B-X
contributions	B-X
,	B-X
there	B-X
were	B-X
more	B-X
male	B-X
authors	B-X
than	B-X
female	B-X
authors	B-X
in	B-X
the	B-X
first	B-X
position	B-X
and	B-X
more	B-X
all-male	B-X
than	B-X
all-female	B-X
author	B-X
combinations	B-X
.	B-X
The	B-X
gender	B-X
inequalities	B-X
observed	B-X
among	B-X
authors	B-X
who	B-X
made	B-X
equal	B-X
contributions	B-X
are	B-X
not	B-X
consistent	B-X
with	B-X
random	B-X
or	B-X
alphabetical	B-X
ordering	B-X
of	B-X
authors	B-X
.	B-X

AM	O
conceptualized	O
the	O
design	O
and	O
composed	O
the	O
survey	O
instruments	O
,	O
carried	O
out	O
the	O
study	O
,	O
entered	O
and	O
analyzed	O
the	O
data	O
,	O
drafted	O
the	O
original	O
manuscript	O
,	O
and	O
modified	O
subsequent	O
drafts	O
based	O
on	O
authors	O
'	O
and	O
reviewers	O
'	O
feedback	O
.	O

MF	O
,	O
RMM	O
,	O
IS	O
,	O
MM	O
,	O
and	O
DG	O
reviewed	O
and	O
suggested	O
revisions	O
to	O
the	O
survey	O
tools	O
,	O
covering	O
letters	O
,	O
overall	O
study	O
design	O
,	O
and	O
contributed	O
to	O
feedback	O
on	O
the	O
analysis	O
and	O
manuscript	O
revisions	O
.	O

Pre	O
-	O
publication	O
history	O
<EOS>	B-X
The	B-X
choice	B-X
of	B-X
Sydney	B-X
Brenner	B-X
to	B-X
adopt	B-X
this	B-X
species	B-X
in	B-X
the	B-X
mid-1960s	B-X
and	B-X
the	B-X
success	B-X
of	B-X
his	B-X
team	B-X
in	B-X
raising	B-X
it	B-X
to	B-X
a	B-X
model	B-X
organism	B-X
status	B-X
have	B-X
been	B-X
told	B-X
(	B-X
http	B-X
:	B-X
//www.wormbook.org/toc_wormhistory.html	B-X
;	B-X
Brenner	B-X
,	B-X
2001	B-X
;	B-X
Ankeny	B-X
,	B-X
2001	B-X
)	B-X
.	B-X
Here	B-X
we	B-X
review	B-X
the	B-X
pre-Brenner	B-X
history	B-X
of	B-X
the	B-X
use	B-X
of	B-X
free-living	B-X
nematodes	B-X
as	B-X
models	B-X
for	B-X
general	B-X
questions	B-X
in	B-X
biology	B-X
.	B-X
We	B-X
focus	B-X
on	B-X
the	B-X
period	B-X
that	B-X
started	B-X
in	B-X
1899	B-X
with	B-X
the	B-X
first	B-X
publication	B-X
of	B-X
Emile	B-X
Maupas	B-X
mentioning	B-X
Rhabditis	B-X
elegans	B-X
and	B-X
ended	B-X
in	B-X
1974	B-X
with	B-X
the	B-X
first	B-X
publications	B-X
by	B-X
Brenner	B-X
.	B-X
Oral	B-X
Cancer	B-X
:	B-X
A	B-X
Historical	B-X
Review	B-X
.	B-X

The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O
<EOS>	B-X
Humans	B-X
'	B-X
great	B-X
and	B-X
quick	B-X
technological	B-X
breakthroughs	B-X
in	B-X
the	B-X
previous	B-X
decade	B-X
have	B-X
undoubtedly	B-X
influenced	B-X
how	B-X
surgical	B-X
procedures	B-X
are	B-X
executed	B-X
in	B-X
the	B-X
operating	B-X
room	B-X
.	B-X
AI	B-X
is	B-X
becoming	B-X
incredibly	B-X
influential	B-X
for	B-X
surgical	B-X
decision-making	B-X
to	B-X
help	B-X
surgeons	B-X
make	B-X
better	B-X
projections	B-X
about	B-X
the	B-X
implications	B-X
of	B-X
surgical	B-X
operations	B-X
by	B-X
considering	B-X
different	B-X
sources	B-X
of	B-X
data	B-X
such	B-X
as	B-X
patient	B-X
health	B-X
conditions	B-X
,	B-X
disease	B-X
natural	B-X
history	B-X
,	B-X
patient	B-X
values	B-X
,	B-X
and	B-X
finance	B-X
.	B-X
By	B-X
leveraging	B-X
techniques	B-X
such	B-X
as	B-X
machine	B-X
learning	B-X
,	B-X
computer	B-X
vision	B-X
,	B-X
and	B-X
robotics	B-X
,	B-X
AI	B-X
may	B-X
play	B-X
a	B-X
key	B-X
role	B-X
in	B-X
diagnostic	B-X
augmentation	B-X
,	B-X
operative	B-X
management	B-X
,	B-X
pre-and	B-X
post-surgical	B-X
patient	B-X
management	B-X
,	B-X
and	B-X
upholding	B-X
safety	B-X
standards	B-X
.	B-X
In	B-X
this	B-X
paper	B-X
,	B-X
we	B-X
present	B-X
an	B-X
overview	B-X
of	B-X
AI	B-X
applications	B-X
in	B-X
thoracic	B-X
surgery	B-X
and	B-X
its	B-X
related	B-X
components	B-X
,	B-X
including	B-X
contemporary	B-X
projects	B-X
and	B-X
technology	B-X
that	B-X
use	B-X
AI	B-X
in	B-X
cardiothoracic	B-X
surgery	B-X
and	B-X
general	B-X
care	B-X
.	B-X

Supplementary	O
Material	O
<EOS>	B-X
These	B-X
slides	B-X
can	B-X
be	B-X
retrieved	B-X
under	B-X
Electronic	B-X
Supplementary	B-X
Material	B-X
.	B-X
On-line	B-X
publication	B-X
of	B-X
supplementary	B-X
material	B-X
.	B-X
Citations	B-X
in	B-X
supplementary	B-X
material	B-X
.	B-X
Supplementary	B-X
material	B-X
is	B-X
a	B-X
ubiquitous	B-X
feature	B-X
of	B-X
scientific	B-X
articles	B-X
,	B-X
particularly	B-X
in	B-X
journals	B-X
that	B-X
limit	B-X
the	B-X
length	B-X
of	B-X
the	B-X
articles	B-X
.	B-X

Expression	O
of	O
C	O
-	O
terminal	O
deleted	O
p53	O
isoforms	O
in	O
neuroblastoma	O
<EOS>	B-X
The	B-X
tumor	B-X
suppressor	B-X
gene	B-X
,	B-X
p53	B-X
,	B-X
is	B-X
rarely	B-X
mutated	B-X
in	B-X
neuroblastomas	B-X
(	B-X
NB	B-X
)	B-X
at	B-X
the	B-X
time	B-X
of	B-X
diagnosis	B-X
,	B-X
but	B-X
its	B-X
dysfunction	B-X
could	B-X
result	B-X
from	B-X
a	B-X
nonfunctional	B-X
conformation	B-X
or	B-X
cytoplasmic	B-X
sequestration	B-X
of	B-X
the	B-X
wild-type	B-X
p53	B-X
protein	B-X
.	B-X
However	B-X
,	B-X
p53	B-X
mutation	B-X
,	B-X
when	B-X
it	B-X
occurs	B-X
,	B-X
is	B-X
found	B-X
in	B-X
NB	B-X
tumors	B-X
with	B-X
drug	B-X
resistance	B-X
acquired	B-X
over	B-X
the	B-X
course	B-X
of	B-X
chemotherapy	B-X
.	B-X
As	B-X
yet	B-X
,	B-X
no	B-X
study	B-X
has	B-X
been	B-X
devoted	B-X
to	B-X
the	B-X
function	B-X
of	B-X
the	B-X
specific	B-X
p53	B-X
mutants	B-X
identified	B-X
in	B-X
NB	B-X
cells	B-X
.	B-X
This	B-X
study	B-X
includes	B-X
characterization	B-X
and	B-X
functional	B-X
analysis	B-X
of	B-X
p53	B-X
expressed	B-X
in	B-X
eight	B-X
cell	B-X
lines	B-X
:	B-X
three	B-X
wild-type	B-X
cell	B-X
lines	B-X
and	B-X
five	B-X
cell	B-X
lines	B-X
harboring	B-X
mutations	B-X
.	B-X
We	B-X
identified	B-X
two	B-X
transcription-inactive	B-X
p53	B-X
variants	B-X
truncated	B-X
in	B-X
the	B-X
C-terminus	B-X
,	B-X
one	B-X
of	B-X
which	B-X
corresponded	B-X
to	B-X
the	B-X
p53beta	B-X
isoform	B-X
recently	B-X
identified	B-X
in	B-X
normal	B-X
tissue	B-X
by	B-X
Bourdon	B-X
et	B-X
al	B-X
.	B-X
[	B-X
J.	B-X
C.	B-X
Bourdon	B-X
,	B-X
K.	B-X
Fernandes	B-X
,	B-X
F.	B-X
Murray-Zmijewski	B-X
,	B-X
G.	B-X
Liu	B-X
,	B-X
A.	B-X
Diot	B-X
,	B-X
D.	B-X
P.	B-X
Xirodimas	B-X
,	B-X
M.	B-X
K.	B-X
Saville	B-X
and	B-X
D.	B-X
P.	B-X
Lane	B-X
(	B-X
2005	B-X
)	B-X
Genes	B-X
Dev.	B-X
,	B-X
19	B-X
,	B-X
2122-2137	B-X
]	B-X
.	B-X
Our	B-X
results	B-X
show	B-X
,	B-X
for	B-X
the	B-X
first	B-X
time	B-X
,	B-X
that	B-X
the	B-X
p53beta	B-X
isoform	B-X
is	B-X
the	B-X
only	B-X
p53	B-X
species	B-X
to	B-X
be	B-X
endogenously	B-X
expressed	B-X
in	B-X
the	B-X
human	B-X
NB	B-X
cell	B-X
line	B-X
SK-N-AS	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
C-terminus	B-X
truncated	B-X
p53	B-X
isoforms	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
NB	B-X
tumor	B-X
development	B-X
.	B-X

Abstract	O
<EOS>	B-X
Abstract	B-X
writing	B-X
.	B-X
The	B-X
informative	B-X
abstract	B-X
.	B-X
Crafting	B-X
a	B-X
compelling	B-X
abstract	B-X
.	B-X
Why	B-X
the	B-X
structured	B-X
abstract	B-X
?	B-X

The	O
tumor	O
suppressor	O
gene	O
,	O
p53	O
,	O
is	O
rarely	O
mutated	O
in	O
neuroblastomas	O
(	O
NB	O
)	O
at	O
the	O
time	O
of	O
diagnosis	O
,	O
but	O
its	O
dysfunction	O
could	O
result	O
from	O
a	O
nonfunctional	O
conformation	O
or	O
cytoplasmic	O
sequestration	O
of	O
the	O
wild	O
-	O
type	O
p53	O
protein	O
.	O
<EOS>	B-X
Long	B-X
noncoding	B-X
RNAs	B-X
(	B-X
lncRNA	B-X
)	B-X
have	B-X
been	B-X
associated	B-X
with	B-X
various	B-X
types	B-X
of	B-X
cancer	B-X
;	B-X
however	B-X
,	B-X
the	B-X
precise	B-X
role	B-X
of	B-X
many	B-X
lncRNAs	B-X
in	B-X
tumorigenesis	B-X
remains	B-X
elusive	B-X
.	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
cytosolic	B-X
lncRNA	B-X
P53RRA	B-X
is	B-X
downregulated	B-X
in	B-X
cancers	B-X
and	B-X
functions	B-X
as	B-X
a	B-X
tumor	B-X
suppressor	B-X
by	B-X
inhibiting	B-X
cancer	B-X
progression	B-X
.	B-X
Chromatin	B-X
remodeling	B-X
proteins	B-X
LSH	B-X
and	B-X
Cfp1	B-X
silenced	B-X
or	B-X
increased	B-X
P53RRA	B-X
expression	B-X
,	B-X
respectively	B-X
.	B-X
P53RRA	B-X
bound	B-X
Ras	B-X
GTPase-activating	B-X
protein-binding	B-X
protein	B-X
1	B-X
(	B-X
G3BP1	B-X
)	B-X
using	B-X
nucleotides	B-X
1	B-X
and	B-X
871	B-X
of	B-X
P53RRA	B-X
and	B-X
the	B-X
RRM	B-X
interaction	B-X
domain	B-X
of	B-X
G3BP1	B-X
(	B-X
aa	B-X
177-466	B-X
)	B-X
.	B-X
The	B-X
cytosolic	B-X
P53RRA-G3BP1	B-X
interaction	B-X
displaced	B-X
p53	B-X
from	B-X
a	B-X
G3BP1	B-X
complex	B-X
,	B-X
resulting	B-X
in	B-X
greater	B-X
p53	B-X
retention	B-X
in	B-X
the	B-X
nucleus	B-X
,	B-X
which	B-X
led	B-X
to	B-X
cell-cycle	B-X
arrest	B-X
,	B-X
apoptosis	B-X
,	B-X
and	B-X
ferroptosis	B-X
.	B-X
P53RRA	B-X
promoted	B-X
ferroptosis	B-X
and	B-X
apoptosis	B-X
by	B-X
affecting	B-X
transcription	B-X
of	B-X
several	B-X
metabolic	B-X
genes	B-X
.	B-X
Low	B-X
P53RRA	B-X
expression	B-X
significantly	B-X
correlated	B-X
with	B-X
poor	B-X
survival	B-X
in	B-X
patients	B-X
with	B-X
breast	B-X
and	B-X
lung	B-X
cancers	B-X
harboring	B-X
wild-type	B-X
p53	B-X
.	B-X
These	B-X
data	B-X
show	B-X
that	B-X
lncRNAs	B-X
can	B-X
directly	B-X
interact	B-X
with	B-X
the	B-X
functional	B-X
domain	B-X
of	B-X
signaling	B-X
proteins	B-X
in	B-X
the	B-X
cytoplasm	B-X
,	B-X
thus	B-X
regulating	B-X
p53	B-X
modulators	B-X
to	B-X
suppress	B-X
cancer	B-X
progression	B-X
.	B-X

However	O
,	O
p53	O
mutation	O
,	O
when	O
it	O
occurs	O
,	O
is	O
found	O
in	O
NB	O
tumors	O
with	O
drug	O
resistance	O
acquired	O
over	O
the	O
course	O
of	O
chemotherapy	O
.	O
<EOS>	B-X
The	B-X
tumor	B-X
suppressor	B-X
gene	B-X
,	B-X
p53	B-X
,	B-X
is	B-X
rarely	B-X
mutated	B-X
in	B-X
neuroblastomas	B-X
(	B-X
NB	B-X
)	B-X
at	B-X
the	B-X
time	B-X
of	B-X
diagnosis	B-X
,	B-X
but	B-X
its	B-X
dysfunction	B-X
could	B-X
result	B-X
from	B-X
a	B-X
nonfunctional	B-X
conformation	B-X
or	B-X
cytoplasmic	B-X
sequestration	B-X
of	B-X
the	B-X
wild-type	B-X
p53	B-X
protein	B-X
.	B-X
However	B-X
,	B-X
p53	B-X
mutation	B-X
,	B-X
when	B-X
it	B-X
occurs	B-X
,	B-X
is	B-X
found	B-X
in	B-X
NB	B-X
tumors	B-X
with	B-X
drug	B-X
resistance	B-X
acquired	B-X
over	B-X
the	B-X
course	B-X
of	B-X
chemotherapy	B-X
.	B-X
As	B-X
yet	B-X
,	B-X
no	B-X
study	B-X
has	B-X
been	B-X
devoted	B-X
to	B-X
the	B-X
function	B-X
of	B-X
the	B-X
specific	B-X
p53	B-X
mutants	B-X
identified	B-X
in	B-X
NB	B-X
cells	B-X
.	B-X
This	B-X
study	B-X
includes	B-X
characterization	B-X
and	B-X
functional	B-X
analysis	B-X
of	B-X
p53	B-X
expressed	B-X
in	B-X
eight	B-X
cell	B-X
lines	B-X
:	B-X
three	B-X
wild-type	B-X
cell	B-X
lines	B-X
and	B-X
five	B-X
cell	B-X
lines	B-X
harboring	B-X
mutations	B-X
.	B-X
We	B-X
identified	B-X
two	B-X
transcription-inactive	B-X
p53	B-X
variants	B-X
truncated	B-X
in	B-X
the	B-X
C-terminus	B-X
,	B-X
one	B-X
of	B-X
which	B-X
corresponded	B-X
to	B-X
the	B-X
p53beta	B-X
isoform	B-X
recently	B-X
identified	B-X
in	B-X
normal	B-X
tissue	B-X
by	B-X
Bourdon	B-X
et	B-X
al	B-X
.	B-X
Our	B-X
results	B-X
show	B-X
,	B-X
for	B-X
the	B-X
first	B-X
time	B-X
,	B-X
that	B-X
the	B-X
p53beta	B-X
isoform	B-X
is	B-X
the	B-X
only	B-X
p53	B-X
species	B-X
to	B-X
be	B-X
endogenously	B-X
expressed	B-X
in	B-X
the	B-X
human	B-X
NB	B-X
cell	B-X
line	B-X
SK-N-AS	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
C-terminus	B-X
truncated	B-X
p53	B-X
isoforms	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
NB	B-X
tumor	B-X
development	B-X
.	B-X

As	O
yet	O
,	O
no	O
study	O
has	O
been	O
devoted	O
to	O
the	O
function	O
of	O
the	O
specific	O
p53	O
mutants	O
identified	O
in	O
NB	O
cells	O
.	O

This	O
study	O
includes	O
characterization	O
and	O
functional	O
analysis	O
of	O
p53	O
expressed	O
in	O
eight	O
cell	O
lines	O
:	O
three	O
wild	O
-	O
type	O
cell	O
lines	O
and	O
five	O
cell	O
lines	O
harboring	O
mutations	O
.	O
<EOS>	B-X
The	B-X
tumor	B-X
suppressor	B-X
gene	B-X
,	B-X
p53	B-X
,	B-X
is	B-X
rarely	B-X
mutated	B-X
in	B-X
neuroblastomas	B-X
(	B-X
NB	B-X
)	B-X
at	B-X
the	B-X
time	B-X
of	B-X
diagnosis	B-X
,	B-X
but	B-X
its	B-X
dysfunction	B-X
could	B-X
result	B-X
from	B-X
a	B-X
nonfunctional	B-X
conformation	B-X
or	B-X
cytoplasmic	B-X
sequestration	B-X
of	B-X
the	B-X
wild-type	B-X
p53	B-X
protein	B-X
.	B-X
However	B-X
,	B-X
p53	B-X
mutation	B-X
,	B-X
when	B-X
it	B-X
occurs	B-X
,	B-X
is	B-X
found	B-X
in	B-X
NB	B-X
tumors	B-X
with	B-X
drug	B-X
resistance	B-X
acquired	B-X
over	B-X
the	B-X
course	B-X
of	B-X
chemotherapy	B-X
.	B-X
As	B-X
yet	B-X
,	B-X
no	B-X
study	B-X
has	B-X
been	B-X
devoted	B-X
to	B-X
the	B-X
function	B-X
of	B-X
the	B-X
specific	B-X
p53	B-X
mutants	B-X
identified	B-X
in	B-X
NB	B-X
cells	B-X
.	B-X
This	B-X
study	B-X
includes	B-X
characterization	B-X
and	B-X
functional	B-X
analysis	B-X
of	B-X
p53	B-X
expressed	B-X
in	B-X
eight	B-X
cell	B-X
lines	B-X
:	B-X
three	B-X
wild-type	B-X
cell	B-X
lines	B-X
and	B-X
five	B-X
cell	B-X
lines	B-X
harboring	B-X
mutations	B-X
.	B-X
We	B-X
identified	B-X
two	B-X
transcription-inactive	B-X
p53	B-X
variants	B-X
truncated	B-X
in	B-X
the	B-X
C-terminus	B-X
,	B-X
one	B-X
of	B-X
which	B-X
corresponded	B-X
to	B-X
the	B-X
p53beta	B-X
isoform	B-X
recently	B-X
identified	B-X
in	B-X
normal	B-X
tissue	B-X
by	B-X
Bourdon	B-X
et	B-X
al	B-X
.	B-X
Our	B-X
results	B-X
show	B-X
,	B-X
for	B-X
the	B-X
first	B-X
time	B-X
,	B-X
that	B-X
the	B-X
p53beta	B-X
isoform	B-X
is	B-X
the	B-X
only	B-X
p53	B-X
species	B-X
to	B-X
be	B-X
endogenously	B-X
expressed	B-X
in	B-X
the	B-X
human	B-X
NB	B-X
cell	B-X
line	B-X
SK-N-AS	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
C-terminus	B-X
truncated	B-X
p53	B-X
isoforms	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
NB	B-X
tumor	B-X
development	B-X
.	B-X

We	O
identified	O
two	O
transcription	O
-	O
inactive	O
p53	O
variants	O
truncated	O
in	O
the	O
C	O
-	O
terminus	O
,	O
one	O
of	O
which	O
corresponded	O
to	O
the	O
p53	O
beta	O
isoform	O
recently	O
identified	O
in	O
normal	O
tissue	O
by	O
Bourdon	O
et	O
al	O
.	O

[	O
J	O
.	O
C	O
.	O
Bourdon	O
,	O
K	O
.	O
Fernandes	O
,	O
F	O
.	O
Murray	O
-	O
Zmijewski	O
,	O
G	O
.	O
Liu	O
,	O
A	O
.	O
Diot	O
,	O
D	O
.	O
P	O
.	O
Xirodimas	O
,	O
M	O
.	O
K	O
.	O
Saville	O
and	O
D	O
.	O
P	O
.	O
Lane	O
(	O
2005	O
)	O
Genes	O
Dev	O
.	O
,	O
19	O
,	O
2122	O
-	O
2137	O
]	O
.	O

Our	O
results	O
show	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
the	O
p53	O
beta	O
isoform	O
is	O
the	O
only	O
p53	O
species	O
to	O
be	O
endogenously	O
expressed	O
in	O
the	O
human	B-Species
NB	O
cell	O
line	O
SK	O
-	O
N	O
-	O
AS	O
,	O
suggesting	O
that	O
the	O
C	O
-	O
terminus	O
truncated	O
p53	O
isoforms	O
may	O
play	O
an	O
important	O
role	O
in	O
NB	O
tumor	O
development	O
.	O

INTRODUCTION	O

The	O
p53	O
tumor	O
suppressor	O
gene	O
remains	O
the	O
most	O
frequently	O
altered	O
gene	O
in	O
human	B-Species
tumors	O
.	O
<EOS>	B-X
The	B-X
transcription	B-X
factor	B-X
p53	B-X
functions	B-X
as	B-X
a	B-X
critical	B-X
tumor	B-X
suppressor	B-X
by	B-X
orchestrating	B-X
a	B-X
plethora	B-X
of	B-X
cellular	B-X
responses	B-X
such	B-X
as	B-X
DNA	B-X
repair	B-X
,	B-X
cell	B-X
cycle	B-X
arrest	B-X
,	B-X
cellular	B-X
senescence	B-X
,	B-X
cell	B-X
death	B-X
,	B-X
cell	B-X
differentiation	B-X
,	B-X
and	B-X
metabolism	B-X
.	B-X
In	B-X
unstressed	B-X
cells	B-X
,	B-X
p53	B-X
levels	B-X
are	B-X
kept	B-X
low	B-X
due	B-X
to	B-X
its	B-X
polyubiquitination	B-X
by	B-X
the	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
MDM2	B-X
.	B-X
In	B-X
response	B-X
to	B-X
various	B-X
stress	B-X
signals	B-X
,	B-X
including	B-X
DNA	B-X
damage	B-X
and	B-X
aberrant	B-X
growth	B-X
signals	B-X
,	B-X
the	B-X
interaction	B-X
between	B-X
p53	B-X
and	B-X
MDM2	B-X
is	B-X
blocked	B-X
and	B-X
p53	B-X
becomes	B-X
stabilized	B-X
,	B-X
allowing	B-X
p53	B-X
to	B-X
regulate	B-X
a	B-X
diverse	B-X
set	B-X
of	B-X
cellular	B-X
responses	B-X
mainly	B-X
through	B-X
the	B-X
transactivation	B-X
of	B-X
its	B-X
target	B-X
genes	B-X
.	B-X
The	B-X
outcome	B-X
of	B-X
p53	B-X
activation	B-X
is	B-X
controlled	B-X
by	B-X
its	B-X
dynamics	B-X
,	B-X
its	B-X
interactions	B-X
with	B-X
other	B-X
proteins	B-X
,	B-X
and	B-X
post-translational	B-X
modifications	B-X
.	B-X
Due	B-X
to	B-X
its	B-X
involvement	B-X
in	B-X
several	B-X
tumor-suppressing	B-X
pathways	B-X
,	B-X
p53	B-X
function	B-X
is	B-X
frequently	B-X
impaired	B-X
in	B-X
human	B-X
cancers	B-X
.	B-X
In	B-X
colorectal	B-X
cancer	B-X
(	B-X
CRC	B-X
)	B-X
,	B-X
the	B-X
TP53	B-X
gene	B-X
is	B-X
mutated	B-X
in	B-X
43	B-X
%	B-X
of	B-X
tumors	B-X
,	B-X
and	B-X
the	B-X
remaining	B-X
tumors	B-X
often	B-X
have	B-X
compromised	B-X
p53	B-X
functioning	B-X
because	B-X
of	B-X
alterations	B-X
in	B-X
the	B-X
genes	B-X
encoding	B-X
proteins	B-X
involved	B-X
in	B-X
p53	B-X
regulation	B-X
,	B-X
such	B-X
as	B-X
ATM	B-X
(	B-X
13	B-X
%	B-X
)	B-X
or	B-X
DNA-PKcs	B-X
(	B-X
11	B-X
%	B-X
)	B-X
.	B-X
TP53	B-X
mutations	B-X
in	B-X
CRC	B-X
are	B-X
usually	B-X
missense	B-X
mutations	B-X
that	B-X
impair	B-X
wild-type	B-X
p53	B-X
function	B-X
(	B-X
loss-of-function	B-X
)	B-X
and	B-X
that	B-X
even	B-X
might	B-X
provide	B-X
neo-morphic	B-X
(	B-X
gain-of-function	B-X
)	B-X
activities	B-X
such	B-X
as	B-X
promoting	B-X
cancer	B-X
cell	B-X
stemness	B-X
,	B-X
cell	B-X
proliferation	B-X
,	B-X
invasion	B-X
,	B-X
and	B-X
metastasis	B-X
,	B-X
thereby	B-X
promoting	B-X
cancer	B-X
progression	B-X
.	B-X
Although	B-X
the	B-X
first	B-X
compounds	B-X
targeting	B-X
p53	B-X
are	B-X
in	B-X
clinical	B-X
trials	B-X
,	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
wild-type	B-X
and	B-X
mutant	B-X
p53	B-X
functions	B-X
will	B-X
likely	B-X
pave	B-X
the	B-X
way	B-X
for	B-X
novel	B-X
CRC	B-X
therapies	B-X
.	B-X

Several	O
p53	O
mutation	O
databases	O
have	O
been	O
reported	O
previously	O
(	O
1	O
-	O
3	O
)	O
,	O
and	O
to	O
date	O
,	O
more	O
than	O
1500	O
different	O
p53	O
mutants	O
have	O
been	O
described	O
(	O
4	O
)	O
.	O

Functional	O
inactivation	O
of	O
p53	O
is	O
usually	O
due	O
to	O
gene	O
mutation	O
,	O
deletion	O
or	O
protein	O
degradation	O
.	O
<EOS>	B-X
Targeted	B-X
protein	B-X
degradation	B-X
(	B-X
TPD	B-X
)	B-X
is	B-X
an	B-X
emerging	B-X
therapeutic	B-X
modality	B-X
with	B-X
the	B-X
potential	B-X
to	B-X
tackle	B-X
disease-causing	B-X
proteins	B-X
that	B-X
have	B-X
historically	B-X
been	B-X
highly	B-X
challenging	B-X
to	B-X
target	B-X
with	B-X
conventional	B-X
small	B-X
molecules	B-X
.	B-X
In	B-X
the	B-X
20	B-X
years	B-X
since	B-X
the	B-X
concept	B-X
of	B-X
a	B-X
proteolysis-targeting	B-X
chimera	B-X
(	B-X
PROTAC	B-X
)	B-X
molecule	B-X
harnessing	B-X
the	B-X
ubiquitin-proteasome	B-X
system	B-X
to	B-X
degrade	B-X
a	B-X
target	B-X
protein	B-X
was	B-X
reported	B-X
,	B-X
TPD	B-X
has	B-X
moved	B-X
from	B-X
academia	B-X
to	B-X
industry	B-X
,	B-X
where	B-X
numerous	B-X
companies	B-X
have	B-X
disclosed	B-X
programmes	B-X
in	B-X
preclinical	B-X
and	B-X
early	B-X
clinical	B-X
development	B-X
.	B-X
Targeted	B-X
protein	B-X
degradation	B-X
using	B-X
Proteolysis	B-X
Targeting	B-X
Chimeras	B-X
(	B-X
PROTACs	B-X
)	B-X
has	B-X
emerged	B-X
as	B-X
a	B-X
novel	B-X
therapeutic	B-X
modality	B-X
in	B-X
drug	B-X
discovery	B-X
.	B-X
PROTACs	B-X
mediate	B-X
the	B-X
degradation	B-X
of	B-X
select	B-X
proteins	B-X
of	B-X
interest	B-X
(	B-X
POIs	B-X
)	B-X
by	B-X
hijacking	B-X
the	B-X
activity	B-X
of	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
for	B-X
POI	B-X
ubiquitination	B-X
and	B-X
subsequent	B-X
degradation	B-X
by	B-X
the	B-X
26S	B-X
proteasome	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
aim	B-X
to	B-X
highlight	B-X
the	B-X
recent	B-X
advances	B-X
in	B-X
targeted	B-X
protein	B-X
degradation	B-X
and	B-X
describe	B-X
the	B-X
challenges	B-X
that	B-X
need	B-X
to	B-X
be	B-X
addressed	B-X
in	B-X
order	B-X
to	B-X
efficiently	B-X
develop	B-X
potent	B-X
PROTACs	B-X
.	B-X

In	O
general	O
,	O
the	O
majority	O
of	O
p53	O
mutations	O
in	O
human	B-Species
neoplasia	O
are	O
missense	O
mutations	O
affecting	O
the	O
DNA	O
-	O
binding	O
domain	O
(	O
DBD	O
)	O
.	O

Unlike	O
other	O
human	B-Species
cancers	O
,	O
p53	O
in	O
neuroblastoma	O
(	O
NB	O
)	O
is	O
rarely	O
mutated	O
in	O
the	O
primary	O
tumor	O
at	O
diagnosis	O
but	O
high	O
levels	O
of	O
wild	O
-	O
type	O
p53	O
(	O
wt	O
p53	O
)	O
protein	O
expression	O
have	O
been	O
found	O
in	O
the	O
cytoplasm	O
of	O
undifferentiated	O
tumors	O
(	O
5	O
,	O
6	O
)	O
.	O

More	O
recently	O
,	O
in	O
normal	O
unstressed	O
cells	O
,	O
wt	O
p53	O
protein	O
was	O
found	O
to	O
be	O
retained	O
in	O
the	O
cytoplasm	O
as	O
a	O
latent	O
form	O
,	O
in	O
huge	O
,	O
p53	O
-	O
associated	O
protein	O
complexes	O
known	O
as	O
'	O
Parc	O
'	O
(	O
7	O
)	O
.	O

The	O
steady	O
-	O
state	O
concentration	O
of	O
p53	O
in	O
normal	O
unstressed	O
cells	O
is	O
usually	O
very	O
low	O
because	O
of	O
the	O
short	O
half	O
-	O
life	O
of	O
the	O
wild	O
-	O
type	O
(	O
wt	O
)	O
protein	O
.	O

Overexpression	O
of	O
p53	O
in	O
most	O
of	O
the	O
transformed	O
cells	O
containing	O
a	O
missense	O
mutation	O
within	O
the	O
p53	O
gene	O
appears	O
to	O
be	O
due	O
to	O
the	O
increased	O
stability	O
of	O
mutated	O
p53	O
(	O
8	O
)	O
.	O

In	O
unstressed	O
NB	O
cells	O
,	O
high	O
wt	O
p53	O
expression	O
may	O
reflect	O
the	O
embryonic	O
origin	O
of	O
NBs	O
,	O
in	O
which	O
precursor	O
cells	O
fail	O
to	O
mature	O
(	O
9	O
)	O
.	O

p53	O
mutations	O
are	O
unusual	O
in	O
human	B-Species
NB	O
but	O
,	O
when	O
they	O
do	O
occur	O
,	O
are	O
found	O
in	O
post	O
-	O
chemotherapy	O
tumors	O
.	O

In	O
this	O
respect	O
,	O
Tweddle	O
et	O
al	O
.	O

(	O
10	O
)	O
described	O
how	O
two	O
NB	O
cell	O
lines	O
derived	O
from	O
the	O
same	O
patient	B-Species
can	O
elicit	O
a	O
different	O
p53	O
status	O
:	O
wt	O
p53	O
for	O
SK	O
-	O
N	O
-	O
BE	O
(	O
1a	O
)	O
established	O
before	O
treatment	O
,	O
and	O
mutated	O
p53	O
for	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2c	O
)	O
established	O
after	O
relapse	O
of	O
the	O
patient	B-Species
under	O
treatment	O
with	O
cytotoxic	O
agents	O
such	O
as	O
cyclophosphamide	O
,	O
doxorubicin	O
,	O
vincristine	O
and	O
radiotherapy	O
.	O

In	O
NB	O
cell	O
lines	O
,	O
p53	O
mutation	O
has	O
been	O
found	O
in	O
multidrug	O
-	O
resistant	O
cells	O
(	O
11	O
)	O
.	O
<EOS>	B-X
Adaptation	B-X
of	B-X
wild-type	B-X
p53	B-X
expressing	B-X
UKF-NB-3	B-X
cancer	B-X
cells	B-X
to	B-X
the	B-X
murine	B-X
double	B-X
minute	B-X
2	B-X
inhibitor	B-X
nutlin-3	B-X
causes	B-X
de	B-X
novo	B-X
p53	B-X
mutations	B-X
at	B-X
high	B-X
frequency	B-X
(	B-X
13/20	B-X
)	B-X
and	B-X
multi-drug	B-X
resistance	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
same	B-X
cells	B-X
respond	B-X
very	B-X
differently	B-X
when	B-X
adapted	B-X
to	B-X
RITA	B-X
,	B-X
a	B-X
drug	B-X
that	B-X
,	B-X
like	B-X
nutlin-3	B-X
,	B-X
also	B-X
disrupts	B-X
the	B-X
p53/Mdm2	B-X
interaction	B-X
.	B-X
All	B-X
of	B-X
the	B-X
11	B-X
UKF-NB-3	B-X
sub-lines	B-X
adapted	B-X
to	B-X
RITA	B-X
that	B-X
we	B-X
established	B-X
retained	B-X
functional	B-X
wild-type	B-X
p53	B-X
although	B-X
RITA	B-X
induced	B-X
a	B-X
substantial	B-X
p53	B-X
response	B-X
.	B-X
Moreover	B-X
,	B-X
all	B-X
RITA-adapted	B-X
cell	B-X
lines	B-X
remained	B-X
sensitive	B-X
to	B-X
nutlin-3	B-X
,	B-X
whereas	B-X
only	B-X
five	B-X
out	B-X
of	B-X
10	B-X
nutlin-3-adapted	B-X
cell	B-X
lines	B-X
retained	B-X
their	B-X
sensitivity	B-X
to	B-X
RITA	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
repeated	B-X
adaptation	B-X
of	B-X
the	B-X
RITA-adapted	B-X
sub-line	B-X
UKF-NB-3	B-X
(	B-X
r	B-X
)	B-X
RITA	B-X
(	B-X
10	B-X
Î¼M	B-X
)	B-X
to	B-X
nutlin-3	B-X
resulted	B-X
in	B-X
p53	B-X
mutations	B-X
.	B-X
The	B-X
RITA-adapted	B-X
UKF-NB-3	B-X
sub-lines	B-X
displayed	B-X
no	B-X
or	B-X
less	B-X
pronounced	B-X
resistance	B-X
to	B-X
vincristine	B-X
,	B-X
cisplatin	B-X
,	B-X
and	B-X
irradiation	B-X
than	B-X
nutlin-3-adapted	B-X
UKF-NB-3	B-X
sub-lines	B-X
.	B-X
Transcriptomic	B-X
analyses	B-X
indicated	B-X
the	B-X
RITA-adapted	B-X
sub-lines	B-X
to	B-X
be	B-X
more	B-X
similar	B-X
at	B-X
the	B-X
gene	B-X
expression	B-X
level	B-X
to	B-X
the	B-X
parental	B-X
UKF-NB-3	B-X
cells	B-X
than	B-X
nutlin-3-adapted	B-X
UKF-NB-3	B-X
sub-lines	B-X
,	B-X
which	B-X
correlates	B-X
with	B-X
the	B-X
observed	B-X
chemotherapy	B-X
and	B-X
irradiation	B-X
sensitivity	B-X
phenotypes	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
RITA-adapted	B-X
cells	B-X
retain	B-X
functional	B-X
p53	B-X
,	B-X
remain	B-X
sensitive	B-X
to	B-X
nutlin-3	B-X
,	B-X
and	B-X
display	B-X
a	B-X
less	B-X
pronounced	B-X
resistance	B-X
phenotype	B-X
than	B-X
nutlin-3-adapted	B-X
cells	B-X
.	B-X

Various	O
types	O
of	O
p53	O
mutation	O
have	O
been	O
detected	O
in	O
NB	O
cells	O
and	O
can	O
lead	O
to	O
inactivation	O
either	O
by	O
shut	O
-	O
down	O
of	O
protein	O
expression	O
or	O
production	O
of	O
aberrant	O
p53	O
products	O
.	O
<EOS>	B-X
The	B-X
clinical	B-X
relevance	B-X
of	B-X
proper	B-X
classification	B-X
is	B-X
explained	B-X
,	B-X
and	B-X
the	B-X
importance	B-X
of	B-X
hormonal	B-X
function	B-X
is	B-X
examined	B-X
,	B-X
including	B-X
eutopic	B-X
and	B-X
ectopic	B-X
hormone	B-X
production	B-X
.	B-X
The	B-X
recognition	B-X
of	B-X
highly	B-X
proliferative	B-X
,	B-X
well-differentiated	B-X
NETs	B-X
has	B-X
resulted	B-X
in	B-X
the	B-X
need	B-X
for	B-X
biomarkers	B-X
that	B-X
can	B-X
distinguish	B-X
these	B-X
G3	B-X
NETs	B-X
from	B-X
NECs	B-X
,	B-X
including	B-X
stains	B-X
to	B-X
determine	B-X
expression	B-X
of	B-X
SSTRs	B-X
and	B-X
those	B-X
that	B-X
can	B-X
indicate	B-X
the	B-X
unique	B-X
molecular	B-X
pathogenetic	B-X
alterations	B-X
that	B-X
underlie	B-X
the	B-X
distinction	B-X
,	B-X
for	B-X
example	B-X
,	B-X
global	B-X
loss	B-X
of	B-X
RB	B-X
and	B-X
aberrant	B-X
p53	B-X
in	B-X
pancreatic	B-X
NECs	B-X
compared	B-X
with	B-X
loss	B-X
of	B-X
ATRX	B-X
,	B-X
DAXX	B-X
,	B-X
and	B-X
menin	B-X
in	B-X
pancreatic	B-X
NETs	B-X
.	B-X
Given	B-X
the	B-X
significant	B-X
proportion	B-X
of	B-X
NENs	B-X
that	B-X
are	B-X
associated	B-X
with	B-X
germline	B-X
mutations	B-X
that	B-X
predispose	B-X
to	B-X
this	B-X
disease	B-X
,	B-X
we	B-X
explain	B-X
the	B-X
role	B-X
of	B-X
the	B-X
pathologist	B-X
in	B-X
identifying	B-X
precursor	B-X
lesions	B-X
and	B-X
applying	B-X
molecular	B-X
immunohistochemistry	B-X
to	B-X
guide	B-X
genetic	B-X
testing	B-X
.	B-X
ARID1A	B-X
is	B-X
a	B-X
SWI/SNF	B-X
subunit	B-X
gene	B-X
whose	B-X
protein	B-X
product	B-X
binds	B-X
DNA	B-X
.	B-X
It	B-X
is	B-X
the	B-X
most	B-X
commonly	B-X
mutated	B-X
member	B-X
of	B-X
the	B-X
SWI/SNF	B-X
complex	B-X
,	B-X
being	B-X
aberrant	B-X
in	B-X
â¼6	B-X
%	B-X
of	B-X
cancers	B-X
overall	B-X
,	B-X
including	B-X
ovarian	B-X
clear	B-X
cell	B-X
cancers	B-X
(	B-X
â¼45	B-X
%	B-X
of	B-X
patients	B-X
)	B-X
and	B-X
uterine	B-X
endometrioid	B-X
cancers	B-X
(	B-X
â¼37	B-X
%	B-X
)	B-X
.	B-X
ARID1A	B-X
has	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
regulating	B-X
gene	B-X
expression	B-X
that	B-X
drives	B-X
oncogenesis	B-X
or	B-X
tumor	B-X
suppression	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
ARID1A	B-X
participates	B-X
in	B-X
control	B-X
of	B-X
the	B-X
PI3K/AKT/mTOR	B-X
pathway	B-X
,	B-X
immune	B-X
responsiveness	B-X
to	B-X
cancer	B-X
,	B-X
EZH2	B-X
methyltransferase	B-X
activity	B-X
,	B-X
steroid	B-X
receptor	B-X
modulation	B-X
,	B-X
DNA	B-X
damage	B-X
checkpoints	B-X
,	B-X
and	B-X
regulation	B-X
of	B-X
p53	B-X
targets	B-X
and	B-X
KRAS	B-X
signaling	B-X
.	B-X

Indeed	O
,	O
in	O
LAN	O
-	O
1	O
cells	O
,	O
p53	O
nonsense	O
mutation	O
at	O
cysteine	O
182	O
in	O
exon	O
5	O
leads	O
to	O
the	O
absence	O
of	O
protein	O
(	O
9	O
)	O
,	O
whereas	O
in	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
cells	O
,	O
missense	O
mutation	O
at	O
codon	O
135	O
(	O
C135F	O
)	O
leads	O
to	O
stable	O
overexpressed	O
protein	O
(	O
11	O
)	O
.	O

By	O
analyzing	O
IGR	O
-	O
N	O
-	O
91	O
,	O
a	O
cell	O
line	O
established	O
in	O
our	O
laboratory	O
from	O
the	O
bone	O
marrow	O
of	O
a	O
patient	B-Species
with	O
metastatic	O
NB	O
after	O
unsuccessful	O
Adriamycin	O
-	O
vincristine	O
chemotherapy	O
(	O
12	O
)	O
,	O
we	O
identified	O
another	O
type	O
of	O
aberrant	O
protein	O
that	O
arises	O
from	O
the	O
duplication	O
of	O
exons	O
7	O
-	O
8	O
-	O
9	O
.	O

This	O
duplication	O
spans	O
from	O
amino	O
acids	O
225	O
to	O
331	O
,	O
which	O
represent	O
part	O
of	O
the	O
DBD	O
and	O
part	O
of	O
the	O
oligomerization	O
domain	O
(	O
13	O
)	O
.	O

However	O
,	O
each	O
p53	O
mutant	O
has	O
been	O
described	O
in	O
the	O
literature	O
as	O
a	O
case	O
report	O
,	O
and	O
so	O
far	O
,	O
no	O
comparative	O
study	O
has	O
been	O
undertaken	O
to	O
link	O
their	O
biochemical	O
features	O
with	O
functional	O
properties	O
.	O

In	O
the	O
present	O
study	O
we	O
report	O
two	O
novel	O
p53	O
C	O
-	O
terminus	O
mutants	O
identified	O
in	O
SK	O
-	O
N	O
-	O
AS	O
and	O
IGR	O
-	O
NB8	O
human	B-Species
NB	O
cell	O
lines	O
.	O

The	O
biological	O
properties	O
of	O
these	O
two	O
new	O
variants	O
were	O
analyzed	O
in	O
comparison	O
with	O
p53	O
isolated	O
from	O
six	O
other	O
human	B-Species
NB	O
lines	O
:	O
three	O
[	O
LAN	O
-	O
1	O
,	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
and	O
IGR	O
-	O
N	O
-	O
91	O
]	O
expressing	O
mutant	O
p53	O
and	O
three	O
(	O
SH	O
-	O
SY5Y	O
,	O
LAN	O
-	O
5	O
and	O
IMR	O
-	O
32	O
)	O
expressing	O
the	O
wt	O
protein	O
.	O

This	O
characterization	O
was	O
done	O
by	O
using	O
a	O
range	O
of	O
functional	O
assays	O
:	O
(	O
i	O
)	O
the	O
ability	O
of	O
the	O
protein	O
to	O
bind	O
with	O
p53	O
consensus	O
sequence	O
using	O
the	O
functional	O
analysis	O
of	O
separated	O
allele	O
in	O
yeast	B-Species
(	O
FASAY	O
)	O
;	O
(	O
ii	O
)	O
the	O
ability	O
of	O
the	O
protein	O
to	O
transactivate	O
the	O
p53	O
-	O
responsive	O
element	O
(	O
RE	O
)	O
identified	O
either	O
in	O
the	O
promoter	O
of	O
p21	O
/	O
WAF1	O
or	O
in	O
the	O
first	O
intron	O
of	O
BAX	O
,	O
using	O
luciferase	O
reporter	O
assay	O
;	O
(	O
iii	O
)	O
the	O
induction	O
of	O
endogenous	O
p21	O
/	O
WAF1	O
gene	O
expression	O
under	O
stress	O
conditions	O
.	O

MATERIALS	O
AND	O
METHODS	O

Neuroblastoma	O
cell	O
lines	O
,	O
culture	O
and	O
drug	O
treatments	O
<EOS>	B-X
The	B-X
use	B-X
of	B-X
primary	B-X
mammalian	B-X
neurons	B-X
derived	B-X
from	B-X
embryonic	B-X
central	B-X
nervous	B-X
system	B-X
tissue	B-X
is	B-X
limited	B-X
by	B-X
the	B-X
fact	B-X
that	B-X
once	B-X
terminally	B-X
differentiated	B-X
into	B-X
mature	B-X
neurons	B-X
,	B-X
the	B-X
cells	B-X
can	B-X
no	B-X
longer	B-X
be	B-X
propagated	B-X
.	B-X
Transformed	B-X
neuronal-like	B-X
cell	B-X
lines	B-X
can	B-X
be	B-X
used	B-X
in	B-X
vitro	B-X
to	B-X
overcome	B-X
this	B-X
limitation	B-X
.	B-X
However	B-X
,	B-X
several	B-X
caveats	B-X
exist	B-X
when	B-X
utilizing	B-X
cells	B-X
derived	B-X
from	B-X
malignant	B-X
tumors	B-X
.	B-X
In	B-X
this	B-X
context	B-X
,	B-X
the	B-X
popular	B-X
SH-SY5Y	B-X
neuroblastoma	B-X
cell	B-X
line	B-X
and	B-X
its	B-X
use	B-X
in	B-X
in	B-X
vitro	B-X
systems	B-X
is	B-X
described	B-X
.	B-X
Originally	B-X
derived	B-X
from	B-X
a	B-X
metastatic	B-X
bone	B-X
tumor	B-X
biopsy	B-X
,	B-X
SH-SY5Y	B-X
(	B-X
ATCC	B-X
(	B-X
Â®	B-X
)	B-X
CRL-2266â¢	B-X
)	B-X
cells	B-X
are	B-X
a	B-X
subline	B-X
of	B-X
the	B-X
parental	B-X
line	B-X
SK-N-SH	B-X
(	B-X
ATCC	B-X
(	B-X
Â®	B-X
)	B-X
HTB-11â¢	B-X
)	B-X
.	B-X
SH-SY5Y	B-X
were	B-X
deposited	B-X
to	B-X
the	B-X
ATCC	B-X
(	B-X
Â®	B-X
)	B-X
in	B-X
1970	B-X
by	B-X
June	B-X
L.	B-X
Biedler.Three	B-X
important	B-X
characteristics	B-X
of	B-X
SH-SY5Y	B-X
cells	B-X
should	B-X
be	B-X
considered	B-X
when	B-X
using	B-X
these	B-X
cells	B-X
in	B-X
in	B-X
vitro	B-X
studies	B-X
.	B-X
First	B-X
,	B-X
cultures	B-X
include	B-X
both	B-X
adherent	B-X
and	B-X
floating	B-X
cells	B-X
,	B-X
both	B-X
types	B-X
of	B-X
which	B-X
are	B-X
viable	B-X
.	B-X
Few	B-X
studies	B-X
address	B-X
the	B-X
biological	B-X
significance	B-X
of	B-X
the	B-X
adherent	B-X
versus	B-X
floating	B-X
phenotypes	B-X
,	B-X
but	B-X
most	B-X
reported	B-X
studies	B-X
utilize	B-X
adherent	B-X
populations	B-X
and	B-X
discard	B-X
the	B-X
floating	B-X
cells	B-X
during	B-X
media	B-X
changes	B-X
.	B-X
Second	B-X
,	B-X
early	B-X
studies	B-X
by	B-X
Biedler	B-X
's	B-X
group	B-X
indicated	B-X
that	B-X
the	B-X
parental	B-X
differentiated	B-X
SK-N-SH	B-X
cells	B-X
contained	B-X
two	B-X
morphologically	B-X
distinct	B-X
phenotypes	B-X
:	B-X
neuroblast-like	B-X
cells	B-X
and	B-X
epithelial-like	B-X
cells	B-X
(	B-X
Ross	B-X
et	B-X
al.	B-X
,	B-X
J	B-X
Nat	B-X
Cancer	B-X
Inst	B-X
71:741-747	B-X
,	B-X
1983	B-X
)	B-X
.	B-X
Cells	B-X
with	B-X
neuroblast-like	B-X
morphology	B-X
are	B-X
positive	B-X
for	B-X
tyrosine	B-X
hydroxylase	B-X
(	B-X
TH	B-X
)	B-X
and	B-X
dopamine-Î²-hydroxylase	B-X
characteristic	B-X
of	B-X
catecholaminergic	B-X
neurons	B-X
,	B-X
whereas	B-X
the	B-X
epithelial-like	B-X
counterpart	B-X
cells	B-X
lacked	B-X
these	B-X
enzymatic	B-X
activities	B-X
(	B-X
Ross	B-X
et	B-X
al.	B-X
,	B-X
J	B-X
Nat	B-X
Cancer	B-X
Inst	B-X
71:741-747	B-X
,	B-X
1983	B-X
)	B-X
.	B-X
Third	B-X
,	B-X
SH-SY5Y	B-X
cells	B-X
can	B-X
be	B-X
differentiated	B-X
to	B-X
a	B-X
more	B-X
mature	B-X
neuron-like	B-X
phenotype	B-X
that	B-X
is	B-X
characterized	B-X
by	B-X
neuronal	B-X
markers	B-X
.	B-X
There	B-X
are	B-X
several	B-X
methods	B-X
to	B-X
differentiate	B-X
SH-SY5Y	B-X
cells	B-X
and	B-X
are	B-X
mentioned	B-X
below	B-X
.	B-X

The	O
parental	O
human	B-Species
NB	O
SH	O
-	O
SY5Y	O
,	O
SK	O
-	O
N	O
-	O
AS	O
,	O
IMR	O
-	O
32	O
and	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
cell	O
lines	O
were	O
purchased	O
from	O
the	O
European	O
Collection	O
of	O
Cell	O
Cultures	O
(	O
ECACC	O
,	O
Wiltshire	O
,	O
UK	O
)	O
.	O

The	O
human	B-Species
IGR	O
-	O
NB8	O
cells	O
(	O
a	O
gift	O
of	O
Prof	O
.	O
Gilles	O
Vassal	O
,	O
UPRES	O
EA	O
3535	O
,	O
Institut	O
Gustave	O
Roussy	O
,	O
Villejuif	O
)	O
were	O
derived	O
from	O
a	O
previously	O
untreated	O
localized	O
NB	O
(	O
14	O
)	O
.	O

The	O
LAN	O
-	O
1	O
and	O
LAN	O
-	O
5	O
cell	O
lines	O
were	O
provided	O
by	O
Dr	O
Nicole	O
Gross	O
(	O
Pediatric	O
Oncology	O
Research	O
,	O
Lausanne	O
,	O
Switzerland	O
)	O
.	O

The	O
human	B-Species
IGR	O
-	O
N	O
-	O
91	O
cell	O
line	O
was	O
established	O
in	O
our	O
laboratory	O
from	O
the	O
bone	O
marrow	O
of	O
a	O
patient	B-Species
with	O
metastatic	O
NB	O
after	O
unsuccessful	O
adriamycin	O
-	O
vincristin	O
chemotherapy	O
(	O
12	O
)	O
.	O

LAN	O
-	O
1	O
,	O
LAN	O
-	O
5	O
and	O
IMR	O
-	O
32	O
were	O
grown	O
in	O
RPMI	O
medium	O
supplemented	O
with	O
2	O
mM	O
l	O
-	O
glutamine	O
and	O
10	O
%	O
fetal	O
calf	O
serum	O
and	O
gentamicine	O
10	O
mu	O
g	O
/	O
ml	O
.	O

Others	O
cell	O
lines	O
were	O
cultured	O
in	O
DMEM	O
.	O
<EOS>	B-X
Accumulated	B-X
evidence	B-X
have	B-X
well	B-X
established	B-X
that	B-X
protein	B-X
sumoylation	B-X
plays	B-X
multiple	B-X
roles	B-X
in	B-X
various	B-X
cellular	B-X
processes	B-X
.	B-X
Various	B-X
ocular	B-X
cell	B-X
lines	B-X
including	B-X
human	B-X
embryonic	B-X
cell	B-X
line	B-X
(	B-X
FHL124	B-X
)	B-X
,	B-X
the	B-X
SV40-large	B-X
T-transformed	B-X
human	B-X
lens	B-X
epithelial	B-X
cell	B-X
line	B-X
(	B-X
HLE	B-X
)	B-X
,	B-X
the	B-X
SV40-large	B-X
T-transformed	B-X
mouse	B-X
lens	B-X
epithelial	B-X
cell	B-X
line	B-X
(	B-X
Î±TN4-1	B-X
)	B-X
,	B-X
the	B-X
rabbit	B-X
lens	B-X
epithelial	B-X
cell	B-X
line	B-X
(	B-X
N/N1003A	B-X
)	B-X
and	B-X
the	B-X
human	B-X
retina	B-X
pigment	B-X
epithelial	B-X
cell	B-X
line	B-X
(	B-X
ARPE-19	B-X
)	B-X
have	B-X
been	B-X
extensively	B-X
used	B-X
for	B-X
studying	B-X
various	B-X
cellular	B-X
functions	B-X
and	B-X
disease	B-X
processes	B-X
including	B-X
sumoylation	B-X
functions	B-X
,	B-X
and	B-X
mechanisms	B-X
for	B-X
cataract	B-X
and	B-X
age-related	B-X
macular	B-X
degeneration	B-X
(	B-X
AMD	B-X
)	B-X
.	B-X
Protein	B-X
sumoylation	B-X
is	B-X
a	B-X
well	B-X
established	B-X
regulatory	B-X
mechanism	B-X
to	B-X
control	B-X
many	B-X
cellular	B-X
processes	B-X
such	B-X
as	B-X
chromatin	B-X
structure	B-X
dynamics	B-X
,	B-X
transcriptional	B-X
regulation	B-X
of	B-X
gene	B-X
expression	B-X
,	B-X
cell	B-X
proliferation	B-X
and	B-X
differentiation	B-X
,	B-X
cell	B-X
transformation	B-X
and	B-X
carcinogenesis	B-X
,	B-X
autophagy	B-X
and	B-X
senescence	B-X
.	B-X
Currently	B-X
,	B-X
the	B-X
five	B-X
major	B-X
cell	B-X
lines	B-X
including	B-X
Î±TN4-1	B-X
,	B-X
FHL124	B-X
,	B-X
HLE	B-X
,	B-X
N/N1003A	B-X
and	B-X
ARPE-19	B-X
have	B-X
been	B-X
extensively	B-X
used	B-X
to	B-X
test	B-X
the	B-X
biochemical	B-X
and	B-X
molecular	B-X
aspects	B-X
of	B-X
normal	B-X
vision	B-X
physiology	B-X
and	B-X
various	B-X
disease	B-X
processes	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
conducted	B-X
the	B-X
study	B-X
on	B-X
the	B-X
expression	B-X
patterns	B-X
of	B-X
the	B-X
three	B-X
types	B-X
of	B-X
sumoylation	B-X
enzymes	B-X
,	B-X
the	B-X
activating	B-X
enzymes	B-X
SAE1	B-X
and	B-X
UBA2	B-X
,	B-X
the	B-X
conjugating	B-X
enzyme	B-X
UBC9	B-X
,	B-X
and	B-X
the	B-X
ligating	B-X
enzymes	B-X
such	B-X
as	B-X
RanBP2	B-X
and	B-X
PIAS1	B-X
in	B-X
these	B-X
ocular	B-X
cell	B-X
lines	B-X
.	B-X

For	O
activation	O
of	O
endogenous	O
p53	O
,	O
cells	O
were	O
treated	O
with	O
cis	O
-	O
platinum	O
(	O
Sigma	O
)	O
(	O
10	O
mu	O
g	O
/	O
ml	O
)	O
for	O
24	O
h	O
then	O
lysed	O
for	O
western	O
blot	O
analysis	O
.	O

Western	O
blot	O
analysis	O
<EOS>	B-X
Appropriate	B-X
protein	B-X
extraction	B-X
method	B-X
,	B-X
electrophoresis	B-X
,	B-X
and	B-X
transfer	B-X
of	B-X
proteins	B-X
,	B-X
immunodetection	B-X
of	B-X
blotted	B-X
protein	B-X
by	B-X
antibodies	B-X
,	B-X
and	B-X
the	B-X
ultimate	B-X
step	B-X
of	B-X
imaging	B-X
and	B-X
analyzing	B-X
the	B-X
data	B-X
is	B-X
nothing	B-X
short	B-X
of	B-X
a	B-X
symphony	B-X
.	B-X
Like	B-X
with	B-X
any	B-X
other	B-X
technology	B-X
in	B-X
life-sciences	B-X
research	B-X
,	B-X
Western	B-X
blotting	B-X
can	B-X
produce	B-X
erroneous	B-X
and	B-X
irreproducible	B-X
data	B-X
.	B-X
We	B-X
provide	B-X
a	B-X
systematic	B-X
approach	B-X
to	B-X
generate	B-X
quantitative	B-X
data	B-X
from	B-X
Western	B-X
blot	B-X
experiments	B-X
that	B-X
incorporates	B-X
critical	B-X
validation	B-X
steps	B-X
to	B-X
identify	B-X
and	B-X
minimize	B-X
sources	B-X
of	B-X
error	B-X
and	B-X
variability	B-X
throughout	B-X
the	B-X
Western	B-X
blot	B-X
process	B-X
.	B-X
Electrophoresis	B-X
and	B-X
the	B-X
following	B-X
western	B-X
blot	B-X
analysis	B-X
are	B-X
indispensable	B-X
to	B-X
investigate	B-X
biochemical	B-X
changes	B-X
in	B-X
cells	B-X
and	B-X
tissues	B-X
exposed	B-X
to	B-X
nanoparticles	B-X
or	B-X
nanomaterials	B-X
.	B-X
It	B-X
is	B-X
important	B-X
to	B-X
select	B-X
a	B-X
good	B-X
blocking	B-X
agent	B-X
and	B-X
an	B-X
appropriate	B-X
pair	B-X
of	B-X
primary	B-X
and	B-X
peroxidase-tagged	B-X
secondary	B-X
antibodies	B-X
to	B-X
obtain	B-X
good	B-X
results	B-X
in	B-X
western	B-X
blot	B-X
analysis	B-X
.	B-X
In	B-X
this	B-X
chapter	B-X
the	B-X
whole	B-X
process	B-X
of	B-X
western	B-X
blot	B-X
analysis	B-X
,	B-X
from	B-X
sample	B-X
preparation	B-X
to	B-X
quantitative	B-X
measurement	B-X
of	B-X
target	B-X
proteins	B-X
,	B-X
is	B-X
described	B-X
.	B-X

This	O
procedure	O
was	O
carried	O
out	O
as	O
described	O
previously	O
(	O
13	O
)	O
.	O
<EOS>	B-X
The	B-X
current	B-X
narrative	B-X
review	B-X
was	B-X
carried	B-X
out	B-X
with	B-X
an	B-X
aim	B-X
to	B-X
(	B-X
1	B-X
)	B-X
describe	B-X
the	B-X
spectrum	B-X
of	B-X
complications	B-X
previously	B-X
recognized	B-X
in	B-X
patients	B-X
with	B-X
peritonsillar	B-X
abscess	B-X
(	B-X
PTA	B-X
)	B-X
,	B-X
(	B-X
2	B-X
)	B-X
describe	B-X
the	B-X
bacterial	B-X
findings	B-X
in	B-X
PTA-associated	B-X
complications	B-X
,	B-X
and	B-X
(	B-X
3	B-X
)	B-X
describe	B-X
the	B-X
time	B-X
relation	B-X
between	B-X
PTA	B-X
and	B-X
complications	B-X
.	B-X
This	B-X
is	B-X
an	B-X
update	B-X
of	B-X
a	B-X
review	B-X
previously	B-X
published	B-X
in	B-X
2013	B-X
,	B-X
2006	B-X
and	B-X
2001	B-X
.	B-X
This	B-X
systematic	B-X
review	B-X
aims	B-X
to	B-X
identify	B-X
and	B-X
describe	B-X
crucial	B-X
areas	B-X
for	B-X
a	B-X
healthy	B-X
and	B-X
sustainable	B-X
lifestyle	B-X
among	B-X
patrolling	B-X
police	B-X
officers	B-X
in	B-X
Europe	B-X
,	B-X
an	B-X
area	B-X
not	B-X
previously	B-X
studied	B-X
.	B-X
Our	B-X
objective	B-X
was	B-X
to	B-X
describe	B-X
the	B-X
clinico-biological	B-X
characteristics	B-X
and	B-X
treatments	B-X
used	B-X
,	B-X
in	B-X
patients	B-X
affected	B-X
by	B-X
telomeropathies	B-X
previously	B-X
seen	B-X
by	B-X
an	B-X
hematologist	B-X
followed	B-X
at	B-X
the	B-X
Lille	B-X
University	B-X
Hospital	B-X
Center	B-X
.	B-X

Protein	O
lysates	O
(	O
50	O
mu	O
g	O
)	O
were	O
submitted	O
to	O
10	O
%	O
SDS	O
-	O
PAGE	O
,	O
and	O
then	O
transferred	O
onto	O
nitrocellulose	O
filters	O
.	O

After	O
saturation	O
,	O
the	O
membranes	O
were	O
incubated	O
with	O
primary	O
antibody	O
diluted	O
in	O
0	O
.	O
1	O
%	O
phosphate	O
-	O
buffered	O
saline	O
,	O
Tween	O
-	O
20	O
and	O
3	O
%	O
skim	O
milk	O
.	O

The	O
primary	O
antibodies	O
used	O
were	O
anti	O
-	O
p53	O
monoclonal	O
antibody	O
(	O
clone	O
DO	O
-	O
7	O
,	O
1	O
/	O
1000	O
,	O
DAKO	O
)	O
,	O
anti	O
-	O
p21	O
/	O
WAF1	O
monoclonal	O
antibody	O
(	O
Ab	O
-	O
1	O
,	O
1	O
/	O
200	O
,	O
Oncogene	O
Research	O
)	O
and	O
anti	O
-	O
beta	O
-	O
actin	O
monoclonal	O
antibody	O
(	O
1	O
/	O
1000	O
;	O
Chemicon	O
)	O
as	O
internal	O
control	O
.	O

Protein	O
bands	O
were	O
detected	O
by	O
ECL	O
system	O
(	O
Amersham	O
)	O
.	O

PCR	O
,	O
plasmids	O
cloning	O
<EOS>	B-X
Chimeric	B-X
primers	B-X
containing	B-X
plasmid	B-X
sequence	B-X
at	B-X
the	B-X
5	B-X
'	B-X
ends	B-X
and	B-X
insert	B-X
sequence	B-X
at	B-X
the	B-X
3	B-X
'	B-X
ends	B-X
were	B-X
used	B-X
to	B-X
PCR-amplify	B-X
insertion	B-X
sequences	B-X
of	B-X
various	B-X
sizes	B-X
,	B-X
namely	B-X
the	B-X
genes	B-X
for	B-X
GFP	B-X
(	B-X
gfp	B-X
)	B-X
,	B-X
beta-d-glucuronidase	B-X
(	B-X
gusA	B-X
)	B-X
,	B-X
and	B-X
beta-galactosidase	B-X
(	B-X
lacZ	B-X
)	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
entire	B-X
luxABCDE	B-X
operon	B-X
.	B-X
These	B-X
inserts	B-X
were	B-X
employed	B-X
as	B-X
mega-primers	B-X
in	B-X
a	B-X
second	B-X
PCR	B-X
with	B-X
a	B-X
circular	B-X
plasmid	B-X
template	B-X
.	B-X
The	B-X
original	B-X
plasmid	B-X
templates	B-X
were	B-X
then	B-X
destroyed	B-X
in	B-X
restriction	B-X
digests	B-X
with	B-X
DpnI	B-X
,	B-X
and	B-X
the	B-X
overlap	B-X
extension	B-X
PCR	B-X
products	B-X
were	B-X
used	B-X
to	B-X
transform	B-X
competent	B-X
Escherichia	B-X
coli	B-X
cells	B-X
.	B-X
QuickStep-Cloning	B-X
is	B-X
a	B-X
novel	B-X
molecular	B-X
cloning	B-X
technique	B-X
that	B-X
builds	B-X
upon	B-X
the	B-X
concepts	B-X
of	B-X
asymmetric	B-X
PCR	B-X
and	B-X
megaprimer-based	B-X
amplification	B-X
of	B-X
whole	B-X
plasmid	B-X
.	B-X
It	B-X
was	B-X
designed	B-X
specifically	B-X
to	B-X
address	B-X
the	B-X
major	B-X
drawbacks	B-X
of	B-X
previously	B-X
reported	B-X
cloning	B-X
methods	B-X
.	B-X
QuickStep-Cloning	B-X
can	B-X
be	B-X
completed	B-X
in	B-X
less	B-X
than	B-X
6	B-X
h	B-X
,	B-X
significantly	B-X
faster	B-X
than	B-X
most	B-X
of	B-X
the	B-X
existing	B-X
cloning	B-X
methods	B-X
,	B-X
while	B-X
retaining	B-X
high	B-X
efficiency	B-X
.	B-X

Genomic	O
DNA	O
was	O
extracted	O
using	O
lysis	O
buffer	O
containing	O
20	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH	O
7	O
.	O
5	O
;	O
0	O
.	O
4	O
M	O
NaCl	O
;	O
0	O
.	O
5	O
%	O
SDS	O
;	O
10	O
mM	O
EDTA	O
,	O
treated	O
with	O
proteinase	O
K	O
(	O
200	O
mu	O
g	O
/	O
mu	O
l	O
)	O
,	O
purified	O
with	O
phenol	O
/	O
chloroform	O
,	O
precipitated	O
with	O
ethanol	O
and	O
dissolved	O
in	O
DNase	O
free	O
water	O
.	O

Total	O
RNA	O
were	O
purified	O
using	O
RNAble	O
reagent	O
(	O
Eurobio	O
)	O
,	O
precipitated	O
with	O
isopropanol	O
and	O
dissolved	O
in	O
RNase	O
free	O
water	O
.	O

cDNA	O
was	O
obtained	O
by	O
reverse	O
transcription	O
of	O
1	O
mu	O
g	O
of	O
total	O
RNA	O
using	O
Superscript	O
II	O
(TM)	O
RNase	O
H	O
-	O
Reverse	O
transcriptase	O
(	O
Invitrogen	O
)	O
and	O
Oligo	O
-	O
d	O
(	O
T	O
)	O
16	O
in	O
conditions	O
specified	O
by	O
the	O
manufacturer	O
.	O

Amplification	O
of	O
full	O
-	O
length	O
p53	O
coding	O
region	O
from	O
SH	O
-	O
SY5Y	O
,	O
IGR	O
-	O
N	O
-	O
91	O
,	O
IGR	O
-	O
NB8	O
and	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
cell	O
lines	O
was	O
performed	O
using	O
forward	O
primer	O
at	O
position	O
152	O
and	O
reverse	O
primer	O
at	O
position	O
1583	O
(	O
F1	O
and	O
R7	O
,	O
respectively	O
,	O
Table	O
1	O
;	O
GenBank	O
accession	O
no	O
.	O
K03199	O
)	O
.	O

p53	O
cDNA	O
from	O
SK	O
-	O
N	O
-	O
AS	O
cells	O
for	O
cloning	O
was	O
obtained	O
from	O
RT	O
-	O
PCR	O
using	O
F1	O
and	O
reverse	O
primer	O
i9	O
+	O
:	O
5	O
'	O
-	O
GCAAAGTCATAGAACCATTTTCAT	O
-	O
3	O
'	O
(	O
nucleotide	O
position	O
14989	O
,	O
GenBank	O
accession	O
no	O
.	O
X54156	O
)	O
primers	O
which	O
encompass	O
from	O
exon	O
1	O
to	O
exon	O
i9	O
+	O
first	O
identified	O
by	O
Flaman	O
et	O
al	O
.	O

(	O
15	O
)	O
included	O
.	O
<EOS>	B-X
TMD	B-X
affects	B-X
up	B-X
to	B-X
15	B-X
%	B-X
of	B-X
adults	B-X
,	B-X
with	B-X
a	B-X
peak	B-X
incidence	B-X
at	B-X
20	B-X
to	B-X
40	B-X
years	B-X
of	B-X
age	B-X
.	B-X
Lung	B-X
cancer	B-X
is	B-X
the	B-X
leading	B-X
cause	B-X
of	B-X
cancer-related	B-X
death	B-X
in	B-X
the	B-X
United	B-X
States	B-X
,	B-X
with	B-X
an	B-X
average	B-X
five-year	B-X
survival	B-X
rate	B-X
of	B-X
15	B-X
percent	B-X
.	B-X
Assessment	B-X
of	B-X
pathological	B-X
lymph	B-X
nodes	B-X
is	B-X
now	B-X
incorporated	B-X
:	B-X
nodes	B-X
with	B-X
a	B-X
short	B-X
axis	B-X
of	B-X
15	B-X
mm	B-X
are	B-X
considered	B-X
measurable	B-X
and	B-X
assessable	B-X
as	B-X
target	B-X
lesions	B-X
.	B-X
The	B-X
short	B-X
axis	B-X
measurement	B-X
should	B-X
be	B-X
included	B-X
in	B-X
the	B-X
sum	B-X
of	B-X
lesions	B-X
in	B-X
calculation	B-X
of	B-X
tumour	B-X
response	B-X
.	B-X
Finally	B-X
,	B-X
a	B-X
section	B-X
on	B-X
detection	B-X
of	B-X
new	B-X
lesions	B-X
,	B-X
including	B-X
the	B-X
interpretation	B-X
of	B-X
FDG-PET	B-X
scan	B-X
assessment	B-X
is	B-X
included	B-X
.	B-X

The	O
PCR	O
was	O
done	O
in	O
the	O
presence	O
of	O
pfu	O
Hotstart	O
DNA	O
polymerase	O
(	O
Stratagene	O
)	O
for	O
30	O
cycles	O
of	O
1	O
min	O
at	O
90	O
degrees	O
C	O
,	O
1	O
min	O
at	O
65	O
degrees	O
C	O
and	O
2	O
min	O
30	O
s	O
at	O
72	O
degrees	O
C	O
using	O
PTC	O
-	O
100	O
thermocycler	O
(	O
MJ	O
-	O
Research	O
)	O
.	O

The	O
p53	O
cDNA	O
from	O
SH	O
-	O
SY5Y	O
,	O
SK	O
-	O
N	O
-	O
AS	O
,	O
IGR	O
-	O
N	O
-	O
91	O
,	O
IGR	O
-	O
NB8	O
and	O
SK	O
-	O
N	O
-	O
AS	O
cells	O
were	O
then	O
cloned	O
into	O
pcDNA3	O
.	O
1	O
/	O
V5	O
-	O
His	O
-	O
Topo	O
vector	O
(	O
Invitrogen	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instruction	O
.	O

The	O
p53	O
sequence	O
of	O
each	O
cell	O
line	O
was	O
investigated	O
by	O
sequencing	O
of	O
plasmids	O
after	O
cloning	O
.	O
<EOS>	B-X
A	B-X
p53-inducible	B-X
gene	B-X
,	B-X
the	B-X
growth	B-X
arrest	B-X
and	B-X
DNA	B-X
damage-inducible	B-X
gene	B-X
45	B-X
(	B-X
gadd45	B-X
)	B-X
,	B-X
is	B-X
associated	B-X
with	B-X
cell	B-X
growth	B-X
inhibition	B-X
,	B-X
DNA	B-X
damage	B-X
response	B-X
and	B-X
DNA	B-X
repair	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
Delta12-prostaglandin	B-X
J2	B-X
(	B-X
Delta12-PGJ2	B-X
)	B-X
,	B-X
an	B-X
in	B-X
vivo	B-X
metabolite	B-X
of	B-X
arachidonic	B-X
acid	B-X
,	B-X
which	B-X
inhibits	B-X
cell	B-X
proliferation	B-X
,	B-X
induces	B-X
gadd45	B-X
mRNA	B-X
in	B-X
HeLa	B-X
cells	B-X
.	B-X
Because	B-X
the	B-X
p53	B-X
protein	B-X
in	B-X
HeLa	B-X
cells	B-X
is	B-X
inactivated	B-X
by	B-X
papilloma	B-X
virus	B-X
E6	B-X
,	B-X
this	B-X
type	B-X
of	B-X
gadd45	B-X
induction	B-X
appears	B-X
to	B-X
be	B-X
p53-independent	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
transcriptional	B-X
mechanism	B-X
of	B-X
gadd45	B-X
mRNA	B-X
induction	B-X
,	B-X
we	B-X
cloned	B-X
a	B-X
human	B-X
genomic	B-X
DNA	B-X
fragment	B-X
containing	B-X
the	B-X
gadd45	B-X
promoter	B-X
region	B-X
,	B-X
and	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
Delta12-PGJ2	B-X
on	B-X
the	B-X
gadd45	B-X
promoter	B-X
activity	B-X
.	B-X
In	B-X
HeLa	B-X
cells	B-X
,	B-X
7.5	B-X
microgram/ml	B-X
Delta12-PGJ2	B-X
markedly	B-X
stimulated	B-X
the	B-X
gadd45	B-X
gene	B-X
promoter	B-X
about	B-X
20-fold	B-X
or	B-X
more	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
Delta12-PGJ2	B-X
did	B-X
not	B-X
stimulate	B-X
the	B-X
promoter	B-X
activity	B-X
of	B-X
a	B-X
reporter	B-X
plasmid	B-X
containing	B-X
only	B-X
p53	B-X
binding	B-X
sites	B-X
in	B-X
HeLa	B-X
cells	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
gadd45	B-X
promoter	B-X
activation	B-X
by	B-X
Delta12-PGJ2	B-X
was	B-X
not	B-X
mediated	B-X
by	B-X
p53	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
one	B-X
of	B-X
the	B-X
mechanisms	B-X
of	B-X
cell	B-X
growth	B-X
arrest	B-X
by	B-X
Delta12-PGJ2	B-X
is	B-X
mediated	B-X
through	B-X
a	B-X
p53-independent	B-X
induction	B-X
of	B-X
gadd45	B-X
.	B-X

Sequencing	O
was	O
performed	O
by	O
Genome	O
Express	O
(	O
Meylan	O
,	O
France	O
)	O
.	O

The	O
pDDm	O
-	O
TO	O
harboring	O
p53	O
dominant	O
negative	O
form	O
(	O
p53DD	O
)	O
pGL3	O
-	O
E1bTATA	O
and	O
the	O
pE1B	O
-	O
hWAF1	O
firefly	O
luciferase	O
reporter	O
containing	O
the	O
p53	O
-	O
responsive	O
element	O
of	O
the	O
p21	O
/	O
WAF1	O
promoter	O
were	O
described	O
previously	O
(	O
16	O
,	O
17	O
)	O
pE1B	O
-	O
BAXi	O
contains	O
the	O
p53RE	O
identified	O
in	O
the	O
intron	O
1	O
of	O
the	O
BAX	O
gene	O
[	O
(	O
18	O
)	O
and	O
D	O
.	O
Munsch	O
,	O
personal	O
communication	O
]	O
.	O

Oligonucleotides	O
TCGAGGGCAGGCCCGGGCTTGTCG	O
and	O
CTAGCGACAAGCCCGGGCCTGCCC	O
were	O
annealed	O
and	O
cloned	O
into	O
pGL3	O
-	O
E1bTATA	O
digested	O
with	O
NheI	O
and	O
XhoI	O
to	O
obtain	O
pE1B	O
-	O
BAXi	O
.	O

The	O
pcDNA3	O
-	O
Delta	O
Np73	O
alpha	O
expression	O
plasmid	O
was	O
a	O
gift	O
of	O
Dr	O
Daniel	O
Caput	O
(	O
SANOFI	O
,	O
Lab	O
e	O
ges	O
,	O
France	O
)	O
.	O

Fluorescent	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
<EOS>	B-X
In	B-X
situ	B-X
hybridization	B-X
(	B-X
ISH	B-X
)	B-X
is	B-X
a	B-X
technique	B-X
that	B-X
uses	B-X
nucleic	B-X
acid	B-X
probes	B-X
to	B-X
allow	B-X
for	B-X
visualization	B-X
of	B-X
nucleic	B-X
acid	B-X
sequences	B-X
in	B-X
cellular/tissue	B-X
preparations	B-X
.	B-X
This	B-X
chapter	B-X
will	B-X
focus	B-X
on	B-X
fluorescent	B-X
in	B-X
situ	B-X
hybridization	B-X
.	B-X
Fluorescence	B-X
in	B-X
situ	B-X
Hybridization	B-X
(	B-X
FISH	B-X
)	B-X
involves	B-X
the	B-X
preparation	B-X
of	B-X
two	B-X
main	B-X
components	B-X
:	B-X
the	B-X
DNA	B-X
probe	B-X
and	B-X
the	B-X
target	B-X
DNA	B-X
to	B-X
which	B-X
the	B-X
probe	B-X
will	B-X
be	B-X
hybridized	B-X
.	B-X
Post-hybridization	B-X
washes	B-X
and	B-X
fluorescently-labeled	B-X
antibody	B-X
incubations	B-X
follow	B-X
the	B-X
24-hour	B-X
hybridization	B-X
,	B-X
and	B-X
the	B-X
specimen	B-X
is	B-X
ready	B-X
for	B-X
visualization	B-X
by	B-X
fluorescent	B-X
microscopy	B-X
.	B-X
Successful	B-X
interpretation	B-X
of	B-X
FISH	B-X
experiments	B-X
is	B-X
dependent	B-X
on	B-X
the	B-X
quality	B-X
of	B-X
the	B-X
starting	B-X
materials	B-X
,	B-X
hybridization	B-X
efficiencies	B-X
,	B-X
and	B-X
stringency	B-X
of	B-X
post-hybridization	B-X
washes	B-X
and	B-X
antibody	B-X
detections	B-X
.	B-X

Cytogenetic	O
preparations	O
<EOS>	B-X
Cytogenetic	B-X
studies	B-X
in	B-X
marine	B-X
fish	B-X
are	B-X
scarce	B-X
,	B-X
and	B-X
elemental	B-X
cytogenetic	B-X
information	B-X
is	B-X
available	B-X
for	B-X
not	B-X
>	B-X
2	B-X
%	B-X
of	B-X
the	B-X
species	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
present	B-X
a	B-X
detailed	B-X
new	B-X
protocol	B-X
to	B-X
obtain	B-X
cytogenetic	B-X
preparations	B-X
from	B-X
marine	B-X
fish	B-X
,	B-X
through	B-X
access	B-X
to	B-X
specimens	B-X
in	B-X
postmortem	B-X
condition	B-X
.	B-X
The	B-X
preparations	B-X
processed	B-X
with	B-X
this	B-X
method	B-X
are	B-X
especially	B-X
useful	B-X
for	B-X
the	B-X
automated	B-X
analysis	B-X
of	B-X
micronuclei	B-X
of	B-X
cultured	B-X
cells	B-X
with	B-X
cytochalasin	B-X
B	B-X
and	B-X
of	B-X
chromosome	B-X
aberrations	B-X
induced	B-X
by	B-X
radiation	B-X
.	B-X
However	B-X
,	B-X
good	B-X
hybridization	B-X
results	B-X
are	B-X
often	B-X
associated	B-X
with	B-X
sample	B-X
quality	B-X
,	B-X
storage	B-X
conditions	B-X
,	B-X
and	B-X
the	B-X
age	B-X
of	B-X
metaphase	B-X
preparations	B-X
.	B-X
Particularly	B-X
,	B-X
aging	B-X
metaphase	B-X
preparations	B-X
over	B-X
a	B-X
prolonged	B-X
period	B-X
of	B-X
time	B-X
has	B-X
been	B-X
considered	B-X
a	B-X
critical	B-X
and	B-X
limiting	B-X
factor	B-X
in	B-X
FISH	B-X
success	B-X
.	B-X
This	B-X
study	B-X
reports	B-X
on	B-X
the	B-X
successful	B-X
use	B-X
of	B-X
the	B-X
FISH-WCP	B-X
procedure	B-X
to	B-X
hybridize	B-X
chromosome	B-X
preparations	B-X
that	B-X
were	B-X
aged	B-X
for	B-X
approximately	B-X
12	B-X
years	B-X
.	B-X
The	B-X
results	B-X
suggested	B-X
that	B-X
it	B-X
is	B-X
possible	B-X
to	B-X
validate	B-X
the	B-X
use	B-X
of	B-X
FISH-WCP	B-X
as	B-X
a	B-X
method	B-X
of	B-X
choice	B-X
to	B-X
study	B-X
aged	B-X
chromosome	B-X
preparations	B-X
,	B-X
even	B-X
if	B-X
the	B-X
slides	B-X
were	B-X
stored	B-X
in	B-X
undesirable	B-X
conditions	B-X
of	B-X
temperature	B-X
and	B-X
humidity	B-X
.	B-X

Metaphase	O
spreads	O
from	O
healthy	O
human	B-Species
male	O
lymphocytes	O
and	O
tumor	O
cell	O
lines	O
were	O
prepared	O
as	O
described	O
previously	O
(	O
19	O
)	O
.	O

BAC	O
probe	O
RP11	O
-	O
199F11	O
,	O
containing	O
a	O
167	O
kb	O
region	O
spanning	O
TP53	O
gene	O
,	O
was	O
labeled	O
by	O
random	O
priming	O
in	O
the	O
presence	O
of	O
Alexa	O
594	O
-	O
dUTP	O
(	O
Molecular	O
Probes	O
)	O
.	O

A	O
commercial	O
probe	O
specific	O
for	O
chromosome	O
17	O
centromere	O
,	O
and	O
labeled	O
with	O
spectrum	O
green	O
,	O
was	O
obtained	O
from	O
Vysis	O
.	O

After	O
over	O
-	O
night	O
cohybridization	O
of	O
the	O
probes	O
in	O
the	O
presence	O
of	O
Cot	O
-	O
1	O
DNA	O
,	O
the	O
slides	O
were	O
washed	O
and	O
DNA	O
counterstained	O
with	O
DAPI	O
.	O

The	O
preparations	O
were	O
observed	O
with	O
an	O
epifluorescence	O
microscope	O
and	O
images	O
captured	O
with	O
a	O
Vysis	O
imaging	O
station	O
.	O

Between	O
3	O
and	O
14	O
metaphases	O
spreads	O
and	O
30	O
-	O
200	O
nuclei	O
were	O
examined	O
for	O
each	O
cell	O
line	O
.	O

Luciferase	O
reporter	O
assays	O
<EOS>	B-X
Luciferase	B-X
assays	B-X
are	B-X
an	B-X
invaluable	B-X
tool	B-X
for	B-X
identifying	B-X
and	B-X
characterizing	B-X
functional	B-X
variants	B-X
,	B-X
allowing	B-X
investigations	B-X
of	B-X
gene	B-X
expression	B-X
,	B-X
intracellular	B-X
signaling	B-X
,	B-X
transcription	B-X
factors	B-X
,	B-X
receptor	B-X
activity	B-X
,	B-X
and	B-X
protein	B-X
folding	B-X
.	B-X
In	B-X
this	B-X
chapter	B-X
,	B-X
we	B-X
provide	B-X
an	B-X
overview	B-X
of	B-X
the	B-X
different	B-X
ways	B-X
that	B-X
luciferase	B-X
assays	B-X
can	B-X
be	B-X
used	B-X
to	B-X
validate	B-X
functionality	B-X
of	B-X
a	B-X
variant	B-X
.	B-X
In	B-X
this	B-X
approach	B-X
,	B-X
a	B-X
series	B-X
of	B-X
promoter	B-X
deletion	B-X
fragments	B-X
are	B-X
fused	B-X
to	B-X
a	B-X
reporter	B-X
gene	B-X
,	B-X
such	B-X
as	B-X
chloramphenicol	B-X
acetyltransferase	B-X
or	B-X
luciferase	B-X
gene	B-X
in	B-X
a	B-X
vector	B-X
,	B-X
and	B-X
then	B-X
transfected	B-X
into	B-X
cells	B-X
for	B-X
induction	B-X
.	B-X
Screening	B-X
the	B-X
expression	B-X
level	B-X
of	B-X
the	B-X
reporter	B-X
gene	B-X
using	B-X
either	B-X
a	B-X
qualitative	B-X
or	B-X
a	B-X
quantitative	B-X
assay	B-X
,	B-X
allows	B-X
to	B-X
identify	B-X
the	B-X
regulatory	B-X
regions	B-X
of	B-X
interest	B-X
(	B-X
e.g.	B-X
,	B-X
cis-acting	B-X
elements	B-X
or	B-X
enhancer	B-X
)	B-X
in	B-X
the	B-X
promoter.Luciferase	B-X
genes	B-X
have	B-X
been	B-X
widely	B-X
used	B-X
as	B-X
reporter	B-X
genes	B-X
for	B-X
their	B-X
sensitivity	B-X
and	B-X
efficiency	B-X
.	B-X
Firefly	B-X
and	B-X
Renilla	B-X
luciferases	B-X
are	B-X
two	B-X
commonly	B-X
used	B-X
reporters	B-X
,	B-X
which	B-X
oxidize	B-X
different	B-X
substrates	B-X
to	B-X
generate	B-X
quantifiable	B-X
luminescence	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
a	B-X
dual-luciferase	B-X
reporter	B-X
assay	B-X
,	B-X
where	B-X
the	B-X
promoter	B-X
of	B-X
interest	B-X
is	B-X
fused	B-X
to	B-X
a	B-X
firefly	B-X
luciferase	B-X
reporter	B-X
and	B-X
is	B-X
co-transfected	B-X
into	B-X
cells	B-X
with	B-X
an	B-X
internal	B-X
control	B-X
vector	B-X
(	B-X
pRL-CMV	B-X
)	B-X
to	B-X
express	B-X
Renilla	B-X
luciferase	B-X
.	B-X
Both	B-X
the	B-X
Firefly	B-X
and	B-X
Renilla	B-X
luciferases	B-X
are	B-X
measured	B-X
using	B-X
a	B-X
dual-luciferase	B-X
reporter	B-X
assay	B-X
system	B-X
which	B-X
improves	B-X
experimental	B-X
accuracy	B-X
.	B-X

LAN	O
-	O
1	O
or	O
SH	O
-	O
SY5Y	O
cells	O
were	O
seeded	O
in	O
duplicates	O
onto	O
6	O
-	O
well	O
plates	O
at	O
a	O
density	O
of	O
2	O
x	O
104	O
cells	O
per	O
cm2	O
and	O
cotransfected	O
24	O
h	O
later	O
with	O
0	O
.	O
5	O
mu	O
g	O
(	O
2	O
.	O
5	O
mu	O
g	O
/	O
ml	O
)	O
of	O
pGL3	O
firefly	O
luciferase	O
reporter	O
gene	O
plasmid	O
under	O
the	O
control	O
of	O
either	O
pE1B	O
-	O
hWAF1	O
or	O
pE1B	O
-	O
BAX	O
using	O
lipofectamine	O
2000	O
and	O
1	O
mu	O
g	O
of	O
either	O
a	O
p53	O
expressing	O
plasmid	O
or	O
an	O
empty	O
vector	O
.	O
<EOS>	B-X
Adeno-associated	B-X
virus	B-X
(	B-X
AAV	B-X
)	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
promising	B-X
viral	B-X
gene	B-X
delivery	B-X
vectors	B-X
with	B-X
long-term	B-X
gene	B-X
expression	B-X
and	B-X
disease	B-X
correction	B-X
,	B-X
featuring	B-X
high	B-X
efficiency	B-X
and	B-X
excellent	B-X
safety	B-X
in	B-X
human	B-X
clinical	B-X
trials	B-X
.	B-X
During	B-X
the	B-X
production	B-X
of	B-X
AAV	B-X
vectors	B-X
,	B-X
there	B-X
are	B-X
several	B-X
quality	B-X
control	B-X
(	B-X
QC	B-X
)	B-X
parameters	B-X
that	B-X
should	B-X
be	B-X
rigorously	B-X
monitored	B-X
to	B-X
comply	B-X
with	B-X
clinical	B-X
safety	B-X
and	B-X
efficacy	B-X
.	B-X
This	B-X
review	B-X
gives	B-X
a	B-X
short	B-X
summary	B-X
of	B-X
the	B-X
most	B-X
frequently	B-X
used	B-X
AVV	B-X
production	B-X
and	B-X
purification	B-X
methods	B-X
,	B-X
focusing	B-X
on	B-X
the	B-X
analytical	B-X
techniques	B-X
applied	B-X
to	B-X
determine	B-X
the	B-X
full/empty	B-X
capsid	B-X
ratio	B-X
and	B-X
the	B-X
integrity	B-X
of	B-X
the	B-X
encapsidated	B-X
therapeutic	B-X
DNA	B-X
of	B-X
the	B-X
products	B-X
.	B-X
Transient	B-X
and	B-X
stable	B-X
vector	B-X
transfections	B-X
have	B-X
played	B-X
important	B-X
roles	B-X
in	B-X
illustrating	B-X
the	B-X
function	B-X
of	B-X
specific	B-X
genes/proteins	B-X
.	B-X
The	B-X
general	B-X
assumption	B-X
is	B-X
that	B-X
such	B-X
a	B-X
platform	B-X
could	B-X
effectively	B-X
link	B-X
a	B-X
given	B-X
gene/protein	B-X
to	B-X
gained	B-X
phenotypes	B-X
,	B-X
revealing	B-X
the	B-X
mechanism	B-X
of	B-X
how	B-X
a	B-X
gene	B-X
works	B-X
.	B-X
However	B-X
,	B-X
in	B-X
reality	B-X
,	B-X
increased	B-X
studies	B-X
have	B-X
surprisingly	B-X
noticed	B-X
some	B-X
unexpected	B-X
results	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
an	B-X
assumption	B-X
that	B-X
empty	B-X
vector-transfected	B-X
cells	B-X
preserve	B-X
the	B-X
cytogenetic	B-X
and	B-X
phenotypic	B-X
characteristics	B-X
,	B-X
and	B-X
represent	B-X
the	B-X
adequate	B-X
control	B-X
in	B-X
transfection	B-X
experiments	B-X
is	B-X
not	B-X
universally	B-X
valid	B-X
.	B-X
A	B-X
DNA	B-X
vector	B-X
,	B-X
a	B-X
transfection	B-X
reagent	B-X
,	B-X
expression	B-X
of	B-X
an	B-X
antibiotic	B-X
resistance	B-X
(	B-X
trans	B-X
)	B-X
gene	B-X
,	B-X
expression	B-X
of	B-X
a	B-X
reporter	B-X
(	B-X
trans	B-X
)	B-X
gene	B-X
,	B-X
and	B-X
selection	B-X
by	B-X
acute/chronic	B-X
antibiotic	B-X
treatment	B-X
may	B-X
evoke	B-X
cellular	B-X
responses	B-X
that	B-X
affect	B-X
the	B-X
biochemical	B-X
processes	B-X
under	B-X
investigation	B-X
.	B-X
We	B-X
exemplify	B-X
a	B-X
number	B-X
of	B-X
studies	B-X
,	B-X
which	B-X
reported	B-X
obvious	B-X
genomic	B-X
,	B-X
transcriptomic	B-X
and	B-X
phenotypic	B-X
changes	B-X
of	B-X
tumor	B-X
cells	B-X
after	B-X
transient/stable	B-X
transfection	B-X
of	B-X
an	B-X
empty	B-X
vector	B-X
.	B-X
To	B-X
further	B-X
address	B-X
the	B-X
common	B-X
mechanisms	B-X
of	B-X
these	B-X
unexpected	B-X
findings	B-X
,	B-X
we	B-X
will	B-X
apply	B-X
the	B-X
genome	B-X
theory	B-X
of	B-X
somatic	B-X
evolution	B-X
to	B-X
explain	B-X
stress-mediated	B-X
system	B-X
dynamics	B-X
and	B-X
the	B-X
limitations	B-X
of	B-X
predicting	B-X
the	B-X
system	B-X
behavior	B-X
solely	B-X
based	B-X
on	B-X
targeted	B-X
genes	B-X
.	B-X
We	B-X
conceptualize	B-X
that	B-X
the	B-X
diverse	B-X
experimental	B-X
manipulations	B-X
(	B-X
e.g.	B-X
,	B-X
transgene	B-X
overexpression	B-X
,	B-X
gene	B-X
knock	B-X
out/down	B-X
,	B-X
chemical	B-X
treatments	B-X
,	B-X
acute	B-X
changes	B-X
in	B-X
culture	B-X
conditions	B-X
,	B-X
etc	B-X
.	B-X
)	B-X
may	B-X
act	B-X
as	B-X
a	B-X
system	B-X
stress	B-X
,	B-X
promoting	B-X
intensive	B-X
genome-level	B-X
alterations	B-X
(	B-X
chromosomal	B-X
instability	B-X
,	B-X
CIN	B-X
)	B-X
,	B-X
epigenetic	B-X
and	B-X
phenotypic	B-X
alterations	B-X
,	B-X
which	B-X
are	B-X
beyond	B-X
the	B-X
function	B-X
of	B-X
manipulated	B-X
genes	B-X
.	B-X
Such	B-X
analysis	B-X
calls	B-X
for	B-X
more	B-X
attention	B-X
on	B-X
the	B-X
reduced	B-X
specificities	B-X
of	B-X
gene-focused	B-X
methodologies	B-X
.	B-X

At	O
24	O
h	O
after	O
transfection	O
,	O
cells	O
were	O
lysed	O
with	O
200	O
mu	O
l	O
/	O
well	O
of	O
passive	O
lysis	O
buffer	O
provided	O
with	O
the	O
'	O
Luciferase	O
assay	O
kit	O
'	O
(	O
Promega	O
)	O
.	O

Luciferase	O
activity	O
was	O
measured	O
using	O
Microlumat	O
LB96P	O
luminometer	O
(	O
EG	O
&	O
G	O
Berthold	O
Instrument	O
)	O
.	O

Functional	O
assay	O
in	O
yeast	B-Species
<EOS>	B-X
Several	B-X
yeasts	B-X
,	B-X
which	B-X
are	B-X
eukaryotic	B-X
microorganisms	B-X
,	B-X
have	B-X
long	B-X
been	B-X
used	B-X
in	B-X
different	B-X
industries	B-X
due	B-X
to	B-X
their	B-X
potential	B-X
applications	B-X
,	B-X
both	B-X
for	B-X
fermentation	B-X
and	B-X
for	B-X
the	B-X
production	B-X
of	B-X
specific	B-X
metabolites	B-X
.	B-X
Kluyveromyces	B-X
marxianus	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
auspicious	B-X
nonconventional	B-X
yeasts	B-X
,	B-X
generally	B-X
isolated	B-X
from	B-X
wide-ranging	B-X
natural	B-X
habitats	B-X
such	B-X
as	B-X
fermented	B-X
traditional	B-X
dairy	B-X
products	B-X
,	B-X
kefir	B-X
grain	B-X
,	B-X
sewage	B-X
from	B-X
sugar	B-X
industries	B-X
,	B-X
sisal	B-X
leaves	B-X
,	B-X
and	B-X
plants	B-X
.	B-X
This	B-X
is	B-X
a	B-X
food-grade	B-X
yeast	B-X
with	B-X
various	B-X
beneficial	B-X
traits	B-X
,	B-X
such	B-X
as	B-X
rapid	B-X
growth	B-X
rate	B-X
and	B-X
thermotolerance	B-X
that	B-X
make	B-X
it	B-X
appealing	B-X
for	B-X
different	B-X
industrial	B-X
food	B-X
and	B-X
biotechnological	B-X
applications	B-X
.	B-X
K.	B-X
marxianus	B-X
is	B-X
a	B-X
respiro-fermentative	B-X
yeast	B-X
likely	B-X
to	B-X
produce	B-X
energy	B-X
by	B-X
either	B-X
respiration	B-X
or	B-X
fermentation	B-X
pathways	B-X
.	B-X
Finally	B-X
,	B-X
this	B-X
review	B-X
provides	B-X
a	B-X
discussion	B-X
of	B-X
the	B-X
main	B-X
challenges	B-X
and	B-X
some	B-X
perspectives	B-X
for	B-X
targeted	B-X
applications	B-X
of	B-X
K.	B-X
marxianus	B-X
in	B-X
the	B-X
modern	B-X
food	B-X
technology	B-X
and	B-X
applied	B-X
biotechnology	B-X
in	B-X
order	B-X
to	B-X
exploit	B-X
the	B-X
full	B-X
potential	B-X
of	B-X
this	B-X
yeast	B-X
which	B-X
can	B-X
be	B-X
used	B-X
as	B-X
a	B-X
cell	B-X
factory	B-X
with	B-X
great	B-X
efficiency	B-X
.	B-X

cDNA	O
was	O
obtained	O
by	O
RT	O
of	O
1	O
mu	O
g	O
of	O
total	O
RNA	O
using	O
Superscript	O
II	O
(TM)	O
RNase	O
H	O
-	O
Reverse	O
transcriptase	O
(	O
Invitrogen	O
)	O
and	O
random	O
hexamers	O
to	O
prime	O
the	O
synthesis	O
in	O
conditions	O
specified	O
by	O
the	O
manufacturer	O
.	O

p53	O
cDNA	O
was	O
amplified	O
by	O
PCR	O
and	O
cotransformed	O
into	O
yeast	B-Species
,	O
IG397	O
Ade2	O
strain	O
,	O
together	O
with	O
either	O
pRDI	O
-	O
22	O
vector	O
for	O
p53	O
-	O
standard	O
assay	O
or	O
pFW35	O
and	O
pFW34	O
plasmid	O
for	O
5	O
'	O
or	O
3	O
'	O
split	O
assay	O
,	O
respectively	O
,	O
carrying	O
the	O
ADE2	O
open	O
reading	O
frame	O
under	O
the	O
control	O
of	O
a	O
p53	O
-	O
responsive	O
promoter	O
(	O
20	O
)	O
.	O
<EOS>	B-X
Bacterial	B-X
antimicrobial	B-X
resistance	B-X
(	B-X
AMR	B-X
)	B-X
is	B-X
constantly	B-X
evolving	B-X
and	B-X
horizontal	B-X
gene	B-X
transfer	B-X
through	B-X
plasmids	B-X
plays	B-X
a	B-X
major	B-X
role	B-X
.	B-X
The	B-X
identification	B-X
of	B-X
plasmid	B-X
characteristics	B-X
and	B-X
their	B-X
association	B-X
with	B-X
different	B-X
bacterial	B-X
hosts	B-X
provides	B-X
crucial	B-X
knowledge	B-X
that	B-X
is	B-X
essential	B-X
to	B-X
understand	B-X
the	B-X
contribution	B-X
of	B-X
plasmids	B-X
to	B-X
the	B-X
transmission	B-X
of	B-X
AMR	B-X
determinants	B-X
.	B-X
Molecular	B-X
identification	B-X
of	B-X
plasmid	B-X
and	B-X
strain	B-X
genotypes	B-X
elicits	B-X
a	B-X
distinction	B-X
between	B-X
spread	B-X
of	B-X
AMR	B-X
genes	B-X
by	B-X
plasmids	B-X
and	B-X
dissemination	B-X
of	B-X
these	B-X
genes	B-X
by	B-X
spread	B-X
of	B-X
bacterial	B-X
clones	B-X
.	B-X
For	B-X
this	B-X
reason	B-X
several	B-X
methods	B-X
are	B-X
used	B-X
to	B-X
type	B-X
the	B-X
plasmids	B-X
,	B-X
e.g	B-X
.	B-X
PCR-based	B-X
replicon	B-X
typing	B-X
(	B-X
PBRT	B-X
)	B-X
or	B-X
relaxase	B-X
typing	B-X
.	B-X
Currently	B-X
,	B-X
there	B-X
are	B-X
28	B-X
known	B-X
plasmid	B-X
types	B-X
in	B-X
Enterobacteriaceae	B-X
distinguished	B-X
by	B-X
PBRT	B-X
.	B-X
Frequently	B-X
reported	B-X
plasmids	B-X
[	B-X
IncF	B-X
,	B-X
IncI	B-X
,	B-X
IncA/C	B-X
,	B-X
IncL	B-X
(	B-X
previously	B-X
designated	B-X
IncL/M	B-X
)	B-X
,	B-X
IncN	B-X
and	B-X
IncH	B-X
]	B-X
are	B-X
the	B-X
ones	B-X
that	B-X
bear	B-X
the	B-X
greatest	B-X
variety	B-X
of	B-X
resistance	B-X
genes	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
review	B-X
is	B-X
to	B-X
provide	B-X
an	B-X
overview	B-X
of	B-X
all	B-X
known	B-X
AMR-related	B-X
plasmid	B-X
families	B-X
in	B-X
Enterobacteriaceae	B-X
,	B-X
the	B-X
resistance	B-X
genes	B-X
they	B-X
carry	B-X
and	B-X
their	B-X
geographical	B-X
distribution	B-X
.	B-X

In	O
a	O
selective	O
medium	O
lacking	O
leucine	O
,	O
wt	O
-	O
p53	O
activates	O
transcription	O
of	O
ADE2	O
gene	O
that	O
encodes	O
enzyme	O
--	O
phosphoribosylimidazole	O
carboxylase	O
--	O
implicated	O
in	O
adenine	O
biosynthesis	O
.	O

Therefore	O
,	O
a	O
colony	O
of	O
cells	O
that	O
expresses	O
ADE2	O
gene	O
is	O
white	O
whereas	O
the	O
one	O
composed	O
of	O
cells	O
where	O
ADE2	O
gene	O
is	O
not	O
expressed	O
owing	O
p53	O
mutation	O
is	O
red	O
.	O

RESULTS	O

P53	O
status	O
in	O
SK	O
-	O
N	O
-	O
AS	O
and	O
IGR	O
-	O
NB8	O
cells	O

We	O
first	O
compared	O
the	O
migration	O
profiles	O
of	O
p53	O
expressed	O
in	O
SK	O
-	O
N	O
-	O
AS	O
and	O
IGR	O
-	O
NB8	O
with	O
those	O
expressed	O
in	O
the	O
other	O
six	O
NB	O
cells	O
,	O
SH	O
-	O
SY5Y	O
,	O
LAN	O
-	O
5	O
,	O
LAN	O
-	O
1	O
,	O
IMR	O
-	O
32	O
,	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
and	O
IGR	O
-	O
N	O
-	O
91	O
.	O

Western	O
blots	O
from	O
50	O
mu	O
g	O
of	O
total	O
protein	O
extracts	O
were	O
revealed	O
with	O
p53	O
monoclonal	O
antibody	O
(	O
DO	O
-	O
7	O
)	O
.	O

A	O
range	O
of	O
profiles	O
was	O
identified	O
as	O
shown	O
in	O
Figure	O
1A	O
.	O
<EOS>	B-X
The	B-X
CLPG	B-X
mutation	B-X
was	B-X
identified	B-X
as	B-X
an	B-X
A	B-X
to	B-X
G	B-X
transition	B-X
in	B-X
a	B-X
highly	B-X
conserved	B-X
dodecamer	B-X
motif	B-X
located	B-X
between	B-X
the	B-X
imprinted	B-X
DLK1	B-X
and	B-X
GTL2	B-X
genes	B-X
.	B-X
This	B-X
motif	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
part	B-X
of	B-X
a	B-X
long-range	B-X
control	B-X
element	B-X
(	B-X
LRCE	B-X
)	B-X
because	B-X
the	B-X
CLPG	B-X
mutation	B-X
was	B-X
shown	B-X
,	B-X
in	B-X
postnatal	B-X
skeletal	B-X
muscle	B-X
,	B-X
to	B-X
enhance	B-X
the	B-X
transcript	B-X
levels	B-X
of	B-X
the	B-X
DLK1	B-X
,	B-X
PEG11	B-X
,	B-X
GTL2	B-X
,	B-X
and	B-X
MEG8	B-X
genes	B-X
in	B-X
cis	B-X
without	B-X
altering	B-X
their	B-X
imprinting	B-X
status	B-X
.	B-X
As	B-X
a	B-X
result	B-X
,	B-X
the	B-X
+	B-X
(	B-X
MAT	B-X
)	B-X
/CLPG	B-X
(	B-X
PAT	B-X
)	B-X
individuals	B-X
have	B-X
a	B-X
unique	B-X
expression	B-X
profile	B-X
thought	B-X
to	B-X
underlie	B-X
the	B-X
callipyge	B-X
phenotype	B-X
:	B-X
an	B-X
overexpression	B-X
of	B-X
the	B-X
paternally	B-X
expressed	B-X
protein	B-X
encoding	B-X
DLK1	B-X
(	B-X
Figure	B-X
1A	B-X
)	B-X
and	B-X
PEG11	B-X
transcripts	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
an	B-X
overexpression	B-X
of	B-X
the	B-X
maternally	B-X
expressed	B-X
noncoding	B-X
GTL2	B-X
and	B-X
MEG8	B-X
transcripts	B-X
.	B-X
The	B-X
four	B-X
landmarks	B-X
were	B-X
identified	B-X
three	B-X
times	B-X
with	B-X
7-day	B-X
intervals	B-X
between	B-X
readings	B-X
.	B-X
The	B-X
mean	B-X
radius	B-X
from	B-X
the	B-X
sample	B-X
mean	B-X
point	B-X
of	B-X
impact	B-X
(	B-X
MPI	B-X
)	B-X
ranged	B-X
from	B-X
0.585	B-X
mm	B-X
to	B-X
1.758	B-X
mm	B-X
.	B-X

As	O
expected	O
,	O
p53	O
extracted	O
from	O
the	O
three	O
cell	O
lines	O
,	O
SH	O
-	O
SY5Y	O
,	O
LAN	O
-	O
5	O
and	O
IMR	O
-	O
32	O
,	O
expressing	O
wt	O
protein	O
(	O
13	O
,	O
21	O
)	O
migrated	O
at	O
the	O
wt	O
position	O
.	O

Of	O
particular	O
note	O
in	O
these	O
three	O
wt	O
p53	O
cell	O
lines	O
was	O
an	O
additional	O
faint	O
band	O
that	O
migrated	O
faster	O
than	O
the	O
full	O
-	O
length	O
protein	O
.	O

The	O
LAN	O
-	O
1	O
cells	O
were	O
found	O
to	O
be	O
p53	O
deficient	O
(	O
9	O
)	O
.	O

The	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
cell	O
line	O
showed	O
an	O
intense	O
band	O
reflecting	O
p53	O
stability	O
due	O
to	O
a	O
missense	O
mutation	O
at	O
codon	O
135	O
(	O
11	O
)	O
.	O

As	O
expected	O
,	O
due	O
to	O
the	O
previously	O
identified	O
duplication	O
of	O
exons	O
7	O
-	O
8	O
-	O
9	O
(	O
13	O
)	O
,	O
p53	O
protein	O
migration	O
was	O
delayed	O
in	O
the	O
IGR	O
-	O
N	O
-	O
91	O
cells	O
.	O

In	O
contrast	O
,	O
the	O
p53	O
protein	O
in	O
the	O
SK	O
-	O
N	O
-	O
AS	O
cell	O
line	O
migrated	O
noticeably	O
faster	O
than	O
the	O
wt	O
protein	O
,	O
indicating	O
that	O
it	O
was	O
smaller	O
in	O
size	O
.	O

The	O
p53	O
protein	O
in	O
the	O
IGR	O
-	O
NB8	O
cell	O
line	O
was	O
even	O
smaller	O
than	O
that	O
in	O
SK	O
-	O
N	O
-	O
AS	O
.	O

To	O
analyze	O
the	O
coding	O
region	O
of	O
each	O
of	O
the	O
p53	O
variants	O
,	O
RT	O
-	O
PCR	O
was	O
performed	O
using	O
p53	O
-	O
specific	O
F1	O
-	O
R7	O
primers	O
(	O
Table	O
1	O
and	O
Figure	O
1B	O
)	O
.	O

The	O
expected	O
1430	O
bp	O
for	O
full	O
-	O
length	O
p53	O
was	O
amplified	O
from	O
wt	O
p53	O
-	O
expressing	O
SH	O
-	O
SY5Y	O
,	O
LAN	O
-	O
5	O
and	O
IMR	O
-	O
32	O
cell	O
lines	O
.	O

As	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
harbors	O
a	O
single	O
point	O
mutation	O
at	O
codon	O
135	O
(	O
C135F	O
)	O
,	O
the	O
amplified	O
fragment	O
analyzed	O
by	O
electrophoresis	O
migrated	O
as	O
wt	O
p53	O
(	O
Figure	O
1B	O
)	O
.	O

The	O
longer	O
RT	O
-	O
PCR	O
fragment	O
from	O
the	O
mutated	O
IGR	O
-	O
N	O
-	O
91	O
cell	O
line	O
resulted	O
from	O
the	O
duplication	O
of	O
exons	O
7	O
-	O
8	O
-	O
9	O
,	O
as	O
shown	O
in	O
our	O
previous	O
data	O
(	O
13	O
)	O
,	O
which	O
corresponds	O
to	O
extra	O
nucleic	O
material	O
of	O
321	O
nt	O
.	O

For	O
the	O
LAN	O
-	O
1	O
cells	O
,	O
no	O
amplified	O
fragment	O
was	O
observed	O
in	O
accordance	O
with	O
published	O
data	O
,	O
which	O
demonstrates	O
the	O
extremely	O
low	O
levels	O
of	O
p53	O
mRNA	O
and	O
the	O
undetectable	O
level	O
of	O
protein	O
(	O
9	O
)	O
.	O

An	O
amplified	O
fragment	O
of	O
the	O
same	O
length	O
as	O
the	O
wt	O
protein	O
was	O
observed	O
in	O
the	O
IGR	O
-	O
NB8	O
cell	O
line	O
(	O
Figure	O
1B	O
)	O
.	O

Indeed	O
,	O
complete	O
gene	O
sequencing	O
revealed	O
a	O
point	O
mutation	O
E326STOP	O
leading	O
to	O
a	O
truncated	O
protein	O
at	O
C	O
-	O
terminus	O
.	O

No	O
fragment	O
,	O
however	O
,	O
was	O
amplified	O
from	O
SK	O
-	O
N	O
-	O
AS	O
with	O
F1	O
-	O
R7	O
primers	O
.	O

To	O
further	O
map	O
the	O
p53	O
mRNA	O
transcribed	O
in	O
these	O
cells	O
,	O
series	O
of	O
RT	O
-	O
PCR	O
tests	O
were	O
performed	O
using	O
the	O
forward	O
primer	O
,	O
F2	O
(	O
exon	O
8	O
position	O
1008th	O
according	O
to	O
GenBank	O
accession	O
no	O
.	O
K03199	O
)	O
,	O
matched	O
with	O
different	O
reverse	O
primers	O
,	O
R3	O
(	O
at	O
the	O
junction	O
of	O
exon	O
8	O
/	O
9	O
,	O
nt	O
position	O
1124	O
)	O
,	O
R4	O
,	O
R5	O
(	O
in	O
exon	O
9	O
at	O
positions	O
1154	O
and	O
1184	O
,	O
respectively	O
)	O
,	O
and	O
R6	O
(	O
in	O
exon	O
10	O
,	O
at	O
position	O
1230	O
)	O
.	O

The	O
sequences	O
of	O
these	O
primers	O
are	O
given	O
in	O
Table	O
1	O
and	O
the	O
results	O
are	O
presented	O
in	O
Figure	O
2A	O
.	O

SK	O
-	O
N	O
-	O
AS	O
cDNA	O
gave	O
an	O
amplified	O
fragment	O
of	O
the	O
same	O
size	O
as	O
SH	O
-	O
SY5Y	O
cDNA	O
with	O
the	O
three	O
primer	O
pairs	O
,	O
F2	O
/	O
R3	O
,	O
F2	O
/	O
R4	O
and	O
F3	O
/	O
R5	O
.	O

However	O
,	O
in	O
contrast	O
to	O
SH	O
-	O
SY5Y	O
,	O
no	O
fragment	O
was	O
obtained	O
with	O
SK	O
-	O
N	O
-	O
AS	O
cDNA	O
using	O
the	O
F2	O
/	O
R6	O
primer	O
pair	O
,	O
which	O
suggests	O
the	O
absence	O
of	O
exon	O
10	O
in	O
SK	O
-	O
N	O
-	O
AS	O
mRNA	O
.	O

The	O
p53	O
protein	O
expressed	O
in	O
SK	O
-	O
N	O
-	O
AS	O
is	O
the	O
p53	O
beta	O
isoform	O

An	O
alternatively	O
spliced	O
form	O
of	O
human	B-Species
p53	O
mRNA	O
with	O
an	O
additional	O
133	O
bp	O
exon	O
derived	O
from	O
intron	O
9	O
has	O
been	O
detected	O
in	O
normal	O
human	B-Species
lymphocytes	O
(	O
15	O
)	O
.	O

This	O
spliced	O
variant	O
named	O
'	O
i9	O
+	O
'	O
encodes	O
a	O
truncated	O
protein	O
of	O
341	O
amino	O
acids	O
including	O
10	O
new	O
amino	O
acids	O
derived	O
from	O
the	O
novel	O
exon	O
,	O
the	O
p53	O
beta	O
isoform	O
according	O
to	O
Bourdon	O
et	O
al	O
.	O
nomenclature	O
(	O
22	O
)	O
.	O

This	O
led	O
us	O
to	O
hypothesize	O
that	O
the	O
shorter	O
protein	O
expressed	O
by	O
the	O
SK	O
-	O
N	O
-	O
AS	O
cell	O
line	O
could	O
be	O
the	O
p53	O
beta	O
isoform	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
RT	O
-	O
PCRs	O
were	O
performed	O
using	O
primer	O
sets	O
designed	O
to	O
amplify	O
the	O
3	O
'	O
region	O
of	O
p53	O
mRNA	O
encoding	O
either	O
the	O
specific	O
C	O
-	O
terminal	O
part	O
of	O
the	O
wt	O
protein	O
(	O
wt	O
C	O
-	O
ter	O
)	O
or	O
the	O
specific	O
C	O
-	O
terminal	O
part	O
of	O
the	O
beta	O
isoform	O
(	O
beta	O
C	O
-	O
ter	O
)	O
.	O

In	O
parallel	O
amplification	O
with	O
a	O
primer	O
pair	O
amplifying	O
the	O
DBD	O
was	O
used	O
as	O
control	O
.	O

The	O
sequences	O
of	O
these	O
oligonucleotides	O
are	O
given	O
in	O
Table	O
1	O
.	O
<EOS>	B-X
1	B-X
)	B-X
.	B-X
In	B-X
an	B-X
unprecedented	B-X
manner	B-X
,	B-X
these	B-X
drugs	B-X
cure	B-X
more	B-X
than	B-X
95	B-X
%	B-X
of	B-X
hepatitis	B-X
C	B-X
patients	B-X
when	B-X
given	B-X
for	B-X
only	B-X
2-3	B-X
months	B-X
.	B-X
As	B-X
shown	B-X
in	B-X
figure	B-X
1	B-X
,	B-X
once	B-X
infection	B-X
of	B-X
targeted	B-X
cells	B-X
has	B-X
occurred	B-X
,	B-X
the	B-X
viral	B-X
genetic	B-X
material	B-X
only	B-X
replicates	B-X
in	B-X
the	B-X
cytosol	B-X
for	B-X
HCV	B-X
whereas	B-X
it	B-X
enters	B-X
the	B-X
nucleus	B-X
and	B-X
integrates	B-X
into	B-X
the	B-X
chromosomes	B-X
as	B-X
provirus	B-X
for	B-X
HIV	B-X
or	B-X
is	B-X
converted	B-X
in	B-X
a	B-X
circular	B-X
covalently	B-X
closed	B-X
form	B-X
(	B-X
cccDNA	B-X
)	B-X
for	B-X
HBV	B-X
(	B-X
Fig	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
blocking	B-X
viral	B-X
replication	B-X
has	B-X
only	B-X
a	B-X
transient	B-X
effect	B-X
on	B-X
HIV	B-X
or	B-X
HBV	B-X
,	B-X
as	B-X
mRNA	B-X
expression	B-X
resumes	B-X
following	B-X
treatment	B-X
discontinuation	B-X
,	B-X
given	B-X
the	B-X
stability	B-X
of	B-X
the	B-X
HIV	B-X
provirus	B-X
or	B-X
the	B-X
HBV	B-X
cccDNA	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
European	B-X
Liver	B-X
meeting	B-X
took	B-X
held	B-X
in	B-X
Paris	B-X
on	B-X
April	B-X
2018	B-X
.	B-X
Table	B-X
1	B-X
summarizes	B-X
some	B-X
of	B-X
the	B-X
molecules	B-X
that	B-X
have	B-X
been	B-X
investigated	B-X
so	B-X
far	B-X
with	B-X
more	B-X
promising	B-X
results	B-X
,	B-X
grouping	B-X
them	B-X
into	B-X
distinct	B-X
drug	B-X
classes	B-X
(	B-X
Soriano	B-X
et	B-X
al	B-X
.	B-X
Exp	B-X
Op	B-X
Inv	B-X
Drugs	B-X
2017	B-X
;	B-X
26:843-51	B-X
)	B-X
,	B-X
based	B-X
on	B-X
their	B-X
distinct	B-X
mechanism	B-X
of	B-X
action	B-X
and	B-X
targeted	B-X
steps	B-X
in	B-X
the	B-X
HBV	B-X
life	B-X
cycle	B-X
(	B-X
Fig	B-X
.	B-X
J	B-X
Hepatol	B-X
2018	B-X
;	B-X
68:412-20	B-X
)	B-X
.	B-X
Exp	B-X
Op	B-X
Biol	B-X
Ther	B-X
,	B-X
in	B-X
press	B-X
)	B-X
,	B-X
including	B-X
ARB-1467	B-X
and	B-X
AB-729	B-X
(	B-X
Arbutus	B-X
)	B-X
,	B-X
ARO-HBV	B-X
(	B-X
Arrowhead	B-X
)	B-X
,	B-X
ALN-HBV	B-X
(	B-X
Alnylam	B-X
)	B-X
,	B-X
and	B-X
IONIS-HBVRx	B-X
(	B-X
Ionis	B-X
)	B-X
.	B-X
NAPs	B-X
are	B-X
phosphorothioate	B-X
40	B-X
length	B-X
oligonucleotides	B-X
that	B-X
no	B-X
map	B-X
any	B-X
HBV	B-X
sequence	B-X
.	B-X
Mol	B-X
Ther	B-X
Nuc	B-X
Acids	B-X
2017	B-X
;	B-X
8:1-12	B-X
)	B-X
.	B-X
In	B-X
a	B-X
pilot	B-X
study	B-X
with	B-X
intravenous	B-X
REP-2139	B-X
,	B-X
investigators	B-X
from	B-X
Replicor	B-X
demonstrated	B-X
strong	B-X
reductions	B-X
in	B-X
HBV-DNA	B-X
along	B-X
with	B-X
significant	B-X
drops	B-X
in	B-X
HBsAg	B-X
and	B-X
seroconversion	B-X
in	B-X
some	B-X
patients	B-X
.	B-X
EASL	B-X
,	B-X
Paris	B-X
2018	B-X
;	B-X
abstract	B-X
FRI-343	B-X
)	B-X
.	B-X
An	B-X
improved	B-X
NAP	B-X
,	B-X
named	B-X
REP-2165	B-X
and	B-X
subcutaneous	B-X
administration	B-X
are	B-X
currently	B-X
being	B-X
tested	B-X
.	B-X

The	O
results	O
presented	O
in	O
Figure	O
2B	O
are	O
consistent	O
with	O
the	O
only	O
expression	O
of	O
the	O
p53	O
beta	O
isoform	O
in	O
SK	O
-	O
N	O
-	O
AS	O
as	O
no	O
band	O
was	O
observed	O
in	O
lane	O
using	O
specific	O
C	O
-	O
ter	O
primer	O
located	O
in	O
exon	O
10	O
.	O

Interestingly	O
,	O
RT	O
-	O
PCR	O
using	O
SH	O
-	O
SY5Y	O
(	O
SH	O
)	O
gave	O
an	O
amplified	O
fragment	O
not	O
only	O
with	O
the	O
primer	O
pair	O
specific	O
to	O
the	O
C	O
-	O
ter	O
domain	O
of	O
wt	O
p53	O
but	O
also	O
with	O
the	O
primer	O
pair	O
specific	O
to	O
the	O
p53	O
beta	O
isoform	O
.	O

This	O
result	O
,	O
combined	O
with	O
the	O
presence	O
of	O
an	O
additional	O
faint	O
band	O
migrating	O
faster	O
than	O
wt	O
p53	O
in	O
denaturing	O
polyacrylamide	O
gel	O
(	O
Figure	O
1A	O
)	O
,	O
strongly	O
suggests	O
that	O
both	O
the	O
p53	O
full	O
-	O
length	O
protein	O
and	O
the	O
beta	O
isoform	O
were	O
expressed	O
in	O
the	O
SH	O
-	O
SY5Y	O
cells	O
.	O

The	O
full	O
-	O
length	O
SK	O
-	O
N	O
-	O
AS	O
p53	O
cDNA	O
was	O
then	O
amplified	O
with	O
the	O
forward	O
primer	O
F1	O
and	O
a	O
reverse	O
primer	O
located	O
within	O
the	O
novel	O
exon	O
i9	O
+	O
(	O
Table	O
1	O
)	O
.	O

This	O
amplified	O
fragment	O
was	O
cloned	O
in	O
pcDNA3	O
/	O
V5	O
-	O
His	O
-	O
Topo	O
,	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O

Its	O
sequence	O
analysis	O
confirmed	O
that	O
the	O
truncated	O
p53	O
expressed	O
in	O
SK	O
-	O
N	O
-	O
AS	O
was	O
encoded	O
by	O
the	O
i9	O
+	O
splice	O
variant	O
described	O
previously	O
by	O
Flaman	O
et	O
al	O
.	O

(	O
15	O
)	O
that	O
encodes	O
the	O
p53	O
beta	O
isoform	O
characterized	O
by	O
Bourdon	O
et	O
al	O
.	O

(	O
22	O
)	O
.	O

A	O
series	O
of	O
genomic	O
amplifications	O
were	O
performed	O
to	O
identify	O
a	O
possible	O
deletion	O
within	O
the	O
intron	O
9	O
that	O
could	O
account	O
for	O
the	O
absence	O
of	O
normal	O
size	O
p53	O
in	O
SK	O
-	O
N	O
-	O
AS	O
cells	O
.	O

The	O
primer	O
sequences	O
are	O
given	O
in	O
Table	O
1	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
:	B-X
To	B-X
identify	B-X
of	B-X
fungal	B-X
isolates	B-X
using	B-X
PCR	B-X
techniques	B-X
with	B-X
universal	B-X
primer	B-X
(	B-X
ITS1-ITS4	B-X
and	B-X
ITS3-ITS4	B-X
)	B-X
.	B-X
For	B-X
cloning	B-X
and	B-X
expressing	B-X
the	B-X
antigen-binding	B-X
variable	B-X
(	B-X
Fv	B-X
)	B-X
portion	B-X
of	B-X
an	B-X
antibody	B-X
in	B-X
Escherzchia	B-X
coli	B-X
,	B-X
vectors	B-X
have	B-X
been	B-X
constructed	B-X
that	B-X
combine	B-X
the	B-X
two	B-X
variable	B-X
regions	B-X
(	B-X
V	B-X
(	B-X
H	B-X
)	B-X
and	B-X
V	B-X
(	B-X
L	B-X
)	B-X
)	B-X
with	B-X
a	B-X
peptide	B-X
linker	B-X
(	B-X
1-3	B-X
)	B-X
.	B-X
The	B-X
genetic	B-X
information	B-X
for	B-X
V	B-X
(	B-X
H	B-X
)	B-X
and	B-X
V	B-X
(	B-X
L	B-X
)	B-X
is	B-X
generally	B-X
amplified	B-X
from	B-X
hybridoma	B-X
cells	B-X
using	B-X
the	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
with	B-X
antibody-specific	B-X
primers	B-X
A	B-X
variety	B-X
of	B-X
primer	B-X
sets	B-X
for	B-X
the	B-X
amplification	B-X
of	B-X
mouse-variable	B-X
domams	B-X
has	B-X
been	B-X
developed	B-X
that	B-X
are	B-X
particulary	B-X
suitable	B-X
for	B-X
the	B-X
generation	B-X
of	B-X
complex	B-X
mouse	B-X
libraries	B-X
consisting	B-X
of	B-X
more	B-X
than	B-X
10	B-X
(	B-X
5	B-X
)	B-X
different	B-X
antibody	B-X
sequences	B-X
(	B-X
4,5	B-X
)	B-X
.	B-X
Therefore	B-X
,	B-X
complex	B-X
sets	B-X
of	B-X
primers	B-X
have	B-X
been	B-X
designed	B-X
Everyone	B-X
of	B-X
the	B-X
target	B-X
cDNAs	B-X
should	B-X
be	B-X
prrmed	B-X
with	B-X
an	B-X
oltgonucle-otide	B-X
hybridizing	B-X
with	B-X
a	B-X
standardized	B-X
affinity	B-X
to	B-X
prevent	B-X
stronger	B-X
amplification	B-X
of	B-X
sequences	B-X
with	B-X
a	B-X
better	B-X
match	B-X
to	B-X
a	B-X
primer	B-X
.	B-X
Long	B-X
primers	B-X
allowing	B-X
a	B-X
high	B-X
number	B-X
of	B-X
mismatches	B-X
have	B-X
been	B-X
successfully	B-X
used	B-X
to	B-X
specifically	B-X
amplify	B-X
antibody	B-X
DNA	B-X
from	B-X
a	B-X
variety	B-X
of	B-X
cell	B-X
lines	B-X
,	B-X
including	B-X
rat	B-X
hybridomas	B-X
(	B-X
6-8	B-X
)	B-X
.	B-X
The	B-X
resulting	B-X
primer	B-X
list	B-X
IS	B-X
described	B-X
in	B-X
Table	B-X
1	B-X
,	B-X
and	B-X
a	B-X
protocol	B-X
for	B-X
the	B-X
amplification	B-X
of	B-X
V	B-X
(	B-X
H	B-X
)	B-X
and	B-X
V	B-X
(	B-X
L	B-X
)	B-X
DNA	B-X
is	B-X
given	B-X
in	B-X
Section	B-X
3.1	B-X
..	B-X
Table	B-X
1	B-X
Oligonucleotides	B-X
for	B-X
the	B-X
Amplification	B-X
of	B-X
Mouse	B-X
and	B-X
Rat	B-X
Immunoglobulin-Variable	B-X
Region	B-X
DNA	B-X
Î³-Chain	B-X
CHl	B-X
domain	B-X
:	B-X
Bi4	B-X
5	B-X
'	B-X
-CCAGGGGCCAGTGGATAGACAAGCTTGGGTGTCGTTTT	B-X
Hind	B-X
III	B-X
Heavy-cham	B-X
variable	B-X
domain	B-X
:	B-X
Bi3f	B-X
5	B-X
'	B-X
-CAGCCGGCCATGGCGCAGGT	B-X
(	B-X
C/G	B-X
)	B-X
CAGCTGCAG	B-X
(	B-X
C/G	B-X
)	B-X
AG	B-X
NcoI	B-X
PvuII	B-X
,	B-X
Pst	B-X
I	B-X
Îº-Chain	B-X
constant	B-X
domain	B-X
:	B-X
Bi5c	B-X
5	B-X
'	B-X
-GAAGATGGATCCAGCGGCCGCAGCATCAGC	B-X
BamHI	B-X
NotI	B-X
Îº-Chain	B-X
variable	B-X
domain	B-X
Bi8b	B-X
5	B-X
'	B-X
-ATTTTCAGAAGCACGCGTAGATATC	B-X
(	B-X
G/T	B-X
)	B-X
TG	B-X
(	B-X
A/C	B-X
)	B-X
T	B-X
(	B-X
G/C	B-X
)	B-X
ACCCAA	B-X
(	B-X
T/A	B-X
)	B-X
CTCCA	B-X
MluI	B-X
EcoRV	B-X
.	B-X

Amplifications	O
were	O
performed	O
in	O
parallel	O
with	O
total	O
DNA	O
extracted	O
from	O
SH	O
-	O
SY5Y	O
and	O
SK	O
-	O
N	O
-	O
AS	O
cells	O
.	O

Results	O
are	O
presented	O
in	O
Figure	O
3	O
.	O
<EOS>	B-X
Of	B-X
these	B-X
271	B-X
myopathogenes	B-X
,	B-X
83	B-X
respond	B-X
to	B-X
Pax7	B-X
,	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
satellite	B-X
cells	B-X
.	B-X
Methods-Descriptive	B-X
tabulations	B-X
of	B-X
data	B-X
reported	B-X
on	B-X
the	B-X
birth	B-X
certificates	B-X
of	B-X
the	B-X
3.79	B-X
million	B-X
births	B-X
that	B-X
occurred	B-X
in	B-X
2018	B-X
are	B-X
presented	B-X
.	B-X
Data	B-X
are	B-X
presented	B-X
for	B-X
maternal	B-X
age	B-X
,	B-X
live-birth	B-X
order	B-X
,	B-X
race	B-X
and	B-X
Hispanic	B-X
origin	B-X
,	B-X
marital	B-X
status	B-X
,	B-X
tobacco	B-X
use	B-X
,	B-X
prenatal	B-X
care	B-X
,	B-X
source	B-X
of	B-X
payment	B-X
for	B-X
the	B-X
delivery	B-X
,	B-X
method	B-X
of	B-X
delivery	B-X
,	B-X
gestational	B-X
age	B-X
,	B-X
birthweight	B-X
,	B-X
and	B-X
plurality	B-X
.	B-X
Trend	B-X
data	B-X
for	B-X
2010	B-X
through	B-X
2018	B-X
are	B-X
presented	B-X
for	B-X
selected	B-X
items	B-X
.	B-X
Results-3,791,712	B-X
births	B-X
were	B-X
registered	B-X
in	B-X
the	B-X
United	B-X
States	B-X
in	B-X
2018	B-X
,	B-X
down	B-X
2	B-X
%	B-X
from	B-X
2017	B-X
.	B-X
Birth	B-X
rates	B-X
declined	B-X
for	B-X
women	B-X
aged	B-X
20-34	B-X
and	B-X
increased	B-X
for	B-X
women	B-X
aged	B-X
35-44	B-X
.	B-X
The	B-X
cesarean	B-X
delivery	B-X
rate	B-X
decreased	B-X
to	B-X
31.9	B-X
%	B-X
in	B-X
2018	B-X
following	B-X
an	B-X
increase	B-X
in	B-X
2017	B-X
.	B-X
Medicaid	B-X
was	B-X
the	B-X
source	B-X
of	B-X
payment	B-X
for	B-X
42.3	B-X
%	B-X
of	B-X
all	B-X
2018	B-X
births	B-X
,	B-X
down	B-X
2	B-X
%	B-X
from	B-X
2017	B-X
.	B-X
Twin	B-X
and	B-X
triplet	B-X
and	B-X
higher-order	B-X
multiple	B-X
birth	B-X
rates	B-X
declined	B-X
in	B-X
2018	B-X
(	B-X
Figure	B-X
1	B-X
)	B-X
.	B-X

Normal	O
size	O
fragments	O
that	O
encompass	O
the	O
acceptor	O
site	O
of	O
intron	O
9	O
were	O
amplified	O
with	O
SH	O
-	O
SY5Y	O
as	O
well	O
as	O
with	O
SK	O
-	O
N	O
-	O
AS	O
DNA	O
.	O

On	O
the	O
contrary	O
amplification	O
fragments	O
that	O
encompass	O
the	O
intron	O
9	O
donor	O
site	O
were	O
obtained	O
only	O
with	O
SH	O
-	O
SY5Y	O
but	O
not	O
with	O
SK	O
-	O
N	O
-	O
AS	O
DNA	O
.	O

These	O
results	O
identify	O
a	O
deletion	O
of	O
the	O
intron	O
9	O
/	O
exon	O
10	O
junction	O
within	O
the	O
SK	O
-	O
N	O
-	O
AS	O
p53	O
gene	O
.	O

A	O
yeast	B-Species
functional	O
assay	O
confirmed	O
the	O
absence	O
of	O
p53	O
full	O
-	O
length	O
expression	O
in	O
SK	O
-	O
N	O
-	O
AS	O
and	O
IGR	O
-	O
NB8	O

It	O
is	O
possible	O
to	O
detect	O
p53	O
mutation	O
using	O
a	O
simple	O
yeast	B-Species
colony	O
color	O
assay	O
as	O
described	O
by	O
Flaman	O
et	O
al	O
.	O

(	O
23	O
)	O
.	O

When	O
the	O
strain	O
is	O
transformed	O
with	O
a	O
plasmid	O
-	O
encoding	O
wt	O
p53	O
,	O
the	O
cells	O
express	O
the	O
ADE2	O
gene	O
and	O
produce	O
white	O
colonies	O
(	O
Figure	O
4A	O
,	O
a	O
,	O
b2	O
and	O
c1	O
,	O
and	O
Figure	O
4B	O
,	O
dish	O
a	O
)	O
.	O

Cells	O
containing	O
mutant	O
p53	O
fail	O
to	O
express	O
ADE2	O
and	O
form	O
small	O
red	O
colonies	O
(	O
Figure	O
4A	O
,	O
b	O
and	O
b1	O
,	O
and	O
Figure	O
4B	O
,	O
dish	O
c	O
)	O
.	O

When	O
the	O
p53	O
cDNA	O
fragment	O
is	O
deleted	O
,	O
cells	O
are	O
unable	O
to	O
form	O
a	O
colony	O
(	O
Figure	O
4A	O
,	O
c	O
and	O
c2	O
)	O
.	O

As	O
shown	O
in	O
Table	O
2	O
,	O
FASAY	O
was	O
performed	O
as	O
a	O
p53	O
-	O
standard	O
test	O
with	O
full	O
-	O
length	O
cDNA	O
or	O
with	O
the	O
split	O
version	O
at	O
the	O
5	O
'	O
and	O
3	O
'	O
end	O
(	O
15	O
)	O
.	O
<EOS>	B-X
The	B-X
standard	B-X
preoperative	B-X
radiotherapy	B-X
regimen	B-X
of	B-X
50	B-X
Gy	B-X
delivered	B-X
in	B-X
25	B-X
fractions	B-X
for	B-X
5	B-X
weeks	B-X
for	B-X
soft	B-X
tissue	B-X
sarcomas	B-X
results	B-X
in	B-X
excellent	B-X
local	B-X
control	B-X
,	B-X
with	B-X
major	B-X
wound	B-X
complications	B-X
occurring	B-X
in	B-X
approximately	B-X
35	B-X
%	B-X
of	B-X
patients	B-X
.	B-X
The	B-X
break-out	B-X
session	B-X
``	B-X
Interventions	B-X
to	B-X
Improve	B-X
the	B-X
Timeliness	B-X
of	B-X
Emergency	B-X
Care	B-X
''	B-X
at	B-X
the	B-X
June	B-X
2011	B-X
Academic	B-X
Emergency	B-X
Medicine	B-X
consensus	B-X
conference	B-X
``	B-X
Interventions	B-X
to	B-X
Assure	B-X
Quality	B-X
in	B-X
the	B-X
Crowded	B-X
Emergency	B-X
Department	B-X
''	B-X
posed	B-X
the	B-X
challenge	B-X
for	B-X
more	B-X
research	B-X
of	B-X
the	B-X
split	B-X
Emergency	B-X
Severity	B-X
Index	B-X
(	B-X
ESI	B-X
)	B-X
3	B-X
patient	B-X
flow	B-X
model	B-X
.	B-X
A	B-X
split	B-X
ESI	B-X
3	B-X
patient	B-X
flow	B-X
model	B-X
divides	B-X
high-variability	B-X
ESI	B-X
3	B-X
patients	B-X
from	B-X
low-variability	B-X
ESI	B-X
3	B-X
patients	B-X
.	B-X
The	B-X
study	B-X
objective	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
effect	B-X
of	B-X
implementing	B-X
a	B-X
split	B-X
ESI	B-X
3	B-X
flow	B-X
model	B-X
has	B-X
on	B-X
patient	B-X
length	B-X
of	B-X
stay	B-X
(	B-X
LOS	B-X
)	B-X
for	B-X
discharged	B-X
patients	B-X
.	B-X

The	O
background	O
of	O
FASAY	O
experiments	O
is	O
around	O
10	O
%	O
.	O

p53	O
wt	O
expressing	O
SH	O
-	O
SY5Y	O
and	O
LAN	O
-	O
5	O
,	O
2	O
wt	O
cell	O
lines	O
,	O
yielded	O
~	O
92	O
-	O
97	O
%	O
of	O
white	O
colonies	O
(	O
Table	O
2	O
)	O
.	O

One	O
hundred	O
percent	O
of	O
the	O
colonies	O
carrying	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
p53	O
,	O
which	O
is	O
homozygous	O
for	O
the	O
C135F	O
mutation	O
,	O
turned	O
red	O
with	O
the	O
standard	O
or	O
5	O
'	O
split	O
assay	O
,	O
whereas	O
94	O
%	O
of	O
the	O
colonies	O
turned	O
white	O
with	O
the	O
3	O
'	O
split	O
assay	O
since	O
the	O
missense	O
mutation	O
does	O
not	O
extend	O
to	O
the	O
C	O
'	O
-	O
terminus	O
of	O
the	O
gene	O
(	O
Table	O
2	O
and	O
Figure	O
4B	O
,	O
dish	O
c	O
)	O
.	O

No	O
colonies	O
were	O
observed	O
with	O
p53	O
-	O
deficient	O
LAN	O
-	O
1	O
cells	O
,	O
(	O
see	O
also	O
Figure	O
4A	O
,	O
c	O
and	O
c2	O
)	O
.	O

With	O
SK	O
-	O
N	O
-	O
AS	O
cells	O
,	O
the	O
split	O
5	O
'	O
assay	O
gave	O
96	O
%	O
white	O
colonies	O
,	O
while	O
the	O
p53	O
-	O
standard	O
and	O
split	O
3	O
'	O
assay	O
did	O
not	O
produce	O
any	O
colonies	O
(	O
Table	O
2	O
)	O
.	O

This	O
means	O
that	O
the	O
5	O
'	O
terminus	O
was	O
intact	O
whereas	O
the	O
3	O
'	O
terminus	O
had	O
been	O
deleted	O
,	O
as	O
was	O
confirmed	O
by	O
nucleotide	O
sequence	O
analysis	O
.	O

The	O
IGR	O
-	O
NB8	O
colonies	O
,	O
however	O
,	O
were	O
red	O
both	O
with	O
the	O
p53	O
-	O
standard	O
assay	O
and	O
the	O
split	O
3	O
'	O
assay	O
.	O

In	O
the	O
IGR	O
-	O
N	O
-	O
91	O
cell	O
line	O
,	O
where	O
p53	O
harbors	O
two	O
contiguous	O
sets	O
of	O
exons	O
7	O
-	O
9	O
,	O
spanning	O
the	O
DBD	O
and	O
oligomerization	O
domain	O
,	O
it	O
is	O
interesting	O
to	O
note	O
that	O
the	O
yeast	B-Species
colonies	O
were	O
predominantly	O
white	O
(	O
Figure	O
4B	O
,	O
dish	O
b	O
)	O
with	O
the	O
split	O
5	O
'	O
and	O
the	O
split	O
3	O
'	O
assay	O
(	O
96	O
and	O
87	O
%	O
of	O
white	O
colonies	O
,	O
respectively	O
)	O
This	O
suggests	O
that	O
the	O
cells	O
express	O
a	O
binding	O
ability	O
that	O
is	O
specific	O
to	O
wild	O
-	O
type	O
p53	O
rather	O
than	O
mutated	O
p53	O
(	O
Table	O
2	O
)	O
.	O

Transcription	O
activity	O
of	O
SH	O
-	O
SY5Y	O
,	O
IGR	O
-	O
N	O
-	O
91	O
,	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
,	O
SK	O
-	O
N	O
-	O
AS	O
and	O
IGR	O
-	O
NB8	O
p53	O
variants	O
in	O
mammalian	O
cells	O

To	O
determine	O
the	O
transactivation	O
ability	O
of	O
p53	O
variants	O
in	O
mammalian	O
cells	O
,	O
we	O
used	O
a	O
reporter	O
gene	O
strategy	O
.	O

The	O
p53RE	O
located	O
within	O
either	O
the	O
human	B-Species
p21	O
/	O
WAF1	O
promoter	O
or	O
the	O
intron	O
1	O
of	O
the	O
mouse	B-Species
and	O
human	B-Species
BAX	O
gene	O
[	O
(	O
18	O
)	O
and	O
D	O
.	O

Munsch	O
,	O
personnal	O
communication	O
)	O
were	O
cloned	O
in	O
a	O
luciferase	O
reporter	O
gene	O
plasmid	O
upstream	O
of	O
the	O
E1B	O
minimal	O
promoter	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O

The	O
p53	O
-	O
negative	O
LAN	O
-	O
1	O
cells	O
were	O
cotransfected	O
with	O
the	O
p53	O
vectors	O
expressing	O
the	O
p53	O
cloned	O
from	O
either	O
SH	O
-	O
SY5Y	O
,	O
IGR	O
-	O
N	O
-	O
91	O
,	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
,	O
SK	O
-	O
N	O
-	O
AS	O
or	O
IGR	O
-	O
NB8	O
and	O
the	O
luciferase	O
reporter	O
plasmids	O
.	O

Both	O
p53RE	O
were	O
strongly	O
stimulated	O
in	O
cells	O
cotransfected	O
with	O
wt	O
p53	O
cloned	O
from	O
SH	O
-	O
SY5Y	O
,	O
as	O
compared	O
to	O
cells	O
cotransfected	O
with	O
an	O
empty	O
plasmid	O
.	O

In	O
contrast	O
,	O
none	O
of	O
the	O
p53	O
variants	O
was	O
able	O
to	O
transactivate	O
the	O
expression	O
of	O
luciferase	O
driven	O
by	O
either	O
p21	O
/	O
WAF1	O
or	O
BAX	O
p53RE	O
(	O
Figure	O
5	O
)	O
.	O

To	O
test	O
transactivation	O
capability	O
at	O
the	O
protein	O
level	O
,	O
each	O
variant	O
was	O
transfected	O
into	O
p53	O
-	O
negative	O
LAN	O
-	O
1	O
cells	O
and	O
the	O
stimulation	O
of	O
endogenous	O
p21	O
/	O
Waf1	O
gene	O
expression	O
was	O
analyzed	O
by	O
western	O
blotting	O
.	O

As	O
shown	O
in	O
Figure	O
6	O
,	O
in	O
contrast	O
to	O
wt	O
p53	O
,	O
none	O
of	O
the	O
p53	O
variants	O
was	O
able	O
to	O
induce	O
p21	O
protein	O
accumulation	O
.	O

We	O
then	O
tested	O
for	O
a	O
possible	O
dominant	O
negative	O
effect	O
of	O
these	O
various	O
mutants	O
on	O
wt	O
p53	O
-	O
dependent	O
transcriptional	O
activity	O
.	O

To	O
this	O
end	O
,	O
SH	O
-	O
SY5Y	O
cells	O
were	O
cotransfected	O
with	O
constructs	O
encoding	O
the	O
luciferase	O
gene	O
driven	O
by	O
either	O
the	O
p21	O
/	O
Waf1	O
or	O
BAX	O
p53RE	O
and	O
the	O
constructs	O
expressing	O
the	O
various	O
p53s	O
cloned	O
from	O
IGR	O
-	O
NB8	O
,	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
,	O
IGR	O
-	O
N	O
-	O
91	O
,	O
SK	O
-	O
N	O
-	O
AS	O
and	O
IGR	O
-	O
NB8	O
NB	O
cells	O
or	O
p53DD	O
,	O
a	O
dominant	O
negative	O
mutant	O
of	O
wt	O
p53	O
(	O
24	O
)	O
.	O

The	O
stress	O
induced	O
by	O
transfection	O
activated	O
the	O
transcriptional	O
activity	O
of	O
the	O
wt	O
p53	O
expressed	O
in	O
SH	O
-	O
SY5Y	O
,	O
leading	O
to	O
a	O
p53	O
-	O
dependent	O
expression	O
of	O
luciferase	O
as	O
illustrated	O
by	O
the	O
fact	O
that	O
coexpression	O
of	O
p53DD	O
led	O
to	O
a	O
substantial	O
decrease	O
in	O
luciferase	O
activity	O
when	O
compared	O
to	O
the	O
luciferase	O
activity	O
of	O
cells	O
cotransfected	O
with	O
an	O
empty	O
plasmid	O
(	O
Figure	O
5	O
)	O
.	O

Compared	O
to	O
p53DD	O
,	O
mutants	O
within	O
the	O
DBD	O
isolated	O
from	O
IGR	O
-	O
N	O
-	O
91	O
or	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
had	O
only	O
a	O
moderate	O
dominant	O
negative	O
effect	O
on	O
endogenous	O
wt	O
p53	O
transcriptional	O
activity	O
.	O

More	O
surprisingly	O
,	O
the	O
transfection	O
of	O
the	O
C	O
-	O
terminal	O
truncated	O
variant	O
IGR	O
-	O
NB8	O
enhanced	O
both	O
BAX	O
and	O
p21	O
/	O
WAF1	O
p53RE	O
activity	O
.	O

The	O
coexpression	O
of	O
p53	O
beta	O
cloned	O
from	O
SK	O
-	O
N	O
-	O
AS	O
also	O
enhanced	O
BAX	O
p53RE	O
activity	O
.	O

A	O
similar	O
effect	O
has	O
been	O
reported	O
already	O
for	O
p53	O
beta	O
by	O
Bourdon	O
et	O
al	O
.	O

(	O
22	O
)	O
.	O

When	O
combined	O
,	O
these	O
results	O
show	O
that	O
all	O
the	O
p53	O
variants	O
isolated	O
from	O
the	O
NB	O
cells	O
had	O
lost	O
the	O
ability	O
to	O
specifically	O
transactivate	O
the	O
p53	O
target	O
genes	O
.	O

Their	O
effect	O
on	O
the	O
transcriptional	O
activity	O
of	O
endogenous	O
wt	O
p53	O
expressed	O
in	O
SH	O
-	O
SY5Y	O
cells	O
,	O
however	O
,	O
largely	O
depended	O
on	O
the	O
p53	O
domain	O
affected	O
by	O
the	O
modification	O
.	O

All	O
the	O
identified	O
p53	O
variants	O
inhibited	O
the	O
induction	O
of	O
endogenous	O
p21	O
/	O
WAF1	O
gene	O
expression	O
under	O
stress	O
conditions	O

We	O
further	O
examined	O
whether	O
the	O
four	O
p53	O
variants	O
,	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
,	O
IGR	O
-	O
N	O
-	O
91	O
,	O
SK	O
-	O
N	O
-	O
AS	O
and	O
IGR	O
-	O
NB8	O
,	O
had	O
loss	O
their	O
ability	O
to	O
stimulate	O
the	O
endogenous	O
expression	O
of	O
the	O
p21	O
/	O
WAF1	O
gene	O
,	O
the	O
archetypical	O
cell	O
cycle	O
inhibitor	O
and	O
the	O
true	O
target	O
of	O
p53	O
.	O

To	O
this	O
end	O
,	O
cellular	O
response	O
to	O
genotoxic	O
stress	O
was	O
analyzed	O
by	O
western	O
blot	O
following	O
treatment	O
of	O
the	O
various	O
cell	O
lines	O
with	O
cisplatin	O
,	O
one	O
of	O
the	O
most	O
potent	O
antitumor	O
agents	O
used	O
in	O
neuroblastoma	O
.	O

Results	O
are	O
presented	O
in	O
Figure	O
7	O
.	O
<EOS>	B-X
Methods-Descriptive	B-X
tabulations	B-X
of	B-X
data	B-X
reported	B-X
on	B-X
the	B-X
birth	B-X
certificates	B-X
of	B-X
the	B-X
3.79	B-X
million	B-X
births	B-X
that	B-X
occurred	B-X
in	B-X
2018	B-X
are	B-X
presented	B-X
.	B-X
Data	B-X
are	B-X
presented	B-X
for	B-X
maternal	B-X
age	B-X
,	B-X
live-birth	B-X
order	B-X
,	B-X
race	B-X
and	B-X
Hispanic	B-X
origin	B-X
,	B-X
marital	B-X
status	B-X
,	B-X
tobacco	B-X
use	B-X
,	B-X
prenatal	B-X
care	B-X
,	B-X
source	B-X
of	B-X
payment	B-X
for	B-X
the	B-X
delivery	B-X
,	B-X
method	B-X
of	B-X
delivery	B-X
,	B-X
gestational	B-X
age	B-X
,	B-X
birthweight	B-X
,	B-X
and	B-X
plurality	B-X
.	B-X
Trend	B-X
data	B-X
for	B-X
2010	B-X
through	B-X
2018	B-X
are	B-X
presented	B-X
for	B-X
selected	B-X
items	B-X
.	B-X
Results-3,791,712	B-X
births	B-X
were	B-X
registered	B-X
in	B-X
the	B-X
United	B-X
States	B-X
in	B-X
2018	B-X
,	B-X
down	B-X
2	B-X
%	B-X
from	B-X
2017	B-X
.	B-X
Compared	B-X
with	B-X
rates	B-X
in	B-X
2017	B-X
,	B-X
the	B-X
general	B-X
fertility	B-X
rate	B-X
declined	B-X
to	B-X
59.1	B-X
births	B-X
per	B-X
1,000	B-X
women	B-X
aged	B-X
15-44	B-X
.	B-X
The	B-X
birth	B-X
rate	B-X
for	B-X
females	B-X
aged	B-X
15-19	B-X
fell	B-X
7	B-X
%	B-X
in	B-X
2018	B-X
.	B-X
The	B-X
total	B-X
fertility	B-X
rate	B-X
declined	B-X
to	B-X
1,729.5	B-X
births	B-X
per	B-X
1,000	B-X
women	B-X
in	B-X
2018	B-X
.	B-X
Birth	B-X
rates	B-X
for	B-X
both	B-X
married	B-X
and	B-X
unmarried	B-X
women	B-X
declined	B-X
from	B-X
2017	B-X
to	B-X
2018	B-X
.	B-X
The	B-X
percentage	B-X
of	B-X
women	B-X
who	B-X
began	B-X
prenatal	B-X
care	B-X
in	B-X
the	B-X
first	B-X
trimester	B-X
of	B-X
pregnancy	B-X
rose	B-X
to	B-X
77.5	B-X
%	B-X
in	B-X
2018	B-X
;	B-X
the	B-X
percentage	B-X
of	B-X
all	B-X
women	B-X
who	B-X
smoked	B-X
during	B-X
pregnancy	B-X
declined	B-X
to	B-X
6.5	B-X
%	B-X
.	B-X
The	B-X
cesarean	B-X
delivery	B-X
rate	B-X
decreased	B-X
to	B-X
31.9	B-X
%	B-X
in	B-X
2018	B-X
following	B-X
an	B-X
increase	B-X
in	B-X
2017	B-X
.	B-X
Medicaid	B-X
was	B-X
the	B-X
source	B-X
of	B-X
payment	B-X
for	B-X
42.3	B-X
%	B-X
of	B-X
all	B-X
2018	B-X
births	B-X
,	B-X
down	B-X
2	B-X
%	B-X
from	B-X
2017	B-X
.	B-X
Twin	B-X
and	B-X
triplet	B-X
and	B-X
higher-order	B-X
multiple	B-X
birth	B-X
rates	B-X
declined	B-X
in	B-X
2018	B-X
(	B-X
Figure	B-X
1	B-X
)	B-X
.	B-X

None	O
of	O
the	O
mutant	O
cells	O
,	O
regardless	O
of	O
the	O
type	O
of	O
mutation	O
,	O
was	O
able	O
to	O
induce	O
p21	O
/	O
WAF1	O
protein	O
accumulation	O
,	O
unlike	O
the	O
3	O
p53	O
wild	O
-	O
type	O
cells	O
(	O
SH	O
-	O
SY5Y	O
,	O
IMR	O
-	O
32	O
and	O
LAN	O
-	O
5	O
)	O
.	O

Genomic	O
status	O
of	O
TP53	O
region	O
in	O
the	O
various	O
cell	O
lines	O
<EOS>	B-X
To	B-X
comprehensively	B-X
understand	B-X
the	B-X
underlying	B-X
molecular	B-X
events	B-X
accounting	B-X
for	B-X
aberrant	B-X
Wnt	B-X
signaling	B-X
activation	B-X
in	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
.	B-X
To	B-X
conduct	B-X
high-throughput	B-X
mutational	B-X
analysis	B-X
in	B-X
6	B-X
commonly	B-X
used	B-X
head	B-X
and	B-X
neck	B-X
cancer	B-X
cell	B-X
lines	B-X
.	B-X
Comprehensive	B-X
mutation	B-X
analysis	B-X
of	B-X
primary	B-X
head	B-X
and	B-X
neck	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
(	B-X
HNSCC	B-X
)	B-X
tumors	B-X
has	B-X
recently	B-X
been	B-X
reported	B-X
,	B-X
and	B-X
mutations	B-X
in	B-X
the	B-X
NOTCH	B-X
receptors	B-X
,	B-X
TP53	B-X
and	B-X
CDKN2A	B-X
,	B-X
were	B-X
key	B-X
findings	B-X
.	B-X
Established	B-X
cell	B-X
lines	B-X
are	B-X
valuable	B-X
tools	B-X
to	B-X
study	B-X
cancer	B-X
in	B-X
vitro	B-X
.	B-X
Similar	B-X
high-throughput	B-X
mutational	B-X
analysis	B-X
of	B-X
head	B-X
and	B-X
neck	B-X
cancer	B-X
cell	B-X
lines	B-X
is	B-X
necessary	B-X
to	B-X
confirm	B-X
their	B-X
mutational	B-X
profile	B-X
.	B-X

According	O
to	O
Knudson	O
'	O
s	O
'	O
two	O
hit	O
'	O
model	O
of	O
tumor	O
suppressor	O
gene	O
functional	O
inactivation	O
,	O
the	O
mutation	O
of	O
one	O
allele	O
is	O
supposed	O
to	O
be	O
associated	O
with	O
a	O
deletion	O
of	O
the	O
second	O
allele	O
.	O

To	O
assess	O
this	O
genetic	O
mechanism	O
,	O
we	O
performed	O
FISH	O
experiments	O
to	O
search	O
for	O
deletions	O
of	O
one	O
copy	O
of	O
the	O
TP53	O
region	O
,	O
especially	O
in	O
cell	O
lines	O
with	O
a	O
mutated	O
TP53	O
gene	O
.	O

For	O
this	O
purpose	O
,	O
metaphase	O
preparations	O
of	O
the	O
studied	O
cell	O
lines	O
were	O
cohybridized	O
with	O
a	O
p53	O
DNA	O
probe	O
labeled	O
in	O
red	O
(	O
BAC	O
clone	O
RP11	O
-	O
199F11	O
)	O
as	O
described	O
previously	O
(	O
25	O
)	O
and	O
a	O
chromosome	O
17	O
-	O
specific	O
centromeric	O
probe	O
labeled	O
in	O
green	O
.	O

The	O
three	O
cell	O
lines	O
shown	O
previously	O
to	O
express	O
a	O
wt	O
p53	O
protein	O
(	O
LAN5	O
,	O
IMR32	O
and	O
SH	O
-	O
SY5Y	O
)	O
,	O
displayed	O
as	O
expected	O
two	O
signals	O
with	O
each	O
probe	O
,	O
confirming	O
the	O
presence	O
of	O
both	O
TP53	O
alleles	O
in	O
these	O
cells	O
(	O
Figure	O
8	O
and	O
Table	O
3	O
)	O
.	O

Conversely	O
,	O
IGR	O
-	O
N	O
-	O
91	O
and	O
SK	O
-	O
N	O
-	O
AS	O
cell	O
lines	O
displayed	O
only	O
one	O
fluorescent	O
signal	O
for	O
each	O
probe	O
,	O
suggesting	O
a	O
whole	O
chromosome	O
17	O
lost	O
,	O
or	O
at	O
least	O
losses	O
of	O
the	O
17p	O
arm	O
and	O
the	O
centromeric	O
region	O
.	O

The	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
cell	O
line	O
has	O
been	O
described	O
as	O
containing	O
only	O
one	O
chromosome	O
17	O
and	O
one	O
TP53	O
signal	O
(	O
10	O
)	O
.	O

In	O
our	O
analysis	O
,	O
only	O
10	O
%	O
of	O
the	O
cells	O
displayed	O
this	O
characteristic	O
,	O
whilst	O
most	O
of	O
the	O
cells	O
had	O
two	O
copies	O
of	O
both	O
(	O
Figure	O
8	O
and	O
Table	O
3	O
)	O
.	O

p53	O
sequencing	O
,	O
however	O
,	O
confirmed	O
the	O
previously	O
described	O
mutation	O
,	O
and	O
the	O
absence	O
of	O
a	O
normal	O
allele	O
,	O
suggesting	O
that	O
the	O
cells	O
used	O
in	O
our	O
study	O
had	O
acquired	O
,	O
during	O
culture	O
,	O
an	O
uniparental	O
disomy	O
for	O
the	O
TP53	O
-	O
mutated	O
chromosome	O
17	O
.	O

Finally	O
,	O
the	O
other	O
two	O
cell	O
lines	O
(	O
LAN	O
-	O
1	O
and	O
IGR	O
-	O
NB8	O
)	O
displayed	O
highly	O
variable	O
genetic	O
heterogeneity	O
from	O
one	O
cell	O
to	O
the	O
next	O
(	O
Table	O
3	O
)	O
.	O

Surprisingly	O
,	O
although	O
p53	O
transcripts	O
are	O
extremely	O
faintly	O
expressed	O
in	O
LAN	O
-	O
1	O
cell	O
line	O
,	O
all	O
cells	O
showed	O
several	O
FISH	O
signals	O
with	O
the	O
167	O
kb	O
BAC	O
probe	O
used	O
here	O
.	O

To	O
understand	O
this	O
apparent	O
contradiction	O
,	O
an	O
array	O
-	O
CGH	O
experiment	O
was	O
performed	O
on	O
an	O
oligo	O
-	O
array	O
Agilent	O
,	O
which	O
indicated	O
a	O
133	O
kb	O
interstitial	O
deletion	O
corresponding	O
to	O
the	O
p53	O
coding	O
region	O
and	O
the	O
97	O
kb	O
upstream	O
region	O
.	O

Accordingly	O
,	O
the	O
fluorescent	O
spots	O
observed	O
in	O
FISH	O
experiments	O
on	O
LAN	O
-	O
1	O
cells	O
should	O
be	O
related	O
to	O
the	O
hybridization	O
of	O
the	O
57	O
kb	O
region	O
downstream	O
of	O
p53	O
gene	O
present	O
in	O
the	O
BAC	O
probe	O
.	O

IGRN	O
-	O
B8	O
cell	O
line	O
displayed	O
a	O
number	O
of	O
signals	O
of	O
both	O
colors	O
ranging	O
from	O
0	O
to	O
4	O
,	O
with	O
87	O
%	O
of	O
cells	O
displaying	O
a	O
loss	O
for	O
one	O
TP53	O
allele	O
.	O

Despite	O
this	O
genomic	O
variability	O
,	O
analysis	O
of	O
the	O
p53	O
protein	O
showed	O
a	O
single	O
shortened	O
form	O
in	O
IGR	O
-	O
N	O
-	O
B8	O
cell	O
line	O
(	O
Figure	O
1	O
)	O
.	O

Consequently	O
,	O
and	O
as	O
suggested	O
for	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
cell	O
line	O
,	O
IGR	O
-	O
N	O
-	O
B8	O
cell	O
line	O
should	O
contain	O
a	O
variable	O
number	O
of	O
copies	O
of	O
chromosome	O
17	O
with	O
mutated	O
p53	O
.	O

DISCUSSION	O

The	O
p53	O
gene	O
,	O
the	O
'	O
genome	O
guardian	O
'	O
,	O
is	O
mutated	O
in	O
over	O
50	O
%	O
of	O
human	B-Species
cancers	O
,	O
with	O
the	O
most	O
common	O
mutations	O
being	O
missense	O
mutations	O
(	O
>	O
2	O
/	O
3	O
of	O
mutations	O
)	O
(	O
26	O
)	O
.	O

In	O
human	B-Species
neuroblastoma	O
tumors	O
,	O
p53	O
mutations	O
are	O
rarely	O
present	O
at	O
the	O
time	O
of	O
diagnosis	O
(	O
5	O
,	O
27	O
)	O
;	O
however	O
,	O
oncogenic	O
p53	O
mutations	O
can	O
be	O
found	O
in	O
advanced	O
neuroblastomas	O
that	O
often	O
relapse	O
following	O
high	O
-	O
dose	O
chemotherapy	O
(	O
10	O
)	O
.	O

In	O
contrast	O
,	O
in	O
breast	O
cancers	O
,	O
it	O
has	O
been	O
reported	O
that	O
p53	O
mutations	O
might	O
improve	O
response	O
to	O
high	O
-	O
dose	O
chemotherapy	O
including	O
therapy	O
with	O
epirubicin	O
and	O
cyclophosphamide	O
(	O
28	O
)	O
.	O

An	O
investigation	O
into	O
the	O
p53	O
genomic	O
status	O
and	O
functions	O
of	O
eight	O
human	B-Species
NB	O
lines	O
revealed	O
that	O
all	O
five	O
of	O
the	O
mutated	O
cell	O
lines	O
had	O
distinct	O
genetic	O
characteristics	O
as	O
is	O
schematically	O
represented	O
in	O
Figure	O
9	O
:	O
SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
with	O
a	O
single	O
missense	O
mutation	O
in	O
the	O
p53	O
gene	O
,	O
encoding	O
a	O
highly	O
stable	O
full	O
-	O
length	O
protein	O
.	O

SK	O
-	O
N	O
-	O
AS	O
and	O
IGR	O
-	O
NB8	O
proteins	O
,	O
although	O
they	O
have	O
intact	O
transactivation	O
and	O
DBDs	O
,	O
were	O
truncated	O
at	O
the	O
C	O
-	O
terminus	O
generating	O
341	O
and	O
326	O
amino	O
acids	O
respectively	O
;	O
they	O
therefore	O
lack	O
the	O
tetramerization	O
domain	O
that	O
is	O
essential	O
for	O
an	O
active	O
conformation	O
.	O

Very	O
recently	O
,	O
Bourdon	O
et	O
al	O
.	O
<EOS>	B-X
Day	B-X
(	B-X
1990	B-X
)	B-X
and	B-X
Day	B-X
,	B-X
Mitchell	B-X
,	B-X
and	B-X
Stecher	B-X
(	B-X
1990	B-X
)	B-X
recently	B-X
reported	B-X
new	B-X
data	B-X
on	B-X
the	B-X
Bourdon	B-X
illusion	B-X
,	B-X
showing	B-X
that	B-X
the	B-X
effect	B-X
occurs	B-X
in	B-X
novel	B-X
variations	B-X
of	B-X
the	B-X
classic	B-X
figure	B-X
--	B-X
for	B-X
example	B-X
,	B-X
with	B-X
orthogonal	B-X
and	B-X
parallel	B-X
test	B-X
edges	B-X
--	B-X
and	B-X
also	B-X
that	B-X
it	B-X
occurs	B-X
in	B-X
the	B-X
haptic	B-X
modality	B-X
.	B-X
Day	B-X
(	B-X
1990	B-X
)	B-X
criticized	B-X
theories	B-X
of	B-X
the	B-X
Bourdon	B-X
effect	B-X
proposed	B-X
by	B-X
Wenderoth	B-X
,	B-X
Criss	B-X
,	B-X
and	B-X
van	B-X
der	B-X
Zwan	B-X
(	B-X
1990	B-X
)	B-X
,	B-X
Wenderoth	B-X
and	B-X
O'Connor	B-X
(	B-X
1987a	B-X
,	B-X
1987b	B-X
)	B-X
,	B-X
and	B-X
Wenderoth	B-X
,	B-X
O'Connor	B-X
,	B-X
and	B-X
Johnson	B-X
(	B-X
1986	B-X
)	B-X
,	B-X
and	B-X
proposed	B-X
his	B-X
own	B-X
``	B-X
perceptual	B-X
compromise	B-X
''	B-X
hypothesis	B-X
.	B-X
It	B-X
is	B-X
argued	B-X
that	B-X
Day	B-X
has	B-X
inaccurately	B-X
portrayed	B-X
the	B-X
Wenderoth	B-X
et	B-X
al	B-X
.	B-X
theory	B-X
,	B-X
and	B-X
that	B-X
his	B-X
own	B-X
hypothesis	B-X
lacks	B-X
predictive	B-X
power	B-X
because	B-X
it	B-X
lacks	B-X
any	B-X
reference	B-X
to	B-X
neural	B-X
mechanisms	B-X
.	B-X
It	B-X
is	B-X
demonstrated	B-X
how	B-X
Day	B-X
's	B-X
novel	B-X
experiments	B-X
provide	B-X
insights	B-X
into	B-X
the	B-X
mechanisms	B-X
of	B-X
the	B-X
Bourdon	B-X
effect	B-X
,	B-X
and	B-X
also	B-X
how	B-X
the	B-X
Wenderoth	B-X
et	B-X
al	B-X
.	B-X
theory	B-X
can	B-X
account	B-X
for	B-X
the	B-X
new	B-X
data	B-X
of	B-X
Day	B-X
(	B-X
1990	B-X
)	B-X
and	B-X
Day	B-X
et	B-X
al	B-X
.	B-X

(	O
22	O
)	O
reported	O
the	O
putative	O
occurrence	O
of	O
beta	O
and	O
gamma	O
isoforms	O
from	O
different	O
tissues	O
due	O
to	O
alternate	O
splicing	O
that	O
indicates	O
the	O
similarity	O
to	O
those	O
of	O
p73	O
and	O
p63	O
as	O
identified	O
previously	O
by	O
Daniel	O
Caput	O
and	O
co	O
-	O
workers	O
(	O
29	O
)	O
.	O

In	O
the	O
p53	O
isoforms	O
scheme	O
proposed	O
by	O
Bourdon	O
et	O
al	O
.	O

(	O
22	O
)	O
,	O
the	O
SK	O
-	O
N	O
-	O
AS	O
cell	O
line	O
that	O
elicits	O
p53i9	O
protein	O
expression	O
is	O
consistent	O
with	O
the	O
p53	O
beta	O
isoform	O
.	O

Genomic	O
analysis	O
reveals	O
that	O
the	O
only	O
occurrence	O
of	O
the	O
p53	O
beta	O
isoform	O
in	O
SK	O
-	O
N	O
-	O
AS	O
results	O
from	O
a	O
deletion	O
spanning	O
the	O
intron	O
9	O
/	O
exon	O
10	O
junction	O
.	O

Similar	O
to	O
the	O
p53	O
beta	O
isoform	O
in	O
SK	O
-	O
N	O
-	O
AS	O
,	O
the	O
p53	O
in	O
IGR	O
-	O
NB8	O
that	O
lacks	O
67	O
amino	O
acids	O
at	O
C	O
-	O
terminus	O
was	O
,	O
alone	O
,	O
unable	O
to	O
induce	O
p21	O
/	O
WAF1	O
promoter	O
activation	O
except	O
with	O
endogenous	O
wt	O
-	O
p53	O
on	O
SH	O
-	O
SY5Y	O
cells	O
where	O
transfection	O
with	O
IGR	O
-	O
NB8	O
significantly	O
augmented	O
the	O
transcriptional	O
activation	O
of	O
the	O
p21	O
/	O
Waf	O
-	O
1	O
promoter	O
(	O
Figure	O
5A	O
)	O
.	O

Studies	O
by	O
other	O
authors	O
have	O
reported	O
the	O
interaction	O
between	O
the	O
C	O
-	O
terminal	O
domain	O
and	O
another	O
region	O
that	O
impedes	O
the	O
active	O
conformation	O
of	O
p53	O
,	O
suggesting	O
an	O
allosteric	O
model	O
for	O
p53	O
activity	O
regulation	O
(	O
30	O
)	O
.	O

Such	O
events	O
have	O
been	O
demonstrated	O
for	O
the	O
342	O
-	O
stop	O
mutant	O
,	O
generated	O
by	O
mutagenesis	O
,	O
which	O
can	O
modulate	O
transactivation	O
,	O
growth	O
and	O
apoptosis	O
(	O
31	O
)	O
.	O

Moreover	O
,	O
Harms	O
and	O
Chen	O
(	O
32	O
)	O
reported	O
that	O
the	O
C	O
-	O
terminal	O
basic	O
domain	O
inhibits	O
induction	O
of	O
the	O
proapoptotic	O
target	O
gene	O
insulin	O
-	O
like	O
growth	O
factor	O
binding	O
protein	O
3	O
,	O
suggesting	O
that	O
IGR	O
-	O
NB8	O
might	O
induce	O
this	O
gene	O
.	O

IGR	O
-	O
N	O
-	O
91	O
had	O
an	O
abnormally	O
high	O
molecular	O
weight	O
protein	O
due	O
to	O
the	O
duplication	O
of	O
wild	O
-	O
type	O
exons	O
7	O
-	O
8	O
-	O
9	O
,	O
thus	O
affecting	O
the	O
DBD	O
and	O
OD	O
;	O
and	O
LAN	O
-	O
1	O
,	O
with	O
a	O
mutation	O
at	O
codon	O
182	O
(	O
Cys	O
-->	O
stop	O
)	O
concurred	O
with	O
an	O
earlier	O
report	O
showing	O
extremely	O
low	O
levels	O
of	O
mRNA	O
and	O
undetectable	O
protein	O
expression	O
(	O
9	O
)	O
.	O

Notably	O
,	O
all	O
the	O
p53	O
variants	O
,	O
including	O
SK	O
-	O
N	O
-	O
AS	O
(	O
beta	O
isoform	O
)	O
and	O
IGR	O
-	O
NB8	O
(	O
C	O
-	O
terminal	O
truncated	O
p53	O
)	O
,	O
elicited	O
a	O
total	O
lack	O
of	O
p21	O
promoter	O
activation	O
.	O

In	O
particular	O
,	O
the	O
p53	O
beta	O
isoform	O
was	O
unable	O
to	O
induce	O
endogenous	O
p21	O
expression	O
in	O
SK	O
-	O
N	O
-	O
AS	O
(	O
Figure	O
6	O
)	O
,	O
concurring	O
with	O
data	O
obtained	O
from	O
in	O
vitro	O
transfection	O
experiments	O
in	O
H1299	O
cells	O
by	O
Bourdon	O
et	O
al	O
.	O

(	O
22	O
)	O
.	O

For	O
the	O
IGR	O
-	O
N	O
-	O
91	O
cells	O
,	O
although	O
p53	O
was	O
mutated	O
and	O
unable	O
to	O
transactivate	O
the	O
p21	O
/	O
WAF1	O
promoter	O
,	O
the	O
FASAY	O
global	O
test	O
was	O
not	O
conclusive	O
since	O
~	O
80	O
%	O
of	O
colonies	O
were	O
white	O
and	O
nearly	O
20	O
%	O
(	O
see	O
also	O
Table	O
2	O
)	O
,	O
though	O
not	O
enough	O
,	O
were	O
red	O
.	O

Moreover	O
,	O
in	O
this	O
particular	O
line	O
,	O
standard	O
sequencing	O
on	O
cDNA	O
using	O
primers	O
located	O
within	O
each	O
exon	O
as	O
used	O
for	O
routine	O
tumor	O
analysis	O
was	O
unable	O
to	O
detect	O
any	O
anomalies	O
in	O
p53	O
genetic	O
status	O
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
results	O
enlighten	O
the	O
limit	O
of	O
the	O
conventional	O
tests	O
to	O
detect	O
a	O
transcription	O
inactivation	O
of	O
p53	O
brought	O
by	O
duplication	O
within	O
the	O
DBD	O
.	O

Analysis	O
of	O
p53	O
genomic	O
status	O
was	O
explored	O
by	O
FISH	O
experiments	O
,	O
in	O
search	O
for	O
a	O
potential	O
biallelic	O
inactivation	O
of	O
p53	O
,	O
with	O
a	O
mutation	O
of	O
one	O
allele	O
and	O
a	O
deletion	O
of	O
the	O
second	O
one	O
.	O

This	O
situation	O
was	O
indeed	O
clearly	O
observed	O
in	O
IGR	O
-	O
N	O
-	O
91	O
and	O
SK	O
-	O
N	O
-	O
AS	O
cell	O
lines	O
,	O
with	O
an	O
unambiguous	O
loss	O
of	O
one	O
chromosome	O
17p	O
arm	O
in	O
all	O
cells	O
of	O
both	O
.	O

SK	O
-	O
N	O
-	O
BE	O
(	O
2	O
)	O
,	O
LAN	O
-	O
1	O
and	O
IGR	O
-	O
NB	O
-	O
8	O
cell	O
lines	O
showed	O
a	O
more	O
complex	O
genomic	O
situation	O
which	O
should	O
be	O
relevant	O
of	O
variable	O
copy	O
numbers	O
of	O
chromosome	O
17	O
bearing	O
in	O
most	O
cases	O
(	O
LAN	O
-	O
1	O
)	O
or	O
in	O
all	O
cases	O
[	O
SKN	O
-	O
BE	O
(	O
2	O
)	O
,	O
IGR	O
-	O
NB8	O
]	O
the	O
mutated	O
characteristic	O
p53	O
allele	O
.	O

Our	O
data	O
therefore	O
clearly	O
demonstrate	O
that	O
each	O
technique	O
has	O
a	O
role	O
and	O
a	O
combination	O
of	O
techniques	O
is	O
required	O
in	O
order	O
to	O
correctly	O
define	O
the	O
p53	O
phenotype	O
and	O
genotype	O
in	O
tumor	O
and	O
particularly	O
in	O
NB	O
cells	O
.	O

Our	O
data	O
enlighten	O
a	O
high	O
frequency	O
of	O
the	O
C	O
-	O
terminal	O
abnormalities	O
(	O
3	O
/	O
5	O
mutated	O
)	O
in	O
NB	O
cell	O
lines	O
.	O

For	O
SK	O
-	O
N	O
-	O
AS	O
and	O
IGR	O
-	O
NB8	O
,	O
a	O
part	O
of	O
the	O
oligomerization	O
domain	O
was	O
lost	O
and	O
IGR	O
-	O
N	O
-	O
91	O
gained	O
an	O
extra	O
oligomerization	O
domain	O
.	O

According	O
to	O
FASAY	O
assay	O
the	O
p53	O
expressed	O
in	O
IGR	O
-	O
N	O
-	O
91	O
still	O
specifically	O
bind	O
DNA	O
but	O
not	O
the	O
p53	O
expressed	O
in	O
SK	O
-	O
N	O
-	O
AS	O
and	O
IGR	O
-	O
NB8	O
in	O
agreement	O
with	O
previous	O
published	O
data	O
obtained	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
33	O
)	O
.	O

With	O
regards	O
to	O
biological	O
relevance	O
,	O
different	O
mutants	O
within	O
the	O
DBD	O
vary	O
in	O
their	O
oncogenicity	O
.	O

They	O
are	O
classified	O
into	O
two	O
types	O
depending	O
of	O
the	O
location	O
of	O
the	O
mutation	O
,	O
mutations	O
of	O
class	O
I	O
occur	O
in	O
the	O
DNA	O
contact	O
areas	O
,	O
while	O
class	O
II	O
mutations	O
occur	O
in	O
areas	O
important	O
for	O
the	O
conformational	O
stability	O
of	O
p53	O
protein	O
(	O
30	O
)	O
.	O

Although	O
both	O
class	O
I	O
and	O
class	O
II	O
mutants	O
have	O
loss	O
its	O
ability	O
to	O
specifically	O
bind	O
DNA	O
,	O
class	O
II	O
mutations	O
have	O
been	O
shown	O
to	O
be	O
more	O
oncogenic	O
than	O
class	O
I	O
.	O

However	O
,	O
to	O
our	O
knowledge	O
the	O
oncogenicity	O
of	O
mutant	O
affecting	O
the	O
C	O
-	O
terminal	O
domain	O
have	O
not	O
been	O
studied	O
.	O

The	O
biological	O
role	O
of	O
the	O
C	O
-	O
terminal	O
mutants	O
needs	O
now	O
to	O
be	O
thoroughly	O
investigated	O
in	O
NB	O
tumors	O
.	O

MUC1	O
alters	O
oncogenic	O
events	O
and	O
transcription	O
in	O
human	B-Species
breast	O
cancer	O
cells	O
<EOS>	B-X
MUC1	B-X
is	B-X
an	B-X
oncoprotein	B-X
whose	B-X
overexpression	B-X
correlates	B-X
with	B-X
aggressiveness	B-X
of	B-X
tumors	B-X
and	B-X
poor	B-X
survival	B-X
of	B-X
cancer	B-X
patients	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
oncogenic	B-X
effects	B-X
of	B-X
MUC1	B-X
are	B-X
believed	B-X
to	B-X
occur	B-X
through	B-X
interaction	B-X
of	B-X
its	B-X
cytoplasmic	B-X
tail	B-X
with	B-X
signaling	B-X
molecules	B-X
.	B-X
As	B-X
expected	B-X
for	B-X
a	B-X
protein	B-X
with	B-X
oncogenic	B-X
functions	B-X
,	B-X
MUC1	B-X
is	B-X
linked	B-X
to	B-X
regulation	B-X
of	B-X
proliferation	B-X
,	B-X
apoptosis	B-X
,	B-X
invasion	B-X
,	B-X
and	B-X
transcription	B-X
.	B-X
The	B-X
transmembrane	B-X
mucin	B-X
MUC1	B-X
is	B-X
overexpressed	B-X
in	B-X
most	B-X
ductal	B-X
carcinomas	B-X
,	B-X
and	B-X
its	B-X
overexpression	B-X
is	B-X
frequently	B-X
associated	B-X
with	B-X
metastatic	B-X
progression	B-X
.	B-X
MUC1	B-X
can	B-X
drive	B-X
tumor	B-X
initiation	B-X
and	B-X
progression	B-X
via	B-X
interactions	B-X
with	B-X
many	B-X
oncogenic	B-X
partners	B-X
,	B-X
including	B-X
Î²-catenin	B-X
,	B-X
the	B-X
EGF	B-X
receptor	B-X
(	B-X
EGFR	B-X
)	B-X
and	B-X
Src	B-X
.	B-X
The	B-X
decoy	B-X
peptide	B-X
protein	B-X
transduction	B-X
domain	B-X
MUC1	B-X
inhibitory	B-X
peptide	B-X
(	B-X
PMIP	B-X
)	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
inhibit	B-X
the	B-X
tumor	B-X
promoting	B-X
activities	B-X
of	B-X
MUC1	B-X
in	B-X
breast	B-X
and	B-X
lung	B-X
cancer	B-X
,	B-X
including	B-X
cell	B-X
growth	B-X
and	B-X
invasion	B-X
,	B-X
and	B-X
its	B-X
usage	B-X
suppresses	B-X
metastatic	B-X
progression	B-X
in	B-X
mouse	B-X
models	B-X
of	B-X
breast	B-X
cancer	B-X
.	B-X
To	B-X
further	B-X
characterize	B-X
the	B-X
reduced	B-X
metastasis	B-X
observed	B-X
upon	B-X
PMIP	B-X
treatment	B-X
,	B-X
we	B-X
conducted	B-X
motility	B-X
assays	B-X
and	B-X
observed	B-X
that	B-X
PMIP	B-X
inhibits	B-X
cell	B-X
motility	B-X
of	B-X
breast	B-X
cancer	B-X
cells	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
PMIP	B-X
inhibits	B-X
motility	B-X
,	B-X
we	B-X
evaluated	B-X
changes	B-X
in	B-X
global	B-X
gene	B-X
transcription	B-X
upon	B-X
PMIP	B-X
treatment	B-X
,	B-X
and	B-X
identified	B-X
a	B-X
number	B-X
of	B-X
genes	B-X
with	B-X
altered	B-X
expression	B-X
in	B-X
response	B-X
to	B-X
PMIP	B-X
.	B-X
To	B-X
further	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
c-Met	B-X
in	B-X
MUC1-dependent	B-X
metastatic	B-X
events	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
effects	B-X
of	B-X
MUC1	B-X
expression	B-X
and	B-X
EGFR	B-X
activation	B-X
on	B-X
breast	B-X
cancer	B-X
cell	B-X
scattering	B-X
,	B-X
branching	B-X
,	B-X
and	B-X
migration	B-X
.	B-X
We	B-X
found	B-X
that	B-X
MUC1	B-X
strongly	B-X
promoted	B-X
all	B-X
of	B-X
these	B-X
events	B-X
and	B-X
this	B-X
effect	B-X
was	B-X
further	B-X
amplified	B-X
by	B-X
EGF	B-X
treatment	B-X
.	B-X
Importantly	B-X
,	B-X
the	B-X
effect	B-X
of	B-X
MUC1	B-X
and	B-X
EGF	B-X
on	B-X
these	B-X
phenotypes	B-X
was	B-X
dependent	B-X
upon	B-X
c-Met	B-X
activity	B-X
.	B-X

Abstract	O
<EOS>	B-X
Abstract	B-X
writing	B-X
.	B-X
The	B-X
informative	B-X
abstract	B-X
.	B-X
Crafting	B-X
a	B-X
compelling	B-X
abstract	B-X
.	B-X
Why	B-X
the	B-X
structured	B-X
abstract	B-X
?	B-X

Introduction	O

MUC1	O
is	O
an	O
oncoprotein	O
whose	O
overexpression	O
correlates	O
with	O
aggressiveness	O
of	O
tumors	O
and	O
poor	O
survival	O
of	O
cancer	O
patients	B-Species
.	O
<EOS>	B-X
MUC1	B-X
is	B-X
an	B-X
oncoprotein	B-X
whose	B-X
overexpression	B-X
correlates	B-X
with	B-X
aggressiveness	B-X
of	B-X
tumors	B-X
and	B-X
poor	B-X
survival	B-X
of	B-X
cancer	B-X
patients	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
oncogenic	B-X
effects	B-X
of	B-X
MUC1	B-X
are	B-X
believed	B-X
to	B-X
occur	B-X
through	B-X
interaction	B-X
of	B-X
its	B-X
cytoplasmic	B-X
tail	B-X
with	B-X
signaling	B-X
molecules	B-X
.	B-X
As	B-X
expected	B-X
for	B-X
a	B-X
protein	B-X
with	B-X
oncogenic	B-X
functions	B-X
,	B-X
MUC1	B-X
is	B-X
linked	B-X
to	B-X
regulation	B-X
of	B-X
proliferation	B-X
,	B-X
apoptosis	B-X
,	B-X
invasion	B-X
,	B-X
and	B-X
transcription	B-X
.	B-X

Many	O
of	O
the	O
oncogenic	O
effects	O
of	O
MUC1	O
are	O
believed	O
to	O
occur	O
through	O
interaction	O
of	O
its	O
cytoplasmic	O
tail	O
with	O
signaling	O
molecules	O
.	O
<EOS>	B-X
MUC1	B-X
is	B-X
an	B-X
oncoprotein	B-X
whose	B-X
overexpression	B-X
correlates	B-X
with	B-X
aggressiveness	B-X
of	B-X
tumors	B-X
and	B-X
poor	B-X
survival	B-X
of	B-X
cancer	B-X
patients	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
oncogenic	B-X
effects	B-X
of	B-X
MUC1	B-X
are	B-X
believed	B-X
to	B-X
occur	B-X
through	B-X
interaction	B-X
of	B-X
its	B-X
cytoplasmic	B-X
tail	B-X
with	B-X
signaling	B-X
molecules	B-X
.	B-X
As	B-X
expected	B-X
for	B-X
a	B-X
protein	B-X
with	B-X
oncogenic	B-X
functions	B-X
,	B-X
MUC1	B-X
is	B-X
linked	B-X
to	B-X
regulation	B-X
of	B-X
proliferation	B-X
,	B-X
apoptosis	B-X
,	B-X
invasion	B-X
,	B-X
and	B-X
transcription	B-X
.	B-X

As	O
expected	O
for	O
a	O
protein	O
with	O
oncogenic	O
functions	O
,	O
MUC1	O
is	O
linked	O
to	O
regulation	O
of	O
proliferation	O
,	O
apoptosis	O
,	O
invasion	O
,	O
and	O
transcription	O
.	O
<EOS>	B-X
MUC1	B-X
is	B-X
an	B-X
oncoprotein	B-X
whose	B-X
overexpression	B-X
correlates	B-X
with	B-X
aggressiveness	B-X
of	B-X
tumors	B-X
and	B-X
poor	B-X
survival	B-X
of	B-X
cancer	B-X
patients	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
oncogenic	B-X
effects	B-X
of	B-X
MUC1	B-X
are	B-X
believed	B-X
to	B-X
occur	B-X
through	B-X
interaction	B-X
of	B-X
its	B-X
cytoplasmic	B-X
tail	B-X
with	B-X
signaling	B-X
molecules	B-X
.	B-X
As	B-X
expected	B-X
for	B-X
a	B-X
protein	B-X
with	B-X
oncogenic	B-X
functions	B-X
,	B-X
MUC1	B-X
is	B-X
linked	B-X
to	B-X
regulation	B-X
of	B-X
proliferation	B-X
,	B-X
apoptosis	B-X
,	B-X
invasion	B-X
,	B-X
and	B-X
transcription	B-X
.	B-X

Methods	O
<EOS>	B-X
Methods	B-X
to	B-X
calculate	B-X
the	B-X
sample	B-X
size	B-X
are	B-X
explained	B-X
in	B-X
statistical	B-X
textbooks	B-X
,	B-X
but	B-X
because	B-X
there	B-X
are	B-X
many	B-X
different	B-X
formulas	B-X
available	B-X
,	B-X
it	B-X
can	B-X
be	B-X
difficult	B-X
for	B-X
investigators	B-X
to	B-X
decide	B-X
which	B-X
method	B-X
to	B-X
use	B-X
.	B-X

To	O
clarify	O
the	O
role	O
of	O
MUC1	O
in	O
cancer	O
,	O
we	O
transfected	O
two	O
breast	O
cancer	O
cell	O
lines	O
(	O
MDA	O
-	O
MB	O
-	O
468	O
and	O
BT	O
-	O
20	O
)	O
with	O
small	O
interfering	O
(	O
si	O
)	O
RNA	O
directed	O
against	O
MUC1	O
and	O
analyzed	O
transcriptional	O
responses	O
and	O
oncogenic	O
events	O
(	O
proliferation	O
,	O
apoptosis	O
and	O
invasion	O
)	O
.	O
<EOS>	B-X
MUC1	B-X
is	B-X
an	B-X
oncoprotein	B-X
whose	B-X
overexpression	B-X
correlates	B-X
with	B-X
aggressiveness	B-X
of	B-X
tumors	B-X
and	B-X
poor	B-X
survival	B-X
of	B-X
cancer	B-X
patients	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
oncogenic	B-X
effects	B-X
of	B-X
MUC1	B-X
are	B-X
believed	B-X
to	B-X
occur	B-X
through	B-X
interaction	B-X
of	B-X
its	B-X
cytoplasmic	B-X
tail	B-X
with	B-X
signaling	B-X
molecules	B-X
.	B-X
As	B-X
expected	B-X
for	B-X
a	B-X
protein	B-X
with	B-X
oncogenic	B-X
functions	B-X
,	B-X
MUC1	B-X
is	B-X
linked	B-X
to	B-X
regulation	B-X
of	B-X
proliferation	B-X
,	B-X
apoptosis	B-X
,	B-X
invasion	B-X
,	B-X
and	B-X
transcription	B-X
.	B-X

Results	O

Transcription	O
of	O
several	O
genes	O
was	O
altered	O
after	O
transfection	O
of	O
MUC1	O
siRNA	O
,	O
including	O
decreased	O
MAP2K1	O
(	O
MEK1	O
)	O
,	O
JUN	O
,	O
PDGFA	O
,	O
CDC25A	O
,	O
VEGF	O
and	O
ITGAV	O
(	O
integrin	O
alpha	O
v	O
)	O
,	O
and	O
increased	O
TNF	O
,	O
RAF1	O
,	O
and	O
MMP2	O
.	O
<EOS>	B-X
MUC1	B-X
is	B-X
an	B-X
oncoprotein	B-X
whose	B-X
overexpression	B-X
correlates	B-X
with	B-X
aggressiveness	B-X
of	B-X
tumors	B-X
and	B-X
poor	B-X
survival	B-X
of	B-X
cancer	B-X
patients	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
oncogenic	B-X
effects	B-X
of	B-X
MUC1	B-X
are	B-X
believed	B-X
to	B-X
occur	B-X
through	B-X
interaction	B-X
of	B-X
its	B-X
cytoplasmic	B-X
tail	B-X
with	B-X
signaling	B-X
molecules	B-X
.	B-X
As	B-X
expected	B-X
for	B-X
a	B-X
protein	B-X
with	B-X
oncogenic	B-X
functions	B-X
,	B-X
MUC1	B-X
is	B-X
linked	B-X
to	B-X
regulation	B-X
of	B-X
proliferation	B-X
,	B-X
apoptosis	B-X
,	B-X
invasion	B-X
,	B-X
and	B-X
transcription	B-X
.	B-X

Additional	O
changes	O
were	O
seen	O
at	O
the	O
protein	O
level	O
,	O
such	O
as	O
increased	O
expression	O
of	O
c	O
-	O
Myc	O
,	O
heightened	O
phosphorylation	O
of	O
AKT	O
,	O
and	O
decreased	O
activation	O
of	O
MEK1	O
/	O
2	O
and	O
ERK1	O
/	O
2	O
.	O
<EOS>	B-X
MUC1	B-X
is	B-X
an	B-X
oncoprotein	B-X
whose	B-X
overexpression	B-X
correlates	B-X
with	B-X
aggressiveness	B-X
of	B-X
tumors	B-X
and	B-X
poor	B-X
survival	B-X
of	B-X
cancer	B-X
patients	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
oncogenic	B-X
effects	B-X
of	B-X
MUC1	B-X
are	B-X
believed	B-X
to	B-X
occur	B-X
through	B-X
interaction	B-X
of	B-X
its	B-X
cytoplasmic	B-X
tail	B-X
with	B-X
signaling	B-X
molecules	B-X
.	B-X
As	B-X
expected	B-X
for	B-X
a	B-X
protein	B-X
with	B-X
oncogenic	B-X
functions	B-X
,	B-X
MUC1	B-X
is	B-X
linked	B-X
to	B-X
regulation	B-X
of	B-X
proliferation	B-X
,	B-X
apoptosis	B-X
,	B-X
invasion	B-X
,	B-X
and	B-X
transcription	B-X
.	B-X

These	O
were	O
correlated	O
with	O
cellular	O
events	O
,	O
as	O
MUC1	O
siRNA	O
in	O
the	O
MDA	O
-	O
MB	O
-	O
468	O
line	O
decreased	O
proliferation	O
and	O
invasion	O
,	O
and	O
increased	O
stress	O
-	O
induced	O
apoptosis	O
.	O
<EOS>	B-X
MUC1	B-X
is	B-X
an	B-X
oncoprotein	B-X
whose	B-X
overexpression	B-X
correlates	B-X
with	B-X
aggressiveness	B-X
of	B-X
tumors	B-X
and	B-X
poor	B-X
survival	B-X
of	B-X
cancer	B-X
patients	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
oncogenic	B-X
effects	B-X
of	B-X
MUC1	B-X
are	B-X
believed	B-X
to	B-X
occur	B-X
through	B-X
interaction	B-X
of	B-X
its	B-X
cytoplasmic	B-X
tail	B-X
with	B-X
signaling	B-X
molecules	B-X
.	B-X
As	B-X
expected	B-X
for	B-X
a	B-X
protein	B-X
with	B-X
oncogenic	B-X
functions	B-X
,	B-X
MUC1	B-X
is	B-X
linked	B-X
to	B-X
regulation	B-X
of	B-X
proliferation	B-X
,	B-X
apoptosis	B-X
,	B-X
invasion	B-X
,	B-X
and	B-X
transcription	B-X
.	B-X

Intriguingly	O
,	O
BT	O
-	O
20	O
cells	O
displayed	O
similar	O
levels	O
of	O
apoptosis	O
regardless	O
of	O
siRNA	O
,	O
and	O
actually	O
increased	O
proliferation	O
after	O
MUC1	O
siRNA	O
.	O
<EOS>	B-X
MUC1	B-X
is	B-X
an	B-X
oncoprotein	B-X
whose	B-X
overexpression	B-X
correlates	B-X
with	B-X
aggressiveness	B-X
of	B-X
tumors	B-X
and	B-X
poor	B-X
survival	B-X
of	B-X
cancer	B-X
patients	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
oncogenic	B-X
effects	B-X
of	B-X
MUC1	B-X
are	B-X
believed	B-X
to	B-X
occur	B-X
through	B-X
interaction	B-X
of	B-X
its	B-X
cytoplasmic	B-X
tail	B-X
with	B-X
signaling	B-X
molecules	B-X
.	B-X
As	B-X
expected	B-X
for	B-X
a	B-X
protein	B-X
with	B-X
oncogenic	B-X
functions	B-X
,	B-X
MUC1	B-X
is	B-X
linked	B-X
to	B-X
regulation	B-X
of	B-X
proliferation	B-X
,	B-X
apoptosis	B-X
,	B-X
invasion	B-X
,	B-X
and	B-X
transcription	B-X
.	B-X

Conclusion	O
<EOS>	B-X
Conclusion	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X

These	O
results	O
further	O
the	O
growing	O
knowledge	O
of	O
the	O
role	O
of	O
MUC1	O
in	O
transcription	O
,	O
and	O
suggest	O
that	O
the	O
regulation	O
of	O
MUC1	O
in	O
breast	O
cancer	O
may	O
be	O
more	O
complex	O
than	O
previously	O
appreciated	O
.	O
<EOS>	B-X
MUC1	B-X
is	B-X
an	B-X
oncoprotein	B-X
whose	B-X
overexpression	B-X
correlates	B-X
with	B-X
aggressiveness	B-X
of	B-X
tumors	B-X
and	B-X
poor	B-X
survival	B-X
of	B-X
cancer	B-X
patients	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
oncogenic	B-X
effects	B-X
of	B-X
MUC1	B-X
are	B-X
believed	B-X
to	B-X
occur	B-X
through	B-X
interaction	B-X
of	B-X
its	B-X
cytoplasmic	B-X
tail	B-X
with	B-X
signaling	B-X
molecules	B-X
.	B-X
As	B-X
expected	B-X
for	B-X
a	B-X
protein	B-X
with	B-X
oncogenic	B-X
functions	B-X
,	B-X
MUC1	B-X
is	B-X
linked	B-X
to	B-X
regulation	B-X
of	B-X
proliferation	B-X
,	B-X
apoptosis	B-X
,	B-X
invasion	B-X
,	B-X
and	B-X
transcription	B-X
.	B-X

The	O
differences	O
between	O
these	O
two	O
cell	O
lines	O
emphasize	O
the	O
importance	O
of	O
understanding	O
the	O
context	O
of	O
cell	O
-	O
specific	O
signaling	O
events	O
when	O
analyzing	O
the	O
oncogenic	O
functions	O
of	O
MUC1	O
,	O
and	O
caution	O
against	O
generalizing	O
the	O
results	O
of	O
individual	O
cell	O
lines	O
without	O
adequate	O
confirmation	O
in	O
intact	O
biological	O
systems	O
.	O
<EOS>	B-X
MUC1	B-X
is	B-X
an	B-X
oncoprotein	B-X
whose	B-X
overexpression	B-X
correlates	B-X
with	B-X
aggressiveness	B-X
of	B-X
tumors	B-X
and	B-X
poor	B-X
survival	B-X
of	B-X
cancer	B-X
patients	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
oncogenic	B-X
effects	B-X
of	B-X
MUC1	B-X
are	B-X
believed	B-X
to	B-X
occur	B-X
through	B-X
interaction	B-X
of	B-X
its	B-X
cytoplasmic	B-X
tail	B-X
with	B-X
signaling	B-X
molecules	B-X
.	B-X
As	B-X
expected	B-X
for	B-X
a	B-X
protein	B-X
with	B-X
oncogenic	B-X
functions	B-X
,	B-X
MUC1	B-X
is	B-X
linked	B-X
to	B-X
regulation	B-X
of	B-X
proliferation	B-X
,	B-X
apoptosis	B-X
,	B-X
invasion	B-X
,	B-X
and	B-X
transcription	B-X
.	B-X

Introduction	O

MUC1	O
is	O
the	O
founding	O
member	O
of	O
the	O
mucin	O
family	O
:	O
proteins	O
characterized	O
by	O
heavy	O
O	O
-	O
glycosylation	O
centering	O
around	O
a	O
variable	O
number	O
of	O
tandem	O
repeats	O
that	O
are	O
rich	O
in	O
serine	O
and	O
threonine	O
residues	O
[	O
1	O
,	O
2	O
]	O
.	O

MUC1	O
is	O
a	O
transmembrane	O
heterodimer	O
with	O
one	O
subunit	O
solely	O
extracellular	O
(	O
MUC1	O
-	O
EX	O
)	O
,	O
and	O
the	O
other	O
subunit	O
composed	O
of	O
a	O
short	O
extracellular	O
stem	O
,	O
a	O
single	O
transmembrane	O
domain	O
,	O
and	O
the	O
cytoplasmic	O
tail	O
(	O
together	O
called	O
the	O
MUC1	O
-	O
CT	O
)	O
.	O

MUC1	O
possesses	O
both	O
pro	O
-	O
and	O
anti	O
-	O
adhesive	O
capacities	O
,	O
as	O
the	O
MUC1	O
-	O
EX	O
provides	O
binding	O
sites	O
for	O
a	O
variety	O
of	O
adhesion	O
proteins	O
,	O
while	O
its	O
large	O
size	O
and	O
extended	O
structure	O
prevents	O
cell	O
-	O
cell	O
contact	O
[	O
3	O
-	O
5	O
]	O
.	O

Initially	O
described	O
as	O
a	O
tumor	O
antigen	O
overexpressed	O
in	O
>	O
90	O
%	O
of	O
breast	O
cancers	O
,	O
MUC1	O
is	O
now	O
known	O
to	O
be	O
an	O
oncogene	O
with	O
roles	O
in	O
both	O
tumor	O
formation	O
and	O
progression	O
[	O
1	O
,	O
6	O
]	O
.	O

Mouse	B-Species
studies	O
have	O
been	O
integral	O
to	O
the	O
current	O
understanding	O
of	O
MUC1	O
in	O
cancer	O
.	O

Muc1	O
knockout	O
mice	B-Species
(	O
Muc1	O
-	O
/	O
-	O
;	O
MUC1	O
is	O
human	B-Species
;	O
Muc1	O
is	O
mouse	B-Species
)	O
show	O
a	O
reduction	O
in	O
tumorigenic	O
phenotype	O
when	O
crossed	O
onto	O
mice	B-Species
overexpressing	O
the	O
Wnt	O
-	O
1	O
[	O
7	O
]	O
or	O
polyomavirus	O
middle	O
T	O
antigen	O
[	O
8	O
]	O
oncogenes	O
in	O
the	O
mammary	O
gland	O
.	O
<EOS>	B-X
Mucin	B-X
1	B-X
(	B-X
MUC1	B-X
)	B-X
is	B-X
a	B-X
tumor	B-X
antigen	B-X
that	B-X
is	B-X
aberrantly	B-X
overexpressed	B-X
in	B-X
various	B-X
cancers	B-X
,	B-X
including	B-X
lung	B-X
cancer	B-X
.	B-X
Our	B-X
previous	B-X
in	B-X
vitro	B-X
studies	B-X
showed	B-X
that	B-X
MUC1	B-X
facilitates	B-X
carcinogen-induced	B-X
EGFR	B-X
activation	B-X
and	B-X
transformation	B-X
in	B-X
human	B-X
lung	B-X
bronchial	B-X
epithelial	B-X
cells	B-X
(	B-X
HBECs	B-X
)	B-X
,	B-X
which	B-X
along	B-X
with	B-X
other	B-X
reports	B-X
suggests	B-X
an	B-X
oncogenic	B-X
property	B-X
for	B-X
MUC1	B-X
in	B-X
lung	B-X
cancer	B-X
.	B-X
However	B-X
,	B-X
direct	B-X
evidence	B-X
for	B-X
the	B-X
role	B-X
of	B-X
MUC1	B-X
in	B-X
lung	B-X
carcinogenesis	B-X
is	B-X
lacking	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
used	B-X
the	B-X
4-	B-X
(	B-X
methylnitrosamino	B-X
)	B-X
-1-	B-X
(	B-X
3-pyridyl	B-X
)	B-X
-1-butanone	B-X
(	B-X
NNK	B-X
)	B-X
-induced	B-X
A/J	B-X
mouse	B-X
lung	B-X
tumor	B-X
model	B-X
to	B-X
investigate	B-X
the	B-X
effect	B-X
of	B-X
whole-body	B-X
Muc1	B-X
knockout	B-X
(	B-X
KO	B-X
)	B-X
on	B-X
carcinogen-induced	B-X
lung	B-X
carcinogenesis	B-X
.	B-X
Surprisingly	B-X
,	B-X
lung	B-X
tumor	B-X
multiplicity	B-X
was	B-X
significantly	B-X
increased	B-X
in	B-X
Muc1	B-X
KO	B-X
compared	B-X
to	B-X
wild-type	B-X
(	B-X
WT	B-X
)	B-X
mice	B-X
.	B-X
The	B-X
EGFR/AKT	B-X
pathway	B-X
was	B-X
unexpectedly	B-X
activated	B-X
,	B-X
and	B-X
expression	B-X
of	B-X
the	B-X
EGFR	B-X
ligand	B-X
epiregulin	B-X
(	B-X
EREG	B-X
)	B-X
was	B-X
increased	B-X
in	B-X
the	B-X
lung	B-X
tissues	B-X
of	B-X
the	B-X
Muc1	B-X
KO	B-X
compared	B-X
to	B-X
the	B-X
WT	B-X
mice	B-X
.	B-X
EREG	B-X
stimulated	B-X
proliferation	B-X
and	B-X
protected	B-X
against	B-X
cigarette	B-X
smoke	B-X
extract	B-X
(	B-X
CSE	B-X
)	B-X
-induced	B-X
cytotoxicity	B-X
in	B-X
in	B-X
vitro	B-X
cultured	B-X
human	B-X
bronchial	B-X
epithelial	B-X
cells	B-X
.	B-X
Additionally	B-X
,	B-X
we	B-X
determined	B-X
that	B-X
MUC1	B-X
was	B-X
expressed	B-X
in	B-X
human	B-X
fibroblast	B-X
cell	B-X
lines	B-X
where	B-X
it	B-X
suppressed	B-X
CSE-induced	B-X
EREG	B-X
production	B-X
.	B-X
Further	B-X
,	B-X
suppression	B-X
of	B-X
MUC1	B-X
cellular	B-X
activity	B-X
with	B-X
GO-201	B-X
enhanced	B-X
EREG	B-X
production	B-X
in	B-X
lung	B-X
cancer	B-X
cells	B-X
,	B-X
which	B-X
in	B-X
turn	B-X
protected	B-X
cancer	B-X
cells	B-X
from	B-X
GO-201-induced	B-X
cell	B-X
death	B-X
.	B-X
Moreover	B-X
,	B-X
an	B-X
inverse	B-X
association	B-X
between	B-X
MUC1	B-X
and	B-X
EREG	B-X
was	B-X
detected	B-X
in	B-X
human	B-X
lung	B-X
cancer	B-X
,	B-X
and	B-X
EREG	B-X
expression	B-X
was	B-X
inversely	B-X
associated	B-X
with	B-X
patient	B-X
survival	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
support	B-X
a	B-X
promiscuous	B-X
role	B-X
of	B-X
MUC1	B-X
in	B-X
lung	B-X
cancer	B-X
development	B-X
that	B-X
may	B-X
be	B-X
related	B-X
to	B-X
cell-type	B-X
specific	B-X
functions	B-X
of	B-X
MUC1	B-X
in	B-X
the	B-X
tumor	B-X
microenvironment	B-X
,	B-X
and	B-X
MUC1	B-X
deficiency	B-X
in	B-X
fibroblasts	B-X
and	B-X
malignant	B-X
cells	B-X
results	B-X
in	B-X
increased	B-X
EREG	B-X
production	B-X
that	B-X
activates	B-X
the	B-X
EGFR	B-X
pathway	B-X
for	B-X
lung	B-X
carcinogenesis	B-X
.	B-X

In	O
contrast	O
,	O
MUC1	O
overexpression	O
in	O
the	O
mammary	O
gland	O
drives	O
tumor	O
formation	O
[	O
9	O
]	O
,	O
indicating	O
that	O
MUC1	O
is	O
a	O
true	O
oncogene	O
.	O

Many	O
of	O
the	O
oncogenic	O
effects	O
of	O
MUC1	O
stem	O
from	O
its	O
cytoplasmic	O
tail	O
,	O
which	O
binds	O
to	O
several	O
proteins	O
implicated	O
in	O
cancer	O
,	O
including	O
c	O
-	O
Src	O
[	O
10	O
,	O
11	O
]	O
and	O
the	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
family	O
[	O
12	O
,	O
13	O
]	O
.	O

MUC1	O
stimulates	O
mitogen	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
signaling	O
through	O
the	O
extracellular	O
signal	O
regulated	O
kinases	O
(	O
ERK1	O
/	O
2	O
)	O
[	O
12	O
,	O
14	O
]	O
;	O
this	O
can	O
occur	O
through	O
MUC1	O
association	O
with	O
Grb2	O
and	O
son	O
of	O
sevenless	O
to	O
activate	O
Ras	O
[	O
15	O
]	O
.	O

ERK1	O
/	O
2	O
signaling	O
is	O
commonly	O
stimulated	O
by	O
the	O
Ras	O
-	O
Raf	O
-	O
MEK	O
(	O
MAPK	O
and	O
ERK	O
kinase	O
)	O
cascade	O
downstream	O
of	O
mitogens	O
such	O
as	O
EGFR	O
[	O
16	O
]	O
,	O
and	O
regulates	O
transcription	O
via	O
factors	O
like	O
the	O
activator	O
protein	O
-	O
1	O
complex	O
.	O

Loss	O
of	O
MUC1	O
can	O
reduce	O
EGFR	O
expression	O
[	O
17	O
]	O
,	O
providing	O
another	O
means	O
of	O
affecting	O
MAPK	O
signaling	O
.	O

Our	O
results	O
describe	O
a	O
novel	O
mechanism	O
by	O
which	O
MUC1	O
regulates	O
the	O
ERK1	O
/	O
2	O
pathway	O
,	O
through	O
modulating	O
transcription	O
of	O
the	O
genes	O
encoding	O
MEK1	O
,	O
Raf	O
-	O
1	O
,	O
and	O
c	O
-	O
Jun	O
.	O

MUC1	O
expression	O
correlates	O
with	O
increased	O
survival	O
in	O
response	O
to	O
cytotoxic	O
or	O
oxidative	O
agents	O
[	O
18	O
-	O
21	O
]	O
,	O
and	O
can	O
activate	O
the	O
phosphoinositol	O
-	O
3	O
kinase	O
-	O
AKT	O
pathway	O
as	O
part	O
of	O
an	O
anti	O
-	O
apoptotic	O
response	O
[	O
18	O
]	O
.	O
<EOS>	B-X
The	B-X
Mucin	B-X
1	B-X
(	B-X
MUC1	B-X
)	B-X
protein	B-X
is	B-X
overexpressed	B-X
in	B-X
various	B-X
cancers	B-X
and	B-X
mediates	B-X
chemotherapy	B-X
resistance	B-X
.	B-X
Given	B-X
that	B-X
most	B-X
chemotherapeutic	B-X
drugs	B-X
disrupt	B-X
ER	B-X
homeostasis	B-X
as	B-X
part	B-X
of	B-X
their	B-X
toxicity	B-X
,	B-X
and	B-X
MUC1	B-X
expression	B-X
is	B-X
regulated	B-X
by	B-X
proteins	B-X
involved	B-X
in	B-X
ER	B-X
homeostasis	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
link	B-X
between	B-X
MUC1	B-X
and	B-X
ER	B-X
homeostasis	B-X
.	B-X
MUC1	B-X
knockdown	B-X
in	B-X
pancreatic	B-X
cancer	B-X
cells	B-X
enhanced	B-X
unfolded	B-X
protein	B-X
response	B-X
(	B-X
UPR	B-X
)	B-X
signaling	B-X
and	B-X
cell	B-X
death	B-X
upon	B-X
ER	B-X
stress	B-X
induction	B-X
.	B-X
Transcriptomic	B-X
analysis	B-X
revealed	B-X
alterations	B-X
in	B-X
the	B-X
pyrimidine	B-X
metabolic	B-X
pathway	B-X
and	B-X
cytidine	B-X
deaminase	B-X
(	B-X
CDA	B-X
)	B-X
.	B-X
ChIP	B-X
and	B-X
CDA	B-X
activity	B-X
assays	B-X
showed	B-X
that	B-X
MUC1	B-X
occupied	B-X
CDA	B-X
gene	B-X
promoter	B-X
upon	B-X
ER	B-X
stress	B-X
induction	B-X
correlating	B-X
with	B-X
increased	B-X
CDA	B-X
expression	B-X
and	B-X
activity	B-X
in	B-X
MUC1-expressing	B-X
cells	B-X
as	B-X
compared	B-X
with	B-X
MUC1	B-X
knockdown	B-X
cells	B-X
.	B-X
Inhibition	B-X
of	B-X
either	B-X
the	B-X
CDA	B-X
or	B-X
pyrimidine	B-X
metabolic	B-X
pathway	B-X
diminished	B-X
survival	B-X
in	B-X
MUC1-expressing	B-X
cancer	B-X
cells	B-X
upon	B-X
ER	B-X
stress	B-X
induction	B-X
.	B-X
Metabolomic	B-X
analysis	B-X
demonstrated	B-X
that	B-X
MUC1-mediated	B-X
CDA	B-X
activity	B-X
corresponded	B-X
to	B-X
deoxycytidine	B-X
to	B-X
deoxyuridine	B-X
metabolic	B-X
reprogramming	B-X
upon	B-X
ER	B-X
stress	B-X
induction	B-X
.	B-X
The	B-X
resulting	B-X
increase	B-X
in	B-X
deoxyuridine	B-X
mitigated	B-X
ER	B-X
stress-induced	B-X
cytotoxicity	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
given	B-X
(	B-X
1	B-X
)	B-X
the	B-X
established	B-X
roles	B-X
of	B-X
MUC1	B-X
in	B-X
protecting	B-X
cells	B-X
against	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
insults	B-X
,	B-X
(	B-X
2	B-X
)	B-X
ER	B-X
stress-generated	B-X
ROS	B-X
further	B-X
promote	B-X
ER	B-X
stress	B-X
and	B-X
(	B-X
3	B-X
)	B-X
the	B-X
emerging	B-X
anti-oxidant	B-X
property	B-X
of	B-X
deoxyuridine	B-X
,	B-X
we	B-X
further	B-X
investigated	B-X
if	B-X
MUC1	B-X
regulated	B-X
ER	B-X
stress	B-X
by	B-X
a	B-X
deoxyuridine-mediated	B-X
modulation	B-X
of	B-X
ROS	B-X
levels	B-X
.	B-X
We	B-X
observed	B-X
that	B-X
deoxyuridine	B-X
could	B-X
abrogate	B-X
ROS-induced	B-X
ER	B-X
stress	B-X
to	B-X
promote	B-X
cancer	B-X
cell	B-X
survival	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
findings	B-X
demonstrate	B-X
a	B-X
novel	B-X
MUC1-CDA	B-X
axis	B-X
of	B-X
the	B-X
adaptive	B-X
UPR	B-X
that	B-X
provides	B-X
survival	B-X
advantage	B-X
upon	B-X
ER	B-X
stress	B-X
induction	B-X
.	B-X

MUC1	O
has	O
also	O
recently	O
been	O
linked	O
to	O
transcription	O
,	O
as	O
the	O
MUC1	O
-	O
CT	O
localizes	O
to	O
the	O
nucleus	O
[	O
22	O
]	O
and	O
affects	O
transcription	O
by	O
beta	O
-	O
catenin	O
[	O
22	O
,	O
23	O
]	O
,	O
FOXO3a	O
[	O
21	O
]	O
,	O
p53	O
[	O
24	O
]	O
,	O
and	O
estrogen	O
receptor	O
alpha	O
[	O
25	O
]	O
.	O

However	O
,	O
there	O
are	O
indications	O
that	O
the	O
role	O
of	O
MUC1	O
in	O
oncogenesis	O
is	O
regulated	O
by	O
cell	O
type	O
and	O
signaling	O
context	O
.	O

For	O
example	O
,	O
MUC1	O
can	O
stimulate	O
Fas	O
-	O
mediated	O
apoptosis	O
[	O
26	O
]	O
,	O
while	O
Muc1	O
is	O
specifically	O
down	O
-	O
regulated	O
in	O
c	O
-	O
neu	O
-	O
induced	O
mammary	O
tumors	O
[	O
27	O
]	O
.	O

This	O
report	O
emphasizes	O
the	O
complexity	O
of	O
MUC1	O
signaling	O
in	O
breast	O
cancer	O
by	O
contrasting	O
results	O
from	O
two	O
established	O
breast	O
cancer	O
cell	O
lines	O
.	O

To	O
understand	O
MUC1	O
function	O
in	O
cells	O
with	O
high	O
endogenous	O
expression	O
,	O
that	O
is	O
,	O
cells	O
likely	O
to	O
have	O
evolved	O
with	O
active	O
MUC1	O
signaling	O
,	O
we	O
used	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
to	O
knock	O
down	O
MUC1	O
in	O
MDA	O
-	O
MB	O
-	O
468	O
and	O
BT	O
-	O
20	O
cells	O
.	O

We	O
then	O
analyzed	O
transcription	O
of	O
84	O
genes	O
involved	O
in	O
cancer	O
,	O
as	O
well	O
as	O
the	O
effects	O
upon	O
cellular	O
events	O
linked	O
to	O
oncogenesis	O
,	O
such	O
as	O
apoptosis	O
and	O
proliferation	O
.	O

Though	O
the	O
cell	O
lines	O
show	O
some	O
similarity	O
in	O
transcriptional	O
alterations	O
after	O
transfection	O
with	O
MUC1	O
siRNA	O
,	O
their	O
phenotypes	O
are	O
quite	O
dissimilar	O
:	O
MDA	O
-	O
MB	O
-	O
468	O
increases	O
apoptosis	O
and	O
reduces	O
proliferation	O
and	O
invasion	O
,	O
while	O
BT	O
-	O
20	O
proliferates	O
more	O
rapidly	O
after	O
loss	O
of	O
MUC1	O
.	O

This	O
last	O
may	O
reflect	O
the	O
striking	O
amount	O
of	O
active	O
AKT	O
in	O
BT	O
-	O
20	O
;	O
AKT	O
activity	O
is	O
increased	O
in	O
both	O
cell	O
lines	O
after	O
MUC1	O
siRNA	O
,	O
which	O
agrees	O
with	O
a	O
previous	O
study	O
of	O
MUC1	O
siRNA	O
[	O
21	O
]	O
,	O
but	O
disagrees	O
with	O
results	O
from	O
3Y1	O
fibroblasts	O
[	O
18	O
]	O
.	O

Recent	O
studies	O
have	O
emphasized	O
the	O
complex	O
and	O
context	O
-	O
specific	O
regulation	O
of	O
even	O
such	O
classic	O
oncogenes	O
as	O
AKT	O
[	O
28	O
]	O
.	O

The	O
differences	O
between	O
the	O
two	O
breast	O
cancer	O
cell	O
lines	O
in	O
this	O
study	O
suggest	O
that	O
MUC1	O
oncogenic	O
functions	O
are	O
also	O
subject	O
to	O
cell	O
-	O
specific	O
regulation	O
,	O
and	O
stress	O
the	O
need	O
for	O
understanding	O
the	O
cellular	O
signaling	O
context	O
when	O
interpreting	O
results	O
.	O

Materials	O
and	O
methods	O
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
effective	B-X
teaching	B-X
strategies	B-X
and	B-X
methods	B-X
of	B-X
delivery	B-X
for	B-X
patient	B-X
education	B-X
(	B-X
PE	B-X
)	B-X
.	B-X
A	B-X
systematic	B-X
review	B-X
was	B-X
conducted	B-X
and	B-X
reviews	B-X
with	B-X
or	B-X
without	B-X
meta-analyses	B-X
,	B-X
which	B-X
examined	B-X
teaching	B-X
strategies	B-X
and	B-X
methods	B-X
of	B-X
delivery	B-X
for	B-X
PE	B-X
,	B-X
were	B-X
included	B-X
.	B-X
Recommendations	B-X
concerning	B-X
the	B-X
efficacy	B-X
of	B-X
the	B-X
teaching	B-X
strategies	B-X
and	B-X
delivery	B-X
methods	B-X
are	B-X
provided	B-X
.	B-X
The	B-X
methods	B-X
section	B-X
of	B-X
a	B-X
research	B-X
paper	B-X
provides	B-X
the	B-X
information	B-X
by	B-X
which	B-X
a	B-X
study	B-X
's	B-X
validity	B-X
is	B-X
judged	B-X
.	B-X
The	B-X
methods	B-X
section	B-X
should	B-X
describe	B-X
what	B-X
was	B-X
done	B-X
to	B-X
answer	B-X
the	B-X
research	B-X
question	B-X
,	B-X
describe	B-X
how	B-X
it	B-X
was	B-X
done	B-X
,	B-X
justify	B-X
the	B-X
experimental	B-X
design	B-X
,	B-X
and	B-X
explain	B-X
how	B-X
the	B-X
results	B-X
were	B-X
analyzed	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
methods	B-X
section	B-X
structure	B-X
should	B-X
:	B-X
describe	B-X
the	B-X
materials	B-X
used	B-X
in	B-X
the	B-X
study	B-X
,	B-X
explain	B-X
how	B-X
the	B-X
materials	B-X
were	B-X
prepared	B-X
for	B-X
the	B-X
study	B-X
,	B-X
describe	B-X
the	B-X
research	B-X
protocol	B-X
,	B-X
explain	B-X
how	B-X
measurements	B-X
were	B-X
made	B-X
and	B-X
what	B-X
calculations	B-X
were	B-X
performed	B-X
,	B-X
and	B-X
state	B-X
which	B-X
statistical	B-X
tests	B-X
were	B-X
done	B-X
to	B-X
analyze	B-X
the	B-X
data	B-X
.	B-X
Once	B-X
all	B-X
elements	B-X
of	B-X
the	B-X
methods	B-X
section	B-X
are	B-X
written	B-X
,	B-X
subsequent	B-X
drafts	B-X
should	B-X
focus	B-X
on	B-X
how	B-X
to	B-X
present	B-X
those	B-X
elements	B-X
as	B-X
clearly	B-X
and	B-X
logically	B-X
as	B-X
possibly	B-X
.	B-X

Cell	O
culture	O
and	O
siRNA	O
transfection	O
<EOS>	B-X
Transfection	B-X
with	B-X
siRNA	B-X
and	B-X
plasmid	B-X
DNA	B-X
is	B-X
an	B-X
efficient	B-X
tool	B-X
for	B-X
studying	B-X
their	B-X
function	B-X
,	B-X
but	B-X
transfection	B-X
of	B-X
macrophages	B-X
is	B-X
not	B-X
a	B-X
trivial	B-X
matter	B-X
.	B-X
Although	B-X
many	B-X
different	B-X
approaches	B-X
for	B-X
transfection	B-X
of	B-X
eukaryotic	B-X
cells	B-X
are	B-X
available	B-X
,	B-X
only	B-X
few	B-X
allow	B-X
reliable	B-X
and	B-X
efficient	B-X
transfection	B-X
of	B-X
macrophages	B-X
,	B-X
but	B-X
reduced	B-X
cell	B-X
vitality	B-X
and	B-X
severely	B-X
altered	B-X
cell	B-X
behavior	B-X
like	B-X
diminished	B-X
capability	B-X
for	B-X
differentiation	B-X
or	B-X
polarization	B-X
are	B-X
frequently	B-X
observed	B-X
.	B-X
Therefore	B-X
a	B-X
transfection	B-X
protocol	B-X
is	B-X
required	B-X
that	B-X
is	B-X
capable	B-X
of	B-X
transferring	B-X
siRNA	B-X
and	B-X
plasmid	B-X
DNA	B-X
into	B-X
macrophages	B-X
without	B-X
causing	B-X
serious	B-X
side-effects	B-X
thus	B-X
allowing	B-X
the	B-X
investigation	B-X
of	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
siRNA	B-X
or	B-X
plasmid	B-X
in	B-X
the	B-X
context	B-X
of	B-X
normal	B-X
cell	B-X
behavior	B-X
.	B-X
The	B-X
protocol	B-X
presented	B-X
here	B-X
provides	B-X
a	B-X
method	B-X
for	B-X
reliably	B-X
and	B-X
efficiently	B-X
transfecting	B-X
human	B-X
THP-1	B-X
macrophages	B-X
and	B-X
monocytes	B-X
with	B-X
high	B-X
cell	B-X
vitality	B-X
,	B-X
high	B-X
transfection	B-X
efficiency	B-X
,	B-X
and	B-X
minimal	B-X
effects	B-X
on	B-X
cell	B-X
behavior	B-X
.	B-X
This	B-X
approach	B-X
is	B-X
based	B-X
on	B-X
Nucleofection	B-X
and	B-X
the	B-X
protocol	B-X
has	B-X
been	B-X
optimized	B-X
to	B-X
maintain	B-X
maximum	B-X
capability	B-X
for	B-X
cell	B-X
activation	B-X
after	B-X
transfection	B-X
.	B-X
Apart	B-X
from	B-X
presenting	B-X
results	B-X
characterizing	B-X
macrophages	B-X
transfected	B-X
according	B-X
to	B-X
this	B-X
protocol	B-X
in	B-X
comparison	B-X
to	B-X
an	B-X
alternative	B-X
chemical	B-X
method	B-X
,	B-X
the	B-X
impact	B-X
of	B-X
cell	B-X
culture	B-X
medium	B-X
selection	B-X
after	B-X
transfection	B-X
on	B-X
cell	B-X
behavior	B-X
is	B-X
also	B-X
discussed	B-X
.	B-X

MDA	O
-	O
MB	O
-	O
468	O
and	O
BT	O
-	O
20	O
cells	O
(	O
American	O
Type	O
Culture	O
Collection	O
)	O
were	O
cultured	O
in	O
Dulbecco	O
'	O
s	O
modified	O
Eagle	O
'	O
s	O
medium	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
plus	O
10	O
%	O
fetal	O
calf	B-Species
serum	O
,	O
1	O
%	O
Glutamax	O
(	O
Invitrogen	O
)	O
and	O
1	O
%	O
penicillin	O
/	O
streptomycin	O
.	O

Stable	O
cell	O
lines	O
(	O
468	O
.	O
Neo	O
and	O
468	O
.	O
MUC1	O
Delta	O
8	O
)	O
were	O
selected	O
with	O
0	O
.	O
5	O
mg	O
/	O
ml	O
G418	O
.	O

For	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
stimulation	O
,	O
MDA	O
-	O
MB	O
-	O
468	O
cells	O
were	O
serum	O
-	O
starved	O
overnight	O
and	O
treated	O
for	O
10	O
minutes	O
at	O
37	O
degrees	O
C	O
with	O
100	O
ng	O
/	O
ml	O
EGF	O
.	O

Transient	O
siRNA	O
transfection	O
was	O
performed	O
with	O
Lipofectamine2000	O
(	O
Invitrogen	O
)	O
and	O
100	O
nM	O
siRNA	O
oligonucleotides	O
.	O

The	O
commercially	O
available	O
siRNA	O
constructs	O
(	O
all	O
from	O
Dharmacon	O
,	O
Lafayette	O
,	O
CO	O
,	O
USA	O
)	O
were	O
scrambled	O
(	O
siCONTROL	O
non	O
-	O
targeting	O
siRNA	O
#	O
1	O
)	O
,	O
or	O
directed	O
against	O
firefly	O
luciferase	O
(	O
siCONTROL	O
non	O
-	O
targeting	O
siRNA	O
#	O
2	O
)	O
or	O
MUC1	O
(	O
siGENOME	O
smartpool	O
)	O
.	O

The	O
independent	O
oligonucleotides	O
designed	O
in	O
our	O
laboratory	O
target	O
sequences	O
beginning	O
at	O
MUC1	O
codons	O
882	O
and	O
956	O
,	O
and	O
have	O
been	O
described	O
previously	O
[	O
29	O
]	O
.	O

The	O
scrambled	O
siRNA	O
construct	O
was	O
used	O
only	O
in	O
BT	O
-	O
20	O
cells	O
as	O
it	O
causes	O
a	O
non	O
-	O
specific	O
knockdown	O
of	O
MUC1	O
in	O
the	O
MDA	O
-	O
MB	O
-	O
468	O
line	O
.	O

Cloning	O
of	O
MUC1	O
WT	O
vector	O
and	O
stable	O
transfection	O

Two	O
silent	O
mutations	O
(	O
G891A	O
and	O
T894C	O
)	O
were	O
introduced	O
into	O
the	O
MUC1	O
cDNA	O
(	O
called	O
MUC1	O
Delta	O
8	O
)	O
to	O
make	O
it	O
resistant	O
to	O
the	O
882	O
siRNA	O
that	O
targets	O
that	O
region	O
of	O
the	O
mRNA	O
.	O

The	O
mutant	O
cDNA	O
was	O
cloned	O
into	O
the	O
pLNCX	O
.	O
1	O
vector	O
with	O
neomycin	O
resistance	O
(	O
gift	O
of	O
Joseph	O
Loftus	O
,	O
Mayo	O
Clinic	O
,	O
Arizona	O
,	O
USA	O
)	O
.	O

Stable	O
transfection	O
was	O
performed	O
with	O
Lipofectamine2000	O
;	O
cells	O
were	O
selected	O
beginning	O
24	O
hours	O
post	O
-	O
transfection	O
and	O
maintained	O
as	O
a	O
polyclonal	O
population	O
.	O
<EOS>	B-X
The	B-X
siRNA	B-X
transfection	B-X
rates	B-X
have	B-X
usually	B-X
been	B-X
limited	B-X
due	B-X
to	B-X
the	B-X
declining	B-X
contact	B-X
probability	B-X
among	B-X
polyplexes	B-X
and	B-X
the	B-X
non-adherent	B-X
nature	B-X
of	B-X
leukemic	B-X
cells	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
the	B-X
BCR-ABL	B-X
level	B-X
in	B-X
K562	B-X
cells	B-X
as	B-X
a	B-X
result	B-X
of	B-X
RNAi	B-X
was	B-X
analyzed	B-X
by	B-X
real-time	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT-PCR	B-X
)	B-X
.	B-X
We	B-X
observed	B-X
that	B-X
BCPV	B-X
was	B-X
able	B-X
to	B-X
form	B-X
stable	B-X
nanoplexes	B-X
with	B-X
siRNA	B-X
molecules	B-X
,	B-X
even	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
fetal	B-X
bovine	B-X
serum	B-X
(	B-X
FBS	B-X
)	B-X
,	B-X
and	B-X
successfully	B-X
assisted	B-X
in	B-X
vitro	B-X
siRNA	B-X
transfection	B-X
in	B-X
the	B-X
non-adherent	B-X
K562	B-X
cells	B-X
.	B-X
All	B-X
results	B-X
were	B-X
compared	B-X
with	B-X
a	B-X
commercial	B-X
transfection	B-X
reagent	B-X
,	B-X
Lipofectamine2000â¢	B-X
,	B-X
which	B-X
served	B-X
as	B-X
a	B-X
positive	B-X
control	B-X
.	B-X
More	B-X
importantly	B-X
,	B-X
this	B-X
class	B-X
of	B-X
non-viral	B-X
vector	B-X
exhibits	B-X
biodegradable	B-X
features	B-X
and	B-X
negligible	B-X
cytotoxicity	B-X
,	B-X
thus	B-X
providing	B-X
a	B-X
versatile	B-X
platform	B-X
to	B-X
deliver	B-X
siRNA	B-X
to	B-X
non-adherent	B-X
leukemia	B-X
cells	B-X
with	B-X
high	B-X
transfection	B-X
efficiency	B-X
by	B-X
effectively	B-X
overcoming	B-X
extra-	B-X
and	B-X
intra-cellular	B-X
barriers	B-X
.	B-X
Due	B-X
to	B-X
the	B-X
excellent	B-X
in	B-X
vitro	B-X
transfection	B-X
results	B-X
from	B-X
BCPV-siRNA	B-X
,	B-X
a	B-X
newly	B-X
developed	B-X
biodegradable	B-X
transfection	B-X
agent	B-X
,	B-X
BCPV	B-X
,	B-X
is	B-X
being	B-X
probed	B-X
for	B-X
transfection	B-X
performance	B-X
in	B-X
an	B-X
animal	B-X
model	B-X
.	B-X

Western	O
blots	O
and	O
antibodies	O
<EOS>	B-X
Western	B-X
blotting	B-X
is	B-X
a	B-X
technique	B-X
that	B-X
involves	B-X
the	B-X
separation	B-X
of	B-X
proteins	B-X
by	B-X
gel	B-X
electrophoresis	B-X
,	B-X
their	B-X
blotting	B-X
or	B-X
transfer	B-X
to	B-X
a	B-X
membrane	B-X
,	B-X
and	B-X
selective	B-X
immunodetection	B-X
of	B-X
an	B-X
immobilized	B-X
antigen	B-X
.	B-X
Western	B-X
blotting	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
commonly	B-X
used	B-X
laboratory	B-X
techniques	B-X
for	B-X
identifying	B-X
proteins	B-X
and	B-X
semi-quantifying	B-X
protein	B-X
amounts	B-X
;	B-X
however	B-X
,	B-X
several	B-X
recent	B-X
findings	B-X
suggest	B-X
that	B-X
western	B-X
blots	B-X
may	B-X
not	B-X
be	B-X
as	B-X
reliable	B-X
as	B-X
previously	B-X
assumed	B-X
.	B-X
In	B-X
this	B-X
manuscript	B-X
,	B-X
we	B-X
review	B-X
essential	B-X
strategies	B-X
for	B-X
improving	B-X
confidence	B-X
in	B-X
the	B-X
accuracy	B-X
of	B-X
western	B-X
blots	B-X
.	B-X
These	B-X
strategies	B-X
include	B-X
selecting	B-X
the	B-X
best	B-X
normalization	B-X
standard	B-X
,	B-X
proper	B-X
sample	B-X
preparation	B-X
,	B-X
determining	B-X
the	B-X
linear	B-X
range	B-X
for	B-X
antibodies	B-X
and	B-X
protein	B-X
stains	B-X
relevant	B-X
to	B-X
the	B-X
sample	B-X
of	B-X
interest	B-X
,	B-X
confirming	B-X
the	B-X
quality	B-X
of	B-X
the	B-X
primary	B-X
antibody	B-X
,	B-X
preventing	B-X
signal	B-X
saturation	B-X
and	B-X
accurately	B-X
quantifying	B-X
the	B-X
signal	B-X
intensity	B-X
of	B-X
the	B-X
target	B-X
protein	B-X
.	B-X

Cells	O
were	O
lysed	O
in	O
buffer	O
(	O
20	O
mM	O
HEPES	O
pH	O
8	O
.	O
0	O
,	O
150	O
mM	O
sodium	O
chloride	O
,	O
1	O
%	O
Triton	O
X	O
-	O
100	O
,	O
2	O
mM	O
EDTA	O
)	O
with	O
commercial	O
protease	O
(	O
Complete	O
inhibitor	O
cocktail	O
,	O
Roche	O
,	O
Pleasanton	O
,	O
CA	O
,	O
USA	O
)	O
and	O
phosphatase	O
inhibitors	O
(	O
10	O
mM	O
sodium	O
fluoride	O
,	O
2	O
mM	O
sodium	O
vanadate	O
,	O
50	O
mu	O
M	O
ammonium	O
molybdate	O
)	O
.	O

Protein	O
concentration	O
was	O
determined	O
by	O
BCA	O
(	O
Pierce	O
,	O
Rockford	O
,	O
IL	O
,	O
USA	O
)	O
;	O
50	O
mu	O
g	O
of	O
lysate	O
were	O
loaded	O
on	O
SDS	O
-	O
PAGE	O
gels	O
for	O
each	O
experiment	O
,	O
except	O
for	O
the	O
pMEK1	O
/	O
2	O
blot	O
in	O
MDA	O
-	O
MB	O
-	O
468	O
,	O
where	O
150	O
mu	O
g	O
were	O
used	O
.	O

Non	O
-	O
commercial	O
antibodies	O
used	O
were	O
:	O
BC2	O
,	O
a	O
mouse	B-Species
monoclonal	O
to	O
the	O
MUC1	O
-	O
EX	O
(	O
gift	O
of	O
Dr	O
McGuckin	O
,	O
Queensland	O
University	O
,	O
Queensland	O
,	O
Australia	O
)	O
,	O
and	O
CT2	O
,	O
an	O
Armenian	B-Species
hamster	I-Species
monoclonal	O
to	O
the	O
MUC1	O
-	O
CT	O
developed	O
in	O
our	O
lab	O
[	O
12	O
]	O
.	O

Antibodies	O
to	O
pMEK1	O
/	O
2	O
,	O
MEK1	O
/	O
2	O
,	O
ERK1	O
/	O
2	O
,	O
Myc	O
,	O
pAKT	O
,	O
AKT	O
,	O
beta	O
-	O
tubulin	O
(	O
all	O
Cell	O
Signaling	O
,	O
Danvers	O
,	O
MA	O
,	O
USA	O
)	O
,	O
beta	O
-	O
actin	O
and	O
dpERK1	O
/	O
2	O
(	O
both	O
Sigma	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
were	O
used	O
according	O
to	O
manufacturers	O
'	O
recommendations	O
.	O

All	O
antibodies	O
except	O
beta	O
-	O
actin	O
(	O
1	O
:	O
2	O
,	O
500	O
)	O
and	O
dpERK1	O
/	O
2	O
(	O
1	O
:	O
10	O
,	O
000	O
)	O
were	O
used	O
at	O
1	O
:	O
1	O
,	O
000	O
dilution	O
for	O
western	O
blots	O
.	O

Flow	O
cytometric	O
analysis	O
of	O
MUC1	O
was	O
done	O
with	O
HMPV	O
-	O
FITC	O
,	O
which	O
recognizes	O
the	O
core	O
peptide	O
of	O
the	O
MUC1	O
-	O
EX	O
tandem	O
repeats	O
(	O
Pharmingen	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Bromodeoxyuridine	O
(	O
BrdU	O
)	O
staining	O
was	O
performed	O
with	O
a	O
fluorescently	O
conjugated	O
antibody	O
to	O
BrdU	O
(	O
BrdU	O
-	O
PE	O
,	O
BD	O
Biosciences	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
as	O
described	O
below	O
.	O

Densitometry	O
was	O
performed	O
using	O
the	O
public	O
domain	O
ImageJ	O
program	O
(	O
developed	O
at	O
the	O
NIH	O
and	O
available	O
at	O
[	O
30	O
]	O
.	O

Each	O
band	O
was	O
measured	O
in	O
three	O
places	O
;	O
the	O
results	O
were	O
averaged	O
and	O
normalized	O
to	O
tubulin	O
to	O
control	O
for	O
loading	O
.	O
<EOS>	B-X
The	B-X
dangers	B-X
of	B-X
analyzing	B-X
the	B-X
myocardium	B-X
on	B-X
the	B-X
basis	B-X
of	B-X
arrangement	B-X
of	B-X
the	B-X
skeletal	B-X
myocytes	B-X
have	B-X
long	B-X
been	B-X
appreciated	B-X
,	B-X
yet	B-X
some	B-X
still	B-X
described	B-X
the	B-X
ventricular	B-X
myocardium	B-X
in	B-X
terms	B-X
of	B-X
a	B-X
unique	B-X
band	B-X
extending	B-X
from	B-X
the	B-X
pulmonary	B-X
trunk	B-X
to	B-X
the	B-X
aorta	B-X
.	B-X
Our	B-X
own	B-X
investigations	B-X
show	B-X
that	B-X
,	B-X
rather	B-X
than	B-X
forming	B-X
a	B-X
continuous	B-X
band	B-X
,	B-X
or	B-X
being	B-X
arranged	B-X
as	B-X
sheets	B-X
,	B-X
the	B-X
myocytes	B-X
are	B-X
aggregated	B-X
together	B-X
as	B-X
a	B-X
three-dimensional	B-X
mesh	B-X
within	B-X
a	B-X
supporting	B-X
matrix	B-X
of	B-X
fibrous	B-X
tissue	B-X
.	B-X
Correlation	B-X
with	B-X
measurements	B-X
taken	B-X
using	B-X
force	B-X
probes	B-X
shows	B-X
that	B-X
these	B-X
myocytes	B-X
produce	B-X
the	B-X
major	B-X
unloading	B-X
of	B-X
the	B-X
blood	B-X
during	B-X
ventricular	B-X
systole	B-X
.	B-X
The	B-X
three-dimensional	B-X
arrangement	B-X
of	B-X
the	B-X
mesh	B-X
also	B-X
serves	B-X
to	B-X
account	B-X
for	B-X
the	B-X
realignment	B-X
of	B-X
the	B-X
myocytes	B-X
that	B-X
must	B-X
take	B-X
place	B-X
during	B-X
ventricular	B-X
contraction	B-X
so	B-X
as	B-X
to	B-X
account	B-X
for	B-X
the	B-X
extent	B-X
of	B-X
systolic	B-X
mural	B-X
thickening	B-X
.	B-X

Transwell	O
invasion	O
assays	O
<EOS>	B-X
The	B-X
need	B-X
to	B-X
identify	B-X
inhibitors	B-X
of	B-X
cancer	B-X
invasion	B-X
has	B-X
driven	B-X
the	B-X
development	B-X
of	B-X
quantitative	B-X
in	B-X
vitro	B-X
invasion	B-X
assays	B-X
.	B-X
The	B-X
most	B-X
common	B-X
assays	B-X
used	B-X
are	B-X
based	B-X
on	B-X
the	B-X
original	B-X
Boyden	B-X
assay	B-X
system	B-X
.	B-X
Today	B-X
commercially	B-X
available	B-X
plastic	B-X
inserts	B-X
for	B-X
multi-well	B-X
plates	B-X
,	B-X
which	B-X
possess	B-X
a	B-X
cell-permeable	B-X
membrane	B-X
,	B-X
as	B-X
typified	B-X
by	B-X
Transwell	B-X
(	B-X
Â®	B-X
)	B-X
Permeable	B-X
Supports	B-X
,	B-X
permit	B-X
accurate	B-X
repeatable	B-X
invasion	B-X
assays	B-X
.	B-X
To	B-X
create	B-X
an	B-X
invasion	B-X
assay	B-X
the	B-X
pores	B-X
in	B-X
the	B-X
membrane	B-X
are	B-X
blocked	B-X
with	B-X
a	B-X
gel	B-X
composed	B-X
of	B-X
extracellular	B-X
matrix	B-X
that	B-X
is	B-X
meant	B-X
to	B-X
mimic	B-X
the	B-X
typical	B-X
matrices	B-X
that	B-X
tumour	B-X
cells	B-X
encounter	B-X
during	B-X
the	B-X
invasion	B-X
process	B-X
in	B-X
vivo	B-X
.	B-X
By	B-X
placing	B-X
the	B-X
cells	B-X
on	B-X
one	B-X
side	B-X
of	B-X
the	B-X
gel	B-X
and	B-X
a	B-X
chemoattractant	B-X
on	B-X
the	B-X
other	B-X
side	B-X
of	B-X
the	B-X
gel	B-X
,	B-X
invasion	B-X
is	B-X
determined	B-X
by	B-X
counting	B-X
those	B-X
cells	B-X
that	B-X
have	B-X
traversed	B-X
the	B-X
cell-permeable	B-X
membrane	B-X
having	B-X
invaded	B-X
towards	B-X
the	B-X
higher	B-X
concentration	B-X
of	B-X
chemoattractant	B-X
.	B-X
In	B-X
this	B-X
chapter	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
protocols	B-X
for	B-X
performing	B-X
Transwell	B-X
invasion	B-X
assays	B-X
,	B-X
there	B-X
is	B-X
consideration	B-X
of	B-X
the	B-X
limitations	B-X
of	B-X
current	B-X
assay	B-X
designs	B-X
with	B-X
regard	B-X
to	B-X
available	B-X
matrices	B-X
and	B-X
the	B-X
absence	B-X
of	B-X
tumour	B-X
microenvironment	B-X
cells	B-X
.	B-X

Cells	O
were	O
serum	O
-	O
starved	O
beginning	O
24	O
hours	O
post	O
-	O
siRNA	O
transfection	O
.	O

Cells	O
were	O
re	O
-	O
plated	O
in	O
serum	O
-	O
free	O
medium	O
48	O
hours	O
post	O
-	O
transfection	O
at	O
50	O
,	O
000	O
cells	O
per	O
insert	O
(	O
sized	O
for	O
24	O
-	O
well	O
plates	O
)	O
,	O
with	O
serum	O
-	O
containing	O
medium	O
in	O
the	O
bottom	O
of	O
the	O
growth	O
well	O
as	O
an	O
attractant	O
.	O

Transwell	O
inserts	O
(	O
BD	O
Biosciences	O
)	O
pre	O
-	O
coated	O
with	O
laminin	O
,	O
fibronectin	O
,	O
collagen	O
IV	O
,	O
or	O
control	O
(	O
no	O
matrix	O
)	O
were	O
used	O
,	O
and	O
cells	O
were	O
permitted	O
to	O
invade	O
for	O
48	O
hours	O
.	O

At	O
this	O
point	O
(	O
96	O
hours	O
post	O
-	O
transfection	O
)	O
,	O
visual	O
inspection	O
of	O
the	O
growth	O
wells	O
confirmed	O
that	O
negligible	O
numbers	O
of	O
cells	O
went	O
through	O
to	O
the	O
bottom	O
of	O
the	O
plate	O
.	O

Non	O
-	O
invaded	O
cells	O
were	O
swabbed	O
from	O
the	O
tops	O
of	O
half	O
of	O
the	O
inserts	O
(	O
'	O
samples	O
'	O
,	O
containing	O
only	O
invaded	O
cells	O
)	O
,	O
and	O
retained	O
in	O
the	O
others	O
(	O
'	O
controls	O
'	O
,	O
all	O
cells	O
)	O
.	O

Inserts	O
were	O
stained	O
for	O
10	O
minutes	O
with	O
crystal	O
violet	O
(	O
0	O
.	O
5	O
%	O
in	O
20	O
%	O
methanol	O
)	O
and	O
washed	O
with	O
water	O
.	O

Membranes	O
were	O
cut	O
out	O
and	O
destained	O
for	O
10	O
minutes	O
in	O
10	O
%	O
acetic	O
acid	O
in	O
a	O
96	O
-	O
well	O
plate	O
;	O
membranes	O
were	O
removed	O
and	O
absorbance	O
was	O
read	O
at	O
570	O
nm	O
.	O

Percent	O
invasion	O
is	O
defined	O
as	O
(	O
absorbance	O
of	O
samples	O
/	O
absorbance	O
of	O
controls	O
)	O
x	O
100	O
.	O

[	O
3H	O
]	O
Thymidine	O
incorporation	O
assays	O
<EOS>	B-X
The	B-X
sensitivity	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
thymidine	B-X
incorporation	B-X
and	B-X
MTT/MTS	B-X
colorimetric	B-X
bioassays	B-X
for	B-X
detection	B-X
and	B-X
quantitation	B-X
of	B-X
murine	B-X
and	B-X
human	B-X
IL-4	B-X
and	B-X
IL-2	B-X
were	B-X
compared	B-X
in	B-X
CT.4S	B-X
,	B-X
CT.h4S	B-X
and	B-X
HT-2	B-X
bioassays	B-X
respectively	B-X
.	B-X
We	B-X
reasoned	B-X
that	B-X
low	B-X
levels	B-X
of	B-X
cytokine	B-X
,	B-X
insufficient	B-X
to	B-X
induce	B-X
cell	B-X
proliferation	B-X
(	B-X
thus	B-X
,	B-X
DNA	B-X
synthesis	B-X
and	B-X
[	B-X
3H	B-X
]	B-X
thymidine	B-X
incorporation	B-X
)	B-X
,	B-X
may	B-X
be	B-X
sufficient	B-X
to	B-X
maintain	B-X
the	B-X
viability	B-X
of	B-X
the	B-X
bioassay	B-X
cells	B-X
in	B-X
culture	B-X
.	B-X
Because	B-X
colorimetric	B-X
assays	B-X
such	B-X
as	B-X
those	B-X
employing	B-X
MTT	B-X
(	B-X
3-	B-X
(	B-X
4,5	B-X
dimethylthiazol-2-yl	B-X
)	B-X
-2,5-diphenyl	B-X
tetrazolium	B-X
bromide	B-X
)	B-X
or	B-X
MTS	B-X
(	B-X
3-	B-X
(	B-X
4,5-dimethylthiazol-2-yl	B-X
)	B-X
-5-	B-X
(	B-X
3-carboxymethoxyphenyl	B-X
)	B-X
-2-	B-X
(	B-X
4-sulfonyl	B-X
)	B-X
-2H-	B-X
tetrazolium	B-X
)	B-X
measure	B-X
conversion	B-X
of	B-X
these	B-X
salts	B-X
to	B-X
intensely	B-X
colored	B-X
formazan	B-X
products	B-X
by	B-X
mitochondrial	B-X
enzymes	B-X
independent	B-X
of	B-X
whether	B-X
proliferation	B-X
is	B-X
induced	B-X
,	B-X
we	B-X
reasoned	B-X
that	B-X
such	B-X
assays	B-X
could	B-X
be	B-X
superior	B-X
for	B-X
detection	B-X
of	B-X
low	B-X
levels	B-X
of	B-X
cytokine	B-X
protein	B-X
.	B-X
Direct	B-X
comparison	B-X
of	B-X
these	B-X
approaches	B-X
demonstrated	B-X
that	B-X
the	B-X
MTT-	B-X
and	B-X
MTS-based	B-X
assays	B-X
were	B-X
consistently	B-X
able	B-X
to	B-X
detect	B-X
2-16-fold	B-X
lower	B-X
cytokine	B-X
levels	B-X
than	B-X
methods	B-X
based	B-X
on	B-X
[	B-X
3H	B-X
]	B-X
thymidine	B-X
incorporation	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
MTT	B-X
and	B-X
MTS	B-X
assays	B-X
exhibited	B-X
higher	B-X
precision	B-X
with	B-X
standard	B-X
deviations	B-X
of	B-X
<	B-X
1-4	B-X
%	B-X
vs.	B-X
5-15	B-X
%	B-X
for	B-X
thymidine	B-X
incorporation	B-X
.	B-X

Cells	O
were	O
re	O
-	O
plated	O
in	O
quadruplicate	O
24	O
hours	O
post	O
-	O
siRNA	O
transfection	O
at	O
15	O
,	O
000	O
cells	O
/	O
well	O
(	O
96	O
-	O
well	O
plate	O
)	O
with	O
[	O
3H	O
]	O
thymidine	O
(	O
1	O
mu	O
Ci	O
/	O
well	O
)	O
,	O
then	O
incubated	O
in	O
normal	O
conditions	O
for	O
24	O
hours	O
.	O

At	O
this	O
time	O
(	O
48	O
hours	O
post	O
-	O
siRNA	O
transfection	O
)	O
excess	O
radioactivity	O
was	O
washed	O
off	O
and	O
the	O
cells	O
were	O
harvested	O
and	O
read	O
on	O
a	O
TopCount	O
plate	O
reader	O
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
JMP	O
5	O
.	O
1	O
.	O
2	O
software	O
(	O
SAS	O
Institute	O
,	O
Inc	O
.	O
,	O
Cary	O
,	O
NC	O
,	O
USA	O
)	O
;	O
the	O
student	O
'	O
s	O
t	O
test	O
was	O
used	O
to	O
determine	O
p	O
values	O
and	O
significance	O
was	O
confirmed	O
with	O
Wilcoxon	O
rank	O
sum	O
and	O
Pearson	O
chi	O
squared	O
analyses	O
.	O

BrdU	O
incorporation	O
<EOS>	B-X
Bromo-deoxyuridine	B-X
(	B-X
BrdU	B-X
)	B-X
incorporation	B-X
into	B-X
replicating	B-X
DNA	B-X
is	B-X
a	B-X
commonly	B-X
used	B-X
and	B-X
highly	B-X
reproducible	B-X
method	B-X
to	B-X
detect	B-X
cell	B-X
division	B-X
history	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
a	B-X
protocol	B-X
for	B-X
BrdU	B-X
incorporation	B-X
analysis	B-X
in	B-X
hematopoietic	B-X
stem	B-X
and	B-X
progenitor	B-X
cells	B-X
that	B-X
can	B-X
provide	B-X
a	B-X
sensitive	B-X
measure	B-X
of	B-X
cell	B-X
division	B-X
even	B-X
in	B-X
rare	B-X
cell	B-X
populations	B-X
.	B-X
5-Bromo-2'-deoxyuridine	B-X
(	B-X
bromodeoxyuridine	B-X
(	B-X
BrdU	B-X
)	B-X
)	B-X
,	B-X
a	B-X
modified	B-X
nucleotide	B-X
and	B-X
analog	B-X
of	B-X
thymidine	B-X
,	B-X
is	B-X
commonly	B-X
used	B-X
for	B-X
detecting	B-X
proliferating	B-X
cells	B-X
.	B-X
For	B-X
detection	B-X
,	B-X
an	B-X
anti-BrdU	B-X
antibody	B-X
(	B-X
probe	B-X
)	B-X
with	B-X
a	B-X
fluorescent	B-X
dye	B-X
is	B-X
applied	B-X
to	B-X
bind	B-X
the	B-X
BrdU	B-X
label	B-X
after	B-X
DNA	B-X
denaturation	B-X
.	B-X
In	B-X
this	B-X
protocol	B-X
,	B-X
we	B-X
provide	B-X
the	B-X
BrdU	B-X
labeling	B-X
method	B-X
for	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
studies	B-X
,	B-X
along	B-X
with	B-X
immunocytochemistry	B-X
(	B-X
ICC	B-X
)	B-X
/immunofluorescence	B-X
(	B-X
IF	B-X
)	B-X
and	B-X
immunohistochemistry	B-X
(	B-X
IHC	B-X
)	B-X
staining	B-X
procedures	B-X
,	B-X
respectively	B-X
.	B-X

BrdU	O
(	O
50	O
mu	O
M	O
)	O
was	O
given	O
to	O
cells	O
48	O
hours	O
post	O
-	O
siRNA	O
transfection	O
and	O
permitted	O
to	O
incorporate	O
for	O
1	O
.	O
5	O
hours	O
.	O

Cells	O
were	O
then	O
washed	O
with	O
PBS	O
,	O
trypsinized	O
,	O
and	O
washed	O
again	O
.	O
<EOS>	B-X
A	B-X
healthy	B-X
,	B-X
exponentially	B-X
expanding	B-X
culture	B-X
is	B-X
washed	B-X
with	B-X
PBS	B-X
to	B-X
remove	B-X
residual	B-X
media	B-X
that	B-X
could	B-X
otherwise	B-X
quench	B-X
the	B-X
Trypsin	B-X
reaction	B-X
.	B-X
Cells	B-X
are	B-X
resuspended	B-X
growth	B-X
media	B-X
at	B-X
a	B-X
concentration	B-X
of	B-X
approximately	B-X
one	B-X
million	B-X
cells	B-X
in	B-X
one	B-X
mL	B-X
of	B-X
media	B-X
,	B-X
a	B-X
concentration	B-X
such	B-X
that	B-X
one	B-X
frozen	B-X
aliquot	B-X
is	B-X
sufficient	B-X
to	B-X
resurrect	B-X
a	B-X
culture	B-X
on	B-X
a	B-X
10	B-X
cm	B-X
plate	B-X
.	B-X
The	B-X
treatment	B-X
standard	B-X
(	B-X
TS	B-X
)	B-X
comprised	B-X
phosphate-buffered	B-X
saline	B-X
(	B-X
PBS	B-X
)	B-X
+	B-X
0.4	B-X
%	B-X
BSA	B-X
(	B-X
five	B-X
times	B-X
over	B-X
for	B-X
10	B-X
s	B-X
)	B-X
,	B-X
Hank	B-X
's	B-X
+0.25	B-X
%	B-X
trypsin	B-X
(	B-X
twice	B-X
for	B-X
45	B-X
s	B-X
)	B-X
,	B-X
and	B-X
then	B-X
PBS	B-X
+	B-X
0.4	B-X
%	B-X
BSA	B-X
again	B-X
(	B-X
five	B-X
times	B-X
for	B-X
10	B-X
s	B-X
)	B-X
.	B-X
The	B-X
four	B-X
other	B-X
washing	B-X
procedures	B-X
all	B-X
included	B-X
the	B-X
same	B-X
first	B-X
and	B-X
last	B-X
washing	B-X
steps	B-X
with	B-X
PBS	B-X
but	B-X
without	B-X
BSA	B-X
(	B-X
five	B-X
times	B-X
for	B-X
10	B-X
s	B-X
)	B-X
and	B-X
with	B-X
PBS	B-X
+	B-X
0.4	B-X
%	B-X
BSA	B-X
(	B-X
five	B-X
times	B-X
for	B-X
10	B-X
s	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X

BrdU	O
staining	O
was	O
performed	O
according	O
to	O
an	O
adaptation	O
of	O
the	O
manufacturer	O
'	O
s	O
protocol	O
:	O
cells	O
were	O
re	O
-	O
suspended	O
in	O
PBS	O
,	O
mixed	O
1	O
:	O
1	O
with	O
-	O
20	O
degrees	O
C	O
neat	O
ethanol	O
,	O
and	O
incubated	O
1	O
hour	O
at	O
-	O
20	O
degrees	O
C	O
to	O
fix	O
.	O

Fixed	O
cells	O
were	O
then	O
washed	O
gently	O
and	O
denatured	O
in	O
2	O
M	O
HCl	O
for	O
20	O
minutes	O
at	O
room	O
temperature	O
.	O

Following	O
washing	O
and	O
2	O
minute	O
'	O
s	O
incubation	O
with	O
0	O
.	O
1	O
M	O
Tris	O
to	O
neutralize	O
the	O
acid	O
,	O
cells	O
were	O
re	O
-	O
suspended	O
in	O
FACS	O
buffer	O
(	O
0	O
.	O
5	O
%	O
fetal	O
calf	B-Species
serum	O
in	O
PBS	O
)	O
and	O
stained	O
with	O
Phycoerythrin	O
(	O
PE	O
)	O
-	O
conjugated	O
anti	O
-	O
BrdU	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
for	O
flow	O
cytometry	O
analysis	O
on	O
a	O
FACScan	O
instrument	O
.	O

Apoptosis	O
and	O
trypan	O
blue	O
staining	O
<EOS>	B-X
Trypan	B-X
blue	B-X
is	B-X
a	B-X
colorimetric	B-X
dye	B-X
that	B-X
stains	B-X
dead	B-X
cells	B-X
with	B-X
a	B-X
blue	B-X
color	B-X
easily	B-X
observed	B-X
using	B-X
light	B-X
microscopy	B-X
at	B-X
low	B-X
resolution	B-X
.	B-X
The	B-X
staining	B-X
procedure	B-X
is	B-X
rapid	B-X
and	B-X
cells	B-X
can	B-X
be	B-X
analyzed	B-X
within	B-X
minutes	B-X
.	B-X
The	B-X
number	B-X
of	B-X
live	B-X
(	B-X
unstained	B-X
)	B-X
and	B-X
dead	B-X
(	B-X
blue	B-X
)	B-X
cells	B-X
can	B-X
be	B-X
counted	B-X
using	B-X
a	B-X
hemocytometer	B-X
on	B-X
a	B-X
basic	B-X
upright	B-X
microscope	B-X
.	B-X
Trypan	B-X
blue	B-X
staining	B-X
is	B-X
therefore	B-X
a	B-X
convenient	B-X
assay	B-X
for	B-X
rapidly	B-X
determining	B-X
the	B-X
overall	B-X
viability	B-X
of	B-X
cells	B-X
in	B-X
a	B-X
culture	B-X
before	B-X
commencing	B-X
scientific	B-X
experimentation	B-X
,	B-X
or	B-X
for	B-X
quantitating	B-X
cell	B-X
death	B-X
following	B-X
treatment	B-X
with	B-X
any	B-X
cytotoxic	B-X
stimuli	B-X
.	B-X

Apoptosis	O
was	O
measured	O
using	O
a	O
kit	O
(	O
BD	O
Biosciences	O
)	O
containing	O
propidium	O
iodide	O
(	O
PI	O
)	O
and	O
FITC	O
-	O
conjugated	O
annexin	O
V	O
.	O

Cells	O
were	O
stained	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
and	O
the	O
level	O
of	O
apoptosis	O
determined	O
by	O
flow	O
cytometry	O
.	O

Quadrants	O
are	O
:	O
early	O
apoptosis	O
(	O
annexin	O
V	O
+	O
/	O
PI	O
-	O
,	O
lower	O
right	O
)	O
late	O
apoptosis	O
(	O
annexin	O
V	O
+	O
/	O
PI	O
+	O
,	O
upper	O
right	O
)	O
and	O
non	O
-	O
apoptotic	O
cell	O
death	O
(	O
annexin	O
V	O
-	O
/	O
PI	O
+	O
,	O
upper	O
left	O
)	O
.	O

Treatments	O
for	O
the	O
stress	O
panel	O
were	O
:	O
no	O
treatment	O
(	O
control	O
)	O
;	O
DMSO	O
as	O
a	O
control	O
for	O
celecoxib	O
;	O
20	O
mM	O
celecoxib	O
,	O
brand	O
name	O
Celebrex	O
(TM)	O
(	O
dissolved	O
in	O
DMSO	O
)	O
[	O
31	O
]	O
;	O
0	O
.	O
2	O
mM	O
H2O2	O
[	O
32	O
]	O
;	O
or	O
1	O
mg	O
/	O
mL	O
G418	O
(	O
Pfizer	O
,	O
New	O
York	O
,	O
NY	O
,	O
USA	O
)	O
.	O
<EOS>	B-X
Enhanced	B-X
Recovery	B-X
After	B-X
Surgery	B-X
(	B-X
ERAS	B-X
)	B-X
is	B-X
a	B-X
multimodal	B-X
,	B-X
evidence-based	B-X
,	B-X
program	B-X
of	B-X
care	B-X
developed	B-X
to	B-X
minimize	B-X
the	B-X
response	B-X
to	B-X
surgical	B-X
stress	B-X
,	B-X
associated	B-X
with	B-X
reduced	B-X
perioperative	B-X
morbidity	B-X
and	B-X
hospital	B-X
stay	B-X
.	B-X
An	B-X
international	B-X
consensus	B-X
panel	B-X
recommended	B-X
a	B-X
consistent	B-X
set	B-X
of	B-X
guidelines	B-X
in	B-X
2003	B-X
based	B-X
on	B-X
American	B-X
Diabetes	B-X
Association	B-X
glucose	B-X
criteria	B-X
but	B-X
did	B-X
not	B-X
exclude	B-X
the	B-X
immediate	B-X
post-transplant	B-X
hospitalization	B-X
when	B-X
many	B-X
patients	B-X
receive	B-X
large	B-X
doses	B-X
of	B-X
corticosteroids	B-X
.	B-X
As	B-X
a	B-X
result	B-X
,	B-X
the	B-X
international	B-X
consensus	B-X
panel	B-X
reviewed	B-X
its	B-X
earlier	B-X
guidelines	B-X
and	B-X
recommended	B-X
delaying	B-X
screening	B-X
and	B-X
diagnosis	B-X
of	B-X
PTDM	B-X
until	B-X
the	B-X
recipient	B-X
is	B-X
on	B-X
stable	B-X
doses	B-X
of	B-X
immunosuppression	B-X
after	B-X
discharge	B-X
from	B-X
initial	B-X
transplant	B-X
hospitalization	B-X
.	B-X
The	B-X
group	B-X
cautioned	B-X
that	B-X
whereas	B-X
hemoglobin	B-X
A1C	B-X
has	B-X
been	B-X
adopted	B-X
as	B-X
a	B-X
diagnostic	B-X
criterion	B-X
by	B-X
many	B-X
,	B-X
it	B-X
is	B-X
not	B-X
reliable	B-X
as	B-X
the	B-X
sole	B-X
diabetes	B-X
screening	B-X
method	B-X
during	B-X
the	B-X
first	B-X
year	B-X
after	B-X
transplant	B-X
.	B-X
Risk	B-X
factors	B-X
for	B-X
PTDM	B-X
include	B-X
many	B-X
of	B-X
the	B-X
immunosuppressant	B-X
medications	B-X
themselves	B-X
as	B-X
well	B-X
as	B-X
those	B-X
for	B-X
type	B-X
2	B-X
diabetes	B-X
.	B-X

Real	O
-	O
time	O
PCR	O
arrays	O
<EOS>	B-X
Real-time	B-X
quantitative	B-X
PCR	B-X
is	B-X
a	B-X
technique	B-X
used	B-X
to	B-X
monitor	B-X
the	B-X
PCR	B-X
reaction	B-X
in	B-X
real	B-X
time	B-X
.	B-X
RT-qPCR	B-X
is	B-X
broadly	B-X
classified	B-X
into	B-X
two	B-X
types	B-X
based	B-X
on	B-X
its	B-X
purpose	B-X
:	B-X
absolute	B-X
and	B-X
relative	B-X
quantification	B-X
.	B-X
A	B-X
laboratory	B-X
work	B-X
that	B-X
covers	B-X
the	B-X
basic	B-X
principles	B-X
involved	B-X
in	B-X
RT-qPCR	B-X
and	B-X
data	B-X
analysis	B-X
using	B-X
the	B-X
manual	B-X
as	B-X
well	B-X
as	B-X
the	B-X
software	B-X
methods	B-X
are	B-X
incorporated	B-X
.	B-X
The	B-X
laboratory	B-X
experiment	B-X
was	B-X
designed	B-X
to	B-X
provide	B-X
insights	B-X
on	B-X
certain	B-X
important	B-X
principles	B-X
such	B-X
as	B-X
primer	B-X
characteristics	B-X
,	B-X
PCR	B-X
efficiency	B-X
,	B-X
and	B-X
melt	B-X
curve	B-X
analysis	B-X
.	B-X
This	B-X
laboratory	B-X
exercise	B-X
provides	B-X
all	B-X
the	B-X
significant	B-X
components	B-X
of	B-X
RT-qPCR	B-X
,	B-X
which	B-X
can	B-X
be	B-X
useful	B-X
while	B-X
performing	B-X
an	B-X
experiment	B-X
in	B-X
an	B-X
undergraduate	B-X
and	B-X
graduate	B-X
laboratory	B-X
.	B-X

Transcriptional	O
analysis	O
using	O
Cancer	O
PathwayFinder	O
RT2	O
profiler	O
arrays	O
(	O
SuperArray	O
,	O
Frederick	O
,	O
MD	O
,	O
USA	O
)	O
was	O
performed	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Briefly	O
,	O
total	O
RNA	O
was	O
isolated	O
using	O
an	O
RNeasy	O
extraction	O
kit	O
(	O
Qiagen	O
,	O
Valencia	O
,	O
CA	O
,	O
USA	O
)	O
;	O
1	O
mu	O
g	O
of	O
RNA	O
was	O
reverse	O
transcribed	O
with	O
the	O
cDNA	O
synthesis	O
kit	O
(	O
SuperArray	O
)	O
and	O
cDNA	O
was	O
subjected	O
to	O
real	O
-	O
time	O
PCR	O
using	O
SYBR	O
green	O
to	O
detect	O
product	O
.	O

Arrays	O
were	O
performed	O
independently	O
at	O
least	O
twice	O
for	O
each	O
cell	O
line	O
;	O
all	O
PCR	O
products	O
were	O
checked	O
on	O
agarose	O
gels	O
.	O
<EOS>	B-X
The	B-X
options	B-X
for	B-X
first-line	B-X
treatment	B-X
of	B-X
advanced	B-X
oesophageal	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
are	B-X
scarce	B-X
,	B-X
and	B-X
the	B-X
outcomes	B-X
remain	B-X
poor	B-X
.	B-X
The	B-X
anti-PD-1	B-X
antibody	B-X
,	B-X
tislelizumab	B-X
,	B-X
has	B-X
shown	B-X
antitumour	B-X
activity	B-X
in	B-X
previously	B-X
treated	B-X
patients	B-X
with	B-X
advanced	B-X
oesophageal	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
.	B-X
We	B-X
report	B-X
interim	B-X
analysis	B-X
results	B-X
from	B-X
the	B-X
RATIONALE-306	B-X
study	B-X
,	B-X
which	B-X
aimed	B-X
to	B-X
assess	B-X
tislelizumab	B-X
plus	B-X
chemotherapy	B-X
versus	B-X
placebo	B-X
plus	B-X
chemotherapy	B-X
as	B-X
first-line	B-X
treatment	B-X
for	B-X
advanced	B-X
or	B-X
metastatic	B-X
oesophageal	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
.	B-X

Values	O
were	O
obtained	O
for	O
the	O
threshold	O
cycle	O
(	O
Ct	O
)	O
for	O
each	O
gene	O
and	O
normalized	O
using	O
the	O
average	O
of	O
four	O
housekeeping	O
genes	O
on	O
the	O
same	O
array	O
(	O
HPRT1	O
,	O
RPL13A	O
,	O
GAPD	O
,	O
ACTB	O
)	O
.	O

Ct	O
values	O
for	O
housekeeping	O
genes	O
and	O
a	O
dilution	O
series	O
of	O
ACTB	O
were	O
monitored	O
for	O
consistency	O
between	O
arrays	O
.	O

Change	O
(	O
Delta	O
Ct	O
)	O
between	O
MUC1	O
siRNA	O
and	O
control	O
siRNA	O
was	O
found	O
by	O
:	O

Delta	O
Ct	O
=	O
Ct	O
(	O
MUC1	O
siRNA	O
)	O
-	O
Ct	O
(	O
control	O
siRNA	O
)	O

and	O
fold	O
change	O
by	O
:	O
<EOS>	B-X
We	B-X
conducted	B-X
a	B-X
systematic	B-X
review	B-X
to	B-X
describe	B-X
dynamic	B-X
changes	B-X
in	B-X
LUS	B-X
findings	B-X
of	B-X
pulmonary	B-X
congestion	B-X
(	B-X
B-lines	B-X
)	B-X
in	B-X
HF	B-X
and	B-X
to	B-X
examine	B-X
the	B-X
prognostic	B-X
utility	B-X
of	B-X
B-lines	B-X
in	B-X
HF	B-X
.	B-X
Standing	B-X
genetic	B-X
variation	B-X
enables	B-X
or	B-X
restricts	B-X
a	B-X
population	B-X
's	B-X
capacity	B-X
to	B-X
respond	B-X
to	B-X
changing	B-X
conditions	B-X
,	B-X
including	B-X
the	B-X
extreme	B-X
disturbances	B-X
expected	B-X
to	B-X
increase	B-X
in	B-X
frequency	B-X
and	B-X
intensity	B-X
with	B-X
continuing	B-X
anthropogenic	B-X
climate	B-X
change	B-X
.	B-X
However	B-X
,	B-X
we	B-X
know	B-X
little	B-X
about	B-X
how	B-X
populations	B-X
might	B-X
respond	B-X
to	B-X
extreme	B-X
events	B-X
with	B-X
rapid	B-X
genetic	B-X
shifts	B-X
,	B-X
or	B-X
how	B-X
population	B-X
dynamics	B-X
may	B-X
influence	B-X
and	B-X
be	B-X
influenced	B-X
by	B-X
population	B-X
genomic	B-X
change	B-X
.	B-X
This	B-X
article	B-X
reviews	B-X
the	B-X
three	B-X
breast	B-X
dimensions	B-X
and	B-X
how	B-X
they	B-X
can	B-X
be	B-X
changed	B-X
.	B-X

Fold	O
change	O
=	O
2	O
(	O
-	O
Delta	O
Ct	O
)	O
<EOS>	B-X
SARS-CoV-2	B-X
evolves	B-X
rapidly	B-X
in	B-X
part	B-X
because	B-X
of	B-X
its	B-X
high	B-X
mutation	B-X
rate	B-X
.	B-X
Here	B-X
we	B-X
examine	B-X
whether	B-X
this	B-X
mutational	B-X
process	B-X
itself	B-X
has	B-X
changed	B-X
during	B-X
viral	B-X
evolution	B-X
.	B-X
To	B-X
do	B-X
this	B-X
,	B-X
we	B-X
quantify	B-X
the	B-X
relative	B-X
rates	B-X
of	B-X
different	B-X
types	B-X
of	B-X
single	B-X
nucleotide	B-X
mutations	B-X
at	B-X
four-fold	B-X
degenerate	B-X
sites	B-X
in	B-X
the	B-X
viral	B-X
genome	B-X
across	B-X
millions	B-X
of	B-X
human	B-X
SARS-CoV-2	B-X
sequences	B-X
.	B-X
We	B-X
find	B-X
clear	B-X
shifts	B-X
in	B-X
the	B-X
relative	B-X
rates	B-X
of	B-X
several	B-X
types	B-X
of	B-X
mutations	B-X
during	B-X
SARS-CoV-2	B-X
evolution	B-X
.	B-X
The	B-X
most	B-X
striking	B-X
trend	B-X
is	B-X
a	B-X
roughly	B-X
two-fold	B-X
decrease	B-X
in	B-X
the	B-X
relative	B-X
rate	B-X
of	B-X
GâT	B-X
mutations	B-X
in	B-X
Omicron	B-X
versus	B-X
early	B-X
clades	B-X
,	B-X
as	B-X
was	B-X
recently	B-X
noted	B-X
by	B-X
Ruis	B-X
et	B-X
al	B-X
(	B-X
2022	B-X
)	B-X
.	B-X
There	B-X
is	B-X
also	B-X
a	B-X
decrease	B-X
in	B-X
the	B-X
relative	B-X
rate	B-X
of	B-X
CâT	B-X
mutations	B-X
in	B-X
Delta	B-X
,	B-X
and	B-X
other	B-X
subtle	B-X
changes	B-X
in	B-X
the	B-X
mutation	B-X
spectrum	B-X
along	B-X
the	B-X
phylogeny	B-X
.	B-X
We	B-X
speculate	B-X
that	B-X
these	B-X
changes	B-X
in	B-X
the	B-X
mutation	B-X
spectrum	B-X
could	B-X
arise	B-X
from	B-X
viral	B-X
mutations	B-X
that	B-X
affect	B-X
genome	B-X
replication	B-X
,	B-X
packaging	B-X
,	B-X
and	B-X
antagonization	B-X
of	B-X
host	B-X
innate-immune	B-X
factors-although	B-X
environmental	B-X
factors	B-X
could	B-X
also	B-X
play	B-X
a	B-X
role	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
mutation	B-X
spectrum	B-X
of	B-X
Omicron	B-X
is	B-X
more	B-X
similar	B-X
than	B-X
that	B-X
of	B-X
earlier	B-X
SARS-CoV-2	B-X
clades	B-X
to	B-X
the	B-X
spectrum	B-X
that	B-X
shaped	B-X
the	B-X
long-term	B-X
evolution	B-X
of	B-X
sarbecoviruses	B-X
.	B-X
Overall	B-X
,	B-X
our	B-X
work	B-X
shows	B-X
that	B-X
the	B-X
mutation	B-X
process	B-X
is	B-X
itself	B-X
a	B-X
dynamic	B-X
variable	B-X
during	B-X
SARS-CoV-2	B-X
evolution	B-X
,	B-X
and	B-X
suggests	B-X
that	B-X
human	B-X
SARS-CoV-2	B-X
may	B-X
be	B-X
trending	B-X
towards	B-X
a	B-X
mutation	B-X
spectrum	B-X
more	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
other	B-X
animal	B-X
sarbecoviruses	B-X
.	B-X

Values	O
are	O
given	O
as	O
fold	O
change	O
;	O
only	O
genes	O
showing	O
two	O
-	O
fold	O
or	O
greater	O
change	O
were	O
considered	O
.	O
<EOS>	B-X
Differential	B-X
expression	B-X
of	B-X
microRNAs	B-X
(	B-X
miRNAs	B-X
)	B-X
has	B-X
been	B-X
reported	B-X
separately	B-X
in	B-X
people	B-X
with	B-X
obesity	B-X
and	B-X
sarcopenia	B-X
and	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
sarcopenic	B-X
obesity	B-X
.	B-X
We	B-X
performed	B-X
a	B-X
systematic	B-X
review	B-X
on	B-X
Embase	B-X
and	B-X
MEDLINE	B-X
(	B-X
PROSPERO	B-X
,	B-X
CRD42020224486	B-X
)	B-X
for	B-X
differentially	B-X
expressed	B-X
miRNAs	B-X
(	B-X
fold	B-X
change	B-X
>	B-X
1.5	B-X
or	B-X
P-value	B-X
<	B-X
0.05	B-X
)	B-X
in	B-X
(	B-X
i	B-X
)	B-X
sarcopenia	B-X
or	B-X
frailty	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
obesity	B-X
or	B-X
metabolic	B-X
syndrome	B-X
.	B-X
The	B-X
functions	B-X
and	B-X
targets	B-X
of	B-X
miRNAs	B-X
commonly	B-X
changed	B-X
in	B-X
both	B-X
conditions	B-X
,	B-X
in	B-X
the	B-X
same	B-X
direction	B-X
,	B-X
were	B-X
searched	B-X
using	B-X
PubMed	B-X
.	B-X
Twenty-four	B-X
miRNAs	B-X
were	B-X
identified	B-X
from	B-X
10	B-X
of	B-X
the	B-X
included	B-X
studies	B-X
as	B-X
commonly	B-X
changed	B-X
in	B-X
the	B-X
same	B-X
direction	B-X
(	B-X
22	B-X
in	B-X
plasma	B-X
and	B-X
one	B-X
each	B-X
in	B-X
serum	B-X
and	B-X
skeletal	B-X
muscle	B-X
)	B-X
in	B-X
obesity	B-X
and	B-X
sarcopenia	B-X
.	B-X
The	B-X
majority	B-X
of	B-X
commonly	B-X
changed	B-X
miRNAs	B-X
were	B-X
involved	B-X
in	B-X
protein	B-X
homeostasis	B-X
,	B-X
mitochondrial	B-X
dynamics	B-X
,	B-X
determination	B-X
of	B-X
muscle	B-X
fibre	B-X
type	B-X
,	B-X
insulin	B-X
resistance	B-X
,	B-X
and	B-X
adipogenesis	B-X
.	B-X
Twenty-four	B-X
miRNAs	B-X
were	B-X
identified	B-X
as	B-X
commonly	B-X
dysregulated	B-X
in	B-X
obesity	B-X
and	B-X
sarcopenia	B-X
with	B-X
functions	B-X
and	B-X
targets	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
sarcopenic	B-X
obesity	B-X
.	B-X
Given	B-X
the	B-X
adverse	B-X
health	B-X
outcomes	B-X
associated	B-X
with	B-X
sarcopenic	B-X
obesity	B-X
,	B-X
understanding	B-X
the	B-X
pathogenesis	B-X
underlying	B-X
this	B-X
phenotype	B-X
has	B-X
the	B-X
potential	B-X
to	B-X
lead	B-X
to	B-X
effective	B-X
screening	B-X
,	B-X
monitoring	B-X
,	B-X
or	B-X
treatment	B-X
strategies	B-X
.	B-X

Both	O
luciferase	O
and	O
scrambled	O
siRNA	O
controls	O
were	O
used	O
in	O
BT	O
-	O
20	O
;	O
only	O
genes	O
showing	O
consistent	O
alteration	O
with	O
both	O
controls	O
were	O
included	O
in	O
the	O
results	O
reported	O
here	O
.	O

The	O
scrambled	O
siRNA	O
could	O
be	O
not	O
used	O
in	O
MDA	O
-	O
MB	O
-	O
468	O
as	O
these	O
cells	O
decrease	O
MUC1	O
expression	O
in	O
response	O
to	O
this	O
construct	O
.	O
<EOS>	B-X
To	B-X
study	B-X
the	B-X
expression	B-X
patterns	B-X
of	B-X
long	B-X
noncoding	B-X
RNA	B-X
(	B-X
lncRNA	B-X
)	B-X
colon	B-X
cancer-associated	B-X
transcript	B-X
1	B-X
(	B-X
CCAT1	B-X
)	B-X
and	B-X
the	B-X
changes	B-X
in	B-X
cell	B-X
proliferation	B-X
,	B-X
apoptosis	B-X
,	B-X
migration	B-X
and	B-X
invasion	B-X
induced	B-X
by	B-X
silencing	B-X
CCAT1	B-X
in	B-X
bladder	B-X
cancer	B-X
cells	B-X
.	B-X
Hepatic	B-X
fibrosis	B-X
is	B-X
a	B-X
wound	B-X
healing	B-X
response	B-X
that	B-X
results	B-X
in	B-X
excessive	B-X
extracellular	B-X
matrix	B-X
(	B-X
ECM	B-X
)	B-X
accumulation	B-X
in	B-X
response	B-X
to	B-X
chronic	B-X
hepatic	B-X
injury	B-X
.	B-X
Exosomes	B-X
are	B-X
extracellular	B-X
vesicles	B-X
generated	B-X
by	B-X
all	B-X
cell	B-X
types	B-X
with	B-X
a	B-X
capacity	B-X
to	B-X
efficiently	B-X
enter	B-X
cells	B-X
across	B-X
different	B-X
biological	B-X
barriers	B-X
.	B-X
Exosomes	B-X
derived	B-X
from	B-X
clinical	B-X
grade	B-X
fibroblast-like	B-X
mesenchymal	B-X
stem	B-X
cells	B-X
(	B-X
MSCs	B-X
)	B-X
were	B-X
engineered	B-X
to	B-X
carry	B-X
siRNA	B-X
or	B-X
antisense	B-X
oligonucleotide	B-X
(	B-X
ASO	B-X
)	B-X
targeting	B-X
STAT3	B-X
(	B-X
iExo	B-X

Results	O

siRNA	O
transfection	O
decreases	O
MUC1	O
expression	O
in	O
breast	O
cancer	O
cell	O
lines	O
<EOS>	B-X
MUC1	B-X
is	B-X
an	B-X
oncoprotein	B-X
whose	B-X
overexpression	B-X
correlates	B-X
with	B-X
aggressiveness	B-X
of	B-X
tumors	B-X
and	B-X
poor	B-X
survival	B-X
of	B-X
cancer	B-X
patients	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
oncogenic	B-X
effects	B-X
of	B-X
MUC1	B-X
are	B-X
believed	B-X
to	B-X
occur	B-X
through	B-X
interaction	B-X
of	B-X
its	B-X
cytoplasmic	B-X
tail	B-X
with	B-X
signaling	B-X
molecules	B-X
.	B-X
As	B-X
expected	B-X
for	B-X
a	B-X
protein	B-X
with	B-X
oncogenic	B-X
functions	B-X
,	B-X
MUC1	B-X
is	B-X
linked	B-X
to	B-X
regulation	B-X
of	B-X
proliferation	B-X
,	B-X
apoptosis	B-X
,	B-X
invasion	B-X
,	B-X
and	B-X
transcription	B-X
.	B-X
A	B-X
good	B-X
correlation	B-X
between	B-X
the	B-X
expression	B-X
of	B-X
mucin1	B-X
(	B-X
MUC1	B-X
)	B-X
and	B-X
T	B-X
antigen	B-X
was	B-X
found	B-X
in	B-X
breast	B-X
cancer	B-X
tumors	B-X
and	B-X
breast	B-X
cancer	B-X
cell	B-X
lines	B-X
,	B-X
especially	B-X
after	B-X
treatment	B-X
with	B-X
neuraminidase	B-X
.	B-X
The	B-X
association	B-X
between	B-X
the	B-X
appearance	B-X
of	B-X
T	B-X
antigen	B-X
and	B-X
the	B-X
overexpression	B-X
of	B-X
MUC1	B-X
was	B-X
further	B-X
confirmed	B-X
by	B-X
transfecting	B-X
MDA-MB-231	B-X
cells	B-X
and	B-X
murine	B-X
4T1	B-X
mammary	B-X
carcinoma	B-X
cells	B-X
with	B-X
cDNA	B-X
for	B-X
MUC1	B-X
and	B-X
using	B-X
an	B-X
RNAi	B-X
approach	B-X
to	B-X
inhibit	B-X
the	B-X
expression	B-X
of	B-X
MUC1	B-X
gene	B-X
in	B-X
T47D	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
discovered	B-X
that	B-X
in	B-X
4T1	B-X
cells	B-X
which	B-X
express	B-X
the	B-X
sialyl	B-X
Le	B-X
(	B-X
X	B-X
)	B-X
antigen	B-X
,	B-X
overexpression	B-X
of	B-X
MUC1	B-X
caused	B-X
not	B-X
only	B-X
appearance	B-X
of	B-X
T	B-X
antigen	B-X
,	B-X
but	B-X
also	B-X
loss	B-X
of	B-X
the	B-X
sialyl	B-X
Le	B-X
(	B-X
X	B-X
)	B-X
structure	B-X
.	B-X
As	B-X
the	B-X
observed	B-X
changes	B-X
in	B-X
O-glycan	B-X
synthesis	B-X
can	B-X
be	B-X
associated	B-X
with	B-X
changes	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
specific	B-X
glycosyltransferases	B-X
,	B-X
core	B-X
1	B-X
Î²1,3-galactosyltransferase	B-X
,	B-X
core	B-X
2	B-X
Î²1,6-N-acetylglucosaminyltransferase	B-X
(	B-X
C2GnT1	B-X
)	B-X
and	B-X
Î²-galactoside	B-X
Î±2,3-sialyltransferase	B-X
(	B-X
ST3Gal	B-X
I	B-X
)	B-X
,	B-X
we	B-X
studied	B-X
their	B-X
expression	B-X
in	B-X
parental	B-X
,	B-X
vector-transfected	B-X
and	B-X
MUC1-transfected	B-X
MDA-MB-231	B-X
and	B-X
4T1	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
T47D	B-X
cells	B-X
transduced	B-X
with	B-X
small	B-X
hairpin	B-X
RNA	B-X
targeted	B-X
MUC1	B-X
mRNA	B-X
.	B-X
It	B-X
was	B-X
found	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
C2GnT1	B-X
and	B-X
ST3Gal	B-X
I	B-X
is	B-X
highly	B-X
decreased	B-X
in	B-X
MUC1-expressing	B-X
MDA-MB-231	B-X
and	B-X
4T1	B-X
cells	B-X
and	B-X
increased	B-X
in	B-X
T47D	B-X
cells	B-X
with	B-X
suppressed	B-X
expression	B-X
of	B-X
MUC1	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
found	B-X
that	B-X
changes	B-X
in	B-X
the	B-X
structure	B-X
of	B-X
O-linked	B-X
oligosaccharides	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
occurrence	B-X
of	B-X
T	B-X
antigen	B-X
,	B-X
are	B-X
at	B-X
least	B-X
partially	B-X
associated	B-X
with	B-X
MUC1	B-X
overexpression	B-X
which	B-X
down-regulates	B-X
the	B-X
expression	B-X
of	B-X
C2GnT1	B-X
and	B-X
ST3Gal	B-X
I	B-X
.	B-X
We	B-X
showed	B-X
also	B-X
that	B-X
the	B-X
overexpression	B-X
of	B-X
MUC1	B-X
in	B-X
4T1	B-X
cells	B-X
changes	B-X
their	B-X
adhesive	B-X
properties	B-X
,	B-X
as	B-X
MUC1-expressing	B-X
cells	B-X
do	B-X
not	B-X
adhere	B-X
to	B-X
E-selectin	B-X
,	B-X
but	B-X
bind	B-X
galectin-3	B-X
.	B-X

Two	O
human	B-Species
breast	O
cancer	O
cell	O
lines	O
,	O
MDA	O
-	O
MB	O
-	O
468	O
and	O
BT	O
-	O
20	O
,	O
were	O
transiently	O
transfected	O
with	O
a	O
pool	O
of	O
four	O
siRNA	O
oligonucleotides	O
directed	O
against	O
the	O
MUC1	O
mRNA	O
(	O
468	O
.	O
siMUC1	O
and	O
BT	O
.	O
siMUC1	O
)	O
,	O
or	O
a	O
control	O
oligonucleotide	O
directed	O
against	O
luciferase	O
(	O
468	O
.	O
siLuc	O
and	O
BT	O
.	O
siLuc	O
)	O
.	O

Both	O
cell	O
lines	O
express	O
high	O
levels	O
of	O
MUC1	O
,	O
making	O
them	O
promising	O
targets	O
for	O
this	O
analysis	O
.	O

Western	O
blots	O
(	O
Figure	O
1a	O
)	O
show	O
successful	O
knockdown	O
of	O
both	O
the	O
extracellular	O
domain	O
and	O
cytoplasmic	O
tail	O
fragments	O
of	O
MUC1	O
;	O
luciferase	O
siRNA	O
does	O
not	O
substantially	O
change	O
the	O
level	O
of	O
MUC1	O
compared	O
to	O
parental	O
cells	O
.	O

468	O
.	O
siMUC1	O
show	O
a	O
substantial	O
decrease	O
in	O
the	O
amount	O
of	O
MUC1	O
-	O
CT	O
,	O
while	O
BT	O
.	O
siMUC1	O
show	O
slightly	O
less	O
knockdown	O
of	O
MUC1	O
-	O
CT	O
.	O

Both	O
MDA	O
-	O
MB	O
-	O
468	O
and	O
BT	O
-	O
20	O
display	O
a	O
less	O
dramatic	O
decrease	O
of	O
MUC1	O
extracellular	O
domain	O
compared	O
to	O
MUC1	O
-	O
CT	O
(	O
Figure	O
1a	O
)	O
;	O
this	O
likely	O
represents	O
protein	O
synthesized	O
prior	O
to	O
transfection	O
,	O
and	O
may	O
reflect	O
differences	O
in	O
the	O
turnover	O
rates	O
of	O
the	O
two	O
subunits	O
.	O

Analysis	O
of	O
the	O
MUC1	O
extracellular	O
domain	O
by	O
flow	O
cytometry	O
confirms	O
that	O
both	O
cell	O
lines	O
substantially	O
decrease	O
MUC1	O
expression	O
after	O
siRNA	O
(	O
Figure	O
1b	O
)	O
.	O

By	O
flow	O
cytometry	O
,	O
468	O
.	O
siMUC1	O
averaged	O
75	O
%	O
knockdown	O
of	O
MUC1	O
compared	O
to	O
468	O
.	O
siLuc	O
;	O
and	O
BT	O
.	O
siMUC1	O
averaged	O
50	O
%	O
knockdown	O
relative	O
to	O
BT	O
.	O
siLuc	O
.	O

These	O
effects	O
could	O
be	O
titrated	O
with	O
the	O
concentration	O
of	O
siRNA	O
,	O
were	O
seen	O
as	O
early	O
as	O
24	O
hours	O
post	O
-	O
transfection	O
(	O
data	O
not	O
shown	O
)	O
and	O
lasted	O
to	O
at	O
least	O
96	O
h	O
post	O
-	O
transfection	O
(	O
Figure	O
1b	O
)	O
.	O

All	O
experiments	O
were	O
conducted	O
within	O
48	O
to	O
96	O
hours	O
after	O
siRNA	O
transfection	O
.	O
<EOS>	B-X
[	B-X
Receptor	B-X
pathways	B-X
of	B-X
glycated	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor	B-X
affecting	B-X
the	B-X
proliferation	B-X
and	B-X
vascularization	B-X
of	B-X
human	B-X
dermal	B-X
microvascular	B-X
endothelial	B-X
cells	B-X
]	B-X
.	B-X

Similar	O
results	O
were	O
obtained	O
using	O
two	O
independent	O
oligonucleotides	O
designed	O
in	O
our	O
lab	O
(	O
data	O
not	O
shown	O
)	O
,	O
designated	O
'	O
882	O
'	O
and	O
'	O
956	O
'	O
for	O
the	O
initial	O
codon	O
recognized	O
by	O
each	O
.	O

Transcriptional	O
changes	O
are	O
seen	O
after	O
MUC1	O
siRNA	O
<EOS>	B-X
MUC1	B-X
is	B-X
an	B-X
oncoprotein	B-X
whose	B-X
overexpression	B-X
correlates	B-X
with	B-X
aggressiveness	B-X
of	B-X
tumors	B-X
and	B-X
poor	B-X
survival	B-X
of	B-X
cancer	B-X
patients	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
oncogenic	B-X
effects	B-X
of	B-X
MUC1	B-X
are	B-X
believed	B-X
to	B-X
occur	B-X
through	B-X
interaction	B-X
of	B-X
its	B-X
cytoplasmic	B-X
tail	B-X
with	B-X
signaling	B-X
molecules	B-X
.	B-X
As	B-X
expected	B-X
for	B-X
a	B-X
protein	B-X
with	B-X
oncogenic	B-X
functions	B-X
,	B-X
MUC1	B-X
is	B-X
linked	B-X
to	B-X
regulation	B-X
of	B-X
proliferation	B-X
,	B-X
apoptosis	B-X
,	B-X
invasion	B-X
,	B-X
and	B-X
transcription	B-X
.	B-X
Remarkably	B-X
,	B-X
despite	B-X
prominent	B-X
changes	B-X
in	B-X
cell	B-X
morphology	B-X
and	B-X
BST	B-X
marker	B-X
expression	B-X
,	B-X
we	B-X
show	B-X
using	B-X
inducible	B-X
model	B-X
systems	B-X
that	B-X
c-FOS-mediated	B-X
BST	B-X
demonstrates	B-X
reversibility	B-X
.	B-X

Recent	O
work	O
indicates	O
that	O
MUC1	O
may	O
affect	O
transcription	O
both	O
directly	O
via	O
interaction	O
with	O
transcription	O
factors	O
and	O
indirectly	O
(	O
for	O
example	O
,	O
through	O
modulating	O
signaling	O
)	O
.	O

To	O
study	O
the	O
effects	O
of	O
MUC1	O
knockdown	O
in	O
breast	O
cancer	O
cell	O
lines	O
,	O
real	O
-	O
time	O
PCR	O
arrays	O
were	O
used	O
to	O
analyze	O
transcription	O
of	O
84	O
genes	O
implicated	O
in	O
cancer	O
.	O

Only	O
genes	O
with	O
greater	O
than	O
two	O
-	O
fold	O
change	O
were	O
considered	O
.	O
<EOS>	B-X
Radiotherapy	B-X
with	B-X
heavy	B-X
ions	B-X
is	B-X
considered	B-X
advantageous	B-X
compared	B-X
to	B-X
irradiation	B-X
with	B-X
photons	B-X
due	B-X
to	B-X
the	B-X
characteristics	B-X
of	B-X
the	B-X
Braggs	B-X
peak	B-X
and	B-X
the	B-X
high	B-X
linear	B-X
energy	B-X
transfer	B-X
(	B-X
LET	B-X
)	B-X
value	B-X
.	B-X
To	B-X
understand	B-X
the	B-X
mechanisms	B-X
of	B-X
cellular	B-X
responses	B-X
to	B-X
different	B-X
LET	B-X
values	B-X
and	B-X
dosages	B-X
of	B-X
heavy	B-X
ion	B-X
radiation	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
proteomic	B-X
profiles	B-X
of	B-X
mouse	B-X
embryo	B-X
fibroblast	B-X
MEF	B-X
cells	B-X
exposed	B-X
to	B-X
two	B-X
doses	B-X
from	B-X
different	B-X
LET	B-X
values	B-X
of	B-X
heavy	B-X
ion	B-X
12C	B-X
.	B-X
Using	B-X
bioinformatics	B-X
approaches	B-X
,	B-X
differentially	B-X
expressed	B-X
proteins	B-X
with	B-X
1.5	B-X
or	B-X
2.0-fold	B-X
changes	B-X
between	B-X
different	B-X
dosages	B-X
of	B-X
exposure	B-X
were	B-X
compared	B-X
.	B-X
For	B-X
instance	B-X
,	B-X
compared	B-X
to	B-X
the	B-X
control	B-X
(	B-X
0	B-X
Gy	B-X
)	B-X
,	B-X
771	B-X
(	B-X
20.2	B-X
%	B-X
)	B-X
proteins	B-X
in	B-X
cells	B-X
irradiated	B-X
at	B-X
0.2	B-X
Gy	B-X
of	B-X
carbon-ion	B-X
radiation	B-X
with	B-X
12.6	B-X
keV/Î¼m	B-X
,	B-X
313	B-X
proteins	B-X
(	B-X
8.2	B-X
%	B-X
)	B-X
in	B-X
cells	B-X
irradiated	B-X
at	B-X
2	B-X
Gy	B-X
of	B-X
carbon-ion	B-X
radiation	B-X
with	B-X
12.6	B-X
keV/Î¼m	B-X
,	B-X
and	B-X
243	B-X
proteins	B-X
(	B-X
6.4	B-X
%	B-X
)	B-X
in	B-X
cells	B-X
irradiated	B-X
at	B-X
2	B-X
Gy	B-X
of	B-X
carbon-ion	B-X
radiation	B-X
with	B-X
31.5	B-X
keV/Î¼m	B-X
exhibited	B-X
changes	B-X
of	B-X
1.5-fold	B-X
or	B-X
greater	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
network	B-X
analysis	B-X
revealed	B-X
that	B-X
cellular	B-X
pathways	B-X
involving	B-X
proteins	B-X
such	B-X
as	B-X
Col1a1	B-X
and	B-X
Fn1	B-X
continued	B-X
to	B-X
respond	B-X
to	B-X
high	B-X
dosages	B-X
of	B-X
heavy-ion	B-X
irradiation	B-X
,	B-X
suggesting	B-X
that	B-X
these	B-X
pathways	B-X
still	B-X
protect	B-X
cells	B-X
against	B-X
damage	B-X
.	B-X
However	B-X
,	B-X
pathways	B-X
such	B-X
as	B-X
those	B-X
involving	B-X
Ikbkg1	B-X
responded	B-X
better	B-X
at	B-X
lower	B-X
dosages	B-X
than	B-X
at	B-X
higher	B-X
dosages	B-X
,	B-X
implying	B-X
that	B-X
cell	B-X
damage	B-X
would	B-X
occur	B-X
when	B-X
the	B-X
networks	B-X
involving	B-X
these	B-X
proteins	B-X
stop	B-X
responding	B-X
.	B-X

Three	O
genes	O
(	O
MAP2K1	O
,	O
VEGF	O
,	O
PDGFA	O
)	O
were	O
altered	O
two	O
-	O
fold	O
or	O
more	O
after	O
MUC1	O
siRNA	O
in	O
both	O
MDA	O
-	O
MB	O
-	O
468	O
and	O
BT	O
-	O
20	O
cells	O
(	O
Figure	O
2	O
)	O
;	O
two	O
genes	O
(	O
ITGAV	O
,	O
MMP2	O
)	O
changed	O
only	O
in	O
468	O
.	O
siMUC1	O
;	O
and	O
five	O
genes	O
(	O
TIMP3	O
,	O
RAF1	O
,	O
JUN	O
,	O
TNF	O
,	O
CDC25A	O
)	O
only	O
in	O
BT	O
.	O
siMUC1	O
.	O

This	O
list	O
represents	O
all	O
genes	O
affected	O
greater	O
than	O
two	O
-	O
fold	O
after	O
MUC1	O
siRNA	O
,	O
rather	O
than	O
a	O
select	O
group	O
.	O

Three	O
genes	O
whose	O
transcription	O
was	O
changed	O
by	O
less	O
than	O
two	O
-	O
fold	O
are	O
shown	O
,	O
two	O
of	O
which	O
(	O
PDGFB	O
and	O
ITGB1	O
)	O
are	O
listed	O
because	O
they	O
relate	O
closely	O
to	O
genes	O
altered	O
by	O
two	O
-	O
fold	O
(	O
PDGFA	O
and	O
ITGAV	O
)	O
.	O

The	O
third	O
,	O
MYC	O
,	O
is	O
included	O
because	O
western	O
blots	O
confirmed	O
a	O
substantial	O
change	O
at	O
the	O
protein	O
level	O
(	O
Figure	O
3a	O
)	O
that	O
may	O
reflect	O
both	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
regulation	O
.	O

Interestingly	O
,	O
transcription	O
of	O
MAP2K1	O
was	O
decreased	O
in	O
both	O
cell	O
lines	O
after	O
MUC1	O
siRNA	O
.	O

This	O
gene	O
encodes	O
MEK1	O
,	O
one	O
of	O
the	O
primary	O
regulators	O
of	O
the	O
ERK1	O
/	O
2	O
MAPK	O
pathway	O
[	O
33	O
]	O
,	O
a	O
network	O
that	O
has	O
been	O
linked	O
several	O
times	O
to	O
MUC1	O
[	O
12	O
,	O
34	O
-	O
36	O
]	O
.	O

We	O
examined	O
MEK1	O
and	O
MEK2	O
levels	O
by	O
western	O
blot	O
to	O
confirm	O
decreased	O
protein	O
in	O
MUC1	O
siRNA	O
-	O
treated	O
cells	O
(	O
Figure	O
3a	O
)	O
,	O
and	O
found	O
that	O
not	O
only	O
were	O
total	O
MEK1	O
/	O
2	O
levels	O
lower	O
in	O
468	O
.	O
siMUC1	O
and	O
BT	O
.	O
siMUC1	O
compared	O
to	O
controls	O
(	O
0	O
.	O
48	O
and	O
0	O
.	O
68	O
relative	O
to	O
siLuc	O
,	O
respectively	O
)	O
,	O
but	O
so	O
were	O
the	O
basal	O
amounts	O
of	O
active	O
(	O
phosphorylated	O
)	O
MEK1	O
/	O
2	O
(	O
pMEK1	O
/	O
2	O
;	O
0	O
.	O
12	O
and	O
0	O
.	O
42	O
relative	O
to	O
siLuc	O
,	O
respectively	O
)	O
.	O

Both	O
468	O
.	O
siMUC1	O
and	O
BT	O
.	O
siMUC1	O
also	O
showed	O
reduced	O
activation	O
of	O
ERK1	O
/	O
2	O
(	O
dpERK1	O
/	O
2	O
;	O
0	O
.	O
21	O
and	O
0	O
.	O
27	O
relative	O
to	O
siLuc	O
,	O
respectively	O
)	O
,	O
as	O
would	O
be	O
expected	O
with	O
diminished	O
signaling	O
through	O
MEK1	O
/	O
2	O
;	O
total	O
ERK1	O
/	O
2	O
levels	O
remain	O
unchanged	O
.	O

As	O
both	O
lines	O
have	O
high	O
levels	O
of	O
EGFR	O
and	O
thus	O
activate	O
the	O
MEK	O
-	O
ERK	O
cascade	O
intensely	O
when	O
stimulated	O
with	O
EGF	O
[	O
37	O
]	O
,	O
siRNA	O
-	O
transfected	O
cells	O
were	O
treated	O
with	O
EGF	O
.	O

Notably	O
,	O
MUC1	O
siRNA	O
impairs	O
this	O
important	O
oncogenic	O
pathway	O
in	O
MDA	O
-	O
MB	O
-	O
468	O
cells	O
,	O
as	O
468	O
.	O
siMUC1	O
display	O
less	O
pMEK1	O
/	O
2	O
in	O
response	O
to	O
EGF	O
than	O
do	O
468	O
.	O
siLuc	O
(	O
Figure	O
3b	O
)	O
.	O

Interestingly	O
,	O
EGF	O
treatment	O
of	O
BT	O
-	O
20	O
cells	O
results	O
in	O
slightly	O
higher	O
pMEK1	O
/	O
2	O
levels	O
in	O
BT	O
.	O
siMUC1	O
compared	O
to	O
BT	O
.	O
siLuc	O
.	O

Though	O
this	O
result	O
seems	O
paradoxical	O
in	O
light	O
of	O
decreased	O
MAP2K1	O
transcription	O
in	O
BT	O
.	O
siMUC1	O
,	O
it	O
likely	O
results	O
from	O
differential	O
functions	O
of	O
Raf	O
isoforms	O
in	O
combination	O
with	O
the	O
increased	O
RAF1	O
transcription	O
(	O
Figure	O
2	O
)	O
and	O
protein	O
level	O
(	O
Figure	O
3a	O
)	O
in	O
these	O
cells	O
.	O

Specifically	O
,	O
B	O
-	O
Raf	O
is	O
thought	O
to	O
be	O
the	O
main	O
activator	O
of	O
MEK	O
under	O
normal	O
conditions	O
;	O
Raf	O
-	O
1	O
activates	O
MEK	O
in	O
response	O
to	O
stimulus	O
[	O
38	O
]	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
basal	O
pMEK1	O
/	O
2	O
levels	O
are	O
not	O
greatly	O
affected	O
by	O
Raf	O
-	O
1	O
overexpression	O
in	O
BT	O
.	O
siMUC1	O
cells	O
,	O
likely	O
because	O
MEK	O
is	O
regulated	O
primarily	O
by	O
B	O
-	O
Raf	O
under	O
normal	O
growth	O
conditions	O
.	O

In	O
contrast	O
,	O
when	O
the	O
cells	O
are	O
stimulated	O
(	O
EGF	O
)	O
,	O
increased	O
Raf	O
-	O
1	O
levels	O
in	O
BT	O
.	O
siMUC1	O
leads	O
to	O
heightened	O
pMEK1	O
/	O
2	O
(	O
Figure	O
3b	O
)	O
.	O

MUC1	O
siRNA	O
increases	O
apoptosis	O
in	O
MDA	O
-	O
MB	O
-	O
468	O
but	O
not	O
BT	O
-	O
20	O

We	O
next	O
examined	O
whether	O
MUC1	O
knockdown	O
and	O
its	O
associated	O
transcriptional	O
alterations	O
would	O
affect	O
overall	O
cellular	O
events	O
.	O

As	O
several	O
of	O
the	O
genes	O
shown	O
in	O
Figure	O
2	O
are	O
important	O
in	O
regulating	O
proliferation	O
and	O
survival	O
,	O
and	O
because	O
of	O
the	O
recently	O
described	O
role	O
of	O
MUC1	O
in	O
modulating	O
apoptosis	O
in	O
response	O
to	O
cellular	O
stresses	O
[	O
20	O
,	O
21	O
,	O
24	O
]	O
,	O
we	O
first	O
analyzed	O
whether	O
MUC1	O
siRNA	O
would	O
alter	O
apoptosis	O
in	O
these	O
lines	O
.	O

Although	O
there	O
was	O
no	O
change	O
in	O
basal	O
apoptosis	O
in	O
either	O
line	O
(	O
Figure	O
4a	O
)	O
,	O
we	O
observed	O
that	O
the	O
cell	O
lines	O
responded	O
differently	O
when	O
trypsinized	O
for	O
re	O
-	O
plating	O
24	O
hours	O
after	O
transfection	O
(	O
Figure	O
4b	O
)	O
.	O

Interestingly	O
,	O
468	O
.	O
siMUC1	O
cells	O
show	O
greater	O
apoptosis	O
after	O
trypsinization	O
than	O
do	O
468	O
.	O
siLuc	O
(	O
49	O
.	O
8	O
%	O
versus	O
34	O
.	O
0	O
%	O
,	O
respectively	O
)	O
,	O
while	O
BT	O
-	O
20	O
cells	O
from	O
both	O
siRNA	O
treatments	O
display	O
similar	O
levels	O
of	O
apoptosis	O
(	O
around	O
22	O
%	O
)	O
.	O

To	O
examine	O
whether	O
this	O
phenomenon	O
is	O
specific	O
to	O
trypsin	O
treatment	O
or	O
part	O
of	O
a	O
general	O
stress	O
response	O
involving	O
MUC1	O
,	O
we	O
subjected	O
cells	O
to	O
a	O
panel	O
of	O
stresses	O
and	O
measured	O
cell	O
death	O
.	O

In	O
agreement	O
with	O
the	O
patterns	O
seen	O
with	O
trypsinization	O
,	O
BT	O
.	O
siLuc	O
and	O
BT	O
.	O
siMUC1	O
respond	O
similarly	O
to	O
all	O
treatments	O
(	O
data	O
not	O
shown	O
)	O
,	O
while	O
468	O
.	O
siMUC1	O
die	O
more	O
readily	O
than	O
468	O
.	O
siLuc	O
in	O
response	O
to	O
trypsin	O
,	O
G418	O
,	O
hydrogen	O
peroxide	O
,	O
or	O
celecoxib	O
,	O
a	O
chemotherapeutic	O
that	O
targets	O
the	O
cyclooxygenase	O
-	O
2	O
(	O
COX	O
-	O
2	O
)	O
pathway	O
(	O
Figure	O
4c	O
)	O
;	O
these	O
data	O
were	O
confirmed	O
with	O
two	O
independent	O
siRNA	O
constructs	O
(	O
data	O
not	O
shown	O
)	O
.	O

Like	O
the	O
MAPK	O
pathway	O
,	O
AKT	O
signaling	O
has	O
been	O
linked	O
to	O
MUC1	O
in	O
cancer	O
.	O

Although	O
transcription	O
of	O
AKT	O
was	O
not	O
altered	O
in	O
MUC1	O
siRNA	O
-	O
treated	O
cells	O
,	O
the	O
results	O
of	O
our	O
apoptosis	O
studies	O
prompted	O
us	O
to	O
investigate	O
levels	O
of	O
AKT	O
further	O
.	O
<EOS>	B-X
Fatty	B-X
acid	B-X
and	B-X
fat	B-X
synthesis	B-X
in	B-X
the	B-X
liver	B-X
is	B-X
a	B-X
highly	B-X
regulated	B-X
metabolic	B-X
pathway	B-X
that	B-X
is	B-X
important	B-X
for	B-X
very	B-X
low-density	B-X
lipoprotein	B-X
(	B-X
VLDL	B-X
)	B-X
production	B-X
and	B-X
thus	B-X
energy	B-X
distribution	B-X
to	B-X
other	B-X
tissues	B-X
.	B-X
Having	B-X
common	B-X
features	B-X
at	B-X
their	B-X
promoter	B-X
regions	B-X
,	B-X
lipogenic	B-X
genes	B-X
are	B-X
coordinately	B-X
regulated	B-X
at	B-X
the	B-X
transcriptional	B-X
level	B-X
.	B-X
Recently	B-X
,	B-X
insights	B-X
have	B-X
been	B-X
gained	B-X
into	B-X
the	B-X
signalling	B-X
pathways	B-X
that	B-X
regulate	B-X
these	B-X
transcription	B-X
factors	B-X
.	B-X
After	B-X
feeding	B-X
,	B-X
high	B-X
blood	B-X
glucose	B-X
and	B-X
insulin	B-X
levels	B-X
activate	B-X
lipogenic	B-X
genes	B-X
through	B-X
several	B-X
pathways	B-X
,	B-X
including	B-X
the	B-X
DNA-dependent	B-X
protein	B-X
kinase	B-X
(	B-X
DNA-PK	B-X
)	B-X
,	B-X
atypical	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
aPKC	B-X
)	B-X
and	B-X
AKT-mTOR	B-X
pathways	B-X
.	B-X
These	B-X
pathways	B-X
control	B-X
the	B-X
post-translational	B-X
modifications	B-X
of	B-X
transcription	B-X
factors	B-X
and	B-X
co-regulators	B-X
,	B-X
such	B-X
as	B-X
phosphorylation	B-X
,	B-X
acetylation	B-X
or	B-X
ubiquitylation	B-X
,	B-X
that	B-X
affect	B-X
their	B-X
function	B-X
,	B-X
stability	B-X
and/or	B-X
localization	B-X
.	B-X

As	O
expected	O
,	O
the	O
total	O
AKT	O
protein	O
level	O
is	O
not	O
greatly	O
changed	O
after	O
MUC1	O
siRNA	O
in	O
either	O
cell	O
line	O
,	O
though	O
the	O
active	O
form	O
(	O
pAKT	O
)	O
is	O
increased	O
in	O
both	O
468	O
.	O
siMUC1	O
and	O
BT	O
.	O
siMUC1	O
compared	O
to	O
controls	O
(	O
Figure	O
3a	O
)	O
.	O

This	O
result	O
disagrees	O
with	O
MUC1	O
activation	O
of	O
the	O
AKT	O
pathway	O
in	O
rat	B-Species
3Y1	O
cells	O
[	O
18	O
]	O
,	O
and	O
may	O
reflect	O
regulation	O
more	O
appropriate	O
to	O
breast	O
cancer	O
cells	O
;	O
this	O
is	O
supported	O
by	O
activation	O
of	O
AKT	O
in	O
response	O
to	O
MUC1	O
siRNA	O
in	O
other	O
lines	O
[	O
21	O
]	O
.	O

In	O
addition	O
,	O
there	O
is	O
a	O
striking	O
difference	O
in	O
the	O
relative	O
amounts	O
of	O
AKT	O
and	O
pAKT	O
in	O
the	O
two	O
cell	O
lines	O
(	O
Figure	O
4d	O
)	O
.	O

When	O
lysates	O
from	O
both	O
lines	O
are	O
exposed	O
to	O
film	O
for	O
the	O
same	O
length	O
of	O
time	O
(	O
overexposure	O
masks	O
the	O
differences	O
between	O
BT	O
.	O
siLuc	O
and	O
BT	O
.	O
siMUC1	O
that	O
are	O
apparent	O
in	O
Figure	O
3a	O
)	O
,	O
it	O
is	O
clear	O
that	O
pAKT	O
levels	O
are	O
much	O
higher	O
in	O
BT	O
-	O
20	O
than	O
in	O
MDA	O
-	O
MB	O
-	O
468	O
,	O
despite	O
lower	O
total	O
AKT	O
expression	O
.	O

This	O
difference	O
in	O
AKT	O
activation	O
between	O
MDA	O
-	O
MB	O
-	O
468	O
and	O
BT	O
-	O
20	O
likely	O
contributes	O
to	O
the	O
disparity	O
in	O
their	O
sensitivity	O
to	O
the	O
increased	O
apoptosis	O
expected	O
with	O
loss	O
of	O
MUC1	O
.	O

MUC1	O
siRNA	O
alters	O
proliferation	O
and	O
invasion	O
<EOS>	B-X
MUC1	B-X
is	B-X
an	B-X
oncoprotein	B-X
whose	B-X
overexpression	B-X
correlates	B-X
with	B-X
aggressiveness	B-X
of	B-X
tumors	B-X
and	B-X
poor	B-X
survival	B-X
of	B-X
cancer	B-X
patients	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
oncogenic	B-X
effects	B-X
of	B-X
MUC1	B-X
are	B-X
believed	B-X
to	B-X
occur	B-X
through	B-X
interaction	B-X
of	B-X
its	B-X
cytoplasmic	B-X
tail	B-X
with	B-X
signaling	B-X
molecules	B-X
.	B-X
As	B-X
expected	B-X
for	B-X
a	B-X
protein	B-X
with	B-X
oncogenic	B-X
functions	B-X
,	B-X
MUC1	B-X
is	B-X
linked	B-X
to	B-X
regulation	B-X
of	B-X
proliferation	B-X
,	B-X
apoptosis	B-X
,	B-X
invasion	B-X
,	B-X
and	B-X
transcription	B-X
.	B-X
MUC1	B-X
is	B-X
a	B-X
highly	B-X
glycosylated	B-X
,	B-X
type	B-X
I	B-X
transmembrane	B-X
protein	B-X
expressed	B-X
by	B-X
normal	B-X
ductal	B-X
epithelial	B-X
cells	B-X
of	B-X
the	B-X
pancreas	B-X
,	B-X
breast	B-X
,	B-X
lung	B-X
,	B-X
and	B-X
gastrointestinal	B-X
tract	B-X
,	B-X
and	B-X
overexpressed	B-X
in	B-X
many	B-X
cases	B-X
of	B-X
adenocarcinoma	B-X
.	B-X
We	B-X
down-regulated	B-X
MUC1	B-X
expression	B-X
by	B-X
RNA	B-X
interference	B-X
and	B-X
investigated	B-X
the	B-X
effects	B-X
on	B-X
malignant	B-X
and	B-X
metastatic	B-X
potential	B-X
of	B-X
a	B-X
human	B-X
pancreatic	B-X
cancer	B-X
cell	B-X
line	B-X
,	B-X
S2-013	B-X
.	B-X
MUC1-suppressed	B-X
clones	B-X
,	B-X
S2-013.MTII.C1	B-X
and	B-X
S2-013.MTII.C2	B-X
,	B-X
were	B-X
established	B-X
by	B-X
targeting	B-X
a	B-X
sequence	B-X
3,151	B-X
bp	B-X
from	B-X
the	B-X
initiation	B-X
codon	B-X
and	B-X
characterized	B-X
in	B-X
vitro	B-X
for	B-X
proliferation	B-X
,	B-X
invasion	B-X
,	B-X
and	B-X
adhesion	B-X
.	B-X
We	B-X
evaluated	B-X
the	B-X
effects	B-X
of	B-X
MUC1	B-X
suppression	B-X
in	B-X
vivo	B-X
on	B-X
tumor	B-X
growth	B-X
and	B-X
metastatic	B-X
properties	B-X
following	B-X
implantation	B-X
into	B-X
the	B-X
cecum	B-X
or	B-X
pancreas	B-X
of	B-X
athymic	B-X
mice	B-X
.	B-X
MUC1-suppressed	B-X
clones	B-X
showed	B-X
significantly	B-X
decreased	B-X
proliferation	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
Surprisingly	B-X
,	B-X
genes	B-X
predicted	B-X
to	B-X
increase	B-X
doubling	B-X
times	B-X
(	B-X
cyclin	B-X
B1	B-X
and	B-X
cyclin	B-X
D3	B-X
)	B-X
were	B-X
overexpressed	B-X
in	B-X
MUC1-suppressed	B-X
clones	B-X
.	B-X
Adhesion	B-X
of	B-X
MUC1-suppressed	B-X
cells	B-X
in	B-X
vitro	B-X
to	B-X
type	B-X
IV	B-X
collagen	B-X
and	B-X
fibronectin	B-X
was	B-X
slightly	B-X
increased	B-X
,	B-X
and	B-X
adhesion	B-X
was	B-X
slightly	B-X
decreased	B-X
to	B-X
type	B-X
I	B-X
collagen	B-X
and	B-X
laminin	B-X
.	B-X
These	B-X
results	B-X
support	B-X
the	B-X
hypothesis	B-X
that	B-X
MUC1	B-X
contributes	B-X
significantly	B-X
to	B-X
growth	B-X
and	B-X
metastasis	B-X
,	B-X
and	B-X
that	B-X
down-regulation	B-X
of	B-X
MUC1	B-X
protein	B-X
expression	B-X
decreases	B-X
the	B-X
metastatic	B-X
potential	B-X
of	B-X
pancreatic	B-X
adenocarcinoma	B-X
.	B-X

As	O
MUC1	O
is	O
involved	O
in	O
apoptosis	O
,	O
we	O
next	O
analyzed	O
its	O
effects	O
on	O
proliferation	O
.	O

BrdU	O
and	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
were	O
used	O
to	O
analyze	O
proliferation	O
after	O
MUC1	O
siRNA	O
.	O

468	O
.	O
siMUC1	O
cells	O
show	O
a	O
significant	O
decrease	O
in	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
compared	O
to	O
468	O
.	O
siLuc	O
,	O
while	O
intriguingly	O
,	O
BT	O
.	O
siMUC1	O
cells	O
show	O
a	O
significant	O
increase	O
in	O
proliferation	O
(	O
Figure	O
5a	O
)	O
.	O

Growth	O
curves	O
mirror	O
these	O
results	O
,	O
as	O
do	O
experiments	O
with	O
the	O
two	O
independent	O
MUC1	O
siRNA	O
oligonucleotides	O
(	O
data	O
not	O
shown	O
)	O
.	O

Note	O
that	O
these	O
assays	O
require	O
trypsinizing	O
cells	O
24	O
hours	O
post	O
-	O
transfection	O
;	O
therefore	O
,	O
the	O
results	O
in	O
the	O
MDA	O
-	O
MB	O
-	O
468	O
line	O
could	O
stem	O
from	O
the	O
changes	O
in	O
apoptosis	O
described	O
in	O
the	O
previous	O
section	O
,	O
rather	O
than	O
a	O
true	O
effect	O
on	O
proliferation	O
.	O

To	O
control	O
for	O
this	O
,	O
we	O
incubated	O
non	O
-	O
trypsinized	O
,	O
siRNA	O
-	O
transfected	O
cells	O
at	O
similar	O
confluence	O
with	O
BrdU	O
to	O
measure	O
incorporation	O
.	O

The	O
'	O
clumped	O
'	O
profile	O
of	O
cells	O
(	O
contrast	O
to	O
Figure	O
4b	O
)	O
is	O
likely	O
a	O
result	O
of	O
the	O
acid	O
denaturation	O
(	O
recommended	O
by	O
the	O
antibody	O
manufacturer	O
)	O
,	O
as	O
it	O
occurs	O
uniformly	O
in	O
these	O
experiments	O
.	O

BrdU	O
incorporation	O
(	O
Figure	O
5b	O
)	O
confirms	O
that	O
the	O
[	O
3H	O
]	O
thymidine	O
results	O
are	O
not	O
solely	O
due	O
to	O
alterations	O
in	O
apoptosis	O
,	O
as	O
468	O
.	O
siMUC1	O
cells	O
incorporate	O
less	O
BrdU	O
than	O
468	O
.	O
siLuc	O
;	O
once	O
again	O
,	O
BT	O
.	O
siMUC1	O
cells	O
show	O
increased	O
proliferation	O
over	O
BT	O
.	O
siLuc	O
.	O

Given	O
the	O
role	O
of	O
MUC1	O
in	O
adhesion	O
,	O
we	O
examined	O
whether	O
MUC1	O
siRNA	O
affects	O
cellular	O
invasion	O
.	O

In	O
transwell	O
assays	O
,	O
BT	O
-	O
20	O
cells	O
invaded	O
poorly	O
,	O
regardless	O
of	O
the	O
siRNA	O
used	O
(	O
data	O
not	O
shown	O
)	O
.	O

However	O
,	O
MDA	O
-	O
MB	O
-	O
468	O
cells	O
invade	O
more	O
readily	O
,	O
and	O
were	O
analyzed	O
on	O
a	O
panel	O
of	O
three	O
different	O
extracellular	O
matrix	O
proteins	O
.	O

Interestingly	O
,	O
468	O
.	O
siMUC1	O
cells	O
display	O
somewhat	O
decreased	O
invasion	O
on	O
collagen	O
IV	O
,	O
laminin	O
,	O
and	O
fibronectin	O
matrices	O
,	O
and	O
on	O
a	O
no	O
-	O
matrix	O
control	O
(	O
Figure	O
5c	O
)	O
,	O
which	O
is	O
in	O
agreement	O
with	O
the	O
trend	O
towards	O
decreased	O
metastasis	O
observed	O
in	O
Muc1	O
-	O
/	O
-	O
x	O
MMTV	B-Species
-	O
PyV	O
MT	O
mice	B-Species
[	O
8	O
]	O
.	O

Transfection	O
of	O
MUC1	O
rescues	O
the	O
468	O
.	O
siMUC1	O
phenotype	O

To	O
determine	O
if	O
the	O
above	O
effects	O
are	O
specific	O
to	O
MUC1	O
,	O
we	O
created	O
stable	O
transfectants	O
of	O
the	O
MDA	O
-	O
MB	O
-	O
468	O
line	O
using	O
empty	O
vector	O
(	O
468	O
.	O
Neo	O
)	O
or	O
a	O
full	O
-	O
length	O
MUC1	O
construct	O
(	O
468	O
.	O
MUC1	O
Delta	O
8	O
)	O
that	O
is	O
resistant	O
to	O
one	O
of	O
the	O
independent	O
MUC1	O
-	O
directed	O
oligonucleotides	O
(	O
'	O
882	O
'	O
)	O
.	O

These	O
cells	O
were	O
maintained	O
in	O
G418	O
-	O
containing	O
medium	O
to	O
retain	O
transgene	O
selection	O
.	O

As	O
expected	O
,	O
468	O
.	O
MUC1	O
Delta	O
8	O
cells	O
show	O
higher	O
levels	O
of	O
both	O
the	O
MUC1	O
extracellular	O
domain	O
and	O
the	O
MUC1	O
-	O
CT	O
than	O
do	O
468	O
.	O
Neo	O
(	O
Figure	O
6a	O
)	O
.	O

Note	O
that	O
468	O
.	O
Neo	O
have	O
MUC1	O
expression	O
comparable	O
to	O
parental	O
MDA	O
-	O
MB	O
-	O
468	O
;	O
the	O
exposures	O
in	O
Figure	O
6a	O
are	O
lighter	O
than	O
those	O
in	O
Figure	O
1a	O
,	O
in	O
order	O
to	O
clearly	O
show	O
the	O
relative	O
levels	O
of	O
MUC1	O
in	O
the	O
stable	O
transfectants	O
.	O

After	O
MUC1	O
siRNA	O
,	O
468	O
.	O
MUC1	O
Delta	O
8	O
lose	O
some	O
MUC1	O
(	O
likely	O
endogenous	O
protein	O
,	O
which	O
is	O
not	O
siRNA	O
-	O
resistant	O
)	O
but	O
retain	O
high	O
-	O
level	O
expression	O
,	O
while	O
468	O
.	O
Neo	O
show	O
a	O
decrease	O
in	O
MUC1	O
levels	O
similar	O
to	O
parental	O
468	O
.	O
siMUC1	O
cells	O
(	O
Figures	O
6a	O
,	O
b	O
)	O
.	O

The	O
difference	O
in	O
the	O
amount	O
of	O
MUC1	O
knockdown	O
between	O
468	O
.	O
Neo	O
and	O
468	O
.	O
MUC1	O
Delta	O
8	O
is	O
highlighted	O
by	O
the	O
purple	O
shading	O
in	O
Figure	O
6b	O
.	O

BrdU	O
incorporation	O
(	O
Figure	O
6c	O
)	O
indicates	O
that	O
468	O
.	O
Neo	O
show	O
decreased	O
nucleotide	O
incorporation	O
after	O
MUC1	O
siRNA	O
compared	O
to	O
control	O
(	O
3	O
.	O
3	O
%	O
versus	O
25	O
.	O
0	O
%	O
,	O
respectively	O
)	O
;	O
this	O
is	O
not	O
seen	O
in	O
468	O
.	O
MUC1	O
Delta	O
8	O
cells	O
,	O
which	O
show	O
similar	O
levels	O
of	O
BrdU	O
incorporation	O
regardless	O
of	O
the	O
siRNA	O
used	O
(	O
21	O
.	O
5	O
%	O
for	O
luciferase	O
,	O
23	O
.	O
9	O
%	O
for	O
MUC1	O
)	O
.	O

468	O
.	O
Neo	O
cells	O
display	O
a	O
more	O
dramatic	O
decrease	O
in	O
BrdU	O
incorporation	O
after	O
MUC1	O
siRNA	O
than	O
what	O
is	O
seen	O
in	O
parental	O
468	O
.	O
siMUC1	O
cells	O
,	O
which	O
may	O
reflect	O
the	O
additional	O
stress	O
of	O
being	O
maintained	O
in	O
G418	O
-	O
containing	O
medium	O
.	O

Similarly	O
,	O
analysis	O
of	O
apoptosis	O
in	O
trypsinized	O
cells	O
indicates	O
that	O
the	O
increased	O
apoptosis	O
seen	O
in	O
parental	O
468	O
.	O
siMUC1	O
cells	O
is	O
also	O
present	O
in	O
the	O
468	O
.	O
Neo	O
line	O
after	O
MUC1	O
siRNA	O
(	O
Figure	O
6d	O
;	O
43	O
.	O
6	O
%	O
in	O
control	O
versus	O
59	O
.	O
6	O
%	O
in	O
MUC1	O
siRNA	O
)	O
.	O

However	O
,	O
in	O
468	O
.	O
MUC1	O
Delta	O
8	O
cells	O
,	O
the	O
level	O
of	O
apoptosis	O
after	O
luciferase	O
siRNA	O
(	O
34	O
.	O
1	O
%	O
)	O
is	O
lower	O
than	O
that	O
in	O
468	O
.	O
Neo	O
cells	O
;	O
MUC1	O
siRNA	O
increases	O
the	O
amount	O
of	O
apoptosis	O
slightly	O
(	O
42	O
.	O
8	O
%	O
)	O
,	O
restoring	O
it	O
to	O
a	O
level	O
similar	O
to	O
that	O
seen	O
in	O
luciferase	O
siRNA	O
-	O
treated	O
468	O
.	O
Neo	O
cells	O
.	O

Together	O
,	O
these	O
studies	O
suggest	O
that	O
the	O
above	O
-	O
described	O
results	O
are	O
specific	O
to	O
MUC1	O
,	O
as	O
stable	O
transfection	O
of	O
an	O
siRNA	O
-	O
resistant	O
MUC1	O
rescues	O
the	O
phenotype	O
seen	O
in	O
468	O
.	O
siMUC1	O
cells	O
.	O

Discussion	O
<EOS>	B-X
Discussion	B-X
structures	B-X
are	B-X
argumentation-theoretical	B-X
tools	B-X
that	B-X
can	B-X
be	B-X
employed	B-X
to	B-X
tackle	B-X
three	B-X
barriers	B-X
that	B-X
separate	B-X
lay	B-X
stakeholders	B-X
from	B-X
policy	B-X
debates	B-X
:	B-X
difficulty	B-X
,	B-X
magnitude	B-X
,	B-X
and	B-X
complexity	B-X
.	B-X
Discussions	B-X
about	B-X
preventive	B-X
behaviors	B-X
were	B-X
assessed	B-X
before	B-X
testing	B-X
and	B-X
1	B-X
and	B-X
6	B-X
months	B-X
post-testing	B-X
.	B-X
Discussion	B-X
of	B-X
preventive	B-X
behaviors	B-X
declined	B-X
following	B-X
test	B-X
reporting	B-X
,	B-X
with	B-X
more	B-X
rapid	B-X
decline	B-X
reported	B-X
by	B-X
noncarriers	B-X
.	B-X
Discussions	B-X
are	B-X
an	B-X
important	B-X
part	B-X
of	B-X
medical	B-X
education	B-X
research	B-X
papers	B-X
,	B-X
but	B-X
there	B-X
is	B-X
little	B-X
guidance	B-X
on	B-X
how	B-X
to	B-X
write	B-X
up	B-X
the	B-X
discussion	B-X
section	B-X
.	B-X

This	O
report	O
describes	O
both	O
the	O
transcriptional	O
alterations	O
seen	O
after	O
transfection	O
with	O
MUC1	O
siRNA	O
in	O
human	B-Species
breast	O
cancer	O
cells	O
and	O
the	O
effects	O
on	O
events	O
such	O
as	O
apoptosis	O
and	O
proliferation	O
.	O

The	O
two	O
cell	O
lines	O
used	O
(	O
MDA	O
-	O
MB	O
-	O
468	O
and	O
BT	O
-	O
20	O
)	O
were	O
chosen	O
for	O
high	O
expression	O
of	O
MUC1	O
and	O
a	O
substantial	O
(	O
50	O
%	O
to	O
75	O
%	O
)	O
,	O
consistent	O
decrease	O
in	O
MUC1	O
expression	O
after	O
siRNA	O
.	O

Both	O
lines	O
have	O
epithelial	O
morphology	O
,	O
form	O
tumors	O
slowly	O
in	O
nude	B-Species
mice	I-Species
[	O
37	O
]	O
,	O
have	O
mutant	O
p53	O
[	O
39	O
,	O
40	O
]	O
,	O
express	O
EGFR	O
[	O
37	O
]	O
,	O
and	O
lack	O
estrogen	O
receptor	O
alpha	O
[	O
41	O
]	O
.	O

One	O
striking	O
difference	O
between	O
these	O
lines	O
,	O
however	O
,	O
is	O
their	O
response	O
to	O
MUC1	O
siRNA	O
.	O

MDA	O
-	O
MB	O
-	O
468	O
cells	O
behave	O
as	O
expected	O
for	O
loss	O
of	O
an	O
oncogene	O
:	O
MUC1	O
siRNA	O
correlates	O
with	O
increased	O
apoptosis	O
in	O
response	O
to	O
stress	O
,	O
decreased	O
proliferation	O
,	O
and	O
reduced	O
invasion	O
.	O

In	O
contrast	O
,	O
BT	O
.	O
siMUC1	O
cells	O
proliferate	O
more	O
rapidly	O
than	O
BT	O
.	O
siLuc	O
cells	O
with	O
little	O
effect	O
on	O
apoptosis	O
.	O

Much	O
of	O
the	O
phenotype	O
of	O
these	O
cells	O
can	O
be	O
understood	O
in	O
light	O
of	O
protein	O
levels	O
and	O
transcriptional	O
activity	O
after	O
MUC1	O
siRNA	O
.	O

As	O
mentioned	O
,	O
both	O
MDA	O
-	O
MB	O
-	O
468	O
and	O
BT	O
-	O
20	O
display	O
increased	O
pAKT	O
after	O
MUC1	O
siRNA	O
,	O
but	O
the	O
ratio	O
of	O
active	O
to	O
total	O
AKT	O
is	O
considerably	O
higher	O
in	O
the	O
BT	O
-	O
20	O
line	O
,	O
which	O
may	O
help	O
these	O
cells	O
resist	O
the	O
increased	O
apoptosis	O
expected	O
with	O
loss	O
of	O
MUC1	O
.	O

Myc	O
levels	O
are	O
also	O
higher	O
in	O
both	O
cell	O
lines	O
after	O
MUC1	O
siRNA	O
,	O
although	O
the	O
ability	O
of	O
Myc	O
to	O
promote	O
proliferation	O
and	O
apoptosis	O
in	O
different	O
cellular	O
contexts	O
[	O
42	O
]	O
complicates	O
the	O
interpretation	O
of	O
this	O
finding	O
.	O

Both	O
cell	O
lines	O
show	O
reduced	O
transcription	O
of	O
VEGF	O
,	O
PDGFA	O
,	O
PDGFB	O
,	O
and	O
MAP2K1	O
(	O
MEK1	O
)	O
after	O
MUC1	O
siRNA	O
.	O

The	O
genes	O
encoding	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
the	O
A	O
and	O
B	O
chains	O
of	O
platelet	O
-	O
derived	O
growth	O
factor	O
(	O
PDGF	O
-	O
A	O
and	O
PDGF	O
-	O
B	O
)	O
are	O
interesting	O
as	O
these	O
proteins	O
have	O
been	O
heavily	O
implicated	O
in	O
angiogenesis	O
,	O
suggesting	O
a	O
novel	O
function	O
for	O
MUC1	O
in	O
regulating	O
this	O
process	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
expression	O
in	O
cancer	O
is	O
linked	O
to	O
tumor	O
growth	O
and	O
metastasis	O
[	O
43	O
,	O
44	O
]	O
;	O
platelet	O
-	O
derived	O
growth	O
factor	O
is	O
also	O
angiogenic	O
,	O
but	O
has	O
an	O
additional	O
role	O
in	O
stimulating	O
desmoplasia	O
[	O
45	O
]	O
.	O
<EOS>	B-X
Angiogenesis	B-X
is	B-X
a	B-X
fundamental	B-X
process	B-X
that	B-X
involves	B-X
in	B-X
tumor	B-X
progression	B-X
and	B-X
metastasis	B-X
.	B-X
Vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
family	B-X
and	B-X
their	B-X
receptors	B-X
are	B-X
identified	B-X
as	B-X
the	B-X
most	B-X
prominent	B-X
regulators	B-X
of	B-X
angiogenesis	B-X
.	B-X
However	B-X
,	B-X
the	B-X
clinical	B-X
efficacy	B-X
of	B-X
anti-VEGF/VEGFR	B-X
therapy	B-X
is	B-X
not	B-X
ideal	B-X
,	B-X
prompting	B-X
the	B-X
needs	B-X
to	B-X
further	B-X
understand	B-X
mechanisms	B-X
behind	B-X
tumor	B-X
angiogenesis	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
found	B-X
that	B-X
Dickkopf	B-X
associated	B-X
protein	B-X
2	B-X
(	B-X
DKK2	B-X
)	B-X
,	B-X
a	B-X
secretory	B-X
protein	B-X
highly	B-X
expressed	B-X
in	B-X
metastatic	B-X
colorectal	B-X
cancer	B-X
tissues	B-X
,	B-X
could	B-X
stimulate	B-X
angiogenesis	B-X
via	B-X
a	B-X
classic	B-X
VEGF/VEGFR	B-X
independent	B-X
pathway	B-X
.	B-X

Reduced	O
transcription	O
of	O
these	O
genes	O
after	O
MUC1	O
siRNA	O
suggests	O
that	O
MUC1	O
may	O
foster	O
angiogenesis	O
and	O
stromal	O
proliferation	O
,	O
although	O
this	O
must	O
be	O
confirmed	O
in	O
a	O
more	O
appropriate	O
model	O
system	O
.	O

Decreased	O
MAP2K1	O
(	O
MEK1	O
)	O
transcription	O
after	O
MUC1	O
siRNA	O
provides	O
a	O
novel	O
mechanism	O
by	O
which	O
MUC1	O
can	O
affect	O
the	O
ERK1	O
/	O
2	O
MAPK	O
pathway	O
.	O

MUC1	O
has	O
often	O
been	O
linked	O
to	O
the	O
Ras	O
-	O
Raf	O
-	O
MEK	O
-	O
ERK	O
cascade	O
[	O
12	O
,	O
34	O
-	O
36	O
,	O
46	O
]	O
,	O
and	O
at	O
least	O
two	O
mechanisms	O
by	O
which	O
MUC1	O
can	O
alter	O
MAPK	O
signaling	O
have	O
been	O
described	O
:	O
MUC1	O
interaction	O
with	O
and	O
phosphorylation	O
by	O
the	O
EGFR	O
family	O
[	O
12	O
,	O
13	O
]	O
,	O
and	O
MUC1	O
binding	O
to	O
the	O
Grb2	O
/	O
Sos	O
complex	O
that	O
activates	O
Ras	O
[	O
46	O
]	O
.	O

Reduction	O
of	O
MEK1	O
levels	O
after	O
MUC1	O
siRNA	O
agrees	O
with	O
the	O
role	O
of	O
MUC1	O
in	O
strengthening	O
MAPK	O
signaling	O
,	O
and	O
indicates	O
that	O
MUC1	O
can	O
regulate	O
both	O
the	O
transcription	O
and	O
activity	O
of	O
members	O
of	O
this	O
pathway	O
.	O

Two	O
additional	O
MAPK	O
pathway	O
members	O
are	O
altered	O
specifically	O
in	O
BT	O
.	O
siMUC1	O
,	O
with	O
no	O
corresponding	O
change	O
in	O
468	O
.	O
siMUC1	O
cells	O
.	O

These	O
genes	O
are	O
RAF1	O
and	O
JUN	O
which	O
are	O
increased	O
and	O
decreased	O
,	O
respectively	O
,	O
after	O
MUC1	O
siRNA	O
.	O

Raf	O
-	O
1	O
and	O
c	O
-	O
Jun	O
both	O
function	O
outside	O
of	O
the	O
ERK1	O
/	O
2	O
MAPK	O
pathway	O
,	O
which	O
may	O
explain	O
the	O
seeming	O
paradox	O
of	O
increased	O
RAF1	O
transcription	O
with	O
simultaneous	O
decreases	O
in	O
MAP2K1	O
and	O
JUN	O
.	O

Specifically	O
,	O
Raf	O
-	O
1	O
can	O
inhibit	O
ASK1	O
(	O
apoptosis	O
signal	O
-	O
regulated	O
kinase	O
1	O
)	O
upstream	O
of	O
p38	O
and	O
JNK	O
(	O
Jun	O
N	O
-	O
terminal	O
kinase	O
)	O
[	O
38	O
]	O
.	O

ASK1	O
phosphorylates	O
JNK	O
in	O
response	O
to	O
stress	O
,	O
resulting	O
in	O
activation	O
of	O
c	O
-	O
Jun	O
and	O
stimulation	O
of	O
apoptosis	O
[	O
47	O
]	O
,	O
indicating	O
that	O
the	O
coordinate	O
up	O
-	O
regulation	O
of	O
RAF1	O
and	O
down	O
-	O
regulation	O
of	O
JUN	O
may	O
provide	O
a	O
potent	O
anti	O
-	O
apoptotic	O
effect	O
in	O
BT	O
.	O
siMUC1	O
.	O

Regulation	O
of	O
life	O
and	O
death	O
is	O
also	O
a	O
hallmark	O
of	O
the	O
CDC25A	O
and	O
TNF	O
gene	O
products	O
.	O

CDC25A	O
is	O
a	O
phosphatase	O
that	O
stimulates	O
cell	O
cycle	O
progression	O
[	O
48	O
]	O
,	O
thus	O
the	O
effects	O
of	O
its	O
decrease	O
in	O
BT	O
.	O
siMUC1	O
are	O
unclear	O
in	O
light	O
of	O
the	O
increased	O
proliferation	O
of	O
these	O
cells	O
.	O

However	O
,	O
the	O
CDC25	O
proteins	O
(	O
A	O
,	O
B	O
,	O
and	O
C	O
)	O
were	O
recently	O
shown	O
to	O
have	O
greater	O
functional	O
overlap	O
than	O
was	O
previously	O
thought	O
[	O
49	O
]	O
,	O
suggesting	O
that	O
the	O
other	O
two	O
isoforms	O
may	O
compensate	O
for	O
reduced	O
CDC25A	O
levels	O
.	O

TNF	O
encodes	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
alpha	O
,	O
known	O
for	O
its	O
potent	O
,	O
cell	O
type	O
-	O
specific	O
control	O
of	O
life	O
and	O
death	O
.	O

In	O
tumor	O
cells	O
,	O
TNF	O
alpha	O
expression	O
can	O
promote	O
proliferation	O
and	O
inhibit	O
apoptosis	O
[	O
50	O
]	O
,	O
suggesting	O
that	O
increased	O
TNF	O
transcription	O
in	O
BT	O
.	O
siMUC1	O
could	O
contribute	O
to	O
the	O
increased	O
proliferation	O
seen	O
in	O
these	O
cells	O
.	O

Interestingly	O
,	O
the	O
increase	O
in	O
TNF	O
is	O
accompanied	O
by	O
decreased	O
transcription	O
of	O
TIMP3	O
,	O
encoding	O
tissue	O
inhibitor	O
of	O
metalloproteinases	O
(	O
TIMP	O
)	O
3	O
.	O

The	O
TIMP	O
family	O
disrupts	O
the	O
function	O
of	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
,	O
generally	O
resulting	O
in	O
decreased	O
invasion	O
[	O
51	O
]	O
.	O

TIMP3	O
is	O
unique	O
in	O
that	O
it	O
can	O
also	O
inhibit	O
TNF	O
alpha	O
converting	O
enzyme	O
(	O
TACE	O
)	O
,	O
which	O
activates	O
TNF	O
alpha	O
by	O
cleaving	O
it	O
from	O
the	O
cell	O
surface	O
[	O
50	O
]	O
.	O

Reduced	O
expression	O
of	O
TIMP3	O
would	O
,	O
therefore	O
,	O
foster	O
signaling	O
through	O
TNF	O
alpha	O
by	O
releasing	O
inhibition	O
of	O
TNF	O
alpha	O
converting	O
enzyme	O
.	O

In	O
agreement	O
with	O
this	O
,	O
TIMP3	O
can	O
promote	O
apoptosis	O
[	O
52	O
]	O
;	O
thus	O
,	O
its	O
down	O
-	O
regulation	O
in	O
BT	O
.	O
siMUC1	O
provides	O
another	O
mechanism	O
by	O
which	O
these	O
cells	O
are	O
able	O
to	O
resist	O
the	O
increased	O
apoptosis	O
expected	O
with	O
loss	O
of	O
MUC1	O
.	O

Another	O
TIMP	O
target	O
responds	O
to	O
MUC1	O
siRNA	O
,	O
as	O
468	O
.	O
siMUC1	O
cells	O
show	O
significantly	O
increased	O
expression	O
of	O
MMP2	O
(	O
encoding	O
MMP	O
-	O
2	O
/	O
gelatinase	O
A	O
)	O
,	O
the	O
product	O
of	O
which	O
degrades	O
type	O
IV	O
collagen	O
[	O
52	O
]	O
.	O

In	O
breast	O
cancer	O
,	O
the	O
ratio	O
of	O
active	O
to	O
latent	O
MMP	O
-	O
2	O
increases	O
with	O
tumor	O
progression	O
;	O
MMP	O
-	O
2	O
may	O
facilitate	O
both	O
angiogenesis	O
and	O
metastasis	O
[	O
52	O
]	O
.	O

Its	O
increase	O
after	O
loss	O
of	O
MUC1	O
is	O
,	O
therefore	O
,	O
unexpected	O
,	O
but	O
at	O
least	O
two	O
factors	O
may	O
clarify	O
this	O
result	O
.	O

First	O
,	O
though	O
MMP	O
-	O
2	O
levels	O
are	O
increased	O
in	O
mouse	B-Species
mammary	O
tumors	O
,	O
its	O
expression	O
is	O
confined	O
to	O
the	O
stroma	O
[	O
53	O
]	O
,	O
suggesting	O
that	O
increased	O
MMP2	O
transcription	O
after	O
loss	O
of	O
the	O
epithelium	O
-	O
specific	O
MUC1	O
might	O
reflect	O
a	O
shift	O
towards	O
a	O
more	O
mesenchymal	O
phenotype	O
.	O

Second	O
,	O
MMP	O
-	O
2	O
levels	O
are	O
increased	O
by	O
overexpression	O
of	O
erbB2	O
[	O
52	O
]	O
;	O
previous	O
studies	O
have	O
shown	O
that	O
erbB2	O
and	O
Muc1	O
expression	O
are	O
mutually	O
exclusive	O
in	O
mammary	O
tumors	O
[	O
27	O
]	O
,	O
implying	O
that	O
MMP2	O
might	O
be	O
part	O
of	O
a	O
transcriptional	O
profile	O
linked	O
to	O
low	O
MUC1	O
levels	O
.	O
<EOS>	B-X
To	B-X
explore	B-X
the	B-X
myocardial	B-X
protective	B-X
effect	B-X
of	B-X
Neuregulin-4	B-X
(	B-X
NRG-4	B-X
)	B-X
gene	B-X
expression	B-X
on	B-X
spontaneous	B-X
hypertension	B-X
(	B-X
SHR	B-X
)	B-X
rats	B-X
and	B-X
its	B-X
mechanism	B-X
through	B-X
mediating	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
ErbB	B-X
signaling	B-X
pathway	B-X
,	B-X
this	B-X
study	B-X
was	B-X
conducted	B-X
.	B-X
For	B-X
this	B-X
purpose	B-X
,	B-X
forty	B-X
24-week-old	B-X
male	B-X
SPF	B-X
SHR	B-X
rats	B-X
were	B-X
selected	B-X
as	B-X
the	B-X
experimental	B-X
group	B-X
,	B-X
and	B-X
10	B-X
age	B-X
and	B-X
sex-matched	B-X
Wistar	B-X
Kyoto	B-X
(	B-X
WKY	B-X
)	B-X
rats	B-X
were	B-X
selected	B-X
as	B-X
the	B-X
control	B-X
group	B-X
.	B-X
Following	B-X
tail	B-X
vein	B-X
injection	B-X
of	B-X
recombinant	B-X
lentiviral	B-X
vectors	B-X
,	B-X
the	B-X
experimental	B-X
groups	B-X
were	B-X
constructed	B-X
as	B-X
the	B-X
control	B-X
group	B-X
(	B-X
SHR	B-X
rats	B-X
without	B-X
any	B-X
treatment	B-X
)	B-X
,	B-X
Empty	B-X
vector	B-X
group	B-X
(	B-X
Empty	B-X
Vector	B-X
transfection	B-X
)	B-X
,	B-X
shRNA	B-X
negative	B-X
control	B-X
(	B-X
NC	B-X
)	B-X
group	B-X
(	B-X
LV-shRNA-NRG-4	B-X
NC	B-X
transfection	B-X
to	B-X
silence	B-X
the	B-X
expression	B-X
of	B-X
NRG-4	B-X
)	B-X
,	B-X
shRNA	B-X
group	B-X
(	B-X
LV-shRNA-NRG-4	B-X
transfection	B-X
)	B-X
,	B-X
pcDNA3.1	B-X
(	B-X
-	B-X
)	B-X
NC	B-X
group	B-X
(	B-X
pcDNA3.1	B-X
(	B-X
-	B-X
)	B-X
-NRG-4	B-X
empty	B-X
vector	B-X
transfection	B-X
)	B-X
and	B-X
pcDNA3.1	B-X
(	B-X
-	B-X
)	B-X
group	B-X
(	B-X
pcDNA3.1	B-X
(	B-X
-	B-X
)	B-X
-NRG-4	B-X
transfection	B-X
to	B-X
overexpress	B-X
NRG-4	B-X
)	B-X
.	B-X
Quantitative	B-X
real-time	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
qRT-PCR	B-X
)	B-X
and	B-X
Western	B-X
blot	B-X
were	B-X
used	B-X
to	B-X
detect	B-X
the	B-X
expression	B-X
levels	B-X
In	B-X
addition	B-X
,	B-X
methyl	B-X
thiazolyl	B-X
tetrazolium	B-X
salt	B-X
(	B-X
MTT	B-X
)	B-X
assay	B-X
and	B-X
flow	B-X
cytometry	B-X
were	B-X
performed	B-X
to	B-X
detect	B-X
the	B-X
proliferation	B-X
and	B-X
apoptosis	B-X
of	B-X
cardiomyocytes	B-X
,	B-X
respectively	B-X
.	B-X
Results	B-X
showed	B-X
that	B-X
in	B-X
the	B-X
SHR	B-X
group	B-X
,	B-X
the	B-X
cardiomyocytes	B-X
showed	B-X
hypertrophy	B-X
,	B-X
disordered	B-X
arrangement	B-X
,	B-X
hyperchromatic	B-X
nucleus	B-X
,	B-X
irregular	B-X
shape	B-X
,	B-X
obvious	B-X
rupture	B-X
of	B-X
myocardial	B-X
fibers	B-X
,	B-X
and	B-X
obvious	B-X
proliferation	B-X
of	B-X
fibrous	B-X
stroma	B-X
;	B-X
obvious	B-X
myocardial	B-X
fibrosis	B-X
,	B-X
and	B-X
there	B-X
were	B-X
more	B-X
blue	B-X
collagen	B-X
fibers	B-X
around	B-X
cardiomyocytes	B-X
and	B-X
myocardial	B-X
arterioles	B-X
;	B-X
cardiomyocytes	B-X
were	B-X
swollen	B-X
,	B-X
muscle	B-X
fibers	B-X
arranged	B-X
disorderly	B-X
,	B-X
collagen	B-X
around	B-X
the	B-X
coronary	B-X
artery	B-X
and	B-X
myocardial	B-X
interstitium	B-X
increased	B-X
significantly	B-X
with	B-X
a	B-X
cross-linking	B-X
appearance	B-X
;	B-X
besides	B-X
,	B-X
compared	B-X
with	B-X
WKY	B-X
group	B-X
,	B-X
the	B-X
apoptosis	B-X
index	B-X
of	B-X
cardiomyocytes	B-X
in	B-X
SHR	B-X
group	B-X
was	B-X
significantly	B-X
increased	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
NRG-4	B-X
protein	B-X
was	B-X
decreased	B-X
in	B-X
the	B-X
SHR	B-X
group	B-X
compared	B-X
with	B-X
the	B-X
WKY	B-X
group	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
In	B-X
vitro	B-X
,	B-X
there	B-X
was	B-X
no	B-X
difference	B-X
in	B-X
the	B-X
mRNA	B-X
expression	B-X
of	B-X
NRG-4	B-X
,	B-X
ErbB2	B-X
and	B-X
ErbB4	B-X
,	B-X
MMP2	B-X
,	B-X
TGFÎ²1	B-X
and	B-X
Î±-SMA	B-X
,	B-X
as	B-X
well	B-X
as	B-X
Caspase3	B-X
,	B-X
Bax	B-X
and	B-X
Bcl-2	B-X
among	B-X
the	B-X
control	B-X
group	B-X
,	B-X
Empty	B-X
vector	B-X
group	B-X
,	B-X
shRNA	B-X
NC	B-X
group	B-X
and	B-X
pcDNA3.1	B-X
(	B-X
-	B-X
)	B-X
NC	B-X
group	B-X
(	B-X
P	B-X
>	B-X
0.05	B-X
)	B-X
.	B-X
While	B-X
shRNA	B-X
group	B-X
showed	B-X
decreased	B-X
expressions	B-X
of	B-X
NRG-4	B-X
,	B-X
ErbB2	B-X
,	B-X
ErbB4	B-X
,	B-X
MMP2	B-X
,	B-X
TGFÎ²1	B-X
,	B-X
Î±-SMA	B-X
and	B-X
Bcl-2	B-X
,	B-X
while	B-X
increased	B-X
Caspase3	B-X
and	B-X
Bax	B-X
expressions	B-X
,	B-X
as	B-X
well	B-X
as	B-X
promoted	B-X
cell	B-X
proliferation	B-X
and	B-X
cell	B-X
apoptosis	B-X
when	B-X
compared	B-X
with	B-X
the	B-X
shRNA	B-X
NC	B-X
group	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
;	B-X
while	B-X
compared	B-X
with	B-X
pcDNA3.1	B-X
(	B-X
-	B-X
)	B-X
NC	B-X
group	B-X
,	B-X
pcDNA3.1	B-X
(	B-X
-	B-X
)	B-X
group	B-X
had	B-X
highly	B-X
increased	B-X
expressions	B-X
of	B-X
NRG-4	B-X
,	B-X
ErbB2	B-X
,	B-X
ErbB4	B-X
,	B-X
MMP2	B-X
,	B-X
TGFÎ²1	B-X
,	B-X
Î±-SMA	B-X
and	B-X
Bcl-2	B-X
,	B-X
while	B-X
decreased	B-X
Caspase3	B-X
and	B-X
Bax	B-X
expressions	B-X
,	B-X
inhibited	B-X
cell	B-X
proliferation	B-X
and	B-X
cell	B-X
apoptosis	B-X
(	B-X
all	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
It	B-X
is	B-X
concluded	B-X
Upregulation	B-X
of	B-X
NRG-4	B-X
gene	B-X
expression	B-X
can	B-X
promote	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
ErbB	B-X
signaling	B-X
pathway	B-X
,	B-X
thus	B-X
inhibiting	B-X
the	B-X
proliferation	B-X
and	B-X
apoptosis	B-X
of	B-X
cardiomyocytes	B-X
in	B-X
SHR	B-X
rats	B-X
,	B-X
reversing	B-X
myocardial	B-X
fibrosis	B-X
,	B-X
and	B-X
playing	B-X
its	B-X
cardioprotective	B-X
role	B-X
.	B-X

It	O
is	O
intriguing	O
that	O
,	O
despite	O
increased	O
MMP2	O
transcription	O
,	O
invasion	O
is	O
decreased	O
in	O
468	O
.	O
siMUC1	O
cells	O
,	O
even	O
on	O
collagen	O
IV	O
.	O

This	O
may	O
reflect	O
insufficient	O
activation	O
of	O
MMP	O
-	O
2	O
,	O
as	O
the	O
precursor	O
protein	O
must	O
be	O
cleaved	O
for	O
enzymatic	O
function	O
[	O
52	O
]	O
.	O

Alternatively	O
,	O
the	O
slowed	O
invasion	O
of	O
these	O
cells	O
may	O
relate	O
to	O
impaired	O
adhesion	O
resulting	O
from	O
decreased	O
transcription	O
of	O
ITGAV	O
and	O
ITGB1	O
(	O
alpha	O
v	O
and	O
beta	O
1	O
integrins	O
,	O
respectively	O
)	O
.	O

Integrin	O
signaling	O
is	O
tied	O
to	O
life	O
-	O
or	O
-	O
death	O
decisions	O
in	O
epithelial	O
cells	O
,	O
and	O
integrin	O
expression	O
is	O
vital	O
for	O
processes	O
from	O
wound	O
healing	O
to	O
metastasis	O
[	O
54	O
]	O
.	O

Integrin	O
alpha	O
v	O
beta	O
3	O
is	O
implicated	O
in	O
facilitating	O
metastasis	O
of	O
breast	O
cancer	O
cells	O
to	O
bone	O
[	O
55	O
]	O
;	O
decreased	O
transcription	O
of	O
ITGAV	O
after	O
MUC1	O
siRNA	O
may	O
,	O
therefore	O
,	O
suggest	O
that	O
MUC1	O
is	O
involved	O
in	O
this	O
lethal	O
process	O
as	O
well	O
.	O

The	O
MUC1	O
oncogene	O
has	O
been	O
linked	O
to	O
apoptosis	O
[	O
18	O
,	O
20	O
,	O
26	O
]	O
,	O
proliferation	O
[	O
17	O
]	O
,	O
and	O
transcription	O
[	O
21	O
,	O
23	O
-	O
25	O
]	O
in	O
cancer	O
.	O
<EOS>	B-X
MUC1	B-X
is	B-X
an	B-X
oncoprotein	B-X
whose	B-X
overexpression	B-X
correlates	B-X
with	B-X
aggressiveness	B-X
of	B-X
tumors	B-X
and	B-X
poor	B-X
survival	B-X
of	B-X
cancer	B-X
patients	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
oncogenic	B-X
effects	B-X
of	B-X
MUC1	B-X
are	B-X
believed	B-X
to	B-X
occur	B-X
through	B-X
interaction	B-X
of	B-X
its	B-X
cytoplasmic	B-X
tail	B-X
with	B-X
signaling	B-X
molecules	B-X
.	B-X
As	B-X
expected	B-X
for	B-X
a	B-X
protein	B-X
with	B-X
oncogenic	B-X
functions	B-X
,	B-X
MUC1	B-X
is	B-X
linked	B-X
to	B-X
regulation	B-X
of	B-X
proliferation	B-X
,	B-X
apoptosis	B-X
,	B-X
invasion	B-X
,	B-X
and	B-X
transcription	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
carbonic	B-X
anhydrase	B-X
XII	B-X
(	B-X
CA12	B-X
)	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
expression	B-X
of	B-X
estrogen	B-X
receptor	B-X
alpha	B-X
(	B-X
ERÎ±	B-X
)	B-X
in	B-X
breast	B-X
cancer	B-X
and	B-X
is	B-X
linked	B-X
to	B-X
a	B-X
good	B-X
prognosis	B-X
with	B-X
a	B-X
lower	B-X
risk	B-X
of	B-X
metastasis	B-X
.	B-X
Transcription	B-X
Factor	B-X
Activator	B-X
Protein	B-X
2Î³	B-X
(	B-X
TFAP2C	B-X
,	B-X
AP-2Î³	B-X
)	B-X
governs	B-X
luminal	B-X
breast	B-X
cancer	B-X
phenotype	B-X
through	B-X
direct	B-X
and	B-X
indirect	B-X
regulation	B-X
of	B-X
ERÎ±	B-X
and	B-X
ERÎ±-associated	B-X
genes	B-X
,	B-X
GATA3	B-X
,	B-X
FOXA1	B-X
,	B-X
EGFR	B-X
,	B-X
CDH1	B-X
,	B-X
DSP	B-X
,	B-X
KRT7	B-X
,	B-X
FBP1	B-X
,	B-X
MYB	B-X
,	B-X
RET	B-X
,	B-X
KRT8	B-X
,	B-X
MUC1	B-X
,	B-X
and	B-X
ERBB2-genes	B-X
which	B-X
are	B-X
responsible	B-X
for	B-X
the	B-X
luminal	B-X
signature	B-X
in	B-X
breast	B-X
cancer	B-X
.	B-X
Herein	B-X
,	B-X
utilizing	B-X
chromatin	B-X
immunoprecipitation	B-X
and	B-X
direct	B-X
sequencing	B-X
(	B-X
ChIP-seq	B-X
)	B-X
,	B-X
we	B-X
show	B-X
that	B-X
CA12	B-X
is	B-X
regulated	B-X
by	B-X
AP-2Î³	B-X
through	B-X
binding	B-X
with	B-X
its	B-X
promoter	B-X
region	B-X
in	B-X
luminal	B-X
breast	B-X
cancer	B-X
cell	B-X
lines	B-X
and	B-X
indirectly	B-X
through	B-X
a	B-X
distal	B-X
estrogen-responsive	B-X
region	B-X
in	B-X
ERÎ±-positive	B-X
cell	B-X
lines	B-X
by	B-X
upregulation	B-X
of	B-X
ERÎ±	B-X
.	B-X
CA12	B-X
is	B-X
transcriptionally	B-X
silenced	B-X
in	B-X
basal	B-X
breast	B-X
cancer	B-X
cell	B-X
lines	B-X
through	B-X
histone	B-X
deacetylation	B-X
and	B-X
CpG	B-X
methylation	B-X
of	B-X
the	B-X
promoter	B-X
region	B-X
and	B-X
can	B-X
be	B-X
re-activated	B-X
with	B-X
Trichostatin	B-X
A	B-X
(	B-X
histone	B-X
deacetylase	B-X
inhibitor	B-X
)	B-X
and/or	B-X
5-aza-dC	B-X
(	B-X
an	B-X
inhibitor	B-X
of	B-X
DNA	B-X
methylation	B-X
)	B-X
.	B-X

However	O
,	O
the	O
two	O
cell	O
lines	O
chosen	O
for	O
our	O
study	O
display	O
very	O
different	O
responses	O
to	O
MUC1	O
siRNA	O
,	O
indicating	O
that	O
regulation	O
of	O
MUC1	O
in	O
breast	O
cancer	O
is	O
likely	O
quite	O
complex	O
and	O
cautioning	O
against	O
over	O
-	O
generalization	O
of	O
results	O
from	O
individual	O
cell	O
lines	O
.	O

Previous	O
reports	O
suggest	O
that	O
,	O
though	O
most	O
studies	O
outline	O
a	O
clearly	O
oncogenic	O
role	O
for	O
MUC1	O
in	O
breast	O
cancer	O
,	O
the	O
exact	O
details	O
may	O
vary	O
depending	O
on	O
factors	O
such	O
as	O
cell	O
type	O
and	O
signaling	O
context	O
.	O

For	O
example	O
,	O
MUC1	O
stimulates	O
Fas	O
-	O
mediated	O
apoptosis	O
in	O
CHO	O
cells	O
[	O
26	O
]	O
,	O
quite	O
unlike	O
the	O
inhibition	O
of	O
apoptosis	O
seen	O
in	O
other	O
cell	O
lines	O
.	O

Similarly	O
,	O
though	O
MUC1	O
drives	O
mammary	O
oncogenesis	O
in	O
its	O
own	O
right	O
[	O
9	O
]	O
and	O
facilitates	O
tumorigenesis	O
driven	O
by	O
other	O
oncogenes	O
[	O
7	O
,	O
8	O
]	O
,	O
Muc1	O
is	O
selectively	O
down	O
-	O
regulated	O
in	O
c	O
-	O
neu	O
-	O
induced	O
mouse	B-Species
mammary	O
tumors	O
[	O
27	O
]	O
,	O
indicating	O
that	O
the	O
context	O
of	O
oncogenic	O
signaling	O
is	O
vital	O
to	O
understanding	O
the	O
function	O
of	O
MUC1	O
.	O

Thus	O
,	O
it	O
is	O
important	O
to	O
consider	O
the	O
relative	O
levels	O
of	O
knockdown	O
of	O
MUC1	O
in	O
the	O
two	O
cell	O
lines	O
:	O
BT	O
-	O
20	O
cells	O
reduce	O
MUC1	O
expression	O
after	O
siRNA	O
less	O
strongly	O
than	O
do	O
MDA	O
-	O
MB	O
-	O
468	O
(	O
50	O
%	O
versus	O
75	O
%	O
knockdown	O
,	O
respectively	O
)	O
.	O

As	O
MUC1	O
serves	O
as	O
a	O
scaffold	O
[	O
11	O
]	O
,	O
overexpression	O
of	O
MUC1	O
relative	O
to	O
its	O
associated	O
signaling	O
proteins	O
might	O
create	O
a	O
dilution	O
effect	O
,	O
sequestering	O
signal	O
transducers	O
away	O
from	O
each	O
other	O
;	O
this	O
would	O
be	O
relieved	O
by	O
MUC1	O
siRNA	O
.	O

Thus	O
,	O
enough	O
MUC1	O
may	O
be	O
retained	O
in	O
BT	O
.	O
siMUC1	O
cells	O
for	O
its	O
oncogenic	O
effects	O
,	O
while	O
signaling	O
complex	O
formation	O
would	O
be	O
enhanced	O
by	O
lowering	O
the	O
amount	O
of	O
MUC1	O
relative	O
to	O
other	O
signaling	O
proteins	O
.	O

Conclusion	O
<EOS>	B-X
Conclusion	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X

The	O
contrast	O
between	O
the	O
MDA	O
-	O
MB	O
-	O
468	O
and	O
BT	O
-	O
20	O
lines	O
in	O
response	O
to	O
MUC1	O
siRNA	O
serves	O
as	O
a	O
reminder	O
that	O
simplified	O
models	O
such	O
as	O
cell	O
lines	O
fail	O
to	O
encompass	O
the	O
complexity	O
of	O
intact	O
biological	O
systems	O
.	O

This	O
report	O
describes	O
transcriptional	O
alterations	O
seen	O
after	O
MUC1	O
knockdown	O
:	O
decreased	O
transcription	O
of	O
MAP2K1	O
,	O
VEGF	O
,	O
PDGFA	O
,	O
ITGAV	O
,	O
TIMP3	O
,	O
CDC25A	O
,	O
and	O
JUN	O
,	O
and	O
increased	O
transcription	O
of	O
MMP2	O
,	O
TNF	O
,	O
and	O
RAF1	O
.	O

The	O
alterations	O
in	O
MAP2K1	O
,	O
RAF1	O
,	O
and	O
JUN	O
represent	O
a	O
novel	O
means	O
by	O
which	O
MUC1	O
can	O
affect	O
ERK1	O
/	O
2	O
signaling	O
:	O
transcriptional	O
regulation	O
of	O
MAPK	O
pathway	O
members	O
.	O

Oncogenic	O
events	O
are	O
also	O
altered	O
in	O
both	O
cell	O
lines	O
after	O
MUC1	O
siRNA	O
.	O
<EOS>	B-X
MUC1	B-X
is	B-X
an	B-X
oncoprotein	B-X
whose	B-X
overexpression	B-X
correlates	B-X
with	B-X
aggressiveness	B-X
of	B-X
tumors	B-X
and	B-X
poor	B-X
survival	B-X
of	B-X
cancer	B-X
patients	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
oncogenic	B-X
effects	B-X
of	B-X
MUC1	B-X
are	B-X
believed	B-X
to	B-X
occur	B-X
through	B-X
interaction	B-X
of	B-X
its	B-X
cytoplasmic	B-X
tail	B-X
with	B-X
signaling	B-X
molecules	B-X
.	B-X
As	B-X
expected	B-X
for	B-X
a	B-X
protein	B-X
with	B-X
oncogenic	B-X
functions	B-X
,	B-X
MUC1	B-X
is	B-X
linked	B-X
to	B-X
regulation	B-X
of	B-X
proliferation	B-X
,	B-X
apoptosis	B-X
,	B-X
invasion	B-X
,	B-X
and	B-X
transcription	B-X
.	B-X

These	O
results	O
strengthen	O
the	O
growing	O
ties	O
linking	O
MUC1	O
and	O
transcriptional	O
regulation	O
,	O
and	O
suggest	O
that	O
the	O
role	O
of	O
MUC1	O
in	O
breast	O
cancer	O
may	O
be	O
more	O
complex	O
than	O
a	O
direct	O
correlation	O
between	O
MUC1	O
level	O
and	O
oncogenic	O
function	O
.	O

Abbreviations	O
<EOS>	B-X
Abbreviations	B-X
can	B-X
be	B-X
clinical	B-X
jargon	B-X
(	B-X
writing	B-X
``	B-X
HIT	B-X
''	B-X
for	B-X
``	B-X
heparin	B-X
induced	B-X
thrombocytopenia	B-X
''	B-X
)	B-X
,	B-X
ambiguous	B-X
terms	B-X
that	B-X
require	B-X
expertise	B-X
to	B-X
disambiguate	B-X
(	B-X
using	B-X
``	B-X
MS	B-X
''	B-X
for	B-X
``	B-X
multiple	B-X
sclerosis	B-X
''	B-X
or	B-X
``	B-X
mental	B-X
status	B-X
''	B-X
)	B-X
,	B-X
or	B-X
domain-specific	B-X
vernacular	B-X
(	B-X
``	B-X
cb	B-X
''	B-X
for	B-X
``	B-X
complicated	B-X
by	B-X
''	B-X
)	B-X
.	B-X
Acronyms	B-X
,	B-X
initialisms	B-X
,	B-X
and	B-X
abbreviations	B-X
.	B-X
Medical	B-X
abbreviations	B-X
.	B-X
Undecipherable	B-X
abbreviations	B-X
.	B-X

BrdU	O
=	O
bromodeoxyuridine	O
;	O
EGF	O
=	O
epidermal	O
growth	O
factor	O
;	O
EGFR	O
=	O
epidermal	O
growth	O
factor	O
receptor	O
;	O
ERK	O
=	O
extracellular	O
signal	O
regulated	O
kinase	O
;	O
MAPK	O
=	O
mitogen	O
activated	O
protein	O
kinase	O
;	O
MEK	O
=	O
MAPK	O
and	O
ERK	O
kinase	O
;	O
MMP	O
=	O
matrix	O
metalloproteinases	O
;	O
MUC1	O
-	O
CT	O
=	O
MUC1	O
cytoplasmic	O
tail	O
;	O
MUC1	O
-	O
EX	O
=	O
MUC1	O
extracellular	O
subunit	O
;	O
PBS	O
=	O
phosphate	O
-	O
buffered	O
saline	O
;	O
PI	O
=	O
propidium	O
iodide	O
;	O
siRNA	O
=	O
small	O
interfering	O
RNA	O
;	O
TIMP	O
=	O
tissue	O
inhibitor	O
of	O
metalloproteinases	O
;	O
TNF	O
=	O
tumor	O
necrosis	O
factor	O
.	O
<EOS>	B-X
[	B-X
Bromodeoxyuridine	B-X
(	B-X
BrdU	B-X
)	B-X
.	B-X
Analysis	B-X
of	B-X
cellular	B-X
proliferation	B-X
]	B-X
.	B-X
5-Bromo-2'-deoxyuridine	B-X
(	B-X
bromodeoxyuridine	B-X
(	B-X
BrdU	B-X
)	B-X
)	B-X
,	B-X
a	B-X
modified	B-X
nucleotide	B-X
and	B-X
analog	B-X
of	B-X
thymidine	B-X
,	B-X
is	B-X
commonly	B-X
used	B-X
for	B-X
detecting	B-X
proliferating	B-X
cells	B-X
.	B-X
For	B-X
detection	B-X
,	B-X
an	B-X
anti-BrdU	B-X
antibody	B-X
(	B-X
probe	B-X
)	B-X
with	B-X
a	B-X
fluorescent	B-X
dye	B-X
is	B-X
applied	B-X
to	B-X
bind	B-X
the	B-X
BrdU	B-X
label	B-X
after	B-X
DNA	B-X
denaturation	B-X
.	B-X
In	B-X
this	B-X
protocol	B-X
,	B-X
we	B-X
provide	B-X
the	B-X
BrdU	B-X
labeling	B-X
method	B-X
for	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
studies	B-X
,	B-X
along	B-X
with	B-X
immunocytochemistry	B-X
(	B-X
ICC	B-X
)	B-X
/immunofluorescence	B-X
(	B-X
IF	B-X
)	B-X
and	B-X
immunohistochemistry	B-X
(	B-X
IHC	B-X
)	B-X
staining	B-X
procedures	B-X
,	B-X
respectively	B-X
.	B-X

Competing	O
interests	O
<EOS>	B-X
Elective	B-X
ventilation	B-X
and	B-X
interests	B-X
.	B-X
An	B-X
examination	B-X
of	B-X
the	B-X
principle	B-X
of	B-X
precedent	B-X
autonomy	B-X
reveals	B-X
that	B-X
a	B-X
future-binding	B-X
research	B-X
decision	B-X
is	B-X
within	B-X
the	B-X
scope	B-X
of	B-X
a	B-X
competent	B-X
person	B-X
's	B-X
critical	B-X
interests	B-X
,	B-X
if	B-X
the	B-X
decision	B-X
is	B-X
consistent	B-X
with	B-X
what	B-X
the	B-X
person	B-X
believes	B-X
gives	B-X
her	B-X
life	B-X
intrinsic	B-X
value	B-X
.	B-X
Safety	B-X
of	B-X
young	B-X
drivers	B-X
.	B-X
In	B-X
this	B-X
article	B-X
I	B-X
will	B-X
show	B-X
that	B-X
'best	B-X
interests	B-X
'	B-X
is	B-X
a	B-X
concept	B-X
that	B-X
fits	B-X
nicely	B-X
with	B-X
many	B-X
of	B-X
the	B-X
features	B-X
of	B-X
pragmatism	B-X
--	B-X
Holm	B-X
and	B-X
Edgar	B-X
's	B-X
rejection	B-X
of	B-X
the	B-X
principle	B-X
in	B-X
favour	B-X
of	B-X
pragmatism	B-X
it	B-X
will	B-X
be	B-X
suggested	B-X
is	B-X
misplaced	B-X
.	B-X
'Best	B-X
interests	B-X
'	B-X
as	B-X
a	B-X
principle	B-X
may	B-X
be	B-X
considered	B-X
an	B-X
embodiment	B-X
of	B-X
the	B-X
ideals	B-X
of	B-X
pragmatic	B-X
adjudication	B-X
.	B-X
The	B-X
paper	B-X
starts	B-X
by	B-X
briefly	B-X
introducing	B-X
the	B-X
concept	B-X
of	B-X
'best	B-X
interests	B-X
'	B-X
and	B-X
theories	B-X
of	B-X
judicial	B-X
and	B-X
legal	B-X
'pragmatism	B-X
'	B-X
.	B-X
The	B-X
paper	B-X
concludes	B-X
by	B-X
suggesting	B-X
how	B-X
we	B-X
view	B-X
the	B-X
relationship	B-X
between	B-X
'best	B-X
interests	B-X
'	B-X
and	B-X
'pragmatism	B-X
'	B-X
.	B-X

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O
<EOS>	B-X
In	B-X
this	B-X
letter	B-X
,	B-X
I	B-X
argue	B-X
that	B-X
in	B-X
reality	B-X
and	B-X
in	B-X
practice	B-X
,	B-X
authorship	B-X
delimitations	B-X
are	B-X
not	B-X
that	B-X
clear-cut	B-X
,	B-X
nor	B-X
are	B-X
all	B-X
contributions	B-X
equal	B-X
or	B-X
equally	B-X
weighted	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
contributions	B-X
of	B-X
each	B-X
author	B-X
to	B-X
multiauthored	B-X
biomedical	B-X
research	B-X
papers	B-X
.	B-X
Much	B-X
research	B-X
on	B-X
APP	B-X
focusses	B-X
on	B-X
potential	B-X
contributions	B-X
to	B-X
neurodegeneration	B-X
,	B-X
mostly	B-X
based	B-X
on	B-X
mouse	B-X
models	B-X
with	B-X
altered	B-X
expression	B-X
or	B-X
mutated	B-X
forms	B-X
of	B-X
APP	B-X
.	B-X
For	B-X
papers	B-X
in	B-X
which	B-X
the	B-X
first	B-X
and	B-X
second	B-X
authors	B-X
made	B-X
equal	B-X
contributions	B-X
,	B-X
mixed-gender	B-X
combinations	B-X
were	B-X
most	B-X
frequent	B-X
,	B-X
followed	B-X
by	B-X
male-male	B-X
and	B-X
then	B-X
female-female	B-X
author	B-X
combinations	B-X
.	B-X
For	B-X
papers	B-X
in	B-X
which	B-X
three	B-X
or	B-X
more	B-X
authors	B-X
made	B-X
equal	B-X
contributions	B-X
,	B-X
there	B-X
were	B-X
more	B-X
male	B-X
authors	B-X
than	B-X
female	B-X
authors	B-X
in	B-X
the	B-X
first	B-X
position	B-X
and	B-X
more	B-X
all-male	B-X
than	B-X
all-female	B-X
author	B-X
combinations	B-X
.	B-X
The	B-X
gender	B-X
inequalities	B-X
observed	B-X
among	B-X
authors	B-X
who	B-X
made	B-X
equal	B-X
contributions	B-X
are	B-X
not	B-X
consistent	B-X
with	B-X
random	B-X
or	B-X
alphabetical	B-X
ordering	B-X
of	B-X
authors	B-X
.	B-X

CLH	O
performed	O
all	O
studies	O
and	O
composed	O
the	O
manuscript	O
.	O

SJG	O
participated	O
in	O
the	O
design	O
and	O
coordination	O
of	O
the	O
studies	O
and	O
contributed	O
strongly	O
to	O
the	O
revision	O
of	O
the	O
manuscript	O
.	O

Both	O
authors	O
have	O
read	O
and	O
approved	O
the	O
manuscript	O
.	O
<EOS>	B-X
Depression	B-X
and	B-X
anxiety	B-X
in	B-X
patients	B-X
with	B-X
cancer	B-X
.	B-X
The	B-X
volume	B-X
was	B-X
similar	B-X
to	B-X
2016	B-X
despite	B-X
an	B-X
increase	B-X
in	B-X
manuscript	B-X
submissions	B-X
to	B-X
405	B-X
and	B-X
thus	B-X
reflects	B-X
a	B-X
slight	B-X
decrease	B-X
in	B-X
the	B-X
acceptance	B-X
rate	B-X
to	B-X
26.7	B-X
%	B-X
.	B-X
For	B-X
this	B-X
reason	B-X
,	B-X
over	B-X
the	B-X
years	B-X
,	B-X
the	B-X
Editors	B-X
have	B-X
felt	B-X
that	B-X
it	B-X
is	B-X
useful	B-X
to	B-X
annually	B-X
summarize	B-X
the	B-X
publications	B-X
into	B-X
broad	B-X
areas	B-X
of	B-X
interest	B-X
or	B-X
theme	B-X
,	B-X
so	B-X
that	B-X
readers	B-X
can	B-X
view	B-X
areas	B-X
of	B-X
interest	B-X
in	B-X
a	B-X
single	B-X
article	B-X
in	B-X
relation	B-X
to	B-X
each	B-X
other	B-X
and	B-X
other	B-X
contemporary	B-X
JCMR	B-X
articles	B-X
.	B-X
In	B-X
this	B-X
publication	B-X
,	B-X
the	B-X
manuscripts	B-X
are	B-X
presented	B-X
in	B-X
broad	B-X
themes	B-X
and	B-X
set	B-X
in	B-X
context	B-X
with	B-X
related	B-X
literature	B-X
and	B-X
previously	B-X
published	B-X
JCMR	B-X
papers	B-X
to	B-X
guide	B-X
continuity	B-X
of	B-X
thought	B-X
within	B-X
the	B-X
journal	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
I	B-X
have	B-X
elected	B-X
to	B-X
use	B-X
this	B-X
format	B-X
to	B-X
convey	B-X
information	B-X
regarding	B-X
the	B-X
editorial	B-X
process	B-X
to	B-X
the	B-X
readership.I	B-X
hope	B-X
that	B-X
you	B-X
find	B-X
the	B-X
open-access	B-X
system	B-X
increases	B-X
wider	B-X
reading	B-X
and	B-X
citation	B-X
of	B-X
your	B-X
papers	B-X
,	B-X
and	B-X
that	B-X
you	B-X
will	B-X
continue	B-X
to	B-X
send	B-X
your	B-X
very	B-X
best	B-X
,	B-X
high	B-X
quality	B-X
manuscripts	B-X
to	B-X
JCMR	B-X
for	B-X
consideration	B-X
.	B-X

The	O
recombination	O
-	O
associated	O
protein	O
RdgC	O
adopts	O
a	O
novel	O
toroidal	O
architecture	O
for	O
DNA	O
binding	O
<EOS>	B-X
RdgC	B-X
,	B-X
a	B-X
recombination-associated	B-X
DNA-binding	B-X
protein	B-X
,	B-X
is	B-X
a	B-X
potential	B-X
negative	B-X
regulator	B-X
of	B-X
RecA	B-X
function	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
have	B-X
determined	B-X
the	B-X
crystal	B-X
structure	B-X
of	B-X
RdgC	B-X
from	B-X
Pseudomonas	B-X
aeruginosa	B-X
.	B-X
The	B-X
structure	B-X
allows	B-X
us	B-X
to	B-X
propose	B-X
that	B-X
the	B-X
RdgC	B-X
dimer	B-X
binds	B-X
dsDNA	B-X
through	B-X
the	B-X
central	B-X
hole	B-X
of	B-X
approximately	B-X
30	B-X
A	B-X
diameter	B-X
.	B-X
The	B-X
proposed	B-X
model	B-X
is	B-X
supported	B-X
by	B-X
our	B-X
DNA-binding	B-X
assays	B-X
coupled	B-X
with	B-X
mutagenesis	B-X
,	B-X
which	B-X
indicate	B-X
that	B-X
the	B-X
conserved	B-X
positively	B-X
charged	B-X
residues	B-X
on	B-X
the	B-X
protein	B-X
surface	B-X
around	B-X
the	B-X
central	B-X
hole	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
DNA	B-X
binding	B-X
.	B-X
The	B-X
novel	B-X
ring-shaped	B-X
architecture	B-X
of	B-X
the	B-X
RdgC	B-X
dimer	B-X
has	B-X
significant	B-X
implications	B-X
for	B-X
its	B-X
role	B-X
in	B-X
homologous	B-X
recombination	B-X
.	B-X

Abstract	O
<EOS>	B-X
Abstract	B-X
writing	B-X
.	B-X
The	B-X
informative	B-X
abstract	B-X
.	B-X
Crafting	B-X
a	B-X
compelling	B-X
abstract	B-X
.	B-X
Why	B-X
the	B-X
structured	B-X
abstract	B-X
?	B-X

RecA	O
plays	O
a	O
central	O
role	O
in	O
the	O
nonmutagenic	O
repair	O
of	O
stalled	O
replication	O
forks	O
in	O
bacteria	O
.	O

RdgC	O
,	O
a	O
recombination	O
-	O
associated	O
DNA	O
-	O
binding	O
protein	O
,	O
is	O
a	O
potential	O
negative	O
regulator	O
of	O
RecA	O
function	O
.	O
<EOS>	B-X
RecA	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
in	B-X
the	B-X
nonmutagenic	B-X
repair	B-X
of	B-X
stalled	B-X
replication	B-X
forks	B-X
in	B-X
bacteria	B-X
.	B-X
RdgC	B-X
,	B-X
a	B-X
recombination-associated	B-X
DNA-binding	B-X
protein	B-X
,	B-X
is	B-X
a	B-X
potential	B-X
negative	B-X
regulator	B-X
of	B-X
RecA	B-X
function	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
have	B-X
determined	B-X
the	B-X
crystal	B-X
structure	B-X
of	B-X
RdgC	B-X
from	B-X
Pseudomonas	B-X
aeruginosa	B-X
.	B-X
The	B-X
structure	B-X
allows	B-X
us	B-X
to	B-X
propose	B-X
that	B-X
the	B-X
RdgC	B-X
dimer	B-X
binds	B-X
dsDNA	B-X
through	B-X
the	B-X
central	B-X
hole	B-X
of	B-X
approximately	B-X
30	B-X
A	B-X
diameter	B-X
.	B-X
The	B-X
proposed	B-X
model	B-X
is	B-X
supported	B-X
by	B-X
our	B-X
DNA-binding	B-X
assays	B-X
coupled	B-X
with	B-X
mutagenesis	B-X
,	B-X
which	B-X
indicate	B-X
that	B-X
the	B-X
conserved	B-X
positively	B-X
charged	B-X
residues	B-X
on	B-X
the	B-X
protein	B-X
surface	B-X
around	B-X
the	B-X
central	B-X
hole	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
DNA	B-X
binding	B-X
.	B-X
The	B-X
novel	B-X
ring-shaped	B-X
architecture	B-X
of	B-X
the	B-X
RdgC	B-X
dimer	B-X
has	B-X
significant	B-X
implications	B-X
for	B-X
its	B-X
role	B-X
in	B-X
homologous	B-X
recombination	B-X
.	B-X

Here	O
,	O
we	O
have	O
determined	O
the	O
crystal	O
structure	O
of	O
RdgC	O
from	O
Pseudomonas	B-Species
aeruginosa	I-Species
.	O
<EOS>	B-X
RdgC	B-X
,	B-X
a	B-X
recombination-associated	B-X
DNA-binding	B-X
protein	B-X
,	B-X
is	B-X
a	B-X
potential	B-X
negative	B-X
regulator	B-X
of	B-X
RecA	B-X
function	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
have	B-X
determined	B-X
the	B-X
crystal	B-X
structure	B-X
of	B-X
RdgC	B-X
from	B-X
Pseudomonas	B-X
aeruginosa	B-X
.	B-X
The	B-X
structure	B-X
allows	B-X
us	B-X
to	B-X
propose	B-X
that	B-X
the	B-X
RdgC	B-X
dimer	B-X
binds	B-X
dsDNA	B-X
through	B-X
the	B-X
central	B-X
hole	B-X
of	B-X
approximately	B-X
30	B-X
A	B-X
diameter	B-X
.	B-X
The	B-X
novel	B-X
ring-shaped	B-X
architecture	B-X
of	B-X
the	B-X
RdgC	B-X
dimer	B-X
has	B-X
significant	B-X
implications	B-X
for	B-X
its	B-X
role	B-X
in	B-X
homologous	B-X
recombination	B-X
.	B-X

The	O
J	O
-	O
shaped	O
monomer	O
has	O
a	O
unique	O
fold	O
and	O
can	O
be	O
divided	O
into	O
three	O
structural	O
domains	O
:	O
tip	O
domain	O
,	O
center	O
domain	O
and	O
base	O
domain	O
.	O

Two	O
such	O
monomers	O
dimerize	O
to	O
form	O
a	O
ring	O
-	O
shaped	O
molecule	O
of	O
approximate	O
2	O
-	O
fold	O
symmetry	O
.	O

Of	O
the	O
two	O
inter	O
-	O
subunit	O
interfaces	O
within	O
the	O
dimer	O
,	O
one	O
interface	O
(	O
'	O
interface	O
A	O
'	O
)	O
between	O
tip	O
/	O
center	O
domains	O
is	O
more	O
nonpolar	O
than	O
the	O
other	O
(	O
'	O
interface	O
B	O
'	O
)	O
between	O
base	O
domains	O
.	O

The	O
structure	O
allows	O
us	O
to	O
propose	O
that	O
the	O
RdgC	O
dimer	O
binds	O
dsDNA	O
through	O
the	O
central	O
hole	O
of	O
~	O
30	O
A	O
diameter	O
.	O
<EOS>	B-X
RecA	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
in	B-X
the	B-X
nonmutagenic	B-X
repair	B-X
of	B-X
stalled	B-X
replication	B-X
forks	B-X
in	B-X
bacteria	B-X
.	B-X
RdgC	B-X
,	B-X
a	B-X
recombination-associated	B-X
DNA-binding	B-X
protein	B-X
,	B-X
is	B-X
a	B-X
potential	B-X
negative	B-X
regulator	B-X
of	B-X
RecA	B-X
function	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
have	B-X
determined	B-X
the	B-X
crystal	B-X
structure	B-X
of	B-X
RdgC	B-X
from	B-X
Pseudomonas	B-X
aeruginosa	B-X
.	B-X
Two	B-X
such	B-X
monomers	B-X
dimerize	B-X
to	B-X
form	B-X
a	B-X
ring-shaped	B-X
molecule	B-X
of	B-X
approximate	B-X
2-fold	B-X
symmetry	B-X
.	B-X
Of	B-X
the	B-X
two	B-X
inter-subunit	B-X
interfaces	B-X
within	B-X
the	B-X
dimer	B-X
,	B-X
one	B-X
interface	B-X
(	B-X
'interface	B-X
A	B-X
'	B-X
)	B-X
between	B-X
tip/center	B-X
domains	B-X
is	B-X
more	B-X
nonpolar	B-X
than	B-X
the	B-X
other	B-X
(	B-X
'interface	B-X
B	B-X
'	B-X
)	B-X
between	B-X
base	B-X
domains	B-X
.	B-X
The	B-X
structure	B-X
allows	B-X
us	B-X
to	B-X
propose	B-X
that	B-X
the	B-X
RdgC	B-X
dimer	B-X
binds	B-X
dsDNA	B-X
through	B-X
the	B-X
central	B-X
hole	B-X
of	B-X
approximately	B-X
30	B-X
A	B-X
diameter	B-X
.	B-X
The	B-X
proposed	B-X
model	B-X
is	B-X
supported	B-X
by	B-X
our	B-X
DNA-binding	B-X
assays	B-X
coupled	B-X
with	B-X
mutagenesis	B-X
,	B-X
which	B-X
indicate	B-X
that	B-X
the	B-X
conserved	B-X
positively	B-X
charged	B-X
residues	B-X
on	B-X
the	B-X
protein	B-X
surface	B-X
around	B-X
the	B-X
central	B-X
hole	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
DNA	B-X
binding	B-X
.	B-X
The	B-X
novel	B-X
ring-shaped	B-X
architecture	B-X
of	B-X
the	B-X
RdgC	B-X
dimer	B-X
has	B-X
significant	B-X
implications	B-X
for	B-X
its	B-X
role	B-X
in	B-X
homologous	B-X
recombination	B-X
.	B-X

The	O
proposed	O
model	O
is	O
supported	O
by	O
our	O
DNA	O
-	O
binding	O
assays	O
coupled	O
with	O
mutagenesis	O
,	O
which	O
indicate	O
that	O
the	O
conserved	O
positively	O
charged	O
residues	O
on	O
the	O
protein	O
surface	O
around	O
the	O
central	O
hole	O
play	O
important	O
roles	O
in	O
DNA	O
binding	O
.	O
<EOS>	B-X
RecA	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
in	B-X
the	B-X
nonmutagenic	B-X
repair	B-X
of	B-X
stalled	B-X
replication	B-X
forks	B-X
in	B-X
bacteria	B-X
.	B-X
RdgC	B-X
,	B-X
a	B-X
recombination-associated	B-X
DNA-binding	B-X
protein	B-X
,	B-X
is	B-X
a	B-X
potential	B-X
negative	B-X
regulator	B-X
of	B-X
RecA	B-X
function	B-X
.	B-X
The	B-X
structure	B-X
allows	B-X
us	B-X
to	B-X
propose	B-X
that	B-X
the	B-X
RdgC	B-X
dimer	B-X
binds	B-X
dsDNA	B-X
through	B-X
the	B-X
central	B-X
hole	B-X
of	B-X
approximately	B-X
30	B-X
A	B-X
diameter	B-X
.	B-X
The	B-X
proposed	B-X
model	B-X
is	B-X
supported	B-X
by	B-X
our	B-X
DNA-binding	B-X
assays	B-X
coupled	B-X
with	B-X
mutagenesis	B-X
,	B-X
which	B-X
indicate	B-X
that	B-X
the	B-X
conserved	B-X
positively	B-X
charged	B-X
residues	B-X
on	B-X
the	B-X
protein	B-X
surface	B-X
around	B-X
the	B-X
central	B-X
hole	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
DNA	B-X
binding	B-X
.	B-X

The	O
novel	O
ring	O
-	O
shaped	O
architecture	O
of	O
the	O
RdgC	O
dimer	O
has	O
significant	O
implications	O
for	O
its	O
role	O
in	O
homologous	O
recombination	O
.	O
<EOS>	B-X
RecA	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
in	B-X
the	B-X
nonmutagenic	B-X
repair	B-X
of	B-X
stalled	B-X
replication	B-X
forks	B-X
in	B-X
bacteria	B-X
.	B-X
RdgC	B-X
,	B-X
a	B-X
recombination-associated	B-X
DNA-binding	B-X
protein	B-X
,	B-X
is	B-X
a	B-X
potential	B-X
negative	B-X
regulator	B-X
of	B-X
RecA	B-X
function	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
have	B-X
determined	B-X
the	B-X
crystal	B-X
structure	B-X
of	B-X
RdgC	B-X
from	B-X
Pseudomonas	B-X
aeruginosa	B-X
.	B-X
The	B-X
J-shaped	B-X
monomer	B-X
has	B-X
a	B-X
unique	B-X
fold	B-X
and	B-X
can	B-X
be	B-X
divided	B-X
into	B-X
three	B-X
structural	B-X
domains	B-X
:	B-X
tip	B-X
domain	B-X
,	B-X
center	B-X
domain	B-X
and	B-X
base	B-X
domain	B-X
.	B-X
Two	B-X
such	B-X
monomers	B-X
dimerize	B-X
to	B-X
form	B-X
a	B-X
ring-shaped	B-X
molecule	B-X
of	B-X
approximate	B-X
2-fold	B-X
symmetry	B-X
.	B-X
Of	B-X
the	B-X
two	B-X
inter-subunit	B-X
interfaces	B-X
within	B-X
the	B-X
dimer	B-X
,	B-X
one	B-X
interface	B-X
(	B-X
'interface	B-X
A	B-X
'	B-X
)	B-X
between	B-X
tip/center	B-X
domains	B-X
is	B-X
more	B-X
nonpolar	B-X
than	B-X
the	B-X
other	B-X
(	B-X
'interface	B-X
B	B-X
'	B-X
)	B-X
between	B-X
base	B-X
domains	B-X
.	B-X
The	B-X
structure	B-X
allows	B-X
us	B-X
to	B-X
propose	B-X
that	B-X
the	B-X
RdgC	B-X
dimer	B-X
binds	B-X
dsDNA	B-X
through	B-X
the	B-X
central	B-X
hole	B-X
of	B-X
approximately	B-X
30	B-X
A	B-X
diameter	B-X
.	B-X
The	B-X
proposed	B-X
model	B-X
is	B-X
supported	B-X
by	B-X
our	B-X
DNA-binding	B-X
assays	B-X
coupled	B-X
with	B-X
mutagenesis	B-X
,	B-X
which	B-X
indicate	B-X
that	B-X
the	B-X
conserved	B-X
positively	B-X
charged	B-X
residues	B-X
on	B-X
the	B-X
protein	B-X
surface	B-X
around	B-X
the	B-X
central	B-X
hole	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
DNA	B-X
binding	B-X
.	B-X
The	B-X
novel	B-X
ring-shaped	B-X
architecture	B-X
of	B-X
the	B-X
RdgC	B-X
dimer	B-X
has	B-X
significant	B-X
implications	B-X
for	B-X
its	B-X
role	B-X
in	B-X
homologous	B-X
recombination	B-X
.	B-X

INTRODUCTION	O

Homologous	O
recombination	O
systems	O
contribute	O
to	O
the	O
maintenance	O
of	O
genome	O
integrity	O
and	O
are	O
essential	O
for	O
the	O
repair	O
of	O
stalled	O
replication	O
forks	O
(	O
1	O
)	O
.	O

Genetic	O
studies	O
of	O
the	O
recombination	O
-	O
dependent	O
growth	O
C	O
(	O
rdgC	O
)	O
gene	O
in	O
bacterial	O
systems	O
have	O
suggested	O
that	O
it	O
is	O
involved	O
in	O
DNA	O
replication	O
and	O
recombination	O
(	O
2	O
,	O
3	O
)	O
.	O

In	O
Neisseria	B-Species
gonorrhoeae	I-Species
(	O
the	O
gonococcus	O
)	O
,	O
RdgC	O
is	O
required	O
for	O
efficient	O
pilin	O
antigenic	O
variation	O
and	O
plays	O
some	O
role	O
in	O
cell	O
growth	O
(	O
4	O
,	O
5	O
)	O
.	O

The	O
Escherichia	B-Species
coli	I-Species
rdgC	O
gene	O
encodes	O
a	O
DNA	O
-	O
binding	O
protein	O
of	O
34	O
kDa	O
,	O
whose	O
expression	O
level	O
was	O
at	O
its	O
highest	O
during	O
exponential	O
phase	O
,	O
reaching	O
its	O
maximum	O
at	O
~	O
1000	O
dimers	O
per	O
cell	O
(	O
2	O
)	O
.	O

Its	O
level	O
decreased	O
sharply	O
to	O
~	O
50	O
dimers	O
per	O
cell	O
in	O
stationary	O
phase	O
.	O

This	O
profile	O
suggests	O
that	O
RdgC	O
might	O
function	O
during	O
the	O
period	O
of	O
DNA	O
replication	O
(	O
2	O
)	O
.	O

The	O
RecA	O
proteins	O
and	O
their	O
homologs	O
play	O
a	O
key	O
role	O
in	O
recombinational	O
DNA	O
repair	O
in	O
bacteria	O
and	O
eukaryotes	O
.	O
<EOS>	B-X
Homologous	B-X
recombinational	B-X
repair	B-X
is	B-X
an	B-X
essential	B-X
mechanism	B-X
for	B-X
repair	B-X
of	B-X
double-strand	B-X
breaks	B-X
in	B-X
DNA	B-X
.	B-X
Recombinases	B-X
of	B-X
the	B-X
RecA-fold	B-X
family	B-X
play	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
this	B-X
process	B-X
,	B-X
forming	B-X
filaments	B-X
that	B-X
utilize	B-X
ATP	B-X
to	B-X
mediate	B-X
their	B-X
interactions	B-X
with	B-X
single-	B-X
and	B-X
double-stranded	B-X
DNA	B-X
.	B-X
The	B-X
recombinase	B-X
molecules	B-X
present	B-X
in	B-X
the	B-X
archaea	B-X
(	B-X
RadA	B-X
)	B-X
and	B-X
eukaryota	B-X
(	B-X
Rad51	B-X
)	B-X
are	B-X
more	B-X
closely	B-X
related	B-X
to	B-X
each	B-X
other	B-X
than	B-X
to	B-X
their	B-X
bacterial	B-X
counterpart	B-X
(	B-X
RecA	B-X
)	B-X
and	B-X
,	B-X
as	B-X
a	B-X
result	B-X
,	B-X
RadA	B-X
makes	B-X
a	B-X
suitable	B-X
model	B-X
for	B-X
the	B-X
eukaryotic	B-X
system	B-X
.	B-X
The	B-X
crystal	B-X
structure	B-X
of	B-X
Sulfolobus	B-X
solfataricus	B-X
RadA	B-X
has	B-X
been	B-X
solved	B-X
to	B-X
a	B-X
resolution	B-X
of	B-X
3.2	B-X
A	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
nucleotide	B-X
analogues	B-X
or	B-X
DNA	B-X
,	B-X
revealing	B-X
a	B-X
narrow	B-X
filamentous	B-X
assembly	B-X
with	B-X
three	B-X
molecules	B-X
per	B-X
helical	B-X
turn	B-X
.	B-X
As	B-X
observed	B-X
in	B-X
other	B-X
RecA-family	B-X
recombinases	B-X
,	B-X
each	B-X
RadA	B-X
molecule	B-X
in	B-X
the	B-X
filament	B-X
is	B-X
linked	B-X
to	B-X
its	B-X
neighbour	B-X
via	B-X
interactions	B-X
of	B-X
a	B-X
short	B-X
beta-strand	B-X
with	B-X
the	B-X
neighbouring	B-X
ATPase	B-X
domain	B-X
.	B-X
However	B-X
,	B-X
despite	B-X
apparent	B-X
flexibility	B-X
between	B-X
domains	B-X
,	B-X
comparison	B-X
with	B-X
other	B-X
structures	B-X
indicates	B-X
conservation	B-X
of	B-X
a	B-X
number	B-X
of	B-X
key	B-X
interactions	B-X
that	B-X
introduce	B-X
rigidity	B-X
to	B-X
the	B-X
system	B-X
,	B-X
allowing	B-X
allosteric	B-X
control	B-X
of	B-X
the	B-X
filament	B-X
by	B-X
interaction	B-X
with	B-X
ATP	B-X
.	B-X

Their	O
aberrant	O
reactions	O
could	O
result	O
in	O
gross	O
chromosomal	O
rearrangements	O
that	O
lead	O
to	O
human	B-Species
diseases	O
,	O
including	O
cancer	O
.	O

Therefore	O
,	O
their	O
functions	O
must	O
be	O
tightly	O
regulated	O
,	O
and	O
understanding	O
how	O
the	O
RecA	O
family	O
of	O
recombinases	O
is	O
regulated	O
is	O
of	O
utmost	O
importance	O
(	O
1	O
)	O
.	O

The	O
E	B-Species
.	I-Species
coli	I-Species
RdgC	O
protein	O
is	O
a	O
potential	O
negative	O
regulator	O
of	O
the	O
function	O
of	O
RecA	O
(	O
1	O
)	O
.	O

It	O
inhibits	O
RecA	O
-	O
promoted	O
DNA	O
strand	O
exchange	O
,	O
RecA	O
-	O
mediated	O
ATPase	O
activity	O
and	O
RecA	O
-	O
dependent	O
LexA	O
cleavage	O
(	O
1	O
)	O
.	O

Sedimentation	O
equilibrium	O
data	O
indicated	O
that	O
E	B-Species
.	I-Species
coli	I-Species
RdgC	O
exists	O
in	O
solution	O
as	O
a	O
mixture	O
of	O
oligomeric	O
states	O
in	O
equilibrium	O
,	O
most	O
likely	O
monomers	O
,	O
dimers	O
and	O
tetramers	O
(	O
1	O
)	O
.	O

This	O
concentration	O
-	O
dependent	O
change	O
in	O
the	O
oligomeric	O
state	O
appears	O
to	O
affect	O
its	O
mode	O
of	O
binding	O
to	O
DNA	O
and	O
its	O
capacity	O
to	O
inhibit	O
RecA	O
(	O
1	O
)	O
.	O

The	O
primary	O
mechanism	O
of	O
RdgC	O
inhibition	O
appears	O
to	O
involve	O
a	O
simple	O
competition	O
for	O
DNA	O
-	O
binding	O
sites	O
,	O
especially	O
on	O
double	O
-	O
stranded	O
DNA	O
(	O
dsDNA	O
)	O
(	O
1	O
)	O
.	O

Deletion	O
of	O
the	O
E	B-Species
.	I-Species
coli	I-Species
rdgC	O
gene	O
alone	O
causes	O
no	O
obvious	O
phenotype	O
but	O
is	O
highly	O
deleterious	O
in	O
strains	O
lacking	O
certain	O
enzymes	O
involved	O
in	O
recombination	O
and	O
replication	O
restart	O
(	O
2	O
,	O
3	O
)	O
.	O

RdgC	O
is	O
essential	O
for	O
the	O
growth	O
of	O
an	O
E	B-Species
.	I-Species
coli	I-Species
strain	O
lacking	O
PriA	O
,	O
indicating	O
that	O
it	O
might	O
affect	O
replication	O
fork	O
progression	O
or	O
fork	O
rescue	O
(	O
2	O
)	O
.	O
<EOS>	B-X
Cells	B-X
deficient	B-X
in	B-X
the	B-X
Brca1	B-X
and	B-X
Brca2	B-X
genes	B-X
have	B-X
reduced	B-X
capacity	B-X
to	B-X
repair	B-X
DNA	B-X
double-strand	B-X
breaks	B-X
by	B-X
homologous	B-X
recombination	B-X
and	B-X
consequently	B-X
are	B-X
hypersensitive	B-X
to	B-X
DNA-damaging	B-X
agents	B-X
,	B-X
including	B-X
cisplatin	B-X
and	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerase	B-X
(	B-X
PARP	B-X
)	B-X
inhibitors	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
loss	B-X
of	B-X
the	B-X
MLL3/4	B-X
complex	B-X
protein	B-X
,	B-X
PTIP	B-X
,	B-X
protects	B-X
Brca1/2-deficient	B-X
cells	B-X
from	B-X
DNA	B-X
damage	B-X
and	B-X
rescues	B-X
the	B-X
lethality	B-X
of	B-X
Brca2-deficient	B-X
embryonic	B-X
stem	B-X
cells	B-X
.	B-X
Instead	B-X
,	B-X
its	B-X
absence	B-X
inhibits	B-X
the	B-X
recruitment	B-X
of	B-X
the	B-X
MRE11	B-X
nuclease	B-X
to	B-X
stalled	B-X
replication	B-X
forks	B-X
,	B-X
which	B-X
in	B-X
turn	B-X
protects	B-X
nascent	B-X
DNA	B-X
strands	B-X
from	B-X
extensive	B-X
degradation	B-X
.	B-X
More	B-X
generally	B-X
,	B-X
acquisition	B-X
of	B-X
PARP	B-X
inhibitors	B-X
and	B-X
cisplatin	B-X
resistance	B-X
is	B-X
associated	B-X
with	B-X
replication	B-X
fork	B-X
protection	B-X
in	B-X
Brca2-deficient	B-X
tumour	B-X
cells	B-X
that	B-X
do	B-X
not	B-X
develop	B-X
Brca2	B-X
reversion	B-X
mutations	B-X
.	B-X
Disruption	B-X
of	B-X
multiple	B-X
proteins	B-X
,	B-X
including	B-X
PARP1	B-X
and	B-X
CHD4	B-X
,	B-X
leads	B-X
to	B-X
the	B-X
same	B-X
end	B-X
point	B-X
of	B-X
replication	B-X
fork	B-X
protection	B-X
,	B-X
highlighting	B-X
the	B-X
complexities	B-X
by	B-X
which	B-X
tumour	B-X
cells	B-X
evade	B-X
chemotherapeutic	B-X
interventions	B-X
and	B-X
acquire	B-X
drug	B-X
resistance	B-X
.	B-X

PriA	O
provides	O
a	O
means	O
to	O
load	O
the	O
DnaB	O
replicative	O
helicase	O
at	O
DNA	O
replication	O
fork	O
and	O
D	O
loop	O
structures	O
(	O
2	O
)	O
.	O

RdgC	O
is	O
,	O
therefore	O
,	O
a	O
key	O
factor	O
in	O
the	O
rescue	O
of	O
stalled	O
or	O
broken	O
forks	O
and	O
subsequent	O
replication	O
restart	O
.	O
<EOS>	B-X
PriA	B-X
protein	B-X
provides	B-X
a	B-X
means	B-X
to	B-X
load	B-X
the	B-X
DnaB	B-X
replicative	B-X
helicase	B-X
at	B-X
DNA	B-X
replication	B-X
fork	B-X
and	B-X
D	B-X
loop	B-X
structures	B-X
,	B-X
and	B-X
is	B-X
therefore	B-X
a	B-X
key	B-X
factor	B-X
in	B-X
the	B-X
rescue	B-X
of	B-X
stalled	B-X
or	B-X
broken	B-X
forks	B-X
and	B-X
subsequent	B-X
replication	B-X
restart	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
nucleoid-associated	B-X
RdgC	B-X
protein	B-X
binds	B-X
non-specifically	B-X
to	B-X
single-stranded	B-X
(	B-X
ss	B-X
)	B-X
DNA	B-X
and	B-X
double-stranded	B-X
DNA	B-X
.	B-X
It	B-X
is	B-X
also	B-X
essential	B-X
for	B-X
growth	B-X
of	B-X
a	B-X
strain	B-X
lacking	B-X
PriA	B-X
,	B-X
indicating	B-X
that	B-X
it	B-X
might	B-X
affect	B-X
replication	B-X
fork	B-X
progression	B-X
or	B-X
fork	B-X
rescue	B-X
.	B-X
dnaC	B-X
suppressors	B-X
of	B-X
priA	B-X
overcome	B-X
this	B-X
inviability	B-X
,	B-X
especially	B-X
when	B-X
RecF	B-X
,	B-X
RecO	B-X
or	B-X
RecR	B-X
is	B-X
inactivated	B-X
,	B-X
indicating	B-X
that	B-X
RdgC	B-X
avoids	B-X
or	B-X
counters	B-X
a	B-X
toxic	B-X
effect	B-X
of	B-X
these	B-X
proteins	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
binding	B-X
of	B-X
RdgC	B-X
to	B-X
DNA	B-X
limits	B-X
RecA	B-X
loading	B-X
,	B-X
avoiding	B-X
problems	B-X
at	B-X
replication	B-X
forks	B-X
that	B-X
would	B-X
otherwise	B-X
require	B-X
PriA	B-X
to	B-X
promote	B-X
replication	B-X
restart	B-X
.	B-X
Mutations	B-X
in	B-X
RNA	B-X
polymerase	B-X
also	B-X
reduce	B-X
the	B-X
toxic	B-X
effect	B-X
of	B-X
RecFOR	B-X
,	B-X
providing	B-X
a	B-X
further	B-X
link	B-X
between	B-X
DNA	B-X
replication	B-X
,	B-X
transcription	B-X
and	B-X
repair	B-X
.	B-X

dnaC	O
suppressors	O
of	O
PriA	O
can	O
overcome	O
this	O
inviability	O
,	O
especially	O
when	O
RecF	O
,	O
RecO	O
or	O
RecR	O
is	O
inactivated	O
,	O
which	O
indicates	O
that	O
RdgC	O
avoids	O
or	O
counters	O
the	O
toxic	O
effect	O
of	O
these	O
proteins	O
by	O
limiting	O
inappropriate	O
RecA	O
loading	O
on	O
SSB	O
-	O
coated	O
ssDNA	O
(	O
2	O
)	O
.	O
<EOS>	B-X
PriA	B-X
protein	B-X
provides	B-X
a	B-X
means	B-X
to	B-X
load	B-X
the	B-X
DnaB	B-X
replicative	B-X
helicase	B-X
at	B-X
DNA	B-X
replication	B-X
fork	B-X
and	B-X
D	B-X
loop	B-X
structures	B-X
,	B-X
and	B-X
is	B-X
therefore	B-X
a	B-X
key	B-X
factor	B-X
in	B-X
the	B-X
rescue	B-X
of	B-X
stalled	B-X
or	B-X
broken	B-X
forks	B-X
and	B-X
subsequent	B-X
replication	B-X
restart	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
nucleoid-associated	B-X
RdgC	B-X
protein	B-X
binds	B-X
non-specifically	B-X
to	B-X
single-stranded	B-X
(	B-X
ss	B-X
)	B-X
DNA	B-X
and	B-X
double-stranded	B-X
DNA	B-X
.	B-X
It	B-X
is	B-X
also	B-X
essential	B-X
for	B-X
growth	B-X
of	B-X
a	B-X
strain	B-X
lacking	B-X
PriA	B-X
,	B-X
indicating	B-X
that	B-X
it	B-X
might	B-X
affect	B-X
replication	B-X
fork	B-X
progression	B-X
or	B-X
fork	B-X
rescue	B-X
.	B-X
dnaC	B-X
suppressors	B-X
of	B-X
priA	B-X
overcome	B-X
this	B-X
inviability	B-X
,	B-X
especially	B-X
when	B-X
RecF	B-X
,	B-X
RecO	B-X
or	B-X
RecR	B-X
is	B-X
inactivated	B-X
,	B-X
indicating	B-X
that	B-X
RdgC	B-X
avoids	B-X
or	B-X
counters	B-X
a	B-X
toxic	B-X
effect	B-X
of	B-X
these	B-X
proteins	B-X
.	B-X
Mutations	B-X
modifying	B-X
ssDNA-binding	B-X
(	B-X
SSB	B-X
)	B-X
protein	B-X
also	B-X
negate	B-X
this	B-X
toxic	B-X
effect	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
toxicity	B-X
reflects	B-X
inappropriate	B-X
loading	B-X
of	B-X
RecA	B-X
on	B-X
SSB-coated	B-X
ssDNA	B-X
,	B-X
leading	B-X
to	B-X
excessive	B-X
or	B-X
untimely	B-X
RecA	B-X
activity	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
binding	B-X
of	B-X
RdgC	B-X
to	B-X
DNA	B-X
limits	B-X
RecA	B-X
loading	B-X
,	B-X
avoiding	B-X
problems	B-X
at	B-X
replication	B-X
forks	B-X
that	B-X
would	B-X
otherwise	B-X
require	B-X
PriA	B-X
to	B-X
promote	B-X
replication	B-X
restart	B-X
.	B-X
Mutations	B-X
in	B-X
RNA	B-X
polymerase	B-X
also	B-X
reduce	B-X
the	B-X
toxic	B-X
effect	B-X
of	B-X
RecFOR	B-X
,	B-X
providing	B-X
a	B-X
further	B-X
link	B-X
between	B-X
DNA	B-X
replication	B-X
,	B-X
transcription	B-X
and	B-X
repair	B-X
.	B-X

The	O
DNA	O
-	O
binding	O
ability	O
of	O
the	O
RdgC	O
protein	O
has	O
been	O
demonstrated	O
clearly	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
2	O
)	O
.	O

Escherichia	B-Species
coli	I-Species
RdgC	O
binds	O
non	O
-	O
specifically	O
to	O
dsDNA	O
and	O
with	O
higher	O
affinity	O
than	O
ssDNA	O
(	O
2	O
)	O
.	O

RdgC	O
from	O
N	B-Species
.	I-Species
meningitidis	I-Species
also	O
binds	O
DNA	O
with	O
little	O
specificity	O
for	O
sequence	O
or	O
structure	O
,	O
like	O
the	O
E	B-Species
.	I-Species
coli	I-Species
protein	O
(	O
4	O
)	O
.	O

RdgC	O
exhibits	O
no	O
preference	O
for	O
DNA	O
replication	O
or	O
recombination	O
intermediates	O
(	O
2	O
)	O
.	O
<EOS>	B-X
Given	B-X
the	B-X
low	B-X
rate	B-X
of	B-X
herpesvirus	B-X
nucleotide	B-X
substitution	B-X
,	B-X
recombination	B-X
can	B-X
be	B-X
seen	B-X
as	B-X
an	B-X
essential	B-X
evolutionary	B-X
driving	B-X
force	B-X
although	B-X
it	B-X
is	B-X
likely	B-X
underestimated	B-X
.	B-X
Recombination	B-X
in	B-X
alphaherpesviruses	B-X
is	B-X
intimately	B-X
linked	B-X
to	B-X
DNA	B-X
replication	B-X
.	B-X
Both	B-X
viral	B-X
and	B-X
cellular	B-X
proteins	B-X
participate	B-X
in	B-X
this	B-X
recombination-dependent	B-X
replication	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
inverted	B-X
repeats	B-X
in	B-X
the	B-X
alphaherpesvirus	B-X
genomes	B-X
allows	B-X
segment	B-X
inversion	B-X
as	B-X
a	B-X
consequence	B-X
of	B-X
specific	B-X
recombination	B-X
between	B-X
repeated	B-X
sequences	B-X
during	B-X
DNA	B-X
replication	B-X
.	B-X
High	B-X
molecular	B-X
weight	B-X
intermediates	B-X
of	B-X
replication	B-X
,	B-X
called	B-X
concatemers	B-X
,	B-X
are	B-X
the	B-X
site	B-X
of	B-X
early	B-X
recombination	B-X
events	B-X
.	B-X
The	B-X
analysis	B-X
of	B-X
concatemers	B-X
from	B-X
cells	B-X
coinfected	B-X
by	B-X
two	B-X
distinguishable	B-X
alphaherpesviruses	B-X
provides	B-X
an	B-X
efficient	B-X
tool	B-X
to	B-X
study	B-X
recombination	B-X
without	B-X
the	B-X
bias	B-X
introduced	B-X
by	B-X
invisible	B-X
or	B-X
non-viable	B-X
recombinants	B-X
,	B-X
and	B-X
by	B-X
dominance	B-X
of	B-X
a	B-X
virus	B-X
over	B-X
recombinants	B-X
.	B-X
Intraspecific	B-X
recombination	B-X
frequently	B-X
occurs	B-X
between	B-X
strains	B-X
of	B-X
the	B-X
same	B-X
alphaherpesvirus	B-X
species	B-X
.	B-X
Interspecific	B-X
recombination	B-X
depends	B-X
on	B-X
enough	B-X
sequence	B-X
similarity	B-X
to	B-X
enable	B-X
recombination	B-X
between	B-X
distinct	B-X
alphaherpesvirus	B-X
species	B-X
.	B-X
The	B-X
most	B-X
important	B-X
prerequisite	B-X
for	B-X
successful	B-X
recombination	B-X
is	B-X
coinfection	B-X
of	B-X
the	B-X
individual	B-X
host	B-X
by	B-X
different	B-X
virus	B-X
strains	B-X
or	B-X
species	B-X
.	B-X

However	O
,	O
no	O
detectable	O
domains	O
or	O
nuclease	O
activity	O
could	O
be	O
identified	O
for	O
the	O
E	B-Species
.	I-Species
coli	I-Species
RdgC	O
protein	O
(	O
2	O
,	O
6	O
)	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
38	B-X
wheat	B-X
PYL	B-X
genes	B-X
(	B-X
TaPYLs	B-X
)	B-X
belonging	B-X
to	B-X
13	B-X
homoeologous	B-X
groups	B-X
were	B-X
identified	B-X
using	B-X
the	B-X
genome-search	B-X
method	B-X
,	B-X
with	B-X
26	B-X
and	B-X
12	B-X
PYL	B-X
genes	B-X
identified	B-X
in	B-X
Triticum	B-X
dicoccoides	B-X
and	B-X
Aegilops	B-X
tauschii	B-X
,	B-X
respectively	B-X
.	B-X
Interaction	B-X
network	B-X
and	B-X
miRNA	B-X
target	B-X
prediction	B-X
found	B-X
that	B-X
TaPYLs	B-X
could	B-X
interact	B-X
with	B-X
the	B-X
important	B-X
components	B-X
of	B-X
ABA	B-X
signaling	B-X
pathway	B-X
and	B-X
Tae-miR966b-3p	B-X
might	B-X
be	B-X
a	B-X
hub	B-X
regulator	B-X
mediating	B-X
wheat	B-X
ABA	B-X
signal	B-X
network	B-X
.	B-X
Expressions	B-X
of	B-X
10	B-X
TaPYLs	B-X
were	B-X
validated	B-X
by	B-X
QPCR	B-X
analysis	B-X
and	B-X
the	B-X
homoeologous	B-X
genes	B-X
showed	B-X
significantly	B-X
differential	B-X
expression	B-X
,	B-X
suggesting	B-X
subfunctionalization	B-X
of	B-X
them	B-X
has	B-X
occurred	B-X
.	B-X
Finally	B-X
,	B-X
3D	B-X
structures	B-X
of	B-X
the	B-X
TaPYL	B-X
proteins	B-X
were	B-X
predicted	B-X
by	B-X
homology	B-X
modeling	B-X
.	B-X

The	O
complexes	O
of	O
E	B-Species
.	I-Species
coli	I-Species
RdgC	O
with	O
both	O
linear	O
and	O
supercoiled	O
circular	O
plasmid	O
DNA	O
were	O
imaged	O
using	O
atomic	O
force	O
microscopy	O
(	O
7	O
)	O
.	O

RdgC	O
was	O
found	O
to	O
have	O
an	O
increased	O
affinity	O
to	O
DNA	O
ends	O
and	O
to	O
promote	O
bending	O
of	O
DNA	O
(	O
7	O
)	O
.	O

RdgC	O
has	O
the	O
effect	O
on	O
DNA	O
superstructure	O
;	O
the	O
promotion	O
of	O
DNA	O
condensation	O
was	O
observed	O
at	O
high	O
protein	O
concentrations	O
(	O
7	O
)	O
.	O
<EOS>	B-X
However	B-X
,	B-X
the	B-X
exact	B-X
function	B-X
of	B-X
the	B-X
corresponding	B-X
protein	B-X
,	B-X
RdgC	B-X
,	B-X
is	B-X
unknown	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
imaged	B-X
complexes	B-X
of	B-X
RdgC	B-X
with	B-X
both	B-X
linear	B-X
and	B-X
supercoiled	B-X
circular	B-X
plasmid	B-X
DNA	B-X
using	B-X
atomic	B-X
force	B-X
microscopy	B-X
.	B-X
We	B-X
confirm	B-X
that	B-X
RdgC	B-X
does	B-X
not	B-X
target	B-X
any	B-X
specific	B-X
sequences	B-X
in	B-X
double-stranded	B-X
DNA	B-X
,	B-X
as	B-X
has	B-X
been	B-X
suggested	B-X
from	B-X
biochemical	B-X
data	B-X
.	B-X
However	B-X
,	B-X
we	B-X
detect	B-X
an	B-X
increased	B-X
affinity	B-X
of	B-X
the	B-X
protein	B-X
to	B-X
DNA	B-X
ends	B-X
,	B-X
and	B-X
an	B-X
ability	B-X
to	B-X
promote	B-X
bending	B-X
of	B-X
DNA	B-X
.	B-X
Protein	B-X
complexes	B-X
with	B-X
supercoiled	B-X
plasmid	B-X
DNA	B-X
further	B-X
enabled	B-X
us	B-X
to	B-X
study	B-X
the	B-X
effect	B-X
of	B-X
RdgC	B-X
on	B-X
DNA	B-X
superstructure	B-X
.	B-X
At	B-X
high	B-X
concentrations	B-X
of	B-X
protein	B-X
we	B-X
observed	B-X
promotion	B-X
of	B-X
DNA	B-X
condensation	B-X
.	B-X
Recombination	B-X
is	B-X
largely	B-X
enhanced	B-X
by	B-X
close	B-X
contacts	B-X
of	B-X
distant	B-X
regions	B-X
along	B-X
the	B-X
DNA	B-X
strands	B-X
,	B-X
as	B-X
can	B-X
occur	B-X
,	B-X
for	B-X
instance	B-X
,	B-X
through	B-X
condensation	B-X
.	B-X
Our	B-X
data	B-X
thus	B-X
support	B-X
a	B-X
possible	B-X
function	B-X
of	B-X
RdgC	B-X
as	B-X
a	B-X
midwife	B-X
of	B-X
recombination	B-X
.	B-X

Recombination	O
is	O
largely	O
enhanced	O
by	O
close	O
contacts	O
of	O
distant	O
regions	O
along	O
the	O
DNA	O
strands	O
through	O
condensation	O
(	O
7	O
)	O
.	O

Pseudomonas	B-Species
aeruginosa	I-Species
is	O
a	O
ubiquitous	O
environmental	O
Gram	O
-	O
negative	O
bacterium	O
that	O
belongs	O
to	O
the	O
gamma	O
subdivision	O
of	O
the	O
Proteobacteria	O
.	O

Orthologs	O
of	O
the	O
rdgC	O
gene	O
are	O
found	O
only	O
in	O
beta	O
and	O
gamma	O
subdivisions	O
of	O
the	O
Proteobacteria	O
(	O
2	O
)	O
.	O

The	O
amino	O
acid	O
sequence	O
of	O
P	B-Species
.	I-Species
aeruginosa	I-Species
RdgC	O
,	O
a	O
306	O
-	O
residue	O
protein	O
,	O
shows	O
46	O
and	O
36	O
%	O
identities	O
against	O
those	O
of	O
E	B-Species
.	I-Species
coli	I-Species
and	O
N	B-Species
.	I-Species
meningitidis	I-Species
,	O
respectively	O
.	O

Despite	O
the	O
importance	O
of	O
DNA	O
-	O
binding	O
ability	O
of	O
RdgC	O
in	O
its	O
biological	O
roles	O
,	O
the	O
structural	O
details	O
of	O
RdgC	O
and	O
the	O
mechanism	O
of	O
its	O
action	O
remain	O
unclear	O
.	O

Here	O
,	O
we	O
report	O
the	O
crystal	O
structure	O
of	O
P	B-Species
.	I-Species
aeruginosa	I-Species
RdgC	O
as	O
determined	O
by	O
the	O
multiwavelength	O
anomalous	O
diffraction	O
(	O
MAD	O
)	O
method	O
of	O
X	O
-	O
ray	O
crystallography	O
.	O

It	O
reveals	O
that	O
RdgC	O
dimer	O
is	O
ring	O
-	O
shaped	O
,	O
with	O
a	O
central	O
hole	O
of	O
~	O
30	O
A	O
diameter	O
.	O

The	O
inside	O
surface	O
around	O
the	O
central	O
hole	O
is	O
rich	O
in	O
conserved	O
,	O
positively	O
charged	O
residues	O
,	O
which	O
are	O
implicated	O
in	O
DNA	O
-	O
binding	O
by	O
mutagenesis	O
.	O

We	O
propose	O
that	O
dsDNA	O
binds	O
to	O
RdgC	O
through	O
this	O
central	O
hole	O
.	O
<EOS>	B-X
RecA	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
in	B-X
the	B-X
nonmutagenic	B-X
repair	B-X
of	B-X
stalled	B-X
replication	B-X
forks	B-X
in	B-X
bacteria	B-X
.	B-X
RdgC	B-X
,	B-X
a	B-X
recombination-associated	B-X
DNA-binding	B-X
protein	B-X
,	B-X
is	B-X
a	B-X
potential	B-X
negative	B-X
regulator	B-X
of	B-X
RecA	B-X
function	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
have	B-X
determined	B-X
the	B-X
crystal	B-X
structure	B-X
of	B-X
RdgC	B-X
from	B-X
Pseudomonas	B-X
aeruginosa	B-X
.	B-X
The	B-X
structure	B-X
allows	B-X
us	B-X
to	B-X
propose	B-X
that	B-X
the	B-X
RdgC	B-X
dimer	B-X
binds	B-X
dsDNA	B-X
through	B-X
the	B-X
central	B-X
hole	B-X
of	B-X
approximately	B-X
30	B-X
A	B-X
diameter	B-X
.	B-X
The	B-X
proposed	B-X
model	B-X
is	B-X
supported	B-X
by	B-X
our	B-X
DNA-binding	B-X
assays	B-X
coupled	B-X
with	B-X
mutagenesis	B-X
,	B-X
which	B-X
indicate	B-X
that	B-X
the	B-X
conserved	B-X
positively	B-X
charged	B-X
residues	B-X
on	B-X
the	B-X
protein	B-X
surface	B-X
around	B-X
the	B-X
central	B-X
hole	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
DNA	B-X
binding	B-X
.	B-X
The	B-X
novel	B-X
ring-shaped	B-X
architecture	B-X
of	B-X
the	B-X
RdgC	B-X
dimer	B-X
has	B-X
significant	B-X
implications	B-X
for	B-X
its	B-X
role	B-X
in	B-X
homologous	B-X
recombination	B-X
.	B-X

Our	O
structure	O
provides	O
a	O
solid	O
structural	O
framework	O
for	O
a	O
better	O
understanding	O
of	O
the	O
role	O
of	O
RdgC	O
in	O
homologous	O
recombination	O
.	O

MATERIALS	O
AND	O
METHODS	O

Protein	O
expression	O
and	O
purification	O
<EOS>	B-X
Fusion	B-X
tags	B-X
are	B-X
versatile	B-X
tools	B-X
to	B-X
facilitate	B-X
efficient	B-X
protein	B-X
purification	B-X
and	B-X
to	B-X
improve	B-X
soluble	B-X
overexpression	B-X
of	B-X
proteins	B-X
.	B-X
Various	B-X
purification	B-X
and	B-X
fusion	B-X
tags	B-X
have	B-X
been	B-X
widely	B-X
used	B-X
for	B-X
overexpression	B-X
in	B-X
Escherichia	B-X
coli	B-X
.	B-X
Therefore	B-X
,	B-X
an	B-X
additional	B-X
purification	B-X
step	B-X
to	B-X
remove	B-X
fusion	B-X
tags	B-X
by	B-X
proteolytic	B-X
digestion	B-X
might	B-X
be	B-X
required	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
a	B-X
set	B-X
of	B-X
new	B-X
vectors	B-X
in	B-X
which	B-X
yeast	B-X
SUMO	B-X
(	B-X
SMT3	B-X
)	B-X
was	B-X
used	B-X
as	B-X
the	B-X
highly	B-X
specific	B-X
recognition	B-X
sequence	B-X
of	B-X
ubiquitin-like	B-X
protease	B-X
1	B-X
,	B-X
together	B-X
with	B-X
other	B-X
commonly	B-X
used	B-X
solubility	B-X
enhancing	B-X
proteins	B-X
,	B-X
such	B-X
as	B-X
glutathione	B-X
S-transferase	B-X
,	B-X
maltose	B-X
binding	B-X
protein	B-X
,	B-X
thioredoxin	B-X
and	B-X
trigger	B-X
factor	B-X
for	B-X
optimizing	B-X
soluble	B-X
expression	B-X
of	B-X
protein	B-X
of	B-X
interest	B-X
.	B-X
This	B-X
tandem	B-X
SUMO	B-X
(	B-X
T-SUMO	B-X
)	B-X
fusion	B-X
system	B-X
was	B-X
tested	B-X
for	B-X
soluble	B-X
expression	B-X
of	B-X
the	B-X
C-terminal	B-X
domain	B-X
of	B-X
TonB	B-X
from	B-X
different	B-X
organisms	B-X
and	B-X
for	B-X
the	B-X
antiviral	B-X
protein	B-X
scytovirin	B-X
.	B-X

The	O
rdgC	O
gene	O
(	O
PA3263	O
)	O
was	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
using	O
the	O
genomic	O
DNA	O
of	O
P	B-Species
.	I-Species
aeruginosa	I-Species
strain	O
PAO1	O
as	O
a	O
template	O
.	O

The	O
oligonucleotide	O
primers	O
designed	O
using	O
the	O
published	O
genome	O
sequence	O
(	O
8	O
)	O
were	O
5	O
'	O
-	O
G	O
GAA	O
TTC	O
CAT	O
ATG	O
TGG	O
TTC	O
CGC	O
AAT	O
CTG	O
CTC	O
G	O
-	O
3	O
'	O
(	O
forward	O
)	O
and	O
5	O
'	O
-	O
CCG	O
CCG	O
CTC	O
GAG	O
GAC	O
GCC	O
CTG	O
GGG	O
GAT	O
TTC	O
TTC	O
-	O
3	O
'	O
(	O
reverse	O
)	O
.	O

The	O
bases	O
in	O
bold	O
denote	O
the	O
NdeI	O
and	O
XhoI	O
cleavage	O
sites	O
,	O
respectively	O
.	O

The	O
PCR	O
product	O
was	O
digested	O
with	O
NdeI	O
and	O
XhoI	O
,	O
and	O
was	O
then	O
inserted	O
into	O
the	O
NdeI	O
/	O
XhoI	O
-	O
digested	O
expression	O
vector	O
pET	O
-	O
21a	O
(	O
+	O
)	O
(	O
Novagen	O
)	O
.	O

This	O
vector	O
construction	O
adds	O
an	O
eight	O
-	O
residue	O
tag	O
(	O
LEHHHHHH	O
)	O
to	O
the	O
carboxyl	O
terminus	O
of	O
the	O
gene	O
product	O
to	O
facilitate	O
protein	O
purification	O
.	O

The	O
protein	O
was	O
expressed	O
in	O
E	B-Species
.	I-Species
coli	I-Species
C41	O
(	O
DE3	O
)	O
cells	O
(	O
9	O
)	O
.	O

The	O
cells	O
were	O
grown	O
at	O
37	O
degrees	O
C	O
up	O
to	O
OD600	O
of	O
0	O
.	O
6	O
in	O
Luria	O
-	O
Bertani	O
medium	O
that	O
contained	O
50	O
mu	O
g	O
ml	O
-	O
1	O
ampicillin	O
,	O
and	O
the	O
protein	O
expression	O
was	O
induced	O
by	O
0	O
.	O
5	O
mM	O
isopropyl	O
-	O
beta	O
-	O
d	O
-	O
thiogalactopyranoside	O
(	O
IPTG	O
)	O
.	O

The	O
cells	O
were	O
allowed	O
to	O
grow	O
at	O
20	O
degrees	O
C	O
for	O
22	O
h	O
after	O
IPTG	O
induction	O
and	O
were	O
harvested	O
by	O
centrifugation	O
at	O
4200	O
g	O
(	O
6000	O
rev	O
min	O
-	O
1	O
;	O
Sorvall	O
GSA	O
rotor	O
)	O
for	O
10	O
min	O
at	O
4	O
degrees	O
C	O
.	O

The	O
cell	O
pellet	O
was	O
resuspended	O
in	O
an	O
ice	O
-	O
cold	O
lysis	O
buffer	O
[	O
20	O
mM	O
Tris	O
-	O
HCl	O
(	O
pH	O
7	O
.	O
9	O
)	O
,	O
500	O
mM	O
sodium	O
chloride	O
,	O
5	O
mM	O
imidazole	O
]	O
and	O
was	O
then	O
homogenized	O
with	O
an	O
ultrasonic	O
processor	O
.	O

The	O
crude	O
cell	O
extract	O
was	O
centrifuged	O
at	O
36	O
000	O
g	O
(	O
18	O
000	O
rev	O
min	O
-	O
1	O
;	O
Hanil	O
Supra	O
21	O
K	O
rotor	O
)	O
for	O
60	O
min	O
at	O
4	O
degrees	O
C	O
,	O
and	O
the	O
recombinant	O
protein	O
in	O
the	O
supernatant	O
fraction	O
was	O
purified	O
in	O
three	O
chromatographic	O
steps	O
.	O

The	O
first	O
purification	O
step	O
utilized	O
the	O
C	O
-	O
terminal	O
hexahistidine	O
-	O
tag	O
by	O
Ni2	O
+	O
-	O
chelated	O
HiTrap	O
chelating	O
column	O
(	O
GE	O
Healthcare	O
)	O
.	O

The	O
eluent	O
was	O
diluted	O
3	O
-	O
fold	O
with	O
50	O
mM	O
Tris	O
-	O
HCl	O
at	O
pH	O
7	O
.	O
4	O
.	O

The	O
diluted	O
solution	O
was	O
applied	O
to	O
a	O
20	O
-	O
ml	O
heparin	O
-	O
Sepharose	O
column	O
(	O
GE	O
Healthcare	O
)	O
,	O
which	O
was	O
previously	O
equilibrated	O
with	O
a	O
buffer	O
of	O
50	O
mM	O
Tris	O
-	O
HCl	O
(	O
pH	O
7	O
.	O
4	O
)	O
,	O
1	O
mM	O
dithiothreitol	O
and	O
1	O
mM	O
EDTA	O
.	O

The	O
protein	O
was	O
eluted	O
with	O
a	O
linear	O
gradient	O
of	O
0	O
-	O
2	O
.	O
0	O
M	O
sodium	O
chloride	O
in	O
the	O
same	O
buffer	O
.	O

The	O
first	O
peak	O
corresponded	O
to	O
high	O
molecular	O
aggregates	O
of	O
RdgC	O
and	O
the	O
second	O
peak	O
to	O
RdgC	O
dimers	O
,	O
which	O
was	O
also	O
consistent	O
with	O
our	O
dynamic	O
light	O
scattering	O
measurements	O
.	O

When	O
the	O
aggregates	O
were	O
not	O
separated	O
from	O
the	O
dimers	O
,	O
the	O
protein	O
readily	O
aggregated	O
within	O
a	O
day	O
.	O
<EOS>	B-X
Protein	B-X
aggregates	B-X
are	B-X
both	B-X
associated	B-X
with	B-X
disease	B-X
and	B-X
function	B-X
.	B-X
Because	B-X
a	B-X
variety	B-X
of	B-X
factors	B-X
induce	B-X
protein	B-X
aggregation	B-X
,	B-X
a	B-X
given	B-X
protein	B-X
can	B-X
aggregate	B-X
into	B-X
different	B-X
states	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
compare	B-X
the	B-X
structures	B-X
and	B-X
activities	B-X
of	B-X
five	B-X
distinct	B-X
protein	B-X
aggregates	B-X
of	B-X
a	B-X
single	B-X
protein	B-X
.	B-X
However	B-X
,	B-X
they	B-X
are	B-X
structurally	B-X
distinct	B-X
,	B-X
having	B-X
different	B-X
segments	B-X
of	B-X
the	B-X
protein	B-X
sequence	B-X
involved	B-X
in	B-X
secondary	B-X
structure	B-X
formation	B-X
.	B-X
The	B-X
observed	B-X
multidimensional	B-X
structure-activity	B-X
relationship	B-X
of	B-X
protein	B-X
aggregates	B-X
may	B-X
be	B-X
important	B-X
for	B-X
amyloid	B-X
diseases	B-X
but	B-X
may	B-X
also	B-X
be	B-X
advantageous	B-X
in	B-X
nanotechnology	B-X
.	B-X

The	O
dimer	O
fractions	O
were	O
concentrated	O
to	O
~	O
6	O
mg	O
ml	O
-	O
1	O
concentration	O
using	O
an	O
YM10	O
ultrafiltration	O
membrane	O
(	O
Millipore	O
-	O
Amicon	O
)	O
and	O
further	O
purified	O
by	O
gel	O
filtration	O
on	O
a	O
HiLoad	O
XK	O
16	O
Superdex	O
200	O
prep	O
-	O
grade	O
column	O
(	O
GE	O
Healthcare	O
)	O
,	O
which	O
was	O
previously	O
equilibrated	O
with	O
a	O
buffer	O
of	O
50	O
mM	O
Tris	O
-	O
HCl	O
(	O
pH	O
7	O
.	O
4	O
)	O
,	O
200	O
mM	O
sodium	O
chloride	O
,	O
1	O
mM	O
dithiothreitol	O
and	O
1	O
mM	O
EDTA	O
.	O

The	O
first	O
peak	O
corresponding	O
to	O
the	O
high	O
molecular	O
aggregates	O
of	O
RdgC	O
was	O
only	O
a	O
minor	O
component	O
,	O
and	O
the	O
second	O
peak	O
corresponding	O
to	O
RdgC	O
dimers	O
was	O
stable	O
for	O
several	O
weeks	O
when	O
frozen	O
at	O
-	O
70	O
degrees	O
C	O
.	O

The	O
procedure	O
for	O
purifying	O
the	O
SeMet	O
-	O
substituted	O
protein	O
was	O
the	O
same	O
,	O
except	O
for	O
the	O
presence	O
of	O
10	O
mM	O
dithiothreitol	O
in	O
all	O
buffers	O
used	O
during	O
purification	O
steps	O
.	O

Dynamic	O
light	O
scattering	O
experiments	O
were	O
performed	O
at	O
24	O
degrees	O
C	O
,	O
with	O
the	O
protein	O
(	O
at	O
2	O
mg	O
ml	O
-	O
1	O
concentration	O
)	O
dissolved	O
in	O
a	O
buffer	O
consisting	O
of	O
50	O
mM	O
Tris	O
-	O
HCl	O
(	O
pH	O
7	O
.	O
4	O
)	O
,	O
1	O
mM	O
dithiothreitol	O
,	O
1	O
mM	O
EDTA	O
and	O
200	O
mM	O
sodium	O
chloride	O
on	O
a	O
Model	O
DynaPro	O
-	O
801	O
instrument	O
(	O
Wyatt	O
,	O
Santa	O
Barbara	O
,	O
CA	O
,	O
USA	O
)	O
.	O

The	O
protein	O
concentration	O
was	O
estimated	O
by	O
measuring	O
the	O
absorbance	O
at	O
280	O
nm	O
,	O
employing	O
the	O
calculated	O
extinction	O
coefficient	O
of	O
20	O
910	O
M	O
-	O
1	O
cm	O
-	O
1	O
(	O
SWISS	O
-	O
PROT	O
;	O
http	O
:	O
/	O
/	O
www	O
.	O
expasy	O
.	O
ch	O
/	O
)	O
.	O

Mutagenesis	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
<EOS>	B-X
By	B-X
placing	B-X
deletion	B-X
in	B-X
the	B-X
oligonucleotide	B-X
adjacent	B-X
to	B-X
the	B-X
mutational	B-X
site	B-X
,	B-X
difference	B-X
in	B-X
electrophoretic	B-X
mobility	B-X
between	B-X
loop-hybrids	B-X
with	B-X
normal	B-X
and	B-X
mutated	B-X
DNA	B-X
was	B-X
distinguishable	B-X
in	B-X
a	B-X
native	B-X
polyacrylamide	B-X
gel	B-X
.	B-X
Our	B-X
mutation	B-X
detection	B-X
system	B-X
,	B-X
designated	B-X
the	B-X
loop-hybrid	B-X
mobility	B-X
shift	B-X
assay	B-X
was	B-X
sensitive	B-X
enough	B-X
to	B-X
detect	B-X
mutant	B-X
DNA	B-X
comprising	B-X
7.5	B-X
%	B-X
of	B-X
the	B-X
total	B-X
DNA	B-X
.	B-X
As	B-X
a	B-X
simple	B-X
and	B-X
straightforward	B-X
mutation	B-X
detection	B-X
technique	B-X
,	B-X
loop-hybrid	B-X
mobility	B-X
shift	B-X
assay	B-X
may	B-X
be	B-X
useful	B-X
for	B-X
the	B-X
molecular	B-X
diagnosis	B-X
of	B-X
certain	B-X
types	B-X
of	B-X
clinical	B-X
cancers	B-X
.	B-X
Given	B-X
these	B-X
premises	B-X
,	B-X
a	B-X
rigorous	B-X
and	B-X
comprehensive	B-X
understanding	B-X
of	B-X
interactions	B-X
between	B-X
pseudogene-parental	B-X
gene	B-X
RNA	B-X
pairs	B-X
and	B-X
RBPs	B-X
could	B-X
provide	B-X
further	B-X
insights	B-X
into	B-X
the	B-X
biological	B-X
bases	B-X
of	B-X
complex	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
cancer	B-X
,	B-X
cardiovascular	B-X
disease	B-X
,	B-X
and	B-X
type	B-X
2	B-X
diabetes	B-X
,	B-X
identifying	B-X
novel	B-X
predictive	B-X
and/or	B-X
prognostic	B-X
biomarkers.Herein	B-X
,	B-X
we	B-X
detail	B-X
easily	B-X
adaptable	B-X
protocols	B-X
of	B-X
plasmid-based	B-X
molecular	B-X
cloning	B-X
and	B-X
RNA-electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
used	B-X
in	B-X
our	B-X
laboratory	B-X
for	B-X
determining	B-X
the	B-X
interaction	B-X
between	B-X
a	B-X
cytoplasmatic	B-X
stabilizing	B-X
protein	B-X
(	B-X
Î±CP1	B-X
)	B-X
and	B-X
the	B-X
pseudogene-parental	B-X
gene	B-X
RNA	B-X
pair	B-X
HMGA1-p	B-X
/HMGA1	B-X
.	B-X

Point	O
mutants	O
were	O
prepared	O
using	O
the	O
QuikChange	O
Site	O
-	O
Directed	O
Mutagenesis	O
kit	O
(	O
Stratagene	O
)	O
,	O
and	O
the	O
mutations	O
were	O
confirmed	O
by	O
DNA	O
sequencing	O
.	O

The	O
seven	O
mutants	O
R4A	O
,	O
F120A	O
,	O
K146A	O
,	O
R198A	O
,	O
R208A	O
,	O
Q212A	O
and	O
R252A	O
were	O
well	O
expressed	O
and	O
soluble	O
.	O

The	O
three	O
mutants	O
K70A	O
,	O
R81A	O
and	O
R211A	O
were	O
not	O
expressed	O
,	O
while	O
R122A	O
mutant	O
was	O
expressed	O
but	O
was	O
not	O
soluble	O
.	O

Therefore	O
,	O
we	O
mutated	O
Lys70	O
,	O
Arg81	O
,	O
Arg122	O
and	O
Arg211	O
into	O
aspartate	O
.	O

The	O
K70D	O
,	O
R81D	O
,	O
R122D	O
and	O
R211D	O
mutants	O
were	O
well	O
expressed	O
and	O
soluble	O
.	O

The	O
soluble	O
mutants	O
were	O
expressed	O
and	O
purified	O
under	O
the	O
conditions	O
identical	O
to	O
those	O
for	O
the	O
wild	O
type	O
,	O
except	O
that	O
the	O
heparin	O
-	O
Sepharose	O
column	O
step	O
was	O
omitted	O
.	O

All	O
of	O
the	O
soluble	O
mutants	O
had	O
similar	O
elution	O
profiles	O
as	O
the	O
wild	O
type	O
upon	O
gel	O
filtration	O
,	O
and	O
the	O
dimer	O
fractions	O
were	O
used	O
for	O
DNA	O
-	O
binding	O
assays	O
.	O

We	O
mixed	O
5	O
mu	O
l	O
of	O
RdgC	O
(	O
1	O
.	O
1	O
mu	O
g	O
mu	O
l	O
-	O
1	O
)	O
and	O
5	O
mu	O
l	O
of	O
a	O
linear	O
dsDNA	O
with	O
414	O
bp	O
(	O
63	O
ng	O
mu	O
l	O
-	O
1	O
)	O
,	O
corresponding	O
to	O
the	O
molar	O
ratio	O
of	O
64	O
:	O
1	O
for	O
RdgC	O
dimer	O
to	O
dsDNA	O
.	O

The	O
reaction	O
mixtures	O
were	O
incubated	O
for	O
10	O
min	O
at	O
room	O
temperature	O
.	O

RdgC	O
-	O
DNA	O
complexes	O
were	O
analyzed	O
by	O
1	O
.	O
5	O
%	O
(	O
w	O
/	O
v	O
)	O
agarose	O
gel	O
electrophoresis	O
in	O
1	O
x	O
TAE	O
buffer	O
(	O
45	O
mM	O
Tris	O
-	O
acetate	O
at	O
pH	O
8	O
.	O
3	O
,	O
1	O
mM	O
EDTA	O
)	O
.	O

DNA	O
bands	O
were	O
visualized	O
by	O
ethidium	O
bromide	O
staining	O
.	O
<EOS>	B-X
Agarose	B-X
gel	B-X
electrophoresis	B-X
is	B-X
the	B-X
most	B-X
effective	B-X
way	B-X
of	B-X
separating	B-X
DNA	B-X
fragments	B-X
of	B-X
varying	B-X
sizes	B-X
ranging	B-X
from	B-X
100	B-X
bp	B-X
to	B-X
25	B-X
kb	B-X
(	B-X
1	B-X
)	B-X
.	B-X
The	B-X
use	B-X
of	B-X
agarose	B-X
gel	B-X
electrophoresis	B-X
revolutionized	B-X
the	B-X
separation	B-X
of	B-X
DNA	B-X
.	B-X
Prior	B-X
to	B-X
the	B-X
adoption	B-X
of	B-X
agarose	B-X
gels	B-X
,	B-X
DNA	B-X
was	B-X
primarily	B-X
separated	B-X
using	B-X
sucrose	B-X
density	B-X
gradient	B-X
centrifugation	B-X
,	B-X
which	B-X
only	B-X
provided	B-X
an	B-X
approximation	B-X
of	B-X
size	B-X
.	B-X
To	B-X
separate	B-X
DNA	B-X
using	B-X
agarose	B-X
gel	B-X
electrophoresis	B-X
,	B-X
the	B-X
DNA	B-X
is	B-X
loaded	B-X
into	B-X
pre-cast	B-X
wells	B-X
in	B-X
the	B-X
gel	B-X
and	B-X
a	B-X
current	B-X
applied	B-X
.	B-X
The	B-X
phosphate	B-X
backbone	B-X
of	B-X
the	B-X
DNA	B-X
(	B-X
and	B-X
RNA	B-X
)	B-X
molecule	B-X
is	B-X
negatively	B-X
charged	B-X
,	B-X
therefore	B-X
when	B-X
placed	B-X
in	B-X
an	B-X
electric	B-X
field	B-X
,	B-X
DNA	B-X
fragments	B-X
will	B-X
migrate	B-X
to	B-X
the	B-X
positively	B-X
charged	B-X
anode	B-X
.	B-X
Because	B-X
DNA	B-X
has	B-X
a	B-X
uniform	B-X
mass/charge	B-X
ratio	B-X
,	B-X
DNA	B-X
molecules	B-X
are	B-X
separated	B-X
by	B-X
size	B-X
within	B-X
an	B-X
agarose	B-X
gel	B-X
in	B-X
a	B-X
pattern	B-X
such	B-X
that	B-X
the	B-X
distance	B-X
traveled	B-X
is	B-X
inversely	B-X
proportional	B-X
to	B-X
the	B-X
log	B-X
of	B-X
its	B-X
molecular	B-X
weight	B-X
(	B-X
3	B-X
)	B-X
.	B-X
The	B-X
leading	B-X
model	B-X
for	B-X
DNA	B-X
movement	B-X
through	B-X
an	B-X
agarose	B-X
gel	B-X
is	B-X
``	B-X
biased	B-X
reptation	B-X
''	B-X
,	B-X
whereby	B-X
the	B-X
leading	B-X
edge	B-X
moves	B-X
forward	B-X
and	B-X
pulls	B-X
the	B-X
rest	B-X
of	B-X
the	B-X
molecule	B-X
along	B-X
(	B-X
4	B-X
)	B-X
.	B-X
The	B-X
rate	B-X
of	B-X
migration	B-X
of	B-X
a	B-X
DNA	B-X
molecule	B-X
through	B-X
a	B-X
gel	B-X
is	B-X
determined	B-X
by	B-X
the	B-X
following	B-X
:	B-X
1	B-X
)	B-X
size	B-X
of	B-X
DNA	B-X
molecule	B-X
;	B-X
2	B-X
)	B-X
agarose	B-X
concentration	B-X
;	B-X
3	B-X
)	B-X
DNA	B-X
conformation	B-X
(	B-X
5	B-X
)	B-X
;	B-X
4	B-X
)	B-X
voltage	B-X
applied	B-X
,	B-X
5	B-X
)	B-X
presence	B-X
of	B-X
ethidium	B-X
bromide	B-X
,	B-X
6	B-X
)	B-X
type	B-X
of	B-X
agarose	B-X
and	B-X
7	B-X
)	B-X
electrophoresis	B-X
buffer	B-X
.	B-X
After	B-X
separation	B-X
,	B-X
the	B-X
DNA	B-X
molecules	B-X
can	B-X
be	B-X
visualized	B-X
under	B-X
uv	B-X
light	B-X
after	B-X
staining	B-X
with	B-X
an	B-X
appropriate	B-X
dye	B-X
.	B-X
By	B-X
following	B-X
this	B-X
protocol	B-X
,	B-X
students	B-X
should	B-X
be	B-X
able	B-X
to	B-X
:	B-X
Understand	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
DNA	B-X
fragments	B-X
are	B-X
separated	B-X
within	B-X
a	B-X
gel	B-X
matrix	B-X
Understand	B-X
how	B-X
conformation	B-X
of	B-X
the	B-X
DNA	B-X
molecule	B-X
will	B-X
determine	B-X
its	B-X
mobility	B-X
through	B-X
a	B-X
gel	B-X
matrix	B-X
Identify	B-X
an	B-X
agarose	B-X
solution	B-X
of	B-X
appropriate	B-X
concentration	B-X
for	B-X
their	B-X
needs	B-X
Prepare	B-X
an	B-X
agarose	B-X
gel	B-X
for	B-X
electrophoresis	B-X
of	B-X
DNA	B-X
samples	B-X
Set	B-X
up	B-X
the	B-X
gel	B-X
electrophoresis	B-X
apparatus	B-X
and	B-X
power	B-X
supply	B-X
Select	B-X
an	B-X
appropriate	B-X
voltage	B-X
for	B-X
the	B-X
separation	B-X
of	B-X
DNA	B-X
fragments	B-X
Understand	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
ethidium	B-X
bromide	B-X
allows	B-X
for	B-X
the	B-X
visualization	B-X
of	B-X
DNA	B-X
bands	B-X
Determine	B-X
the	B-X
sizes	B-X
of	B-X
separated	B-X
DNA	B-X
fragments	B-X
.	B-X

For	O
DNA	O
-	O
binding	O
assays	O
,	O
the	O
protein	O
concentration	O
was	O
measured	O
with	O
a	O
Bio	O
-	O
Rad	O
protein	O
assay	O
kit	O
.	O

Crystallization	O
and	O
X	O
-	O
ray	O
data	O
collection	O

Crystals	O
were	O
grown	O
by	O
the	O
hanging	O
-	O
drop	O
vapor	O
diffusion	O
method	O
at	O
24	O
degrees	O
C	O
by	O
mixing	O
equal	O
volumes	O
(	O
2	O
mu	O
l	O
each	O
)	O
of	O
the	O
protein	O
solution	O
(	O
at	O
19	O
mg	O
ml	O
-	O
1	O
concentration	O
in	O
a	O
buffer	O
consisting	O
of	O
50	O
mM	O
Tris	O
-	O
HCl	O
(	O
pH	O
7	O
.	O
4	O
)	O
,	O
1	O
mM	O
dithiothreitol	O
,	O
1	O
mM	O
EDTA	O
and	O
200	O
mM	O
sodium	O
chloride	O
)	O
and	O
the	O
reservoir	O
solution	O
.	O

To	O
grow	O
the	O
native	O
crystals	O
,	O
we	O
used	O
a	O
reservoir	O
solution	O
consisting	O
of	O
0	O
.	O
1	O
M	O
sodium	O
HEPES	O
(	O
pH	O
7	O
.	O
5	O
)	O
,	O
1	O
.	O
0	O
M	O
tri	O
-	O
sodium	O
citrate	O
and	O
1	O
%	O
(	O
w	O
/	O
v	O
)	O
Anapoe	O
(R)	O
35	O
as	O
the	O
detergent	O
.	O

Native	O
crystals	O
grew	O
to	O
approximate	O
dimensions	O
of	O
0	O
.	O
2	O
mm	O
x	O
0	O
.	O
1	O
mm	O
x	O
0	O
.	O
1	O
mm	O
within	O
a	O
few	O
days	O
.	O

The	O
SeMet	O
-	O
substituted	O
protein	O
was	O
crystallized	O
under	O
conditions	O
identical	O
to	O
those	O
for	O
the	O
native	O
crystals	O
except	O
for	O
the	O
presence	O
of	O
10	O
mM	O
dithiothreitol	O
in	O
the	O
protein	O
solution	O
.	O

A	O
crystal	O
of	O
the	O
SeMet	O
-	O
substituted	O
protein	O
was	O
dipped	O
into	O
a	O
cryoprotectant	O
solution	O
for	O
a	O
few	O
seconds	O
and	O
was	O
flash	O
-	O
cooled	O
in	O
the	O
cold	O
nitrogen	O
gas	O
stream	O
at	O
100	O
K	O
.	O

The	O
cryoprotectant	O
solution	O
consisted	O
of	O
0	O
.	O
1	O
M	O
sodium	O
HEPES	O
(	O
pH	O
7	O
.	O
5	O
)	O
,	O
1	O
.	O
0	O
M	O
tri	O
-	O
sodium	O
citrate	O
,	O
1	O
%	O
(	O
w	O
/	O
v	O
)	O
Anapoe	O
(R)	O
35	O
as	O
the	O
detergent	O
and	O
10	O
%	O
(	O
v	O
/	O
v	O
)	O
glycerol	O
.	O

A	O
set	O
of	O
Se	O
MAD	O
data	O
was	O
collected	O
at	O
100	O
K	O
at	O
three	O
different	O
wavelengths	O
using	O
an	O
Area	O
Detector	O
System	O
Corporation	O
Quantum	O
210	O
charge	O
-	O
coupled	O
device	O
detector	O
at	O
the	O
beamline	O
NW12A	O
of	O
Photon	O
Factory	O
,	O
Tsukuba	O
,	O
Japan	O
.	O

The	O
crystal	O
was	O
rotated	O
through	O
a	O
total	O
of	O
180	O
degrees	O
with	O
a	O
1	O
degrees	O
oscillation	O
range	O
per	O
frame	O
.	O

The	O
raw	O
data	O
were	O
processed	O
and	O
scaled	O
using	O
the	O
program	O
suit	O
HKL2000	O
(	O
10	O
)	O
.	O

The	O
SeMet	O
-	O
substituted	O
crystal	O
belongs	O
to	O
the	O
space	O
group	O
P21212	O
,	O
with	O
unit	O
cell	O
parameters	O
of	O
a	O
=	O
87	O
.	O
04	O
A	O
,	O
b	O
=	O
115	O
.	O
60	O
A	O
and	O
c	O
=	O
76	O
.	O
07	O
A	O
.	O

The	O
native	O
crystals	O
were	O
soaked	O
for	O
10	O
min	O
in	O
10	O
mM	O
ethyl	O
mercury	O
thiosalicylate	O
(	O
EMTS	O
)	O
to	O
collect	O
a	O
set	O
of	O
Hg	O
MAD	O
data	O
at	O
four	O
different	O
wavelengths	O
.	O

X	O
-	O
ray	O
diffraction	O
data	O
from	O
the	O
EMTS	O
-	O
derivatized	O
crystal	O
,	O
as	O
well	O
as	O
a	O
native	O
crystal	O
,	O
were	O
collected	O
on	O
a	O
Bruker	O
charge	O
-	O
coupled	O
device	O
detector	O
at	O
the	O
beamline	O
BL	O
-	O
6B	O
of	O
Pohang	O
Light	O
Source	O
,	O
Pohang	O
,	O
Korea	O
.	O

The	O
EMTS	O
-	O
soaked	O
crystal	O
belongs	O
to	O
the	O
space	O
group	O
P21212	O
,	O
with	O
unit	O
cell	O
parameters	O
of	O
a	O
=	O
87	O
.	O
16	O
A	O
,	O
b	O
=	O
116	O
.	O
02	O
A	O
and	O
c	O
=	O
74	O
.	O
97	O
A	O
.	O

The	O
native	O
crystal	O
belongs	O
to	O
the	O
space	O
group	O
P21212	O
,	O
with	O
unit	O
cell	O
parameters	O
of	O
a	O
=	O
87	O
.	O
49	O
A	O
,	O
b	O
=	O
116	O
.	O
04	O
A	O
and	O
c	O
=	O
76	O
.	O
03	O
A	O
.	O

If	O
the	O
presence	O
of	O
a	O
dimeric	O
molecule	O
in	O
the	O
asymmetric	O
unit	O
is	O
assumed	O
,	O
the	O
calculated	O
crystal	O
volume	O
per	O
protein	O
mass	O
(	O
VM	O
)	O
is	O
2	O
.	O
75	O
A	O
3	O
Da	O
-	O
1	O
and	O
the	O
solvent	O
content	O
is	O
55	O
.	O
3	O
%	O
.	O

Supplementary	O
Table	O
1	O
summarizes	O
the	O
statistics	O
of	O
X	O
-	O
ray	O
diffraction	O
data	O
collection	O
.	O

Structure	O
solution	O
and	O
refinement	O
<EOS>	B-X
The	B-X
solution	B-X
structure	B-X
of	B-X
human	B-X
adult	B-X
carbonmonoxy	B-X
hemoglobin	B-X
(	B-X
HbCO	B-X
A	B-X
)	B-X
was	B-X
refined	B-X
using	B-X
stereospecifically	B-X
assigned	B-X
methyl	B-X
groups	B-X
and	B-X
residual	B-X
dipolar	B-X
couplings	B-X
based	B-X
on	B-X
our	B-X
previous	B-X
nuclear	B-X
magnetic	B-X
resonance	B-X
structure	B-X
.	B-X
The	B-X
tertiary	B-X
structures	B-X
of	B-X
individual	B-X
chains	B-X
were	B-X
found	B-X
to	B-X
be	B-X
very	B-X
similar	B-X
to	B-X
the	B-X
X-ray	B-X
structures	B-X
,	B-X
while	B-X
the	B-X
quaternary	B-X
structures	B-X
in	B-X
solution	B-X
at	B-X
low	B-X
salt	B-X
concentrations	B-X
resembled	B-X
the	B-X
X-ray	B-X
R	B-X
structure	B-X
more	B-X
than	B-X
the	B-X
R2	B-X
structure	B-X
.	B-X
All	B-X
the	B-X
data	B-X
strongly	B-X
suggest	B-X
a	B-X
dynamic	B-X
Î±1Î²2	B-X
interface	B-X
that	B-X
allows	B-X
conformational	B-X
changes	B-X
among	B-X
different	B-X
forms	B-X
(	B-X
like	B-X
T	B-X
,	B-X
R	B-X
,	B-X
and	B-X
R2	B-X
)	B-X
easily	B-X
in	B-X
solution	B-X
.	B-X
A	B-X
method	B-X
towards	B-X
the	B-X
solution	B-X
and	B-X
refinement	B-X
of	B-X
organic	B-X
crystal	B-X
structures	B-X
by	B-X
fitting	B-X
to	B-X
the	B-X
atomic	B-X
pair	B-X
distribution	B-X
function	B-X
(	B-X
PDF	B-X
)	B-X
is	B-X
developed	B-X
.	B-X
The	B-X
method	B-X
resembles	B-X
`	B-X
real-space	B-X
'	B-X
methods	B-X
for	B-X
structure	B-X
solution	B-X
from	B-X
powder	B-X
data	B-X
,	B-X
but	B-X
works	B-X
with	B-X
PDF	B-X
data	B-X
instead	B-X
of	B-X
the	B-X
diffraction	B-X
pattern	B-X
itself	B-X
.	B-X

Heavy	O
atom	O
sites	O
were	O
located	O
with	O
the	O
program	O
SOLVE	O
(	O
11	O
)	O
.	O

Four	O
Se	O
sites	O
from	O
the	O
SeMet	O
-	O
substituted	O
crystal	O
and	O
two	O
Hg	O
sites	O
from	O
the	O
EMTS	O
-	O
soaked	O
crystal	O
were	O
located	O
.	O

Two	O
sets	O
of	O
the	O
initial	O
Se	O
and	O
Hg	O
MAD	O
phases	O
were	O
separately	O
improved	O
using	O
the	O
program	O
RESOLVE	O
(	O
12	O
)	O
.	O

Two	O
electron	O
density	O
maps	O
were	O
independently	O
interpreted	O
,	O
and	O
the	O
fragments	O
of	O
the	O
two	O
models	O
were	O
combined	O
into	O
a	O
single	O
model	O
,	O
since	O
the	O
two	O
maps	O
were	O
complementary	O
to	O
each	O
other	O
.	O

Non	O
-	O
crystallographic	O
symmetry	O
(	O
NCS	O
)	O
matrices	O
were	O
found	O
from	O
a	O
partial	O
model	O
built	O
from	O
the	O
initial	O
electron	O
density	O
map	O
,	O
and	O
phases	O
were	O
further	O
improved	O
by	O
the	O
2	O
-	O
fold	O
NCS	O
averaging	O
,	O
solvent	O
flattening	O
and	O
histogram	O
matching	O
with	O
the	O
program	O
DM	O
(	O
13	O
)	O
.	O

The	O
model	O
was	O
built	O
with	O
O	O
(	O
14	O
)	O
.	O

The	O
model	O
was	O
refined	O
with	O
the	O
program	O
CNS	O
(	O
15	O
)	O
,	O
including	O
the	O
bulk	O
solvent	O
correction	O
.	O

10	O
%	O
of	O
the	O
data	O
were	O
randomly	O
set	O
aside	O
as	O
the	O
test	O
data	O
for	O
the	O
calculation	O
of	O
Rfree	O
(	O
16	O
)	O
.	O

Several	O
rounds	O
of	O
model	O
building	O
,	O
simulated	O
annealing	O
,	O
positional	O
refinement	O
and	O
individual	O
B	O
-	O
factor	O
refinement	O
were	O
performed	O
.	O

Subsequently	O
,	O
this	O
model	O
was	O
used	O
to	O
refine	O
the	O
structure	O
of	O
the	O
native	O
protein	O
.	O
<EOS>	B-X
Song	B-X
,	B-X
A.	B-X
Lazar	B-X
,	B-X
J.	B-X
Gershenwald	B-X
,	B-X
M.	B-X
Davies	B-X
,	B-X
C.	B-X
Bernatchez	B-X
,	B-X
J.	B-X
Zhang	B-X
,	B-X
A.	B-X
Futreal	B-X
,	B-X
S.	B-X
Woodman	B-X
O39	B-X
Data-driven	B-X
refinement	B-X
of	B-X
complex	B-X
disease	B-X
classification	B-X
from	B-X
integration	B-X
of	B-X
heterogeneous	B-X
functional	B-X
genomics	B-X
data	B-X
in	B-X
GeneWeaver	B-X
E.	B-X
J.	B-X
Chesler	B-X
,	B-X
T.	B-X
Reynolds	B-X
,	B-X
J.	B-X
Glenn	B-X
,	B-X
Z.	B-X
Momin	B-X
,	B-X
B.	B-X
Dilrukshi	B-X
,	B-X
H.	B-X
Chao	B-X
,	B-X
Q.	B-X
Meng	B-X
,	B-X
B.	B-X
Gudenkauf	B-X
,	B-X
R.	B-X
Kshitij	B-X
,	B-X
J.	B-X
Jayaseelan	B-X
,	B-X
C.	B-X
Nessner	B-X
,	B-X
S.	B-X
Lee	B-X
,	B-X
K.	B-X
Blankenberg	B-X
,	B-X
L.	B-X
Lewis	B-X
,	B-X
J.	B-X
Hu	B-X
,	B-X
Y.	B-X
Han	B-X
,	B-X
H.	B-X
Dinh	B-X
,	B-X
S.	B-X
Jireh	B-X
,	B-X
K.	B-X
Walker	B-X
,	B-X
E.	B-X
Boerwinkle	B-X
,	B-X
D.	B-X
Muzny	B-X
,	B-X
R.	B-X
Gibbs	B-X
O55	B-X
Rapid	B-X
capture	B-X
methods	B-X
for	B-X
clinical	B-X
sequencing	B-X
J.	B-X
Hu	B-X
,	B-X
K.	B-X
Walker	B-X
,	B-X
C.	B-X
Buhay	B-X
,	B-X
X.	B-X
Liu	B-X
,	B-X
Q.	B-X
Wang	B-X
,	B-X
R.	B-X
Sanghvi	B-X
,	B-X
H.	B-X
Doddapaneni	B-X
,	B-X
Y.	B-X
Ding	B-X
,	B-X
N.	B-X
Veeraraghavan	B-X
,	B-X
Y.	B-X
Yang	B-X
,	B-X
E.	B-X
Boerwinkle	B-X
,	B-X
A.	B-X
L.	B-X
Beaudet	B-X
,	B-X
C.	B-X
M.	B-X
Eng	B-X
,	B-X
D.	B-X
M.	B-X
Muzny	B-X
,	B-X
R.	B-X
A.	B-X
Gibbs	B-X
O56	B-X
A	B-X
diploid	B-X
personal	B-X
human	B-X
genome	B-X
model	B-X
for	B-X
better	B-X
genomes	B-X
from	B-X
diverse	B-X
sequence	B-X
data	B-X
K.	B-X
C.	B-X
C.	B-X
Worley	B-X
,	B-X
Y.	B-X
Liu	B-X
,	B-X
D.	B-X
S.	B-X
T.	B-X
Hughes	B-X
,	B-X
S.	B-X
C.	B-X
Murali	B-X
,	B-X
R.	B-X
A.	B-X
Harris	B-X
,	B-X
A.	B-X
C.	B-X
English	B-X
,	B-X
X.	B-X
Qin	B-X
,	B-X
O	B-X
.	B-X
Below	B-X
,	B-X
D.	B-X
Muzny	B-X
,	B-X
R.	B-X
Gibbs	B-X
,	B-X
F.	B-X
Yu	B-X
,	B-X
J.	B-X
Rogers	B-X
O59	B-X
Assessing	B-X
RNA	B-X
structure	B-X
disruption	B-X
induced	B-X
by	B-X
single-nucleotide	B-X
variation	B-X
J.	B-X
Lin	B-X
,	B-X
Y.	B-X
Zhang	B-X
,	B-X
Z.	B-X
Ouyang	B-X
P1	B-X
A	B-X
meta-analysis	B-X
of	B-X
genome-wide	B-X
association	B-X
studies	B-X
of	B-X
mitochondrial	B-X
dna	B-X
copy	B-X
number	B-X
A.	B-X
Moore	B-X
,	B-X
Z.	B-X
Wang	B-X
,	B-X
J.	B-X
Hofmann	B-X
,	B-X
M.	B-X
Purdue	B-X
,	B-X
R.	B-X
Stolzenberg-Solomon	B-X
,	B-X
S.	B-X
Weinstein	B-X
,	B-X
D.	B-X
Albanes	B-X
,	B-X
C.-S.	B-X
Liu	B-X
,	B-X
W.-L.	B-X
Cheng	B-X
,	B-X
T.-T.	B-X
Lin	B-X
,	B-X
Q.	B-X
Lan	B-X
,	B-X
N.	B-X
Rothman	B-X
,	B-X
S.	B-X
Berndt	B-X
P2	B-X
Missense	B-X
polymorphic	B-X
genetic	B-X
combinations	B-X
underlying	B-X
down	B-X
syndrome	B-X
susceptibility	B-X
E.	B-X
S.	B-X
Chen	B-X
P4	B-X
The	B-X
evaluation	B-X
of	B-X
alteration	B-X
of	B-X
ELAM-1	B-X
expression	B-X
in	B-X
the	B-X
endometriosis	B-X
patients	B-X
H.	B-X
Bahrami	B-X
,	B-X
A.	B-X
Khoshzaban	B-X
,	B-X
S.	B-X
Heidari	B-X
Keshal	B-X
P5	B-X
Obesity	B-X
and	B-X
the	B-X
incidence	B-X
of	B-X
apolipoprotein	B-X
E	B-X
polymorphisms	B-X
in	B-X
an	B-X
assorted	B-X
population	B-X
from	B-X
Saudi	B-X
Arabia	B-X
population	B-X
K.	B-X
K.	B-X
R.	B-X
Alharbi	B-X
P6	B-X
Genome-associated	B-X
personalized	B-X
antithrombotical	B-X
therapy	B-X
for	B-X
patients	B-X
with	B-X
high	B-X
risk	B-X
of	B-X
thrombosis	B-X
and	B-X
bleeding	B-X
M.	B-X
Zhalbinova	B-X
,	B-X
A.	B-X
Akilzhanova	B-X
,	B-X
S.	B-X
Rakhimova	B-X
,	B-X
M.	B-X
Bekbosynova	B-X
,	B-X
S.	B-X
Myrzakhmetova	B-X
P7	B-X
Frequency	B-X
of	B-X
Xmn1	B-X
polymorphism	B-X
among	B-X
sickle	B-X
cell	B-X
carrier	B-X
cases	B-X
in	B-X
UAE	B-X
population	B-X
M.	B-X
Matar	B-X
P8	B-X
Differentiating	B-X
inflammatory	B-X
bowel	B-X
diseases	B-X
by	B-X
using	B-X
genomic	B-X
data	B-X
:	B-X
dimension	B-X
of	B-X
the	B-X
problem	B-X
and	B-X
network	B-X
organization	B-X
N.	B-X
Mili	B-X
,	B-X
R.	B-X
Molinari	B-X
,	B-X
Y.	B-X
Ma	B-X
,	B-X
S.	B-X
Guerrier	B-X
P9	B-X
Vulnerability	B-X
of	B-X
genetic	B-X
variants	B-X
to	B-X
the	B-X
risk	B-X
of	B-X
autism	B-X
among	B-X
Saudi	B-X
children	B-X
N.	B-X
Elhawary	B-X
,	B-X
M.	B-X
Tayeb	B-X
,	B-X
N.	B-X
Bogari	B-X
,	B-X
N.	B-X
Qotb	B-X
P10	B-X
Chromatin	B-X
profiles	B-X
from	B-X
ex	B-X
vivo	B-X
purified	B-X
dopaminergic	B-X
neurons	B-X
establish	B-X
a	B-X
promising	B-X
model	B-X
to	B-X
support	B-X
studies	B-X
of	B-X
neurological	B-X
function	B-X
and	B-X
dysfunction	B-X
S.	B-X
A.	B-X
McClymont	B-X
,	B-X
P.	B-X
W.	B-X
Hook	B-X
,	B-X
L.	B-X
A.	B-X
Goff	B-X
,	B-X
A.	B-X
McCallion	B-X
P11	B-X
Utilization	B-X
of	B-X
a	B-X
sensitized	B-X
chemical	B-X
mutagenesis	B-X
screen	B-X
to	B-X
identify	B-X
genetic	B-X
modifiers	B-X
of	B-X
retinal	B-X
dysplasia	B-X
in	B-X
homozygous	B-X
Nr2e3	B-X
The	B-X
glycine	B-X
receptor	B-X
(	B-X
GlyR	B-X
)	B-X
is	B-X
by	B-X
far	B-X
the	B-X
best-characterized	B-X
pentameric	B-X
ligand-gated	B-X
ion	B-X
channel	B-X
,	B-X
with	B-X
several	B-X
high-resolution	B-X
structures	B-X
from	B-X
X-ray	B-X
crystallography	B-X
,	B-X
cryoelectron	B-X
microscopy	B-X
(	B-X
cryo-EM	B-X
)	B-X
,	B-X
and	B-X
modeling	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
physiological	B-X
significance	B-X
of	B-X
existing	B-X
models	B-X
of	B-X
the	B-X
GlyR	B-X
active	B-X
state	B-X
based	B-X
on	B-X
conductance	B-X
and	B-X
selectivity	B-X
measurements	B-X
by	B-X
computational	B-X
electrophysiology	B-X
.	B-X
The	B-X
results	B-X
support	B-X
the	B-X
conclusion	B-X
that	B-X
the	B-X
original	B-X
cryo-EM	B-X
reconstruction	B-X
of	B-X
the	B-X
active	B-X
state	B-X
obtained	B-X
in	B-X
detergents	B-X
as	B-X
well	B-X
as	B-X
its	B-X
subsequent	B-X
refinement	B-X
by	B-X
molecular	B-X
dynamics	B-X
simulations	B-X
are	B-X
likely	B-X
to	B-X
be	B-X
non-physiological	B-X
as	B-X
they	B-X
feature	B-X
artificially	B-X
dilated	B-X
ion	B-X
pores	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
calculations	B-X
indicate	B-X
that	B-X
a	B-X
physiologically	B-X
relevant	B-X
open	B-X
pore	B-X
should	B-X
be	B-X
constricted	B-X
within	B-X
a	B-X
radius	B-X
of	B-X
2.5	B-X
and	B-X
2.8	B-X
Ã	B-X
,	B-X
which	B-X
is	B-X
consistent	B-X
with	B-X
previous	B-X
modeling	B-X
,	B-X
electrophysiology	B-X
measurements	B-X
,	B-X
and	B-X
the	B-X
most	B-X
recent	B-X
cryo-EM	B-X
structures	B-X
obtained	B-X
in	B-X
a	B-X
native	B-X
lipid	B-X
membrane	B-X
environment	B-X
.	B-X

The	O
model	O
has	O
excellent	O
stereochemistry	O
,	O
as	O
evaluated	O
by	O
the	O
program	O
PROCHECK	O
(	O
17	O
)	O
.	O

Refinement	O
statistics	O
are	O
summarized	O
in	O
Supplementary	O
Table	O
1	O
.	O

RESULTS	O
AND	O
DISCUSSION	O

Model	O
quality	O
and	O
monomer	O
structure	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
reported	B-X
a	B-X
high-quality	B-X
and	B-X
almost	B-X
complete	B-X
Col-0	B-X
genome	B-X
assembly	B-X
with	B-X
two	B-X
gaps	B-X
(	B-X
named	B-X
Col-XJTU	B-X
)	B-X
by	B-X
combining	B-X
the	B-X
Oxford	B-X
Nanopore	B-X
Technologies	B-X
ultra-long	B-X
reads	B-X
,	B-X
Pacific	B-X
Biosciences	B-X
high-fidelity	B-X
long	B-X
reads	B-X
,	B-X
and	B-X
Hi-C	B-X
data	B-X
.	B-X
All	B-X
five	B-X
chromosomes	B-X
of	B-X
the	B-X
Col-XJTU	B-X
assembly	B-X
are	B-X
highly	B-X
accurate	B-X
with	B-X
consensus	B-X
quality	B-X
(	B-X
QV	B-X
)	B-X
scores	B-X
>	B-X
60	B-X
(	B-X
ranging	B-X
from	B-X
62	B-X
to	B-X
68	B-X
)	B-X
,	B-X
which	B-X
are	B-X
higher	B-X
than	B-X
those	B-X
of	B-X
the	B-X
TAIR10.1	B-X
reference	B-X
(	B-X
ranging	B-X
from	B-X
45	B-X
to	B-X
52	B-X
)	B-X
.	B-X
We	B-X
also	B-X
investigated	B-X
the	B-X
structure	B-X
and	B-X
epigenetics	B-X
of	B-X
centromeres	B-X
.	B-X
Four	B-X
clusters	B-X
of	B-X
CEN180	B-X
monomers	B-X
were	B-X
detected	B-X
,	B-X
and	B-X
the	B-X
centromere-specific	B-X
histone	B-X
H3-like	B-X
protein	B-X
(	B-X
CENH3	B-X
)	B-X
exhibited	B-X
a	B-X
strong	B-X
preference	B-X
for	B-X
CEN180	B-X
Cluster	B-X
3	B-X
.	B-X
We	B-X
believe	B-X
that	B-X
this	B-X
high-quality	B-X
genome	B-X
assembly	B-X
,	B-X
Col-XJTU	B-X
,	B-X
would	B-X
serve	B-X
as	B-X
a	B-X
valuable	B-X
reference	B-X
to	B-X
better	B-X
understand	B-X
the	B-X
global	B-X
pattern	B-X
of	B-X
centromeric	B-X
polymorphisms	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
genetic	B-X
and	B-X
epigenetic	B-X
features	B-X
in	B-X
plants	B-X
.	B-X

The	O
structure	O
of	O
P	B-Species
.	I-Species
aeruginosa	I-Species
RdgC	O
was	O
solved	O
using	O
two	O
sets	O
of	O
MAD	O
data	O
collected	O
from	O
a	O
crystal	O
of	O
the	O
selenomethionine	O
(	O
SeMet	O
)	O
-	O
substituted	O
protein	O
and	O
from	O
a	O
mercury	O
derivative	O
crystal	O
of	O
the	O
native	O
protein	O
(	O
Supplementary	O
Table	O
1	O
)	O
.	O

The	O
model	O
has	O
subsequently	O
been	O
refined	O
using	O
the	O
20	O
.	O
0	O
-	O
2	O
.	O
50	O
A	O
data	O
from	O
a	O
native	O
crystal	O
to	O
crystallographic	O
Rwork	O
and	O
Rfree	O
values	O
of	O
23	O
.	O
4	O
and	O
27	O
.	O
9	O
%	O
,	O
respectively	O
,	O
with	O
no	O
sigma	O
cut	O
-	O
off	O
.	O

The	O
refined	O
model	O
contains	O
612	O
residues	O
of	O
the	O
two	O
monomers	O
in	O
the	O
asymmetric	O
unit	O
of	O
the	O
crystal	O
(	O
residues	O
1	O
-	O
306	O
for	O
both	O
chains	O
A	O
and	O
B	O
)	O
and	O
87	O
water	O
molecules	O
.	O

The	O
C	O
-	O
terminal	O
eight	O
-	O
residue	O
fusion	O
tag	O
has	O
no	O
electron	O
density	O
in	O
both	O
subunits	O
and	O
has	O
not	O
been	O
modeled	O
.	O

Conformations	O
of	O
the	O
two	O
monomers	O
in	O
the	O
asymmetric	O
unit	O
are	O
similar	O
.	O
<EOS>	B-X
dsRNA	B-X
mycovirus	B-X
capsids	B-X
are	B-X
based	B-X
on	B-X
a	B-X
120-subunit	B-X
T	B-X
=	B-X
1	B-X
capsid	B-X
,	B-X
with	B-X
a	B-X
dimer	B-X
as	B-X
the	B-X
asymmetric	B-X
unit	B-X
.	B-X
In	B-X
the	B-X
asymmetric	B-X
unit	B-X
,	B-X
the	B-X
crystal	B-X
contains	B-X
two	B-X
V-1	B-X
monomers	B-X
that	B-X
exhibit	B-X
nearly	B-X
identical	B-X
structures	B-X
(	B-X
C	B-X
There	B-X
are	B-X
two	B-X
molecules	B-X
in	B-X
the	B-X
asymmetric	B-X
unit	B-X
,	B-X
related	B-X
by	B-X
pseudo	B-X
4-fold	B-X
screw	B-X
symmetry	B-X
.	B-X
The	B-X
refined	B-X
model	B-X
consists	B-X
of	B-X
3587	B-X
non-hydrogen	B-X
atoms	B-X
from	B-X
440	B-X
residues	B-X
(	B-X
two	B-X
monomers	B-X
)	B-X
,	B-X
and	B-X
159	B-X
water	B-X
molecules	B-X
.	B-X
The	B-X
GlnBP	B-X
molecule	B-X
has	B-X
overall	B-X
dimensions	B-X
of	B-X
approximately	B-X
60	B-X
A	B-X
x	B-X
40	B-X
A	B-X
x	B-X
35	B-X
A	B-X
and	B-X
is	B-X
made	B-X
up	B-X
of	B-X
two	B-X
domains	B-X
(	B-X
termed	B-X
large	B-X
and	B-X
small	B-X
)	B-X
,	B-X
which	B-X
exhibit	B-X
a	B-X
similar	B-X
supersecondary	B-X
structure	B-X
,	B-X
linked	B-X
by	B-X
two	B-X
antiparallel	B-X
beta-strands	B-X
.	B-X
The	B-X
large	B-X
domain	B-X
is	B-X
similar	B-X
to	B-X
the	B-X
small	B-X
domain	B-X
but	B-X
contains	B-X
two	B-X
additional	B-X
alpha-helices	B-X
and	B-X
three	B-X
more	B-X
short	B-X
antiparallel	B-X
beta-strands	B-X
.	B-X

The	O
root	O
-	O
mean	O
-	O
square	O
(	O
r	O
.	O
m	O
.	O
s	O
.	O
)	O
difference	O
between	O
the	O
two	O
monomers	O
is	O
0	O
.	O
69	O
A	O
for	O
306	O
C	O
alpha	O
atom	O
pairs	O
,	O
with	O
a	O
maximum	O
deviation	O
of	O
8	O
.	O
8	O
A	O
for	O
the	O
C	O
alpha	O
atom	O
of	O
Gly305	O
.	O

The	O
residues	O
giving	O
r	O
.	O
m	O
.	O
s	O
.	O
differences	O
larger	O
than	O
2	O
.	O
0	O
A	O
are	O
14	O
-	O
16	O
,	O
94	O
-	O
96	O
,	O
201	O
-	O
202	O
and	O
303	O
-	O
306	O
,	O
which	O
correspond	O
to	O
loops	O
connecting	O
secondary	O
structure	O
elements	O
or	O
the	O
C	O
-	O
terminus	O
.	O

They	O
are	O
located	O
on	O
the	O
surface	O
of	O
the	O
dimer	O
.	O
<EOS>	B-X
With	B-X
its	B-X
compact	B-X
surface	B-X
,	B-X
ZIKV	B-X
is	B-X
more	B-X
thermally	B-X
stable	B-X
than	B-X
the	B-X
dengue	B-X
virus	B-X
(	B-X
DENV	B-X
)	B-X
.	B-X
The	B-X
ZIKV	B-X
E	B-X
protein	B-X
,	B-X
the	B-X
major	B-X
protein	B-X
involved	B-X
in	B-X
receptor	B-X
binding	B-X
and	B-X
fusion	B-X
,	B-X
is	B-X
formed	B-X
as	B-X
a	B-X
head-to-tail	B-X
dimer	B-X
on	B-X
the	B-X
surfaces	B-X
of	B-X
viral	B-X
particles	B-X
.	B-X
Quaternary	B-X
E	B-X
:	B-X
E	B-X
dimer	B-X
epitopes	B-X
located	B-X
at	B-X
the	B-X
interaction	B-X
site	B-X
of	B-X
prM	B-X
and	B-X
E	B-X
dimers	B-X
can	B-X
be	B-X
further	B-X
divided	B-X
into	B-X
two	B-X
dimer	B-X
epitopes	B-X
.	B-X
Stabilized	B-X
forms	B-X
of	B-X
ZIKV	B-X
E	B-X
:	B-X
E	B-X
dimer	B-X
proteins	B-X
have	B-X
been	B-X
successfully	B-X
obtained	B-X
either	B-X
by	B-X
introducing	B-X
additional	B-X
inter-subunit	B-X
disulfide	B-X
bond	B-X
(	B-X
s	B-X
)	B-X
in	B-X
DII	B-X
or	B-X
via	B-X
the	B-X
direct	B-X
assembly	B-X
of	B-X
E	B-X
:	B-X
E	B-X
dimer	B-X
proteins	B-X
by	B-X
immobilization	B-X
with	B-X
monomeric	B-X
E	B-X
proteins	B-X
.	B-X
The	B-X
VLP-based	B-X
approach	B-X
is	B-X
another	B-X
alternative	B-X
method	B-X
for	B-X
presenting	B-X
native	B-X
E	B-X
:	B-X
E	B-X
dimer	B-X
antigens	B-X
among	B-X
the	B-X
vaccine	B-X
components	B-X
.	B-X

Subunit	O
A	O
has	O
a	O
better	O
map	O
quality	O
than	O
subunit	O
B	O
,	O
and	O
thus	O
has	O
a	O
lower	O
mean	O
B	O
-	O
factor	O
than	O
subunit	O
B	O
(	O
40	O
.	O
3	O
A	O
2	O
versus	O
.	O
56	O
.	O
1	O
A	O
2	O
for	O
all	O
4788	O
atoms	O
)	O
(	O
Supplementary	O
Figure	O
1	O
)	O
.	O

Therefore	O
,	O
subunit	O
A	O
is	O
chosen	O
for	O
discussions	O
,	O
unless	O
otherwise	O
stated	O
.	O

The	O
P	B-Species
.	I-Species
aeruginosa	I-Species
RdgC	O
monomer	O
is	O
J	O
-	O
shaped	O
and	O
has	O
approximate	O
dimensions	O
of	O
72	O
A	O
x	O
60	O
A	O
x	O
40	O
A	O
(	O
Figure	O
1	O
)	O
.	O

It	O
can	O
be	O
divided	O
into	O
three	O
structural	O
domains	O
:	O
center	O
domain	O
,	O
tip	O
domain	O
and	O
base	O
domain	O
.	O
<EOS>	B-X
The	B-X
J-shaped	B-X
monomer	B-X
has	B-X
a	B-X
unique	B-X
fold	B-X
and	B-X
can	B-X
be	B-X
divided	B-X
into	B-X
three	B-X
structural	B-X
domains	B-X
:	B-X
tip	B-X
domain	B-X
,	B-X
center	B-X
domain	B-X
and	B-X
base	B-X
domain	B-X
.	B-X
Of	B-X
the	B-X
two	B-X
inter-subunit	B-X
interfaces	B-X
within	B-X
the	B-X
dimer	B-X
,	B-X
one	B-X
interface	B-X
(	B-X
'interface	B-X
A	B-X
'	B-X
)	B-X
between	B-X
tip/center	B-X
domains	B-X
is	B-X
more	B-X
nonpolar	B-X
than	B-X
the	B-X
other	B-X
(	B-X
'interface	B-X
B	B-X
'	B-X
)	B-X
between	B-X
base	B-X
domains	B-X
.	B-X

Center	O
domain	O
(	O
residues	O
1	O
-	O
73	O
and	O
121	O
-	O
167	O
)	O
includes	O
a	O
six	O
-	O
stranded	O
anti	O
-	O
parallel	O
beta	O
-	O
sheet	O
with	O
two	O
flanking	O
alpha	O
helices	O
(	O
alpha	O
1	O
and	O
alpha	O
4	O
)	O
.	O

The	O
helix	O
alpha	O
1	O
runs	O
nearly	O
parallel	O
to	O
the	O
two	O
outermost	O
strands	O
beta	O
2	O
and	O
beta	O
3	O
,	O
which	O
in	O
turn	O
lie	O
adjacent	O
to	O
beta	O
4	O
.	O

Strands	O
beta	O
2	O
and	O
beta	O
3	O
are	O
separated	O
by	O
a	O
loop	O
.	O
<EOS>	B-X
Using	B-X
bacteriophage	B-X
T7	B-X
as	B-X
a	B-X
model	B-X
system	B-X
,	B-X
we	B-X
determined	B-X
cryo-electron	B-X
microscopy	B-X
structures	B-X
up	B-X
to	B-X
3.2-angstroms	B-X
resolution	B-X
of	B-X
helicase	B-X
translocating	B-X
along	B-X
DNA	B-X
and	B-X
of	B-X
helicase-polymerase-primase	B-X
complexes	B-X
engaging	B-X
in	B-X
synthesis	B-X
of	B-X
both	B-X
DNA	B-X
strands	B-X
.	B-X
Here	B-X
,	B-X
the	B-X
crystal	B-X
structure	B-X
of	B-X
Mycobacterium	B-X
tuberculosis	B-X
(	B-X
Mtb	B-X
)	B-X
IGPD	B-X
is	B-X
reported	B-X
together	B-X
with	B-X
the	B-X
first	B-X
crystal	B-X
structures	B-X
of	B-X
substrate-bound	B-X
and	B-X
inhibited	B-X
(	B-X
by	B-X
3-amino-1,2,4-triazole	B-X
;	B-X
ATZ	B-X
)	B-X
forms	B-X
of	B-X
IGPD	B-X
from	B-X
any	B-X
organism	B-X
.	B-X
The	B-X
overall	B-X
tertiary	B-X
structure	B-X
of	B-X
Mtb	B-X
IGPD	B-X
,	B-X
a	B-X
four-helix-bundle	B-X
sandwiched	B-X
between	B-X
two	B-X
four-stranded	B-X
mixed	B-X
Î²-sheets	B-X
,	B-X
resembles	B-X
the	B-X
three-dimensional	B-X
structures	B-X
of	B-X
IPGD	B-X
from	B-X
other	B-X
organisms	B-X
;	B-X
however	B-X
,	B-X
Mtb	B-X
IGPD	B-X
possesses	B-X
a	B-X
unique	B-X
structural	B-X
feature	B-X
:	B-X
the	B-X
insertion	B-X
of	B-X
a	B-X
one-turn	B-X
310-helix	B-X
followed	B-X
by	B-X
a	B-X
loop	B-X
ten	B-X
residues	B-X
in	B-X
length	B-X
.	B-X
The	B-X
functional	B-X
form	B-X
of	B-X
IGPD	B-X
is	B-X
24-meric	B-X
,	B-X
exhibiting	B-X
432	B-X
point-group	B-X
symmetry	B-X
.	B-X
The	B-X
structure	B-X
of	B-X
the	B-X
IGPD-IGP	B-X
complex	B-X
revealed	B-X
that	B-X
the	B-X
imidazole	B-X
ring	B-X
of	B-X
the	B-X
IGP	B-X
is	B-X
firmly	B-X
anchored	B-X
between	B-X
the	B-X
two	B-X
Mn	B-X
atoms	B-X
,	B-X
that	B-X
the	B-X
rest	B-X
of	B-X
the	B-X
substrate	B-X
interacts	B-X
through	B-X
hydrogen	B-X
bonds	B-X
mainly	B-X
with	B-X
residues	B-X
Glu21	B-X
,	B-X
Arg99	B-X
,	B-X
Glu180	B-X
,	B-X
Arg121	B-X
and	B-X
Lys184	B-X
which	B-X
protrude	B-X
from	B-X
three	B-X
separate	B-X
protomers	B-X
and	B-X
that	B-X
the	B-X
24-mer	B-X
assembly	B-X
contains	B-X
24	B-X
catalytic	B-X
centres	B-X
.	B-X
Both	B-X
the	B-X
structural	B-X
and	B-X
the	B-X
kinetic	B-X
data	B-X
demonstrate	B-X
that	B-X
the	B-X
inhibitor	B-X
3-amino-1,2,4-triazole	B-X
inhibits	B-X
IGPD	B-X
competitively	B-X
.	B-X

The	O
helix	O
alpha	O
4	O
is	O
nearly	O
orthogonal	O
to	O
the	O
beta	O
-	O
strands	O
.	O

Tip	O
domain	O
(	O
residues	O
74	O
-	O
120	O
)	O
contains	O
two	O
alpha	O
helices	O
(	O
alpha	O
2	O
and	O
alpha	O
3	O
)	O
and	O
is	O
inserted	O
between	O
strands	O
beta	O
4	O
and	O
beta	O
5	O
of	O
the	O
center	O
domain	O
.	O

It	O
sticks	O
out	O
from	O
the	O
center	O
domain	O
.	O

The	O
two	O
connections	O
between	O
the	O
center	O
domain	O
and	O
the	O
tip	O
domain	O
are	O
rich	O
in	O
conserved	O
residues	O
,	O
hinting	O
at	O
an	O
important	O
functional	O
role	O
of	O
these	O
joints	O
.	O

They	O
could	O
act	O
as	O
a	O
hinge	O
for	O
a	O
possible	O
conformational	O
change	O
.	O
<EOS>	B-X
The	B-X
activity	B-X
of	B-X
all	B-X
family	B-X
members	B-X
is	B-X
focused	B-X
on	B-X
membranes	B-X
,	B-X
but	B-X
the	B-X
proteins	B-X
are	B-X
themselves	B-X
involved	B-X
in	B-X
a	B-X
diverse	B-X
range	B-X
of	B-X
phenomena	B-X
.	B-X
An	B-X
overview	B-X
of	B-X
some	B-X
of	B-X
these	B-X
phenomena	B-X
is	B-X
provided	B-X
here	B-X
,	B-X
along	B-X
with	B-X
an	B-X
historical	B-X
perspective	B-X
of	B-X
CDCs	B-X
themselves	B-X
and	B-X
how	B-X
our	B-X
understanding	B-X
of	B-X
their	B-X
mechanism	B-X
of	B-X
action	B-X
has	B-X
developed	B-X
over	B-X
the	B-X
years	B-X
.	B-X
The	B-X
way	B-X
in	B-X
which	B-X
pore	B-X
formation	B-X
depends	B-X
on	B-X
specific	B-X
characteristics	B-X
of	B-X
the	B-X
membrane	B-X
under	B-X
attack	B-X
as	B-X
well	B-X
as	B-X
of	B-X
the	B-X
protein	B-X
doing	B-X
the	B-X
attacking	B-X
is	B-X
emphasised	B-X
.	B-X
In	B-X
this	B-X
chapter	B-X
I	B-X
aim	B-X
to	B-X
provide	B-X
an	B-X
overview	B-X
of	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
interaction	B-X
between	B-X
CDCs	B-X
and	B-X
other	B-X
members	B-X
of	B-X
what	B-X
is	B-X
now	B-X
called	B-X
the	B-X
MACPF/CDC	B-X
superfamily	B-X
,	B-X
with	B-X
their	B-X
target	B-X
membranes	B-X
.	B-X
CDCs	B-X
(	B-X
also	B-X
in	B-X
the	B-X
past	B-X
known	B-X
as	B-X
thiol-activated	B-X
toxins	B-X
or	B-X
cholesterol-binding	B-X
toxins	B-X
)	B-X
were	B-X
originally	B-X
identified	B-X
from	B-X
four	B-X
Gram-positive	B-X
bacterial	B-X
genera	B-X
(	B-X
Clostridium	B-X
,	B-X
Listeria	B-X
,	B-X
Bacillus	B-X
and	B-X
Streptococcus	B-X
)	B-X
.	B-X
Listeriolysin	B-X
from	B-X
L.	B-X
monocytogenes	B-X
is	B-X
responsible	B-X
for	B-X
the	B-X
escape	B-X
of	B-X
bacteria	B-X
from	B-X
the	B-X
phagosome	B-X
to	B-X
colonise	B-X
the	B-X
cytoplasm	B-X
and	B-X
has	B-X
been	B-X
applied	B-X
as	B-X
a	B-X
protein	B-X
adjuvant	B-X
in	B-X
the	B-X
development	B-X
of	B-X
vaccines	B-X
against	B-X
cancer	B-X
and	B-X
tuberculosis	B-X
,	B-X
for	B-X
example	B-X
.	B-X
Pneumolysin	B-X
is	B-X
a	B-X
major	B-X
virulence	B-X
determinant	B-X
for	B-X
S.	B-X
pneumoniae	B-X
,	B-X
allowing	B-X
bacterial	B-X
invasion	B-X
of	B-X
tissues	B-X
and	B-X
mediating	B-X
inflammation	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
complement	B-X
cascade	B-X
.	B-X
However	B-X
,	B-X
CDCs	B-X
have	B-X
now	B-X
,	B-X
for	B-X
example	B-X
,	B-X
been	B-X
identified	B-X
in	B-X
the	B-X
bacteria	B-X
Arcanobacterium	B-X
pyogenes	B-X
and	B-X
Gardnerella	B-X
vaginalis	B-X
and	B-X
there	B-X
also	B-X
appear	B-X
to	B-X
be	B-X
homologues	B-X
outside	B-X
prokaryotes	B-X
such	B-X
as	B-X
the	B-X
sea	B-X
anemone	B-X
Metridium	B-X
senile	B-X
pore-forming	B-X
toxin	B-X
metridiolysin	B-X
.	B-X
The	B-X
homology	B-X
with	B-X
the	B-X
MACPF	B-X
family	B-X
was	B-X
unknown	B-X
until	B-X
the	B-X
first	B-X
structures	B-X
of	B-X
the	B-X
canonical	B-X
fold	B-X
of	B-X
that	B-X
family	B-X
were	B-X
solved	B-X
,	B-X
revealing	B-X
the	B-X
now	B-X
characteristic	B-X
MACPF/CDC	B-X
fold	B-X
of	B-X
a	B-X
twisted	B-X
3-sheet	B-X
around	B-X
which	B-X
helices	B-X
are	B-X
clustered	B-X
(	B-X
Fig	B-X
.	B-X
The	B-X
glycines	B-X
presumably	B-X
act	B-X
as	B-X
critical	B-X
hinges	B-X
during	B-X
the	B-X
dramatic	B-X
refolding	B-X
that	B-X
CDCs	B-X
are	B-X
known	B-X
to	B-X
undergo	B-X
and	B-X
which	B-X
is	B-X
presumably	B-X
the	B-X
selective	B-X
advantage	B-X
of	B-X
this	B-X
specific	B-X
structure	B-X
that	B-X
has	B-X
caused	B-X
it	B-X
to	B-X
be	B-X
conserved	B-X
over	B-X
such	B-X
a	B-X
vast	B-X
evolutionary	B-X
timescale	B-X
.	B-X
While	B-X
not	B-X
all	B-X
MACPF	B-X
domains	B-X
are	B-X
involved	B-X
in	B-X
pore	B-X
formation-for	B-X
example	B-X
,	B-X
C6	B-X
and	B-X
C8beta	B-X
--	B-X
they	B-X
are	B-X
all	B-X
apparently	B-X
involved	B-X
in	B-X
action	B-X
on	B-X
membranes	B-X
.	B-X
It	B-X
is	B-X
obviously	B-X
the	B-X
basic	B-X
assumption	B-X
that	B-X
where	B-X
nonCDC	B-X
members	B-X
of	B-X
the	B-X
superfamily-such	B-X
as	B-X
complement	B-X
proteins	B-X
and	B-X
perforin-act	B-X
on	B-X
membranes	B-X
they	B-X
do	B-X
so	B-X
by	B-X
a	B-X
mechanism	B-X
involving	B-X
similar	B-X
refolding.58	B-X
Even	B-X
where	B-X
a	B-X
member	B-X
of	B-X
the	B-X
MACPF/CDC	B-X
superfamily	B-X
is	B-X
not	B-X
known	B-X
to	B-X
form	B-X
a	B-X
pore	B-X
,	B-X
or	B-X
has	B-X
been	B-X
shown	B-X
not	B-X
to-at	B-X
least	B-X
alone-the	B-X
same	B-X
conformational	B-X
change	B-X
could	B-X
have	B-X
other	B-X
adaptive	B-X
functions	B-X
during	B-X
activity	B-X
on	B-X
or	B-X
at	B-X
membranes	B-X
.	B-X
However	B-X
,	B-X
the	B-X
bicomponent	B-X
nature	B-X
of	B-X
some	B-X
pore-forming	B-X
toxins	B-X
alerts	B-X
us	B-X
that	B-X
showing	B-X
an	B-X
absence	B-X
of	B-X
activity	B-X
for	B-X
one	B-X
pure	B-X
protein	B-X
does	B-X
not	B-X
mean	B-X
that	B-X
they	B-X
do	B-X
not	B-X
contribute	B-X
to	B-X
pore	B-X
formation	B-X
quite	B-X
directly	B-X
,	B-X
since	B-X
that	B-X
may	B-X
require	B-X
the	B-X
presence	B-X
of	B-X
another	B-X
MACPF/CDC	B-X
family	B-X
member	B-X
or	B-X
members	B-X
from	B-X
the	B-X
same	B-X
specific	B-X
system	B-X
.	B-X
Complement	B-X
acts	B-X
by	B-X
a	B-X
combination	B-X
of	B-X
the	B-X
C5b-8	B-X
complex	B-X
of	B-X
proteins	B-X
preassembled	B-X
on	B-X
a	B-X
target	B-X
membrane	B-X
recruiting	B-X
C9	B-X
to	B-X
form	B-X
a	B-X
lesion	B-X
,	B-X
which	B-X
may	B-X
be	B-X
a	B-X
complete	B-X
ring	B-X
of	B-X
C9	B-X
associated	B-X
with	B-X
the	B-X
C5b-8	B-X
or	B-X
an	B-X
arc-electron	B-X
microscopy	B-X
images	B-X
show	B-X
both	B-X
possibilities.Perforin	B-X
acts	B-X
in	B-X
concert	B-X
with	B-X
granzymes	B-X
,	B-X
to	B-X
trigger	B-X
apoptosis	B-X
when	B-X
delivered	B-X
by	B-X
cytotoxic	B-X
cells	B-X
at	B-X
their	B-X
targets	B-X
(	B-X
damaged	B-X
,	B-X
transformed	B-X
and	B-X
infected	B-X
host	B-X
cells	B-X
)	B-X
.	B-X

The	O
C	O
-	O
terminal	O
region	O
of	O
the	O
polypeptide	O
chain	O
is	O
folded	O
into	O
the	O
base	O
domain	O
(	O
residues	O
168	O
-	O
306	O
)	O
,	O
which	O
consists	O
of	O
a	O
five	O
-	O
stranded	O
anti	O
-	O
parallel	O
beta	O
-	O
sheet	O
with	O
four	O
alpha	O
-	O
helices	O
,	O
three	O
of	O
which	O
(	O
alpha	O
5	O
,	O
alpha	O
6	O
and	O
alpha	O
8	O
)	O
cover	O
one	O
side	O
of	O
the	O
beta	O
-	O
sheet	O
.	O

The	O
long	O
helix	O
alpha	O
8	O
is	O
slightly	O
bent	O
.	O

Structural	O
similarity	O
searches	O
<EOS>	B-X
Consequently	B-X
,	B-X
numerous	B-X
algorithms	B-X
have	B-X
been	B-X
developed	B-X
that	B-X
facilitate	B-X
structure	B-X
comparison	B-X
,	B-X
including	B-X
rapid	B-X
searches	B-X
against	B-X
a	B-X
steadily	B-X
growing	B-X
collection	B-X
of	B-X
protein	B-X
structures	B-X
.	B-X
Here	B-X
we	B-X
present	B-X
VAST+	B-X
,	B-X
an	B-X
extension	B-X
to	B-X
the	B-X
existing	B-X
VAST	B-X
service	B-X
,	B-X
which	B-X
summarizes	B-X
and	B-X
presents	B-X
structural	B-X
similarity	B-X
on	B-X
the	B-X
level	B-X
of	B-X
biological	B-X
assemblies	B-X
or	B-X
macromolecular	B-X
complexes	B-X
.	B-X
VAST+	B-X
simplifies	B-X
structure	B-X
neighboring	B-X
results	B-X
and	B-X
shows	B-X
,	B-X
for	B-X
macromolecular	B-X
complexes	B-X
tracked	B-X
in	B-X
MMDB	B-X
,	B-X
lists	B-X
of	B-X
similar	B-X
complexes	B-X
ranked	B-X
by	B-X
the	B-X
extent	B-X
of	B-X
similarity	B-X
.	B-X
Distance	B-X
matrix	B-X
alignment	B-X
(	B-X
Dali	B-X
)	B-X
is	B-X
used	B-X
routinely	B-X
by	B-X
crystallographers	B-X
worldwide	B-X
to	B-X
screen	B-X
the	B-X
database	B-X
of	B-X
known	B-X
structures	B-X
for	B-X
similarity	B-X
to	B-X
newly	B-X
determined	B-X
structures	B-X
.	B-X

When	O
we	O
searched	O
for	O
structural	O
similarity	O
against	O
the	O
Protein	O
Data	O
Bank	O
database	O
using	O
the	O
program	O
DALI	O
(	O
18	O
)	O
,	O
the	O
P	B-Species
.	I-Species
aeruginosa	I-Species
RdgC	O
monomer	O
showed	O
no	O
significant	O
similarity	O
with	O
a	O
Z	O
score	O
above	O
5	O
.	O

Therefore	O
,	O
we	O
conclude	O
that	O
the	O
overall	O
fold	O
of	O
the	O
RdgC	O
polypeptide	O
chain	O
is	O
unique	O
.	O

When	O
we	O
elaborated	O
the	O
structural	O
comparisons	O
with	O
individual	O
domains	O
of	O
P	B-Species
.	I-Species
aeruginosa	I-Species
RdgC	O
,	O
only	O
the	O
center	O
domain	O
gave	O
a	O
Z	O
score	O
above	O
5	O
.	O

Using	O
the	O
center	O
domain	O
(	O
residues	O
1	O
-	O
73	O
and	O
121	O
-	O
167	O
)	O
alone	O
,	O
the	O
highest	O
structural	O
similarity	O
is	O
found	O
with	O
the	O
human	B-Species
beta	O
2	O
-	O
adaptin	O
appendage	O
domain	O
(	O
PDB	O
code	O
1E42	O
,	O
Z	O
score	O
=	O
7	O
.	O
1	O
,	O
r	O
.	O
m	O
.	O
s	O
.	O
deviation	O
=	O
2	O
.	O
5	O
A	O
for	O
85	O
structurally	O
aligned	O
residues	O
,	O
residues	O
1	O
-	O
12	O
,	O
14	O
-	O
30	O
,	O
44	O
-	O
47	O
,	O
58	O
-	O
72	O
,	O
122	O
-	O
133	O
and	O
135	O
-	O
160	O
of	O
P	B-Species
.	I-Species
aeruginosa	I-Species
RdgC	O
chain	O
A	O
and	O
residues	O
838	O
-	O
841	O
,	O
848	O
-	O
880	O
,	O
885	O
-	O
906	O
and	O
912	O
-	O
967	O
of	O
the	O
human	B-Species
beta	O
2	O
-	O
adaptin	O
appendage	O
domain	O
chain	O
A	O
)	O
(	O
19	O
)	O
.	O

There	O
does	O
not	O
appear	O
to	O
be	O
any	O
functional	O
relatedness	O
between	O
these	O
two	O
proteins	O
.	O

The	O
next	O
highest	O
similarity	O
is	O
found	O
with	O
the	O
yeast	B-Species
TATA	O
-	O
box	O
-	O
binding	O
protein	O
(	O
PDB	O
code	O
1YTB	O
,	O
Z	O
score	O
=	O
5	O
.	O
7	O
,	O
r	O
.	O
m	O
.	O
s	O
.	O
deviation	O
=	O
2	O
.	O
6	O
A	O
for	O
79	O
structurally	O
aligned	O
residues	O
,	O
residues	O
4	O
-	O
12	O
,	O
14	O
-	O
19	O
,	O
21	O
-	O
27	O
,	O
56	O
-	O
70	O
,	O
124	O
-	O
132	O
and	O
134	O
-	O
166	O
of	O
P	B-Species
.	I-Species
aeruginosa	I-Species
RdgC	O
chain	O
A	O
and	O
residues	O
69	O
-	O
96	O
,	O
100	O
-	O
126	O
and	O
132	O
-	O
155	O
of	O
TATA	O
-	O
box	O
-	O
binding	O
protein	O
,	O
N	O
-	O
terminal	O
half	O
of	O
chain	O
A	O
)	O
(	O
20	O
)	O
.	O

The	O
TATA	O
-	O
box	O
-	O
binding	O
protein	O
is	O
composed	O
of	O
a	O
ten	O
-	O
stranded	O
antiparallel	O
beta	O
-	O
sheet	O
with	O
four	O
flanking	O
alpha	O
-	O
helices	O
on	O
the	O
convex	O
side	O
of	O
the	O
beta	O
-	O
sheet	O
(	O
20	O
)	O
.	O

It	O
has	O
an	O
internal	O
quasi	O
2	O
-	O
fold	O
symmetry	O
,	O
and	O
its	O
beta	O
-	O
strands	O
are	O
involved	O
in	O
DNA	O
binding	O
.	O

There	O
is	O
,	O
however	O
,	O
no	O
structural	O
similarity	O
of	O
functional	O
significance	O
,	O
because	O
the	O
two	O
center	O
domains	O
of	O
the	O
RdgC	O
dimer	O
are	O
well	O
separated	O
and	O
do	O
not	O
associate	O
into	O
a	O
single	O
unit	O
(	O
Figure	O
1C	O
and	O
D	O
)	O
.	O

Using	O
the	O
tip	O
domain	O
(	O
residues	O
74	O
-	O
120	O
)	O
alone	O
,	O
the	O
ATPase	O
domain	O
of	O
bovine	B-Species
Hsc70	O
chaperone	O
shows	O
highest	O
structural	O
similarity	O
(	O
PDB	O
code	O
1BA1	O
,	O
Z	O
score	O
=	O
4	O
.	O
8	O
,	O
r	O
.	O
m	O
.	O
s	O
.	O
deviation	O
=	O
1	O
.	O
7	O
A	O
for	O
45	O
structurally	O
aligned	O
residues	O
,	O
residues	O
76	O
-	O
120	O
of	O
P	B-Species
.	I-Species
aeruginosa	I-Species
RdgC	O
chain	O
A	O
and	O
residues	O
230	O
-	O
253	O
and	O
256	O
-	O
276	O
of	O
the	O
Hsc70	O
ATPase	O
domain	O
)	O
(	O
21	O
)	O
.	O

There	O
does	O
not	O
seem	O
to	O
be	O
any	O
significant	O
functional	O
relationship	O
between	O
these	O
two	O
proteins	O
.	O

The	O
alpha	O
-	O
helix	O
-	O
loop	O
-	O
alpha	O
-	O
helix	O
structure	O
of	O
the	O
tip	O
domain	O
is	O
reminiscent	O
of	O
the	O
helix	O
-	O
hairpin	O
-	O
helix	O
(	O
HhH	O
)	O
DNA	O
-	O
binding	O
motif	O
that	O
is	O
present	O
in	O
a	O
number	O
of	O
DNA	O
repair	O
enzymes	O
(	O
22	O
-	O
25	O
)	O
.	O

The	O
HhH	O
motifs	O
are	O
characterized	O
by	O
the	O
conserved	O
sequence	O
motif	O
hxxhxGhGxxxAxxxhh	O
,	O
where	O
h	O
is	O
any	O
hydrophobic	O
residue	O
(	O
VILMWFYA	O
)	O
and	O
x	O
any	O
residue	O
(	O
23	O
)	O
.	O

Two	O
conserved	O
glycines	O
allow	O
a	O
tight	O
turn	O
between	O
two	O
alpha	O
-	O
helices	O
.	O

However	O
,	O
the	O
tip	O
domain	O
of	O
P	B-Species
.	I-Species
aeruginosa	I-Species
RdgC	O
protein	O
does	O
not	O
have	O
such	O
a	O
sequence	O
motif	O
,	O
and	O
the	O
loop	O
in	O
the	O
RdgC	O
tip	O
domain	O
is	O
much	O
more	O
extended	O
than	O
that	O
of	O
the	O
HhH	O
motifs	O
.	O
<EOS>	B-X
RdgC	B-X
,	B-X
a	B-X
recombination-associated	B-X
DNA-binding	B-X
protein	B-X
,	B-X
is	B-X
a	B-X
potential	B-X
negative	B-X
regulator	B-X
of	B-X
RecA	B-X
function	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
have	B-X
determined	B-X
the	B-X
crystal	B-X
structure	B-X
of	B-X
RdgC	B-X
from	B-X
Pseudomonas	B-X
aeruginosa	B-X
.	B-X
The	B-X
J-shaped	B-X
monomer	B-X
has	B-X
a	B-X
unique	B-X
fold	B-X
and	B-X
can	B-X
be	B-X
divided	B-X
into	B-X
three	B-X
structural	B-X
domains	B-X
:	B-X
tip	B-X
domain	B-X
,	B-X
center	B-X
domain	B-X
and	B-X
base	B-X
domain	B-X
.	B-X
Of	B-X
the	B-X
two	B-X
inter-subunit	B-X
interfaces	B-X
within	B-X
the	B-X
dimer	B-X
,	B-X
one	B-X
interface	B-X
(	B-X
'interface	B-X
A	B-X
'	B-X
)	B-X
between	B-X
tip/center	B-X
domains	B-X
is	B-X
more	B-X
nonpolar	B-X
than	B-X
the	B-X
other	B-X
(	B-X
'interface	B-X
B	B-X
'	B-X
)	B-X
between	B-X
base	B-X
domains	B-X
.	B-X
The	B-X
structure	B-X
allows	B-X
us	B-X
to	B-X
propose	B-X
that	B-X
the	B-X
RdgC	B-X
dimer	B-X
binds	B-X
dsDNA	B-X
through	B-X
the	B-X
central	B-X
hole	B-X
of	B-X
approximately	B-X
30	B-X
A	B-X
diameter	B-X
.	B-X
The	B-X
proposed	B-X
model	B-X
is	B-X
supported	B-X
by	B-X
our	B-X
DNA-binding	B-X
assays	B-X
coupled	B-X
with	B-X
mutagenesis	B-X
,	B-X
which	B-X
indicate	B-X
that	B-X
the	B-X
conserved	B-X
positively	B-X
charged	B-X
residues	B-X
on	B-X
the	B-X
protein	B-X
surface	B-X
around	B-X
the	B-X
central	B-X
hole	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
DNA	B-X
binding	B-X
.	B-X
The	B-X
novel	B-X
ring-shaped	B-X
architecture	B-X
of	B-X
the	B-X
RdgC	B-X
dimer	B-X
has	B-X
significant	B-X
implications	B-X
for	B-X
its	B-X
role	B-X
in	B-X
homologous	B-X
recombination	B-X
.	B-X

Therefore	O
,	O
the	O
RdgC	O
tip	O
domain	O
is	O
uniquely	O
folded	O
.	O

With	O
the	O
base	O
domain	O
(	O
residues	O
168	O
-	O
306	O
)	O
alone	O
,	O
the	O
highest	O
similarity	O
is	O
found	O
with	O
P	B-Species
.	I-Species
aeruginosa	I-Species
isochorismate	O
-	O
pyruvate	O
lyase	O
(	O
unpublished	O
deposition	O
;	O
PDB	O
code	O
2H9C	O
,	O
Z	O
score	O
=	O
4	O
.	O
0	O
,	O
r	O
.	O
m	O
.	O
s	O
.	O
deviation	O
=	O
4	O
.	O
8	O
A	O
for	O
51	O
structurally	O
aligned	O
residues	O
,	O
residues	O
186	O
-	O
191	O
,	O
237	O
-	O
240	O
,	O
257	O
-	O
272	O
and	O
274	O
-	O
298	O
of	O
P	B-Species
.	I-Species
aeruginosa	I-Species
RdgC	O
chain	O
A	O
and	O
residues	O
36	O
-	O
41	O
,	O
50	O
-	O
53	O
,	O
55	O
-	O
66	O
and	O
68	O
-	O
96	O
of	O
P	B-Species
.	I-Species
aeruginosa	I-Species
isochorismate	O
-	O
pyruvate	O
lyase	O
chain	O
A	O
)	O
.	O

There	O
does	O
not	O
appear	O
to	O
be	O
any	O
functional	O
relationship	O
between	O
the	O
two	O
proteins	O
,	O
and	O
the	O
base	O
domain	O
of	O
RdgC	O
is	O
uniquely	O
folded	O
.	O

The	O
101	O
-	O
residue	O
chain	O
of	O
P	B-Species
.	I-Species
aeruginosa	I-Species
isochorismate	O
-	O
pyruvate	O
lyase	O
is	O
folded	O
into	O
three	O
alpha	O
-	O
helices	O
,	O
two	O
of	O
which	O
overlap	O
with	O
two	O
alpha	O
-	O
helices	O
(	O
alpha	O
2	O
and	O
alpha	O
3	O
)	O
of	O
the	O
base	O
domain	O
of	O
RdgC	O
.	O

Ring	O
-	O
shaped	O
dimer	O
structure	O
and	O
inter	O
-	O
subunit	O
interface	O
<EOS>	B-X
In	B-X
order	B-X
to	B-X
pinpoint	B-X
structural	B-X
disparities	B-X
among	B-X
them	B-X
,	B-X
we	B-X
determined	B-X
the	B-X
crystal	B-X
structure	B-X
of	B-X
CG-1B	B-X
.	B-X
Alteration	B-X
of	B-X
the	B-X
position	B-X
of	B-X
the	B-X
Trp	B-X
ring	B-X
in	B-X
the	B-X
lectin	B-X
site	B-X
and	B-X
the	B-X
presence	B-X
of	B-X
only	B-X
two	B-X
ordered	B-X
water	B-X
molecules	B-X
therein	B-X
,	B-X
as	B-X
well	B-X
as	B-X
changes	B-X
in	B-X
the	B-X
interface	B-X
region	B-X
between	B-X
the	B-X
two	B-X
subunits	B-X
,	B-X
set	B-X
the	B-X
structure	B-X
of	B-X
CG-1B	B-X
clearly	B-X
apart	B-X
from	B-X
that	B-X
of	B-X
CG-1A	B-X
.	B-X
Intriguingly	B-X
,	B-X
the	B-X
unique	B-X
presence	B-X
of	B-X
two	B-X
Cys	B-X
residues	B-X
at	B-X
positions	B-X
2	B-X
and	B-X
7	B-X
in	B-X
the	B-X
N-terminal	B-X
region	B-X
translated	B-X
into	B-X
formation	B-X
of	B-X
an	B-X
intersubunit	B-X
disulfide	B-X
bridge	B-X
between	B-X
the	B-X
Cys7	B-X
residues	B-X
of	B-X
the	B-X
homodimer	B-X
in	B-X
the	B-X
crystal	B-X
.	B-X
In	B-X
solution	B-X
,	B-X
oxidation	B-X
is	B-X
associated	B-X
with	B-X
significant	B-X
shape	B-X
changes	B-X
in	B-X
the	B-X
dimeric	B-X
protein	B-X
and	B-X
the	B-X
additional	B-X
occurrence	B-X
of	B-X
a	B-X
compacted	B-X
form	B-X
with	B-X
an	B-X
intrasubunit	B-X
disulfide	B-X
bridge	B-X
between	B-X
Cys2	B-X
and	B-X
Cys7	B-X
.	B-X

Our	O
structure	O
reveals	O
that	O
P	B-Species
.	I-Species
aeruginosa	I-Species
RdgC	O
forms	O
a	O
ring	O
-	O
shaped	O
dimer	O
of	O
approximate	O
2	O
-	O
fold	O
symmetry	O
in	O
the	O
crystal	O
(	O
Figure	O
1	O
)	O
.	O

This	O
observation	O
is	O
consistent	O
with	O
the	O
results	O
of	O
previous	O
gel	O
filtration	O
and	O
sedimentation	O
equilibrium	O
experiments	O
,	O
which	O
suggested	O
the	O
presence	O
of	O
dimeric	O
species	O
of	O
E	B-Species
.	I-Species
coli	I-Species
RdgC	O
in	O
solution	O
(	O
1	O
,	O
2	O
)	O
.	O

Depending	O
on	O
the	O
concentration	O
,	O
RdgC	O
could	O
also	O
exist	O
in	O
solution	O
as	O
monomers	O
,	O
tetramers	O
and	O
higher	O
oligomers	O
(	O
1	O
)	O
.	O

In	O
the	O
crystal	O
lattice	O
,	O
no	O
monomeric	O
,	O
trimeric	O
or	O
tetrameric	O
species	O
exist	O
.	O
<EOS>	B-X
Physiologically	B-X
,	B-X
Î±S	B-X
may	B-X
populate	B-X
disordered	B-X
monomeric	B-X
,	B-X
helically	B-X
folded	B-X
tetrameric	B-X
,	B-X
or	B-X
membrane-bound	B-X
oligomeric	B-X
states	B-X
.	B-X
Notably	B-X
,	B-X
Î±S	B-X
does	B-X
not	B-X
adopt	B-X
a	B-X
single	B-X
``	B-X
amyloid	B-X
fold	B-X
''	B-X
,	B-X
but	B-X
rather	B-X
exists	B-X
as	B-X
structurally	B-X
distinct	B-X
amyloid-like	B-X
conformations	B-X
referred	B-X
to	B-X
as	B-X
``	B-X
strains	B-X
''	B-X
.	B-X
We	B-X
then	B-X
discuss	B-X
recent	B-X
studies	B-X
on	B-X
the	B-X
influence	B-X
of	B-X
micro-environmental	B-X
factors	B-X
on	B-X
Î±S	B-X
species	B-X
formation	B-X
,	B-X
propagation	B-X
,	B-X
and	B-X
the	B-X
resultant	B-X
pathological	B-X
characteristics	B-X
.	B-X
The	B-X
lactate	B-X
dehydrogenase	B-X
(	B-X
LDH	B-X
)	B-X
has	B-X
been	B-X
studied	B-X
widely	B-X
because	B-X
it	B-X
exists	B-X
in	B-X
various	B-X
isozymic	B-X
forms	B-X
.	B-X
The	B-X
association	B-X
of	B-X
A	B-X
and	B-X
B	B-X
subunits	B-X
of	B-X
LDH	B-X
can	B-X
generate	B-X
five	B-X
tetrameric	B-X
isozymes	B-X
,	B-X
but	B-X
the	B-X
finding	B-X
of	B-X
the	B-X
sixth	B-X
isozyme	B-X
in	B-X
mature	B-X
human	B-X
testis	B-X
and	B-X
sperm	B-X
indicated	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
additional	B-X
subunit	B-X
of	B-X
LDH	B-X
,	B-X
designated	B-X
as	B-X
LDH-X	B-X
(	B-X
also	B-X
termed	B-X
LDH-C4	B-X
due	B-X
to	B-X
tetrameric	B-X
nature	B-X
of	B-X
C-subunit	B-X
)	B-X
.	B-X
The	B-X
major	B-X
aim	B-X
of	B-X
this	B-X
article	B-X
is	B-X
to	B-X
review	B-X
the	B-X
salient	B-X
features	B-X
of	B-X
LDH-C	B-X
subunit	B-X
and	B-X
the	B-X
immune	B-X
responses	B-X
of	B-X
LDH-C4	B-X
in	B-X
homologous	B-X
and	B-X
heterologous	B-X
species	B-X
in	B-X
relation	B-X
to	B-X
its	B-X
role	B-X
in	B-X
acceptance	B-X
or	B-X
rejection	B-X
of	B-X
the	B-X
allograft	B-X
and	B-X
its	B-X
application	B-X
in	B-X
contraception	B-X
and	B-X
immunotherapy	B-X
of	B-X
cancer	B-X
,	B-X
directly	B-X
or	B-X
indirectly	B-X
through	B-X
the	B-X
regulation	B-X
of	B-X
its	B-X
substrate	B-X
,	B-X
the	B-X
lactate	B-X
.	B-X

Our	O
structure	O
unequivocally	O
rules	O
out	O
the	O
monomer	O
-	O
trimer	O
model	O
,	O
which	O
fits	O
the	O
sedimentation	O
equilibrium	O
data	O
approximately	O
,	O
as	O
well	O
as	O
the	O
monomer	O
-	O
dimer	O
-	O
tetramer	O
model	O
(	O
1	O
)	O
.	O

The	O
RdgC	O
dimer	O
has	O
approximate	O
dimensions	O
of	O
80	O
A	O
x	O
60	O
A	O
x	O
40	O
A	O
,	O
with	O
a	O
central	O
hole	O
of	O
~	O
30	O
A	O
diameter	O
.	O

Only	O
a	O
moderate	O
amount	O
of	O
surface	O
area	O
is	O
buried	O
upon	O
the	O
formation	O
of	O
the	O
RdgC	O
dimer	O
.	O

The	O
monomer	O
-	O
monomer	O
interface	O
buries	O
a	O
solvent	O
-	O
accessible	O
surface	O
area	O
of	O
~	O
1360	O
A	O
2	O
per	O
monomer	O
,	O
corresponding	O
to	O
~	O
8	O
%	O
of	O
the	O
total	O
surface	O
area	O
of	O
the	O
monomer	O
(	O
Protein	O
-	O
Protein	O
Interaction	O
Server	O
at	O
http	O
:	O
/	O
/	O
www	O
.	O
biochem	O
.	O
ucl	O
.	O
ac	O
.	O
uk	O
/	O
bsm	O
/	O
PP	O
/	O
server	O
/	O
)	O
.	O

Polar	O
and	O
nonpolar	O
atoms	O
in	O
interface	O
are	O
44	O
and	O
56	O
%	O
,	O
respectively	O
.	O

The	O
interface	O
can	O
be	O
divided	O
into	O
two	O
kinds	O
:	O
'	O
interface	O
A	O
'	O
involving	O
both	O
the	O
tip	O
domains	O
and	O
center	O
domains	O
,	O
and	O
'	O
interface	O
B	O
'	O
involving	O
the	O
base	O
domains	O
(	O
Figure	O
2A	O
)	O
.	O

These	O
two	O
interfaces	O
have	O
significantly	O
different	O
characters	O
.	O
<EOS>	B-X
Surface	B-X
plasmon	B-X
polaritons	B-X
are	B-X
electromagnetic	B-X
waves	B-X
coupled	B-X
to	B-X
collective	B-X
electron	B-X
oscillations	B-X
propagating	B-X
along	B-X
metal-dielectric	B-X
interfaces	B-X
,	B-X
exhibiting	B-X
a	B-X
bosonic	B-X
character	B-X
.	B-X
Recent	B-X
experiments	B-X
involving	B-X
surface	B-X
plasmons	B-X
guided	B-X
by	B-X
wires	B-X
or	B-X
stripes	B-X
allowed	B-X
the	B-X
reproduction	B-X
of	B-X
quantum	B-X
optics	B-X
effects	B-X
,	B-X
such	B-X
as	B-X
antibunching	B-X
with	B-X
a	B-X
single	B-X
surface	B-X
plasmon	B-X
state	B-X
,	B-X
coalescence	B-X
with	B-X
a	B-X
two-plasmon	B-X
state	B-X
,	B-X
conservation	B-X
of	B-X
squeezing	B-X
,	B-X
or	B-X
entanglement	B-X
through	B-X
plasmonic	B-X
channels	B-X
.	B-X
We	B-X
develop	B-X
a	B-X
platform	B-X
that	B-X
enables	B-X
two	B-X
complementary	B-X
experiments	B-X
,	B-X
one	B-X
revealing	B-X
the	B-X
particle	B-X
behavior	B-X
of	B-X
the	B-X
single-plasmon	B-X
state	B-X
through	B-X
antibunching	B-X
,	B-X
and	B-X
the	B-X
other	B-X
one	B-X
where	B-X
the	B-X
interferences	B-X
prove	B-X
its	B-X
wave	B-X
nature	B-X
.	B-X
This	B-X
result	B-X
opens	B-X
up	B-X
new	B-X
ways	B-X
to	B-X
exploit	B-X
quantum	B-X
conversion	B-X
effects	B-X
between	B-X
different	B-X
bosonic	B-X
species	B-X
as	B-X
shown	B-X
here	B-X
with	B-X
photons	B-X
and	B-X
polaritons	B-X
.	B-X

The	O
interface	O
A	O
is	O
formed	O
largely	O
by	O
the	O
crossing	O
over	O
of	O
the	O
two	O
tip	O
domains	O
in	O
the	O
dimer	O
(	O
Figure	O
1	O
)	O
.	O

This	O
interface	O
covers	O
a	O
surface	O
area	O
of	O
~	O
565	O
A	O
2	O
and	O
is	O
largely	O
nonpolar	O
,	O
with	O
the	O
polar	O
and	O
nonpolar	O
atoms	O
in	O
the	O
interface	O
being	O
37	O
.	O
5	O
and	O
2	O
.	O
5	O
%	O
,	O
respectively	O
.	O

Phe120	O
contributes	O
considerably	O
to	O
the	O
nonpolar	O
character	O
of	O
the	O
interface	O
between	O
the	O
tip	O
domains	O
,	O
accounting	O
for	O
~	O
150	O
A	O
2	O
of	O
the	O
interface	O
area	O
.	O

Phe120	O
is	O
part	O
of	O
a	O
highly	O
conserved	O
sequence	O
segment	O
and	O
lies	O
at	O
the	O
boundary	O
between	O
the	O
tip	O
domain	O
and	O
the	O
center	O
domain	O
.	O

The	O
aromatic	O
ring	O
of	O
Phe120	O
'	O
inserts	O
into	O
a	O
hydrophobic	O
pocket	O
,	O
which	O
is	O
formed	O
by	O
the	O
hydrophobic	O
residues	O
Ile74	O
,	O
Leu75	O
,	O
Pro76	O
,	O
Val79	O
,	O
Leu115	O
,	O
Ala119	O
and	O
Phe120	O
of	O
the	O
neighboring	O
monomer	O
(	O
Figure	O
2B	O
)	O
.	O

The	O
primed	O
residue	O
belongs	O
to	O
the	O
adjacent	O
subunit	O
.	O

These	O
residues	O
are	O
well	O
conserved	O
in	O
the	O
RdgC	O
family	O
(	O
indicated	O
by	O
green	O
triangles	O
below	O
the	O
aligned	O
sequences	O
in	O
Figure	O
3	O
)	O
.	O

As	O
these	O
hydrophobic	O
residues	O
are	O
located	O
near	O
the	O
molecular	O
2	O
-	O
fold	O
axis	O
,	O
the	O
two	O
clusters	O
of	O
hydrophobic	O
side	O
chains	O
are	O
merged	O
into	O
a	O
single	O
,	O
large	O
cluster	O
in	O
the	O
dimer	O
(	O
Figure	O
2B	O
)	O
.	O

Of	O
the	O
16	O
hydrogen	O
bonds	O
that	O
exist	O
between	O
the	O
two	O
subunits	O
,	O
only	O
one	O
is	O
made	O
in	O
this	O
interface	O
between	O
Arg118	O
and	O
Arg118	O
'	O
.	O

The	O
interface	O
B	O
is	O
contributed	O
to	O
exclusively	O
by	O
the	O
two	O
base	O
domains	O
.	O
<EOS>	B-X
The	B-X
3alpha-HSD/CR	B-X
gene	B-X
(	B-X
hsdA	B-X
)	B-X
is	B-X
774	B-X
base	B-X
pairs	B-X
long	B-X
and	B-X
the	B-X
deduced	B-X
amino	B-X
acid	B-X
sequence	B-X
comprises	B-X
258	B-X
residues	B-X
with	B-X
a	B-X
calculated	B-X
molecular	B-X
mass	B-X
of	B-X
26.4	B-X
kDa	B-X
.	B-X
Dimerisation	B-X
takes	B-X
place	B-X
via	B-X
an	B-X
interface	B-X
essentially	B-X
built-up	B-X
by	B-X
helix	B-X
alphaG	B-X
and	B-X
strand	B-X
betaG	B-X
of	B-X
each	B-X
subunit	B-X
.	B-X
So	B-X
far	B-X
,	B-X
this	B-X
type	B-X
of	B-X
intermolecular	B-X
contact	B-X
has	B-X
exclusively	B-X
been	B-X
observed	B-X
in	B-X
homotetrameric	B-X
SDRs	B-X
,	B-X
but	B-X
never	B-X
in	B-X
the	B-X
structure	B-X
of	B-X
a	B-X
homodimeric	B-X
SDR	B-X
.	B-X
Interestingly	B-X
,	B-X
hsdA	B-X
expression	B-X
was	B-X
found	B-X
to	B-X
be	B-X
under	B-X
negative	B-X
control	B-X
by	B-X
two	B-X
repressor	B-X
proteins	B-X
,	B-X
the	B-X
genes	B-X
of	B-X
which	B-X
were	B-X
found	B-X
in	B-X
opposite	B-X
direction	B-X
downstream	B-X
or	B-X
overlapping	B-X
with	B-X
hsdA	B-X
.	B-X
Based	B-X
on	B-X
our	B-X
results	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
induction	B-X
of	B-X
hsdA	B-X
expression	B-X
in	B-X
C.	B-X
testosteroni	B-X
by	B-X
steroids	B-X
actually	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
de-repression	B-X
by	B-X
preventing	B-X
the	B-X
binding	B-X
of	B-X
repressor	B-X
proteins	B-X
to	B-X
regulatory	B-X
regions	B-X
.	B-X

This	O
interface	O
covers	O
a	O
surface	O
area	O
of	O
~	O
795	O
A	O
2	O
.	O
<EOS>	B-X
The	B-X
behavior	B-X
of	B-X
cholesteryl	B-X
myristoleate	B-X
in	B-X
mixtures	B-X
with	B-X
dioleoylphosphatidylcholine	B-X
was	B-X
investigated	B-X
at	B-X
the	B-X
air	B-X
--	B-X
water	B-X
interface	B-X
.	B-X
20	B-X
,	B-X
789	B-X
--	B-X
795	B-X
]	B-X
,	B-X
a	B-X
second	B-X
surface	B-X
phase	B-X
has	B-X
been	B-X
identified	B-X
.	B-X
Analysis	B-X
of	B-X
surface	B-X
pressure	B-X
and	B-X
molecular	B-X
area	B-X
data	B-X
as	B-X
a	B-X
function	B-X
of	B-X
composition	B-X
shows	B-X
that	B-X
the	B-X
molecules	B-X
in	B-X
the	B-X
second	B-X
phase	B-X
can	B-X
exist	B-X
in	B-X
two	B-X
miscible	B-X
,	B-X
double-layer	B-X
states	B-X
or	B-X
packing	B-X
arrangements	B-X
,	B-X
only	B-X
one	B-X
of	B-X
which	B-X
contains	B-X
lecithin	B-X
.	B-X
The	B-X
mixed	B-X
double-layer	B-X
state	B-X
is	B-X
preferentially	B-X
formed	B-X
and	B-X
has	B-X
stoichiometry	B-X
ranging	B-X
between	B-X
2.0	B-X
and	B-X
9.5	B-X
molecules	B-X
of	B-X
cholesteryl	B-X
ester	B-X
for	B-X
each	B-X
lecithin	B-X
molecule	B-X
.	B-X
The	B-X
structure	B-X
of	B-X
this	B-X
state	B-X
resembles	B-X
a	B-X
mixed	B-X
monolayer	B-X
of	B-X
pressure-dependent	B-X
composition	B-X
and	B-X
area	B-X
which	B-X
is	B-X
covered	B-X
by	B-X
a	B-X
second	B-X
layer	B-X
of	B-X
cholesteryl	B-X
ester	B-X
at	B-X
38.2	B-X
A2/molecule	B-X
.	B-X
The	B-X
cholesteryl	B-X
myristoleate/lecithin	B-X
ratio	B-X
of	B-X
the	B-X
layer	B-X
in	B-X
contact	B-X
with	B-X
the	B-X
aqueous	B-X
phase	B-X
ranges	B-X
from	B-X
0	B-X
to	B-X
2.8	B-X
between	B-X
39	B-X
and	B-X
0	B-X
mN/m	B-X
.	B-X
The	B-X
second	B-X
double-layer	B-X
state	B-X
is	B-X
equivalent	B-X
to	B-X
a	B-X
monolayer	B-X
of	B-X
cholesteryl	B-X
ester	B-X
at	B-X
the	B-X
lipid	B-X
--	B-X
water	B-X
interface	B-X
,	B-X
covered	B-X
by	B-X
a	B-X
layer	B-X
of	B-X
cholesteryl	B-X
ester	B-X
molecules	B-X
at	B-X
38.2	B-X
A2	B-X
.	B-X
Overall	B-X
,	B-X
our	B-X
data	B-X
show	B-X
that	B-X
the	B-X
presence	B-X
of	B-X
lecithin	B-X
at	B-X
a	B-X
lipid	B-X
--	B-X
water	B-X
inferface	B-X
has	B-X
a	B-X
definite	B-X
ordering	B-X
effect	B-X
on	B-X
cholesteryl	B-X
ester	B-X
molecules	B-X
at	B-X
least	B-X
30	B-X
--	B-X
50	B-X
A	B-X
from	B-X
the	B-X
interface	B-X
.	B-X

The	O
polar	O
and	O
nonpolar	O
atoms	O
in	O
this	O
interface	O
are	O
50	O
%	O
each	O
.	O
<EOS>	B-X
The	B-X
lipid	B-X
bilayers	B-X
differ	B-X
in	B-X
their	B-X
lipid	B-X
composition	B-X
and	B-X
consist	B-X
of	B-X
(	B-X
i	B-X
)	B-X
unsaturated	B-X
phosphatidylcholine	B-X
(	B-X
palmitoyloleoylphosphatidylcholine	B-X
,	B-X
POPC	B-X
)	B-X
,	B-X
(	B-X
ii	B-X
)	B-X
POPC	B-X
and	B-X
20	B-X
mol	B-X
%	B-X
of	B-X
cholesterol	B-X
(	B-X
Chol	B-X
)	B-X
,	B-X
(	B-X
iii	B-X
)	B-X
sphingomyelin	B-X
(	B-X
SM	B-X
)	B-X
and	B-X
20	B-X
mol	B-X
%	B-X
of	B-X
Chol	B-X
,	B-X
and	B-X
(	B-X
iv	B-X
)	B-X
SM	B-X
and	B-X
50	B-X
mol	B-X
%	B-X
of	B-X
Chol	B-X
.	B-X
Only	B-X
1	B-X
out	B-X
of	B-X
26	B-X
residues	B-X
in	B-X
the	B-X
EGF-peptide	B-X
sequence	B-X
is	B-X
polar	B-X
(	B-X
Thr	B-X
)	B-X
.	B-X
Chol	B-X
increases	B-X
packing	B-X
of	B-X
atoms	B-X
relative	B-X
to	B-X
the	B-X
peptide	B-X
side	B-X
chains	B-X
,	B-X
and	B-X
thus	B-X
increases	B-X
van	B-X
der	B-X
Waals	B-X
interactions	B-X
.	B-X
In	B-X
the	B-X
bilayer	B-X
center	B-X
,	B-X
packing	B-X
is	B-X
higher	B-X
in	B-X
POPC-based	B-X
bilayers	B-X
,	B-X
while	B-X
in	B-X
regions	B-X
closer	B-X
to	B-X
the	B-X
interface	B-X
packing	B-X
is	B-X
higher	B-X
in	B-X
SM-based	B-X
bilayers	B-X
.	B-X

The	O
two	O
beta	O
-	O
sheets	O
of	O
the	O
two	O
base	O
domains	O
merge	O
into	O
a	O
single	O
ten	O
-	O
stranded	O
antiparallel	O
beta	O
-	O
sheet	O
in	O
this	O
interface	O
(	O
Figure	O
2A	O
)	O
.	O

Thus	O
,	O
15	O
of	O
16	O
inter	O
-	O
subunit	O
hydrogen	O
bonds	O
are	O
clustered	O
in	O
this	O
interface	O
.	O
<EOS>	B-X
Protein-protein	B-X
interactions	B-X
are	B-X
an	B-X
important	B-X
phenomenon	B-X
in	B-X
biological	B-X
processes	B-X
and	B-X
functions	B-X
.	B-X
We	B-X
used	B-X
the	B-X
manually	B-X
curated	B-X
non-redundant	B-X
dataset	B-X
of	B-X
118	B-X
phycocyanin	B-X
interfaces	B-X
to	B-X
gain	B-X
additional	B-X
insight	B-X
into	B-X
this	B-X
phenomenon	B-X
using	B-X
a	B-X
robust	B-X
inter-atomic	B-X
non-covalent	B-X
interaction	B-X
analyzing	B-X
tool	B-X
PPCheck	B-X
.	B-X
Our	B-X
observations	B-X
indicate	B-X
that	B-X
there	B-X
is	B-X
a	B-X
relatively	B-X
high	B-X
composition	B-X
of	B-X
hydrophobic	B-X
residues	B-X
at	B-X
the	B-X
interfaces	B-X
.	B-X
Most	B-X
of	B-X
the	B-X
interface	B-X
residues	B-X
are	B-X
clustered	B-X
at	B-X
the	B-X
middle	B-X
of	B-X
the	B-X
range	B-X
which	B-X
we	B-X
call	B-X
``	B-X
standard-size	B-X
''	B-X
interfaces	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
multiple	B-X
interaction	B-X
patterns	B-X
founded	B-X
in	B-X
the	B-X
present	B-X
study	B-X
indicate	B-X
that	B-X
more	B-X
than	B-X
half	B-X
of	B-X
the	B-X
residues	B-X
involved	B-X
in	B-X
these	B-X
interactions	B-X
participate	B-X
in	B-X
multiple	B-X
and	B-X
water-bridged	B-X
hydrogen	B-X
bonds	B-X
.	B-X
Thus	B-X
,	B-X
hydrogen	B-X
bonds	B-X
contribute	B-X
maximally	B-X
towards	B-X
the	B-X
stability	B-X
of	B-X
protein-protein	B-X
complexes	B-X
.	B-X
The	B-X
analysis	B-X
shows	B-X
that	B-X
hydrogen	B-X
bond	B-X
energies	B-X
contribute	B-X
to	B-X
about	B-X
88	B-X
%	B-X
to	B-X
the	B-X
total	B-X
energy	B-X
and	B-X
it	B-X
also	B-X
increases	B-X
with	B-X
interface	B-X
size	B-X
.	B-X
Nevertheless	B-X
,	B-X
the	B-X
role	B-X
by	B-X
vdW	B-X
and	B-X
electrostatic	B-X
energy	B-X
could	B-X
not	B-X
be	B-X
ignored	B-X
in	B-X
interface	B-X
binding	B-X
.	B-X
Results	B-X
show	B-X
that	B-X
the	B-X
total	B-X
binding	B-X
energy	B-X
is	B-X
more	B-X
for	B-X
large	B-X
phycocyanin	B-X
interfaces	B-X
.	B-X
The	B-X
normalized	B-X
energy	B-X
per	B-X
residue	B-X
was	B-X
less	B-X
than	B-X
-16	B-X
kJ	B-X
mol	B-X

The	O
hydrogen	O
bond	O
networks	O
can	O
be	O
divided	O
into	O
two	O
types	O
.	O
<EOS>	B-X
In	B-X
Anopheles	B-X
dirus	B-X
glutathione	B-X
transferase	B-X
D3-3	B-X
,	B-X
position	B-X
64	B-X
is	B-X
occupied	B-X
by	B-X
a	B-X
functionally	B-X
conserved	B-X
glutamate	B-X
residue	B-X
,	B-X
which	B-X
interacts	B-X
directly	B-X
with	B-X
the	B-X
gamma-glutamate	B-X
moiety	B-X
of	B-X
GSH	B-X
(	B-X
glutathione	B-X
)	B-X
as	B-X
part	B-X
of	B-X
an	B-X
electron-sharing	B-X
network	B-X
present	B-X
in	B-X
all	B-X
soluble	B-X
GSTs	B-X
(	B-X
glutathione	B-X
transferases	B-X
)	B-X
.	B-X
Available	B-X
crystal	B-X
structures	B-X
as	B-X
well	B-X
as	B-X
consideration	B-X
of	B-X
the	B-X
property	B-X
of	B-X
the	B-X
equivalent	B-X
residue	B-X
at	B-X
position	B-X
64	B-X
,	B-X
acidic	B-X
or	B-X
polar	B-X
,	B-X
suggest	B-X
that	B-X
the	B-X
GST	B-X
electron-sharing	B-X
motif	B-X
can	B-X
be	B-X
divided	B-X
into	B-X
two	B-X
types	B-X
.	B-X

The	O
first	O
type	O
involves	O
the	O
main	O
chain	O
atoms	O
of	O
Val206	O
,	O
Arg208	O
and	O
Lys210	O
in	O
strand	O
beta	O
9	O
;	O
this	O
strand	O
associates	O
with	O
the	O
equivalent	O
strand	O
from	O
the	O
other	O
subunit	O
in	O
an	O
antiparallel	O
manner	O
(	O
Figure	O
2C	O
)	O
.	O

The	O
other	O
type	O
involves	O
both	O
the	O
side	O
chain	O
and	O
main	O
chain	O
atoms	O
.	O
<EOS>	B-X
We	B-X
find	B-X
a	B-X
significant	B-X
contribution	B-X
of	B-X
main-chain	B-X
atoms	B-X
to	B-X
protein-protein	B-X
interactions	B-X
.	B-X
These	B-X
include	B-X
interactions	B-X
both	B-X
with	B-X
other	B-X
main-chain	B-X
and	B-X
side-chain	B-X
atoms	B-X
on	B-X
the	B-X
interacting	B-X
chain	B-X
.	B-X
We	B-X
find	B-X
that	B-X
the	B-X
type	B-X
of	B-X
interaction	B-X
depends	B-X
on	B-X
both	B-X
amino	B-X
acid	B-X
and	B-X
secondary	B-X
structure	B-X
type	B-X
involved	B-X
in	B-X
the	B-X
contact	B-X
.	B-X
For	B-X
example	B-X
,	B-X
residues	B-X
in	B-X
Î±-helices	B-X
and	B-X
large	B-X
amino	B-X
acids	B-X
are	B-X
the	B-X
most	B-X
likely	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
interactions	B-X
through	B-X
their	B-X
side-chain	B-X
atoms	B-X
.	B-X
Our	B-X
findings	B-X
demonstrate	B-X
that	B-X
the	B-X
manner	B-X
in	B-X
which	B-X
protein-protein	B-X
interactions	B-X
are	B-X
formed	B-X
is	B-X
determined	B-X
by	B-X
the	B-X
residue	B-X
type	B-X
and	B-X
the	B-X
secondary	B-X
structure	B-X
found	B-X
in	B-X
the	B-X
interface	B-X
.	B-X

The	O
side	O
chain	O
of	O
Arg211	O
'	O
interacts	O
with	O
the	O
backbone	O
of	O
Gly204	O
,	O
while	O
the	O
side	O
chain	O
of	O
Lys227	O
hydrogen	O
bonds	O
to	O
those	O
of	O
both	O
Gln212	O
'	O
and	O
Glu218	O
(	O
Figure	O
2D	O
)	O
.	O

In	O
addition	O
,	O
the	O
side	O
chain	O
of	O
Gln212	O
'	O
interacts	O
with	O
that	O
of	O
Asp199	O
and	O
the	O
backbone	O
of	O
Arg211	O
'	O
(	O
Figure	O
2D	O
)	O
.	O

Arg211	O
,	O
Gln212	O
,	O
Glu218	O
and	O
Lys227	O
are	O
highly	O
conserved	O
among	O
the	O
RdgC	O
family	O
members	O
.	O

The	O
residues	O
participating	O
in	O
the	O
hydrogen	O
bond	O
networks	O
are	O
indicated	O
by	O
red	O
circles	O
below	O
the	O
aligned	O
sequences	O
in	O
Figure	O
3	O
.	O

The	O
observation	O
that	O
conserved	O
residues	O
play	O
important	O
roles	O
in	O
forming	O
the	O
dimer	O
implies	O
that	O
dimerization	O
of	O
RdgC	O
is	O
critical	O
for	O
its	O
function	O
.	O

If	O
one	O
or	O
both	O
of	O
interfaces	O
A	O
and	O
B	O
are	O
to	O
be	O
broken	O
for	O
functional	O
reasons	O
such	O
as	O
for	O
allowing	O
dsDNA	O
to	O
enter	O
into	O
the	O
central	O
hole	O
of	O
the	O
RdgC	O
dimer	O
,	O
we	O
can	O
conceive	O
of	O
three	O
scenarios	O
.	O
<EOS>	B-X
However	B-X
,	B-X
in	B-X
order	B-X
to	B-X
build	B-X
sustainability	B-X
of	B-X
One	B-X
Health	B-X
in	B-X
these	B-X
efforts	B-X
,	B-X
One	B-X
Health	B-X
champions	B-X
and	B-X
implementers	B-X
need	B-X
to	B-X
collect	B-X
and	B-X
provide	B-X
government	B-X
decision-makers	B-X
with	B-X
country-level	B-X
data	B-X
on	B-X
One	B-X
Health	B-X
's	B-X
impact	B-X
to	B-X
help	B-X
justify	B-X
policy	B-X
decisions	B-X
and	B-X
resource	B-X
allocations	B-X
.	B-X
Cells	B-X
require	B-X
one-carbon	B-X
units	B-X
for	B-X
nucleotide	B-X
synthesis	B-X
,	B-X
methylation	B-X
and	B-X
reductive	B-X
metabolism	B-X
,	B-X
and	B-X
these	B-X
pathways	B-X
support	B-X
the	B-X
high	B-X
proliferative	B-X
rate	B-X
of	B-X
cancer	B-X
cells	B-X
.	B-X
As	B-X
such	B-X
,	B-X
anti-folates	B-X
,	B-X
drugs	B-X
that	B-X
target	B-X
one-carbon	B-X
metabolism	B-X
,	B-X
have	B-X
long	B-X
been	B-X
used	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
cancer	B-X
.	B-X
Amino	B-X
acids	B-X
,	B-X
such	B-X
as	B-X
serine	B-X
are	B-X
a	B-X
major	B-X
one-carbon	B-X
source	B-X
,	B-X
and	B-X
cancer	B-X
cells	B-X
are	B-X
particularly	B-X
susceptible	B-X
to	B-X
deprivation	B-X
of	B-X
one-carbon	B-X
units	B-X
by	B-X
serine	B-X
restriction	B-X
or	B-X
inhibition	B-X
of	B-X
de	B-X
novo	B-X
serine	B-X
synthesis	B-X
.	B-X
Recent	B-X
work	B-X
has	B-X
also	B-X
begun	B-X
to	B-X
decipher	B-X
the	B-X
specific	B-X
pathways	B-X
and	B-X
sub-cellular	B-X
compartments	B-X
that	B-X
are	B-X
important	B-X
for	B-X
one-carbon	B-X
metabolism	B-X
in	B-X
cancer	B-X
cells	B-X
.	B-X
In	B-X
this	B-X
review	B-X
we	B-X
summarise	B-X
the	B-X
historical	B-X
understanding	B-X
of	B-X
one-carbon	B-X
metabolism	B-X
in	B-X
cancer	B-X
,	B-X
describe	B-X
the	B-X
recent	B-X
findings	B-X
regarding	B-X
the	B-X
generation	B-X
and	B-X
usage	B-X
of	B-X
one-carbon	B-X
units	B-X
and	B-X
explore	B-X
possible	B-X
future	B-X
therapeutics	B-X
that	B-X
could	B-X
exploit	B-X
the	B-X
dependency	B-X
of	B-X
cancer	B-X
cells	B-X
on	B-X
one-carbon	B-X
metabolism	B-X
.	B-X

The	O
first	O
possibility	O
would	O
be	O
a	O
simultaneous	O
breakage	O
of	O
the	O
two	O
interfaces	O
A	O
and	O
B	O
.	O

The	O
second	O
would	O
be	O
the	O
sequential	O
disruption	O
of	O
the	O
interfaces	O
A	O
and	O
B	O
.	O

The	O
third	O
would	O
be	O
the	O
disruption	O
of	O
only	O
one	O
of	O
the	O
two	O
interfaces	O
A	O
and	O
B	O
.	O

Sedimentation	O
equilibrium	O
indicated	O
the	O
presence	O
of	O
monomers	O
in	O
solution	O
(	O
1	O
)	O
,	O
which	O
is	O
consistent	O
with	O
the	O
first	O
two	O
scenarios	O
.	O

If	O
the	O
third	O
scenario	O
holds	O
,	O
RdgC	O
dimers	O
could	O
possibly	O
exist	O
in	O
two	O
conformations	O
in	O
solution	O
,	O
i	O
.	O
e	O
.	O
a	O
closed	O
form	O
as	O
observed	O
in	O
the	O
present	O
crystal	O
structure	O
,	O
and	O
an	O
open	O
form	O
,	O
in	O
which	O
one	O
of	O
the	O
two	O
interfaces	O
A	O
and	O
B	O
is	O
broken	O
.	O

A	O
model	O
for	O
DNA	O
binding	O
by	O
RdgC	O
and	O
DNA	O
-	O
binding	O
assay	O

The	O
net	O
charge	O
of	O
P	B-Species
.	I-Species
aeruginosa	I-Species
RdgC	O
is	O
highly	O
negative	O
,	O
since	O
each	O
monomer	O
contains	O
12	O
aspartate	O
,	O
13	O
glutamate	O
,	O
10	O
lysine	O
,	O
9	O
arginine	O
and	O
2	O
histidine	O
residues	O
.	O

The	O
net	O
charge	O
of	O
a	O
dimer	O
would	O
be	O
-	O
12	O
(	O
or	O
-	O
8	O
)	O
,	O
if	O
we	O
assume	O
none	O
(	O
or	O
all	O
)	O
of	O
histidines	O
to	O
be	O
positively	O
charged	O
.	O

The	O
electrostatic	O
potential	O
at	O
the	O
molecular	O
surface	O
of	O
RdgC	O
dimer	O
shows	O
that	O
the	O
charge	O
distribution	O
on	O
the	O
protein	O
surface	O
is	O
highly	O
nonuniform	O
(	O
Figure	O
4A	O
)	O
.	O

Since	O
the	O
inner	O
surface	O
of	O
the	O
RdgC	O
dimer	O
is	O
rich	O
in	O
conserved	O
,	O
positively	O
charged	O
residues	O
and	O
the	O
diameter	O
of	O
the	O
central	O
hole	O
(	O
~	O
30	O
A	O
)	O
is	O
approximately	O
similar	O
to	O
that	O
of	O
other	O
toroidal	O
DNA	O
-	O
binding	O
proteins	O
(	O
26	O
)	O
,	O
it	O
appears	O
likely	O
that	O
RdgC	O
dimers	O
bind	O
dsDNA	O
through	O
the	O
central	O
hole	O
.	O

Despite	O
extensive	O
co	O
-	O
crystallization	O
and	O
soaking	O
trials	O
with	O
linear	O
dsDNAs	O
of	O
different	O
lengths	O
(	O
14	O
-	O
mer	O
,	O
16	O
-	O
mer	O
and	O
18	O
-	O
mer	O
)	O
,	O
we	O
could	O
not	O
locate	O
the	O
bound	O
DNA	O
experimentally	O
.	O

We	O
attribute	O
this	O
difficulty	O
to	O
the	O
nature	O
of	O
sequence	O
-	O
nonspecific	O
DNA	O
binding	O
by	O
RdgC	O
.	O

Therefore	O
,	O
we	O
built	O
a	O
crude	O
model	O
of	O
a	O
DNA	O
complex	O
of	O
the	O
RdgC	O
dimer	O
by	O
fitting	O
dsDNA	O
into	O
the	O
central	O
hole	O
(	O
Figure	O
4B	O
)	O
.	O

This	O
model	O
is	O
supported	O
by	O
the	O
DNA	O
-	O
binding	O
assays	O
coupled	O
with	O
mutagenesis	O
,	O
as	O
described	O
below	O
.	O

It	O
is	O
also	O
consistent	O
with	O
the	O
suggested	O
binding	O
site	O
size	O
of	O
~	O
16	O
nt	O
for	O
the	O
E	B-Species
.	I-Species
coli	I-Species
RdgC	O
dimer	O
(	O
1	O
)	O
and	O
the	O
approximate	O
thickness	O
(	O
~	O
40	O
A	O
)	O
of	O
the	O
P	B-Species
.	I-Species
aeruginosa	I-Species
RdgC	O
dimer	O
.	O

When	O
we	O
performed	O
electrophoretic	O
mobility	O
shift	O
assay	O
for	O
dsDNA	O
binding	O
,	O
P	B-Species
.	I-Species
aeruginosa	I-Species
RdgC	O
did	O
not	O
require	O
Mg2	O
+	O
ions	O
(	O
Supplementary	O
Figure	O
2	O
)	O
,	O
unlike	O
Deinococcus	B-Species
radiodurans	I-Species
RecR	O
,	O
which	O
required	O
high	O
concentrations	O
of	O
Mg2	O
+	O
ions	O
(	O
27	O
)	O
.	O

ATP	O
was	O
not	O
required	O
for	O
dsDNA	O
binding	O
by	O
P	B-Species
.	I-Species
aeruginosa	I-Species
RdgC	O
,	O
either	O
(	O
Supplementary	O
Figure	O
2	O
)	O
.	O
<EOS>	B-X
Since	B-X
1929	B-X
,	B-X
when	B-X
it	B-X
was	B-X
discovered	B-X
that	B-X
ATP	B-X
is	B-X
a	B-X
substrate	B-X
for	B-X
muscle	B-X
contraction	B-X
,	B-X
the	B-X
knowledge	B-X
about	B-X
this	B-X
purine	B-X
nucleotide	B-X
has	B-X
been	B-X
greatly	B-X
expanded	B-X
.	B-X
Many	B-X
aspects	B-X
of	B-X
cell	B-X
metabolism	B-X
revolve	B-X
around	B-X
ATP	B-X
production	B-X
and	B-X
consumption	B-X
.	B-X
ATP	B-X
is	B-X
universally	B-X
seen	B-X
as	B-X
the	B-X
energy	B-X
exchange	B-X
factor	B-X
that	B-X
connects	B-X
anabolism	B-X
and	B-X
catabolism	B-X
but	B-X
also	B-X
fuels	B-X
processes	B-X
such	B-X
as	B-X
motile	B-X
contraction	B-X
,	B-X
phosphorylations	B-X
,	B-X
and	B-X
active	B-X
transport	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
will	B-X
discuss	B-X
all	B-X
the	B-X
main	B-X
mechanisms	B-X
of	B-X
ATP	B-X
production	B-X
linked	B-X
to	B-X
ADP	B-X
phosphorylation	B-X
as	B-X
well	B-X
the	B-X
regulation	B-X
of	B-X
these	B-X
mechanisms	B-X
during	B-X
stress	B-X
conditions	B-X
and	B-X
in	B-X
connection	B-X
with	B-X
calcium	B-X
signalling	B-X
events	B-X
.	B-X
Recent	B-X
advances	B-X
regarding	B-X
ATP	B-X
storage	B-X
and	B-X
its	B-X
special	B-X
significance	B-X
for	B-X
purinergic	B-X
signalling	B-X
will	B-X
also	B-X
be	B-X
reviewed	B-X
.	B-X

This	O
is	O
consistent	O
with	O
an	O
apparent	O
lack	O
of	O
an	O
ATP	O
-	O
binding	O
pocket	O
in	O
the	O
RdgC	O
dimer	O
structure	O
.	O

In	O
order	O
to	O
identify	O
the	O
residues	O
that	O
are	O
important	O
for	O
dsDNA	O
binding	O
,	O
we	O
carried	O
out	O
mutational	O
analyses	O
.	O

The	O
residues	O
for	O
mutagenesis	O
were	O
selected	O
on	O
the	O
basis	O
of	O
the	O
modeled	O
complex	O
between	O
RdgC	O
dimer	O
and	O
dsDNA	O
,	O
together	O
with	O
sequence	O
conservation	O
(	O
Figure	O
4C	O
)	O
.	O

We	O
prepared	O
eleven	O
point	O
mutants	O
(	O
R4A	O
,	O
K70D	O
,	O
R81D	O
,	O
F120A	O
,	O
R122D	O
,	O
K146A	O
,	O
R198A	O
,	O
R208A	O
,	O
R211D	O
,	O
Q212A	O
and	O
R252A	O
)	O
.	O

These	O
eleven	O
mutated	O
residues	O
are	O
well	O
conserved	O
among	O
RdgC	O
proteins	O
.	O

Eight	O
mutants	O
(	O
R4A	O
,	O
K70D	O
,	O
R81D	O
,	O
R122D	O
,	O
K146A	O
,	O
R198A	O
,	O
R208A	O
and	O
R252A	O
)	O
had	O
a	O
lower	O
affinity	O
for	O
dsDNA	O
than	O
the	O
wild	O
-	O
type	O
RdgC	O
(	O
Figure	O
4D	O
)	O
.	O

These	O
eight	O
mutated	O
residues	O
are	O
indicated	O
by	O
blue	O
squares	O
below	O
the	O
aligned	O
sequences	O
in	O
Figure	O
3	O
.	O

This	O
result	O
indicates	O
that	O
dsDNA	O
binds	O
to	O
the	O
inside	O
surface	O
around	O
the	O
central	O
hole	O
of	O
the	O
RdgC	O
dimer	O
,	O
since	O
the	O
mutated	O
residues	O
are	O
located	O
on	O
the	O
inner	O
surface	O
of	O
the	O
RdgC	O
dimer	O
.	O

It	O
is	O
worth	O
mentioning	O
that	O
a	O
single	O
mutation	O
introduces	O
two	O
alterations	O
per	O
RdgC	O
dimer	O
.	O

The	O
three	O
mutants	O
(	O
F120A	O
,	O
R211D	O
and	O
Q212A	O
)	O
were	O
prepared	O
to	O
investigate	O
whether	O
dimerization	O
of	O
RdgC	O
is	O
crucial	O
for	O
dsDNA	O
binding	O
.	O

Phe120	O
is	O
a	O
key	O
residue	O
located	O
in	O
the	O
inter	O
-	O
subunit	O
interface	O
A	O
(	O
Figure	O
2B	O
)	O
,	O
while	O
Arg211	O
makes	O
hydrogen	O
bonds	O
in	O
the	O
interface	O
B	O
(	O
Figure	O
2D	O
)	O
and	O
Gln212	O
is	O
involved	O
in	O
both	O
intra	O
-	O
and	O
inter	O
-	O
subunit	O
interactions	O
(	O
Figure	O
2D	O
)	O
.	O

dsDNA	O
binding	O
by	O
the	O
F120A	O
mutant	O
is	O
considerably	O
weakened	O
,	O
compared	O
to	O
either	O
the	O
R211D	O
or	O
Q212A	O
mutant	O
(	O
Figure	O
4D	O
)	O
.	O
<EOS>	B-X
In	B-X
eukaryotes	B-X
,	B-X
the	B-X
cytosolic	B-X
aggregation	B-X
quality	B-X
control	B-X
load	B-X
is	B-X
partitioned	B-X
between	B-X
two	B-X
compartments	B-X
:	B-X
the	B-X
juxtanuclear	B-X
quality	B-X
control	B-X
compartment	B-X
(	B-X
JUNQ	B-X
)	B-X
and	B-X
the	B-X
insoluble	B-X
protein	B-X
deposit	B-X
(	B-X
IPOD	B-X
)	B-X
(	B-X
Figure	B-X
1	B-X
-	B-X
model	B-X
)	B-X
.	B-X
3D	B-X
timelapse	B-X
(	B-X
4D	B-X
imaging	B-X
)	B-X
is	B-X
not	B-X
merely	B-X
a	B-X
technical	B-X
challenge	B-X
;	B-X
rather	B-X
,	B-X
it	B-X
also	B-X
facilitates	B-X
a	B-X
dramatic	B-X
shift	B-X
in	B-X
the	B-X
conceptual	B-X
framework	B-X
used	B-X
to	B-X
analyze	B-X
cellular	B-X
structure	B-X
.	B-X
We	B-X
utilize	B-X
a	B-X
cytosolic	B-X
folding	B-X
sensor	B-X
protein	B-X
in	B-X
live	B-X
yeast	B-X
to	B-X
visualize	B-X
distinct	B-X
fates	B-X
for	B-X
misfolded	B-X
proteins	B-X
in	B-X
cellular	B-X
aggregation	B-X
quality	B-X
control	B-X
,	B-X
using	B-X
rapid	B-X
4D	B-X
fluorescent	B-X
imaging	B-X
.	B-X
The	B-X
temperature	B-X
sensitive	B-X
mutant	B-X
of	B-X
the	B-X
Ubc9	B-X
protein	B-X
(	B-X
Ubc9	B-X
(	B-X
ts	B-X
)	B-X
)	B-X
is	B-X
extremely	B-X
effective	B-X
both	B-X
as	B-X
a	B-X
sensor	B-X
of	B-X
cellular	B-X
proteostasis	B-X
,	B-X
and	B-X
a	B-X
physiological	B-X
model	B-X
for	B-X
tracking	B-X
aggregation	B-X
quality	B-X
control	B-X
.	B-X

This	O
result	O
suggests	O
that	O
destabilization	O
of	O
the	O
ring	O
-	O
shaped	O
architecture	O
of	O
the	O
RdgC	O
dimer	O
is	O
deleterious	O
for	O
tight	O
dsDNA	O
binding	O
and	O
that	O
interface	O
A	O
is	O
probably	O
more	O
important	O
than	O
interface	O
B	O
for	O
dsDNA	O
binding	O
.	O

dsDNA	O
-	O
binding	O
affinity	O
of	O
the	O
Q212A	O
mutant	O
was	O
lower	O
than	O
the	O
wild	O
type	O
(	O
Figure	O
4D	O
)	O
,	O
whereas	O
that	O
of	O
the	O
R211D	O
mutant	O
was	O
comparable	O
to	O
the	O
wild	O
type	O
(	O
Figure	O
4D	O
)	O
.	O

This	O
result	O
suggests	O
that	O
disruption	O
of	O
the	O
inter	O
-	O
subunit	O
interface	O
B	O
is	O
also	O
detrimental	O
for	O
dsDNA	O
binding	O
but	O
to	O
a	O
smaller	O
extent	O
than	O
disruption	O
of	O
the	O
interface	O
A	O
.	O

It	O
further	O
suggests	O
that	O
the	O
side	O
chain	O
of	O
Arg211	O
is	O
not	O
involved	O
in	O
recognizing	O
dsDNA	O
.	O
<EOS>	B-X
Both	B-X
isozymes	B-X
hydrolyze	B-X
terminal	B-X
beta-linked	B-X
GalNAc	B-X
or	B-X
GlcNAc	B-X
residues	B-X
from	B-X
numerous	B-X
artificial	B-X
and	B-X
natural	B-X
substrates	B-X
;	B-X
however	B-X
,	B-X
in	B-X
vivo	B-X
GM2	B-X
ganglioside	B-X
is	B-X
a	B-X
substrate	B-X
for	B-X
only	B-X
the	B-X
heterodimeric	B-X
A	B-X
isozyme	B-X
.	B-X
Thus	B-X
,	B-X
mutations	B-X
in	B-X
either	B-X
gene	B-X
encoding	B-X
its	B-X
alpha	B-X
or	B-X
beta	B-X
subunits	B-X
can	B-X
result	B-X
in	B-X
GM2	B-X
ganglioside	B-X
storage	B-X
and	B-X
Tay-Sachs	B-X
or	B-X
Sandhoff	B-X
disease	B-X
,	B-X
respectively	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
incubation	B-X
of	B-X
hexosaminidase	B-X
with	B-X
a	B-X
chemical	B-X
modifier	B-X
specific	B-X
for	B-X
carboxyl	B-X
side	B-X
chains	B-X
produces	B-X
a	B-X
time-dependent	B-X
loss	B-X
of	B-X
activity	B-X
,	B-X
and	B-X
that	B-X
this	B-X
effect	B-X
can	B-X
be	B-X
blocked	B-X
by	B-X
the	B-X
inclusion	B-X
of	B-X
a	B-X
strong	B-X
competitive	B-X
inhibitor	B-X
in	B-X
the	B-X
reaction	B-X
mix	B-X
.	B-X
This	B-X
region	B-X
includes	B-X
beta	B-X
Arg211	B-X
(	B-X
invariant	B-X
in	B-X
15	B-X
sequences	B-X
)	B-X
,	B-X
which	B-X
we	B-X
have	B-X
previously	B-X
shown	B-X
to	B-X
be	B-X
an	B-X
active	B-X
residue	B-X
.	B-X

It	O
is	O
interesting	O
that	O
the	O
DNA	O
complex	O
for	O
wild	O
type	O
forms	O
a	O
distinct	O
band	O
(	O
lane	O
3	O
in	O
Figure	O
4D	O
)	O
,	O
as	O
opposed	O
to	O
a	O
more	O
diffuse	O
band	O
as	O
one	O
would	O
expect	O
if	O
the	O
complexes	O
contained	O
different	O
numbers	O
of	O
RdgC	O
dimers	O
.	O

Assuming	O
a	O
binding	O
site	O
size	O
of	O
~	O
16	O
nt	O
(	O
1	O
)	O
,	O
the	O
414	O
-	O
bp	O
duplex	O
DNA	O
would	O
bind	O
~	O
25	O
RdgC	O
dimers	O
if	O
it	O
is	O
fully	O
saturated	O
.	O

RdgC	O
is	O
unique	O
among	O
ring	O
-	O
shaped	O
DNA	O
-	O
binding	O
proteins	O
<EOS>	B-X
RdgC	B-X
,	B-X
a	B-X
recombination-associated	B-X
DNA-binding	B-X
protein	B-X
,	B-X
is	B-X
a	B-X
potential	B-X
negative	B-X
regulator	B-X
of	B-X
RecA	B-X
function	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
have	B-X
determined	B-X
the	B-X
crystal	B-X
structure	B-X
of	B-X
RdgC	B-X
from	B-X
Pseudomonas	B-X
aeruginosa	B-X
.	B-X
The	B-X
J-shaped	B-X
monomer	B-X
has	B-X
a	B-X
unique	B-X
fold	B-X
and	B-X
can	B-X
be	B-X
divided	B-X
into	B-X
three	B-X
structural	B-X
domains	B-X
:	B-X
tip	B-X
domain	B-X
,	B-X
center	B-X
domain	B-X
and	B-X
base	B-X
domain	B-X
.	B-X
Two	B-X
such	B-X
monomers	B-X
dimerize	B-X
to	B-X
form	B-X
a	B-X
ring-shaped	B-X
molecule	B-X
of	B-X
approximate	B-X
2-fold	B-X
symmetry	B-X
.	B-X
The	B-X
structure	B-X
allows	B-X
us	B-X
to	B-X
propose	B-X
that	B-X
the	B-X
RdgC	B-X
dimer	B-X
binds	B-X
dsDNA	B-X
through	B-X
the	B-X
central	B-X
hole	B-X
of	B-X
approximately	B-X
30	B-X
A	B-X
diameter	B-X
.	B-X
The	B-X
proposed	B-X
model	B-X
is	B-X
supported	B-X
by	B-X
our	B-X
DNA-binding	B-X
assays	B-X
coupled	B-X
with	B-X
mutagenesis	B-X
,	B-X
which	B-X
indicate	B-X
that	B-X
the	B-X
conserved	B-X
positively	B-X
charged	B-X
residues	B-X
on	B-X
the	B-X
protein	B-X
surface	B-X
around	B-X
the	B-X
central	B-X
hole	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
DNA	B-X
binding	B-X
.	B-X
The	B-X
novel	B-X
ring-shaped	B-X
architecture	B-X
of	B-X
the	B-X
RdgC	B-X
dimer	B-X
has	B-X
significant	B-X
implications	B-X
for	B-X
its	B-X
role	B-X
in	B-X
homologous	B-X
recombination	B-X
.	B-X

Pseudomonas	B-Species
aeruginosa	I-Species
RdgC	O
adds	O
a	O
unique	O
member	O
to	O
the	O
repertoire	O
of	O
toroidal	O
DNA	O
-	O
binding	O
proteins	O
(	O
26	O
)	O
such	O
as	O
D	B-Species
.	I-Species
radiodurans	I-Species
RecR	O
(	O
27	O
)	O
and	O
DNA	O
polymerase	O
processivity	O
factors	O
,	O
including	O
the	O
beta	O
subunit	O
of	O
E	B-Species
.	I-Species
coli	I-Species
DNA	O
polymerase	O
III	O
(	O
28	O
)	O
,	O
gp45	O
of	O
T4	O
DNA	O
polymerase	O
(	O
29	O
)	O
and	O
PCNA	O
of	O
eukaryotic	O
DNA	O
polymerase	O
delta	O
(	O
30	O
,	O
31	O
)	O
(	O
Figure	O
5	O
)	O
.	O

These	O
proteins	O
do	O
not	O
have	O
an	O
overall	O
sequence	O
similarity	O
among	O
themselves	O
,	O
and	O
their	O
quaternary	O
structures	O
also	O
vary	O
.	O
<EOS>	B-X
The	B-X
intracellular	B-X
sorting	B-X
of	B-X
newly	B-X
synthesized	B-X
precursor	B-X
proteins	B-X
(	B-X
preproteins	B-X
)	B-X
to	B-X
mitochondria	B-X
depends	B-X
on	B-X
the	B-X
``	B-X
mitochondria-targeting	B-X
sequence	B-X
''	B-X
(	B-X
MTS	B-X
)	B-X
,	B-X
which	B-X
is	B-X
located	B-X
at	B-X
the	B-X
amino	B-X
termini	B-X
of	B-X
the	B-X
preproteins	B-X
.	B-X
MTS	B-X
is	B-X
required	B-X
,	B-X
however	B-X
,	B-X
not	B-X
only	B-X
for	B-X
targeting	B-X
newly	B-X
synthesized	B-X
preproteins	B-X
to	B-X
mitochondria	B-X
,	B-X
but	B-X
also	B-X
for	B-X
all	B-X
the	B-X
following	B-X
steps	B-X
along	B-X
the	B-X
mitochondrial	B-X
protein	B-X
import	B-X
pathway	B-X
.	B-X
MTS	B-X
of	B-X
nascent	B-X
preproteins	B-X
is	B-X
first	B-X
recognized	B-X
by	B-X
a	B-X
cytoplasmic	B-X
molecular	B-X
chaperone	B-X
,	B-X
MSF	B-X
,	B-X
and	B-X
then	B-X
by	B-X
Tom70	B-X
and	B-X
Tom20	B-X
of	B-X
the	B-X
mitochondrial	B-X
outer	B-X
membrane	B-X
receptor	B-X
complex	B-X
,	B-X
Tom5	B-X
and	B-X
Tom40	B-X
of	B-X
the	B-X
outer	B-X
membrane	B-X
protein	B-X
translocation	B-X
machinery	B-X
,	B-X
Tim23	B-X
of	B-X
the	B-X
inner	B-X
membrane	B-X
protein	B-X
translocation	B-X
machinery	B-X
,	B-X
and	B-X
finally	B-X
the	B-X
processing	B-X
peptidase	B-X
,	B-X
MPP	B-X
,	B-X
in	B-X
the	B-X
matrix	B-X
.	B-X
MTS	B-X
is	B-X
a	B-X
multi-role	B-X
sorting	B-X
sequence	B-X
which	B-X
specifically	B-X
interacts	B-X
with	B-X
various	B-X
components	B-X
along	B-X
the	B-X
mitochondrial	B-X
protein	B-X
import	B-X
pathway	B-X
.	B-X
Recognition	B-X
of	B-X
MTS	B-X
at	B-X
multiple	B-X
steps	B-X
during	B-X
the	B-X
import	B-X
of	B-X
preproteins	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
strict	B-X
sorting	B-X
of	B-X
proteins	B-X
destined	B-X
for	B-X
mitochondria	B-X
.	B-X

P	B-Species
.	I-Species
aeruginosa	I-Species
RdgC	O
and	O
E	B-Species
.	I-Species
coli	I-Species
beta	O
clamp	O
are	O
homodimers	O
,	O
T4	O
gp45	O
and	O
eukaryotic	O
PCNAs	O
are	O
homotrimers	O
and	O
D	B-Species
.	I-Species
radiodurans	I-Species
RecR	O
is	O
a	O
homotetramer	O
.	O

In	O
P	B-Species
.	I-Species
aeruginosa	I-Species
RdgC	O
,	O
the	O
inner	O
surface	O
of	O
the	O
ring	O
-	O
shaped	O
dimer	O
is	O
largely	O
formed	O
by	O
beta	O
-	O
strands	O
,	O
while	O
the	O
outer	O
surface	O
of	O
the	O
ring	O
is	O
mostly	O
formed	O
by	O
alpha	O
-	O
helices	O
(	O
Figure	O
5	O
)	O
.	O

The	O
predicted	O
DNA	O
-	O
binding	O
site	O
of	O
P	B-Species
.	I-Species
aeruginosa	I-Species
RdgC	O
dimer	O
is	O
primarily	O
formed	O
by	O
beta	O
-	O
strands	O
and	O
loops	O
.	O

In	O
contrast	O
,	O
in	O
other	O
ring	O
-	O
shaped	O
DNA	O
-	O
binding	O
proteins	O
such	O
as	O
the	O
beta	O
subunit	O
of	O
E	B-Species
.	I-Species
coli	I-Species
DNA	O
polymerase	O
III	O
(	O
28	O
)	O
,	O
gp45	O
of	O
T4	O
DNA	O
polymerase	O
(	O
29	O
)	O
,	O
PCNA	O
of	O
eukaryotic	O
DNA	O
polymerases	O
delta	O
(	O
30	O
,	O
31	O
)	O
and	O
D	B-Species
.	I-Species
radiodurans	I-Species
RecR	O
(	O
27	O
)	O
,	O
alpha	O
-	O
helices	O
are	O
located	O
toward	O
the	O
center	O
of	O
the	O
ring	O
and	O
are	O
surrounded	O
by	O
beta	O
-	O
strands	O
in	O
the	O
outermost	O
side	O
of	O
the	O
ring	O
(	O
Figure	O
5	O
)	O
.	O

Despite	O
a	O
superficial	O
resemblance	O
of	O
the	O
overall	O
ring	O
-	O
shaped	O
architecture	O
of	O
the	O
RdgC	O
dimer	O
with	O
those	O
of	O
other	O
toroidal	O
DNA	O
-	O
binding	O
proteins	O
,	O
the	O
internal	O
arrangement	O
of	O
the	O
secondary	O
structure	O
elements	O
in	O
the	O
RdgC	O
dimer	O
is	O
strikingly	O
different	O
from	O
those	O
of	O
other	O
toroidal	O
DNA	O
-	O
binding	O
proteins	O
.	O

Thus	O
,	O
RdgC	O
is	O
unique	O
among	O
ring	O
-	O
shaped	O
DNA	O
-	O
binding	O
proteins	O
.	O
<EOS>	B-X
RdgC	B-X
,	B-X
a	B-X
recombination-associated	B-X
DNA-binding	B-X
protein	B-X
,	B-X
is	B-X
a	B-X
potential	B-X
negative	B-X
regulator	B-X
of	B-X
RecA	B-X
function	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
have	B-X
determined	B-X
the	B-X
crystal	B-X
structure	B-X
of	B-X
RdgC	B-X
from	B-X
Pseudomonas	B-X
aeruginosa	B-X
.	B-X
The	B-X
J-shaped	B-X
monomer	B-X
has	B-X
a	B-X
unique	B-X
fold	B-X
and	B-X
can	B-X
be	B-X
divided	B-X
into	B-X
three	B-X
structural	B-X
domains	B-X
:	B-X
tip	B-X
domain	B-X
,	B-X
center	B-X
domain	B-X
and	B-X
base	B-X
domain	B-X
.	B-X
Two	B-X
such	B-X
monomers	B-X
dimerize	B-X
to	B-X
form	B-X
a	B-X
ring-shaped	B-X
molecule	B-X
of	B-X
approximate	B-X
2-fold	B-X
symmetry	B-X
.	B-X
The	B-X
structure	B-X
allows	B-X
us	B-X
to	B-X
propose	B-X
that	B-X
the	B-X
RdgC	B-X
dimer	B-X
binds	B-X
dsDNA	B-X
through	B-X
the	B-X
central	B-X
hole	B-X
of	B-X
approximately	B-X
30	B-X
A	B-X
diameter	B-X
.	B-X
The	B-X
proposed	B-X
model	B-X
is	B-X
supported	B-X
by	B-X
our	B-X
DNA-binding	B-X
assays	B-X
coupled	B-X
with	B-X
mutagenesis	B-X
,	B-X
which	B-X
indicate	B-X
that	B-X
the	B-X
conserved	B-X
positively	B-X
charged	B-X
residues	B-X
on	B-X
the	B-X
protein	B-X
surface	B-X
around	B-X
the	B-X
central	B-X
hole	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
DNA	B-X
binding	B-X
.	B-X
The	B-X
novel	B-X
ring-shaped	B-X
architecture	B-X
of	B-X
the	B-X
RdgC	B-X
dimer	B-X
has	B-X
significant	B-X
implications	B-X
for	B-X
its	B-X
role	B-X
in	B-X
homologous	B-X
recombination	B-X
.	B-X

A	O
number	O
of	O
other	O
proteins	O
involved	O
in	O
DNA	O
metabolism	O
also	O
adopt	O
a	O
ring	O
-	O
shaped	O
structure	O
despite	O
diversity	O
in	O
the	O
molecular	O
functions	O
(	O
26	O
)	O
.	O

They	O
include	O
NAD	O
+	O
-	O
dependent	O
DNA	O
ligase	O
(	O
25	O
)	O
,	O
lambda	O
exonuclease	O
(	O
32	O
)	O
,	O
hexameric	O
helicases	O
,	O
topoisomerases	O
,	O
the	O
trp	O
RNA	O
-	O
binding	O
attenuation	O
protein	O
,	O
the	O
bacteriophage	O
head	O
-	O
to	O
-	O
tail	O
connector	O
and	O
translin	O
(	O
26	O
)	O
.	O

There	O
are	O
also	O
many	O
examples	O
of	O
the	O
proteins	O
in	O
DNA	O
recombination	O
pathways	O
that	O
assemble	O
into	O
multi	O
-	O
subunit	O
toroids	O
containing	O
a	O
central	O
channel	O
(	O
26	O
)	O
.	O

Electron	O
microscopy	O
showed	O
that	O
the	O
E	B-Species
.	I-Species
coli	I-Species
RuvB	O
protein	O
,	O
in	O
the	O
presence	O
of	O
ATP	O
,	O
forms	O
a	O
dodecamer	O
on	O
double	O
-	O
stranded	O
DNA	O
in	O
which	O
two	O
stacked	O
hexameric	O
rings	O
encircle	O
the	O
DNA	O
and	O
are	O
oriented	O
in	O
opposite	O
directions	O
with	O
D6	O
symmetry	O
(	O
33	O
)	O
.	O

The	O
human	B-Species
RAD52	O
protein	O
was	O
found	O
to	O
assemble	O
into	O
heptameric	O
rings	O
with	O
a	O
large	O
funnel	O
-	O
shaped	O
channel	O
,	O
40	O
-	O
60	O
A	O
in	O
diameter	O
(	O
34	O
)	O
.	O

The	O
human	B-Species
DMC1	O
protein	O
has	O
so	O
far	O
been	O
detected	O
only	O
as	O
an	O
octameric	O
ring	O
(	O
35	O
)	O
.	O

Inhibition	O
mechanism	O
of	O
RecA	O
function	O
by	O
RdgC	O
<EOS>	B-X
The	B-X
Escherichia	B-X
coli	B-X
RdgC	B-X
protein	B-X
is	B-X
a	B-X
potential	B-X
negative	B-X
regulator	B-X
of	B-X
RecA	B-X
function	B-X
.	B-X
RdgC	B-X
inhibits	B-X
RecA	B-X
protein-promoted	B-X
DNA	B-X
strand	B-X
exchange	B-X
,	B-X
ATPase	B-X
activity	B-X
,	B-X
and	B-X
RecA-dependent	B-X
LexA	B-X
cleavage	B-X
.	B-X
The	B-X
primary	B-X
mechanism	B-X
of	B-X
RdgC	B-X
inhibition	B-X
appears	B-X
to	B-X
involve	B-X
a	B-X
simple	B-X
competition	B-X
for	B-X
DNA	B-X
binding	B-X
sites	B-X
,	B-X
especially	B-X
on	B-X
duplex	B-X
DNA	B-X
.	B-X
The	B-X
capacity	B-X
of	B-X
RecA	B-X
to	B-X
compete	B-X
with	B-X
RdgC	B-X
is	B-X
improved	B-X
by	B-X
the	B-X
DinI	B-X
protein	B-X
.	B-X
RdgC	B-X
protein	B-X
can	B-X
inhibit	B-X
DNA	B-X
strand	B-X
exchange	B-X
catalyzed	B-X
by	B-X
RecA	B-X
nucleoprotein	B-X
filaments	B-X
formed	B-X
on	B-X
single-stranded	B-X
DNA	B-X
by	B-X
binding	B-X
to	B-X
the	B-X
homologous	B-X
duplex	B-X
DNA	B-X
and	B-X
thereby	B-X
blocking	B-X
access	B-X
to	B-X
that	B-X
DNA	B-X
by	B-X
the	B-X
RecA	B-X
nucleoprotein	B-X
filaments	B-X
.	B-X
RdgC	B-X
protein	B-X
binds	B-X
to	B-X
single-stranded	B-X
and	B-X
double-stranded	B-X
DNA	B-X
,	B-X
and	B-X
the	B-X
protein	B-X
can	B-X
be	B-X
visualized	B-X
on	B-X
DNA	B-X
using	B-X
electron	B-X
microscopy	B-X
.	B-X
RdgC	B-X
protein	B-X
exists	B-X
in	B-X
solution	B-X
as	B-X
a	B-X
mixture	B-X
of	B-X
oligomeric	B-X
states	B-X
in	B-X
equilibrium	B-X
,	B-X
most	B-X
likely	B-X
as	B-X
monomers	B-X
,	B-X
dimers	B-X
,	B-X
and	B-X
tetramers	B-X
.	B-X
This	B-X
concentration-dependent	B-X
change	B-X
of	B-X
state	B-X
appears	B-X
to	B-X
affect	B-X
its	B-X
mode	B-X
of	B-X
binding	B-X
to	B-X
DNA	B-X
and	B-X
its	B-X
capacity	B-X
to	B-X
inhibit	B-X
RecA	B-X
.	B-X
The	B-X
various	B-X
species	B-X
differ	B-X
in	B-X
their	B-X
capacity	B-X
to	B-X
inhibit	B-X
RecA	B-X
function	B-X
.	B-X

RdgC	O
inhibits	O
RecA	O
-	O
promoted	O
DNA	O
strand	O
exchange	O
,	O
RecA	O
-	O
mediated	O
ATPase	O
activity	O
and	O
RecA	O
-	O
dependent	O
LexA	O
cleavage	O
(	O
1	O
)	O
.	O

It	O
was	O
observed	O
that	O
the	O
effects	O
of	O
RdgC	O
on	O
RecA	O
-	O
promoted	O
DNA	O
strand	O
exchange	O
were	O
much	O
more	O
pronounced	O
than	O
the	O
effects	O
of	O
RdgC	O
on	O
other	O
RecA	O
functions	O
,	O
when	O
RdgC	O
was	O
added	O
to	O
the	O
reaction	O
late	O
(	O
1	O
)	O
.	O

By	O
examining	O
the	O
effects	O
of	O
the	O
DinI	O
protein	O
on	O
RdgC	O
-	O
mediated	O
inhibition	O
of	O
RecA	O
activities	O
,	O
it	O
was	O
concluded	O
that	O
the	O
potent	O
effect	O
of	O
RdgC	O
in	O
the	O
inhibition	O
of	O
strand	O
exchange	O
did	O
not	O
primarily	O
reflect	O
a	O
displacement	O
of	O
RecA	O
in	O
the	O
nucleoprotein	O
filament	O
by	O
RdgC	O
,	O
but	O
instead	O
a	O
binding	O
of	O
RdgC	O
to	O
the	O
dsDNA	O
substrate	O
so	O
as	O
to	O
make	O
it	O
unavailable	O
to	O
the	O
filaments	O
for	O
strand	O
exchange	O
(	O
1	O
)	O
.	O

Our	O
work	O
contributes	O
to	O
a	O
better	O
understanding	O
of	O
the	O
inhibition	O
mechanism	O
of	O
RecA	O
function	O
by	O
RdgC	O
.	O

The	O
ring	O
-	O
shaped	O
architecture	O
with	O
a	O
central	O
hole	O
that	O
is	O
suitable	O
for	O
the	O
binding	O
of	O
dsDNA	O
lends	O
RdgC	O
with	O
a	O
capacity	O
to	O
hold	O
dsDNA	O
very	O
tightly	O
.	O

Therefore	O
,	O
we	O
suggest	O
that	O
RdgC	O
dimers	O
probably	O
function	O
as	O
a	O
tight	O
dsDNA	O
gripper	O
and	O
physically	O
block	O
access	O
to	O
the	O
target	O
dsDNA	O
by	O
RecA	O
filaments	O
,	O
because	O
tight	O
encircling	O
of	O
dsDNA	O
by	O
RdgC	O
dimers	O
,	O
possibly	O
as	O
a	O
linear	O
aggregate	O
,	O
would	O
prevent	O
the	O
two	O
strands	O
from	O
dissociating	O
.	O

However	O
,	O
it	O
remains	O
unclear	O
how	O
the	O
closed	O
-	O
ring	O
structure	O
of	O
the	O
RdgC	O
dimer	O
might	O
allow	O
binding	O
of	O
a	O
large	O
number	O
of	O
RdgC	O
dimers	O
on	O
the	O
duplex	O
DNA	O
.	O

It	O
may	O
be	O
conceivable	O
that	O
each	O
RdgC	O
dimer	O
can	O
open	O
temporarily	O
at	O
one	O
or	O
both	O
of	O
its	O
two	O
inter	O
-	O
subunit	O
interfaces	O
so	O
that	O
dsDNA	O
can	O
enter	O
the	O
central	O
hole	O
.	O

RdgC	O
was	O
at	O
its	O
highest	O
level	O
during	O
exponential	O
phase	O
,	O
reaching	O
its	O
maximum	O
of	O
~	O
1000	O
dimers	O
per	O
E	B-Species
.	I-Species
coli	I-Species
cell	O
.	O

Its	O
level	O
decreased	O
sharply	O
to	O
~	O
50	O
dimers	O
per	O
cell	O
in	O
stationary	O
phase	O
(	O
2	O
)	O
.	O

Under	O
normal	O
cellular	O
conditions	O
,	O
RecA	O
is	O
maintained	O
at	O
~	O
1000	O
molecules	O
per	O
cell	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
els	O
.	O
net	O
/	O
)	O
.	O

Following	O
LexA	O
repressor	O
cleavage	O
,	O
the	O
level	O
of	O
RecA	O
protein	O
in	O
the	O
cell	O
increases	O
by	O
as	O
much	O
as	O
20	O
-	O
fold	O
.	O

RdgC	O
inhibition	O
of	O
the	O
RecA	O
function	O
by	O
a	O
simple	O
competition	O
mechanism	O
at	O
the	O
cellular	O
concentration	O
of	O
RdgC	O
clearly	O
requires	O
a	O
much	O
higher	O
affinity	O
for	O
DNA	O
by	O
RdgC	O
than	O
RecA	O
.	O

Possible	O
protein	O
-	O
protein	O
interactions	O
between	O
RdgC	O
dimers	O
might	O
have	O
a	O
profound	O
effect	O
on	O
the	O
affinity	O
for	O
DNA	O
,	O
when	O
a	O
large	O
number	O
of	O
RdgC	O
dimers	O
are	O
bound	O
on	O
a	O
duplex	O
DNA	O
.	O

If	O
only	O
one	O
of	O
the	O
two	O
inter	O
-	O
subunit	O
interfaces	O
can	O
open	O
up	O
and	O
the	O
2	O
-	O
fold	O
symmetry	O
axes	O
of	O
the	O
RdgC	O
dimers	O
are	O
misaligned	O
sufficiently	O
,	O
the	O
escape	O
of	O
DNA	O
from	O
a	O
linear	O
array	O
of	O
interacting	O
RdgC	O
dimers	O
would	O
be	O
extremely	O
difficult	O
.	O

Alternatively	O
,	O
both	O
inter	O
-	O
subunit	O
interfaces	O
of	O
each	O
dimer	O
may	O
open	O
up	O
simultaneously	O
.	O

A	O
line	O
of	O
indirect	O
evidence	O
for	O
the	O
possible	O
protein	O
-	O
protein	O
interactions	O
between	O
RdgC	O
dimers	O
is	O
provided	O
by	O
the	O
cooperative	O
binding	O
of	O
RdgC	O
to	O
DNA	O
(	O
7	O
)	O
.	O

Cooperativity	O
of	O
RdgC	O
binding	O
may	O
be	O
caused	O
by	O
local	O
and	O
distant	O
protein	O
-	O
protein	O
interactions	O
(	O
7	O
)	O
.	O

A	O
kind	O
of	O
side	O
-	O
by	O
-	O
side	O
interaction	O
between	O
two	O
adjacent	O
molecules	O
of	O
RdgC	O
dimer	O
is	O
present	O
in	O
the	O
crystal	O
,	O
burying	O
an	O
accessible	O
surface	O
area	O
of	O
~	O
750	O
A	O
2	O
at	O
the	O
interface	O
.	O

The	O
interaction	O
involves	O
mostly	O
the	O
less	O
polar	O
side	O
surface	O
of	O
the	O
dimer	O
(	O
left	O
side	O
of	O
Figure	O
4A	O
)	O
,	O
with	O
2	O
-	O
fold	O
symmetry	O
axes	O
of	O
the	O
two	O
interacting	O
RdgC	O
molecules	O
making	O
an	O
angle	O
of	O
~	O
90	O
degrees	O
when	O
viewed	O
down	O
the	O
central	O
holes	O
and	O
~	O
15	O
degrees	O
when	O
viewed	O
perpendicular	O
to	O
the	O
holes	O
.	O

This	O
may	O
explain	O
the	O
observed	O
DNA	O
bending	O
by	O
RdgC	O
,	O
which	O
was	O
speculated	O
to	O
be	O
a	O
necessary	O
step	O
in	O
the	O
working	O
mechanism	O
of	O
RdgC	O
,	O
if	O
one	O
can	O
assume	O
that	O
the	O
strong	O
protein	O
-	O
protein	O
interactions	O
in	O
the	O
crystal	O
were	O
relevant	O
for	O
protein	O
-	O
protein	O
interactions	O
in	O
solution	O
(	O
7	O
)	O
.	O

RdgC	O
protein	O
was	O
shown	O
to	O
have	O
a	O
potent	O
effect	O
on	O
RecA	O
protein	O
-	O
promoted	O
DNA	O
strand	O
exchange	O
in	O
E	B-Species
.	I-Species
coli	I-Species
(	O
1	O
)	O
.	O

In	O
a	O
series	O
of	O
experiments	O
,	O
RdgC	O
was	O
added	O
after	O
RecA	O
filaments	O
had	O
formed	O
on	O
the	O
ssDNA	O
and	O
5	O
min	O
after	O
the	O
linear	O
dsDNA	O
was	O
added	O
.	O

With	O
3	O
mu	O
M	O
RecA	O
,	O
a	O
sharp	O
reduction	O
in	O
DNA	O
strand	O
exchange	O
products	O
was	O
seen	O
with	O
0	O
.	O
4	O
mu	O
M	O
RdgC	O
,	O
and	O
the	O
generation	O
of	O
products	O
was	O
abolished	O
at	O
0	O
.	O
8	O
mu	O
M	O
RdgC	O
(	O
1	O
)	O
.	O

This	O
suggests	O
that	O
the	O
binding	O
affinity	O
of	O
RdgC	O
to	O
dsDNA	O
is	O
considerably	O
higher	O
than	O
that	O
of	O
RecA	O
.	O

The	O
high	O
affinity	O
of	O
RdgC	O
could	O
be	O
explained	O
by	O
its	O
ring	O
shape	O
and	O
the	O
suggested	O
mode	O
of	O
DNA	O
binding	O
.	O

Tetrameric	O
species	O
of	O
E	B-Species
.	I-Species
coli	I-Species
RdgC	O
,	O
which	O
started	O
to	O
form	O
at	O
around	O
2	O
micro	O
M	O
concentrations	O
,	O
were	O
speculated	O
to	O
be	O
the	O
species	O
with	O
the	O
most	O
potent	O
inhibitory	O
effect	O
,	O
possibly	O
by	O
having	O
a	O
higher	O
affinity	O
for	O
DNA	O
(	O
1	O
)	O
.	O

Higher	O
affinity	O
for	O
DNA	O
of	O
the	O
tetrameric	O
species	O
could	O
be	O
understood	O
,	O
if	O
the	O
formation	O
of	O
a	O
tetramer	O
in	O
solution	O
involves	O
a	O
protein	O
-	O
protein	O
interaction	O
similar	O
to	O
the	O
side	O
-	O
by	O
-	O
side	O
interaction	O
between	O
two	O
adjacent	O
RdgC	O
dimers	O
in	O
the	O
crystal	O
,	O
although	O
there	O
is	O
no	O
experimental	O
evidence	O
.	O

Obviously	O
,	O
there	O
are	O
still	O
many	O
open	O
questions	O
that	O
need	O
to	O
be	O
addressed	O
in	O
future	O
biochemical	O
experiments	O
.	O

SUMMARY	O
<EOS>	B-X
Improving	B-X
Patient	B-X
Discharge	B-X
Summary	B-X
Communication	B-X
.	B-X
This	B-X
Is	B-X
the	B-X
Story	B-X
of	B-X
a	B-X
Discharge	B-X
Summary	B-X
.	B-X
The	B-X
discharge	B-X
summary	B-X
as	B-X
a	B-X
medium	B-X
for	B-X
teaching	B-X
and	B-X
learning	B-X
.	B-X

The	O
crystal	O
structure	O
of	O
RdgC	O
,	O
a	O
recombination	O
-	O
associated	O
DNA	O
-	O
binding	O
protein	O
,	O
determined	O
in	O
this	O
study	O
reveals	O
that	O
the	O
polypeptide	O
chain	O
is	O
uniquely	O
folded	O
and	O
two	O
monomers	O
associate	O
to	O
form	O
a	O
ring	O
-	O
shaped	O
dimer	O
with	O
a	O
central	O
hole	O
of	O
~	O
30	O
A	O
diameter	O
.	O

The	O
inner	O
surface	O
around	O
the	O
central	O
hole	O
is	O
rich	O
in	O
positively	O
charged	O
residues	O
.	O

These	O
structural	O
features	O
suggest	O
that	O
dsDNA	O
runs	O
through	O
the	O
central	O
hole	O
when	O
it	O
binds	O
to	O
RdgC	O
dimers	O
.	O

This	O
idea	O
is	O
supported	O
by	O
our	O
mutational	O
studies	O
,	O
which	O
indicate	O
that	O
the	O
conserved	O
,	O
positively	O
charged	O
residues	O
around	O
the	O
central	O
hole	O
are	O
important	O
for	O
dsDNA	O
binding	O
.	O

The	O
toroidal	O
architecture	O
of	O
the	O
RdgC	O
dimer	O
provides	O
a	O
sound	O
framework	O
for	O
a	O
better	O
understanding	O
of	O
its	O
role	O
in	O
homologous	O
recombination	O
.	O

Coordinates	O

Atomic	O
coordinates	O
and	O
the	O
structure	O
factor	O
data	O
have	O
been	O
deposited	O
in	O
the	O
Protein	O
Data	O
Bank	O
(	O
accession	O
code	O
2OWY	O
)	O
.	O

SUPPLEMENTARY	O
DATA	O
<EOS>	B-X
Moderating	B-X
supplementary	B-X
data	B-X
.	B-X
[	B-X
Supplementary	B-X
Data	B-X
]	B-X
.	B-X

Supplementary	O
Data	O
are	O
available	O
at	O
NAR	O
Online	O
.	O
<EOS>	B-X
This	B-X
article	B-X
defines	B-X
the	B-X
FASTQ	B-X
format	B-X
,	B-X
covering	B-X
the	B-X
original	B-X
Sanger	B-X
standard	B-X
,	B-X
the	B-X
Solexa/Illumina	B-X
variants	B-X
and	B-X
conversion	B-X
between	B-X
them	B-X
,	B-X
based	B-X
on	B-X
publicly	B-X
available	B-X
information	B-X
such	B-X
as	B-X
the	B-X
MAQ	B-X
documentation	B-X
and	B-X
conventions	B-X
recently	B-X
agreed	B-X
by	B-X
the	B-X
Open	B-X
Bioinformatics	B-X
Foundation	B-X
projects	B-X
Biopython	B-X
,	B-X
BioPerl	B-X
,	B-X
BioRuby	B-X
,	B-X
BioJava	B-X
and	B-X
EMBOSS	B-X
.	B-X
Being	B-X
an	B-X
open	B-X
access	B-X
publication	B-X
,	B-X
it	B-X
is	B-X
hoped	B-X
that	B-X
this	B-X
description	B-X
,	B-X
with	B-X
the	B-X
example	B-X
files	B-X
provided	B-X
as	B-X
Supplementary	B-X
Data	B-X
,	B-X
will	B-X
serve	B-X
in	B-X
future	B-X
as	B-X
a	B-X
reference	B-X
for	B-X
this	B-X
important	B-X
file	B-X
format	B-X
.	B-X
WACA	B-X
and	B-X
associated	B-X
files	B-X
are	B-X
freely	B-X
available	B-X
as	B-X
Supplementary	B-X
Data	B-X
.	B-X
edu/pir/	B-X
)	B-X
supports	B-X
research	B-X
on	B-X
molecular	B-X
evolution	B-X
,	B-X
functional	B-X
genomics	B-X
,	B-X
and	B-X
computational	B-X
biology	B-X
by	B-X
maintaining	B-X
a	B-X
comprehensive	B-X
,	B-X
non-redundant	B-X
,	B-X
well-organized	B-X
and	B-X
freely	B-X
available	B-X
protein	B-X
sequence	B-X
database	B-X
.	B-X
The	B-X
PIR	B-X
Protein	B-X
Sequence	B-X
Database	B-X
entries	B-X
are	B-X
classified	B-X
into	B-X
superfamilies	B-X
,	B-X
families	B-X
and	B-X
homology	B-X
domains	B-X
,	B-X
for	B-X
which	B-X
sequence	B-X
alignments	B-X
are	B-X
available	B-X
.	B-X
The	B-X
PIR	B-X
WWW	B-X
server	B-X
supports	B-X
direct	B-X
on-line	B-X
sequence	B-X
similarity	B-X
searches	B-X
,	B-X
information	B-X
retrieval	B-X
,	B-X
and	B-X
knowledge	B-X
discovery	B-X
by	B-X
providing	B-X
the	B-X
Protein	B-X
Sequence	B-X
Database	B-X
and	B-X
other	B-X
supplementary	B-X
databases	B-X
.	B-X
The	B-X
weekly	B-X
release	B-X
of	B-X
the	B-X
Protein	B-X
Sequence	B-X
Database	B-X
can	B-X
be	B-X
accessed	B-X
through	B-X
the	B-X
PIR	B-X
Web	B-X
site	B-X
.	B-X
The	B-X
quarterly	B-X
release	B-X
of	B-X
the	B-X
database	B-X
is	B-X
freely	B-X
available	B-X
from	B-X
our	B-X
anonymous	B-X
FTP	B-X
server	B-X
and	B-X
is	B-X
also	B-X
available	B-X
on	B-X
CD-ROM	B-X
with	B-X
the	B-X
accompanying	B-X
ATLAS	B-X
database	B-X
search	B-X
program	B-X
.	B-X

Supplementary	O
Material	O
<EOS>	B-X
These	B-X
slides	B-X
can	B-X
be	B-X
retrieved	B-X
under	B-X
Electronic	B-X
Supplementary	B-X
Material	B-X
.	B-X
On-line	B-X
publication	B-X
of	B-X
supplementary	B-X
material	B-X
.	B-X
Citations	B-X
in	B-X
supplementary	B-X
material	B-X
.	B-X
Supplementary	B-X
material	B-X
is	B-X
a	B-X
ubiquitous	B-X
feature	B-X
of	B-X
scientific	B-X
articles	B-X
,	B-X
particularly	B-X
in	B-X
journals	B-X
that	B-X
limit	B-X
the	B-X
length	B-X
of	B-X
the	B-X
articles	B-X
.	B-X

Port	O
site	O
herniation	O
of	O
the	O
small	O
bowel	O
following	O
laparoscopy	O
-	O
assisted	O
distal	O
gastrectomy	O
:	O
a	O
case	O
report	O
<EOS>	B-X
Port-site	B-X
herniation	B-X
is	B-X
a	B-X
rare	B-X
but	B-X
potentially	B-X
dangerous	B-X
complication	B-X
after	B-X
laparoscopic	B-X
surgery	B-X
.	B-X
Closure	B-X
of	B-X
port	B-X
sites	B-X
,	B-X
especially	B-X
those	B-X
measuring	B-X
10	B-X
mm	B-X
or	B-X
more	B-X
,	B-X
has	B-X
been	B-X
recommended	B-X
to	B-X
avoid	B-X
such	B-X
an	B-X
event	B-X
.	B-X

Abstract	O
<EOS>	B-X
Abstract	B-X
writing	B-X
.	B-X
The	B-X
informative	B-X
abstract	B-X
.	B-X
Crafting	B-X
a	B-X
compelling	B-X
abstract	B-X
.	B-X
Why	B-X
the	B-X
structured	B-X
abstract	B-X
?	B-X

Introduction	O

Port	O
-	O
site	O
herniation	O
is	O
a	O
rare	O
but	O
potentially	O
dangerous	O
complication	O
after	O
laparoscopic	O
surgery	O
.	O
<EOS>	B-X
Trocar	B-X
site	B-X
hernia	B-X
(	B-X
TSH	B-X
)	B-X
is	B-X
a	B-X
rare	B-X
but	B-X
potentially	B-X
dangerous	B-X
complication	B-X
of	B-X
laparoscopic	B-X
surgery	B-X
,	B-X
and	B-X
the	B-X
drain-site	B-X
TSH	B-X
is	B-X
an	B-X
even	B-X
rarer	B-X
type	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
report	B-X
an	B-X
unusual	B-X
case	B-X
of	B-X
drain-site	B-X
TSH	B-X
,	B-X
followed	B-X
by	B-X
a	B-X
brief	B-X
literature	B-X
review	B-X
.	B-X
Port-site	B-X
herniation	B-X
is	B-X
a	B-X
rare	B-X
but	B-X
potentially	B-X
dangerous	B-X
complication	B-X
after	B-X
laparoscopic	B-X
surgery	B-X
.	B-X
Closure	B-X
of	B-X
port	B-X
sites	B-X
,	B-X
especially	B-X
those	B-X
measuring	B-X
10	B-X
mm	B-X
or	B-X
more	B-X
,	B-X
has	B-X
been	B-X
recommended	B-X
to	B-X
avoid	B-X
such	B-X
an	B-X
event	B-X
.	B-X

Closure	O
of	O
port	O
sites	O
,	O
especially	O
those	O
measuring	O
10	O
mm	O
or	O
more	O
,	O
has	O
been	O
recommended	O
to	O
avoid	O
such	O
an	O
event	O
.	O
<EOS>	B-X
Dual	B-X
antiplatelet	B-X
therapy	B-X
(	B-X
DAPT	B-X
)	B-X
,	B-X
consisting	B-X
of	B-X
aspirin	B-X
and	B-X
a	B-X
P2Y12	B-X
inhibitor	B-X
(	B-X
clopidogrel	B-X
,	B-X
ticagrelor	B-X
,	B-X
or	B-X
prasugrel	B-X
)	B-X
reduces	B-X
cardiovascular	B-X
event	B-X
rates	B-X
after	B-X
ACS	B-X
.	B-X
Nerve	B-X
injury	B-X
is	B-X
a	B-X
common	B-X
complication	B-X
following	B-X
intramuscular	B-X
injection	B-X
and	B-X
the	B-X
sciatic	B-X
nerve	B-X
is	B-X
the	B-X
most	B-X
frequently	B-X
affected	B-X
nerve	B-X
,	B-X
especially	B-X
in	B-X
children	B-X
,	B-X
the	B-X
elderly	B-X
and	B-X
underweight	B-X
patients	B-X
.	B-X
Sciatic	B-X
nerve	B-X
injection	B-X
injury	B-X
is	B-X
a	B-X
preventable	B-X
event	B-X
.	B-X
Total	B-X
avoidance	B-X
of	B-X
intramuscular	B-X
injection	B-X
is	B-X
recommended	B-X
if	B-X
other	B-X
administration	B-X
routes	B-X
can	B-X
be	B-X
used	B-X
.	B-X

Case	O
presentation	O
<EOS>	B-X
Although	B-X
it	B-X
usually	B-X
presents	B-X
as	B-X
a	B-X
liver	B-X
mass	B-X
,	B-X
rarely	B-X
HCC	B-X
can	B-X
have	B-X
an	B-X
initial	B-X
presentation	B-X
at	B-X
an	B-X
extrahepatic	B-X
site	B-X
before	B-X
the	B-X
diagnosis	B-X
of	B-X
the	B-X
primary	B-X
lesion	B-X
in	B-X
the	B-X
liver	B-X
.	B-X
Even	B-X
rarely	B-X
was	B-X
that	B-X
brain	B-X
metastasis	B-X
as	B-X
initial	B-X
extrahepatic	B-X
presentations	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
initial	B-X
presentation	B-X
of	B-X
HCC	B-X
as	B-X
brain	B-X
metastases	B-X
has	B-X
been	B-X
with	B-X
most	B-X
cases	B-X
being	B-X
secondary	B-X
to	B-X
hepatitis-related	B-X
hepatoma	B-X
.	B-X
In	B-X
this	B-X
case	B-X
report	B-X
,	B-X
we	B-X
are	B-X
presenting	B-X
a	B-X
rare	B-X
and	B-X
unusual	B-X
case	B-X
of	B-X
hemorrhagic	B-X
cerebral	B-X
metastasis	B-X
as	B-X
an	B-X
initial	B-X
extrahepatic	B-X
presentation	B-X
of	B-X
an	B-X
alcohol-related	B-X
hepatoma	B-X
.	B-X
Due	B-X
to	B-X
the	B-X
uncommonness	B-X
of	B-X
presentation	B-X
,	B-X
there	B-X
can	B-X
be	B-X
diagnostic	B-X
dilemmas	B-X
and	B-X
delay	B-X
in	B-X
treatment	B-X
.	B-X

We	O
herein	O
report	O
the	O
only	O
case	O
of	O
a	O
port	O
site	O
hernia	O
among	O
a	O
series	O
52	O
consecutive	O
cases	O
of	O
laparoscopy	O
-	O
assisted	O
distal	O
gastrectomy	O
(	O
LADG	O
)	O
carried	O
out	O
by	O
our	O
unit	O
between	O
July	O
2002	O
and	O
March	O
2007	O
.	O
<EOS>	B-X
Port-site	B-X
herniation	B-X
is	B-X
a	B-X
rare	B-X
but	B-X
potentially	B-X
dangerous	B-X
complication	B-X
after	B-X
laparoscopic	B-X
surgery	B-X
.	B-X
Closure	B-X
of	B-X
port	B-X
sites	B-X
,	B-X
especially	B-X
those	B-X
measuring	B-X
10	B-X
mm	B-X
or	B-X
more	B-X
,	B-X
has	B-X
been	B-X
recommended	B-X
to	B-X
avoid	B-X
such	B-X
an	B-X
event	B-X
.	B-X

In	O
this	O
case	O
the	O
small	O
bowel	O
herniated	O
and	O
incarcerated	O
through	O
the	O
port	O
site	O
on	O
day	O
4	O
after	O
LADG	O
despite	O
closure	O
of	O
the	O
fascia	O
.	O
<EOS>	B-X
Port-site	B-X
herniation	B-X
is	B-X
a	B-X
rare	B-X
but	B-X
potentially	B-X
dangerous	B-X
complication	B-X
after	B-X
laparoscopic	B-X
surgery	B-X
.	B-X
Closure	B-X
of	B-X
port	B-X
sites	B-X
,	B-X
especially	B-X
those	B-X
measuring	B-X
10	B-X
mm	B-X
or	B-X
more	B-X
,	B-X
has	B-X
been	B-X
recommended	B-X
to	B-X
avoid	B-X
such	B-X
an	B-X
event	B-X
.	B-X

Initial	O
manifestations	O
experienced	O
by	O
the	O
patient	B-Species
,	O
possibly	O
due	O
to	O
obstruction	O
,	O
and	O
including	O
mild	O
abdominal	O
pain	O
and	O
nausea	O
,	O
occurred	O
on	O
the	O
third	O
day	O
postoperatively	O
.	O

The	O
definitive	O
diagnosis	O
was	O
made	O
on	O
day	O
4	O
based	O
on	O
symptoms	O
related	O
to	O
leakage	O
from	O
the	O
duodenal	O
stump	O
,	O
which	O
was	O
considered	O
to	O
have	O
developed	O
after	O
severe	O
obstruction	O
of	O
the	O
bowel	O
.	O

Re	O
-	O
operation	O
for	O
reduction	O
of	O
the	O
incarcerated	O
bowel	O
and	O
tube	O
duodenostomy	O
with	O
peritoneal	O
drainage	O
were	O
required	O
to	O
manage	O
this	O
complication	O
.	O
<EOS>	B-X
Port-site	B-X
herniation	B-X
is	B-X
a	B-X
rare	B-X
but	B-X
potentially	B-X
dangerous	B-X
complication	B-X
after	B-X
laparoscopic	B-X
surgery	B-X
.	B-X

Conclusion	O
<EOS>	B-X
Conclusion	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X

We	O
present	O
this	O
case	O
report	O
and	O
review	O
of	O
literature	O
to	O
discuss	O
further	O
regarding	O
methods	O
of	O
fascial	O
closure	O
after	O
laparoscopic	O
surgery	O
.	O
<EOS>	B-X
Bowel	B-X
herniation	B-X
,	B-X
through	B-X
fascial	B-X
defects	B-X
secondary	B-X
to	B-X
laparoscopic	B-X
surgery	B-X
at	B-X
the	B-X
site	B-X
of	B-X
trocar	B-X
entry	B-X
,	B-X
is	B-X
a	B-X
rare	B-X
,	B-X
but	B-X
potentially	B-X
serious	B-X
,	B-X
complication	B-X
.	B-X
We	B-X
report	B-X
a	B-X
case	B-X
of	B-X
a	B-X
small	B-X
bowel	B-X
which	B-X
herniated	B-X
and	B-X
strangulated	B-X
through	B-X
the	B-X
port	B-X
site	B-X
immediately	B-X
after	B-X
laparoscopic	B-X
myomectomy	B-X
.	B-X
We	B-X
present	B-X
this	B-X
case	B-X
report	B-X
with	B-X
literature	B-X
review	B-X
to	B-X
discuss	B-X
the	B-X
risk	B-X
factors	B-X
and	B-X
the	B-X
methods	B-X
to	B-X
prevent	B-X
such	B-X
a	B-X
complication	B-X
post	B-X
laparoscopic	B-X
surgery	B-X
.	B-X
Port-site	B-X
herniation	B-X
is	B-X
a	B-X
rare	B-X
but	B-X
potentially	B-X
dangerous	B-X
complication	B-X
after	B-X
laparoscopic	B-X
surgery	B-X
.	B-X

Introduction	O

Bowel	O
herniation	O
through	O
the	O
fascial	O
defect	O
created	O
by	O
the	O
entry	O
of	O
trocars	O
is	O
now	O
recognized	O
as	O
a	O
rare	O
but	O
potentially	O
serious	O
complication	O
of	O
laparoscopic	O
surgery	O
[	O
1	O
]	O
.	O

Although	O
port	O
site	O
herniation	O
is	O
an	O
infrequent	O
complication	O
,	O
there	O
are	O
still	O
some	O
reports	O
of	O
port	O
site	O
herniation	O
after	O
these	O
procedures	O
,	O
even	O
with	O
closure	O
of	O
trocar	O
sites	O
[	O
1	O
,	O
2	O
]	O
.	O

The	O
following	O
report	O
describes	O
a	O
case	O
of	O
a	O
trocar	O
site	O
hernia	O
that	O
evolved	O
into	O
leakage	O
from	O
the	O
duodenal	O
stump	O
after	O
laparoscopy	O
-	O
assisted	O
distal	O
gastrectomy	O
(	O
LADG	O
)	O
.	O

Progression	O
occurred	O
because	O
of	O
complete	O
obstruction	O
of	O
the	O
incarcerated	O
bowel	O
after	O
a	O
Roux	O
-	O
en	O
-	O
Y	O
reconstruction	O
.	O

We	O
describe	O
the	O
significance	O
of	O
complete	O
closure	O
of	O
the	O
fascial	O
defect	O
at	O
the	O
trocar	O
site	O
including	O
the	O
peritoneum	O
in	O
the	O
prevention	O
of	O
this	O
condition	O
,	O
as	O
well	O
as	O
the	O
importance	O
of	O
early	O
diagnosis	O
to	O
avoid	O
serious	O
subsequent	O
events	O
.	O

Case	O
presentation	O
<EOS>	B-X
Although	B-X
it	B-X
usually	B-X
presents	B-X
as	B-X
a	B-X
liver	B-X
mass	B-X
,	B-X
rarely	B-X
HCC	B-X
can	B-X
have	B-X
an	B-X
initial	B-X
presentation	B-X
at	B-X
an	B-X
extrahepatic	B-X
site	B-X
before	B-X
the	B-X
diagnosis	B-X
of	B-X
the	B-X
primary	B-X
lesion	B-X
in	B-X
the	B-X
liver	B-X
.	B-X
Even	B-X
rarely	B-X
was	B-X
that	B-X
brain	B-X
metastasis	B-X
as	B-X
initial	B-X
extrahepatic	B-X
presentations	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
initial	B-X
presentation	B-X
of	B-X
HCC	B-X
as	B-X
brain	B-X
metastases	B-X
has	B-X
been	B-X
with	B-X
most	B-X
cases	B-X
being	B-X
secondary	B-X
to	B-X
hepatitis-related	B-X
hepatoma	B-X
.	B-X
In	B-X
this	B-X
case	B-X
report	B-X
,	B-X
we	B-X
are	B-X
presenting	B-X
a	B-X
rare	B-X
and	B-X
unusual	B-X
case	B-X
of	B-X
hemorrhagic	B-X
cerebral	B-X
metastasis	B-X
as	B-X
an	B-X
initial	B-X
extrahepatic	B-X
presentation	B-X
of	B-X
an	B-X
alcohol-related	B-X
hepatoma	B-X
.	B-X
Due	B-X
to	B-X
the	B-X
uncommonness	B-X
of	B-X
presentation	B-X
,	B-X
there	B-X
can	B-X
be	B-X
diagnostic	B-X
dilemmas	B-X
and	B-X
delay	B-X
in	B-X
treatment	B-X
.	B-X

An	O
80	O
-	O
year	O
-	O
old	O
man	B-Species
was	O
found	O
to	O
have	O
early	O
gastric	O
cancer	O
during	O
his	O
yearly	O
check	O
-	O
up	O
by	O
gastrointestinal	O
endoscopy	O
.	O

He	O
was	O
158	O
cm	O
in	O
height	O
and	O
weighed	O
62	O
kg	O
.	O

Gastrointestinal	O
endoscopy	O
showed	O
a	O
depressed	O
lesion	O
that	O
was	O
diagnosed	O
as	O
early	O
gastric	O
cancer	O
by	O
pathological	O
examination	O
of	O
biopsy	O
specimens	O
.	O
<EOS>	B-X
In	B-X
Japan	B-X
,	B-X
endoscopic	B-X
mucosal	B-X
resection	B-X
(	B-X
EMR	B-X
)	B-X
is	B-X
accepted	B-X
as	B-X
a	B-X
treatment	B-X
option	B-X
for	B-X
cases	B-X
of	B-X
early	B-X
gastric	B-X
cancer	B-X
(	B-X
EGC	B-X
)	B-X
where	B-X
the	B-X
probability	B-X
of	B-X
lymph	B-X
node	B-X
metastasis	B-X
is	B-X
low	B-X
.	B-X
Thirty-eight	B-X
patients	B-X
with	B-X
early	B-X
gastric	B-X
cancer	B-X
have	B-X
been	B-X
successfully	B-X
treated	B-X
by	B-X
laparoscopic	B-X
wedge	B-X
resection	B-X
of	B-X
the	B-X
stomach	B-X
in	B-X
our	B-X
institute	B-X
since	B-X
March	B-X
1992	B-X
.	B-X
Our	B-X
indication	B-X
of	B-X
the	B-X
surgery	B-X
is	B-X
as	B-X
follows	B-X
:	B-X
1	B-X
)	B-X
preoperatively	B-X
diagnosed	B-X
mucosal	B-X
cancer	B-X
,	B-X
2	B-X
)	B-X
<	B-X
25	B-X
mm	B-X
,	B-X
if	B-X
the	B-X
lesion	B-X
is	B-X
elevated	B-X
type	B-X
,	B-X
and	B-X
3	B-X
)	B-X
<	B-X
15	B-X
mm	B-X
and	B-X
no	B-X
ulcer	B-X
scar	B-X
,	B-X
if	B-X
the	B-X
lesion	B-X
is	B-X
depressed	B-X
type	B-X
.	B-X
After	B-X
laparoscopic	B-X
exposure	B-X
of	B-X
the	B-X
gastric	B-X
wall	B-X
around	B-X
a	B-X
cancerous	B-X
lesion	B-X
,	B-X
a	B-X
sheathed	B-X
needle	B-X
was	B-X
inserted	B-X
into	B-X
the	B-X
stomach	B-X
through	B-X
the	B-X
abdominal	B-X
wall	B-X
at	B-X
the	B-X
vicinity	B-X
of	B-X
the	B-X
lesion	B-X
under	B-X
gastroscopy	B-X
guidance	B-X
.	B-X
A	B-X
small	B-X
metal	B-X
rod	B-X
was	B-X
introduced	B-X
into	B-X
the	B-X
stomach	B-X
near	B-X
the	B-X
lesion	B-X
through	B-X
the	B-X
outer	B-X
sheath	B-X
.	B-X
While	B-X
the	B-X
lesion	B-X
was	B-X
lifted	B-X
up	B-X
precisely	B-X
with	B-X
the	B-X
support	B-X
of	B-X
the	B-X
metal	B-X
rod	B-X
,	B-X
wedge	B-X
resection	B-X
of	B-X
the	B-X
stomach	B-X
was	B-X
performed	B-X
using	B-X
an	B-X
endoscopic	B-X
stapler	B-X
(	B-X
lesion-lifting	B-X
method	B-X
)	B-X
.	B-X
Perigastric	B-X
lymph	B-X
nodes	B-X
could	B-X
be	B-X
also	B-X
resected	B-X
when	B-X
necessary	B-X
.	B-X
The	B-X
resected	B-X
specimens	B-X
were	B-X
50	B-X
to	B-X
110	B-X
mm	B-X
in	B-X
diameter	B-X
,	B-X
and	B-X
there	B-X
was	B-X
a	B-X
sufficient	B-X
surgical	B-X
margin	B-X
(	B-X
16	B-X
+/-	B-X
5mm	B-X
)	B-X
.	B-X
There	B-X
has	B-X
been	B-X
one	B-X
recurrence	B-X
and	B-X
one	B-X
separate	B-X
occurence	B-X
of	B-X
early	B-X
gastric	B-X
cancer	B-X
in	B-X
the	B-X
series	B-X
,	B-X
which	B-X
were	B-X
curatively	B-X
treated	B-X
by	B-X
gastrectomy	B-X
.	B-X
Advantages	B-X
of	B-X
the	B-X
surgery	B-X
are	B-X
as	B-X
follows	B-X
:	B-X
1	B-X
)	B-X
it	B-X
is	B-X
minimally	B-X
invasive	B-X
,	B-X
2	B-X
)	B-X
most	B-X
of	B-X
the	B-X
stomach	B-X
is	B-X
preserved	B-X
,	B-X
3	B-X
)	B-X
a	B-X
sufficient	B-X
surgical	B-X
margin	B-X
can	B-X
be	B-X
obtained	B-X
,	B-X
and	B-X
4	B-X
)	B-X
a	B-X
detailed	B-X
histologic	B-X
examination	B-X
is	B-X
feasible	B-X
.	B-X
If	B-X
the	B-X
indication	B-X
is	B-X
selected	B-X
properly	B-X
,	B-X
this	B-X
laparoscopic	B-X
surgery	B-X
can	B-X
be	B-X
a	B-X
curative	B-X
and	B-X
minimally	B-X
invasive	B-X
treatment	B-X
for	B-X
early	B-X
gastric	B-X
cancer	B-X
.	B-X

He	O
underwent	O
LADG	O
with	O
regional	O
lymph	O
node	O
dissection	O
(	O
D1	O
including	O
the	O
nodes	O
surrounding	O
the	O
origin	O
of	O
left	O
gastric	O
artery	O
)	O
.	O

A	O
12	O
-	O
mm	O
trocar	O
for	O
the	O
laparoscope	O
was	O
placed	O
in	O
the	O
umbilicus	O
.	O
<EOS>	B-X
This	B-X
is	B-X
a	B-X
four-trocar	B-X
approach	B-X
consistent	B-X
with	B-X
the	B-X
four	B-X
incisions	B-X
utilized	B-X
in	B-X
conventional	B-X
laparoscopic	B-X
cholecystectomy	B-X
.	B-X
After	B-X
administration	B-X
of	B-X
general	B-X
anesthesia	B-X
,	B-X
marcaine	B-X
is	B-X
injected	B-X
at	B-X
the	B-X
umbilicus	B-X
and	B-X
a	B-X
12-mm	B-X
vertical	B-X
incision	B-X
is	B-X
made	B-X
through	B-X
the	B-X
already	B-X
existing	B-X
anatomical	B-X
scar	B-X
of	B-X
the	B-X
umbilicus	B-X
.	B-X
A	B-X
single	B-X
four-trocar	B-X
port	B-X
is	B-X
inserted	B-X
.	B-X
A	B-X
5-mm	B-X
deflectable-tip	B-X
laparoscope	B-X
is	B-X
placed	B-X
through	B-X
the	B-X
trocar	B-X
at	B-X
the	B-X
8	B-X
o'clock	B-X
position	B-X
,	B-X
a	B-X
bariatric	B-X
length	B-X
rigid	B-X
grasper	B-X
is	B-X
inserted	B-X
through	B-X
the	B-X
trocar	B-X
at	B-X
the	B-X
4	B-X
o'clock	B-X
position	B-X
(	B-X
to	B-X
grasp	B-X
the	B-X
fundus	B-X
)	B-X
,	B-X
and	B-X
a	B-X
rigid	B-X
bent	B-X
grasper	B-X
is	B-X
placed	B-X
through	B-X
the	B-X
10-mm	B-X
port	B-X
(	B-X
to	B-X
grasp	B-X
the	B-X
infundibulum	B-X
)	B-X
.	B-X

Pneumoperitoneum	O
was	O
then	O
established	O
with	O
carbon	O
dioxide	O
and	O
the	O
intraperitoneal	O
pressure	O
was	O
maintained	O
at	O
10	O
mm	O
Hg	O
.	O

Two	O
more	O
12	O
-	O
mm	O
trocars	O
were	O
inserted	O
in	O
the	O
midclavicular	O
line	O
below	O
the	O
costal	O
margin	O
and	O
2	O
cm	O
above	O
the	O
umbilicus	O
on	O
each	O
of	O
both	O
flanks	O
and	O
were	O
used	O
for	O
active	O
surgical	O
instruments	O
.	O

All	O
trocars	O
used	O
were	O
the	O
non	O
-	O
bladed	O
type	O
.	O
<EOS>	B-X
Laparoscopic	B-X
surgery	B-X
has	B-X
led	B-X
to	B-X
great	B-X
clinical	B-X
improvements	B-X
in	B-X
many	B-X
fields	B-X
of	B-X
surgery	B-X
;	B-X
however	B-X
,	B-X
it	B-X
requires	B-X
the	B-X
use	B-X
of	B-X
trocars	B-X
,	B-X
which	B-X
may	B-X
lead	B-X
to	B-X
complications	B-X
as	B-X
well	B-X
as	B-X
postoperative	B-X
pain	B-X
.	B-X
Many	B-X
of	B-X
these	B-X
are	B-X
extremely	B-X
rare	B-X
,	B-X
such	B-X
as	B-X
vascular	B-X
and	B-X
visceral	B-X
injury	B-X
,	B-X
but	B-X
may	B-X
be	B-X
life-threatening	B-X
;	B-X
therefore	B-X
,	B-X
it	B-X
is	B-X
important	B-X
to	B-X
determine	B-X
how	B-X
these	B-X
types	B-X
of	B-X
complications	B-X
may	B-X
be	B-X
prevented	B-X
.	B-X
It	B-X
is	B-X
hypothesised	B-X
that	B-X
trocar-related	B-X
complications	B-X
and	B-X
pain	B-X
may	B-X
be	B-X
attributable	B-X
to	B-X
certain	B-X
types	B-X
of	B-X
trocars	B-X
.	B-X
This	B-X
systematic	B-X
review	B-X
was	B-X
designed	B-X
to	B-X
improve	B-X
patient	B-X
safety	B-X
by	B-X
determining	B-X
which	B-X
,	B-X
if	B-X
any	B-X
,	B-X
specific	B-X
trocar	B-X
types	B-X
are	B-X
less	B-X
likely	B-X
to	B-X
result	B-X
in	B-X
complications	B-X
and	B-X
postoperative	B-X
pain	B-X
.	B-X

The	O
specimen	O
was	O
removed	O
through	O
a	O
small	O
medial	O
incision	O
which	O
was	O
55	O
mm	O
in	O
length	O
placed	O
after	O
resection	O
of	O
the	O
stomach	O
,	O
and	O
then	O
Roux	O
-	O
en	O
-	O
Y	O
reconstruction	O
(	O
RY	O
)	O
was	O
carried	O
out	O
(	O
Fig	O
.	O
1	O
)	O
.	O

A	O
tubular	O
shaped	O
drainage	O
tube	O
10	O
mm	O
in	O
diameter	O
was	O
inserted	O
and	O
placed	O
through	O
the	O
upper	O
trocar	O
site	O
made	O
on	O
the	O
right	O
flank	O
.	O

Wound	O
defect	O
at	O
the	O
umbilical	O
port	O
site	O
was	O
sutured	O
completely	O
including	O
the	O
peritoneum	O
with	O
0	O
absorbable	O
suture	O
and	O
fascial	O
incisions	O
at	O
all	O
other	O
trocar	O
insertion	O
sites	O
were	O
closed	O
with	O
2	O
-	O
0	O
absorbable	O
sutures	O
.	O

Surgical	O
duration	O
was	O
263	O
min	O
,	O
and	O
the	O
volume	O
of	O
blood	O
loss	O
was	O
less	O
than	O
50	O
mL	O
with	O
no	O
blood	O
transfusion	O
.	O

Postoperatively	O
,	O
the	O
patient	B-Species
complained	O
of	O
an	O
acidic	O
feeling	O
in	O
his	O
stomach	O
;	O
however	O
,	O
there	O
were	O
no	O
remarkable	O
abnormalities	O
on	O
biochemical	O
examination	O
of	O
serum	O
.	O

Radiological	O
findings	O
did	O
not	O
suggest	O
bowel	O
obstruction	O
until	O
3	O
days	O
postoperatively	O
,	O
although	O
mild	O
symptoms	O
such	O
as	O
general	O
malaise	O
and	O
vague	O
abdominal	O
pain	O
were	O
reported	O
on	O
day	O
three	O
.	O
<EOS>	B-X
The	B-X
prevalence	B-X
of	B-X
chronic	B-X
pain	B-X
and	B-X
prescription	B-X
opioid	B-X
abuse	B-X
has	B-X
resulted	B-X
in	B-X
epidemic	B-X
problems	B-X
for	B-X
patients	B-X
and	B-X
clinicians	B-X
.	B-X
Specific	B-X
to	B-X
radiology	B-X
,	B-X
a	B-X
significant	B-X
need	B-X
exists	B-X
for	B-X
best	B-X
practice	B-X
assessment	B-X
and	B-X
treatment	B-X
approaches	B-X
for	B-X
pain	B-X
management	B-X
,	B-X
as	B-X
patients	B-X
with	B-X
chronic	B-X
pain	B-X
often	B-X
undergo	B-X
radiological	B-X
tests	B-X
of	B-X
unclear	B-X
clinical	B-X
relevance	B-X
.	B-X
Errors	B-X
can	B-X
be	B-X
summarized	B-X
into	B-X
four	B-X
main	B-X
categories	B-X
:	B-X
observer	B-X
errors	B-X
,	B-X
errors	B-X
in	B-X
interpretation	B-X
,	B-X
failure	B-X
to	B-X
suggest	B-X
the	B-X
next	B-X
appropriate	B-X
procedure	B-X
,	B-X
failure	B-X
to	B-X
communicate	B-X
in	B-X
a	B-X
timely	B-X
and	B-X
a	B-X
clinically	B-X
appropriate	B-X
manner	B-X
.	B-X
In	B-X
order	B-X
to	B-X
minimize	B-X
the	B-X
possibility	B-X
of	B-X
error	B-X
,	B-X
it	B-X
is	B-X
important	B-X
to	B-X
be	B-X
aware	B-X
of	B-X
various	B-X
presentations	B-X
of	B-X
pathology	B-X
,	B-X
obtain	B-X
clinical	B-X
information	B-X
,	B-X
know	B-X
current	B-X
practice	B-X
guidelines	B-X
,	B-X
review	B-X
after	B-X
interpreting	B-X
a	B-X
diagnostic	B-X
study	B-X
,	B-X
suggest	B-X
follow-up	B-X
studies	B-X
when	B-X
appropriate	B-X
,	B-X
communicate	B-X
significant	B-X
abnormal	B-X
findings	B-X
appropriately	B-X
and	B-X
in	B-X
a	B-X
timely	B-X
fashion	B-X
directly	B-X
with	B-X
the	B-X
treatment	B-X
team	B-X
.	B-X

However	O
,	O
on	O
day	O
4	O
,	O
the	O
patient	B-Species
started	O
to	O
complain	O
of	O
upper	O
abdominal	O
pain	O
and	O
developed	O
a	O
high	O
grade	O
fever	O
(	O
38	O
degrees	O
C	O
)	O
.	O

Complete	O
obstruction	O
of	O
the	O
small	O
bowel	O
and	O
leakage	O
of	O
contrast	O
media	O
were	O
demonstrated	O
by	O
Gastrografin	O
swallow	O
and	O
subsequent	O
abdominal	O
computed	O
tomography	O
(	O
CT	O
)	O
.	O

CT	O
also	O
showed	O
a	O
mass	O
lesion	O
at	O
the	O
trocar	O
insertion	O
site	O
on	O
the	O
upper	O
left	O
flank	O
,	O
suggesting	O
herniation	O
through	O
the	O
port	O
site	O
(	O
Fig	O
.	O
2	O
)	O
.	O

Marked	O
dilatation	O
of	O
the	O
duodenum	O
including	O
the	O
horizontal	O
part	O
and	O
second	O
portion	O
was	O
observed	O
.	O

A	O
diagnosis	O
of	O
staple	O
failure	O
of	O
the	O
stump	O
of	O
the	O
duodenum	O
and	O
port	O
-	O
site	O
herniation	O
of	O
the	O
small	O
bowel	O
was	O
made	O
,	O
and	O
exploratory	O
laparotomy	O
was	O
carried	O
out	O
.	O

A	O
small	O
medial	O
incision	O
that	O
had	O
been	O
made	O
at	O
the	O
initial	O
surgery	O
was	O
extended	O
downward	O
to	O
the	O
umbilicus	O
to	O
open	O
the	O
peritoneal	O
cavity	O
.	O

As	O
we	O
expected	O
,	O
the	O
small	O
bowel	O
was	O
incarcerated	O
into	O
the	O
peritoneal	O
defect	O
in	O
the	O
abdominal	O
wall	O
created	O
by	O
the	O
trocar	O
placed	O
in	O
the	O
left	O
upper	O
flank	O
leading	O
to	O
complete	O
obstruction	O
of	O
the	O
bowel	O
(	O
Fig	O
.	O
3	O
)	O
.	O

Part	O
of	O
the	O
jejunum	O
30	O
cm	O
distal	O
from	O
the	O
ligament	O
of	O
Treitz	O
herniated	O
around	O
the	O
fascial	O
stitch	O
,	O
which	O
still	O
existed	O
at	O
the	O
time	O
of	O
the	O
re	O
-	O
exploration	O
.	O

The	O
peritoneal	O
cavity	O
was	O
contaminated	O
with	O
intestinal	O
juice	O
.	O
<EOS>	B-X
The	B-X
intestinal	B-X
juices	B-X
free	B-X
the	B-X
ovum	B-X
from	B-X
its	B-X
cuticle	B-X
and	B-X
,	B-X
having	B-X
entered	B-X
a	B-X
capillary	B-X
,	B-X
it	B-X
is	B-X
carried	B-X
by	B-X
the	B-X
blood	B-X
stream	B-X
to	B-X
the	B-X
liver	B-X
or	B-X
lung	B-X
,	B-X
where	B-X
it	B-X
develops	B-X
into	B-X
a	B-X
hydatid	B-X
cyst	B-X
.	B-X
Man	B-X
becomes	B-X
infected	B-X
by	B-X
ingesting	B-X
contaminated	B-X
vegetables	B-X
or	B-X
drinking	B-X
contaminated	B-X
water.In	B-X
a	B-X
mature	B-X
hydatid	B-X
cyst	B-X
there	B-X
may	B-X
be	B-X
thousands	B-X
of	B-X
scolices	B-X
and	B-X
each	B-X
one	B-X
of	B-X
these	B-X
,	B-X
if	B-X
released	B-X
from	B-X
the	B-X
hydatid	B-X
cyst	B-X
,	B-X
may	B-X
form	B-X
a	B-X
new	B-X
cyst	B-X
if	B-X
it	B-X
is	B-X
planted	B-X
in	B-X
a	B-X
suitable	B-X
environment	B-X
.	B-X
Hydatid	B-X
cysts	B-X
are	B-X
most	B-X
commonly	B-X
found	B-X
in	B-X
the	B-X
liver	B-X
and	B-X
the	B-X
lung	B-X
,	B-X
but	B-X
may	B-X
occur	B-X
in	B-X
other	B-X
organs.A	B-X
hepatic	B-X
cyst	B-X
may	B-X
rupture	B-X
into	B-X
the	B-X
peritoneal	B-X
cavity	B-X
and	B-X
produce	B-X
a	B-X
hydatidoperitoneum	B-X
.	B-X
It	B-X
is	B-X
now	B-X
known	B-X
that	B-X
a	B-X
sylvatic	B-X
cycle	B-X
has	B-X
been	B-X
established	B-X
in	B-X
North	B-X
America	B-X
and	B-X
that	B-X
it	B-X
serves	B-X
as	B-X
a	B-X
source	B-X
of	B-X
infection	B-X
of	B-X
the	B-X
dog	B-X
and	B-X
man.The	B-X
patient	B-X
reported	B-X
herein	B-X
had	B-X
spontaneous	B-X
rupture	B-X
of	B-X
a	B-X
hepatic	B-X
hydatid	B-X
cyst	B-X
,	B-X
with	B-X
subsequent	B-X
development	B-X
of	B-X
secondary	B-X
peritoneal	B-X
echinococcosis	B-X
.	B-X

Close	O
examination	O
after	O
reduction	O
of	O
the	O
incarcerated	O
bowel	O
did	O
not	O
demonstrate	O
necrosis	O
of	O
the	O
intestine	O
,	O
and	O
thus	O
,	O
we	O
decided	O
not	O
to	O
resect	O
this	O
lesion	O
.	O

Leakage	O
of	O
intestinal	O
juice	O
through	O
a	O
pinhole	O
fistula	O
at	O
the	O
duodenal	O
stump	O
was	O
also	O
observed	O
.	O

Tube	O
duodenostomy	O
was	O
performed	O
with	O
an	O
omental	O
patch	O
used	O
for	O
closure	O
of	O
the	O
fistula	O
.	O

The	O
peritoneal	O
defect	O
was	O
also	O
closed	O
.	O
<EOS>	B-X
Excision	B-X
is	B-X
feasible	B-X
in	B-X
over	B-X
90	B-X
%	B-X
of	B-X
cases	B-X
often	B-X
requiring	B-X
suture	B-X
of	B-X
the	B-X
bowel	B-X
muscularis	B-X
or	B-X
full-thickness	B-X
defects	B-X
.	B-X
BEST	B-X
PRACTICE	B-X
ADVICE	B-X
11	B-X
:	B-X
Because	B-X
type	B-X
2	B-X
periampullary	B-X
(	B-X
retroperitoneal	B-X
)	B-X
perforations	B-X
are	B-X
subtle	B-X
and	B-X
can	B-X
be	B-X
easily	B-X
missed	B-X
,	B-X
the	B-X
endoscopist	B-X
should	B-X
carefully	B-X
assess	B-X
the	B-X
gas	B-X
pattern	B-X
on	B-X
fluoroscopy	B-X
to	B-X
avoid	B-X
delays	B-X
in	B-X
treatment	B-X
and	B-X
request	B-X
a	B-X
computed	B-X
tomography	B-X
scan	B-X
if	B-X
there	B-X
is	B-X
a	B-X
concern	B-X
for	B-X
such	B-X
a	B-X
perforation	B-X
;	B-X
identified	B-X
perforations	B-X
of	B-X
this	B-X
type	B-X
at	B-X
the	B-X
time	B-X
of	B-X
ERCP	B-X
may	B-X
be	B-X
closed	B-X
with	B-X
TTSCs	B-X
if	B-X
feasible	B-X
and/or	B-X
by	B-X
placing	B-X
a	B-X
fully	B-X
covered	B-X
SEMS	B-X
into	B-X
the	B-X
bile	B-X
duct	B-X
across	B-X
the	B-X
ampulla	B-X
.	B-X
BEST	B-X
PRACTICE	B-X
ADVICE	B-X
12	B-X
:	B-X
For	B-X
the	B-X
management	B-X
of	B-X
large	B-X
duodenal	B-X
polyps	B-X
,	B-X
endoscopic	B-X
mucosal	B-X
resection	B-X
(	B-X
EMR	B-X
)	B-X
should	B-X
only	B-X
be	B-X
performed	B-X
by	B-X
experienced	B-X
endoscopists	B-X
and	B-X
endoscopic	B-X
submucosal	B-X
dissection	B-X
(	B-X
ESD	B-X
)	B-X
only	B-X
by	B-X
experts	B-X
because	B-X
both	B-X
EMR	B-X
and	B-X
ESD	B-X
in	B-X
the	B-X
duodenum	B-X
require	B-X
proficiency	B-X
in	B-X
resection	B-X
and	B-X
mucosal	B-X
defect	B-X
closure	B-X
techniques	B-X
to	B-X
manage	B-X
immediate	B-X
and/or	B-X
delayed	B-X
perforations	B-X
(	B-X
caused	B-X
by	B-X
the	B-X
proteolytic	B-X
enzymes	B-X
of	B-X
the	B-X
pancreas	B-X
)	B-X
.	B-X
Such	B-X
tears	B-X
recognized	B-X
at	B-X
the	B-X
time	B-X
of	B-X
colonoscopy	B-X
may	B-X
be	B-X
closed	B-X
by	B-X
TTSCs	B-X
or	B-X
OTSCs	B-X
if	B-X
the	B-X
bowel	B-X
preparation	B-X
is	B-X
good	B-X
and	B-X
the	B-X
patient	B-X
is	B-X
stable	B-X
.	B-X
Recently	B-X
a	B-X
new	B-X
suture-based	B-X
device	B-X
for	B-X
defect	B-X
closure	B-X
has	B-X
been	B-X
introduced	B-X
allowing	B-X
deep	B-X
submucosal	B-X
and	B-X
intramuscular	B-X
enhanced	B-X
fixation	B-X
through	B-X
a	B-X
standard	B-X
gastroscope	B-X
or	B-X
colonoscope	B-X
.	B-X
BEST	B-X
PRACTICE	B-X
ADVICE	B-X
15	B-X
:	B-X
Patients	B-X
with	B-X
perforations	B-X
who	B-X
are	B-X
hemodynamically	B-X
unstable	B-X
or	B-X
who	B-X
have	B-X
suffered	B-X
a	B-X
delayed	B-X
perforation	B-X
with	B-X
peritoneal	B-X
signs	B-X
or	B-X
frank	B-X
peritonitis	B-X
should	B-X
be	B-X
surgically	B-X
managed	B-X
without	B-X
any	B-X
attempt	B-X
at	B-X
endoscopic	B-X
closure	B-X
.	B-X

The	O
postoperative	O
course	O
was	O
fairly	O
good	O
without	O
high	O
output	O
of	O
the	O
intestinal	O
juice	O
leakage	O
or	O
sepsis	O
.	O
<EOS>	B-X
Sepsis	B-X
is	B-X
an	B-X
overwhelming	B-X
reaction	B-X
to	B-X
infection	B-X
that	B-X
comes	B-X
with	B-X
high	B-X
morbidity	B-X
and	B-X
mortality	B-X
,	B-X
which	B-X
requires	B-X
urgent	B-X
interventions	B-X
in	B-X
order	B-X
to	B-X
improve	B-X
outcomes	B-X
.	B-X
Surviving	B-X
Sepsis	B-X
is	B-X
an	B-X
international	B-X
campaign	B-X
that	B-X
aims	B-X
to	B-X
improve	B-X
sepsis	B-X
outcomes	B-X
.	B-X
The	B-X
2016	B-X
guideline	B-X
modifies	B-X
the	B-X
previous	B-X
definition	B-X
of	B-X
sepsis	B-X
and	B-X
proposes	B-X
some	B-X
specific	B-X
diagnostic	B-X
and	B-X
therapeutic	B-X
measures	B-X
,	B-X
such	B-X
as	B-X
the	B-X
protocolized	B-X
use	B-X
of	B-X
fluid	B-X
resuscitation	B-X
and	B-X
antibiotics	B-X
.	B-X
Biomarkers	B-X
to	B-X
diagnose	B-X
sepsis	B-X
may	B-X
allow	B-X
early	B-X
intervention	B-X
which	B-X
,	B-X
although	B-X
primarily	B-X
supportive	B-X
,	B-X
can	B-X
reduce	B-X
the	B-X
risk	B-X
of	B-X
death	B-X
.	B-X
Although	B-X
lactate	B-X
is	B-X
currently	B-X
the	B-X
most	B-X
commonly	B-X
used	B-X
biomarker	B-X
to	B-X
identify	B-X
sepsis	B-X
,	B-X
other	B-X
biomarkers	B-X
may	B-X
help	B-X
to	B-X
enhance	B-X
lactate	B-X
's	B-X
effectiveness	B-X
;	B-X
these	B-X
include	B-X
markers	B-X
of	B-X
the	B-X
hyper-inflammatory	B-X
phase	B-X
of	B-X
sepsis	B-X
,	B-X
such	B-X
as	B-X
pro-inflammatory	B-X
cytokines	B-X
and	B-X
chemokines	B-X
;	B-X
proteins	B-X
such	B-X
as	B-X
C-reactive	B-X
protein	B-X
and	B-X
procalcitonin	B-X
which	B-X
are	B-X
synthesized	B-X
in	B-X
response	B-X
to	B-X
infection	B-X
and	B-X
inflammation	B-X
;	B-X
and	B-X
markers	B-X
of	B-X
neutrophil	B-X
and	B-X
monocyte	B-X
activation	B-X
.	B-X
Recently	B-X
,	B-X
markers	B-X
of	B-X
the	B-X
immunosuppressive	B-X
phase	B-X
of	B-X
sepsis	B-X
,	B-X
such	B-X
as	B-X
anti-inflammatory	B-X
cytokines	B-X
,	B-X
and	B-X
alterations	B-X
of	B-X
the	B-X
cell	B-X
surface	B-X
markers	B-X
of	B-X
monocytes	B-X
and	B-X
lymphocytes	B-X
have	B-X
been	B-X
examined	B-X
.	B-X
Combinations	B-X
of	B-X
pro-	B-X
and	B-X
anti-inflammatory	B-X
biomarkers	B-X
in	B-X
a	B-X
multi-marker	B-X
panel	B-X
may	B-X
help	B-X
identify	B-X
patients	B-X
who	B-X
are	B-X
developing	B-X
severe	B-X
sepsis	B-X
before	B-X
organ	B-X
dysfunction	B-X
has	B-X
advanced	B-X
too	B-X
far	B-X
.	B-X
Combined	B-X
with	B-X
innovative	B-X
approaches	B-X
to	B-X
treatment	B-X
that	B-X
target	B-X
the	B-X
immunosuppressive	B-X
phase	B-X
,	B-X
these	B-X
biomarkers	B-X
may	B-X
help	B-X
to	B-X
reduce	B-X
the	B-X
mortality	B-X
rate	B-X
associated	B-X
with	B-X
severe	B-X
sepsis	B-X
which	B-X
,	B-X
despite	B-X
advances	B-X
in	B-X
supportive	B-X
measures	B-X
,	B-X
remains	B-X
high	B-X
.	B-X

The	O
patient	B-Species
remained	O
in	O
the	O
intensive	O
care	O
unit	O
for	O
5	O
days	O
after	O
re	O
-	O
operation	O
,	O
and	O
was	O
then	O
transferred	O
to	O
the	O
general	O
ward	O
.	O

Discussion	O
<EOS>	B-X
Discussion	B-X
structures	B-X
are	B-X
argumentation-theoretical	B-X
tools	B-X
that	B-X
can	B-X
be	B-X
employed	B-X
to	B-X
tackle	B-X
three	B-X
barriers	B-X
that	B-X
separate	B-X
lay	B-X
stakeholders	B-X
from	B-X
policy	B-X
debates	B-X
:	B-X
difficulty	B-X
,	B-X
magnitude	B-X
,	B-X
and	B-X
complexity	B-X
.	B-X
Discussions	B-X
about	B-X
preventive	B-X
behaviors	B-X
were	B-X
assessed	B-X
before	B-X
testing	B-X
and	B-X
1	B-X
and	B-X
6	B-X
months	B-X
post-testing	B-X
.	B-X
Discussion	B-X
of	B-X
preventive	B-X
behaviors	B-X
declined	B-X
following	B-X
test	B-X
reporting	B-X
,	B-X
with	B-X
more	B-X
rapid	B-X
decline	B-X
reported	B-X
by	B-X
noncarriers	B-X
.	B-X
Discussions	B-X
are	B-X
an	B-X
important	B-X
part	B-X
of	B-X
medical	B-X
education	B-X
research	B-X
papers	B-X
,	B-X
but	B-X
there	B-X
is	B-X
little	B-X
guidance	B-X
on	B-X
how	B-X
to	B-X
write	B-X
up	B-X
the	B-X
discussion	B-X
section	B-X
.	B-X

Port	O
-	O
site	O
herniation	O
,	O
which	O
is	O
one	O
of	O
the	O
major	O
complications	O
after	O
laparoscopic	O
procedures	O
[	O
1	O
]	O
,	O
sometimes	O
develops	O
into	O
serious	O
complications	O
,	O
such	O
as	O
bowel	O
obstruction	O
due	O
to	O
incarceration	O
into	O
the	O
fascial	O
defect	O
at	O
the	O
port	O
site	O
.	O

Boughey	O
et	O
al	O
.	O
have	O
reported	O
four	O
cases	O
of	O
Richter	O
'	O
s	O
hernia	O
that	O
occurred	O
at	O
a	O
port	O
site	O
after	O
laparoscopic	O
surgery	O
[	O
1	O
]	O
.	O

They	O
reviewed	O
previous	O
reports	O
and	O
found	O
the	O
incidence	O
to	O
be	O
0	O
.	O
2	O
to	O
3	O
%	O
.	O
<EOS>	B-X
We	B-X
aim	B-X
to	B-X
explore	B-X
the	B-X
nature	B-X
and	B-X
outcome	B-X
of	B-X
adverse	B-X
events	B-X
following	B-X
BNT162B2	B-X
vaccine	B-X
in	B-X
a	B-X
community	B-X
vaccination	B-X
center	B-X
,	B-X
Riyadh	B-X
,	B-X
Saudi	B-X
Arabia	B-X
.	B-X

A	O
report	O
describes	O
the	O
incidence	O
of	O
hernia	O
as	O
0	O
.	O
23	O
%	O
for	O
10	O
-	O
mm	O
trocar	O
use	O
,	O
rising	O
to	O
3	O
.	O
1	O
%	O
for	O
the	O
12	O
-	O
mm	O
trocar	O
[	O
2	O
]	O
suggesting	O
that	O
the	O
wound	O
created	O
by	O
a	O
larger	O
port	O
carries	O
a	O
greater	O
risk	O
of	O
herniation	O
.	O

Most	O
surgeons	O
now	O
routinely	O
close	O
the	O
fascia	O
of	O
port	O
sites	O
to	O
prevent	O
this	O
complication	O
[	O
2	O
]	O
.	O

According	O
to	O
previous	O
reports	O
,	O
port	O
site	O
herniation	O
apparently	O
happens	O
more	O
often	O
with	O
the	O
use	O
of	O
bladed	O
type	O
trocars	O
than	O
non	O
-	O
bladed	O
type	O
trocars	O
[	O
3	O
]	O
.	O

Indeed	O
,	O
Kolata	O
demonstrated	O
that	O
the	O
wounds	O
made	O
by	O
the	O
non	O
-	O
bladed	O
trocar	O
were	O
narrower	O
than	O
those	O
created	O
by	O
cutting	O
tip	O
trocars	O
in	O
a	O
pig	B-Species
experimental	O
model	O
[	O
4	O
]	O
.	O

Several	O
reports	O
even	O
concluded	O
that	O
port	O
sites	O
created	O
by	O
non	O
-	O
bladed	O
trocars	O
do	O
not	O
require	O
fascial	O
closure	O
[	O
3	O
]	O
.	O

However	O
,	O
the	O
current	O
case	O
suggests	O
that	O
thick	O
preperitoneum	O
is	O
a	O
potential	O
space	O
that	O
allows	O
for	O
the	O
development	O
of	O
bowel	O
herniation	O
even	O
with	O
the	O
use	O
of	O
non	O
-	O
bladed	O
type	O
trocars	O
.	O

A	O
previous	O
report	O
also	O
described	O
port	O
-	O
site	O
herniation	O
,	O
despite	O
the	O
closure	O
of	O
the	O
superficial	O
layer	O
of	O
the	O
fascial	O
defect	O
[	O
5	O
]	O
.	O

The	O
current	O
case	O
did	O
not	O
demonstrate	O
any	O
of	O
the	O
risk	O
factors	O
suggested	O
previously	O
[	O
6	O
]	O
;	O
1	O
)	O
enlargement	O
of	O
a	O
port	O
site	O
to	O
remove	O
specimen	O
;	O
2	O
)	O
glucose	O
intolerance	O
;	O
3	O
)	O
obesity	O
;	O
or	O
4	O
)	O
extensive	O
manipulation	O
of	O
the	O
trocar	O
during	O
relatively	O
prolonged	O
surgical	O
duration	O
,	O
which	O
might	O
have	O
enlarged	O
the	O
trocar	O
site	O
and	O
thus	O
induced	O
bowel	O
herniation	O
.	O
<EOS>	B-X
The	B-X
voltage	B-X
sensor	B-X
consists	B-X
of	B-X
charges	B-X
or	B-X
dipoles	B-X
that	B-X
move	B-X
in	B-X
response	B-X
to	B-X
changes	B-X
in	B-X
the	B-X
electric	B-X
field	B-X
,	B-X
and	B-X
their	B-X
movement	B-X
produces	B-X
an	B-X
electric	B-X
current	B-X
that	B-X
has	B-X
been	B-X
called	B-X
gating	B-X
current	B-X
.	B-X
In	B-X
the	B-X
case	B-X
of	B-X
voltage-gated	B-X
ion	B-X
channels	B-X
,	B-X
the	B-X
kinetic	B-X
and	B-X
steady-state	B-X
properties	B-X
of	B-X
the	B-X
gating	B-X
charges	B-X
provide	B-X
information	B-X
of	B-X
conformational	B-X
changes	B-X
between	B-X
closed	B-X
states	B-X
that	B-X
are	B-X
not	B-X
visible	B-X
when	B-X
observing	B-X
ionic	B-X
currents	B-X
only	B-X
.	B-X
However	B-X
,	B-X
orchestrated	B-X
bidirectional	B-X
ionic	B-X
currents	B-X
across	B-X
the	B-X
cell	B-X
membrane	B-X
via	B-X
the	B-X
channels	B-X
are	B-X
important	B-X
for	B-X
the	B-X
functioning	B-X
of	B-X
organs	B-X
of	B-X
organisms	B-X
,	B-X
and	B-X
equally	B-X
concern	B-X
both	B-X
fauna	B-X
or	B-X
flora	B-X
.	B-X
One	B-X
of	B-X
the	B-X
hallmarks	B-X
of	B-X
voltage-dependent	B-X
channels	B-X
is	B-X
a	B-X
'tail	B-X
current'	B-X
-	B-X
deactivation	B-X
as	B-X
observed	B-X
after	B-X
prior	B-X
and	B-X
sufficient	B-X
activation	B-X
predominantly	B-X
at	B-X
more	B-X
depolarized	B-X
potentials	B-X
e.g	B-X
.	B-X
Tail	B-X
current	B-X
also	B-X
reflects	B-X
the	B-X
timing	B-X
of	B-X
channel	B-X
closure	B-X
that	B-X
is	B-X
initiated	B-X
upon	B-X
termination	B-X
of	B-X
stimuli	B-X
.	B-X
Finally	B-X
,	B-X
deactivation	B-X
of	B-X
currents	B-X
during	B-X
repolarization	B-X
could	B-X
be	B-X
a	B-X
selective	B-X
estimate	B-X
for	B-X
given	B-X
channel	B-X
as	B-X
in	B-X
case	B-X
of	B-X
HERG	B-X
,	B-X
if	B-X
dedicated	B-X
long	B-X
and	B-X
more	B-X
depolarized	B-X
'tail	B-X
pulse	B-X
'	B-X
is	B-X
used	B-X
.	B-X

Therefore	O
,	O
we	O
recommend	O
closing	O
the	O
fascial	O
defect	O
,	O
including	O
the	O
peritoneum	O
,	O
especially	O
if	O
the	O
trocar	O
size	O
is	O
more	O
than	O
10	O
-	O
mm	O
and	O
in	O
the	O
presence	O
of	O
any	O
of	O
the	O
risk	O
factors	O
described	O
above	O
.	O

However	O
,	O
it	O
is	O
sometimes	O
difficult	O
to	O
completely	O
close	O
the	O
defect	O
,	O
including	O
the	O
peritoneum	O
,	O
especially	O
in	O
obese	O
patients	B-Species
.	O

Shaher	O
reviewed	O
different	O
wound	O
closure	O
techniques	O
by	O
a	O
literature	O
search	O
[	O
7	O
]	O
.	O
<EOS>	B-X
Laparoscopic	B-X
trocars	B-X
do	B-X
create	B-X
wounds	B-X
.	B-X
This	B-X
article	B-X
aims	B-X
to	B-X
review	B-X
and	B-X
list	B-X
different	B-X
techniques	B-X
used	B-X
for	B-X
closure	B-X
of	B-X
the	B-X
fascia	B-X
incision	B-X
at	B-X
trocar	B-X
sites	B-X
.	B-X

In	O
this	O
review	O
,	O
old	O
methods	O
using	O
classical	O
instruments	O
including	O
Deschamps	O
needle	O
are	O
also	O
useful	O
as	O
well	O
as	O
special	O
wound	O
devices	O
designed	O
for	O
port	O
site	O
closure	O
.	O

Elashry	O
et	O
al	O
.	O
described	O
a	O
prospective	O
randomized	O
study	O
demonstrating	O
that	O
the	O
Carter	O
-	O
Thomason	O
device	O
was	O
faster	O
and	O
resulted	O
in	O
fewer	O
port	O
-	O
closure	O
-	O
related	O
complications	O
among	O
eight	O
different	O
techniques	O
tested	O
[	O
8	O
]	O
.	O

Insertion	O
of	O
a	O
SURGICEL	O
plug	O
into	O
the	O
muscular	O
layer	O
of	O
trocar	O
wounds	O
has	O
also	O
been	O
proposed	O
by	O
Chiu	O
et	O
al	O
[	O
9	O
]	O
.	O

Alternatively	O
,	O
tangential	O
insertion	O
of	O
a	O
trocar	O
through	O
the	O
abdominal	O
wall	O
might	O
be	O
effective	O
in	O
reducing	O
the	O
size	O
of	O
fascial	O
defects	O
.	O

Moreover	O
,	O
recent	O
publications	O
have	O
demonstrated	O
that	O
radially	O
expanding	O
type	O
trocars	O
could	O
be	O
useful	O
to	O
avoid	O
the	O
necessity	O
of	O
closing	O
the	O
fascial	O
defect	O
[	O
10	O
]	O
.	O

Symptoms	O
of	O
trocar	O
-	O
site	O
herniation	O
vary	O
depending	O
on	O
the	O
severity	O
of	O
bowel	O
obstruction	O
.	O

Mild	O
symptoms	O
such	O
as	O
slight	O
nausea	O
and	O
vague	O
abdominal	O
pain	O
,	O
both	O
of	O
which	O
are	O
most	O
frequently	O
seen	O
in	O
the	O
early	O
normal	O
postoperative	O
course	O
after	O
abdominal	O
surgery	O
,	O
could	O
be	O
the	O
first	O
and	O
only	O
complaints	O
at	O
the	O
early	O
stage	O
of	O
this	O
complication	O
.	O

Thus	O
,	O
the	O
diagnosis	O
may	O
be	O
delayed	O
.	O
<EOS>	B-X
Early	B-X
and	B-X
accurate	B-X
diagnosis	B-X
and	B-X
treatment	B-X
of	B-X
schizophrenia	B-X
may	B-X
have	B-X
long-term	B-X
advantages	B-X
for	B-X
the	B-X
patient	B-X
;	B-X
the	B-X
longer	B-X
psychosis	B-X
goes	B-X
untreated	B-X
the	B-X
more	B-X
severe	B-X
the	B-X
repercussions	B-X
for	B-X
relapse	B-X
and	B-X
recovery	B-X
.	B-X
If	B-X
the	B-X
correct	B-X
diagnosis	B-X
is	B-X
not	B-X
schizophrenia	B-X
,	B-X
but	B-X
another	B-X
psychotic	B-X
disorder	B-X
with	B-X
some	B-X
symptoms	B-X
similar	B-X
to	B-X
schizophrenia	B-X
,	B-X
appropriate	B-X
treatment	B-X
might	B-X
be	B-X
delayed	B-X
,	B-X
with	B-X
possible	B-X
severe	B-X
repercussions	B-X
for	B-X
the	B-X
person	B-X
involved	B-X
and	B-X
their	B-X
family	B-X
.	B-X
Early	B-X
diagnosis	B-X
of	B-X
Duchenne	B-X
muscular	B-X
dystrophy	B-X
(	B-X
DMD	B-X
)	B-X
is	B-X
important	B-X
for	B-X
timely	B-X
intervention	B-X
to	B-X
prolong	B-X
function	B-X
and	B-X
preserve	B-X
quality	B-X
of	B-X
life	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
highlight	B-X
cases	B-X
of	B-X
delayed	B-X
DMD	B-X
diagnosis	B-X
that	B-X
resulted	B-X
from	B-X
misattribution	B-X
of	B-X
early	B-X
motor	B-X
symptoms	B-X
to	B-X
co-occurring	B-X
neurocognitive	B-X
conditions	B-X
.	B-X
We	B-X
also	B-X
investigate	B-X
the	B-X
difference	B-X
in	B-X
age	B-X
at	B-X
DMD	B-X
diagnosis	B-X
in	B-X
the	B-X
setting	B-X
of	B-X
specific	B-X
co-occurring	B-X
neurocognitive	B-X
conditions	B-X
.	B-X

In	O
our	O
case	O
,	O
mild	O
abdominal	O
pain	O
with	O
general	O
malaise	O
might	O
have	O
been	O
symptoms	O
related	O
to	O
the	O
early	O
stage	O
of	O
the	O
onset	O
.	O

Abdominal	O
CT	O
showing	O
the	O
enlarged	O
duodenum	O
also	O
suggested	O
that	O
leakage	O
from	O
the	O
duodenal	O
stump	O
occurred	O
due	O
to	O
the	O
obstruction	O
of	O
the	O
distal	O
bowel	O
.	O

Thus	O
,	O
severe	O
complication	O
might	O
have	O
been	O
avoided	O
,	O
if	O
early	O
diagnosis	O
had	O
been	O
made	O
.	O
<EOS>	B-X
Though	B-X
self-limiting	B-X
in	B-X
many	B-X
cases	B-X
,	B-X
it	B-X
can	B-X
lead	B-X
to	B-X
severe	B-X
complications	B-X
like	B-X
coronary	B-X
artery	B-X
aneurysms	B-X
and	B-X
thrombo-embolic	B-X
occlusions	B-X
,	B-X
and	B-X
hence	B-X
requires	B-X
early	B-X
diagnosis	B-X
and	B-X
urgent	B-X
attention	B-X
to	B-X
avoid	B-X
them	B-X
.	B-X
The	B-X
association	B-X
between	B-X
hypertension	B-X
,	B-X
diabetes	B-X
,	B-X
cardio	B-X
and	B-X
cerebrovascular	B-X
disease	B-X
and	B-X
severe	B-X
and	B-X
fatal	B-X
COVID-19	B-X
,	B-X
described	B-X
in	B-X
different	B-X
countries	B-X
,	B-X
is	B-X
remarkable	B-X
.	B-X
A	B-X
substantial	B-X
number	B-X
of	B-X
patients	B-X
admitted	B-X
to	B-X
the	B-X
ICU	B-X
because	B-X
of	B-X
an	B-X
acute	B-X
illness	B-X
,	B-X
complicated	B-X
surgery	B-X
,	B-X
severe	B-X
trauma	B-X
,	B-X
or	B-X
burn	B-X
injury	B-X
will	B-X
develop	B-X
a	B-X
de	B-X
novo	B-X
form	B-X
of	B-X
muscle	B-X
weakness	B-X
during	B-X
the	B-X
ICU	B-X
stay	B-X
that	B-X
is	B-X
referred	B-X
to	B-X
as	B-X
``	B-X
intensive	B-X
care	B-X
unit	B-X
acquired	B-X
weakness	B-X
''	B-X
(	B-X
ICUAW	B-X
)	B-X
.	B-X
In	B-X
cases	B-X
of	B-X
atypical	B-X
clinical	B-X
presentation	B-X
or	B-X
evolution	B-X
,	B-X
additional	B-X
electrophysiological	B-X
testing	B-X
may	B-X
be	B-X
required	B-X
for	B-X
differential	B-X
diagnosis	B-X
.	B-X
The	B-X
cornerstones	B-X
of	B-X
prevention	B-X
are	B-X
aggressive	B-X
treatment	B-X
of	B-X
sepsis	B-X
,	B-X
early	B-X
mobilization	B-X
,	B-X
preventing	B-X
hyperglycemia	B-X
with	B-X
insulin	B-X
,	B-X
and	B-X
avoiding	B-X
the	B-X
use	B-X
parenteral	B-X
nutrition	B-X
during	B-X
the	B-X
first	B-X
week	B-X
of	B-X
critical	B-X
illness	B-X
.	B-X
Weak	B-X
patients	B-X
clearly	B-X
have	B-X
worse	B-X
acute	B-X
outcomes	B-X
and	B-X
consume	B-X
more	B-X
healthcare	B-X
resources	B-X
.	B-X
Future	B-X
research	B-X
should	B-X
focus	B-X
on	B-X
new	B-X
preventive	B-X
and/or	B-X
therapeutic	B-X
strategies	B-X
for	B-X
this	B-X
detrimental	B-X
complication	B-X
of	B-X
critical	B-X
illness	B-X
and	B-X
on	B-X
clarifying	B-X
how	B-X
ICUAW	B-X
contributes	B-X
to	B-X
poor	B-X
longer-term	B-X
prognosis	B-X
.	B-X

Although	O
the	O
benefit	O
of	O
Roux	O
-	O
en	O
-	O
Y	O
is	O
apparent	O
[	O
11	O
]	O
,	O
the	O
duodenal	O
stump	O
could	O
be	O
vulnerable	O
to	O
leakage	O
due	O
to	O
increased	O
intrabowel	O
pressure	O
.	O

Therefore	O
,	O
careful	O
management	O
of	O
the	O
postoperative	O
course	O
is	O
warranted	O
,	O
especially	O
after	O
procedures	O
involving	O
division	O
of	O
the	O
bowel	O
such	O
as	O
LADG	O
.	O

Moreover	O
,	O
special	O
attention	O
should	O
be	O
paid	O
in	O
patients	B-Species
with	O
risk	O
factors	O
for	O
port	O
site	O
hernia	O
such	O
as	O
obesity	O
,	O
aggressive	O
manipulation	O
through	O
the	O
port	O
sites	O
,	O
and	O
prolonged	O
surgery	O
.	O

Conclusion	O
<EOS>	B-X
Conclusion	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X

Port	O
-	O
site	O
herniation	O
is	O
a	O
potentially	O
dangerous	O
complication	O
after	O
laparoscopic	O
procedures	O
.	O
<EOS>	B-X
Trocar	B-X
site	B-X
hernia	B-X
or	B-X
port	B-X
site	B-X
hernia	B-X
(	B-X
PSH	B-X
)	B-X
is	B-X
a	B-X
type	B-X
of	B-X
incisional	B-X
hernia	B-X
occurring	B-X
at	B-X
the	B-X
trocar	B-X
sites	B-X
after	B-X
laparoscopic	B-X
surgeries	B-X
.	B-X
This	B-X
is	B-X
a	B-X
rare	B-X
but	B-X
a	B-X
potentially	B-X
dangerous	B-X
complication	B-X
,	B-X
as	B-X
it	B-X
can	B-X
lead	B-X
to	B-X
considerable	B-X
morbidity	B-X
requiring	B-X
surgical	B-X
intervention	B-X
.	B-X
We	B-X
present	B-X
here	B-X
five	B-X
cases	B-X
of	B-X
port	B-X
site	B-X
herniae	B-X
.	B-X
Port-site	B-X
herniation	B-X
is	B-X
a	B-X
rare	B-X
but	B-X
potentially	B-X
dangerous	B-X
complication	B-X
after	B-X
laparoscopic	B-X
surgery	B-X
.	B-X
Closure	B-X
of	B-X
port	B-X
sites	B-X
,	B-X
especially	B-X
those	B-X
measuring	B-X
10	B-X
mm	B-X
or	B-X
more	B-X
,	B-X
has	B-X
been	B-X
recommended	B-X
to	B-X
avoid	B-X
such	B-X
an	B-X
event	B-X
.	B-X

Careful	O
management	O
of	O
the	O
postoperative	O
course	O
is	O
recommended	O
especially	O
for	O
patients	B-Species
with	O
risk	O
factors	O
such	O
as	O
obesity	O
and	O
extensive	O
manipulation	O
of	O
the	O
trocar	O
during	O
prolonged	O
surgical	O
duration	O
.	O

Competing	O
interests	O
<EOS>	B-X
Elective	B-X
ventilation	B-X
and	B-X
interests	B-X
.	B-X
An	B-X
examination	B-X
of	B-X
the	B-X
principle	B-X
of	B-X
precedent	B-X
autonomy	B-X
reveals	B-X
that	B-X
a	B-X
future-binding	B-X
research	B-X
decision	B-X
is	B-X
within	B-X
the	B-X
scope	B-X
of	B-X
a	B-X
competent	B-X
person	B-X
's	B-X
critical	B-X
interests	B-X
,	B-X
if	B-X
the	B-X
decision	B-X
is	B-X
consistent	B-X
with	B-X
what	B-X
the	B-X
person	B-X
believes	B-X
gives	B-X
her	B-X
life	B-X
intrinsic	B-X
value	B-X
.	B-X
Safety	B-X
of	B-X
young	B-X
drivers	B-X
.	B-X
In	B-X
this	B-X
article	B-X
I	B-X
will	B-X
show	B-X
that	B-X
'best	B-X
interests	B-X
'	B-X
is	B-X
a	B-X
concept	B-X
that	B-X
fits	B-X
nicely	B-X
with	B-X
many	B-X
of	B-X
the	B-X
features	B-X
of	B-X
pragmatism	B-X
--	B-X
Holm	B-X
and	B-X
Edgar	B-X
's	B-X
rejection	B-X
of	B-X
the	B-X
principle	B-X
in	B-X
favour	B-X
of	B-X
pragmatism	B-X
it	B-X
will	B-X
be	B-X
suggested	B-X
is	B-X
misplaced	B-X
.	B-X
'Best	B-X
interests	B-X
'	B-X
as	B-X
a	B-X
principle	B-X
may	B-X
be	B-X
considered	B-X
an	B-X
embodiment	B-X
of	B-X
the	B-X
ideals	B-X
of	B-X
pragmatic	B-X
adjudication	B-X
.	B-X
The	B-X
paper	B-X
starts	B-X
by	B-X
briefly	B-X
introducing	B-X
the	B-X
concept	B-X
of	B-X
'best	B-X
interests	B-X
'	B-X
and	B-X
theories	B-X
of	B-X
judicial	B-X
and	B-X
legal	B-X
'pragmatism	B-X
'	B-X
.	B-X
The	B-X
paper	B-X
concludes	B-X
by	B-X
suggesting	B-X
how	B-X
we	B-X
view	B-X
the	B-X
relationship	B-X
between	B-X
'best	B-X
interests	B-X
'	B-X
and	B-X
'pragmatism	B-X
'	B-X
.	B-X

The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O
<EOS>	B-X
In	B-X
this	B-X
letter	B-X
,	B-X
I	B-X
argue	B-X
that	B-X
in	B-X
reality	B-X
and	B-X
in	B-X
practice	B-X
,	B-X
authorship	B-X
delimitations	B-X
are	B-X
not	B-X
that	B-X
clear-cut	B-X
,	B-X
nor	B-X
are	B-X
all	B-X
contributions	B-X
equal	B-X
or	B-X
equally	B-X
weighted	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
contributions	B-X
of	B-X
each	B-X
author	B-X
to	B-X
multiauthored	B-X
biomedical	B-X
research	B-X
papers	B-X
.	B-X
Much	B-X
research	B-X
on	B-X
APP	B-X
focusses	B-X
on	B-X
potential	B-X
contributions	B-X
to	B-X
neurodegeneration	B-X
,	B-X
mostly	B-X
based	B-X
on	B-X
mouse	B-X
models	B-X
with	B-X
altered	B-X
expression	B-X
or	B-X
mutated	B-X
forms	B-X
of	B-X
APP	B-X
.	B-X
For	B-X
papers	B-X
in	B-X
which	B-X
the	B-X
first	B-X
and	B-X
second	B-X
authors	B-X
made	B-X
equal	B-X
contributions	B-X
,	B-X
mixed-gender	B-X
combinations	B-X
were	B-X
most	B-X
frequent	B-X
,	B-X
followed	B-X
by	B-X
male-male	B-X
and	B-X
then	B-X
female-female	B-X
author	B-X
combinations	B-X
.	B-X
For	B-X
papers	B-X
in	B-X
which	B-X
three	B-X
or	B-X
more	B-X
authors	B-X
made	B-X
equal	B-X
contributions	B-X
,	B-X
there	B-X
were	B-X
more	B-X
male	B-X
authors	B-X
than	B-X
female	B-X
authors	B-X
in	B-X
the	B-X
first	B-X
position	B-X
and	B-X
more	B-X
all-male	B-X
than	B-X
all-female	B-X
author	B-X
combinations	B-X
.	B-X
The	B-X
gender	B-X
inequalities	B-X
observed	B-X
among	B-X
authors	B-X
who	B-X
made	B-X
equal	B-X
contributions	B-X
are	B-X
not	B-X
consistent	B-X
with	B-X
random	B-X
or	B-X
alphabetical	B-X
ordering	B-X
of	B-X
authors	B-X
.	B-X

TI	O
,	O
NF	O
,	O
HT	O
and	O
TK	O
performed	O
the	O
first	O
and	O
second	O
operation	O
.	O
<EOS>	B-X
Guidelines	B-X
for	B-X
the	B-X
use	B-X
and	B-X
interpretation	B-X
of	B-X
assays	B-X
for	B-X
monitoring	B-X
autophagy	B-X
(	B-X
3rd	B-X
edition	B-X
)	B-X
.	B-X

TI	O
and	O
KK	O
were	O
responsible	O
for	O
the	O
postoperative	O
management	O
.	O

TI	O
,	O
HT	O
,	O
TW	O
,	O
and	O
KN	O
were	O
involved	O
in	O
editing	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O
<EOS>	B-X
As	B-X
a	B-X
Generally	B-X
Recognized	B-X
As	B-X
Safe	B-X
(	B-X
GRAS	B-X
)	B-X
approved	B-X
substance	B-X
,	B-X
MSM	B-X
is	B-X
well-tolerated	B-X
by	B-X
most	B-X
individuals	B-X
at	B-X
dosages	B-X
of	B-X
up	B-X
to	B-X
four	B-X
grams	B-X
daily	B-X
,	B-X
with	B-X
few	B-X
known	B-X
and	B-X
mild	B-X
side	B-X
effects	B-X
.	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
manuscript	B-X
is	B-X
to	B-X
provide	B-X
a	B-X
description	B-X
of	B-X
the	B-X
epidemiology	B-X
and	B-X
presentation	B-X
of	B-X
piriformis	B-X
as	B-X
well	B-X
as	B-X
both	B-X
non-operative	B-X
and	B-X
operative	B-X
treatment	B-X
options	B-X
.	B-X
Due	B-X
to	B-X
the	B-X
widespread	B-X
use	B-X
of	B-X
landfilling	B-X
,	B-X
even	B-X
as	B-X
of	B-X
today	B-X
,	B-X
it	B-X
is	B-X
imperative	B-X
to	B-X
examine	B-X
any	B-X
environmental-	B-X
and/or	B-X
health-related	B-X
issues	B-X
that	B-X
have	B-X
emerged	B-X
.	B-X

Consent	O
<EOS>	B-X
In	B-X
this	B-X
respect	B-X
,	B-X
consent	B-X
documents	B-X
according	B-X
to	B-X
the	B-X
IHE	B-X
APPC	B-X
(	B-X
Advanced	B-X
Patient	B-X
Privacy	B-X
Consents	B-X
)	B-X
profile	B-X
enable	B-X
the	B-X
documentation	B-X
of	B-X
the	B-X
patient	B-X
's	B-X
consent	B-X
,	B-X
including	B-X
information	B-X
about	B-X
planned	B-X
authorized	B-X
people	B-X
,	B-X
document	B-X
types	B-X
,	B-X
period	B-X
and	B-X
type	B-X
of	B-X
document	B-X
access	B-X
allowed	B-X
.	B-X
Consent	B-X
governs	B-X
innumerable	B-X
everyday	B-X
social	B-X
interactions	B-X
,	B-X
including	B-X
sex	B-X
,	B-X
medical	B-X
exams	B-X
,	B-X
the	B-X
use	B-X
of	B-X
property	B-X
,	B-X
and	B-X
economic	B-X
transactions	B-X
.	B-X
Consenting	B-X
to	B-X
a	B-X
treatment	B-X
or	B-X
procedure	B-X
is	B-X
a	B-X
complex	B-X
medical	B-X
,	B-X
ethical	B-X
,	B-X
and	B-X
legal	B-X
issue	B-X
.	B-X

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
the	O
patient	B-Species
for	O
publication	O
of	O
this	O
case	O
report	O
and	O
any	O
accompanying	O
images	O
.	O
<EOS>	B-X
We	B-X
report	B-X
a	B-X
new	B-X
case	B-X
and	B-X
review	B-X
the	B-X
literature	B-X
for	B-X
relevant	B-X
data	B-X
.	B-X
Retroperitoneal	B-X
ectopic	B-X
pregnancy	B-X
(	B-X
REP	B-X
)	B-X
is	B-X
an	B-X
extremely	B-X
rare	B-X
type	B-X
of	B-X
ectopic	B-X
pregnancy	B-X
,	B-X
with	B-X
a	B-X
total	B-X
of	B-X
less	B-X
than	B-X
20	B-X
cases	B-X
reported	B-X
in	B-X
the	B-X
English	B-X
literature	B-X
.	B-X
Ehrlichiosis	B-X
can	B-X
transiently	B-X
cause	B-X
white	B-X
blood	B-X
cells	B-X
abnormalities	B-X
that	B-X
mimic	B-X
leukemia/lymphoma	B-X
and	B-X
cases	B-X
have	B-X
been	B-X
,	B-X
on	B-X
rare	B-X
occasions	B-X
,	B-X
initially	B-X
mistaken	B-X
for	B-X
hematological	B-X
malignancies	B-X
.	B-X
We	B-X
report	B-X
a	B-X
case	B-X
of	B-X

A	O
copy	O
of	O
the	O
written	O
consent	O
is	O
available	O
for	O
review	O
by	O
the	O
Editor	O
-	O
in	O
-	O
Chief	O
of	O
this	O
journal	O
.	O

Comparison	O
of	O
strategies	O
for	O
identification	O
of	O
regulatory	O
quantitative	O
trait	O
loci	O
of	O
transcript	O
expression	O
traits	O
<EOS>	B-X
In	B-X
order	B-X
to	B-X
identify	B-X
regulatory	B-X
genes	B-X
,	B-X
we	B-X
determined	B-X
the	B-X
heritability	B-X
of	B-X
gene	B-X
transcripts	B-X
,	B-X
performed	B-X
linkage	B-X
analysis	B-X
to	B-X
identify	B-X
quantitative	B-X
trait	B-X
loci	B-X
(	B-X
QTLs	B-X
)	B-X
,	B-X
and	B-X
evaluated	B-X
the	B-X
evidence	B-X
for	B-X
shared	B-X
genetic	B-X
effects	B-X
among	B-X
transcripts	B-X
with	B-X
co-localized	B-X
QTLs	B-X
in	B-X
non-diseased	B-X
participants	B-X
from	B-X
14	B-X
CEPH	B-X
(	B-X
Centre	B-X
d'Etude	B-X
du	B-X
Polymorphisme	B-X
Humain	B-X
)	B-X
Utah	B-X
families	B-X
.	B-X
Seventy-six	B-X
percent	B-X
of	B-X
transcripts	B-X
had	B-X
a	B-X
significant	B-X
heritability	B-X
and	B-X
54	B-X
%	B-X
of	B-X
them	B-X
had	B-X
LOD	B-X
score	B-X
>	B-X
or=	B-X
1.8	B-X
.	B-X
Bivariate	B-X
genetic	B-X
analysis	B-X
of	B-X
15	B-X
transcripts	B-X
that	B-X
had	B-X
co-localized	B-X
QTLs	B-X
on	B-X
4q28.2-q31.1	B-X
identified	B-X
significant	B-X
genetic	B-X
correlation	B-X
among	B-X
some	B-X
transcripts	B-X
although	B-X
no	B-X
improvement	B-X
in	B-X
the	B-X
magnitude	B-X
of	B-X
LOD	B-X
scores	B-X
in	B-X
this	B-X
region	B-X
was	B-X
noted	B-X
.	B-X
Similar	B-X
results	B-X
were	B-X
found	B-X
in	B-X
analysis	B-X
of	B-X
12	B-X
transcripts	B-X
,	B-X
that	B-X
had	B-X
co-localized	B-X
QTLs	B-X
in	B-X
the	B-X
13q34	B-X
region	B-X
.	B-X
Principal-component	B-X
analyses	B-X
did	B-X
not	B-X
improve	B-X
the	B-X
ability	B-X
to	B-X
identify	B-X
chromosomal	B-X
regions	B-X
of	B-X
co-localized	B-X
gene	B-X
expressions	B-X
.	B-X

Abstract	O
<EOS>	B-X
Abstract	B-X
writing	B-X
.	B-X
The	B-X
informative	B-X
abstract	B-X
.	B-X
Crafting	B-X
a	B-X
compelling	B-X
abstract	B-X
.	B-X
Why	B-X
the	B-X
structured	B-X
abstract	B-X
?	B-X

In	O
order	O
to	O
identify	O
regulatory	O
genes	O
,	O
we	O
determined	O
the	O
heritability	O
of	O
gene	O
transcripts	O
,	O
performed	O
linkage	O
analysis	O
to	O
identify	O
quantitative	O
trait	O
loci	O
(	O
QTLs	O
)	O
,	O
and	O
evaluated	O
the	O
evidence	O
for	O
shared	O
genetic	O
effects	O
among	O
transcripts	O
with	O
co	O
-	O
localized	O
QTLs	O
in	O
non	O
-	O
diseased	O
participants	B-Species
from	O
14	O
CEPH	O
(	O
Centre	O
d	O
'	O
Etude	O
du	O
Polymorphisme	O
Humain	O
)	O
Utah	O
families	O
.	O
<EOS>	B-X
In	B-X
order	B-X
to	B-X
identify	B-X
regulatory	B-X
genes	B-X
,	B-X
we	B-X
determined	B-X
the	B-X
heritability	B-X
of	B-X
gene	B-X
transcripts	B-X
,	B-X
performed	B-X
linkage	B-X
analysis	B-X
to	B-X
identify	B-X
quantitative	B-X
trait	B-X
loci	B-X
(	B-X
QTLs	B-X
)	B-X
,	B-X
and	B-X
evaluated	B-X
the	B-X
evidence	B-X
for	B-X
shared	B-X
genetic	B-X
effects	B-X
among	B-X
transcripts	B-X
with	B-X
co-localized	B-X
QTLs	B-X
in	B-X
non-diseased	B-X
participants	B-X
from	B-X
14	B-X
CEPH	B-X
(	B-X
Centre	B-X
d'Etude	B-X
du	B-X
Polymorphisme	B-X
Humain	B-X
)	B-X
Utah	B-X
families	B-X
.	B-X
Seventy-six	B-X
percent	B-X
of	B-X
transcripts	B-X
had	B-X
a	B-X
significant	B-X
heritability	B-X
and	B-X
54	B-X
%	B-X
of	B-X
them	B-X
had	B-X
LOD	B-X
score	B-X
>	B-X
or=	B-X
1.8	B-X
.	B-X
Bivariate	B-X
genetic	B-X
analysis	B-X
of	B-X
15	B-X
transcripts	B-X
that	B-X
had	B-X
co-localized	B-X
QTLs	B-X
on	B-X
4q28.2-q31.1	B-X
identified	B-X
significant	B-X
genetic	B-X
correlation	B-X
among	B-X
some	B-X
transcripts	B-X
although	B-X
no	B-X
improvement	B-X
in	B-X
the	B-X
magnitude	B-X
of	B-X
LOD	B-X
scores	B-X
in	B-X
this	B-X
region	B-X
was	B-X
noted	B-X
.	B-X
Similar	B-X
results	B-X
were	B-X
found	B-X
in	B-X
analysis	B-X
of	B-X
12	B-X
transcripts	B-X
,	B-X
that	B-X
had	B-X
co-localized	B-X
QTLs	B-X
in	B-X
the	B-X
13q34	B-X
region	B-X
.	B-X
Principal-component	B-X
analyses	B-X
did	B-X
not	B-X
improve	B-X
the	B-X
ability	B-X
to	B-X
identify	B-X
chromosomal	B-X
regions	B-X
of	B-X
co-localized	B-X
gene	B-X
expressions	B-X
.	B-X

Seventy	O
-	O
six	O
percent	O
of	O
transcripts	O
had	O
a	O
significant	O
heritability	O
and	O
54	O
%	O
of	O
them	O
had	O
LOD	O
score	O
>=	O
1	O
.	O
8	O
.	O
<EOS>	B-X
In	B-X
order	B-X
to	B-X
identify	B-X
regulatory	B-X
genes	B-X
,	B-X
we	B-X
determined	B-X
the	B-X
heritability	B-X
of	B-X
gene	B-X
transcripts	B-X
,	B-X
performed	B-X
linkage	B-X
analysis	B-X
to	B-X
identify	B-X
quantitative	B-X
trait	B-X
loci	B-X
(	B-X
QTLs	B-X
)	B-X
,	B-X
and	B-X
evaluated	B-X
the	B-X
evidence	B-X
for	B-X
shared	B-X
genetic	B-X
effects	B-X
among	B-X
transcripts	B-X
with	B-X
co-localized	B-X
QTLs	B-X
in	B-X
non-diseased	B-X
participants	B-X
from	B-X
14	B-X
CEPH	B-X
(	B-X
Centre	B-X
d'Etude	B-X
du	B-X
Polymorphisme	B-X
Humain	B-X
)	B-X
Utah	B-X
families	B-X
.	B-X
Seventy-six	B-X
percent	B-X
of	B-X
transcripts	B-X
had	B-X
a	B-X
significant	B-X
heritability	B-X
and	B-X
54	B-X
%	B-X
of	B-X
them	B-X
had	B-X
LOD	B-X
score	B-X
>	B-X
or=	B-X
1.8	B-X
.	B-X
Bivariate	B-X
genetic	B-X
analysis	B-X
of	B-X
15	B-X
transcripts	B-X
that	B-X
had	B-X
co-localized	B-X
QTLs	B-X
on	B-X
4q28.2-q31.1	B-X
identified	B-X
significant	B-X
genetic	B-X
correlation	B-X
among	B-X
some	B-X
transcripts	B-X
although	B-X
no	B-X
improvement	B-X
in	B-X
the	B-X
magnitude	B-X
of	B-X
LOD	B-X
scores	B-X
in	B-X
this	B-X
region	B-X
was	B-X
noted	B-X
.	B-X
Similar	B-X
results	B-X
were	B-X
found	B-X
in	B-X
analysis	B-X
of	B-X
12	B-X
transcripts	B-X
,	B-X
that	B-X
had	B-X
co-localized	B-X
QTLs	B-X
in	B-X
the	B-X
13q34	B-X
region	B-X
.	B-X

Bivariate	O
genetic	O
analysis	O
of	O
15	O
transcripts	O
that	O
had	O
co	O
-	O
localized	O
QTLs	O
on	O
4q28	O
.	O
2	O
-	O
q31	O
.	O
1	O
identified	O
significant	O
genetic	O
correlation	O
among	O
some	O
transcripts	O
although	O
no	O
improvement	O
in	O
the	O
magnitude	O
of	O
LOD	O
scores	O
in	O
this	O
region	O
was	O
noted	O
.	O
<EOS>	B-X
In	B-X
order	B-X
to	B-X
identify	B-X
regulatory	B-X
genes	B-X
,	B-X
we	B-X
determined	B-X
the	B-X
heritability	B-X
of	B-X
gene	B-X
transcripts	B-X
,	B-X
performed	B-X
linkage	B-X
analysis	B-X
to	B-X
identify	B-X
quantitative	B-X
trait	B-X
loci	B-X
(	B-X
QTLs	B-X
)	B-X
,	B-X
and	B-X
evaluated	B-X
the	B-X
evidence	B-X
for	B-X
shared	B-X
genetic	B-X
effects	B-X
among	B-X
transcripts	B-X
with	B-X
co-localized	B-X
QTLs	B-X
in	B-X
non-diseased	B-X
participants	B-X
from	B-X
14	B-X
CEPH	B-X
(	B-X
Centre	B-X
d'Etude	B-X
du	B-X
Polymorphisme	B-X
Humain	B-X
)	B-X
Utah	B-X
families	B-X
.	B-X
Seventy-six	B-X
percent	B-X
of	B-X
transcripts	B-X
had	B-X
a	B-X
significant	B-X
heritability	B-X
and	B-X
54	B-X
%	B-X
of	B-X
them	B-X
had	B-X
LOD	B-X
score	B-X
>	B-X
or=	B-X
1.8	B-X
.	B-X
Bivariate	B-X
genetic	B-X
analysis	B-X
of	B-X
15	B-X
transcripts	B-X
that	B-X
had	B-X
co-localized	B-X
QTLs	B-X
on	B-X
4q28.2-q31.1	B-X
identified	B-X
significant	B-X
genetic	B-X
correlation	B-X
among	B-X
some	B-X
transcripts	B-X
although	B-X
no	B-X
improvement	B-X
in	B-X
the	B-X
magnitude	B-X
of	B-X
LOD	B-X
scores	B-X
in	B-X
this	B-X
region	B-X
was	B-X
noted	B-X
.	B-X
Similar	B-X
results	B-X
were	B-X
found	B-X
in	B-X
analysis	B-X
of	B-X
12	B-X
transcripts	B-X
,	B-X
that	B-X
had	B-X
co-localized	B-X
QTLs	B-X
in	B-X
the	B-X
13q34	B-X
region	B-X
.	B-X
Principal-component	B-X
analyses	B-X
did	B-X
not	B-X
improve	B-X
the	B-X
ability	B-X
to	B-X
identify	B-X
chromosomal	B-X
regions	B-X
of	B-X
co-localized	B-X
gene	B-X
expressions	B-X
.	B-X

Similar	O
results	O
were	O
found	O
in	O
analysis	O
of	O
12	O
transcripts	O
,	O
that	O
had	O
co	O
-	O
localized	O
QTLs	O
in	O
the	O
13q34	O
region	O
.	O
<EOS>	B-X
In	B-X
order	B-X
to	B-X
identify	B-X
regulatory	B-X
genes	B-X
,	B-X
we	B-X
determined	B-X
the	B-X
heritability	B-X
of	B-X
gene	B-X
transcripts	B-X
,	B-X
performed	B-X
linkage	B-X
analysis	B-X
to	B-X
identify	B-X
quantitative	B-X
trait	B-X
loci	B-X
(	B-X
QTLs	B-X
)	B-X
,	B-X
and	B-X
evaluated	B-X
the	B-X
evidence	B-X
for	B-X
shared	B-X
genetic	B-X
effects	B-X
among	B-X
transcripts	B-X
with	B-X
co-localized	B-X
QTLs	B-X
in	B-X
non-diseased	B-X
participants	B-X
from	B-X
14	B-X
CEPH	B-X
(	B-X
Centre	B-X
d'Etude	B-X
du	B-X
Polymorphisme	B-X
Humain	B-X
)	B-X
Utah	B-X
families	B-X
.	B-X
Seventy-six	B-X
percent	B-X
of	B-X
transcripts	B-X
had	B-X
a	B-X
significant	B-X
heritability	B-X
and	B-X
54	B-X
%	B-X
of	B-X
them	B-X
had	B-X
LOD	B-X
score	B-X
>	B-X
or=	B-X
1.8	B-X
.	B-X
Bivariate	B-X
genetic	B-X
analysis	B-X
of	B-X
15	B-X
transcripts	B-X
that	B-X
had	B-X
co-localized	B-X
QTLs	B-X
on	B-X
4q28.2-q31.1	B-X
identified	B-X
significant	B-X
genetic	B-X
correlation	B-X
among	B-X
some	B-X
transcripts	B-X
although	B-X
no	B-X
improvement	B-X
in	B-X
the	B-X
magnitude	B-X
of	B-X
LOD	B-X
scores	B-X
in	B-X
this	B-X
region	B-X
was	B-X
noted	B-X
.	B-X
Similar	B-X
results	B-X
were	B-X
found	B-X
in	B-X
analysis	B-X
of	B-X
12	B-X
transcripts	B-X
,	B-X
that	B-X
had	B-X
co-localized	B-X
QTLs	B-X
in	B-X
the	B-X
13q34	B-X
region	B-X
.	B-X
Principal-component	B-X
analyses	B-X
did	B-X
not	B-X
improve	B-X
the	B-X
ability	B-X
to	B-X
identify	B-X
chromosomal	B-X
regions	B-X
of	B-X
co-localized	B-X
gene	B-X
expressions	B-X
.	B-X

Principal	O
-	O
component	O
analyses	O
did	O
not	O
improve	O
the	O
ability	O
to	O
identify	O
chromosomal	O
regions	O
of	O
co	O
-	O
localized	O
gene	O
expressions	O
.	O
<EOS>	B-X
Based	B-X
on	B-X
the	B-X
design	B-X
of	B-X
the	B-X
experiments	B-X
,	B-X
it	B-X
is	B-X
not	B-X
uncommon	B-X
for	B-X
these	B-X
analyses	B-X
to	B-X
include	B-X
matrices	B-X
of	B-X
thousands	B-X
of	B-X
variables	B-X
.	B-X
In	B-X
order	B-X
to	B-X
handle	B-X
such	B-X
large	B-X
datasets	B-X
,	B-X
many	B-X
have	B-X
turned	B-X
to	B-X
multivariate	B-X
statistical	B-X
analyses	B-X
to	B-X
analyze	B-X
and	B-X
understand	B-X
their	B-X
data	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
present	B-X
protocols	B-X
for	B-X
using	B-X
R	B-X
to	B-X
analyze	B-X
metabolomic	B-X
data	B-X
using	B-X
some	B-X
of	B-X
the	B-X
more	B-X
common	B-X
multivariate	B-X
statistical	B-X
techniques	B-X
.	B-X
Principal	B-X
components	B-X
(	B-X
PCs	B-X
)	B-X
are	B-X
widely	B-X
used	B-X
in	B-X
statistics	B-X
and	B-X
refer	B-X
to	B-X
a	B-X
relatively	B-X
small	B-X
number	B-X
of	B-X
uncorrelated	B-X
variables	B-X
derived	B-X
from	B-X
an	B-X
initial	B-X
pool	B-X
of	B-X
variables	B-X
,	B-X
while	B-X
explaining	B-X
as	B-X
much	B-X
of	B-X
the	B-X
total	B-X
variance	B-X
as	B-X
possible	B-X
.	B-X
Also	B-X
in	B-X
statistical	B-X
genetics	B-X
,	B-X
principal	B-X
component	B-X
analysis	B-X
(	B-X
PCA	B-X
)	B-X
is	B-X
a	B-X
popular	B-X
technique	B-X
.	B-X
To	B-X
achieve	B-X
optimal	B-X
results	B-X
,	B-X
a	B-X
thorough	B-X
understanding	B-X
about	B-X
the	B-X
different	B-X
implementations	B-X
of	B-X
PCA	B-X
is	B-X
required	B-X
and	B-X
their	B-X
impact	B-X
on	B-X
study	B-X
results	B-X
,	B-X
compared	B-X
to	B-X
alternative	B-X
approaches	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
focus	B-X
on	B-X
the	B-X
possibilities	B-X
,	B-X
limitations	B-X
and	B-X
role	B-X
of	B-X
PCs	B-X
in	B-X
ancestry	B-X
prediction	B-X
,	B-X
genome-wide	B-X
association	B-X
studies	B-X
,	B-X
rare	B-X
variants	B-X
analyses	B-X
,	B-X
imputation	B-X
strategies	B-X
,	B-X
meta-analysis	B-X
and	B-X
epistasis	B-X
detection	B-X
.	B-X
We	B-X
also	B-X
describe	B-X
several	B-X
variations	B-X
of	B-X
classic	B-X
PCA	B-X
that	B-X
deserve	B-X
increased	B-X
attention	B-X
in	B-X
statistical	B-X
genetics	B-X
applications	B-X
.	B-X

Background	O
<EOS>	B-X
Background	B-X
matching	B-X
is	B-X
the	B-X
most	B-X
familiar	B-X
and	B-X
widespread	B-X
camouflage	B-X
strategy	B-X
:	B-X
avoiding	B-X
detection	B-X
by	B-X
having	B-X
a	B-X
similar	B-X
colour	B-X
and	B-X
pattern	B-X
to	B-X
the	B-X
background	B-X
.	B-X
Background	B-X
is	B-X
thus	B-X
a	B-X
relatively	B-X
modest	B-X
correction	B-X
for	B-X
all	B-X
Z	B-X
opacity	B-X
data	B-X
published	B-X
to	B-X
date	B-X
.	B-X
Background	B-X
estimation	B-X
and	B-X
foreground	B-X
segmentation	B-X
are	B-X
important	B-X
steps	B-X
in	B-X
many	B-X
high-level	B-X
vision	B-X
tasks	B-X
.	B-X
Patient	B-X
Preference	B-X
for	B-X
Telehealth	B-X
Background	B-X
Shapes	B-X
Impressions	B-X
of	B-X
Physicians	B-X
and	B-X
Information	B-X
Recall	B-X
:	B-X
A	B-X
Randomized	B-X
Experiment	B-X
.	B-X

There	O
is	O
a	O
breadth	O
of	O
information	O
being	O
generated	O
by	O
the	O
Human	B-Species
Genome	O
Project	O
and	O
the	O
interpretation	O
of	O
these	O
data	O
has	O
been	O
a	O
major	O
area	O
of	O
research	O
.	O

For	O
simple	O
Mendelian	O
disorders	O
,	O
the	O
identification	O
of	O
genetic	O
effects	O
is	O
fairly	O
straightforward	O
due	O
to	O
understanding	O
the	O
biology	O
that	O
drives	O
these	O
disorders	O
.	O

However	O
,	O
for	O
complex	O
oligogenic	O
or	O
polygenic	O
disorders	O
,	O
understanding	O
all	O
the	O
interconnections	O
between	O
genes	O
influencing	O
a	O
trait	O
is	O
a	O
difficult	O
task	O
because	O
the	O
understanding	O
of	O
the	O
biology	O
of	O
many	O
of	O
these	O
disorders	O
is	O
still	O
evolving	O
.	O
<EOS>	B-X
The	B-X
discovery	B-X
of	B-X
genes	B-X
associated	B-X
with	B-X
amyotrophic	B-X
lateral	B-X
sclerosis	B-X
,	B-X
commencing	B-X
with	B-X
SOD1	B-X
in	B-X
1993	B-X
,	B-X
started	B-X
fairly	B-X
gradually	B-X
.	B-X
Recent	B-X
advances	B-X
in	B-X
genetic	B-X
technology	B-X
have	B-X
led	B-X
to	B-X
the	B-X
rapid	B-X
identification	B-X
of	B-X
multiple	B-X
new	B-X
genes	B-X
associated	B-X
with	B-X
the	B-X
disease	B-X
,	B-X
and	B-X
to	B-X
a	B-X
new	B-X
understanding	B-X
of	B-X
oligogenic	B-X
and	B-X
polygenic	B-X
disease	B-X
risk	B-X
.	B-X
The	B-X
overlap	B-X
of	B-X
genes	B-X
associated	B-X
with	B-X
amyotrophic	B-X
lateral	B-X
sclerosis	B-X
with	B-X
those	B-X
of	B-X
other	B-X
neurodegenerative	B-X
diseases	B-X
is	B-X
shedding	B-X
light	B-X
on	B-X
the	B-X
phenotypic	B-X
spectrum	B-X
of	B-X
neurodegeneration	B-X
,	B-X
leading	B-X
to	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
genotype-phenotype	B-X
correlations	B-X
.	B-X
Our	B-X
improved	B-X
understanding	B-X
of	B-X
all	B-X
these	B-X
aspects	B-X
will	B-X
lead	B-X
to	B-X
long-awaited	B-X
therapies	B-X
and	B-X
the	B-X
identification	B-X
of	B-X
modifiable	B-X
risks	B-X
factors	B-X
.	B-X

Multiple	O
gene	O
x	O
gene	O
and	O
gene	O
x	O
environment	O
interactions	O
can	O
influence	O
the	O
expression	O
of	O
phenotypes	O
.	O

Genes	O
can	O
interact	O
by	O
modifying	O
the	O
expression	O
of	O
other	O
genes	O
and	O
therefore	O
function	O
as	O
regulatory	O
genes	O
[	O
1	O
]	O
.	O
<EOS>	B-X
Cancer	B-X
statistics	B-X
in	B-X
2018	B-X
highlight	B-X
an	B-X
8.6	B-X
million	B-X
incidence	B-X
in	B-X
female	B-X
cancers	B-X
,	B-X
and	B-X
4.2	B-X
million	B-X
cancer	B-X
deaths	B-X
globally	B-X
.	B-X
This	B-X
provides	B-X
only	B-X
a	B-X
small	B-X
chance	B-X
for	B-X
successful	B-X
therapy	B-X
,	B-X
and	B-X
identification	B-X
of	B-X
new	B-X
molecular	B-X
markers	B-X
for	B-X
the	B-X
diagnosis	B-X
and	B-X
prognostic	B-X
prediction	B-X
of	B-X
metastatic	B-X
disease	B-X
and	B-X
development	B-X
of	B-X
innovative	B-X
therapeutic	B-X
molecules	B-X
are	B-X
therefore	B-X
urgently	B-X
required	B-X
.	B-X
Differentially	B-X
expressed	B-X
microRNAs	B-X
(	B-X
miRNAs	B-X
)	B-X
in	B-X
cancers	B-X
cause	B-X
multiple	B-X
changes	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
tumorigenesis-promoting	B-X
genes	B-X
which	B-X
have	B-X
mostly	B-X
been	B-X
investigated	B-X
in	B-X
breast	B-X
cancers	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
summarize	B-X
recent	B-X
data	B-X
on	B-X
breast	B-X
cancer-specific	B-X
miRNA	B-X
expression	B-X
profiles	B-X
and	B-X
their	B-X
participation	B-X
in	B-X
regulating	B-X
invasive	B-X
processes	B-X
,	B-X
in	B-X
association	B-X
with	B-X
changes	B-X
in	B-X
cytoskeletal	B-X
structure	B-X
,	B-X
cell-cell	B-X
adhesion	B-X
junctions	B-X
,	B-X
cancer	B-X
cell-extracellular	B-X
matrix	B-X
interactions	B-X
,	B-X
tumor	B-X
microenvironments	B-X
,	B-X
epithelial-to-mesenchymal	B-X
transitions	B-X
and	B-X
cancer	B-X
cell	B-X
stem	B-X
abilities	B-X
.	B-X
We	B-X
then	B-X
focused	B-X
on	B-X
the	B-X
epigenetic	B-X
regulation	B-X
of	B-X
individual	B-X
miRNAs	B-X
and	B-X
their	B-X
modified	B-X
interactions	B-X
with	B-X
other	B-X
regulatory	B-X
genes	B-X
,	B-X
and	B-X
reviewed	B-X
the	B-X
function	B-X
of	B-X
miRNA	B-X
isoforms	B-X
and	B-X
exosome-mediated	B-X
miRNA	B-X
transfer	B-X
in	B-X
cancer	B-X
invasiveness	B-X
.	B-X
Although	B-X
research	B-X
into	B-X
miRNA	B-X
's	B-X
function	B-X
in	B-X
cancer	B-X
is	B-X
still	B-X
ongoing	B-X
,	B-X
results	B-X
herein	B-X
contribute	B-X
to	B-X
improved	B-X
metastatic	B-X
cancer	B-X
management	B-X
.	B-X

In	O
an	O
effort	O
to	O
dissect	O
some	O
of	O
these	O
complexities	O
,	O
we	O
performed	O
linkage	O
analysis	O
of	O
gene	O
expression	O
transcripts	O
of	O
members	O
of	O
Centre	O
d	O
'	O
Etude	O
du	O
Polymorphisme	O
Humain	O
(	O
CEPH	O
)	O
Utah	O
families	O
to	O
determine	O
the	O
heritability	O
of	O
transcripts	O
and	O
the	O
evidence	O
for	O
regulatory	O
quantitative	O
trait	O
loci	O
(	O
QTLs	O
)	O
and	O
we	O
performed	O
pairwise	O
bivariate	O
linkage	O
analysis	O
and	O
principal	O
-	O
component	O
analysis	O
(	O
PCA	O
)	O
for	O
data	O
-	O
reduction	O
to	O
evaluate	O
the	O
evidence	O
for	O
shared	O
genetic	O
effects	O
.	O

The	O
ability	O
to	O
assess	O
gene	O
expression	O
traits	O
simultaneously	O
and	O
to	O
link	O
them	O
to	O
QTLs	O
offers	O
the	O
possibility	O
of	O
identifying	O
previously	O
unknown	O
underlying	O
molecular	O
processes	O
for	O
future	O
investigation	O
.	O

Methods	O
<EOS>	B-X
Methods	B-X
to	B-X
calculate	B-X
the	B-X
sample	B-X
size	B-X
are	B-X
explained	B-X
in	B-X
statistical	B-X
textbooks	B-X
,	B-X
but	B-X
because	B-X
there	B-X
are	B-X
many	B-X
different	B-X
formulas	B-X
available	B-X
,	B-X
it	B-X
can	B-X
be	B-X
difficult	B-X
for	B-X
investigators	B-X
to	B-X
decide	B-X
which	B-X
method	B-X
to	B-X
use	B-X
.	B-X

Population	O
and	O
phenotypes	O
<EOS>	B-X
Together	B-X
,	B-X
these	B-X
analyses	B-X
reveal	B-X
that	B-X
our	B-X
statistic	B-X
can	B-X
aid	B-X
in	B-X
uncovering	B-X
genes	B-X
involved	B-X
in	B-X
population-specific	B-X
genetic	B-X
and	B-X
expression	B-X
differentiation	B-X
,	B-X
and	B-X
that	B-X
such	B-X
genes	B-X
often	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
a	B-X
diversity	B-X
of	B-X
adaptive	B-X
and	B-X
disease-related	B-X
phenotypes	B-X
in	B-X
humans	B-X
.	B-X
The	B-X
pursuit	B-X
to	B-X
discover	B-X
the	B-X
fundamental	B-X
biology	B-X
and	B-X
mechanisms	B-X
of	B-X
aging	B-X
within	B-X
the	B-X
context	B-X
of	B-X
the	B-X
physical	B-X
and	B-X
social	B-X
environment	B-X
is	B-X
critical	B-X
to	B-X
designing	B-X
interventions	B-X
to	B-X
prevent	B-X
and	B-X
treat	B-X
its	B-X
complex	B-X
phenotypes	B-X
.	B-X
We	B-X
further	B-X
suggest	B-X
that	B-X
it	B-X
will	B-X
be	B-X
important	B-X
to	B-X
explore	B-X
results	B-X
in	B-X
homogeneous	B-X
population	B-X
subsets	B-X
as	B-X
we	B-X
seek	B-X
to	B-X
define	B-X
the	B-X
extent	B-X
to	B-X
which	B-X
genomic	B-X
variation	B-X
influences	B-X
complex	B-X
phenotypes	B-X
.	B-X
We	B-X
performed	B-X
a	B-X
systematic	B-X
review	B-X
designed	B-X
to	B-X
characterize	B-X
clinical	B-X
phenotypes	B-X
and	B-X
outcomes	B-X
in	B-X
Indigenous	B-X
populations	B-X
with	B-X
rheumatic	B-X
disease	B-X
to	B-X
enhance	B-X
the	B-X
understanding	B-X
of	B-X
how	B-X
rheumatic	B-X
disease	B-X
presents	B-X
in	B-X
Indigenous	B-X
populations	B-X
and	B-X
allow	B-X
for	B-X
better	B-X
projection	B-X
of	B-X
the	B-X
healthcare	B-X
needs	B-X
of	B-X
the	B-X
communities	B-X
affected	B-X
.	B-X

We	O
used	O
the	O
Genetic	O
Analysis	O
Workshop	O
15	O
(	O
GAW	O
15	O
)	O
Problem	O
1	O
microarray	O
gene	O
expression	O
profiles	O
for	O
the	O
analyses	O
.	O

Data	O
were	O
available	O
for	O
14	O
three	O
-	O
generation	O
CEPH	O
Utah	O
families	O
.	O

Expression	O
levels	O
of	O
genes	O
were	O
obtained	O
from	O
lymphoblastoid	O
cells	O
using	O
the	O
Affymetrix	O
Human	B-Species
Focus	O
Arrays	O
[	O
2	O
]	O
.	O

We	O
were	O
provided	O
with	O
data	O
on	O
3554	O
transcripts	O
that	O
showed	O
greater	O
variation	O
between	O
individuals	O
than	O
within	O
the	O
same	O
individual	O
.	O

Family	O
members	O
were	O
genotyped	O
for	O
2882	O
autosomal	O
and	O
X	O
-	O
linked	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNP	O
)	O
generated	O
by	O
the	O
SNP	O
Consortium	O
.	O

Genetic	O
map	O
positions	O
were	O
obtained	O
using	O
the	O
SNP	O
Mapping	O
web	O
application	O
developed	O
by	O
the	O
University	O
College	O
Dublin	O
Conway	O
Institute	O
of	O
Biomolecular	O
and	O
Biomedical	O
Research	O
,	O
which	O
uses	O
the	O
Rutgers	O
Combined	O
Linkage	O
-	O
Physical	O
Map	O
of	O
the	O
Human	B-Species
Genome	O
and	O
data	O
taken	O
from	O
the	O
NCBI	O
dbSNP	O
Build	O
123	O
(	O
in	O
Kosambi	O
centimorgans	O
)	O
.	O

This	O
information	O
was	O
used	O
to	O
calculate	O
multipoint	O
identity	O
by	O
descent	O
matrices	O
(	O
MIBDs	O
)	O
with	O
Merlin	O
and	O
Minx	O
[	O
3	O
]	O
,	O
after	O
removal	O
of	O
Mendelian	O
inconsistencies	O
and	O
double	O
recombinants	O
with	O
Preswalk	O
(	O
based	O
on	O
Simwalk	O
mistyping	O
probabilities	O
)	O
[	O
4	O
]	O
.	O

MIBDs	O
were	O
used	O
for	O
linkage	O
analyses	O
.	O

Transcript	O
distributions	O
were	O
normalized	O
using	O
an	O
inverse	O
normalization	O
transformation	O
of	O
z	O
-	O
scores	O
of	O
individual	O
transcripts	O
regressed	O
on	O
the	O
mean	O
individual	O
transcript	O
level	O
.	O

We	O
further	O
adjusted	O
for	O
the	O
effects	O
of	O
age	O
,	O
age2	O
,	O
sex	O
,	O
age	O
x	O
sex	O
and	O
age2	O
x	O
sex	O
interaction	O
using	O
predictive	O
linear	O
regression	O
models	O
in	O
SAS	O
9	O
.	O
1	O
(	O
Cary	O
,	O
NC	O
)	O
.	O

We	O
generated	O
these	O
residuals	O
as	O
part	O
of	O
our	O
processing	O
of	O
the	O
transcripts	O
for	O
linkage	O
analyses	O
.	O

Heritability	O
estimation	O
and	O
linkage	O
analysis	O
<EOS>	B-X
Compared	B-X
to	B-X
medium-density	B-X
single	B-X
nucleotide	B-X
polymorphism	B-X
(	B-X
SNP	B-X
)	B-X
data	B-X
,	B-X
high-density	B-X
SNP	B-X
data	B-X
contain	B-X
abundant	B-X
genetic	B-X
variants	B-X
and	B-X
provide	B-X
more	B-X
information	B-X
for	B-X
the	B-X
genetic	B-X
evaluation	B-X
of	B-X
livestock	B-X
,	B-X
but	B-X
it	B-X
has	B-X
been	B-X
shown	B-X
that	B-X
they	B-X
do	B-X
not	B-X
confer	B-X
any	B-X
advantage	B-X
for	B-X
genomic	B-X
prediction	B-X
and	B-X
heritability	B-X
estimation	B-X
.	B-X
One	B-X
possible	B-X
reason	B-X
is	B-X
the	B-X
uneven	B-X
distribution	B-X
of	B-X
the	B-X
linkage	B-X
disequilibrium	B-X
(	B-X
LD	B-X
)	B-X
along	B-X
the	B-X
genome	B-X
,	B-X
i.e.	B-X
,	B-X
LD	B-X
heterogeneity	B-X
among	B-X
regions	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
effectively	B-X
use	B-X
genome-wide	B-X
SNP	B-X
data	B-X
for	B-X
genomic	B-X
prediction	B-X
and	B-X
heritability	B-X
estimation	B-X
by	B-X
using	B-X
models	B-X
that	B-X
control	B-X
LD	B-X
heterogeneity	B-X
among	B-X
regions	B-X
.	B-X
Through	B-X
candidate	B-X
gene	B-X
,	B-X
genomewide	B-X
linkage	B-X
,	B-X
and	B-X
genomewide	B-X
association	B-X
studies	B-X
,	B-X
over	B-X
50	B-X
vitiligo	B-X
susceptibility	B-X
loci	B-X
have	B-X
been	B-X
discovered	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
summarize	B-X
progress	B-X
to	B-X
date	B-X
including	B-X
dissection	B-X
of	B-X
heritability	B-X
,	B-X
discovery	B-X
of	B-X
vitiligo	B-X
susceptibility	B-X
loci	B-X
through	B-X
candidate	B-X
gene	B-X
,	B-X
genomewide	B-X
linkage	B-X
,	B-X
and	B-X
genomewide	B-X
association	B-X
studies	B-X
,	B-X
relationships	B-X
to	B-X
other	B-X
autoimmune	B-X
diseases	B-X
,	B-X
polygenic	B-X
architecture	B-X
of	B-X
vitiligo	B-X
risk	B-X
,	B-X
vitiligo	B-X
triggering	B-X
,	B-X
and	B-X
disease	B-X
onset	B-X
,	B-X
and	B-X
provide	B-X
suggestions	B-X
for	B-X
future	B-X
directions	B-X
.	B-X

Heritability	O
was	O
estimated	O
using	O
maximum	O
likelihood	O
variance	O
decomposition	O
methods	O
in	O
SOLAR	O
[	O
5	O
,	O
6	O
]	O
.	O

Genome	O
scans	O
were	O
performed	O
using	O
multipoint	O
variance	O
-	O
components	O
models	O
that	O
test	O
for	O
linkage	O
between	O
traits	O
and	O
genetic	O
variants	O
by	O
partitioning	O
the	O
variance	O
of	O
the	O
expression	O
level	O
into	O
its	O
additive	O
genetic	O
and	O
environmental	O
variance	O
components	O
[	O
7	O
]	O
.	O

For	O
transcripts	O
with	O
co	O
-	O
localized	O
QTLs	O
,	O
we	O
performed	O
bivariate	O
linkage	O
analysis	O
to	O
identify	O
shared	O
genetic	O
effects	O
.	O
<EOS>	B-X
In	B-X
order	B-X
to	B-X
identify	B-X
regulatory	B-X
genes	B-X
,	B-X
we	B-X
determined	B-X
the	B-X
heritability	B-X
of	B-X
gene	B-X
transcripts	B-X
,	B-X
performed	B-X
linkage	B-X
analysis	B-X
to	B-X
identify	B-X
quantitative	B-X
trait	B-X
loci	B-X
(	B-X
QTLs	B-X
)	B-X
,	B-X
and	B-X
evaluated	B-X
the	B-X
evidence	B-X
for	B-X
shared	B-X
genetic	B-X
effects	B-X
among	B-X
transcripts	B-X
with	B-X
co-localized	B-X
QTLs	B-X
in	B-X
non-diseased	B-X
participants	B-X
from	B-X
14	B-X
CEPH	B-X
(	B-X
Centre	B-X
d'Etude	B-X
du	B-X
Polymorphisme	B-X
Humain	B-X
)	B-X
Utah	B-X
families	B-X
.	B-X
Seventy-six	B-X
percent	B-X
of	B-X
transcripts	B-X
had	B-X
a	B-X
significant	B-X
heritability	B-X
and	B-X
54	B-X
%	B-X
of	B-X
them	B-X
had	B-X
LOD	B-X
score	B-X
>	B-X
or=	B-X
1.8	B-X
.	B-X
Bivariate	B-X
genetic	B-X
analysis	B-X
of	B-X
15	B-X
transcripts	B-X
that	B-X
had	B-X
co-localized	B-X
QTLs	B-X
on	B-X
4q28.2-q31.1	B-X
identified	B-X
significant	B-X
genetic	B-X
correlation	B-X
among	B-X
some	B-X
transcripts	B-X
although	B-X
no	B-X
improvement	B-X
in	B-X
the	B-X
magnitude	B-X
of	B-X
LOD	B-X
scores	B-X
in	B-X
this	B-X
region	B-X
was	B-X
noted	B-X
.	B-X
Similar	B-X
results	B-X
were	B-X
found	B-X
in	B-X
analysis	B-X
of	B-X
12	B-X
transcripts	B-X
,	B-X
that	B-X
had	B-X
co-localized	B-X
QTLs	B-X
in	B-X
the	B-X
13q34	B-X
region	B-X
.	B-X
Principal-component	B-X
analyses	B-X
did	B-X
not	B-X
improve	B-X
the	B-X
ability	B-X
to	B-X
identify	B-X
chromosomal	B-X
regions	B-X
of	B-X
co-localized	B-X
gene	B-X
expressions	B-X
.	B-X

The	O
bivariate	O
polygenic	O
model	O
estimates	O
correlations	O
caused	O
by	O
residual	O
additive	O
genetic	O
effects	O
(	O
rho	O
G	O
)	O
and	O
correlations	O
caused	O
by	O
random	O
environmental	O
effects	O
(	O
rho	O
E	O
)	O
[	O
8	O
]	O
.	O

To	O
test	O
for	O
additive	O
genetic	O
correlation	O
among	O
pairs	O
of	O
traits	O
,	O
the	O
log	O
likelihood	O
of	O
a	O
model	O
in	O
which	O
rho	O
G	O
is	O
constrained	O
to	O
0	O
(	O
null	O
hypothesis	O
,	O
no	O
correlation	O
)	O
or	O
rho	O
G	O
=	O
1	O
(	O
null	O
hypothesis	O
,	O
complete	O
shared	O
genetic	O
effect	O
)	O
is	O
compared	O
to	O
that	O
of	O
a	O
model	O
in	O
which	O
rho	O
G	O
is	O
estimated	O
for	O
the	O
traits	O
.	O

Significant	O
differences	O
among	O
the	O
models	O
(	O
rho	O
G	O
!=	O
0	O
)	O
suggest	O
that	O
some	O
of	O
the	O
same	O
genes	O
influence	O
both	O
traits	O
.	O

We	O
also	O
performed	O
linkage	O
analysis	O
using	O
the	O
factors	O
obtained	O
from	O
the	O
PCA	O
in	O
a	O
sample	O
of	O
transcripts	O
with	O
co	O
-	O
localized	O
QTLs	O
.	O

Principal	O
-	O
component	O
analysis	O
<EOS>	B-X
What	B-X
is	B-X
principal	B-X
component	B-X
analysis	B-X
?	B-X
It	B-X
has	B-X
become	B-X
commonplace	B-X
to	B-X
employ	B-X
principal	B-X
component	B-X
analysis	B-X
to	B-X
reveal	B-X
the	B-X
most	B-X
important	B-X
motions	B-X
in	B-X
proteins	B-X
.	B-X
While	B-X
most	B-X
popular	B-X
molecular	B-X
dynamics	B-X
packages	B-X
inevitably	B-X
provide	B-X
PCA	B-X
tools	B-X
to	B-X
analyze	B-X
protein	B-X
trajectories	B-X
,	B-X
researchers	B-X
often	B-X
make	B-X
inferences	B-X
of	B-X
their	B-X
results	B-X
without	B-X
having	B-X
insight	B-X
into	B-X
how	B-X
to	B-X
make	B-X
interpretations	B-X
,	B-X
and	B-X
they	B-X
are	B-X
often	B-X
unaware	B-X
of	B-X
limitations	B-X
and	B-X
generalizations	B-X
of	B-X
such	B-X
analysis	B-X
.	B-X
The	B-X
kernel	B-X
principal	B-X
component	B-X
analysis	B-X
(	B-X
KPCA	B-X
)	B-X
serves	B-X
as	B-X
an	B-X
efficient	B-X
approach	B-X
for	B-X
dimensionality	B-X
reduction	B-X
.	B-X
To	B-X
strengthen	B-X
the	B-X
robustness	B-X
of	B-X
KPCA	B-X
method	B-X
,	B-X
we	B-X
propose	B-X
a	B-X
novel	B-X
robust	B-X
kernel	B-X
principal	B-X
component	B-X
analysis	B-X
with	B-X
optimal	B-X
mean	B-X
(	B-X
RKPCA-OM	B-X
)	B-X
method	B-X
.	B-X

PCA	O
was	O
used	O
to	O
reduce	O
the	O
number	O
of	O
expression	O
profiles	O
into	O
statistically	O
meaningful	O
groups	O
while	O
retaining	O
the	O
original	O
total	O
variance	O
using	O
all	O
the	O
expression	O
profiles	O
[	O
9	O
,	O
10	O
]	O
.	O

We	O
selected	O
two	O
different	O
chromosomal	O
regions	O
of	O
a	O
length	O
of	O
10	O
to	O
12	O
MB	O
in	O
which	O
the	O
QTLs	O
of	O
at	O
least	O
10	O
transcripts	O
were	O
co	O
-	O
localized	O
.	O

Only	O
transcripts	O
of	O
genes	O
that	O
were	O
not	O
located	O
in	O
these	O
selected	O
chromosomal	O
regions	O
were	O
included	O
in	O
the	O
analyses	O
(	O
trans	O
-	O
regulatory	O
genes	O
)	O
.	O
<EOS>	B-X
In	B-X
cells	B-X
,	B-X
MYC	B-X
binds	B-X
DNA	B-X
preferentially	B-X
within	B-X
transcriptionally	B-X
active	B-X
promoter	B-X
regions	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
binding	B-X
site	B-X
recognition	B-X
is	B-X
determined	B-X
by	B-X
low-affinity	B-X
protein-protein	B-X
interactions	B-X
between	B-X
MYC/MAX	B-X
dimers	B-X
and	B-X
components	B-X
of	B-X
the	B-X
basal	B-X
transcriptional	B-X
machinery	B-X
,	B-X
other	B-X
chromatin-associated	B-X
protein	B-X
complexes	B-X
,	B-X
and/or	B-X
DNA-bound	B-X
transcription	B-X
factors	B-X
.	B-X
This	B-X
model	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
invasion	B-X
of	B-X
all	B-X
active	B-X
promoters	B-X
that	B-X
occurs	B-X
at	B-X
elevated	B-X
MYC	B-X
levels	B-X
,	B-X
but	B-X
posits	B-X
that	B-X
important	B-X
differences	B-X
in	B-X
affinity	B-X
persist	B-X
between	B-X
physiological	B-X
target	B-X
sites	B-X
and	B-X
the	B-X
newly	B-X
invaded	B-X
elements	B-X
,	B-X
which	B-X
may	B-X
not	B-X
all	B-X
be	B-X
bound	B-X
in	B-X
a	B-X
productive	B-X
regulatory	B-X
mode	B-X
.	B-X
The	B-X
implications	B-X
of	B-X
this	B-X
model	B-X
for	B-X
transcriptional	B-X
control	B-X
by	B-X
MYC	B-X
in	B-X
normal	B-X
and	B-X
cancer	B-X
cells	B-X
are	B-X
discussed	B-X
in	B-X
the	B-X
light	B-X
of	B-X
the	B-X
latest	B-X
literature	B-X
.	B-X

Because	O
of	O
the	O
small	O
number	O
of	O
individuals	O
in	O
the	O
study	O
and	O
concerns	O
of	O
overfitting	O
the	O
model	O
,	O
a	O
maximum	O
sample	O
of	O
50	O
transcript	O
values	O
were	O
considered	O
at	O
one	O
time	O
[	O
11	O
]	O
.	O

The	O
number	O
of	O
factors	O
was	O
determined	O
using	O
the	O
eigenvalue	O
-	O
one	O
requirement	O
[	O
11	O
]	O
.	O
<EOS>	B-X
One	B-X
of	B-X
the	B-X
most	B-X
significant	B-X
challenges	B-X
when	B-X
one	B-X
is	B-X
performing	B-X
EFA	B-X
is	B-X
determining	B-X
how	B-X
many	B-X
factors	B-X
to	B-X
retain	B-X
.	B-X
Parallel	B-X
analysis	B-X
(	B-X
PA	B-X
)	B-X
is	B-X
an	B-X
effective	B-X
stopping	B-X
rule	B-X
that	B-X
compares	B-X
the	B-X
eigenvalues	B-X
of	B-X
randomly	B-X
generated	B-X
data	B-X
with	B-X
those	B-X
for	B-X
the	B-X
actual	B-X
data	B-X
.	B-X
Comparison	B-X
data	B-X
(	B-X
CD	B-X
)	B-X
with	B-X
known	B-X
factorial	B-X
structure	B-X
are	B-X
first	B-X
generated	B-X
using	B-X
1	B-X
factor	B-X
,	B-X
and	B-X
then	B-X
the	B-X
number	B-X
of	B-X
factors	B-X
is	B-X
increased	B-X
until	B-X
the	B-X
reproduction	B-X
of	B-X
the	B-X
observed	B-X
eigenvalues	B-X
fails	B-X
to	B-X
improve	B-X
significantly	B-X
.	B-X
Our	B-X
first	B-X
goal	B-X
is	B-X
to	B-X
establish	B-X
how	B-X
the	B-X
rank	B-X
of	B-X
a	B-X
typical	B-X
geometric	B-X
morphometric	B-X
covariance	B-X
matrix	B-X
relates	B-X
to	B-X
the	B-X
information	B-X
entropy	B-X
of	B-X
its	B-X
eigenvalue	B-X
spectrum	B-X
.	B-X
This	B-X
requires	B-X
clear	B-X
definitions	B-X
of	B-X
matrix	B-X
rank	B-X
,	B-X
of	B-X
which	B-X
we	B-X
define	B-X
three	B-X
:	B-X
the	B-X
full	B-X
matrix	B-X
rank	B-X
(	B-X
equal	B-X
to	B-X
the	B-X
number	B-X
of	B-X
input	B-X
variables	B-X
)	B-X
,	B-X
the	B-X
mathematical	B-X
rank	B-X
(	B-X
the	B-X
number	B-X
of	B-X
nonzero	B-X
eigenvalues	B-X
)	B-X
,	B-X
and	B-X
the	B-X
information	B-X
rank	B-X
or	B-X
``	B-X
effective	B-X
rank	B-X
''	B-X
(	B-X
equal	B-X
to	B-X
the	B-X
number	B-X
of	B-X
nonredundant	B-X
eigenvalues	B-X
)	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
effective	B-X
rank	B-X
deficiency	B-X
arises	B-X
from	B-X
a	B-X
combination	B-X
of	B-X
methodological	B-X
factors-Generalized	B-X
Procrustes	B-X
analysis	B-X
,	B-X
use	B-X
of	B-X
the	B-X
correlation	B-X
matrix	B-X
,	B-X
and	B-X
insufficient	B-X
sample	B-X
size-as	B-X
well	B-X
as	B-X
phenotypic	B-X
covariance	B-X
.	B-X
The	B-X
eigenvalue	B-X
variance	B-X
characterizes	B-X
the	B-X
integration	B-X
change	B-X
incorrectly	B-X
,	B-X
and	B-X
the	B-X
standardized	B-X
generalized	B-X
variance	B-X
lacks	B-X
the	B-X
sensitivity	B-X
needed	B-X
to	B-X
detect	B-X
subtle	B-X
changes	B-X
in	B-X
integration	B-X
.	B-X
Both	B-X
metrics	B-X
are	B-X
impacted	B-X
by	B-X
the	B-X
inclusion	B-X
of	B-X
many	B-X
small	B-X
,	B-X
but	B-X
nonzero	B-X
,	B-X
eigenvalues	B-X
arising	B-X
from	B-X
a	B-X
lack	B-X
of	B-X
information	B-X
in	B-X
the	B-X
covariance	B-X
matrix	B-X
,	B-X
a	B-X
problem	B-X
that	B-X
usually	B-X
becomes	B-X
more	B-X
pronounced	B-X
as	B-X
the	B-X
number	B-X
of	B-X
landmarks	B-X
increases	B-X
.	B-X
This	B-X
metric	B-X
is	B-X
equivalent	B-X
to	B-X
the	B-X
standardized	B-X
generalized	B-X
variance	B-X
but	B-X
calculated	B-X
only	B-X
from	B-X
those	B-X
eigenvalues	B-X
that	B-X
carry	B-X
nonredundant	B-X
information	B-X
.	B-X
It	B-X
is	B-X
the	B-X
standardized	B-X
generalized	B-X
variance	B-X
scaled	B-X
to	B-X
the	B-X
effective	B-X
rank	B-X
of	B-X
the	B-X
eigenvalue	B-X
spectrum	B-X
.	B-X
Our	B-X
third	B-X
goal	B-X
is	B-X
to	B-X
generalize	B-X
the	B-X
new	B-X
metric	B-X
to	B-X
compare	B-X
data	B-X
sets	B-X
with	B-X
different	B-X
sample	B-X
sizes	B-X
and	B-X
numbers	B-X
of	B-X
variables	B-X
.	B-X

Factors	O
are	O
interpreted	O
by	O
examining	O
the	O
varimax	O
-	O
rotated	O
factor	O
loadings	O
,	O
which	O
are	O
the	O
correlations	O
between	O
each	O
phenotype	O
and	O
the	O
factor	O
in	O
question	O
.	O

Factor	O
loadings	O
greater	O
than	O
or	O
equal	O
to	O
0	O
.	O
40	O
in	O
absolute	O
value	O
were	O
used	O
to	O
interpret	O
factors	O
and	O
to	O
characterize	O
the	O
factor	O
structures	O
;	O
this	O
criterion	O
ensures	O
that	O
the	O
individual	O
factor	O
variables	O
share	O
at	O
least	O
15	O
%	O
of	O
their	O
variance	O
with	O
the	O
given	O
factor	O
[	O
9	O
]	O
.	O
<EOS>	B-X
Female	B-X
athletes	B-X
participating	B-X
in	B-X
high-risk	B-X
sports	B-X
suffer	B-X
anterior	B-X
cruciate	B-X
ligament	B-X
injury	B-X
at	B-X
a	B-X
4-	B-X
to	B-X
6-fold	B-X
greater	B-X
rate	B-X
than	B-X
do	B-X
male	B-X
athletes	B-X
.	B-X
Kinematic	B-X
and	B-X
kinetic	B-X
studies	B-X
of	B-X
the	B-X
golf	B-X
swing	B-X
have	B-X
reported	B-X
results	B-X
relevant	B-X
to	B-X
the	B-X
knee	B-X
,	B-X
but	B-X
consensus	B-X
as	B-X
to	B-X
the	B-X
loads	B-X
experienced	B-X
during	B-X
a	B-X
swing	B-X
and	B-X
how	B-X
the	B-X
biomechanics	B-X
of	B-X
an	B-X
individual	B-X
's	B-X
technique	B-X
may	B-X
expose	B-X
the	B-X
knee	B-X
to	B-X
risk	B-X
of	B-X
injury	B-X
is	B-X
lacking	B-X
.	B-X
The	B-X
loads	B-X
that	B-X
are	B-X
generated	B-X
during	B-X
these	B-X
dynamic	B-X
activities	B-X
are	B-X
substantially	B-X
greater	B-X
than	B-X
the	B-X
loads	B-X
that	B-X
can	B-X
be	B-X
generated	B-X
during	B-X
static	B-X
postures	B-X
.	B-X
Therefore	B-X
,	B-X
limb	B-X
alignment	B-X
based	B-X
on	B-X
static	B-X
radiographic	B-X
measurements	B-X
provides	B-X
one	B-X
component	B-X
to	B-X
the	B-X
complete	B-X
analysis	B-X
of	B-X
the	B-X
factors	B-X
influencing	B-X
loading	B-X
at	B-X
the	B-X
knee	B-X
joint	B-X
.	B-X

The	O
principle	O
components	O
were	O
obtained	O
by	O
calculating	O
the	O
eigenvalues	O
of	O
the	O
sample	O
covariance	O
matrix	O
,	O
which	O
represent	O
the	O
amount	O
of	O
variance	O
contributed	O
by	O
each	O
factor	O
.	O

Only	O
factors	O
with	O
eigenvalues	O
higher	O
than	O
1	O
were	O
considered	O
for	O
linkage	O
analysis	O
.	O

Integrating	O
data	O
from	O
linkage	O
analysis	O
for	O
gene	O
co	O
-	O
expression	O
<EOS>	B-X
Common	B-X
single-nucleotide	B-X
polymorphisms	B-X
(	B-X
SNPs	B-X
)	B-X
are	B-X
predicted	B-X
to	B-X
collectively	B-X
explain	B-X
40-50	B-X
%	B-X
of	B-X
phenotypic	B-X
variation	B-X
in	B-X
human	B-X
height	B-X
,	B-X
but	B-X
identifying	B-X
the	B-X
specific	B-X
variants	B-X
and	B-X
associated	B-X
regions	B-X
requires	B-X
huge	B-X
sample	B-X
sizes	B-X
The	B-X
functional	B-X
interpretation	B-X
of	B-X
genome-wide	B-X
association	B-X
studies	B-X
(	B-X
GWAS	B-X
)	B-X
is	B-X
challenging	B-X
due	B-X
to	B-X
the	B-X
cell-type-dependent	B-X
influences	B-X
of	B-X
genetic	B-X
variants	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
generated	B-X
comprehensive	B-X
maps	B-X
of	B-X
expression	B-X
quantitative	B-X
trait	B-X
loci	B-X
(	B-X
eQTLs	B-X
)	B-X
for	B-X
659	B-X
microdissected	B-X
human	B-X
kidney	B-X
samples	B-X
and	B-X
identified	B-X
cell-type-eQTLs	B-X
by	B-X
mapping	B-X
interactions	B-X
between	B-X
cell	B-X
type	B-X
abundances	B-X
and	B-X
genotypes	B-X
.	B-X
By	B-X
partitioning	B-X
heritability	B-X
using	B-X
stratified	B-X
linkage	B-X
disequilibrium	B-X
score	B-X
regression	B-X
to	B-X
integrate	B-X
GWAS	B-X
with	B-X
single-cell	B-X
RNA	B-X
sequencing	B-X
and	B-X
single-nucleus	B-X
assay	B-X
for	B-X
transposase-accessible	B-X
chromatin	B-X
with	B-X
high-throughput	B-X
sequencing	B-X
data	B-X
,	B-X
we	B-X
prioritized	B-X
proximal	B-X
tubules	B-X
for	B-X
kidney	B-X
function	B-X
and	B-X
endothelial	B-X
cells	B-X
and	B-X
distal	B-X
tubule	B-X
segments	B-X
for	B-X
blood	B-X
pressure	B-X
pathogenesis	B-X
.	B-X
Bayesian	B-X
colocalization	B-X
analysis	B-X
nominated	B-X
more	B-X
than	B-X
200	B-X
genes	B-X
for	B-X
kidney	B-X
function	B-X
and	B-X
hypertension	B-X
.	B-X
Our	B-X
study	B-X
clarifies	B-X
the	B-X
mechanism	B-X
of	B-X
commonly	B-X
used	B-X
antihypertensive	B-X
and	B-X
renal-protective	B-X
drugs	B-X
and	B-X
identifies	B-X
drug	B-X
repurposing	B-X
opportunities	B-X
for	B-X
kidney	B-X
disease	B-X
.	B-X

Linkage	O
signals	O
of	O
individual	O
transcript	O
expressions	O
were	O
recorded	O
and	O
the	O
location	O
of	O
QTLs	O
was	O
compared	O
to	O
the	O
location	O
of	O
the	O
transcript	O
gene	O
in	O
order	O
to	O
identify	O
trans	O
-	O
regulatory	O
sites	O
.	O

In	O
addition	O
,	O
the	O
location	O
and	O
LOD	O
scores	O
of	O
QTLs	O
identified	O
in	O
single	O
individual	O
transcript	O
analysis	O
(	O
univariate	O
analysis	O
)	O
were	O
compared	O
with	O
the	O
location	O
of	O
the	O
QTLs	O
identified	O
using	O
bivariate	O
analysis	O
or	O
factors	O
of	O
the	O
PCA	O
.	O
<EOS>	B-X
Data	B-X
was	B-X
obtained	B-X
from	B-X
several	B-X
literature	B-X
reviews	B-X
and	B-X
journal	B-X
resources	B-X
that	B-X
have	B-X
correlation	B-X
with	B-X
the	B-X
risk	B-X
factors	B-X
involved	B-X
in	B-X
PCa	B-X
including	B-X
age	B-X
,	B-X
ethnicity	B-X
,	B-X
family	B-X
history	B-X
,	B-X
insulin-Like	B-X
growth	B-X
factor	B-X
,	B-X
sexually	B-X
transmitted	B-X
disease	B-X
,	B-X
obesity	B-X
,	B-X
smoking	B-X
,	B-X
alcohol	B-X
consumption	B-X
,	B-X
vasectomy	B-X
,	B-X
and	B-X
diet	B-X
,	B-X
and	B-X
the	B-X
prevention	B-X
of	B-X
PCa	B-X
including	B-X
soy	B-X
,	B-X
lycopene	B-X
,	B-X
green	B-X
tea	B-X
,	B-X
supplementation	B-X
,	B-X
and	B-X
exercise.Numerous	B-X
epidemiologic	B-X
studies	B-X
have	B-X
linked	B-X
PCa	B-X
risk	B-X
to	B-X
various	B-X
factors	B-X
,	B-X
i.e	B-X
.	B-X
age	B-X
,	B-X
ethnicity	B-X
,	B-X
family	B-X
history	B-X
,	B-X
insulin	B-X
like-growth	B-X
factors	B-X
,	B-X
lifestyle	B-X
,	B-X
diet	B-X
,	B-X
environmental	B-X
and	B-X
occupational	B-X
exposures	B-X
.	B-X
More	B-X
studies	B-X
are	B-X
still	B-X
needed	B-X
to	B-X
explore	B-X
and	B-X
find	B-X
the	B-X
risk	B-X
factors	B-X
and	B-X
preventive	B-X
methods	B-X
of	B-X
PCa	B-X
development	B-X
.	B-X
From	B-X
the	B-X
various	B-X
scientific	B-X
evidence	B-X
,	B-X
it	B-X
is	B-X
proved	B-X
that	B-X
both	B-X
diseases	B-X
share	B-X
some	B-X
common	B-X
transcription	B-X
factors	B-X
and	B-X
signalling	B-X
pathways	B-X
.	B-X
Along	B-X
with	B-X
androgen	B-X
signalling	B-X
,	B-X
imbalanced	B-X
apoptosis	B-X
,	B-X
oxidative	B-X
stress	B-X
,	B-X
and	B-X
microbial	B-X
infection	B-X
also	B-X
crucial	B-X
factors	B-X
that	B-X
significantly	B-X
affect	B-X
the	B-X
pathogenesis	B-X
of	B-X
BPH	B-X
.	B-X
In	B-X
PCa	B-X
androgen	B-X
signalling	B-X
is	B-X
upregulated	B-X
as	B-X
compared	B-X
to	B-X
a	B-X
healthy	B-X
prostate	B-X
.	B-X

This	O
allowed	O
a	O
determination	O
of	O
whether	O
the	O
bivariate	O
analysis	O
or	O
PCA	O
data	O
reduction	O
analysis	O
improved	O
our	O
evidence	O
for	O
linkage	O
,	O
and	O
if	O
so	O
,	O
a	O
more	O
in	O
-	O
depth	O
examination	O
of	O
the	O
transcripts	O
included	O
in	O
the	O
principal	O
components	O
needs	O
to	O
be	O
examined	O
for	O
biologic	O
interactions	O
on	O
complex	O
disorders	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
such	B-X
a	B-X
review	B-X
is	B-X
to	B-X
investigate	B-X
whether	B-X
a	B-X
test	B-X
is	B-X
sufficiently	B-X
specific	B-X
or	B-X
sensitive	B-X
to	B-X
fit	B-X
its	B-X
role	B-X
in	B-X
practice	B-X
,	B-X
to	B-X
compare	B-X
the	B-X
accuracy	B-X
of	B-X
two	B-X
or	B-X
more	B-X
diagnostic	B-X
tests	B-X
,	B-X
or	B-X
to	B-X
investigate	B-X
where	B-X
existing	B-X
variation	B-X
in	B-X
results	B-X
comes	B-X
from	B-X
.	B-X
The	B-X
quality	B-X
of	B-X
included	B-X
studies	B-X
is	B-X
assessed	B-X
with	B-X
the	B-X
Quality	B-X
Assessment	B-X
of	B-X
Diagnostic	B-X
Accuracy	B-X
Studies-2	B-X
checklist	B-X
,	B-X
containing	B-X
items	B-X
such	B-X
as	B-X
a	B-X
consecutive	B-X
and	B-X
all-inclusive	B-X
patient	B-X
selection	B-X
process	B-X
,	B-X
blinding	B-X
of	B-X
index	B-X
test	B-X
and	B-X
reference	B-X
standard	B-X
assessment	B-X
,	B-X
a	B-X
valid	B-X
reference	B-X
standard	B-X
,	B-X
and	B-X
complete	B-X
verification	B-X
of	B-X
all	B-X
included	B-X
participants	B-X
.	B-X
For	B-X
meta-analysis	B-X
,	B-X
the	B-X
bivariate	B-X
model	B-X
or	B-X
the	B-X
hierarchical	B-X
summary	B-X
receiver	B-X
operating	B-X
characteristic	B-X
model	B-X
is	B-X
used	B-X
.	B-X
Technologies	B-X
to	B-X
manipulate	B-X
endoscopic	B-X
optical	B-X
outputs	B-X
can	B-X
be	B-X
used	B-X
to	B-X
predict	B-X
polyp	B-X
histology	B-X
in	B-X
vivo	B-X
;	B-X
however	B-X
,	B-X
it	B-X
remains	B-X
unclear	B-X
how	B-X
accuracy	B-X
has	B-X
progressed	B-X
and	B-X
whether	B-X
it	B-X
is	B-X
sufficient	B-X
for	B-X
routine	B-X
clinical	B-X
implementation	B-X
.	B-X

Results	O

Among	O
194	O
individuals	O
from	O
14	O
families	O
,	O
17	O
individuals	O
with	O
missing	O
information	O
on	O
age	O
were	O
excluded	O
.	O

Seventy	O
-	O
six	O
percent	O
(	O
n	O
=	O
2688	O
)	O
of	O
the	O
transcripts	O
had	O
significant	O
heritability	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
were	O
considered	O
for	O
the	O
linkage	O
analysis	O
.	O

Of	O
this	O
,	O
1448	O
(	O
54	O
%	O
)	O
transcripts	O
displayed	O
suggestive	O
evidence	O
of	O
linkage	O
(	O
had	O
a	O
maximum	O
LOD	O
score	O
>=	O
1	O
.	O
8	O
[	O
12	O
]	O
)	O
.	O

The	O
QTLs	O
of	O
1661	O
transcripts	O
(	O
759	O
of	O
which	O
with	O
LOD	O
>=	O
1	O
.	O
8	O
)	O
were	O
localized	O
in	O
a	O
different	O
region	O
than	O
the	O
gene	O
transcript	O
(	O
trans	O
-	O
regulatory	O
sites	O
)	O
.	O

We	O
used	O
two	O
different	O
chromosomal	O
regions	O
with	O
co	O
-	O
localized	O
transcript	O
QTLs	O
,	O
chromosomes	O
4q28	O
.	O
2	O
-	O
q31	O
.	O
1	O
and	O
13q34	O
,	O
for	O
more	O
in	O
-	O
depth	O
analyses	O
.	O

Chromosome	O
4q28	O
.	O
2	O
-	O
q31	O
.	O
1	O
region	O
<EOS>	B-X
Profiles	B-X
of	B-X
33	B-X
samples	B-X
(	B-X
17	B-X
first-passage	B-X
xenografts	B-X
and	B-X
16	B-X
cell	B-X
lines	B-X
)	B-X
identified	B-X
numerous	B-X
chromosomal	B-X
regions	B-X
with	B-X
CNAs	B-X
,	B-X
including	B-X
losses	B-X
at	B-X
1p36.33	B-X
approximately	B-X
p34.3	B-X
,	B-X
1p13.3	B-X
approximately	B-X
p13.2	B-X
,	B-X
3p26	B-X
,	B-X
3p25.2	B-X
approximately	B-X
p22.3	B-X
,	B-X
3p22.1	B-X
approximately	B-X
p14.1	B-X
,	B-X
4q28.3	B-X
,	B-X
4q31	B-X
,	B-X
4q35.1	B-X
,	B-X
5q14.3	B-X
,	B-X
6p	B-X
,	B-X
6q	B-X
,	B-X
8p23.3	B-X
approximately	B-X
p12	B-X
,	B-X
9p	B-X
,	B-X
9q22.32	B-X
approximately	B-X
q31.1	B-X
,	B-X
13q33.2	B-X
,	B-X
15q11.2	B-X
,	B-X
16p13.3	B-X
,	B-X
17p	B-X
,	B-X
18q11.21	B-X
approximately	B-X
q23	B-X
,	B-X
19p13.3	B-X
approximately	B-X
p13.12	B-X
,	B-X
19q13.2	B-X
,	B-X
21p	B-X
,	B-X
21q	B-X
,	B-X
and	B-X
22p	B-X
,	B-X
22q	B-X
and	B-X
gains	B-X
at	B-X
7p21.1	B-X
approximately	B-X
p11.2	B-X
,	B-X
7q31.32	B-X
,	B-X
7q33	B-X
,	B-X
8q11.1	B-X
approximately	B-X
q24	B-X
,	B-X
11p13	B-X
,	B-X
14q22.2	B-X
,	B-X
20p12.2	B-X
,	B-X
and	B-X
20q11.23	B-X
approximately	B-X
q13.33	B-X
.	B-X
Novel	B-X
regions	B-X
containing	B-X
CNAs	B-X
were	B-X
identified	B-X
and	B-X
refined	B-X
by	B-X
combining	B-X
the	B-X
increased	B-X
resolution	B-X
of	B-X
our	B-X
BAC	B-X
CGH	B-X
array	B-X
with	B-X
a	B-X
statistical	B-X
algorithm	B-X
developed	B-X
for	B-X
assigning	B-X
significance	B-X
values	B-X
to	B-X
altered	B-X
BACs	B-X
across	B-X
samples	B-X
.	B-X
In	B-X
mice	B-X
,	B-X
the	B-X
Hsp110/SSE	B-X
family	B-X
is	B-X
composed	B-X
of	B-X
the	B-X
heat	B-X
shock	B-X
protein	B-X
(	B-X
Hsp	B-X
)	B-X
110/105	B-X
,	B-X
Apg-1	B-X
and	B-X
Apg-2	B-X
.	B-X
In	B-X
humans	B-X
,	B-X
however	B-X
,	B-X
only	B-X
the	B-X
Hsp110/105	B-X
homolog	B-X
has	B-X
been	B-X
identified	B-X
as	B-X
a	B-X
member	B-X
,	B-X
and	B-X
two	B-X
cDNAs	B-X
,	B-X
Hsp70RY	B-X
and	B-X
HS24/p52	B-X
,	B-X
potentially	B-X
encoding	B-X
proteins	B-X
structurally	B-X
similar	B-X
to	B-X
,	B-X
but	B-X
smaller	B-X
than	B-X
,	B-X
mouse	B-X
Apg-2	B-X
have	B-X
been	B-X
reported	B-X
.	B-X
To	B-X
clarify	B-X
the	B-X
membership	B-X
of	B-X
Hsp110	B-X
family	B-X
in	B-X
humans	B-X
,	B-X
we	B-X
isolated	B-X
Apg-1	B-X
and	B-X
Apg-2	B-X
cDNAs	B-X
from	B-X
a	B-X
human	B-X
testis	B-X
cDNA	B-X
library	B-X
.	B-X
The	B-X
human	B-X
Apg-1	B-X
was	B-X
100	B-X
%	B-X
and	B-X
91.8	B-X
%	B-X
identical	B-X
in	B-X
length	B-X
and	B-X
amino	B-X
acid	B-X
(	B-X
aa	B-X
)	B-X
sequence	B-X
,	B-X
respectively	B-X
,	B-X
to	B-X
mouse	B-X
Apg-1	B-X
.	B-X
Human	B-X
Apg-2	B-X
was	B-X
one	B-X
aa	B-X
shorter	B-X
than	B-X
and	B-X
95.5	B-X
%	B-X
identical	B-X
in	B-X
sequence	B-X
to	B-X
mouse	B-X
Apg-2	B-X
.	B-X
In	B-X
ECV304	B-X
,	B-X
human	B-X
endothelial	B-X
cells	B-X
Apg-1	B-X
but	B-X
not	B-X
Apg-2	B-X
transcripts	B-X
were	B-X
induced	B-X
in	B-X
2	B-X
h	B-X
by	B-X
a	B-X
temperature	B-X
shift	B-X
from	B-X
32	B-X
degrees	B-X
C	B-X
to	B-X
39	B-X
degrees	B-X
C.	B-X
As	B-X
found	B-X
in	B-X
mice	B-X
,	B-X
the	B-X
response	B-X
was	B-X
stronger	B-X
than	B-X
that	B-X
to	B-X
a	B-X
37-42	B-X
degrees	B-X
C	B-X
shift	B-X
.	B-X
The	B-X
human	B-X
Apg-1	B-X
and	B-X
Apg-2	B-X
genes	B-X
were	B-X
mapped	B-X
to	B-X
the	B-X
chromosomal	B-X
loci	B-X
4q28	B-X
and	B-X
5q23.3-q31.1	B-X
,	B-X
respectively	B-X
,	B-X
by	B-X
fluorescence	B-X
in-situ	B-X
hybridization	B-X
.	B-X
We	B-X
isolated	B-X
cDNA	B-X
and	B-X
genomic	B-X
clones	B-X
encompassing	B-X
the	B-X
region	B-X
critical	B-X
for	B-X
the	B-X
difference	B-X
between	B-X
Apg-2	B-X
and	B-X
HS24/p52	B-X
.	B-X
Although	B-X
the	B-X
primer	B-X
sets	B-X
used	B-X
were	B-X
derived	B-X
from	B-X
the	B-X
sequences	B-X
common	B-X
to	B-X
both	B-X
cDNAs	B-X
,	B-X
all	B-X
cDNA	B-X
and	B-X
genomic	B-X
clones	B-X
corresponded	B-X
to	B-X
Apg-2	B-X
.	B-X
Using	B-X
a	B-X
similar	B-X
approach	B-X
,	B-X
the	B-X
relationship	B-X
between	B-X
Apg-2	B-X
and	B-X
Hsp70RY	B-X
was	B-X
assessed	B-X
,	B-X
and	B-X
no	B-X
clone	B-X
corresponding	B-X
to	B-X
Hsp70RY	B-X
was	B-X
obtained	B-X
.	B-X
These	B-X
results	B-X
demonstrated	B-X
that	B-X
the	B-X
Hsp110	B-X
family	B-X
consists	B-X
of	B-X
at	B-X
least	B-X
three	B-X
members	B-X
,	B-X
Apg-1	B-X
,	B-X
Apg-2	B-X
and	B-X
Hsp110	B-X
in	B-X
humans	B-X
as	B-X
well	B-X
as	B-X
in	B-X
mice	B-X
.	B-X
The	B-X
significance	B-X
of	B-X
HS24/p52	B-X
and	B-X
Hsp70RY	B-X
cDNAs	B-X
previously	B-X
reported	B-X
remains	B-X
to	B-X
be	B-X
determined	B-X
.	B-X

Table	O
1	O
reports	O
the	O
results	O
for	O
the	O
chromosome	O
4q28	O
.	O
2	O
-	O
q31	O
.	O
1	O
region	O
.	O

Fifteen	O
transcripts	O
co	O
-	O
localized	O
in	O
this	O
region	O
in	O
the	O
univariate	O
linkage	O
analysis	O
,	O
and	O
the	O
LOD	O
scores	O
ranged	O
from	O
1	O
.	O
17	O
to	O
3	O
.	O
72	O
.	O

The	O
strongest	O
linkage	O
signals	O
were	O
observed	O
for	O
the	O
transcripts	O
of	O
the	O
MX2	O
,	O
NUCB2	O
,	O
and	O
SNX4	O
genes	O
.	O

Using	O
PCA	O
,	O
we	O
obtained	O
five	O
factors	O
from	O
the	O
15	O
transcripts	O
with	O
eigenvalues	O
greater	O
than	O
1	O
.	O

Only	O
one	O
factor	O
,	O
with	O
a	O
high	O
positive	O
loading	O
for	O
the	O
MX2	O
gene	O
transcript	O
,	O
had	O
a	O
significant	O
heritability	O
and	O
a	O
LOD	O
score	O
>=	O
1	O
.	O
8	O
.	O

The	O
linkage	O
analysis	O
using	O
this	O
factor	O
identified	O
the	O
chromosome	O
region	O
for	O
the	O
MX2	O
gene	O
,	O
but	O
the	O
LOD	O
score	O
was	O
lower	O
than	O
the	O
one	O
obtained	O
by	O
single	O
linkage	O
analysis	O
of	O
the	O
MX2	O
transcript	O
.	O

We	O
then	O
performed	O
bivariate	O
analysis	O
of	O
all	O
pairwise	O
co	O
-	O
localized	O
transcripts	O
on	O
4q28	O
.	O
2	O
-	O
q31	O
.	O
1	O
and	O
found	O
evidence	O
for	O
genetic	O
correlation	O
of	O
co	O
-	O
localized	O
genes	O
,	O
although	O
without	O
much	O
increase	O
in	O
the	O
magnitude	O
of	O
the	O
LOD	O
score	O
(	O
Figure	O
1	O
)	O
.	O

This	O
analysis	O
identified	O
two	O
networks	O
of	O
gene	O
expressions	O
(	O
Figure	O
1	O
)	O
.	O
<EOS>	B-X
Osteoarthritis	B-X
(	B-X
OA	B-X
)	B-X
occurs	B-X
mostly	B-X
in	B-X
the	B-X
knees	B-X
,	B-X
hips	B-X
,	B-X
finger	B-X
interphalangeal	B-X
joints	B-X
,	B-X
and	B-X
spinal	B-X
facet	B-X
joints	B-X
,	B-X
and	B-X
is	B-X
characterized	B-X
by	B-X
cartilage	B-X
degeneration	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
analyze	B-X
these	B-X
two	B-X
types	B-X
of	B-X
sequencing	B-X
data	B-X
in	B-X
order	B-X
to	B-X
obtain	B-X
a	B-X
more	B-X
comprehensive	B-X
understanding	B-X
of	B-X
OA	B-X
.	B-X
We	B-X
compared	B-X
the	B-X
analysis	B-X
results	B-X
of	B-X
bulk	B-X
RNA-seq	B-X
and	B-X
scRNA-seq	B-X
from	B-X
the	B-X
dataset	B-X
GSE114007	B-X
and	B-X
the	B-X
dataset	B-X
GSE104782	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
identified	B-X
the	B-X
differentially	B-X
expressed	B-X
genes	B-X
(	B-X
DEGs	B-X
)	B-X
.	B-X
We	B-X
highlighted	B-X
271	B-X
genes	B-X
that	B-X
were	B-X
simultaneously	B-X
suggested	B-X
by	B-X
these	B-X
two	B-X
types	B-X
of	B-X
data	B-X
and	B-X
provided	B-X
their	B-X
possible	B-X
expression	B-X
pattern	B-X
in	B-X
OA	B-X
.	B-X
Among	B-X
the	B-X
271	B-X
genes	B-X
,	B-X
we	B-X
identified	B-X
14	B-X
TFs	B-X
,	B-X
and	B-X
TWIST2	B-X
,	B-X
MYBL2	B-X
,	B-X
RELA	B-X
,	B-X
JUN	B-X
,	B-X
KLF4	B-X
,	B-X
and	B-X
PTTG1	B-X
could	B-X
be	B-X
the	B-X
key	B-X
TFs	B-X
for	B-X
the	B-X
271	B-X
genes	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
8	B-X
lncRNAs	B-X
among	B-X
the	B-X
271	B-X
genes	B-X
and	B-X
the	B-X
lncRNA	B-X
regulation	B-X
between	B-X
CYTOR	B-X
and	B-X
NRP1	B-X
could	B-X
contribute	B-X
to	B-X
the	B-X
pain	B-X
and	B-X
vascularization	B-X
of	B-X
cartilage	B-X
in	B-X
the	B-X
osteoarthritic	B-X
knee	B-X
.	B-X
In	B-X
short	B-X
,	B-X
our	B-X
research	B-X
combined	B-X
the	B-X
analysis	B-X
results	B-X
of	B-X
bulk	B-X
RNA-seq	B-X
and	B-X
scRNA-seq	B-X
data	B-X
for	B-X
OA	B-X
chondrocytes	B-X
,	B-X
which	B-X
will	B-X
contribute	B-X
to	B-X
further	B-X
elucidation	B-X
of	B-X
the	B-X
molecular	B-X
mechanisms	B-X
of	B-X
OA	B-X
pathogenesis	B-X
.	B-X
[	B-X
Figure	B-X
:	B-X
see	B-X
text	B-X
]	B-X
.	B-X

We	O
obtained	O
two	O
factors	O
using	O
PCA	O
of	O
the	O
first	O
network	O
(	O
Group	O
1	O
,	O
SNX4	O
,	O
YWHAQ	O
,	O
ASS	O
,	O
MX2	O
,	O
and	O
ISGF3G	O
gene	O
transcripts	O
)	O
.	O

Both	O
factors	O
had	O
significant	O
heritability	O
;	O
however	O
,	O
only	O
Factor	O
1	O
,	O
loading	O
heavily	O
on	O
the	O
MX2	O
gene	O
,	O
localized	O
to	O
the	O
4q28	O
.	O
2	O
-	O
q31	O
.	O
1	O
region	O
(	O
Table	O
1	O
)	O
,	O
and	O
the	O
magnitude	O
of	O
the	O
LOD	O
score	O
was	O
lower	O
than	O
that	O
of	O
the	O
univariate	O
MX2	O
gene	O
transcript	O
analysis	O
(	O
LOD	O
=	O
2	O
.	O
28	O
)	O
.	O
<EOS>	B-X
The	B-X
term	B-X
'heritability	B-X
,	B-X
'	B-X
as	B-X
it	B-X
is	B-X
used	B-X
today	B-X
in	B-X
human	B-X
behavioral	B-X
genetics	B-X
,	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
misleading	B-X
in	B-X
the	B-X
history	B-X
of	B-X
science	B-X
.	B-X
Contrary	B-X
to	B-X
popular	B-X
belief	B-X
,	B-X
the	B-X
measurable	B-X
heritability	B-X
of	B-X
a	B-X
trait	B-X
does	B-X
not	B-X
tell	B-X
us	B-X
how	B-X
'genetically	B-X
inheritable	B-X
'	B-X
that	B-X
trait	B-X
is	B-X
.	B-X
Further	B-X
,	B-X
it	B-X
does	B-X
not	B-X
inform	B-X
us	B-X
about	B-X
what	B-X
causes	B-X
a	B-X
trait	B-X
,	B-X
the	B-X
relative	B-X
influence	B-X
of	B-X
genes	B-X
in	B-X
the	B-X
development	B-X
of	B-X
a	B-X
trait	B-X
,	B-X
or	B-X
the	B-X
relative	B-X
influence	B-X
of	B-X
the	B-X
environment	B-X
in	B-X
the	B-X
development	B-X
of	B-X
a	B-X
trait	B-X
.	B-X
Because	B-X
we	B-X
already	B-X
know	B-X
that	B-X
genetic	B-X
factors	B-X
have	B-X
significant	B-X
influence	B-X
on	B-X
the	B-X
development	B-X
of	B-X
all	B-X
human	B-X
traits	B-X
,	B-X
measures	B-X
of	B-X
heritability	B-X
are	B-X
of	B-X
little	B-X
value	B-X
,	B-X
except	B-X
in	B-X
very	B-X
rare	B-X
cases	B-X
.	B-X
WIREs	B-X
Cogn	B-X
Sci	B-X
2017	B-X
,	B-X
8	B-X
:	B-X
e1400	B-X
.	B-X
doi	B-X
:	B-X
10.1002/wcs.1400	B-X
For	B-X
further	B-X
resources	B-X
related	B-X
to	B-X
this	B-X
article	B-X
,	B-X
please	B-X
visit	B-X
the	B-X
WIREs	B-X
website	B-X
.	B-X

The	O
heritability	O
of	O
one	O
factor	O
obtained	O
using	O
PCA	O
for	O
Group	O
2	O
transcripts	O
was	O
not	O
significant	O
and	O
further	O
analysis	O
was	O
not	O
performed	O
.	O

Chromosome	O
13q34	O
region	O
<EOS>	B-X
We	B-X
report	B-X
terminal	B-X
microdeletions	B-X
in	B-X
13q34	B-X
chromosome	B-X
region	B-X
in	B-X
5	B-X
adult	B-X
patients	B-X
of	B-X
two	B-X
unrelated	B-X
families	B-X
.	B-X
Patients	B-X
harboring	B-X
13q34	B-X
microdeletions	B-X
display	B-X
common	B-X
clinical	B-X
features	B-X
,	B-X
including	B-X
intellectual	B-X
disability	B-X
,	B-X
obesity	B-X
,	B-X
and	B-X
mild	B-X
facial	B-X
dysmorphism	B-X
.	B-X
Further	B-X
systematic	B-X
analysis	B-X
of	B-X
the	B-X
genes	B-X
comprised	B-X
in	B-X
the	B-X
deleted	B-X
region	B-X
will	B-X
allow	B-X
the	B-X
identification	B-X
of	B-X
genes	B-X
whose	B-X
haploinsufficiency	B-X
is	B-X
expected	B-X
to	B-X
lead	B-X
to	B-X
disease	B-X
manifestations	B-X
,	B-X
in	B-X
particular	B-X
intellectual	B-X
disability	B-X
.	B-X
Previously	B-X
we	B-X
described	B-X
a	B-X
patient	B-X
with	B-X
congenital	B-X
heart	B-X
defect	B-X
and	B-X
mental	B-X
retardation	B-X
and	B-X
proposed	B-X
that	B-X
a	B-X
distal	B-X
6Mb	B-X
region	B-X
might	B-X
contain	B-X
the	B-X
causative	B-X
gene	B-X
of	B-X
congenital	B-X
heart	B-X
defect	B-X
.	B-X
We	B-X
identified	B-X
a	B-X
1.1Mb	B-X
deletion	B-X
at	B-X
chromosome	B-X
13q34	B-X
with	B-X
high	B-X
resolution	B-X
SNP-array	B-X
BeadChips	B-X
(	B-X
HumanOmni1-Quad	B-X
,	B-X
Illumina	B-X
,	B-X
USA	B-X
)	B-X
.	B-X
This	B-X
chromosome	B-X
region	B-X
contains	B-X
ten	B-X
annotated	B-X
genes	B-X
,	B-X
including	B-X
GRK1	B-X
,	B-X
TFDP1	B-X
,	B-X
RASA3	B-X
and	B-X
GAS6	B-X
.	B-X
To	B-X
our	B-X
knowledge	B-X
,	B-X
this	B-X
represents	B-X
the	B-X
smallest	B-X
13q34	B-X
deletion	B-X
identified	B-X
to	B-X
date	B-X
.	B-X
Our	B-X
study	B-X
provides	B-X
additional	B-X
support	B-X
that	B-X
distal	B-X
13q34	B-X
deletion	B-X
region	B-X
might	B-X
contain	B-X
key	B-X
gene	B-X
(	B-X
s	B-X
)	B-X
responsible	B-X
for	B-X
cardiac	B-X
development	B-X
.	B-X

We	O
performed	O
analysis	O
in	O
an	O
additional	O
chromosome	O
region	O
of	O
co	O
-	O
localized	O
transcripts	O
,	O
13q34	O
region	O
,	O
and	O
noted	O
similar	O
results	O
.	O

Using	O
univariate	O
analysis	O
,	O
12	O
transcripts	O
co	O
-	O
localized	O
in	O
this	O
region	O
;	O
and	O
bivariate	O
analysis	O
revealed	O
an	O
intricate	O
network	O
of	O
correlated	O
traits	O
(	O
Table	O
2	O
and	O
Figure	O
2	O
)	O
.	O
<EOS>	B-X
This	B-X
study	B-X
was	B-X
aimed	B-X
at	B-X
analyzing	B-X
the	B-X
recurrence-related	B-X
prognostic	B-X
significance	B-X
of	B-X
12	B-X
candidate	B-X
molecular	B-X
biomarkers	B-X
in	B-X
node-negative	B-X
stage	B-X
I-II	B-X
non-small	B-X
cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
.	B-X
In	B-X
general	B-X
,	B-X
MYB	B-X
fusion	B-X
and	B-X
somatic	B-X
mutations	B-X
accounted	B-X
for	B-X
a	B-X
high	B-X
proportion	B-X
,	B-X
which	B-X
was	B-X
46.7	B-X
%	B-X
(	B-X
35/75	B-X
)	B-X
.	B-X
The	B-X
antigen-presenting	B-X
machinery	B-X
(	B-X
APM	B-X
)	B-X
expression	B-X
score	B-X
and	B-X
immune	B-X
infiltration	B-X
score	B-X
(	B-X
IIS	B-X
)	B-X
were	B-X
the	B-X
lowest	B-X
among	B-X
ACC	B-X
patients	B-X
,	B-X
compared	B-X
with	B-X
other	B-X
cancer	B-X
types	B-X
.	B-X
For	B-X
61	B-X
primary	B-X
cases	B-X
,	B-X
the	B-X
locoregional	B-X
recurrence-free	B-X
survival	B-X
(	B-X
LRRFS	B-X
)	B-X
was	B-X
statistically	B-X
significantly	B-X
correlated	B-X
with	B-X
the	B-X
IIS	B-X
[	B-X
univariate	B-X
analysis	B-X
;	B-X
hazard	B-X
ratio	B-X
(	B-X
HR	B-X
)	B-X
=	B-X
0.32	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
0.11-0.92	B-X
;	B-X
p	B-X
=	B-X
0.035	B-X
]	B-X
and	B-X
T-cell	B-X
infiltration	B-X
score	B-X
(	B-X
TIS	B-X
)	B-X
(	B-X
univariate	B-X
analysis	B-X
;	B-X
HR	B-X
=	B-X
0.33	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
0.12-0.94	B-X
;	B-X
p	B-X
=	B-X
0.037	B-X
]	B-X
.	B-X
Additionally	B-X
,	B-X
solid	B-X
pattern	B-X
was	B-X
also	B-X
a	B-X
prognostic	B-X
factor	B-X
related	B-X
to	B-X
locoregional	B-X
recurrence	B-X
,	B-X
whereas	B-X
postoperative	B-X
radiotherapy	B-X
(	B-X
PORT	B-X
)	B-X
exerted	B-X
its	B-X
beneficial	B-X
effects	B-X
.	B-X
Patients	B-X
who	B-X
responded	B-X
to	B-X
camrelizumab	B-X
or	B-X
pembrolizumab	B-X
observed	B-X
elevated	B-X
APM	B-X
and	B-X
TIS	B-X
,	B-X
compared	B-X
with	B-X
patients	B-X
with	B-X
progressive	B-X
disease	B-X
.	B-X

Using	O
PCA	O
,	O
we	O
obtained	O
five	O
factors	O
,	O
three	O
of	O
them	O
with	O
significant	O
heritability	O
.	O
<EOS>	B-X
Evaluation	B-X
of	B-X
population	B-X
structure	B-X
by	B-X
neighbor-joining	B-X
and	B-X
principal	B-X
components	B-X
analysis	B-X
(	B-X
PCA	B-X
)	B-X
clustered	B-X
all	B-X
accessions	B-X
into	B-X
three	B-X
major	B-X
groups	B-X
and	B-X
six	B-X
subgroups	B-X
,	B-X
mainly	B-X
according	B-X
to	B-X
fruit	B-X
shape	B-X
,	B-X
hairy	B-X
vs.	B-X
glabrous	B-X
fruit	B-X
skin	B-X
,	B-X
pedigree	B-X
,	B-X
geographic	B-X
origin	B-X
,	B-X
and	B-X
domestication	B-X
history	B-X
.	B-X
Five	B-X
SNPs	B-X
were	B-X
found	B-X
to	B-X
be	B-X
significantly	B-X
associated	B-X
with	B-X
gummosis	B-X
disease	B-X
resistance	B-X
,	B-X
of	B-X
which	B-X
SNPrs285957	B-X
,	B-X
located	B-X
on	B-X
chromosome6	B-X
across	B-X
28	B-X
Mb	B-X
,	B-X
was	B-X
detected	B-X
by	B-X
both	B-X
the	B-X
BLINK	B-X
and	B-X
the	B-X
FarmCPU	B-X
model	B-X
.	B-X
Six	B-X
candidate	B-X
genes	B-X
flanked	B-X
by	B-X
or	B-X
harboring	B-X
the	B-X
significant	B-X
SNPs	B-X
,	B-X
previously	B-X
implicated	B-X
in	B-X
biotic	B-X
stress	B-X
tolerance	B-X
,	B-X
were	B-X
significantly	B-X
associated	B-X
with	B-X
this	B-X
resistance	B-X
.	B-X
Ten	B-X
agronomic	B-X
and	B-X
yield-related	B-X
traits	B-X
were	B-X
scored	B-X
,	B-X
and	B-X
the	B-X
data	B-X
were	B-X
subjected	B-X
to	B-X
analysis	B-X
of	B-X
variance	B-X
(	B-X
ANOVA	B-X
)	B-X
,	B-X
principal	B-X
component	B-X
analysis	B-X
(	B-X
PCA	B-X
)	B-X
,	B-X
correlation	B-X
,	B-X
and	B-X
cluster	B-X
analysis	B-X
.	B-X
Also	B-X
,	B-X
there	B-X
were	B-X
significant	B-X
differences	B-X
in	B-X
the	B-X
phenotypes	B-X
among	B-X
accessions	B-X
of	B-X
different	B-X
germplasm	B-X
types	B-X
.	B-X
The	B-X
broad-sense	B-X
heritability	B-X
of	B-X
traits	B-X
studied	B-X
ranged	B-X
from	B-X
4.4	B-X
%	B-X
to	B-X
77.8	B-X
%	B-X
.	B-X
The	B-X
number	B-X
of	B-X
seeds	B-X
per	B-X
pod	B-X
(	B-X
77.8	B-X
%	B-X
)	B-X
,	B-X
100-seed	B-X
weight	B-X
(	B-X
68.0	B-X
%	B-X
)	B-X
,	B-X
and	B-X
number	B-X
of	B-X
plant	B-X
branches	B-X
(	B-X
63.9	B-X
%	B-X
)	B-X
had	B-X
a	B-X
high	B-X
heritability	B-X
.	B-X
A	B-X
total	B-X
of	B-X
10	B-X
traits	B-X
were	B-X
transformed	B-X
into	B-X
3	B-X
comprehensive	B-X
factors	B-X
by	B-X
principal	B-X
component	B-X
analysis	B-X
,	B-X
and	B-X
the	B-X
first	B-X
three	B-X
principal	B-X
component	B-X
factors	B-X
contributed	B-X
72.31	B-X
%	B-X
of	B-X
the	B-X
total	B-X
variability	B-X
.	B-X
Cluster	B-X
analysis	B-X
categorized	B-X
the	B-X
475	B-X
adzuki	B-X
bean	B-X
accessions	B-X
into	B-X
five	B-X
distinct	B-X
groups	B-X
.	B-X

Similar	O
to	O
our	O
previous	O
findings	O
on	O
chomosome	O
4	O
,	O
PCA	O
factors	O
did	O
not	O
improve	O
the	O
magnitude	O
of	O
the	O
LOD	O
scores	O
when	O
compared	O
to	O
univariate	O
analysis	O
.	O

Discussion	O
<EOS>	B-X
Discussion	B-X
structures	B-X
are	B-X
argumentation-theoretical	B-X
tools	B-X
that	B-X
can	B-X
be	B-X
employed	B-X
to	B-X
tackle	B-X
three	B-X
barriers	B-X
that	B-X
separate	B-X
lay	B-X
stakeholders	B-X
from	B-X
policy	B-X
debates	B-X
:	B-X
difficulty	B-X
,	B-X
magnitude	B-X
,	B-X
and	B-X
complexity	B-X
.	B-X
Discussions	B-X
about	B-X
preventive	B-X
behaviors	B-X
were	B-X
assessed	B-X
before	B-X
testing	B-X
and	B-X
1	B-X
and	B-X
6	B-X
months	B-X
post-testing	B-X
.	B-X
Discussion	B-X
of	B-X
preventive	B-X
behaviors	B-X
declined	B-X
following	B-X
test	B-X
reporting	B-X
,	B-X
with	B-X
more	B-X
rapid	B-X
decline	B-X
reported	B-X
by	B-X
noncarriers	B-X
.	B-X
Discussions	B-X
are	B-X
an	B-X
important	B-X
part	B-X
of	B-X
medical	B-X
education	B-X
research	B-X
papers	B-X
,	B-X
but	B-X
there	B-X
is	B-X
little	B-X
guidance	B-X
on	B-X
how	B-X
to	B-X
write	B-X
up	B-X
the	B-X
discussion	B-X
section	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
identified	O
co	O
-	O
localized	O
QTLs	O
of	O
individual	O
transcripts	O
and	O
compared	O
the	O
univariate	O
and	O
bivariate	O
linkage	O
results	O
using	O
single	O
transcripts	O
to	O
those	O
using	O
factors	O
obtained	O
from	O
PCA	O
.	O

By	O
using	O
factors	O
that	O
accounted	O
for	O
the	O
variance	O
of	O
multiple	O
transcripts	O
with	O
co	O
-	O
localized	O
QTLs	O
,	O
we	O
attempted	O
to	O
reduce	O
the	O
number	O
of	O
linkage	O
analyses	O
performed	O
as	O
well	O
as	O
possibly	O
identifying	O
previously	O
unknown	O
patterns	O
of	O
associated	O
gene	O
expression	O
profiles	O
.	O

The	O
PCA	O
did	O
in	O
fact	O
reduce	O
the	O
number	O
of	O
linkage	O
analyses	O
performed	O
,	O
but	O
it	O
did	O
not	O
improve	O
the	O
magnitude	O
of	O
signals	O
in	O
the	O
target	O
QTLs	O
as	O
compared	O
with	O
univariate	O
or	O
bivariate	O
analyses	O
.	O
<EOS>	B-X
Research	B-X
into	B-X
the	B-X
physiology	B-X
of	B-X
exercise	B-X
and	B-X
kinanthropometry	B-X
is	B-X
intended	B-X
to	B-X
improve	B-X
our	B-X
understanding	B-X
of	B-X
how	B-X
the	B-X
body	B-X
responds	B-X
and	B-X
adapts	B-X
to	B-X
exercise	B-X
.	B-X
Advances	B-X
in	B-X
personal	B-X
computing	B-X
have	B-X
made	B-X
available	B-X
statistical	B-X
analyses	B-X
that	B-X
were	B-X
previously	B-X
the	B-X
preserve	B-X
of	B-X
elaborate	B-X
mainframe	B-X
systems	B-X
and	B-X
have	B-X
increased	B-X
opportunities	B-X
for	B-X
investigation	B-X
.	B-X
However	B-X
,	B-X
the	B-X
ease	B-X
with	B-X
which	B-X
analyses	B-X
can	B-X
be	B-X
performed	B-X
can	B-X
mask	B-X
underlying	B-X
philosophical	B-X
and	B-X
epistemological	B-X
shortcomings	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
review	B-X
is	B-X
to	B-X
examine	B-X
the	B-X
use	B-X
of	B-X
four	B-X
techniques	B-X
that	B-X
are	B-X
especially	B-X
relevant	B-X
to	B-X
physiological	B-X
studies	B-X
:	B-X
(	B-X
1	B-X
)	B-X
bivariate	B-X
correlation	B-X
and	B-X
linear	B-X
and	B-X
non-linear	B-X
regression	B-X
,	B-X
(	B-X
2	B-X
)	B-X
multiple	B-X
regression	B-X
,	B-X
(	B-X
3	B-X
)	B-X
repeated-measures	B-X
analysis	B-X
of	B-X
variance	B-X
and	B-X
(	B-X
4	B-X
)	B-X
multi-level	B-X
modelling	B-X
.	B-X

In	O
fact	O
,	O
in	O
at	O
least	O
one	O
case	O
,	O
PCA	O
was	O
unable	O
to	O
detect	O
a	O
linkage	O
signal	O
for	O
the	O
main	O
gene	O
transcript	O
loading	O
in	O
the	O
factor	O
(	O
Table	O
1	O
,	O
Group	O
1	O
,	O
Factor	O
2	O
)	O
.	O

We	O
also	O
performed	O
pairwise	O
bivariate	O
genetic	O
analysis	O
on	O
those	O
transcripts	O
that	O
co	O
-	O
localized	O
to	O
the	O
same	O
genomic	O
region	O
,	O
presumably	O
because	O
this	O
area	O
of	O
the	O
genome	O
harbored	O
genes	O
involved	O
in	O
the	O
regulation	O
of	O
these	O
transcripts	O
[	O
2	O
]	O
.	O

We	O
detected	O
significant	O
genetic	O
correlation	O
of	O
these	O
co	O
-	O
localized	O
transcripts	O
,	O
indicating	O
potential	O
gene	O
networks	O
operating	O
in	O
these	O
regions	O
.	O

However	O
,	O
in	O
most	O
cases	O
,	O
bivariate	O
linkage	O
analysis	O
did	O
not	O
improve	O
the	O
magnitude	O
of	O
the	O
LOD	O
score	O
compared	O
to	O
univariate	O
analysis	O
.	O
<EOS>	B-X
We	B-X
evaluate	B-X
five	B-X
exhaustive	B-X
bivariate	B-X
interaction	B-X
methods	B-X
,	B-X
fastepi	B-X
,	B-X
GBOOST	B-X
,	B-X
SHEsisEpi	B-X
,	B-X
DSS	B-X
,	B-X
and	B-X
IndOR	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
performed	B-X
genome-wide	B-X
association	B-X
studies	B-X
of	B-X
8	B-X
chronic	B-X
pain	B-X
types	B-X
using	B-X
UK	B-X
Biobank	B-X
data	B-X
(	B-X
N	B-X
=4,037-79,089	B-X
cases	B-X
;	B-X
N	B-X
=	B-X
239,125	B-X
controls	B-X
)	B-X
,	B-X
followed	B-X
by	B-X
bivariate	B-X
linkage	B-X
disequilibrium-score	B-X
regression	B-X
and	B-X
latent	B-X
causal	B-X
variable	B-X
analyses	B-X
to	B-X
determine	B-X
(	B-X
respectively	B-X
)	B-X
their	B-X
genetic	B-X
correlations	B-X
and	B-X
genetic	B-X
causal	B-X
proportion	B-X
(	B-X
GCP	B-X
)	B-X
parameters	B-X
with	B-X
1,492	B-X
other	B-X
complex	B-X
traits	B-X
.	B-X
This	B-X
data-driven	B-X
phenome-wide	B-X
association	B-X
analysis	B-X
has	B-X
demonstrated	B-X
a	B-X
novel	B-X
and	B-X
efficient	B-X
strategy	B-X
for	B-X
identifying	B-X
genetically	B-X
supported	B-X
risk	B-X
&	B-X
protective	B-X
traits	B-X
to	B-X
enhance	B-X
the	B-X
design	B-X
of	B-X
interventional	B-X
trials	B-X
targeting	B-X
underlying	B-X
causal	B-X
factors	B-X
and	B-X
accelerate	B-X
the	B-X
development	B-X
of	B-X
more	B-X
effective	B-X
treatments	B-X
with	B-X
broader	B-X
clinical	B-X
utility	B-X
.	B-X
We	B-X
used	B-X
population-based	B-X
data	B-X
to	B-X
identify	B-X
incident	B-X
cancer	B-X
cases	B-X
and	B-X
correlates	B-X
of	B-X
cancer	B-X
among	B-X
women	B-X
living	B-X
with	B-X
HIV/AIDS	B-X
in	B-X
British	B-X
Columbia	B-X
(	B-X
BC	B-X
)	B-X
,	B-X
Canada	B-X
between	B-X
1994	B-X
and	B-X
2008	B-X
.	B-X

Most	O
traits	O
were	O
highly	O
correlated	O
(	O
rho	O
G	O
>	O
0	O
.	O
60	O
)	O
,	O
and	O
therefore	O
they	O
may	O
provide	O
redundant	O
information	O
that	O
may	O
reduce	O
the	O
power	O
for	O
detection	O
of	O
the	O
bivariate	O
signal	O
[	O
8	O
]	O
.	O

In	O
addition	O
,	O
because	O
rho	O
G	O
is	O
a	O
test	O
of	O
the	O
overall	O
additive	O
genetic	O
correlation	O
among	O
two	O
traits	O
and	O
not	O
the	O
QTL	O
-	O
specific	O
pleiotropy	O
,	O
it	O
is	O
possible	O
that	O
the	O
co	O
-	O
localized	O
linkage	O
signals	O
are	O
not	O
in	O
fact	O
genetically	O
correlated	O
.	O

Further	O
analysis	O
is	O
required	O
to	O
address	O
these	O
issues	O
.	O
<EOS>	B-X
Discrete-choice	B-X
experiments	B-X
(	B-X
DCEs	B-X
)	B-X
have	B-X
become	B-X
a	B-X
commonly	B-X
used	B-X
instrument	B-X
in	B-X
health	B-X
economics	B-X
and	B-X
patient-preference	B-X
analysis	B-X
,	B-X
addressing	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
policy	B-X
questions	B-X
.	B-X
Although	B-X
theory	B-X
exists	B-X
as	B-X
to	B-X
the	B-X
calculation	B-X
of	B-X
sample	B-X
size	B-X
requirements	B-X
for	B-X
stated	B-X
choice	B-X
data	B-X
,	B-X
it	B-X
does	B-X
not	B-X
address	B-X
the	B-X
issue	B-X
of	B-X
minimum	B-X
sample	B-X
size	B-X
requirements	B-X
in	B-X
terms	B-X
of	B-X
the	B-X
statistical	B-X
power	B-X
of	B-X
hypothesis	B-X
tests	B-X
on	B-X
the	B-X
estimated	B-X
coefficients	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
paper	B-X
is	B-X
threefold	B-X
:	B-X
(	B-X
1	B-X
)	B-X
to	B-X
provide	B-X
insight	B-X
into	B-X
whether	B-X
and	B-X
how	B-X
researchers	B-X
have	B-X
dealt	B-X
with	B-X
sample	B-X
size	B-X
calculations	B-X
for	B-X
healthcare-related	B-X
DCE	B-X
studies	B-X
;	B-X
(	B-X
2	B-X
)	B-X
to	B-X
introduce	B-X
and	B-X
explain	B-X
the	B-X
required	B-X
sample	B-X
size	B-X
for	B-X
parameter	B-X
estimates	B-X
in	B-X
DCEs	B-X
;	B-X
and	B-X
(	B-X
3	B-X
)	B-X
to	B-X
provide	B-X
a	B-X
step-by-step	B-X
guide	B-X
for	B-X
the	B-X
calculation	B-X
of	B-X
the	B-X
minimum	B-X
sample	B-X
size	B-X
requirements	B-X
for	B-X
DCEs	B-X
in	B-X
health	B-X
care	B-X
.	B-X
We	B-X
also	B-X
address	B-X
the	B-X
potentially	B-X
data-driven	B-X
,	B-X
adaptive	B-X
selection	B-X
of	B-X
estimands	B-X
in	B-X
an	B-X
ongoing	B-X
trial	B-X
and	B-X
disentangle	B-X
certain	B-X
statistical	B-X
issues	B-X
that	B-X
pertain	B-X
to	B-X
estimation	B-X
rather	B-X
than	B-X
to	B-X
estimands	B-X
,	B-X
such	B-X
as	B-X
the	B-X
borrowing	B-X
of	B-X
nonconcurrent	B-X
information	B-X
.	B-X

The	O
chromosome	O
regions	O
selected	O
for	O
detailed	O
analyses	O
were	O
arbitrarily	O
chosen	O
as	O
we	O
identified	O
multiple	O
other	O
regions	O
with	O
co	O
-	O
localized	O
linkage	O
of	O
gene	O
expressions	O
.	O

The	O
results	O
from	O
our	O
univariate	O
genome	O
scan	O
differ	O
markedly	O
from	O
those	O
reported	O
by	O
Morley	O
et	O
al	O
.	O

[	O
2	O
]	O
because	O
we	O
included	O
a	O
smaller	O
sample	O
of	O
individuals	O
so	O
that	O
adjustment	O
for	O
covariate	O
effects	O
of	O
age	O
could	O
be	O
made	O
.	O
<EOS>	B-X
This	B-X
cross-sectional	B-X
study	B-X
had	B-X
two	B-X
goals	B-X
:	B-X
(	B-X
1	B-X
)	B-X
Identify	B-X
and	B-X
quantify	B-X
the	B-X
effects	B-X
of	B-X
aging	B-X
on	B-X
the	B-X
auditory	B-X
brainstem	B-X
response	B-X
(	B-X
ABR	B-X
)	B-X
;	B-X
(	B-X
2	B-X
)	B-X
Describe	B-X
how	B-X
click	B-X
rate	B-X
and	B-X
hearing	B-X
impairment	B-X
modify	B-X
effects	B-X
of	B-X
aging	B-X
.	B-X
RESEARCH	B-X
DESIGN	B-X
AND	B-X
ANALYSIS	B-X
:	B-X
ABR	B-X
measures	B-X
were	B-X
obtained	B-X
from	B-X
131	B-X
predominately	B-X
male	B-X
Veteran	B-X
participants	B-X
aged	B-X
26	B-X
to	B-X
71	B-X
yr.	B-X
Metrics	B-X
analyzed	B-X
include	B-X
amplitude	B-X
and	B-X
latency	B-X
for	B-X
waves	B-X
I	B-X
,	B-X
III	B-X
,	B-X
and	B-X
V	B-X
,	B-X
and	B-X
the	B-X
I-V	B-X
interpeak	B-X
latency	B-X
interval	B-X
(	B-X
IPI	B-X
)	B-X
at	B-X
three	B-X
repetition	B-X
rates	B-X
(	B-X
11	B-X
,	B-X
51	B-X
,	B-X
and	B-X
71	B-X
clicks/sec	B-X
)	B-X
using	B-X
both	B-X
polarities	B-X
.	B-X
In	B-X
order	B-X
to	B-X
avoid	B-X
confounding	B-X
from	B-X
missing	B-X
data	B-X
due	B-X
to	B-X
hearing	B-X
impairment	B-X
,	B-X
participants	B-X
had	B-X
hearing	B-X
thresholds	B-X
<	B-X
40	B-X
dB	B-X
HL	B-X
at	B-X
2	B-X
kHz	B-X
and	B-X
70	B-X
dB	B-X
HL	B-X
at	B-X
4	B-X
kHz	B-X
in	B-X
at	B-X
least	B-X
one	B-X
ear	B-X
.	B-X
Additionally	B-X
,	B-X
the	B-X
median	B-X
2	B-X
,	B-X
3	B-X
,	B-X
and	B-X
4	B-X
kHz	B-X
pure	B-X
tone	B-X
threshold	B-X
average	B-X
(	B-X
PTA2,3,4	B-X
)	B-X
for	B-X
the	B-X
sample	B-X
,	B-X
â¼17	B-X
dB	B-X
HL	B-X
,	B-X
was	B-X
used	B-X
to	B-X
delineate	B-X
subgroups	B-X
of	B-X
better	B-X
and	B-X
worse	B-X
hearing	B-X
ears	B-X
,	B-X
and	B-X
only	B-X
the	B-X
better	B-X
hearing	B-X
sample	B-X
was	B-X
modeled	B-X
statistically	B-X
.	B-X
We	B-X
modeled	B-X
ABR	B-X
responses	B-X
using	B-X
age	B-X
,	B-X
repetition	B-X
rate	B-X
,	B-X
and	B-X
PTA2,3,4	B-X
as	B-X
covariates	B-X
.	B-X
Random	B-X
effects	B-X
were	B-X
used	B-X
to	B-X
model	B-X
correlation	B-X
between	B-X
the	B-X
two	B-X
ears	B-X
of	B-X
a	B-X
subject	B-X
and	B-X
across	B-X
repetition	B-X
rates	B-X
.	B-X
Inferences	B-X
regarding	B-X
effects	B-X
of	B-X
aging	B-X
on	B-X
ABR	B-X
measures	B-X
at	B-X
each	B-X
rate	B-X
were	B-X
derived	B-X
from	B-X
the	B-X
fitted	B-X
model	B-X
.	B-X

Our	O
analysis	O
strategy	O
also	O
adjusted	O
for	O
the	O
effects	O
of	O
age	O
and	O
sex	O
,	O
which	O
could	O
also	O
add	O
to	O
the	O
observed	O
differences	O
[	O
13	O
]	O
.	O

Finally	O
,	O
our	O
definition	O
of	O
genome	O
window	O
size	O
for	O
co	O
-	O
localized	O
gene	O
expressions	O
was	O
twice	O
larger	O
than	O
the	O
one	O
described	O
in	O
the	O
study	O
of	O
Morley	O
et	O
al	O
.	O

Conclusion	O
<EOS>	B-X
Conclusion	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X

We	O
identified	O
several	O
chromosomal	O
regions	O
of	O
co	O
-	O
localized	O
trans	O
-	O
regulatory	O
genes	O
with	O
significant	O
heritability	O
.	O

Some	O
of	O
these	O
regulatory	O
genes	O
displayed	O
strong	O
additive	O
genetic	O
correlations	O
,	O
and	O
may	O
be	O
part	O
of	O
genetic	O
networks	O
.	O

However	O
,	O
when	O
compared	O
to	O
univariate	O
analysis	O
,	O
linkage	O
analysis	O
of	O
bivariate	O
phenotypes	O
and	O
factor	O
scores	O
obtained	O
from	O
PCA	O
did	O
not	O
improve	O
the	O
ability	O
to	O
identify	O
chromosomal	O
regions	O
of	O
co	O
-	O
localized	O
gene	O
expressions	O
.	O

List	O
of	O
Abbreviations	O
<EOS>	B-X
List	B-X
of	B-X
Abbreviations	B-X
.	B-X
List	B-X
of	B-X
abbreviations	B-X
.	B-X
List	B-X
of	B-X
abbreviations	B-X
.	B-X
[	B-X
List	B-X
of	B-X
abbreviations	B-X
]	B-X
.	B-X

CEPH	O
:	O
Centre	O
d	O
'	O
Etude	O
du	O
Polymorphisme	O
Humain	O
<EOS>	B-X
A	B-X
set	B-X
of	B-X
Centre	B-X
d'Ãtude	B-X
du	B-X
Polymorphisme	B-X
Humain	B-X
(	B-X
CEPH	B-X
)	B-X
cell	B-X
lines	B-X
serves	B-X
as	B-X
a	B-X
large	B-X
reference	B-X
collection	B-X
that	B-X
has	B-X
been	B-X
widely	B-X
used	B-X
as	B-X
a	B-X
benchmark	B-X
for	B-X
allele	B-X
frequencies	B-X
in	B-X
the	B-X
analysis	B-X
of	B-X
genetic	B-X
variants	B-X
,	B-X
to	B-X
create	B-X
linkage	B-X
maps	B-X
of	B-X
the	B-X
human	B-X
genome	B-X
,	B-X
to	B-X
study	B-X
the	B-X
genetics	B-X
of	B-X
gene	B-X
expression	B-X
,	B-X
to	B-X
provide	B-X
samples	B-X
to	B-X
the	B-X
HapMap	B-X
and	B-X
1000	B-X
Genomes	B-X
projects	B-X
,	B-X
and	B-X
for	B-X
a	B-X
variety	B-X
of	B-X
other	B-X
applications	B-X
.	B-X
An	B-X
explicit	B-X
feature	B-X
of	B-X
the	B-X
CEPH	B-X
collection	B-X
is	B-X
that	B-X
these	B-X
multigenerational	B-X
families	B-X
represent	B-X
reference	B-X
panels	B-X
of	B-X
known	B-X
relatedness	B-X
,	B-X
consisting	B-X
mostly	B-X
of	B-X
three-generation	B-X
pedigrees	B-X
with	B-X
large	B-X
sibships	B-X
,	B-X
two	B-X
parents	B-X
,	B-X
and	B-X
grandparents	B-X
.	B-X
We	B-X
applied	B-X
identity-by-state	B-X
(	B-X
IBS	B-X
)	B-X
and	B-X
identity-by-descent	B-X
(	B-X
IBD	B-X
)	B-X
methods	B-X
to	B-X
high-density	B-X
genotype	B-X
data	B-X
from	B-X
186	B-X
CEPH	B-X
individuals	B-X
in	B-X
13	B-X
families	B-X
.	B-X
Our	B-X
findings	B-X
support	B-X
and	B-X
extend	B-X
a	B-X
1999	B-X
report	B-X
,	B-X
based	B-X
on	B-X
the	B-X
use	B-X
of	B-X
short	B-X
tandem-repeat	B-X
polymorphisms	B-X
,	B-X
that	B-X
several	B-X
CEPH	B-X
families	B-X
had	B-X
regions	B-X
of	B-X
homozygosity	B-X
consistent	B-X
with	B-X
autozygosity	B-X
.	B-X
Our	B-X
findings	B-X
may	B-X
affect	B-X
the	B-X
interpretation	B-X
of	B-X
previous	B-X
studies	B-X
and	B-X
the	B-X
design	B-X
of	B-X
future	B-X
studies	B-X
that	B-X
rely	B-X
on	B-X
the	B-X
CEPH	B-X
resource	B-X
.	B-X

GAW	O
:	O
Genetic	O
Analysis	O
Workshop	O
<EOS>	B-X
For	B-X
Genetic	B-X
Analysis	B-X
Workshop	B-X
15	B-X
Problem	B-X
2	B-X
,	B-X
we	B-X
organized	B-X
data	B-X
from	B-X
several	B-X
ongoing	B-X
studies	B-X
designed	B-X
to	B-X
identify	B-X
genetic	B-X
and	B-X
environmental	B-X
risk	B-X
factors	B-X
for	B-X
rheumatoid	B-X
arthritis	B-X
.	B-X
Here	B-X
we	B-X
describe	B-X
the	B-X
data	B-X
provided	B-X
for	B-X
Problem	B-X
1	B-X
of	B-X
Genetic	B-X
Analysis	B-X
Workshop	B-X
15	B-X
.	B-X
Genetic	B-X
Analysis	B-X
Workshop	B-X
19	B-X
provided	B-X
a	B-X
platform	B-X
for	B-X
developing	B-X
and	B-X
evaluating	B-X
statistical	B-X
methods	B-X
to	B-X
analyze	B-X
whole-genome	B-X
sequence	B-X
and	B-X
gene	B-X
expression	B-X
data	B-X
from	B-X
a	B-X
pedigree-based	B-X
sample	B-X
,	B-X
as	B-X
well	B-X
as	B-X
whole-exome	B-X
sequence	B-X
data	B-X
from	B-X
a	B-X
large	B-X
cohort	B-X
of	B-X
unrelated	B-X
individuals	B-X
.	B-X
In	B-X
this	B-X
article	B-X
we	B-X
present	B-X
an	B-X
overview	B-X
of	B-X
the	B-X
data	B-X
sets	B-X
,	B-X
the	B-X
GAW	B-X
experience	B-X
,	B-X
and	B-X
summaries	B-X
of	B-X
the	B-X
contributions	B-X
arranged	B-X
into	B-X
nine	B-X
methodological	B-X
themes	B-X
.	B-X

H2	O
:	O
heritability	O
<EOS>	B-X
Our	B-X
study	B-X
aimed	B-X
to	B-X
determine	B-X
whether	B-X
significant	B-X
heritability	B-X
exists	B-X
between	B-X
parents	B-X
and	B-X
children	B-X
using	B-X
multiple	B-X
soft	B-X
and	B-X
hard	B-X
tissue	B-X
measurements	B-X
of	B-X
nasal	B-X
dimensions	B-X
.	B-X
There	B-X
are	B-X
four	B-X
major	B-X
hypotheses	B-X
(	B-X
H1	B-X
,	B-X
H2	B-X
,	B-X
H3	B-X
,	B-X
and	B-X
H4	B-X
)	B-X
as	B-X
to	B-X
the	B-X
source	B-X
of	B-X
missing	B-X
heritability	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
estimates	B-X
obtained	B-X
from	B-X
GWAS	B-X
underestimate	B-X
heritability	B-X
by	B-X
not	B-X
taking	B-X
into	B-X
account	B-X
non-DNA	B-X
(	B-X
epigenetic	B-X
)	B-X
sources	B-X
of	B-X
heritability	B-X
.	B-X
Taking	B-X
those	B-X
factors	B-X
into	B-X
account	B-X
(	B-X
H4	B-X
)	B-X
should	B-X
result	B-X
in	B-X
increased	B-X
heritability	B-X
estimates	B-X
.	B-X

LOD	O
:	O
logarithm	O
of	O
the	O
odds	O
<EOS>	B-X
Evidence	B-X
for	B-X
linkage	B-X
is	B-X
most	B-X
commonly	B-X
expressed	B-X
as	B-X
a	B-X
logarithm	B-X
of	B-X
the	B-X
odds	B-X
score	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
,	B-X
a	B-X
)	B-X
22	B-X
recombination	B-X
events	B-X
happened	B-X
within	B-X
the	B-X
tightly	B-X
linked	B-X
X-STR	B-X
clusters	B-X
,	B-X
which	B-X
span	B-X
<	B-X
1.0	B-X
Mb	B-X
;	B-X
b	B-X
)	B-X
significantly	B-X
linked	B-X
marker	B-X
pairs	B-X
were	B-X
observed	B-X
with	B-X
the	B-X
LOD	B-X
(	B-X
logarithm	B-X
of	B-X
the	B-X
odds	B-X
)	B-X
scores	B-X
>	B-X
2.0	B-X
(	B-X
2.0104	B-X
to	B-X
54.8316	B-X
)	B-X
;	B-X
c	B-X
)	B-X
the	B-X
average	B-X
mutation	B-X
rate	B-X
of	B-X
the	B-X
38	B-X
X-STR	B-X
loci	B-X
was	B-X
1.32	B-X
Ã	B-X
10	B-X
Parametric	B-X
and	B-X
non-parametric	B-X
multipoint	B-X
linkage	B-X
analyses	B-X
were	B-X
carried	B-X
out	B-X
with	B-X
Genespring	B-X
GT	B-X
v.2.0	B-X
software	B-X
,	B-X
and	B-X
the	B-X
logarithm	B-X
of	B-X
odds	B-X
(	B-X
LOD	B-X
)	B-X
score	B-X
and	B-X
nonparametric	B-X
linkage	B-X
(	B-X
NPL	B-X
)	B-X
score	B-X
were	B-X
calculated	B-X
.	B-X
The	B-X
strongest	B-X
evidence	B-X
for	B-X
linkage	B-X
was	B-X
found	B-X
on	B-X
chromosome	B-X
8q23-24	B-X
,	B-X
with	B-X
a	B-X
peak	B-X
LOD	B-X
score	B-X
of	B-X
2.658	B-X
(	B-X
Î¸=0	B-X
)	B-X
,	B-X
covering	B-X
2.377	B-X
Mb	B-X
from	B-X
single	B-X
nucleotide	B-X
polymorphisms	B-X
(	B-X
SNPs	B-X
)	B-X
rs724717	B-X
to	B-X
rs720132	B-X
.	B-X
Additionally	B-X
,	B-X
the	B-X
second	B-X
highest	B-X
NPL	B-X
score	B-X
of	B-X
2.727	B-X
(	B-X
P=0.0156	B-X
)	B-X
and	B-X
LOD	B-X
score	B-X
of	B-X
2.528	B-X
(	B-X
Î¸=0	B-X
)	B-X
were	B-X
obtained	B-X
on	B-X
chromosome	B-X
12p12	B-X
for	B-X
three	B-X
consecutive	B-X
markers	B-X
(	B-X
rs1919980	B-X
,	B-X
rs763853	B-X
and	B-X
rs725124	B-X
)	B-X
.	B-X
Notably	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
these	B-X
two	B-X
regions	B-X
;	B-X
no	B-X
significant	B-X
linkage	B-X
was	B-X
identified	B-X
for	B-X
other	B-X
chromosomal	B-X
regions	B-X
(	B-X
with	B-X
LOD	B-X
and	B-X
NPL	B-X
scores	B-X
>	B-X
2.0	B-X
)	B-X
.	B-X

MIBD	O
:	O
multipoint	O
identity	O
-	O
by	O
-	O
descent	O
matrices	O
<EOS>	B-X
Multipoint	B-X
identity-by-descent	B-X
(	B-X
MIBD	B-X
)	B-X
matrices	B-X
were	B-X
derived	B-X
from	B-X
genotypes	B-X
using	B-X
IBDLD	B-X
.	B-X

N	O
/	O
A	O
:	O
not	O
apply	O
<EOS>	B-X
Being	B-X
a	B-X
dual	B-X
purpose	B-X
enzyme	B-X
,	B-X
the	B-X
DNA	B-X
polymerase	B-X
is	B-X
responsible	B-X
for	B-X
elongation	B-X
of	B-X
the	B-X
newly	B-X
formed	B-X
DNA	B-X
strand	B-X
as	B-X
well	B-X
as	B-X
cleaving	B-X
the	B-X
erroneous	B-X
growth	B-X
in	B-X
case	B-X
of	B-X
a	B-X
misincorporation	B-X
.	B-X
The	B-X
efficiency	B-X
of	B-X
replication	B-X
depends	B-X
on	B-X
the	B-X
coordination	B-X
of	B-X
the	B-X
polymerization	B-X
and	B-X
exonuclease	B-X
activity	B-X
of	B-X
DNA	B-X
polymerase	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
propose	B-X
and	B-X
analyze	B-X
a	B-X
minimal	B-X
kinetic	B-X
model	B-X
of	B-X
DNA	B-X
replication	B-X
and	B-X
determine	B-X
exact	B-X
expressions	B-X
for	B-X
the	B-X
velocity	B-X
of	B-X
elongation	B-X
and	B-X
the	B-X
accuracy	B-X
of	B-X
replication	B-X
.	B-X
The	B-X
accuracy	B-X
of	B-X
the	B-X
process	B-X
is	B-X
mainly	B-X
controlled	B-X
by	B-X
the	B-X
crucial	B-X
role	B-X
of	B-X
stepping	B-X
after	B-X
erroneous	B-X
incorporation	B-X
,	B-X
which	B-X
has	B-X
impact	B-X
on	B-X
both	B-X
polymerase	B-X
and	B-X
exonuclease	B-X
activities	B-X
of	B-X
DNA	B-X
polymerase	B-X
.	B-X

NCBI	O
:	O
National	O
Center	O
for	O
Biotechnology	O
Information	O
<EOS>	B-X
The	B-X
National	B-X
Center	B-X
for	B-X
Biotechnology	B-X
Information	B-X
(	B-X
NCBI	B-X
)	B-X
provides	B-X
a	B-X
large	B-X
suite	B-X
of	B-X
online	B-X
resources	B-X
for	B-X
biological	B-X
information	B-X
and	B-X
data	B-X
,	B-X
including	B-X
the	B-X
GenBankÂ®	B-X
nucleic	B-X
acid	B-X
sequence	B-X
database	B-X
and	B-X
the	B-X
PubMedÂ®	B-X
database	B-X
of	B-X
citations	B-X
and	B-X
abstracts	B-X
published	B-X
in	B-X
life	B-X
science	B-X
journals	B-X
.	B-X
New	B-X
resources	B-X
released	B-X
in	B-X
the	B-X
past	B-X
year	B-X
include	B-X
a	B-X
new	B-X
PubMed	B-X
interface	B-X
and	B-X
NCBI	B-X
datasets	B-X
.	B-X
All	B-X
of	B-X
these	B-X
resources	B-X
can	B-X
be	B-X
accessed	B-X
through	B-X
the	B-X
NCBI	B-X
home	B-X
page	B-X
at	B-X
https	B-X
:	B-X
//www.ncbi.nlm.nih.gov	B-X
.	B-X
The	B-X
National	B-X
Center	B-X
for	B-X
Biotechnology	B-X
Information	B-X
(	B-X
NCBI	B-X
)	B-X
produces	B-X
a	B-X
variety	B-X
of	B-X
online	B-X
information	B-X
resources	B-X
for	B-X
biology	B-X
,	B-X
including	B-X
the	B-X
GenBankÂ®	B-X
nucleic	B-X
acid	B-X
sequence	B-X
database	B-X
and	B-X
the	B-X
PubMedÂ®	B-X
database	B-X
of	B-X
citations	B-X
and	B-X
abstracts	B-X
published	B-X
in	B-X
life	B-X
science	B-X
journals	B-X
.	B-X
NCBI	B-X
provides	B-X
search	B-X
and	B-X
retrieval	B-X
operations	B-X
for	B-X
most	B-X
of	B-X
these	B-X
data	B-X
from	B-X
35	B-X
distinct	B-X
databases	B-X
.	B-X
These	B-X
resources	B-X
can	B-X
be	B-X
accessed	B-X
through	B-X
the	B-X
NCBI	B-X
home	B-X
page	B-X
at	B-X
https	B-X
:	B-X
//www.ncbi.nlm.nih.gov	B-X
.	B-X

PCA	O
:	O
principal	O
-	O
component	O
analysis	O
<EOS>	B-X
It	B-X
has	B-X
become	B-X
commonplace	B-X
to	B-X
employ	B-X
principal	B-X
component	B-X
analysis	B-X
to	B-X
reveal	B-X
the	B-X
most	B-X
important	B-X
motions	B-X
in	B-X
proteins	B-X
.	B-X
This	B-X
method	B-X
is	B-X
more	B-X
commonly	B-X
known	B-X
by	B-X
its	B-X
acronym	B-X
,	B-X
PCA	B-X
.	B-X
While	B-X
most	B-X
popular	B-X
molecular	B-X
dynamics	B-X
packages	B-X
inevitably	B-X
provide	B-X
PCA	B-X
tools	B-X
to	B-X
analyze	B-X
protein	B-X
trajectories	B-X
,	B-X
researchers	B-X
often	B-X
make	B-X
inferences	B-X
of	B-X
their	B-X
results	B-X
without	B-X
having	B-X
insight	B-X
into	B-X
how	B-X
to	B-X
make	B-X
interpretations	B-X
,	B-X
and	B-X
they	B-X
are	B-X
often	B-X
unaware	B-X
of	B-X
limitations	B-X
and	B-X
generalizations	B-X
of	B-X
such	B-X
analysis	B-X
.	B-X
Here	B-X
we	B-X
review	B-X
best	B-X
practices	B-X
for	B-X
applying	B-X
standard	B-X
PCA	B-X
,	B-X
describe	B-X
useful	B-X
variants	B-X
,	B-X
discuss	B-X
why	B-X
one	B-X
may	B-X
wish	B-X
to	B-X
make	B-X
comparison	B-X
studies	B-X
,	B-X
and	B-X
describe	B-X
a	B-X
set	B-X
of	B-X
metrics	B-X
that	B-X
make	B-X
comparisons	B-X
possible	B-X
.	B-X
The	B-X
topic	B-X
of	B-X
PCA	B-X
is	B-X
reviewed	B-X
from	B-X
the	B-X
perspective	B-X
of	B-X
many	B-X
practical	B-X
considerations	B-X
,	B-X
and	B-X
useful	B-X
recipes	B-X
are	B-X
provided	B-X
.	B-X

QTL	O
:	O
quantitative	O
trait	O
loci	O
<EOS>	B-X
Advancement	B-X
in	B-X
the	B-X
field	B-X
of	B-X
genetics	B-X
and	B-X
genomics	B-X
after	B-X
the	B-X
discovery	B-X
of	B-X
Mendel	B-X
's	B-X
laws	B-X
of	B-X
inheritance	B-X
has	B-X
led	B-X
to	B-X
map	B-X
the	B-X
genes	B-X
controlling	B-X
qualitative	B-X
and	B-X
quantitative	B-X
traits	B-X
in	B-X
crop	B-X
plant	B-X
species	B-X
.	B-X
Mapping	B-X
of	B-X
genomic	B-X
regions	B-X
controlling	B-X
the	B-X
variation	B-X
of	B-X
quantitatively	B-X
inherited	B-X
traits	B-X
has	B-X
become	B-X
routine	B-X
after	B-X
the	B-X
advent	B-X
of	B-X
different	B-X
types	B-X
of	B-X
molecular	B-X
markers	B-X
.	B-X
Recently	B-X
,	B-X
the	B-X
next	B-X
generation	B-X
sequencing	B-X
methods	B-X
have	B-X
accelerated	B-X
the	B-X
research	B-X
on	B-X
QTL	B-X
analysis	B-X
.	B-X
These	B-X
efforts	B-X
have	B-X
led	B-X
to	B-X
the	B-X
identification	B-X
of	B-X
more	B-X
closely	B-X
linked	B-X
molecular	B-X
markers	B-X
with	B-X
gene/QTLs	B-X
and	B-X
also	B-X
identified	B-X
markers	B-X
even	B-X
within	B-X
gene/QTL	B-X
controlling	B-X
the	B-X
trait	B-X
of	B-X
interest	B-X
.	B-X
Efforts	B-X
have	B-X
also	B-X
been	B-X
made	B-X
towards	B-X
cloning	B-X
gene/QTLs	B-X
or	B-X
identification	B-X
of	B-X
potential	B-X
candidate	B-X
genes	B-X
responsible	B-X
for	B-X
a	B-X
trait	B-X
.	B-X
Further	B-X
new	B-X
concepts	B-X
like	B-X
crop	B-X
QTLome	B-X
and	B-X
QTL	B-X
prioritization	B-X
have	B-X
accelerated	B-X
precise	B-X
application	B-X
of	B-X
QTLs	B-X
for	B-X
genetic	B-X
improvement	B-X
of	B-X
complex	B-X
traits	B-X
.	B-X
In	B-X
the	B-X
past	B-X
years	B-X
,	B-X
efforts	B-X
have	B-X
also	B-X
been	B-X
made	B-X
in	B-X
exploitation	B-X
of	B-X
a	B-X
number	B-X
of	B-X
QTL	B-X
for	B-X
improving	B-X
grain	B-X
yield	B-X
or	B-X
other	B-X
agronomic	B-X
traits	B-X
in	B-X
various	B-X
crops	B-X
through	B-X
markers	B-X
assisted	B-X
selection	B-X
leading	B-X
to	B-X
cultivation	B-X
of	B-X
these	B-X
improved	B-X
varieties	B-X
at	B-X
farmers	B-X
'	B-X
field	B-X
.	B-X
In	B-X
present	B-X
article	B-X
,	B-X
we	B-X
reviewed	B-X
QTLs	B-X
from	B-X
their	B-X
identification	B-X
to	B-X
exploitation	B-X
in	B-X
plant	B-X
breeding	B-X
programs	B-X
and	B-X
also	B-X
reviewed	B-X
that	B-X
how	B-X
improved	B-X
cultivars	B-X
developed	B-X
through	B-X
introgression	B-X
of	B-X
QTLs	B-X
have	B-X
improved	B-X
the	B-X
yield	B-X
productivity	B-X
in	B-X
many	B-X
crops	B-X
.	B-X

SE	O
:	O
standard	O
error	O
of	O
the	O
mean	O
<EOS>	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
profile	B-X
the	B-X
distribution	B-X
of	B-X
ocular	B-X
biometry	B-X
parameters	B-X
and	B-X
to	B-X
identify	B-X
correlates	B-X
of	B-X
spherical	B-X
equivalent	B-X
refraction	B-X
(	B-X
SE	B-X
)	B-X
among	B-X
school	B-X
children	B-X
in	B-X
South	B-X
India	B-X
.	B-X
To	B-X
evaluate	B-X
the	B-X
association	B-X
between	B-X
refractive	B-X
error	B-X
and	B-X
the	B-X
prevalence	B-X
of	B-X
glaucoma	B-X
by	B-X
race	B-X
or	B-X
ethnicity	B-X
.	B-X
The	B-X
mean	B-X
platelet	B-X
volume	B-X
(	B-X
MPV	B-X
)	B-X
is	B-X
a	B-X
rapid	B-X
measure	B-X
of	B-X
platelet	B-X
activation	B-X
and	B-X
a	B-X
prognostic	B-X
marker	B-X
in	B-X
patients	B-X
with	B-X
cardiovascular	B-X
disease	B-X
.	B-X
The	B-X
SE	B-X
for	B-X
the	B-X
treatment	B-X
effect	B-X
in	B-X
the	B-X
MMRM	B-X
analysis	B-X
is	B-X
usually	B-X
estimated	B-X
by	B-X
assuming	B-X
the	B-X
orthogonality	B-X
of	B-X
the	B-X
fixed	B-X
effect	B-X
and	B-X
variance-covariance	B-X
parameters	B-X
,	B-X
which	B-X
is	B-X
the	B-X
orthogonality	B-X
property	B-X
of	B-X
a	B-X
multivariate	B-X
normal	B-X
distribution	B-X
,	B-X
because	B-X
of	B-X
default	B-X
settings	B-X
of	B-X
most	B-X
standard	B-X
statistical	B-X
software	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
assumption	B-X
of	B-X
the	B-X
orthogonality	B-X
property	B-X
on	B-X
the	B-X
estimation	B-X
of	B-X
the	B-X
SE	B-X
for	B-X
the	B-X
MMRM	B-X
analysis	B-X
.	B-X
From	B-X
simulation	B-X
and	B-X
case	B-X
studies	B-X
,	B-X
it	B-X
was	B-X
shown	B-X
that	B-X
the	B-X
SE	B-X
with	B-X
the	B-X
assumption	B-X
of	B-X
orthogonality	B-X
property	B-X
had	B-X
nonnegligible	B-X
bias	B-X
,	B-X
especially	B-X
when	B-X
the	B-X
analysis	B-X
models	B-X
assuming	B-X
heteroscedasticity	B-X
between	B-X
treatment	B-X
groups	B-X
were	B-X
applied	B-X
.	B-X
Assuming	B-X
the	B-X
orthogonality	B-X
property	B-X
in	B-X
the	B-X
MMRM	B-X
analysis	B-X
would	B-X
lead	B-X
to	B-X
invalid	B-X
statistical	B-X
inference	B-X
,	B-X
and	B-X
it	B-X
is	B-X
necessary	B-X
to	B-X
be	B-X
careful	B-X
when	B-X
applying	B-X
the	B-X
MMRM	B-X
analysis	B-X
with	B-X
most	B-X
standard	B-X
software	B-X
.	B-X

SNP	O
:	O
single	O
-	O
nucleotide	O
polymorphism	O
<EOS>	B-X
Single-nucleotide	B-X
polymorphisms	B-X
(	B-X
SNPs	B-X
)	B-X
and	B-X
single-nucleotide	B-X
mutations	B-X
result	B-X
from	B-X
the	B-X
substitution	B-X
of	B-X
only	B-X
a	B-X
single	B-X
base	B-X
.	B-X
The	B-X
SNP	B-X
or	B-X
mutation	B-X
can	B-X
be	B-X
relevant	B-X
to	B-X
disease	B-X
susceptibility	B-X
,	B-X
pathogenesis	B-X
of	B-X
disease	B-X
,	B-X
and	B-X
efficacy	B-X
of	B-X
specific	B-X
drugs	B-X
.	B-X
It	B-X
is	B-X
important	B-X
to	B-X
detect	B-X
SNPs	B-X
or	B-X
mutations	B-X
clinically	B-X
.	B-X
Methods	B-X
to	B-X
distinguish/detect	B-X
SNPs	B-X
or	B-X
mutations	B-X
should	B-X
be	B-X
highly	B-X
specific	B-X
and	B-X
sensitive	B-X
.	B-X
PCR-based	B-X
methods	B-X
for	B-X
SNP/mutation	B-X
detection	B-X
are	B-X
broadly	B-X
categorized	B-X
into	B-X
two	B-X
types-	B-X
(	B-X
1	B-X
)	B-X
polymorphic	B-X
or	B-X
mutant	B-X
allele-directed	B-X
specific	B-X
analysis	B-X
using	B-X
primers	B-X
matched	B-X
with	B-X
substituted	B-X
nucleotide	B-X
or	B-X
using	B-X
oligonucleotides	B-X
to	B-X
block	B-X
or	B-X
clamp	B-X
the	B-X
nontargeted	B-X
template	B-X
,	B-X
and	B-X
(	B-X
2	B-X
)	B-X
melting	B-X
curve	B-X
analysis	B-X
,	B-X
which	B-X
is	B-X
combined	B-X
with	B-X
the	B-X
real-time	B-X
PCR	B-X
techniques	B-X
using	B-X
hydrolysis	B-X
probes	B-X
,	B-X
hybridization	B-X
probes	B-X
,	B-X
or	B-X
double-stranded	B-X
DNA-binding	B-X
fluorescent	B-X
dyes	B-X
.	B-X
Innovative	B-X
and	B-X
novel	B-X
approaches	B-X
as	B-X
well	B-X
as	B-X
technical	B-X
improvements	B-X
have	B-X
made	B-X
SNP-	B-X
or	B-X
mutation-detection	B-X
methods	B-X
increasingly	B-X
more	B-X
sophisticated	B-X
.	B-X

SOLAR	O
:	O
Sequential	O
Oligogenic	O
Linkage	O
Analysis	O
Routines	O
<EOS>	B-X
The	B-X
Sequential	B-X
Oligogenic	B-X
Linkage	B-X
Analysis	B-X
Routines	B-X
(	B-X
SOLAR	B-X
)	B-X
imaging	B-X
genetics	B-X
software	B-X
can	B-X
estimate	B-X
the	B-X
heritability	B-X
of	B-X
a	B-X
trait	B-X
in	B-X
complex	B-X
pedigrees	B-X
.	B-X
We	B-X
investigate	B-X
the	B-X
ability	B-X
of	B-X
SOLAR	B-X
to	B-X
accurately	B-X
estimate	B-X
heritability	B-X
and	B-X
common	B-X
environmental	B-X
effects	B-X
on	B-X
simulated	B-X
imaging	B-X
phenotypes	B-X
in	B-X
various	B-X
family	B-X
structures	B-X
.	B-X
Analyzing	B-X
genotype	B-X
,	B-X
phenotype	B-X
and	B-X
expression	B-X
data	B-X
from	B-X
20	B-X
pedigrees	B-X
,	B-X
the	B-X
members	B-X
of	B-X
our	B-X
Genetic	B-X
Analysis	B-X
Workshop	B-X
(	B-X
GAW	B-X
)	B-X
19	B-X
gene	B-X
expression	B-X
group	B-X
published	B-X
9	B-X
papers	B-X
,	B-X
tackling	B-X
some	B-X
timely	B-X
and	B-X
important	B-X
problems	B-X
and	B-X
questions	B-X
.	B-X
The	B-X
general	B-X
pedigree	B-X
variance	B-X
component	B-X
and	B-X
IBD	B-X
estimation	B-X
methods	B-X
have	B-X
been	B-X
implemented	B-X
in	B-X
the	B-X
SOLAR	B-X
(	B-X
Sequential	B-X
Oligogenic	B-X
Linkage	B-X
Analysis	B-X
Routines	B-X
)	B-X
computer	B-X
package	B-X
.	B-X

Competing	O
interests	O
<EOS>	B-X
Elective	B-X
ventilation	B-X
and	B-X
interests	B-X
.	B-X
An	B-X
examination	B-X
of	B-X
the	B-X
principle	B-X
of	B-X
precedent	B-X
autonomy	B-X
reveals	B-X
that	B-X
a	B-X
future-binding	B-X
research	B-X
decision	B-X
is	B-X
within	B-X
the	B-X
scope	B-X
of	B-X
a	B-X
competent	B-X
person	B-X
's	B-X
critical	B-X
interests	B-X
,	B-X
if	B-X
the	B-X
decision	B-X
is	B-X
consistent	B-X
with	B-X
what	B-X
the	B-X
person	B-X
believes	B-X
gives	B-X
her	B-X
life	B-X
intrinsic	B-X
value	B-X
.	B-X
Safety	B-X
of	B-X
young	B-X
drivers	B-X
.	B-X
In	B-X
this	B-X
article	B-X
I	B-X
will	B-X
show	B-X
that	B-X
'best	B-X
interests	B-X
'	B-X
is	B-X
a	B-X
concept	B-X
that	B-X
fits	B-X
nicely	B-X
with	B-X
many	B-X
of	B-X
the	B-X
features	B-X
of	B-X
pragmatism	B-X
--	B-X
Holm	B-X
and	B-X
Edgar	B-X
's	B-X
rejection	B-X
of	B-X
the	B-X
principle	B-X
in	B-X
favour	B-X
of	B-X
pragmatism	B-X
it	B-X
will	B-X
be	B-X
suggested	B-X
is	B-X
misplaced	B-X
.	B-X
'Best	B-X
interests	B-X
'	B-X
as	B-X
a	B-X
principle	B-X
may	B-X
be	B-X
considered	B-X
an	B-X
embodiment	B-X
of	B-X
the	B-X
ideals	B-X
of	B-X
pragmatic	B-X
adjudication	B-X
.	B-X
The	B-X
paper	B-X
starts	B-X
by	B-X
briefly	B-X
introducing	B-X
the	B-X
concept	B-X
of	B-X
'best	B-X
interests	B-X
'	B-X
and	B-X
theories	B-X
of	B-X
judicial	B-X
and	B-X
legal	B-X
'pragmatism	B-X
'	B-X
.	B-X
The	B-X
paper	B-X
concludes	B-X
by	B-X
suggesting	B-X
how	B-X
we	B-X
view	B-X
the	B-X
relationship	B-X
between	B-X
'best	B-X
interests	B-X
'	B-X
and	B-X
'pragmatism	B-X
'	B-X
.	B-X

The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Potentiation	O
of	O
Nerve	O
Growth	O
Factor	O
-	O
Induced	O
Neurite	O
Outgrowth	O
by	O
Fluvoxamine	O
:	O
Role	O
of	O
Sigma	O
-	O
1	O
Receptors	O
,	O
IP3	O
Receptors	O
and	O
Cellular	O
Signaling	O
Pathways	O
<EOS>	B-X
The	B-X
SSRI	B-X
fluvoxamine	B-X
,	B-X
with	B-X
sigma-1	B-X
receptor	B-X
agonism	B-X
,	B-X
is	B-X
shown	B-X
to	B-X
potentiate	B-X
nerve-growth	B-X
factor	B-X
(	B-X
NGF	B-X
)	B-X
-induced	B-X
neurite	B-X
outgrowth	B-X
in	B-X
PC	B-X
12	B-X
cells	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
roles	B-X
of	B-X
cellular	B-X
signaling	B-X
pathways	B-X
in	B-X
the	B-X
potentiation	B-X
of	B-X
NGF-induced	B-X
neurite	B-X
outgrowth	B-X
by	B-X
fluvoxamine	B-X
and	B-X
sigma-1	B-X
receptor	B-X
agonists	B-X
.	B-X

Abstract	O
<EOS>	B-X
Abstract	B-X
writing	B-X
.	B-X
The	B-X
informative	B-X
abstract	B-X
.	B-X
Crafting	B-X
a	B-X
compelling	B-X
abstract	B-X
.	B-X
Why	B-X
the	B-X
structured	B-X
abstract	B-X
?	B-X

Background	O
<EOS>	B-X
Background	B-X
matching	B-X
is	B-X
the	B-X
most	B-X
familiar	B-X
and	B-X
widespread	B-X
camouflage	B-X
strategy	B-X
:	B-X
avoiding	B-X
detection	B-X
by	B-X
having	B-X
a	B-X
similar	B-X
colour	B-X
and	B-X
pattern	B-X
to	B-X
the	B-X
background	B-X
.	B-X
Background	B-X
is	B-X
thus	B-X
a	B-X
relatively	B-X
modest	B-X
correction	B-X
for	B-X
all	B-X
Z	B-X
opacity	B-X
data	B-X
published	B-X
to	B-X
date	B-X
.	B-X
Background	B-X
estimation	B-X
and	B-X
foreground	B-X
segmentation	B-X
are	B-X
important	B-X
steps	B-X
in	B-X
many	B-X
high-level	B-X
vision	B-X
tasks	B-X
.	B-X
Patient	B-X
Preference	B-X
for	B-X
Telehealth	B-X
Background	B-X
Shapes	B-X
Impressions	B-X
of	B-X
Physicians	B-X
and	B-X
Information	B-X
Recall	B-X
:	B-X
A	B-X
Randomized	B-X
Experiment	B-X
.	B-X

Selective	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
have	O
been	O
widely	O
used	O
and	O
are	O
a	O
major	O
therapeutic	O
advance	O
in	O
psychopharmacology	O
.	O

However	O
,	O
their	O
pharmacology	O
is	O
quite	O
heterogeneous	O
.	O
<EOS>	B-X
Awareness	B-X
that	B-X
the	B-X
metabolic	B-X
phenotype	B-X
of	B-X
cells	B-X
within	B-X
tumours	B-X
is	B-X
heterogeneous	B-X
-	B-X
and	B-X
distinct	B-X
from	B-X
that	B-X
of	B-X
their	B-X
normal	B-X
counterparts	B-X
-	B-X
is	B-X
growing	B-X
.	B-X
Diffuse	B-X
large	B-X
B-cell	B-X
lymphomas	B-X
(	B-X
DLBCLs	B-X
)	B-X
are	B-X
phenotypically	B-X
and	B-X
genetically	B-X
heterogeneous	B-X
.	B-X
Diffuse	B-X
large	B-X
B	B-X
cell	B-X
lymphoma	B-X
(	B-X
DLBCL	B-X
)	B-X
,	B-X
the	B-X
most	B-X
common	B-X
lymphoid	B-X
malignancy	B-X
in	B-X
adults	B-X
,	B-X
is	B-X
a	B-X
clinically	B-X
and	B-X
genetically	B-X
heterogeneous	B-X
disease	B-X
that	B-X
is	B-X
further	B-X
classified	B-X
into	B-X
transcriptionally	B-X
defined	B-X
activated	B-X
B	B-X
cell	B-X
(	B-X
ABC	B-X
)	B-X
and	B-X
germinal	B-X
center	B-X
B	B-X
cell	B-X
(	B-X
GCB	B-X
)	B-X
subtypes	B-X
.	B-X
However	B-X
,	B-X
CAFs	B-X
present	B-X
a	B-X
heterogeneous	B-X
population	B-X
of	B-X
cells	B-X
and	B-X
more	B-X
detailed	B-X
classification	B-X
of	B-X
CAFs	B-X
and	B-X
investigation	B-X
of	B-X
functions	B-X
of	B-X
each	B-X
subset	B-X
is	B-X
needed	B-X
to	B-X
develop	B-X
novel	B-X
CAF-targeted	B-X
therapies	B-X
.	B-X

The	O
SSRI	O
fluvoxamine	O
,	O
with	O
sigma	O
-	O
1	O
receptor	O
agonism	O
,	O
is	O
shown	O
to	O
potentiate	O
nerve	O
-	O
growth	O
factor	O
(	O
NGF	O
)	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC	O
12	O
cells	O
.	O
<EOS>	B-X
Selective	B-X
serotonin	B-X
reuptake	B-X
inhibitors	B-X
(	B-X
SSRIs	B-X
)	B-X
have	B-X
been	B-X
widely	B-X
used	B-X
and	B-X
are	B-X
a	B-X
major	B-X
therapeutic	B-X
advance	B-X
in	B-X
psychopharmacology	B-X
.	B-X
The	B-X
SSRI	B-X
fluvoxamine	B-X
,	B-X
with	B-X
sigma-1	B-X
receptor	B-X
agonism	B-X
,	B-X
is	B-X
shown	B-X
to	B-X
potentiate	B-X
nerve-growth	B-X
factor	B-X
(	B-X
NGF	B-X
)	B-X
-induced	B-X
neurite	B-X
outgrowth	B-X
in	B-X
PC	B-X
12	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
precise	B-X
cellular	B-X
and	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
potentiation	B-X
by	B-X
fluvoxamine	B-X
are	B-X
not	B-X
fully	B-X
understood	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
roles	B-X
of	B-X
cellular	B-X
signaling	B-X
pathways	B-X
in	B-X
the	B-X
potentiation	B-X
of	B-X
NGF-induced	B-X
neurite	B-X
outgrowth	B-X
by	B-X
fluvoxamine	B-X
and	B-X
sigma-1	B-X
receptor	B-X
agonists	B-X
.	B-X

However	O
,	O
the	O
precise	O
cellular	O
and	O
molecular	O
mechanisms	O
underlying	O
potentiation	O
by	O
fluvoxamine	O
are	O
not	O
fully	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
roles	O
of	O
cellular	O
signaling	O
pathways	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
fluvoxamine	O
and	O
sigma	O
-	O
1	O
receptor	O
agonists	O
.	O
<EOS>	B-X
The	B-X
SSRI	B-X
fluvoxamine	B-X
,	B-X
with	B-X
sigma-1	B-X
receptor	B-X
agonism	B-X
,	B-X
is	B-X
shown	B-X
to	B-X
potentiate	B-X
nerve-growth	B-X
factor	B-X
(	B-X
NGF	B-X
)	B-X
-induced	B-X
neurite	B-X
outgrowth	B-X
in	B-X
PC	B-X
12	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
precise	B-X
cellular	B-X
and	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
potentiation	B-X
by	B-X
fluvoxamine	B-X
are	B-X
not	B-X
fully	B-X
understood	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
roles	B-X
of	B-X
cellular	B-X
signaling	B-X
pathways	B-X
in	B-X
the	B-X
potentiation	B-X
of	B-X
NGF-induced	B-X
neurite	B-X
outgrowth	B-X
by	B-X
fluvoxamine	B-X
and	B-X
sigma-1	B-X
receptor	B-X
agonists	B-X
.	B-X

Methods	O
and	O
Findings	O
<EOS>	B-X
This	B-X
glossary	B-X
was	B-X
developed	B-X
by	B-X
a	B-X
working	B-X
group	B-X
of	B-X
the	B-X
ILAE	B-X
Commission	B-X
on	B-X
Diagnostic	B-X
Methods	B-X
incorporating	B-X
the	B-X
EEG	B-X
Task	B-X
Force	B-X
.	B-X

The	O
effects	O
of	O
three	O
SSRIs	O
(	O
fluvoxamine	O
,	O
sertraline	O
,	O
paroxetine	O
)	O
and	O
three	O
sigma	O
-	O
1	O
receptor	O
agonists	O
(	O
SA4503	O
,	O
4	O
-	O
phenyl	O
-	O
1	O
-	O
(	O
4	O
-	O
phenylbutyl	O
)	O
piperidine	O
(	O
PPBP	O
)	O
,	O
and	O
dehydroepiandrosterone	O
(	O
DHEA	O
)	O
-	O
sulfate	O
)	O
on	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
were	O
examined	O
.	O
<EOS>	B-X
Selective	B-X
serotonin	B-X
reuptake	B-X
inhibitors	B-X
(	B-X
SSRIs	B-X
)	B-X
have	B-X
been	B-X
widely	B-X
used	B-X
and	B-X
are	B-X
a	B-X
major	B-X
therapeutic	B-X
advance	B-X
in	B-X
psychopharmacology	B-X
.	B-X
The	B-X
SSRI	B-X
fluvoxamine	B-X
,	B-X
with	B-X
sigma-1	B-X
receptor	B-X
agonism	B-X
,	B-X
is	B-X
shown	B-X
to	B-X
potentiate	B-X
nerve-growth	B-X
factor	B-X
(	B-X
NGF	B-X
)	B-X
-induced	B-X
neurite	B-X
outgrowth	B-X
in	B-X
PC	B-X
12	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
precise	B-X
cellular	B-X
and	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
potentiation	B-X
by	B-X
fluvoxamine	B-X
are	B-X
not	B-X
fully	B-X
understood	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
roles	B-X
of	B-X
cellular	B-X
signaling	B-X
pathways	B-X
in	B-X
the	B-X
potentiation	B-X
of	B-X
NGF-induced	B-X
neurite	B-X
outgrowth	B-X
by	B-X
fluvoxamine	B-X
and	B-X
sigma-1	B-X
receptor	B-X
agonists	B-X
.	B-X

Also	O
examined	O
were	O
the	O
effects	O
of	O
the	O
sigma	O
-	O
1	O
receptor	O
antagonist	O
NE	O
-	O
100	O
,	O
inositol	O
1	O
,	O
4	O
,	O
5	O
-	O
triphosphate	O
(	O
IP3	O
)	O
receptor	O
antagonist	O
,	O
and	O
specific	O
inhibitors	O
of	O
signaling	O
pathways	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
selective	O
sigma	O
-	O
1	O
receptor	O
agonist	O
SA4503	O
.	O
<EOS>	B-X
Selective	B-X
serotonin	B-X
reuptake	B-X
inhibitors	B-X
(	B-X
SSRIs	B-X
)	B-X
have	B-X
been	B-X
widely	B-X
used	B-X
and	B-X
are	B-X
a	B-X
major	B-X
therapeutic	B-X
advance	B-X
in	B-X
psychopharmacology	B-X
.	B-X
The	B-X
SSRI	B-X
fluvoxamine	B-X
,	B-X
with	B-X
sigma-1	B-X
receptor	B-X
agonism	B-X
,	B-X
is	B-X
shown	B-X
to	B-X
potentiate	B-X
nerve-growth	B-X
factor	B-X
(	B-X
NGF	B-X
)	B-X
-induced	B-X
neurite	B-X
outgrowth	B-X
in	B-X
PC	B-X
12	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
precise	B-X
cellular	B-X
and	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
potentiation	B-X
by	B-X
fluvoxamine	B-X
are	B-X
not	B-X
fully	B-X
understood	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
roles	B-X
of	B-X
cellular	B-X
signaling	B-X
pathways	B-X
in	B-X
the	B-X
potentiation	B-X
of	B-X
NGF-induced	B-X
neurite	B-X
outgrowth	B-X
by	B-X
fluvoxamine	B-X
and	B-X
sigma-1	B-X
receptor	B-X
agonists	B-X
.	B-X

Fluvoxamine	O
(	O
but	O
not	O
sertraline	O
or	O
paroxetine	O
)	O
and	O
the	O
sigma	O
-	O
1	O
receptor	O
agonists	O
SA4503	O
,	O
PPBP	O
,	O
and	O
DHEA	O
-	O
sulfate	O
significantly	O
potentiated	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

The	O
potentiation	O
by	O
fluvoxamine	O
and	O
the	O
three	O
sigma	O
-	O
1	O
receptor	O
agonists	O
was	O
blocked	O
by	O
co	O
-	O
administration	O
of	O
the	O
selective	O
sigma	O
-	O
1	O
receptor	O
antagonist	O
NE	O
-	O
100	O
,	O
suggesting	O
that	O
sigma	O
-	O
1	O
receptors	O
play	O
a	O
role	O
in	O
blocking	O
the	O
enhancement	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
.	O
<EOS>	B-X
Selective	B-X
serotonin	B-X
reuptake	B-X
inhibitors	B-X
(	B-X
SSRIs	B-X
)	B-X
have	B-X
been	B-X
widely	B-X
used	B-X
and	B-X
are	B-X
a	B-X
major	B-X
therapeutic	B-X
advance	B-X
in	B-X
psychopharmacology	B-X
.	B-X
However	B-X
,	B-X
their	B-X
pharmacology	B-X
is	B-X
quite	B-X
heterogeneous	B-X
.	B-X
The	B-X
SSRI	B-X
fluvoxamine	B-X
,	B-X
with	B-X
sigma-1	B-X
receptor	B-X
agonism	B-X
,	B-X
is	B-X
shown	B-X
to	B-X
potentiate	B-X
nerve-growth	B-X
factor	B-X
(	B-X
NGF	B-X
)	B-X
-induced	B-X
neurite	B-X
outgrowth	B-X
in	B-X
PC	B-X
12	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
precise	B-X
cellular	B-X
and	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
potentiation	B-X
by	B-X
fluvoxamine	B-X
are	B-X
not	B-X
fully	B-X
understood	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
roles	B-X
of	B-X
cellular	B-X
signaling	B-X
pathways	B-X
in	B-X
the	B-X
potentiation	B-X
of	B-X
NGF-induced	B-X
neurite	B-X
outgrowth	B-X
by	B-X
fluvoxamine	B-X
and	B-X
sigma-1	B-X
receptor	B-X
agonists	B-X
.	B-X

Moreover	O
,	O
the	O
potentiation	O
by	O
SA4503	O
was	O
blocked	O
by	O
co	O
-	O
administration	O
of	O
the	O
IP3	O
receptor	O
antagonist	O
xestospongin	O
C	O
.	O
<EOS>	B-X
Selective	B-X
serotonin	B-X
reuptake	B-X
inhibitors	B-X
(	B-X
SSRIs	B-X
)	B-X
have	B-X
been	B-X
widely	B-X
used	B-X
and	B-X
are	B-X
a	B-X
major	B-X
therapeutic	B-X
advance	B-X
in	B-X
psychopharmacology	B-X
.	B-X
However	B-X
,	B-X
their	B-X
pharmacology	B-X
is	B-X
quite	B-X
heterogeneous	B-X
.	B-X
The	B-X
SSRI	B-X
fluvoxamine	B-X
,	B-X
with	B-X
sigma-1	B-X
receptor	B-X
agonism	B-X
,	B-X
is	B-X
shown	B-X
to	B-X
potentiate	B-X
nerve-growth	B-X
factor	B-X
(	B-X
NGF	B-X
)	B-X
-induced	B-X
neurite	B-X
outgrowth	B-X
in	B-X
PC	B-X
12	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
precise	B-X
cellular	B-X
and	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
potentiation	B-X
by	B-X
fluvoxamine	B-X
are	B-X
not	B-X
fully	B-X
understood	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
roles	B-X
of	B-X
cellular	B-X
signaling	B-X
pathways	B-X
in	B-X
the	B-X
potentiation	B-X
of	B-X
NGF-induced	B-X
neurite	B-X
outgrowth	B-X
by	B-X
fluvoxamine	B-X
and	B-X
sigma-1	B-X
receptor	B-X
agonists	B-X
.	B-X

In	O
addition	O
,	O
the	O
specific	O
inhibitors	O
of	O
phospholipase	O
C	O
(	O
PLC	O
-	O
gamma	O
)	O
,	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
,	O
p38MAPK	O
,	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
,	O
and	O
the	O
Ras	O
/	O
Raf	O
/	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
signaling	O
pathways	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
.	O
<EOS>	B-X
Selective	B-X
serotonin	B-X
reuptake	B-X
inhibitors	B-X
(	B-X
SSRIs	B-X
)	B-X
have	B-X
been	B-X
widely	B-X
used	B-X
and	B-X
are	B-X
a	B-X
major	B-X
therapeutic	B-X
advance	B-X
in	B-X
psychopharmacology	B-X
.	B-X
However	B-X
,	B-X
their	B-X
pharmacology	B-X
is	B-X
quite	B-X
heterogeneous	B-X
.	B-X
The	B-X
SSRI	B-X
fluvoxamine	B-X
,	B-X
with	B-X
sigma-1	B-X
receptor	B-X
agonism	B-X
,	B-X
is	B-X
shown	B-X
to	B-X
potentiate	B-X
nerve-growth	B-X
factor	B-X
(	B-X
NGF	B-X
)	B-X
-induced	B-X
neurite	B-X
outgrowth	B-X
in	B-X
PC	B-X
12	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
precise	B-X
cellular	B-X
and	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
potentiation	B-X
by	B-X
fluvoxamine	B-X
are	B-X
not	B-X
fully	B-X
understood	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
roles	B-X
of	B-X
cellular	B-X
signaling	B-X
pathways	B-X
in	B-X
the	B-X
potentiation	B-X
of	B-X
NGF-induced	B-X
neurite	B-X
outgrowth	B-X
by	B-X
fluvoxamine	B-X
and	B-X
sigma-1	B-X
receptor	B-X
agonists	B-X
.	B-X

Conclusion	O
<EOS>	B-X
Conclusion	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X

These	O
findings	O
suggest	O
that	O
stimulation	O
of	O
sigma	O
-	O
1	O
receptors	O
and	O
subsequent	O
interaction	O
with	O
IP3	O
receptors	O
,	O
PLC	O
-	O
gamma	O
,	O
PI3K	O
,	O
p38MAPK	O
,	O
JNK	O
,	O
and	O
the	O
Ras	O
/	O
Raf	O
/	O
MAPK	O
signaling	O
pathways	O
are	O
involved	O
in	O
the	O
mechanisms	O
of	O
action	O
of	O
sigma	O
-	O
1	O
receptor	O
agonists	O
such	O
as	O
fluvoxamine	O
and	O
SA4503	O
.	O
<EOS>	B-X
The	B-X
SSRI	B-X
fluvoxamine	B-X
,	B-X
with	B-X
sigma-1	B-X
receptor	B-X
agonism	B-X
,	B-X
is	B-X
shown	B-X
to	B-X
potentiate	B-X
nerve-growth	B-X
factor	B-X
(	B-X
NGF	B-X
)	B-X
-induced	B-X
neurite	B-X
outgrowth	B-X
in	B-X
PC	B-X
12	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
precise	B-X
cellular	B-X
and	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
potentiation	B-X
by	B-X
fluvoxamine	B-X
are	B-X
not	B-X
fully	B-X
understood	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
roles	B-X
of	B-X
cellular	B-X
signaling	B-X
pathways	B-X
in	B-X
the	B-X
potentiation	B-X
of	B-X
NGF-induced	B-X
neurite	B-X
outgrowth	B-X
by	B-X
fluvoxamine	B-X
and	B-X
sigma-1	B-X
receptor	B-X
agonists	B-X
.	B-X

Introduction	O

Selective	O
serotonin	O
(	O
5	O
-	O
HT	O
;	O
5	O
-	O
hydroxytryptamine	O
)	O
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
have	O
emerged	O
as	O
a	O
major	O
therapeutic	O
advance	O
in	O
psychopharmacology	O
.	O
<EOS>	B-X
Serotonin	B-X
is	B-X
perhaps	B-X
best	B-X
known	B-X
as	B-X
a	B-X
neurotransmitter	B-X
that	B-X
modulates	B-X
neural	B-X
activity	B-X
and	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
neuropsychological	B-X
processes	B-X
,	B-X
and	B-X
drugs	B-X
that	B-X
target	B-X
serotonin	B-X
receptors	B-X
are	B-X
used	B-X
widely	B-X
in	B-X
psychiatry	B-X
and	B-X
neurology	B-X
.	B-X
However	B-X
,	B-X
most	B-X
serotonin	B-X
is	B-X
found	B-X
outside	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
,	B-X
and	B-X
virtually	B-X
all	B-X
of	B-X
the	B-X
15	B-X
serotonin	B-X
receptors	B-X
are	B-X
expressed	B-X
outside	B-X
as	B-X
well	B-X
as	B-X
within	B-X
the	B-X
brain	B-X
.	B-X
Additionally	B-X
,	B-X
new	B-X
work	B-X
suggests	B-X
that	B-X
serotonin	B-X
may	B-X
regulate	B-X
some	B-X
processes	B-X
,	B-X
including	B-X
platelet	B-X
aggregation	B-X
,	B-X
by	B-X
receptor-independent	B-X
,	B-X
transglutaminase-dependent	B-X
covalent	B-X
linkage	B-X
to	B-X
cellular	B-X
proteins	B-X
.	B-X
We	B-X
review	B-X
this	B-X
new	B-X
``	B-X
expanded	B-X
serotonin	B-X
biology	B-X
''	B-X
and	B-X
discuss	B-X
how	B-X
drugs	B-X
targeting	B-X
specific	B-X
serotonin	B-X
receptors	B-X
are	B-X
beginning	B-X
to	B-X
help	B-X
treat	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
diseases	B-X
.	B-X

SSRIs	O
are	O
the	O
treatment	O
of	O
choice	O
for	O
many	O
indications	O
,	O
including	O
major	O
depressive	O
disorder	O
,	O
dysthymia	O
,	O
panic	O
disorder	O
,	O
obsessive	O
-	O
compulsive	O
disorder	O
,	O
eating	O
disorders	O
,	O
and	O
premenstrual	O
dysphoric	O
disorder	O
.	O
<EOS>	B-X
Selective	B-X
serotonin-reuptake	B-X
inhibitors	B-X
(	B-X
SSRIs	B-X
)	B-X
,	B-X
including	B-X
fluoxetine	B-X
,	B-X
sertraline	B-X
,	B-X
paroxetine	B-X
,	B-X
fluvoxamine	B-X
,	B-X
and	B-X
citalopram	B-X
,	B-X
represent	B-X
an	B-X
important	B-X
advance	B-X
in	B-X
the	B-X
pharmacotherapy	B-X
of	B-X
mood	B-X
and	B-X
other	B-X
disorders	B-X
.	B-X
SSRIs	B-X
are	B-X
the	B-X
treatment	B-X
of	B-X
choice	B-X
for	B-X
many	B-X
indications	B-X
,	B-X
including	B-X
major	B-X
depression	B-X
,	B-X
dysthymia	B-X
,	B-X
panic	B-X
disorder	B-X
,	B-X
obsessive-compulsive	B-X
disorder	B-X
,	B-X
eating	B-X
disorders	B-X
,	B-X
and	B-X
premenstrual	B-X
dysphoric	B-X
disorder	B-X
,	B-X
because	B-X
of	B-X
their	B-X
efficacy	B-X
,	B-X
good	B-X
side-effect	B-X
profile	B-X
,	B-X
tolerability	B-X
,	B-X
and	B-X
safety	B-X
in	B-X
overdose	B-X
,	B-X
as	B-X
well	B-X
as	B-X
patient	B-X
compliance	B-X
.	B-X
A	B-X
review	B-X
of	B-X
the	B-X
literature	B-X
was	B-X
conducted	B-X
using	B-X
Medline	B-X
and	B-X
the	B-X
terms	B-X
``	B-X
SSRIs	B-X
,	B-X
''	B-X
``	B-X
fluoxetine	B-X
,	B-X
''	B-X
``	B-X
sertraline	B-X
,	B-X
''	B-X
``	B-X
paroxetine	B-X
,	B-X
''	B-X
``	B-X
fluvoxamine	B-X
,	B-X
''	B-X
and	B-X
``	B-X
citalopram	B-X
.	B-X
''	B-X
The	B-X
search	B-X
revealed	B-X
that	B-X
indications	B-X
for	B-X
antidepressants	B-X
include	B-X
unipolar	B-X
depression	B-X
,	B-X
dysthymia	B-X
,	B-X
bipolar	B-X
depression	B-X
,	B-X
treatment-resistant	B-X
depression	B-X
,	B-X
depression	B-X
in	B-X
the	B-X
medically	B-X
ill	B-X
,	B-X
panic	B-X
disorder	B-X
,	B-X
obsessive-compulsive	B-X
disorder	B-X
,	B-X
eating	B-X
disorders	B-X
,	B-X
social	B-X
phobia	B-X
,	B-X
and	B-X
premenstrual	B-X
dysphoric	B-X
disorder	B-X
.	B-X
Side	B-X
effects	B-X
of	B-X
SSRIs	B-X
include	B-X
gastrointestinal	B-X
disturbances	B-X
,	B-X
headache	B-X
,	B-X
sedation	B-X
,	B-X
insomnia	B-X
,	B-X
activation	B-X
,	B-X
weight	B-X
gain	B-X
,	B-X
impaired	B-X
memory	B-X
,	B-X
excessive	B-X
perspiration	B-X
,	B-X
paresthesia	B-X
,	B-X
and	B-X
sexual	B-X
dysfunction	B-X
.	B-X

In	O
contrast	O
,	O
it	O
is	O
well	O
known	O
that	O
their	O
pharmacology	O
is	O
quite	O
heterogeneous	O
,	O
although	O
all	O
of	O
them	O
block	O
5	O
-	O
HT	O
transporters	O
,	O
thus	O
increasing	O
5	O
-	O
HT	O
levels	O
throughout	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
[	O
1	O
]	O
-	O
[	O
9	O
]	O
.	O

Accumulating	O
evidence	O
suggests	O
that	O
sigma	O
-	O
1	O
receptors	O
,	O
which	O
are	O
intracellular	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
proteins	O
,	O
are	O
involved	O
in	O
both	O
the	O
neuroplasticity	O
and	O
pathophysiology	O
of	O
neuropsychiatric	O
diseases	O
such	O
as	O
major	O
depressive	O
disorder	O
,	O
anxiety	O
,	O
schizophrenia	O
,	O
and	O
Alzheimer	O
'	O
s	O
disease	O
[	O
10	O
]	O
-	O
[	O
18	O
]	O
.	O

Previously	O
,	O
we	O
reported	O
that	O
some	O
SSRIs	O
possess	O
high	O
to	O
moderate	O
affinities	O
for	O
sigma	O
-	O
1	O
receptors	O
in	O
the	O
rat	B-Species
brain	O
.	O

The	O
rank	O
order	O
of	O
SSRIs	O
affinities	O
for	O
sigma	O
-	O
1	O
receptors	O
is	O
fluvoxamine	O
(	O
Ki	O
=	O
36	O
nM	O
)	O
>	O
sertraline	O
(	O
Ki	O
=	O
57	O
nM	O
)	O
>	O
>	O
paroxetine	O
(	O
Ki	O
=	O
1893	O
nM	O
)	O
[	O
19	O
]	O
.	O

Recently	O
,	O
we	O
reported	O
that	O
fluvoxamine	O
,	O
but	O
not	O
paroxetine	O
,	O
significantly	O
ameliorated	O
cognitive	O
deficits	O
in	O
mice	B-Species
after	O
repeated	O
phencyclidine	O
administration	O
,	O
and	O
that	O
the	O
effects	O
of	O
fluvoxamine	O
were	O
antagonized	O
by	O
co	O
-	O
administration	O
of	O
the	O
selective	O
sigma	O
-	O
1	O
receptor	O
antagonist	O
NE	O
-	O
100	O
[	O
20	O
]	O
,	O
suggesting	O
that	O
sigma	O
-	O
1	O
receptors	O
are	O
involved	O
in	O
the	O
mechanism	O
of	O
action	O
of	O
fluvoxamine	O
[	O
9	O
]	O
.	O
<EOS>	B-X
To	B-X
report	B-X
QT	B-X
prolongation	B-X
potential	B-X
in	B-X
selective	B-X
serotonin	B-X
reuptake	B-X
inhibitors	B-X
(	B-X
SSRIs	B-X
)	B-X
in	B-X
order	B-X
to	B-X
advise	B-X
clinicians	B-X
on	B-X
safe	B-X
use	B-X
of	B-X
SSRIs	B-X
other	B-X
than	B-X
citalopram	B-X
in	B-X
light	B-X
of	B-X
citalopram	B-X
warnings	B-X
.	B-X
Recent	B-X
evidence	B-X
indicates	B-X
a	B-X
potential	B-X
therapeutic	B-X
role	B-X
of	B-X
fluvoxamine	B-X
for	B-X
COVID-19	B-X
.	B-X
In	B-X
the	B-X
TOGETHER	B-X
trial	B-X
for	B-X
acutely	B-X
symptomatic	B-X
patients	B-X
with	B-X
COVID-19	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
assess	B-X
the	B-X
efficacy	B-X
of	B-X
fluvoxamine	B-X
versus	B-X
placebo	B-X
in	B-X
preventing	B-X
hospitalisation	B-X
defined	B-X
as	B-X
either	B-X
retention	B-X
in	B-X
a	B-X
COVID-19	B-X
emergency	B-X
setting	B-X
or	B-X
transfer	B-X
to	B-X
a	B-X
tertiary	B-X
hospital	B-X
due	B-X
to	B-X
COVID-19	B-X
.	B-X
Since	B-X
the	B-X
beginning	B-X
of	B-X
the	B-X
coronavirus	B-X
disease	B-X
(	B-X
COVID	B-X
)	B-X
-19	B-X
pandemic	B-X
,	B-X
the	B-X
need	B-X
for	B-X
effective	B-X
treatments	B-X
for	B-X
COVID-19	B-X
led	B-X
to	B-X
the	B-X
idea	B-X
of	B-X
``	B-X
repurposing	B-X
''	B-X
drugs	B-X
for	B-X
antiviral	B-X
treatment	B-X
.	B-X
Several	B-X
antipsychotics	B-X
and	B-X
antidepressants	B-X
have	B-X
been	B-X
tested	B-X
for	B-X
in	B-X
vitro	B-X
activity	B-X
against	B-X
the	B-X
severe	B-X
acute	B-X
respiratory	B-X
syndrome	B-X
coronavirus	B-X
2	B-X
.	B-X
However	B-X
,	B-X
whether	B-X
effective	B-X
plasma	B-X
concentrations	B-X
can	B-X
be	B-X
obtained	B-X
with	B-X
clinically	B-X
accepted	B-X
doses	B-X
of	B-X
these	B-X
drugs	B-X
is	B-X
not	B-X
clear	B-X
.	B-X
Data	B-X
of	B-X
COVID-19	B-X
patients	B-X
are	B-X
not	B-X
yet	B-X
available	B-X
but	B-X
several	B-X
clinical	B-X
studies	B-X
are	B-X
currently	B-X
underway.The	B-X
specific	B-X
serotonin	B-X
reuptake	B-X
inhibitor	B-X
fluvoxamine	B-X
is	B-X
a	B-X
potent	B-X
Sigma-1	B-X
receptor	B-X
agonist	B-X
and	B-X
reduces	B-X
inflammation	B-X
in	B-X
animal	B-X
models	B-X
of	B-X
cytokine-stress	B-X
.	B-X
Accordingly	B-X
,	B-X
fluvoxamine	B-X
treatment	B-X
was	B-X
superior	B-X
to	B-X
placebo	B-X
in	B-X
reducing	B-X
impaired	B-X
respiratory	B-X
function	B-X
and	B-X
other	B-X
symptoms	B-X
of	B-X
inflammation	B-X
in	B-X
COVID-19	B-X
patients	B-X
in	B-X
a	B-X
placebo-controlled	B-X
clinical	B-X
study	B-X
and	B-X
another	B-X
open	B-X
clinical	B-X
trial	B-X
.	B-X
The	B-X
beneficial	B-X
effects	B-X
of	B-X
fluvoxamine	B-X
on	B-X
the	B-X
course	B-X
of	B-X
COVID-19	B-X
were	B-X
recently	B-X
confirmed	B-X
in	B-X
a	B-X
large	B-X
placebo-controlled	B-X
double-blind	B-X
trial	B-X
with	B-X
several	B-X
hundred	B-X
patients.Inflammation	B-X
represents	B-X
a	B-X
major	B-X
risk	B-X
factor	B-X
for	B-X
many	B-X
psychiatric	B-X
disorders	B-X
which	B-X
explains	B-X
the	B-X
high	B-X
susceptibilitiy	B-X
of	B-X
COVID-19	B-X
patients	B-X
for	B-X
psychiatric	B-X
diseases	B-X
.	B-X
Many	B-X
antidepressants	B-X
and	B-X
antipsychotics	B-X
possess	B-X
anti-inflammatory	B-X
properties	B-X
independent	B-X
of	B-X
sigma-1	B-X
activity	B-X
which	B-X
might	B-X
be	B-X
important	B-X
to	B-X
reduce	B-X
psychiatric	B-X
symptoms	B-X
of	B-X
COVID-19	B-X
patients	B-X
and	B-X
to	B-X
improve	B-X
respiratory	B-X
dysfunction	B-X
and	B-X
other	B-X
consequences	B-X
of	B-X
inflammation	B-X
.	B-X
This	B-X
might	B-X
explain	B-X
the	B-X
rather	B-X
unspecific	B-X
benefit	B-X
which	B-X
has	B-X
been	B-X
reported	B-X
for	B-X
several	B-X
cohorts	B-X
of	B-X
COVID-19	B-X
patients	B-X
treated	B-X
with	B-X
different	B-X
psychotropic	B-X
drugs	B-X
.	B-X

Interestingly	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
sigma	O
-	O
1	O
receptor	O
agonists	O
including	O
fluvoxamine	O
could	O
potentiate	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
,	O
and	O
that	O
NE	O
-	O
100	O
blocked	O
the	O
potentiation	O
by	O
sigma	O
-	O
1	O
receptor	O
agonists	O
,	O
suggesting	O
sigma	O
-	O
1	O
receptors	O
are	O
involved	O
in	O
neuroplasticity	O
[	O
21	O
]	O
.	O

However	O
,	O
the	O
precise	O
cellular	O
mechanisms	O
underlying	O
the	O
potentiation	O
by	O
sigma	O
-	O
1	O
receptor	O
agonists	O
are	O
not	O
fully	O
understood	O
[	O
13	O
]	O
,	O
[	O
21	O
]	O
.	O
<EOS>	B-X
However	B-X
,	B-X
their	B-X
pharmacology	B-X
is	B-X
quite	B-X
heterogeneous	B-X
.	B-X
The	B-X
SSRI	B-X
fluvoxamine	B-X
,	B-X
with	B-X
sigma-1	B-X
receptor	B-X
agonism	B-X
,	B-X
is	B-X
shown	B-X
to	B-X
potentiate	B-X
nerve-growth	B-X
factor	B-X
(	B-X
NGF	B-X
)	B-X
-induced	B-X
neurite	B-X
outgrowth	B-X
in	B-X
PC	B-X
12	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
precise	B-X
cellular	B-X
and	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
potentiation	B-X
by	B-X
fluvoxamine	B-X
are	B-X
not	B-X
fully	B-X
understood	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
roles	B-X
of	B-X
cellular	B-X
signaling	B-X
pathways	B-X
in	B-X
the	B-X
potentiation	B-X
of	B-X
NGF-induced	B-X
neurite	B-X
outgrowth	B-X
by	B-X
fluvoxamine	B-X
and	B-X
sigma-1	B-X
receptor	B-X
agonists	B-X
.	B-X

It	O
is	O
therefore	O
of	O
great	O
interest	O
to	O
study	O
the	O
precise	O
cellular	O
mechanisms	O
underlying	O
the	O
enhancement	O
by	O
fluvoxamine	O
on	O
NGF	O
-	O
induced	O
neurite	O
sprouting	O
in	O
PC12	O
cells	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
effects	O
of	O
three	O
SSRIs	O
(	O
fluvoxamine	O
,	O
sertraline	O
,	O
paroxetine	O
)	O
,	O
as	O
well	O
as	O
the	O
effects	O
of	O
a	O
sigma	O
-	O
1	O
receptor	O
agonist	O
(	O
4	O
-	O
phenyl	O
-	O
1	O
-	O
(	O
4	O
-	O
phenylbutyl	O
)	O
piperidine	O
(	O
PPBP	O
)	O
,	O
dehydroepiandrosterone	O
-	O
sulphate	O
(	O
DHEA	O
)	O
-	O
sulfate	O
)	O
[	O
9	O
]	O
,	O
[	O
22	O
]	O
-	O
[	O
28	O
]	O
and	O
the	O
selective	O
sigma	O
-	O
1	O
receptor	O
agonist	O
SA4503	O
[	O
29	O
]	O
,	O
[	O
30	O
]	O
,	O
on	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
.	O

Furthermore	O
,	O
it	O
is	O
also	O
known	O
that	O
sigma	O
-	O
1	O
receptors	O
have	O
been	O
shown	O
to	O
interact	O
with	O
IP3	O
receptors	O
(	O
17	O
,	O
18	O
)	O
.	O

Therefore	O
,	O
we	O
examined	O
the	O
effects	O
of	O
NE	O
-	O
100	O
and	O
xestospongin	O
C	O
(	O
a	O
selective	O
inositol	O
1	O
,	O
4	O
,	O
5	O
-	O
triphosphate	O
(	O
IP3	O
)	O
receptor	O
antagonist	O
)	O
[	O
31	O
]	O
in	O
order	O
to	O
investigate	O
the	O
roles	O
of	O
sigma	O
-	O
1	O
receptors	O
and	O
IP3	O
receptors	O
in	O
the	O
mechanisms	O
underlying	O
the	O
enhancement	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
.	O

Moreover	O
,	O
we	O
examined	O
the	O
effects	O
of	O
specific	O
inhibitors	O
of	O
several	O
cellular	O
signaling	O
targets	O
on	O
the	O
enhancement	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
,	O
since	O
several	O
signal	O
transduction	O
molecules	O
have	O
been	O
implicated	O
in	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
[	O
32	O
]	O
.	O

Materials	O
and	O
Methods	O
<EOS>	B-X
Methods	B-X
of	B-X
delivery	B-X
focused	B-X
on	B-X
how	B-X
to	B-X
deliver	B-X
the	B-X
teaching	B-X
strategies	B-X
.	B-X

Drugs	O
<EOS>	B-X
Chiral	B-X
drugs	B-X
:	B-X
synopsis	B-X
.	B-X
Pharmaceuticals	B-X
and	B-X
related	B-X
drugs	B-X
.	B-X
Advances	B-X
in	B-X
cell-based	B-X
permeability	B-X
assays	B-X
to	B-X
screen	B-X
drugs	B-X
for	B-X
intestinal	B-X
absorption	B-X
.	B-X
[	B-X
Drugs	B-X
in	B-X
tablets	B-X
]	B-X
.	B-X

The	O
drugs	O
were	O
obtained	O
from	O
the	O
following	O
sources	O
:	O
fluvoxamine	O
maleate	O
(	O
Solvay	O
Seiyaku	O
K	O
.	O
K	O
.	O
,	O
Tokyo	O
,	O
Japan	O
)	O
;	O
paroxetine	O
hydrochloride	O
,	O
dehydroepiandosterone	O
-	O
sulfate	O
(	O
DHEA	O
-	O
sulfate	O
)	O
,	O
LY294002	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
;	O
sertraline	O
(	O
Toronto	O
Research	O
Chemicals	O
Inc	O
.	O
,	O
North	O
York	O
,	O
ON	O
,	O
Canada	O
)	O
;	O
SA4503	O
(	O
M	O
'	O
s	O
Science	O
Corporation	O
,	O
Kobe	O
,	O
Japan	O
)	O
;	O
NGF	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
)	O
;	O
xestospongin	O
C	O
,	O
lovastatin	O
,	O
PD98059	O
,	O
GW5074	O
,	O
SB203580	O
,	O
MEK	O
1	O
/	O
2	O
inhibitor	O
(	O
SL327	O
)	O
,	O
and	O
SP600125	O
(	O
Calbiochem	O
-	O
Novabiochem	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

The	O
selective	O
sigma	O
-	O
1	O
receptor	O
antagonists	O
NE	O
-	O
100	O
and	O
4	O
-	O
phenyl	O
-	O
1	O
-	O
(	O
4	O
-	O
phenylbutyl	O
)	O
piperidine	O
(	O
PPBP	O
)	O
were	O
synthesized	O
in	O
our	O
laboratory	O
.	O

Other	O
drugs	O
were	O
purchased	O
from	O
commercial	O
sources	O
.	O
<EOS>	B-X
Furocoumarins	B-X
are	B-X
phototoxic	B-X
and	B-X
photogenotoxic	B-X
natural	B-X
plant	B-X
constituents	B-X
occurring	B-X
in	B-X
cosmetics	B-X
,	B-X
food	B-X
and	B-X
drugs	B-X
.	B-X
We	B-X
analyzed	B-X
the	B-X
major	B-X
furocoumarins	B-X
in	B-X
eight	B-X
commercial	B-X
grapefruit	B-X
juices	B-X
and	B-X
in	B-X
freshly	B-X
prepared	B-X
juices	B-X
made	B-X
from	B-X
pink	B-X
grapefruit	B-X
obtained	B-X
from	B-X
German	B-X
retailers	B-X
.	B-X
Bergaptol	B-X
was	B-X
the	B-X
major	B-X
furocoumarin	B-X
in	B-X
commercial	B-X
juices	B-X
,	B-X
followed	B-X
by	B-X
bergamottin	B-X
and	B-X
6',7'-dihydroxy-bergamottin	B-X
(	B-X
DHB	B-X
)	B-X
,	B-X
whereas	B-X
an	B-X
inverse	B-X
picture	B-X
(	B-X
DHB	B-X
>	B-X
bergamottin	B-X
>	B-X
bergaptol	B-X
)	B-X
was	B-X
obtained	B-X
in	B-X
freshly	B-X
prepared	B-X
juices	B-X
.	B-X
Results	B-X
from	B-X
different	B-X
batches	B-X
of	B-X
a	B-X
single	B-X
brand	B-X
of	B-X
commercial	B-X
juice	B-X
,	B-X
purchased	B-X
over	B-X
a	B-X
period	B-X
of	B-X
7	B-X
months	B-X
,	B-X
revealed	B-X
a	B-X
variability	B-X
of	B-X
about	B-X
50	B-X
%	B-X
for	B-X
the	B-X
individual	B-X
furocoumarins	B-X
and	B-X
the	B-X
sum	B-X
.	B-X
In	B-X
a	B-X
study	B-X
with	B-X
healthy	B-X
volunteers	B-X
,	B-X
consumption	B-X
of	B-X
900	B-X
ml	B-X
commercial	B-X
grapefruit	B-X
juice	B-X
(	B-X
containing	B-X
12.5mg	B-X
bergaptol	B-X
,	B-X
6.9	B-X
mg	B-X
bergamottin	B-X
,	B-X
and	B-X
0.6	B-X
mg	B-X
DHB	B-X
)	B-X
resulted	B-X
in	B-X
an	B-X
average	B-X
urinary	B-X
excretion	B-X
of	B-X
0.36	B-X
mg	B-X
free	B-X
plus	B-X
13.23	B-X
mg	B-X
conjugated	B-X
bergaptol	B-X
within	B-X
6h	B-X
.	B-X

Cell	O
culture	O
<EOS>	B-X
This	B-X
overview	B-X
describes	B-X
a	B-X
series	B-X
of	B-X
articles	B-X
to	B-X
provide	B-X
an	B-X
unmet	B-X
need	B-X
for	B-X
information	B-X
on	B-X
best	B-X
practices	B-X
in	B-X
animal	B-X
cell	B-X
culture	B-X
.	B-X
The	B-X
target	B-X
audience	B-X
primarily	B-X
consists	B-X
of	B-X
entry-level	B-X
scientists	B-X
with	B-X
minimal	B-X
experience	B-X
in	B-X
cell	B-X
culture	B-X
.	B-X
It	B-X
also	B-X
include	B-X
scientists	B-X
,	B-X
journalists	B-X
,	B-X
and	B-X
educators	B-X
with	B-X
some	B-X
experience	B-X
in	B-X
cell	B-X
culture	B-X
,	B-X
but	B-X
in	B-X
need	B-X
of	B-X
a	B-X
refresher	B-X
in	B-X
best	B-X
practices	B-X
.	B-X
The	B-X
articles	B-X
will	B-X
be	B-X
published	B-X
in	B-X
this	B-X
journal	B-X
over	B-X
a	B-X
six-month	B-X
period	B-X
and	B-X
will	B-X
emphasize	B-X
best	B-X
practices	B-X
in	B-X
:	B-X
(	B-X
1	B-X
)	B-X
media	B-X
selection	B-X
;	B-X
(	B-X
2	B-X
)	B-X
use	B-X
and	B-X
evaluation	B-X
of	B-X
animal	B-X
serum	B-X
as	B-X
a	B-X
component	B-X
of	B-X
cell	B-X
culture	B-X
medium	B-X
;	B-X
(	B-X
3	B-X
)	B-X
receipt	B-X
of	B-X
new	B-X
cells	B-X
into	B-X
the	B-X
laboratory	B-X
;	B-X
(	B-X
4	B-X
)	B-X
naming	B-X
cell	B-X
lines	B-X
;	B-X
(	B-X
5	B-X
)	B-X
authenticating	B-X
cell	B-X
line	B-X
identity	B-X
;	B-X
(	B-X
6	B-X
)	B-X
detecting	B-X
and	B-X
mitigating	B-X
risk	B-X
of	B-X
cell	B-X
culture	B-X
contamination	B-X
;	B-X
(	B-X
7	B-X
)	B-X
cryopreservation	B-X
and	B-X
thawing	B-X
of	B-X
cells	B-X
;	B-X
and	B-X
(	B-X
8	B-X
)	B-X
storing	B-X
and	B-X
shipping	B-X
viable	B-X
cells	B-X
.	B-X

PC12	O
sells	O
(	O
RIKEN	O
Cell	O
Bank	O
,	O
Tsukuba	O
,	O
Japan	O
)	O
were	O
cultured	O
at	O
37	O
degrees	O
C	O
,	O
5	O
%	O
CO2	O
with	O
Dulbecco	O
'	O
s	O
modified	O
Eagle	O
'	O
s	O
medium	O
(	O
DMEM	O
)	O
supplemented	O
with	O
5	O
%	O
heat	O
-	O
inactivated	O
fetal	O
bovine	B-Species
serum	O
(	O
FBS	O
)	O
,	O
10	O
%	O
heat	O
-	O
inactivated	O
horse	B-Species
serum	O
,	O
and	O
1	O
%	O
penicillin	O
.	O

The	O
medium	O
was	O
changed	O
two	O
or	O
three	O
times	O
a	O
week	O
.	O
<EOS>	B-X
In	B-X
two	B-X
experiments	B-X
,	B-X
students	B-X
studied	B-X
prose	B-X
passages	B-X
and	B-X
took	B-X
one	B-X
or	B-X
three	B-X
immediate	B-X
free-recall	B-X
tests	B-X
,	B-X
without	B-X
feedback	B-X
,	B-X
or	B-X
restudied	B-X
the	B-X
material	B-X
the	B-X
same	B-X
number	B-X
of	B-X
times	B-X
as	B-X
the	B-X
students	B-X
who	B-X
received	B-X
tests	B-X
.	B-X
Students	B-X
then	B-X
took	B-X
a	B-X
final	B-X
retention	B-X
test	B-X
5	B-X
min	B-X
,	B-X
2	B-X
days	B-X
,	B-X
or	B-X
1	B-X
week	B-X
later	B-X
.	B-X
Three	B-X
Hours	B-X
,	B-X
Three	B-X
Days	B-X
a	B-X
Week	B-X
.	B-X
Goals	B-X
to	B-X
walk	B-X
10000	B-X
steps	B-X
per	B-X
day	B-X
or	B-X
to	B-X
call	B-X
one	B-X
's	B-X
parents	B-X
once	B-X
a	B-X
week	B-X
,	B-X
for	B-X
example	B-X
,	B-X
are	B-X
defined	B-X
by	B-X
time	B-X
(	B-X
e.g	B-X
.	B-X
a	B-X
day	B-X
or	B-X
week	B-X
)	B-X
,	B-X
pursued	B-X
over	B-X
time	B-X
(	B-X
e.g	B-X
.	B-X
for	B-X
multiple	B-X
days	B-X
or	B-X
multiple	B-X
weeks	B-X
)	B-X
,	B-X
and	B-X
subject	B-X
to	B-X
constraints	B-X
on	B-X
time	B-X
(	B-X
e.g	B-X
.	B-X
This	B-X
article	B-X
discusses	B-X
three	B-X
key	B-X
ways	B-X
to	B-X
think	B-X
about	B-X
time	B-X
in	B-X
relation	B-X
to	B-X
goals	B-X
:	B-X
time	B-X
as	B-X
a	B-X
defining	B-X
feature	B-X
of	B-X
goals	B-X
,	B-X
as	B-X
a	B-X
dimension	B-X
of	B-X
goal	B-X
pursuit	B-X
,	B-X
and	B-X
as	B-X
a	B-X
constraint	B-X
on	B-X
goal	B-X
pursuit	B-X
.	B-X

PC12	O
cells	O
were	O
plated	O
onto	O
24	O
-	O
well	O
tissue	O
culture	O
plates	O
coated	O
with	O
poly	O
-	O
D	O
-	O
lysine	O
/	O
laminin	O
.	O

Cells	O
were	O
plated	O
at	O
relatively	O
low	O
density	O
(	O
0	O
.	O
25	O
x	O
104	O
cells	O
/	O
cm2	O
)	O
in	O
DMEM	O
medium	O
containing	O
0	O
.	O
5	O
%	O
FBS	O
,	O
1	O
%	O
penicillin	O
streptomycin	O
.	O

Medium	O
containing	O
a	O
minimal	O
level	O
of	O
serum	O
(	O
0	O
.	O
5	O
%	O
FBS	O
)	O
was	O
used	O
,	O
since	O
serum	O
is	O
known	O
to	O
contain	O
steroid	O
hormones	O
that	O
bind	O
to	O
sigma	O
-	O
1	O
receptors	O
[	O
21	O
]	O
.	O

First	O
,	O
we	O
examined	O
the	O
optimal	O
concentration	O
of	O
NGF	O
for	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
.	O

NGF	O
(	O
2	O
.	O
5	O
,	O
5	O
,	O
10	O
,	O
20	O
,	O
40	O
ng	O
/	O
ml	O
)	O
increased	O
the	O
number	O
of	O
cells	O
with	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Figure	O
1	O
)	O
.	O

In	O
the	O
subsequent	O
studies	O
,	O
2	O
.	O
5	O
ng	O
/	O
ml	O
of	O
NGF	O
was	O
used	O
to	O
study	O
the	O
potentiating	O
effects	O
of	O
sigma	O
-	O
1	O
receptor	O
agonists	O
on	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
.	O

Twenty	O
-	O
four	O
hours	O
after	O
plating	O
,	O
the	O
medium	O
was	O
replaced	O
with	O
DMEM	O
medium	O
containing	O
0	O
.	O
5	O
%	O
FBS	O
and	O
1	O
%	O
penicillin	O
streptomycin	O
with	O
NGF	O
(	O
2	O
.	O
5	O
ng	O
/	O
ml	O
)	O
with	O
or	O
without	O
several	O
drugs	O
.	O
<EOS>	B-X
This	B-X
article	B-X
provides	B-X
an	B-X
overview	B-X
about	B-X
the	B-X
stereochemistry	B-X
and	B-X
its	B-X
role	B-X
in	B-X
drugs	B-X
,	B-X
and	B-X
also	B-X
,	B-X
offers	B-X
approved	B-X
isolation	B-X
methods	B-X
for	B-X
enantiomeric	B-X
pairs	B-X
.	B-X
Off-target	B-X
effects	B-X
of	B-X
systemically	B-X
administered	B-X
drugs	B-X
have	B-X
been	B-X
a	B-X
major	B-X
hurdle	B-X
in	B-X
designing	B-X
therapies	B-X
with	B-X
desired	B-X
efficacy	B-X
and	B-X
acceptable	B-X
toxicity	B-X
.	B-X
Developing	B-X
targeting	B-X
strategies	B-X
to	B-X
enable	B-X
site-specific	B-X
drug	B-X
delivery	B-X
holds	B-X
promise	B-X
in	B-X
reducing	B-X
off-target	B-X
effects	B-X
,	B-X
decreasing	B-X
unwanted	B-X
toxicities	B-X
,	B-X
and	B-X
thereby	B-X
enhancing	B-X
a	B-X
drug	B-X
's	B-X
therapeutic	B-X
efficacy	B-X
.	B-X
Over	B-X
the	B-X
past	B-X
three	B-X
decades	B-X
,	B-X
a	B-X
large	B-X
body	B-X
of	B-X
literature	B-X
has	B-X
focused	B-X
on	B-X
understanding	B-X
the	B-X
biological	B-X
barriers	B-X
that	B-X
hinder	B-X
tissue-specific	B-X
drug	B-X
delivery	B-X
and	B-X
strategies	B-X
to	B-X
overcome	B-X
them	B-X
.	B-X
These	B-X
efforts	B-X
have	B-X
led	B-X
to	B-X
several	B-X
targeting	B-X
strategies	B-X
that	B-X
modulate	B-X
drug	B-X
delivery	B-X
in	B-X
both	B-X
the	B-X
preclinical	B-X
and	B-X
clinical	B-X
settings	B-X
,	B-X
including	B-X
small	B-X
molecule-	B-X
,	B-X
nucleic	B-X
acid-	B-X
,	B-X
peptide-	B-X
,	B-X
antibody-	B-X
,	B-X
and	B-X
cell-based	B-X
strategies	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
discuss	B-X
key	B-X
advances	B-X
and	B-X
emerging	B-X
concepts	B-X
for	B-X
tissue-specific	B-X
drug	B-X
delivery	B-X
approaches	B-X
and	B-X
their	B-X
clinical	B-X
translation	B-X
.	B-X

Quantification	O
of	O
neurite	O
sprouting	O
<EOS>	B-X
Bundling	B-X
of	B-X
neurite	B-X
extensions	B-X
occur	B-X
during	B-X
nerve	B-X
development	B-X
and	B-X
regeneration	B-X
.	B-X
Understanding	B-X
the	B-X
factors	B-X
that	B-X
drive	B-X
neurite	B-X
bundling	B-X
is	B-X
important	B-X
for	B-X
designing	B-X
biomaterials	B-X
for	B-X
nerve	B-X
regeneration	B-X
toward	B-X
the	B-X
innervation	B-X
target	B-X
and	B-X
preventing	B-X
nociceptive	B-X
collateral	B-X
sprouting	B-X
.	B-X
Although	B-X
some	B-X
semi-automated	B-X
image	B-X
processing	B-X
methods	B-X
exist	B-X
for	B-X
quantification	B-X
of	B-X
neurite	B-X
outgrowth	B-X
,	B-X
methods	B-X
to	B-X
quantify	B-X
axonal	B-X
fasciculation	B-X
in	B-X
terms	B-X
of	B-X
direction	B-X
of	B-X
neurite	B-X
outgrowth	B-X
are	B-X
lacking	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
addition	B-X
of	B-X
hevin	B-X
in	B-X
the	B-X
culture	B-X
medium	B-X
improved	B-X
neurite	B-X
sprouting	B-X
and	B-X
outgrowth	B-X
of	B-X
differentiated	B-X
neural	B-X
stem	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
our	B-X
results	B-X
indicate	B-X
that	B-X
soluble	B-X
factors	B-X
secreted	B-X
by	B-X
OECs	B-X
provide	B-X
a	B-X
permissive	B-X
environment	B-X
for	B-X
nerve	B-X
repair	B-X
,	B-X
and	B-X
hevin	B-X
is	B-X
one	B-X
of	B-X
the	B-X
key	B-X
molecules	B-X
facilitating	B-X
neurite	B-X
sprouting	B-X
and	B-X
outgrowth	B-X
.	B-X

Five	O
days	O
after	O
incubation	O
with	O
NGF	O
(	O
2	O
.	O
5	O
ng	O
/	O
ml	O
)	O
with	O
or	O
without	O
the	O
several	O
drugs	O
,	O
morphometric	O
analysis	O
was	O
performed	O
on	O
digitized	O
images	O
of	O
live	O
cells	O
taken	O
under	O
phase	O
-	O
contrast	O
illumination	O
with	O
an	O
inverted	O
microscope	O
linked	O
to	O
a	O
camera	O
.	O

Images	O
of	O
three	O
fields	O
per	O
well	O
were	O
taken	O
,	O
with	O
an	O
average	O
of	O
100	O
cells	O
per	O
field	O
.	O

Differentiated	O
cells	O
were	O
counted	O
by	O
visual	O
examination	O
of	O
the	O
field	O
;	O
only	O
cells	O
that	O
had	O
at	O
least	O
one	O
neurite	O
with	O
a	O
length	O
equal	O
to	O
the	O
cell	O
body	O
diameter	O
were	O
counted	O
,	O
and	O
were	O
then	O
expressed	O
as	O
a	O
percentage	O
of	O
the	O
total	O
cells	O
in	O
the	O
field	O
.	O
<EOS>	B-X
However	B-X
,	B-X
AQP-4-antibody-positive	B-X
NMOSD	B-X
coexisting	B-X
with	B-X
ankylosing	B-X
spondylitis	B-X
(	B-X
AS	B-X
)	B-X
is	B-X
rare	B-X
.	B-X
Juraska	B-X
,	B-X
The	B-X
size	B-X
of	B-X
the	B-X
splenium	B-X
of	B-X
the	B-X
rat	B-X
corpus	B-X
callosum	B-X
:	B-X
influence	B-X
of	B-X
hormones	B-X
,	B-X
sex	B-X
ratio	B-X
and	B-X
neonatal	B-X
cryoanesthesia	B-X
,	B-X
Dev	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
effect	B-X
of	B-X
exposure	B-X
to	B-X
neonatal	B-X
hypothermia	B-X
(	B-X
0	B-X
,	B-X
15	B-X
,	B-X
30	B-X
and	B-X
60	B-X
min	B-X
at	B-X
4	B-X
degreesC	B-X
,	B-X
within	B-X
2	B-X
h	B-X
of	B-X
birth	B-X
)	B-X
on	B-X
the	B-X
thickness	B-X
and	B-X
volume	B-X
of	B-X
the	B-X
binocular	B-X
(	B-X
Oc1B	B-X
)	B-X
and	B-X
monocular	B-X
(	B-X
Oc1M	B-X
)	B-X
fields	B-X
of	B-X
the	B-X
adult	B-X
rat	B-X
visual	B-X
cortex	B-X
.	B-X
Cryoanesthesia	B-X
significantly	B-X
decreased	B-X
the	B-X
length	B-X
,	B-X
thickness	B-X
,	B-X
volume	B-X
and	B-X
number	B-X
of	B-X
neurons	B-X
and	B-X
glia	B-X
in	B-X
both	B-X
Oc1M	B-X
and	B-X
Oc1B	B-X
.	B-X
Juraska	B-X
,	B-X
Sex	B-X
differences	B-X
in	B-X
neuron	B-X
number	B-X
in	B-X
the	B-X
binocular	B-X
area	B-X
of	B-X
the	B-X
rat	B-X
visual	B-X
cortex	B-X
,	B-X
J.	B-X
Comp	B-X
.	B-X

The	O
counting	O
was	O
performed	O
in	O
a	O
blinded	O
manner	O
.	O

Immunocytochemistry	O
<EOS>	B-X
Immunocytochemistry	B-X
(	B-X
ICC	B-X
)	B-X
is	B-X
the	B-X
most	B-X
common	B-X
and	B-X
practical	B-X
ancillary	B-X
tool	B-X
used	B-X
to	B-X
reach	B-X
a	B-X
diagnosis	B-X
when	B-X
cytomorphology	B-X
is	B-X
equivocal	B-X
,	B-X
to	B-X
differentiate	B-X
entities	B-X
with	B-X
overlapping	B-X
morphological	B-X
features	B-X
,	B-X
and	B-X
to	B-X
determine	B-X
the	B-X
cell	B-X
lineage	B-X
and	B-X
the	B-X
site	B-X
of	B-X
origin	B-X
of	B-X
a	B-X
metastatic	B-X
neoplasm	B-X
.	B-X
cGMP-immunocytochemistry	B-X
.	B-X
Immunocytochemistry	B-X
has	B-X
opened	B-X
a	B-X
new	B-X
era	B-X
in	B-X
research	B-X
and	B-X
diagnosis	B-X
.	B-X
Immunocytochemistry	B-X
as	B-X
a	B-X
routine	B-X
ancillary	B-X
test	B-X
remains	B-X
a	B-X
distant	B-X
reality	B-X
for	B-X
most	B-X
diagnostic	B-X
laboratories	B-X
.	B-X

Cells	O
were	O
fixed	O
for	O
30	O
min	O
at	O
room	O
temperature	O
with	O
4	O
%	O
paraformaldehyde	O
then	O
permeabilized	O
with	O
0	O
.	O
2	O
%	O
Triton	O
and	O
blocked	O
with	O
1	O
.	O
5	O
%	O
normal	O
goat	B-Species
serum	O
,	O
0	O
.	O
1	O
%	O
bovine	B-Species
serum	O
albumin	O
(	O
BSA	O
)	O
in	O
0	O
.	O
1	O
M	O
phosphate	O
-	O
buffer	O
saline	O
for	O
1	O
h	O
to	O
reduce	O
nonspecific	O
binding	O
.	O

Cells	O
were	O
incubated	O
overnight	O
at	O
4	O
degrees	O
C	O
with	O
anti	O
-	O
microtubule	O
-	O
associated	O
protein	O
2	O
(	O
MAP	O
-	O
2	O
)	O
antibodies	O
(	O
1	O
:	O
1000	O
dilution	O
in	O
blocking	O
solution	O
,	O
Chemicon	O
International	O
,	O
Temecula	O
,	O
CA	O
,	O
USA	O
)	O
.	O

The	O
immunolabeling	O
was	O
visualized	O
with	O
secondary	O
antibodies	O
conjugated	O
to	O
Alexa	O
-	O
488	O
(	O
1	O
:	O
1000	O
;	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
.	O

MAP	O
-	O
2	O
immuncytochemistry	O
was	O
visualized	O
with	O
a	O
fluorescence	O
microscope	O
(	O
Axiovert	O
200	O
,	O
Carl	O
Zeiss	O
,	O
Oberkocken	O
,	O
Germany	O
)	O
.	O

Statistical	O
analysis	O

Data	O
are	O
expressed	O
as	O
means	O
+/-	O
S	O
.	O
E	O
.	O
M	O
.	O

Statistical	O
analysis	O
was	O
performed	O
by	O
using	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
and	O
the	O
post	O
hoc	O
Bonferroni	O
/	O
Dunn	O
test	O
.	O

P	O
values	O
less	O
than	O
0	O
.	O
05	O
were	O
considered	O
statistically	O
significant	O
.	O

Results	O

Effects	O
of	O
SSRIs	O
on	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
fluvoxamine	B-X
on	B-X
nerve	B-X
growth	B-X
factor	B-X
(	B-X
NGF	B-X
)	B-X
-induced	B-X
neurite	B-X
outgrowth	B-X
inhibition	B-X
by	B-X
dexamethasone	B-X
(	B-X
DEX	B-X
)	B-X
in	B-X
PC12	B-X
cells	B-X
.	B-X
Fluvoxamine	B-X
increased	B-X
NGF-induced	B-X
neurite	B-X
outgrowth	B-X
.	B-X
Compared	B-X
with	B-X
co-treatment	B-X
with	B-X
NGF	B-X
and	B-X
fluvoxamine	B-X
,	B-X
p-Akt	B-X
levels	B-X
were	B-X
higher	B-X
than	B-X
the	B-X
values	B-X
without	B-X
fluvoxamine	B-X
.	B-X
The	B-X
phosphorylated	B-X
extracellular	B-X
regulated	B-X
kinase	B-X
1/2	B-X
levels	B-X
were	B-X
slightly	B-X
increased	B-X
by	B-X
co-treatment	B-X
with	B-X
NGF	B-X
and	B-X
fluvoxamine	B-X
.	B-X
Fluvoxamine	B-X
concentration-dependently	B-X
improved	B-X
NGF-induced	B-X
neurite	B-X
outgrowth	B-X
inhibition	B-X
by	B-X
DEX	B-X
.	B-X
Fluvoxamine	B-X
also	B-X
improved	B-X
the	B-X
decrease	B-X
in	B-X
the	B-X
NGF-induced	B-X
p-Akt	B-X
level	B-X
caused	B-X
by	B-X
DEX	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
sigma-1	B-X
receptor	B-X
antagonist	B-X
NE-100	B-X
blocked	B-X
the	B-X
improvement	B-X
effects	B-X
of	B-X
fluvoxamine	B-X
on	B-X
NGF-induced	B-X
neurite	B-X
outgrowth	B-X
inhibition	B-X
by	B-X
DEX	B-X
.	B-X
The	B-X
selective	B-X
sigma-1	B-X
receptor	B-X
agonist	B-X
PRE-084	B-X
also	B-X
improved	B-X
NGF-induced	B-X
neurite	B-X
outgrowth	B-X
inhibition	B-X
by	B-X
DEX	B-X
,	B-X
which	B-X
is	B-X
blocked	B-X
by	B-X
NE-100	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
improvement	B-X
effects	B-X
of	B-X
fluvoxamine	B-X
on	B-X
NGF-induced	B-X
neurite	B-X
outgrowth	B-X
inhibition	B-X
by	B-X
DEX	B-X
may	B-X
be	B-X
attributable	B-X
to	B-X
the	B-X
phosphorylation	B-X
of	B-X
Akt	B-X
and	B-X
the	B-X
sigma-1	B-X
receptor	B-X
.	B-X

Fluvoxamine	O
(	O
0	O
.	O
1	O
,	O
1	O
.	O
0	O
,	O
or	O
10	O
micro	O
M	O
)	O
significantly	O
increased	O
the	O
number	O
of	O
cells	O
with	O
neurite	O
outgrowth	O
by	O
NGF	O
(	O
2	O
.	O
5	O
ng	O
/	O
ml	O
)	O
in	O
PC12	O
cells	O
,	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Figure	O
2	O
and	O
4	O
)	O
.	O

In	O
contrast	O
,	O
sertraline	O
(	O
0	O
.	O
1	O
,	O
1	O
.	O
0	O
,	O
or	O
10	O
micro	O
M	O
)	O
and	O
paroxetine	O
(	O
0	O
.	O
1	O
,	O
1	O
.	O
0	O
,	O
or	O
10	O
micro	O
M	O
)	O
did	O
not	O
increase	O
the	O
number	O
of	O
cells	O
with	O
neurite	O
outgrowth	O
by	O
NGF	O
(	O
2	O
.	O
5	O
ng	O
/	O
ml	O
)	O
.	O

A	O
higher	O
concentration	O
(	O
10	O
micro	O
M	O
)	O
of	O
paroxetine	O
and	O
sertraline	O
significantly	O
decreased	O
the	O
number	O
of	O
cells	O
with	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
,	O
suggesting	O
the	O
cellular	O
toxicity	O
of	O
these	O
drugs	O
in	O
PC12	O
cells	O
(	O
Figure	O
2	O
)	O
.	O

Role	O
of	O
sigma	O
-	O
1	O
receptors	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
fluvoxamine	O
and	O
SA4503	O
<EOS>	B-X
The	B-X
SSRI	B-X
fluvoxamine	B-X
,	B-X
with	B-X
sigma-1	B-X
receptor	B-X
agonism	B-X
,	B-X
is	B-X
shown	B-X
to	B-X
potentiate	B-X
nerve-growth	B-X
factor	B-X
(	B-X
NGF	B-X
)	B-X
-induced	B-X
neurite	B-X
outgrowth	B-X
in	B-X
PC	B-X
12	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
precise	B-X
cellular	B-X
and	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
potentiation	B-X
by	B-X
fluvoxamine	B-X
are	B-X
not	B-X
fully	B-X
understood	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
roles	B-X
of	B-X
cellular	B-X
signaling	B-X
pathways	B-X
in	B-X
the	B-X
potentiation	B-X
of	B-X
NGF-induced	B-X
neurite	B-X
outgrowth	B-X
by	B-X
fluvoxamine	B-X
and	B-X
sigma-1	B-X
receptor	B-X
agonists	B-X
.	B-X
Endoplasmic	B-X
protein	B-X
sigma-1	B-X
receptors	B-X
represent	B-X
unique	B-X
binding	B-X
sites	B-X
in	B-X
the	B-X
brain	B-X
,	B-X
and	B-X
they	B-X
exert	B-X
a	B-X
potent	B-X
influence	B-X
on	B-X
a	B-X
number	B-X
of	B-X
neurotransmitter	B-X
systems	B-X
.	B-X
Several	B-X
lines	B-X
of	B-X
evidence	B-X
suggest	B-X
that	B-X
sigma-1	B-X
receptors	B-X
play	B-X
roles	B-X
in	B-X
the	B-X
pathophysiology	B-X
of	B-X
psychiatric	B-X
diseases	B-X
,	B-X
as	B-X
well	B-X
as	B-X
in	B-X
the	B-X
active	B-X
mechanisms	B-X
of	B-X
some	B-X
selective	B-X
serotonin	B-X
reuptake	B-X
inhibitors	B-X
(	B-X
SSRIs	B-X
)	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
reported	B-X
that	B-X
some	B-X
SSRIs	B-X
possess	B-X
moderate	B-X
to	B-X
high	B-X
affinities	B-X
at	B-X
sigma-1	B-X
receptors	B-X
in	B-X
the	B-X
brain	B-X
.	B-X
Among	B-X
them	B-X
,	B-X
the	B-X
order	B-X
of	B-X
affinity	B-X
for	B-X
sigma-1	B-X
receptors	B-X
was	B-X
as	B-X
follows	B-X
:	B-X
fluvoxamine	B-X
>	B-X
sertraline	B-X
>	B-X
fluoxetine	B-X
>	B-X
citalopram	B-X
``	B-X
paroxetine	B-X
.	B-X
In	B-X
a	B-X
cell	B-X
culture	B-X
system	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
fluvoxamine	B-X
,	B-X
but	B-X
not	B-X
sertraline	B-X
or	B-X
paroxetine	B-X
,	B-X
significantly	B-X
potentiated	B-X
nerve-growth	B-X
factor	B-X
(	B-X
NGF	B-X
)	B-X
-induced	B-X
neurite	B-X
outgrowth	B-X
in	B-X
PC12	B-X
cells	B-X
,	B-X
and	B-X
that	B-X
the	B-X
effect	B-X
of	B-X
fluvoxamine	B-X
on	B-X
NGF-induced	B-X
neurite	B-X
outgrowth	B-X
was	B-X
significantly	B-X
antagonized	B-X
by	B-X
treatment	B-X
with	B-X
the	B-X
selective	B-X
sigma-1	B-X
receptor	B-X
antagonist	B-X
NE-100	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
reported	B-X
that	B-X
phencyclidine	B-X
(	B-X
PCP	B-X
)	B-X
-induced	B-X
cognitive	B-X
deficits	B-X
in	B-X
mice	B-X
were	B-X
significantly	B-X
improved	B-X
by	B-X
subsequent	B-X
subchronic	B-X
administration	B-X
of	B-X
fluvoxamine	B-X
,	B-X
but	B-X
not	B-X
sertraline	B-X
and	B-X
paroxetine	B-X
,	B-X
and	B-X
that	B-X
the	B-X
effect	B-X
of	B-X
fluvoxamine	B-X
on	B-X
PCP-induced	B-X
cognitive	B-X
deficits	B-X
was	B-X
antagonized	B-X
by	B-X
co-administration	B-X
of	B-X
NE-100	B-X
.	B-X
Moreover	B-X
,	B-X
a	B-X
recent	B-X
study	B-X
using	B-X
the	B-X
specific	B-X
sigma-1	B-X
receptor	B-X
ligand	B-X
[	B-X
(	B-X
11	B-X
)	B-X
C	B-X
]	B-X
SA4503	B-X
and	B-X
positron	B-X
emission	B-X
tomography	B-X
(	B-X
PET	B-X
)	B-X
have	B-X
demonstrated	B-X
that	B-X
an	B-X
oral	B-X
administration	B-X
of	B-X
fluvoxamine	B-X
,	B-X
but	B-X
not	B-X
paroxetine	B-X
,	B-X
could	B-X
bind	B-X
to	B-X
sigma-1	B-X
receptors	B-X
in	B-X
the	B-X
healthy	B-X
human	B-X
brain	B-X
,	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
sigma-1	B-X
receptors	B-X
might	B-X
be	B-X
implicated	B-X
in	B-X
the	B-X
active	B-X
mechanisms	B-X
of	B-X
fluvoxamine	B-X
.	B-X
In	B-X
this	B-X
article	B-X
,	B-X
the	B-X
author	B-X
would	B-X
like	B-X
to	B-X
discuss	B-X
the	B-X
novel	B-X
role	B-X
of	B-X
sigma-1	B-X
receptors	B-X
in	B-X
the	B-X
active	B-X
mechanisms	B-X
of	B-X
some	B-X
SSRIs	B-X
including	B-X
fluvoxamine	B-X
.	B-X

The	O
selective	O
and	O
potent	O
sigma	O
-	O
1	O
receptor	O
agonist	O
SA4503	O
(	O
0	O
.	O
01	O
,	O
0	O
.	O
1	O
,	O
or	O
1	O
.	O
0	O
micro	O
M	O
)	O
significantly	O
increased	O
the	O
number	O
of	O
cells	O
with	O
neurite	O
outgrowth	O
by	O
NGF	O
(	O
2	O
.	O
5	O
ng	O
/	O
ml	O
)	O
in	O
PC12	O
cells	O
,	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Figure	O
3	O
and	O
4	O
)	O
.	O

In	O
addition	O
,	O
other	O
sigma	O
-	O
1	O
receptor	O
agonists	O
-	O
PPBP	O
(	O
0	O
.	O
1	O
,	O
1	O
.	O
0	O
,	O
or	O
10	O
micro	O
M	O
)	O
[	O
22	O
]	O
-	O
[	O
26	O
]	O
and	O
DHEA	O
-	O
sulphate	O
(	O
0	O
.	O
1	O
,	O
1	O
.	O
0	O
,	O
or	O
10	O
micro	O
M	O
)	O
[	O
9	O
]	O
,	O
[	O
27	O
]	O
,	O
[	O
28	O
]	O
-	O
significantly	O
increased	O
the	O
number	O
of	O
such	O
cells	O
,	O
also	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Figure	O
3	O
)	O
.	O

In	O
the	O
absence	O
of	O
NGF	O
,	O
sigma	O
-	O
1	O
receptor	O
agonists	O
did	O
not	O
produce	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

To	O
investigate	O
the	O
role	O
of	O
sigma	O
-	O
1	O
receptors	O
,	O
we	O
examined	O
the	O
effects	O
of	O
NE	O
-	O
100	O
(	O
a	O
selective	O
sigma	O
-	O
1	O
receptor	O
antagonist	O
)	O
on	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
fluvoxamine	O
,	O
SA4503	O
,	O
PPBP	O
,	O
and	O
DHEA	O
-	O
sulphate	O
.	O

Co	O
-	O
administration	O
of	O
NE	O
-	O
100	O
(	O
1	O
.	O
0	O
micro	O
M	O
)	O
significantly	O
blocked	O
such	O
potentiation	O
by	O
fluvoxamine	O
(	O
10	O
micro	O
M	O
)	O
,	O
SA4503	O
(	O
1	O
.	O
0	O
micro	O
M	O
)	O
,	O
PPBP	O
(	O
10	O
micro	O
M	O
)	O
,	O
or	O
DHEA	O
-	O
sulphate	O
(	O
10	O
micro	O
M	O
)	O
(	O
Figure	O
2	O
and	O
3	O
)	O
.	O

Furthermore	O
,	O
administration	O
of	O
NE	O
-	O
100	O
(	O
1	O
.	O
0	O
micro	O
M	O
)	O
alone	O
did	O
not	O
alter	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
(	O
Figure	O
2	O
)	O
.	O

Role	O
of	O
IP3	O
receptors	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
<EOS>	B-X
The	B-X
SSRI	B-X
fluvoxamine	B-X
,	B-X
with	B-X
sigma-1	B-X
receptor	B-X
agonism	B-X
,	B-X
is	B-X
shown	B-X
to	B-X
potentiate	B-X
nerve-growth	B-X
factor	B-X
(	B-X
NGF	B-X
)	B-X
-induced	B-X
neurite	B-X
outgrowth	B-X
in	B-X
PC	B-X
12	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
precise	B-X
cellular	B-X
and	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
potentiation	B-X
by	B-X
fluvoxamine	B-X
are	B-X
not	B-X
fully	B-X
understood	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
roles	B-X
of	B-X
cellular	B-X
signaling	B-X
pathways	B-X
in	B-X
the	B-X
potentiation	B-X
of	B-X
NGF-induced	B-X
neurite	B-X
outgrowth	B-X
by	B-X
fluvoxamine	B-X
and	B-X
sigma-1	B-X
receptor	B-X
agonists	B-X
.	B-X
The	B-X
selective	B-X
ROCK	B-X
inhibitor	B-X
Y-27632	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
induce	B-X
neurite	B-X
outgrowth	B-X
in	B-X
PC12	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
precise	B-X
cellular	B-X
and	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
ROCK	B-X
inhibition-induced	B-X
neurite	B-X
outgrowth	B-X
are	B-X
not	B-X
fully	B-X
understood	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
roles	B-X
of	B-X
cellular	B-X
signaling	B-X
pathways	B-X
in	B-X
the	B-X
potentiation	B-X
of	B-X
nerve	B-X
growth	B-X
factor	B-X
(	B-X
NGF	B-X
)	B-X
-induced	B-X
neurite	B-X
outgrowth	B-X
by	B-X
Y-27632	B-X
.	B-X
Y-27632	B-X
significantly	B-X
potentiated	B-X
NGF	B-X
(	B-X
2.5	B-X
ng/ml	B-X
)	B-X
-induced	B-X
neurite	B-X
outgrowth	B-X
in	B-X
PC12	B-X
cells	B-X
,	B-X
in	B-X
a	B-X
concentration-dependent	B-X
manner	B-X
.	B-X
Furthermore	B-X
,	B-X
another	B-X
ROCK	B-X
inhibitor	B-X
,	B-X
H-1152	B-X
,	B-X
and	B-X
the	B-X
Rho	B-X
inhibitor	B-X
botulinum	B-X
exoenzyme	B-X
C3	B-X
also	B-X
potentiated	B-X
NGF	B-X
(	B-X
2.5	B-X
ng/ml	B-X
)	B-X
-induced	B-X
neurite	B-X
outgrowth	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
potentiation	B-X
by	B-X
Y-27632	B-X
was	B-X
blocked	B-X
by	B-X
co-administration	B-X
of	B-X
the	B-X
phosphatidylinositol	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
inhibitor	B-X
LY294002	B-X
or	B-X
an	B-X
Akt	B-X
inhibitor	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
specific	B-X
inhibitors	B-X
of	B-X
phospholipase	B-X
C	B-X
(	B-X
PLC-Î³	B-X
)	B-X
,	B-X
p38MAPK	B-X
,	B-X
c-Jun	B-X
N-terminal	B-X
kinase	B-X
(	B-X
JNK	B-X
)	B-X
,	B-X
and	B-X
the	B-X
Ras/Raf/mitogen-activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
signaling	B-X
pathways	B-X
did	B-X
not	B-X
affect	B-X
the	B-X
potentiation	B-X
of	B-X
NGF-induced	B-X
neurite	B-X
outgrowth	B-X
by	B-X
Y-27632	B-X
.	B-X
The	B-X
results	B-X
of	B-X
double-staining	B-X
immunocytochemistry	B-X
suggested	B-X
that	B-X
both	B-X
ROCK1	B-X
and	B-X
type-1	B-X
IPâ	B-X
receptors	B-X
may	B-X
be	B-X
co-localized	B-X
in	B-X
the	B-X
cell	B-X
body	B-X
of	B-X
PC12	B-X
cells	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
these	B-X
findings	B-X
suggest	B-X
that	B-X
IPâ	B-X
receptors	B-X
and	B-X
PI3K-Akt	B-X
signaling	B-X
pathways	B-X
might	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
mechanisms	B-X
of	B-X
potentiation	B-X
of	B-X
NGF-induced	B-X
neurite	B-X
outgrowth	B-X
by	B-X
ROCK	B-X
inhibitors	B-X
.	B-X

Sigma	O
-	O
1	O
receptors	O
have	O
been	O
shown	O
to	O
interact	O
with	O
IP3	O
receptors	O
(	O
17	O
,	O
18	O
,	O
33	O
-	O
35	O
)	O
.	O

To	O
investigate	O
the	O
role	O
of	O
IP3	O
receptors	O
in	O
the	O
effects	O
of	O
SA4503	O
on	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
,	O
we	O
examined	O
the	O
effects	O
of	O
xestospongin	O
C	O
(	O
a	O
selective	O
,	O
reversible	O
,	O
and	O
membrane	O
-	O
permeable	O
inhibitor	O
of	O
IP3	O
receptors	O
)	O
[	O
31	O
]	O
on	O
the	O
effects	O
of	O
SA4503	O
on	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
.	O

Co	O
-	O
administration	O
of	O
xestospongin	O
C	O
(	O
1	O
.	O
0	O
micro	O
M	O
)	O
significantly	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
(	O
1	O
.	O
0	O
micro	O
M	O
)	O
(	O
Figure	O
5	O
)	O
.	O

Furthermore	O
,	O
administration	O
of	O
xestospongin	O
C	O
(	O
1	O
.	O
0	O
micro	O
M	O
)	O
alone	O
did	O
not	O
alter	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
(	O
Figure	O
5	O
)	O
.	O

Role	O
of	O
signaling	O
molecules	O
proximal	O
to	O
TrkA	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O

Next	O
,	O
we	O
examined	O
the	O
effects	O
of	O
the	O
specific	O
inhibitors	O
of	O
PLC	O
-	O
gamma	O
,	O
PI3K	O
,	O
p38	O
MAPK	O
,	O
and	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
,	O
since	O
these	O
signaling	O
molecules	O
are	O
activated	O
upon	O
the	O
addition	O
of	O
NGF	O
[	O
36	O
]	O
.	O

The	O
PLC	O
-	O
gamma	O
inhibitor	O
(	O
U73122	O
;	O
1	O
.	O
0	O
micro	O
M	O
)	O
,	O
PI3K	O
inhibitor	O
(	O
LY294002	O
;	O
1	O
.	O
0	O
micro	O
M	O
)	O
,	O
p38	O
MAPK	O
inhibitor	O
(	O
SB203580	O
;	O
1	O
.	O
0	O
micro	O
M	O
)	O
,	O
and	O
JNK	O
inhibitor	O
(	O
SP600125	O
;	O
1	O
.	O
0	O
micro	O
M	O
)	O
significantly	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
(	O
1	O
.	O
0	O
micro	O
M	O
)	O
(	O
Figure	O
6	O
)	O
.	O
<EOS>	B-X
Activation	B-X
of	B-X
phospholipase	B-X
C	B-X
(	B-X
PLC	B-X
)	B-X
is	B-X
a	B-X
central	B-X
component	B-X
of	B-X
the	B-X
signal	B-X
transduction	B-X
process	B-X
in	B-X
numerous	B-X
cells	B-X
,	B-X
including	B-X
platelets	B-X
.	B-X
U73122	B-X
has	B-X
been	B-X
widely	B-X
used	B-X
as	B-X
a	B-X
selective	B-X
PLC	B-X
inhibitor	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
U73122	B-X
on	B-X
platelet	B-X
function	B-X
have	B-X
been	B-X
further	B-X
examined	B-X
.	B-X
Platelets	B-X
were	B-X
stimulated	B-X
with	B-X
collagen	B-X
(	B-X
via	B-X
PLC-gamma	B-X
)	B-X
,	B-X
the	B-X
stable	B-X
thromboxane	B-X
mimetic	B-X
U46619	B-X
(	B-X
via	B-X
PLC-beta	B-X
)	B-X
,	B-X
or	B-X
phorbol	B-X
myristate	B-X
acetate	B-X
(	B-X
PMA	B-X
)	B-X
via	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
.	B-X
Consistent	B-X
with	B-X
inhibition	B-X
of	B-X
PLC	B-X
,	B-X
U73122	B-X
inhibited	B-X
platelet	B-X
aggregation	B-X
and	B-X
[	B-X
3H	B-X
]	B-X
-serotonin	B-X
release	B-X
in	B-X
response	B-X
to	B-X
collagen	B-X
and	B-X
U46619	B-X
in	B-X
a	B-X
concentration-dependent	B-X
manner	B-X
.	B-X
Similarly	B-X
,	B-X
U73122	B-X
blocked	B-X
collagen-induced	B-X
release	B-X
of	B-X
thromboxane	B-X
A2	B-X
.	B-X
U73122	B-X
also	B-X
inhibited	B-X
U46619-induced	B-X
[	B-X
32P	B-X
]	B-X
phosphatidic	B-X
acid	B-X
production	B-X
and	B-X
phosphorylation	B-X
of	B-X
the	B-X
major	B-X
PKC	B-X
substrate	B-X
,	B-X
pleckstrin	B-X
.	B-X
U73122	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
PMA-induced	B-X
pleckstrin	B-X
phosphorylation	B-X
,	B-X
[	B-X
3H	B-X
]	B-X
-serotonin	B-X
release	B-X
,	B-X
or	B-X
intracellular	B-X
vacuole	B-X
formation	B-X
.	B-X
However	B-X
,	B-X
U73122	B-X
did	B-X
inhibit	B-X
PMA-induced	B-X
platelet	B-X
aggregation	B-X
and	B-X
fibrinogen	B-X
binding	B-X
.	B-X
Overall	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
U73122	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
its	B-X
inhibition	B-X
of	B-X
PLC	B-X
,	B-X
also	B-X
affects	B-X
PKC-independent	B-X
events	B-X
that	B-X
interfere	B-X
with	B-X
platelet	B-X
aggregation	B-X
.	B-X

In	O
contrast	O
,	O
these	O
inhibitors	O
alone	O
did	O
not	O
alter	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
(	O
Figure	O
6	O
)	O
.	O
<EOS>	B-X
To	B-X
simultaneously	B-X
evaluate	B-X
the	B-X
relative	B-X
efficacy	B-X
of	B-X
multiple	B-X
pharmacologic	B-X
strategies	B-X
for	B-X
preventing	B-X
contrast-induced	B-X
acute	B-X
kidney	B-X
injury	B-X
(	B-X
AKI	B-X
)	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
also	B-X
found	B-X
that	B-X
the	B-X
expression	B-X
level	B-X
of	B-X
PKM2	B-X
is	B-X
also	B-X
higher	B-X
in	B-X
cisplatin	B-X
resistant	B-X
BC	B-X
cells	B-X
and	B-X
tumors	B-X
.	B-X
Down-regulation	B-X
of	B-X
PKM2	B-X
by	B-X
siRNA	B-X
or	B-X
inhibition	B-X
of	B-X
PKM2	B-X
by	B-X
shikonin	B-X
re-sensitized	B-X
the	B-X
cisplatin	B-X
resistant	B-X
T24	B-X
cells	B-X
.	B-X
Shikonin	B-X
and	B-X
cisplatin	B-X
together	B-X
exhibit	B-X
significantly	B-X
greater	B-X
killing	B-X
effects	B-X
than	B-X
when	B-X
used	B-X
alone	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
shikonin	B-X
kills	B-X
the	B-X
T24	B-X
cisplatin	B-X
resistant	B-X
cells	B-X
by	B-X
inducing	B-X
necroptosis	B-X
,	B-X
as	B-X
the	B-X
cell	B-X
death	B-X
could	B-X
not	B-X
inhibited	B-X
by	B-X
apoptosis	B-X
inhibitor	B-X
,	B-X
z-VAD	B-X
,	B-X
but	B-X
compromised	B-X
by	B-X
RIP3	B-X
inhibitor	B-X
,	B-X
GSK872	B-X
,	B-X
or	B-X
RIP3	B-X
siRNA	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
shikonin	B-X
induced	B-X
apoptosis	B-X
in	B-X
T24	B-X
parental	B-X
cells	B-X
.	B-X
We	B-X
further	B-X
investigate	B-X
the	B-X
underlying	B-X
mechanism	B-X
,	B-X
and	B-X
found	B-X
that	B-X
the	B-X
dysregulation	B-X
of	B-X
Bcl-2	B-X
family	B-X
proteins	B-X
,	B-X
including	B-X
Bcl-2	B-X
,	B-X
PUMA	B-X
,	B-X
Bax	B-X
,	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
deciding	B-X
that	B-X
shikonin	B-X
kills	B-X
the	B-X
BC	B-X
cells	B-X
by	B-X
necroptosis	B-X
or	B-X
apoptosis	B-X
.	B-X
Collectively	B-X
,	B-X
our	B-X
results	B-X
suggested	B-X
that	B-X
inducing	B-X
necroptosis	B-X
is	B-X
an	B-X
alternative	B-X
way	B-X
to	B-X
overcome	B-X
the	B-X
apoptosis	B-X
resistant	B-X
in	B-X
BC	B-X
therapy	B-X
,	B-X
and	B-X
orchestrating	B-X
the	B-X
regulation	B-X
of	B-X
Bcl-2	B-X
,	B-X
PUMA	B-X
,	B-X
and	B-X
Bax	B-X
in	B-X
BC	B-X
cisplatin	B-X
resistant	B-X
cells	B-X
may	B-X
improve	B-X
the	B-X
therapy	B-X
effect	B-X
of	B-X
cisplatin	B-X
in	B-X
BC	B-X
tumor	B-X
.	B-X

Role	O
of	O
Raf	O
/	O
Ras	O
/	O
ERK	O
/	O
MAPK	O
pathway	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O

The	O
Raf	O
/	O
Ras	O
/	O
ERK	O
/	O
MAPK	O
pathway	O
is	O
known	O
to	O
be	O
involved	O
in	O
NGF	O
-	O
induced	O
outgrowth	O
[	O
32	O
]	O
.	O

Therefore	O
,	O
we	O
examined	O
the	O
effects	O
of	O
this	O
pathway	O
'	O
s	O
specific	O
inhibitors	O
.	O
<EOS>	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
examine	B-X
the	B-X
regulatory	B-X
and	B-X
effector	B-X
components	B-X
of	B-X
this	B-X
pathway	B-X
,	B-X
focusing	B-X
on	B-X
their	B-X
emerging	B-X
roles	B-X
in	B-X
biological	B-X
processes	B-X
involved	B-X
in	B-X
different	B-X
pathologies	B-X
.	B-X
We	B-X
summarize	B-X
how	B-X
this	B-X
pathway	B-X
has	B-X
been	B-X
exploited	B-X
for	B-X
the	B-X
development	B-X
of	B-X
therapeutics	B-X
and	B-X
discuss	B-X
the	B-X
potential	B-X
obstacles	B-X
of	B-X
targeting	B-X
this	B-X
promiscuous	B-X
protein	B-X
kinase	B-X
pathway	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
different	B-X
diseases	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
discuss	B-X
how	B-X
the	B-X
p38	B-X
(	B-X
MAPK	B-X
)	B-X
pathway	B-X
might	B-X
be	B-X
best	B-X
exploited	B-X
for	B-X
the	B-X
development	B-X
of	B-X
more	B-X
effective	B-X
therapeutics	B-X
with	B-X
minimal	B-X
side	B-X
effects	B-X
in	B-X
a	B-X
range	B-X
of	B-X
specific	B-X
disease	B-X
settings	B-X
.	B-X
We	B-X
examined	B-X
a	B-X
large	B-X
dataset	B-X
of	B-X
female	B-X
metastatic	B-X
breast	B-X
cancers	B-X
(	B-X
MBCs	B-X
)	B-X
profiled	B-X
with	B-X
comprehensive	B-X
genomic	B-X
profiling	B-X
(	B-X
CGP	B-X
)	B-X
to	B-X
identify	B-X
the	B-X
prevalence	B-X
and	B-X
distribution	B-X
of	B-X
immunotherapy	B-X
responsiveness-associated	B-X
biomarkers	B-X
.	B-X

The	O
Ras	O
inhibitor	O
(	O
GW5074	O
;	O
1	O
.	O
0	O
micro	O
M	O
)	O
,	O
Raf	O
inhibitor	O
(	O
lovastatin	O
;	O
1	O
.	O
0	O
micro	O
M	O
)	O
,	O
MEK1	O
/	O
2	O
inhibitor	O
(	O
SL327	O
;	O
1	O
.	O
0	O
micro	O
M	O
)	O
,	O
and	O
MAPK	O
inhibitor	O
(	O
PD98059	O
;	O
1	O
.	O
0	O
micro	O
M	O
)	O
significantly	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
(	O
1	O
.	O
0	O
micro	O
M	O
)	O
(	O
Figure	O
7	O
)	O
.	O
<EOS>	B-X
LK-induced	B-X
cell	B-X
death	B-X
is	B-X
blocked	B-X
by	B-X
GW5074	B-X
[	B-X
5-Iodo-3-	B-X
[	B-X
(	B-X
3,5-dibromo-4-hydroxyphenyl	B-X
)	B-X
methylene	B-X
]	B-X
-2-indolinone	B-X
]	B-X
,	B-X
a	B-X
synthetic	B-X
drug	B-X
that	B-X
inhibits	B-X
c-Raf	B-X
activity	B-X
in	B-X
vitro	B-X
.	B-X
GW5074	B-X
has	B-X
no	B-X
direct	B-X
effect	B-X
on	B-X
the	B-X
activities	B-X
of	B-X
several	B-X
apoptosis-associated	B-X
kinases	B-X
when	B-X
assayed	B-X
in	B-X
vitro	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
its	B-X
effect	B-X
in	B-X
vitro	B-X
,	B-X
treatment	B-X
of	B-X
neurons	B-X
with	B-X
GW5074	B-X
causes	B-X
c-Raf	B-X
activation	B-X
(	B-X
when	B-X
measured	B-X
in	B-X
vitro	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
the	B-X
drug	B-X
)	B-X
and	B-X
stimulates	B-X
the	B-X
Raf-MEK-ERK	B-X
pathway	B-X
.	B-X
Treatment	B-X
of	B-X
neurons	B-X
with	B-X
GW5074	B-X
also	B-X
leads	B-X
to	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
activity	B-X
of	B-X
B-Raf	B-X
,	B-X
which	B-X
is	B-X
not	B-X
inhibited	B-X
by	B-X
GW5074	B-X
in	B-X
vitro	B-X
at	B-X
concentrations	B-X
at	B-X
which	B-X
the	B-X
drug	B-X
exerts	B-X
its	B-X
neuroprotective	B-X
effect	B-X
.	B-X
PD98059	B-X
and	B-X
U0126	B-X
,	B-X
two	B-X
distinct	B-X
inhibitors	B-X
of	B-X
MEK	B-X
,	B-X
block	B-X
the	B-X
activation	B-X
of	B-X
ERK	B-X
by	B-X
GW5074	B-X
but	B-X
have	B-X
no	B-X
effect	B-X
on	B-X
its	B-X
ability	B-X
to	B-X
prevent	B-X
cell	B-X
death	B-X
.	B-X
Overexpression	B-X
of	B-X
a	B-X
dominant-negative	B-X
form	B-X
of	B-X
Akt	B-X
does	B-X
not	B-X
reduce	B-X
the	B-X
efficacy	B-X
of	B-X
GW5074	B-X
,	B-X
demonstrating	B-X
an	B-X
Akt-independent	B-X
mechanism	B-X
of	B-X
action	B-X
.	B-X
Neuroprotection	B-X
is	B-X
inhibited	B-X
by	B-X
SN-50	B-X
,	B-X
a	B-X
specific	B-X
inhibitor	B-X
of	B-X
nuclear	B-X
factor-kappa	B-X
B	B-X
(	B-X
NF-kappaB	B-X
)	B-X
and	B-X
by	B-X
the	B-X
Ras	B-X
inhibitor	B-X
S-trans	B-X
,	B-X
trans-farnesylthiosalicylic	B-X
acid	B-X
(	B-X
FTS	B-X
)	B-X
implicating	B-X
NF-kappaB	B-X
and	B-X
Ras	B-X
in	B-X
the	B-X
neuroprotective	B-X
signaling	B-X
pathway	B-X
activated	B-X
by	B-X
GW5074	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
preventing	B-X
LK-induced	B-X
apoptosis	B-X
,	B-X
treatment	B-X
with	B-X
GW5074	B-X
protects	B-X
against	B-X
the	B-X
neurotoxic	B-X
effects	B-X
of	B-X
MPP+	B-X
and	B-X
methylmercury	B-X
in	B-X
cerebellar	B-X
granule	B-X
neurons	B-X
,	B-X
and	B-X
glutathione	B-X
depletion-induced	B-X
oxidative	B-X
stress	B-X
in	B-X
cortical	B-X
neurons	B-X
.	B-X
Furthermore	B-X
,	B-X
GW5074	B-X
prevents	B-X
neurodegeneration	B-X
and	B-X
improves	B-X
behavioral	B-X
outcome	B-X
in	B-X
an	B-X
animal	B-X
model	B-X
of	B-X
Huntington	B-X
's	B-X
disease	B-X
.	B-X
Given	B-X
its	B-X
neuroprotective	B-X
effect	B-X
on	B-X
distinct	B-X
types	B-X
of	B-X
cultured	B-X
neurons	B-X
,	B-X
in	B-X
response	B-X
to	B-X
different	B-X
neurotoxic	B-X
stimuli	B-X
,	B-X
and	B-X
in	B-X
an	B-X
animal	B-X
model	B-X
of	B-X
neurodegeneration	B-X
,	B-X
GW5074	B-X
could	B-X
have	B-X
therapeutic	B-X
value	B-X
against	B-X
neurodegenerative	B-X
pathologies	B-X
in	B-X
humans	B-X
.	B-X

In	O
contrast	O
,	O
these	O
inhibitors	O
alone	O
did	O
not	O
alter	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
(	O
Figure	O
7	O
)	O
.	O
<EOS>	B-X
To	B-X
simultaneously	B-X
evaluate	B-X
the	B-X
relative	B-X
efficacy	B-X
of	B-X
multiple	B-X
pharmacologic	B-X
strategies	B-X
for	B-X
preventing	B-X
contrast-induced	B-X
acute	B-X
kidney	B-X
injury	B-X
(	B-X
AKI	B-X
)	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
also	B-X
found	B-X
that	B-X
the	B-X
expression	B-X
level	B-X
of	B-X
PKM2	B-X
is	B-X
also	B-X
higher	B-X
in	B-X
cisplatin	B-X
resistant	B-X
BC	B-X
cells	B-X
and	B-X
tumors	B-X
.	B-X
Down-regulation	B-X
of	B-X
PKM2	B-X
by	B-X
siRNA	B-X
or	B-X
inhibition	B-X
of	B-X
PKM2	B-X
by	B-X
shikonin	B-X
re-sensitized	B-X
the	B-X
cisplatin	B-X
resistant	B-X
T24	B-X
cells	B-X
.	B-X
Shikonin	B-X
and	B-X
cisplatin	B-X
together	B-X
exhibit	B-X
significantly	B-X
greater	B-X
killing	B-X
effects	B-X
than	B-X
when	B-X
used	B-X
alone	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
shikonin	B-X
kills	B-X
the	B-X
T24	B-X
cisplatin	B-X
resistant	B-X
cells	B-X
by	B-X
inducing	B-X
necroptosis	B-X
,	B-X
as	B-X
the	B-X
cell	B-X
death	B-X
could	B-X
not	B-X
inhibited	B-X
by	B-X
apoptosis	B-X
inhibitor	B-X
,	B-X
z-VAD	B-X
,	B-X
but	B-X
compromised	B-X
by	B-X
RIP3	B-X
inhibitor	B-X
,	B-X
GSK872	B-X
,	B-X
or	B-X
RIP3	B-X
siRNA	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
shikonin	B-X
induced	B-X
apoptosis	B-X
in	B-X
T24	B-X
parental	B-X
cells	B-X
.	B-X
We	B-X
further	B-X
investigate	B-X
the	B-X
underlying	B-X
mechanism	B-X
,	B-X
and	B-X
found	B-X
that	B-X
the	B-X
dysregulation	B-X
of	B-X
Bcl-2	B-X
family	B-X
proteins	B-X
,	B-X
including	B-X
Bcl-2	B-X
,	B-X
PUMA	B-X
,	B-X
Bax	B-X
,	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
deciding	B-X
that	B-X
shikonin	B-X
kills	B-X
the	B-X
BC	B-X
cells	B-X
by	B-X
necroptosis	B-X
or	B-X
apoptosis	B-X
.	B-X
Collectively	B-X
,	B-X
our	B-X
results	B-X
suggested	B-X
that	B-X
inducing	B-X
necroptosis	B-X
is	B-X
an	B-X
alternative	B-X
way	B-X
to	B-X
overcome	B-X
the	B-X
apoptosis	B-X
resistant	B-X
in	B-X
BC	B-X
therapy	B-X
,	B-X
and	B-X
orchestrating	B-X
the	B-X
regulation	B-X
of	B-X
Bcl-2	B-X
,	B-X
PUMA	B-X
,	B-X
and	B-X
Bax	B-X
in	B-X
BC	B-X
cisplatin	B-X
resistant	B-X
cells	B-X
may	B-X
improve	B-X
the	B-X
therapy	B-X
effect	B-X
of	B-X
cisplatin	B-X
in	B-X
BC	B-X
tumor	B-X
.	B-X

Discussion	O
<EOS>	B-X
Discussion	B-X
structures	B-X
are	B-X
argumentation-theoretical	B-X
tools	B-X
that	B-X
can	B-X
be	B-X
employed	B-X
to	B-X
tackle	B-X
three	B-X
barriers	B-X
that	B-X
separate	B-X
lay	B-X
stakeholders	B-X
from	B-X
policy	B-X
debates	B-X
:	B-X
difficulty	B-X
,	B-X
magnitude	B-X
,	B-X
and	B-X
complexity	B-X
.	B-X
Discussions	B-X
about	B-X
preventive	B-X
behaviors	B-X
were	B-X
assessed	B-X
before	B-X
testing	B-X
and	B-X
1	B-X
and	B-X
6	B-X
months	B-X
post-testing	B-X
.	B-X
Discussion	B-X
of	B-X
preventive	B-X
behaviors	B-X
declined	B-X
following	B-X
test	B-X
reporting	B-X
,	B-X
with	B-X
more	B-X
rapid	B-X
decline	B-X
reported	B-X
by	B-X
noncarriers	B-X
.	B-X
Discussions	B-X
are	B-X
an	B-X
important	B-X
part	B-X
of	B-X
medical	B-X
education	B-X
research	B-X
papers	B-X
,	B-X
but	B-X
there	B-X
is	B-X
little	B-X
guidance	B-X
on	B-X
how	B-X
to	B-X
write	B-X
up	B-X
the	B-X
discussion	B-X
section	B-X
.	B-X

In	O
the	O
present	O
study	O
,	O
we	O
found	O
that	O
fluvoxamine	O
(	O
but	O
not	O
sertraline	O
or	O
paroxetine	O
)	O
and	O
the	O
sigma	O
-	O
1	O
receptor	O
agonists	O
(	O
SA4503	O
,	O
PPBP	O
,	O
DHEA	O
-	O
sulfate	O
)	O
could	O
potentiate	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
,	O
and	O
that	O
the	O
effects	O
of	O
these	O
drugs	O
were	O
blocked	O
by	O
co	O
-	O
incubation	O
with	O
the	O
selective	O
sigma	O
-	O
1	O
receptor	O
antagonist	O
NE	O
-	O
100	O
.	O

These	O
findings	O
suggest	O
that	O
agonism	O
at	O
sigma	O
-	O
1	O
receptors	O
for	O
these	O
drugs	O
is	O
involved	O
in	O
the	O
mechanisms	O
underlying	O
the	O
drugs	O
'	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
.	O

As	O
shown	O
in	O
Figure	O
1	O
,	O
NGF	O
increased	O
the	O
number	O
of	O
cells	O
with	O
neurite	O
outgrowth	O
in	O
PC12	O
,	O
in	O
a	O
concentration	O
dependent	O
manner	O
.	O

To	O
examine	O
whether	O
or	O
not	O
the	O
NGF	O
levels	O
are	O
altered	O
by	O
incubation	O
with	O
sigma	O
-	O
1	O
receptor	O
agonists	O
,	O
we	O
measured	O
the	O
levels	O
of	O
NGF	O
in	O
PC12	O
cells	O
with	O
or	O
without	O
sigma	O
-	O
1	O
receptor	O
agonist	O
SA4503	O
.	O
<EOS>	B-X
Time-Restricted	B-X
Eating	B-X
is	B-X
an	B-X
eating	B-X
pattern	B-X
based	B-X
on	B-X
the	B-X
circadian	B-X
rhythm	B-X
which	B-X
limits	B-X
daily	B-X
food	B-X
intake	B-X
(	B-X
usually	B-X
to	B-X
â¤12	B-X
h/day	B-X
)	B-X
,	B-X
unique	B-X
in	B-X
that	B-X
no	B-X
overt	B-X
restriction	B-X
is	B-X
imposed	B-X
on	B-X
the	B-X
quality	B-X
,	B-X
nor	B-X
quantity	B-X
,	B-X
of	B-X
food	B-X
intake	B-X
.	B-X
This	B-X
paper	B-X
aimed	B-X
to	B-X
examine	B-X
the	B-X
effects	B-X
of	B-X
two	B-X
patterns	B-X
of	B-X
TRE	B-X
,	B-X
traditional	B-X
TRE	B-X
,	B-X
and	B-X
Ramadan	B-X
fasting	B-X
,	B-X
on	B-X
two	B-X
markers	B-X
of	B-X
circadian	B-X
rhythm	B-X
,	B-X
cortisol	B-X
and	B-X
melatonin	B-X
.	B-X
Therefore	B-X
,	B-X
there	B-X
is	B-X
a	B-X
unique	B-X
opportunity	B-X
to	B-X
examine	B-X
the	B-X
evidence	B-X
surrounding	B-X
nipple	B-X
confusion	B-X
by	B-X
assessing	B-X
the	B-X
research	B-X
that	B-X
supports/refutes	B-X
that	B-X
bottle	B-X
feeding/pacifier	B-X
use	B-X
impedes	B-X
breastfeeding	B-X
efficacy/success/duration	B-X
.	B-X
This	B-X
review	B-X
examined	B-X
14	B-X
articles	B-X
supporting	B-X
and	B-X
refuting	B-X
nipple	B-X
confusion	B-X
.	B-X
The	B-X
primary	B-X
difficulty	B-X
in	B-X
conclusively	B-X
studying	B-X
nipple	B-X
confusion	B-X
is	B-X
establishing	B-X
causality	B-X
,	B-X
namely	B-X
determining	B-X
whether	B-X
bottles'/pacifiers	B-X
'	B-X
nipples	B-X
are	B-X
causing	B-X
infants	B-X
to	B-X
refuse	B-X
the	B-X
breast	B-X
or	B-X
whether	B-X
they	B-X
are	B-X
simply	B-X
markers	B-X
of	B-X
other	B-X
maternal/infant	B-X
characteristics	B-X
.	B-X

No	O
differences	O
of	O
NGF	O
levels	O
were	O
shown	O
in	O
the	O
between	O
control	O
group	O
and	O
SA4503	O
-	O
treated	O
group	O
(	O
data	O
not	O
shown	O
)	O
.	O

It	O
is	O
,	O
therefore	O
,	O
unlikely	O
that	O
the	O
potentaition	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
sigma	O
-	O
1	O
receptor	O
agonists	O
might	O
be	O
due	O
to	O
increased	O
levels	O
of	O
NGF	O
.	O

Unlike	O
fluvoxamine	O
,	O
sertraline	O
,	O
which	O
has	O
a	O
moderate	O
affinity	O
for	O
sigma	O
-	O
1	O
receptors	O
,	O
did	O
not	O
alter	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
.	O

The	O
reasons	O
underlying	O
this	O
discrepancy	O
between	O
these	O
two	O
SSRIs	O
are	O
currently	O
unclear	O
.	O

One	O
possibility	O
may	O
involve	O
the	O
difference	O
in	O
pharmacological	O
actions	O
(	O
agonist	O
vs	O
.	O
antagonist	O
)	O
between	O
these	O
SSRIs	O
at	O
sigma	O
-	O
1	O
receptors	O
.	O

Interestingly	O
,	O
we	O
recently	O
found	O
that	O
,	O
in	O
a	O
novel	O
object	O
recognition	O
test	O
,	O
phencyclidine	O
-	O
induced	O
cognitive	O
deficits	O
could	O
be	O
significantly	O
improved	O
by	O
subsequent	O
subchronic	O
(	O
14	O
days	O
)	O
administration	O
of	O
fluvoxamine	O
,	O
but	O
not	O
of	O
sertraline	O
,	O
suggesting	O
that	O
sigma	O
-	O
1	O
receptor	O
agonism	O
is	O
involved	O
in	O
fluvoxamine	O
'	O
s	O
mechanism	O
of	O
action	O
[	O
9	O
]	O
,	O
Ishima	O
et	O
al	O
.	O
,	O
submitted	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
fluvoxamine	O
and	O
sertraline	O
may	O
function	O
as	O
an	O
agonist	O
and	O
an	O
antagonist	O
at	O
sigma	O
-	O
1	O
receptors	O
,	O
respectively	O
,	O
although	O
further	O
study	O
is	O
necessary	O
.	O

Another	O
possibility	O
may	O
be	O
that	O
other	O
pharmacological	O
activities	O
of	O
sertraline	O
mask	O
the	O
effects	O
of	O
sigma	O
-	O
1	O
receptor	O
agonism	O
.	O

In	O
this	O
study	O
,	O
we	O
also	O
found	O
that	O
high	O
concentration	O
(	O
10	O
micro	O
M	O
)	O
of	O
paroxetine	O
and	O
sertraline	O
,	O
but	O
not	O
fluvoxamine	O
,	O
showed	O
cytotoxicity	O
in	O
PC12	O
cells	O
,	O
suggesting	O
that	O
fluvoxamine	O
may	O
be	O
a	O
safe	O
drug	O
than	O
paroxetine	O
and	O
sertraline	O
.	O

Sigma	O
-	O
1	O
receptors	O
have	O
been	O
shown	O
to	O
affect	O
intracellular	O
Ca2	O
+	O
signaling	O
,	O
although	O
the	O
precise	O
molecular	O
and	O
cellular	O
mechanisms	O
underlying	O
this	O
effect	O
are	O
unknown	O
.	O

Sigma	O
-	O
1	O
receptors	O
bind	O
to	O
IP3	O
receptors	O
in	O
ER	O
,	O
and	O
sigma	O
-	O
1	O
receptors	O
regulate	O
Ca2	O
+	O
release	O
from	O
intracellular	O
Ca2	O
+	O
storage	O
sites	O
[	O
12	O
]	O
.	O

Very	O
recently	O
,	O
Hayashi	O
and	O
Su	O
[	O
17	O
]	O
reported	O
that	O
sigma	O
-	O
1	O
receptors	O
function	O
as	O
novel	O
ligand	O
-	O
operated	O
chaperones	O
that	O
specifically	O
target	O
mitochondrion	O
-	O
associated	O
ER	O
membrane	O
.	O

Furthermore	O
,	O
sigma	O
-	O
1	O
receptors	O
form	O
Ca2	O
+	O
-	O
sensitive	O
chaperone	O
machinery	O
with	O
another	O
chaperone	O
,	O
BiP	O
,	O
and	O
prolong	O
Ca2	O
+	O
signaling	O
from	O
ER	O
into	O
mitochondria	O
by	O
stabilizing	O
IP3	O
receptors	O
at	O
mitochondrion	O
-	O
associated	O
ER	O
membrane	O
[	O
17	O
]	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
the	O
IP3	O
receptor	O
antagonist	O
xestospongin	O
C	O
significantly	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
,	O
suggesting	O
the	O
role	O
of	O
IP3	O
receptors	O
on	O
sigma	O
-	O
1	O
receptor	O
-	O
mediated	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
.	O

Therefore	O
,	O
it	O
is	O
likely	O
that	O
stimulation	O
at	O
sigma	O
-	O
1	O
receptors	O
by	O
sigma	O
-	O
1	O
receptor	O
agonists	O
and	O
subsequent	O
interaction	O
with	O
IP3	O
receptors	O
are	O
involved	O
in	O
the	O
mechanism	O
underlying	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
sigma	O
-	O
1	O
receptor	O
agonists	O
.	O

NGF	O
binds	O
to	O
the	O
high	O
-	O
affinity	O
tyrosine	O
receptor	O
TrkA	O
,	O
initiating	O
several	O
signaling	O
pathways	O
affecting	O
both	O
morphological	O
and	O
transcriptional	O
targets	O
[	O
32	O
]	O
,	O
[	O
36	O
]	O
,	O
[	O
37	O
]	O
.	O

The	O
signaling	O
molecules	O
,	O
including	O
PLC	O
-	O
gamma	O
,	O
PI3K	O
,	O
p38	O
MAPK	O
,	O
and	O
JNK	O
,	O
are	O
activated	O
upon	O
the	O
addition	O
of	O
NGF	O
[	O
38	O
]	O
.	O

PLC	O
-	O
gamma	O
catalyzes	O
the	O
hydrolysis	O
of	O
phosphatidylinositol	O
-	O
4	O
,	O
5	O
-	O
bisphosphate	O
(	O
PIP2	O
)	O
to	O
diacylglycerol	O
(	O
DAG	O
)	O
and	O
inositol	O
triphosphate	O
(	O
IP3	O
)	O
.	O
<EOS>	B-X
Phosphatidylinositol-specific	B-X
phospholipase	B-X
C	B-X
(	B-X
PLC	B-X
)	B-X
enzymes	B-X
catalyze	B-X
hydrolysis	B-X
of	B-X
phosphatidylinositol	B-X
4,5-bisphosphate	B-X
(	B-X
PIP2	B-X
)	B-X
generating	B-X
diacylglycerol	B-X
(	B-X
DAG	B-X
)	B-X
and	B-X
inositol	B-X
1,4,5-triphosphate	B-X
(	B-X
IP	B-X
(	B-X
3	B-X
)	B-X
)	B-X
.	B-X
The	B-X
PLC	B-X
beta	B-X
isoforms	B-X
of	B-X
PLCs	B-X
are	B-X
activated	B-X
by	B-X
G	B-X
proteins	B-X
after	B-X
hormone	B-X
or	B-X
neurotransmitter	B-X
stimulation	B-X
of	B-X
G	B-X
protein-coupled	B-X
receptors	B-X
(	B-X
GPCR	B-X
)	B-X
.	B-X
PLC	B-X
epsilon	B-X
is	B-X
a	B-X
recently	B-X
identified	B-X
PLC	B-X
isoform	B-X
that	B-X
is	B-X
activated	B-X
by	B-X
Ras	B-X
and	B-X
G	B-X
beta	B-X
gamma	B-X
subunit	B-X
although	B-X
the	B-X
physiological	B-X
role	B-X
of	B-X
this	B-X
enzyme	B-X
is	B-X
not	B-X
well	B-X
understood	B-X
.	B-X
Methods	B-X
for	B-X
purification	B-X
of	B-X
PLC	B-X
beta	B-X
and	B-X
PLC	B-X
epsilon	B-X
from	B-X
Sf9	B-X
cells	B-X
are	B-X
described	B-X
.	B-X
In	B-X
the	B-X
case	B-X
of	B-X
hexahistidine	B-X
(	B-X
6-His	B-X
)	B-X
-tagged	B-X
PLC	B-X
beta	B-X
the	B-X
purification	B-X
involves	B-X
two	B-X
steps	B-X
,	B-X
affinity	B-X
chromatography	B-X
with	B-X
Ni-NTA	B-X
agarose	B-X
followed	B-X
by	B-X
heparin	B-X
Sepharose	B-X
chromatography	B-X
.	B-X
6-His-tagged	B-X
PLC	B-X
epsilon	B-X
can	B-X
be	B-X
purified	B-X
in	B-X
a	B-X
single	B-X
step	B-X
with	B-X
nickel	B-X
nitrilotriacetic	B-X
acid-agarose	B-X
(	B-X
Ni-NTA	B-X
)	B-X
affinity	B-X
chromatography	B-X
.	B-X

DAG	O
activates	O
protein	O
kinase	O
C	O
,	O
and	O
IP3	O
promotes	O
transient	O
release	O
of	O
Ca2	O
+	O
from	O
the	O
ER	O
[	O
39	O
]	O
.	O

The	O
pathway	O
via	O
PLC	O
-	O
gamma	O
is	O
responsible	O
for	O
NGF	O
-	O
induced	O
cell	O
differentiation	O
[	O
40	O
]	O
and	O
neurite	O
outgrowth	O
[	O
41	O
]	O
.	O

Furthermore	O
,	O
stimulation	O
of	O
PI3K	O
is	O
reported	O
to	O
be	O
involved	O
in	O
the	O
promotion	O
of	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
[	O
42	O
]	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
the	O
PLC	O
-	O
gamma	O
inhibitor	O
U73122	O
and	O
the	O
PI3K	O
inhibitor	O
LY294002	O
significantly	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
.	O

Moreover	O
,	O
we	O
found	O
that	O
both	O
the	O
p38MAPK	O
inhibitor	O
SB203580	O
and	O
the	O
JNK	O
inhibitor	O
SP600125	O
significantly	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
.	O

In	O
addition	O
,	O
it	O
is	O
also	O
interesting	O
that	O
neurite	O
outgrowth	O
induced	O
by	O
low	O
concentration	O
(	O
2	O
.	O
5	O
ng	O
/	O
ml	O
)	O
of	O
NGF	O
was	O
not	O
blocked	O
by	O
these	O
inihibitors	O
,	O
consistent	O
with	O
a	O
previous	O
report	O
[	O
43	O
]	O
,	O
[	O
44	O
]	O
,	O
suggesting	O
the	O
existence	O
of	O
novel	O
pathway	O
(	O
s	O
)	O
for	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
PLC	O
-	O
gamma	O
,	O
PI3K	O
,	O
p38MAPK	O
,	O
and	O
JNK	O
signaling	O
pathways	O
are	O
involved	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
sigma	O
-	O
1	O
receptor	O
agonists	O
(	O
Figure	O
8	O
)	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
the	O
specific	O
inhibitors	O
for	O
the	O
Raf	O
/	O
Ras	O
/	O
MEK	O
/	O
MAPK	O
pathways	O
significantly	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
,	O
suggesting	O
that	O
these	O
pathways	O
are	O
involved	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
sigma	O
-	O
1	O
receptor	O
agonists	O
(	O
Figure	O
8	O
)	O
.	O

Our	O
recent	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
study	O
demonstrated	O
that	O
,	O
after	O
a	O
single	O
oral	O
administration	O
,	O
fluvoxamine	O
bound	O
to	O
sigma	O
-	O
1	O
receptors	O
in	O
the	O
living	O
human	B-Species
brain	O
[	O
45	O
]	O
.	O

This	O
finding	O
suggests	O
that	O
sigma	O
-	O
1	O
receptors	O
are	O
involved	O
in	O
the	O
mechanism	O
of	O
action	O
of	O
fluvoxamine	O
in	O
the	O
human	B-Species
brain	O
[	O
45	O
]	O
.	O

Taken	O
together	O
,	O
the	O
past	O
and	O
present	O
findings	O
suggest	O
that	O
,	O
unlike	O
paroxetine	O
and	O
sertraline	O
,	O
the	O
SSRI	O
fluvoxamine	O
,	O
with	O
its	O
sigma	O
-	O
1	O
receptor	O
agonistic	O
activity	O
,	O
might	O
be	O
a	O
unique	O
therapeutic	O
drug	O
for	O
neuropsychiatric	O
diseases	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
results	O
suggest	O
that	O
,	O
as	O
a	O
sigma	O
-	O
1	O
receptor	O
agonist	O
,	O
fluvoxamine	O
could	O
potentiate	O
the	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
.	O

Furthermore	O
,	O
it	O
is	O
likely	O
that	O
interaction	O
with	O
IP3	O
receptors	O
and	O
several	O
subsequent	O
signaling	O
molecules	O
are	O
involved	O
in	O
the	O
mechanism	O
underlying	O
the	O
pharmacological	O
action	O
of	O
sigma	O
-	O
1	O
receptor	O
agonists	O
.	O

Therefore	O
,	O
it	O
is	O
likely	O
that	O
sigma	O
-	O
1	O
receptor	O
agonists	O
such	O
as	O
fluvoxamine	O
and	O
DHEA	O
-	O
sulfate	O
,	O
which	O
are	O
available	O
around	O
the	O
world	O
,	O
would	O
be	O
unique	O
therapeutic	O
drugs	O
for	O
neuropsychiatric	O
diseases	O
.	O

A	O
novel	O
,	O
non	O
-	O
invasive	O
,	O
online	O
-	O
monitoring	O
,	O
versatile	O
and	O
easy	O
plant	O
-	O
based	O
probe	O
for	O
measuring	O
leaf	O
water	O
status	O
<EOS>	B-X
A	B-X
high-precision	B-X
pressure	B-X
probe	B-X
is	B-X
described	B-X
which	B-X
allows	B-X
non-invasive	B-X
online-monitoring	B-X
of	B-X
the	B-X
water	B-X
relations	B-X
of	B-X
intact	B-X
leaves	B-X
.	B-X
Real-time	B-X
recording	B-X
of	B-X
the	B-X
leaf	B-X
water	B-X
status	B-X
occurred	B-X
by	B-X
data	B-X
transfer	B-X
to	B-X
an	B-X
Internet	B-X
server	B-X
.	B-X
The	B-X
leaf	B-X
patch	B-X
clamp	B-X
pressure	B-X
probe	B-X
measures	B-X
the	B-X
attenuated	B-X
pressure	B-X
,	B-X
P	B-X
(	B-X
p	B-X
)	B-X
,	B-X
of	B-X
a	B-X
leaf	B-X
patch	B-X
in	B-X
response	B-X
to	B-X
a	B-X
constant	B-X
clamp	B-X
pressure	B-X
,	B-X
P	B-X
(	B-X
clamp	B-X
)	B-X
.	B-X
The	B-X
magnitude	B-X
of	B-X
P	B-X
(	B-X
p	B-X
)	B-X
is	B-X
dictated	B-X
by	B-X
the	B-X
transfer	B-X
function	B-X
of	B-X
the	B-X
leaf	B-X
,	B-X
T	B-X
(	B-X
f	B-X
)	B-X
,	B-X
which	B-X
is	B-X
a	B-X
function	B-X
of	B-X
leaf	B-X
patch	B-X
volume	B-X
and	B-X
ultimately	B-X
of	B-X
cell	B-X
turgor	B-X
pressure	B-X
,	B-X
P	B-X
(	B-X
c	B-X
)	B-X
,	B-X
as	B-X
shown	B-X
theoretically	B-X
.	B-X
The	B-X
power	B-X
function	B-X
T	B-X
(	B-X
f	B-X
)	B-X
=f	B-X
(	B-X
P	B-X
(	B-X
c	B-X
)	B-X
)	B-X
theoretically	B-X
derived	B-X
was	B-X
experimentally	B-X
confirmed	B-X
by	B-X
concomitant	B-X
P	B-X
(	B-X
p	B-X
)	B-X
and	B-X
P	B-X
(	B-X
c	B-X
)	B-X
measurements	B-X
on	B-X
intact	B-X
leaflets	B-X
of	B-X
the	B-X
liana	B-X
Tetrastigma	B-X
voinierianum	B-X
under	B-X
greenhouse	B-X
conditions	B-X
.	B-X
Simultaneous	B-X
P	B-X
(	B-X
p	B-X
)	B-X
recordings	B-X
on	B-X
leaflets	B-X
up	B-X
to	B-X
10	B-X
m	B-X
height	B-X
above	B-X
ground	B-X
demonstrated	B-X
that	B-X
changes	B-X
in	B-X
T	B-X
(	B-X
f	B-X
)	B-X
induced	B-X
by	B-X
P	B-X
(	B-X
c	B-X
)	B-X
changes	B-X
due	B-X
to	B-X
changes	B-X
of	B-X
microclimate	B-X
and/or	B-X
of	B-X
the	B-X
irrigation	B-X
regime	B-X
were	B-X
sensitively	B-X
reflected	B-X
in	B-X
corresponding	B-X
changes	B-X
of	B-X
P	B-X
(	B-X
p	B-X
)	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
data	B-X
show	B-X
that	B-X
transpirational	B-X
water	B-X
loss	B-X
during	B-X
the	B-X
morning	B-X
hours	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
transient	B-X
rise	B-X
in	B-X
turgor	B-X
pressure	B-X
gradients	B-X
within	B-X
the	B-X
leaflets	B-X
.	B-X
Subsequent	B-X
recovery	B-X
of	B-X
turgescence	B-X
during	B-X
the	B-X
afternoon	B-X
was	B-X
much	B-X
faster	B-X
than	B-X
the	B-X
preceding	B-X
transpiration-induced	B-X
water	B-X
loss	B-X
if	B-X
the	B-X
plants	B-X
were	B-X
well	B-X
irrigated	B-X
.	B-X
Our	B-X
data	B-X
show	B-X
the	B-X
enormous	B-X
potential	B-X
of	B-X
the	B-X
leaf	B-X
patch	B-X
clamp	B-X
pressure	B-X
probe	B-X
for	B-X
leaf	B-X
water	B-X
studies	B-X
including	B-X
unravelling	B-X
of	B-X
the	B-X
hydraulic	B-X
communication	B-X
between	B-X
neighbouring	B-X
leaves	B-X
and	B-X
over	B-X
long	B-X
distances	B-X
within	B-X
tall	B-X
plants	B-X
(	B-X
trees	B-X
)	B-X
.	B-X

Abstract	O
<EOS>	B-X
Abstract	B-X
writing	B-X
.	B-X
The	B-X
informative	B-X
abstract	B-X
.	B-X
Crafting	B-X
a	B-X
compelling	B-X
abstract	B-X
.	B-X
Why	B-X
the	B-X
structured	B-X
abstract	B-X
?	B-X

A	O
high	O
-	O
precision	O
pressure	O
probe	O
is	O
described	O
which	O
allows	O
non	O
-	O
invasive	O
online	O
-	O
monitoring	O
of	O
the	O
water	O
relations	O
of	O
intact	O
leaves	O
.	O
<EOS>	B-X
A	B-X
high-precision	B-X
pressure	B-X
probe	B-X
is	B-X
described	B-X
which	B-X
allows	B-X
non-invasive	B-X
online-monitoring	B-X
of	B-X
the	B-X
water	B-X
relations	B-X
of	B-X
intact	B-X
leaves	B-X
.	B-X
Real-time	B-X
recording	B-X
of	B-X
the	B-X
leaf	B-X
water	B-X
status	B-X
occurred	B-X
by	B-X
data	B-X
transfer	B-X
to	B-X
an	B-X
Internet	B-X
server	B-X
.	B-X
The	B-X
leaf	B-X
patch	B-X
clamp	B-X
pressure	B-X
probe	B-X
measures	B-X
the	B-X
attenuated	B-X
pressure	B-X
,	B-X
P	B-X
(	B-X
p	B-X
)	B-X
,	B-X
of	B-X
a	B-X
leaf	B-X
patch	B-X
in	B-X
response	B-X
to	B-X
a	B-X
constant	B-X
clamp	B-X
pressure	B-X
,	B-X
P	B-X
(	B-X
clamp	B-X
)	B-X
.	B-X
P	B-X
(	B-X
p	B-X
)	B-X
is	B-X
sensed	B-X
by	B-X
a	B-X
miniaturized	B-X
silicone	B-X
pressure	B-X
sensor	B-X
integrated	B-X
into	B-X
the	B-X
device	B-X
.	B-X
The	B-X
magnitude	B-X
of	B-X
P	B-X
(	B-X
p	B-X
)	B-X
is	B-X
dictated	B-X
by	B-X
the	B-X
transfer	B-X
function	B-X
of	B-X
the	B-X
leaf	B-X
,	B-X
T	B-X
(	B-X
f	B-X
)	B-X
,	B-X
which	B-X
is	B-X
a	B-X
function	B-X
of	B-X
leaf	B-X
patch	B-X
volume	B-X
and	B-X
ultimately	B-X
of	B-X
cell	B-X
turgor	B-X
pressure	B-X
,	B-X
P	B-X
(	B-X
c	B-X
)	B-X
,	B-X
as	B-X
shown	B-X
theoretically	B-X
.	B-X
The	B-X
power	B-X
function	B-X
T	B-X
(	B-X
f	B-X
)	B-X
=f	B-X
(	B-X
P	B-X
(	B-X
c	B-X
)	B-X
)	B-X
theoretically	B-X
derived	B-X
was	B-X
experimentally	B-X
confirmed	B-X
by	B-X
concomitant	B-X
P	B-X
(	B-X
p	B-X
)	B-X
and	B-X
P	B-X
(	B-X
c	B-X
)	B-X
measurements	B-X
on	B-X
intact	B-X
leaflets	B-X
of	B-X
the	B-X
liana	B-X
Tetrastigma	B-X
voinierianum	B-X
under	B-X
greenhouse	B-X
conditions	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
data	B-X
show	B-X
that	B-X
transpirational	B-X
water	B-X
loss	B-X
during	B-X
the	B-X
morning	B-X
hours	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
transient	B-X
rise	B-X
in	B-X
turgor	B-X
pressure	B-X
gradients	B-X
within	B-X
the	B-X
leaflets	B-X
.	B-X
Subsequent	B-X
recovery	B-X
of	B-X
turgescence	B-X
during	B-X
the	B-X
afternoon	B-X
was	B-X
much	B-X
faster	B-X
than	B-X
the	B-X
preceding	B-X
transpiration-induced	B-X
water	B-X
loss	B-X
if	B-X
the	B-X
plants	B-X
were	B-X
well	B-X
irrigated	B-X
.	B-X
Our	B-X
data	B-X
show	B-X
the	B-X
enormous	B-X
potential	B-X
of	B-X
the	B-X
leaf	B-X
patch	B-X
clamp	B-X
pressure	B-X
probe	B-X
for	B-X
leaf	B-X
water	B-X
studies	B-X
including	B-X
unravelling	B-X
of	B-X
the	B-X
hydraulic	B-X
communication	B-X
between	B-X
neighbouring	B-X
leaves	B-X
and	B-X
over	B-X
long	B-X
distances	B-X
within	B-X
tall	B-X
plants	B-X
(	B-X
trees	B-X
)	B-X
.	B-X

Real	O
-	O
time	O
recording	O
of	O
the	O
leaf	O
water	O
status	O
occurred	O
by	O
data	O
transfer	O
to	O
an	O
Internet	O
server	O
.	O

The	O
leaf	O
patch	O
clamp	O
pressure	O
probe	O
measures	O
the	O
attenuated	O
pressure	O
,	O
Pp	O
,	O
of	O
a	O
leaf	O
patch	O
in	O
response	O
to	O
a	O
constant	O
clamp	O
pressure	O
,	O
Pclamp	O
.	O
<EOS>	B-X
A	B-X
high-precision	B-X
pressure	B-X
probe	B-X
is	B-X
described	B-X
which	B-X
allows	B-X
non-invasive	B-X
online-monitoring	B-X
of	B-X
the	B-X
water	B-X
relations	B-X
of	B-X
intact	B-X
leaves	B-X
.	B-X
Real-time	B-X
recording	B-X
of	B-X
the	B-X
leaf	B-X
water	B-X
status	B-X
occurred	B-X
by	B-X
data	B-X
transfer	B-X
to	B-X
an	B-X
Internet	B-X
server	B-X
.	B-X
The	B-X
leaf	B-X
patch	B-X
clamp	B-X
pressure	B-X
probe	B-X
measures	B-X
the	B-X
attenuated	B-X
pressure	B-X
,	B-X
P	B-X
(	B-X
p	B-X
)	B-X
,	B-X
of	B-X
a	B-X
leaf	B-X
patch	B-X
in	B-X
response	B-X
to	B-X
a	B-X
constant	B-X
clamp	B-X
pressure	B-X
,	B-X
P	B-X
(	B-X
clamp	B-X
)	B-X
.	B-X
P	B-X
(	B-X
p	B-X
)	B-X
is	B-X
sensed	B-X
by	B-X
a	B-X
miniaturized	B-X
silicone	B-X
pressure	B-X
sensor	B-X
integrated	B-X
into	B-X
the	B-X
device	B-X
.	B-X
The	B-X
magnitude	B-X
of	B-X
P	B-X
(	B-X
p	B-X
)	B-X
is	B-X
dictated	B-X
by	B-X
the	B-X
transfer	B-X
function	B-X
of	B-X
the	B-X
leaf	B-X
,	B-X
T	B-X
(	B-X
f	B-X
)	B-X
,	B-X
which	B-X
is	B-X
a	B-X
function	B-X
of	B-X
leaf	B-X
patch	B-X
volume	B-X
and	B-X
ultimately	B-X
of	B-X
cell	B-X
turgor	B-X
pressure	B-X
,	B-X
P	B-X
(	B-X
c	B-X
)	B-X
,	B-X
as	B-X
shown	B-X
theoretically	B-X
.	B-X
The	B-X
power	B-X
function	B-X
T	B-X
(	B-X
f	B-X
)	B-X
=f	B-X
(	B-X
P	B-X
(	B-X
c	B-X
)	B-X
)	B-X
theoretically	B-X
derived	B-X
was	B-X
experimentally	B-X
confirmed	B-X
by	B-X
concomitant	B-X
P	B-X
(	B-X
p	B-X
)	B-X
and	B-X
P	B-X
(	B-X
c	B-X
)	B-X
measurements	B-X
on	B-X
intact	B-X
leaflets	B-X
of	B-X
the	B-X
liana	B-X
Tetrastigma	B-X
voinierianum	B-X
under	B-X
greenhouse	B-X
conditions	B-X
.	B-X
Simultaneous	B-X
P	B-X
(	B-X
p	B-X
)	B-X
recordings	B-X
on	B-X
leaflets	B-X
up	B-X
to	B-X
10	B-X
m	B-X
height	B-X
above	B-X
ground	B-X
demonstrated	B-X
that	B-X
changes	B-X
in	B-X
T	B-X
(	B-X
f	B-X
)	B-X
induced	B-X
by	B-X
P	B-X
(	B-X
c	B-X
)	B-X
changes	B-X
due	B-X
to	B-X
changes	B-X
of	B-X
microclimate	B-X
and/or	B-X
of	B-X
the	B-X
irrigation	B-X
regime	B-X
were	B-X
sensitively	B-X
reflected	B-X
in	B-X
corresponding	B-X
changes	B-X
of	B-X
P	B-X
(	B-X
p	B-X
)	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
data	B-X
show	B-X
that	B-X
transpirational	B-X
water	B-X
loss	B-X
during	B-X
the	B-X
morning	B-X
hours	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
transient	B-X
rise	B-X
in	B-X
turgor	B-X
pressure	B-X
gradients	B-X
within	B-X
the	B-X
leaflets	B-X
.	B-X
Our	B-X
data	B-X
show	B-X
the	B-X
enormous	B-X
potential	B-X
of	B-X
the	B-X
leaf	B-X
patch	B-X
clamp	B-X
pressure	B-X
probe	B-X
for	B-X
leaf	B-X
water	B-X
studies	B-X
including	B-X
unravelling	B-X
of	B-X
the	B-X
hydraulic	B-X
communication	B-X
between	B-X
neighbouring	B-X
leaves	B-X
and	B-X
over	B-X
long	B-X
distances	B-X
within	B-X
tall	B-X
plants	B-X
(	B-X
trees	B-X
)	B-X
.	B-X

Pp	O
is	O
sensed	O
by	O
a	O
miniaturized	O
silicone	O
pressure	O
sensor	O
integrated	O
into	O
the	O
device	O
.	O
<EOS>	B-X
A	B-X
high-precision	B-X
pressure	B-X
probe	B-X
is	B-X
described	B-X
which	B-X
allows	B-X
non-invasive	B-X
online-monitoring	B-X
of	B-X
the	B-X
water	B-X
relations	B-X
of	B-X
intact	B-X
leaves	B-X
.	B-X
The	B-X
leaf	B-X
patch	B-X
clamp	B-X
pressure	B-X
probe	B-X
measures	B-X
the	B-X
attenuated	B-X
pressure	B-X
,	B-X
P	B-X
(	B-X
p	B-X
)	B-X
,	B-X
of	B-X
a	B-X
leaf	B-X
patch	B-X
in	B-X
response	B-X
to	B-X
a	B-X
constant	B-X
clamp	B-X
pressure	B-X
,	B-X
P	B-X
(	B-X
clamp	B-X
)	B-X
.	B-X
P	B-X
(	B-X
p	B-X
)	B-X
is	B-X
sensed	B-X
by	B-X
a	B-X
miniaturized	B-X
silicone	B-X
pressure	B-X
sensor	B-X
integrated	B-X
into	B-X
the	B-X
device	B-X
.	B-X
The	B-X
magnitude	B-X
of	B-X
P	B-X
(	B-X
p	B-X
)	B-X
is	B-X
dictated	B-X
by	B-X
the	B-X
transfer	B-X
function	B-X
of	B-X
the	B-X
leaf	B-X
,	B-X
T	B-X
(	B-X
f	B-X
)	B-X
,	B-X
which	B-X
is	B-X
a	B-X
function	B-X
of	B-X
leaf	B-X
patch	B-X
volume	B-X
and	B-X
ultimately	B-X
of	B-X
cell	B-X
turgor	B-X
pressure	B-X
,	B-X
P	B-X
(	B-X
c	B-X
)	B-X
,	B-X
as	B-X
shown	B-X
theoretically	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
data	B-X
show	B-X
that	B-X
transpirational	B-X
water	B-X
loss	B-X
during	B-X
the	B-X
morning	B-X
hours	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
transient	B-X
rise	B-X
in	B-X
turgor	B-X
pressure	B-X
gradients	B-X
within	B-X
the	B-X
leaflets	B-X
.	B-X
Our	B-X
data	B-X
show	B-X
the	B-X
enormous	B-X
potential	B-X
of	B-X
the	B-X
leaf	B-X
patch	B-X
clamp	B-X
pressure	B-X
probe	B-X
for	B-X
leaf	B-X
water	B-X
studies	B-X
including	B-X
unravelling	B-X
of	B-X
the	B-X
hydraulic	B-X
communication	B-X
between	B-X
neighbouring	B-X
leaves	B-X
and	B-X
over	B-X
long	B-X
distances	B-X
within	B-X
tall	B-X
plants	B-X
(	B-X
trees	B-X
)	B-X
.	B-X

The	O
magnitude	O
of	O
Pp	O
is	O
dictated	O
by	O
the	O
transfer	O
function	O
of	O
the	O
leaf	O
,	O
Tf	O
,	O
which	O
is	O
a	O
function	O
of	O
leaf	O
patch	O
volume	O
and	O
ultimately	O
of	O
cell	O
turgor	O
pressure	O
,	O
Pc	O
,	O
as	O
shown	O
theoretically	O
.	O
<EOS>	B-X
A	B-X
high-precision	B-X
pressure	B-X
probe	B-X
is	B-X
described	B-X
which	B-X
allows	B-X
non-invasive	B-X
online-monitoring	B-X
of	B-X
the	B-X
water	B-X
relations	B-X
of	B-X
intact	B-X
leaves	B-X
.	B-X
Real-time	B-X
recording	B-X
of	B-X
the	B-X
leaf	B-X
water	B-X
status	B-X
occurred	B-X
by	B-X
data	B-X
transfer	B-X
to	B-X
an	B-X
Internet	B-X
server	B-X
.	B-X
The	B-X
leaf	B-X
patch	B-X
clamp	B-X
pressure	B-X
probe	B-X
measures	B-X
the	B-X
attenuated	B-X
pressure	B-X
,	B-X
P	B-X
(	B-X
p	B-X
)	B-X
,	B-X
of	B-X
a	B-X
leaf	B-X
patch	B-X
in	B-X
response	B-X
to	B-X
a	B-X
constant	B-X
clamp	B-X
pressure	B-X
,	B-X
P	B-X
(	B-X
clamp	B-X
)	B-X
.	B-X
P	B-X
(	B-X
p	B-X
)	B-X
is	B-X
sensed	B-X
by	B-X
a	B-X
miniaturized	B-X
silicone	B-X
pressure	B-X
sensor	B-X
integrated	B-X
into	B-X
the	B-X
device	B-X
.	B-X
The	B-X
magnitude	B-X
of	B-X
P	B-X
(	B-X
p	B-X
)	B-X
is	B-X
dictated	B-X
by	B-X
the	B-X
transfer	B-X
function	B-X
of	B-X
the	B-X
leaf	B-X
,	B-X
T	B-X
(	B-X
f	B-X
)	B-X
,	B-X
which	B-X
is	B-X
a	B-X
function	B-X
of	B-X
leaf	B-X
patch	B-X
volume	B-X
and	B-X
ultimately	B-X
of	B-X
cell	B-X
turgor	B-X
pressure	B-X
,	B-X
P	B-X
(	B-X
c	B-X
)	B-X
,	B-X
as	B-X
shown	B-X
theoretically	B-X
.	B-X
The	B-X
power	B-X
function	B-X
T	B-X
(	B-X
f	B-X
)	B-X
=f	B-X
(	B-X
P	B-X
(	B-X
c	B-X
)	B-X
)	B-X
theoretically	B-X
derived	B-X
was	B-X
experimentally	B-X
confirmed	B-X
by	B-X
concomitant	B-X
P	B-X
(	B-X
p	B-X
)	B-X
and	B-X
P	B-X
(	B-X
c	B-X
)	B-X
measurements	B-X
on	B-X
intact	B-X
leaflets	B-X
of	B-X
the	B-X
liana	B-X
Tetrastigma	B-X
voinierianum	B-X
under	B-X
greenhouse	B-X
conditions	B-X
.	B-X
Simultaneous	B-X
P	B-X
(	B-X
p	B-X
)	B-X
recordings	B-X
on	B-X
leaflets	B-X
up	B-X
to	B-X
10	B-X
m	B-X
height	B-X
above	B-X
ground	B-X
demonstrated	B-X
that	B-X
changes	B-X
in	B-X
T	B-X
(	B-X
f	B-X
)	B-X
induced	B-X
by	B-X
P	B-X
(	B-X
c	B-X
)	B-X
changes	B-X
due	B-X
to	B-X
changes	B-X
of	B-X
microclimate	B-X
and/or	B-X
of	B-X
the	B-X
irrigation	B-X
regime	B-X
were	B-X
sensitively	B-X
reflected	B-X
in	B-X
corresponding	B-X
changes	B-X
of	B-X
P	B-X
(	B-X
p	B-X
)	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
data	B-X
show	B-X
that	B-X
transpirational	B-X
water	B-X
loss	B-X
during	B-X
the	B-X
morning	B-X
hours	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
transient	B-X
rise	B-X
in	B-X
turgor	B-X
pressure	B-X
gradients	B-X
within	B-X
the	B-X
leaflets	B-X
.	B-X
Our	B-X
data	B-X
show	B-X
the	B-X
enormous	B-X
potential	B-X
of	B-X
the	B-X
leaf	B-X
patch	B-X
clamp	B-X
pressure	B-X
probe	B-X
for	B-X
leaf	B-X
water	B-X
studies	B-X
including	B-X
unravelling	B-X
of	B-X
the	B-X
hydraulic	B-X
communication	B-X
between	B-X
neighbouring	B-X
leaves	B-X
and	B-X
over	B-X
long	B-X
distances	B-X
within	B-X
tall	B-X
plants	B-X
(	B-X
trees	B-X
)	B-X
.	B-X

The	O
power	O
function	O
Tf	O
=	O
f	O
(	O
Pc	O
)	O
theoretically	O
derived	O
was	O
experimentally	O
confirmed	O
by	O
concomitant	O
Pp	O
and	O
Pc	O
measurements	O
on	O
intact	O
leaflets	O
of	O
the	O
liana	O
Tetrastigma	B-Species
voinierianum	I-Species
under	O
greenhouse	O
conditions	O
.	O
<EOS>	B-X
A	B-X
high-precision	B-X
pressure	B-X
probe	B-X
is	B-X
described	B-X
which	B-X
allows	B-X
non-invasive	B-X
online-monitoring	B-X
of	B-X
the	B-X
water	B-X
relations	B-X
of	B-X
intact	B-X
leaves	B-X
.	B-X
Real-time	B-X
recording	B-X
of	B-X
the	B-X
leaf	B-X
water	B-X
status	B-X
occurred	B-X
by	B-X
data	B-X
transfer	B-X
to	B-X
an	B-X
Internet	B-X
server	B-X
.	B-X
The	B-X
leaf	B-X
patch	B-X
clamp	B-X
pressure	B-X
probe	B-X
measures	B-X
the	B-X
attenuated	B-X
pressure	B-X
,	B-X
P	B-X
(	B-X
p	B-X
)	B-X
,	B-X
of	B-X
a	B-X
leaf	B-X
patch	B-X
in	B-X
response	B-X
to	B-X
a	B-X
constant	B-X
clamp	B-X
pressure	B-X
,	B-X
P	B-X
(	B-X
clamp	B-X
)	B-X
.	B-X
The	B-X
magnitude	B-X
of	B-X
P	B-X
(	B-X
p	B-X
)	B-X
is	B-X
dictated	B-X
by	B-X
the	B-X
transfer	B-X
function	B-X
of	B-X
the	B-X
leaf	B-X
,	B-X
T	B-X
(	B-X
f	B-X
)	B-X
,	B-X
which	B-X
is	B-X
a	B-X
function	B-X
of	B-X
leaf	B-X
patch	B-X
volume	B-X
and	B-X
ultimately	B-X
of	B-X
cell	B-X
turgor	B-X
pressure	B-X
,	B-X
P	B-X
(	B-X
c	B-X
)	B-X
,	B-X
as	B-X
shown	B-X
theoretically	B-X
.	B-X
The	B-X
power	B-X
function	B-X
T	B-X
(	B-X
f	B-X
)	B-X
=f	B-X
(	B-X
P	B-X
(	B-X
c	B-X
)	B-X
)	B-X
theoretically	B-X
derived	B-X
was	B-X
experimentally	B-X
confirmed	B-X
by	B-X
concomitant	B-X
P	B-X
(	B-X
p	B-X
)	B-X
and	B-X
P	B-X
(	B-X
c	B-X
)	B-X
measurements	B-X
on	B-X
intact	B-X
leaflets	B-X
of	B-X
the	B-X
liana	B-X
Tetrastigma	B-X
voinierianum	B-X
under	B-X
greenhouse	B-X
conditions	B-X
.	B-X
Simultaneous	B-X
P	B-X
(	B-X
p	B-X
)	B-X
recordings	B-X
on	B-X
leaflets	B-X
up	B-X
to	B-X
10	B-X
m	B-X
height	B-X
above	B-X
ground	B-X
demonstrated	B-X
that	B-X
changes	B-X
in	B-X
T	B-X
(	B-X
f	B-X
)	B-X
induced	B-X
by	B-X
P	B-X
(	B-X
c	B-X
)	B-X
changes	B-X
due	B-X
to	B-X
changes	B-X
of	B-X
microclimate	B-X
and/or	B-X
of	B-X
the	B-X
irrigation	B-X
regime	B-X
were	B-X
sensitively	B-X
reflected	B-X
in	B-X
corresponding	B-X
changes	B-X
of	B-X
P	B-X
(	B-X
p	B-X
)	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
data	B-X
show	B-X
that	B-X
transpirational	B-X
water	B-X
loss	B-X
during	B-X
the	B-X
morning	B-X
hours	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
transient	B-X
rise	B-X
in	B-X
turgor	B-X
pressure	B-X
gradients	B-X
within	B-X
the	B-X
leaflets	B-X
.	B-X
Subsequent	B-X
recovery	B-X
of	B-X
turgescence	B-X
during	B-X
the	B-X
afternoon	B-X
was	B-X
much	B-X
faster	B-X
than	B-X
the	B-X
preceding	B-X
transpiration-induced	B-X
water	B-X
loss	B-X
if	B-X
the	B-X
plants	B-X
were	B-X
well	B-X
irrigated	B-X
.	B-X
Our	B-X
data	B-X
show	B-X
the	B-X
enormous	B-X
potential	B-X
of	B-X
the	B-X
leaf	B-X
patch	B-X
clamp	B-X
pressure	B-X
probe	B-X
for	B-X
leaf	B-X
water	B-X
studies	B-X
including	B-X
unravelling	B-X
of	B-X
the	B-X
hydraulic	B-X
communication	B-X
between	B-X
neighbouring	B-X
leaves	B-X
and	B-X
over	B-X
long	B-X
distances	B-X
within	B-X
tall	B-X
plants	B-X
(	B-X
trees	B-X
)	B-X
.	B-X

Simultaneous	O
Pp	O
recordings	O
on	O
leaflets	O
up	O
to	O
10	O
m	O
height	O
above	O
ground	O
demonstrated	O
that	O
changes	O
in	O
Tf	O
induced	O
by	O
Pc	O
changes	O
due	O
to	O
changes	O
of	O
microclimate	O
and	O
/	O
or	O
of	O
the	O
irrigation	O
regime	O
were	O
sensitively	O
reflected	O
in	O
corresponding	O
changes	O
of	O
Pp	O
.	O
<EOS>	B-X
The	B-X
power	B-X
function	B-X
T	B-X
(	B-X
f	B-X
)	B-X
=f	B-X
(	B-X
P	B-X
(	B-X
c	B-X
)	B-X
)	B-X
theoretically	B-X
derived	B-X
was	B-X
experimentally	B-X
confirmed	B-X
by	B-X
concomitant	B-X
P	B-X
(	B-X
p	B-X
)	B-X
and	B-X
P	B-X
(	B-X
c	B-X
)	B-X
measurements	B-X
on	B-X
intact	B-X
leaflets	B-X
of	B-X
the	B-X
liana	B-X
Tetrastigma	B-X
voinierianum	B-X
under	B-X
greenhouse	B-X
conditions	B-X
.	B-X
Simultaneous	B-X
P	B-X
(	B-X
p	B-X
)	B-X
recordings	B-X
on	B-X
leaflets	B-X
up	B-X
to	B-X
10	B-X
m	B-X
height	B-X
above	B-X
ground	B-X
demonstrated	B-X
that	B-X
changes	B-X
in	B-X
T	B-X
(	B-X
f	B-X
)	B-X
induced	B-X
by	B-X
P	B-X
(	B-X
c	B-X
)	B-X
changes	B-X
due	B-X
to	B-X
changes	B-X
of	B-X
microclimate	B-X
and/or	B-X
of	B-X
the	B-X
irrigation	B-X
regime	B-X
were	B-X
sensitively	B-X
reflected	B-X
in	B-X
corresponding	B-X
changes	B-X
of	B-X
P	B-X
(	B-X
p	B-X
)	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
data	B-X
show	B-X
that	B-X
transpirational	B-X
water	B-X
loss	B-X
during	B-X
the	B-X
morning	B-X
hours	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
transient	B-X
rise	B-X
in	B-X
turgor	B-X
pressure	B-X
gradients	B-X
within	B-X
the	B-X
leaflets	B-X
.	B-X
Subsequent	B-X
recovery	B-X
of	B-X
turgescence	B-X
during	B-X
the	B-X
afternoon	B-X
was	B-X
much	B-X
faster	B-X
than	B-X
the	B-X
preceding	B-X
transpiration-induced	B-X
water	B-X
loss	B-X
if	B-X
the	B-X
plants	B-X
were	B-X
well	B-X
irrigated	B-X
.	B-X

Analysis	O
of	O
the	O
data	O
show	O
that	O
transpirational	O
water	O
loss	O
during	O
the	O
morning	O
hours	O
was	O
associated	O
with	O
a	O
transient	O
rise	O
in	O
turgor	O
pressure	O
gradients	O
within	O
the	O
leaflets	O
.	O
<EOS>	B-X
A	B-X
high-precision	B-X
pressure	B-X
probe	B-X
is	B-X
described	B-X
which	B-X
allows	B-X
non-invasive	B-X
online-monitoring	B-X
of	B-X
the	B-X
water	B-X
relations	B-X
of	B-X
intact	B-X
leaves	B-X
.	B-X
Real-time	B-X
recording	B-X
of	B-X
the	B-X
leaf	B-X
water	B-X
status	B-X
occurred	B-X
by	B-X
data	B-X
transfer	B-X
to	B-X
an	B-X
Internet	B-X
server	B-X
.	B-X
The	B-X
leaf	B-X
patch	B-X
clamp	B-X
pressure	B-X
probe	B-X
measures	B-X
the	B-X
attenuated	B-X
pressure	B-X
,	B-X
P	B-X
(	B-X
p	B-X
)	B-X
,	B-X
of	B-X
a	B-X
leaf	B-X
patch	B-X
in	B-X
response	B-X
to	B-X
a	B-X
constant	B-X
clamp	B-X
pressure	B-X
,	B-X
P	B-X
(	B-X
clamp	B-X
)	B-X
.	B-X
P	B-X
(	B-X
p	B-X
)	B-X
is	B-X
sensed	B-X
by	B-X
a	B-X
miniaturized	B-X
silicone	B-X
pressure	B-X
sensor	B-X
integrated	B-X
into	B-X
the	B-X
device	B-X
.	B-X
The	B-X
magnitude	B-X
of	B-X
P	B-X
(	B-X
p	B-X
)	B-X
is	B-X
dictated	B-X
by	B-X
the	B-X
transfer	B-X
function	B-X
of	B-X
the	B-X
leaf	B-X
,	B-X
T	B-X
(	B-X
f	B-X
)	B-X
,	B-X
which	B-X
is	B-X
a	B-X
function	B-X
of	B-X
leaf	B-X
patch	B-X
volume	B-X
and	B-X
ultimately	B-X
of	B-X
cell	B-X
turgor	B-X
pressure	B-X
,	B-X
P	B-X
(	B-X
c	B-X
)	B-X
,	B-X
as	B-X
shown	B-X
theoretically	B-X
.	B-X
The	B-X
power	B-X
function	B-X
T	B-X
(	B-X
f	B-X
)	B-X
=f	B-X
(	B-X
P	B-X
(	B-X
c	B-X
)	B-X
)	B-X
theoretically	B-X
derived	B-X
was	B-X
experimentally	B-X
confirmed	B-X
by	B-X
concomitant	B-X
P	B-X
(	B-X
p	B-X
)	B-X
and	B-X
P	B-X
(	B-X
c	B-X
)	B-X
measurements	B-X
on	B-X
intact	B-X
leaflets	B-X
of	B-X
the	B-X
liana	B-X
Tetrastigma	B-X
voinierianum	B-X
under	B-X
greenhouse	B-X
conditions	B-X
.	B-X
Simultaneous	B-X
P	B-X
(	B-X
p	B-X
)	B-X
recordings	B-X
on	B-X
leaflets	B-X
up	B-X
to	B-X
10	B-X
m	B-X
height	B-X
above	B-X
ground	B-X
demonstrated	B-X
that	B-X
changes	B-X
in	B-X
T	B-X
(	B-X
f	B-X
)	B-X
induced	B-X
by	B-X
P	B-X
(	B-X
c	B-X
)	B-X
changes	B-X
due	B-X
to	B-X
changes	B-X
of	B-X
microclimate	B-X
and/or	B-X
of	B-X
the	B-X
irrigation	B-X
regime	B-X
were	B-X
sensitively	B-X
reflected	B-X
in	B-X
corresponding	B-X
changes	B-X
of	B-X
P	B-X
(	B-X
p	B-X
)	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
data	B-X
show	B-X
that	B-X
transpirational	B-X
water	B-X
loss	B-X
during	B-X
the	B-X
morning	B-X
hours	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
transient	B-X
rise	B-X
in	B-X
turgor	B-X
pressure	B-X
gradients	B-X
within	B-X
the	B-X
leaflets	B-X
.	B-X
Subsequent	B-X
recovery	B-X
of	B-X
turgescence	B-X
during	B-X
the	B-X
afternoon	B-X
was	B-X
much	B-X
faster	B-X
than	B-X
the	B-X
preceding	B-X
transpiration-induced	B-X
water	B-X
loss	B-X
if	B-X
the	B-X
plants	B-X
were	B-X
well	B-X
irrigated	B-X
.	B-X
Our	B-X
data	B-X
show	B-X
the	B-X
enormous	B-X
potential	B-X
of	B-X
the	B-X
leaf	B-X
patch	B-X
clamp	B-X
pressure	B-X
probe	B-X
for	B-X
leaf	B-X
water	B-X
studies	B-X
including	B-X
unravelling	B-X
of	B-X
the	B-X
hydraulic	B-X
communication	B-X
between	B-X
neighbouring	B-X
leaves	B-X
and	B-X
over	B-X
long	B-X
distances	B-X
within	B-X
tall	B-X
plants	B-X
(	B-X
trees	B-X
)	B-X
.	B-X

Subsequent	O
recovery	O
of	O
turgescence	O
during	O
the	O
afternoon	O
was	O
much	O
faster	O
than	O
the	O
preceding	O
transpiration	O
-	O
induced	O
water	O
loss	O
if	O
the	O
plants	O
were	O
well	O
irrigated	O
.	O

Our	O
data	O
show	O
the	O
enormous	O
potential	O
of	O
the	O
leaf	O
patch	O
clamp	O
pressure	O
probe	O
for	O
leaf	O
water	O
studies	O
including	O
unravelling	O
of	O
the	O
hydraulic	O
communication	O
between	O
neighbouring	O
leaves	O
and	O
over	O
long	O
distances	O
within	O
tall	O
plants	O
(	O
trees	O
)	O
.	O
<EOS>	B-X
A	B-X
high-precision	B-X
pressure	B-X
probe	B-X
is	B-X
described	B-X
which	B-X
allows	B-X
non-invasive	B-X
online-monitoring	B-X
of	B-X
the	B-X
water	B-X
relations	B-X
of	B-X
intact	B-X
leaves	B-X
.	B-X
Real-time	B-X
recording	B-X
of	B-X
the	B-X
leaf	B-X
water	B-X
status	B-X
occurred	B-X
by	B-X
data	B-X
transfer	B-X
to	B-X
an	B-X
Internet	B-X
server	B-X
.	B-X
The	B-X
leaf	B-X
patch	B-X
clamp	B-X
pressure	B-X
probe	B-X
measures	B-X
the	B-X
attenuated	B-X
pressure	B-X
,	B-X
P	B-X
(	B-X
p	B-X
)	B-X
,	B-X
of	B-X
a	B-X
leaf	B-X
patch	B-X
in	B-X
response	B-X
to	B-X
a	B-X
constant	B-X
clamp	B-X
pressure	B-X
,	B-X
P	B-X
(	B-X
clamp	B-X
)	B-X
.	B-X
P	B-X
(	B-X
p	B-X
)	B-X
is	B-X
sensed	B-X
by	B-X
a	B-X
miniaturized	B-X
silicone	B-X
pressure	B-X
sensor	B-X
integrated	B-X
into	B-X
the	B-X
device	B-X
.	B-X
The	B-X
magnitude	B-X
of	B-X
P	B-X
(	B-X
p	B-X
)	B-X
is	B-X
dictated	B-X
by	B-X
the	B-X
transfer	B-X
function	B-X
of	B-X
the	B-X
leaf	B-X
,	B-X
T	B-X
(	B-X
f	B-X
)	B-X
,	B-X
which	B-X
is	B-X
a	B-X
function	B-X
of	B-X
leaf	B-X
patch	B-X
volume	B-X
and	B-X
ultimately	B-X
of	B-X
cell	B-X
turgor	B-X
pressure	B-X
,	B-X
P	B-X
(	B-X
c	B-X
)	B-X
,	B-X
as	B-X
shown	B-X
theoretically	B-X
.	B-X
The	B-X
power	B-X
function	B-X
T	B-X
(	B-X
f	B-X
)	B-X
=f	B-X
(	B-X
P	B-X
(	B-X
c	B-X
)	B-X
)	B-X
theoretically	B-X
derived	B-X
was	B-X
experimentally	B-X
confirmed	B-X
by	B-X
concomitant	B-X
P	B-X
(	B-X
p	B-X
)	B-X
and	B-X
P	B-X
(	B-X
c	B-X
)	B-X
measurements	B-X
on	B-X
intact	B-X
leaflets	B-X
of	B-X
the	B-X
liana	B-X
Tetrastigma	B-X
voinierianum	B-X
under	B-X
greenhouse	B-X
conditions	B-X
.	B-X
Simultaneous	B-X
P	B-X
(	B-X
p	B-X
)	B-X
recordings	B-X
on	B-X
leaflets	B-X
up	B-X
to	B-X
10	B-X
m	B-X
height	B-X
above	B-X
ground	B-X
demonstrated	B-X
that	B-X
changes	B-X
in	B-X
T	B-X
(	B-X
f	B-X
)	B-X
induced	B-X
by	B-X
P	B-X
(	B-X
c	B-X
)	B-X
changes	B-X
due	B-X
to	B-X
changes	B-X
of	B-X
microclimate	B-X
and/or	B-X
of	B-X
the	B-X
irrigation	B-X
regime	B-X
were	B-X
sensitively	B-X
reflected	B-X
in	B-X
corresponding	B-X
changes	B-X
of	B-X
P	B-X
(	B-X
p	B-X
)	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
data	B-X
show	B-X
that	B-X
transpirational	B-X
water	B-X
loss	B-X
during	B-X
the	B-X
morning	B-X
hours	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
transient	B-X
rise	B-X
in	B-X
turgor	B-X
pressure	B-X
gradients	B-X
within	B-X
the	B-X
leaflets	B-X
.	B-X
Subsequent	B-X
recovery	B-X
of	B-X
turgescence	B-X
during	B-X
the	B-X
afternoon	B-X
was	B-X
much	B-X
faster	B-X
than	B-X
the	B-X
preceding	B-X
transpiration-induced	B-X
water	B-X
loss	B-X
if	B-X
the	B-X
plants	B-X
were	B-X
well	B-X
irrigated	B-X
.	B-X
Our	B-X
data	B-X
show	B-X
the	B-X
enormous	B-X
potential	B-X
of	B-X
the	B-X
leaf	B-X
patch	B-X
clamp	B-X
pressure	B-X
probe	B-X
for	B-X
leaf	B-X
water	B-X
studies	B-X
including	B-X
unravelling	B-X
of	B-X
the	B-X
hydraulic	B-X
communication	B-X
between	B-X
neighbouring	B-X
leaves	B-X
and	B-X
over	B-X
long	B-X
distances	B-X
within	B-X
tall	B-X
plants	B-X
(	B-X
trees	B-X
)	B-X
.	B-X

Introduction	O

Optimum	O
water	O
supply	O
,	O
particularly	O
at	O
peak	O
needs	O
of	O
the	O
plants	O
,	O
is	O
an	O
important	O
issue	O
for	O
greenhouse	O
and	O
field	O
vegetable	O
production	O
.	O

In	O
a	O
greenhouse	O
on	O
a	O
sunny	O
day	O
,	O
evaporation	O
and	O
transpiration	O
(	O
so	O
-	O
called	O
evapotranspiration	O
)	O
can	O
occur	O
so	O
rapidly	O
that	O
water	O
loss	O
can	O
cause	O
plant	O
damage	O
before	O
wilting	O
symptoms	O
are	O
visible	O
.	O

Even	O
at	O
lower	O
temperatures	O
the	O
restricted	O
rooting	O
in	O
greenhouses	O
leads	O
frequently	O
to	O
plant	O
water	O
deficiency	O
.	O

Thus	O
,	O
no	O
matter	O
how	O
slight	O
,	O
drought	O
stress	O
will	O
result	O
in	O
a	O
significant	O
reduction	O
in	O
growth	O
and	O
,	O
in	O
turn	O
,	O
of	O
harvest	O
yield	O
.	O

On	O
the	O
other	O
hand	O
,	O
over	O
-	O
irrigation	O
must	O
be	O
avoided	O
and	O
the	O
appropriate	O
method	O
of	O
watering	O
must	O
be	O
selected	O
because	O
wet	O
soils	O
and	O
permanent	O
moisture	O
on	O
plant	O
organs	O
promote	O
the	O
incidence	O
of	O
root	O
mould	O
,	O
grey	O
mould	O
(	O
Botrytis	O
blight	O
)	O
,	O
formation	O
of	O
leaf	O
oedema	O
,	O
and	O
other	O
plant	O
diseases	O
(	O
Sherf	O
and	O
MacNab	O
,	O
1986	O
)	O
.	O

Conservation	O
of	O
water	O
is	O
another	O
important	O
issue	O
in	O
semi	O
-	O
arid	O
and	O
arid	O
regions	O
where	O
water	O
is	O
scarce	O
.	O

The	O
advent	O
of	O
(	O
subsurface	O
)	O
drip	O
irrigation	O
has	O
considerably	O
reduced	O
water	O
consumption	O
of	O
agricultural	O
,	O
horticultural	O
,	O
and	O
greenhouse	O
crops	O
,	O
but	O
has	O
also	O
highlighted	O
the	O
need	O
for	O
sensors	O
monitoring	O
water	O
deficiency	O
of	O
plants	O
directly	O
and	O
online	O
(	O
Jones	O
,	O
2004	O
)	O
.	O

In	O
plant	O
physiology	O
and	O
agriculture	O
the	O
pressure	O
bomb	O
technique	O
pioneered	O
by	O
Scholander	O
et	O
al	O
.	O

(	O
1965	O
)	O
is	O
a	O
widely	O
accepted	O
reference	O
technique	O
for	O
measuring	O
leaf	O
water	O
status	O
.	O

However	O
,	O
the	O
method	O
is	O
massively	O
invasive	O
,	O
slow	O
,	O
labour	O
-	O
intensive	O
(	O
and	O
therefore	O
expensive	O
)	O
,	O
unsuitable	O
for	O
automation	O
,	O
and	O
gives	O
only	O
spot	O
measurements	O
.	O

Furthermore	O
,	O
interpretation	O
of	O
the	O
data	O
is	O
still	O
a	O
matter	O
of	O
debate	O
(	O
Zimmermann	O
U	O
et	O
al	O
.	O
,	O
2004	O
;	O
Zimmermann	O
D	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

Leaf	O
thickness	O
is	O
also	O
sometimes	O
used	O
as	O
an	O
indicator	O
for	O
water	O
stress	O
(	O
Burquez	O
,	O
1987	O
;	O
McBurney	O
,	O
1992	O
;	O
Malone	O
,	O
1993	O
)	O
.	O

Leaf	O
thickness	O
monitoring	O
devices	O
are	O
commercially	O
available	O
.	O
<EOS>	B-X
For	B-X
this	B-X
purpose	B-X
,	B-X
a	B-X
commercially	B-X
available	B-X
cryotransfer	B-X
system	B-X
was	B-X
modified	B-X
and	B-X
coupled	B-X
to	B-X
the	B-X
experimental	B-X
chamber	B-X
of	B-X
the	B-X
nuclear	B-X
microprobe	B-X
(	B-X
NMP	B-X
)	B-X
.	B-X

They	O
are	O
non	O
-	O
invasive	O
and	O
suitable	O
for	O
online	O
measurements	O
,	O
but	O
have	O
the	O
disadvantage	O
that	O
changes	O
in	O
water	O
status	O
are	O
frequently	O
not	O
reflected	O
sensitively	O
in	O
changes	O
of	O
leaf	O
thickness	O
.	O

The	O
pressure	O
probe	O
technique	O
pioneered	O
by	O
Zimmermann	O
,	O
Tomos	O
,	O
and	O
others	O
(	O
Zimmermann	O
et	O
al	O
.	O
,	O
1969	O
,	O
2004	O
;	O
Tomos	O
,	O
1988	O
;	O
Balling	O
and	O
Zimmermann	O
,	O
1990	O
)	O
,	O
on	O
the	O
other	O
hand	O
,	O
is	O
a	O
well	O
established	O
technology	O
for	O
measuring	O
turgor	O
and	O
xylem	O
pressure	O
on	O
the	O
levels	O
of	O
individual	O
cells	O
and	O
xylem	O
vessels	O
,	O
respectively	O
.	O

This	O
technique	O
is	O
not	O
suitable	O
for	O
automation	O
.	O
<EOS>	B-X
This	B-X
paper	B-X
provides	B-X
an	B-X
overview	B-X
of	B-X
the	B-X
NGT	B-X
and	B-X
Delphi	B-X
technique	B-X
,	B-X
including	B-X
the	B-X
steps	B-X
involved	B-X
and	B-X
the	B-X
types	B-X
of	B-X
research	B-X
questions	B-X
best	B-X
suited	B-X
to	B-X
each	B-X
method	B-X
,	B-X
with	B-X
examples	B-X
from	B-X
the	B-X
pharmacy	B-X
literature	B-X
.	B-X
The	B-X
Delphi	B-X
technique	B-X
uses	B-X
a	B-X
multistage	B-X
self-completed	B-X
questionnaire	B-X
with	B-X
individual	B-X
feedback	B-X
,	B-X
to	B-X
determine	B-X
consensus	B-X
from	B-X
a	B-X
larger	B-X
group	B-X
of	B-X
'experts	B-X
.	B-X
'	B-X
When	B-X
to	B-X
use	B-X
The	B-X
NGT	B-X
has	B-X
been	B-X
used	B-X
to	B-X
explore	B-X
consumer	B-X
and	B-X
stakeholder	B-X
views	B-X
,	B-X
while	B-X
the	B-X
Delphi	B-X
technique	B-X
is	B-X
commonly	B-X
used	B-X
to	B-X
develop	B-X
guidelines	B-X
with	B-X
health	B-X
professionals	B-X
.	B-X
The	B-X
Delphi	B-X
technique	B-X
can	B-X
take	B-X
weeks	B-X
or	B-X
months	B-X
to	B-X
conclude	B-X
,	B-X
especially	B-X
if	B-X
multiple	B-X
rounds	B-X
are	B-X
required	B-X
,	B-X
and	B-X
may	B-X
be	B-X
complex	B-X
for	B-X
lay	B-X
people	B-X
to	B-X
complete	B-X
.	B-X

Moreover	O
,	O
the	O
probe	O
technique	O
requires	O
rather	O
sophisticated	O
equipment	O
and	O
a	O
high	O
level	O
of	O
technical	O
skill	O
.	O

These	O
disadvantages	O
are	O
also	O
shared	O
by	O
the	O
ball	O
tonometry	O
,	O
a	O
method	O
which	O
allows	O
non	O
-	O
invasive	O
monitoring	O
of	O
cell	O
turgor	O
pressure	O
by	O
application	O
of	O
an	O
external	O
pressure	O
(	O
Lintilhac	O
et	O
al	O
.	O
,	O
2000	O
;	O
Geitmann	O
,	O
2006	O
)	O
.	O

Other	O
water	O
stress	O
monitoring	O
devices	O
are	O
described	O
in	O
the	O
literature	O
,	O
but	O
all	O
of	O
them	O
have	O
various	O
disadvantages	O
which	O
prevented	O
their	O
implementation	O
for	O
leaf	O
water	O
status	O
measurements	O
in	O
greenhouses	O
or	O
in	O
the	O
field	O
(	O
see	O
,	O
for	O
example	O
,	O
the	O
review	O
article	O
of	O
Jones	O
,	O
2004	O
,	O
and	O
also	O
Grant	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

In	O
this	O
communication	O
a	O
novel	O
,	O
non	O
-	O
invasive	O
,	O
online	O
-	O
monitoring	O
plant	O
-	O
based	O
probe	O
is	O
described	O
that	O
meets	O
the	O
demands	O
of	O
controlling	O
horticultural	O
and	O
agricultural	O
water	O
applications	O
.	O

The	O
probe	O
is	O
characterized	O
by	O
high	O
precision	O
,	O
operating	O
convenience	O
,	O
minimum	O
costs	O
,	O
and	O
by	O
automation	O
suitability	O
.	O

Data	O
can	O
be	O
transferred	O
wireless	O
to	O
a	O
personal	O
computer	O
or	O
to	O
an	O
Internet	O
server	O
via	O
a	O
mobile	O
phone	O
network	O
for	O
real	O
-	O
time	O
evaluation	O
and	O
for	O
the	O
automatic	O
regulation	O
of	O
irrigation	O
.	O
<EOS>	B-X
They	B-X
provide	B-X
early	B-X
detection	B-X
of	B-X
important	B-X
physiological	B-X
events	B-X
,	B-X
leading	B-X
to	B-X
timely	B-X
alerts	B-X
for	B-X
seeking	B-X
medical	B-X
attention	B-X
.	B-X
The	B-X
authors	B-X
cover	B-X
solutions	B-X
based	B-X
on	B-X
wearable	B-X
devices	B-X
,	B-X
smartphones	B-X
,	B-X
and	B-X
other	B-X
ambulatory	B-X
sensors	B-X
.	B-X
Lastly	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
possibilities	B-X
opened	B-X
by	B-X
this	B-X
new	B-X
paradigm	B-X
,	B-X
for	B-X
the	B-X
future	B-X
of	B-X
health	B-X
care	B-X
and	B-X
personalized	B-X
medicine	B-X
.	B-X
Point-of-care	B-X
(	B-X
POC	B-X
)	B-X
tests	B-X
provide	B-X
an	B-X
alternative	B-X
to	B-X
traditional	B-X
laboratory-based	B-X
diagnostics	B-X
due	B-X
to	B-X
reduced	B-X
turnaround	B-X
times	B-X
,	B-X
portability	B-X
and	B-X
no	B-X
need	B-X
for	B-X
highly	B-X
trained	B-X
laboratory	B-X
staff	B-X
.	B-X
Smartphones	B-X
can	B-X
be	B-X
integrated	B-X
into	B-X
POC	B-X
platforms	B-X
because	B-X
of	B-X
their	B-X
multifunctionality	B-X
,	B-X
enabled	B-X
by	B-X
high-quality	B-X
digital	B-X
cameras	B-X
,	B-X
computer	B-X
processors	B-X
,	B-X
touchscreen	B-X
interface	B-X
and	B-X
wireless	B-X
data	B-X
transfer	B-X
.	B-X
It	B-X
is	B-X
predicted	B-X
that	B-X
by	B-X
2020	B-X
about	B-X
80	B-X
%	B-X
of	B-X
the	B-X
world	B-X
population	B-X
will	B-X
use	B-X
smartphones	B-X
.	B-X

The	O
technology	O
includes	O
a	O
miniaturized	O
silicone	O
pressure	O
sensor	O
integrated	O
into	O
a	O
spring	O
clamp	O
that	O
is	O
clamped	O
to	O
a	O
patch	O
of	O
an	O
intact	O
plant	O
leaf	O
.	O

The	O
patch	O
clamp	O
pressure	O
probe	O
measures	O
the	O
attenuated	O
pressure	O
response	O
of	O
the	O
leaf	O
patch	O
upon	O
the	O
application	O
of	O
a	O
constant	O
,	O
clamped	O
pressure	O
.	O

The	O
attenuation	O
of	O
the	O
applied	O
pressure	O
depends	O
on	O
the	O
transfer	O
function	O
of	O
the	O
leaf	O
.	O
<EOS>	B-X
An	B-X
advanced	B-X
non-invasive	B-X
,	B-X
field-suitable	B-X
and	B-X
inexpensive	B-X
leaf	B-X
patch	B-X
clamp	B-X
pressure	B-X
probe	B-X
for	B-X
online-monitoring	B-X
of	B-X
the	B-X
water	B-X
relations	B-X
of	B-X
intact	B-X
leaves	B-X
is	B-X
described	B-X
.	B-X
The	B-X
probe	B-X
measures	B-X
the	B-X
attenuated	B-X
output	B-X
patch	B-X
clamp	B-X
pressure	B-X
,	B-X
P	B-X
(	B-X
p	B-X
)	B-X
,	B-X
of	B-X
a	B-X
clamped	B-X
leaf	B-X
in	B-X
response	B-X
to	B-X
an	B-X
externally	B-X
applied	B-X
input	B-X
pressure	B-X
,	B-X
P	B-X
(	B-X
clamp	B-X
)	B-X
.	B-X
P	B-X
(	B-X
p	B-X
)	B-X
is	B-X
sensed	B-X
by	B-X
a	B-X
pressure	B-X
sensor	B-X
integrated	B-X
into	B-X
the	B-X
magnetic	B-X
clamp	B-X
.	B-X
The	B-X
magnitude	B-X
of	B-X
P	B-X
(	B-X
p	B-X
)	B-X
depends	B-X
on	B-X
the	B-X
transfer	B-X
function	B-X
,	B-X
T	B-X
(	B-X
f	B-X
)	B-X
,	B-X
of	B-X
the	B-X
leaf	B-X
cells	B-X
.	B-X
T	B-X
(	B-X
f	B-X
)	B-X
consists	B-X
of	B-X
a	B-X
turgor	B-X
pressure-independent	B-X
(	B-X
related	B-X
to	B-X
the	B-X
compression	B-X
of	B-X
the	B-X
cuticle	B-X
,	B-X
cell	B-X
walls	B-X
and	B-X
other	B-X
structural	B-X
elements	B-X
)	B-X
and	B-X
a	B-X
turgor	B-X
pressure-dependent	B-X
term	B-X
.	B-X
Theory	B-X
shows	B-X
that	B-X
T	B-X
(	B-X
f	B-X
)	B-X
is	B-X
a	B-X
power	B-X
function	B-X
of	B-X
cell	B-X
turgor	B-X
pressure	B-X
P	B-X
(	B-X
c	B-X
)	B-X
.	B-X

The	O
magnitude	O
of	O
the	O
transfer	O
function	O
depends	O
on	O
two	O
terms	O
,	O
a	O
turgor	O
pressure	O
-	O
independent	O
term	O
(	O
related	O
to	O
the	O
compression	O
of	O
the	O
cuticle	O
,	O
cell	O
walls	O
,	O
and	O
other	O
structural	O
elements	O
)	O
and	O
a	O
turgor	O
pressure	O
-	O
dependent	O
term	O
.	O

Theory	O
shows	O
that	O
the	O
turgor	O
pressure	O
-	O
dependent	O
part	O
of	O
the	O
transfer	O
function	O
Tf	O
is	O
a	O
power	O
function	O
of	O
the	O
cell	O
turgor	O
pressure	O
,	O
Pc	O
,	O
and	O
predicts	O
that	O
Tf	O
assumes	O
values	O
close	O
to	O
zero	O
if	O
Pc	O
is	O
high	O
and	O
,	O
vice	O
versa	O
,	O
values	O
close	O
to	O
unity	O
if	O
Pc	O
is	O
low	O
.	O

This	O
could	O
be	O
verified	O
by	O
combined	O
turgor	O
pressure	O
probe	O
and	O
leaf	O
patch	O
clamp	O
pressure	O
probe	O
measurements	O
on	O
leaflets	O
of	O
the	O
liana	O
Tetrastigma	B-Species
voinierianum	I-Species
.	O

The	O
10	O
-	O
m	O
tall	O
liana	O
growing	O
in	O
a	O
tropical	O
greenhouse	O
was	O
selected	O
for	O
the	O
first	O
studies	O
because	O
a	O
comprehensive	O
data	O
set	O
about	O
diurnal	O
changes	O
in	O
xylem	O
and	O
turgor	O
pressure	O
gradients	O
under	O
various	O
environmental	O
conditions	O
existed	O
for	O
this	O
greenhouse	O
plant	O
(	O
Benkert	O
et	O
al	O
.	O
,	O
1995	O
;	O
Th	O
u	O
rmer	O
et	O
al	O
.	O
,	O
1999	O
;	O
see	O
also	O
Zimmermann	O
et	O
al	O
.	O
,	O
2004	O
)	O
.	O

Measurements	O
of	O
diurnal	O
changes	O
of	O
the	O
patch	O
clamp	O
pressure	O
performed	O
here	O
yielded	O
results	O
which	O
were	O
consistent	O
with	O
the	O
previous	O
pressure	O
probe	O
work	O
on	O
the	O
liana	O
.	O

The	O
data	O
also	O
demonstrated	O
that	O
changes	O
in	O
the	O
irrigation	O
regime	O
and	O
in	O
microclimate	O
can	O
be	O
sensed	O
by	O
this	O
novel	O
probe	O
very	O
sensitively	O
and	O
that	O
use	O
of	O
several	O
probes	O
allowed	O
the	O
study	O
of	O
the	O
diurnal	O
water	O
transport	O
at	O
multiple	O
scales	O
from	O
single	O
leaves	O
to	O
the	O
whole	O
organism	O
(	O
Meinzer	O
et	O
al	O
.	O
,	O
2001	O
)	O
.	O

This	O
can	O
be	O
done	O
without	O
knowledge	O
of	O
the	O
turgor	O
pressure	O
because	O
the	O
transfer	O
function	O
is	O
a	O
direct	O
measure	O
of	O
leaf	O
water	O
status	O
.	O

Materials	O
and	O
methods	O
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
effective	B-X
teaching	B-X
strategies	B-X
and	B-X
methods	B-X
of	B-X
delivery	B-X
for	B-X
patient	B-X
education	B-X
(	B-X
PE	B-X
)	B-X
.	B-X
A	B-X
systematic	B-X
review	B-X
was	B-X
conducted	B-X
and	B-X
reviews	B-X
with	B-X
or	B-X
without	B-X
meta-analyses	B-X
,	B-X
which	B-X
examined	B-X
teaching	B-X
strategies	B-X
and	B-X
methods	B-X
of	B-X
delivery	B-X
for	B-X
PE	B-X
,	B-X
were	B-X
included	B-X
.	B-X
Recommendations	B-X
concerning	B-X
the	B-X
efficacy	B-X
of	B-X
the	B-X
teaching	B-X
strategies	B-X
and	B-X
delivery	B-X
methods	B-X
are	B-X
provided	B-X
.	B-X
The	B-X
methods	B-X
section	B-X
of	B-X
a	B-X
research	B-X
paper	B-X
provides	B-X
the	B-X
information	B-X
by	B-X
which	B-X
a	B-X
study	B-X
's	B-X
validity	B-X
is	B-X
judged	B-X
.	B-X
The	B-X
methods	B-X
section	B-X
should	B-X
describe	B-X
what	B-X
was	B-X
done	B-X
to	B-X
answer	B-X
the	B-X
research	B-X
question	B-X
,	B-X
describe	B-X
how	B-X
it	B-X
was	B-X
done	B-X
,	B-X
justify	B-X
the	B-X
experimental	B-X
design	B-X
,	B-X
and	B-X
explain	B-X
how	B-X
the	B-X
results	B-X
were	B-X
analyzed	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
methods	B-X
section	B-X
structure	B-X
should	B-X
:	B-X
describe	B-X
the	B-X
materials	B-X
used	B-X
in	B-X
the	B-X
study	B-X
,	B-X
explain	B-X
how	B-X
the	B-X
materials	B-X
were	B-X
prepared	B-X
for	B-X
the	B-X
study	B-X
,	B-X
describe	B-X
the	B-X
research	B-X
protocol	B-X
,	B-X
explain	B-X
how	B-X
measurements	B-X
were	B-X
made	B-X
and	B-X
what	B-X
calculations	B-X
were	B-X
performed	B-X
,	B-X
and	B-X
state	B-X
which	B-X
statistical	B-X
tests	B-X
were	B-X
done	B-X
to	B-X
analyze	B-X
the	B-X
data	B-X
.	B-X
Once	B-X
all	B-X
elements	B-X
of	B-X
the	B-X
methods	B-X
section	B-X
are	B-X
written	B-X
,	B-X
subsequent	B-X
drafts	B-X
should	B-X
focus	B-X
on	B-X
how	B-X
to	B-X
present	B-X
those	B-X
elements	B-X
as	B-X
clearly	B-X
and	B-X
logically	B-X
as	B-X
possibly	B-X
.	B-X

Plant	O
material	O
<EOS>	B-X
Exocytosis	B-X
is	B-X
a	B-X
key	B-X
mechanism	B-X
for	B-X
delivering	B-X
materials	B-X
into	B-X
the	B-X
extracellular	B-X
space	B-X
for	B-X
cell	B-X
function	B-X
and	B-X
communication	B-X
.	B-X
Plant	B-X
tissue	B-X
culture	B-X
techniques	B-X
are	B-X
the	B-X
most	B-X
frequently	B-X
used	B-X
biotechnological	B-X
tools	B-X
for	B-X
basic	B-X
and	B-X
applied	B-X
purposes	B-X
ranging	B-X
from	B-X
investigation	B-X
on	B-X
plant	B-X
developmental	B-X
processes	B-X
,	B-X
functional	B-X
gene	B-X
studies	B-X
,	B-X
commercial	B-X
plant	B-X
micropropagation	B-X
,	B-X
generation	B-X
of	B-X
transgenic	B-X
plants	B-X
with	B-X
specific	B-X
industrial	B-X
and	B-X
agronomical	B-X
traits	B-X
,	B-X
plant	B-X
breeding	B-X
and	B-X
crop	B-X
improvement	B-X
,	B-X
virus	B-X
elimination	B-X
from	B-X
infected	B-X
materials	B-X
to	B-X
render	B-X
high-quality	B-X
healthy	B-X
plant	B-X
material	B-X
,	B-X
preservation	B-X
and	B-X
conservation	B-X
of	B-X
germplasm	B-X
of	B-X
vegetative	B-X
propagated	B-X
plant	B-X
crops	B-X
,	B-X
and	B-X
rescue	B-X
of	B-X
threatened	B-X
or	B-X
endangered	B-X
plant	B-X
species	B-X
.	B-X
Biogenic	B-X
secondary	B-X
organic	B-X
aerosol	B-X
(	B-X
SOA	B-X
)	B-X
and	B-X
deposited	B-X
secondary	B-X
organic	B-X
material	B-X
(	B-X
SOM	B-X
)	B-X
are	B-X
formed	B-X
by	B-X
oxidation	B-X
of	B-X
volatile	B-X
organic	B-X
compounds	B-X
(	B-X
VOCs	B-X
)	B-X
emitted	B-X
by	B-X
plants	B-X
.	B-X
The	B-X
world	B-X
's	B-X
herbaria	B-X
provide	B-X
a	B-X
rich	B-X
resource	B-X
of	B-X
already	B-X
preserved	B-X
and	B-X
identified	B-X
material	B-X
and	B-X
these	B-X
can	B-X
be	B-X
used	B-X
for	B-X
DNA	B-X
barcoding	B-X
as	B-X
well	B-X
as	B-X
by	B-X
collecting	B-X
fresh	B-X
samples	B-X
from	B-X
the	B-X
wild	B-X
.	B-X
These	B-X
protocols	B-X
describe	B-X
the	B-X
whole	B-X
DNA	B-X
barcoding	B-X
process	B-X
,	B-X
from	B-X
the	B-X
collection	B-X
of	B-X
plant	B-X
material	B-X
from	B-X
the	B-X
wild	B-X
or	B-X
from	B-X
the	B-X
herbarium	B-X
,	B-X
how	B-X
to	B-X
extract	B-X
and	B-X
amplify	B-X
the	B-X
DNA	B-X
,	B-X
and	B-X
how	B-X
to	B-X
check	B-X
the	B-X
quality	B-X
of	B-X
the	B-X
data	B-X
after	B-X
sequencing	B-X
.	B-X

Experiments	O
were	O
performed	O
on	O
two	O
specimens	O
of	O
the	O
liana	O
Tetrastigma	B-Species
voinierianum	I-Species
,	O
growing	O
in	O
the	O
c	O
.	O

12	O
m	O
tall	O
tropical	O
greenhouse	O
of	O
the	O
University	O
of	O
Salzburg	O
,	O
Austria	O
.	O

The	O
ground	O
ascended	O
by	O
about	O
5	O
m	O
towards	O
the	O
backstage	O
of	O
the	O
greenhouse	O
.	O

The	O
height	O
of	O
the	O
plant	O
in	O
this	O
area	O
was	O
about	O
4	O
.	O
5	O
m	O
,	O
whereas	O
the	O
height	O
of	O
the	O
plant	O
in	O
the	O
front	O
area	O
reached	O
10	O
m	O
.	O

However	O
,	O
the	O
stem	O
and	O
the	O
branches	O
of	O
the	O
two	O
plants	O
were	O
considerably	O
longer	O
,	O
because	O
the	O
plants	O
had	O
grown	O
vertically	O
upwards	O
and	O
then	O
part	O
of	O
the	O
way	O
downwards	O
.	O

First	O
measurements	O
were	O
performed	O
during	O
the	O
last	O
week	O
of	O
May	O
,	O
2007	O
.	O
<EOS>	B-X
This	B-X
review	B-X
was	B-X
first	B-X
published	B-X
in	B-X
Issue	B-X
1	B-X
,	B-X
2002	B-X
and	B-X
updated	B-X
in	B-X
Issue	B-X
4	B-X
,	B-X
2007	B-X
.	B-X
Paraneoplastic	B-X
Encephalopathy	B-X
in	B-X
a	B-X
Patient	B-X
With	B-X
Metastatic	B-X
Lung	B-X
Cancer	B-X
:	B-X
A	B-X
Case	B-X
Study	B-X
.	B-X
Eleven	B-X
subjects	B-X
performed	B-X
one-legged	B-X
exercise	B-X
four	B-X
times	B-X
per	B-X
week	B-X
for	B-X
5	B-X
wk	B-X
.	B-X
mRNA	B-X
and	B-X
protein	B-X
expression	B-X
were	B-X
measured	B-X
in	B-X
biopsies	B-X
from	B-X
the	B-X
vastus	B-X
lateralis	B-X
muscle	B-X
obtained	B-X
at	B-X
rest	B-X
before	B-X
the	B-X
training	B-X
period	B-X
,	B-X
after	B-X
10	B-X
days	B-X
,	B-X
and	B-X
after	B-X
5	B-X
wk	B-X
of	B-X
training	B-X
,	B-X
as	B-X
well	B-X
as	B-X
120	B-X
min	B-X
after	B-X
the	B-X
first	B-X
and	B-X
last	B-X
exercise	B-X
bouts	B-X
.	B-X

This	O
week	O
was	O
very	O
sunny	O
and	O
warm	O
.	O

Experiments	O
were	O
repeated	O
during	O
the	O
last	O
week	O
of	O
August	O
and	O
the	O
first	O
week	O
of	O
September	O
,	O
2007	O
.	O

At	O
this	O
time	O
of	O
the	O
year	O
the	O
weather	O
conditions	O
were	O
quite	O
poor	O
.	O
<EOS>	B-X
There	B-X
is	B-X
sufficient	B-X
epidemiological	B-X
and	B-X
biological	B-X
evidence	B-X
of	B-X
increased	B-X
human	B-X
susceptibility	B-X
to	B-X
viral	B-X
pathogens	B-X
such	B-X
as	B-X
Middle	B-X
East	B-X
respiratory	B-X
syndrome	B-X
coronavirus	B-X
,	B-X
respiratory	B-X
syncytial	B-X
virus	B-X
,	B-X
human	B-X
metapneumovirus	B-X
and	B-X
influenza	B-X
virus	B-X
,	B-X
in	B-X
cold	B-X
weather	B-X
.	B-X
The	B-X
pattern	B-X
of	B-X
outbreak	B-X
of	B-X
the	B-X
coronavirus	B-X
disease	B-X
2019	B-X
(	B-X
COVID-19	B-X
)	B-X
in	B-X
China	B-X
during	B-X
the	B-X
flu	B-X
season	B-X
is	B-X
further	B-X
proof	B-X
that	B-X
meteorological	B-X
conditions	B-X
may	B-X
potentially	B-X
influence	B-X
the	B-X
susceptibility	B-X
of	B-X
human	B-X
populations	B-X
to	B-X
coronaviruses	B-X
,	B-X
a	B-X
situation	B-X
that	B-X
may	B-X
become	B-X
increasingly	B-X
evident	B-X
as	B-X
the	B-X
current	B-X
global	B-X
pandemic	B-X
of	B-X
COVID-19	B-X
unfolds	B-X
.	B-X
The	B-X
Kingdom	B-X
of	B-X
Saudi	B-X
Arabia	B-X
has	B-X
been	B-X
privileged	B-X
to	B-X
host	B-X
this	B-X
event	B-X
,	B-X
which	B-X
brings	B-X
close	B-X
to	B-X
2	B-X
million	B-X
pilgrims	B-X
from	B-X
all	B-X
over	B-X
the	B-X
world	B-X
every	B-X
year	B-X
.	B-X
Recorded	B-X
temperatures	B-X
during	B-X
the	B-X
Hajj	B-X
time	B-X
is	B-X
in	B-X
the	B-X
range	B-X
between	B-X
37	B-X
degrees	B-X
C	B-X
and	B-X
45	B-X
degrees	B-X
C.	B-X
Overcrowding	B-X
and	B-X
the	B-X
hot	B-X
climate	B-X
subject	B-X
the	B-X
pilgrims	B-X
to	B-X
environmental	B-X
and	B-X
health	B-X
hazards	B-X
.	B-X
Dermatologic	B-X
conditions	B-X
,	B-X
whether	B-X
exacerbations	B-X
of	B-X
preexisting	B-X
disease	B-X
or	B-X
the	B-X
occurrence	B-X
of	B-X
new	B-X
ones	B-X
,	B-X
account	B-X
for	B-X
4.5	B-X
%	B-X
to	B-X
5.5	B-X
%	B-X
of	B-X
all	B-X
diseases	B-X
seen	B-X
during	B-X
the	B-X
3-week	B-X
periods	B-X
of	B-X
the	B-X
Hajj	B-X
.	B-X
Overcrowding	B-X
and	B-X
poor	B-X
hygiene	B-X
also	B-X
contribute	B-X
to	B-X
a	B-X
myriad	B-X
of	B-X
infections	B-X
:	B-X
viral	B-X
,	B-X
bacterial	B-X
,	B-X
fungal	B-X
,	B-X
and/or	B-X
parasitic	B-X
.	B-X

The	O
weeks	O
were	O
rainy	O
,	O
sunshine	O
occurred	O
only	O
occasionally	O
.	O

On	O
average	O
,	O
the	O
sky	O
was	O
very	O
cloudy	O
.	O
<EOS>	B-X
One	B-X
of	B-X
the	B-X
technical	B-X
solutions	B-X
to	B-X
boost	B-X
this	B-X
quantity	B-X
,	B-X
and	B-X
thusly	B-X
also	B-X
maximize	B-X
the	B-X
return	B-X
on	B-X
PV	B-X
investments	B-X
,	B-X
is	B-X
solar	B-X
tracking	B-X
,	B-X
which	B-X
makes	B-X
the	B-X
following	B-X
of	B-X
the	B-X
sun	B-X
on	B-X
its	B-X
daily	B-X
and	B-X
annual	B-X
journey	B-X
in	B-X
the	B-X
sky	B-X
possible	B-X
and	B-X
also	B-X
takes	B-X
changes	B-X
in	B-X
cloud	B-X
conditions	B-X
into	B-X
consideration	B-X
.	B-X
Their	B-X
active	B-X
sensor-tracking	B-X
algorithms	B-X
leave	B-X
room	B-X
for	B-X
improvement	B-X
for	B-X
at	B-X
least	B-X
three	B-X
major	B-X
reasons	B-X
,	B-X
as	B-X
they	B-X
do	B-X
not	B-X
prevent	B-X
the	B-X
unnecessary	B-X
operation	B-X
of	B-X
the	B-X
motors	B-X
in	B-X
cloudy	B-X
weather	B-X
,	B-X
they	B-X
do	B-X
not	B-X
make	B-X
the	B-X
modules	B-X
assume	B-X
an	B-X
appropriate	B-X
position	B-X
after	B-X
nightfall	B-X
,	B-X
and	B-X
they	B-X
do	B-X
not	B-X
make	B-X
sure	B-X
that	B-X
the	B-X
structure	B-X
and	B-X
the	B-X
electronics	B-X
of	B-X
the	B-X
PV	B-X
systems	B-X
are	B-X
protected	B-X
from	B-X
rain	B-X
and	B-X
the	B-X
strong	B-X
winds	B-X
in	B-X
the	B-X
event	B-X
of	B-X
storms	B-X
.	B-X
A	B-X
positive	B-X
feature	B-X
of	B-X
the	B-X
new	B-X
system	B-X
for	B-X
PV	B-X
power	B-X
plant	B-X
operators	B-X
is	B-X
that	B-X
it	B-X
performs	B-X
the	B-X
tracking	B-X
of	B-X
the	B-X
sun	B-X
practically	B-X
without	B-X
any	B-X
decrease	B-X
in	B-X
power	B-X
compared	B-X
to	B-X
the	B-X
focal	B-X
point	B-X
position	B-X
,	B-X
since	B-X
it	B-X
works	B-X
with	B-X
an	B-X
average	B-X
inaccuracy	B-X
of	B-X
1.9Â°	B-X
.	B-X
BLH	B-X
during	B-X
daytime	B-X
is	B-X
deeper	B-X
during	B-X
clear-sky	B-X
conditions	B-X
compared	B-X
to	B-X
cloudy	B-X
sky	B-X
conditions	B-X
,	B-X
indicating	B-X
a	B-X
significant	B-X
effect	B-X
of	B-X
clouds	B-X
;	B-X
BLH	B-X
during	B-X
nighttime	B-X
is	B-X
deeper	B-X
under	B-X
cloudy	B-X
conditions	B-X
.	B-X
Annual	B-X
BLH	B-X
recorded	B-X
an	B-X
average	B-X
increasing	B-X
trend	B-X
(	B-X
38.9-42.1	B-X
m/decade	B-X
)	B-X
,	B-X
and	B-X
LTS	B-X
is	B-X
more	B-X
dominant	B-X
than	B-X
WS	B-X
from	B-X
a	B-X
contribution	B-X
perspective	B-X
,	B-X
especially	B-X
for	B-X
increased	B-X
BLH	B-X
anomaly	B-X
.	B-X

Due	O
to	O
the	O
variable	O
weather	O
conditions	O
the	O
ambient	O
temperature	O
,	O
T	O
,	O
in	O
the	O
greenhouse	O
usually	O
varied	O
between	O
19	O
degrees	O
C	O
and	O
27	O
degrees	O
C	O
.	O

By	O
contrast	O
,	O
during	O
the	O
hot	O
week	O
in	O
May	O
temperatures	O
at	O
the	O
top	O
of	O
the	O
plants	O
could	O
reach	O
up	O
to	O
44	O
degrees	O
C	O
.	O

The	O
greenhouse	O
was	O
illuminated	O
between	O
07	O
.	O
30	O
h	O
and	O
19	O
.	O
00	O
h	O
(	O
CET	O
=	O
Central	O
European	O
Time	O
)	O
.	O

During	O
the	O
day	O
-	O
time	O
,	O
the	O
artificial	O
illumination	O
was	O
switched	O
off	O
automatically	O
once	O
the	O
natural	O
irradiance	O
exceeded	O
about	O
45	O
mu	O
mol	O
photons	O
m	O
-	O
2	O
s	O
-	O
1	O
at	O
ground	O
level	O
.	O

At	O
full	O
sunshine	O
,	O
the	O
light	O
intensity	O
was	O
limited	O
by	O
automatically	O
operating	O
blinds	O
.	O

The	O
relative	O
humidity	O
(	O
r	O
.	O
h	O
.	O
)	O
of	O
the	O
air	O
was	O
regulated	O
by	O
overhead	O
misters	O
.	O

Despite	O
attempts	O
to	O
keep	O
the	O
r	O
.	O
h	O
.	O
above	O
60	O
-	O
70	O
%	O
large	O
axial	O
r	O
.	O
h	O
.	O
gradients	O
along	O
the	O
stem	O
of	O
the	O
liana	O
were	O
observed	O
during	O
sunny	O
days	O
(	O
see	O
below	O
)	O
.	O

The	O
ambient	O
temperature	O
and	O
relative	O
humidity	O
at	O
the	O
measuring	O
sites	O
were	O
determined	O
by	O
using	O
thermistors	O
(	O
Tinytag	O
;	O
RS	O
Components	O
GmbH	O
,	O
M	O
o	O
rfelden	O
-	O
Walldorf	O
,	O
Germany	O
)	O
.	O

Leaf	O
patch	O
clamp	O
pressure	O
probe	O
and	O
data	O
acquisition	O

The	O
pressure	O
sensor	O
chip	O
allows	O
pressure	O
measurements	O
up	O
to	O
100	O
kPa	O
.	O

The	O
sensor	O
consists	O
of	O
a	O
miniature	O
piezoresistive	O
Wheatstone	O
bridge	O
.	O

The	O
sensors	O
used	O
in	O
this	O
work	O
were	O
purchased	O
from	O
the	O
company	O
'	O
Raumedic	O
'	O
(	O
Helmbrechts	O
,	O
Germany	O
)	O
and	O
from	O
the	O
company	O
'	O
Keller	O
'	O
(	O
AG	O
,	O
Druckmesstechnik	O
;	O
Winterthur	O
,	O
Switzerland	O
)	O
.	O

However	O
,	O
it	O
has	O
to	O
be	O
pointed	O
out	O
that	O
any	O
other	O
miniaturized	O
pressure	O
or	O
force	O
sensor	O
could	O
be	O
used	O
.	O
<EOS>	B-X
Force	B-X
and	B-X
strain	B-X
sensors	B-X
made	B-X
of	B-X
soft	B-X
materials	B-X
enable	B-X
robots	B-X
to	B-X
interact	B-X
intelligently	B-X
with	B-X
their	B-X
surroundings	B-X
.	B-X
Capacitive	B-X
sensors	B-X
are	B-X
,	B-X
however	B-X
,	B-X
susceptible	B-X
to	B-X
electromagnetic	B-X
interference	B-X
and	B-X
proximity	B-X
effects	B-X
and	B-X
thus	B-X
require	B-X
electrical	B-X
shielding	B-X
.	B-X
Shielding	B-X
has	B-X
not	B-X
been	B-X
previously	B-X
implemented	B-X
in	B-X
soft	B-X
capacitive	B-X
sensors	B-X
due	B-X
to	B-X
the	B-X
parasitic	B-X
capacitance	B-X
between	B-X
the	B-X
shield	B-X
and	B-X
sensing	B-X
electrodes	B-X
,	B-X
which	B-X
changes	B-X
when	B-X
the	B-X
sensor	B-X
is	B-X
deformed	B-X
.	B-X
The	B-X
force	B-X
resolution	B-X
is	B-X
sub-mN	B-X
both	B-X
in	B-X
normal	B-X
and	B-X
shear	B-X
directions	B-X
,	B-X
yet	B-X
the	B-X
sensor	B-X
withstands	B-X
large	B-X
forces	B-X
(	B-X
>	B-X
20	B-X
N	B-X
)	B-X
,	B-X
demonstrating	B-X
a	B-X
wide	B-X
dynamic	B-X
range	B-X
.	B-X

The	O
sensor	O
chip	O
was	O
integrated	O
into	O
one	O
of	O
the	O
planar	O
circular	O
pads	O
of	O
a	O
spring	O
clamp	O
shown	O
schematically	O
in	O
Fig	O
.	O

1	O
.	O
<EOS>	B-X
Formate	B-X
assay	B-X
in	B-X
body	B-X
fluids	B-X
:	B-X
application	B-X
in	B-X
methanol	B-X
poisoning	B-X
.	B-X

The	O
spring	O
clamp	O
consisted	O
of	O
two	O
curved	O
arms	O
bridged	O
by	O
a	O
spring	O
in	O
the	O
middle	O
(	O
Wolfcraft	O
GmbH	O
;	O
microfix	O
S	O
(	O
B3630Fz60	O
)	O
,	O
Kempenich	O
,	O
Germany	O
)	O
.	O

The	O
clamp	O
pressure	O
exerted	O
by	O
the	O
spring	O
on	O
the	O
leaf	O
,	O
Pclamp	O
,	O
could	O
be	O
varied	O
by	O
a	O
stiff	O
strap	O
(	O
made	O
of	O
synthetic	O
material	O
)	O
spanned	O
between	O
the	O
arms	O
of	O
the	O
spring	O
clip	O
at	O
the	O
handhold	O
site	O
(	O
Fig	O
.	O
1	O
)	O
.	O

The	O
length	O
of	O
the	O
strap	O
and	O
thus	O
the	O
spring	O
load	O
acting	O
on	O
the	O
leaflet	O
between	O
the	O
two	O
pads	O
could	O
be	O
varied	O
by	O
regularly	O
punched	O
holes	O
(	O
as	O
in	O
a	O
belt	O
)	O
.	O

Calibration	O
of	O
the	O
sensor	O
chips	O
was	O
performed	O
by	O
pressurization	O
in	O
a	O
pressure	O
chamber	O
equipped	O
with	O
an	O
integrated	O
manometer	O
(	O
LEO	O
1	O
,	O
Keller	O
AG	O
,	O
Winterthur	O
,	O
Switzerland	O
)	O
.	O

The	O
readings	O
of	O
all	O
sensors	O
used	O
in	O
this	O
study	O
increased	O
linearly	O
with	O
pressure	O
in	O
the	O
range	O
between	O
0	O
kPa	O
and	O
100	O
kPa	O
.	O

The	O
pressure	O
sensitivity	O
of	O
the	O
various	O
sensors	O
was	O
found	O
to	O
be	O
almost	O
identical	O
for	O
all	O
probes	O
.	O
<EOS>	B-X
Vascular	B-X
wall	B-X
stiffness	B-X
indices	B-X
are	B-X
related	B-X
to	B-X
local	B-X
pulse	B-X
pressure	B-X
(	B-X
ÎP	B-X
)	B-X
level	B-X
,	B-X
mechanical	B-X
and	B-X
geometrical	B-X
characteristics	B-X
of	B-X
the	B-X
arterial	B-X
vessel	B-X
.	B-X
To	B-X
compare	B-X
the	B-X
effects	B-X
of	B-X
pressure-	B-X
and	B-X
flow-triggered	B-X
pressure-support	B-X
ventilation	B-X
on	B-X
weaning	B-X
parameters	B-X
during	B-X
recovery	B-X
from	B-X
acute	B-X
respiratory	B-X
failure	B-X
.	B-X
As	B-X
a	B-X
consequence	B-X
,	B-X
TEWL	B-X
has	B-X
been	B-X
found	B-X
to	B-X
be	B-X
a	B-X
very	B-X
useful	B-X
technique	B-X
for	B-X
studying	B-X
skin	B-X
irritation	B-X
induced	B-X
by	B-X
various	B-X
physical	B-X
and	B-X
chemical	B-X
effects	B-X
.	B-X
The	B-X
instrument	B-X
is	B-X
based	B-X
on	B-X
the	B-X
open	B-X
chamber	B-X
system	B-X
with	B-X
two	B-X
humidity	B-X
and	B-X
temperature	B-X
sensors	B-X
which	B-X
measure	B-X
the	B-X
water	B-X
evaporation	B-X
gradient	B-X
at	B-X
the	B-X
surface	B-X
of	B-X
the	B-X
skin	B-X
.	B-X
The	B-X
accuracy	B-X
,	B-X
sensitivity	B-X
,	B-X
variability	B-X
and	B-X
reproducibility	B-X
of	B-X
both	B-X
instruments	B-X
were	B-X
compared	B-X
in	B-X
vivo	B-X
under	B-X
identical	B-X
conditions	B-X
on	B-X
normal	B-X
skin	B-X
and	B-X
skin	B-X
damaged	B-X
by	B-X
external	B-X
conditions	B-X
.	B-X
The	B-X
influence	B-X
of	B-X
external	B-X
and	B-X
environmental	B-X
factors	B-X
such	B-X
as	B-X
air	B-X
and	B-X
probe	B-X
temperature	B-X
,	B-X
relative	B-X
humidity	B-X
,	B-X
air	B-X
turbulence	B-X
and	B-X
pressure	B-X
of	B-X
application	B-X
was	B-X
evaluated	B-X
for	B-X
both	B-X
instruments	B-X
.	B-X
A	B-X
very	B-X
good	B-X
correlation	B-X
(	B-X
r	B-X
=	B-X
+0.97	B-X
)	B-X
was	B-X
found	B-X
between	B-X
the	B-X
results	B-X
of	B-X
the	B-X
two	B-X
instruments	B-X
over	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
TEWL	B-X
values	B-X
.	B-X

Before	O
use	O
the	O
probes	O
were	O
also	O
tested	O
for	O
temperature	O
-	O
sensitivity	O
in	O
an	O
accessible	O
climate	O
chamber	O
because	O
it	O
is	O
well	O
-	O
known	O
that	O
silicone	O
-	O
embedded	O
sensors	O
tend	O
to	O
become	O
temperature	O
-	O
sensitive	O
during	O
storage	O
.	O

Probes	O
were	O
subject	O
to	O
temperature	O
regimes	O
ranging	O
from	O
10	O
degrees	O
C	O
to	O
35	O
degrees	O
C	O
.	O

Probes	O
were	O
not	O
used	O
if	O
the	O
temperature	O
treatment	O
induced	O
a	O
pressure	O
change	O
larger	O
than	O
0	O
.	O
5	O
kPa	O
.	O
<EOS>	B-X
To	B-X
test	B-X
the	B-X
effectiveness	B-X
of	B-X
the	B-X
proposed	B-X
passive	B-X
LWIR	B-X
dual-probe	B-X
s-SNOM	B-X
system	B-X
,	B-X
each	B-X
probe	B-X
was	B-X
precisely	B-X
controlled	B-X
using	B-X
a	B-X
shear-force	B-X
feedback	B-X
system	B-X
,	B-X
and	B-X
the	B-X
mechanical	B-X
interference	B-X
between	B-X
the	B-X
probes	B-X
was	B-X
used	B-X
to	B-X
monitor	B-X
the	B-X
distance	B-X
between	B-X
the	B-X
probes	B-X
.	B-X
We	B-X
achieved	B-X
simultaneous	B-X
near-field	B-X
measurements	B-X
at	B-X
two	B-X
different	B-X
positions	B-X
500	B-X
nm	B-X
apart	B-X
using	B-X
the	B-X
proposed	B-X
passive	B-X
LWIR	B-X
dual-probe	B-X
s-SNOM	B-X
system	B-X
.	B-X
Periodontal	B-X
probes	B-X
are	B-X
the	B-X
main	B-X
instruments	B-X
that	B-X
are	B-X
used	B-X
to	B-X
assess	B-X
the	B-X
status	B-X
of	B-X
the	B-X
periodontium	B-X
,	B-X
either	B-X
for	B-X
screening	B-X
purposes	B-X
or	B-X
to	B-X
evaluate	B-X
periodontal	B-X
changes	B-X
throughout	B-X
the	B-X
treatment	B-X
process	B-X
.	B-X
Because	B-X
SMT	B-X
follows	B-X
the	B-X
motion	B-X
of	B-X
an	B-X
individual	B-X
probe	B-X
over	B-X
a	B-X
large	B-X
area	B-X
(	B-X
approximately	B-X
10	B-X
x	B-X
10	B-X
microm2	B-X
)	B-X
,	B-X
transitions	B-X
between	B-X
environments	B-X
can	B-X
be	B-X
observed	B-X
directly	B-X
by	B-X
monitoring	B-X
the	B-X
path	B-X
of	B-X
each	B-X
protein	B-X
or	B-X
lipid	B-X
.	B-X

The	O
signals	O
of	O
the	O
leaf	O
patch	O
clamp	O
pressure	O
probe	O
were	O
transmitted	O
by	O
a	O
telemetry	O
system	O
(	O
teleBITcom	O
gmbh	O
,	O
Teltow	O
,	O
Germany	O
)	O
.	O

The	O
operating	O
distance	O
between	O
the	O
battery	O
-	O
powered	O
wireless	O
telemetric	O
transmitter	O
and	O
the	O
receiver	O
base	O
station	O
was	O
up	O
to	O
400	O
m	O
.	O

Each	O
transmitter	O
read	O
,	O
amplified	O
,	O
and	O
converted	O
the	O
analogue	O
signals	O
of	O
the	O
pressure	O
sensor	O
into	O
digitalized	O
signals	O
.	O

The	O
data	O
were	O
sent	O
together	O
with	O
the	O
transmitter	O
ID	O
-	O
code	O
every	O
90	O
s	O
via	O
the	O
ISM	O
band	O
of	O
433	O
MHz	O
to	O
the	O
receiver	O
base	O
station	O
which	O
logged	O
and	O
transferred	O
the	O
data	O
to	O
a	O
personal	O
computer	O
or	O
to	O
a	O
GPRS	O
modem	O
linked	O
to	O
an	O
Internet	O
server	O
(	O
NTBB	O
Systemtechnik	O
GmbH	O
,	O
Zeuthen	O
,	O
Germany	O
)	O
for	O
analysis	O
and	O
archival	O
storage	O
.	O

For	O
sensor	O
calibration	O
and	O
data	O
recording	O
the	O
SENBIT	O
software	O
(	O
teleBITcom	O
gmbh	O
,	O
Teltow	O
,	O
Germany	O
)	O
was	O
used	O
.	O

The	O
software	O
allowed	O
communication	O
with	O
up	O
to	O
32	O
sensors	O
at	O
regular	O
short	O
intervals	O
(	O
90	O
s	O
to	O
5	O
min	O
)	O
.	O

In	O
this	O
study	O
,	O
up	O
to	O
10	O
sensor	O
/	O
transmitter	O
units	O
were	O
installed	O
at	O
different	O
heights	O
on	O
the	O
two	O
lianas	O
.	O

Data	O
transfer	O
to	O
the	O
Internet	O
server	O
operated	O
without	O
any	O
problem	O
during	O
the	O
entire	O
experimental	O
period	O
.	O

However	O
,	O
for	O
safety	O
reasons	O
hard	O
-	O
wired	O
conventional	O
data	O
acquisition	O
was	O
also	O
performed	O
using	O
dataloggers	O
(	O
Raumedic	O
,	O
Helmbrechts	O
,	O
Germany	O
)	O
.	O

The	O
dataloggers	O
were	O
controlled	O
by	O
a	O
computer	O
program	O
that	O
provided	O
functions	O
for	O
data	O
storage	O
and	O
sensor	O
calibration	O
.	O

Data	O
were	O
transferred	O
regularly	O
from	O
the	O
dataloggers	O
to	O
a	O
personal	O
computer	O
.	O

Cell	O
turgor	O
pressure	O
probe	O
<EOS>	B-X
To	B-X
fully	B-X
describe	B-X
the	B-X
factors	B-X
that	B-X
influence	B-X
cell	B-X
expansion	B-X
,	B-X
it	B-X
is	B-X
necessary	B-X
to	B-X
quantify	B-X
the	B-X
counteracting	B-X
forces	B-X
of	B-X
turgor	B-X
pressure	B-X
and	B-X
cell	B-X
wall	B-X
stiffness	B-X
,	B-X
which	B-X
together	B-X
determine	B-X
whether	B-X
and	B-X
how	B-X
a	B-X
cell	B-X
expands	B-X
.	B-X
Furthermore	B-X
,	B-X
available	B-X
methods	B-X
for	B-X
turgor	B-X
measurement	B-X
are	B-X
either	B-X
accurate	B-X
but	B-X
invasive	B-X
,	B-X
like	B-X
the	B-X
pressure	B-X
probe	B-X
;	B-X
or	B-X
they	B-X
lack	B-X
accuracy	B-X
,	B-X
such	B-X
as	B-X
incipient	B-X
plasmolysis	B-X
or	B-X
indentation-based	B-X
methods	B-X
that	B-X
rely	B-X
on	B-X
information	B-X
about	B-X
the	B-X
mechanical	B-X
properties	B-X
of	B-X
the	B-X
cell	B-X
wall	B-X
.	B-X
By	B-X
combining	B-X
non-invasive	B-X
microindentation	B-X
and	B-X
cell	B-X
compression	B-X
experiments	B-X
,	B-X
we	B-X
separately	B-X
measure	B-X
turgor	B-X
pressure	B-X
and	B-X
cell	B-X
wall	B-X
elasticity	B-X
on	B-X
the	B-X
same	B-X
pollen	B-X
tube	B-X
in	B-X
parallel	B-X
.	B-X
Leaf	B-X
dehydration	B-X
decreases	B-X
water	B-X
potential	B-X
and	B-X
cell	B-X
turgor	B-X
pressure	B-X
.	B-X
Therefore	B-X
,	B-X
changes	B-X
in	B-X
cell	B-X
turgor	B-X
pressure	B-X
may	B-X
regulate	B-X
water	B-X
transport	B-X
across	B-X
plant	B-X
cell	B-X
membranes	B-X
.	B-X
Using	B-X
a	B-X
cell	B-X
pressure	B-X
probe	B-X
,	B-X
the	B-X
hydraulic	B-X
properties	B-X
of	B-X
parenchyma	B-X
cells	B-X
in	B-X
the	B-X
midrib	B-X
of	B-X
maize	B-X
(	B-X

Turgor	O
pressure	O
measurements	O
were	O
performed	O
on	O
leaflets	O
of	O
the	O
10	O
-	O
m	O
tall	O
liana	O
at	O
c	O
.	O

0	O
.	O
2	O
m	O
height	O
above	O
the	O
roots	O
.	O

The	O
construction	O
and	O
function	O
of	O
the	O
cell	O
turgor	O
pressure	O
probe	O
has	O
been	O
described	O
elsewhere	O
(	O
Zimmermann	O
et	O
al	O
.	O
,	O
1969	O
,	O
2004	O
)	O
.	O

Briefly	O
,	O
the	O
microcapillary	O
was	O
filled	O
with	O
oil	O
up	O
to	O
the	O
very	O
tip	O
and	O
was	O
then	O
inserted	O
into	O
the	O
upper	O
leaflet	O
surface	O
between	O
the	O
main	O
vein	O
and	O
the	O
leaflet	O
edge	O
.	O

Insertion	O
was	O
made	O
under	O
a	O
small	O
overpressure	O
(	O
about	O
20	O
kPa	O
)	O
achieved	O
by	O
appropriate	O
displacement	O
of	O
the	O
metal	O
rod	O
in	O
the	O
probe	O
in	O
order	O
to	O
avoid	O
tip	O
clogging	O
.	O

Penetration	O
was	O
stopped	O
upon	O
reaching	O
the	O
mesophyll	O
cell	O
layer	O
and	O
formation	O
of	O
a	O
stable	O
oil	O
/	O
sap	O
meniscus	O
within	O
the	O
tip	O
region	O
of	O
the	O
microcapillary	O
of	O
the	O
probe	O
.	O

During	O
the	O
measurements	O
it	O
was	O
regularly	O
proved	O
whether	O
the	O
tip	O
was	O
clogged	O
or	O
not	O
by	O
appropriate	O
displacement	O
of	O
the	O
metal	O
rod	O
.	O
<EOS>	B-X
Polyetheretherketone	B-X
(	B-X
PEEK	B-X
)	B-X
,	B-X
a	B-X
high-strength	B-X
,	B-X
aesthetic	B-X
,	B-X
and	B-X
non-allergic	B-X
thermoplastic	B-X
polymer	B-X
,	B-X
recently	B-X
became	B-X
a	B-X
candidate	B-X
for	B-X
replacing	B-X
metallic	B-X
components	B-X
in	B-X
dental	B-X
prosthesis	B-X
.	B-X

Theoretical	O
background	O
<EOS>	B-X
Theoretical	B-X
neuroscience	B-X
has	B-X
experienced	B-X
explosive	B-X
growth	B-X
over	B-X
the	B-X
past	B-X
20	B-X
years	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
bringing	B-X
new	B-X
researchers	B-X
into	B-X
the	B-X
field	B-X
with	B-X
backgrounds	B-X
in	B-X
physics	B-X
,	B-X
mathematics	B-X
,	B-X
computer	B-X
science	B-X
,	B-X
and	B-X
engineering	B-X
,	B-X
theoretical	B-X
approaches	B-X
have	B-X
helped	B-X
to	B-X
introduce	B-X
new	B-X
ideas	B-X
and	B-X
shape	B-X
directions	B-X
of	B-X
neuroscience	B-X
research	B-X
.	B-X
No	B-X
theoretical	B-X
background	B-X
is	B-X
behind	B-X
the	B-X
model	B-X
,	B-X
however	B-X
the	B-X
generic	B-X
model	B-X
clearly	B-X
improves	B-X
the	B-X
results	B-X
obtained	B-X
by	B-X
simple	B-X
first	B-X
order	B-X
kinetics	B-X
.	B-X
This	B-X
paper	B-X
explored	B-X
the	B-X
theoretical	B-X
background	B-X
and	B-X
methodological	B-X
development	B-X
of	B-X
subjective	B-X
health	B-X
status	B-X
measures	B-X
commonly	B-X
used	B-X
in	B-X
osteoarthritis	B-X
research	B-X
.	B-X

The	O
input	O
pressure	O
,	O
Pin	O
,	O
experienced	O
by	O
the	O
cells	O
in	O
a	O
leaf	O
patch	O
is	O
equal	O
to	O
the	O
clamp	O
pressure	O
,	O
Pclamp	O
,	O
only	O
if	O
the	O
pressure	O
signal	O
is	O
transferred	O
lossless	O
to	O
the	O
cells	O
in	O
the	O
leaves	O
.	O

However	O
,	O
losses	O
usually	O
occur	O
due	O
to	O
the	O
compressibility	O
and	O
the	O
deformability	O
of	O
the	O
silicone	O
of	O
the	O
pressure	O
sensor	O
as	O
well	O
as	O
of	O
the	O
compressibility	O
of	O
the	O
cuticle	O
and	O
other	O
structural	O
elements	O
of	O
the	O
leaf	O
.	O

Therefore	O
,	O
theory	O
shows	O
that	O
only	O
a	O
fraction	O
of	O
Pclamp	O
may	O
arrive	O
at	O
the	O
cells	O
,	O
i	O
.	O
e	O
.	O
that	O
the	O
attenuation	O
factor	O
,	O
Fa	O
=	O
Pin	O
/	O
Pclamp	O
,	O
is	O
smaller	O
than	O
unity	O
.	O

Fa	O
depends	O
on	O
the	O
individual	O
leaf	O
properties	O
.	O

Fa	O
can	O
be	O
assumed	O
to	O
be	O
constant	O
(	O
and	O
leaf	O
thickness	O
changes	O
are	O
negligible	O
)	O
if	O
the	O
structural	O
elements	O
are	O
completely	O
pre	O
-	O
compressed	O
by	O
application	O
of	O
an	O
appropriate	O
Pclamp	O
.	O

If	O
Pclamp	O
is	O
kept	O
constant	O
during	O
the	O
following	O
experimental	O
period	O
,	O
Pin	O
is	O
constant	O
and	O
the	O
output	O
pressure	O
,	O
Pp	O
,	O
is	O
only	O
determined	O
by	O
the	O
cell	O
transfer	O
function	O
,	O
Tf	O
(	O
V	O
)	O
,	O
where	O
V	O
is	O
the	O
leaf	O
patch	O
volume	O
.	O

In	O
other	O
words	O
,	O
Tf	O
(	O
V	O
)	O
determines	O
the	O
fraction	O
of	O
Pin	O
sensed	O
by	O
the	O
probe	O
.	O

It	O
is	O
dimensionless	O
and	O
assumes	O
values	O
between	O
zero	O
and	O
unity	O
:	O
(	O
1	O
)	O
Tf	O
depends	O
on	O
the	O
volume	O
of	O
the	O
leaf	O
patch	O
,	O
V	O
,	O
at	O
constant	O
ambient	O
temperature	O
,	O
T	O
:	O
(	O
2	O
)	O
delta	O
V	O
depends	O
on	O
changes	O
in	O
cell	O
turgor	O
pressure	O
,	O
delta	O
Pc	O
,	O
as	O
follows	O
:	O
(	O
3	O
)	O
where	O
op	O
is	O
the	O
average	O
volumetric	O
elastic	O
modulus	O
of	O
the	O
clamped	O
tissue	O
(	O
Philip	O
,	O
1958	O
)	O
.	O

op	O
is	O
a	O
very	O
complex	O
parameter	O
and	O
will	O
be	O
dictated	O
by	O
the	O
turgor	O
pressure	O
in	O
the	O
turgescent	O
state	O
.	O

For	O
a	O
first	O
approximation	O
it	O
is	O
assumed	O
that	O
op	O
increases	O
linearly	O
with	O
Pc	O
(	O
support	O
for	O
this	O
assumption	O
is	O
given	O
by	O
Zimmermann	O
and	O
Steudle	O
,	O
1978	O
;	O
Zimmermann	O
and	O
H	O
u	O
sken	O
,	O
1980	O
;	O
Wendler	O
et	O
al	O
.	O
,	O
1983	O
)	O
:	O
(	O
4	O
)	O
where	O
a	O
and	O
b	O
are	O
constants	O
for	O
individual	O
leaf	O
properties	O
.	O

Because	O
of	O
the	O
viscoelastic	O
properties	O
of	O
the	O
cell	O
wall	O
,	O
the	O
magnitude	O
of	O
the	O
constants	O
depends	O
on	O
the	O
duration	O
of	O
the	O
external	O
pressure	O
application	O
(	O
Zimmermann	O
and	O
H	O
u	O
sken	O
,	O
1980	O
)	O
.	O

The	O
constants	O
are	O
relatively	O
large	O
if	O
rapid	O
turgor	O
pressure	O
changes	O
are	O
induced	O
(	O
e	O
.	O
g	O
.	O
by	O
using	O
the	O
cell	O
turgor	O
pressure	O
probe	O
)	O
,	O
whereas	O
slow	O
turgor	O
pressure	O
changes	O
(	O
e	O
.	O
g	O
.	O
under	O
transpirational	O
conditions	O
)	O
result	O
in	O
small	O
values	O
.	O

Combining	O
equations	O
2	O
-	O
4	O
leads	O
to	O
equation	O
5	O
.	O
(	O
5	O
)	O
<EOS>	B-X
We	B-X
first	B-X
measured	B-X
steady-state	B-X
rates	B-X
of	B-X
oxygen	B-X
uptake	B-X
in	B-X
20	B-X
healthy	B-X
adult	B-X
subjects	B-X
during	B-X
unloaded	B-X
treadmill	B-X
trials	B-X
from	B-X
0.4	B-X
to	B-X
1.6	B-X
m/s	B-X
on	B-X
six	B-X
gradients	B-X
:	B-X
-6	B-X
,	B-X
-3	B-X
,	B-X
0	B-X
,	B-X
3	B-X
,	B-X
6	B-X
,	B-X
and	B-X
9Â°	B-X
.	B-X
Next	B-X
,	B-X
we	B-X
tested	B-X
a	B-X
second	B-X
set	B-X
of	B-X
20	B-X
subjects	B-X
under	B-X
three	B-X
torso-loading	B-X
conditions	B-X
(	B-X
no-load	B-X
,	B-X
+18	B-X
,	B-X
and	B-X
+31	B-X
%	B-X
body	B-X
weight	B-X
)	B-X
at	B-X
speeds	B-X
from	B-X
0.6	B-X
to	B-X
1.4	B-X
m/s	B-X
on	B-X
the	B-X
same	B-X
six	B-X
gradients	B-X
.	B-X
Metabolic	B-X
rates	B-X
spanned	B-X
a	B-X
14-fold	B-X
range	B-X
from	B-X
supine	B-X
rest	B-X
to	B-X
the	B-X
greatest	B-X
single-trial	B-X
walking	B-X
mean	B-X
(	B-X
3.1	B-X
Â±	B-X
0.1	B-X
to	B-X
43.3	B-X
Â±	B-X
0.5	B-X
ml	B-X
O	B-X
4-Hydroxyphenylpyruvate	B-X
dioxygenase	B-X
(	B-X
HPPD	B-X
)	B-X
,	B-X
converting	B-X
phydroxyphenylpyruvate	B-X
(	B-X
HPPA	B-X
)	B-X
to	B-X
homogentisate	B-X
(	B-X
HGA	B-X
)	B-X
,	B-X
is	B-X
an	B-X
important	B-X
target	B-X
for	B-X
treating	B-X
type	B-X
I	B-X
tyrosinemia	B-X
and	B-X
synthesizing	B-X
novel	B-X
herbicides	B-X
due	B-X
to	B-X
its	B-X
significant	B-X
role	B-X
in	B-X
tyrosine	B-X
catabolism	B-X
.	B-X
Hence	B-X
,	B-X
it	B-X
is	B-X
imperative	B-X
to	B-X
design	B-X
novel	B-X
HPPD	B-X
inhibitors	B-X
that	B-X
can	B-X
block	B-X
HPPA-HGA	B-X
conversion	B-X
,	B-X
which	B-X
leads	B-X
to	B-X
the	B-X
deficiency	B-X
in	B-X
isoprenoid	B-X
redox	B-X
cofactors	B-X
such	B-X
as	B-X
plastoquinone	B-X
and	B-X
tocopherol	B-X
,	B-X
and	B-X
finally	B-X
caused	B-X
growth	B-X
inhibition	B-X
.	B-X

Equation	O
5	O
can	O
be	O
integrated	O
by	O
assuming	O
for	O
a	O
first	O
approximation	O
that	O
at	O
Pc	O
=	O
0	O
Tf	O
=	O
1	O
and	O
that	O
the	O
internal	O
osmotic	O
pressure	O
of	O
the	O
cells	O
remained	O
constant	O
.	O

After	O
appropriate	O
re	O
-	O
arrangements	O
equation	O
6	O
is	O
obtained	O
:	O
(	O
6	O
)	O
and	O
,	O
respectively	O
,	O
if	O
the	O
denominator	O
is	O
replaced	O
by	O
equation	O
4	O
:	O
(	O
7	O
)	O

Introducing	O
equation	O
6	O
into	O
equation	O
1	O
yields	O
the	O
wanted	O
relationship	O
between	O
the	O
parameters	O
Pp	O
and	O
Pin	O
:	O
(	O
8	O
)	O

Equation	O
8	O
can	O
be	O
verified	O
experimentally	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
the	B-X
compliance	B-X
equations	B-X
were	B-X
verified	B-X
by	B-X
means	B-X
of	B-X
finite	B-X
element	B-X
analysis	B-X
and	B-X
experiments	B-X
.	B-X
The	B-X
errors	B-X
in	B-X
the	B-X
finite	B-X
element	B-X
and	B-X
experimental	B-X
results	B-X
were	B-X
within	B-X
10	B-X
%	B-X
and	B-X
8	B-X
%	B-X
compared	B-X
to	B-X
the	B-X
analytical	B-X
results	B-X
,	B-X
respectively	B-X
.	B-X
For	B-X
both	B-X
materials	B-X
nth	B-X
order	B-X
reaction	B-X
was	B-X
proposed	B-X
with	B-X
reaction	B-X
order	B-X
of	B-X
7.69-8.70	B-X
for	B-X
BSG	B-X
and	B-X
6.32-6.55	B-X
for	B-X
MDF	B-X
.	B-X
These	B-X
curves	B-X
indicated	B-X
the	B-X
highest	B-X
conversion	B-X
at	B-X
the	B-X
temperature	B-X
of	B-X
the	B-X
degradation	B-X
of	B-X
dominant	B-X
component	B-X
,	B-X
which	B-X
was	B-X
experimentally	B-X
verified	B-X
.	B-X

Inspection	O
of	O
the	O
equation	O
shows	O
that	O
the	O
patch	O
clamp	O
pressure	O
,	O
Pp	O
,	O
is	O
a	O
power	O
function	O
of	O
the	O
turgor	O
pressure	O
,	O
Pc	O
.	O

The	O
exponent	O
of	O
the	O
function	O
is	O
equal	O
to	O
or	O
smaller	O
than	O
unity	O
.	O
<EOS>	B-X
We	B-X
discuss	B-X
patterns	B-X
of	B-X
eco-physiological	B-X
traits	B-X
of	B-X
turtles	B-X
and	B-X
crocodiles	B-X
,	B-X
as	B-X
functions	B-X
of	B-X
parameter	B-X
values	B-X
,	B-X
and	B-X
compare	B-X
them	B-X
with	B-X
other	B-X
taxa	B-X
.	B-X
Turtles	B-X
and	B-X
crocodiles	B-X
accurately	B-X
match	B-X
the	B-X
general	B-X
rule	B-X
that	B-X
the	B-X
life-time	B-X
cumulated	B-X
neonate	B-X
mass	B-X
production	B-X
equals	B-X
ultimate	B-X
weight	B-X
.	B-X
The	B-X
scaling	B-X
exponent	B-X
is	B-X
between	B-X
that	B-X
of	B-X
amphibians	B-X
and	B-X
birds	B-X
,	B-X
while	B-X
that	B-X
for	B-X
mammals	B-X
is	B-X
close	B-X
to	B-X
1	B-X
.	B-X
With	B-X
the	B-X
aim	B-X
to	B-X
quantify	B-X
the	B-X
abrupt	B-X
changes	B-X
during	B-X
A-phases	B-X
,	B-X
in	B-X
this	B-X
work	B-X
the	B-X
wavelet	B-X
analysis	B-X
is	B-X
considered	B-X
to	B-X
compute	B-X
HÃ¶lder	B-X
exponents	B-X
,	B-X
which	B-X
measure	B-X
the	B-X
singularity	B-X
strength	B-X
.	B-X
Whereas	B-X
outside	B-X
of	B-X
A-phases	B-X
,	B-X
it	B-X
is	B-X
observed	B-X
that	B-X
the	B-X
HÃ¶lder	B-X
value	B-X
is	B-X
approximately	B-X
equal	B-X
to	B-X
0.3	B-X
,	B-X
which	B-X
implies	B-X
stronger	B-X
singularities	B-X
,	B-X
i.e.	B-X
,	B-X
a	B-X
more	B-X
evident	B-X
discontinuity	B-X
in	B-X
the	B-X
signal	B-X
behavior	B-X
.	B-X

If	O
a	O
=	O
1	O
and	O
b	O
<	O
<	O
Pc	O
,	O
equation	O
8	O
turns	O
into	O
Pp	O
=	O
b	O
/	O
Pc	O
,	O
i	O
.	O
e	O
.	O
both	O
parameters	O
are	O
directly	O
reciprocally	O
coupled	O
with	O
each	O
other	O
.	O

Thus	O
Tf	O
assumes	O
low	O
values	O
if	O
Pc	O
is	O
high	O
and	O
,	O
vice	O
versa	O
,	O
a	O
value	O
close	O
to	O
unity	O
if	O
Pc	O
is	O
close	O
to	O
zero	O
.	O

Using	O
appropriate	O
values	O
for	O
a	O
and	O
b	O
for	O
a	O
given	O
leaf	O
(	O
see	O
below	O
)	O
it	O
can	O
be	O
shown	O
that	O
below	O
Pc	O
=	O
100	O
kPa	O
,	O
Pp	O
increases	O
dramatically	O
.	O

This	O
means	O
that	O
the	O
transfer	O
function	O
responds	O
very	O
sensitively	O
upon	O
loss	O
of	O
complete	O
turgor	O
pressure	O
.	O

In	O
the	O
derivation	O
of	O
equation	O
8	O
it	O
was	O
assumed	O
that	O
op	O
is	O
temperature	O
-	O
independent	O
.	O

However	O
,	O
temperature	O
effects	O
on	O
cell	O
elasticity	O
are	O
well	O
-	O
known	O
,	O
although	O
they	O
are	O
not	O
very	O
large	O
in	O
the	O
temperature	O
range	O
investigated	O
here	O
(	O
see	O
,	O
for	O
example	O
,	O
Petersen	O
et	O
al	O
.	O
,	O
1982	O
;	O
Niklas	O
,	O
1992	O
;	O
Hogan	O
and	O
Niklas	O
,	O
2004	O
;	O
Edelmann	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O
<EOS>	B-X
Magnetoelectric	B-X
(	B-X
ME	B-X
)	B-X
effect	B-X
experimentally	B-X
discovered	B-X
about	B-X
60	B-X
years	B-X
ago	B-X
remains	B-X
one	B-X
of	B-X
the	B-X
promising	B-X
research	B-X
fields	B-X
with	B-X
the	B-X
main	B-X
applications	B-X
in	B-X
microelectronics	B-X
and	B-X
sensors	B-X
.	B-X
However	B-X
,	B-X
its	B-X
applications	B-X
to	B-X
biology	B-X
and	B-X
medicine	B-X
are	B-X
still	B-X
in	B-X
their	B-X
infancy	B-X
.	B-X
For	B-X
the	B-X
diagnosis	B-X
and	B-X
treatment	B-X
of	B-X
diseases	B-X
at	B-X
the	B-X
intracellular	B-X
level	B-X
,	B-X
it	B-X
is	B-X
necessary	B-X
to	B-X
develop	B-X
a	B-X
maximally	B-X
non-invasive	B-X
way	B-X
of	B-X
local	B-X
stimulation	B-X
of	B-X
individual	B-X
neurons	B-X
,	B-X
navigation	B-X
,	B-X
and	B-X
distribution	B-X
of	B-X
biomolecules	B-X
in	B-X
damaged	B-X
cells	B-X
with	B-X
relatively	B-X
high	B-X
efficiency	B-X
and	B-X
adequate	B-X
spatial	B-X
and	B-X
temporal	B-X
resolution	B-X
.	B-X
Recently	B-X
developed	B-X
ME	B-X
materials	B-X
(	B-X
composites	B-X
)	B-X
,	B-X
which	B-X
combine	B-X
elastically	B-X
coupled	B-X
piezoelectric	B-X
(	B-X
PE	B-X
)	B-X
and	B-X
magnetostrictive	B-X
(	B-X
MS	B-X
)	B-X
phases	B-X
,	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
yield	B-X
very	B-X
strong	B-X
ME	B-X
effects	B-X
even	B-X
at	B-X
room	B-X
temperature	B-X
.	B-X
The	B-X
main	B-X
ME	B-X
materials	B-X
,	B-X
processing	B-X
technologies	B-X
,	B-X
as	B-X
well	B-X
as	B-X
most	B-X
prospective	B-X
biomedical	B-X
applications	B-X
will	B-X
be	B-X
overviewed	B-X
,	B-X
and	B-X
modern	B-X
trends	B-X
in	B-X
using	B-X
ME	B-X
materials	B-X
for	B-X
future	B-X
therapies	B-X
,	B-X
wireless	B-X
power	B-X
transfer	B-X
,	B-X
and	B-X
optogenetics	B-X
will	B-X
be	B-X
considered	B-X
.	B-X

Temperature	O
effects	O
on	O
op	O
cannot	O
be	O
excluded	O
if	O
different	O
values	O
for	O
the	O
Pclamp	O
,	O
and	O
,	O
in	O
turn	O
,	O
for	O
the	O
input	O
pressure	O
,	O
Pin	O
,	O
are	O
selected	O
,	O
as	O
well	O
as	O
if	O
significantly	O
different	O
values	O
for	O
the	O
constants	O
a	O
and	O
b	O
are	O
assumed	O
for	O
optimum	O
fitting	O
of	O
the	O
Pp	O
=	O
f	O
(	O
Pc	O
)	O
curves	O
.	O

Therefore	O
,	O
in	O
the	O
case	O
of	O
large	O
temperature	O
gradients	O
as	O
observed	O
here	O
(	O
see	O
Figs	O
2	O
and	O
3	O
)	O
only	O
the	O
relative	O
,	O
but	O
not	O
the	O
absolute	O
changes	O
in	O
Pp	O
measured	O
at	O
the	O
different	O
heights	O
can	O
be	O
compared	O
with	O
each	O
other	O
.	O

However	O
,	O
Pp	O
values	O
measured	O
at	O
the	O
same	O
height	O
are	O
still	O
comparable	O
and	O
give	O
information	O
about	O
the	O
turgescence	O
,	O
i	O
.	O
e	O
.	O
about	O
the	O
water	O
status	O
of	O
the	O
leaf	O
cells	O
.	O

Results	O

The	O
leaf	O
patch	O
clamp	O
pressure	O
probe	O
was	O
clamped	O
about	O
2	O
cm	O
away	O
from	O
the	O
edge	O
of	O
a	O
leaflet	O
of	O
the	O
compound	O
leaves	O
.	O

Leaflets	O
of	O
similar	O
size	O
(	O
176	O
+/-	O
58	O
cm2	O
,	O
n	O
=	O
12	O
)	O
were	O
used	O
.	O

Inspection	O
of	O
the	O
leaf	O
patches	O
after	O
removal	O
of	O
the	O
probes	O
under	O
the	O
microscope	O
revealed	O
no	O
changes	O
in	O
leaflet	O
appearance	O
beneath	O
the	O
pads	O
,	O
even	O
after	O
several	O
weeks	O
.	O

Lesions	O
on	O
the	O
leaves	O
were	O
never	O
found	O
.	O
<EOS>	B-X
Another	B-X
possibility	B-X
,	B-X
the	B-X
only	B-X
one	B-X
in	B-X
case	B-X
of	B-X
metastatic	B-X
BCC	B-X
,	B-X
was	B-X
chemotherapy	B-X
which	B-X
efficacy	B-X
has	B-X
never	B-X
been	B-X
proven	B-X
in	B-X
a	B-X
clinical	B-X
trial	B-X
.	B-X
This	B-X
leaves	B-X
about	B-X
40	B-X
%	B-X
who	B-X
have	B-X
not	B-X
benefited	B-X
or	B-X
in	B-X
a	B-X
few	B-X
cases	B-X
may	B-X
be	B-X
worse	B-X
.	B-X
Careful	B-X
safeguards	B-X
,	B-X
including	B-X
approval	B-X
by	B-X
an	B-X
independent	B-X
multidisciplinary	B-X
legally	B-X
constituted	B-X
review	B-X
board	B-X
are	B-X
mandatory	B-X
in	B-X
selecting	B-X
and	B-X
following	B-X
the	B-X
patients	B-X
,	B-X
but	B-X
unfortunately	B-X
,	B-X
there	B-X
are	B-X
individuals	B-X
who	B-X
are	B-X
never	B-X
referred	B-X
or	B-X
reside	B-X
in	B-X
a	B-X
society	B-X
which	B-X
proscribes	B-X
the	B-X
operation	B-X
,	B-X
whose	B-X
lives	B-X
could	B-X
be	B-X
made	B-X
more	B-X
tolerable	B-X
.	B-X
These	B-X
difficulties	B-X
are	B-X
mostly	B-X
due	B-X
to	B-X
the	B-X
fact	B-X
that	B-X
stained	B-X
2-dimensional	B-X
sections	B-X
can	B-X
never	B-X
truly	B-X
represent	B-X
the	B-X
3-dimensional	B-X
framework	B-X
of	B-X
the	B-X
intestinal	B-X
tissue	B-X
under	B-X
investigation	B-X
.	B-X

Only	O
occasionally	O
were	O
very	O
slight	O
impressions	O
of	O
the	O
pads	O
on	O
the	O
leaflet	O
surface	O
observed	O
.	O

Clamping	O
of	O
the	O
leaves	O
could	O
be	O
performed	O
at	O
any	O
time	O
of	O
the	O
day	O
.	O
<EOS>	B-X
A	B-X
base-line	B-X
PLR	B-X
measurement	B-X
is	B-X
captured	B-X
from	B-X
C57BL/6J	B-X
wild	B-X
type	B-X
mice	B-X
followed	B-X
by	B-X
a	B-X
single	B-X
intraperitoneal	B-X
administration	B-X
of	B-X
200	B-X
mg/kg	B-X
streptozotocin	B-X
(	B-X
STZ	B-X
)	B-X
and	B-X
citrate	B-X
buffer	B-X
(	B-X
vehicle	B-X
)	B-X
for	B-X
the	B-X
``	B-X
diabetic	B-X
''	B-X
(	B-X
n=5	B-X
)	B-X
and	B-X
``	B-X
control	B-X
''	B-X
(	B-X
n=5	B-X
)	B-X
mice	B-X
respectively	B-X
,	B-X
the	B-X
very	B-X
next	B-X
day	B-X
.	B-X
Immunohistochemistry	B-X
(	B-X
IHC	B-X
)	B-X
staining	B-X
of	B-X
mRGCs	B-X
and	B-X
RT-PCR	B-X
of	B-X
melanopsin	B-X
mRNA	B-X
are	B-X
performed	B-X
at	B-X
the	B-X
end-point	B-X
.	B-X
The	B-X
vascular	B-X
calibre	B-X
of	B-X
both	B-X
control	B-X
and	B-X
STZ-treated	B-X
diabetic	B-X
mice	B-X
is	B-X
assessed	B-X
via	B-X
in	B-X
vivo	B-X
fluorescein	B-X
angiography	B-X
(	B-X
FA	B-X
)	B-X
on	B-X
day	B-X
0	B-X
(	B-X
base-line	B-X
)	B-X
,	B-X
1/2	B-X
,	B-X
1	B-X
and	B-X
4	B-X
months	B-X
post-STZ	B-X
treatment	B-X
.	B-X
The	B-X
annual	B-X
sequence	B-X
of	B-X
sickness	B-X
leaves	B-X
was	B-X
studied	B-X
in	B-X
162	B-X
industrial	B-X
workers	B-X
with	B-X
a	B-X
high	B-X
absenteeism	B-X
level	B-X
.	B-X
An	B-X
investigation	B-X
of	B-X
the	B-X
swings	B-X
in	B-X
haemodynamic	B-X
balance	B-X
,	B-X
and	B-X
imbalances	B-X
linked	B-X
to	B-X
alternations	B-X
in	B-X
vessel	B-X
constriction	B-X
and	B-X
dilation	B-X
throughout	B-X
the	B-X
biorhythmic	B-X
cycle	B-X
influenced	B-X
by	B-X
the	B-X
alternation	B-X
of	B-X
night	B-X
and	B-X
day	B-X
,	B-X
hot	B-X
and	B-X
cold	B-X
seasons	B-X
,	B-X
showed	B-X
that	B-X
each	B-X
period	B-X
of	B-X
sick	B-X
leave	B-X
coincided	B-X
with	B-X
each	B-X
period	B-X
of	B-X
haemodynamic	B-X
balance	B-X
caused	B-X
by	B-X
particular	B-X
shifts	B-X
.	B-X

Clamp	O
pressures	O
,	O
Pclamp	O
,	O
applied	O
to	O
the	O
leaves	O
were	O
of	O
the	O
order	O
of	O
80	O
-	O
200	O
kPa	O
.	O

The	O
optimum	O
value	O
for	O
Pclamp	O
of	O
a	O
given	O
leaf	O
has	O
to	O
be	O
found	O
empirically	O
.	O

Experience	O
shows	O
that	O
Pclamp	O
values	O
could	O
be	O
considered	O
as	O
optimal	O
if	O
the	O
output	O
pressure	O
Pp	O
assumed	O
values	O
between	O
10	O
kPa	O
and	O
25	O
kPa	O
upon	O
clamping	O
in	O
the	O
early	O
morning	O
(	O
when	O
turgor	O
pressure	O
was	O
high	O
)	O
or	O
between	O
50	O
kPa	O
and	O
70	O
kPa	O
upon	O
clamping	O
around	O
noon	O
or	O
towards	O
early	O
afternoon	O
(	O
when	O
turgor	O
pressure	O
was	O
usually	O
low	O
)	O
.	O

The	O
magnitude	O
of	O
Pp	O
depended	O
on	O
the	O
compressibility	O
and	O
deformability	O
properties	O
of	O
the	O
individual	O
leaves	O
which	O
may	O
vary	O
considerably	O
due	O
to	O
age	O
,	O
morphology	O
,	O
leaf	O
thickness	O
,	O
abiotic	O
factors	O
etc	O
.	O

The	O
magnitude	O
of	O
Pclamp	O
had	O
no	O
effect	O
on	O
the	O
diurnal	O
profiles	O
of	O
Pp	O
,	O
in	O
response	O
to	O
changes	O
in	O
microclimate	O
and	O
/	O
or	O
changes	O
in	O
the	O
irrigation	O
regime	O
.	O
<EOS>	B-X
Compressed	B-X
vintages	B-X
,	B-X
high	B-X
alcohol	B-X
and	B-X
low	B-X
wine	B-X
acidity	B-X
are	B-X
but	B-X
a	B-X
few	B-X
repercussions	B-X
of	B-X
climate	B-X
change	B-X
effects	B-X
on	B-X
Australian	B-X
viticulture	B-X
.	B-X
Moreover	B-X
,	B-X
distorted	B-X
pest	B-X
and	B-X
disease	B-X
cycles	B-X
and	B-X
changes	B-X
in	B-X
pathogen	B-X
geographical	B-X
distribution	B-X
have	B-X
altered	B-X
biotic	B-X
stress	B-X
dynamics	B-X
that	B-X
require	B-X
novel	B-X
management	B-X
strategies	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
modifying	B-X
and	B-X
incorporating	B-X
novel	B-X
irrigation	B-X
regimes	B-X
,	B-X
vine	B-X
architecture	B-X
and	B-X
canopy	B-X
manipulation	B-X
,	B-X
vineyard	B-X
floor	B-X
management	B-X
,	B-X
soil	B-X
amendments	B-X
and	B-X
foliar	B-X
products	B-X
such	B-X
as	B-X
antitranspirants	B-X
and	B-X
other	B-X
film-forming	B-X
barriers	B-X
are	B-X
potential	B-X
levers	B-X
that	B-X
can	B-X
be	B-X
used	B-X
to	B-X
manage	B-X
the	B-X
effects	B-X
of	B-X
climate	B-X
change	B-X
.	B-X
This	B-X
research	B-X
analyzed	B-X
the	B-X
effect	B-X
of	B-X
agriculture	B-X
(	B-X
spring	B-X
onion-Allium	B-X
fistulosum	B-X
,	B-X
potato-Solanum	B-X
tuberosum	B-X
,	B-X
and	B-X
livestock	B-X
farming	B-X
)	B-X
on	B-X
water	B-X
quality	B-X
in	B-X
pÃ¡ramo	B-X
ecosystems	B-X
.	B-X
A	B-X
Hydrographic	B-X
Unit	B-X
upstream	B-X
of	B-X
the	B-X
Jordan	B-X
river	B-X
catchment	B-X
(	B-X
Colombia	B-X
)	B-X
was	B-X
selected	B-X
and	B-X
monitored	B-X
in	B-X
two	B-X
different	B-X
rainfall	B-X
regimes	B-X
,	B-X
following	B-X
the	B-X
paired	B-X
catchments	B-X
and	B-X
upstream-downstream	B-X
approaches	B-X
to	B-X
compare	B-X
water	B-X
quality	B-X
from	B-X
natural	B-X
and	B-X
anthropic	B-X
areas	B-X
.	B-X

Probes	O
clamped	O
on	O
the	O
same	O
leaflet	O
or	O
nearby	O
leaflets	O
of	O
leaves	O
responded	O
almost	O
identically	O
upon	O
temporary	O
changes	O
in	O
transpiration	O
and	O
/	O
or	O
water	O
supply	O
even	O
if	O
the	O
Pclamp	O
values	O
were	O
different	O
due	O
to	O
different	O
leaf	O
thickness	O
as	O
well	O
as	O
local	O
compressibility	O
and	O
deformability	O
properties	O
(	O
data	O
not	O
shown	O
)	O
.	O

This	O
was	O
found	O
over	O
the	O
entire	O
height	O
of	O
the	O
plants	O
.	O
<EOS>	B-X
Previous	B-X
evaluation	B-X
methods	B-X
are	B-X
not	B-X
suitable	B-X
for	B-X
assessing	B-X
the	B-X
impact	B-X
of	B-X
floods	B-X
on	B-X
the	B-X
biodiversity	B-X
of	B-X
all	B-X
species	B-X
in	B-X
the	B-X
entire	B-X
submerged	B-X
area	B-X
,	B-X
nor	B-X
do	B-X
they	B-X
accurately	B-X
reflect	B-X
variability	B-X
in	B-X
the	B-X
degree	B-X
of	B-X
impact	B-X
.	B-X
First	B-X
,	B-X
the	B-X
influencing	B-X
factors	B-X
were	B-X
boiled	B-X
down	B-X
to	B-X
four	B-X
:	B-X
ratio	B-X
of	B-X
flood	B-X
duration	B-X
to	B-X
survival	B-X
time	B-X
of	B-X
animals	B-X
in	B-X
floods	B-X
(	B-X
D	B-X
)	B-X
,	B-X
ratio	B-X
of	B-X
flood	B-X
depth	B-X
to	B-X
plant	B-X
height	B-X
(	B-X
S	B-X
)	B-X
,	B-X
migration	B-X
ability	B-X
of	B-X
animals	B-X
(	B-X
M	B-X
)	B-X
,	B-X
and	B-X
temperature	B-X
(	B-X
T	B-X
)	B-X
,	B-X
which	B-X
are	B-X
represented	B-X
by	B-X
a	B-X
coefficient	B-X
I	B-X
.	B-X
Finally	B-X
,	B-X
the	B-X
impact	B-X
of	B-X
extreme	B-X
floods	B-X
on	B-X
the	B-X
biodiversity	B-X
of	B-X
terrestrial	B-X
animals	B-X
in	B-X
the	B-X
submerged	B-X
area	B-X
was	B-X
evaluated	B-X
monthly	B-X
,	B-X
and	B-X
it	B-X
was	B-X
found	B-X
that	B-X
(	B-X
1	B-X
)	B-X
TBI	B-X
and	B-X
ABI	B-X
changed	B-X
with	B-X
space	B-X
;	B-X
(	B-X
2	B-X
)	B-X
the	B-X
ABI	B-X
of	B-X
different	B-X
animals	B-X
in	B-X
descending	B-X
order	B-X
were	B-X
mammals	B-X
,	B-X
insects	B-X
,	B-X
reptiles	B-X
,	B-X
amphibians	B-X
,	B-X
and	B-X
birds	B-X
;	B-X
(	B-X
3	B-X
)	B-X
the	B-X
ABI	B-X
of	B-X
different	B-X
land	B-X
use	B-X
types	B-X
in	B-X
descending	B-X
order	B-X
were	B-X
cropland	B-X
,	B-X
orchard	B-X
and	B-X
shrubland	B-X
,	B-X
grassland	B-X
,	B-X
and	B-X
forest	B-X
and	B-X
for	B-X
TBI	B-X
were	B-X
orchard	B-X
and	B-X
shrubland	B-X
,	B-X
cropland	B-X
,	B-X
forest	B-X
,	B-X
and	B-X
grassland	B-X
;	B-X
and	B-X
(	B-X
4	B-X
)	B-X
the	B-X
TBI	B-X
and	B-X
ABI	B-X
of	B-X
different	B-X
animals	B-X
and	B-X
land	B-X
use	B-X
types	B-X
changed	B-X
over	B-X
time	B-X
.	B-X
The	B-X
LiDAR	B-X
mean	B-X
top	B-X
canopy	B-X
height	B-X
measurements	B-X
were	B-X
trained	B-X
to	B-X
develop	B-X
an	B-X
unbiased	B-X
carbon	B-X
estimator	B-X
by	B-X
using	B-X
92	B-X
1-ha	B-X
ground	B-X
plots	B-X
distributed	B-X
across	B-X
key	B-X
forest	B-X
types	B-X
in	B-X
DRC	B-X
.	B-X
LiDAR	B-X
samples	B-X
provided	B-X
estimates	B-X
of	B-X
mean	B-X
and	B-X
uncertainty	B-X
of	B-X
aboveground	B-X
carbon	B-X
density	B-X
at	B-X
provincial	B-X
scales	B-X
and	B-X
were	B-X
combined	B-X
with	B-X
optical	B-X
and	B-X
radar	B-X
satellite	B-X
imagery	B-X
in	B-X
a	B-X
machine	B-X
learning	B-X
algorithm	B-X
to	B-X
map	B-X
forest	B-X
height	B-X
and	B-X
carbon	B-X
density	B-X
over	B-X
the	B-X
entire	B-X
country	B-X
.	B-X
By	B-X
using	B-X
the	B-X
forest	B-X
definition	B-X
of	B-X
DRC	B-X
,	B-X
we	B-X
found	B-X
a	B-X
total	B-X
of	B-X
23.3	B-X
Â±	B-X
1.6	B-X
GtC	B-X
carbon	B-X
with	B-X
a	B-X
mean	B-X
carbon	B-X
density	B-X
of	B-X
140	B-X
Â±	B-X
9	B-X
MgC	B-X
ha	B-X

Screening	O
experiments	O
proved	O
further	O
that	O
a	O
high	O
surface	O
roughness	O
prevented	O
a	O
uniform	O
contact	O
between	O
the	O
pads	O
of	O
the	O
probe	O
and	O
the	O
leaf	O
.	O

Non	O
-	O
uniform	O
contact	O
resulted	O
in	O
a	O
reduced	O
pressure	O
response	O
of	O
the	O
probe	O
(	O
data	O
not	O
shown	O
)	O
.	O

Thus	O
,	O
in	O
order	O
to	O
obtain	O
maximum	O
resolution	O
of	O
microclimate	O
-	O
induced	O
and	O
/	O
or	O
plant	O
-	O
based	O
effects	O
on	O
the	O
Pp	O
values	O
,	O
it	O
was	O
crucial	O
that	O
the	O
probe	O
was	O
placed	O
on	O
relatively	O
smooth	O
areas	O
,	O
i	O
.	O
e	O
.	O
preferentially	O
between	O
the	O
veins	O
rather	O
than	O
on	O
the	O
veins	O
in	O
order	O
to	O
guarantee	O
a	O
uniform	O
pressure	O
transmission	O
.	O

It	O
also	O
turned	O
out	O
that	O
areas	O
with	O
lesions	O
or	O
covered	O
with	O
dust	O
should	O
be	O
avoided	O
.	O
<EOS>	B-X
The	B-X
persistently	B-X
high	B-X
prevalence	B-X
of	B-X
allergic	B-X
diseases	B-X
in	B-X
Western	B-X
industrial	B-X
nations	B-X
and	B-X
the	B-X
limited	B-X
possibilities	B-X
of	B-X
causal	B-X
therapy	B-X
make	B-X
evidence-based	B-X
recommendations	B-X
for	B-X
primary	B-X
prevention	B-X
necessary	B-X
.	B-X
Currently	B-X
,	B-X
therapy	B-X
of	B-X
AD	B-X
is	B-X
mainly	B-X
based	B-X
on	B-X
symptomatic	B-X
treatment	B-X
and	B-X
avoidance	B-X
of	B-X
irritating/allergenic	B-X
factors	B-X
,	B-X
house	B-X
dust	B-X
mites	B-X
being	B-X
particularly	B-X
important	B-X
.	B-X
Areas	B-X
covered	B-X
:	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
review	B-X
is	B-X
investigating	B-X
the	B-X
putative	B-X
role	B-X
of	B-X
AIT	B-X
in	B-X
AD	B-X
through	B-X
the	B-X
evaluation	B-X
of	B-X
the	B-X
most	B-X
recent	B-X
scientific	B-X
literature	B-X
.	B-X
Light	B-X
,	B-X
humidity	B-X
,	B-X
temperature	B-X
,	B-X
dust	B-X
pollution	B-X
and	B-X
,	B-X
undoubtedly	B-X
,	B-X
microorganisms	B-X
lead	B-X
to	B-X
the	B-X
deterioration	B-X
of	B-X
optical	B-X
and	B-X
mechanical	B-X
properties	B-X
.	B-X
However	B-X
,	B-X
the	B-X
polysiloxane	B-X
coatings	B-X
themselves	B-X
also	B-X
can	B-X
not	B-X
avoid	B-X
deterioration	B-X
during	B-X
operation	B-X
that	B-X
implies	B-X
the	B-X
constant	B-X
development	B-X
of	B-X
new	B-X
protective	B-X
materials	B-X
.	B-X

Probably	O
due	O
to	O
the	O
absence	O
of	O
dust	O
,	O
high	O
resolution	O
results	O
were	O
obtained	O
when	O
the	O
sensor	O
-	O
containing	O
pad	O
faced	O
the	O
abaxial	O
side	O
,	O
but	O
not	O
the	O
adaxial	O
side	O
of	O
the	O
leaf	O
.	O

Diurnal	O
changes	O
in	O
the	O
patch	O
clamp	O
pressure	O
<EOS>	B-X
The	B-X
non-invasive	B-X
leaf	B-X
patch	B-X
clamp	B-X
pressure	B-X
(	B-X
LPCP	B-X
)	B-X
probe	B-X
measures	B-X
the	B-X
attenuated	B-X
pressure	B-X
of	B-X
a	B-X
leaf	B-X
patch	B-X
,	B-X
P	B-X
(	B-X
p	B-X
)	B-X
,	B-X
in	B-X
response	B-X
to	B-X
an	B-X
externally	B-X
applied	B-X
magnetic	B-X
force	B-X
.	B-X
P	B-X
(	B-X
p	B-X
)	B-X
is	B-X
inversely	B-X
coupled	B-X
with	B-X
leaf	B-X
turgor	B-X
pressure	B-X
,	B-X
P	B-X
(	B-X
c	B-X
)	B-X
,	B-X
i.e	B-X
.	B-X
This	B-X
relationship	B-X
between	B-X
P	B-X
(	B-X
c	B-X
)	B-X
and	B-X
P	B-X
(	B-X
p	B-X
)	B-X
could	B-X
also	B-X
be	B-X
verified	B-X
for	B-X
2-m	B-X
tall	B-X
olive	B-X
trees	B-X
under	B-X
laboratory	B-X
conditions	B-X
using	B-X
the	B-X
cell	B-X
turgor	B-X
pressure	B-X
probe	B-X
.	B-X
50	B-X
kPa	B-X
)	B-X
,	B-X
P	B-X
(	B-X
p	B-X
)	B-X
curves	B-X
show	B-X
reverse	B-X
diurnal	B-X
changes	B-X
,	B-X
i.e	B-X
.	B-X
Upon	B-X
watering	B-X
,	B-X
the	B-X
original	B-X
diurnal	B-X
P	B-X
(	B-X
p	B-X
)	B-X
changes	B-X
were	B-X
re-established	B-X
within	B-X
2-3	B-X
days	B-X
.	B-X
Significantly	B-X
larger	B-X
amounts	B-X
of	B-X
air	B-X
could	B-X
also	B-X
be	B-X
extracted	B-X
from	B-X
water-stressed	B-X
leaves	B-X
than	B-X
from	B-X
well-watered	B-X
leaves	B-X
using	B-X
the	B-X
cell	B-X
turgor	B-X
pressure	B-X
probe	B-X
.	B-X
Furthermore	B-X
,	B-X
theoretical	B-X
analysis	B-X
of	B-X
the	B-X
experimental	B-X
P	B-X
(	B-X
p	B-X
)	B-X
curves	B-X
shows	B-X
that	B-X
the	B-X
propagation	B-X
of	B-X
pressure	B-X
through	B-X
the	B-X
nearly	B-X
turgorless	B-X
leaf	B-X
must	B-X
be	B-X
exclusively	B-X
dictated	B-X
by	B-X
air	B-X
.	B-X

Figure	O
2A	O
represents	O
Pp	O
recordings	O
conducted	O
on	O
the	O
10	O
m	O
tall	O
liana	O
on	O
24	O
May	O
and	O
25	O
May	O
,	O
2007	O
.	O

The	O
plant	O
was	O
well	O
-	O
watered	O
before	O
the	O
beginning	O
of	O
the	O
measurements	O
(	O
22	O
May	O
)	O
and	O
was	O
also	O
watered	O
regularly	O
during	O
the	O
experimental	O
period	O
.	O

The	O
sufficient	O
supply	O
of	O
the	O
leaves	O
with	O
water	O
was	O
indicated	O
by	O
high	O
turgor	O
pressure	O
values	O
of	O
c	O
.	O

500	O
kPa	O
at	O
predawn	O
and	O
guttation	O
up	O
to	O
a	O
height	O
of	O
6	O
m	O
around	O
sunrise	O
(	O
see	O
also	O
Th	O
u	O
rmer	O
et	O
al	O
.	O
,	O
1999	O
)	O
.	O

Diurnal	O
changes	O
of	O
the	O
Pp	O
values	O
were	O
recorded	O
simultaneously	O
at	O
0	O
.	O
2	O
m	O
,	O
6	O
m	O
,	O
and	O
10	O
m	O
height	O
.	O

The	O
corresponding	O
diurnal	O
changes	O
in	O
the	O
ambient	O
temperature	O
,	O
T	O
,	O
and	O
relative	O
humidity	O
,	O
r	O
.	O
h	O
.	O
,	O
measured	O
close	O
to	O
the	O
sites	O
of	O
the	O
patch	O
clamp	O
pressure	O
probes	O
,	O
are	O
given	O
in	O
Fig	O
.	O

2B	O
and	O
C	O
.	O

It	O
was	O
very	O
sunny	O
on	O
24	O
May	O
resulting	O
in	O
a	O
rapid	O
heating	O
-	O
up	O
of	O
the	O
greenhouse	O
,	O
particularly	O
in	O
the	O
upper	O
part	O
.	O

This	O
led	O
to	O
the	O
development	O
of	O
large	O
vertical	O
gradients	O
in	O
T	O
and	O
r	O
.	O
h	O
.	O
along	O
the	O
stem	O
of	O
the	O
liana	O
(	O
Fig	O
.	O
2B	O
,	O
C	O
)	O
.	O

Because	O
sunlight	O
was	O
dimmed	O
by	O
operation	O
of	O
the	O
automatic	O
blinds	O
at	O
noon	O
(	O
see	O
Materials	O
and	O
methods	O
)	O
the	O
gradients	O
did	O
not	O
reach	O
maximum	O
values	O
before	O
the	O
afternoon	O
.	O

Between	O
15	O
.	O
30	O
h	O
and	O
16	O
.	O
30	O
h	O
an	O
ambient	O
temperature	O
of	O
44	O
degrees	O
C	O
and	O
a	O
relative	O
humidity	O
of	O
20	O
%	O
were	O
recorded	O
at	O
the	O
top	O
of	O
the	O
liana	O
,	O
whereas	O
at	O
0	O
.	O
2	O
m	O
height	O
T	O
and	O
r	O
.	O
h	O
.	O
were	O
27	O
degrees	O
C	O
and	O
70	O
%	O
,	O
respectively	O
.	O

The	O
gradients	O
in	O
T	O
and	O
r	O
.	O
h	O
.	O
disappeared	O
at	O
c	O
.	O

22	O
.	O
00	O
h	O
.	O
<EOS>	B-X
Little	B-X
is	B-X
known	B-X
about	B-X
chronopharmacokinetics	B-X
of	B-X
PDE	B-X
V	B-X
inhibitors	B-X
in	B-X
rats	B-X
as	B-X
well	B-X
as	B-X
in	B-X
humans	B-X
.	B-X
Hence	B-X
,	B-X
the	B-X
pharmacokinetics	B-X
of	B-X
DA-8159	B-X
and	B-X
one	B-X
of	B-X
its	B-X
metabolites	B-X
,	B-X
DA-8164	B-X
,	B-X
were	B-X
investigated	B-X
after	B-X
intravenous	B-X
and	B-X
oral	B-X
administration	B-X
of	B-X
DA-8159	B-X
at	B-X
a	B-X
dose	B-X
of	B-X
30	B-X
mg/kg	B-X
administered	B-X
at	B-X
10:00	B-X
h	B-X
versus	B-X
22:00	B-X
h	B-X
in	B-X
rats	B-X
.	B-X
After	B-X
intravenous	B-X
administration	B-X
of	B-X
DA-8159	B-X
at	B-X
22:00	B-X
h	B-X
,	B-X
the	B-X
AUC	B-X
of	B-X
DA-8159	B-X
was	B-X
significantly	B-X
greater	B-X
(	B-X
528	B-X
versus	B-X
368	B-X
microg	B-X
min/ml	B-X
)	B-X
due	B-X
to	B-X
significantly	B-X
slower	B-X
CL	B-X
(	B-X
56.1	B-X
versus	B-X
79.5	B-X
ml/min/kg	B-X
)	B-X
in	B-X
the	B-X
rats	B-X
.	B-X
After	B-X
intravenous	B-X
administration	B-X
of	B-X
DA-8159	B-X
at	B-X
22:00	B-X
h	B-X
,	B-X
the	B-X
AUC	B-X
of	B-X
DA-8164	B-X
was	B-X
also	B-X
significantly	B-X
greater	B-X
(	B-X
108	B-X
versus	B-X
66.8	B-X
microg	B-X
min/ml	B-X
)	B-X
possibly	B-X
due	B-X
to	B-X
significantly	B-X
greater	B-X
exposure	B-X
of	B-X
the	B-X
parent	B-X
drug	B-X
(	B-X
AUC	B-X
of	B-X
DA-8159	B-X
)	B-X
.	B-X
After	B-X
intravenous	B-X
administration	B-X
of	B-X
DA-8164	B-X
at	B-X
22:00	B-X
h	B-X
,	B-X
the	B-X
CL	B-X
of	B-X
DA-8164	B-X
was	B-X
significantly	B-X
slower	B-X
;	B-X
hence	B-X
,	B-X
this	B-X
factor	B-X
could	B-X
also	B-X
contribute	B-X
to	B-X
the	B-X
greater	B-X
AUC	B-X
of	B-X
DA-8164	B-X
after	B-X
intravenous	B-X
administration	B-X
of	B-X
DA-8159	B-X
.	B-X
However	B-X
,	B-X
after	B-X
oral	B-X
administration	B-X
of	B-X
DA-8159	B-X
,	B-X
the	B-X
AUC	B-X
values	B-X
of	B-X
both	B-X
DA-8159	B-X
and	B-X
DA-8164	B-X
were	B-X
not	B-X
significantly	B-X
different	B-X
between	B-X
10:00	B-X
h	B-X
and	B-X
22:00	B-X
h.	B-X
This	B-X
was	B-X
not	B-X
due	B-X
to	B-X
decrease	B-X
in	B-X
gastrointestinal	B-X
absorption	B-X
of	B-X
DA-8159	B-X
at	B-X
22:00	B-X
h	B-X
and	B-X
may	B-X
be	B-X
due	B-X
to	B-X
changes	B-X
in	B-X
intestinal	B-X
first-pass	B-X
effect	B-X
at	B-X
22:00	B-X
h.	B-X
The	B-X
above	B-X
data	B-X
suggested	B-X
that	B-X
modification	B-X
of	B-X
dosage	B-X
regimen	B-X
of	B-X
oral	B-X
DA-8159	B-X
is	B-X
not	B-X
necessary	B-X
in	B-X
humans	B-X
between	B-X
10:00	B-X
h	B-X
and	B-X
22:00	B-X
h.	B-X
Further	B-X
studies	B-X
are	B-X
needed	B-X
in	B-X
humans	B-X
.	B-X

Due	O
to	O
the	O
dense	O
foliage	O
of	O
the	O
plant	O
above	O
c	O
.	O

7	O
m	O
and	O
due	O
to	O
light	O
dimming	O
by	O
the	O
blinds	O
,	O
leaves	O
closer	O
to	O
the	O
ground	O
only	O
became	O
exposed	O
to	O
direct	O
sunshine	O
towards	O
the	O
early	O
afternoon	O
.	O

In	O
contrast	O
to	O
24	O
May	O
,	O
the	O
following	O
day	O
was	O
cloudy	O
until	O
noon	O
.	O

Thus	O
,	O
leaves	O
in	O
the	O
upper	O
part	O
of	O
the	O
liana	O
became	O
fully	O
exposed	O
to	O
bright	O
sunshine	O
first	O
around	O
14	O
.	O
00	O
h	O
as	O
indicated	O
by	O
the	O
rapid	O
increase	O
in	O
T	O
and	O
the	O
corresponding	O
decrease	O
of	O
r	O
.	O
h	O
.	O
above	O
a	O
height	O
of	O
6	O
m	O
(	O
Fig	O
.	O
2B	O
,	O
C	O
)	O
.	O

Despite	O
the	O
strongly	O
delayed	O
exposure	O
of	O
the	O
leaves	O
to	O
sunshine	O
,	O
comparable	O
maximum	O
values	O
for	O
T	O
and	O
r	O
.	O
h	O
.	O
at	O
the	O
three	O
measuring	O
sites	O
,	O
as	O
well	O
as	O
vertical	O
gradients	O
in	O
T	O
and	O
r	O
.	O
h	O
.	O
of	O
comparable	O
size	O
,	O
were	O
measured	O
between	O
15	O
.	O
30	O
h	O
and	O
16	O
.	O
30	O
h	O
as	O
on	O
the	O
day	O
before	O
.	O

Inspection	O
of	O
Fig	O
.	O
<EOS>	B-X
The	B-X
corresponding	B-X
author	B-X
,	B-X
Dr	B-X
Byoungduck	B-X
Park	B-X
,	B-X
requested	B-X
publication	B-X
of	B-X
a	B-X
corrigendum	B-X
to	B-X
correct	B-X
Fig	B-X
.	B-X
Upon	B-X
further	B-X
inspection	B-X
,	B-X
the	B-X
Biochimie	B-X
editorial	B-X
team	B-X
noticed	B-X
that	B-X
:	B-X
Comparison	B-X
of	B-X
Fig	B-X
.	B-X
2B	B-X
with	B-X
Fig	B-X
.	B-X
4C	B-X
of	B-X
a	B-X
previous	B-X
publication	B-X
in	B-X
International	B-X
Immunopharmacology	B-X
by	B-X
two	B-X
co-authors	B-X
(	B-X
doi	B-X
:	B-X
10.1016/j.intimp.2015.02.014	B-X
)	B-X
reveals	B-X
that	B-X
western	B-X
blot	B-X
Î²-actin	B-X
control	B-X
data	B-X
from	B-X
the	B-X
earlier	B-X
paper	B-X
were	B-X
re-used	B-X
in	B-X
a	B-X
different	B-X
experiment	B-X
shown	B-X
in	B-X
Fig	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
same	B-X
bands	B-X
,	B-X
after	B-X
more	B-X
image	B-X
manipulation	B-X
were	B-X
presented	B-X
as	B-X
Smad3	B-X
data	B-X
in	B-X
Fig	B-X
.	B-X

2	O
shows	O
that	O
the	O
diurnal	O
changes	O
of	O
T	O
and	O
r	O
.	O
h	O
.	O
at	O
the	O
three	O
measuring	O
sites	O
are	O
reflected	O
in	O
corresponding	O
changes	O
of	O
Pp	O
.	O

During	O
the	O
nights	O
the	O
Pp	O
values	O
were	O
low	O
.	O
<EOS>	B-X
The	B-X
effects	B-X
on	B-X
rapid	B-X
eye	B-X
movement	B-X
(	B-X
REM	B-X
)	B-X
sleep	B-X
in	B-X
the	B-X
first	B-X
half	B-X
of	B-X
sleep	B-X
appear	B-X
to	B-X
be	B-X
dose	B-X
related	B-X
with	B-X
low	B-X
and	B-X
moderate	B-X
doses	B-X
showing	B-X
no	B-X
clear	B-X
trend	B-X
on	B-X
REM	B-X
sleep	B-X
in	B-X
the	B-X
first	B-X
half	B-X
of	B-X
the	B-X
night	B-X
whereas	B-X
at	B-X
high	B-X
doses	B-X
,	B-X
REM	B-X
sleep	B-X
reduction	B-X
in	B-X
the	B-X
first	B-X
part	B-X
of	B-X
sleep	B-X
is	B-X
significant	B-X
.	B-X
Total	B-X
night	B-X
REM	B-X
sleep	B-X
percentage	B-X
is	B-X
decreased	B-X
in	B-X
the	B-X
majority	B-X
of	B-X
studies	B-X
at	B-X
moderate	B-X
and	B-X
high	B-X
doses	B-X
with	B-X
no	B-X
clear	B-X
trend	B-X
apparent	B-X
at	B-X
low	B-X
doses	B-X
.	B-X
The	B-X
onset	B-X
of	B-X
the	B-X
first	B-X
REM	B-X
sleep	B-X
period	B-X
is	B-X
significantly	B-X
delayed	B-X
at	B-X
all	B-X
doses	B-X
and	B-X
appears	B-X
to	B-X
be	B-X
the	B-X
most	B-X
recognizable	B-X
effect	B-X
of	B-X
alcohol	B-X
on	B-X
REM	B-X
sleep	B-X
followed	B-X
by	B-X
the	B-X
reduction	B-X
in	B-X
total	B-X
night	B-X
REM	B-X
sleep	B-X
.	B-X
The	B-X
majority	B-X
of	B-X
studies	B-X
,	B-X
across	B-X
dose	B-X
,	B-X
age	B-X
and	B-X
gender	B-X
,	B-X
confirm	B-X
an	B-X
increase	B-X
in	B-X
slow	B-X
wave	B-X
sleep	B-X
(	B-X
SWS	B-X
)	B-X
in	B-X
the	B-X
first	B-X
half	B-X
of	B-X
the	B-X
night	B-X
relative	B-X
to	B-X
baseline	B-X
values	B-X
.	B-X

After	O
sunrise	O
at	O
04	O
.	O
24	O
h	O
the	O
Pp	O
values	O
remained	O
low	O
for	O
further	O
4	O
-	O
5	O
h	O
,	O
except	O
at	O
6	O
m	O
height	O
where	O
a	O
slight	O
and	O
continuous	O
increase	O
in	O
the	O
Pp	O
values	O
was	O
very	O
often	O
recorded	O
.	O

After	O
about	O
09	O
.	O
00	O
h	O
the	O
Pp	O
values	O
increased	O
over	O
the	O
entire	O
height	O
of	O
the	O
liana	O
.	O

Peaking	O
of	O
the	O
Pp	O
values	O
occurred	O
between	O
15	O
.	O
30	O
h	O
and	O
16	O
.	O
30	O
h	O
at	O
all	O
heights	O
when	O
the	O
T	O
and	O
r	O
.	O
h	O
.	O
gradients	O
reached	O
maximum	O
values	O
.	O

Towards	O
the	O
evening	O
the	O
Pp	O
values	O
decreased	O
again	O
in	O
order	O
to	O
reach	O
the	O
original	O
low	O
values	O
at	O
c	O
.	O

22	O
.	O
00	O
h	O
.	O
<EOS>	B-X
Little	B-X
is	B-X
known	B-X
about	B-X
chronopharmacokinetics	B-X
of	B-X
PDE	B-X
V	B-X
inhibitors	B-X
in	B-X
rats	B-X
as	B-X
well	B-X
as	B-X
in	B-X
humans	B-X
.	B-X
Hence	B-X
,	B-X
the	B-X
pharmacokinetics	B-X
of	B-X
DA-8159	B-X
and	B-X
one	B-X
of	B-X
its	B-X
metabolites	B-X
,	B-X
DA-8164	B-X
,	B-X
were	B-X
investigated	B-X
after	B-X
intravenous	B-X
and	B-X
oral	B-X
administration	B-X
of	B-X
DA-8159	B-X
at	B-X
a	B-X
dose	B-X
of	B-X
30	B-X
mg/kg	B-X
administered	B-X
at	B-X
10:00	B-X
h	B-X
versus	B-X
22:00	B-X
h	B-X
in	B-X
rats	B-X
.	B-X
After	B-X
intravenous	B-X
administration	B-X
of	B-X
DA-8159	B-X
at	B-X
22:00	B-X
h	B-X
,	B-X
the	B-X
AUC	B-X
of	B-X
DA-8159	B-X
was	B-X
significantly	B-X
greater	B-X
(	B-X
528	B-X
versus	B-X
368	B-X
microg	B-X
min/ml	B-X
)	B-X
due	B-X
to	B-X
significantly	B-X
slower	B-X
CL	B-X
(	B-X
56.1	B-X
versus	B-X
79.5	B-X
ml/min/kg	B-X
)	B-X
in	B-X
the	B-X
rats	B-X
.	B-X
After	B-X
intravenous	B-X
administration	B-X
of	B-X
DA-8159	B-X
at	B-X
22:00	B-X
h	B-X
,	B-X
the	B-X
AUC	B-X
of	B-X
DA-8164	B-X
was	B-X
also	B-X
significantly	B-X
greater	B-X
(	B-X
108	B-X
versus	B-X
66.8	B-X
microg	B-X
min/ml	B-X
)	B-X
possibly	B-X
due	B-X
to	B-X
significantly	B-X
greater	B-X
exposure	B-X
of	B-X
the	B-X
parent	B-X
drug	B-X
(	B-X
AUC	B-X
of	B-X
DA-8159	B-X
)	B-X
.	B-X
After	B-X
intravenous	B-X
administration	B-X
of	B-X
DA-8164	B-X
at	B-X
22:00	B-X
h	B-X
,	B-X
the	B-X
CL	B-X
of	B-X
DA-8164	B-X
was	B-X
significantly	B-X
slower	B-X
;	B-X
hence	B-X
,	B-X
this	B-X
factor	B-X
could	B-X
also	B-X
contribute	B-X
to	B-X
the	B-X
greater	B-X
AUC	B-X
of	B-X
DA-8164	B-X
after	B-X
intravenous	B-X
administration	B-X
of	B-X
DA-8159	B-X
.	B-X
However	B-X
,	B-X
after	B-X
oral	B-X
administration	B-X
of	B-X
DA-8159	B-X
,	B-X
the	B-X
AUC	B-X
values	B-X
of	B-X
both	B-X
DA-8159	B-X
and	B-X
DA-8164	B-X
were	B-X
not	B-X
significantly	B-X
different	B-X
between	B-X
10:00	B-X
h	B-X
and	B-X
22:00	B-X
h.	B-X
This	B-X
was	B-X
not	B-X
due	B-X
to	B-X
decrease	B-X
in	B-X
gastrointestinal	B-X
absorption	B-X
of	B-X
DA-8159	B-X
at	B-X
22:00	B-X
h	B-X
and	B-X
may	B-X
be	B-X
due	B-X
to	B-X
changes	B-X
in	B-X
intestinal	B-X
first-pass	B-X
effect	B-X
at	B-X
22:00	B-X
h.	B-X
The	B-X
above	B-X
data	B-X
suggested	B-X
that	B-X
modification	B-X
of	B-X
dosage	B-X
regimen	B-X
of	B-X
oral	B-X
DA-8159	B-X
is	B-X
not	B-X
necessary	B-X
in	B-X
humans	B-X
between	B-X
10:00	B-X
h	B-X
and	B-X
22:00	B-X
h.	B-X
Further	B-X
studies	B-X
are	B-X
needed	B-X
in	B-X
humans	B-X
.	B-X

Until	O
peaking	O
in	O
the	O
afternoon	O
,	O
more	O
or	O
less	O
pronounced	O
fluctuations	O
of	O
the	O
Pp	O
values	O
were	O
seen	O
.	O
<EOS>	B-X
Age-adjusted	B-X
voxelwise	B-X
fractional	B-X
amplitude	B-X
of	B-X
low-frequency	B-X
fluctuations	B-X
(	B-X
fALFF	B-X
;	B-X
0.01-0.08	B-X
Hz	B-X
)	B-X
of	B-X
the	B-X
BOLD	B-X
signal	B-X
was	B-X
compared	B-X
among	B-X
the	B-X
three	B-X
groups	B-X
.	B-X
Significant	B-X
main	B-X
effects	B-X
of	B-X
Group	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
revealed	B-X
decreased	B-X
fALFF	B-X
in	B-X
ESZ	B-X
and	B-X
CHR	B-X
groups	B-X
relative	B-X
to	B-X
HCs	B-X
,	B-X
with	B-X
values	B-X
in	B-X
the	B-X
CHR	B-X
group	B-X
falling	B-X
between	B-X
those	B-X
of	B-X
ESZ	B-X
and	B-X
HC	B-X
groups	B-X
.	B-X
These	B-X
data	B-X
support	B-X
an	B-X
intermediate	B-X
phenotype	B-X
of	B-X
reduced	B-X
posterior	B-X
cortical	B-X
LFO	B-X
amplitude	B-X
in	B-X
CHR	B-X
individuals	B-X
,	B-X
with	B-X
resting	B-X
fALFF	B-X
values	B-X
smaller	B-X
than	B-X
in	B-X
HCs	B-X
but	B-X
higher	B-X
than	B-X
in	B-X
ESZ	B-X
patients	B-X
.	B-X
Findings	B-X
indicate	B-X
that	B-X
LFO	B-X
magnitude	B-X
alterations	B-X
relate	B-X
to	B-X
clinical	B-X
symptoms	B-X
and	B-X
predate	B-X
psychosis	B-X
onset	B-X
but	B-X
are	B-X
more	B-X
pronounced	B-X
in	B-X
the	B-X
early	B-X
stages	B-X
of	B-X
schizophrenia	B-X
.	B-X

A	O
part	O
of	O
these	O
fluctuations	O
seemed	O
to	O
be	O
correlated	O
with	O
changes	O
in	O
the	O
local	O
ambient	O
temperature	O
,	O
relative	O
humidity	O
and	O
/	O
or	O
with	O
a	O
temporary	O
exposure	O
of	O
the	O
clamped	O
leaflet	O
to	O
sunshine	O
(	O
compare	O
Fig	O
.	O
2A	O
with	O
Fig	O
.	O
2B	O
,	O
C	O
)	O
.	O

However	O
,	O
there	O
was	O
also	O
a	O
considerable	O
number	O
of	O
fluctuations	O
which	O
could	O
not	O
be	O
traced	O
back	O
to	O
changes	O
in	O
the	O
microclimate	O
.	O
<EOS>	B-X
Apart	B-X
from	B-X
the	B-X
risk	B-X
of	B-X
developing	B-X
glaucoma	B-X
there	B-X
is	B-X
also	B-X
the	B-X
risk	B-X
that	B-X
it	B-X
is	B-X
not	B-X
detected	B-X
and	B-X
irreversible	B-X
loss	B-X
of	B-X
vision	B-X
ensues	B-X
.	B-X
However	B-X
,	B-X
negative	B-X
family	B-X
histories	B-X
can	B-X
often	B-X
be	B-X
unreliable	B-X
due	B-X
to	B-X
large	B-X
numbers	B-X
of	B-X
glaucoma	B-X
cases	B-X
being	B-X
undiagnosed	B-X
.	B-X
In	B-X
examining	B-X
the	B-X
potential	B-X
diagnostic	B-X
contribution	B-X
from	B-X
a	B-X
patient	B-X
history	B-X
,	B-X
this	B-X
review	B-X
considers	B-X
,	B-X
age	B-X
,	B-X
frailty	B-X
,	B-X
race	B-X
,	B-X
type	B-X
and	B-X
degree	B-X
of	B-X
refractive	B-X
error	B-X
,	B-X
systemic	B-X
hyper-	B-X
and	B-X
hypotension	B-X
,	B-X
vasospasm	B-X
,	B-X
migraine	B-X
,	B-X
pigmentary	B-X
dispersion	B-X
syndrome	B-X
,	B-X
pseudoexfoliation	B-X
syndrome	B-X
,	B-X
obstructive	B-X
sleep	B-X
apnea	B-X
syndrome	B-X
,	B-X
diabetes	B-X
,	B-X
medication	B-X
interactions	B-X
and	B-X
side	B-X
effects	B-X
,	B-X
the	B-X
degree	B-X
of	B-X
exposure	B-X
to	B-X
intraocular	B-X
and	B-X
intracranial	B-X
pressure	B-X
elevations	B-X
and	B-X
fluctuations	B-X
,	B-X
smoking	B-X
,	B-X
and	B-X
symptoms	B-X
in	B-X
addition	B-X
to	B-X
genetics	B-X
and	B-X
family	B-X
history	B-X
of	B-X
the	B-X
disease	B-X
.	B-X
Special	B-X
consideration	B-X
related	B-X
to	B-X
the	B-X
diagnosis	B-X
and	B-X
management	B-X
in	B-X
women	B-X
during	B-X
pregnancy	B-X
and	B-X
in	B-X
children	B-X
will	B-X
also	B-X
be	B-X
reviewed	B-X
.	B-X
This	B-X
article	B-X
also	B-X
includes	B-X
an	B-X
overview	B-X
of	B-X
congenital	B-X
myasthenic	B-X
syndromes	B-X
.	B-X

An	O
example	O
can	O
be	O
found	O
in	O
Fig	O
.	O
<EOS>	B-X
It	B-X
is	B-X
now	B-X
clear	B-X
that	B-X
PCOS	B-X
is	B-X
often	B-X
associated	B-X
with	B-X
profound	B-X
insulin	B-X
resistance	B-X
as	B-X
well	B-X
as	B-X
with	B-X
defects	B-X
in	B-X
insulin	B-X
secretion	B-X
.	B-X
A	B-X
factor	B-X
extrinsic	B-X
to	B-X
the	B-X
insulin	B-X
receptor	B-X
,	B-X
presumably	B-X
a	B-X
serine/threonine	B-X
kinase	B-X
,	B-X
causes	B-X
this	B-X
abnormality	B-X
and	B-X
is	B-X
an	B-X
example	B-X
of	B-X
an	B-X
important	B-X
new	B-X
mechanism	B-X
for	B-X
human	B-X
insulin	B-X
resistance	B-X
related	B-X
to	B-X
factors	B-X
controlling	B-X
insulin	B-X
receptor	B-X
signaling	B-X
.	B-X
It	B-X
is	B-X
thus	B-X
possible	B-X
that	B-X
a	B-X
single	B-X
defect	B-X
produces	B-X
both	B-X
the	B-X
insulin	B-X
resistance	B-X
and	B-X
the	B-X
hyperandrogenism	B-X
in	B-X
some	B-X
PCOS	B-X
women	B-X
(	B-X
Fig	B-X
.	B-X
The	B-X
purpose	B-X
high	B-X
performance	B-X
liquid	B-X
chromatography	B-X
(	B-X
HPLC	B-X
)	B-X
analysis	B-X
of	B-X
any	B-X
drugs	B-X
is	B-X
to	B-X
confirm	B-X
the	B-X
identity	B-X
of	B-X
a	B-X
drug	B-X
and	B-X
provide	B-X
quantitative	B-X
results	B-X
and	B-X
also	B-X
to	B-X
monitor	B-X
the	B-X
progress	B-X
of	B-X
the	B-X
therapy	B-X
of	B-X
a	B-X
disease.1	B-X
)	B-X
Measuring	B-X
presented	B-X
on	B-X
the	B-X
Fig	B-X
.	B-X
Neutral	B-X
or	B-X
weakly	B-X
acidic	B-X
drugs	B-X
for	B-X
instance	B-X
barbiturates	B-X
can	B-X
be	B-X
chromatographed	B-X
on	B-X
a	B-X
reversed	B-X
phase	B-X
system	B-X
whilst	B-X
acidic	B-X
drugs	B-X
for	B-X
example	B-X
paracetamol	B-X
,	B-X
cannabis	B-X
are	B-X
separated	B-X
either	B-X
by	B-X
ion	B-X
suppression	B-X
or	B-X
ion-pair	B-X
chromatography	B-X
on	B-X
a	B-X
reversed-phase	B-X
packing	B-X
material	B-X
.	B-X

2A	O
(	O
arrow	O
)	O
.	O
<EOS>	B-X
The	B-X
conflict	B-X
similarity	B-X
was	B-X
defined	B-X
by	B-X
the	B-X
degree	B-X
of	B-X
component	B-X
overlap	B-X
,	B-X
as	B-X
manipulated	B-X
by	B-X
the	B-X
polar	B-X
angle	B-X
of	B-X
the	B-X
target	B-X
arrow	B-X
in	B-X
Experiments	B-X
2a	B-X
and	B-X
2b	B-X
and	B-X
by	B-X
the	B-X
Euclidean	B-X
distance	B-X
of	B-X
the	B-X
target	B-X
arrow	B-X
in	B-X
Experiments	B-X
3a	B-X
and	B-X
3b	B-X
.	B-X
It	B-X
has	B-X
been	B-X
suggested	B-X
that	B-X
two	B-X
types	B-X
of	B-X
uninformative	B-X
central	B-X
cues	B-X
produce	B-X
reflexive	B-X
orienting	B-X
:	B-X
gaze	B-X
and	B-X
arrow	B-X
cues	B-X
.	B-X
A	B-X
cued	B-X
letter	B-X
discrimination	B-X
task	B-X
was	B-X
used	B-X
with	B-X
both	B-X
gaze	B-X
(	B-X
Experiments	B-X
1A	B-X
and	B-X
1B	B-X
)	B-X
and	B-X
arrow	B-X
(	B-X
Experiments	B-X
2A	B-X
and	B-X
2B	B-X
)	B-X
cues	B-X
,	B-X
in	B-X
which	B-X
participants	B-X
responded	B-X
to	B-X
the	B-X
identity	B-X
of	B-X
the	B-X
target	B-X
letter	B-X
.	B-X
For	B-X
both	B-X
cue	B-X
types	B-X
,	B-X
compatible	B-X
cues	B-X
were	B-X
found	B-X
to	B-X
facilitate	B-X
response	B-X
speed	B-X
but	B-X
not	B-X
perceptual	B-X
accuracy	B-X
,	B-X
indicating	B-X
that	B-X
both	B-X
gaze	B-X
and	B-X
arrow	B-X
cues	B-X
generate	B-X
reflexive	B-X
shifts	B-X
in	B-X
attention	B-X
.	B-X

The	O
peaking	O
of	O
the	O
Pp	O
value	O
measured	O
at	O
a	O
height	O
of	O
0	O
.	O
2	O
m	O
around	O
14	O
.	O
00	O
h	O
is	O
obviously	O
not	O
induced	O
by	O
changes	O
in	O
the	O
local	O
temperature	O
and	O
relative	O
humidity	O
or	O
by	O
exposure	O
to	O
sunshine	O
.	O
<EOS>	B-X
Excessive	B-X
exposure	B-X
of	B-X
the	B-X
skin	B-X
to	B-X
sunlight	B-X
can	B-X
lead	B-X
to	B-X
many	B-X
negative	B-X
effects	B-X
,	B-X
such	B-X
as	B-X
sunburn	B-X
,	B-X
photoaging	B-X
and	B-X
skin	B-X
cancer	B-X
development	B-X
.	B-X
Pollution	B-X
and	B-X
stratospheric	B-X
ozone	B-X
layer	B-X
depletion	B-X
are	B-X
factors	B-X
that	B-X
increase	B-X
exposure	B-X
to	B-X
ultraviolet	B-X
radiation	B-X
.	B-X
This	B-X
work	B-X
is	B-X
an	B-X
accurate	B-X
summary	B-X
of	B-X
the	B-X
current	B-X
state	B-X
of	B-X
knowledge	B-X
on	B-X
broad-spectrum	B-X
photoprotection	B-X
.	B-X
Avoiding	B-X
the	B-X
sun	B-X
,	B-X
skin	B-X
protection	B-X
through	B-X
the	B-X
use	B-X
of	B-X
protective	B-X
clothing	B-X
and	B-X
protective	B-X
filters	B-X
are	B-X
currently	B-X
the	B-X
most	B-X
effective	B-X
methods	B-X
of	B-X
sunscreen	B-X
provided	B-X
that	B-X
they	B-X
are	B-X
suitably	B-X
used	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
discussed	B-X
are	B-X
controversial	B-X
issues	B-X
such	B-X
as	B-X
the	B-X
toxicity	B-X
of	B-X
zinc	B-X
used	B-X
in	B-X
sunscreen	B-X
preparations	B-X
and	B-X
the	B-X
potential	B-X
for	B-X
deficiency	B-X
of	B-X
vitamin	B-X
D3	B-X
in	B-X
relation	B-X
with	B-X
the	B-X
application	B-X
of	B-X
strict	B-X
photoprotection	B-X
.	B-X
The	B-X
study	B-X
has	B-X
also	B-X
addressed	B-X
issues	B-X
concerning	B-X
the	B-X
most	B-X
recent	B-X
lines	B-X
of	B-X
research	B-X
in	B-X
the	B-X
exploration	B-X
of	B-X
modern	B-X
methods	B-X
of	B-X
photoprotection	B-X
both	B-X
local	B-X
and	B-X
systemic	B-X
,	B-X
such	B-X
as	B-X
with	B-X
the	B-X
use	B-X
of	B-X
photolyase	B-X
or	B-X
examination	B-X
of	B-X
various	B-X
enzymes	B-X
repairing	B-X
damage	B-X
after	B-X
sun	B-X
exposure	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
promising	B-X
future	B-X
in	B-X
photoprotection	B-X
technology	B-X
.	B-X

Similar	O
diurnal	O
changes	O
in	O
Pp	O
,	O
T	O
,	O
and	O
r	O
.	O
h	O
.	O
were	O
also	O
found	O
for	O
the	O
4	O
.	O
5	O
m	O
tall	O
liana	O
in	O
the	O
backstage	O
of	O
the	O
greenhouse	O
(	O
data	O
not	O
shown	O
)	O
.	O

Figure	O
3	O
shows	O
long	O
-	O
term	O
Pp	O
,	O
T	O
,	O
and	O
r	O
.	O
h	O
.	O
measurements	O
performed	O
at	O
0	O
.	O
2	O
m	O
,	O
6	O
m	O
,	O
and	O
10	O
m	O
height	O
in	O
late	O
summer	O
2007	O
.	O

In	O
contrast	O
to	O
the	O
experimental	O
conditions	O
in	O
late	O
spring	O
(	O
Fig	O
.	O
2	O
)	O
the	O
liana	O
had	O
been	O
watered	O
only	O
sporadically	O
during	O
the	O
weeks	O
before	O
the	O
measurements	O
.	O

The	O
soil	O
was	O
extremely	O
dry	O
and	O
no	O
guttation	O
was	O
observed	O
at	O
predawn	O
,	O
even	O
at	O
0	O
.	O
2	O
m	O
height	O
.	O

Turgor	O
pressure	O
measurements	O
performed	O
at	O
0	O
.	O
2	O
m	O
height	O
yielded	O
values	O
below	O
250	O
kPa	O
at	O
predawn	O
.	O

Continuous	O
irrigation	O
was	O
started	O
at	O
10	O
.	O
00	O
h	O
on	O
28	O
August	O
(	O
c	O
.	O
400	O
l	O
d	O
-	O
1	O
)	O
.	O

Guttation	O
occurred	O
at	O
0	O
.	O
2	O
m	O
height	O
,	O
but	O
not	O
at	O
6	O
m	O
height	O
on	O
1	O
September	O
.	O

At	O
sunrise	O
(	O
05	O
.	O
25	O
h	O
)	O
,	O
turgor	O
pressures	O
of	O
c	O
.	O

500	O
kPa	O
were	O
recorded	O
at	O
the	O
base	O
of	O
the	O
liana	O
.	O

Guttation	O
at	O
6	O
m	O
height	O
was	O
still	O
not	O
observed	O
on	O
3	O
September	O
indicating	O
that	O
the	O
hydration	O
state	O
of	O
the	O
plant	O
was	O
still	O
less	O
than	O
in	O
the	O
last	O
week	O
of	O
May	O
.	O

The	O
T	O
and	O
r	O
.	O
h	O
.	O
profiles	O
during	O
the	O
end	O
of	O
summer	O
were	O
also	O
different	O
to	O
those	O
in	O
late	O
spring	O
(	O
compare	O
Fig	O
.	O
2B	O
,	O
C	O
with	O
Fig	O
.	O
3B	O
,	O
C	O
)	O
.	O

On	O
28	O
August	O
when	O
irrigation	O
started	O
it	O
was	O
sunny	O
.	O

Similarly	O
to	O
May	O
,	O
peak	O
values	O
of	O
T	O
and	O
r	O
.	O
h	O
.	O
were	O
reached	O
at	O
c	O
.	O

15	O
.	O
30	O
h	O
.	O
<EOS>	B-X
Reliability	B-X
and	B-X
Validity	B-X
of	B-X
the	B-X
30-15	B-X
Intermittent	B-X
Field	B-X
Test	B-X
With	B-X
and	B-X
Without	B-X
a	B-X
Soccer	B-X
Ball	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
investigation	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
reliability	B-X
of	B-X
the	B-X
30-15	B-X
Intermittent	B-X
Fitness	B-X
Test	B-X
(	B-X
30-15	B-X
(	B-X
IFT	B-X
)	B-X
)	B-X
in	B-X
semiprofessional	B-X
soccer	B-X
players	B-X
.	B-X
The	B-X
30-15	B-X
Intermittent	B-X
Fitness	B-X
Test	B-X
:	B-X
A	B-X
Reliable	B-X
,	B-X
Valid	B-X
,	B-X
and	B-X
Useful	B-X
Tool	B-X
to	B-X
Assess	B-X
Aerobic	B-X
Capacity	B-X
in	B-X
Female	B-X
Basketball	B-X
Players	B-X
.	B-X
Previous	B-X
studies	B-X
have	B-X
suggested	B-X
that	B-X
the	B-X
acid	B-X
secretory	B-X
capacity	B-X
of	B-X
the	B-X
Chinese	B-X
population	B-X
is	B-X
lower	B-X
than	B-X
that	B-X
of	B-X
the	B-X
Western	B-X
population	B-X
.	B-X

However	O
,	O
temperatures	O
at	O
the	O
top	O
of	O
the	O
plant	O
did	O
not	O
exceed	O
35	O
degrees	O
C	O
and	O
r	O
.	O
h	O
.	O
did	O
not	O
drop	O
below	O
40	O
%	O
.	O
<EOS>	B-X
Plants	B-X
are	B-X
sessile	B-X
and	B-X
photo-autotrophic	B-X
;	B-X
their	B-X
entire	B-X
life	B-X
cycle	B-X
is	B-X
thus	B-X
strongly	B-X
influenced	B-X
by	B-X
the	B-X
ever-changing	B-X
light	B-X
environment	B-X
.	B-X
In	B-X
order	B-X
to	B-X
sense	B-X
and	B-X
respond	B-X
to	B-X
those	B-X
fluctuating	B-X
conditions	B-X
higher	B-X
plants	B-X
possess	B-X
several	B-X
families	B-X
of	B-X
photoreceptors	B-X
that	B-X
can	B-X
monitor	B-X
light	B-X
from	B-X
UV-B	B-X
to	B-X
the	B-X
near	B-X
infrared	B-X
(	B-X
far-red	B-X
)	B-X
.	B-X
The	B-X
molecular	B-X
nature	B-X
of	B-X
UV-B	B-X
sensors	B-X
remains	B-X
unknown	B-X
,	B-X
red	B-X
(	B-X
R	B-X
)	B-X
and	B-X
far-red	B-X
(	B-X
FR	B-X
)	B-X
light	B-X
is	B-X
sensed	B-X
by	B-X
the	B-X
phytochromes	B-X
(	B-X
phyA-phyE	B-X
in	B-X
Arabidopsis	B-X
)	B-X
while	B-X
three	B-X
classes	B-X
of	B-X
UV-A/blue	B-X
photoreceptors	B-X
have	B-X
been	B-X
identified	B-X
:	B-X
cryptochromes	B-X
,	B-X
phototropins	B-X
,	B-X
and	B-X
members	B-X
of	B-X
the	B-X
Zeitlupe	B-X
family	B-X
(	B-X
cry1	B-X
,	B-X
cry2	B-X
,	B-X
phot1	B-X
,	B-X
phot2	B-X
,	B-X
ZTL	B-X
,	B-X
FKF1	B-X
,	B-X
and	B-X
LKP2	B-X
in	B-X
Arabidopsis	B-X
)	B-X
.	B-X
Functional	B-X
specialization	B-X
within	B-X
photoreceptor	B-X
families	B-X
gave	B-X
rise	B-X
to	B-X
members	B-X
optimized	B-X
for	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
light	B-X
intensities	B-X
.	B-X
Genetic	B-X
and	B-X
photobiological	B-X
studies	B-X
performed	B-X
in	B-X
Arabidopsis	B-X
have	B-X
shown	B-X
that	B-X
these	B-X
light	B-X
sensors	B-X
mediate	B-X
numerous	B-X
adaptive	B-X
responses	B-X
(	B-X
e.g.	B-X
,	B-X
phototropism	B-X
and	B-X
shade	B-X
avoidance	B-X
)	B-X
and	B-X
developmental	B-X
transitions	B-X
(	B-X
e.g.	B-X
,	B-X
germination	B-X
and	B-X
flowering	B-X
)	B-X
.	B-X
Some	B-X
physiological	B-X
responses	B-X
are	B-X
specifically	B-X
triggered	B-X
by	B-X
a	B-X
single	B-X
photoreceptor	B-X
but	B-X
in	B-X
many	B-X
cases	B-X
multiple	B-X
light	B-X
sensors	B-X
ensure	B-X
a	B-X
coordinated	B-X
response	B-X
.	B-X
Recent	B-X
studies	B-X
also	B-X
provide	B-X
examples	B-X
of	B-X
crosstalk	B-X
between	B-X
the	B-X
responses	B-X
of	B-X
Arabidopsis	B-X
to	B-X
different	B-X
external	B-X
factors	B-X
,	B-X
in	B-X
particular	B-X
among	B-X
light	B-X
,	B-X
temperature	B-X
,	B-X
and	B-X
pathogens	B-X
.	B-X
Although	B-X
the	B-X
different	B-X
photoreceptors	B-X
are	B-X
unrelated	B-X
in	B-X
structure	B-X
,	B-X
in	B-X
many	B-X
cases	B-X
they	B-X
trigger	B-X
similar	B-X
signaling	B-X
mechanisms	B-X
including	B-X
light-regulated	B-X
protein-protein	B-X
interactions	B-X
or	B-X
light-regulated	B-X
stability	B-X
of	B-X
several	B-X
transcription	B-X
factors	B-X
.	B-X
The	B-X
breath	B-X
and	B-X
complexity	B-X
of	B-X
this	B-X
topic	B-X
forced	B-X
us	B-X
to	B-X
concentrate	B-X
on	B-X
specific	B-X
aspects	B-X
of	B-X
photomorphogenesis	B-X
and	B-X
we	B-X
point	B-X
the	B-X
readers	B-X
to	B-X
recent	B-X
reviews	B-X
for	B-X
some	B-X
aspects	B-X
of	B-X
light-mediated	B-X
signaling	B-X
(	B-X
e.g.	B-X
,	B-X
transition	B-X
to	B-X
flowering	B-X
)	B-X
.	B-X

Accordingly	O
,	O
the	O
vertical	O
T	O
and	O
r	O
.	O
h	O
.	O
gradients	O
were	O
smaller	O
than	O
those	O
measured	O
at	O
the	O
end	O
of	O
May	O
.	O

On	O
29	O
August	O
,	O
when	O
it	O
became	O
very	O
rainy	O
and	O
light	O
irradiance	O
dropped	O
dramatically	O
,	O
gradients	O
in	O
T	O
and	O
r	O
.	O
h	O
.	O
of	O
slightly	O
decreased	O
size	O
were	O
still	O
recorded	O
.	O

Peaking	O
of	O
T	O
and	O
r	O
.	O
h	O
.	O
occurred	O
at	O
c	O
.	O

14	O
.	O
30	O
h	O
.	O
<EOS>	B-X
Solid-state	B-X
sodium	B-X
batteries	B-X
have	B-X
attracted	B-X
great	B-X
attention	B-X
owing	B-X
to	B-X
their	B-X
improved	B-X
safety	B-X
,	B-X
high	B-X
energy	B-X
density	B-X
,	B-X
large	B-X
abundance	B-X
and	B-X
low	B-X
cost	B-X
of	B-X
sodium	B-X
compared	B-X
to	B-X
the	B-X
current	B-X
Li-ion	B-X
batteries	B-X
.	B-X
Sodium-boranes	B-X
have	B-X
been	B-X
studied	B-X
as	B-X
potential	B-X
solid-state	B-X
electrolytes	B-X
and	B-X
the	B-X
search	B-X
for	B-X
new	B-X
materials	B-X
is	B-X
necessary	B-X
for	B-X
future	B-X
battery	B-X
applications	B-X
.	B-X
Here	B-X
,	B-X
a	B-X
facile	B-X
and	B-X
cost-effective	B-X
solution-based	B-X
synthesis	B-X
of	B-X
Na	B-X
A	B-X
comprehensive	B-X
distribution	B-X
study	B-X
was	B-X
conducted	B-X
in	B-X
female	B-X
rats	B-X
and	B-X
mice	B-X
exposed	B-X
to	B-X
a	B-X
suspension	B-X
of	B-X
uniformly	B-X
carbon-14-labeled	B-X
C60	B-X
(	B-X
[	B-X
(	B-X
14	B-X
)	B-X
C	B-X
(	B-X
U	B-X
)	B-X
]	B-X
C60	B-X
)	B-X
.	B-X
Rodents	B-X
were	B-X
administered	B-X
[	B-X
(	B-X
14	B-X
)	B-X
C	B-X
(	B-X
U	B-X
)	B-X
]	B-X
C60	B-X
(	B-X
~0.9	B-X
mg	B-X
kg	B-X
(	B-X
-1	B-X
)	B-X
body	B-X
weight	B-X
)	B-X
or	B-X
5	B-X
%	B-X
polyvinylpyrrolidone-saline	B-X
vehicle	B-X
alone	B-X
via	B-X
a	B-X
single	B-X
tail	B-X
vein	B-X
injection	B-X
.	B-X
Tissues	B-X
were	B-X
collected	B-X
at	B-X
1	B-X
h	B-X
and	B-X
1	B-X
,	B-X
7	B-X
,	B-X
14	B-X
and	B-X
30	B-X
days	B-X
after	B-X
administration	B-X
.	B-X
A	B-X
separate	B-X
group	B-X
of	B-X
rodents	B-X
received	B-X
five	B-X
daily	B-X
injections	B-X
of	B-X
suspensions	B-X
of	B-X
either	B-X
[	B-X
(	B-X
14	B-X
)	B-X
C	B-X
(	B-X
U	B-X
)	B-X
]	B-X
C60	B-X
or	B-X
vehicle	B-X
with	B-X
tissue	B-X
collection	B-X
14	B-X
days	B-X
post	B-X
exposure	B-X
.	B-X
The	B-X
highest	B-X
concentration	B-X
of	B-X
radioactivity	B-X
in	B-X
rodents	B-X
at	B-X
each	B-X
time	B-X
point	B-X
was	B-X
in	B-X
liver	B-X
,	B-X
lungs	B-X
and	B-X
spleen	B-X
.	B-X
Elimination	B-X
of	B-X
[	B-X
(	B-X
14	B-X
)	B-X
C	B-X
(	B-X
U	B-X
)	B-X
]	B-X
C60	B-X
was	B-X
<	B-X
2	B-X
%	B-X
in	B-X
urine	B-X
and	B-X
feces	B-X
at	B-X
any	B-X
24	B-X
h	B-X
time	B-X
points	B-X
.	B-X
[	B-X
(	B-X
14	B-X
)	B-X
C	B-X
(	B-X
U	B-X
)	B-X
]	B-X
C60	B-X
and	B-X
[	B-X
(	B-X
14	B-X
)	B-X
C	B-X
(	B-X
U	B-X
)	B-X
]	B-X
C60	B-X
-retinol	B-X
were	B-X
detected	B-X
in	B-X
liver	B-X
of	B-X
rats	B-X
and	B-X
together	B-X
accounted	B-X
for	B-X
~99	B-X
%	B-X
and	B-X
~56	B-X
%	B-X
of	B-X
the	B-X
total	B-X
recovered	B-X
at	B-X
1	B-X
and	B-X
30	B-X
days	B-X
postexposure	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
blood	B-X
radioactivity	B-X
at	B-X
1	B-X
h	B-X
after	B-X
[	B-X
(	B-X
14	B-X
)	B-X
C	B-X
(	B-X
U	B-X
)	B-X
]	B-X
C60	B-X
exposure	B-X
was	B-X
fourfold	B-X
higher	B-X
in	B-X
rats	B-X
than	B-X
in	B-X
mice	B-X
;	B-X
blood	B-X
radioactivity	B-X
was	B-X
still	B-X
in	B-X
circulation	B-X
at	B-X
30	B-X
days	B-X
post	B-X
[	B-X
(	B-X
14	B-X
)	B-X
C	B-X
(	B-X
U	B-X
)	B-X
]	B-X
C60	B-X
exposure	B-X
in	B-X
both	B-X
species	B-X
(	B-X
<	B-X
1	B-X
%	B-X
)	B-X
.	B-X
Levels	B-X
of	B-X
oxidative	B-X
stress	B-X
markers	B-X
increased	B-X
by	B-X
5	B-X
days	B-X
after	B-X
exposure	B-X
and	B-X
remained	B-X
elevated	B-X
,	B-X
while	B-X
levels	B-X
of	B-X
inflammation	B-X
markers	B-X
initially	B-X
increased	B-X
and	B-X
then	B-X
returned	B-X
to	B-X
control	B-X
values	B-X
.	B-X
The	B-X
level	B-X
of	B-X
cardiovascular	B-X
marker	B-X
von	B-X
Willebrand	B-X
factor	B-X
,	B-X
increased	B-X
in	B-X
rats	B-X
,	B-X
but	B-X
remained	B-X
at	B-X
control	B-X
levels	B-X
in	B-X
mice	B-X
.	B-X
This	B-X
study	B-X
demonstrates	B-X
that	B-X
[	B-X
(	B-X
14	B-X
)	B-X
C	B-X
(	B-X
U	B-X
)	B-X
]	B-X
C60	B-X
is	B-X
retained	B-X
in	B-X
female	B-X
rodents	B-X
with	B-X
little	B-X
elimination	B-X
by	B-X
30	B-X
days	B-X
after	B-X
i.v	B-X
.	B-X

T	O
and	O
r	O
.	O
h	O
.	O
gradients	O
did	O
not	O
develop	O
in	O
the	O
following	O
three	O
days	O
which	O
were	O
very	O
cloudy	O
and	O
rainy	O
.	O

An	O
almost	O
constant	O
temperature	O
of	O
c	O
.	O
<EOS>	B-X
We	B-X
evaluated	B-X
how	B-X
constant	B-X
incubation	B-X
temperatures	B-X
affect	B-X
life-history	B-X
traits	B-X
pre-hatching	B-X
and	B-X
post-hatching	B-X
of	B-X
the	B-X
six-tubercled	B-X
Amazon	B-X
River	B-X
turtle	B-X
,	B-X
Podocnemis	B-X
sextuberculata	B-X
.	B-X
Quantifying	B-X
basic	B-X
biological	B-X
data	B-X
,	B-X
such	B-X
as	B-X
the	B-X
effects	B-X
of	B-X
variable	B-X
temperatures	B-X
on	B-X
development	B-X
and	B-X
survival	B-X
,	B-X
is	B-X
crucial	B-X
to	B-X
predicting	B-X
and	B-X
monitoring	B-X
population	B-X
growth	B-X
rates	B-X
of	B-X
pest	B-X
species	B-X
,	B-X
many	B-X
of	B-X
which	B-X
are	B-X
highly	B-X
invasive	B-X
.	B-X
One	B-X
of	B-X
the	B-X
most	B-X
globally	B-X
important	B-X
pests	B-X
of	B-X
cereals	B-X
is	B-X
the	B-X
eriophyoid	B-X
wheat	B-X
curl	B-X
mite	B-X
(	B-X
WCM	B-X
)	B-X
,	B-X
Aceria	B-X
tosichella	B-X
,	B-X
which	B-X
is	B-X
the	B-X
primary	B-X
vector	B-X
of	B-X
several	B-X
plant	B-X
viruses	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
temperature-dependent	B-X
development	B-X
and	B-X
survival	B-X
of	B-X
WCM	B-X
at	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
constant	B-X
temperatures	B-X
in	B-X
the	B-X
laboratory	B-X
(	B-X
17-33	B-X
Â°C	B-X
)	B-X
.	B-X
The	B-X
development	B-X
time	B-X
of	B-X
each	B-X
stage	B-X
depended	B-X
significantly	B-X
on	B-X
temperature	B-X
and	B-X
it	B-X
was	B-X
negatively	B-X
correlated	B-X
with	B-X
temperature	B-X
increase	B-X
.	B-X
At	B-X
high	B-X
temperatures	B-X
(	B-X
27-33	B-X
Â°C	B-X
)	B-X
,	B-X
individuals	B-X
had	B-X
shorter	B-X
developmental	B-X
times	B-X
,	B-X
with	B-X
the	B-X
shortest	B-X
(	B-X
6	B-X
days	B-X
)	B-X
at	B-X
33	B-X
Â°C	B-X
,	B-X
whereas	B-X
at	B-X
the	B-X
lowest	B-X
tested	B-X
temperatures	B-X
(	B-X
17-19	B-X
Â°C	B-X
)	B-X
,	B-X
developmental	B-X
time	B-X
was	B-X
almost	B-X
3Ã	B-X
longer	B-X
.	B-X
Moreover	B-X
,	B-X
temperature	B-X
had	B-X
a	B-X
clear	B-X
effect	B-X
on	B-X
survival	B-X
:	B-X
the	B-X
higher	B-X
the	B-X
temperature	B-X
,	B-X
the	B-X
lower	B-X
the	B-X
survival	B-X
rate	B-X
.	B-X
These	B-X
data	B-X
provide	B-X
information	B-X
promoting	B-X
more	B-X
efficient	B-X
and	B-X
effective	B-X
manipulation	B-X
of	B-X
WCM	B-X
laboratory	B-X
colonies	B-X
,	B-X
and	B-X
further	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
ramifications	B-X
of	B-X
temperature	B-X
change	B-X
on	B-X
WCM	B-X
physiology	B-X
and	B-X
implications	B-X
for	B-X
the	B-X
growth	B-X
and	B-X
spread	B-X
of	B-X
this	B-X
globally	B-X
invasive	B-X
pest	B-X
.	B-X

25	O
degrees	O
C	O
and	O
a	O
relative	O
humidity	O
of	O
80	O
%	O
were	O
measured	O
on	O
the	O
ground	O
and	O
at	O
the	O
top	O
of	O
the	O
greenhouse	O
throughout	O
the	O
day	O
;	O
light	O
irradiance	O
did	O
not	O
exceed	O
40	O
mu	O
mol	O
photons	O
m	O
-	O
2	O
s	O
-	O
1	O
.	O

Only	O
on	O
31	O
August	O
,	O
did	O
the	O
rain	O
stop	O
and	O
the	O
upper	O
part	O
of	O
the	O
liana	O
was	O
exposed	O
to	O
sunshine	O
for	O
1	O
-	O
2	O
h	O
and	O
thus	O
small	O
T	O
and	O
r	O
.	O
h	O
.	O
gradients	O
developed	O
.	O

The	O
following	O
days	O
of	O
2	O
and	O
3	O
September	O
were	O
partly	O
cloudy	O
and	O
sunny	O
and	O
the	O
peaking	O
of	O
T	O
and	O
r	O
.	O
h	O
.	O
occurred	O
at	O
c	O
.	O

13	O
.	O
00	O
h	O
.	O
<EOS>	B-X
In	B-X
our	B-X
modern	B-X
society	B-X
,	B-X
artificial	B-X
light	B-X
is	B-X
available	B-X
around	B-X
the	B-X
clock	B-X
and	B-X
most	B-X
people	B-X
expose	B-X
themselves	B-X
to	B-X
electrical	B-X
light	B-X
and	B-X
light-emissive	B-X
screens	B-X
during	B-X
the	B-X
dark	B-X
period	B-X
of	B-X
the	B-X
natural	B-X
light/dark	B-X
cycle	B-X
.	B-X
Such	B-X
suboptimal	B-X
lighting	B-X
conditions	B-X
have	B-X
been	B-X
associated	B-X
with	B-X
adverse	B-X
metabolic	B-X
effects	B-X
,	B-X
and	B-X
redesigning	B-X
indoor	B-X
lighting	B-X
conditions	B-X
to	B-X
mimic	B-X
the	B-X
natural	B-X
light/dark	B-X
cycle	B-X
more	B-X
closely	B-X
holds	B-X
promise	B-X
to	B-X
improve	B-X
metabolic	B-X
health	B-X
.	B-X
Our	B-X
objective	B-X
was	B-X
to	B-X
compare	B-X
metabolic	B-X
responses	B-X
to	B-X
lighting	B-X
conditions	B-X
that	B-X
resemble	B-X
the	B-X
natural	B-X
light/dark	B-X
cycle	B-X
in	B-X
contrast	B-X
to	B-X
suboptimal	B-X
lighting	B-X
in	B-X
individuals	B-X
at	B-X
risk	B-X
of	B-X
developing	B-X
metabolic	B-X
diseases	B-X
.	B-X
The	B-X
title	B-X
compound	B-X
,	B-X
C	B-X
(	B-X
14	B-X
)	B-X
H	B-X
(	B-X
13	B-X
)	B-X
NO	B-X
,	B-X
is	B-X
non-planar	B-X
with	B-X
a	B-X
dihedral	B-X
angle	B-X
of	B-X
47.00	B-X
(	B-X
6	B-X
)	B-X
Â°	B-X
between	B-X
the	B-X
planes	B-X
of	B-X
the	B-X
two	B-X
aromatic	B-X
rings	B-X
.	B-X
Intra-molecular	B-X
hydrogen	B-X
bonding	B-X
is	B-X
observed	B-X
between	B-X
the	B-X
O-H	B-X
group	B-X
and	B-X
the	B-X
N	B-X
atom	B-X
,	B-X
resulting	B-X
in	B-X
a	B-X
phenol-imine	B-X
tautomeric	B-X
form	B-X
.	B-X

The	O
upper	O
,	O
but	O
not	O
the	O
lower	O
part	O
of	O
the	O
liana	O
was	O
exposed	O
to	O
sunshine	O
for	O
several	O
hours	O
.	O
<EOS>	B-X
People	B-X
with	B-X
chronic	B-X
obstructive	B-X
pulmonary	B-X
disease	B-X
(	B-X
COPD	B-X
)	B-X
often	B-X
experience	B-X
difficulty	B-X
with	B-X
performing	B-X
upper	B-X
limb	B-X
exercise	B-X
due	B-X
to	B-X
dyspnoea	B-X
and	B-X
arm	B-X
fatigue	B-X
.	B-X
Consequently	B-X
,	B-X
upper	B-X
limb	B-X
exercise	B-X
training	B-X
is	B-X
typically	B-X
incorporated	B-X
in	B-X
pulmonary	B-X
rehabilitation	B-X
programmes	B-X
to	B-X
improve	B-X
upper	B-X
limb	B-X
exercise	B-X
capacity	B-X
;	B-X
however	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
this	B-X
training	B-X
on	B-X
dyspnoea	B-X
and	B-X
health-related	B-X
quality	B-X
of	B-X
life	B-X
(	B-X
HRQoL	B-X
)	B-X
remain	B-X
unclear	B-X
.	B-X
This	B-X
review	B-X
aims	B-X
to	B-X
describe	B-X
the	B-X
epidemiology	B-X
,	B-X
pathophysiology	B-X
,	B-X
risk	B-X
factors	B-X
,	B-X
presentation	B-X
,	B-X
complications	B-X
,	B-X
evaluation/diagnosis	B-X
,	B-X
and	B-X
treatment	B-X
of	B-X
upper	B-X
extremity	B-X
deep	B-X
vein	B-X
thrombosis	B-X
(	B-X
UEDVT	B-X
)	B-X
.	B-X
The	B-X
rationale	B-X
behind	B-X
endoscopic	B-X
screening	B-X
of	B-X
the	B-X
upper	B-X
gastrointestinal	B-X
tract	B-X
(	B-X
GIT	B-X
)	B-X
in	B-X
the	B-X
West	B-X
is	B-X
different	B-X
from	B-X
Asian	B-X
countries	B-X
with	B-X
a	B-X
high	B-X
prevalence	B-X
of	B-X
gastric	B-X
cancer	B-X
.	B-X
If	B-X
epidemiological	B-X
data	B-X
on	B-X
upper	B-X
GIT	B-X
cancer	B-X
in	B-X
the	B-X
Western	B-X
world	B-X
is	B-X
considered	B-X
,	B-X
then	B-X
endoscopic	B-X
screening	B-X
of	B-X
the	B-X
upper	B-X
GIT	B-X
must	B-X
target	B-X
premalignant	B-X
conditions	B-X
as	B-X
well	B-X
and	B-X
,	B-X
furthermore	B-X
,	B-X
lay	B-X
emphasis	B-X
on	B-X
the	B-X
assessment	B-X
of	B-X
the	B-X
entire	B-X
upper	B-X
GIT	B-X
in	B-X
high-risk	B-X
individuals	B-X
from	B-X
the	B-X
mouth	B-X
till	B-X
the	B-X
duodenum	B-X
.	B-X
Although	B-X
data	B-X
on	B-X
the	B-X
incidence	B-X
,	B-X
prevalence	B-X
,	B-X
and	B-X
further	B-X
development	B-X
of	B-X
premalignant	B-X
conditions	B-X
in	B-X
the	B-X
upper	B-X
GIT	B-X
is	B-X
lacking	B-X
,	B-X
a	B-X
risk-based	B-X
approach	B-X
to	B-X
endoscopic	B-X
screening	B-X
will	B-X
be	B-X
more	B-X
cost-effective	B-X
than	B-X
a	B-X
general	B-X
screening	B-X
approach	B-X
.	B-X
Finally	B-X
,	B-X
endoscopists	B-X
need	B-X
to	B-X
be	B-X
educated	B-X
and	B-X
trained	B-X
in	B-X
the	B-X
assessment	B-X
of	B-X
the	B-X
upper	B-X
GIT	B-X
during	B-X
screening	B-X
endoscopy	B-X
.	B-X

This	O
resulted	O
in	O
the	O
formation	O
of	O
T	O
and	O
r	O
.	O
h	O
.	O
gradients	O
.	O

The	O
size	O
of	O
the	O
gradients	O
was	O
similar	O
to	O
that	O
measured	O
on	O
29	O
August	O
.	O

Inspection	O
of	O
Fig	O
.	O
<EOS>	B-X
The	B-X
corresponding	B-X
author	B-X
,	B-X
Dr	B-X
Byoungduck	B-X
Park	B-X
,	B-X
requested	B-X
publication	B-X
of	B-X
a	B-X
corrigendum	B-X
to	B-X
correct	B-X
Fig	B-X
.	B-X
Upon	B-X
further	B-X
inspection	B-X
,	B-X
the	B-X
Biochimie	B-X
editorial	B-X
team	B-X
noticed	B-X
that	B-X
:	B-X
Comparison	B-X
of	B-X
Fig	B-X
.	B-X
2B	B-X
with	B-X
Fig	B-X
.	B-X
4C	B-X
of	B-X
a	B-X
previous	B-X
publication	B-X
in	B-X
International	B-X
Immunopharmacology	B-X
by	B-X
two	B-X
co-authors	B-X
(	B-X
doi	B-X
:	B-X
10.1016/j.intimp.2015.02.014	B-X
)	B-X
reveals	B-X
that	B-X
western	B-X
blot	B-X
Î²-actin	B-X
control	B-X
data	B-X
from	B-X
the	B-X
earlier	B-X
paper	B-X
were	B-X
re-used	B-X
in	B-X
a	B-X
different	B-X
experiment	B-X
shown	B-X
in	B-X
Fig	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
same	B-X
bands	B-X
,	B-X
after	B-X
more	B-X
image	B-X
manipulation	B-X
were	B-X
presented	B-X
as	B-X
Smad3	B-X
data	B-X
in	B-X
Fig	B-X
.	B-X

3A	O
indicates	O
that	O
peaking	O
of	O
the	O
Pp	O
values	O
coincided	O
with	O
peaking	O
of	O
r	O
.	O
h	O
.	O
and	O
T	O
in	O
Fig	O
.	O

3B	O
and	O
C	O
.	O

Figure	O
3A	O
shows	O
further	O
that	O
the	O
peak	O
amplitude	O
of	O
the	O
Pp	O
values	O
recorded	O
at	O
the	O
three	O
measuring	O
sites	O
decreased	O
continuously	O
from	O
28	O
August	O
whereas	O
the	O
low	O
Pp	O
values	O
at	O
the	O
nights	O
remained	O
unaltered	O
.	O

The	O
peak	O
amplitude	O
measured	O
on	O
29	O
August	O
was	O
only	O
slightly	O
lower	O
than	O
that	O
measured	O
on	O
the	O
day	O
before	O
,	O
the	O
peak	O
amplitude	O
was	O
rather	O
low	O
on	O
30	O
August	O
.	O

It	O
remained	O
at	O
this	O
low	O
level	O
until	O
2	O
September	O
,	O
except	O
that	O
on	O
31	O
August	O
the	O
peak	O
amplitude	O
at	O
the	O
three	O
measuring	O
sites	O
increased	O
slightly	O
,	O
presumably	O
because	O
of	O
the	O
short	O
-	O
time	O
exposure	O
of	O
the	O
upper	O
leaves	O
to	O
sun	O
(	O
see	O
above	O
)	O
.	O

Comparison	O
of	O
the	O
diurnal	O
changes	O
in	O
the	O
Pp	O
values	O
with	O
the	O
corresponding	O
T	O
and	O
r	O
.	O
h	O
.	O
changes	O
in	O
Fig	O
.	O

3B	O
and	O
C	O
indicates	O
that	O
part	O
of	O
the	O
changes	O
in	O
the	O
peak	O
amplitude	O
of	O
the	O
Pp	O
values	O
were	O
induced	O
by	O
changes	O
in	O
the	O
environmental	O
parameters	O
.	O

However	O
,	O
part	O
of	O
the	O
changes	O
must	O
obviously	O
be	O
attributed	O
to	O
irrigation	O
.	O

This	O
conclusion	O
can	O
be	O
drawn	O
if	O
,	O
for	O
example	O
,	O
the	O
peaking	O
of	O
Pp	O
on	O
2	O
and	O
3	O
September	O
is	O
compared	O
with	O
the	O
peaking	O
of	O
Pp	O
on	O
29	O
August	O
.	O

Despite	O
the	O
comparable	O
size	O
of	O
the	O
T	O
and	O
r	O
.	O
h	O
.	O
gradients	O
,	O
the	O
peak	O
Pp	O
values	O
were	O
much	O
smaller	O
,	O
particularly	O
at	O
0	O
.	O
2	O
m	O
height	O
,	O
on	O
2	O
and	O
3	O
September	O
compared	O
with	O
29	O
August	O
.	O

Plots	O
of	O
the	O
Pp	O
values	O
measured	O
at	O
6	O
m	O
and	O
10	O
m	O
height	O
on	O
24	O
May	O
,	O
28	O
August	O
,	O
and	O
2	O
September	O
against	O
r	O
.	O
h	O
.	O

(	O
or	O
against	O
T	O
since	O
both	O
parameters	O
were	O
usually	O
closely	O
related	O
)	O
also	O
support	O
the	O
view	O
that	O
the	O
local	O
microclimate	O
is	O
not	O
the	O
only	O
factor	O
which	O
determined	O
the	O
magnitude	O
of	O
the	O
Pp	O
values	O
at	O
the	O
three	O
measuring	O
sites	O
.	O

Figure	O
4	O
shows	O
that	O
the	O
Pp	O
values	O
recorded	O
at	O
6	O
m	O
and	O
10	O
m	O
height	O
increased	O
with	O
decreasing	O
r	O
.	O
h	O
.	O
from	O
c	O
.	O

09	O
.	O
00	O
h	O
until	O
r	O
.	O
h	O
.	O
reached	O
the	O
minimum	O
value	O
(	O
and	O
T	O
the	O
maximum	O
value	O
,	O
respectively	O
)	O
,	O
when	O
with	O
the	O
progression	O
of	O
the	O
day	O
r	O
.	O
h	O
.	O
increased	O
and	O
T	O
decreased	O
,	O
Pp	O
decreased	O
again	O
.	O

This	O
decrease	O
was	O
much	O
faster	O
than	O
expected	O
in	O
the	O
light	O
of	O
the	O
preceding	O
r	O
.	O
h	O
.	O
-	O
induced	O
increase	O
of	O
Pp	O
if	O
the	O
plant	O
was	O
well	O
-	O
watered	O
(	O
24	O
May	O
;	O
Fig	O
.	O
4A	O
,	O
B	O
)	O
.	O

Refilling	O
of	O
the	O
leaf	O
cells	O
was	O
apparently	O
enhanced	O
by	O
the	O
high	O
hydration	O
state	O
of	O
the	O
plant	O
.	O

By	O
contrast	O
,	O
when	O
the	O
liana	O
had	O
not	O
been	O
irrigated	O
well	O
(	O
28	O
August	O
,	O
Fig	O
.	O
4C	O
,	O
D	O
)	O
both	O
kinetics	O
of	O
the	O
changes	O
of	O
Pp	O
with	O
r	O
.	O
h	O
.	O
were	O
comparable	O
.	O
<EOS>	B-X
WHO	B-X
documents	B-X
characterize	B-X
stunting	B-X
as	B-X
,	B-X
``	B-X
â¦impaired	B-X
growth	B-X
and	B-X
development	B-X
that	B-X
children	B-X
experience	B-X
from	B-X
poor	B-X
nutrition	B-X
,	B-X
repeated	B-X
infection	B-X
,	B-X
and	B-X
inadequate	B-X
psychosocial	B-X
stimulation	B-X
.	B-X
''	B-X
The	B-X
equation	B-X
of	B-X
stunting	B-X
with	B-X
malnutrition	B-X
is	B-X
common	B-X
.	B-X
This	B-X
contrasts	B-X
with	B-X
historic	B-X
and	B-X
modern	B-X
observations	B-X
indicating	B-X
that	B-X
growth	B-X
in	B-X
height	B-X
is	B-X
largely	B-X
independent	B-X
of	B-X
the	B-X
extent	B-X
and	B-X
nature	B-X
of	B-X
the	B-X
diet	B-X
.	B-X
Hepatopulmonary	B-X
syndrome	B-X
(	B-X
HPS	B-X
)	B-X
is	B-X
a	B-X
clinical	B-X
threesome	B-X
composed	B-X
of	B-X
liver	B-X
disease	B-X
,	B-X
intrapulmonary	B-X
vascular	B-X
dilatation	B-X
(	B-X
IPVD	B-X
)	B-X
and	B-X
arterial	B-X
gas	B-X
abnormalities	B-X
.	B-X
Its	B-X
occurrence	B-X
has	B-X
been	B-X
described	B-X
in	B-X
up	B-X
to	B-X
32	B-X
%	B-X
of	B-X
cirrhotic	B-X
candidates	B-X
for	B-X
liver	B-X
transplantation	B-X
.	B-X
It	B-X
also	B-X
affects	B-X
non-cirrhotic	B-X
patients	B-X
with	B-X
portal	B-X
hypertension	B-X
.	B-X
Its	B-X
pathogenesis	B-X
is	B-X
not	B-X
well	B-X
defined	B-X
,	B-X
but	B-X
an	B-X
association	B-X
of	B-X
factors	B-X
such	B-X
as	B-X
imbalance	B-X
in	B-X
the	B-X
endothelin	B-X
receptor	B-X
response	B-X
,	B-X
pulmonary	B-X
microvascular	B-X
remodeling	B-X
and	B-X
genetic	B-X
predisposition	B-X
is	B-X
thought	B-X
to	B-X
lead	B-X
to	B-X
IPVD	B-X
.	B-X
Diagnosis	B-X
is	B-X
based	B-X
on	B-X
imaging	B-X
methods	B-X
that	B-X
identify	B-X
these	B-X
dilatations	B-X
,	B-X
such	B-X
as	B-X
contrast	B-X
echocardiography	B-X
or	B-X
perfusion	B-X
scintigraphy	B-X
with	B-X
99mTc	B-X
,	B-X
as	B-X
well	B-X
as	B-X
analysis	B-X
of	B-X
arterial	B-X
gases	B-X
to	B-X
identify	B-X
elevated	B-X
alveolar-arterial	B-X
differences	B-X
in	B-X
O2	B-X
or	B-X
hypoxemia	B-X
.	B-X
There	B-X
is	B-X
no	B-X
effective	B-X
pharmacological	B-X
treatment	B-X
and	B-X
complete	B-X
resolution	B-X
only	B-X
occurs	B-X
through	B-X
liver	B-X
transplantation	B-X
.	B-X
The	B-X
importance	B-X
of	B-X
diagnosing	B-X
HPS	B-X
lies	B-X
in	B-X
prioritizing	B-X
transplant	B-X
candidates	B-X
,	B-X
since	B-X
presence	B-X
of	B-X
HPS	B-X
is	B-X
associated	B-X
with	B-X
worse	B-X
prognosis	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
paper	B-X
was	B-X
to	B-X
review	B-X
the	B-X
pathogenetic	B-X
theories	B-X
and	B-X
current	B-X
diagnostic	B-X
criteria	B-X
regarding	B-X
HPS	B-X
,	B-X
and	B-X
to	B-X
critically	B-X
analyze	B-X
the	B-X
prioritization	B-X
of	B-X
patients	B-X
with	B-X
HPS	B-X
on	B-X
the	B-X
liver	B-X
transplant	B-X
waiting	B-X
list	B-X
.	B-X
Searches	B-X
were	B-X
carried	B-X
out	B-X
in	B-X
the	B-X
Medline	B-X
(	B-X
Medical	B-X
Literature	B-X
Analysis	B-X
and	B-X
Retrieval	B-X
System	B-X
Online	B-X
)	B-X
via	B-X
PubMed	B-X
,	B-X
Cochrane	B-X
Library	B-X
and	B-X
Lilacs	B-X
(	B-X
Literatura	B-X
Latino-Americana	B-X
e	B-X
do	B-X
Caribe	B-X
em	B-X
CiÃªncias	B-X
da	B-X
SaÃºde	B-X
)	B-X
databases	B-X
for	B-X
articles	B-X
published	B-X
between	B-X
January	B-X
2002	B-X
and	B-X
December	B-X
2007	B-X
involving	B-X
adults	B-X
and	B-X
written	B-X
either	B-X
in	B-X
English	B-X
or	B-X
in	B-X
Portuguese	B-X
,	B-X
using	B-X
the	B-X
term	B-X
hepatopulmonary	B-X
syndrome	B-X
.	B-X
The	B-X
studies	B-X
of	B-X
greatest	B-X
relevance	B-X
were	B-X
included	B-X
in	B-X
the	B-X
review	B-X
,	B-X
along	B-X
with	B-X
text	B-X
books	B-X
and	B-X
articles	B-X
cited	B-X
in	B-X
references	B-X
that	B-X
were	B-X
obtained	B-X
through	B-X
the	B-X
review	B-X
.	B-X

The	O
low	O
hydration	O
state	O
of	O
the	O
plant	O
apparently	O
delayed	O
cell	O
refilling	O
.	O

After	O
4	O
d	O
irrigation	O
(	O
2	O
September	O
)	O
,	O
the	O
low	O
value	O
of	O
Pp	O
recovered	O
at	O
relatively	O
low	O
r	O
.	O
h	O
.	O
as	O
in	O
May	O
at	O
10	O
m	O
height	O
(	O
Fig	O
.	O
4F	O
)	O
,	O
but	O
not	O
at	O
6	O
m	O
height	O
(	O
Fig	O
.	O
4E	O
)	O
.	O

Recovery	O
of	O
the	O
low	O
Pp	O
values	O
at	O
this	O
height	O
occurred	O
,	O
however	O
,	O
at	O
significantly	O
lower	O
r	O
.	O
h	O
.	O
than	O
on	O
28	O
August	O
,	O
indicating	O
that	O
rehydration	O
of	O
the	O
leaves	O
at	O
this	O
height	O
had	O
not	O
been	O
completed	O
.	O

Evaluation	O
of	O
other	O
data	O
sets	O
yielded	O
similar	O
results	O
(	O
not	O
shown	O
)	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
influence	B-X
of	B-X
variable	B-X
density	B-X
and	B-X
data-driven	B-X
k-space	B-X
undersampling	B-X
patterns	B-X
on	B-X
reconstruction	B-X
quality	B-X
for	B-X
compressed	B-X
sensing	B-X
(	B-X
CS	B-X
)	B-X
magnetic	B-X
resonance	B-X
imaging	B-X
to	B-X
provide	B-X
recommendations	B-X
on	B-X
how	B-X
to	B-X
avoid	B-X
suboptimal	B-X
CS	B-X
reconstructions	B-X
.	B-X
Despite	B-X
the	B-X
value	B-X
of	B-X
mass	B-X
spectrometry	B-X
in	B-X
modern	B-X
natural	B-X
products	B-X
discovery	B-X
workflows	B-X
,	B-X
it	B-X
remains	B-X
very	B-X
difficult	B-X
to	B-X
compare	B-X
data	B-X
sets	B-X
between	B-X
laboratories	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
compared	B-X
mass	B-X
spectrometry	B-X
data	B-X
for	B-X
the	B-X
same	B-X
sample	B-X
set	B-X
from	B-X
two	B-X
different	B-X
laboratories	B-X
(	B-X
quadrupole	B-X
time-of-flight	B-X
and	B-X
quadrupole-Orbitrap	B-X
)	B-X
and	B-X
evaluated	B-X
the	B-X
similarity	B-X
between	B-X
these	B-X
two	B-X
data	B-X
sets	B-X
in	B-X
terms	B-X
of	B-X
both	B-X
mass	B-X
spectrometry	B-X
features	B-X
and	B-X
their	B-X
ability	B-X
to	B-X
describe	B-X
the	B-X
chemical	B-X
composition	B-X
of	B-X
the	B-X
sample	B-X
set	B-X
.	B-X
Somewhat	B-X
surprisingly	B-X
,	B-X
the	B-X
two	B-X
data	B-X
sets	B-X
,	B-X
collected	B-X
with	B-X
appropriate	B-X
controls	B-X
and	B-X
replication	B-X
,	B-X
had	B-X
very	B-X
low	B-X
feature	B-X
overlap	B-X
(	B-X
25.7	B-X
%	B-X
of	B-X
Laboratory	B-X
A	B-X
features	B-X
overlapping	B-X
21.8	B-X
%	B-X
of	B-X
Laboratory	B-X
B	B-X
features	B-X
)	B-X
.	B-X
Our	B-X
data	B-X
clearly	B-X
demonstrate	B-X
that	B-X
differences	B-X
in	B-X
fragmentation	B-X
,	B-X
charge	B-X
state	B-X
,	B-X
and	B-X
adduct	B-X
formation	B-X
in	B-X
the	B-X
ionization	B-X
source	B-X
are	B-X
a	B-X
major	B-X
underlying	B-X
cause	B-X
for	B-X
these	B-X
differences	B-X
.	B-X
Consistent	B-X
with	B-X
other	B-X
recent	B-X
literature	B-X
,	B-X
these	B-X
findings	B-X
challenge	B-X
the	B-X
conventional	B-X
wisdom	B-X
that	B-X
electrospray	B-X
ionization	B-X
mass	B-X
spectrometry	B-X
(	B-X
ESI-MS	B-X
)	B-X
yields	B-X
a	B-X
simple	B-X
one-to-one	B-X
correspondence	B-X
between	B-X
analytes	B-X
in	B-X
solution	B-X
and	B-X
features	B-X
in	B-X
the	B-X
data	B-X
set	B-X
.	B-X
Importantly	B-X
,	B-X
despite	B-X
low	B-X
overlap	B-X
in	B-X
feature	B-X
lists	B-X
,	B-X
principal	B-X
component	B-X
analysis	B-X
(	B-X
PCA	B-X
)	B-X
generated	B-X
qualitatively	B-X
similar	B-X
PCA	B-X
plots	B-X
.	B-X
Overall	B-X
,	B-X
our	B-X
findings	B-X
demonstrate	B-X
that	B-X
comparing	B-X
untargeted	B-X
metabolomics	B-X
data	B-X
between	B-X
laboratories	B-X
is	B-X
challenging	B-X
,	B-X
but	B-X
that	B-X
data	B-X
sets	B-X
with	B-X
low	B-X
feature	B-X
overlap	B-X
can	B-X
yield	B-X
the	B-X
same	B-X
qualitative	B-X
description	B-X
of	B-X
a	B-X
sample	B-X
set	B-X
using	B-X
PCA	B-X
.	B-X

Patch	O
clamp	O
pressure	O
versus	O
cell	O
turgor	O
pressure	O
measurements	O

The	O
leaf	O
patch	O
clamp	O
pressure	O
probe	O
measures	O
the	O
pressure	O
transfer	O
function	O
of	O
a	O
defined	O
leaflet	O
area	O
.	O

The	O
above	O
theoretical	O
considerations	O
have	O
shown	O
that	O
the	O
transfer	O
function	O
is	O
mainly	O
determined	O
by	O
turgor	O
pressure	O
provided	O
that	O
the	O
structural	O
elements	O
do	O
not	O
contribute	O
or	O
constantly	O
contribute	O
to	O
the	O
pressure	O
signal	O
transfer	O
.	O

In	O
order	O
to	O
prove	O
the	O
theory	O
parallel	O
measurements	O
of	O
leaf	O
patch	O
clamp	O
pressure	O
(	O
Pp	O
)	O
and	O
cell	O
turgor	O
pressure	O
(	O
Pc	O
)	O
were	O
performed	O
on	O
a	O
leaflet	O
at	O
0	O
.	O
2	O
m	O
height	O
(	O
Fig	O
.	O
5A	O
)	O
.	O

Simultaneously	O
,	O
the	O
Pp	O
values	O
were	O
recorded	O
at	O
6	O
m	O
and	O
10	O
m	O
height	O
(	O
Fig	O
.	O
5B	O
,	O
C	O
)	O
.	O

Measurements	O
were	O
performed	O
after	O
several	O
days	O
of	O
irrigation	O
.	O
<EOS>	B-X
Lung	B-X
Microbiota	B-X
Predict	B-X
Clinical	B-X
Outcomes	B-X
in	B-X
Critically	B-X
Ill	B-X
Patients	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
effects	B-X
of	B-X
different	B-X
post	B-X
space	B-X
irrigation	B-X
protocols	B-X
for	B-X
removing	B-X
residual	B-X
filling	B-X
material	B-X
from	B-X
dentin	B-X
walls	B-X
,	B-X
by	B-X
using	B-X
microcomputed	B-X
tomography	B-X
(	B-X
micro-CT	B-X
)	B-X
,	B-X
and	B-X
the	B-X
influence	B-X
of	B-X
these	B-X
protocols	B-X
on	B-X
dentin	B-X
microhardness	B-X
.	B-X
Post	B-X
space	B-X
preparation	B-X
(	B-X
PSP	B-X
)	B-X
was	B-X
performed	B-X
7	B-X
days	B-X
after	B-X
filling	B-X
,	B-X
using	B-X
the	B-X
Odous	B-X
Touch	B-X
electrical	B-X
system	B-X
(	B-X
Odous	B-X
De	B-X
Deus	B-X
Ind	B-X
.	B-X
e	B-X
Com.	B-X
,	B-X
Belo	B-X
Horizonte	B-X
,	B-X
MG	B-X
,	B-X
Brazil	B-X
)	B-X
,	B-X
followed	B-X
by	B-X
post	B-X
space	B-X
irrigation	B-X
using	B-X
manual	B-X
irrigation	B-X
,	B-X
passive	B-X
ultrasonic	B-X
irrigation	B-X
,	B-X
or	B-X
Easy	B-X
Clean	B-X
,	B-X
together	B-X
with	B-X
2.5	B-X
%	B-X
sodium	B-X
hypochlorite	B-X
(	B-X
NaOCl	B-X
)	B-X
,	B-X
or	B-X
with	B-X
2.5	B-X
%	B-X
NaOCl	B-X
and	B-X
17	B-X
%	B-X
EDTA	B-X
(	B-X
NaOCl/EDTA	B-X
)	B-X
.	B-X
Micro-CT	B-X
scans	B-X
were	B-X
performed	B-X
at	B-X
three	B-X
time	B-X
points	B-X
.	B-X
Statistical	B-X
analysis	B-X
was	B-X
performed	B-X
using	B-X
ANOVA	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
The	B-X
best	B-X
removal	B-X
of	B-X
the	B-X
residual	B-X
filling	B-X
material	B-X
was	B-X
performed	B-X
using	B-X
the	B-X
Easy	B-X
Clean	B-X
tip	B-X
and	B-X
NaOCl/EDTA	B-X
,	B-X
regardless	B-X
of	B-X
the	B-X
activation	B-X
methods	B-X
.	B-X

In	O
these	O
experiments	O
,	O
the	O
microcapillary	O
of	O
the	O
turgor	O
pressure	O
probe	O
was	O
inserted	O
into	O
parenchymal	O
cells	O
located	O
close	O
to	O
the	O
main	O
vein	O
on	O
the	O
abaxial	O
side	O
of	O
a	O
leaflet	O
,	O
i	O
.	O
e	O
.	O
c	O
.	O

10	O
cm	O
away	O
from	O
the	O
leaf	O
patch	O
clamp	O
pressure	O
probe	O
near	O
the	O
leaflet	O
periphery	O
.	O

Turgor	O
pressure	O
measurements	O
on	O
leaf	O
cells	O
of	O
T	B-Species
.	I-Species
voinierianum	I-Species
were	O
difficult	O
to	O
perform	O
because	O
of	O
the	O
presence	O
of	O
mucilage	O
.	O

Mucilage	O
resulted	O
in	O
clogging	O
of	O
the	O
tip	O
of	O
the	O
microcapillary	O
of	O
the	O
cell	O
turgor	O
pressure	O
probe	O
.	O

For	O
this	O
reason	O
,	O
measurements	O
with	O
the	O
Scholander	O
pressure	O
chamber	O
were	O
not	O
very	O
reliable	O
.	O

It	O
was	O
extremely	O
difficult	O
to	O
determine	O
exactly	O
the	O
balancing	O
pressure	O
at	O
which	O
water	O
appears	O
at	O
the	O
cut	O
end	O
of	O
the	O
petiole	O
of	O
the	O
leaf	O
.	O

In	O
Fig	O
.	O
<EOS>	B-X
Fig	B-X
plants	B-X
appear	B-X
to	B-X
have	B-X
discriminatively	B-X
enforced	B-X
fig	B-X
wasps	B-X
to	B-X
evolve	B-X
``	B-X
adaptation	B-X
characteristics	B-X
''	B-X
that	B-X
provide	B-X
greater	B-X
benefit	B-X
to	B-X
the	B-X
fig	B-X
,	B-X
and	B-X
fig	B-X
wasps	B-X
appear	B-X
to	B-X
have	B-X
diversified	B-X
their	B-X
evolutionary	B-X
strategies	B-X
in	B-X
response	B-X
to	B-X
discriminative	B-X
enforcement	B-X
by	B-X
figs	B-X
and	B-X
competition	B-X
among	B-X
different	B-X
fig	B-X
wasp	B-X
species	B-X
.	B-X
Fig	B-X
mosaic	B-X
disease	B-X
(	B-X
FMD	B-X
)	B-X
is	B-X
a	B-X
viral	B-X
disease	B-X
that	B-X
poses	B-X
a	B-X
significant	B-X
danger	B-X
to	B-X
Egypt	B-X
's	B-X
fig-producing	B-X
economy	B-X
.	B-X
Fig	B-X
mosaic	B-X
is	B-X
a	B-X
viral	B-X
disease	B-X
(	B-X
FMD	B-X
)	B-X
that	B-X
spreads	B-X
in	B-X
Palestinian	B-X
common	B-X
fig	B-X
(	B-X
Fig	B-X
.	B-X
3D	B-X
``	B-X
miR-452	B-X
mimics	B-X
''	B-X
is	B-X
very	B-X
similar	B-X
to	B-X
Fig	B-X
.	B-X
3D	B-X
``	B-X
miRNC	B-X
''	B-X
is	B-X
very	B-X
similar	B-X
to	B-X
Fig	B-X
.	B-X
3E	B-X
``	B-X
si-NC	B-X
''	B-X
in	B-X
article	B-X
[	B-X
2	B-X
]	B-X
and	B-X
to	B-X
Fig	B-X
.	B-X

5A	O
the	O
average	O
turgor	O
pressure	O
values	O
are	O
plotted	O
which	O
were	O
calculated	O
from	O
3	O
-	O
8	O
min	O
long	O
measurements	O
.	O

Inspection	O
of	O
Fig	O
.	O
<EOS>	B-X
The	B-X
corresponding	B-X
author	B-X
,	B-X
Dr	B-X
Byoungduck	B-X
Park	B-X
,	B-X
requested	B-X
publication	B-X
of	B-X
a	B-X
corrigendum	B-X
to	B-X
correct	B-X
Fig	B-X
.	B-X
Upon	B-X
further	B-X
inspection	B-X
,	B-X
the	B-X
Biochimie	B-X
editorial	B-X
team	B-X
noticed	B-X
that	B-X
:	B-X
Comparison	B-X
of	B-X
Fig	B-X
.	B-X
2B	B-X
with	B-X
Fig	B-X
.	B-X
4C	B-X
of	B-X
a	B-X
previous	B-X
publication	B-X
in	B-X
International	B-X
Immunopharmacology	B-X
by	B-X
two	B-X
co-authors	B-X
(	B-X
doi	B-X
:	B-X
10.1016/j.intimp.2015.02.014	B-X
)	B-X
reveals	B-X
that	B-X
western	B-X
blot	B-X
Î²-actin	B-X
control	B-X
data	B-X
from	B-X
the	B-X
earlier	B-X
paper	B-X
were	B-X
re-used	B-X
in	B-X
a	B-X
different	B-X
experiment	B-X
shown	B-X
in	B-X
Fig	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
same	B-X
bands	B-X
,	B-X
after	B-X
more	B-X
image	B-X
manipulation	B-X
were	B-X
presented	B-X
as	B-X
Smad3	B-X
data	B-X
in	B-X
Fig	B-X
.	B-X

5A	O
-	O
C	O
shows	O
that	O
Pc	O
exhibited	O
similar	O
diurnal	O
changes	O
as	O
the	O
Pp	O
values	O
at	O
0	O
.	O
2	O
m	O
,	O
6	O
m	O
,	O
and	O
10	O
m	O
height	O
.	O

Changes	O
in	O
Pc	O
after	O
sunrise	O
preceded	O
changes	O
in	O
Pp	O
,	O
most	O
likely	O
due	O
to	O
the	O
different	O
measuring	O
sites	O
on	O
the	O
leaflets	O
.	O

After	O
the	O
onset	O
of	O
transpiration	O
the	O
loss	O
of	O
turgor	O
pressure	O
of	O
cells	O
located	O
at	O
the	O
periphery	O
of	O
the	O
leaflets	O
(	O
where	O
Pp	O
is	O
recorded	O
)	O
is	O
apparently	O
immediately	O
compensated	O
by	O
water	O
shifting	O
from	O
the	O
xylem	O
and	O
the	O
cells	O
located	O
close	O
to	O
the	O
main	O
vein	O
(	O
where	O
Pc	O
is	O
measured	O
)	O
.	O

Consistent	O
with	O
this	O
explanation	O
,	O
towards	O
the	O
afternoon	O
when	O
all	O
cells	O
throughout	O
the	O
leaflets	O
exhibit	O
low	O
turgor	O
pressure	O
,	O
the	O
increase	O
in	O
Pc	O
and	O
the	O
decrease	O
in	O
Pp	O
occurred	O
nearly	O
concomitantly	O
.	O

Interestingly	O
,	O
the	O
delay	O
between	O
the	O
response	O
of	O
Pc	O
and	O
Pp	O
upon	O
changes	O
in	O
T	O
and	O
r	O
.	O
h	O
.	O
in	O
the	O
early	O
morning	O
hours	O
decreased	O
from	O
about	O
2	O
.	O
5	O
h	O
at	O
0	O
.	O
2	O
m	O
height	O
to	O
1	O
.	O
5	O
h	O
at	O
6	O
m	O
height	O
,	O
and	O
to	O
1	O
h	O
at	O
10	O
m	O
height	O
.	O

In	O
Fig	O
.	O
<EOS>	B-X
Fig	B-X
plants	B-X
appear	B-X
to	B-X
have	B-X
discriminatively	B-X
enforced	B-X
fig	B-X
wasps	B-X
to	B-X
evolve	B-X
``	B-X
adaptation	B-X
characteristics	B-X
''	B-X
that	B-X
provide	B-X
greater	B-X
benefit	B-X
to	B-X
the	B-X
fig	B-X
,	B-X
and	B-X
fig	B-X
wasps	B-X
appear	B-X
to	B-X
have	B-X
diversified	B-X
their	B-X
evolutionary	B-X
strategies	B-X
in	B-X
response	B-X
to	B-X
discriminative	B-X
enforcement	B-X
by	B-X
figs	B-X
and	B-X
competition	B-X
among	B-X
different	B-X
fig	B-X
wasp	B-X
species	B-X
.	B-X
Fig	B-X
mosaic	B-X
disease	B-X
(	B-X
FMD	B-X
)	B-X
is	B-X
a	B-X
viral	B-X
disease	B-X
that	B-X
poses	B-X
a	B-X
significant	B-X
danger	B-X
to	B-X
Egypt	B-X
's	B-X
fig-producing	B-X
economy	B-X
.	B-X
Fig	B-X
mosaic	B-X
is	B-X
a	B-X
viral	B-X
disease	B-X
(	B-X
FMD	B-X
)	B-X
that	B-X
spreads	B-X
in	B-X
Palestinian	B-X
common	B-X
fig	B-X
(	B-X
Fig	B-X
.	B-X
3D	B-X
``	B-X
miR-452	B-X
mimics	B-X
''	B-X
is	B-X
very	B-X
similar	B-X
to	B-X
Fig	B-X
.	B-X
3D	B-X
``	B-X
miRNC	B-X
''	B-X
is	B-X
very	B-X
similar	B-X
to	B-X
Fig	B-X
.	B-X
3E	B-X
``	B-X
si-NC	B-X
''	B-X
in	B-X
article	B-X
[	B-X
2	B-X
]	B-X
and	B-X
to	B-X
Fig	B-X
.	B-X

5D	O
the	O
Pp	O
values	O
measured	O
at	O
the	O
three	O
heights	O
are	O
plotted	O
against	O
the	O
corresponding	O
Pc	O
values	O
(	O
i	O
.	O
e	O
.	O
neglecting	O
the	O
delayed	O
response	O
of	O
Pp	O
)	O
.	O

The	O
curves	O
could	O
be	O
fitted	O
quite	O
well	O
by	O
equation	O
8	O
.	O
<EOS>	B-X
Clinical	B-X
doses	B-X
of	B-X
isotretinoin	B-X
range	B-X
from	B-X
0.5	B-X
to	B-X
8	B-X
mg/kg/day	B-X
,	B-X
with	B-X
acute	B-X
side	B-X
effects	B-X
appearing	B-X
following	B-X
doses	B-X
of	B-X
1	B-X
mg/kg/day	B-X
or	B-X
greater	B-X
.	B-X
Isotretinoin	B-X
blood	B-X
concentration-time	B-X
curves	B-X
following	B-X
a	B-X
single-	B-X
or	B-X
multiple-dose	B-X
regimen	B-X
are	B-X
well	B-X
described	B-X
by	B-X
a	B-X
linear	B-X
model	B-X
with	B-X
biphasic	B-X
disposition	B-X
characteristics	B-X
.	B-X
In	B-X
most	B-X
conditions	B-X
,	B-X
the	B-X
retinoids	B-X
produce	B-X
a	B-X
maximal	B-X
effect	B-X
in	B-X
about	B-X
8	B-X
weeks	B-X
(	B-X
at	B-X
the	B-X
highest	B-X
tolerated	B-X
dose	B-X
)	B-X
,	B-X
with	B-X
a	B-X
slow	B-X
recurrence	B-X
of	B-X
symptoms	B-X
usually	B-X
occurring	B-X
within	B-X
several	B-X
weeks	B-X
following	B-X
cessation	B-X
of	B-X
treatment	B-X
-	B-X
except	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
cystic	B-X
acne	B-X
with	B-X
isotretinoin	B-X
.	B-X
Recently	B-X
,	B-X
however	B-X
,	B-X
blood	B-X
concentration	B-X
versus	B-X
time	B-X
curves	B-X
from	B-X
day	B-X
1	B-X
to	B-X
day	B-X
180	B-X
of	B-X
etretinate	B-X
therapy	B-X
have	B-X
been	B-X
fitted	B-X
by	B-X
a	B-X
single	B-X
polyexponential	B-X
pharmacokinetic	B-X
equation	B-X
without	B-X
the	B-X
need	B-X
to	B-X
invoke	B-X
non-linearity	B-X
in	B-X
the	B-X
kinetics	B-X
.	B-X

Fitting	O
of	O
the	O
curves	O
required	O
the	O
assumption	O
of	O
different	O
values	O
for	O
the	O
constants	O
a	O
and	O
b	O
in	O
equation	O
4	O
(	O
see	O
legend	O
to	O
Fig	O
.	O
5	O
)	O
indicating	O
that	O
the	O
elastic	O
properties	O
of	O
the	O
leaves	O
were	O
different	O
,	O
presumably	O
due	O
to	O
changes	O
of	O
the	O
ambient	O
temperature	O
with	O
height	O
(	O
see	O
above	O
)	O
.	O

Turgor	O
pressure	O
measurements	O
at	O
5	O
m	O
height	O
failed	O
because	O
of	O
abundant	O
mucilage	O
in	O
the	O
leaflet	O
tissue	O
at	O
this	O
time	O
of	O
the	O
year	O
.	O

Mucilage	O
in	O
the	O
cells	O
and	O
xylem	O
vessels	O
was	O
less	O
abundant	O
when	O
turgor	O
pressure	O
measurements	O
were	O
performed	O
during	O
the	O
summer	O
of	O
1999	O
.	O

Plot	O
of	O
the	O
Pc	O
data	O
measured	O
by	O
Th	O
u	O
rmer	O
et	O
al	O
.	O

(	O
1999	O
)	O
at	O
5	O
m	O
height	O
against	O
online	O
recordings	O
of	O
Pp	O
in	O
May	O
2007	O
revealed	O
very	O
good	O
agreement	O
between	O
both	O
parameters	O
,	O
even	O
though	O
the	O
microcapillary	O
was	O
inserted	O
into	O
cells	O
located	O
on	O
the	O
upper	O
leaflet	O
surface	O
between	O
the	O
main	O
vein	O
and	O
the	O
leaflet	O
edge	O
(	O
Fig	O
.	O
6	O
)	O
.	O

On	O
both	O
measuring	O
days	O
in	O
1999	O
and	O
2007	O
,	O
similar	O
environmental	O
conditions	O
existed	O
.	O

Inspection	O
of	O
Fig	O
.	O
<EOS>	B-X
The	B-X
corresponding	B-X
author	B-X
,	B-X
Dr	B-X
Byoungduck	B-X
Park	B-X
,	B-X
requested	B-X
publication	B-X
of	B-X
a	B-X
corrigendum	B-X
to	B-X
correct	B-X
Fig	B-X
.	B-X
Upon	B-X
further	B-X
inspection	B-X
,	B-X
the	B-X
Biochimie	B-X
editorial	B-X
team	B-X
noticed	B-X
that	B-X
:	B-X
Comparison	B-X
of	B-X
Fig	B-X
.	B-X
2B	B-X
with	B-X
Fig	B-X
.	B-X
4C	B-X
of	B-X
a	B-X
previous	B-X
publication	B-X
in	B-X
International	B-X
Immunopharmacology	B-X
by	B-X
two	B-X
co-authors	B-X
(	B-X
doi	B-X
:	B-X
10.1016/j.intimp.2015.02.014	B-X
)	B-X
reveals	B-X
that	B-X
western	B-X
blot	B-X
Î²-actin	B-X
control	B-X
data	B-X
from	B-X
the	B-X
earlier	B-X
paper	B-X
were	B-X
re-used	B-X
in	B-X
a	B-X
different	B-X
experiment	B-X
shown	B-X
in	B-X
Fig	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
same	B-X
bands	B-X
,	B-X
after	B-X
more	B-X
image	B-X
manipulation	B-X
were	B-X
presented	B-X
as	B-X
Smad3	B-X
data	B-X
in	B-X
Fig	B-X
.	B-X

6	O
shows	O
that	O
Pp	O
measured	O
at	O
6	O
m	O
height	O
was	O
delayed	O
by	O
c	O
.	O

1	O
.	O
5	O
h	O
.	O
<EOS>	B-X
The	B-X
uranium	B-X
bipyridyl	B-X
metallocene	B-X
,	B-X
[	B-X
Î·	B-X
In	B-X
recent	B-X
years	B-X
,	B-X
the	B-X
high	B-X
prevalence	B-X
of	B-X
avian	B-X
influenza	B-X
viruses	B-X
especially	B-X
H	B-X
Gas-phase	B-X
1,3,5,7-cyclooctatetraene	B-X
(	B-X
C	B-X
The	B-X
reaction	B-X
of	B-X
[	B-X
(	B-X
C	B-X

A	O
plot	O
of	O
the	O
Pp	O
values	O
against	O
the	O
Pc	O
values	O
according	O
to	O
Fig	O
.	O

5D	O
could	O
also	O
be	O
fitted	O
very	O
well	O
by	O
equation	O
8	O
(	O
see	O
inset	O
of	O
Fig	O
.	O
6	O
)	O
indicating	O
the	O
validity	O
of	O
equation	O
8	O
to	O
describe	O
properly	O
the	O
relationship	O
between	O
Pp	O
and	O
Pc	O
.	O

Discussion	O
<EOS>	B-X
Discussion	B-X
structures	B-X
are	B-X
argumentation-theoretical	B-X
tools	B-X
that	B-X
can	B-X
be	B-X
employed	B-X
to	B-X
tackle	B-X
three	B-X
barriers	B-X
that	B-X
separate	B-X
lay	B-X
stakeholders	B-X
from	B-X
policy	B-X
debates	B-X
:	B-X
difficulty	B-X
,	B-X
magnitude	B-X
,	B-X
and	B-X
complexity	B-X
.	B-X
Discussions	B-X
about	B-X
preventive	B-X
behaviors	B-X
were	B-X
assessed	B-X
before	B-X
testing	B-X
and	B-X
1	B-X
and	B-X
6	B-X
months	B-X
post-testing	B-X
.	B-X
Discussion	B-X
of	B-X
preventive	B-X
behaviors	B-X
declined	B-X
following	B-X
test	B-X
reporting	B-X
,	B-X
with	B-X
more	B-X
rapid	B-X
decline	B-X
reported	B-X
by	B-X
noncarriers	B-X
.	B-X
Discussions	B-X
are	B-X
an	B-X
important	B-X
part	B-X
of	B-X
medical	B-X
education	B-X
research	B-X
papers	B-X
,	B-X
but	B-X
there	B-X
is	B-X
little	B-X
guidance	B-X
on	B-X
how	B-X
to	B-X
write	B-X
up	B-X
the	B-X
discussion	B-X
section	B-X
.	B-X

The	O
results	O
presented	O
here	O
demonstrate	O
that	O
the	O
novel	O
patch	O
clamp	O
pressure	O
probe	O
is	O
a	O
very	O
sensitive	O
,	O
versatile	O
,	O
and	O
easy	O
-	O
to	O
-	O
handle	O
plant	O
-	O
based	O
tool	O
for	O
online	O
monitoring	O
of	O
the	O
effects	O
of	O
evapotranspiration	O
and	O
/	O
or	O
of	O
irrigation	O
regimes	O
on	O
the	O
water	O
relations	O
of	O
leaves	O
(	O
Figs	O
2	O
,	O
3	O
)	O
.	O

The	O
probe	O
measures	O
the	O
output	O
signal	O
upon	O
application	O
of	O
a	O
constantly	O
clamped	O
pressure	O
,	O
i	O
.	O
e	O
.	O
the	O
pressure	O
transfer	O
function	O
of	O
leaf	O
patches	O
.	O

Since	O
the	O
application	O
of	O
the	O
probe	O
is	O
not	O
restricted	O
to	O
special	O
leaves	O
,	O
patch	O
clamp	O
pressure	O
measurements	O
will	O
readily	O
show	O
which	O
crop	O
varieties	O
can	O
be	O
grown	O
with	O
the	O
least	O
water	O
for	O
the	O
most	O
yield	O
.	O
<EOS>	B-X
Using	B-X
a	B-X
periodic	B-X
coupling	B-X
field	B-X
the	B-X
response	B-X
of	B-X
the	B-X
medium	B-X
to	B-X
the	B-X
propagating	B-X
plane	B-X
probe	B-X
beam	B-X
becomes	B-X
periodic	B-X
.	B-X
The	B-X
needed	B-X
periodic	B-X
coupling	B-X
field	B-X
is	B-X
generated	B-X
with	B-X
the	B-X
interference	B-X
of	B-X
two	B-X
coherent	B-X
plane	B-X
waves	B-X
having	B-X
a	B-X
small	B-X
angle	B-X
and	B-X
propagating	B-X
almost	B-X
parallel	B-X
to	B-X
the	B-X
probe	B-X
beam	B-X
direction	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
tunneling	B-X
effect	B-X
of	B-X
an	B-X
electron	B-X
between	B-X
two	B-X
adjacent	B-X
QDs	B-X
,	B-X
for	B-X
the	B-X
probe	B-X
beam	B-X
propagating	B-X
through	B-X
the	B-X
QDM	B-X
system	B-X
,	B-X
the	B-X
medium	B-X
becomes	B-X
transparent	B-X
where	B-X
the	B-X
coupling	B-X
fields	B-X
interfere	B-X
constructively	B-X
.	B-X
As	B-X
a	B-X
result	B-X
,	B-X
the	B-X
spatial	B-X
periodicity	B-X
of	B-X
the	B-X
coupling	B-X
field	B-X
modulates	B-X
the	B-X
passing	B-X
plane	B-X
probe	B-X
beam	B-X
.	B-X
We	B-X
determine	B-X
the	B-X
minimum	B-X
length	B-X
of	B-X
the	B-X
QDM	B-X
system	B-X
to	B-X
generate	B-X
a	B-X
periodic	B-X
intensity	B-X
profile	B-X
with	B-X
a	B-X
visibility	B-X
value	B-X
equal	B-X
to	B-X
1	B-X
for	B-X
the	B-X
probe	B-X
field	B-X
at	B-X
the	B-X
exit	B-X
plane	B-X
of	B-X
the	B-X
medium	B-X
.	B-X
It	B-X
is	B-X
also	B-X
shown	B-X
that	B-X
by	B-X
increasing	B-X
the	B-X
propagation	B-X
length	B-X
of	B-X
the	B-X
probe	B-X
beam	B-X
through	B-X
the	B-X
QDM	B-X
medium	B-X
,	B-X
the	B-X
profile	B-X
of	B-X
the	B-X
maximum	B-X
intensity	B-X
areas	B-X
becomes	B-X
sharper	B-X
.	B-X
This	B-X
feature	B-X
is	B-X
quantified	B-X
by	B-X
considering	B-X
a	B-X
sharpness	B-X
factor	B-X
for	B-X
the	B-X
intensity	B-X
profile	B-X
of	B-X
the	B-X
probe	B-X
beam	B-X
at	B-X
the	B-X
transverse	B-X
plane	B-X
.	B-X
The	B-X
presented	B-X
dynamically	B-X
designing	B-X
method	B-X
of	B-X
the	B-X
periodic	B-X
coherent	B-X
intensity	B-X
patterns	B-X
might	B-X
find	B-X
applications	B-X
in	B-X
science	B-X
and	B-X
technology	B-X
.	B-X

It	O
has	O
also	O
been	O
demonstated	O
here	O
that	O
the	O
plant	O
-	O
based	O
data	O
can	O
be	O
sent	O
by	O
small	O
telemetric	O
units	O
connected	O
to	O
the	O
patch	O
clamp	O
pressure	O
probes	O
to	O
a	O
receiver	O
base	O
station	O
which	O
logs	O
and	O
stores	O
the	O
data	O
pending	O
transfer	O
to	O
a	O
GPRS	O
modem	O
linked	O
to	O
an	O
Internet	O
server	O
.	O

The	O
telemetric	O
systems	O
operated	O
faultlessly	O
.	O

This	O
is	O
a	O
very	O
important	O
result	O
because	O
there	O
is	O
agreement	O
between	O
scientists	O
and	O
growers	O
(	O
Jones	O
,	O
2004	O
)	O
that	O
control	O
of	O
irrigation	O
must	O
be	O
tied	O
to	O
remote	O
sensing	O
devices	O
in	O
order	O
to	O
reduce	O
manpower	O
and	O
to	O
conserve	O
water	O
.	O

The	O
patch	O
clamp	O
pressure	O
probe	O
technique	O
introduced	O
here	O
meets	O
these	O
demands	O
.	O

A	O
further	O
advantage	O
is	O
that	O
the	O
probe	O
is	O
cheap	O
and	O
easy	O
to	O
handle	O
.	O

Some	O
care	O
is	O
required	O
only	O
when	O
clamping	O
the	O
leaf	O
.	O

Leaves	O
must	O
be	O
clean	O
and	O
any	O
rough	O
surface	O
topography	O
must	O
be	O
avoided	O
.	O

This	O
implies	O
that	O
the	O
dimensions	O
of	O
the	O
pads	O
of	O
the	O
spring	O
clamp	O
must	O
be	O
adjusted	O
to	O
the	O
size	O
of	O
the	O
intercostal	O
area	O
since	O
non	O
-	O
uniform	O
contact	O
between	O
leaf	O
surface	O
and	O
pads	O
lowered	O
the	O
output	O
pressure	O
signal	O
.	O

Experience	O
collected	O
with	O
patch	O
clamp	O
pressure	O
measurements	O
on	O
T	B-Species
.	I-Species
voinierianum	I-Species
and	O
on	O
preliminary	O
results	O
of	O
other	O
plants	O
(	O
e	O
.	O
g	O
.	O
grapevines	O
,	O
bananas	B-Species
,	O
Eucalyptus	O
,	O
and	O
Arabidopsis	O
)	O
showed	O
that	O
a	O
smooth	O
intercostal	O
leaf	O
area	O
for	O
clamping	O
can	O
readily	O
be	O
found	O
.	O

Equally	O
,	O
optimum	O
values	O
for	O
the	O
clamp	O
pressure	O
can	O
also	O
be	O
relatively	O
quickly	O
selected	O
empirically	O
if	O
the	O
guidelines	O
mentioned	O
above	O
are	O
followed	O
.	O

For	O
many	O
purposes	O
calibration	O
of	O
the	O
leaf	O
patch	O
clamp	O
pressure	O
probe	O
against	O
the	O
cell	O
turgor	O
pressure	O
probe	O
is	O
not	O
stringent	O
.	O

It	O
may	O
be	O
sufficient	O
to	O
know	O
that	O
the	O
transfer	O
function	O
assumes	O
small	O
values	O
at	O
full	O
turgescence	O
and	O
is	O
nearly	O
unity	O
at	O
low	O
turgescence	O
.	O

However	O
,	O
for	O
scientific	O
reasons	O
and	O
for	O
the	O
application	O
of	O
the	O
probe	O
in	O
basic	O
research	O
,	O
the	O
dependency	O
of	O
the	O
transfer	O
function	O
on	O
cell	O
turgor	O
pressure	O
might	O
be	O
of	O
great	O
interest	O
.	O

The	O
theoretical	O
considerations	O
have	O
demonstrated	O
that	O
the	O
relationship	O
between	O
the	O
transfer	O
function	O
and	O
the	O
turgor	O
pressure	O
can	O
obviously	O
be	O
described	O
by	O
equation	O
8	O
,	O
i	O
.	O
e	O
.	O
by	O
a	O
power	O
function	O
.	O

Concomitant	O
measurements	O
of	O
turgor	O
pressure	O
and	O
patch	O
clamp	O
pressure	O
have	O
confirmed	O
the	O
theoretical	O
considerations	O
(	O
Fig	O
.	O
5	O
)	O
.	O

Analogous	O
recordings	O
of	O
turgor	O
pressure	O
and	O
patch	O
clamp	O
pressure	O
on	O
grapevines	O
,	O
bananas	B-Species
,	O
and	O
Eucalyptus	B-Species
trees	O
also	O
yielded	O
results	O
(	O
D	O
Zimmermann	O
,	O
unpublished	O
results	O
)	O
which	O
were	O
consistent	O
with	O
the	O
predictions	O
of	O
equation	O
8	O
.	O

Patch	O
clamp	O
pressure	O
measurements	O
allow	O
,	O
therefore	O
,	O
calculation	O
of	O
turgor	O
pressures	O
if	O
the	O
constants	O
a	O
and	O
b	O
defined	O
by	O
equation	O
4	O
are	O
known	O
.	O

These	O
parameters	O
can	O
be	O
obtained	O
by	O
numerical	O
fitting	O
of	O
Pp	O
versus	O
Pc	O
curves	O
.	O

Online	O
patch	O
clamp	O
pressure	O
measurements	O
open	O
up	O
new	O
possibilities	O
to	O
unravel	O
the	O
hydraulic	O
communication	O
among	O
leaves	O
,	O
including	O
tall	O
trees	O
.	O

It	O
is	O
shown	O
here	O
that	O
the	O
patch	O
clamp	O
pressure	O
can	O
simultaneously	O
be	O
monitored	O
in	O
shaded	O
or	O
sun	O
-	O
exposed	O
leaflets	O
at	O
different	O
heights	O
under	O
greenhouse	O
conditions	O
by	O
using	O
several	O
probes	O
.	O

It	O
was	O
even	O
possible	O
to	O
measure	O
the	O
turgor	O
pressure	O
at	O
different	O
sites	O
on	O
the	O
leaf	O
.	O

Therefore	O
,	O
water	O
shifting	O
between	O
leaf	O
cells	O
via	O
the	O
apoplastic	O
and	O
symplastic	O
pathways	O
can	O
be	O
studied	O
.	O

Physically	O
sound	O
theories	O
are	O
available	O
(	O
Molz	O
and	O
Ikenberry	O
,	O
1974	O
;	O
Molz	O
et	O
al	O
.	O
,	O
1979	O
)	O
,	O
but	O
experimental	O
facts	O
are	O
not	O
available	O
or	O
are	O
mainly	O
based	O
on	O
speculations	O
(	O
Steudle	O
and	O
French	O
,	O
1996	O
)	O
.	O

The	O
first	O
evidence	O
for	O
the	O
dynamics	O
of	O
the	O
hydraulic	O
communication	O
between	O
leaflets	O
at	O
different	O
height	O
and	O
within	O
leaflets	O
is	O
given	O
here	O
.	O

Th	O
u	O
rmer	O
et	O
al	O
.	O

(	O
1999	O
)	O
have	O
shown	O
by	O
using	O
the	O
xylem	O
and	O
turgor	O
pressure	O
probe	O
that	O
the	O
decrease	O
in	O
local	O
xylem	O
pressure	O
after	O
daybreak	O
from	O
positive	O
,	O
sub	O
-	O
atmospheric	O
or	O
slightly	O
above	O
-	O
atmospheric	O
values	O
to	O
negative	O
values	O
was	O
associated	O
with	O
an	O
almost	O
1	O
:	O
1	O
decrease	O
in	O
turgor	O
pressure	O
of	O
the	O
cells	O
located	O
close	O
to	O
the	O
main	O
vein	O
of	O
the	O
leaflets	O
(	O
see	O
also	O
Zimmermann	O
et	O
al	O
.	O
,	O
2004	O
)	O
.	O

Similarly	O
,	O
in	O
the	O
afternoon	O
,	O
the	O
increase	O
of	O
xylem	O
pressure	O
in	O
non	O
-	O
cavitated	O
vessels	O
towards	O
more	O
positive	O
values	O
correlated	O
with	O
a	O
1	O
:	O
1	O
increase	O
in	O
cell	O
turgor	O
pressure	O
.	O

Obviously	O
,	O
changes	O
in	O
transpiration	O
resulted	O
in	O
a	O
very	O
rapid	O
establishment	O
of	O
a	O
new	O
local	O
water	O
equilibrium	O
state	O
between	O
the	O
xylem	O
and	O
the	O
turgor	O
pressure	O
of	O
the	O
adjacent	O
cells	O
.	O

The	O
turgor	O
pressure	O
measurements	O
of	O
Th	O
u	O
rmer	O
et	O
al	O
.	O

(	O
1999	O
)	O
were	O
performed	O
at	O
1	O
m	O
and	O
5	O
m	O
height	O
.	O
<EOS>	B-X
J	B-X
Strength	B-X
Cond	B-X
Res	B-X
35	B-X
(	B-X
7	B-X
)	B-X
:	B-X
1992-1999	B-X
,	B-X
2021-Lower-extremity	B-X
musculoskeletal	B-X
injuries	B-X
in	B-X
soccer	B-X
are	B-X
common	B-X
among	B-X
sexes	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
we	B-X
performed	B-X
a	B-X
retrospective	B-X
cross-sectional	B-X
analysis	B-X
of	B-X
pre-season	B-X
data	B-X
from	B-X
male	B-X
(	B-X
ân	B-X
=	B-X
21	B-X
)	B-X
and	B-X
female	B-X
(	B-X
ân	B-X
=	B-X
19	B-X
)	B-X
professional	B-X
United	B-X
States	B-X
soccer	B-X
organizations	B-X
.	B-X
A	B-X
2-tailed	B-X
independent-samples	B-X
T-test	B-X
was	B-X
used	B-X
for	B-X
comparison	B-X
of	B-X
height	B-X
,	B-X
body	B-X
mass	B-X
,	B-X
body	B-X
mass	B-X
index	B-X
(	B-X
BMI	B-X
)	B-X
,	B-X
mean	B-X
leg	B-X
length	B-X
,	B-X
and	B-X
strength	B-X
ratios	B-X
between	B-X
dominant	B-X
and	B-X
nondominant	B-X
limbs	B-X
between	B-X
sexes	B-X
.	B-X
Type	B-X
I	B-X
error	B-X
was	B-X
set	B-X
at	B-X
Î±	B-X
=	B-X
0.05	B-X
for	B-X
all	B-X
analyses	B-X
.	B-X
Height	B-X
(	B-X
â183.1	B-X
Â±	B-X
6.8	B-X
cm	B-X
,	B-X
â170.0	B-X
Â±	B-X
5.5	B-X
cm	B-X
)	B-X
,	B-X
body	B-X
mass	B-X
(	B-X
â79.0	B-X
Â±	B-X
8.7	B-X
kg	B-X
,	B-X
â65.1	B-X
Â±	B-X
5.6	B-X
kg	B-X
)	B-X
,	B-X
BMI	B-X
(	B-X
â23.5	B-X
Â±	B-X
1.3	B-X
kgÂ·m-2	B-X
,	B-X
â22.5	B-X
Â±	B-X
1.4	B-X
kgÂ·m-2	B-X
)	B-X
,	B-X
and	B-X
mean	B-X
leg	B-X
length	B-X
(	B-X
â95.5	B-X
Â±	B-X
4.34	B-X
cm	B-X
,	B-X
â	B-X
88.3	B-X
Â±	B-X
3.24	B-X
cm	B-X
)	B-X
differed	B-X
between	B-X
groups	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Sex	B-X
differences	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
were	B-X
also	B-X
found	B-X
for	B-X
hip	B-X
abduction	B-X
(	B-X
dominant	B-X
â19.5	B-X
Â±	B-X
3.6	B-X
kg	B-X
,	B-X
â17.3	B-X
Â±	B-X
2.2	B-X
kg	B-X
;	B-X
nondominant	B-X
â18.5	B-X
Â±	B-X
3.7	B-X
kg	B-X
,	B-X
â16.0	B-X
Â±	B-X
2.3	B-X
kg	B-X
)	B-X
,	B-X
adduction	B-X
(	B-X
dominant	B-X
â19.8	B-X
Â±	B-X
3.0	B-X
kg	B-X
,	B-X
â16.7	B-X
Â±	B-X
2.3	B-X
kg	B-X
;	B-X
nondominant	B-X
â20.1	B-X
Â±	B-X
2.9	B-X
kg	B-X
,	B-X
â17.6	B-X
Â±	B-X
2.9	B-X
kg	B-X
)	B-X
,	B-X
external	B-X
rotation	B-X
(	B-X
dominant	B-X
â21.7	B-X
Â±	B-X
3.4	B-X
kg	B-X
,	B-X
â17.7	B-X
Â±	B-X
2.4	B-X
kg	B-X
;	B-X
nondominant	B-X
â21.6	B-X
Â±	B-X
3.9	B-X
kg	B-X
,	B-X
â16.8	B-X
Â±	B-X
2.1	B-X
kg	B-X
)	B-X
,	B-X
and	B-X
dominant	B-X
hamstring	B-X
strength	B-X
(	B-X
â27.9	B-X
Â±	B-X
6.5	B-X
kg	B-X
,	B-X
â23.0	B-X
Â±	B-X
4.9	B-X
kg	B-X
)	B-X
.	B-X
The	B-X
ratio	B-X
of	B-X
hip	B-X
internal	B-X
to	B-X
external	B-X
rotation	B-X
strength	B-X
differed	B-X
in	B-X
the	B-X
nondominant	B-X
leg	B-X
(	B-X
â1.1	B-X
Â±	B-X
0.2	B-X
,	B-X
â0.9	B-X
Â±	B-X
0.2	B-X
,	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X

No	O
significant	O
differences	O
in	O
the	O
turgor	O
pressure	O
values	O
were	O
found	O
over	O
the	O
day	O
.	O

The	O
turgor	O
pressure	O
measurements	O
at	O
0	O
.	O
2	O
m	O
height	O
reported	O
here	O
confirmed	O
the	O
finding	O
of	O
Th	O
u	O
rmer	O
et	O
al	O
.	O

(	O
1999	O
)	O
that	O
the	O
turgor	O
pressure	O
in	O
the	O
cells	O
located	O
near	O
the	O
main	O
vein	O
dropped	O
immediately	O
upon	O
daybreak	O
.	O

However	O
,	O
our	O
patch	O
clamp	O
pressure	O
measurements	O
at	O
the	O
periphery	O
of	O
the	O
leaflets	O
imply	O
that	O
the	O
turgor	O
pressure	O
of	O
these	O
cells	O
apparently	O
had	O
a	O
significantly	O
delayed	O
response	O
upon	O
the	O
onset	O
of	O
transpiration	O
.	O

This	O
finding	O
can	O
be	O
taken	O
as	O
evidence	O
that	O
turgor	O
pressure	O
gradients	O
are	O
temporarily	O
generated	O
within	O
the	O
leaf	O
during	O
the	O
early	O
morning	O
hours	O
.	O

This	O
delay	O
in	O
the	O
response	O
of	O
patch	O
clamp	O
pressure	O
after	O
daybreak	O
was	O
c	O
.	O

1	O
h	O
for	O
leaves	O
at	O
the	O
top	O
,	O
but	O
c	O
.	O

2	O
.	O
5	O
h	O
for	O
leaves	O
at	O
the	O
base	O
.	O
<EOS>	B-X
Books	B-X
with	B-X
titles	B-X
like	B-X
'The	B-X
Call	B-X
of	B-X
the	B-X
Wild	B-X
'	B-X
seemed	B-X
to	B-X
set	B-X
a	B-X
path	B-X
for	B-X
a	B-X
life	B-X
.	B-X
Thus	B-X
,	B-X
I	B-X
would	B-X
be	B-X
an	B-X
explorer-a	B-X
plan	B-X
that	B-X
did	B-X
not	B-X
work	B-X
out	B-X
so	B-X
well	B-X
,	B-X
at	B-X
least	B-X
at	B-X
first	B-X
.	B-X
On	B-X
leaving	B-X
school	B-X
I	B-X
got	B-X
a	B-X
job	B-X
as	B-X
a	B-X
'Works	B-X
Chemist	B-X
Improver	B-X
'	B-X
,	B-X
testing	B-X
Ni	B-X
catalysts	B-X
for	B-X
the	B-X
hydrogenation	B-X
of	B-X
phenol	B-X
to	B-X
cyclohexanol	B-X
.	B-X
Taking	B-X
night	B-X
classes	B-X
I	B-X
passed	B-X
enough	B-X
exams	B-X
to	B-X
study	B-X
geology	B-X
at	B-X
Queen	B-X
Mary	B-X
College	B-X
,	B-X
London	B-X
.	B-X
Armed	B-X
thus	B-X
I	B-X
travelled	B-X
to	B-X
the	B-X
Solomon	B-X
Islands	B-X
where	B-X
geology	B-X
is	B-X
a	B-X
'happening	B-X
'	B-X
!	B-X
Next	B-X
was	B-X
Canada	B-X
to	B-X
visit	B-X
a	B-X
mine	B-X
sunk	B-X
into	B-X
a	B-X
1.5	B-X
billion	B-X
year	B-X
old	B-X
Pb-Zn	B-X
orebody	B-X
precipitated	B-X
from	B-X
submarine	B-X
hot	B-X
springs	B-X
.	B-X
At	B-X
last	B-X
I	B-X
reached	B-X
the	B-X
Yukon	B-X
to	B-X
prospect	B-X
for	B-X
silver	B-X
.	B-X
Thence	B-X
to	B-X
Ireland	B-X
researching	B-X
what	B-X
I	B-X
also	B-X
took	B-X
to	B-X
be	B-X
'exhalative	B-X
'	B-X
(	B-X
i.e	B-X
.	B-X
hot	B-X
spring-related	B-X
)	B-X
Pb-Zn	B-X
orebodies	B-X
.	B-X
While	B-X
there	B-X
in	B-X
1979	B-X
,	B-X
the	B-X
discovery	B-X
of	B-X
350Â°C	B-X
metal-bearing	B-X
acidic	B-X
waters	B-X
issuing	B-X
from	B-X
submarine	B-X
Black	B-X
Smoker	B-X
chimneys	B-X
in	B-X
the	B-X
Pacific	B-X
sent	B-X
us	B-X
searching	B-X
for	B-X
fossil	B-X
examples	B-X
in	B-X
the	B-X
Irish	B-X
mines	B-X
.	B-X
However	B-X
,	B-X
the	B-X
chimneys	B-X
we	B-X
found	B-X
were	B-X
more	B-X
like	B-X
chemical	B-X
gardens	B-X
than	B-X
Black	B-X
Smokers	B-X
,	B-X
a	B-X
finding	B-X
that	B-X
made	B-X
us	B-X
think	B-X
about	B-X
the	B-X
emergence	B-X
of	B-X
life	B-X
.	B-X
After	B-X
all	B-X
,	B-X
what	B-X
better	B-X
for	B-X
life	B-X
's	B-X
emergence	B-X
than	B-X
to	B-X
have	B-X
a	B-X
membrane	B-X
comprising	B-X
Fe	B-X
minerals	B-X
dosed	B-X
with	B-X
Ni	B-X
in	B-X
our	B-X
chimneys	B-X
to	B-X
mediate	B-X
the	B-X
'hydrogenation	B-X
'	B-X
of	B-X
CO	B-X

The	O
data	O
suggest	O
that	O
with	O
progression	O
of	O
the	O
day	O
the	O
gradients	O
collapsed	O
first	O
at	O
the	O
top	O
of	O
the	O
liana	O
,	O
where	O
transpiration	O
was	O
high	O
,	O
before	O
it	O
occurred	O
in	O
leaves	O
further	O
down	O
.	O

During	O
the	O
afternoon	O
hours	O
the	O
increase	O
in	O
the	O
turgor	O
pressure	O
values	O
measured	O
close	O
to	O
the	O
main	O
vein	O
coincided	O
with	O
the	O
values	O
measured	O
by	O
the	O
patch	O
clamp	O
pressure	O
probe	O
(	O
Fig	O
.	O
5	O
)	O
.	O

The	O
unbalanced	O
osmotic	O
pressure	O
throughout	O
the	O
leaflets	O
obviously	O
favoured	O
simultaneous	O
turgor	O
pressure	O
regeneration	O
in	O
all	O
leaflet	O
cells	O
.	O

The	O
process	O
seemed	O
to	O
be	O
very	O
similar	O
to	O
the	O
refilling	O
of	O
the	O
cells	O
of	O
the	O
resurrection	O
plant	O
Myrothamnus	B-Species
flabellifolia	I-Species
with	O
water	O
after	O
desiccation	O
(	O
Wagner	O
et	O
al	O
.	O
,	O
2000	O
)	O
.	O

Uniform	O
radial	O
refilling	O
of	O
cells	O
with	O
water	O
in	O
this	O
species	O
is	O
also	O
driven	O
by	O
the	O
unbalanced	O
osmotic	O
pressure	O
throughout	O
the	O
tissue	O
.	O

As	O
indicated	O
by	O
Fig	O
.	O
<EOS>	B-X
Moreover	B-X
,	B-X
the	B-X
apparent	B-X
binding	B-X
of	B-X
MarR	B-X
to	B-X
TktA-6H	B-X
immobilized	B-X
on	B-X
NiNTA	B-X
resin	B-X
(	B-X
Fig	B-X
.	B-X
The	B-X
split-GFP	B-X
system	B-X
is	B-X
composed	B-X
of	B-X
two	B-X
vectors	B-X
used	B-X
in	B-X
the	B-X
same	B-X
strain	B-X
:	B-X
pTET	B-X
GFP	B-X
11	B-X
and	B-X
pET	B-X
GFP	B-X
1-10	B-X
(	B-X
Fig	B-X
.	B-X
Here	B-X
,	B-X
however	B-X
,	B-X
we	B-X
have	B-X
chosen	B-X
to	B-X
stress	B-X
the	B-X
whole	B-X
circuit	B-X
of	B-X
Ca2+	B-X
action	B-X
indicating	B-X
that	B-X
the	B-X
cell	B-X
is	B-X
organized	B-X
both	B-X
at	B-X
a	B-X
basal	B-X
and	B-X
an	B-X
activated	B-X
state	B-X
kinetic	B-X
level	B-X
by	B-X
the	B-X
steady	B-X
state	B-X
flow	B-X
of	B-X
the	B-X
ion	B-X
(	B-X
see	B-X
Fig	B-X
.	B-X
Familial	B-X
aggregation	B-X
is	B-X
a	B-X
strong	B-X
indicator	B-X
of	B-X
genetic	B-X
regulation	B-X
in	B-X
the	B-X
disease	B-X
process	B-X
iNPH	B-X
(	B-X
Fig	B-X
1	B-X
)	B-X
.	B-X

4A	O
and	O
B	O
,	O
restoration	O
of	O
full	O
turgescence	O
in	O
T	B-Species
.	I-Species
voinierianum	I-Species
was	O
faster	O
than	O
the	O
preceding	O
turgor	O
pressure	O
loss	O
if	O
the	O
lianas	O
were	O
well	O
-	O
watered	O
.	O

By	O
contrast	O
,	O
limitations	O
in	O
water	O
supply	O
resulted	O
in	O
the	O
coincidence	O
of	O
the	O
phases	O
of	O
turgor	O
pressure	O
loss	O
and	O
regeneration	O
.	O

Interestingly	O
,	O
watering	O
of	O
the	O
lianas	O
after	O
non	O
-	O
irrigation	O
seemed	O
to	O
lead	O
preferentially	O
to	O
water	O
shifting	O
to	O
the	O
top	O
of	O
the	O
plant	O
,	O
because	O
,	O
after	O
3	O
d	O
of	O
irrigation	O
,	O
turgor	O
pressure	O
regeneration	O
during	O
the	O
afternoon	O
was	O
very	O
fast	O
again	O
at	O
10	O
m	O
height	O
(	O
Fig	O
.	O
4F	O
)	O
,	O
but	O
not	O
at	O
5	O
m	O
height	O
(	O
Fig	O
.	O
4E	O
)	O
.	O

Rapid	O
water	O
movement	O
to	O
the	O
top	O
is	O
expected	O
if	O
hydrostatic	O
pressure	O
,	O
osmotic	O
pressure	O
,	O
and	O
/	O
or	O
gel	O
-	O
based	O
gradients	O
throughout	O
the	O
vessels	O
exist	O
or	O
are	O
generated	O
rapidly	O
in	O
the	O
afternoon	O
when	O
cavitation	O
has	O
occurred	O
.	O

This	O
was	O
demonstrated	O
by	O
Benkert	O
et	O
al	O
.	O
<EOS>	B-X
The	B-X
need	B-X
for	B-X
an	B-X
antidepressant	B-X
with	B-X
a	B-X
short	B-X
time	B-X
to	B-X
action	B-X
onset	B-X
is	B-X
justified	B-X
by	B-X
the	B-X
need	B-X
to	B-X
reduce	B-X
the	B-X
risk	B-X
of	B-X
suicide	B-X
,	B-X
the	B-X
patients	B-X
suffering	B-X
and	B-X
the	B-X
cost	B-X
of	B-X
the	B-X
disease	B-X
.	B-X
How	B-X
can	B-X
a	B-X
difference	B-X
in	B-X
action	B-X
lag	B-X
time	B-X
be	B-X
demonstrated	B-X
?	B-X
An	B-X
appropriate	B-X
methodology	B-X
specific	B-X
to	B-X
the	B-X
question	B-X
must	B-X
be	B-X
developed	B-X
.	B-X
The	B-X
selection	B-X
of	B-X
sensitive	B-X
scales	B-X
is	B-X
an	B-X
initial	B-X
requirement	B-X
enabling	B-X
detection	B-X
of	B-X
early	B-X
onset	B-X
alleviation	B-X
under	B-X
treatment	B-X
.	B-X
Response	B-X
criteria	B-X
must	B-X
first	B-X
be	B-X
defined	B-X
in	B-X
order	B-X
to	B-X
clearly	B-X
answer	B-X
the	B-X
question	B-X
``	B-X
what	B-X
is	B-X
a	B-X
short	B-X
time	B-X
to	B-X
action	B-X
onset	B-X
?	B-X
''	B-X
.	B-X
Frequent	B-X
scale	B-X
determinations	B-X
(	B-X
Hamilton	B-X
Depression	B-X
Rating	B-X
Scale	B-X
,	B-X
MADRS	B-X
)	B-X
at	B-X
the	B-X
start	B-X
of	B-X
the	B-X
study	B-X
is	B-X
indispensable	B-X
.	B-X
The	B-X
literature	B-X
recommends	B-X
at	B-X
least	B-X
two	B-X
determinations	B-X
per	B-X
week	B-X
over	B-X
the	B-X
first	B-X
two	B-X
weeks	B-X
of	B-X
treatment	B-X
.	B-X
Statistical	B-X
methods	B-X
of	B-X
the	B-X
survival	B-X
curve	B-X
type	B-X
are	B-X
the	B-X
most	B-X
appropriate	B-X
for	B-X
demonstration	B-X
of	B-X
a	B-X
between-treatment	B-X
difference	B-X
in	B-X
terms	B-X
of	B-X
time	B-X
to	B-X
action	B-X
onset	B-X
.	B-X
Some	B-X
authors	B-X
consider	B-X
that	B-X
only	B-X
placebo-controlled	B-X
studies	B-X
enable	B-X
a	B-X
difference	B-X
in	B-X
terms	B-X
of	B-X
time	B-X
to	B-X
action	B-X
onset	B-X
to	B-X
be	B-X
concluded	B-X
.	B-X
For	B-X
other	B-X
authors	B-X
,	B-X
neglecting	B-X
studies	B-X
versus	B-X
reference	B-X
products	B-X
seems	B-X
prejudicial	B-X
to	B-X
demonstrate	B-X
a	B-X
difference	B-X
between	B-X
the	B-X
times	B-X
to	B-X
action	B-X
onset	B-X
of	B-X
reference	B-X
products	B-X
and	B-X
new	B-X
products	B-X
(	B-X
Montgomery	B-X
,	B-X
1997	B-X
)	B-X
.	B-X
The	B-X
literature	B-X
on	B-X
time	B-X
to	B-X
action	B-X
onset	B-X
is	B-X
not	B-X
very	B-X
rich	B-X
.	B-X
An	B-X
initial	B-X
study	B-X
comparing	B-X
amineptine	B-X
and	B-X
fluoxetine	B-X
concluded	B-X
the	B-X
time	B-X
to	B-X
action	B-X
onset	B-X
was	B-X
shorter	B-X
for	B-X
amineptine	B-X
(	B-X
DalÃ©ry	B-X
et	B-X
al.	B-X
,	B-X
1992	B-X
)	B-X
.	B-X
The	B-X
value	B-X
of	B-X
the	B-X
booster	B-X
effect	B-X
of	B-X
pindolol	B-X
in	B-X
combination	B-X
with	B-X
serotonin	B-X
reuptake	B-X
inhibitors	B-X
is	B-X
controversial	B-X
.	B-X
Venlafaxine	B-X
seems	B-X
to	B-X
accelerate	B-X
the	B-X
response	B-X
(	B-X
day	B-X
4	B-X
)	B-X
and	B-X
be	B-X
superior	B-X
to	B-X
a	B-X
comparator	B-X
(	B-X
Clerc	B-X
et	B-X
al.	B-X
,	B-X
1996	B-X
;	B-X
Guelfi	B-X
et	B-X
al.	B-X
,	B-X
1995	B-X
)	B-X
.	B-X
In	B-X
1996	B-X
,	B-X
Benkert	B-X
published	B-X
a	B-X
double-blind	B-X
study	B-X
comparing	B-X
venlafaxine	B-X
and	B-X
imipramine	B-X
in	B-X
severe	B-X
depressions	B-X
.	B-X
Both	B-X
studies	B-X
stressed	B-X
the	B-X
rapid	B-X
action	B-X
onset	B-X
of	B-X
venlafaxine	B-X
(	B-X
between	B-X
day	B-X
4	B-X
and	B-X
week	B-X
2	B-X
)	B-X
in	B-X
severe	B-X
depressions	B-X
.	B-X
The	B-X
number	B-X
of	B-X
patients	B-X
presenting	B-X
with	B-X
a	B-X
characterized	B-X
state	B-X
of	B-X
depression	B-X
and	B-X
not	B-X
responding	B-X
to	B-X
initial	B-X
antidepressant	B-X
treatment	B-X
has	B-X
been	B-X
estimated	B-X
at	B-X
30	B-X
%	B-X
.	B-X
While	B-X
there	B-X
is	B-X
no	B-X
formal	B-X
consensus	B-X
on	B-X
the	B-X
definition	B-X
of	B-X
resistance	B-X
to	B-X
treatment	B-X
,	B-X
certain	B-X
authors	B-X
define	B-X
responders	B-X
as	B-X
those	B-X
showing	B-X
a	B-X
50	B-X
%	B-X
reduction	B-X
in	B-X
the	B-X
total	B-X
score	B-X
on	B-X
the	B-X
Hamilton	B-X
Depression	B-X
Rating	B-X
Scale	B-X
(	B-X
HAM-D	B-X
)	B-X
or	B-X
MADRS	B-X
.	B-X
A	B-X
number	B-X
of	B-X
factors	B-X
must	B-X
be	B-X
considered	B-X
with	B-X
respect	B-X
to	B-X
the	B-X
genesis	B-X
of	B-X
treatment	B-X
failure	B-X
:	B-X
mainly	B-X
psycho-organic	B-X
,	B-X
psychoaffective	B-X
and	B-X
psychosocial	B-X
factors	B-X
.	B-X

(	O
1995	O
)	O
and	O
Th	O
u	O
rmer	O
et	O
al	O
.	O

(	O
1999	O
)	O
by	O
using	O
the	O
xylem	O
pressure	O
probe	O
.	O
<EOS>	B-X
During	B-X
the	B-X
dry	B-X
state	B-X
the	B-X
inner	B-X
walls	B-X
of	B-X
the	B-X
xylem	B-X
vessels	B-X
seemed	B-X
to	B-X
be	B-X
covered	B-X
,	B-X
at	B-X
least	B-X
partly	B-X
,	B-X
by	B-X
a	B-X
lipid	B-X
film	B-X
as	B-X
shown	B-X
by	B-X
Sudan	B-X
III	B-X
and	B-X
Nile	B-X
Red	B-X
staining	B-X
.	B-X
The	B-X
hydrophobic	B-X
nature	B-X
of	B-X
the	B-X
inner	B-X
xylem	B-X
walls	B-X
was	B-X
supported	B-X
by	B-X
the	B-X
finding	B-X
that	B-X
benzene	B-X
ascended	B-X
as	B-X
rapidly	B-X
as	B-X
water	B-X
in	B-X
the	B-X
xylem	B-X
of	B-X
dry	B-X
Myrothamnus	B-X
branches	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
lipid	B-X
bodies	B-X
within	B-X
the	B-X
vessels	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
hydrophobic	B-X
properties	B-X
of	B-X
the	B-X
inner	B-X
xylem	B-X
walls	B-X
,	B-X
could	B-X
explain	B-X
the	B-X
finding	B-X
that	B-X
the	B-X
xylem	B-X
pressure	B-X
of	B-X
hydrated	B-X
,	B-X
well	B-X
watered	B-X
plants	B-X
(	B-X
measured	B-X
both	B-X
under	B-X
laboratory	B-X
and	B-X
field	B-X
conditions	B-X
with	B-X
the	B-X
xylem	B-X
pressure	B-X
probe	B-X
)	B-X
never	B-X
dropped	B-X
below	B-X
c.	B-X
-0.3	B-X
MPa	B-X
and	B-X
that	B-X
cavitation	B-X
occurred	B-X
frequently	B-X
at	B-X
low	B-X
negative	B-X
xylem	B-X
pressure	B-X
values	B-X
(	B-X
-0.05	B-X
to	B-X
-0.15	B-X
MPa	B-X
)	B-X
.	B-X
The	B-X
xylem	B-X
pressure	B-X
of	B-X
M.	B-X
flabellifolia	B-X
responded	B-X
rapidly	B-X
and	B-X
strongly	B-X
to	B-X
changes	B-X
in	B-X
relative	B-X
humidity	B-X
and	B-X
temperature	B-X
,	B-X
but	B-X
less	B-X
obviously	B-X
to	B-X
changes	B-X
in	B-X
irradiance	B-X
(	B-X
which	B-X
varied	B-X
between	B-X
10	B-X
and	B-X
c.	B-X
4000	B-X
Î¼mol	B-X
m	B-X
m	B-X

Continuous	O
xylem	O
pressure	O
gradients	O
during	O
the	O
morning	O
hours	O
can	O
also	O
explain	O
why	O
changes	O
in	O
Pp	O
at	O
lower	O
heights	O
were	O
frequently	O
found	O
which	O
could	O
not	O
be	O
correlated	O
with	O
changes	O
in	O
local	O
temperature	O
or	O
relative	O
humidity	O
.	O
<EOS>	B-X
There	B-X
is	B-X
a	B-X
long-standing	B-X
dispute	B-X
about	B-X
indoor	B-X
air	B-X
humidity	B-X
and	B-X
perceived	B-X
indoor	B-X
air	B-X
quality	B-X
(	B-X
IAQ	B-X
)	B-X
and	B-X
associated	B-X
health	B-X
effects	B-X
.	B-X
This	B-X
calls	B-X
for	B-X
an	B-X
integrated	B-X
analysis	B-X
of	B-X
indoor	B-X
air	B-X
humidity	B-X
and	B-X
eye	B-X
and	B-X
airway	B-X
health	B-X
effects	B-X
.	B-X
This	B-X
overview	B-X
has	B-X
reviewed	B-X
the	B-X
literature	B-X
about	B-X
the	B-X
effects	B-X
of	B-X
extended	B-X
exposure	B-X
to	B-X
low	B-X
humidity	B-X
on	B-X
perceived	B-X
IAQ	B-X
,	B-X
sensory	B-X
irritation	B-X
symptoms	B-X
in	B-X
eyes	B-X
and	B-X
airways	B-X
,	B-X
work	B-X
performance	B-X
,	B-X
sleep	B-X
quality	B-X
,	B-X
virus	B-X
survival	B-X
,	B-X
and	B-X
voice	B-X
disruption	B-X
.	B-X
Elevation	B-X
of	B-X
the	B-X
indoor	B-X
air	B-X
humidity	B-X
may	B-X
positively	B-X
impact	B-X
perceived	B-X
IAQ	B-X
,	B-X
eye	B-X
symptomatology	B-X
,	B-X
and	B-X
possibly	B-X
work	B-X
performance	B-X
in	B-X
the	B-X
office	B-X
environment	B-X
;	B-X
however	B-X
,	B-X
mice	B-X
inhalation	B-X
studies	B-X
do	B-X
not	B-X
show	B-X
exacerbation	B-X
of	B-X
sensory	B-X
irritation	B-X
in	B-X
the	B-X
airways	B-X
by	B-X
low	B-X
humidity	B-X
.	B-X
Both	B-X
low	B-X
and	B-X
high	B-X
RH	B-X
,	B-X
and	B-X
perhaps	B-X
even	B-X
better	B-X
absolute	B-X
humidity	B-X
(	B-X
water	B-X
vapor	B-X
)	B-X
,	B-X
favors	B-X
transmission	B-X
and	B-X
survival	B-X
of	B-X
influenza	B-X
virus	B-X
in	B-X
many	B-X
studies	B-X
,	B-X
but	B-X
the	B-X
relationship	B-X
between	B-X
temperature	B-X
,	B-X
humidity	B-X
,	B-X
and	B-X
the	B-X
virus	B-X
and	B-X
aerosol	B-X
dynamics	B-X
is	B-X
complex	B-X
,	B-X
which	B-X
in	B-X
the	B-X
end	B-X
depends	B-X
on	B-X
the	B-X
individual	B-X
virus	B-X
type	B-X
and	B-X
its	B-X
physical/chemical	B-X
properties	B-X
.	B-X
Dry	B-X
and	B-X
humid	B-X
air	B-X
perception	B-X
continues	B-X
to	B-X
be	B-X
reported	B-X
in	B-X
offices	B-X
and	B-X
in	B-X
residential	B-X
areas	B-X
,	B-X
despite	B-X
the	B-X
IAQ	B-X
parameter	B-X
``	B-X
dry	B-X
air	B-X
''	B-X
(	B-X
or	B-X
``	B-X
wet/humid	B-X
air	B-X
''	B-X
)	B-X
is	B-X
semantically	B-X
misleading	B-X
,	B-X
because	B-X
a	B-X
sensory	B-X
organ	B-X
for	B-X
humidity	B-X
is	B-X
non-existing	B-X
in	B-X
humans	B-X
.	B-X
This	B-X
IAQ	B-X
parameter	B-X
appears	B-X
to	B-X
reflect	B-X
different	B-X
perceptions	B-X
among	B-X
other	B-X
odor	B-X
,	B-X
dustiness	B-X
,	B-X
and	B-X
possibly	B-X
exacerbated	B-X
by	B-X
desiccation	B-X
effect	B-X
of	B-X
low	B-X
air	B-X
humidity	B-X
.	B-X
It	B-X
is	B-X
salient	B-X
to	B-X
distinguish	B-X
between	B-X
indoor	B-X
air	B-X
humidity	B-X
(	B-X
relative	B-X
or	B-X
absolute	B-X
)	B-X
near	B-X
the	B-X
breathing	B-X
and	B-X
ocular	B-X
zone	B-X
and	B-X
phenomena	B-X
caused	B-X
by	B-X
moisture-damage	B-X
of	B-X
the	B-X
building	B-X
construction	B-X
and	B-X
emissions	B-X
therefrom	B-X
.	B-X
Further	B-X
,	B-X
residential	B-X
versus	B-X
public	B-X
environments	B-X
should	B-X
be	B-X
considered	B-X
as	B-X
separate	B-X
entities	B-X
with	B-X
different	B-X
characteristics	B-X
and	B-X
demands	B-X
of	B-X
humidity	B-X
.	B-X
Research	B-X
is	B-X
needed	B-X
about	B-X
particle	B-X
,	B-X
bacteria	B-X
and	B-X
virus	B-X
dynamics	B-X
indoors	B-X
for	B-X
improvement	B-X
of	B-X
quality	B-X
of	B-X
life	B-X
and	B-X
with	B-X
more	B-X
focus	B-X
on	B-X
the	B-X
impact	B-X
of	B-X
absolute	B-X
humidity	B-X
.	B-X

Water	O
loss	O
at	O
the	O
top	O
of	O
the	O
plant	O
induces	O
a	O
drop	O
in	O
xylem	O
pressure	O
which	O
is	O
transferred	O
rapidly	O
to	O
the	O
basal	O
leaves	O
where	O
it	O
induces	O
a	O
temporary	O
turgor	O
pressure	O
loss	O
that	O
is	O
soon	O
compensated	O
by	O
water	O
uptake	O
from	O
the	O
roots	O
(	O
arrow	O
in	O
Fig	O
.	O
2	O
)	O
.	O

Even	O
though	O
more	O
work	O
is	O
required	O
,	O
the	O
present	O
study	O
shows	O
that	O
the	O
leaf	O
patch	O
clamp	O
pressure	O
probe	O
is	O
a	O
promising	O
tool	O
to	O
elucidate	O
short	O
-	O
and	O
long	O
-	O
distance	O
water	O
transport	O
in	O
T	B-Species
.	I-Species
voinierianum	I-Species
and	O
other	O
plants	O
.	O

CHEK2	O
Mutations	O
Affecting	O
Kinase	O
Activity	O
Together	O
With	O
Mutations	O
in	O
TP53	O
Indicate	O
a	O
Functional	O
Pathway	O
Associated	O
with	O
Resistance	O
to	O
Epirubicin	O
in	O
Primary	O
Breast	O
Cancer	O
<EOS>	B-X
While	B-X
we	B-X
previously	B-X
found	B-X
TP53	B-X
mutations	B-X
in	B-X
the	B-X
L2/L3	B-X
domains	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
drug	B-X
resistance	B-X
,	B-X
some	B-X
tumors	B-X
harboring	B-X
wild-type	B-X
TP53	B-X
were	B-X
also	B-X
therapy	B-X
resistant	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
;	B-X
1	B-X
)	B-X
To	B-X
explore	B-X
alterations	B-X
in	B-X
the	B-X
TP53	B-X
gene	B-X
with	B-X
respect	B-X
to	B-X
resistance	B-X
to	B-X
a	B-X
regular	B-X
dose	B-X
epirubicin	B-X
regimen	B-X
(	B-X
90	B-X
mg/m	B-X
(	B-X
2	B-X
)	B-X
every	B-X
3	B-X
week	B-X
)	B-X
in	B-X
patients	B-X
with	B-X
primary	B-X
,	B-X
locally	B-X
advanced	B-X
breast	B-X
cancer	B-X
;	B-X
2	B-X
)	B-X
Identify	B-X
critical	B-X
mechanisms	B-X
activating	B-X
p53	B-X
in	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
in	B-X
breast	B-X
cancer	B-X
;	B-X
3	B-X
)	B-X
Evaluate	B-X
in	B-X
vitro	B-X
function	B-X
of	B-X
Chk2	B-X
and	B-X
p14	B-X
proteins	B-X
corresponding	B-X
to	B-X
identified	B-X
mutations	B-X
in	B-X
the	B-X
CHEK2	B-X
and	B-X
p14	B-X
(	B-X
(	B-X
ARF	B-X
)	B-X
)	B-X
genes	B-X
;	B-X
and	B-X
4	B-X
)	B-X
Explore	B-X
potential	B-X
CHEK2	B-X
or	B-X
p14	B-X
(	B-X
(	B-X
ARF	B-X
)	B-X
)	B-X
germline	B-X
mutations	B-X
with	B-X
respect	B-X
to	B-X
family	B-X
cancer	B-X
incidence	B-X
.	B-X

Abstract	O
<EOS>	B-X
Abstract	B-X
writing	B-X
.	B-X
The	B-X
informative	B-X
abstract	B-X
.	B-X
Crafting	B-X
a	B-X
compelling	B-X
abstract	B-X
.	B-X
Why	B-X
the	B-X
structured	B-X
abstract	B-X
?	B-X

Background	O
<EOS>	B-X
Background	B-X
matching	B-X
is	B-X
the	B-X
most	B-X
familiar	B-X
and	B-X
widespread	B-X
camouflage	B-X
strategy	B-X
:	B-X
avoiding	B-X
detection	B-X
by	B-X
having	B-X
a	B-X
similar	B-X
colour	B-X
and	B-X
pattern	B-X
to	B-X
the	B-X
background	B-X
.	B-X
Background	B-X
is	B-X
thus	B-X
a	B-X
relatively	B-X
modest	B-X
correction	B-X
for	B-X
all	B-X
Z	B-X
opacity	B-X
data	B-X
published	B-X
to	B-X
date	B-X
.	B-X
Background	B-X
estimation	B-X
and	B-X
foreground	B-X
segmentation	B-X
are	B-X
important	B-X
steps	B-X
in	B-X
many	B-X
high-level	B-X
vision	B-X
tasks	B-X
.	B-X
Patient	B-X
Preference	B-X
for	B-X
Telehealth	B-X
Background	B-X
Shapes	B-X
Impressions	B-X
of	B-X
Physicians	B-X
and	B-X
Information	B-X
Recall	B-X
:	B-X
A	B-X
Randomized	B-X
Experiment	B-X
.	B-X

Chemoresistance	O
is	O
the	O
main	O
obstacle	O
to	O
cure	O
in	O
most	O
malignant	O
diseases	O
.	O
<EOS>	B-X
The	B-X
emergence	B-X
of	B-X
cancer	B-X
drug	B-X
resistance	B-X
has	B-X
always	B-X
been	B-X
the	B-X
major	B-X
obstacle	B-X
to	B-X
the	B-X
cure	B-X
of	B-X
tumors	B-X
.	B-X
The	B-X
main	B-X
goal	B-X
of	B-X
modern	B-X
cancer	B-X
pharmacology	B-X
is	B-X
to	B-X
determine	B-X
the	B-X
underlying	B-X
mechanism	B-X
of	B-X
anticancer	B-X
drugs	B-X
.	B-X
Chemoresistance	B-X
is	B-X
the	B-X
main	B-X
obstacle	B-X
to	B-X
cure	B-X
in	B-X
most	B-X
malignant	B-X
diseases	B-X
.	B-X
Anthracyclines	B-X
are	B-X
among	B-X
the	B-X
main	B-X
drugs	B-X
used	B-X
for	B-X
breast	B-X
cancer	B-X
therapy	B-X
and	B-X
in	B-X
many	B-X
other	B-X
malignant	B-X
conditions	B-X
.	B-X
While	B-X
we	B-X
previously	B-X
found	B-X
TP53	B-X
mutations	B-X
in	B-X
the	B-X
L2/L3	B-X
domains	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
drug	B-X
resistance	B-X
,	B-X
some	B-X
tumors	B-X
harboring	B-X
wild-type	B-X
TP53	B-X
were	B-X
also	B-X
therapy	B-X
resistant	B-X
.	B-X

Anthracyclines	O
are	O
among	O
the	O
main	O
drugs	O
used	O
for	O
breast	O
cancer	O
therapy	O
and	O
in	O
many	O
other	O
malignant	O
conditions	O
.	O
<EOS>	B-X
Chemoresistance	B-X
is	B-X
the	B-X
main	B-X
obstacle	B-X
to	B-X
cure	B-X
in	B-X
most	B-X
malignant	B-X
diseases	B-X
.	B-X
Anthracyclines	B-X
are	B-X
among	B-X
the	B-X
main	B-X
drugs	B-X
used	B-X
for	B-X
breast	B-X
cancer	B-X
therapy	B-X
and	B-X
in	B-X
many	B-X
other	B-X
malignant	B-X
conditions	B-X
.	B-X
While	B-X
we	B-X
previously	B-X
found	B-X
TP53	B-X
mutations	B-X
in	B-X
the	B-X
L2/L3	B-X
domains	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
drug	B-X
resistance	B-X
,	B-X
some	B-X
tumors	B-X
harboring	B-X
wild-type	B-X
TP53	B-X
were	B-X
also	B-X
therapy	B-X
resistant	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
;	B-X
1	B-X
)	B-X
To	B-X
explore	B-X
alterations	B-X
in	B-X
the	B-X
TP53	B-X
gene	B-X
with	B-X
respect	B-X
to	B-X
resistance	B-X
to	B-X
a	B-X
regular	B-X
dose	B-X
epirubicin	B-X
regimen	B-X
(	B-X
90	B-X
mg/m	B-X
(	B-X
2	B-X
)	B-X
every	B-X
3	B-X
week	B-X
)	B-X
in	B-X
patients	B-X
with	B-X
primary	B-X
,	B-X
locally	B-X
advanced	B-X
breast	B-X
cancer	B-X
;	B-X
2	B-X
)	B-X
Identify	B-X
critical	B-X
mechanisms	B-X
activating	B-X
p53	B-X
in	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
in	B-X
breast	B-X
cancer	B-X
;	B-X
3	B-X
)	B-X
Evaluate	B-X
in	B-X
vitro	B-X
function	B-X
of	B-X
Chk2	B-X
and	B-X
p14	B-X
proteins	B-X
corresponding	B-X
to	B-X
identified	B-X
mutations	B-X
in	B-X
the	B-X
CHEK2	B-X
and	B-X
p14	B-X
(	B-X
(	B-X
ARF	B-X
)	B-X
)	B-X
genes	B-X
;	B-X
and	B-X
4	B-X
)	B-X
Explore	B-X
potential	B-X
CHEK2	B-X
or	B-X
p14	B-X
(	B-X
(	B-X
ARF	B-X
)	B-X
)	B-X
germline	B-X
mutations	B-X
with	B-X
respect	B-X
to	B-X
family	B-X
cancer	B-X
incidence	B-X
.	B-X

Single	O
parameter	O
analysis	O
or	O
global	O
gene	O
expression	O
profiles	O
have	O
failed	O
to	O
identify	O
mechanisms	O
causing	O
in	O
vivo	O
resistance	O
to	O
anthracyclines	O
.	O
<EOS>	B-X
Polygenic	B-X
scores	B-X
(	B-X
PGS	B-X
)	B-X
summarize	B-X
the	B-X
genetic	B-X
contribution	B-X
of	B-X
a	B-X
person	B-X
's	B-X
genotype	B-X
to	B-X
a	B-X
disease	B-X
or	B-X
phenotype	B-X
.	B-X
We	B-X
also	B-X
propose	B-X
a	B-X
general	B-X
method	B-X
for	B-X
choosing	B-X
the	B-X
value	B-X
of	B-X
the	B-X
tuning	B-X
parameter	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
validation	B-X
data	B-X
.	B-X
In	B-X
our	B-X
simulations	B-X
,	B-X
we	B-X
showed	B-X
that	B-X
pseudovalidation	B-X
often	B-X
resulted	B-X
in	B-X
prediction	B-X
accuracy	B-X
that	B-X
is	B-X
comparable	B-X
to	B-X
using	B-X
a	B-X
dataset	B-X
with	B-X
validation	B-X
phenotype	B-X
and	B-X
was	B-X
clearly	B-X
superior	B-X
to	B-X
the	B-X
conservative	B-X
option	B-X
of	B-X
setting	B-X
the	B-X
tuning	B-X
parameter	B-X
of	B-X
lassosum	B-X
to	B-X
its	B-X
lowest	B-X
value	B-X
.	B-X
This	B-X
phenomenological	B-X
model	B-X
comprises	B-X
a	B-X
single	B-X
set	B-X
of	B-X
parameters	B-X
which	B-X
can	B-X
simulate	B-X
circadian	B-X
responses	B-X
in	B-X
humans	B-X
under	B-X
a	B-X
variety	B-X
of	B-X
environmental	B-X
conditions	B-X
.	B-X
However	B-X
,	B-X
corresponding	B-X
models	B-X
for	B-X
nocturnal	B-X
rodents	B-X
commonly	B-X
used	B-X
in	B-X
circadian	B-X
rhythm	B-X
studies	B-X
are	B-X
not	B-X
available	B-X
and	B-X
may	B-X
require	B-X
new	B-X
parameter	B-X
values	B-X
for	B-X
different	B-X
species	B-X
and	B-X
even	B-X
strains	B-X
.	B-X
Moreover	B-X
,	B-X
due	B-X
to	B-X
a	B-X
considerable	B-X
variation	B-X
in	B-X
experimental	B-X
data	B-X
collected	B-X
from	B-X
mice	B-X
of	B-X
the	B-X
same	B-X
strain	B-X
,	B-X
within	B-X
and	B-X
across	B-X
laboratories	B-X
,	B-X
a	B-X
range	B-X
of	B-X
valid	B-X
parameters	B-X
is	B-X
essential	B-X
.	B-X
This	B-X
study	B-X
develops	B-X
a	B-X
Kronauer-like	B-X
model	B-X
for	B-X
mice	B-X
by	B-X
re-fitting	B-X
relevant	B-X
parameters	B-X
to	B-X
published	B-X
phase	B-X
response	B-X
curve	B-X
and	B-X
period	B-X
data	B-X
using	B-X
total	B-X
least	B-X
squares	B-X
.	B-X
Local	B-X
parameter	B-X
sensitivity	B-X
analysis	B-X
and	B-X
parameter	B-X
distributions	B-X
determine	B-X
the	B-X
parameter	B-X
ranges	B-X
that	B-X
give	B-X
a	B-X
near-identical	B-X
model	B-X
and	B-X
data	B-X
distribution	B-X
of	B-X
periods	B-X
.	B-X
However	B-X
,	B-X
the	B-X
model	B-X
required	B-X
further	B-X
parameter	B-X
adjustments	B-X
to	B-X
match	B-X
characteristics	B-X
of	B-X
other	B-X
mouse	B-X
strains	B-X
,	B-X
implying	B-X
that	B-X
the	B-X
model	B-X
itself	B-X
detects	B-X
changes	B-X
in	B-X
the	B-X
core	B-X
processes	B-X
of	B-X
rhythm	B-X
generation	B-X
and	B-X
control	B-X
.	B-X

While	O
we	O
previously	O
found	O
TP53	O
mutations	O
in	O
the	O
L2	O
/	O
L3	O
domains	O
to	O
be	O
associated	O
with	O
drug	O
resistance	O
,	O
some	O
tumors	O
harboring	O
wild	O
-	O
type	O
TP53	O
were	O
also	O
therapy	O
resistant	O
.	O
<EOS>	B-X
Chemoresistance	B-X
is	B-X
the	B-X
main	B-X
obstacle	B-X
to	B-X
cure	B-X
in	B-X
most	B-X
malignant	B-X
diseases	B-X
.	B-X
Anthracyclines	B-X
are	B-X
among	B-X
the	B-X
main	B-X
drugs	B-X
used	B-X
for	B-X
breast	B-X
cancer	B-X
therapy	B-X
and	B-X
in	B-X
many	B-X
other	B-X
malignant	B-X
conditions	B-X
.	B-X
Single	B-X
parameter	B-X
analysis	B-X
or	B-X
global	B-X
gene	B-X
expression	B-X
profiles	B-X
have	B-X
failed	B-X
to	B-X
identify	B-X
mechanisms	B-X
causing	B-X
in	B-X
vivo	B-X
resistance	B-X
to	B-X
anthracyclines	B-X
.	B-X
While	B-X
we	B-X
previously	B-X
found	B-X
TP53	B-X
mutations	B-X
in	B-X
the	B-X
L2/L3	B-X
domains	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
drug	B-X
resistance	B-X
,	B-X
some	B-X
tumors	B-X
harboring	B-X
wild-type	B-X
TP53	B-X
were	B-X
also	B-X
therapy	B-X
resistant	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
;	B-X
1	B-X
)	B-X
To	B-X
explore	B-X
alterations	B-X
in	B-X
the	B-X
TP53	B-X
gene	B-X
with	B-X
respect	B-X
to	B-X
resistance	B-X
to	B-X
a	B-X
regular	B-X
dose	B-X
epirubicin	B-X
regimen	B-X
(	B-X
90	B-X
mg/m	B-X
(	B-X
2	B-X
)	B-X
every	B-X
3	B-X
week	B-X
)	B-X
in	B-X
patients	B-X
with	B-X
primary	B-X
,	B-X
locally	B-X
advanced	B-X
breast	B-X
cancer	B-X
;	B-X
2	B-X
)	B-X
Identify	B-X
critical	B-X
mechanisms	B-X
activating	B-X
p53	B-X
in	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
in	B-X
breast	B-X
cancer	B-X
;	B-X
3	B-X
)	B-X
Evaluate	B-X
in	B-X
vitro	B-X
function	B-X
of	B-X
Chk2	B-X
and	B-X
p14	B-X
proteins	B-X
corresponding	B-X
to	B-X
identified	B-X
mutations	B-X
in	B-X
the	B-X
CHEK2	B-X
and	B-X
p14	B-X
(	B-X
(	B-X
ARF	B-X
)	B-X
)	B-X
genes	B-X
;	B-X
and	B-X
4	B-X
)	B-X
Explore	B-X
potential	B-X
CHEK2	B-X
or	B-X
p14	B-X
(	B-X
(	B-X
ARF	B-X
)	B-X
)	B-X
germline	B-X
mutations	B-X
with	B-X
respect	B-X
to	B-X
family	B-X
cancer	B-X
incidence	B-X
.	B-X

The	O
aim	O
of	O
this	O
study	O
was	O
;	O
1	O
)	O
To	O
explore	O
alterations	O
in	O
the	O
TP53	O
gene	O
with	O
respect	O
to	O
resistance	O
to	O
a	O
regular	O
dose	O
epirubicin	O
regimen	O
(	O
90	O
mg	O
/	O
m2	O
every	O
3	O
week	O
)	O
in	O
patients	B-Species
with	O
primary	O
,	O
locally	O
advanced	O
breast	O
cancer	O
;	O
2	O
)	O
Identify	O
critical	O
mechanisms	O
activating	O
p53	O
in	O
response	O
to	O
DNA	O
damage	O
in	O
breast	O
cancer	O
;	O
3	O
)	O
Evaluate	O
in	O
vitro	O
function	O
of	O
Chk2	O
and	O
p14	O
proteins	O
corresponding	O
to	O
identified	O
mutations	O
in	O
the	O
CHEK2	O
and	O
p14	O
(	O
ARF	O
)	O
genes	O
;	O
and	O
4	O
)	O
Explore	O
potential	O
CHEK2	O
or	O
p14	O
(	O
ARF	O
)	O
germline	O
mutations	O
with	O
respect	O
to	O
family	O
cancer	O
incidence	O
.	O
<EOS>	B-X
Hypoxia-inducible	B-X
factor-1a	B-X
(	B-X
HIF1Î±	B-X
)	B-X
is	B-X
a	B-X
transcription	B-X
factor	B-X
responsible	B-X
for	B-X
expressing	B-X
several	B-X
proteins	B-X
involved	B-X
in	B-X
angiogenesis	B-X
.	B-X
Quercetin	B-X
can	B-X
suppress	B-X
HIF1Î±	B-X
expression	B-X
due	B-X
to	B-X
the	B-X
inhibition	B-X
of	B-X
protein	B-X
synthesis	B-X
.	B-X
However	B-X
,	B-X
to	B-X
date	B-X
,	B-X
the	B-X
study	B-X
exploring	B-X
the	B-X
potential	B-X
of	B-X
quercetin	B-X
in	B-X
repressing	B-X
HIF1Î±	B-X
through	B-X
its	B-X
degradation	B-X
mechanism	B-X
has	B-X
never	B-X
been	B-X
done	B-X
.	B-X
An	B-X
in	B-X
silico	B-X
study	B-X
is	B-X
needed	B-X
as	B-X
a	B-X
preliminary	B-X
study	B-X
to	B-X
understand	B-X
the	B-X
mechanism	B-X
underlining	B-X
this	B-X
possibility	B-X
.	B-X

Methods	O
and	O
Findings	O
<EOS>	B-X
This	B-X
glossary	B-X
was	B-X
developed	B-X
by	B-X
a	B-X
working	B-X
group	B-X
of	B-X
the	B-X
ILAE	B-X
Commission	B-X
on	B-X
Diagnostic	B-X
Methods	B-X
incorporating	B-X
the	B-X
EEG	B-X
Task	B-X
Force	B-X
.	B-X

Snap	O
-	O
frozen	O
biopsies	O
from	O
109	O
patients	B-Species
collected	O
prior	O
to	O
epirubicin	O
(	O
as	O
preoperative	O
therapy	O
were	O
investigated	O
for	O
TP53	O
,	O
CHEK2	O
and	O
p14	O
(	O
ARF	O
)	O
mutations	O
by	O
sequencing	O
the	O
coding	O
region	O
and	O
p14	O
(	O
ARF	O
)	O
promoter	O
methylations	O
.	O
<EOS>	B-X
Anthracyclines	B-X
are	B-X
among	B-X
the	B-X
main	B-X
drugs	B-X
used	B-X
for	B-X
breast	B-X
cancer	B-X
therapy	B-X
and	B-X
in	B-X
many	B-X
other	B-X
malignant	B-X
conditions	B-X
.	B-X
While	B-X
we	B-X
previously	B-X
found	B-X
TP53	B-X
mutations	B-X
in	B-X
the	B-X
L2/L3	B-X
domains	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
drug	B-X
resistance	B-X
,	B-X
some	B-X
tumors	B-X
harboring	B-X
wild-type	B-X
TP53	B-X
were	B-X
also	B-X
therapy	B-X
resistant	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
;	B-X
1	B-X
)	B-X
To	B-X
explore	B-X
alterations	B-X
in	B-X
the	B-X
TP53	B-X
gene	B-X
with	B-X
respect	B-X
to	B-X
resistance	B-X
to	B-X
a	B-X
regular	B-X
dose	B-X
epirubicin	B-X
regimen	B-X
(	B-X
90	B-X
mg/m	B-X
(	B-X
2	B-X
)	B-X
every	B-X
3	B-X
week	B-X
)	B-X
in	B-X
patients	B-X
with	B-X
primary	B-X
,	B-X
locally	B-X
advanced	B-X
breast	B-X
cancer	B-X
;	B-X
2	B-X
)	B-X
Identify	B-X
critical	B-X
mechanisms	B-X
activating	B-X
p53	B-X
in	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
in	B-X
breast	B-X
cancer	B-X
;	B-X
3	B-X
)	B-X
Evaluate	B-X
in	B-X
vitro	B-X
function	B-X
of	B-X
Chk2	B-X
and	B-X
p14	B-X
proteins	B-X
corresponding	B-X
to	B-X
identified	B-X
mutations	B-X
in	B-X
the	B-X
CHEK2	B-X
and	B-X
p14	B-X
(	B-X
(	B-X
ARF	B-X
)	B-X
)	B-X
genes	B-X
;	B-X
and	B-X
4	B-X
)	B-X
Explore	B-X
potential	B-X
CHEK2	B-X
or	B-X
p14	B-X
(	B-X
(	B-X
ARF	B-X
)	B-X
)	B-X
germline	B-X
mutations	B-X
with	B-X
respect	B-X
to	B-X
family	B-X
cancer	B-X
incidence	B-X
.	B-X

TP53	O
mutastions	O
were	O
associated	O
with	O
chemoresistance	O
,	O
defined	O
as	O
progressive	O
disease	O
on	O
therapy	O
(	O
p	O
=	O
0	O
.	O
0358	O
;	O
p	O
=	O
0	O
.	O
0136	O
for	O
mutations	O
affecting	O
p53	O
loop	O
domains	O
L2	O
/	O
L3	O
)	O
.	O

Germline	O
CHEK2	O
mutations	O
(	O
n	O
=	O
3	O
)	O
were	O
associated	O
with	O
therapy	O
resistance	O
(	O
p	O
=	O
0	O
.	O
0226	O
)	O
.	O

Combined	O
,	O
mutations	O
affecting	O
either	O
CHEK2	O
or	O
TP53	O
strongly	O
predicted	O
therapy	O
resistance	O
(	O
p	O
=	O
0	O
.	O
0101	O
;	O
TP53	O
mutations	O
restricted	O
to	O
the	O
L2	O
/	O
L3	O
domains	O
:	O
p	O
=	O
0	O
.	O
0032	O
)	O
.	O
<EOS>	B-X
Neuroblastoma	B-X
is	B-X
a	B-X
malignancy	B-X
of	B-X
the	B-X
developing	B-X
sympathetic	B-X
nervous	B-X
system	B-X
that	B-X
often	B-X
presents	B-X
with	B-X
widespread	B-X
metastatic	B-X
disease	B-X
,	B-X
resulting	B-X
in	B-X
survival	B-X
rates	B-X
of	B-X
less	B-X
than	B-X
50	B-X
%	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
spectrum	B-X
of	B-X
somatic	B-X
mutation	B-X
in	B-X
high-risk	B-X
neuroblastoma	B-X
,	B-X
we	B-X
studied	B-X
240	B-X
affected	B-X
individuals	B-X
(	B-X
cases	B-X
)	B-X
using	B-X
a	B-X
combination	B-X
of	B-X
whole-exome	B-X
,	B-X
genome	B-X
and	B-X
transcriptome	B-X
sequencing	B-X
as	B-X
part	B-X
of	B-X
the	B-X
Therapeutically	B-X
Applicable	B-X
Research	B-X
to	B-X
Generate	B-X
Effective	B-X
Treatments	B-X
(	B-X
TARGET	B-X
)	B-X
initiative	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
a	B-X
low	B-X
median	B-X
exonic	B-X
mutation	B-X
frequency	B-X
of	B-X
0.60	B-X
per	B-X
Mb	B-X
(	B-X
0.48	B-X
nonsilent	B-X
)	B-X
and	B-X
notably	B-X
few	B-X
recurrently	B-X
mutated	B-X
genes	B-X
in	B-X
these	B-X
tumors	B-X
.	B-X
Genes	B-X
with	B-X
significant	B-X
somatic	B-X
mutation	B-X
frequencies	B-X
included	B-X
ALK	B-X
(	B-X
9.2	B-X
%	B-X
of	B-X
cases	B-X
)	B-X
,	B-X
PTPN11	B-X
(	B-X
2.9	B-X
%	B-X
)	B-X
,	B-X
ATRX	B-X
(	B-X
2.5	B-X
%	B-X
,	B-X
and	B-X
an	B-X
additional	B-X
7.1	B-X
%	B-X
had	B-X
focal	B-X
deletions	B-X
)	B-X
,	B-X
MYCN	B-X
(	B-X
1.7	B-X
%	B-X
,	B-X
causing	B-X
a	B-X
recurrent	B-X
p.Pro44Leu	B-X
alteration	B-X
)	B-X
and	B-X
NRAS	B-X
(	B-X
0.83	B-X
%	B-X
)	B-X
.	B-X
Rare	B-X
,	B-X
potentially	B-X
pathogenic	B-X
germline	B-X
variants	B-X
were	B-X
significantly	B-X
enriched	B-X
in	B-X
ALK	B-X
,	B-X
CHEK2	B-X
,	B-X
PINK1	B-X
and	B-X
BARD1	B-X
.	B-X
The	B-X
relative	B-X
paucity	B-X
of	B-X
recurrent	B-X
somatic	B-X
mutations	B-X
in	B-X
neuroblastoma	B-X
challenges	B-X
current	B-X
therapeutic	B-X
strategies	B-X
that	B-X
rely	B-X
on	B-X
frequently	B-X
altered	B-X
oncogenic	B-X
drivers	B-X
.	B-X

Two	O
patients	B-Species
progressing	O
on	O
therapy	O
harbored	O
the	O
CHEK2	O
mutation	O
,	O
Arg95Ter	O
,	O
completely	O
abrogating	O
Chk2	O
protein	O
dimerization	O
and	O
kinase	O
activity	O
.	O

One	O
patient	B-Species
(	O
Epi132	O
)	O
revealed	O
family	O
cancer	O
occurrence	O
resembling	O
families	O
harboring	O
CHEK2	O
mutations	O
in	O
general	O
,	O
the	O
other	O
patient	B-Species
(	O
epi203	O
)	O
was	O
non	O
-	O
conclusive	O
.	O
<EOS>	B-X
Anthracyclines	B-X
are	B-X
among	B-X
the	B-X
main	B-X
drugs	B-X
used	B-X
for	B-X
breast	B-X
cancer	B-X
therapy	B-X
and	B-X
in	B-X
many	B-X
other	B-X
malignant	B-X
conditions	B-X
.	B-X
While	B-X
we	B-X
previously	B-X
found	B-X
TP53	B-X
mutations	B-X
in	B-X
the	B-X
L2/L3	B-X
domains	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
drug	B-X
resistance	B-X
,	B-X
some	B-X
tumors	B-X
harboring	B-X
wild-type	B-X
TP53	B-X
were	B-X
also	B-X
therapy	B-X
resistant	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
;	B-X
1	B-X
)	B-X
To	B-X
explore	B-X
alterations	B-X
in	B-X
the	B-X
TP53	B-X
gene	B-X
with	B-X
respect	B-X
to	B-X
resistance	B-X
to	B-X
a	B-X
regular	B-X
dose	B-X
epirubicin	B-X
regimen	B-X
(	B-X
90	B-X
mg/m	B-X
(	B-X
2	B-X
)	B-X
every	B-X
3	B-X
week	B-X
)	B-X
in	B-X
patients	B-X
with	B-X
primary	B-X
,	B-X
locally	B-X
advanced	B-X
breast	B-X
cancer	B-X
;	B-X
2	B-X
)	B-X
Identify	B-X
critical	B-X
mechanisms	B-X
activating	B-X
p53	B-X
in	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
in	B-X
breast	B-X
cancer	B-X
;	B-X
3	B-X
)	B-X
Evaluate	B-X
in	B-X
vitro	B-X
function	B-X
of	B-X
Chk2	B-X
and	B-X
p14	B-X
proteins	B-X
corresponding	B-X
to	B-X
identified	B-X
mutations	B-X
in	B-X
the	B-X
CHEK2	B-X
and	B-X
p14	B-X
(	B-X
(	B-X
ARF	B-X
)	B-X
)	B-X
genes	B-X
;	B-X
and	B-X
4	B-X
)	B-X
Explore	B-X
potential	B-X
CHEK2	B-X
or	B-X
p14	B-X
(	B-X
(	B-X
ARF	B-X
)	B-X
)	B-X
germline	B-X
mutations	B-X
with	B-X
respect	B-X
to	B-X
family	B-X
cancer	B-X
incidence	B-X
.	B-X

No	O
mutation	O
or	O
promoter	O
hypermethylation	O
in	O
p14	O
(	O
ARF	O
)	O
were	O
detected	O
.	O
<EOS>	B-X
Rates	B-X
of	B-X
spontaneous	B-X
mutation	B-X
vary	B-X
amply	B-X
among	B-X
viruses	B-X
.	B-X
RNA	B-X
viruses	B-X
mutate	B-X
faster	B-X
than	B-X
DNA	B-X
viruses	B-X
,	B-X
single-stranded	B-X
viruses	B-X
mutate	B-X
faster	B-X
than	B-X
double-strand	B-X
virus	B-X
,	B-X
and	B-X
genome	B-X
size	B-X
appears	B-X
to	B-X
correlate	B-X
negatively	B-X
with	B-X
mutation	B-X
rate	B-X
.	B-X
Viral	B-X
mutation	B-X
rates	B-X
are	B-X
modulated	B-X
at	B-X
different	B-X
levels	B-X
,	B-X
including	B-X
polymerase	B-X
fidelity	B-X
,	B-X
sequence	B-X
context	B-X
,	B-X
template	B-X
secondary	B-X
structure	B-X
,	B-X
cellular	B-X
microenvironment	B-X
,	B-X
replication	B-X
mechanisms	B-X
,	B-X
proofreading	B-X
,	B-X
and	B-X
access	B-X
to	B-X
post-replicative	B-X
repair	B-X
.	B-X
Additionally	B-X
,	B-X
massive	B-X
numbers	B-X
of	B-X
mutations	B-X
can	B-X
be	B-X
introduced	B-X
by	B-X
some	B-X
virus-encoded	B-X
diversity-generating	B-X
elements	B-X
,	B-X
as	B-X
well	B-X
as	B-X
by	B-X
host-encoded	B-X
cytidine/adenine	B-X
deaminases	B-X
.	B-X
Our	B-X
current	B-X
knowledge	B-X
of	B-X
viral	B-X
mutation	B-X
rates	B-X
indicates	B-X
that	B-X
viral	B-X
genetic	B-X
diversity	B-X
is	B-X
determined	B-X
by	B-X
multiple	B-X
virus-	B-X
and	B-X
host-dependent	B-X
processes	B-X
,	B-X
and	B-X
that	B-X
viral	B-X
mutation	B-X
rates	B-X
can	B-X
evolve	B-X
in	B-X
response	B-X
to	B-X
specific	B-X
selective	B-X
pressures	B-X
.	B-X

Conclusion	O
<EOS>	B-X
Conclusion	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X

This	O
study	O
is	O
the	O
first	O
reporting	O
an	O
association	O
between	O
CHEK2	O
mutations	O
and	O
therapy	O
resistance	O
in	O
human	B-Species
cancers	O
and	O
to	O
document	O
mutations	O
in	O
two	O
genes	O
acting	O
direct	O
up	O
/	O
down	O
-	O
stream	O
to	O
each	O
other	O
to	O
cause	O
therapy	O
failure	O
,	O
emphasizing	O
the	O
need	O
to	O
investigate	O
functional	O
cascades	O
in	O
future	O
studies	O
.	O

Introduction	O

Chemoresistance	O
is	O
the	O
main	O
obstacle	O
to	O
cure	O
in	O
most	O
malignancies	O
,	O
including	O
breast	O
cancer	O
.	O

While	O
adjuvant	O
chemotherapy	O
may	O
reduce	O
the	O
hazard	O
rate	O
of	O
relapse	O
by	O
about	O
one	O
third	O
in	O
breast	O
cancer	O
patients	B-Species
[	O
1	O
]	O
,	O
the	O
majority	O
among	O
patients	B-Species
harboring	O
micro	O
-	O
metastases	O
are	O
not	O
cured	O
by	O
today	O
'	O
s	O
standards	O
.	O

Considering	O
patients	B-Species
harboring	O
distant	O
metastases	O
,	O
resistance	O
and	O
therapy	O
failure	O
inevitably	O
occurs	O
,	O
in	O
general	O
over	O
a	O
time	O
period	O
of	O
less	O
than	O
one	O
year	O
for	O
each	O
individual	O
regimen	O
[	O
2	O
]	O
.	O

Despite	O
extensive	O
experimental	O
research	O
[	O
3	O
]	O
,	O
little	O
data	O
are	O
available	O
considering	O
chemoresistance	O
in	O
vivo	O
.	O

For	O
anthracycline	O
therapy	O
in	O
breast	O
cancer	O
,	O
topoisomerase	O
-	O
II	O
amplifications	O
have	O
been	O
associated	O
with	O
a	O
dose	O
-	O
responsiveness	O
different	O
from	O
what	O
is	O
observed	O
in	O
non	O
-	O
amplified	O
tumors	O
4	O
,	O
5	O
.	O

Several	O
studies	O
have	O
tried	O
to	O
generate	O
"	O
prediction	O
profiles	O
"	O
based	O
on	O
gene	O
expression	O
microarrays	O
[	O
6	O
]	O
,	O
[	O
7	O
]	O
,	O
[	O
8	O
]	O
,	O
however	O
,	O
none	O
of	O
the	O
different	O
profiles	O
generated	O
expressed	O
a	O
sensitivity	O
suitable	O
for	O
clinical	O
applications	O
,	O
or	O
have	O
been	O
successfully	O
reproduced	O
by	O
others	O
(	O
see	O
references	O
to	O
original	O
works	O
in	O
[	O
9	O
]	O
and	O
[	O
10	O
]	O
)	O
.	O

p53	O
(	O
the	O
protein	O
encoded	O
by	O
the	O
TP53	O
gene	O
)	O
plays	O
a	O
key	O
role	O
in	O
executing	O
DNA	O
-	O
damage	O
induced	O
apoptosis	O
and	O
growth	O
arrest	O
[	O
11	O
]	O
.	O

Previously	O
,	O
our	O
group	O
reported	O
mutations	O
in	O
the	O
zink	O
-	O
binding	O
domains	O
L2	O
(	O
codons	O
163	O
-	O
195	O
)	O
and	O
L3	O
(	O
codons	O
236	O
-	O
251	O
)	O
of	O
p53	O
critical	O
to	O
DNA	O
binding	O
[	O
12	O
]	O
to	O
be	O
associated	O
with	O
but	O
not	O
fully	O
predictive	O
for	O
resistance	O
to	O
chemotherapy	O
with	O
a	O
low	O
-	O
dose	O
weekly	O
anthracycline	O
[	O
13	O
]	O
or	O
a	O
mitomycin	O
plus	O
5	O
-	O
fluoro	O
-	O
uracil	O
containing	O
[	O
14	O
]	O
regimen	O
.	O
<EOS>	B-X
Studies	B-X
on	B-X
the	B-X
prognostic	B-X
role	B-X
of	B-X
hyperthermic	B-X
intraperitoneal	B-X
chemotherapy	B-X
(	B-X
HIPEC	B-X
)	B-X
in	B-X
pseudomyxoma	B-X
peritonei	B-X
(	B-X
PMP	B-X
)	B-X
are	B-X
currently	B-X
not	B-X
available	B-X
.	B-X
This	B-X
is	B-X
a	B-X
review	B-X
of	B-X
randomized	B-X
controlled	B-X
trials	B-X
of	B-X
intravenous	B-X
5-flurorouracil	B-X
(	B-X
5-FU	B-X
)	B-X
-containing	B-X
chemotherapy	B-X
after	B-X
curative	B-X
resection	B-X
versus	B-X
surgery	B-X
alone	B-X
in	B-X
patients	B-X
with	B-X
gastric	B-X
carcinoma	B-X
to	B-X
determine	B-X
the	B-X
impact	B-X
on	B-X
survival	B-X
rate	B-X
,	B-X
safety	B-X
and	B-X
economics	B-X
.	B-X
We	B-X
included	B-X
22	B-X
randomized	B-X
controlled	B-X
trials	B-X
comparing	B-X
4501	B-X
patients	B-X
.	B-X
Intravenous	B-X
5-FU-containing	B-X
chemotherapy	B-X
after	B-X
curative	B-X
resection	B-X
had	B-X
a	B-X
slightly	B-X
significant	B-X
improvement	B-X
in	B-X
3-	B-X
,	B-X
5-	B-X
and	B-X
7-year	B-X
overall	B-X
survival	B-X
rate	B-X
(	B-X
OR	B-X
1.49	B-X
,	B-X
1.41	B-X
and	B-X
1.32	B-X
)	B-X
.	B-X
No	B-X
benefit	B-X
of	B-X
postoperative	B-X
disease-free	B-X
survival	B-X
rate	B-X
was	B-X
induced	B-X
by	B-X
5-FU-containing	B-X
chemotherapy	B-X
.	B-X
Subgroup	B-X
analyses	B-X
found	B-X
borderline	B-X
improved	B-X
overall	B-X
survival	B-X
rate	B-X
in	B-X
both	B-X
Western	B-X
and	B-X
Eastern	B-X
countries	B-X
but	B-X
the	B-X
statistical	B-X
significance	B-X
was	B-X
stronger	B-X
in	B-X
the	B-X
Eastern	B-X
subset	B-X
.	B-X
The	B-X
combinations	B-X
of	B-X
5-FU	B-X
plus	B-X
mitomycin	B-X
C	B-X
,	B-X
5-FU	B-X
plus	B-X
cytosine	B-X
arabinoside	B-X
and	B-X
5-FU	B-X
plus	B-X
adriamycin	B-X
or	B-X
epidoxorubicin	B-X
induced	B-X
potentially	B-X
more	B-X
improvement	B-X
of	B-X
3-	B-X
and	B-X
5-year	B-X
overall	B-X
survival	B-X
rates	B-X
.	B-X
Severe	B-X
toxicities	B-X
were	B-X
reported	B-X
in	B-X
1629	B-X
patients	B-X
from	B-X
15	B-X
included	B-X
trials	B-X
,	B-X
and	B-X
hematological	B-X
and	B-X
gastrointestinal	B-X
toxicities	B-X
were	B-X
the	B-X
most	B-X
remarkable	B-X
side	B-X
effects	B-X
,	B-X
around	B-X
5	B-X
%	B-X
-15	B-X
%	B-X
respectively	B-X
.	B-X
The	B-X
chemotherapy-related	B-X
overall	B-X
mortality	B-X
was	B-X
1.1	B-X
%	B-X
.	B-X
Although	B-X
the	B-X
results	B-X
provide	B-X
some	B-X
evidence	B-X
of	B-X
a	B-X
beneficial	B-X
effect	B-X
of	B-X
adjuvant	B-X
chemotherapy	B-X
with	B-X
5-FU-containing	B-X
regimens	B-X
,	B-X
they	B-X
are	B-X
inconclusive	B-X
due	B-X
to	B-X
the	B-X
limitations	B-X
of	B-X
methodological	B-X
quality	B-X
of	B-X
including	B-X
randomized	B-X
controlled	B-X
trials	B-X
.	B-X
Large	B-X
scale	B-X
randomized	B-X
controlled	B-X
trials	B-X
with	B-X
a	B-X
positive	B-X
result	B-X
are	B-X
still	B-X
mandatory	B-X
before	B-X
postoperative	B-X
chemotherapy	B-X
are	B-X
recommended	B-X
.	B-X

Similar	O
findings	O
were	O
reported	O
by	O
another	O
group	O
[	O
15	O
]	O
.	O
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
review	B-X
is	B-X
to	B-X
synthesize	B-X
the	B-X
best	B-X
available	B-X
evidence	B-X
on	B-X
palliative	B-X
care	B-X
experiences	B-X
of	B-X
adult	B-X
cancer	B-X
patients	B-X
from	B-X
ethnocultural	B-X
groups.More	B-X
specifically	B-X
,	B-X
this	B-X
systematic	B-X
review	B-X
seeks	B-X
to	B-X
answer	B-X
the	B-X
following	B-X
questions:1	B-X
.	B-X
What	B-X
are	B-X
the	B-X
palliative	B-X
care	B-X
experiences	B-X
of	B-X
adult	B-X
cancer	B-X
patients	B-X
from	B-X
diverse	B-X
ethnocultural	B-X
groups	B-X
?	B-X
2	B-X
.	B-X
What	B-X
meanings	B-X
do	B-X
adult	B-X
patients	B-X
with	B-X
cancer	B-X
from	B-X
diverse	B-X
ethnocultural	B-X
groups	B-X
assign	B-X
to	B-X
their	B-X
experiences	B-X
with	B-X
palliative	B-X
care	B-X
?	B-X
The	B-X
efficacy	B-X
of	B-X
behavioural	B-X
lifestyle	B-X
interventions	B-X
(	B-X
BLI	B-X
)	B-X
for	B-X
weight	B-X
loss	B-X
and	B-X
prevention	B-X
and	B-X
treatment	B-X
of	B-X
diabetes	B-X
and	B-X
hypertension	B-X
is	B-X
well	B-X
established	B-X
but	B-X
may	B-X
vary	B-X
among	B-X
racial/ethnic	B-X
subgroups	B-X
.	B-X
We	B-X
identified	B-X
seven	B-X
relevant	B-X
trials	B-X
that	B-X
reported	B-X
subgroup	B-X
analyses	B-X
for	B-X
AA	B-X
.	B-X
There	B-X
were	B-X
no	B-X
reported	B-X
differences	B-X
between	B-X
races	B-X
in	B-X
diabetes	B-X
incidence	B-X
.	B-X
Three	B-X
analyses	B-X
reported	B-X
no	B-X
differences	B-X
in	B-X
blood	B-X
pressure	B-X
;	B-X
however	B-X
,	B-X
a	B-X
fourth	B-X
reported	B-X
that	B-X
AA	B-X
women	B-X
were	B-X
the	B-X
only	B-X
group	B-X
that	B-X
did	B-X
not	B-X
experience	B-X
a	B-X
significant	B-X
change	B-X
in	B-X
blood	B-X
pressure	B-X
.	B-X
Despite	B-X
increased	B-X
attention	B-X
to	B-X
cultural	B-X
relevance	B-X
,	B-X
race-specific	B-X
differences	B-X
in	B-X
weight	B-X
loss	B-X
persist	B-X
in	B-X
trials	B-X
spanning	B-X
20	B-X
years	B-X
;	B-X
however	B-X
,	B-X
risk	B-X
factor	B-X
modification	B-X
was	B-X
similar	B-X
across	B-X
race/ethnic	B-X
groups	B-X
.	B-X

In	O
contrast	O
,	O
others	O
reported	O
TP53	O
mutations	O
to	O
predict	O
sensitivity	O
to	O
a	O
dose	O
-	O
dense	O
epirubicin	O
-	O
cyclophosphamide	O
regimen	O
[	O
16	O
]	O
.	O

The	O
finding	O
that	O
some	O
tumors	O
harboring	O
wild	O
-	O
type	O
TP53	O
may	O
be	O
resistant	O
to	O
anthracycline	O
therapy	O
lead	O
us	O
to	O
postulate	O
that	O
other	O
genes	O
involved	O
in	O
the	O
p53	O
pathway	O
could	O
be	O
mutated	O
in	O
these	O
tumors	O
[	O
3	O
]	O
.	O

p53	O
is	O
activated	O
by	O
post	O
-	O
translational	O
modifications	O
,	O
and	O
the	O
protein	O
is	O
phosphorylated	O
at	O
multiple	O
amino	O
acids	O
[	O
17	O
]	O
.	O
<EOS>	B-X
p53	B-X
has	B-X
been	B-X
called	B-X
the	B-X
``	B-X
cellular	B-X
gatekeeper	B-X
''	B-X
and	B-X
the	B-X
``	B-X
genome	B-X
guard	B-X
,	B-X
''	B-X
because	B-X
in	B-X
response	B-X
to	B-X
exposure	B-X
to	B-X
DNA-damaging	B-X
agents	B-X
,	B-X
it	B-X
induces	B-X
cell-cycle	B-X
arrest	B-X
in	B-X
G1	B-X
or	B-X
apoptosis	B-X
and	B-X
also	B-X
directly	B-X
affects	B-X
DNA	B-X
replication	B-X
.	B-X
Multiple	B-X
mechanisms	B-X
regulate	B-X
p53	B-X
activity	B-X
and	B-X
posttranslational	B-X
modification	B-X
,	B-X
including	B-X
multisite	B-X
phosphorylation	B-X
of	B-X
wild-type	B-X
p53	B-X
,	B-X
in	B-X
particular	B-X
.	B-X
Normal	B-X
functions	B-X
of	B-X
wild-type	B-X
p53	B-X
are	B-X
abrogated	B-X
by	B-X
mutation	B-X
of	B-X
this	B-X
gene	B-X
,	B-X
and	B-X
oncogenic	B-X
studies	B-X
have	B-X
revealed	B-X
that	B-X
p53	B-X
mutation	B-X
is	B-X
among	B-X
the	B-X
most	B-X
common	B-X
genetic	B-X
alteration	B-X
in	B-X
human	B-X
cancers	B-X
.	B-X
It	B-X
is	B-X
generally	B-X
accepted	B-X
that	B-X
mutant	B-X
p53	B-X
protein	B-X
may	B-X
not	B-X
only	B-X
lose	B-X
the	B-X
tumor	B-X
suppressor	B-X
functions	B-X
of	B-X
wild-type	B-X
p53	B-X
but	B-X
also	B-X
acquire	B-X
additional	B-X
tumorigenetic	B-X
roles	B-X
,	B-X
including	B-X
dominant-negative	B-X
effects	B-X
and	B-X
gain	B-X
of	B-X
function	B-X
.	B-X
Although	B-X
many	B-X
studies	B-X
have	B-X
revealed	B-X
such	B-X
aberrant	B-X
functions	B-X
of	B-X
mutant	B-X
p53	B-X
,	B-X
less	B-X
is	B-X
known	B-X
about	B-X
the	B-X
posttranslational	B-X
phosphorylation	B-X
status	B-X
of	B-X
mutant	B-X
p53	B-X
and	B-X
novel	B-X
biological	B-X
functions	B-X
of	B-X
phosphorylation	B-X
in	B-X
carcinogenesis	B-X
.	B-X

Phosphorylation	O
at	O
Ser	O
20	O
(	O
Ser	O
23	O
in	O
mice	B-Species
)	O
by	O
the	O
Chk2	O
protein	O
(	O
coded	O
by	O
the	O
CHEK2	O
gene	O
)	O
in	O
response	O
to	O
DNA	O
damage	O
activates	O
p53	O
by	O
inhibiting	O
binding	O
to	O
,	O
and	O
deactivation	O
by	O
,	O
the	O
MDM2	O
(	O
Mouse	B-Species
Minute	O
2	O
homolog	O
;	O
HDM2	O
)	O
protein	O
[	O
18	O
]	O
,	O
[	O
19	O
]	O
,	O
[	O
20	O
]	O
.	O

While	O
experimental	O
studies	O
have	O
suggested	O
a	O
critical	O
role	O
of	O
Chk2	O
in	O
activating	O
p53	O
apoptotic	O
response	O
to	O
genotoxic	O
stress	O
[	O
21	O
]	O
,	O
[	O
22	O
]	O
,	O
others	O
claim	O
Chk2	O
to	O
be	O
dispensable	O
for	O
p53	O
activation	O
with	O
respect	O
to	O
apoptosis	O
as	O
well	O
as	O
growth	O
arrest	O
[	O
23	O
]	O
.	O

Following	O
an	O
initial	O
report	O
of	O
a	O
CHEK2	O
germline	O
mutation	O
in	O
a	O
family	O
filling	O
the	O
characteristics	O
of	O
a	O
Li	O
-	O
Fraumeni	O
syndrome	O
(	O
LFS	O
)	O
[	O
24	O
]	O
,	O
recent	O
papers	O
have	O
suggested	O
germline	O
mutations	O
in	O
CHEK2	O
to	O
be	O
associated	O
with	O
a	O
moderately	O
increased	O
risk	O
of	O
breast	O
and	O
colon	O
cancers	O
(	O
see	O
references	O
in	O
[	O
25	O
]	O
)	O
.	O

Recently	O
,	O
we	O
discovered	O
a	O
somatic	O
,	O
nonsense	O
CHEK2	O
mutation	O
in	O
a	O
single	O
patient	B-Species
expressing	O
resistance	O
to	O
doxorubicin	O
low	O
dose	O
therapy	O
[	O
26	O
]	O
.	O

A	O
second	O
mechanism	O
of	O
p53	O
activation	O
is	O
through	O
p14	O
(	O
ARF	O
)	O
(	O
p19	O
in	O
mice	B-Species
)	O
function	O
.	O

p14	O
(	O
ARF	O
)	O
does	O
not	O
phosphorylate	O
p53	O
,	O
but	O
inhibits	O
MDM2	O
dependent	O
p53	O
degradation	O
through	O
direct	O
MDM2	O
binding	O
.	O
<EOS>	B-X
p14	B-X
ARF	B-X
,	B-X
encoded	B-X
by	B-X
the	B-X
The	B-X
strongest	B-X
genetic	B-X
risk	B-X
for	B-X
the	B-X
development	B-X
of	B-X
melanoma	B-X
results	B-X
from	B-X
heritable	B-X
alterations	B-X
in	B-X
cyclin-dependent	B-X
kinase	B-X
inhibitor	B-X
2A	B-X
(	B-X
CDKN2A	B-X
)	B-X
gene	B-X
,	B-X
which	B-X
encodes	B-X
two	B-X
separate	B-X
but	B-X
related	B-X
proteins	B-X
,	B-X
p16/INK4a	B-X
and	B-X
p14/ARF	B-X
.	B-X
Other	B-X
important	B-X
genes	B-X
include	B-X
CDK4/6	B-X
and	B-X
retinoblastoma	B-X
(	B-X
RB1	B-X
)	B-X
,	B-X
which	B-X
encode	B-X
downstream	B-X
proteins	B-X
in	B-X
the	B-X
same	B-X
pathway	B-X
as	B-X
p16/INK4a	B-X
and	B-X
p14/ARF	B-X
.	B-X

While	O
p14	O
(	O
ARF	O
)	O
-	O
mediated	O
p53	O
activation	O
has	O
been	O
linked	O
to	O
oncogene	O
-	O
induced	O
p53	O
activation	O
and	O
,	O
in	O
general	O
,	O
considered	O
not	O
involved	O
in	O
response	O
to	O
DNA	O
damage	O
(	O
see	O
references	O
in	O
[	O
27	O
]	O
)	O
,	O
p14	O
(	O
ARF	O
)	O
may	O
be	O
activated	O
through	O
the	O
E2F1	O
/	O
retinoblastoma	O
pathway	O
[	O
28	O
]	O
.	O

Importantly	O
,	O
two	O
recent	O
studies	O
revealed	O
lack	O
of	O
p19	O
(	O
mouse	B-Species
homologue	O
of	O
human	B-Species
p14	O
(	O
ARF	O
)	O
)	O
function	O
in	O
mice	B-Species
to	O
inhibit	O
p53	O
tumor	O
suppressor	O
function	O
in	O
response	O
to	O
ionizing	O
radiation	O
as	O
well	O
as	O
DNA	O
damaging	O
agents	O
[	O
29	O
]	O
,	O
[	O
30	O
]	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
1	O
)	O
to	O
explore	O
alterations	O
in	O
the	O
TP53	O
gene	O
with	O
respect	O
to	O
resistance	O
to	O
a	O
regular	O
dose	O
epirubicin	O
regimen	O
(	O
90	O
mg	O
/	O
m2	O
body	O
surface	O
every	O
3	O
week	O
)	O
in	O
patient	B-Species
with	O
primary	O
,	O
locally	O
advanced	O
,	O
breast	O
cancer	O
;	O
2	O
)	O
To	O
explore	O
defects	O
in	O
potential	O
mechanisms	O
activating	O
p53	O
in	O
response	O
to	O
DNA	O
damage	O
in	O
breast	O
cancer	O
as	O
a	O
cause	O
of	O
drug	O
resistance	O
in	O
wild	O
-	O
type	O
tumors	O
.	O

To	O
do	O
so	O
,	O
we	O
sequenced	O
the	O
complete	O
coding	O
regions	O
for	O
the	O
CHEK2	O
and	O
p14	O
(	O
ARF	O
)	O
genes	O
and	O
analyzed	O
for	O
p14	O
(	O
ARF	O
)	O
promoter	O
hypermetylations	O
;	O
3	O
)	O
Evaluate	O
in	O
vitro	O
function	O
of	O
potential	O
Chk2	O
and	O
p14	O
(	O
ARF	O
)	O
protein	O
translates	O
corresponding	O
to	O
identified	O
mutations	O
in	O
the	O
CHEK2	O
and	O
p14	O
(	O
ARF	O
)	O
genes	O
;	O
4	O
)	O
Identify	O
potential	O
TP53	O
,	O
CHEK2	O
and	O
p14	O
(	O
ARF	O
)	O
mutations	O
to	O
be	O
germline	O
,	O
explore	O
the	O
incidence	O
of	O
different	O
cancers	O
among	O
affected	O
relatives	O
with	O
respect	O
to	O
specific	O
mutations	O
.	O

By	O
comparing	O
in	O
vitro	O
characteristics	O
of	O
specific	O
mutations	O
to	O
drug	O
sensitivity	O
and	O
family	O
cancer	O
risk	O
syndromes	O
,	O
this	O
may	O
add	O
to	O
our	O
understanding	O
of	O
the	O
importance	O
of	O
these	O
gene	O
cascades	O
executing	O
response	O
to	O
DNA	O
damage	O
versus	O
tumor	O
suppression	O
activity	O
.	O

Analyzing	O
tumor	O
samples	O
from	O
a	O
total	O
of	O
109	O
primary	O
locally	O
advanced	O
breast	O
cancer	O
patients	B-Species
treated	O
with	O
epirubicin	O
90mg	O
/	O
3	O
weekly	O
,	O
we	O
found	O
TP53	O
mutations	O
affecting	O
the	O
L2	O
/	O
L3	O
domains	O
or	O
protein	O
dimerization	O
,	O
as	O
well	O
as	O
non	O
-	O
functional	O
CHEK2	O
mutations	O
abrogating	O
dimerization	O
and	O
phosphorylation	O
,	O
to	O
be	O
associated	O
with	O
therapy	O
resistance	O
;	O
no	O
mutation	O
or	O
promoter	O
hypermethylations	O
of	O
the	O
p14	O
(	O
ARF	O
)	O
gene	O
was	O
discovered	O
.	O

Our	O
findings	O
suggest	O
a	O
critical	O
role	O
for	O
Chk2	O
with	O
respect	O
to	O
DNA	O
-	O
damage	O
-	O
dependent	O
p53	O
activation	O
and	O
resistance	O
to	O
anthracycline	O
therapy	O
in	O
human	B-Species
breast	O
cancer	O
.	O

Materials	O
and	O
Methods	O
<EOS>	B-X
Methods	B-X
of	B-X
delivery	B-X
focused	B-X
on	B-X
how	B-X
to	B-X
deliver	B-X
the	B-X
teaching	B-X
strategies	B-X
.	B-X

Patients	B-Species
<EOS>	B-X
``	B-X
Patients	B-X
deserve	B-X
agency	B-X
when	B-X
it	B-X
comes	B-X
to	B-X
their	B-X
body	B-X
''	B-X
:	B-X
a	B-X
patient	B-X
's	B-X
experience	B-X
with	B-X
endometriosis	B-X
.	B-X

A	O
total	O
of	O
223	O
patients	B-Species
with	O
locally	O
advanced	O
non	O
-	O
inflammatory	O
breast	O
cancer	O
(	O
T3	O
-	O
4	O
and	O
/	O
or	O
N2	O
)	O
were	O
randomly	O
allocated	O
to	O
primary	O
treatment	O
either	O
with	O
epirubicin	O
90	O
mg	O
/	O
m2	O
or	O
paclitaxel	O
200	O
mg	O
/	O
m2	O
.	O
<EOS>	B-X
To	B-X
evaluate	B-X
sintilimab	B-X
versus	B-X
placebo	B-X
in	B-X
combination	B-X
with	B-X
chemotherapy	B-X
(	B-X
cisplatin	B-X
plus	B-X
paclitaxel	B-X
or	B-X
cisplatin	B-X
plus	B-X
5-fluorouracil	B-X
)	B-X
as	B-X
first	B-X
line	B-X
treatment	B-X
of	B-X
unresectable	B-X
locally	B-X
advanced	B-X
,	B-X
recurrent	B-X
,	B-X
or	B-X
metastatic	B-X
oesophageal	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
.	B-X
This	B-X
study	B-X
demonstrates	B-X
that	B-X
tislelizumab	B-X
in	B-X
combination	B-X
with	B-X
chemotherapy	B-X
is	B-X
associated	B-X
with	B-X
improved	B-X
progression-free	B-X
survival	B-X
(	B-X
PFS	B-X
)	B-X
in	B-X
patients	B-X
with	B-X
advanced	B-X
squamous	B-X
non-small-cell	B-X
lung	B-X
cancer	B-X
(	B-X
sq-NSCLC	B-X
)	B-X
.	B-X
Camrelizumab	B-X
,	B-X
an	B-X
mAb	B-X
against	B-X
programmed	B-X
cell	B-X
death	B-X
protein	B-X
1	B-X
(	B-X
PD-1	B-X
)	B-X
,	B-X
plus	B-X
nab-paclitaxel	B-X
exhibited	B-X
promising	B-X
antitumor	B-X
activity	B-X
in	B-X
refractory	B-X
metastatic	B-X
immunomodulatory	B-X
triple-negative	B-X
breast	B-X
cancer	B-X
(	B-X
TNBC	B-X
)	B-X
.	B-X
We	B-X
aimed	B-X
to	B-X
assess	B-X
the	B-X
efficacy	B-X
and	B-X
safety	B-X
of	B-X
a	B-X
novel	B-X
combination	B-X
of	B-X
famitinib	B-X
,	B-X
camrelizumab	B-X
,	B-X
and	B-X
nab-paclitaxel	B-X
in	B-X
advanced	B-X
immunomodulatory	B-X
TNBC	B-X
.	B-X

The	O
primary	O
aim	O
of	O
the	O
study	O
was	O
identification	O
of	O
markers	O
predicting	O
drug	O
resistance	O
to	O
the	O
regimens	O
.	O

Thus	O
,	O
the	O
reason	O
for	O
randomizing	O
patients	B-Species
was	O
not	O
for	O
effect	O
comparison	O
,	O
but	O
to	O
achieve	O
similar	O
patient	B-Species
cohorts	O
in	O
the	O
two	O
arms	O
.	O
<EOS>	B-X
At	B-X
six	B-X
centers	B-X
,	B-X
203	B-X
patients	B-X
with	B-X
hypoxemic	B-X
chronic	B-X
obstructive	B-X
lung	B-X
disease	B-X
were	B-X
randomly	B-X
allocated	B-X
to	B-X
either	B-X
continuous	B-X
oxygen	B-X
(	B-X
O2	B-X
)	B-X
therapy	B-X
or	B-X
12-hour	B-X
nocturnal	B-X
O2	B-X
therapy	B-X
and	B-X
followed	B-X
for	B-X
at	B-X
least	B-X
12	B-X
months	B-X
(	B-X
mean	B-X
,	B-X
19.3	B-X
months	B-X
)	B-X
.	B-X
The	B-X
two	B-X
groups	B-X
were	B-X
initially	B-X
well	B-X
matched	B-X
in	B-X
terms	B-X
of	B-X
physiological	B-X
and	B-X
neuropsychological	B-X
function	B-X
.	B-X
This	B-X
trend	B-X
was	B-X
striking	B-X
in	B-X
patients	B-X
with	B-X
carbon	B-X
dioxide	B-X
retention	B-X
and	B-X
also	B-X
present	B-X
in	B-X
patients	B-X
with	B-X
relatively	B-X
poor	B-X
lung	B-X
function	B-X
,	B-X
low	B-X
mean	B-X
nocturnal	B-X
oxygen	B-X
saturation	B-X
,	B-X
more	B-X
severe	B-X
brain	B-X
dysfunction	B-X
,	B-X
and	B-X
prominent	B-X
mood	B-X
disturbances	B-X
.	B-X
Continuous	B-X
O2	B-X
therapy	B-X
also	B-X
appeared	B-X
to	B-X
benefit	B-X
patients	B-X
with	B-X
low	B-X
mean	B-X
pulmonary	B-X
artery	B-X
pressure	B-X
and	B-X
pulmonary	B-X
vascular	B-X
resistance	B-X
and	B-X
those	B-X
with	B-X
relatively	B-X
well-preserved	B-X
exercise	B-X
capacity	B-X
.	B-X
The	B-X
reason	B-X
for	B-X
this	B-X
difference	B-X
is	B-X
not	B-X
clear	B-X
.	B-X

Based	O
on	O
the	O
findings	O
of	O
a	O
clinical	O
lack	O
of	O
cross	O
-	O
resistance	O
between	O
anthracyclines	O
and	O
taxane	O
therapies	O
in	O
breast	O
cancer	O
[	O
31	O
]	O
,	O
we	O
hypothesized	O
the	O
mechanisms	O
of	O
resistance	O
to	O
be	O
different	O
between	O
the	O
two	O
compounds	O
.	O

While	O
the	O
analysis	O
of	O
tumor	O
samples	O
from	O
the	O
paclitaxel	O
is	O
ongoing	O
,	O
we	O
here	O
report	O
our	O
findings	O
from	O
the	O
patients	B-Species
allocated	O
to	O
the	O
epirubicin	O
arm	O
.	O

The	O
epirubicin	O
arm	O
included	O
a	O
total	O
of	O
109	O
patients	B-Species
(	O
age	O
28	O
to	O
70	O
years	O
,	O
median	O
51	O
years	O
)	O
.	O

Two	O
patients	B-Species
were	O
analyzed	O
for	O
gene	O
mutations	O
but	O
omitted	O
from	O
statistical	O
analysis	O
as	O
protocol	O
violators	O
;	O
histopathological	O
examination	O
revealed	O
one	O
patient	B-Species
(	O
Epi089	O
)	O
to	O
harbor	O
a	O
sarcomatoid	O
tumor	O
,	O
while	O
one	O
patient	B-Species
Epi232	O
was	O
erroneously	O
enrolled	O
with	O
stage	O
II	O
disease	O
.	O

The	O
study	O
protocol	O
was	O
approved	O
by	O
the	O
Regional	O
Ethical	O
Committee	O
(	O
Norwegian	O
Health	O
Region	O
III	O
)	O
,	O
including	O
formal	O
Biobank	O
registration	O
in	O
accordance	O
to	O
Norwegian	O
law	O
.	O

The	O
study	O
and	O
protocol	O
is	O
registered	O
under	O
the	O
Norwegian	O
Social	O
Science	O
Data	O
services	O
(	O
(	O
www	O
.	O
nsd	O
/	O
uib	O
/	O
personvern	O
/	O
database	O
/	O
)	O
,	O
University	O
of	O
Bergen	O
project	O
no	O
16297	O
and	O
Helse	O
Bergen	O
project	O
no	O
13025	O
)	O
.	O

Each	O
patient	B-Species
gave	O
written	O
informed	O
consent	O
.	O
<EOS>	B-X
However	B-X
,	B-X
the	B-X
assessment	B-X
of	B-X
the	B-X
vitamin	B-X
D	B-X
status	B-X
of	B-X
depressed	B-X
juvenile	B-X
patients	B-X
,	B-X
or	B-X
supplementation	B-X
of	B-X
vitamin	B-X
D	B-X
is	B-X
currently	B-X
not	B-X
part	B-X
of	B-X
routine	B-X
treatment	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
clinical	B-X
trial	B-X
was	B-X
to	B-X
assess	B-X
the	B-X
efficacy	B-X
and	B-X
safety	B-X
of	B-X
curcuminoid	B-X
complex	B-X
extract	B-X
from	B-X
turmeric	B-X
rhizome	B-X
with	B-X
turmeric	B-X
volatile	B-X
oil	B-X
(	B-X
CuraMedÂ®	B-X
)	B-X
and	B-X
its	B-X
combination	B-X
with	B-X
boswellic	B-X
acid	B-X
extract	B-X
from	B-X
Indian	B-X
frankincense	B-X
root	B-X
(	B-X
CuraminÂ®	B-X
)	B-X
vs	B-X
placebo	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
40-	B-X
to	B-X
70-year-old	B-X
patients	B-X
with	B-X
osteoarthritis	B-X
(	B-X
OA	B-X
)	B-X
.	B-X
We	B-X
assessed	B-X
whether	B-X
the	B-X
wearable	B-X
exoskeleton	B-X
,	B-X
Eksoâ¢	B-X
,	B-X
could	B-X
get	B-X
higher	B-X
gait	B-X
performance	B-X
than	B-X
conventional	B-X
overground	B-X
gait	B-X
training	B-X
(	B-X
OGT	B-X
)	B-X
in	B-X
patients	B-X
with	B-X
hemiparesis	B-X
due	B-X
to	B-X
stroke	B-X
in	B-X
a	B-X
chronic	B-X
phase	B-X
,	B-X
and	B-X
foster	B-X
the	B-X
recovery	B-X
of	B-X
specific	B-X
brain	B-X
plasticity	B-X
mechanisms	B-X
.	B-X
The	B-X
Netherlands	B-X
Brain	B-X
Bank	B-X
(	B-X
NBB	B-X
)	B-X
performs	B-X
rapid	B-X
autopsies	B-X
of	B-X
donors	B-X
who	B-X
gave	B-X
written	B-X
informed	B-X
consent	B-X
during	B-X
life	B-X
for	B-X
the	B-X
use	B-X
of	B-X
their	B-X
brain	B-X
tissue	B-X
and	B-X
medical	B-X
files	B-X
for	B-X
research	B-X
.	B-X
The	B-X
ultimate	B-X
goal	B-X
of	B-X
NBB-Psy	B-X
is	B-X
to	B-X
reduce	B-X
the	B-X
burden	B-X
of	B-X
psychiatric	B-X
disorders	B-X
for	B-X
patients	B-X
,	B-X
their	B-X
families	B-X
,	B-X
and	B-X
for	B-X
society	B-X
as	B-X
a	B-X
whole	B-X
.	B-X
This	B-X
chapter	B-X
focuses	B-X
on	B-X
the	B-X
design	B-X
of	B-X
NBB-Psy	B-X
and	B-X
the	B-X
antemortem	B-X
donor	B-X
program	B-X
,	B-X
where	B-X
patients	B-X
and	B-X
relatives	B-X
are	B-X
actively	B-X
informed	B-X
on	B-X
the	B-X
possibility	B-X
to	B-X
become	B-X
a	B-X
brain	B-X
donor	B-X
.	B-X

Tissue	O
Sampling	O
<EOS>	B-X
Sampling	B-X
was	B-X
performed	B-X
with	B-X
mouse	B-X
brain	B-X
tissue	B-X
slices	B-X
to	B-X
characterize	B-X
basal	B-X
neurotransmitter	B-X
content	B-X
in	B-X
this	B-X
model	B-X
system	B-X
.	B-X

Before	O
commencing	O
chemotherapy	O
,	O
each	O
patient	B-Species
had	O
an	O
incisional	O
tumor	O
biopsy	O
as	O
described	O
previously	O
[	O
14	O
]	O
.	O

All	O
tissue	O
samples	O
were	O
snap	O
-	O
frozen	O
immediately	O
on	O
removal	O
in	O
the	O
theatre	O
.	O

Treatment	O
Regime	O
and	O
Staging	O
<EOS>	B-X
Treatment	B-X
of	B-X
metastatic	B-X
CRC	B-X
has	B-X
been	B-X
considered	B-X
palliative	B-X
for	B-X
many	B-X
years	B-X
;	B-X
aiming	B-X
to	B-X
increase	B-X
the	B-X
duration	B-X
and	B-X
quality	B-X
of	B-X
the	B-X
patient	B-X
&	B-X
amp	B-X
;	B-X
#	B-X
039	B-X
;	B-X
s	B-X
remaining	B-X
life	B-X
,	B-X
with	B-X
little	B-X
hope	B-X
of	B-X
cure	B-X
,	B-X
highlighting	B-X
the	B-X
need	B-X
for	B-X
novel	B-X
DNA	B-X
and	B-X
RNA	B-X
targeted	B-X
therapies	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
CRC	B-X
.	B-X
Treatment	B-X
algorithms	B-X
dictate	B-X
an	B-X
aggressive	B-X
approach	B-X
with	B-X
surgical	B-X
debridement	B-X
and	B-X
antibiotic	B-X
treatment	B-X
.	B-X
We	B-X
use	B-X
data	B-X
from	B-X
the	B-X
Adaptive	B-X
Pharmacological	B-X
and	B-X
Behavioral	B-X
Treatments	B-X
for	B-X
Children	B-X
with	B-X
ADHD	B-X
Trial	B-X
as	B-X
an	B-X
illustrative	B-X
example	B-X
.	B-X

Primary	O
treatment	O
consisted	O
of	O
epirubicin	O
(	O
90	O
mg	O
/	O
m2	O
)	O
administered	O
as	O
a	O
3	O
-	O
weekly	O
schedule	O
.	O
<EOS>	B-X
Trastuzumab	B-X
plus	B-X
chemotherapy	B-X
is	B-X
the	B-X
standard	B-X
adjuvant	B-X
treatment	B-X
for	B-X
patients	B-X
with	B-X
human	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
2	B-X
(	B-X
HER2	B-X
)	B-X
-positive	B-X
early	B-X
breast	B-X
cancer	B-X
.	B-X
While	B-X
the	B-X
standard	B-X
duration	B-X
of	B-X
trastuzumab	B-X
treatment	B-X
is	B-X
12	B-X
months	B-X
,	B-X
the	B-X
benefits	B-X
and	B-X
harms	B-X
of	B-X
trastuzumab	B-X
continued	B-X
beyond	B-X
the	B-X
chemotherapy	B-X
are	B-X
unclear	B-X
.	B-X

Treatment	O
was	O
scheduled	O
for	O
four	O
cycles	O
unless	O
progression	O
occurred	O
at	O
an	O
earlier	O
stage	O
.	O

Clinical	O
response	O
was	O
assessed	O
before	O
each	O
treatment	O
cycle	O
,	O
and	O
the	O
final	O
response	O
evaluated	O
3	O
weeks	O
after	O
the	O
4th	O
cycle	O
for	O
overall	O
response	O
classification	O
.	O

Because	O
the	O
protocol	O
was	O
implemented	O
by	O
October	O
1997	O
with	O
patients	B-Species
enrolled	O
between	O
November	O
1997	O
and	O
December	O
2003	O
,	O
responses	O
were	O
consistently	O
graded	O
by	O
the	O
UICC	O
system	O
[	O
32	O
]	O
and	O
not	O
the	O
more	O
recently	O
implemented	O
"	O
RECIST	O
"	O
criteria	O
[	O
33	O
]	O
.	O

Thus	O
,	O
responses	O
were	O
classified	O
as	O
CR	O
(	O
Complete	O
Response	O
,	O
complete	O
disappearance	O
of	O
all	O
tumor	O
lesions	O
)	O
,	O
PR	O
(	O
Partial	O
Response	O
,	O
reduction	O
>=	O
50	O
%	O
in	O
the	O
sum	O
of	O
all	O
tumor	O
lesions	O
,	O
calculated	O
for	O
each	O
as	O
the	O
product	O
of	O
the	O
largest	O
diameter	O
and	O
the	O
one	O
perpendicular	O
to	O
it	O
)	O
,	O
PD	O
(	O
Progressive	O
Disease	O
,	O
increase	O
in	O
the	O
diameter	O
product	O
of	O
any	O
individual	O
tumor	O
lesion	O
by	O
>=	O
25	O
%	O
)	O
,	O
and	O
SD	O
(	O
Stable	O
Disease	O
,	O
anything	O
between	O
PR	O
and	O
PD	O
)	O
.	O

To	O
analyze	O
for	O
the	O
predictive	O
value	O
of	O
the	O
different	O
parameters	O
,	O
similar	O
to	O
our	O
previous	O
studies	O
[	O
13	O
]	O
,	O
[	O
14	O
]	O
we	O
compared	O
PD	O
tumors	O
(	O
non	O
responders	O
)	O
with	O
the	O
combined	O
group	O
of	O
tumors	O
classified	O
as	O
SD	O
/	O
PR	O
/	O
CR	O
(	O
responders	O
)	O
;	O
the	O
reason	O
for	O
this	O
approach	O
is	O
discussed	O
in	O
detail	O
elsewhere	O
[	O
34	O
]	O
.	O

Median	O
follow	O
-	O
up	O
time	O
was	O
defined	O
from	O
patient	B-Species
inclusion	O
in	O
the	O
study	O
up	O
to	O
October	O
31	O
,	O
2006	O
.	O

Deaths	O
attributable	O
to	O
causes	O
other	O
than	O
breast	O
cancer	O
were	O
treated	O
as	O
censored	O
observations	O
.	O

All	O
patient	B-Species
records	O
were	O
subject	O
to	O
central	O
audit	O
for	O
response	O
classification	O
(	O
by	O
E	O
.	O
L	O
.	O
,	O
B	O
.	O
O	O
.	O
and	O
P	O
.	O
E	O
.	O
L	O
.	O
)	O
.	O

Response	O
classifications	O
were	O
completed	O
and	O
approved	O
without	O
any	O
knowledge	O
about	O
result	O
from	O
laboratory	O
analysis	O
.	O

RNA	O
Purification	O
<EOS>	B-X
Ribonucleic	B-X
acid	B-X
(	B-X
RNA	B-X
)	B-X
represents	B-X
an	B-X
important	B-X
target	B-X
of	B-X
a	B-X
wide	B-X
array	B-X
of	B-X
laboratory	B-X
anal	B-X
yses	B-X
.	B-X
Thus	B-X
,	B-X
RNA	B-X
purification	B-X
is	B-X
a	B-X
critical	B-X
first	B-X
preceding	B-X
step	B-X
of	B-X
a	B-X
number	B-X
of	B-X
preparative	B-X
and	B-X
analytical	B-X
methods	B-X
,	B-X
important	B-X
particularly	B-X
in	B-X
diagnostics	B-X
of	B-X
dozens	B-X
of	B-X
viral	B-X
,	B-X
bacterial	B-X
,	B-X
and	B-X
parasitic	B-X
diseases	B-X
,	B-X
dia	B-X
gnosis	B-X
of	B-X
inherited	B-X
disorders	B-X
,	B-X
and	B-X
tumours	B-X
,	B-X
as	B-X
well	B-X
as	B-X
in	B-X
basic	B-X
research	B-X
.	B-X
To	B-X
provide	B-X
relevant	B-X
and	B-X
reliable	B-X
results	B-X
,	B-X
techniques	B-X
of	B-X
molecular	B-X
biology	B-X
used	B-X
for	B-X
such	B-X
purposes	B-X
require	B-X
pure	B-X
and	B-X
intact	B-X
molecules	B-X
of	B-X
purified	B-X
RNA	B-X
.	B-X
Moreover	B-X
,	B-X
RNA	B-X
has	B-X
to	B-X
be	B-X
purified	B-X
effectively	B-X
and	B-X
reproducibly	B-X
from	B-X
various	B-X
heterogeneous	B-X
materials	B-X
such	B-X
as	B-X
fresh	B-X
or	B-X
frozen	B-X
tissues	B-X
,	B-X
cell	B-X
lines	B-X
,	B-X
PCR	B-X
products	B-X
or	B-X
long-term	B-X
chemically	B-X
preserved	B-X
samples	B-X
.	B-X
Principally	B-X
,	B-X
methods	B-X
of	B-X
RNA	B-X
purification	B-X
can	B-X
be	B-X
divided	B-X
into	B-X
three	B-X
groups	B-X
.	B-X
The	B-X
second	B-X
group	B-X
encompasses	B-X
methods	B-X
of	B-X
RNA	B-X
purification	B-X
by	B-X
means	B-X
of	B-X
its	B-X
ability	B-X
to	B-X
bind	B-X
specific	B-X
surfaces	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
chaotropic	B-X
salt	B-X
,	B-X
and	B-X
the	B-X
third	B-X
group	B-X
includes	B-X
methods	B-X
exploiting	B-X
RNA	B-X
isolation	B-X
on	B-X
isopycnic	B-X
gradients	B-X
.	B-X
Although	B-X
RNA	B-X
can	B-X
be	B-X
isolated	B-X
from	B-X
either	B-X
prokaryotic	B-X
or	B-X
eukaryotic	B-X
organisms	B-X
,	B-X
this	B-X
review	B-X
is	B-X
to	B-X
give	B-X
out	B-X
a	B-X
basic	B-X
outline	B-X
of	B-X
methods	B-X
available	B-X
for	B-X
eukaryotic	B-X
,	B-X
with	B-X
emphasis	B-X
on	B-X
mammalian	B-X
,	B-X
tissues	B-X
.	B-X

Total	O
RNA	O
was	O
purified	O
by	O
Trizol	O
(	O
Life	O
Technologies	O
,	O
Inc	O
.	O
)	O
extraction	O
from	O
snap	O
-	O
frozen	O
tissue	O
samples	O
according	O
to	O
manufacturer	O
'	O
s	O
instructions	O
.	O

After	O
extraction	O
,	O
the	O
RNA	O
was	O
dissolved	O
in	O
100	O
micro	O
l	O
of	O
DEPC	O
treated	O
ddH2O	O
.	O

cDNA	O
was	O
synthesized	O
by	O
reverse	O
transcription	O
using	O
Transcriptor	O
reverse	O
transcriptase	O
(	O
Roche	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

DNA	O
Purification	O
<EOS>	B-X
Column	B-X
chromatography	B-X
has	B-X
evolved	B-X
to	B-X
provide	B-X
a	B-X
rapid	B-X
and	B-X
effective	B-X
alternative	B-X
to	B-X
more	B-X
laborious	B-X
methods	B-X
for	B-X
preparing	B-X
high-quality	B-X
DNA	B-X
,	B-X
such	B-X
as	B-X
CsCl-gradient	B-X
centrifugation	B-X
.	B-X
This	B-X
unit	B-X
describes	B-X
the	B-X
use	B-X
of	B-X
a	B-X
column	B-X
made	B-X
of	B-X
a	B-X
unique	B-X
anion-exchange	B-X
resin	B-X
that	B-X
selectively	B-X
binds	B-X
nucleic	B-X
acids	B-X
,	B-X
allowing	B-X
rapid	B-X
separation	B-X
of	B-X
DNA	B-X
from	B-X
contaminating	B-X
RNA	B-X
,	B-X
proteins	B-X
,	B-X
carbohydrates	B-X
,	B-X
and	B-X
metabolites	B-X
.	B-X
Contaminants	B-X
in	B-X
the	B-X
sample	B-X
are	B-X
washed	B-X
from	B-X
the	B-X
column	B-X
with	B-X
a	B-X
moderate-salt	B-X
buffer	B-X
,	B-X
and	B-X
DNA	B-X
is	B-X
eluted	B-X
using	B-X
a	B-X
high-salt	B-X
buffer	B-X
.	B-X
In	B-X
the	B-X
winter	B-X
of	B-X
1868/9	B-X
the	B-X
young	B-X
Swiss	B-X
doctor	B-X
Friedrich	B-X
Miescher	B-X
,	B-X
working	B-X
in	B-X
the	B-X
laboratory	B-X
of	B-X
Felix	B-X
Hoppe-Seyler	B-X
at	B-X
the	B-X
University	B-X
of	B-X
TÃ¼bingen	B-X
,	B-X
performed	B-X
experiments	B-X
on	B-X
the	B-X
chemical	B-X
composition	B-X
of	B-X
leukocytes	B-X
that	B-X
lead	B-X
to	B-X
the	B-X
discovery	B-X
of	B-X
DNA	B-X
.	B-X
This	B-X
article	B-X
reviews	B-X
the	B-X
events	B-X
and	B-X
circumstances	B-X
leading	B-X
to	B-X
Miescher	B-X
's	B-X
discovery	B-X
of	B-X
DNA	B-X
and	B-X
places	B-X
them	B-X
within	B-X
their	B-X
historic	B-X
context	B-X
.	B-X
It	B-X
also	B-X
tries	B-X
to	B-X
elucidate	B-X
why	B-X
it	B-X
was	B-X
Miescher	B-X
who	B-X
discovered	B-X
DNA	B-X
and	B-X
why	B-X
his	B-X
name	B-X
is	B-X
not	B-X
universally	B-X
associated	B-X
with	B-X
this	B-X
molecule	B-X
today	B-X
.	B-X

Genomic	O
DNA	O
from	O
tumor	O
biopsies	O
and	O
blood	O
lymphocytes	O
was	O
isolated	O
using	O
QIAamp	O
DNA	O
Mini	O
kit	O
(	O
Qiagen	O
,	O
Chatsworth	O
,	O
CA	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Mutation	O
Analysis	O
<EOS>	B-X
Mutations	B-X
in	B-X
adenomatous	B-X
polyposis	B-X
coli	B-X
(	B-X
APC	B-X
)	B-X
gene	B-X
play	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
adenoma-carcinoma	B-X
pathway	B-X
of	B-X
colorectal	B-X
tumorigenesis	B-X
.	B-X
Mutational	B-X
hotspots	B-X
indicate	B-X
selective	B-X
pressure	B-X
across	B-X
a	B-X
population	B-X
of	B-X
tumor	B-X
samples	B-X
,	B-X
but	B-X
their	B-X
prevalence	B-X
within	B-X
and	B-X
across	B-X
cancer	B-X
types	B-X
is	B-X
incompletely	B-X
characterized	B-X
.	B-X
Mutation	B-X
analysis	B-X
of	B-X
a	B-X
large	B-X
cohort	B-X
of	B-X
GNE	B-X
myopathy	B-X
reveals	B-X
a	B-X
diverse	B-X
array	B-X
of	B-X
GNE	B-X
mutations	B-X
affecting	B-X
sialic	B-X
acid	B-X
biosynthesis	B-X
.	B-X
DiffMut	B-X
is	B-X
available	B-X
at	B-X
https	B-X
:	B-X
//github.com/Singh-Lab/Differential-Mutation-Analysis	B-X
.	B-X

All	O
mutational	O
analysis	O
was	O
performed	O
blinded	O
to	O
clinical	O
data	O
.	O
<EOS>	B-X
In	B-X
the	B-X
primary	B-X
analysis	B-X
of	B-X
SOLO1/GOG	B-X
3004	B-X
,	B-X
the	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerase	B-X
(	B-X
PARP	B-X
)	B-X
inhibitor	B-X
olaparib	B-X
significantly	B-X
improved	B-X
progression-free	B-X
survival	B-X
versus	B-X
placebo	B-X
in	B-X
patients	B-X
with	B-X
a	B-X
BRCA	B-X
mutation	B-X
;	B-X
median	B-X
progression-free	B-X
survival	B-X
was	B-X
not	B-X
reached	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
an	B-X
updated	B-X
,	B-X
post-hoc	B-X
analysis	B-X
of	B-X
progression-free	B-X
survival	B-X
from	B-X
SOLO1	B-X
,	B-X
after	B-X
5	B-X
years	B-X
of	B-X
follow-up	B-X
.	B-X
In	B-X
the	B-X
primary	B-X
analysis	B-X
of	B-X
CheckMate	B-X
9ER	B-X
,	B-X
nivolumab	B-X
plus	B-X
cabozantinib	B-X
showed	B-X
superior	B-X
progression-free	B-X
survival	B-X
,	B-X
overall	B-X
survival	B-X
,	B-X
and	B-X
objective	B-X
response	B-X
over	B-X
sunitinib	B-X
in	B-X
patients	B-X
with	B-X
previously	B-X
untreated	B-X
advanced	B-X
renal	B-X
cell	B-X
carcinoma	B-X
(	B-X
median	B-X
follow-up	B-X
of	B-X
18Â·1	B-X
months	B-X
)	B-X
.	B-X
To	B-X
conduct	B-X
an	B-X
updated	B-X
exploratory	B-X
analysis	B-X
of	B-X
overall	B-X
survival	B-X
(	B-X
OS	B-X
)	B-X
with	B-X
a	B-X
longer	B-X
median	B-X
follow-up	B-X
of	B-X
73.3	B-X
months	B-X
and	B-X
evaluate	B-X
the	B-X
prognostic	B-X
value	B-X
of	B-X
molecular	B-X
analysis	B-X
by	B-X
circulating	B-X
tumor	B-X
DNA	B-X
(	B-X
ctDNA	B-X
)	B-X
.	B-X

Mutations	O
in	O
TP53	O
,	O
CHEK2	O
and	O
p14	O
(	O
ARF	O
)	O
genes	O
were	O
analyzed	O
by	O
PCR	O
(	O
or	O
nested	O
PCR	O
)	O
amplification	O
and	O
sequencing	O
of	O
PCR	O
product	O
,	O
or	O
by	O
cloning	O
of	O
PCR	O
products	O
and	O
sequencing	O
of	O
the	O
resulting	O
plasmids	O
(	O
all	O
primers	O
described	O
in	O
Table	O
1	O
)	O
.	O

Cloning	O
was	O
performed	O
using	O
the	O
TOPO	O
TA	O
Cloning	O
kit	O
(	O
Invitrogen	O
)	O
.	O
<EOS>	B-X
Tests	B-X
for	B-X
transmission	B-X
by	B-X
grafting	B-X
were	B-X
conducted	B-X
using	B-X
symptomatic	B-X
periwinkle	B-X
plants	B-X
.	B-X
Preliminary	B-X
examination	B-X
was	B-X
performed	B-X
by	B-X
ELISA	B-X
with	B-X
Spiroplasma	B-X
citri	B-X
Saglio	B-X
polyclonal	B-X
antibody	B-X
that	B-X
was	B-X
prepared	B-X
against	B-X
an	B-X
Iranian	B-X
S.	B-X
citri	B-X
isolate	B-X
(	B-X
H.	B-X
Rahimian	B-X
,	B-X
unpublished	B-X
data	B-X
)	B-X
.	B-X
Initial	B-X
screenings	B-X
for	B-X
possible	B-X
viruses	B-X
using	B-X
ELISA	B-X
(	B-X
Agdia	B-X
,	B-X
Elkhart	B-X
,	B-X
IN	B-X
)	B-X
,	B-X
as	B-X
well	B-X
as	B-X
a	B-X
reverse	B-X
transcription	B-X
(	B-X
RT	B-X
)	B-X
-PCR	B-X
panel	B-X
of	B-X
15	B-X
common	B-X
tomato	B-X
viruses	B-X
in	B-X
our	B-X
laboratory	B-X
were	B-X
negative	B-X
.	B-X
Total	B-X
plant	B-X
RNA	B-X
was	B-X
prepared	B-X
using	B-X
TRIzol	B-X
reagent	B-X
(	B-X
Invitrogen	B-X
,	B-X
Carlsbad	B-X
,	B-X
CA	B-X
)	B-X
from	B-X
leaf	B-X
tissues	B-X
of	B-X
eight	B-X
diseased	B-X
plants	B-X
and	B-X
one	B-X
seed	B-X
sample	B-X
.	B-X
To	B-X
obtain	B-X
a	B-X
full	B-X
viroid	B-X
genome	B-X
,	B-X
RT-PCR	B-X
using	B-X
two	B-X
different	B-X
sets	B-X
of	B-X
primers	B-X
,	B-X
one	B-X
specific	B-X
for	B-X
PSTVd	B-X
(	B-X
PSTVd-F	B-X
and	B-X
PSTVd-R	B-X
)	B-X
(	B-X
2	B-X
)	B-X
,	B-X
and	B-X
a	B-X
universal	B-X
primer	B-X
set	B-X
for	B-X
pospiviroids	B-X
(	B-X
MTTVd-F	B-X
and	B-X
MTTVd-R	B-X
)	B-X
(	B-X
3	B-X
)	B-X
was	B-X
performed	B-X
.	B-X
PCR	B-X
products	B-X
were	B-X
cloned	B-X
using	B-X
the	B-X
TOPO	B-X
TA	B-X
cloning	B-X
kit	B-X
(	B-X
Invitrogen	B-X
,	B-X
Carlsbad	B-X
,	B-X
CA	B-X
)	B-X
.	B-X

Sequencing	O
of	O
clones	O
was	O
performed	O
until	O
at	O
least	O
10	O
different	O
sequences	O
covered	O
all	O
parts	O
of	O
the	O
CHEK2	O
coding	O
sequence	O
.	O

DNA	O
sequencing	O
was	O
carried	O
out	O
directly	O
on	O
1	O
micro	O
l	O
PCR	O
product	O
or	O
plasmid	O
using	O
Big	O
Dye	O
terminator	O
mix	O
(	O
Applied	O
Biosystems	O
)	O
.	O

Capillary	O
gel	O
electrophoresis	O
,	O
data	O
collection	O
,	O
and	O
sequence	O
analysis	O
were	O
done	O
on	O
an	O
automated	O
DNA	O
sequencer	O
(	O
ABI	O
3700	O
)	O
.	O

When	O
a	O
mutation	O
was	O
detected	O
,	O
the	O
relevant	O
exon	O
was	O
amplified	O
by	O
PCR	O
from	O
genomic	O
tumor	O
DNA	O
and	O
DNA	O
from	O
blood	O
lymphocytes	O
and	O
sequenced	O
for	O
verification	O
and	O
germline	O
detection	O
.	O

(	O
Primers	O
described	O
in	O
Table	O
1	O
)	O
.	O
<EOS>	B-X
This	B-X
review	B-X
has	B-X
described	B-X
several	B-X
experimental	B-X
approaches	B-X
for	B-X
controlling	B-X
the	B-X
fidelity	B-X
of	B-X
enzymatic	B-X
DNA	B-X
amplification	B-X
.	B-X
As	B-X
demonstrated	B-X
by	B-X
the	B-X
data	B-X
in	B-X
Tables	B-X
2	B-X
and	B-X
3	B-X
,	B-X
high-fidelity	B-X
DNA	B-X
amplification	B-X
will	B-X
be	B-X
best	B-X
achieved	B-X
by	B-X
using	B-X
a	B-X
polymerase	B-X
with	B-X
an	B-X
active	B-X
3	B-X
'	B-X
--	B-X
>	B-X
5	B-X
'	B-X
proofreading	B-X
exonuclease	B-X
activity	B-X
(	B-X
Fig	B-X
.	B-X
1E	B-X
)	B-X
.	B-X
1A	B-X
,	B-X
B	B-X
)	B-X
,	B-X
any	B-X
type	B-X
of	B-X
deoxynucleoside	B-X
triphosphate	B-X
pool	B-X
imbalance	B-X
should	B-X
be	B-X
avoided	B-X
.	B-X
1D	B-X
)	B-X
can	B-X
be	B-X
minimized	B-X
by	B-X
reactions	B-X
using	B-X
short	B-X
synthesis	B-X
times	B-X
,	B-X
low	B-X
dNTP	B-X
concentrations	B-X
,	B-X
and	B-X
low	B-X
enzyme	B-X
concentrations	B-X
.	B-X
To	B-X
perform	B-X
high-fidelity	B-X
PCR	B-X
with	B-X
Taq	B-X
polymerase	B-X
,	B-X
reactions	B-X
should	B-X
contain	B-X
a	B-X
low	B-X
MgCl2	B-X
concentration	B-X
,	B-X
not	B-X
in	B-X
large	B-X
excess	B-X
over	B-X
the	B-X
total	B-X
concentration	B-X
of	B-X
dNTP	B-X
substrates	B-X
,	B-X
and	B-X
be	B-X
buffered	B-X
to	B-X
approximately	B-X
pH	B-X
6	B-X
(	B-X
70	B-X
degrees	B-X
C	B-X
)	B-X
using	B-X
Bis-Tris	B-X
Propane	B-X
or	B-X
PIPES	B-X
(	B-X
Table	B-X
2	B-X
)	B-X
.	B-X

Loss	O
of	O
Heterozygosity	O
(	O
LOH	O
)	O
<EOS>	B-X
Here	B-X
,	B-X
using	B-X
SCRaMbLE	B-X
,	B-X
different	B-X
levels	B-X
of	B-X
loss	B-X
of	B-X
heterozygosity	B-X
(	B-X
LOH	B-X
)	B-X
events	B-X
including	B-X
short-range	B-X
LOH	B-X
,	B-X
long-range	B-X
LOH	B-X
and	B-X
whole	B-X
chromosome	B-X
LOH	B-X
were	B-X
detected	B-X
in	B-X
evolved	B-X
strains	B-X
.	B-X
It	B-X
was	B-X
further	B-X
found	B-X
that	B-X
deletion	B-X
of	B-X
gene	B-X
GLN3	B-X
,	B-X
long-range	B-X
LOH	B-X
in	B-X
the	B-X
left	B-X
arm	B-X
of	B-X
synthetic	B-X
chromosome	B-X
X	B-X
,	B-X
whole	B-X
chromosome	B-X
LOH	B-X
of	B-X
synthetic	B-X
chromosome	B-X
X	B-X
,	B-X
and	B-X
duplication	B-X
of	B-X
chromosome	B-X
VIII	B-X
(	B-X
trisomy	B-X
)	B-X
lead	B-X
to	B-X
increased	B-X
rapamycin	B-X
resistance	B-X
in	B-X
synthetic	B-X
yeast	B-X
.	B-X
Loss	B-X
of	B-X
heterozygosity	B-X
(	B-X
LOH	B-X
)	B-X
is	B-X
a	B-X
common	B-X
genetic	B-X
event	B-X
in	B-X
cancer	B-X
development	B-X
,	B-X
and	B-X
is	B-X
known	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
somatic	B-X
loss	B-X
of	B-X
wild-type	B-X
alleles	B-X
in	B-X
many	B-X
inherited	B-X
cancer	B-X
syndromes	B-X
.	B-X
The	B-X
wider	B-X
involvement	B-X
of	B-X
LOH	B-X
in	B-X
cancer	B-X
is	B-X
assumed	B-X
to	B-X
relate	B-X
to	B-X
unmasking	B-X
a	B-X
somatically	B-X
mutated	B-X
tumour	B-X
suppressor	B-X
gene	B-X
through	B-X
loss	B-X
of	B-X
the	B-X
wild	B-X
type	B-X
allele	B-X
.	B-X

Loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
in	O
tumors	O
with	O
mutations	O
in	O
CHEK2	O
was	O
assessed	O
using	O
the	O
microsatellite	O
marker	O
,	O
D22S275	O
,	O
which	O
maps	O
to	O
intron	O
4	O
of	O
CHEK2	O
.	O

LOH	O
in	O
tumors	O
with	O
mutation	O
in	O
TP53	O
was	O
assessed	O
using	O
two	O
markers	O
,	O
one	O
variable	O
number	O
tandem	O
repeat	O
in	O
intron	O
1	O
[	O
35	O
]	O
and	O
a	O
CA	O
repeat	O
close	O
to	O
the	O
TP53	O
gene	O
[	O
36	O
]	O
.	O

Fluorescently	O
end	O
-	O
labeled	O
primers	O
were	O
used	O
in	O
the	O
PCR	O
,	O
and	O
the	O
PCR	O
products	O
were	O
analyzed	O
on	O
an	O
ABI	O
3700	O
.	O

LOH	O
was	O
evaluated	O
by	O
comparing	O
the	O
allele	O
peak	O
-	O
height	O
ratios	O
from	O
blood	O
DNA	O
and	O
tumor	O
DNA	O
.	O

A	O
sample	O
was	O
scored	O
as	O
having	O
AI	O
(	O
Allelic	O
Imbalance	O
)	O
when	O
a	O
reduction	O
in	O
peak	O
height	O
of	O
one	O
allele	O
in	O
tumor	O
sample	O
was	O
at	O
least	O
18	O
%	O
compared	O
with	O
that	O
of	O
blood	O
DNA	O
from	O
the	O
same	O
patient	B-Species
[	O
37	O
]	O
.	O

Analysis	O
of	O
p14	O
(	O
ARF	O
)	O
promoter	O
methylation	O
<EOS>	B-X
For	B-X
this	B-X
purpose	B-X
,	B-X
we	B-X
analyzed	B-X
27	B-X
papillomatous	B-X
lesions	B-X
from	B-X
patients	B-X
with	B-X
RRP	B-X
to	B-X
evaluate	B-X
somatic	B-X
mutations	B-X
and	B-X
methylation	B-X
status	B-X
in	B-X
CDKN2A	B-X
(	B-X
p14	B-X
To	B-X
study	B-X
the	B-X
methylation	B-X
status	B-X
of	B-X
genes	B-X
that	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
p53-Bax	B-X
mitochondrial	B-X
apoptosis	B-X
pathway	B-X
and	B-X
its	B-X
clinical	B-X
significance	B-X
in	B-X
cholangiocarcinoma	B-X
.	B-X
In	B-X
this	B-X
article	B-X
,	B-X
we	B-X
report	B-X
the	B-X
DNA	B-X
methylation	B-X
pattern	B-X
in	B-X
CDKN2A	B-X
(	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
/p16	B-X
(	B-X
INK4a	B-X
)	B-X
)	B-X
and	B-X
in	B-X
ATM	B-X
gene	B-X
promoters	B-X
from	B-X
62	B-X
impalpable	B-X
lesions	B-X
,	B-X
39	B-X
peripheral	B-X
blood	B-X
samples	B-X
,	B-X
and	B-X
39	B-X
saliva	B-X
samples	B-X
,	B-X
assessed	B-X
by	B-X
methylation-specific	B-X
polymerase	B-X
chain	B-X
reaction	B-X
method	B-X
.	B-X
ATM	B-X
showed	B-X
the	B-X
greatest	B-X
percentage	B-X
of	B-X
methylation	B-X
in	B-X
DNA	B-X
from	B-X
lesions	B-X
(	B-X
benign	B-X
and	B-X
malignant	B-X
)	B-X
,	B-X
blood	B-X
(	B-X
even	B-X
with	B-X
p16	B-X
(	B-X
INK4a	B-X
)	B-X
)	B-X
,	B-X
and	B-X
saliva	B-X
,	B-X
followed	B-X
by	B-X
p16	B-X
(	B-X
INK4a	B-X
)	B-X
and	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
.	B-X
Among	B-X
the	B-X
malignant	B-X
cases	B-X
,	B-X
ATM	B-X
promoter	B-X
was	B-X
the	B-X
most	B-X
hypermethylated	B-X
in	B-X
lesion	B-X
DNA	B-X
and	B-X
in	B-X
blood	B-X
and	B-X
saliva	B-X
DNAs	B-X
,	B-X
and	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
,	B-X
the	B-X
least	B-X
.	B-X
The	B-X
highest	B-X
percentage	B-X
of	B-X
p16	B-X
(	B-X
INK4a	B-X
)	B-X
methylation	B-X
was	B-X
found	B-X
in	B-X
the	B-X
blood	B-X
.	B-X

Genomic	O
DNA	O
was	O
subjected	O
to	O
bisulphate	O
conversion	O
using	O
the	O
CpGenome	O
DNA	O
Modification	O
Kit	O
(	O
Intergen	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Both	O
the	O
unmethylated	O
-	O
and	O
methylated	O
-	O
specific	O
PCRs	O
were	O
performed	O
in	O
50	O
micro	O
l	O
reaction	O
mixes	O
containing	O
2	O
.	O
5	O
U	O
AmpliTaq	O
Gold	O
DNA	O
Polymerase	O
(	O
Applied	O
Biosystems	O
)	O
,	O
1	O
x	O
PCR	O
buffer	O
,	O
1	O
.	O
5	O
mM	O
MgCl2	O
,	O
0	O
.	O
1	O
mM	O
of	O
each	O
deoxynucleotide	O
triphosphate	O
,	O
0	O
.	O
2	O
micro	O
M	O
of	O
each	O
primer	O
(	O
Table	O
1	O
)	O
and	O
2	O
micro	O
l	O
of	O
modified	O
genomic	O
DNA	O
.	O

Thermocycling	O
conditions	O
for	O
both	O
the	O
unmethylated	O
-	O
and	O
methylated	O
-	O
specific	O
PCRs	O
were	O
an	O
initial	O
step	O
of	O
5	O
minutes	O
at	O
95	O
degrees	O
C	O
followed	O
by	O
35	O
cycles	O
of	O
30	O
sec	O
.	O
at	O
94	O
degrees	O
C	O
,	O
30	O
sec	O
.	O
at	O
60	O
.	O
5	O
degrees	O
C	O
and	O
60	O
sec	O
.	O
at	O
72	O
degrees	O
C	O
before	O
a	O
final	O
elongation	O
step	O
at	O
72	O
degrees	O
C	O
for	O
7	O
min	O
.	O

Chk2	O
Dimerisation	O
<EOS>	B-X
In	B-X
vivo	B-X
,	B-X
genetic	B-X
deletion	B-X
of	B-X
Chk2	B-X
rescues	B-X
the	B-X
neonatal	B-X
lethality	B-X
of	B-X
Sirt1	B-X
Checkpoint	B-X
kinase	B-X
2	B-X
(	B-X
human	B-X
CHEK2	B-X
;	B-X
murine	B-X
Chk2	B-X
)	B-X
is	B-X
a	B-X
critical	B-X
mediator	B-X
of	B-X
the	B-X
DNA	B-X
damage	B-X
response	B-X
and	B-X
has	B-X
established	B-X
roles	B-X
in	B-X
DNA	B-X
double	B-X
strand	B-X
break	B-X
(	B-X
DSB	B-X
)	B-X
-induced	B-X
apoptosis	B-X
and	B-X
cell	B-X
cycle	B-X
arrest	B-X
.	B-X
Persistently	B-X
stalled	B-X
and	B-X
unresolved	B-X
DNA	B-X
replication	B-X
forks	B-X
can	B-X
``	B-X
collapse	B-X
''	B-X
to	B-X
generate	B-X
DSBs	B-X
that	B-X
induce	B-X
signaling	B-X
via	B-X
Chk2	B-X
and	B-X
its	B-X
upstream	B-X
activator	B-X
the	B-X
ataxia	B-X
telangiectasia-mutated	B-X
(	B-X
ATM	B-X
)	B-X
protein	B-X
kinase	B-X
.	B-X
This	B-X
review	B-X
focuses	B-X
on	B-X
recently	B-X
defined	B-X
roles	B-X
of	B-X
Chk2	B-X
in	B-X
protecting	B-X
against	B-X
DNA	B-X
replication-associated	B-X
genotoxicity	B-X
.	B-X
Defects	B-X
in	B-X
the	B-X
primary	B-X
responders	B-X
to	B-X
DNA	B-X
replication	B-X
fork	B-X
stalling	B-X
lead	B-X
to	B-X
generation	B-X
of	B-X
DSB	B-X
and	B-X
reveal	B-X
``	B-X
back-up	B-X
''	B-X
roles	B-X
for	B-X
Chk2	B-X
in	B-X
S-phase	B-X
progression	B-X
and	B-X
genomic	B-X
stability	B-X
.	B-X
It	B-X
is	B-X
likely	B-X
therefore	B-X
that	B-X
the	B-X
Chk2/CHEK2-deficiency	B-X
is	B-X
associated	B-X
with	B-X
elevated	B-X
risk	B-X
for	B-X
tumorigenesis	B-X
caused	B-X
by	B-X
replication-associated	B-X
genotoxicities	B-X
that	B-X
are	B-X
exacerbated	B-X
by	B-X
environmental	B-X
genotoxins	B-X
and	B-X
intrinsic	B-X
DNA-damaging	B-X
agents	B-X
.	B-X

Chk2	O
mutant	O
'	O
s	O
ability	O
to	O
form	O
dimers	O
with	O
the	O
wild	O
-	O
type	O
protein	O
was	O
investigated	O
by	O
immunoprecipitation	O
.	O

U	O
-	O
2	O
-	O
OS	O
cells	O
were	O
co	O
-	O
transfected	O
with	O
expression	O
vectors	O
expressing	O
wild	O
-	O
type	O
Chk2	O
with	O
N	O
-	O
terminal	O
Xpr	O
-	O
tag	O
(	O
pcDNA4	O
/	O
HisMax	O
,	O
Invitrogen	O
)	O
and	O
mutated	O
Chk2	O
forms	O
with	O
C	O
-	O
terminal	O
V5	O
-	O
tag	O
(	O
pcDNA3	O
.	O
1	O
/	O
V5	O
-	O
His	O
,	O
Invitrogen	O
)	O
.	O

Transfection	O
was	O
performed	O
using	O
FuGene	O
6	O
.	O
0	O
transfection	O
reagent	O
(	O
Roche	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Cells	O
were	O
harvested	O
in	O
lysisbuffer	O
(	O
50	O
mM	O
TrisHCl	O
pH	O
8	O
.	O
0	O
,	O
150	O
mM	O
NaCl	O
,	O
0	O
.	O
5	O
%	O
NP40	O
,	O
5	O
mM	O
EDTA	O
pH	O
8	O
.	O
0	O
)	O
48	O
hours	O
after	O
transfection	O
.	O

An	O
aliquote	O
of	O
the	O
cell	O
lysate	O
was	O
harvested	O
for	O
subsequent	O
Chk2	O
-	O
mutant	O
-	O
V5	O
transfection	O
verification	O
.	O

Samples	O
were	O
further	O
incubated	O
with	O
A	O
/	O
G	O
Pluss	O
Agarose	O
beads	O
(	O
Santa	O
Cruz	O
Biotechnology	O
)	O
at	O
4	O
degrees	O
C	O
for	O
25	O
minutes	O
before	O
the	O
beads	O
were	O
removed	O
by	O
centrifugation	O
at	O
5000g	O
for	O
4	O
minutes	O
and	O
the	O
samples	O
were	O
incubated	O
with	O
1	O
.	O
5	O
micro	O
g	O
anti	O
-	O
V5	O
(	O
Invitrogen	O
)	O
at	O
4	O
degrees	O
C	O
for	O
90	O
minutes	O
.	O

Fresh	O
A	O
/	O
G	O
Pluss	O
Agarose	O
beads	O
were	O
added	O
and	O
the	O
samples	O
were	O
incubated	O
for	O
another	O
90	O
minutes	O
at	O
4	O
degrees	O
C	O
.	O

The	O
beads	O
were	O
washed	O
three	O
times	O
with	O
1	O
x	O
PBS	O
,	O
before	O
being	O
separated	O
on	O
a	O
10	O
%	O
polyacrylamide	O
gel	O
and	O
blotted	O
on	O
to	O
a	O
nitrocellulose	O
membrane	O
.	O

Chk2	O
-	O
wild	O
-	O
type	O
-	O
Xpr	O
co	O
-	O
precipitated	O
with	O
Chk2	O
-	O
mutant	O
-	O
V5	O
was	O
detected	O
through	O
incubations	O
with	O
anti	O
-	O
Xpr	O
antibody	O
(	O
Invitrogen	O
)	O
,	O
HRP	O
-	O
conjugated	O
secondary	O
antibody	O
and	O
ECL	O
detection	O
reagent	O
(	O
GE	O
Healthcare	O
)	O
.	O

Kinase	O
Activity	O

Chk2	O
mutant	O
'	O
s	O
ability	O
to	O
function	O
as	O
kinases	O
was	O
investigated	O
through	O
an	O
in	O
vitro	O
kinase	O
assay	O
.	O

The	O
V5	O
expression	O
vectors	O
used	O
for	O
the	O
dimerisation	O
study	O
were	O
also	O
used	O
to	O
express	O
Chk2	O
mutants	O
in	O
the	O
kinase	O
assay	O
.	O

U	O
-	O
2	O
-	O
OS	O
cells	O
were	O
transfected	O
using	O
the	O
FuGene	O
6	O
.	O
0	O
transfection	O
reagent	O
(	O
Roche	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Cells	O
were	O
then	O
incubated	O
at	O
37	O
degrees	O
C	O
in	O
5	O
%	O
CO2	O
and	O
humidified	O
atmosphere	O
.	O
<EOS>	B-X
Cultures	B-X
obtained	B-X
from	B-X
the	B-X
retinas	B-X
of	B-X
fetal	B-X
rats	B-X
were	B-X
incubated	B-X
in	B-X
Eagle	B-X
's	B-X
minimal	B-X
essential	B-X
medium	B-X
supplemented	B-X
with	B-X
10	B-X
%	B-X
fetal	B-X
calf	B-X
serum	B-X
or	B-X
10	B-X
%	B-X
horse	B-X
serum	B-X
at	B-X
37	B-X
degrees	B-X
C	B-X
in	B-X
a	B-X
humidified	B-X
5	B-X
%	B-X
CO2	B-X
atmosphere	B-X
for	B-X
10-14	B-X
days	B-X
.	B-X
Retinal	B-X
ischemia	B-X
was	B-X
induced	B-X
by	B-X
elevating	B-X
the	B-X
intraocular	B-X
pressure	B-X
for	B-X
45	B-X
min	B-X
through	B-X
the	B-X
needle	B-X
which	B-X
was	B-X
placed	B-X
in	B-X
the	B-X
anterior	B-X
chamber	B-X
.	B-X
Both	B-X
APAN	B-X
and	B-X
EAN	B-X
follicles	B-X
(	B-X
152	B-X
to	B-X
886	B-X
microns	B-X
in	B-X
diameter	B-X
)	B-X
were	B-X
isolated	B-X
from	B-X
ovaries	B-X
by	B-X
treatment	B-X
with	B-X
collagenase	B-X
and	B-X
DNase	B-X
.	B-X
The	B-X
follicles	B-X
were	B-X
cultured	B-X
in	B-X
Dulbecco	B-X
's	B-X
Modified	B-X
Eagle	B-X
's	B-X
medium/nutrient	B-X
mixture	B-X
F-12	B-X
Ham	B-X
culture	B-X
medium	B-X
supplemented	B-X
with	B-X
20	B-X
%	B-X
(	B-X
v/v	B-X
)	B-X
fetal	B-X
bovine	B-X
serum	B-X
(	B-X
FBS	B-X
)	B-X
,	B-X
2	B-X
mM	B-X
L-glutamine	B-X
,	B-X
1	B-X
%	B-X
(	B-X
v/v	B-X
)	B-X
antibiotic-antimycotic	B-X
,	B-X
1	B-X
microgram	B-X
FSH/ml	B-X
,	B-X
10	B-X
IU	B-X
hCG/ml	B-X
and	B-X
1	B-X
microgram	B-X
estradiol/ml	B-X
.	B-X
Within	B-X
each	B-X
group	B-X
(	B-X
APAN	B-X
or	B-X
EAN	B-X
)	B-X
,	B-X
control	B-X
follicles	B-X
were	B-X
not	B-X
cultured	B-X
(	B-X
0	B-X
h	B-X
)	B-X
,	B-X
and	B-X
2	B-X
to	B-X
12	B-X
follicles	B-X
per	B-X
well	B-X
were	B-X
incubated	B-X
under	B-X
a	B-X
humidified	B-X
atmosphere	B-X
of	B-X
5	B-X
%	B-X
CO2	B-X
in	B-X
air	B-X
at	B-X
37	B-X
degrees	B-X
C	B-X
for	B-X
24	B-X
,	B-X
48	B-X
or	B-X
72	B-X
h.	B-X
After	B-X
24	B-X
h	B-X
of	B-X
culture	B-X
,	B-X
significantly	B-X
more	B-X
(	B-X
5.3	B-X
%	B-X
,	B-X
20/374	B-X
;	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
oocytes	B-X
from	B-X
APAN	B-X
follicles	B-X
reached	B-X
the	B-X
metaphase	B-X
I	B-X
to	B-X
metaphase	B-X
II	B-X
stages	B-X
(	B-X
MI	B-X
to	B-X
MII	B-X
)	B-X
than	B-X
the	B-X
percentage	B-X
of	B-X
control	B-X
follicles	B-X
observed	B-X
at	B-X
0	B-X
h	B-X
(	B-X
0.9	B-X
%	B-X
,	B-X
3/318	B-X
)	B-X
.	B-X
Continued	B-X
culture	B-X
resulted	B-X
in	B-X
a	B-X
further	B-X
increase	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
in	B-X
the	B-X
percentage	B-X
of	B-X
oocytes	B-X
reaching	B-X
MI	B-X
to	B-X
MII	B-X
by	B-X
48	B-X
h	B-X
(	B-X
11.5	B-X
%	B-X
,	B-X
47/407	B-X
)	B-X
,	B-X
which	B-X
remained	B-X
unchanged	B-X
at	B-X
72	B-X
h	B-X
(	B-X
9.9	B-X
%	B-X
,	B-X
40/404	B-X
)	B-X
.	B-X
However	B-X
,	B-X
there	B-X
was	B-X
an	B-X
increase	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
by	B-X
48	B-X
h	B-X
of	B-X
culture	B-X
(	B-X
8.7	B-X
%	B-X
,	B-X
11/126	B-X
)	B-X
,	B-X
which	B-X
remained	B-X
unchanged	B-X
at	B-X
72	B-X
h	B-X
(	B-X
7.5	B-X
%	B-X
,	B-X
8/106	B-X
)	B-X
.	B-X

After	O
24	O
hours	O
doxorubicin	O
(	O
Nycomed	O
Pharma	O
)	O
was	O
added	O
to	O
the	O
media	O
to	O
a	O
final	O
concentration	O
of	O
50ng	O
/	O
ml	O
and	O
the	O
cells	O
were	O
further	O
incubated	O
for	O
24	O
hours	O
before	O
harvest	O
.	O

75	O
cm2	O
of	O
90	O
%	O
confluent	O
cells	O
were	O
harvested	O
in	O
500	O
micro	O
l	O
lysis	O
buffer	O
(	O
50	O
mM	O
HEPES	O
,	O
150	O
mM	O
NaCl	O
,	O
10	O
%	O
glycerol	O
,	O
0	O
.	O
5	O
%	O
Triton	O
X	O
-	O
100	O
,	O
2	O
mM	O
MgCl2	O
,	O
5	O
mM	O
EDTA	O
)	O
,	O
and	O
the	O
cytosol	O
was	O
incubated	O
for	O
90	O
minutes	O
at	O
4	O
degrees	O
C	O
with	O
50	O
micro	O
l	O
50	O
%	O
Glutathione	O
Sepharose	O
beads	O
(	O
Amersham	O
Biosciences	O
)	O
linked	O
to	O
anti	O
-	O
V5	O
antibody	O
(	O
Invitrogen	O
)	O
.	O

The	O
beads	O
were	O
then	O
washed	O
twice	O
with	O
lysisbuffer	O
containing	O
500	O
mM	O
NaCl	O
and	O
twice	O
with	O
kinase	O
assay	O
buffer	O
(	O
50	O
mM	O
HEPES	O
,	O
10	O
mM	O
MgCl2	O
,	O
5	O
mM	O
MnCl2	O
,	O
2	O
.	O
5	O
mM	O
EGTA	O
)	O
.	O

The	O
beads	O
received	O
30	O
micro	O
l	O
kinase	O
assay	O
buffer	O
with	O
7	O
.	O
5	O
micro	O
M	O
cold	O
ATP	O
,	O
10	O
micro	O
Ci	O
32P	O
-	O
gamma	O
-	O
ATP	O
(	O
GE	O
Healthcare	O
)	O
and	O
2	O
micro	O
g	O
isolated	O
Cdc25C	O
peptide	O
,	O
and	O
was	O
incubated	O
at	O
30	O
degrees	O
C	O
for	O
30	O
minutes	O
.	O

Samples	O
were	O
separated	O
on	O
a	O
12	O
.	O
5	O
%	O
polyacrylamide	O
gel	O
and	O
blotted	O
on	O
to	O
a	O
nitrocellulose	O
membrane	O
.	O

A	O
radiosensitive	O
imaging	O
plate	O
was	O
exposed	O
to	O
the	O
membrane	O
and	O
the	O
plate	O
was	O
read	O
in	O
a	O
FLA200	O
imager	O
(	O
Fuji	O
)	O
.	O

The	O
kinase	O
assay	O
described	O
above	O
was	O
also	O
used	O
to	O
determine	O
the	O
Chk2	O
mutants	O
'	O
kinase	O
activity	O
after	O
co	O
-	O
transfection	O
of	O
each	O
Chk2	O
mutant	O
and	O
wild	O
-	O
type	O
Chk2	O
in	O
equal	O
amounts	O
.	O

Statistical	O
Analysis	O

Statistical	O
analysis	O
was	O
performed	O
using	O
the	O
Primer	O
of	O
Biostatistics	O
system	O
,	O
version	O
5	O
.	O
0	O
[	O
38	O
]	O
.	O

The	O
differences	O
in	O
the	O
distribution	O
of	O
TP53	O
and	O
CHEK2	O
mutations	O
among	O
patients	B-Species
revealing	O
a	O
PD	O
and	O
the	O
responders	O
were	O
analyzed	O
with	O
use	O
of	O
Fisher	O
'	O
s	O
exact	O
test	O
.	O

P	O
-	O
values	O
are	O
reported	O
as	O
accumulated	O
two	O
-	O
sided	O
.	O
<EOS>	B-X
Symptomatic	B-X
lymphocele	B-X
following	B-X
radical	B-X
prostatectomy	B-X
(	B-X
RP	B-X
)	B-X
and	B-X
concomitant	B-X
bilateral	B-X
extended	B-X
pelvic	B-X
lymph	B-X
node	B-X
dissection	B-X
(	B-X
ePLND	B-X
)	B-X
has	B-X
a	B-X
significant	B-X
impact	B-X
on	B-X
postoperative	B-X
recovery	B-X
and	B-X
may	B-X
sometimes	B-X
require	B-X
surgical	B-X
intervention	B-X
.	B-X
P-glycoprotein	B-X
(	B-X
Pgp	B-X
)	B-X
is	B-X
a	B-X
membrane	B-X
protein	B-X
that	B-X
acts	B-X
as	B-X
an	B-X
extrusion	B-X
pump	B-X
for	B-X
many	B-X
cytotoxic	B-X
drugs	B-X
.	B-X
Pgp	B-X
is	B-X
expressed	B-X
in	B-X
normal	B-X
tissues	B-X
,	B-X
and	B-X
its	B-X
(	B-X
over	B-X
)	B-X
expression	B-X
in	B-X
tumor	B-X
cells	B-X
contributes	B-X
to	B-X
their	B-X
drug	B-X
resistance	B-X
.	B-X
Human	B-X
Pgp	B-X
is	B-X
encoded	B-X
by	B-X
the	B-X
MDR1	B-X
gene	B-X
,	B-X
In	B-X
mice	B-X
,	B-X
two	B-X
Pgps	B-X
(	B-X
encoded	B-X
by	B-X
the	B-X
mdr1a	B-X
and	B-X
mdr1b	B-X
genes	B-X
)	B-X
appear	B-X
to	B-X
perform	B-X
the	B-X
same	B-X
function	B-X
as	B-X
the	B-X
single	B-X
human	B-X
protein	B-X
.	B-X
The	B-X
simultaneous	B-X
use	B-X
of	B-X
cytotoxic	B-X
drugs	B-X
and	B-X
agents	B-X
that	B-X
block	B-X
Pgp	B-X
function	B-X
has	B-X
raised	B-X
questions	B-X
of	B-X
safety	B-X
,	B-X
since	B-X
a	B-X
blockade	B-X
of	B-X
Pgp	B-X
in	B-X
normal	B-X
tissues	B-X
could	B-X
alter	B-X
drug	B-X
pharmacokinetics	B-X
and	B-X
change	B-X
the	B-X
spectrum	B-X
of	B-X
toxic	B-X
side	B-X
effects	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
consequences	B-X
of	B-X
Pgp	B-X
blockade	B-X
has	B-X
been	B-X
facilitated	B-X
by	B-X
the	B-X
generation	B-X
of	B-X
mice	B-X
with	B-X
disrupted	B-X
mdr1a	B-X
genes	B-X
[	B-X
mdr1a	B-X
(	B-X
-/-	B-X
)	B-X
]	B-X
.	B-X

Because	O
of	O
the	O
limited	O
time	O
of	O
the	O
follow	O
-	O
up	O
,	O
no	O
formal	O
statistical	O
assessment	O
of	O
overall	O
survival	O
was	O
performed	O
.	O

Relapse	O
-	O
free	O
survival	O
was	O
analyzed	O
by	O
the	O
log	O
-	O
rank	O
test	O
.	O
<EOS>	B-X
To	B-X
develop	B-X
and	B-X
validate	B-X
a	B-X
survival	B-X
model	B-X
with	B-X
clinico-biological	B-X
features	B-X
and	B-X
Demographic	B-X
data	B-X
,	B-X
clinical	B-X
features	B-X
,	B-X
treatment	B-X
method	B-X
(	B-X
surgery	B-X
and/or	B-X
chemotherapy	B-X
)	B-X
,	B-X
recurrence	B-X
rate	B-X
,	B-X
and	B-X
survival	B-X
were	B-X
analyzed	B-X
.	B-X
Differences	B-X
in	B-X
survival	B-X
were	B-X
evaluated	B-X
by	B-X
the	B-X
log-rank	B-X
test	B-X
and	B-X
the	B-X
interval	B-X
of	B-X
disease-free	B-X
survival	B-X
was	B-X
calculated	B-X
using	B-X
the	B-X
Kaplan-Meier	B-X
method	B-X
.	B-X
Presenting	B-X
symptoms	B-X
were	B-X
diarrhea	B-X
(	B-X
53.5	B-X
%	B-X
)	B-X
,	B-X
lower	B-X
gastrointestinal	B-X
bleeding	B-X
(	B-X
13.3	B-X
%	B-X
)	B-X
,	B-X
and	B-X
nausea	B-X
and	B-X
vomiting	B-X
(	B-X
46.7	B-X
%	B-X
)	B-X
secondary	B-X
to	B-X
low-grade	B-X
obstruction	B-X
.	B-X
According	B-X
to	B-X
the	B-X
clinical	B-X
classification	B-X
of	B-X
primary	B-X
non-Hodgkin	B-X
lymphoma	B-X
(	B-X
NHL	B-X
)	B-X
of	B-X
the	B-X
gastrointestinal	B-X
tract	B-X
(	B-X
Lugano	B-X
,	B-X
1993	B-X
)	B-X
all	B-X
patients	B-X
corresponded	B-X
to	B-X
stage	B-X
IE	B-X
.	B-X

Details	O
regarding	O
outcome	O
in	O
individual	O
patients	B-Species
with	O
mutations	O
are	O
shown	O
in	O
Table	O
2	O
and	O
3	O
to	O
make	O
them	O
available	O
to	O
the	O
reader	O
.	O

Results	O

TP53	O
Mutations	O
and	O
Response	O
to	O
Therapy	O
<EOS>	B-X
TP53	B-X
is	B-X
the	B-X
most	B-X
frequently	B-X
mutated	B-X
gene	B-X
in	B-X
breast	B-X
cancer	B-X
,	B-X
but	B-X
its	B-X
role	B-X
in	B-X
survival	B-X
is	B-X
confounded	B-X
by	B-X
different	B-X
studies	B-X
concluding	B-X
that	B-X
TP53	B-X
mutations	B-X
are	B-X
associated	B-X
with	B-X
negative	B-X
,	B-X
neutral	B-X
,	B-X
or	B-X
positive	B-X
outcomes	B-X
.	B-X
Closer	B-X
examination	B-X
showed	B-X
that	B-X
many	B-X
studies	B-X
were	B-X
limited	B-X
by	B-X
factors	B-X
such	B-X
as	B-X
imprecise	B-X
methods	B-X
to	B-X
detect	B-X
TP53	B-X
mutations	B-X
and	B-X
small	B-X
cohorts	B-X
that	B-X
combined	B-X
patients	B-X
treated	B-X
with	B-X
drugs	B-X
having	B-X
very	B-X
different	B-X
mechanisms	B-X
of	B-X
action	B-X
.	B-X
These	B-X
analyses	B-X
reveal	B-X
a	B-X
role	B-X
for	B-X
TP53	B-X
in	B-X
response	B-X
to	B-X
different	B-X
treatments	B-X
as	B-X
complex	B-X
as	B-X
its	B-X
different	B-X
biological	B-X
activities	B-X
.	B-X
We	B-X
discuss	B-X
studies	B-X
that	B-X
have	B-X
assessed	B-X
the	B-X
role	B-X
of	B-X
TP53	B-X
mutations	B-X
in	B-X
breast	B-X
cancer	B-X
treatment	B-X
and	B-X
limitations	B-X
in	B-X
interpreting	B-X
reported	B-X
results	B-X
.	B-X

The	O
TP53	O
mutations	O
identified	O
in	O
the	O
tumors	O
of	O
the	O
patients	B-Species
treated	O
with	O
epirubicin	O
together	O
with	O
the	O
clinical	O
response	O
to	O
therapy	O
and	O
follow	O
-	O
up	O
data	O
are	O
presented	O
in	O
Table	O
2	O
.	O

Somatic	O
TP53	O
mutations	O
were	O
identified	O
in	O
23	O
(	O
21	O
.	O
5	O
%	O
)	O
of	O
the	O
patients	B-Species
.	O

Normal	O
tissue	O
(	O
WBC	O
)	O
was	O
available	O
from	O
18	O
of	O
these	O
for	O
germline	O
characterization	O
,	O
revealing	O
none	O
of	O
the	O
mutations	O
identified	O
to	O
be	O
germline	O
alterations	O
.	O

Of	O
the	O
23	O
mutations	O
detected	O
,	O
20	O
were	O
missense	O
and	O
3	O
were	O
nonsense	O
.	O
<EOS>	B-X
BRCA1	B-X
and	B-X
BRCA2	B-X
(	B-X
BRCA	B-X
)	B-X
mutations	B-X
explain	B-X
less	B-X
than	B-X
one-half	B-X
of	B-X
hereditary	B-X
BC	B-X
,	B-X
and	B-X
the	B-X
proportion	B-X
associated	B-X
with	B-X
other	B-X
BC	B-X
susceptibility	B-X
genes	B-X
is	B-X
unknown	B-X
.	B-X
The	B-X
recurrent	B-X
11q22-23	B-X
deletions	B-X
found	B-X
in	B-X
mantle	B-X
cell	B-X
lymphoma	B-X
(	B-X
MCL	B-X
)	B-X
suggest	B-X
that	B-X
ATM	B-X
could	B-X
be	B-X
inactivated	B-X
in	B-X
these	B-X
lymphomas	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
ATM	B-X
gene	B-X
alterations	B-X
and	B-X
protein	B-X
expression	B-X
were	B-X
examined	B-X
in	B-X
20	B-X
and	B-X
17	B-X
MCL	B-X
tumor	B-X
specimens	B-X
,	B-X
respectively	B-X
.	B-X
Previously	B-X
,	B-X
these	B-X
patients	B-X
had	B-X
been	B-X
examined	B-X
for	B-X
p53	B-X
and	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
gene	B-X
status	B-X
and	B-X
analyzed	B-X
by	B-X
comparative	B-X
genomic	B-X
hybridization	B-X
.	B-X
Nine	B-X
patients	B-X
had	B-X
11q22-23	B-X
losses	B-X
.	B-X
Eight	B-X
ATM	B-X
gene	B-X
mutations	B-X
were	B-X
detected	B-X
in	B-X
7	B-X
patients	B-X
.	B-X
These	B-X
alterations	B-X
were	B-X
3	B-X
missense	B-X
mutations	B-X
in	B-X
the	B-X
phosphatidylinositol-3	B-X
kinase	B-X
(	B-X
PI-3K	B-X
)	B-X
domain	B-X
and	B-X
5	B-X
truncating	B-X
mutations	B-X
,	B-X
including	B-X
3	B-X
frameshifts	B-X
,	B-X
a	B-X
nonsense	B-X
mutation	B-X
,	B-X
and	B-X
a	B-X
substitution	B-X
of	B-X
the	B-X
initial	B-X
methionine	B-X
.	B-X
All	B-X
truncating	B-X
mutations	B-X
were	B-X
associated	B-X
with	B-X
lack	B-X
of	B-X
protein	B-X
expression	B-X
.	B-X
Somatic	B-X
origin	B-X
was	B-X
demonstrated	B-X
in	B-X
3	B-X
mutations	B-X
,	B-X
whereas	B-X
one	B-X
mutation	B-X
was	B-X
carried	B-X
heterozygously	B-X
in	B-X
the	B-X
patient	B-X
germ	B-X
line	B-X
.	B-X
Chromosomal	B-X
imbalances	B-X
were	B-X
significantly	B-X
higher	B-X
in	B-X
typical	B-X
MCL	B-X
with	B-X
ATM	B-X
inactivation	B-X
(	B-X
7.8	B-X
+/-	B-X
1.3	B-X
)	B-X
than	B-X
in	B-X
tumors	B-X
with	B-X
the	B-X
wild-type	B-X
gene	B-X
(	B-X
3	B-X
+/-	B-X
1.1	B-X
)	B-X
(	B-X
P	B-X
=.001	B-X
)	B-X
.	B-X
Moreover	B-X
,	B-X
tumors	B-X
with	B-X
bi-allelic	B-X
ATM	B-X
alteration	B-X
were	B-X
associated	B-X
with	B-X
3q	B-X
gains	B-X
(	B-X
P	B-X
=.015	B-X
)	B-X
and	B-X
frequent	B-X
extranodal	B-X
involvement	B-X
(	B-X
P	B-X
=.049	B-X
)	B-X
.	B-X
ATM	B-X
gene	B-X
alterations	B-X
were	B-X
not	B-X
related	B-X
to	B-X
the	B-X
histologic	B-X
variant	B-X
of	B-X
the	B-X
tumors	B-X
,	B-X
p53/p14	B-X
(	B-X
ARF	B-X
)	B-X
gene	B-X
status	B-X
,	B-X
survival	B-X
,	B-X
or	B-X
other	B-X
clinicopathologic	B-X
features	B-X
of	B-X
the	B-X
patients	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
ATM	B-X
gene	B-X
mutations	B-X
in	B-X
MCL	B-X
are	B-X
mainly	B-X
truncating	B-X
or	B-X
missense	B-X
mutations	B-X
involving	B-X
the	B-X
PI-3K	B-X
domain	B-X
,	B-X
and	B-X
that	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
a	B-X
subset	B-X
of	B-X
these	B-X
tumors	B-X
with	B-X
increased	B-X
numbers	B-X
of	B-X
chromosomal	B-X
imbalances	B-X
.	B-X

One	O
mutation	O
(	O
del483CAT	O
)	O
has	O
not	O
been	O
reported	O
previously	O
either	O
in	O
breast	O
cancer	O
or	O
in	O
any	O
other	O
tumor	O
type	O
(	O
IARC	O
database	O
:	O
http	O
:	O
/	O
/	O
www	O
.	O
iarc	O
.	O
fr	O
/	O
p53	O
/	O
)	O
.	O
<EOS>	B-X
A	B-X
large	B-X
amount	B-X
of	B-X
data	B-X
is	B-X
available	B-X
on	B-X
the	B-X
functional	B-X
impact	B-X
of	B-X
missense	B-X
mutations	B-X
in	B-X
TP53	B-X
and	B-X
on	B-X
mutation	B-X
patterns	B-X
in	B-X
many	B-X
different	B-X
cancers	B-X
.	B-X
New	B-X
data	B-X
on	B-X
mutant	B-X
p53	B-X
protein	B-X
function	B-X
,	B-X
cancer	B-X
phenotype	B-X
and	B-X
prognosis	B-X
have	B-X
recently	B-X
been	B-X
integrated	B-X
in	B-X
the	B-X
International	B-X
Agency	B-X
for	B-X
Research	B-X
on	B-X
Cancer	B-X
TP53	B-X
database	B-X
(	B-X
http	B-X
:	B-X
//www-p53.iarc.fr/	B-X
)	B-X
.	B-X
Based	B-X
on	B-X
these	B-X
data	B-X
,	B-X
we	B-X
summarize	B-X
here	B-X
current	B-X
knowledge	B-X
on	B-X
the	B-X
respective	B-X
roles	B-X
of	B-X
mutagenesis	B-X
and	B-X
biological	B-X
selection	B-X
of	B-X
mutations	B-X
with	B-X
specific	B-X
functional	B-X
characteristic	B-X
in	B-X
shaping	B-X
the	B-X
patterns	B-X
and	B-X
phenotypes	B-X
of	B-X
mutations	B-X
observed	B-X
in	B-X
human	B-X
cancers	B-X
.	B-X
The	B-X
main	B-X
conclusion	B-X
is	B-X
that	B-X
intrinsic	B-X
mutagenicity	B-X
rates	B-X
,	B-X
loss	B-X
of	B-X
transactivation	B-X
activities	B-X
,	B-X
and	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
,	B-X
dominant-negative	B-X
activities	B-X
are	B-X
the	B-X
main	B-X
driving	B-X
forces	B-X
that	B-X
determine	B-X
TP53	B-X
mutation	B-X
patterns	B-X
and	B-X
influence	B-X
tumor	B-X
phenotype	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
current	B-X
experimental	B-X
data	B-X
on	B-X
the	B-X
acquisition	B-X
of	B-X
oncogenic	B-X
activities	B-X
(	B-X
gain	B-X
of	B-X
function	B-X
)	B-X
by	B-X
p53	B-X
mutants	B-X
are	B-X
too	B-X
scarce	B-X
and	B-X
heterogenous	B-X
to	B-X
assess	B-X
whether	B-X
this	B-X
property	B-X
has	B-X
an	B-X
impact	B-X
on	B-X
tumor	B-X
development	B-X
and	B-X
outcome	B-X
.	B-X
In	B-X
the	B-X
case	B-X
of	B-X
inherited	B-X
TP53	B-X
mutations	B-X
causing	B-X
Li-Fraumeni	B-X
and	B-X
related	B-X
syndromes	B-X
,	B-X
the	B-X
age	B-X
at	B-X
onset	B-X
of	B-X
some	B-X
tumor	B-X
types	B-X
is	B-X
in	B-X
direct	B-X
relation	B-X
with	B-X
the	B-X
degree	B-X
of	B-X
loss	B-X
of	B-X
transactivation	B-X
capacity	B-X
of	B-X
missense	B-X
mutations	B-X
.	B-X
Finally	B-X
,	B-X
studies	B-X
on	B-X
large	B-X
case	B-X
series	B-X
demonstrate	B-X
that	B-X
TP53	B-X
mutations	B-X
are	B-X
independent	B-X
markers	B-X
of	B-X
bad	B-X
prognosis	B-X
in	B-X
breast	B-X
and	B-X
several	B-X
other	B-X
cancers	B-X
,	B-X
and	B-X
that	B-X
the	B-X
exact	B-X
type	B-X
and	B-X
position	B-X
of	B-X
the	B-X
mutation	B-X
influences	B-X
disease	B-X
outcome	B-X
.	B-X
Further	B-X
studies	B-X
are	B-X
needed	B-X
to	B-X
determine	B-X
how	B-X
TP53	B-X
haplotypes	B-X
or	B-X
loss	B-X
of	B-X
alleles	B-X
interact	B-X
with	B-X
mutations	B-X
to	B-X
modulate	B-X
their	B-X
impact	B-X
on	B-X
cancer	B-X
development	B-X
and	B-X
prognosis	B-X
.	B-X

Twelve	O
of	O
the	O
mutations	O
directly	O
or	O
indirectly	O
affected	O
the	O
L2	O
/	O
L3	O
domains	O
of	O
the	O
p53	O
protein	O
(	O
Table	O
2	O
)	O
previous	O
found	O
to	O
predict	O
a	O
poor	O
prognosis	O
[	O
39	O
]	O
and	O
drug	O
resistance	O
[	O
14	O
]	O
,	O
[	O
40	O
]	O
.	O
<EOS>	B-X
Base-editing	B-X
,	B-X
the	B-X
newest	B-X
evolution	B-X
of	B-X
clustered	B-X
regularly	B-X
interspaced	B-X
short	B-X
palindromic	B-X
repeats	B-X
(	B-X
CRISPR	B-X
)	B-X
-Cas-based	B-X
technologies	B-X
,	B-X
can	B-X
directly	B-X
install	B-X
point-mutations	B-X
in	B-X
cellular	B-X
DNA	B-X
without	B-X
inducing	B-X
a	B-X
double-strand	B-X
DNA	B-X
break	B-X
(	B-X
DSB	B-X
)	B-X
.	B-X
Recently	B-X
,	B-X
prime-editing	B-X
(	B-X
PE	B-X
)	B-X
has	B-X
further	B-X
expanded	B-X
the	B-X
CRISPR-base-edit	B-X
toolkit	B-X
to	B-X
all	B-X
twelve	B-X
possible	B-X
transition	B-X
and	B-X
transversion	B-X
mutations	B-X
,	B-X
as	B-X
well	B-X
as	B-X
small	B-X
insertion	B-X
or	B-X
deletion	B-X
mutations	B-X
.	B-X
Primary	B-X
immunodeficiency	B-X
diseases	B-X
(	B-X
PIDDs	B-X
)	B-X
are	B-X
clinically	B-X
and	B-X
genetically	B-X
heterogeneous	B-X
disorders	B-X
thus	B-X
far	B-X
associated	B-X
with	B-X
mutations	B-X
in	B-X
more	B-X
than	B-X
300	B-X
genes	B-X
.	B-X
From	B-X
the	B-X
analysis	B-X
of	B-X
published	B-X
causal	B-X
mutations	B-X
,	B-X
we	B-X
identified	B-X
130	B-X
genes	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
mitochondrial	B-X
heart	B-X
diseases	B-X
.	B-X
A	B-X
large	B-X
proportion	B-X
of	B-X
these	B-X
genes	B-X
(	B-X
34.3	B-X
%	B-X
)	B-X
encode	B-X
for	B-X
key	B-X
proteins	B-X
involved	B-X
in	B-X
the	B-X
oxidative	B-X
phosphorylation	B-X
system	B-X
(	B-X
OXPHOS	B-X
)	B-X
,	B-X
either	B-X
as	B-X
directly	B-X
OXPHOS	B-X
subunits	B-X
(	B-X
22.8	B-X
%	B-X
)	B-X
,	B-X
and	B-X
as	B-X
OXPHOS	B-X
assembly	B-X
factors	B-X
(	B-X
11.5	B-X
%	B-X
)	B-X
.	B-X

For	O
statistical	O
comparison	O
,	O
mutation	O
Gly325Ter	O
(	O
patient	B-Species
Epi215	O
)	O
located	O
to	O
the	O
tetramerization	O
domain	O
is	O
grouped	O
together	O
with	O
the	O
mutations	O
affecting	O
the	O
L2	O
/	O
L3	O
domain	O
,	O
since	O
this	O
mutation	O
leads	O
to	O
truncation	O
of	O
the	O
protein	O
and	O
with	O
loss	O
of	O
tetramerization	O
and	O
functional	O
defects	O
similar	O
to	O
L2	O
/	O
L3	O
mutations	O
[	O
41	O
]	O
.	O

There	O
was	O
a	O
statistical	O
significant	O
correlation	O
between	O
TP53	O
mutation	O
status	O
and	O
lack	O
of	O
treatment	O
response	O
(	O
PD	O
)	O
(	O
Table	O
4	O
;	O
p	O
=	O
0	O
.	O
0358	O
;	O
Fisher	O
exact	O
test	O
)	O
.	O

When	O
tumors	O
harboring	O
TP53	O
mutations	O
affecting	O
the	O
p53	O
L2	O
/	O
L3	O
DNA	O
-	O
binding	O
domains	O
were	O
compared	O
to	O
those	O
with	O
wild	O
-	O
type	O
TP53	O
or	O
TP53	O
mutations	O
outside	O
the	O
L2	O
/	O
L3	O
domains	O
,	O
this	O
correlation	O
was	O
further	O
strengthened	O
(	O
p	O
=	O
0	O
.	O
0136	O
)	O
.	O

The	O
previously	O
described	O
TP53	O
polymorphism	O
,	O
Arg72Pro	O
[	O
42	O
]	O
was	O
detected	O
in	O
31	O
(	O
29	O
%	O
)	O
of	O
our	O
patients	B-Species
.	O

No	O
correlation	O
was	O
found	O
between	O
this	O
polymorphism	O
and	O
lack	O
of	O
treatment	O
response	O
(	O
p	O
=	O
0	O
.	O
2750	O
;	O
Fisher	O
exact	O
test	O
)	O
or	O
TP53	O
mutational	O
status	O
(	O
p	O
=	O
0	O
.	O
2024	O
)	O
.	O

CHEK2	O
Mutations	O
and	O
Response	O
to	O
Therapy	O
<EOS>	B-X
A	B-X
number	B-X
of	B-X
other	B-X
hereditary	B-X
ovarian	B-X
cancers	B-X
are	B-X
associated	B-X
with	B-X
different	B-X
genes	B-X
,	B-X
with	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
DNA	B-X
damage	B-X
response	B-X
pathway	B-X
,	B-X
such	B-X
as	B-X
the	B-X
mismatch	B-X
repair	B-X
genes	B-X
in	B-X
Lynch	B-X
syndrome	B-X
,	B-X
TP53	B-X
in	B-X
Li-Fraumeni	B-X
syndrome	B-X
,	B-X
STK11	B-X
in	B-X
Peutz-Jeghers	B-X
syndrome	B-X
,	B-X
CHEK2	B-X
,	B-X
RAD51	B-X
,	B-X
BRIP1	B-X
,	B-X
and	B-X
PALB2	B-X
.	B-X
Mutations	B-X
in	B-X
ASXL1	B-X
are	B-X
enriched	B-X
in	B-X
current	B-X
or	B-X
former	B-X
smokers	B-X
,	B-X
whereas	B-X
cancer	B-X
therapy	B-X
with	B-X
radiation	B-X
,	B-X
platinum	B-X
and	B-X
topoisomerase	B-X
II	B-X
inhibitors	B-X
preferentially	B-X
selects	B-X
for	B-X
mutations	B-X
in	B-X
DNA	B-X
damage	B-X
response	B-X
genes	B-X
(	B-X
TP53	B-X
,	B-X
PPM1D	B-X
,	B-X
CHEK2	B-X
)	B-X
.	B-X
Deficiencies	B-X
in	B-X
the	B-X
homologous	B-X
recombination	B-X
(	B-X
HR	B-X
)	B-X
pathway	B-X
can	B-X
lead	B-X
to	B-X
defective	B-X
DNA	B-X
damage	B-X
responses	B-X
,	B-X
and	B-X
this	B-X
can	B-X
occur	B-X
through	B-X
inherited	B-X
germline	B-X
mutations	B-X
in	B-X
HR	B-X
pathway	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
CHEK2	B-X
and	B-X
ATM	B-X
.	B-X
We	B-X
now	B-X
understand	B-X
that	B-X
germline	B-X
mutations	B-X
can	B-X
be	B-X
identified	B-X
frequently	B-X
(	B-X
~	B-X
5-10	B-X
%	B-X
)	B-X
in	B-X
patients	B-X
with	B-X
myeloid	B-X
and	B-X
lymphoid	B-X
malignancies	B-X
,	B-X
and	B-X
among	B-X
the	B-X
most	B-X
common	B-X
of	B-X
these	B-X
are	B-X
CHEK2	B-X
and	B-X
ATM	B-X
.	B-X
We	B-X
review	B-X
the	B-X
role	B-X
that	B-X
deleterious	B-X
germline	B-X
CHEK2	B-X
and	B-X
ATM	B-X
variants	B-X
play	B-X
in	B-X
the	B-X
development	B-X
of	B-X
hematopoietic	B-X
malignancies	B-X
,	B-X
and	B-X
how	B-X
this	B-X
influences	B-X
clinical	B-X
practice	B-X
,	B-X
including	B-X
cancer	B-X
screening	B-X
,	B-X
hematopoietic	B-X
stem	B-X
cell	B-X
transplantation	B-X
,	B-X
and	B-X
therapy	B-X
choice	B-X
.	B-X

Table	O
3	O
presents	O
the	O
patients	B-Species
with	O
detected	O
CHEK2	O
mutations	O
together	O
with	O
a	O
description	O
of	O
the	O
clinical	O
response	O
and	O
follow	O
up	O
-	O
data	O
.	O

CHEK2	O
mutations	O
were	O
identified	O
in	O
three	O
out	O
of	O
the	O
109	O
patients	B-Species
(	O
2	O
.	O
8	O
%	O
)	O
.	O

Notably	O
,	O
each	O
of	O
the	O
CHEK2	O
mutations	O
identified	O
was	O
also	O
present	O
in	O
patient	B-Species
lymphocyte	O
DNA	O
,	O
confirming	O
a	O
germline	O
origin	O
.	O

The	O
Arg95Ter	O
(	O
C283T	O
)	O
mutation	O
is	O
novel	O
.	O

This	O
mutation	O
was	O
present	O
in	O
two	O
patients	B-Species
(	O
Epi132	O
and	O
Epi203	O
)	O
living	O
in	O
different	O
parts	O
of	O
Norway	O
with	O
no	O
known	O
family	O
relationship	O
.	O

However	O
,	O
linkage	O
analysis	O
using	O
microsatellite	O
markers	O
(	O
D22S275	O
,	O
D22S272	O
,	O
D22S1172	O
and	O
D22S423	O
)	O
suggested	O
a	O
common	O
founder	O
mutation	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
C283T	O
transition	O
generates	O
a	O
novel	O
stop	O
codon	O
in	O
exon	O
1	O
of	O
CHEK2	O
,	O
leading	O
to	O
truncation	O
of	O
the	O
Chk2	O
protein	O
.	O

LOH	O
analysis	O
indicated	O
loss	O
of	O
the	O
wild	O
-	O
type	O
CHEK2	O
allele	O
in	O
the	O
both	O
tumors	O
from	O
the	O
two	O
patients	B-Species
harboring	O
this	O
mutation	O
(	O
Epi132	O
and	O
Epi203	O
)	O
.	O

Both	O
these	O
tumors	O
were	O
non	O
-	O
responsive	O
to	O
epirubicin	O
therapy	O
(	O
PD	O
)	O
.	O
<EOS>	B-X
In	B-X
people	B-X
with	B-X
advanced	B-X
disease	B-X
,	B-X
significant	B-X
benefits	B-X
from	B-X
targeted	B-X
therapies	B-X
are	B-X
currently	B-X
limited	B-X
to	B-X
HER-2	B-X
positive	B-X
disease	B-X
treated	B-X
with	B-X
trastuzumab	B-X
,	B-X
in	B-X
combination	B-X
with	B-X
chemotherapy	B-X
,	B-X
in	B-X
first-line	B-X
.	B-X
Thus	B-X
,	B-X
systemic	B-X
chemotherapy	B-X
remains	B-X
the	B-X
mainstay	B-X
of	B-X
treatment	B-X
for	B-X
advanced	B-X
gastric	B-X
cancer	B-X
.	B-X
Programmed	B-X
death	B-X
ligand	B-X
1	B-X
(	B-X
PD-L1	B-X
)	B-X
has	B-X
conventionally	B-X
been	B-X
considered	B-X
as	B-X
a	B-X
type	B-X
I	B-X
transmembrane	B-X
protein	B-X
that	B-X
can	B-X
interact	B-X
with	B-X
its	B-X
receptor	B-X
,	B-X
programmed	B-X
cell	B-X
death	B-X
1	B-X
(	B-X
PD-1	B-X
)	B-X
,	B-X
thus	B-X
inducing	B-X
T	B-X
cell	B-X
deactivation	B-X
and	B-X
immune	B-X
escape	B-X
.	B-X
However	B-X
,	B-X
targeting	B-X
the	B-X
PD-1/PD-L1	B-X
axis	B-X
has	B-X
achieved	B-X
adequate	B-X
clinical	B-X
responses	B-X
in	B-X
very	B-X
few	B-X
specific	B-X
malignancies	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
explored	B-X
the	B-X
extracellularly	B-X
and	B-X
subcellularly	B-X
located	B-X
PD-L1	B-X
,	B-X
namely	B-X
,	B-X
nuclear	B-X
PD-L1	B-X
(	B-X
nPD-L1	B-X
)	B-X
,	B-X
cytoplasmic	B-X
PD-L1	B-X
(	B-X
cPD-L1	B-X
)	B-X
,	B-X
soluble	B-X
PD-L1	B-X
(	B-X
sPD-L1	B-X
)	B-X
,	B-X
and	B-X
extracellular	B-X
vesicle	B-X
PD-L1	B-X
(	B-X
EV	B-X
PD-L1	B-X
)	B-X
,	B-X
which	B-X
might	B-X
shed	B-X
light	B-X
on	B-X
the	B-X
resistance	B-X
to	B-X
anti-PD1/PDL1	B-X
therapy	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
summarize	B-X
the	B-X
four	B-X
atypical	B-X
localizations	B-X
of	B-X
PD-L1	B-X
with	B-X
a	B-X
focus	B-X
on	B-X
their	B-X
novel	B-X
functions	B-X
,	B-X
such	B-X
as	B-X
gene	B-X
transcription	B-X
regulation	B-X
,	B-X
therapeutic	B-X
efficacy	B-X
prediction	B-X
,	B-X
and	B-X
resistance	B-X
to	B-X
various	B-X
cancer	B-X
therapies	B-X
.	B-X
Additionally	B-X
,	B-X
we	B-X
highlight	B-X
that	B-X
non-cytomembrane	B-X
PD-L1s	B-X
are	B-X
of	B-X
significant	B-X
cancer	B-X
diagnostic	B-X
value	B-X
and	B-X
are	B-X
promising	B-X
therapeutic	B-X
targets	B-X
to	B-X
treat	B-X
cancer	B-X
.	B-X

In	O
contrast	O
,	O
the	O
third	O
patient	B-Species
with	O
a	O
germline	O
CHEK2	O
mutation	O
(	O
patient	B-Species
Epi151	O
;	O
point	O
mutation	O
at	O
T1091C	O
,	O
Ile364Thr	O
)	O
had	O
a	O
partial	O
response	O
to	O
epirubicin	O
therapy	O
.	O

This	O
tumor	O
was	O
non	O
-	O
informative	O
with	O
respect	O
to	O
LOH	O
.	O
<EOS>	B-X
Angiosarcomas	B-X
are	B-X
rare	B-X
,	B-X
clinically	B-X
aggressive	B-X
tumors	B-X
with	B-X
limited	B-X
treatment	B-X
options	B-X
and	B-X
a	B-X
dismal	B-X
prognosis	B-X
.	B-X
We	B-X
analyzed	B-X
angiosarcomas	B-X
from	B-X
68	B-X
patients	B-X
,	B-X
integrating	B-X
information	B-X
from	B-X
multiomic	B-X
sequencing	B-X
,	B-X
NanoString	B-X
immuno-oncology	B-X
profiling	B-X
,	B-X
and	B-X
multiplex	B-X
immunohistochemistry	B-X
and	B-X
immunofluorescence	B-X
for	B-X
tumor-infiltrating	B-X
immune	B-X
cells	B-X
.	B-X
Through	B-X
whole-genome	B-X
sequencing	B-X
(	B-X
n	B-X
=	B-X
18	B-X
)	B-X
,	B-X
50	B-X
%	B-X
of	B-X
the	B-X
cutaneous	B-X
head	B-X
and	B-X
neck	B-X
angiosarcomas	B-X
exhibited	B-X
higher	B-X
tumor	B-X
mutation	B-X
burden	B-X
(	B-X
TMB	B-X
)	B-X
and	B-X
UV	B-X
mutational	B-X
signatures	B-X
;	B-X
others	B-X
were	B-X
mutationally	B-X
quiet	B-X
and	B-X
non-UV	B-X
driven	B-X
.	B-X
Likewise	B-X
,	B-X
tumor	B-X
inflammation	B-X
signature	B-X
(	B-X
TIS	B-X
)	B-X
scores	B-X
were	B-X
highest	B-X
in	B-X
cluster	B-X
3	B-X
(	B-X
7.54	B-X
vs.	B-X
6.71	B-X
vs.	B-X
5.75	B-X
,	B-X
respectively	B-X
;	B-X
P	B-X
<	B-X
0.0001	B-X
)	B-X
.	B-X

Taking	O
all	O
CHEK2	O
mutations	O
together	O
,	O
they	O
predicted	O
resistance	O
to	O
epirubicin	O
(	O
p	O
=	O
0	O
.	O
0226	O
)	O
.	O

The	O
previously	O
described	O
silent	O
Glu84Glu	O
(	O
A252G	O
)	O
polymorphism	O
[	O
24	O
]	O
,	O
[	O
43	O
]	O
in	O
exon	O
1	O
was	O
detected	O
in	O
two	O
(	O
1	O
.	O
9	O
%	O
)	O
patients	B-Species
.	O

No	O
association	O
between	O
this	O
polymorphism	O
and	O
treatment	O
response	O
was	O
recorded	O
.	O
<EOS>	B-X
Common	B-X
single-nucleotide	B-X
polymorphisms	B-X
(	B-X
SNPs	B-X
)	B-X
are	B-X
predicted	B-X
to	B-X
collectively	B-X
explain	B-X
40-50	B-X
%	B-X
of	B-X
phenotypic	B-X
variation	B-X
in	B-X
human	B-X
height	B-X
,	B-X
but	B-X
identifying	B-X
the	B-X
specific	B-X
variants	B-X
and	B-X
associated	B-X
regions	B-X
requires	B-X
huge	B-X
sample	B-X
sizes	B-X
Family	B-X
studies	B-X
in	B-X
clinical	B-X
samples	B-X
as	B-X
well	B-X
as	B-X
twin	B-X
studies	B-X
suggest	B-X
a	B-X
familial	B-X
liability	B-X
and	B-X
consequently	B-X
different	B-X
genes	B-X
were	B-X
investigated	B-X
in	B-X
association	B-X
studies	B-X
.	B-X
Pharmacotherapy	B-X
with	B-X
methylphenidate	B-X
(	B-X
MPH	B-X
)	B-X
seems	B-X
to	B-X
be	B-X
the	B-X
first-line	B-X
treatment	B-X
of	B-X
choice	B-X
in	B-X
adults	B-X
with	B-X
attention-deficit	B-X
hyperactive	B-X
disorder	B-X
(	B-X
ADHD	B-X
)	B-X
and	B-X
some	B-X
studies	B-X
were	B-X
conducted	B-X
on	B-X
the	B-X
genes	B-X
influencing	B-X
the	B-X
response	B-X
to	B-X
this	B-X
drug	B-X
.	B-X
We	B-X
believe	B-X
this	B-X
work	B-X
is	B-X
the	B-X
first	B-X
systematic	B-X
review	B-X
and	B-X
meta-analysis	B-X
of	B-X
candidate	B-X
gene	B-X
association	B-X
studies	B-X
,	B-X
pharmacogenetic	B-X
and	B-X
biochemical	B-X
(	B-X
metabolomics	B-X
)	B-X
studies	B-X
performed	B-X
in	B-X
adults	B-X
with	B-X
ADHD	B-X
to	B-X
identify	B-X
potential	B-X
genetic	B-X
,	B-X
predictive	B-X
and	B-X
peripheral	B-X
markers	B-X
linked	B-X
specifically	B-X
to	B-X
ADHD	B-X
in	B-X
adults	B-X
.	B-X
After	B-X
screening	B-X
5129	B-X
records	B-X
,	B-X
we	B-X
selected	B-X
87	B-X
studies	B-X
of	B-X
which	B-X
61	B-X
were	B-X
available	B-X
for	B-X
candidate	B-X
gene	B-X
association	B-X
studies	B-X
,	B-X
5	B-X
for	B-X
pharmacogenetics	B-X
and	B-X
21	B-X
for	B-X
biochemical	B-X
studies	B-X
.	B-X
We	B-X
obtained	B-X
an	B-X
association	B-X
between	B-X
adult	B-X
ADHD	B-X
and	B-X
the	B-X
gene	B-X
BAIAP2	B-X
(	B-X
brain-specific	B-X
angiogenesis	B-X
inhibitor	B-X
1-associated	B-X
protein	B-X
2	B-X
)	B-X
,	B-X
even	B-X
after	B-X
Bonferroni	B-X
correction	B-X
,	B-X
with	B-X
any	B-X
heterogeneity	B-X
in	B-X
effect	B-X
size	B-X
and	B-X
no	B-X
publication	B-X
bias	B-X
.	B-X
If	B-X
we	B-X
did	B-X
not	B-X
apply	B-X
the	B-X
Bonferroni	B-X
correction	B-X
,	B-X
a	B-X
trend	B-X
was	B-X
found	B-X
for	B-X
the	B-X
carriers	B-X
allele	B-X
9R	B-X
of	B-X
dopamine	B-X
transporter	B-X
SLC6A3	B-X
40	B-X
bp	B-X
variable	B-X
tandem	B-X
repeat	B-X
polymorphism	B-X
(	B-X
VNTR	B-X
)	B-X
and	B-X
for	B-X
6/6	B-X
homozygotes	B-X
of	B-X
SLC6A3	B-X
30	B-X
bp	B-X
VNTR	B-X
.	B-X
Concerning	B-X
pharmacogenetic	B-X
studies	B-X
,	B-X
no	B-X
association	B-X
was	B-X
found	B-X
for	B-X
the	B-X
SLC6A3	B-X
40	B-X
bp	B-X
and	B-X
response	B-X
to	B-X
MPH	B-X
with	B-X
only	B-X
two	B-X
studies	B-X
selected	B-X
.	B-X
This	B-X
last	B-X
association	B-X
was	B-X
significant	B-X
even	B-X
after	B-X
Bonferroni	B-X
correction	B-X
and	B-X
in	B-X
absence	B-X
of	B-X
heterogeneity	B-X
.	B-X

One	O
of	O
the	O
tumors	O
(	O
Epi203	O
)	O
harboring	O
the	O
C283T	O
substitution	O
(	O
Arg95Ter	O
)	O
also	O
harbored	O
a	O
somatic	O
TP53	O
mutation	O
in	O
codon	O
175	O
,	O
Arg175His	O
,	O
located	O
in	O
the	O
L2	O
domain	O
of	O
p53	O
(	O
Table	O
2	O
)	O
.	O

This	O
mutation	O
was	O
detected	O
in	O
another	O
four	O
of	O
our	O
patients	B-Species
treated	O
with	O
epirubicin	O
(	O
Table	O
2	O
)	O
.	O

In	O
addition	O
,	O
TP53	O
Arg175His	O
mutation	O
was	O
recorded	O
in	O
one	O
patient	B-Species
of	O
our	O
previous	O
study	O
evaluating	O
response	O
to	O
doxorubicin	O
[	O
13	O
]	O
.	O

The	O
fact	O
that	O
none	O
of	O
the	O
Arg175His	O
patients	B-Species
presented	O
here	O
or	O
in	O
our	O
previous	O
study	O
revealed	O
resistance	O
to	O
therapy	O
(	O
PD	O
)	O
suggests	O
this	O
mutation	O
may	O
not	O
cause	O
resistance	O
to	O
anthracyclines	O
in	O
breast	O
cancers	O
in	O
vivo	O
.	O
<EOS>	B-X
Tumor	B-X
heterogeneity	B-X
underlies	B-X
resistance	B-X
to	B-X
tyrosine	B-X
kinase	B-X
inhibitors	B-X
(	B-X
TKI	B-X
)	B-X
in	B-X
lung	B-X
cancers	B-X
harboring	B-X
Chemoresistance	B-X
remains	B-X
the	B-X
primary	B-X
challenge	B-X
of	B-X
clinical	B-X
treatment	B-X
of	B-X
gastric	B-X
cancer	B-X
(	B-X
GC	B-X
)	B-X
,	B-X
making	B-X
the	B-X
biomarkers	B-X
of	B-X
chemoresistance	B-X
crucial	B-X
for	B-X
treatment	B-X
decision	B-X
.	B-X
Our	B-X
previous	B-X
study	B-X
has	B-X
reported	B-X
that	B-X
p21-actived	B-X
kinase	B-X
6	B-X
(	B-X
PAK6	B-X
)	B-X
is	B-X
a	B-X
prognostic	B-X
factor	B-X
for	B-X
selecting	B-X
which	B-X
patients	B-X
with	B-X
GC	B-X
are	B-X
resistant	B-X
to	B-X
5-fluorouracil/oxaliplatin	B-X
chemotherapy	B-X
.	B-X
The	B-X
present	B-X
study	B-X
identified	B-X
PAK6	B-X
as	B-X
an	B-X
important	B-X
modulator	B-X
of	B-X
the	B-X
DNA	B-X
damage	B-X
response	B-X
(	B-X
DDR	B-X
)	B-X
and	B-X
chemosensitivity	B-X
in	B-X
GC	B-X
.	B-X
Analysis	B-X
of	B-X
specimens	B-X
from	B-X
patients	B-X
revealed	B-X
significant	B-X
associations	B-X
between	B-X
the	B-X
expression	B-X
of	B-X
PAK6	B-X
and	B-X
poorer	B-X
stages	B-X
,	B-X
deeper	B-X
invasion	B-X
,	B-X
more	B-X
lymph	B-X
node	B-X
metastases	B-X
,	B-X
higher	B-X
recurrence	B-X
rates	B-X
,	B-X
and	B-X
resistance	B-X
to	B-X
oxaliplatin	B-X
.	B-X
Functionally	B-X
,	B-X
PAK6	B-X
mediates	B-X
cancer	B-X
chemoresistance	B-X
by	B-X
enhancing	B-X
homologous	B-X
recombination	B-X
(	B-X
HR	B-X
)	B-X
to	B-X
facilitate	B-X
the	B-X
DNA	B-X
double-strand	B-X
break	B-X
repair	B-X
.	B-X
Activation	B-X
of	B-X
ATR	B-X
is	B-X
the	B-X
necessary	B-X
step	B-X
for	B-X
PAK6	B-X
mediated	B-X
HR	B-X
repair	B-X
to	B-X
protect	B-X
GC	B-X
cells	B-X
from	B-X
oxaliplatin-induced	B-X
apoptosis	B-X
,	B-X
and	B-X
ATR	B-X
inhibitor	B-X
(	B-X
AZD6738	B-X
)	B-X
could	B-X
block	B-X
the	B-X
PAK6-mediated	B-X
HR	B-X
repair	B-X
,	B-X
thereby	B-X
reversing	B-X
the	B-X
resistance	B-X
to	B-X
oxaliplatin	B-X
and	B-X
even	B-X
promoting	B-X
the	B-X
sensitivity	B-X
to	B-X
oxaliplatin	B-X
regardless	B-X
of	B-X
high	B-X
expression	B-X
of	B-X
PAK6	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
these	B-X
findings	B-X
indicate	B-X
a	B-X
novel	B-X
regulatory	B-X
mechanism	B-X
of	B-X
PAK6	B-X
in	B-X
modulating	B-X
the	B-X
DDR	B-X
and	B-X
chemoresistance	B-X
in	B-X
GC	B-X
and	B-X
provide	B-X
a	B-X
reversal	B-X
suggestion	B-X
in	B-X
clinical	B-X
decision	B-X
.	B-X

Omitting	O
the	O
tumor	O
harboring	O
both	O
a	O
CHEK2	O
and	O
a	O
TP53	O
mutation	O
(	O
patient	B-Species
Epi203	O
)	O
from	O
statistical	O
analysis	O
,	O
Chk2	O
mutations	O
(	O
n	O
=	O
2	O
)	O
were	O
non	O
-	O
significantly	O
associated	O
with	O
therapy	O
resistance	O
(	O
p	O
=	O
0	O
.	O
1633	O
)	O
.	O

In	O
a	O
previous	O
study	O
[	O
26	O
]	O
,	O
however	O
,	O
we	O
analyzed	O
for	O
CHEK2	O
mutation	O
status	O
in	O
relation	O
to	O
therapy	O
outcome	O
in	O
a	O
cohort	O
of	O
patients	B-Species
from	O
doxorubicin	O
study	O
[	O
13	O
]	O
.	O

In	O
that	O
study	O
[	O
26	O
]	O
,	O
we	O
detected	O
the	O
previously	O
identified	O
mutation	O
Ile157Thr	O
.	O

In	O
addition	O
,	O
we	O
detected	O
a	O
novel	O
nonsense	O
somatic	O
mutation	O
(	O
1368InsA	O
)	O
.	O

This	O
mutation	O
was	O
associated	O
with	O
lack	O
of	O
function	O
in	O
vitro	O
;	O
moreover	O
,	O
it	O
was	O
associated	O
with	O
drug	O
resistance	O
in	O
vivo	O
.	O
<EOS>	B-X
Constitutional	B-X
heterozygous	B-X
mutations	B-X
of	B-X
ATP1A2	B-X
and	B-X
ATP1A3	B-X
,	B-X
encoding	B-X
for	B-X
two	B-X
distinct	B-X
isoforms	B-X
of	B-X
the	B-X
Na+/K+-ATPase	B-X
(	B-X
NKA	B-X
)	B-X
alpha-subunit	B-X
,	B-X
have	B-X
been	B-X
associated	B-X
with	B-X
familial	B-X
hemiplegic	B-X
migraine	B-X
(	B-X
ATP1A2	B-X
)	B-X
,	B-X
alternating	B-X
hemiplegia	B-X
of	B-X
childhood	B-X
(	B-X
ATP1A2/A3	B-X
)	B-X
,	B-X
rapid-onset	B-X
dystonia-parkinsonism	B-X
,	B-X
cerebellar	B-X
ataxia-areflexia-progressive	B-X
optic	B-X
atrophy	B-X
,	B-X
and	B-X
relapsing	B-X
encephalopathy	B-X
with	B-X
cerebellar	B-X
ataxia	B-X
(	B-X
all	B-X
ATP1A3	B-X
)	B-X
.	B-X
A	B-X
few	B-X
reports	B-X
have	B-X
described	B-X
single	B-X
individuals	B-X
with	B-X
heterozygous	B-X
mutations	B-X
of	B-X
ATP1A2/A3	B-X
associated	B-X
with	B-X
severe	B-X
childhood	B-X
epilepsies	B-X
.	B-X
Early	B-X
lethal	B-X
hydrops	B-X
fetalis	B-X
,	B-X
arthrogryposis	B-X
,	B-X
microcephaly	B-X
,	B-X
and	B-X
polymicrogyria	B-X
have	B-X
been	B-X
associated	B-X
with	B-X
homozygous	B-X
truncating	B-X
mutations	B-X
in	B-X
ATP1A2	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
genetic	B-X
causes	B-X
of	B-X
developmental	B-X
and	B-X
epileptic	B-X
encephalopathies	B-X
variably	B-X
associated	B-X
with	B-X
malformations	B-X
of	B-X
cortical	B-X
development	B-X
in	B-X
a	B-X
large	B-X
cohort	B-X
and	B-X
identified	B-X
22	B-X
patients	B-X
with	B-X
de	B-X
novo	B-X
or	B-X
inherited	B-X
heterozygous	B-X
ATP1A2/A3	B-X
mutations	B-X
.	B-X
We	B-X
characterized	B-X
clinical	B-X
,	B-X
neuroimaging	B-X
and	B-X
neuropathological	B-X
findings	B-X
,	B-X
performed	B-X
in	B-X
silico	B-X
and	B-X
in	B-X
vitro	B-X
assays	B-X
of	B-X
the	B-X
mutations	B-X
'	B-X
effects	B-X
on	B-X
the	B-X
NKA-pump	B-X
function	B-X
,	B-X
and	B-X
studied	B-X
genotype-phenotype	B-X
correlations	B-X
.	B-X
Twenty-two	B-X
patients	B-X
harboured	B-X
19	B-X
distinct	B-X
heterozygous	B-X
mutations	B-X
of	B-X
ATP1A2	B-X
(	B-X
six	B-X
patients	B-X
,	B-X
five	B-X
mutations	B-X
)	B-X
and	B-X
ATP1A3	B-X
(	B-X
16	B-X
patients	B-X
,	B-X
14	B-X
mutations	B-X
,	B-X
including	B-X
a	B-X
mosaic	B-X
individual	B-X
)	B-X
.	B-X
In	B-X
silico	B-X
evaluation	B-X
predicted	B-X
all	B-X
mutations	B-X
to	B-X
be	B-X
detrimental	B-X
.	B-X
We	B-X
tested	B-X
14	B-X
mutations	B-X
in	B-X
transfected	B-X
COS-1	B-X
cells	B-X
and	B-X
demonstrated	B-X
impaired	B-X
NKA-pump	B-X
activity	B-X
,	B-X
consistent	B-X
with	B-X
severe	B-X
loss	B-X
of	B-X
function	B-X
.	B-X
Genotype-phenotype	B-X
analysis	B-X
suggested	B-X
a	B-X
link	B-X
between	B-X
the	B-X
most	B-X
severe	B-X
phenotypes	B-X
and	B-X
lack	B-X
of	B-X
COS-1	B-X
cell	B-X
survival	B-X
,	B-X
and	B-X
also	B-X
revealed	B-X
a	B-X
wide	B-X
continuum	B-X
of	B-X
severity	B-X
distributed	B-X
across	B-X
mutations	B-X
that	B-X
variably	B-X
impair	B-X
NKA-pump	B-X
activity	B-X
.	B-X
We	B-X
performed	B-X
neuropathological	B-X
analysis	B-X
of	B-X
the	B-X
whole	B-X
brain	B-X
in	B-X
two	B-X
individuals	B-X
with	B-X
polymicrogyria	B-X
respectively	B-X
related	B-X
to	B-X
a	B-X
heterozygous	B-X
ATP1A3	B-X
mutation	B-X
and	B-X
a	B-X
homozygous	B-X
ATP1A2	B-X
mutation	B-X
and	B-X
found	B-X
close	B-X
similarities	B-X
with	B-X
findings	B-X
suggesting	B-X
a	B-X
mainly	B-X
neural	B-X
pathogenesis	B-X
,	B-X
compounded	B-X
by	B-X
vascular	B-X
and	B-X
leptomeningeal	B-X
abnormalities	B-X
.	B-X
Combining	B-X
our	B-X
report	B-X
with	B-X
other	B-X
studies	B-X
,	B-X
we	B-X
estimate	B-X
that	B-X
â¼5	B-X
%	B-X
of	B-X
mutations	B-X
in	B-X
ATP1A2	B-X
and	B-X
12	B-X
%	B-X
in	B-X
ATP1A3	B-X
can	B-X
be	B-X
associated	B-X
with	B-X
the	B-X
severe	B-X
and	B-X
novel	B-X
phenotypes	B-X
that	B-X
we	B-X
describe	B-X
here	B-X
.	B-X
Notably	B-X
,	B-X
a	B-X
few	B-X
of	B-X
these	B-X
mutations	B-X
were	B-X
associated	B-X
with	B-X
more	B-X
than	B-X
one	B-X
phenotype	B-X
.	B-X
These	B-X
findings	B-X
assign	B-X
novel	B-X
,	B-X
'profound	B-X
'	B-X
and	B-X
early	B-X
lethal	B-X
phenotypes	B-X
of	B-X
developmental	B-X
and	B-X
epileptic	B-X
encephalopathies	B-X
and	B-X
polymicrogyria	B-X
to	B-X
the	B-X
phenotypic	B-X
spectrum	B-X
associated	B-X
with	B-X
heterozygous	B-X
ATP1A2/A3	B-X
mutations	B-X
and	B-X
indicate	B-X
that	B-X
severely	B-X
impaired	B-X
NKA	B-X
pump	B-X
function	B-X
can	B-X
disrupt	B-X
brain	B-X
morphogenesis	B-X
.	B-X

Analyzing	O
our	O
material	O
and	O
this	O
cohort	O
[	O
26	O
]	O
together	O
,	O
(	O
n	O
=	O
160	O
)	O
,	O
CHEK2	O
mutations	O
(	O
n	O
=	O
5	O
in	O
total	O
)	O
predicted	O
for	O
resistance	O
to	O
doxorubicin	O
and	O
epirubicin	O
therapy	O
(	O
p	O
=	O
0	O
.	O
0123	O
)	O
.	O

Even	O
though	O
,	O
excluding	O
patient	B-Species
Epi203	O
(	O
harboring	O
TP53	O
Arg175His	O
and	O
Arg95Ter	O
CHEK2	O
mutation	O
)	O
as	O
well	O
as	O
other	O
patients	B-Species
harboring	O
TP53	O
L2	O
/	O
L3	O
mutations	O
(	O
n	O
=	O
129	O
)	O
,	O
CHEK2	O
mutations	O
(	O
n	O
=	O
4	O
in	O
total	O
)	O
predicted	O
for	O
resistance	O
to	O
doxorubicin	O
and	O
epirubicin	O
therapy	O
(	O
p	O
=	O
0	O
.	O
030	O
)	O
.	O

TP53	O
and	O
CHEK2	O
Mutations	O
Combined	O
and	O
Response	O
to	O
Therapy	O
<EOS>	B-X
Specifically	B-X
,	B-X
MMS22L	B-X
deletion	B-X
,	B-X
frequently	B-X
observed	B-X
(	B-X
up	B-X
to	B-X
14	B-X
%	B-X
)	B-X
in	B-X
prostate	B-X
cancer	B-X
,	B-X
renders	B-X
cells	B-X
hypersensitive	B-X
to	B-X
PARP	B-X
inhibitors	B-X
by	B-X
disrupting	B-X
RAD51	B-X
loading	B-X
required	B-X
for	B-X
homologous	B-X
recombination	B-X
repair	B-X
,	B-X
although	B-X
this	B-X
response	B-X
is	B-X
TP53-dependent	B-X
.	B-X
Unexpectedly	B-X
,	B-X
loss	B-X
of	B-X
CHEK2	B-X
confers	B-X
resistance	B-X
rather	B-X
than	B-X
sensitivity	B-X
to	B-X
PARP	B-X
inhibition	B-X
through	B-X
increased	B-X
expression	B-X
of	B-X
BRCA2	B-X
,	B-X
a	B-X
target	B-X
of	B-X
CHEK2-TP53-E2F7-mediated	B-X
transcriptional	B-X
repression	B-X
.	B-X
Combined	B-X
PARP	B-X
and	B-X
ATR	B-X
inhibition	B-X
overcomes	B-X
PARP	B-X
inhibitor	B-X
resistance	B-X
caused	B-X
by	B-X
CHEK2	B-X
loss	B-X
.	B-X
While	B-X
we	B-X
previously	B-X
found	B-X
TP53	B-X
mutations	B-X
in	B-X
the	B-X
L2/L3	B-X
domains	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
drug	B-X
resistance	B-X
,	B-X
some	B-X
tumors	B-X
harboring	B-X
wild-type	B-X
TP53	B-X
were	B-X
also	B-X
therapy	B-X
resistant	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
;	B-X
1	B-X
)	B-X
To	B-X
explore	B-X
alterations	B-X
in	B-X
the	B-X
TP53	B-X
gene	B-X
with	B-X
respect	B-X
to	B-X
resistance	B-X
to	B-X
a	B-X
regular	B-X
dose	B-X
epirubicin	B-X
regimen	B-X
(	B-X
90	B-X
mg/m	B-X
(	B-X
2	B-X
)	B-X
every	B-X
3	B-X
week	B-X
)	B-X
in	B-X
patients	B-X
with	B-X
primary	B-X
,	B-X
locally	B-X
advanced	B-X
breast	B-X
cancer	B-X
;	B-X
2	B-X
)	B-X
Identify	B-X
critical	B-X
mechanisms	B-X
activating	B-X
p53	B-X
in	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
in	B-X
breast	B-X
cancer	B-X
;	B-X
3	B-X
)	B-X
Evaluate	B-X
in	B-X
vitro	B-X
function	B-X
of	B-X
Chk2	B-X
and	B-X
p14	B-X
proteins	B-X
corresponding	B-X
to	B-X
identified	B-X
mutations	B-X
in	B-X
the	B-X
CHEK2	B-X
and	B-X
p14	B-X
(	B-X
(	B-X
ARF	B-X
)	B-X
)	B-X
genes	B-X
;	B-X
and	B-X
4	B-X
)	B-X
Explore	B-X
potential	B-X
CHEK2	B-X
or	B-X
p14	B-X
(	B-X
(	B-X
ARF	B-X
)	B-X
)	B-X
germline	B-X
mutations	B-X
with	B-X
respect	B-X
to	B-X
family	B-X
cancer	B-X
incidence	B-X
.	B-X

Assuming	O
that	O
TP53	O
and	O
CHEK2	O
mutations	O
may	O
substitute	O
for	O
each	O
other	O
,	O
we	O
analyzed	O
for	O
the	O
predictive	O
effect	O
of	O
mutations	O
in	O
both	O
genes	O
.	O

The	O
occurrence	O
of	O
a	O
mutation	O
affecting	O
either	O
CHEK2	O
or	O
TP53	O
strongly	O
predicted	O
therapy	O
resistance	O
(	O
p	O
=	O
0	O
.	O
0101	O
;	O
Fisher	O
exact	O
test	O
)	O
.	O
<EOS>	B-X
Clonal	B-X
hematopoiesis	B-X
(	B-X
CH	B-X
)	B-X
,	B-X
the	B-X
clonal	B-X
expansion	B-X
of	B-X
a	B-X
blood	B-X
stem	B-X
cell	B-X
and	B-X
its	B-X
progeny	B-X
driven	B-X
by	B-X
somatic	B-X
driver	B-X
mutations	B-X
,	B-X
affects	B-X
over	B-X
a	B-X
third	B-X
of	B-X
people	B-X
,	B-X
yet	B-X
remains	B-X
poorly	B-X
understood	B-X
.	B-X
Here	B-X
we	B-X
analyze	B-X
genetic	B-X
data	B-X
from	B-X
200,453	B-X
UK	B-X
Biobank	B-X
participants	B-X
to	B-X
map	B-X
the	B-X
landscape	B-X
of	B-X
inherited	B-X
predisposition	B-X
to	B-X
CH	B-X
,	B-X
increasing	B-X
the	B-X
number	B-X
of	B-X
germline	B-X
associations	B-X
with	B-X
CH	B-X
in	B-X
European-ancestry	B-X
populations	B-X
from	B-X
4	B-X
to	B-X
14	B-X
.	B-X
Genes	B-X
at	B-X
new	B-X
loci	B-X
implicate	B-X
DNA	B-X
damage	B-X
repair	B-X
(	B-X
PARP1	B-X
,	B-X
ATM	B-X
,	B-X
CHEK2	B-X
)	B-X
,	B-X
hematopoietic	B-X
stem	B-X
cell	B-X
migration/homing	B-X
(	B-X
CD164	B-X
)	B-X
and	B-X
myeloid	B-X
oncogenesis	B-X
(	B-X
SETBP1	B-X
)	B-X
.	B-X
Several	B-X
associations	B-X
were	B-X
CH-subtype-specific	B-X
including	B-X
variants	B-X
at	B-X
TCL1A	B-X
and	B-X
CD164	B-X
that	B-X
had	B-X
opposite	B-X
associations	B-X
with	B-X
DNMT3A-	B-X
versus	B-X
TET2-mutant	B-X
CH	B-X
,	B-X
the	B-X
two	B-X
most	B-X
common	B-X
CH	B-X
subtypes	B-X
,	B-X
proposing	B-X
key	B-X
roles	B-X
for	B-X
these	B-X
two	B-X
loci	B-X
in	B-X
CH	B-X
development	B-X
.	B-X
Mendelian	B-X
randomization	B-X
analyses	B-X
showed	B-X
that	B-X
smoking	B-X
and	B-X
longer	B-X
leukocyte	B-X
telomere	B-X
length	B-X
are	B-X
causal	B-X
risk	B-X
factors	B-X
for	B-X
CH	B-X
and	B-X
that	B-X
genetic	B-X
predisposition	B-X
to	B-X
CH	B-X
increases	B-X
risks	B-X
of	B-X
myeloproliferative	B-X
neoplasia	B-X
,	B-X
nonhematological	B-X
malignancies	B-X
,	B-X
atrial	B-X
fibrillation	B-X
and	B-X
blood	B-X
epigenetic	B-X
ageing	B-X
.	B-X

When	O
tumors	O
harboring	O
TP53	O
-	O
L2	O
/	O
L3	O
mutations	O
and	O
CHEK2	O
mutations	O
were	O
compared	O
with	O
those	O
wild	O
-	O
type	O
or	O
TP53	O
mutations	O
outside	O
the	O
L2	O
/	O
L3	O
domain	O
,	O
the	O
correlation	O
was	O
further	O
strengthened	O
(	O
p	O
=	O
0	O
.	O
0032	O
;	O
Fisher	O
exact	O
test	O
)	O
.	O

The	O
significance	O
was	O
preserved	O
when	O
comparing	O
patients	B-Species
with	O
a	O
PD	O
to	O
objective	O
responders	O
(	O
CR	O
and	O
PR	O
)	O
excluding	O
patients	B-Species
with	O
stable	O
disease	O
(	O
SD	O
)	O
from	O
the	O
statistical	O
analysis	O
(	O
Table	O
4	O
)	O
.	O

p14	O
(	O
ARF	O
)	O
Mutations	O
and	O
Promoter	O
Methylations	O
<EOS>	B-X
In	B-X
this	B-X
article	B-X
,	B-X
we	B-X
report	B-X
the	B-X
DNA	B-X
methylation	B-X
pattern	B-X
in	B-X
CDKN2A	B-X
(	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
/p16	B-X
(	B-X
INK4a	B-X
)	B-X
)	B-X
and	B-X
in	B-X
ATM	B-X
gene	B-X
promoters	B-X
from	B-X
62	B-X
impalpable	B-X
lesions	B-X
,	B-X
39	B-X
peripheral	B-X
blood	B-X
samples	B-X
,	B-X
and	B-X
39	B-X
saliva	B-X
samples	B-X
,	B-X
assessed	B-X
by	B-X
methylation-specific	B-X
polymerase	B-X
chain	B-X
reaction	B-X
method	B-X
.	B-X
ATM	B-X
showed	B-X
the	B-X
greatest	B-X
percentage	B-X
of	B-X
methylation	B-X
in	B-X
DNA	B-X
from	B-X
lesions	B-X
(	B-X
benign	B-X
and	B-X
malignant	B-X
)	B-X
,	B-X
blood	B-X
(	B-X
even	B-X
with	B-X
p16	B-X
(	B-X
INK4a	B-X
)	B-X
)	B-X
,	B-X
and	B-X
saliva	B-X
,	B-X
followed	B-X
by	B-X
p16	B-X
(	B-X
INK4a	B-X
)	B-X
and	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
.	B-X
Among	B-X
the	B-X
malignant	B-X
cases	B-X
,	B-X
ATM	B-X
promoter	B-X
was	B-X
the	B-X
most	B-X
hypermethylated	B-X
in	B-X
lesion	B-X
DNA	B-X
and	B-X
in	B-X
blood	B-X
and	B-X
saliva	B-X
DNAs	B-X
,	B-X
and	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
,	B-X
the	B-X
least	B-X
.	B-X
For	B-X
this	B-X
purpose	B-X
,	B-X
we	B-X
analyzed	B-X
27	B-X
papillomatous	B-X
lesions	B-X
from	B-X
patients	B-X
with	B-X
RRP	B-X
to	B-X
evaluate	B-X
somatic	B-X
mutations	B-X
and	B-X
methylation	B-X
status	B-X
in	B-X
CDKN2A	B-X
(	B-X
p14	B-X

Neither	O
mutations	O
nor	O
polymorphisms	O
in	O
the	O
coding	O
region	O
of	O
p14	O
(	O
ARF	O
)	O
were	O
observed	O
among	O
the	O
107	O
patients	B-Species
analyzed	O
.	O

Likewise	O
,	O
no	O
promoter	O
methylations	O
were	O
detected	O
.	O
<EOS>	B-X
Likewise	B-X
,	B-X
epigenetic	B-X
aberrations	B-X
have	B-X
ability	B-X
to	B-X
regulate	B-X
cancer	B-X
pathogenesis	B-X
and	B-X
progression	B-X
.	B-X
Recent	B-X
research	B-X
suggested	B-X
that	B-X
methylation	B-X
has	B-X
been	B-X
detected	B-X
already	B-X
at	B-X
precancerous	B-X
stages	B-X
,	B-X
which	B-X
methylation	B-X
markers	B-X
may	B-X
have	B-X
significant	B-X
value	B-X
in	B-X
cervical	B-X
cancer	B-X
screening	B-X
.	B-X
No	B-X
methylation	B-X
differences	B-X
were	B-X
detected	B-X
when	B-X
comparing	B-X
PB	B-X
T	B-X
derived	B-X
from	B-X
normal	B-X
to	B-X
IBD	B-X
patients	B-X
.	B-X
In	B-X
fact	B-X
,	B-X
IFNG	B-X
DNA	B-X
promoter	B-X
methylation	B-X
levels	B-X
functionally	B-X
correlate	B-X
with	B-X
IFNG	B-X
mRNA	B-X
expression	B-X
in	B-X
unstimulated	B-X
T	B-X
cells	B-X
,	B-X
using	B-X
quantitative	B-X
real-time	B-X
PCR	B-X
.	B-X
A	B-X
5	B-X
%	B-X
decrease	B-X
in	B-X
promoter	B-X
methylation	B-X
status	B-X
is	B-X
associated	B-X
with	B-X
nearly	B-X
a	B-X
3-fold	B-X
increase	B-X
in	B-X
IFNG	B-X
expression	B-X
.	B-X
Likewise	B-X
,	B-X
methylation	B-X
of	B-X
the	B-X
single	B-X
-54	B-X
bp	B-X
IFNG	B-X
SnaB1	B-X
site	B-X
strongly	B-X
inhibited	B-X
IFNG	B-X
promoter	B-X
expression	B-X
.	B-X

Influence	O
of	O
CHEK2	O
and	O
TP53	O
Mutation	O
Status	O
on	O
Relapse	O
-	O
Free	O
Survival	O

Because	O
of	O
the	O
limited	O
time	O
of	O
the	O
follow	O
-	O
up	O
,	O
no	O
formal	O
statistical	O
assessment	O
of	O
overall	O
survival	O
was	O
performed	O
.	O

Details	O
regarding	O
outcome	O
for	O
individual	O
patients	B-Species
with	O
mutations	O
are	O
described	O
in	O
Table	O
2	O
and	O
3	O
to	O
make	O
these	O
data	O
available	O
to	O
the	O
reader	O
.	O

Relapse	O
-	O
free	O
survival	O
is	O
depicted	O
in	O
(	O
Figure	O
1	O
)	O
.	O

Figure	O
1A	O
shows	O
relapse	O
-	O
free	O
survival	O
for	O
the	O
patients	B-Species
with	O
TP53	O
and	O
CHEK2	O
mutations	O
(	O
all	O
mutations	O
found	O
)	O
compared	O
to	O
patients	B-Species
without	O
any	O
TP53	O
or	O
CHEK2	O
mutations	O
,	O
no	O
difference	O
in	O
relapse	O
-	O
free	O
survival	O
was	O
observed	O
.	O

Similar	O
,	O
no	O
difference	O
was	O
seen	O
when	O
grouping	O
TP53	O
mutations	O
outside	O
L2	O
/	O
L3	O
and	O
CHEK2	O
mutation	O
not	O
affecting	O
kinase	O
function	O
(	O
Ile364Thr	O
)	O
as	O
wild	O
-	O
type	O
(	O
Figure	O
1B	O
)	O
.	O

Grouping	O
tumors	O
harboring	O
a	O
mutation	O
in	O
L2	O
/	O
L3	O
together	O
with	O
CHEK2	O
mutations	O
affecting	O
kinase	O
domain	O
(	O
Arg95Ter	O
)	O
in	O
one	O
group	O
,	O
mutations	O
outside	O
TP53	O
L2	O
/	O
L3	O
and	O
Ile364Thr	O
as	O
one	O
group	O
and	O
tumors	O
without	O
any	O
found	O
mutations	O
in	O
TP53	O
and	O
CHEK2	O
separately	O
,	O
again	O
no	O
noticeably	O
difference	O
in	O
relapse	O
-	O
free	O
survival	O
were	O
seen	O
(	O
Figure	O
1C	O
)	O
.	O

Notably	O
,	O
in	O
addition	O
to	O
a	O
short	O
median	O
follow	O
-	O
up	O
time	O
,	O
a	O
total	O
of	O
35	O
patients	B-Species
with	O
a	O
sub	O
-	O
optimal	O
response	O
to	O
epirubicin	O
received	O
subsequent	O
treatment	O
with	O
paclitaxel	O
,	O
which	O
may	O
have	O
influenced	O
the	O
outcome	O
.	O

CHEK2	O
Mutant	O
'	O
s	O
Capability	O
to	O
Form	O
Dimers	O

To	O
investigate	O
whether	O
the	O
identified	O
CHEK2	O
mutations	O
affect	O
the	O
ability	O
of	O
the	O
Chk2	O
protein	O
to	O
form	O
dimers	O
,	O
co	O
-	O
transfection	O
and	O
immunopresipitation	O
of	O
V5	O
-	O
tagged	O
mutants	O
and	O
Xpress	O
-	O
tagged	O
wild	O
-	O
type	O
Chk2	O
were	O
performed	O
using	O
CHEK2	O
low	O
-	O
expressing	O
U	O
-	O
2	O
-	O
OS	O
cells	O
.	O

As	O
we	O
identified	O
the	O
previously	O
characterized	O
CHEK2	O
germline	O
mutants	O
variants	O
Arg117His	O
(	O
n	O
=	O
2	O
and	O
Ile157Thr	O
(	O
n	O
=	O
1	O
)	O
among	O
patients	B-Species
allocated	O
to	O
primary	O
treatment	O
with	O
paclitaxel	O
in	O
our	O
ongoing	O
study	O
,	O
these	O
mutants	O
were	O
evaluated	O
together	O
with	O
Arg95Ter	O
and	O
Ile364Thr	O
.	O

The	O
results	O
presented	O
in	O
Figure	O
2	O
show	O
that	O
all	O
Chk2	O
variants	O
carrying	O
a	O
point	O
mutation	O
were	O
able	O
to	O
form	O
dimers	O
with	O
wild	O
-	O
type	O
Chk2	O
,	O
whereas	O
the	O
Arg95Ter	O
variant	O
was	O
not	O
.	O

Kinase	O
Activity	O
of	O
CHEK2	O
Mutants	O
<EOS>	B-X
The	B-X
checkpoint	B-X
kinase	B-X
2	B-X
(	B-X
CHEK2	B-X
,	B-X
also	B-X
known	B-X
as	B-X
CHK2	B-X
)	B-X
is	B-X
a	B-X
tumor	B-X
suppressor	B-X
that	B-X
participates	B-X
in	B-X
the	B-X
DNA	B-X
damage-signaling	B-X
pathway	B-X
.	B-X
Previously	B-X
,	B-X
we	B-X
reported	B-X
germline	B-X
CHEK2	B-X
mutations	B-X
in	B-X
patients	B-X
with	B-X
prostate	B-X
cancer	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
identified	B-X
two	B-X
novel	B-X
somatic	B-X
CHEK2	B-X
mutations	B-X
,	B-X
c.349A	B-X
>	B-X
G	B-X
(	B-X
p.R117G	B-X
)	B-X
and	B-X
c.967A	B-X
>	B-X
C	B-X
(	B-X
p.E321K	B-X
)	B-X
,	B-X
in	B-X
prostate	B-X
tumor	B-X
specimens	B-X
and	B-X
investigated	B-X
the	B-X
functions	B-X
of	B-X
these	B-X
mutants	B-X
in	B-X
vivo	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
that	B-X
most	B-X
of	B-X
the	B-X
germline	B-X
CHEK2	B-X
mutations	B-X
and	B-X
one	B-X
somatic	B-X
mutation	B-X
(	B-X
p.R117G	B-X
)	B-X
within	B-X
FHA	B-X
domain	B-X
have	B-X
modestly	B-X
reduced	B-X
CHEK2	B-X
kinase	B-X
activity	B-X
in	B-X
comparison	B-X
with	B-X
wild-type	B-X
CHEK2	B-X
while	B-X
the	B-X
other	B-X
somatic	B-X
mutation	B-X
(	B-X
p.E321K	B-X
)	B-X
within	B-X
the	B-X
kinase	B-X
domain	B-X
of	B-X
CHEK2	B-X
totally	B-X
abolished	B-X
CHEK2	B-X
kinase	B-X
activity	B-X
.	B-X
Given	B-X
that	B-X
several	B-X
clinical	B-X
CHEK2	B-X
mutations	B-X
reside	B-X
in	B-X
the	B-X
Forkhead-associated	B-X
(	B-X
FHA	B-X
)	B-X
domain	B-X
,	B-X
we	B-X
further	B-X
generated	B-X
a	B-X
series	B-X
of	B-X
missense	B-X
mutations	B-X
within	B-X
this	B-X
domain	B-X
and	B-X
demonstrated	B-X
the	B-X
requirement	B-X
of	B-X
an	B-X
intact	B-X
FHA	B-X
domain	B-X
for	B-X
the	B-X
full	B-X
activation	B-X
of	B-X
CHEK2	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
provide	B-X
evidence	B-X
that	B-X
both	B-X
germline	B-X
and	B-X
somatic	B-X
CHEK2	B-X
mutations	B-X
identified	B-X
in	B-X
prostate	B-X
cancer	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
development	B-X
of	B-X
prostate	B-X
cancer	B-X
through	B-X
the	B-X
reduction	B-X
of	B-X
CHEK2	B-X
activation	B-X
in	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
and/or	B-X
oncogenic	B-X
stress	B-X
.	B-X

To	O
investigate	O
whether	O
the	O
identified	O
CHEK2	O
mutants	O
retained	O
the	O
wild	O
-	O
type	O
kinase	O
activity	O
,	O
an	O
in	O
vitro	O
Chk2	O
kinase	O
assay	O
with	O
respect	O
to	O
Chk2	O
autophosphorylation	O
and	O
Cdc25	O
substrate	O
phosphorylation	O
was	O
performed	O
.	O

The	O
U	O
-	O
2	O
-	O
OS	O
cells	O
were	O
preferred	O
for	O
this	O
assay	O
because	O
they	O
were	O
previously	O
found	O
to	O
express	O
only	O
low	O
levels	O
of	O
endogenous	O
Chk2	O
[	O
44	O
]	O
.	O

This	O
was	O
confirmed	O
by	O
us	O
using	O
an	O
antibody	O
recognizing	O
endogenous	O
protein	O
(	O
data	O
not	O
shown	O
)	O
.	O
<EOS>	B-X
The	B-X
pioneer	B-X
characterization	B-X
of	B-X
the	B-X
BPPs	B-X
precursor	B-X
from	B-X
the	B-X
snake	B-X
venom	B-X
glands	B-X
by	B-X
our	B-X
group	B-X
showed	B-X
for	B-X
the	B-X
first	B-X
time	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
C-type	B-X
natriuretic	B-X
peptide	B-X
(	B-X
CNP	B-X
)	B-X
in	B-X
this	B-X
same	B-X
viper	B-X
precursor	B-X
protein	B-X
.	B-X
The	B-X
confirmation	B-X
of	B-X
the	B-X
BPP/CNP	B-X
expression	B-X
in	B-X
snake	B-X
brain	B-X
regions	B-X
correlated	B-X
with	B-X
neuroendocrine	B-X
functions	B-X
stimulated	B-X
us	B-X
to	B-X
pursue	B-X
the	B-X
physiological	B-X
correlates	B-X
of	B-X
these	B-X
vasoactive	B-X
peptides	B-X
in	B-X
mammals	B-X
.	B-X
Notably	B-X
,	B-X
several	B-X
snake	B-X
toxins	B-X
were	B-X
shown	B-X
to	B-X
have	B-X
endogenous	B-X
physiological	B-X
correlates	B-X
in	B-X
mammals	B-X
.	B-X
In	B-X
the	B-X
present	B-X
work	B-X
,	B-X
we	B-X
expressed	B-X
in	B-X
bacteria	B-X
the	B-X
BPPs	B-X
domain	B-X
of	B-X
the	B-X
snake	B-X
venom	B-X
gland	B-X
precursor	B-X
protein	B-X
,	B-X
and	B-X
this	B-X
purified	B-X
recombinant	B-X
protein	B-X
was	B-X
used	B-X
to	B-X
raise	B-X
specific	B-X
polyclonal	B-X
anti-BPPs	B-X
antibodies	B-X
.	B-X
The	B-X
correspondent	B-X
single	B-X
protein	B-X
band	B-X
immune-recognized	B-X
in	B-X
adult	B-X
rat	B-X
brain	B-X
cytosol	B-X
was	B-X
isolated	B-X
by	B-X
2D-SDS/PAGE	B-X
and/or	B-X
HPLC	B-X
,	B-X
before	B-X
characterization	B-X
by	B-X
MS	B-X
fingerprint	B-X
analysis	B-X
,	B-X
which	B-X
identified	B-X
this	B-X
protein	B-X
as	B-X
superoxide	B-X
dismutase	B-X
(	B-X
SOD	B-X
,	B-X
EC	B-X
1.15.1.1	B-X
)	B-X
,	B-X
a	B-X
classically	B-X
known	B-X
enzyme	B-X
with	B-X
antioxidant	B-X
activity	B-X
and	B-X
important	B-X
roles	B-X
in	B-X
the	B-X
blood	B-X
pressure	B-X
modulation	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
data	B-X
suggest	B-X
that	B-X
SOD	B-X
protein	B-X
have	B-X
the	B-X
potential	B-X
to	B-X
be	B-X
a	B-X
source	B-X
for	B-X
putative	B-X
BPP-like	B-X
bioactive	B-X
peptides	B-X
,	B-X
which	B-X
once	B-X
released	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
blood	B-X
pressure	B-X
control	B-X
in	B-X
mammals	B-X
.	B-X

These	O
cells	O
have	O
previously	O
been	O
used	O
by	O
other	O
investigators	O
to	O
study	O
Chk2	O
kinase	O
activity	O
[	O
44	O
]	O
,	O
[	O
45	O
]	O
,	O
[	O
46	O
]	O
.	O

The	O
two	O
mutants	O
Arg117Gly	O
and	O
Ile157Thr	O
were	O
previously	O
tested	O
for	O
in	O
vitro	O
kinase	O
activity	O
[	O
47	O
]	O
,	O
but	O
were	O
both	O
included	O
here	O
,	O
together	O
with	O
wild	O
-	O
type	O
CHEK2	O
as	O
controls	O
.	O

Compared	O
to	O
wild	O
-	O
type	O
Chk2	O
,	O
the	O
Ile157Thr	O
mutant	O
retained	O
wild	O
-	O
type	O
kinase	O
activity	O
.	O

The	O
mutant	O
Ile364Thr	O
showed	O
partially	O
reduced	O
kinase	O
activity	O
both	O
in	O
term	O
of	O
Cdc25	O
-	O
phosphorylation	O
and	O
autophosphorylation	O
(	O
Figure	O
3	O
)	O
.	O

In	O
contrast	O
,	O
the	O
mutant	O
Arg117Gly	O
showed	O
strongly	O
reduced	O
kinase	O
activity	O
while	O
the	O
Arg95Ter	O
mutant	O
was	O
totally	O
devoid	O
of	O
any	O
Chk2	O
kinase	O
activity	O
.	O

The	O
activity	O
recorded	O
for	O
Ile157Thr	O
and	O
Arg117Gly	O
was	O
consistent	O
with	O
previously	O
reported	O
results	O
for	O
these	O
two	O
mutants	O
[	O
47	O
]	O
.	O

Notably	O
,	O
there	O
was	O
an	O
internal	O
consistency	O
with	O
respect	O
to	O
percentage	O
activity	O
reduction	O
comparing	O
individual	O
mutants	O
with	O
respect	O
to	O
autophosphorylation	O
and	O
phosphorylation	O
of	O
Cdc25	O
(	O
Figure	O
3	O
)	O
.	O

Since	O
enzymatically	O
active	O
Chk2	O
exists	O
as	O
dimers	O
,	O
it	O
was	O
important	O
to	O
determine	O
the	O
effect	O
of	O
Chk2	O
mutants	O
on	O
wild	O
-	O
type	O
/	O
mutant	O
heterodimer	O
kinase	O
activity	O
.	O

The	O
effect	O
on	O
Chk2	O
kinase	O
activities	O
(	O
Chk2	O
autophosphorylation	O
and	O
Cdc25	O
substrate	O
phosphorylation	O
)	O
of	O
the	O
individual	O
mutants	O
were	O
therefore	O
determined	O
after	O
co	O
-	O
transfection	O
with	O
wild	O
-	O
type	O
Chk2	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O

The	O
results	O
from	O
this	O
co	O
-	O
transfection	O
-	O
kinase	O
assay	O
(	O
Figure	O
4	O
)	O
were	O
similar	O
to	O
those	O
of	O
the	O
single	O
-	O
transfection	O
assay	O
(	O
Figure	O
3	O
)	O
except	O
in	O
the	O
case	O
of	O
the	O
Arg117Gly	O
mutant	O
,	O
which	O
expressed	O
a	O
substantial	O
kinase	O
activity	O
when	O
complexed	O
with	O
wild	O
-	O
type	O
Chk2	O
.	O

This	O
is	O
consistent	O
with	O
previous	O
data	O
indicating	O
that	O
the	O
Arg117Gly	O
mutant	O
has	O
neglectable	O
kinase	O
activity	O
itself	O
but	O
dimerizes	O
efficiently	O
to	O
Chk2	O
wild	O
-	O
type	O
without	O
strongly	O
affecting	O
the	O
wild	O
-	O
type	O
Chk2	O
activity	O
.	O

Hence	O
,	O
the	O
activity	O
detected	O
is	O
probably	O
caused	O
by	O
the	O
co	O
-	O
transfected	O
and	O
co	O
-	O
precipitated	O
wild	O
-	O
type	O
protein	O
.	O

To	O
rule	O
out	O
the	O
possibility	O
that	O
endogenously	O
expressed	O
wild	O
-	O
type	O
Chk2	O
contributed	O
to	O
observed	O
Arg117Gly	O
kinase	O
activity	O
shown	O
in	O
Figure	O
4	O
,	O
we	O
compared	O
the	O
Arg117Gly	O
variant	O
activity	O
in	O
the	O
presence	O
or	O
absence	O
of	O
co	O
-	O
transfected	O
wild	O
-	O
type	O
Chk2	O
to	O
the	O
activities	O
of	O
Arg95Ter	O
under	O
the	O
same	O
conditions	O
.	O

The	O
Arg95Ter	O
variant	O
does	O
not	O
form	O
dimers	O
with	O
wild	O
-	O
type	O
Chk2	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
reported	B-X
that	B-X
the	B-X
Arg95Ter	B-X
nonsense	B-X
variant	B-X
of	B-X
GPR151	B-X
,	B-X
an	B-X
orphan	B-X
G	B-X
protein-coupled	B-X
receptor	B-X
,	B-X
is	B-X
associated	B-X
with	B-X
reduced	B-X
BMI	B-X
and	B-X
reduced	B-X
risk	B-X
of	B-X
Type	B-X
2	B-X
Diabetes	B-X
(	B-X
T2D	B-X
)	B-X
.	B-X
Among	B-X
PGR	B-X
participants	B-X
,	B-X
we	B-X
identify	B-X
eleven	B-X
GPR151	B-X
putative	B-X
loss-of-function	B-X
(	B-X
plof	B-X
)	B-X
variants	B-X
,	B-X
three	B-X
of	B-X
which	B-X
are	B-X
present	B-X
at	B-X
homozygosity	B-X
(	B-X
Arg95Ter	B-X
,	B-X
Tyr99Ter	B-X
,	B-X
and	B-X
Phe175LeufsTer7	B-X
)	B-X
,	B-X
with	B-X
a	B-X
cumulative	B-X
allele	B-X
frequency	B-X
of	B-X
2.2	B-X
%	B-X
.	B-X
Features	B-X
include	B-X
striated	B-X
skin-pigmentation	B-X
,	B-X
ocular	B-X
and	B-X
skeletal	B-X
malformations	B-X
and	B-X
supernumerary	B-X
or	B-X
hypoplastic	B-X
nipples	B-X
.	B-X
Also	B-X
,	B-X
precise	B-X
descriptions	B-X
of	B-X
neurological	B-X
deficits	B-X
in	B-X
GS	B-X
are	B-X
rare	B-X
and	B-X
less	B-X
severe	B-X
phenotypes	B-X
might	B-X
not	B-X
only	B-X
be	B-X
caused	B-X
by	B-X
mosaicism	B-X
but	B-X
also	B-X
by	B-X
less	B-X
pathogenic	B-X
mutations	B-X
suggesting	B-X
the	B-X
need	B-X
of	B-X
a	B-X
molecular	B-X
genetics	B-X
and	B-X
functional	B-X
work-up	B-X
of	B-X
these	B-X
rare	B-X
variants	B-X
.	B-X

As	O
seen	O
in	O
Figure	O
5	O
,	O
Arg117Gly	O
,	O
which	O
forms	O
dimers	O
with	O
Chk2	O
wild	O
-	O
type	O
,	O
allows	O
increased	O
activity	O
when	O
co	O
-	O
transfected	O
with	O
wild	O
-	O
type	O
as	O
compared	O
to	O
the	O
corresponding	O
activity	O
for	O
the	O
Arg95Ter	O
mutant	O
.	O

The	O
fact	O
that	O
Arg117Gly	O
,	O
when	O
transfected	O
alone	O
,	O
displays	O
very	O
similar	O
activity	O
as	O
Arg95Ter	O
or	O
negative	O
control	O
(	O
background	O
levels	O
)	O
,	O
strongly	O
indicates	O
that	O
the	O
contribution	O
of	O
endogenous	O
Chk2	O
,	O
which	O
,	O
similarly	O
to	O
exogenously	O
expressed	O
wild	O
-	O
type	O
Chk2	O
co	O
-	O
precipitate	O
with	O
Arg117Gly	O
is	O
non	O
-	O
significant	O
.	O

Family	O
Cancer	O
Incidence	O
in	O
Relation	O
to	O
CHEK2	O
Germline	O
Mutations	O
<EOS>	B-X
Target	B-X
sequencing	B-X
was	B-X
designed	B-X
to	B-X
cover	B-X
27	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
ATM	B-X
,	B-X
APC	B-X
,	B-X
BARD1	B-X
,	B-X
BRCA1	B-X
,	B-X
BRCA2	B-X
,	B-X
BRIP1	B-X
,	B-X
CDH1	B-X
,	B-X
CHEK2	B-X
and	B-X
others	B-X
.	B-X
Cell-cycle-checkpoint	B-X
kinase	B-X
2	B-X
(	B-X
CHEK2	B-X
)	B-X
is	B-X
an	B-X
important	B-X
moderate-penetrance	B-X
breast	B-X
cancer	B-X
predisposition	B-X
gene	B-X
;	B-X
however	B-X
,	B-X
recurrent	B-X
CHEK2	B-X
mutations	B-X
found	B-X
in	B-X
Caucasian	B-X
women	B-X
are	B-X
very	B-X
rare	B-X
in	B-X
Chinese	B-X
population	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
mutation	B-X
spectrum	B-X
and	B-X
clinical	B-X
relevance	B-X
of	B-X
CHEK2	B-X
germline	B-X
mutations	B-X
in	B-X
Chinese	B-X
breast	B-X
cancer	B-X
patients	B-X
.	B-X
Results	B-X
of	B-X
our	B-X
study	B-X
support	B-X
a	B-X
central	B-X
role	B-X
of	B-X
PALB2	B-X
in	B-X
MBC	B-X
susceptibility	B-X
and	B-X
show	B-X
a	B-X
low	B-X
impact	B-X
of	B-X
CHEK2	B-X
on	B-X
MBC	B-X
predisposition	B-X
in	B-X
the	B-X
Italian	B-X
population	B-X
.	B-X

Following	O
an	O
initial	O
report	O
of	O
a	O
family	O
with	O
a	O
CHEK2	O
germline	O
mutation	O
expressing	O
an	O
increased	O
cancer	O
incidence	O
resembling	O
the	O
Li	O
-	O
Fraumeni	O
syndrome	O
[	O
24	O
]	O
,	O
recent	O
studies	O
have	O
revealed	O
the	O
more	O
common	O
CHEK2	O
mutations	O
to	O
be	O
associated	O
with	O
a	O
moderately	O
increased	O
risk	O
of	O
breast	O
and	O
colorectal	O
cancers	O
.	O

We	O
hypothesized	O
that	O
CHEK2	O
mutations	O
having	O
a	O
detrimental	O
effect	O
on	O
drug	O
sensitivity	O
could	O
be	O
associated	O
with	O
a	O
more	O
aggressive	O
,	O
Li	O
-	O
Fraumeni	O
or	O
a	O
Li	O
-	O
Fraumeni	O
-	O
like	O
(	O
LFL	O
)	O
cancer	O
syndrome	O
[	O
48	O
]	O
.	O
<EOS>	B-X
BACKGROUND	B-X
Li-Fraumeni	B-X
syndrome	B-X
(	B-X
LFS	B-X
)	B-X
is	B-X
a	B-X
rare	B-X
autosomal	B-X
dominant	B-X
cancer	B-X
predisposition	B-X
syndrome	B-X
.	B-X
Most	B-X
families	B-X
fulfilling	B-X
the	B-X
classical	B-X
diagnostic	B-X
criteria	B-X
harbour	B-X
TP53	B-X
germline	B-X
mutations	B-X
.	B-X
However	B-X
,	B-X
TP53	B-X
germline	B-X
mutations	B-X
may	B-X
also	B-X
occur	B-X
in	B-X
less	B-X
obvious	B-X
phenotypes	B-X
.	B-X
As	B-X
a	B-X
result	B-X
,	B-X
different	B-X
criteria	B-X
are	B-X
in	B-X
use	B-X
to	B-X
decide	B-X
which	B-X
patients	B-X
qualify	B-X
for	B-X
TP53	B-X
mutation	B-X
analysis	B-X
,	B-X
including	B-X
the	B-X
LFS	B-X
,	B-X
Li-Fraumeni-like	B-X
(	B-X
LFL	B-X
)	B-X
and	B-X
Chompret	B-X
criteria	B-X
.	B-X
We	B-X
investigated	B-X
which	B-X
criteria	B-X
for	B-X
TP53	B-X
mutation	B-X
analysis	B-X
resulted	B-X
in	B-X
the	B-X
highest	B-X
mutation	B-X
detection	B-X
rate	B-X
and	B-X
sensitivity	B-X
in	B-X
Dutch	B-X
families	B-X
.	B-X
When	B-X
the	B-X
Chompret	B-X
criteria	B-X
were	B-X
used	B-X
22/24	B-X
mutations	B-X
were	B-X
detected	B-X
(	B-X
sensitivity	B-X
92	B-X
%	B-X
,	B-X
mutation	B-X
detection	B-X
rate	B-X
21	B-X
%	B-X
)	B-X
.	B-X
In	B-X
LFS	B-X
and	B-X
LFL	B-X
families	B-X
18/24	B-X
mutations	B-X
were	B-X
found	B-X
(	B-X
sensitivity	B-X
75	B-X
%	B-X
)	B-X
.	B-X
The	B-X
two	B-X
mutations	B-X
detected	B-X
outside	B-X
the	B-X
'Chompret	B-X
group	B-X
'	B-X
were	B-X
found	B-X
in	B-X
a	B-X
child	B-X
with	B-X
rhabdomyosarcoma	B-X
and	B-X
a	B-X
young	B-X
woman	B-X
with	B-X
breast	B-X
cancer	B-X
.	B-X
In	B-X
the	B-X
mutation	B-X
carriers	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
the	B-X
classical	B-X
LFS	B-X
tumour	B-X
types	B-X
,	B-X
colon	B-X
and	B-X
pancreatic	B-X
cancer	B-X
were	B-X
also	B-X
found	B-X
significantly	B-X
more	B-X
often	B-X
than	B-X
in	B-X
the	B-X
general	B-X
population	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
TP53	B-X
mutation	B-X
testing	B-X
can	B-X
be	B-X
considered	B-X
in	B-X
the	B-X
event	B-X
of	B-X
childhood	B-X
sarcoma	B-X
and	B-X
breast	B-X
cancer	B-X
before	B-X
30	B-X
years	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
the	B-X
risk	B-X
for	B-X
established	B-X
LFS	B-X
tumour	B-X
types	B-X
,	B-X
TP53-positive	B-X
individuals	B-X
may	B-X
also	B-X
have	B-X
an	B-X
elevated	B-X
risk	B-X
for	B-X
pancreatic	B-X
and	B-X
colon	B-X
cancer	B-X
.	B-X

Except	O
from	O
the	O
patient	B-Species
harboring	O
the	O
Ile364Thr	O
mutation	O
who	O
did	O
not	O
have	O
any	O
known	O
congestion	O
of	O
cancer	O
disease	O
in	O
the	O
family	O
,	O
a	O
detailed	O
assessment	O
of	O
family	O
cancer	O
history	O
was	O
performed	O
for	O
each	O
patient	B-Species
harboring	O
a	O
germline	O
CHEK2	O
mutation	O
.	O
<EOS>	B-X
Diffuse	B-X
midline	B-X
glioma	B-X
(	B-X
DMG	B-X
)	B-X
which	B-X
occurs	B-X
in	B-X
midline	B-X
structures	B-X
and	B-X
characterized	B-X
by	B-X
harboring	B-X
K27M	B-X
mutation	B-X
in	B-X
genes	B-X
encoding	B-X
the	B-X
histone	B-X
3	B-X
protein	B-X
is	B-X
classified	B-X
as	B-X
World	B-X
Health	B-X
Organization	B-X
(	B-X
WHO	B-X
)	B-X
grade	B-X
IV	B-X
regardless	B-X
of	B-X
histological	B-X
findings	B-X
and	B-X
has	B-X
a	B-X
poor	B-X
prognosis	B-X
.	B-X
To	B-X
clarify	B-X
the	B-X
phenotype-genotype	B-X
relation	B-X
associated	B-X
with	B-X
the	B-X
A3243G	B-X
mitochondrial	B-X
DNA	B-X
mutation	B-X
.	B-X
Without	B-X
treatment	B-X
,	B-X
familial	B-X
adenomatous	B-X
polyposis	B-X
(	B-X
FAP	B-X
)	B-X
patients	B-X
will	B-X
inevitably	B-X
develop	B-X
colorectal	B-X
cancer	B-X
(	B-X
CRC	B-X
)	B-X
during	B-X
lifetime	B-X
.	B-X
Yet	B-X
,	B-X
surgical	B-X
trauma	B-X
is	B-X
a	B-X
high	B-X
risk	B-X
of	B-X
desmoid	B-X
tumor	B-X
(	B-X
DT	B-X
)	B-X
,	B-X
one	B-X
of	B-X
the	B-X
main	B-X
causes	B-X
of	B-X
death	B-X
in	B-X
FAP	B-X
patients	B-X
.	B-X
So	B-X
far	B-X
,	B-X
the	B-X
timing	B-X
for	B-X
colectomy	B-X
is	B-X
primarily	B-X
based	B-X
on	B-X
the	B-X
clinician	B-X
's	B-X
experience	B-X
and	B-X
the	B-X
patient	B-X
's	B-X
preference	B-X
;	B-X
most	B-X
patients	B-X
undergo	B-X
surgery	B-X
at	B-X
mid-20	B-X
's	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
germline	B-X
mutation	B-X
distribution	B-X
in	B-X
35	B-X
FAP	B-X
patients	B-X
from	B-X
different	B-X
families	B-X
,	B-X
16	B-X
of	B-X
them	B-X
diagnosed	B-X
with	B-X
DTs	B-X
.	B-X
Capture-based	B-X
targeted	B-X
sequencing	B-X
using	B-X
a	B-X
panel	B-X
of	B-X
520	B-X
genes	B-X
was	B-X
performed	B-X
on	B-X
tumor	B-X
tissue	B-X
and	B-X
paired	B-X
normal	B-X
mucosa	B-X
or	B-X
white	B-X
blood	B-X
cells	B-X
from	B-X
18	B-X
FAP	B-X
probands	B-X
who	B-X
were	B-X
initially	B-X
diagnosed	B-X
with	B-X
CRC	B-X
.	B-X
Of	B-X
all	B-X
35	B-X
FAP	B-X
patients	B-X
,	B-X
30	B-X
(	B-X
85.7	B-X
%	B-X
)	B-X
of	B-X
them	B-X
harbored	B-X
germline	B-X

The	O
family	O
cancer	O
pedigrees	O
are	O
depicted	O
in	O
Figure	O
6	O
.	O

While	O
patients	B-Species
harboring	O
CHEK2	O
germline	O
mutations	O
revealed	O
different	O
types	O
of	O
cancers	O
(	O
mainly	O
breast	O
and	O
tumors	O
of	O
the	O
gastrointestinal	O
area	O
)	O
in	O
their	O
family	O
,	O
surprisingly	O
,	O
no	O
distinct	O
pattern	O
discriminating	O
families	O
harboring	O
the	O
Arg95Ter	O
mutation	O
from	O
the	O
other	O
CHEK2	O
mutated	O
families	O
could	O
be	O
identified	O
.	O

One	O
of	O
them	O
(	O
Epi203	O
)	O
,	O
who	O
inherited	O
the	O
mutation	O
from	O
her	O
father	O
'	O
s	O
side	O
of	O
the	O
family	O
,	O
had	O
no	O
accumulation	O
of	O
either	O
breast	O
or	O
colorectal	O
cancer	O
on	O
that	O
side	O
.	O
<EOS>	B-X
Colorectal	B-X
cancer	B-X
(	B-X
CRC	B-X
)	B-X
is	B-X
the	B-X
third	B-X
most	B-X
common	B-X
cancer	B-X
and	B-X
the	B-X
fourth	B-X
most	B-X
common	B-X
cause	B-X
of	B-X
cancer-related	B-X
death	B-X
.	B-X
The	B-X
probability	B-X
of	B-X
suffering	B-X
from	B-X
colorectal	B-X
cancer	B-X
is	B-X
about	B-X
4	B-X
%	B-X
-5	B-X
%	B-X
and	B-X
the	B-X
risk	B-X
for	B-X
developing	B-X
CRC	B-X
is	B-X
associated	B-X
with	B-X
personal	B-X
features	B-X
or	B-X
habits	B-X
such	B-X
as	B-X
age	B-X
,	B-X
chronic	B-X
disease	B-X
history	B-X
and	B-X
lifestyle	B-X
.	B-X
Colorectal	B-X
cancer	B-X
is	B-X
the	B-X
third	B-X
most	B-X
common	B-X
cancer	B-X
in	B-X
the	B-X
world	B-X
with	B-X
increasing	B-X
incidence	B-X
and	B-X
mortality	B-X
rates	B-X
globally	B-X
.	B-X
Standard	B-X
treatments	B-X
for	B-X
colorectal	B-X
cancer	B-X
have	B-X
always	B-X
been	B-X
surgery	B-X
,	B-X
chemotherapy	B-X
and	B-X
radiotherapy	B-X
which	B-X
may	B-X
be	B-X
used	B-X
in	B-X
combination	B-X
to	B-X
treat	B-X
patients	B-X
.	B-X
However	B-X
,	B-X
these	B-X
treatments	B-X
have	B-X
many	B-X
side	B-X
effects	B-X
due	B-X
to	B-X
their	B-X
non-specificity	B-X
and	B-X
cytotoxicity	B-X
toward	B-X
any	B-X
cells	B-X
including	B-X
normal	B-X
cells	B-X
that	B-X
are	B-X
growing	B-X
and	B-X
dividing	B-X
.	B-X
Immunotherapy	B-X
is	B-X
one	B-X
of	B-X
the	B-X
new	B-X
alternatives	B-X
in	B-X
cancer	B-X
treatment	B-X
.	B-X
The	B-X
strategy	B-X
is	B-X
to	B-X
utilize	B-X
patients	B-X
'	B-X
own	B-X
immune	B-X
systems	B-X
in	B-X
combating	B-X
the	B-X
cancer	B-X
cells	B-X
.	B-X
The	B-X
normal	B-X
cells	B-X
with	B-X
no	B-X
cancer	B-X
antigens	B-X
are	B-X
not	B-X
affected	B-X
.	B-X
The	B-X
outcomes	B-X
of	B-X
some	B-X
cancer	B-X
immunotherapy	B-X
have	B-X
been	B-X
astonishing	B-X
in	B-X
some	B-X
cases	B-X
,	B-X
but	B-X
some	B-X
which	B-X
rely	B-X
on	B-X
the	B-X
status	B-X
of	B-X
patients	B-X
'	B-X
own	B-X
immune	B-X
systems	B-X
are	B-X
not	B-X
.	B-X
Those	B-X
patients	B-X
who	B-X
responded	B-X
well	B-X
to	B-X
cancer	B-X
immunotherapy	B-X
have	B-X
a	B-X
better	B-X
prognostic	B-X
and	B-X
better	B-X
quality	B-X
of	B-X
life	B-X
.	B-X

It	O
should	O
be	O
noted	O
,	O
however	O
,	O
that	O
two	O
brothers	O
of	O
her	O
fathers	O
mother	O
had	O
prostate	O
cancer	O
,	O
and	O
two	O
siblings	O
of	O
his	O
father	O
having	O
hepatocellular	O
carcinoma	O
and	O
bladder	O
cancer	O
,	O
respectively	O
)	O
,	O
while	O
the	O
other	O
expressed	O
a	O
disease	O
pattern	O
resembling	O
what	O
has	O
been	O
seen	O
with	O
the	O
more	O
common	O
CHEK2	O
mutations	O
,	O
like	O
del1100C	O
[	O
25	O
]	O
.	O

Discussion	O
<EOS>	B-X
Discussion	B-X
structures	B-X
are	B-X
argumentation-theoretical	B-X
tools	B-X
that	B-X
can	B-X
be	B-X
employed	B-X
to	B-X
tackle	B-X
three	B-X
barriers	B-X
that	B-X
separate	B-X
lay	B-X
stakeholders	B-X
from	B-X
policy	B-X
debates	B-X
:	B-X
difficulty	B-X
,	B-X
magnitude	B-X
,	B-X
and	B-X
complexity	B-X
.	B-X
Discussions	B-X
about	B-X
preventive	B-X
behaviors	B-X
were	B-X
assessed	B-X
before	B-X
testing	B-X
and	B-X
1	B-X
and	B-X
6	B-X
months	B-X
post-testing	B-X
.	B-X
Discussion	B-X
of	B-X
preventive	B-X
behaviors	B-X
declined	B-X
following	B-X
test	B-X
reporting	B-X
,	B-X
with	B-X
more	B-X
rapid	B-X
decline	B-X
reported	B-X
by	B-X
noncarriers	B-X
.	B-X
Discussions	B-X
are	B-X
an	B-X
important	B-X
part	B-X
of	B-X
medical	B-X
education	B-X
research	B-X
papers	B-X
,	B-X
but	B-X
there	B-X
is	B-X
little	B-X
guidance	B-X
on	B-X
how	B-X
to	B-X
write	B-X
up	B-X
the	B-X
discussion	B-X
section	B-X
.	B-X

TP53	O
plays	O
a	O
key	O
role	O
as	O
a	O
tumor	O
suppressor	O
gene	O
.	O

Its	O
protein	O
product	O
activates	O
processes	O
such	O
as	O
growth	O
arrest	O
,	O
DNA	O
repair	O
,	O
apoptosis	O
and	O
/	O
or	O
senescence	O
in	O
response	O
to	O
genotoxic	O
damage	O
as	O
well	O
as	O
oncogene	O
activity	O
[	O
49	O
]	O
,	O
[	O
50	O
]	O
.	O
<EOS>	B-X
To	B-X
date	B-X
,	B-X
lncRNAs	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
diverse	B-X
biological	B-X
processes	B-X
,	B-X
including	B-X
radioresistance	B-X
.	B-X
Here	B-X
,	B-X
the	B-X
sources	B-X
of	B-X
cellular	B-X
stress	B-X
that	B-X
can	B-X
cause	B-X
oncogenic	B-X
mutations	B-X
and	B-X
the	B-X
responses	B-X
of	B-X
cells	B-X
to	B-X
DNA	B-X
damage	B-X
are	B-X
reviewed	B-X
.	B-X
The	B-X
role	B-X
of	B-X
different	B-X
repair	B-X
pathways	B-X
and	B-X
the	B-X
potential	B-X
for	B-X
cell-	B-X
and	B-X
tissue-specific	B-X
reliance	B-X
on	B-X
individual	B-X
repair	B-X
mechanisms	B-X
are	B-X
discussed	B-X
.	B-X
Evidence	B-X
for	B-X
cell-	B-X
and	B-X
tissue-specific	B-X
activation	B-X
of	B-X
p53-mediated	B-X
growth	B-X
arrest	B-X
and	B-X
apoptosis	B-X
after	B-X
exposure	B-X
to	B-X
an	B-X
individual	B-X
genotoxin	B-X
is	B-X
assessed	B-X
and	B-X
some	B-X
of	B-X
the	B-X
potential	B-X
mediators	B-X
of	B-X
these	B-X
different	B-X
responses	B-X
are	B-X
provided	B-X
.	B-X
These	B-X
cell-	B-X
and	B-X
tissue-specific	B-X
responses	B-X
to	B-X
particular	B-X
forms	B-X
of	B-X
DNA	B-X
damage	B-X
are	B-X
likely	B-X
to	B-X
be	B-X
key	B-X
determinants	B-X
of	B-X
tissue-specific	B-X
tumour	B-X
susceptibility	B-X
,	B-X
and	B-X
there	B-X
is	B-X
good	B-X
evidence	B-X
for	B-X
genetic	B-X
variations	B-X
in	B-X
these	B-X
responses	B-X
.	B-X
The	B-X
role	B-X
that	B-X
genotoxic	B-X
agents	B-X
play	B-X
in	B-X
altering	B-X
the	B-X
microenvironment	B-X
to	B-X
produce	B-X
indirect	B-X
effects	B-X
on	B-X
tumourigenesis	B-X
through	B-X
altered	B-X
production	B-X
of	B-X
free	B-X
radicals	B-X
and	B-X
cytokines	B-X
that	B-X
are	B-X
characteristic	B-X
of	B-X
inflammatory-type	B-X
processes	B-X
is	B-X
also	B-X
evaluated	B-X
.	B-X
Changes	B-X
to	B-X
the	B-X
microenvironment	B-X
as	B-X
direct	B-X
or	B-X
indirect	B-X
effects	B-X
of	B-X
genotoxic	B-X
stress	B-X
can	B-X
be	B-X
involved	B-X
in	B-X
both	B-X
tumour	B-X
initiation	B-X
and	B-X
progression	B-X
and	B-X
may	B-X
even	B-X
be	B-X
a	B-X
prerequisite	B-X
for	B-X
tumourigenesis	B-X
.	B-X
Therefore	B-X
,	B-X
tumour	B-X
susceptibility	B-X
after	B-X
endogenous	B-X
or	B-X
exogenous	B-X
genotoxic	B-X
stress	B-X
represents	B-X
a	B-X
balance	B-X
between	B-X
cell-intrinsic	B-X
responses	B-X
of	B-X
target	B-X
cells	B-X
and	B-X
changes	B-X
to	B-X
the	B-X
microenvironment	B-X
.	B-X
A	B-X
fuller	B-X
understanding	B-X
of	B-X
cell-	B-X
and	B-X
tissue-specific	B-X
responses	B-X
,	B-X
alterations	B-X
to	B-X
the	B-X
microenvironment	B-X
,	B-X
and	B-X
genetic	B-X
modifiers	B-X
of	B-X
these	B-X
responses	B-X
could	B-X
lead	B-X
to	B-X
novel	B-X
prevention	B-X
and	B-X
therapeutic	B-X
strategies	B-X
for	B-X
common	B-X
forms	B-X
of	B-X
human	B-X
malignancy	B-X
.	B-X

Despite	O
being	O
extensively	O
studied	O
,	O
critical	O
issues	O
regarding	O
regulation	O
of	O
the	O
p53	O
protein	O
remain	O
poorly	O
understood	O
,	O
and	O
conflicting	O
evidence	O
obtained	O
in	O
different	O
experimental	O
systems	O
make	O
the	O
clinical	O
relevance	O
of	O
experimental	O
data	O
questionable	O
.	O

Chemoresistance	O
is	O
the	O
main	O
obstacle	O
to	O
cancer	O
cure	O
in	O
most	O
malignancies	O
,	O
including	O
breast	O
cancer	O
.	O

Previously	O
,	O
we	O
found	O
TP53	O
mutations	O
affecting	O
the	O
L2	O
/	O
L3	O
DNA	O
binding	O
domain	O
to	O
be	O
associated	O
with	O
lack	O
of	O
responsiveness	O
to	O
doxorubicin	O
monotherapy	O
[	O
13	O
]	O
as	O
well	O
as	O
mitomycin	O
and	O
5	O
-	O
fluoro	O
-	O
uracil	O
in	O
concert	O
[	O
14	O
]	O
.	O

However	O
,	O
some	O
tumors	O
revealed	O
therapy	O
resistance	O
despite	O
harboring	O
wild	O
-	O
type	O
TP53	O
.	O
<EOS>	B-X
Fludarabine	B-X
,	B-X
cyclophosphamide	B-X
,	B-X
and	B-X
rituximab	B-X
(	B-X
FCR	B-X
)	B-X
is	B-X
first-line	B-X
treatment	B-X
of	B-X
medically	B-X
fit	B-X
chronic	B-X
lymphocytic	B-X
leukemia	B-X
(	B-X
CLL	B-X
)	B-X
patients	B-X
;	B-X
however	B-X
,	B-X
despite	B-X
good	B-X
response	B-X
rates	B-X
,	B-X
many	B-X
patients	B-X
eventually	B-X
relapse	B-X
.	B-X
Although	B-X
recent	B-X
high-throughput	B-X
studies	B-X
have	B-X
identified	B-X
novel	B-X
recurrent	B-X
genetic	B-X
lesions	B-X
in	B-X
adverse	B-X
prognostic	B-X
CLL	B-X
,	B-X
the	B-X
mechanisms	B-X
leading	B-X
to	B-X
relapse	B-X
after	B-X
FCR	B-X
therapy	B-X
are	B-X
not	B-X
completely	B-X
understood	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
mutations	B-X
with	B-X
known	B-X
adverse-prognostic	B-X
impact	B-X
(	B-X
TP53	B-X
,	B-X
NOTCH1	B-X
,	B-X
ATM	B-X
,	B-X
SF3B1	B-X
,	B-X
NFKBIE	B-X
,	B-X
and	B-X
BIRC3	B-X
)	B-X
,	B-X
a	B-X
large	B-X
proportion	B-X
of	B-X
cases	B-X
(	B-X
19.5	B-X
%	B-X
)	B-X
harbored	B-X
mutations	B-X
in	B-X
RPS15	B-X
,	B-X
a	B-X
gene	B-X
encoding	B-X
a	B-X
component	B-X
of	B-X
the	B-X
40S	B-X
ribosomal	B-X
subunit	B-X
.	B-X
Extended	B-X
screening	B-X
,	B-X
totaling	B-X
1119	B-X
patients	B-X
,	B-X
supported	B-X
a	B-X
role	B-X
for	B-X
RPS15	B-X
mutations	B-X
in	B-X
aggressive	B-X
CLL	B-X
,	B-X
with	B-X
one-third	B-X
of	B-X
RPS15-mutant	B-X
cases	B-X
also	B-X
carrying	B-X
TP53	B-X
aberrations	B-X
.	B-X
However	B-X
,	B-X
RPS15	B-X
mutations	B-X
were	B-X
clonal	B-X
before	B-X
treatment	B-X
and	B-X
remained	B-X
stable	B-X
at	B-X
relapse	B-X
.	B-X
We	B-X
confirmed	B-X
the	B-X
recently	B-X
postulated	B-X
direct	B-X
interaction	B-X
between	B-X
RPS15	B-X
and	B-X
MDM2/MDMX	B-X
and	B-X
transient	B-X
expression	B-X
of	B-X
mutant	B-X
RPS15	B-X
revealed	B-X
defective	B-X
regulation	B-X
of	B-X
endogenous	B-X
p53	B-X
compared	B-X
with	B-X
wild-type	B-X
RPS15	B-X
.	B-X

Postulating	O
that	O
these	O
tumors	O
may	O
harbor	O
genetic	O
disturbances	O
in	O
genes	O
playing	O
a	O
key	O
role	O
in	O
the	O
p53	O
pathway	O
,	O
we	O
here	O
sequenced	O
TP53	O
along	O
with	O
CHEK2	O
and	O
p14	O
(	O
ARF	O
)	O
,	O
the	O
latter	O
two	O
known	O
to	O
play	O
a	O
critical	O
role	O
as	O
p53	O
activators	O
,	O
in	O
tumors	O
from	O
109	O
patients	B-Species
treated	O
with	O
epirubicin	O
monotherapy	O
.	O

Our	O
results	O
confirm	O
TP53	O
mutations	O
,	O
in	O
particular	O
those	O
affecting	O
the	O
L2	O
/	O
L3	O
domains	O
,	O
to	O
be	O
associated	O
with	O
drug	O
resistance	O
.	O

Most	O
importantly	O
,	O
we	O
also	O
found	O
CHEK2	O
mutations	O
generating	O
a	O
non	O
-	O
functional	O
protein	O
in	O
our	O
in	O
vitro	O
assays	O
to	O
be	O
associated	O
with	O
drug	O
resistance	O
.	O

In	O
contrast	O
,	O
none	O
of	O
our	O
tumors	O
harbored	O
either	O
mutations	O
or	O
expressed	O
promoter	O
hypermethylations	O
affecting	O
the	O
p14	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
SF3B1	B-X
and	B-X
KIT	B-X
have	B-X
higher	B-X
mutation	B-X
rate	B-X
in	B-X
mucosal	B-X
melanoma	B-X
as	B-X
compared	B-X
to	B-X
cutaneous	B-X
melanoma	B-X
.	B-X
Mutations	B-X
identified	B-X
in	B-X
mucosal	B-X
melanoma	B-X
should	B-X
be	B-X
incorporated	B-X
into	B-X
routine	B-X
clinical	B-X
testing	B-X
,	B-X
as	B-X
there	B-X
are	B-X
targeted	B-X
therapies	B-X
already	B-X
developed	B-X
for	B-X
treating	B-X
patients	B-X
with	B-X
these	B-X
mutations	B-X
in	B-X
the	B-X
precision	B-X
medicine	B-X
era	B-X
.	B-X
Despite	B-X
numerous	B-X
studies	B-X
that	B-X
have	B-X
carefully	B-X
scrutinized	B-X
the	B-X
ovaries	B-X
for	B-X
precursor	B-X
lesions	B-X
,	B-X
none	B-X
have	B-X
been	B-X
found	B-X
.	B-X
Studies	B-X
have	B-X
shown	B-X
that	B-X
epithelial	B-X
ovarian	B-X
cancer	B-X
is	B-X
not	B-X
a	B-X
single	B-X
disease	B-X
but	B-X
is	B-X
composed	B-X
of	B-X
a	B-X
diverse	B-X
group	B-X
of	B-X
tumors	B-X
that	B-X
can	B-X
be	B-X
classified	B-X
based	B-X
on	B-X
distinctive	B-X
morphologic	B-X
and	B-X
molecular	B-X
genetic	B-X
features	B-X
.	B-X
One	B-X
group	B-X
of	B-X
tumors	B-X
,	B-X
designated	B-X
type	B-X
I	B-X
,	B-X
is	B-X
composed	B-X
of	B-X
low-grade	B-X
serous	B-X
,	B-X
low-grade	B-X
endometrioid	B-X
,	B-X
clear	B-X
cell	B-X
,	B-X
mucinous	B-X
and	B-X
transitional	B-X
(	B-X
Brenner	B-X
)	B-X
carcinomas	B-X
.	B-X
These	B-X
tumors	B-X
generally	B-X
behave	B-X
in	B-X
an	B-X
indolent	B-X
fashion	B-X
,	B-X
are	B-X
confined	B-X
to	B-X
the	B-X
ovary	B-X
at	B-X
presentation	B-X
and	B-X
,	B-X
as	B-X
a	B-X
group	B-X
,	B-X
are	B-X
relatively	B-X
genetically	B-X
stable	B-X
.	B-X
They	B-X
lack	B-X
mutations	B-X
of	B-X
TP53	B-X
,	B-X
but	B-X
each	B-X
histologic	B-X
type	B-X
exhibits	B-X
a	B-X
distinctive	B-X
molecular	B-X
genetic	B-X
profile	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
another	B-X
group	B-X
of	B-X
tumors	B-X
,	B-X
designated	B-X
type	B-X
II	B-X
,	B-X
is	B-X
highly	B-X
aggressive	B-X
,	B-X
evolves	B-X
rapidly	B-X
and	B-X
almost	B-X
always	B-X
presents	B-X
in	B-X
advanced	B-X
stage	B-X
.	B-X
Type	B-X
II	B-X
tumors	B-X
include	B-X
conventional	B-X
high-grade	B-X
serous	B-X
carcinoma	B-X
,	B-X
undifferentiated	B-X
carcinoma	B-X
,	B-X
and	B-X
malignant	B-X
mixed	B-X
mesodermal	B-X
tumors	B-X
(	B-X
carcinosarcoma	B-X
)	B-X
.	B-X
They	B-X
displayTP53	B-X
mutations	B-X
in	B-X
over	B-X
80	B-X
%	B-X
of	B-X
cases	B-X
and	B-X
rarely	B-X
harbor	B-X
the	B-X
mutations	B-X
that	B-X
are	B-X
found	B-X
in	B-X
the	B-X
type	B-X
I	B-X
tumors	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
also	B-X
provided	B-X
cogent	B-X
evidence	B-X
that	B-X
what	B-X
have	B-X
been	B-X
traditionally	B-X
thought	B-X
to	B-X
be	B-X
primary	B-X
ovarian	B-X
tumors	B-X
actually	B-X
originate	B-X
in	B-X
other	B-X
pelvic	B-X
organs	B-X
and	B-X
involve	B-X
the	B-X
ovary	B-X
secondarily	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
has	B-X
been	B-X
proposed	B-X
that	B-X
serous	B-X
tumors	B-X
arise	B-X
from	B-X
the	B-X
implantation	B-X
of	B-X
epithelium	B-X
(	B-X
benign	B-X
or	B-X
malignant	B-X
)	B-X
from	B-X
the	B-X
fallopian	B-X
tube	B-X
.	B-X
Endometrioid	B-X
and	B-X
clear	B-X
cell	B-X
tumors	B-X
have	B-X
been	B-X
associated	B-X
with	B-X
endometriosis	B-X
that	B-X
is	B-X
regarded	B-X
as	B-X
the	B-X
precursor	B-X
of	B-X
these	B-X
tumors	B-X
.	B-X
Finally	B-X
,	B-X
preliminary	B-X
data	B-X
suggest	B-X
that	B-X
mucinous	B-X
and	B-X
transitional	B-X
(	B-X
Brenner	B-X
)	B-X
tumors	B-X
arise	B-X
from	B-X
transitional-type	B-X
epithelial	B-X
nests	B-X
at	B-X
the	B-X
tubal-mesothelial	B-X
junction	B-X
by	B-X
a	B-X
process	B-X
of	B-X
metaplasia	B-X
.	B-X

Based	O
on	O
in	O
vitro	O
assays	O
,	O
we	O
were	O
able	O
to	O
classify	O
the	O
different	O
Chk2	O
mutants	O
with	O
respect	O
to	O
dimerization	O
capability	O
as	O
well	O
as	O
kinase	O
activity	O
(	O
Chk2	O
autophosphorylation	O
and	O
Cdc25	O
substrate	O
phosphorylation	O
)	O
.	O

In	O
addition	O
,	O
the	O
kinase	O
activities	O
of	O
the	O
Chk2	O
wild	O
-	O
type	O
/	O
mutant	O
complexes	O
were	O
monitored	O
in	O
co	O
-	O
transfection	O
experiments	O
.	O

Notably	O
,	O
each	O
point	O
mutation	O
(	O
except	O
for	O
Arg117Gly	O
)	O
revealed	O
similar	O
relative	O
kinase	O
efficacy	O
whether	O
co	O
-	O
transfected	O
with	O
wild	O
-	O
type	O
Chk2	O
or	O
not	O
(	O
Figure	O
3	O
and	O
4	O
)	O
.	O
<EOS>	B-X
Neuromuscular	B-X
disorders	B-X
are	B-X
a	B-X
heterogeneous	B-X
group	B-X
of	B-X
acquired	B-X
or	B-X
hereditary	B-X
conditions	B-X
that	B-X
affect	B-X
striated	B-X
muscle	B-X
function	B-X
.	B-X
Muscular	B-X
weakness	B-X
is	B-X
often	B-X
progressive	B-X
and	B-X
paralleled	B-X
by	B-X
continuous	B-X
decline	B-X
in	B-X
the	B-X
ability	B-X
of	B-X
skeletal	B-X
muscle	B-X
to	B-X
functionally	B-X
adapt	B-X
and	B-X
regenerate	B-X
.	B-X
We	B-X
recently	B-X
defined	B-X
'Satellite	B-X
Cell-opathies	B-X
'	B-X
as	B-X
those	B-X
inherited	B-X
neuromuscular	B-X
conditions	B-X
presenting	B-X
satellite	B-X
cell	B-X
dysfunction	B-X
in	B-X
muscular	B-X
dystrophies	B-X
and	B-X
myopathies	B-X
(	B-X
doi:10.1016/j.yexcr.2021.112906	B-X
)	B-X
.	B-X
We	B-X
explore	B-X
the	B-X
expression	B-X
dynamics	B-X
of	B-X
myopathogenes	B-X
,	B-X
genes	B-X
whose	B-X
mutation	B-X
leads	B-X
to	B-X
skeletal	B-X
muscle	B-X
pathogenesis	B-X
,	B-X
using	B-X
transcriptomic	B-X
analysis	B-X
.	B-X
This	B-X
revealed	B-X
that	B-X
45	B-X
%	B-X
of	B-X
myopathogenes	B-X
are	B-X
differentially	B-X
expressed	B-X
during	B-X
early	B-X
satellite	B-X
cell	B-X
activation	B-X
(	B-X
0	B-X
-	B-X
5	B-X
hours	B-X
)	B-X
.	B-X
Of	B-X
these	B-X
271	B-X
myopathogenes	B-X
,	B-X
83	B-X
respond	B-X
to	B-X
Pax7	B-X
,	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
satellite	B-X
cells	B-X
.	B-X

Cells	O
co	O
-	O
transfected	O
with	O
Arg117Gly	O
and	O
wild	O
-	O
type	O
Chk2	O
revealed	O
kinase	O
activity	O
,	O
probably	O
due	O
to	O
the	O
contribution	O
of	O
the	O
wild	O
type	O
protein	O
in	O
Chk2	O
mutant	O
-	O
wild	O
-	O
type	O
heterodimers	O
.	O

In	O
contrast	O
,	O
cells	O
transfected	O
with	O
Arg95Ter	O
revealed	O
no	O
kinase	O
activity	O
whether	O
co	O
-	O
transfected	O
with	O
wild	O
-	O
type	O
Chk2	O
or	O
not	O
,	O
clearly	O
distinguishing	O
this	O
mutation	O
from	O
the	O
others	O
(	O
Figure	O
3	O
and	O
5	O
)	O
.	O

All	O
in	O
vitro	O
assays	O
were	O
based	O
on	O
transfection	O
of	O
the	O
U	O
-	O
2	O
-	O
OS	O
cell	O
line	O
,	O
a	O
cell	O
line	O
known	O
to	O
express	O
wild	O
-	O
type	O
Chk2	O
at	O
low	O
levels	O
,	O
and	O
previously	O
used	O
by	O
other	O
investigators	O
to	O
study	O
Chk2	O
activity	O
[	O
44	O
]	O
,	O
[	O
45	O
]	O
,	O
[	O
46	O
]	O
.	O

Since	O
we	O
were	O
not	O
able	O
to	O
obtain	O
satisfactory	O
technical	O
quality	O
of	O
the	O
kinase	O
assay	O
in	O
cell	O
lines	O
negative	O
for	O
Chk2	O
(	O
HCT	O
15	O
and	O
HCT	O
116	O
)	O
,	O
we	O
assessed	O
potential	O
background	O
kinase	O
activity	O
due	O
to	O
endogenous	O
Chk2	O
by	O
performing	O
western	O
blot	O
analysis	O
revealing	O
the	O
endogenous	O
levels	O
of	O
Chk2	O
in	O
U	O
-	O
2	O
-	O
OS	O
cells	O
to	O
be	O
non	O
-	O
significant	O
compared	O
to	O
the	O
exogenously	O
expressed	O
Chk2	O
levels	O
(	O
data	O
not	O
shown	O
)	O
.	O

We	O
also	O
performed	O
a	O
separate	O
kinase	O
assay	O
,	O
directly	O
comparing	O
the	O
effect	O
of	O
binding	O
partners	O
for	O
the	O
dimerizing	O
Arg117Gly	O
and	O
the	O
non	O
-	O
dimerizing	O
Arg95Ter	O
.	O

This	O
assay	O
also	O
revealed	O
the	O
contribution	O
of	O
endogenous	O
Chk2	O
to	O
be	O
non	O
-	O
significant	O
(	O
Figure	O
5	O
)	O
.	O

Taking	O
our	O
in	O
vitro	O
findings	O
together	O
with	O
in	O
vivo	O
observations	O
,	O
our	O
present	O
data	O
confirm	O
that	O
the	O
functionally	O
defective	O
CHEK2	O
Arg95Ter	O
mutation	O
,	O
together	O
with	O
LOH	O
,	O
is	O
associated	O
with	O
resistance	O
to	O
anthracycline	O
therapy	O
.	O

In	O
contrast	O
,	O
the	O
patient	B-Species
harboring	O
the	O
Ile364Thr	O
mutation	O
,	O
moderately	O
reducing	O
phosphorylation	O
activity	O
,	O
responded	O
well	O
to	O
therapy	O
.	O

The	O
other	O
missense	O
mutations	O
;	O
Arg117Gly	O
and	O
Ile157Thr	O
were	O
observed	O
among	O
patients	B-Species
receiving	O
paclitaxel	O
therapy	O
only	O
;	O
thus	O
,	O
their	O
influence	O
on	O
anthracycline	O
sensitivity	O
in	O
vivo	O
could	O
not	O
be	O
addressed	O
.	O
<EOS>	B-X
319	B-X
missense	B-X
mutations	B-X
were	B-X
identified	B-X
solely	B-X
in	B-X
the	B-X
proline	B-X
domain	B-X
from	B-X
human	B-X
cancers	B-X
.	B-X
Six	B-X
hotspot	B-X
mutations	B-X
were	B-X
identified	B-X
at	B-X
amino	B-X
acids	B-X
72	B-X
,	B-X
73	B-X
,	B-X
82	B-X
,	B-X
84	B-X
,	B-X
89	B-X
,	B-X
and	B-X
98	B-X
.	B-X
Cancers	B-X
associated	B-X
with	B-X
mutations	B-X
in	B-X
the	B-X
proline	B-X
domain	B-X
were	B-X
considerably	B-X
enriched	B-X
for	B-X
melanomas	B-X
and	B-X
skin	B-X
cancers	B-X
compared	B-X
to	B-X
mutations	B-X
in	B-X
other	B-X
p53	B-X
domains	B-X
.	B-X
These	B-X
hotspot	B-X
mutations	B-X
are	B-X
enriched	B-X
at	B-X
UV	B-X
mutational	B-X
signatures	B-X
disrupting	B-X
amino	B-X
acid	B-X
signals	B-X
for	B-X
binding	B-X
SH-3-containing	B-X
proteins	B-X
important	B-X
for	B-X
p53	B-X
function	B-X
.	B-X
Among	B-X
the	B-X
protein-protein	B-X
interaction	B-X
sites	B-X
identified	B-X
by	B-X
hotspot	B-X
mutations	B-X
were	B-X
MDM-2	B-X
,	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
p53	B-X
,	B-X
XAF-1	B-X
,	B-X
promoting	B-X
p53	B-X
mediated	B-X
apoptosis	B-X
,	B-X
and	B-X
PIN-1	B-X
,	B-X
a	B-X
proline	B-X
isomerase	B-X
essential	B-X
for	B-X
structural	B-X
folding	B-X
of	B-X
this	B-X
domain	B-X
.	B-X

Yet	O
,	O
based	O
on	O
the	O
finding	O
that	O
the	O
Arg117Gly	O
mutant	O
expressed	O
no	O
intrinsic	O
activity	O
,	O
but	O
readily	O
dimerized	O
to	O
the	O
wild	O
-	O
type	O
protein	O
without	O
abolishing	O
its	O
activity	O
,	O
we	O
hypothesize	O
that	O
this	O
mutation	O
and	O
,	O
probably	O
,	O
other	O
yet	O
unidentified	O
CHEK2	O
mutations	O
with	O
a	O
similar	O
lack	O
of	O
intrinsic	O
kinase	O
activity	O
,	O
may	O
cause	O
resistance	O
to	O
anthracycline	O
therapy	O
if	O
combined	O
with	O
LOH	O
in	O
breast	O
cancer	O
.	O

Our	O
present	O
findings	O
have	O
two	O
major	O
implications	O
.	O
<EOS>	B-X
Thanks	B-X
to	B-X
ready	B-X
access	B-X
to	B-X
hydrogen	B-X
breath	B-X
testing	B-X
,	B-X
small	B-X
intestinal	B-X
bacterial	B-X
overgrowth	B-X
(	B-X
SIBO	B-X
)	B-X
is	B-X
now	B-X
commonly	B-X
diagnosed	B-X
among	B-X
individuals	B-X
presenting	B-X
with	B-X
a	B-X
variety	B-X
of	B-X
gastrointestinal	B-X
and	B-X
even	B-X
nongastrointestinal	B-X
symptoms	B-X
and	B-X
is	B-X
increasingly	B-X
implicated	B-X
in	B-X
lay	B-X
press	B-X
and	B-X
media	B-X
in	B-X
the	B-X
causation	B-X
of	B-X
a	B-X
diverse	B-X
array	B-X
of	B-X
disorders	B-X
.	B-X
Methionine	B-X
is	B-X
a	B-X
precursor	B-X
for	B-X
a	B-X
major	B-X
DNA	B-X
methyl	B-X
donor	B-X
and	B-X
is	B-X
important	B-X
for	B-X
DNA	B-X
methylation	B-X
and	B-X
gene	B-X
regulation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
two	B-X
polymorphic	B-X
variants	B-X
in	B-X
this	B-X
gene	B-X
(	B-X
C677T	B-X
and	B-X
A1298C	B-X
)	B-X
have	B-X
been	B-X
implicated	B-X
in	B-X
a	B-X
mild	B-X
form	B-X
of	B-X
MTHFR	B-X
deficiency	B-X
associated	B-X
with	B-X
hyperhomocysteinemia	B-X
.	B-X
Given	B-X
this	B-X
wide	B-X
spectrum	B-X
of	B-X
purported	B-X
clinical	B-X
implications	B-X
and	B-X
the	B-X
prevalence	B-X
of	B-X
these	B-X
polymorphisms	B-X
,	B-X
genetic	B-X
counselors	B-X
may	B-X
encounter	B-X
questions	B-X
regarding	B-X
the	B-X
significance	B-X
of	B-X
MTHFR	B-X
polymorphisms	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
settings	B-X
.	B-X
Here	B-X
we	B-X
present	B-X
a	B-X
brief	B-X
background	B-X
of	B-X
the	B-X
MTHFR	B-X
polymorphisms	B-X
,	B-X
review	B-X
of	B-X
the	B-X
literature	B-X
regarding	B-X
clinical	B-X
considerations	B-X
,	B-X
and	B-X
discussion	B-X
of	B-X
relevant	B-X
genetic	B-X
counseling	B-X
aspects	B-X
through	B-X
case	B-X
vignettes	B-X
.	B-X

First	O
,	O
we	O
confirm	O
that	O
mutations	O
in	O
genes	O
encoding	O
proteins	O
located	O
within	O
the	O
same	O
functional	O
pathway	O
may	O
substitute	O
for	O
each	O
other	O
with	O
respect	O
to	O
drug	O
sensitivity	O
,	O
revealing	O
for	O
the	O
first	O
time	O
a	O
functional	O
pathway	O
critical	O
to	O
chemotherapy	O
response	O
in	O
vivo	O
.	O

Second	O
,	O
the	O
identification	O
of	O
mutations	O
in	O
the	O
CHEK2	O
but	O
not	O
in	O
the	O
p14	O
(	O
ARF	O
)	O
gene	O
in	O
resistant	O
tumors	O
suggests	O
that	O
Chk2	O
mediated	O
phosphorylation	O
of	O
p53	O
is	O
a	O
critical	O
event	O
in	O
executing	O
anti	O
-	O
tumor	O
effect	O
as	O
a	O
response	O
to	O
DNA	O
damaging	O
agents	O
in	O
breast	O
cancer	O
.	O
<EOS>	B-X
Malignant	B-X
peritoneal	B-X
mesothelioma	B-X
is	B-X
a	B-X
rare	B-X
aggressive	B-X
tumor	B-X
that	B-X
arises	B-X
from	B-X
the	B-X
peritoneal	B-X
lining	B-X
.	B-X
While	B-X
recurrent	B-X
BAP1	B-X
mutations	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
a	B-X
subset	B-X
of	B-X
mesotheliomas	B-X
,	B-X
molecular	B-X
characteristics	B-X
of	B-X
peritoneal	B-X
mesotheliomas	B-X
,	B-X
including	B-X
those	B-X
lacking	B-X
BAP1	B-X
alterations	B-X
,	B-X
remain	B-X
poorly	B-X
understood	B-X
.	B-X
Using	B-X
targeted	B-X
next-generation	B-X
sequencing	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
molecular	B-X
features	B-X
of	B-X
26	B-X
diffuse	B-X
malignant	B-X
peritoneal	B-X
mesotheliomas	B-X
.	B-X
Genomic	B-X
characterization	B-X
identified	B-X
categories	B-X
of	B-X
diffuse	B-X
malignant	B-X
peritoneal	B-X
mesotheliomas	B-X
:	B-X
The	B-X
first	B-X
group	B-X
included	B-X
18	B-X
(	B-X
69	B-X
%	B-X
)	B-X
tumors	B-X
with	B-X
recurrent	B-X
BAP1	B-X
alterations	B-X
,	B-X
with	B-X
eight	B-X
(	B-X
31	B-X
%	B-X
)	B-X
having	B-X
more	B-X
than	B-X
one	B-X
BAP1	B-X
alterations	B-X
,	B-X
and	B-X
concomitant	B-X
alterations	B-X
in	B-X
PBRM1	B-X
(	B-X
46	B-X
%	B-X
)	B-X
and	B-X
SETD2	B-X
(	B-X
35	B-X
%	B-X
)	B-X
.	B-X
All	B-X
tumors	B-X
with	B-X
complete	B-X
loss	B-X
of	B-X
BAP1	B-X
expression	B-X
by	B-X
immunohistochemistry	B-X
harbored	B-X
BAP1	B-X
molecular	B-X
alterations	B-X
.	B-X
The	B-X
second	B-X
group	B-X
included	B-X
eight	B-X
(	B-X
31	B-X
%	B-X
)	B-X
BAP1-wild-type	B-X
tumors	B-X
:	B-X
two	B-X
with	B-X
TP53	B-X
mutations	B-X
,	B-X
one	B-X
with	B-X
a	B-X
TRAF7	B-X
activating	B-X
mutation	B-X
,	B-X
one	B-X
with	B-X
a	B-X
SUZ12	B-X
inactivating	B-X
mutation	B-X
,	B-X
and	B-X
three	B-X
with	B-X
ALK	B-X
rearrangements	B-X
that	B-X
we	B-X
previously	B-X
published	B-X
.	B-X
The	B-X
localized	B-X
peritoneal	B-X
mesothelioma	B-X
harbored	B-X
a	B-X
nonsense	B-X
CHEK2	B-X
mutation	B-X
,	B-X
and	B-X
the	B-X
well-differentiated	B-X
papillary	B-X
mesothelioma	B-X
with	B-X
invasive	B-X
foci	B-X
harbored	B-X
no	B-X
reportable	B-X
variants	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
we	B-X
described	B-X
the	B-X
genetic	B-X
categories	B-X
of	B-X
diffuse	B-X
malignant	B-X
peritoneal	B-X
mesotheliomas	B-X
,	B-X
with	B-X
BAP1-mutant	B-X
and	B-X
BAP1-wild-type	B-X
groups	B-X
.	B-X
Our	B-X
findings	B-X
implicated	B-X
DNA	B-X
repair	B-X
,	B-X
epigenetics	B-X
,	B-X
and	B-X
cell	B-X
cycle	B-X
regulation	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
peritoneal	B-X
mesotheliomas	B-X
,	B-X
with	B-X
identification	B-X
of	B-X
potential	B-X
therapeutic	B-X
targets	B-X
.	B-X

This	O
adds	O
to	O
our	O
understanding	O
not	O
only	O
of	O
the	O
function	O
of	O
p53	O
but	O
Chk2	O
as	O
well	O
.	O
<EOS>	B-X
The	B-X
placenta	B-X
adds	B-X
another	B-X
layer	B-X
of	B-X
complexity	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
teratogenic	B-X
effects	B-X
of	B-X
medications	B-X
are	B-X
often	B-X
extrapolated	B-X
from	B-X
animals	B-X
,	B-X
which	B-X
further	B-X
adds	B-X
uncertainties	B-X
.	B-X
ABSTRACT	B-X
:	B-X
Introduction	B-X
Although	B-X
compassionate	B-X
care	B-X
is	B-X
an	B-X
essential	B-X
component	B-X
of	B-X
mental	B-X
health	B-X
nursing	B-X
,	B-X
understandings	B-X
of	B-X
the	B-X
impact	B-X
of	B-X
compassion	B-X
fatigue	B-X
is	B-X
poorly	B-X
understood	B-X
.	B-X
Strong	B-X
leadership	B-X
and	B-X
positive	B-X
workplace	B-X
cultures	B-X
,	B-X
clinical	B-X
supervision	B-X
,	B-X
reflection	B-X
,	B-X
self-care	B-X
and	B-X
personal	B-X
well-being	B-X
may	B-X
protect	B-X
mental	B-X
health	B-X
nurses	B-X
against	B-X
compassion	B-X
fatigue	B-X
.	B-X
Discussion	B-X
Future	B-X
research	B-X
is	B-X
needed	B-X
on	B-X
mental	B-X
health	B-X
nurses	B-X
lived	B-X
experience	B-X
of	B-X
compassion	B-X
fatigue	B-X
and	B-X
their	B-X
understandings	B-X
of	B-X
compassion	B-X
.	B-X

p53	O
undergoes	O
phosphorylation	O
at	O
multiple	O
sites	O
by	O
different	O
kinases	O
,	O
including	O
Chk2	O
[	O
51	O
]	O
.	O

While	O
activation	O
of	O
the	O
ATM	O
leading	O
to	O
direct	O
(	O
Ser	O
15	O
)	O
and	O
Chk2	O
-	O
mediated	O
(	O
Ser	O
20	O
)	O
phosphorylation	O
of	O
p53	O
is	O
considered	O
an	O
important	O
mechanism	O
for	O
triggering	O
p53	O
activation	O
in	O
response	O
to	O
DNA	O
damage	O
[	O
52	O
]	O
,	O
some	O
reports	O
suggest	O
ATM	O
[	O
53	O
]	O
and	O
even	O
Chk2	O
[	O
23	O
]	O
to	O
be	O
redundant	O
to	O
this	O
function	O
.	O

Importantly	O
,	O
Chk2	O
has	O
been	O
shown	O
capable	O
of	O
inducing	O
ATM	O
-	O
independent	O
apoptosis	O
in	O
vitro	O
[	O
21	O
]	O
.	O

While	O
Chk2	O
phosphorylates	O
p53	O
at	O
Ser	O
20	O
,	O
thereby	O
stabilizing	O
p53	O
by	O
preventing	O
MDM2	O
binding	O
[	O
19	O
]	O
,	O
Chk2	O
also	O
phosphorylates	O
p53	O
at	O
six	O
additional	O
sites	O
,	O
including	O
Ser	O
313	O
and	O
Ser	O
314	O
located	O
in	O
the	O
nuclear	O
localization	O
signal	O
domain	O
of	O
p53	O
[	O
51	O
]	O
.	O

In	O
addition	O
,	O
Chk2	O
phosphorylates	O
other	O
important	O
targets	O
like	O
BRCA1	O
,	O
Cdc25A	O
and	O
Cdc25C	O
involved	O
in	O
DNA	O
repair	O
,	O
G1	O
and	O
G2	O
arrest	O
,	O
respectively	O
[	O
54	O
]	O
.	O

Despite	O
the	O
wide	O
range	O
of	O
known	O
Chk2	O
substrates	O
relevant	O
for	O
DNA	O
repair	O
and	O
cell	O
cycle	O
control	O
,	O
our	O
present	O
findings	O
that	O
CHEK2	O
mutations	O
leading	O
to	O
non	O
-	O
functional	O
Chk2	O
protein	O
may	O
substitute	O
for	O
p53	O
mutations	O
strongly	O
advocate	O
a	O
role	O
for	O
Chk2	O
with	O
respect	O
to	O
drug	O
sensitivity	O
executed	O
through	O
p53	O
activation	O
.	O

Notably	O
,	O
one	O
of	O
the	O
tumors	O
(	O
Epi203	O
)	O
with	O
the	O
Arg95Ter	O
CHEK2	O
mutation	O
in	O
addition	O
harbored	O
a	O
somatic	O
TP53	O
mutation	O
,	O
Arg175His	O
,	O
with	O
allelic	O
imbalance	O
for	O
the	O
TP53	O
gene	O
(	O
Table	O
2	O
)	O
.	O

Importantly	O
,	O
among	O
another	O
four	O
patients	B-Species
in	O
this	O
study	O
(	O
Epi063	O
,	O
Epi071	O
,	O
Epi087	O
,	O
Epi153	O
)	O
and	O
one	O
patient	B-Species
from	O
our	O
previous	O
doxorubicin	O
protocol	O
[	O
13	O
]	O
harboring	O
the	O
Arg175His	O
mutation	O
together	O
with	O
allelic	O
imbalance	O
for	O
TP53	O
,	O
all	O
five	O
of	O
these	O
patients	B-Species
responded	O
to	O
anthracycline	O
therapy	O
either	O
with	O
a	O
partial	O
response	O
or	O
stable	O
disease	O
.	O
<EOS>	B-X
In	B-X
the	B-X
Emergency	B-X
Department	B-X
(	B-X
ED	B-X
)	B-X
,	B-X
most	B-X
patients	B-X
with	B-X
potential	B-X
signs/symptoms	B-X
of	B-X
AASs	B-X
are	B-X
finally	B-X
found	B-X
affected	B-X
by	B-X
other	B-X
alternative	B-X
diagnoses	B-X
.	B-X
In	B-X
critically	B-X
ill	B-X
patients	B-X
,	B-X
decision	B-X
to	B-X
perform	B-X
CTA	B-X
is	B-X
usually	B-X
straightforward	B-X
,	B-X
as	B-X
exam	B-X
benefits	B-X
largely	B-X
outweigh	B-X
risks	B-X
.	B-X
In	B-X
patients	B-X
with	B-X
ST-tract	B-X
elevation	B-X
on	B-X
ECG	B-X
,	B-X
suspected	B-X
primary	B-X
ischemic	B-X
stroke	B-X
and	B-X
in	B-X
stable	B-X
patients	B-X
(	B-X
representing	B-X
the	B-X
most	B-X
prevalent	B-X
ED	B-X
scenarios	B-X
)	B-X
,	B-X
proper	B-X
selection	B-X
of	B-X
patients	B-X
necessitating	B-X
CTA	B-X
is	B-X
cumbersome	B-X
,	B-X
due	B-X
to	B-X
concurrent	B-X
risks	B-X
of	B-X
misdiagnosis	B-X
and	B-X
over-testing	B-X
.	B-X
Therapeutic	B-X
management	B-X
includes	B-X
medical	B-X
therapy	B-X
for	B-X
all	B-X
patients	B-X
including	B-X
an	B-X
opioid	B-X
and	B-X
anti-impulse	B-X
drugs	B-X
(	B-X
a	B-X
beta-blocker	B-X
and	B-X
a	B-X
vasodilator	B-X
)	B-X
,	B-X
targeting	B-X
a	B-X
heart	B-X
rate	B-X
of	B-X
60	B-X
bpm	B-X
and	B-X
systolic	B-X
blood	B-X
pressure	B-X
of	B-X
100-120	B-X
mmHg	B-X
.	B-X
For	B-X
uncomplicated	B-X
type	B-X
B	B-X
AASs	B-X
,	B-X
optimal	B-X
medical	B-X
therapy	B-X
is	B-X
the	B-X
current	B-X
standard	B-X
of	B-X
care	B-X
.	B-X

In	O
contrast	O
,	O
Epi132	O
and	O
the	O
only	O
patient	B-Species
for	O
whom	O
we	O
previously	O
identified	O
a	O
non	O
-	O
functional	O
CHEK2	O
mutation	O
(	O
1368InsA	O
;	O
coding	O
for	O
a	O
non	O
-	O
functional	O
protein	O
translate	O
with	O
cytoplasmic	O
location	O
[	O
26	O
]	O
)	O
expressed	O
resistance	O
to	O
epirubicin	O
and	O
doxorubicin	O
,	O
respectively	O
.	O

Arg175His	O
is	O
a	O
p53	O
"	O
hot	O
-	O
spot	O
"	O
structural	O
mutation	O
reported	O
to	O
have	O
defects	O
with	O
respect	O
to	O
transcriptional	O
activation	O
and	O
also	O
to	O
negatively	O
interact	O
with	O
wild	O
-	O
type	O
p53	O
[	O
55	O
]	O
.	O

While	O
this	O
mutation	O
has	O
been	O
shown	O
to	O
enhance	O
chemoresistance	O
upon	O
transfection	O
into	O
p53	O
null	O
Saos	O
-	O
2	O
cells	O
[	O
56	O
]	O
,	O
these	O
osteosarcoma	O
-	O
derived	O
cells	O
may	O
not	O
necessarily	O
be	O
representative	O
for	O
breast	O
cancers	O
in	O
vivo	O
.	O

Recent	O
evidence	O
strongly	O
support	O
p53	O
to	O
be	O
involved	O
also	O
in	O
non	O
-	O
transcriptional	O
mediated	O
apoptosis	O
by	O
interacting	O
with	O
the	O
Bcl	O
-	O
2	O
/	O
Bax	O
system	O
[	O
57	O
]	O
,	O
and	O
transcription	O
-	O
defect	O
structural	O
p53	O
mutants	O
have	O
been	O
shown	O
to	O
execute	O
non	O
-	O
transcriptional	O
apoptosis	O
in	O
experimental	O
systems	O
[	O
58	O
]	O
.	O

Concomitant	O
inactivation	O
of	O
Chk2	O
and	O
p53	O
in	O
breast	O
cancer	O
has	O
been	O
recorded	O
by	O
others	O
[	O
59	O
]	O
,	O
and	O
the	O
finding	O
that	O
a	O
somatic	O
mutation	O
may	O
generate	O
a	O
"	O
growth	O
advantage	O
"	O
in	O
tumor	O
cells	O
already	O
harboring	O
a	O
germline	O
CHEK2	O
mutation	O
may	O
not	O
implicate	O
an	O
effect	O
on	O
drug	O
sensitivity	O
in	O
tumors	O
not	O
yet	O
exposed	O
to	O
cytotoxic	O
compounds	O
.	O

Rather	O
,	O
it	O
may	O
indicate	O
a	O
growth	O
advantage	O
,	O
probably	O
related	O
to	O
loss	O
of	O
p21	O
function	O
.	O

Notably	O
,	O
in	O
a	O
previous	O
study	O
we	O
found	O
the	O
p21	O
polymorphism	O
G251A	O
to	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
developing	O
large	O
breast	O
cancers	O
but	O
to	O
have	O
no	O
effect	O
on	O
drug	O
sensitivity	O
[	O
60	O
]	O
,	O
indicating	O
that	O
growth	O
rate	O
and	O
drug	O
resistance	O
may	O
be	O
regulated	O
independently	O
.	O

Taken	O
together	O
,	O
we	O
believe	O
our	O
findings	O
advocate	O
a	O
role	O
for	O
Chk2	O
in	O
executing	O
cellular	O
response	O
to	O
anthracycline	O
-	O
induced	O
DNA	O
damage	O
.	O

As	O
mentioned	O
above	O
,	O
removing	O
TP53	O
mutated	O
tumors	O
including	O
the	O
double	O
-	O
mutated	O
Epi203	O
from	O
statistical	O
analysis	O
,	O
CHEK2	O
mutation	O
status	O
still	O
predicted	O
for	O
resistance	O
to	O
anthracycline	O
therapy	O
.	O

In	O
addition	O
,	O
removing	O
the	O
tumors	O
harboring	O
the	O
Arg175His	O
mutation	O
from	O
the	O
p53	O
"	O
L2	O
/	O
L3	O
"	O
group	O
strengthened	O
the	O
correlation	O
to	O
lack	O
of	O
treatment	O
response	O
to	O
epirubicin	O
(	O
p	O
=	O
0	O
.	O
0005	O
)	O
.	O

Comparing	O
the	O
effects	O
of	O
mutations	O
in	O
the	O
CHEK2	O
gene	O
to	O
TP53	O
mutations	O
indirectly	O
underlines	O
the	O
importance	O
of	O
the	O
role	O
of	O
Chk2	O
to	O
chemoresistance	O
.	O

Our	O
present	O
findings	O
as	O
well	O
as	O
results	O
from	O
our	O
previous	O
studies	O
[	O
13	O
]	O
,	O
[	O
14	O
]	O
revealed	O
that	O
about	O
50	O
%	O
of	O
the	O
patients	B-Species
with	O
tumors	O
harboring	O
TP53	O
L2	O
/	O
L3	O
mutations	O
to	O
be	O
non	O
-	O
responders	O
to	O
primary	O
therapy	O
.	O

In	O
contrast	O
,	O
all	O
our	O
three	O
patients	B-Species
harboring	O
a	O
non	O
-	O
functional	O
CHEK2	O
mutation	O
(	O
the	O
two	O
Arg95Ter	O
mutated	O
patients	B-Species
here	O
and	O
our	O
previous	O
patient	B-Species
harboring	O
the	O
1368InsA	O
)	O
expressed	O
primary	O
resistance	O
to	O
therapy	O
.	O

We	O
previously	O
hypothesized	O
that	O
therapy	O
response	O
in	O
tumors	O
harboring	O
TP53	O
L2	O
/	O
L3	O
mutations	O
could	O
be	O
due	O
to	O
redundant	O
pathways	O
acting	O
in	O
concert	O
[	O
3	O
]	O
.	O

Although	O
no	O
definite	O
conclusion	O
should	O
be	O
drawn	O
from	O
a	O
limited	O
number	O
of	O
observation	O
,	O
the	O
fact	O
that	O
Chk2	O
not	O
only	O
phosphorylates	O
p53	O
but	O
also	O
phosphorylates	O
other	O
substrates	O
such	O
as	O
Cdc25A	O
and	O
Cdc25C	O
[	O
54	O
]	O
and	O
E2F1	O
in	O
response	O
to	O
etoposide	O
-	O
induced	O
DNA	O
damage	O
[	O
61	O
]	O
may	O
indicate	O
that	O
inactivation	O
of	O
redundant	O
pathways	O
could	O
take	O
place	O
in	O
parallel	O
.	O

The	O
literature	O
remains	O
inconsistent	O
with	O
respect	O
to	O
whether	O
the	O
border	O
amino	O
acids	O
163	O
,	O
195	O
,	O
236	O
and	O
251	O
should	O
be	O
included	O
in	O
the	O
p53	O
L2	O
and	O
L3	O
domains	O
[	O
12	O
]	O
.	O

Taking	O
a	O
conservative	O
approach	O
,	O
we	O
classified	O
patient	B-Species
Epi56	O
,	O
harboring	O
a	O
mutation	O
in	O
codon	O
163	O
,	O
as	O
a	O
L2	O
/	O
L3	O
mutant	O
.	O

The	O
patient	B-Species
harboring	O
this	O
mutation	O
responded	O
to	O
therapy	O
(	O
PR	O
)	O
.	O
<EOS>	B-X
Tyrosine	B-X
kinase	B-X
inhibitors	B-X
(	B-X
TKIs	B-X
)	B-X
have	B-X
greatly	B-X
improved	B-X
the	B-X
survival	B-X
of	B-X
non-small	B-X
cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
patients	B-X
with	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
(	B-X
EGFR	B-X
)	B-X
-TKI	B-X
sensitive	B-X
mutations	B-X
such	B-X
as	B-X
L858R	B-X
and	B-X
exon	B-X
19	B-X
deletions	B-X
.	B-X
The	B-X
third-generation	B-X
EGFR-TKI	B-X
osimertinib	B-X
,	B-X
an	B-X
irreversible	B-X
TKI	B-X
,	B-X
is	B-X
approved	B-X
as	B-X
a	B-X
therapy	B-X
for	B-X
advanced	B-X
NSCLC	B-X
with	B-X
EGFR	B-X
sensitive	B-X
mutations	B-X
.	B-X
Recently	B-X
,	B-X
osimertinib	B-X
showed	B-X
antitumor	B-X
activity	B-X
against	B-X
NSCLC	B-X
in	B-X
patients	B-X
harboring	B-X
an	B-X
uncommon	B-X
mutation	B-X
such	B-X
as	B-X
an	B-X
exon	B-X
20	B-X
insertion	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
present	B-X
a	B-X
patient	B-X
diagnosed	B-X
with	B-X
stage	B-X
IV	B-X
NSCLC	B-X
with	B-X
an	B-X
EGFR	B-X
L858R/V843I	B-X
mutation	B-X
complex	B-X
who	B-X
benefited	B-X
remarkably	B-X
from	B-X
osimertinib	B-X
therapy	B-X
.	B-X
The	B-X
patient	B-X
was	B-X
a	B-X
41-year-old	B-X
Chinese	B-X
female	B-X
who	B-X
complained	B-X
of	B-X
backache	B-X
in	B-X
October	B-X
2018	B-X
.	B-X
Targeted	B-X
next-generation	B-X
sequencing	B-X
(	B-X
NGS	B-X
)	B-X
of	B-X
hydrothorax	B-X
was	B-X
performed	B-X
and	B-X
the	B-X
coexistence	B-X
of	B-X
somatic	B-X
L858RI	B-X
and	B-X
V843I	B-X
mutations	B-X
in	B-X
EGFR	B-X
exon	B-X
21	B-X
was	B-X
discovered	B-X
on	B-X
November	B-X
13	B-X
,	B-X
2018	B-X
.	B-X
Osimertinib	B-X
therapy	B-X
(	B-X
80	B-X
mg	B-X
daily	B-X
)	B-X
was	B-X
administered	B-X
for	B-X
12	B-X
months	B-X
which	B-X
resulted	B-X
in	B-X
an	B-X
initial	B-X
partial	B-X
response	B-X
(	B-X
PR	B-X
)	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
patient	B-X
began	B-X
combination	B-X
therapy	B-X
with	B-X
osimertinib	B-X
(	B-X
80	B-X
mg	B-X
daily	B-X
)	B-X
and	B-X
bevacizumab	B-X
(	B-X
500	B-X
mg	B-X
daily	B-X
)	B-X
,	B-X
leading	B-X
to	B-X
disease	B-X
stabilisation	B-X
until	B-X
June	B-X
2020	B-X
.	B-X
Of	B-X
note	B-X
,	B-X
during	B-X
treatment	B-X
,	B-X
the	B-X
patient	B-X
achieved	B-X
sustained	B-X
control	B-X
of	B-X
metastatic	B-X
brain	B-X
and	B-X
bone	B-X
lesions	B-X
.	B-X
To	B-X
the	B-X
best	B-X
of	B-X
our	B-X
knowledge	B-X
,	B-X
we	B-X
report	B-X
here	B-X
the	B-X
first	B-X
known	B-X
case	B-X
of	B-X
an	B-X
NSCLC	B-X
patient	B-X
with	B-X
a	B-X
somatic	B-X
EGFR	B-X
L858R/V843I	B-X
mutation	B-X
complex	B-X
who	B-X
responded	B-X
well	B-X
to	B-X
osimertinib	B-X
.	B-X
Our	B-X
findings	B-X
provide	B-X
theoretical	B-X
guidance	B-X
and	B-X
expand	B-X
the	B-X
list	B-X
of	B-X
potential	B-X
beneficiaries	B-X
of	B-X
EGFR-TKI	B-X
therapy	B-X
.	B-X

If	O
this	O
mutation	O
was	O
classified	O
as	O
outside	O
the	O
L2	O
domain	O
,	O
our	O
p	O
-	O
value	O
had	O
been	O
strengthened	O
from	O
p	O
=	O
0	O
.	O
0136	O
to	O
p	O
=	O
0	O
.	O
0096	O
.	O

Germline	O
mutations	O
in	O
TP53	O
cause	O
the	O
Li	O
-	O
Fraumeni	O
and	O
Li	O
-	O
Fraumeni	O
-	O
like	O
cancer	O
disposition	O
syndromes	O
.	O

However	O
,	O
while	O
the	O
germline	O
and	O
somatic	O
mutations	O
associated	O
with	O
these	O
syndromes	O
reveal	O
a	O
preference	O
for	O
the	O
same	O
codons	O
[	O
48	O
]	O
,	O
TP53	O
mutations	O
affecting	O
the	O
DNA	O
-	O
binding	O
domains	O
seem	O
associated	O
with	O
a	O
poor	O
prognosis	O
[	O
62	O
]	O
,	O
[	O
63	O
]	O
,	O
[	O
64	O
]	O
and	O
,	O
in	O
particular	O
,	O
drug	O
resistance	O
[	O
14	O
]	O
,	O
[	O
40	O
]	O
in	O
breast	O
cancer	O
.	O

Thus	O
,	O
tumor	O
suppression	O
and	O
tumor	O
cell	O
response	O
to	O
chemotherapeutics	O
may	O
involve	O
different	O
parts	O
of	O
p53	O
protein	O
function	O
.	O

Following	O
an	O
initial	O
report	O
identifying	O
a	O
CHEK2	O
mutation	O
in	O
a	O
family	O
expressing	O
characteristics	O
of	O
the	O
Li	O
-	O
Fraumeni	O
syndrome	O
[	O
65	O
]	O
,	O
recent	O
evidence	O
has	O
linked	O
CHEK2	O
founder	O
mutations	O
to	O
a	O
moderately	O
increased	O
risk	O
of	O
breast	O
-	O
and	O
colorectal	O
cancers	O
with	O
some	O
additional	O
disposition	O
for	O
other	O
malignancies	O
as	O
well	O
[	O
66	O
]	O
.	O

However	O
,	O
cancer	O
incidence	O
and	O
phenotypes	O
did	O
not	O
reveal	O
an	O
aggressive	O
Li	O
-	O
Fraumeni	O
or	O
Li	O
-	O
Fraumeni	O
-	O
like	O
tumor	O
pattern	O
.	O
<EOS>	B-X
Factors	B-X
associated	B-X
with	B-X
more	B-X
aggressive	B-X
disease	B-X
biology	B-X
tend	B-X
to	B-X
increase	B-X
in	B-X
frequency	B-X
with	B-X
increasing	B-X
age	B-X
,	B-X
whilst	B-X
tolerability	B-X
of	B-X
treatment	B-X
strategies	B-X
decreases	B-X
.	B-X
The	B-X
Clinical	B-X
Spectrum	B-X
of	B-X
The	B-X
incidence	B-X
of	B-X
cutaneous	B-X
melanoma	B-X
continues	B-X
to	B-X
increase	B-X
in	B-X
pale	B-X
skinned	B-X
peoples	B-X
in	B-X
Europe	B-X
and	B-X
elsewhere	B-X
.	B-X
Epidemiological	B-X
studies	B-X
identified	B-X
genetically	B-X
determined	B-X
phenotypes	B-X
such	B-X
as	B-X
pale	B-X
skin	B-X
,	B-X
freckles	B-X
and	B-X
red	B-X
hair	B-X
,	B-X
and	B-X
sunburn	B-X
as	B-X
risk	B-X
factors	B-X
for	B-X
this	B-X
cancer	B-X
.	B-X

Similar	O
to	O
the	O
two	O
patients	B-Species
in	O
our	O
paclitaxel	O
treatment	O
arm	O
harboring	O
the	O
rare	O
but	O
previously	O
characterized	O
mutation	O
Arg117Gly	O
and	O
the	O
patient	B-Species
with	O
the	O
Ile157Thr	O
mutation	O
,	O
they	O
expressed	O
a	O
moderately	O
increased	O
risk	O
of	O
breast	O
and	O
gastrointestinal	O
cancers	O
(	O
Fig	O
.	O
6	O
)	O
.	O

Thus	O
,	O
CHEK2	O
resembles	O
TP53	O
in	O
as	O
much	O
as	O
there	O
seems	O
to	O
be	O
no	O
direct	O
correlation	O
between	O
effects	O
of	O
individual	O
mutations	O
with	O
respect	O
to	O
tumor	O
suppression	O
and	O
drug	O
resistance	O
.	O

Our	O
finding	O
that	O
TP53	O
mutations	O
located	O
to	O
the	O
DNA	O
-	O
binding	O
domains	O
predicts	O
drug	O
resistance	O
may	O
indicate	O
transcriptional	O
mechanisms	O
to	O
be	O
involved	O
in	O
drug	O
-	O
induced	O
cell	O
death	O
.	O

p53	O
induced	O
apoptosis	O
has	O
been	O
associated	O
with	O
transcriptional	O
induction	O
of	O
genes	O
including	O
Puma	O
and	O
Noxa	O
as	O
well	O
as	O
Bax	O
in	O
experimental	O
systems	O
[	O
55	O
]	O
,	O
[	O
67	O
]	O
,	O
[	O
68	O
]	O
.	O

Yet	O
,	O
recent	O
evidence	O
has	O
revealed	O
p53	O
to	O
induce	O
apoptosis	O
through	O
non	O
-	O
transcriptional	O
mechanisms	O
by	O
direct	O
protein	O
interactions	O
with	O
members	O
of	O
the	O
Bcl	O
-	O
2	O
/	O
Bax	O
system	O
and	O
mitochondrial	O
release	O
of	O
cytochrom	O
c	O
[	O
57	O
]	O
,	O
[	O
69	O
]	O
.	O

In	O
deed	O
,	O
there	O
is	O
evidence	O
that	O
the	O
DNA	O
-	O
binding	O
domains	O
,	O
in	O
particular	O
the	O
L3	O
part	O
of	O
the	O
protein	O
,	O
may	O
be	O
critical	O
also	O
to	O
transcriptional	O
-	O
independent	O
apoptosis	O
[	O
70	O
]	O
.	O

Of	O
particular	O
note	O
is	O
the	O
finding	O
that	O
Chk2	O
may	O
regulate	O
transcriptional	O
-	O
independent	O
p53	O
-	O
mediated	O
apoptosis	O
in	O
response	O
to	O
DNA	O
-	O
damage	O
created	O
through	O
ionizing	O
irradiation	O
[	O
71	O
]	O
.	O

Interestingly	O
,	O
Krajewski	O
et	O
al	O
[	O
72	O
]	O
reported	O
low	O
expression	O
of	O
Bax	O
assessed	O
by	O
immunostaining	O
to	O
be	O
associated	O
with	O
a	O
low	O
response	O
to	O
chemotherapy	O
in	O
metastatic	O
breast	O
cancer	O
.	O

Although	O
no	O
conclusion	O
should	O
be	O
drawn	O
at	O
this	O
stage	O
,	O
together	O
these	O
findings	O
are	O
consistent	O
with	O
the	O
challenging	O
hypothesis	O
that	O
transcription	O
-	O
independent	O
activation	O
of	O
Bax	O
following	O
Chk2	O
-	O
phosphorylation	O
may	O
represent	O
a	O
key	O
pathway	O
in	O
p53	O
dependent	O
cell	O
death	O
in	O
breast	O
cancer	O
in	O
vivo	O
.	O

p14	O
acts	O
by	O
releasing	O
p53	O
from	O
MDM2	O
binding	O
,	O
and	O
has	O
been	O
related	O
to	O
oncogene	O
-	O
induced	O
p53	O
activation	O
[	O
73	O
]	O
.	O

Recently	O
,	O
p14	O
was	O
shown	O
to	O
affect	O
p53	O
by	O
additional	O
mechanisms	O
,	O
including	O
acetylations	O
[	O
74	O
]	O
,	O
response	O
to	O
ionizing	O
radiation	O
in	O
human	B-Species
fibroblasts	O
[	O
75	O
]	O
,	O
and	O
tumor	O
-	O
suppression	O
following	O
ionizing	O
radiation	O
in	O
mice	B-Species
[	O
76	O
]	O
,	O
[	O
77	O
]	O
.	O

These	O
findings	O
further	O
links	O
the	O
retinoblastoma	O
and	O
p53	O
pathways	O
[	O
28	O
]	O
.	O
<EOS>	B-X
At	B-X
recurrence	B-X
,	B-X
these	B-X
tumors	B-X
were	B-X
hypermutated	B-X
and	B-X
harbored	B-X
driver	B-X
mutations	B-X
in	B-X
the	B-X
RB	B-X
(	B-X
retinoblastoma	B-X
)	B-X
and	B-X
Akt-mTOR	B-X
(	B-X
mammalian	B-X
target	B-X
of	B-X
rapamycin	B-X
)	B-X
pathways	B-X
that	B-X
bore	B-X
the	B-X
signature	B-X
of	B-X
TMZ-induced	B-X
mutagenesis	B-X
.	B-X
These	B-X
complexes	B-X
exert	B-X
their	B-X
regulatory	B-X
function	B-X
by	B-X
phosphorylation	B-X
of	B-X
key	B-X
proteins	B-X
involved	B-X
in	B-X
cell	B-X
cycle	B-X
transitions	B-X
,	B-X
such	B-X
as	B-X
the	B-X
product	B-X
encoded	B-X
by	B-X
the	B-X
retinoblastoma	B-X
gene	B-X
(	B-X
pRB	B-X
)	B-X
.	B-X
It	B-X
appears	B-X
that	B-X
the	B-X
molecular	B-X
networking	B-X
of	B-X
these	B-X
proteins	B-X
and	B-X
complexes	B-X
impact	B-X
on	B-X
two	B-X
fundamental	B-X
cell	B-X
cycle	B-X
regulators	B-X
:	B-X
p53	B-X
and	B-X
pRB	B-X
.	B-X
Cross-talk	B-X
pathways	B-X
between	B-X
these	B-X
two	B-X
nuclear	B-X
proteins	B-X
are	B-X
being	B-X
delineated	B-X
,	B-X
implying	B-X
potential	B-X
links	B-X
between	B-X
p53	B-X
and	B-X
pRB	B-X
in	B-X
cell	B-X
cycle	B-X
control	B-X
,	B-X
apoptosis	B-X
,	B-X
and	B-X
tumor	B-X
progression	B-X
.	B-X
Based	B-X
on	B-X
these	B-X
findings	B-X
,	B-X
new	B-X
strategies	B-X
are	B-X
being	B-X
developed	B-X
in	B-X
the	B-X
emerging	B-X
field	B-X
of	B-X
gene	B-X
replacement-therapy	B-X
.	B-X

As	O
such	O
,	O
we	O
believe	O
the	O
negative	O
finding	O
with	O
respect	O
to	O
its	O
role	O
in	O
chemoresistance	O
adds	O
important	O
information	O
.	O

Contrasting	O
earlier	O
findings	O
by	O
us	O
and	O
others	O
[	O
15	O
]	O
,	O
a	O
recent	O
study	O
revealed	O
TP53	O
mutations	O
to	O
be	O
associated	O
with	O
increased	O
likelihood	O
of	O
having	O
a	O
complete	O
response	O
to	O
chemotherapy	O
[	O
16	O
]	O
.	O

These	O
results	O
may	O
not	O
necessarily	O
be	O
at	O
conflict	O
.	O
<EOS>	B-X
This	B-X
review	B-X
provides	B-X
a	B-X
discussion	B-X
of	B-X
the	B-X
cellular	B-X
mechanisms	B-X
and	B-X
pathways	B-X
involved	B-X
in	B-X
burn	B-X
injury	B-X
,	B-X
resultant	B-X
systemic	B-X
effects	B-X
on	B-X
organ	B-X
systems	B-X
,	B-X
current	B-X
management	B-X
and	B-X
treatment	B-X
,	B-X
and	B-X
potential	B-X
therapies	B-X
that	B-X
we	B-X
may	B-X
see	B-X
implemented	B-X
in	B-X
the	B-X
future	B-X
.	B-X
Scars	B-X
are	B-X
inflexible	B-X
and	B-X
cause	B-X
functional	B-X
impairment	B-X
which	B-X
may	B-X
prompt	B-X
a	B-X
change	B-X
in	B-X
career	B-X
and	B-X
have	B-X
financial	B-X
repercussions	B-X
.	B-X
Fatigue	B-X
may	B-X
be	B-X
defined	B-X
as	B-X
physical	B-X
and/or	B-X
mental	B-X
weariness	B-X
resulting	B-X
from	B-X
exertion	B-X
,	B-X
that	B-X
is	B-X
,	B-X
an	B-X
inability	B-X
to	B-X
continue	B-X
exercise	B-X
at	B-X
the	B-X
same	B-X
intensity	B-X
with	B-X
a	B-X
resultant	B-X
deterioration	B-X
in	B-X
performance	B-X
.	B-X
Because	B-X
fatigue	B-X
may	B-X
result	B-X
from	B-X
a	B-X
number	B-X
of	B-X
causes	B-X
,	B-X
including	B-X
loss	B-X
of	B-X
muscle	B-X
mass	B-X
,	B-X
deconditioning	B-X
,	B-X
nutritional	B-X
deficiencies	B-X
,	B-X
oxygen	B-X
delivery	B-X
,	B-X
and	B-X
anemia	B-X
,	B-X
it	B-X
should	B-X
be	B-X
treated	B-X
comprehensively	B-X
.	B-X

In	O
the	O
latter	O
study	O
,	O
patients	B-Species
received	O
treatment	O
with	O
a	O
"	O
dose	O
-	O
dense	O
"	O
chemotherapy	O
regimen	O
;	O
if	O
confirmed	O
,	O
the	O
combined	O
data	O
may	O
outline	O
a	O
therapeutic	O
indication	O
for	O
aggressive	O
dose	O
-	O
dense	O
therapy	O
based	O
on	O
tumor	O
TP53	O
/	O
CHEK2	O
status	O
.	O

So	O
far	O
attempts	O
to	O
identify	O
single	O
markers	O
and	O
,	O
more	O
recently	O
,	O
gene	O
expression	O
arrays	O
predicting	O
chemoresistance	O
have	O
not	O
proved	O
successful	O
(	O
see	O
refs	O
in	O
[	O
9	O
]	O
,	O
[	O
10	O
]	O
)	O
.	O

The	O
findings	O
presented	O
here	O
reveal	O
for	O
the	O
first	O
time	O
defects	O
in	O
a	O
functional	O
gene	O
cascade	O
to	O
be	O
associated	O
with	O
drug	O
resistance	O
in	O
a	O
human	B-Species
cancer	O
in	O
vivo	O
.	O

Moreover	O
,	O
the	O
findings	O
are	O
made	O
in	O
breast	O
cancer	O
,	O
the	O
most	O
frequent	O
malignant	O
disease	O
among	O
women	O
in	O
the	O
industrialized	O
world	O
,	O
and	O
relate	O
to	O
resistance	O
to	O
anthracyclines	O
,	O
the	O
type	O
of	O
cytotoxic	O
compounds	O
most	O
frequently	O
employed	O
for	O
this	O
malignancy	O
.	O

While	O
the	O
only	O
study	O
we	O
are	O
aware	O
of	O
comparing	O
TP53	O
mutation	O
status	O
in	O
primaries	O
and	O
their	O
distant	O
metastases	O
suggested	O
an	O
increasing	O
fraction	O
of	O
tumors	O
to	O
express	O
mutated	O
TP53	O
during	O
progression	O
[	O
78	O
]	O
,	O
we	O
do	O
not	O
know	O
the	O
potential	O
contribution	O
of	O
either	O
TP53	O
or	O
CHEK2	O
mutations	O
to	O
drug	O
resistance	O
in	O
micrometastases	O
or	O
in	O
metastatic	O
disease	O
.	O
<EOS>	B-X
Recent	B-X
work	B-X
has	B-X
uncovered	B-X
the	B-X
unique	B-X
biology	B-X
of	B-X
metastasis-initiating	B-X
cells	B-X
that	B-X
results	B-X
in	B-X
tumor	B-X
growth	B-X
in	B-X
distant	B-X
organs	B-X
,	B-X
evasion	B-X
of	B-X
immune	B-X
surveillance	B-X
and	B-X
co-option	B-X
of	B-X
metastatic	B-X
microenvironments	B-X
.	B-X
Here	B-X
we	B-X
review	B-X
recent	B-X
progress	B-X
that	B-X
is	B-X
enabling	B-X
therapeutic	B-X
advances	B-X
in	B-X
treating	B-X
both	B-X
micro-	B-X
and	B-X
macrometastases	B-X
.	B-X
These	B-X
studies	B-X
reveal	B-X
both	B-X
the	B-X
origins	B-X
and	B-X
nature	B-X
of	B-X
metastases	B-X
and	B-X
identify	B-X
new	B-X
opportunities	B-X
for	B-X
developing	B-X
more	B-X
effective	B-X
strategies	B-X
to	B-X
target	B-X
metastatic	B-X
relapse	B-X
and	B-X
improve	B-X
patient	B-X
outcomes	B-X
.	B-X
The	B-X
lack	B-X
of	B-X
a	B-X
systemic	B-X
understanding	B-X
of	B-X
this	B-X
complex	B-X
phenomenon	B-X
has	B-X
limited	B-X
progress	B-X
in	B-X
developing	B-X
treatments	B-X
for	B-X
metastatic	B-X
disease	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
present	B-X
some	B-X
of	B-X
the	B-X
current	B-X
perspectives	B-X
on	B-X
the	B-X
complexity	B-X
of	B-X
cancer	B-X
metastasis	B-X
,	B-X
the	B-X
multiscale	B-X
nature	B-X
of	B-X
its	B-X
progression	B-X
,	B-X
and	B-X
a	B-X
systems-level	B-X
view	B-X
of	B-X
the	B-X
processes	B-X
underlying	B-X
the	B-X
invasive	B-X
spread	B-X
of	B-X
cancer	B-X
cells	B-X
.	B-X

Yet	O
the	O
finding	O
that	O
one	O
of	O
our	O
non	O
-	O
functional	O
CHEK2	O
mutations	O
associated	O
with	O
chemoresistance	O
(	O
1368InsA	O
)	O
occurred	O
as	O
a	O
somatic	O
,	O
not	O
germline	O
mutation	O
,	O
suggest	O
such	O
mutations	O
may	O
be	O
selected	O
for	O
during	O
tumor	O
progression	O
.	O

We	O
propose	O
the	O
findings	O
presented	O
here	O
provide	O
important	O
beacons	O
identifying	O
a	O
functional	O
pathway	O
[	O
3	O
]	O
likely	O
to	O
be	O
disturbed	O
through	O
different	O
mechanisms	O
in	O
relation	O
to	O
therapy	O
resistance	O
in	O
advanced	O
disease	O
.	O

In	O
conclusion	O
,	O
we	O
believe	O
our	O
findings	O
here	O
that	O
mutations	O
in	O
the	O
TP53	O
and	O
CHEK2	O
genes	O
each	O
may	O
cause	O
resistance	O
to	O
anthracycline	O
therapy	O
in	O
primary	O
tumors	O
to	O
have	O
wide	O
implications	O
to	O
future	O
research	O
in	O
this	O
area	O
.	O

While	O
results	O
from	O
experimental	O
systems	O
are	O
mandatory	O
generating	O
hypotheses	O
,	O
conflicting	O
data	O
from	O
in	O
vitro	O
studies	O
underlines	O
the	O
pivotal	O
role	O
of	O
identifying	O
defects	O
associated	O
with	O
therapy	O
resistance	O
in	O
vivo	O
.	O

Either	O
through	O
mutations	O
of	O
the	O
genes	O
themselves	O
,	O
or	O
inactivation	O
of	O
this	O
functional	O
cascade	O
through	O
co	O
-	O
factors	O
,	O
we	O
believe	O
identification	O
of	O
the	O
Chk2	O
-	O
p53	O
axis	O
as	O
critical	O
to	O
anthracycline	O
therapy	O
response	O
provides	O
a	O
functional	O
clue	O
for	O
further	O
investigations	O
in	O
this	O
area	O
.	O
<EOS>	B-X
Autism	B-X
spectrum	B-X
disorders	B-X
(	B-X
ASD	B-X
)	B-X
are	B-X
believed	B-X
to	B-X
have	B-X
genetic	B-X
and	B-X
environmental	B-X
origins	B-X
,	B-X
yet	B-X
in	B-X
only	B-X
a	B-X
modest	B-X
fraction	B-X
of	B-X
individuals	B-X
can	B-X
specific	B-X
causes	B-X
be	B-X
identified	B-X
.	B-X
To	B-X
identify	B-X
further	B-X
genetic	B-X
risk	B-X
factors	B-X
,	B-X
here	B-X
we	B-X
assess	B-X
the	B-X
role	B-X
of	B-X
de	B-X
novo	B-X
mutations	B-X
in	B-X
ASD	B-X
by	B-X
sequencing	B-X
the	B-X
exomes	B-X
of	B-X
ASD	B-X
cases	B-X
and	B-X
their	B-X
parents	B-X
(	B-X
n	B-X
=	B-X
175	B-X
trios	B-X
)	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
proteins	B-X
encoded	B-X
by	B-X
genes	B-X
that	B-X
harboured	B-X
de	B-X
novo	B-X
missense	B-X
or	B-X
nonsense	B-X
mutations	B-X
showed	B-X
a	B-X
higher	B-X
degree	B-X
of	B-X
connectivity	B-X
among	B-X
themselves	B-X
and	B-X
to	B-X
previous	B-X
ASD	B-X
genes	B-X
as	B-X
indexed	B-X
by	B-X
protein-protein	B-X
interaction	B-X
screens	B-X
.	B-X
The	B-X
small	B-X
increase	B-X
in	B-X
the	B-X
rate	B-X
of	B-X
de	B-X
novo	B-X
events	B-X
,	B-X
when	B-X
taken	B-X
together	B-X
with	B-X
the	B-X
protein	B-X
interaction	B-X
results	B-X
,	B-X
are	B-X
consistent	B-X
with	B-X
an	B-X
important	B-X
but	B-X
limited	B-X
role	B-X
for	B-X
de	B-X
novo	B-X
point	B-X
mutations	B-X
in	B-X
ASD	B-X
,	B-X
similar	B-X
to	B-X
that	B-X
documented	B-X
for	B-X
de	B-X
novo	B-X
copy	B-X
number	B-X
variants	B-X
.	B-X
Genetic	B-X
models	B-X
incorporating	B-X
these	B-X
data	B-X
indicate	B-X
that	B-X
most	B-X
of	B-X
the	B-X
observed	B-X
de	B-X
novo	B-X
events	B-X
are	B-X
unconnected	B-X
to	B-X
ASD	B-X
;	B-X
those	B-X
that	B-X
do	B-X
confer	B-X
risk	B-X
are	B-X
distributed	B-X
across	B-X
many	B-X
genes	B-X
and	B-X
are	B-X
incompletely	B-X
penetrant	B-X
(	B-X
that	B-X
is	B-X
,	B-X
not	B-X
necessarily	B-X
sufficient	B-X
for	B-X
disease	B-X
)	B-X
.	B-X
Our	B-X
results	B-X
support	B-X
polygenic	B-X
models	B-X
in	B-X
which	B-X
spontaneous	B-X
coding	B-X
mutations	B-X
in	B-X
any	B-X
of	B-X
a	B-X
large	B-X
number	B-X
of	B-X
genes	B-X
increases	B-X
risk	B-X
by	B-X
5-	B-X
to	B-X
20-fold	B-X
.	B-X
Despite	B-X
the	B-X
challenge	B-X
posed	B-X
by	B-X
such	B-X
models	B-X
,	B-X
results	B-X
from	B-X
de	B-X
novo	B-X
events	B-X
and	B-X
a	B-X
large	B-X
parallel	B-X
case-control	B-X
study	B-X
provide	B-X
strong	B-X
evidence	B-X
in	B-X
favour	B-X
of	B-X
CHD8	B-X
and	B-X
KATNAL2	B-X
as	B-X
genuine	B-X
autism	B-X
risk	B-X
factors	B-X
.	B-X

Host	O
immunity	O
in	O
the	O
protective	O
response	O
to	O
vaccination	O
with	O
heat	O
-	O
killed	O
Burkholderia	B-Species
mallei	I-Species
<EOS>	B-X
We	B-X
performed	B-X
initial	B-X
cell	B-X
,	B-X
cytokine	B-X
and	B-X
complement	B-X
depletion	B-X
studies	B-X
to	B-X
investigate	B-X
the	B-X
possible	B-X
role	B-X
of	B-X
these	B-X
effectors	B-X
in	B-X
response	B-X
to	B-X
vaccination	B-X
with	B-X
heat-killed	B-X
Burkholderia	B-X
mallei	B-X
in	B-X
a	B-X
susceptible	B-X
BALB/c	B-X
mouse	B-X
model	B-X
of	B-X
infection	B-X
.	B-X

Abstract	O
<EOS>	B-X
Abstract	B-X
writing	B-X
.	B-X
The	B-X
informative	B-X
abstract	B-X
.	B-X
Crafting	B-X
a	B-X
compelling	B-X
abstract	B-X
.	B-X
Why	B-X
the	B-X
structured	B-X
abstract	B-X
?	B-X

Background	O
<EOS>	B-X
Background	B-X
matching	B-X
is	B-X
the	B-X
most	B-X
familiar	B-X
and	B-X
widespread	B-X
camouflage	B-X
strategy	B-X
:	B-X
avoiding	B-X
detection	B-X
by	B-X
having	B-X
a	B-X
similar	B-X
colour	B-X
and	B-X
pattern	B-X
to	B-X
the	B-X
background	B-X
.	B-X
Background	B-X
is	B-X
thus	B-X
a	B-X
relatively	B-X
modest	B-X
correction	B-X
for	B-X
all	B-X
Z	B-X
opacity	B-X
data	B-X
published	B-X
to	B-X
date	B-X
.	B-X
Background	B-X
estimation	B-X
and	B-X
foreground	B-X
segmentation	B-X
are	B-X
important	B-X
steps	B-X
in	B-X
many	B-X
high-level	B-X
vision	B-X
tasks	B-X
.	B-X
Patient	B-X
Preference	B-X
for	B-X
Telehealth	B-X
Background	B-X
Shapes	B-X
Impressions	B-X
of	B-X
Physicians	B-X
and	B-X
Information	B-X
Recall	B-X
:	B-X
A	B-X
Randomized	B-X
Experiment	B-X
.	B-X

We	O
performed	O
initial	O
cell	O
,	O
cytokine	O
and	O
complement	O
depletion	O
studies	O
to	O
investigate	O
the	O
possible	O
role	O
of	O
these	O
effectors	O
in	O
response	O
to	O
vaccination	O
with	O
heat	O
-	O
killed	O
Burkholderia	B-Species
mallei	I-Species
in	O
a	O
susceptible	O
BALB	O
/	O
c	O
mouse	B-Species
model	O
of	O
infection	O
.	O

Results	O

While	O
protection	O
with	O
heat	O
-	O
killed	O
bacilli	O
did	O
not	O
result	O
in	O
sterilizing	O
immunity	O
,	O
limited	O
protection	O
was	O
afforded	O
against	O
an	O
otherwise	O
lethal	O
infection	O
and	O
provided	O
insight	O
into	O
potential	O
host	O
protective	O
mechanisms	O
.	O
<EOS>	B-X
Since	B-X
the	B-X
spores	B-X
of	B-X
some	B-X
species	B-X
are	B-X
causative	B-X
agents	B-X
of	B-X
much	B-X
food	B-X
spoilage	B-X
,	B-X
food	B-X
poisoning	B-X
,	B-X
and	B-X
human	B-X
disease	B-X
,	B-X
and	B-X
the	B-X
spores	B-X
of	B-X
Bacillus	B-X
anthracis	B-X
are	B-X
a	B-X
major	B-X
bioweapon	B-X
,	B-X
there	B-X
is	B-X
much	B-X
interest	B-X
in	B-X
the	B-X
mechanisms	B-X
of	B-X
spore	B-X
resistance	B-X
and	B-X
how	B-X
these	B-X
spores	B-X
can	B-X
be	B-X
killed	B-X
.	B-X
This	B-X
article	B-X
will	B-X
discuss	B-X
the	B-X
factors	B-X
involved	B-X
in	B-X
spore	B-X
resistance	B-X
to	B-X
agents	B-X
such	B-X
as	B-X
wet	B-X
and	B-X
dry	B-X
heat	B-X
,	B-X
desiccation	B-X
,	B-X
UV	B-X
and	B-X
Î³-radiation	B-X
,	B-X
enzymes	B-X
that	B-X
hydrolyze	B-X
bacterial	B-X
cell	B-X
walls	B-X
,	B-X
and	B-X
a	B-X
variety	B-X
of	B-X
toxic	B-X
chemicals	B-X
,	B-X
including	B-X
genotoxic	B-X
agents	B-X
,	B-X
oxidizing	B-X
agents	B-X
,	B-X
aldehydes	B-X
,	B-X
acid	B-X
,	B-X
and	B-X
alkali	B-X
.	B-X
These	B-X
resistance	B-X
factors	B-X
include	B-X
the	B-X
outer	B-X
layers	B-X
of	B-X
the	B-X
spore	B-X
,	B-X
such	B-X
as	B-X
the	B-X
thick	B-X
proteinaceous	B-X
coat	B-X
that	B-X
detoxifies	B-X
reactive	B-X
chemicals	B-X
;	B-X
the	B-X
relatively	B-X
impermeable	B-X
inner	B-X
spore	B-X
membrane	B-X
that	B-X
restricts	B-X
access	B-X
of	B-X
toxic	B-X
chemicals	B-X
to	B-X
the	B-X
spore	B-X
core	B-X
containing	B-X
the	B-X
spore	B-X
's	B-X
DNA	B-X
and	B-X
most	B-X
enzymes	B-X
;	B-X
the	B-X
low	B-X
water	B-X
content	B-X
and	B-X
high	B-X
level	B-X
of	B-X
dipicolinic	B-X
acid	B-X
in	B-X
the	B-X
spore	B-X
core	B-X
that	B-X
protect	B-X
core	B-X
macromolecules	B-X
from	B-X
the	B-X
effects	B-X
of	B-X
heat	B-X
and	B-X
desiccation	B-X
;	B-X
the	B-X
saturation	B-X
of	B-X
spore	B-X
DNA	B-X
with	B-X
a	B-X
novel	B-X
group	B-X
of	B-X
proteins	B-X
that	B-X
protect	B-X
the	B-X
DNA	B-X
against	B-X
heat	B-X
,	B-X
genotoxic	B-X
chemicals	B-X
,	B-X
and	B-X
radiation	B-X
;	B-X
and	B-X
the	B-X
repair	B-X
of	B-X
radiation	B-X
damage	B-X
to	B-X
DNA	B-X
when	B-X
spores	B-X
germinate	B-X
and	B-X
return	B-X
to	B-X
life	B-X
.	B-X
Despite	B-X
their	B-X
extreme	B-X
resistance	B-X
,	B-X
spores	B-X
can	B-X
be	B-X
killed	B-X
,	B-X
including	B-X
by	B-X
damage	B-X
to	B-X
DNA	B-X
,	B-X
crucial	B-X
spore	B-X
proteins	B-X
,	B-X
the	B-X
spore	B-X
's	B-X
inner	B-X
membrane	B-X
,	B-X
and	B-X
one	B-X
or	B-X
more	B-X
components	B-X
of	B-X
the	B-X
spore	B-X
germination	B-X
apparatus	B-X
.	B-X

Our	O
results	O
demonstrated	O
that	O
mice	B-Species
depleted	O
of	O
either	O
B	O
cells	O
,	O
TNF	O
-	O
alpha	O
or	O
IFN	O
-	O
gamma	O
exhibited	O
decreased	O
survival	O
rates	O
,	O
indicating	O
a	O
role	O
for	O
these	O
effectors	O
in	O
obtaining	O
partial	O
protection	O
from	O
a	O
lethal	O
challenge	O
by	O
the	O
intraperitoneal	O
route	O
.	O
<EOS>	B-X
Neutralization	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
represents	B-X
a	B-X
widely	B-X
used	B-X
therapeutic	B-X
strategy	B-X
for	B-X
autoimmune	B-X
diseases	B-X
including	B-X
inflammatory	B-X
bowel	B-X
disease	B-X
(	B-X
IBD	B-X
)	B-X
.	B-X
However	B-X
,	B-X
the	B-X
fact	B-X
that	B-X
many	B-X
patients	B-X
with	B-X
IBD	B-X
are	B-X
non-responsive	B-X
to	B-X
anti-TNF	B-X
therapies	B-X
suggests	B-X
the	B-X
need	B-X
for	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
TNF	B-X
signaling	B-X
in	B-X
IBD	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
co-deletion	B-X
of	B-X
TNF	B-X
receptor	B-X
1	B-X
(	B-X
TNFR1	B-X
,	B-X
Tnfrsf1a	B-X
)	B-X
in	B-X
the	B-X
Il10	B-X
Aims	B-X
of	B-X
this	B-X
study	B-X
were	B-X
to	B-X
investigate	B-X
the	B-X
effects	B-X
of	B-X
oxaliplatin	B-X
treatment	B-X
on	B-X
the	B-X
proportions	B-X
of	B-X
(	B-X
1	B-X
)	B-X
splenic	B-X
T	B-X
cells	B-X
,	B-X
B	B-X
cells	B-X
,	B-X
macrophages	B-X
,	B-X
pro-/anti-inflammatory	B-X
cytokines	B-X
,	B-X
gene	B-X
expression	B-X
of	B-X
splenic	B-X
cytokines	B-X
,	B-X
chemokines	B-X
,	B-X
and	B-X
mediators	B-X
;	B-X
(	B-X
2	B-X
)	B-X
double-positive	B-X
and	B-X
single-positive	B-X
CD4	B-X

Additionally	O
,	O
complement	O
depletion	O
had	O
no	O
effect	O
on	O
immunoglobulin	O
production	O
when	O
compared	O
to	O
non	O
-	O
complement	O
depleted	O
controls	O
infected	O
intranasally	O
.	O
<EOS>	B-X
We	B-X
performed	B-X
initial	B-X
cell	B-X
,	B-X
cytokine	B-X
and	B-X
complement	B-X
depletion	B-X
studies	B-X
to	B-X
investigate	B-X
the	B-X
possible	B-X
role	B-X
of	B-X
these	B-X
effectors	B-X
in	B-X
response	B-X
to	B-X
vaccination	B-X
with	B-X
heat-killed	B-X
Burkholderia	B-X
mallei	B-X
in	B-X
a	B-X
susceptible	B-X
BALB/c	B-X
mouse	B-X
model	B-X
of	B-X
infection	B-X
.	B-X

Conclusion	O
<EOS>	B-X
Conclusion	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X

The	O
data	O
provide	O
a	O
basis	O
for	O
future	O
studies	O
of	O
protection	O
via	O
vaccination	O
using	O
either	O
subunit	O
or	O
whole	O
-	O
organism	O
vaccine	O
preparations	O
from	O
lethal	O
infection	O
in	O
the	O
experimental	O
BALB	O
/	O
c	O
mouse	B-Species
model	O
.	O
<EOS>	B-X
We	B-X
performed	B-X
initial	B-X
cell	B-X
,	B-X
cytokine	B-X
and	B-X
complement	B-X
depletion	B-X
studies	B-X
to	B-X
investigate	B-X
the	B-X
possible	B-X
role	B-X
of	B-X
these	B-X
effectors	B-X
in	B-X
response	B-X
to	B-X
vaccination	B-X
with	B-X
heat-killed	B-X
Burkholderia	B-X
mallei	B-X
in	B-X
a	B-X
susceptible	B-X
BALB/c	B-X
mouse	B-X
model	B-X
of	B-X
infection	B-X
.	B-X

The	O
results	O
of	O
this	O
study	O
demonstrate	O
participation	O
of	O
B220	O
+	O
cells	O
and	O
pro	O
-	O
inflammatory	O
cytokines	O
IFN	O
-	O
gamma	O
and	O
TNF	O
-	O
alpha	O
in	O
protection	O
following	O
HK	O
vaccination	O
.	O
<EOS>	B-X
We	B-X
performed	B-X
initial	B-X
cell	B-X
,	B-X
cytokine	B-X
and	B-X
complement	B-X
depletion	B-X
studies	B-X
to	B-X
investigate	B-X
the	B-X
possible	B-X
role	B-X
of	B-X
these	B-X
effectors	B-X
in	B-X
response	B-X
to	B-X
vaccination	B-X
with	B-X
heat-killed	B-X
Burkholderia	B-X
mallei	B-X
in	B-X
a	B-X
susceptible	B-X
BALB/c	B-X
mouse	B-X
model	B-X
of	B-X
infection	B-X
.	B-X

Background	O
<EOS>	B-X
Background	B-X
matching	B-X
is	B-X
the	B-X
most	B-X
familiar	B-X
and	B-X
widespread	B-X
camouflage	B-X
strategy	B-X
:	B-X
avoiding	B-X
detection	B-X
by	B-X
having	B-X
a	B-X
similar	B-X
colour	B-X
and	B-X
pattern	B-X
to	B-X
the	B-X
background	B-X
.	B-X
Background	B-X
is	B-X
thus	B-X
a	B-X
relatively	B-X
modest	B-X
correction	B-X
for	B-X
all	B-X
Z	B-X
opacity	B-X
data	B-X
published	B-X
to	B-X
date	B-X
.	B-X
Background	B-X
estimation	B-X
and	B-X
foreground	B-X
segmentation	B-X
are	B-X
important	B-X
steps	B-X
in	B-X
many	B-X
high-level	B-X
vision	B-X
tasks	B-X
.	B-X
Patient	B-X
Preference	B-X
for	B-X
Telehealth	B-X
Background	B-X
Shapes	B-X
Impressions	B-X
of	B-X
Physicians	B-X
and	B-X
Information	B-X
Recall	B-X
:	B-X
A	B-X
Randomized	B-X
Experiment	B-X
.	B-X

Burkholderia	B-Species
mallei	I-Species
,	O
the	O
etiologic	O
agent	O
of	O
glanders	O
,	O
is	O
a	O
gram	O
-	O
negative	O
,	O
capsulated	O
,	O
non	O
-	O
motile	O
,	O
facultative	O
intracelluar	O
bacterium	O
.	O

Most	O
known	O
members	O
of	O
the	O
Burkholderiaceae	O
are	O
resident	O
in	O
the	O
soil	O
;	O
however	O
,	O
B	B-Species
.	I-Species
mallei	I-Species
is	O
thought	O
to	O
be	O
an	O
obligate	O
mammalian	O
pathogen	O
.	O

Horses	B-Species
are	O
highly	O
susceptible	O
to	O
infection	O
and	O
considered	O
the	O
natural	O
reservoir	O
for	O
infection	O
,	O
although	O
mules	B-Species
and	O
donkeys	B-Species
are	O
also	O
susceptible	O
[	O
1	O
]	O
.	O
<EOS>	B-X
Clostridium	B-X
difficile	B-X
is	B-X
considered	B-X
one	B-X
of	B-X
the	B-X
most	B-X
important	B-X
causes	B-X
of	B-X
diarrhea	B-X
and	B-X
enterocolitis	B-X
in	B-X
horses	B-X
.	B-X
Foals	B-X
and	B-X
adult	B-X
horses	B-X
are	B-X
equally	B-X
susceptible	B-X
to	B-X
the	B-X
infection	B-X
.	B-X
The	B-X
highly	B-X
resistant	B-X
spore	B-X
of	B-X
C.	B-X
difficile	B-X
is	B-X
the	B-X
infectious	B-X
unit	B-X
of	B-X
transmission	B-X
,	B-X
which	B-X
occurs	B-X
primarily	B-X
via	B-X
the	B-X
fecal-oral	B-X
route	B-X
,	B-X
with	B-X
sources	B-X
of	B-X
infection	B-X
including	B-X
equine	B-X
feces	B-X
,	B-X
contaminated	B-X
soil	B-X
,	B-X
animal	B-X
hospitals	B-X
,	B-X
and	B-X
feces	B-X
of	B-X
other	B-X
animals	B-X
.	B-X
Two	B-X
major	B-X
risk	B-X
factors	B-X
for	B-X
the	B-X
development	B-X
of	B-X
C.	B-X
difficile	B-X
associated	B-X
disease	B-X
(	B-X
CDAD	B-X
)	B-X
in	B-X
adult	B-X
horses	B-X
are	B-X
hospitalization	B-X
and	B-X
antimicrobial	B-X
treatment	B-X
,	B-X
although	B-X
sporadically	B-X
,	B-X
cases	B-X
of	B-X
CDAD	B-X
can	B-X
occur	B-X
in	B-X
horses	B-X
that	B-X
have	B-X
not	B-X
received	B-X
antimicrobials	B-X
or	B-X
been	B-X
hospitalized	B-X
.	B-X
Clinical	B-X
signs	B-X
and	B-X
intestinal	B-X
lesions	B-X
of	B-X
CDAD	B-X
infection	B-X
are	B-X
not	B-X
specific	B-X
and	B-X
they	B-X
can	B-X
not	B-X
be	B-X
used	B-X
to	B-X
distinguish	B-X
infections	B-X
by	B-X
C.	B-X
difficile	B-X
from	B-X
infections	B-X
by	B-X
other	B-X
agents	B-X
,	B-X
such	B-X
as	B-X
Clostridium	B-X
perfringens	B-X
or	B-X
Salmonella	B-X
sp	B-X
.	B-X
Small	B-X
intestine	B-X
is	B-X
invariably	B-X
affected	B-X
,	B-X
and	B-X
colon	B-X
and	B-X
cecum	B-X
may	B-X
or	B-X
may	B-X
not	B-X
have	B-X
lesions	B-X
in	B-X
foals	B-X
<	B-X
1-month	B-X
old	B-X
.	B-X
Detection	B-X
of	B-X
toxin	B-X
A	B-X
,	B-X
toxin	B-X
B	B-X
or	B-X
both	B-X
in	B-X
intestinal	B-X
contents	B-X
or	B-X
feces	B-X
is	B-X
considered	B-X
the	B-X
most	B-X
reliable	B-X
diagnostic	B-X
criterion	B-X
for	B-X
CDAD	B-X
in	B-X
horses	B-X
.	B-X
Isolation	B-X
of	B-X
toxigenic	B-X
strains	B-X
of	B-X
C.	B-X
difficile	B-X
from	B-X
horses	B-X
with	B-X
intestinal	B-X
disease	B-X
is	B-X
highly	B-X
suggestive	B-X
of	B-X
CDAD	B-X
.	B-X
A	B-X
better	B-X
understanding	B-X
of	B-X
pathogenesis	B-X
,	B-X
reservoirs	B-X
of	B-X
infection	B-X
,	B-X
and	B-X
vaccines	B-X
and	B-X
other	B-X
methods	B-X
of	B-X
control	B-X
is	B-X
needed	B-X
.	B-X

Clinically	O
,	O
glanders	O
in	O
solipeds	O
can	O
present	O
as	O
either	O
a	O
chronic	O
(	O
horses	B-Species
)	O
or	O
acute	O
(	O
mules	B-Species
and	O
donkeys	B-Species
)	O
form	O
.	O
<EOS>	B-X
Osteoarthritis	B-X
,	B-X
the	B-X
most	B-X
common	B-X
form	B-X
of	B-X
arthritis	B-X
,	B-X
is	B-X
a	B-X
crippling	B-X
,	B-X
chronic	B-X
debilitating	B-X
bone	B-X
disease	B-X
that	B-X
commonly	B-X
affects	B-X
humans	B-X
,	B-X
dogs	B-X
,	B-X
and	B-X
horses	B-X
.	B-X
Laminitis	B-X
is	B-X
considered	B-X
chronic	B-X
once	B-X
the	B-X
distal	B-X
phalanx	B-X
has	B-X
displaced	B-X
within	B-X
the	B-X
hoof	B-X
capsule	B-X
.	B-X
Chronic	B-X
laminitis	B-X
generally	B-X
occurs	B-X
as	B-X
a	B-X
direct	B-X
sequel	B-X
to	B-X
acute	B-X
laminitis	B-X
.	B-X
Clinical	B-X
evaluation	B-X
of	B-X
chronic	B-X
laminitis	B-X
is	B-X
best	B-X
performed	B-X
with	B-X
a	B-X
thorough	B-X
clinical	B-X
examination	B-X
and	B-X
radiography	B-X
.	B-X
In	B-X
this	B-X
article	B-X
,	B-X
the	B-X
goals	B-X
and	B-X
principles	B-X
of	B-X
hoof	B-X
care	B-X
,	B-X
the	B-X
appropriate	B-X
trim	B-X
and	B-X
various	B-X
shoes	B-X
that	B-X
form	B-X
the	B-X
bulk	B-X
of	B-X
farriery	B-X
for	B-X
chronic	B-X
laminitis	B-X
,	B-X
and	B-X
surgical	B-X
treatments	B-X
are	B-X
discussed	B-X
.	B-X

Naturally	O
acquired	O
human	B-Species
infection	O
with	O
B	B-Species
.	I-Species
mallei	I-Species
,	O
although	O
not	O
seen	O
in	O
the	O
United	O
States	O
since	O
1945	O
,	O
has	O
occurred	O
rarely	O
and	O
sporadically	O
among	O
laboratory	O
workers	O
and	O
those	O
in	O
direct	O
contact	O
with	O
infected	O
animals	O
[	O
2	O
]	O
.	O
<EOS>	B-X
Burkholderia	B-X
mallei	B-X
causes	B-X
a	B-X
highly	B-X
fatal	B-X
infectious	B-X
disease	B-X
in	B-X
equines	B-X
known	B-X
as	B-X
glanders	B-X
.	B-X
It	B-X
is	B-X
one	B-X
of	B-X
the	B-X
OIE	B-X
listed	B-X
notifiable	B-X
diseases	B-X
,	B-X
which	B-X
entails	B-X
strict	B-X
control	B-X
policy	B-X
measures	B-X
once	B-X
B.	B-X
mallei	B-X
infection	B-X
is	B-X
confirmed	B-X
in	B-X
the	B-X
susceptible	B-X
hosts	B-X
.	B-X
Humans	B-X
,	B-X
especially	B-X
equine	B-X
handlers	B-X
,	B-X
veterinary	B-X
professionals	B-X
and	B-X
laboratory	B-X
workers	B-X
are	B-X
at	B-X
greater	B-X
risk	B-X
to	B-X
acquire	B-X
the	B-X
B.	B-X
mallei	B-X
infection	B-X
directly	B-X
through	B-X
prolonged	B-X
contact	B-X
with	B-X
glanderous	B-X
equines	B-X
,	B-X
and	B-X
indirectly	B-X
through	B-X
unprotected	B-X
handling	B-X
of	B-X
B.	B-X
mallei	B-X
contaminated	B-X
materials	B-X
.	B-X
Further	B-X
,	B-X
natural	B-X
resistance	B-X
of	B-X
B.	B-X
mallei	B-X
to	B-X
multiple	B-X
antibiotics	B-X
,	B-X
aerosol	B-X
transmission	B-X
,	B-X
lack	B-X
of	B-X
effective	B-X
vaccine	B-X
and	B-X
treatment	B-X
make	B-X
this	B-X
organism	B-X
a	B-X
potential	B-X
agent	B-X
of	B-X
biological	B-X
warfare	B-X
.	B-X
Results	B-X
of	B-X
experimental	B-X
B.	B-X
mallei	B-X
infection	B-X
in	B-X
mouse	B-X
and	B-X
non-human	B-X
primates	B-X
and	B-X
immunization	B-X
with	B-X
live	B-X
attenuated	B-X
B.	B-X
mallei	B-X
strains	B-X
demonstrated	B-X
that	B-X
activation	B-X
of	B-X
early	B-X
innate	B-X
and	B-X
adaptive	B-X
immune	B-X
responses	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
controlling	B-X
B.	B-X
mallei	B-X
infection	B-X
.	B-X
However	B-X
,	B-X
the	B-X
immune	B-X
response	B-X
elicited	B-X
by	B-X
the	B-X
primary	B-X
hosts	B-X
(	B-X
equids	B-X
)	B-X
B.	B-X
mallei	B-X
infection	B-X
is	B-X
poorly	B-X
understood	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
investigate	B-X
immune	B-X
responses	B-X
in	B-X
glanders	B-X
affected	B-X
horses	B-X
(	B-X
n	B-X
=	B-X
23	B-X
)	B-X
and	B-X
mules	B-X
(	B-X
n	B-X
=	B-X
1	B-X
)	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
chronically	B-X
infected	B-X
equids	B-X
showed	B-X
strong	B-X
humoral	B-X
responses	B-X
(	B-X
IgM	B-X
,	B-X
IgG	B-X
and	B-X
IgA	B-X
)	B-X
specific	B-X
to	B-X
B.	B-X
mallei	B-X
type	B-X
6	B-X
secretory	B-X
proteins	B-X
such	B-X
as	B-X
Hcp1	B-X
,	B-X
TssA	B-X
and	B-X
TssB	B-X
.	B-X
The	B-X
infected	B-X
equids	B-X
also	B-X
elicited	B-X
robust	B-X
cellular	B-X
responses	B-X
characterized	B-X
by	B-X
significantly	B-X
elevated	B-X
levels	B-X
of	B-X
IFN-Î³	B-X
,	B-X
TNF-Î±	B-X
,	B-X
IL-12	B-X
,	B-X
IL-17	B-X
and	B-X
IL-6	B-X
in	B-X
PBMCs	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
stimulation	B-X
of	B-X
equine	B-X
PBMCs	B-X
by	B-X
Hcp1	B-X
resulted	B-X
in	B-X
the	B-X
further	B-X
elevation	B-X
of	B-X
these	B-X
cytokines	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
present	B-X
study	B-X
indicated	B-X
that	B-X
antibody	B-X
response	B-X
and	B-X
T	B-X
helper	B-X
cell	B-X
(	B-X
Th	B-X
)	B-X
type	B-X
1-associated	B-X
cytokines	B-X
were	B-X
the	B-X
salient	B-X
features	B-X
of	B-X
chronic	B-X
B.	B-X
mallei	B-X
infection	B-X
in	B-X
horses	B-X
.	B-X

However	O
,	O
glanders	O
is	O
endemic	O
among	O
domestic	O
animals	O
in	O
Africa	O
,	O
Asia	O
,	O
the	O
Middle	O
East	O
,	O
and	O
Central	O
and	O
South	O
America	O
.	O

The	O
course	O
of	O
infection	O
is	O
dependent	O
on	O
the	O
route	O
of	O
exposure	O
.	O
<EOS>	B-X
Not	B-X
every	B-X
exposure	B-X
to	B-X
virus	B-X
establishes	B-X
infection	B-X
in	B-X
the	B-X
host	B-X
;	B-X
instead	B-X
,	B-X
the	B-X
small	B-X
amount	B-X
of	B-X
initial	B-X
virus	B-X
could	B-X
become	B-X
extinct	B-X
due	B-X
to	B-X
stochastic	B-X
events	B-X
.	B-X
Different	B-X
diseases	B-X
and	B-X
routes	B-X
of	B-X
transmission	B-X
have	B-X
a	B-X
different	B-X
average	B-X
number	B-X
of	B-X
exposures	B-X
required	B-X
to	B-X
establish	B-X
an	B-X
infection	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
host	B-X
immune	B-X
response	B-X
and	B-X
antiviral	B-X
treatment	B-X
affect	B-X
not	B-X
only	B-X
the	B-X
time	B-X
course	B-X
of	B-X
the	B-X
viral	B-X
load	B-X
provided	B-X
infection	B-X
occurs	B-X
,	B-X
but	B-X
can	B-X
prevent	B-X
infection	B-X
altogether	B-X
by	B-X
increasing	B-X
the	B-X
extinction	B-X
probability	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
extinction	B-X
probability	B-X
when	B-X
there	B-X
is	B-X
a	B-X
time-dependent	B-X
immune	B-X
response	B-X
depends	B-X
on	B-X
the	B-X
chosen	B-X
form	B-X
of	B-X
the	B-X
model-specifically	B-X
,	B-X
on	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
a	B-X
delay	B-X
between	B-X
infection	B-X
of	B-X
a	B-X
cell	B-X
and	B-X
production	B-X
of	B-X
virus	B-X
,	B-X
and	B-X
the	B-X
distribution	B-X
of	B-X
latent	B-X
and	B-X
infectious	B-X
periods	B-X
of	B-X
an	B-X
infected	B-X
cell	B-X
.	B-X

Direct	O
contact	O
with	O
the	O
skin	O
can	O
lead	O
to	O
a	O
systemic	O
infection	O
.	O
<EOS>	B-X
After	B-X
tuberculosis	B-X
and	B-X
leprosy	B-X
,	B-X
Buruli-ulcer	B-X
disease	B-X
(	B-X
caused	B-X
by	B-X
infection	B-X
with	B-X
Mycobacterium	B-X
ulcerans	B-X
)	B-X
is	B-X
the	B-X
third	B-X
most	B-X
common	B-X
mycobacterial	B-X
disease	B-X
in	B-X
immunocompetent	B-X
people	B-X
.	B-X
Current	B-X
evidence	B-X
suggests	B-X
that	B-X
the	B-X
infection	B-X
is	B-X
transmitted	B-X
through	B-X
abraded	B-X
skin	B-X
or	B-X
mild	B-X
traumatic	B-X
injuries	B-X
after	B-X
contact	B-X
with	B-X
contaminated	B-X
water	B-X
,	B-X
soil	B-X
,	B-X
or	B-X
vegetation	B-X
;	B-X
there	B-X
is	B-X
one	B-X
unconfirmed	B-X
preliminary	B-X
report	B-X
on	B-X
possible	B-X
transmission	B-X
by	B-X
insects	B-X
.	B-X
The	B-X
disease	B-X
is	B-X
accompanied	B-X
by	B-X
remarkably	B-X
few	B-X
systemic	B-X
symptoms	B-X
,	B-X
but	B-X
occasionally	B-X
secondary	B-X
infections	B-X
resulting	B-X
in	B-X
sepsis	B-X
or	B-X
tetanus	B-X
cause	B-X
severe	B-X
systemic	B-X
disease	B-X
and	B-X
death	B-X
.	B-X
Extensive	B-X
scarring	B-X
can	B-X
lead	B-X
to	B-X
contractures	B-X
of	B-X
the	B-X
limbs	B-X
,	B-X
blindness	B-X
,	B-X
and	B-X
other	B-X
adverse	B-X
sequelae	B-X
,	B-X
which	B-X
impose	B-X
a	B-X
substantial	B-X
health	B-X
and	B-X
economic	B-X
burden	B-X
.	B-X
Treatment	B-X
is	B-X
still	B-X
primarily	B-X
surgical	B-X
,	B-X
and	B-X
includes	B-X
excision	B-X
,	B-X
skin	B-X
grafting	B-X
,	B-X
or	B-X
both	B-X
.	B-X

Inhalation	O
of	O
aerosol	O
or	O
dust	O
containing	O
B	B-Species
.	I-Species
mallei	I-Species
can	O
lead	O
to	O
septicemic	O
,	O
pulmonary	O
,	O
or	O
chronic	O
infections	O
of	O
the	O
muscle	O
,	O
liver	O
and	O
spleen	O
.	O
<EOS>	B-X
Drug	B-X
delivery	B-X
by	B-X
inhalation	B-X
is	B-X
the	B-X
principal	B-X
strategy	B-X
to	B-X
treat	B-X
obstructive	B-X
lung	B-X
diseases	B-X
,	B-X
which	B-X
affect	B-X
about	B-X
15	B-X
%	B-X
of	B-X
the	B-X
population	B-X
in	B-X
the	B-X
United	B-X
States	B-X
.	B-X
Aerosol	B-X
delivery	B-X
devices	B-X
have	B-X
evolved	B-X
over	B-X
more	B-X
than	B-X
60	B-X
years	B-X
from	B-X
the	B-X
basic	B-X
pressurized	B-X
metered-dose	B-X
inhaler	B-X
and	B-X
nebulizer	B-X
to	B-X
numerous	B-X
types	B-X
of	B-X
inhalers	B-X
and	B-X
devices	B-X
,	B-X
including	B-X
valved	B-X
holder	B-X
chambers	B-X
,	B-X
dry	B-X
powder	B-X
inhalers	B-X
,	B-X
soft	B-X
mist	B-X
inhalers	B-X
,	B-X
as	B-X
well	B-X
as	B-X
smart	B-X
inhalers	B-X
and	B-X
nebulizers	B-X
.	B-X
Although	B-X
these	B-X
devices	B-X
improve	B-X
a	B-X
patient	B-X
's	B-X
ability	B-X
to	B-X
self-administer	B-X
medication	B-X
,	B-X
many	B-X
problems	B-X
with	B-X
optimal	B-X
delivery	B-X
still	B-X
exist	B-X
.	B-X
Aerosol	B-X
science	B-X
is	B-X
evolving	B-X
,	B-X
with	B-X
methods	B-X
of	B-X
measurement	B-X
that	B-X
include	B-X
radio-scintigraphy	B-X
and	B-X
magnetic	B-X
resonance	B-X
imaging	B-X
,	B-X
to	B-X
provide	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
aerosol	B-X
delivery	B-X
and	B-X
effects	B-X
.	B-X
Understanding	B-X
the	B-X
science	B-X
and	B-X
clinical	B-X
application	B-X
of	B-X
aerosol	B-X
drug	B-X
delivery	B-X
can	B-X
substantially	B-X
aid	B-X
clinicians	B-X
in	B-X
optimizing	B-X
these	B-X
therapies	B-X
for	B-X
their	B-X
patients	B-X
.	B-X

The	O
disease	O
has	O
a	O
95	O
%	O
case	O
fatality	O
rate	O
for	O
untreated	O
septicemic	O
infections	O
and	O
a	O
50	O
%	O
case	O
fatality	O
rate	O
in	O
antibiotic	O
-	O
treated	O
individuals	O
[	O
3	O
]	O
.	O

There	O
is	O
no	O
human	B-Species
or	O
animal	O
vaccine	O
available	O
for	O
glanders	O
,	O
and	O
development	O
of	O
a	O
partial	O
or	O
fully	O
protective	O
adaptive	O
host	O
response	O
to	O
the	O
organism	O
has	O
not	O
been	O
well	O
-	O
defined	O
.	O
<EOS>	B-X
The	B-X
exact	B-X
relationship	B-X
between	B-X
age	B-X
of	B-X
the	B-X
animals	B-X
compared	B-X
with	B-X
the	B-X
age	B-X
of	B-X
humans	B-X
is	B-X
still	B-X
subject	B-X
to	B-X
discussion	B-X
and	B-X
controversy	B-X
.	B-X
Over	B-X
a	B-X
human	B-X
's	B-X
life	B-X
span	B-X
,	B-X
keratinized	B-X
skin	B-X
cells	B-X
,	B-X
immune	B-X
cells	B-X
,	B-X
and	B-X
microbes	B-X
all	B-X
interact	B-X
to	B-X
integrate	B-X
the	B-X
processes	B-X
of	B-X
maintaining	B-X
skin	B-X
's	B-X
physical	B-X
and	B-X
immune	B-X
barrier	B-X
under	B-X
homeostatic	B-X
healthy	B-X
conditions	B-X
and	B-X
also	B-X
under	B-X
multiple	B-X
stresses	B-X
,	B-X
such	B-X
as	B-X
wounding	B-X
or	B-X
infection	B-X
.	B-X
In	B-X
this	B-X
Review	B-X
,	B-X
we	B-X
explore	B-X
the	B-X
intricate	B-X
interactions	B-X
of	B-X
microbes	B-X
and	B-X
immune	B-X
cells	B-X
on	B-X
the	B-X
skin	B-X
surface	B-X
and	B-X
within	B-X
associated	B-X
appendages	B-X
to	B-X
regulate	B-X
this	B-X
orchestrated	B-X
maturation	B-X
in	B-X
the	B-X
context	B-X
of	B-X
both	B-X
host	B-X
physiological	B-X
changes	B-X
and	B-X
environmental	B-X
challenges	B-X
.	B-X
Streptococcus	B-X
suis	B-X
is	B-X
a	B-X
major	B-X
porcine	B-X
pathogen	B-X
worldwide	B-X
,	B-X
and	B-X
can	B-X
be	B-X
transmitted	B-X
to	B-X
human	B-X
beings	B-X
by	B-X
close	B-X
contact	B-X
with	B-X
sick	B-X
or	B-X
carrier	B-X
pigs	B-X
.	B-X
S	B-X
suis	B-X
causes	B-X
meningitis	B-X
,	B-X
septicaemia	B-X
,	B-X
endocarditis	B-X
,	B-X
arthritis	B-X
,	B-X
and	B-X
septic	B-X
shock	B-X
in	B-X
both	B-X
pigs	B-X
and	B-X
human	B-X
beings	B-X
,	B-X
and	B-X
mortality	B-X
is	B-X
high	B-X
.	B-X
Outbreaks	B-X
of	B-X
human	B-X
S	B-X
suis	B-X
infection	B-X
are	B-X
uncommon	B-X
,	B-X
although	B-X
several	B-X
outbreaks	B-X
have	B-X
occurred	B-X
in	B-X
China	B-X
in	B-X
recent	B-X
years	B-X
.	B-X
In	B-X
July	B-X
,	B-X
2005	B-X
,	B-X
the	B-X
largest	B-X
outbreak	B-X
of	B-X
human	B-X
S	B-X
suis	B-X
infection	B-X
occurred	B-X
in	B-X
Sichuan	B-X
province	B-X
,	B-X
China	B-X
,	B-X
where	B-X
204	B-X
people	B-X
were	B-X
infected	B-X
and	B-X
38	B-X
of	B-X
them	B-X
died	B-X
.	B-X
There	B-X
have	B-X
been	B-X
409	B-X
cases	B-X
of	B-X
human	B-X
S	B-X
suis	B-X
infection	B-X
worldwide	B-X
,	B-X
most	B-X
of	B-X
which	B-X
have	B-X
occurred	B-X
in	B-X
China	B-X
,	B-X
Thailand	B-X
,	B-X
and	B-X
the	B-X
Netherlands	B-X
,	B-X
and	B-X
these	B-X
infections	B-X
have	B-X
led	B-X
to	B-X
73	B-X
deaths	B-X
.	B-X
This	B-X
review	B-X
provides	B-X
background	B-X
information	B-X
on	B-X
the	B-X
biology	B-X
and	B-X
molecular	B-X
characteristics	B-X
of	B-X
this	B-X
Gram-positive	B-X
bacterium	B-X
,	B-X
and	B-X
describes	B-X
the	B-X
clinical	B-X
signs	B-X
,	B-X
pathology	B-X
,	B-X
epidemiology	B-X
,	B-X
diagnosis	B-X
,	B-X
and	B-X
treatment	B-X
of	B-X
human	B-X
infection	B-X
with	B-X
S	B-X
suis	B-X
.	B-X

Previous	O
studies	O
with	O
B	B-Species
.	I-Species
mallei	I-Species
and	O
the	O
host	O
response	O
have	O
shown	O
that	O
a	O
mixed	O
immune	O
response	O
consisting	O
of	O
both	O
Th1	O
and	O
Th2	O
-	O
associated	O
cytokines	O
with	O
a	O
predominant	O
IgG1	O
subclass	O
does	O
not	O
correlate	O
with	O
protection	O
[	O
4	O
]	O
.	O

Additional	O
studies	O
with	O
passive	O
transfer	O
of	O
monoclonal	O
antibodies	O
specific	O
for	O
B	B-Species
.	I-Species
mallei	I-Species
have	O
correlated	O
with	O
early	O
protection	O
from	O
infection	O
[	O
5	O
]	O
.	O

Recent	O
studies	O
have	O
also	O
shown	O
the	O
Th1	O
cytokine	O
IL	O
-	O
12	O
to	O
mediate	O
partial	O
protection	O
to	O
non	O
-	O
viable	O
B	B-Species
.	I-Species
mallei	I-Species
-	O
vaccinated	O
mice	B-Species
[	O
6	O
]	O
.	O

Thus	O
,	O
full	O
correlates	O
of	O
protection	O
mediated	O
by	O
the	O
adaptive	O
immune	O
system	O
against	O
B	B-Species
.	I-Species
mallei	I-Species
remain	O
to	O
be	O
fully	O
elucidated	O
.	O

In	O
this	O
series	O
of	O
studies	O
,	O
we	O
sought	O
to	O
address	O
the	O
impact	O
of	O
depletion	O
of	O
the	O
major	O
effector	O
lymphoid	O
cell	O
populations	O
(	O
B220	O
+	O
B	O
cells	O
,	O
CD4	O
+	O
or	O
CD8	O
+	O
T	O
cells	O
)	O
and	O
key	O
pro	O
-	O
inflammatory	O
/	O
Type	O
1	O
cytokines	O
(	O
IFN	O
-	O
gamma	O
or	O
TNF	O
-	O
alpha	O
)	O
on	O
survival	O
in	O
BALB	O
/	O
c	O
mice	B-Species
vaccinated	O
with	O
heat	O
killed	O
(	O
HK	O
)	O
bacilli	O
followed	O
by	O
an	O
intraperitoneal	O
(	O
i	O
.	O
p	O
.	O
)	O
challenge	O
with	O
live	O
organism	O
.	O

In	O
addition	O
,	O
studies	O
investigating	O
the	O
effect	O
of	O
complement	O
on	O
opsonization	O
of	O
organism	O
and	O
antibody	O
production	O
were	O
assessed	O
.	O

Heat	O
killed	O
bacteria	O
were	O
used	O
as	O
a	O
model	O
of	O
vaccination	O
to	O
allow	O
evaluation	O
of	O
B	B-Species
.	I-Species
mallei	I-Species
specific	O
immune	O
responses	O
.	O

The	O
results	O
of	O
this	O
study	O
demonstrate	O
participation	O
of	O
B220	O
+	O
cells	O
and	O
pro	O
-	O
inflammatory	O
cytokines	O
IFN	O
-	O
gamma	O
and	O
TNF	O
-	O
alpha	O
in	O
protection	O
following	O
HK	O
vaccination	O
.	O
<EOS>	B-X
We	B-X
performed	B-X
initial	B-X
cell	B-X
,	B-X
cytokine	B-X
and	B-X
complement	B-X
depletion	B-X
studies	B-X
to	B-X
investigate	B-X
the	B-X
possible	B-X
role	B-X
of	B-X
these	B-X
effectors	B-X
in	B-X
response	B-X
to	B-X
vaccination	B-X
with	B-X
heat-killed	B-X
Burkholderia	B-X
mallei	B-X
in	B-X
a	B-X
susceptible	B-X
BALB/c	B-X
mouse	B-X
model	B-X
of	B-X
infection	B-X
.	B-X

Results	O

Heat	O
-	O
killed	O
B	B-Species
.	I-Species
mallei	I-Species
vaccination	O
mediates	O
partial	O
protection	O
from	O
lethal	O
challenge	O

To	O
begin	O
to	O
address	O
this	O
issue	O
in	O
an	O
animal	O
model	O
of	O
acute	O
infection	O
,	O
we	O
established	O
that	O
immunologically	O
naive	O
BALB	O
/	O
c	O
mice	B-Species
challenged	O
i	O
.	O
p	O
.	O
with	O
2	O
x	O
107	O
CFU	O
resulted	O
in	O
death	O
by	O
day	O
4	O
-	O
6	O
,	O
while	O
i	O
.	O
p	O
.	O
immunization	O
with	O
1	O
x	O
105	O
heat	O
killed	O
(	O
HK	O
)	O
bacteria	O
provided	O
partial	O
protection	O
against	O
a	O
subsequent	O
challenge	O
.	O

Two	O
independent	O
experiments	O
resulted	O
in	O
similar	O
findings	O
of	O
40	O
%	O
survival	O
for	O
HK	O
-	O
vaccinated	O
mice	B-Species
with	O
a	O
mean	O
survival	O
time	O
(	O
MST	O
)	O
of	O
8	O
days	O
versus	O
4	O
days	O
in	O
na	O
i	O
ve	O
mice	B-Species
(	O
Fig	O
.	O
1	O
)	O
.	O

The	O
administration	O
of	O
vaccines	O
for	O
B	B-Species
.	I-Species
mallei	I-Species
during	O
an	O
outbreak	O
would	O
mandate	O
relatively	O
rapid	O
onset	O
of	O
protection	O
for	O
human	B-Species
or	O
veterinary	O
use	O
.	O
<EOS>	B-X
Creating	B-X
a	B-X
transparent	B-X
and	B-X
deliberate	B-X
approach	B-X
to	B-X
ethical	B-X
issues	B-X
empowers	B-X
the	B-X
entire	B-X
veterinary	B-X
team	B-X
and	B-X
reduces	B-X
stress	B-X
associated	B-X
with	B-X
these	B-X
dilemmas	B-X
.	B-X
This	B-X
article	B-X
discusses	B-X
ethical	B-X
considerations	B-X
and	B-X
principles	B-X
and	B-X
propose	B-X
use	B-X
of	B-X
the	B-X
4Es	B-X
model	B-X
and	B-X
core	B-X
communication	B-X
skills	B-X
to	B-X
address	B-X
ethical	B-X
dilemmas	B-X
in	B-X
veterinary	B-X
practice	B-X
.	B-X
The	B-X
goal	B-X
is	B-X
to	B-X
provide	B-X
veterinary	B-X
professionals	B-X
with	B-X
an	B-X
approach	B-X
they	B-X
can	B-X
use	B-X
to	B-X
frame	B-X
and	B-X
address	B-X
their	B-X
own	B-X
ethical	B-X
decisions	B-X
.	B-X
It	B-X
is	B-X
important	B-X
to	B-X
remember	B-X
that	B-X
dentistry	B-X
is	B-X
one	B-X
area	B-X
of	B-X
the	B-X
veterinary	B-X
practice	B-X
that	B-X
veterinary	B-X
technicians/nurses/hygienists	B-X
can	B-X
take	B-X
ownership	B-X
of	B-X
and	B-X
drive	B-X
the	B-X
dental	B-X
program	B-X
forward	B-X
under	B-X
the	B-X
supervision	B-X
of	B-X
a	B-X
veterinarian	B-X
.	B-X
The	B-X
veterinary	B-X
technician/nurse/hygienist	B-X
should	B-X
educate	B-X
the	B-X
client	B-X
about	B-X
the	B-X
dental	B-X
procedure	B-X
,	B-X
perform	B-X
a	B-X
thorough	B-X
oral	B-X
examination	B-X
and	B-X
report	B-X
findings	B-X
on	B-X
the	B-X
dental	B-X
chart	B-X
,	B-X
take	B-X
dental	B-X
radiographs	B-X
,	B-X
perform	B-X
dental	B-X
scaling	B-X
and	B-X
polishing	B-X
,	B-X
administer	B-X
nerve	B-X
blocks	B-X
,	B-X
administer	B-X
perioceutics	B-X
,	B-X
maintain	B-X
instruments	B-X
and	B-X
equipment	B-X
,	B-X
and	B-X
provide	B-X
discharge	B-X
and	B-X
home	B-X
care	B-X
instructions	B-X
to	B-X
the	B-X
pet	B-X
owner	B-X
.	B-X

Based	O
on	O
non	O
-	O
routine	O
use	O
and	O
vaccine	O
implementation	O
in	O
the	O
course	O
of	O
an	O
outbreak	O
,	O
a	O
14	O
day	O
window	O
was	O
chosen	O
for	O
assessment	O
of	O
protection	O
.	O

Our	O
results	O
indicate	O
that	O
HK	O
vaccination	O
can	O
afford	O
partial	O
protection	O
to	O
an	O
otherwise	O
lethal	O
challenge	O
of	O
B	B-Species
.	I-Species
mallei	I-Species
by	O
the	O
i	O
.	O
p	O
.	O
route	O
.	O

Effects	O
of	O
cell	O
depletion	O
on	O
HK	O
-	O
vaccinated	O
survival	O

To	O
dissect	O
the	O
cellular	O
basis	O
for	O
protection	O
mediated	O
by	O
HK	O
vaccination	O
,	O
13	O
days	O
after	O
immunization	O
with	O
HK	O
bacteria	O
(	O
day	O
-	O
1	O
)	O
,	O
and	O
at	O
day	O
of	O
challenge	O
,	O
mice	B-Species
were	O
dosed	O
with	O
antibodies	O
to	O
deplete	O
CD4	O
+	O
,	O
CD8	O
+	O
or	O
B220	O
+	O
cells	O
.	O
<EOS>	B-X
During	B-X
the	B-X
past	B-X
decade	B-X
,	B-X
considerable	B-X
progress	B-X
has	B-X
been	B-X
made	B-X
on	B-X
the	B-X
development	B-X
of	B-X
flow	B-X
cytometry	B-X
(	B-X
FCM	B-X
)	B-X
and	B-X
fluorescence-activated	B-X
cell	B-X
sorting	B-X
(	B-X
FACS	B-X
)	B-X
methods	B-X
for	B-X
the	B-X
analysis	B-X
and	B-X
isolation	B-X
of	B-X
both	B-X
murine	B-X
and	B-X
human	B-X
erythroid	B-X
cells	B-X
at	B-X
distinct	B-X
stages	B-X
of	B-X
erythropoiesis	B-X
,	B-X
based	B-X
on	B-X
changes	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
cell	B-X
surface	B-X
markers	B-X
.	B-X
A	B-X
method	B-X
for	B-X
the	B-X
identification	B-X
of	B-X
murine	B-X
BFU-E	B-X
and	B-X
CFU-E	B-X
cells	B-X
was	B-X
reported	B-X
by	B-X
Flygare	B-X
et	B-X
al.	B-X
,	B-X
by	B-X
negative	B-X
selection	B-X
for	B-X
Ter119	B-X
,	B-X
B220	B-X
,	B-X
Mac-1	B-X
,	B-X
CD3	B-X
,	B-X
Gr1	B-X
,	B-X
Sca-1	B-X
,	B-X
CD16/CD32	B-X
,	B-X
CD41	B-X
,	B-X
and	B-X
CD34	B-X
cells	B-X
,	B-X
followed	B-X
by	B-X
separation	B-X
based	B-X
on	B-X
the	B-X
expression	B-X
levels	B-X
of	B-X
CD71	B-X
.	B-X
We	B-X
developed	B-X
an	B-X
alternative	B-X
method	B-X
in	B-X
which	B-X
Ter119	B-X
is	B-X
used	B-X
as	B-X
an	B-X
erythroid	B-X
lineage	B-X
marker	B-X
,	B-X
and	B-X
in	B-X
conjunction	B-X
with	B-X
CD44	B-X
and	B-X
cell	B-X
size	B-X
as	B-X
differentiation	B-X
markers	B-X
,	B-X
it	B-X
is	B-X
possible	B-X
to	B-X
unambiguously	B-X
distinguish	B-X
erythroblasts	B-X
at	B-X
each	B-X
developmental	B-X
stage	B-X
during	B-X
murine	B-X
terminal	B-X
erythroid	B-X
differentiation	B-X
.	B-X
We	B-X
also	B-X
developed	B-X
methods	B-X
for	B-X
the	B-X
analysis	B-X
and	B-X
isolation	B-X
of	B-X
human	B-X
erythroid	B-X
cells	B-X
at	B-X
all	B-X
developmental	B-X
stages	B-X
.	B-X
BFU-E	B-X
and	B-X
CFU-E	B-X
are	B-X
characterized	B-X
by	B-X
CD45	B-X

Antibody	O
depletion	O
of	O
CD4	O
+	O
,	O
CD8	O
+	O
,	O
or	O
B220	O
+	O
cells	O
in	O
these	O
mice	B-Species
was	O
confirmed	O
by	O
flow	O
cytometric	O
analysis	O
with	O
depletion	O
efficiencies	O
for	O
CD4	O
,	O
CD8	O
,	O
and	O
B220	O
populations	O
at	O
99	O
.	O
7	O
%	O
,	O
96	O
%	O
,	O
and	O
95	O
%	O
,	O
respectively	O
,	O
relative	O
to	O
mice	B-Species
treated	O
with	O
isotype	O
control	O
monoclonal	O
antibodies	O
(	O
data	O
not	O
shown	O
)	O
.	O
<EOS>	B-X
Programmed	B-X
cell	B-X
death	B-X
1	B-X
ligand	B-X
1	B-X
(	B-X
PD-L1	B-X
)	B-X
,	B-X
expressed	B-X
on	B-X
some	B-X
cancer	B-X
cells	B-X
,	B-X
binds	B-X
to	B-X
the	B-X
receptor	B-X
programmed	B-X
cell	B-X
death	B-X
1	B-X
(	B-X
PDCD1	B-X
,	B-X
also	B-X
called	B-X
PD1	B-X
)	B-X
on	B-X
T	B-X
cells	B-X
to	B-X
prevent	B-X
their	B-X
proliferation	B-X
and	B-X
reduce	B-X
the	B-X
antigen-tumor	B-X
immune	B-X
response	B-X
.	B-X
Immune	B-X
cells	B-X
that	B-X
infiltrate	B-X
some	B-X
types	B-X
of	B-X
HCCs	B-X
secrete	B-X
interferon	B-X
gamma	B-X
(	B-X
IFNG	B-X
)	B-X
.	B-X
Some	B-X
HCC	B-X
cells	B-X
express	B-X
myocyte	B-X
enhancer	B-X
factor	B-X
2D	B-X
(	B-X
MEF2D	B-X
)	B-X
,	B-X
which	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
shorter	B-X
survival	B-X
times	B-X
of	B-X
patients	B-X
.	B-X
This	B-X
randomized	B-X
phase	B-X
II	B-X
study	B-X
defines	B-X
safety	B-X
and	B-X
response	B-X
rate	B-X
of	B-X
epigenetic	B-X
priming	B-X
in	B-X
ER-positive	B-X
breast	B-X
cancer	B-X
patients	B-X
treated	B-X
with	B-X
checkpoint	B-X
inhibitors	B-X
as	B-X
primary	B-X
endpoints	B-X
.	B-X
T-cell	B-X
exhaustion	B-X
(	B-X
CD8	B-X

Our	O
results	O
demonstrated	O
decreased	O
survival	O
rates	O
in	O
B220	O
(	O
p	O
=	O
0	O
.	O
3418	O
)	O
,	O
CD4	O
+	O
(	O
p	O
=	O
0	O
.	O
5417	O
)	O
and	O
CD8	O
+	O
(	O
p	O
=	O
0	O
.	O
4684	O
)	O
antibody	O
depleted	O
mice	B-Species
,	O
compared	O
to	O
isotype	O
control	O
antibody	O
,	O
a	O
finding	O
that	O
indicated	O
a	O
possible	O
role	O
for	O
vaccine	O
induced	O
antibody	O
production	O
.	O

When	O
challenged	O
with	O
2	O
x	O
107	O
CFU	O
/	O
mouse	B-Species
by	O
the	O
i	O
.	O
p	O
.	O
route	O
,	O
loss	O
of	O
T	O
cells	O
resulted	O
in	O
reduced	O
survival	O
(	O
50	O
%	O
)	O
relative	O
to	O
the	O
non	O
-	O
specific	O
isotype	O
control	O
(	O
Fig	O
.	O
2	O
)	O
.	O

In	O
contrast	O
to	O
the	O
loss	O
of	O
T	O
cells	O
,	O
depletion	O
of	O
B220	O
+	O
cells	O
resulted	O
in	O
100	O
%	O
mortality	O
relative	O
to	O
the	O
non	O
-	O
specific	O
isotype	O
control	O
(	O
Fig	O
.	O
2	O
)	O
.	O

To	O
further	O
evaluate	O
the	O
necessity	O
of	O
these	O
effector	O
cells	O
in	O
providing	O
protection	O
following	O
HK	O
vaccination	O
,	O
relatively	O
resistant	O
C57BL	O
/	O
6	O
mice	B-Species
,	O
deficient	O
in	O
mature	O
B	O
-	O
cells	O
(	O
mu	O
MT	O
)	O
,	O
CD4	O
T	O
-	O
cells	O
(	O
CD4	O
-	O
/	O
-	O
)	O
or	O
CD8	O
T	O
-	O
cells	O
(	O
CD8	O
-	O
/	O
-	O
)	O
were	O
subjected	O
to	O
an	O
identical	O
HK	O
vaccination	O
and	O
challenge	O
regimen	O
.	O

Mature	O
,	O
B	O
-	O
cell	O
-	O
deficient	O
mice	B-Species
demonstrated	O
a	O
50	O
%	O
decreased	O
survival	O
(	O
p	O
=	O
0	O
.	O
0888	O
)	O
compared	O
to	O
the	O
wild	O
-	O
type	O
mice	B-Species
with	O
an	O
MST	O
of	O
35	O
.	O
5	O
days	O
(	O
Fig	O
.	O
3	O
)	O
.	O

CD4	O
-	O
/	O
-	O
and	O
CD8	O
-	O
/	O
-	O
mice	B-Species
exhibited	O
a	O
60	O
%	O
(	O
p	O
=	O
0	O
.	O
1343	O
)	O
and	O
0	O
%	O
reduced	O
survival	O
,	O
respectively	O
(	O
Fig	O
.	O
3	O
)	O
.	O

Effects	O
of	O
cytokine	O
depletion	O
on	O
HK	O
vaccination	O

Similar	O
studies	O
were	O
performed	O
to	O
determine	O
the	O
role	O
of	O
IFN	O
-	O
gamma	O
or	O
TNF	O
-	O
alpha	O
in	O
acute	O
infection	O
in	O
BALB	O
/	O
c	O
mice	B-Species
immunized	O
with	O
HK	O
bacteria	O
.	O
<EOS>	B-X
Prostate	B-X
cancer	B-X
(	B-X
PCa	B-X
)	B-X
is	B-X
a	B-X
leading	B-X
cause	B-X
of	B-X
cancer-related	B-X
death	B-X
in	B-X
males	B-X
worldwide	B-X
.	B-X
Exacerbated	B-X
inflammation	B-X
and	B-X
angiogenesis	B-X
have	B-X
been	B-X
largely	B-X
demonstrated	B-X
to	B-X
contribute	B-X
to	B-X
PCa	B-X
progression	B-X
.	B-X
Diverse	B-X
naturally	B-X
occurring	B-X
compounds	B-X
and	B-X
dietary	B-X
supplements	B-X
are	B-X
endowed	B-X
with	B-X
anti-oxidant	B-X
,	B-X
anti-inflammatory	B-X
and	B-X
anti-angiogenic	B-X
activities	B-X
,	B-X
representing	B-X
valid	B-X
compounds	B-X
to	B-X
target	B-X
the	B-X
aberrant	B-X
cytokine/chemokine	B-X
production	B-X
governing	B-X
PCa	B-X
progression	B-X
and	B-X
angiogenesis	B-X
,	B-X
in	B-X
a	B-X
chemopreventive	B-X
setting	B-X
.	B-X
Using	B-X
mass	B-X
spectrometry	B-X
analysis	B-X
on	B-X
serum	B-X
samples	B-X
of	B-X
prostate	B-X
cancer	B-X
patients	B-X
,	B-X
we	B-X
have	B-X
previously	B-X
found	B-X
higher	B-X
levels	B-X
of	B-X
carnitines	B-X
in	B-X
non-cancer	B-X
individuals	B-X
,	B-X
suggesting	B-X
a	B-X
protective	B-X
role	B-X
.	B-X
Here	B-X
we	B-X
investigated	B-X
the	B-X
ability	B-X
of	B-X
Acetyl-L-carnitine	B-X
(	B-X
ALCAR	B-X
)	B-X
to	B-X
interfere	B-X
with	B-X
key	B-X
functional	B-X
properties	B-X
of	B-X
prostate	B-X
cancer	B-X
progression	B-X
and	B-X
angiogenesis	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
and	B-X
identified	B-X
target	B-X
molecules	B-X
modulated	B-X
by	B-X
ALCAR	B-X
.	B-X

Six	O
hours	O
before	O
challenge	O
,	O
mice	B-Species
were	O
dosed	O
with	O
antibodies	O
that	O
neutralize	O
IFN	O
-	O
gamma	O
or	O
TNF	O
-	O
alpha	O
.	O
<EOS>	B-X
Tumour	B-X
Necrosis	B-X
Factor	B-X
alpha	B-X
(	B-X
TNF	B-X
alpha	B-X
)	B-X
,	B-X
is	B-X
an	B-X
inflammatory	B-X
cytokine	B-X
produced	B-X
by	B-X
macrophages/monocytes	B-X
during	B-X
acute	B-X
inflammation	B-X
and	B-X
is	B-X
responsible	B-X
for	B-X
a	B-X
diverse	B-X
range	B-X
of	B-X
signalling	B-X
events	B-X
within	B-X
cells	B-X
,	B-X
leading	B-X
to	B-X
necrosis	B-X
or	B-X
apoptosis	B-X
.	B-X
TNF	B-X
alpha	B-X
exerts	B-X
many	B-X
of	B-X
its	B-X
effects	B-X
by	B-X
binding	B-X
,	B-X
as	B-X
a	B-X
trimer	B-X
,	B-X
to	B-X
either	B-X
a	B-X
55	B-X
kDa	B-X
cell	B-X
membrane	B-X
receptor	B-X
termed	B-X
TNFR-1	B-X
or	B-X
a	B-X
75	B-X
kDa	B-X
cell	B-X
membrane	B-X
receptor	B-X
termed	B-X
TNFR-2	B-X
.	B-X
Both	B-X
these	B-X
receptors	B-X
belong	B-X
to	B-X
the	B-X
so-called	B-X
TNF	B-X
receptor	B-X
superfamily	B-X
.	B-X
Additionally	B-X
,	B-X
a	B-X
number	B-X
of	B-X
structurally	B-X
related	B-X
``	B-X
decoy	B-X
receptors	B-X
''	B-X
exist	B-X
that	B-X
act	B-X
to	B-X
sequester	B-X
TNF	B-X
molecules	B-X
,	B-X
thereby	B-X
rescuing	B-X
cells	B-X
from	B-X
apoptosis	B-X
.	B-X
The	B-X
crystal	B-X
structures	B-X
of	B-X
TNF	B-X
alpha	B-X
,	B-X
TNF	B-X
beta	B-X
,	B-X
the	B-X
extracellular	B-X
domain	B-X
of	B-X
TNFR-1	B-X
(	B-X
denoted	B-X
sTNFR-1	B-X
)	B-X
,	B-X
and	B-X
the	B-X
TNF	B-X
beta	B-X
sTNFR-1	B-X
complex	B-X
have	B-X
been	B-X
defined	B-X
by	B-X
crystallography	B-X
.	B-X
This	B-X
article	B-X
will	B-X
review	B-X
the	B-X
structure/function	B-X
relationships	B-X
of	B-X
the	B-X
TNF	B-X
alpha	B-X
and	B-X
the	B-X
TNF	B-X
receptor	B-X
superfamily	B-X
.	B-X
It	B-X
will	B-X
also	B-X
discuss	B-X
insights	B-X
as	B-X
to	B-X
how	B-X
structural	B-X
features	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
pleiotropic	B-X
effects	B-X
of	B-X
TNF	B-X
alpha	B-X
.	B-X

Individual	O
depletion	O
of	O
either	O
TNF	O
-	O
alpha	O
(	O
p	O
=	O
0	O
.	O
0145	O
)	O
or	O
IFN	O
-	O
gamma	O
(	O
p	O
=	O
0	O
.	O
0446	O
)	O
resulted	O
in	O
100	O
%	O
mortality	O
with	O
an	O
MST	O
of	O
3	O
and	O
2	O
days	O
,	O
respectively	O
,	O
compared	O
to	O
the	O
HK	O
-	O
vaccinated	O
isotype	O
control	O
mice	B-Species
(	O
Fig	O
.	O
4	O
)	O
.	O

In	O
contrast	O
,	O
40	O
%	O
of	O
HK	O
-	O
vaccinated	O
,	O
isotype	O
control	O
mice	B-Species
survived	O
to	O
at	O
least	O
12	O
days	O
post	O
-	O
challenge	O
(	O
Fig	O
4	O
)	O
.	O

To	O
further	O
evaluate	O
the	O
host	O
TNF	O
-	O
alpha	O
response	O
during	O
an	O
established	O
B	B-Species
.	I-Species
mallei	I-Species
chronic	O
infection	O
,	O
we	O
infected	O
12	O
BALB	O
/	O
c	O
mice	B-Species
by	O
the	O
i	O
.	O
p	O
.	O
route	O
with	O
1	O
x	O
106	O
CFU	O
B	B-Species
.	I-Species
mallei	I-Species
.	O

One	O
animal	O
was	O
terminally	O
ill	O
on	O
day	O
37	O
post	O
-	O
infection	O
.	O

On	O
day	O
42	O
post	O
-	O
infection	O
,	O
the	O
remaining	O
11	O
mice	B-Species
were	O
dosed	O
with	O
either	O
anti	O
-	O
TNF	O
-	O
alpha	O
(	O
n	O
=	O
6	O
)	O
,	O
or	O
control	O
mAb	O
(	O
AFRC	O
Mac	O
49	O
)	O
(	O
n	O
=	O
5	O
)	O
.	O

No	O
further	O
deaths	O
were	O
observed	O
in	O
the	O
control	O
mAb	O
-	O
treated	O
mice	B-Species
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
administration	B-X
of	B-X
JES6	B-X
early	B-X
after	B-X
allo-HCT	B-X
in	B-X
mice	B-X
markedly	B-X
attenuates	B-X
acute	B-X
GVHD	B-X
while	B-X
preserving	B-X
GVL	B-X
activity	B-X
that	B-X
is	B-X
dramatically	B-X
stronger	B-X
than	B-X
observed	B-X
with	B-X
tacrolimus	B-X
(	B-X
TAC	B-X
)	B-X
treatment	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
an	B-X
anti-MRP1	B-X
antibody	B-X
(	B-X
Mab	B-X
)	B-X
-IR700	B-X
conjugate	B-X
(	B-X
Mab-IR700	B-X
)	B-X
was	B-X
synthesized	B-X
,	B-X
purified	B-X
and	B-X
used	B-X
to	B-X
treat	B-X
chemoresistant	B-X
SCLC	B-X
H69AR	B-X
cells	B-X
that	B-X
overexpressed	B-X
MRP1	B-X
,	B-X
while	B-X
non-MRP1-expressing	B-X
H69	B-X
cells	B-X
were	B-X
used	B-X
as	B-X
a	B-X
control	B-X
.	B-X
Due	B-X
to	B-X
the	B-X
targeting	B-X
activity	B-X
of	B-X
Mab	B-X
,	B-X
stronger	B-X
photokilling	B-X
effect	B-X
was	B-X
found	B-X
both	B-X
in	B-X
H69AR	B-X
cells	B-X
and	B-X
spheroids	B-X
treated	B-X
with	B-X
Mab-IR700	B-X
,	B-X
while	B-X
superior	B-X
tumor	B-X
suppression	B-X
effect	B-X
was	B-X
also	B-X
observed	B-X
in	B-X
the	B-X
mice	B-X
treated	B-X
with	B-X
Mab-IR700	B-X
and	B-X
light	B-X
illumination	B-X
.	B-X
Chimeric	B-X
antigen	B-X
receptor	B-X
(	B-X
CAR	B-X
)	B-X
T	B-X
cell	B-X
therapy	B-X
in	B-X
hematologic	B-X
malignancies	B-X
has	B-X
shown	B-X
remarkable	B-X
responses	B-X
,	B-X
but	B-X
the	B-X
same	B-X
level	B-X
of	B-X
success	B-X
has	B-X
not	B-X
been	B-X
observed	B-X
in	B-X
solid	B-X
tumors	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
antitumor	B-X
efficacy	B-X
of	B-X
human	B-X
CAR	B-X
T	B-X
cells	B-X
targeting	B-X
human	B-X
prostate-specific	B-X
membrane	B-X
antigen	B-X
(	B-X
hPSMA	B-X
)	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
and	B-X
absence	B-X
of	B-X
the	B-X
target	B-X
antigen	B-X
;	B-X
first	B-X
alone	B-X
and	B-X
then	B-X
combined	B-X
with	B-X
a	B-X
monoclonal	B-X
antibody	B-X
targeting	B-X
the	B-X
human	B-X
programmed	B-X
death	B-X
receptor	B-X
1	B-X
(	B-X
anti-hPD1	B-X
mAb	B-X
)	B-X
.	B-X
PDL-1	B-X
expression	B-X
was	B-X
detected	B-X
in	B-X
Myc-CaP	B-X
murine	B-X
prostate	B-X
tumors	B-X
growing	B-X
in	B-X
immune	B-X
competent	B-X
FVB/N	B-X
and	B-X
immune-deficient	B-X
SCID	B-X
mice	B-X
.	B-X

Rapid	O
mortality	O
was	O
observed	O
in	O
the	O
anti	O
-	O
TNF	O
-	O
alpha	O
-	O
treated	O
group	O
,	O
with	O
all	O
mice	B-Species
dying	O
within	O
7	O
days	O
of	O
treatment	O
(	O
p	O
=	O
0	O
.	O
0023	O
)	O
relative	O
to	O
the	O
isotype	O
-	O
treated	O
controls	O
(	O
Fig	O
.	O
5	O
)	O
.	O

J774A	O
.	O
1	O
uptake	O
of	O
serum	O
treated	O
B	B-Species
.	I-Species
mallei	I-Species

Complement	O
mediated	O
uptake	O
assays	O
were	O
performed	O
to	O
evaluate	O
opsonization	O
.	O

Results	O
indicated	O
enhanced	O
bacterial	O
uptake	O
in	O
J774A	O
.	O
1	O
phagocytes	O
inoculated	O
with	O
serum	O
treated	O
B	B-Species
.	I-Species
mallei	I-Species
(	O
p	O
=	O
.	O
0082	O
)	O
,	O
compared	O
to	O
B	B-Species
.	I-Species
mallei	I-Species
alone	O
,	O
while	O
heat	O
-	O
inactivated	O
serum	O
produced	O
uptake	O
percentages	O
similar	O
to	O
those	O
prior	O
to	O
serum	O
addition	O
(	O
Fig	O
.	O
6	O
)	O
.	O

Taken	O
together	O
,	O
these	O
results	O
imply	O
an	O
active	O
role	O
for	O
complement	O
components	O
in	O
the	O
uptake	O
of	O
organism	O
by	O
macrophages	O
.	O

Immunoglobulin	O
production	O
in	O
HK	O
vaccinated	O
BALB	O
/	O
c	O
mice	B-Species

We	O
further	O
characterized	O
the	O
ability	O
of	O
HK	O
vaccination	O
to	O
induce	O
a	O
predominant	O
IgG	O
isotype	O
by	O
determining	O
IgG2a	O
/	O
IgG1	O
ratios	O
in	O
i	O
.	O
p	O
.	O
and	O
i	O
.	O
n	O
.	O
vaccinated	O
BALB	O
/	O
c	O
mice	B-Species
.	O

Pre	O
(	O
day	O
14	O
post	O
vaccination	O
)	O
and	O
post	O
(	O
day	O
2	O
post	O
infection	O
)	O
exposure	O
serum	O
samples	O
were	O
obtained	O
and	O
evaluated	O
for	O
IgG	O
isotype	O
concentrations	O
(	O
Table	O
1	O
)	O
.	O

No	O
appreciable	O
differences	O
in	O
IgG	O
pre	O
-	O
exposure	O
levels	O
were	O
seen	O
when	O
comparing	O
i	O
.	O
n	O
.	O
to	O
i	O
.	O
p	O
.	O
vaccination	O
.	O

In	O
addition	O
,	O
cobra	O
venom	O
factor	O
-	O
treated	O
animals	O
showed	O
no	O
significant	O
differences	O
to	O
non	O
-	O
cobra	O
venom	O
factor	O
-	O
treated	O
animals	O
in	O
IgG	O
pre	O
-	O
exposure	O
(	O
challenge	O
)	O
levels	O
.	O

Conversely	O
,	O
isotype	O
switching	O
in	O
the	O
cobra	O
venom	O
factor	O
treated	O
animals	O
was	O
enhanced	O
in	O
post	O
-	O
exposure	O
serum	O
IgG2a	O
(	O
Table	O
1	O
)	O
.	O

Discussion	O
<EOS>	B-X
Discussion	B-X
structures	B-X
are	B-X
argumentation-theoretical	B-X
tools	B-X
that	B-X
can	B-X
be	B-X
employed	B-X
to	B-X
tackle	B-X
three	B-X
barriers	B-X
that	B-X
separate	B-X
lay	B-X
stakeholders	B-X
from	B-X
policy	B-X
debates	B-X
:	B-X
difficulty	B-X
,	B-X
magnitude	B-X
,	B-X
and	B-X
complexity	B-X
.	B-X
Discussions	B-X
about	B-X
preventive	B-X
behaviors	B-X
were	B-X
assessed	B-X
before	B-X
testing	B-X
and	B-X
1	B-X
and	B-X
6	B-X
months	B-X
post-testing	B-X
.	B-X
Discussion	B-X
of	B-X
preventive	B-X
behaviors	B-X
declined	B-X
following	B-X
test	B-X
reporting	B-X
,	B-X
with	B-X
more	B-X
rapid	B-X
decline	B-X
reported	B-X
by	B-X
noncarriers	B-X
.	B-X
Discussions	B-X
are	B-X
an	B-X
important	B-X
part	B-X
of	B-X
medical	B-X
education	B-X
research	B-X
papers	B-X
,	B-X
but	B-X
there	B-X
is	B-X
little	B-X
guidance	B-X
on	B-X
how	B-X
to	B-X
write	B-X
up	B-X
the	B-X
discussion	B-X
section	B-X
.	B-X

Recent	O
studies	O
have	O
shown	O
a	O
key	O
role	O
in	O
protection	O
from	O
lethal	O
challenge	O
for	O
IFN	O
-	O
gamma	O
in	O
non	O
-	O
vaccinated	O
mice	B-Species
from	O
either	O
NK	O
and	O
/	O
or	O
NKT	O
cells	O
following	O
experimental	O
exposure	O
to	O
B	B-Species
.	I-Species
mallei	I-Species
and	O
B	B-Species
.	I-Species
pseudomallei	I-Species
[	O
7	O
,	O
8	O
]	O
.	O

A	O
similar	O
protective	O
role	O
in	O
the	O
innate	O
response	O
to	O
infection	O
has	O
been	O
demonstrated	O
for	O
TNF	O
-	O
alpha	O
in	O
B	B-Species
.	I-Species
pseudomallei	I-Species
infection	O
[	O
8	O
]	O
.	O

The	O
studies	O
presented	O
here	O
are	O
consistent	O
with	O
the	O
essential	O
role	O
of	O
these	O
factors	O
in	O
the	O
relative	O
levels	O
of	O
protection	O
conferred	O
by	O
vaccination	O
with	O
heat	O
-	O
killed	O
B	B-Species
.	I-Species
pseudomallei	I-Species
and	O
would	O
appear	O
to	O
be	O
viable	O
early	O
markers	O
for	O
protection	O
from	O
lethal	O
acute	O
infection	O
[	O
9	O
]	O
.	O

Currently	O
,	O
there	O
are	O
no	O
fully	O
protective	O
vaccines	O
against	O
B	B-Species
.	I-Species
mallei	I-Species
or	O
B	B-Species
.	I-Species
pseudomallei	I-Species
in	O
a	O
murine	B-Species
model	O
,	O
particularly	O
for	O
the	O
sensitive	O
BALB	O
/	O
c	O
versus	O
C57BL6	O
models	O
.	O

Previous	O
studies	O
have	O
also	O
demonstrated	O
that	O
both	O
the	O
humoral	O
and	O
cell	O
-	O
mediated	O
arms	O
are	O
essential	O
for	O
protection	O
from	O
B	B-Species
.	I-Species
pseudomallei	I-Species
infection	O
[	O
10	O
]	O
.	O

Thus	O
,	O
loss	O
or	O
reduction	O
of	O
TNF	O
-	O
alpha	O
and	O
IFN	O
-	O
gamma	O
levels	O
result	O
in	O
significantly	O
reduced	O
survival	O
rates	O
,	O
substantiating	O
previous	O
reports	O
of	O
the	O
role	O
of	O
these	O
factors	O
in	O
protection	O
against	O
B	B-Species
.	I-Species
mallei	I-Species
[	O
7	O
]	O
.	O
<EOS>	B-X
Sudden	B-X
sensorineural	B-X
hearing	B-X
loss	B-X
(	B-X
SSNHL	B-X
)	B-X
is	B-X
commonly	B-X
encountered	B-X
in	B-X
audiologic	B-X
and	B-X
otolaryngologic	B-X
practice	B-X
.	B-X
SSNHL	B-X
is	B-X
most	B-X
commonly	B-X
defined	B-X
as	B-X
sensorineural	B-X
hearing	B-X
loss	B-X
of	B-X
30	B-X
dB	B-X
or	B-X
greater	B-X
over	B-X
at	B-X
least	B-X
three	B-X
contiguous	B-X
audiometric	B-X
frequencies	B-X
occurring	B-X
within	B-X
a	B-X
72-hr	B-X
period	B-X
.	B-X
Treatment	B-X
for	B-X
SSNHL	B-X
of	B-X
known	B-X
etiology	B-X
is	B-X
directed	B-X
toward	B-X
that	B-X
agent	B-X
,	B-X
with	B-X
poor	B-X
hearing	B-X
outcomes	B-X
characteristic	B-X
for	B-X
discoverable	B-X
etiologies	B-X
that	B-X
cause	B-X
inner	B-X
ear	B-X
hair	B-X
cell	B-X
loss	B-X
.	B-X
The	B-X
prognosis	B-X
for	B-X
hearing	B-X
recovery	B-X
for	B-X
idiopathic	B-X
SSNHL	B-X
is	B-X
dependent	B-X
on	B-X
a	B-X
number	B-X
of	B-X
factors	B-X
including	B-X
the	B-X
severity	B-X
of	B-X
hearing	B-X
loss	B-X
,	B-X
age	B-X
,	B-X
presence	B-X
of	B-X
vertigo	B-X
,	B-X
and	B-X
shape	B-X
of	B-X
the	B-X
audiogram	B-X
.	B-X

Moreover	O
,	O
we	O
demonstrate	O
a	O
role	O
for	O
sustained	O
TNF	O
-	O
alpha	O
production	O
in	O
the	O
maintenance	O
of	O
host	O
survival	O
throughout	O
the	O
course	O
of	O
B	B-Species
.	I-Species
mallei	I-Species
infection	O
.	O

Mice	B-Species
with	O
an	O
established	O
B	B-Species
.	I-Species
mallei	I-Species
chronic	O
infection	O
rapidly	O
lost	O
the	O
ability	O
to	O
control	O
the	O
growth	O
of	O
the	O
bacillus	O
upon	O
neutralization	O
of	O
TNF	O
-	O
alpha	O
.	O

This	O
would	O
suggest	O
a	O
potential	O
role	O
for	O
TNF	O
-	O
alpha	O
in	O
the	O
maintenance	O
of	O
productive	O
granulomas	O
which	O
may	O
limit	O
the	O
spread	O
of	O
bacteria	O
in	O
chronically	O
infected	O
hosts	O
,	O
or	O
,	O
alternatively	O
,	O
in	O
direct	O
or	O
indirect	O
microbicidal	O
or	O
bacteriostatic	O
activities	O
at	O
the	O
sites	O
of	O
infection	O
.	O
<EOS>	B-X
The	B-X
female	B-X
reproductive	B-X
tract	B-X
(	B-X
FRT	B-X
)	B-X
,	B-X
similar	B-X
to	B-X
other	B-X
mucosal	B-X
sites	B-X
,	B-X
harbours	B-X
a	B-X
site-specific	B-X
microbiome	B-X
,	B-X
which	B-X
has	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
maintaining	B-X
health	B-X
and	B-X
homeostasis	B-X
.	B-X
In	B-X
the	B-X
majority	B-X
of	B-X
women	B-X
of	B-X
reproductive	B-X
age	B-X
,	B-X
the	B-X
microbiota	B-X
of	B-X
the	B-X
lower	B-X
FRT	B-X
(	B-X
vagina	B-X
and	B-X
cervix	B-X
)	B-X
microenvironment	B-X
is	B-X
dominated	B-X
by	B-X
Lactobacillus	B-X
species	B-X
,	B-X
which	B-X
benefit	B-X
the	B-X
host	B-X
through	B-X
symbiotic	B-X
relationships	B-X
.	B-X
Emerging	B-X
evidence	B-X
shows	B-X
that	B-X
genital	B-X
dysbiosis	B-X
and/or	B-X
specific	B-X
bacteria	B-X
might	B-X
have	B-X
an	B-X
active	B-X
role	B-X
in	B-X
the	B-X
development	B-X
and/or	B-X
progression	B-X
and	B-X
metastasis	B-X
of	B-X
gynaecological	B-X
malignancies	B-X
,	B-X
such	B-X
as	B-X
cervical	B-X
,	B-X
endometrial	B-X
and	B-X
ovarian	B-X
cancers	B-X
,	B-X
through	B-X
direct	B-X
and	B-X
indirect	B-X
mechanisms	B-X
,	B-X
including	B-X
modulation	B-X
of	B-X
oestrogen	B-X
metabolism	B-X
.	B-X
Cancer	B-X
therapies	B-X
might	B-X
also	B-X
alter	B-X
microbiota	B-X
at	B-X
sites	B-X
throughout	B-X
the	B-X
body	B-X
.	B-X
Elucidating	B-X
these	B-X
complex	B-X
host-microbiome	B-X
interactions	B-X
,	B-X
including	B-X
the	B-X
crosstalk	B-X
between	B-X
distal	B-X
and	B-X
local	B-X
sites	B-X
,	B-X
will	B-X
translate	B-X
into	B-X
interventions	B-X
for	B-X
prevention	B-X
,	B-X
therapeutic	B-X
efficacy	B-X
and	B-X
toxic	B-X
effects	B-X
to	B-X
enhance	B-X
health	B-X
outcomes	B-X
for	B-X
women	B-X
with	B-X
gynaecological	B-X
cancers	B-X
.	B-X

Additional	O
studies	O
are	O
underway	O
to	O
determine	O
more	O
precisely	O
the	O
role	O
of	O
TNF	O
-	O
alpha	O
in	O
host	O
protection	O
to	O
B	B-Species
.	I-Species
mallei	I-Species
.	O

Multiple	O
innate	O
and	O
adaptive	O
cell	O
types	O
may	O
contribute	O
to	O
the	O
production	O
of	O
IFN	O
-	O
gamma	O
in	O
response	O
to	O
infection	O
with	O
B	B-Species
.	I-Species
mallei	I-Species
following	O
vaccination	O
.	O

Our	O
results	O
with	O
individual	O
depletion	O
of	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cells	O
suggests	O
that	O
both	O
cell	O
types	O
may	O
compensate	O
for	O
the	O
functional	O
loss	O
of	O
the	O
other	O
effector	O
cell	O
type	O
in	O
the	O
production	O
of	O
this	O
key	O
cytokine	O
.	O

The	O
effector	O
role	O
for	O
IFN	O
-	O
gamma	O
in	O
mediating	O
protection	O
against	O
B	B-Species
.	I-Species
mallei	I-Species
may	O
include	O
both	O
immunoregulatory	O
and	O
non	O
-	O
regulatory	O
functions	O
.	O

Regardless	O
,	O
the	O
requirement	O
of	O
IFN	O
-	O
gamma	O
,	O
as	O
demonstrated	O
by	O
administration	O
of	O
neutralizing	O
antibody	O
prior	O
to	O
infection	O
,	O
indicates	O
that	O
stimulation	O
of	O
IFN	O
-	O
gamma	O
response	O
is	O
a	O
desirable	O
goal	O
for	O
a	O
B	B-Species
.	I-Species
mallei	I-Species
vaccine	O
.	O

Similarly	O
,	O
B220	O
-	O
positive	O
cells	O
appear	O
to	O
play	O
a	O
role	O
in	O
protection	O
following	O
vaccination	O
with	O
heat	O
-	O
killed	O
B	B-Species
.	I-Species
mallei	I-Species
.	O

Interestingly	O
,	O
this	O
protective	O
immunity	O
,	O
occurring	O
in	O
other	O
intracellular	O
pathogens	O
,	O
is	O
not	O
exclusively	O
dependent	O
on	O
B	O
cells	O
[	O
11	O
]	O
.	O

Passive	O
protection	O
has	O
been	O
demonstrated	O
against	O
acute	O
Burkholderia	O
infection	O
by	O
monoclonal	O
antibodies	O
[	O
5	O
,	O
12	O
]	O
.	O

Protection	O
against	O
B	B-Species
.	I-Species
pseudomallei	I-Species
infection	O
by	O
anti	O
-	O
LPS	O
,	O
capsular	O
polysaccharide	O
and	O
proteins	O
has	O
been	O
short	O
-	O
lived	O
,	O
suggesting	O
that	O
antibody	O
production	O
offers	O
limited	O
protection	O
in	O
the	O
initial	O
stages	O
of	O
infection	O
by	O
an	O
as	O
-	O
yet	O
-	O
undefined	O
mechanism	O
[	O
12	O
]	O
.	O

We	O
have	O
shown	O
that	O
following	O
depletion	O
of	O
B220	O
+	O
cells	O
,	O
survival	O
rates	O
decreased	O
as	O
much	O
as	O
100	O
%	O
relative	O
to	O
non	O
-	O
depleted	O
controls	O
and	O
individual	O
CD4	O
/	O
CD8	O
-	O
depleted	O
mice	B-Species
via	O
the	O
intraperitoneal	O
route	O
.	O

Results	O
from	O
C57BL	O
/	O
6	O
mice	B-Species
deficient	O
in	O
mature	O
B	O
-	O
cells	O
(	O
mu	O
MT	O
)	O
,	O
CD4	O
T	O
-	O
cells	O
(	O
CD4	O
-	O
/	O
-	O
)	O
or	O
CD8	O
T	O
-	O
cells	O
(	O
CD8	O
-	O
/	O
-	O
)	O
substantiate	O
the	O
requirement	O
for	O
B	O
-	O
cell	O
involvement	O
by	O
evidence	O
of	O
mu	O
MT	O
and	O
CD4	O
-	O
/	O
-	O
decreased	O
survival	O
.	O

The	O
lack	O
of	O
an	O
effective	O
CTL	O
response	O
to	O
vaccination	O
did	O
not	O
appear	O
to	O
alter	O
survival	O
in	O
what	O
would	O
appear	O
to	O
be	O
a	O
CD4	O
/	O
B	O
-	O
cell	O
(	O
humoral	O
)	O
-	O
driven	O
response	O
.	O
<EOS>	B-X
The	B-X
liposome-encapsulated	B-X
condensed	B-X
RNA-peptide	B-X
complex	B-X
,	B-X
the	B-X
condensed	B-X
RNA-peptide	B-X
complex	B-X
without	B-X
liposome	B-X
or	B-X
naked	B-X
,	B-X
unprotected	B-X
RNA	B-X
,	B-X
was	B-X
injected	B-X
into	B-X
BALB/c	B-X
(	B-X
H-2	B-X
(	B-X
d	B-X
)	B-X
)	B-X
mice	B-X
.	B-X
All	B-X
preparations	B-X
led	B-X
to	B-X
protein	B-X
expression	B-X
in	B-X
the	B-X
local	B-X
tissue	B-X
,	B-X
activation	B-X
of	B-X
L	B-X
(	B-X
d	B-X
)	B-X
-restricted	B-X
specific	B-X
cytotoxic	B-X
T	B-X
lymphocytes	B-X
(	B-X
CTL	B-X
)	B-X
and	B-X
production	B-X
of	B-X
IgG	B-X
antibodies	B-X
reactive	B-X
against	B-X
beta-gal	B-X
.	B-X
RNA-triggered	B-X
CTL	B-X
were	B-X
as	B-X
efficient	B-X
in	B-X
the	B-X
lysis	B-X
of	B-X
lacZ-transfected	B-X
target	B-X
cells	B-X
as	B-X
CTL	B-X
triggered	B-X
by	B-X
a	B-X
lacZ-DNA	B-X
eukaryotic	B-X
expression	B-X
vector	B-X
.	B-X
Immunization	B-X
with	B-X
RNA	B-X
transcribed	B-X
from	B-X
a	B-X
cDNA	B-X
library	B-X
from	B-X
the	B-X
beta-gal-expressing	B-X
cell	B-X
line	B-X
P13.1	B-X
again	B-X
led	B-X
to	B-X
beta-gal-specific	B-X
CTL	B-X
and	B-X
IgG	B-X
induction	B-X
.	B-X
Thus	B-X
,	B-X
both	B-X
naked	B-X
and	B-X
protected	B-X
RNA	B-X
can	B-X
be	B-X
used	B-X
to	B-X
elicit	B-X
a	B-X
specific	B-X
immune	B-X
response	B-X
in	B-X
vivo	B-X
,	B-X
whereby	B-X
the	B-X
protected	B-X
RNA	B-X
is	B-X
stable	B-X
in	B-X
vitro	B-X
for	B-X
a	B-X
longer	B-X
period	B-X
of	B-X
time	B-X
.	B-X
RNA	B-X
vaccines	B-X
can	B-X
be	B-X
produced	B-X
in	B-X
high	B-X
amounts	B-X
and	B-X
have	B-X
the	B-X
same	B-X
major	B-X
advantages	B-X
as	B-X
DNA	B-X
vaccines	B-X
but	B-X
lack	B-X
the	B-X
potentially	B-X
harmful	B-X
effect	B-X
of	B-X
DNA	B-X
integration	B-X
into	B-X
the	B-X
genome	B-X
.	B-X

In	O
CD4	O
-	O
deficient	O
mice	B-Species
,	O
we	O
have	O
the	O
additional	O
potential	O
variable	O
that	O
a	O
CD4	O
-	O
dependent	O
antibody	O
response	O
might	O
also	O
be	O
inhibited	O
during	O
the	O
vaccination	O
phase	O
relative	O
to	O
mice	B-Species
treated	O
with	O
antibody	O
immediately	O
prior	O
to	O
and	O
during	O
the	O
early	O
phases	O
of	O
infection	O
.	O

Although	O
not	O
statistically	O
significant	O
,	O
we	O
did	O
observe	O
a	O
decrease	O
in	O
survival	O
in	O
mu	O
MT	O
(	O
mature	O
B	O
cell	O
)	O
deficient	O
mice	B-Species
as	O
early	O
as	O
day	O
9	O
post	O
challenge	O
,	O
whereas	O
CD4	O
-	O
deficient	O
mice	B-Species
produced	O
similar	O
results	O
at	O
day	O
32	O
post	O
challenge	O
,	O
indicating	O
a	O
role	O
for	O
B	O
cells	O
independent	O
of	O
CD4	O
T	O
cell	O
help	O
,	O
perhaps	O
through	O
a	O
T	O
-	O
independent	O
mechanism	O
of	O
antibody	O
production	O
.	O

Although	O
CD8	O
-	O
/	O
-	O
C57BL	O
/	O
6	O
demonstrated	O
no	O
decreased	O
survival	O
in	O
our	O
HK	O
-	O
vaccinated	O
model	O
,	O
a	O
lack	O
of	O
potential	O
endogenous	O
protein	O
production	O
by	O
HK	O
B	B-Species
.	I-Species
mallei	I-Species
may	O
have	O
contributed	O
to	O
limited	O
MHC	O
-	O
I	O
presentation	O
.	O

Complement	O
associated	O
studies	O
revealed	O
increased	O
J774A	O
.	O
1	O
uptake	O
of	O
serum	O
-	O
treated	O
B	B-Species
.	I-Species
mallei	I-Species
.	O

Complement	O
-	O
mediated	O
uptake	O
studies	O
of	O
B	B-Species
.	I-Species
pseudomallei	I-Species
by	O
polymorphonuclear	O
leukocytes	O
(	O
PMNs	O
)	O
suggest	O
that	O
capsule	O
production	O
contributes	O
to	O
resistance	O
of	O
phagocytosis	O
by	O
reducing	O
C3b	O
bacterial	O
deposition	O
[	O
13	O
]	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
a	O
polysaccharide	O
capsule	O
is	O
present	O
in	O
B	B-Species
.	I-Species
mallei	I-Species
,	O
[	O
14	O
,	O
15	O
]	O
although	O
in	O
the	O
present	O
study	O
enhanced	O
uptake	O
with	O
serum	O
-	O
treated	O
B	B-Species
.	I-Species
mallei	I-Species
was	O
observed	O
.	O

Intracellular	O
survival	O
assays	O
of	O
complement	O
mediated	O
uptake	O
of	O
organisms	O
were	O
not	O
performed	O
in	O
the	O
present	O
study	O
,	O
thus	O
,	O
the	O
role	O
of	O
complement	O
opsonization	O
on	O
intracellular	O
survival	O
is	O
not	O
fully	O
resolved	O
.	O
<EOS>	B-X
For	B-X
all	B-X
of	B-X
these	B-X
organisms	B-X
,	B-X
intracellular	B-X
trafficking	B-X
is	B-X
vital	B-X
for	B-X
maintenance	B-X
of	B-X
the	B-X
host-pathogen	B-X
interface	B-X
,	B-X
modulation/evasion	B-X
of	B-X
host	B-X
immune	B-X
system	B-X
responses	B-X
and	B-X
nutrient	B-X
uptake	B-X
.	B-X
Soluble	B-X
N-ethylmaleimide-sensitive	B-X
factor	B-X
attachment	B-X
protein	B-X
receptors	B-X
(	B-X
SNAREs	B-X
)	B-X
are	B-X
critical	B-X
components	B-X
of	B-X
the	B-X
intracellular	B-X
trafficking	B-X
machinery	B-X
in	B-X
eukaryotes	B-X
,	B-X
mediating	B-X
membrane	B-X
fusion	B-X
and	B-X
contributing	B-X
to	B-X
organelle	B-X
specificity	B-X
.	B-X
We	B-X
asked	B-X
how	B-X
the	B-X
SNARE	B-X
complement	B-X
evolved	B-X
across	B-X
the	B-X
trypanosomatids	B-X
.	B-X
Only	B-X
limited	B-X
variation	B-X
in	B-X
number	B-X
and	B-X
identity	B-X
of	B-X
SNAREs	B-X
was	B-X
found	B-X
,	B-X
with	B-X
Leishmania	B-X
major	B-X
having	B-X
27	B-X
and	B-X
T.	B-X
brucei	B-X
26	B-X
,	B-X
suggesting	B-X
a	B-X
stable	B-X
SNARE	B-X
complement	B-X
post-speciation	B-X
.	B-X
Expression	B-X
analysis	B-X
of	B-X
T.	B-X
brucei	B-X
SNAREs	B-X
revealed	B-X
significant	B-X
differential	B-X
expression	B-X
between	B-X
mammalian	B-X
and	B-X
insect	B-X
infective	B-X
forms	B-X
,	B-X
especially	B-X
within	B-X
R	B-X
and	B-X
Qb-SNARE	B-X
subclasses	B-X
,	B-X
suggesting	B-X
possible	B-X
roles	B-X
in	B-X
adaptation	B-X
to	B-X
different	B-X
environments	B-X
.	B-X
Despite	B-X
highly	B-X
distinct	B-X
life	B-X
styles	B-X
,	B-X
the	B-X
complement	B-X
of	B-X
trypanosomatid	B-X
SNAREs	B-X
is	B-X
quite	B-X
stable	B-X
between	B-X
the	B-X
three	B-X
pathogenic	B-X
lineages	B-X
,	B-X
suggesting	B-X
establishment	B-X
in	B-X
the	B-X
last	B-X
common	B-X
ancestor	B-X
of	B-X
trypanosomes	B-X
and	B-X
Leishmania	B-X
.	B-X

Previous	O
reports	O
have	O
demonstrated	O
the	O
ability	O
of	O
B	B-Species
.	I-Species
mallei	I-Species
to	O
survive	O
within	O
macrophage	O
without	O
the	O
aid	O
of	O
serum	O
coating	O
organisms	O
[	O
16	O
]	O
.	O

Conversely	O
,	O
the	O
idea	O
of	O
antibody	O
mediated	O
opsonization	O
to	O
facilitate	O
macrophage	O
activation	O
and	O
clearance	O
of	O
intracellular	O
organisms	O
may	O
offer	O
support	O
to	O
the	O
role	O
of	O
B	O
cells	O
in	O
an	O
effective	O
immune	O
response	O
.	O

A	O
possible	O
protective	O
mechanism	O
may	O
include	O
HK	O
vaccination	O
induced	O
production	O
of	O
opsonizing	O
antibodies	O
which	O
may	O
aid	O
in	O
complement	O
mediated	O
uptake	O
,	O
thereby	O
limiting	O
the	O
initial	O
bacterial	O
threshold	O
below	O
a	O
lethal	O
level	O
.	O

Immunoglobulin	O
responses	O
to	O
HK	O
vaccination	O
resulted	O
in	O
modest	O
levels	O
of	O
IgG1	O
following	O
2	O
weeks	O
post	O
vaccination	O
,	O
while	O
post	O
-	O
exposure	O
levels	O
were	O
indicative	O
of	O
efficient	O
class	O
switching	O
to	O
a	O
favorable	O
IgG2a	O
isotype	O
.	O

Importantly	O
,	O
cobra	O
venom	O
factor	O
treatment	O
of	O
animals	O
at	O
time	O
of	O
vaccination	O
did	O
not	O
alter	O
their	O
ability	O
to	O
produce	O
immunoglobulin	O
.	O

In	O
fact	O
,	O
cobra	O
venom	O
factor	O
treated	O
animals	O
resulted	O
in	O
higher	O
IgG2a	O
levels	O
when	O
compared	O
to	O
non	O
-	O
treated	O
.	O

Complement	O
activation	O
can	O
modulate	O
both	O
the	O
primary	O
and	O
secondary	O
immune	O
responses	O
and	O
has	O
been	O
shown	O
to	O
enhance	O
secondary	O
immune	O
responses	O
to	O
vaccination	O
[	O
17	O
]	O
.	O
<EOS>	B-X
Complement	B-X
activation	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
immune	B-X
response	B-X
to	B-X
T-cell-dependent	B-X
and	B-X
T-cell-independent	B-X
antigens	B-X
.	B-X
However	B-X
,	B-X
the	B-X
effect	B-X
of	B-X
conjugation	B-X
of	B-X
T-cell-dependent	B-X
protein	B-X
carriers	B-X
to	B-X
T-cell-independent	B-X
type	B-X
2	B-X
antigens	B-X
on	B-X
the	B-X
requirement	B-X
for	B-X
complement	B-X
in	B-X
the	B-X
humoral	B-X
immune	B-X
response	B-X
to	B-X
such	B-X
antigens	B-X
remains	B-X
unknown	B-X
.	B-X
We	B-X
studied	B-X
the	B-X
role	B-X
of	B-X
complement	B-X
activation	B-X
on	B-X
the	B-X
antibody	B-X
response	B-X
of	B-X
BALB/c	B-X
mice	B-X
immunized	B-X
with	B-X
the	B-X
T-cell-independent	B-X
type	B-X
2	B-X
antigen	B-X
serotype	B-X
14	B-X
pneumococcal	B-X
capsular	B-X
polysaccharide	B-X
(	B-X
PPS14	B-X
)	B-X
,	B-X
either	B-X
in	B-X
unmodified	B-X
form	B-X
or	B-X
conjugated	B-X
to	B-X
ovalbumin	B-X
(	B-X
OVA	B-X
)	B-X
.	B-X
In	B-X
mice	B-X
immunized	B-X
with	B-X
either	B-X
PPS14	B-X
or	B-X
PPS14-OVA	B-X
,	B-X
depletion	B-X
of	B-X
endogenous	B-X
complement	B-X
at	B-X
the	B-X
time	B-X
of	B-X
primary	B-X
immunization	B-X
by	B-X
treatment	B-X
with	B-X
cobra	B-X
venom	B-X
factor	B-X
(	B-X
CVF	B-X
)	B-X
diminished	B-X
serum	B-X
anti-PPS14	B-X
concentrations	B-X
after	B-X
primary	B-X
immunization	B-X
but	B-X
enhanced	B-X
antibody	B-X
responses	B-X
after	B-X
secondary	B-X
immunization	B-X
.	B-X
The	B-X
secondary	B-X
immunoglobulin	B-X
G	B-X
(	B-X
IgG	B-X
)	B-X
anti-PPS14	B-X
antibody	B-X
response	B-X
after	B-X
immunization	B-X
with	B-X
PPS14-OVA	B-X
was	B-X
especially	B-X
enhanced	B-X
by	B-X
complement	B-X
depletion	B-X
,	B-X
was	B-X
observed	B-X
at	B-X
doses	B-X
as	B-X
low	B-X
as	B-X
0.2	B-X
mug	B-X
of	B-X
antigen	B-X
,	B-X
and	B-X
was	B-X
maximal	B-X
when	B-X
CVF	B-X
was	B-X
administered	B-X
within	B-X
2	B-X
days	B-X
of	B-X
immunization	B-X
.	B-X
Serum	B-X
anti-PPS14	B-X
antibody	B-X
concentrations	B-X
were	B-X
near	B-X
normal	B-X
,	B-X
and	B-X
the	B-X
enhancing	B-X
effects	B-X
of	B-X
CVF	B-X
treatment	B-X
on	B-X
the	B-X
secondary	B-X
anti-PPS14	B-X
antibody	B-X
response	B-X
were	B-X
also	B-X
apparent	B-X
in	B-X
splenectomized	B-X
mice	B-X
immunized	B-X
with	B-X
PPS14-OVA	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
complement	B-X
activation	B-X
can	B-X
have	B-X
distinct	B-X
effects	B-X
on	B-X
the	B-X
primary	B-X
and	B-X
secondary	B-X
antibody	B-X
responses	B-X
to	B-X
a	B-X
T-cell-independent	B-X
type	B-X
2	B-X
antigen	B-X
,	B-X
either	B-X
unmodified	B-X
or	B-X
conjugated	B-X
to	B-X
a	B-X
T-cell-dependent	B-X
protein	B-X
carrier	B-X
.	B-X
These	B-X
differences	B-X
should	B-X
be	B-X
taken	B-X
into	B-X
consideration	B-X
when	B-X
using	B-X
complement	B-X
to	B-X
modulate	B-X
the	B-X
immune	B-X
response	B-X
to	B-X
vaccines	B-X
.	B-X

The	O
current	O
results	O
suggest	O
that	O
cobra	O
venom	O
factor	O
treatment	O
may	O
affect	O
the	O
modulation	O
of	O
the	O
immune	O
response	O
to	O
B	B-Species
.	I-Species
mallei	I-Species
infection	O
through	O
B	O
cell	O
activation	O
and	O
/	O
or	O
memory	O
B	O
cell	O
generation	O
.	O
<EOS>	B-X
Immunological	B-X
memory	B-X
is	B-X
a	B-X
composite	B-X
of	B-X
lasting	B-X
antibody	B-X
titers	B-X
maintained	B-X
by	B-X
plasma	B-X
cells	B-X
in	B-X
conjunction	B-X
with	B-X
memory	B-X
T	B-X
and	B-X
B	B-X
cells	B-X
.	B-X
Memory	B-X
B	B-X
cells	B-X
are	B-X
a	B-X
critical	B-X
reservoir	B-X
for	B-X
plasma	B-X
cell	B-X
generation	B-X
in	B-X
the	B-X
secondary	B-X
response	B-X
.	B-X
Identification	B-X
of	B-X
memory	B-X
B	B-X
cells	B-X
requires	B-X
that	B-X
they	B-X
be	B-X
distinguished	B-X
from	B-X
naÃ¯ve	B-X
,	B-X
activated	B-X
,	B-X
and	B-X
germinal	B-X
center	B-X
precursors	B-X
and	B-X
from	B-X
plasma	B-X
cells	B-X
.	B-X
Memory	B-X
B	B-X
cells	B-X
are	B-X
heterogeneous	B-X
in	B-X
isotype	B-X
usage	B-X
,	B-X
immunoglobulin	B-X
mutational	B-X
content	B-X
,	B-X
and	B-X
phenotypic	B-X
marker	B-X
expression	B-X
.	B-X
Phenotypic	B-X
subsets	B-X
of	B-X
memory	B-X
B	B-X
cells	B-X
are	B-X
defined	B-X
by	B-X
PD-L2	B-X
,	B-X
CD80	B-X
,	B-X
and	B-X
CD73	B-X
expression	B-X
in	B-X
mice	B-X
,	B-X
by	B-X
CD27	B-X
and	B-X
FCRL4	B-X
expression	B-X
in	B-X
humans	B-X
and	B-X
by	B-X
T-bet	B-X
in	B-X
both	B-X
mice	B-X
and	B-X
humans	B-X
.	B-X
These	B-X
subsets	B-X
display	B-X
marked	B-X
functional	B-X
heterogeneity	B-X
,	B-X
including	B-X
the	B-X
ability	B-X
to	B-X
rapidly	B-X
differentiate	B-X
into	B-X
plasma	B-X
cells	B-X
versus	B-X
seed	B-X
germinal	B-X
centers	B-X
in	B-X
the	B-X
secondary	B-X
response	B-X
.	B-X
Memory	B-X
B	B-X
cells	B-X
are	B-X
located	B-X
in	B-X
the	B-X
spleen	B-X
,	B-X
blood	B-X
,	B-X
other	B-X
lymphoid	B-X
organs	B-X
,	B-X
and	B-X
barrier	B-X
tissues	B-X
,	B-X
and	B-X
recent	B-X
evidence	B-X
indicates	B-X
that	B-X
some	B-X
memory	B-X
B	B-X
cells	B-X
may	B-X
be	B-X
dedicated	B-X
tissue-resident	B-X
populations	B-X
.	B-X
Open	B-X
questions	B-X
about	B-X
memory	B-X
B	B-X
cell	B-X
longevity	B-X
,	B-X
renewal	B-X
and	B-X
progenitor-successor	B-X
relationships	B-X
with	B-X
plasma	B-X
cells	B-X
are	B-X
discussed	B-X
.	B-X

Conclusion	O
<EOS>	B-X
Conclusion	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X

In	O
summary	O
,	O
our	O
results	O
provide	O
a	O
basis	O
for	O
future	O
studies	O
of	O
protection	O
via	O
vaccination	O
using	O
either	O
subunit	O
or	O
whole	O
-	O
organism	O
vaccine	O
preparations	O
from	O
lethal	O
infection	O
in	O
the	O
experimental	O
BALB	O
/	O
c	O
mouse	B-Species
model	O
.	O
<EOS>	B-X
We	B-X
performed	B-X
initial	B-X
cell	B-X
,	B-X
cytokine	B-X
and	B-X
complement	B-X
depletion	B-X
studies	B-X
to	B-X
investigate	B-X
the	B-X
possible	B-X
role	B-X
of	B-X
these	B-X
effectors	B-X
in	B-X
response	B-X
to	B-X
vaccination	B-X
with	B-X
heat-killed	B-X
Burkholderia	B-X
mallei	B-X
in	B-X
a	B-X
susceptible	B-X
BALB/c	B-X
mouse	B-X
model	B-X
of	B-X
infection	B-X
.	B-X

Understanding	O
and	O
defining	O
the	O
role	O
of	O
B	O
cells	O
in	O
adaptive	O
B	B-Species
.	I-Species
mallei	I-Species
immunity	O
will	O
likely	O
be	O
fundamental	O
to	O
the	O
design	O
of	O
an	O
efficacious	O
vaccine	O
and	O
important	O
goals	O
of	O
future	O
research	O
.	O

Methods	O
<EOS>	B-X
Methods	B-X
to	B-X
calculate	B-X
the	B-X
sample	B-X
size	B-X
are	B-X
explained	B-X
in	B-X
statistical	B-X
textbooks	B-X
,	B-X
but	B-X
because	B-X
there	B-X
are	B-X
many	B-X
different	B-X
formulas	B-X
available	B-X
,	B-X
it	B-X
can	B-X
be	B-X
difficult	B-X
for	B-X
investigators	B-X
to	B-X
decide	B-X
which	B-X
method	B-X
to	B-X
use	B-X
.	B-X

Bacterial	O
strain	O
and	O
mice	B-Species
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
work	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
effect	B-X
of	B-X
prophylactic	B-X
use	B-X
of	B-X
Echinacea	B-X
purpurea	B-X
extract	B-X
on	B-X
the	B-X
development	B-X
of	B-X
Pseudomonas	B-X
aeruginosa	B-X
infection	B-X
in	B-X
various	B-X
strains	B-X
of	B-X
mice	B-X
and	B-X
on	B-X
some	B-X
parameters	B-X
of	B-X
non-specific	B-X
and	B-X
also	B-X
specific	B-X
cellular	B-X
immunity	B-X
.	B-X
Mice	B-X
expressed	B-X
various	B-X
,	B-X
depending	B-X
on	B-X
the	B-X
strain	B-X
used	B-X
,	B-X
susceptibility	B-X
to	B-X
infection	B-X
.	B-X
Echinacea	B-X
feeding	B-X
resulted	B-X
in	B-X
diminishing	B-X
of	B-X
bacteria	B-X
number	B-X
in	B-X
livers	B-X
of	B-X
C57Bl/6	B-X
(	B-X
susceptible	B-X
strain	B-X
)	B-X
as	B-X
well	B-X
as	B-X
B6C3F1	B-X
(	B-X
relative	B-X
resistant	B-X
strain	B-X
)	B-X
mice	B-X
.	B-X
Echinacea	B-X
feeding	B-X
of	B-X
the	B-X
second	B-X
relative	B-X
resistant	B-X
strain	B-X
(	B-X
BALB/c	B-X
x	B-X
C3H	B-X
)	B-X
F1	B-X
resulted	B-X
in	B-X
stimulation	B-X
of	B-X
granulocytes	B-X
chemiluminescent	B-X
and	B-X
lymphocytes	B-X
proliferative	B-X
response	B-X
.	B-X

B	B-Species
.	I-Species
mallei	I-Species
strain	O
ATCC	O
23344	O
(	O
China	O
7	O
)	O
was	O
cultured	O
on	O
Luria	O
-	O
Bertani	O
agar	O
supplemented	O
with	O
4	O
%	O
glycerol	O
(	O
LB	O
+	O
4	O
%	O
G	O
)	O
agar	O
plates	O
for	O
48	O
h	O
at	O
37	O
degrees	O
C	O
.	O

Isolated	O
colonies	O
were	O
sub	O
-	O
cultured	O
to	O
LB	O
+	O
4	O
%	O
G	O
broth	O
,	O
and	O
cultures	O
were	O
incubated	O
at	O
37	O
degrees	O
C	O
until	O
optical	O
density	O
readings	O
at	O
600	O
nm	O
(	O
OD600	O
)	O
reached	O
an	O
exponential	O
phase	O
of	O
growth	O
.	O

Bacteria	O
were	O
pelleted	O
by	O
centrifugation	O
,	O
washed	O
and	O
re	O
-	O
suspended	O
in	O
sterile	O
1	O
x	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
,	O
pH	O
7	O
.	O
4	O
)	O
to	O
obtain	O
the	O
desired	O
CFU	O
/	O
ml	O
.	O

To	O
obtain	O
HK	O
inoculums	O
,	O
bacterial	O
suspensions	O
were	O
incubated	O
at	O
85	O
degrees	O
C	O
for	O
3	O
h	O
and	O
stored	O
at	O
4	O
degrees	O
C	O
until	O
use	O
.	O

The	O
absence	O
of	O
live	O
B	B-Species
.	I-Species
mallei	I-Species
organisms	O
in	O
the	O
HK	O
preparations	O
was	O
confirmed	O
after	O
plating	O
10	O
%	O
of	O
the	O
total	O
inoculums	O
(	O
v	O
/	O
v	O
)	O
and	O
incubating	O
these	O
at	O
37	O
degrees	O
C	O
for	O
48	O
h	O
.	O

All	O
procedures	O
were	O
performed	O
under	O
a	O
class	O
II	O
biosafety	O
cabinet	O
in	O
a	O
biosafety	O
level	O
3	O
laboratory	O
.	O

Female	O
,	O
6	O
-	O
to	O
8	O
-	O
week	O
-	O
old	O
,	O
BALB	O
/	O
c	O
mice	B-Species
(	O
n	O
=	O
5	O
-	O
7	O
)	O
were	O
obtained	O
from	O
Harlan	O
Sprague	O
Dawley	O
,	O
Inc	O
.	O

(	O
Indianapolis	O
,	O
Indiana	O
)	O
.	O
<EOS>	B-X
Recurrent	B-X
outbreaks	B-X
of	B-X
histoplasmosis	B-X
in	B-X
Indianapolis	B-X
since	B-X
1978	B-X
have	B-X
expanded	B-X
our	B-X
understanding	B-X
of	B-X
histoplasmosis	B-X
.	B-X
Histoplasmosis	B-X
has	B-X
emerged	B-X
as	B-X
the	B-X
leading	B-X
opportunistic	B-X
infection	B-X
in	B-X
patients	B-X
with	B-X
AIDS	B-X
from	B-X
Indianapolis	B-X
.	B-X
We	B-X
examine	B-X
racial	B-X
disparities	B-X
in	B-X
drug	B-X
overdose	B-X
death	B-X
rates	B-X
by	B-X
analyzing	B-X
trends	B-X
in	B-X
fatal	B-X
and	B-X
nonfatal	B-X
overdose	B-X
outcomes	B-X
in	B-X
a	B-X
large	B-X
metropolitan	B-X
area	B-X
(	B-X
Indianapolis	B-X
,	B-X
Indiana	B-X
)	B-X
.	B-X
A	B-X
comprehensive	B-X
smoke-free	B-X
air	B-X
law	B-X
was	B-X
enacted	B-X
on	B-X
June	B-X
1	B-X
,	B-X
2012	B-X
in	B-X
most	B-X
of	B-X
Marion	B-X
County	B-X
,	B-X
Indiana	B-X
,	B-X
including	B-X
all	B-X
of	B-X
the	B-X
City	B-X
of	B-X
Indianapolis	B-X
.	B-X
We	B-X
evaluated	B-X
changes	B-X
in	B-X
acute	B-X
myocardial	B-X
infarction	B-X
(	B-X
AMI	B-X
)	B-X
admission	B-X
rates	B-X
in	B-X
Indianapolis	B-X
and	B-X
Marion	B-X
County	B-X
before	B-X
compared	B-X
to	B-X
after	B-X
the	B-X
law	B-X
.	B-X

Female	O
,	O
6	O
-	O
to	O
8	O
-	O
week	O
-	O
old	O
,	O
C57BL	O
/	O
6	O
mice	B-Species
deficient	O
in	O
mature	O
B	O
-	O
cells	O
(	O
mu	O
MT	O
)	O
,	O
CD4	O
T	O
-	O
cells	O
(	O
CD4	O
-	O
/	O
-	O
)	O
and	O
CD8	O
T	O
-	O
cells	O
(	O
CD8	O
-	O
/	O
-	O
)	O
and	O
wild	O
-	O
type	O
mice	B-Species
were	O
obtained	O
from	O
The	O
Jackson	O
Laboratory	O
(	O
Bar	O
Harbor	O
,	O
Maine	O
)	O
.	O

Vaccination	O
and	O
challenge	O
<EOS>	B-X
Vaccination	B-X
constitutes	B-X
a	B-X
major	B-X
advance	B-X
in	B-X
the	B-X
prevention	B-X
of	B-X
infectious	B-X
diseases	B-X
.	B-X
While	B-X
most	B-X
people	B-X
vaccinate	B-X
according	B-X
to	B-X
the	B-X
recommended	B-X
schedule	B-X
,	B-X
this	B-X
success	B-X
is	B-X
challenged	B-X
by	B-X
individuals	B-X
and	B-X
groups	B-X
who	B-X
delay	B-X
or	B-X
refuse	B-X
vaccines	B-X
.	B-X
Vaccine	B-X
hesitancy	B-X
poses	B-X
serious	B-X
challenges	B-X
for	B-X
achieving	B-X
coverage	B-X
for	B-X
population	B-X
immunity	B-X
.	B-X
This	B-X
review	B-X
will	B-X
discuss	B-X
viral	B-X
vector	B-X
and	B-X
nucleic	B-X
acid-based	B-X
vaccines	B-X
(	B-X
DNA	B-X
and	B-X
mRNA	B-X
vaccines	B-X
)	B-X
as	B-X
new	B-X
approaches	B-X
that	B-X
might	B-X
be	B-X
able	B-X
to	B-X
tackle	B-X
these	B-X
challenges	B-X
to	B-X
global	B-X
health	B-X
.	B-X

BALB	O
/	O
c	O
and	O
C57BL	O
/	O
6	O
mice	B-Species
were	O
grouped	O
and	O
vaccinated	O
with	O
0	O
.	O
5	O
mu	O
g	O
of	O
HK	O
B	B-Species
.	I-Species
mallei	I-Species
(	O
without	O
adjuvant	O
)	O
by	O
i	O
.	O
p	O
.	O
injection	O
using	O
a	O
25	O
-	O
gauge	O
syringe	O
.	O

Two	O
weeks	O
post	O
HK	O
vaccination	O
mice	B-Species
were	O
injected	O
i	O
.	O
p	O
.	O
with	O
2	O
x	O
107	O
CFU	O
/	O
100	O
mu	O
l	O
of	O
live	O
B	B-Species
.	I-Species
mallei	I-Species
(	O
~	O
20	O
LD50	O
)	O
[	O
18	O
]	O
.	O

Complement	O
depleted	O
animals	O
were	O
challenged	O
with	O
2	O
.	O
5	O
x	O
104	O
CFU	O
/	O
50	O
mu	O
l	O
(	O
~	O
0	O
.	O
25	O
LD50	O
)	O
by	O
intranasal	O
(	O
i	O
.	O
n	O
.	O
)	O
route	O
.	O

Aliquots	O
from	O
the	O
inoculums	O
were	O
plated	O
to	O
confirm	O
the	O
infecting	O
dose	O
.	O

All	O
procedures	O
and	O
animal	O
protocols	O
used	O
in	O
this	O
study	O
were	O
approved	O
by	O
the	O
Biosafety	O
and	O
IACUC	O
committees	O
at	O
UTMB	O
and	O
conducted	O
in	O
either	O
BSL	O
-	O
3	O
or	O
ABSL	O
-	O
3	O
laboratories	O
.	O
<EOS>	B-X
The	B-X
Regional	B-X
Biocontainment	B-X
Laboratory	B-X
(	B-X
RBL	B-X
)	B-X
at	B-X
the	B-X
University	B-X
of	B-X
Pittsburgh	B-X
is	B-X
a	B-X
state-of-the-art	B-X
ABSL-3	B-X
facility	B-X
that	B-X
supports	B-X
research	B-X
on	B-X
highly	B-X
pathogenic	B-X
viruses	B-X
and	B-X
bacteria	B-X
.	B-X
Recent	B-X
advances	B-X
in	B-X
radiologic	B-X
imaging	B-X
provide	B-X
several	B-X
noninvasive	B-X
,	B-X
in	B-X
vivo	B-X
imaging	B-X
modalities	B-X
that	B-X
can	B-X
be	B-X
used	B-X
to	B-X
longitudinally	B-X
monitor	B-X
animals	B-X
following	B-X
experimental	B-X
infection	B-X
or	B-X
vaccination	B-X
.	B-X
Operating	B-X
these	B-X
platforms	B-X
in	B-X
an	B-X
ABSL-3	B-X
poses	B-X
unique	B-X
challenges	B-X
.	B-X
Animal	B-X
experiments	B-X
on	B-X
African	B-X
swine	B-X
fever	B-X
virus	B-X
(	B-X
ASFV	B-X
)	B-X
are	B-X
vital	B-X
to	B-X
the	B-X
study	B-X
of	B-X
ASFV	B-X
;	B-X
however	B-X
,	B-X
ASFV	B-X
can	B-X
only	B-X
infect	B-X
pigs	B-X
,	B-X
and	B-X
animal	B-X
experiments	B-X
need	B-X
to	B-X
be	B-X
performed	B-X
in	B-X
animal	B-X
biosafety	B-X
level	B-X
3	B-X
(	B-X
ABSL-3	B-X
)	B-X
laboratories	B-X
,	B-X
meaning	B-X
that	B-X
many	B-X
small	B-X
ABSL-3	B-X
laboratories	B-X
are	B-X
unable	B-X
to	B-X
carry	B-X
out	B-X

Cell	O
and	O
cytokine	O
depletions	O
<EOS>	B-X
B	B-X
cells	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
immune	B-X
response	B-X
beyond	B-X
the	B-X
production	B-X
of	B-X
antibodies	B-X
through	B-X
mechanisms	B-X
such	B-X
as	B-X
antigen	B-X
presentation	B-X
and	B-X
cytokine	B-X
production	B-X
.	B-X
Regulatory	B-X
B	B-X
cells	B-X
negatively	B-X
regulate	B-X
immune	B-X
responses	B-X
by	B-X
the	B-X
production	B-X
of	B-X
anti-inflammatory	B-X
cytokines	B-X
such	B-X
as	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-10	B-X
,	B-X
IL-35	B-X
,	B-X
and	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
.	B-X
Thus	B-X
,	B-X
a	B-X
balance	B-X
between	B-X
effector	B-X
and	B-X
regulatory	B-X
B	B-X
cells	B-X
regulates	B-X
the	B-X
immune	B-X
response	B-X
through	B-X
the	B-X
release	B-X
of	B-X
cytokines	B-X
.	B-X
Stimuli	B-X
,	B-X
such	B-X
as	B-X
IFNÎ³	B-X
and	B-X
LPS	B-X
,	B-X
can	B-X
promote	B-X
an	B-X
inflammatory	B-X
activation	B-X
state	B-X
,	B-X
which	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
production	B-X
of	B-X
reactive	B-X
oxygen	B-X
species	B-X
,	B-X
and	B-X
pro-inflammatory	B-X
cytokines	B-X
and	B-X
chemokines	B-X
.	B-X
Immune	B-X
complexes	B-X
and	B-X
LPS	B-X
can	B-X
promote	B-X
an	B-X
anti-inflammatory	B-X
activation	B-X
state	B-X
to	B-X
prevent	B-X
damage	B-X
to	B-X
the	B-X
host	B-X
,	B-X
which	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
production	B-X
of	B-X
high	B-X
levels	B-X
of	B-X
the	B-X
anti-inflammatory	B-X
cytokine	B-X
IL-10	B-X
and	B-X
low	B-X
levels	B-X
of	B-X
pro-inflammatory	B-X
cytokines	B-X
.	B-X

Acute	O
in	O
vivo	O
cell	O
/	O
cytokine	O
depletion	O
was	O
performed	O
with	O
monoclonal	O
rat	B-Species
anti	O
-	O
mouse	B-Species
CD4	O
(	O
GK1	O
.	O
5	O
)	O
,	O
CD8	O
alpha	O
(	O
53	O
-	O
6	O
.	O
7	O
)	O
or	O
B220	O
(	O
RA3	O
-	O
6B2	O
)	O
obtained	O
from	O
R	O
&	O
D	O
Systems	O
,	O
Inc	O
.	O

(	O
Minneapolis	O
,	O
MN	O
)	O
by	O
methods	O
similar	O
to	O
those	O
we	O
have	O
previously	O
described	O
[	O
19	O
]	O
.	O
<EOS>	B-X
This	B-X
cloud	B-X
may	B-X
or	B-X
may	B-X
not	B-X
be	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
other	B-X
people	B-X
,	B-X
both	B-X
in	B-X
terms	B-X
of	B-X
the	B-X
average	B-X
microbiome	B-X
profile	B-X
(	B-X
conformity	B-X
)	B-X
and	B-X
the	B-X
diameter	B-X
of	B-X
the	B-X
cloud	B-X
(	B-X
stability	B-X
)	B-X
.	B-X
Reverse-genetic	B-X
interaction	B-X
screens	B-X
in	B-X
model	B-X
organisms	B-X
have	B-X
shown	B-X
that	B-X
genetic	B-X
interactions	B-X
frequently	B-X
cluster	B-X
into	B-X
highly	B-X
structured	B-X
motifs	B-X
,	B-X
where	B-X
members	B-X
of	B-X
the	B-X
same	B-X
pathway	B-X
share	B-X
similar	B-X
patterns	B-X
of	B-X
genetic	B-X
interactions	B-X
.	B-X
Notably	B-X
,	B-X
while	B-X
many	B-X
of	B-X
the	B-X
pathways	B-X
identified	B-X
by	B-X
BridGE	B-X
show	B-X
clear	B-X
relevance	B-X
to	B-X
breast	B-X
cancer	B-X
,	B-X
variants	B-X
in	B-X
these	B-X
pathways	B-X
had	B-X
not	B-X
been	B-X
previously	B-X
discovered	B-X
by	B-X
traditional	B-X
single	B-X
variant	B-X
association	B-X
tests	B-X
,	B-X
or	B-X
single	B-X
pathway	B-X
enrichment	B-X
analysis	B-X
that	B-X
does	B-X
not	B-X
consider	B-X
SNP-SNP	B-X
interactions	B-X
.	B-X
In	B-X
this	B-X
study	B-X
two	B-X
experiments	B-X
were	B-X
performed	B-X
to	B-X
characterize	B-X
distortions	B-X
in	B-X
the	B-X
visual	B-X
perception	B-X
of	B-X
the	B-X
shape	B-X
of	B-X
quadrilaterals	B-X
and	B-X
the	B-X
extent	B-X
to	B-X
which	B-X
these	B-X
distortions	B-X
were	B-X
similar	B-X
to	B-X
the	B-X
distortions	B-X
of	B-X
haptically	B-X
sensed	B-X
shapes	B-X
.	B-X
The	B-X
width/height	B-X
errors	B-X
and	B-X
the	B-X
inner	B-X
angle	B-X
errors	B-X
were	B-X
comparable	B-X
to	B-X
those	B-X
described	B-X
previously	B-X
when	B-X
subjects	B-X
felt	B-X
the	B-X
outline	B-X
of	B-X
a	B-X
quadrilateral	B-X
and	B-X
then	B-X
drew	B-X
its	B-X
reproduction	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
vision	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
distortion	B-X
occurs	B-X
in	B-X
the	B-X
process	B-X
of	B-X
remembering	B-X
the	B-X
shape	B-X
.	B-X

Functional	O
grade	O
purified	O
rat	B-Species
anti	O
-	O
mouse	B-Species
interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
,	O
AN	O
-	O
18	O
)	O
was	O
obtained	O
from	O
eBioscience	O
(	O
San	O
Diego	O
,	O
CA	O
)	O
and	O
purified	O
anti	O
-	O
mouse	B-Species
tumor	O
necrosis	O
factor	O
(	O
TNF	O
-	O
alpha	O
,	O
MP6	O
-	O
XT3	O
)	O
from	O
BD	O
Pharmingen	O
(	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

IFN	O
-	O
gamma	O
and	O
TNF	O
-	O
alpha	O
antibodies	O
were	O
injected	O
i	O
.	O
p	O
.	O

6	O
h	O
prior	O
to	O
challenge	O
,	O
200	O
mu	O
g	O
per	O
mouse	B-Species
in	O
200	O
mu	O
l	O
PBS	O
or	O
at	O
later	O
time	O
points	O
as	O
indicated	O
.	O
<EOS>	B-X
A	B-X
number	B-X
of	B-X
school	B-X
systems	B-X
worldwide	B-X
have	B-X
proposed	B-X
and	B-X
implemented	B-X
later	B-X
school	B-X
start	B-X
times	B-X
as	B-X
a	B-X
means	B-X
of	B-X
avoiding	B-X
the	B-X
potentially	B-X
negative	B-X
impacts	B-X
that	B-X
early	B-X
morning	B-X
schedules	B-X
can	B-X
have	B-X
on	B-X
adolescent	B-X
students	B-X
.	B-X
Even	B-X
mild	B-X
sleep	B-X
deprivation	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
significant	B-X
health	B-X
and	B-X
educational	B-X
concerns	B-X
:	B-X
increased	B-X
risk	B-X
for	B-X
accidents	B-X
and	B-X
injuries	B-X
,	B-X
impaired	B-X
learning	B-X
,	B-X
aggression	B-X
,	B-X
memory	B-X
loss	B-X
,	B-X
poor	B-X
self-esteem	B-X
,	B-X
and	B-X
changes	B-X
in	B-X
metabolism	B-X
.	B-X
Although	B-X
researchers	B-X
have	B-X
begun	B-X
to	B-X
explore	B-X
the	B-X
effects	B-X
of	B-X
delayed	B-X
school	B-X
start	B-X
time	B-X
,	B-X
no	B-X
one	B-X
has	B-X
conducted	B-X
a	B-X
rigorous	B-X
review	B-X
of	B-X
evidence	B-X
to	B-X
determine	B-X
whether	B-X
later	B-X
school	B-X
start	B-X
times	B-X
support	B-X
adolescent	B-X
health	B-X
,	B-X
education	B-X
,	B-X
and	B-X
well-being	B-X
.	B-X
Reperfusion	B-X
therapy	B-X
for	B-X
acute	B-X
stroke	B-X
has	B-X
evolved	B-X
from	B-X
the	B-X
initial	B-X
use	B-X
of	B-X
intravenous	B-X
tissue	B-X
plasminogen	B-X
activator	B-X
(	B-X
tPA	B-X
)	B-X
within	B-X
3	B-X
hours	B-X
of	B-X
symptom	B-X
onset	B-X
to	B-X
more	B-X
recent	B-X
guideline-recommended	B-X
use	B-X
up	B-X
to	B-X
4.5	B-X
hours	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
endovascular	B-X
therapy	B-X
is	B-X
increasingly	B-X
utilized	B-X
for	B-X
stroke	B-X
treatment	B-X
and	B-X
is	B-X
typically	B-X
initiated	B-X
up	B-X
to	B-X
8	B-X
hours	B-X
after	B-X
onset	B-X
.	B-X
Recent	B-X
studies	B-X
demonstrate	B-X
that	B-X
imaging	B-X
of	B-X
the	B-X
ischemic	B-X
penumbra	B-X
with	B-X
diffusion/perfusion	B-X
magnetic	B-X
resonance	B-X
imaging	B-X
(	B-X
MRI	B-X
)	B-X
can	B-X
identify	B-X
subgroups	B-X
of	B-X
patients	B-X
who	B-X
are	B-X
likely	B-X
to	B-X
improve	B-X
following	B-X
successful	B-X
reperfusion	B-X
(	B-X
Target	B-X
Mismatch	B-X
profile	B-X
)	B-X
and	B-X
others	B-X
who	B-X
are	B-X
at	B-X
increased	B-X
risk	B-X
for	B-X
hemorrhage	B-X
and	B-X
poor	B-X
clinical	B-X
outcomes	B-X
(	B-X
Malignant	B-X
profile	B-X
)	B-X
.	B-X
New	B-X
data	B-X
indicate	B-X
that	B-X
stent	B-X
retriever	B-X
devices	B-X
provide	B-X
better	B-X
recanalization	B-X
efficacy	B-X
and	B-X
clinical	B-X
outcomes	B-X
than	B-X
the	B-X
previously	B-X
available	B-X
mechanical	B-X
thrombectomy	B-X
devices	B-X
.	B-X
Going	B-X
forward	B-X
,	B-X
we	B-X
believe	B-X
that	B-X
the	B-X
use	B-X
of	B-X
penumbral	B-X
imaging	B-X
with	B-X
validated	B-X
MRI	B-X
techniques	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
currently	B-X
less	B-X
well-validated	B-X
computed	B-X
tomography	B-X
(	B-X
CT	B-X
)	B-X
perfusion	B-X
approach	B-X
,	B-X
will	B-X
maximize	B-X
benefit	B-X
and	B-X
reduce	B-X
the	B-X
risk	B-X
of	B-X
adverse	B-X
events	B-X
and	B-X
poor	B-X
outcomes	B-X
when	B-X
used	B-X
both	B-X
early	B-X
after	B-X
stroke	B-X
onset	B-X
and	B-X
at	B-X
later	B-X
time	B-X
points	B-X
.	B-X
New	B-X
trials	B-X
that	B-X
feature	B-X
diffusion/perfusion	B-X
MRI	B-X
or	B-X
CT	B-X
perfusion-based	B-X
patient	B-X
selection	B-X
for	B-X
treatment	B-X
with	B-X
intravenous	B-X
tPA	B-X
and	B-X
or	B-X
endovascular	B-X
therapies	B-X
versus	B-X
nonreperfused	B-X
control	B-X
groups	B-X
are	B-X
planned	B-X
or	B-X
in	B-X
progress	B-X
.	B-X
We	B-X
predict	B-X
that	B-X
these	B-X
trials	B-X
will	B-X
confirm	B-X
the	B-X
hypothesis	B-X
that	B-X
penumbral	B-X
imaging	B-X
can	B-X
enhance	B-X
patient	B-X
selection	B-X
and	B-X
extend	B-X
the	B-X
therapeutic	B-X
time	B-X
window	B-X
for	B-X
acute	B-X
ischemic	B-X
stroke	B-X
.	B-X

Rat	B-Species
IgG	O
isotype	O
control	O
was	O
obtained	O
from	O
Southern	O
Biotech	O
(	O
Birmingham	O
,	O
AL	O
)	O
and	O
administered	O
i	O
.	O
p	O
.	O
on	O
day	O
of	O
challenge	O
,	O
200	O
mu	O
g	O
/	O
mouse	B-Species
.	O

Rat	B-Species
anti	O
-	O
mouse	B-Species
CD4	O
,	O
CD8	O
alpha	O
and	O
B220	O
were	O
injected	O
i	O
.	O
p	O
.	O
twice	O
,	O
1	O
day	O
prior	O
to	O
challenge	O
and	O
on	O
day	O
of	O
challenge	O
,	O
with	O
an	O
equivalent	O
dosage	O
sufficient	O
to	O
deplete	O
T	O
or	O
B	O
cells	O
from	O
6	O
x	O
108	O
bone	O
marrow	O
cells	O
per	O
injection	O
.	O

The	O
efficiency	O
of	O
depletion	O
at	O
time	O
of	O
infection	O
for	O
CD4	O
+	O
,	O
CD8	O
+	O
,	O
and	O
B220	O
+	O
cells	O
was	O
confirmed	O
by	O
flow	O
cytometry	O
analysis	O
immediately	O
prior	O
to	O
infection	O
.	O

Complement	O
depletion	O
with	O
cobra	O
venom	O
factor	O
<EOS>	B-X
We	B-X
have	B-X
developed	B-X
a	B-X
conceptually	B-X
different	B-X
approach	B-X
of	B-X
not	B-X
inhibiting	B-X
but	B-X
depleting	B-X
complement	B-X
,	B-X
based	B-X
on	B-X
the	B-X
complement-depleting	B-X
activities	B-X
of	B-X
cobra	B-X
venom	B-X
factor	B-X
(	B-X
CVF	B-X
)	B-X
,	B-X
a	B-X
non-toxic	B-X
cobra	B-X
venom	B-X
component	B-X
with	B-X
structural	B-X
and	B-X
functional	B-X
homology	B-X
to	B-X
complement	B-X
component	B-X
C3	B-X
.	B-X
Cobra	B-X
venom	B-X
factor	B-X
(	B-X
CVF	B-X
)	B-X
is	B-X
the	B-X
complement-activating	B-X
protein	B-X
in	B-X
cobra	B-X
venom	B-X
.	B-X
These	B-X
human	B-X
C3	B-X
derivatives	B-X
represent	B-X
humanized	B-X
CVF	B-X
,	B-X
and	B-X
are	B-X
a	B-X
conceptually	B-X
different	B-X
concept	B-X
for	B-X
pharmacological	B-X
intervention	B-X
of	B-X
the	B-X
complement	B-X
system	B-X
,	B-X
therapeutic	B-X
complement	B-X
depletion	B-X
.	B-X
The	B-X
use	B-X
of	B-X
humanized	B-X
CVF	B-X
for	B-X
therapeutic	B-X
complement	B-X
depletion	B-X
in	B-X
several	B-X
pre-clinical	B-X
models	B-X
of	B-X
human	B-X
diseases	B-X
is	B-X
also	B-X
reviewed	B-X
.	B-X

Mice	B-Species
,	O
six	O
to	O
seven	O
per	O
group	O
,	O
were	O
vaccinated	O
i	O
.	O
p	O
.	O
with	O
1	O
x	O
105	O
CFU	O
of	O
nonviable	O
B	B-Species
.	I-Species
mallei	I-Species
cell	O
preparation	O
in	O
a	O
total	O
volume	O
of	O
0	O
.	O
1	O
ml	O
.	O

Two	O
weeks	O
later	O
,	O
24	O
h	O
and	O
1	O
h	O
before	O
challenge	O
,	O
complement	O
depleted	O
mice	B-Species
were	O
treated	O
i	O
.	O
p	O
.	O
with	O
12	O
.	O
5	O
units	O
total	O
cobra	O
venom	O
factor	O
(	O
Quidel	O
Corporation	O
Speciality	O
Products	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
in	O
0	O
.	O
1	O
ml	O
of	O
PBS	O
.	O

Complement	O
depletion	O
was	O
confirmed	O
prior	O
to	O
challenge	O
by	O
micro	O
-	O
titer	O
hemolytic	O
complement	O
activity	O
(	O
CH50	O
)	O
assay	O
as	O
previously	O
described	O
[	O
20	O
]	O
.	O

B	B-Species
.	I-Species
mallei	I-Species
J774A	O
.	O
1	O
uptake	O
assays	O

J774A	O
.	O
1	O
cells	O
were	O
seeded	O
(	O
5	O
x	O
105	O
)	O
onto	O
Corning	O
costar	O
24	O
well	O
plates	O
(	O
Corning	O
,	O
NY	O
)	O
with	O
DMEM	O
and	O
incubated	O
overnight	O
at	O
37	O
degrees	O
C	O
with	O
5	O
%	O
CO2	O
.	O

Bacterial	O
suspensions	O
were	O
incubated	O
at	O
37	O
degrees	O
C	O
for	O
45	O
minutes	O
supplemented	O
with	O
2	O
%	O
mouse	B-Species
serum	O
from	O
Sigma	O
-	O
Aldrich	O
(	O
St	O
.	O
Louis	O
,	O
MO	O
.	O
)	O
,	O
heat	O
inactivated	O
mouse	B-Species
serum	O
(	O
56	O
degrees	O
C	O
30	O
minutes	O
)	O
,	O
or	O
bacteria	O
alone	O
and	O
then	O
added	O
at	O
an	O
MOI	O
of	O
10	O
:	O
1	O
to	O
J774A	O
.	O
1	O
cells	O
in	O
triplicate	O
.	O

Inoculated	O
wells	O
were	O
centrifuged	O
at	O
800	O
g	O
for	O
2	O
minutes	O
and	O
incubated	O
for	O
2	O
hours	O
at	O
37	O
degrees	O
C	O
with	O
5	O
%	O
CO2	O
followed	O
by	O
a	O
PBS	O
wash	O
(	O
x	O
2	O
)	O
and	O
2	O
hour	O
incubation	O
with	O
250	O
mu	O
g	O
/	O
ml	O
kanamycin	O
.	O

Wells	O
were	O
washed	O
twice	O
with	O
PBS	O
and	O
lysed	O
with	O
0	O
.	O
1	O
%	O
Triton	O
X	O
-	O
100	O
,	O
followed	O
by	O
serial	O
10	O
-	O
fold	O
dilutions	O
plated	O
on	O
LBG	O
plates	O
and	O
incubated	O
at	O
37	O
degrees	O
C	O
for	O
2	O
days	O
.	O

Colony	O
forming	O
units	O
were	O
enumerated	O
and	O
uptake	O
expressed	O
as	O
a	O
percentage	O
of	O
initial	O
inoculating	O
dose	O
+/-	O
SEM	O
.	O

Antibodies	O
and	O
flow	O
cytometry	O
<EOS>	B-X
Multicolor	B-X
flow	B-X
cytometry	B-X
is	B-X
a	B-X
rapidly	B-X
evolving	B-X
technology	B-X
that	B-X
uses	B-X
multiple	B-X
fluorescent	B-X
markers	B-X
to	B-X
identify	B-X
and	B-X
characterize	B-X
cellular	B-X
subpopulations	B-X
of	B-X
interest	B-X
,	B-X
allowing	B-X
rapid	B-X
analysis	B-X
on	B-X
tens	B-X
of	B-X
thousands	B-X
of	B-X
cells	B-X
per	B-X
second	B-X
,	B-X
with	B-X
the	B-X
possibility	B-X
of	B-X
isolating	B-X
pure	B-X
,	B-X
viable	B-X
populations	B-X
by	B-X
cell	B-X
sorting	B-X
for	B-X
further	B-X
experimentation	B-X
.	B-X
Receptor	B-X
occupancy	B-X
(	B-X
RO	B-X
)	B-X
assays	B-X
by	B-X
flow	B-X
cytometry	B-X
describe	B-X
the	B-X
qualitative	B-X
and/or	B-X
quantitative	B-X
assessment	B-X
of	B-X
the	B-X
binding	B-X
of	B-X
a	B-X
therapeutic	B-X
agent	B-X
to	B-X
its	B-X
cell	B-X
surface	B-X
target	B-X
.	B-X
There	B-X
are	B-X
a	B-X
variety	B-X
of	B-X
approaches	B-X
that	B-X
can	B-X
be	B-X
used	B-X
when	B-X
undertaking	B-X
RO	B-X
assays	B-X
and	B-X
with	B-X
the	B-X
ability	B-X
to	B-X
measure	B-X
distinct	B-X
subsets	B-X
in	B-X
heterogeneous	B-X
populations	B-X
,	B-X
flow	B-X
cytometry	B-X
is	B-X
ideally	B-X
suited	B-X
to	B-X
RO	B-X
measurements	B-X
.	B-X
This	B-X
article	B-X
highlights	B-X
the	B-X
importance	B-X
of	B-X
RO	B-X
assays	B-X
on	B-X
the	B-X
flow	B-X
cytometric	B-X
platform	B-X
in	B-X
the	B-X
development	B-X
of	B-X
biotherapeutic	B-X
agents	B-X
.	B-X

Flow	O
cytometric	O
analysis	O
was	O
performed	O
on	O
0	O
.	O
1	O
-	O
ml	O
blood	O
samples	O
transferred	O
to	O
micro	O
centrifuge	O
tubes	O
containing	O
90	O
mu	O
l	O
of	O
acid	O
citrate	O
dextrose	O
(	O
ACD	O
)	O
solution	O
.	O

Red	O
blood	O
cells	O
were	O
lysed	O
using	O
ACK	O
-	O
lysing	O
buffer	O
(	O
Biosource	O
International	O
,	O
Inc	O
.	O
,	O
Camarillo	O
,	O
CA	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instruction	O
.	O

Antibodies	O
used	O
for	O
analysis	O
of	O
surface	O
markers	O
included	O
:	O
FITC	O
-	O
conjugated	O
rat	B-Species
anti	O
-	O
mouse	B-Species
CD45R	O
/	O
B220	O
(	O
RA3	O
-	O
6B2	O
,	O
BD	O
Pharmingen	O
San	O
Diego	O
,	O
CA	O
)	O
for	O
B	O
cells	O
;	O
FITC	O
-	O
conjugated	O
rat	B-Species
anti	O
-	O
mouse	B-Species
CD8	O
alpha	O
(	O
53	O
-	O
6	O
.	O
7	O
)	O
and	O
CD4	O
(	O
GK1	O
.	O
5	O
,	O
BD	O
Pharmingen	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
for	O
CD8	O
+	O
or	O
CD4	O
+	O
cells	O
,	O
respectively	O
.	O

Samples	O
evaluated	O
for	O
CD4	O
+	O
and	O
CD8	O
alpha	O
+	O
cells	O
were	O
also	O
incubated	O
with	O
biotin	O
-	O
conjugated	O
hamster	O
anti	O
-	O
mouse	B-Species
CD3e	O
(	O
145	O
-	O
2C11	O
)	O
monoclonal	O
antibody	O
(	O
BD	O
Pharmingen	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
and	O
subsequently	O
with	O
streptavidin	O
APC	O
Cy7	O
.	O

Isotype	O
-	O
matched	O
,	O
non	O
-	O
specific	O
controls	O
were	O
assayed	O
in	O
parallel	O
(	O
BD	O
Pharmingen	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

Surface	O
staining	O
was	O
performed	O
according	O
to	O
previously	O
published	O
protocols	O
[	O
21	O
]	O
.	O

Following	O
cell	O
staining	O
,	O
the	O
samples	O
were	O
fixed	O
with	O
2	O
%	O
buffered	O
paraformaldehyde	O
overnight	O
prior	O
to	O
analysis	O
by	O
flow	O
cytometry	O
.	O

Samples	O
were	O
analyzed	O
using	O
a	O
FACSCalibur	O
flow	O
cytometer	O
with	O
BD	O
CellQuest	O
Pro	O
software	O
.	O

Antibody	O
assays	O
<EOS>	B-X
Harnessing	B-X
anti-idiotypic	B-X
antibody	B-X
alternatives	B-X
to	B-X
advance	B-X
biotherapeutic	B-X
pharmacokinetic	B-X
assays	B-X
.	B-X
The	B-X
never-ending	B-X
quest	B-X
for	B-X
antibody	B-X
assays	B-X
standardization	B-X
and	B-X
appropriate	B-X
measurement	B-X
units	B-X
.	B-X
The	B-X
increasing	B-X
demand	B-X
on	B-X
diagnostic	B-X
assays	B-X
that	B-X
are	B-X
sensitive	B-X
and	B-X
specific	B-X
for	B-X
pathogenic	B-X
antibodies	B-X
,	B-X
and	B-X
the	B-X
interest	B-X
in	B-X
identifying	B-X
new	B-X
antigens	B-X
,	B-X
prompted	B-X
the	B-X
development	B-X
of	B-X
cell-based	B-X
assays	B-X
for	B-X
the	B-X
detection	B-X
of	B-X
autoantibodies	B-X
in	B-X
myasthenia	B-X
gravis	B-X
and	B-X
other	B-X
autoimmune	B-X
disorders	B-X
.	B-X
Cell-based	B-X
assays	B-X
were	B-X
initially	B-X
used	B-X
to	B-X
show	B-X
that	B-X
clustering	B-X
the	B-X
AChR	B-X
improved	B-X
the	B-X
positivity	B-X
in	B-X
myasthenia	B-X
gravis	B-X
,	B-X
and	B-X
similar	B-X
assays	B-X
have	B-X
now	B-X
been	B-X
applied	B-X
to	B-X
detection	B-X
of	B-X
antibodies	B-X
to	B-X
neuromuscular	B-X
junction	B-X
candidate	B-X
proteins	B-X
such	B-X
as	B-X
LRP4	B-X
and	B-X
agrin	B-X
.	B-X
In	B-X
addition	B-X
cell-based	B-X
assays	B-X
have	B-X
been	B-X
used	B-X
in	B-X
the	B-X
routine	B-X
detection	B-X
of	B-X
antibodies	B-X
to	B-X
proteins	B-X
expressed	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
neurons	B-X
(	B-X
NMDAR	B-X
,	B-X
LGI1	B-X
,	B-X
CASPR2	B-X
,	B-X
AMPAR	B-X
,	B-X
GABA-A/B	B-X
,	B-X
GlyR	B-X
,	B-X
and	B-X
DPPX	B-X
)	B-X
and	B-X
glia	B-X
(	B-X
AQP4	B-X
,	B-X
MOG	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
summarize	B-X
the	B-X
findings	B-X
in	B-X
myasthenia	B-X
and	B-X
discuss	B-X
the	B-X
advantages	B-X
,	B-X
disadvantages	B-X
and	B-X
controversial	B-X
issues	B-X
of	B-X
using	B-X
cell-based	B-X
assays	B-X
in	B-X
the	B-X
detection	B-X
of	B-X
these	B-X
antibodies	B-X
,	B-X
and	B-X
their	B-X
relevance	B-X
to	B-X
the	B-X
testing	B-X
of	B-X
preclinical	B-X
models	B-X
of	B-X
disease	B-X
.	B-X

Immunoglobulin	O
subclass	O
IgG1	O
and	O
IgG2a	O
titers	O
in	O
mice	B-Species
were	O
determined	O
by	O
a	O
whole	O
bacterial	O
cell	O
ELISA	O
performed	O
in	O
96	O
-	O
well	O
,	O
Immulon	O
2	O
HB	O
,	O
round	O
-	O
bottom	O
plates	O
(	O
Dynex	O
Technologies	O
)	O
.	O

B	B-Species
.	I-Species
mallei	I-Species
antigen	O
was	O
diluted	O
in	O
0	O
.	O
1	O
M	O
carbonate	O
buffer	O
(	O
pH	O
9	O
.	O
5	O
)	O
and	O
50	O
mu	O
l	O
of	O
diluted	O
cells	O
placed	O
into	O
wells	O
.	O

Plates	O
were	O
stored	O
overnight	O
at	O
4	O
degrees	O
C	O
.	O
<EOS>	B-X
Six	B-X
hundred	B-X
and	B-X
thirteen	B-X
fresh	B-X
diarrhoeal	B-X
faeces	B-X
were	B-X
inoculated	B-X
on	B-X
Skirrow	B-X
blood	B-X
agar	B-X
(	B-X
SK	B-X
)	B-X
,	B-X
on	B-X
Preston	B-X
blood	B-X
free	B-X
agar	B-X
(	B-X
PBF	B-X
)	B-X
,	B-X
and	B-X
in	B-X
Campy-thioglycolate	B-X
broth	B-X
(	B-X
CT	B-X
)	B-X
.	B-X
After	B-X
24	B-X
h	B-X
of	B-X
storage	B-X
at	B-X
4	B-X
degrees	B-X
C	B-X
,	B-X
specimens	B-X
were	B-X
again	B-X
inoculated	B-X
on	B-X
SK	B-X
and	B-X
PBF	B-X
,	B-X
and	B-X
in	B-X
Campylobacter	B-X
enrichment	B-X
broth	B-X
(	B-X
CEB	B-X
)	B-X
.	B-X
CT	B-X
tubes	B-X
were	B-X
placed	B-X
overnight	B-X
at	B-X
4	B-X
degrees	B-X
C.	B-X
Plates	B-X
and	B-X
CEB	B-X
tubes	B-X
were	B-X
incubated	B-X
at	B-X
43	B-X
degrees	B-X
C	B-X
in	B-X
microaerophilic	B-X
conditions	B-X
.	B-X
Sixty-four	B-X
of	B-X
them	B-X
were	B-X
also	B-X
recovered	B-X
after	B-X
subculturing	B-X
from	B-X
CT	B-X
,	B-X
and	B-X
only	B-X
51	B-X
from	B-X
CEB	B-X
.	B-X
Delayed	B-X
inoculation	B-X
of	B-X
plates	B-X
after	B-X
storage	B-X
of	B-X
samples	B-X
at	B-X
4	B-X
degrees	B-X
C	B-X
yielded	B-X
57	B-X
isolates	B-X
.	B-X
The	B-X
storage	B-X
of	B-X
faeces	B-X
at	B-X
4	B-X
degrees	B-X
C	B-X
for	B-X
24	B-X
h	B-X
significantly	B-X
reduces	B-X
the	B-X
number	B-X
of	B-X
campylobacter	B-X
isolates	B-X
.	B-X
When	B-X
samples	B-X
are	B-X
not	B-X
plated	B-X
immediately	B-X
we	B-X
recommend	B-X
inoculating	B-X
a	B-X
CT	B-X
tube	B-X
maintained	B-X
at	B-X
4	B-X
degrees	B-X
C	B-X
overnight	B-X
as	B-X
a	B-X
holding	B-X
medium	B-X
.	B-X

The	O
plates	O
were	O
washed	O
with	O
washing	O
solution	O
(	O
1	O
x	O
PBS	O
,	O
0	O
.	O
05	O
%	O
Tween	O
20	O
)	O
,	O
and	O
incubated	O
with	O
100	O
mu	O
l	O
of	O
blocking	O
solution	O
(	O
1	O
x	O
PBS	O
,	O
1	O
%	O
bovine	B-Species
serum	O
albumin	O
,	O
0	O
.	O
05	O
%	O
Tween	O
20	O
)	O
for	O
1	O
h	O
at	O
37	O
degrees	O
C	O
.	O

Dilutions	O
of	O
mouse	B-Species
sera	O
were	O
made	O
with	O
blocking	O
solution	O
in	O
duplicate	O
and	O
plates	O
were	O
incubated	O
for	O
1	O
h	O
at	O
37	O
degrees	O
C	O
.	O

Following	O
incubation	O
,	O
plates	O
were	O
washed	O
and	O
50	O
mu	O
l	O
of	O
anti	O
-	O
Ig	O
-	O
horseradish	B-Species
peroxidase	O
subclass	O
conjugate	O
,	O
diluted	O
accordingly	O
to	O
manufacturer	O
'	O
s	O
instructions	O
(	O
Southern	O
Biotechnology	O
Associates	O
,	O
Inc	O
.	O
Birmingham	O
,	O
Ala	O
.	O
)	O
,	O
was	O
added	O
to	O
each	O
well	O
and	O
incubated	O
for	O
1	O
h	O
at	O
37	O
degrees	O
C	O
.	O

After	O
washing	O
,	O
50	O
mu	O
l	O
of	O
2	O
,	O
2	O
'	O
-	O
azino	O
-	O
di	O
-	O
(	O
3	O
-	O
ethylbenzthizoline	O
)	O
-	O
6	O
-	O
sulfonate	O
(	O
ABTS	O
)	O
peroxidase	O
substrate	O
(	O
KPL	O
,	O
Inc	O
.	O
,	O
Gaithersburg	O
,	O
Maryland	O
)	O
was	O
added	O
to	O
each	O
well	O
and	O
plates	O
incubated	O
for	O
25	O
min	O
at	O
room	O
temperature	O
.	O

The	O
amount	O
of	O
bound	O
antibody	O
was	O
determined	O
colorimetrically	O
by	O
absorbance	O
at	O
405	O
nm	O
.	O

Statistical	O
analysis	O

Survival	O
curves	O
were	O
calculated	O
by	O
Kaplan	O
Meier	O
survival	O
analysis	O
with	O
log	O
-	O
rank	O
tests	O
between	O
groups	O
using	O
GraphPad	O
Prism	O
(	O
V	O
.	O
4	O
.	O
03	O
for	O
windows	O
)	O
.	O

Statistical	O
analysis	O
was	O
generally	O
performed	O
with	O
the	O
paired	O
Student	O
'	O
s	O
t	O
-	O
test	O
.	O

P	O
value	O
<=	O
0	O
.	O
05	O
was	O
considered	O
significant	O
.	O

Abbreviations	O
<EOS>	B-X
Abbreviations	B-X
can	B-X
be	B-X
clinical	B-X
jargon	B-X
(	B-X
writing	B-X
``	B-X
HIT	B-X
''	B-X
for	B-X
``	B-X
heparin	B-X
induced	B-X
thrombocytopenia	B-X
''	B-X
)	B-X
,	B-X
ambiguous	B-X
terms	B-X
that	B-X
require	B-X
expertise	B-X
to	B-X
disambiguate	B-X
(	B-X
using	B-X
``	B-X
MS	B-X
''	B-X
for	B-X
``	B-X
multiple	B-X
sclerosis	B-X
''	B-X
or	B-X
``	B-X
mental	B-X
status	B-X
''	B-X
)	B-X
,	B-X
or	B-X
domain-specific	B-X
vernacular	B-X
(	B-X
``	B-X
cb	B-X
''	B-X
for	B-X
``	B-X
complicated	B-X
by	B-X
''	B-X
)	B-X
.	B-X
Acronyms	B-X
,	B-X
initialisms	B-X
,	B-X
and	B-X
abbreviations	B-X
.	B-X
Medical	B-X
abbreviations	B-X
.	B-X
Undecipherable	B-X
abbreviations	B-X
.	B-X

HK	O
:	O
Heat	O
-	O
killed	O
;	O
i	O
.	O
p	O
.	O
:	O
intraperitoneal	O
;	O
i	O
.	O
n	O
.	O
:	O
intranasal	O
.	O
<EOS>	B-X
The	B-X
effects	B-X
of	B-X
probiotic	B-X
Bifidobacterium	B-X
animalis	B-X
subsp	B-X
.	B-X
lactis	B-X
CECT	B-X
8145	B-X
(	B-X
Ba8145	B-X
)	B-X
and	B-X
those	B-X
of	B-X
its	B-X
heat-killed	B-X
form	B-X
(	B-X
h-k	B-X
Ba8145	B-X
)	B-X
on	B-X
human	B-X
anthropometric	B-X
adiposity	B-X
biomarkers	B-X
are	B-X
unknown	B-X
.	B-X
For	B-X
decades	B-X
,	B-X
Lactobacillus	B-X
has	B-X
been	B-X
extensively	B-X
used	B-X
as	B-X
beneficial	B-X
probiotics	B-X
because	B-X
it	B-X
positively	B-X
effects	B-X
on	B-X
the	B-X
intestinal	B-X
health	B-X
of	B-X
the	B-X
host	B-X
and	B-X
has	B-X
been	B-X
studying	B-X
its	B-X
possible	B-X
serve	B-X
to	B-X
treat	B-X
obesity	B-X
as	B-X
well	B-X
as	B-X
various	B-X
diseases	B-X
.	B-X
This	B-X
research	B-X
aimed	B-X
to	B-X
investigate	B-X
the	B-X
effects	B-X
of	B-X
heat-killed	B-X
Ligilactobacillus	B-X
salivarius	B-X
strain	B-X
189	B-X
(	B-X
HK	B-X
LS	B-X
189	B-X
)	B-X
supplementation	B-X
on	B-X
anti-obesity	B-X
and	B-X
gut	B-X
microbiota	B-X
.	B-X
A	B-X
total	B-X
of	B-X
48	B-X
pigs	B-X
were	B-X
fed	B-X
either	B-X
a	B-X
basal	B-X
diet	B-X
or	B-X
a	B-X
diet	B-X
supplemented	B-X
with	B-X
HK	B-X
LS	B-X
189	B-X
for	B-X
4	B-X
weeks	B-X
.	B-X
The	B-X
impact	B-X
of	B-X
HK	B-X
LS	B-X
189	B-X
supplementation	B-X
on	B-X
the	B-X
composition	B-X
and	B-X
function	B-X
of	B-X
the	B-X
intestinal	B-X
microbiota	B-X
was	B-X
revealed	B-X
by	B-X
16	B-X
S	B-X
rRNA	B-X
gene	B-X
sequencing	B-X
.	B-X
HK	B-X
LS	B-X
189	B-X
supplementation	B-X
significantly	B-X
decreased	B-X
growth	B-X
performance	B-X
.	B-X
Moreover	B-X
,	B-X
HK	B-X
LS	B-X
189	B-X
supplementation	B-X
altered	B-X
the	B-X
gut	B-X
microbiota	B-X
of	B-X
the	B-X
pigs	B-X
by	B-X
decreasing	B-X
the	B-X
proportion	B-X
of	B-X
Prevotella	B-X
and	B-X
increasing	B-X
the	B-X
proportion	B-X
of	B-X
Parabacteroides	B-X
.	B-X
Beta-diversity	B-X
analysis	B-X
showed	B-X
a	B-X
significant	B-X
difference	B-X
between	B-X
the	B-X
two	B-X
groups	B-X
.	B-X
The	B-X
results	B-X
support	B-X
the	B-X
potential	B-X
use	B-X
of	B-X
HK	B-X
LS	B-X
189	B-X
for	B-X
its	B-X
anti-obesity	B-X
effect	B-X
in	B-X
pigs	B-X
through	B-X
modulation	B-X
of	B-X
the	B-X
gut	B-X
microbiota	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
found	B-X
changes	B-X
in	B-X
the	B-X
functional	B-X
pathways	B-X
of	B-X
the	B-X
gut	B-X
microbiota	B-X
.	B-X
The	B-X
functional	B-X
pathway	B-X
study	B-X
indicated	B-X
that	B-X
metabolism	B-X
and	B-X
lipid	B-X
metabolism	B-X
differed	B-X
between	B-X
the	B-X
two	B-X
groups	B-X
.	B-X
Our	B-X
data	B-X
may	B-X
contribute	B-X
to	B-X
understanding	B-X
the	B-X
potential	B-X
use	B-X
of	B-X
postbiotic	B-X
supplementation	B-X
with	B-X
HK	B-X
LS	B-X
189	B-X
for	B-X
improving	B-X
the	B-X
anti-obesity	B-X
effects	B-X
.	B-X

Authors	O
'	O
contributions	O
<EOS>	B-X
In	B-X
this	B-X
letter	B-X
,	B-X
I	B-X
argue	B-X
that	B-X
in	B-X
reality	B-X
and	B-X
in	B-X
practice	B-X
,	B-X
authorship	B-X
delimitations	B-X
are	B-X
not	B-X
that	B-X
clear-cut	B-X
,	B-X
nor	B-X
are	B-X
all	B-X
contributions	B-X
equal	B-X
or	B-X
equally	B-X
weighted	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
contributions	B-X
of	B-X
each	B-X
author	B-X
to	B-X
multiauthored	B-X
biomedical	B-X
research	B-X
papers	B-X
.	B-X
Much	B-X
research	B-X
on	B-X
APP	B-X
focusses	B-X
on	B-X
potential	B-X
contributions	B-X
to	B-X
neurodegeneration	B-X
,	B-X
mostly	B-X
based	B-X
on	B-X
mouse	B-X
models	B-X
with	B-X
altered	B-X
expression	B-X
or	B-X
mutated	B-X
forms	B-X
of	B-X
APP	B-X
.	B-X
For	B-X
papers	B-X
in	B-X
which	B-X
the	B-X
first	B-X
and	B-X
second	B-X
authors	B-X
made	B-X
equal	B-X
contributions	B-X
,	B-X
mixed-gender	B-X
combinations	B-X
were	B-X
most	B-X
frequent	B-X
,	B-X
followed	B-X
by	B-X
male-male	B-X
and	B-X
then	B-X
female-female	B-X
author	B-X
combinations	B-X
.	B-X
For	B-X
papers	B-X
in	B-X
which	B-X
three	B-X
or	B-X
more	B-X
authors	B-X
made	B-X
equal	B-X
contributions	B-X
,	B-X
there	B-X
were	B-X
more	B-X
male	B-X
authors	B-X
than	B-X
female	B-X
authors	B-X
in	B-X
the	B-X
first	B-X
position	B-X
and	B-X
more	B-X
all-male	B-X
than	B-X
all-female	B-X
author	B-X
combinations	B-X
.	B-X
The	B-X
gender	B-X
inequalities	B-X
observed	B-X
among	B-X
authors	B-X
who	B-X
made	B-X
equal	B-X
contributions	B-X
are	B-X
not	B-X
consistent	B-X
with	B-X
random	B-X
or	B-X
alphabetical	B-X
ordering	B-X
of	B-X
authors	B-X
.	B-X

GCW	O
designed	O
and	O
conducted	O
experiments	O
and	O
drafted	O
the	O
manuscript	O
.	O

BMJ	O
carried	O
out	O
the	O
immunoassays	O
and	O
animal	O
work	O
.	O

SP	O
provided	O
analysis	O
of	O
data	O
and	O
contributed	O
to	O
design	O
and	O
animal	O
work	O
.	O
<EOS>	B-X
Marine	B-X
algae	B-X
are	B-X
a	B-X
poorly	B-X
explored	B-X
and	B-X
promising	B-X
alternative	B-X
that	B-X
can	B-X
provide	B-X
lead	B-X
compounds	B-X
,	B-X
and	B-X
the	B-X
use	B-X
of	B-X
multivariate	B-X
analysis	B-X
could	B-X
contribute	B-X
to	B-X
quicker	B-X
discovery	B-X
.	B-X
1:2006	B-X
has	B-X
been	B-X
thoroughly	B-X
evaluated	B-X
and	B-X
adapted	B-X
to	B-X
the	B-X
way	B-X
that	B-X
dentists	B-X
work	B-X
by	B-X
the	B-X
European	B-X
Society	B-X
of	B-X
Dental	B-X
Ergonomics	B-X
(	B-X
ESDE	B-X
)	B-X
.	B-X
For	B-X
data	B-X
analysis	B-X
,	B-X
Software	B-X
IBM	B-X
SPSS	B-X
27	B-X
and	B-X
RStudio	B-X
was	B-X
used	B-X
.	B-X
Poisson	B-X
distribution	B-X
was	B-X
carried	B-X
out	B-X
with	B-X
log	B-X
link	B-X
function	B-X
and	B-X
network	B-X
analyses	B-X
.	B-X

RAL	O
participated	O
in	O
the	O
generation	O
and	O
analysis	O
of	O
chronic	O
TNF	O
-	O
alpha	O
data	O
.	O

DME	O
conceived	O
the	O
study	O
,	O
and	O
participated	O
in	O
its	O
design	O
and	O
coordination	O
and	O
helped	O
to	O
draft	O
the	O
manuscript	O
.	O

AGT	O
participated	O
in	O
the	O
bacterial	O
work	O
and	O
drafting	O
of	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O
<EOS>	B-X
As	B-X
a	B-X
Generally	B-X
Recognized	B-X
As	B-X
Safe	B-X
(	B-X
GRAS	B-X
)	B-X
approved	B-X
substance	B-X
,	B-X
MSM	B-X
is	B-X
well-tolerated	B-X
by	B-X
most	B-X
individuals	B-X
at	B-X
dosages	B-X
of	B-X
up	B-X
to	B-X
four	B-X
grams	B-X
daily	B-X
,	B-X
with	B-X
few	B-X
known	B-X
and	B-X
mild	B-X
side	B-X
effects	B-X
.	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
manuscript	B-X
is	B-X
to	B-X
provide	B-X
a	B-X
description	B-X
of	B-X
the	B-X
epidemiology	B-X
and	B-X
presentation	B-X
of	B-X
piriformis	B-X
as	B-X
well	B-X
as	B-X
both	B-X
non-operative	B-X
and	B-X
operative	B-X
treatment	B-X
options	B-X
.	B-X
Due	B-X
to	B-X
the	B-X
widespread	B-X
use	B-X
of	B-X
landfilling	B-X
,	B-X
even	B-X
as	B-X
of	B-X
today	B-X
,	B-X
it	B-X
is	B-X
imperative	B-X
to	B-X
examine	B-X
any	B-X
environmental-	B-X
and/or	B-X
health-related	B-X
issues	B-X
that	B-X
have	B-X
emerged	B-X
.	B-X

The	O
ineffectiveness	O
of	O
tobramycin	O
combination	O
therapy	O
in	O
Streptococcus	B-Species
faecium	I-Species
endocarditis	O
.	O
<EOS>	B-X
A	B-X
patient	B-X
required	B-X
mitral	B-X
valve	B-X
replacement	B-X
following	B-X
ineffective	B-X
antibiotic	B-X
treatment	B-X
of	B-X
enterococcal	B-X
endocarditis	B-X
caused	B-X
by	B-X
Streptococcus	B-X
faecium	B-X
.	B-X
Endocarditis	B-X
had	B-X
relapsed	B-X
despite	B-X
therapy	B-X
with	B-X
ampicillin	B-X
and	B-X
tobramycin	B-X
for	B-X
six	B-X
weeks	B-X
.	B-X
Initial	B-X
failure	B-X
of	B-X
antibiotic	B-X
therapy	B-X
may	B-X
be	B-X
related	B-X
to	B-X
the	B-X
known	B-X
lack	B-X
of	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
synergy	B-X
between	B-X
penicillin	B-X
and	B-X
tobramycin	B-X
against	B-X
S.	B-X
faecium	B-X
.	B-X
Effective	B-X
therapy	B-X
of	B-X
enterococcal	B-X
endocarditis	B-X
requires	B-X
considerations	B-X
of	B-X
bacterial	B-X
speciation	B-X
,	B-X
determination	B-X
of	B-X
high-level	B-X
aminoglycoside	B-X
resistance	B-X
,	B-X
and	B-X
preferably	B-X
adequate	B-X
antibiotic	B-X
synergy	B-X
studies	B-X
to	B-X
assure	B-X
effective	B-X
therapy	B-X
.	B-X

Abstract	O
<EOS>	B-X
Abstract	B-X
writing	B-X
.	B-X
The	B-X
informative	B-X
abstract	B-X
.	B-X
Crafting	B-X
a	B-X
compelling	B-X
abstract	B-X
.	B-X
Why	B-X
the	B-X
structured	B-X
abstract	B-X
?	B-X

A	O
patient	B-Species
required	O
mitral	O
valve	O
replacement	O
following	O
ineffective	O
antibiotic	O
treatment	O
of	O
enterococcal	O
endocarditis	O
caused	O
by	O
Streptococcus	B-Species
faecium	I-Species
.	O
<EOS>	B-X
A	B-X
patient	B-X
required	B-X
mitral	B-X
valve	B-X
replacement	B-X
following	B-X
ineffective	B-X
antibiotic	B-X
treatment	B-X
of	B-X
enterococcal	B-X
endocarditis	B-X
caused	B-X
by	B-X
Streptococcus	B-X
faecium	B-X
.	B-X
A	B-X
second	B-X
relapse	B-X
had	B-X
occurred	B-X
following	B-X
treatment	B-X
with	B-X
penicillin	B-X
and	B-X
gentamicin	B-X
.	B-X
Initial	B-X
failure	B-X
of	B-X
antibiotic	B-X
therapy	B-X
may	B-X
be	B-X
related	B-X
to	B-X
the	B-X
known	B-X
lack	B-X
of	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
synergy	B-X
between	B-X
penicillin	B-X
and	B-X
tobramycin	B-X
against	B-X
S.	B-X
faecium	B-X
.	B-X
Effective	B-X
therapy	B-X
of	B-X
enterococcal	B-X
endocarditis	B-X
requires	B-X
considerations	B-X
of	B-X
bacterial	B-X
speciation	B-X
,	B-X
determination	B-X
of	B-X
high-level	B-X
aminoglycoside	B-X
resistance	B-X
,	B-X
and	B-X
preferably	B-X
adequate	B-X
antibiotic	B-X
synergy	B-X
studies	B-X
to	B-X
assure	B-X
effective	B-X
therapy	B-X
.	B-X

Endocarditis	O
had	O
relapsed	O
despite	O
therapy	O
with	O
ampicillin	O
and	O
tobramycin	O
for	O
six	O
weeks	O
.	O
<EOS>	B-X
Endocarditis	B-X
had	B-X
relapsed	B-X
despite	B-X
therapy	B-X
with	B-X
ampicillin	B-X
and	B-X
tobramycin	B-X
for	B-X
six	B-X
weeks	B-X
.	B-X
Initial	B-X
failure	B-X
of	B-X
antibiotic	B-X
therapy	B-X
may	B-X
be	B-X
related	B-X
to	B-X
the	B-X
known	B-X
lack	B-X
of	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
synergy	B-X
between	B-X
penicillin	B-X
and	B-X
tobramycin	B-X
against	B-X
S.	B-X
faecium	B-X
.	B-X
Effective	B-X
therapy	B-X
of	B-X
enterococcal	B-X
endocarditis	B-X
requires	B-X
considerations	B-X
of	B-X
bacterial	B-X
speciation	B-X
,	B-X
determination	B-X
of	B-X
high-level	B-X
aminoglycoside	B-X
resistance	B-X
,	B-X
and	B-X
preferably	B-X
adequate	B-X
antibiotic	B-X
synergy	B-X
studies	B-X
to	B-X
assure	B-X
effective	B-X
therapy	B-X
.	B-X

A	O
second	O
relapse	O
had	O
occurred	O
following	O
treatment	O
with	O
penicillin	O
and	O
gentamicin	O
.	O
<EOS>	B-X
The	B-X
second	B-X
trimester	B-X
is	B-X
considered	B-X
the	B-X
safest	B-X
for	B-X
surgery	B-X
,	B-X
with	B-X
early	B-X
involvement	B-X
of	B-X
intensive	B-X
care	B-X
as	B-X
the	B-X
condition	B-X
can	B-X
deteriorate	B-X
rapidly	B-X
.	B-X
A	B-X
patient	B-X
required	B-X
mitral	B-X
valve	B-X
replacement	B-X
following	B-X
ineffective	B-X
antibiotic	B-X
treatment	B-X
of	B-X
enterococcal	B-X
endocarditis	B-X
caused	B-X
by	B-X
Streptococcus	B-X
faecium	B-X
.	B-X
Endocarditis	B-X
had	B-X
relapsed	B-X
despite	B-X
therapy	B-X
with	B-X
ampicillin	B-X
and	B-X
tobramycin	B-X
for	B-X
six	B-X
weeks	B-X
.	B-X
A	B-X
second	B-X
relapse	B-X
had	B-X
occurred	B-X
following	B-X
treatment	B-X
with	B-X
penicillin	B-X
and	B-X
gentamicin	B-X
.	B-X
Initial	B-X
failure	B-X
of	B-X
antibiotic	B-X
therapy	B-X
may	B-X
be	B-X
related	B-X
to	B-X
the	B-X
known	B-X
lack	B-X
of	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
synergy	B-X
between	B-X
penicillin	B-X
and	B-X
tobramycin	B-X
against	B-X
S.	B-X
faecium	B-X
.	B-X

Initial	O
failure	O
of	O
antibiotic	O
therapy	O
may	O
be	O
related	O
to	O
the	O
known	O
lack	O
of	O
in	O
vitro	O
and	O
in	O
vivo	O
synergy	O
between	O
penicillin	O
and	O
tobramycin	O
against	O
S	B-Species
.	I-Species
faecium	I-Species
.	O

Effective	O
therapy	O
of	O
enterococcal	O
endocarditis	O
requires	O
considerations	O
of	O
bacterial	O
speciation	O
,	O
determination	O
of	O
high	O
-	O
level	O
aminoglycoside	O
resistance	O
,	O
and	O
preferably	O
adequate	O
antibiotic	O
synergy	O
studies	O
to	O
assure	O
effective	O
therapy	O
.	O
<EOS>	B-X
A	B-X
patient	B-X
required	B-X
mitral	B-X
valve	B-X
replacement	B-X
following	B-X
ineffective	B-X
antibiotic	B-X
treatment	B-X
of	B-X
enterococcal	B-X
endocarditis	B-X
caused	B-X
by	B-X
Streptococcus	B-X
faecium	B-X
.	B-X
Endocarditis	B-X
had	B-X
relapsed	B-X
despite	B-X
therapy	B-X
with	B-X
ampicillin	B-X
and	B-X
tobramycin	B-X
for	B-X
six	B-X
weeks	B-X
.	B-X
Initial	B-X
failure	B-X
of	B-X
antibiotic	B-X
therapy	B-X
may	B-X
be	B-X
related	B-X
to	B-X
the	B-X
known	B-X
lack	B-X
of	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
synergy	B-X
between	B-X
penicillin	B-X
and	B-X
tobramycin	B-X
against	B-X
S.	B-X
faecium	B-X
.	B-X
Effective	B-X
therapy	B-X
of	B-X
enterococcal	B-X
endocarditis	B-X
requires	B-X
considerations	B-X
of	B-X
bacterial	B-X
speciation	B-X
,	B-X
determination	B-X
of	B-X
high-level	B-X
aminoglycoside	B-X
resistance	B-X
,	B-X
and	B-X
preferably	B-X
adequate	B-X
antibiotic	B-X
synergy	B-X
studies	B-X
to	B-X
assure	B-X
effective	B-X
therapy	B-X
.	B-X

THE	O
YALE	O
JOURNAL	O
OF	O
BIOLOGY	O
AND	O
MEDICINE	O
56	O
(	O
1983	O
)	O
,	O
243	O
-	O
249	O

The	O
Ineffectiveness	O
of	O
Tobramycin	O
Combination	O
Therapy	O
<EOS>	B-X
Tobramycin	B-X
was	B-X
at	B-X
least	B-X
twice	B-X
as	B-X
active	B-X
as	B-X
gentamicin	B-X
against	B-X
P.	B-X
aeruginosa	B-X
.	B-X
Tobramycin	B-X
was	B-X
essentially	B-X
similar	B-X
to	B-X
gentamicin	B-X
in	B-X
laboratory	B-X
characteristics	B-X
and	B-X
clinical	B-X
application	B-X
but	B-X
was	B-X
more	B-X
active	B-X
against	B-X
P.	B-X
aeruginosa	B-X
in	B-X
general	B-X
and	B-X
against	B-X
gentamicin-resistant	B-X
strains	B-X
in	B-X
particular	B-X
.	B-X

in	O
Streptococcus	B-Species
Faecium	I-Species
Endocarditis	O
<EOS>	B-X
The	B-X
genus	B-X
Streptococcus	B-X
consists	B-X
of	B-X
more	B-X
than	B-X
60	B-X
species	B-X
,	B-X
but	B-X
only	B-X
Streptococcus	B-X
equi	B-X
subspecies	B-X
zooepidemicus	B-X
,	B-X
Streptococcus	B-X
gallolyticus	B-X
ssp	B-X
.	B-X
gallolyticus	B-X
,	B-X
Streptococcus	B-X
gallinaceus	B-X
,	B-X
Streptococcus	B-X
dysgalactiae	B-X
,	B-X
Streptococcus	B-X
mutans	B-X
and	B-X
Streptococcus	B-X
suis	B-X
have	B-X
been	B-X
isolated	B-X
from	B-X
poultry	B-X
.	B-X
Phenotypic	B-X
characterization	B-X
using	B-X
the	B-X
API20	B-X
STREP	B-X
kit	B-X
identified	B-X
the	B-X
isolates	B-X
as	B-X
Aerococcus	B-X
viridans	B-X
(	B-X
10	B-X
)	B-X
,	B-X
Aerococcus	B-X
urinae	B-X
(	B-X
2	B-X
)	B-X
,	B-X
Leuconostoc	B-X
species	B-X
(	B-X
4	B-X
)	B-X
,	B-X
Streptococcus	B-X
salivarius	B-X
(	B-X
2	B-X
)	B-X
,	B-X
Streptococcus	B-X
bovis	B-X
II	B-X
3	B-X
(	B-X
1	B-X
)	B-X
,	B-X
Enterococcus	B-X
avium	B-X
(	B-X
3	B-X
)	B-X
,	B-X
Enterococcus	B-X
faecium	B-X
(	B-X
1	B-X
)	B-X
or	B-X
Gemella	B-X
morbillorum	B-X
(	B-X
1	B-X
)	B-X
.	B-X
However	B-X
,	B-X
this	B-X
identification	B-X
was	B-X
misleading	B-X
as	B-X
subsequent	B-X
genetic	B-X
investigations	B-X
using	B-X
pulse	B-X
field	B-X
gel	B-X
electrophoresis	B-X
and	B-X
sequencing	B-X
of	B-X
16S	B-X
rRNA	B-X
genes	B-X
showed	B-X
that	B-X
19	B-X
isolates	B-X
were	B-X
classified	B-X
as	B-X
Streptococcus	B-X
pluranimalium	B-X
,	B-X
while	B-X
the	B-X
remaining	B-X
isolates	B-X
were	B-X
E.	B-X
avium	B-X
(	B-X
3	B-X
)	B-X
,	B-X
E.	B-X
faecium	B-X
(	B-X
1	B-X
)	B-X
or	B-X
Lactobacillus	B-X
species	B-X
(	B-X
1	B-X
)	B-X
.	B-X

JUDITH	O
A	O
.	O
<EOS>	B-X
Biopsychosocial	B-X
wellbeing	B-X
and	B-X
family	B-X
support	B-X
for	B-X
menopausal	B-X
women	B-X
in	B-X
Karnataka	B-X
.	B-X

GOLDSTEIN	O
,	O
M	O
.	O
D	O
.	O
,	O
a	O
HOWARD	O
COHEN	O
,	O
M	O
.	O
D	O
.	O
,	O
a	O
AND	O

FRANK	O
J	O
.	O
<EOS>	B-X
[	B-X
Not	B-X
Available	B-X
]	B-X
.	B-X
[	B-X
Not	B-X
Available	B-X
]	B-X
.	B-X
[	B-X
Not	B-X
Available	B-X
]	B-X
.	B-X
[	B-X
Not	B-X
Available	B-X
]	B-X
.	B-X

BIA	O
,	O
M	O
.	O
D	O
.	O
,	O
M	O
.	O
P	O
.	O
H	O
.	O
a	O
,	O
b	O

aInfectious	O
Disease	O
Section	O
of	O
the	O
Department	O
of	O
Medicine	O
,	O
and	O
bThe	O
Department	O
of	O

Laboratory	O
Medicine	O
,	O
Veterans	O
Administration	O
Medical	O
Center	O
,	O
<EOS>	B-X
Chronic	B-X
Traumatic	B-X
Encephalopathy	B-X
.	B-X
Responding	B-X
to	B-X
the	B-X
opioid	B-X
crisis	B-X
in	B-X
North	B-X
America	B-X
and	B-X
beyond	B-X
:	B-X
recommendations	B-X
of	B-X
the	B-X
Stanford-Lancet	B-X
Commission	B-X
.	B-X

West	O
Haven	O
,	O
and	O
Yale	O
University	O
School	O
of	O
Medicine	O
,	O

New	O
Haven	O
,	O
Connecticut	O
<EOS>	B-X
We	B-X
calculated	B-X
RCDI	B-X
incidence	B-X
and	B-X
identified	B-X
factors	B-X
associated	B-X
with	B-X
RCDI	B-X
cases	B-X
in	B-X
New	B-X
Haven	B-X
County	B-X
,	B-X
Connecticut	B-X
,	B-X
USA	B-X
,	B-X
during	B-X
2015-2020	B-X
by	B-X
using	B-X
data	B-X
from	B-X
population-based	B-X
laboratory	B-X
surveillance	B-X
.	B-X
This	B-X
article	B-X
examines	B-X
five	B-X
different	B-X
Medical-Legal	B-X
Partnerships	B-X
(	B-X
MLPs	B-X
)	B-X
associated	B-X
with	B-X
Yale	B-X
Law	B-X
School	B-X
in	B-X
New	B-X
Haven	B-X
,	B-X
Connecticut	B-X
to	B-X
illustrate	B-X
how	B-X
MLP	B-X
addresses	B-X
the	B-X
social	B-X
determinants	B-X
of	B-X
poor	B-X
health	B-X
.	B-X
To	B-X
assess	B-X
Connecticut	B-X
medical	B-X
providers	B-X
'	B-X
concordance	B-X
(	B-X
2018-2019	B-X
)	B-X
with	B-X
the	B-X
2017	B-X
Clostridioides	B-X
difficile	B-X
infection	B-X
(	B-X
CDI	B-X
)	B-X
treatment	B-X
update	B-X
by	B-X
the	B-X
Infectious	B-X
Disease	B-X
Society	B-X
of	B-X
America	B-X
(	B-X
IDSA	B-X
)	B-X
and	B-X
the	B-X
Society	B-X
for	B-X
Healthcare	B-X
Epidemiology	B-X
of	B-X
America	B-X
(	B-X
SHEA	B-X
)	B-X
.	B-X
In	B-X
July	B-X
2011	B-X
,	B-X
renovations	B-X
to	B-X
Yale-New	B-X
Haven	B-X
Hospital	B-X
inadvertently	B-X
exposed	B-X
the	B-X
cemetery	B-X
of	B-X
Christ	B-X
Church	B-X
,	B-X
New	B-X
Haven	B-X
,	B-X
Connecticut	B-X
's	B-X
first	B-X
Catholic	B-X
cemetery	B-X
.	B-X
These	B-X
individuals	B-X
provide	B-X
biocultural	B-X
evidence	B-X
of	B-X
New	B-X
Haven	B-X
's	B-X
Industrial	B-X
Revolution	B-X
and	B-X
the	B-X
plasticity	B-X
of	B-X
ethnic	B-X
and	B-X
religious	B-X
identity	B-X
in	B-X
the	B-X
immigrant	B-X
experience	B-X
.	B-X

Received	O
July	O
11	O
,	O
1983	O
<EOS>	B-X
1	B-X
)	B-X
is	B-X
Group	B-X
Leader	B-X
and	B-X
Director	B-X
at	B-X
the	B-X
Max	B-X
Planck	B-X
Institute	B-X
of	B-X
Molecular	B-X
Cell	B-X
Biology	B-X
and	B-X
Genetics	B-X
;	B-X
he	B-X
and	B-X
his	B-X
research	B-X
group	B-X
moved	B-X
to	B-X
Dresden	B-X
,	B-X
Germany	B-X
,	B-X
in	B-X
July	B-X
2001	B-X
.	B-X
Howard	B-X
received	B-X
his	B-X
PhD	B-X
in	B-X
neurobiology	B-X
in	B-X
1983	B-X
from	B-X
the	B-X
Australian	B-X
National	B-X
University	B-X
in	B-X
Canberra	B-X
.	B-X
To	B-X
describe	B-X
the	B-X
Orange	B-X
County	B-X
trauma	B-X
system	B-X
's	B-X
nine-year	B-X
(	B-X
July	B-X
1980	B-X
through	B-X
June	B-X
1989	B-X
)	B-X
experience	B-X
with	B-X
patient	B-X
triage	B-X
.	B-X
Changes	B-X
in	B-X
patterns	B-X
were	B-X
sought	B-X
after	B-X
the	B-X
1983	B-X
revisions	B-X
in	B-X
triage	B-X
criteria	B-X
.	B-X

A	O
patient	B-Species
required	O
mitral	O
valve	O
replacement	O
following	O
ineffective	O
antibiotic	O
treatment	O
of	O
enterococcal	O
endocarditis	O
caused	O
by	O
Streptococcusfaecium	B-Species
.	O
<EOS>	B-X
A	B-X
patient	B-X
required	B-X
mitral	B-X
valve	B-X
replacement	B-X
following	B-X
ineffective	B-X
antibiotic	B-X
treatment	B-X
of	B-X
enterococcal	B-X
endocarditis	B-X
caused	B-X
by	B-X
Streptococcus	B-X
faecium	B-X
.	B-X
A	B-X
second	B-X
relapse	B-X
had	B-X
occurred	B-X
following	B-X
treatment	B-X
with	B-X
penicillin	B-X
and	B-X
gentamicin	B-X
.	B-X
Initial	B-X
failure	B-X
of	B-X
antibiotic	B-X
therapy	B-X
may	B-X
be	B-X
related	B-X
to	B-X
the	B-X
known	B-X
lack	B-X
of	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
synergy	B-X
between	B-X
penicillin	B-X
and	B-X
tobramycin	B-X
against	B-X
S.	B-X
faecium	B-X
.	B-X
Effective	B-X
therapy	B-X
of	B-X
enterococcal	B-X
endocarditis	B-X
requires	B-X
considerations	B-X
of	B-X
bacterial	B-X
speciation	B-X
,	B-X
determination	B-X
of	B-X
high-level	B-X
aminoglycoside	B-X
resistance	B-X
,	B-X
and	B-X
preferably	B-X
adequate	B-X
antibiotic	B-X
synergy	B-X
studies	B-X
to	B-X
assure	B-X
effective	B-X
therapy	B-X
.	B-X

Endocarditis	O
had	O
relapsed	O
despite	O
therapy	O
with	O
ampicillin	O
and	O
tobramycin	O
for	O
six	O
weeks	O
.	O
<EOS>	B-X
Endocarditis	B-X
had	B-X
relapsed	B-X
despite	B-X
therapy	B-X
with	B-X
ampicillin	B-X
and	B-X
tobramycin	B-X
for	B-X
six	B-X
weeks	B-X
.	B-X
Initial	B-X
failure	B-X
of	B-X
antibiotic	B-X
therapy	B-X
may	B-X
be	B-X
related	B-X
to	B-X
the	B-X
known	B-X
lack	B-X
of	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
synergy	B-X
between	B-X
penicillin	B-X
and	B-X
tobramycin	B-X
against	B-X
S.	B-X
faecium	B-X
.	B-X
Effective	B-X
therapy	B-X
of	B-X
enterococcal	B-X
endocarditis	B-X
requires	B-X
considerations	B-X
of	B-X
bacterial	B-X
speciation	B-X
,	B-X
determination	B-X
of	B-X
high-level	B-X
aminoglycoside	B-X
resistance	B-X
,	B-X
and	B-X
preferably	B-X
adequate	B-X
antibiotic	B-X
synergy	B-X
studies	B-X
to	B-X
assure	B-X
effective	B-X
therapy	B-X
.	B-X

A	O
second	O
relapse	O
had	O
occurred	O
following	O
treatment	O
with	O
penicillin	O
and	O
gentamicin	O
.	O
<EOS>	B-X
The	B-X
second	B-X
trimester	B-X
is	B-X
considered	B-X
the	B-X
safest	B-X
for	B-X
surgery	B-X
,	B-X
with	B-X
early	B-X
involvement	B-X
of	B-X
intensive	B-X
care	B-X
as	B-X
the	B-X
condition	B-X
can	B-X
deteriorate	B-X
rapidly	B-X
.	B-X
A	B-X
patient	B-X
required	B-X
mitral	B-X
valve	B-X
replacement	B-X
following	B-X
ineffective	B-X
antibiotic	B-X
treatment	B-X
of	B-X
enterococcal	B-X
endocarditis	B-X
caused	B-X
by	B-X
Streptococcus	B-X
faecium	B-X
.	B-X
Endocarditis	B-X
had	B-X
relapsed	B-X
despite	B-X
therapy	B-X
with	B-X
ampicillin	B-X
and	B-X
tobramycin	B-X
for	B-X
six	B-X
weeks	B-X
.	B-X
A	B-X
second	B-X
relapse	B-X
had	B-X
occurred	B-X
following	B-X
treatment	B-X
with	B-X
penicillin	B-X
and	B-X
gentamicin	B-X
.	B-X
Initial	B-X
failure	B-X
of	B-X
antibiotic	B-X
therapy	B-X
may	B-X
be	B-X
related	B-X
to	B-X
the	B-X
known	B-X
lack	B-X
of	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
synergy	B-X
between	B-X
penicillin	B-X
and	B-X
tobramycin	B-X
against	B-X
S.	B-X
faecium	B-X
.	B-X

Initial	O
failure	O
of	O
antibiotic	O
therapy	O
may	O
be	O
related	O
to	O
the	O
known	O
lack	O
of	O
in	O
vitro	O
and	O
in	O
vivo	O
synergy	O
between	O
penicillin	O
and	O
tobramycin	O
against	O
S	B-Species
.	I-Species
faecium	I-Species
.	O

Effective	O
therapy	O
of	O
enterococcal	O
endocarditis	O
requires	O
considerations	O
of	O
bacterial	O
speciation	O
,	O
determination	O
of	O
high	O
-	O
level	O
aminoglycoside	O
resistance	O
,	O
and	O
preferably	O
adequate	O
antibiotic	O
synergy	O
studies	O
to	O
assure	O
effective	O
therapy	O
.	O
<EOS>	B-X
A	B-X
patient	B-X
required	B-X
mitral	B-X
valve	B-X
replacement	B-X
following	B-X
ineffective	B-X
antibiotic	B-X
treatment	B-X
of	B-X
enterococcal	B-X
endocarditis	B-X
caused	B-X
by	B-X
Streptococcus	B-X
faecium	B-X
.	B-X
Endocarditis	B-X
had	B-X
relapsed	B-X
despite	B-X
therapy	B-X
with	B-X
ampicillin	B-X
and	B-X
tobramycin	B-X
for	B-X
six	B-X
weeks	B-X
.	B-X
Initial	B-X
failure	B-X
of	B-X
antibiotic	B-X
therapy	B-X
may	B-X
be	B-X
related	B-X
to	B-X
the	B-X
known	B-X
lack	B-X
of	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
synergy	B-X
between	B-X
penicillin	B-X
and	B-X
tobramycin	B-X
against	B-X
S.	B-X
faecium	B-X
.	B-X
Effective	B-X
therapy	B-X
of	B-X
enterococcal	B-X
endocarditis	B-X
requires	B-X
considerations	B-X
of	B-X
bacterial	B-X
speciation	B-X
,	B-X
determination	B-X
of	B-X
high-level	B-X
aminoglycoside	B-X
resistance	B-X
,	B-X
and	B-X
preferably	B-X
adequate	B-X
antibiotic	B-X
synergy	B-X
studies	B-X
to	B-X
assure	B-X
effective	B-X
therapy	B-X
.	B-X

INTRODUCTION	O

Enterococcal	O
endocarditis	O
requires	O
special	O
therapeutic	O
considerations	O
because	O
the	O
responsible	O
organisms	O
are	O
relatively	O
penicillin	O
-	O
resistant	O
streptococci	O
which	O
require	O
synergistic	O
combinations	O
of	O
antibiotics	O
to	O
achieve	O
acceptable	O
cure	O
rates	O
[	O
1	O
,	O
2	O
]	O
.	O

The	O
group	O
D	O
enterococci	O
include	O
three	O
main	O
species	O
S	B-Species
.	I-Species
faecalis	I-Species
,	O
S	B-Species
.	I-Species
faecium	I-Species
,	O
and	O
S	B-Species
.	I-Species
durans	I-Species
.	O

S	B-Species
.	I-Species
faecium	I-Species
cause	O
a	O
minority	O
of	O
all	O
cases	O
of	O
enterococcal	O
endocarditis	O
,	O
in	O
those	O
instances	O
in	O
which	O
enterococci	O
have	O
been	O
speciated	O
[	O
3	O
]	O
,	O
but	O
they	O
have	O
been	O
more	O
resistant	O
both	O
to	O
penicillin	O
and	O
penicillin	O
-	O
aminoglycoside	O
combinations	O
than	O
S	B-Species
.	I-Species
faecalis	I-Species
[	O
4	O
,	O
5	O
,	O
6	O
]	O
.	O

We	O
describe	O
a	O
64	O
-	O
year	O
-	O
old	O
man	B-Species
with	O
S	B-Species
.	I-Species
faecium	I-Species
endocarditis	O
in	O
whom	O
a	O
six	O
-	O
week	O
course	O
of	O
ampicillin	O
and	O
tobramycin	O
,	O
followed	O
by	O
additional	O
courses	O
of	O
penicillin	O
and	O
other	O
aminoglycosides	O
,	O
failed	O
to	O
eradicate	O
the	O
organism	O
from	O
the	O
patient	B-Species
'	O
s	O
mitral	O
valve	O
.	O

This	O
case	O
is	O
of	O
interest	O
because	O
therapeutic	O
failure	O
of	O
ampicillin	O
and	O
tobramycin	O
in	O
S	B-Species
.	I-Species
faecium	I-Species
endocarditis	O
has	O
not	O
been	O
reported	O
previously	O
,	O
but	O
might	O
have	O
been	O
predicted	O
on	O
the	O
basis	O
of	O
previous	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
[	O
6	O
]	O
.	O

Although	O
the	O
need	O
for	O
both	O
a	O
penicillin	O
derivative	O
and	O
an	O
aminoglycoside	O
in	O
the	O
therapy	O
of	O
enterococcal	O
endocarditis	O
is	O
widely	O
known	O
,	O
it	O
is	O
important	O
to	O
distinguish	O
between	O
the	O
differing	O
efficacies	O
of	O
penicillin	O
-	O
aminoglycoside	O
combinations	O
for	O
treating	O
various	O
species	O
of	O
enterococci	O
such	O
as	O
S	B-Species
.	I-Species
faecium	I-Species
.	O

243	O
<EOS>	B-X
Primary	B-X
culture	B-X
of	B-X
parenchymal	B-X
liver	B-X
cells	B-X
on	B-X
collagen	B-X
membranes	B-X
.	B-X
Morphological	B-X
and	B-X
biochemical	B-X
observations	B-X
.	B-X

Address	O
reprint	O
requests	O
to	O
:	O
Judith	O
A	O
.	O
Goldstein	O
,	O
M	O
.	O
D	O
.	O
,	O
Section	O
of	O
Infectious	O
Diseases	O
,	O
Department	O
of	O
Medicine	O
,	O
Long	O
Island	O
Jewish	O
-	O
Hillside	O
Medical	O
Center	O
,	O
Queen	O
'	O
s	O
Hosp	O
.	O

Center	O
Affiliate	O
,	O
82	O
-	O
68	O
164th	O
Street	O
,	O
Jamaica	O
,	O
NY	O
11432	O

Copyright	O
c	O
1983	O
by	O
The	O
Yale	O
Journal	O
of	O
Biology	O
and	O
Medicine	O
,	O
Inc	O
.	O

All	O
rights	O
of	O
reproduction	O
in	O
any	O
form	O
reserved	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
since	B-X
excision	B-X
ceremonies	B-X
and	B-X
rituals	B-X
are	B-X
exclusively	B-X
reserved	B-X
for	B-X
women	B-X
,	B-X
many	B-X
see	B-X
them	B-X
as	B-X
a	B-X
way	B-X
of	B-X
freeing	B-X
themselves	B-X
from	B-X
the	B-X
rules	B-X
of	B-X
patriarchy	B-X
and	B-X
male	B-X
domination	B-X
that	B-X
are	B-X
omnipresent	B-X
in	B-X
the	B-X
societies	B-X
concerned	B-X
.	B-X
Informal	B-X
mechanisms	B-X
such	B-X
as	B-X
the	B-X
use	B-X
of	B-X
witchcraft	B-X
,	B-X
gossip	B-X
,	B-X
and	B-X
beliefs	B-X
related	B-X
to	B-X
the	B-X
supernatural	B-X
power	B-X
of	B-X
the	B-X
excisors	B-X
underpin	B-X
the	B-X
cultural-cognitive	B-X
nature	B-X
of	B-X
FGM/C	B-X
practice	B-X
.	B-X
The	B-X
fight	B-X
against	B-X
FGM/C	B-X
can	B-X
be	B-X
more	B-X
effective	B-X
by	B-X
addressing	B-X
the	B-X
normative	B-X
and	B-X
cultural-cognitive	B-X
roots	B-X
that	B-X
form	B-X
the	B-X
basis	B-X
for	B-X
its	B-X
perpetuation	B-X
.	B-X
This	B-X
will	B-X
create	B-X
a	B-X
social	B-X
environment	B-X
in	B-X
which	B-X
FGM/C	B-X
is	B-X
increasingly	B-X
perceived	B-X
as	B-X
less	B-X
favourable	B-X
and	B-X
will	B-X
ultimately	B-X
allow	B-X
for	B-X
a	B-X
gradual	B-X
reform	B-X
of	B-X
the	B-X
normative	B-X
and	B-X
cultural-cognitive	B-X
character	B-X
of	B-X
societies	B-X
that	B-X
practice	B-X
FGM/C	B-X
.	B-X

GOLDSTEIN	O
ET	O
AL	O
.	O

CASE	O
REPORT	O
<EOS>	B-X
Case	B-X
Report	B-X
:	B-X
A	B-X
Case	B-X
Report	B-X
and	B-X
Literature	B-X
Review	B-X
on	B-X
Severe	B-X
Bullous	B-X
Skin	B-X
Reaction	B-X
Induced	B-X
by	B-X
anti-PD-1	B-X
Immunotherapy	B-X
in	B-X
a	B-X
Cervical	B-X
Cancer	B-X
Patient	B-X
.	B-X
Case	B-X
Report	B-X
:	B-X
Hypopituitarism	B-X
Presenting	B-X
With	B-X
Nonconvulsive	B-X
Status	B-X
Epilepticus	B-X
.	B-X
A	B-X
case	B-X
report	B-X
of	B-X
necrotizing	B-X
fasciitis	B-X
with	B-X
growth	B-X
of	B-X

A	O
64	O
-	O
year	O
-	O
old	O
male	O
was	O
in	O
good	O
health	O
until	O
December	O
1980	O
,	O
when	O
he	O
noted	O
intermittent	O
night	O
sweats	O
,	O
malaise	O
,	O
fever	O
,	O
and	O
fatigue	O
.	O

He	O
received	O
oral	O
erythromycin	O
for	O
14	O
days	O
with	O
transient	O
improvement	O
of	O
symptoms	O
.	O

However	O
,	O
after	O
completing	O
therapy	O
,	O
symptoms	O
reappeared	O
and	O
he	O
noted	O
a	O
15	O
-	O
pound	O
weight	O
loss	O
with	O
low	O
-	O
grade	O
fever	O
(	O
99	O
-	O
100	O
.	O
5	O
?	O
F	O
)	O
during	O
the	O
two	O
months	O
preceding	O
admission	O
.	O

There	O
was	O
no	O
previous	O
history	O
of	O
rheumatic	O
or	O
congenital	O
heart	O
disease	O
.	O
<EOS>	B-X
Congenital	B-X
heart	B-X
disease	B-X
(	B-X
CHD	B-X
)	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
common	B-X
birth	B-X
defects	B-X
.	B-X
About	B-X
400	B-X
genes	B-X
have	B-X
been	B-X
implicated	B-X
in	B-X
CHD	B-X
,	B-X
encompassing	B-X
transcription	B-X
factors	B-X
,	B-X
cell	B-X
signaling	B-X
molecules	B-X
,	B-X
and	B-X
structural	B-X
proteins	B-X
that	B-X
are	B-X
important	B-X
for	B-X
heart	B-X
development	B-X
.	B-X
Among	B-X
congenital	B-X
malformations	B-X
,	B-X
heart	B-X
defects	B-X
are	B-X
the	B-X
most	B-X
common	B-X
type	B-X
of	B-X
anomaly	B-X
,	B-X
and	B-X
these	B-X
are	B-X
associated	B-X
with	B-X
a	B-X
high	B-X
perinatal	B-X
,	B-X
longterm	B-X
morbidity	B-X
and	B-X
mortality	B-X
.	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
update	B-X
was	B-X
to	B-X
review	B-X
the	B-X
rate	B-X
of	B-X
prenatal	B-X
detection	B-X
,	B-X
screening	B-X
characteristics	B-X
throughout	B-X
the	B-X
pregnancy	B-X
,	B-X
in	B-X
both	B-X
the	B-X
first	B-X
and	B-X
second	B-X
trimesters	B-X
,	B-X
indications	B-X
for	B-X
advanced	B-X
echocardiography	B-X
,	B-X
and	B-X
to	B-X
establish	B-X
a	B-X
management	B-X
algorithm	B-X
in	B-X
case	B-X
of	B-X
prenatal	B-X
diagnosis	B-X
of	B-X
a	B-X
congenital	B-X
heart	B-X
disease	B-X
.	B-X
Finally	B-X
,	B-X
the	B-X
main	B-X
characteristics	B-X
of	B-X
fetal	B-X
therapy	B-X
in	B-X
heart	B-X
anomalies	B-X
will	B-X
be	B-X
reviewed	B-X
,	B-X
both	B-X
cardiac	B-X
interventions	B-X
and	B-X
intrauterine	B-X
treatment	B-X
of	B-X
arrhythmias	B-X
.	B-X

In	O
March	O
1981	O
,	O
the	O
patient	B-Species
was	O
admitted	O
to	O
his	O
community	O
hospital	O
where	O
evaluation	O
revealed	O
a	O
new	O
apical	O
systolic	O
murmur	O
radiating	O
to	O
the	O
axilla	O
.	O

There	O
were	O
no	O
petechiae	O
,	O
Janeway	O
lesions	O
,	O
Osler	O
'	O
s	O
nodes	O
,	O
Roth	O
spots	O
,	O
or	O
splenomegaly	O
.	O
<EOS>	B-X
This	B-X
remarkable	B-X
property	B-X
of	B-X
the	B-X
spleen	B-X
to	B-X
expand	B-X
is	B-X
termed	B-X
splenomegaly	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
will	B-X
discuss	B-X
the	B-X
normal	B-X
function	B-X
and	B-X
physiology	B-X
of	B-X
the	B-X
spleen	B-X
,	B-X
the	B-X
pathophysiological	B-X
bases	B-X
of	B-X
splenomegaly	B-X
and	B-X
the	B-X
commonly	B-X
available	B-X
therapeutic	B-X
options	B-X
.	B-X
Additionally	B-X
we	B-X
will	B-X
address	B-X
experimental	B-X
systems	B-X
to	B-X
determine	B-X
the	B-X
regulatory	B-X
mechanisms	B-X
underlying	B-X
splenomegaly	B-X
.	B-X
This	B-X
review	B-X
examines	B-X
the	B-X
aetiology	B-X
of	B-X
splenomegaly	B-X
in	B-X
the	B-X
developed	B-X
world	B-X
,	B-X
and	B-X
describes	B-X
a	B-X
logical	B-X
approach	B-X
to	B-X
the	B-X
patient	B-X
with	B-X
splenomegaly	B-X
.	B-X
In	B-X
some	B-X
patients	B-X
,	B-X
extensive	B-X
radiological	B-X
and	B-X
laboratory	B-X
investigations	B-X
will	B-X
fail	B-X
to	B-X
yield	B-X
a	B-X
diagnosis	B-X
:	B-X
these	B-X
cases	B-X
of	B-X
``	B-X
isolated	B-X
''	B-X
splenomegaly	B-X
are	B-X
not	B-X
uncommon	B-X
and	B-X
can	B-X
be	B-X
particularly	B-X
challenging	B-X
to	B-X
manage	B-X
.	B-X
We	B-X
discuss	B-X
the	B-X
options	B-X
in	B-X
isolated	B-X
splenomegaly	B-X
and	B-X
their	B-X
evidence	B-X
base	B-X
,	B-X
and	B-X
incorporate	B-X
them	B-X
into	B-X
a	B-X
management	B-X
strategy	B-X
to	B-X
aid	B-X
the	B-X
clinician	B-X
in	B-X
cases	B-X
of	B-X
diagnostic	B-X
difficulty	B-X
.	B-X

The	O
hematocrit	O
was	O
34	O
.	O
8	O
percent	O
,	O
WBC	O
count	O
9	O
,	O
300	O
cells	O
per	O
cu	O
mm	O
with	O
a	O
differential	O
count	O
of	O
67	O
segmented	O
forms	O
,	O
9	O
bands	O
,	O
15	O
lymphocytes	O
,	O
7	O
monocytes	O
,	O
1	O
eosinophil	O
,	O
and	O
1	O
basophil	O
.	O

The	O
erythrocyte	O
sedimentation	O
rate	O
(	O
ESR	O
)	O
was	O
62	O
mm	O
per	O
hour	O
(	O
nl	O
<	O
10	O
mm	O
per	O
hour	O
)	O
and	O
the	O
serum	O
rheumatoid	O
factor	O
titer	O
was	O
1	O
:	O
320	O
.	O

Chest	O
films	O
and	O
electrocardiogram	O
were	O
reportedly	O
normal	O
.	O

Group	O
D	O
streptococci	O
grew	O
from	O
three	O
sets	O
of	O
blood	O
cultures	O
.	O

Enterococcal	O
endocarditis	O
was	O
diagnosed	O
and	O
he	O
was	O
treated	O
with	O
six	O
weeks	O
of	O
parenteral	O
ampicillin	O
(	O
12	O
grams	O
per	O
day	O
)	O
and	O
tobramycin	O
(	O
3	O
mg	O
per	O
kg	O
per	O
day	O
)	O
.	O

Resolution	O
of	O
symptoms	O
occurred	O
within	O
several	O
days	O
after	O
antibiotics	O
were	O
begun	O
.	O
<EOS>	B-X
Lesions	B-X
typically	B-X
appear	B-X
24	B-X
hours	B-X
to	B-X
15	B-X
days	B-X
after	B-X
the	B-X
first	B-X
dose	B-X
of	B-X
vancomycin	B-X
.	B-X
Five	B-X
days	B-X
following	B-X
initiation	B-X
of	B-X
antibiotic	B-X
therapy	B-X
,	B-X
he	B-X
presented	B-X
with	B-X
a	B-X
vesiculobullous	B-X
eruption	B-X
on	B-X
an	B-X
erythematous	B-X
base	B-X
over	B-X
his	B-X
trunk	B-X
,	B-X
extremities	B-X
,	B-X
and	B-X
oral	B-X
mucosa	B-X
.	B-X
The	B-X
eruption	B-X
resolved	B-X
completely	B-X
when	B-X
intravenous	B-X
vancomycin	B-X
was	B-X
discontinued	B-X
and	B-X
colchicine	B-X
treatment	B-X
was	B-X
begun	B-X
.	B-X
Curiously	B-X
,	B-X
complete	B-X
resolution	B-X
occurred	B-X
despite	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
vancomycin	B-X
containing	B-X
joint	B-X
spacer	B-X
.	B-X

Serum	O
bactericidal	O
titers	O
against	O
the	O
organism	O
,	O
obtained	O
during	O
peak	O
antibiotic	O
levels	O
,	O
were	O
1	O
:	O
8	O
or	O
greater	O
on	O
several	O
occasions	O
,	O
and	O
blood	O
cultures	O
were	O
negative	O
while	O
the	O
patient	B-Species
was	O
receiving	O
antibiotics	O
.	O
<EOS>	B-X
Two	B-X
dosages	B-X
of	B-X
clindamycin	B-X
,	B-X
300	B-X
and	B-X
600	B-X
mg	B-X
,	B-X
were	B-X
given	B-X
orally	B-X
to	B-X
10	B-X
patients	B-X
each	B-X
.	B-X
The	B-X
patients	B-X
were	B-X
admitted	B-X
for	B-X
minor	B-X
elective	B-X
surgery	B-X
.	B-X
None	B-X
of	B-X
them	B-X
had	B-X
taken	B-X
antibiotics	B-X
for	B-X
at	B-X
least	B-X
1	B-X
month	B-X
.	B-X
After	B-X
administration	B-X
of	B-X
a	B-X
single	B-X
dose	B-X
,	B-X
blood	B-X
samples	B-X
were	B-X
obtained	B-X
at	B-X
0.5	B-X
,	B-X
1	B-X
,	B-X
1.5	B-X
,	B-X
2	B-X
,	B-X
3	B-X
,	B-X
4	B-X
,	B-X
6	B-X
,	B-X
8	B-X
,	B-X
10	B-X
and	B-X
12	B-X
h	B-X
after	B-X
dosing	B-X
.	B-X
Drug	B-X
levels	B-X
were	B-X
determined	B-X
by	B-X
the	B-X
bioassay	B-X
method	B-X
using	B-X
Micrococcus	B-X
luteus	B-X
as	B-X
test	B-X
organism	B-X
.	B-X
Serum	B-X
inhibitory	B-X
and	B-X
bactericidal	B-X
activities	B-X
against	B-X
five	B-X
isolates	B-X
each	B-X
of	B-X
Staphylococcus	B-X
aureus	B-X
and	B-X
Streptococcus	B-X
pyogenes	B-X
were	B-X
determined	B-X
by	B-X
the	B-X
microdilution	B-X
method	B-X
according	B-X
to	B-X
the	B-X
National	B-X
Committee	B-X
for	B-X
Clinical	B-X
Laboratory	B-X
Standards	B-X
guidelines	B-X
.	B-X
The	B-X
mean	B-X
peak	B-X
serum	B-X
level	B-X
was	B-X
3.4	B-X
mg/l	B-X
for	B-X
the	B-X
300-mg	B-X
dose	B-X
and	B-X
4.8	B-X
mg/l	B-X
for	B-X
the	B-X
600-mg	B-X
dose	B-X
.	B-X
The	B-X
mean	B-X
reciprocal	B-X
peak	B-X
inhibitory	B-X
titers	B-X
for	B-X
the	B-X
300-/600-mg	B-X
doses	B-X
were	B-X
13.7/23.8	B-X
and	B-X
15.2/34.7	B-X
against	B-X
S.	B-X
aureus	B-X
and	B-X
S.	B-X
pyogenes	B-X
,	B-X
respectively	B-X
.	B-X
Most	B-X
serum	B-X
samples	B-X
did	B-X
not	B-X
show	B-X
bactericidal	B-X
activity	B-X
against	B-X
S.	B-X
aureus	B-X
.	B-X

M	O
-	O
mode	O
echocardiography	O
demonstrated	O
left	O
atrial	O
enlargement	O
but	O
no	O
definable	O
abnormalities	O
of	O
the	O
mitral	O
or	O
aortic	O
valves	O
.	O
<EOS>	B-X
Bicuspid	B-X
aortic	B-X
valve	B-X
related	B-X
aortopathy	B-X
is	B-X
known	B-X
to	B-X
significantly	B-X
increase	B-X
the	B-X
risk	B-X
for	B-X
catastrophic	B-X
aortic	B-X
events	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
represents	B-X
a	B-X
considerable	B-X
health	B-X
burden	B-X
.	B-X
Albeit	B-X
of	B-X
ongoing	B-X
research	B-X
in	B-X
this	B-X
field	B-X
including	B-X
genetic	B-X
,	B-X
molecular	B-X
,	B-X
hemodynamic	B-X
and	B-X
morphologic	B-X
aspects	B-X
,	B-X
bicuspid	B-X
aortic	B-X
valve	B-X
related	B-X
aortopathy	B-X
still	B-X
represents	B-X
an	B-X
imperfectly	B-X
understood	B-X
disorder	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
provided	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
etiology	B-X
and	B-X
clinical	B-X
impacts	B-X
of	B-X
bicuspid	B-X
aortic	B-X
valve	B-X
related	B-X
aortopathy	B-X
in	B-X
different	B-X
clinical	B-X
settings	B-X
,	B-X
leading	B-X
to	B-X
a	B-X
growing	B-X
body	B-X
of	B-X
opinion	B-X
towards	B-X
a	B-X
more	B-X
individualized	B-X
surgical	B-X
approach	B-X
than	B-X
currently	B-X
provided	B-X
by	B-X
the	B-X
guidelines	B-X
.	B-X
Especially	B-X
valvular	B-X
hemodynamics-stenosis	B-X
and	B-X
regurgitation-seem	B-X
to	B-X
have	B-X
significant	B-X
impact	B-X
on	B-X
the	B-X
development	B-X
of	B-X
bicuspid	B-X
aortic	B-X
valve	B-X
related	B-X
aortopathy	B-X
.	B-X
In	B-X
this	B-X
context	B-X
,	B-X
there	B-X
is	B-X
evidence	B-X
that	B-X
regurgitation	B-X
of	B-X
bicuspid	B-X
aortic	B-X
valves	B-X
is	B-X
the	B-X
more	B-X
fatal	B-X
pathomechanism	B-X
.	B-X

Intravenous	O
pyelogram	O
,	O
oral	O
cholecystogram	O
,	O
cystoscopy	O
,	O
liver	O
-	O
spleen	O
scan	O
,	O
and	O
upper	O
and	O
lower	O
gastrointestinal	O
series	O
were	O
normal	O
except	O
for	O
a	O
few	O
sigmoid	O
diverticuli	O
.	O

Flexible	O
signoidoscopy	O
demonstrated	O
both	O
a	O
small	O
perianal	O
fissure	O
and	O
hemorrhoids	O
.	O

Blood	O
cultures	O
two	O
weeks	O
after	O
therapy	O
were	O
negative	O
.	O
<EOS>	B-X
The	B-X
treatment	B-X
consists	B-X
of	B-X
abscess	B-X
drainage	B-X
and	B-X
antimicrobial	B-X
therapy	B-X
.	B-X
We	B-X
also	B-X
analysed	B-X
sera	B-X
taken	B-X
acutely	B-X
and	B-X
at	B-X
least	B-X
two	B-X
weeks	B-X
after	B-X
surgery	B-X
for	B-X
the	B-X
presence	B-X
of	B-X
anti-FN	B-X
antibodies	B-X
.	B-X
We	B-X
found	B-X
increasing	B-X
levels	B-X
(	B-X
at	B-X
least	B-X
two-fold	B-X
)	B-X
of	B-X
anti-FN	B-X
antibodies	B-X
in	B-X
eight	B-X
of	B-X
11	B-X
FN-positive	B-X
(	B-X
in	B-X
the	B-X
tonsillar	B-X
cultures	B-X
)	B-X
PTA	B-X
patients	B-X
,	B-X
which	B-X
was	B-X
significantly	B-X
more	B-X
frequent	B-X
compared	B-X
to	B-X
none	B-X
of	B-X
four	B-X
FN-negative	B-X
PTA	B-X
patients	B-X
and	B-X
nine	B-X
of	B-X
47	B-X
electively	B-X
tonsillectomized	B-X
controls	B-X
(	B-X
P	B-X
=	B-X
0.026	B-X
and	B-X
P	B-X
<	B-X
0.001	B-X
,	B-X
respectively	B-X
)	B-X
.	B-X
Blood	B-X
cultures	B-X
obtained	B-X
during	B-X
acute	B-X
tonsillectomy	B-X
mirrored	B-X
the	B-X
bacterial	B-X
findings	B-X
in	B-X
the	B-X
tonsillar	B-X
specimens	B-X
with	B-X
22	B-X
%	B-X
of	B-X
patients	B-X
having	B-X
bacteremia	B-X
with	B-X
FN	B-X
.	B-X
The	B-X
results	B-X
of	B-X
our	B-X
routine	B-X
cultures	B-X
could	B-X
not	B-X
support	B-X
a	B-X
frequent	B-X
role	B-X
of	B-X
FN	B-X
in	B-X
PPA	B-X
.	B-X
Furthermore	B-X
,	B-X
cultures	B-X
made	B-X
from	B-X
PTA	B-X
aspirates	B-X
should	B-X
include	B-X
a	B-X
selective	B-X
FN-agar	B-X
plate	B-X
in	B-X
order	B-X
to	B-X
identify	B-X
growth	B-X
of	B-X
this	B-X
bacterium	B-X
.	B-X

Second	O
Admission	O
(	O
June	O
19	O
-	O
August	O
4	O
,	O
1981	O
)	O

In	O
June	O
1981	O
,	O
he	O
again	O
noted	O
intermittent	O
fever	O
,	O
night	O
sweats	O
,	O
and	O
fatigue	O
.	O

Group	O
D	O
streptococci	O
grew	O
from	O
three	O
sets	O
of	O
blood	O
cultures	O
and	O
he	O
was	O
admitted	O
to	O
the	O
West	O
Haven	O
VA	O
Medical	O
Center	O
for	O
recurrent	O
endocarditis	O
.	O

On	O
examination	O
a	O
somewhat	O
louder	O
apical	O
systolic	O
murmur	O
was	O
noted	O
.	O

The	O
ESR	O
was	O
50	O
mm	O
/	O
hour	O
and	O
rheumatoid	O
factor	O
titer	O
was	O
1	O
:	O
320	O
.	O

Serum	O
complement	O
levels	O
were	O
normal	O
and	O
cryoglobulins	O
were	O
not	O
detectable	O
.	O
<EOS>	B-X
Laboratory	B-X
investigations	B-X
were	B-X
normal	B-X
or	B-X
negative	B-X
,	B-X
including	B-X
complete	B-X
blood	B-X
cell	B-X
count	B-X
,	B-X
platelets	B-X
,	B-X
coagulation	B-X
indexes	B-X
,	B-X
erythrocyte	B-X
sedimentation	B-X
rate	B-X
,	B-X
serum	B-X
immunoglobulins	B-X
,	B-X
antinuclear	B-X
antibodies	B-X
,	B-X
anti-double-stranded	B-X
DNA	B-X
,	B-X
anticardiolipin	B-X
,	B-X
antiphospholipids	B-X
,	B-X
antineutrophilic	B-X
cytoplasmic	B-X
antibodies	B-X
,	B-X
circulating	B-X
immunocomplexes	B-X
,	B-X
complement	B-X
fractions	B-X
(	B-X
C3	B-X
,	B-X
C4	B-X
)	B-X
,	B-X
cryoglobulins	B-X
,	B-X
rheumatoid	B-X
factor	B-X
,	B-X
and	B-X
Rose-Waaler	B-X
reaction	B-X
.	B-X
The	B-X
only	B-X
laboratory	B-X
abnormality	B-X
was	B-X
an	B-X
elevated	B-X
fibrinogen	B-X
level	B-X
(	B-X
472	B-X
mg/dL	B-X
)	B-X
.	B-X
Thoracic	B-X
x-ray	B-X
and	B-X
abdominal	B-X
ultrasound	B-X
were	B-X
normal	B-X
.	B-X
Coeliac	B-X
disease	B-X
may	B-X
be	B-X
defined	B-X
as	B-X
a	B-X
condition	B-X
in	B-X
which	B-X
there	B-X
is	B-X
an	B-X
abnormal	B-X
jejunal	B-X
mucosa	B-X
with	B-X
loss	B-X
of	B-X
villi	B-X
,	B-X
which	B-X
improves	B-X
morphologically	B-X
after	B-X
treatment	B-X
with	B-X
a	B-X
gluten-free	B-X
diet	B-X
.	B-X
On	B-X
conventional	B-X
or	B-X
scanning	B-X
electron	B-X
microscopy	B-X
the	B-X
enterocytes	B-X
are	B-X
markedly	B-X
abnormal	B-X
.	B-X
Histochemically	B-X
,	B-X
the	B-X
normal	B-X
punctate	B-X
appearance	B-X
of	B-X
the	B-X
lysosomes	B-X
is	B-X
lost	B-X
and	B-X
sensitive	B-X
lysosomal	B-X
enzyme	B-X
assays	B-X
on	B-X
mucosal	B-X
biopsy	B-X
samples	B-X
using	B-X
isopycnic	B-X
centrifugation	B-X
techniques	B-X
show	B-X
that	B-X
there	B-X
is	B-X
an	B-X
increase	B-X
in	B-X
total	B-X
lysosomal	B-X
activity	B-X
with	B-X
reduction	B-X
in	B-X
lysosomal	B-X
latency	B-X
.	B-X
Studies	B-X
following	B-X
gluten	B-X
feeding	B-X
in	B-X
patients	B-X
whose	B-X
mucosa	B-X
has	B-X
returned	B-X
to	B-X
normal	B-X
after	B-X
treatment	B-X
with	B-X
a	B-X
gluten-free	B-X
diet	B-X
show	B-X
that	B-X
pathological	B-X
abnormalities	B-X
appear	B-X
within	B-X
4	B-X
--	B-X
8	B-X
hours	B-X
of	B-X
gluten	B-X
challenge	B-X
.	B-X
In	B-X
untreated	B-X
coeliac	B-X
disease	B-X
there	B-X
is	B-X
a	B-X
significant	B-X
reduction	B-X
in	B-X
serum	B-X
levels	B-X
of	B-X
C3	B-X
and	B-X
C4	B-X
.	B-X
Coeliac	B-X
disease	B-X
may	B-X
therefore	B-X
be	B-X
an	B-X
intestinal	B-X
model	B-X
of	B-X
an	B-X
immune	B-X
complex	B-X
disease	B-X
,	B-X
in	B-X
which	B-X
an	B-X
antigen	B-X
derived	B-X
from	B-X
gluten	B-X
reacts	B-X
with	B-X
an	B-X
antibody	B-X
formed	B-X
locally	B-X
in	B-X
the	B-X
gut	B-X
,	B-X
fixing	B-X
complement	B-X
and	B-X
causing	B-X
damage	B-X
to	B-X
the	B-X
enterocyte	B-X
by	B-X
activation	B-X
of	B-X
lysosomes	B-X
.	B-X

Chest	O
films	O
,	O
EKG	O
,	O
and	O
urinalysis	O
were	O
normal	O
.	O

Cardiac	O
M	O
-	O
mode	O
echocardiogram	O
revealed	O
a	O
globular	O
mass	O
attached	O
to	O
the	O
posterior	O
mitral	O
valve	O
leaflet	O
with	O
prolapse	O
into	O
a	O
slightly	O
enlarged	O
left	O
atrium	O
.	O

A	O
twodimensional	O
echocardiogram	O
confirmed	O
mitral	O
valve	O
prolapse	O
and	O
suggested	O
a	O
posterior	O
leaflet	O
vegetation	O
.	O

Gallium	O
citrate	O
scan	O
was	O
negative	O
.	O
<EOS>	B-X
Although	B-X
bone	B-X
scintigraphy	B-X
frequently	B-X
is	B-X
used	B-X
as	B-X
a	B-X
screening	B-X
test	B-X
,	B-X
false	B-X
negative	B-X
results	B-X
can	B-X
occur	B-X
early	B-X
in	B-X
the	B-X
course	B-X
of	B-X
the	B-X
infection	B-X
and	B-X
in	B-X
the	B-X
elderly	B-X
.	B-X
Gallium-67	B-X
citrate	B-X
improves	B-X
the	B-X
specificity	B-X
of	B-X
the	B-X
bone	B-X
scan	B-X
,	B-X
can	B-X
detect	B-X
infection	B-X
earlier	B-X
than	B-X
the	B-X
bone	B-X
scan	B-X
,	B-X
may	B-X
be	B-X
more	B-X
sensitive	B-X
,	B-X
especially	B-X
in	B-X
elderly	B-X
patients	B-X
,	B-X
and	B-X
identifies	B-X
accompanying	B-X
soft	B-X
tissue	B-X
infection	B-X
.	B-X
Whole-body	B-X
gallium	B-X
scan	B-X
was	B-X
performed	B-X
to	B-X
evaluate	B-X
the	B-X
usefulness	B-X
of	B-X
gallium	B-X
scan	B-X
for	B-X
detecting	B-X
extrapulmonary	B-X
tuberculosis	B-X
(	B-X
TB	B-X
)	B-X
lesions	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
compare	B-X
the	B-X
usefulness	B-X
of	B-X
gallium-67	B-X
citrate	B-X
(	B-X
67Ga	B-X
)	B-X
and	B-X
technetium-99m	B-X
tetrofosmin	B-X
(	B-X
Tc-TF	B-X
)	B-X
scan	B-X
to	B-X
detect	B-X
Hodgkin	B-X
's	B-X
disease	B-X
(	B-X
HD	B-X
)	B-X
.	B-X

Three	O
separate	O
morphologic	O
colony	O
variants	O
were	O
isolated	O
from	O
blood	O
,	O
each	O
identified	O
as	O
S	B-Species
.	I-Species
faecium	I-Species
by	O
Dr	O
.	O
R	O
.	O
R	O
.	O

Facklam	O
(	O
Center	O
for	O
Disease	O
Control	O
,	O
Atlanta	O
,	O
Georgia	O
)	O
.	O
<EOS>	B-X
These	B-X
strains	B-X
included	B-X
nine	B-X
strains	B-X
from	B-X
the	B-X
Centers	B-X
for	B-X
Disease	B-X
Control	B-X
Streptococcus	B-X
Laboratory	B-X
culture	B-X
collection	B-X
that	B-X
were	B-X
previously	B-X
included	B-X
in	B-X
comparative	B-X
16S	B-X
rRNA	B-X
gene	B-X
sequencing	B-X
studies	B-X
as	B-X
well	B-X
as	B-X
six	B-X
additional	B-X
phenotypically	B-X
variant	B-X
isolates	B-X
.	B-X
We	B-X
conducted	B-X
a	B-X
laboratory-based	B-X
surveillance	B-X
for	B-X
drug-resistant	B-X
S.	B-X
pneumoniae	B-X
among	B-X
patients	B-X
with	B-X
invasive	B-X
pneumococcal	B-X
infections	B-X
in	B-X
Atlanta	B-X
.	B-X
The	B-X
prevalence	B-X
increased	B-X
from	B-X
0.56	B-X
%	B-X
(	B-X
14	B-X
of	B-X
2,507	B-X
)	B-X
of	B-X
isolates	B-X
in	B-X
1995	B-X
to	B-X
0.87	B-X
%	B-X
in	B-X
2001	B-X
(	B-X
P	B-X
=	B-X
0.03	B-X
)	B-X
,	B-X
with	B-X
peaks	B-X
in	B-X
1996	B-X
and	B-X
2000	B-X
associated	B-X
with	B-X
epidemics	B-X
in	B-X
Georgia	B-X
and	B-X
Maryland	B-X
.	B-X
We	B-X
evaluated	B-X
three	B-X
rapid	B-X
identification	B-X
systems-The	B-X
Biomerieux	B-X
rapid	B-X
ID	B-X
32	B-X
STREP	B-X
(	B-X
ID32	B-X
)	B-X
,	B-X
the	B-X
BBL	B-X
Crystal	B-X
rapid	B-X
gram-positive	B-X
identification	B-X
(	B-X
Crystal	B-X
)	B-X
,	B-X
and	B-X
the	B-X
Remel	B-X
IDS	B-X
RapID	B-X
STR	B-X
(	B-X
IDS	B-X
)	B-X
systems-for	B-X
their	B-X
ability	B-X
to	B-X
identify	B-X
7	B-X
strains	B-X
of	B-X
Alloiococcus	B-X
otitidis	B-X
,	B-X
27	B-X
strains	B-X
of	B-X
Dolosigranulum	B-X
pigrum	B-X
,	B-X
3	B-X
strains	B-X
of	B-X
Ignavigranum	B-X
ruoffiae	B-X
,	B-X
and	B-X
18	B-X
strains	B-X
of	B-X
4	B-X
different	B-X
Facklamia	B-X
species	B-X
.	B-X
The	B-X
ID32	B-X
system	B-X
identified	B-X
all	B-X
27	B-X
strains	B-X
of	B-X
D.	B-X
pigrum	B-X
,	B-X
6	B-X
of	B-X
18	B-X
Facklamia	B-X
species	B-X
,	B-X
and	B-X
2	B-X
of	B-X
3	B-X
cultures	B-X
of	B-X
I.	B-X
ruoffiae	B-X
as	B-X
``	B-X
unacceptable	B-X
ID	B-X
.	B-X
''	B-X
The	B-X
Crystal	B-X
system	B-X
identified	B-X
10	B-X
of	B-X
27	B-X
D.	B-X
pigrum	B-X
,	B-X
2	B-X
of	B-X
18	B-X
Facklamia	B-X
species	B-X
,	B-X
and	B-X
2	B-X
of	B-X
3	B-X
I.	B-X
ruoffiae	B-X
strains	B-X
as	B-X
``	B-X
unacceptable	B-X
ID	B-X
.	B-X
''	B-X
A	B-X
total	B-X
of	B-X
2	B-X
of	B-X
the	B-X
18	B-X
cultures	B-X
of	B-X
Facklamia	B-X
and	B-X
all	B-X
3	B-X
of	B-X
the	B-X
I.	B-X
ruoffiae	B-X
cultures	B-X
were	B-X
correctly	B-X
identified	B-X
as	B-X
``	B-X
no	B-X
choice	B-X
.	B-X
''	B-X
The	B-X
most	B-X
common	B-X
misidentifications	B-X
of	B-X
Facklamia	B-X
species	B-X
by	B-X
the	B-X
ID32	B-X
and	B-X
IDS	B-X
systems	B-X
were	B-X
as	B-X
various	B-X
Streptococcus	B-X
species	B-X
and	B-X
as	B-X
Gemella	B-X
species	B-X
.	B-X

The	O
patient	B-Species
received	O
intravenous	O
penicillin	O
(	O
20	O
million	O
units	O
per	O
day	O
)	O
and	O
gentamicin	O
(	O
3	O
mg	O
per	O
kg	O
per	O
day	O
)	O
for	O
six	O
weeks	O
with	O
improvement	O
.	O

Peak	O
serum	O
bactericidal	O
titers	O
of	O
1	O
:	O
8	O
or	O
greater	O
were	O
achieved	O
against	O
two	O
of	O
the	O
colony	O
variants	O
;	O
however	O
,	O
against	O
the	O
large	O
colony	O
morphotype	O
,	O
a	O
titer	O
of	O
only	O
1	O
:	O
2	O
was	O
obtained	O
.	O
<EOS>	B-X
The	B-X
serum	B-X
bactericidal	B-X
test	B-X
(	B-X
SBT	B-X
)	B-X
has	B-X
been	B-X
used	B-X
for	B-X
almost	B-X
40	B-X
years	B-X
to	B-X
monitor	B-X
therapy	B-X
in	B-X
patients	B-X
with	B-X
bacterial	B-X
endocarditis	B-X
,	B-X
osteomyelitis	B-X
,	B-X
and	B-X
other	B-X
serious	B-X
infections	B-X
.	B-X
The	B-X
SBT	B-X
is	B-X
basically	B-X
a	B-X
variation	B-X
of	B-X
the	B-X
broth	B-X
dilution	B-X
test	B-X
adapted	B-X
to	B-X
assess	B-X
the	B-X
activity	B-X
of	B-X
a	B-X
treated	B-X
patient	B-X
's	B-X
own	B-X
serum	B-X
against	B-X
the	B-X
infecting	B-X
microorganism	B-X
.	B-X
Only	B-X
recently	B-X
,	B-X
however	B-X
,	B-X
have	B-X
rigorous	B-X
attempts	B-X
been	B-X
made	B-X
to	B-X
standardize	B-X
all	B-X
the	B-X
relevant	B-X
variables	B-X
that	B-X
affect	B-X
results	B-X
of	B-X
the	B-X
SBT	B-X
.	B-X
The	B-X
widely	B-X
recommended	B-X
goal	B-X
of	B-X
a	B-X
peak	B-X
bactericidal	B-X
titer	B-X
of	B-X
1:8	B-X
in	B-X
the	B-X
therapy	B-X
for	B-X
infective	B-X
endocarditis	B-X
may	B-X
be	B-X
inadequate	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
some	B-X
patients	B-X
.	B-X
Peak	B-X
titers	B-X
of	B-X
1:64	B-X
or	B-X
greater	B-X
in	B-X
the	B-X
microdilution	B-X
SBT	B-X
should	B-X
be	B-X
sought	B-X
if	B-X
they	B-X
can	B-X
be	B-X
achieved	B-X
without	B-X
toxicity	B-X
.	B-X
Titers	B-X
of	B-X
less	B-X
than	B-X
1:8	B-X
may	B-X
be	B-X
acceptable	B-X
,	B-X
although	B-X
they	B-X
are	B-X
less	B-X
often	B-X
successful	B-X
,	B-X
if	B-X
serious	B-X
toxicity	B-X
would	B-X
result	B-X
from	B-X
increased	B-X
dosage	B-X
.	B-X
Peak	B-X
SBT	B-X
titers	B-X
of	B-X
1:8	B-X
or	B-X
greater	B-X
yield	B-X
high	B-X
cure	B-X
rates	B-X
for	B-X
acute	B-X
osteomyelitis	B-X
in	B-X
children	B-X
;	B-X
data	B-X
are	B-X
limited	B-X
in	B-X
adults	B-X
.	B-X

An	O
enlarged	O
left	O
atrium	O
with	O
intermittent	O
fluttering	O
and	O
prolapse	O
of	O
the	O
mitral	O
valve	O
was	O
noted	O
on	O
echocardiography	O
three	O
weeks	O
into	O
therapy	O
.	O

Multiple	O
blood	O
cultures	O
taken	O
while	O
the	O
patient	B-Species
was	O
receiving	O
antibiotics	O
were	O
negative	O
,	O
as	O
were	O
those	O
obtained	O
48	O
and	O
72	O
hours	O
after	O
discontinuation	O
of	O
antibiotics	O
.	O

244	O
<EOS>	B-X
Cell	B-X
transformation	B-X
in	B-X
isolated	B-X
striated	B-X
muscle	B-X
of	B-X
hydromedusae	B-X
independent	B-X
of	B-X
DNA	B-X
synthesis	B-X
.	B-X

S	B-Species
.	I-Species
<EOS>	B-X
Finkelstein	B-X
's	B-X
Test	B-X
Is	B-X
Superior	B-X
to	B-X
Eichhoff	B-X
's	B-X
Test	B-X
in	B-X
the	B-X
Investigation	B-X
of	B-X
de	B-X
Quervain	B-X
's	B-X
Disease	B-X
.	B-X
Protein	B-X
S	B-X
deficiency	B-X
.	B-X
Letter	B-X
:	B-X
Craniometrics	B-X
and	B-X
Ventricular	B-X
Access	B-X
:	B-X
A	B-X
Review	B-X
of	B-X
Kocher	B-X
's	B-X
,	B-X
Kaufman	B-X
's	B-X
,	B-X
Paine	B-X
's	B-X
,	B-X
Menovksy	B-X
's	B-X
,	B-X
Tubbs	B-X
'	B-X
,	B-X
Keen	B-X
's	B-X
,	B-X
Frazier	B-X
's	B-X
,	B-X
Dandy	B-X
's	B-X
,	B-X
and	B-X
Sanchez	B-X
's	B-X
Points	B-X
.	B-X

FAECIUM	B-Species
ENDOCARDITIS	O

Third	O
Admission	O
(	O
August	O
12	O
-	O
October	O
4	O
,	O
1981	O
)	O

Withing	O
a	O
week	O
following	O
discharge	O
,	O
the	O
patient	B-Species
again	O
developed	O
fever	O
,	O
nocturnal	O
sweats	O
,	O
and	O
malaise	O
.	O

S	B-Species
.	I-Species
faecium	I-Species
(	O
large	O
colony	O
morphotype	O
,	O
and	O
poorly	O
growing	O
small	O
colony	O
morphotype	O
)	O
grew	O
from	O
six	O
sets	O
of	O
blood	O
cultures	O
obtained	O
on	O
admission	O
.	O

Penicillin	O
(	O
30	O
million	O
units	O
/	O
day	O
)	O
and	O
gentamicin	O
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
)	O
were	O
again	O
administered	O
,	O
initially	O
achieving	O
peak	O
serum	O
inhibitory	O
and	O
bactericidal	O
dilutions	O
of	O
1	O
:	O
16	O
and	O
1	O
:	O
8	O
against	O
the	O
organism	O
,	O
respectively	O
.	O

However	O
,	O
the	O
organism	O
had	O
a	O
lowlevel	O
resistance	O
to	O
streptomycin	O
(	O
MIC	O
<	O
125	O
/	O
Ag	O
/	O
ml	O
)	O
,	O
and	O
streptomycin	O
(	O
2	O
grams	O
per	O
day	O
)	O
was	O
substituted	O
for	O
gentamicin	O
two	O
weeks	O
into	O
antibiotic	O
therapy	O
.	O

Repeat	O
echocardiograms	O
showed	O
irregular	O
and	O
shaggy	O
densities	O
of	O
both	O
mitral	O
valve	O
leaflets	O
with	O
partial	O
prolapse	O
.	O

Cardiac	O
catheterization	O
demonstrated	O
marked	O
mitral	O
valve	O
prolapse	O
with	O
mitral	O
regurgitation	O
.	O
<EOS>	B-X
Group	B-X
I	B-X
included	B-X
25	B-X
patients	B-X
presenting	B-X
evidence	B-X
of	B-X
a	B-X
normal	B-X
left	B-X
ventricle	B-X
(	B-X
LV	B-X
)	B-X
after	B-X
left	B-X
heart	B-X
catheterization	B-X
.	B-X
Group	B-X
II	B-X
consisted	B-X
of	B-X
21	B-X
patients	B-X
suffering	B-X
from	B-X
an	B-X
isolated	B-X
pure	B-X
idiopathic	B-X
mitral	B-X
valve	B-X
prolapse	B-X
(	B-X
MVP	B-X
)	B-X
,	B-X
with	B-X
no	B-X
mitral	B-X
insufficiency	B-X
and	B-X
with	B-X
an	B-X
unaffected	B-X
global	B-X
LV	B-X
function	B-X
.	B-X
This	B-X
is	B-X
principally	B-X
marked	B-X
by	B-X
a	B-X
stronger	B-X
and	B-X
faster	B-X
contraction	B-X
in	B-X
anterolateral	B-X
segments	B-X
(	B-X
segments	B-X
7	B-X
,	B-X
8	B-X
,	B-X
9	B-X
)	B-X
and	B-X
by	B-X
a	B-X
shorter	B-X
duration	B-X
of	B-X
the	B-X
contraction	B-X
in	B-X
this	B-X
region	B-X
.	B-X
Angiographic	B-X
studies	B-X
demonstrating	B-X
alterations	B-X
in	B-X
left	B-X
ventricular	B-X
contraction	B-X
have	B-X
been	B-X
cited	B-X
as	B-X
evidence	B-X
that	B-X
isolated	B-X
mitral	B-X
valve	B-X
prolapse	B-X
(	B-X
MVP	B-X
)	B-X
may	B-X
be	B-X
associated	B-X
with	B-X
a	B-X
cardiomyopathy	B-X
.	B-X
We	B-X
studied	B-X
17	B-X
patients	B-X
with	B-X
isolated	B-X
MVP	B-X
undergoing	B-X
cardiac	B-X
catheterization	B-X
who	B-X
had	B-X
chest	B-X
pain	B-X
,	B-X
palpitations	B-X
,	B-X
and/or	B-X
a	B-X
murmur	B-X
of	B-X
mitral	B-X
regurgitation	B-X
.	B-X
Eleven	B-X
of	B-X
13	B-X
patients	B-X
(	B-X
85	B-X
%	B-X
)	B-X
with	B-X
no	B-X
or	B-X
mild	B-X
(	B-X
Grade	B-X
1+	B-X
)	B-X
mitral	B-X
regurgitation	B-X
had	B-X
normal	B-X
left	B-X
ventricular	B-X
hemodynamic	B-X
measurements	B-X
,	B-X
while	B-X
three	B-X
of	B-X
four	B-X
patients	B-X
(	B-X
75	B-X
%	B-X
)	B-X
with	B-X
moderate	B-X
or	B-X
marked	B-X
(	B-X
Grades	B-X
2+-4+	B-X
)	B-X
regurgitation	B-X
had	B-X
abnormal	B-X
left	B-X
ventricular	B-X
hemodynamic	B-X
measurements	B-X
.	B-X
Localization	B-X
of	B-X
alterations	B-X
in	B-X
contraction	B-X
predominantly	B-X
in	B-X
the	B-X
basal	B-X
and	B-X
mid-segments	B-X
of	B-X
the	B-X
left	B-X
ventricular	B-X
and	B-X
the	B-X
association	B-X
of	B-X
hemodynamic	B-X
abnormalities	B-X
with	B-X
mitral	B-X
regurgitation	B-X
suggest	B-X
that	B-X
changes	B-X
in	B-X
ventricular	B-X
contraction	B-X
are	B-X
primarily	B-X
related	B-X
to	B-X
an	B-X
alteration	B-X
of	B-X
mitral	B-X
valve	B-X
function	B-X
in	B-X
this	B-X
condition	B-X
.	B-X

A	O
radiolucent	O
filling	O
defect	O
was	O
noted	O
,	O
suggesting	O
a	O
coronary	O
artery	O
embolus	O
at	O
the	O
origin	O
of	O
the	O
left	O
anterior	O
descending	O
(	O
LAD	O
)	O
artery	O
,	O
causing	O
75	O
percent	O
occlusion	O
of	O
the	O
lumen	O
.	O

The	O
patient	B-Species
underwent	O
mitral	O
valve	O
replacement	O
,	O
receiving	O
a	O
number	O
31	O
porcine	O
Hancock	O
bioprosthesis	O
and	O
bypass	O
graft	O
to	O
the	O
midportion	O
of	O
the	O
LAD	O
.	O

The	O
mitral	O
valve	O
was	O
thickened	O
with	O
several	O
ruptured	O
chordae	O
of	O
the	O
posterior	O
leaflet	O
noted	O
,	O
but	O
no	O
vegetations	O
.	O

The	O
aortic	O
valve	O
appeared	O
normal	O
,	O
with	O
no	O
visible	O
septal	O
or	O
ring	O
abscesses	O
.	O
<EOS>	B-X
The	B-X
most	B-X
frequent	B-X
characteristics	B-X
are	B-X
focal	B-X
subacute	B-X
neurological	B-X
deficits	B-X
and	B-X
ring-enhancing	B-X
brain	B-X
lesions	B-X
in	B-X
the	B-X
basal	B-X
ganglia	B-X
,	B-X
but	B-X
the	B-X
spectrum	B-X
of	B-X
clinical	B-X
and	B-X
neuroradiological	B-X
manifestations	B-X
is	B-X
broad	B-X
.	B-X
Although	B-X
the	B-X
prognosis	B-X
of	B-X
brain	B-X
abscesses	B-X
has	B-X
historically	B-X
improved	B-X
,	B-X
the	B-X
mortality	B-X
rate	B-X
still	B-X
ranges	B-X
from	B-X
5	B-X
to	B-X
32	B-X
%	B-X
,	B-X
with	B-X
ventricular	B-X
perforation	B-X
reaching	B-X
50	B-X
%	B-X
and	B-X
85-100	B-X
%	B-X
in	B-X
fungal	B-X
brain	B-X
abscesses	B-X
.	B-X
The	B-X
characteristic	B-X
finding	B-X
of	B-X
ring-like	B-X
enhancement	B-X
by	B-X
contrast-enhanced	B-X
imaging	B-X
is	B-X
non-specific	B-X
,	B-X
and	B-X
DWI	B-X
,	B-X
SWI	B-X
and	B-X
MR	B-X
spectroscopy	B-X
are	B-X
very	B-X
useful	B-X
in	B-X
differentiating	B-X
brain	B-X
abcesses	B-X
from	B-X
necrotizing	B-X
brain	B-X
tumors	B-X
.	B-X
Brain	B-X
abscesses	B-X
show	B-X
apparent	B-X
diffusion	B-X
restriction	B-X
on	B-X
the	B-X
DWI/apparent	B-X
diffusion	B-X
coefficient	B-X
(	B-X
ADC	B-X
)	B-X
map	B-X
,	B-X
whereas	B-X
necrotizing	B-X
brain	B-X
tumors	B-X
often	B-X
show	B-X
a	B-X
weak	B-X
diffusion	B-X
restriction	B-X
.	B-X

The	O
occlusion	O
in	O
the	O
LAD	O
was	O
not	O
approached	O
to	O
avoid	O
embolizing	O
distal	O
fragments	O
.	O
<EOS>	B-X
Chronic	B-X
total	B-X
occlusions	B-X
(	B-X
CTOs	B-X
)	B-X
are	B-X
found	B-X
in	B-X
about	B-X
a	B-X
third	B-X
of	B-X
patients	B-X
with	B-X
coronary	B-X
artery	B-X
disease	B-X
(	B-X
CAD	B-X
)	B-X
and	B-X
can	B-X
pose	B-X
a	B-X
significant	B-X
challenge	B-X
during	B-X
percutaneous	B-X
revascularization	B-X
.	B-X
The	B-X
reported	B-X
positive	B-X
predictive	B-X
value	B-X
(	B-X
PPV	B-X
)	B-X
for	B-X
the	B-X
``	B-X
de	B-X
Winter	B-X
ECG	B-X
pattern	B-X
''	B-X
to	B-X
predict	B-X
an	B-X
acute	B-X
left	B-X
anterior	B-X
descending	B-X
artery	B-X
(	B-X
LAD	B-X
)	B-X
lesion	B-X
is	B-X
inconsistent	B-X
.	B-X
The	B-X
ECG	B-X
is	B-X
most	B-X
sensitive	B-X
in	B-X
patients	B-X
with	B-X
occlusion	B-X
of	B-X
the	B-X
LAD	B-X
artery	B-X
,	B-X
followed	B-X
by	B-X
the	B-X
RCA	B-X
and	B-X
the	B-X
left	B-X
CFA	B-X
.	B-X
Classic	B-X
ECG	B-X
changes	B-X
are	B-X
seen	B-X
in	B-X
90	B-X
%	B-X
of	B-X
the	B-X
LAD	B-X
artery	B-X
,	B-X
in	B-X
70	B-X
%	B-X
to	B-X
80	B-X
%	B-X
of	B-X
RCA	B-X
,	B-X
and	B-X
in	B-X
only	B-X
50	B-X
%	B-X
of	B-X
CFA	B-X
occlusions	B-X
.	B-X

Histopathologically	O
the	O
mitral	O
valve	O
showed	O
mild	O
fibrosis	O
and	O
myxoid	O
degeneration	O
without	O
inflammatory	O
changes	O
.	O

Bacterial	O
and	O
fungal	O
stains	O
were	O
negative	O
but	O
S	B-Species
.	I-Species
faecium	I-Species
grew	O
from	O
fragments	O
of	O
the	O
resected	O
valve	O
.	O

Following	O
surgery	O
the	O
patient	B-Species
received	O
six	O
additional	O
weeks	O
parenteral	O
penicillin	O
and	O
streptomycin	O
.	O

Repeat	O
blood	O
cultures	O
on	O
this	O
regimen	O
and	O
following	O
therapy	O
were	O
negative	O
.	O
<EOS>	B-X
Cryptococcal	B-X
meningitis	B-X
requires	B-X
antifungal	B-X
therapy	B-X
,	B-X
the	B-X
duration	B-X
of	B-X
which	B-X
varies	B-X
among	B-X
different	B-X
population	B-X
groups	B-X
.	B-X
Subsequent	B-X
blood	B-X
cultures	B-X
grew	B-X
Meropenem	B-X
,	B-X
a	B-X
broad-spectrum	B-X
carbapenem	B-X
,	B-X
is	B-X
commonly	B-X
used	B-X
for	B-X
empirical	B-X
and	B-X
definitive	B-X
therapy	B-X
in	B-X
the	B-X
pediatric	B-X
intensive	B-X
care	B-X
unit	B-X
(	B-X
ICU	B-X
)	B-X
.	B-X
Alterations	B-X
in	B-X
the	B-X
volume	B-X
of	B-X
distribution	B-X
and	B-X
clearance	B-X
of	B-X
antimicrobials	B-X
in	B-X
patients	B-X
with	B-X
sepsis	B-X
and	B-X
septic	B-X
shock	B-X
have	B-X
also	B-X
been	B-X
documented	B-X
,	B-X
and	B-X
these	B-X
patients	B-X
have	B-X
demonstrated	B-X
lower	B-X
than	B-X
expected	B-X
antimicrobial	B-X
serum	B-X
concentrations	B-X
based	B-X
on	B-X
standard	B-X
dosing	B-X
regimens	B-X
.	B-X
Therefore	B-X
,	B-X
an	B-X
understanding	B-X
of	B-X
the	B-X
pharmacokinetic	B-X
changes	B-X
in	B-X
critically	B-X
ill	B-X
children	B-X
receiving	B-X
ECMO	B-X
is	B-X
crucial	B-X
to	B-X
determining	B-X
the	B-X
most	B-X
appropriate	B-X
dose	B-X
and	B-X
dosing	B-X
interval	B-X
selection	B-X
for	B-X
any	B-X
antimicrobial	B-X
therapy	B-X
.	B-X
On	B-X
day	B-X
11	B-X
of	B-X
ECMO	B-X
,	B-X
a	B-X
bronchoalveolar	B-X
lavage	B-X
was	B-X
performed	B-X
,	B-X
and	B-X
blood	B-X
cultures	B-X
from	B-X
days	B-X
11	B-X
and	B-X
12	B-X
of	B-X
ECMO	B-X
grew	B-X
Pseudomonas	B-X
aeruginosa	B-X
,	B-X
with	B-X
a	B-X
meropenem	B-X
minimum	B-X
inhibitory	B-X
concentration	B-X
(	B-X
MIC	B-X
)	B-X
of	B-X
0.5	B-X
Î¼g/ml	B-X
.	B-X
Repeat	B-X
levels	B-X
were	B-X
measured	B-X
on	B-X
days	B-X
3	B-X
and	B-X
9	B-X
of	B-X
meropenem	B-X
therapy	B-X
and	B-X
were	B-X
39	B-X
and	B-X
42	B-X
Î¼g/ml	B-X
,	B-X
respectively	B-X
.	B-X
Repeat	B-X
blood	B-X
and	B-X
respiratory	B-X
cultures	B-X
remained	B-X
negative	B-X
.	B-X
This	B-X
meropenem	B-X
regimen	B-X
(	B-X
40-mg/kg	B-X
bolus	B-X
followed	B-X
by	B-X
a	B-X
continuous	B-X
infusion	B-X
of	B-X
200	B-X
mg/kg/day	B-X
)	B-X
was	B-X
successful	B-X
in	B-X
providing	B-X
a	B-X
target	B-X
attainment	B-X
of	B-X
100	B-X
%	B-X
for	B-X
serum	B-X
and	B-X
lung	B-X
concentrations	B-X
above	B-X
the	B-X
MIC	B-X
for	B-X
at	B-X
least	B-X
40	B-X
%	B-X
of	B-X
the	B-X
dosing	B-X
interval	B-X
and	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
successful	B-X
clinical	B-X
outcome	B-X
.	B-X

Evaluation	O
six	O
months	O
following	O
discontinuation	O
of	O
antibiotics	O
showed	O
no	O
evidence	O
of	O
recurrent	O
endocarditis	O
.	O

LABORATORY	O
EVALUATION	O
<EOS>	B-X
Evaluation	B-X
of	B-X
the	B-X
impact	B-X
of	B-X
laboratory	B-X
accreditation	B-X
on	B-X
downstream	B-X
outcomes	B-X
.	B-X
Evaluation	B-X
of	B-X
laboratory	B-X
tests	B-X
.	B-X

The	O
minimum	O
inhibitory	O
and	O
bactericidal	O
concentrations	O
of	O
penicillin	O
,	O
ampicillin	O
,	O
and	O
tobramycin	O
against	O
the	O
S	B-Species
.	I-Species
faecium	I-Species
isolated	O
from	O
the	O
patient	B-Species
'	O
s	O
blood	O
cultures	O

TABLE	O
1	O
<EOS>	B-X
If	B-X
well-executed	B-X
,	B-X
this	B-X
``	B-X
Table	B-X
1	B-X
''	B-X
can	B-X
illuminate	B-X
potential	B-X
threats	B-X
to	B-X
internal	B-X
and	B-X
external	B-X
validity	B-X
.	B-X
However	B-X
,	B-X
little	B-X
guidance	B-X
exists	B-X
on	B-X
best	B-X
practices	B-X
for	B-X
designing	B-X
a	B-X
Table	B-X
1	B-X
,	B-X
especially	B-X
for	B-X
complex	B-X
study	B-X
designs	B-X
and	B-X
analyses	B-X
.	B-X
The	B-X
present	B-X
chapter	B-X
describes	B-X
isolation	B-X
,	B-X
biogenetic	B-X
proposals	B-X
,	B-X
and	B-X
syntheses	B-X
of	B-X
the	B-X
natural	B-X
products	B-X
1-4	B-X
and	B-X
10-11	B-X
with	B-X
a	B-X
pyrrolo	B-X
[	B-X
2,1-a	B-X
]	B-X
-isoquinoline	B-X
framework	B-X
.	B-X
The	B-X
pyrrolo	B-X
[	B-X
2,1-a	B-X
]	B-X
isoquinolines	B-X
are	B-X
of	B-X
interest	B-X
due	B-X
to	B-X
their	B-X
promising	B-X
biological	B-X
activities	B-X
.	B-X
For	B-X
crispine	B-X
A	B-X
(	B-X
1	B-X
)	B-X
,	B-X
many	B-X
total	B-X
syntheses	B-X
have	B-X
been	B-X
reported	B-X
and	B-X
for	B-X
trolline	B-X
(	B-X
3	B-X
)	B-X
,	B-X
only	B-X
three	B-X
.	B-X
Only	B-X
one	B-X
total	B-X
synthesis	B-X
has	B-X
been	B-X
reported	B-X
for	B-X
each	B-X
of	B-X
the	B-X
following	B-X
natural	B-X
products	B-X
:	B-X
peyoglutam	B-X
(	B-X
10	B-X
)	B-X
,	B-X
mescalotam	B-X
(	B-X
11	B-X
)	B-X
,	B-X
and	B-X
the	B-X
antitumor	B-X
active	B-X
crispine	B-X
B	B-X
(	B-X
2	B-X
)	B-X
.	B-X
Some	B-X
of	B-X
the	B-X
pyrrolo	B-X
[	B-X
2,1-a	B-X
]	B-X
isoquinoline	B-X
alkaloids	B-X
have	B-X
not	B-X
been	B-X
synthesized	B-X
yet	B-X
.	B-X
The	B-X
following	B-X
three	B-X
tables	B-X
summarize	B-X
the	B-X
synthetic	B-X
efforts	B-X
toward	B-X
crispine	B-X
A	B-X
(	B-X
1	B-X
)	B-X
(	B-X
Table	B-X
1	B-X
:	B-X
racemic	B-X
syntheses	B-X
;	B-X
Table	B-X
2	B-X
:	B-X
enantioselective	B-X
syntheses	B-X
)	B-X
and	B-X
trolline	B-X
(	B-X
3	B-X
)	B-X
(	B-X
Table	B-X
3	B-X
)	B-X
.	B-X

Minimum	O
Inhibitory	O
and	O
Bactericidal	O
Concentrations	O
of	O
Antibiotics	O
,	O
<EOS>	B-X
Minimum	B-X
inhibitory	B-X
concentrations	B-X
(	B-X
MICs	B-X
)	B-X
are	B-X
defined	B-X
as	B-X
the	B-X
lowest	B-X
concentration	B-X
of	B-X
an	B-X
antimicrobial	B-X
that	B-X
will	B-X
inhibit	B-X
the	B-X
visible	B-X
growth	B-X
of	B-X
a	B-X
microorganism	B-X
after	B-X
overnight	B-X
incubation	B-X
,	B-X
and	B-X
minimum	B-X
bactericidal	B-X
concentrations	B-X
(	B-X
MBCs	B-X
)	B-X
as	B-X
the	B-X
lowest	B-X
concentration	B-X
of	B-X
antimicrobial	B-X
that	B-X
will	B-X
prevent	B-X
the	B-X
growth	B-X
of	B-X
an	B-X
organism	B-X
after	B-X
subculture	B-X
on	B-X
to	B-X
antibiotic-free	B-X
media	B-X
.	B-X
Antibiotics	B-X
are	B-X
often	B-X
prescribed	B-X
in	B-X
acne	B-X
treatment	B-X
;	B-X
however	B-X
,	B-X
Determination	B-X
of	B-X
minimum	B-X
inhibitory	B-X
and	B-X
minimum	B-X
bactericidal	B-X
concentrations	B-X
of	B-X
Brazilian	B-X
strains	B-X
of	B-X
Minimum	B-X
inhibitory	B-X
and	B-X
bactericidal	B-X
concentrations	B-X
of	B-X
various	B-X
antibiotics	B-X
were	B-X
determined	B-X
for	B-X
90	B-X
strains	B-X
of	B-X
five	B-X
organisms	B-X
by	B-X
Sensititre	B-X
and	B-X
compared	B-X
with	B-X
those	B-X
obtained	B-X
by	B-X
conventional	B-X
methods	B-X
.	B-X

Against	O
Streptococcus	B-Species
faecium	I-Species
Isolates	O
from	O
Blood	O
Cultures	O
<EOS>	B-X
The	B-X
combination	B-X
of	B-X
the	B-X
new	B-X
glycopeptide	B-X
LY264826	B-X
and	B-X
gentamicin	B-X
was	B-X
compared	B-X
with	B-X
the	B-X
combination	B-X
of	B-X
vancomycin	B-X
and	B-X
gentamicin	B-X
against	B-X
30	B-X
strains	B-X
of	B-X
enterococci	B-X
,	B-X
comprising	B-X
20	B-X
strains	B-X
of	B-X
Enterococcus	B-X
faecalis	B-X
,	B-X
five	B-X
strains	B-X
of	B-X
Enterococcus	B-X
faecium	B-X
and	B-X
five	B-X
strains	B-X
of	B-X
Enterococcus	B-X
avium	B-X
,	B-X
isolated	B-X
from	B-X
blood	B-X
cultures	B-X
.	B-X
LY264826	B-X
plus	B-X
gentamicin	B-X
was	B-X
synergic	B-X
against	B-X
E.	B-X
faecalis	B-X
and	B-X
E.	B-X
faecium	B-X
,	B-X
but	B-X
not	B-X
against	B-X
E.	B-X
avium	B-X
.	B-X
The	B-X
minimal	B-X
inhibitory	B-X
(	B-X
MICs	B-X
)	B-X
and	B-X
bactericidal	B-X
concentrations	B-X
of	B-X
14	B-X
antimicrobial	B-X
drugs	B-X
were	B-X
determined	B-X
against	B-X
17	B-X
clinical	B-X
isolates	B-X
of	B-X
Enterococcus	B-X
faecium	B-X
,	B-X
including	B-X
4	B-X
glycopeptide-resistant	B-X
strains	B-X
.	B-X
However	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
human	B-X
blood	B-X
,	B-X
rifampin	B-X
(	B-X
2	B-X
micrograms/ml	B-X
)	B-X
combined	B-X
with	B-X
co-trimoxazole	B-X
(	B-X
0.25/4.75	B-X
micrograms/ml	B-X
)	B-X
killed	B-X
rifampin-susceptible	B-X
and	B-X
low-level-rifampin-resistant	B-X
,	B-X
but	B-X
not	B-X
moderate-level-rifampin-resistant	B-X
(	B-X
MICs	B-X
=	B-X
16-32	B-X
micrograms/ml	B-X
)	B-X
strains	B-X
of	B-X
E.	B-X
faecium	B-X
.	B-X
Of	B-X
two	B-X
topical	B-X
drugs	B-X
examined	B-X
,	B-X
mupirocin	B-X
merely	B-X
inhibited	B-X
strains	B-X
of	B-X
E.	B-X
faecium	B-X
;	B-X
conversely	B-X
,	B-X
taurolidine	B-X
at	B-X
2,000	B-X
micrograms/ml	B-X
was	B-X
efficacious	B-X
against	B-X
all	B-X
strains	B-X
examined	B-X
,	B-X
although	B-X
the	B-X
kinetics	B-X
of	B-X
bactericidal	B-X
activity	B-X
were	B-X
retarded	B-X
somewhat	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
65	B-X
vol	B-X
%	B-X
human	B-X
blood	B-X
.	B-X

Date	O
Penicillin	O
Ampicillin	O
Tobramycin	O
<EOS>	B-X
In	B-X
spite	B-X
of	B-X
different	B-X
modes	B-X
of	B-X
actions	B-X
,	B-X
a	B-X
number	B-X
of	B-X
antibiotics	B-X
such	B-X
as	B-X
,	B-X
Ampicillin	B-X
,	B-X
Carbenicillin	B-X
,	B-X
Penicillin	B-X
,	B-X
Cefalexin	B-X
,	B-X
Rifampicin	B-X
and	B-X
Sulfadimethoxine	B-X
were	B-X
all	B-X
highly	B-X
effective	B-X
in	B-X
eliminating	B-X
or	B-X
suppressing	B-X
Candidatus	B-X
Liberibacter	B-X
asiaticus	B-X
indicated	B-X
by	B-X
both	B-X
the	B-X
lowest	B-X
Las	B-X
infection	B-X
rate	B-X
and	B-X
titers	B-X
of	B-X
the	B-X
treated	B-X
scions	B-X
and	B-X
inoculated	B-X
rootstock	B-X
.	B-X
The	B-X
non-effective	B-X
group	B-X
,	B-X
including	B-X
11	B-X
antibiotics	B-X
alone	B-X
with	B-X
three	B-X
controls	B-X
,	B-X
such	B-X
as	B-X
Amikacin	B-X
,	B-X
Cinoxacin	B-X
,	B-X
Gentamicin	B-X
,	B-X
Kasugamycin	B-X
,	B-X
Lincomycin	B-X
,	B-X
Neomycin	B-X
,	B-X
Polymixin	B-X
B	B-X
and	B-X
Tobramycin	B-X
,	B-X
did	B-X
not	B-X
eliminate	B-X
or	B-X
suppress	B-X
Las	B-X
in	B-X
the	B-X
tested	B-X
concentrations	B-X
,	B-X
resulting	B-X
in	B-X
plants	B-X
with	B-X
increased	B-X
titers	B-X
of	B-X
Las	B-X
.	B-X

Organism	O
Isolated	O
MIC	O
MIC	O
MBC	O
MIC	O
MBC	O
S	B-Species
.	I-Species
faecium	I-Species
,	O
prior	O
to	O
ampicillin	O
/	O

tobramycin	O
therapy	O
3	O
/	O
17	O
/	O
81	O
2	O
1	O
2	O
>	O
32	O
>	O
32	O
S	B-Species
.	I-Species
faecium	I-Species
,	O
after	O
ampicillin	O
/	O

tobramycin	O
therapy	O
<EOS>	B-X
In	B-X
placebo-controlled	B-X
and	B-X
comparative	B-X
studies	B-X
with	B-X
traditional	B-X
tobramycin	B-X
formulations	B-X
,	B-X
TIP	B-X
is	B-X
equally	B-X
efficacious	B-X
and	B-X
is	B-X
associated	B-X
with	B-X
increased	B-X
patient	B-X
convenience	B-X
and	B-X
satisfaction	B-X
.	B-X
TIP	B-X
has	B-X
been	B-X
recommended	B-X
in	B-X
the	B-X
2013	B-X
CF	B-X
Foundation	B-X
and	B-X
the	B-X
2014	B-X
European	B-X
guidelines	B-X
as	B-X
a	B-X
therapy	B-X
in	B-X
CF	B-X
for	B-X
the	B-X
maintenance	B-X
of	B-X
lung	B-X
health	B-X
.	B-X
Going	B-X
forward	B-X
,	B-X
TIP	B-X
may	B-X
offer	B-X
a	B-X
therapeutic	B-X
advantage	B-X
over	B-X
traditional	B-X
formulations	B-X
of	B-X
tobramycin	B-X
as	B-X
recent	B-X
prospective	B-X
'real	B-X
world	B-X
'	B-X
studies	B-X
of	B-X
TIP	B-X
have	B-X
demonstrated	B-X
high	B-X
patient	B-X
tolerance	B-X
and	B-X
improved	B-X
adherence	B-X
compared	B-X
with	B-X
traditional	B-X
formulations	B-X
.	B-X
Nowadays	B-X
,	B-X
antimicrobial	B-X
resistance	B-X
(	B-X
AMR	B-X
)	B-X
represents	B-X
a	B-X
challenge	B-X
for	B-X
antibiotic	B-X
therapy	B-X
,	B-X
mostly	B-X
involving	B-X
Gram-negative	B-X
bacteria	B-X
.	B-X

a	O
.	O

Large	O
colony	O
<EOS>	B-X
To	B-X
understand	B-X
the	B-X
molecular	B-X
distinction	B-X
for	B-X
the	B-X
different	B-X
growth	B-X
rates	B-X
,	B-X
we	B-X
performed	B-X
whole	B-X
genome	B-X
sequencing	B-X
(	B-X
WGS	B-X
)	B-X
analysis	B-X
of	B-X
the	B-X
large	B-X
and	B-X
small	B-X
colony	B-X
mutants	B-X
generated	B-X
from	B-X
the	B-X
MLA	B-X
.	B-X
Three	B-X
large	B-X
colony	B-X
and	B-X
three	B-X
small	B-X
colony	B-X
mutants	B-X
generated	B-X
from	B-X
cells	B-X
treated	B-X
with	B-X
4-nitroquinoline	B-X
1-oxide	B-X
(	B-X
4-NQO	B-X
)	B-X
or	B-X
the	B-X
vehicle	B-X
control	B-X
were	B-X
selected	B-X
for	B-X
analysis	B-X
.	B-X
Although	B-X
there	B-X
were	B-X
LOH	B-X
alterations	B-X
in	B-X
both	B-X
large	B-X
and	B-X
small	B-X
colony	B-X
mutants	B-X
,	B-X
copy	B-X
number	B-X
changes	B-X
near	B-X
Tk	B-X
locus	B-X
were	B-X
found	B-X
only	B-X
in	B-X
small	B-X
colony	B-X
mutants	B-X
produced	B-X
by	B-X
the	B-X
vehicle	B-X
control	B-X
and	B-X
4-NQO	B-X
treatments	B-X
.	B-X
The	B-X
chromosome	B-X
copy	B-X
number	B-X
in	B-X
the	B-X
regions	B-X
near	B-X
the	B-X
Tk	B-X
locus	B-X
increased	B-X
from	B-X
two	B-X
to	B-X
three	B-X
or	B-X
four	B-X
in	B-X
the	B-X
spontaneous	B-X
small	B-X
colony	B-X
mutants	B-X
and	B-X
decreased	B-X
from	B-X
two	B-X
to	B-X
one	B-X
in	B-X
the	B-X
4-NQO-induced	B-X
small	B-X
colony	B-X
mutants	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
chromosome	B-X
damage	B-X
was	B-X
repaired	B-X
differently	B-X
in	B-X
the	B-X
large	B-X
and	B-X
small	B-X
colony	B-X
mutants	B-X
,	B-X
resulting	B-X
in	B-X
significant	B-X
chromosome	B-X
alterations	B-X
in	B-X
the	B-X
small	B-X
colony	B-X
mutants	B-X
,	B-X
but	B-X
not	B-X
in	B-X
the	B-X
large	B-X
colony	B-X
mutants	B-X
.	B-X
Thus	B-X
,	B-X
chromosome	B-X
alterations	B-X
near	B-X
the	B-X
Tk	B-X
locus	B-X
may	B-X
play	B-X
a	B-X
major	B-X
role	B-X
in	B-X
the	B-X
inhibition	B-X
of	B-X
cell	B-X
growth	B-X
in	B-X
the	B-X
Tk	B-X
small	B-X
colony	B-X
mutants	B-X
.	B-X

variant	O
6	O
/	O
16	O
/	O
81	O
2	O
1	O
1	O
>	O
32	O
>	O
32	O
b	O
.	O
<EOS>	B-X
Knowing	B-X
whether	B-X
COVID-19	B-X
vaccine	B-X
effectiveness	B-X
wanes	B-X
is	B-X
crucial	B-X
for	B-X
informing	B-X
vaccine	B-X
policy	B-X
,	B-X
such	B-X
as	B-X
the	B-X
need	B-X
for	B-X
and	B-X
timing	B-X
of	B-X
booster	B-X
doses	B-X
.	B-X
We	B-X
aimed	B-X
to	B-X
systematically	B-X
review	B-X
the	B-X
evidence	B-X
for	B-X
the	B-X
duration	B-X
of	B-X
protection	B-X
of	B-X
COVID-19	B-X
vaccines	B-X
against	B-X
various	B-X
clinical	B-X
outcomes	B-X
,	B-X
and	B-X
to	B-X
assess	B-X
changes	B-X
in	B-X
the	B-X
rates	B-X
of	B-X
breakthrough	B-X
infection	B-X
caused	B-X
by	B-X
the	B-X
delta	B-X
variant	B-X
with	B-X
increasing	B-X
time	B-X
since	B-X
vaccination	B-X
.	B-X
With	B-X
the	B-X
surge	B-X
of	B-X
new	B-X
SARS-CoV-2	B-X
variants	B-X
,	B-X
countries	B-X
have	B-X
begun	B-X
offering	B-X
COVID-19	B-X
vaccine	B-X
booster	B-X
doses	B-X
to	B-X
high-risk	B-X
groups	B-X
and	B-X
,	B-X
more	B-X
recently	B-X
,	B-X
to	B-X
the	B-X
adult	B-X
population	B-X
in	B-X
general	B-X
.	B-X
However	B-X
,	B-X
uncertainty	B-X
remains	B-X
over	B-X
how	B-X
long	B-X
primary	B-X
vaccination	B-X
series	B-X
remain	B-X
effective	B-X
,	B-X
the	B-X
ideal	B-X
timing	B-X
for	B-X
booster	B-X
doses	B-X
,	B-X
and	B-X
the	B-X
safety	B-X
of	B-X
heterologous	B-X
booster	B-X
regimens	B-X
.	B-X
We	B-X
aimed	B-X
to	B-X
investigate	B-X
COVID-19	B-X
primary	B-X
vaccine	B-X
series	B-X
effectiveness	B-X
and	B-X
its	B-X
waning	B-X
,	B-X
and	B-X
the	B-X
safety	B-X
and	B-X
effectiveness	B-X
of	B-X
booster	B-X
doses	B-X
,	B-X
in	B-X
a	B-X
UK	B-X
community	B-X
setting	B-X
.	B-X

Medium	O
colony	O
<EOS>	B-X
All	B-X
of	B-X
the	B-X
colony-stimulating	B-X
activity	B-X
was	B-X
coincident	B-X
with	B-X
the	B-X
protein	B-X
band	B-X
.	B-X
The	B-X
molecular	B-X
weight	B-X
of	B-X
colony-stimulating	B-X
factor	B-X
estimated	B-X
by	B-X
gel	B-X
filtration	B-X
was	B-X
approximately	B-X
29,000	B-X
and	B-X
by	B-X
electrophoresis	B-X
approximately	B-X
23,000	B-X
.	B-X
The	B-X
specific	B-X
activity	B-X
of	B-X
purified	B-X
colony-stimulating	B-X
factor	B-X
from	B-X
mouse	B-X
lung-conditioned	B-X
medium	B-X
bound	B-X
to	B-X
concanavalin	B-X
A-Sapharose	B-X
,	B-X
indicating	B-X
that	B-X
it	B-X
is	B-X
a	B-X
glycoprotein	B-X
.	B-X
The	B-X
small	B-X
percentage	B-X
of	B-X
colony-stimulating	B-X
factor	B-X
in	B-X
mouse	B-X
lung-conditioned	B-X
medium	B-X
which	B-X
did	B-X
not	B-X
bind	B-X
to	B-X
concanavalin	B-X
A-Sepharose	B-X
appeared	B-X
to	B-X
represent	B-X
molecules	B-X
which	B-X
lacked	B-X
the	B-X
carbohydrate	B-X
moieties	B-X
required	B-X
for	B-X
binding	B-X
to	B-X
this	B-X
lectin	B-X
.	B-X
It	B-X
was	B-X
necessary	B-X
to	B-X
include	B-X
low	B-X
concentrations	B-X
(	B-X
less	B-X
than	B-X
0.01	B-X
%	B-X
,	B-X
v/v	B-X
)	B-X
of	B-X
polymers	B-X
such	B-X
as	B-X
gelatin	B-X
and	B-X
polyethylene	B-X
glycol	B-X
,	B-X
or	B-X
nonionic	B-X
detergents	B-X
such	B-X
as	B-X
Triton	B-X
X-100	B-X
,	B-X
in	B-X
all	B-X
of	B-X
the	B-X
buffers	B-X
used	B-X
throughout	B-X
the	B-X
purification	B-X
scheme	B-X
,	B-X
otherwise	B-X
colony-stimulating	B-X
factor	B-X
was	B-X
lost	B-X
from	B-X
solution	B-X
.	B-X
As	B-X
the	B-X
concentration	B-X
of	B-X
purified	B-X
colony-stimulating	B-X
factor	B-X
was	B-X
decreased	B-X
,	B-X
the	B-X
frequency	B-X
of	B-X
colonies	B-X
containing	B-X
granulocytes	B-X
also	B-X
decreased	B-X
.	B-X
At	B-X
low	B-X
concentrations	B-X
of	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
less	B-X
than	B-X
70	B-X
pg/ml	B-X
)	B-X
only	B-X
macrophage	B-X
colonies	B-X
were	B-X
stimulated	B-X
.	B-X

variant	O
6	O
/	O
16	O
/	O
81	O
2	O
1	O
2	O
32	O
32	O
c	O
.	O
<EOS>	B-X
Information	B-X
regarding	B-X
the	B-X
protection	B-X
conferred	B-X
by	B-X
vaccination	B-X
and	B-X
previous	B-X
infection	B-X
against	B-X
infection	B-X
with	B-X
the	B-X
B.1.1.529	B-X
(	B-X
omicron	B-X
)	B-X
variant	B-X
of	B-X
severe	B-X
acute	B-X
respiratory	B-X
syndrome	B-X
coronavirus	B-X
2	B-X
(	B-X
SARS-CoV-2	B-X
)	B-X
is	B-X
limited	B-X
.	B-X
Background	B-X
Five	B-X
classic	B-X
thrombophilias	B-X
have	B-X
been	B-X
recognized	B-X
:	B-X
factor	B-X
V	B-X
Leiden	B-X
(	B-X
rs6025	B-X
)	B-X
,	B-X
the	B-X
prothrombin	B-X
G20210A	B-X
variant	B-X
(	B-X
rs1799963	B-X
)	B-X
,	B-X
and	B-X
protein	B-X
C	B-X
,	B-X
protein	B-X
S	B-X
,	B-X
and	B-X
antithrombin	B-X
deficiencies	B-X
.	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
determine	B-X
the	B-X
thrombotic	B-X
risk	B-X
of	B-X
classic	B-X
thrombophilias	B-X
in	B-X
a	B-X
cohort	B-X
of	B-X
middle-aged	B-X
and	B-X
older	B-X
adults	B-X
.	B-X
Methods	B-X
and	B-X
Results	B-X
Factor	B-X
V	B-X
Leiden	B-X
,	B-X
prothrombin	B-X
G20210A	B-X
and	B-X
protein-coding	B-X
variants	B-X
in	B-X
the	B-X

Small	O
colony	O
<EOS>	B-X
Small	B-X
extracellular	B-X
vesicles	B-X
(	B-X
sEVs	B-X
)	B-X
secreted	B-X
by	B-X
mesenchymal	B-X
stem	B-X
cells	B-X
(	B-X
MSCs	B-X
)	B-X
have	B-X
been	B-X
extensively	B-X
studied	B-X
in	B-X
recent	B-X
years	B-X
.	B-X
RNA-sequencing	B-X
analysis	B-X
indicates	B-X
that	B-X
high	B-X
miR-27b-3p	B-X
expression	B-X
levels	B-X
in	B-X
IAE	B-X
may	B-X
regulate	B-X
macrophages	B-X
by	B-X
targeting	B-X
macrophage	B-X
colony-stimulating	B-X
factor-1	B-X
(	B-X
CSF-1	B-X
)	B-X
.	B-X
These	B-X
organisms	B-X
grow	B-X
slowly	B-X
and	B-X
are	B-X
typical	B-X
of	B-X
the	B-X
previously	B-X
described	B-X
small	B-X
colony	B-X
variants	B-X
(	B-X
SCVs	B-X
)	B-X
.	B-X
To	B-X
understand	B-X
the	B-X
molecular	B-X
distinction	B-X
for	B-X
the	B-X
different	B-X
growth	B-X
rates	B-X
,	B-X
we	B-X
performed	B-X
whole	B-X
genome	B-X
sequencing	B-X
(	B-X
WGS	B-X
)	B-X
analysis	B-X
of	B-X
the	B-X
large	B-X
and	B-X
small	B-X
colony	B-X
mutants	B-X
generated	B-X
from	B-X
the	B-X
MLA	B-X
.	B-X
Three	B-X
large	B-X
colony	B-X
and	B-X
three	B-X
small	B-X
colony	B-X
mutants	B-X
generated	B-X
from	B-X
cells	B-X
treated	B-X
with	B-X
4-nitroquinoline	B-X
1-oxide	B-X
(	B-X
4-NQO	B-X
)	B-X
or	B-X
the	B-X
vehicle	B-X
control	B-X
were	B-X
selected	B-X
for	B-X
analysis	B-X
.	B-X
Although	B-X
there	B-X
were	B-X
LOH	B-X
alterations	B-X
in	B-X
both	B-X
large	B-X
and	B-X
small	B-X
colony	B-X
mutants	B-X
,	B-X
copy	B-X
number	B-X
changes	B-X
near	B-X
Tk	B-X
locus	B-X
were	B-X
found	B-X
only	B-X
in	B-X
small	B-X
colony	B-X
mutants	B-X
produced	B-X
by	B-X
the	B-X
vehicle	B-X
control	B-X
and	B-X
4-NQO	B-X
treatments	B-X
.	B-X
The	B-X
chromosome	B-X
copy	B-X
number	B-X
in	B-X
the	B-X
regions	B-X
near	B-X
the	B-X
Tk	B-X
locus	B-X
increased	B-X
from	B-X
two	B-X
to	B-X
three	B-X
or	B-X
four	B-X
in	B-X
the	B-X
spontaneous	B-X
small	B-X
colony	B-X
mutants	B-X
and	B-X
decreased	B-X
from	B-X
two	B-X
to	B-X
one	B-X
in	B-X
the	B-X
4-NQO-induced	B-X
small	B-X
colony	B-X
mutants	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
chromosome	B-X
damage	B-X
was	B-X
repaired	B-X
differently	B-X
in	B-X
the	B-X
large	B-X
and	B-X
small	B-X
colony	B-X
mutants	B-X
,	B-X
resulting	B-X
in	B-X
significant	B-X
chromosome	B-X
alterations	B-X
in	B-X
the	B-X
small	B-X
colony	B-X
mutants	B-X
,	B-X
but	B-X
not	B-X
in	B-X
the	B-X
large	B-X
colony	B-X
mutants	B-X
.	B-X
Thus	B-X
,	B-X
chromosome	B-X
alterations	B-X
near	B-X
the	B-X
Tk	B-X
locus	B-X
may	B-X
play	B-X
a	B-X
major	B-X
role	B-X
in	B-X
the	B-X
inhibition	B-X
of	B-X
cell	B-X
growth	B-X
in	B-X
the	B-X
Tk	B-X
small	B-X
colony	B-X
mutants	B-X
.	B-X

variant	O
6	O
/	O
16	O
/	O
81	O
4	O
2	O
4	O
>	O
32	O
>	O
32	O
aMIC	O
and	O
MBC	O
are	O
minimum	O
inhibitory	O
and	O
bactericidal	O
concentrations	O
of	O
antibiotics	O
,	O
respectively	O
,	O
in	O
tig	O
/	O
ml	O
.	O

245	O
<EOS>	B-X
Induction	B-X
of	B-X
DNA	B-X
synthesis	B-X
by	B-X
dichloroisoproterenol	B-X
without	B-X
initial	B-X
rise	B-X
of	B-X
the	B-X
cAMP	B-X
level	B-X
in	B-X
the	B-X
parotid	B-X
gland	B-X
of	B-X
mouse	B-X
.	B-X

GOLDSTEIN	O
ET	O
AL	O
.	O

FIG	O
.	O

1	O
.	O
<EOS>	B-X
Formate	B-X
assay	B-X
in	B-X
body	B-X
fluids	B-X
:	B-X
application	B-X
in	B-X
methanol	B-X
poisoning	B-X
.	B-X

Time	O
-	O
kill	O
curve	O
demonstrat8	O
3	O
-	O
\	O
"	O
'	O
'	O
ing	O
the	O
effects	O
of	O
various	O
penicillinO	O
aminoglycoside	O
combinations	O
on	O
S	O
.	O

{	O
73	O
2	O
-	O
\	O
>	O
,	O
faecium	O
obtained	O
from	O
the	O
patient	B-Species
'	O
s	O
<EOS>	B-X
To	B-X
study	B-X
the	B-X
relationship	B-X
between	B-X
preoperative	B-X
urine	B-X
culture	B-X
,	B-X
bacterial	B-X
species	B-X
and	B-X
infection	B-X
after	B-X
percutaneous	B-X
nephrolithotomy	B-X
in	B-X
patients	B-X
with	B-X
upper	B-X
urinary	B-X
tract	B-X
stones	B-X
,	B-X
and	B-X
summarize	B-X
the	B-X
clinical	B-X
characteristics	B-X
of	B-X
different	B-X
bacterial	B-X
infections	B-X
.	B-X
From	B-X
January	B-X
2014	B-X
and	B-X
January	B-X
2020	B-X
,	B-X
963	B-X
patients	B-X
with	B-X
upper	B-X
urinary	B-X
tract	B-X
stones	B-X
who	B-X
underwent	B-X
PCNL	B-X
in	B-X
the	B-X
department	B-X
of	B-X
urology	B-X
of	B-X
Fujian	B-X
provincial	B-X
hospital	B-X
were	B-X
included	B-X
in	B-X
the	B-X
study	B-X
.	B-X
Information	B-X
included	B-X
the	B-X
patient	B-X
's	B-X
age	B-X
,	B-X
gender	B-X
,	B-X
weight	B-X
,	B-X
diabetes	B-X
,	B-X
chronic	B-X
disease	B-X
history	B-X
,	B-X
urine	B-X
routine	B-X
,	B-X
preoperative	B-X
urine	B-X
culture	B-X
results	B-X
,	B-X
stone	B-X
size	B-X
,	B-X
number	B-X
of	B-X
stones	B-X
,	B-X
hydronephrosis	B-X
level	B-X
,	B-X
operation	B-X
time	B-X
,	B-X
body	B-X
temperature	B-X
,	B-X
heart	B-X
rate	B-X
,	B-X
blood	B-X
pressure	B-X
,	B-X
breathing	B-X
rate	B-X
,	B-X
hemoglobin	B-X
,	B-X
serum	B-X
creatinine	B-X
,	B-X
bilirubin	B-X
,	B-X
platelets	B-X
and	B-X
whether	B-X
there	B-X
was	B-X
preoperative	B-X
infection	B-X
were	B-X
recorded	B-X
.	B-X
141	B-X
patients	B-X
(	B-X
14.6	B-X
%	B-X
)	B-X
had	B-X
a	B-X
positive	B-X
urine	B-X
culture	B-X
before	B-X
surgery	B-X
,	B-X
and	B-X
7	B-X
of	B-X
them	B-X
had	B-X
multiple	B-X
bacterial	B-X
infections	B-X
.	B-X
A	B-X
total	B-X
of	B-X
74	B-X
cases	B-X
(	B-X
7.7	B-X
%	B-X
)	B-X
of	B-X
963	B-X
patients	B-X
with	B-X
infection	B-X
after	B-X
PCNL	B-X
occurred	B-X
,	B-X
24	B-X
cases	B-X
(	B-X
32.4	B-X
%	B-X
)	B-X
of	B-X
infected	B-X
patients	B-X
progressed	B-X
to	B-X
urinary	B-X
septic	B-X
shock	B-X
.	B-X
Univariate	B-X
analysis	B-X
shown	B-X
that	B-X
the	B-X
probability	B-X
of	B-X
infection	B-X
in	B-X
patients	B-X
with	B-X
long	B-X
operation	B-X
time	B-X
and	B-X
positive	B-X
urine	B-X
culture	B-X
was	B-X
significantly	B-X
higher	B-X
,	B-X
and	B-X
the	B-X
difference	B-X
was	B-X
statistically	B-X
significant	B-X
.	B-X
Among	B-X
the	B-X
29	B-X
patients	B-X
with	B-X
septic	B-X
shock	B-X
,	B-X
18	B-X
cases	B-X
(	B-X
62.1	B-X
%	B-X
)	B-X
had	B-X
a	B-X
positive	B-X
urine	B-X
culture	B-X
before	B-X
surgery	B-X
.	B-X
The	B-X
incidence	B-X
(	B-X
43.9	B-X
%	B-X
)	B-X
of	B-X
postoperative	B-X
infection	B-X
in	B-X
Escherichia	B-X
coli	B-X
positive	B-X
patients	B-X
was	B-X
significantly	B-X
higher	B-X
than	B-X
that	B-X
in	B-X
the	B-X
negative	B-X
group	B-X
,	B-X
and	B-X
the	B-X
difference	B-X
was	B-X
statistically	B-X
significant	B-X
.	B-X
The	B-X
rate	B-X
of	B-X
patients	B-X
with	B-X
Escherichia	B-X
coli	B-X
infection	B-X
progressing	B-X
to	B-X
septic	B-X
shock	B-X
was	B-X
9	B-X
cases	B-X
(	B-X
60	B-X
%	B-X
)	B-X
.	B-X
2	B-X
patients	B-X
with	B-X
Enterococcus	B-X
faecium	B-X
infection	B-X
and	B-X
2	B-X
patients	B-X
with	B-X
Klebsiella	B-X
pneumoniae	B-X
infection	B-X
all	B-X
progressed	B-X
to	B-X
septic	B-X
shock	B-X
.	B-X
The	B-X
age	B-X
of	B-X
patients	B-X
with	B-X
post-PCNL	B-X
infection	B-X
caused	B-X
by	B-X
Escherichia	B-X
Coli	B-X
,	B-X
Enterococcus	B-X
faecium	B-X
and	B-X
Klebsiella	B-X
pneumoniae	B-X
were	B-X
58.53	B-X
Â±	B-X
11.73	B-X
years	B-X
,	B-X
76.5	B-X
years	B-X
and	B-X
74	B-X
years.The	B-X
body	B-X
temperature	B-X
of	B-X
patients	B-X
with	B-X
post-PCNL	B-X
infection	B-X
caused	B-X
by	B-X
Escherichia	B-X
Coli	B-X
,	B-X
Enterococcus	B-X
faecium	B-X
and	B-X
Klebsiella	B-X
pneumoniae	B-X
were	B-X
39.10	B-X
Â±	B-X
0.25	B-X
Â°C	B-X
,	B-X
39.45	B-X
Â°C	B-X
and	B-X
38.65	B-X
Â°C	B-X
.	B-X
The	B-X
highest	B-X
pct	B-X
value	B-X
of	B-X
patients	B-X
with	B-X
post-PCNL	B-X
infection	B-X
caused	B-X
by	B-X
Escherichia	B-X
Coli	B-X
,	B-X
Enterococcus	B-X
faecium	B-X
and	B-X
Klebsiella	B-X
pneumoniae	B-X
were	B-X
80.62	B-X
Â±	B-X
31.45	B-X
ng/mL	B-X
,	B-X
24.32	B-X
ng/mL	B-X
and	B-X
8.45	B-X
ng/mL	B-X
.	B-X
The	B-X
nitrite	B-X
positive	B-X
rate	B-X
of	B-X
patients	B-X
with	B-X
post-PCNL	B-X
infection	B-X
caused	B-X
by	B-X
Escherichia	B-X
Coli	B-X
,	B-X
Enterococcus	B-X
faecium	B-X
and	B-X
Klebsiella	B-X
pneumoniae	B-X
were	B-X
64.51	B-X
%	B-X
,	B-X
16.6	B-X
%	B-X
and	B-X
0	B-X
.	B-X
Enterococcus	B-X
faecium	B-X
and	B-X
Klebsiella	B-X
pneumoniae	B-X
infections	B-X
mostly	B-X
occur	B-X
in	B-X
elderly	B-X
patients	B-X
and	B-X
often	B-X
progress	B-X
to	B-X
septic	B-X
shock	B-X
.	B-X
Patients	B-X
with	B-X
Enterococcus	B-X
faecium	B-X
infection	B-X
have	B-X
a	B-X
high	B-X
fever	B-X
,	B-X
and	B-X
the	B-X
PCT	B-X
value	B-X
is	B-X
significantly	B-X
higher	B-X
(	B-X
often	B-X
exceeded	B-X
20	B-X
ng/ml	B-X
)	B-X
.	B-X

blood	O
cultures	O
immediately	O
prior	O
to	O
mitral	O
valve	O
excision	O
.	O

Note	O
the	O
lack	O
of	O
4u	O
,	O
synergy	O
between	O
penicillin	O
and	O
tobra25kg	O
/	O
rm	O
Streporrrychn	O
t	O
mycin	O
against	O
this	O
organism	O
when	O

/	O
0	O
units	O
/	O
mI	O
Penicillin	O
_	O
compared	O
to	O
synergistic	O
combinations	O
0	O
4	O
8	O
12	O
6	O
20	O
24	O
of	O
penicillin	O
-	O
gentamicin	O
and	O
penicillin	O

HOURS	O
streptomycin	O
.	O
<EOS>	B-X
Treatment	B-X
consists	B-X
of	B-X
intramuscular	B-X
streptomycin	B-X
0.5	B-X
g	B-X
every	B-X
12	B-X
hours	B-X
until	B-X
the	B-X
temperature	B-X
is	B-X
normal	B-X
.	B-X
Using	B-X
the	B-X
examples	B-X
of	B-X
biosynthesis	B-X
of	B-X
streptomycin	B-X
,	B-X
bialaphos	B-X
,	B-X
actinorhodin	B-X
,	B-X
oligoketides	B-X
and	B-X
autoregulators	B-X
during	B-X
the	B-X
first	B-X
hours	B-X
of	B-X
streptomycete	B-X
cultivation	B-X
,	B-X
it	B-X
is	B-X
stressed	B-X
that	B-X
the	B-X
external	B-X
environment	B-X
in	B-X
cooperation	B-X
with	B-X
the	B-X
internal	B-X
metabolic	B-X
abilities	B-X
of	B-X
the	B-X
cell	B-X
determines	B-X
the	B-X
metabolic	B-X
type	B-X
that	B-X
would	B-X
develop	B-X
during	B-X
the	B-X
life	B-X
cycle	B-X
of	B-X
the	B-X
producing	B-X
streptomycetes	B-X
.	B-X
Previously	B-X
described	B-X
cases	B-X
of	B-X
streptomycin	B-X
inactivation	B-X
by	B-X
R-factor	B-X
carrying	B-X
strains	B-X
of	B-X
E.	B-X
coli	B-X
have	B-X
not	B-X
lead	B-X
to	B-X
any	B-X
measurable	B-X
decrease	B-X
in	B-X
antimicrobial	B-X
potency	B-X
in	B-X
the	B-X
bulk	B-X
substrate	B-X
toward	B-X
the	B-X
culture	B-X
.	B-X
Out	B-X
of	B-X
1,800	B-X
strains	B-X
of	B-X
E.	B-X
coli	B-X
we	B-X
have	B-X
isolated	B-X
five	B-X
strains	B-X
which	B-X
inactivate	B-X
streptomycin	B-X
in	B-X
large	B-X
amounts	B-X
giving	B-X
a	B-X
final	B-X
concentration	B-X
of	B-X
the	B-X
inactivation	B-X
product	B-X
of	B-X
0.25	B-X
mg/ml	B-X
in	B-X
36	B-X
hours	B-X
.	B-X
Unlike	B-X
all	B-X
other	B-X
streptomycin-resistant	B-X
strains	B-X
in	B-X
investigated	B-X
these	B-X
five	B-X
strains	B-X
were	B-X
sensitive	B-X
to	B-X
butyl-streptomycylamine	B-X
,	B-X
a	B-X
streptomycin	B-X
derivative	B-X
acting	B-X
in	B-X
the	B-X
same	B-X
way	B-X
as	B-X
streptomycin	B-X
.	B-X
Inorganic	B-X
phosphate	B-X
is	B-X
liberated	B-X
by	B-X
treatment	B-X
with	B-X
alkaline	B-X
phosphatase	B-X
resulting	B-X
in	B-X
a	B-X
streptomycin-like	B-X
compound	B-X
without	B-X
any	B-X
antimicrobial	B-X
activity	B-X
.	B-X

after	O
initial	O
oral	O
erythromycin	O
therapy	O
,	O
and	O
prior	O
to	O
therapy	O
for	O
endocarditis	O
,	O
are	O
shown	O
in	O
Table	O
1	O
.	O

Following	O
combined	O
therapy	O
with	O
ampicillin	O
and	O
tobramycin	O
and	O
relapse	O
of	O
endocarditis	O
,	O
three	O
morphological	O
variants	O
were	O
isolated	O
from	O
blood	O
cultures	O
and	O
also	O
evaluated	O
.	O

Twenty	O
-	O
four	O
hour	O
time	O
-	O
kill	O
curves	O
for	O
penicillin	O
in	O
combination	O
with	O
various	O
aminoglycosides	O
were	O
performed	O
by	O
Dr	O
.	O
Robert	O
Moellering	O
on	O
the	O
S	B-Species
.	I-Species
faecium	I-Species
isolated	O
from	O
the	O
patient	B-Species
'	O
s	O
blood	O
immediately	O
prior	O
to	O
mitral	O
valve	O
excision	O
and	O
replacement	O
(	O
Fig	O
.	O
1	O
)	O
.	O

Synergy	O
was	O
readily	O
demonstrable	O
against	O
this	O
organism	O
by	O
penicillin	O
-	O
streptomycin	O
and	O
penicillin	O
-	O
gentamicin	O
combinations	O
in	O
vitro	O
,	O
but	O
not	O
by	O
penicillin	O
-	O
tobramycin	O
.	O

DISCUSSION	O

Among	O
streptococci	O
,	O
the	O
enterococci	O
are	O
unusual	O
in	O
their	O
relative	O
resistance	O
to	O
a	O
broad	O
spectrum	O
of	O
antimicrobial	O
agents	O
,	O
and	O
single	O
-	O
agent	O
therapy	O
is	O
rarely	O
bactericidal	O
against	O
them	O
[	O
2	O
]	O
.	O

Since	O
Hunter	O
'	O
s	O
original	O
observations	O
in	O
1947	O
,	O
it	O
has	O
become	O
increasingly	O
clear	O
that	O
effective	O
synergistic	O
combinations	O
of	O
antibiotics	O
are	O
necessary	O
to	O
successfully	O
treat	O
enterococcal	O
endocarditis	O
[	O
1	O
]	O
.	O

Although	O
S	B-Species
.	I-Species
faecalis	I-Species
represents	O
the	O
majority	O
of	O
clinical	O
enterococcal	O
isolates	O
,	O
S	B-Species
.	I-Species
faecium	I-Species
nonetheless	O
comprises	O
5	O
-	O
10	O
percent	O
of	O
these	O
isolates	O
in	O
some	O
series	O
[	O
3	O
,	O
4	O
]	O
.	O

Moreover	O
,	O
major	O
differences	O
exist	O
in	O
antimicrobial	O
susceptibility	O
and	O
resistance	O
to	O
penicillin	O
-	O
aminoglycoside	O
synergism	O
between	O
these	O
two	O
enterococcal	O
species	O
.	O

The	O
MIC	O
of	O
penicillin	O
against	O
S	B-Species
.	I-Species
faecium	I-Species
is	O
higher	O
and	O
this	O
organism	O
is	O
more	O
resistant	O
to	O
a	O
number	O
of	O
different	O
combinations	O
of	O
penicillin	O
and	O
various	O
aminoglycosides	O
than	O
is	O
S	B-Species
.	I-Species
faecalis	I-Species
[	O
6	O
]	O
.	O

The	O
mechanisms	O
of	O
resistance	O
exhibited	O
by	O
enterococci	O
to	O
penicillin	O
-	O
aminoglycoside	O
synergy	O
have	O
been	O
investigated	O
.	O

Clinically	O
achievable	O
levels	O
of	O
amino	O
<EOS>	B-X
We	B-X
demonstrate	B-X
that	B-X
amino	B-X
acid	B-X
uptake	B-X
,	B-X
steady-state	B-X
levels	B-X
,	B-X
and	B-X
catabolism	B-X
are	B-X
all	B-X
elevated	B-X
in	B-X
the	B-X
leukemia	B-X
stem	B-X
cell	B-X
(	B-X
LSC	B-X
)	B-X
population	B-X
.	B-X
Furthermore	B-X
,	B-X
LSCs	B-X
isolated	B-X
from	B-X
de	B-X
novo	B-X
AML	B-X
patients	B-X
are	B-X
uniquely	B-X
reliant	B-X
on	B-X
amino	B-X
acid	B-X
metabolism	B-X
for	B-X
oxidative	B-X
phosphorylation	B-X
and	B-X
survival	B-X
.	B-X
Pharmacological	B-X
inhibition	B-X
of	B-X
amino	B-X
acid	B-X
metabolism	B-X
reduces	B-X
oxidative	B-X
phosphorylation	B-X
and	B-X
induces	B-X
cell	B-X
death	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
LSCs	B-X
obtained	B-X
from	B-X
relapsed	B-X
AML	B-X
patients	B-X
are	B-X
not	B-X
reliant	B-X
on	B-X
amino	B-X
acid	B-X
metabolism	B-X
due	B-X
to	B-X
their	B-X
ability	B-X
to	B-X
compensate	B-X
through	B-X
increased	B-X
fatty	B-X
acid	B-X
metabolism	B-X
.	B-X

246	O
<EOS>	B-X
Cell	B-X
density-dependent	B-X
stimulation	B-X
of	B-X
glutamine	B-X
synthetase	B-X
activity	B-X
in	B-X
cultured	B-X
mouse	B-X
teratoma	B-X
cells	B-X
.	B-X

S	B-Species
.	I-Species
<EOS>	B-X
Finkelstein	B-X
's	B-X
Test	B-X
Is	B-X
Superior	B-X
to	B-X
Eichhoff	B-X
's	B-X
Test	B-X
in	B-X
the	B-X
Investigation	B-X
of	B-X
de	B-X
Quervain	B-X
's	B-X
Disease	B-X
.	B-X
Protein	B-X
S	B-X
deficiency	B-X
.	B-X
Letter	B-X
:	B-X
Craniometrics	B-X
and	B-X
Ventricular	B-X
Access	B-X
:	B-X
A	B-X
Review	B-X
of	B-X
Kocher	B-X
's	B-X
,	B-X
Kaufman	B-X
's	B-X
,	B-X
Paine	B-X
's	B-X
,	B-X
Menovksy	B-X
's	B-X
,	B-X
Tubbs	B-X
'	B-X
,	B-X
Keen	B-X
's	B-X
,	B-X
Frazier	B-X
's	B-X
,	B-X
Dandy	B-X
's	B-X
,	B-X
and	B-X
Sanchez	B-X
's	B-X
Points	B-X
.	B-X

FAECIUM	B-Species
ENDOCARDITIS	O

glycosides	O
are	O
generally	O
ineffective	O
against	O
enterococci	O
.	O
<EOS>	B-X
Because	B-X
only	B-X
limited	B-X
data	B-X
are	B-X
available	B-X
on	B-X
the	B-X
antimicrobial	B-X
sensitivity	B-X
of	B-X
enterococci	B-X
of	B-X
subgingival	B-X
origin	B-X
,	B-X
this	B-X
study	B-X
evaluates	B-X
the	B-X
in	B-X
vitro	B-X
antibiotic	B-X
susceptibility	B-X
of	B-X
E.	B-X
faecalis	B-X
isolated	B-X
from	B-X
periodontitis	B-X
patients	B-X
in	B-X
the	B-X
United	B-X
States	B-X
.	B-X

This	O
intrinsic	O
low	O
-	O
level	O
resistance	O
(	O
MIC	O
c	O
250	O
isg	O
/	O
ml	O
)	O
is	O
thought	O
to	O
be	O
the	O
result	O
of	O
poor	O
antibiotic	O
penetration	O
of	O
the	O
bacterial	O
cell	O
wall	O
.	O

However	O
,	O
in	O
the	O
presence	O
of	O
antibiotics	O
that	O
interfere	O
with	O
cell	O
wall	O
synthesis	O
,	O
there	O
is	O
enhanced	O
aminoglycoside	O
uptake	O
[	O
7	O
]	O
.	O

In	O
concert	O
,	O
these	O
events	O
are	O
the	O
basis	O
for	O
penicillin	O
-	O
aminoglycoside	O
synergism	O
.	O

Ribosomal	O
resistance	O
of	O
the	O
30S	O
subunit	O
to	O
streptomycin	O
and	O
defective	O
uptake	O
of	O
gentamicin	O
in	O
the	O
presence	O
of	O
penicillin	O
have	O
been	O
reported	O
mechanisms	O
of	O
resistance	O
among	O
enterococcal	O
isolates	O
[	O
8	O
,	O
9	O
]	O
.	O

However	O
,	O
in	O
the	O
majority	O
of	O
instances	O
,	O
failure	O
of	O
synergy	O
involves	O
plasmid	O
-	O
mediated	O
production	O
of	O
aminoglycoside	O
-	O
modifying	O
enzymes	O
.	O

For	O
streptomycin	O
and	O
kanamycin	O
,	O
plasmid	O
-	O
mediated	O
enzymatic	O
inactivation	O
confers	O
high	O
-	O
level	O
resistance	O
(	O
MIC	O
>	O
2	O
,	O
000	O
Ag	O
/	O
ml	O
)	O
and	O
correlates	O
with	O
failure	O
of	O
these	O
aminoglycosides	O
to	O
exert	O
a	O
synergistic	O
effect	O
when	O
combined	O
with	O
penicillin	O
[	O
10	O
,	O
11	O
]	O
.	O

Plasmid	O
-	O
mediated	O
modifying	O
enzymes	O
have	O
been	O
found	O
in	O
both	O
S	B-Species
.	I-Species
faecalis	I-Species
and	O
S	B-Species
.	I-Species
faecium	I-Species
'	O
[	O
12	O
]	O
.	O

Currently	O
,	O
approximately	O
one	O
-	O
half	O
of	O
clinical	O
enterococcal	O
isolates	O
demonstrate	O
high	O
-	O
level	O
resistance	O
to	O
streptomycin	O
and	O
kanamycin	O
[	O
13	O
]	O
.	O

Combinations	O
of	O
penicillin	O
with	O
kanamycin	O
,	O
tobramycin	O
,	O
sisomicin	O
,	O
and	O
netilmicin	O
have	O
consistently	O
failed	O
to	O
demonstrate	O
synergistic	O
killing	O
of	O
S	B-Species
.	I-Species
faecium	I-Species
in	O
vitro	O
[	O
6	O
]	O
.	O

This	O
failure	O
of	O
synergy	O
occurs	O
even	O
when	O
high	O
-	O
level	O
resistance	O
to	O
these	O
aminoglycosides	O
is	O
not	O
present	O
.	O

The	O
mechanism	O
of	O
resistance	O
appears	O
to	O
be	O
related	O
to	O
the	O
production	O
of	O
an	O
inactivating	O
enzyme	O
that	O
acetylates	O
the	O
aminoglycoside	O
substrate	O
at	O
the	O
6	O
'	O
position1	O
[	O
14	O
]	O
.	O

The	O
genetic	O
basis	O
for	O
production	O
of	O
this	O
enzyme	O
has	O
not	O
been	O
well	O
-	O
defined	O
and	O
plasmid	O
transfer	O
experiments	O
have	O
thus	O
far	O
been	O
unsucessful	O
in	O
demonstrating	O
the	O
encodement	O
of	O
this	O
enzyme	O
by	O
extrachromosomal	O
DNA	O
[	O
14	O
]	O
.	O
<EOS>	B-X
An	B-X
introduction	B-X
to	B-X
the	B-X
pharmacokinetic	B-X
basis	B-X
of	B-X
DDIs	B-X
is	B-X
provided	B-X
,	B-X
and	B-X
potential	B-X
DDIs	B-X
associated	B-X
with	B-X
opioids	B-X
are	B-X
reviewed	B-X
.	B-X
Opioids	B-X
metabolized	B-X
by	B-X
the	B-X
drug	B-X
metabolizing	B-X
enzymes	B-X
of	B-X
the	B-X
cytochrome	B-X
P450	B-X
(	B-X
CYP450	B-X
)	B-X
system	B-X
(	B-X
codeine	B-X
,	B-X
oxycodone	B-X
,	B-X
hydrocodone	B-X
,	B-X
fentanyl	B-X
,	B-X
tramadol	B-X
,	B-X
and	B-X
methadone	B-X
)	B-X
are	B-X
associated	B-X
with	B-X
numerous	B-X
DDIs	B-X
that	B-X
can	B-X
result	B-X
in	B-X
either	B-X
a	B-X
reduction	B-X
in	B-X
opioid	B-X
effect	B-X
or	B-X
excess	B-X
opioid	B-X
effects	B-X
.	B-X
Fundamental	B-X
features	B-X
of	B-X
microbial	B-X
cellulose	B-X
utilization	B-X
are	B-X
examined	B-X
at	B-X
successively	B-X
higher	B-X
levels	B-X
of	B-X
aggregation	B-X
encompassing	B-X
the	B-X
structure	B-X
and	B-X
composition	B-X
of	B-X
cellulosic	B-X
biomass	B-X
,	B-X
taxonomic	B-X
diversity	B-X
,	B-X
cellulase	B-X
enzyme	B-X
systems	B-X
,	B-X
molecular	B-X
biology	B-X
of	B-X
cellulase	B-X
enzymes	B-X
,	B-X
physiology	B-X
of	B-X
cellulolytic	B-X
microorganisms	B-X
,	B-X
ecological	B-X
aspects	B-X
of	B-X
cellulase-degrading	B-X
communities	B-X
,	B-X
and	B-X
rate-limiting	B-X
factors	B-X
in	B-X
nature	B-X
.	B-X
The	B-X
methodological	B-X
basis	B-X
for	B-X
studying	B-X
microbial	B-X
cellulose	B-X
utilization	B-X
is	B-X
considered	B-X
relative	B-X
to	B-X
quantification	B-X
of	B-X
cells	B-X
and	B-X
enzymes	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
solid	B-X
substrates	B-X
as	B-X
well	B-X
as	B-X
apparatus	B-X
and	B-X
analysis	B-X
for	B-X
cellulose-grown	B-X
continuous	B-X
cultures	B-X
.	B-X
Quantitative	B-X
description	B-X
of	B-X
cellulose	B-X
hydrolysis	B-X
is	B-X
addressed	B-X
with	B-X
respect	B-X
to	B-X
adsorption	B-X
of	B-X
cellulase	B-X
enzymes	B-X
,	B-X
rates	B-X
of	B-X
enzymatic	B-X
hydrolysis	B-X
,	B-X
bioenergetics	B-X
of	B-X
microbial	B-X
cellulose	B-X
utilization	B-X
,	B-X
kinetics	B-X
of	B-X
microbial	B-X
cellulose	B-X
utilization	B-X
,	B-X
and	B-X
contrasting	B-X
features	B-X
compared	B-X
to	B-X
soluble	B-X
substrate	B-X
kinetics	B-X
.	B-X
Organism	B-X
development	B-X
is	B-X
considered	B-X
for	B-X
``	B-X
consolidated	B-X
bioprocessing	B-X
''	B-X
(	B-X
CBP	B-X
)	B-X
,	B-X
in	B-X
which	B-X
the	B-X
production	B-X
of	B-X
cellulolytic	B-X
enzymes	B-X
,	B-X
hydrolysis	B-X
of	B-X
biomass	B-X
,	B-X
and	B-X
fermentation	B-X
of	B-X
resulting	B-X
sugars	B-X
to	B-X
desired	B-X
products	B-X
occur	B-X
in	B-X
one	B-X
step	B-X
.	B-X

Moellering	O
et	O
al	O
.	O
demonstrated	O
in	O
vivo	O
,	O
utilizing	O
the	O
rabbit	B-Species
model	O
of	O
endocarditis	O
,	O
that	O
penicillin	O
and	O
netilmicin	O
were	O
not	O
efficacious	O
in	O
the	O
treatment	O
of	O
endocarditis	O
caused	O
by	O
a	O
low	O
-	O
level	O
aminoglycoside	O
-	O
resistant	O
strain	O
of	O
S	B-Species
.	I-Species
faecium	I-Species
[	O
6	O
]	O
.	O

Although	O
combinations	O
of	O
penicillin	O
with	O
tobramycin	O
,	O
kanamycin	O
,	O
or	O
sisomicin	O
were	O
not	O
evaluated	O
,	O
the	O
authors	O
postulated	O
that	O
the	O
same	O
ineffectual	O
result	O
would	O
have	O
occurred	O
.	O
<EOS>	B-X
A	B-X
systematic	B-X
review	B-X
and	B-X
meta-analysis	B-X
was	B-X
performed	B-X
including	B-X
pharmacokinetic/pharmacodynamic	B-X
(	B-X
PK/PD	B-X
)	B-X
and	B-X
time-kill	B-X
(	B-X
TK	B-X
)	B-X
studies	B-X
examining	B-X
the	B-X
in	B-X
vitro	B-X
efficacy	B-X
of	B-X
antibiotic	B-X
combinations	B-X
against	B-X
CR-GNB	B-X
[	B-X
PROSPERO	B-X
registration	B-X
no	B-X
.	B-X
Compared	B-X
with	B-X
monotherapy	B-X
,	B-X
increased	B-X
bactericidal	B-X
activity	B-X
and	B-X
lower	B-X
re-growth	B-X
rates	B-X
were	B-X
reported	B-X
for	B-X
colistin/fosfomycin	B-X
and	B-X
polymyxin/rifampicin	B-X
in	B-X
K.	B-X
pneumoniae	B-X
and	B-X
for	B-X
imipenem/amikacin	B-X
or	B-X
imipenem/tobramycin	B-X
against	B-X
P.	B-X
aeruginosa	B-X
.	B-X
Amikacin	B-X
,	B-X
a	B-X
semisynthetic	B-X
analog	B-X
of	B-X
kanamycin	B-X
,	B-X
is	B-X
very	B-X
active	B-X
against	B-X
most	B-X
gram-negative	B-X
bacteria	B-X
including	B-X
gentamicin-	B-X
and	B-X
tobramycin-resistant	B-X
strains	B-X
.	B-X
Due	B-X
to	B-X
its	B-X
resistance	B-X
to	B-X
inactivating	B-X
enzymes	B-X
,	B-X
it	B-X
is	B-X
the	B-X
aminoglycoside	B-X
of	B-X
choice	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
known	B-X
or	B-X
suspected	B-X
serious	B-X
gram-negative	B-X
infections	B-X
caused	B-X
by	B-X
organisms	B-X
resistant	B-X
to	B-X
gentamicin	B-X
or	B-X
tobramycin	B-X
.	B-X
It	B-X
exhibits	B-X
impressive	B-X
in	B-X
vitro	B-X
synergy	B-X
against	B-X
aminoglycoside-sensitive	B-X
and	B-X
-resistant	B-X
organisms	B-X
when	B-X
used	B-X
in	B-X
combination	B-X
with	B-X
the	B-X
new	B-X
acylureidopenicillins	B-X
and	B-X
third-generation	B-X
cephalosporins	B-X
.	B-X
Amikacin	B-X
has	B-X
the	B-X
advantage	B-X
of	B-X
being	B-X
the	B-X
aminoglycoside	B-X
least	B-X
inactivated	B-X
by	B-X
the	B-X
semisynthetic	B-X
penicillins	B-X
.	B-X
Its	B-X
potential	B-X
for	B-X
nephrotoxicity	B-X
and	B-X
ototoxicity	B-X
is	B-X
not	B-X
significantly	B-X
different	B-X
than	B-X
that	B-X
encountered	B-X
with	B-X
gentamicin	B-X
or	B-X
tobramycin	B-X
.	B-X
Amikacin	B-X
appears	B-X
to	B-X
be	B-X
the	B-X
preferred	B-X
aminoglycoside	B-X
for	B-X
use	B-X
at	B-X
the	B-X
present	B-X
time	B-X
because	B-X
of	B-X
its	B-X
activity	B-X
against	B-X
gentamicin-	B-X
and	B-X
tobramycin-resistant	B-X
organisms	B-X
,	B-X
its	B-X
low	B-X
resistance	B-X
potential	B-X
,	B-X
its	B-X
relative	B-X
low	B-X
degree	B-X
of	B-X
inactivation	B-X
by	B-X
the	B-X
semisynthetic	B-X
penicillins	B-X
,	B-X
and	B-X
its	B-X
superior	B-X
pharmacokinetic	B-X
profile	B-X
.	B-X

In	O
the	O
present	O
case	O
,	O
the	O
recurrence	O
of	O
S	B-Species
.	I-Species
faecium	I-Species
endocarditis	O
after	O
six	O
weeks	O
of	O
therapy	O
with	O
ampicillin	O
and	O
tobramycin	O
confirms	O
the	O
therapeutic	O
and	O
clinical	O
significance	O
of	O
their	O
data	O
,	O
and	O
emphasizes	O
that	O
tobramycin	O
is	O
not	O
an	O
aminoglycoside	O
to	O
be	O
used	O
for	O
treatment	O
of	O
serious	O
S	B-Species
.	I-Species
faecium	I-Species
infections	O
.	O

Bacterial	O
tolerance	O
has	O
been	O
suggested	O
as	O
a	O
possible	O
basis	O
for	O
therapeutic	O
failures	O
,	O
particularly	O
in	O
the	O
treatment	O
of	O
infections	O
caused	O
by	O
Staphylococcus	B-Species
aureus	I-Species
with	O
defects	O
in	O
the	O
production	O
of	O
autolysins	O
.	O

MBCs	O
are	O
generally	O
several	O
-	O
fold	O
higher	O
than	O
MICs	O
and	O
this	O
phenomenon	O
appears	O
to	O
be	O
associated	O
with	O
the	O
autolysin	O
defect	O
[	O
5	O
]	O
.	O

Lorian	O
has	O
also	O
described	O
the	O
formation	O
of	O
numerous	O
aberrant	O
cross	O
-	O
walls	O
by	O
S	B-Species
.	I-Species
faecalis	I-Species
grown	O
in	O
the	O
presence	O
of	O
subinhibitory	O
concentrations	O
of	O
penicillin	O
[	O
15	O
]	O
.	O

MBCs	O
were	O
only	O
slightly	O
higher	O
than	O
MICs	O
for	O
the	O
three	O
S	B-Species
.	I-Species
faecium	I-Species
variants	O
obtained	O
from	O
our	O
patient	B-Species
,	O
and	O
they	O
did	O
not	O
appear	O
to	O
be	O
tolerant	O
strains	O
of	O
S	B-Species
.	I-Species
faecium	I-Species
.	O

There	O
was	O
no	O
evidence	O
that	O
any	O
of	O
the	O
morphological	O
variants	O
isolated	O
were	O
unusually	O
resistant	O
to	O
antibiotics	O
.	O

Therefore	O
,	O
subsequent	O
failure	O
of	O
therapy	O
could	O
not	O
be	O
explained	O
on	O
the	O
basis	O
of	O
antibiotic	O
resistance	O
patterns	O
.	O
<EOS>	B-X
Patients	B-X
typically	B-X
present	B-X
with	B-X
progressive	B-X
lymphadenopathy	B-X
,	B-X
extranodal	B-X
disease	B-X
,	B-X
or	B-X
both	B-X
and	B-X
require	B-X
therapy	B-X
.	B-X
Despite	B-X
the	B-X
advanced	B-X
stage	B-X
at	B-X
presentation	B-X
in	B-X
the	B-X
majority	B-X
of	B-X
patients	B-X
,	B-X
more	B-X
than	B-X
60	B-X
%	B-X
can	B-X
be	B-X
cured	B-X
with	B-X
R-CHOP	B-X
(	B-X
rituximab	B-X
,	B-X
cyclophosphamide	B-X
,	B-X
doxorubicin	B-X
,	B-X
vincristine	B-X
,	B-X
and	B-X
prednisone	B-X
)	B-X
immunochemotherapy	B-X
(	B-X
Fig	B-X
.	B-X
Patients	B-X
with	B-X
treatment	B-X
failure	B-X
after	B-X
R-CHOP	B-X
often	B-X
have	B-X
a	B-X
poor	B-X
outcome	B-X
â	B-X
in	B-X
particular	B-X
,	B-X
those	B-X
with	B-X
disease	B-X
that	B-X
is	B-X
refractory	B-X
to	B-X
frontline	B-X
or	B-X
subsequent	B-X
therapies	B-X
â	B-X
although	B-X
some	B-X
patients	B-X
can	B-X
have	B-X
a	B-X
durable	B-X
remission	B-X
and	B-X
be	B-X
cured	B-X
after	B-X
secondary	B-X
therapies	B-X
.	B-X
SGLT2	B-X
inhibitors	B-X
are	B-X
strongly	B-X
recommended	B-X
in	B-X
guidelines	B-X
to	B-X
treat	B-X
patients	B-X
with	B-X
heart	B-X
failure	B-X
with	B-X
reduced	B-X
ejection	B-X
fraction	B-X
,	B-X
but	B-X
their	B-X
clinical	B-X
benefits	B-X
at	B-X
higher	B-X
ejection	B-X
fractions	B-X
are	B-X
less	B-X
well	B-X
established	B-X
.	B-X
Two	B-X
large-scale	B-X
trials	B-X
,	B-X
DELIVER	B-X
and	B-X
EMPEROR-Preserved	B-X
,	B-X
in	B-X
heart	B-X
failure	B-X
with	B-X
mildly	B-X
reduced	B-X
or	B-X
preserved	B-X
ejection	B-X
fraction	B-X
have	B-X
been	B-X
done	B-X
,	B-X
providing	B-X
power	B-X
to	B-X
examine	B-X
therapeutic	B-X
effects	B-X
on	B-X
cardiovascular	B-X
mortality	B-X
and	B-X
in	B-X
patient	B-X
subgroups	B-X
when	B-X
combined	B-X
with	B-X
the	B-X
earlier	B-X
trials	B-X
in	B-X
reduced	B-X
ejection	B-X
fraction	B-X
.	B-X

The	O
initial	O
failure	O
of	O
ampicillin	O
and	O
tobramycin	O
therapy	O
may	O
have	O
allowed	O
the	O
infecting	O
organism	O
to	O
become	O
better	O
established	O
and	O
more	O
difficult	O
to	O
eradicate	O
from	O
the	O
valve	O
.	O

Alternatively	O
,	O
a	O

'	O
Wennersten	O
C	O
,	O
Moellering	O
RC	O
Jr	O
:	O
Mechanism	O
of	O
resistance	O
to	O
penicillin	O
-	O
aminoglycoside	O
synergism	O
in	O
Streptococcus	B-Species
faecium	I-Species
.	O

Proceedings	O
of	O
the	O
1th	O
International	O
Congress	O
of	O
Chemotherapy	O
and	O
19th	O
Interscience	O
Conference	O
on	O
Antimicrobial	O
Agents	O
and	O
Chemotherapy	O
1	O
:	O
710	O
-	O
711	O
,	O
1979	O

247	O
<EOS>	B-X
Polyadenylation	B-X
of	B-X
nascent	B-X
RNA	B-X
during	B-X
the	B-X
embryogenesis	B-X
of	B-X
Ilyanassa	B-X
obsoleta	B-X
.	B-X

248	O
GOLDSTEIN	O
ET	O
AL	O
.	O

persistent	O
focus	O
of	O
infection	O
causing	O
the	O
LAD	O
lesion	O
seen	O
by	O
arteriography	O
may	O
have	O
slowly	O
resolved	O
and	O
accounted	O
for	O
the	O
apparent	O
failure	O
to	O
respond	O
to	O
synergistic	O
combinations	O
of	O
antibiotics	O
.	O

In	O
summary	O
,	O
our	O
patient	B-Species
was	O
treated	O
for	O
Streptococcusfaecium	B-Species
endocarditis	O
with	O
both	O
ampicillin	O
and	O
the	O
aminoglycoside	O
antibiotic	O
,	O
tobramycin	O
.	O

Relapse	O
of	O
endocarditis	O
might	O
have	O
been	O
anticipated	O
on	O
the	O
basis	O
of	O
previous	O
experimental	O
data	O
showing	O
lack	O
of	O
synergy	O
when	O
tobramycin	O
is	O
used	O
against	O
this	O
organism	O
.	O

This	O
case	O
graphically	O
illustrates	O
the	O
relevance	O
of	O
synergy	O
studies	O
to	O
therapeutic	O
considerations	O
in	O
the	O
treatment	O
of	O
endocarditis	O
.	O

However	O
,	O
subsequent	O
therapy	O
with	O
synergistic	O
combinations	O
of	O
antibiotics	O
did	O
not	O
result	O
in	O
cure	O
.	O
<EOS>	B-X
Infectious	B-X
diseases	B-X
(	B-X
IDs	B-X
)	B-X
are	B-X
life-threatening	B-X
illnesses	B-X
,	B-X
which	B-X
result	B-X
from	B-X
the	B-X
spread	B-X
of	B-X
pathogenic	B-X
microorganisms	B-X
such	B-X
as	B-X
bacteria	B-X
,	B-X
viruses	B-X
,	B-X
fungi	B-X
,	B-X
and	B-X
parasites	B-X
.	B-X
Despite	B-X
the	B-X
capability	B-X
of	B-X
frontline-approved	B-X
medications	B-X
to	B-X
partially	B-X
prevent	B-X
or	B-X
mitigate	B-X
the	B-X
invasion	B-X
and	B-X
subsequent	B-X
damage	B-X
of	B-X
IDs	B-X
to	B-X
host	B-X
tissues	B-X
and	B-X
cells	B-X
,	B-X
problems	B-X
such	B-X
as	B-X
drug	B-X
resistance	B-X
,	B-X
insufficient	B-X
efficacy	B-X
,	B-X
unpleasant	B-X
side	B-X
effects	B-X
,	B-X
and	B-X
high	B-X
expenses	B-X
stand	B-X
in	B-X
the	B-X
way	B-X
of	B-X
their	B-X
beneficial	B-X
applications	B-X
.	B-X
Curcumin	B-X
can	B-X
also	B-X
potentiate	B-X
the	B-X
efficacy	B-X
of	B-X
available	B-X
anti-bacterial	B-X
and	B-X
anti-parasitic	B-X
drugs	B-X
in	B-X
a	B-X
synergistic	B-X
fashion	B-X
.	B-X
Despite	B-X
30	B-X
years	B-X
of	B-X
scientific	B-X
and	B-X
clinical	B-X
investigation	B-X
,	B-X
the	B-X
pathogenesis	B-X
of	B-X
pouchitis	B-X
is	B-X
unknown	B-X
;	B-X
however	B-X
,	B-X
recent	B-X
advances	B-X
in	B-X
molecular	B-X
and	B-X
cell	B-X
biology	B-X
make	B-X
a	B-X
synergistic	B-X
hypothesis	B-X
possible	B-X
.	B-X
This	B-X
causes	B-X
mucosal	B-X
depletion	B-X
and	B-X
subsequent	B-X
inflammation	B-X
.	B-X
Although	B-X
in	B-X
most	B-X
cases	B-X
antibiotics	B-X
lead	B-X
to	B-X
bacterial	B-X
clearance	B-X
and	B-X
symptom	B-X
resolution	B-X
,	B-X
immunogenetic	B-X
subpopulations	B-X
can	B-X
develop	B-X
a	B-X
chronic	B-X
refractory	B-X
variant	B-X
of	B-X
pouchitis	B-X
.	B-X

The	O
data	O
do	O
not	O
implicate	O
tolerant	O
organisms	O
as	O
a	O
cause	O
for	O
relapses	O
.	O
<EOS>	B-X
Designing	B-X
,	B-X
conducting	B-X
,	B-X
analyzing	B-X
,	B-X
reporting	B-X
,	B-X
and	B-X
interpreting	B-X
the	B-X
findings	B-X
of	B-X
a	B-X
research	B-X
study	B-X
require	B-X
an	B-X
understanding	B-X
of	B-X
the	B-X
types	B-X
and	B-X
characteristics	B-X
of	B-X
data	B-X
and	B-X
variables	B-X
.	B-X
Descriptive	B-X
statistics	B-X
are	B-X
typically	B-X
used	B-X
simply	B-X
to	B-X
calculate	B-X
,	B-X
describe	B-X
,	B-X
and	B-X
summarize	B-X
the	B-X
collected	B-X
research	B-X
data	B-X
in	B-X
a	B-X
logical	B-X
,	B-X
meaningful	B-X
,	B-X
and	B-X
efficient	B-X
way	B-X
.	B-X
Inferential	B-X
statistics	B-X
allow	B-X
researchers	B-X
to	B-X
make	B-X
a	B-X
valid	B-X
estimate	B-X
of	B-X
the	B-X
association	B-X
between	B-X
an	B-X
intervention	B-X
and	B-X
the	B-X
treatment	B-X
effect	B-X
in	B-X
a	B-X
specific	B-X
population	B-X
,	B-X
based	B-X
upon	B-X
their	B-X
randomly	B-X
collected	B-X
,	B-X
representative	B-X
sample	B-X
data	B-X
.	B-X
Categorical	B-X
data	B-X
can	B-X
be	B-X
either	B-X
dichotomous	B-X
or	B-X
polytomous	B-X
.	B-X
Dichotomous	B-X
data	B-X
have	B-X
only	B-X
2	B-X
categories	B-X
,	B-X
and	B-X
thus	B-X
are	B-X
considered	B-X
binary	B-X
.	B-X
Polytomous	B-X
data	B-X
have	B-X
more	B-X
than	B-X
2	B-X
categories	B-X
.	B-X
Unlike	B-X
dichotomous	B-X
and	B-X
polytomous	B-X
data	B-X
,	B-X
ordinal	B-X
data	B-X
are	B-X
rank	B-X
ordered	B-X
,	B-X
typically	B-X
based	B-X
on	B-X
a	B-X
numerical	B-X
scale	B-X
that	B-X
is	B-X
comprised	B-X
of	B-X
a	B-X
small	B-X
set	B-X
of	B-X
discrete	B-X
classes	B-X
or	B-X
integers	B-X
.	B-X
Continuous	B-X
data	B-X
are	B-X
measured	B-X
on	B-X
a	B-X
continuum	B-X
and	B-X
can	B-X
have	B-X
any	B-X
numeric	B-X
value	B-X
over	B-X
this	B-X
continuous	B-X
range	B-X
.	B-X
Continuous	B-X
data	B-X
can	B-X
be	B-X
meaningfully	B-X
divided	B-X
into	B-X
smaller	B-X
and	B-X
smaller	B-X
or	B-X
finer	B-X
and	B-X
finer	B-X
increments	B-X
,	B-X
depending	B-X
upon	B-X
the	B-X
precision	B-X
of	B-X
the	B-X
measurement	B-X
instrument	B-X
.	B-X
Interval	B-X
data	B-X
are	B-X
a	B-X
form	B-X
of	B-X
continuous	B-X
data	B-X
in	B-X
which	B-X
equal	B-X
intervals	B-X
represent	B-X
equal	B-X
differences	B-X
in	B-X
the	B-X
property	B-X
being	B-X
measured	B-X
.	B-X
Ratio	B-X
data	B-X
are	B-X
another	B-X
form	B-X
of	B-X
continuous	B-X
data	B-X
,	B-X
which	B-X
have	B-X
the	B-X
same	B-X
properties	B-X
as	B-X
interval	B-X
data	B-X
,	B-X
plus	B-X
a	B-X
true	B-X
definition	B-X
of	B-X
an	B-X
absolute	B-X
zero	B-X
point	B-X
,	B-X
and	B-X
the	B-X
ratios	B-X
of	B-X
the	B-X
values	B-X
on	B-X
the	B-X
measurement	B-X
scale	B-X
make	B-X
sense	B-X
.	B-X
Many	B-X
applied	B-X
inferential	B-X
statistical	B-X
tests	B-X
are	B-X
predicated	B-X
on	B-X
the	B-X
assumption	B-X
that	B-X
the	B-X
analyzed	B-X
data	B-X
follow	B-X
a	B-X
normal	B-X
distribution	B-X
.	B-X
The	B-X
histogram	B-X
and	B-X
the	B-X
Q-Q	B-X
plot	B-X
are	B-X
2	B-X
graphical	B-X
methods	B-X
to	B-X
assess	B-X
if	B-X
a	B-X
set	B-X
of	B-X
data	B-X
have	B-X
a	B-X
normal	B-X
distribution	B-X
(	B-X
display	B-X
``	B-X
normality	B-X
''	B-X
)	B-X
.	B-X
The	B-X
Shapiro-Wilk	B-X
test	B-X
and	B-X
the	B-X
Kolmogorov-Smirnov	B-X
test	B-X
are	B-X
2	B-X
well-known	B-X
and	B-X
historically	B-X
widely	B-X
applied	B-X
quantitative	B-X
methods	B-X
to	B-X
assess	B-X
for	B-X
data	B-X
normality	B-X
.	B-X
If	B-X
the	B-X
normality	B-X
test	B-X
concludes	B-X
that	B-X
the	B-X
study	B-X
data	B-X
deviate	B-X
significantly	B-X
from	B-X
a	B-X
Gaussian	B-X
distribution	B-X
,	B-X
rather	B-X
than	B-X
applying	B-X
a	B-X
less	B-X
robust	B-X
nonparametric	B-X
test	B-X
,	B-X
the	B-X
problem	B-X
can	B-X
potentially	B-X
be	B-X
remedied	B-X
by	B-X
judiciously	B-X
and	B-X
openly	B-X
:	B-X
(	B-X
1	B-X
)	B-X
performing	B-X
a	B-X
data	B-X
transformation	B-X
of	B-X
all	B-X
the	B-X
data	B-X
values	B-X
;	B-X
or	B-X
(	B-X
2	B-X
)	B-X
eliminating	B-X
any	B-X
obvious	B-X
data	B-X
outlier	B-X
(	B-X
s	B-X
)	B-X
.	B-X

Failure	O
of	O
therapy	O
may	O
have	O
been	O
related	O
to	O
the	O
presence	O
of	O
protected	O
organisms	O
in	O
vegetations	O
which	O
were	O
seen	O
on	O
echocardiograms	O
,	O
and	O
also	O
suggested	O
by	O
the	O
presence	O
of	O
a	O
possible	O
coronary	O
artery	O
embolus	O
seen	O
on	O
coronary	O
arteriograms	O
.	O

In	O
conclusion	O
,	O
speciation	O
of	O
isolates	O
suspected	O
of	O
causing	O
endocarditis	O
and	O
adequate	O
synergy	O
studies	O
of	O
antibiotic	O
combinations	O
are	O
indicated	O
before	O
a	O
long	O
and	O
expensive	O
course	O
of	O
therapy	O
with	O
antimicrobial	O
agents	O
is	O
undertaken	O
for	O
this	O
disease	O
.	O

However	O
,	O
as	O
this	O
case	O
also	O
illustrates	O
,	O
demonstration	O
of	O
synergism	O
in	O
vitro	O
does	O
not	O
assure	O
clinical	O
cure	O
.	O

ACKNOWLEDGEMENTS	O
<EOS>	B-X
Addiction	B-X
's	B-X
policy	B-X
on	B-X
fair	B-X
authorship	B-X
and	B-X
acknowledgment	B-X
practices	B-X
.	B-X

Dr	O
.	O
Goldstein	O
was	O
supported	O
by	O
training	O
grant	O
Al	O
07033	O
-	O
05	O
from	O
the	O
National	O
Institute	O
of	O
Allergy	O
and	O
Infectious	O
Diseases	O
.	O

The	O
authors	O
gratefully	O
acknowledge	O
the	O
advice	O
,	O
laboratory	O
assistance	O
,	O
and	O
careful	O
review	O
of	O
this	O
manuscript	O
by	O
Dr	O
.	O
Robert	O
C	O
.	O
Moellering	O
,	O
Jr	O
.	O

The	O
authors	O
also	O
wish	O
to	O
thank	O
Dr	O
.	O
Howard	O
S	O
.	O
Forster	O
for	O
referring	O
this	O
patient	B-Species
to	O
us	O
,	O
Ms	O
.	O
Mary	O
Murray	O
and	O
Deborah	O
Beauvais	O
for	O
manuscript	O
preparation	O
,	O
and	O
Ms	O
.	O
Gertrude	O
Barden	O
,	O
MT	O
(	O
ASCP	O
)	O
,	O
MHS	O
,	O
for	O
technical	O
assistance	O
and	O
advice	O
in	O
evaluation	O
of	O
this	O
patient	B-Species
.	O

REFERENCES	O

1	O
.	O
<EOS>	B-X
Formate	B-X
assay	B-X
in	B-X
body	B-X
fluids	B-X
:	B-X
application	B-X
in	B-X
methanol	B-X
poisoning	B-X
.	B-X

Hunter	O
TH	O
:	O
Use	O
of	O
streptomycin	O
in	O
the	O
treatment	O
of	O
bacterial	O
endocarditis	O
.	O
<EOS>	B-X
Use	B-X
of	B-X
streptomycin	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
bacterial	B-X
endocarditis	B-X
.	B-X

Am	O
J	O
Med	O
2	O
:	O
436	O
-	O
442	O
,	O

1947	O
<EOS>	B-X
This	B-X
review	B-X
deals	B-X
with	B-X
the	B-X
evolution	B-X
of	B-X
psychiatry	B-X
in	B-X
Pakistan	B-X
since	B-X
its	B-X
inception	B-X
in	B-X
1947	B-X
.	B-X
It	B-X
describes	B-X
the	B-X
situation	B-X
of	B-X
psychiatric	B-X
services	B-X
,	B-X
education	B-X
and	B-X
research	B-X
through	B-X
the	B-X
years	B-X
1947-2006	B-X
,	B-X
presenting	B-X
a	B-X
picture	B-X
of	B-X
existing	B-X
mental	B-X
health	B-X
scenario	B-X
,	B-X
suggesting	B-X
the	B-X
ways	B-X
for	B-X
improvement	B-X
and	B-X
comment	B-X
on	B-X
possible	B-X
future	B-X
developments	B-X
.	B-X
Influenza	B-X
,	B-X
1946-1947	B-X
.	B-X
The	B-X
present	B-X
article	B-X
comments	B-X
on	B-X
a	B-X
classic	B-X
study	B-X
by	B-X
Garfield	B-X
(	B-X
1947	B-X
)	B-X
then	B-X
reviews	B-X
research	B-X
on	B-X
the	B-X
Rorschach	B-X
and	B-X
psychiatric	B-X
diagnoses	B-X
.	B-X

2	O
.	O
<EOS>	B-X
Delineation	B-X
of	B-X
the	B-X
intimate	B-X
details	B-X
of	B-X
the	B-X
backbone	B-X
conformation	B-X
of	B-X
pyridine	B-X
nucleotide	B-X
coenzymes	B-X
in	B-X
aqueous	B-X
solution	B-X
.	B-X

Moellering	O
RC	O
Jr	O
,	O
Krogstad	O
DJ	O
:	O
Antibiotic	O
resistance	O
in	O
enterococci	O
.	O
<EOS>	B-X
Mating	B-X
experiments	B-X
have	B-X
shown	B-X
that	B-X
high-level	B-X
resistance	B-X
(	B-X
minimal	B-X
inhibitory	B-X
concentration	B-X
greater	B-X
than	B-X
2,000	B-X
microgram/ml	B-X
)	B-X
to	B-X
streptomycin	B-X
and	B-X
kanamycin	B-X
,	B-X
and	B-X
resistance	B-X
to	B-X
penicillin-streptomycin	B-X
and	B-X
penicillin-kanamycin	B-X
synergism	B-X
are	B-X
transferable	B-X
by	B-X
conjugation	B-X
from	B-X
resistant	B-X
clinical	B-X
isolates	B-X
of	B-X
enterococci	B-X
to	B-X
a	B-X
sensitive	B-X
recipient	B-X
strain	B-X
.	B-X
Novobiocin	B-X
treatment	B-X
of	B-X
a	B-X
resistant	B-X
clinical	B-X
isolate	B-X
produced	B-X
simultaneous	B-X
loss	B-X
of	B-X
high-level	B-X
resistance	B-X
to	B-X
streptomycin	B-X
and	B-X
kanamycin	B-X
,	B-X
and	B-X
of	B-X
resistance	B-X
to	B-X
penicillin-aminoglycoside	B-X
synergism	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
(	B-X
a	B-X
)	B-X
high-level	B-X
resistance	B-X
to	B-X
streptomycin	B-X
and	B-X
kanamycin	B-X
among	B-X
some	B-X
clinical	B-X
isolates	B-X
of	B-X
enterococci	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
45	B-X
megadalton	B-X
plasmid	B-X
,	B-X
and	B-X
(	B-X
b	B-X
)	B-X
the	B-X
same	B-X
plasmid	B-X
is	B-X
also	B-X
responsible	B-X
for	B-X
the	B-X
resistance	B-X
to	B-X
penicillin-aminoglycoside	B-X
synergism	B-X
observed	B-X
in	B-X
these	B-X
strains	B-X
.	B-X
Clinical	B-X
isolates	B-X
of	B-X
enterococci	B-X
(	B-X
Streptococcus	B-X
faecalis	B-X
)	B-X
with	B-X
high-level	B-X
resistance	B-X
to	B-X
both	B-X
streptomycin	B-X
and	B-X
kanamycin	B-X
(	B-X
minimal	B-X
inhibitory	B-X
concentration	B-X
>	B-X
2,000	B-X
mug/ml	B-X
)	B-X
,	B-X
and	B-X
resistant	B-X
to	B-X
synergism	B-X
with	B-X
penicillin	B-X
and	B-X
streptomycin	B-X
or	B-X
kanamycin	B-X
were	B-X
examined	B-X
for	B-X
aminoglycoside-inactivating	B-X
enzymes	B-X
.	B-X
A	B-X
transconjugant	B-X
strain	B-X
,	B-X
which	B-X
acquired	B-X
high-level	B-X
aminoglycoside	B-X
resistance	B-X
and	B-X
resistance	B-X
to	B-X
antibiotic	B-X
synergism	B-X
after	B-X
mating	B-X
with	B-X
a	B-X
resistant	B-X
clinical	B-X
isolate	B-X
,	B-X
also	B-X
acquired	B-X
both	B-X
enzyme	B-X
activities	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
conclude	B-X
that	B-X
aminoglycoside-inactivating	B-X
enzymes	B-X
are	B-X
responsible	B-X
for	B-X
the	B-X
aminoglycoside	B-X
resistance	B-X
,	B-X
and	B-X
resistance	B-X
to	B-X
antibiotic	B-X
synergism	B-X
observed	B-X
in	B-X
these	B-X
strains	B-X
.	B-X

Microbiology	O
293	O
-	O
298	O
,	O
1979	O
3	O
.	O

Facklam	O
RR	O
:	O
Recognition	O
of	O
group	O
D	O
streptococcal	O
species	O
of	O
human	B-Species
origin	O
by	O
biochemical	O
and	O

physiological	O
tests	O
.	O
<EOS>	B-X
In	B-X
order	B-X
to	B-X
measure	B-X
cardiopulmonary	B-X
performance	B-X
for	B-X
clinical	B-X
and	B-X
investigation	B-X
purposes	B-X
we	B-X
need	B-X
standardized	B-X
tests	B-X
which	B-X
allow	B-X
the	B-X
comparison	B-X
with	B-X
standard	B-X
values	B-X
,	B-X
between	B-X
people	B-X
,	B-X
or	B-X
individuals	B-X
with	B-X
themselves	B-X
over	B-X
time	B-X
.	B-X
The	B-X
quest	B-X
for	B-X
the	B-X
ideal	B-X
exercise	B-X
test	B-X
has	B-X
led	B-X
to	B-X
the	B-X
development	B-X
of	B-X
several	B-X
formats	B-X
,	B-X
the	B-X
so	B-X
called	B-X
laboratory	B-X
and	B-X
field	B-X
tests	B-X
.	B-X
Incremental	B-X
exercise	B-X
tests	B-X
allow	B-X
measurement	B-X
of	B-X
maximal	B-X
exercise	B-X
capacity	B-X
and	B-X
a	B-X
host	B-X
of	B-X
submaximal	B-X
variables	B-X
of	B-X
great	B-X
interest	B-X
.	B-X
The	B-X
physiological	B-X
rationale	B-X
of	B-X
the	B-X
tests	B-X
and	B-X
of	B-X
the	B-X
detection	B-X
of	B-X
interesting	B-X
submaximal	B-X
variables	B-X
can	B-X
be	B-X
explained	B-X
from	B-X
the	B-X
oxygen	B-X
uptake	B-X
and	B-X
carbon	B-X
dioxide	B-X
output	B-X
kinetic	B-X
response	B-X
to	B-X
constant	B-X
power	B-X
exercise	B-X
.	B-X
When	B-X
the	B-X
muscles	B-X
have	B-X
to	B-X
produce	B-X
very	B-X
high	B-X
energy	B-X
,	B-X
the	B-X
exercise	B-X
is	B-X
physiologically	B-X
limited	B-X
to	B-X
relatively	B-X
short	B-X
duration	B-X
.	B-X
This	B-X
shape	B-X
provides	B-X
the	B-X
rationale	B-X
for	B-X
understanding	B-X
the	B-X
properties	B-X
,	B-X
limitations	B-X
and	B-X
responsiveness	B-X
to	B-X
interventions	B-X
of	B-X
endurance	B-X
tests	B-X
such	B-X
as	B-X
constant	B-X
power	B-X
test	B-X
on	B-X
a	B-X
cycle-ergometer	B-X
or	B-X
treadmill	B-X
,	B-X
endurance	B-X
shuttle	B-X
walk	B-X
test	B-X
and	B-X
six-minute	B-X
walk	B-X
test	B-X
.	B-X

Appl	O
Microbiol	O
23	O
:	O
1131	O
-	O
1139	O
,	O
1972	O

4	O
.	O
<EOS>	B-X
Effect	B-X
of	B-X
chloroquine	B-X
on	B-X
cultured	B-X
fibroblasts	B-X
:	B-X
release	B-X
of	B-X
lysosomal	B-X
hydrolases	B-X
and	B-X
inhibition	B-X
of	B-X
their	B-X
uptake	B-X
.	B-X

Toala	O
P	O
,	O
McDonald	O
A	O
,	O
Wilcox	O
C	O
,	O
et	O
al	O
:	O
Susceptibility	O
of	O
group	O
D	O
streptococcus	O
(	O
enterococcus	O
)	O
to	O
21	O

antibiotics	O
in	O
vitro	O
,	O
with	O
special	O
reference	O
to	O
species	O
differences	O
.	O
<EOS>	B-X
Leukocytospermia	B-X
is	B-X
associated	B-X
with	B-X
reduced	B-X
in	B-X
vitro	B-X
fertilization	B-X
rate	B-X
,	B-X
and	B-X
experimentally-measured	B-X
sperm	B-X
functions	B-X
(	B-X
e.g.	B-X
,	B-X
motility	B-X
)	B-X
are	B-X
inhibited	B-X
by	B-X
high	B-X
concentrations	B-X
of	B-X
certain	B-X
WBC	B-X
products	B-X
(	B-X
e.g.	B-X
,	B-X
reactive	B-X
oxygen	B-X
species	B-X
and	B-X
interferon-gamma	B-X
)	B-X
.	B-X
Infections	B-X
dominated	B-X
by	B-X
organisms	B-X
of	B-X
the	B-X
Burkholderia	B-X
cepacia	B-X
complex	B-X
,	B-X
a	B-X
group	B-X
of	B-X
at	B-X
least	B-X
18	B-X
closely-related	B-X
species	B-X
of	B-X
gram-negative	B-X
bacteria	B-X
,	B-X
are	B-X
particularly	B-X
difficult	B-X
to	B-X
treat	B-X
.	B-X
Burkholderia	B-X
cepacia	B-X
complex	B-X
bacteria	B-X
are	B-X
resistant	B-X
to	B-X
many	B-X
common	B-X
antibiotics	B-X
and	B-X
able	B-X
to	B-X
acquire	B-X
resistance	B-X
against	B-X
many	B-X
more	B-X
.	B-X
Susceptibility	B-X
testing	B-X
using	B-X
the	B-X
EUCAST-AFST	B-X
method	B-X
against	B-X
39	B-X
clinical	B-X
Fusarium	B-X
strains	B-X
consecutively	B-X
collected	B-X
from	B-X
local	B-X
and	B-X
invasive	B-X
infections	B-X
during	B-X
the	B-X
last	B-X
10years	B-X
assessed	B-X
the	B-X
in	B-X
vitro	B-X
activities	B-X
of	B-X
amphotericin	B-X
B	B-X
(	B-X
AmB	B-X
)	B-X
and	B-X
triazole	B-X
antifungal	B-X
agents	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
susceptibility	B-X
pattern	B-X
of	B-X
12	B-X
reference	B-X
strains	B-X
from	B-X
the	B-X
CBS-KNAW	B-X
Fungal	B-X
Biodiversity	B-X
Centre	B-X
(	B-X
CBS	B-X
)	B-X
was	B-X
evaluated	B-X
.	B-X
Itraconazole	B-X
(	B-X
ITC	B-X
)	B-X
showed	B-X
high	B-X
MIC	B-X
values	B-X
,	B-X
displaying	B-X
in	B-X
vitro	B-X
resistance	B-X
.	B-X
Clinical	B-X
isolates	B-X
were	B-X
significantly	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
more	B-X
resistant	B-X
to	B-X
AmB	B-X
,	B-X
VRC	B-X
,	B-X
and	B-X
POC	B-X
,	B-X
than	B-X
the	B-X
CBS	B-X
reference	B-X
isolates	B-X
probably	B-X
due	B-X
to	B-X
previous	B-X
exposure	B-X
to	B-X
antifungal	B-X
therapy	B-X
.	B-X
The	B-X
present	B-X
antifungal	B-X
susceptibility	B-X
profiles	B-X
showed	B-X
that	B-X
species-	B-X
and	B-X
strain-specific	B-X
differences	B-X
in	B-X
antifungal	B-X
susceptibility	B-X
exist	B-X
within	B-X
Fusarium	B-X
and	B-X
that	B-X
susceptibility	B-X
testing	B-X
is	B-X
important	B-X
and	B-X
may	B-X
improve	B-X
the	B-X
prognosis	B-X
of	B-X
these	B-X
infections	B-X
.	B-X

Am	O
J	O
Med	O
Sci	O
258	O
:	O
416	O
-	O
430	O
,	O
1969	O
5	O
.	O

Shungu	O
DL	O
,	O
Cornett	O
JB	O
,	O
Shockman	O
GD	O
:	O
Morphological	O
and	O
physiological	O
study	O
of	O
autolytic	O
<EOS>	B-X
Three	B-X
autolytic-defective	B-X
mutants	B-X
of	B-X
Streptococcus	B-X
faecium	B-X
(	B-X
S.	B-X
faecalis	B-X
ATCC	B-X
9790	B-X
)	B-X
were	B-X
isolated	B-X
.	B-X
All	B-X
three	B-X
autolytic-defective	B-X
mutants	B-X
exhibited	B-X
the	B-X
following	B-X
properties	B-X
relative	B-X
to	B-X
the	B-X
parental	B-X
strain	B-X
:	B-X
(	B-X
i	B-X
)	B-X
slower	B-X
growth	B-X
rates	B-X
,	B-X
especially	B-X
in	B-X
chemically	B-X
defined	B-X
medium	B-X
;	B-X
(	B-X
ii	B-X
)	B-X
decreased	B-X
rates	B-X
of	B-X
cellular	B-X
autolysis	B-X
and	B-X
increased	B-X
survival	B-X
after	B-X
exposure	B-X
to	B-X
antibiotics	B-X
which	B-X
block	B-X
cell	B-X
wall	B-X
biosynthesis	B-X
;	B-X
(	B-X
iii	B-X
)	B-X
decreased	B-X
rates	B-X
of	B-X
cellular	B-X
autolysis	B-X
when	B-X
treated	B-X
with	B-X
detergents	B-X
,	B-X
suspended	B-X
in	B-X
autolysis	B-X
buffers	B-X
,	B-X
or	B-X
grown	B-X
in	B-X
medium	B-X
lacking	B-X
essential	B-X
cell	B-X
wall	B-X
precursors	B-X
;	B-X
(	B-X
iv	B-X
)	B-X
a	B-X
reduction	B-X
in	B-X
the	B-X
total	B-X
level	B-X
of	B-X
cellular	B-X
autolytic	B-X
enzyme	B-X
(	B-X
active	B-X
plus	B-X
latent	B-X
forms	B-X
of	B-X
the	B-X
enzyme	B-X
)	B-X
;	B-X
(	B-X
v	B-X
)	B-X
an	B-X
increased	B-X
ratio	B-X
of	B-X
latent	B-X
to	B-X
active	B-X
forms	B-X
of	B-X
autolysin	B-X
;	B-X
and	B-X
(	B-X
vi	B-X
)	B-X
increased	B-X
levels	B-X
of	B-X
both	B-X
cellular	B-X
lipoteichoic	B-X
acid	B-X
and	B-X
lipids	B-X
.	B-X

defective	O
Streptococcus	B-Species
faecium	I-Species
strains	O
.	O
<EOS>	B-X
Two	B-X
of	B-X
four	B-X
previously	B-X
isolated	B-X
autolysis-defective	B-X
mutants	B-X
of	B-X
Streptococcus	B-X
faecium	B-X
(	B-X
Streptococcus	B-X
faecalis	B-X
ATCC	B-X
9790	B-X
)	B-X
incorporated	B-X
substantially	B-X
more	B-X
[	B-X
14C	B-X
]	B-X
glycerol	B-X
into	B-X
lipids	B-X
and	B-X
lipoteichoic	B-X
acid	B-X
than	B-X
did	B-X
the	B-X
parent	B-X
strain	B-X
.	B-X
Consistent	B-X
with	B-X
increased	B-X
accumulation	B-X
of	B-X
lipids	B-X
and	B-X
lipoteichoic	B-X
acid	B-X
,	B-X
significantly	B-X
higher	B-X
levels	B-X
of	B-X
phosphorus	B-X
were	B-X
found	B-X
in	B-X
the	B-X
corresponding	B-X
fractions	B-X
of	B-X
the	B-X
two	B-X
mutant	B-X
strains	B-X
than	B-X
in	B-X
the	B-X
wild	B-X
type	B-X
.	B-X
Although	B-X
the	B-X
autolysis-defective	B-X
mutant	B-X
strains	B-X
contained	B-X
the	B-X
same	B-X
assortment	B-X
of	B-X
lipids	B-X
as	B-X
the	B-X
wild	B-X
type	B-X
,	B-X
the	B-X
relative	B-X
amount	B-X
of	B-X
[	B-X
14C	B-X
]	B-X
glycerol	B-X
incorporated	B-X
into	B-X
diphosphatidylglycerol	B-X
increased	B-X
,	B-X
accompanied	B-X
by	B-X
a	B-X
decreased	B-X
fraction	B-X
of	B-X
phosphatidylglycerol	B-X
.	B-X
These	B-X
results	B-X
suggested	B-X
that	B-X
increased	B-X
cellular	B-X
content	B-X
of	B-X
two	B-X
types	B-X
of	B-X
substances	B-X
,	B-X
acylated	B-X
lipoteichoic	B-X
acid	B-X
and	B-X
lipids	B-X
(	B-X
notably	B-X
diphosphatidylglycerol	B-X
)	B-X
,	B-X
which	B-X
previously	B-X
had	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
potent	B-X
inhibitors	B-X
of	B-X
the	B-X
N-acetylmuramoylhydrolase	B-X
of	B-X
this	B-X
species	B-X
,	B-X
contributed	B-X
to	B-X
the	B-X
autolysis-defective	B-X
phenotype	B-X
of	B-X
these	B-X
mutants	B-X
.	B-X

J	O
Bacteriol	O
138	O
:	O
598	O
-	O
608	O
,	O
1979	O

6	O
.	O
<EOS>	B-X
Studies	B-X
of	B-X
oxygen	B-X
binding	B-X
energy	B-X
to	B-X
hemoglobin	B-X
molecule	B-X
.	B-X

Moellering	O
RC	O
Jr	O
,	O
Korzeniowski	O
OM	O
,	O
Sande	O
MA	O
,	O
et	O
al	O
:	O
Species	O
-	O
specific	O
resistance	O
to	O
antimicrobial	O

synergism	O
in	O
Streptococcusfaecium	B-Species
and	O
Streptococcusfaecalis	B-Species
.	O

J	O
Infect	O
Dis	O
140	O
:	O
203	O
-	O
208	O
,	O
1979	O

7	O
.	O
<EOS>	B-X
Maturation	B-X
of	B-X
the	B-X
adrenal	B-X
medulla	B-X
--	B-X
IV	B-X
.	B-X
Effects	B-X
of	B-X
morphine	B-X
.	B-X

Moellering	O
RC	O
Jr	O
,	O
Weinberg	O
AN	O
:	O
Studies	O
on	O
antibiotic	O
synergism	O
against	O
enterococci	O
.	O
<EOS>	B-X
The	B-X
mechanism	B-X
by	B-X
which	B-X
agents	B-X
that	B-X
inhibit	B-X
bacterial	B-X
cell	B-X
wall	B-X
synthesis	B-X
produce	B-X
a	B-X
synergistic	B-X
effect	B-X
against	B-X
enterococci	B-X
when	B-X
combined	B-X
with	B-X
aminoglycoside	B-X
antibiotics	B-X
has	B-X
not	B-X
been	B-X
elucidated	B-X
.	B-X
Using	B-X
(	B-X
14	B-X
)	B-X
C-labeled	B-X
streptomycin	B-X
,	B-X
it	B-X
could	B-X
be	B-X
shown	B-X
that	B-X
uptake	B-X
of	B-X
this	B-X
aminoglycoside	B-X
antibiotic	B-X
was	B-X
markedly	B-X
enhanced	B-X
in	B-X
enterococci	B-X
growing	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
penicillin	B-X
or	B-X
other	B-X
agents	B-X
which	B-X
inhibit	B-X
the	B-X
synthesis	B-X
of	B-X
bacterial	B-X
cell	B-X
walls	B-X
.	B-X
There	B-X
was	B-X
no	B-X
enhancement	B-X
of	B-X
streptomycin	B-X
uptake	B-X
when	B-X
the	B-X
cells	B-X
were	B-X
incubated	B-X
with	B-X
antibiotics	B-X
which	B-X
primarily	B-X
affect	B-X
the	B-X
bacterial	B-X
cell	B-X
membrane	B-X
or	B-X
inhibit	B-X
protein	B-X
synthesis	B-X
.	B-X
These	B-X
observations	B-X
are	B-X
consistent	B-X
with	B-X
the	B-X
hypothesis	B-X
that	B-X
enterococci	B-X
exhibit	B-X
a	B-X
natural	B-X
barrier	B-X
to	B-X
the	B-X
entry	B-X
of	B-X
streptomycin	B-X
which	B-X
can	B-X
be	B-X
overcome	B-X
by	B-X
agents	B-X
which	B-X
inhibit	B-X
cell	B-X
wall	B-X
synthesis	B-X
,	B-X
thus	B-X
producing	B-X
a	B-X
synergistic	B-X
effect	B-X
.	B-X

11	O
.	O
<EOS>	B-X
Identification	B-X
of	B-X
adenylate	B-X
cyclase-coupled	B-X
beta-adrenergic	B-X
receptors	B-X
with	B-X
radiolabeled	B-X
beta-adrenergic	B-X
antagonists	B-X
.	B-X

Effect	O
of	O
<EOS>	B-X
How	B-X
Can	B-X
Synergism	B-X
of	B-X
Traditional	B-X
Medicines	B-X
Benefit	B-X
from	B-X
Network	B-X
Pharmacology	B-X
?	B-X
Self-Rated	B-X
Effectiveness	B-X
of	B-X
Microdosing	B-X
With	B-X
Psychedelics	B-X
for	B-X
Mental	B-X
and	B-X
Physical	B-X
Health	B-X
Problems	B-X
Among	B-X
Microdosers	B-X
.	B-X

various	O
antibiotics	O
on	O
the	O
uptake	O
of	O
'	O
4C	O
-	O
labelled	O
streptomycin	O
by	O
enterococci	O
.	O

J	O
Clin	O
Invest	O
50	O
:	O
2580	O
-	O
2584	O
,	O
1971	O

8	O
.	O
<EOS>	B-X
Comparison	B-X
between	B-X
procaine	B-X
and	B-X
isocarboxazid	B-X
metabolism	B-X
in	B-X
vitro	B-X
by	B-X
a	B-X
liver	B-X
microsomal	B-X
amidase-esterase	B-X
.	B-X

Zimmermann	O
RA	O
,	O
Moellering	O
RC	O
Jr	O
,	O
Weinberg	O
AN	O
:	O
Mechanisms	O
of	O
resistance	O
to	O
antibiotic	O
<EOS>	B-X
Enterococci	B-X
exhibit	B-X
two	B-X
types	B-X
of	B-X
resistance	B-X
to	B-X
streptomycin	B-X
.	B-X
Moderately	B-X
high-level	B-X
resistance	B-X
is	B-X
observed	B-X
in	B-X
most	B-X
naturally	B-X
occurring	B-X
strains	B-X
and	B-X
can	B-X
be	B-X
overcome	B-X
by	B-X
simultaneous	B-X
exposure	B-X
to	B-X
penicillin	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
very	B-X
high-level	B-X
resistance	B-X
is	B-X
found	B-X
in	B-X
those	B-X
strains	B-X
against	B-X
which	B-X
penicillin	B-X
plus	B-X
streptomycin	B-X
fail	B-X
to	B-X
produce	B-X
synergism	B-X
in	B-X
vitro	B-X
.	B-X
To	B-X
study	B-X
the	B-X
mechanism	B-X
of	B-X
streptomycin	B-X
resistance	B-X
in	B-X
enterococci	B-X
,	B-X
ribosomes	B-X
from	B-X
a	B-X
wild-type	B-X
strain	B-X
and	B-X
from	B-X
a	B-X
highly	B-X
streptomycin-resistant	B-X
mutant	B-X
were	B-X
isolated	B-X
,	B-X
characterized	B-X
,	B-X
and	B-X
studied	B-X
in	B-X
an	B-X
in	B-X
vitro	B-X
amino	B-X
acid	B-X
incorporation	B-X
system	B-X
.	B-X
The	B-X
ribosomes	B-X
from	B-X
the	B-X
organism	B-X
with	B-X
moderately	B-X
high-level	B-X
streptomycin	B-X
resistance	B-X
were	B-X
sensitive	B-X
to	B-X
streptomycin	B-X
in	B-X
vitro	B-X
,	B-X
suggesting	B-X
that	B-X
this	B-X
type	B-X
of	B-X
resistance	B-X
is	B-X
caused	B-X
by	B-X
failure	B-X
of	B-X
streptomycin	B-X
to	B-X
reach	B-X
the	B-X
ribosomes	B-X
.	B-X
Very	B-X
high-level	B-X
resistance	B-X
(	B-X
and	B-X
lack	B-X
of	B-X
penicillin-streptomycin	B-X
synergism	B-X
)	B-X
,	B-X
on	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
appears	B-X
to	B-X
be	B-X
due	B-X
to	B-X
ribosomally	B-X
mediated	B-X
streptomycin	B-X
resistance	B-X
.	B-X

synergism	O
in	O
enterococci	O
.	O
<EOS>	B-X
While	B-X
ampicillin	B-X
plus	B-X
ceftriaxone	B-X
has	B-X
emerged	B-X
as	B-X
a	B-X
preferred	B-X
treatment	B-X
option	B-X
,	B-X
mortality	B-X
rates	B-X
continue	B-X
to	B-X
be	B-X
high	B-X
,	B-X
and	B-X
from	B-X
a	B-X
safety	B-X
standpoint	B-X
,	B-X
ceftriaxone	B-X
,	B-X
unlike	B-X
other	B-X
cephalosporins	B-X
,	B-X
promotes	B-X
colonization	B-X
with	B-X
vancomycin	B-X
resistant-enterococci	B-X
due	B-X
to	B-X
high	B-X
biliary	B-X
concentrations	B-X
.	B-X
High-level	B-X
aminoglycoside	B-X
resistance	B-X
in	B-X
enterococci	B-X
is	B-X
mediated	B-X
generally	B-X
by	B-X
aminoglycoside-modifying	B-X
enzymes	B-X
,	B-X
which	B-X
eliminate	B-X
the	B-X
synergistic	B-X
bactericidal	B-X
effect	B-X
usually	B-X
seen	B-X
when	B-X
a	B-X
cell	B-X
wall-active	B-X
agent	B-X
is	B-X
combined	B-X
with	B-X
an	B-X
aminoglycoside	B-X
.	B-X
Clinical	B-X
microbiology	B-X
laboratories	B-X
currently	B-X
screen	B-X
for	B-X
aminoglycoside	B-X
resistance	B-X
in	B-X
enterococci	B-X
by	B-X
testing	B-X
gentamicin	B-X
and	B-X
streptomycin	B-X
susceptibility	B-X
.	B-X
If	B-X
the	B-X
recently	B-X
detected	B-X
aminoglycoside	B-X
resistance	B-X
genes	B-X
,	B-X
aph	B-X
(	B-X
2	B-X
''	B-X
)	B-X
-Ib	B-X
,	B-X
aph	B-X
(	B-X
2	B-X
''	B-X
)	B-X
-Ic	B-X
,	B-X
and	B-X
aph	B-X
(	B-X
2	B-X
''	B-X
)	B-X
-Id	B-X
,	B-X
become	B-X
more	B-X
prevalent	B-X
among	B-X
clinical	B-X
isolates	B-X
,	B-X
the	B-X
approach	B-X
for	B-X
detecting	B-X
susceptibility	B-X
to	B-X
aminoglycoside	B-X
synergism	B-X
in	B-X
enterococci	B-X
will	B-X
require	B-X
modification	B-X
.	B-X
More	B-X
potent	B-X
aminoglycosides	B-X
need	B-X
to	B-X
be	B-X
developed	B-X
that	B-X
will	B-X
be	B-X
resistant	B-X
to	B-X
modification	B-X
by	B-X
a	B-X
broad	B-X
spectrum	B-X
of	B-X
aminoglycoside-modifying	B-X
enzymes	B-X
present	B-X
in	B-X
enterococci	B-X
.	B-X

J	O
Bacteriol	O
105	O
:	O
873	O
-	O
879	O
,	O
1971	O

9	O
.	O
<EOS>	B-X
Radiochemical	B-X
assay	B-X
of	B-X
glutathione	B-X
S-epoxide	B-X
transferase	B-X
and	B-X
its	B-X
enhancement	B-X
by	B-X
phenobarbital	B-X
in	B-X
rat	B-X
liver	B-X
in	B-X
vivo	B-X
.	B-X

Moellering	O
RC	O
Jr	O
,	O
Murray	O
BE	O
,	O
Schoenbaum	O
SC	O
,	O
et	O
al	O
:	O
A	O
novel	O
mechanism	O
of	O
resistance	O
to	O
penicillin	O

gentamicin	O
synergism	O
in	O
S	B-Species
.	I-Species
faecalis	I-Species
.	O

J	O
Infect	O
Dis	O
141	O
:	O
81	O
-	O
86	O
,	O
1980	O

10	O
.	O
<EOS>	B-X
Digitoxin	B-X
metabolism	B-X
by	B-X
rat	B-X
liver	B-X
microsomes	B-X
.	B-X

Krogstad	O
DJ	O
,	O
Korfhagen	O
TR	O
,	O
Moellering	O
RC	O
Jr	O
,	O
et	O
al	O
:	O
Plasmid	O
-	O
mediated	O
resistance	O
to	O
antibiotic	O

synergism	O
in	O
enterococci	O
.	O
<EOS>	B-X
While	B-X
ampicillin	B-X
plus	B-X
ceftriaxone	B-X
has	B-X
emerged	B-X
as	B-X
a	B-X
preferred	B-X
treatment	B-X
option	B-X
,	B-X
mortality	B-X
rates	B-X
continue	B-X
to	B-X
be	B-X
high	B-X
,	B-X
and	B-X
from	B-X
a	B-X
safety	B-X
standpoint	B-X
,	B-X
ceftriaxone	B-X
,	B-X
unlike	B-X
other	B-X
cephalosporins	B-X
,	B-X
promotes	B-X
colonization	B-X
with	B-X
vancomycin	B-X
resistant-enterococci	B-X
due	B-X
to	B-X
high	B-X
biliary	B-X
concentrations	B-X
.	B-X
High-level	B-X
aminoglycoside	B-X
resistance	B-X
in	B-X
enterococci	B-X
is	B-X
mediated	B-X
generally	B-X
by	B-X
aminoglycoside-modifying	B-X
enzymes	B-X
,	B-X
which	B-X
eliminate	B-X
the	B-X
synergistic	B-X
bactericidal	B-X
effect	B-X
usually	B-X
seen	B-X
when	B-X
a	B-X
cell	B-X
wall-active	B-X
agent	B-X
is	B-X
combined	B-X
with	B-X
an	B-X
aminoglycoside	B-X
.	B-X
Clinical	B-X
microbiology	B-X
laboratories	B-X
currently	B-X
screen	B-X
for	B-X
aminoglycoside	B-X
resistance	B-X
in	B-X
enterococci	B-X
by	B-X
testing	B-X
gentamicin	B-X
and	B-X
streptomycin	B-X
susceptibility	B-X
.	B-X
If	B-X
the	B-X
recently	B-X
detected	B-X
aminoglycoside	B-X
resistance	B-X
genes	B-X
,	B-X
aph	B-X
(	B-X
2	B-X
''	B-X
)	B-X
-Ib	B-X
,	B-X
aph	B-X
(	B-X
2	B-X
''	B-X
)	B-X
-Ic	B-X
,	B-X
and	B-X
aph	B-X
(	B-X
2	B-X
''	B-X
)	B-X
-Id	B-X
,	B-X
become	B-X
more	B-X
prevalent	B-X
among	B-X
clinical	B-X
isolates	B-X
,	B-X
the	B-X
approach	B-X
for	B-X
detecting	B-X
susceptibility	B-X
to	B-X
aminoglycoside	B-X
synergism	B-X
in	B-X
enterococci	B-X
will	B-X
require	B-X
modification	B-X
.	B-X
More	B-X
potent	B-X
aminoglycosides	B-X
need	B-X
to	B-X
be	B-X
developed	B-X
that	B-X
will	B-X
be	B-X
resistant	B-X
to	B-X
modification	B-X
by	B-X
a	B-X
broad	B-X
spectrum	B-X
of	B-X
aminoglycoside-modifying	B-X
enzymes	B-X
present	B-X
in	B-X
enterococci	B-X
.	B-X

J	O
Clin	O
Invest	O
61	O
:	O
1645	O
-	O
1653	O
,	O
1978	O

11	O
.	O
<EOS>	B-X
Identification	B-X
of	B-X
adenylate	B-X
cyclase-coupled	B-X
beta-adrenergic	B-X
receptors	B-X
with	B-X
radiolabeled	B-X
beta-adrenergic	B-X
antagonists	B-X
.	B-X

Krogstad	O
DJ	O
,	O
Korfhagen	O
TR	O
,	O
Moellering	O
RC	O
Jr	O
,	O
et	O
al	O
:	O
Aminoglycoside	O
-	O
inactivating	O
enzymes	O
in	O

clinical	O
isolates	O
of	O
Streptococcusfaecalis	B-Species
:	O
An	O
explanation	O
for	O
resistance	O
to	O
antibiotic	O
synergism	O
.	O

J	O
Clin	O
Invest	O
62	O
:	O
480	O
-	O
486	O
,	O
1978	O

S	B-Species
.	I-Species
<EOS>	B-X
Finkelstein	B-X
's	B-X
Test	B-X
Is	B-X
Superior	B-X
to	B-X
Eichhoff	B-X
's	B-X
Test	B-X
in	B-X
the	B-X
Investigation	B-X
of	B-X
de	B-X
Quervain	B-X
's	B-X
Disease	B-X
.	B-X
Protein	B-X
S	B-X
deficiency	B-X
.	B-X
Letter	B-X
:	B-X
Craniometrics	B-X
and	B-X
Ventricular	B-X
Access	B-X
:	B-X
A	B-X
Review	B-X
of	B-X
Kocher	B-X
's	B-X
,	B-X
Kaufman	B-X
's	B-X
,	B-X
Paine	B-X
's	B-X
,	B-X
Menovksy	B-X
's	B-X
,	B-X
Tubbs	B-X
'	B-X
,	B-X
Keen	B-X
's	B-X
,	B-X
Frazier	B-X
's	B-X
,	B-X
Dandy	B-X
's	B-X
,	B-X
and	B-X
Sanchez	B-X
's	B-X
Points	B-X
.	B-X

FAECIUM	B-Species
ENDOCARDITIS	O
249	O

12	O
.	O
<EOS>	B-X
The	B-X
effect	B-X
of	B-X
adrenaline	B-X
and	B-X
of	B-X
alpha-	B-X
and	B-X
beta-adrenergic	B-X
blocking	B-X
agents	B-X
on	B-X
ATP	B-X
concentration	B-X
and	B-X
on	B-X
incorporation	B-X
of	B-X
32Pi	B-X
into	B-X
ATP	B-X
in	B-X
rat	B-X
fat	B-X
cells	B-X
.	B-X

Courvalin	O
PM	O
,	O
Shaw	O
WV	O
,	O
Jacob	O
AE	O
:	O
Plasmid	O
-	O
mediated	O
mechanisms	O
of	O
resistance	O
to	O
<EOS>	B-X
Genes	B-X
conferring	B-X
resistance	B-X
to	B-X
aminoglycoside-aminocyclitol	B-X
antibiotics	B-X
in	B-X
three	B-X
group	B-X
D	B-X
streptococcal	B-X
strains	B-X
,	B-X
Streptococcus	B-X
faecalis	B-X
JH1	B-X
and	B-X
JH6	B-X
and	B-X
S.	B-X
faecium	B-X
JH7	B-X
,	B-X
and	B-X
to	B-X
chloramphenicol	B-X
in	B-X
JH6	B-X
are	B-X
carried	B-X
by	B-X
plasmids	B-X
that	B-X
can	B-X
transfer	B-X
to	B-X
other	B-X
S.	B-X
faecalis	B-X
cells	B-X
.	B-X
The	B-X
aminoglycoside	B-X
resistance	B-X
is	B-X
mediated	B-X
by	B-X
constitutively	B-X
synthesized	B-X
phosphotransferase	B-X
enzymes	B-X
that	B-X
have	B-X
substrate	B-X
profiles	B-X
very	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
aminoglycoside	B-X
phosphotransferases	B-X
found	B-X
in	B-X
gram-negative	B-X
bacteria	B-X
.	B-X
Plasmid-borne	B-X
streptomycin	B-X
resistance	B-X
is	B-X
due	B-X
to	B-X
production	B-X
of	B-X
the	B-X
enzyme	B-X
streptomycin	B-X
adenylyltransferase	B-X
,	B-X
which	B-X
,	B-X
as	B-X
in	B-X
staphylococci	B-X
and	B-X
in	B-X
contrast	B-X
to	B-X
that	B-X
detected	B-X
in	B-X
gram-negative	B-X
bacteria	B-X
,	B-X
is	B-X
less	B-X
effective	B-X
against	B-X
spectinomycin	B-X
as	B-X
substrate	B-X
.	B-X

aminoglycoside	O
-	O
aminocyclitol	O
antibiotics	O
and	O
to	O
chloramphenicol	O
in	O
group	O
D	O
streptococci	O
.	O

Antimicrob	O
Agents	O
Chemother	O
13	O
:	O
716	O
-	O
725	O
,	O
1978	O

13	O
.	O
<EOS>	B-X
Action	B-X
of	B-X
propranolol	B-X
on	B-X
mitochondrial	B-X
functions	B-X
--	B-X
effects	B-X
on	B-X
energized	B-X
ion	B-X
fluxes	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
valinomycin	B-X
.	B-X

Calderwood	O
SA	O
,	O
Wennersten	O
C	O
,	O
Moellering	O
RC	O
Jr	O
,	O
et	O
al	O
:	O
Resistance	O
to	O
six	O
aminoglycosidic	O

aminocyclitol	O
antibiotics	O
among	O
enterococci	O
:	O
Prevalence	O
,	O
evolution	O
,	O
and	O
relationship	O
to	O
synergism	O
with	O
penicillin	O
.	O
<EOS>	B-X
Two	B-X
hundred	B-X
and	B-X
three	B-X
recent	B-X
clinical	B-X
isolates	B-X
of	B-X
enterococci	B-X
were	B-X
tested	B-X
for	B-X
susceptibility	B-X
to	B-X
streptomycin	B-X
,	B-X
kanamycin	B-X
,	B-X
amikacin	B-X
,	B-X
gentamicin	B-X
,	B-X
sisomicin	B-X
,	B-X
and	B-X
tobramycin	B-X
.	B-X
Depending	B-X
upon	B-X
the	B-X
source	B-X
of	B-X
the	B-X
isolate	B-X
,	B-X
36	B-X
to	B-X
54	B-X
%	B-X
of	B-X
the	B-X
enterococci	B-X
demonstrated	B-X
high-level	B-X
resistance	B-X
(	B-X
minimal	B-X
inhibitory	B-X
concentration	B-X
,	B-X
>	B-X
2,000	B-X
mug/ml	B-X
)	B-X
to	B-X
streptomycin	B-X
,	B-X
16	B-X
to	B-X
49	B-X
%	B-X
to	B-X
kanamycin	B-X
,	B-X
and	B-X
0	B-X
to	B-X
14	B-X
%	B-X
to	B-X
amikacin	B-X
.	B-X
A	B-X
comparison	B-X
with	B-X
isolates	B-X
of	B-X
enterococci	B-X
obtained	B-X
in	B-X
1968	B-X
revealed	B-X
that	B-X
there	B-X
has	B-X
been	B-X
a	B-X
decrease	B-X
in	B-X
prevalence	B-X
of	B-X
high-level	B-X
resistance	B-X
among	B-X
organisms	B-X
isolated	B-X
from	B-X
wound	B-X
cultures	B-X
in	B-X
1976	B-X
.	B-X
However	B-X
,	B-X
no	B-X
decrease	B-X
in	B-X
resistance	B-X
to	B-X
streptomycin	B-X
or	B-X
kanamycin	B-X
was	B-X
demonstrated	B-X
among	B-X
blood	B-X
or	B-X
urine	B-X
isolates	B-X
.	B-X
For	B-X
streptomycin	B-X
and	B-X
kanamycin	B-X
,	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
synergism	B-X
with	B-X
penicillin	B-X
correlated	B-X
with	B-X
the	B-X
absence	B-X
or	B-X
presence	B-X
of	B-X
high-level	B-X
aminoglycoside	B-X
resistance	B-X
.	B-X
Nonetheless	B-X
,	B-X
combinations	B-X
of	B-X
penicillin	B-X
plus	B-X
amikacin	B-X
failed	B-X
to	B-X
produce	B-X
synergistic	B-X
killing	B-X
against	B-X
6	B-X
of	B-X
the	B-X
10	B-X
strains	B-X
.	B-X

Antimicrob	O
Agents	O
Chemother	O
12	O
:	O
401	O
-	O
405	O
,	O
1977	O

14	O
.	O
<EOS>	B-X
Malathion	B-X
A	B-X
and	B-X
B	B-X
esterases	B-X
of	B-X
mouse	B-X
liver-I	B-X
.	B-X

Bisno	O
AL	O
:	O
Treatment	O
of	O
infective	O
endocarditis	O
.	O
<EOS>	B-X
To	B-X
provide	B-X
guidelines	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
endocarditis	B-X
in	B-X
adults	B-X
caused	B-X
by	B-X
the	B-X
following	B-X
microorganisms	B-X
:	B-X
viridans	B-X
streptococci	B-X
and	B-X
other	B-X
streptococci	B-X
,	B-X
enterococci	B-X
,	B-X
staphylococci	B-X
,	B-X
and	B-X
fastidious	B-X
gram-negative	B-X
bacilli	B-X
of	B-X
the	B-X
HACEK	B-X
group	B-X
.	B-X
Antimicrobial	B-X
treatment	B-X
of	B-X
infective	B-X
endocarditis	B-X
due	B-X
to	B-X
viridans	B-X
streptococci	B-X
,	B-X
enterococci	B-X
,	B-X
and	B-X
staphylococci	B-X
.	B-X
These	B-X
guidelines	B-X
describe	B-X
the	B-X
design	B-X
and	B-X
implementation	B-X
of	B-X
clinical	B-X
trials	B-X
to	B-X
assess	B-X
the	B-X
safety	B-X
and	B-X
efficacy	B-X
of	B-X
anti-infective	B-X
drugs	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
infective	B-X
endocarditis	B-X
.	B-X
To	B-X
accrue	B-X
a	B-X
sufficient	B-X
number	B-X
of	B-X
patients	B-X
,	B-X
only	B-X
those	B-X
with	B-X
streptococcal	B-X
or	B-X
staphylococcal	B-X
endocarditis	B-X
should	B-X
be	B-X
included	B-X
in	B-X
studies	B-X
.	B-X

New	O
York	O
,	O
Grune	O
and	O
Stratton	O
,	O
1981	O
,	O
p	O
90	O

15	O
.	O
<EOS>	B-X
Increase	B-X
in	B-X
acetyl	B-X
CoA	B-X
synthetase	B-X
activity	B-X
after	B-X
phenobarbital	B-X
treatment	B-X
.	B-X

Lorian	O
V	O
:	O
Effects	O
of	O
subminimum	O
inhibitory	O
concentrations	O
of	O
antibiotics	O
on	O
bacteria	O
.	O
<EOS>	B-X
Low	B-X
concentrations	B-X
of	B-X
antibiotics	B-X
or	B-X
sub-minimum	B-X
inhibitory	B-X
concentrations	B-X
(	B-X
sub-MIC	B-X
)	B-X
have	B-X
been	B-X
shown	B-X
in	B-X
vitro	B-X
to	B-X
alter	B-X
the	B-X
ultrastructure	B-X
and	B-X
antigenicity	B-X
of	B-X
bacteria	B-X
,	B-X
their	B-X
adherence	B-X
to	B-X
epithelial	B-X
cells	B-X
,	B-X
their	B-X
synthesis	B-X
and	B-X
excretion	B-X
of	B-X
pathogenic	B-X
enzymes	B-X
and	B-X
their	B-X
rate	B-X
of	B-X
growth	B-X
.	B-X
The	B-X
same	B-X
effects	B-X
have	B-X
been	B-X
detected	B-X
when	B-X
low	B-X
concentrations	B-X
of	B-X
antibiotic	B-X
act	B-X
on	B-X
bacteria	B-X
in	B-X
vivo	B-X
.	B-X
When	B-X
grown	B-X
at	B-X
pH	B-X
5	B-X
,	B-X
5.5	B-X
,	B-X
7.8	B-X
and	B-X
8.3	B-X
,	B-X
however	B-X
,	B-X
seven	B-X
of	B-X
the	B-X
oxacillin-resistant	B-X
strains	B-X
and	B-X
seven	B-X
of	B-X
the	B-X
oxacillin-sensitive	B-X
strains	B-X
produced	B-X
bacterial	B-X
cells	B-X
1.5	B-X
to	B-X
2	B-X
micron	B-X
in	B-X
diameter	B-X
.	B-X
Their	B-X
structure	B-X
is	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
staphylococci	B-X
grown	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
subminimum	B-X
inhibitory	B-X
concentrations	B-X
of	B-X
beta-lactam	B-X
antibiotics	B-X
,	B-X
which	B-X
inhibit	B-X
autolysis	B-X
of	B-X
cross	B-X
walls	B-X
.	B-X

In	O
Antibiotics	O
<EOS>	B-X
Antibiotics	B-X
were	B-X
initially	B-X
viewed	B-X
as	B-X
``	B-X
wonder	B-X
drugs	B-X
''	B-X
primarily	B-X
because	B-X
they	B-X
were	B-X
introduced	B-X
at	B-X
a	B-X
time	B-X
when	B-X
only	B-X
surgical	B-X
drainage	B-X
or	B-X
spontaneous	B-X
cures	B-X
were	B-X
available	B-X
to	B-X
treat	B-X
serious	B-X
bacterial	B-X
infections	B-X
.	B-X
Antibiotics	B-X
represent	B-X
a	B-X
first	B-X
line	B-X
of	B-X
defense	B-X
of	B-X
diverse	B-X
microorganisms	B-X
,	B-X
which	B-X
produce	B-X
and	B-X
use	B-X
antibiotics	B-X
to	B-X
counteract	B-X
natural	B-X
enemies	B-X
or	B-X
competitors	B-X
for	B-X
nutritional	B-X
resources	B-X
in	B-X
their	B-X
nearby	B-X
environment	B-X
.	B-X
Antibiotics	B-X
are	B-X
antimicrobial	B-X
agents	B-X
primarily	B-X
produced	B-X
by	B-X
certain	B-X
bacteria	B-X
and	B-X
fungi	B-X
.	B-X

in	O
Laboratory	O
Medicine	O
.	O
<EOS>	B-X
Laboratory	B-X
Medicine	B-X
Turns	B-X
50	B-X
!	B-X
Laboratory	B-X
professionals	B-X
,	B-X
consultants	B-X
,	B-X
and	B-X
treating	B-X
physicians	B-X
may	B-X
encounter	B-X
discrepancies	B-X
in	B-X
serological	B-X
testing	B-X
results	B-X
for	B-X
numerous	B-X
reasons	B-X
;	B-X
identifying	B-X
the	B-X
reason	B-X
(	B-X
s	B-X
)	B-X
for	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
unexpected	B-X
antibody	B-X
or	B-X
antigen	B-X
can	B-X
be	B-X
challenging	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
aim	B-X
to	B-X
determine	B-X
the	B-X
student	B-X
and	B-X
faculty	B-X
diversity	B-X
in	B-X
the	B-X
Clinical	B-X
Laboratory	B-X
Sciences	B-X
programs	B-X
at	B-X
Stony	B-X
Brook	B-X
University	B-X
.	B-X
Pathology-The	B-X
Beginnings	B-X
of	B-X
Laboratory	B-X
Medicine	B-X
.	B-X

Edited	O
by	O
V	O
Lorian	O
.	O

Baltimore	O
,	O
Williams	O
and	O
Wilkins	O
,	O
1980	O
,	O
p	O
342	O

Structural	O
organization	O
of	O
a	O
17	O
KB	O
segment	O
of	O
the	O
alpha	O
2	O
collagen	O
gene	O
:	O
evaluation	O
by	O
R	O
loop	O
mapping	O
.	O

Abstract	O
<EOS>	B-X
Abstract	B-X
writing	B-X
.	B-X
The	B-X
informative	B-X
abstract	B-X
.	B-X
Crafting	B-X
a	B-X
compelling	B-X
abstract	B-X
.	B-X
Why	B-X
the	B-X
structured	B-X
abstract	B-X
?	B-X

A	O
recombinant	O
phage	O
,	O
SpC3	O
,	O
containing	O
a	O
17	O
kb	O
genomic	O
DNA	O
insert	O
representing	O
approximately	O
60	O
%	O
of	O
the	O
3	O
'	O
portion	O
of	O
the	O
sheep	B-Species
collagen	O
alpha	O
2	O
gene	O
,	O
was	O
evaluated	O
by	O
electron	O
microscopic	O
R	O
loop	O
analysis	O
.	O
<EOS>	B-X
A	B-X
recombinant	B-X
phage	B-X
,	B-X
SpC3	B-X
,	B-X
containing	B-X
a	B-X
17	B-X
kb	B-X
genomic	B-X
DNA	B-X
insert	B-X
representing	B-X
approximately	B-X
60	B-X
%	B-X
of	B-X
the	B-X
3	B-X
'	B-X
portion	B-X
of	B-X
the	B-X
sheep	B-X
collagen	B-X
alpha	B-X
2	B-X
gene	B-X
,	B-X
was	B-X
evaluated	B-X
by	B-X
electron	B-X
microscopic	B-X
R	B-X
loop	B-X
analysis	B-X
.	B-X
A	B-X
minimum	B-X
of	B-X
17	B-X
intervening	B-X
sequences	B-X
(	B-X
introns	B-X
)	B-X
and	B-X
18	B-X
alpha	B-X
2	B-X
coding	B-X
sequences	B-X
(	B-X
exons	B-X
)	B-X
were	B-X
mapped	B-X
.	B-X
With	B-X
the	B-X
exception	B-X
of	B-X
the	B-X
850	B-X
base	B-X
pair	B-X
exon	B-X
located	B-X
at	B-X
the	B-X
extreme	B-X
3	B-X
'	B-X
end	B-X
of	B-X
the	B-X
insert	B-X
,	B-X
all	B-X
exons	B-X
contained	B-X
250	B-X
base	B-X
pairs	B-X
or	B-X
less	B-X
.	B-X
The	B-X
total	B-X
length	B-X
of	B-X
all	B-X
the	B-X
exons	B-X
in	B-X
SpC3	B-X
was	B-X
3,014	B-X
base	B-X
pairs	B-X
.	B-X
The	B-X
length	B-X
distribution	B-X
of	B-X
the	B-X
17	B-X
introns	B-X
ranged	B-X
from	B-X
300	B-X
to	B-X
1600	B-X
base	B-X
pairs	B-X
;	B-X
together	B-X
,	B-X
all	B-X
of	B-X
the	B-X
introns	B-X
comprised	B-X
14,070	B-X
base	B-X
pairs	B-X
of	B-X
SpC3	B-X
DNA	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
DNA	B-X
region	B-X
required	B-X
for	B-X
coding	B-X
the	B-X
interspersed	B-X
3	B-X
kb	B-X
of	B-X
alpha	B-X
2	B-X
collagen	B-X
genetic	B-X
information	B-X
was	B-X
5.6	B-X
fold	B-X
longer	B-X
than	B-X
the	B-X
corresponding	B-X
alpha	B-X
2	B-X
mRNA	B-X
coding	B-X
sequences	B-X
.	B-X

A	O
minimum	O
of	O
17	O
intervening	O
sequences	O
(	O
introns	O
)	O
and	O
18	O
alpha	O
2	O
coding	O
sequences	O
(	O
exons	O
)	O
were	O
mapped	O
.	O
<EOS>	B-X
A	B-X
recombinant	B-X
phage	B-X
,	B-X
SpC3	B-X
,	B-X
containing	B-X
a	B-X
17	B-X
kb	B-X
genomic	B-X
DNA	B-X
insert	B-X
representing	B-X
approximately	B-X
60	B-X
%	B-X
of	B-X
the	B-X
3	B-X
'	B-X
portion	B-X
of	B-X
the	B-X
sheep	B-X
collagen	B-X
alpha	B-X
2	B-X
gene	B-X
,	B-X
was	B-X
evaluated	B-X
by	B-X
electron	B-X
microscopic	B-X
R	B-X
loop	B-X
analysis	B-X
.	B-X
A	B-X
minimum	B-X
of	B-X
17	B-X
intervening	B-X
sequences	B-X
(	B-X
introns	B-X
)	B-X
and	B-X
18	B-X
alpha	B-X
2	B-X
coding	B-X
sequences	B-X
(	B-X
exons	B-X
)	B-X
were	B-X
mapped	B-X
.	B-X
With	B-X
the	B-X
exception	B-X
of	B-X
the	B-X
850	B-X
base	B-X
pair	B-X
exon	B-X
located	B-X
at	B-X
the	B-X
extreme	B-X
3	B-X
'	B-X
end	B-X
of	B-X
the	B-X
insert	B-X
,	B-X
all	B-X
exons	B-X
contained	B-X
250	B-X
base	B-X
pairs	B-X
or	B-X
less	B-X
.	B-X
The	B-X
total	B-X
length	B-X
of	B-X
all	B-X
the	B-X
exons	B-X
in	B-X
SpC3	B-X
was	B-X
3,014	B-X
base	B-X
pairs	B-X
.	B-X
The	B-X
length	B-X
distribution	B-X
of	B-X
the	B-X
17	B-X
introns	B-X
ranged	B-X
from	B-X
300	B-X
to	B-X
1600	B-X
base	B-X
pairs	B-X
;	B-X
together	B-X
,	B-X
all	B-X
of	B-X
the	B-X
introns	B-X
comprised	B-X
14,070	B-X
base	B-X
pairs	B-X
of	B-X
SpC3	B-X
DNA	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
DNA	B-X
region	B-X
required	B-X
for	B-X
coding	B-X
the	B-X
interspersed	B-X
3	B-X
kb	B-X
of	B-X
alpha	B-X
2	B-X
collagen	B-X
genetic	B-X
information	B-X
was	B-X
5.6	B-X
fold	B-X
longer	B-X
than	B-X
the	B-X
corresponding	B-X
alpha	B-X
2	B-X
mRNA	B-X
coding	B-X
sequences	B-X
.	B-X

With	O
the	O
exception	O
of	O
the	O
850	O
base	O
pair	O
exon	O
located	O
at	O
the	O
extreme	O
3	O
'	O
end	O
of	O
the	O
insert	O
,	O
all	O
exons	O
contained	O
250	O
base	O
pairs	O
or	O
less	O
.	O
<EOS>	B-X
The	B-X
use	B-X
of	B-X
a	B-X
less-sentient	B-X
species	B-X
is	B-X
in	B-X
line	B-X
with	B-X
the	B-X
concept	B-X
of	B-X
Replacement	B-X
,	B-X
one	B-X
of	B-X
the	B-X
well-known	B-X
3Rs	B-X
of	B-X
laboratory	B-X
animal	B-X
use	B-X
.	B-X
But	B-X
what	B-X
is	B-X
a	B-X
less-sentient	B-X
species	B-X
?	B-X
Is	B-X
a	B-X
chimpanzee	B-X
less	B-X
sentient	B-X
than	B-X
a	B-X
human	B-X
;	B-X
is	B-X
a	B-X
dog	B-X
less	B-X
sentient	B-X
than	B-X
a	B-X
chimpanzee	B-X
;	B-X
and	B-X
is	B-X
a	B-X
mouse	B-X
less	B-X
sentient	B-X
than	B-X
a	B-X
dog	B-X
?	B-X
Does	B-X
'less	B-X
sentient	B-X
'	B-X
imply	B-X
that	B-X
a	B-X
species	B-X
is	B-X
less	B-X
able	B-X
to	B-X
experience	B-X
pain	B-X
,	B-X
is	B-X
less	B-X
intelligent	B-X
or	B-X
has	B-X
less	B-X
self-awareness	B-X
?	B-X

The	O
total	O
length	O
of	O
all	O
the	O
exons	O
in	O
SpC3	O
was	O
3	O
,	O
014	O
base	O
pairs	O
.	O
<EOS>	B-X
A	B-X
recombinant	B-X
phage	B-X
,	B-X
SpC3	B-X
,	B-X
containing	B-X
a	B-X
17	B-X
kb	B-X
genomic	B-X
DNA	B-X
insert	B-X
representing	B-X
approximately	B-X
60	B-X
%	B-X
of	B-X
the	B-X
3	B-X
'	B-X
portion	B-X
of	B-X
the	B-X
sheep	B-X
collagen	B-X
alpha	B-X
2	B-X
gene	B-X
,	B-X
was	B-X
evaluated	B-X
by	B-X
electron	B-X
microscopic	B-X
R	B-X
loop	B-X
analysis	B-X
.	B-X
A	B-X
minimum	B-X
of	B-X
17	B-X
intervening	B-X
sequences	B-X
(	B-X
introns	B-X
)	B-X
and	B-X
18	B-X
alpha	B-X
2	B-X
coding	B-X
sequences	B-X
(	B-X
exons	B-X
)	B-X
were	B-X
mapped	B-X
.	B-X
With	B-X
the	B-X
exception	B-X
of	B-X
the	B-X
850	B-X
base	B-X
pair	B-X
exon	B-X
located	B-X
at	B-X
the	B-X
extreme	B-X
3	B-X
'	B-X
end	B-X
of	B-X
the	B-X
insert	B-X
,	B-X
all	B-X
exons	B-X
contained	B-X
250	B-X
base	B-X
pairs	B-X
or	B-X
less	B-X
.	B-X
The	B-X
total	B-X
length	B-X
of	B-X
all	B-X
the	B-X
exons	B-X
in	B-X
SpC3	B-X
was	B-X
3,014	B-X
base	B-X
pairs	B-X
.	B-X
The	B-X
length	B-X
distribution	B-X
of	B-X
the	B-X
17	B-X
introns	B-X
ranged	B-X
from	B-X
300	B-X
to	B-X
1600	B-X
base	B-X
pairs	B-X
;	B-X
together	B-X
,	B-X
all	B-X
of	B-X
the	B-X
introns	B-X
comprised	B-X
14,070	B-X
base	B-X
pairs	B-X
of	B-X
SpC3	B-X
DNA	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
DNA	B-X
region	B-X
required	B-X
for	B-X
coding	B-X
the	B-X
interspersed	B-X
3	B-X
kb	B-X
of	B-X
alpha	B-X
2	B-X
collagen	B-X
genetic	B-X
information	B-X
was	B-X
5.6	B-X
fold	B-X
longer	B-X
than	B-X
the	B-X
corresponding	B-X
alpha	B-X
2	B-X
mRNA	B-X
coding	B-X
sequences	B-X
.	B-X

The	O
length	O
distribution	O
of	O
the	O
17	O
introns	O
ranged	O
from	O
300	O
to	O
1600	O
base	O
pairs	O
;	O
together	O
,	O
all	O
of	O
the	O
introns	O
comprised	O
14	O
,	O
070	O
base	O
pairs	O
of	O
SpC3	O
DNA	O
.	O
<EOS>	B-X
A	B-X
recombinant	B-X
phage	B-X
,	B-X
SpC3	B-X
,	B-X
containing	B-X
a	B-X
17	B-X
kb	B-X
genomic	B-X
DNA	B-X
insert	B-X
representing	B-X
approximately	B-X
60	B-X
%	B-X
of	B-X
the	B-X
3	B-X
'	B-X
portion	B-X
of	B-X
the	B-X
sheep	B-X
collagen	B-X
alpha	B-X
2	B-X
gene	B-X
,	B-X
was	B-X
evaluated	B-X
by	B-X
electron	B-X
microscopic	B-X
R	B-X
loop	B-X
analysis	B-X
.	B-X
A	B-X
minimum	B-X
of	B-X
17	B-X
intervening	B-X
sequences	B-X
(	B-X
introns	B-X
)	B-X
and	B-X
18	B-X
alpha	B-X
2	B-X
coding	B-X
sequences	B-X
(	B-X
exons	B-X
)	B-X
were	B-X
mapped	B-X
.	B-X
With	B-X
the	B-X
exception	B-X
of	B-X
the	B-X
850	B-X
base	B-X
pair	B-X
exon	B-X
located	B-X
at	B-X
the	B-X
extreme	B-X
3	B-X
'	B-X
end	B-X
of	B-X
the	B-X
insert	B-X
,	B-X
all	B-X
exons	B-X
contained	B-X
250	B-X
base	B-X
pairs	B-X
or	B-X
less	B-X
.	B-X
The	B-X
total	B-X
length	B-X
of	B-X
all	B-X
the	B-X
exons	B-X
in	B-X
SpC3	B-X
was	B-X
3,014	B-X
base	B-X
pairs	B-X
.	B-X
The	B-X
length	B-X
distribution	B-X
of	B-X
the	B-X
17	B-X
introns	B-X
ranged	B-X
from	B-X
300	B-X
to	B-X
1600	B-X
base	B-X
pairs	B-X
;	B-X
together	B-X
,	B-X
all	B-X
of	B-X
the	B-X
introns	B-X
comprised	B-X
14,070	B-X
base	B-X
pairs	B-X
of	B-X
SpC3	B-X
DNA	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
DNA	B-X
region	B-X
required	B-X
for	B-X
coding	B-X
the	B-X
interspersed	B-X
3	B-X
kb	B-X
of	B-X
alpha	B-X
2	B-X
collagen	B-X
genetic	B-X
information	B-X
was	B-X
5.6	B-X
fold	B-X
longer	B-X
than	B-X
the	B-X
corresponding	B-X
alpha	B-X
2	B-X
mRNA	B-X
coding	B-X
sequences	B-X
.	B-X

Thus	O
,	O
the	O
DNA	O
region	O
required	O
for	O
coding	O
the	O
interspersed	O
3	O
kb	O
of	O
alpha	O
2	O
collagen	O
genetic	O
information	O
was	O
5	O
.	O
6	O
fold	O
longer	O
than	O
the	O
corresponding	O
alpha	O
2	O
mRNA	O
coding	O
sequences	O
.	O
Images	O

Nucleic	O
Acids	O
Research	O
<EOS>	B-X
The	B-X
2021	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
database	B-X
Issue	B-X
contains	B-X
189	B-X
papers	B-X
spanning	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
biological	B-X
fields	B-X
and	B-X
investigation	B-X
.	B-X
The	B-X
entire	B-X
Database	B-X
Issue	B-X
is	B-X
freely	B-X
available	B-X
online	B-X
on	B-X
the	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
website	B-X
(	B-X
https	B-X
:	B-X
//academic.oup.com/nar	B-X
)	B-X
.	B-X
Editorial	B-X
:	B-X
the	B-X
19th	B-X
annual	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
web	B-X
server	B-X
issue	B-X
2021	B-X
.	B-X
Editorial	B-X
:	B-X
Critical	B-X
reviews	B-X
and	B-X
perspectives	B-X
in	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
.	B-X

Structural	O
organization	O
of	O
a	O
17	O
KB	O
segment	O
of	O
the	O
a2	O
collagen	O
gene	O
:	O
evaluation	O
by	O
R	O
loop	O
mapping	O
Millie	O
P	O
.	O
Schafer	O
,	O
Charles	O
D	O
.	O
Boyd	O
,	O
Paul	O
Tolstoshev	O
and	O
Ronald	O
G	O
.	O
Crystal	O

Pulmonary	O
Branch	O
,	O
National	O
Heart	O
,	O
Lung	O
and	O
Blood	O
Institute	O
,	O
National	O
Institutes	O
of	O
Health	O
,	O
Bethesda	O
,	O
MD	O
20205	O
,	O
USA	O

Received	O
13	O
February	O
1980	O
<EOS>	B-X
However	B-X
,	B-X
a	B-X
system	B-X
of	B-X
community	B-X
surveillance	B-X
of	B-X
febrile	B-X
respiratory	B-X
illness	B-X
with	B-X
cultures	B-X
for	B-X
influenza	B-X
virus	B-X
during	B-X
late	B-X
January	B-X
and	B-X
early	B-X
February	B-X
1975	B-X
gave	B-X
unmistakable	B-X
evidence	B-X
of	B-X
an	B-X
influenza	B-X
epidemic	B-X
,	B-X
with	B-X
more	B-X
than	B-X
600	B-X
virus	B-X
isolations	B-X
and	B-X
an	B-X
estimated	B-X
occurrence	B-X
of	B-X
50,000	B-X
cases	B-X
of	B-X
the	B-X
disease	B-X
.	B-X
Current	B-X
speculation	B-X
is	B-X
that	B-X
there	B-X
will	B-X
be	B-X
another	B-X
world	B-X
pandemic	B-X
before	B-X
1980	B-X
caused	B-X
by	B-X
a	B-X
derivative	B-X
of	B-X
A	B-X
strains	B-X
presently	B-X
circulating	B-X
;	B-X
in	B-X
1985-1991	B-X
,	B-X
a	B-X
pandemic	B-X
is	B-X
predicted	B-X
to	B-X
be	B-X
caused	B-X
by	B-X
a	B-X
virus	B-X
antigenically	B-X
related	B-X
to	B-X
the	B-X
swine	B-X
agent	B-X
of	B-X
1918	B-X
.	B-X

ABSTRACT	O
<EOS>	B-X
Abstract	B-X
writing	B-X
.	B-X
The	B-X
informative	B-X
abstract	B-X
.	B-X
Crafting	B-X
a	B-X
compelling	B-X
abstract	B-X
.	B-X
Why	B-X
the	B-X
structured	B-X
abstract	B-X
?	B-X

A	O
recombinant	O
phage	O
,	O
SpC3	O
,	O
containing	O
a	O
17	O
kb	O
genomic	O
DNA	O
insert	O
rep	O

resenting	O
approximately	O
60	O
%	O
of	O
the	O
3	O
'	O
portion	O
of	O
the	O
sheep	B-Species
collagen	O
a2	O
gene	O
,	O
was	O
evaluated	O
by	O
electron	O
microscopic	O
R	O
loop	O
analysis	O
.	O

A	O
minimum	O
of	O
17	O
intervening	O
sequences	O
(	O
introns	O
)	O
and	O
18	O
a2	O
coding	O
sequences	O
(	O
exons	O
)	O
were	O

mapped	O
.	O
<EOS>	B-X
We	B-X
compared	B-X
short-	B-X
and	B-X
long-term	B-X
retention	B-X
of	B-X
fast	B-X
mapped	B-X
color	B-X
,	B-X
shape	B-X
,	B-X
and	B-X
texture	B-X
words	B-X
as	B-X
well	B-X
as	B-X
object	B-X
labels	B-X
.	B-X
Our	B-X
findings	B-X
suggest	B-X
that	B-X
fast	B-X
mapped	B-X
object	B-X
labels	B-X
are	B-X
retained	B-X
long	B-X
term	B-X
better	B-X
than	B-X
color	B-X
,	B-X
shape	B-X
,	B-X
and	B-X
texture	B-X
words	B-X
.	B-X
If	B-X
we	B-X
accept	B-X
these	B-X
premises	B-X
,	B-X
then	B-X
a	B-X
natural	B-X
way	B-X
to	B-X
study	B-X
hormones	B-X
is	B-X
to	B-X
hypothesize	B-X
and	B-X
test	B-X
how	B-X
multiple	B-X
eliciting	B-X
conditions	B-X
are	B-X
mapped	B-X
into	B-X
coordinated	B-X
output	B-X
effects	B-X
via	B-X
hormonal	B-X
signals	B-X
.	B-X
100	B-X
%	B-X
4-digit	B-X
code	B-X
ICD-10-CN	B-X
terms	B-X
were	B-X
mapped	B-X
to	B-X
SNOMED-CT	B-X
terms	B-X
through	B-X
exsit	B-X
code	B-X
mappings	B-X
.	B-X

With	O
the	O
exception	O
of	O
the	O
850	O
base	O
pair	O
exon	O
located	O
at	O
the	O
extreme	O
3	O
'	O
end	O
of	O
the	O
insert	O
,	O
all	O
exons	O
contained	O
250	O
base	O
pairs	O
or	O
less	O
.	O
<EOS>	B-X
The	B-X
use	B-X
of	B-X
a	B-X
less-sentient	B-X
species	B-X
is	B-X
in	B-X
line	B-X
with	B-X
the	B-X
concept	B-X
of	B-X
Replacement	B-X
,	B-X
one	B-X
of	B-X
the	B-X
well-known	B-X
3Rs	B-X
of	B-X
laboratory	B-X
animal	B-X
use	B-X
.	B-X
But	B-X
what	B-X
is	B-X
a	B-X
less-sentient	B-X
species	B-X
?	B-X
Is	B-X
a	B-X
chimpanzee	B-X
less	B-X
sentient	B-X
than	B-X
a	B-X
human	B-X
;	B-X
is	B-X
a	B-X
dog	B-X
less	B-X
sentient	B-X
than	B-X
a	B-X
chimpanzee	B-X
;	B-X
and	B-X
is	B-X
a	B-X
mouse	B-X
less	B-X
sentient	B-X
than	B-X
a	B-X
dog	B-X
?	B-X
Does	B-X
'less	B-X
sentient	B-X
'	B-X
imply	B-X
that	B-X
a	B-X
species	B-X
is	B-X
less	B-X
able	B-X
to	B-X
experience	B-X
pain	B-X
,	B-X
is	B-X
less	B-X
intelligent	B-X
or	B-X
has	B-X
less	B-X
self-awareness	B-X
?	B-X

The	O
total	O
length	O
of	O
all	O
the	O
exons	O
in	O
SpC3	O
was	O
3	O
,	O
014	O
base	O
pairs	O
.	O
<EOS>	B-X
A	B-X
recombinant	B-X
phage	B-X
,	B-X
SpC3	B-X
,	B-X
containing	B-X
a	B-X
17	B-X
kb	B-X
genomic	B-X
DNA	B-X
insert	B-X
representing	B-X
approximately	B-X
60	B-X
%	B-X
of	B-X
the	B-X
3	B-X
'	B-X
portion	B-X
of	B-X
the	B-X
sheep	B-X
collagen	B-X
alpha	B-X
2	B-X
gene	B-X
,	B-X
was	B-X
evaluated	B-X
by	B-X
electron	B-X
microscopic	B-X
R	B-X
loop	B-X
analysis	B-X
.	B-X
A	B-X
minimum	B-X
of	B-X
17	B-X
intervening	B-X
sequences	B-X
(	B-X
introns	B-X
)	B-X
and	B-X
18	B-X
alpha	B-X
2	B-X
coding	B-X
sequences	B-X
(	B-X
exons	B-X
)	B-X
were	B-X
mapped	B-X
.	B-X
With	B-X
the	B-X
exception	B-X
of	B-X
the	B-X
850	B-X
base	B-X
pair	B-X
exon	B-X
located	B-X
at	B-X
the	B-X
extreme	B-X
3	B-X
'	B-X
end	B-X
of	B-X
the	B-X
insert	B-X
,	B-X
all	B-X
exons	B-X
contained	B-X
250	B-X
base	B-X
pairs	B-X
or	B-X
less	B-X
.	B-X
The	B-X
total	B-X
length	B-X
of	B-X
all	B-X
the	B-X
exons	B-X
in	B-X
SpC3	B-X
was	B-X
3,014	B-X
base	B-X
pairs	B-X
.	B-X
The	B-X
length	B-X
distribution	B-X
of	B-X
the	B-X
17	B-X
introns	B-X
ranged	B-X
from	B-X
300	B-X
to	B-X
1600	B-X
base	B-X
pairs	B-X
;	B-X
together	B-X
,	B-X
all	B-X
of	B-X
the	B-X
introns	B-X
comprised	B-X
14,070	B-X
base	B-X
pairs	B-X
of	B-X
SpC3	B-X
DNA	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
DNA	B-X
region	B-X
required	B-X
for	B-X
coding	B-X
the	B-X
interspersed	B-X
3	B-X
kb	B-X
of	B-X
alpha	B-X
2	B-X
collagen	B-X
genetic	B-X
information	B-X
was	B-X
5.6	B-X
fold	B-X
longer	B-X
than	B-X
the	B-X
corresponding	B-X
alpha	B-X
2	B-X
mRNA	B-X
coding	B-X
sequences	B-X
.	B-X

The	O
length	O
distribution	O
of	O
the	O
17	O
introns	O
ranged	O
from	O
300	O
to	O
1600	O
base	O
pairs	O
;	O
together	O
,	O
all	O
of	O
the	O
introns	O
comprised	O
14	O
,	O
070	O
base	O
pairs	O
of	O
SpC3	O
DNA	O
.	O
<EOS>	B-X
A	B-X
recombinant	B-X
phage	B-X
,	B-X
SpC3	B-X
,	B-X
containing	B-X
a	B-X
17	B-X
kb	B-X
genomic	B-X
DNA	B-X
insert	B-X
representing	B-X
approximately	B-X
60	B-X
%	B-X
of	B-X
the	B-X
3	B-X
'	B-X
portion	B-X
of	B-X
the	B-X
sheep	B-X
collagen	B-X
alpha	B-X
2	B-X
gene	B-X
,	B-X
was	B-X
evaluated	B-X
by	B-X
electron	B-X
microscopic	B-X
R	B-X
loop	B-X
analysis	B-X
.	B-X
A	B-X
minimum	B-X
of	B-X
17	B-X
intervening	B-X
sequences	B-X
(	B-X
introns	B-X
)	B-X
and	B-X
18	B-X
alpha	B-X
2	B-X
coding	B-X
sequences	B-X
(	B-X
exons	B-X
)	B-X
were	B-X
mapped	B-X
.	B-X
With	B-X
the	B-X
exception	B-X
of	B-X
the	B-X
850	B-X
base	B-X
pair	B-X
exon	B-X
located	B-X
at	B-X
the	B-X
extreme	B-X
3	B-X
'	B-X
end	B-X
of	B-X
the	B-X
insert	B-X
,	B-X
all	B-X
exons	B-X
contained	B-X
250	B-X
base	B-X
pairs	B-X
or	B-X
less	B-X
.	B-X
The	B-X
total	B-X
length	B-X
of	B-X
all	B-X
the	B-X
exons	B-X
in	B-X
SpC3	B-X
was	B-X
3,014	B-X
base	B-X
pairs	B-X
.	B-X
The	B-X
length	B-X
distribution	B-X
of	B-X
the	B-X
17	B-X
introns	B-X
ranged	B-X
from	B-X
300	B-X
to	B-X
1600	B-X
base	B-X
pairs	B-X
;	B-X
together	B-X
,	B-X
all	B-X
of	B-X
the	B-X
introns	B-X
comprised	B-X
14,070	B-X
base	B-X
pairs	B-X
of	B-X
SpC3	B-X
DNA	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
DNA	B-X
region	B-X
required	B-X
for	B-X
coding	B-X
the	B-X
interspersed	B-X
3	B-X
kb	B-X
of	B-X
alpha	B-X
2	B-X
collagen	B-X
genetic	B-X
information	B-X
was	B-X
5.6	B-X
fold	B-X
longer	B-X
than	B-X
the	B-X
corresponding	B-X
alpha	B-X
2	B-X
mRNA	B-X
coding	B-X
sequences	B-X
.	B-X

Thus	O
,	O
the	O
DNA	O
region	O
<EOS>	B-X
The	B-X
Pacific	B-X
region	B-X
provides	B-X
unique	B-X
opportunities	B-X
to	B-X
study	B-X
human	B-X
evolution	B-X
including	B-X
through	B-X
analyses	B-X
of	B-X
ancient	B-X
DNA	B-X
.	B-X
While	B-X
some	B-X
of	B-X
the	B-X
earliest	B-X
studies	B-X
involving	B-X
ancient	B-X
DNA	B-X
from	B-X
skeletal	B-X
remains	B-X
focused	B-X
on	B-X
Pacific	B-X
samples	B-X
,	B-X
in	B-X
the	B-X
following	B-X
25	B-X
years	B-X
,	B-X
several	B-X
factors	B-X
meant	B-X
that	B-X
little	B-X
aDNA	B-X
research	B-X
,	B-X
particularly	B-X
research	B-X
focused	B-X
on	B-X
human	B-X
populations	B-X
,	B-X
has	B-X
emerged	B-X
.	B-X
This	B-X
paper	B-X
briefly	B-X
presents	B-X
the	B-X
genetic	B-X
evidence	B-X
for	B-X
population	B-X
origins	B-X
,	B-X
reviews	B-X
what	B-X
ancient	B-X
DNA	B-X
work	B-X
has	B-X
been	B-X
undertaken	B-X
to	B-X
address	B-X
human	B-X
history	B-X
and	B-X
evolution	B-X
in	B-X
the	B-X
Pacific	B-X
region	B-X
,	B-X
and	B-X
argues	B-X
that	B-X
the	B-X
future	B-X
is	B-X
bright	B-X
but	B-X
research	B-X
requires	B-X
a	B-X
collaborative	B-X
approach	B-X
between	B-X
academic	B-X
disciplines	B-X
but	B-X
also	B-X
with	B-X
local	B-X
communities	B-X
.	B-X
The	B-X
forensic	B-X
application	B-X
of	B-X
mitochondrial	B-X
DNA	B-X
(	B-X
mtDNA	B-X
)	B-X
typing	B-X
requires	B-X
large	B-X
and	B-X
regionally	B-X
well-defined	B-X
databases	B-X
.	B-X
To	B-X
expand	B-X
the	B-X
database	B-X
for	B-X
forensic	B-X
identification	B-X
purposes	B-X
in	B-X
Slovenia	B-X
,	B-X
the	B-X
mtDNA	B-X
control	B-X
region	B-X
sequences	B-X
of	B-X
the	B-X
hypervariable	B-X
regions	B-X
HVI	B-X
and	B-X
HVII	B-X
were	B-X
determined	B-X
in	B-X
a	B-X
population	B-X
of	B-X
129	B-X
maternally	B-X
unrelated	B-X
Slovenians	B-X
,	B-X
using	B-X
a	B-X
fluorescent-based	B-X
capillary	B-X
electrophoresis	B-X
sequencing	B-X
method	B-X
.	B-X
Of	B-X
these	B-X
,	B-X
101	B-X
mtDNA	B-X
types	B-X
were	B-X
unique	B-X
,	B-X
6	B-X
haplotypes	B-X
were	B-X
shared	B-X
by	B-X
2	B-X
individuals	B-X
,	B-X
1	B-X
haplotype	B-X
by	B-X
3	B-X
individuals	B-X
,	B-X
2	B-X
haplotypes	B-X
by	B-X
4	B-X
individuals	B-X
,	B-X
and	B-X
the	B-X
most	B-X
common	B-X
haplotype	B-X
was	B-X
found	B-X
in	B-X
5	B-X
individuals	B-X
.	B-X
The	B-X
data	B-X
support	B-X
the	B-X
concept	B-X
that	B-X
these	B-X
haplotypes	B-X
may	B-X
represent	B-X
a	B-X
common	B-X
European	B-X
mtDNA	B-X
sequence	B-X
types	B-X
.	B-X
The	B-X
length	B-X
heteroplasmy	B-X
in	B-X
the	B-X
homopolymeric	B-X
C-stretch	B-X
regions	B-X
located	B-X
at	B-X
nucleotide	B-X
positions	B-X
16184-16193	B-X
in	B-X
HVI	B-X
and	B-X
at	B-X
positions	B-X
303-315	B-X
in	B-X
HVII	B-X
was	B-X
observed	B-X
in	B-X
17	B-X
%	B-X
and	B-X
8	B-X
%	B-X
of	B-X
individuals	B-X
,	B-X
respectively	B-X
.	B-X

required	O
for	O
coding	O
the	O
interspersed	O
3	O
kb	O
of	O
a2	O
collagen	O
genetic	O
information	O
was	O
5	O
.	O
6	O
fold	O
longer	O
than	O
the	O
corresponding	O
a2	O
mRNA	O
coding	O
sequences	O
.	O

INTRODUCTION	O

Type	O
I	O
collagen	O
,	O
composed	O
of	O
two	O
al	O
(	O
I	O
)	O
and	O
one	O
a2	O
polypeptide	O
chains	O
,	O
is	O
the	O
most	O
abundant	O
of	O
the	O
five	O
known	O
mammalian	O
collagen	O
types	O
.	O

It	O
is	O
a	O
major	O
extracellular	O
constituent	O
of	O
tissues	O
such	O
as	O
bone	O
,	O
tendon	O
,	O
skin	O
and	O
lung	O
where	O
,	O
because	O
of	O
its	O
great	O
tensile	O
strength	O
,	O
it	O
plays	O
an	O
important	O

role	O
in	O
tissue	O
structure	O
and	O
function	O
.	O
<EOS>	B-X
Meniscal	B-X
injuries	B-X
have	B-X
posed	B-X
a	B-X
challenging	B-X
problem	B-X
for	B-X
many	B-X
years	B-X
,	B-X
especially	B-X
considering	B-X
that	B-X
historically	B-X
the	B-X
meniscus	B-X
was	B-X
considered	B-X
to	B-X
be	B-X
a	B-X
structure	B-X
with	B-X
no	B-X
important	B-X
role	B-X
in	B-X
the	B-X
knee	B-X
joint	B-X
.	B-X
This	B-X
led	B-X
to	B-X
earlier	B-X
treatments	B-X
aiming	B-X
at	B-X
the	B-X
removal	B-X
of	B-X
the	B-X
entire	B-X
structure	B-X
in	B-X
a	B-X
procedure	B-X
known	B-X
as	B-X
a	B-X
meniscectomy	B-X
.	B-X
However	B-X
,	B-X
with	B-X
the	B-X
current	B-X
understanding	B-X
of	B-X
the	B-X
function	B-X
and	B-X
roles	B-X
of	B-X
the	B-X
meniscus	B-X
,	B-X
meniscectomy	B-X
has	B-X
been	B-X
identified	B-X
to	B-X
accelerate	B-X
joint	B-X
degradation	B-X
significantly	B-X
and	B-X
is	B-X
no	B-X
longer	B-X
a	B-X
preferred	B-X
treatment	B-X
option	B-X
in	B-X
meniscal	B-X
tears	B-X
.	B-X
Current	B-X
therapies	B-X
are	B-X
now	B-X
focused	B-X
to	B-X
regenerate	B-X
,	B-X
repair	B-X
,	B-X
or	B-X
replace	B-X
the	B-X
injured	B-X
meniscus	B-X
to	B-X
restore	B-X
its	B-X
native	B-X
function	B-X
.	B-X
More	B-X
recently	B-X
,	B-X
strategies	B-X
have	B-X
applied	B-X
stem	B-X
cells	B-X
,	B-X
tissue	B-X
engineering	B-X
,	B-X
and	B-X
their	B-X
combination	B-X
to	B-X
potentiate	B-X
healing	B-X
to	B-X
achieve	B-X
superior	B-X
quality	B-X
repair	B-X
tissue	B-X
and	B-X
retard	B-X
the	B-X
joint	B-X
degeneration	B-X
associated	B-X
with	B-X
an	B-X
injured	B-X
or	B-X
inadequately	B-X
functioning	B-X
meniscus	B-X
.	B-X
Accordingly	B-X
,	B-X
the	B-X
purpose	B-X
of	B-X
this	B-X
current	B-X
review	B-X
is	B-X
to	B-X
summarize	B-X
the	B-X
current	B-X
available	B-X
pre-clinical	B-X
and	B-X
clinical	B-X
literature	B-X
using	B-X
stem	B-X
cells	B-X
and	B-X
tissue	B-X
engineering	B-X
for	B-X
meniscal	B-X
repair	B-X
and	B-X
regeneration	B-X
.	B-X

The	O
polypeptides	O
comprising	O
type	O
I	O
<EOS>	B-X
Tirzepatide	B-X
,	B-X
a	B-X
dual	B-X
glucose-dependent	B-X
insulinotropic	B-X
polypeptide	B-X
(	B-X
GIP	B-X
)	B-X
/GLP-1	B-X
receptor	B-X
agonist	B-X
,	B-X
shows	B-X
a	B-X
remarkable	B-X
ability	B-X
to	B-X
lower	B-X
blood	B-X
glucose	B-X
,	B-X
enabling	B-X
many	B-X
patients	B-X
with	B-X
long-standing	B-X
type	B-X
2	B-X
diabetes	B-X
to	B-X
achieve	B-X
normoglycaemia	B-X
.	B-X
We	B-X
aimed	B-X
to	B-X
understand	B-X
the	B-X
physiological	B-X
mechanisms	B-X
underlying	B-X
the	B-X
action	B-X
of	B-X
tirzepatide	B-X
in	B-X
type	B-X
2	B-X
diabetes	B-X
.	B-X
Currently	B-X
,	B-X
we	B-X
distinguish	B-X
three	B-X
types	B-X
of	B-X
interferons	B-X
.	B-X
The	B-X
following	B-X
interferons	B-X
are	B-X
classified	B-X
as	B-X
type	B-X
I	B-X
:	B-X
Î±	B-X
,	B-X
Î²	B-X
,	B-X
Ï	B-X
,	B-X
Îº	B-X
,	B-X
Îµ	B-X
,	B-X
Î¶	B-X
,	B-X
Ï	B-X
,	B-X
Î´	B-X
,	B-X
Î½	B-X
.	B-X
Representative	B-X
of	B-X
type	B-X
II	B-X
interferons	B-X
is	B-X
interferon-Î³	B-X
.	B-X
The	B-X
recently	B-X
classified	B-X
type	B-X
III	B-X
interferons	B-X
comprise	B-X
IFN-Î»1	B-X
,	B-X
IFN-Î»2	B-X
,	B-X
and	B-X
IFN-Î»3	B-X
.	B-X

collagen	O
are	O
synthesized	O
in	O
long	O
,	O
precursor	O
forms	O
,	O
referred	O
to	O
as	O
pro	O
al	O
(	O
I	O
)	O
and	O
pro	O
a2	O
chains	O
,	O
1	O
each	O
containing	O
approximately	O
1500	O
amino	O
acid	O
residues	O
(	O
1	O
)	O
.	O

1	O
The	O
terminology	O
for	O
the	O
primary	O
translation	O
products	O
of	O
the	O
various	O
<EOS>	B-X
Flow	B-X
cytometry	B-X
is	B-X
a	B-X
complex	B-X
measurement	B-X
characterization	B-X
technique	B-X
,	B-X
utilized	B-X
within	B-X
the	B-X
manufacture	B-X
,	B-X
measurement	B-X
,	B-X
and	B-X
release	B-X
of	B-X
cell	B-X
and	B-X
gene	B-X
therapy	B-X
products	B-X
for	B-X
rapid	B-X
,	B-X
high-content	B-X
,	B-X
and	B-X
multiplexed	B-X
discriminatory	B-X
cell	B-X
analysis	B-X
.	B-X
The	B-X
various	B-X
stages	B-X
of	B-X
the	B-X
gating	B-X
sequence	B-X
were	B-X
combined	B-X
through	B-X
summation	B-X
in	B-X
quadrature	B-X
and	B-X
expanded	B-X
to	B-X
give	B-X
each	B-X
participant	B-X
a	B-X
representative	B-X
uncertainty	B-X
value	B-X
.	B-X
Of	B-X
the	B-X
participants	B-X
surveyed	B-X
,	B-X
85	B-X
%	B-X
preferred	B-X
manual	B-X
gating	B-X
to	B-X
automated	B-X
data	B-X
analysis	B-X
,	B-X
with	B-X
the	B-X
primary	B-X
reasons	B-X
being	B-X
legacy	B-X
(	B-X
``	B-X
it	B-X
's	B-X
always	B-X
been	B-X
done	B-X
that	B-X
way	B-X
''	B-X
)	B-X
and	B-X
accuracy	B-X
,	B-X
not	B-X
in	B-X
the	B-X
metrological	B-X
sense	B-X
but	B-X
in	B-X
the	B-X
clear	B-X
definition	B-X
of	B-X
the	B-X
correct	B-X
target	B-X
population	B-X
.	B-X
Operator	B-X
subjectivity	B-X
can	B-X
be	B-X
quantified	B-X
to	B-X
include	B-X
within	B-X
measurement	B-X
uncertainty	B-X
budgets	B-X
,	B-X
required	B-X
for	B-X
various	B-X
standards	B-X
and	B-X
qualifications	B-X
.	B-X
An	B-X
emphasis	B-X
on	B-X
biomanufacturing	B-X
measurement	B-X
terminology	B-X
is	B-X
needed	B-X
to	B-X
help	B-X
understand	B-X
future	B-X
and	B-X
potential	B-X
solutions	B-X
,	B-X
possibly	B-X
looking	B-X
at	B-X
translational	B-X
clinical	B-X
models	B-X
to	B-X
engage	B-X
and	B-X
enhance	B-X
better	B-X
training	B-X
and	B-X
protocols	B-X
within	B-X
industrial	B-X
and	B-X
research	B-X
settings	B-X
.	B-X

collagen	O
messenger	O
RNAs	O
is	O
still	O
in	O
a	O
state	O
of	O
flux	O
.	O

It	O
is	O
known	O
that	O
al	O
(	O
I	O
)	O
and	O
a2	O
chains	O
are	O
synthesized	O
in	O
precursor	O
forms	O
;	O
these	O
are	O
currently	O
termed	O
pro	O
al	O
(	O
I	O
)	O
and	O
pro	O
a2	O
chains	O
(	O
1	O
)	O
.	O

However	O
,	O
recent	O
studies	O
(	O
43	O
,	O
44	O
)	O
have	O
shown	O
that	O
the	O
actual	O
primary	O
translation	O
product	O
of	O
al	O
(	O
I	O
)	O
mRNA	O
is	O
somewhat	O
larger	O

than	O
the	O
pro	O
al	O
(	O
I	O
)	O
chain	O
;	O
this	O
translation	O
product	O
has	O
been	O
termed	O
a	O
"	O
pre	O
-	O
pro	O
al	O
(	O
I	O
)	O
chain	O
.	O
"	O
Although	O
the	O
corresponding	O
"	O
pre	O
-	O
pro	O
a2	O
chain	O
"	O
likely	O
exists	O
,	O
it	O
has	O
not	O
yet	O
been	O
characterized	O
.	O

For	O
simplicity	O
,	O
therefore	O
,	O
until	O
the	O
<EOS>	B-X
Some	B-X
like	B-X
the	B-X
MCTQ	B-X
's	B-X
simplicity	B-X
and	B-X
some	B-X
view	B-X
it	B-X
critically	B-X
.	B-X
Despite	B-X
the	B-X
simplicity	B-X
of	B-X
the	B-X
treatment	B-X
,	B-X
it	B-X
has	B-X
proven	B-X
itself	B-X
to	B-X
be	B-X
very	B-X
successful	B-X
over	B-X
the	B-X
past	B-X
two	B-X
years	B-X
of	B-X
clinical	B-X
use	B-X
.	B-X
Our	B-X
results	B-X
show	B-X
that	B-X
simplicity	B-X
and	B-X
versatility	B-X
are	B-X
the	B-X
key	B-X
features	B-X
for	B-X
the	B-X
success	B-X
of	B-X
cercariae	B-X
transmission	B-X
by	B-X
using	B-X
their	B-X
organs	B-X
for	B-X
different	B-X
purposes	B-X
.	B-X
The	B-X
simplicity	B-X
and	B-X
portability	B-X
of	B-X
the	B-X
SMFR	B-X
tools	B-X
allow	B-X
it	B-X
to	B-X
be	B-X
easily	B-X
implemented	B-X
in	B-X
any	B-X
type	B-X
of	B-X
fitness	B-X
or	B-X
rehabilitation	B-X
program	B-X
.	B-X

proper	O
terminology	O
for	O
the	O
primary	O
translation	O
product	O
is	O
clarified	O
,	O
we	O
have	O

chosen	O
to	O
use	O
the	O
terms	O
"	O
al	O
(	O
I	O
)	O
"	O
and	O
"	O
a2	O
"	O
to	O
refer	O
to	O
the	O
type	O
I	O
collagen	O
mRNAs	O
and	O
collagen	O
structural	O
gene	O
sequences	O
.	O

?	O
)	O
IRL	O
Press	O
Umited	O
,	O
1	O
Falconberg	O
Court	O
,	O
London	O
W1V	O
5FG	O
,	O
U	O
.	O
K	O
.	O

Volurne	O
8	O
Number	O
10	O
1980	O
<EOS>	B-X
Leishmaniasis	B-X
is	B-X
considered	B-X
endemic	B-X
in	B-X
98	B-X
countries	B-X
,	B-X
most	B-X
of	B-X
which	B-X
are	B-X
developing	B-X
.	B-X
Oman	B-X
's	B-X
LBW	B-X
rate	B-X
has	B-X
been	B-X
increasing	B-X
since	B-X
the	B-X
1980s	B-X
.	B-X
It	B-X
was	B-X
approximately	B-X
4	B-X
%	B-X
in	B-X
1980	B-X
and	B-X
had	B-X
nearly	B-X
doubled	B-X
(	B-X
8.1	B-X
%	B-X
)	B-X
by	B-X
2000	B-X
.	B-X
Since	B-X
then	B-X
,	B-X
it	B-X
has	B-X
shown	B-X
a	B-X
slow	B-X
but	B-X
steady	B-X
rise	B-X
,	B-X
reaching	B-X
10	B-X
%	B-X
in	B-X
recent	B-X
times	B-X
.	B-X

2241	O

Nucleic	O
Acids	O
Research	O
<EOS>	B-X
The	B-X
2021	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
database	B-X
Issue	B-X
contains	B-X
189	B-X
papers	B-X
spanning	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
biological	B-X
fields	B-X
and	B-X
investigation	B-X
.	B-X
The	B-X
entire	B-X
Database	B-X
Issue	B-X
is	B-X
freely	B-X
available	B-X
online	B-X
on	B-X
the	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
website	B-X
(	B-X
https	B-X
:	B-X
//academic.oup.com/nar	B-X
)	B-X
.	B-X
Editorial	B-X
:	B-X
the	B-X
19th	B-X
annual	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
web	B-X
server	B-X
issue	B-X
2021	B-X
.	B-X
Editorial	B-X
:	B-X
Critical	B-X
reviews	B-X
and	B-X
perspectives	B-X
in	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
.	B-X

There	O
is	O
increasing	O
evidence	O
that	O
the	O
quantities	O
of	O
al	O
(	O
I	O
)	O
and	O
a2	O
<EOS>	B-X
Recent	B-X
evidence	B-X
suggests	B-X
a	B-X
human-like	B-X
susceptibility	B-X
to	B-X
social	B-X
influence	B-X
in	B-X
dogs	B-X
.	B-X
For	B-X
example	B-X
,	B-X
dogs	B-X
tend	B-X
to	B-X
ignore	B-X
their	B-X
'natural	B-X
'	B-X
preference	B-X
for	B-X
the	B-X
larger	B-X
amount	B-X
of	B-X
food	B-X
after	B-X
having	B-X
seen	B-X
a	B-X
human	B-X
's	B-X
explicit	B-X
preference	B-X
for	B-X
a	B-X
smaller	B-X
quantity	B-X
.	B-X
However	B-X
,	B-X
it	B-X
is	B-X
still	B-X
unclear	B-X
whether	B-X
this	B-X
tendency	B-X
to	B-X
conform	B-X
to	B-X
the	B-X
partner	B-X
's	B-X
behaviour	B-X
can	B-X
be	B-X
influenced	B-X
by	B-X
social	B-X
stimuli	B-X
and/or	B-X
the	B-X
neurohormone	B-X
oxytocin	B-X
as	B-X
primers	B-X
to	B-X
prosocial	B-X
predispositions	B-X
.	B-X
In	B-X
Experiment	B-X
I	B-X
,	B-X
eighty	B-X
two	B-X
dogs	B-X
were	B-X
tested	B-X
using	B-X
Prato-Previde	B-X
et	B-X
al	B-X
.	B-X
In	B-X
Experiment	B-X
I	B-X
,	B-X
we	B-X
investigated	B-X
in	B-X
a	B-X
2	B-X
Ã	B-X
2	B-X
design	B-X
how	B-X
(	B-X
i	B-X
)	B-X
a	B-X
10-minute-long	B-X
social	B-X
stimulation	B-X
by	B-X
the	B-X
owner	B-X
versus	B-X
a	B-X
socially	B-X
ignoring	B-X
pre-treatment	B-X
as	B-X
well	B-X
as	B-X
(	B-X
ii	B-X
)	B-X
on-line	B-X
ostensive	B-X
communications	B-X
versus	B-X
no	B-X
communication	B-X
during	B-X
task	B-X
demonstration	B-X
affect	B-X
dogs	B-X
'	B-X
(	B-X
N	B-X
=	B-X
82	B-X
)	B-X
choices	B-X
in	B-X
the	B-X
abovementioned	B-X
food	B-X
choice	B-X
task	B-X
.	B-X
Results	B-X
indicate	B-X
that	B-X
the	B-X
owners	B-X
'	B-X
pre-treatment	B-X
with	B-X
social	B-X
stimuli	B-X
(	B-X
eye	B-X
contact	B-X
,	B-X
petting	B-X
)	B-X
increased	B-X
dogs	B-X
'	B-X
susceptibility	B-X
to	B-X
the	B-X
experimenter	B-X
's	B-X
food	B-X
preference	B-X
,	B-X
but	B-X
the	B-X
salient	B-X
ostensive	B-X
addressing	B-X
signals	B-X
accompanying	B-X
human	B-X
demonstration	B-X
masked	B-X
this	B-X
social	B-X
priming	B-X
effect	B-X
.	B-X
This	B-X
experiment	B-X
aimed	B-X
to	B-X
study	B-X
whether	B-X
intranasal	B-X
administration	B-X
of	B-X
oxytocin	B-X
as	B-X
compared	B-X
to	B-X
placebo	B-X
treatment	B-X
would	B-X
similarly	B-X
increase	B-X
dogs	B-X
'	B-X
tendency	B-X
to	B-X
re-enact	B-X
the	B-X
human	B-X
demonstrator	B-X
's	B-X
counterproductive	B-X
choice	B-X
in	B-X
the	B-X
same	B-X
task	B-X
.	B-X
Results	B-X
showed	B-X
an	B-X
increased	B-X
susceptibility	B-X
to	B-X
the	B-X
human	B-X
preference	B-X
in	B-X
the	B-X
OT	B-X
group	B-X
,	B-X
suggesting	B-X
that	B-X
both	B-X
socially	B-X
stimulating	B-X
pre-treatment	B-X
and	B-X
the	B-X
intranasal	B-X
administration	B-X
of	B-X
oxytocin	B-X
have	B-X
similar	B-X
priming	B-X
effects	B-X
on	B-X
dogs	B-X
'	B-X
social	B-X
susceptibility	B-X
.	B-X

chains	O
produced	O
by	O
cells	O
may	O
be	O
regulated	O
,	O
in	O
part	O
,	O
at	O
the	O
genomic	O
level	O
<EOS>	B-X
Studies	B-X
of	B-X
first-degree	B-X
relatives	B-X
of	B-X
women	B-X
diagnosed	B-X
with	B-X
PCOS	B-X
reveal	B-X
familial	B-X
clustering	B-X
of	B-X
the	B-X
disease	B-X
,	B-X
particularly	B-X
hyperandrogenemia	B-X
.	B-X
These	B-X
observations	B-X
suggest	B-X
a	B-X
dominantly	B-X
inherited	B-X
trait	B-X
controlling	B-X
androgen	B-X
levels	B-X
.	B-X
Studies	B-X
on	B-X
cultures	B-X
of	B-X
human	B-X
theca	B-X
cells	B-X
derived	B-X
from	B-X
follicles	B-X
isolated	B-X
from	B-X
the	B-X
ovaries	B-X
of	B-X
PCOS	B-X
and	B-X
normal	B-X
women	B-X
demonstrated	B-X
that	B-X
PCOS	B-X
theca	B-X
cells	B-X
produce	B-X
greater	B-X
amounts	B-X
of	B-X
testosterone	B-X
,	B-X
17alpha-hydroxyprogesterone	B-X
,	B-X
and	B-X
progesterone	B-X
than	B-X
normal	B-X
theca	B-X
cells	B-X
,	B-X
despite	B-X
the	B-X
fact	B-X
that	B-X
cells	B-X
were	B-X
cultured	B-X
under	B-X
identical	B-X
conditions	B-X
for	B-X
multiple	B-X
population	B-X
doublings	B-X
.	B-X
Examination	B-X
of	B-X
the	B-X
metabolism	B-X
of	B-X
radiolabeled	B-X
steroid	B-X
hormone	B-X
precursors	B-X
and	B-X
steady-state	B-X
levels	B-X
of	B-X
mRNAs	B-X
encoding	B-X
steroidogenic	B-X
enzymes	B-X
revealed	B-X
that	B-X
there	B-X
are	B-X
multiple	B-X
alterations	B-X
in	B-X
the	B-X
steroidogenic	B-X
machinery	B-X
of	B-X
PCOS	B-X
theca	B-X
cells	B-X
,	B-X
including	B-X
elevated	B-X
expression	B-X
of	B-X
the	B-X
CYP11A	B-X
,	B-X
3BHSD2	B-X
,	B-X
and	B-X
CYP17	B-X
genes	B-X
.	B-X
The	B-X
increased	B-X
mRNA	B-X
levels	B-X
are	B-X
the	B-X
result	B-X
,	B-X
in	B-X
least	B-X
in	B-X
part	B-X
,	B-X
of	B-X
increased	B-X
gene	B-X
transcription	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
STAR	B-X
gene	B-X
is	B-X
not	B-X
expressed	B-X
at	B-X
a	B-X
higher	B-X
level	B-X
in	B-X
PCOS	B-X
theca	B-X
cells	B-X
.	B-X
The	B-X
stable	B-X
up-regulation	B-X
of	B-X
steroidogenesis	B-X
in	B-X
PCOS	B-X
thecal	B-X
cells	B-X
indicates	B-X
either	B-X
a	B-X
genetic	B-X
abnormality	B-X
in	B-X
these	B-X
cells	B-X
or	B-X
a	B-X
persistent	B-X
metabolic	B-X
imprint	B-X
established	B-X
in	B-X
vivo	B-X
.	B-X

(	O
1	O
)	O
.	O
<EOS>	B-X
Formate	B-X
assay	B-X
in	B-X
body	B-X
fluids	B-X
:	B-X
application	B-X
in	B-X
methanol	B-X
poisoning	B-X
.	B-X

However	O
,	O
to	O
understand	O
the	O
processes	O
which	O
mediate	O
their	O
expression	O
,	O
<EOS>	B-X
In	B-X
addition	B-X
to	B-X
antioxidant	B-X
responses	B-X
,	B-X
Nrf2	B-X
is	B-X
involved	B-X
in	B-X
other	B-X
cellular	B-X
processes	B-X
,	B-X
such	B-X
as	B-X
autophagy	B-X
,	B-X
intermediary	B-X
metabolism	B-X
,	B-X
stem	B-X
cell	B-X
quiescence	B-X
,	B-X
and	B-X
unfolded	B-X
protein	B-X
response	B-X
.	B-X
Given	B-X
the	B-X
wide	B-X
range	B-X
of	B-X
processes	B-X
that	B-X
Nrf2	B-X
controls	B-X
,	B-X
its	B-X
activity	B-X
is	B-X
tightly	B-X
regulated	B-X
at	B-X
multiple	B-X
levels	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
the	B-X
different	B-X
modes	B-X
of	B-X
regulation	B-X
of	B-X
Nrf2	B-X
activity	B-X
and	B-X
the	B-X
current	B-X
knowledge	B-X
of	B-X
Nrf2-mediated	B-X
transcriptional	B-X
control	B-X
.	B-X
Thus	B-X
it	B-X
is	B-X
imperative	B-X
to	B-X
understand	B-X
the	B-X
biology	B-X
of	B-X
oral	B-X
cancer	B-X
and	B-X
examine	B-X
alternative	B-X
prognostic	B-X
and	B-X
therapeutic	B-X
targets	B-X
for	B-X
oral	B-X
cancer	B-X
.	B-X
MicroRNAs	B-X
(	B-X
miRNAs	B-X
)	B-X
are	B-X
small	B-X
non-coding	B-X
RNAs	B-X
mediating	B-X
gene	B-X
expression	B-X
at	B-X
the	B-X
post-transcriptional	B-X
level	B-X
through	B-X
mRNA	B-X
degradation	B-X
or	B-X
translational	B-X
repression	B-X
.	B-X
miRNAs	B-X
play	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
cancer	B-X
development	B-X
and	B-X
oncogenic	B-X
cell	B-X
processes	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
miRNAs	B-X
and	B-X
their	B-X
clinical	B-X
implications	B-X
in	B-X
oral	B-X
cancer	B-X
is	B-X
not	B-X
clear	B-X
.	B-X
miRNAs	B-X
mediate	B-X
activation	B-X
or	B-X
suppression	B-X
of	B-X
signalling	B-X
pathways	B-X
associated	B-X
with	B-X
oral	B-X
cancer	B-X
.	B-X

it	O
is	O
necessary	O
to	O
understand	O
the	O
structural	O
organization	O
of	O
these	O
collagen	O
genes	O
and	O
the	O
various	O
enzymes	O
that	O
modify	O
the	O
collagen	O
chains	O
after	O
its	O

synthesis	O
(	O
1	O
)	O
.	O
<EOS>	B-X
Today	B-X
,	B-X
Fmoc	B-X
SPPS	B-X
is	B-X
the	B-X
method	B-X
of	B-X
choice	B-X
for	B-X
peptide	B-X
synthesis	B-X
.	B-X
Improvements	B-X
are	B-X
being	B-X
continually	B-X
reported	B-X
for	B-X
peptide	B-X
quality	B-X
,	B-X
synthesis	B-X
time	B-X
and	B-X
novel	B-X
synthetic	B-X
targets	B-X
.	B-X
Deciphering	B-X
how	B-X
different	B-X
organ/physiological	B-X
systems	B-X
respond	B-X
to	B-X
the	B-X
acute	B-X
and	B-X
chronic	B-X
demands	B-X
of	B-X
exercise	B-X
depends	B-X
on	B-X
a	B-X
foundational	B-X
understanding	B-X
of	B-X
the	B-X
redox	B-X
and	B-X
bioenergetic	B-X
principles	B-X
that	B-X
underlie	B-X
the	B-X
flow	B-X
of	B-X
electrons	B-X
in	B-X
living	B-X
systems	B-X
and	B-X
its	B-X
coupling	B-X
to	B-X
ATP	B-X
synthesis	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
review	B-X
is	B-X
to	B-X
set	B-X
the	B-X
stage	B-X
to	B-X
cover	B-X
(	B-X
1	B-X
)	B-X
the	B-X
thermodynamic	B-X
driving	B-X
forces	B-X
responsible	B-X
for	B-X
generating	B-X
and	B-X
maintaining	B-X
the	B-X
energy	B-X
charge	B-X
that	B-X
establishes	B-X
and	B-X
sustains	B-X
life	B-X
for	B-X
cells	B-X
,	B-X
and	B-X
(	B-X
2	B-X
)	B-X
how	B-X
cellular	B-X
energy	B-X
transfer	B-X
systems	B-X
respond	B-X
to	B-X
changes	B-X
in	B-X
energy	B-X
demand	B-X
to	B-X
ensure	B-X
energy	B-X
charge	B-X
is	B-X
preserved	B-X
.	B-X

As	O
an	O
initial	O
approach	O
to	O
this	O
problem	O
,	O
we	O
have	O
recently	O
<EOS>	B-X
Recent	B-X
research	B-X
has	B-X
expanded	B-X
on	B-X
previous	B-X
research	B-X
,	B-X
which	B-X
established	B-X
that	B-X
sleep	B-X
problems	B-X
are	B-X
an	B-X
important	B-X
predictor	B-X
of	B-X
depression	B-X
and	B-X
that	B-X
sleep	B-X
problems	B-X
are	B-X
associated	B-X
with	B-X
more	B-X
severe	B-X
depression	B-X
,	B-X
more	B-X
suicidality	B-X
,	B-X
and	B-X
worse	B-X
outcomes	B-X
for	B-X
treatment	B-X
of	B-X
depression	B-X
.	B-X
The	B-X
relationship	B-X
between	B-X
sleep	B-X
problems	B-X
and	B-X
depression	B-X
is	B-X
complex	B-X
,	B-X
likely	B-X
bidirectional	B-X
,	B-X
and	B-X
impactful	B-X
.	B-X
To	B-X
further	B-X
improve	B-X
the	B-X
lives	B-X
of	B-X
patients	B-X
with	B-X
depression	B-X
who	B-X
experience	B-X
insomnia	B-X
,	B-X
it	B-X
will	B-X
be	B-X
important	B-X
to	B-X
investigate	B-X
which	B-X
patients	B-X
will	B-X
do	B-X
better	B-X
in	B-X
a	B-X
sequential	B-X
versus	B-X
concomitant	B-X
approach	B-X
.	B-X
Traditional	B-X
treatment	B-X
approaches	B-X
for	B-X
psychogenic	B-X
erectile	B-X
dysfunction	B-X
have	B-X
included	B-X
anxiety	B-X
reduction	B-X
and	B-X
desensitization	B-X
procedures	B-X
,	B-X
cognitive-behavioral	B-X
interventions	B-X
,	B-X
guided	B-X
sexual	B-X
stimulation	B-X
techniques	B-X
,	B-X
and	B-X
couples	B-X
'	B-X
or	B-X
relationship	B-X
counseling	B-X
.	B-X
Recently	B-X
,	B-X
these	B-X
approaches	B-X
increasingly	B-X
have	B-X
been	B-X
combined	B-X
with	B-X
pharmacologic	B-X
therapy	B-X
such	B-X
as	B-X
sildenafil	B-X
.	B-X
These	B-X
situations	B-X
include	B-X
problems	B-X
of	B-X
sexual	B-X
initiation	B-X
,	B-X
low	B-X
sexual	B-X
desire	B-X
,	B-X
other	B-X
sexual	B-X
dysfunctions	B-X
,	B-X
and	B-X
significant	B-X
couples	B-X
'	B-X
or	B-X
relationship	B-X
problems	B-X
.	B-X

isolated	O
a	O
recombinant	O
bacteriophage	O
,	O
termed	O
SpC3	O
,	O
containing	O
approximately	O
60	O
%	O
of	O
the	O
a2	O
gene	O
for	O
type	O
I	O
collagen	O
.	O

Partial	O
characterization	O
of	O
this	O
<EOS>	B-X
Based	B-X
on	B-X
morphological	B-X
and	B-X
molecular	B-X
characterizations	B-X
,	B-X
a	B-X
new	B-X
Babesia	B-X
species	B-X
belonging	B-X
to	B-X
the	B-X
Peircei	B-X
group	B-X
,	B-X
a	B-X
clade	B-X
of	B-X
avian-specific	B-X
piroplasms	B-X
,	B-X
was	B-X
identified	B-X
.	B-X
We	B-X
hypothesize	B-X
that	B-X
the	B-X
study	B-X
was	B-X
feasible	B-X
and	B-X
the	B-X
addition	B-X
of	B-X
CEUS	B-X
would	B-X
improve	B-X
lesion	B-X
identification	B-X
and	B-X
characterization	B-X
.	B-X
The	B-X
combination	B-X
of	B-X
Sanger	B-X
and	B-X
second-generation	B-X
sequencing	B-X
technologies	B-X
also	B-X
greatly	B-X
improved	B-X
swine	B-X
IAV	B-X
characterization	B-X
.	B-X
Physiological	B-X
characterization	B-X
was	B-X
performed	B-X
based	B-X
on	B-X
phenotypic	B-X
characteristics	B-X
,	B-X
carbohydrate	B-X
fermentation	B-X
patterns	B-X
,	B-X
enzyme	B-X
profiles	B-X
,	B-X
fructose-6-phosphate	B-X
phosphoketolase	B-X
(	B-X
F6PPK	B-X
)	B-X
assays	B-X
,	B-X
and	B-X
antibiotic	B-X
sensitivities	B-X
.	B-X

a2	O
gene	O
demonstrated	O
that	O
,	O
like	O
most	O
other	O
structurally	O
evaluated	O
eukaryotic	O
genes	O
,	O
the	O
coding	O
sequences	O
are	O
interspersed	O
with	O
intervening	O
sequences	O
(	O
2	O
)	O
.	O

The	O
present	O
study	O
further	O
characterizes	O
this	O
portion	O
of	O
the	O
a2	O
<EOS>	B-X
The	B-X
increase	B-X
in	B-X
risk	B-X
is	B-X
particularly	B-X
evident	B-X
in	B-X
younger-age	B-X
groups	B-X
,	B-X
and	B-X
in	B-X
women	B-X
:	B-X
females	B-X
with	B-X
type-2	B-X
DM	B-X
appear	B-X
to	B-X
lose	B-X
a	B-X
great	B-X
deal	B-X
of	B-X
the	B-X
protection	B-X
that	B-X
characterizes	B-X
non-diabetic	B-X
females	B-X
.	B-X
Although	B-X
a	B-X
significant	B-X
portion	B-X
of	B-X
this	B-X
increased	B-X
risk	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
presence	B-X
of	B-X
well-characterized	B-X
risk	B-X
factors	B-X
for	B-X
CHD	B-X
,	B-X
a	B-X
significant	B-X
proportion	B-X
remains	B-X
unexplained	B-X
.	B-X
Patients	B-X
with	B-X
DM	B-X
,	B-X
particularly	B-X
those	B-X
with	B-X
type-2	B-X
DM	B-X
,	B-X
have	B-X
abnormal	B-X
plasma	B-X
lipid	B-X
and	B-X
lipoprotein	B-X
concentrations	B-X
that	B-X
are	B-X
less	B-X
commonly	B-X
present	B-X
in	B-X
non-diabetics	B-X
[	B-X
4-6	B-X
]	B-X
.	B-X
Chiari	B-X
described	B-X
these	B-X
malformations	B-X
as	B-X
congenital	B-X
anomalies	B-X
of	B-X
the	B-X
hindbrain	B-X
characterized	B-X
by	B-X
downward	B-X
elongation	B-X
of	B-X
the	B-X
brain	B-X
stem	B-X
and	B-X
cerebellum	B-X
into	B-X
the	B-X
cervical	B-X
portion	B-X
of	B-X
spinal	B-X
cord	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
measure	B-X
the	B-X
peak	B-X
CSF	B-X
velocity	B-X
at	B-X
the	B-X
foramen	B-X
magnum	B-X
and	B-X
record	B-X
the	B-X
changes	B-X
after	B-X
foramen	B-X
magnum	B-X
decompression	B-X
in	B-X
patients	B-X
with	B-X
CMI	B-X
aged	B-X
<	B-X
18	B-X
years	B-X
.	B-X

gene	O
by	O
utilizing	O
electron	O
microscopic	O
R	O
loop	O
analysis	O
to	O
map	O
the	O
coding	O
regions	O
(	O
exons	O
)	O
and	O
intervening	O
sequences	O
(	O
introns	O
)	O
contained	O
within	O
the	O
sheep	B-Species
genomic	O
insert	O
of	O
SpC3	O
.	O

The	O
data	O
suggests	O
that	O
the	O
structural	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
analyze	B-X
the	B-X
structure	B-X
of	B-X
an	B-X
SCLC	B-X
TF	B-X
network	B-X
by	B-X
using	B-X
graph	B-X
theory	B-X
concepts	B-X
and	B-X
identify	B-X
its	B-X
structurally	B-X
important	B-X
components	B-X
responsible	B-X
for	B-X
complex	B-X
signal	B-X
processing	B-X
,	B-X
called	B-X
hubs	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
hubs	B-X
of	B-X
the	B-X
network	B-X
are	B-X
regulators	B-X
of	B-X
different	B-X
SCLC	B-X
subtypes	B-X
by	B-X
analyzing	B-X
first	B-X
the	B-X
unbiased	B-X
network	B-X
structure	B-X
and	B-X
then	B-X
integrating	B-X
RNA-seq	B-X
data	B-X
as	B-X
weights	B-X
assigned	B-X
to	B-X
each	B-X
interaction	B-X
.	B-X
Overall	B-X
,	B-X
structural	B-X
analyses	B-X
of	B-X
complex	B-X
networks	B-X
can	B-X
identify	B-X
their	B-X
functionally	B-X
important	B-X
components	B-X
and	B-X
pathways	B-X
driving	B-X
the	B-X
network	B-X
dynamics	B-X
.	B-X
There	B-X
is	B-X
yet	B-X
no	B-X
data	B-X
that	B-X
analyzes	B-X
the	B-X
structural	B-X
similarity	B-X
of	B-X
the	B-X
molecules	B-X
used	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
these	B-X
comorbid	B-X
diseases	B-X
.	B-X
Molecules	B-X
with	B-X
two	B-X
aromatic	B-X
rings	B-X
linked	B-X
with	B-X
a	B-X
heteroatom	B-X
or	B-X
a	B-X
carbonyl	B-X
group	B-X
(	B-X
vortioxetine	B-X
,	B-X
ketoprofen	B-X
,	B-X
diclofenac	B-X
)	B-X
,	B-X
or	B-X
presenting	B-X
a	B-X
naphtyl	B-X
moiety	B-X
in	B-X
their	B-X
structure	B-X
(	B-X
duloxetine	B-X
,	B-X
agomelatine	B-X
,	B-X
naproxen	B-X
,	B-X
nabumetone	B-X
)	B-X
were	B-X
found	B-X
to	B-X
be	B-X
structurally	B-X
related	B-X
.	B-X
The	B-X
literature	B-X
search	B-X
interestingly	B-X
revealed	B-X
reports	B-X
indicating	B-X
a	B-X
serotonin-related	B-X
antidepressant	B-X
activity	B-X
of	B-X
the	B-X
NSAIDs	B-X
for	B-X
structures	B-X
found	B-X
to	B-X
be	B-X
structurally	B-X
similar	B-X
to	B-X
some	B-X
antidepressants	B-X
.	B-X

organization	O
of	O
this	O
portion	O
of	O
the	O
a2	O
collagen	O
gene	O
represents	O
3	O
kb	O
of	O
coding	O
information	O
that	O
is	O
interspersed	O
in	O
a	O
complex	O
fashion	O
with	O
17	O
introns	O
over	O
17	O
kb	O
of	O
genome	O
.	O

MATERIALS	O
AND	O
METHODS	O

Isolation	O
and	O
characterization	O
of	O
a2	O
collagen	O
recombinant	O
clone	O
,	O
SpC3	O
.	O

The	O
sheep	B-Species
a2	O
collagen	O
recombinant	O
clone	O
,	O
SpC3	O
,	O
containing	O
a	O
portion	O
of	O
the	O
sheep	B-Species
a2	O
gene	O
,	O
was	O
isolated	O
as	O
previously	O
described	O
(	O
2	O
)	O
.	O

Briefly	O
,	O
<EOS>	B-X
Facebook	B-X
anti-vaccine	B-X
policy	B-X
worked	B-X
briefly	B-X
.	B-X
Briefly	B-X
is	B-X
mentioned	B-X
Clinical	B-X
symptoms	B-X
of	B-X
hypoglycemia	B-X
are	B-X
briefly	B-X
mentioned	B-X
and	B-X
several	B-X
ways	B-X
to	B-X
classify	B-X
the	B-X
hypoglycemic	B-X
events	B-X
are	B-X
offered	B-X
.	B-X
[	B-X
Briefly	B-X
stated	B-X
]	B-X
.	B-X
Briefly	B-X
noted	B-X
.	B-X

high	O
molecular	O
weight	O
fetal	O
sheep	B-Species
liver	O
DNA	O
was	O
extracted	O
by	O
the	O
method	O
of	O
Blin	O
and	O
Stafford	O
(	O
3	O
)	O
,	O
and	O
15	O
-	O
20	O
kb	O
DNA	O
fragments	O
,	O
resulting	O
from	O
partial	O
Eco	O
RI	O
digestion	O
,	O
were	O
isolated	O
and	O
ligated	O
to	O
the	O
left	O
and	O
right	O
arms	O
of	O
Charon	O
4A	O
.	O

The	O
recombinant	O
DNA	O
was	O
then	O
packaged	O
in	O
vitro	O
and	O
the	O
sheep	B-Species
<EOS>	B-X
Luminal	B-X
(	B-X
LE	B-X
)	B-X
and	B-X
glandular	B-X
epithelial	B-X
(	B-X
GE	B-X
)	B-X
cells	B-X
and	B-X
stromal	B-X
(	B-X
ST	B-X
)	B-X
cells	B-X
were	B-X
enzymatically	B-X
isolated	B-X
from	B-X
the	B-X
uterus	B-X
of	B-X
a	B-X
Day	B-X
5	B-X
cyclic	B-X
ewe	B-X
(	B-X
estrus	B-X
on	B-X
Day	B-X
0	B-X
)	B-X
,	B-X
and	B-X
primary	B-X
cultures	B-X
were	B-X
immortalized	B-X
by	B-X
transduction	B-X
with	B-X
a	B-X
retroviral	B-X
vector	B-X
(	B-X
LXSN-16E6E7	B-X
)	B-X
packaged	B-X
by	B-X
the	B-X
amphotropic	B-X
fibroblast	B-X
line	B-X
PA-317	B-X
.	B-X
These	B-X
ovine	B-X
endometrial	B-X
cell	B-X
lines	B-X
provide	B-X
useful	B-X
in	B-X
vitro	B-X
model	B-X
systems	B-X
for	B-X
the	B-X
study	B-X
of	B-X
hormone	B-X
and	B-X
cytokine	B-X
action	B-X
,	B-X
signal	B-X
transduction	B-X
pathways	B-X
,	B-X
cell-cell	B-X
interactions	B-X
,	B-X
and	B-X
gene	B-X
expression	B-X
in	B-X
specific	B-X
cell	B-X
types	B-X
of	B-X
the	B-X
ovine	B-X
endometrium	B-X
.	B-X
In	B-X
vitro	B-X
PrP	B-X
binds	B-X
large	B-X
nucleic	B-X
acids	B-X
causing	B-X
the	B-X
formation	B-X
of	B-X
nucleoprotein	B-X
complexes	B-X
resembling	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
nucleocapsid-RNA	B-X
complexes	B-X
and	B-X
in	B-X
vivo	B-X
MuLV	B-X
replication	B-X
accelerates	B-X
the	B-X
scrapie	B-X
infectious	B-X
process	B-X
,	B-X
suggesting	B-X
possible	B-X
interactions	B-X
between	B-X
retroviruses	B-X
and	B-X
PrP	B-X
.	B-X
NC	B-X
is	B-X
required	B-X
in	B-X
virus	B-X
assembly	B-X
and	B-X
infection	B-X
to	B-X
chaperone	B-X
RNA	B-X
dimerization	B-X
and	B-X
packaging	B-X
and	B-X
in	B-X
proviral	B-X
DNA	B-X
synthesis	B-X
by	B-X
reverse	B-X
transcriptase	B-X
(	B-X
RT	B-X
)	B-X
.	B-X
Results	B-X
show	B-X
that	B-X
PrP	B-X
has	B-X
properties	B-X
characteristic	B-X
of	B-X
NCp7	B-X
with	B-X
respect	B-X
to	B-X
viral	B-X
RNA	B-X
dimerization	B-X
and	B-X
proviral	B-X
DNA	B-X
synthesis	B-X
by	B-X
RT	B-X
.	B-X

genomic	O
library	O
amplified	O
(	O
4	O
-	O
6	O
)	O
.	O
<EOS>	B-X
To	B-X
develop	B-X
additional	B-X
microsatellite	B-X
(	B-X
MS	B-X
)	B-X
markers	B-X
in	B-X
the	B-X
region	B-X
of	B-X
the	B-X
porcine	B-X
skeletal	B-X
muscle	B-X
ryanodine	B-X
receptor	B-X
gene	B-X
(	B-X
RYR1	B-X
)	B-X
,	B-X
a	B-X
microdissected	B-X
genomic	B-X
library	B-X
was	B-X
generated	B-X
from	B-X
the	B-X
proximal	B-X
half	B-X
of	B-X
the	B-X
q	B-X
arm	B-X
of	B-X
swine	B-X
chromosome	B-X
6	B-X
.	B-X
Purified	B-X
DNA	B-X
was	B-X
restriction	B-X
enzyme-digested	B-X
,	B-X
ligated	B-X
to	B-X
oligonucleotide	B-X
adaptors	B-X
and	B-X
amplified	B-X
by	B-X
PCR	B-X
using	B-X
primers	B-X
complementary	B-X
to	B-X
the	B-X
adaptor	B-X
sequences	B-X
.	B-X
The	B-X
purity	B-X
of	B-X
the	B-X
amplified	B-X
products	B-X
and	B-X
boundaries	B-X
of	B-X
the	B-X
microdissected	B-X
chromosomal	B-X
region	B-X
were	B-X
verified	B-X
by	B-X
fluorescence	B-X
in	B-X
situ	B-X
hybridization	B-X
.	B-X
(	B-X
CA	B-X
)	B-X
n-containing	B-X
sequences	B-X
were	B-X
then	B-X
identified	B-X
in	B-X
a	B-X
small	B-X
insert	B-X
genomic	B-X
library	B-X
generated	B-X
from	B-X
the	B-X
PCR-amplified	B-X
microdissected	B-X
DNA	B-X
.	B-X
Oligonucleotide	B-X
primers	B-X
were	B-X
developed	B-X
for	B-X
the	B-X
PCR	B-X
amplification	B-X
of	B-X
30	B-X
of	B-X
the	B-X
46	B-X
(	B-X
CA	B-X
)	B-X
n	B-X
repeat-containing	B-X
clones	B-X
,	B-X
which	B-X
were	B-X
subsequently	B-X
used	B-X
to	B-X
amplify	B-X
DNA	B-X
isolated	B-X
from	B-X
unrelated	B-X
pigs	B-X
of	B-X
different	B-X
breeds	B-X
to	B-X
determine	B-X
the	B-X
informativeness	B-X
of	B-X
these	B-X
MS	B-X
markers	B-X
.	B-X
These	B-X
22	B-X
markers	B-X
were	B-X
all	B-X
assigned	B-X
within	B-X
a	B-X
50.7-CM	B-X
region	B-X
of	B-X
the	B-X
swine	B-X
chromosome	B-X
6	B-X
linkage	B-X
map	B-X
,	B-X
indicating	B-X
the	B-X
specificity	B-X
of	B-X
the	B-X
microdissected	B-X
library	B-X
.	B-X

Screening	O
of	O
the	O
sheep	B-Species
genomic	O
library	O
was	O
<EOS>	B-X
Genomic	B-X
DNA	B-X
from	B-X
a	B-X
fetal	B-X
sheep	B-X
homozygous	B-X
for	B-X
the	B-X
beta	B-X
A	B-X
gene	B-X
was	B-X
used	B-X
to	B-X
construct	B-X
a	B-X
library	B-X
of	B-X
one	B-X
million	B-X
cloned	B-X
DNA	B-X
fragments	B-X
using	B-X
the	B-X
bacteriophage	B-X
vector	B-X
,	B-X
Charon	B-X
4A	B-X
.	B-X
Screening	B-X
of	B-X
150,000	B-X
plaques	B-X
from	B-X
this	B-X
library	B-X
using	B-X
radioactive	B-X
beta-globin	B-X
gene	B-X
sequences	B-X
resulted	B-X
in	B-X
the	B-X
isolation	B-X
of	B-X
two	B-X
recombinant	B-X
bacteriophage	B-X
containing	B-X
globin	B-X
genes	B-X
.	B-X
The	B-X
second	B-X
recombinant	B-X
bacteriophage	B-X
,	B-X
SG-4	B-X
,	B-X
contains	B-X
a	B-X
complete	B-X
embryonic	B-X
beta-like	B-X
globin	B-X
gene	B-X
which	B-X
is	B-X
expressed	B-X
in	B-X
the	B-X
sheep	B-X
embryo	B-X
as	B-X
demonstrated	B-X
by	B-X
hybridization	B-X
analysis	B-X
with	B-X
cDNA	B-X
made	B-X
from	B-X
sheep	B-X
embryonic	B-X
globin	B-X
mRNA	B-X
.	B-X
Finally	B-X
,	B-X
preliminary	B-X
evidence	B-X
is	B-X
discussed	B-X
which	B-X
indicates	B-X
that	B-X
a	B-X
Pvu	B-X
II	B-X
site	B-X
just	B-X
5	B-X
'	B-X
to	B-X
the	B-X
Cap	B-X
site	B-X
may	B-X
be	B-X
a	B-X
common	B-X
feature	B-X
of	B-X
sheep	B-X
globin	B-X
genes	B-X
.	B-X

conducted	O
utilizing	O
[	O
32	O
P	O
]	O
-	O
labeled	O
fetal	O
sheep	B-Species
tendon	O
type	O
I	O
collagen	O
cDNA	O
and	O

several	O
positive	O
recombinant	O
phages	O
were	O
isolated	O
.	O
<EOS>	B-X
CLDN18.2-specific	B-X
VHHs	B-X
were	B-X
isolated	B-X
by	B-X
panning	B-X
a	B-X
phage	B-X
display	B-X
library	B-X
from	B-X
an	B-X
Properties	B-X
of	B-X
some	B-X
of	B-X
the	B-X
bacteriophages	B-X
of	B-X
Streptococcus	B-X
pneumoniae	B-X
are	B-X
reviewed	B-X
.	B-X
Studies	B-X
with	B-X
these	B-X
phages	B-X
have	B-X
yielded	B-X
several	B-X
interesting	B-X
observations	B-X
and	B-X
results	B-X
.	B-X
(	B-X
1	B-X
)	B-X
A	B-X
simple	B-X
transfection	B-X
system	B-X
that	B-X
uses	B-X
DNA	B-X
of	B-X
mature	B-X
pneumococcal	B-X
phages	B-X
was	B-X
developed	B-X
;	B-X
results	B-X
of	B-X
studies	B-X
utilizing	B-X
this	B-X
system	B-X
have	B-X
determined	B-X
the	B-X
intracellular	B-X
events	B-X
that	B-X
followed	B-X
infection	B-X
with	B-X
these	B-X
bacteriophages	B-X
.	B-X
(	B-X
2	B-X
)	B-X
Some	B-X
pneumococcal	B-X
phages	B-X
have	B-X
shown	B-X
dependence	B-X
on	B-X
the	B-X
bacterial	B-X
(	B-X
host	B-X
)	B-X
murein	B-X
hydrolase	B-X
for	B-X
the	B-X
liberation	B-X
of	B-X
phage	B-X
progeny	B-X
.	B-X
(	B-X
3	B-X
)	B-X
Phage	B-X
Dp-1	B-X
has	B-X
been	B-X
described	B-X
as	B-X
the	B-X
first	B-X
lipid-containing	B-X
phage	B-X
with	B-X
a	B-X
gram-positive	B-X
bacterial	B-X
host	B-X
.	B-X
(	B-X
4	B-X
)	B-X
Phage	B-X
Cp-1	B-X
,	B-X
a	B-X
recently	B-X
isolated	B-X
phage	B-X
of	B-X
unique	B-X
morphology	B-X
,	B-X
promises	B-X
to	B-X
become	B-X
a	B-X
useful	B-X
phage	B-X
for	B-X
studies	B-X
of	B-X
the	B-X
genetic	B-X
of	B-X
the	B-X
pneumococcus	B-X
.	B-X

One	O
recombinant	O
,	O
containing	O
a	O
17	O
kb	O
sheep	B-Species
genomic	O
insert	O
,	O
was	O
demonstrated	O
to	O
have	O
coding	O
sequences	O
corresponding	O
to	O
60	O
%	O
of	O
the	O
3	O
'	O
end	O
of	O
a2	O
mRNA	O
.	O

Prior	O
studies	O
showed	O
that	O
the	O
insert	O
in	O
SpC3	O
was	O
not	O
due	O
to	O
ligation	O
of	O
noncontiguous	O
restriction	O
fragments	O
and	O
/	O
or	O
genetic	O
rearrangement	O
during	O
the	O
cloning	O
process	O
(	O
2	O
)	O
.	O
<EOS>	B-X
Genomic	B-X
expression	B-X
vectors	B-X
have	B-X
been	B-X
constructed	B-X
containing	B-X
the	B-X
rearranged	B-X
gene	B-X
segments	B-X
coding	B-X
for	B-X
the	B-X
V	B-X
region	B-X
domains	B-X
of	B-X
the	B-X
heavy	B-X
(	B-X
VH	B-X
)	B-X
and	B-X
light	B-X
(	B-X
VL	B-X
)	B-X
chains	B-X
of	B-X
an	B-X
anti-2,4,6-trinitrophenyl	B-X
(	B-X
TNP	B-X
)	B-X
antibody	B-X
(	B-X
SP6	B-X
)	B-X
spliced	B-X
to	B-X
either	B-X
one	B-X
of	B-X
the	B-X
C-region	B-X
gene	B-X
segments	B-X
of	B-X
the	B-X
alpha	B-X
or	B-X
beta	B-X
TcR	B-X
chains	B-X
.	B-X
The	B-X
transfectants	B-X
specifically	B-X
killed	B-X
and	B-X
produced	B-X
interleukin	B-X
2	B-X
in	B-X
response	B-X
to	B-X
TNP-bearing	B-X
target	B-X
cells	B-X
across	B-X
strain	B-X
and	B-X
species	B-X
barriers	B-X
.	B-X
Moreover	B-X
,	B-X
such	B-X
transfectants	B-X
responded	B-X
to	B-X
immobilized	B-X
TNP-protein	B-X
conjugates	B-X
,	B-X
bypassing	B-X
the	B-X
need	B-X
for	B-X
cellular	B-X
processing	B-X
and	B-X
presentation	B-X
.	B-X
The	B-X
distribution	B-X
of	B-X
common	B-X
fragile	B-X
sites	B-X
parallels	B-X
the	B-X
positions	B-X
of	B-X
neoplasia-associated	B-X
chromosomal	B-X
rearrangements	B-X
,	B-X
prompting	B-X
the	B-X
proposal	B-X
that	B-X
fragility	B-X
disposes	B-X
to	B-X
chromosomal	B-X
rearrangements	B-X
.	B-X
Implicit	B-X
in	B-X
this	B-X
hypothesis	B-X
is	B-X
that	B-X
genes	B-X
at	B-X
fragile	B-X
sites	B-X
are	B-X
altered	B-X
by	B-X
chromosome	B-X
rearrangement	B-X
and	B-X
thus	B-X
contribute	B-X
to	B-X
neoplastic	B-X
growth	B-X
.	B-X
Chromosome	B-X
band	B-X
3p14.2	B-X
,	B-X
encompassing	B-X
the	B-X
most	B-X
inducible	B-X
common	B-X
fragile	B-X
region	B-X
,	B-X
FRA3B	B-X
,	B-X
has	B-X
been	B-X
cloned	B-X
and	B-X
the	B-X
FHIT	B-X
gene	B-X
,	B-X
straddling	B-X
FRA3B	B-X
,	B-X
characterized	B-X
.	B-X
FRA3B	B-X
thus	B-X
fulfills	B-X
the	B-X
prophecy	B-X
that	B-X
fragile	B-X
site	B-X
alterations	B-X
contribute	B-X
to	B-X
the	B-X
neoplastic	B-X
process	B-X
through	B-X
inactivation	B-X
of	B-X
a	B-X
tumor	B-X
suppressor	B-X
gene	B-X
.	B-X

Electron	O
mi	O
croscopy	O
.	O

To	O
visualize	O
the	O
recombinant	O
bacteriophage	O
DNA	O
structure	O
complementary	O
to	O
a2	O
collagen	O
mRNA	O
,	O
1	O
iig	O
of	O
SpC3	O
DNA	O
was	O
lyophilized	O
with	O
1	O
ig	O
or	O
100	O
ng	O
of	O
mRNA	O
<EOS>	B-X
Endocrine-disrupting	B-X
chemicals	B-X
are	B-X
assessed	B-X
based	B-X
on	B-X
their	B-X
physiological	B-X
potential	B-X
and	B-X
their	B-X
potential	B-X
associated	B-X
adverse	B-X
effects	B-X
.	B-X
The	B-X
pharmacology	B-X
,	B-X
pharmacokinetics	B-X
,	B-X
and	B-X
safety	B-X
of	B-X
modified	B-X
mRNA	B-X
formulated	B-X
in	B-X
lipid	B-X
nanoparticles	B-X
(	B-X
LNPs	B-X
)	B-X
were	B-X
evaluated	B-X
after	B-X
repeat	B-X
intravenous	B-X
infusion	B-X
to	B-X
rats	B-X
and	B-X
monkeys	B-X
.	B-X
In	B-X
both	B-X
species	B-X
,	B-X
modified	B-X
mRNA	B-X
encoding	B-X
the	B-X
protein	B-X
for	B-X
human	B-X
erythropoietin	B-X
(	B-X
hEPO	B-X
)	B-X
had	B-X
predictable	B-X
and	B-X
consistent	B-X
pharmacologic	B-X
and	B-X
toxicologic	B-X
effects	B-X
.	B-X
Pharmacokinetic	B-X
analysis	B-X
conducted	B-X
following	B-X
the	B-X
first	B-X
dose	B-X
showed	B-X
that	B-X
measured	B-X
hEPO	B-X
levels	B-X
were	B-X
maximal	B-X
at	B-X
6	B-X
hours	B-X
after	B-X
the	B-X
end	B-X
of	B-X
intravenous	B-X
infusion	B-X
and	B-X
in	B-X
excess	B-X
of	B-X
100-fold	B-X
the	B-X
anticipated	B-X
efficacious	B-X
exposure	B-X
(	B-X
17.6	B-X
ng/ml	B-X
)	B-X
at	B-X
the	B-X
highest	B-X
dose	B-X
tested	B-X
.	B-X

to	O
give	O
DNA	O
:	O
mRNA	O
ratios	O
of	O
1	O
:	O
1	O
and	O
10	O
:	O
1	O
,	O
respectively	O
.	O
<EOS>	B-X
Herein	B-X
we	B-X
characterize	B-X
the	B-X
organization	B-X
of	B-X
the	B-X
mouse	B-X
CD3	B-X
eta	B-X
gene	B-X
and	B-X
show	B-X
that	B-X
it	B-X
is	B-X
part	B-X
of	B-X
one	B-X
gene	B-X
locus	B-X
that	B-X
also	B-X
encodes	B-X
CD3	B-X
zeta	B-X
on	B-X
chromosome	B-X
1	B-X
.	B-X
The	B-X
NH2-terminal	B-X
sequence	B-X
of	B-X
CD3	B-X
zeta	B-X
and	B-X
CD3	B-X
eta	B-X
,	B-X
which	B-X
share	B-X
the	B-X
same	B-X
leader	B-X
peptide	B-X
and	B-X
are	B-X
identical	B-X
through	B-X
amino	B-X
acid	B-X
122	B-X
of	B-X
each	B-X
mature	B-X
protein	B-X
,	B-X
is	B-X
encoded	B-X
by	B-X
exons	B-X
1-7	B-X
.	B-X
However	B-X
,	B-X
exons	B-X
8	B-X
and	B-X
9	B-X
are	B-X
differentially	B-X
spliced	B-X
to	B-X
give	B-X
rise	B-X
to	B-X
CD3	B-X
zeta	B-X
and	B-X
CD3	B-X
eta	B-X
:	B-X
exons	B-X
1-8	B-X
encode	B-X
CD3	B-X
zeta	B-X
and	B-X
exons	B-X
1-7	B-X
plus	B-X
9	B-X
encode	B-X
CD3	B-X
eta	B-X
.	B-X
Importantly	B-X
,	B-X
expression	B-X
of	B-X
CD3	B-X
zeta	B-X
and	B-X
CD3	B-X
eta	B-X
mRNA	B-X
appears	B-X
before	B-X
or	B-X
on	B-X
day	B-X
16	B-X
of	B-X
fetal	B-X
gestation	B-X
.	B-X
The	B-X
steady-state	B-X
level	B-X
of	B-X
CD3	B-X
zeta	B-X
mRNA	B-X
is	B-X
greater	B-X
than	B-X
or	B-X
equal	B-X
to	B-X
40-60	B-X
times	B-X
that	B-X
of	B-X
CD3	B-X
eta	B-X
mRNA	B-X
.	B-X
In	B-X
immature	B-X
CD4+CD8+CD3low	B-X
double-positive	B-X
thymocytes	B-X
and	B-X
CD4+CD8-CD3high	B-X
or	B-X
CD4-CD8+CD3high	B-X
single-positive	B-X
thymocytes	B-X
,	B-X
the	B-X
respective	B-X
steady-state	B-X
CD3	B-X
zeta	B-X
and	B-X
CD3	B-X
eta	B-X
mRNA	B-X
levels	B-X
are	B-X
equivalent	B-X
,	B-X
whereas	B-X
the	B-X
amount	B-X
of	B-X
receptor-associated	B-X
CD3	B-X
zeta	B-X
and	B-X
CD3	B-X
eta	B-X
proteins	B-X
in	B-X
double-positive	B-X
thymocytes	B-X
is	B-X
approximately	B-X
10	B-X
times	B-X
less	B-X
than	B-X
in	B-X
single-positive	B-X
thymocytes	B-X
.	B-X
Nevertheless	B-X
,	B-X
the	B-X
CD3	B-X
zeta/CD3	B-X
eta	B-X
protein	B-X
ratio	B-X
remains	B-X
constant	B-X
in	B-X
all	B-X
populations	B-X
(	B-X
40-60:1	B-X
)	B-X
.	B-X
Furthermore	B-X
,	B-X
discordance	B-X
between	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
for	B-X
CD3	B-X
zeta	B-X
and	B-X
CD3	B-X
eta	B-X
is	B-X
also	B-X
observed	B-X
in	B-X
splenic	B-X
T	B-X
cells	B-X
.	B-X

These	O
were	O
then	O
dissolved	O
in	O
10	O
i1	O
of	O
R	O
loop	O
buffer	O
[	O
70	O
%	O
(	O
v	O
/	O
v	O
)	O
deionized	O
formamide	O
,	O
0	O
.	O
1	O
N	O
-	O
[	O
tris	O
(	O
hydroxy	O

2242	O

Nucleic	O
Acids	O
Research	O
<EOS>	B-X
The	B-X
2021	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
database	B-X
Issue	B-X
contains	B-X
189	B-X
papers	B-X
spanning	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
biological	B-X
fields	B-X
and	B-X
investigation	B-X
.	B-X
The	B-X
entire	B-X
Database	B-X
Issue	B-X
is	B-X
freely	B-X
available	B-X
online	B-X
on	B-X
the	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
website	B-X
(	B-X
https	B-X
:	B-X
//academic.oup.com/nar	B-X
)	B-X
.	B-X
Editorial	B-X
:	B-X
the	B-X
19th	B-X
annual	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
web	B-X
server	B-X
issue	B-X
2021	B-X
.	B-X
Editorial	B-X
:	B-X
Critical	B-X
reviews	B-X
and	B-X
perspectives	B-X
in	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
.	B-X

methyl	O
)	O
methyl	O
]	O
glycine	O
(	O
tricine	O
)	O
-	O
NaOH	O
,	O
pH	O
8	O
.	O
0	O
,	O
0	O
.	O
5	O
M	O
NaCl	O
,	O
and	O
0	O
.	O
01	O
M	O
ethyl	O

enediaminetetraacetate	O
(	O
EDTA	O
)	O
]	O
,	O
incubated	O
in	O
sealed	O
capillary	O
tubes	O
at	O
520	O
for	O
14	O
hr	O
(	O
7	O
)	O
,	O
and	O
then	O
diluted	O
1	O
:	O
10	O
with	O
R	O
loop	O
buffer	O
.	O

Two	O
spreading	O
methods	O
were	O
used	O
to	O
subsequently	O
prepare	O
the	O
hybrids	O
for	O
visualization	O
in	O
the	O
electron	O
microscope	O
.	O

70	O
%	O
formamide	O
method	O
.	O
<EOS>	B-X
Although	B-X
various	B-X
synthetic	B-X
methods	B-X
have	B-X
been	B-X
documented	B-X
in	B-X
this	B-X
regard	B-X
,	B-X
the	B-X
use	B-X
of	B-X
N-formylcarbazole	B-X
as	B-X
a	B-X
formylation	B-X
reagent	B-X
for	B-X
amines	B-X
has	B-X
not	B-X
yet	B-X
been	B-X
reported	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
a	B-X
tubular	B-X
nanofibrous	B-X
membrane	B-X
of	B-X
polysulfone	B-X
nanofibers	B-X
was	B-X
produced	B-X
via	B-X
electrospinning	B-X
method	B-X
to	B-X
remove	B-X
urea	B-X
and	B-X
creatinine	B-X
from	B-X
urine	B-X
and	B-X
blood	B-X
serums	B-X
of	B-X
dialysis	B-X
patients	B-X
.	B-X
Nanofibrous	B-X
membranes	B-X
were	B-X
electrospun	B-X
at	B-X
a	B-X
concentration	B-X
of	B-X
11.5	B-X
wt	B-X
%	B-X
of	B-X
polysulfone	B-X
(	B-X
PS	B-X
)	B-X
and	B-X
dimethylformamide	B-X
(	B-X
DMF	B-X
)	B-X
/tetrahydrofuran	B-X
(	B-X
THF	B-X
)	B-X
with	B-X
a	B-X
ratio	B-X
of	B-X
70/30	B-X
.	B-X
We	B-X
demonstrated	B-X
that	B-X
analyzing	B-X
the	B-X
formed	B-X
gels	B-X
containing	B-X
exfoliated	B-X
nitrate	B-X
or	B-X
glycine	B-X
intercalated	B-X
layered	B-X
double	B-X
hydroxide	B-X
(	B-X
LDH	B-X
)	B-X
nanosheets	B-X
in	B-X
formamide	B-X
using	B-X
X-ray	B-X
diffraction	B-X
is	B-X
a	B-X
simple	B-X
and	B-X
reliable	B-X
method	B-X
for	B-X
determining	B-X
the	B-X
delamination	B-X
degree	B-X
of	B-X
LDHs	B-X
in	B-X
formamide	B-X
,	B-X
which	B-X
shows	B-X
many	B-X
advantages	B-X
compared	B-X
to	B-X
the	B-X
common	B-X
characterization	B-X
technologies	B-X
.	B-X

Immediately	O
before	O
spreading	O
onto	O
a	O
deionized	O

water	O
hypophase	O
,	O
the	O
nucleic	O
acid	O
mixtures	O
were	O
diluted	O
an	O
additional	O
10	O
-	O
fold	O
in	O
R	O
loop	O
buffer	O
and	O
cytochrome	O
c	O
,	O
100	O
vg	O
/	O
ml	O
,	O
was	O
added	O
.	O

Urea	O
-	O
formamide	O
method	O
.	O
<EOS>	B-X
Other	B-X
denaturants	B-X
such	B-X
as	B-X
formamide	B-X
and	B-X
urea	B-X
do	B-X
not	B-X
work	B-X
well	B-X
because	B-X
they	B-X
cause	B-X
the	B-X
agarose	B-X
to	B-X
become	B-X
rubbery	B-X
.	B-X
This	B-X
step	B-X
is	B-X
generally	B-X
carried	B-X
out	B-X
at	B-X
high	B-X
temperatures	B-X
and	B-X
in	B-X
a	B-X
denaturing	B-X
solution	B-X
,	B-X
called	B-X
hybridization	B-X
buffer	B-X
,	B-X
commonly	B-X
containing	B-X
50	B-X
%	B-X
(	B-X
v/v	B-X
)	B-X
formamide	B-X
-	B-X
a	B-X
hazardous	B-X
chemical	B-X
.	B-X
We	B-X
thus	B-X
tested	B-X
alternative	B-X
solutions	B-X
for	B-X
in	B-X
situ	B-X
detection	B-X
of	B-X
gene	B-X
expression	B-X
and	B-X
,	B-X
inspired	B-X
by	B-X
optimized	B-X
protocols	B-X
for	B-X
Northern	B-X
and	B-X
Southern	B-X
blot	B-X
analysis	B-X
,	B-X
we	B-X
substituted	B-X
the	B-X
50	B-X
%	B-X
formamide	B-X
with	B-X
an	B-X
equal	B-X
volume	B-X
of	B-X
8M	B-X
urea	B-X
solution	B-X
in	B-X
the	B-X
hybridization	B-X
buffer	B-X
.	B-X
Overall	B-X
,	B-X
substitution	B-X
of	B-X
formamide	B-X
by	B-X
urea	B-X
during	B-X
in	B-X
situ	B-X
hybridization	B-X
offers	B-X
a	B-X
safer	B-X
alternative	B-X
,	B-X
potentially	B-X
of	B-X
widespread	B-X
use	B-X
in	B-X
research	B-X
,	B-X
medical	B-X
and	B-X
teaching	B-X
contexts	B-X
.	B-X

The	O
nucleic	O
acid	O
solutions	O
were	O
spread	O
using	O
a	O
modification	O
of	O
the	O
method	O
of	O
Westphal	O
and	O
Lai	O
(	O
8	O
,	O
9	O
)	O
.	O

The	O
hyperphase	O
contained	O
55	O
%	O
formamide	O
,	O
2	O
.	O
6	O
M	O
urea	O
,	O
0	O
.	O
009	O
M	O
EDTA	O
,	O
0	O
.	O
09	O
M	O
tricine	O
-	O
NaOH	O
,	O
pH	O
8	O
.	O
0	O
,	O
and	O
the	O
nucleic	O
acid	O
mixture	O
(	O
approximately	O
0	O
.	O
1	O
to	O
1	O
.	O
0	O
ig	O
/	O
ml	O
)	O
.	O

The	O
mixture	O
was	O
heated	O
at	O
40	O
?	O
for	O
30	O
sec	O
,	O
placed	O
in	O
ice	O
water	O
,	O
and	O
then	O
allowed	O
to	O
reach	O
room	O
temperature	O
.	O

Cytochrome	O
c	O
,	O
100	O
pg	O
/	O
ml	O
,	O
was	O
added	O
immediately	O
before	O
spreading	O
onto	O
a	O
deionized	O
water	O
hypophase	O
.	O

The	O
nucleic	O
acid	O
-	O
protein	O
films	O
from	O
both	O
methods	O
were	O
absorbed	O
onto	O

parlodion	O
-	O
coated	O
grids	O
,	O
stained	O
with	O
uranyl	O
acetate	O
(	O
10	O
)	O
,	O
dehydrated	O
in	O
90	O
%	O
ethanol	O
and	O
rotary	O
-	O
shadowed	O
with	O
platinum	O
-	O
palladium	O
(	O
80	O
:	O
20	O
)	O
at	O
an	O
angle	O
of	O
50	O
.	O

Micrographs	O
were	O
taken	O
with	O
a	O
Siemens	O
Elmiskop	O
101	O
electron	O
microscope	O
at	O
an	O
original	O
magnification	O
of	O
10	O
,	O
000	O
and	O
an	O
accelerating	O
voltage	O
of	O
60	O
kv	O
.	O

Nucleic	O
acid	O
lengths	O
were	O
measured	O
at	O
a	O
final	O
magnification	O
of	O
43	O
,	O
000	O
with	O
a	O

Hewlett	O
-	O
Packard	O
9810A	O
calculator	O
equipped	O
with	O
a	O
9864A	O
digitizer	O
using	O
pBR322	O
and	O
fX	O
-	O
174	O
double	O
and	O
single	O
stranded	O
DNA	O
,	O
respectively	O
,	O
as	O
internal	O
length	O
standards	O
.	O

Approximately	O
10	O
,	O
000	O
hybrid	O
molecules	O
were	O
screened	O
for	O
these	O
studies	O
;	O
approximately	O
200	O
represented	O
molecules	O
containing	O
unambiguous	O
regions	O
<EOS>	B-X
In	B-X
order	B-X
to	B-X
screen	B-X
candidate	B-X
genes	B-X
related	B-X
to	B-X
tenderness	B-X
trait	B-X
in	B-X
Qinchuan	B-X
cattle	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
gene	B-X
expression	B-X
profile	B-X
of	B-X
Longuissimus	B-X
dorsi	B-X
muscle	B-X
(	B-X
LDM	B-X
)	B-X
tissue	B-X
and	B-X
screened	B-X
differentially	B-X
expressed	B-X
genes	B-X
in	B-X
LDM	B-X
from	B-X
both	B-X
male	B-X
and	B-X
female	B-X
Qinchuan	B-X
cattle	B-X
at	B-X
36	B-X
months	B-X
of	B-X
age	B-X
utilising	B-X
Bovine	B-X
Genome	B-X
Array	B-X
.	B-X
Approximately	B-X
11,000	B-X
probe	B-X
sets	B-X
representing	B-X
10,000	B-X
genes	B-X
were	B-X
detected	B-X
in	B-X
LDM	B-X
of	B-X
36	B-X
month	B-X
old	B-X
Qinchuan	B-X
cattle	B-X
.	B-X
They	B-X
included	B-X
cell	B-X
adhesion	B-X
molecules	B-X
(	B-X
CAMs	B-X
)	B-X
and	B-X
ECM-receptor	B-X
interaction	B-X
molecules	B-X
.	B-X
Approximately	B-X
3	B-X
000	B-X
genes	B-X
are	B-X
regulated	B-X
in	B-X
a	B-X
time-	B-X
,	B-X
tissue-	B-X
,	B-X
and	B-X
stimulus-dependent	B-X
manner	B-X
by	B-X
degradation	B-X
or	B-X
stabilization	B-X
of	B-X
their	B-X
mRNAs	B-X
.	B-X
The	B-X
process	B-X
is	B-X
mediated	B-X
by	B-X
interaction	B-X
of	B-X
AU-rich	B-X
elements	B-X
(	B-X
AREs	B-X
)	B-X
in	B-X
the	B-X
mRNA	B-X
's	B-X
3'-untranslated	B-X
regions	B-X
with	B-X
trans-acting	B-X
factors	B-X
.	B-X

appropriate	O
for	O
quantitative	O
analysis	O
.	O
<EOS>	B-X
Reverse-transcription	B-X
quantitative	B-X
real-time	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT-qPCR	B-X
)	B-X
using	B-X
fluorescent	B-X
DNA-binding	B-X
dyes	B-X
is	B-X
now	B-X
a	B-X
gold-standard	B-X
methodology	B-X
to	B-X
study	B-X
bacterial	B-X
gene	B-X
expression	B-X
through	B-X
relative	B-X
quantitation	B-X
of	B-X
target	B-X
mRNAs	B-X
under	B-X
specific	B-X
experimental	B-X
conditions	B-X
,	B-X
and	B-X
recent	B-X
developments	B-X
in	B-X
the	B-X
technology	B-X
allow	B-X
for	B-X
gene	B-X
expression	B-X
analysis	B-X
in	B-X
single	B-X
cells	B-X
.	B-X
Nevertheless	B-X
,	B-X
several	B-X
critical	B-X
steps	B-X
of	B-X
the	B-X
RT-qPCR	B-X
protocol	B-X
need	B-X
to	B-X
be	B-X
carefully	B-X
addressed	B-X
in	B-X
order	B-X
to	B-X
obtain	B-X
reliable	B-X
results	B-X
,	B-X
particularly	B-X
regarding	B-X
RNA	B-X
sample	B-X
quality	B-X
and	B-X
appropriate	B-X
choice	B-X
of	B-X
reference	B-X
genes	B-X
.	B-X
Label-free	B-X
technologies	B-X
have	B-X
recently	B-X
attracted	B-X
significant	B-X
interest	B-X
for	B-X
sensitive	B-X
and	B-X
quantitative	B-X
multiparameter	B-X
analysis	B-X
of	B-X
biological	B-X
systems	B-X
.	B-X
We	B-X
describe	B-X
the	B-X
fundamental	B-X
principles	B-X
of	B-X
these	B-X
different	B-X
methods	B-X
and	B-X
discuss	B-X
advantages	B-X
and	B-X
disadvantages	B-X
that	B-X
might	B-X
potentially	B-X
help	B-X
one	B-X
in	B-X
selecting	B-X
the	B-X
appropriate	B-X
technology	B-X
for	B-X
a	B-X
given	B-X
bioanalytical	B-X
application	B-X
.	B-X

The	O
mean	O
lengths	O
of	O
each	O
intron	O
and	O
exon	O
were	O
determined	O
for	O
each	O
method	O
and	O
the	O
data	O
expressed	O
as	O
mean	O
?	O
<EOS>	B-X
Besides	B-X
359	B-X
million	B-X
RNA-seq	B-X
reads	B-X
,	B-X
4,165,527	B-X
Iso-seq	B-X
reads	B-X
were	B-X
generated	B-X
with	B-X
a	B-X
mean	B-X
length	B-X
of	B-X
14,875	B-X
bp	B-X
,	B-X
covering	B-X
11,466	B-X
human	B-X
genes	B-X
,	B-X
and	B-X
10,159	B-X
macaque	B-X
genes	B-X
.	B-X
With	B-X
Iso-seq	B-X
data	B-X
,	B-X
we	B-X
substantially	B-X
expanded	B-X
the	B-X
repertoire	B-X
of	B-X
alternative	B-X
RNA	B-X
processing	B-X
events	B-X
in	B-X
primates	B-X
,	B-X
and	B-X
found	B-X
that	B-X
intron	B-X
retention	B-X
and	B-X
alternative	B-X
polyadenylation	B-X
are	B-X
surprisingly	B-X
more	B-X
prevalent	B-X
in	B-X
primates	B-X
than	B-X
previously	B-X
estimated	B-X
.	B-X
Using	B-X
the	B-X
previously	B-X
determined	B-X
complementary	B-X
DNA	B-X
Sequence	B-X
of	B-X
Crassostrea	B-X
gigas	B-X
amylase	B-X
(	B-X
Y08370	B-X
)	B-X
,	B-X
we	B-X
designed	B-X
several	B-X
oligonucleotide	B-X
primers	B-X
and	B-X
used	B-X
them	B-X
with	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
technology	B-X
to	B-X
characterize	B-X
oyster	B-X
amylase	B-X
gene	B-X
sequences	B-X
.	B-X
The	B-X
2	B-X
genes	B-X
are	B-X
similarly	B-X
organized	B-X
with	B-X
8	B-X
exons	B-X
and	B-X
7	B-X
introns	B-X
.	B-X
Sizes	B-X
and	B-X
nucleotide	B-X
sequences	B-X
are	B-X
different	B-X
for	B-X
the	B-X
different	B-X
introns	B-X
inside	B-X
each	B-X
gene	B-X
and	B-X
different	B-X
for	B-X
the	B-X
corresponding	B-X
introns	B-X
in	B-X
the	B-X
2	B-X
genes	B-X
.	B-X
Comparing	B-X
the	B-X
2	B-X
genes	B-X
,	B-X
around	B-X
10	B-X
%	B-X
of	B-X
the	B-X
nucleotides	B-X
are	B-X
different	B-X
along	B-X
the	B-X
exons	B-X
,	B-X
and	B-X
comparing	B-X
the	B-X
2	B-X
deduced	B-X
protein	B-X
sequences	B-X
,	B-X
a	B-X
mean	B-X
value	B-X
of	B-X
10.4	B-X
%	B-X
of	B-X
amino	B-X
acids	B-X
are	B-X
changed	B-X
.	B-X
A	B-X
microsatellite	B-X
(	B-X
TC	B-X
(	B-X
37	B-X
)	B-X
)	B-X
that	B-X
constitutes	B-X
the	B-X
largest	B-X
part	B-X
of	B-X
intron	B-X
4	B-X
of	B-X
gene	B-X
A	B-X
has	B-X
been	B-X
used	B-X
as	B-X
a	B-X
polymorphic	B-X
marker	B-X
.	B-X
A	B-X
method	B-X
consisting	B-X
of	B-X
a	B-X
PCR	B-X
step	B-X
followed	B-X
by	B-X
EcoRI	B-X
digestion	B-X
of	B-X
the	B-X
obtained	B-X
fragments	B-X
was	B-X
used	B-X
to	B-X
observe	B-X
polymorphism	B-X
in	B-X
these	B-X
2	B-X
genes	B-X
.	B-X
The	B-X
2	B-X
genes	B-X
are	B-X
ubiquitously	B-X
expressed	B-X
in	B-X
the	B-X
different	B-X
digestive	B-X
tissues	B-X
with	B-X
quantitative	B-X
differences	B-X
.	B-X
Gene	B-X
A	B-X
is	B-X
strongly	B-X
expressed	B-X
in	B-X
the	B-X
digestive	B-X
gland	B-X
and	B-X
at	B-X
a	B-X
lower	B-X
level	B-X
in	B-X
stomach	B-X
,	B-X
while	B-X
gene	B-X
B	B-X
is	B-X
preferentially	B-X
expressed	B-X
in	B-X
the	B-X
labial	B-X
palps	B-X
.	B-X
A	B-X
high	B-X
level	B-X
of	B-X
polymorphism	B-X
observed	B-X
with	B-X
30	B-X
different	B-X
alleles	B-X
of	B-X
gene	B-X
A	B-X
inside	B-X
the	B-X
populations	B-X
should	B-X
allow	B-X
their	B-X
characterization	B-X
using	B-X
the	B-X
mean	B-X
value	B-X
of	B-X
the	B-X
microsatellite	B-X
allelic	B-X
distribution	B-X
.	B-X

standard	O
deviation	O
.	O
<EOS>	B-X
The	B-X
relative	B-X
expression	B-X
ratio	B-X
is	B-X
calculated	B-X
only	B-X
from	B-X
the	B-X
real-time	B-X
PCR	B-X
efficiencies	B-X
and	B-X
the	B-X
crossing	B-X
point	B-X
deviation	B-X
of	B-X
an	B-X
unknown	B-X
sample	B-X
versus	B-X
a	B-X
control	B-X
.	B-X
Control	B-X
levels	B-X
were	B-X
included	B-X
in	B-X
the	B-X
model	B-X
to	B-X
standardise	B-X
each	B-X
reaction	B-X
run	B-X
with	B-X
respect	B-X
to	B-X
RNA	B-X
integrity	B-X
,	B-X
sample	B-X
loading	B-X
and	B-X
inter-PCR	B-X
variations	B-X
.	B-X
This	B-X
article	B-X
introduces	B-X
a	B-X
new	B-X
measure	B-X
,	B-X
the	B-X
skewness	B-X
of	B-X
the	B-X
standardized	B-X
deviates	B-X
,	B-X
to	B-X
quantify	B-X
publication	B-X
bias	B-X
.	B-X
The	B-X
mysterious	B-X
standard	B-X
deviation	B-X
.	B-X

Nucleic	O
acid	O
lengths	O
of	O
<	O
50	O
base	O
pairs	O
could	O
not	O
be	O
<EOS>	B-X
These	B-X
highly	B-X
contiguous	B-X
haplotype	B-X
assemblies	B-X
(	B-X
average	B-X
minimum	B-X
contig	B-X
length	B-X
needed	B-X
to	B-X
cover	B-X
50	B-X
%	B-X
of	B-X
the	B-X
genome	B-X
:	B-X
26	B-X
million	B-X
base	B-X
pairs	B-X
)	B-X
integrate	B-X
all	B-X
forms	B-X
of	B-X
genetic	B-X
variation	B-X
,	B-X
even	B-X
across	B-X
complex	B-X
loci	B-X
.	B-X
We	B-X
identified	B-X
107,590	B-X
structural	B-X
variants	B-X
(	B-X
SVs	B-X
)	B-X
,	B-X
of	B-X
which	B-X
68	B-X
%	B-X
were	B-X
not	B-X
discovered	B-X
with	B-X
short-read	B-X
sequencing	B-X
,	B-X
and	B-X
278	B-X
SV	B-X
hotspots	B-X
(	B-X
spanning	B-X
megabases	B-X
of	B-X
gene-rich	B-X
sequence	B-X
)	B-X
.	B-X
This	B-X
resource	B-X
enables	B-X
reliable	B-X
graph-based	B-X
genotyping	B-X
from	B-X
short	B-X
reads	B-X
of	B-X
up	B-X
to	B-X
50,340	B-X
SVs	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
identification	B-X
of	B-X
1526	B-X
expression	B-X
quantitative	B-X
trait	B-X
loci	B-X
as	B-X
well	B-X
as	B-X
SV	B-X
candidates	B-X
for	B-X
adaptive	B-X
selection	B-X
within	B-X
the	B-X
human	B-X
population	B-X
.	B-X
A	B-X
method	B-X
is	B-X
presented	B-X
for	B-X
the	B-X
rapid	B-X
isolation	B-X
of	B-X
high	B-X
molecular	B-X
weight	B-X
plant	B-X
DNA	B-X
(	B-X
50,000	B-X
base	B-X
pairs	B-X
or	B-X
more	B-X
in	B-X
length	B-X
)	B-X
which	B-X
is	B-X
free	B-X
of	B-X
contaminants	B-X
which	B-X
interfere	B-X
with	B-X
complete	B-X
digestion	B-X
by	B-X
restriction	B-X
endonucleases	B-X
.	B-X

accurately	O
determined	O
using	O
the	O
methods	O
outlined	O
above	O
.	O
<EOS>	B-X
Recently	B-X
many	B-X
detection	B-X
methods	B-X
have	B-X
been	B-X
developed	B-X
to	B-X
measure	B-X
the	B-X
level	B-X
of	B-X
UA	B-X
in	B-X
human	B-X
serum	B-X
and	B-X
urine	B-X
sample	B-X
even	B-X
saliva	B-X
and	B-X
nails	B-X
and	B-X
tears	B-X
.	B-X
This	B-X
review	B-X
outlines	B-X
the	B-X
importance	B-X
of	B-X
UA	B-X
detection	B-X
and	B-X
the	B-X
history	B-X
of	B-X
the	B-X
development	B-X
of	B-X
UA	B-X
detection	B-X
methods	B-X
.	B-X
Most	B-X
of	B-X
the	B-X
above	B-X
detection	B-X
methods	B-X
contain	B-X
both	B-X
enzymatic	B-X
and	B-X
nonenzymatic	B-X
strategies	B-X
.	B-X
The	B-X
materials	B-X
used	B-X
in	B-X
mentioned	B-X
methods	B-X
above	B-X
tend	B-X
to	B-X
be	B-X
diversified	B-X
,	B-X
hence	B-X
an	B-X
overview	B-X
of	B-X
materials	B-X
used	B-X
in	B-X
UA	B-X
detection	B-X
are	B-X
also	B-X
reported	B-X
.	B-X

Thus	O
,	O
in	O
the	O
cases	O
<EOS>	B-X
There	B-X
are	B-X
approximately	B-X
a	B-X
dozen	B-X
cases	B-X
of	B-X
xanthogranulomatous	B-X
salpingitis	B-X
reported	B-X
in	B-X
the	B-X
literature	B-X
,	B-X
mostly	B-X
as	B-X
case	B-X
reports	B-X
.	B-X
Thirteen	B-X
such	B-X
cases	B-X
were	B-X
identified	B-X
from	B-X
2003	B-X
to	B-X
2018	B-X
at	B-X
our	B-X
institution	B-X
.	B-X
Clinical	B-X
presentations	B-X
and	B-X
surgical	B-X
indications	B-X
included	B-X
pelvic	B-X
inflammatory	B-X
disease	B-X
(	B-X
5	B-X
cases	B-X
)	B-X
,	B-X
endometrial	B-X
carcinoma	B-X
(	B-X
4	B-X
cases	B-X
)	B-X
,	B-X
suspicion	B-X
of	B-X
ovarian	B-X
malignancy	B-X
(	B-X
1	B-X
case	B-X
)	B-X
,	B-X
symptomatic	B-X
fibroids	B-X
(	B-X
1	B-X
case	B-X
)	B-X
,	B-X
endometriosis	B-X
(	B-X
1	B-X
case	B-X
)	B-X
,	B-X
and	B-X
infertility	B-X
(	B-X
1	B-X
case	B-X
)	B-X
.	B-X
Surgical-pathologic	B-X
correlation	B-X
resulted	B-X
in	B-X
diagnoses	B-X
of	B-X
tubo-ovarian	B-X
abscess	B-X
(	B-X
4	B-X
cases	B-X
)	B-X
,	B-X
ovarian	B-X
abscess	B-X
(	B-X
2	B-X
cases	B-X
)	B-X
,	B-X
pyosalpinx	B-X
(	B-X
2	B-X
cases	B-X
)	B-X
,	B-X
and	B-X
chronic	B-X
endometritis	B-X
(	B-X
2	B-X
cases	B-X
)	B-X
.	B-X
Of	B-X
the	B-X
remaining	B-X
3	B-X
cases	B-X
,	B-X
2	B-X
presented	B-X
clinically	B-X
as	B-X
pelvic	B-X
inflammatory	B-X
disease	B-X
and	B-X
the	B-X
other	B-X
was	B-X
seen	B-X
in	B-X
the	B-X
context	B-X
of	B-X
an	B-X
endometrial	B-X
carcinoma	B-X
.	B-X
With	B-X
one	B-X
exception	B-X
,	B-X
the	B-X
cases	B-X
in	B-X
this	B-X
series	B-X
represent	B-X
pelvic	B-X
inflammatory	B-X
disease	B-X
despite	B-X
variable	B-X
clinical	B-X
presentations	B-X
.	B-X

where	O
introns	O
or	O
exons	O
were	O
of	O
this	O
length	O
or	O
less	O
,	O
accurate	O
error	O
estimates	O
could	O
not	O
be	O
made	O
.	O
<EOS>	B-X
The	B-X
26,564	B-X
annotated	B-X
genes	B-X
in	B-X
the	B-X
human	B-X
genome	B-X
(	B-X
build	B-X
October	B-X
,	B-X
2003	B-X
)	B-X
contain	B-X
233,785	B-X
exons	B-X
and	B-X
207,344	B-X
introns	B-X
.	B-X
On	B-X
average	B-X
,	B-X
there	B-X
are	B-X
8.8	B-X
exons	B-X
and	B-X
7.8	B-X
introns	B-X
per	B-X
gene	B-X
.	B-X
About	B-X
80	B-X
%	B-X
of	B-X
the	B-X
exons	B-X
on	B-X
each	B-X
chromosome	B-X
are	B-X
<	B-X
200	B-X
bp	B-X
in	B-X
length	B-X
.	B-X
<	B-X
0.01	B-X
%	B-X
of	B-X
the	B-X
introns	B-X
are	B-X
<	B-X
20	B-X
bp	B-X
in	B-X
length	B-X
and	B-X
<	B-X
10	B-X
%	B-X
of	B-X
introns	B-X
are	B-X
more	B-X
than	B-X
11,000	B-X
bp	B-X
in	B-X
length	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
constraints	B-X
on	B-X
the	B-X
splicing	B-X
machinery	B-X
to	B-X
splice	B-X
out	B-X
very	B-X
long	B-X
or	B-X
very	B-X
short	B-X
introns	B-X
and	B-X
provide	B-X
insight	B-X
to	B-X
optimal	B-X
intron	B-X
length	B-X
selection	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
total	B-X
length	B-X
in	B-X
introns	B-X
and	B-X
intergenic	B-X
DNA	B-X
on	B-X
each	B-X
chromosome	B-X
is	B-X
significantly	B-X
correlated	B-X
to	B-X
the	B-X
determined	B-X
chromosome	B-X
size	B-X
with	B-X
a	B-X
coefficient	B-X
of	B-X
correlation	B-X
r	B-X
=	B-X
0.95	B-X
and	B-X
r	B-X
=	B-X
0.97	B-X
,	B-X
respectively	B-X
.	B-X

Bi	O
ohazard	O
precauti	O
ons	O
.	O
<EOS>	B-X
Since	B-X
ON	B-X
production	B-X
is	B-X
projected	B-X
to	B-X
expand	B-X
to	B-X
the	B-X
large	B-X
scale	B-X
,	B-X
automatized	B-X
multicolumn	B-X
countercurrent	B-X
technologies	B-X
will	B-X
reasonably	B-X
be	B-X
required	B-X
soon	B-X
to	B-X
replace	B-X
the	B-X
current	B-X
ones	B-X
based	B-X
on	B-X
batch	B-X
single-column	B-X
operations	B-X
.	B-X
This	B-X
consideration	B-X
is	B-X
supported	B-X
by	B-X
a	B-X
recent	B-X
cutting-edge	B-X
application	B-X
of	B-X
continuous	B-X
chromatography	B-X
for	B-X
the	B-X
ON	B-X
purification	B-X
.	B-X
Actinide	B-X
and	B-X
technetium	B-X
complexes	B-X
with	B-X
O-	B-X
,	B-X
N-	B-X
,	B-X
N	B-X
,	B-X
O	B-X
,	B-X
N	B-X
,	B-X
S-	B-X
,	B-X
P-containing	B-X
ligands	B-X
,	B-X
as	B-X
well	B-X
Ï-organometallics	B-X
are	B-X
discussed	B-X
from	B-X
the	B-X
view	B-X
point	B-X
of	B-X
their	B-X
synthesis	B-X
,	B-X
properties	B-X
,	B-X
and	B-X
main	B-X
applications	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
their	B-X
properties	B-X
,	B-X
several	B-X
mono-	B-X
,	B-X
bi-	B-X
,	B-X
tri-	B-X
,	B-X
tetra-	B-X
or	B-X
polydentate	B-X
ligands	B-X
have	B-X
been	B-X
designed	B-X
for	B-X
specific	B-X
recognition	B-X
of	B-X
some	B-X
particular	B-X
radionuclides	B-X
,	B-X
and	B-X
can	B-X
be	B-X
used	B-X
in	B-X
the	B-X
processes	B-X
of	B-X
nuclear	B-X
waste	B-X
remediation	B-X
,	B-X
i.e.	B-X
,	B-X
recycling	B-X
of	B-X
nuclear	B-X
fuel	B-X
and	B-X
the	B-X
separation	B-X
of	B-X
actinides	B-X
and	B-X
fission	B-X
products	B-X
from	B-X
waste	B-X
solutions	B-X
or	B-X
for	B-X
analytical	B-X
determination	B-X
of	B-X
actinides	B-X
in	B-X
solutions	B-X
;	B-X
actinide	B-X
metal	B-X
complexes	B-X
are	B-X
also	B-X
usefulas	B-X
catalysts	B-X
forcoupling	B-X
gaseous	B-X
carbon	B-X
monoxide	B-X
,	B-X
as	B-X
well	B-X
as	B-X
antimicrobial	B-X
and	B-X
anti-fungi	B-X
agents	B-X
due	B-X
to	B-X
their	B-X
biological	B-X
activity	B-X
.	B-X
Finally	B-X
,	B-X
the	B-X
promising	B-X
applications	B-X
of	B-X
technetium	B-X
labeling	B-X
of	B-X
nanomaterials	B-X
,	B-X
with	B-X
potential	B-X
applications	B-X
as	B-X
drug	B-X
transport	B-X
and	B-X
delivery	B-X
vehicles	B-X
,	B-X
radiotherapeutic	B-X
agents	B-X
or	B-X
radiotracers	B-X
for	B-X
monitoring	B-X
metabolic	B-X
pathways	B-X
,	B-X
are	B-X
also	B-X
described	B-X
.	B-X

The	O
construction	O
and	O
screening	O
of	O
the	O
sheep	B-Species
genomic	O
library	O
together	O
with	O
amplification	O
of	O
pCg45	O
and	O
preparation	O
of	O
high	O
titre	O
lysates	O
of	O
chimaeric	O

Charon	O
4A	O
were	O
performed	O
under	O
the	O
physical	O
and	O
biological	O
containment	O
levels	O
specified	O
by	O
the	O
NIH	O
guidelines	O
for	O
recombinant	O
DNA	O
research	O
(	O
11	O
)	O
.	O

2243	O

Nucleic	O
Acids	O
Research	O
<EOS>	B-X
The	B-X
2021	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
database	B-X
Issue	B-X
contains	B-X
189	B-X
papers	B-X
spanning	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
biological	B-X
fields	B-X
and	B-X
investigation	B-X
.	B-X
The	B-X
entire	B-X
Database	B-X
Issue	B-X
is	B-X
freely	B-X
available	B-X
online	B-X
on	B-X
the	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
website	B-X
(	B-X
https	B-X
:	B-X
//academic.oup.com/nar	B-X
)	B-X
.	B-X
Editorial	B-X
:	B-X
the	B-X
19th	B-X
annual	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
web	B-X
server	B-X
issue	B-X
2021	B-X
.	B-X
Editorial	B-X
:	B-X
Critical	B-X
reviews	B-X
and	B-X
perspectives	B-X
in	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
.	B-X

RESULTS	O

Location	O
and	O
orientation	O
of	O
the	O
intervening	O
and	O
a2	O
mRNA	O
coding	O
sequences	O
in	O
the	O
SpC3	O
recombinant	O
DNA	O
.	O

Hybridization	O
of	O
fetal	O
sheep	B-Species
tendon	O
type	O
I	O
collagen	O
mRNA	O
to	O
SpC3	O
DNA	O
<EOS>	B-X
DNA	B-X
fragments	B-X
,	B-X
prepared	B-X
by	B-X
partial	B-X
Eco	B-X
RI	B-X
digestion	B-X
of	B-X
fetal	B-X
sheep	B-X
liver	B-X
genomic	B-X
DNA	B-X
,	B-X
were	B-X
used	B-X
to	B-X
prepare	B-X
a	B-X
``	B-X
library	B-X
''	B-X
of	B-X
amplified	B-X
genomic	B-X
sequences	B-X
with	B-X
the	B-X
lambda	B-X
vector	B-X
Charon	B-X
4A	B-X
.	B-X
Several	B-X
recombinant	B-X
plaques	B-X
were	B-X
identified	B-X
by	B-X
their	B-X
ability	B-X
to	B-X
hybridize	B-X
to	B-X
32P-labeled	B-X
cDNA	B-X
prepared	B-X
from	B-X
fetal	B-X
sheep	B-X
tendon	B-X
type	B-X
I	B-X
procollagen	B-X
mRNA	B-X
.	B-X
Two	B-X
of	B-X
these	B-X
recombinant	B-X
DNA	B-X
bacteriophages	B-X
(	B-X
SpC3	B-X
and	B-X
SpC7	B-X
)	B-X
were	B-X
identified	B-X
as	B-X
containing	B-X
procollagen	B-X
pro	B-X
alpha	B-X
2	B-X
gene	B-X
sequences	B-X
by	B-X
their	B-X
ability	B-X
to	B-X
specifically	B-X
anneal	B-X
to	B-X
procollagen	B-X
pro	B-X
alpha	B-X
2	B-X
mRNA	B-X
.	B-X
Restriction	B-X
endonuclease	B-X
and	B-X
hybridization	B-X
to	B-X
a	B-X
cloned	B-X
pro	B-X
alpha	B-X
2	B-X
cDNA	B-X
demonstrated	B-X
that	B-X
approximately	B-X
half	B-X
(	B-X
2.5	B-X
kilobases	B-X
)	B-X
of	B-X
the	B-X
pro	B-X
alpha	B-X
2	B-X
mRNA	B-X
sequence	B-X
is	B-X
distributed	B-X
over	B-X
15	B-X
kilobases	B-X
of	B-X
genomic	B-X
DNA	B-X
.	B-X
Restriction	B-X
maps	B-X
of	B-X
SpC3	B-X
and	B-X
SpC7	B-X
demonstrated	B-X
that	B-X
these	B-X
two	B-X
DNA	B-X
fragments	B-X
contain	B-X
overlapping	B-X
sequences	B-X
of	B-X
the	B-X
pro	B-X
alpha	B-X
2	B-X
gene	B-X
.	B-X
Electron	B-X
microscopy	B-X
and	B-X
R-loop	B-X
analysis	B-X
of	B-X
SpC3	B-X
revealed	B-X
that	B-X
at	B-X
least	B-X
12	B-X
to	B-X
16	B-X
intervening	B-X
sequences	B-X
are	B-X
distributed	B-X
throughout	B-X
the	B-X
length	B-X
of	B-X
this	B-X
gene	B-X
fragment	B-X
.	B-X

yielded	O
a	O
complex	O
R	O
loop	O
pattern	O
in	O
the	O
region	O
where	O
the	O
sheep	B-Species
genomic	O
insert	O
was	O
expected	O
to	O
be	O
ligated	O
to	O
the	O
arms	O
of	O
the	O
lambda	O
vector	O
,	O
Charon	O
4A	O
.	O

To	O
<EOS>	B-X
Response	B-X
to	B-X
Goldberg	B-X
and	B-X
Villeneuve	B-X
re	B-X
:	B-X
An	B-X
ecological	B-X
analysis	B-X
of	B-X
long-term	B-X
exposure	B-X
to	B-X
PM	B-X

confirm	O
that	O
these	O
hybridization	O
events	O
were	O
restricted	O
to	O
the	O
inserted	O
sheep	B-Species
DNA	O
fragment	O
,	O
duplex	O
DNA	O
strands	O
on	O
both	O
sides	O
of	O
this	O
hybridization	O
area	O
were	O
measured	O
.	O

Using	O
pBR322	O
as	O
an	O
internal	O
length	O
standard	O
,	O
the	O
left	O
arm	O
of	O
the	O
phage	O
was	O
found	O
to	O
contain	O
21	O
,	O
780	O
?	O

1500	O
bp	O
,	O
and	O
the	O
right	O
arm	O
,	O
11	O
,	O
950	O
?	O

1030	O
bp	O
,	O
corresponding	O
to	O
the	O
report	O
values	O
for	O
the	O
left	O
and	O
right	O
arms	O
,	O
respectively	O
,	O
of	O
Charon	O
4A	O
DNA	O
(	O
5	O
,	O
6	O
)	O
.	O

The	O
hybridization	O
of	O
SpC3	O
to	O
a2	O
mRNA	O
resulted	O
in	O
the	O
destabilization	O
of	O

the	O
inserted	O
helical	O
duplex	O
DNA	O
fragment	O
such	O
that	O
one	O
DNA	O
strand	O
was	O
displaced	O
(	O
Figure	O
1	O
)	O
.	O

Occasionally	O
,	O
the	O
displaced	O
DNA	O
strand	O
was	O
mostly	O
absent	O
,	O
probably	O
due	O
to	O
fragmentation	O
induced	O
by	O
accidental	O
mechanical	O
shearing	O
.	O

This	O
event	O
considerably	O
enhanced	O
the	O
visualization	O
and	O
ordering	O
of	O
the	O
introns	O
.	O

As	O
the	O
a2	O
mRNA	O
annealed	O
to	O
complementary	O
DNA	O
regions	O
present	O
in	O
one	O

DNA	O
strand	O
,	O
numerous	O
single	O
-	O
stranded	O
loops	O
resulted	O
.	O
<EOS>	B-X
G-quadruplexes	B-X
(	B-X
G4s	B-X
)	B-X
are	B-X
distinctive	B-X
four-stranded	B-X
DNA	B-X
or	B-X
RNA	B-X
structures	B-X
found	B-X
within	B-X
cells	B-X
that	B-X
are	B-X
thought	B-X
to	B-X
play	B-X
functional	B-X
roles	B-X
in	B-X
gene	B-X
regulation	B-X
and	B-X
transcription	B-X
,	B-X
translation	B-X
,	B-X
recombination	B-X
,	B-X
and	B-X
DNA	B-X
damage/repair	B-X
.	B-X
While	B-X
G4	B-X
structures	B-X
can	B-X
be	B-X
uni-	B-X
,	B-X
bi-	B-X
,	B-X
or	B-X
tetramolecular	B-X
with	B-X
respect	B-X
to	B-X
strands	B-X
,	B-X
folded	B-X
unimolecular	B-X
conformations	B-X
are	B-X
most	B-X
significant	B-X
Replication	B-X
is	B-X
carried	B-X
out	B-X
by	B-X
a	B-X
multiprotein	B-X
complex	B-X
called	B-X
the	B-X
replisome	B-X
,	B-X
which	B-X
encounters	B-X
numerous	B-X
obstacles	B-X
to	B-X
its	B-X
progression	B-X
.	B-X
All	B-X
eukaryotes	B-X
contain	B-X
the	B-X
accessory	B-X
helicase	B-X
Pif1	B-X
,	B-X
which	B-X
tracks	B-X
in	B-X
a	B-X
5'-3	B-X
'	B-X
direction	B-X
on	B-X
single-stranded	B-X
DNA	B-X
and	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
genome	B-X
maintenance	B-X
processes	B-X
.	B-X

These	O
loops	O
,	O
referred	O
to	O
as	O
introns	O
,	O
represented	O
DNA	O
sequences	O
not	O
complementary	O
to	O
the	O
mRNA	O
.	O

Although	O
,	O
by	O
convention	O
,	O
introns	O
are	O
usually	O
sequentially	O
labeled	O
5	O
'	O
to	O
3	O
'	O
,	O
an	O
opposite	O
order	O
had	O
to	O
be	O
employed	O
in	O
this	O
case	O
as	O
SpC3	O
does	O
not	O
contain	O
the	O
sequences	O
coding	O
for	O
the	O
5	O
'	O
end	O
of	O
sheep	B-Species
a2	O
mRNA	O
.	O

Infrequently	O
,	O
all	O
introns	O
<EOS>	B-X
Stwintrons	B-X
are	B-X
nested	B-X
spliceosomal	B-X
introns	B-X
,	B-X
where	B-X
an	B-X
internal	B-X
intron	B-X
splits	B-X
a	B-X
second	B-X
donor	B-X
sequence	B-X
into	B-X
two	B-X
consecutive	B-X
splicing	B-X
reactions	B-X
leading	B-X
to	B-X
mature	B-X
mRNA	B-X
.	B-X
While	B-X
some	B-X
of	B-X
them	B-X
are	B-X
so	B-X
rare	B-X
that	B-X
they	B-X
become	B-X
recognizable	B-X
only	B-X
in	B-X
the	B-X
superposition	B-X
of	B-X
dozens	B-X
or	B-X
hundreds	B-X
of	B-X
transcriptome	B-X
datasets	B-X
and	B-X
not	B-X
infrequently	B-X
include	B-X
introns	B-X
or	B-X
exons	B-X
that	B-X
have	B-X
not	B-X
been	B-X
included	B-X
in	B-X
available	B-X
genome	B-X
annotation	B-X
data	B-X
,	B-X
there	B-X
is	B-X
still	B-X
a	B-X
very	B-X
limited	B-X
number	B-X
of	B-X
processing	B-X
products	B-X
for	B-X
any	B-X
given	B-X
locus	B-X
.	B-X
PCR	B-X
amplification	B-X
of	B-X
introns	B-X
with	B-X
primers	B-X
that	B-X
anneal	B-X
to	B-X
conserved	B-X
,	B-X
flanking	B-X
exons	B-X
is	B-X
effective	B-X
for	B-X
the	B-X
development	B-X
of	B-X
polymorphic	B-X
nuclear	B-X
genome	B-X
markers	B-X
.	B-X
To	B-X
explore	B-X
the	B-X
potential	B-X
for	B-X
broadly	B-X
applicable	B-X
plant	B-X
mitochondrial	B-X
intron	B-X
markers	B-X
,	B-X
PCR	B-X
primer	B-X
sets	B-X
based	B-X
upon	B-X
conserved	B-X
sequences	B-X
flanking	B-X
11	B-X
introns	B-X
common	B-X
to	B-X
seven	B-X
angiosperm	B-X
species	B-X
were	B-X
tested	B-X
across	B-X
a	B-X
range	B-X
of	B-X
plant	B-X
orders	B-X
.	B-X
PCR-amplified	B-X
introns	B-X
were	B-X
screened	B-X
for	B-X
indel	B-X
polymorphisms	B-X
among	B-X
a	B-X
group	B-X
of	B-X
cross-compatible	B-X

were	O
clearly	O
observed	O
within	O
the	O
same	O
hybrid	O
molecule	O
(	O
Figure	O
1	O
)	O
.	O

The	O
largest	O
introns	O
were	O
towards	O
the	O
left	O
arm	O
of	O
Charon	O
4A	O
and	O
were	O
more	O
clustered	O
than	O
the	O
introns	O
at	O
the	O
opposite	O
end	O
of	O
the	O
hybrid	O
.	O

Thus	O
,	O
much	O
of	O
the	O
genetic	O
<EOS>	B-X
The	B-X
realization	B-X
that	B-X
altering	B-X
diet	B-X
can	B-X
alter	B-X
the	B-X
epigenetic	B-X
state	B-X
of	B-X
genes	B-X
and	B-X
that	B-X
these	B-X
epigenetic	B-X
alterations	B-X
might	B-X
increase	B-X
or	B-X
decrease	B-X
cancer	B-X
risk	B-X
is	B-X
a	B-X
more	B-X
modern	B-X
notion	B-X
,	B-X
driven	B-X
largely	B-X
by	B-X
studies	B-X
in	B-X
animal	B-X
models	B-X
.	B-X
The	B-X
connections	B-X
between	B-X
diet	B-X
and	B-X
epigenetic	B-X
alterations	B-X
,	B-X
on	B-X
the	B-X
one	B-X
hand	B-X
,	B-X
and	B-X
between	B-X
epigenetic	B-X
alterations	B-X
and	B-X
cancer	B-X
,	B-X
on	B-X
the	B-X
other	B-X
,	B-X
are	B-X
supported	B-X
by	B-X
both	B-X
observational	B-X
studies	B-X
in	B-X
humans	B-X
as	B-X
well	B-X
as	B-X
animal	B-X
models	B-X
.	B-X
However	B-X
,	B-X
the	B-X
conclusion	B-X
that	B-X
diet	B-X
is	B-X
linked	B-X
directly	B-X
to	B-X
epigenetic	B-X
alterations	B-X
and	B-X
that	B-X
these	B-X
epigenetic	B-X
alterations	B-X
directly	B-X
increase	B-X
or	B-X
decrease	B-X
the	B-X
risk	B-X
of	B-X
human	B-X
cancer	B-X
is	B-X
much	B-X
less	B-X
certain	B-X
.	B-X
However	B-X
,	B-X
there	B-X
is	B-X
little	B-X
guidance	B-X
about	B-X
how	B-X
much	B-X
weight	B-X
should	B-X
be	B-X
given	B-X
to	B-X
genetic	B-X
evidence	B-X
in	B-X
making	B-X
these	B-X
key	B-X
decisions	B-X
.	B-X
To	B-X
answer	B-X
this	B-X
question	B-X
,	B-X
we	B-X
investigated	B-X
how	B-X
well	B-X
the	B-X
current	B-X
archive	B-X
of	B-X
genetic	B-X
evidence	B-X
predicts	B-X
drug	B-X
mechanisms	B-X
.	B-X
We	B-X
found	B-X
that	B-X
,	B-X
among	B-X
well-studied	B-X
indications	B-X
,	B-X
the	B-X
proportion	B-X
of	B-X
drug	B-X
mechanisms	B-X
with	B-X
direct	B-X
genetic	B-X
support	B-X
increases	B-X
significantly	B-X
across	B-X
the	B-X
drug	B-X
development	B-X
pipeline	B-X
,	B-X
from	B-X
2.0	B-X
%	B-X
at	B-X
the	B-X
preclinical	B-X
stage	B-X
to	B-X
8.2	B-X
%	B-X
among	B-X
mechanisms	B-X
for	B-X
approved	B-X
drugs	B-X
,	B-X
and	B-X
varies	B-X
dramatically	B-X
among	B-X
disease	B-X
areas	B-X
.	B-X
We	B-X
estimate	B-X
that	B-X
selecting	B-X
genetically	B-X
supported	B-X
targets	B-X
could	B-X
double	B-X
the	B-X
success	B-X
rate	B-X
in	B-X
clinical	B-X
development	B-X
.	B-X
Therefore	B-X
,	B-X
using	B-X
the	B-X
growing	B-X
wealth	B-X
of	B-X
human	B-X
genetic	B-X
data	B-X
to	B-X
select	B-X
the	B-X
best	B-X
targets	B-X
and	B-X
indications	B-X
should	B-X
have	B-X
a	B-X
measurable	B-X
impact	B-X
on	B-X
the	B-X
successful	B-X
development	B-X
of	B-X
new	B-X
drugs	B-X
.	B-X

information	O
coding	O
for	O
the	O
a2	O
mRNA	O
was	O
contained	O
in	O
that	O
half	O
of	O
the	O
hybrid	O
attached	O
to	O
the	O
right	O
arm	O
.	O

A	O
small	O
non	O
-	O
hybridized	O
tail	O
was	O
consistently	O
found	O
in	O
the	O
region	O
where	O

the	O
right	O
arm	O
of	O
the	O
phage	O
was	O
ligated	O
to	O
the	O
sheep	B-Species
genomic	O
insert	O
(	O
Figure	O
1	O
)	O
.	O

This	O
tail	O
likely	O
corresponded	O
to	O
the	O
3	O
'	O
poly	O
A	O
sequence	O
of	O
the	O
a2	O
mRNA	O
.	O

At	O

the	O
extreme	O
5	O
'	O
end	O
of	O
the	O
insert	O
,	O
a	O
variable	O
length	O
was	O
often	O
observed	O
for	O
the	O
remaining	O
unhybridized	O
mRNA	O
strand	O
.	O

This	O
was	O
most	O
likely	O
due	O
to	O
the	O
size	O
heterogeneity	O
of	O
the	O
a2	O
mRNA	O
used	O
in	O
these	O
studies	O
.	O

Size	O
determination	O
and	O
comparative	O
analysis	O
of	O
SpC3	O
introns	O
.	O

Although	O
localization	O
of	O
exon	O
and	O
intron	O
sequences	O
was	O
possible	O
with	O
both	O
the	O
70	O
%	O
formamide	O
and	O
urea	O
-	O
formamide	O
spreading	O
methods	O
,	O
the	O
probability	O
of	O

detecting	O
unambiguous	O
regions	O
in	O
a	O
hybrid	O
molecule	O
was	O
far	O
greater	O
with	O
the	O

2244	O

Nucleic	O
Acids	O
Research	O
<EOS>	B-X
The	B-X
2021	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
database	B-X
Issue	B-X
contains	B-X
189	B-X
papers	B-X
spanning	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
biological	B-X
fields	B-X
and	B-X
investigation	B-X
.	B-X
The	B-X
entire	B-X
Database	B-X
Issue	B-X
is	B-X
freely	B-X
available	B-X
online	B-X
on	B-X
the	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
website	B-X
(	B-X
https	B-X
:	B-X
//academic.oup.com/nar	B-X
)	B-X
.	B-X
Editorial	B-X
:	B-X
the	B-X
19th	B-X
annual	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
web	B-X
server	B-X
issue	B-X
2021	B-X
.	B-X
Editorial	B-X
:	B-X
Critical	B-X
reviews	B-X
and	B-X
perspectives	B-X
in	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
.	B-X

A	O
B	O
'	O
,	O
:	O
'	O
14	O
.	O
0	O
.	O

13	O
<EOS>	B-X
Action	B-X
of	B-X
propranolol	B-X
on	B-X
mitochondrial	B-X
functions	B-X
--	B-X
effects	B-X
on	B-X
energized	B-X
ion	B-X
fluxes	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
valinomycin	B-X
.	B-X

7	O
1	O
<EOS>	B-X
Maturation	B-X
of	B-X
the	B-X
adrenal	B-X
medulla	B-X
--	B-X
IV	B-X
.	B-X
Effects	B-X
of	B-X
morphine	B-X
.	B-X
Formate	B-X
assay	B-X
in	B-X
body	B-X
fluids	B-X
:	B-X
application	B-X
in	B-X
methanol	B-X
poisoning	B-X
.	B-X

-	O
5	O
13	O
<EOS>	B-X
Atomic	B-X
models	B-X
for	B-X
the	B-X
polypeptide	B-X
backbones	B-X
of	B-X
myohemerythrin	B-X
and	B-X
hemerythrin	B-X
.	B-X
Action	B-X
of	B-X
propranolol	B-X
on	B-X
mitochondrial	B-X
functions	B-X
--	B-X
effects	B-X
on	B-X
energized	B-X
ion	B-X
fluxes	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
valinomycin	B-X
.	B-X

.	O
.	O

.	O
.	O

,	O
4	O
x2	O
%	O
.	O
<EOS>	B-X
Association	B-X
of	B-X
X2-CBM3	B-X
with	B-X
xyloglucanase	B-X
and	B-X
endoglucanase	B-X
led	B-X
to	B-X
up	B-X
to	B-X
4.6-fold	B-X
increase	B-X
in	B-X
activity	B-X
towards	B-X
insoluble	B-X
substrates	B-X
.	B-X
The	B-X
effects	B-X
of	B-X
cultivation	B-X
medium	B-X
compositions	B-X
including	B-X
soybean	B-X
meal	B-X
,	B-X
peptone	B-X
,	B-X
soybean	B-X
oil	B-X
and	B-X
cornstarch	B-X
for	B-X
actinomycin	B-X
X2	B-X
production	B-X
by	B-X
Streptomyces	B-X
spp	B-X
JAU4234	B-X
were	B-X
accessed	B-X
by	B-X
using	B-X
response	B-X
surface	B-X
methodology	B-X
.	B-X
The	B-X
2	B-X
(	B-X
4	B-X
)	B-X
full	B-X
factorial	B-X
designs	B-X
and	B-X
the	B-X
paths	B-X
of	B-X
steepest	B-X
ascent	B-X
were	B-X
effective	B-X
in	B-X
searching	B-X
for	B-X
the	B-X
major	B-X
factors	B-X
of	B-X
actinomycin	B-X
X2	B-X
production	B-X
.	B-X
Estimated	B-X
optimum	B-X
compositions	B-X
for	B-X
the	B-X
production	B-X
of	B-X
actionmycin	B-X
X2	B-X
were	B-X
as	B-X
follows	B-X
(	B-X
g/l	B-X
)	B-X
:	B-X
soybean	B-X
meal	B-X
21.65	B-X
and	B-X
peptone	B-X
9.41	B-X
,	B-X
and	B-X
result	B-X
in	B-X
a	B-X
maximum	B-X
actionmycin	B-X
X2	B-X
production	B-X
of	B-X
617.4	B-X
mg/l	B-X
.	B-X
The	B-X
yield	B-X
of	B-X
actionmycin	B-X
X2	B-X
was	B-X
increased	B-X
by	B-X
36.9	B-X
%	B-X
by	B-X
culturing	B-X
the	B-X
strain	B-X
Streptomyces	B-X
spp	B-X
JAU4234	B-X
in	B-X
the	B-X
nutritionally	B-X
optimized	B-X
fermentation	B-X
medium	B-X
.	B-X

N1	O
<EOS>	B-X
Some	B-X
properties	B-X
and	B-X
applications	B-X
of	B-X
the	B-X
N1-P2	B-X
complex	B-X
(	B-X
100-200	B-X
ms	B-X
latency	B-X
)	B-X
are	B-X
reviewed	B-X
.	B-X
N1-P2	B-X
is	B-X
currently	B-X
the	B-X
auditory-evoked	B-X
potential	B-X
(	B-X
AEP	B-X
)	B-X
of	B-X
choice	B-X
for	B-X
estimating	B-X
the	B-X
pure-tone	B-X
audiogram	B-X
in	B-X
certain	B-X
subjects	B-X
for	B-X
whom	B-X
a	B-X
frequency-specific	B-X
,	B-X
non-behavioural	B-X
measure	B-X
is	B-X
required	B-X
.	B-X
Successful	B-X
use	B-X
of	B-X
N1-P2	B-X
requires	B-X
substantial	B-X
tester	B-X
training	B-X
and	B-X
skill	B-X
,	B-X
as	B-X
well	B-X
as	B-X
carefully	B-X
designed	B-X
and	B-X
efficient	B-X
measurement	B-X
protocols	B-X
.	B-X
N1-P2	B-X
reflects	B-X
conscious	B-X
detection	B-X
of	B-X
any	B-X
discrete	B-X
change	B-X
in	B-X
any	B-X
subjective	B-X
dimension	B-X
of	B-X
the	B-X
auditory	B-X
environment	B-X
.	B-X
Thus	B-X
,	B-X
N1-P2	B-X
may	B-X
have	B-X
many	B-X
applications	B-X
as	B-X
an	B-X
'objective	B-X
'	B-X
proxy	B-X
for	B-X
psychoacoustic	B-X
measures	B-X
that	B-X
may	B-X
be	B-X
impractical	B-X
in	B-X
clinical	B-X
subjects	B-X
.	B-X
Advances	B-X
in	B-X
dipole	B-X
source	B-X
localization	B-X
and	B-X
in	B-X
auditory-evoked	B-X
magnetic	B-X
fields	B-X
(	B-X
AEMFs	B-X
)	B-X
have	B-X
clarified	B-X
the	B-X
multiple	B-X
,	B-X
cortical	B-X
origins	B-X
of	B-X
N1	B-X
and	B-X
P2	B-X
.	B-X
A	B-X
wide	B-X
variety	B-X
of	B-X
potential	B-X
research	B-X
and	B-X
clinical	B-X
applications	B-X
of	B-X
N1	B-X
and	B-X
P2	B-X
,	B-X
and	B-X
considerable	B-X
value	B-X
as	B-X
part	B-X
of	B-X
an	B-X
integrated	B-X
,	B-X
goal-directed	B-X
AEP/AEMF	B-X
measurement	B-X
scheme	B-X
,	B-X
have	B-X
yet	B-X
to	B-X
be	B-X
fully	B-X
realized	B-X
.	B-X

9	O
<EOS>	B-X
Radiochemical	B-X
assay	B-X
of	B-X
glutathione	B-X
S-epoxide	B-X
transferase	B-X
and	B-X
its	B-X
enhancement	B-X
by	B-X
phenobarbital	B-X
in	B-X
rat	B-X
liver	B-X
in	B-X
vivo	B-X
.	B-X

>	O
10	O
R	O
4	O
<EOS>	B-X
In	B-X
the	B-X
title	B-X
compound	B-X
,	B-X
C	B-X
(	B-X
15	B-X
)	B-X
H	B-X
(	B-X
10	B-X
)	B-X
O	B-X
(	B-X
5	B-X
)	B-X
,	B-X
the	B-X
cyclo-penta-none	B-X
(	B-X
r.m.s	B-X
.	B-X
deviation	B-X
=	B-X
0.049	B-X
Ã	B-X
)	B-X
and	B-X
oxolane	B-X
(	B-X
r.m.s	B-X
.	B-X
deviation	B-X
=	B-X
0.048	B-X
Ã	B-X
)	B-X
rings	B-X
make	B-X
a	B-X
dihedral	B-X
angle	B-X
of	B-X
67.91	B-X
(	B-X
4	B-X
)	B-X
Â°	B-X
.	B-X
Previous	B-X
reports	B-X
showed	B-X
that	B-X
H-	B-X
(	B-X
Pro-4	B-X
(	B-X
R	B-X
)	B-X
Hyp-Gly	B-X
)	B-X
(	B-X
10	B-X
)	B-X
-OH	B-X
(	B-X
where	B-X
'	B-X
4	B-X
(	B-X
R	B-X
)	B-X
Hyp	B-X
'	B-X
is	B-X
(	B-X
2S,4R	B-X
)	B-X
-4-hydroxyproline	B-X
)	B-X
forms	B-X
a	B-X
trimeric	B-X
structure	B-X
,	B-X
whereas	B-X
H-	B-X
(	B-X
4	B-X
(	B-X
R	B-X
)	B-X
Hyp-Pro-Gly	B-X
)	B-X
(	B-X
10	B-X
)	B-X
-OH	B-X
does	B-X
not	B-X
form	B-X
a	B-X
triple	B-X
helix	B-X
.	B-X
Compared	B-X
with	B-X
H-	B-X
(	B-X
Pro-Pro-Gly	B-X
)	B-X
(	B-X
10	B-X
)	B-X
-OH	B-X
,	B-X
the	B-X
melting	B-X
temperature	B-X
of	B-X
H-	B-X
(	B-X
Pro-4	B-X
(	B-X
R	B-X
)	B-X
Hyp-Gly	B-X
)	B-X
(	B-X
10	B-X
)	B-X
-OH	B-X
is	B-X
higher	B-X
,	B-X
suggesting	B-X
that	B-X
4	B-X
(	B-X
R	B-X
)	B-X
Hyp	B-X
in	B-X
the	B-X
Yaa	B-X
position	B-X
has	B-X
a	B-X
stabilizing	B-X
effect	B-X
.	B-X
The	B-X
inability	B-X
of	B-X
triple	B-X
helix	B-X
formation	B-X
of	B-X
H-	B-X
(	B-X
4	B-X
(	B-X
R	B-X
)	B-X
Hyp-Pro-Gly	B-X
)	B-X
(	B-X
10	B-X
)	B-X
-OH	B-X
has	B-X
been	B-X
explained	B-X
by	B-X
a	B-X
stereoelectronic	B-X
effect	B-X
,	B-X
but	B-X
the	B-X
details	B-X
are	B-X
unknown	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
synthesized	B-X
a	B-X
peptide	B-X
that	B-X
contains	B-X
4	B-X
(	B-X
R	B-X
)	B-X
Hyp	B-X
in	B-X
both	B-X
the	B-X
Xaa	B-X
and	B-X
the	B-X
Yaa	B-X
positions	B-X
,	B-X
that	B-X
is	B-X
,	B-X
Ac-	B-X
(	B-X
Gly-4	B-X
(	B-X
R	B-X
)	B-X
Hyp-4	B-X
(	B-X
R	B-X
)	B-X
Hyp	B-X
)	B-X
(	B-X
10	B-X
)	B-X
-NH	B-X
(	B-X
2	B-X
)	B-X
and	B-X
compared	B-X
it	B-X
to	B-X
Ac-	B-X
(	B-X
Gly-Pro-4	B-X
(	B-X
R	B-X
)	B-X
Hyp	B-X
)	B-X
(	B-X
10	B-X
)	B-X
-NH	B-X
(	B-X
2	B-X
)	B-X
,	B-X
and	B-X
Ac-	B-X
(	B-X
Gly-4	B-X
(	B-X
R	B-X
)	B-X
Hyp-Pro	B-X
)	B-X
(	B-X
10	B-X
)	B-X
-NH	B-X
(	B-X
2	B-X
)	B-X
.	B-X
Ac-	B-X
(	B-X
Gly-4	B-X
(	B-X
R	B-X
)	B-X
Hyp-4	B-X
(	B-X
R	B-X
)	B-X
Hyp	B-X
)	B-X
(	B-X
10	B-X
)	B-X
-NH	B-X
(	B-X
2	B-X
)	B-X
showed	B-X
a	B-X
polyproline	B-X
II-like	B-X
circular	B-X
dichroic	B-X
spectrum	B-X
in	B-X
water	B-X
.	B-X
The	B-X
thermal	B-X
transition	B-X
temperatures	B-X
measured	B-X
by	B-X
circular	B-X
dichroism	B-X
and	B-X
differential	B-X
scanning	B-X
calorimetry	B-X
were	B-X
slightly	B-X
higher	B-X
than	B-X
the	B-X
values	B-X
measured	B-X
for	B-X
Ac-	B-X
(	B-X
Gly-Pro-4	B-X
(	B-X
R	B-X
)	B-X
Hyp	B-X
)	B-X
(	B-X
10	B-X
)	B-X
-NH	B-X
(	B-X
2	B-X
)	B-X
under	B-X
the	B-X
same	B-X
conditions	B-X
.	B-X
For	B-X
Ac-	B-X
(	B-X
Gly-4	B-X
(	B-X
R	B-X
)	B-X
Hyp-4	B-X
(	B-X
R	B-X
)	B-X
Hyp	B-X
)	B-X
(	B-X
10	B-X
)	B-X
-NH	B-X
(	B-X
2	B-X
)	B-X
,	B-X
the	B-X
calorimetric	B-X
and	B-X
the	B-X
va	B-X
n't	B-X
Hoff	B-X
transition	B-X
enthalpy	B-X
DeltaH	B-X
were	B-X
significantly	B-X
smaller	B-X
than	B-X
that	B-X
of	B-X
Ac-	B-X
(	B-X
Gly-Pro-4	B-X
(	B-X
R	B-X
)	B-X
Hyp	B-X
)	B-X
(	B-X
10	B-X
)	B-X
-NH	B-X
(	B-X
2	B-X
)	B-X
.	B-X
We	B-X
postulate	B-X
that	B-X
the	B-X
denatured	B-X
states	B-X
of	B-X
the	B-X
two	B-X
peptides	B-X
are	B-X
significantly	B-X
different	B-X
,	B-X
with	B-X
Ac-	B-X
(	B-X
Gly-4	B-X
(	B-X
R	B-X
)	B-X
Hyp-4	B-X
(	B-X
R	B-X
)	B-X
Hyp	B-X
)	B-X
(	B-X
10	B-X
)	B-X
-NH	B-X
(	B-X
2	B-X
)	B-X
forming	B-X
a	B-X
more	B-X
polyproline	B-X
II-like	B-X
structure	B-X
instead	B-X
of	B-X
a	B-X
random	B-X
coil	B-X
.	B-X
Two-dimensional	B-X
nuclear	B-X
Overhauser	B-X
effect	B-X
spectroscopy	B-X
suggests	B-X
that	B-X
the	B-X
triple	B-X
helical	B-X
structure	B-X
of	B-X
Ac-	B-X
(	B-X
Gly-4	B-X
(	B-X
R	B-X
)	B-X
Hyp-4	B-X
(	B-X
R	B-X
)	B-X
Hyp	B-X
)	B-X
(	B-X
10	B-X
)	B-X
-NH	B-X
(	B-X
2	B-X
)	B-X
is	B-X
more	B-X
flexible	B-X
than	B-X
that	B-X
of	B-X
Ac-	B-X
(	B-X
Gly-Pro-4	B-X
(	B-X
R	B-X
)	B-X
Hyp	B-X
)	B-X
(	B-X
10	B-X
)	B-X
-NH	B-X
(	B-X
2	B-X
)	B-X
.	B-X
This	B-X
is	B-X
confirmed	B-X
by	B-X
the	B-X
kinetics	B-X
of	B-X
amide	B-X
(	B-X
1	B-X
)	B-X
H	B-X
exchange	B-X
with	B-X
solvent	B-X
deuterium	B-X
of	B-X
Ac-	B-X
(	B-X
Gly-4	B-X
(	B-X
R	B-X
)	B-X
Hyp-4	B-X
(	B-X
R	B-X
)	B-X
Hyp	B-X
)	B-X
(	B-X
10	B-X
)	B-X
-NH	B-X
(	B-X
2	B-X
)	B-X
,	B-X
which	B-X
is	B-X
faster	B-X
than	B-X
that	B-X
of	B-X
Ac-	B-X
(	B-X
Gly-Pro-4	B-X
(	B-X
R	B-X
)	B-X
Hyp	B-X
)	B-X
(	B-X
10	B-X
)	B-X
-NH	B-X
(	B-X
2	B-X
)	B-X
.	B-X
The	B-X
higher	B-X
transition	B-X
temperature	B-X
of	B-X
Ac-	B-X
(	B-X
Gly-4	B-X
(	B-X
R	B-X
)	B-X
Hyp-4	B-X
(	B-X
R	B-X
)	B-X
Hyp	B-X
)	B-X
(	B-X
10	B-X
)	B-X
-NH	B-X
(	B-X
2	B-X
)	B-X
,	B-X
can	B-X
be	B-X
explained	B-X
by	B-X
the	B-X
higher	B-X
trans/cis	B-X
ratio	B-X
of	B-X
the	B-X
Gly-4	B-X
(	B-X
R	B-X
)	B-X
Hyp	B-X
peptide	B-X
bonds	B-X
than	B-X
that	B-X
of	B-X
the	B-X
Gly-Pro	B-X
bonds	B-X
,	B-X
and	B-X
this	B-X
ratio	B-X
compensates	B-X
for	B-X
the	B-X
weaker	B-X
interchain	B-X
hydrogen	B-X
bonds	B-X
.	B-X

Figure	O
1	O
.	O
<EOS>	B-X
and	B-X
Kilic	B-X
F.	B-X
,	B-X
Journal	B-X
of	B-X
Neurochemistry	B-X
101	B-X
(	B-X
4	B-X
)	B-X
937-948	B-X
,	B-X
2007	B-X
(	B-X
https	B-X
:	B-X
//doi.org/10.1111/j.1471-4159.2007.04469.x	B-X
)	B-X
.	B-X
The	B-X
corresponding	B-X
author	B-X
,	B-X
Dr.	B-X
Fusun	B-X
Kilic	B-X
,	B-X
notified	B-X
the	B-X
Journal	B-X
's	B-X
Editorial	B-X
Office	B-X
of	B-X
the	B-X
following	B-X
concerns	B-X
related	B-X
to	B-X
the	B-X
article	B-X
that	B-X
were	B-X
brought	B-X
to	B-X
his	B-X
attention	B-X
:	B-X
Figures	B-X
2C	B-X
and	B-X
2D	B-X
are	B-X
duplicates	B-X
The	B-X
'Lysate	B-X
'	B-X
and	B-X
the	B-X
'Bound	B-X
'	B-X
lanes	B-X
in	B-X
Figure	B-X
7A	B-X
are	B-X
identical	B-X
The	B-X
Myc-SERT	B-X
bands	B-X
in	B-X
Figure	B-X
7B	B-X
,	B-X
lanes	B-X
2	B-X
and	B-X
3	B-X
are	B-X
duplicates	B-X
of	B-X
lanes	B-X
4	B-X
and	B-X
5	B-X
,	B-X
and	B-X
again	B-X
of	B-X
lanes	B-X
6	B-X
and	B-X
7	B-X
The	B-X
45	B-X
kD	B-X
bands	B-X
in	B-X
Figure	B-X
7B	B-X
,	B-X
lanes	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
are	B-X
duplicates	B-X
of	B-X
lanes	B-X
5	B-X
,	B-X
6	B-X
,	B-X
and	B-X
7	B-X
Dr.	B-X
Kilic	B-X
investigated	B-X
the	B-X
concerns	B-X
and	B-X
,	B-X
in	B-X
response	B-X
to	B-X
the	B-X
journal	B-X
,	B-X
concluded	B-X
that	B-X
they	B-X
were	B-X
unjustified	B-X
.	B-X
The	B-X
Journal	B-X
's	B-X
Editorial	B-X
Office	B-X
undertook	B-X
its	B-X
own	B-X
visual	B-X
inspection	B-X
and	B-X
,	B-X
in	B-X
relation	B-X
to	B-X
Figure	B-X
7B	B-X
,	B-X
maintains	B-X
that	B-X
duplication	B-X
is	B-X
present	B-X
.	B-X
They	B-X
concluded	B-X
:	B-X
In	B-X
Figure	B-X
7B	B-X
,	B-X
45	B-X
kD	B-X
,	B-X
lanes	B-X
1	B-X
and	B-X
5	B-X
appear	B-X
identical	B-X
,	B-X
as	B-X
well	B-X
as	B-X
lane	B-X
2	B-X
and	B-X
6	B-X
,	B-X
and	B-X
lanes	B-X
3	B-X
,	B-X
4	B-X
,	B-X
and	B-X
7	B-X
(	B-X
with	B-X
lane	B-X
4	B-X
being	B-X
clipped	B-X
at	B-X
the	B-X
right-hand	B-X
side	B-X
)	B-X
In	B-X
the	B-X
Flag-SERT	B-X
,	B-X
lanes	B-X
2	B-X
and	B-X
6	B-X
appear	B-X
identical	B-X
,	B-X
as	B-X
well	B-X
as	B-X
lanes	B-X
3	B-X
and	B-X
7	B-X
In	B-X
the	B-X
Myc-SERT	B-X
,	B-X
lanes	B-X
2	B-X
and	B-X
6	B-X
appear	B-X
identical	B-X
,	B-X
as	B-X
well	B-X
as	B-X
lanes	B-X
3	B-X
,	B-X
5	B-X
,	B-X
and	B-X
7	B-X
.	B-X
The	B-X
problems	B-X
are	B-X
highlighted	B-X
in	B-X
the	B-X
following	B-X
screenshot	B-X
of	B-X
Figure	B-X
7B	B-X
.	B-X

Electron	O
microscopic	O
visualization	O
of	O
all	O
17	O
introns	O
and	O
18	O
exons	O

from	O
hybrid	O
molecules	O
formed	O
between	O
recombinant	O
clone	O
SpC3	O
DNA	O
and	O
fetal	O
sheep	B-Species

tendon	O
a2	O
mRNA	O
.	O
<EOS>	B-X
The	B-X
mRNA-1273	B-X
SARS-CoV-2	B-X
vaccine	B-X
received	B-X
emergency	B-X
use	B-X
authorization	B-X
in	B-X
December	B-X
2021	B-X
.	B-X
A	B-X
30-year-old	B-X
man	B-X
developed	B-X
acute	B-X
onset	B-X
diplopia	B-X
,	B-X
2	B-X
days	B-X
after	B-X
receiving	B-X
his	B-X
first	B-X
mRNA-1273	B-X
vaccination	B-X
against	B-X
SARS-CoV-2	B-X
.	B-X
Cranial	B-X
nerves	B-X
,	B-X
sensory	B-X
examination	B-X
and	B-X
deep	B-X
tendon	B-X
reflexes	B-X
were	B-X
normal	B-X
.	B-X
We	B-X
present	B-X
a	B-X
case	B-X
of	B-X
newly	B-X
diagnosed	B-X
MG	B-X
after	B-X
administration	B-X
of	B-X
mRNA-1273	B-X
vaccination	B-X
against	B-X
SARS-CoV-2	B-X
.	B-X

(	O
A	O
,	O
B	O
)	O
Shown	O
are	O
the	O
double	O
-	O
stranded	O
segment	O
of	O
the	O
right	O
arm	O
CR	O
)	O
of	O
Charon	O
4A	O
;	O
double	O
-	O
stranded	O
segment	O
of	O
the	O
left	O
arm	O
CL	O
)	O
of	O
Charon	O
4A	O
;	O
the	O

displaced	O
single	O
-	O
stranded	O
DNA	O
segment	O
of	O
the	O
insert	O
(	O
5	O
)	O
;	O
single	O
-	O
stranded	O
DNA	O
loops	O
representing	O
introns	O
sequentially	O
labeled	O
1	O
through	O
17	O
in	O
the	O
3	O
'	O
to	O
5	O
'	O
direction	O
;	O
and	O
18	O
regions	O
of	O
insert	O
DNA	O
sequences	O
hybridized	O
to	O
ct2	O
mRNA	O
<EOS>	B-X
Type	B-X
I	B-X
accounts	B-X
for	B-X
95	B-X
%	B-X
of	B-X
CRISPR	B-X
systems	B-X
,	B-X
and	B-X
has	B-X
been	B-X
used	B-X
to	B-X
control	B-X
gene	B-X
expression	B-X
and	B-X
cell	B-X
fate	B-X
.	B-X
During	B-X
CRISPR	B-X
RNA	B-X
(	B-X
crRNA	B-X
)	B-X
-guided	B-X
interference	B-X
,	B-X
Cascade	B-X
(	B-X
CRISPR-associated	B-X
complex	B-X
for	B-X
antiviral	B-X
defence	B-X
)	B-X
facilitates	B-X
the	B-X
crRNA-guided	B-X
invasion	B-X
of	B-X
double-stranded	B-X
DNA	B-X
for	B-X
complementary	B-X
base-pairing	B-X
with	B-X
the	B-X
target	B-X
DNA	B-X
strand	B-X
while	B-X
displacing	B-X
the	B-X
non-target	B-X
strand	B-X
,	B-X
forming	B-X
an	B-X
R-loop	B-X
.	B-X
Cas3	B-X
,	B-X
which	B-X
has	B-X
nuclease	B-X
and	B-X
helicase	B-X
activities	B-X
,	B-X
is	B-X
subsequently	B-X
recruited	B-X
to	B-X
degrade	B-X
two	B-X
DNA	B-X
strands	B-X
.	B-X
A	B-X
protospacer	B-X
adjacent	B-X
motif	B-X
(	B-X
PAM	B-X
)	B-X
sequence	B-X
flanking	B-X
target	B-X
DNA	B-X
is	B-X
crucial	B-X
for	B-X
self	B-X
versus	B-X
foreign	B-X
discrimination	B-X
.	B-X
Here	B-X
we	B-X
present	B-X
the	B-X
2.45	B-X
Ã	B-X
crystal	B-X
structure	B-X
of	B-X
Escherichia	B-X
coli	B-X
Cascade	B-X
bound	B-X
to	B-X
a	B-X
foreign	B-X
double-stranded	B-X
DNA	B-X
target	B-X
.	B-X
The	B-X
5'-ATG	B-X
PAM	B-X
is	B-X
recognized	B-X
in	B-X
duplex	B-X
form	B-X
,	B-X
from	B-X
the	B-X
minor	B-X
groove	B-X
side	B-X
,	B-X
by	B-X
three	B-X
structural	B-X
features	B-X
in	B-X
the	B-X
Cascade	B-X
Cse1	B-X
subunit	B-X
.	B-X
The	B-X
promiscuity	B-X
inherent	B-X
to	B-X
minor	B-X
groove	B-X
DNA	B-X
recognition	B-X
rationalizes	B-X
the	B-X
observation	B-X
that	B-X
a	B-X
single	B-X
Cascade	B-X
complex	B-X
can	B-X
respond	B-X
to	B-X
several	B-X
distinct	B-X
PAM	B-X
sequences	B-X
.	B-X
Optimal	B-X
PAM	B-X
recognition	B-X
coincides	B-X
with	B-X
wedge	B-X
insertion	B-X
,	B-X
initiating	B-X
directional	B-X
target	B-X
DNA	B-X
strand	B-X
unwinding	B-X
to	B-X
allow	B-X
segmented	B-X
base-pairing	B-X
with	B-X
crRNA	B-X
.	B-X
The	B-X
non-target	B-X
strand	B-X
is	B-X
guided	B-X
along	B-X
a	B-X
parallel	B-X
path	B-X
25	B-X
Ã	B-X
apart	B-X
,	B-X
and	B-X
the	B-X
R-loop	B-X
structure	B-X
is	B-X
further	B-X
stabilized	B-X
by	B-X
locking	B-X
this	B-X
strand	B-X
behind	B-X
the	B-X
Cse2	B-X
dimer	B-X
.	B-X
These	B-X
observations	B-X
provide	B-X
the	B-X
structural	B-X
basis	B-X
for	B-X
understanding	B-X
the	B-X
PAM-dependent	B-X
directional	B-X
R-loop	B-X
formation	B-X
process	B-X
.	B-X

-	O
-	O
-	O
-	O
)	O
.	O

(	O
C	O
,	O
D	O
)	O
Similar	O
to	O
(	O
A	O
,	O
B	O
)	O
but	O
the	O
single	O
-	O
stranded	O
DNA	O
segment	O
(	O
5	O
)	O
of	O
the	O
insert	O
is	O
mostly	O
absent	O
.	O

The	O
urea	O
-	O
formamide	O
spreading	O
method	O
,	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
,	O
was	O
employed	O
.	O

2245	O

Nucleic	O
Acids	O
Research	O
<EOS>	B-X
The	B-X
2021	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
database	B-X
Issue	B-X
contains	B-X
189	B-X
papers	B-X
spanning	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
biological	B-X
fields	B-X
and	B-X
investigation	B-X
.	B-X
The	B-X
entire	B-X
Database	B-X
Issue	B-X
is	B-X
freely	B-X
available	B-X
online	B-X
on	B-X
the	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
website	B-X
(	B-X
https	B-X
:	B-X
//academic.oup.com/nar	B-X
)	B-X
.	B-X
Editorial	B-X
:	B-X
the	B-X
19th	B-X
annual	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
web	B-X
server	B-X
issue	B-X
2021	B-X
.	B-X
Editorial	B-X
:	B-X
Critical	B-X
reviews	B-X
and	B-X
perspectives	B-X
in	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
.	B-X

urea	O
-	O
formamide	O
method	O
than	O
with	O
the	O
70	O
%	O
formamide	O
procedure	O
.	O
<EOS>	B-X
After	B-X
spreading	B-X
under	B-X
moderately	B-X
denaturing	B-X
conditions	B-X
(	B-X
50	B-X
or	B-X
60	B-X
%	B-X
formamide	B-X
)	B-X
,	B-X
50	B-X
to	B-X
70	B-X
%	B-X
of	B-X
the	B-X
molecules	B-X
were	B-X
circular	B-X
.	B-X
Increasing	B-X
the	B-X
formamide	B-X
concentration	B-X
to	B-X
70	B-X
and	B-X
85	B-X
%	B-X
decreased	B-X
the	B-X
number	B-X
of	B-X
circular	B-X
forms	B-X
,	B-X
and	B-X
only	B-X
linear	B-X
forms	B-X
were	B-X
observed	B-X
after	B-X
incubation	B-X
of	B-X
the	B-X
RNA	B-X
at	B-X
60	B-X
degrees	B-X
C	B-X
for	B-X
15	B-X
min	B-X
in	B-X
99	B-X
%	B-X
formamide	B-X
.	B-X
When	B-X
spread	B-X
from	B-X
4	B-X
M	B-X
urea-80	B-X
%	B-X
formamide	B-X
--	B-X
another	B-X
condition	B-X
known	B-X
to	B-X
denature	B-X
RNA	B-X
--	B-X
only	B-X
5	B-X
to	B-X
30	B-X
%	B-X
circular	B-X
molecules	B-X
were	B-X
observed	B-X
.	B-X
Pretreatment	B-X
of	B-X
the	B-X
RNA	B-X
with	B-X
0.5	B-X
M	B-X
glyoxal	B-X
at	B-X
37	B-X
degrees	B-X
C	B-X
for	B-X
15	B-X
min	B-X
prior	B-X
to	B-X
spreading	B-X
from	B-X
50	B-X
%	B-X
formamide	B-X
gave	B-X
less	B-X
than	B-X
5	B-X
%	B-X
cirucular	B-X
forms	B-X
.	B-X
Length	B-X
measurement	B-X
of	B-X
the	B-X
molecules	B-X
showed	B-X
that	B-X
they	B-X
were	B-X
not	B-X
significantly	B-X
degraded	B-X
by	B-X
any	B-X
of	B-X
the	B-X
methods	B-X
employed	B-X
.	B-X

For	O
this	O
reason	O
,	O
most	O
measurements	O
were	O
made	O
with	O
the	O
urea	O
-	O
formamide	O
method	O
(	O
Tables	O
1	O
,	O
2	O
)	O
.	O

For	O

example	O
,	O
the	O
lowest	O
probability	O
event	O
,	O
the	O
detection	O
of	O
intron	O
17	O
and	O
the	O
surrounding	O
small	O
exons	O
,	O
"	O
q	O
"	O
and	O
"	O
r	O
"	O
,	O
was	O
only	O
observed	O
by	O
way	O
of	O
the	O
ureaformamide	O
spreading	O
procedure	O
.	O

The	O
smallest	O
introns	O
,	O
7	O
and	O
12	O
,	O
were	O
found	O
to	O
contain	O
approximately	O
<EOS>	B-X
The	B-X
hypothesis	B-X
of	B-X
Pleistocene	B-X
forest	B-X
refugia	B-X
was	B-X
tested	B-X
using	B-X
comparative	B-X
phylogeography	B-X
of	B-X
Scotonycterini	B-X
,	B-X
a	B-X
fruit	B-X
bat	B-X
tribe	B-X
endemic	B-X
to	B-X
Africa	B-X
containing	B-X
four	B-X
species	B-X
:	B-X
Scotonycteris	B-X
zenkeri	B-X
,	B-X
Casinycteris	B-X
argynnis	B-X
,	B-X
C.	B-X
campomaanensis	B-X
,	B-X
and	B-X
C.	B-X
ophiodon	B-X
.	B-X
Patterns	B-X
of	B-X
genetic	B-X
structure	B-X
were	B-X
assessed	B-X
using	B-X
105	B-X
Scotonycterini	B-X
(	B-X
including	B-X
material	B-X
from	B-X
three	B-X
holotypes	B-X
)	B-X
collected	B-X
at	B-X
37	B-X
localities	B-X
,	B-X
and	B-X
DNA	B-X
sequences	B-X
from	B-X
the	B-X
mitochondrial	B-X
cytochrome	B-X
b	B-X
gene	B-X
(	B-X
1140	B-X
nt	B-X
)	B-X
and	B-X
12	B-X
nuclear	B-X
introns	B-X
(	B-X
9641	B-X
nt	B-X
)	B-X
.	B-X
Mitochondrial	B-X
analyses	B-X
reveal	B-X
strong	B-X
phylogeographical	B-X
structure	B-X
in	B-X
Scotonycteris	B-X
,	B-X
with	B-X
four	B-X
divergent	B-X
haplogroups	B-X
(	B-X
4.9-8.7	B-X
%	B-X
)	B-X
,	B-X
from	B-X
Upper	B-X
Guinea	B-X
,	B-X
Cameroon	B-X
,	B-X
western	B-X
Equatorial	B-X
Africa	B-X
,	B-X
and	B-X
eastern	B-X
Democratic	B-X
Republic	B-X
of	B-X
the	B-X
Congo	B-X
(	B-X
DRC	B-X
)	B-X
.	B-X
All	B-X
mtDNA	B-X
clusters	B-X
detected	B-X
in	B-X
Scotonycteris	B-X
are	B-X
found	B-X
to	B-X
be	B-X
monophyletic	B-X
based	B-X
on	B-X
the	B-X
nuclear	B-X
dataset	B-X
,	B-X
except	B-X
in	B-X
eastern	B-X
DRC	B-X
.	B-X
Molecular	B-X
dating	B-X
indicates	B-X
that	B-X
Pleistocene	B-X
forest	B-X
refugia	B-X
have	B-X
played	B-X
an	B-X
important	B-X
role	B-X
in	B-X
shaping	B-X
the	B-X
evolution	B-X
of	B-X
Scotonycterini	B-X
,	B-X
with	B-X
two	B-X
phases	B-X
of	B-X
allopatric	B-X
speciation	B-X
at	B-X
approximately	B-X
2.7	B-X
and	B-X
1.6	B-X
Mya	B-X
,	B-X
resulting	B-X
from	B-X
isolation	B-X
in	B-X
three	B-X
main	B-X
forest	B-X
areas	B-X
corresponding	B-X
to	B-X
Upper	B-X
Guinea	B-X
,	B-X
Cameroon	B-X
,	B-X
and	B-X
Equatorial	B-X
Africa	B-X
.	B-X
Female	B-X
philopatry	B-X
and	B-X
male	B-X
biased	B-X
dispersal	B-X
are	B-X
supported	B-X
for	B-X
the	B-X
smallest	B-X
taxa	B-X
,	B-X
i.e.	B-X
,	B-X
the	B-X
three	B-X
species	B-X
of	B-X
Scotonycteris	B-X
and	B-X
C.	B-X
argynnis	B-X
.	B-X

the	O
same	O
number	O
of	O
bases	O
.	O
<EOS>	B-X
For	B-X
example	B-X
,	B-X
when	B-X
identifying	B-X
single-nucleotide	B-X
variants	B-X
de	B-X
novo	B-X
,	B-X
the	B-X
number	B-X
of	B-X
reads	B-X
supporting	B-X
a	B-X
particular	B-X
variant	B-X
call	B-X
determines	B-X
our	B-X
confidence	B-X
in	B-X
that	B-X
variant	B-X
call	B-X
.	B-X
However	B-X
,	B-X
the	B-X
influence	B-X
of	B-X
implant	B-X
number	B-X
on	B-X
the	B-X
movement	B-X
of	B-X
IODs	B-X
has	B-X
not	B-X
been	B-X
investigated	B-X
.	B-X
There	B-X
is	B-X
growing	B-X
acceptance	B-X
that	B-X
the	B-X
illegal	B-X
trade	B-X
in	B-X
wildlife	B-X
is	B-X
having	B-X
devasting	B-X
effects	B-X
on	B-X
the	B-X
numbers	B-X
of	B-X
iconic	B-X
species	B-X
.	B-X
Sequencing	B-X
the	B-X
whole	B-X
locus	B-X
may	B-X
not	B-X
be	B-X
needed	B-X
if	B-X
specific	B-X
bases	B-X
can	B-X
be	B-X
targeted	B-X
.	B-X

Introns	O
1	O
through	O
8	O
,	O
representing	O
the	O
DNA	O
sequences	O
which	O
split	O
the	O
a2	O
coding	O
sequence	O
corresponding	O
to	O
the	O
3	O
'	O
end	O
of	O
the	O
a2	O
mRNA	O
,	O
varied	O
in	O
length	O
over	O
approximately	O
a	O
2	O
.	O
4	O
-	O
fold	O
range	O
.	O

With	O
the	O
exception	O
of	O
<EOS>	B-X
Since	B-X
the	B-X
implementation	B-X
of	B-X
the	B-X
model	B-X
for	B-X
end-stage	B-X
liver	B-X
disease	B-X
(	B-X
MELD	B-X
)	B-X
standard	B-X
exception	B-X
policy	B-X
,	B-X
outcomes	B-X
in	B-X
patients	B-X
with	B-X
HPS	B-X
have	B-X
been	B-X
significantly	B-X
better	B-X
than	B-X
they	B-X
were	B-X
in	B-X
the	B-X
pre-MELD	B-X
era	B-X
.	B-X
In	B-X
specific	B-X
situations	B-X
it	B-X
may	B-X
be	B-X
necessary	B-X
to	B-X
make	B-X
an	B-X
exception	B-X
to	B-X
the	B-X
general	B-X
rule	B-X
of	B-X
informed	B-X
consent	B-X
for	B-X
scientific	B-X
research	B-X
with	B-X
an	B-X
intervention	B-X
.	B-X
Earlier	B-X
reviews	B-X
only	B-X
described	B-X
subsets	B-X
of	B-X
arguments	B-X
for	B-X
exceptions	B-X
to	B-X
waive	B-X
consent	B-X
.	B-X
We	B-X
examine	B-X
the	B-X
evolution	B-X
of	B-X
policies	B-X
permitting	B-X
exceptions	B-X
to	B-X
or	B-X
waivers	B-X
of	B-X
informed	B-X
consent	B-X
for	B-X
research	B-X
in	B-X
the	B-X
United	B-X
States	B-X
.	B-X
This	B-X
review	B-X
reveals	B-X
that	B-X
(	B-X
1	B-X
)	B-X
exceptions	B-X
to	B-X
the	B-X
duty	B-X
to	B-X
secure	B-X
informed	B-X
consent	B-X
were	B-X
originally	B-X
quite	B-X
narrow	B-X
;	B-X
(	B-X
2	B-X
)	B-X
there	B-X
were	B-X
two	B-X
alternative	B-X
approaches	B-X
to	B-X
allowing	B-X
research	B-X
on	B-X
human	B-X
subjects	B-X
without	B-X
their	B-X
prospective	B-X
consent	B-X
:	B-X
(	B-X
i	B-X
)	B-X
exceptions	B-X
in	B-X
which	B-X
individual	B-X
capacity	B-X
to	B-X
consent	B-X
is	B-X
to	B-X
be	B-X
assessed	B-X
and	B-X
consent	B-X
tailored	B-X
to	B-X
each	B-X
person	B-X
's	B-X
abilities	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
waivers	B-X
of	B-X
the	B-X
general	B-X
requirement	B-X
for	B-X
a	B-X
population	B-X
of	B-X
potential	B-X
subjects	B-X
,	B-X
where	B-X
securing	B-X
prospective	B-X
consent	B-X
would	B-X
``	B-X
destroy	B-X
or	B-X
invalidate	B-X
''	B-X
critically	B-X
important	B-X
research	B-X
;	B-X
(	B-X
3	B-X
)	B-X
waivers	B-X
only	B-X
appeared	B-X
in	B-X
the	B-X
final	B-X
rulemakings	B-X
for	B-X
research	B-X
regulations	B-X
issued	B-X
by	B-X
the	B-X
National	B-X
Institute	B-X
of	B-X
Education	B-X
in	B-X
1974	B-X
and	B-X
the	B-X
Department	B-X
of	B-X
Health	B-X
and	B-X
Human	B-X
Services	B-X
in	B-X
1981	B-X
,	B-X
limiting	B-X
the	B-X
opportunity	B-X
for	B-X
the	B-X
public	B-X
to	B-X
weigh	B-X
in	B-X
on	B-X
the	B-X
scope	B-X
and	B-X
use	B-X
of	B-X
waivers	B-X
;	B-X
and	B-X
(	B-X
4	B-X
)	B-X
rules	B-X
adopted	B-X
since	B-X
1981	B-X
have	B-X
almost	B-X
uniformly	B-X
added	B-X
extra	B-X
requirements	B-X
to	B-X
justify	B-X
waivers	B-X
.	B-X

Table	O
1	O
.	O
<EOS>	B-X
If	B-X
well-executed	B-X
,	B-X
this	B-X
``	B-X
Table	B-X
1	B-X
''	B-X
can	B-X
illuminate	B-X
potential	B-X
threats	B-X
to	B-X
internal	B-X
and	B-X
external	B-X
validity	B-X
.	B-X
However	B-X
,	B-X
little	B-X
guidance	B-X
exists	B-X
on	B-X
best	B-X
practices	B-X
for	B-X
designing	B-X
a	B-X
Table	B-X
1	B-X
,	B-X
especially	B-X
for	B-X
complex	B-X
study	B-X
designs	B-X
and	B-X
analyses	B-X
.	B-X
The	B-X
present	B-X
chapter	B-X
describes	B-X
isolation	B-X
,	B-X
biogenetic	B-X
proposals	B-X
,	B-X
and	B-X
syntheses	B-X
of	B-X
the	B-X
natural	B-X
products	B-X
1-4	B-X
and	B-X
10-11	B-X
with	B-X
a	B-X
pyrrolo	B-X
[	B-X
2,1-a	B-X
]	B-X
-isoquinoline	B-X
framework	B-X
.	B-X
The	B-X
pyrrolo	B-X
[	B-X
2,1-a	B-X
]	B-X
isoquinolines	B-X
are	B-X
of	B-X
interest	B-X
due	B-X
to	B-X
their	B-X
promising	B-X
biological	B-X
activities	B-X
.	B-X
For	B-X
crispine	B-X
A	B-X
(	B-X
1	B-X
)	B-X
,	B-X
many	B-X
total	B-X
syntheses	B-X
have	B-X
been	B-X
reported	B-X
and	B-X
for	B-X
trolline	B-X
(	B-X
3	B-X
)	B-X
,	B-X
only	B-X
three	B-X
.	B-X
Only	B-X
one	B-X
total	B-X
synthesis	B-X
has	B-X
been	B-X
reported	B-X
for	B-X
each	B-X
of	B-X
the	B-X
following	B-X
natural	B-X
products	B-X
:	B-X
peyoglutam	B-X
(	B-X
10	B-X
)	B-X
,	B-X
mescalotam	B-X
(	B-X
11	B-X
)	B-X
,	B-X
and	B-X
the	B-X
antitumor	B-X
active	B-X
crispine	B-X
B	B-X
(	B-X
2	B-X
)	B-X
.	B-X
Some	B-X
of	B-X
the	B-X
pyrrolo	B-X
[	B-X
2,1-a	B-X
]	B-X
isoquinoline	B-X
alkaloids	B-X
have	B-X
not	B-X
been	B-X
synthesized	B-X
yet	B-X
.	B-X
The	B-X
following	B-X
three	B-X
tables	B-X
summarize	B-X
the	B-X
synthetic	B-X
efforts	B-X
toward	B-X
crispine	B-X
A	B-X
(	B-X
1	B-X
)	B-X
(	B-X
Table	B-X
1	B-X
:	B-X
racemic	B-X
syntheses	B-X
;	B-X
Table	B-X
2	B-X
:	B-X
enantioselective	B-X
syntheses	B-X
)	B-X
and	B-X
trolline	B-X
(	B-X
3	B-X
)	B-X
(	B-X
Table	B-X
3	B-X
)	B-X
.	B-X

Electron	O
microscopic	O
R	O
loop	O
analysis	O
<EOS>	B-X
An	B-X
electron	B-X
microscope	B-X
method	B-X
is	B-X
described	B-X
which	B-X
allows	B-X
improved	B-X
analysis	B-X
of	B-X
in	B-X
vitro	B-X
transcription	B-X
.	B-X
Transcription	B-X
complexes	B-X
are	B-X
fixed	B-X
with	B-X
glutaraldehyde	B-X
,	B-X
subjected	B-X
to	B-X
R-loop	B-X
conditions	B-X
which	B-X
allow	B-X
the	B-X
nascent	B-X
RNA	B-X
chains	B-X
to	B-X
hybridize	B-X
to	B-X
the	B-X
DNA	B-X
templates	B-X
,	B-X
and	B-X
mounted	B-X
for	B-X
electron	B-X
microscopy	B-X
by	B-X
a	B-X
protein-free	B-X
preparation	B-X
method	B-X
.	B-X
An	B-X
RNA	B-X
polymerase	B-X
molecule	B-X
(	B-X
or	B-X
parts	B-X
of	B-X
it	B-X
)	B-X
associated	B-X
with	B-X
only	B-X
one	B-X
end	B-X
of	B-X
the	B-X
R-loop	B-X
identifies	B-X
the	B-X
polarity	B-X
of	B-X
the	B-X
transcript	B-X
,	B-X
thus	B-X
determining	B-X
the	B-X
origin	B-X
and	B-X
direction	B-X
of	B-X
transcription	B-X
.	B-X
The	B-X
most	B-X
important	B-X
methods	B-X
are	B-X
based	B-X
on	B-X
nucleic	B-X
acid	B-X
hybridizations	B-X
:	B-X
DNA-DNA	B-X
hybridization	B-X
(	B-X
heteroduplex	B-X
,	B-X
D-loop	B-X
)	B-X
,	B-X
RNA-DNA	B-X
hybridization	B-X
(	B-X
R-loop	B-X
)	B-X
,	B-X
or	B-X
combinations	B-X
of	B-X
both	B-X
(	B-X
R-hybrid	B-X
)	B-X
.	B-X
They	B-X
allow	B-X
both	B-X
qualitative	B-X
and	B-X
quantitative	B-X
analysis	B-X
of	B-X
gene	B-X
organization	B-X
,	B-X
position	B-X
and	B-X
extension	B-X
of	B-X
homology	B-X
regions	B-X
,	B-X
and	B-X
characterization	B-X
of	B-X
transcription	B-X
.	B-X
Special	B-X
methods	B-X
have	B-X
been	B-X
developed	B-X
also	B-X
for	B-X
the	B-X
analysis	B-X
of	B-X
protein-DNA	B-X
interaction	B-X
:	B-X
e.g.	B-X
,	B-X
direct	B-X
visualization	B-X
of	B-X
specific	B-X
protein-DNA	B-X
complexes	B-X
(	B-X
enzymes	B-X
,	B-X
regulatory	B-X
proteins	B-X
)	B-X
,	B-X
and	B-X
analysis	B-X
of	B-X
structures	B-X
with	B-X
higher	B-X
complexity	B-X
(	B-X
chromatin	B-X
,	B-X
transcription	B-X
complexes	B-X
)	B-X
.	B-X

present	O
in	O
SpC3	O
DNA1	O
.	O

of	O
the	O
sheep	B-Species
a2	O
introns	O
<EOS>	B-X
Here	B-X
we	B-X
report	B-X
the	B-X
generation	B-X
of	B-X
transgenic	B-X
sheep	B-X
bearing	B-X
a	B-X
fusion	B-X
gene	B-X
construct	B-X
with	B-X
the	B-X
human	B-X
blood	B-X
clotting	B-X
factor	B-X
VIII	B-X
(	B-X
hFVIII	B-X
)	B-X
cDNA	B-X
under	B-X
the	B-X
transcriptional	B-X
control	B-X
of	B-X
a	B-X
2.2	B-X
kb	B-X
fragment	B-X
of	B-X
the	B-X
mammary	B-X
gland	B-X
specific	B-X
promoter	B-X
of	B-X
the	B-X
ovine	B-X
beta-Lactoglobulin	B-X
(	B-X
beta-Lac	B-X
)	B-X
gene	B-X
.	B-X
Six	B-X
founder	B-X
animals	B-X
were	B-X
generated	B-X
bearing	B-X
a	B-X
hFVIII	B-X
cDNA	B-X
construct	B-X
with	B-X
the	B-X
introns	B-X
of	B-X
the	B-X
murine	B-X
metallothionein	B-X
(	B-X
MtI	B-X
)	B-X
gene	B-X
(	B-X
beta-Lac/hFVIII-MtI	B-X
)	B-X
.	B-X
ALS	B-X
has	B-X
been	B-X
studied	B-X
almost	B-X
exclusively	B-X
in	B-X
rodents	B-X
and	B-X
primates	B-X
,	B-X
and	B-X
no	B-X
information	B-X
exists	B-X
in	B-X
the	B-X
sheep	B-X
despite	B-X
its	B-X
extensive	B-X
use	B-X
to	B-X
study	B-X
the	B-X
circulating	B-X
IGF	B-X
system	B-X
.	B-X
To	B-X
initiate	B-X
studies	B-X
in	B-X
the	B-X
sheep	B-X
,	B-X
we	B-X
isolated	B-X
the	B-X
ovine	B-X
ALS	B-X
gene	B-X
and	B-X
characterized	B-X
its	B-X
spatial	B-X
and	B-X
developmental	B-X
regulation	B-X
.	B-X
A	B-X
DNA	B-X
fragment	B-X
extending	B-X
from	B-X
-727	B-X
to	B-X
-	B-X
11	B-X
of	B-X
the	B-X
sheep	B-X
ALS	B-X
gene	B-X
directed	B-X
basal	B-X
expression	B-X
of	B-X
a	B-X
luciferase	B-X
reporter	B-X
plasmid	B-X
in	B-X
the	B-X
rat	B-X
liver	B-X
cell	B-X
line	B-X
H4-II-E.	B-X
GH	B-X
increased	B-X
promoter	B-X
activity	B-X
by	B-X
1.8-fold	B-X
,	B-X
consistent	B-X
with	B-X
conservation	B-X
in	B-X
the	B-X
sheep	B-X
promoter	B-X
of	B-X
the	B-X
GH	B-X
response	B-X
element	B-X
previously	B-X
identified	B-X
in	B-X
the	B-X
mouse	B-X
gene	B-X
.	B-X
The	B-X
sheep	B-X
is	B-X
a	B-X
useful	B-X
model	B-X
to	B-X
understand	B-X
the	B-X
regulation	B-X
and	B-X
role	B-X
of	B-X
ALS	B-X
,	B-X
particularly	B-X
around	B-X
the	B-X
time	B-X
of	B-X
birth	B-X
,	B-X
when	B-X
final	B-X
maturation	B-X
of	B-X
the	B-X
circulating	B-X
IGF	B-X
system	B-X
occurs	B-X
.	B-X

SpC3	O
was	O
hybridized	O
to	O
sheep	B-Species
a2	O
mRNA	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
;	O
intron	O
lengths	O
were	O
determined	O
by	O
comparison	O
with	O
*	O
X	O
-	O
174	O
DNA	O
lengths	O
.	O

2	O
Introns	O
are	O
designated	O
sequentially	O
3	O
'	O
to	O
5	O
'	O
.	O

3	O
All	O
data	O
is	O
presented	O
as	O
mean	O
?	O
<EOS>	B-X
Conjunctival	B-X
and	B-X
Corneal	B-X
Fibrous	B-X
Histiocytoma	B-X
:	B-X
Brief	B-X
review	B-X
.	B-X
The	B-X
reported	B-X
prevalence	B-X
of	B-X
voice	B-X
disorders	B-X
in	B-X
the	B-X
pediatric	B-X
population	B-X
varies	B-X
widely	B-X
between	B-X
studies	B-X
,	B-X
ranging	B-X
from	B-X
3.9	B-X
%	B-X
to	B-X
23	B-X
%	B-X
.	B-X
In	B-X
all	B-X
,	B-X
272	B-X
(	B-X
59.3	B-X
%	B-X
)	B-X
were	B-X
male	B-X
and	B-X
187	B-X
(	B-X
40.7	B-X
%	B-X
)	B-X
were	B-X
female	B-X
.	B-X
CAPE-V	B-X
data	B-X
were	B-X
available	B-X
for	B-X
439	B-X
patients	B-X
,	B-X
and	B-X
pVHI	B-X
data	B-X
were	B-X
available	B-X
for	B-X
109	B-X
patients	B-X
.	B-X
The	B-X
mean	B-X
CAPE-V	B-X
Overall	B-X
Severity	B-X
score	B-X
was	B-X
38.2	B-X
.	B-X
The	B-X
mean	B-X
total	B-X
pVHI	B-X
score	B-X
was	B-X
25.4	B-X
.	B-X
Males	B-X
had	B-X
higher	B-X
CAPE-V	B-X
Overall	B-X
Severity	B-X
(	B-X
40.0	B-X
vs.	B-X
35.4	B-X
)	B-X
,	B-X
Roughness	B-X
(	B-X
32.2	B-X
vs.	B-X
27.6	B-X
)	B-X
,	B-X
and	B-X
Strain	B-X
scores	B-X
(	B-X
37.2	B-X
vs.	B-X
32.4	B-X
)	B-X
than	B-X
females	B-X
.	B-X
In	B-X
all	B-X
,	B-X
283	B-X
patients	B-X
self-reported	B-X
a	B-X
length	B-X
of	B-X
symptoms	B-X
prior	B-X
to	B-X
evaluation	B-X
.	B-X
Overall	B-X
,	B-X
310	B-X
patients	B-X
(	B-X
67.5	B-X
%	B-X
)	B-X
were	B-X
recommended	B-X
intervention	B-X
for	B-X
their	B-X
dysphonia	B-X
.	B-X
Males	B-X
were	B-X
more	B-X
likely	B-X
than	B-X
females	B-X
to	B-X
present	B-X
with	B-X
dysphonia	B-X
and	B-X
presented	B-X
with	B-X
more	B-X
severe	B-X
perceptual	B-X
dysphonia	B-X
scores	B-X
on	B-X
average	B-X
.	B-X
Referrals	B-X
to	B-X
a	B-X
pediatric	B-X
voice	B-X
clinic	B-X
should	B-X
be	B-X
considered	B-X
in	B-X
patients	B-X
with	B-X
a	B-X
dysphonia	B-X
history	B-X
lasting	B-X
greater	B-X
than	B-X
3	B-X
months	B-X
and	B-X
in	B-X
patients	B-X
with	B-X
more	B-X
severe	B-X
symptoms	B-X
.	B-X

standard	O
deviation	O
.	O
<EOS>	B-X
The	B-X
relative	B-X
expression	B-X
ratio	B-X
is	B-X
calculated	B-X
only	B-X
from	B-X
the	B-X
real-time	B-X
PCR	B-X
efficiencies	B-X
and	B-X
the	B-X
crossing	B-X
point	B-X
deviation	B-X
of	B-X
an	B-X
unknown	B-X
sample	B-X
versus	B-X
a	B-X
control	B-X
.	B-X
Control	B-X
levels	B-X
were	B-X
included	B-X
in	B-X
the	B-X
model	B-X
to	B-X
standardise	B-X
each	B-X
reaction	B-X
run	B-X
with	B-X
respect	B-X
to	B-X
RNA	B-X
integrity	B-X
,	B-X
sample	B-X
loading	B-X
and	B-X
inter-PCR	B-X
variations	B-X
.	B-X
This	B-X
article	B-X
introduces	B-X
a	B-X
new	B-X
measure	B-X
,	B-X
the	B-X
skewness	B-X
of	B-X
the	B-X
standardized	B-X
deviates	B-X
,	B-X
to	B-X
quantify	B-X
publication	B-X
bias	B-X
.	B-X
The	B-X
mysterious	B-X
standard	B-X
deviation	B-X
.	B-X

4	O
Intron	O
17	O
was	O
visualized	O
only	O
by	O
the	O
urea	O
-	O
formamide	O
method	O
.	O

2246	O

70	O
%	O
Formamide	O
Method	O
Urea	O
-	O
Formamide	O
Method	O
<EOS>	B-X
Nanofibrous	B-X
membranes	B-X
were	B-X
electrospun	B-X
at	B-X
a	B-X
concentration	B-X
of	B-X
11.5	B-X
wt	B-X
%	B-X
of	B-X
polysulfone	B-X
(	B-X
PS	B-X
)	B-X
and	B-X
dimethylformamide	B-X
(	B-X
DMF	B-X
)	B-X
/tetrahydrofuran	B-X
(	B-X
THF	B-X
)	B-X
with	B-X
a	B-X
ratio	B-X
of	B-X
70/30	B-X
.	B-X
After	B-X
spreading	B-X
under	B-X
moderately	B-X
denaturing	B-X
conditions	B-X
(	B-X
50	B-X
or	B-X
60	B-X
%	B-X
formamide	B-X
)	B-X
,	B-X
50	B-X
to	B-X
70	B-X
%	B-X
of	B-X
the	B-X
molecules	B-X
were	B-X
circular	B-X
.	B-X
Increasing	B-X
the	B-X
formamide	B-X
concentration	B-X
to	B-X
70	B-X
and	B-X
85	B-X
%	B-X
decreased	B-X
the	B-X
number	B-X
of	B-X
circular	B-X
forms	B-X
,	B-X
and	B-X
only	B-X
linear	B-X
forms	B-X
were	B-X
observed	B-X
after	B-X
incubation	B-X
of	B-X
the	B-X
RNA	B-X
at	B-X
60	B-X
degrees	B-X
C	B-X
for	B-X
15	B-X
min	B-X
in	B-X
99	B-X
%	B-X
formamide	B-X
.	B-X
The	B-X
GC-clamp	B-X
PCR	B-X
amplicons	B-X
were	B-X
separated	B-X
according	B-X
to	B-X
their	B-X
sequences	B-X
by	B-X
the	B-X
DGGE	B-X
using	B-X
10	B-X
%	B-X
(	B-X
w/v	B-X
)	B-X
polyacrylamide	B-X
gel	B-X
containing	B-X
45-70	B-X
%	B-X
urea	B-X
and	B-X
formamide	B-X
denaturants	B-X
.	B-X

Intron2	O
Number	O
of	O
Intron	O
length	O
Number	O
of	O
Intron	O
length	O
<EOS>	B-X
High	B-X
length	B-X
and	B-X
nucleotide	B-X
polymorphisms	B-X
in	B-X
intron2	B-X
of	B-X
GH	B-X
I	B-X
gene	B-X
were	B-X
detected	B-X
in	B-X
162	B-X
individuals	B-X
,	B-X
which	B-X
were	B-X
from	B-X
seven	B-X
wild	B-X
crucian	B-X
carp	B-X
colonies	B-X
,	B-X
two	B-X
goldfish	B-X
colonies	B-X
and	B-X
one	B-X
Fangzheng	B-X
crucian	B-X
carp	B-X
colony	B-X
.	B-X
Using	B-X
denaturating	B-X
polyareylamide	B-X
gel	B-X
electrophoresis	B-X
(	B-X
DPAGE	B-X
)	B-X
and	B-X
single-strand	B-X
conformation	B-X
polymorphism	B-X
(	B-X
SSCP	B-X
)	B-X
,	B-X
seven	B-X
length	B-X
variants	B-X
and	B-X
15	B-X
haplotypes	B-X
were	B-X
identified	B-X
in	B-X
these	B-X
fishes	B-X
.	B-X
The	B-X
length	B-X
types	B-X
and	B-X
haplotypes	B-X
diversity	B-X
was	B-X
4.32	B-X
%	B-X
and	B-X
9.26	B-X
%	B-X
,	B-X
respectively	B-X
.	B-X
(	B-X
2	B-X
)	B-X
The	B-X
seven	B-X
length	B-X
variants	B-X
(	B-X
A	B-X
,	B-X
B	B-X
,	B-X
C	B-X
,	B-X
D	B-X
,	B-X
E	B-X
,	B-X
F	B-X
and	B-X
G	B-X
)	B-X
were	B-X
determined	B-X
to	B-X
be	B-X
189	B-X
,	B-X
196	B-X
,	B-X
204	B-X
,	B-X
205	B-X
,	B-X
206	B-X
,	B-X
207	B-X
and	B-X
209	B-X
bp	B-X
,	B-X
respectively	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
distributions	B-X
of	B-X
the	B-X
length	B-X
types	B-X
,	B-X
haplotypes	B-X
and	B-X
composite	B-X
genotypes	B-X
suggested	B-X
that	B-X
genetic	B-X
diversity	B-X
was	B-X
varied	B-X
in	B-X
different	B-X
colonies	B-X
.	B-X
In	B-X
the	B-X
goldfish	B-X
colonies	B-X
,	B-X
only	B-X
one	B-X
length	B-X
type	B-X
(	B-X
A	B-X
)	B-X
,	B-X
two	B-X
haplotypes	B-X
(	B-X
A1	B-X
and	B-X
A2	B-X
)	B-X
and	B-X
one	B-X
composite	B-X
genotype	B-X
(	B-X
A1A2	B-X
)	B-X
were	B-X
observed	B-X
.	B-X
Two	B-X
length	B-X
types	B-X
(	B-X
C	B-X
and	B-X
D	B-X
)	B-X
,	B-X
four	B-X
haplotypes	B-X
(	B-X
C1	B-X
,	B-X
C2	B-X
,	B-X
D2	B-X
and	B-X
D5	B-X
)	B-X
and	B-X
one	B-X
composite	B-X
genotype	B-X
(	B-X
C1C2D2D5	B-X
)	B-X
presented	B-X
in	B-X
the	B-X
Fangzheng	B-X
crucian	B-X
carp	B-X
colonies	B-X
.	B-X
The	B-X
highest	B-X
level	B-X
of	B-X
genetic	B-X
diversity	B-X
was	B-X
exhibited	B-X
in	B-X
the	B-X
seven	B-X
wild	B-X
crucian	B-X
carp	B-X
colonies	B-X
:	B-X
seven	B-X
length	B-X
types	B-X
(	B-X
A	B-X
,	B-X
B	B-X
,	B-X
C	B-X
,	B-X
D	B-X
,	B-X
E	B-X
,	B-X
F	B-X
and	B-X
G	B-X
)	B-X
,	B-X
14	B-X
haplotypes	B-X
(	B-X
A1	B-X
,	B-X
A2	B-X
,	B-X
A3	B-X
,	B-X
B	B-X
,	B-X
C1	B-X
,	B-X
C2	B-X
,	B-X
D1	B-X
,	B-X
D2	B-X
,	B-X
D3	B-X
,	B-X
D4	B-X
,	B-X
E1	B-X
,	B-X
E2	B-X
,	B-X
F	B-X
and	B-X
G	B-X
)	B-X
and	B-X
14	B-X
composite	B-X
genotypes	B-X
(	B-X
A1A2A3	B-X
,	B-X
A1A2A3B	B-X
,	B-X
A1C1C2D1D2D3	B-X
,	B-X
A1C1C2D2	B-X
,	B-X
A1C1C2D2D3	B-X
,	B-X
A1C1C2D3E2	B-X
,	B-X
BC1C2D2	B-X
,	B-X
BC1C2D3D4	B-X
,	B-X
C1C2D2	B-X
,	B-X
C1C2D2D3	B-X
,	B-X
C1C2D3D4	B-X
,	B-X
C1C2D3D4F	B-X
,	B-X
C1C2D4	B-X
,	B-X
D2E1G	B-X
)	B-X
were	B-X
shared	B-X
by	B-X
the	B-X
seven	B-X
wild	B-X
colonies	B-X
.	B-X
The	B-X
numbers	B-X
of	B-X
observed	B-X
length	B-X
types	B-X
,	B-X
haplotypes	B-X
and	B-X
genotypes	B-X
within	B-X
the	B-X
wild	B-X
colonies	B-X
ranged	B-X
from	B-X
3	B-X
to	B-X
6	B-X
,	B-X
6	B-X
to	B-X
10	B-X
and	B-X
2	B-X
to	B-X
6	B-X
,	B-X
respectively	B-X
.	B-X
Whether	B-X
the	B-X
length	B-X
and	B-X
nucleotide	B-X
polymorphisms	B-X
in	B-X
the	B-X
intron2	B-X
of	B-X
crucian	B-X
carp	B-X
GH	B-X
I	B-X
gene	B-X
were	B-X
associated	B-X
with	B-X
gene	B-X
expression	B-X
and	B-X
gene	B-X
regulation	B-X
remained	B-X
unsolved	B-X
and	B-X
required	B-X
further	B-X
investigations	B-X
.	B-X

introns	O
analyzed	O
(	O
bases	O
)	O
introns	O
analyzed	O
(	O
bases	O
)	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
present	B-X
a	B-X
dimethyl	B-X
sulfate-based	B-X
(	B-X
DMS	B-X
)	B-X
chemical	B-X
probing	B-X
method	B-X
coupled	B-X
with	B-X
Next	B-X
Generation	B-X
sequencing	B-X
(	B-X
DMS-MaPseq	B-X
)	B-X
to	B-X
study	B-X
RNA	B-X
secondary	B-X
structure	B-X
in	B-X
vivo.DMS	B-X
modifies	B-X
unpaired	B-X
adenine	B-X
and	B-X
cytosine	B-X
bases	B-X
which	B-X
are	B-X
then	B-X
converted	B-X
to	B-X
mutations/mismatches	B-X
using	B-X
a	B-X
thermostable	B-X
group	B-X
II	B-X
intron	B-X
reverse	B-X
transcriptase	B-X
(	B-X
TGIRT	B-X
)	B-X
and	B-X
further	B-X
analyzed	B-X
using	B-X
sequencing	B-X
.	B-X
The	B-X
human	B-X
HPRT	B-X
gene	B-X
contains	B-X
spans	B-X
approximately	B-X
42,000	B-X
base	B-X
pairs	B-X
in	B-X
genomic	B-X
DNA	B-X
,	B-X
has	B-X
a	B-X
mRNA	B-X
of	B-X
approximately	B-X
900	B-X
bases	B-X
and	B-X
a	B-X
protein	B-X
coding	B-X
sequence	B-X
of	B-X
657	B-X
bases	B-X
(	B-X
initiation	B-X
codon	B-X
AUG	B-X
to	B-X
termination	B-X
codon	B-X
UAA	B-X
)	B-X
.	B-X
In	B-X
a	B-X
database	B-X
of	B-X
human	B-X
HPRT	B-X
mutations	B-X
,	B-X
277	B-X
of	B-X
2224	B-X
(	B-X
12.5	B-X
%	B-X
)	B-X
mutations	B-X
result	B-X
in	B-X
alterations	B-X
in	B-X
splicing	B-X
of	B-X
the	B-X
mRNA	B-X
as	B-X
analyzed	B-X
by	B-X
both	B-X
reverse	B-X
transcriptase	B-X
mediated	B-X
production	B-X
of	B-X
a	B-X
cDNA	B-X
followed	B-X
by	B-X
PCR	B-X
amplification	B-X
and	B-X
cDNA	B-X
sequencing	B-X
and	B-X
by	B-X
genomic	B-X
DNA	B-X
PCR	B-X
amplification	B-X
and	B-X
sequencing	B-X
.	B-X
Mutations	B-X
in	B-X
the	B-X
5	B-X
'	B-X
splice	B-X
sequences	B-X
of	B-X
introns	B-X
1	B-X
and	B-X
5	B-X
result	B-X
in	B-X
intron	B-X
inclusion	B-X
in	B-X
the	B-X
cDNA	B-X
due	B-X
to	B-X
the	B-X
use	B-X
of	B-X
cryptic	B-X
donor	B-X
splice	B-X
sequences	B-X
within	B-X
the	B-X
introns	B-X
;	B-X
mutations	B-X
in	B-X
the	B-X
other	B-X
six	B-X
5	B-X
'	B-X
sites	B-X
result	B-X
in	B-X
simple	B-X
exon	B-X
exclusion	B-X
.	B-X
Mutations	B-X
in	B-X
the	B-X
3	B-X
'	B-X
splice	B-X
sequences	B-X
of	B-X
introns	B-X
1	B-X
,	B-X
3	B-X
,	B-X
7	B-X
and	B-X
8	B-X
result	B-X
in	B-X
partial	B-X
exon	B-X
exclusion	B-X
due	B-X
to	B-X
the	B-X
use	B-X
of	B-X
cryptic	B-X
acceptor	B-X
splice	B-X
sequences	B-X
within	B-X
the	B-X
exons	B-X
;	B-X
mutations	B-X
in	B-X
the	B-X
other	B-X
four	B-X
3	B-X
'	B-X
sites	B-X
result	B-X
in	B-X
simple	B-X
exon	B-X
exclusion	B-X
.	B-X
A	B-X
base	B-X
substitution	B-X
in	B-X
exon	B-X
3	B-X
(	B-X
209G	B-X
--	B-X
>	B-X
T	B-X
)	B-X
creates	B-X
a	B-X
new	B-X
5	B-X
'	B-X
(	B-X
donor	B-X
)	B-X
splice	B-X
site	B-X
which	B-X
results	B-X
in	B-X
the	B-X
exclusion	B-X
of	B-X
110	B-X
bases	B-X
of	B-X
exon	B-X
3	B-X
from	B-X
the	B-X
cDNA	B-X
.	B-X

1	O
10	O
819	O
t	O
063	O
35	O
806	O
t	O
76	O
2	O
12	O
771	O
?	O

89	O
46	O
757	O
t	O
78	O
3	O
11	O
458	O
?	O
<EOS>	B-X
[	B-X
Specific	B-X
changes	B-X
of	B-X
intestinal	B-X
microflora	B-X
in	B-X
children	B-X
with	B-X
nonalcoholic	B-X
fatty	B-X
liver	B-X
disease	B-X
]	B-X
.	B-X

58	O
47	O
464	O
?	O

66	O
4	O
6	O
627	O
?	O
<EOS>	B-X
Studies	B-X
of	B-X
oxygen	B-X
binding	B-X
energy	B-X
to	B-X
hemoglobin	B-X
molecule	B-X
.	B-X
Effect	B-X
of	B-X
chloroquine	B-X
on	B-X
cultured	B-X
fibroblasts	B-X
:	B-X
release	B-X
of	B-X
lysosomal	B-X
hydrolases	B-X
and	B-X
inhibition	B-X
of	B-X
their	B-X
uptake	B-X
.	B-X
No	B-X
difference	B-X
was	B-X
found	B-X
with	B-X
0.12	B-X
mM	B-X
acetaldehyde	B-X
,	B-X
2	B-X
mM	B-X
glycolaldehyde	B-X
,	B-X
6	B-X
mM	B-X
formaldehyde	B-X
or	B-X
0.5	B-X
mM	B-X
betaine	B-X
aldehyde	B-X
.	B-X
The	B-X
pA2	B-X
values	B-X
of	B-X
phentolamine	B-X
againstoxymethazoline	B-X
,	B-X
phenylephrine	B-X
,	B-X
alpha-methylnoradrenaline	B-X
and	B-X
methoxamine	B-X
were	B-X
7.43	B-X
,	B-X
7.48	B-X
,	B-X
7.59	B-X
and	B-X
7.69	B-X
,	B-X
respectively	B-X
.	B-X
4	B-X
.	B-X

53	O
41	O
611	O
?	O

73	O
5	O
5	O
554	O
?	O
<EOS>	B-X
Atomic	B-X
models	B-X
for	B-X
the	B-X
polypeptide	B-X
backbones	B-X
of	B-X
myohemerythrin	B-X
and	B-X
hemerythrin	B-X
.	B-X
In	B-X
all	B-X
3	B-X
types	B-X
of	B-X
myosin	B-X
the	B-X
hydrolytic	B-X
cycle	B-X
of	B-X
Mg	B-X
(	B-X
2+	B-X
)	B-X
-	B-X
ATP	B-X
was	B-X
found	B-X
to	B-X
be	B-X
controlled	B-X
by	B-X
the	B-X
same	B-X
step	B-X
at	B-X
25	B-X
degrees	B-X
C.	B-X
In	B-X
all	B-X
three	B-X
cases	B-X
,	B-X
this	B-X
rate-limiting	B-X
step	B-X
is	B-X
changed	B-X
in	B-X
the	B-X
same	B-X
way	B-X
by	B-X
lowereing	B-X
temperature	B-X
.	B-X
Sex-role	B-X
adjustment	B-X
and	B-X
drinking	B-X
disposition	B-X
of	B-X
women	B-X
college	B-X
students	B-X
.	B-X

51	O
34	O
562	O
?	O
<EOS>	B-X
Determinants	B-X
of	B-X
intracellular	B-X
pH	B-X
in	B-X
the	B-X
erythrocyte	B-X
.	B-X

76	O
6	O
6	O
675	O
?	O
<EOS>	B-X
The	B-X
proteins	B-X
required	B-X
for	B-X
this	B-X
reaction	B-X
are	B-X
a	B-X
flavoprotien	B-X
with	B-X
a	B-X
molecular	B-X
weight	B-X
of	B-X
approximately	B-X
185,000	B-X
which	B-X
is	B-X
functionally	B-X
similar	B-X
to	B-X
thioredoxin	B-X
reductase	B-X
(	B-X
NADPH	B-X
)	B-X
,	B-X
EC	B-X
1.6.4.5	B-X
,	B-X
and	B-X
another	B-X
protein	B-X
(	B-X
Protein	B-X
I	B-X
)	B-X
whose	B-X
function	B-X
in	B-X
the	B-X
reaction	B-X
is	B-X
unknown	B-X
.	B-X
Studies	B-X
of	B-X
oxygen	B-X
binding	B-X
energy	B-X
to	B-X
hemoglobin	B-X
molecule	B-X
.	B-X
Studies	B-X
employing	B-X
sucrose	B-X
density	B-X
gradient	B-X
centrifugation	B-X
indicate	B-X
that	B-X
kinase	B-X
I	B-X
has	B-X
a	B-X
molecular	B-X
weight	B-X
of	B-X
about	B-X
9.5	B-X
-	B-X
10	B-X
(	B-X
5	B-X
)	B-X
(	B-X
25	B-X
S	B-X
)	B-X
and	B-X
kinase	B-X
II	B-X
about	B-X
1.4	B-X
-	B-X
10	B-X
(	B-X
6	B-X
)	B-X
(	B-X
32	B-X
S	B-X
)	B-X
.	B-X
The	B-X
enzymes	B-X
have	B-X
apparent	B-X
Km	B-X
values	B-X
of	B-X
2.5	B-X
-	B-X
10	B-X
(	B-X
-5	B-X
)	B-X
M	B-X
for	B-X
GTP	B-X
,	B-X
2	B-X
-	B-X
10	B-X
(	B-X
-5	B-X
)	B-X
M	B-X
for	B-X
ATP	B-X
,	B-X
and	B-X
0.4	B-X
--	B-X
0.6	B-X
mg/ml	B-X
for	B-X
casein	B-X
.	B-X

19	O
40	O
684	O
?	O
<EOS>	B-X
Antidepressant	B-X
drugs	B-X
affect	B-X
dopamine	B-X
uptake	B-X
.	B-X
[	B-X
Picolylamides	B-X
of	B-X
the	B-X
nicethamide	B-X
type	B-X
.	B-X
6	B-X
.	B-X
Structure-activity	B-X
relationships	B-X
of	B-X
analeptics	B-X
of	B-X
the	B-X
nicethamide	B-X
type	B-X
]	B-X
.	B-X

76	O
7	O
5	O
386	O
?	O
<EOS>	B-X
Two	B-X
rabbit	B-X
erythrocyte	B-X
casein	B-X
kinases	B-X
,	B-X
GTP	B-X
:	B-X
casein	B-X
kinase	B-X
I	B-X
and	B-X
GTP	B-X
:	B-X
casein	B-X
kinase	B-X
II	B-X
,	B-X
have	B-X
been	B-X
purified	B-X
29	B-X
000-	B-X
and	B-X
47	B-X
000-fold	B-X
,	B-X
respectively	B-X
.	B-X
Studies	B-X
employing	B-X
sucrose	B-X
density	B-X
gradient	B-X
centrifugation	B-X
indicate	B-X
that	B-X
kinase	B-X
I	B-X
has	B-X
a	B-X
molecular	B-X
weight	B-X
of	B-X
about	B-X
9.5	B-X
-	B-X
10	B-X
(	B-X
5	B-X
)	B-X
(	B-X
25	B-X
S	B-X
)	B-X
and	B-X
kinase	B-X
II	B-X
about	B-X
1.4	B-X
-	B-X
10	B-X
(	B-X
6	B-X
)	B-X
(	B-X
32	B-X
S	B-X
)	B-X
.	B-X
Among	B-X
various	B-X
protein	B-X
substrates	B-X
examined	B-X
,	B-X
these	B-X
kinases	B-X
catalyze	B-X
the	B-X
phosphorylation	B-X
of	B-X
casein	B-X
greater	B-X
than	B-X
50	B-X
%	B-X
dephosphorylated	B-X
phosvitin	B-X
congruent	B-X
to	B-X
50	B-X
%	B-X
dephosphorylated	B-X
casein	B-X
greater	B-X
than	B-X
phosvitin	B-X
.	B-X
The	B-X
enzymes	B-X
have	B-X
apparent	B-X
Km	B-X
values	B-X
of	B-X
2.5	B-X
-	B-X
10	B-X
(	B-X
-5	B-X
)	B-X
M	B-X
for	B-X
GTP	B-X
,	B-X
2	B-X
-	B-X
10	B-X
(	B-X
-5	B-X
)	B-X
M	B-X
for	B-X
ATP	B-X
,	B-X
and	B-X
0.4	B-X
--	B-X
0.6	B-X
mg/ml	B-X
for	B-X
casein	B-X
.	B-X
The	B-X
incorporation	B-X
of	B-X
the	B-X
terminal	B-X
phosphate	B-X
of	B-X
GTP	B-X
into	B-X
casein	B-X
as	B-X
catalyzed	B-X
by	B-X
these	B-X
enzymes	B-X
is	B-X
inhibited	B-X
to	B-X
varying	B-X
degrees	B-X
by	B-X
ATP	B-X
,	B-X
ITP	B-X
,	B-X
ADP	B-X
,	B-X
and	B-X
GDP	B-X
but	B-X
not	B-X
by	B-X
UTP	B-X
,	B-X
CTP	B-X
,	B-X
GMP	B-X
,	B-X
adenosine	B-X
3':5'-cyclic	B-X
monophosphate	B-X
,	B-X
and	B-X
guanosine	B-X
3':5'-cyclic	B-X
monophosphate	B-X
.	B-X

48	O
50	O
342	O
?	O

54	O
8	O
7	O
771	O
?	O
<EOS>	B-X
Maturation	B-X
of	B-X
the	B-X
adrenal	B-X
medulla	B-X
--	B-X
IV	B-X
.	B-X
Effects	B-X
of	B-X
morphine	B-X
.	B-X
Comparison	B-X
between	B-X
procaine	B-X
and	B-X
isocarboxazid	B-X
metabolism	B-X
in	B-X
vitro	B-X
by	B-X
a	B-X
liver	B-X
microsomal	B-X
amidase-esterase	B-X
.	B-X
The	B-X
hydrolytic	B-X
action	B-X
of	B-X
the	B-X
basic	B-X
enzyme	B-X
was	B-X
found	B-X
to	B-X
consist	B-X
of	B-X
two	B-X
sequential	B-X
events	B-X
:	B-X
(	B-X
a	B-X
)	B-X
hydrolysis	B-X
of	B-X
70	B-X
%	B-X
of	B-X
the	B-X
total	B-X
cell	B-X
ph	B-X
osphatidylcholine	B-X
without	B-X
any	B-X
evident	B-X
hemolysis	B-X
;	B-X
and	B-X
(	B-X
b	B-X
)	B-X
complete	B-X
hydrolysis	B-X
of	B-X
the	B-X
remaining	B-X
phosphatidylcholine	B-X
,	B-X
followed	B-X
closely	B-X
by	B-X
extensive	B-X
phosphatidylethanolamine	B-X
hydrolysis	B-X
and	B-X
finally	B-X
with	B-X
onset	B-X
of	B-X
hemolysis	B-X
,	B-X
attack	B-X
on	B-X
the	B-X
phosphatidylserine	B-X
.	B-X
At	B-X
pH	B-X
7.4	B-X
and	B-X
10	B-X
mM	B-X
Ca2+	B-X
only	B-X
stage	B-X
(	B-X
a	B-X
)	B-X
occurred	B-X
.	B-X
However	B-X
,	B-X
a	B-X
slight	B-X
elevation	B-X
of	B-X
the	B-X
pH	B-X
of	B-X
incubation	B-X
to	B-X
pH	B-X
8.0	B-X
and/or	B-X
inclusion	B-X
of	B-X
40	B-X
mM	B-X
Ca2+	B-X
in	B-X
the	B-X
reaction	B-X
mixture	B-X
caused	B-X
both	B-X
events	B-X
(	B-X
a	B-X
)	B-X
and	B-X
(	B-X
b	B-X
)	B-X
to	B-X
occur	B-X
.	B-X

84	O
49	O
757	O
?	O
<EOS>	B-X
[	B-X
Post-traumatic	B-X
hemorrhagic	B-X
subacute	B-X
constrictive	B-X
pericarditis	B-X
]	B-X
.	B-X

82	O
9	O
8	O
1	O
,	O
181	O
?	O
<EOS>	B-X
Aestivation	B-X
and	B-X
thermoregulation	B-X
in	B-X
the	B-X
Texas	B-X
tortoise	B-X
,	B-X
Gopherus	B-X
berlandieri	B-X
.	B-X
Formate	B-X
assay	B-X
in	B-X
body	B-X
fluids	B-X
:	B-X
application	B-X
in	B-X
methanol	B-X
poisoning	B-X
.	B-X
Radiochemical	B-X
assay	B-X
of	B-X
glutathione	B-X
S-epoxide	B-X
transferase	B-X
and	B-X
its	B-X
enhancement	B-X
by	B-X
phenobarbital	B-X
in	B-X
rat	B-X
liver	B-X
in	B-X
vivo	B-X
.	B-X
Comparison	B-X
between	B-X
procaine	B-X
and	B-X
isocarboxazid	B-X
metabolism	B-X
in	B-X
vitro	B-X
by	B-X
a	B-X
liver	B-X
microsomal	B-X
amidase-esterase	B-X
.	B-X

94	O
52	O
1	O
,	O
124	O
?	O
122	O
10	O
8	O
1	O
,	O
133	O
?	O
106	O
53	O
1	O
,	O
124	O
?	O
137	O
11	O
10	O
964	O
t	O
?	O
79	O
61	O
952	O
?	O
105	O
12	O
9	O
362	O
?	O

77	O
62	O
342	O
?	O

71	O
13	O
4	O
723	O
?	O
222	O
53	O
806	O
?	O
105	O
14	O
4	O
1	O
,	O
085	O
?	O
142	O
53	O
1	O
,	O
075	O
?	O
105	O
15	O
3	O
795	O
?	O

60	O
47	O
806	O
?	O
100	O
16	O
2	O
1	O
,	O
229	O
?	O
<EOS>	B-X
Delineation	B-X
of	B-X
the	B-X
intimate	B-X
details	B-X
of	B-X
the	B-X
backbone	B-X
conformation	B-X
of	B-X
pyridine	B-X
nucleotide	B-X
coenzymes	B-X
in	B-X
aqueous	B-X
solution	B-X
.	B-X
1	B-X
.	B-X
The	B-X
superoxide	B-X
anion	B-X
radical	B-X
(	B-X
O2-	B-X
)	B-X
reacts	B-X
with	B-X
ferricytochrome	B-X
c	B-X
to	B-X
form	B-X
ferrocytochrome	B-X
c.	B-X
No	B-X
intermediate	B-X
complexes	B-X
are	B-X
observable	B-X
.	B-X
No	B-X
reaction	B-X
could	B-X
be	B-X
detected	B-X
between	B-X
O2-	B-X
and	B-X
ferrocytochrome	B-X
c.	B-X
2	B-X
.	B-X
At	B-X
20	B-X
degrees	B-X
C	B-X
the	B-X
rate	B-X
constant	B-X
for	B-X
the	B-X
reaction	B-X
at	B-X
pH	B-X
4.7	B-X
to	B-X
6.7	B-X
is	B-X
1.4-10	B-X
(	B-X
6	B-X
)	B-X
M-1	B-X
.	B-X
S	B-X
-1	B-X
and	B-X
as	B-X
the	B-X
pH	B-X
increases	B-X
above	B-X
6.7	B-X
the	B-X
rate	B-X
constant	B-X
steadily	B-X
decreases	B-X
.	B-X
The	B-X
dependence	B-X
on	B-X
pH	B-X
is	B-X
the	B-X
same	B-X
for	B-X
tuna	B-X
heart	B-X
and	B-X
horse	B-X
heart	B-X
cytochrome	B-X
c.	B-X
No	B-X
reaction	B-X
could	B-X
be	B-X
demonstrated	B-X
between	B-X
O2-	B-X
and	B-X
the	B-X
form	B-X
of	B-X
cytochrome	B-X
c	B-X
which	B-X
exists	B-X
above	B-X
pH	B-X
approximately	B-X
9.2	B-X
.	B-X
The	B-X
dependence	B-X
of	B-X
the	B-X
rate	B-X
constant	B-X
on	B-X
pH	B-X
can	B-X
be	B-X
explained	B-X
if	B-X
cytochrome	B-X
c	B-X
has	B-X
pKs	B-X
of	B-X
7.45	B-X
and	B-X
9.2	B-X
,	B-X
and	B-X
O2-	B-X
reacts	B-X
with	B-X
the	B-X
form	B-X
present	B-X
below	B-X
pH	B-X
7.45	B-X
with	B-X
k	B-X
=	B-X
1.4-10	B-X
(	B-X
6	B-X
)	B-X
M-1	B-X
-	B-X
S-1	B-X
,	B-X
the	B-X
form	B-X
above	B-X
pH	B-X
7.45	B-X
with	B-X
k	B-X
=	B-X
3.0-	B-X
10	B-X
(	B-X
5	B-X
)	B-X
M-1	B-X
-	B-X
S-1	B-X
,	B-X
and	B-X
the	B-X
form	B-X
present	B-X
above	B-X
pH	B-X
9.2	B-X
with	B-X
k	B-X
=	B-X
0	B-X
.	B-X
The	B-X
reaction	B-X
has	B-X
an	B-X
activation	B-X
energy	B-X
of	B-X
20	B-X
kJ	B-X
mol-1	B-X
and	B-X
an	B-X
enthalpy	B-X
of	B-X
activation	B-X
at	B-X
25	B-X
degrees	B-X
C	B-X
of	B-X
18	B-X
kJ	B-X
mol-1	B-X
both	B-X
above	B-X
and	B-X
below	B-X
pH	B-X
7.45	B-X
.	B-X
It	B-X
is	B-X
suggested	B-X
that	B-X
O2-	B-X
may	B-X
reduce	B-X
cytochrome	B-X
c	B-X
through	B-X
a	B-X
track	B-X
composed	B-X
of	B-X
aromatic	B-X
amino	B-X
acids	B-X
,	B-X
and	B-X
that	B-X
little	B-X
protein	B-X
rearrangement	B-X
is	B-X
required	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
activated	B-X
complex	B-X
.	B-X
No	B-X
reduction	B-X
of	B-X
ferricytochrome	B-X
c	B-X
by	B-X
HO2	B-X
radicals	B-X
could	B-X
be	B-X
demonstrated	B-X
at	B-X
pH	B-X
1.2-6.2	B-X
but	B-X
at	B-X
pH	B-X
5.3	B-X
,	B-X
HO2	B-X
radicals	B-X
oxidize	B-X
ferrocytochrome	B-X
c	B-X
with	B-X
a	B-X
rate	B-X
constant	B-X
of	B-X
about	B-X
5-10	B-X
(	B-X
5	B-X
)	B-X
-5-10	B-X
(	B-X
6	B-X
)	B-X
M-1	B-X
-	B-X
S-1	B-X
.	B-X

48	O
43	O
1	O
,	O
319	O
?	O
146	O
174	O
-	O
-	O
12	O
1	O
,	O
539	O
?	O
166	O
<EOS>	B-X
[	B-X
Inborn	B-X
error	B-X
of	B-X
glycolipid	B-X
metabolism	B-X
]	B-X
.	B-X
EKG	B-X
of	B-X
the	B-X
month	B-X
.	B-X
Studies	B-X
on	B-X
the	B-X
lipid	B-X
content	B-X
of	B-X
pigeon	B-X
breast	B-X
muscle	B-X
.	B-X
Formate	B-X
assay	B-X
in	B-X
body	B-X
fluids	B-X
:	B-X
application	B-X
in	B-X
methanol	B-X
poisoning	B-X
.	B-X

1	O
<EOS>	B-X
Formate	B-X
assay	B-X
in	B-X
body	B-X
fluids	B-X
:	B-X
application	B-X
in	B-X
methanol	B-X
poisoning	B-X
.	B-X

Nucleic	O
Acids	O
Research	O
<EOS>	B-X
The	B-X
2021	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
database	B-X
Issue	B-X
contains	B-X
189	B-X
papers	B-X
spanning	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
biological	B-X
fields	B-X
and	B-X
investigation	B-X
.	B-X
The	B-X
entire	B-X
Database	B-X
Issue	B-X
is	B-X
freely	B-X
available	B-X
online	B-X
on	B-X
the	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
website	B-X
(	B-X
https	B-X
:	B-X
//academic.oup.com/nar	B-X
)	B-X
.	B-X
Editorial	B-X
:	B-X
the	B-X
19th	B-X
annual	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
web	B-X
server	B-X
issue	B-X
2021	B-X
.	B-X
Editorial	B-X
:	B-X
Critical	B-X
reviews	B-X
and	B-X
perspectives	B-X
in	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
.	B-X

Table	O
2	O
.	O
<EOS>	B-X
The	B-X
present	B-X
chapter	B-X
describes	B-X
isolation	B-X
,	B-X
biogenetic	B-X
proposals	B-X
,	B-X
and	B-X
syntheses	B-X
of	B-X
the	B-X
natural	B-X
products	B-X
1-4	B-X
and	B-X
10-11	B-X
with	B-X
a	B-X
pyrrolo	B-X
[	B-X
2,1-a	B-X
]	B-X
-isoquinoline	B-X
framework	B-X
.	B-X
The	B-X
pyrrolo	B-X
[	B-X
2,1-a	B-X
]	B-X
isoquinolines	B-X
are	B-X
of	B-X
interest	B-X
due	B-X
to	B-X
their	B-X
promising	B-X
biological	B-X
activities	B-X
.	B-X
Only	B-X
one	B-X
total	B-X
synthesis	B-X
has	B-X
been	B-X
reported	B-X
for	B-X
each	B-X
of	B-X
the	B-X
following	B-X
natural	B-X
products	B-X
:	B-X
peyoglutam	B-X
(	B-X
10	B-X
)	B-X
,	B-X
mescalotam	B-X
(	B-X
11	B-X
)	B-X
,	B-X
and	B-X
the	B-X
antitumor	B-X
active	B-X
crispine	B-X
B	B-X
(	B-X
2	B-X
)	B-X
.	B-X
Some	B-X
of	B-X
the	B-X
pyrrolo	B-X
[	B-X
2,1-a	B-X
]	B-X
isoquinoline	B-X
alkaloids	B-X
have	B-X
not	B-X
been	B-X
synthesized	B-X
yet	B-X
.	B-X
The	B-X
following	B-X
three	B-X
tables	B-X
summarize	B-X
the	B-X
synthetic	B-X
efforts	B-X
toward	B-X
crispine	B-X
A	B-X
(	B-X
1	B-X
)	B-X
(	B-X
Table	B-X
1	B-X
:	B-X
racemic	B-X
syntheses	B-X
;	B-X
Table	B-X
2	B-X
:	B-X
enantioselective	B-X
syntheses	B-X
)	B-X
and	B-X
trolline	B-X
(	B-X
3	B-X
)	B-X
(	B-X
Table	B-X
3	B-X
)	B-X
.	B-X

Electron	O
microscopic	O
R	O
loop	O
analysis	O
of	O
the	O
sheep	B-Species
a2	O
exons	O

present	O
in	O
SpC3	O
DNA1	O
.	O

70	O
%	O
Formamide	O
Method	O
Urea	O
-	O
Formamide	O
Method	O
<EOS>	B-X
Nanofibrous	B-X
membranes	B-X
were	B-X
electrospun	B-X
at	B-X
a	B-X
concentration	B-X
of	B-X
11.5	B-X
wt	B-X
%	B-X
of	B-X
polysulfone	B-X
(	B-X
PS	B-X
)	B-X
and	B-X
dimethylformamide	B-X
(	B-X
DMF	B-X
)	B-X
/tetrahydrofuran	B-X
(	B-X
THF	B-X
)	B-X
with	B-X
a	B-X
ratio	B-X
of	B-X
70/30	B-X
.	B-X
After	B-X
spreading	B-X
under	B-X
moderately	B-X
denaturing	B-X
conditions	B-X
(	B-X
50	B-X
or	B-X
60	B-X
%	B-X
formamide	B-X
)	B-X
,	B-X
50	B-X
to	B-X
70	B-X
%	B-X
of	B-X
the	B-X
molecules	B-X
were	B-X
circular	B-X
.	B-X
Increasing	B-X
the	B-X
formamide	B-X
concentration	B-X
to	B-X
70	B-X
and	B-X
85	B-X
%	B-X
decreased	B-X
the	B-X
number	B-X
of	B-X
circular	B-X
forms	B-X
,	B-X
and	B-X
only	B-X
linear	B-X
forms	B-X
were	B-X
observed	B-X
after	B-X
incubation	B-X
of	B-X
the	B-X
RNA	B-X
at	B-X
60	B-X
degrees	B-X
C	B-X
for	B-X
15	B-X
min	B-X
in	B-X
99	B-X
%	B-X
formamide	B-X
.	B-X
The	B-X
GC-clamp	B-X
PCR	B-X
amplicons	B-X
were	B-X
separated	B-X
according	B-X
to	B-X
their	B-X
sequences	B-X
by	B-X
the	B-X
DGGE	B-X
using	B-X
10	B-X
%	B-X
(	B-X
w/v	B-X
)	B-X
polyacrylamide	B-X
gel	B-X
containing	B-X
45-70	B-X
%	B-X
urea	B-X
and	B-X
formamide	B-X
denaturants	B-X
.	B-X

Exon2	O
Number	O
of	O
Exon	O
length	O
Number	O
of	O
Exon	O
length	O
<EOS>	B-X
High	B-X
length	B-X
and	B-X
nucleotide	B-X
polymorphisms	B-X
in	B-X
intron2	B-X
of	B-X
GH	B-X
I	B-X
gene	B-X
were	B-X
detected	B-X
in	B-X
162	B-X
individuals	B-X
,	B-X
which	B-X
were	B-X
from	B-X
seven	B-X
wild	B-X
crucian	B-X
carp	B-X
colonies	B-X
,	B-X
two	B-X
goldfish	B-X
colonies	B-X
and	B-X
one	B-X
Fangzheng	B-X
crucian	B-X
carp	B-X
colony	B-X
.	B-X
Using	B-X
denaturating	B-X
polyareylamide	B-X
gel	B-X
electrophoresis	B-X
(	B-X
DPAGE	B-X
)	B-X
and	B-X
single-strand	B-X
conformation	B-X
polymorphism	B-X
(	B-X
SSCP	B-X
)	B-X
,	B-X
seven	B-X
length	B-X
variants	B-X
and	B-X
15	B-X
haplotypes	B-X
were	B-X
identified	B-X
in	B-X
these	B-X
fishes	B-X
.	B-X
The	B-X
length	B-X
types	B-X
and	B-X
haplotypes	B-X
diversity	B-X
was	B-X
4.32	B-X
%	B-X
and	B-X
9.26	B-X
%	B-X
,	B-X
respectively	B-X
.	B-X
(	B-X
2	B-X
)	B-X
The	B-X
seven	B-X
length	B-X
variants	B-X
(	B-X
A	B-X
,	B-X
B	B-X
,	B-X
C	B-X
,	B-X
D	B-X
,	B-X
E	B-X
,	B-X
F	B-X
and	B-X
G	B-X
)	B-X
were	B-X
determined	B-X
to	B-X
be	B-X
189	B-X
,	B-X
196	B-X
,	B-X
204	B-X
,	B-X
205	B-X
,	B-X
206	B-X
,	B-X
207	B-X
and	B-X
209	B-X
bp	B-X
,	B-X
respectively	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
distributions	B-X
of	B-X
the	B-X
length	B-X
types	B-X
,	B-X
haplotypes	B-X
and	B-X
composite	B-X
genotypes	B-X
suggested	B-X
that	B-X
genetic	B-X
diversity	B-X
was	B-X
varied	B-X
in	B-X
different	B-X
colonies	B-X
.	B-X
In	B-X
the	B-X
goldfish	B-X
colonies	B-X
,	B-X
only	B-X
one	B-X
length	B-X
type	B-X
(	B-X
A	B-X
)	B-X
,	B-X
two	B-X
haplotypes	B-X
(	B-X
A1	B-X
and	B-X
A2	B-X
)	B-X
and	B-X
one	B-X
composite	B-X
genotype	B-X
(	B-X
A1A2	B-X
)	B-X
were	B-X
observed	B-X
.	B-X
Two	B-X
length	B-X
types	B-X
(	B-X
C	B-X
and	B-X
D	B-X
)	B-X
,	B-X
four	B-X
haplotypes	B-X
(	B-X
C1	B-X
,	B-X
C2	B-X
,	B-X
D2	B-X
and	B-X
D5	B-X
)	B-X
and	B-X
one	B-X
composite	B-X
genotype	B-X
(	B-X
C1C2D2D5	B-X
)	B-X
presented	B-X
in	B-X
the	B-X
Fangzheng	B-X
crucian	B-X
carp	B-X
colonies	B-X
.	B-X
The	B-X
highest	B-X
level	B-X
of	B-X
genetic	B-X
diversity	B-X
was	B-X
exhibited	B-X
in	B-X
the	B-X
seven	B-X
wild	B-X
crucian	B-X
carp	B-X
colonies	B-X
:	B-X
seven	B-X
length	B-X
types	B-X
(	B-X
A	B-X
,	B-X
B	B-X
,	B-X
C	B-X
,	B-X
D	B-X
,	B-X
E	B-X
,	B-X
F	B-X
and	B-X
G	B-X
)	B-X
,	B-X
14	B-X
haplotypes	B-X
(	B-X
A1	B-X
,	B-X
A2	B-X
,	B-X
A3	B-X
,	B-X
B	B-X
,	B-X
C1	B-X
,	B-X
C2	B-X
,	B-X
D1	B-X
,	B-X
D2	B-X
,	B-X
D3	B-X
,	B-X
D4	B-X
,	B-X
E1	B-X
,	B-X
E2	B-X
,	B-X
F	B-X
and	B-X
G	B-X
)	B-X
and	B-X
14	B-X
composite	B-X
genotypes	B-X
(	B-X
A1A2A3	B-X
,	B-X
A1A2A3B	B-X
,	B-X
A1C1C2D1D2D3	B-X
,	B-X
A1C1C2D2	B-X
,	B-X
A1C1C2D2D3	B-X
,	B-X
A1C1C2D3E2	B-X
,	B-X
BC1C2D2	B-X
,	B-X
BC1C2D3D4	B-X
,	B-X
C1C2D2	B-X
,	B-X
C1C2D2D3	B-X
,	B-X
C1C2D3D4	B-X
,	B-X
C1C2D3D4F	B-X
,	B-X
C1C2D4	B-X
,	B-X
D2E1G	B-X
)	B-X
were	B-X
shared	B-X
by	B-X
the	B-X
seven	B-X
wild	B-X
colonies	B-X
.	B-X
The	B-X
numbers	B-X
of	B-X
observed	B-X
length	B-X
types	B-X
,	B-X
haplotypes	B-X
and	B-X
genotypes	B-X
within	B-X
the	B-X
wild	B-X
colonies	B-X
ranged	B-X
from	B-X
3	B-X
to	B-X
6	B-X
,	B-X
6	B-X
to	B-X
10	B-X
and	B-X
2	B-X
to	B-X
6	B-X
,	B-X
respectively	B-X
.	B-X
Whether	B-X
the	B-X
length	B-X
and	B-X
nucleotide	B-X
polymorphisms	B-X
in	B-X
the	B-X
intron2	B-X
of	B-X
crucian	B-X
carp	B-X
GH	B-X
I	B-X
gene	B-X
were	B-X
associated	B-X
with	B-X
gene	B-X
expression	B-X
and	B-X
gene	B-X
regulation	B-X
remained	B-X
unsolved	B-X
and	B-X
required	B-X
further	B-X
investigations	B-X
.	B-X

Exon2	O
Number	O
of	O
Exon	O
length	O
Number	O
of	O
Exon	O
length	O
<EOS>	B-X
High	B-X
length	B-X
and	B-X
nucleotide	B-X
polymorphisms	B-X
in	B-X
intron2	B-X
of	B-X
GH	B-X
I	B-X
gene	B-X
were	B-X
detected	B-X
in	B-X
162	B-X
individuals	B-X
,	B-X
which	B-X
were	B-X
from	B-X
seven	B-X
wild	B-X
crucian	B-X
carp	B-X
colonies	B-X
,	B-X
two	B-X
goldfish	B-X
colonies	B-X
and	B-X
one	B-X
Fangzheng	B-X
crucian	B-X
carp	B-X
colony	B-X
.	B-X
Using	B-X
denaturating	B-X
polyareylamide	B-X
gel	B-X
electrophoresis	B-X
(	B-X
DPAGE	B-X
)	B-X
and	B-X
single-strand	B-X
conformation	B-X
polymorphism	B-X
(	B-X
SSCP	B-X
)	B-X
,	B-X
seven	B-X
length	B-X
variants	B-X
and	B-X
15	B-X
haplotypes	B-X
were	B-X
identified	B-X
in	B-X
these	B-X
fishes	B-X
.	B-X
The	B-X
length	B-X
types	B-X
and	B-X
haplotypes	B-X
diversity	B-X
was	B-X
4.32	B-X
%	B-X
and	B-X
9.26	B-X
%	B-X
,	B-X
respectively	B-X
.	B-X
(	B-X
2	B-X
)	B-X
The	B-X
seven	B-X
length	B-X
variants	B-X
(	B-X
A	B-X
,	B-X
B	B-X
,	B-X
C	B-X
,	B-X
D	B-X
,	B-X
E	B-X
,	B-X
F	B-X
and	B-X
G	B-X
)	B-X
were	B-X
determined	B-X
to	B-X
be	B-X
189	B-X
,	B-X
196	B-X
,	B-X
204	B-X
,	B-X
205	B-X
,	B-X
206	B-X
,	B-X
207	B-X
and	B-X
209	B-X
bp	B-X
,	B-X
respectively	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
distributions	B-X
of	B-X
the	B-X
length	B-X
types	B-X
,	B-X
haplotypes	B-X
and	B-X
composite	B-X
genotypes	B-X
suggested	B-X
that	B-X
genetic	B-X
diversity	B-X
was	B-X
varied	B-X
in	B-X
different	B-X
colonies	B-X
.	B-X
In	B-X
the	B-X
goldfish	B-X
colonies	B-X
,	B-X
only	B-X
one	B-X
length	B-X
type	B-X
(	B-X
A	B-X
)	B-X
,	B-X
two	B-X
haplotypes	B-X
(	B-X
A1	B-X
and	B-X
A2	B-X
)	B-X
and	B-X
one	B-X
composite	B-X
genotype	B-X
(	B-X
A1A2	B-X
)	B-X
were	B-X
observed	B-X
.	B-X
Two	B-X
length	B-X
types	B-X
(	B-X
C	B-X
and	B-X
D	B-X
)	B-X
,	B-X
four	B-X
haplotypes	B-X
(	B-X
C1	B-X
,	B-X
C2	B-X
,	B-X
D2	B-X
and	B-X
D5	B-X
)	B-X
and	B-X
one	B-X
composite	B-X
genotype	B-X
(	B-X
C1C2D2D5	B-X
)	B-X
presented	B-X
in	B-X
the	B-X
Fangzheng	B-X
crucian	B-X
carp	B-X
colonies	B-X
.	B-X
The	B-X
highest	B-X
level	B-X
of	B-X
genetic	B-X
diversity	B-X
was	B-X
exhibited	B-X
in	B-X
the	B-X
seven	B-X
wild	B-X
crucian	B-X
carp	B-X
colonies	B-X
:	B-X
seven	B-X
length	B-X
types	B-X
(	B-X
A	B-X
,	B-X
B	B-X
,	B-X
C	B-X
,	B-X
D	B-X
,	B-X
E	B-X
,	B-X
F	B-X
and	B-X
G	B-X
)	B-X
,	B-X
14	B-X
haplotypes	B-X
(	B-X
A1	B-X
,	B-X
A2	B-X
,	B-X
A3	B-X
,	B-X
B	B-X
,	B-X
C1	B-X
,	B-X
C2	B-X
,	B-X
D1	B-X
,	B-X
D2	B-X
,	B-X
D3	B-X
,	B-X
D4	B-X
,	B-X
E1	B-X
,	B-X
E2	B-X
,	B-X
F	B-X
and	B-X
G	B-X
)	B-X
and	B-X
14	B-X
composite	B-X
genotypes	B-X
(	B-X
A1A2A3	B-X
,	B-X
A1A2A3B	B-X
,	B-X
A1C1C2D1D2D3	B-X
,	B-X
A1C1C2D2	B-X
,	B-X
A1C1C2D2D3	B-X
,	B-X
A1C1C2D3E2	B-X
,	B-X
BC1C2D2	B-X
,	B-X
BC1C2D3D4	B-X
,	B-X
C1C2D2	B-X
,	B-X
C1C2D2D3	B-X
,	B-X
C1C2D3D4	B-X
,	B-X
C1C2D3D4F	B-X
,	B-X
C1C2D4	B-X
,	B-X
D2E1G	B-X
)	B-X
were	B-X
shared	B-X
by	B-X
the	B-X
seven	B-X
wild	B-X
colonies	B-X
.	B-X
The	B-X
numbers	B-X
of	B-X
observed	B-X
length	B-X
types	B-X
,	B-X
haplotypes	B-X
and	B-X
genotypes	B-X
within	B-X
the	B-X
wild	B-X
colonies	B-X
ranged	B-X
from	B-X
3	B-X
to	B-X
6	B-X
,	B-X
6	B-X
to	B-X
10	B-X
and	B-X
2	B-X
to	B-X
6	B-X
,	B-X
respectively	B-X
.	B-X
Whether	B-X
the	B-X
length	B-X
and	B-X
nucleotide	B-X
polymorphisms	B-X
in	B-X
the	B-X
intron2	B-X
of	B-X
crucian	B-X
carp	B-X
GH	B-X
I	B-X
gene	B-X
were	B-X
associated	B-X
with	B-X
gene	B-X
expression	B-X
and	B-X
gene	B-X
regulation	B-X
remained	B-X
unsolved	B-X
and	B-X
required	B-X
further	B-X
investigations	B-X
.	B-X

exons	O
analyzed	O
(	O
base	O
pairs	O
)	O
exons	O
analyzed	O
(	O
base	O
pairs	O
)	O
<EOS>	B-X
The	B-X
human	B-X
HPRT	B-X
gene	B-X
contains	B-X
spans	B-X
approximately	B-X
42,000	B-X
base	B-X
pairs	B-X
in	B-X
genomic	B-X
DNA	B-X
,	B-X
has	B-X
a	B-X
mRNA	B-X
of	B-X
approximately	B-X
900	B-X
bases	B-X
and	B-X
a	B-X
protein	B-X
coding	B-X
sequence	B-X
of	B-X
657	B-X
bases	B-X
(	B-X
initiation	B-X
codon	B-X
AUG	B-X
to	B-X
termination	B-X
codon	B-X
UAA	B-X
)	B-X
.	B-X
This	B-X
coding	B-X
sequence	B-X
is	B-X
distributed	B-X
into	B-X
9	B-X
exons	B-X
ranging	B-X
from	B-X
18	B-X
(	B-X
exon	B-X
5	B-X
)	B-X
to	B-X
184	B-X
(	B-X
exon	B-X
3	B-X
)	B-X
base	B-X
pairs	B-X
.	B-X
Intron	B-X
sizes	B-X
range	B-X
from	B-X
170	B-X
(	B-X
intron	B-X
7	B-X
)	B-X
to	B-X
13,075	B-X
(	B-X
intron	B-X
1	B-X
)	B-X
base	B-X
pairs	B-X
.	B-X
In	B-X
a	B-X
database	B-X
of	B-X
human	B-X
HPRT	B-X
mutations	B-X
,	B-X
277	B-X
of	B-X
2224	B-X
(	B-X
12.5	B-X
%	B-X
)	B-X
mutations	B-X
result	B-X
in	B-X
alterations	B-X
in	B-X
splicing	B-X
of	B-X
the	B-X
mRNA	B-X
as	B-X
analyzed	B-X
by	B-X
both	B-X
reverse	B-X
transcriptase	B-X
mediated	B-X
production	B-X
of	B-X
a	B-X
cDNA	B-X
followed	B-X
by	B-X
PCR	B-X
amplification	B-X
and	B-X
cDNA	B-X
sequencing	B-X
and	B-X
by	B-X
genomic	B-X
DNA	B-X
PCR	B-X
amplification	B-X
and	B-X
sequencing	B-X
.	B-X
Mutations	B-X
in	B-X
the	B-X
3	B-X
'	B-X
splice	B-X
sequences	B-X
of	B-X
introns	B-X
1	B-X
,	B-X
3	B-X
,	B-X
7	B-X
and	B-X
8	B-X
result	B-X
in	B-X
partial	B-X
exon	B-X
exclusion	B-X
due	B-X
to	B-X
the	B-X
use	B-X
of	B-X
cryptic	B-X
acceptor	B-X
splice	B-X
sequences	B-X
within	B-X
the	B-X
exons	B-X
;	B-X
mutations	B-X
in	B-X
the	B-X
other	B-X
four	B-X
3	B-X
'	B-X
sites	B-X
result	B-X
in	B-X
simple	B-X
exon	B-X
exclusion	B-X
.	B-X
A	B-X
base	B-X
substitution	B-X
in	B-X
exon	B-X
3	B-X
(	B-X
209G	B-X
--	B-X
>	B-X
T	B-X
)	B-X
creates	B-X
a	B-X
new	B-X
5	B-X
'	B-X
(	B-X
donor	B-X
)	B-X
splice	B-X
site	B-X
which	B-X
results	B-X
in	B-X
the	B-X
exclusion	B-X
of	B-X
110	B-X
bases	B-X
of	B-X
exon	B-X
3	B-X
from	B-X
the	B-X
cDNA	B-X
.	B-X
Two	B-X
base	B-X
substitutions	B-X
in	B-X
intron	B-X
8	B-X
(	B-X
IVS8-16G	B-X
--	B-X
>	B-X
A	B-X
and	B-X
IVS8-3T	B-X
--	B-X
>	B-X
G	B-X
)	B-X
result	B-X
in	B-X
the	B-X
inclusion	B-X
of	B-X
intron	B-X
8	B-X
sequences	B-X
in	B-X
the	B-X
cDNA	B-X
due	B-X
to	B-X
the	B-X
creation	B-X
of	B-X
new	B-X
3	B-X
'	B-X
(	B-X
acceptor	B-X
)	B-X
splice	B-X
sites	B-X
.	B-X
Base	B-X
substitution	B-X
within	B-X
exons	B-X
1	B-X
,	B-X
3	B-X
,	B-X
4	B-X
,	B-X
6	B-X
and	B-X
8	B-X
also	B-X
result	B-X
in	B-X
splice	B-X
alterations	B-X
in	B-X
cDNA	B-X
.	B-X
Those	B-X
in	B-X
exons	B-X
1	B-X
and	B-X
6	B-X
are	B-X
at	B-X
the	B-X
3	B-X
'	B-X
end	B-X
of	B-X
the	B-X
exon	B-X
and	B-X
may	B-X
directly	B-X
affect	B-X
splicing	B-X
.	B-X
Those	B-X
within	B-X
exons	B-X
3	B-X
and	B-X
4	B-X
may	B-X
be	B-X
the	B-X
result	B-X
of	B-X
the	B-X
creation	B-X
of	B-X
nonsense	B-X
codons	B-X
,	B-X
while	B-X
those	B-X
in	B-X
exon	B-X
8	B-X
can	B-X
not	B-X
be	B-X
explained	B-X
by	B-X
this	B-X
mechanism	B-X
.	B-X

a	O
7	O
807	O
?	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
study	B-X
was	B-X
to	B-X
assess	B-X
whether	B-X
the	B-X
level	B-X
of	B-X
physical	B-X
activity	B-X
in	B-X
daily	B-X
life	B-X
in	B-X
previously	B-X
sedentary	B-X
adults	B-X
had	B-X
been	B-X
sustained	B-X
7	B-X
years	B-X
beyond	B-X
a	B-X
1-year	B-X
supervised	B-X
walking	B-X
program	B-X
.	B-X
One	B-X
hundred	B-X
ten	B-X
participants	B-X
(	B-X
63	B-X
females	B-X
,	B-X
57.5	B-X
Â±	B-X
8.4	B-X
years	B-X
;	B-X
47	B-X
males	B-X
,	B-X
66.4	B-X
Â±	B-X
7.9	B-X
years	B-X
)	B-X
were	B-X
recalled	B-X
and	B-X
assessed	B-X
for	B-X
physical	B-X
activity	B-X
in	B-X
daily	B-X
life	B-X
,	B-X
weight	B-X
,	B-X
body	B-X
mass	B-X
index	B-X
,	B-X
blood	B-X
pressure	B-X
,	B-X
and	B-X
walking	B-X
speed	B-X
.	B-X
In	B-X
both	B-X
groups	B-X
,	B-X
we	B-X
observed	B-X
a	B-X
significant	B-X
decrease	B-X
of	B-X
weight	B-X
(	B-X
72.0	B-X
Â±	B-X
14.0	B-X
kg	B-X
vs.	B-X
69.7	B-X
Â±	B-X
14.0	B-X
kg	B-X
in	B-X
Group	B-X
1	B-X
;	B-X
77.4	B-X
Â±	B-X
19.5	B-X
kg	B-X
vs.	B-X
75.4	B-X
Â±	B-X
18.6	B-X
kg	B-X
in	B-X
Group	B-X
2	B-X
)	B-X
and	B-X
body	B-X
mass	B-X
index	B-X
(	B-X
25.9	B-X
Â±	B-X
3.7	B-X
vs.	B-X
25.1	B-X
Â±	B-X
3.9	B-X
in	B-X
Group	B-X
1	B-X
;	B-X
27.9	B-X
Â±	B-X
5.6	B-X
vs.	B-X
27.2	B-X
Â±	B-X
5.4	B-X
in	B-X
Group	B-X
2	B-X
)	B-X
.	B-X
Group	B-X
1	B-X
showed	B-X
a	B-X
significant	B-X
increase	B-X
in	B-X
walking	B-X
speed	B-X
(	B-X
5.8	B-X
Â±	B-X
0.7	B-X
km/hr	B-X
vs.	B-X
6.2	B-X
Â±	B-X
0.8	B-X
km/hr	B-X
)	B-X
,	B-X
while	B-X
systolic	B-X
pressure	B-X
did	B-X
not	B-X
change	B-X
from	B-X
the	B-X
baseline	B-X
.	B-X

883	O
26	O
883	O
?	O
132	O
b	O
10	O
252	O
?	O

35	O
41	O
234	O
?	O

49	O
c	O
11	O
151	O
?	O
<EOS>	B-X
Lipid	B-X
management	B-X
typically	B-X
focuses	B-X
on	B-X
levels	B-X
of	B-X
low-density	B-X
lipoprotein	B-X
cholesterol	B-X
(	B-X
LDL-C	B-X
)	B-X
and	B-X
,	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
,	B-X
triglycerides	B-X
(	B-X
TG	B-X
)	B-X
.	B-X
However	B-X
,	B-X
animal	B-X
models	B-X
and	B-X
genetic	B-X
studies	B-X
suggest	B-X
that	B-X
the	B-X
atherogenic	B-X
particle	B-X
subpopulations	B-X
(	B-X
LDL	B-X
and	B-X
very-low-density	B-X
lipoprotein	B-X
[	B-X
VLDL	B-X
]	B-X
)	B-X
are	B-X
both	B-X
important	B-X
and	B-X
that	B-X
the	B-X
number	B-X
of	B-X
particles	B-X
is	B-X
more	B-X
predictive	B-X
of	B-X
cardiac	B-X
events	B-X
than	B-X
their	B-X
lipid	B-X
content	B-X
.	B-X
Upadacitinib	B-X
is	B-X
an	B-X
oral	B-X
Janus	B-X
kinase	B-X
(	B-X
JAK	B-X
)	B-X
inhibitor	B-X
with	B-X
greater	B-X
inhibitory	B-X
potency	B-X
for	B-X
JAK1	B-X
than	B-X
JAK2	B-X
,	B-X
JAK3	B-X
,	B-X
and	B-X
tyrosine	B-X
kinase	B-X
2	B-X
.	B-X
We	B-X
aimed	B-X
to	B-X
assess	B-X
the	B-X
efficacy	B-X
and	B-X
safety	B-X
of	B-X
upadacitinib	B-X
compared	B-X
with	B-X
placebo	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
moderate-to-severe	B-X
atopic	B-X
dermatitis	B-X
.	B-X

25	O
48	O
182	O
?	O
<EOS>	B-X
The	B-X
respiratory	B-X
quotient	B-X
of	B-X
Gammarus	B-X
pulex	B-X
L	B-X
.	B-X

42	O
d	O
6	O
252	O
?	O
<EOS>	B-X
The	B-X
development	B-X
dataset	B-X
comprised	B-X
94,075	B-X
case	B-X
subjects	B-X
and	B-X
75,017	B-X
control	B-X
subjects	B-X
of	B-X
European	B-X
ancestry	B-X
from	B-X
69	B-X
studies	B-X
,	B-X
divided	B-X
into	B-X
training	B-X
and	B-X
validation	B-X
sets	B-X
.	B-X
The	B-X
best	B-X
performing	B-X
PRSs	B-X
were	B-X
validated	B-X
in	B-X
an	B-X
independent	B-X
test	B-X
set	B-X
comprising	B-X
11,428	B-X
case	B-X
subjects	B-X
and	B-X
18,323	B-X
control	B-X
subjects	B-X
from	B-X
10	B-X
prospective	B-X
studies	B-X
and	B-X
190,040	B-X
women	B-X
from	B-X
UK	B-X
Biobank	B-X
(	B-X
3,215	B-X
incident	B-X
breast	B-X
cancers	B-X
)	B-X
.	B-X
For	B-X
the	B-X
best	B-X
PRSs	B-X
(	B-X
313	B-X
SNPs	B-X
)	B-X
,	B-X
the	B-X
odds	B-X
ratio	B-X
for	B-X
overall	B-X
disease	B-X
per	B-X
1	B-X
standard	B-X
deviation	B-X
in	B-X
ten	B-X
prospective	B-X
studies	B-X
was	B-X
1.61	B-X
(	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
1.57-1.65	B-X
)	B-X
with	B-X
area	B-X
under	B-X
receiver-operator	B-X
curve	B-X
(	B-X
AUC	B-X
)	B-X
=	B-X
0.630	B-X
(	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
0.628-0.651	B-X
)	B-X
.	B-X
The	B-X
lifetime	B-X
risk	B-X
of	B-X
overall	B-X
breast	B-X
cancer	B-X
in	B-X
the	B-X
top	B-X
centile	B-X
of	B-X
the	B-X
PRSs	B-X
was	B-X
32.6	B-X
%	B-X
.	B-X
Compared	B-X
with	B-X
women	B-X
in	B-X
the	B-X
middle	B-X
quintile	B-X
,	B-X
those	B-X
in	B-X
the	B-X
highest	B-X
1	B-X
%	B-X
of	B-X
risk	B-X
had	B-X
4.37-	B-X
and	B-X
2.78-fold	B-X
risks	B-X
,	B-X
and	B-X
those	B-X
in	B-X
the	B-X
lowest	B-X
1	B-X
%	B-X
of	B-X
risk	B-X
had	B-X
0.16-	B-X
and	B-X
0.27-fold	B-X
risks	B-X
,	B-X
of	B-X
developing	B-X
ER-positive	B-X
and	B-X
ER-negative	B-X
disease	B-X
,	B-X
respectively	B-X
.	B-X

60	O
44	O
234	O
?	O

62	O
e	O
5	O
126	O
?	O
<EOS>	B-X
The	B-X
clinical	B-X
effect	B-X
of	B-X
routine	B-X
oxygen	B-X
therapy	B-X
in	B-X
patients	B-X
with	B-X
suspected	B-X
acute	B-X
myocardial	B-X
infarction	B-X
who	B-X
do	B-X
not	B-X
have	B-X
hypoxemia	B-X
at	B-X
baseline	B-X
is	B-X
uncertain	B-X
.	B-X
Glioblastoma	B-X
(	B-X
GBM	B-X
)	B-X
is	B-X
the	B-X
most	B-X
commonly	B-X
occurring	B-X
primary	B-X
malignant	B-X
brain	B-X
tumor	B-X
,	B-X
and	B-X
it	B-X
carries	B-X
a	B-X
dismal	B-X
prognosis	B-X
.	B-X
Focusing	B-X
on	B-X
the	B-X
tumor	B-X
microenvironment	B-X
may	B-X
provide	B-X
new	B-X
insights	B-X
into	B-X
pathogenesis	B-X
,	B-X
but	B-X
no	B-X
clinical	B-X
tools	B-X
are	B-X
available	B-X
to	B-X
do	B-X
this	B-X
.	B-X
We	B-X
hypothesized	B-X
that	B-X
the	B-X
infiltration	B-X
of	B-X
different	B-X
leukocyte	B-X
populations	B-X
in	B-X
the	B-X
tumoral	B-X
and	B-X
peritumoral	B-X
brain	B-X
tissues	B-X
may	B-X
be	B-X
measured	B-X
by	B-X
magnetic	B-X
resonance	B-X
imaging	B-X
(	B-X
MRI	B-X
)	B-X
.	B-X

45	O
37	O
129	O
?	O
<EOS>	B-X
Automatic	B-X
Edman	B-X
degradation	B-X
has	B-X
been	B-X
used	B-X
to	B-X
determine	B-X
34	B-X
of	B-X
the	B-X
amino-terminal	B-X
37	B-X
amino	B-X
acid	B-X
residues	B-X
.	B-X

47	O
f	O
5	O
126	O
?	O
<EOS>	B-X
Alectinib	B-X
,	B-X
a	B-X
highly	B-X
selective	B-X
inhibitor	B-X
of	B-X
anaplastic	B-X
lymphoma	B-X
kinase	B-X
(	B-X
ALK	B-X
)	B-X
,	B-X
has	B-X
shown	B-X
systemic	B-X
and	B-X
central	B-X
nervous	B-X
system	B-X
(	B-X
CNS	B-X
)	B-X
efficacy	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
ALK-positive	B-X
non-small-cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
.	B-X
Elexacaftor-tezacaftor-ivacaftor	B-X
is	B-X
a	B-X
small-molecule	B-X
cystic	B-X
fibrosis	B-X
transmembrane	B-X
conductance	B-X
regulator	B-X
(	B-X
CFTR	B-X
)	B-X
modulator	B-X
regimen	B-X
shown	B-X
to	B-X
be	B-X
efficacious	B-X
in	B-X
patients	B-X
with	B-X
at	B-X
least	B-X
one	B-X
At	B-X
present	B-X
,	B-X
no	B-X
approved	B-X
pharmacotherapies	B-X
are	B-X
available	B-X
for	B-X
unclassifiable	B-X
interstitial	B-X
lung	B-X
disease	B-X
(	B-X
ILD	B-X
)	B-X
,	B-X
which	B-X
is	B-X
characterised	B-X
by	B-X
progressive	B-X
fibrosis	B-X
of	B-X
the	B-X
lung	B-X
.	B-X
We	B-X
aimed	B-X
to	B-X
assess	B-X
the	B-X
efficacy	B-X
and	B-X
safety	B-X
of	B-X
pirfenidone	B-X
in	B-X
patients	B-X
with	B-X
progressive	B-X
fibrosing	B-X
unclassifiable	B-X
ILD	B-X
.	B-X

38	O
35	O
104	O
?	O

41	O
9	O
5	O
176	O
?	O
<EOS>	B-X
Atomic	B-X
models	B-X
for	B-X
the	B-X
polypeptide	B-X
backbones	B-X
of	B-X
myohemerythrin	B-X
and	B-X
hemerythrin	B-X
.	B-X
The	B-X
auditory	B-X
system	B-X
of	B-X
the	B-X
goldfish	B-X
(	B-X
Carassius	B-X
auratus	B-X
)	B-X
:	B-X
effects	B-X
of	B-X
intense	B-X
acoustic	B-X
stimulation	B-X
.	B-X
Radiochemical	B-X
assay	B-X
of	B-X
glutathione	B-X
S-epoxide	B-X
transferase	B-X
and	B-X
its	B-X
enhancement	B-X
by	B-X
phenobarbital	B-X
in	B-X
rat	B-X
liver	B-X
in	B-X
vivo	B-X
.	B-X
Increasing	B-X
concentrations	B-X
of	B-X
chloride	B-X
were	B-X
found	B-X
to	B-X
increase	B-X
the	B-X
resolution	B-X
between	B-X
two	B-X
visible	B-X
absorbance	B-X
spectral	B-X
transitions	B-X
associated	B-X
with	B-X
acidification	B-X
of	B-X
ferricytochrome	B-X
c.	B-X
Analysis	B-X
of	B-X
a	B-X
variety	B-X
of	B-X
spectral	B-X
and	B-X
viscosity	B-X
measurements	B-X
indicates	B-X
that	B-X
protonation	B-X
of	B-X
a	B-X
single	B-X
group	B-X
having	B-X
an	B-X
apparent	B-X
pK	B-X
of	B-X
2.1	B-X
+/-	B-X
0.2	B-X
and	B-X
an	B-X
intrinsic	B-X
pK	B-X
of	B-X
about	B-X
5.3	B-X
displaces	B-X
the	B-X
methionine	B-X
ligand	B-X
without	B-X
significantly	B-X
perturbing	B-X
the	B-X
native	B-X
globular	B-X
conformation	B-X
.	B-X
Such	B-X
ligation	B-X
stabilizes	B-X
a	B-X
globular	B-X
conformation	B-X
of	B-X
ferricytochrome	B-X
c	B-X
at	B-X
pH	B-X
0.0	B-X
and	B-X
25	B-X
degrees	B-X
.	B-X

48	O
40	O
182	O
?	O
<EOS>	B-X
The	B-X
respiratory	B-X
quotient	B-X
of	B-X
Gammarus	B-X
pulex	B-X
L	B-X
.	B-X

54	O
h	O
5	O
100	O
?	O
<EOS>	B-X
In	B-X
the	B-X
title	B-X
compound	B-X
,	B-X
C	B-X
(	B-X
13	B-X
)	B-X
H	B-X
(	B-X
13	B-X
)	B-X
NO	B-X
(	B-X
3	B-X
)	B-X
S	B-X
,	B-X
the	B-X
benzene	B-X
ring	B-X
of	B-X
the	B-X
benzene-sulfonamide	B-X
moiety	B-X
is	B-X
disordered	B-X
with	B-X
an	B-X
occupancy	B-X
ratio	B-X
of	B-X
0.56	B-X
(	B-X
3	B-X
)	B-X
:0.44	B-X
(	B-X
3	B-X
)	B-X
,	B-X
the	B-X
disorder	B-X
components	B-X
being	B-X
twisted	B-X
at	B-X
and	B-X
angle	B-X
of	B-X
21	B-X
(	B-X
1	B-X
)	B-X
Â°	B-X
to	B-X
each	B-X
other	B-X
.	B-X
The	B-X
meth-oxy-benzene	B-X
group	B-X
is	B-X
roughly	B-X
planar	B-X
(	B-X
r.m.s	B-X
.	B-X
deviation	B-X
=	B-X
0.0144	B-X
Ã	B-X
)	B-X
and	B-X
the	B-X
amide	B-X
N	B-X
atom	B-X
is	B-X
displaced	B-X
from	B-X
this	B-X
plane	B-X
by	B-X
0.090	B-X
(	B-X
6	B-X
)	B-X
Ã	B-X
.	B-X
The	B-X
dihedral	B-X
angles	B-X
between	B-X
the	B-X
meth-oxy-benzene	B-X
group	B-X
and	B-X
the	B-X
major	B-X
and	B-X
minor	B-X
occupancy	B-X
components	B-X
of	B-X
the	B-X
disordered	B-X
benzene	B-X
ring	B-X
are	B-X
54.6	B-X
(	B-X
4	B-X
)	B-X
and	B-X
62.9	B-X
(	B-X
5	B-X
)	B-X
Â°	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
the	B-X
crystal	B-X
,	B-X
infinite	B-X
polymeric	B-X
chains	B-X
are	B-X
formed	B-X
along	B-X
[	B-X
100	B-X
]	B-X
due	B-X
to	B-X
inter-molecular	B-X
N-Hâ¯O	B-X
hydrogen	B-X
bonding	B-X
.	B-X
Weak	B-X
C-Hâ¯Ï	B-X
inter-actions	B-X
are	B-X
also	B-X
present	B-X
in	B-X
the	B-X
crystal	B-X
.	B-X

43	O
47	O
104	O
?	O

31	O

7	O
100	O
?	O

35	O
50	O
104	O
?	O

28	O
j	O
7	O
126	O
?	O
<EOS>	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
breast	B-X
cancer	B-X
death	B-X
rate	B-X
continues	B-X
to	B-X
decline	B-X
,	B-X
dropping	B-X
40	B-X
%	B-X
from	B-X
1989	B-X
to	B-X
2017	B-X
and	B-X
translating	B-X
to	B-X
375,900	B-X
breast	B-X
cancer	B-X
deaths	B-X
averted	B-X
.	B-X
Notably	B-X
,	B-X
the	B-X
pace	B-X
of	B-X
the	B-X
decline	B-X
has	B-X
slowed	B-X
from	B-X
an	B-X
annual	B-X
decrease	B-X
of	B-X
1.9	B-X
%	B-X
during	B-X
1998	B-X
through	B-X
2011	B-X
to	B-X
1.3	B-X
%	B-X
during	B-X
2011	B-X
through	B-X
2017	B-X
,	B-X
largely	B-X
driven	B-X
by	B-X
the	B-X
trend	B-X
in	B-X
white	B-X
women	B-X
.	B-X
Nevertheless	B-X
,	B-X
the	B-X
death	B-X
rate	B-X
remains	B-X
40	B-X
%	B-X
higher	B-X
in	B-X
blacks	B-X
(	B-X
28.4	B-X
vs	B-X
20.3	B-X
deaths	B-X
per	B-X
100,000	B-X
)	B-X
despite	B-X
a	B-X
lower	B-X
incidence	B-X
rate	B-X
(	B-X
126.7	B-X
vs	B-X
130.8	B-X
)	B-X
;	B-X
this	B-X
disparity	B-X
is	B-X
magnified	B-X
among	B-X
black	B-X
women	B-X
aged	B-X
<	B-X
50	B-X
years	B-X
,	B-X
who	B-X
have	B-X
a	B-X
death	B-X
rate	B-X
double	B-X
that	B-X
of	B-X
whites	B-X
.	B-X
In	B-X
the	B-X
most	B-X
recent	B-X
5-year	B-X
period	B-X
(	B-X
2013-2017	B-X
)	B-X
,	B-X
the	B-X
death	B-X
rate	B-X
declined	B-X
in	B-X
Hispanics	B-X
(	B-X
2.1	B-X
%	B-X
per	B-X
year	B-X
)	B-X
,	B-X
blacks	B-X
(	B-X
1.5	B-X
%	B-X
)	B-X
,	B-X
whites	B-X
(	B-X
1.0	B-X
%	B-X
)	B-X
,	B-X
and	B-X
Asians/Pacific	B-X
Islanders	B-X
(	B-X
0.8	B-X
%	B-X
)	B-X
but	B-X
was	B-X
stable	B-X
in	B-X
American	B-X
Indians/Alaska	B-X
Natives	B-X
.	B-X
Breast	B-X
cancer	B-X
was	B-X
the	B-X
leading	B-X
cause	B-X
of	B-X
cancer	B-X
death	B-X
in	B-X
women	B-X
(	B-X
surpassing	B-X
lung	B-X
cancer	B-X
)	B-X
in	B-X
four	B-X
Southern	B-X
and	B-X
two	B-X
Midwestern	B-X
states	B-X
among	B-X
blacks	B-X
and	B-X
in	B-X
Utah	B-X
among	B-X
whites	B-X
during	B-X
2016-2017	B-X
.	B-X

48	O
45	O
130	O
?	O
<EOS>	B-X
Uptake	B-X
of	B-X
radiolabeled	B-X
glucose	B-X
analogues	B-X
by	B-X
organotypic	B-X
pia	B-X
arachnoid	B-X
cultures	B-X
.	B-X

47	O
k	O
8	O
50	O
?	O
<EOS>	B-X
Health	B-X
care	B-X
workers	B-X
(	B-X
HCW	B-X
)	B-X
are	B-X
at	B-X
high	B-X
risk	B-X
of	B-X
developing	B-X
physical/mental	B-X
health	B-X
outcomes	B-X
related	B-X
to	B-X
coronavirus	B-X
syndromes	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
a	B-X
crystal	B-X
phase	B-X
transition	B-X
and	B-X
polyhedron	B-X
transformation	B-X
strategy	B-X
The	B-X
greatest	B-X
number	B-X
and	B-X
biomass	B-X
of	B-X
earthworms	B-X
was	B-X
found	B-X
in	B-X
the	B-X
variant	B-X
with	B-X
25	B-X
%	B-X
malt	B-X
house	B-X
sludge	B-X
+	B-X
75	B-X
%	B-X
straw	B-X
pellets	B-X
(	B-X
on	B-X
average	B-X
of	B-X
all	B-X
layers	B-X
:	B-X
320	B-X
earthworms/kg	B-X
and	B-X
35	B-X
g/kg	B-X
,	B-X
respectively	B-X
)	B-X
,	B-X
followed	B-X
by	B-X
a	B-X
variant	B-X
with	B-X
50	B-X
%	B-X
malt	B-X
house	B-X
sludge	B-X
+	B-X
50	B-X
%	B-X
straw	B-X
pellets	B-X
(	B-X
on	B-X
average	B-X
of	B-X
all	B-X
layers	B-X
:	B-X
47	B-X
earthworms/kg	B-X
and	B-X
13	B-X
g/kg	B-X
,	B-X
respectively	B-X
)	B-X
,	B-X
indicating	B-X
that	B-X
a	B-X
minimum	B-X
of	B-X
50	B-X
%	B-X
(	B-X
vol	B-X
.	B-X
)	B-X
On	B-X
the	B-X
contrary	B-X
,	B-X
the	B-X
oldest	B-X
bottom	B-X
layers	B-X
(	B-X
final	B-X
vermicomposts	B-X
)	B-X
after	B-X
180	B-X
days	B-X
of	B-X
vermicomposting	B-X
were	B-X
characterized	B-X
by	B-X
maturity	B-X
,	B-X
indicating	B-X
lesser	B-X
contents	B-X
of	B-X
microorganisms	B-X
and	B-X
enzyme	B-X
activity	B-X
.	B-X
These	B-X
vermicomposts	B-X
had	B-X
favorable	B-X
agrochemical	B-X
properties	B-X
(	B-X
pH	B-X
=	B-X
7.8	B-X
,	B-X
EC	B-X
=	B-X
1.2	B-X
mS	B-X
cm	B-X

48	O
51	O
52	O
?	O

39	O
1	O
9	O
75	O
?	O
<EOS>	B-X
The	B-X
phosphorylated	B-X
form	B-X
of	B-X
liver	B-X
glycogen	B-X
phosphorylase	B-X
(	B-X
alpha-1,4-glucan	B-X
:	B-X
orthophosphate	B-X
alpha-glucosyl-transferase	B-X
,	B-X
EC	B-X
2.4.1.1	B-X
)	B-X
(	B-X
phosphorylase	B-X
a	B-X
)	B-X
is	B-X
active	B-X
and	B-X
easily	B-X
measured	B-X
while	B-X
the	B-X
dephosphorylated	B-X
form	B-X
(	B-X
phosphorylase	B-X
b	B-X
)	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
the	B-X
muscle	B-X
enzyme	B-X
,	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
be	B-X
essentially	B-X
inactive	B-X
even	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
AMP	B-X
.	B-X
Substrate	B-X
binding	B-X
to	B-X
phosphorylase	B-X
b	B-X
was	B-X
poor	B-X
(	B-X
KM	B-X
glycogen	B-X
=	B-X
2.5	B-X
mM	B-X
,	B-X
glucose-1-P	B-X
=	B-X
250	B-X
mM	B-X
)	B-X
compared	B-X
to	B-X
phosphorylase	B-X
a	B-X
(	B-X
KM	B-X
glycogen	B-X
=	B-X
1.8	B-X
mM	B-X
,	B-X
KM	B-X
glucose-1-P	B-X
=	B-X
0.7	B-X
mM	B-X
)	B-X
.	B-X
However	B-X
,	B-X
AMP	B-X
lowered	B-X
the	B-X
KM	B-X
for	B-X
glucose-1-P	B-X
to	B-X
80	B-X
mM	B-X
for	B-X
purified	B-X
phosphorylase	B-X
b	B-X
and	B-X
to	B-X
60	B-X
mM	B-X
for	B-X
the	B-X
enzyme	B-X
in	B-X
crude	B-X
extract	B-X
(	B-X
Ka	B-X
=	B-X
0.5	B-X
mM	B-X
)	B-X
.	B-X
Using	B-X
appropriate	B-X
substrate	B-X
,	B-X
buffer	B-X
and	B-X
AMP	B-X
concentrations	B-X
,	B-X
assay	B-X
conditions	B-X
have	B-X
been	B-X
developed	B-X
which	B-X
allow	B-X
determination	B-X
of	B-X
phosphorylase	B-X
a	B-X
and	B-X
90	B-X
%	B-X
of	B-X
the	B-X
phosphorylase	B-X
b	B-X
activity	B-X
in	B-X
liver	B-X
extracts	B-X
.	B-X

10	O
60	O
52	O
?	O
<EOS>	B-X
Digitoxin	B-X
metabolism	B-X
by	B-X
rat	B-X
liver	B-X
microsomes	B-X
.	B-X
At	B-X
20	B-X
degrees	B-X
C	B-X
the	B-X
rate	B-X
constant	B-X
for	B-X
the	B-X
reaction	B-X
at	B-X
pH	B-X
4.7	B-X
to	B-X
6.7	B-X
is	B-X
1.4-10	B-X
(	B-X
6	B-X
)	B-X
M-1	B-X
.	B-X
The	B-X
dependence	B-X
of	B-X
the	B-X
rate	B-X
constant	B-X
on	B-X
pH	B-X
can	B-X
be	B-X
explained	B-X
if	B-X
cytochrome	B-X
c	B-X
has	B-X
pKs	B-X
of	B-X
7.45	B-X
and	B-X
9.2	B-X
,	B-X
and	B-X
O2-	B-X
reacts	B-X
with	B-X
the	B-X
form	B-X
present	B-X
below	B-X
pH	B-X
7.45	B-X
with	B-X
k	B-X
=	B-X
1.4-10	B-X
(	B-X
6	B-X
)	B-X
M-1	B-X
-	B-X
S-1	B-X
,	B-X
the	B-X
form	B-X
above	B-X
pH	B-X
7.45	B-X
with	B-X
k	B-X
=	B-X
3.0-	B-X
10	B-X
(	B-X
5	B-X
)	B-X
M-1	B-X
-	B-X
S-1	B-X
,	B-X
and	B-X
the	B-X
form	B-X
present	B-X
above	B-X
pH	B-X
9.2	B-X
with	B-X
k	B-X
=	B-X
0	B-X
.	B-X
No	B-X
reduction	B-X
of	B-X
ferricytochrome	B-X
c	B-X
by	B-X
HO2	B-X
radicals	B-X
could	B-X
be	B-X
demonstrated	B-X
at	B-X
pH	B-X
1.2-6.2	B-X
but	B-X
at	B-X
pH	B-X
5.3	B-X
,	B-X
HO2	B-X
radicals	B-X
oxidize	B-X
ferrocytochrome	B-X
c	B-X
with	B-X
a	B-X
rate	B-X
constant	B-X
of	B-X
about	B-X
5-10	B-X
(	B-X
5	B-X
)	B-X
-5-10	B-X
(	B-X
6	B-X
)	B-X
M-1	B-X
-	B-X
S-1	B-X
.	B-X

44	O
m	O
6	O
126	O
?	O
<EOS>	B-X
The	B-X
median	B-X
fasting	B-X
plasma	B-X
glucose	B-X
and	B-X
HbA1c	B-X
levels	B-X
were	B-X
147	B-X
(	B-X
interquartile	B-X
range	B-X
126-178	B-X
)	B-X
mg/dL	B-X
and	B-X
7.5	B-X
(	B-X
6.9-8.4	B-X
)	B-X
%	B-X
,	B-X
respectively	B-X
.	B-X
deviation	B-X
=	B-X
0.0107	B-X
Ã	B-X
)	B-X
makes	B-X
dihedral	B-X
angles	B-X
of	B-X
28.18	B-X
(	B-X
14	B-X
)	B-X
,	B-X
63.76	B-X
(	B-X
14	B-X
)	B-X
and	B-X
77.01	B-X
(	B-X
18	B-X
)	B-X
Â°	B-X
,	B-X
respectively	B-X
,	B-X
with	B-X
the	B-X
trimeth-oxy-	B-X
,	B-X
bromo-	B-X
,	B-X
and	B-X
difluoro-substituted	B-X
benzene	B-X
rings	B-X
.	B-X
Data	B-X
were	B-X
collected	B-X
from	B-X
the	B-X
preoperative	B-X
and	B-X
postoperative	B-X
follow-up	B-X
visits	B-X
at	B-X
1	B-X
,	B-X
3	B-X
,	B-X
6	B-X
,	B-X
and	B-X
12	B-X
mo	B-X
.	B-X
The	B-X
study	B-X
population	B-X
consists	B-X
of	B-X
694	B-X
hypertensive	B-X
and	B-X
176	B-X
normotensive	B-X
patients	B-X
.	B-X
From	B-X
the	B-X
baseline	B-X
to	B-X
12	B-X
mo	B-X
after	B-X
LSG	B-X
,	B-X
(	B-X
1	B-X
)	B-X
mean	B-X
body	B-X
weight/body	B-X
mass	B-X
index	B-X
decreased	B-X
from	B-X
123	B-X
kg/44	B-X
kg/m	B-X

43	O
51	O
182	O
?	O
<EOS>	B-X
The	B-X
respiratory	B-X
quotient	B-X
of	B-X
Gammarus	B-X
pulex	B-X
L	B-X
.	B-X

54	O
n	O
4	O
100	O
?	O
<EOS>	B-X
In	B-X
the	B-X
title	B-X
compound	B-X
,	B-X
C	B-X
(	B-X
13	B-X
)	B-X
H	B-X
(	B-X
13	B-X
)	B-X
NO	B-X
(	B-X
3	B-X
)	B-X
S	B-X
,	B-X
the	B-X
benzene	B-X
ring	B-X
of	B-X
the	B-X
benzene-sulfonamide	B-X
moiety	B-X
is	B-X
disordered	B-X
with	B-X
an	B-X
occupancy	B-X
ratio	B-X
of	B-X
0.56	B-X
(	B-X
3	B-X
)	B-X
:0.44	B-X
(	B-X
3	B-X
)	B-X
,	B-X
the	B-X
disorder	B-X
components	B-X
being	B-X
twisted	B-X
at	B-X
and	B-X
angle	B-X
of	B-X
21	B-X
(	B-X
1	B-X
)	B-X
Â°	B-X
to	B-X
each	B-X
other	B-X
.	B-X
The	B-X
meth-oxy-benzene	B-X
group	B-X
is	B-X
roughly	B-X
planar	B-X
(	B-X
r.m.s	B-X
.	B-X
deviation	B-X
=	B-X
0.0144	B-X
Ã	B-X
)	B-X
and	B-X
the	B-X
amide	B-X
N	B-X
atom	B-X
is	B-X
displaced	B-X
from	B-X
this	B-X
plane	B-X
by	B-X
0.090	B-X
(	B-X
6	B-X
)	B-X
Ã	B-X
.	B-X
The	B-X
dihedral	B-X
angles	B-X
between	B-X
the	B-X
meth-oxy-benzene	B-X
group	B-X
and	B-X
the	B-X
major	B-X
and	B-X
minor	B-X
occupancy	B-X
components	B-X
of	B-X
the	B-X
disordered	B-X
benzene	B-X
ring	B-X
are	B-X
54.6	B-X
(	B-X
4	B-X
)	B-X
and	B-X
62.9	B-X
(	B-X
5	B-X
)	B-X
Â°	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
the	B-X
crystal	B-X
,	B-X
infinite	B-X
polymeric	B-X
chains	B-X
are	B-X
formed	B-X
along	B-X
[	B-X
100	B-X
]	B-X
due	B-X
to	B-X
inter-molecular	B-X
N-Hâ¯O	B-X
hydrogen	B-X
bonding	B-X
.	B-X
Weak	B-X
C-Hâ¯Ï	B-X
inter-actions	B-X
are	B-X
also	B-X
present	B-X
in	B-X
the	B-X
crystal	B-X
.	B-X

45	O
53	O
52	O
?	O

42	O
o	O
3	O
<	O
504	O
50	O
78	O
?	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
four	B-X
sorghum	B-X
grain	B-X
varieties	B-X
,	B-X
SESO	B-X
1	B-X
,	B-X
SESO	B-X
3	B-X
,	B-X
Participants	B-X
were	B-X
303	B-X
African	B-X
American	B-X
and	B-X
Caucasian	B-X
women	B-X
(	B-X
42-52	B-X
years	B-X
at	B-X
baseline	B-X
)	B-X
recruited	B-X
into	B-X
the	B-X
Study	B-X
of	B-X
Women	B-X
's	B-X
Health	B-X
Across	B-X
the	B-X
Nation	B-X
(	B-X
SWAN	B-X
)	B-X
and	B-X
the	B-X
Women	B-X
's	B-X
Mental	B-X
Health	B-X
Study	B-X
(	B-X
MHS	B-X
)	B-X
in	B-X
Pittsburgh	B-X
.	B-X
The	B-X
odds	B-X
of	B-X
experiencing	B-X
major	B-X
depression	B-X
during	B-X
the	B-X
study	B-X
were	B-X
three	B-X
times	B-X
greater	B-X
for	B-X
those	B-X
with	B-X
a	B-X
family	B-X
history	B-X
than	B-X
for	B-X
those	B-X
without	B-X
a	B-X
family	B-X
history	B-X
(	B-X
OR	B-X
=	B-X
3.22	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
=	B-X
1.95-5.31	B-X
)	B-X
.	B-X
Family	B-X
history	B-X
predicted	B-X
depression	B-X
(	B-X
OR	B-X
=	B-X
2.67	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
=	B-X
1.50-4.78	B-X
)	B-X
after	B-X
adjusting	B-X
for	B-X
lifetime	B-X
history	B-X
of	B-X
depression	B-X
,	B-X
age	B-X
,	B-X
trait	B-X
anxiety	B-X
,	B-X
chronic	B-X
medical	B-X
conditions	B-X
,	B-X
and	B-X
stressful	B-X
life	B-X
events	B-X
.	B-X

36	O
p	O
2	O
126	O
?	O
<EOS>	B-X
In	B-X
observational	B-X
studies	B-X
,	B-X
testosterone	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
some	B-X
types	B-X
of	B-X
cancers	B-X
.	B-X
However	B-X
,	B-X
the	B-X
direction	B-X
and	B-X
magnitude	B-X
of	B-X
the	B-X
causal	B-X
association	B-X
between	B-X
testosterone	B-X
and	B-X
different	B-X
types	B-X
of	B-X
cancer	B-X
remain	B-X
unclear	B-X
.	B-X
Current	B-X
clinical	B-X
guidelines	B-X
by	B-X
the	B-X
American	B-X
Academy	B-X
of	B-X
Pediatrics	B-X
recommends	B-X
adenotonsillectomy	B-X
(	B-X
T	B-X
&	B-X
A	B-X
)	B-X
as	B-X
the	B-X
first-line	B-X
treatment	B-X
for	B-X
pediatric	B-X
OSA	B-X
.	B-X
However	B-X
,	B-X
obese	B-X
children	B-X
experience	B-X
a	B-X
decreased	B-X
incidence	B-X
of	B-X
cure	B-X
from	B-X
T	B-X
&	B-X
A	B-X
compared	B-X
to	B-X
non-obese	B-X
children	B-X
,	B-X
with	B-X
obesity	B-X
increasing	B-X
risk	B-X
of	B-X
residual	B-X
post-operative	B-X
OSA	B-X
by	B-X
up	B-X
to	B-X
3.7-fold	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
how	B-X
age	B-X
effects	B-X
the	B-X
post-operative	B-X
outcome	B-X
in	B-X
obese	B-X
children	B-X
with	B-X
OSA	B-X
.	B-X

71	O
47	O
104	O
?	O

36	O
q5	O
-	O
_	O
33	O
130	O
?	O
47	O
r5	O
r	O
6	O
78	O
?	O
36	O

SpC3	O
was	O
hybridized	O
to	O
sheep	B-Species
a2	O
mRNA	O
as	O
described	O
in	O
M4aterials	O
and	O

Methods	O
;	O
exon	O
lengths	O
were	O
determined	O
by	O
comparison	O
with	O
pBR322	O
DNA	O
lengths	O
.	O
<EOS>	B-X
Methods	B-X
to	B-X
calculate	B-X
the	B-X
sample	B-X
size	B-X
are	B-X
explained	B-X
in	B-X
statistical	B-X
textbooks	B-X
,	B-X
but	B-X
because	B-X
there	B-X
are	B-X
many	B-X
different	B-X
formulas	B-X
available	B-X
,	B-X
it	B-X
can	B-X
be	B-X
difficult	B-X
for	B-X
investigators	B-X
to	B-X
decide	B-X
which	B-X
method	B-X
to	B-X
use	B-X
.	B-X

2	O
Exons	O
are	O
designated	O
sequentially	O
3	O
'	O
to	O
5	O
'	O
.	O

3	O
All	O
data	O
is	O
presented	O
as	O
mean	O
?	O
<EOS>	B-X
Conjunctival	B-X
and	B-X
Corneal	B-X
Fibrous	B-X
Histiocytoma	B-X
:	B-X
Brief	B-X
review	B-X
.	B-X
The	B-X
reported	B-X
prevalence	B-X
of	B-X
voice	B-X
disorders	B-X
in	B-X
the	B-X
pediatric	B-X
population	B-X
varies	B-X
widely	B-X
between	B-X
studies	B-X
,	B-X
ranging	B-X
from	B-X
3.9	B-X
%	B-X
to	B-X
23	B-X
%	B-X
.	B-X
In	B-X
all	B-X
,	B-X
272	B-X
(	B-X
59.3	B-X
%	B-X
)	B-X
were	B-X
male	B-X
and	B-X
187	B-X
(	B-X
40.7	B-X
%	B-X
)	B-X
were	B-X
female	B-X
.	B-X
CAPE-V	B-X
data	B-X
were	B-X
available	B-X
for	B-X
439	B-X
patients	B-X
,	B-X
and	B-X
pVHI	B-X
data	B-X
were	B-X
available	B-X
for	B-X
109	B-X
patients	B-X
.	B-X
The	B-X
mean	B-X
CAPE-V	B-X
Overall	B-X
Severity	B-X
score	B-X
was	B-X
38.2	B-X
.	B-X
The	B-X
mean	B-X
total	B-X
pVHI	B-X
score	B-X
was	B-X
25.4	B-X
.	B-X
Males	B-X
had	B-X
higher	B-X
CAPE-V	B-X
Overall	B-X
Severity	B-X
(	B-X
40.0	B-X
vs.	B-X
35.4	B-X
)	B-X
,	B-X
Roughness	B-X
(	B-X
32.2	B-X
vs.	B-X
27.6	B-X
)	B-X
,	B-X
and	B-X
Strain	B-X
scores	B-X
(	B-X
37.2	B-X
vs.	B-X
32.4	B-X
)	B-X
than	B-X
females	B-X
.	B-X
In	B-X
all	B-X
,	B-X
283	B-X
patients	B-X
self-reported	B-X
a	B-X
length	B-X
of	B-X
symptoms	B-X
prior	B-X
to	B-X
evaluation	B-X
.	B-X
Overall	B-X
,	B-X
310	B-X
patients	B-X
(	B-X
67.5	B-X
%	B-X
)	B-X
were	B-X
recommended	B-X
intervention	B-X
for	B-X
their	B-X
dysphonia	B-X
.	B-X
Males	B-X
were	B-X
more	B-X
likely	B-X
than	B-X
females	B-X
to	B-X
present	B-X
with	B-X
dysphonia	B-X
and	B-X
presented	B-X
with	B-X
more	B-X
severe	B-X
perceptual	B-X
dysphonia	B-X
scores	B-X
on	B-X
average	B-X
.	B-X
Referrals	B-X
to	B-X
a	B-X
pediatric	B-X
voice	B-X
clinic	B-X
should	B-X
be	B-X
considered	B-X
in	B-X
patients	B-X
with	B-X
a	B-X
dysphonia	B-X
history	B-X
lasting	B-X
greater	B-X
than	B-X
3	B-X
months	B-X
and	B-X
in	B-X
patients	B-X
with	B-X
more	B-X
severe	B-X
symptoms	B-X
.	B-X

standard	O
deviation	O
.	O
<EOS>	B-X
The	B-X
relative	B-X
expression	B-X
ratio	B-X
is	B-X
calculated	B-X
only	B-X
from	B-X
the	B-X
real-time	B-X
PCR	B-X
efficiencies	B-X
and	B-X
the	B-X
crossing	B-X
point	B-X
deviation	B-X
of	B-X
an	B-X
unknown	B-X
sample	B-X
versus	B-X
a	B-X
control	B-X
.	B-X
Control	B-X
levels	B-X
were	B-X
included	B-X
in	B-X
the	B-X
model	B-X
to	B-X
standardise	B-X
each	B-X
reaction	B-X
run	B-X
with	B-X
respect	B-X
to	B-X
RNA	B-X
integrity	B-X
,	B-X
sample	B-X
loading	B-X
and	B-X
inter-PCR	B-X
variations	B-X
.	B-X
This	B-X
article	B-X
introduces	B-X
a	B-X
new	B-X
measure	B-X
,	B-X
the	B-X
skewness	B-X
of	B-X
the	B-X
standardized	B-X
deviates	B-X
,	B-X
to	B-X
quantify	B-X
publication	B-X
bias	B-X
.	B-X
The	B-X
mysterious	B-X
standard	B-X
deviation	B-X
.	B-X

4	O
5	O
<EOS>	B-X
Effect	B-X
of	B-X
chloroquine	B-X
on	B-X
cultured	B-X
fibroblasts	B-X
:	B-X
release	B-X
of	B-X
lysosomal	B-X
hydrolases	B-X
and	B-X
inhibition	B-X
of	B-X
their	B-X
uptake	B-X
.	B-X
Atomic	B-X
models	B-X
for	B-X
the	B-X
polypeptide	B-X
backbones	B-X
of	B-X
myohemerythrin	B-X
and	B-X
hemerythrin	B-X
.	B-X

No	O
statistical	O
evaluation	O
was	O
possible	O
because	O
of	O
the	O
size	O
of	O
the	O
exon	O
(	O
see	O
(	O
Materials	O
and	O
Methods	O
)	O
.	O

Exons	O
q	O
and	O
r	O
were	O
only	O
analyzed	O
by	O
the	O
urea	O
-	O
formamide	O
method	O
.	O

intron	O
1	O
,	O
the	O
nucleotide	O
size	O
of	O
these	O
introns	O
was	O
less	O
than	O
800	O
bases	O
.	O

In	O
contrast	O
,	O
introns	O
9	O
through	O
17	O
varied	O
over	O
a	O
4	O
.	O
5	O
-	O
fold	O
range	O
.	O

Except	O
for	O
intron	O
12	O
,	O
all	O
of	O
the	O
introns	O
9	O
through	O
17	O
contained	O
800	O
bases	O
or	O
more	O
.	O
<EOS>	B-X
To	B-X
summarise	B-X
specific	B-X
adverse	B-X
effects	B-X
of	B-X
remdesivir	B-X
,	B-X
hydroxychloroquine	B-X
and	B-X
lopinavir/ritonavir	B-X
in	B-X
patients	B-X
with	B-X
COVID-19	B-X
.	B-X
Lurbinectedin	B-X
.	B-X
In	B-X
1985	B-X
the	B-X
first	B-X
lamellarins	B-X
were	B-X
isolated	B-X
from	B-X
a	B-X
small	B-X
oceanic	B-X
sea	B-X
snail	B-X
.	B-X
In	B-X
August	B-X
2009	B-X
,	B-X
asenapine	B-X
(	B-X
Saphris	B-X
;	B-X
Schering-Plough	B-X
)	B-X
was	B-X
approved	B-X
by	B-X
the	B-X
US	B-X
FDA	B-X
for	B-X
the	B-X
acute	B-X
treatment	B-X
of	B-X
schizophrenia	B-X
and	B-X
manic	B-X
or	B-X
mixed	B-X
episodes	B-X
associated	B-X
with	B-X
bipolar	B-X
I	B-X
disorder	B-X
in	B-X
adults	B-X
.	B-X

Summation	O
of	O
introns	O
1	O
through	O
16	O
for	O
the	O
70	O
%	O
formamide	O
and	O
urea	O

formamide	O
spreading	O
methods	O
yielded	O
12	O
,	O
533	O
and	O
12	O
,	O
531	O
bases	O
,	O
respectively	O
.	O

However	O
,	O
detection	O
of	O
intron	O
17	O
by	O
the	O
urea	O
-	O
formamide	O
method	O
indicates	O
that	O

the	O
actual	O
summed	O
value	O
for	O
the	O
intervening	O
sequences	O
of	O
SpC3	O
is	O
14	O
,	O
070	O
bases	O
.	O

2247	O

1	O
<EOS>	B-X
Formate	B-X
assay	B-X
in	B-X
body	B-X
fluids	B-X
:	B-X
application	B-X
in	B-X
methanol	B-X
poisoning	B-X
.	B-X

Nucleic	O
Acids	O
Research	O
<EOS>	B-X
The	B-X
2021	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
database	B-X
Issue	B-X
contains	B-X
189	B-X
papers	B-X
spanning	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
biological	B-X
fields	B-X
and	B-X
investigation	B-X
.	B-X
The	B-X
entire	B-X
Database	B-X
Issue	B-X
is	B-X
freely	B-X
available	B-X
online	B-X
on	B-X
the	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
website	B-X
(	B-X
https	B-X
:	B-X
//academic.oup.com/nar	B-X
)	B-X
.	B-X
Editorial	B-X
:	B-X
the	B-X
19th	B-X
annual	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
web	B-X
server	B-X
issue	B-X
2021	B-X
.	B-X
Editorial	B-X
:	B-X
Critical	B-X
reviews	B-X
and	B-X
perspectives	B-X
in	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
.	B-X

Size	O
determination	O
and	O
the	O
comparative	O
analysis	O
of	O
SpC3	O
exons	O
.	O

Eighteen	O
exons	O
,	O
"	O
a	O
"	O
through	O
"	O
r	O
"	O
,	O
were	O
mapped	O
(	O
Table	O
2	O
)	O
.	O

The	O
largest	O
exon	O
,	O
"	O
a	O
"	O
,	O
located	O
on	O
the	O
extreme	O
3	O
'	O
end	O
of	O
the	O
sheep	B-Species
genomic	O
insert	O
,	O
contained	O

approximately	O
800	O
bp	O
.	O
<EOS>	B-X
Transactivation	B-X
function	B-X
of	B-X
an	B-X
approximately	B-X
800-bp	B-X
evolutionarily	B-X
conserved	B-X
sequence	B-X
at	B-X
the	B-X
SHOX	B-X
3	B-X
'	B-X
region	B-X
:	B-X
implication	B-X
for	B-X
the	B-X
downstream	B-X
enhancer	B-X
.	B-X
Lisinopril	B-X
bioavailability	B-X
(	B-X
approximately	B-X
25	B-X
%	B-X
)	B-X
is	B-X
not	B-X
significantly	B-X
affected	B-X
by	B-X
food	B-X
,	B-X
age	B-X
,	B-X
or	B-X
coadministration	B-X
of	B-X
hydrochlorothiazide	B-X
(	B-X
HCTZ	B-X
)	B-X
,	B-X
propranolol	B-X
,	B-X
digoxin	B-X
,	B-X
and	B-X
glibenclamide	B-X
.	B-X
Human	B-X
experience	B-X
to	B-X
date	B-X
(	B-X
2,800	B-X
patients/subjects	B-X
)	B-X
indicates	B-X
that	B-X
lisinopril	B-X
is	B-X
well	B-X
tolerated	B-X
and	B-X
has	B-X
a	B-X
good	B-X
safety	B-X
profile	B-X
.	B-X
It	B-X
has	B-X
been	B-X
estimated	B-X
that	B-X
approximately	B-X
600,000	B-X
to	B-X
800,000	B-X
Americans	B-X
will	B-X
develop	B-X
a	B-X
hypertensive	B-X
crisis	B-X
(	B-X
Calhoun	B-X
and	B-X
Oparil	B-X
,	B-X
1990	B-X
)	B-X
.	B-X

With	O
the	O
exception	O
of	O
exon	O
"	O
m	O
"	O
,	O
exons	O
larger	O
than	O
150	O

base	O
pairs	O
were	O
confined	O
to	O
the	O
genetic	O
region	O
corresponding	O
to	O
the	O
far	O
3	O
'	O
end	O
of	O
the	O
a2	O
mRNA	O
.	O

Exon	O
"	O
a	O
"	O
and	O
exon	O
"	O
b	O
"	O
,	O
the	O
two	O
exons	O
situated	O
on	O
either	O
side	O
of	O
intron	O
1	O
,	O
coded	O
for	O
around	O
1000	O
bases	O
of	O
a2	O
collagen	O
information	O
;	O
these	O
two	O

exons	O
contained	O
one	O
-	O
third	O
of	O
the	O
mapped	O
3	O
,	O
014	O
DNA	O
bases	O
complementary	O
to	O
a2	O
mRNA	O
Length	O
distribution	O
and	O
organization	O
of	O
the	O
introns	O
and	O
exons	O
in	O
the	O
sheep	B-Species
genomi	O
c	O
i	O
nsert	O
.	O

There	O
was	O
a	O
sharp	O
contrast	O
in	O
the	O
size	O
distribution	O
of	O
the	O
exons	O
and	O
introns	O
contained	O
within	O
SpC3	O
(	O
Figure	O
2	O
)	O
.	O

While	O
the	O
intron	O
sizes	O
varied	O
<EOS>	B-X
Herein	B-X
,	B-X
we	B-X
first	B-X
described	B-X
its	B-X
mitogenome	B-X
and	B-X
then	B-X
inferred	B-X
intron	B-X
evolution	B-X
from	B-X
both	B-X
intraspecific	B-X
and	B-X
interspecific	B-X
perspectives	B-X
.	B-X
The	B-X
fungus	B-X
represented	B-X
the	B-X
largest	B-X
mitogenome	B-X
(	B-X
56.6	B-X
kb	B-X
in	B-X
strain	B-X
CCAD02	B-X
)	B-X
known	B-X
in	B-X
Cordycipitaceae	B-X
due	B-X
to	B-X
the	B-X
presence	B-X
of	B-X
25	B-X
introns	B-X
interrupting	B-X
nine	B-X
genes	B-X
.	B-X
Comparison	B-X
of	B-X
three	B-X
I.	B-X
cicadae	B-X
strains	B-X
revealed	B-X
intron	B-X
presence/absence	B-X
dynamics	B-X
at	B-X
six	B-X
intron	B-X
loci	B-X
plus	B-X
a	B-X
few	B-X
indels	B-X
and	B-X
single	B-X
nucleotide	B-X
polymorphisms	B-X
.	B-X
They	B-X
,	B-X
however	B-X
,	B-X
varied	B-X
in	B-X
intron	B-X
numbers	B-X
(	B-X
1-25	B-X
per	B-X
species	B-X
)	B-X
with	B-X
overall	B-X
34	B-X
intron	B-X
loci	B-X
identified	B-X
,	B-X
which	B-X
resulted	B-X
in	B-X
more	B-X
than	B-X
twofold	B-X
variations	B-X
in	B-X
mitogenome	B-X
sizes	B-X
(	B-X
24.5-56.6	B-X
kb	B-X
)	B-X
.	B-X
An	B-X
rnl	B-X
intron	B-X
encoding	B-X
ribosomal	B-X
protein	B-X
S3	B-X
was	B-X
present	B-X
in	B-X
all	B-X
species	B-X
,	B-X
suggesting	B-X
its	B-X
early	B-X
invasion	B-X
in	B-X
Cordycipitaceae	B-X
,	B-X
while	B-X
further	B-X
divergence	B-X
occurred	B-X
for	B-X
this	B-X
intron	B-X
.	B-X
The	B-X
other	B-X
introns	B-X
identified	B-X
in	B-X
this	B-X
study	B-X
were	B-X
present	B-X
in	B-X
some	B-X
,	B-X
but	B-X
not	B-X
all	B-X
of	B-X
the	B-X
species	B-X
and	B-X
have	B-X
undergone	B-X
multiple	B-X
gains	B-X
and	B-X
losses	B-X
in	B-X
Cordycipitaceae	B-X
.	B-X
This	B-X
study	B-X
greatly	B-X
enhanced	B-X
our	B-X
understanding	B-X
of	B-X
intron	B-X
evolution	B-X
in	B-X
Cordycipitaceae	B-X
.	B-X

considerably	O
,	O
the	O
exons	O
,	O
in	O
general	O
,	O
showed	O
a	O
very	O
narrow	O
distribution	O
of	O

lengths	O
,	O
and	O
thus	O
tended	O
to	O
cluster	O
at	O
the	O
lowest	O
end	O
of	O
the	O
length	O
distri	O

A	O
.	O

(	O
I	O
)	O

z	O
6	O
0	O
<EOS>	B-X
Severe	B-X
acute	B-X
respiratory	B-X
syndrome	B-X
coronavirus	B-X
2	B-X
(	B-X
SARS-CoV-2	B-X
)	B-X
infection	B-X
and	B-X
the	B-X
resulting	B-X
coronavirus	B-X
disease	B-X
2019	B-X
(	B-X
Covid-19	B-X
)	B-X
have	B-X
afflicted	B-X
tens	B-X
of	B-X
millions	B-X
of	B-X
people	B-X
in	B-X
a	B-X
worldwide	B-X
pandemic	B-X
.	B-X
BNT162b2	B-X
is	B-X
a	B-X
lipid	B-X
nanoparticle-formulated	B-X
,	B-X
nucleoside-modified	B-X
RNA	B-X
vaccine	B-X
encoding	B-X
a	B-X
prefusion-stabilized	B-X
,	B-X
membrane-anchored	B-X
severe	B-X
acute	B-X
respiratory	B-X
syndrome	B-X
coronavirus	B-X
2	B-X
(	B-X
SARS-CoV-2	B-X
)	B-X
full-length	B-X
spike	B-X
protein	B-X
.	B-X
BNT162b2	B-X
is	B-X
highly	B-X
efficacious	B-X
against	B-X
coronavirus	B-X
disease	B-X
2019	B-X
(	B-X
Covid-19	B-X
)	B-X
and	B-X
is	B-X
currently	B-X
approved	B-X
,	B-X
conditionally	B-X
approved	B-X
,	B-X
or	B-X
authorized	B-X
for	B-X
emergency	B-X
use	B-X
worldwide	B-X
.	B-X
At	B-X
the	B-X
time	B-X
of	B-X
initial	B-X
authorization	B-X
,	B-X
data	B-X
beyond	B-X
2	B-X
months	B-X
after	B-X
vaccination	B-X
were	B-X
unavailable	B-X
.	B-X

z	O
<EOS>	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
provide	B-X
insights	B-X
in	B-X
Z-nucleic	B-X
acid	B-X
research	B-X
and	B-X
highlight	B-X
the	B-X
unsolved	B-X
puzzles	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
summarize	B-X
the	B-X
latest	B-X
findings	B-X
regarding	B-X
vertebrate	B-X
H2A.Z-associated	B-X
factors	B-X
and	B-X
focus	B-X
on	B-X
their	B-X
roles	B-X
in	B-X
gene	B-X
activation	B-X
and	B-X
repression	B-X
,	B-X
cell	B-X
cycle	B-X
regulation	B-X
,	B-X
(	B-X
neuro	B-X
)	B-X
development	B-X
,	B-X
and	B-X
tumorigenesis	B-X
.	B-X
The	B-X
debate	B-X
about	B-X
the	B-X
physiological	B-X
relevance	B-X
of	B-X
Z-DNA	B-X
was	B-X
settled	B-X
only	B-X
after	B-X
a	B-X
class	B-X
of	B-X
proteins	B-X
was	B-X
found	B-X
to	B-X
potentially	B-X
recognize	B-X
the	B-X
Z-form	B-X
architecture	B-X
of	B-X
DNA	B-X
.	B-X
h-ZÎ±ADAR1	B-X
that	B-X
a	B-X
Z-DNA	B-X
's	B-X
binding	B-X
domain	B-X
,	B-X
binds	B-X
and	B-X
stabilizes	B-X
one	B-X
part	B-X
in	B-X
Z	B-X
configuration	B-X
and	B-X
therefore	B-X
the	B-X
remaining	B-X
half	B-X
in	B-X
B	B-X
deoxyribonucleic	B-X
acid	B-X
configuration	B-X
.	B-X

ZL4	O
0	O

021	O
<EOS>	B-X
Effects	B-X
of	B-X
5,6-dihydroxytryptamine	B-X
on	B-X
tyrosine-hydroxylase	B-X
activity	B-X
in	B-X
central	B-X
catecholaminergic	B-X
neurons	B-X
of	B-X
the	B-X
rat	B-X
.	B-X

z	O
<EOS>	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
provide	B-X
insights	B-X
in	B-X
Z-nucleic	B-X
acid	B-X
research	B-X
and	B-X
highlight	B-X
the	B-X
unsolved	B-X
puzzles	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
summarize	B-X
the	B-X
latest	B-X
findings	B-X
regarding	B-X
vertebrate	B-X
H2A.Z-associated	B-X
factors	B-X
and	B-X
focus	B-X
on	B-X
their	B-X
roles	B-X
in	B-X
gene	B-X
activation	B-X
and	B-X
repression	B-X
,	B-X
cell	B-X
cycle	B-X
regulation	B-X
,	B-X
(	B-X
neuro	B-X
)	B-X
development	B-X
,	B-X
and	B-X
tumorigenesis	B-X
.	B-X
The	B-X
debate	B-X
about	B-X
the	B-X
physiological	B-X
relevance	B-X
of	B-X
Z-DNA	B-X
was	B-X
settled	B-X
only	B-X
after	B-X
a	B-X
class	B-X
of	B-X
proteins	B-X
was	B-X
found	B-X
to	B-X
potentially	B-X
recognize	B-X
the	B-X
Z-form	B-X
architecture	B-X
of	B-X
DNA	B-X
.	B-X
h-ZÎ±ADAR1	B-X
that	B-X
a	B-X
Z-DNA	B-X
's	B-X
binding	B-X
domain	B-X
,	B-X
binds	B-X
and	B-X
stabilizes	B-X
one	B-X
part	B-X
in	B-X
Z	B-X
configuration	B-X
and	B-X
therefore	B-X
the	B-X
remaining	B-X
half	B-X
in	B-X
B	B-X
deoxyribonucleic	B-X
acid	B-X
configuration	B-X
.	B-X

10	O
<EOS>	B-X
Digitoxin	B-X
metabolism	B-X
by	B-X
rat	B-X
liver	B-X
microsomes	B-X
.	B-X

B	O
.	O
<EOS>	B-X
Hepatitis	B-X
B	B-X
is	B-X
caused	B-X
by	B-X
the	B-X
hepatitis	B-X
B	B-X
virus	B-X
(	B-X
HBV	B-X
)	B-X
,	B-X
which	B-X
infects	B-X
the	B-X
liver	B-X
and	B-X
may	B-X
lead	B-X
to	B-X
chronic	B-X
liver	B-X
disease	B-X
,	B-X
including	B-X
cirrhosis	B-X
and	B-X
hepatocellular	B-X
carcinoma	B-X
.	B-X
HBV	B-X
represents	B-X
a	B-X
worldwide	B-X
public	B-X
health	B-X
problem	B-X
,	B-X
causing	B-X
major	B-X
morbidity	B-X
and	B-X
mortality	B-X
.	B-X
Affordable	B-X
,	B-X
safe	B-X
,	B-X
and	B-X
effective	B-X
,	B-X
hepatitis	B-X
B	B-X
vaccines	B-X
are	B-X
the	B-X
best	B-X
tools	B-X
we	B-X
have	B-X
to	B-X
control	B-X
and	B-X
prevent	B-X
hepatitis	B-X
B	B-X
.	B-X
In	B-X
2019	B-X
,	B-X
coverage	B-X
of	B-X
3	B-X
doses	B-X
of	B-X
the	B-X
hepatitis	B-X
B	B-X
vaccine	B-X
reached	B-X
85	B-X
%	B-X
worldwide	B-X
compared	B-X
to	B-X
around	B-X
30	B-X
%	B-X
in	B-X
2000	B-X
.	B-X
The	B-X
effective	B-X
implementation	B-X
of	B-X
hepatitis	B-X
B	B-X
vaccination	B-X
programs	B-X
has	B-X
resulted	B-X
in	B-X
a	B-X
substantial	B-X
decrease	B-X
in	B-X
the	B-X
HBV	B-X
carrier	B-X
rate	B-X
and	B-X
hepatitis	B-X
B-related	B-X
morbidity	B-X
and	B-X
mortality	B-X
.	B-X
This	B-X
article	B-X
summarizes	B-X
the	B-X
great	B-X
triumphs	B-X
of	B-X
the	B-X
hepatitis	B-X
B	B-X
vaccine	B-X
,	B-X
the	B-X
first	B-X
anticancer	B-X
and	B-X
virus-like-particle-based	B-X
vaccine	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
existing	B-X
unresolved	B-X
issues	B-X
and	B-X
future	B-X
perspectives	B-X
on	B-X
hepatitis	B-X
B	B-X
vaccination	B-X
required	B-X
for	B-X
global	B-X
prevention	B-X
of	B-X
HBV	B-X
infection	B-X
are	B-X
discussed	B-X
.	B-X

8	O
<EOS>	B-X
Comparison	B-X
between	B-X
procaine	B-X
and	B-X
isocarboxazid	B-X
metabolism	B-X
in	B-X
vitro	B-X
by	B-X
a	B-X
liver	B-X
microsomal	B-X
amidase-esterase	B-X
.	B-X

z	O
0	O
<EOS>	B-X
Severe	B-X
acute	B-X
respiratory	B-X
syndrome	B-X
coronavirus	B-X
2	B-X
(	B-X
SARS-CoV-2	B-X
)	B-X
infection	B-X
and	B-X
the	B-X
resulting	B-X
coronavirus	B-X
disease	B-X
2019	B-X
(	B-X
Covid-19	B-X
)	B-X
have	B-X
afflicted	B-X
tens	B-X
of	B-X
millions	B-X
of	B-X
people	B-X
in	B-X
a	B-X
worldwide	B-X
pandemic	B-X
.	B-X
BNT162b2	B-X
is	B-X
a	B-X
lipid	B-X
nanoparticle-formulated	B-X
,	B-X
nucleoside-modified	B-X
RNA	B-X
vaccine	B-X
encoding	B-X
a	B-X
prefusion-stabilized	B-X
,	B-X
membrane-anchored	B-X
severe	B-X
acute	B-X
respiratory	B-X
syndrome	B-X
coronavirus	B-X
2	B-X
(	B-X
SARS-CoV-2	B-X
)	B-X
full-length	B-X
spike	B-X
protein	B-X
.	B-X
BNT162b2	B-X
is	B-X
highly	B-X
efficacious	B-X
against	B-X
coronavirus	B-X
disease	B-X
2019	B-X
(	B-X
Covid-19	B-X
)	B-X
and	B-X
is	B-X
currently	B-X
approved	B-X
,	B-X
conditionally	B-X
approved	B-X
,	B-X
or	B-X
authorized	B-X
for	B-X
emergency	B-X
use	B-X
worldwide	B-X
.	B-X
At	B-X
the	B-X
time	B-X
of	B-X
initial	B-X
authorization	B-X
,	B-X
data	B-X
beyond	B-X
2	B-X
months	B-X
after	B-X
vaccination	B-X
were	B-X
unavailable	B-X
.	B-X

16	O
0	O
z	O
<EOS>	B-X
Severe	B-X
acute	B-X
respiratory	B-X
syndrome	B-X
coronavirus	B-X
2	B-X
(	B-X
SARS-CoV-2	B-X
)	B-X
infection	B-X
and	B-X
the	B-X
resulting	B-X
coronavirus	B-X
disease	B-X
2019	B-X
(	B-X
Covid-19	B-X
)	B-X
have	B-X
afflicted	B-X
tens	B-X
of	B-X
millions	B-X
of	B-X
people	B-X
in	B-X
a	B-X
worldwide	B-X
pandemic	B-X
.	B-X
BNT162b2	B-X
is	B-X
a	B-X
lipid	B-X
nanoparticle-formulated	B-X
,	B-X
nucleoside-modified	B-X
RNA	B-X
vaccine	B-X
encoding	B-X
a	B-X
prefusion-stabilized	B-X
,	B-X
membrane-anchored	B-X
severe	B-X
acute	B-X
respiratory	B-X
syndrome	B-X
coronavirus	B-X
2	B-X
(	B-X
SARS-CoV-2	B-X
)	B-X
full-length	B-X
spike	B-X
protein	B-X
.	B-X
BNT162b2	B-X
is	B-X
highly	B-X
efficacious	B-X
against	B-X
coronavirus	B-X
disease	B-X
2019	B-X
(	B-X
Covid-19	B-X
)	B-X
and	B-X
is	B-X
currently	B-X
approved	B-X
,	B-X
conditionally	B-X
approved	B-X
,	B-X
or	B-X
authorized	B-X
for	B-X
emergency	B-X
use	B-X
worldwide	B-X
.	B-X
At	B-X
the	B-X
time	B-X
of	B-X
initial	B-X
authorization	B-X
,	B-X
data	B-X
beyond	B-X
2	B-X
months	B-X
after	B-X
vaccination	B-X
were	B-X
unavailable	B-X
.	B-X

2	O
<EOS>	B-X
Delineation	B-X
of	B-X
the	B-X
intimate	B-X
details	B-X
of	B-X
the	B-X
backbone	B-X
conformation	B-X
of	B-X
pyridine	B-X
nucleotide	B-X
coenzymes	B-X
in	B-X
aqueous	B-X
solution	B-X
.	B-X

20	O
400	O
600	O
800	O
1000	O
1200	O
1400	O
1600	O
<EOS>	B-X
Aggregation	B-X
of	B-X
blood	B-X
platelets	B-X
by	B-X
adrenaline	B-X
and	B-X
its	B-X
uptake	B-X
.	B-X
Choosing	B-X
a	B-X
computer	B-X
system	B-X
.	B-X
The	B-X
role	B-X
of	B-X
the	B-X
tail	B-X
in	B-X
temperature	B-X
regulation	B-X
of	B-X
the	B-X
cotton	B-X
rat	B-X
,	B-X
Sigmodon	B-X
hispidus	B-X
.	B-X
All	B-X
of	B-X
these	B-X
species	B-X
possess	B-X
high-molecular	B-X
weight	B-X
luciferases	B-X
(	B-X
200,000-400,000	B-X
daltons	B-X
)	B-X
with	B-X
similar	B-X
pH	B-X
activity	B-X
profiles	B-X
.	B-X
A	B-X
luciferin	B-X
binding	B-X
protein	B-X
(	B-X
LBP	B-X
)	B-X
can	B-X
easily	B-X
be	B-X
extracted	B-X
from	B-X
the	B-X
two	B-X
Gonyaulax	B-X
species	B-X
(	B-X
MW	B-X
approximately	B-X
120,000	B-X
daltons	B-X
)	B-X
,	B-X
but	B-X
none	B-X
could	B-X
be	B-X
detected	B-X
in	B-X
extracts	B-X
of	B-X
either	B-X
D.	B-X
lunula	B-X
or	B-X
P.	B-X
noctiluca	B-X
.	B-X

LENGTH	O
IN	O
NUCLEOTIDES	O

Figure	O
2	O
.	O
<EOS>	B-X
and	B-X
Kilic	B-X
F.	B-X
,	B-X
Journal	B-X
of	B-X
Neurochemistry	B-X
101	B-X
(	B-X
4	B-X
)	B-X
937-948	B-X
,	B-X
2007	B-X
(	B-X
https	B-X
:	B-X
//doi.org/10.1111/j.1471-4159.2007.04469.x	B-X
)	B-X
.	B-X
The	B-X
above	B-X
article	B-X
,	B-X
published	B-X
online	B-X
on	B-X
23rd	B-X
January	B-X
2007	B-X
in	B-X
Wiley	B-X
Online	B-X
Library	B-X
(	B-X
wileyonlinelibrary.com	B-X
)	B-X
,	B-X
has	B-X
been	B-X
retracted	B-X
by	B-X
agreement	B-X
between	B-X
the	B-X
Journal	B-X
's	B-X
Editor	B-X
in	B-X
Chief	B-X
,	B-X
JÃ¶rg	B-X
B.	B-X
Schulz	B-X
,	B-X
and	B-X
John	B-X
Wiley	B-X
&	B-X
Sons	B-X
Ltd	B-X
.	B-X
The	B-X
corresponding	B-X
author	B-X
,	B-X
Dr.	B-X
Fusun	B-X
Kilic	B-X
,	B-X
notified	B-X
the	B-X
Journal	B-X
's	B-X
Editorial	B-X
Office	B-X
of	B-X
the	B-X
following	B-X
concerns	B-X
related	B-X
to	B-X
the	B-X
article	B-X
that	B-X
were	B-X
brought	B-X
to	B-X
his	B-X
attention	B-X
:	B-X
Figures	B-X
2C	B-X
and	B-X
2D	B-X
are	B-X
duplicates	B-X
The	B-X
'Lysate	B-X
'	B-X
and	B-X
the	B-X
'Bound	B-X
'	B-X
lanes	B-X
in	B-X
Figure	B-X
7A	B-X
are	B-X
identical	B-X
The	B-X
Myc-SERT	B-X
bands	B-X
in	B-X
Figure	B-X
7B	B-X
,	B-X
lanes	B-X
2	B-X
and	B-X
3	B-X
are	B-X
duplicates	B-X
of	B-X
lanes	B-X
4	B-X
and	B-X
5	B-X
,	B-X
and	B-X
again	B-X
of	B-X
lanes	B-X
6	B-X
and	B-X
7	B-X
The	B-X
45	B-X
kD	B-X
bands	B-X
in	B-X
Figure	B-X
7B	B-X
,	B-X
lanes	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
are	B-X
duplicates	B-X
of	B-X
lanes	B-X
5	B-X
,	B-X
6	B-X
,	B-X
and	B-X
7	B-X
Dr.	B-X
Kilic	B-X
investigated	B-X
the	B-X
concerns	B-X
and	B-X
,	B-X
in	B-X
response	B-X
to	B-X
the	B-X
journal	B-X
,	B-X
concluded	B-X
that	B-X
they	B-X
were	B-X
unjustified	B-X
.	B-X
The	B-X
Journal	B-X
's	B-X
Editorial	B-X
Office	B-X
undertook	B-X
its	B-X
own	B-X
visual	B-X
inspection	B-X
and	B-X
,	B-X
in	B-X
relation	B-X
to	B-X
Figure	B-X
7B	B-X
,	B-X
maintains	B-X
that	B-X
duplication	B-X
is	B-X
present	B-X
.	B-X
They	B-X
concluded	B-X
:	B-X
In	B-X
Figure	B-X
7B	B-X
,	B-X
45	B-X
kD	B-X
,	B-X
lanes	B-X
1	B-X
and	B-X
5	B-X
appear	B-X
identical	B-X
,	B-X
as	B-X
well	B-X
as	B-X
lane	B-X
2	B-X
and	B-X
6	B-X
,	B-X
and	B-X
lanes	B-X
3	B-X
,	B-X
4	B-X
,	B-X
and	B-X
7	B-X
(	B-X
with	B-X
lane	B-X
4	B-X
being	B-X
clipped	B-X
at	B-X
the	B-X
right-hand	B-X
side	B-X
)	B-X
In	B-X
the	B-X
Flag-SERT	B-X
,	B-X
lanes	B-X
2	B-X
and	B-X
6	B-X
appear	B-X
identical	B-X
,	B-X
as	B-X
well	B-X
as	B-X
lanes	B-X
3	B-X
and	B-X
7	B-X
In	B-X
the	B-X
Myc-SERT	B-X
,	B-X
lanes	B-X
2	B-X
and	B-X
6	B-X
appear	B-X
identical	B-X
,	B-X
as	B-X
well	B-X
as	B-X
lanes	B-X
3	B-X
,	B-X
5	B-X
,	B-X
and	B-X
7	B-X
.	B-X
The	B-X
problems	B-X
are	B-X
highlighted	B-X
in	B-X
the	B-X
following	B-X
screenshot	B-X
of	B-X
Figure	B-X
7B	B-X
.	B-X

Length	O
distribution	O
of	O
the	O
intron	O
and	O
exon	O
mean	O
lengths	O
measured	O
from	O
micrographs	O
prepared	O
by	O
the	O
urea	O
-	O
formamide	O
method	O
.	O

(	O
A	O
)	O
Introns	O
;	O
(	O
b	O
)	O
Exons	O
.	O
<EOS>	B-X
Group	B-X
â¡	B-X
introns	B-X
are	B-X
self-splicing	B-X
ribozymes	B-X
,	B-X
which	B-X
insert	B-X
directly	B-X
into	B-X
target	B-X
sites	B-X
in	B-X
DNA	B-X
with	B-X
high	B-X
frequency	B-X
through	B-X
``	B-X
retrohoming	B-X
''	B-X
.	B-X
This	B-X
paper	B-X
reviewed	B-X
the	B-X
gene	B-X
targeting	B-X
principle	B-X
of	B-X
group	B-X
â¡	B-X
introns	B-X
and	B-X
the	B-X
application	B-X
in	B-X
microbial	B-X
genetic	B-X
modification	B-X
,	B-X
and	B-X
then	B-X
analyzed	B-X
the	B-X
limitations	B-X
of	B-X
them	B-X
in	B-X
multi-functional	B-X
gene	B-X
editing	B-X
and	B-X
eukaryotes	B-X
based	B-X
on	B-X
the	B-X
``	B-X
retrohoming	B-X
''	B-X
characteristics	B-X
and	B-X
the	B-X
dependence	B-X
on	B-X
high	B-X
Mg	B-X
In	B-X
many	B-X
eukaryotes	B-X
,	B-X
including	B-X
mammals	B-X
,	B-X
plants	B-X
,	B-X
yeast	B-X
,	B-X
and	B-X
insects	B-X
,	B-X
introns	B-X
can	B-X
increase	B-X
gene	B-X
expression	B-X
without	B-X
functioning	B-X
as	B-X
a	B-X
binding	B-X
site	B-X
for	B-X
transcription	B-X
factors	B-X
.	B-X
Introns	B-X
can	B-X
increase	B-X
transcript	B-X
levels	B-X
by	B-X
affecting	B-X
the	B-X
rate	B-X
of	B-X
transcription	B-X
,	B-X
nuclear	B-X
export	B-X
,	B-X
and	B-X
transcript	B-X
stability	B-X
.	B-X
This	B-X
review	B-X
discusses	B-X
the	B-X
current	B-X
knowledge	B-X
about	B-X
these	B-X
processes	B-X
.	B-X
The	B-X
role	B-X
of	B-X
splicing	B-X
in	B-X
IME	B-X
and	B-X
the	B-X
significance	B-X
of	B-X
intron	B-X
position	B-X
relative	B-X
to	B-X
the	B-X
sites	B-X
of	B-X
transcription	B-X
and	B-X
translation	B-X
initiation	B-X
are	B-X
elaborated	B-X
.	B-X
Particular	B-X
emphasis	B-X
is	B-X
placed	B-X
on	B-X
the	B-X
question	B-X
why	B-X
different	B-X
introns	B-X
,	B-X
present	B-X
at	B-X
the	B-X
same	B-X
location	B-X
of	B-X
the	B-X
same	B-X
genes	B-X
and	B-X
spliced	B-X
at	B-X
a	B-X
similar	B-X
high	B-X
efficiency	B-X
,	B-X
can	B-X
have	B-X
very	B-X
different	B-X
impacts	B-X
on	B-X
expression	B-X
-	B-X
from	B-X
almost	B-X
no	B-X
effect	B-X
to	B-X
considerable	B-X
stimulation	B-X
.	B-X
This	B-X
situation	B-X
can	B-X
be	B-X
at	B-X
least	B-X
partly	B-X
accounted	B-X
for	B-X
by	B-X
the	B-X
identification	B-X
of	B-X
splicing-unrelated	B-X
intronic	B-X
elements	B-X
with	B-X
a	B-X
special	B-X
ability	B-X
to	B-X
enhance	B-X
mRNA	B-X
accumulation	B-X
or	B-X
translational	B-X
efficiency	B-X
.	B-X
The	B-X
many	B-X
factors	B-X
that	B-X
could	B-X
lead	B-X
to	B-X
the	B-X
large	B-X
variation	B-X
observed	B-X
between	B-X
the	B-X
impact	B-X
of	B-X
introns	B-X
in	B-X
different	B-X
genes	B-X
and	B-X
experimental	B-X
systems	B-X
are	B-X
highlighted	B-X
.	B-X
Rather	B-X
,	B-X
each	B-X
intron-gene	B-X
combination	B-X
might	B-X
undergo	B-X
its	B-X
own	B-X
unique	B-X
mixture	B-X
of	B-X
processes	B-X
that	B-X
lead	B-X
to	B-X
the	B-X
perceptible	B-X
outcome	B-X
.	B-X

See	O
Tables	O
1	O
and	O
2	O
for	O
details	O
.	O
<EOS>	B-X
Since	B-X
1980	B-X
,	B-X
the	B-X
American	B-X
College	B-X
of	B-X
Cardiology	B-X
(	B-X
ACC	B-X
)	B-X
and	B-X
American	B-X
Heart	B-X
Association	B-X
(	B-X
AHA	B-X
)	B-X
have	B-X
translated	B-X
scientific	B-X
evidence	B-X
into	B-X
clinical	B-X
practice	B-X
guidelines	B-X
with	B-X
recommendations	B-X
to	B-X
improve	B-X
cardiovascular	B-X
health	B-X
.	B-X
Beginning	B-X
in	B-X
2017	B-X
,	B-X
numerous	B-X
modifications	B-X
to	B-X
the	B-X
guidelines	B-X
have	B-X
been	B-X
and	B-X
continue	B-X
to	B-X
be	B-X
implemented	B-X
to	B-X
make	B-X
guidelines	B-X
shorter	B-X
and	B-X
enhance	B-X
â	B-X
user	B-X
friendliness.	B-X
â	B-X
Guidelines	B-X
are	B-X
written	B-X
and	B-X
presented	B-X
in	B-X
a	B-X
modular	B-X
knowledge	B-X
chunk	B-X
format	B-X
,	B-X
in	B-X
which	B-X
each	B-X
chunk	B-X
includes	B-X
a	B-X
table	B-X
of	B-X
recommendations	B-X
,	B-X
a	B-X
brief	B-X
synopsis	B-X
,	B-X
recommendation-specific	B-X
supportive	B-X
text	B-X
and	B-X
,	B-X
when	B-X
appropriate	B-X
,	B-X
flow	B-X
diagrams	B-X
or	B-X
additional	B-X
tables	B-X
.	B-X
More	B-X
structured	B-X
guidelinesâincluding	B-X
word	B-X
limits	B-X
(	B-X
â	B-X
targets	B-X
â	B-X
)	B-X
and	B-X
a	B-X
web	B-X
guideline	B-X
supplement	B-X
for	B-X
useful	B-X
but	B-X
noncritical	B-X
tables	B-X
and	B-X
figuresâare	B-X
2	B-X
such	B-X
changes	B-X
.	B-X
The	B-X
reader	B-X
is	B-X
encouraged	B-X
to	B-X
consult	B-X
the	B-X
full-text	B-X
guideline	B-X
for	B-X
additional	B-X
guidance	B-X
and	B-X
details	B-X
,	B-X
since	B-X
the	B-X
executive	B-X
summary	B-X
contains	B-X
mainly	B-X
the	B-X
recommendations	B-X
.	B-X

2248	O

Nucleic	O
Acids	O
Research	O
bution	O
graph	O
.	O

The	O
exon	O
in	O
the	O
800	O
-	O
900	O
bp	O
region	O
was	O
unique	O
and	O
was	O
the	O
only	O
exon	O
which	O
exhibited	O
length	O
overlap	O
with	O
introns	O
.	O

The	O
maps	O
of	O
the	O
a2	O
collagen	O
gene	O
obtained	O
with	O
both	O
electron	O
micro	O

scopic	O
spreading	O
methods	O
were	O
almost	O
identical	O
(	O
Figure	O
3	O
)	O
,	O
except	O
that	O
the	O

region	O
at	O
the	O
extreme	O
5	O
'	O
end	O
of	O
the	O
insert	O
could	O
only	O
be	O
mapped	O
with	O
the	O
ureaformamide	O
method	O
.	O

From	O
these	O
measurements	O
we	O
concluded	O
that	O
the	O
length	O
of	O
the	O
a2	O
collagen	O
genetic	O
regi	O
?	O
on	O
in	O
SpC3	O
was	O
17	O
,	O
084	O
bases	O
long	O
with	O
only	O
3	O
,	O
014	O
bases	O
actually	O
coding	O
for	O
a2	O
mRNA	O
.	O

Therefore	O
,	O
only	O
18	O
%	O
of	O
the	O
mapped	O
17	O
kb	O
sheep	B-Species
genetic	O
insert	O
actually	O
contained	O
a2	O
structural	O
information	O
.	O

DISCUSSION	O

The	O
organizational	O
structure	O
of	O
the	O
a2	O
collagen	O
gene	O
is	O
complex	O
.	O

A	O
minimum	O
of	O
17	O
introns	O
interrupt	O
the	O
3	O
kb	O
of	O
ca2	O
genetic	O
information	O
interspersed	O
as	O
18	O
exons	O
over	O
17	O
kb	O
of	O
sheep	B-Species
DNA	O
.	O

With	O
the	O
exception	O
of	O
exon	O
"	O
a	O
"	O
located	O
at	O
the	O
extreme	O
3	O
'	O
end	O
of	O
the	O
inserted	O
a2	O
gene	O
,	O
all	O
other	O
mapped	O
exons	O
are	O
rather	O
small	O
,	O
exhibiting	O
a	O
size	O
distribution	O
range	O
of	O
50	O
to	O
250	O
bp	O
.	O

In	O
<EOS>	B-X
Laminagraphy	B-X
in	B-X
acute	B-X
maxillofacial	B-X
injuries	B-X
.	B-X

contrast	O
,	O
the	O
intron	O
sizes	O
range	O
from	O
340	O
to	O
1540	O
bases	O
occupying	O
a	O
total	O

of	O
14	O
kb	O
.	O
<EOS>	B-X
Overlapping	B-X
``	B-X
cassettes	B-X
''	B-X
of	B-X
5	B-X
to	B-X
7	B-X
kilobases	B-X
(	B-X
kb	B-X
)	B-X
,	B-X
assembled	B-X
from	B-X
chemically	B-X
synthesized	B-X
oligonucleotides	B-X
,	B-X
were	B-X
joined	B-X
by	B-X
in	B-X
vitro	B-X
recombination	B-X
to	B-X
produce	B-X
intermediate	B-X
assemblies	B-X
of	B-X
approximately	B-X
24	B-X
kb	B-X
,	B-X
72	B-X
kb	B-X
(	B-X
``	B-X
1/8	B-X
genome	B-X
''	B-X
)	B-X
,	B-X
and	B-X
144	B-X
kb	B-X
(	B-X
``	B-X
1/4	B-X
genome	B-X
''	B-X
)	B-X
,	B-X
which	B-X
were	B-X
all	B-X
cloned	B-X
as	B-X
bacterial	B-X
artificial	B-X
chromosomes	B-X
in	B-X
Escherichia	B-X
coli	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
sequenced	B-X
and	B-X
assembled	B-X
chloroplast	B-X
genomes	B-X
of	B-X
14	B-X
mangrove	B-X
species	B-X
from	B-X
eight	B-X
families	B-X
spanning	B-X
five	B-X
rosid	B-X
orders	B-X
and	B-X
one	B-X
asterid	B-X
order	B-X
:	B-X
Fabales	B-X
(	B-X
We	B-X
have	B-X
cloned	B-X
and	B-X
sequenced	B-X
a	B-X
1.7-kb	B-X
Mu	B-X
element	B-X
from	B-X
a	B-X
Mutator	B-X
line	B-X
of	B-X
maize	B-X
and	B-X
compared	B-X
its	B-X
structure	B-X
to	B-X
Mu1	B-X
,	B-X
a	B-X
1.4-kb	B-X
element	B-X
.	B-X
With	B-X
the	B-X
exception	B-X
of	B-X
a	B-X
385-bp	B-X
block	B-X
of	B-X
DNA	B-X
present	B-X
in	B-X
the	B-X
1.7-kb	B-X
element	B-X
,	B-X
these	B-X
transposable	B-X
elements	B-X
are	B-X
structurally	B-X
similar	B-X
,	B-X
sharing	B-X
terminally	B-X
inverted	B-X
and	B-X
internal	B-X
direct	B-X
repeated	B-X
sequences	B-X
.	B-X
Derivation	B-X
of	B-X
1.4-kb	B-X
elements	B-X
from	B-X
the	B-X
1.7-kb	B-X
class	B-X
via	B-X
deletion	B-X
of	B-X
internal	B-X
sequence	B-X
is	B-X
suggested	B-X
by	B-X
the	B-X
finding	B-X
that	B-X
a	B-X
portion	B-X
of	B-X
the	B-X
extra	B-X
DNA	B-X
in	B-X
Mu1.7	B-X
is	B-X
part	B-X
of	B-X
a	B-X
truncated	B-X
direct	B-X
repeat	B-X
sequence	B-X
in	B-X
the	B-X
1.4-kb	B-X
element	B-X
.	B-X

Thus	O
,	O
the	O
DNA	O
region	O
containing	O
the	O
3	O
kb	O
of	O
a2	O
collagen	O
genetic	O
information	O
is	O
5	O
.	O
6	O
fold	O
longer	O
than	O
the	O
corresponding	O
co2	O
mRNA	O
sequences	O
.	O

Although	O
the	O
total	O
number	O
of	O
introns	O
present	O
within	O
the	O
60	O
%	O
3	O
'	O
portion	O
<EOS>	B-X
We	B-X
use	B-X
a	B-X
rat	B-X
cytochrome	B-X
c	B-X
gene	B-X
that	B-X
we	B-X
previously	B-X
isolated	B-X
and	B-X
determined	B-X
the	B-X
sequence	B-X
of	B-X
to	B-X
estimate	B-X
the	B-X
number	B-X
of	B-X
related	B-X
sequences	B-X
present	B-X
in	B-X
the	B-X
rat	B-X
genome	B-X
.	B-X
Approximately	B-X
25	B-X
different	B-X
EcoRI	B-X
restriction	B-X
endonuclease	B-X
fragments	B-X
from	B-X
total	B-X
rat	B-X
DNA	B-X
hybridize	B-X
to	B-X
the	B-X
gene	B-X
of	B-X
known	B-X
structure	B-X
.	B-X
Four	B-X
of	B-X
these	B-X
correspond	B-X
to	B-X
homologous	B-X
sequences	B-X
present	B-X
in	B-X
four	B-X
different	B-X
lambda	B-X
Charon	B-X
4A-rat	B-X
cytochrome	B-X
c	B-X
recombinants	B-X
previously	B-X
isolated	B-X
.	B-X
Intact	B-X
or	B-X
nearly	B-X
intact	B-X
genes	B-X
appear	B-X
to	B-X
reside	B-X
on	B-X
almost	B-X
all	B-X
of	B-X
the	B-X
genomic	B-X
fragments	B-X
,	B-X
because	B-X
they	B-X
hybridize	B-X
strongly	B-X
to	B-X
gene	B-X
subfragments	B-X
representing	B-X
both	B-X
5	B-X
'	B-X
and	B-X
3	B-X
'	B-X
portions	B-X
of	B-X
the	B-X
coding	B-X
sequence	B-X
as	B-X
well	B-X
as	B-X
to	B-X
3	B-X
'	B-X
noncoding	B-X
DNA	B-X
that	B-X
is	B-X
found	B-X
specifically	B-X
associated	B-X
with	B-X
the	B-X
coding	B-X
region	B-X
.	B-X
A	B-X
subgroup	B-X
of	B-X
about	B-X
six	B-X
of	B-X
the	B-X
fragments	B-X
also	B-X
shares	B-X
homology	B-X
within	B-X
the	B-X
73	B-X
nucleotides	B-X
immediately	B-X
preceding	B-X
the	B-X
AUG	B-X
codon	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
the	B-X
temperature	B-X
of	B-X
complete	B-X
dissociation	B-X
of	B-X
the	B-X
coding	B-X
region	B-X
probe	B-X
in	B-X
0.75	B-X
M	B-X
NaCl/0.075	B-X
M	B-X
Na3	B-X
citrate/50	B-X
%	B-X
(	B-X
vol/vol	B-X
)	B-X
formamide	B-X
,	B-X
the	B-X
25	B-X
fragments	B-X
are	B-X
separable	B-X
into	B-X
three	B-X
stringency	B-X
classes	B-X
of	B-X
40-50	B-X
degrees	B-X
C	B-X
,	B-X
50-55	B-X
degrees	B-X
C	B-X
,	B-X
and	B-X
55-60	B-X
degrees	B-X
C.	B-X
The	B-X
latter	B-X
,	B-X
high-stringency	B-X
group	B-X
of	B-X
about	B-X
seven	B-X
fragments	B-X
includes	B-X
those	B-X
cloned	B-X
in	B-X
the	B-X
recombinant	B-X
phage	B-X
isolates	B-X
,	B-X
whose	B-X
regions	B-X
homologous	B-X
to	B-X
cytochrome	B-X
c	B-X
are	B-X
shown	B-X
to	B-X
differ	B-X
from	B-X
the	B-X
purified	B-X
gene	B-X
of	B-X
known	B-X
sequence	B-X
by	B-X
an	B-X
amount	B-X
equivalent	B-X
to	B-X
about	B-X
2	B-X
%	B-X
mismatched	B-X
bases	B-X
.	B-X

of	O
the	O
a2	O
sheep	B-Species
gene	O
was	O
determined	O
to	O
be	O
17	O
,	O
variation	O
in	O
the	O
precise	O
number	O

TRANSRIPTlO	O

A	O
5w	O
r	O
<EOS>	B-X
Virulizin	B-X
(	B-X
R	B-X
)	B-X
(	B-X
registered	B-X
trademark	B-X
of	B-X
Lorus	B-X
Therapeutics	B-X
,	B-X
Inc.	B-X
)	B-X
is	B-X
a	B-X
novel	B-X
biological	B-X
response	B-X
modifier	B-X
(	B-X
BRM	B-X
)	B-X
that	B-X
enhances	B-X
cell-mediated	B-X
immune	B-X
response	B-X
to	B-X
tumour	B-X
cells	B-X
by	B-X
direct	B-X
macrophage	B-X
activation	B-X
.	B-X
The	B-X
agent	B-X
,	B-X
an	B-X
aqueous	B-X
solution	B-X
containing	B-X
a	B-X
5	B-X
%	B-X
(	B-X
w/v	B-X
)	B-X
solid	B-X
material	B-X
mixture	B-X
comprised	B-X
of	B-X
inorganic	B-X
salts	B-X
(	B-X
95	B-X
-	B-X
99	B-X
%	B-X
of	B-X
the	B-X
dry	B-X
weight	B-X
)	B-X
and	B-X
organic	B-X
compounds	B-X
of	B-X
molecular	B-X
weight	B-X
<	B-X
3000	B-X
Daltons	B-X
(	B-X
1	B-X
-	B-X
5	B-X
%	B-X
of	B-X
the	B-X
dry	B-X
weight	B-X
)	B-X
,	B-X
is	B-X
provided	B-X
as	B-X
a	B-X
sterile	B-X
,	B-X
injectable	B-X
formulation	B-X
.	B-X
Virtually	B-X
all	B-X
the	B-X
organic	B-X
compounds	B-X
and	B-X
ionic	B-X
components	B-X
in	B-X
the	B-X
mixture	B-X
have	B-X
been	B-X
identified	B-X
by	B-X
chemical	B-X
and	B-X
spectroscopic	B-X
methods	B-X
.	B-X
Virulizin	B-X
(	B-X
R	B-X
)	B-X
is	B-X
obtained	B-X
from	B-X
bovine	B-X
bile	B-X
by	B-X
a	B-X
standardised	B-X
process	B-X
involving	B-X
solvent	B-X
extraction	B-X
and	B-X
heat	B-X
hydrolysis	B-X
.	B-X
In	B-X
vitro	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
Virulizin	B-X
(	B-X
R	B-X
)	B-X
can	B-X
stimulate	B-X
blood	B-X
monocytes	B-X
,	B-X
peritoneal	B-X
macrophages	B-X
and	B-X
alveolar	B-X
macrophages	B-X
from	B-X
patients	B-X
with	B-X
malignant	B-X
and	B-X
non-malignant	B-X
diseases	B-X
to	B-X
mediate	B-X
a	B-X
level	B-X
of	B-X
tumour	B-X
cell	B-X
cytolysis	B-X
that	B-X
is	B-X
equal	B-X
to	B-X
,	B-X
or	B-X
greater	B-X
than	B-X
,	B-X
that	B-X
elicited	B-X
in	B-X
the	B-X
same	B-X
cells	B-X
by	B-X
other	B-X
,	B-X
more	B-X
conventional	B-X
biological	B-X
activators	B-X
.	B-X
Other	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
the	B-X
stimulation	B-X
of	B-X
cytotoxic	B-X
function	B-X
by	B-X
Virulizin	B-X
(	B-X
R	B-X
)	B-X
is	B-X
insensitive	B-X
to	B-X
the	B-X
inhibitory	B-X
effects	B-X
of	B-X
prostaglandins	B-X
and	B-X
,	B-X
hence	B-X
,	B-X
is	B-X
distinct	B-X
from	B-X
many	B-X
other	B-X
activators	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
blood	B-X
monocytes	B-X
of	B-X
patients	B-X
currently	B-X
receiving	B-X
cytotoxic	B-X
chemotherapy	B-X
showed	B-X
activation	B-X
with	B-X
Virulizin	B-X
(	B-X
R	B-X
)	B-X
.	B-X
In	B-X
preclinical	B-X
studies	B-X
,	B-X
Virulizin	B-X
(	B-X
R	B-X
)	B-X
showed	B-X
modest	B-X
inhibition	B-X
of	B-X
tumour	B-X
growth	B-X
in	B-X
a	B-X
human	B-X
pancreatic	B-X
cancer	B-X
xenograft	B-X
model	B-X
(	B-X
T/C	B-X
,	B-X
0.60	B-X
;	B-X
p	B-X
=	B-X
0.012	B-X
)	B-X
and	B-X
increased	B-X
survival	B-X
time	B-X
by	B-X
8	B-X
%	B-X
(	B-X
p	B-X
=	B-X
0.046	B-X
)	B-X
in	B-X
a	B-X
murine	B-X
melanoma	B-X
model	B-X
.	B-X
Toxicity	B-X
studies	B-X
in	B-X
rats	B-X
indicated	B-X
that	B-X
Virulizin	B-X
(	B-X
R	B-X
)	B-X
injected	B-X
intramuscularly	B-X
was	B-X
well-tolerated	B-X
by	B-X
the	B-X
animals	B-X
.	B-X
Except	B-X
for	B-X
a	B-X
lower	B-X
rate	B-X
of	B-X
body	B-X
weight	B-X
gain	B-X
in	B-X
the	B-X
high	B-X
dose	B-X
group	B-X
,	B-X
no	B-X
toxicological	B-X
effect	B-X
related	B-X
to	B-X
treatment	B-X
was	B-X
observed	B-X
in	B-X
a	B-X
chronic	B-X
13-week	B-X
study	B-X
(	B-X
three	B-X
weekly	B-X
im	B-X
.	B-X
Mutagenicity	B-X
studies	B-X
with	B-X
Virulizin	B-X
(	B-X
R	B-X
)	B-X
were	B-X
negative	B-X
.	B-X
Many	B-X
Phase	B-X
I/II	B-X
and	B-X
Phase	B-X
II	B-X
clinical	B-X
trials	B-X
were	B-X
carried	B-X
out	B-X
with	B-X
Virulizin	B-X
(	B-X
R	B-X
)	B-X
to	B-X
evaluate	B-X
the	B-X
safety	B-X
and	B-X
efficacy	B-X
of	B-X
the	B-X
agent	B-X
to	B-X
treat	B-X
cancer	B-X
patients	B-X
.	B-X
Three	B-X
of	B-X
those	B-X
studies	B-X
involved	B-X
the	B-X
treatment	B-X
of	B-X
patients	B-X
with	B-X
pancreatic	B-X
adenocarcinoma	B-X
.	B-X
The	B-X
majority	B-X
of	B-X
patients	B-X
participating	B-X
in	B-X
these	B-X
studies	B-X
were	B-X
those	B-X
who	B-X
had	B-X
failed	B-X
conventional	B-X
treatment	B-X
including	B-X
surgery	B-X
or	B-X
chemotherapy	B-X
.	B-X
Disease	B-X
stabilisation	B-X
was	B-X
observed	B-X
in	B-X
patients	B-X
treated	B-X
with	B-X
Virulizin	B-X
(	B-X
R	B-X
)	B-X
,	B-X
and	B-X
,	B-X
based	B-X
on	B-X
a	B-X
meta-analysis	B-X
of	B-X
the	B-X
data	B-X
from	B-X
the	B-X
three	B-X
studies	B-X
,	B-X
the	B-X
survival	B-X
of	B-X
the	B-X
patients	B-X
treated	B-X
with	B-X
Virulizin	B-X
(	B-X
R	B-X
)	B-X
was	B-X
better	B-X
than	B-X
a	B-X
similar	B-X
patient	B-X
population	B-X
receiving	B-X
standard	B-X
chemotherapeutic	B-X
agent	B-X
for	B-X
that	B-X
disease	B-X
indication	B-X
.	B-X
However	B-X
,	B-X
randomised	B-X
studies	B-X
may	B-X
be	B-X
required	B-X
to	B-X
confirm	B-X
the	B-X
effect	B-X
of	B-X
Virulizin	B-X
(	B-X
R	B-X
)	B-X
on	B-X
disease	B-X
stabilisation	B-X
and	B-X
survival	B-X
.	B-X
In	B-X
the	B-X
three	B-X
studies	B-X
on	B-X
patients	B-X
with	B-X
malignant	B-X
melanoma	B-X
,	B-X
at	B-X
least	B-X
69	B-X
%	B-X
treated	B-X
with	B-X
Virulizin	B-X
(	B-X
R	B-X
)	B-X
showed	B-X
no	B-X
additional	B-X
deterioration	B-X
or	B-X
had	B-X
improved	B-X
at	B-X
four	B-X
weeks	B-X
with	B-X
response	B-X
being	B-X
only	B-X
slightly	B-X
reduced	B-X
after	B-X
eight	B-X
weeks	B-X
.	B-X
In	B-X
the	B-X
evaluation	B-X
of	B-X
safety	B-X
,	B-X
assessed	B-X
overall	B-X
from	B-X
these	B-X
clinical	B-X
studies	B-X
in	B-X
200	B-X
patients	B-X
treated	B-X
with	B-X
Virulizin	B-X
(	B-X
R	B-X
)	B-X
,	B-X
the	B-X
number	B-X
and	B-X
severity	B-X
of	B-X
adverse	B-X
events	B-X
were	B-X
small	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
Virulizin	B-X
(	B-X
R	B-X
)	B-X
is	B-X
a	B-X
novel	B-X
,	B-X
clinically	B-X
non-toxic	B-X
biological	B-X
response	B-X
modifier	B-X
that	B-X
appears	B-X
to	B-X
have	B-X
a	B-X
clinical	B-X
effect	B-X
on	B-X
disease	B-X
stabilisation	B-X
and	B-X
survival	B-X
in	B-X
patients	B-X
with	B-X
pancreatic	B-X
cancer	B-X
and	B-X
malignant	B-X
melanoma	B-X
.	B-X
However	B-X
,	B-X
additional	B-X
randomised	B-X
studies	B-X
may	B-X
be	B-X
required	B-X
to	B-X
confirm	B-X
those	B-X
effects	B-X
.	B-X
Future	B-X
studies	B-X
on	B-X
Virulizin	B-X
(	B-X
R	B-X
)	B-X
will	B-X
focus	B-X
on	B-X
the	B-X
characterisation	B-X
of	B-X
the	B-X
active	B-X
components	B-X
in	B-X
the	B-X
agent	B-X
and	B-X
the	B-X
development	B-X
of	B-X
a	B-X
synthetic	B-X
formulation	B-X
.	B-X
Subsequently	B-X
,	B-X
the	B-X
preclinical	B-X
and	B-X
clinical	B-X
pharmacokinetics	B-X
of	B-X
Virulizin	B-X
(	B-X
R	B-X
)	B-X
will	B-X
be	B-X
determined	B-X
and	B-X
studies	B-X
to	B-X
optimise	B-X
the	B-X
human	B-X
dose	B-X
of	B-X
the	B-X
agent	B-X
will	B-X
be	B-X
carried	B-X
out	B-X
.	B-X

1	O
"	O
2a4	O
133	O
112s	O
11	O
.	O
17	O
0	O
.	O

3O	O
2	O
715	O
6	O
.	O
2	O
313	O
04	O
4	O
.	O
2B	O
3	O
.	O
51	O
2	O
.	O
2	O
12	O

EXON0	O
p	O
o	O
n	O
5	O
Ik	O
h	O
f	O
d	O
4	O
.	O

b	O
<EOS>	B-X
Hepatitis	B-X
B	B-X
is	B-X
caused	B-X
by	B-X
the	B-X
hepatitis	B-X
B	B-X
virus	B-X
(	B-X
HBV	B-X
)	B-X
,	B-X
which	B-X
infects	B-X
the	B-X
liver	B-X
and	B-X
may	B-X
lead	B-X
to	B-X
chronic	B-X
liver	B-X
disease	B-X
,	B-X
including	B-X
cirrhosis	B-X
and	B-X
hepatocellular	B-X
carcinoma	B-X
.	B-X
HBV	B-X
represents	B-X
a	B-X
worldwide	B-X
public	B-X
health	B-X
problem	B-X
,	B-X
causing	B-X
major	B-X
morbidity	B-X
and	B-X
mortality	B-X
.	B-X
Affordable	B-X
,	B-X
safe	B-X
,	B-X
and	B-X
effective	B-X
,	B-X
hepatitis	B-X
B	B-X
vaccines	B-X
are	B-X
the	B-X
best	B-X
tools	B-X
we	B-X
have	B-X
to	B-X
control	B-X
and	B-X
prevent	B-X
hepatitis	B-X
B	B-X
.	B-X
The	B-X
effective	B-X
implementation	B-X
of	B-X
hepatitis	B-X
B	B-X
vaccination	B-X
programs	B-X
has	B-X
resulted	B-X
in	B-X
a	B-X
substantial	B-X
decrease	B-X
in	B-X
the	B-X
HBV	B-X
carrier	B-X
rate	B-X
and	B-X
hepatitis	B-X
B-related	B-X
morbidity	B-X
and	B-X
mortality	B-X
.	B-X
This	B-X
article	B-X
summarizes	B-X
the	B-X
great	B-X
triumphs	B-X
of	B-X
the	B-X
hepatitis	B-X
B	B-X
vaccine	B-X
,	B-X
the	B-X
first	B-X
anticancer	B-X
and	B-X
virus-like-particle-based	B-X
vaccine	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
existing	B-X
unresolved	B-X
issues	B-X
and	B-X
future	B-X
perspectives	B-X
on	B-X
hepatitis	B-X
B	B-X
vaccination	B-X
required	B-X
for	B-X
global	B-X
prevention	B-X
of	B-X
HBV	B-X
infection	B-X
are	B-X
discussed	B-X
.	B-X

WPM300	O
16	O
16	O
14	O
13	O
12	O
11	O
10	O
9	O
6	O
7	O
6	O
5	O
4	O
3	O
2	O
1	O
<EOS>	B-X
The	B-X
title	B-X
compound	B-X
,	B-X
C28H52Si8	B-X
,	B-X
was	B-X
synthesized	B-X
by	B-X
condensation	B-X
of	B-X
two	B-X
mol-ecules	B-X
of	B-X
1,2,3,4-tetra-kis-	B-X
(	B-X
chloro-dimethyl-sil-yl	B-X
)	B-X
benzene	B-X
with	B-X
lithium	B-X
.	B-X
The	B-X
3,4-disila-1,2-benzocyclo-butene	B-X
rings	B-X
in	B-X
the	B-X
centrosymmetric	B-X
molecule	B-X
are	B-X
bridged	B-X
by	B-X
1,1,2,2-tetra-methyl-disilanylene	B-X
chains	B-X
with	B-X
an	B-X
anti	B-X
conformation	B-X
.	B-X
The	B-X
benzene	B-X
rings	B-X
are	B-X
deformed	B-X
by	B-X
fusion	B-X
with	B-X
a	B-X
3,4-disilacyclo-butene	B-X
ring	B-X
resulting	B-X
in	B-X
a	B-X
slight	B-X
boat	B-X
conformation	B-X
.	B-X
In	B-X
the	B-X
title	B-X
compound	B-X
,	B-X
C	B-X
(	B-X
30	B-X
)	B-X
H	B-X
(	B-X
27	B-X
)	B-X
N	B-X
(	B-X
3	B-X
)	B-X
O	B-X
(	B-X
6	B-X
)	B-X
,	B-X
the	B-X
furan	B-X
and	B-X
pyrrolidine	B-X
rings	B-X
adopt	B-X
envelope	B-X
conformations	B-X
(	B-X
with	B-X
C	B-X
and	B-X
N	B-X
atoms	B-X
as	B-X
the	B-X
flaps	B-X
,	B-X
respectively	B-X
)	B-X
.	B-X
The	B-X
Î²-lactam	B-X
ring	B-X
is	B-X
planar	B-X
[	B-X
maximum	B-X
deviation	B-X
=	B-X
0.0044	B-X
(	B-X
16	B-X
)	B-X
Ã	B-X
]	B-X
and	B-X
forms	B-X
dihedral	B-X
angles	B-X
of	B-X
30.61	B-X
(	B-X
9	B-X
)	B-X
and	B-X
85.51	B-X
(	B-X
9	B-X
)	B-X
Â°	B-X
,	B-X
respectively	B-X
,	B-X
with	B-X
the	B-X
attached	B-X
meth-oxy-phenyl	B-X
and	B-X
phen-oxy	B-X
rings	B-X
.	B-X
The	B-X
crystal	B-X
packing	B-X
is	B-X
stabilized	B-X
by	B-X
N-Hâ¯O	B-X
and	B-X
C-Hâ¯O	B-X
inter-actions	B-X
forming	B-X
R	B-X
(	B-X
2	B-X
)	B-X
(	B-X
2	B-X
)	B-X
(	B-X
8	B-X
)	B-X
,	B-X
R	B-X
(	B-X
2	B-X
)	B-X
(	B-X
2	B-X
)	B-X
(	B-X
20	B-X
)	B-X
and	B-X
R	B-X
(	B-X
2	B-X
)	B-X
(	B-X
2	B-X
)	B-X
(	B-X
14	B-X
)	B-X
ring	B-X
motifs	B-X
.	B-X

B	O
<EOS>	B-X
Hepatitis	B-X
B	B-X
is	B-X
caused	B-X
by	B-X
the	B-X
hepatitis	B-X
B	B-X
virus	B-X
(	B-X
HBV	B-X
)	B-X
,	B-X
which	B-X
infects	B-X
the	B-X
liver	B-X
and	B-X
may	B-X
lead	B-X
to	B-X
chronic	B-X
liver	B-X
disease	B-X
,	B-X
including	B-X
cirrhosis	B-X
and	B-X
hepatocellular	B-X
carcinoma	B-X
.	B-X
HBV	B-X
represents	B-X
a	B-X
worldwide	B-X
public	B-X
health	B-X
problem	B-X
,	B-X
causing	B-X
major	B-X
morbidity	B-X
and	B-X
mortality	B-X
.	B-X
Affordable	B-X
,	B-X
safe	B-X
,	B-X
and	B-X
effective	B-X
,	B-X
hepatitis	B-X
B	B-X
vaccines	B-X
are	B-X
the	B-X
best	B-X
tools	B-X
we	B-X
have	B-X
to	B-X
control	B-X
and	B-X
prevent	B-X
hepatitis	B-X
B	B-X
.	B-X
In	B-X
2019	B-X
,	B-X
coverage	B-X
of	B-X
3	B-X
doses	B-X
of	B-X
the	B-X
hepatitis	B-X
B	B-X
vaccine	B-X
reached	B-X
85	B-X
%	B-X
worldwide	B-X
compared	B-X
to	B-X
around	B-X
30	B-X
%	B-X
in	B-X
2000	B-X
.	B-X
The	B-X
effective	B-X
implementation	B-X
of	B-X
hepatitis	B-X
B	B-X
vaccination	B-X
programs	B-X
has	B-X
resulted	B-X
in	B-X
a	B-X
substantial	B-X
decrease	B-X
in	B-X
the	B-X
HBV	B-X
carrier	B-X
rate	B-X
and	B-X
hepatitis	B-X
B-related	B-X
morbidity	B-X
and	B-X
mortality	B-X
.	B-X
This	B-X
article	B-X
summarizes	B-X
the	B-X
great	B-X
triumphs	B-X
of	B-X
the	B-X
hepatitis	B-X
B	B-X
vaccine	B-X
,	B-X
the	B-X
first	B-X
anticancer	B-X
and	B-X
virus-like-particle-based	B-X
vaccine	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
existing	B-X
unresolved	B-X
issues	B-X
and	B-X
future	B-X
perspectives	B-X
on	B-X
hepatitis	B-X
B	B-X
vaccination	B-X
required	B-X
for	B-X
global	B-X
prevention	B-X
of	B-X
HBV	B-X
infection	B-X
are	B-X
discussed	B-X
.	B-X

110	O
16	O
4	O
.	O
2	O
13111	O
112n	O
1113104	O
3	O
.	O
6	O
gm74	O
2	O
6	O
.	O

4	O
4	O
2	O
3	O
.	O
2	O
22	O
in	O
<EOS>	B-X
The	B-X
asymmetric	B-X
unit	B-X
of	B-X
the	B-X
title	B-X
compound	B-X
,	B-X
C	B-X
(	B-X
9	B-X
)	B-X
H	B-X
(	B-X
4	B-X
)	B-X
S	B-X
(	B-X
7	B-X
)	B-X
,	B-X
contains	B-X
two	B-X
independent	B-X
mol-ecules	B-X
,	B-X
in	B-X
one	B-X
of	B-X
which	B-X
the	B-X
central	B-X
five-membered	B-X
ring	B-X
is	B-X
disordered	B-X
over	B-X
two	B-X
orientations	B-X
in	B-X
a	B-X
0.924	B-X
(	B-X
3	B-X
)	B-X
:0.076	B-X
(	B-X
3	B-X
)	B-X
ratio	B-X
.	B-X
The	B-X
mol-ecular	B-X
skeleton	B-X
is	B-X
almost	B-X
planar	B-X
:	B-X
the	B-X
average	B-X
distance	B-X
of	B-X
the	B-X
atoms	B-X
from	B-X
their	B-X
mean	B-X
plane	B-X
is	B-X
0.128	B-X
(	B-X
7	B-X
)	B-X
Ã	B-X
in	B-X
the	B-X
ordered	B-X
mol-ecule	B-X
,	B-X
and	B-X
0.088	B-X
(	B-X
5	B-X
)	B-X
and	B-X
0.123	B-X
(	B-X
2	B-X
)	B-X
Ã	B-X
in	B-X
the	B-X
major	B-X
and	B-X
minor	B-X
disorder	B-X
components	B-X
,	B-X
respectively	B-X
.	B-X
Adjacent	B-X
columns	B-X
inter-act	B-X
via	B-X
short	B-X
Sâ¯S	B-X
[	B-X
3.33	B-X
(	B-X
2	B-X
)	B-X
,	B-X
3.434	B-X
(	B-X
3	B-X
)	B-X
,	B-X
3.444	B-X
(	B-X
2	B-X
)	B-X
,	B-X
3.503	B-X
(	B-X
2	B-X
)	B-X
,	B-X
3.519	B-X
(	B-X
3	B-X
)	B-X
and	B-X
3.53	B-X
(	B-X
4	B-X
)	B-X
Ã	B-X
]	B-X
and	B-X
Sâ¯H	B-X
[	B-X
2.814	B-X
(	B-X
2	B-X
)	B-X
,	B-X
2.87	B-X
(	B-X
7	B-X
)	B-X
,	B-X
2.92	B-X
(	B-X
2	B-X
)	B-X
,	B-X
2.9269	B-X
(	B-X
18	B-X
)	B-X
,	B-X
2.93	B-X
(	B-X
2	B-X
)	B-X
,	B-X
2.94	B-X
(	B-X
2	B-X
)	B-X
,	B-X
2.939	B-X
(	B-X
2	B-X
)	B-X
,	B-X
2.967	B-X
(	B-X
2	B-X
)	B-X
and	B-X
2.974	B-X
(	B-X
1	B-X
)	B-X
Ã	B-X
]	B-X
contacts	B-X
.	B-X
Single	B-X
crystals	B-X
of	B-X
garnet-type	B-X
trimanganese	B-X
(	B-X
II	B-X
)	B-X
dichrom-i-um	B-X
(	B-X
III	B-X
)	B-X
tris-	B-X
[	B-X
orthogermanate	B-X
(	B-X
IV	B-X
)	B-X
]	B-X
,	B-X
Mn	B-X
(	B-X
II	B-X
)	B-X
(	B-X
3	B-X
)	B-X
Cr	B-X
(	B-X
III	B-X
)	B-X
(	B-X
2	B-X
)	B-X
(	B-X
GeO	B-X
(	B-X
4	B-X
)	B-X
)	B-X
(	B-X
3	B-X
)	B-X
,	B-X
were	B-X
obtained	B-X
by	B-X
utilizing	B-X
a	B-X
chemical	B-X
transport	B-X
reaction	B-X
.	B-X
Corres-ponding	B-X
to	B-X
the	B-X
mineral	B-X
garnet	B-X
with	B-X
the	B-X
general	B-X
formula	B-X
A	B-X
(	B-X
II	B-X
)	B-X
(	B-X
3	B-X
)	B-X
B	B-X
(	B-X
III	B-X
)	B-X
(	B-X
2	B-X
)	B-X
(	B-X
SiO	B-X
(	B-X
4	B-X
)	B-X
)	B-X
(	B-X
3	B-X
)	B-X
,	B-X
each	B-X
of	B-X
the	B-X
four	B-X
elements	B-X
occupies	B-X
only	B-X
one	B-X
crystallographically	B-X
distinct	B-X
position	B-X
.	B-X
Mn	B-X
(	B-X
2+	B-X
)	B-X
occupies	B-X
the	B-X
respective	B-X
A	B-X
position	B-X
(	B-X
Wyckoff	B-X
site	B-X
24c	B-X
,	B-X
site	B-X
symmetry	B-X
2.22	B-X
)	B-X
,	B-X
being	B-X
surrounded	B-X
by	B-X
eight	B-X
O	B-X
atoms	B-X
that	B-X
form	B-X
a	B-X
distorted	B-X
cube	B-X
[	B-X
d	B-X
(	B-X
Mn-O	B-X
)	B-X
=	B-X
2.291	B-X
(	B-X
2	B-X
)	B-X
and	B-X
2.422	B-X
(	B-X
2	B-X
)	B-X
Ã	B-X
,	B-X
4Ã	B-X
each	B-X
]	B-X
,	B-X
while	B-X
Cr	B-X
(	B-X
3+	B-X
)	B-X
on	B-X
the	B-X
B	B-X
position	B-X
(	B-X
Wyckoff	B-X
site	B-X
16a	B-X
,	B-X
site	B-X
symmetry	B-X
.-3	B-X
.	B-X
)	B-X
is	B-X
situated	B-X
in	B-X
a	B-X
slightly	B-X
distorted	B-X
octa-hedron	B-X
of	B-X
six	B-X
O	B-X
(	B-X
2-	B-X
)	B-X
anions	B-X
[	B-X
d	B-X
(	B-X
Cr-O	B-X
)	B-X
=	B-X
1.972	B-X
(	B-X
2	B-X
)	B-X
Ã	B-X
,	B-X
6Ã	B-X
]	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
O	B-X
atoms	B-X
on	B-X
general	B-X
site	B-X
96h	B-X
form	B-X
isolated	B-X
[	B-X
GeO	B-X
(	B-X
4	B-X
)	B-X
]	B-X
(	B-X
4-	B-X
)	B-X
tetra-hedra	B-X
with	B-X
Ge	B-X
(	B-X
4+	B-X
)	B-X
on	B-X
site	B-X
24d	B-X
[	B-X
site	B-X
symmetry	B-X
-4	B-X
..	B-X
;	B-X
d	B-X
(	B-X
Ge-O	B-X
)	B-X
=	B-X
1.744	B-X
(	B-X
2	B-X
)	B-X
Ã	B-X
,	B-X
4Ã	B-X
]	B-X
.	B-X

1	O
a1m03	O
133	O
1	O
.	O
2	O
11	O
10	O
01	O
341	O
6	O
.	O
<EOS>	B-X
Twenty-three	B-X
common	B-X
clinical	B-X
autoantibodies	B-X
in	B-X
pre-	B-X
and	B-X
posttreatment	B-X
sera	B-X
from	B-X
133	B-X
ipilimumab-treated	B-X
melanoma	B-X
patients	B-X
were	B-X
determined	B-X
,	B-X
and	B-X
their	B-X
development	B-X
linked	B-X
to	B-X
the	B-X
occurrence	B-X
of	B-X
irAEs	B-X
,	B-X
best	B-X
overall	B-X
response	B-X
,	B-X
and	B-X
survival	B-X
.	B-X
Autoantibodies	B-X
developed	B-X
in	B-X
19.2	B-X
%	B-X
(	B-X
19/99	B-X
)	B-X
of	B-X
patients	B-X
who	B-X
were	B-X
autoantibody-negative	B-X
pretreatment	B-X
.	B-X
A	B-X
nonsignificant	B-X
association	B-X
was	B-X
observed	B-X
between	B-X
development	B-X
of	B-X
any	B-X
autoantibodies	B-X
and	B-X
any	B-X
irAEs	B-X
[	B-X
OR	B-X
,	B-X
2.92	B-X
;	B-X
95	B-X
%	B-X
confidence	B-X
interval	B-X
(	B-X
CI	B-X
)	B-X
0.85-10.01	B-X
]	B-X
.	B-X
Patients	B-X
with	B-X
antithyroid	B-X
antibodies	B-X
after	B-X
ipilimumab	B-X
had	B-X
significantly	B-X
more	B-X
thyroid	B-X
dysfunction	B-X
under	B-X
subsequent	B-X
anti-PD-1	B-X
therapy	B-X
:	B-X
7/11	B-X
(	B-X
54.6	B-X
%	B-X
)	B-X
patients	B-X
with	B-X
antithyroid	B-X
antibodies	B-X
after	B-X
ipilimumab	B-X
developed	B-X
thyroid	B-X
dysfunction	B-X
under	B-X
anti-PD1	B-X
versus	B-X
7/49	B-X
(	B-X
14.3	B-X
%	B-X
)	B-X
patients	B-X
without	B-X
antibodies	B-X
(	B-X
OR	B-X
,	B-X
9.96	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
1.94-51.1	B-X
)	B-X
.	B-X
Patients	B-X
who	B-X
developed	B-X
autoantibodies	B-X
showed	B-X
a	B-X
trend	B-X
for	B-X
better	B-X
survival	B-X
(	B-X
HR	B-X
for	B-X
all-cause	B-X
death	B-X
:	B-X
0.66	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
0.34-1.26	B-X
)	B-X
and	B-X
therapy	B-X
response	B-X
(	B-X
OR	B-X
,	B-X
2.64	B-X
;	B-X
95	B-X
%	B-X
CI	B-X
,	B-X
0.85-8.16	B-X
)	B-X
.	B-X

1	O
117	O
6	O
.	O
2	O
4	O
12	O
417	O
3I5	O
'	O
m	O
2	O

DM00	O
1	O
q5	O
p	O
0	O
n	O
m	O
I	O
k	O
.	O

j	O
i	O
h	O
g	O
f	O
d	O
c	O
b	O
a	O
147306	O
17	O
16	O
15	O
14	O
13	O
12	O
11	O
10	O
9	O
a	O
7	O
6	O
5	O
4	O
3	O
2	O
1	O

175	O
17	O
.	O
0	O
16	O
.	O
6	O
&	O
16	O
'	O
5	O
.	O
5	O
15	O
.	O
0	O
14	O
.	O
5	O
14	O
.	O
<EOS>	B-X
Studies	B-X
of	B-X
oxygen	B-X
binding	B-X
energy	B-X
to	B-X
hemoglobin	B-X
molecule	B-X
.	B-X
Effects	B-X
of	B-X
5,6-dihydroxytryptamine	B-X
on	B-X
tyrosine-hydroxylase	B-X
activity	B-X
in	B-X
central	B-X
catecholaminergic	B-X
neurons	B-X
of	B-X
the	B-X
rat	B-X
.	B-X
Inhibition	B-X
of	B-X
aldehyde	B-X
reductase	B-X
by	B-X
acidic	B-X
metabolites	B-X
of	B-X
the	B-X
biogenic	B-X
amines	B-X
.	B-X
Seasonal	B-X
variation	B-X
in	B-X
diet	B-X
,	B-X
volatile	B-X
fatty	B-X
acid	B-X
production	B-X
and	B-X
size	B-X
of	B-X
the	B-X
cecum	B-X
of	B-X
roch	B-X
ptarmigan	B-X
.	B-X

13	O
.	O
5	O
13	O
.	O
0	O
12	O
.	O
5	O
12	O
.	O
0	O
11	O
.	O
5	O
11	O
10	O
.	O
5M	O
10	O
.	O
0	O
9	O
.	O
5	O
9	O
.	O
0	O
8	O
.	O

5	O
.	O
0	O
71	O
7	O
.	O
0	O
6	O
.	O
5	O
6	O
.	O
<EOS>	B-X
The	B-X
characterization	B-X
and	B-X
localization	B-X
of	B-X
a	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-ATPase	B-X
(	B-X
ATP	B-X
phosphohydrolase	B-X
,	B-X
EC	B-X
3.6.1.3	B-X
)	B-X
in	B-X
the	B-X
tooth	B-X
germ	B-X
of	B-X
the	B-X
porcine	B-X
fetus	B-X
are	B-X
reported	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
0.5	B-X
mM	B-X
ATP	B-X
,	B-X
maximal	B-X
enzyme	B-X
activity	B-X
is	B-X
obtained	B-X
at	B-X
0.5	B-X
--	B-X
1.0	B-X
mM	B-X
CaCl2	B-X
.	B-X
20	B-X
mumol	B-X
per	B-X
h	B-X
per	B-X
mg	B-X
of	B-X
protein	B-X
as	B-X
the	B-X
enzyme	B-X
preparation	B-X
is	B-X
used	B-X
here	B-X
.	B-X
The	B-X
Km	B-X
for	B-X
ATP	B-X
is	B-X
8.85	B-X
-	B-X
10	B-X
(	B-X
-5	B-X
)	B-X
M.	B-X
The	B-X
optimal	B-X
pH	B-X
for	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
activation	B-X
of	B-X
the	B-X
enzyme	B-X
lies	B-X
around	B-X
9.2	B-X
.	B-X

5	O
.	O
5	O
50	O
4	O
.	O
5	O
4	O
.	O
0	O
3	O
.	O
5	O
3	O
.	O
0	O
2	O
.	O
5	O
2	O
.	O
0	O
1	O
.	O
5	O
1	O
.	O
0	O
<EOS>	B-X
Delineation	B-X
of	B-X
the	B-X
intimate	B-X
details	B-X
of	B-X
the	B-X
backbone	B-X
conformation	B-X
of	B-X
pyridine	B-X
nucleotide	B-X
coenzymes	B-X
in	B-X
aqueous	B-X
solution	B-X
.	B-X
Atomic	B-X
models	B-X
for	B-X
the	B-X
polypeptide	B-X
backbones	B-X
of	B-X
myohemerythrin	B-X
and	B-X
hemerythrin	B-X
.	B-X
Metal	B-X
substitutions	B-X
incarbonic	B-X
anhydrase	B-X
:	B-X
a	B-X
halide	B-X
ion	B-X
probe	B-X
study	B-X
.	B-X
Formate	B-X
assay	B-X
in	B-X
body	B-X
fluids	B-X
:	B-X
application	B-X
in	B-X
methanol	B-X
poisoning	B-X
.	B-X

KILOBASE	O

Fiue3	O
Organization	O
of	O
60	O
%	O
of	O
the	O
3	O
'	O
end	O
of	O
the	O
sheep	B-Species
a2	O
collagen	O
gene	O
.	O

(	O
A	O
)	O
}	O
The	O
exon	O
(	O
)	O
and	O
intron	O
(	O
CDJ	O
)	O
order	O
within	O
the	O
a2	O
gene	O
as	O
determined	O
by	O
R	O
loop	O
analysis	O
of	O
SpC3	O
DNA	O
-	O
a2	O
mRNA	O
hybrid	O
molecules	O
visualized	O
by	O
the	O
electron	O
microscopic	O
70	O
%	O
formamide	O
spreading	O
method	O
.	O

(	O
B	O
)	O
The	O
exon	O
Um	O
)	O

and	O
intron	O
(	O
Efl	O
)	O
order	O
within	O
the	O
a2	O
gene	O
as	O
determined	O
by	O
R	O
loop	O
analysis	O
of	O
SpC3	O
DNA	O
-	O
a2	O
mRNA	O
hybrid	O
molecules	O
evaluated	O
by	O
the	O
electron	O
microscopic	O

urea	O
-	O
formamide	O
spreading	O
method	O
.	O
<EOS>	B-X
After	B-X
spreading	B-X
under	B-X
moderately	B-X
denaturing	B-X
conditions	B-X
(	B-X
50	B-X
or	B-X
60	B-X
%	B-X
formamide	B-X
)	B-X
,	B-X
50	B-X
to	B-X
70	B-X
%	B-X
of	B-X
the	B-X
molecules	B-X
were	B-X
circular	B-X
.	B-X
Increasing	B-X
the	B-X
formamide	B-X
concentration	B-X
to	B-X
70	B-X
and	B-X
85	B-X
%	B-X
decreased	B-X
the	B-X
number	B-X
of	B-X
circular	B-X
forms	B-X
,	B-X
and	B-X
only	B-X
linear	B-X
forms	B-X
were	B-X
observed	B-X
after	B-X
incubation	B-X
of	B-X
the	B-X
RNA	B-X
at	B-X
60	B-X
degrees	B-X
C	B-X
for	B-X
15	B-X
min	B-X
in	B-X
99	B-X
%	B-X
formamide	B-X
.	B-X
When	B-X
spread	B-X
from	B-X
4	B-X
M	B-X
urea-80	B-X
%	B-X
formamide	B-X
--	B-X
another	B-X
condition	B-X
known	B-X
to	B-X
denature	B-X
RNA	B-X
--	B-X
only	B-X
5	B-X
to	B-X
30	B-X
%	B-X
circular	B-X
molecules	B-X
were	B-X
observed	B-X
.	B-X
Pretreatment	B-X
of	B-X
the	B-X
RNA	B-X
with	B-X
0.5	B-X
M	B-X
glyoxal	B-X
at	B-X
37	B-X
degrees	B-X
C	B-X
for	B-X
15	B-X
min	B-X
prior	B-X
to	B-X
spreading	B-X
from	B-X
50	B-X
%	B-X
formamide	B-X
gave	B-X
less	B-X
than	B-X
5	B-X
%	B-X
cirucular	B-X
forms	B-X
.	B-X
Length	B-X
measurement	B-X
of	B-X
the	B-X
molecules	B-X
showed	B-X
that	B-X
they	B-X
were	B-X
not	B-X
significantly	B-X
degraded	B-X
by	B-X
any	B-X
of	B-X
the	B-X
methods	B-X
employed	B-X
.	B-X

Arrows	O
represent	O
the	O
approximate	O
location	O
of	O
intron	O
-	O
exon	O
junctions	O
.	O

All	O
values	O
are	O
presented	O
as	O
kilobase	O
pairs	O
.	O
<EOS>	B-X
Whole-genome	B-X
sequencing	B-X
using	B-X
nanopore	B-X
technologies	B-X
can	B-X
uncover	B-X
structural	B-X
variants	B-X
,	B-X
which	B-X
are	B-X
DNA	B-X
rearrangements	B-X
larger	B-X
than	B-X
50	B-X
base	B-X
pairs	B-X
.	B-X
Nanopore	B-X
technologies	B-X
can	B-X
also	B-X
characterize	B-X
their	B-X
boundaries	B-X
with	B-X
single-base	B-X
accuracy	B-X
,	B-X
owing	B-X
to	B-X
the	B-X
kilobase-long	B-X
reads	B-X
that	B-X
encompass	B-X
either	B-X
full	B-X
variants	B-X
or	B-X
their	B-X
junctions	B-X
.	B-X
The	B-X
consensus	B-X
is	B-X
1287	B-X
base	B-X
pairs	B-X
(	B-X
bp	B-X
)	B-X
long	B-X
,	B-X
has	B-X
30	B-X
bp	B-X
perfect	B-X
inverted	B-X
terminal	B-X
repeats	B-X
(	B-X
ITRs	B-X
)	B-X
,	B-X
and	B-X
encodes	B-X
a	B-X
343	B-X
amino	B-X
acid	B-X
(	B-X
aa	B-X
)	B-X
mariner	B-X
transposase	B-X
.	B-X
They	B-X
differ	B-X
from	B-X
the	B-X
consensus	B-X
by	B-X
an	B-X
average	B-X
of	B-X
7.8	B-X
%	B-X
in	B-X
DNA	B-X
sequence	B-X
and	B-X
7.5	B-X
indels	B-X
per	B-X
kilobase	B-X
,	B-X
both	B-X
of	B-X
which	B-X
values	B-X
indicate	B-X
that	B-X
the	B-X
copies	B-X
were	B-X
formed	B-X
about	B-X
50	B-X
Myr	B-X
ago	B-X
.	B-X
A	B-X
remarkable	B-X
exception	B-X
to	B-X
this	B-X
loss	B-X
of	B-X
functionality	B-X
is	B-X
revealed	B-X
by	B-X
a	B-X
set	B-X
of	B-X
ten	B-X
cDNA	B-X
clones	B-X
derived	B-X
from	B-X
a	B-X
particular	B-X
genomic	B-X
copy	B-X
that	B-X
has	B-X
diverged	B-X
only	B-X
2.4	B-X
%	B-X
from	B-X
the	B-X
consensus	B-X
,	B-X
retained	B-X
54	B-X
%	B-X
of	B-X
its	B-X
hypermutable	B-X
CpG	B-X
pairs	B-X
,	B-X
and	B-X
which	B-X
has	B-X
a	B-X
full-length	B-X
transposase	B-X
open	B-X
reading	B-X
frame	B-X
.	B-X

2249	O

Nucleic	O
Acids	O
Research	O
<EOS>	B-X
The	B-X
2021	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
database	B-X
Issue	B-X
contains	B-X
189	B-X
papers	B-X
spanning	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
biological	B-X
fields	B-X
and	B-X
investigation	B-X
.	B-X
The	B-X
entire	B-X
Database	B-X
Issue	B-X
is	B-X
freely	B-X
available	B-X
online	B-X
on	B-X
the	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
website	B-X
(	B-X
https	B-X
:	B-X
//academic.oup.com/nar	B-X
)	B-X
.	B-X
Editorial	B-X
:	B-X
the	B-X
19th	B-X
annual	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
web	B-X
server	B-X
issue	B-X
2021	B-X
.	B-X
Editorial	B-X
:	B-X
Critical	B-X
reviews	B-X
and	B-X
perspectives	B-X
in	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
.	B-X

of	O
introns	O
present	O
in	O
individual	O
hybrid	O
molecules	O
was	O
observed	O
.	O
<EOS>	B-X
A	B-X
contiguous	B-X
sequence	B-X
of	B-X
1729	B-X
bases	B-X
was	B-X
obtained	B-X
corresponding	B-X
to	B-X
an	B-X
observed	B-X
message	B-X
size	B-X
of	B-X
1.8	B-X
kilobases	B-X
(	B-X
kb	B-X
)	B-X
.	B-X
The	B-X
gene	B-X
consists	B-X
of	B-X
3	B-X
exons	B-X
separated	B-X
by	B-X
introns	B-X
of	B-X
2.2	B-X
and	B-X
3.5	B-X
kb	B-X
.	B-X
Lumican	B-X
is	B-X
present	B-X
in	B-X
the	B-X
extracellular	B-X
matrix	B-X
of	B-X
human	B-X
articular	B-X
cartilage	B-X
at	B-X
all	B-X
ages	B-X
,	B-X
although	B-X
its	B-X
abundance	B-X
is	B-X
far	B-X
greater	B-X
in	B-X
the	B-X
adult	B-X
.	B-X

The	O
reason	O
<EOS>	B-X
To	B-X
explore	B-X
the	B-X
reasons	B-X
why	B-X
women	B-X
stop	B-X
breastfeeding	B-X
completely	B-X
before	B-X
their	B-X
infants	B-X
are	B-X
six	B-X
months	B-X
of	B-X
age	B-X
and	B-X
to	B-X
identify	B-X
the	B-X
factors	B-X
associated	B-X
with	B-X
cessation	B-X
and	B-X
the	B-X
timing	B-X
of	B-X
cessation	B-X
.	B-X
Children	B-X
come	B-X
to	B-X
joint	B-X
action	B-X
with	B-X
a	B-X
generalized	B-X
sense	B-X
of	B-X
``	B-X
reason	B-X
,	B-X
''	B-X
which	B-X
carries	B-X
normative	B-X
implications	B-X
,	B-X
before	B-X
personalizing	B-X
reasons	B-X
.	B-X
The	B-X
demanding	B-X
and	B-X
giving	B-X
of	B-X
reasons	B-X
for	B-X
their	B-X
actions	B-X
are	B-X
core	B-X
business	B-X
for	B-X
public	B-X
policy	B-X
makers	B-X
in	B-X
a	B-X
democracy	B-X
.	B-X
But	B-X
there	B-X
are	B-X
many	B-X
different	B-X
reasons	B-X
for	B-X
asking	B-X
why	B-X
questions	B-X
,	B-X
and	B-X
correspondingly	B-X
many	B-X
different	B-X
responses	B-X
that	B-X
might	B-X
count	B-X
as	B-X
adequate	B-X
answers	B-X
.	B-X
Seven	B-X
different	B-X
reasons	B-X
for	B-X
reason-giving	B-X
are	B-X
here	B-X
distinguished	B-X
and	B-X
categorized	B-X
along	B-X
two	B-X
dimensions	B-X
:	B-X
political	B-X
moralism	B-X
versus	B-X
political	B-X
realism	B-X
,	B-X
and	B-X
high	B-X
versus	B-X
low	B-X
politics	B-X
.	B-X
The	B-X
attempts	B-X
at	B-X
repealing	B-X
it	B-X
were	B-X
characterized	B-X
by	B-X
low-politics	B-X
and	B-X
political-realist	B-X
modes	B-X
of	B-X
reason-giving	B-X
more	B-X
exclusively	B-X
.	B-X

for	O
this	O
may	O
be	O
due	O
to	O
size	O
heterogeneity	O
of	O
the	O
a2	O
mRNA	O
used	O
as	O
a	O
complementary	O
probe	O
.	O
<EOS>	B-X
Despite	B-X
the	B-X
virtual	B-X
identity	B-X
of	B-X
reported	B-X
cDNA	B-X
sequences	B-X
for	B-X
the	B-X
alpha	B-X
subunit	B-X
of	B-X
Go	B-X
(	B-X
Go	B-X
alpha	B-X
)	B-X
,	B-X
multiple	B-X
molecular	B-X
weight	B-X
forms	B-X
of	B-X
mRNA	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
tissues	B-X
from	B-X
all	B-X
species	B-X
examined	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
molecular	B-X
basis	B-X
for	B-X
the	B-X
size	B-X
heterogeneity	B-X
of	B-X
Go	B-X
alpha	B-X
mRNAs	B-X
,	B-X
four	B-X
cDNA	B-X
clones	B-X
were	B-X
isolated	B-X
from	B-X
the	B-X
same	B-X
retinal	B-X
lambda	B-X
gt10	B-X
cDNA	B-X
library	B-X
that	B-X
was	B-X
used	B-X
earlier	B-X
to	B-X
isolate	B-X
lambda	B-X
GO9	B-X
,	B-X
a	B-X
clone	B-X
encompassing	B-X
the	B-X
complete	B-X
coding	B-X
region	B-X
of	B-X
Go	B-X
alpha	B-X
.	B-X
An	B-X
oligonucleotide	B-X
probe	B-X
complementary	B-X
to	B-X
a	B-X
portion	B-X
of	B-X
the	B-X
3'-untranslated	B-X
region	B-X
of	B-X
lambda	B-X
GO9	B-X
that	B-X
differs	B-X
from	B-X
the	B-X
newly	B-X
isolated	B-X
clones	B-X
hybridized	B-X
with	B-X
3.0-	B-X
and	B-X
4.0-kb	B-X
mRNAs	B-X
present	B-X
in	B-X
bovine	B-X
brain	B-X
and	B-X
retina	B-X
whereas	B-X
a	B-X
similar	B-X
probe	B-X
for	B-X
the	B-X
unique	B-X
region	B-X
of	B-X
the	B-X
new	B-X
clones	B-X
hybridized	B-X
with	B-X
a	B-X
4.0-kb	B-X
mRNA	B-X
in	B-X
both	B-X
tissues	B-X
and	B-X
with	B-X
a	B-X
2.0-kb	B-X
mRNA	B-X
found	B-X
predominantly	B-X
in	B-X
retina	B-X
.	B-X
A	B-X
similar	B-X
hybridization	B-X
pattern	B-X
was	B-X
observed	B-X
when	B-X
brain	B-X
poly	B-X
(	B-X
A+	B-X
)	B-X
RNA	B-X
from	B-X
other	B-X
species	B-X
was	B-X
hybridized	B-X
with	B-X
the	B-X
different	B-X
3'-untranslated	B-X
region	B-X
probes	B-X
.	B-X
It	B-X
appears	B-X
that	B-X
differences	B-X
in	B-X
the	B-X
3'-untranslated	B-X
regions	B-X
could	B-X
,	B-X
in	B-X
part	B-X
,	B-X
be	B-X
the	B-X
basis	B-X
for	B-X
the	B-X
observed	B-X
heterogeneity	B-X
in	B-X
Go	B-X
alpha	B-X
mRNAs	B-X
.	B-X

Although	O
the	O
a2	O
mRNA	O
was	O
extensively	O
purified	O
(	O
2	O
)	O
,	O
some	O
degradation	O
was	O
likely	O
present	O
.	O

It	O
is	O
also	O
possible	O
that	O
additional	O
introns	O
exist	O
that	O
are	O
too	O
small	O
to	O
be	O
detected	O
by	O
electron	O
microscopic	O
R	O
loop	O
analysis	O
.	O

The	O
most	O
likely	O
a2	O
genetic	O
regions	O
containing	O
such	O
introns	O
are	O
exons	O
"	O
g	O
"	O
and	O
"	O
m	O
"	O
.	O

Small	O
<EOS>	B-X
In	B-X
the	B-X
field	B-X
of	B-X
nano-	B-X
and	B-X
microscale	B-X
science	B-X
and	B-X
technology	B-X
,	B-X
Small	B-X
has	B-X
become	B-X
one	B-X
of	B-X
the	B-X
worldwide	B-X
leading	B-X
journals	B-X
since	B-X
its	B-X
initiation	B-X
15	B-X
years	B-X
ago	B-X
.	B-X
Among	B-X
all	B-X
the	B-X
topics	B-X
covered	B-X
in	B-X
Small	B-X
,	B-X
``	B-X
nanosafety	B-X
''	B-X
has	B-X
received	B-X
growing	B-X
interest	B-X
over	B-X
the	B-X
years	B-X
,	B-X
which	B-X
accounts	B-X
for	B-X
a	B-X
large	B-X
proportion	B-X
of	B-X
the	B-X
total	B-X
publications	B-X
of	B-X
Small	B-X
.	B-X
Herein	B-X
,	B-X
inspired	B-X
by	B-X
its	B-X
coming	B-X
Special	B-X
Issue	B-X
``	B-X
Rethinking	B-X
Nanosafety	B-X
,	B-X
''	B-X
a	B-X
general	B-X
bibliometric	B-X
overview	B-X
of	B-X
the	B-X
nanosafety	B-X
studies	B-X
that	B-X
have	B-X
been	B-X
published	B-X
in	B-X
Small	B-X
is	B-X
presented	B-X
.	B-X
A	B-X
special	B-X
emphasis	B-X
on	B-X
the	B-X
impact	B-X
of	B-X
the	B-X
previous	B-X
Special	B-X
Issue	B-X
from	B-X
Small	B-X
that	B-X
is	B-X
related	B-X
to	B-X
nanosafety	B-X
research	B-X
is	B-X
given	B-X
and	B-X
the	B-X
research	B-X
trend	B-X
from	B-X
the	B-X
most	B-X
highly	B-X
cited	B-X
papers	B-X
during	B-X
last	B-X
15	B-X
years	B-X
is	B-X
analyzed	B-X
.	B-X

"	O
protrusions	O
"	O
were	O
sometimes	O
observed	O
within	O
these	O
exons	O
that	O
could	O
represent	O
small	O
introns	O
.	O

Very	O
small	O
introns	O
have	O
been	O
reported	O
for	O
tRNA	O
genes	O
(	O
12	O
,	O
13	O
)	O
,	O
<EOS>	B-X
Comparative	B-X
and	B-X
Phylogenetic	B-X
Analysis	B-X
Based	B-X
on	B-X
the	B-X
Chloroplast	B-X
Genome	B-X
of	B-X
In	B-X
Trichoplax	B-X
and	B-X
Hoilungia	B-X
,	B-X
previous	B-X
studies	B-X
on	B-X
six	B-X
haplotypes	B-X
belonging	B-X
to	B-X
four	B-X
different	B-X
clades	B-X
have	B-X
shown	B-X
that	B-X
their	B-X
mtDNAs	B-X
are	B-X
circular	B-X
chromosomes	B-X
of	B-X
32-43	B-X
kb	B-X
in	B-X
size	B-X
,	B-X
which	B-X
encode	B-X
12	B-X
protein-coding	B-X
genes	B-X
,	B-X
24	B-X
tRNAs	B-X
,	B-X
and	B-X
two	B-X
rRNAs	B-X
.	B-X
These	B-X
mitochondrial	B-X
genomes	B-X
(	B-X
mitogenomes	B-X
)	B-X
also	B-X
show	B-X
unique	B-X
features	B-X
rarely	B-X
seen	B-X
in	B-X
other	B-X
metazoans	B-X
,	B-X
including	B-X
open	B-X
reading	B-X
frames	B-X
(	B-X
ORFs	B-X
)	B-X
of	B-X
unknown	B-X
function	B-X
,	B-X
and	B-X
group	B-X
I	B-X
and	B-X
II	B-X
introns	B-X
.	B-X
We	B-X
found	B-X
small	B-X
inverted	B-X
repeats	B-X
in	B-X
all	B-X
13	B-X
mitochondrial	B-X
genomes	B-X
of	B-X
the	B-X
Trichoplax	B-X
and	B-X
Hoilungia	B-X
genera	B-X
and	B-X
evaluated	B-X
their	B-X
distribution	B-X
patterns	B-X
among	B-X
haplotypes	B-X
.	B-X
Because	B-X
Polyplacotoma	B-X
mediterranea	B-X
(	B-X
H0	B-X
)	B-X
,	B-X
the	B-X
sister	B-X
to	B-X
the	B-X
remaining	B-X
haplotypes	B-X
,	B-X
has	B-X
a	B-X
small	B-X
mitochondrial	B-X
genome	B-X
with	B-X
few	B-X
small	B-X
inverted	B-X
repeats	B-X
and	B-X
ORFs	B-X
,	B-X
we	B-X
hypothesized	B-X
that	B-X
the	B-X
proliferation	B-X
of	B-X
inverted	B-X
repeats	B-X
and	B-X
ORFs	B-X
substantially	B-X
contributed	B-X
to	B-X
the	B-X
observed	B-X
increase	B-X
in	B-X
the	B-X
size	B-X
and	B-X
GC	B-X
content	B-X
of	B-X
the	B-X
Trichoplax	B-X
and	B-X
Hoilungia	B-X
mitochondrial	B-X
genomes	B-X
.	B-X

and	O
it	O
will	O
be	O
necessary	O
to	O
sequence	O
these	O
regions	O
of	O
SpC3	O
to	O
determine	O
if	O
such	O
introns	O
are	O
present	O
within	O
the	O
a2	O
sheep	B-Species
genome	O
.	O

The	O
existence	O
of	O
mRNAs	O
comprised	O
of	O
sequences	O
complementary	O
to	O
noncontiguous	O
regions	O
in	O
a	O
DNA	O
genome	O
was	O
first	O
described	O
for	O
adenovirus	B-Species
(	O
14	O
,	O
15	O
)	O
and	O

simian	O
virus	O
(	O
16	O
,	O
17	O
)	O
genes	O
.	O
<EOS>	B-X
Certain	B-X
major	B-X
histocompatibility	B-X
complex	B-X
class	B-X
I	B-X
(	B-X
MHC-I	B-X
)	B-X
alleles	B-X
are	B-X
associated	B-X
with	B-X
spontaneous	B-X
control	B-X
of	B-X
viral	B-X
replication	B-X
in	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
(	B-X
HIV	B-X
)	B-X
-infected	B-X
people	B-X
and	B-X
simian	B-X
immunodeficiency	B-X
virus	B-X
(	B-X
SIV	B-X
)	B-X
-infected	B-X
rhesus	B-X
macaques	B-X
(	B-X
RMs	B-X
)	B-X
.	B-X
A	B-X
species	B-X
classification	B-X
regarding	B-X
Old	B-X
World	B-X
monkey	B-X
adenoviruses	B-X
is	B-X
proposed	B-X
.	B-X
We	B-X
determined	B-X
the	B-X
nucleotide	B-X
sequences	B-X
of	B-X
PCR-amplified	B-X
fragments	B-X
from	B-X
the	B-X
genes	B-X
of	B-X
the	B-X
IVa2	B-X
,	B-X
DNA-dependent	B-X
DNA	B-X
polymerase	B-X
,	B-X
penton	B-X
base	B-X
,	B-X
and	B-X
hexon	B-X
proteins	B-X
from	B-X
every	B-X
simian	B-X
adenovirus	B-X
(	B-X
SAdV	B-X
)	B-X
serotype	B-X
that	B-X
originated	B-X
from	B-X
Old	B-X
World	B-X
monkeys	B-X
for	B-X
which	B-X
the	B-X
full	B-X
genome	B-X
sequence	B-X
had	B-X
not	B-X
yet	B-X
been	B-X
published	B-X
.	B-X
Interestingly	B-X
,	B-X
one	B-X
is	B-X
the	B-X
most	B-X
recently	B-X
established	B-X
human	B-X
AdV	B-X
species	B-X
,	B-X
Human	B-X
mastadenovirus	B-X
G	B-X
,	B-X
which	B-X
includes	B-X
a	B-X
single	B-X
human	B-X
virus	B-X
,	B-X
HAdV-52	B-X
,	B-X
as	B-X
well	B-X
as	B-X
SAdV-1	B-X
,	B-X
-2	B-X
,	B-X
-7	B-X
,	B-X
-11	B-X
,	B-X
-12	B-X
,	B-X
and	B-X
-15	B-X
.	B-X
The	B-X
other	B-X
approved	B-X
species	B-X
,	B-X
Simian	B-X
mastadenovirus	B-X
A	B-X
includes	B-X
SAdV-3	B-X
,	B-X
-4	B-X
,	B-X
-6	B-X
,	B-X
-9	B-X
,	B-X
-10	B-X
,	B-X
-14	B-X
,	B-X
and	B-X
-48	B-X
.	B-X
Several	B-X
SAdVs	B-X
(	B-X
SAdV-5	B-X
,	B-X
-8	B-X
,	B-X
-49	B-X
,	B-X
-50	B-X
)	B-X
together	B-X
with	B-X
baboon	B-X
AdV-1	B-X
and	B-X
rhesus	B-X
monkey	B-X
AdV	B-X
strains	B-X
A1139	B-X
,	B-X
A1163	B-X
,	B-X
A1173	B-X
,	B-X
A1258	B-X
,	B-X
A1285	B-X
,	B-X
A1296	B-X
,	B-X
A1312	B-X
,	B-X
A1327	B-X
and	B-X
A1335	B-X
have	B-X
been	B-X
proposed	B-X
to	B-X
be	B-X
classified	B-X
into	B-X
an	B-X
additional	B-X
species	B-X
,	B-X
Simian	B-X
mastadenovirus	B-X
B	B-X
.	B-X
Another	B-X
proposed	B-X
species	B-X
,	B-X
Simian	B-X
mastadenovirus	B-X
C	B-X
has	B-X
been	B-X
described	B-X
for	B-X
SAdV-19	B-X
,	B-X
baboon	B-X
AdV-2/4	B-X
and	B-X
-3	B-X
.	B-X
The	B-X
corresponding	B-X
new	B-X
candidate	B-X
species	B-X
are	B-X
Simian	B-X
mastadenovirus	B-X
D	B-X
(	B-X
for	B-X
SAdV-13	B-X
)	B-X
,	B-X
Simian	B-X
mastadenovirus	B-X
E	B-X
(	B-X
for	B-X
SAdV-16	B-X
)	B-X
,	B-X
Simian	B-X
mastadenovirus	B-X
F	B-X
(	B-X
for	B-X
SAdV-17	B-X
and	B-X
-18	B-X
)	B-X
,	B-X
and	B-X
Simian	B-X
mastadenovirus	B-X
G	B-X
(	B-X
for	B-X
SAdV-20	B-X
)	B-X
.	B-X
Several	B-X
biological	B-X
and	B-X
genomic	B-X
properties	B-X
,	B-X
such	B-X
as	B-X
the	B-X
host	B-X
origin	B-X
,	B-X
haemagglutination	B-X
profile	B-X
,	B-X
number	B-X
of	B-X
fibre	B-X
genes	B-X
,	B-X
and	B-X
G+C	B-X
content	B-X
of	B-X
the	B-X
genome	B-X
,	B-X
strongly	B-X
support	B-X
this	B-X
classification	B-X
.	B-X
Three	B-X
SAdV	B-X
strains	B-X
originating	B-X
from	B-X
the	B-X
American	B-X
Type	B-X
Culture	B-X
Collection	B-X
turned	B-X
out	B-X
to	B-X
be	B-X
mixtures	B-X
of	B-X
at	B-X
least	B-X
two	B-X
virus	B-X
types	B-X
,	B-X
either	B-X
of	B-X
the	B-X
same	B-X
species	B-X
(	B-X
SAdV-12	B-X
and	B-X
-15	B-X
types	B-X
from	B-X
Human	B-X
mastadenovirus	B-X
G	B-X
)	B-X
or	B-X
of	B-X
two	B-X
different	B-X
species	B-X
(	B-X
SAdV-5	B-X
types	B-X
from	B-X
Simian	B-X
mastadenovirus	B-X
B	B-X
and	B-X
Human	B-X
mastadenovirus	B-X
G	B-X
)	B-X
.	B-X

Similar	O
observations	O
were	O
soon	O
reported	O
for	O
eukaryotic	O
genes	O
,	O
including	O
serum	O
albumin	O
(	O
18	O
)	O
,	O
conalbumin	O
(	O
19	O
)	O
,	O
fibroin	O
(	O
20	O
)	O
,	O
s	O

globin	O
(	O
21	O
,	O
22	O
)	O
,	O
growth	O
hormones	O
(	O
23	O
,	O
24	O
)	O
,	O
immunoglobulin	O
(	O
25	O
)	O
,	O
lysozyme	O
(	O
26	O
)	O
,	O

ovalbumin	O
(	O
27	O
-	O
29	O
)	O
,	O
ovomucoid	O
(	O
30	O
)	O
,	O
rRNA	O
(	O
31	O
-	O
34	O
)	O
,	O
tRNA	O
(	O
12	O
,	O
13	O
)	O
,	O
and	O
vitellogenin	O
(	O
35	O
)	O
.	O

The	O
precise	O
number	O
or	O
occurrence	O
of	O
introns	O
within	O
these	O
genes	O
does	O
not	O
seem	O
to	O
follow	O
any	O
clear	O
pattern	O
.	O
<EOS>	B-X
Removal	B-X
of	B-X
introns	B-X
from	B-X
messenger	B-X
RNA	B-X
precursors	B-X
(	B-X
pre-mRNA	B-X
splicing	B-X
)	B-X
is	B-X
an	B-X
essential	B-X
step	B-X
for	B-X
the	B-X
expression	B-X
of	B-X
most	B-X
eukaryotic	B-X
genes	B-X
.	B-X
These	B-X
splicing	B-X
alterations	B-X
are	B-X
often	B-X
linked	B-X
to	B-X
the	B-X
occurrence	B-X
of	B-X
cancer	B-X
driver	B-X
mutations	B-X
in	B-X
genes	B-X
encoding	B-X
either	B-X
core	B-X
components	B-X
or	B-X
regulators	B-X
of	B-X
the	B-X
splicing	B-X
machinery	B-X
.	B-X
Some	B-X
of	B-X
those	B-X
functions	B-X
,	B-X
as	B-X
for	B-X
example	B-X
playing	B-X
a	B-X
role	B-X
in	B-X
the	B-X
life	B-X
cycle	B-X
of	B-X
viral	B-X
and	B-X
viroid	B-X
genomes	B-X
or	B-X
in	B-X
the	B-X
maturation	B-X
of	B-X
tRNA	B-X
genes	B-X
,	B-X
have	B-X
been	B-X
elucidated	B-X
;	B-X
other	B-X
putative	B-X
functions	B-X
still	B-X
remain	B-X
elusive	B-X
.	B-X
In	B-X
this	B-X
review	B-X
we	B-X
illustrate	B-X
the	B-X
occurrence	B-X
and	B-X
mechanisms	B-X
of	B-X
RNA	B-X
circularization	B-X
in	B-X
vivo	B-X
,	B-X
survey	B-X
methods	B-X
for	B-X
the	B-X
generation	B-X
of	B-X
circRNA	B-X
in	B-X
vitro	B-X
and	B-X
provide	B-X
appropriate	B-X
protocols	B-X
.	B-X

However	O
,	O
the	O
genes	O
for	O
albumin	O
,	O
conalbumin	O
,	O
<EOS>	B-X
Extensive	B-X
studies	B-X
have	B-X
been	B-X
carried	B-X
out	B-X
in	B-X
the	B-X
genes	B-X
coding	B-X
for	B-X
egg	B-X
white	B-X
proteins	B-X
.	B-X
Transcriptional	B-X
regulation	B-X
of	B-X
the	B-X
ovalbumin	B-X
and	B-X
conalbumin	B-X
genes	B-X
by	B-X
steroid	B-X
hormones	B-X
in	B-X
chick	B-X
oviduct	B-X
.	B-X
However	B-X
,	B-X
the	B-X
responsible	B-X
genes	B-X
and	B-X
detailed	B-X
molecular	B-X
mechanisms	B-X
regulating	B-X
eggshell	B-X
brownness	B-X
have	B-X
not	B-X
been	B-X
defined	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
applied	B-X
the	B-X
RNA-seq	B-X
technology	B-X
to	B-X
analyze	B-X
the	B-X
transcriptome	B-X
data	B-X
of	B-X
the	B-X
shell	B-X
gland	B-X
epithelium	B-X
of	B-X
hens	B-X
and	B-X
investigated	B-X
the	B-X
candidate	B-X
genes	B-X
associated	B-X
with	B-X
eggshell	B-X
brownness	B-X
.	B-X
The	B-X
results	B-X
indicated	B-X
that	B-X
8461	B-X
genes	B-X
were	B-X
expressed	B-X
in	B-X
the	B-X
shell	B-X
gland	B-X
epithelium	B-X
,	B-X
of	B-X
which	B-X
34	B-X
genes	B-X
were	B-X
differentially	B-X
expressed	B-X
in	B-X
hens	B-X
laying	B-X
dark	B-X
vs.	B-X
light	B-X
brown	B-X
eggs	B-X
.	B-X
Functional	B-X
analysis	B-X
revealed	B-X
that	B-X
two	B-X
genes	B-X
,	B-X
ovotransferrin	B-X
(	B-X
TF	B-X
)	B-X
and	B-X
heat-shock	B-X
protein	B-X
70	B-X
(	B-X
HSP70	B-X
)	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
oxidative	B-X
phosphorylation	B-X
pathway	B-X
were	B-X
involved	B-X
in	B-X
the	B-X
synthesis	B-X
and	B-X
transport	B-X
of	B-X
protoporphyrin	B-X
â¨	B-X
,	B-X
which	B-X
might	B-X
influence	B-X
the	B-X
formation	B-X
of	B-X
eggshell	B-X
brownness	B-X
and	B-X
result	B-X
in	B-X
different	B-X
shades	B-X
of	B-X
brown	B-X
.	B-X

lysozyme	O
,	O
ovalbumin	O
,	O
and	O
ovomucoid	O
exhibit	O
a	O
structural	O
organization	O
comparable	O
to	O
the	O
a2	O
collagen	O
gene	O
.	O

All	O
of	O
these	O
genes	O
are	O
composed	O
of	O
numerous	O
small	O
<EOS>	B-X
pigs	B-X
and	B-X
numerous	B-X
domestic	B-X
and	B-X
wild	B-X
living	B-X
ruminants	B-X
.	B-X
Despite	B-X
some	B-X
common	B-X
features	B-X
in	B-X
their	B-X
natural	B-X
hosts	B-X
,	B-X
pathogenesis	B-X
of	B-X
pestivirus-induced	B-X
disease	B-X
is	B-X
complex	B-X
;	B-X
especially	B-X
some	B-X
aspects	B-X
of	B-X
highly	B-X
fatal	B-X
mucosal	B-X
disease	B-X
of	B-X
cattle	B-X
are	B-X
still	B-X
enigmatic	B-X
.	B-X
Pestiviruses	B-X
are	B-X
amongst	B-X
the	B-X
smallest	B-X
enveloped	B-X
single-stranded	B-X
RNA	B-X
viruses	B-X
with	B-X
an	B-X
icosaeder-shaped	B-X
nucleocapsid	B-X
.	B-X
Structural	B-X
proteins	B-X
are	B-X
coded	B-X
for	B-X
by	B-X
genes	B-X
located	B-X
at	B-X
the	B-X
5	B-X
'	B-X
end	B-X
of	B-X
the	B-X
RNA	B-X
.	B-X
Virions	B-X
are	B-X
composed	B-X
of	B-X
a	B-X
major	B-X
and	B-X
one	B-X
minor	B-X
envelope	B-X
glycoprotein	B-X
with	B-X
molecular	B-X
weights	B-X
of	B-X
53	B-X
and	B-X
48	B-X
kD	B-X
respectively	B-X
.	B-X
The	B-X
core	B-X
is	B-X
composed	B-X
of	B-X
a	B-X
small	B-X
protein	B-X
with	B-X
a	B-X
molecular	B-X
weight	B-X
of	B-X
20	B-X
kD	B-X
.	B-X

exons	O
,	O
usually	O
less	O
than	O
250	O
base	O
pairs	O
,	O
and	O
introns	O
which	O
show	O
a	O
large	O
size	O
variation	O
within	O
an	O
individual	O
gene	O
.	O

Within	O
all	O
of	O
these	O
genomes	O
,	O
the	O
DNA	O
<EOS>	B-X
Single-cell	B-X
DNA	B-X
sequencing	B-X
has	B-X
shed	B-X
light	B-X
on	B-X
biological	B-X
questions	B-X
that	B-X
were	B-X
previously	B-X
inaccessible	B-X
across	B-X
diverse	B-X
fields	B-X
of	B-X
research	B-X
,	B-X
including	B-X
somatic	B-X
mutagenesis	B-X
,	B-X
organismal	B-X
development	B-X
,	B-X
genome	B-X
function	B-X
,	B-X
and	B-X
microbiology	B-X
.	B-X
Single-cell	B-X
DNA	B-X
sequencing	B-X
also	B-X
promises	B-X
significant	B-X
future	B-X
biomedical	B-X
and	B-X
clinical	B-X
impact	B-X
,	B-X
spanning	B-X
oncology	B-X
,	B-X
fertility	B-X
,	B-X
and	B-X
beyond	B-X
.	B-X
While	B-X
single-cell	B-X
approaches	B-X
that	B-X
profile	B-X
RNA	B-X
and	B-X
protein	B-X
have	B-X
greatly	B-X
expanded	B-X
our	B-X
understanding	B-X
of	B-X
cellular	B-X
diversity	B-X
,	B-X
many	B-X
fundamental	B-X
questions	B-X
in	B-X
biology	B-X
and	B-X
important	B-X
biomedical	B-X
applications	B-X
require	B-X
analysis	B-X
of	B-X
the	B-X
DNA	B-X
of	B-X
single	B-X
cells	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
the	B-X
applications	B-X
and	B-X
biological	B-X
questions	B-X
for	B-X
which	B-X
single-cell	B-X
DNA	B-X
sequencing	B-X
is	B-X
uniquely	B-X
suited	B-X
or	B-X
required	B-X
.	B-X
We	B-X
include	B-X
a	B-X
discussion	B-X
of	B-X
the	B-X
fields	B-X
that	B-X
will	B-X
be	B-X
impacted	B-X
by	B-X
single-cell	B-X
DNA	B-X
sequencing	B-X
as	B-X
the	B-X
technology	B-X
continues	B-X
to	B-X
advance	B-X
.	B-X

regions	O
required	O
for	O
coding	O
structural	O
formation	O
are	O
4	O
to	O
7	O
times	O
longer	O
than	O
the	O
corresponding	O
mRNA	O
coding	O
sequences	O
.	O

As	O
with	O
the	O
a2	O
collagen	O
gene	O
,	O
a	O
large	O
unique	O
exon	O
at	O
the	O
extreme	O
3	O
'	O
end	O

is	O
also	O
present	O
in	O
the	O
ovalbumin	O
gene	O
(	O
36	O
,	O
37	O
)	O
.	O

In	O
the	O
a2	O
gene	O
,	O
this	O
exon	O
was	O
800	O
to	O
900	O
nucleotides	O
in	O
length	O
,	O
while	O
in	O
the	O
ovalbumin	O
gene	O
the	O
exon	O
contained	O
1	O
,	O
030	O
base	O
pairs	O
.	O

Interestingly	O
,	O
this	O
ovalbumin	O
exon	O
contained	O
634	O
-	O
650	O
base	O
pairs	O
ot	O
DNA	O
sequence	O
to	O
the	O
3	O
'	O
side	O
of	O
the	O
terminator	O

triplet	O
,	O
suggesting	O
the	O
ovalbumin	O
mRNA	O
has	O
a	O
large	O
untranslated	O
region	O
at	O
the	O
3	O
'	O
end	O
.	O

The	O
consistent	O
appearance	O
of	O
a	O
small	O
non	O
-	O
hybridized	O
tail	O
,	O
approximately	O
100	O
nucleotides	O
in	O
length	O
,	O
in	O
the	O
region	O
where	O
the	O
right	O
arm	O
of	O
the	O
phage	O
was	O
ligated	O
to	O
the	O
sheep	B-Species
genomic	O
insert	O
of	O
SpC3	O
very	O
likely	O
corresponded	O
to	O
the	O

3	O
'	O
poly	O
A	O
sequence	O
of	O
the	O
a2	O
mRNA	O
.	O
<EOS>	B-X
The	B-X
expression	B-X
and	B-X
localization	B-X
of	B-X
the	B-X
oncoprotein	B-X
c-Myc	B-X
is	B-X
highly	B-X
regulated	B-X
at	B-X
the	B-X
level	B-X
of	B-X
transcription	B-X
,	B-X
mRNA	B-X
transport	B-X
,	B-X
translation	B-X
,	B-X
as	B-X
well	B-X
as	B-X
stability	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
We	B-X
previously	B-X
showed	B-X
that	B-X
Annexin	B-X
A2	B-X
(	B-X
AnxA2	B-X
)	B-X
binds	B-X
to	B-X
a	B-X
specific	B-X
localization	B-X
element	B-X
in	B-X
the	B-X
3'untranslated	B-X
region	B-X
(	B-X
UTR	B-X
)	B-X
of	B-X
c-	B-X
The	B-X
polyadenylation	B-X
signal	B-X
(	B-X
PAS	B-X
)	B-X
is	B-X
a	B-X
key	B-X
sequence	B-X
element	B-X
for	B-X
3'-end	B-X
cleavage	B-X
and	B-X
polyadenylation	B-X
of	B-X
messenger	B-X
RNA	B-X
precursors	B-X
(	B-X
pre-mRNAs	B-X
)	B-X
.	B-X
This	B-X
hexanucleotide	B-X
motif	B-X
is	B-X
recognized	B-X
by	B-X
the	B-X
mammalian	B-X
polyadenylation	B-X
specificity	B-X
factor	B-X
(	B-X
mPSF	B-X
)	B-X
,	B-X
consisting	B-X
of	B-X
CPSF160	B-X
,	B-X
WDR33	B-X
,	B-X
CPSF30	B-X
,	B-X
and	B-X
Fip1	B-X
subunits	B-X
.	B-X
The	B-X
5	B-X
'	B-X
phosphate	B-X
of	B-X
U2	B-X
moves	B-X
by	B-X
2.6	B-X
Ã	B-X
and	B-X
the	B-X
U2	B-X
base	B-X
is	B-X
placed	B-X
near	B-X
the	B-X
six-membered	B-X
ring	B-X
of	B-X
A2	B-X
in	B-X
AAUAAA	B-X
,	B-X
where	B-X
it	B-X
makes	B-X
two	B-X
hydrogen	B-X
bonds	B-X
with	B-X
zinc	B-X
finger	B-X
2	B-X
(	B-X
ZF2	B-X
)	B-X
of	B-X
CPSF30	B-X
,	B-X
which	B-X
undergoes	B-X
conformational	B-X
changes	B-X
as	B-X
well	B-X
.	B-X
The	B-X
residues	B-X
in	B-X
CPSF30	B-X
(	B-X
ZF2	B-X
and	B-X
ZF3	B-X
)	B-X
and	B-X
WDR33	B-X
that	B-X
recognize	B-X
PAS	B-X
are	B-X
disordered	B-X
in	B-X
these	B-X
two	B-X
structures	B-X
.	B-X

This	O
would	O
suggest	O
that	O
the	O
a2	O
mRNA	O
coding	O
sequence	O
terminates	O
very	O
near	O
or	O
at	O
this	O
point	O
in	O
the	O
genome	O
.	O
<EOS>	B-X
Strategies	B-X
for	B-X
sequencing	B-X
fungal	B-X
genomes	B-X
on	B-X
next-generation	B-X
sequencing	B-X
(	B-X
NGS	B-X
)	B-X
platforms	B-X
depend	B-X
on	B-X
the	B-X
characteristics	B-X
of	B-X
the	B-X
genome	B-X
of	B-X
the	B-X
targeted	B-X
species	B-X
,	B-X
quantity	B-X
and	B-X
quality	B-X
of	B-X
the	B-X
genomic	B-X
DNA	B-X
,	B-X
and	B-X
cost	B-X
considerations	B-X
.	B-X
Massively	B-X
parallel	B-X
sequencing	B-X
with	B-X
sequencing	B-X
by	B-X
synthesis	B-X
(	B-X
SBS	B-X
)	B-X
approach	B-X
by	B-X
Illumina	B-X
produces	B-X
terabases	B-X
of	B-X
short	B-X
read	B-X
sequences	B-X
(	B-X
i.e.	B-X
,	B-X
~300	B-X
bp	B-X
)	B-X
in	B-X
a	B-X
time	B-X
and	B-X
cost-effective	B-X
manner	B-X
,	B-X
though	B-X
the	B-X
read	B-X
length	B-X
can	B-X
limit	B-X
the	B-X
assembly	B-X
particularly	B-X
in	B-X
repetitive	B-X
regions	B-X
.	B-X
The	B-X
single	B-X
molecule	B-X
,	B-X
real-time	B-X
(	B-X
SMRT	B-X
)	B-X
sequencing	B-X
approach	B-X
by	B-X
Pacific	B-X
Biosciences	B-X
(	B-X
PacBio	B-X
)	B-X
produces	B-X
longer	B-X
reads	B-X
(	B-X
i.e.	B-X
,	B-X
~12,500	B-X
bp	B-X
)	B-X
which	B-X
can	B-X
facilitate	B-X
de	B-X
novo	B-X
assembly	B-X
of	B-X
genomes	B-X
that	B-X
contain	B-X
long	B-X
repetitive	B-X
sequences	B-X
,	B-X
though	B-X
due	B-X
to	B-X
the	B-X
lower-throughput	B-X
of	B-X
this	B-X
platform	B-X
achieving	B-X
the	B-X
coverage	B-X
needed	B-X
for	B-X
assembly	B-X
is	B-X
more	B-X
expensive	B-X
than	B-X
by	B-X
SBS	B-X
.	B-X
Both	B-X
platforms	B-X
are	B-X
discussed	B-X
in	B-X
this	B-X
chapter	B-X
including	B-X
key	B-X
decision-making	B-X
points	B-X
.	B-X

Previously	O
published	O
biochemical	O
evidence	O
(	O
2	O
)	O
obtained	O
from	O
restriction	O
mapping	O
and	O
Southern	O
blot	O
analysis	O
using	O
[	O
32P	O
]	O
-	O
labeled	O
chick	O
a2	O
cDNA	O
probe	O
supports	O

2250	O

Nucleic	O
Acids	O
Research	O
<EOS>	B-X
The	B-X
2021	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
database	B-X
Issue	B-X
contains	B-X
189	B-X
papers	B-X
spanning	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
biological	B-X
fields	B-X
and	B-X
investigation	B-X
.	B-X
The	B-X
entire	B-X
Database	B-X
Issue	B-X
is	B-X
freely	B-X
available	B-X
online	B-X
on	B-X
the	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
website	B-X
(	B-X
https	B-X
:	B-X
//academic.oup.com/nar	B-X
)	B-X
.	B-X
Editorial	B-X
:	B-X
the	B-X
19th	B-X
annual	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
web	B-X
server	B-X
issue	B-X
2021	B-X
.	B-X
Editorial	B-X
:	B-X
Critical	B-X
reviews	B-X
and	B-X
perspectives	B-X
in	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
.	B-X

this	O
observation	O
.	O
<EOS>	B-X
Barrett	B-X
's	B-X
esophagus	B-X
:	B-X
diagnosis	B-X
and	B-X
management	B-X
.	B-X
In	B-X
an	B-X
arts	B-X
observation	B-X
pedagogy	B-X
,	B-X
nature	B-X
writing	B-X
serves	B-X
as	B-X
an	B-X
apt	B-X
model	B-X
for	B-X
precise	B-X
,	B-X
clinically	B-X
relevant	B-X
linguistic	B-X
noticing	B-X
because	B-X
meticulous	B-X
attention	B-X
to	B-X
the	B-X
natural	B-X
world	B-X
involves	B-X
scientific	B-X
precision	B-X
;	B-X
additionally	B-X
,	B-X
a	B-X
number	B-X
of	B-X
visual	B-X
metaphors	B-X
employed	B-X
in	B-X
medicine	B-X
are	B-X
derived	B-X
from	B-X
close	B-X
observation	B-X
of	B-X
the	B-X
natural	B-X
world	B-X
.	B-X
Close	B-X
reading	B-X
reinforces	B-X
observational	B-X
skills	B-X
as	B-X
part	B-X
of	B-X
integrative	B-X
,	B-X
multidisciplinary	B-X
clinical	B-X
practice	B-X
.	B-X
In	B-X
weighing	B-X
multiple	B-X
perspectives	B-X
,	B-X
observation	B-X
applied	B-X
to	B-X
practice	B-X
helps	B-X
learners	B-X
understand	B-X
the	B-X
nuances	B-X
of	B-X
the	B-X
role	B-X
of	B-X
witness	B-X
,	B-X
activating	B-X
reflection	B-X
consonant	B-X
with	B-X
the	B-X
viewer	B-X
's	B-X
professional	B-X
identity	B-X
.	B-X
The	B-X
realization	B-X
that	B-X
seeing	B-X
is	B-X
highly	B-X
filtered	B-X
through	B-X
the	B-X
observer	B-X
's	B-X
values	B-X
allows	B-X
the	B-X
act	B-X
of	B-X
observation	B-X
to	B-X
come	B-X
under	B-X
scrutiny	B-X
,	B-X
opening	B-X
the	B-X
observer	B-X
's	B-X
gaze	B-X
to	B-X
disturbance	B-X
and	B-X
challenging	B-X
the	B-X
values	B-X
and	B-X
precepts	B-X
of	B-X
the	B-X
prevailing	B-X
medical	B-X
culture	B-X
.	B-X
Application	B-X
of	B-X
observational	B-X
skills	B-X
can	B-X
,	B-X
for	B-X
example	B-X
,	B-X
help	B-X
observers	B-X
recognize	B-X
and	B-X
address	B-X
noxious	B-X
effects	B-X
of	B-X
the	B-X
built	B-X
environment	B-X
.	B-X

It	O
is	O
unclear	O
what	O
role	O
introns	O
play	O
in	O
genetic	O
expression	O
.	O
<EOS>	B-X
The	B-X
aberrant	B-X
classical	B-X
miRNAs	B-X
are	B-X
considered	B-X
to	B-X
play	B-X
significant	B-X
roles	B-X
in	B-X
tumor	B-X
progression	B-X
.	B-X
However	B-X
,	B-X
it	B-X
remains	B-X
unclear	B-X
for	B-X
nonclassical	B-X
miRNAs	B-X
,	B-X
a	B-X
set	B-X
of	B-X
Drosha-independent	B-X
miRNAs	B-X
in	B-X
the	B-X
process	B-X
of	B-X
various	B-X
biology	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
reveal	B-X
that	B-X
a	B-X
nonclassical	B-X
miR-4646-5p	B-X
plays	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
gastric	B-X
cancer	B-X
(	B-X
GC	B-X
)	B-X
metastasis	B-X
.	B-X
The	B-X
enhanced	B-X
miR-4646-5p	B-X
can	B-X
stabilize	B-X
HIF1A	B-X
by	B-X
targeting	B-X
PHD3	B-X
to	B-X
positive	B-X
feedback	B-X
regulate	B-X
Abhd16a	B-X
and	B-X
miR-4646-5p	B-X
itself	B-X
expressions	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
miR-4646-5p/PHD3/HIF1A	B-X
signaling	B-X
can	B-X
also	B-X
up-regulate	B-X
RhoA	B-X
expression	B-X
and	B-X
synergistically	B-X
promote	B-X
gastric	B-X
cancer	B-X
cell	B-X
invasion	B-X
and	B-X
metastasis	B-X
.	B-X

However	O
,	O

it	O
is	O
known	O
that	O
these	O
sequences	O
are	O
tranncribed	O
as	O
part	O
of	O
larger	O
precursor	O
mRNAs	O
and	O
the	O
introns	O
are	O
then	O
excised	O
and	O
the	O
fragmented	O
mRNA	O
chains	O

covalently	O
rejoined	O
(	O
38	O
)	O
.	O
<EOS>	B-X
Conjugal	B-X
transfer	B-X
of	B-X
plasmid	B-X
DNA	B-X
is	B-X
terminated	B-X
when	B-X
the	B-X
transferred	B-X
strand	B-X
,	B-X
linearized	B-X
at	B-X
the	B-X
38	B-X
base-pair	B-X
origin	B-X
of	B-X
transfer	B-X
(	B-X
oriT	B-X
)	B-X
,	B-X
is	B-X
recircularized	B-X
.	B-X
For	B-X
the	B-X
plasmid	B-X
R1162	B-X
,	B-X
it	B-X
is	B-X
the	B-X
protein	B-X
MobA	B-X
,	B-X
covalently	B-X
linked	B-X
to	B-X
the	B-X
linear	B-X
strand	B-X
,	B-X
that	B-X
rejoins	B-X
the	B-X
ends	B-X
by	B-X
a	B-X
reversible	B-X
transesterification	B-X
reaction	B-X
.	B-X

Some	O
evidence	O
has	O
recently	O
accumulated	O
demonstrating	O
the	O
existence	O
of	O
precursor	O
a2	O
mRNAs	O
(	O
39	O
,	O
40	O
)	O
.	O

However	O
,	O
if	O
the	O
introns	O
in	O
the	O
a2	O
gene	O
are	O
transcribed	O
in	O
their	O
entirety	O
,	O
as	O
has	O
been	O
<EOS>	B-X
We	B-X
now	B-X
describe	B-X
the	B-X
characterization	B-X
of	B-X
a	B-X
genomic	B-X
fragment	B-X
(	B-X
H5E7	B-X
)	B-X
that	B-X
encodes	B-X
the	B-X
entirety	B-X
of	B-X
the	B-X
first	B-X
translated	B-X
exon	B-X
(	B-X
Exon	B-X
2	B-X
)	B-X
,	B-X
Intron	B-X
1	B-X
,	B-X
a	B-X
short	B-X
transcribed	B-X
untranslated	B-X
sequence	B-X
(	B-X
Exon	B-X
1	B-X
;	B-X
39	B-X
bp	B-X
)	B-X
,	B-X
and	B-X
approximately	B-X
4	B-X
kb	B-X
of	B-X
sequence	B-X
upstream	B-X
from	B-X
the	B-X
transcription	B-X
initiation	B-X
site	B-X
.	B-X
These	B-X
studies	B-X
emphasize	B-X
the	B-X
potential	B-X
complexity	B-X
of	B-X
SP-D	B-X
gene	B-X
regulation	B-X
,	B-X
and	B-X
further	B-X
support	B-X
the	B-X
hypothesis	B-X
that	B-X
the	B-X
effects	B-X
of	B-X
glucocorticoids	B-X
on	B-X
SP-D	B-X
production	B-X
in	B-X
vivo	B-X
are	B-X
regulated	B-X
at	B-X
the	B-X
level	B-X
of	B-X
transcription	B-X
.	B-X

demonstrated	O
for	O
the	O
introns	O
in	O
ovalbumin	O
and	O
globin	O
(	O
41	O
,	O
42	O
)	O
,	O
much	O
larger	O
precursor	O
a2	O
mRNAs	O
may	O
exist	O
than	O
those	O
reported	O
to	O
date	O
.	O

For	O
if	O
the	O
re	O
<EOS>	B-X
Re	B-X
:	B-X
SF2	B-X
:	B-X
clothes	B-X
for	B-X
the	B-X
emperor	B-X
?	B-X
Preventing	B-X
radiation	B-X
injuries	B-X
:	B-X
``	B-X
if	B-X
you	B-X
stay	B-X
out	B-X
in	B-X
the	B-X
sun	B-X
too	B-X
long	B-X
,	B-X
you	B-X
're	B-X
gon	B-X
na	B-X
get	B-X
burnt	B-X
''	B-X
--	B-X
conventional	B-X
wisdom	B-X
.	B-X

mainder	O
of	O
the	O
a2	O
collagen	O
gene	O
has	O
a	O
structural	O
organization	O
comparable	O
to	O
the	O
60	O
%	O
3	O
'	O
portion	O
that	O
has	O
been	O
analyzed	O
,	O
it	O
is	O
probable	O
that	O
the	O
a2	O

collagen	O
gene	O
in	O
its	O
entirety	O
is	O
dispersed	O
throughout	O
a	O
30	O
kb	O
DNA	O
segment	O
.	O

ACKNOWLEDGMENTS	O
<EOS>	B-X
Acknowledgments	B-X
in	B-X
publications	B-X
and	B-X
research	B-X
integrity	B-X
:	B-X
who	B-X
gets	B-X
acknowledged	B-X
,	B-X
what	B-X
for	B-X
,	B-X
and	B-X
do	B-X
they	B-X
know	B-X
?	B-X
Addiction	B-X
's	B-X
policy	B-X
on	B-X
fair	B-X
authorship	B-X
and	B-X
acknowledgment	B-X
practices	B-X
.	B-X

We	O
thank	O
Dr	O
.	O
John	O
Dahlberg	O
and	O
Frances	O
Loebenstein	O
,	O
Laboratory	O
of	O
Cellular	O
and	O
Molecular	O
Biology	O
,	O
National	O
Cancer	O
Institute	O
,	O
for	O
the	O
generous	O
use	O
of	O
a	O

Siemens	O
Elmiskop	O
101	O
electron	O
microscope	O
;	O
Dr	O
.	O
Ursula	O
Heine	O
and	O
Benjamin	O
Elliott	O
,	O
Laboratory	O
of	O
Viral	O
Carcinogenesis	O
,	O
National	O
Cancer	O
Institute	O
,	O
for	O
the	O
use	O
of	O
a	O
Hewlett	O
-	O
Packard	O
calculator	O
equipped	O
with	O
a	O
digitizer	O
and	O
a	O
Denton	O
vacuum	O
<EOS>	B-X
A	B-X
simple	B-X
additional	B-X
device	B-X
is	B-X
shown	B-X
to	B-X
introduce	B-X
specimen	B-X
without	B-X
contact	B-X
to	B-X
air	B-X
into	B-X
the	B-X
Siemens	B-X
electron	B-X
microscope	B-X
EM-101	B-X
.	B-X
The	B-X
device	B-X
is	B-X
used	B-X
to	B-X
study	B-X
oxidable	B-X
crystals	B-X
by	B-X
electron	B-X
microscopy	B-X
and	B-X
diffraction	B-X
,	B-X
and	B-X
might	B-X
also	B-X
be	B-X
promising	B-X
for	B-X
ultracytochemical	B-X
and	B-X
molecular	B-X
biological	B-X
problems	B-X
.	B-X
Thick	B-X
sections	B-X
stained	B-X
with	B-X
1	B-X
%	B-X
Toluidine	B-X
blue	B-X
were	B-X
examined	B-X
and	B-X
photographed	B-X
using	B-X
a	B-X
Zeiss	B-X
Photo	B-X
II	B-X
microscope	B-X
.	B-X
Thin	B-X
sections	B-X
were	B-X
stained	B-X
with	B-X
uranyl	B-X
acetate	B-X
and	B-X
lead	B-X
citrate	B-X
and	B-X
examined	B-X
in	B-X
a	B-X
Siemens	B-X
ElmisKop	B-X
101	B-X
electron	B-X
microscope	B-X
.	B-X

evaporator	O
,	O
and	O
Drs	O
.	O

Victor	O
Ferrans	O
and	O
Oichi	O
Kawanami	O
,	O
Laboratory	O
of	O
Pathology	O
,	O

National	O
Heart	O
,	O
Lung	O
,	O
and	O
Blood	O
Institute	O
,	O
for	O
expert	O
assistance	O
with	O
photography	O
.	O

We	O
are	O
also	O
grateful	O
to	O
Margery	O
Sullivan	O
,	O
Laboratory	O
of	O
Molecular	O
Genetics	O
,	O

National	O
Institute	O
of	O
Child	B-Species
Health	O
and	O
Human	B-Species
Development	O
,	O
for	O
helpful	O
discussions	O
and	O
to	O
Dr	O
.	O
Helga	O
Boedtker	O
,	O
Department	O
of	O
Chemistry	O
,	O
Harvard	O
University	O
,	O
for	O
making	O
available	O
the	O
recombinant	O
plasmid	O
pCg45	O
.	O

References	O
<EOS>	B-X
References	B-X
to	B-X
internal	B-X
states	B-X
(	B-X
e.g.	B-X
,	B-X
thoughts	B-X
,	B-X
feelings	B-X
,	B-X
and	B-X
desires	B-X
)	B-X
indicate	B-X
children	B-X
's	B-X
appreciation	B-X
of	B-X
people	B-X
's	B-X
inner	B-X
worlds	B-X
.	B-X

1	O
.	O
<EOS>	B-X
Formate	B-X
assay	B-X
in	B-X
body	B-X
fluids	B-X
:	B-X
application	B-X
in	B-X
methanol	B-X
poisoning	B-X
.	B-X

Prockop	O
,	O
D	O
.	O
<EOS>	B-X
Heritable	B-X
diseases	B-X
of	B-X
collagen	B-X
.	B-X
Hardly	B-X
Tendentious	B-X
--	B-X
Repairing	B-X
Like	B-X
with	B-X
Like	B-X
.	B-X
The	B-X
biosynthesis	B-X
of	B-X
collagen	B-X
.	B-X
2	B-X
.	B-X
New	B-X
targets	B-X
for	B-X
osteoporosis	B-X
.	B-X

J	O
.	O
,	O
Kivirikko	O
,	O
k	O
.	O
<EOS>	B-X
This	B-X
procedure	B-X
is	B-X
based	B-X
on	B-X
the	B-X
previous	B-X
finding	B-X
that	B-X
the	B-X
beta-subunit	B-X
of	B-X
the	B-X
prolyl	B-X
4-hydroxylase	B-X
tetramer	B-X
(	B-X
alpha	B-X
2	B-X
beta	B-X
2	B-X
)	B-X
is	B-X
identical	B-X
with	B-X
PDI	B-X
[	B-X
Koivu	B-X
,	B-X
MyllylÃ¤	B-X
,	B-X
Helaakoski	B-X
,	B-X
Pihlajaniemi	B-X
,	B-X
Tasanen	B-X
&	B-X
Kivirikko	B-X
(	B-X
1987	B-X
)	B-X
J.	B-X
Biol	B-X
.	B-X
262	B-X
,	B-X
6447-6449	B-X
;	B-X
Pihlajaniemi	B-X
,	B-X
Helaakoski	B-X
,	B-X
Tasanen	B-X
,	B-X
MyllylÃ¤	B-X
,	B-X
Huhtala	B-X
,	B-X
Koivu	B-X
&	B-X
Kivirikko	B-X
(	B-X
1987	B-X
)	B-X
EMBO	B-X
J	B-X
.	B-X
It	B-X
was	B-X
recently	B-X
reported	B-X
that	B-X
co-expression	B-X
of	B-X
the	B-X
proalpha1	B-X
(	B-X
III	B-X
)	B-X
chain	B-X
of	B-X
human	B-X
type	B-X
III	B-X
procollagen	B-X
with	B-X
the	B-X
subunits	B-X
of	B-X
human	B-X
prolyl	B-X
4-hydroxylase	B-X
in	B-X
Pichia	B-X
pastoris	B-X
produces	B-X
fully	B-X
hydroxylated	B-X
and	B-X
properly	B-X
folded	B-X
recombinant	B-X
type	B-X
III	B-X
procollagen	B-X
molecules	B-X
(	B-X
Vuorela	B-X
,	B-X
A.	B-X
,	B-X
Myllyharju	B-X
,	B-X
J.	B-X
,	B-X
Nissi	B-X
,	B-X
R.	B-X
,	B-X
Pihlajaniemi	B-X
,	B-X
T.	B-X
,	B-X
Kivirikko	B-X
,	B-X
K.I.	B-X
,	B-X
1997	B-X
.	B-X
EMBO	B-X
J.	B-X
Non-helical	B-X
proalpha1	B-X
(	B-X
III	B-X
)	B-X
chains	B-X
produced	B-X
by	B-X
expression	B-X
without	B-X
recombinant	B-X
prolyl	B-X
4-hydroxylase	B-X
likewise	B-X
accumulated	B-X
within	B-X
these	B-X
compartments	B-X
.	B-X

I	O
.	O
,	O
Tuderman	O
,	O
L	O
.	O
,	O
and	O
Guzman	O
,	O
N	O
.	O
<EOS>	B-X
The	B-X
biosynthesis	B-X
of	B-X
collagen	B-X
and	B-X
its	B-X
disorders	B-X
(	B-X
second	B-X
of	B-X
two	B-X
parts	B-X
)	B-X
.	B-X
The	B-X
biosynthesis	B-X
of	B-X
collagen	B-X
and	B-X
its	B-X
disorders	B-X
(	B-X
first	B-X
of	B-X
two	B-X
parts	B-X
)	B-X
.	B-X

A	O
.	O

(	O
1979	O
)	O
New	O
Engl	O
.	O
<EOS>	B-X
In	B-X
1979	B-X
Moskowitz	B-X
and	B-X
Fox	B-X
attempted	B-X
to	B-X
address	B-X
this	B-X
issue	B-X
,	B-X
using	B-X
data	B-X
from	B-X
the	B-X
Breast	B-X
Cancer	B-X
Detection	B-X
Demonstration	B-X
Project	B-X
in	B-X
Cincinnati	B-X
,	B-X
but	B-X
additional	B-X
analysis	B-X
is	B-X
required	B-X
.	B-X
Plague	B-X
pneumonia	B-X
.	B-X
The	B-X
randomized	B-X
consent	B-X
design	B-X
for	B-X
clinical	B-X
trials	B-X
,	B-X
proposed	B-X
by	B-X
Zelen	B-X
(	B-X
N	B-X
Engl	B-X
J	B-X
Med	B-X
1979	B-X
;	B-X
300:1242-1245	B-X
)	B-X
,	B-X
permitted	B-X
physicians	B-X
to	B-X
randomize	B-X
patients	B-X
without	B-X
consent	B-X
,	B-X
then	B-X
obtain	B-X
informed	B-X
consent	B-X
from	B-X
only	B-X
those	B-X
patients	B-X
randomized	B-X
to	B-X
the	B-X
experimental	B-X
(	B-X
as	B-X
opposed	B-X
to	B-X
the	B-X
standard	B-X
treatment	B-X
)	B-X
arm	B-X
.	B-X
Asthma	B-X
deaths	B-X
have	B-X
increased	B-X
11	B-X
%	B-X
between	B-X
1979	B-X
and	B-X
1982	B-X
.	B-X

J	O
.	O
<EOS>	B-X
Heat	B-X
shock	B-X
proteins	B-X
of	B-X
40	B-X
kDa	B-X
(	B-X
Hsp40s	B-X
)	B-X
,	B-X
also	B-X
called	B-X
J	B-X
proteins	B-X
,	B-X
are	B-X
obligate	B-X
partners	B-X
of	B-X
Hsp70s	B-X
.	B-X
Via	B-X
their	B-X
highly	B-X
conserved	B-X
and	B-X
functionally	B-X
critical	B-X
J	B-X
domain	B-X
,	B-X
J	B-X
proteins	B-X
interact	B-X
and	B-X
modulate	B-X
the	B-X
activity	B-X
of	B-X
their	B-X
Hsp70	B-X
partners	B-X
.	B-X
Mutations	B-X
in	B-X
the	B-X
critical	B-X
residues	B-X
in	B-X
the	B-X
J	B-X
domain	B-X
often	B-X
result	B-X
in	B-X
the	B-X
null	B-X
phenotype	B-X
for	B-X
the	B-X
J	B-X
protein	B-X
in	B-X
question	B-X
.	B-X
However	B-X
,	B-X
as	B-X
more	B-X
J	B-X
proteins	B-X
have	B-X
been	B-X
characterized	B-X
,	B-X
it	B-X
is	B-X
becoming	B-X
increasingly	B-X
clear	B-X
that	B-X
a	B-X
significant	B-X
number	B-X
of	B-X
J	B-X
proteins	B-X
do	B-X
not	B-X
``	B-X
completely	B-X
''	B-X
rely	B-X
on	B-X
their	B-X
J	B-X
domains	B-X
to	B-X
carry	B-X
out	B-X
their	B-X
cellular	B-X
functions	B-X
,	B-X
as	B-X
previously	B-X
thought	B-X
.	B-X
In	B-X
some	B-X
cases	B-X
,	B-X
regions	B-X
outside	B-X
the	B-X
highly	B-X
conserved	B-X
J	B-X
domain	B-X
have	B-X
become	B-X
more	B-X
important	B-X
making	B-X
the	B-X
J	B-X
domain	B-X
dispensable	B-X
for	B-X
some	B-X
,	B-X
if	B-X
not	B-X
for	B-X
all	B-X
functions	B-X
of	B-X
a	B-X
J	B-X
protein	B-X
.	B-X
This	B-X
has	B-X
profound	B-X
effects	B-X
on	B-X
the	B-X
evolution	B-X
of	B-X
such	B-X
J	B-X
proteins	B-X
.	B-X
Here	B-X
we	B-X
present	B-X
selected	B-X
examples	B-X
of	B-X
J	B-X
proteins	B-X
that	B-X
perform	B-X
J	B-X
domain	B-X
independent	B-X
functions	B-X
and	B-X
discuss	B-X
this	B-X
in	B-X
the	B-X
context	B-X
of	B-X
evolution	B-X
of	B-X
J	B-X
proteins	B-X
with	B-X
dispensable	B-X
J	B-X
domains	B-X
and	B-X
J-like	B-X
proteins	B-X
in	B-X
eukaryotes	B-X
.	B-X

Med	O
.	O
<EOS>	B-X
Welcome	B-X
to	B-X
Med	B-X
.	B-X
Methods	B-X
The	B-X
investigators	B-X
conducted	B-X
a	B-X
cross-sectional	B-X
survey	B-X
of	B-X
med-peds	B-X
hospitalists	B-X
via	B-X
distribution	B-X
through	B-X
online	B-X
platforms	B-X
supported	B-X
by	B-X
the	B-X
Society	B-X
of	B-X
Hospital	B-X
Medicine	B-X
(	B-X
SHM	B-X
)	B-X
,	B-X
the	B-X
American	B-X
Academy	B-X
of	B-X
Pediatrics	B-X
(	B-X
AAP	B-X
)	B-X
,	B-X
and	B-X
Twitterâ¢	B-X
.	B-X
Conclusions	B-X
Med-peds	B-X
hospitalists	B-X
have	B-X
a	B-X
unique	B-X
role	B-X
within	B-X
the	B-X
hospitalist	B-X
workforce	B-X
given	B-X
the	B-X
variety	B-X
of	B-X
practice	B-X
patterns	B-X
and	B-X
clinical	B-X
needs	B-X
they	B-X
can	B-X
fill	B-X
within	B-X
a	B-X
hospital	B-X
system	B-X
.	B-X
Thymomas	B-X
in	B-X
children	B-X
.	B-X

301	O
,	O
13	O
-	O
23	O
and	O
77	O
-	O
85	O
.	O
<EOS>	B-X
Using	B-X
genome-wide	B-X
association	B-X
study	B-X
summary	B-X
statistics	B-X
across	B-X
six	B-X
cancer	B-X
types	B-X
based	B-X
on	B-X
a	B-X
total	B-X
of	B-X
296,215	B-X
cases	B-X
and	B-X
301,319	B-X
controls	B-X
of	B-X
European	B-X
ancestry	B-X
,	B-X
here	B-X
we	B-X
estimate	B-X
the	B-X
pair-wise	B-X
genetic	B-X
correlations	B-X
between	B-X
breast	B-X
,	B-X
colorectal	B-X
,	B-X
head/neck	B-X
,	B-X
lung	B-X
,	B-X
ovary	B-X
and	B-X
prostate	B-X
cancer	B-X
,	B-X
and	B-X
between	B-X
cancers	B-X
and	B-X
38	B-X
other	B-X
diseases	B-X
.	B-X
Results	B-X
A	B-X
total	B-X
of	B-X
155	B-X
participants	B-X
(	B-X
median	B-X
age	B-X
,	B-X
41	B-X
years	B-X
[	B-X
interquartile	B-X
range	B-X
,	B-X
32-48	B-X
years	B-X
]	B-X
;	B-X
85	B-X
women	B-X
)	B-X
were	B-X
in	B-X
group	B-X
1	B-X
(	B-X
training	B-X
set	B-X
:	B-X
Twenty-eight	B-X
healthy	B-X
adults	B-X
with	B-X
ages	B-X
ranging	B-X
from	B-X
18	B-X
to	B-X
35	B-X
years	B-X
(	B-X
average	B-X
:	B-X
23.85	B-X
years	B-X
)	B-X
were	B-X
enrolled	B-X
in	B-X
the	B-X
study	B-X
.	B-X
The	B-X
disease	B-X
affected	B-X
23,152	B-X
people	B-X
and	B-X
killed	B-X
843	B-X
,	B-X
with	B-X
the	B-X
South	B-X
West	B-X
Region	B-X
registering	B-X
336	B-X
cases	B-X
and	B-X
13	B-X
deaths	B-X
.	B-X

2	O
.	O
<EOS>	B-X
Delineation	B-X
of	B-X
the	B-X
intimate	B-X
details	B-X
of	B-X
the	B-X
backbone	B-X
conformation	B-X
of	B-X
pyridine	B-X
nucleotide	B-X
coenzymes	B-X
in	B-X
aqueous	B-X
solution	B-X
.	B-X

Boyd	O
,	O
C	O
.	O
<EOS>	B-X
The	B-X
American	B-X
College	B-X
of	B-X
Physicians	B-X
(	B-X
ACP	B-X
)	B-X
developed	B-X
this	B-X
guideline	B-X
to	B-X
present	B-X
the	B-X
evidence	B-X
and	B-X
provide	B-X
clinical	B-X
recommendations	B-X
on	B-X
noninvasive	B-X
treatment	B-X
of	B-X
low	B-X
back	B-X
pain	B-X
.	B-X
Multimorbidity	B-X
occurs	B-X
in	B-X
adults	B-X
of	B-X
all	B-X
ages	B-X
,	B-X
but	B-X
the	B-X
number	B-X
and	B-X
complexity	B-X
of	B-X
comorbid	B-X
conditions	B-X
commonly	B-X
increase	B-X
with	B-X
advancing	B-X
age	B-X
such	B-X
that	B-X
cardiovascular	B-X
disease	B-X
(	B-X
CVD	B-X
)	B-X
in	B-X
older	B-X
adults	B-X
typically	B-X
occurs	B-X
in	B-X
a	B-X
context	B-X
of	B-X
multimorbidity	B-X
.	B-X
Current	B-X
clinical	B-X
practice	B-X
and	B-X
research	B-X
mainly	B-X
target	B-X
single	B-X
disease-specific	B-X
care	B-X
that	B-X
does	B-X
not	B-X
embrace	B-X
the	B-X
complexities	B-X
imposed	B-X
by	B-X
concurrent	B-X
conditions	B-X
.	B-X
In	B-X
this	B-X
paper	B-X
,	B-X
emerging	B-X
concepts	B-X
regarding	B-X
CVD	B-X
in	B-X
combination	B-X
with	B-X
multimorbidity	B-X
are	B-X
reviewed	B-X
,	B-X
including	B-X
recommendations	B-X
for	B-X
incorporating	B-X
multimorbidity	B-X
into	B-X
clinical	B-X
decision	B-X
making	B-X
,	B-X
critical	B-X
knowledge	B-X
gaps	B-X
,	B-X
and	B-X
research	B-X
priorities	B-X
to	B-X
optimize	B-X
care	B-X
of	B-X
complex	B-X
older	B-X
patients	B-X
.	B-X

D	O
.	O
,	O
Tolstoshev	O
,	O
P	O
.	O
,	O
Schafer	O
,	O
M	O
.	O

P	O
.	O
,	O
Trapnell	O
,	O
B	O
.	O
<EOS>	B-X
Autoimmune	B-X
pulmonary	B-X
alveolar	B-X
proteinosis	B-X
(	B-X
aPAP	B-X
)	B-X
is	B-X
a	B-X
rare	B-X
disease	B-X
characterized	B-X
by	B-X
progressive	B-X
surfactant	B-X
accumulation	B-X
and	B-X
hypoxemia	B-X
.	B-X
Recently	B-X
,	B-X
inhaled	B-X
GM-CSF	B-X
was	B-X
shown	B-X
to	B-X
improve	B-X
the	B-X
partial	B-X
pressure	B-X
of	B-X
arterial	B-X
oxygen	B-X
in	B-X
patients	B-X
with	B-X
aPAP	B-X
.	B-X
To	B-X
help	B-X
define	B-X
the	B-X
minimum	B-X
amount	B-X
of	B-X
normal	B-X
CFTR	B-X
gene	B-X
expression	B-X
necessary	B-X
to	B-X
maintain	B-X
normalcy	B-X
,	B-X
we	B-X
have	B-X
capitalized	B-X
on	B-X
our	B-X
prior	B-X
observation	B-X
(	B-X
Chu	B-X
,	B-X
C.-S.	B-X
,	B-X
B.	B-X
C.	B-X
Trapnell	B-X
,	B-X
J.	B-X
J.	B-X
Murtagh	B-X
,	B-X
Jr.	B-X
,	B-X
J.	B-X
Moss	B-X
,	B-X
W.	B-X
Dalemans	B-X
,	B-X
S.	B-X
Jallat	B-X
,	B-X
A.	B-X
Mercenier	B-X
,	B-X
A.	B-X
Pavirani	B-X
,	B-X
J.-P.	B-X
Lecocq	B-X
,	B-X
G.	B-X
R.	B-X
Cutting	B-X
,	B-X
et	B-X
al	B-X
.	B-X
EMBO	B-X
[	B-X
Eur	B-X
.	B-X
Biol	B-X
.	B-X
10:1355-1363	B-X
)	B-X
that	B-X
normal	B-X
individuals	B-X
can	B-X
have	B-X
up	B-X
to	B-X
66	B-X
%	B-X
of	B-X
bronchial	B-X
CFTR	B-X
mRNA	B-X
transcripts	B-X
that	B-X
are	B-X
missing	B-X
exon	B-X
9	B-X
,	B-X
a	B-X
region	B-X
representing	B-X
21	B-X
%	B-X
of	B-X
the	B-X
sequence	B-X
coding	B-X
for	B-X
the	B-X
critical	B-X
nucleotide	B-X
(	B-X
ATP	B-X
)	B-X
-binding	B-X
fold	B-X
1	B-X
(	B-X
NBF1	B-X
)	B-X
of	B-X
the	B-X
predicted	B-X
CFTR	B-X
protein	B-X
.	B-X

C	O
.	O
,	O
Coon	O
,	O
<EOS>	B-X
Vaccines	B-X
are	B-X
needed	B-X
to	B-X
prevent	B-X
coronavirus	B-X
disease	B-X
2019	B-X
(	B-X
Covid-19	B-X
)	B-X
and	B-X
to	B-X
protect	B-X
persons	B-X
who	B-X
are	B-X
at	B-X
high	B-X
risk	B-X
for	B-X
complications	B-X
.	B-X
The	B-X
mRNA-1273	B-X
vaccine	B-X
is	B-X
a	B-X
lipid	B-X
nanoparticle-encapsulated	B-X
mRNA-based	B-X
vaccine	B-X
that	B-X
encodes	B-X
the	B-X
prefusion	B-X
stabilized	B-X
full-length	B-X
spike	B-X
protein	B-X
of	B-X
the	B-X
severe	B-X
acute	B-X
respiratory	B-X
syndrome	B-X
coronavirus	B-X
2	B-X
(	B-X
SARS-CoV-2	B-X
)	B-X
,	B-X
the	B-X
virus	B-X
that	B-X
causes	B-X
Covid-19	B-X
.	B-X
Here	B-X
,	B-X
using	B-X
a	B-X
mouse	B-X
model	B-X
,	B-X
we	B-X
report	B-X
the	B-X
host	B-X
C-type	B-X
lectin	B-X
antimicrobial	B-X
peptide	B-X
Reg3Î³	B-X
works	B-X
with	B-X
key	B-X
ileal	B-X
microbes	B-X
to	B-X
orchestrate	B-X
these	B-X
interactions	B-X
in	B-X
a	B-X
bidirectional	B-X
manner	B-X
and	B-X
does	B-X
not	B-X
correlate	B-X
with	B-X
the	B-X
intestinal	B-X
core	B-X
circadian	B-X
clock	B-X
.	B-X
At	B-X
interim	B-X
analysis	B-X
in	B-X
a	B-X
phase	B-X
3	B-X
,	B-X
observer-blinded	B-X
,	B-X
placebo-controlled	B-X
clinical	B-X
trial	B-X
,	B-X
the	B-X
mRNA-1273	B-X
vaccine	B-X
showed	B-X
94.1	B-X
%	B-X
efficacy	B-X
in	B-X
preventing	B-X
coronavirus	B-X
disease	B-X
2019	B-X
(	B-X
Covid-19	B-X
)	B-X
.	B-X

H	O
.	O
<EOS>	B-X
In	B-X
plants	B-X
,	B-X
cytosolic	B-X
and	B-X
extracellular	B-X
pH	B-X
homeostasis	B-X
are	B-X
crucial	B-X
for	B-X
various	B-X
physiological	B-X
processes	B-X
,	B-X
including	B-X
the	B-X
uptake	B-X
of	B-X
macronutrients	B-X
and	B-X
micronutrients	B-X
,	B-X
cell	B-X
elongation	B-X
,	B-X
cell	B-X
expansion	B-X
,	B-X
and	B-X
enzyme	B-X
activity	B-X
.	B-X
Proton	B-X
(	B-X
H	B-X
The	B-X
membrane	B-X
surrounding	B-X
the	B-X
central	B-X
vacuole	B-X
of	B-X
plant	B-X
cells	B-X
contains	B-X
an	B-X
H	B-X
(	B-X
+	B-X
)	B-X
-translocating	B-X
ATPase	B-X
(	B-X
H	B-X
(	B-X
+	B-X
)	B-X
-ATPase	B-X
)	B-X
and	B-X
an	B-X
H	B-X
(	B-X
+	B-X
)	B-X
-translocating	B-X
inorganic	B-X
pyrophosphatase	B-X
(	B-X
H	B-X
(	B-X
+	B-X
)	B-X
-PPase	B-X
)	B-X
.	B-X
Both	B-X
enzymes	B-X
are	B-X
abundant	B-X
and	B-X
ubiquitous	B-X
in	B-X
plants	B-X
but	B-X
the	B-X
H	B-X
(	B-X
+	B-X
)	B-X
-PPase	B-X
is	B-X
unusual	B-X
in	B-X
its	B-X
exclusive	B-X
use	B-X
of	B-X
inorganic	B-X
pyrophosphate	B-X
(	B-X
PPi	B-X
)	B-X
as	B-X
an	B-X
energy	B-X
source	B-X
.	B-X
The	B-X
lack	B-X
of	B-X
sequence	B-X
identity	B-X
between	B-X
the	B-X
vacuolar	B-X
H	B-X
(	B-X
+	B-X
)	B-X
-PPase	B-X
and	B-X
any	B-X
other	B-X
characterized	B-X
ion	B-X
pump	B-X
implies	B-X
a	B-X
different	B-X
evolutionary	B-X
origin	B-X
for	B-X
this	B-X
translocase	B-X
.	B-X
The	B-X
existence	B-X
of	B-X
the	B-X
vacuolar	B-X
H	B-X
(	B-X
+	B-X
)	B-X
-PPase	B-X
,	B-X
in	B-X
conjunction	B-X
with	B-X
increasing	B-X
recognition	B-X
of	B-X
PPi	B-X
as	B-X
a	B-X
key	B-X
metabolite	B-X
in	B-X
plant	B-X
systems	B-X
,	B-X
necessitates	B-X
reconsideration	B-X
of	B-X
ATP	B-X
as	B-X
the	B-X
primary	B-X
energy	B-X
source	B-X
for	B-X
membrane	B-X
transport	B-X
in	B-X
plant	B-X
cells	B-X
.	B-X

C	O
.	O
,	O
Kretschmer	O
,	O
P	O
.	O
<EOS>	B-X
Procalcitonin	B-X
as	B-X
a	B-X
biomarker	B-X
to	B-X
differentiate	B-X
bacterial	B-X
infections	B-X
from	B-X
engraftment	B-X
syndrome	B-X
following	B-X
autologous	B-X
hematopoietic	B-X
stem	B-X
cell	B-X
transplantation	B-X
for	B-X
multiple	B-X
myeloma	B-X
.	B-X
Differential	B-X
expression	B-X
of	B-X
the	B-X
closely	B-X
linked	B-X
gamma	B-X
,	B-X
beta	B-X
(	B-X
A	B-X
)	B-X
(	B-X
or	B-X
beta	B-X
(	B-X
B	B-X
)	B-X
)	B-X
,	B-X
and	B-X
beta	B-X
(	B-X
C	B-X
)	B-X
globin	B-X
genes	B-X
in	B-X
sheep	B-X
results	B-X
in	B-X
the	B-X
production	B-X
of	B-X
fetal	B-X
hemoglobin	B-X
(	B-X
Hb	B-X
F	B-X
,	B-X
alpha	B-X
(	B-X
2	B-X
)	B-X
gamma	B-X
(	B-X
2	B-X
)	B-X
)	B-X
during	B-X
gestation	B-X
and	B-X
the	B-X
adult	B-X
hemoglobins	B-X
(	B-X
Hb	B-X
A	B-X
,	B-X
alpha	B-X
(	B-X
2	B-X
)	B-X
beta	B-X
(	B-X
2	B-X
)	B-X
(	B-X
A	B-X
)	B-X
,	B-X
and	B-X
Hb	B-X
B	B-X
,	B-X
alpha	B-X
(	B-X
2	B-X
)	B-X
beta	B-X
(	B-X
2	B-X
)	B-X
(	B-X
B	B-X
)	B-X
)	B-X
after	B-X
birth	B-X
.	B-X
Erythropoietic	B-X
stress	B-X
in	B-X
certain	B-X
animals	B-X
leads	B-X
to	B-X
production	B-X
of	B-X
Hb	B-X
C	B-X
(	B-X
alpha	B-X
(	B-X
2	B-X
)	B-X
beta	B-X
(	B-X
2	B-X
)	B-X
(	B-X
C	B-X
)	B-X
)	B-X
.	B-X
In	B-X
nuclei	B-X
from	B-X
sheep	B-X
fetal	B-X
liver	B-X
erythroid	B-X
cells	B-X
,	B-X
the	B-X
gamma	B-X
genes	B-X
but	B-X
not	B-X
the	B-X
beta	B-X
genes	B-X
were	B-X
digested	B-X
by	B-X
DNase	B-X
I	B-X
;	B-X
the	B-X
gamma	B-X
locus	B-X
was	B-X
open	B-X
but	B-X
the	B-X
beta	B-X
(	B-X
A	B-X
)	B-X
or	B-X
beta	B-X
(	B-X
C	B-X
)	B-X
loci	B-X
was	B-X
closed	B-X
,	B-X
consistent	B-X
with	B-X
synthesis	B-X
of	B-X
only	B-X
Hb	B-X
F	B-X
by	B-X
these	B-X
cells	B-X
.	B-X
DNase	B-X
I	B-X
digestion	B-X
of	B-X
nuclei	B-X
from	B-X
bone	B-X
marrow	B-X
of	B-X
anemic	B-X
sheep	B-X
making	B-X
only	B-X
Hb	B-X
C	B-X
or	B-X
Hb	B-X
B	B-X
resulted	B-X
in	B-X
equivalent	B-X
digestion	B-X
of	B-X
the	B-X
beta	B-X
and	B-X
gamma	B-X
gene	B-X
sequences	B-X
,	B-X
although	B-X
gamma	B-X
mRNA	B-X
was	B-X
not	B-X
detected	B-X
in	B-X
these	B-X
cells	B-X
.	B-X

J	O
.	O
,	O
Nienhuis	O
,	O
A	O
.	O
<EOS>	B-X
We	B-X
demonstrated	B-X
previously	B-X
that	B-X
ligand-induced	B-X
kinase	B-X
activation	B-X
of	B-X
the	B-X
colony-stimulating	B-X
factor-1	B-X
receptor	B-X
(	B-X
CSF-1R	B-X
)	B-X
occurs	B-X
via	B-X
receptor	B-X
oligomerization	B-X
without	B-X
propagation	B-X
of	B-X
conformational	B-X
changes	B-X
through	B-X
the	B-X
transmembrane	B-X
(	B-X
TM	B-X
)	B-X
domain	B-X
(	B-X
Lee	B-X
,	B-X
A.	B-X
W.	B-X
,	B-X
and	B-X
Nienhuis	B-X
,	B-X
A.	B-X
W.	B-X
(	B-X
1990	B-X
)	B-X
Proc	B-X
.	B-X
Vitamin	B-X
C	B-X
and	B-X
iron	B-X
.	B-X
Mapping	B-X
a	B-X
human	B-X
genome	B-X
.	B-X
Jane	B-X
,	B-X
P.A	B-X
.	B-X
Nienhuis	B-X
.	B-X
EMBO	B-X
J	B-X
.	B-X

W	O
.	O
,	O
and	O
Crystal	O
,	O
R	O
.	O
<EOS>	B-X
Whether	B-X
more	B-X
iron	B-X
in	B-X
the	B-X
extracellular	B-X
milieu	B-X
of	B-X
the	B-X
lung	B-X
associates	B-X
with	B-X
distinct	B-X
clinical	B-X
phenotypes	B-X
of	B-X
COPD	B-X
,	B-X
including	B-X
increased	B-X
exacerbation	B-X
susceptibility	B-X
,	B-X
is	B-X
unknown	B-X
.	B-X
We	B-X
measured	B-X
iron	B-X
and	B-X
ferritin	B-X
levels	B-X
in	B-X
the	B-X
bronchoalveolar	B-X
lavage	B-X
fluid	B-X
(	B-X
BALF	B-X
)	B-X
of	B-X
participants	B-X
enrolled	B-X
in	B-X
the	B-X
SubPopulations	B-X
and	B-X
InteRmediate	B-X
Outcome	B-X
Measures	B-X
In	B-X
COPD	B-X
(	B-X
SPIROMICS	B-X
)	B-X
bronchoscopy	B-X
sub-study	B-X
(	B-X
n	B-X
=	B-X
195	B-X
)	B-X
.	B-X
Based	B-X
on	B-X
the	B-X
knowledge	B-X
that	B-X
bone	B-X
morphogenetic	B-X
protein	B-X
4	B-X
(	B-X
BMP4	B-X
)	B-X
influences	B-X
epithelial	B-X
progenitor	B-X
function	B-X
in	B-X
the	B-X
developing	B-X
and	B-X
adult	B-X
mouse	B-X
lung	B-X
,	B-X
we	B-X
hypothesised	B-X
that	B-X
BMP4	B-X
signalling	B-X
may	B-X
regulate	B-X
the	B-X
biology	B-X
of	B-X
adult	B-X
human	B-X
airway	B-X
BCs	B-X
relevant	B-X
to	B-X
COPD.BMP4	B-X
signalling	B-X
components	B-X
in	B-X
human	B-X
airway	B-X
epithelium	B-X
were	B-X
analysed	B-X
at	B-X
the	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
,	B-X
and	B-X
the	B-X
differentiation	B-X
of	B-X
BCs	B-X
was	B-X
assessed	B-X
using	B-X
the	B-X
BC	B-X
expansion	B-X
and	B-X
air-liquid	B-X
interface	B-X
models	B-X
in	B-X
the	B-X
absence/presence	B-X
of	B-X
BMP4	B-X
,	B-X
BMP	B-X
receptor	B-X
inhibitor	B-X
and/or	B-X
small	B-X
interfering	B-X
RNAs	B-X
against	B-X
BMP	B-X
receptors	B-X
and	B-X
downstream	B-X
signalling.The	B-X
data	B-X
demonstrate	B-X
that	B-X
in	B-X
cigarette	B-X
smokers	B-X
,	B-X
BMP4	B-X
is	B-X
upregulated	B-X
in	B-X
ciliated	B-X
and	B-X
intermediate	B-X
undifferentiated	B-X
cells	B-X
,	B-X
and	B-X
expression	B-X
of	B-X
the	B-X
BMP4	B-X
receptor	B-X
BMPR1A	B-X
is	B-X
enriched	B-X
in	B-X
BCs	B-X
.	B-X
RNA	B-X
sequencing	B-X
analyses	B-X
revealed	B-X
the	B-X
deregulation	B-X
of	B-X
marker	B-X
genes	B-X
for	B-X
basal	B-X
and	B-X
secretory	B-X
cells	B-X
upon	B-X
CS	B-X
exposure	B-X
.	B-X

G	O
.	O
<EOS>	B-X
Advances	B-X
in	B-X
electron	B-X
cryo-microscopy	B-X
(	B-X
cryo-EM	B-X
)	B-X
now	B-X
permit	B-X
the	B-X
structure	B-X
determination	B-X
of	B-X
G	B-X
protein-coupled	B-X
receptors	B-X
(	B-X
GPCRs	B-X
)	B-X
coupled	B-X
to	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
by	B-X
single-particle	B-X
imaging	B-X
.	B-X
A	B-X
combination	B-X
of	B-X
G	B-X
protein	B-X
engineering	B-X
and	B-X
the	B-X
development	B-X
of	B-X
antibodies	B-X
that	B-X
stabilise	B-X
the	B-X
heterotrimeric	B-X
G	B-X
protein	B-X
facilitate	B-X
the	B-X
formation	B-X
of	B-X
stable	B-X
GPCR-G	B-X
protein	B-X
complexes	B-X
suitable	B-X
for	B-X
structural	B-X
biology	B-X
.	B-X
Structures	B-X
have	B-X
been	B-X
determined	B-X
of	B-X
GPCRs	B-X
coupled	B-X
to	B-X
either	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
(	B-X
G	B-X
Guanine	B-X
nucleotide-binding	B-X
(	B-X
G	B-X
)	B-X
proteins	B-X
,	B-X
namely	B-X
,	B-X
phosphate-binding	B-X
(	B-X
P	B-X
)	B-X
loop	B-X
GTPases	B-X
,	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
life	B-X
processes	B-X
among	B-X
different	B-X
species	B-X
.	B-X
Based	B-X
on	B-X
the	B-X
structural	B-X
characteristics	B-X
,	B-X
G	B-X
proteins	B-X
can	B-X
be	B-X
divided	B-X
into	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
,	B-X
small	B-X
G	B-X
proteins	B-X
and	B-X
multiple	B-X
unique	B-X
unconventional	B-X
G	B-X
proteins	B-X
.	B-X
The	B-X
highly	B-X
conserved	B-X
unconventional	B-X
G	B-X
protein	B-X
YchF	B-X
is	B-X
composed	B-X
of	B-X
a	B-X
core	B-X
G	B-X
domain	B-X
,	B-X
an	B-X
inserted	B-X
coiled-coil	B-X
domain	B-X
,	B-X
and	B-X
a	B-X
TGS	B-X
domain	B-X
from	B-X
the	B-X
N-terminus	B-X
to	B-X
the	B-X
C-terminus	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
compared	B-X
the	B-X
structural	B-X
characteristics	B-X
of	B-X
the	B-X
G	B-X
domain	B-X
in	B-X
rice	B-X
OsYchF1	B-X
with	B-X
those	B-X
of	B-X

(	O
1980	O
)	O
J	O
.	O
<EOS>	B-X
Franz	B-X
J.	B-X
Ingelfinger	B-X
,	B-X
1910	B-X
--	B-X
1980	B-X
.	B-X
The	B-X
journal	B-X
--	B-X
1980	B-X
.	B-X
Since	B-X
,	B-X
as	B-X
far	B-X
as	B-X
we	B-X
were	B-X
aware	B-X
,	B-X
there	B-X
had	B-X
been	B-X
no	B-X
previous	B-X
detailed	B-X
evaluation	B-X
of	B-X
the	B-X
pattern	B-X
of	B-X
surgery	B-X
for	B-X
peptic	B-X
ulcers	B-X
in	B-X
this	B-X
country	B-X
during	B-X
the	B-X
modern	B-X
era	B-X
of	B-X
ulcer	B-X
therapy	B-X
,	B-X
we	B-X
decided	B-X
to	B-X
look	B-X
at	B-X
our	B-X
experience	B-X
since	B-X
1980	B-X
.	B-X
Morokoff	B-X
,	B-X
P.	B-X
J.	B-X
,	B-X
&	B-X
Heiman	B-X
,	B-X
J.	B-X
R.	B-X
(	B-X
1980	B-X
)	B-X
.	B-X
Effects	B-X
of	B-X
erotic	B-X
stimuli	B-X
on	B-X
sexually	B-X
functional	B-X
and	B-X
dysfunctional	B-X
women	B-X
:	B-X
multiple	B-X
measures	B-X
before	B-X
and	B-X
after	B-X
sex	B-X
therapy	B-X
.	B-X

Biol	O
.	O
<EOS>	B-X
Retraction	B-X
of	B-X
DNA	B-X
Cell	B-X
Biol	B-X
:	B-X
31:1064-1069	B-X
,	B-X
2012	B-X
,	B-X
DOI	B-X
:	B-X
10.1089/dna.2011.1552	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
provide	B-X
a	B-X
brief	B-X
synopsis	B-X
of	B-X
all	B-X
manuscripts	B-X
published	B-X
in	B-X
Histochem	B-X
Cell	B-X
Biol	B-X
in	B-X
the	B-X
year	B-X
2013	B-X
.	B-X
Retraction	B-X
notice	B-X
to	B-X
``	B-X
Nicorandil	B-X
versus	B-X
nifedipine	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
preterm	B-X
labour	B-X
:	B-X
A	B-X
randomized	B-X
clinical	B-X
trial	B-X
''	B-X
[	B-X
Eur	B-X
.	B-X
J.	B-X
Obstetr	B-X
.	B-X
Gynecol	B-X
.	B-X
Reprod	B-X
.	B-X
Biol	B-X
.	B-X
195	B-X
(	B-X
2015	B-X
)	B-X
27-30	B-X
]	B-X
.	B-X
Retraction	B-X
notice	B-X
to	B-X
``	B-X
Reducing	B-X
blood	B-X
loss	B-X
at	B-X
abdominal	B-X
myomectomy	B-X
with	B-X
preoperative	B-X
use	B-X
of	B-X
dinoprostone	B-X
intravaginal	B-X
suppository	B-X
:	B-X
A	B-X
randomized	B-X
placebo-controlled	B-X
pilot	B-X
study	B-X
''	B-X
[	B-X
Eur	B-X
.	B-X
J.	B-X
Obst	B-X
.	B-X
Gynecol	B-X
.	B-X
Reprod	B-X
.	B-X
Biol	B-X
.	B-X
166/1	B-X
(	B-X
2012	B-X
)	B-X
61-64	B-X
]	B-X
.	B-X

Chem	O
.	O
,	O
in	O
press	O
.	O
<EOS>	B-X
Science	B-X
that	B-X
Inspires	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
advantages	B-X
and	B-X
disadvantages	B-X
of	B-X
the	B-X
innovative	B-X
,	B-X
low-oxygen	B-X
spiral-filter	B-X
press	B-X
system	B-X
were	B-X
studied	B-X
in	B-X
comparison	B-X
with	B-X
the	B-X
belt	B-X
press	B-X
,	B-X
commonly	B-X
applied	B-X
in	B-X
small	B-X
and	B-X
medium	B-X
size	B-X
enterprises	B-X
for	B-X
the	B-X
production	B-X
of	B-X
cloudy	B-X
apple	B-X
juice	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
equivalent	B-X
throughput	B-X
,	B-X
a	B-X
higher	B-X
juice	B-X
yield	B-X
could	B-X
be	B-X
achieved	B-X
with	B-X
spiral-filter	B-X
press	B-X
.	B-X
Moreover	B-X
,	B-X
it	B-X
was	B-X
found	B-X
that	B-X
juice	B-X
produced	B-X
with	B-X
spiral-filter	B-X
press	B-X
demonstrates	B-X
a	B-X
higher	B-X
retention	B-X
of	B-X
phenolic	B-X
compounds	B-X
during	B-X
the	B-X
downstream	B-X
processing	B-X
steps	B-X
and	B-X
storage	B-X
.	B-X
The	B-X
results	B-X
demonstrates	B-X
the	B-X
advantage	B-X
of	B-X
the	B-X
use	B-X
of	B-X
a	B-X
spiral-filter	B-X
press	B-X
in	B-X
comparison	B-X
with	B-X
belt	B-X
press	B-X
in	B-X
the	B-X
production	B-X
of	B-X
a	B-X
high	B-X
quality	B-X
cloudy	B-X
apple	B-X
juice	B-X
rich	B-X
in	B-X
phenolic	B-X
compounds	B-X
,	B-X
without	B-X
the	B-X
use	B-X
of	B-X
oxidation	B-X
inhibiting	B-X
additives	B-X
.	B-X

3	O
.	O
<EOS>	B-X
Metal	B-X
substitutions	B-X
incarbonic	B-X
anhydrase	B-X
:	B-X
a	B-X
halide	B-X
ion	B-X
probe	B-X
study	B-X
.	B-X

Blin	O
,	O
N	O
.	O
,	O
and	O
Stafford	O
,	O
D	O
.	O
<EOS>	B-X
A	B-X
new	B-X
method	B-X
for	B-X
isolation	B-X
of	B-X
high	B-X
molecular	B-X
weight	B-X
DNA	B-X
from	B-X
eukaryotes	B-X
is	B-X
presented	B-X
.	B-X
This	B-X
procedure	B-X
allows	B-X
preparation	B-X
of	B-X
DNA	B-X
from	B-X
a	B-X
variety	B-X
of	B-X
tissues	B-X
such	B-X
as	B-X
calf	B-X
thymus	B-X
or	B-X
human	B-X
placenta	B-X
and	B-X
from	B-X
cells	B-X
which	B-X
were	B-X
more	B-X
difficult	B-X
to	B-X
lyse	B-X
until	B-X
now	B-X
(	B-X
e.g	B-X
.	B-X
The	B-X
DNA	B-X
obtained	B-X
in	B-X
such	B-X
a	B-X
way	B-X
has	B-X
an	B-X
average	B-X
molecular	B-X
weight	B-X
of	B-X
about	B-X
200	B-X
X	B-X
10	B-X
(	B-X
6	B-X
)	B-X
d	B-X
and	B-X
contains	B-X
very	B-X
few	B-X
,	B-X
if	B-X
any	B-X
,	B-X
single	B-X
strand	B-X
breaks	B-X
.	B-X
A	B-X
1.35-kb	B-X
EcoRI	B-X
fragment	B-X
of	B-X
Lytechinus	B-X
variegatus	B-X
DNA	B-X
containing	B-X
a	B-X
single	B-X
5S	B-X
rRNA	B-X
gene	B-X
has	B-X
been	B-X
cloned	B-X
into	B-X
the	B-X
plasmid	B-X
vector	B-X
pACYC184	B-X
.	B-X
Four	B-X
clones	B-X
from	B-X
different	B-X
transformation	B-X
experiments	B-X
contain	B-X
5S	B-X
rDNA	B-X
inserts	B-X
of	B-X
about	B-X
the	B-X
same	B-X
size	B-X
and	B-X
have	B-X
the	B-X
same	B-X
restriction	B-X
enzyme	B-X
digestion	B-X
patterns	B-X
for	B-X
the	B-X
enzymes	B-X
HaeIII	B-X
,	B-X
HinfI	B-X
,	B-X
HhaI	B-X
,	B-X
and	B-X
AluI	B-X
.	B-X
By	B-X
DNA	B-X
sequencing	B-X
,	B-X
the	B-X
missing	B-X
EcoRI	B-X
ws	B-X
found	B-X
to	B-X
be	B-X
EcoRI	B-X
site	B-X
,	B-X
d	B-X
(	B-X
AAATTN	B-X
)	B-X
d	B-X
(	B-X
TTTAAN	B-X
)	B-X
in	B-X
pLu103	B-X
,	B-X
one	B-X
of	B-X
the	B-X
four	B-X
5S	B-X
rDNA	B-X
clones	B-X
.	B-X
Three	B-X
restriction	B-X
fragments	B-X
,	B-X
1.0-kb	B-X
HaeIII/HaeIII	B-X
,	B-X
0.375-kb	B-X
AluI/AluI	B-X
and	B-X
0.249-kb	B-X
MboII/MboII	B-X
,	B-X
which	B-X
contain	B-X
the	B-X
5S	B-X
rRNA	B-X
coding	B-X
region	B-X
,	B-X
have	B-X
been	B-X
subcloned	B-X
into	B-X
the	B-X
EcoRI	B-X
site	B-X
of	B-X
the	B-X
plasmid	B-X
pACYC184	B-X
.	B-X
The	B-X
organization	B-X
of	B-X
5S	B-X
rRNA	B-X
genes	B-X
in	B-X
the	B-X
sea	B-X
urchin	B-X
genome	B-X
was	B-X
also	B-X
investigated	B-X
.	B-X
It	B-X
was	B-X
found	B-X
that	B-X
restriction	B-X
endonuclease	B-X
HaeIII	B-X
has	B-X
a	B-X
single	B-X
recognition	B-X
site	B-X
within	B-X
each	B-X
5S	B-X
rDNA	B-X
repeat	B-X
,	B-X
and	B-X
yields	B-X
two	B-X
fragment	B-X
lengths	B-X
,	B-X
1.2	B-X
and	B-X
1.3	B-X
kb	B-X
.	B-X
The	B-X
behavior	B-X
of	B-X
these	B-X
5S	B-X
rRNA	B-X
genes	B-X
when	B-X
total	B-X
L.	B-X
variegatus	B-X
DNA	B-X
is	B-X
partially	B-X
digested	B-X
with	B-X
HaeIII	B-X
is	B-X
consistent	B-X
with	B-X
an	B-X
arrangement	B-X
of	B-X
5S	B-X
rRNA	B-X
genes	B-X
in	B-X
at	B-X
least	B-X
two	B-X
tandemly	B-X
repeated	B-X
,	B-X
non-interspersed	B-X
families	B-X
.	B-X
Both	B-X
the	B-X
coding	B-X
region	B-X
and	B-X
spacer	B-X
region	B-X
of	B-X
the	B-X
5S	B-X
rRNA	B-X
gene	B-X
in	B-X
pLu103	B-X
hybridize	B-X
to	B-X
1.2	B-X
and	B-X
1.3-kb	B-X
rDNA	B-X
families	B-X
.	B-X
This	B-X
indicates	B-X
that	B-X
the	B-X
cloned	B-X
EcoRI	B-X
fragment	B-X
of	B-X
5S	B-X
rDNA	B-X
in	B-X
pLu103	B-X
represents	B-X
one	B-X
single	B-X
repeat	B-X
of	B-X
5S	B-X
rDNA	B-X
in	B-X
the	B-X
genome	B-X
.	B-X

W	O
.	O
<EOS>	B-X
We	B-X
present	B-X
a	B-X
novel	B-X
static	B-X
W-shaped	B-X
common-path	B-X
interferometer	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
the	B-X
W-shaped	B-X
common-path	B-X
corner-cube	B-X
retroreflector	B-X
interferometer	B-X
(	B-X
W-CPRI	B-X
)	B-X
is	B-X
introduced	B-X
via	B-X
detailed	B-X
analysis	B-X
of	B-X
its	B-X
working	B-X
principles	B-X
and	B-X
performance	B-X
.	B-X
For	B-X
each	B-X
interference	B-X
output	B-X
of	B-X
an	B-X
ideal	B-X
W-CPRI	B-X
,	B-X
the	B-X
two	B-X
beams	B-X
recombine	B-X
and	B-X
have	B-X
the	B-X
same	B-X
output	B-X
direction	B-X
,	B-X
including	B-X
a	B-X
tilted	B-X
CCR	B-X
.	B-X
In	B-X
a	B-X
deformed	B-X
W-CPRI	B-X
structure	B-X
,	B-X
an	B-X
optical	B-X
path	B-X
difference	B-X
can	B-X
be	B-X
produced	B-X
by	B-X
inserting	B-X
an	B-X
optical	B-X
element	B-X
that	B-X
changes	B-X
the	B-X
optical	B-X
path	B-X
in	B-X
the	B-X
interferometer	B-X
arm	B-X
of	B-X
the	B-X
W-CPRI	B-X
.	B-X
The	B-X
posture	B-X
deviations	B-X
of	B-X
the	B-X
RM	B-X
and	B-X
the	B-X
CCRs	B-X
in	B-X
the	B-X
W-CPRI	B-X
are	B-X
analyzed	B-X
.	B-X
The	B-X
average	B-X
cosine	B-X
similarity	B-X
is	B-X
0.9953	B-X
,	B-X
revealing	B-X
that	B-X
this	B-X
W-CPRI	B-X
has	B-X
high	B-X
stability	B-X
and	B-X
strong	B-X
coherence	B-X
while	B-X
avoiding	B-X
the	B-X
tilt	B-X
and	B-X
displacement	B-X
of	B-X
the	B-X
interferometer	B-X
arm	B-X
.	B-X

(	O
1976	O
)	O
Nucl	O
.	O
<EOS>	B-X
Nuclear	B-X
medicine	B-X
techniques	B-X
are	B-X
currently	B-X
playing	B-X
an	B-X
important	B-X
complementary	B-X
role	B-X
in	B-X
the	B-X
evaluation	B-X
,	B-X
management	B-X
,	B-X
and	B-X
follow-up	B-X
of	B-X
the	B-X
patient	B-X
who	B-X
is	B-X
suspected	B-X
of	B-X
having	B-X
Paget	B-X
's	B-X
disease	B-X
of	B-X
bone	B-X
.	B-X
Letter	B-X
:	B-X
Jugular	B-X
vein	B-X
reflux	B-X
.	B-X
In	B-X
1976	B-X
,	B-X
2	B-X
major	B-X
molecular	B-X
imaging	B-X
events	B-X
coincidentally	B-X
took	B-X
place	B-X
:	B-X
Clinical	B-X
Nuclear	B-X
Medicine	B-X
was	B-X
first	B-X
published	B-X
in	B-X
June	B-X
,	B-X
and	B-X
in	B-X
August	B-X
researchers	B-X
at	B-X
the	B-X
Hospital	B-X
of	B-X
the	B-X
University	B-X
of	B-X
Pennsylvania	B-X
created	B-X
the	B-X
first	B-X
images	B-X
in	B-X
humans	B-X
with	B-X
F-FDG	B-X
.	B-X
Today	B-X
,	B-X
Clinical	B-X
Nuclear	B-X
Medicine	B-X
is	B-X
a	B-X
valued	B-X
scientific	B-X
contributor	B-X
to	B-X
the	B-X
molecular	B-X
imaging	B-X
community	B-X
,	B-X
and	B-X
FDG	B-X
PET	B-X
is	B-X
considered	B-X
the	B-X
backbone	B-X
of	B-X
this	B-X
evolving	B-X
and	B-X
exciting	B-X
discipline	B-X
.	B-X

Acids	O
Res	O
.	O
<EOS>	B-X
Over	B-X
the	B-X
course	B-X
of	B-X
the	B-X
past	B-X
few	B-X
decades	B-X
,	B-X
the	B-X
theory	B-X
of	B-X
Hard	B-X
and	B-X
Soft	B-X
,	B-X
Acids	B-X
and	B-X
Bases	B-X
(	B-X
HSAB	B-X
)	B-X
has	B-X
proven	B-X
to	B-X
be	B-X
a	B-X
useful	B-X
tool	B-X
in	B-X
predicting	B-X
the	B-X
outcome	B-X
of	B-X
such	B-X
reactions	B-X
.	B-X
Mutagenesis	B-X
.	B-X
Plasma	B-X
acids	B-X
.	B-X

3	O
,	O
2303	O
-	O
2308	O
.	O
<EOS>	B-X
Prolyl	B-X
dipeptidase	B-X
(	B-X
iminodipeptidase	B-X
,	B-X
L-prolyl-amino	B-X
acid	B-X
hydrolase	B-X
,	B-X
EC	B-X
3.4.13.8	B-X
)	B-X
was	B-X
purified	B-X
180-fold	B-X
from	B-X
bovine	B-X
kidney	B-X
.	B-X
The	B-X
enzyme	B-X
which	B-X
was	B-X
obtained	B-X
in	B-X
a	B-X
10	B-X
%	B-X
yield	B-X
was	B-X
completely	B-X
separated	B-X
from	B-X
a	B-X
number	B-X
of	B-X
known	B-X
kidney	B-X
peptidases	B-X
including	B-X
an	B-X
enzyme	B-X
of	B-X
very	B-X
similar	B-X
substrate	B-X
specificity	B-X
,	B-X
proline	B-X
aminopeptidase	B-X
(	B-X
L-prolyl-peptide	B-X
hydrolase	B-X
,	B-X
EC	B-X
3.4.11.5	B-X
)	B-X
.	B-X
Metal	B-X
substitutions	B-X
incarbonic	B-X
anhydrase	B-X
:	B-X
a	B-X
halide	B-X
ion	B-X
probe	B-X
study	B-X
.	B-X
3	B-X
.	B-X
Items	B-X
3	B-X
and	B-X
4	B-X
taken	B-X
together	B-X
suggest	B-X
that	B-X
the	B-X
conformations	B-X
are	B-X
ligand	B-X
induced	B-X
and	B-X
do	B-X
not	B-X
arise	B-X
via	B-X
ligand	B-X
stabilization	B-X
of	B-X
spontaneously	B-X
arising	B-X
conformers	B-X
.	B-X

4	O
.	O
<EOS>	B-X
Effect	B-X
of	B-X
chloroquine	B-X
on	B-X
cultured	B-X
fibroblasts	B-X
:	B-X
release	B-X
of	B-X
lysosomal	B-X
hydrolases	B-X
and	B-X
inhibition	B-X
of	B-X
their	B-X
uptake	B-X
.	B-X

Kretschmer	O
,	O
P	O
.	O
<EOS>	B-X
Covalent	B-X
attachment	B-X
of	B-X
a	B-X
synthetic	B-X
triantennary	B-X
N-acetylagalactosamine	B-X
(	B-X
GalNAc	B-X
)	B-X
ligand	B-X
to	B-X
chemically	B-X
modified	B-X
siRNA	B-X
has	B-X
enabled	B-X
asialoglycoprotein	B-X
(	B-X
ASGPR	B-X
)	B-X
-mediated	B-X
targeted	B-X
delivery	B-X
of	B-X
therapeutically	B-X
active	B-X
siRNAs	B-X
to	B-X
hepatocytes	B-X
in	B-X
vivo	B-X
.	B-X
Educational	B-X
Case	B-X
:	B-X
Immune	B-X
and	B-X
inflammatory	B-X
diseases	B-X
:	B-X
A	B-X
case	B-X
of	B-X
pulmonary	B-X
sarcoidosis	B-X
.	B-X
[	B-X
Disinfectants	B-X
.	B-X
8	B-X
]	B-X
.	B-X
[	B-X
Laxatives	B-X
and	B-X
antidiarrheals	B-X
.	B-X
27	B-X
]	B-X
.	B-X

J	O
.	O
,	O
Kaufman	O
,	O
R	O
.	O
<EOS>	B-X
The	B-X
unfolded	B-X
protein	B-X
response	B-X
(	B-X
UPR	B-X
)	B-X
is	B-X
activated	B-X
upon	B-X
the	B-X
accumulation	B-X
of	B-X
misfolded	B-X
proteins	B-X
in	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
that	B-X
are	B-X
sensed	B-X
by	B-X
the	B-X
binding	B-X
immunoglobulin	B-X
protein	B-X
(	B-X
BiP	B-X
)	B-X
/glucose-regulated	B-X
protein	B-X
78	B-X
(	B-X
GRP78	B-X
)	B-X
.	B-X
The	B-X
accumulation	B-X
of	B-X
unfolded	B-X
proteins	B-X
sequesters	B-X
BiP	B-X
so	B-X
it	B-X
dissociates	B-X
from	B-X
three	B-X
ER-transmembrane	B-X
transducers	B-X
leading	B-X
to	B-X
their	B-X
activation	B-X
.	B-X
These	B-X
transducers	B-X
are	B-X
inositol	B-X
requiring	B-X
(	B-X
IRE	B-X
)	B-X
1Î±	B-X
,	B-X
PKR-like	B-X
ER	B-X
kinase	B-X
(	B-X
PERK	B-X
)	B-X
,	B-X
and	B-X
activating	B-X
transcription	B-X
factor	B-X
(	B-X
ATF	B-X
)	B-X
6Î±	B-X
.	B-X
PERK	B-X
phosphorylates	B-X
eukaryotic	B-X
initiation	B-X
factor	B-X
2	B-X
alpha	B-X
(	B-X
eIF2Î±	B-X
)	B-X
resulting	B-X
in	B-X
global	B-X
mRNA	B-X
translation	B-X
attenuation	B-X
,	B-X
and	B-X
concurrently	B-X
selectively	B-X
increases	B-X
the	B-X
translation	B-X
of	B-X
several	B-X
mRNAs	B-X
,	B-X
including	B-X
the	B-X
transcription	B-X
factor	B-X
ATF4	B-X
,	B-X
and	B-X
its	B-X
downstream	B-X
target	B-X
CHOP	B-X
.	B-X
IRE1Î±	B-X
has	B-X
kinase	B-X
and	B-X
endoribonuclease	B-X
(	B-X
RNase	B-X
)	B-X
activities	B-X
.	B-X
IRE1Î±	B-X
autophosphorylation	B-X
activates	B-X
the	B-X
RNase	B-X
activity	B-X
to	B-X
splice	B-X
XBP1	B-X
mRNA	B-X
,	B-X
to	B-X
produce	B-X
the	B-X
active	B-X
transcription	B-X
factor	B-X
sXBP1	B-X
.	B-X
IRE1Î±	B-X
activation	B-X
also	B-X
recruits	B-X
and	B-X
activates	B-X
the	B-X
stress	B-X
kinase	B-X
JNK	B-X
.	B-X
These	B-X
UPR	B-X
pathways	B-X
act	B-X
in	B-X
concert	B-X
to	B-X
increase	B-X
ER	B-X
content	B-X
,	B-X
expand	B-X
the	B-X
ER	B-X
protein	B-X
folding	B-X
capacity	B-X
,	B-X
degrade	B-X
misfolded	B-X
proteins	B-X
,	B-X
and	B-X
reduce	B-X
the	B-X
load	B-X
of	B-X
new	B-X
proteins	B-X
entering	B-X
the	B-X
ER	B-X
.	B-X
Faced	B-X
with	B-X
persistent	B-X
ER	B-X
stress	B-X
,	B-X
adaptation	B-X
starts	B-X
to	B-X
fail	B-X
and	B-X
apoptosis	B-X
occurs	B-X
,	B-X
possibly	B-X
mediated	B-X
through	B-X
calcium	B-X
perturbations	B-X
,	B-X
reactive	B-X
oxygen	B-X
species	B-X
,	B-X
and	B-X
the	B-X
proapoptotic	B-X
transcription	B-X
factor	B-X
CHOP	B-X
.	B-X
The	B-X
UPR	B-X
is	B-X
activated	B-X
in	B-X
several	B-X
liver	B-X
diseases	B-X
;	B-X
including	B-X
obesity	B-X
associated	B-X
fatty	B-X
liver	B-X
disease	B-X
,	B-X
viral	B-X
hepatitis	B-X
,	B-X
and	B-X
alcohol-induced	B-X
liver	B-X
injury	B-X
,	B-X
all	B-X
of	B-X
which	B-X
are	B-X
associated	B-X
with	B-X
steatosis	B-X
,	B-X
raising	B-X
the	B-X
possibility	B-X
that	B-X
ER	B-X
stress-dependent	B-X
alteration	B-X
in	B-X
lipid	B-X
homeostasis	B-X
is	B-X
the	B-X
mechanism	B-X
that	B-X
underlies	B-X
the	B-X
steatosis	B-X
.	B-X
Hepatocyte	B-X
apoptosis	B-X
is	B-X
a	B-X
pathogenic	B-X
event	B-X
in	B-X
several	B-X
liver	B-X
diseases	B-X
,	B-X
and	B-X
may	B-X
be	B-X
linked	B-X
to	B-X
unresolved	B-X
ER	B-X
stress	B-X
.	B-X
If	B-X
this	B-X
is	B-X
true	B-X
,	B-X
restoration	B-X
of	B-X
ER	B-X
homeostasis	B-X
prior	B-X
to	B-X
ER	B-X
stress-induced	B-X
cell	B-X
death	B-X
may	B-X
provide	B-X
a	B-X
therapeutic	B-X
rationale	B-X
in	B-X
these	B-X
diseases	B-X
.	B-X
Herein	B-X
we	B-X
discuss	B-X
each	B-X
branch	B-X
of	B-X
the	B-X
UPR	B-X
and	B-X
how	B-X
they	B-X
may	B-X
impact	B-X
hepatocyte	B-X
function	B-X
in	B-X
different	B-X
pathologic	B-X
states	B-X
.	B-X

E	O
.	O
,	O
Coon	O
,	O
H	O
.	O
<EOS>	B-X
Expressed	B-X
early	B-X
in	B-X
brain	B-X
development	B-X
,	B-X
most	B-X
risk	B-X
genes	B-X
have	B-X
roles	B-X
in	B-X
regulation	B-X
of	B-X
gene	B-X
expression	B-X
or	B-X
neuronal	B-X
communication	B-X
(	B-X
i.e.	B-X
,	B-X
mutations	B-X
effect	B-X
neurodevelopmental	B-X
and	B-X
neurophysiological	B-X
changes	B-X
)	B-X
,	B-X
and	B-X
13	B-X
fall	B-X
within	B-X
loci	B-X
recurrently	B-X
hit	B-X
by	B-X
copy	B-X
number	B-X
variants	B-X
.	B-X
Most	B-X
previous	B-X
genome-wide	B-X
association	B-X
studies	B-X
(	B-X
GWAS	B-X
)	B-X
of	B-X
depression	B-X
have	B-X
used	B-X
data	B-X
from	B-X
individuals	B-X
of	B-X
European	B-X
descent	B-X
.	B-X
To	B-X
examine	B-X
shared	B-X
genetic	B-X
etiology	B-X
,	B-X
we	B-X
use	B-X
genome-wide	B-X
genotype	B-X
data	B-X
from	B-X
the	B-X
Psychiatric	B-X
Genomics	B-X
Consortium	B-X
(	B-X
PGC	B-X
)	B-X
for	B-X
cases	B-X
and	B-X
controls	B-X
in	B-X
schizophrenia	B-X
,	B-X
bipolar	B-X
disorder	B-X
,	B-X
major	B-X
depressive	B-X
disorder	B-X
,	B-X
autism	B-X
spectrum	B-X
disorders	B-X
(	B-X
ASD	B-X
)	B-X
and	B-X
attention-deficit/hyperactivity	B-X
disorder	B-X
(	B-X
ADHD	B-X
)	B-X
.	B-X
)	B-X
,	B-X
and	B-X
ADHD	B-X
and	B-X
major	B-X
depressive	B-X
disorder	B-X
(	B-X
0.32	B-X
Â±	B-X
0.07	B-X
s.e	B-X
.	B-X

C	O
.	O
,	O
Chen	O
,	O
M	O
.	O

JY	O
.	O
,	O
Geist	O

C	O
.	O
<EOS>	B-X
[	B-X
Hepatitis	B-X
C	B-X
]	B-X
.	B-X
Hepatitis	B-X
C	B-X
virus	B-X
(	B-X
HCV	B-X
)	B-X
infection	B-X
is	B-X
a	B-X
leading	B-X
cause	B-X
of	B-X
chronic	B-X
hepatitis	B-X
,	B-X
liver	B-X
cirrhosis	B-X
,	B-X
and	B-X
hepatocellular	B-X
carcinoma	B-X
worldwide	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
briefly	B-X
review	B-X
the	B-X
virology	B-X
,	B-X
diagnosis	B-X
and	B-X
therapy	B-X
of	B-X
hepatitis	B-X
C.	B-X
Standard	B-X
therapy	B-X
with	B-X
pegylated	B-X
interferon-alpha	B-X
and	B-X
ribavirin	B-X
results	B-X
in	B-X
a	B-X
sustained	B-X
virological	B-X
response	B-X
in	B-X
40-50	B-X
%	B-X
of	B-X
genotype	B-X
1-	B-X
and	B-X
in	B-X
about	B-X
80	B-X
%	B-X
of	B-X
genotype	B-X
2-	B-X
or	B-X
3-infected	B-X
patients	B-X
.	B-X
Hepatitis	B-X
C	B-X
.	B-X

E	O
.	O
,	O
and	O
Nienhuis	O
,	O
A	O
.	O
<EOS>	B-X
An	B-X
analysis	B-X
of	B-X
hemoglobin	B-X
(	B-X
Hb	B-X
)	B-X
synthesis	B-X
in	B-X
BFU-E-	B-X
and	B-X
CFU-E-derived	B-X
colonies	B-X
from	B-X
fetuses	B-X
either	B-X
homozygous	B-X
for	B-X
HbA	B-X
(	B-X
AA	B-X
)	B-X
(	B-X
homozygous	B-X
also	B-X
for	B-X
the	B-X
beta	B-X
c	B-X
gene	B-X
responsible	B-X
for	B-X
HbC	B-X
production	B-X
)	B-X
or	B-X
HbB	B-X
(	B-X
BB	B-X
)	B-X
(	B-X
lacking	B-X
the	B-X
beta	B-X
c	B-X
gene	B-X
)	B-X
indicated	B-X
the	B-X
following	B-X
.	B-X
Erythropoietic	B-X
precursor	B-X
cells	B-X
from	B-X
a	B-X
124-day	B-X
BB	B-X
fetus	B-X
were	B-X
already	B-X
committed	B-X
to	B-X
HbB	B-X
synthesis	B-X
,	B-X
since	B-X
HbF	B-X
production	B-X
was	B-X
replaced	B-X
by	B-X
HbB	B-X
on	B-X
successive	B-X
days	B-X
in	B-X
vitro	B-X
as	B-X
erythroid	B-X
colonies	B-X
matured	B-X
;	B-X
this	B-X
switch	B-X
was	B-X
not	B-X
affected	B-X
by	B-X
varying	B-X
the	B-X
epo	B-X
concentration	B-X
.	B-X
Erythropoietic	B-X
stress	B-X
did	B-X
not	B-X
result	B-X
in	B-X
induction	B-X
of	B-X
HbF	B-X
in	B-X
vivo	B-X
or	B-X
in	B-X
erythroid	B-X
colonies	B-X
derived	B-X
from	B-X
CFU-E	B-X
in	B-X
young	B-X
adult	B-X
BB	B-X
sheep	B-X
,	B-X
whereas	B-X
our	B-X
prior	B-X
studies	B-X
had	B-X
shown	B-X
induction	B-X
of	B-X
HbC	B-X
synthesis	B-X
under	B-X
analogous	B-X
conditions	B-X
in	B-X
colonies	B-X
derived	B-X
from	B-X
young	B-X
adult	B-X
AA	B-X
sheep	B-X
.	B-X
The	B-X
human	B-X
gamma-globin	B-X
gene	B-X
promoter	B-X
contains	B-X
a	B-X
stage	B-X
selector	B-X
element	B-X
(	B-X
SSE	B-X
)	B-X
responsible	B-X
for	B-X
preferential	B-X
interaction	B-X
of	B-X
the	B-X
promoter	B-X
with	B-X
a	B-X
powerful	B-X
erythroid-specific	B-X
enhancer	B-X
in	B-X
the	B-X
fetal	B-X
developmental	B-X
stage	B-X
(	B-X
S.M	B-X
.	B-X
Ney	B-X
,	B-X
E.F.	B-X
Vanin	B-X
,	B-X
D.L	B-X
.	B-X
Nienhuis	B-X
.	B-X
EMBO	B-X
J	B-X
.	B-X
Binding	B-X
of	B-X
the	B-X
second	B-X
protein	B-X
correlates	B-X
with	B-X
SSE	B-X
activity	B-X
in	B-X
transient-transfection	B-X
assays	B-X
.	B-X
This	B-X
site	B-X
functions	B-X
in	B-X
an	B-X
analogous	B-X
manner	B-X
to	B-X
the	B-X
SSE	B-X
in	B-X
hybrid	B-X
beta-promoter/reporter	B-X
gene	B-X
constructs	B-X
transfected	B-X
into	B-X
K562	B-X
cells	B-X
.	B-X
Gel	B-X
mobility	B-X
shift	B-X
assays	B-X
with	B-X
nuclear	B-X
extract	B-X
from	B-X
K562	B-X
cells	B-X
(	B-X
which	B-X
contain	B-X
both	B-X
Sp1	B-X
and	B-X
SSP	B-X
)	B-X
demonstrate	B-X
preferential	B-X
binding	B-X
of	B-X
SSP	B-X
to	B-X
the	B-X
SSE	B-X
and	B-X
HPFH	B-X
sites	B-X
under	B-X
conditions	B-X
in	B-X
which	B-X
probe	B-X
was	B-X
limiting	B-X
.	B-X
Methylation	B-X
of	B-X
the	B-X
CpG	B-X
residues	B-X
reverses	B-X
this	B-X
preference	B-X
only	B-X
in	B-X
the	B-X
SSE	B-X
site	B-X
,	B-X
with	B-X
a	B-X
marked	B-X
increase	B-X
in	B-X
the	B-X
binding	B-X
of	B-X
Sp1	B-X
at	B-X
the	B-X
expense	B-X
of	B-X
the	B-X
SSP	B-X
.	B-X
The	B-X
methylation-induced	B-X
preferential	B-X
binding	B-X
of	B-X
Sp1	B-X
to	B-X
the	B-X
SSE	B-X
at	B-X
the	B-X
expense	B-X
of	B-X
SSP	B-X
may	B-X
be	B-X
part	B-X
of	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
the	B-X
gamma	B-X
genes	B-X
are	B-X
repressed	B-X
in	B-X
normal	B-X
adult	B-X
erythroid	B-X
cells	B-X
.	B-X

W	O
.	O
<EOS>	B-X
We	B-X
present	B-X
a	B-X
novel	B-X
static	B-X
W-shaped	B-X
common-path	B-X
interferometer	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
the	B-X
W-shaped	B-X
common-path	B-X
corner-cube	B-X
retroreflector	B-X
interferometer	B-X
(	B-X
W-CPRI	B-X
)	B-X
is	B-X
introduced	B-X
via	B-X
detailed	B-X
analysis	B-X
of	B-X
its	B-X
working	B-X
principles	B-X
and	B-X
performance	B-X
.	B-X
For	B-X
each	B-X
interference	B-X
output	B-X
of	B-X
an	B-X
ideal	B-X
W-CPRI	B-X
,	B-X
the	B-X
two	B-X
beams	B-X
recombine	B-X
and	B-X
have	B-X
the	B-X
same	B-X
output	B-X
direction	B-X
,	B-X
including	B-X
a	B-X
tilted	B-X
CCR	B-X
.	B-X
In	B-X
a	B-X
deformed	B-X
W-CPRI	B-X
structure	B-X
,	B-X
an	B-X
optical	B-X
path	B-X
difference	B-X
can	B-X
be	B-X
produced	B-X
by	B-X
inserting	B-X
an	B-X
optical	B-X
element	B-X
that	B-X
changes	B-X
the	B-X
optical	B-X
path	B-X
in	B-X
the	B-X
interferometer	B-X
arm	B-X
of	B-X
the	B-X
W-CPRI	B-X
.	B-X
The	B-X
posture	B-X
deviations	B-X
of	B-X
the	B-X
RM	B-X
and	B-X
the	B-X
CCRs	B-X
in	B-X
the	B-X
W-CPRI	B-X
are	B-X
analyzed	B-X
.	B-X
The	B-X
average	B-X
cosine	B-X
similarity	B-X
is	B-X
0.9953	B-X
,	B-X
revealing	B-X
that	B-X
this	B-X
W-CPRI	B-X
has	B-X
high	B-X
stability	B-X
and	B-X
strong	B-X
coherence	B-X
while	B-X
avoiding	B-X
the	B-X
tilt	B-X
and	B-X
displacement	B-X
of	B-X
the	B-X
interferometer	B-X
arm	B-X
.	B-X

(	O
1980	O
)	O
J	O
.	O
<EOS>	B-X
Franz	B-X
J.	B-X
Ingelfinger	B-X
,	B-X
1910	B-X
--	B-X
1980	B-X
.	B-X
The	B-X
journal	B-X
--	B-X
1980	B-X
.	B-X
Since	B-X
,	B-X
as	B-X
far	B-X
as	B-X
we	B-X
were	B-X
aware	B-X
,	B-X
there	B-X
had	B-X
been	B-X
no	B-X
previous	B-X
detailed	B-X
evaluation	B-X
of	B-X
the	B-X
pattern	B-X
of	B-X
surgery	B-X
for	B-X
peptic	B-X
ulcers	B-X
in	B-X
this	B-X
country	B-X
during	B-X
the	B-X
modern	B-X
era	B-X
of	B-X
ulcer	B-X
therapy	B-X
,	B-X
we	B-X
decided	B-X
to	B-X
look	B-X
at	B-X
our	B-X
experience	B-X
since	B-X
1980	B-X
.	B-X
Morokoff	B-X
,	B-X
P.	B-X
J.	B-X
,	B-X
&	B-X
Heiman	B-X
,	B-X
J.	B-X
R.	B-X
(	B-X
1980	B-X
)	B-X
.	B-X
Effects	B-X
of	B-X
erotic	B-X
stimuli	B-X
on	B-X
sexually	B-X
functional	B-X
and	B-X
dysfunctional	B-X
women	B-X
:	B-X
multiple	B-X
measures	B-X
before	B-X
and	B-X
after	B-X
sex	B-X
therapy	B-X
.	B-X

Biol	O
.	O
<EOS>	B-X
Retraction	B-X
of	B-X
DNA	B-X
Cell	B-X
Biol	B-X
:	B-X
31:1064-1069	B-X
,	B-X
2012	B-X
,	B-X
DOI	B-X
:	B-X
10.1089/dna.2011.1552	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
provide	B-X
a	B-X
brief	B-X
synopsis	B-X
of	B-X
all	B-X
manuscripts	B-X
published	B-X
in	B-X
Histochem	B-X
Cell	B-X
Biol	B-X
in	B-X
the	B-X
year	B-X
2013	B-X
.	B-X
Retraction	B-X
notice	B-X
to	B-X
``	B-X
Nicorandil	B-X
versus	B-X
nifedipine	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
preterm	B-X
labour	B-X
:	B-X
A	B-X
randomized	B-X
clinical	B-X
trial	B-X
''	B-X
[	B-X
Eur	B-X
.	B-X
J.	B-X
Obstetr	B-X
.	B-X
Gynecol	B-X
.	B-X
Reprod	B-X
.	B-X
Biol	B-X
.	B-X
195	B-X
(	B-X
2015	B-X
)	B-X
27-30	B-X
]	B-X
.	B-X
Retraction	B-X
notice	B-X
to	B-X
``	B-X
Reducing	B-X
blood	B-X
loss	B-X
at	B-X
abdominal	B-X
myomectomy	B-X
with	B-X
preoperative	B-X
use	B-X
of	B-X
dinoprostone	B-X
intravaginal	B-X
suppository	B-X
:	B-X
A	B-X
randomized	B-X
placebo-controlled	B-X
pilot	B-X
study	B-X
''	B-X
[	B-X
Eur	B-X
.	B-X
J.	B-X
Obst	B-X
.	B-X
Gynecol	B-X
.	B-X
Reprod	B-X
.	B-X
Biol	B-X
.	B-X
166/1	B-X
(	B-X
2012	B-X
)	B-X
61-64	B-X
]	B-X
.	B-X

Chem	O
.	O
,	O
in	O
press	O
.	O
<EOS>	B-X
Science	B-X
that	B-X
Inspires	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
advantages	B-X
and	B-X
disadvantages	B-X
of	B-X
the	B-X
innovative	B-X
,	B-X
low-oxygen	B-X
spiral-filter	B-X
press	B-X
system	B-X
were	B-X
studied	B-X
in	B-X
comparison	B-X
with	B-X
the	B-X
belt	B-X
press	B-X
,	B-X
commonly	B-X
applied	B-X
in	B-X
small	B-X
and	B-X
medium	B-X
size	B-X
enterprises	B-X
for	B-X
the	B-X
production	B-X
of	B-X
cloudy	B-X
apple	B-X
juice	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
equivalent	B-X
throughput	B-X
,	B-X
a	B-X
higher	B-X
juice	B-X
yield	B-X
could	B-X
be	B-X
achieved	B-X
with	B-X
spiral-filter	B-X
press	B-X
.	B-X
Moreover	B-X
,	B-X
it	B-X
was	B-X
found	B-X
that	B-X
juice	B-X
produced	B-X
with	B-X
spiral-filter	B-X
press	B-X
demonstrates	B-X
a	B-X
higher	B-X
retention	B-X
of	B-X
phenolic	B-X
compounds	B-X
during	B-X
the	B-X
downstream	B-X
processing	B-X
steps	B-X
and	B-X
storage	B-X
.	B-X
The	B-X
results	B-X
demonstrates	B-X
the	B-X
advantage	B-X
of	B-X
the	B-X
use	B-X
of	B-X
a	B-X
spiral-filter	B-X
press	B-X
in	B-X
comparison	B-X
with	B-X
belt	B-X
press	B-X
in	B-X
the	B-X
production	B-X
of	B-X
a	B-X
high	B-X
quality	B-X
cloudy	B-X
apple	B-X
juice	B-X
rich	B-X
in	B-X
phenolic	B-X
compounds	B-X
,	B-X
without	B-X
the	B-X
use	B-X
of	B-X
oxidation	B-X
inhibiting	B-X
additives	B-X
.	B-X

5	O
.	O
<EOS>	B-X
Atomic	B-X
models	B-X
for	B-X
the	B-X
polypeptide	B-X
backbones	B-X
of	B-X
myohemerythrin	B-X
and	B-X
hemerythrin	B-X
.	B-X

Maniatis	O
,	O
T	O
.	O
,	O
Hardison	O
,	O
R	O
.	O
<EOS>	B-X
Four	B-X
different	B-X
regions	B-X
of	B-X
rabbit	B-X
beta-like	B-X
globin	B-X
gene	B-X
sequences	B-X
designated	B-X
beta	B-X
1	B-X
,	B-X
beta	B-X
2	B-X
,	B-X
beta	B-X
3	B-X
and	B-X
beta	B-X
4	B-X
were	B-X
identified	B-X
in	B-X
a	B-X
set	B-X
of	B-X
clones	B-X
isolated	B-X
from	B-X
a	B-X
bacteriophage	B-X
lambda	B-X
library	B-X
of	B-X
chromosomal	B-X
DNA	B-X
fragments	B-X
(	B-X
Maniatis	B-X
et	B-X
al.	B-X
,	B-X
1978	B-X
)	B-X
.	B-X
Restriction	B-X
mapping	B-X
and	B-X
blot	B-X
hybridization	B-X
(	B-X
Southern	B-X
,	B-X
1975	B-X
)	B-X
studies	B-X
indicate	B-X
that	B-X
a	B-X
subset	B-X
of	B-X
these	B-X
clones	B-X
containing	B-X
beta	B-X
1	B-X
and	B-X
beta	B-X
2	B-X
hybridizes	B-X
to	B-X
an	B-X
adult	B-X
beta-globin	B-X
cDNA	B-X
clone	B-X
(	B-X
Maniatis	B-X
et	B-X
al.	B-X
,	B-X
1976	B-X
)	B-X
more	B-X
efficiently	B-X
than	B-X
to	B-X
a	B-X
human	B-X
gamma-globin	B-X
cDNA	B-X
clone	B-X
(	B-X
Wilson	B-X
et	B-X
al.	B-X
,	B-X
1978	B-X
)	B-X
,	B-X
while	B-X
another	B-X
subset	B-X
containing	B-X
beta	B-X
3	B-X
and	B-X
beta	B-X
4	B-X
displays	B-X
the	B-X
converse	B-X
hybridization	B-X
specificity	B-X
.	B-X
Restriction	B-X
mapping	B-X
and	B-X
hybridization	B-X
studies	B-X
reveal	B-X
the	B-X
presence	B-X
of	B-X
closely	B-X
linked	B-X
beta-globin	B-X
genes	B-X
.	B-X
Rabbit	B-X
chromosomal	B-X
DNA	B-X
contains	B-X
a	B-X
cluster	B-X
of	B-X
four	B-X
linked	B-X
beta-like	B-X
globin	B-X
genes	B-X
arranged	B-X
in	B-X
the	B-X
orientation	B-X
5'-beta	B-X
4-	B-X
(	B-X
8kb	B-X
)	B-X
-beta	B-X
3-	B-X
(	B-X
5	B-X
kb	B-X
)	B-X
-beta	B-X
2-	B-X
(	B-X
7-kb	B-X
)	B-X
-beta	B-X
1-3	B-X
'	B-X
.	B-X
A	B-X
14S	B-X
polyadenylated	B-X
transcript	B-X
containing	B-X
large	B-X
intron	B-X
sequences	B-X
(	B-X
possibly	B-X
a	B-X
mRNA	B-X
precursor	B-X
)	B-X
is	B-X
detected	B-X
in	B-X
the	B-X
bone	B-X
marrow	B-X
cells	B-X
of	B-X
anemic	B-X
rabbits	B-X
.	B-X
Gene	B-X
beta	B-X
2	B-X
has	B-X
limited	B-X
sequence	B-X
homology	B-X
to	B-X
adult	B-X
and	B-X
embryonic	B-X
beta-globin	B-X
probes	B-X
and	B-X
lacks	B-X
a	B-X
detectable	B-X
mRNA	B-X
transcript	B-X
in	B-X
the	B-X
erythropoietic	B-X
tissues	B-X
examined	B-X
.	B-X

C	O
.	O
,	O
Lacey	O
,	O
E	O
.	O
,	O
Laver	O
,	O
H	O
.	O
,	O
O	O
'	O
Connell	O
,	O
C	O
.	O
,	O

Quon	O
,	O
D	O
.	O
,	O
Sim	O
,	O
G	O
.	O

K	O
.	O
,	O
and	O
Efstratiadis	O
,	O
A	O
.	O

(	O
1975	O
)	O
Cell	O
15	O
,	O
687	O
-	O
701	O
.	O

6	O
.	O
<EOS>	B-X
Studies	B-X
of	B-X
oxygen	B-X
binding	B-X
energy	B-X
to	B-X
hemoglobin	B-X
molecule	B-X
.	B-X

Blattner	O
,	O
F	O
.	O
<EOS>	B-X
Biological	B-X
frontiers	B-X
.	B-X
Sequence	B-X
of	B-X
lambda	B-X
ric5b	B-X
.	B-X
Four	B-X
others	B-X
ensure	B-X
plasmid	B-X
maintenance	B-X
.	B-X
Genome	B-X
Size	B-X
and	B-X
Chromosome	B-X
Number	B-X
Evaluation	B-X
of	B-X

R	O
.	O
,	O
Blechl	O
,	O
A	O
.	O
<EOS>	B-X
The	B-X
soilborne	B-X
necrotrophic	B-X
pathogens	B-X
Rhizoctonia	B-X
and	B-X
Pythium	B-X
infect	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
crops	B-X
in	B-X
the	B-X
US	B-X
and	B-X
worldwide	B-X
.	B-X
Although	B-X
a	B-X
combination	B-X
of	B-X
management	B-X
practices	B-X
are	B-X
likely	B-X
to	B-X
be	B-X
required	B-X
for	B-X
control	B-X
of	B-X
Rhizoctonia	B-X
and	B-X
Pythium	B-X
,	B-X
genetic	B-X
resistance	B-X
remains	B-X
a	B-X
key	B-X
missing	B-X
component	B-X
.	B-X
This	B-X
review	B-X
discusses	B-X
the	B-X
recent	B-X
deployment	B-X
of	B-X
introduced	B-X
genes	B-X
and	B-X
genome-based	B-X
information	B-X
for	B-X
control	B-X
of	B-X
Rhizoctonia	B-X
,	B-X
with	B-X
emphasis	B-X
on	B-X
three	B-X
pathosystems	B-X
:	B-X
Rhizoctonia	B-X
solani	B-X
AG8	B-X
and	B-X
wheat	B-X
,	B-X
R.	B-X
solani	B-X
AG1-IA	B-X
and	B-X
rice	B-X
,	B-X
and	B-X
R.	B-X
solani	B-X
AG3	B-X
or	B-X
AG4	B-X
and	B-X
potato	B-X
.	B-X
Prospects	B-X
for	B-X
resistance	B-X
to	B-X
Rhizoctonia	B-X
and	B-X
Pythium	B-X
spp	B-X
.	B-X

E	O
.	O
,	O
Denniston	O
-	O
Thompson	O
,	O
K	O
.	O
,	O
Faber	O
,	O
H	O
.	O

E	O
.	O
,	O
<EOS>	B-X
The	B-X
GRADE	B-X
approach	B-X
was	B-X
used	B-X
to	B-X
evaluate	B-X
the	B-X
certainty	B-X
of	B-X
the	B-X
evidence	B-X
.	B-X
Recent	B-X
epidemiological	B-X
studies	B-X
suggest	B-X
that	B-X
some	B-X
patients	B-X
with	B-X
diabetes	B-X
progress	B-X
to	B-X
kidney	B-X
failure	B-X
without	B-X
significant	B-X
albuminuria	B-X
and	B-X
glomerular	B-X
injury	B-X
,	B-X
suggesting	B-X
a	B-X
critical	B-X
role	B-X
of	B-X
kidney	B-X
tubular	B-X
epithelial	B-X
cell	B-X
(	B-X
TEC	B-X
)	B-X
injury	B-X
in	B-X
diabetic	B-X
kidney	B-X
disease	B-X
(	B-X
DKD	B-X
)	B-X
progression	B-X
.	B-X
However	B-X
,	B-X
the	B-X
major	B-X
risk	B-X
factors	B-X
contributing	B-X
to	B-X
TEC	B-X
injury	B-X
and	B-X
progression	B-X
in	B-X
DKD	B-X
remain	B-X
unclear	B-X
.	B-X
We	B-X
previously	B-X
showed	B-X
that	B-X
expression	B-X
of	B-X
endoplasmic	B-X
reticulum-resident	B-X
protein	B-X
Reticulon-1A	B-X
(	B-X
RTN1A	B-X
)	B-X
increased	B-X
in	B-X
human	B-X
DKD	B-X
,	B-X
and	B-X
the	B-X
increased	B-X
RTN1A	B-X
expression	B-X
promoted	B-X
TEC	B-X
injury	B-X
through	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
stress	B-X
response	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
TEC-specific	B-X
RTN1A	B-X
overexpression	B-X
worsened	B-X
DKD	B-X
in	B-X
mice	B-X
,	B-X
evidenced	B-X
by	B-X
enhanced	B-X
tubular	B-X
injury	B-X
,	B-X
tubulointerstitial	B-X
fibrosis	B-X
,	B-X
and	B-X
kidney	B-X
function	B-X
decline	B-X
.	B-X
Notably	B-X
,	B-X
RTN1A	B-X
overexpression	B-X
worsened	B-X
both	B-X
ER	B-X
stress	B-X
and	B-X
mitochondrial	B-X
dysfunction	B-X
in	B-X
TECs	B-X
under	B-X
diabetic	B-X
conditions	B-X
by	B-X
regulation	B-X
of	B-X
ER-mitochondria	B-X
contacts	B-X
.	B-X
Mechanistically	B-X
,	B-X
ER-bound	B-X
RTN1A	B-X
interacted	B-X
with	B-X
mitochondrial	B-X
hexokinase-1	B-X
and	B-X
the	B-X
voltage-dependent	B-X
anion	B-X
channel-1	B-X
(	B-X
VDAC1	B-X
)	B-X
,	B-X
interfering	B-X
with	B-X
their	B-X
association	B-X
.	B-X
This	B-X
disengagement	B-X
of	B-X
VDAC1	B-X
from	B-X
hexokinase-1	B-X
resulted	B-X
in	B-X
activation	B-X
of	B-X
apoptotic	B-X
and	B-X
inflammasome	B-X
pathways	B-X
,	B-X
leading	B-X
to	B-X
TEC	B-X
injury	B-X
and	B-X
loss	B-X
.	B-X
Thus	B-X
,	B-X
our	B-X
observations	B-X
highlight	B-X
the	B-X
importance	B-X
of	B-X
ER-mitochondrial	B-X
crosstalk	B-X
in	B-X
TEC	B-X
injury	B-X
and	B-X
the	B-X
salient	B-X
role	B-X
of	B-X
RTN1A-mediated	B-X
ER-mitochondrial	B-X
contact	B-X
regulation	B-X
in	B-X
DKD	B-X
progression	B-X
.	B-X

Richards	O
,	O
J	O
.	O
<EOS>	B-X
Our	B-X
scoping	B-X
review	B-X
used	B-X
combinations	B-X
of	B-X
running	B-X
terms	B-X
(	B-X
e.g.	B-X
,	B-X
Run	B-X
*	B-X
and	B-X
Jog	B-X
*	B-X
)	B-X
and	B-X
mental	B-X
health	B-X
terms	B-X
(	B-X
general	B-X
and	B-X
condition	B-X
specific	B-X
)	B-X
.	B-X
Coronamolars	B-X
?	B-X

E	O
.	O
,	O
Slightom	O
,	O
H	O
.	O
<EOS>	B-X
The	B-X
interleukin-1	B-X
receptor	B-X
antagonist	B-X
(	B-X
IL-1ra	B-X
)	B-X
inhibits	B-X
the	B-X
binding	B-X
of	B-X
interleukin-1	B-X
(	B-X
IL-1	B-X
)	B-X
to	B-X
T-cell	B-X
lines	B-X
possessing	B-X
the	B-X
type	B-X
I	B-X
IL-1	B-X
receptor	B-X
;	B-X
evidence	B-X
has	B-X
been	B-X
published	B-X
(	B-X
Carter	B-X
,	B-X
D.	B-X
B.	B-X
,	B-X
Deibel	B-X
,	B-X
M.	B-X
R.	B-X
J.	B-X
,	B-X
Dunn	B-X
,	B-X
C.	B-X
J.	B-X
,	B-X
Tomich	B-X
,	B-X
C.	B-X
S.	B-X
,	B-X
Laborde	B-X
,	B-X
A.	B-X
L.	B-X
,	B-X
Slightom	B-X
,	B-X
J.	B-X
L.	B-X
,	B-X
Berger	B-X
,	B-X
A.	B-X
E.	B-X
,	B-X
Bienkowski	B-X
,	B-X
M.	B-X
J.	B-X
,	B-X
Sun	B-X
,	B-X
F.	B-X
F.	B-X
,	B-X
McEwan	B-X
,	B-X
R.	B-X
N.	B-X
,	B-X
Harris	B-X
,	B-X
P.	B-X
K.	B-X
W.	B-X
,	B-X
Yem	B-X
,	B-X
A.	B-X
W.	B-X
,	B-X
Waszak	B-X
,	B-X
G.	B-X
A.	B-X
,	B-X
Chosay	B-X
,	B-X
J.	B-X
G.	B-X
,	B-X
Sieu	B-X
,	B-X
L.	B-X
C.	B-X
,	B-X
Hardee	B-X
,	B-X
M.	B-X
M.	B-X
,	B-X
Zurcher-Neely	B-X
,	B-X
H.	B-X
A.	B-X
,	B-X
Reardon	B-X
,	B-X
I.	B-X
M.	B-X
,	B-X
Heinrickson	B-X
,	B-X
R.	B-X
L.	B-X
,	B-X
Truesdell	B-X
,	B-X
S.	B-X
E.	B-X
,	B-X
Shelly	B-X
,	B-X
J	B-X
.	B-X
A.	B-X
,	B-X
Eessalu	B-X
,	B-X
T.	B-X
E.	B-X
,	B-X
Taylor	B-X
,	B-X
B.	B-X
M.	B-X
,	B-X
and	B-X
Tracey	B-X
,	B-X
D.	B-X
E.	B-X
(	B-X
1990	B-X
)	B-X
Nature	B-X
344	B-X
,	B-X
633-638	B-X
;	B-X
Hannum	B-X
,	B-X
C.	B-X
H.	B-X
,	B-X
Wilcox	B-X
,	B-X
C.	B-X
J.	B-X
,	B-X
Arend	B-X
,	B-X
W.	B-X
P.	B-X
,	B-X
Joslin	B-X
,	B-X
F.	B-X
G.	B-X
,	B-X
Dripps	B-X
,	B-X
D.	B-X
J.	B-X
,	B-X
Heimdal	B-X
,	B-X
P.	B-X
L.	B-X
,	B-X
Armes	B-X
,	B-X
L.	B-X
G.	B-X
,	B-X
Sommer	B-X
,	B-X
A.	B-X
,	B-X
Eisenberg	B-X
,	B-X
S.	B-X
P.	B-X
,	B-X
and	B-X
Thompson	B-X
,	B-X
R.	B-X
C.	B-X
(	B-X
1990	B-X
)	B-X
Nature	B-X
343	B-X
,	B-X
336-340	B-X
)	B-X
that	B-X
IL-Ira	B-X
does	B-X
not	B-X
bind	B-X
to	B-X
the	B-X
type	B-X
II	B-X
IL-1	B-X
receptor	B-X
(	B-X
IL-1RtII	B-X
)	B-X
.	B-X
However	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
excess	B-X
of	B-X
either	B-X
unlabeled	B-X
IL-1	B-X
or	B-X
IL-1ra	B-X
,	B-X
the	B-X
85-kDa	B-X
IL-1.IL-1RtII	B-X
complex	B-X
was	B-X
not	B-X
present	B-X
.	B-X
A	B-X
phylogenetic	B-X
comparison	B-X
of	B-X
the	B-X
psi	B-X
eta-globin	B-X
DNA	B-X
sequence	B-X
of	B-X
the	B-X
spider	B-X
monkey	B-X
(	B-X
Ateles	B-X
geoffroyi	B-X
)	B-X
to	B-X
orthologous	B-X
sequences	B-X
from	B-X
other	B-X
primates	B-X
provides	B-X
evidence	B-X
for	B-X
an	B-X
evolutionarily	B-X
recent	B-X
(	B-X
less	B-X
than	B-X
17	B-X
million	B-X
years	B-X
ago	B-X
(	B-X
MYA	B-X
]	B-X
insertion	B-X
of	B-X
a	B-X
truncated	B-X
L1	B-X
LINE	B-X
(	B-X
long	B-X
interspersed	B-X
repetitive	B-X
element	B-X
)	B-X
.	B-X
An	B-X
Alu	B-X
SINE	B-X
(	B-X
short	B-X
interspersed	B-X
element	B-X
)	B-X
,	B-X
found	B-X
3	B-X
kb	B-X
downstream	B-X
of	B-X
the	B-X
poly	B-X
(	B-X
A	B-X
)	B-X
addition	B-X
site	B-X
,	B-X
arose	B-X
less	B-X
than	B-X
40	B-X
MYA	B-X
subsequent	B-X
to	B-X
the	B-X
divergence	B-X
of	B-X
platyrrhinies	B-X
(	B-X
New	B-X
World	B-X
monkeys	B-X
)	B-X
from	B-X
catarrhines	B-X
(	B-X
humans	B-X
,	B-X
apes	B-X
,	B-X
and	B-X
Old	B-X
World	B-X
monkeys	B-X
)	B-X
.	B-X
Alignment	B-X
of	B-X
the	B-X
Ateles	B-X
psi	B-X
eta	B-X
sequence	B-X
with	B-X
orthologous	B-X
hominoid	B-X
sequences	B-X
(	B-X
M.	B-X
M.	B-X
Miyamoto	B-X
,	B-X
J.	B-X
L.	B-X
Slightom	B-X
,	B-X
and	B-X
M.	B-X
Goodman	B-X
,	B-X
1987	B-X
,	B-X
Science	B-X
238	B-X
:	B-X
369-373	B-X
)	B-X
provides	B-X
unequivocal	B-X
evidence	B-X
against	B-X
the	B-X
view	B-X
(	B-X
J.	B-X
H.	B-X
Schwartz	B-X
,	B-X
1987	B-X
,	B-X
``	B-X
The	B-X
Red	B-X
Ape	B-X
:	B-X
Orang-utans	B-X
and	B-X
Human	B-X
Origins	B-X
,	B-X
''	B-X
Houghton	B-X
Mifflin	B-X
,	B-X
Boston	B-X
,	B-X
MA	B-X
)	B-X
that	B-X
the	B-X
orangutan	B-X
forms	B-X
a	B-X
monophyletic	B-X
group	B-X
with	B-X
human	B-X
.	B-X
Furthermore	B-X
,	B-X
a	B-X
critical	B-X
analysis	B-X
of	B-X
potential	B-X
sources	B-X
of	B-X
homoplasy	B-X
(	B-X
i.e.	B-X
,	B-X
parallel	B-X
evolution	B-X
)	B-X
reaffirms	B-X
a	B-X
Homo-Pan	B-X
monophyletic	B-X
clade	B-X
(	B-X
Miyamoto	B-X
et	B-X
al.	B-X
,	B-X
1987	B-X
)	B-X
.	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
250	B-X
WORDS	B-X
)	B-X

L	O
.	O
,	O
Tucker	O
,	O
P	O
.	O

W	O
.	O
,	O
and	O
Smithies	O
,	O
0	O
.	O

(	O
1978	O
)	O
Science	O
202	O
,	O
1279	O
-	O
1284	O
.	O

7	O
.	O
<EOS>	B-X
Maturation	B-X
of	B-X
the	B-X
adrenal	B-X
medulla	B-X
--	B-X
IV	B-X
.	B-X
Effects	B-X
of	B-X
morphine	B-X
.	B-X

Meyer	O
,	O
J	O
.	O
,	O
Neuwald	O
,	O
P	O
.	O
<EOS>	B-X
We	B-X
present	B-X
a	B-X
refined	B-X
map	B-X
of	B-X
adenovirus	B-X
gene	B-X
functions	B-X
which	B-X
is	B-X
based	B-X
on	B-X
results	B-X
documented	B-X
in	B-X
this	B-X
and	B-X
the	B-X
accompanying	B-X
study	B-X
by	B-X
Meyer	B-X
et	B-X
al	B-X
.	B-X

D	O
.	O
,	O
Lai	O
,	O
S	O
.	O
,	O
Maizel	O
,	O
J	O
.	O

V	O
.	O
,	O
Jr	O
.	O
,	O
and	O
Westphal	O
,	O

H	O
.	O
<EOS>	B-X
In	B-X
plants	B-X
,	B-X
cytosolic	B-X
and	B-X
extracellular	B-X
pH	B-X
homeostasis	B-X
are	B-X
crucial	B-X
for	B-X
various	B-X
physiological	B-X
processes	B-X
,	B-X
including	B-X
the	B-X
uptake	B-X
of	B-X
macronutrients	B-X
and	B-X
micronutrients	B-X
,	B-X
cell	B-X
elongation	B-X
,	B-X
cell	B-X
expansion	B-X
,	B-X
and	B-X
enzyme	B-X
activity	B-X
.	B-X
Proton	B-X
(	B-X
H	B-X
The	B-X
membrane	B-X
surrounding	B-X
the	B-X
central	B-X
vacuole	B-X
of	B-X
plant	B-X
cells	B-X
contains	B-X
an	B-X
H	B-X
(	B-X
+	B-X
)	B-X
-translocating	B-X
ATPase	B-X
(	B-X
H	B-X
(	B-X
+	B-X
)	B-X
-ATPase	B-X
)	B-X
and	B-X
an	B-X
H	B-X
(	B-X
+	B-X
)	B-X
-translocating	B-X
inorganic	B-X
pyrophosphatase	B-X
(	B-X
H	B-X
(	B-X
+	B-X
)	B-X
-PPase	B-X
)	B-X
.	B-X
Both	B-X
enzymes	B-X
are	B-X
abundant	B-X
and	B-X
ubiquitous	B-X
in	B-X
plants	B-X
but	B-X
the	B-X
H	B-X
(	B-X
+	B-X
)	B-X
-PPase	B-X
is	B-X
unusual	B-X
in	B-X
its	B-X
exclusive	B-X
use	B-X
of	B-X
inorganic	B-X
pyrophosphate	B-X
(	B-X
PPi	B-X
)	B-X
as	B-X
an	B-X
energy	B-X
source	B-X
.	B-X
The	B-X
lack	B-X
of	B-X
sequence	B-X
identity	B-X
between	B-X
the	B-X
vacuolar	B-X
H	B-X
(	B-X
+	B-X
)	B-X
-PPase	B-X
and	B-X
any	B-X
other	B-X
characterized	B-X
ion	B-X
pump	B-X
implies	B-X
a	B-X
different	B-X
evolutionary	B-X
origin	B-X
for	B-X
this	B-X
translocase	B-X
.	B-X
The	B-X
existence	B-X
of	B-X
the	B-X
vacuolar	B-X
H	B-X
(	B-X
+	B-X
)	B-X
-PPase	B-X
,	B-X
in	B-X
conjunction	B-X
with	B-X
increasing	B-X
recognition	B-X
of	B-X
PPi	B-X
as	B-X
a	B-X
key	B-X
metabolite	B-X
in	B-X
plant	B-X
systems	B-X
,	B-X
necessitates	B-X
reconsideration	B-X
of	B-X
ATP	B-X
as	B-X
the	B-X
primary	B-X
energy	B-X
source	B-X
for	B-X
membrane	B-X
transport	B-X
in	B-X
plant	B-X
cells	B-X
.	B-X

(	O
1977	O
)	O
J	O
.	O
<EOS>	B-X
Hemoptysis	B-X
1977	B-X
.	B-X
J	B-X
Trueta	B-X
.	B-X
Photocoagulation	B-X
1977	B-X
.	B-X
Editorial	B-X
announcement	B-X
.	B-X

Virol	O
.	O
<EOS>	B-X
Virol	B-X
.	B-X
Retraction	B-X
.	B-X
Corrigendum	B-X
.	B-X
Corrigendum	B-X
.	B-X

21	O
,	O
1010	O
-	O
1014	O
.	O
<EOS>	B-X
Formation	B-X
of	B-X
non-amidine	B-X
products	B-X
in	B-X
the	B-X
chemical	B-X
modification	B-X
of	B-X
horse	B-X
liver	B-X
alcohol	B-X
dehydrogenase	B-X
with	B-X
imido	B-X
esters	B-X
.	B-X
Evidence	B-X
for	B-X
histidine	B-X
as	B-X
another	B-X
functional	B-X
group	B-X
of	B-X
delta-aminolevulinic	B-X
acid	B-X
dehydratase	B-X
from	B-X
beef	B-X
liver	B-X
.	B-X

2251	O

Nucleic	O
Acids	O
Research	O
<EOS>	B-X
The	B-X
2021	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
database	B-X
Issue	B-X
contains	B-X
189	B-X
papers	B-X
spanning	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
biological	B-X
fields	B-X
and	B-X
investigation	B-X
.	B-X
The	B-X
entire	B-X
Database	B-X
Issue	B-X
is	B-X
freely	B-X
available	B-X
online	B-X
on	B-X
the	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
website	B-X
(	B-X
https	B-X
:	B-X
//academic.oup.com/nar	B-X
)	B-X
.	B-X
Editorial	B-X
:	B-X
the	B-X
19th	B-X
annual	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
web	B-X
server	B-X
issue	B-X
2021	B-X
.	B-X
Editorial	B-X
:	B-X
Critical	B-X
reviews	B-X
and	B-X
perspectives	B-X
in	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
.	B-X

8	O
.	O
<EOS>	B-X
Comparison	B-X
between	B-X
procaine	B-X
and	B-X
isocarboxazid	B-X
metabolism	B-X
in	B-X
vitro	B-X
by	B-X
a	B-X
liver	B-X
microsomal	B-X
amidase-esterase	B-X
.	B-X

Westphal	O
,	O
H	O
.	O
,	O
and	O
Lai	O
,	O
S	O
.	O
<EOS>	B-X
Displacement	B-X
loops	B-X
in	B-X
adenovirus	B-X
DNA-RNA	B-X
hybrids	B-X
.	B-X
Quantitative	B-X
electron	B-X
microscopy	B-X
of	B-X
early	B-X
adenovirus	B-X
RNA	B-X
.	B-X
Analysis	B-X
of	B-X
adenovirus	B-X
type	B-X
2	B-X
gene	B-X
functions	B-X
by	B-X
cell-free	B-X
translation	B-X
of	B-X
viral	B-X
messenger	B-X
RNA	B-X
.	B-X
Mosaic	B-X
adenovirus-SV40	B-X
RNA	B-X
specified	B-X
by	B-X
the	B-X
non-defective	B-X
hybrid	B-X
virus	B-X
Ad2+ND4	B-X
.	B-X

P	O
.	O
<EOS>	B-X
Diabetic	B-X
retinopathic	B-X
patients	B-X
were	B-X
likely	B-X
to	B-X
be	B-X
elder	B-X
(	B-X
P	B-X
=	B-X
.0003	B-X
)	B-X
,	B-X
men	B-X
(	B-X
P	B-X
=	B-X
.018	B-X
)	B-X
,	B-X
hypertensive	B-X
(	B-X
P	B-X
<	B-X
.0001	B-X
)	B-X
,	B-X
and	B-X
had	B-X
high	B-X
body	B-X
mass	B-X
index	B-X
(	B-X
P	B-X
<	B-X
.0001	B-X
)	B-X
,	B-X
metabolic	B-X
abnormalities	B-X
,	B-X
and	B-X
longer	B-X
duration	B-X
of	B-X
diabetes	B-X
(	B-X
P	B-X
<	B-X
.0001	B-X
)	B-X
.	B-X
Higher	B-X
intraocular	B-X
pressure	B-X
(	B-X
P	B-X
=	B-X
.0008	B-X
)	B-X
,	B-X
fasting	B-X
blood	B-X
glucose	B-X
(	B-X
P	B-X
<	B-X
.0001	B-X
)	B-X
,	B-X
serum	B-X
total	B-X
cholesterol	B-X
(	B-X
P	B-X
<	B-X
.0001	B-X
)	B-X
,	B-X
serum	B-X
triglyceride	B-X
(	B-X
P	B-X
=	B-X
.0006	B-X
)	B-X
,	B-X
%	B-X
glycated	B-X
hemoglobin	B-X
(	B-X
HbA1c	B-X
)	B-X
(	B-X
P	B-X
<	B-X
.0001	B-X
)	B-X
,	B-X
and	B-X
disc	B-X
asymmetry	B-X
including	B-X
cup-disc	B-X
ratio	B-X
(	B-X
P	B-X
=	B-X
.041	B-X
)	B-X
reported	B-X
in	B-X
patients	B-X
with	B-X
diabetic	B-X
retinopathy	B-X
.	B-X
Age	B-X
(	B-X
P	B-X
=	B-X
.049	B-X
)	B-X
,	B-X
male	B-X
sex	B-X
(	B-X
P	B-X
=	B-X
.048	B-X
)	B-X
,	B-X
hypertension	B-X
(	B-X
P	B-X
=	B-X
.048	B-X
)	B-X
,	B-X
duration	B-X
of	B-X
diabetes	B-X
(	B-X
P	B-X
=	B-X
.012	B-X
)	B-X
,	B-X
diabetic	B-X
neuropathy	B-X
(	B-X
P	B-X
=	B-X
.048	B-X
)	B-X
,	B-X
diabetic	B-X
nephropathy	B-X
(	B-X
P	B-X
=	B-X
.048	B-X
)	B-X
,	B-X
diabetic	B-X
foot	B-X
ulcer	B-X
(	B-X
P	B-X
=	B-X
.041	B-X
)	B-X
,	B-X
foot	B-X
amputation	B-X
(	B-X
P	B-X
=	B-X
.042	B-X
)	B-X
,	B-X
fasting	B-X
blood	B-X
glucose	B-X
(	B-X
P	B-X
=	B-X
.022	B-X
)	B-X
,	B-X
serum	B-X
total	B-X
cholesterol	B-X
(	B-X
P	B-X
=	B-X
.028	B-X
)	B-X
,	B-X
serum	B-X
triglyceride	B-X
(	B-X
P	B-X
=	B-X
.035	B-X
)	B-X
,	B-X
and	B-X
HbA1c	B-X
(	B-X
P	B-X
=	B-X
.042	B-X
)	B-X
were	B-X
associated	B-X
with	B-X
diabetic	B-X
retinopathy.Diabetic	B-X
retinopathy	B-X
was	B-X
the	B-X
most	B-X
common	B-X
ocular	B-X
fundus	B-X
disease	B-X
in	B-X
diabetic	B-X
patients	B-X
.	B-X
Applied	B-X
phosphorus	B-X
(	B-X
P	B-X
)	B-X
use	B-X
efficiency	B-X
is	B-X
generally	B-X
low	B-X
due	B-X
to	B-X
the	B-X
low	B-X
mobility	B-X
of	B-X
P	B-X
in	B-X
soil	B-X
and	B-X
its	B-X
affinity	B-X
to	B-X
form	B-X
insoluble	B-X
complexes	B-X
.	B-X
Localized	B-X
P	B-X
application	B-X
nearby	B-X
the	B-X
root	B-X
zone	B-X
is	B-X
a	B-X
potential	B-X
approach	B-X
to	B-X
overcome	B-X
this	B-X
issue	B-X
in	B-X
crop	B-X
production	B-X
.	B-X
Using	B-X
root-box	B-X
experiments	B-X
and	B-X
changing	B-X
P-retention	B-X
capacity	B-X
of	B-X
soils	B-X
,	B-X
we	B-X
revealed	B-X
that	B-X
applied	B-X
P	B-X
use	B-X
efficiency	B-X
of	B-X
rice	B-X
can	B-X
be	B-X
substantially	B-X
improved	B-X
by	B-X
dipping	B-X
seedlings	B-X
in	B-X
P-enriched	B-X
slurry	B-X
at	B-X
transplanting	B-X
(	B-X
P-dipping	B-X
)	B-X
even	B-X
in	B-X
highly	B-X
P-fixing	B-X
soils	B-X
.	B-X
Spatial	B-X
analysis	B-X
of	B-X
soluble	B-X
P	B-X
in	B-X
soils	B-X
indicated	B-X
that	B-X
P-dipping	B-X
creates	B-X
a	B-X
P	B-X
hotspot	B-X
because	B-X
the	B-X
P-enriched	B-X
slurry	B-X
is	B-X
transferred	B-X
with	B-X
seedling	B-X
roots	B-X
.	B-X
The	B-X
P	B-X
hotspot	B-X
could	B-X
have	B-X
induced	B-X
vigorous	B-X
surface	B-X
root	B-X
and	B-X
facilitated	B-X
further	B-X
P	B-X
uptake	B-X
from	B-X
the	B-X
spot	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
effect	B-X
of	B-X
conventional	B-X
P	B-X
incorporation	B-X
depended	B-X
on	B-X
P-retention	B-X
capacity	B-X
of	B-X
soils	B-X
;	B-X
no	B-X
increases	B-X
in	B-X
soluble	B-X
P	B-X
content	B-X
in	B-X
soils	B-X
or	B-X
plant	B-X
P	B-X
uptakes	B-X
were	B-X
observed	B-X
when	B-X
P-retention	B-X
capacity	B-X
was	B-X
high	B-X
.	B-X
Our	B-X
finding	B-X
of	B-X
significant	B-X
interaction	B-X
between	B-X
localized	B-X
P	B-X
application	B-X
and	B-X
a	B-X
specific	B-X
soil	B-X
property	B-X
should	B-X
help	B-X
improving	B-X
applied	B-X
P	B-X
use	B-X
efficiency	B-X
and	B-X
achieving	B-X
sustainable	B-X
rice	B-X
production	B-X
against	B-X
depleting	B-X
P	B-X
fertilizer	B-X
resources	B-X
.	B-X

(	O
1977	O
)	O
J	O
.	O
<EOS>	B-X
Hemoptysis	B-X
1977	B-X
.	B-X
J	B-X
Trueta	B-X
.	B-X
Photocoagulation	B-X
1977	B-X
.	B-X
Editorial	B-X
announcement	B-X
.	B-X

Mol	O
.	O
<EOS>	B-X
Mol-ecules	B-X
A	B-X
and	B-X
B	B-X
are	B-X
approximate	B-X
mirror	B-X
images	B-X
of	B-X
each	B-X
other	B-X
,	B-X
and	B-X
mol-ecule	B-X
C	B-X
has	B-X
an	B-X
inter-mediate	B-X
conformation	B-X
.	B-X
Mol-ecules	B-X
of	B-X
A	B-X
and	B-X
B	B-X
assemble	B-X
into	B-X
layers	B-X
four	B-X
mol-ecules	B-X
thick	B-X
in	B-X
the	B-X
ac	B-X
plane	B-X
via	B-X
C-Hâ¯S	B-X
and	B-X
C-Hâ¯Ï	B-X
inter-actions	B-X
.	B-X
Mol-ecules	B-X
of	B-X
C	B-X
self-assemble	B-X
into	B-X
layers	B-X
in	B-X
the	B-X
ac	B-X
plane	B-X
via	B-X
C-Hâ¯S	B-X
inter-actions	B-X
.	B-X
They	B-X
are	B-X
separated	B-X
with	B-X
a	B-X
centroid-centroid	B-X
distance	B-X
of	B-X
3.9096	B-X
(	B-X
10	B-X
)	B-X
Ã	B-X
in	B-X
mol-ecule	B-X
A	B-X
and	B-X
3.9118	B-X
(	B-X
10	B-X
)	B-X
Ã	B-X
in	B-X
mol-ecule	B-X
B.	B-X
Mol-ecules	B-X
A	B-X
and	B-X
B	B-X
lie	B-X
adjacent	B-X
to	B-X
one	B-X
another	B-X
,	B-X
with	B-X
a	B-X
centroid-centroid	B-X
distance	B-X
of	B-X
3.7592	B-X
(	B-X
10	B-X
)	B-X
Ã	B-X
between	B-X
the	B-X
fluoro-phenyl	B-X
ring	B-X
of	B-X
mol-ecule	B-X
A	B-X
and	B-X
the	B-X
chloro-phenyl-sulfonyl	B-X
ring	B-X
of	B-X
mol-ecule	B-X
B	B-X
and	B-X
with	B-X
a	B-X
dihedral	B-X
angle	B-X
of	B-X
5.75	B-X
(	B-X
8	B-X
)	B-X
Â°	B-X
between	B-X
the	B-X
ring	B-X
planes	B-X
.	B-X

Biol	O
.	O
<EOS>	B-X
Retraction	B-X
of	B-X
DNA	B-X
Cell	B-X
Biol	B-X
:	B-X
31:1064-1069	B-X
,	B-X
2012	B-X
,	B-X
DOI	B-X
:	B-X
10.1089/dna.2011.1552	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
provide	B-X
a	B-X
brief	B-X
synopsis	B-X
of	B-X
all	B-X
manuscripts	B-X
published	B-X
in	B-X
Histochem	B-X
Cell	B-X
Biol	B-X
in	B-X
the	B-X
year	B-X
2013	B-X
.	B-X
Retraction	B-X
notice	B-X
to	B-X
``	B-X
Nicorandil	B-X
versus	B-X
nifedipine	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
preterm	B-X
labour	B-X
:	B-X
A	B-X
randomized	B-X
clinical	B-X
trial	B-X
''	B-X
[	B-X
Eur	B-X
.	B-X
J.	B-X
Obstetr	B-X
.	B-X
Gynecol	B-X
.	B-X
Reprod	B-X
.	B-X
Biol	B-X
.	B-X
195	B-X
(	B-X
2015	B-X
)	B-X
27-30	B-X
]	B-X
.	B-X
Retraction	B-X
notice	B-X
to	B-X
``	B-X
Reducing	B-X
blood	B-X
loss	B-X
at	B-X
abdominal	B-X
myomectomy	B-X
with	B-X
preoperative	B-X
use	B-X
of	B-X
dinoprostone	B-X
intravaginal	B-X
suppository	B-X
:	B-X
A	B-X
randomized	B-X
placebo-controlled	B-X
pilot	B-X
study	B-X
''	B-X
[	B-X
Eur	B-X
.	B-X
J.	B-X
Obst	B-X
.	B-X
Gynecol	B-X
.	B-X
Reprod	B-X
.	B-X
Biol	B-X
.	B-X
166/1	B-X
(	B-X
2012	B-X
)	B-X
61-64	B-X
]	B-X
.	B-X

116	O
,	O
525	O
-	O
548	O
.	O
<EOS>	B-X
Extracellular	B-X
volume	B-X
Expansion	B-X
after	B-X
ethanol	B-X
in	B-X
dogs	B-X
.	B-X
Proceedings	B-X
:	B-X
The	B-X
mechanism	B-X
of	B-X
``	B-X
adrenaline	B-X
reversal	B-X
''	B-X
in	B-X
the	B-X
anaesthetized	B-X
cat	B-X
and	B-X
rabbit	B-X
.	B-X

9	O
.	O
<EOS>	B-X
Radiochemical	B-X
assay	B-X
of	B-X
glutathione	B-X
S-epoxide	B-X
transferase	B-X
and	B-X
its	B-X
enhancement	B-X
by	B-X
phenobarbital	B-X
in	B-X
rat	B-X
liver	B-X
in	B-X
vivo	B-X
.	B-X

Schafer	O
,	O
M	O
.	O
<EOS>	B-X
Commentary	B-X
:	B-X
In	B-X
vortices	B-X
veritas-quantitative	B-X
approach	B-X
.	B-X

P	O
.	O
,	O
Rohrmann	O
,	O
G	O
.	O
,	O
Heine	O
,	O
U	O
.	O
,	O
and	O
Beaudreau	O
,	O
G	O
.	O

S	O
.	O
<EOS>	B-X
Finkelstein	B-X
's	B-X
Test	B-X
Is	B-X
Superior	B-X
to	B-X
Eichhoff	B-X
's	B-X
Test	B-X
in	B-X
the	B-X
Investigation	B-X
of	B-X
de	B-X
Quervain	B-X
's	B-X
Disease	B-X
.	B-X
Protein	B-X
S	B-X
deficiency	B-X
.	B-X
Letter	B-X
:	B-X
Craniometrics	B-X
and	B-X
Ventricular	B-X
Access	B-X
:	B-X
A	B-X
Review	B-X
of	B-X
Kocher	B-X
's	B-X
,	B-X
Kaufman	B-X
's	B-X
,	B-X
Paine	B-X
's	B-X
,	B-X
Menovksy	B-X
's	B-X
,	B-X
Tubbs	B-X
'	B-X
,	B-X
Keen	B-X
's	B-X
,	B-X
Frazier	B-X
's	B-X
,	B-X
Dandy	B-X
's	B-X
,	B-X
and	B-X
Sanchez	B-X
's	B-X
Points	B-X
.	B-X

(	O
1979	O
)	O
Virol	O
.	O
<EOS>	B-X
Variation	B-X
in	B-X
orbiviruses	B-X
.	B-X
The	B-X
replication	B-X
of	B-X
picornaviruses	B-X
.	B-X
Phylogenetic	B-X
and	B-X
evolutionary	B-X
analyses	B-X
of	B-X
all	B-X
11	B-X
genes	B-X
of	B-X
31	B-X
influenza	B-X
B	B-X
viruses	B-X
isolated	B-X
from	B-X
1979	B-X
to	B-X
2003	B-X
were	B-X
used	B-X
to	B-X
study	B-X
the	B-X
evolution	B-X
of	B-X
whole	B-X
genomes	B-X
.	B-X
Frequent	B-X
reassortment	B-X
generated	B-X
14	B-X
different	B-X
genotypes	B-X
distinct	B-X
from	B-X
the	B-X
gene	B-X
constellation	B-X
of	B-X
viruses	B-X
circulating	B-X
prior	B-X
to	B-X
1979	B-X
.	B-X

95	O
,	O
176	O
-	O
184	O
.	O
<EOS>	B-X
Insect	B-X
morphogenetic	B-X
hormones	B-X
and	B-X
developmental	B-X
mechanisms	B-X
in	B-X
the	B-X
nematode	B-X
,	B-X
Nematospiroides	B-X
dubius	B-X
.	B-X
The	B-X
auditory	B-X
system	B-X
of	B-X
the	B-X
goldfish	B-X
(	B-X
Carassius	B-X
auratus	B-X
)	B-X
:	B-X
effects	B-X
of	B-X
intense	B-X
acoustic	B-X
stimulation	B-X
.	B-X

10	O
.	O
<EOS>	B-X
Digitoxin	B-X
metabolism	B-X
by	B-X
rat	B-X
liver	B-X
microsomes	B-X
.	B-X

Davis	O
,	O
R	O
.	O
<EOS>	B-X
DNA	B-X
polymerase	B-X
theta	B-X
(	B-X
POLÎ¸	B-X
)	B-X
is	B-X
synthetic	B-X
lethal	B-X
with	B-X
Homologous	B-X
Recombination	B-X
(	B-X
HR	B-X
)	B-X
deficiency	B-X
and	B-X
thus	B-X
a	B-X
candidate	B-X
target	B-X
for	B-X
HR-deficient	B-X
cancers	B-X
.	B-X
Through	B-X
high-throughput	B-X
small	B-X
molecule	B-X
screens	B-X
we	B-X
identified	B-X
the	B-X
antibiotic	B-X
Novobiocin	B-X
(	B-X
NVB	B-X
)	B-X
as	B-X
a	B-X
specific	B-X
POLÎ¸	B-X
inhibitor	B-X
that	B-X
selectively	B-X
kills	B-X
HR-deficient	B-X
tumor	B-X
cells	B-X
ACSS2	B-X
interacts	B-X
with	B-X
oncoprotein	B-X
interferon	B-X
regulatory	B-X
factor	B-X
4	B-X
(	B-X
IRF4	B-X
)	B-X
,	B-X
and	B-X
enhances	B-X
IRF4	B-X
stability	B-X
and	B-X
IRF4-mediated	B-X
gene	B-X
transcription	B-X
through	B-X
activation	B-X
of	B-X
acetylation	B-X
.	B-X
We	B-X
performed	B-X
gene/protein	B-X
expression	B-X
,	B-X
metabolomic	B-X
and	B-X
methylation	B-X
analyses	B-X
of	B-X
isogenic	B-X
AML	B-X
cell	B-X
lines	B-X
sensitive	B-X
or	B-X
resistant	B-X
to	B-X
VEN	B-X
,	B-X
and	B-X
identified	B-X
the	B-X
activation	B-X
of	B-X
RAS/MAPK	B-X
pathway	B-X
,	B-X
leading	B-X
to	B-X
increased	B-X
stability	B-X
and	B-X
higher	B-X
levels	B-X
of	B-X
MCL-1	B-X
protein	B-X
,	B-X
as	B-X
a	B-X
major	B-X
acquired	B-X
mechanism	B-X
of	B-X
VEN	B-X
resistance	B-X
.	B-X
MCL-1	B-X
sustained	B-X
survival	B-X
and	B-X
maintained	B-X
mitochondrial	B-X
respiration	B-X
in	B-X
VEN-RE	B-X
cells	B-X
,	B-X
which	B-X
had	B-X
impaired	B-X
electron	B-X
transport	B-X
chain	B-X
(	B-X
ETC	B-X
)	B-X
complex	B-X
II	B-X
activity	B-X
,	B-X
and	B-X
MCL-1	B-X
silencing	B-X
or	B-X
pharmacologic	B-X
inhibition	B-X
restored	B-X
VEN	B-X
sensitivity	B-X
.	B-X
In	B-X
support	B-X
of	B-X
the	B-X
importance	B-X
of	B-X
RAS/MAPK	B-X
activation	B-X
,	B-X
we	B-X
found	B-X
by	B-X
single-cell	B-X
DNA	B-X
sequencing	B-X
rapid	B-X
clonal	B-X
selection	B-X
of	B-X
RAS-mutated	B-X
clones	B-X
in	B-X
AML	B-X
patients	B-X
treated	B-X
with	B-X
VEN-containing	B-X
regimens	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
these	B-X
findings	B-X
establish	B-X
RAS/MAPK/MCL-1	B-X
and	B-X
mitochondrial	B-X
fitness	B-X
as	B-X
key	B-X
survival	B-X
mechanisms	B-X
of	B-X
VEN-RE	B-X
AML	B-X
and	B-X
provide	B-X
the	B-X
rationale	B-X
for	B-X
combinatorial	B-X
strategies	B-X
effectively	B-X
targeting	B-X
these	B-X
pathways	B-X
.	B-X

W	O
.	O
,	O
Simon	O
,	O
M	O
.	O
<EOS>	B-X
We	B-X
identified	B-X
known	B-X
SARS-CoV-2	B-X
host	B-X
factors	B-X
,	B-X
including	B-X
the	B-X
receptor	B-X
ACE2	B-X
and	B-X
protease	B-X
Cathepsin	B-X
L.	B-X
We	B-X
additionally	B-X
discovered	B-X
pro-viral	B-X
genes	B-X
and	B-X
pathways	B-X
,	B-X
including	B-X
HMGB1	B-X
and	B-X
the	B-X
SWI/SNF	B-X
chromatin	B-X
remodeling	B-X
complex	B-X
,	B-X
that	B-X
are	B-X
SARS	B-X
lineage	B-X
and	B-X
pan-coronavirus	B-X
specific	B-X
,	B-X
respectively	B-X
.	B-X
We	B-X
show	B-X
that	B-X
HMGB1	B-X
regulates	B-X
ACE2	B-X
expression	B-X
and	B-X
is	B-X
critical	B-X
for	B-X
entry	B-X
of	B-X
SARS-CoV-2	B-X
,	B-X
SARS-CoV-1	B-X
,	B-X
and	B-X
NL63	B-X
.	B-X
We	B-X
also	B-X
show	B-X
that	B-X
small-molecule	B-X
antagonists	B-X
of	B-X
identified	B-X
gene	B-X
products	B-X
inhibited	B-X
SARS-CoV-2	B-X
infection	B-X
in	B-X
monkey	B-X
and	B-X
human	B-X
cells	B-X
,	B-X
demonstrating	B-X
the	B-X
conserved	B-X
role	B-X
of	B-X
these	B-X
genetic	B-X
hits	B-X
across	B-X
species	B-X
.	B-X
We	B-X
evaluated	B-X
secukinumab	B-X
,	B-X
a	B-X
fully	B-X
human	B-X
anti-interleukin-17A	B-X
monoclonal	B-X
antibody	B-X
,	B-X
in	B-X
patients	B-X
with	B-X
moderate-to-severe	B-X
plaque	B-X
psoriasis	B-X
.	B-X

M	O
.	O
,	O
and	O
Davison	O
,	O
N	O
.	O

(	O
1971	O
)	O
in	O
Methods	O
in	O
<EOS>	B-X
[	B-X
Bibliography	B-X
]	B-X
.	B-X
``	B-X
Having	B-X
verified	B-X
,	B-X
in	B-X
the	B-X
1971	B-X
[	B-X
Italian	B-X
]	B-X
census	B-X
,	B-X
the	B-X
presence	B-X
of	B-X
certain	B-X
anomalous	B-X
data	B-X
for	B-X
cohorts	B-X
born	B-X
in	B-X
1900	B-X
,	B-X
1911	B-X
,	B-X
1920	B-X
,	B-X
1924	B-X
,	B-X
1930	B-X
,	B-X
1936	B-X
,	B-X
1940	B-X
,	B-X
1948	B-X
,	B-X
1950	B-X
and	B-X
1960	B-X
,	B-X
we	B-X
assessed	B-X
the	B-X
size	B-X
of	B-X
the	B-X
error	B-X
and	B-X
estimated	B-X
the	B-X
new	B-X
population	B-X
total	B-X
which	B-X
emerged	B-X
both	B-X
by	B-X
age	B-X
and	B-X
year	B-X
of	B-X
birth	B-X
.	B-X
Antimicrobial	B-X
susceptibility	B-X
testing	B-X
by	B-X
the	B-X
Kirby-Bauer	B-X
disc	B-X
diffusion	B-X
method	B-X
.	B-X
Multiple	B-X
choice	B-X
.	B-X

Enzymology	O
(	O
Grossman	O
,	O
L	O
.	O
and	O
Moldave	O
,	O
K	O
.	O
,	O
eds	O
)	O
Vol	O
.	O

21	O
,	O
pp	O
.	O
<EOS>	B-X
PubMed	B-X
,	B-X
EMBASE	B-X
,	B-X
ProQuest	B-X
,	B-X
SCOPUS	B-X
,	B-X
Web	B-X
of	B-X
Sciences	B-X
,	B-X
Cochrane	B-X
library	B-X
,	B-X
and	B-X
Google	B-X
Scholar	B-X
were	B-X
searched	B-X
up	B-X
to	B-X
1st	B-X
January	B-X
2021	B-X
.	B-X
In	B-X
this	B-X
JLB	B-X
issue	B-X
,	B-X
IL-21	B-X
is	B-X
reported	B-X
to	B-X
dampen	B-X
TGF-beta1-induced	B-X
IgG2b	B-X
but	B-X
not	B-X
IgA	B-X
production	B-X
by	B-X
mouse	B-X
B	B-X
cells	B-X
,	B-X
possibly	B-X
explaining	B-X
why	B-X
IgA	B-X
(	B-X
+	B-X
)	B-X
B	B-X
cells	B-X
predominate	B-X
in	B-X
PP	B-X
.	B-X
It	B-X
is	B-X
critical	B-X
to	B-X
understand	B-X
the	B-X
current	B-X
level	B-X
of	B-X
evolution	B-X
of	B-X
pharmaceutical	B-X
activities	B-X
to	B-X
support	B-X
evidence-based	B-X
decision-making	B-X
.	B-X
The	B-X
crystal	B-X
structure	B-X
of	B-X
the	B-X
title	B-X
compound	B-X
,	B-X
[	B-X
Pt	B-X
(	B-X
C	B-X
(	B-X
8	B-X
)	B-X
H	B-X
(	B-X
18	B-X
)	B-X
P	B-X
(	B-X
2	B-X
)	B-X
)	B-X
(	B-X
C	B-X
(	B-X
9	B-X
)	B-X
H	B-X
(	B-X
21	B-X
)	B-X
P	B-X
)	B-X
(	B-X
C	B-X
(	B-X
18	B-X
)	B-X
H	B-X
(	B-X
15	B-X
)	B-X
P	B-X
)	B-X
]	B-X
or	B-X
[	B-X
(	B-X
Ph	B-X
(	B-X
3	B-X
)	B-X
P	B-X
)	B-X
(	B-X
(	B-X
t	B-X
)	B-X
Bu	B-X
(	B-X
2	B-X
)	B-X
PMe	B-X
)	B-X
Pt	B-X
(	B-X
eta	B-X
(	B-X
2	B-X
)	B-X
-	B-X
(	B-X
t	B-X
)	B-X
Bu	B-X
(	B-X
2	B-X
)	B-X
PP	B-X
)	B-X
]	B-X
,	B-X
contains	B-X
four	B-X
molecules	B-X
in	B-X
the	B-X
asymmetric	B-X
unit	B-X
with	B-X
slightly	B-X
different	B-X
conformations	B-X
.	B-X
All	B-X
planes	B-X
of	B-X
the	B-X
PtP	B-X
(	B-X
4	B-X
)	B-X
groups	B-X
are	B-X
approximately	B-X
parallel	B-X
to	B-X
the	B-X
ab	B-X
plane	B-X
of	B-X
the	B-X
unit	B-X
cell	B-X
.	B-X

413428	O
,	O
Academic	O
Press	O
,	O
New	O
York	O
.	O

11	O
.	O
<EOS>	B-X
Identification	B-X
of	B-X
adenylate	B-X
cyclase-coupled	B-X
beta-adrenergic	B-X
receptors	B-X
with	B-X
radiolabeled	B-X
beta-adrenergic	B-X
antagonists	B-X
.	B-X

Federal	O
Register	O
(	O
1978	O
)	O
43	O
,	O
60108	O
-	O
60131	O
.	O

12	O
.	O
<EOS>	B-X
The	B-X
effect	B-X
of	B-X
adrenaline	B-X
and	B-X
of	B-X
alpha-	B-X
and	B-X
beta-adrenergic	B-X
blocking	B-X
agents	B-X
on	B-X
ATP	B-X
concentration	B-X
and	B-X
on	B-X
incorporation	B-X
of	B-X
32Pi	B-X
into	B-X
ATP	B-X
in	B-X
rat	B-X
fat	B-X
cells	B-X
.	B-X

Goodman	O
,	O
H	O
.	O
<EOS>	B-X
The	B-X
legacy	B-X
of	B-X
Deamonte	B-X
Driver	B-X
.	B-X
Herbal	B-X
therapy	B-X
has	B-X
also	B-X
showed	B-X
some	B-X
promise	B-X
particularly	B-X
ZemaphyteÂ®	B-X
,	B-X
KamillosanÂ®	B-X
,	B-X
and	B-X
ShiunkoÂ®	B-X
.	B-X
Mebendazole	B-X
.	B-X
High	B-X
clinical	B-X
suspicion	B-X
is	B-X
required	B-X
to	B-X
facilitate	B-X
early	B-X
diagnosis	B-X
.	B-X

M	O
.	O
,	O
Olson	O
,	O
M	O
.	O
<EOS>	B-X
Letter	B-X
by	B-X
Olson	B-X
et	B-X
al	B-X
Regarding	B-X
Article	B-X
,	B-X
``	B-X
Emulating	B-X
Randomized	B-X
Clinical	B-X
Trials	B-X
With	B-X
Nonrandomized	B-X
Real-World	B-X
Evidence	B-X
Studies	B-X
:	B-X
First	B-X
Results	B-X
From	B-X
the	B-X
RCT	B-X
DUPLICATE	B-X
Initiative	B-X
''	B-X
.	B-X

V	O
.	O
,	O
Hall	O
,	O
B	O
.	O

D	O
.	O
<EOS>	B-X
Understanding	B-X
vitamin	B-X
D	B-X
deficiency	B-X
.	B-X

(	O
1977	O
)	O
Pro	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
with	B-X
14C-labeled	B-X
synthetic	B-X
peptides	B-X
demonstrated	B-X
that	B-X
prolyl	B-X
hydroxylase	B-X
,	B-X
which	B-X
synthesizes	B-X
the	B-X
hydroxyproline	B-X
in	B-X
collagen	B-X
,	B-X
preferentially	B-X
hydroxylates	B-X
the	B-X
fourth	B-X
triplet	B-X
from	B-X
the	B-X
NH-terminal	B-X
end	B-X
of	B-X
the	B-X
peptide	B-X
(	B-X
Pro-Pro-Gly	B-X
)	B-X
5	B-X
.	B-X
In	B-X
the	B-X
experiments	B-X
reported	B-X
here	B-X
,	B-X
the	B-X
prolyl	B-X
hydroxylase	B-X
reaction	B-X
was	B-X
investigated	B-X
further	B-X
by	B-X
preparing	B-X
chemically	B-X
modified	B-X
derivatives	B-X
of	B-X
(	B-X
Pro-Pro-Gly	B-X
)	B-X
5	B-X
and	B-X
by	B-X
synthesizing	B-X
14C-labeled	B-X
preparations	B-X
of	B-X
(	B-X
Pro-Pro-Gly	B-X
)	B-X
10	B-X
.	B-X
Essentially	B-X
,	B-X
the	B-X
same	B-X
kcat	B-X
value	B-X
was	B-X
found	B-X
for	B-X
the	B-X
hydroxylation	B-X
of	B-X
(	B-X
Pro-Pro-Gly	B-X
)	B-X
5	B-X
,	B-X
N-acetyl-	B-X
(	B-X
Pro-Pro-Gly	B-X
)	B-X
5	B-X
,	B-X
(	B-X
Pro-Pro-Gly	B-X
)	B-X
5	B-X
methyl	B-X
ester	B-X
,	B-X
(	B-X
Pro-Pro-Gly	B-X
)	B-X
10	B-X
,	B-X
and	B-X
for	B-X
larger	B-X
polypeptide	B-X
substrates	B-X
of	B-X
the	B-X
enzyme	B-X
.	B-X
It	B-X
appeared	B-X
therefore	B-X
that	B-X
preferential	B-X
hydroxylation	B-X
of	B-X
specific	B-X
triplets	B-X
in	B-X
peptides	B-X
of	B-X
the	B-X
structure	B-X
(	B-X
Pro-Pro-Gly	B-X
)	B-X
n	B-X
can	B-X
not	B-X
be	B-X
explained	B-X
by	B-X
differences	B-X
in	B-X
the	B-X
kinetic	B-X
constants	B-X
for	B-X
individual	B-X
triplets	B-X
.	B-X
Hydroxylation	B-X
of	B-X
14C-labeled	B-X
preparations	B-X
of	B-X
(	B-X
Pro-Pro-Gly	B-X
)	B-X
10	B-X
demonstrated	B-X
that	B-X
the	B-X
ninth	B-X
triplet	B-X
was	B-X
preferentially	B-X
hydroxylated	B-X
over	B-X
any	B-X
other	B-X
triplet	B-X
.	B-X

Natl	O
.	O
<EOS>	B-X
Obituaries	B-X
.	B-X
Corrigendum	B-X
to	B-X
``	B-X
Visceral	B-X
Adiposity	B-X
Index	B-X
Levels	B-X
in	B-X
Patients	B-X
with	B-X
Hypothyroidism	B-X
''	B-X
[	B-X
J	B-X
Natl	B-X
Med	B-X
Assoc	B-X
110	B-X
(	B-X
6	B-X
)	B-X
(	B-X
2018	B-X
)	B-X
606-613	B-X
]	B-X
.	B-X
Sodium	B-X
channels	B-X
in	B-X
the	B-X
cytoplasm	B-X
of	B-X
Schwann	B-X
cells	B-X
.	B-X
Proc	B-X
.	B-X
Natl	B-X
.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
87	B-X
(	B-X
1990	B-X
)	B-X
9290-9294	B-X
.	B-X
Imhotep	B-X
.	B-X

Acad	O
.	O
<EOS>	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2018	B-X
)	B-X
,	B-X
1423	B-X
,	B-X
166-175	B-X
.	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2018	B-X
)	B-X
,	B-X
1433	B-X
,	B-X
29-40	B-X
.	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2020	B-X
)	B-X
,	B-X
1462	B-X
,	B-X
65-78	B-X
.	B-X
In	B-X
Memoriam	B-X
Acad	B-X
.	B-X
Prof.	B-X
Dr.	B-X
LjubiÅ¡a	B-X
RakiÄ	B-X
(	B-X
1931-2022	B-X
)	B-X
.	B-X

Sci	O
.	O
<EOS>	B-X
Molecules	B-X
and	B-X
Biomaterial	B-X
Technologies	B-X
Affecting	B-X
Stem	B-X
Cell	B-X
Differentiation	B-X
.	B-X

U	O
.	O
S	O
.	O
A	O
.	O
<EOS>	B-X
NUTRITIONAL	B-X
WELL-BEING	B-X
IN	B-X
THE	B-X
U.S.A.	B-X
Nutritional	B-X
status	B-X
,	B-X
U.S.A	B-X
.	B-X
Abortion	B-X
in	B-X
U.S.A	B-X
.	B-X
Persons	B-X
with	B-X
disabilities	B-X
represent	B-X
a	B-X
growing	B-X
population	B-X
in	B-X
both	B-X
the	B-X
European	B-X
Union	B-X
(	B-X
EU	B-X
)	B-X
and	B-X
the	B-X
United	B-X
States	B-X
(	B-X
USA	B-X
)	B-X
.	B-X
The	B-X
EU	B-X
has	B-X
made	B-X
substantial	B-X
policy	B-X
progress	B-X
to	B-X
support	B-X
telework	B-X
,	B-X
but	B-X
persons	B-X
with	B-X
disabilities	B-X
have	B-X
had	B-X
only	B-X
limited	B-X
long-term	B-X
success	B-X
in	B-X
telework	B-X
initiatives	B-X
due	B-X
to	B-X
lack	B-X
of	B-X
work	B-X
support	B-X
services	B-X
.	B-X
The	B-X
USA	B-X
has	B-X
generally	B-X
strong	B-X
support	B-X
services	B-X
but	B-X
lacks	B-X
telework	B-X
policy	B-X
infrastructure	B-X
.	B-X
The	B-X
EU	B-X
and	B-X
the	B-X
USA	B-X
can	B-X
benefit	B-X
from	B-X
collaborative	B-X
work	B-X
to	B-X
enhance	B-X
their	B-X
complementary	B-X
strengths	B-X
.	B-X

74	O
,	O
5453	O
-	O
5457	O
.	O

13	O
.	O
<EOS>	B-X
Action	B-X
of	B-X
propranolol	B-X
on	B-X
mitochondrial	B-X
functions	B-X
--	B-X
effects	B-X
on	B-X
energized	B-X
ion	B-X
fluxes	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
valinomycin	B-X
.	B-X

Valenzuela	O
,	O
P	O
.	O
,	O
Venegas	O
,	O
A	O
.	O
,	O
Weinberg	O
,	O
F	O
.	O
,	O
Bishop	O
,	O
R	O
.	O
,	O
Rutter	O
,	O
<EOS>	B-X
Sixteen	B-X
bacterial	B-X
clones	B-X
containing	B-X
sequences	B-X
complementary	B-X
to	B-X
yeast	B-X
PhetRNA	B-X
were	B-X
isolated	B-X
from	B-X
a	B-X
collection	B-X
of	B-X
hybrid	B-X
plasmids	B-X
containing	B-X
BamHI	B-X
restriction	B-X
endonuclease-generated	B-X
yeast	B-X
DNA	B-X
fragments	B-X
inserted	B-X
in	B-X
the	B-X
plasmid	B-X
vector	B-X
pBR315	B-X
.	B-X
The	B-X
sequence	B-X
of	B-X
the	B-X
Phe-tRNA	B-X
structural	B-X
genes	B-X
and	B-X
adjacent	B-X
regions	B-X
of	B-X
three	B-X
of	B-X
these	B-X
clones	B-X
is	B-X
reported	B-X
here	B-X
.	B-X
In	B-X
the	B-X
region	B-X
flanking	B-X
the	B-X
tRNA	B-X
gene	B-X
,	B-X
the	B-X
sequence	B-X
of	B-X
two	B-X
of	B-X
the	B-X
cloned	B-X
DNAs	B-X
is	B-X
similar	B-X
;	B-X
the	B-X
sequence	B-X
of	B-X
the	B-X
third	B-X
varies	B-X
considerably	B-X
.	B-X
All	B-X
three	B-X
of	B-X
the	B-X
tRNA	B-X
genes	B-X
are	B-X
bordered	B-X
by	B-X
A	B-X
,	B-X
T-rich	B-X
regions	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
near	B-X
the	B-X
region	B-X
coding	B-X
for	B-X
the	B-X
3	B-X
'	B-X
end	B-X
of	B-X
the	B-X
tRNA	B-X
there	B-X
is	B-X
a	B-X
long	B-X
sequence	B-X
of	B-X
As	B-X
in	B-X
the	B-X
coding	B-X
strand	B-X
.	B-X
This	B-X
is	B-X
reminiscent	B-X
of	B-X
the	B-X
region	B-X
of	B-X
termination	B-X
of	B-X
transcription	B-X
of	B-X
the	B-X
yeast	B-X
5S	B-X
rRNA	B-X
gene	B-X
.	B-X
The	B-X
sequences	B-X
coding	B-X
for	B-X
the	B-X
Phe-tRNA	B-X
contain	B-X
an	B-X
additional	B-X
segment	B-X
of	B-X
18	B-X
or	B-X
19	B-X
base	B-X
pairs	B-X
(	B-X
depending	B-X
upon	B-X
the	B-X
clone	B-X
)	B-X
not	B-X
predicted	B-X
by	B-X
the	B-X
yeast	B-X
Phe-tRNA	B-X
sequence	B-X
.	B-X
These	B-X
intervening	B-X
segments	B-X
are	B-X
nearly	B-X
identical	B-X
in	B-X
the	B-X
three	B-X
clones	B-X
and	B-X
are	B-X
located	B-X
within	B-X
the	B-X
structural	B-X
gene	B-X
,	B-X
two	B-X
base	B-X
pairs	B-X
from	B-X
the	B-X
nucleotides	B-X
coding	B-X
for	B-X
the	B-X
tRNA	B-X
anticodon	B-X
.	B-X

W	O
.	O
<EOS>	B-X
We	B-X
present	B-X
a	B-X
novel	B-X
static	B-X
W-shaped	B-X
common-path	B-X
interferometer	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
the	B-X
W-shaped	B-X
common-path	B-X
corner-cube	B-X
retroreflector	B-X
interferometer	B-X
(	B-X
W-CPRI	B-X
)	B-X
is	B-X
introduced	B-X
via	B-X
detailed	B-X
analysis	B-X
of	B-X
its	B-X
working	B-X
principles	B-X
and	B-X
performance	B-X
.	B-X
For	B-X
each	B-X
interference	B-X
output	B-X
of	B-X
an	B-X
ideal	B-X
W-CPRI	B-X
,	B-X
the	B-X
two	B-X
beams	B-X
recombine	B-X
and	B-X
have	B-X
the	B-X
same	B-X
output	B-X
direction	B-X
,	B-X
including	B-X
a	B-X
tilted	B-X
CCR	B-X
.	B-X
In	B-X
a	B-X
deformed	B-X
W-CPRI	B-X
structure	B-X
,	B-X
an	B-X
optical	B-X
path	B-X
difference	B-X
can	B-X
be	B-X
produced	B-X
by	B-X
inserting	B-X
an	B-X
optical	B-X
element	B-X
that	B-X
changes	B-X
the	B-X
optical	B-X
path	B-X
in	B-X
the	B-X
interferometer	B-X
arm	B-X
of	B-X
the	B-X
W-CPRI	B-X
.	B-X
The	B-X
posture	B-X
deviations	B-X
of	B-X
the	B-X
RM	B-X
and	B-X
the	B-X
CCRs	B-X
in	B-X
the	B-X
W-CPRI	B-X
are	B-X
analyzed	B-X
.	B-X
The	B-X
average	B-X
cosine	B-X
similarity	B-X
is	B-X
0.9953	B-X
,	B-X
revealing	B-X
that	B-X
this	B-X
W-CPRI	B-X
has	B-X
high	B-X
stability	B-X
and	B-X
strong	B-X
coherence	B-X
while	B-X
avoiding	B-X
the	B-X
tilt	B-X
and	B-X
displacement	B-X
of	B-X
the	B-X
interferometer	B-X
arm	B-X
.	B-X

J	O
.	O
<EOS>	B-X
Heat	B-X
shock	B-X
proteins	B-X
of	B-X
40	B-X
kDa	B-X
(	B-X
Hsp40s	B-X
)	B-X
,	B-X
also	B-X
called	B-X
J	B-X
proteins	B-X
,	B-X
are	B-X
obligate	B-X
partners	B-X
of	B-X
Hsp70s	B-X
.	B-X
Via	B-X
their	B-X
highly	B-X
conserved	B-X
and	B-X
functionally	B-X
critical	B-X
J	B-X
domain	B-X
,	B-X
J	B-X
proteins	B-X
interact	B-X
and	B-X
modulate	B-X
the	B-X
activity	B-X
of	B-X
their	B-X
Hsp70	B-X
partners	B-X
.	B-X
Mutations	B-X
in	B-X
the	B-X
critical	B-X
residues	B-X
in	B-X
the	B-X
J	B-X
domain	B-X
often	B-X
result	B-X
in	B-X
the	B-X
null	B-X
phenotype	B-X
for	B-X
the	B-X
J	B-X
protein	B-X
in	B-X
question	B-X
.	B-X
However	B-X
,	B-X
as	B-X
more	B-X
J	B-X
proteins	B-X
have	B-X
been	B-X
characterized	B-X
,	B-X
it	B-X
is	B-X
becoming	B-X
increasingly	B-X
clear	B-X
that	B-X
a	B-X
significant	B-X
number	B-X
of	B-X
J	B-X
proteins	B-X
do	B-X
not	B-X
``	B-X
completely	B-X
''	B-X
rely	B-X
on	B-X
their	B-X
J	B-X
domains	B-X
to	B-X
carry	B-X
out	B-X
their	B-X
cellular	B-X
functions	B-X
,	B-X
as	B-X
previously	B-X
thought	B-X
.	B-X
In	B-X
some	B-X
cases	B-X
,	B-X
regions	B-X
outside	B-X
the	B-X
highly	B-X
conserved	B-X
J	B-X
domain	B-X
have	B-X
become	B-X
more	B-X
important	B-X
making	B-X
the	B-X
J	B-X
domain	B-X
dispensable	B-X
for	B-X
some	B-X
,	B-X
if	B-X
not	B-X
for	B-X
all	B-X
functions	B-X
of	B-X
a	B-X
J	B-X
protein	B-X
.	B-X
This	B-X
has	B-X
profound	B-X
effects	B-X
on	B-X
the	B-X
evolution	B-X
of	B-X
such	B-X
J	B-X
proteins	B-X
.	B-X
Here	B-X
we	B-X
present	B-X
selected	B-X
examples	B-X
of	B-X
J	B-X
proteins	B-X
that	B-X
perform	B-X
J	B-X
domain	B-X
independent	B-X
functions	B-X
and	B-X
discuss	B-X
this	B-X
in	B-X
the	B-X
context	B-X
of	B-X
evolution	B-X
of	B-X
J	B-X
proteins	B-X
with	B-X
dispensable	B-X
J	B-X
domains	B-X
and	B-X
J-like	B-X
proteins	B-X
in	B-X
eukaryotes	B-X
.	B-X

(	O
1978	O
)	O
Proc	O
.	O
<EOS>	B-X
Suppressor	B-X
cells	B-X
in	B-X
immunosenescence	B-X
.	B-X
Psoriatic	B-X
arthritis	B-X
.	B-X
By	B-X
using	B-X
a	B-X
formulation	B-X
of	B-X
Kimura	B-X
and	B-X
Crow	B-X
[	B-X
Kimura	B-X
,	B-X
M.	B-X
&	B-X
Crow	B-X
,	B-X
J.	B-X
F.	B-X
(	B-X
1978	B-X
)	B-X
Proc	B-X
.	B-X
Echocardiography	B-X
.	B-X

Natl	O
.	O
<EOS>	B-X
Obituaries	B-X
.	B-X
Corrigendum	B-X
to	B-X
``	B-X
Visceral	B-X
Adiposity	B-X
Index	B-X
Levels	B-X
in	B-X
Patients	B-X
with	B-X
Hypothyroidism	B-X
''	B-X
[	B-X
J	B-X
Natl	B-X
Med	B-X
Assoc	B-X
110	B-X
(	B-X
6	B-X
)	B-X
(	B-X
2018	B-X
)	B-X
606-613	B-X
]	B-X
.	B-X
Sodium	B-X
channels	B-X
in	B-X
the	B-X
cytoplasm	B-X
of	B-X
Schwann	B-X
cells	B-X
.	B-X
Proc	B-X
.	B-X
Natl	B-X
.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
87	B-X
(	B-X
1990	B-X
)	B-X
9290-9294	B-X
.	B-X
Imhotep	B-X
.	B-X

Acad	O
.	O
<EOS>	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2018	B-X
)	B-X
,	B-X
1423	B-X
,	B-X
166-175	B-X
.	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2018	B-X
)	B-X
,	B-X
1433	B-X
,	B-X
29-40	B-X
.	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2020	B-X
)	B-X
,	B-X
1462	B-X
,	B-X
65-78	B-X
.	B-X
In	B-X
Memoriam	B-X
Acad	B-X
.	B-X
Prof.	B-X
Dr.	B-X
LjubiÅ¡a	B-X
RakiÄ	B-X
(	B-X
1931-2022	B-X
)	B-X
.	B-X

Sci	O
.	O
<EOS>	B-X
Molecules	B-X
and	B-X
Biomaterial	B-X
Technologies	B-X
Affecting	B-X
Stem	B-X
Cell	B-X
Differentiation	B-X
.	B-X

U	O
.	O
S	O
.	O
A	O
.	O
<EOS>	B-X
NUTRITIONAL	B-X
WELL-BEING	B-X
IN	B-X
THE	B-X
U.S.A.	B-X
Nutritional	B-X
status	B-X
,	B-X
U.S.A	B-X
.	B-X
Abortion	B-X
in	B-X
U.S.A	B-X
.	B-X
Persons	B-X
with	B-X
disabilities	B-X
represent	B-X
a	B-X
growing	B-X
population	B-X
in	B-X
both	B-X
the	B-X
European	B-X
Union	B-X
(	B-X
EU	B-X
)	B-X
and	B-X
the	B-X
United	B-X
States	B-X
(	B-X
USA	B-X
)	B-X
.	B-X
The	B-X
EU	B-X
has	B-X
made	B-X
substantial	B-X
policy	B-X
progress	B-X
to	B-X
support	B-X
telework	B-X
,	B-X
but	B-X
persons	B-X
with	B-X
disabilities	B-X
have	B-X
had	B-X
only	B-X
limited	B-X
long-term	B-X
success	B-X
in	B-X
telework	B-X
initiatives	B-X
due	B-X
to	B-X
lack	B-X
of	B-X
work	B-X
support	B-X
services	B-X
.	B-X
The	B-X
USA	B-X
has	B-X
generally	B-X
strong	B-X
support	B-X
services	B-X
but	B-X
lacks	B-X
telework	B-X
policy	B-X
infrastructure	B-X
.	B-X
The	B-X
EU	B-X
and	B-X
the	B-X
USA	B-X
can	B-X
benefit	B-X
from	B-X
collaborative	B-X
work	B-X
to	B-X
enhance	B-X
their	B-X
complementary	B-X
strengths	B-X
.	B-X

75	O
,	O
190	O
-	O
194	O
.	O
<EOS>	B-X
Studies	B-X
on	B-X
avian	B-X
erythrocyte	B-X
metabolism	B-X
--	B-X
I	B-X
.	B-X
Procedure	B-X
for	B-X
separation	B-X
and	B-X
quantitation	B-X
of	B-X
the	B-X
major	B-X
phosphorylated	B-X
metabolic	B-X
intermediates	B-X
by	B-X
anion	B-X
exchange	B-X
chromatography	B-X
.	B-X
The	B-X
pronephroi	B-X
as	B-X
the	B-X
site	B-X
of	B-X
presumptive	B-X
interrenal	B-X
cells	B-X
in	B-X
the	B-X
hagfish	B-X
Myxine	B-X
glutinosa	B-X
L	B-X
.	B-X

14	O
.	O
<EOS>	B-X
Malathion	B-X
A	B-X
and	B-X
B	B-X
esterases	B-X
of	B-X
mouse	B-X
liver-I	B-X
.	B-X

Berget	O
,	O
S	O
.	O
<EOS>	B-X
Exon	B-X
recognition	B-X
in	B-X
vertebrate	B-X
splicing	B-X
.	B-X
A	B-X
subset	B-X
of	B-X
nuclear	B-X
receptor	B-X
coregulators	B-X
act	B-X
as	B-X
coupling	B-X
proteins	B-X
during	B-X
synthesis	B-X
and	B-X
maturation	B-X
of	B-X
RNA	B-X
transcripts	B-X
.	B-X
Transcription	B-X
maps	B-X
of	B-X
adenovirus	B-X
.	B-X
Spliced	B-X
segments	B-X
at	B-X
the	B-X
5	B-X
'	B-X
terminus	B-X
of	B-X
adenovirus	B-X
2	B-X
late	B-X
mRNA	B-X
.	B-X
1977	B-X
.	B-X

M	O
.	O
,	O
Moore	O
,	O
C	O
.	O
,	O
and	O
Sharp	O
,	O
P	O
.	O

A	O
.	O

(	O
1977	O
)	O
Proc	O
.	O
<EOS>	B-X
Cholera	B-X
.	B-X
Gallstones	B-X
.	B-X
Dermatitis	B-X
artefacta	B-X
.	B-X
D-penicillamine	B-X
chemical	B-X
quality	B-X
.	B-X

Natl	O
.	O
<EOS>	B-X
Obituaries	B-X
.	B-X
Corrigendum	B-X
to	B-X
``	B-X
Visceral	B-X
Adiposity	B-X
Index	B-X
Levels	B-X
in	B-X
Patients	B-X
with	B-X
Hypothyroidism	B-X
''	B-X
[	B-X
J	B-X
Natl	B-X
Med	B-X
Assoc	B-X
110	B-X
(	B-X
6	B-X
)	B-X
(	B-X
2018	B-X
)	B-X
606-613	B-X
]	B-X
.	B-X
Sodium	B-X
channels	B-X
in	B-X
the	B-X
cytoplasm	B-X
of	B-X
Schwann	B-X
cells	B-X
.	B-X
Proc	B-X
.	B-X
Natl	B-X
.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
87	B-X
(	B-X
1990	B-X
)	B-X
9290-9294	B-X
.	B-X
Imhotep	B-X
.	B-X

Acad	O
.	O
<EOS>	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2018	B-X
)	B-X
,	B-X
1423	B-X
,	B-X
166-175	B-X
.	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2018	B-X
)	B-X
,	B-X
1433	B-X
,	B-X
29-40	B-X
.	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2020	B-X
)	B-X
,	B-X
1462	B-X
,	B-X
65-78	B-X
.	B-X
In	B-X
Memoriam	B-X
Acad	B-X
.	B-X
Prof.	B-X
Dr.	B-X
LjubiÅ¡a	B-X
RakiÄ	B-X
(	B-X
1931-2022	B-X
)	B-X
.	B-X

Sci	O
.	O
<EOS>	B-X
Molecules	B-X
and	B-X
Biomaterial	B-X
Technologies	B-X
Affecting	B-X
Stem	B-X
Cell	B-X
Differentiation	B-X
.	B-X

U	O
.	O
S	O
.	O
A	O
.	O
<EOS>	B-X
NUTRITIONAL	B-X
WELL-BEING	B-X
IN	B-X
THE	B-X
U.S.A.	B-X
Nutritional	B-X
status	B-X
,	B-X
U.S.A	B-X
.	B-X
Abortion	B-X
in	B-X
U.S.A	B-X
.	B-X
Persons	B-X
with	B-X
disabilities	B-X
represent	B-X
a	B-X
growing	B-X
population	B-X
in	B-X
both	B-X
the	B-X
European	B-X
Union	B-X
(	B-X
EU	B-X
)	B-X
and	B-X
the	B-X
United	B-X
States	B-X
(	B-X
USA	B-X
)	B-X
.	B-X
The	B-X
EU	B-X
has	B-X
made	B-X
substantial	B-X
policy	B-X
progress	B-X
to	B-X
support	B-X
telework	B-X
,	B-X
but	B-X
persons	B-X
with	B-X
disabilities	B-X
have	B-X
had	B-X
only	B-X
limited	B-X
long-term	B-X
success	B-X
in	B-X
telework	B-X
initiatives	B-X
due	B-X
to	B-X
lack	B-X
of	B-X
work	B-X
support	B-X
services	B-X
.	B-X
The	B-X
USA	B-X
has	B-X
generally	B-X
strong	B-X
support	B-X
services	B-X
but	B-X
lacks	B-X
telework	B-X
policy	B-X
infrastructure	B-X
.	B-X
The	B-X
EU	B-X
and	B-X
the	B-X
USA	B-X
can	B-X
benefit	B-X
from	B-X
collaborative	B-X
work	B-X
to	B-X
enhance	B-X
their	B-X
complementary	B-X
strengths	B-X
.	B-X

74	O
,	O
3171	O
-	O
3175	O
.	O

15	O
.	O
<EOS>	B-X
Increase	B-X
in	B-X
acetyl	B-X
CoA	B-X
synthetase	B-X
activity	B-X
after	B-X
phenobarbital	B-X
treatment	B-X
.	B-X

Chow	O
,	O
L	O
.	O
<EOS>	B-X
Head	B-X
and	B-X
Neck	B-X
Cancer	B-X
.	B-X
Since	B-X
the	B-X
discovery	B-X
in	B-X
2000	B-X
that	B-X
muscle	B-X
contraction	B-X
releases	B-X
IL-6	B-X
,	B-X
the	B-X
number	B-X
of	B-X
exercise-associated	B-X
signalling	B-X
molecules	B-X
that	B-X
have	B-X
been	B-X
identified	B-X
has	B-X
multiplied	B-X
.	B-X
Small	B-X
incision	B-X
lenticule	B-X
extraction	B-X
(	B-X
SMILE	B-X
)	B-X
was	B-X
introduced	B-X
in	B-X
the	B-X
recent	B-X
decade	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
myopia	B-X
and	B-X
myopic	B-X
astigmatism	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
review	B-X
is	B-X
to	B-X
discuss	B-X
the	B-X
factors	B-X
that	B-X
affect	B-X
astigmatism	B-X
correction	B-X
in	B-X
SMILE	B-X
and	B-X
several	B-X
techniques	B-X
to	B-X
improve	B-X
the	B-X
refractive	B-X
outcomes	B-X
.	B-X

T	O
.	O
,	O
Gelinas	O
,	O
R	O
.	O
<EOS>	B-X
By	B-X
using	B-X
a	B-X
polymerase	B-X
chain	B-X
reaction-based	B-X
assay	B-X
of	B-X
T-cell	B-X
receptor	B-X
beta-chain	B-X
variable	B-X
region	B-X
mRNA	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
patterns	B-X
of	B-X
beta-chain	B-X
mRNAs	B-X
displayed	B-X
in	B-X
14	B-X
samples	B-X
of	B-X
lesional	B-X
skin	B-X
or	B-X
six	B-X
samples	B-X
of	B-X
noninvolved	B-X
skin	B-X
were	B-X
not	B-X
significantly	B-X
less	B-X
diverse	B-X
than	B-X
the	B-X
patterns	B-X
found	B-X
in	B-X
matched	B-X
peripheral	B-X
blood	B-X
samples	B-X
.	B-X
The	B-X
abundance	B-X
of	B-X
beta	B-X
3-adrenergic	B-X
receptors	B-X
(	B-X
Î²3-ARs	B-X
)	B-X
is	B-X
upregulated	B-X
in	B-X
diseased	B-X
human	B-X
myocardium	B-X
.	B-X
We	B-X
previously	B-X
showed	B-X
that	B-X
cardiac-specific	B-X
expression	B-X
of	B-X
Î²3-AR	B-X
inhibits	B-X
the	B-X
hypertrophic	B-X
response	B-X
to	B-X
neurohormonal	B-X
stimulation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
further	B-X
analysed	B-X
signalling	B-X
pathways	B-X
involved	B-X
in	B-X
the	B-X
anti-hypertrophic	B-X
effect	B-X
of	B-X
Î²3-AR	B-X
.	B-X

E	O
.	O
,	O
Broker	O
,	O
T	O
.	O
,	O
and	O
Roberts	O
,	O
R	O
.	O

J	O
.	O
<EOS>	B-X
Heat	B-X
shock	B-X
proteins	B-X
of	B-X
40	B-X
kDa	B-X
(	B-X
Hsp40s	B-X
)	B-X
,	B-X
also	B-X
called	B-X
J	B-X
proteins	B-X
,	B-X
are	B-X
obligate	B-X
partners	B-X
of	B-X
Hsp70s	B-X
.	B-X
Via	B-X
their	B-X
highly	B-X
conserved	B-X
and	B-X
functionally	B-X
critical	B-X
J	B-X
domain	B-X
,	B-X
J	B-X
proteins	B-X
interact	B-X
and	B-X
modulate	B-X
the	B-X
activity	B-X
of	B-X
their	B-X
Hsp70	B-X
partners	B-X
.	B-X
Mutations	B-X
in	B-X
the	B-X
critical	B-X
residues	B-X
in	B-X
the	B-X
J	B-X
domain	B-X
often	B-X
result	B-X
in	B-X
the	B-X
null	B-X
phenotype	B-X
for	B-X
the	B-X
J	B-X
protein	B-X
in	B-X
question	B-X
.	B-X
However	B-X
,	B-X
as	B-X
more	B-X
J	B-X
proteins	B-X
have	B-X
been	B-X
characterized	B-X
,	B-X
it	B-X
is	B-X
becoming	B-X
increasingly	B-X
clear	B-X
that	B-X
a	B-X
significant	B-X
number	B-X
of	B-X
J	B-X
proteins	B-X
do	B-X
not	B-X
``	B-X
completely	B-X
''	B-X
rely	B-X
on	B-X
their	B-X
J	B-X
domains	B-X
to	B-X
carry	B-X
out	B-X
their	B-X
cellular	B-X
functions	B-X
,	B-X
as	B-X
previously	B-X
thought	B-X
.	B-X
In	B-X
some	B-X
cases	B-X
,	B-X
regions	B-X
outside	B-X
the	B-X
highly	B-X
conserved	B-X
J	B-X
domain	B-X
have	B-X
become	B-X
more	B-X
important	B-X
making	B-X
the	B-X
J	B-X
domain	B-X
dispensable	B-X
for	B-X
some	B-X
,	B-X
if	B-X
not	B-X
for	B-X
all	B-X
functions	B-X
of	B-X
a	B-X
J	B-X
protein	B-X
.	B-X
This	B-X
has	B-X
profound	B-X
effects	B-X
on	B-X
the	B-X
evolution	B-X
of	B-X
such	B-X
J	B-X
proteins	B-X
.	B-X
Here	B-X
we	B-X
present	B-X
selected	B-X
examples	B-X
of	B-X
J	B-X
proteins	B-X
that	B-X
perform	B-X
J	B-X
domain	B-X
independent	B-X
functions	B-X
and	B-X
discuss	B-X
this	B-X
in	B-X
the	B-X
context	B-X
of	B-X
evolution	B-X
of	B-X
J	B-X
proteins	B-X
with	B-X
dispensable	B-X
J	B-X
domains	B-X
and	B-X
J-like	B-X
proteins	B-X
in	B-X
eukaryotes	B-X
.	B-X

(	O
1977	O
)	O
<EOS>	B-X
Hemoptysis	B-X
1977	B-X
.	B-X
Photocoagulation	B-X
1977	B-X
.	B-X
Christmas	B-X
quiz	B-X
,	B-X
1977	B-X
.	B-X
Philip	B-X
Bard	B-X
1898-1977	B-X
.	B-X

Cell	O
12	O
,	O
1	O
-	O
8	O
.	O
<EOS>	B-X
Specifically	B-X
,	B-X
we	B-X
highlight	B-X
the	B-X
following	B-X
crucial	B-X
domains	B-X
:	B-X
1	B-X
)	B-X
sources	B-X
of	B-X
pluripotent	B-X
cells	B-X
;	B-X
2	B-X
)	B-X
next-generation	B-X
in	B-X
vivo	B-X
direct	B-X
reprogramming	B-X
technology	B-X
;	B-X
3	B-X
)	B-X
cell	B-X
types	B-X
derived	B-X
from	B-X
PSCs	B-X
and	B-X
the	B-X
influence	B-X
of	B-X
genetic	B-X
memory	B-X
;	B-X
4	B-X
)	B-X
induction	B-X
of	B-X
pluripotency	B-X
with	B-X
genomic	B-X
modifications	B-X
;	B-X
5	B-X
)	B-X
construction	B-X
of	B-X
vectors	B-X
with	B-X
reprogramming	B-X
factor	B-X
combinations	B-X
;	B-X
6	B-X
)	B-X
enhancing	B-X
pluripotency	B-X
with	B-X
small	B-X
molecules	B-X
and	B-X
genetic	B-X
signaling	B-X
pathways	B-X
;	B-X
7	B-X
)	B-X
induction	B-X
of	B-X
cell	B-X
reprogramming	B-X
by	B-X
RNA	B-X
signaling	B-X
;	B-X
8	B-X
)	B-X
induction	B-X
and	B-X
enhancement	B-X
of	B-X
pluripotency	B-X
with	B-X
chemicals	B-X
;	B-X
9	B-X
)	B-X
maintenance	B-X
of	B-X
pluripotency	B-X
and	B-X
genomic	B-X
stability	B-X
in	B-X
induced	B-X
pluripotent	B-X
stem	B-X
cells	B-X
(	B-X
iPSCs	B-X
)	B-X
;	B-X
10	B-X
)	B-X
feeder-free	B-X
and	B-X
xenon-free	B-X
culture	B-X
environments	B-X
;	B-X
11	B-X
)	B-X
biomaterial	B-X
applications	B-X
in	B-X
stem	B-X
cell	B-X
biology	B-X
;	B-X
12	B-X
)	B-X
three-dimensional	B-X
(	B-X
3D	B-X
)	B-X
cell	B-X
technology	B-X
;	B-X
13	B-X
)	B-X
3D	B-X
bioprinting	B-X
;	B-X
14	B-X
)	B-X
downstream	B-X
stem	B-X
cell	B-X
applications	B-X
;	B-X
and	B-X
15	B-X
)	B-X
current	B-X
ethical	B-X
issues	B-X
in	B-X
stem	B-X
cell	B-X
and	B-X
regenerative	B-X
medicine	B-X
.	B-X
To	B-X
study	B-X
the	B-X
affects	B-X
of	B-X
interleukin-8	B-X
(	B-X
IL-8	B-X
)	B-X
,	B-X
anti-IL-8	B-X
,	B-X
and	B-X
IL-12	B-X
on	B-X
in	B-X
vitro	B-X
proliferation	B-X
of	B-X
endometrial	B-X
cells	B-X
.	B-X
The	B-X
comparative	B-X
genotoxic	B-X
effects	B-X
of	B-X
racemic	B-X
trans-8,9-dihydroxy-8	B-X
,	B-X
9-dihydrodibenzo	B-X
[	B-X
a	B-X
,	B-X
l	B-X
]	B-X
pyrene	B-X
(	B-X
trans-DB	B-X
[	B-X
a	B-X
,	B-X
l	B-X
]	B-X
P-8,9-diol	B-X
)	B-X
,	B-X
the	B-X
metabolic	B-X
K-region	B-X
dihydrodiol	B-X
of	B-X
dibenzo	B-X
[	B-X
a	B-X
,	B-X
l	B-X
]	B-X
pyrene	B-X
(	B-X
DB	B-X
[	B-X
a	B-X
,	B-X
l	B-X
]	B-X
P	B-X
)	B-X
(	B-X
dibenzo	B-X
[	B-X
def	B-X
,	B-X
p	B-X
]	B-X
chrysene	B-X
)	B-X
and	B-X
DB	B-X
[	B-X
a	B-X
,	B-X
l	B-X
]	B-X
P	B-X
in	B-X
transformable	B-X
mouse	B-X
embryo	B-X
C3H10T	B-X
(	B-X
1	B-X
)	B-X
/	B-X
(	B-X
2	B-X
)	B-X
Cl8	B-X
(	B-X
C3H10T	B-X
(	B-X
1	B-X
)	B-X
/	B-X
(	B-X
2	B-X
)	B-X
)	B-X
fibroblasts	B-X
was	B-X
investigated	B-X
.	B-X
The	B-X
C3H10T	B-X
(	B-X
1	B-X
)	B-X
/	B-X
(	B-X
2	B-X
)	B-X
mouse	B-X
embryo	B-X
morphological	B-X
cell-transforming	B-X
activities	B-X
of	B-X
these	B-X
polycyclic	B-X
aromatic	B-X
hydrocarbons	B-X
(	B-X
PAHs	B-X
)	B-X
were	B-X
assayed	B-X
using	B-X
concentration-response	B-X
studies	B-X
.	B-X
At	B-X
concentrations	B-X
of	B-X
33	B-X
nM	B-X
and	B-X
above	B-X
both	B-X
trans-DB	B-X
[	B-X
a	B-X
,	B-X
l	B-X
]	B-X
P-8,9-diol	B-X
and	B-X
DB	B-X
[	B-X
a	B-X
,	B-X
l	B-X
]	B-X
P	B-X
produced	B-X
significant	B-X
(	B-X
and	B-X
similar	B-X
)	B-X
numbers	B-X
of	B-X
type	B-X
II	B-X
and	B-X
III	B-X
foci	B-X
per	B-X
dish	B-X
and	B-X
numbers	B-X
of	B-X
dishes	B-X
with	B-X
type	B-X
II	B-X
and	B-X
II	B-X
foci	B-X
.	B-X
Concomitant	B-X
cytotoxicity	B-X
studies	B-X
revealed	B-X
a	B-X
reduction	B-X
in	B-X
colony	B-X
survival	B-X
of	B-X
approximately	B-X
25	B-X
%	B-X
up	B-X
to	B-X
198	B-X
nM	B-X
for	B-X
both	B-X
PAHs	B-X
.	B-X
DNA	B-X
adducts	B-X
of	B-X
trans-DB	B-X
[	B-X
a	B-X
,	B-X
l	B-X
]	B-X
P-8,9-diol	B-X
and	B-X
DB	B-X
[	B-X
a	B-X
,	B-X
l	B-X
]	B-X
P	B-X
in	B-X
C3H10T	B-X
(	B-X
1	B-X
)	B-X
/	B-X
(	B-X
2	B-X
)	B-X
cells	B-X
were	B-X
analyzed	B-X
by	B-X
a	B-X
(	B-X
32	B-X
)	B-X
P-post-labeling	B-X
TLC/HPLC	B-X
method	B-X
.	B-X
No	B-X
adducts	B-X
were	B-X
observed	B-X
in	B-X
the	B-X
DNA	B-X
of	B-X
C3H10T	B-X
(	B-X
1	B-X
)	B-X
/	B-X
(	B-X
2	B-X
)	B-X
cells	B-X
treated	B-X
with	B-X
trans-DB	B-X
[	B-X
a	B-X
,	B-X
l	B-X
]	B-X
P-8,9-diol	B-X
at	B-X
concentrations	B-X
that	B-X
induced	B-X
morphological	B-X
cell	B-X
transformation	B-X
.	B-X
Under	B-X
the	B-X
same	B-X
exposure	B-X
and	B-X
chromatographic	B-X
conditions	B-X
,	B-X
DNA	B-X
adducts	B-X
of	B-X
deoxyadenosine	B-X
and	B-X
deoxyguanosine	B-X
derived	B-X
from	B-X
the	B-X
fjord	B-X
region	B-X
anti-DB	B-X
[	B-X
a	B-X
,	B-X
l	B-X
]	B-X
P-11,12-diol-13,14-epoxide	B-X
and	B-X
syn-DB	B-X
[	B-X
a	B-X
,	B-X
l	B-X
]	B-X
P-11,12-diol-13,14-epoxide	B-X
were	B-X
observed	B-X
in	B-X
the	B-X
DNA	B-X
of	B-X
DB	B-X
[	B-X
a	B-X
,	B-X
l	B-X
]	B-X
P-treated	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
trans-DB	B-X
[	B-X
a	B-X
,	B-X
l	B-X
]	B-X
P-8	B-X
,	B-X
9-diol	B-X
has	B-X
intrinsic	B-X
genotoxic	B-X
activity	B-X
equal	B-X
to	B-X
that	B-X
of	B-X
DB	B-X
[	B-X
a	B-X
,	B-X
l	B-X
]	B-X
P	B-X
,	B-X
based	B-X
on	B-X
morphological	B-X
cell	B-X
transformation	B-X
of	B-X
mouse	B-X
embryo	B-X
fibroblasts	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
trans-DB	B-X
[	B-X
a	B-X
,	B-X
l	B-X
]	B-X
P-8,9-diol	B-X
is	B-X
apparently	B-X
not	B-X
associated	B-X
with	B-X
the	B-X
formation	B-X
of	B-X
observable	B-X
stable	B-X
covalent	B-X
DNA	B-X
adducts	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
under	B-X
appropriate	B-X
conditions	B-X
,	B-X
trans-DB	B-X
[	B-X
a	B-X
,	B-X
l	B-X
]	B-X
P-8,9-diol	B-X
may	B-X
serve	B-X
as	B-X
an	B-X
intermediate	B-X
in	B-X
the	B-X
genotoxicity	B-X
of	B-X
DB	B-X
[	B-X
a	B-X
,	B-X
l	B-X
]	B-X
P	B-X
.	B-X

16	O
.	O
<EOS>	B-X
Inhibition	B-X
of	B-X
aldehyde	B-X
reductase	B-X
by	B-X
acidic	B-X
metabolites	B-X
of	B-X
the	B-X
biogenic	B-X
amines	B-X
.	B-X

Berk	O
,	O
A	O
.	O
<EOS>	B-X
Patient	B-X
perspective	B-X
:	B-X
Financial	B-X
toxicity	B-X
is	B-X
a	B-X
barrier	B-X
to	B-X
clinical	B-X
trials	B-X
and	B-X
personalized	B-X
therapy	B-X
in	B-X
cholangiocarcinoma	B-X
.	B-X
Covid-19	B-X
and	B-X
exacerbation	B-X
of	B-X
psoriasis	B-X
.	B-X
TBP-like	B-X
factors	B-X
come	B-X
into	B-X
focus	B-X
.	B-X

J	O
.	O
,	O
and	O
Sharp	O
,	O
P	O
.	O
<EOS>	B-X
Systems-level	B-X
analysis	B-X
of	B-X
how	B-X
flaviviruses	B-X
hijack	B-X
cellular	B-X
processes	B-X
through	B-X
virus-host	B-X
protein-protein	B-X
interactions	B-X
(	B-X
PPIs	B-X
)	B-X
provides	B-X
information	B-X
about	B-X
their	B-X
replication	B-X
and	B-X
pathogenic	B-X
mechanisms	B-X
.	B-X
We	B-X
used	B-X
affinity	B-X
purification-mass	B-X
spectrometry	B-X
(	B-X
AP-MS	B-X
)	B-X
to	B-X
compare	B-X
flavivirus-host	B-X
interactions	B-X
for	B-X
two	B-X
viruses	B-X
(	B-X
DENV	B-X
and	B-X
ZIKV	B-X
)	B-X
in	B-X
two	B-X
hosts	B-X
(	B-X
human	B-X
and	B-X
mosquito	B-X
)	B-X
.	B-X
Conserved	B-X
virus-host	B-X
PPIs	B-X
revealed	B-X
that	B-X
the	B-X
flavivirus	B-X
NS5	B-X
protein	B-X
suppresses	B-X
interferon	B-X
stimulated	B-X
genes	B-X
by	B-X
inhibiting	B-X
recruitment	B-X
of	B-X
the	B-X
transcription	B-X
complex	B-X
PAF1C	B-X
and	B-X
that	B-X
chemical	B-X
modulation	B-X
of	B-X
SEC61	B-X
inhibits	B-X
DENV	B-X
and	B-X
ZIKV	B-X
replication	B-X
in	B-X
human	B-X
and	B-X
mosquito	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
comparative	B-X
flavivirus-host	B-X
PPI	B-X
mapping	B-X
provides	B-X
biological	B-X
insights	B-X
and	B-X
,	B-X
when	B-X
coupled	B-X
with	B-X
in	B-X
vivo	B-X
models	B-X
,	B-X
can	B-X
be	B-X
used	B-X
to	B-X
unravel	B-X
pathogenic	B-X
mechanisms	B-X
.	B-X

A	O
.	O

(	O
1978	O
)	O
Proc	O
.	O
<EOS>	B-X
Suppressor	B-X
cells	B-X
in	B-X
immunosenescence	B-X
.	B-X
Psoriatic	B-X
arthritis	B-X
.	B-X
By	B-X
using	B-X
a	B-X
formulation	B-X
of	B-X
Kimura	B-X
and	B-X
Crow	B-X
[	B-X
Kimura	B-X
,	B-X
M.	B-X
&	B-X
Crow	B-X
,	B-X
J.	B-X
F.	B-X
(	B-X
1978	B-X
)	B-X
Proc	B-X
.	B-X
Echocardiography	B-X
.	B-X

Natl	O
.	O
<EOS>	B-X
Obituaries	B-X
.	B-X
Corrigendum	B-X
to	B-X
``	B-X
Visceral	B-X
Adiposity	B-X
Index	B-X
Levels	B-X
in	B-X
Patients	B-X
with	B-X
Hypothyroidism	B-X
''	B-X
[	B-X
J	B-X
Natl	B-X
Med	B-X
Assoc	B-X
110	B-X
(	B-X
6	B-X
)	B-X
(	B-X
2018	B-X
)	B-X
606-613	B-X
]	B-X
.	B-X
Sodium	B-X
channels	B-X
in	B-X
the	B-X
cytoplasm	B-X
of	B-X
Schwann	B-X
cells	B-X
.	B-X
Proc	B-X
.	B-X
Natl	B-X
.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
87	B-X
(	B-X
1990	B-X
)	B-X
9290-9294	B-X
.	B-X
Imhotep	B-X
.	B-X

Acad	O
.	O
<EOS>	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2018	B-X
)	B-X
,	B-X
1423	B-X
,	B-X
166-175	B-X
.	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2018	B-X
)	B-X
,	B-X
1433	B-X
,	B-X
29-40	B-X
.	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2020	B-X
)	B-X
,	B-X
1462	B-X
,	B-X
65-78	B-X
.	B-X
In	B-X
Memoriam	B-X
Acad	B-X
.	B-X
Prof.	B-X
Dr.	B-X
LjubiÅ¡a	B-X
RakiÄ	B-X
(	B-X
1931-2022	B-X
)	B-X
.	B-X

Sci	O
.	O
<EOS>	B-X
Molecules	B-X
and	B-X
Biomaterial	B-X
Technologies	B-X
Affecting	B-X
Stem	B-X
Cell	B-X
Differentiation	B-X
.	B-X

U	O
.	O
S	O
.	O
A	O
.	O
<EOS>	B-X
NUTRITIONAL	B-X
WELL-BEING	B-X
IN	B-X
THE	B-X
U.S.A.	B-X
Nutritional	B-X
status	B-X
,	B-X
U.S.A	B-X
.	B-X
Abortion	B-X
in	B-X
U.S.A	B-X
.	B-X
Persons	B-X
with	B-X
disabilities	B-X
represent	B-X
a	B-X
growing	B-X
population	B-X
in	B-X
both	B-X
the	B-X
European	B-X
Union	B-X
(	B-X
EU	B-X
)	B-X
and	B-X
the	B-X
United	B-X
States	B-X
(	B-X
USA	B-X
)	B-X
.	B-X
The	B-X
EU	B-X
has	B-X
made	B-X
substantial	B-X
policy	B-X
progress	B-X
to	B-X
support	B-X
telework	B-X
,	B-X
but	B-X
persons	B-X
with	B-X
disabilities	B-X
have	B-X
had	B-X
only	B-X
limited	B-X
long-term	B-X
success	B-X
in	B-X
telework	B-X
initiatives	B-X
due	B-X
to	B-X
lack	B-X
of	B-X
work	B-X
support	B-X
services	B-X
.	B-X
The	B-X
USA	B-X
has	B-X
generally	B-X
strong	B-X
support	B-X
services	B-X
but	B-X
lacks	B-X
telework	B-X
policy	B-X
infrastructure	B-X
.	B-X
The	B-X
EU	B-X
and	B-X
the	B-X
USA	B-X
can	B-X
benefit	B-X
from	B-X
collaborative	B-X
work	B-X
to	B-X
enhance	B-X
their	B-X
complementary	B-X
strengths	B-X
.	B-X

75	O
,	O
1274	O
-	O
1278	O
.	O

17	O
.	O
<EOS>	B-X
Effects	B-X
of	B-X
5,6-dihydroxytryptamine	B-X
on	B-X
tyrosine-hydroxylase	B-X
activity	B-X
in	B-X
central	B-X
catecholaminergic	B-X
neurons	B-X
of	B-X
the	B-X
rat	B-X
.	B-X

Bratosin	O
,	O
S	O
.	O
,	O
Horowitz	O
,	O
M	O
.	O
,	O
Laub	O
,	O
0	O
.	O
,	O
and	O
Aloni	O
,	O
Y	O
.	O

(	O
1978	O
)	O
<EOS>	B-X
1978	B-X
.	B-X
Hypertension	B-X
--	B-X
1978	B-X
.	B-X
Tetanus	B-X
--	B-X
1978	B-X
.	B-X
Hypertension	B-X
,	B-X
1978	B-X
.	B-X

Cell	O
13	O
,	O
783	O
-	O
790	O
.	O
<EOS>	B-X
The	B-X
MAT-B1	B-X
and	B-X
MAT-C1	B-X
ascites	B-X
sublines	B-X
of	B-X
the	B-X
13762	B-X
rat	B-X
mammary	B-X
adenocarcinoma	B-X
,	B-X
which	B-X
differ	B-X
in	B-X
several	B-X
cell	B-X
surface	B-X
properties	B-X
,	B-X
contain	B-X
a	B-X
major	B-X
mucin-type	B-X
glycoprotein	B-X
,	B-X
termed	B-X
ASGP-1	B-X
.	B-X
255	B-X
,	B-X
783-790	B-X
)	B-X
.	B-X

18	O
.	O
<EOS>	B-X
Inhibition	B-X
of	B-X
aldehyde	B-X
reductase	B-X
isoenzymes	B-X
in	B-X
human	B-X
and	B-X
rat	B-X
brain	B-X
.	B-X

Sargent	O
,	O
T	O
.	O
<EOS>	B-X
Transcriptional	B-X
regulation	B-X
at	B-X
the	B-X
neural	B-X
plate	B-X
border	B-X
.	B-X
Stereotypies	B-X
in	B-X
caged	B-X
canaries	B-X
.	B-X
Methylmalonic	B-X
aciduria	B-X
and	B-X
hypoglycemia	B-X
.	B-X
Role	B-X
of	B-X
3,4-dimethoxyphenethylamine	B-X
in	B-X
schizophrenia	B-X
.	B-X

D	O
.	O
,	O
Wu	O
,	O
J	O
.	O

R	O
.	O
,	O
Sala	O
-	O
Trepat	O
,	O
J	O
.	O
<EOS>	B-X
Preliminary	B-X
R-loop	B-X
and	B-X
restriction	B-X
analysis	B-X
has	B-X
revealed	B-X
that	B-X
this	B-X
gene	B-X
is	B-X
split	B-X
into	B-X
at	B-X
least	B-X
14	B-X
fragments	B-X
(	B-X
exons	B-X
)	B-X
by	B-X
13	B-X
intervening	B-X
sequences	B-X
(	B-X
introns	B-X
)	B-X
,	B-X
and	B-X
that	B-X
it	B-X
occupies	B-X
a	B-X
minimum	B-X
of	B-X
14.5	B-X
kilobases	B-X
of	B-X
genomic	B-X
DNA	B-X
.	B-X
[	B-X
Independance	B-X
of	B-X
the	B-X
binding	B-X
site	B-X
for	B-X
the	B-X
hormone	B-X
and	B-X
of	B-X
interaction	B-X
sites	B-X
with	B-X
chromatin	B-X
of	B-X
the	B-X
uterine	B-X
receptor	B-X
for	B-X
estradiol	B-X
:	B-X
demonstration	B-X
by	B-X
controlled	B-X
proteolysis	B-X
]	B-X
.	B-X

M	O
.	O
,	O
Wallace	O
,	O
R	O
.	O

B	O
.	O
,	O
<EOS>	B-X
They	B-X
act	B-X
by	B-X
inhibiting	B-X
bacterial	B-X
enzymes	B-X
,	B-X
adhesions	B-X
with	B-X
gastric	B-X
mucosa	B-X
,	B-X
suppression	B-X
of	B-X
nuclear	B-X
factor-ÎºB	B-X
and	B-X
by	B-X
inhibition	B-X
of	B-X
oxidative	B-X
stress	B-X
.	B-X
Extracts	B-X
from	B-X
Pistacia	B-X
lentiscus	B-X
,	B-X
Brassica	B-X
oleracea	B-X
,	B-X
Glycyrrhiza	B-X
glabra	B-X
,	B-X
Camellia	B-X
sinensis	B-X
,	B-X
Cinnamomum	B-X
cassia	B-X
,	B-X
Allium	B-X
sativum	B-X
and	B-X
Nigella	B-X
sativa	B-X
plants	B-X
and	B-X
isolated	B-X
phyto-compounds	B-X
such	B-X
as	B-X
curcumin	B-X
,	B-X
resveratrol	B-X
,	B-X
quercetin	B-X
,	B-X
allicin	B-X
and	B-X
ellagic	B-X
acid	B-X
demonstrated	B-X
antimicrobial	B-X
activity	B-X
against	B-X
H.	B-X
pylori	B-X
under	B-X
in	B-X
vivo	B-X
conditions	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
a	B-X
single	B-X
B-cell	B-X
cloning	B-X
method	B-X
was	B-X
used	B-X
to	B-X
screen	B-X
the	B-X
Wuhan-Hu-1	B-X
strain	B-X
of	B-X
SARS-CoV-2	B-X
receptor-binding	B-X
domain	B-X
(	B-X
RBD	B-X
)	B-X
specific	B-X
,	B-X
high	B-X
affinity	B-X
,	B-X
and	B-X
neutralizing	B-X
mAbs	B-X
from	B-X
patients	B-X
'	B-X
blood	B-X
samples	B-X
.	B-X
An	B-X
RBD-specific	B-X
antibody	B-X
,	B-X
SAR03	B-X
,	B-X
was	B-X
discovered	B-X
that	B-X
showed	B-X
high	B-X
binding	B-X
(	B-X
ELISA	B-X
and	B-X
SPR	B-X
)	B-X
and	B-X
neutralizing	B-X
activity	B-X
(	B-X
competitive	B-X
ELISA	B-X
and	B-X
pseudovirus-based	B-X
reporter	B-X
assay	B-X
)	B-X
against	B-X
the	B-X
Wuhan-Hu-1	B-X
strain	B-X
of	B-X
SARS-CoV-2	B-X
.	B-X
Mechanistic	B-X
studies	B-X
on	B-X
human	B-X
cells	B-X
revealed	B-X
that	B-X
SAR03	B-X
competes	B-X
with	B-X
the	B-X
ACE-2	B-X
receptor	B-X
for	B-X
binding	B-X
with	B-X
the	B-X
RBD	B-X
domain	B-X
(	B-X
S1	B-X
subunit	B-X
)	B-X
present	B-X
in	B-X
the	B-X
spike	B-X
protein	B-X
of	B-X
SARS-CoV-2	B-X
.	B-X
This	B-X
study	B-X
highlights	B-X
the	B-X
potential	B-X
of	B-X
the	B-X
single	B-X
B	B-X
cell	B-X
cloning	B-X
method	B-X
for	B-X
the	B-X
rapid	B-X
and	B-X
efficient	B-X
screening	B-X
of	B-X
high-affinity	B-X
and	B-X
effective	B-X
neutralizing	B-X
antibodies	B-X
for	B-X
SARS-CoV-2	B-X
and	B-X
other	B-X
emerging	B-X
infectious	B-X
diseases	B-X
.	B-X

Reyes	O
,	O
A	O
.	O
<EOS>	B-X
Reply	B-X
:	B-X
RE	B-X
:	B-X
Reyes	B-X
A	B-X
,	B-X
RÃ©vil	B-X
C	B-X
,	B-X
Niggli	B-X
M	B-X
,	B-X
et	B-X
al	B-X
.	B-X
Efficacy	B-X
of	B-X
emicizumab	B-X
prophylaxis	B-X
versus	B-X
factor	B-X
VIII	B-X
prophylaxis	B-X
for	B-X
treatment	B-X
of	B-X
hemophilia	B-X
A	B-X
without	B-X
inhibitors	B-X
:	B-X
network	B-X
meta-analysis	B-X
and	B-X
sub-group	B-X
analyses	B-X
of	B-X
the	B-X
intra-patient	B-X
comparison	B-X
of	B-X
the	B-X
HAVEN	B-X
3	B-X
trial	B-X
.	B-X
Curr	B-X
Med	B-X
Res	B-X
Opin	B-X
.	B-X
2019	B-X
;	B-X
35	B-X
(	B-X
12	B-X
)	B-X
:2079-2087	B-X
.	B-X
SPARC	B-X
:	B-X
Community	B-X
advocacy	B-X
through	B-X
a	B-X
student-led	B-X
conference	B-X
.	B-X

A	O
.	O
,	O
and	O
Bonner	O
,	O
J	O
.	O

(	O
1979	O
)	O
Proc	O
.	O
<EOS>	B-X
Pillars	B-X
Article	B-X
:	B-X
Leukotriene	B-X
C	B-X
:	B-X
A	B-X
Slow-Reacting	B-X
Substance	B-X
from	B-X
Murine	B-X
Mastocytoma	B-X
Cells	B-X
.	B-X
Obesity	B-X
--	B-X
who	B-X
is	B-X
to	B-X
blame	B-X
?	B-X
Pillars	B-X
article	B-X
:	B-X
Separation	B-X
of	B-X
functional	B-X
subsets	B-X
of	B-X
human	B-X
T	B-X
cells	B-X
by	B-X
a	B-X
monoclonal	B-X
antibody	B-X
.	B-X
Proc	B-X
.	B-X
Natl	B-X
.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
1979	B-X
.	B-X
76	B-X
:	B-X
4061-4065	B-X
.	B-X
Ebstein	B-X
's	B-X
disease	B-X
.	B-X

Natl	O
.	O
<EOS>	B-X
Obituaries	B-X
.	B-X
Corrigendum	B-X
to	B-X
``	B-X
Visceral	B-X
Adiposity	B-X
Index	B-X
Levels	B-X
in	B-X
Patients	B-X
with	B-X
Hypothyroidism	B-X
''	B-X
[	B-X
J	B-X
Natl	B-X
Med	B-X
Assoc	B-X
110	B-X
(	B-X
6	B-X
)	B-X
(	B-X
2018	B-X
)	B-X
606-613	B-X
]	B-X
.	B-X
Sodium	B-X
channels	B-X
in	B-X
the	B-X
cytoplasm	B-X
of	B-X
Schwann	B-X
cells	B-X
.	B-X
Proc	B-X
.	B-X
Natl	B-X
.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
87	B-X
(	B-X
1990	B-X
)	B-X
9290-9294	B-X
.	B-X
Neosalvarsan	B-X
.	B-X

Acad	O
.	O
<EOS>	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2018	B-X
)	B-X
,	B-X
1423	B-X
,	B-X
166-175	B-X
.	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2018	B-X
)	B-X
,	B-X
1433	B-X
,	B-X
29-40	B-X
.	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2020	B-X
)	B-X
,	B-X
1462	B-X
,	B-X
65-78	B-X
.	B-X
In	B-X
Memoriam	B-X
Acad	B-X
.	B-X
Prof.	B-X
Dr.	B-X
LjubiÅ¡a	B-X
RakiÄ	B-X
(	B-X
1931-2022	B-X
)	B-X
.	B-X

Sci	O
.	O
<EOS>	B-X
Molecules	B-X
and	B-X
Biomaterial	B-X
Technologies	B-X
Affecting	B-X
Stem	B-X
Cell	B-X
Differentiation	B-X
.	B-X

U	O
.	O
S	O
.	O
A	O
.	O
<EOS>	B-X
NUTRITIONAL	B-X
WELL-BEING	B-X
IN	B-X
THE	B-X
U.S.A.	B-X
Nutritional	B-X
status	B-X
,	B-X
U.S.A	B-X
.	B-X
Abortion	B-X
in	B-X
U.S.A	B-X
.	B-X
Persons	B-X
with	B-X
disabilities	B-X
represent	B-X
a	B-X
growing	B-X
population	B-X
in	B-X
both	B-X
the	B-X
European	B-X
Union	B-X
(	B-X
EU	B-X
)	B-X
and	B-X
the	B-X
United	B-X
States	B-X
(	B-X
USA	B-X
)	B-X
.	B-X
The	B-X
EU	B-X
has	B-X
made	B-X
substantial	B-X
policy	B-X
progress	B-X
to	B-X
support	B-X
telework	B-X
,	B-X
but	B-X
persons	B-X
with	B-X
disabilities	B-X
have	B-X
had	B-X
only	B-X
limited	B-X
long-term	B-X
success	B-X
in	B-X
telework	B-X
initiatives	B-X
due	B-X
to	B-X
lack	B-X
of	B-X
work	B-X
support	B-X
services	B-X
.	B-X
The	B-X
USA	B-X
has	B-X
generally	B-X
strong	B-X
support	B-X
services	B-X
but	B-X
lacks	B-X
telework	B-X
policy	B-X
infrastructure	B-X
.	B-X
The	B-X
EU	B-X
and	B-X
the	B-X
USA	B-X
can	B-X
benefit	B-X
from	B-X
collaborative	B-X
work	B-X
to	B-X
enhance	B-X
their	B-X
complementary	B-X
strengths	B-X
.	B-X

76	O
,	O
3256	O
-	O
3260	O
.	O
<EOS>	B-X
Endocrine	B-X
and	B-X
metabolic	B-X
diseases	B-X
.	B-X
Adrenal	B-X
diseases	B-X
.	B-X
Letter	B-X
:	B-X
First	B-X
aid	B-X
in	B-X
acute	B-X
myocardial	B-X
infarction	B-X
.	B-X

19	O
.	O
<EOS>	B-X
Antidepressant	B-X
drugs	B-X
affect	B-X
dopamine	B-X
uptake	B-X
.	B-X

Perrin	O
,	O
F	O
.	O
,	O
Cochet	O
,	O
M	O
.	O
,	O
Gerlinger	O
,	O
P	O
.	O
,	O
Cami	O
,	O
B	O
.	O
,	O
LePennec	O
,	O
J	O
.	O

P	O
.	O
,	O
<EOS>	B-X
The	B-X
transcriptional	B-X
factor	B-X
PPAR-Î³	B-X
belongs	B-X
to	B-X
the	B-X
nuclear	B-X
receptor	B-X
family	B-X
,	B-X
which	B-X
has	B-X
become	B-X
a	B-X
potential	B-X
therapeutic	B-X
target	B-X
for	B-X
several	B-X
neurodegenerative	B-X
diseases	B-X
and	B-X
metabolic	B-X
disorders	B-X
.	B-X
Interestingly	B-X
,	B-X
PPAR-Î³	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
have	B-X
beneficial	B-X
effects	B-X
in	B-X
various	B-X
chronic	B-X
neurological	B-X
conditions	B-X
via	B-X
upregulation	B-X
of	B-X
its	B-X
transcriptional	B-X
co-activator	B-X
PGC-1Î±	B-X
and	B-X
followed	B-X
by	B-X
regulation	B-X
of	B-X
multiple	B-X
molecular	B-X
events	B-X
.	B-X
Although	B-X
several	B-X
factors	B-X
contribute	B-X
to	B-X
the	B-X
progression	B-X
of	B-X
neurodegeneration	B-X
,	B-X
the	B-X
dysfunction	B-X
of	B-X
PGC-1Î±	B-X
expression	B-X
is	B-X
primarily	B-X
interlinked	B-X
with	B-X
the	B-X
pathogenesis	B-X
of	B-X
major	B-X
neurodegenerative	B-X
diseases	B-X
.	B-X
This	B-X
review	B-X
gives	B-X
an	B-X
insight	B-X
that	B-X
ligand-dependent	B-X
activation	B-X
of	B-X
PPAR-Î³	B-X
by	B-X
glitazones	B-X
could	B-X
initiate	B-X
the	B-X
structural	B-X
conformational	B-X
changes	B-X
of	B-X
the	B-X
secondary	B-X
proteins	B-X
,	B-X
thus	B-X
recruiting	B-X
the	B-X
PGC-1Î±	B-X
to	B-X
form	B-X
a	B-X
stable	B-X
regulatory	B-X
complex	B-X
that	B-X
hampers	B-X
the	B-X
various	B-X
molecular	B-X
pathways	B-X
contributing	B-X
to	B-X
neurodegeneration	B-X
.	B-X
The	B-X
promising	B-X
outcomes	B-X
of	B-X
the	B-X
preliminary	B-X
in	B-X
silico	B-X
studies	B-X
included	B-X
in	B-X
this	B-X
review	B-X
support	B-X
that	B-X
PPAR-Î³	B-X
dependent	B-X
activation	B-X
of	B-X
central	B-X
PGC-1Î±	B-X
signaling	B-X
by	B-X
novel	B-X
glitazones	B-X
is	B-X
an	B-X
encouraging	B-X
strategy	B-X
to	B-X
enhance	B-X
the	B-X
oxy-radicals	B-X
detoxifying	B-X
system	B-X
,	B-X
antiinflammatory	B-X
responses	B-X
,	B-X
and	B-X
mitochondrial	B-X
biogenesis	B-X
required	B-X
for	B-X
neuroprotection	B-X
in	B-X
various	B-X
neurodegenerative	B-X
conditions	B-X
.	B-X

and	O
Chambon	O
,	O
P	O
.	O
<EOS>	B-X
Myofibroblast	B-X
reprogramming	B-X
required	B-X
neogenic	B-X
hair	B-X
follicles	B-X
,	B-X
which	B-X
triggered	B-X
bone	B-X
morphogenetic	B-X
protein	B-X
(	B-X
BMP	B-X
)	B-X
signaling	B-X
and	B-X
then	B-X
activation	B-X
of	B-X
adipocyte	B-X
transcription	B-X
factors	B-X
expressed	B-X
during	B-X
development	B-X
.	B-X
Overexpression	B-X
of	B-X
the	B-X
BMP	B-X
antagonist	B-X
Noggin	B-X
in	B-X
hair	B-X
follicles	B-X
or	B-X
deletion	B-X
of	B-X
the	B-X
BMP	B-X
receptor	B-X
in	B-X
myofibroblasts	B-X
prevented	B-X
adipocyte	B-X
formation	B-X
.	B-X
Adipocytes	B-X
formed	B-X
from	B-X
human	B-X
keloid	B-X
fibroblasts	B-X
either	B-X
when	B-X
treated	B-X
with	B-X
BMP	B-X
or	B-X
when	B-X
placed	B-X
with	B-X
human	B-X
hair	B-X
follicles	B-X
in	B-X
vitro	B-X
We	B-X
have	B-X
demonstrated	B-X
that	B-X
cytokine	B-X
thymic	B-X
stromal	B-X
lymphopoietin	B-X
(	B-X
TSLP	B-X
)	B-X
,	B-X
whose	B-X
expression	B-X
is	B-X
rapidly	B-X
induced	B-X
upon	B-X
keratinocyte-selective	B-X
ablation	B-X
of	B-X
retinoid	B-X
X	B-X
receptors	B-X
(	B-X
RXRs	B-X
)	B-X
-alpha	B-X
and	B-X
-beta	B-X
in	B-X
the	B-X
mouse	B-X
(	B-X
RXRalphabeta	B-X
(	B-X
ep-/-	B-X
)	B-X
mice	B-X
)	B-X
,	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
initiating	B-X
a	B-X
skin	B-X
and	B-X
systemic	B-X
atopic	B-X
dermatitis-like	B-X
phenotype	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
topical	B-X
application	B-X
of	B-X
the	B-X
physiologically	B-X
active	B-X
ligand	B-X
[	B-X
1alpha,25-	B-X
(	B-X
OH	B-X
)	B-X
(	B-X
2	B-X
)	B-X
D	B-X
(	B-X
3	B-X
)	B-X
;	B-X
calcitriol	B-X
]	B-X
of	B-X
the	B-X
vitamin	B-X
D	B-X
receptor	B-X
,	B-X
or	B-X
of	B-X
its	B-X
low-calcemic	B-X
analog	B-X
MC903	B-X
(	B-X
calcipotriol	B-X
;	B-X
Dovonex	B-X
)	B-X
,	B-X
induces	B-X
TSLP	B-X
expression	B-X
in	B-X
epidermal	B-X
keratinocytes	B-X
,	B-X
which	B-X
results	B-X
in	B-X
an	B-X
atopic	B-X
dermatitis-like	B-X
syndrome	B-X
mimicking	B-X
that	B-X
seen	B-X
in	B-X
RXRalphabeta	B-X
(	B-X
ep-/-	B-X
)	B-X
mutants	B-X
and	B-X
transgenic	B-X
mice	B-X
overexpressing	B-X
TSLP	B-X
in	B-X
keratinocytes	B-X
.	B-X
Furthermore	B-X
,	B-X
topical	B-X
application	B-X
of	B-X
retinoic	B-X
acid	B-X
receptor	B-X
RARgamma-selective	B-X
agonist	B-X
BMS961	B-X
also	B-X
induces	B-X
TSLP	B-X
expression	B-X
either	B-X
on	B-X
its	B-X
own	B-X
or	B-X
synergistically	B-X
with	B-X
1alpha,25-	B-X
(	B-X
OH	B-X
)	B-X
(	B-X
2	B-X
)	B-X
D	B-X
(	B-X
3	B-X
)	B-X
.	B-X
Our	B-X
data	B-X
demonstrate	B-X
that	B-X
RXR/vitamin	B-X
D	B-X
receptor	B-X
and	B-X
RXR/retinoic	B-X
acid	B-X
receptor-gamma	B-X
heterodimers	B-X
and	B-X
their	B-X
ligands	B-X
cell-autonomously	B-X
control	B-X
the	B-X
expression	B-X
of	B-X
TSLP	B-X
in	B-X
epidermal	B-X
keratinocytes	B-X
of	B-X
the	B-X
mouse	B-X
.	B-X

(	O
1979	O
)	O
Nucl	O
.	O
<EOS>	B-X
Seminars	B-X
in	B-X
nuclear	B-X
medicine	B-X
.	B-X
Forensic	B-X
radioimmunoassay	B-X
--	B-X
a	B-X
new	B-X
area	B-X
.	B-X
Radioassays	B-X
.	B-X
Tumor-localizing	B-X
radionuclides	B-X
in	B-X
retrospect	B-X
and	B-X
prospect	B-X
.	B-X

Acids	O
Res	O
.	O
<EOS>	B-X
Over	B-X
the	B-X
course	B-X
of	B-X
the	B-X
past	B-X
few	B-X
decades	B-X
,	B-X
the	B-X
theory	B-X
of	B-X
Hard	B-X
and	B-X
Soft	B-X
,	B-X
Acids	B-X
and	B-X
Bases	B-X
(	B-X
HSAB	B-X
)	B-X
has	B-X
proven	B-X
to	B-X
be	B-X
a	B-X
useful	B-X
tool	B-X
in	B-X
predicting	B-X
the	B-X
outcome	B-X
of	B-X
such	B-X
reactions	B-X
.	B-X
Mutagenesis	B-X
.	B-X
Plasma	B-X
acids	B-X
.	B-X

6	O
2731	O
-	O
2748	O
.	O
<EOS>	B-X
Studies	B-X
of	B-X
oxygen	B-X
binding	B-X
energy	B-X
to	B-X
hemoglobin	B-X
molecule	B-X
.	B-X
Proceedings	B-X
:	B-X
A	B-X
critical	B-X
analysis	B-X
of	B-X
the	B-X
``	B-X
flip-flop	B-X
''	B-X
phenomenon	B-X
in	B-X
the	B-X
two	B-X
compartment	B-X
pharmacokinetic	B-X
model	B-X
.	B-X
Proceedings	B-X
:	B-X
In	B-X
situ	B-X
fusion	B-X
and	B-X
granulation	B-X
of	B-X
a	B-X
chlorpromaide-urea	B-X
solid	B-X
solution	B-X
for	B-X
compressed	B-X
tablets	B-X
.	B-X

20	O
.	O
<EOS>	B-X
Aggregation	B-X
of	B-X
blood	B-X
platelets	B-X
by	B-X
adrenaline	B-X
and	B-X
its	B-X
uptake	B-X
.	B-X

Tsujimoto	O
,	O
Y	O
.	O
,	O
and	O
Suzuki	O
,	O
Y	O
.	O
<EOS>	B-X
Transcription	B-X
regulation	B-X
of	B-X
silk	B-X
genes	B-X
.	B-X
&	B-X
Suzuki	B-X
,	B-X
Y	B-X
.	B-X
The	B-X
DNA	B-X
sequence	B-X
of	B-X
Bombyx	B-X
mori	B-X
fibroin	B-X
gene	B-X
including	B-X
the	B-X
5	B-X
'	B-X
flanking	B-X
,	B-X
mRNA	B-X
coding	B-X
,	B-X
entire	B-X
intervening	B-X
and	B-X
fibroin	B-X
protein	B-X
coding	B-X
regions	B-X
.	B-X
[	B-X
Structure	B-X
and	B-X
function	B-X
of	B-X
the	B-X
silk	B-X
fibroin	B-X
gene	B-X
(	B-X
author	B-X
's	B-X
transl	B-X
)	B-X
]	B-X
.	B-X

(	O
1979	O
)	O
Cell	O
16	O
425	O
-	O
436	O
.	O

21	O
.	O

Jeffreys	O
,	O
A	O
.	O
<EOS>	B-X
Genetic	B-X
fingerprinting	B-X
.	B-X
In	B-X
this	B-X
interview	B-X
we	B-X
talk	B-X
with	B-X
Professor	B-X
Sir	B-X
Alec	B-X
Jeffreys	B-X
about	B-X
DNA	B-X
fingerprinting	B-X
,	B-X
his	B-X
wider	B-X
scientific	B-X
career	B-X
,	B-X
and	B-X
the	B-X
past	B-X
,	B-X
present	B-X
and	B-X
future	B-X
of	B-X
forensic	B-X
DNA	B-X
applications.The	B-X
podcast	B-X
with	B-X
excerpts	B-X
from	B-X
this	B-X
interview	B-X
is	B-X
available	B-X
at	B-X
:	B-X
http	B-X
:	B-X
//www.biomedcentral.com/biome/alec-jeffreys	B-X
.	B-X
Epidural	B-X
abscesses	B-X
.	B-X

J	O
.	O
,	O
and	O
Flavell	O
,	O
R	O
.	O
<EOS>	B-X
The	B-X
leukocyte	B-X
immunoglobulin-like	B-X
receptor	B-X
B	B-X
(	B-X
LILRB	B-X
)	B-X
family	B-X
members	B-X
are	B-X
negative	B-X
regulators	B-X
of	B-X
myeloid	B-X
cell	B-X
activation	B-X
.	B-X
We	B-X
investigated	B-X
how	B-X
LILRB	B-X
targeting	B-X
could	B-X
modulate	B-X
tumor-associated	B-X
myeloid	B-X
cell	B-X
function	B-X
.	B-X
LILRB2	B-X
antagonism	B-X
inhibited	B-X
receptor-mediated	B-X
activation	B-X
of	B-X
SHP1/2	B-X
and	B-X
enhanced	B-X
proinflammatory	B-X
responses	B-X
.	B-X
LILRB2	B-X
antagonism	B-X
also	B-X
inhibited	B-X
AKT	B-X
and	B-X
STAT6	B-X
activation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
M-CSF	B-X
and	B-X
IL-4	B-X
.	B-X
Transcriptome	B-X
analysis	B-X
revealed	B-X
that	B-X
LILRB2	B-X
antagonism	B-X
altered	B-X
genes	B-X
involved	B-X
in	B-X
cell	B-X
cytoskeleton	B-X
remodeling	B-X
,	B-X
lipid/cholesterol	B-X
metabolism	B-X
,	B-X
and	B-X
endosomal	B-X
sorting	B-X
pathways	B-X
,	B-X
as	B-X
well	B-X
as	B-X
changed	B-X
differentiation	B-X
gene	B-X
networks	B-X
associated	B-X
with	B-X
inflammatory	B-X
myeloid	B-X
cells	B-X
as	B-X
opposed	B-X
to	B-X
their	B-X
alternatively	B-X
activated	B-X
phenotype	B-X
.	B-X
LILRB2	B-X
blockade	B-X
effectively	B-X
suppressed	B-X
granulocytic	B-X
MDSC	B-X
and	B-X
Treg	B-X
infiltration	B-X
and	B-X
significantly	B-X
promoted	B-X
in	B-X
vivo	B-X
antitumor	B-X
effects	B-X
of	B-X
T	B-X
cell	B-X
immune	B-X
checkpoint	B-X
inhibitors	B-X
.	B-X
Furthermore	B-X
,	B-X
LILRB2	B-X
blockade	B-X
polarized	B-X
tumor-infiltrating	B-X
myeloid	B-X
cells	B-X
from	B-X
non-small	B-X
cell	B-X
lung	B-X
carcinoma	B-X
tumor	B-X
tissues	B-X
toward	B-X
an	B-X
inflammatory	B-X
phenotype	B-X
.	B-X
Our	B-X
studies	B-X
suggest	B-X
that	B-X
LILRB2	B-X
can	B-X
potentially	B-X
act	B-X
as	B-X
a	B-X
myeloid	B-X
immune	B-X
checkpoint	B-X
by	B-X
reprogramming	B-X
tumor-associated	B-X
myeloid	B-X
cells	B-X
and	B-X
provoking	B-X
antitumor	B-X
immunity	B-X
.	B-X

A	O
.	O

(	O
1977	O
)	O
Cell	O
12	O
,	O
1097	O
-	O
1108	O
.	O

22	O
.	O

Tilghman	O
,	O
S	O
.	O
<EOS>	B-X
Shirley	B-X
Tilghman	B-X
,	B-X
PhD	B-X
.	B-X
Not	B-X
just	B-X
Salk	B-X
.	B-X
It	B-X
's	B-X
all	B-X
about	B-X
the	B-X
talent	B-X
.	B-X
Interview	B-X
with	B-X
president	B-X
Shirley	B-X
Tilghman	B-X
(	B-X
Princeton	B-X
University	B-X
)	B-X
.	B-X

M	O
.	O
,	O
Tiemeier	O
,	O
D	O
.	O

C	O
.	O
,	O
Seidman	O
,	O
J	O
.	O
<EOS>	B-X
Using	B-X
a	B-X
system	B-X
called	B-X
``	B-X
ICE	B-X
''	B-X
(	B-X
inducible	B-X
changes	B-X
to	B-X
the	B-X
epigenome	B-X
)	B-X
,	B-X
we	B-X
find	B-X
that	B-X
the	B-X
act	B-X
of	B-X
faithful	B-X
DNA	B-X
repair	B-X
advances	B-X
aging	B-X
at	B-X
physiological	B-X
,	B-X
cognitive	B-X
,	B-X
and	B-X
molecular	B-X
levels	B-X
,	B-X
including	B-X
erosion	B-X
of	B-X
the	B-X
epigenetic	B-X
landscape	B-X
,	B-X
cellular	B-X
exdifferentiation	B-X
,	B-X
senescence	B-X
,	B-X
and	B-X
advancement	B-X
of	B-X
the	B-X
DNA	B-X
methylation	B-X
clock	B-X
,	B-X
which	B-X
can	B-X
be	B-X
reversed	B-X
by	B-X
OSK-mediated	B-X
rejuvenation	B-X
.	B-X
Congenital	B-X
heart	B-X
disease	B-X
(	B-X
CHD	B-X
)	B-X
is	B-X
present	B-X
in	B-X
1	B-X
%	B-X
of	B-X
live	B-X
births	B-X
,	B-X
yet	B-X
identification	B-X
of	B-X
causal	B-X
mutations	B-X
remains	B-X
challenging	B-X
.	B-X
We	B-X
hypothesized	B-X
that	B-X
genetic	B-X
determinants	B-X
for	B-X
CHDs	B-X
may	B-X
lie	B-X
in	B-X
the	B-X
protein	B-X
interactomes	B-X
of	B-X
transcription	B-X
factors	B-X
whose	B-X
mutations	B-X
cause	B-X
CHDs	B-X
.	B-X
Defining	B-X
the	B-X
interactomes	B-X
of	B-X
two	B-X
transcription	B-X
factors	B-X
haplo-insufficient	B-X
in	B-X
CHD	B-X
,	B-X
GATA4	B-X
and	B-X
TBX5	B-X
,	B-X
within	B-X
human	B-X
cardiac	B-X
progenitors	B-X
,	B-X
and	B-X
integrating	B-X
the	B-X
results	B-X
with	B-X
nearly	B-X
9,000	B-X
exomes	B-X
from	B-X
proband-parent	B-X
trios	B-X
revealed	B-X
an	B-X
enrichment	B-X
of	B-X
de	B-X
novo	B-X
missense	B-X
variants	B-X
associated	B-X
with	B-X
CHD	B-X
within	B-X
the	B-X
interactomes	B-X
.	B-X
Scoring	B-X
variants	B-X
of	B-X
interactome	B-X
members	B-X
based	B-X
on	B-X
residue	B-X
,	B-X
gene	B-X
,	B-X
and	B-X
proband	B-X
features	B-X
identified	B-X
likely	B-X
CHD-causing	B-X
genes	B-X
,	B-X
including	B-X
the	B-X
epigenetic	B-X
reader	B-X
GLYR1	B-X
.	B-X

C	O
.	O
,	O
Matija	O
Peterlin	O
,	O
B	O
.	O
,	O

Sullivan	O
,	O
M	O
.	O
,	O
Maizel	O
,	O
J	O
.	O
<EOS>	B-X
Characterization	B-X
of	B-X
integrated	B-X
Moloney	B-X
Sarcoma	B-X
proviruses	B-X
and	B-X
flanking	B-X
host	B-X
sequences	B-X
cloned	B-X
in	B-X
bacteriophage	B-X
lambda	B-X
.	B-X
Ribosomal	B-X
binding	B-X
sites	B-X
on	B-X
poliovirus	B-X
RNA	B-X
.	B-X
Secondary	B-X
structure	B-X
map	B-X
of	B-X
psoralen-crosslinked	B-X
adenovirus	B-X
DNA	B-X
studied	B-X
by	B-X
electron	B-X
microscopy	B-X
.	B-X

V	O
.	O
,	O
and	O
Leder	O
,	O
P	O
.	O
<EOS>	B-X
We	B-X
have	B-X
derived	B-X
and	B-X
mated	B-X
separate	B-X
strains	B-X
of	B-X
transgenic	B-X
mice	B-X
that	B-X
carry	B-X
either	B-X
the	B-X
v-Ha-ras	B-X
or	B-X
the	B-X
c-myc	B-X
gene	B-X
driven	B-X
by	B-X
the	B-X
mouse	B-X
mammary	B-X
tumor	B-X
virus	B-X
(	B-X
MMTV	B-X
)	B-X
promoter/enhancer	B-X
.	B-X
Mice	B-X
carrying	B-X
the	B-X
MMTV/v-Ha-ras	B-X
transgene	B-X
manifest	B-X
two	B-X
distinct	B-X
disturbances	B-X
of	B-X
cell	B-X
growth	B-X
.	B-X
When	B-X
the	B-X
MMTV/v-Ha-ras	B-X
and	B-X
MMTV/c-myc	B-X
strains	B-X
are	B-X
crossed	B-X
to	B-X
yield	B-X
hybrid	B-X
mice	B-X
,	B-X
their	B-X
joint	B-X
action	B-X
results	B-X
in	B-X
a	B-X
dramatic	B-X
and	B-X
synergistic	B-X
acceleration	B-X
of	B-X
tumor	B-X
formation	B-X
.	B-X
By	B-X
crossing	B-X
Tg.AC	B-X
mice	B-X
on	B-X
an	B-X
inbred	B-X
FVB	B-X
background	B-X
to	B-X
other	B-X
inbred	B-X
strains	B-X
,	B-X
F1	B-X
mice	B-X
were	B-X
created	B-X
that	B-X
could	B-X
be	B-X
analysed	B-X
using	B-X
genome	B-X
wide	B-X
,	B-X
single	B-X
nucleotide	B-X
polymorphism	B-X
(	B-X
SNP	B-X
)	B-X
screens	B-X
.	B-X

(	O
1978	O
)	O
Proc	O
.	O
<EOS>	B-X
Suppressor	B-X
cells	B-X
in	B-X
immunosenescence	B-X
.	B-X
Psoriatic	B-X
arthritis	B-X
.	B-X
By	B-X
using	B-X
a	B-X
formulation	B-X
of	B-X
Kimura	B-X
and	B-X
Crow	B-X
[	B-X
Kimura	B-X
,	B-X
M.	B-X
&	B-X
Crow	B-X
,	B-X
J.	B-X
F.	B-X
(	B-X
1978	B-X
)	B-X
Proc	B-X
.	B-X
Echocardiography	B-X
.	B-X

Natl	O
.	O
<EOS>	B-X
Obituaries	B-X
.	B-X
Corrigendum	B-X
to	B-X
``	B-X
Visceral	B-X
Adiposity	B-X
Index	B-X
Levels	B-X
in	B-X
Patients	B-X
with	B-X
Hypothyroidism	B-X
''	B-X
[	B-X
J	B-X
Natl	B-X
Med	B-X
Assoc	B-X
110	B-X
(	B-X
6	B-X
)	B-X
(	B-X
2018	B-X
)	B-X
606-613	B-X
]	B-X
.	B-X
Sodium	B-X
channels	B-X
in	B-X
the	B-X
cytoplasm	B-X
of	B-X
Schwann	B-X
cells	B-X
.	B-X
Proc	B-X
.	B-X
Natl	B-X
.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
87	B-X
(	B-X
1990	B-X
)	B-X
9290-9294	B-X
.	B-X
Imhotep	B-X
.	B-X

Acad	O
.	O
<EOS>	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2018	B-X
)	B-X
,	B-X
1423	B-X
,	B-X
166-175	B-X
.	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2018	B-X
)	B-X
,	B-X
1433	B-X
,	B-X
29-40	B-X
.	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2020	B-X
)	B-X
,	B-X
1462	B-X
,	B-X
65-78	B-X
.	B-X
In	B-X
Memoriam	B-X
Acad	B-X
.	B-X
Prof.	B-X
Dr.	B-X
LjubiÅ¡a	B-X
RakiÄ	B-X
(	B-X
1931-2022	B-X
)	B-X
.	B-X

Sci	O
.	O
<EOS>	B-X
Molecules	B-X
and	B-X
Biomaterial	B-X
Technologies	B-X
Affecting	B-X
Stem	B-X
Cell	B-X
Differentiation	B-X
.	B-X

U	O
.	O
S	O
.	O
A	O
.	O
<EOS>	B-X
NUTRITIONAL	B-X
WELL-BEING	B-X
IN	B-X
THE	B-X
U.S.A.	B-X
Nutritional	B-X
status	B-X
,	B-X
U.S.A	B-X
.	B-X
Abortion	B-X
in	B-X
U.S.A	B-X
.	B-X
Persons	B-X
with	B-X
disabilities	B-X
represent	B-X
a	B-X
growing	B-X
population	B-X
in	B-X
both	B-X
the	B-X
European	B-X
Union	B-X
(	B-X
EU	B-X
)	B-X
and	B-X
the	B-X
United	B-X
States	B-X
(	B-X
USA	B-X
)	B-X
.	B-X
The	B-X
EU	B-X
has	B-X
made	B-X
substantial	B-X
policy	B-X
progress	B-X
to	B-X
support	B-X
telework	B-X
,	B-X
but	B-X
persons	B-X
with	B-X
disabilities	B-X
have	B-X
had	B-X
only	B-X
limited	B-X
long-term	B-X
success	B-X
in	B-X
telework	B-X
initiatives	B-X
due	B-X
to	B-X
lack	B-X
of	B-X
work	B-X
support	B-X
services	B-X
.	B-X
The	B-X
USA	B-X
has	B-X
generally	B-X
strong	B-X
support	B-X
services	B-X
but	B-X
lacks	B-X
telework	B-X
policy	B-X
infrastructure	B-X
.	B-X
The	B-X
EU	B-X
and	B-X
the	B-X
USA	B-X
can	B-X
benefit	B-X
from	B-X
collaborative	B-X
work	B-X
to	B-X
enhance	B-X
their	B-X
complementary	B-X
strengths	B-X
.	B-X

75	O
,	O
725	O
-	O
729	O
.	O
<EOS>	B-X
Behavioral	B-X
effects	B-X
of	B-X
hypothalamic	B-X
releasing	B-X
hormones	B-X
in	B-X
animals	B-X
and	B-X
men	B-X
.	B-X

23	O
.	O

Fiddes	O
,	O
J	O
.	O
<EOS>	B-X
Structure	B-X
,	B-X
expression	B-X
,	B-X
and	B-X
evolution	B-X
of	B-X
the	B-X
genes	B-X
for	B-X
the	B-X
human	B-X
glycoprotein	B-X
hormones	B-X
.	B-X
A	B-X
290	B-X
nucleotide	B-X
long	B-X
region	B-X
of	B-X
the	B-X
bacteriophage	B-X
G4	B-X
genome	B-X
including	B-X
the	B-X
end	B-X
of	B-X
the	B-X
overlapping	B-X
genes	B-X
D	B-X
and	B-X
E	B-X
,	B-X
the	B-X
entire	B-X
gene	B-X
J	B-X
and	B-X
the	B-X
untranslated	B-X
region	B-X
between	B-X
genes	B-X
J	B-X
and	B-X
F	B-X
has	B-X
been	B-X
sequenced	B-X
and	B-X
compared	B-X
with	B-X
the	B-X
same	B-X
region	B-X
in	B-X
bacteriophage	B-X
phiX174	B-X
.	B-X
Deletions	B-X
,	B-X
insertions	B-X
,	B-X
duplications	B-X
and	B-X
single	B-X
base	B-X
changes	B-X
in	B-X
G4	B-X
relative	B-X
to	B-X
phiX174	B-X
have	B-X
resulted	B-X
in	B-X
the	B-X
following	B-X
changes	B-X
:	B-X
the	B-X
loss	B-X
of	B-X
the	B-X
phiX174	B-X
overlapping	B-X
gene	B-X
Dtermination	B-X
and	B-X
gene	B-X
J	B-X
initiation	B-X
codons	B-X
,	B-X
resulting	B-X
in	B-X
their	B-X
separation	B-X
by	B-X
32	B-X
untranslated	B-X
nucleotides	B-X
;	B-X
the	B-X
deletion	B-X
of	B-X
one	B-X
third	B-X
of	B-X
the	B-X
gene	B-X
J	B-X
coding	B-X
region	B-X
,	B-X
so	B-X
that	B-X
the	B-X
G4	B-X
protein	B-X
is	B-X
only	B-X
24	B-X
amino	B-X
acids	B-X
long	B-X
compared	B-X
with	B-X
37	B-X
amino	B-X
acids	B-X
in	B-X
phiX174	B-X
;	B-X
and	B-X
the	B-X
establishment	B-X
of	B-X
a	B-X
long	B-X
untranslated	B-X
region	B-X
between	B-X
G4	B-X
genes	B-X
J	B-X
and	B-X
F	B-X
,	B-X
which	B-X
despite	B-X
many	B-X
nucleotide	B-X
changes	B-X
retains	B-X
the	B-X
ability	B-X
to	B-X
form	B-X
a	B-X
stable	B-X
hairpin	B-X
loop	B-X
in	B-X
the	B-X
same	B-X
place	B-X
and	B-X
with	B-X
the	B-X
same	B-X
geometry	B-X
as	B-X
in	B-X
phiX174	B-X
.	B-X
The	B-X
G4	B-X
overlapping	B-X
gene	B-X
E	B-X
is	B-X
longer	B-X
than	B-X
in	B-X
phiX174	B-X
and	B-X
extends	B-X
beyond	B-X
gene	B-X
D.	B-X
Sixteen	B-X
nucleotides	B-X
at	B-X
the	B-X
end	B-X
of	B-X
genes	B-X
D	B-X
and	B-X
E	B-X
in	B-X
phiX174	B-X
are	B-X
duplicated	B-X
in	B-X
G4	B-X
before	B-X
gene	B-X
J	B-X
.	B-X

C	O
.	O
,	O
Seeburg	O
,	O
P	O
.	O
<EOS>	B-X
Nuclear	B-X
pre-mRNA	B-X
editing	B-X
by	B-X
selective	B-X
adenosine	B-X
deamination	B-X
(	B-X
A-to-I	B-X
editing	B-X
)	B-X
occurs	B-X
in	B-X
all	B-X
organisms	B-X
from	B-X
C.	B-X
elegans	B-X
to	B-X
humans	B-X
.	B-X
Pain	B-X
alters	B-X
opioid	B-X
reinforcement	B-X
,	B-X
presumably	B-X
via	B-X
neuroadaptations	B-X
within	B-X
ascending	B-X
pain	B-X
pathways	B-X
interacting	B-X
with	B-X
the	B-X
limbic	B-X
system	B-X
.	B-X
Chronic	B-X
constriction	B-X
injury	B-X
(	B-X
CCI	B-X
)	B-X
of	B-X
the	B-X
sciatic	B-X
nerve	B-X
elevated	B-X
Homer1b/c	B-X
and/or	B-X
Homer2a/b	B-X
expression	B-X
within	B-X
all	B-X
mesolimbic	B-X
structures	B-X
examined	B-X
and	B-X
for	B-X
the	B-X
most	B-X
part	B-X
,	B-X
the	B-X
Homer	B-X
increases	B-X
coincided	B-X
with	B-X
elevated	B-X
mGluR5	B-X
,	B-X
GluN2A/B	B-X
,	B-X
and	B-X
the	B-X
activational	B-X
state	B-X
of	B-X
various	B-X
down-stream	B-X
kinases	B-X
.	B-X
Behaviorally	B-X
,	B-X
CCI	B-X
mice	B-X
showed	B-X
pain	B-X
hypersensitivity	B-X
and	B-X
a	B-X
conditioned	B-X
place-aversion	B-X
(	B-X
CPA	B-X
)	B-X
at	B-X
a	B-X
low	B-X
heroin	B-X
dose	B-X
that	B-X
supported	B-X
conditioned	B-X
place-preference	B-X
(	B-X
CPP	B-X
)	B-X
in	B-X
naÃ¯ve	B-X
controls	B-X
.	B-X
Null	B-X
mutations	B-X
of	B-X
Homer1a	B-X
,	B-X
Homer1	B-X
,	B-X
and	B-X
Homer2	B-X
,	B-X
as	B-X
well	B-X
as	B-X
transgenic	B-X
disruption	B-X
of	B-X
mGluR5-Homer	B-X
interactions	B-X
,	B-X
either	B-X
attenuated	B-X
or	B-X
completely	B-X
blocked	B-X
low-dose	B-X
heroin	B-X
CPP	B-X
,	B-X
and	B-X
none	B-X
of	B-X
the	B-X
CCI	B-X
mutant	B-X
strains	B-X
exhibited	B-X
heroin-induced	B-X
CPA	B-X
.	B-X
However	B-X
,	B-X
heroin	B-X
CPP	B-X
did	B-X
not	B-X
depend	B-X
upon	B-X
full	B-X
Homer1c	B-X
expression	B-X
within	B-X
the	B-X
nucleus	B-X
accumbens	B-X
(	B-X
NAC	B-X
)	B-X
,	B-X
as	B-X
CPP	B-X
occurred	B-X
in	B-X
controls	B-X
infused	B-X
locally	B-X
with	B-X
small	B-X
hairpin	B-X
RNA-Homer1c	B-X
,	B-X
although	B-X
intra-NAC	B-X
and/or	B-X
intrathecal	B-X
cDNA-Homer1c	B-X
,	B-X
-Homer1a	B-X
,	B-X
and	B-X
-Homer2b	B-X
infusions	B-X
(	B-X
to	B-X
best	B-X
mimic	B-X
CCI	B-X
's	B-X
effects	B-X
)	B-X
were	B-X
sufficient	B-X
to	B-X
blunt	B-X
heroin	B-X
CPP	B-X
in	B-X
uninjured	B-X
mice	B-X
.	B-X
However	B-X
,	B-X
arguing	B-X
against	B-X
a	B-X
simple	B-X
role	B-X
for	B-X
CCI-induced	B-X
increases	B-X
in	B-X
either	B-X
spinal	B-X
or	B-X
NAC	B-X
Homer	B-X
expression	B-X
for	B-X
heroin	B-X
CPA	B-X
,	B-X
cDNA	B-X
infusion	B-X
of	B-X
our	B-X
various	B-X
cDNA	B-X
constructs	B-X
either	B-X
did	B-X
not	B-X
affect	B-X
(	B-X
intrathecal	B-X
)	B-X
or	B-X
attenuated	B-X
(	B-X
NAC	B-X
)	B-X
heroin	B-X
CPA	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
data	B-X
implicate	B-X
increases	B-X
in	B-X
glutamate	B-X
receptor/Homer/kinase	B-X
activity	B-X
within	B-X
limbic	B-X
structures	B-X
,	B-X
perhaps	B-X
outside	B-X
the	B-X
NAC	B-X
,	B-X
as	B-X
possibly	B-X
critical	B-X
for	B-X
switching	B-X
the	B-X
incentive	B-X
motivational	B-X
properties	B-X
of	B-X
heroin	B-X
following	B-X
nerve	B-X
injury	B-X
,	B-X
which	B-X
has	B-X
relevance	B-X
for	B-X
opioid	B-X
psychopharmacology	B-X
in	B-X
individuals	B-X
suffering	B-X
from	B-X
neuropathic	B-X
pain	B-X
.	B-X

H	O
.	O
,	O
DeNoto	O
,	O
F	O
.	O

M	O
.	O
,	O
Hallewell	O
,	O
R	O
.	O
<EOS>	B-X
These	B-X
small	B-X
alterations	B-X
in	B-X
conformational	B-X
stability	B-X
do	B-X
not	B-X
correlate	B-X
with	B-X
the	B-X
large	B-X
increases	B-X
in	B-X
resistance	B-X
to	B-X
thermal	B-X
inactivation	B-X
following	B-X
substitution	B-X
of	B-X
free	B-X
Cys	B-X
in	B-X
both	B-X
HSOD	B-X
and	B-X
BSOD	B-X
(	B-X
McRee	B-X
,	B-X
D.E.	B-X
,	B-X
Redford	B-X
,	B-X
S.M.	B-X
,	B-X
Getzoff	B-X
,	B-X
E.D.	B-X
,	B-X
Lepock	B-X
,	B-X
J.R.	B-X
,	B-X
Hallewell	B-X
,	B-X
R.A.	B-X
,	B-X
and	B-X
Tainer	B-X
,	B-X
J.A	B-X
.	B-X
265	B-X
,	B-X
14234-14241	B-X
and	B-X
Hallewell	B-X
,	B-X
R.A.	B-X
,	B-X
Imlay	B-X
,	B-X
K.C.	B-X
,	B-X
Laria	B-X
,	B-X
I.	B-X
,	B-X
Gallegos	B-X
,	B-X
C.	B-X
,	B-X
Fong	B-X
,	B-X
N.	B-X
,	B-X
Irvine	B-X
,	B-X
B.	B-X
,	B-X
Getzoff	B-X
,	B-X
E.D.	B-X
,	B-X
Tainer	B-X
,	B-X
J.A.	B-X
,	B-X
Cubelli	B-X
,	B-X
D.E.	B-X
,	B-X
Bielski	B-X
,	B-X
B.H.J.	B-X
,	B-X
Olson	B-X
,	B-X
P.	B-X
,	B-X
Mallenbach	B-X
,	B-X
G.T.	B-X
,	B-X
and	B-X
Cousens	B-X
,	B-X
L.S	B-X
.	B-X
A	B-X
comparison	B-X
of	B-X
the	B-X
second-order	B-X
association	B-X
rates	B-X
of	B-X
both	B-X
uncharged	B-X
mutants	B-X
with	B-X
9	B-X
serine	B-X
proteinases	B-X
indicated	B-X
that	B-X
each	B-X
reacted	B-X
similarly	B-X
to	B-X
either	B-X
the	B-X
normal	B-X
plasma	B-X
inhibitor	B-X
or	B-X
to	B-X
a	B-X
mutant	B-X
containing	B-X
valine	B-X
in	B-X
this	B-X
position	B-X
(	B-X
Travis	B-X
,	B-X
J.	B-X
,	B-X
Owen	B-X
,	B-X
M.	B-X
,	B-X
George	B-X
,	B-X
P.	B-X
,	B-X
Carrell	B-X
,	B-X
R.	B-X
,	B-X
Rosenberg	B-X
,	B-X
S.	B-X
,	B-X
Hallewell	B-X
,	B-X
R.	B-X
A.	B-X
,	B-X
and	B-X
Barr	B-X
,	B-X
P.	B-X
J	B-X
.	B-X
However	B-X
,	B-X
alteration	B-X
from	B-X
an	B-X
uncharged	B-X
to	B-X
a	B-X
charged	B-X
residue	B-X
may	B-X
cause	B-X
considerable	B-X
changes	B-X
in	B-X
both	B-X
inhibitor	B-X
specificity	B-X
and	B-X
reactivity	B-X
as	B-X
noted	B-X
here	B-X
with	B-X
the	B-X
cysteine	B-X
derivatives	B-X
and	B-X
also	B-X
previously	B-X
with	B-X
a	B-X
natural	B-X
variant	B-X
in	B-X
which	B-X
methionine	B-X
358	B-X
to	B-X
arginine	B-X
358	B-X
conversion	B-X
resulted	B-X
in	B-X
the	B-X
production	B-X
of	B-X
a	B-X
potent	B-X
thrombin	B-X
inhibitor	B-X
(	B-X
Owen	B-X
,	B-X
M.	B-X
C.	B-X
,	B-X
Brennan	B-X
,	B-X
S.	B-X
O.	B-X
,	B-X
Lewis	B-X
,	B-X
J.	B-X
H.	B-X
,	B-X
and	B-X
Carrell	B-X
,	B-X
R.	B-X
W.	B-X
(	B-X
1983	B-X
)	B-X
N.	B-X
Engl	B-X
.	B-X

A	O
.	O
,	O
<EOS>	B-X
A	B-X
4-year-old	B-X
boy	B-X
with	B-X
a	B-X
ventricular	B-X
mass	B-X
.	B-X
A	B-X
Segmental	B-X
Molar	B-X
Uprighting	B-X
Technique	B-X
.	B-X
Germplasm	B-X
Resources	B-X
and	B-X
Strategy	B-X
for	B-X
Genetic	B-X
Breeding	B-X
of	B-X

Baxter	O
,	O
J	O
.	O
<EOS>	B-X
Randomized	B-X
control	B-X
trials	B-X
(	B-X
RCTs	B-X
)	B-X
involving	B-X
any	B-X
aspect	B-X
of	B-X
CD	B-X
technique	B-X
from	B-X
Jan.	B-X
1	B-X
,	B-X
2005	B-X
,	B-X
to	B-X
Sept.	B-X
1	B-X
,	B-X
2012	B-X
,	B-X
were	B-X
evaluated	B-X
to	B-X
update	B-X
a	B-X
previous	B-X
systematic	B-X
review	B-X
.	B-X
The	B-X
scream	B-X
.	B-X
2.7	B-X
Adolescent	B-X
Nutrition	B-X
:	B-X
Issues	B-X
and	B-X
Actions	B-X
.	B-X
Rural	B-X
matters	B-X
.	B-X

D	O
.	O
,	O
and	O
Goodman	O
,	O
H	O
.	O
<EOS>	B-X
However	B-X
,	B-X
evidence	B-X
guiding	B-X
the	B-X
duration	B-X
of	B-X
prophylactic	B-X
treatment	B-X
remains	B-X
limited	B-X
.	B-X
To	B-X
evaluate	B-X
the	B-X
possibility	B-X
that	B-X
some	B-X
of	B-X
the	B-X
metabolic	B-X
effects	B-X
of	B-X
GH	B-X
in	B-X
rat	B-X
adipose	B-X
tissue	B-X
depend	B-X
upon	B-X
phosphorylation-dephosphorylation	B-X
reactions	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
the	B-X
isoquinoline	B-X
sulfonamide	B-X
family	B-X
(	B-X
H-7	B-X
,	B-X
H-8	B-X
,	B-X
and	B-X
HA-1004	B-X
)	B-X
of	B-X
protein	B-X
kinase	B-X
inhibitors	B-X
on	B-X
the	B-X
actions	B-X
of	B-X
GH	B-X
.	B-X
In	B-X
the	B-X
concentration	B-X
range	B-X
of	B-X
50-200	B-X
microM	B-X
,	B-X
H-7	B-X
,	B-X
H-8	B-X
,	B-X
and	B-X
HA-1004	B-X
completely	B-X
blocked	B-X
lipolysis	B-X
in	B-X
response	B-X
to	B-X
the	B-X
combination	B-X
of	B-X
100	B-X
ng/ml	B-X
dexamethasone	B-X
and	B-X
30	B-X
ng/ml	B-X
human	B-X
GH	B-X
in	B-X
segments	B-X
of	B-X
epididymal	B-X
fat	B-X
from	B-X
normal	B-X
rats	B-X
,	B-X
but	B-X
were	B-X
less	B-X
effective	B-X
in	B-X
blocking	B-X
lipolysis	B-X
in	B-X
response	B-X
to	B-X
either	B-X
1	B-X
mM	B-X
(	B-X
Bu	B-X
)	B-X
2cAMP	B-X
or	B-X
1	B-X
ng/ml	B-X
isoproterenol	B-X
,	B-X
which	B-X
are	B-X
known	B-X
to	B-X
depend	B-X
upon	B-X
activation	B-X
of	B-X
protein	B-X
kinase-A	B-X
.	B-X
Activation	B-X
of	B-X
protein	B-X
kinase-C	B-X
with	B-X
phorbol	B-X
myristate	B-X
nearly	B-X
doubled	B-X
the	B-X
rate	B-X
of	B-X
glucose	B-X
oxidation	B-X
in	B-X
segments	B-X
of	B-X
normal	B-X
adipose	B-X
tissue	B-X
,	B-X
and	B-X
this	B-X
insulin-like	B-X
response	B-X
was	B-X
completely	B-X
inhibited	B-X
with	B-X
200	B-X
microM	B-X
H-7	B-X
.	B-X
At	B-X
concentrations	B-X
as	B-X
high	B-X
as	B-X
500	B-X
microM	B-X
,	B-X
H-7	B-X
,	B-X
H-8	B-X
,	B-X
and	B-X
HA-1004	B-X
failed	B-X
to	B-X
inhibit	B-X
the	B-X
insulin-like	B-X
response	B-X
to	B-X
GH	B-X
in	B-X
tissue	B-X
segments	B-X
of	B-X
either	B-X
normal	B-X
or	B-X
hypophysectomized	B-X
rats	B-X
.	B-X
However	B-X
,	B-X
when	B-X
200	B-X
microM	B-X
H-7	B-X
or	B-X
H-8	B-X
,	B-X
but	B-X
not	B-X
HA-1004	B-X
,	B-X
was	B-X
present	B-X
during	B-X
the	B-X
first	B-X
3	B-X
h	B-X
of	B-X
treatment	B-X
with	B-X
GH	B-X
,	B-X
it	B-X
prolonged	B-X
the	B-X
duration	B-X
of	B-X
the	B-X
insulin-like	B-X
response	B-X
(	B-X
acceleration	B-X
of	B-X
glucose	B-X
oxidation	B-X
)	B-X
from	B-X
its	B-X
normal	B-X
termination	B-X
within	B-X
2-3	B-X
h	B-X
to	B-X
more	B-X
than	B-X
4	B-X
h.	B-X
Identical	B-X
results	B-X
were	B-X
obtained	B-X
with	B-X
5	B-X
micrograms/ml	B-X
actinomycin-D	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
H-7	B-X
or	B-X
H-8	B-X
was	B-X
reversible	B-X
and	B-X
required	B-X
the	B-X
continuous	B-X
presence	B-X
of	B-X
these	B-X
agents	B-X
,	B-X
whereas	B-X
actinomycin-D	B-X
was	B-X
required	B-X
only	B-X
during	B-X
the	B-X
first	B-X
60	B-X
min	B-X
after	B-X
GH	B-X
.	B-X
Termination	B-X
of	B-X
the	B-X
insulin-like	B-X
response	B-X
normally	B-X
is	B-X
followed	B-X
by	B-X
a	B-X
period	B-X
of	B-X
several	B-X
hours	B-X
in	B-X
which	B-X
the	B-X
tissues	B-X
are	B-X
refractory	B-X
to	B-X
further	B-X
insulin-like	B-X
stimulation	B-X
by	B-X
GH	B-X
.	B-X
When	B-X
actinomycin-D	B-X
,	B-X
H-7	B-X
,	B-X
H-8	B-X
,	B-X
or	B-X
HA-1004	B-X
was	B-X
added	B-X
to	B-X
tissues	B-X
of	B-X
hypophysectomized	B-X
rats	B-X
60	B-X
min	B-X
after	B-X
GH	B-X
,	B-X
the	B-X
insulin-like	B-X
response	B-X
terminated	B-X
at	B-X
its	B-X
normal	B-X
time	B-X
,	B-X
but	B-X
the	B-X
tissues	B-X
were	B-X
not	B-X
refractory	B-X
to	B-X
insulin-like	B-X
stimulation	B-X
upon	B-X
reexposure	B-X
to	B-X
GH	B-X
.	B-X
These	B-X
agents	B-X
also	B-X
prevented	B-X
GH	B-X
from	B-X
sustaining	B-X
refractoriness	B-X
in	B-X
normal	B-X
adipose	B-X
tissue	B-X
.	B-X

M	O
.	O
<EOS>	B-X
Erratum	B-X
for	B-X
the	B-X
Report	B-X
``	B-X
Worldwide	B-X
evidence	B-X
of	B-X
a	B-X
unimodal	B-X
relationship	B-X
between	B-X
productivity	B-X
and	B-X
plant	B-X
species	B-X
richness	B-X
,	B-X
''	B-X
by	B-X
Lauchlan	B-X
H.	B-X
Fraser	B-X
,	B-X
J.	B-X
Pither	B-X
,	B-X
A.	B-X
Jentsch	B-X
,	B-X
M.	B-X
Sternberg	B-X
,	B-X
M.	B-X
Zobel	B-X
,	B-X
D.	B-X
Askarizadeh	B-X
,	B-X
S.	B-X
Bartha	B-X
,	B-X
C.	B-X
Beierkuhnlein	B-X
,	B-X
J	B-X
.	B-X
A.	B-X
Bennett	B-X
,	B-X
A.	B-X
Bittel	B-X
,	B-X
B.	B-X
Boldgiv	B-X
,	B-X
I.	B-X
I.	B-X
Boldrini	B-X
,	B-X
E.	B-X
Bork	B-X
,	B-X
L.	B-X
Brown	B-X
,	B-X
M.	B-X
Cabido	B-X
,	B-X
J.	B-X
Cahill	B-X
,	B-X
C.	B-X
N.	B-X
Carlyle	B-X
,	B-X
G.	B-X
Campetella	B-X
,	B-X
S.	B-X
Chelli	B-X
,	B-X
O.	B-X
Cohen	B-X
,	B-X
A.-M.	B-X
Csergo	B-X
,	B-X
S.	B-X
DÃ­az	B-X
,	B-X
L.	B-X
Enrico	B-X
,	B-X
D.	B-X
Ensing	B-X
,	B-X
A.	B-X
Fidelis	B-X
,	B-X
J.	B-X
D.	B-X
Fridley	B-X
,	B-X
B	B-X
.	B-X
Foster	B-X
,	B-X
H.	B-X
Garris	B-X
,	B-X
J.	B-X
R.	B-X
Goheen	B-X
,	B-X
H.	B-X
A.	B-X
L.	B-X
Henry	B-X
,	B-X
M.	B-X
Hohn	B-X
,	B-X
M.	B-X
H.	B-X
Jouri	B-X
,	B-X
J.	B-X
Klironomos	B-X
,	B-X
K.	B-X
Koorem	B-X
,	B-X
R.	B-X
Lawrence-Lodge	B-X
,	B-X
R.	B-X
Long	B-X
,	B-X
P.	B-X
Manning	B-X
,	B-X
R.	B-X
Mitchell	B-X
,	B-X
M.	B-X
Moora	B-X
,	B-X
S.	B-X
C.	B-X
MÃ¼ller	B-X
,	B-X
C.	B-X
Nabinger	B-X
,	B-X
K.	B-X
Naseri	B-X
,	B-X
G.	B-X
E.	B-X
Overbeck	B-X
,	B-X
T.	B-X
M.	B-X
Palmer	B-X
,	B-X
S.	B-X
Parsons	B-X
,	B-X
M.	B-X
Pesek	B-X
,	B-X
V.	B-X
D.	B-X
Pillar	B-X
,	B-X
R.	B-X
M.	B-X
Pringle	B-X
,	B-X
K.	B-X
Roccaforte	B-X
,	B-X
A.	B-X
Schmidt	B-X
,	B-X
Z.	B-X
Shang	B-X
,	B-X
R.	B-X
Stahlmann	B-X
,	B-X
G.	B-X
C.	B-X
Stotz	B-X
,	B-X
S.	B-X
Sugiyama	B-X
,	B-X
S.	B-X
Szentes	B-X
,	B-X
D.	B-X
Thompson	B-X
,	B-X
R.	B-X
Tungalag	B-X
,	B-X
S.	B-X
Undrakhbold	B-X
,	B-X
M.	B-X
van	B-X
Rooyen	B-X
,	B-X
C.	B-X
Wellstein	B-X
,	B-X
J	B-X
.	B-X
B.	B-X
Wilson	B-X
,	B-X
T.	B-X
Zupo	B-X
.	B-X
Erratum	B-X
for	B-X
the	B-X
Report	B-X
``	B-X
Global	B-X
distribution	B-X
of	B-X
earthworm	B-X
diversity	B-X
''	B-X
by	B-X
H.	B-X
R.	B-X
P.	B-X
Phillips	B-X
,	B-X
C.	B-X
A.	B-X
Guerra	B-X
,	B-X
M.	B-X
L.	B-X
C.	B-X
Bartz	B-X
,	B-X
M.	B-X
J.	B-X
I.	B-X
Briones	B-X
,	B-X
G.	B-X
Brown	B-X
,	B-X
T.	B-X
W.	B-X
Crowther	B-X
,	B-X
O.	B-X
Ferlian	B-X
,	B-X
K.	B-X
B.	B-X
Gongalsky	B-X
,	B-X
J.	B-X
van	B-X
den	B-X
Hoogen	B-X
,	B-X
J.	B-X
Krebs	B-X
,	B-X
A.	B-X
Orgiazzi	B-X
,	B-X
D.	B-X
Routh	B-X
,	B-X
B.	B-X
Schwarz	B-X
,	B-X
E.	B-X
M.	B-X
Bach	B-X
,	B-X
J.	B-X
Bennett	B-X
,	B-X
U.	B-X
Brose	B-X
,	B-X
T.	B-X
DecaÃ«ns	B-X
,	B-X
B.	B-X
KÃ¶nig-Ries	B-X
,	B-X
M.	B-X
Loreau	B-X
,	B-X
J.	B-X
Mathieu	B-X
,	B-X
C.	B-X
Mulder	B-X
,	B-X
W.	B-X
H.	B-X
van	B-X
der	B-X
Putten	B-X
,	B-X
K.	B-X
S.	B-X
Ramirez	B-X
,	B-X
M.	B-X
C.	B-X
Rillig	B-X
,	B-X
D.	B-X
Russell	B-X
,	B-X
M.	B-X
Rutgers	B-X
,	B-X
M.	B-X
P.	B-X
Thakur	B-X
,	B-X
F.	B-X
T.	B-X
de	B-X
Vries	B-X
,	B-X
D.	B-X
H.	B-X
Wall	B-X
,	B-X
D.	B-X
A.	B-X
Wardle	B-X
,	B-X
M.	B-X
Arai	B-X
,	B-X
F.	B-X
O.	B-X
Ayuke	B-X
,	B-X
G.	B-X
H.	B-X
Baker	B-X
,	B-X
R.	B-X
BeausÃ©jour	B-X
,	B-X
J.	B-X
C.	B-X
Bedano	B-X
,	B-X
K.	B-X
Birkhofer	B-X
,	B-X
E.	B-X
Blanchart	B-X
,	B-X
B.	B-X
Blossey	B-X
,	B-X
T.	B-X
Bolger	B-X
,	B-X
R.	B-X
L.	B-X
Bradley	B-X
,	B-X
M.	B-X
A.	B-X
Callaham	B-X
,	B-X
Y.	B-X
Capowiez	B-X
,	B-X
M.	B-X
E.	B-X
Caulfield	B-X
,	B-X
A.	B-X
Choi	B-X
,	B-X
F.	B-X
V.	B-X
Crotty	B-X
,	B-X
A.	B-X
DÃ¡valos	B-X
,	B-X
D.	B-X
J.	B-X
Diaz	B-X
Cosin	B-X
,	B-X
A.	B-X
Dominguez	B-X
,	B-X
A.	B-X
E.	B-X
Duhour	B-X
,	B-X
N.	B-X
van	B-X
Eekeren	B-X
,	B-X
C.	B-X
Emmerling	B-X
,	B-X
L.	B-X
B.	B-X
Falco	B-X
,	B-X
R.	B-X
FernÃ¡ndez	B-X
,	B-X
S.	B-X
J.	B-X
Fonte	B-X
,	B-X
C.	B-X
Fragoso	B-X
,	B-X
A.	B-X
L.	B-X
C.	B-X
Franco	B-X
,	B-X
M.	B-X
FugÃ¨re	B-X
,	B-X
A.	B-X
T.	B-X
Fusilero	B-X
,	B-X
S.	B-X
Gholami	B-X
,	B-X
M.	B-X
J.	B-X
Gundale	B-X
,	B-X
M.	B-X
GutiÃ©rrez	B-X
LÃ³pez	B-X
,	B-X
D.	B-X
K.	B-X
Hackenberger	B-X
,	B-X
L.	B-X
M.	B-X
HernÃ¡ndez	B-X
,	B-X
T.	B-X
Hishi	B-X
,	B-X
A.	B-X
R.	B-X
Holdsworth	B-X
,	B-X
M.	B-X
Holmstrup	B-X
,	B-X
K.	B-X
N.	B-X
Hopfensperger	B-X
,	B-X
E.	B-X
Huerta	B-X
Lwanga	B-X
,	B-X
V.	B-X
Huhta	B-X
,	B-X
T.	B-X
T.	B-X
Hurisso	B-X
,	B-X
B.	B-X
V.	B-X
Iannone	B-X
III	B-X
,	B-X
M.	B-X
Iordache	B-X
,	B-X
M.	B-X
Joschko	B-X
,	B-X
N.	B-X
Kaneko	B-X
,	B-X
R.	B-X
Kanianska	B-X
,	B-X
A.	B-X
M.	B-X
Keith	B-X
,	B-X
C.	B-X
A.	B-X
Kelly	B-X
,	B-X
M.	B-X
L.	B-X
Kernecker	B-X
,	B-X
J.	B-X
Klaminder	B-X
,	B-X
A.	B-X
W.	B-X
KonÃ©	B-X
,	B-X
Y.	B-X
Kooch	B-X
,	B-X
S.	B-X
T.	B-X
Kukkonen	B-X
,	B-X
H.	B-X
Lalthanzara	B-X
,	B-X
D.	B-X
R.	B-X
Lammel	B-X
,	B-X
I.	B-X
M.	B-X
Lebedev	B-X
,	B-X
Y.	B-X
Li	B-X
,	B-X
J	B-X
.	B-X
B.	B-X
Jesus	B-X
Lidon	B-X
,	B-X
N.	B-X
K.	B-X
Lincoln	B-X
,	B-X
S.	B-X
R.	B-X
Loss	B-X
,	B-X
R.	B-X
Marichal	B-X
,	B-X
R.	B-X
Matula	B-X
,	B-X
J.	B-X
H.	B-X
Moos	B-X
,	B-X
G.	B-X
Moreno	B-X
,	B-X
A.	B-X
MorÃ³n-RÃ­os	B-X
,	B-X
B.	B-X
Muys	B-X
,	B-X
J.	B-X
Neirynck	B-X
,	B-X
L.	B-X
Norgrove	B-X
,	B-X
M.	B-X
Novo	B-X
,	B-X
V.	B-X
Nuutinen	B-X
,	B-X
V.	B-X
Nuzzo	B-X
,	B-X
M.	B-X
Rahman	B-X
P	B-X
,	B-X
J.	B-X
Pansu	B-X
,	B-X
S.	B-X
Paudel	B-X
,	B-X
G.	B-X
PÃ©rÃ¨s	B-X
,	B-X
L.	B-X
PÃ©rez-Camacho	B-X
,	B-X
R.	B-X
PiÃ±eiro	B-X
,	B-X
J.-F.	B-X
Ponge	B-X
,	B-X
M.	B-X
I.	B-X
Rashid	B-X
,	B-X
S.	B-X
Rebollo	B-X
,	B-X
J.	B-X
Rodeiro-Iglesias	B-X
,	B-X
M.	B-X
Ã.	B-X
RodrÃ­guez	B-X
,	B-X
A.	B-X
M.	B-X
Roth	B-X
,	B-X
G.	B-X
X.	B-X
Rousseau	B-X
,	B-X
A.	B-X
Rozen	B-X
,	B-X
E.	B-X
Sayad	B-X
,	B-X
L.	B-X
van	B-X
Schaik	B-X
,	B-X
B.	B-X
C.	B-X
Scharenbroch	B-X
,	B-X
M.	B-X
Schirrmann	B-X
,	B-X
O.	B-X
Schmidt	B-X
,	B-X
B.	B-X
SchrÃ¶der	B-X
,	B-X
J.	B-X
Seeber	B-X
,	B-X
M.	B-X
P.	B-X
Shashkov	B-X
,	B-X
J.	B-X
Singh	B-X
,	B-X
S.	B-X
M.	B-X
Smith	B-X
,	B-X
M.	B-X
Steinwandter	B-X
,	B-X
J	B-X
.	B-X
A.	B-X
Talavera	B-X
,	B-X
D.	B-X
Trigo	B-X
,	B-X
J.	B-X
Tsukamoto	B-X
,	B-X
A.	B-X
W.	B-X
de	B-X
ValenÃ§a	B-X
,	B-X
S.	B-X
J.	B-X
Vanek	B-X
,	B-X
I.	B-X
Virto	B-X
,	B-X
A	B-X
.	B-X
A.	B-X
Wackett	B-X
,	B-X
M.	B-X
W.	B-X
Warren	B-X
,	B-X
N.	B-X
H.	B-X
Wehr	B-X
,	B-X
J.	B-X
K.	B-X
Whalen	B-X
,	B-X
M.	B-X
B.	B-X
Wironen	B-X
,	B-X
V.	B-X
Wolters	B-X
,	B-X
I.	B-X
V.	B-X
Zenkova	B-X
,	B-X
W.	B-X
Zhang	B-X
,	B-X
E.	B-X
K.	B-X
Cameron	B-X
,	B-X
N.	B-X
Eisenhauer	B-X
.	B-X

(	O
1979	O
)	O
Proc	O
.	O
<EOS>	B-X
Pillars	B-X
Article	B-X
:	B-X
Leukotriene	B-X
C	B-X
:	B-X
A	B-X
Slow-Reacting	B-X
Substance	B-X
from	B-X
Murine	B-X
Mastocytoma	B-X
Cells	B-X
.	B-X
Obesity	B-X
--	B-X
who	B-X
is	B-X
to	B-X
blame	B-X
?	B-X
Pillars	B-X
article	B-X
:	B-X
Separation	B-X
of	B-X
functional	B-X
subsets	B-X
of	B-X
human	B-X
T	B-X
cells	B-X
by	B-X
a	B-X
monoclonal	B-X
antibody	B-X
.	B-X
Proc	B-X
.	B-X
Natl	B-X
.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
1979	B-X
.	B-X
76	B-X
:	B-X
4061-4065	B-X
.	B-X
Ebstein	B-X
's	B-X
disease	B-X
.	B-X

Natl	O
.	O
<EOS>	B-X
Obituaries	B-X
.	B-X
Corrigendum	B-X
to	B-X
``	B-X
Visceral	B-X
Adiposity	B-X
Index	B-X
Levels	B-X
in	B-X
Patients	B-X
with	B-X
Hypothyroidism	B-X
''	B-X
[	B-X
J	B-X
Natl	B-X
Med	B-X
Assoc	B-X
110	B-X
(	B-X
6	B-X
)	B-X
(	B-X
2018	B-X
)	B-X
606-613	B-X
]	B-X
.	B-X
Sodium	B-X
channels	B-X
in	B-X
the	B-X
cytoplasm	B-X
of	B-X
Schwann	B-X
cells	B-X
.	B-X
Proc	B-X
.	B-X
Natl	B-X
.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
87	B-X
(	B-X
1990	B-X
)	B-X
9290-9294	B-X
.	B-X
Imhotep	B-X
.	B-X

Acad	O
.	O
<EOS>	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2018	B-X
)	B-X
,	B-X
1423	B-X
,	B-X
166-175	B-X
.	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2018	B-X
)	B-X
,	B-X
1433	B-X
,	B-X
29-40	B-X
.	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2020	B-X
)	B-X
,	B-X
1462	B-X
,	B-X
65-78	B-X
.	B-X
In	B-X
Memoriam	B-X
Acad	B-X
.	B-X
Prof.	B-X
Dr.	B-X
LjubiÅ¡a	B-X
RakiÄ	B-X
(	B-X
1931-2022	B-X
)	B-X
.	B-X

Sci	O
.	O
<EOS>	B-X
Molecules	B-X
and	B-X
Biomaterial	B-X
Technologies	B-X
Affecting	B-X
Stem	B-X
Cell	B-X
Differentiation	B-X
.	B-X

U	O
.	O
S	O
.	O
A	O
.	O
<EOS>	B-X
NUTRITIONAL	B-X
WELL-BEING	B-X
IN	B-X
THE	B-X
U.S.A.	B-X
Nutritional	B-X
status	B-X
,	B-X
U.S.A	B-X
.	B-X
Abortion	B-X
in	B-X
U.S.A	B-X
.	B-X
Persons	B-X
with	B-X
disabilities	B-X
represent	B-X
a	B-X
growing	B-X
population	B-X
in	B-X
both	B-X
the	B-X
European	B-X
Union	B-X
(	B-X
EU	B-X
)	B-X
and	B-X
the	B-X
United	B-X
States	B-X
(	B-X
USA	B-X
)	B-X
.	B-X
The	B-X
EU	B-X
has	B-X
made	B-X
substantial	B-X
policy	B-X
progress	B-X
to	B-X
support	B-X
telework	B-X
,	B-X
but	B-X
persons	B-X
with	B-X
disabilities	B-X
have	B-X
had	B-X
only	B-X
limited	B-X
long-term	B-X
success	B-X
in	B-X
telework	B-X
initiatives	B-X
due	B-X
to	B-X
lack	B-X
of	B-X
work	B-X
support	B-X
services	B-X
.	B-X
The	B-X
USA	B-X
has	B-X
generally	B-X
strong	B-X
support	B-X
services	B-X
but	B-X
lacks	B-X
telework	B-X
policy	B-X
infrastructure	B-X
.	B-X
The	B-X
EU	B-X
and	B-X
the	B-X
USA	B-X
can	B-X
benefit	B-X
from	B-X
collaborative	B-X
work	B-X
to	B-X
enhance	B-X
their	B-X
complementary	B-X
strengths	B-X
.	B-X

76	O
,	O
4294	O
-	O
4298	O
.	O

24	O
.	O

Soreq	O
,	O
H	O
.	O
,	O
Harpold	O
,	O
M	O
.	O
,	O
Evans	O
,	O
R	O
.	O
,	O
Darnell	O
,	O
Jr	O
.	O
,	O
J	O
.	O

E	O
.	O
,	O
and	O
<EOS>	B-X
Electronic	B-X
cigarette	B-X
(	B-X
e-cigarette	B-X
)	B-X
use	B-X
has	B-X
increased	B-X
substantially	B-X
in	B-X
recent	B-X
years	B-X
.	B-X
E-cigarettes	B-X
may	B-X
lead	B-X
to	B-X
initiation	B-X
of	B-X
nicotine	B-X
use	B-X
in	B-X
adult	B-X
and	B-X
youth	B-X
non-smokers	B-X
,	B-X
re-initiation	B-X
of	B-X
nicotine	B-X
dependence	B-X
in	B-X
ex-smokers	B-X
or	B-X
increased	B-X
severity	B-X
of	B-X
nicotine	B-X
dependence	B-X
in	B-X
dual-users	B-X
of	B-X
cigarettes	B-X
and	B-X
e-cigarettes	B-X
.	B-X
Hepatitis	B-X
E	B-X
was	B-X
identified	B-X
as	B-X
an	B-X
epidemic	B-X
of	B-X
non-A	B-X
,	B-X
non-B	B-X
hepatitis	B-X
from	B-X
Kashmir	B-X
,	B-X
India	B-X
in	B-X
1978	B-X
.	B-X
Hepatitis	B-X
E	B-X
virus	B-X
(	B-X
HEV	B-X
)	B-X
,	B-X
the	B-X
etiological	B-X
agent	B-X
is	B-X
the	B-X
sole	B-X
member	B-X
of	B-X
family	B-X
Hepeviridae	B-X
.	B-X
Hepatitis	B-X
E	B-X
is	B-X
a	B-X
disease	B-X
with	B-X
a	B-X
major	B-X
global	B-X
impact	B-X
and	B-X
has	B-X
two	B-X
distinct	B-X
epidemiological	B-X
patterns	B-X
.	B-X
Hepatitis	B-X
E	B-X
is	B-X
an	B-X
imperative	B-X
health	B-X
issue	B-X
in	B-X
developing	B-X
nations	B-X
,	B-X
transmitted	B-X
through	B-X
sullied	B-X
water	B-X
and	B-X
happens	B-X
most	B-X
every	B-X
now	B-X
in	B-X
young	B-X
adults	B-X
.	B-X
Autochthonous	B-X
hepatitis	B-X
E	B-X
is	B-X
increasingly	B-X
recognized	B-X
in	B-X
developed	B-X
countries	B-X
.	B-X
HEV	B-X
infections	B-X
in	B-X
humans	B-X
occur	B-X
by	B-X
eating	B-X
the	B-X
undercooked	B-X
game	B-X
flesh	B-X
,	B-X
raw	B-X
liver	B-X
from	B-X
supermarkets	B-X
and	B-X
Figatelli	B-X
sausages	B-X
.	B-X
Blood	B-X
transfusion-associated	B-X
HEV	B-X
infections	B-X
occur	B-X
in	B-X
many	B-X
countries	B-X
and	B-X
screening	B-X
of	B-X
donors	B-X
for	B-X
HEV	B-X
RNA	B-X
is	B-X
under	B-X
consideration	B-X
.	B-X
Hepatitis	B-X
E	B-X
causes	B-X
a	B-X
number	B-X
of	B-X
extrahepatic	B-X
diseases	B-X
,	B-X
including	B-X
a	B-X
wide	B-X
spectrum	B-X
of	B-X
neurological	B-X
syndromes	B-X
.	B-X
HEV	B-X
genotype	B-X
3	B-X
causes	B-X
prolonged	B-X
viremia	B-X
,	B-X
chronic	B-X
hepatitis	B-X
,	B-X
liver	B-X
fibrosis	B-X
and	B-X
cirrhosis	B-X
in	B-X
organ	B-X
transplant	B-X
patients	B-X
.	B-X
Hepatitis	B-X
E	B-X
vaccine	B-X
-239	B-X
,	B-X
marketed	B-X
in	B-X
China	B-X
,	B-X
has	B-X
shown	B-X
high	B-X
efficacy	B-X
with	B-X
sustained	B-X
protection	B-X
for	B-X
over	B-X
four	B-X
years	B-X
.	B-X

Bancroft	O
,	O
F	O
.	O
<EOS>	B-X
Triple	B-X
Amputation	B-X
.	B-X
Phlebothrombosis	B-X
.	B-X
POSTOPERATIVE	B-X
THROMBOSIS	B-X
AND	B-X
EMBOLISM	B-X
.	B-X
HAEMANGIOMA	B-X
OF	B-X
SIGMOID	B-X
AND	B-X
COLON	B-X
.	B-X

C	O
.	O
<EOS>	B-X
[	B-X
Hepatitis	B-X
C	B-X
]	B-X
.	B-X
Hepatitis	B-X
C	B-X
virus	B-X
(	B-X
HCV	B-X
)	B-X
infection	B-X
is	B-X
a	B-X
leading	B-X
cause	B-X
of	B-X
chronic	B-X
hepatitis	B-X
,	B-X
liver	B-X
cirrhosis	B-X
,	B-X
and	B-X
hepatocellular	B-X
carcinoma	B-X
worldwide	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
briefly	B-X
review	B-X
the	B-X
virology	B-X
,	B-X
diagnosis	B-X
and	B-X
therapy	B-X
of	B-X
hepatitis	B-X
C.	B-X
Standard	B-X
therapy	B-X
with	B-X
pegylated	B-X
interferon-alpha	B-X
and	B-X
ribavirin	B-X
results	B-X
in	B-X
a	B-X
sustained	B-X
virological	B-X
response	B-X
in	B-X
40-50	B-X
%	B-X
of	B-X
genotype	B-X
1-	B-X
and	B-X
in	B-X
about	B-X
80	B-X
%	B-X
of	B-X
genotype	B-X
2-	B-X
or	B-X
3-infected	B-X
patients	B-X
.	B-X
Hepatitis	B-X
C	B-X
.	B-X

(	O
1979	O
)	O
Nucl	O
.	O
<EOS>	B-X
Seminars	B-X
in	B-X
nuclear	B-X
medicine	B-X
.	B-X
Forensic	B-X
radioimmunoassay	B-X
--	B-X
a	B-X
new	B-X
area	B-X
.	B-X
Radioassays	B-X
.	B-X
Tumor-localizing	B-X
radionuclides	B-X
in	B-X
retrospect	B-X
and	B-X
prospect	B-X
.	B-X

Acids	O
Res	O
.	O
<EOS>	B-X
Over	B-X
the	B-X
course	B-X
of	B-X
the	B-X
past	B-X
few	B-X
decades	B-X
,	B-X
the	B-X
theory	B-X
of	B-X
Hard	B-X
and	B-X
Soft	B-X
,	B-X
Acids	B-X
and	B-X
Bases	B-X
(	B-X
HSAB	B-X
)	B-X
has	B-X
proven	B-X
to	B-X
be	B-X
a	B-X
useful	B-X
tool	B-X
in	B-X
predicting	B-X
the	B-X
outcome	B-X
of	B-X
such	B-X
reactions	B-X
.	B-X
Mutagenesis	B-X
.	B-X
Plasma	B-X
acids	B-X
.	B-X

6	O
,	O
2471	O
-	O
2482	O
.	O
<EOS>	B-X
Studies	B-X
of	B-X
oxygen	B-X
binding	B-X
energy	B-X
to	B-X
hemoglobin	B-X
molecule	B-X
.	B-X
After	B-X
a	B-X
338-fold	B-X
purification	B-X
a	B-X
yield	B-X
of	B-X
16	B-X
%	B-X
was	B-X
achieved	B-X
with	B-X
a	B-X
specific	B-X
activity	B-X
of	B-X
81	B-X
mumol	B-X
NADH	B-X
formed	B-X
min-1	B-X
mg	B-X
protein-1	B-X
.	B-X
A	B-X
molecular	B-X
weight	B-X
of	B-X
60	B-X
000	B-X
was	B-X
determined	B-X
by	B-X
gel	B-X
chromatography	B-X
and	B-X
by	B-X
ultracentrifugation	B-X
.	B-X
6	B-X
.	B-X
The	B-X
inhibitor	B-X
constant	B-X
is	B-X
Ki	B-X
=	B-X
60	B-X
muM	B-X
.	B-X

25	O
.	O

Tonegawa	O
,	O
S	O
.	O
,	O
Maxam	O
,	O
A	O
.	O

M	O
.	O
,	O
Tizard	O
,	O
R	O
.	O
,	O
Bernard	O
,	O
0	O
.	O
,	O
and	O
Gilbert	O
,	O
W	O
.	O

(	O
1978	O
)	O
Proc	O
.	O
<EOS>	B-X
Suppressor	B-X
cells	B-X
in	B-X
immunosenescence	B-X
.	B-X
Psoriatic	B-X
arthritis	B-X
.	B-X
By	B-X
using	B-X
a	B-X
formulation	B-X
of	B-X
Kimura	B-X
and	B-X
Crow	B-X
[	B-X
Kimura	B-X
,	B-X
M.	B-X
&	B-X
Crow	B-X
,	B-X
J.	B-X
F.	B-X
(	B-X
1978	B-X
)	B-X
Proc	B-X
.	B-X
Echocardiography	B-X
.	B-X

Natl	O
.	O
<EOS>	B-X
Obituaries	B-X
.	B-X
Corrigendum	B-X
to	B-X
``	B-X
Visceral	B-X
Adiposity	B-X
Index	B-X
Levels	B-X
in	B-X
Patients	B-X
with	B-X
Hypothyroidism	B-X
''	B-X
[	B-X
J	B-X
Natl	B-X
Med	B-X
Assoc	B-X
110	B-X
(	B-X
6	B-X
)	B-X
(	B-X
2018	B-X
)	B-X
606-613	B-X
]	B-X
.	B-X
Sodium	B-X
channels	B-X
in	B-X
the	B-X
cytoplasm	B-X
of	B-X
Schwann	B-X
cells	B-X
.	B-X
Proc	B-X
.	B-X
Natl	B-X
.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
87	B-X
(	B-X
1990	B-X
)	B-X
9290-9294	B-X
.	B-X
Neosalvarsan	B-X
.	B-X

Acad	O
.	O
<EOS>	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2020	B-X
)	B-X
,	B-X
1462	B-X
,	B-X
65-78	B-X
.	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2018	B-X
)	B-X
,	B-X
1423	B-X
,	B-X
166-175	B-X
.	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2018	B-X
)	B-X
,	B-X
1433	B-X
,	B-X
29-40	B-X
.	B-X
In	B-X
Memoriam	B-X
Acad	B-X
.	B-X
Prof.	B-X
Dr.	B-X
LjubiÅ¡a	B-X
RakiÄ	B-X
(	B-X
1931-2022	B-X
)	B-X
.	B-X

Sci	O
.	O
<EOS>	B-X
Molecules	B-X
and	B-X
Biomaterial	B-X
Technologies	B-X
Affecting	B-X
Stem	B-X
Cell	B-X
Differentiation	B-X
.	B-X

U	O
.	O
S	O
.	O
A	O
.	O
<EOS>	B-X
NUTRITIONAL	B-X
WELL-BEING	B-X
IN	B-X
THE	B-X
U.S.A.	B-X
Nutritional	B-X
status	B-X
,	B-X
U.S.A	B-X
.	B-X
Abortion	B-X
in	B-X
U.S.A	B-X
.	B-X
Persons	B-X
with	B-X
disabilities	B-X
represent	B-X
a	B-X
growing	B-X
population	B-X
in	B-X
both	B-X
the	B-X
European	B-X
Union	B-X
(	B-X
EU	B-X
)	B-X
and	B-X
the	B-X
United	B-X
States	B-X
(	B-X
USA	B-X
)	B-X
.	B-X
The	B-X
EU	B-X
has	B-X
made	B-X
substantial	B-X
policy	B-X
progress	B-X
to	B-X
support	B-X
telework	B-X
,	B-X
but	B-X
persons	B-X
with	B-X
disabilities	B-X
have	B-X
had	B-X
only	B-X
limited	B-X
long-term	B-X
success	B-X
in	B-X
telework	B-X
initiatives	B-X
due	B-X
to	B-X
lack	B-X
of	B-X
work	B-X
support	B-X
services	B-X
.	B-X
The	B-X
USA	B-X
has	B-X
generally	B-X
strong	B-X
support	B-X
services	B-X
but	B-X
lacks	B-X
telework	B-X
policy	B-X
infrastructure	B-X
.	B-X
The	B-X
EU	B-X
and	B-X
the	B-X
USA	B-X
can	B-X
benefit	B-X
from	B-X
collaborative	B-X
work	B-X
to	B-X
enhance	B-X
their	B-X
complementary	B-X
strengths	B-X
.	B-X

75	O
,	O
1485	O
-	O
1489	O
.	O
<EOS>	B-X
[	B-X
Pharmacokinetics	B-X
parameters	B-X
of	B-X
the	B-X
gastrointestinal	B-X
absorption	B-X
of	B-X
drugs	B-X
(	B-X
author	B-X
's	B-X
transl	B-X
)	B-X
]	B-X
.	B-X

26	O
.	O

Nguyen	O
-	O
Huu	O
,	O
M	O
.	O
<EOS>	B-X
mRNA	B-X
complexity	B-X
and	B-X
egg	B-X
white	B-X
protein	B-X
mRNA	B-X
content	B-X
in	B-X
mature	B-X
and	B-X
hormone-withdrawn	B-X
oviduct	B-X
.	B-X
Hormonal	B-X
control	B-X
of	B-X
egg	B-X
white	B-X
protein	B-X
messenger	B-X
RNA	B-X
synthesis	B-X
in	B-X
the	B-X
chicken	B-X
oviduct	B-X
.	B-X

C	O
.	O
,	O
Stratmann	O
,	O
M	O
.	O
,	O
Groner	O
,	O
B	O
.	O
,	O
Wurtz	O
,	O
T	O
.	O
,	O
Land	O
,	O
M	O
.	O
,	O

Glesecke	O
,	O
K	O
.	O
,	O
Sippel	O
,	O
A	O
.	O
<EOS>	B-X
The	B-X
eHealth	B-X
Impact	B-X
Questionnaire	B-X
(	B-X
eHIQ	B-X
)	B-X
has	B-X
been	B-X
developed	B-X
in	B-X
the	B-X
United	B-X
Kingdom	B-X
to	B-X
measure	B-X
the	B-X
potential	B-X
effects	B-X
of	B-X
health	B-X
and	B-X
experimental	B-X
information	B-X
websites	B-X
.	B-X

F	O
.	O
,	O
and	O
Schutz	O
,	O
G	O
.	O
<EOS>	B-X
Exon	B-X
2	B-X
codes	B-X
for	B-X
amino	B-X
acids	B-X
28-82	B-X
,	B-X
which	B-X
include	B-X
the	B-X
catalytically	B-X
active	B-X
residues	B-X
and	B-X
a	B-X
cluster	B-X
of	B-X
amino	B-X
acids	B-X
which	B-X
bind	B-X
rings	B-X
C	B-X
,	B-X
D	B-X
,	B-X
E	B-X
,	B-X
and	B-X
F	B-X
of	B-X
the	B-X
oligosaccharide	B-X
substrate	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
used	B-X
single-molecule	B-X
brightness	B-X
analysis	B-X
to	B-X
quantify	B-X
the	B-X
degree	B-X
of	B-X
oligomerization	B-X
of	B-X
heterologously	B-X
expressed	B-X
hDAT	B-X
fused	B-X
to	B-X
monomeric	B-X
GFP	B-X
(	B-X
mGFP-hDAT	B-X
)	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
(	B-X
CHO	B-X
)	B-X
cells	B-X
.	B-X
We	B-X
observed	B-X
that	B-X
monomers	B-X
and	B-X
dimers	B-X
of	B-X
mGFP-hDAT	B-X
co-exist	B-X
and	B-X
that	B-X
higher-order	B-X
molecular	B-X
complexes	B-X
of	B-X
mGFP-hDAT	B-X
are	B-X
absent	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
The	B-X
mGFP-hDAT	B-X
dimers	B-X
were	B-X
stable	B-X
over	B-X
several	B-X
minutes	B-X
,	B-X
and	B-X
the	B-X
fraction	B-X
of	B-X
dimers	B-X
was	B-X
independent	B-X
of	B-X
the	B-X
mGFP-hDAT	B-X
surface	B-X
density	B-X
.	B-X
Furthermore	B-X
,	B-X
neither	B-X
oxidation	B-X
nor	B-X
depletion	B-X
of	B-X
cholesterol	B-X
had	B-X
any	B-X
effect	B-X
on	B-X
the	B-X
fraction	B-X
of	B-X
dimers	B-X
.	B-X

(	O
1979	O
)	O
Proc	O
.	O
<EOS>	B-X
Pillars	B-X
Article	B-X
:	B-X
Leukotriene	B-X
C	B-X
:	B-X
A	B-X
Slow-Reacting	B-X
Substance	B-X
from	B-X
Murine	B-X
Mastocytoma	B-X
Cells	B-X
.	B-X
Obesity	B-X
--	B-X
who	B-X
is	B-X
to	B-X
blame	B-X
?	B-X
Pillars	B-X
article	B-X
:	B-X
Separation	B-X
of	B-X
functional	B-X
subsets	B-X
of	B-X
human	B-X
T	B-X
cells	B-X
by	B-X
a	B-X
monoclonal	B-X
antibody	B-X
.	B-X
Proc	B-X
.	B-X
Natl	B-X
.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
1979	B-X
.	B-X
76	B-X
:	B-X
4061-4065	B-X
.	B-X
Ebstein	B-X
's	B-X
disease	B-X
.	B-X

Natl	O
.	O
<EOS>	B-X
Obituaries	B-X
.	B-X
Corrigendum	B-X
to	B-X
``	B-X
Visceral	B-X
Adiposity	B-X
Index	B-X
Levels	B-X
in	B-X
Patients	B-X
with	B-X
Hypothyroidism	B-X
''	B-X
[	B-X
J	B-X
Natl	B-X
Med	B-X
Assoc	B-X
110	B-X
(	B-X
6	B-X
)	B-X
(	B-X
2018	B-X
)	B-X
606-613	B-X
]	B-X
.	B-X
Sodium	B-X
channels	B-X
in	B-X
the	B-X
cytoplasm	B-X
of	B-X
Schwann	B-X
cells	B-X
.	B-X
Proc	B-X
.	B-X
Natl	B-X
.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
87	B-X
(	B-X
1990	B-X
)	B-X
9290-9294	B-X
.	B-X
Imhotep	B-X
.	B-X

Acad	O
.	O
<EOS>	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2020	B-X
)	B-X
,	B-X
1462	B-X
,	B-X
65-78	B-X
.	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2018	B-X
)	B-X
,	B-X
1423	B-X
,	B-X
166-175	B-X
.	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2018	B-X
)	B-X
,	B-X
1433	B-X
,	B-X
29-40	B-X
.	B-X
In	B-X
Memoriam	B-X
Acad	B-X
.	B-X
Prof.	B-X
Dr.	B-X
LjubiÅ¡a	B-X
RakiÄ	B-X
(	B-X
1931-2022	B-X
)	B-X
.	B-X

Sci	O
.	O
<EOS>	B-X
Molecules	B-X
and	B-X
Biomaterial	B-X
Technologies	B-X
Affecting	B-X
Stem	B-X
Cell	B-X
Differentiation	B-X
.	B-X

U	O
.	O
S	O
.	O
A	O
.	O
<EOS>	B-X
NUTRITIONAL	B-X
WELL-BEING	B-X
IN	B-X
THE	B-X
U.S.A.	B-X
Nutritional	B-X
status	B-X
,	B-X
U.S.A	B-X
.	B-X
Abortion	B-X
in	B-X
U.S.A	B-X
.	B-X
Persons	B-X
with	B-X
disabilities	B-X
represent	B-X
a	B-X
growing	B-X
population	B-X
in	B-X
both	B-X
the	B-X
European	B-X
Union	B-X
(	B-X
EU	B-X
)	B-X
and	B-X
the	B-X
United	B-X
States	B-X
(	B-X
USA	B-X
)	B-X
.	B-X
The	B-X
EU	B-X
has	B-X
made	B-X
substantial	B-X
policy	B-X
progress	B-X
to	B-X
support	B-X
telework	B-X
,	B-X
but	B-X
persons	B-X
with	B-X
disabilities	B-X
have	B-X
had	B-X
only	B-X
limited	B-X
long-term	B-X
success	B-X
in	B-X
telework	B-X
initiatives	B-X
due	B-X
to	B-X
lack	B-X
of	B-X
work	B-X
support	B-X
services	B-X
.	B-X
The	B-X
USA	B-X
has	B-X
generally	B-X
strong	B-X
support	B-X
services	B-X
but	B-X
lacks	B-X
telework	B-X
policy	B-X
infrastructure	B-X
.	B-X
The	B-X
EU	B-X
and	B-X
the	B-X
USA	B-X
can	B-X
benefit	B-X
from	B-X
collaborative	B-X
work	B-X
to	B-X
enhance	B-X
their	B-X
complementary	B-X
strengths	B-X
.	B-X

76	O
,	O
76	O
-	O
80	O
.	O

27	O
.	O
<EOS>	B-X
Editorial	B-X
:	B-X
``	B-X
Old	B-X
lamps	B-X
for	B-X
new	B-X
''	B-X
.	B-X

Breathnach	O
,	O
R	O
.	O
,	O
Mandel	O
,	O
J	O
.	O
<EOS>	B-X
The	B-X
interruptions	B-X
in	B-X
the	B-X
chicken	B-X
ovalbumin	B-X
gene	B-X
which	B-X
were	B-X
reported	B-X
previously	B-X
(	B-X
Breathnach	B-X
,	B-X
Mandel	B-X
and	B-X
Chambon	B-X
,	B-X
1977	B-X
)	B-X
are	B-X
shown	B-X
to	B-X
be	B-X
due	B-X
to	B-X
the	B-X
presence	B-X
of	B-X
intervening	B-X
sequences	B-X
which	B-X
separate	B-X
the	B-X
messenger-coding	B-X
sequences	B-X
.	B-X
All	B-X
of	B-X
these	B-X
intervening	B-X
sequences	B-X
are	B-X
located	B-X
in	B-X
the	B-X
DNA	B-X
region	B-X
that	B-X
corresponds	B-X
to	B-X
the	B-X
part	B-X
of	B-X
the	B-X
ov	B-X
mRNA	B-X
which	B-X
codes	B-X
for	B-X
amino	B-X
acids	B-X
.	B-X
All	B-X
the	B-X
sequences	B-X
coding	B-X
for	B-X
ov	B-X
mRNA	B-X
are	B-X
contained	B-X
in	B-X
a	B-X
chromosomal	B-X
DNA	B-X
region	B-X
of	B-X
6000	B-X
bp	B-X
,	B-X
which	B-X
is	B-X
more	B-X
than	B-X
3	B-X
times	B-X
longer	B-X
than	B-X
ov	B-X
mRNA	B-X
.	B-X
Two	B-X
interruptions	B-X
in	B-X
the	B-X
sequences	B-X
coding	B-X
for	B-X
ovalbumin	B-X
mRNA	B-X
have	B-X
been	B-X
detected	B-X
,	B-X
at	B-X
least	B-X
one	B-X
of	B-X
them	B-X
lying	B-X
in	B-X
the	B-X
protein	B-X
coding	B-X
sequence	B-X
.	B-X

L	O
.	O
,	O
and	O
Chambon	O
,	O
P	O
.	O
<EOS>	B-X
Myofibroblast	B-X
reprogramming	B-X
required	B-X
neogenic	B-X
hair	B-X
follicles	B-X
,	B-X
which	B-X
triggered	B-X
bone	B-X
morphogenetic	B-X
protein	B-X
(	B-X
BMP	B-X
)	B-X
signaling	B-X
and	B-X
then	B-X
activation	B-X
of	B-X
adipocyte	B-X
transcription	B-X
factors	B-X
expressed	B-X
during	B-X
development	B-X
.	B-X
Overexpression	B-X
of	B-X
the	B-X
BMP	B-X
antagonist	B-X
Noggin	B-X
in	B-X
hair	B-X
follicles	B-X
or	B-X
deletion	B-X
of	B-X
the	B-X
BMP	B-X
receptor	B-X
in	B-X
myofibroblasts	B-X
prevented	B-X
adipocyte	B-X
formation	B-X
.	B-X
Adipocytes	B-X
formed	B-X
from	B-X
human	B-X
keloid	B-X
fibroblasts	B-X
either	B-X
when	B-X
treated	B-X
with	B-X
BMP	B-X
or	B-X
when	B-X
placed	B-X
with	B-X
human	B-X
hair	B-X
follicles	B-X
in	B-X
vitro	B-X
With	B-X
the	B-X
exception	B-X
of	B-X
prenatal	B-X
retinal	B-X
dysplasia	B-X
,	B-X
all	B-X
the	B-X
ocular	B-X
abnormalities	B-X
of	B-X
the	B-X
fetal	B-X
VAD	B-X
syndrome	B-X
are	B-X
recapitulated	B-X
in	B-X
mouse	B-X
mutants	B-X
lacking	B-X
either	B-X
RARalpha	B-X
and	B-X
RARbeta2	B-X
,	B-X
RARalpha	B-X
and	B-X
RARgamma	B-X
,	B-X
RARgamma	B-X
and	B-X
RARbeta2	B-X
,	B-X
or	B-X
RXRalpha	B-X
[	B-X
Lohnes	B-X
,	B-X
D.	B-X
,	B-X
Mark	B-X
,	B-X
M.	B-X
,	B-X
Mendelsohn	B-X
,	B-X
C.	B-X
,	B-X
Dolle	B-X
,	B-X
P.	B-X
,	B-X
Dierich	B-X
,	B-X
A.	B-X
,	B-X
Gorry	B-X
,	B-X
P.	B-X
,	B-X
Gansmuller	B-X
,	B-X
A.	B-X
and	B-X
Chambon	B-X
,	B-X
P.	B-X
(	B-X
1994	B-X
)	B-X
Development	B-X
120	B-X
,	B-X
2723-2748	B-X
;	B-X
Mendelsohn	B-X
,	B-X
C.	B-X
,	B-X
Lohnes	B-X
,	B-X
D.	B-X
,	B-X
DÃ©cimo	B-X
,	B-X
D.	B-X
,	B-X
Lufkin	B-X
,	B-X
T.	B-X
,	B-X
LeMeur	B-X
,	B-X
M.	B-X
,	B-X
Chambon	B-X
,	B-X
P.	B-X
and	B-X
Mark	B-X
,	B-X
M.	B-X
(	B-X
1994	B-X
)	B-X
Development	B-X
120	B-X
,	B-X
2749-2771	B-X
;	B-X
Kastner	B-X
,	B-X
P.	B-X
,	B-X
Grondona	B-X
,	B-X
J	B-X
.	B-X
Mark	B-X
,	B-X
M.	B-X
,	B-X
Gansmuller	B-X
,	B-X
A.	B-X
,	B-X
LeMeur	B-X
,	B-X
M.	B-X
,	B-X
DÃ©cimo	B-X
,	B-X
D.	B-X
,	B-X
Vonesch	B-X
,	B-X
J.L.	B-X
,	B-X
DollÃ©	B-X
,	B-X
P.	B-X
and	B-X
Chambon	B-X
,	B-X
P.	B-X
(	B-X
1994	B-X
)	B-X
Cell	B-X
78	B-X
,	B-X
987-1003	B-X
]	B-X
,	B-X
thus	B-X
demonstrating	B-X
that	B-X
retinoic	B-X
acid	B-X
(	B-X
RA	B-X
)	B-X
is	B-X
the	B-X
active	B-X
vitamin	B-X
A	B-X
metabolite	B-X
during	B-X
prenatal	B-X
eye	B-X
morphogenesis	B-X
.	B-X
The	B-X
RARbeta2gamma2	B-X
retinal	B-X
pigment	B-X
epithelium	B-X
(	B-X
RPE	B-X
)	B-X
cells	B-X
display	B-X
histological	B-X
and/or	B-X
ultrastructural	B-X
alterations	B-X
and/or	B-X
fail	B-X
to	B-X
express	B-X
cellular	B-X
retinol	B-X
binding	B-X
protein	B-X
I	B-X
(	B-X
CRBPI	B-X
)	B-X
.	B-X
Taken	B-X
altogether	B-X
,	B-X
the	B-X
early	B-X
onset	B-X
of	B-X
the	B-X
RPE	B-X
histological	B-X
defects	B-X
and	B-X
their	B-X
striking	B-X
colocalisation	B-X
with	B-X
areas	B-X
of	B-X
the	B-X
neural	B-X
retina	B-X
displaying	B-X
a	B-X
faulty	B-X
laminar	B-X
organization	B-X
,	B-X
a	B-X
reduced	B-X
neuroblastic	B-X
proliferation	B-X
,	B-X
and	B-X
a	B-X
lack	B-X
of	B-X
photoreceptor	B-X
differentiation	B-X
and/or	B-X
increased	B-X
apoptosis	B-X
,	B-X
make	B-X
the	B-X
RPE	B-X
a	B-X
likely	B-X
target	B-X
tissue	B-X
of	B-X
the	B-X
RARbeta2gamma2	B-X
double	B-X
null	B-X
mutation	B-X
.	B-X
A	B-X
degeneration	B-X
of	B-X
the	B-X
adult	B-X
neural	B-X
retina	B-X
,	B-X
which	B-X
may	B-X
similarly	B-X
be	B-X
secondary	B-X
to	B-X
a	B-X
defective	B-X
RPE	B-X
,	B-X
is	B-X
also	B-X
observed	B-X
in	B-X
these	B-X
mutants	B-X
,	B-X
thus	B-X
demonstrating	B-X
an	B-X
essential	B-X
role	B-X
of	B-X
RA	B-X
in	B-X
the	B-X
survival	B-X
of	B-X
retinal	B-X
cells	B-X
.	B-X

(	O
1977	O
)	O
Nature	O
270	O
,	O
<EOS>	B-X
Metalloimmunoassay	B-X
.	B-X
Pleiotropic	B-X
theories	B-X
for	B-X
the	B-X
evolutionary	B-X
origins	B-X
of	B-X
senescence	B-X
have	B-X
been	B-X
ascendant	B-X
for	B-X
forty	B-X
years	B-X
(	B-X
see	B-X
,	B-X
for	B-X
example	B-X
,	B-X
G.	B-X
Williams	B-X
(	B-X
1957	B-X
)	B-X
Evolution	B-X
,	B-X
11	B-X
,	B-X
398-411	B-X
;	B-X
T.	B-X
Kirkwood	B-X
(	B-X
1977	B-X
)	B-X
Nature	B-X
,	B-X
270	B-X
,	B-X
301-304	B-X
)	B-X
,	B-X
and	B-X
it	B-X
is	B-X
not	B-X
surprising	B-X
that	B-X
interpreters	B-X
of	B-X
demographic	B-X
data	B-X
seek	B-X
to	B-X
frame	B-X
their	B-X
results	B-X
in	B-X
this	B-X
context	B-X
.	B-X
Med.	B-X
,	B-X
12	B-X
(	B-X
1969	B-X
)	B-X
313-324	B-X
)	B-X
and	B-X
Kirkwood	B-X
(	B-X
Nature	B-X
,	B-X
270	B-X
(	B-X
1977	B-X
)	B-X
301-304	B-X
;	B-X
New	B-X
Sci.	B-X
,	B-X
81	B-X
(	B-X
1979	B-X
)	B-X
1040-1042	B-X
;	B-X
Physiological	B-X
Ecology	B-X
:	B-X
An	B-X
Evolutionary	B-X
Approach	B-X
,	B-X
Blackwell	B-X
,	B-X
Oxford	B-X
,	B-X
1981	B-X
,	B-X
pp	B-X
.	B-X
Asymmetry	B-X
of	B-X
phospholipid	B-X
biosynthesis	B-X
.	B-X

314	O
-	O
319	O
.	O
<EOS>	B-X
EKG	B-X
of	B-X
the	B-X
month	B-X
.	B-X
Second	B-X
primary	B-X
lung	B-X
tumors	B-X
.	B-X

28	O
.	O
<EOS>	B-X
Letter	B-X
:	B-X
Duration	B-X
of	B-X
action	B-X
of	B-X
AH8165	B-X
.	B-X

Dugaiczyk	O
,	O
A	O
.	O
,	O
Woo	O
,	O
S	O
.	O
<EOS>	B-X
The	B-X
ovalbumin	B-X
gene	B-X
:	B-X
organization	B-X
,	B-X
structure	B-X
,	B-X
transcription	B-X
,	B-X
and	B-X
regulation	B-X
.	B-X

L	O
.	O
<EOS>	B-X
L-Cysteine	B-X
is	B-X
an	B-X
important	B-X
amino	B-X
acid	B-X
both	B-X
biologically	B-X
and	B-X
commercially	B-X
.	B-X
Although	B-X
most	B-X
amino	B-X
acids	B-X
are	B-X
industrially	B-X
produced	B-X
by	B-X
microbial	B-X
fermentation	B-X
,	B-X
L-cysteine	B-X
has	B-X
been	B-X
mainly	B-X
produced	B-X
by	B-X
protein	B-X
hydrolysis	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
reviewed	B-X
L-cysteine	B-X
metabolism	B-X
,	B-X
including	B-X
biosynthesis	B-X
,	B-X
degradation	B-X
,	B-X
and	B-X
transport	B-X
,	B-X
and	B-X
biotechnological	B-X
production	B-X
(	B-X
including	B-X
both	B-X
enzymatic	B-X
and	B-X
fermentation	B-X
processes	B-X
)	B-X
of	B-X
L-cysteine	B-X
.	B-X
The	B-X
metabolic	B-X
regulation	B-X
of	B-X
L-cysteine	B-X
including	B-X
novel	B-X
sulfur	B-X
metabolic	B-X
pathways	B-X
found	B-X
in	B-X
microorganisms	B-X
is	B-X
also	B-X
discussed	B-X
.	B-X
Recent	B-X
advancement	B-X
in	B-X
biochemical	B-X
studies	B-X
,	B-X
genome	B-X
sequencing	B-X
,	B-X
structural	B-X
biology	B-X
,	B-X
and	B-X
metabolome	B-X
analysis	B-X
has	B-X
enabled	B-X
us	B-X
to	B-X
use	B-X
various	B-X
approaches	B-X
to	B-X
achieve	B-X
direct	B-X
fermentation	B-X
of	B-X
L-cysteine	B-X
from	B-X
glucose	B-X
.	B-X
For	B-X
example	B-X
,	B-X
worldwide	B-X
companies	B-X
began	B-X
to	B-X
supply	B-X
L-cysteine	B-X
and	B-X
its	B-X
derivatives	B-X
produced	B-X
by	B-X
bacterial	B-X
fermentation	B-X
.	B-X
Basically	B-X
,	B-X
a	B-X
combination	B-X
of	B-X
three	B-X
factors	B-X
should	B-X
be	B-X
required	B-X
for	B-X
improving	B-X
L-cysteine	B-X
fermentation	B-X
:	B-X
that	B-X
is	B-X
,	B-X
(	B-X
1	B-X
)	B-X
enhancing	B-X
biosynthesis	B-X
:	B-X
overexpression	B-X
of	B-X
the	B-X
altered	B-X
cysE	B-X
gene	B-X
encoding	B-X
feedback	B-X
inhibition-insensitive	B-X
L-serine	B-X
O-acetyltransferase	B-X
(	B-X
SAT	B-X
)	B-X
,	B-X
(	B-X
2	B-X
)	B-X
weakening	B-X
degradation	B-X
:	B-X
knockout	B-X
of	B-X
the	B-X
genes	B-X
encoding	B-X
L-cysteine	B-X
desulfhydrases	B-X
,	B-X
and	B-X
(	B-X
3	B-X
)	B-X
exploiting	B-X
export	B-X
system	B-X
:	B-X
overexpression	B-X
of	B-X
the	B-X
gene	B-X
involved	B-X
in	B-X
L-cysteine	B-X
transport	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
found	B-X
that	B-X
``	B-X
thiosulfate	B-X
''	B-X
is	B-X
much	B-X
more	B-X
effective	B-X
sulfur	B-X
source	B-X
than	B-X
commonly	B-X
used	B-X
``	B-X
sulfate	B-X
''	B-X
for	B-X
L-cysteine	B-X
production	B-X
in	B-X
Escherichia	B-X
coli	B-X
,	B-X
because	B-X
thiosulfate	B-X
is	B-X
advantageous	B-X
for	B-X
saving	B-X
consumption	B-X
of	B-X
NADPH	B-X
and	B-X
relating	B-X
energy	B-X
molecules	B-X
.	B-X

C	O
.	O
,	O
Lai	O
,	O
E	O
.	O

C	O
.	O
,	O
Mace	O
,	O
M	O
.	O
<EOS>	B-X
Venetoclax	B-X
(	B-X
VEN	B-X
)	B-X
,	B-X
a	B-X
selective	B-X
BCL2	B-X
inhibitor	B-X
,	B-X
has	B-X
single-agent	B-X
activity	B-X
in	B-X
relapsed	B-X
and	B-X
refractory	B-X
(	B-X
R/R	B-X
)	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
(	B-X
AML	B-X
)	B-X
,	B-X
and	B-X
efficacy	B-X
in	B-X
lower	B-X
intensity	B-X
combinations	B-X
for	B-X
treatment-naÃ¯ve	B-X
elderly	B-X
AML	B-X
patients	B-X
.	B-X
However	B-X
,	B-X
env	B-X
protein	B-X
fusions	B-X
to	B-X
the	B-X
C-terminal	B-X
portion	B-X
of	B-X
invertase	B-X
were	B-X
inactive	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
some	B-X
,	B-X
but	B-X
not	B-X
all	B-X
,	B-X
env	B-X
protein	B-X
fusions	B-X
at	B-X
the	B-X
C-terminal	B-X
region	B-X
of	B-X
PLAP	B-X
were	B-X
enzymatically	B-X
active	B-X
:	B-X
PLAP	B-X
fusions	B-X
containing	B-X
long	B-X
C-terminal	B-X
portions	B-X
of	B-X
env	B-X
localized	B-X
to	B-X
the	B-X
rough	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
RER	B-X
)	B-X
and	B-X
possessed	B-X
low	B-X
enzyme	B-X
activity	B-X
levels	B-X
,	B-X
while	B-X
fusion	B-X
constructs	B-X
containing	B-X
relatively	B-X
short	B-X
portions	B-X
of	B-X
the	B-X
M-MuLV	B-X
env	B-X
gene	B-X
localized	B-X
to	B-X
the	B-X
Golgi	B-X
and	B-X
had	B-X
higher	B-X
activity	B-X
levels	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
the	B-X
striking	B-X
systematics	B-X
of	B-X
two-particle	B-X
azimuthal	B-X
Fourier	B-X
harmonics	B-X
v_	B-X
{	B-X
2	B-X
}	B-X
and	B-X
v_	B-X
{	B-X
3	B-X
}	B-X
in	B-X
ultrarelativistic	B-X
collisions	B-X
of	B-X
protons	B-X
,	B-X
deuterons	B-X
,	B-X
and	B-X
helium-3	B-X
ions	B-X
off	B-X
gold	B-X
nuclei	B-X
measured	B-X
by	B-X
the	B-X
PHENIX	B-X
Collaboration	B-X
at	B-X
the	B-X
Relativistic	B-X
Heavy	B-X
Ion	B-X
Collider	B-X
(	B-X
RHIC	B-X
)	B-X
is	B-X
reproduced	B-X
in	B-X
the	B-X
color	B-X
glass	B-X
condensate	B-X
effective	B-X
field	B-X
theory	B-X
.	B-X
This	B-X
contradicts	B-X
the	B-X
claim	B-X
in	B-X
C.	B-X
Aidala	B-X
et	B-X
al	B-X
.	B-X
(	B-X
PHENIX	B-X
Collaboration	B-X
)	B-X
,	B-X
arXiv:1805.02973	B-X
,	B-X
that	B-X
their	B-X
data	B-X
rule	B-X
out	B-X
initial	B-X
state-based	B-X
explanations	B-X
.	B-X
The	B-X
underlying	B-X
systematics	B-X
of	B-X
the	B-X
effect	B-X
,	B-X
as	B-X
discussed	B-X
previously	B-X
in	B-X
K.	B-X
Dusling	B-X
,	B-X
M.	B-X
Mace	B-X
,	B-X
R.	B-X
Venugopalan	B-X
,	B-X
Phys	B-X
.	B-X
Sci.	B-X
,	B-X
QCDEV2017	B-X
(	B-X
2018	B-X
)	B-X
039	B-X
,	B-X
arise	B-X
from	B-X
the	B-X
differing	B-X
structure	B-X
of	B-X
strong	B-X
color	B-X
correlations	B-X
between	B-X
gluon	B-X
domains	B-X
of	B-X
size	B-X
1/Q_	B-X
{	B-X
S	B-X
}	B-X
at	B-X
fine	B-X
(	B-X
p_	B-X
{	B-X
â¥	B-X
}	B-X
âªQ_	B-X
{	B-X
S	B-X
}	B-X
)	B-X
or	B-X
coarser	B-X
(	B-X
p_	B-X
{	B-X
â¥	B-X
}	B-X
âªQ_	B-X
{	B-X
S	B-X
}	B-X
)	B-X
transverse	B-X
momentum	B-X
resolution	B-X
.	B-X
Further	B-X
tests	B-X
of	B-X
the	B-X
limits	B-X
of	B-X
validity	B-X
of	B-X
this	B-X
framework	B-X
can	B-X
be	B-X
carried	B-X
out	B-X
in	B-X
light-heavy	B-X
ion	B-X
collisions	B-X
at	B-X
both	B-X
RHIC	B-X
and	B-X
the	B-X
Large	B-X
Hadron	B-X
Collider	B-X
.	B-X

L	O
.	O
,	O
Jr	O
.	O
,	O
<EOS>	B-X
Human	B-X
T	B-X
cell	B-X
lymphotropic	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HTLV-1	B-X
)	B-X
was	B-X
detected	B-X
in	B-X
48	B-X
(	B-X
1.8	B-X
%	B-X
)	B-X
of	B-X
the	B-X
patients	B-X
,	B-X
HTLV-2	B-X
was	B-X
detected	B-X
in	B-X
28	B-X
(	B-X
1.1	B-X
%	B-X
)	B-X
,	B-X
and	B-X
HTLV-1	B-X
and	B-X
HTLV-2	B-X
were	B-X
both	B-X
detected	B-X
in	B-X
5	B-X
(	B-X
0.2	B-X
%	B-X
)	B-X
.	B-X
Human	B-X
immunodeficiency	B-X
virus	B-X
infection	B-X
was	B-X
detected	B-X
in	B-X
329	B-X
(	B-X
12.4	B-X
%	B-X
)	B-X
of	B-X
the	B-X
patients	B-X
;	B-X
24	B-X
(	B-X
7.3	B-X
%	B-X
)	B-X
had	B-X
HTLV	B-X
coinfection	B-X
.	B-X
Risk	B-X
factors	B-X
for	B-X
HTLV-1	B-X
and	B-X
HTLV-2	B-X
infection	B-X
varied	B-X
with	B-X
sexual	B-X
role	B-X
.	B-X
The	B-X
child	B-X
was	B-X
treated	B-X
with	B-X
the	B-X
Li	B-X
's	B-X
quick	B-X
repositioning	B-X
maneuver	B-X
and	B-X
the	B-X
vertigo	B-X
was	B-X
disappeared	B-X
.	B-X

McReynolds	O
,	O
L	O
.	O
,	O
and	O
O	O
'	O
Malley	O
,	O
B	O
.	O

W	O
.	O
<EOS>	B-X
We	B-X
present	B-X
a	B-X
novel	B-X
static	B-X
W-shaped	B-X
common-path	B-X
interferometer	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
the	B-X
W-shaped	B-X
common-path	B-X
corner-cube	B-X
retroreflector	B-X
interferometer	B-X
(	B-X
W-CPRI	B-X
)	B-X
is	B-X
introduced	B-X
via	B-X
detailed	B-X
analysis	B-X
of	B-X
its	B-X
working	B-X
principles	B-X
and	B-X
performance	B-X
.	B-X
For	B-X
each	B-X
interference	B-X
output	B-X
of	B-X
an	B-X
ideal	B-X
W-CPRI	B-X
,	B-X
the	B-X
two	B-X
beams	B-X
recombine	B-X
and	B-X
have	B-X
the	B-X
same	B-X
output	B-X
direction	B-X
,	B-X
including	B-X
a	B-X
tilted	B-X
CCR	B-X
.	B-X
In	B-X
a	B-X
deformed	B-X
W-CPRI	B-X
structure	B-X
,	B-X
an	B-X
optical	B-X
path	B-X
difference	B-X
can	B-X
be	B-X
produced	B-X
by	B-X
inserting	B-X
an	B-X
optical	B-X
element	B-X
that	B-X
changes	B-X
the	B-X
optical	B-X
path	B-X
in	B-X
the	B-X
interferometer	B-X
arm	B-X
of	B-X
the	B-X
W-CPRI	B-X
.	B-X
The	B-X
posture	B-X
deviations	B-X
of	B-X
the	B-X
RM	B-X
and	B-X
the	B-X
CCRs	B-X
in	B-X
the	B-X
W-CPRI	B-X
are	B-X
analyzed	B-X
.	B-X
The	B-X
average	B-X
cosine	B-X
similarity	B-X
is	B-X
0.9953	B-X
,	B-X
revealing	B-X
that	B-X
this	B-X
W-CPRI	B-X
has	B-X
high	B-X
stability	B-X
and	B-X
strong	B-X
coherence	B-X
while	B-X
avoiding	B-X
the	B-X
tilt	B-X
and	B-X
displacement	B-X
of	B-X
the	B-X
interferometer	B-X
arm	B-X
.	B-X

(	O
1978	O
)	O
Nature	O
274	O
,	O
328	O
-	O
333	O
.	O

29	O
.	O
<EOS>	B-X
Lorazepam	B-X
in	B-X
sexual	B-X
disorders	B-X
.	B-X

Weinstock	O
,	O
R	O
.	O
,	O
Sweet	O
,	O
R	O
.	O
,	O
Weiss	O
,	O
M	O
.	O
,	O
Cedar	O
,	O
M	O
.	O
,	O
and	O
Axel	O
,	O
R	O
.	O

(	O
1978	O
)	O
Proc	O
.	O
<EOS>	B-X
Suppressor	B-X
cells	B-X
in	B-X
immunosenescence	B-X
.	B-X
Psoriatic	B-X
arthritis	B-X
.	B-X
By	B-X
using	B-X
a	B-X
formulation	B-X
of	B-X
Kimura	B-X
and	B-X
Crow	B-X
[	B-X
Kimura	B-X
,	B-X
M.	B-X
&	B-X
Crow	B-X
,	B-X
J.	B-X
F.	B-X
(	B-X
1978	B-X
)	B-X
Proc	B-X
.	B-X
Echocardiography	B-X
.	B-X

Natl	O
.	O
<EOS>	B-X
Obituaries	B-X
.	B-X
Corrigendum	B-X
to	B-X
``	B-X
Visceral	B-X
Adiposity	B-X
Index	B-X
Levels	B-X
in	B-X
Patients	B-X
with	B-X
Hypothyroidism	B-X
''	B-X
[	B-X
J	B-X
Natl	B-X
Med	B-X
Assoc	B-X
110	B-X
(	B-X
6	B-X
)	B-X
(	B-X
2018	B-X
)	B-X
606-613	B-X
]	B-X
.	B-X
Sodium	B-X
channels	B-X
in	B-X
the	B-X
cytoplasm	B-X
of	B-X
Schwann	B-X
cells	B-X
.	B-X
Proc	B-X
.	B-X
Natl	B-X
.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
87	B-X
(	B-X
1990	B-X
)	B-X
9290-9294	B-X
.	B-X
Imhotep	B-X
.	B-X

Acad	O
.	O
<EOS>	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2020	B-X
)	B-X
,	B-X
1462	B-X
,	B-X
65-78	B-X
.	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2018	B-X
)	B-X
,	B-X
1423	B-X
,	B-X
166-175	B-X
.	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2018	B-X
)	B-X
,	B-X
1433	B-X
,	B-X
29-40	B-X
.	B-X
In	B-X
Memoriam	B-X
Acad	B-X
.	B-X
Prof.	B-X
Dr.	B-X
LjubiÅ¡a	B-X
RakiÄ	B-X
(	B-X
1931-2022	B-X
)	B-X
.	B-X

Sci	O
.	O
<EOS>	B-X
Molecules	B-X
and	B-X
Biomaterial	B-X
Technologies	B-X
Affecting	B-X
Stem	B-X
Cell	B-X
Differentiation	B-X
.	B-X

U	O
.	O
S	O
.	O
A	O
.	O
<EOS>	B-X
NUTRITIONAL	B-X
WELL-BEING	B-X
IN	B-X
THE	B-X
U.S.A.	B-X
Nutritional	B-X
status	B-X
,	B-X
U.S.A	B-X
.	B-X
Abortion	B-X
in	B-X
U.S.A	B-X
.	B-X
Persons	B-X
with	B-X
disabilities	B-X
represent	B-X
a	B-X
growing	B-X
population	B-X
in	B-X
both	B-X
the	B-X
European	B-X
Union	B-X
(	B-X
EU	B-X
)	B-X
and	B-X
the	B-X
United	B-X
States	B-X
(	B-X
USA	B-X
)	B-X
.	B-X
The	B-X
EU	B-X
has	B-X
made	B-X
substantial	B-X
policy	B-X
progress	B-X
to	B-X
support	B-X
telework	B-X
,	B-X
but	B-X
persons	B-X
with	B-X
disabilities	B-X
have	B-X
had	B-X
only	B-X
limited	B-X
long-term	B-X
success	B-X
in	B-X
telework	B-X
initiatives	B-X
due	B-X
to	B-X
lack	B-X
of	B-X
work	B-X
support	B-X
services	B-X
.	B-X
The	B-X
USA	B-X
has	B-X
generally	B-X
strong	B-X
support	B-X
services	B-X
but	B-X
lacks	B-X
telework	B-X
policy	B-X
infrastructure	B-X
.	B-X
The	B-X
EU	B-X
and	B-X
the	B-X
USA	B-X
can	B-X
benefit	B-X
from	B-X
collaborative	B-X
work	B-X
to	B-X
enhance	B-X
their	B-X
complementary	B-X
strengths	B-X
.	B-X

75	O
,	O
1299	O
-	O
1303	O
.	O
<EOS>	B-X
Epidemiology	B-X
and	B-X
infection	B-X
control	B-X
.	B-X
Dr.	B-X
Gordon	B-X
Bates	B-X
:	B-X
a	B-X
personal	B-X
war	B-X
against	B-X
VD	B-X
.	B-X

30	O
.	O

Catterall	O
,	O
J	O
.	O
<EOS>	B-X
Streptococcus	B-X
pneumoniae	B-X
.	B-X
Pulmonary	B-X
toxoplasmosis	B-X
.	B-X
ABC	B-X
of	B-X
sleep	B-X
disorders	B-X
.	B-X
Nocturnal	B-X
asthma	B-X
.	B-X
The	B-X
ovalbumin	B-X
gene	B-X
:	B-X
organization	B-X
,	B-X
structure	B-X
,	B-X
transcription	B-X
,	B-X
and	B-X
regulation	B-X
.	B-X

F	O
.	O
,	O
Stein	O
,	O
J	O
.	O
<EOS>	B-X
Previously	B-X
,	B-X
iterative	B-X
rounds	B-X
of	B-X
protein	B-X
engineering	B-X
were	B-X
performed	B-X
to	B-X
preserve	B-X
the	B-X
prefusion	B-X
conformation	B-X
of	B-X
the	B-X
respiratory	B-X
syncytial	B-X
virus	B-X
(	B-X
RSV	B-X
)	B-X
fusion	B-X
(	B-X
F	B-X
)	B-X
glycoprotein	B-X
,	B-X
resulting	B-X
in	B-X
a	B-X
stabilized	B-X
subunit	B-X
vaccine	B-X
candidate	B-X
(	B-X
DS-Cav1	B-X
)	B-X
,	B-X
which	B-X
showed	B-X
promising	B-X
results	B-X
in	B-X
mice	B-X
and	B-X
macaques	B-X
.	B-X
Here	B-X
,	B-X
phase	B-X
I	B-X
human	B-X
immunogenicity	B-X
data	B-X
reveal	B-X
a	B-X
more	B-X
than	B-X
10-fold	B-X
boost	B-X
in	B-X
neutralizing	B-X
activity	B-X
in	B-X
serum	B-X
from	B-X
antibodies	B-X
targeting	B-X
prefusion-specific	B-X
surfaces	B-X
of	B-X
RSV	B-X
F.	B-X
These	B-X
findings	B-X
represent	B-X
a	B-X
clinical	B-X
proof	B-X
of	B-X
concept	B-X
for	B-X
structure-based	B-X
vaccine	B-X
design	B-X
,	B-X
suggest	B-X
that	B-X
development	B-X
of	B-X
a	B-X
successful	B-X
RSV	B-X
vaccine	B-X
will	B-X
be	B-X
feasible	B-X
,	B-X
and	B-X
portend	B-X
an	B-X
era	B-X
of	B-X
precision	B-X
vaccinology	B-X
.	B-X
Eine	B-X
Untersuchung	B-X
der	B-X
Stiftung	B-X
Warentest	B-X
im	B-X
Jahr	B-X
2017	B-X
stellte	B-X
wesentliche	B-X
Schwachstellen	B-X
bei	B-X
der	B-X
Beratung	B-X
und	B-X
nachfolgend	B-X
ein	B-X
massives	B-X
Versorgungsdefizit	B-X
bei	B-X
Patienten	B-X
mit	B-X
Harninkontinenz	B-X
heraus	B-X
.	B-X
Wesentliche	B-X
Aspekte	B-X
der	B-X
Hilfsmittelberatung	B-X
sind	B-X
die	B-X
Feststellung	B-X
der	B-X
Inkontinenzform	B-X
und	B-X
deren	B-X
AusprÃ¤gung	B-X
,	B-X
sowie	B-X
die	B-X
AbklÃ¤rung	B-X
und	B-X
AufklÃ¤rung	B-X
hinsichtlich	B-X
einer	B-X
mÃ¶glichen	B-X
kurativen	B-X
Therapieform	B-X
.	B-X
FÃ¼r	B-X
eine	B-X
optimale	B-X
Versorgung	B-X
,	B-X
die	B-X
anatomische	B-X
Eigenheiten	B-X
als	B-X
auch	B-X
WÃ¼nsche	B-X
des	B-X
Betroffenen	B-X
berÃ¼cksichtigt	B-X
,	B-X
kommt	B-X
der	B-X
ggf	B-X
.	B-X

P	O
.	O
,	O
Lai	O
,	O
E	O
.	O
<EOS>	B-X
Plasma	B-X
TMAO	B-X
levels	B-X
were	B-X
indeed	B-X
elevated	B-X
in	B-X
hypertensive	B-X
patients	B-X
,	B-X
thus	B-X
the	B-X
potential	B-X
pathways	B-X
by	B-X
which	B-X
TMAO	B-X
mediates	B-X
these	B-X
effects	B-X
were	B-X
explored	B-X
.	B-X
However	B-X
,	B-X
it	B-X
is	B-X
unknown	B-X
whether	B-X
either	B-X
approach	B-X
is	B-X
superior	B-X
,	B-X
especially	B-X
for	B-X
major	B-X
hepatectomy	B-X
such	B-X
as	B-X
right	B-X
hepatectomy	B-X
or	B-X
extended	B-X
right	B-X
hepatectomy	B-X
(	B-X
RH/ERH	B-X
)	B-X
.	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
clarify	B-X
the	B-X
current	B-X
knowledge	B-X
on	B-X
the	B-X
use	B-X
of	B-X
immunotherapy	B-X
in	B-X
patients	B-X
with	B-X
advanced	B-X
gastric	B-X
(	B-X
G	B-X
)	B-X
/gastroesophageal	B-X
(	B-X
GEJ	B-X
)	B-X
cancers	B-X
.	B-X
Evidence	B-X
about	B-X
the	B-X
association	B-X
between	B-X
types	B-X
of	B-X
oral	B-X
anticoagulants	B-X
and	B-X
hazards	B-X
of	B-X
diabetes	B-X
complications	B-X
is	B-X
limited	B-X
in	B-X
patients	B-X
with	B-X
atrial	B-X
fibrillation	B-X
(	B-X
AF	B-X
)	B-X
and	B-X
diabetes	B-X
mellitus	B-X
(	B-X
DM	B-X
)	B-X
.	B-X

C	O
.	O
,	O
Woo	O
,	O
S	O
.	O
<EOS>	B-X
Self-management	B-X
of	B-X
lifestyle	B-X
and	B-X
cardiovascular	B-X
disease	B-X
risk	B-X
factors	B-X
is	B-X
challenging	B-X
in	B-X
older	B-X
patients	B-X
with	B-X
coronary	B-X
heart	B-X
disease	B-X
(	B-X
CHD	B-X
)	B-X
.	B-X
After	B-X
proof-of-principle	B-X
studies	B-X
using	B-X
the	B-X
mouse	B-X
STING	B-X
agonist	B-X
DMXAA	B-X
showed	B-X
a	B-X
potent	B-X
therapeutic	B-X
effect	B-X
,	B-X
we	B-X
generated	B-X
synthetic	B-X
cyclic	B-X
dinucleotide	B-X
(	B-X
CDN	B-X
)	B-X
derivatives	B-X
that	B-X
activated	B-X
all	B-X
human	B-X
STING	B-X
alleles	B-X
as	B-X
well	B-X
as	B-X
murine	B-X
STING	B-X
.	B-X
Synthetic	B-X
CDNs	B-X
have	B-X
high	B-X
translational	B-X
potential	B-X
as	B-X
a	B-X
cancer	B-X
therapeutic	B-X
.	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
procalcitonin	B-X
(	B-X
PCT	B-X
)	B-X
for	B-X
the	B-X
diagnosis	B-X
and	B-X
prognosis	B-X
of	B-X
sepsis	B-X
using	B-X
SEPSIS-3	B-X
.	B-X

L	O
.	O
<EOS>	B-X
L-Cysteine	B-X
is	B-X
an	B-X
important	B-X
amino	B-X
acid	B-X
both	B-X
biologically	B-X
and	B-X
commercially	B-X
.	B-X
Although	B-X
most	B-X
amino	B-X
acids	B-X
are	B-X
industrially	B-X
produced	B-X
by	B-X
microbial	B-X
fermentation	B-X
,	B-X
L-cysteine	B-X
has	B-X
been	B-X
mainly	B-X
produced	B-X
by	B-X
protein	B-X
hydrolysis	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
reviewed	B-X
L-cysteine	B-X
metabolism	B-X
,	B-X
including	B-X
biosynthesis	B-X
,	B-X
degradation	B-X
,	B-X
and	B-X
transport	B-X
,	B-X
and	B-X
biotechnological	B-X
production	B-X
(	B-X
including	B-X
both	B-X
enzymatic	B-X
and	B-X
fermentation	B-X
processes	B-X
)	B-X
of	B-X
L-cysteine	B-X
.	B-X
The	B-X
metabolic	B-X
regulation	B-X
of	B-X
L-cysteine	B-X
including	B-X
novel	B-X
sulfur	B-X
metabolic	B-X
pathways	B-X
found	B-X
in	B-X
microorganisms	B-X
is	B-X
also	B-X
discussed	B-X
.	B-X
Recent	B-X
advancement	B-X
in	B-X
biochemical	B-X
studies	B-X
,	B-X
genome	B-X
sequencing	B-X
,	B-X
structural	B-X
biology	B-X
,	B-X
and	B-X
metabolome	B-X
analysis	B-X
has	B-X
enabled	B-X
us	B-X
to	B-X
use	B-X
various	B-X
approaches	B-X
to	B-X
achieve	B-X
direct	B-X
fermentation	B-X
of	B-X
L-cysteine	B-X
from	B-X
glucose	B-X
.	B-X
For	B-X
example	B-X
,	B-X
worldwide	B-X
companies	B-X
began	B-X
to	B-X
supply	B-X
L-cysteine	B-X
and	B-X
its	B-X
derivatives	B-X
produced	B-X
by	B-X
bacterial	B-X
fermentation	B-X
.	B-X
Basically	B-X
,	B-X
a	B-X
combination	B-X
of	B-X
three	B-X
factors	B-X
should	B-X
be	B-X
required	B-X
for	B-X
improving	B-X
L-cysteine	B-X
fermentation	B-X
:	B-X
that	B-X
is	B-X
,	B-X
(	B-X
1	B-X
)	B-X
enhancing	B-X
biosynthesis	B-X
:	B-X
overexpression	B-X
of	B-X
the	B-X
altered	B-X
cysE	B-X
gene	B-X
encoding	B-X
feedback	B-X
inhibition-insensitive	B-X
L-serine	B-X
O-acetyltransferase	B-X
(	B-X
SAT	B-X
)	B-X
,	B-X
(	B-X
2	B-X
)	B-X
weakening	B-X
degradation	B-X
:	B-X
knockout	B-X
of	B-X
the	B-X
genes	B-X
encoding	B-X
L-cysteine	B-X
desulfhydrases	B-X
,	B-X
and	B-X
(	B-X
3	B-X
)	B-X
exploiting	B-X
export	B-X
system	B-X
:	B-X
overexpression	B-X
of	B-X
the	B-X
gene	B-X
involved	B-X
in	B-X
L-cysteine	B-X
transport	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
found	B-X
that	B-X
``	B-X
thiosulfate	B-X
''	B-X
is	B-X
much	B-X
more	B-X
effective	B-X
sulfur	B-X
source	B-X
than	B-X
commonly	B-X
used	B-X
``	B-X
sulfate	B-X
''	B-X
for	B-X
L-cysteine	B-X
production	B-X
in	B-X
Escherichia	B-X
coli	B-X
,	B-X
because	B-X
thiosulfate	B-X
is	B-X
advantageous	B-X
for	B-X
saving	B-X
consumption	B-X
of	B-X
NADPH	B-X
and	B-X
relating	B-X
energy	B-X
molecules	B-X
.	B-X

C	O
.	O
,	O
<EOS>	B-X
Chlorella	B-X
vulgaris	B-X
growth	B-X
was	B-X
assessed	B-X
for	B-X
lipids	B-X
accumulation	B-X
and	B-X
subsequent	B-X
recovery	B-X
,	B-X
using	B-X
two	B-X
types	B-X
of	B-X
digestate	B-X
:	B-X
organic	B-X
waste	B-X
and	B-X
sewage	B-X
sludge	B-X
digestate	B-X
(	B-X
DIG-OFMSW	B-X
)	B-X
and	B-X
wine	B-X
lees	B-X
digestate	B-X
(	B-X
DIG-WL	B-X
)	B-X
.	B-X
Developing	B-X
Grit	B-X
.	B-X
The	B-X
major	B-X
characteristic	B-X
of	B-X
this	B-X
diseased	B-X
state	B-X
is	B-X
that	B-X
Î²-hCG	B-X
rises	B-X
up	B-X
manifold	B-X
than	B-X
that	B-X
is	B-X
observed	B-X
during	B-X
pregnancy	B-X
.	B-X
Orphan	B-X
cytochromes	B-X
P450	B-X
(	B-X
CYP	B-X
)	B-X
are	B-X
enzymes	B-X
whose	B-X
biological	B-X
functions	B-X
and	B-X
substrates	B-X
are	B-X
unknown	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
we	B-X
review	B-X
the	B-X
regulatory	B-X
pathways	B-X
and	B-X
the	B-X
possible	B-X
role	B-X
of	B-X
orphan	B-X
CYP	B-X
to	B-X
provide	B-X
evidence	B-X
that	B-X
allow	B-X
us	B-X
to	B-X
stop	B-X
considering	B-X
some	B-X
of	B-X
them	B-X
as	B-X
orphan	B-X
enzymes	B-X
and	B-X
to	B-X
propose	B-X
them	B-X
as	B-X
possible	B-X
therapeutic	B-X
targets	B-X
in	B-X
the	B-X
design	B-X
of	B-X
new	B-X
strategies	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
diseases	B-X
associated	B-X
with	B-X
CYP-mediated	B-X
metabolism	B-X
.	B-X

Dugaiczyk	O
,	O
Mace	O
,	O
M	O
.	O

L	O
.	O
,	O
Means	O
,	O
A	O
.	O
<EOS>	B-X
AMPK	B-X
can	B-X
be	B-X
phosphorylated	B-X
and	B-X
activated	B-X
by	B-X
the	B-X
tumor	B-X
suppressor	B-X
LKB1	B-X
or	B-X
the	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
/CaM-dependent	B-X
protein	B-X
kinase	B-X
kinase	B-X
Î²	B-X
(	B-X
CaMKKÎ²	B-X
)	B-X
.	B-X
We	B-X
previously	B-X
identified	B-X
a	B-X
physical	B-X
complex	B-X
between	B-X
CaMKKÎ²	B-X
and	B-X
AMPK	B-X
(	B-X
Anderson	B-X
,	B-X
K.	B-X
A.	B-X
,	B-X
Ribar	B-X
,	B-X
T.	B-X
J.	B-X
,	B-X
Lin	B-X
,	B-X
F.	B-X
,	B-X
Noeldner	B-X
,	B-X
P.	B-X
K.	B-X
,	B-X
Green	B-X
,	B-X
M.	B-X
F.	B-X
,	B-X
Muehlbauer	B-X
,	B-X
M.	B-X
J.	B-X
,	B-X
Witters	B-X
,	B-X
L.	B-X
A.	B-X
,	B-X
Kemp	B-X
,	B-X
B.	B-X
E.	B-X
,	B-X
and	B-X
Means	B-X
,	B-X
A.	B-X
R.	B-X
(	B-X
2008	B-X
)	B-X
Cell	B-X
Metabolism	B-X
7	B-X
,	B-X
377-388	B-X
)	B-X
.	B-X
Smooth	B-X
muscle	B-X
myosin	B-X
light	B-X
chain	B-X
kinase	B-X
contains	B-X
a	B-X
64	B-X
residue	B-X
sequence	B-X
that	B-X
binds	B-X
calmodulin	B-X
in	B-X
a	B-X
Ca2+-dependent	B-X
manner	B-X
(	B-X
Guerriero	B-X
,	B-X
V.	B-X
,	B-X
Jr.	B-X
,	B-X
Russo	B-X
,	B-X
M.	B-X
A.	B-X
,	B-X
and	B-X
Means	B-X
,	B-X
A.	B-X
R.	B-X
(	B-X
1987	B-X
)	B-X
Biochemistry	B-X
,	B-X
in	B-X
press	B-X
)	B-X
.	B-X
Within	B-X
this	B-X
region	B-X
is	B-X
a	B-X
sequence	B-X
with	B-X
homology	B-X
to	B-X
the	B-X
corresponding	B-X
sequence	B-X
reported	B-X
for	B-X
the	B-X
calmodulin	B-X
binding	B-X
region	B-X
of	B-X
skeletal	B-X
muscle	B-X
myosin	B-X
light	B-X
chain	B-X
kinase	B-X
(	B-X
Blumenthal	B-X
,	B-X
D.	B-X
K.	B-X
,	B-X
Takio	B-X
,	B-X
K.	B-X
,	B-X
Edelman	B-X
,	B-X
A.	B-X
M.	B-X
,	B-X
Charbonneau	B-X
,	B-X
H.	B-X
,	B-X
Titani	B-X
,	B-X
L.	B-X
,	B-X
Walsh	B-X
,	B-X
K.	B-X
A.	B-X
,	B-X
and	B-X
Krebs	B-X
,	B-X
E.	B-X
G.	B-X
(	B-X
1985	B-X
)	B-X
Proc	B-X
.	B-X
This	B-X
peptide	B-X
,	B-X
Ala-Lys-Lys-Leu-Ser-Lys-Asp-Arg-Met-Lys-Lys-Tyr-Met-Ala-Arg-Arg-Lys-Trp-	B-X
Gln-Lys-Thr-Gly	B-X
,	B-X
inhibited	B-X
calmodulin-dependent	B-X
activation	B-X
of	B-X
the	B-X
smooth	B-X
muscle	B-X
myosin	B-X
light	B-X
chain	B-X
kinase	B-X
with	B-X
an	B-X
IC50	B-X
of	B-X
46	B-X
nM	B-X
.	B-X
An	B-X
11-residue	B-X
synthetic	B-X
peptide	B-X
analog	B-X
,	B-X
corresponding	B-X
to	B-X
part	B-X
of	B-X
the	B-X
calmodulin-binding	B-X
sequence	B-X
in	B-X
skeletal	B-X
muscle	B-X
myosin	B-X
light	B-X
chain	B-X
kinase	B-X
,	B-X
Lys-Arg-Arg-Trp-Lys-Lys-Asn-Phe-Ile-Ala-Val	B-X
,	B-X
also	B-X
competitively	B-X
inhibited	B-X
synthetic	B-X
peptide	B-X
substrate	B-X
phosphorylation	B-X
with	B-X
a	B-X
Ki	B-X
of	B-X
1	B-X
microM	B-X
.	B-X

R	O
.	O
,	O
and	O
O	O
'	O
Malley	O
,	O
B	O
.	O

W	O
.	O
<EOS>	B-X
We	B-X
present	B-X
a	B-X
novel	B-X
static	B-X
W-shaped	B-X
common-path	B-X
interferometer	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
the	B-X
W-shaped	B-X
common-path	B-X
corner-cube	B-X
retroreflector	B-X
interferometer	B-X
(	B-X
W-CPRI	B-X
)	B-X
is	B-X
introduced	B-X
via	B-X
detailed	B-X
analysis	B-X
of	B-X
its	B-X
working	B-X
principles	B-X
and	B-X
performance	B-X
.	B-X
For	B-X
each	B-X
interference	B-X
output	B-X
of	B-X
an	B-X
ideal	B-X
W-CPRI	B-X
,	B-X
the	B-X
two	B-X
beams	B-X
recombine	B-X
and	B-X
have	B-X
the	B-X
same	B-X
output	B-X
direction	B-X
,	B-X
including	B-X
a	B-X
tilted	B-X
CCR	B-X
.	B-X
In	B-X
a	B-X
deformed	B-X
W-CPRI	B-X
structure	B-X
,	B-X
an	B-X
optical	B-X
path	B-X
difference	B-X
can	B-X
be	B-X
produced	B-X
by	B-X
inserting	B-X
an	B-X
optical	B-X
element	B-X
that	B-X
changes	B-X
the	B-X
optical	B-X
path	B-X
in	B-X
the	B-X
interferometer	B-X
arm	B-X
of	B-X
the	B-X
W-CPRI	B-X
.	B-X
The	B-X
posture	B-X
deviations	B-X
of	B-X
the	B-X
RM	B-X
and	B-X
the	B-X
CCRs	B-X
in	B-X
the	B-X
W-CPRI	B-X
are	B-X
analyzed	B-X
.	B-X
The	B-X
average	B-X
cosine	B-X
similarity	B-X
is	B-X
0.9953	B-X
,	B-X
revealing	B-X
that	B-X
this	B-X
W-CPRI	B-X
has	B-X
high	B-X
stability	B-X
and	B-X
strong	B-X
coherence	B-X
while	B-X
avoiding	B-X
the	B-X
tilt	B-X
and	B-X
displacement	B-X
of	B-X
the	B-X
interferometer	B-X
arm	B-X
.	B-X

(	O
1979	O
)	O
Nature	O
278	O
,	O
323	O
-	O
327	O
.	O

31	O
.	O

White	O
,	O
R	O
.	O
<EOS>	B-X
Using	B-X
a	B-X
combination	B-X
of	B-X
a	B-X
human	B-X
pluripotent	B-X
stem	B-X
cellâderived	B-X
cancer	B-X
model	B-X
along	B-X
with	B-X
zebrafish	B-X
transgenesis	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
transforming	B-X
ability	B-X
of	B-X
BRAF	B-X
Here	B-X
,	B-X
we	B-X
integrate	B-X
spatially	B-X
resolved	B-X
transcriptomics	B-X
,	B-X
single-cell	B-X
RNA-seq	B-X
,	B-X
and	B-X
single-nucleus	B-X
RNA-seq	B-X
to	B-X
characterize	B-X
tumor-microenvironment	B-X
interactions	B-X
at	B-X
the	B-X
tumor	B-X
boundary	B-X
.	B-X
Given	B-X
the	B-X
importance	B-X
of	B-X
flexible	B-X
use	B-X
of	B-X
different	B-X
COVID-19	B-X
vaccines	B-X
within	B-X
the	B-X
same	B-X
schedule	B-X
to	B-X
facilitate	B-X
rapid	B-X
deployment	B-X
,	B-X
we	B-X
studied	B-X
mixed	B-X
priming	B-X
schedules	B-X
incorporating	B-X
an	B-X
adenoviral-vectored	B-X
vaccine	B-X
(	B-X
ChAdOx1	B-X
nCoV-19	B-X
[	B-X
ChAd	B-X
]	B-X
,	B-X
AstraZeneca	B-X
)	B-X
,	B-X
two	B-X
mRNA	B-X
vaccines	B-X
(	B-X
BNT162b2	B-X
[	B-X
BNT	B-X
]	B-X
,	B-X
Pfizer-BioNTech	B-X
,	B-X
and	B-X
mRNA-1273	B-X
[	B-X
m1273	B-X
]	B-X
,	B-X
Moderna	B-X
)	B-X
and	B-X
a	B-X
nanoparticle	B-X
vaccine	B-X
containing	B-X
SARS-CoV-2	B-X
spike	B-X
glycoprotein	B-X
and	B-X
Matrix-M	B-X
adjuvant	B-X
(	B-X
NVX-CoV2373	B-X
[	B-X
NVX	B-X
]	B-X
,	B-X
Novavax	B-X
)	B-X
.	B-X
However	B-X
,	B-X
we	B-X
have	B-X
previously	B-X
reported	B-X
that	B-X
heterologous	B-X
schedules	B-X
incorporating	B-X
an	B-X
adenoviral	B-X
vectored	B-X
vaccine	B-X
(	B-X
ChAdOx1	B-X
nCoV-19	B-X
,	B-X
AstraZeneca	B-X
;	B-X
hereafter	B-X
referred	B-X
to	B-X
as	B-X
ChAd	B-X
)	B-X
and	B-X
an	B-X
mRNA	B-X
vaccine	B-X
(	B-X
BNT162b2	B-X
,	B-X
Pfizer-BioNTech	B-X
;	B-X
hereafter	B-X
referred	B-X
to	B-X
as	B-X
BNT	B-X
)	B-X
at	B-X
a	B-X
4-week	B-X
interval	B-X
are	B-X
more	B-X
reactogenic	B-X
than	B-X
homologous	B-X
schedules	B-X
.	B-X

L	O
.	O
,	O
and	O
Hogness	O
,	O
D	O
.	O

S	O
.	O
<EOS>	B-X
Finkelstein	B-X
's	B-X
Test	B-X
Is	B-X
Superior	B-X
to	B-X
Eichhoff	B-X
's	B-X
Test	B-X
in	B-X
the	B-X
Investigation	B-X
of	B-X
de	B-X
Quervain	B-X
's	B-X
Disease	B-X
.	B-X
Protein	B-X
S	B-X
deficiency	B-X
.	B-X
Letter	B-X
:	B-X
Craniometrics	B-X
and	B-X
Ventricular	B-X
Access	B-X
:	B-X
A	B-X
Review	B-X
of	B-X
Kocher	B-X
's	B-X
,	B-X
Kaufman	B-X
's	B-X
,	B-X
Paine	B-X
's	B-X
,	B-X
Menovksy	B-X
's	B-X
,	B-X
Tubbs	B-X
'	B-X
,	B-X
Keen	B-X
's	B-X
,	B-X
Frazier	B-X
's	B-X
,	B-X
Dandy	B-X
's	B-X
,	B-X
and	B-X
Sanchez	B-X
's	B-X
Points	B-X
.	B-X

(	O
1977	O
)	O
Cell	O
10	O
,	O
177	O
-	O
192	O
.	O

32	O
.	O

Glover	O
,	O
D	O
.	O
<EOS>	B-X
New	B-X
Year	B-X
's	B-X
revolution	B-X
.	B-X
The	B-X
centrosome	B-X
.	B-X
Open	B-X
Biology	B-X
in	B-X
a	B-X
new	B-X
decade	B-X
.	B-X
A	B-X
new	B-X
world	B-X
for	B-X
Open	B-X
Biology	B-X
.	B-X

M	O
.	O
,	O
and	O
Hogness	O
,	O
D	O
.	O

S	O
.	O
<EOS>	B-X
Finkelstein	B-X
's	B-X
Test	B-X
Is	B-X
Superior	B-X
to	B-X
Eichhoff	B-X
's	B-X
Test	B-X
in	B-X
the	B-X
Investigation	B-X
of	B-X
de	B-X
Quervain	B-X
's	B-X
Disease	B-X
.	B-X
Protein	B-X
S	B-X
deficiency	B-X
.	B-X
Letter	B-X
:	B-X
Craniometrics	B-X
and	B-X
Ventricular	B-X
Access	B-X
:	B-X
A	B-X
Review	B-X
of	B-X
Kocher	B-X
's	B-X
,	B-X
Kaufman	B-X
's	B-X
,	B-X
Paine	B-X
's	B-X
,	B-X
Menovksy	B-X
's	B-X
,	B-X
Tubbs	B-X
'	B-X
,	B-X
Keen	B-X
's	B-X
,	B-X
Frazier	B-X
's	B-X
,	B-X
Dandy	B-X
's	B-X
,	B-X
and	B-X
Sanchez	B-X
's	B-X
Points	B-X
.	B-X

(	O
1977	O
)	O
Cell	O
16	O
,	O
167	O
-	O
176	O
.	O

33	O
.	O

Wellauer	O
,	O
P	O
.	O
<EOS>	B-X
Stevenson	B-X
,	B-X
M.	B-X
Strubin	B-X
,	B-X
O.	B-X
HagenbÃ¼chle	B-X
,	B-X
and	B-X
P.	B-X
K.	B-X
Wellauer	B-X
,	B-X
Mol	B-X
.	B-X
Purification	B-X
of	B-X
binding	B-X
activities	B-X
from	B-X
pancreatic	B-X
cells	B-X
by	B-X
DNA	B-X
affinity	B-X
chromatography	B-X
reveals	B-X
several	B-X
distinct	B-X
proteins	B-X
ranging	B-X
in	B-X
size	B-X
from	B-X
45	B-X
to	B-X
54	B-X
kDa	B-X
(	B-X
p45	B-X
,	B-X
p47/48	B-X
,	B-X
and	B-X
p54	B-X
)	B-X
.	B-X
Protein	B-X
sequencing	B-X
,	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
,	B-X
and	B-X
immunoblot	B-X
analyses	B-X
identify	B-X
p54	B-X
and	B-X
p47/48	B-X
as	B-X
members	B-X
of	B-X
the	B-X
hepatocyte	B-X
nuclear	B-X
factor	B-X
3	B-X
(	B-X
HNF3	B-X
[	B-X
forkhead	B-X
]	B-X
)	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
.	B-X
Structural	B-X
arrangement	B-X
and	B-X
tissue-specific	B-X
expression	B-X
of	B-X
the	B-X
two	B-X
murine	B-X
alpha-amylase	B-X
loci	B-X
Amy-1	B-X
and	B-X
Amy-2	B-X
.	B-X

K	O
.	O
,	O
and	O
David	O
,	O
I	O
.	O
<EOS>	B-X
Reconstruction	B-X
quality	B-X
and	B-X
usability	B-X
of	B-X
the	B-X
DCE-MRI	B-X
sequences	B-X
is	B-X
demonstrated	B-X
by	B-X
calculating	B-X
the	B-X
pharmacokinetic	B-X
(	B-X
PK	B-X
)	B-X
parameters	B-X
.	B-X
The	B-X
proposed	B-X
MRI	B-X
reconstruction	B-X
approach	B-X
is	B-X
shown	B-X
to	B-X
outperform	B-X
state-of-the-art	B-X
methods	B-X
for	B-X
all	B-X
datasets	B-X
tested	B-X
in	B-X
terms	B-X
of	B-X
the	B-X
peak	B-X
signal-to-noise	B-X
ratio	B-X
(	B-X
PSNR	B-X
)	B-X
,	B-X
the	B-X
structural	B-X
similarity	B-X
index	B-X
(	B-X
SSIM	B-X
)	B-X
,	B-X
as	B-X
well	B-X
as	B-X
either	B-X
the	B-X
mean	B-X
squared	B-X
error	B-X
(	B-X
MSE	B-X
)	B-X
with	B-X
respect	B-X
to	B-X
the	B-X
PK	B-X
parameters	B-X
,	B-X
calculated	B-X
for	B-X
the	B-X
fully	B-X
sampled	B-X
DCE-MRI	B-X
sequences	B-X
,	B-X
or	B-X
the	B-X
segmentation	B-X
compatibility	B-X
,	B-X
measured	B-X
in	B-X
terms	B-X
of	B-X
Dice	B-X
scores	B-X
and	B-X
Hausdorff	B-X
distance	B-X
.	B-X
Bacteremia	B-X
is	B-X
a	B-X
common	B-X
complication	B-X
of	B-X
pneumonia	B-X
with	B-X
Klebsiella	B-X
pneumoniae	B-X
.	B-X
In	B-X
the	B-X
previous	B-X
work	B-X
,	B-X
we	B-X
have	B-X
shown	B-X
that	B-X
the	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
O-antigen	B-X
in	B-X
K.	B-X
pneumoniae	B-X
O1	B-X
:	B-X
K2	B-X
contributes	B-X
to	B-X
lethality	B-X
during	B-X
pneumonia	B-X
in	B-X
part	B-X
by	B-X
promoting	B-X
bacteremia	B-X
.	B-X
In	B-X
the	B-X
current	B-X
work	B-X
,	B-X
we	B-X
studied	B-X
an	B-X
O-antigen-deficient	B-X
K.	B-X
pneumoniae	B-X
strain	B-X
to	B-X
further	B-X
evaluate	B-X
this	B-X
polysaccharide	B-X
's	B-X
role	B-X
in	B-X
bloodstream	B-X
infection	B-X
.	B-X
O-antigen-deficient	B-X
Klebsiellae	B-X
were	B-X
also	B-X
more	B-X
susceptible	B-X
to	B-X
killing	B-X
by	B-X
murine	B-X
neutrophils	B-X
.	B-X
The	B-X
O-antigen	B-X
surface	B-X
carbohydrate	B-X
of	B-X
O1	B-X
:	B-X
K2	B-X
serotype	B-X
K.	B-X
pneumoniae	B-X
appears	B-X
to	B-X
contribute	B-X
to	B-X
bacterial	B-X
virulence	B-X
by	B-X
lessening	B-X
the	B-X
activation	B-X
of	B-X
macrophages	B-X
,	B-X
conveying	B-X
resistance	B-X
to	B-X
killing	B-X
by	B-X
neutrophils	B-X
,	B-X
and	B-X
by	B-X
promoting	B-X
persistent	B-X
infection	B-X
in	B-X
the	B-X
blood	B-X
,	B-X
liver	B-X
,	B-X
and	B-X
spleen	B-X
after	B-X
the	B-X
onset	B-X
of	B-X
bacteremia	B-X
.	B-X

B	O
.	O
<EOS>	B-X
Hepatitis	B-X
B	B-X
is	B-X
caused	B-X
by	B-X
the	B-X
hepatitis	B-X
B	B-X
virus	B-X
(	B-X
HBV	B-X
)	B-X
,	B-X
which	B-X
infects	B-X
the	B-X
liver	B-X
and	B-X
may	B-X
lead	B-X
to	B-X
chronic	B-X
liver	B-X
disease	B-X
,	B-X
including	B-X
cirrhosis	B-X
and	B-X
hepatocellular	B-X
carcinoma	B-X
.	B-X
HBV	B-X
represents	B-X
a	B-X
worldwide	B-X
public	B-X
health	B-X
problem	B-X
,	B-X
causing	B-X
major	B-X
morbidity	B-X
and	B-X
mortality	B-X
.	B-X
Affordable	B-X
,	B-X
safe	B-X
,	B-X
and	B-X
effective	B-X
,	B-X
hepatitis	B-X
B	B-X
vaccines	B-X
are	B-X
the	B-X
best	B-X
tools	B-X
we	B-X
have	B-X
to	B-X
control	B-X
and	B-X
prevent	B-X
hepatitis	B-X
B	B-X
.	B-X
In	B-X
2019	B-X
,	B-X
coverage	B-X
of	B-X
3	B-X
doses	B-X
of	B-X
the	B-X
hepatitis	B-X
B	B-X
vaccine	B-X
reached	B-X
85	B-X
%	B-X
worldwide	B-X
compared	B-X
to	B-X
around	B-X
30	B-X
%	B-X
in	B-X
2000	B-X
.	B-X
The	B-X
effective	B-X
implementation	B-X
of	B-X
hepatitis	B-X
B	B-X
vaccination	B-X
programs	B-X
has	B-X
resulted	B-X
in	B-X
a	B-X
substantial	B-X
decrease	B-X
in	B-X
the	B-X
HBV	B-X
carrier	B-X
rate	B-X
and	B-X
hepatitis	B-X
B-related	B-X
morbidity	B-X
and	B-X
mortality	B-X
.	B-X
This	B-X
article	B-X
summarizes	B-X
the	B-X
great	B-X
triumphs	B-X
of	B-X
the	B-X
hepatitis	B-X
B	B-X
vaccine	B-X
,	B-X
the	B-X
first	B-X
anticancer	B-X
and	B-X
virus-like-particle-based	B-X
vaccine	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
existing	B-X
unresolved	B-X
issues	B-X
and	B-X
future	B-X
perspectives	B-X
on	B-X
hepatitis	B-X
B	B-X
vaccination	B-X
required	B-X
for	B-X
global	B-X
prevention	B-X
of	B-X
HBV	B-X
infection	B-X
are	B-X
discussed	B-X
.	B-X

(	O
1977	O
)	O
Cell	O
10	O
,	O
193	O
-	O
212	O
.	O
<EOS>	B-X
(	B-X
1977	B-X
)	B-X
Cell	B-X
10	B-X
,	B-X
193-212	B-X
]	B-X
.	B-X

34	O
.	O
<EOS>	B-X
Determinants	B-X
of	B-X
intracellular	B-X
pH	B-X
in	B-X
the	B-X
erythrocyte	B-X
.	B-X

Pellegrini	O
,	O
M	O
.	O
,	O
Manning	O
,	O
J	O
.	O
,	O
and	O
Davidson	O
,	O
N	O
.	O
<EOS>	B-X
The	B-X
sequence	B-X
arrangement	B-X
of	B-X
genes	B-X
coding	B-X
for	B-X
stable	B-X
rRNA	B-X
species	B-X
and	B-X
of	B-X
the	B-X
interspersed	B-X
spacers	B-X
on	B-X
long	B-X
single	B-X
strands	B-X
of	B-X
rDNA	B-X
purified	B-X
from	B-X
total	B-X
chromosomal	B-X
DNA	B-X
of	B-X
Drosophila	B-X
melanogaster	B-X
has	B-X
been	B-X
determined	B-X
by	B-X
a	B-X
study	B-X
of	B-X
the	B-X
structure	B-X
of	B-X
rRNA	B-X
:	B-X
DNA	B-X
hybrids	B-X
which	B-X
were	B-X
mounted	B-X
for	B-X
electron	B-X
microscope	B-X
observation	B-X
by	B-X
the	B-X
gene	B-X
32-ethidium	B-X
bromide	B-X
technique	B-X
.	B-X
A	B-X
short	B-X
sequence	B-X
coding	B-X
for	B-X
the	B-X
5.8S	B-X
and	B-X
perhaps	B-X
the	B-X
2S	B-X
rRNA	B-X
species	B-X
is	B-X
located	B-X
within	B-X
this	B-X
spacer	B-X
.	B-X
However	B-X
,	B-X
about	B-X
45	B-X
%	B-X
of	B-X
the	B-X
28S	B-X
genes	B-X
contain	B-X
an	B-X
insertion	B-X
of	B-X
an	B-X
additional	B-X
segment	B-X
of	B-X
DNA	B-X
that	B-X
is	B-X
not	B-X
complementary	B-X
to	B-X
rRNA	B-X
(	B-X
l	B-X
genes	B-X
)	B-X
.	B-X
The	B-X
sequence	B-X
arrangement	B-X
on	B-X
the	B-X
plasmid	B-X
pDm103	B-X
containing	B-X
one	B-X
repeat	B-X
of	B-X
rDNA	B-X
(	B-X
Glover	B-X
et	B-X
al.	B-X
,	B-X
1975	B-X
)	B-X
has	B-X
been	B-X
determined	B-X
by	B-X
similar	B-X
methods	B-X
.	B-X

(	O
1977	O
)	O
Cell	O
10	O
,	O
<EOS>	B-X
The	B-X
effects	B-X
of	B-X
the	B-X
metal-chelating	B-X
agent	B-X
,	B-X
1,10-phenanthroline	B-X
(	B-X
OP	B-X
)	B-X
,	B-X
on	B-X
the	B-X
cell	B-X
cycle	B-X
progression	B-X
of	B-X
CCRF-CEM	B-X
lymphoblasts	B-X
has	B-X
been	B-X
studied	B-X
by	B-X
flow	B-X
microfluorometry	B-X
.	B-X
Cell-to-cell	B-X
communication	B-X
was	B-X
characterized	B-X
in	B-X
prefusion	B-X
chick	B-X
embryo	B-X
myoblast	B-X
cultures	B-X
,	B-X
and	B-X
it	B-X
was	B-X
determined	B-X
that	B-X
the	B-X
prefusion	B-X
myoblasts	B-X
can	B-X
interact	B-X
via	B-X
gap	B-X
junctions	B-X
,	B-X
ionic	B-X
coupling	B-X
,	B-X
and	B-X
metabolic	B-X
coupling	B-X
.	B-X
In	B-X
cultures	B-X
that	B-X
were	B-X
fusion	B-X
arrested	B-X
by	B-X
treatment	B-X
with	B-X
either	B-X
1.8	B-X
mM	B-X
ethyleneglycolbis-	B-X
(	B-X
beta-aminoethyl	B-X
ether	B-X
)	B-X
N	B-X
,	B-X
N'-tetraacetic	B-X
acid	B-X
(	B-X
EGTA	B-X
)	B-X
,	B-X
3.3	B-X
X	B-X
10	B-X
(	B-X
-6	B-X
)	B-X
M	B-X
5-bromodeoxyuridine	B-X
(	B-X
BUdR	B-X
)	B-X
,	B-X
or	B-X
1	B-X
microgram/ml	B-X
cycloheximide	B-X
(	B-X
CHX	B-X
)	B-X
,	B-X
both	B-X
gap	B-X
junctions	B-X
and	B-X
ionic	B-X
coupling	B-X
were	B-X
present	B-X
.	B-X
Electrically	B-X
gated	B-X
ionic	B-X
channels	B-X
in	B-X
lipid	B-X
bilayers	B-X
.	B-X

213	O
-	O
214	O
.	O
<EOS>	B-X
Multiple	B-X
endocrine	B-X
adenomatosis-I	B-X
and	B-X
II	B-X
.	B-X
Metabolic	B-X
studies	B-X
in	B-X
experimental	B-X
renal	B-X
dysfunction	B-X
resulting	B-X
from	B-X
maleate	B-X
administration	B-X
.	B-X

35	O
.	O

Wahli	O
,	O
W	O
.	O
,	O
David	O
,	O
I	O
.	O

B	O
.	O
,	O
Wyler	O
,	O
T	O
.	O
,	O
Jaggi	O
,	O
R	O
.	O
<EOS>	B-X
Analysis	B-X
of	B-X
cDNA	B-X
clones	B-X
synthesized	B-X
from	B-X
vitellogenin	B-X
mRNA	B-X
of	B-X
X.	B-X
tropicalis	B-X
revealed	B-X
three	B-X
different	B-X
types	B-X
of	B-X
cDNA	B-X
clones	B-X
,	B-X
i.e	B-X
.	B-X
A	B-X
,	B-X
A	B-X
*	B-X
and	B-X
B	B-X
.	B-X
B	B-X
clones	B-X
however	B-X
,	B-X
are	B-X
related	B-X
to	B-X
X.	B-X
laevis	B-X
cDNA	B-X
clones	B-X
of	B-X
subgroup	B-X
B1	B-X
and	B-X
B2	B-X
with	B-X
a	B-X
sequence	B-X
divergence	B-X
of	B-X
about	B-X
7	B-X
%	B-X
.	B-X
While	B-X
the	B-X
A	B-X
and	B-X
B	B-X
clones	B-X
correspond	B-X
to	B-X
vitellogenin	B-X
mRNAs	B-X
of	B-X
similar	B-X
abundance	B-X
,	B-X
A	B-X
*	B-X
clone	B-X
is	B-X
complementary	B-X
to	B-X
a	B-X
vitellogenin	B-X
mRNA	B-X
about	B-X
100	B-X
fold	B-X
less	B-X
abundant	B-X
than	B-X
A	B-X
and	B-X
B	B-X
mRNAs	B-X
although	B-X
all	B-X
three	B-X
vitellogenin	B-X
mRNAs	B-X
are	B-X
encoded	B-X
by	B-X
single	B-X
copy	B-X
genes	B-X
.	B-X
Furthermore	B-X
,	B-X
two	B-X
forms	B-X
of	B-X
A	B-X
*	B-X
mRNA	B-X
were	B-X
found	B-X
.	B-X
Since	B-X
this	B-X
DNA	B-X
fragment	B-X
is	B-X
highly	B-X
repeated	B-X
in	B-X
the	B-X
genome	B-X
,	B-X
we	B-X
suggest	B-X
that	B-X
this	B-X
A	B-X
*	B-X
clone	B-X
was	B-X
synthesized	B-X
from	B-X
a	B-X
processing	B-X
intermediate	B-X
of	B-X
the	B-X
A	B-X
*	B-X
precursor	B-X
vitellogenin	B-X
mRNA	B-X
.	B-X

B	O
.	O
,	O
Weber	O
,	O
R	O
.	O
,	O
and	O
<EOS>	B-X
Varying	B-X
conceptualizations	B-X
of	B-X
treatment-resistant	B-X
depression	B-X
(	B-X
TRD	B-X
)	B-X
have	B-X
made	B-X
translating	B-X
research	B-X
findings	B-X
or	B-X
systematic	B-X
reviews	B-X
into	B-X
clinical	B-X
practice	B-X
guidelines	B-X
challenging	B-X
and	B-X
inconsistent	B-X
.	B-X
The	B-X
availability	B-X
of	B-X
allergen	B-X
molecules	B-X
(	B-X
'components	B-X
'	B-X
)	B-X
from	B-X
several	B-X
protein	B-X
families	B-X
has	B-X
advanced	B-X
our	B-X
understanding	B-X
of	B-X
immunoglobulin	B-X
E	B-X
(	B-X
IgE	B-X
)	B-X
-mediated	B-X
responses	B-X
and	B-X
enabled	B-X
'component-resolved	B-X
diagnosis	B-X
'	B-X
(	B-X
CRD	B-X
)	B-X
.	B-X
The	B-X
European	B-X
Academy	B-X
of	B-X
Allergy	B-X
and	B-X
Clinical	B-X
Immunology	B-X
(	B-X
EAACI	B-X
)	B-X
Molecular	B-X
Allergology	B-X
User	B-X
's	B-X
Guide	B-X
(	B-X
MAUG	B-X
)	B-X
provides	B-X
comprehensive	B-X
information	B-X
on	B-X
important	B-X
allergens	B-X
and	B-X
describes	B-X
the	B-X
diagnostic	B-X
options	B-X
using	B-X
CRD	B-X
.	B-X
Part	B-X
B	B-X
discusses	B-X
the	B-X
clinical	B-X
and	B-X
molecular	B-X
aspects	B-X
of	B-X
IgE-mediated	B-X
allergies	B-X
to	B-X
foods	B-X
(	B-X
including	B-X
nuts	B-X
,	B-X
seeds	B-X
,	B-X
legumes	B-X
,	B-X
fruits	B-X
,	B-X
vegetables	B-X
,	B-X
cereal	B-X
grains	B-X
,	B-X
milk	B-X
,	B-X
egg	B-X
,	B-X
meat	B-X
,	B-X
fish	B-X
,	B-X
and	B-X
shellfish	B-X
)	B-X
,	B-X
inhalants	B-X
(	B-X
pollen	B-X
,	B-X
mold	B-X
spores	B-X
,	B-X
mites	B-X
,	B-X
and	B-X
animal	B-X
dander	B-X
)	B-X
,	B-X
and	B-X
Hymenoptera	B-X
venom	B-X
.	B-X
Diagnostic	B-X
algorithms	B-X
and	B-X
short	B-X
case	B-X
histories	B-X
provide	B-X
useful	B-X
information	B-X
for	B-X
the	B-X
clinical	B-X
workup	B-X
of	B-X
allergic	B-X
individuals	B-X
targeted	B-X
for	B-X
CRD	B-X
.	B-X
Part	B-X
C	B-X
covers	B-X
protein	B-X
families	B-X
containing	B-X
ubiquitous	B-X
,	B-X
highly	B-X
cross-reactive	B-X
panallergens	B-X
from	B-X
plant	B-X
(	B-X
lipid	B-X
transfer	B-X
proteins	B-X
,	B-X
polcalcins	B-X
,	B-X
PR-10	B-X
,	B-X
profilins	B-X
)	B-X
and	B-X
animal	B-X
sources	B-X
(	B-X
lipocalins	B-X
,	B-X
parvalbumins	B-X
,	B-X
serum	B-X
albumins	B-X
,	B-X
tropomyosins	B-X
)	B-X
and	B-X
explains	B-X
their	B-X
diagnostic	B-X
and	B-X
clinical	B-X
utility	B-X
.	B-X

Ryffel	O
,	O
G	O
.	O
<EOS>	B-X
If	B-X
possible	B-X
GM	B-X
plants	B-X
should	B-X
be	B-X
constructed	B-X
using	B-X
either	B-X
site-directed	B-X
mutagenesis	B-X
or	B-X
cisgenic	B-X
strategies	B-X
to	B-X
avoid	B-X
the	B-X
problem	B-X
of	B-X
transgene	B-X
escape	B-X
.	B-X
Such	B-X
a	B-X
cautious	B-X
approach	B-X
in	B-X
developing	B-X
novel	B-X
types	B-X
of	B-X
GM	B-X
crops	B-X
will	B-X
enhance	B-X
the	B-X
sustainable	B-X
potential	B-X
of	B-X
GM	B-X
crops	B-X
and	B-X
thus	B-X
increase	B-X
the	B-X
public	B-X
trust	B-X
in	B-X
green	B-X
gene	B-X
technology	B-X
.	B-X
Xenopus	B-X
vitellogenin	B-X
genes	B-X
.	B-X
Based	B-X
on	B-X
recent	B-X
advances	B-X
in	B-X
plant	B-X
gene	B-X
technology	B-X
,	B-X
I	B-X
propose	B-X
to	B-X
develop	B-X
a	B-X
new	B-X
category	B-X
of	B-X
GM	B-X
plants	B-X
,	B-X
orgenic	B-X
plants	B-X
,	B-X
that	B-X
are	B-X
compatible	B-X
with	B-X
organic	B-X
farming	B-X
.	B-X
These	B-X
GM	B-X
plants	B-X
are	B-X
likely	B-X
to	B-X
be	B-X
acceptable	B-X
to	B-X
most	B-X
skeptics	B-X
of	B-X
GM	B-X
plants	B-X
and	B-X
facilitate	B-X
the	B-X
use	B-X
of	B-X
innovative	B-X
new	B-X
crops	B-X
.	B-X

V	O
.	O
<EOS>	B-X
Type	B-X
V	B-X
collagen	B-X
(	B-X
COLV	B-X
)	B-X
is	B-X
a	B-X
regulatory	B-X
fibril-forming	B-X
collagen	B-X
.	B-X
It	B-X
has	B-X
at	B-X
least	B-X
three	B-X
different	B-X
molecular	B-X
isoforms-Î±1	B-X
(	B-X
V	B-X
)	B-X
2	B-X
Î±2	B-X
(	B-X
V	B-X
)	B-X
,	B-X
Î±1	B-X
(	B-X
V	B-X
)	B-X
3	B-X
,	B-X
and	B-X
Î±1	B-X
(	B-X
V	B-X
)	B-X
Î±2	B-X
(	B-X
V	B-X
)	B-X
Î±3	B-X
(	B-X
V	B-X
)	B-X
-formed	B-X
by	B-X
combinations	B-X
of	B-X
three	B-X
different	B-X
polypeptide	B-X
Î±	B-X
chains-Î±1	B-X
(	B-X
V	B-X
)	B-X
,	B-X
Î±2	B-X
(	B-X
V	B-X
)	B-X
,	B-X
and	B-X
Î±3	B-X
(	B-X
V	B-X
)	B-X
.	B-X
COL	B-X
V	B-X
is	B-X
a	B-X
relatively	B-X
minor	B-X
collagen	B-X
of	B-X
the	B-X
extracellular	B-X
matrix	B-X
(	B-X
ECM	B-X
)	B-X
.	B-X
Morphologically	B-X
,	B-X
COLV	B-X
occurs	B-X
as	B-X
heterotypic	B-X
fibrils	B-X
with	B-X
type	B-X
I	B-X
collagen	B-X
(	B-X
COLI	B-X
)	B-X
,	B-X
microfilaments	B-X
,	B-X
or	B-X
12-nm-thick	B-X
fibrils	B-X
.	B-X
COLV	B-X
is	B-X
synthesized	B-X
in	B-X
various	B-X
mesenchymal	B-X
cells	B-X
and	B-X
its	B-X
gene	B-X
expression	B-X
is	B-X
modulated	B-X
by	B-X
TGF-Î²	B-X
and	B-X
growth	B-X
factors	B-X
.	B-X
While	B-X
resistant	B-X
to	B-X
digestion	B-X
by	B-X
interstitial	B-X
collagenases	B-X
,	B-X
native	B-X
and	B-X
denatured	B-X
COLV	B-X
are	B-X
degraded	B-X
by	B-X
metalloproteinases	B-X
and	B-X
gelatinases	B-X
,	B-X
thereby	B-X
promoting	B-X
ECM	B-X
remodeling	B-X
.	B-X
COLV	B-X
interacts	B-X
with	B-X
matrix	B-X
collagens	B-X
and	B-X
structural	B-X
proteins	B-X
,	B-X
conferring	B-X
structural	B-X
integrity	B-X
to	B-X
tissue	B-X
scaffolds	B-X
.	B-X
COLV	B-X
co-assembles	B-X
with	B-X
COLI	B-X
into	B-X
heterotypic	B-X
fibrils	B-X
in	B-X
the	B-X
cornea	B-X
and	B-X
skin	B-X
dermis	B-X
,	B-X
acting	B-X
as	B-X
a	B-X
dominant	B-X
regulator	B-X
of	B-X
collagen	B-X
fibrillogenesis	B-X
.	B-X
COLV	B-X
deficiency	B-X
is	B-X
associated	B-X
with	B-X
loss	B-X
of	B-X
corneal	B-X
transparency	B-X
and	B-X
classic	B-X
Ehlers-Danlos	B-X
syndrome	B-X
,	B-X
while	B-X
COLV	B-X
overexpression	B-X
is	B-X
found	B-X
in	B-X
cancer	B-X
,	B-X
granulation	B-X
tissue	B-X
,	B-X
inflammation	B-X
,	B-X
atherosclerosis	B-X
,	B-X
and	B-X
fibrosis	B-X
of	B-X
lungs	B-X
,	B-X
skin	B-X
,	B-X
kidneys	B-X
,	B-X
adipose	B-X
tissue	B-X
,	B-X
and	B-X
liver	B-X
.	B-X
COLV	B-X
isoform	B-X
containing	B-X
the	B-X
Î±3	B-X
(	B-X
V	B-X
)	B-X
chain	B-X
is	B-X
involved	B-X
in	B-X
mediating	B-X
pancreatic	B-X
islet	B-X
cell	B-X
functions	B-X
.	B-X
In	B-X
the	B-X
liver	B-X
,	B-X
COLV	B-X
is	B-X
a	B-X
minor	B-X
but	B-X
regular	B-X
component	B-X
of	B-X
the	B-X
ECM	B-X
.	B-X
Increases	B-X
in	B-X
COLV	B-X
are	B-X
associated	B-X
with	B-X
both	B-X
early	B-X
and	B-X
advanced	B-X
hepatic	B-X
fibrosis	B-X
.	B-X
The	B-X
neoepitopes	B-X
of	B-X
COLV	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
a	B-X
useful	B-X
noninvasive	B-X
serum	B-X
biomarker	B-X
for	B-X
assessing	B-X
fibrotic	B-X
progression	B-X
and	B-X
resolution	B-X
in	B-X
experimental	B-X
hepatic	B-X
fibrosis	B-X
.	B-X
COLV	B-X
is	B-X
multifunctional	B-X
in	B-X
health	B-X
,	B-X
disease	B-X
,	B-X
and	B-X
fibrosis	B-X
.	B-X

(	O
1979	O
)	O
Cell	O
16	O
,	O
535	O
-	O
549	O
.	O

36	O
.	O

McReynolds	O
,	O
L	O
.	O
,	O
O	O
'	O
Malley	O
,	O
B	O
.	O
<EOS>	B-X
After	B-X
S.	B-X
nuclease	B-X
treatment	B-X
,	B-X
poly	B-X
(	B-X
dA	B-X
)	B-X
was	B-X
added	B-X
to	B-X
the	B-X
3	B-X
'	B-X
termini	B-X
with	B-X
terminal	B-X
deoxynucleotidyltransferase	B-X
and	B-X
the	B-X
ovalbumin	B-X
gene	B-X
was	B-X
hybridized	B-X
to	B-X
a	B-X
linear	B-X
plasmid	B-X
DNA	B-X
,	B-X
pMB9	B-X
,	B-X
containing	B-X
3'-poly	B-X
(	B-X
dT	B-X
)	B-X
termini	B-X
.	B-X

W	O
.	O
,	O
Nisbet	O
,	O
A	O
.	O
<EOS>	B-X
This	B-X
report	B-X
contains	B-X
the	B-X
recommendations	B-X
of	B-X
the	B-X
Electron	B-X
Dosimetry	B-X
Working	B-X
Party	B-X
of	B-X
the	B-X
UK	B-X
Institute	B-X
of	B-X
Physics	B-X
and	B-X
Engineering	B-X
in	B-X
Medicine	B-X
(	B-X
IPEM	B-X
)	B-X
.	B-X

D	O
.	O
,	O
Fothergill	O
,	O
J	O
.	O
<EOS>	B-X
The	B-X
Dietary	B-X
in	B-X
Indigestion	B-X
.	B-X

E	O
.	O
,	O
<EOS>	B-X
The	B-X
GRADE	B-X
approach	B-X
was	B-X
used	B-X
to	B-X
evaluate	B-X
the	B-X
certainty	B-X
of	B-X
the	B-X
evidence	B-X
.	B-X
Recent	B-X
epidemiological	B-X
studies	B-X
suggest	B-X
that	B-X
some	B-X
patients	B-X
with	B-X
diabetes	B-X
progress	B-X
to	B-X
kidney	B-X
failure	B-X
without	B-X
significant	B-X
albuminuria	B-X
and	B-X
glomerular	B-X
injury	B-X
,	B-X
suggesting	B-X
a	B-X
critical	B-X
role	B-X
of	B-X
kidney	B-X
tubular	B-X
epithelial	B-X
cell	B-X
(	B-X
TEC	B-X
)	B-X
injury	B-X
in	B-X
diabetic	B-X
kidney	B-X
disease	B-X
(	B-X
DKD	B-X
)	B-X
progression	B-X
.	B-X
However	B-X
,	B-X
the	B-X
major	B-X
risk	B-X
factors	B-X
contributing	B-X
to	B-X
TEC	B-X
injury	B-X
and	B-X
progression	B-X
in	B-X
DKD	B-X
remain	B-X
unclear	B-X
.	B-X
We	B-X
previously	B-X
showed	B-X
that	B-X
expression	B-X
of	B-X
endoplasmic	B-X
reticulum-resident	B-X
protein	B-X
Reticulon-1A	B-X
(	B-X
RTN1A	B-X
)	B-X
increased	B-X
in	B-X
human	B-X
DKD	B-X
,	B-X
and	B-X
the	B-X
increased	B-X
RTN1A	B-X
expression	B-X
promoted	B-X
TEC	B-X
injury	B-X
through	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
stress	B-X
response	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
TEC-specific	B-X
RTN1A	B-X
overexpression	B-X
worsened	B-X
DKD	B-X
in	B-X
mice	B-X
,	B-X
evidenced	B-X
by	B-X
enhanced	B-X
tubular	B-X
injury	B-X
,	B-X
tubulointerstitial	B-X
fibrosis	B-X
,	B-X
and	B-X
kidney	B-X
function	B-X
decline	B-X
.	B-X
Notably	B-X
,	B-X
RTN1A	B-X
overexpression	B-X
worsened	B-X
both	B-X
ER	B-X
stress	B-X
and	B-X
mitochondrial	B-X
dysfunction	B-X
in	B-X
TECs	B-X
under	B-X
diabetic	B-X
conditions	B-X
by	B-X
regulation	B-X
of	B-X
ER-mitochondria	B-X
contacts	B-X
.	B-X
Mechanistically	B-X
,	B-X
ER-bound	B-X
RTN1A	B-X
interacted	B-X
with	B-X
mitochondrial	B-X
hexokinase-1	B-X
and	B-X
the	B-X
voltage-dependent	B-X
anion	B-X
channel-1	B-X
(	B-X
VDAC1	B-X
)	B-X
,	B-X
interfering	B-X
with	B-X
their	B-X
association	B-X
.	B-X
This	B-X
disengagement	B-X
of	B-X
VDAC1	B-X
from	B-X
hexokinase-1	B-X
resulted	B-X
in	B-X
activation	B-X
of	B-X
apoptotic	B-X
and	B-X
inflammasome	B-X
pathways	B-X
,	B-X
leading	B-X
to	B-X
TEC	B-X
injury	B-X
and	B-X
loss	B-X
.	B-X
Thus	B-X
,	B-X
our	B-X
observations	B-X
highlight	B-X
the	B-X
importance	B-X
of	B-X
ER-mitochondrial	B-X
crosstalk	B-X
in	B-X
TEC	B-X
injury	B-X
and	B-X
the	B-X
salient	B-X
role	B-X
of	B-X
RTN1A-mediated	B-X
ER-mitochondrial	B-X
contact	B-X
regulation	B-X
in	B-X
DKD	B-X
progression	B-X
.	B-X

2252	O

Nucleic	O
Acids	O
Research	O
<EOS>	B-X
The	B-X
2021	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
database	B-X
Issue	B-X
contains	B-X
189	B-X
papers	B-X
spanning	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
biological	B-X
fields	B-X
and	B-X
investigation	B-X
.	B-X
The	B-X
entire	B-X
Database	B-X
Issue	B-X
is	B-X
freely	B-X
available	B-X
online	B-X
on	B-X
the	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
website	B-X
(	B-X
https	B-X
:	B-X
//academic.oup.com/nar	B-X
)	B-X
.	B-X
Editorial	B-X
:	B-X
the	B-X
19th	B-X
annual	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
web	B-X
server	B-X
issue	B-X
2021	B-X
.	B-X
Editorial	B-X
:	B-X
Critical	B-X
reviews	B-X
and	B-X
perspectives	B-X
in	B-X
Nucleic	B-X
Acids	B-X
Research	B-X
.	B-X

Givol	O
,	O
D	O
.	O
,	O
Fields	O
,	O
S	O
.	O
,	O
Robertson	O
,	O
M	O
.	O
,	O
Brownlee	O
,	O
G	O
.	O

G	O
.	O
<EOS>	B-X
Advances	B-X
in	B-X
electron	B-X
cryo-microscopy	B-X
(	B-X
cryo-EM	B-X
)	B-X
now	B-X
permit	B-X
the	B-X
structure	B-X
determination	B-X
of	B-X
G	B-X
protein-coupled	B-X
receptors	B-X
(	B-X
GPCRs	B-X
)	B-X
coupled	B-X
to	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
by	B-X
single-particle	B-X
imaging	B-X
.	B-X
A	B-X
combination	B-X
of	B-X
G	B-X
protein	B-X
engineering	B-X
and	B-X
the	B-X
development	B-X
of	B-X
antibodies	B-X
that	B-X
stabilise	B-X
the	B-X
heterotrimeric	B-X
G	B-X
protein	B-X
facilitate	B-X
the	B-X
formation	B-X
of	B-X
stable	B-X
GPCR-G	B-X
protein	B-X
complexes	B-X
suitable	B-X
for	B-X
structural	B-X
biology	B-X
.	B-X
Structures	B-X
have	B-X
been	B-X
determined	B-X
of	B-X
GPCRs	B-X
coupled	B-X
to	B-X
either	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
(	B-X
G	B-X
Guanine	B-X
nucleotide-binding	B-X
(	B-X
G	B-X
)	B-X
proteins	B-X
,	B-X
namely	B-X
,	B-X
phosphate-binding	B-X
(	B-X
P	B-X
)	B-X
loop	B-X
GTPases	B-X
,	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
life	B-X
processes	B-X
among	B-X
different	B-X
species	B-X
.	B-X
Based	B-X
on	B-X
the	B-X
structural	B-X
characteristics	B-X
,	B-X
G	B-X
proteins	B-X
can	B-X
be	B-X
divided	B-X
into	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
,	B-X
small	B-X
G	B-X
proteins	B-X
and	B-X
multiple	B-X
unique	B-X
unconventional	B-X
G	B-X
proteins	B-X
.	B-X
The	B-X
highly	B-X
conserved	B-X
unconventional	B-X
G	B-X
protein	B-X
YchF	B-X
is	B-X
composed	B-X
of	B-X
a	B-X
core	B-X
G	B-X
domain	B-X
,	B-X
an	B-X
inserted	B-X
coiled-coil	B-X
domain	B-X
,	B-X
and	B-X
a	B-X
TGS	B-X
domain	B-X
from	B-X
the	B-X
N-terminus	B-X
to	B-X
the	B-X
C-terminus	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
compared	B-X
the	B-X
structural	B-X
characteristics	B-X
of	B-X
the	B-X
G	B-X
domain	B-X
in	B-X
rice	B-X
OsYchF1	B-X
with	B-X
those	B-X
of	B-X

(	O
1978	O
)	O
Nature	O
273	O
,	O
723	O
-	O
728	O
.	O
<EOS>	B-X
[	B-X
Nature	B-X
(	B-X
Lond	B-X
.	B-X
)	B-X
273	B-X
,	B-X
723-728	B-X
(	B-X
1978	B-X
)	B-X
]	B-X
.	B-X
[	B-X
Nature	B-X
273	B-X
,	B-X
723-728	B-X
(	B-X
1978	B-X
)	B-X
]	B-X
.	B-X

37	O
.	O

O	O
'	O
Hare	O
,	O
K	O
.	O
,	O
Breathnach	O
,	O
R	O
.	O
,	O
Benoist	O
,	O
C	O
.	O
,	O
Chambon	O
,	O
P	O
.	O
<EOS>	B-X
Comparison	B-X
with	B-X
corresponding	B-X
areas	B-X
of	B-X
other	B-X
genes	B-X
reveals	B-X
some	B-X
homologous	B-X
regions	B-X
which	B-X
might	B-X
play	B-X
a	B-X
role	B-X
in	B-X
these	B-X
processes	B-X
.	B-X
Comparison	B-X
of	B-X
this	B-X
sequence	B-X
with	B-X
those	B-X
of	B-X
other	B-X
eukaryotic	B-X
genes	B-X
reveals	B-X
striking	B-X
similarities	B-X
,	B-X
possibly	B-X
related	B-X
to	B-X
a	B-X
promoter	B-X
region	B-X
,	B-X
approximately	B-X
30	B-X
base	B-X
pairs	B-X
upstream	B-X
from	B-X
the	B-X
site	B-X
coding	B-X
for	B-X
the	B-X
5	B-X
'	B-X
end	B-X
of	B-X
the	B-X
mRNA	B-X
.	B-X
We	B-X
have	B-X
determined	B-X
the	B-X
sequence	B-X
of	B-X
ovalbumin	B-X
RNA	B-X
(	B-X
ov-mRNA	B-X
)	B-X
using	B-X
a	B-X
double-stranded	B-X
cDNA	B-X
(	B-X
dscDNA	B-X
)	B-X
plasmid	B-X
.	B-X
The	B-X
comparison	B-X
of	B-X
these	B-X
various	B-X
sequences	B-X
has	B-X
shown	B-X
that	B-X
there	B-X
are	B-X
no	B-X
additional	B-X
interruptions	B-X
in	B-X
the	B-X
mRNA-coding	B-X
sequences	B-X
above	B-X
those	B-X
7	B-X
already	B-X
characterized	B-X
.	B-X
There	B-X
is	B-X
only	B-X
one	B-X
single	B-X
base	B-X
discrepancy	B-X
between	B-X
the	B-X
two	B-X
mRNA	B-X
sequences	B-X
determined	B-X
using	B-X
the	B-X
dscDNA	B-X
or	B-X
the	B-X
genomic	B-X
clones	B-X
.	B-X
The	B-X
ovalbumin	B-X
mRNA	B-X
sequence	B-X
was	B-X
found	B-X
to	B-X
be	B-X
1872	B-X
nucleotides	B-X
in	B-X
length	B-X
,	B-X
13	B-X
nucleotides	B-X
larger	B-X
than	B-X
the	B-X
previous	B-X
value	B-X
reported	B-X
by	B-X
McReynolds	B-X
et	B-X
al	B-X
.	B-X

(	O
1979	O
)	O
<EOS>	B-X
Cardiac	B-X
transplantation	B-X
1979	B-X
.	B-X
1979	B-X
election	B-X
results	B-X
.	B-X
Christmas	B-X
quiz	B-X
,	B-X
1979	B-X
.	B-X
Transfusion	B-X
topics	B-X
--	B-X
1979	B-X
.	B-X

Nucl	O
.	O
<EOS>	B-X
Erratum	B-X
.	B-X
Erratum	B-X
.	B-X
Newsbriefs	B-X
.	B-X
Errata	B-X
.	B-X

Acids	O
Res	O
.	O
<EOS>	B-X
Over	B-X
the	B-X
course	B-X
of	B-X
the	B-X
past	B-X
few	B-X
decades	B-X
,	B-X
the	B-X
theory	B-X
of	B-X
Hard	B-X
and	B-X
Soft	B-X
,	B-X
Acids	B-X
and	B-X
Bases	B-X
(	B-X
HSAB	B-X
)	B-X
has	B-X
proven	B-X
to	B-X
be	B-X
a	B-X
useful	B-X
tool	B-X
in	B-X
predicting	B-X
the	B-X
outcome	B-X
of	B-X
such	B-X
reactions	B-X
.	B-X
Mutagenesis	B-X
.	B-X
Plasma	B-X
acids	B-X
.	B-X

7	O
,	O
321	O
-	O
334	O
.	O
<EOS>	B-X
Maturation	B-X
of	B-X
the	B-X
adrenal	B-X
medulla	B-X
--	B-X
IV	B-X
.	B-X
Effects	B-X
of	B-X
morphine	B-X
.	B-X
Utilization	B-X
and	B-X
referral	B-X
patterns	B-X
in	B-X
the	B-X
acute	B-X
illness	B-X
department	B-X
of	B-X
a	B-X
multispecialty	B-X
clinic	B-X
.	B-X

38	O
.	O

Abelson	O
,	O
J	O
.	O
<EOS>	B-X
tRNA	B-X
identity	B-X
.	B-X
tRNA	B-X
splicing	B-X
.	B-X
Evaluating	B-X
patient	B-X
and	B-X
public	B-X
involvement	B-X
in	B-X
research	B-X
.	B-X
Management	B-X
of	B-X
Pneumonia	B-X
Syndromes	B-X
in	B-X
the	B-X
Hospital	B-X
:	B-X
Make	B-X
Pneumonia	B-X
Your	B-X
Best	B-X
Friend	B-X
.	B-X

(	O
1979	O
)	O
Ann	O
.	O
<EOS>	B-X
Marxism	B-X
.	B-X
Pharyngoplasty	B-X
.	B-X
W-plasty	B-X
.	B-X
Viruses	B-X
in	B-X
water	B-X
.	B-X

Rev	O
.	O
<EOS>	B-X
During	B-X
late	B-X
infection	B-X
,	B-X
HIV-1	B-X
bypasses	B-X
this	B-X
regulatory	B-X
mechanism	B-X
by	B-X
expression	B-X
of	B-X
the	B-X
Rev	B-X
protein	B-X
from	B-X
a	B-X
fully	B-X
spliced	B-X
mRNA	B-X
.	B-X
Once	B-X
imported	B-X
into	B-X
the	B-X
nucleus	B-X
,	B-X
Rev	B-X
mediates	B-X
the	B-X
export	B-X
of	B-X
unprocessed	B-X
HIV-1	B-X
RNAs	B-X
to	B-X
the	B-X
cytoplasm	B-X
,	B-X
leading	B-X
to	B-X
the	B-X
production	B-X
of	B-X
the	B-X
viral	B-X
progeny	B-X
.	B-X
While	B-X
regarded	B-X
as	B-X
a	B-X
canonical	B-X
RNA	B-X
export	B-X
factor	B-X
,	B-X
Rev	B-X
has	B-X
also	B-X
been	B-X
linked	B-X
to	B-X
HIV-1	B-X
RNA	B-X
translation	B-X
,	B-X
stabilization	B-X
,	B-X
splicing	B-X
and	B-X
packaging	B-X
.	B-X
However	B-X
,	B-X
Rev	B-X
's	B-X
functions	B-X
beyond	B-X
RNA	B-X
export	B-X
have	B-X
remained	B-X
poorly	B-X
understood	B-X
.	B-X

Biochem	O
.	O
<EOS>	B-X
Retraction	B-X
:	B-X
``	B-X
The	B-X
protective	B-X
effects	B-X
of	B-X
TGR5	B-X
against	B-X
ultraviolet	B-X
B	B-X
irradiation	B-X
in	B-X
epidermal	B-X
stem	B-X
cells	B-X
''	B-X
by	B-X
Yuan	B-X
Chang	B-X
and	B-X
Jianbin	B-X
Yu	B-X
,	B-X
J	B-X
Cell	B-X
Biochem	B-X
.	B-X
Retraction	B-X
:	B-X
``	B-X
MicroRNA-373	B-X
promotes	B-X
the	B-X
development	B-X
of	B-X
endometrial	B-X
cancer	B-X
by	B-X
targeting	B-X
LATS2	B-X
and	B-X
activating	B-X
the	B-X
Wnt/Î²-Catenin	B-X
pathway	B-X
,	B-X
''	B-X
by	B-X
Yan	B-X
Li	B-X
,	B-X
Dongxia	B-X
Sun	B-X
,	B-X
Jie	B-X
Gao	B-X
,	B-X
Zhimin	B-X
Shi	B-X
,	B-X
Pengyu	B-X
Chi	B-X
,	B-X
Yuanyuan	B-X
Meng	B-X
,	B-X
Changjun	B-X
Zou	B-X
,	B-X
and	B-X
Yanhua	B-X
Wang	B-X
,	B-X
J	B-X
Cell	B-X
Biochem	B-X
.	B-X
Retraction	B-X
:	B-X
``	B-X
Elevation	B-X
of	B-X
circular	B-X
RNA	B-X
circ-POSTN	B-X
facilitates	B-X
cell	B-X
growth	B-X
and	B-X
invasion	B-X
by	B-X
sponging	B-X
miR-1205	B-X
in	B-X
glioma	B-X
,	B-X
''	B-X
by	B-X
Yimin	B-X
Yang	B-X
,	B-X
Ying	B-X
Zhang	B-X
,	B-X
Bin	B-X
Chen	B-X
,	B-X
Lili	B-X
Ding	B-X
,	B-X
Zhuang	B-X
Mu	B-X
,	B-X
and	B-X
Yanhua	B-X
Li	B-X
,	B-X
J	B-X
Cell	B-X
Biochem	B-X
.	B-X
Retraction	B-X
:	B-X
``	B-X
Combined	B-X
therapy	B-X
using	B-X
LHRH-PE40	B-X
and	B-X
anti-CD40	B-X
dendritic	B-X
cells	B-X
substantially	B-X
eliminate	B-X
tumor	B-X
cells	B-X
''	B-X
by	B-X
Limin	B-X
Zhang	B-X
,	B-X
TianJiao	B-X
Du	B-X
,	B-X
DongBin	B-X
Ma	B-X
,	B-X
Fang	B-X
Guo	B-X
,	B-X
ZhenWei	B-X
Li	B-X
,	B-X
and	B-X
Hua	B-X
Yan	B-X
,	B-X
J	B-X
Cell	B-X
Biochem	B-X
.	B-X

48	O
,	O
1035	O
-	O
1069	O
.	O
<EOS>	B-X
A	B-X
heparan	B-X
sulfate-degrading	B-X
endoglycosidase	B-X
from	B-X
rat	B-X
liver	B-X
tissue	B-X
.	B-X

39	O
.	O

Adams	O
,	O
S	O
.	O
<EOS>	B-X
Cannabidiol	B-X
for	B-X
Treatment-Resistant	B-X
Anxiety	B-X
Disorders	B-X
in	B-X
Young	B-X
People	B-X
:	B-X
An	B-X
Open-Label	B-X
Trial	B-X
.	B-X

L	O
.	O
,	O
Alwine	O
,	O
J	O
.	O
<EOS>	B-X
The	B-X
simian	B-X
virus	B-X
40	B-X
late	B-X
polyadenylation	B-X
signal	B-X
(	B-X
SVLPA	B-X
)	B-X
forms	B-X
alternate	B-X
secondary	B-X
structures	B-X
in	B-X
equilibrium	B-X
.	B-X
Their	B-X
formation	B-X
correlates	B-X
with	B-X
cleavage-polyadenylation	B-X
efficiency	B-X
(	B-X
H.	B-X
Hans	B-X
and	B-X
J.	B-X
C.	B-X
Alwine	B-X
,	B-X
Mol	B-X
.	B-X
20:2926-2932	B-X
,	B-X
2000	B-X
;	B-X
M.	B-X
I.	B-X
Zarudnaya	B-X
,	B-X
I.	B-X
M.	B-X
Kolomiets	B-X
,	B-X
A.	B-X
L.	B-X
Potyahaylo	B-X
,	B-X
and	B-X
D.	B-X
M.	B-X
Hovorun	B-X
,	B-X
Nucleic	B-X
Acids	B-X
Res	B-X
.	B-X
To	B-X
define	B-X
the	B-X
important	B-X
features	B-X
of	B-X
downstream	B-X
secondary	B-X
structure	B-X
,	B-X
we	B-X
first	B-X
minimized	B-X
the	B-X
SVLPA	B-X
by	B-X
deletion	B-X
,	B-X
forming	B-X
a	B-X
downstream	B-X
region	B-X
with	B-X
fewer	B-X
,	B-X
and	B-X
more	B-X
stable	B-X
,	B-X
stem-loop	B-X
structures	B-X
.	B-X

C	O
.	O
,	O
de	O
Chrombrugghe	O
,	O
B	O
.	O
,	O
and	O
Pastan	O
,	O
I	O
.	O

(	O
1979	O
)	O
J	O
.	O
<EOS>	B-X
Influenza	B-X
--	B-X
1979	B-X
.	B-X
Thomas	B-X
J.	B-X
Kelley	B-X
(	B-X
1922	B-X
--	B-X
1979	B-X
)	B-X
.	B-X
Cardiac	B-X
transplantation	B-X
1979	B-X
.	B-X
Neonatal	B-X
hypoglycemia	B-X
,	B-X
1979	B-X
.	B-X

Biol	O
.	O
<EOS>	B-X
Retraction	B-X
of	B-X
DNA	B-X
Cell	B-X
Biol	B-X
:	B-X
31:1064-1069	B-X
,	B-X
2012	B-X
,	B-X
DOI	B-X
:	B-X
10.1089/dna.2011.1552	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
provide	B-X
a	B-X
brief	B-X
synopsis	B-X
of	B-X
all	B-X
manuscripts	B-X
published	B-X
in	B-X
Histochem	B-X
Cell	B-X
Biol	B-X
in	B-X
the	B-X
year	B-X
2013	B-X
.	B-X
Retraction	B-X
notice	B-X
to	B-X
``	B-X
Nicorandil	B-X
versus	B-X
nifedipine	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
preterm	B-X
labour	B-X
:	B-X
A	B-X
randomized	B-X
clinical	B-X
trial	B-X
''	B-X
[	B-X
Eur	B-X
.	B-X
J.	B-X
Obstetr	B-X
.	B-X
Gynecol	B-X
.	B-X
Reprod	B-X
.	B-X
Biol	B-X
.	B-X
195	B-X
(	B-X
2015	B-X
)	B-X
27-30	B-X
]	B-X
.	B-X
Retraction	B-X
notice	B-X
to	B-X
``	B-X
Reducing	B-X
blood	B-X
loss	B-X
at	B-X
abdominal	B-X
myomectomy	B-X
with	B-X
preoperative	B-X
use	B-X
of	B-X
dinoprostone	B-X
intravaginal	B-X
suppository	B-X
:	B-X
A	B-X
randomized	B-X
placebo-controlled	B-X
pilot	B-X
study	B-X
''	B-X
[	B-X
Eur	B-X
.	B-X
J.	B-X
Obst	B-X
.	B-X
Gynecol	B-X
.	B-X
Reprod	B-X
.	B-X
Biol	B-X
.	B-X
166/1	B-X
(	B-X
2012	B-X
)	B-X
61-64	B-X
]	B-X
.	B-X

Chem	O
.	O
<EOS>	B-X
Chem	B-X
Soc	B-X
Rev	B-X
--	B-X
growing	B-X
stronger	B-X
.	B-X
The	B-X
WRF-Chem	B-X
(	B-X
Weather	B-X
Research	B-X
and	B-X
Forecasting	B-X
with	B-X
Chemistry	B-X
)	B-X
model	B-X
is	B-X
implemented	B-X
and	B-X
validated	B-X
against	B-X
ground-based	B-X
observations	B-X
for	B-X
meteorological	B-X
and	B-X
atmospheric	B-X
variables	B-X
for	B-X
the	B-X
first	B-X
time	B-X
in	B-X
Northern	B-X
Vietnam	B-X
.	B-X
The	B-X
WRF-Chem	B-X
model	B-X
was	B-X
based	B-X
on	B-X
HTAPv2	B-X
emission	B-X
inventory	B-X
with	B-X
MOZCART	B-X
chemical-aerosol	B-X
mechanism	B-X
to	B-X
simulate	B-X
atmospheric	B-X
variables	B-X
for	B-X
winter	B-X
(	B-X
January	B-X
)	B-X
and	B-X
summer	B-X
(	B-X
July	B-X
)	B-X
of	B-X
2014	B-X
.	B-X
Chem	B-X
Soc	B-X
Rev	B-X
leads	B-X
the	B-X
way	B-X
.	B-X

254	O
,	O
4935	O
-	O
4938	O
,	O
<EOS>	B-X
[	B-X
Studies	B-X
on	B-X
the	B-X
eructation	B-X
mechanism	B-X
in	B-X
sheep	B-X
.	B-X
IV	B-X
.	B-X
The	B-X
influence	B-X
of	B-X
prolonged	B-X
fasting	B-X
on	B-X
the	B-X
composition	B-X
of	B-X
the	B-X
eructated	B-X
rumen	B-X
gases	B-X
volume	B-X
per	B-X
cent	B-X
and	B-X
the	B-X
(	B-X
pH	B-X
)	B-X
in	B-X
the	B-X
ruminoreticulum	B-X
]	B-X
.	B-X
[	B-X
Participation	B-X
of	B-X
feldshers	B-X
and	B-X
midwives	B-X
in	B-X
the	B-X
secret	B-X
and	B-X
partisan	B-X
activities	B-X
during	B-X
the	B-X
great	B-X
patriotic	B-X
war	B-X
]	B-X
.	B-X

40	O
.	O

Rave	O
,	O
N	O
.	O
,	O
Crkvenjakow	O
,	O
R	O
.	O
,	O
and	O
Boedtker	O
,	O
H	O
.	O

(	O
1979	O
)	O
Nucl	O
.	O
<EOS>	B-X
Seminars	B-X
in	B-X
nuclear	B-X
medicine	B-X
.	B-X
Forensic	B-X
radioimmunoassay	B-X
--	B-X
a	B-X
new	B-X
area	B-X
.	B-X
Radioassays	B-X
.	B-X
Tumor-localizing	B-X
radionuclides	B-X
in	B-X
retrospect	B-X
and	B-X
prospect	B-X
.	B-X

Acids	O
Res	O
.	O
<EOS>	B-X
Over	B-X
the	B-X
course	B-X
of	B-X
the	B-X
past	B-X
few	B-X
decades	B-X
,	B-X
the	B-X
theory	B-X
of	B-X
Hard	B-X
and	B-X
Soft	B-X
,	B-X
Acids	B-X
and	B-X
Bases	B-X
(	B-X
HSAB	B-X
)	B-X
has	B-X
proven	B-X
to	B-X
be	B-X
a	B-X
useful	B-X
tool	B-X
in	B-X
predicting	B-X
the	B-X
outcome	B-X
of	B-X
such	B-X
reactions	B-X
.	B-X
Mutagenesis	B-X
.	B-X
Plasma	B-X
acids	B-X
.	B-X

6	O
,	O
3559	O
-	O
3567	O
.	O
<EOS>	B-X
Studies	B-X
of	B-X
oxygen	B-X
binding	B-X
energy	B-X
to	B-X
hemoglobin	B-X
molecule	B-X
.	B-X

41	O
.	O

Roop	O
,	O
D	O
.	O
<EOS>	B-X
Loricrin	B-X
Protects	B-X
against	B-X
Chemical	B-X
Carcinogenesis	B-X
.	B-X
Defects	B-X
in	B-X
the	B-X
barrier	B-X
.	B-X
The	B-X
molecular	B-X
biology	B-X
of	B-X
intermediate	B-X
filaments	B-X
.	B-X
Curiously	B-X
,	B-X
this	B-X
protein	B-X
displays	B-X
major	B-X
differences	B-X
from	B-X
the	B-X
recently	B-X
described	B-X
mouse	B-X
loricrin	B-X
(	B-X
Mehrel	B-X
,	B-X
T.	B-X
,	B-X
Hohl	B-X
,	B-X
D.	B-X
,	B-X
Nakazawa	B-X
,	B-X
H.	B-X
,	B-X
Rothnagel	B-X
,	B-X
J.A.	B-X
,	B-X
Longley	B-X
,	B-X
M.A.	B-X
,	B-X
Bundman	B-X
,	B-X
D.	B-X
,	B-X
Cheng	B-X
,	B-X
C.K.	B-X
,	B-X
Lichti	B-X
,	B-X
U.	B-X
,	B-X
Bisher	B-X
,	B-X
M.E.	B-X
,	B-X
Steven	B-X
,	B-X
A.	B-X
C.	B-X
,	B-X
Steinert	B-X
,	B-X
P.M.	B-X
,	B-X
Yuspa	B-X
,	B-X
S.H.	B-X
,	B-X
and	B-X
Roop	B-X
,	B-X
D.R	B-X
.	B-X

R	O
.	O
,	O
Nordstrom	O
,	O
J	O
.	O
<EOS>	B-X
Left-ventricular	B-X
volumes	B-X
and	B-X
ejection	B-X
fraction	B-X
from	B-X
cardiac	B-X
ECG-gated	B-X

L	O
.	O
,	O
Tsai	O
,	O
S	O
.	O

Y	O
.	O
,	O
Tsai	O
,	O
M	O
.	O
<EOS>	B-X
In	B-X
summary	B-X
,	B-X
MYC	B-X
regulates	B-X
abnormal	B-X
O-glycosylation	B-X
,	B-X
thus	B-X
priming	B-X
cells	B-X
for	B-X
binding	B-X
to	B-X
galectin-4	B-X
and	B-X
downstream	B-X
signaling	B-X
,	B-X
which	B-X
promotes	B-X
castration	B-X
resistance	B-X
and	B-X
metastasis.-Tzeng	B-X
,	B-X
S.-F.	B-X
,	B-X
Tsai	B-X
,	B-X
C.-H.	B-X
,	B-X
Chao	B-X
,	B-X
T.-K.	B-X
,	B-X
Chou	B-X
,	B-X
Y.-C.	B-X
,	B-X
Yang	B-X
,	B-X
Y.-C.	B-X
,	B-X
Tsai	B-X
,	B-X
M.-H.	B-X
,	B-X
Cha	B-X
,	B-X
T.-L.	B-X
,	B-X
Hsiao	B-X
,	B-X
P.-W.	B-X
O-Glycosylation-mediated	B-X
signaling	B-X
circuit	B-X
drives	B-X
metastatic	B-X
castration-resistant	B-X
prostate	B-X
cancer	B-X
.	B-X

J	O
.	O
,	O
and	O
<EOS>	B-X
In	B-X
1993	B-X
,	B-X
a	B-X
new	B-X
base	B-X
,	B-X
beta-d-glucopyranosyloxymethyluracil	B-X
(	B-X
base	B-X
J	B-X
)	B-X
,	B-X
was	B-X
identified	B-X
in	B-X
the	B-X
nuclear	B-X
DNA	B-X
of	B-X
Trypanosoma	B-X
brucei	B-X
.	B-X
Base	B-X
J	B-X
is	B-X
the	B-X
first	B-X
hypermodified	B-X
base	B-X
found	B-X
in	B-X
eukaryotic	B-X
DNA	B-X
.	B-X
J	B-X
is	B-X
invariably	B-X
present	B-X
in	B-X
the	B-X
telomeric	B-X
repeats	B-X
of	B-X
all	B-X
organisms	B-X
analyzed	B-X
.	B-X
Whereas	B-X
in	B-X
Leishmania	B-X
nearly	B-X
all	B-X
J	B-X
is	B-X
telomeric	B-X
,	B-X
there	B-X
are	B-X
other	B-X
repetitive	B-X
DNA	B-X
sequences	B-X
containing	B-X
J	B-X
in	B-X
T.	B-X
brucei	B-X
and	B-X
T.	B-X
cruzi	B-X
,	B-X
and	B-X
most	B-X
J	B-X
is	B-X
outside	B-X
telomeres	B-X
in	B-X
Euglena	B-X
.	B-X
The	B-X
biosynthesis	B-X
of	B-X
J	B-X
occurs	B-X
in	B-X
two	B-X
steps	B-X
:	B-X
First	B-X
,	B-X
a	B-X
specific	B-X
thymidine	B-X
in	B-X
DNA	B-X
is	B-X
converted	B-X
into	B-X
hydroxymethyldeoxyuridine	B-X
(	B-X
HOMedU	B-X
)	B-X
,	B-X
and	B-X
then	B-X
this	B-X
HOMedU	B-X
is	B-X
glycosylated	B-X
to	B-X
form	B-X
J	B-X
.	B-X
This	B-X
review	B-X
discusses	B-X
the	B-X
identification	B-X
and	B-X
localization	B-X
of	B-X
base	B-X
J	B-X
in	B-X
the	B-X
genome	B-X
of	B-X
kinetoplastids	B-X
,	B-X
the	B-X
enzymes	B-X
involved	B-X
in	B-X
J	B-X
biosynthesis	B-X
,	B-X
possible	B-X
biological	B-X
functions	B-X
of	B-X
J	B-X
,	B-X
and	B-X
J	B-X
as	B-X
a	B-X
potential	B-X
target	B-X
for	B-X
chemotherapy	B-X
of	B-X
diseases	B-X
caused	B-X
by	B-X
kinetoplastids	B-X
.	B-X

O	O
'	O
Malley	O
,	O
B	O
.	O
<EOS>	B-X
The	B-X
AABB	B-X
(	B-X
formerly	B-X
,	B-X
the	B-X
American	B-X
Association	B-X
of	B-X
Blood	B-X
Banks	B-X
)	B-X
developed	B-X
this	B-X
guideline	B-X
on	B-X
appropriate	B-X
use	B-X
of	B-X
platelet	B-X
transfusion	B-X
in	B-X
adult	B-X
patients	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
find	B-X
that	B-X
high	B-X
steroid	B-X
receptor	B-X
coactivator-3	B-X
(	B-X
SRC-3	B-X
)	B-X
expression	B-X
is	B-X
correlated	B-X
with	B-X
relapse/refractory	B-X
and	B-X
poor	B-X
outcomes	B-X
in	B-X
MM	B-X
patients	B-X
treated	B-X
with	B-X
bortezomib	B-X
(	B-X
BTZ	B-X
)	B-X
-based	B-X
regimens	B-X
.	B-X
Overexpressed	B-X
histone	B-X
methyltransferase	B-X
NSD2	B-X
in	B-X
patients	B-X
bearing	B-X
a	B-X
t	B-X
(	B-X
4	B-X
;	B-X
14	B-X
)	B-X
translocation	B-X
or	B-X
in	B-X
BTZ-resistant	B-X
MM	B-X
cells	B-X
coordinates	B-X
elevated	B-X
SRC-3	B-X
by	B-X
enhancing	B-X
its	B-X
liquid-liquid	B-X
phase	B-X
separation	B-X
to	B-X
supranormally	B-X
modify	B-X
histone	B-X
H3	B-X
lysine	B-X
36	B-X
dimethylation	B-X
(	B-X
H3K36me2	B-X
)	B-X
modifications	B-X
on	B-X
promoters	B-X
of	B-X
anti-apoptotic	B-X
genes	B-X
.	B-X
Targeting	B-X
SRC-3	B-X
or	B-X
interference	B-X
of	B-X
its	B-X
interactions	B-X
with	B-X
NSD2	B-X
using	B-X
a	B-X
newly	B-X
developed	B-X
inhibitor	B-X
,	B-X
SI-2	B-X
,	B-X
sensitizes	B-X
BTZ	B-X
treatment	B-X
and	B-X
overcomes	B-X
drug	B-X
resistance	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X

W	O
.	O
<EOS>	B-X
We	B-X
present	B-X
a	B-X
novel	B-X
static	B-X
W-shaped	B-X
common-path	B-X
interferometer	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
the	B-X
W-shaped	B-X
common-path	B-X
corner-cube	B-X
retroreflector	B-X
interferometer	B-X
(	B-X
W-CPRI	B-X
)	B-X
is	B-X
introduced	B-X
via	B-X
detailed	B-X
analysis	B-X
of	B-X
its	B-X
working	B-X
principles	B-X
and	B-X
performance	B-X
.	B-X
For	B-X
each	B-X
interference	B-X
output	B-X
of	B-X
an	B-X
ideal	B-X
W-CPRI	B-X
,	B-X
the	B-X
two	B-X
beams	B-X
recombine	B-X
and	B-X
have	B-X
the	B-X
same	B-X
output	B-X
direction	B-X
,	B-X
including	B-X
a	B-X
tilted	B-X
CCR	B-X
.	B-X
In	B-X
a	B-X
deformed	B-X
W-CPRI	B-X
structure	B-X
,	B-X
an	B-X
optical	B-X
path	B-X
difference	B-X
can	B-X
be	B-X
produced	B-X
by	B-X
inserting	B-X
an	B-X
optical	B-X
element	B-X
that	B-X
changes	B-X
the	B-X
optical	B-X
path	B-X
in	B-X
the	B-X
interferometer	B-X
arm	B-X
of	B-X
the	B-X
W-CPRI	B-X
.	B-X
The	B-X
posture	B-X
deviations	B-X
of	B-X
the	B-X
RM	B-X
and	B-X
the	B-X
CCRs	B-X
in	B-X
the	B-X
W-CPRI	B-X
are	B-X
analyzed	B-X
.	B-X
The	B-X
average	B-X
cosine	B-X
similarity	B-X
is	B-X
0.9953	B-X
,	B-X
revealing	B-X
that	B-X
this	B-X
W-CPRI	B-X
has	B-X
high	B-X
stability	B-X
and	B-X
strong	B-X
coherence	B-X
while	B-X
avoiding	B-X
the	B-X
tilt	B-X
and	B-X
displacement	B-X
of	B-X
the	B-X
interferometer	B-X
arm	B-X
.	B-X

(	O
1978	O
)	O
Cell	O
15	O
,	O
671	O
-	O
685	O
.	O

42	O
.	O

Tilghman	O
,	O
S	O
.	O
<EOS>	B-X
Shirley	B-X
Tilghman	B-X
,	B-X
PhD	B-X
.	B-X
Not	B-X
just	B-X
Salk	B-X
.	B-X
It	B-X
's	B-X
all	B-X
about	B-X
the	B-X
talent	B-X
.	B-X
Interview	B-X
with	B-X
president	B-X
Shirley	B-X
Tilghman	B-X
(	B-X
Princeton	B-X
University	B-X
)	B-X
.	B-X

M	O
.	O
,	O
Curtis	O
,	O
P	O
.	O
<EOS>	B-X
3-Phenylpropanoic	B-X
,	B-X
2-hydroxybenzoic	B-X
,	B-X
and	B-X
hippuric	B-X
acid	B-X
were	B-X
highly	B-X
abundant	B-X
(	B-X
mean	B-X
>	B-X
1	B-X
ÂµM	B-X
)	B-X
.	B-X
Pilitropic	B-X
and	B-X
flagellotropic	B-X
phages	B-X
adsorb	B-X
to	B-X
bacterial	B-X
pili	B-X
and	B-X
flagella	B-X
.	B-X
Methylenedioxypyrovalerone	B-X
(	B-X
MDPV	B-X
)	B-X
is	B-X
an	B-X
abused	B-X
synthetic	B-X
cathinone	B-X
,	B-X
commonly	B-X
referred	B-X
to	B-X
as	B-X
a	B-X
``	B-X
bath	B-X
salt	B-X
.	B-X
''	B-X
Because	B-X
the	B-X
dopamine	B-X
(	B-X
DA	B-X
)	B-X
transporter	B-X
(	B-X
DAT	B-X
)	B-X
and	B-X
vesicular	B-X
monoamine	B-X
transporter-2	B-X
(	B-X
VMAT-2	B-X
)	B-X
are	B-X
key	B-X
regulators	B-X
of	B-X
both	B-X
the	B-X
abuse	B-X
and	B-X
neurotoxic	B-X
potential	B-X
of	B-X
structurally	B-X
and	B-X
behaviorally	B-X
related	B-X
agents	B-X
,	B-X
the	B-X
impact	B-X
of	B-X
MDPV	B-X
on	B-X
these	B-X
transporters	B-X
was	B-X
investigated	B-X
.	B-X
Results	B-X
revealed	B-X
that	B-X
a	B-X
single	B-X
in	B-X
vivo	B-X
MDPV	B-X
administration	B-X
rapidly	B-X
(	B-X
within	B-X
1	B-X
hour	B-X
)	B-X
and	B-X
reversibly	B-X
increased	B-X
both	B-X
rat	B-X
striatal	B-X
DAT	B-X
and	B-X
VMAT-2	B-X
activity	B-X
,	B-X
as	B-X
assessed	B-X
via	B-X
[	B-X

J	O
.	O
,	O
Tiemeier	O
,	O
D	O
.	O
<EOS>	B-X
Chinese	B-X
hamster	B-X
liver	B-X
glutamine	B-X
synthetase	B-X
.	B-X
Purification	B-X
,	B-X
physical	B-X
and	B-X
biochemical	B-X
properties	B-X
.	B-X
Regulation	B-X
of	B-X
glutamine	B-X
synthetase	B-X
in	B-X
cultured	B-X
Chinese	B-X
hamster	B-X
cells	B-X
.	B-X
Induction	B-X
and	B-X
repression	B-X
by	B-X
glutamine	B-X
.	B-X
The	B-X
structure	B-X
and	B-X
enzyme-coenzyme	B-X
relationship	B-X
of	B-X
supernatant	B-X
aspartate	B-X
transaminase	B-X
after	B-X
dye	B-X
sensitized	B-X
photooxidation	B-X
.	B-X

C	O
.	O
,	O
Leder	O
,	O
P	O
.	O
,	O
and	O
<EOS>	B-X
The	B-X
c-Jun	B-X
and	B-X
c-fos	B-X
proto-oncogenes	B-X
encode	B-X
proteins	B-X
that	B-X
form	B-X
a	B-X
complex	B-X
which	B-X
regulates	B-X
transcription	B-X
from	B-X
promoters	B-X
containing	B-X
AP-1	B-X
activation	B-X
elements	B-X
.	B-X
Following	B-X
in	B-X
vitro	B-X
translation	B-X
,	B-X
c-Jun	B-X
binds	B-X
as	B-X
a	B-X
homodimer	B-X
to	B-X
the	B-X
AP-1	B-X
DNA	B-X
site	B-X
,	B-X
while	B-X
c-Fos	B-X
fails	B-X
to	B-X
dimerize	B-X
and	B-X
displays	B-X
no	B-X
apparent	B-X
affinity	B-X
for	B-X
the	B-X
AP-1	B-X
element	B-X
.	B-X
Cotranslated	B-X
c-Jun	B-X
and	B-X
c-Fos	B-X
proteins	B-X
bind	B-X
25	B-X
times	B-X
more	B-X
efficiently	B-X
to	B-X
the	B-X
AP-1	B-X
DNA	B-X
site	B-X
as	B-X
a	B-X
heterodimer	B-X
than	B-X
does	B-X
the	B-X
c-Jun	B-X
homodimer	B-X
.	B-X
An	B-X
interview	B-X
with	B-X
...	B-X
Philip	B-X
Leder	B-X
.	B-X
Interview	B-X
by	B-X
Errol	B-X
C.	B-X
Friedberg	B-X
.	B-X

Weissmann	O
,	O
C	O
.	O
<EOS>	B-X
Prions	B-X
consist	B-X
mainly	B-X
,	B-X
if	B-X
not	B-X
entirely	B-X
,	B-X
of	B-X
PrP	B-X
(	B-X
Sc	B-X
)	B-X
,	B-X
an	B-X
aggregated	B-X
conformer	B-X
of	B-X
the	B-X
host	B-X
protein	B-X
PrP	B-X
(	B-X
C	B-X
)	B-X
.	B-X
Prions	B-X
come	B-X
in	B-X
different	B-X
strains	B-X
,	B-X
all	B-X
based	B-X
on	B-X
the	B-X
same	B-X
PrP	B-X
(	B-X
C	B-X
)	B-X
sequence	B-X
,	B-X
but	B-X
differing	B-X
in	B-X
their	B-X
conformations	B-X
.	B-X
An	B-X
interview	B-X
of	B-X
Dr.	B-X
Ernesto	B-X
Carafoli	B-X
with	B-X
Charles	B-X
Weissmann	B-X
.	B-X
The	B-X
interferon	B-X
genes	B-X
.	B-X

(	O
1978	O
)	O
Proc	O
.	O
<EOS>	B-X
Suppressor	B-X
cells	B-X
in	B-X
immunosenescence	B-X
.	B-X
Psoriatic	B-X
arthritis	B-X
.	B-X
By	B-X
using	B-X
a	B-X
formulation	B-X
of	B-X
Kimura	B-X
and	B-X
Crow	B-X
[	B-X
Kimura	B-X
,	B-X
M.	B-X
&	B-X
Crow	B-X
,	B-X
J.	B-X
F.	B-X
(	B-X
1978	B-X
)	B-X
Proc	B-X
.	B-X
Echocardiography	B-X
.	B-X

Natl	O
.	O
<EOS>	B-X
Obituaries	B-X
.	B-X
Corrigendum	B-X
to	B-X
``	B-X
Visceral	B-X
Adiposity	B-X
Index	B-X
Levels	B-X
in	B-X
Patients	B-X
with	B-X
Hypothyroidism	B-X
''	B-X
[	B-X
J	B-X
Natl	B-X
Med	B-X
Assoc	B-X
110	B-X
(	B-X
6	B-X
)	B-X
(	B-X
2018	B-X
)	B-X
606-613	B-X
]	B-X
.	B-X
Sodium	B-X
channels	B-X
in	B-X
the	B-X
cytoplasm	B-X
of	B-X
Schwann	B-X
cells	B-X
.	B-X
Proc	B-X
.	B-X
Natl	B-X
.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
87	B-X
(	B-X
1990	B-X
)	B-X
9290-9294	B-X
.	B-X
Imhotep	B-X
.	B-X

Acad	O
.	O
<EOS>	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2018	B-X
)	B-X
,	B-X
1423	B-X
,	B-X
166-175	B-X
.	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2018	B-X
)	B-X
,	B-X
1433	B-X
,	B-X
29-40	B-X
.	B-X
Corrigendum	B-X
for	B-X
Ann	B-X
.	B-X
N.	B-X
Y.	B-X
Acad	B-X
.	B-X
Sci	B-X
.	B-X
(	B-X
2020	B-X
)	B-X
,	B-X
1462	B-X
,	B-X
65-78	B-X
.	B-X
In	B-X
Memoriam	B-X
Acad	B-X
.	B-X
Prof.	B-X
Dr.	B-X
LjubiÅ¡a	B-X
RakiÄ	B-X
(	B-X
1931-2022	B-X
)	B-X
.	B-X

Sci	O
.	O
<EOS>	B-X
Molecules	B-X
and	B-X
Biomaterial	B-X
Technologies	B-X
Affecting	B-X
Stem	B-X
Cell	B-X
Differentiation	B-X
.	B-X

U	O
.	O
S	O
.	O
A	O
.	O
<EOS>	B-X
NUTRITIONAL	B-X
WELL-BEING	B-X
IN	B-X
THE	B-X
U.S.A.	B-X
Nutritional	B-X
status	B-X
,	B-X
U.S.A	B-X
.	B-X
Abortion	B-X
in	B-X
U.S.A	B-X
.	B-X
Persons	B-X
with	B-X
disabilities	B-X
represent	B-X
a	B-X
growing	B-X
population	B-X
in	B-X
both	B-X
the	B-X
European	B-X
Union	B-X
(	B-X
EU	B-X
)	B-X
and	B-X
the	B-X
United	B-X
States	B-X
(	B-X
USA	B-X
)	B-X
.	B-X
The	B-X
EU	B-X
has	B-X
made	B-X
substantial	B-X
policy	B-X
progress	B-X
to	B-X
support	B-X
telework	B-X
,	B-X
but	B-X
persons	B-X
with	B-X
disabilities	B-X
have	B-X
had	B-X
only	B-X
limited	B-X
long-term	B-X
success	B-X
in	B-X
telework	B-X
initiatives	B-X
due	B-X
to	B-X
lack	B-X
of	B-X
work	B-X
support	B-X
services	B-X
.	B-X
The	B-X
USA	B-X
has	B-X
generally	B-X
strong	B-X
support	B-X
services	B-X
but	B-X
lacks	B-X
telework	B-X
policy	B-X
infrastructure	B-X
.	B-X
The	B-X
EU	B-X
and	B-X
the	B-X
USA	B-X
can	B-X
benefit	B-X
from	B-X
collaborative	B-X
work	B-X
to	B-X
enhance	B-X
their	B-X
complementary	B-X
strengths	B-X
.	B-X

75	O
,	O
1309	O
-	O
1313	O
.	O
<EOS>	B-X
Government	B-X
freezes	B-X
administrators	B-X
'	B-X
salaries	B-X
.	B-X
Has	B-X
H.I.S	B-X
.	B-X
attained	B-X
cruising	B-X
speed	B-X
?	B-X

43	O
.	O

Palmiter	O
,	O
R	O
.	O
<EOS>	B-X
This	B-X
review	B-X
focuses	B-X
on	B-X
PBN	B-X
neurons	B-X
expressing	B-X
calcitonin	B-X
gene-related	B-X
peptide	B-X
(	B-X
CGRP	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
melanocortin	B-X
4	B-X
receptor	B-X
(	B-X
MC4R	B-X
)	B-X
neurons	B-X
located	B-X
in	B-X
the	B-X
dorsal	B-X
bed	B-X
nucleus	B-X
of	B-X
the	B-X
stria	B-X
terminus	B-X
(	B-X
dBNST	B-X
)	B-X
engage	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
mentally	B-X
associated	B-X
weight	B-X
gain	B-X
by	B-X
receiving	B-X
GABAergic	B-X
projections	B-X
from	B-X
hypothalamic	B-X
AgRP	B-X
neurons	B-X
onto	B-X
Î±5-containing	B-X
GABA	B-X
Neurons	B-X
that	B-X
express	B-X
calcitonin	B-X
gene-related	B-X
peptide	B-X
in	B-X
the	B-X
parabrachial	B-X
nucleus	B-X
(	B-X
CGRP	B-X
Hunger	B-X
logic	B-X
.	B-X

D	O
.	O
,	O
Davidson	O
,	O
J	O
.	O
<EOS>	B-X
Vitamin	B-X
D	B-X
testing	B-X
.	B-X
Editorial	B-X
:	B-X
Disease	B-X
and	B-X
pest	B-X
resistance	B-X
in	B-X
legume	B-X
crops	B-X
.	B-X
The	B-X
experts	B-X
decided	B-X
to	B-X
adapt	B-X
the	B-X
existing	B-X
treatment	B-X
algorithm	B-X
developed	B-X
in	B-X
Japan	B-X
and	B-X
discuss	B-X
strategies	B-X
for	B-X
clinical	B-X
issues	B-X
that	B-X
have	B-X
been	B-X
problematic	B-X
in	B-X
some	B-X
countries	B-X
.	B-X
To	B-X
provide	B-X
an	B-X
update	B-X
to	B-X
the	B-X
``	B-X
Consensus	B-X
Statement	B-X
on	B-X
Posttraumatic	B-X
Stress	B-X
Disorder	B-X
From	B-X
the	B-X
International	B-X
Consensus	B-X
Group	B-X
on	B-X
Depression	B-X
and	B-X
Anxiety	B-X
''	B-X
that	B-X
was	B-X
published	B-X
in	B-X
a	B-X
supplement	B-X
to	B-X
The	B-X
Journal	B-X
of	B-X
Clinical	B-X
Psychiatry	B-X
(	B-X
2000	B-X
)	B-X
by	B-X
presenting	B-X
important	B-X
developments	B-X
in	B-X
the	B-X
field	B-X
,	B-X
the	B-X
latest	B-X
recommendations	B-X
for	B-X
patient	B-X
care	B-X
,	B-X
and	B-X
suggestions	B-X
for	B-X
future	B-X
research	B-X
.	B-X

M	O
.	O
,	O
Gagnon	O
,	O
H	O
.	O
,	O
Rowe	O
,	O
D	O
.	O

W	O
.	O
,	O
and	O
<EOS>	B-X
Water-in-oil-in-water	B-X
(	B-X
W	B-X
W-particle-reinforced	B-X
Al	B-X
alloys	B-X
were	B-X
prepared	B-X
on	B-X
a	B-X
7075	B-X
aluminum	B-X
alloy	B-X
surface	B-X
via	B-X
laser	B-X
melt	B-X
injection	B-X
to	B-X
improve	B-X
their	B-X
wear	B-X
resistance	B-X
,	B-X
and	B-X
the	B-X
microstructure	B-X
,	B-X
microhardness	B-X
,	B-X
and	B-X
wear	B-X
resistance	B-X
of	B-X
the	B-X
W/Al	B-X
layers	B-X
were	B-X
studied	B-X
.	B-X
Scanning	B-X
electron	B-X
microscopy	B-X
(	B-X
SEM	B-X
)	B-X
results	B-X
confirmed	B-X
that	B-X
a	B-X
W/Al	B-X
laser	B-X
melting	B-X
layer	B-X
of	B-X
about	B-X
1.5	B-X
mm	B-X
thickness	B-X
contained	B-X
W	B-X
particles	B-X
,	B-X
and	B-X
Al	B-X
The	B-X
dissipative	B-X
particle	B-X
dynamics	B-X
simulation	B-X
method	B-X
is	B-X
adopted	B-X
to	B-X
investigate	B-X
the	B-X
microemulsion	B-X
systems	B-X
prepared	B-X
with	B-X
surfactant	B-X
(	B-X
H1T1	B-X
)	B-X
,	B-X
oil	B-X
(	B-X
O	B-X
)	B-X
and	B-X
water	B-X
(	B-X
W	B-X
)	B-X
,	B-X
which	B-X
are	B-X
expressed	B-X
by	B-X
coarse-grained	B-X
models	B-X
.	B-X
Two	B-X
topologies	B-X
of	B-X
O/W	B-X
and	B-X
W/O	B-X
microemulsions	B-X
are	B-X
simulated	B-X
with	B-X
various	B-X
oil	B-X
and	B-X
water	B-X
ratios	B-X
.	B-X
Inverse	B-X
W/O	B-X
microemulsion	B-X
transform	B-X
to	B-X
O/W	B-X
microemulsion	B-X
by	B-X
decreasing	B-X
the	B-X
ratio	B-X
of	B-X
oil-water	B-X
from	B-X
3:1	B-X
to	B-X
1:3	B-X
.	B-X
The	B-X
stability	B-X
of	B-X
O/W	B-X
and	B-X
W/O	B-X
microemulsion	B-X
is	B-X
controlled	B-X
by	B-X
shear	B-X
rate	B-X
,	B-X
inorganic	B-X
salt	B-X
and	B-X
the	B-X
temperature	B-X
,	B-X
and	B-X
the	B-X
corresponding	B-X
results	B-X
are	B-X
analyzed	B-X
by	B-X
the	B-X
translucent	B-X
three-dimensional	B-X
structure	B-X
,	B-X
the	B-X
mean	B-X
interfacial	B-X
tension	B-X
and	B-X
end-to-end	B-X
distance	B-X
of	B-X
H1T1	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
W/O	B-X
microemulsion	B-X
is	B-X
more	B-X
stable	B-X
than	B-X
O/W	B-X
microemulsion	B-X
to	B-X
resist	B-X
higher	B-X
inorganic	B-X
salt	B-X
concentration	B-X
,	B-X
shear	B-X
rate	B-X
and	B-X
temperature	B-X
.	B-X

Bornstein	O
,	O
P	O
.	O
<EOS>	B-X
Thrombospondins	B-X
.	B-X
The	B-X
biosynthesis	B-X
of	B-X
collagen	B-X
.	B-X
Regulation	B-X
of	B-X
collagen	B-X
synthesis	B-X
.	B-X
Structurally	B-X
distinct	B-X
collagen	B-X
types	B-X
.	B-X

(	O
1979	O
)	O
J	O
.	O
<EOS>	B-X
Influenza	B-X
--	B-X
1979	B-X
.	B-X
Thomas	B-X
J.	B-X
Kelley	B-X
(	B-X
1922	B-X
--	B-X
1979	B-X
)	B-X
.	B-X
Cardiac	B-X
transplantation	B-X
1979	B-X
.	B-X
Neonatal	B-X
hypoglycemia	B-X
,	B-X
1979	B-X
.	B-X

Biol	O
.	O
<EOS>	B-X
Retraction	B-X
of	B-X
DNA	B-X
Cell	B-X
Biol	B-X
:	B-X
31:1064-1069	B-X
,	B-X
2012	B-X
,	B-X
DOI	B-X
:	B-X
10.1089/dna.2011.1552	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
provide	B-X
a	B-X
brief	B-X
synopsis	B-X
of	B-X
all	B-X
manuscripts	B-X
published	B-X
in	B-X
Histochem	B-X
Cell	B-X
Biol	B-X
in	B-X
the	B-X
year	B-X
2013	B-X
.	B-X
Retraction	B-X
notice	B-X
to	B-X
``	B-X
Nicorandil	B-X
versus	B-X
nifedipine	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
preterm	B-X
labour	B-X
:	B-X
A	B-X
randomized	B-X
clinical	B-X
trial	B-X
''	B-X
[	B-X
Eur	B-X
.	B-X
J.	B-X
Obstetr	B-X
.	B-X
Gynecol	B-X
.	B-X
Reprod	B-X
.	B-X
Biol	B-X
.	B-X
195	B-X
(	B-X
2015	B-X
)	B-X
27-30	B-X
]	B-X
.	B-X
Retraction	B-X
notice	B-X
to	B-X
``	B-X
Reducing	B-X
blood	B-X
loss	B-X
at	B-X
abdominal	B-X
myomectomy	B-X
with	B-X
preoperative	B-X
use	B-X
of	B-X
dinoprostone	B-X
intravaginal	B-X
suppository	B-X
:	B-X
A	B-X
randomized	B-X
placebo-controlled	B-X
pilot	B-X
study	B-X
''	B-X
[	B-X
Eur	B-X
.	B-X
J.	B-X
Obst	B-X
.	B-X
Gynecol	B-X
.	B-X
Reprod	B-X
.	B-X
Biol	B-X
.	B-X
166/1	B-X
(	B-X
2012	B-X
)	B-X
61-64	B-X
]	B-X
.	B-X

Chem	O
.	O
<EOS>	B-X
Chem	B-X
Soc	B-X
Rev	B-X
--	B-X
growing	B-X
stronger	B-X
.	B-X
The	B-X
WRF-Chem	B-X
(	B-X
Weather	B-X
Research	B-X
and	B-X
Forecasting	B-X
with	B-X
Chemistry	B-X
)	B-X
model	B-X
is	B-X
implemented	B-X
and	B-X
validated	B-X
against	B-X
ground-based	B-X
observations	B-X
for	B-X
meteorological	B-X
and	B-X
atmospheric	B-X
variables	B-X
for	B-X
the	B-X
first	B-X
time	B-X
in	B-X
Northern	B-X
Vietnam	B-X
.	B-X
The	B-X
WRF-Chem	B-X
model	B-X
was	B-X
based	B-X
on	B-X
HTAPv2	B-X
emission	B-X
inventory	B-X
with	B-X
MOZCART	B-X
chemical-aerosol	B-X
mechanism	B-X
to	B-X
simulate	B-X
atmospheric	B-X
variables	B-X
for	B-X
winter	B-X
(	B-X
January	B-X
)	B-X
and	B-X
summer	B-X
(	B-X
July	B-X
)	B-X
of	B-X
2014	B-X
.	B-X
Chem	B-X
Soc	B-X
Rev	B-X
leads	B-X
the	B-X
way	B-X
.	B-X

254	O
,	O
1433	O
-	O
1436	O
.	O
<EOS>	B-X
Chemistry	B-X
of	B-X
tobacco	B-X
constituents	B-X
.	B-X
Oxidation	B-X
of	B-X
alpha-ionone	B-X
and	B-X
the	B-X
acid-catalyzed	B-X
rearrangement	B-X
of	B-X
5-keto-alpha-ionone	B-X
.	B-X
The	B-X
college	B-X
health-practice	B-X
preceptorship	B-X
in	B-X
the	B-X
training	B-X
of	B-X
physician	B-X
's	B-X
assistants	B-X
.	B-X
[	B-X
Participation	B-X
of	B-X
feldshers	B-X
and	B-X
midwives	B-X
in	B-X
the	B-X
secret	B-X
and	B-X
partisan	B-X
activities	B-X
during	B-X
the	B-X
great	B-X
patriotic	B-X
war	B-X
]	B-X
.	B-X

44	O
.	O

Graves	O
,	O
P	O
.	O
<EOS>	B-X
To	B-X
overcome	B-X
this	B-X
bottleneck	B-X
,	B-X
we	B-X
have	B-X
established	B-X
the	B-X
RElevant	B-X
LIterature	B-X
SearcH	B-X
consortium	B-X
consisting	B-X
of	B-X
more	B-X
than	B-X
1500	B-X
scientists	B-X
from	B-X
84	B-X
countries	B-X
,	B-X
who	B-X
have	B-X
collectively	B-X
annotated	B-X
the	B-X
relevance	B-X
of	B-X
over	B-X
180	B-X
000	B-X
PubMed-listed	B-X
articles	B-X
with	B-X
regard	B-X
to	B-X
their	B-X
respective	B-X
seed	B-X
(	B-X
input	B-X
)	B-X
article/s	B-X
.	B-X
The	B-X
collected	B-X
data	B-X
cover	B-X
76	B-X
%	B-X
of	B-X
all	B-X
unique	B-X
PubMed	B-X
Medical	B-X
Subject	B-X
Headings	B-X
descriptors	B-X
.	B-X
We	B-X
further	B-X
show	B-X
that	B-X
the	B-X
three	B-X
representative	B-X
baseline	B-X
methods	B-X
used	B-X
to	B-X
generate	B-X
recommended	B-X
articles	B-X
for	B-X
evaluation	B-X
(	B-X
Okapi	B-X
Best	B-X
Matching	B-X
25	B-X
,	B-X
Term	B-X
Frequency-Inverse	B-X
Document	B-X
Frequency	B-X
and	B-X
PubMed	B-X
Related	B-X
Articles	B-X
)	B-X
had	B-X
similar	B-X
overall	B-X
performances	B-X
.	B-X
Two	B-X
types	B-X
of	B-X
vaccine	B-X
,	B-X
SPf66	B-X
vaccine	B-X
against	B-X
the	B-X
asexual	B-X
stages	B-X
,	B-X
and	B-X
NANP	B-X
vaccines	B-X
against	B-X
the	B-X
sporozoite	B-X
stages	B-X
of	B-X
the	B-X
Plasmodium	B-X
parasite	B-X
,	B-X
have	B-X
been	B-X
tested	B-X
in	B-X
randomised	B-X
clinical	B-X
trials	B-X
in	B-X
endemic	B-X
areas	B-X
.	B-X

N	O
.	O
,	O
Olsen	O
,	O
B	O
.	O
<EOS>	B-X
The	B-X
structure	B-X
of	B-X
type	B-X
XII	B-X
collagen	B-X
.	B-X
Tissue-specific	B-X
expression	B-X
of	B-X
type	B-X
IX	B-X
collagen	B-X
.	B-X
The	B-X
costimulatory	B-X
molecule	B-X
CD40	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
receptor	B-X
superfamily	B-X
and	B-X
is	B-X
expressed	B-X
on	B-X
various	B-X
antigen	B-X
presenting	B-X
cells	B-X
(	B-X
APCs	B-X
)	B-X
as	B-X
well	B-X
as	B-X
some	B-X
tumor	B-X
cells	B-X
.	B-X
Here	B-X
,	B-X
Dacetuzumab	B-X
and	B-X
Lucatumumab	B-X
are	B-X
in	B-X
the	B-X
most	B-X
advanced	B-X
stage	B-X
and	B-X
are	B-X
being	B-X
tested	B-X
as	B-X
treatment	B-X
for	B-X
malignancies	B-X
such	B-X
as	B-X
chronic	B-X
lymphatic	B-X
leukemia	B-X
(	B-X
CLL	B-X
)	B-X
,	B-X
Multiple	B-X
Myeloma	B-X
(	B-X
MM	B-X
)	B-X
,	B-X
and	B-X
non-Hodgkin	B-X
's	B-X
lymphoma	B-X
(	B-X
NHL	B-X
)	B-X
.	B-X

R	O
.	O
,	O
Feitzig	O
,	O
P	O
.	O
<EOS>	B-X
Establishment	B-X
and	B-X
maintenance	B-X
of	B-X
a	B-X
lysogen	B-X
of	B-X
the	B-X
lambdoid	B-X
bacteriophage	B-X
434	B-X
require	B-X
that	B-X
the	B-X
434	B-X
repressor	B-X
both	B-X
activate	B-X
transcription	B-X
from	B-X
the	B-X
P	B-X
(	B-X
RM	B-X
)	B-X
promoter	B-X
and	B-X
repress	B-X
transcription	B-X
from	B-X
the	B-X
divergent	B-X
P	B-X
(	B-X
R	B-X
)	B-X
promoter	B-X
.	B-X
Several	B-X
lines	B-X
of	B-X
evidence	B-X
indicate	B-X
that	B-X
the	B-X
434	B-X
repressor	B-X
activates	B-X
initiation	B-X
of	B-X
P	B-X
(	B-X
RM	B-X
)	B-X
transcription	B-X
by	B-X
occupying	B-X
a	B-X
binding	B-X
site	B-X
adjacent	B-X
to	B-X
the	B-X
P	B-X
(	B-X
RM	B-X
)	B-X
promoter	B-X
and	B-X
directly	B-X
contacting	B-X
RNA	B-X
polymerase	B-X
.	B-X
The	B-X
overlapping	B-X
architecture	B-X
of	B-X
the	B-X
P	B-X
(	B-X
RM	B-X
)	B-X
and	B-X
P	B-X
(	B-X
R	B-X
)	B-X
promoters	B-X
suggests	B-X
that	B-X
an	B-X
RNA	B-X
polymerase	B-X
bound	B-X
at	B-X
P	B-X
(	B-X
R	B-X
)	B-X
may	B-X
repress	B-X
P	B-X
(	B-X
RM	B-X
)	B-X
transcription	B-X
initiation	B-X
.	B-X
Hence	B-X
,	B-X
part	B-X
of	B-X
the	B-X
stimulatory	B-X
effect	B-X
of	B-X
the	B-X
434	B-X
repressor	B-X
may	B-X
be	B-X
relief	B-X
of	B-X
interference	B-X
between	B-X
RNA	B-X
polymerase	B-X
binding	B-X
to	B-X
the	B-X
P	B-X
(	B-X
RM	B-X
)	B-X
promoter	B-X
and	B-X
to	B-X
the	B-X
P	B-X
(	B-X
R	B-X
)	B-X
promoter	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
proposal	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
repressor	B-X
can	B-X
not	B-X
activate	B-X
P	B-X
(	B-X
RM	B-X
)	B-X
transcription	B-X
if	B-X
RNA	B-X
polymerase	B-X
binds	B-X
at	B-X
P	B-X
(	B-X
R	B-X
)	B-X
prior	B-X
to	B-X
addition	B-X
of	B-X
the	B-X
434	B-X
repressor	B-X
.	B-X
However	B-X
,	B-X
unlike	B-X
the	B-X
findings	B-X
with	B-X
the	B-X
related	B-X
lambda	B-X
phage	B-X
,	B-X
formation	B-X
of	B-X
RNA	B-X
polymerase	B-X
promoter	B-X
complexes	B-X
at	B-X
P	B-X
(	B-X
RM	B-X
)	B-X
and	B-X
at	B-X
P	B-X
(	B-X
R	B-X
)	B-X
apparently	B-X
are	B-X
mutually	B-X
exclusive	B-X
.	B-X
We	B-X
find	B-X
that	B-X
the	B-X
RNA	B-X
polymerase-mediated	B-X
inhibition	B-X
of	B-X
repressor-stimulated	B-X
P	B-X
(	B-X
RM	B-X
)	B-X
transcription	B-X
requires	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
open	B-X
complex	B-X
at	B-X
P	B-X
(	B-X
R	B-X
)	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
indicate	B-X
that	B-X
establishment	B-X
of	B-X
an	B-X
open	B-X
complex	B-X
at	B-X
P	B-X
(	B-X
R	B-X
)	B-X
directly	B-X
prevents	B-X
formation	B-X
of	B-X
an	B-X
RNA	B-X
polymerase-P	B-X
(	B-X
RM	B-X
)	B-X
complex	B-X
.	B-X

P	O
.	O
,	O
Monson	O
,	O
J	O
.	O
<EOS>	B-X
The	B-X
epidemiology	B-X
of	B-X
endocrine	B-X
tumours	B-X
.	B-X
Postulated	B-X
mechanisms	B-X
include	B-X
GHD	B-X
and	B-X
gonadal	B-X
steroid	B-X
deficiency	B-X
of	B-X
unknown	B-X
duration	B-X
;	B-X
glucocorticoid	B-X
and	B-X
thyroxine	B-X
replacement	B-X
do	B-X
not	B-X
appear	B-X
to	B-X
exert	B-X
a	B-X
major	B-X
role	B-X
.	B-X
The	B-X
Pharmacia	B-X
International	B-X
Metabolic	B-X
Surveillance	B-X
(	B-X
KIMS	B-X
)	B-X
study	B-X
(	B-X
a	B-X
pharmacoepidemiological	B-X
survey	B-X
of	B-X
the	B-X
safety	B-X
and	B-X
efficacy	B-X
of	B-X
GH	B-X
replacement	B-X
in	B-X
adults	B-X
,	B-X
sponsored	B-X
by	B-X
Pharmacia	B-X
)	B-X
is	B-X
currently	B-X
the	B-X
largest	B-X
database	B-X
,	B-X
with	B-X
information	B-X
on	B-X
over	B-X
8000	B-X
patients	B-X
from	B-X
a	B-X
total	B-X
of	B-X
27	B-X
countries	B-X
.	B-X
Previous	B-X
studies	B-X
have	B-X
demonstrated	B-X
raised	B-X
serum	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-6	B-X
in	B-X
thyrotoxic	B-X
patients	B-X
,	B-X
but	B-X
differentiating	B-X
the	B-X
contribution	B-X
of	B-X
the	B-X
elevated	B-X
thyroid	B-X
hormones	B-X
from	B-X
that	B-X
of	B-X
the	B-X
autoimmune	B-X
inflammation	B-X
present	B-X
in	B-X
Graves	B-X
'	B-X
disease	B-X
(	B-X
GD	B-X
)	B-X
has	B-X
been	B-X
difficult	B-X
.	B-X
The	B-X
following	B-X
measurements	B-X
were	B-X
made	B-X
basally	B-X
and	B-X
for	B-X
6	B-X
months	B-X
after	B-X
carbimazole	B-X
treatment	B-X
:	B-X
serum	B-X
free	B-X
T4	B-X
,	B-X
T3	B-X
,	B-X
bone-specific	B-X
alkaline	B-X
phosphatase	B-X
(	B-X
b-ALP	B-X
)	B-X
,	B-X
IL-6	B-X
,	B-X
IL-8	B-X
,	B-X
IL-1beta	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
,	B-X
IL-11	B-X
,	B-X
and	B-X
urinary	B-X
deoxypyridinoline	B-X
(	B-X
Udpd	B-X
)	B-X
.	B-X
Compared	B-X
with	B-X
controls	B-X
(	B-X
IL-6	B-X
,	B-X
1.1	B-X
+/-	B-X
0.3	B-X
ng/L	B-X
;	B-X
IL-8	B-X
,	B-X
3.2	B-X
+/-	B-X
0.8	B-X
ng/L	B-X
)	B-X
,	B-X
untreated	B-X
patients	B-X
with	B-X
GD	B-X
and	B-X
TNG	B-X
had	B-X
elevated	B-X
IL-6	B-X
(	B-X
GD	B-X
,	B-X
7.11	B-X
+/-	B-X
0.88	B-X
ng/L	B-X
;	B-X
TNG	B-X
,	B-X
7.30	B-X
+/-	B-X
0.77	B-X
ng/L	B-X
;	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
and	B-X
IL-8	B-X
(	B-X
GD	B-X
,	B-X
10.3	B-X
+/-	B-X
1.23	B-X
ng/L	B-X
;	B-X
TNG	B-X
,	B-X
9.81	B-X
+/-	B-X
1.27	B-X
ng/L	B-X
;	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
When	B-X
data	B-X
from	B-X
all	B-X
the	B-X
patients	B-X
were	B-X
pooled	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
IL-6	B-X
and	B-X
IL-8	B-X
correlated	B-X
with	B-X
serum	B-X
T3	B-X
and	B-X
free	B-X
T4	B-X
but	B-X
not	B-X
with	B-X
Udpd	B-X
or	B-X
b-ALP	B-X
.	B-X
The	B-X
site	B-X
of	B-X
the	B-X
presumed	B-X
increased	B-X
production	B-X
of	B-X
IL-6	B-X
and	B-X
-8	B-X
is	B-X
most	B-X
likely	B-X
from	B-X
bone	B-X
osteoblasts	B-X
,	B-X
despite	B-X
the	B-X
inability	B-X
of	B-X
bone	B-X
markers	B-X
(	B-X
such	B-X
as	B-X
Udpd	B-X
and	B-X
b-ALP	B-X
)	B-X
to	B-X
correlate	B-X
with	B-X
acute	B-X
changes	B-X
in	B-X
thyroid	B-X
hormone	B-X
status	B-X
produced	B-X
by	B-X
antithyroid	B-X
therapy	B-X
.	B-X

M	O
.	O
and	O
<EOS>	B-X
Erratum	B-X
for	B-X
the	B-X
Report	B-X
``	B-X
Worldwide	B-X
evidence	B-X
of	B-X
a	B-X
unimodal	B-X
relationship	B-X
between	B-X
productivity	B-X
and	B-X
plant	B-X
species	B-X
richness	B-X
,	B-X
''	B-X
by	B-X
Lauchlan	B-X
H.	B-X
Fraser	B-X
,	B-X
J.	B-X
Pither	B-X
,	B-X
A.	B-X
Jentsch	B-X
,	B-X
M.	B-X
Sternberg	B-X
,	B-X
M.	B-X
Zobel	B-X
,	B-X
D.	B-X
Askarizadeh	B-X
,	B-X
S.	B-X
Bartha	B-X
,	B-X
C.	B-X
Beierkuhnlein	B-X
,	B-X
J	B-X
.	B-X
A.	B-X
Bennett	B-X
,	B-X
A.	B-X
Bittel	B-X
,	B-X
B.	B-X
Boldgiv	B-X
,	B-X
I.	B-X
I.	B-X
Boldrini	B-X
,	B-X
E.	B-X
Bork	B-X
,	B-X
L.	B-X
Brown	B-X
,	B-X
M.	B-X
Cabido	B-X
,	B-X
J.	B-X
Cahill	B-X
,	B-X
C.	B-X
N.	B-X
Carlyle	B-X
,	B-X
G.	B-X
Campetella	B-X
,	B-X
S.	B-X
Chelli	B-X
,	B-X
O.	B-X
Cohen	B-X
,	B-X
A.-M.	B-X
Csergo	B-X
,	B-X
S.	B-X
DÃ­az	B-X
,	B-X
L.	B-X
Enrico	B-X
,	B-X
D.	B-X
Ensing	B-X
,	B-X
A.	B-X
Fidelis	B-X
,	B-X
J.	B-X
D.	B-X
Fridley	B-X
,	B-X
B	B-X
.	B-X
Foster	B-X
,	B-X
H.	B-X
Garris	B-X
,	B-X
J.	B-X
R.	B-X
Goheen	B-X
,	B-X
H.	B-X
A.	B-X
L.	B-X
Henry	B-X
,	B-X
M.	B-X
Hohn	B-X
,	B-X
M.	B-X
H.	B-X
Jouri	B-X
,	B-X
J.	B-X
Klironomos	B-X
,	B-X
K.	B-X
Koorem	B-X
,	B-X
R.	B-X
Lawrence-Lodge	B-X
,	B-X
R.	B-X
Long	B-X
,	B-X
P.	B-X
Manning	B-X
,	B-X
R.	B-X
Mitchell	B-X
,	B-X
M.	B-X
Moora	B-X
,	B-X
S.	B-X
C.	B-X
MÃ¼ller	B-X
,	B-X
C.	B-X
Nabinger	B-X
,	B-X
K.	B-X
Naseri	B-X
,	B-X
G.	B-X
E.	B-X
Overbeck	B-X
,	B-X
T.	B-X
M.	B-X
Palmer	B-X
,	B-X
S.	B-X
Parsons	B-X
,	B-X
M.	B-X
Pesek	B-X
,	B-X
V.	B-X
D.	B-X
Pillar	B-X
,	B-X
R.	B-X
M.	B-X
Pringle	B-X
,	B-X
K.	B-X
Roccaforte	B-X
,	B-X
A.	B-X
Schmidt	B-X
,	B-X
Z.	B-X
Shang	B-X
,	B-X
R.	B-X
Stahlmann	B-X
,	B-X
G.	B-X
C.	B-X
Stotz	B-X
,	B-X
S.	B-X
Sugiyama	B-X
,	B-X
S.	B-X
Szentes	B-X
,	B-X
D.	B-X
Thompson	B-X
,	B-X
R.	B-X
Tungalag	B-X
,	B-X
S.	B-X
Undrakhbold	B-X
,	B-X
M.	B-X
van	B-X
Rooyen	B-X
,	B-X
C.	B-X
Wellstein	B-X
,	B-X
J	B-X
.	B-X
B.	B-X
Wilson	B-X
,	B-X
T.	B-X
Zupo	B-X
.	B-X

Prockop	O
,	O
D	O
.	O
<EOS>	B-X
Heritable	B-X
diseases	B-X
of	B-X
collagen	B-X
.	B-X
Hardly	B-X
Tendentious	B-X
--	B-X
Repairing	B-X
Like	B-X
with	B-X
Like	B-X
.	B-X
The	B-X
biosynthesis	B-X
of	B-X
collagen	B-X
.	B-X
2	B-X
.	B-X
New	B-X
targets	B-X
for	B-X
osteoporosis	B-X
.	B-X

J	O
.	O
<EOS>	B-X
Heat	B-X
shock	B-X
proteins	B-X
of	B-X
40	B-X
kDa	B-X
(	B-X
Hsp40s	B-X
)	B-X
,	B-X
also	B-X
called	B-X
J	B-X
proteins	B-X
,	B-X
are	B-X
obligate	B-X
partners	B-X
of	B-X
Hsp70s	B-X
.	B-X
Via	B-X
their	B-X
highly	B-X
conserved	B-X
and	B-X
functionally	B-X
critical	B-X
J	B-X
domain	B-X
,	B-X
J	B-X
proteins	B-X
interact	B-X
and	B-X
modulate	B-X
the	B-X
activity	B-X
of	B-X
their	B-X
Hsp70	B-X
partners	B-X
.	B-X
Mutations	B-X
in	B-X
the	B-X
critical	B-X
residues	B-X
in	B-X
the	B-X
J	B-X
domain	B-X
often	B-X
result	B-X
in	B-X
the	B-X
null	B-X
phenotype	B-X
for	B-X
the	B-X
J	B-X
protein	B-X
in	B-X
question	B-X
.	B-X
However	B-X
,	B-X
as	B-X
more	B-X
J	B-X
proteins	B-X
have	B-X
been	B-X
characterized	B-X
,	B-X
it	B-X
is	B-X
becoming	B-X
increasingly	B-X
clear	B-X
that	B-X
a	B-X
significant	B-X
number	B-X
of	B-X
J	B-X
proteins	B-X
do	B-X
not	B-X
``	B-X
completely	B-X
''	B-X
rely	B-X
on	B-X
their	B-X
J	B-X
domains	B-X
to	B-X
carry	B-X
out	B-X
their	B-X
cellular	B-X
functions	B-X
,	B-X
as	B-X
previously	B-X
thought	B-X
.	B-X
In	B-X
some	B-X
cases	B-X
,	B-X
regions	B-X
outside	B-X
the	B-X
highly	B-X
conserved	B-X
J	B-X
domain	B-X
have	B-X
become	B-X
more	B-X
important	B-X
making	B-X
the	B-X
J	B-X
domain	B-X
dispensable	B-X
for	B-X
some	B-X
,	B-X
if	B-X
not	B-X
for	B-X
all	B-X
functions	B-X
of	B-X
a	B-X
J	B-X
protein	B-X
.	B-X
This	B-X
has	B-X
profound	B-X
effects	B-X
on	B-X
the	B-X
evolution	B-X
of	B-X
such	B-X
J	B-X
proteins	B-X
.	B-X
Here	B-X
we	B-X
present	B-X
selected	B-X
examples	B-X
of	B-X
J	B-X
proteins	B-X
that	B-X
perform	B-X
J	B-X
domain	B-X
independent	B-X
functions	B-X
and	B-X
discuss	B-X
this	B-X
in	B-X
the	B-X
context	B-X
of	B-X
evolution	B-X
of	B-X
J	B-X
proteins	B-X
with	B-X
dispensable	B-X
J	B-X
domains	B-X
and	B-X
J-like	B-X
proteins	B-X
in	B-X
eukaryotes	B-X
.	B-X

(	O
1979	O
)	O
Fed	O
.	O
<EOS>	B-X
By	B-X
8	B-X
March	B-X
1979	B-X
,	B-X
all	B-X
of	B-X
the	B-X
lab-reared	B-X
nondiapausing	B-X
groups	B-X
,	B-X
of	B-X
mosquitoes	B-X
released	B-X
in	B-X
the	B-X
room	B-X
had	B-X
died	B-X
,	B-X
whereas	B-X
15.7	B-X
,	B-X
22.4	B-X
and	B-X
24.7	B-X
%	B-X
were	B-X
recovered	B-X
from	B-X
the	B-X
``	B-X
lab-reared	B-X
diapausing	B-X
nonblood-fed	B-X
,	B-X
''	B-X
``	B-X
lab-reared	B-X
diapausing	B-X
blood-fed	B-X
''	B-X
(	B-X
gravid	B-X
and	B-X
nongravid	B-X
)	B-X
and	B-X
``	B-X
wild	B-X
caught	B-X
''	B-X
mosquitoes	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
1979	B-X
,	B-X
we	B-X
tested	B-X
dietary	B-X
monosodium	B-X
glutamate	B-X
(	B-X
MSG	B-X
)	B-X
for	B-X
developmental	B-X
neurotoxicity	B-X
in	B-X
rats	B-X
.	B-X
:	B-X
Toxicol	B-X
Appl	B-X
Pharmacol	B-X
1979	B-X
;	B-X
50	B-X
:	B-X
267-282	B-X
]	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
can	B-X
be	B-X
concluded	B-X
,	B-X
as	B-X
was	B-X
done	B-X
in	B-X
1979	B-X
and	B-X
by	B-X
the	B-X
U.S.	B-X
Food	B-X
and	B-X
Drug	B-X
Administration	B-X
who	B-X
sponsored	B-X
the	B-X
study	B-X
,	B-X
that	B-X
there	B-X
is	B-X
no	B-X
evidence	B-X
in	B-X
these	B-X
data	B-X
that	B-X
dietary	B-X
MSG	B-X
is	B-X
developmentally	B-X
neurotoxic	B-X
,	B-X
hence	B-X
,	B-X
the	B-X
study	B-X
provides	B-X
no	B-X
basis	B-X
for	B-X
the	B-X
establishment	B-X
of	B-X
a	B-X
NOAEL	B-X
and	B-X
changing	B-X
the	B-X
ADI	B-X
for	B-X
dietary	B-X
MSG	B-X
.	B-X

Proc	O
.	O
<EOS>	B-X
Proc	B-X
IMechE	B-X
,	B-X
Part	B-X
H	B-X
:	B-X
Journal	B-X
of	B-X
Engineering	B-X
in	B-X
Medicine	B-X
;	B-X
230	B-X
(	B-X
5	B-X
)	B-X
:	B-X
373-388	B-X
.	B-X
Identification	B-X
of	B-X
Alpha	B-X
Thalassemia	B-X
,	B-X

38	O
,	O
620	O
.	O
<EOS>	B-X
Direct	B-X
identification	B-X
and	B-X
characterisation	B-X
of	B-X
beta-adrenergic	B-X
receptors	B-X
in	B-X
rat	B-X
brain	B-X
.	B-X

2253	O

Thumb	O
force	O
deficit	O
after	O
lower	O
median	O
nerve	O
block	O
<EOS>	B-X
PURPOSE	B-X
:	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
characterize	B-X
thumb	B-X
motor	B-X
dysfunction	B-X
resulting	B-X
from	B-X
simulated	B-X
lower	B-X
median	B-X
nerve	B-X
lesions	B-X
at	B-X
the	B-X
wrist	B-X
.	B-X
METHODS	B-X
:	B-X
Bupivacaine	B-X
hydrochloride	B-X
was	B-X
injected	B-X
into	B-X
the	B-X
carpal	B-X
tunnel	B-X
of	B-X
six	B-X
healthy	B-X
subjects	B-X
to	B-X
locally	B-X
anesthetize	B-X
the	B-X
median	B-X
nerve	B-X
.	B-X
Motor	B-X
function	B-X
was	B-X
subsequently	B-X
evaluated	B-X
by	B-X
measuring	B-X
maximal	B-X
force	B-X
production	B-X
in	B-X
all	B-X
directions	B-X
within	B-X
the	B-X
transverse	B-X
plane	B-X
perpendicular	B-X
to	B-X
the	B-X
longitudinal	B-X
axis	B-X
of	B-X
the	B-X
thumb	B-X
.	B-X
Force	B-X
envelopes	B-X
were	B-X
constructed	B-X
using	B-X
these	B-X
measured	B-X
multidirectional	B-X
forces	B-X
.	B-X
RESULTS	B-X
:	B-X
Blockage	B-X
of	B-X
the	B-X
median	B-X
nerve	B-X
resulted	B-X
in	B-X
decreased	B-X
force	B-X
magnitudes	B-X
and	B-X
thus	B-X
smaller	B-X
force	B-X
envelopes	B-X
.	B-X
The	B-X
average	B-X
force	B-X
decrease	B-X
around	B-X
the	B-X
force	B-X
envelope	B-X
was	B-X
27.9	B-X
%	B-X
.	B-X
Areas	B-X
enclosed	B-X
by	B-X
pre-	B-X
and	B-X
post-block	B-X
force	B-X
envelopes	B-X
were	B-X
20628	B-X
+/-	B-X
7747	B-X
N.N	B-X
,	B-X
and	B-X
10700	B-X
+/-	B-X
4474	B-X
N.N	B-X
,	B-X
respectively	B-X
,	B-X
representing	B-X
an	B-X
average	B-X
decrease	B-X
of	B-X
48.1	B-X
%	B-X
.	B-X
CONCLUSION	B-X
:	B-X
Lower	B-X
median	B-X
nerve	B-X
lesion	B-X
,	B-X
simulated	B-X
by	B-X
a	B-X
nerve	B-X
block	B-X
at	B-X
the	B-X
wrist	B-X
,	B-X
compromise	B-X
normal	B-X
motor	B-X
function	B-X
of	B-X
the	B-X
thumb	B-X
.	B-X
A	B-X
median	B-X
nerve	B-X
block	B-X
results	B-X
in	B-X
force	B-X
deficits	B-X
in	B-X
all	B-X
directions	B-X
,	B-X
with	B-X
the	B-X
most	B-X
severe	B-X
impairment	B-X
in	B-X
abduction	B-X
and	B-X
flexion	B-X
.	B-X

Abstract	O
<EOS>	B-X
Abstract	B-X
writing	B-X
.	B-X
The	B-X
informative	B-X
abstract	B-X
.	B-X
Crafting	B-X
a	B-X
compelling	B-X
abstract	B-X
.	B-X
Why	B-X
the	B-X
structured	B-X
abstract	B-X
?	B-X

Purpose	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
characterize	O
thumb	O
motor	O
dysfunction	O
resulting	O
from	O
simulated	O
lower	O
median	O
nerve	O
lesions	O
at	O
the	O
wrist	O
.	O
<EOS>	B-X
PURPOSE	B-X
:	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
characterize	B-X
thumb	B-X
motor	B-X
dysfunction	B-X
resulting	B-X
from	B-X
simulated	B-X
lower	B-X
median	B-X
nerve	B-X
lesions	B-X
at	B-X
the	B-X
wrist	B-X
.	B-X
METHODS	B-X
:	B-X
Bupivacaine	B-X
hydrochloride	B-X
was	B-X
injected	B-X
into	B-X
the	B-X
carpal	B-X
tunnel	B-X
of	B-X
six	B-X
healthy	B-X
subjects	B-X
to	B-X
locally	B-X
anesthetize	B-X
the	B-X
median	B-X
nerve	B-X
.	B-X
Motor	B-X
function	B-X
was	B-X
subsequently	B-X
evaluated	B-X
by	B-X
measuring	B-X
maximal	B-X
force	B-X
production	B-X
in	B-X
all	B-X
directions	B-X
within	B-X
the	B-X
transverse	B-X
plane	B-X
perpendicular	B-X
to	B-X
the	B-X
longitudinal	B-X
axis	B-X
of	B-X
the	B-X
thumb	B-X
.	B-X
RESULTS	B-X
:	B-X
Blockage	B-X
of	B-X
the	B-X
median	B-X
nerve	B-X
resulted	B-X
in	B-X
decreased	B-X
force	B-X
magnitudes	B-X
and	B-X
thus	B-X
smaller	B-X
force	B-X
envelopes	B-X
.	B-X
CONCLUSION	B-X
:	B-X
Lower	B-X
median	B-X
nerve	B-X
lesion	B-X
,	B-X
simulated	B-X
by	B-X
a	B-X
nerve	B-X
block	B-X
at	B-X
the	B-X
wrist	B-X
,	B-X
compromise	B-X
normal	B-X
motor	B-X
function	B-X
of	B-X
the	B-X
thumb	B-X
.	B-X
A	B-X
median	B-X
nerve	B-X
block	B-X
results	B-X
in	B-X
force	B-X
deficits	B-X
in	B-X
all	B-X
directions	B-X
,	B-X
with	B-X
the	B-X
most	B-X
severe	B-X
impairment	B-X
in	B-X
abduction	B-X
and	B-X
flexion	B-X
.	B-X
From	B-X
our	B-X
results	B-X
,	B-X
such	B-X
a	B-X
means	B-X
of	B-X
motor	B-X
function	B-X
assessment	B-X
can	B-X
potentially	B-X
be	B-X
applied	B-X
to	B-X
functionally	B-X
evaluate	B-X
peripheral	B-X
neuropathies	B-X
.	B-X

Methods	O
<EOS>	B-X
Methods	B-X
to	B-X
calculate	B-X
the	B-X
sample	B-X
size	B-X
are	B-X
explained	B-X
in	B-X
statistical	B-X
textbooks	B-X
,	B-X
but	B-X
because	B-X
there	B-X
are	B-X
many	B-X
different	B-X
formulas	B-X
available	B-X
,	B-X
it	B-X
can	B-X
be	B-X
difficult	B-X
for	B-X
investigators	B-X
to	B-X
decide	B-X
which	B-X
method	B-X
to	B-X
use	B-X
.	B-X

Bupivacaine	O
hydrochloride	O
was	O
injected	O
into	O
the	O
carpal	O
tunnel	O
of	O
six	O
healthy	O
subjects	O
to	O
locally	O
anesthetize	O
the	O
median	O
nerve	O
.	O
<EOS>	B-X
PURPOSE	B-X
:	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
characterize	B-X
thumb	B-X
motor	B-X
dysfunction	B-X
resulting	B-X
from	B-X
simulated	B-X
lower	B-X
median	B-X
nerve	B-X
lesions	B-X
at	B-X
the	B-X
wrist	B-X
.	B-X
METHODS	B-X
:	B-X
Bupivacaine	B-X
hydrochloride	B-X
was	B-X
injected	B-X
into	B-X
the	B-X
carpal	B-X
tunnel	B-X
of	B-X
six	B-X
healthy	B-X
subjects	B-X
to	B-X
locally	B-X
anesthetize	B-X
the	B-X
median	B-X
nerve	B-X
.	B-X
RESULTS	B-X
:	B-X
Blockage	B-X
of	B-X
the	B-X
median	B-X
nerve	B-X
resulted	B-X
in	B-X
decreased	B-X
force	B-X
magnitudes	B-X
and	B-X
thus	B-X
smaller	B-X
force	B-X
envelopes	B-X
.	B-X
CONCLUSION	B-X
:	B-X
Lower	B-X
median	B-X
nerve	B-X
lesion	B-X
,	B-X
simulated	B-X
by	B-X
a	B-X
nerve	B-X
block	B-X
at	B-X
the	B-X
wrist	B-X
,	B-X
compromise	B-X
normal	B-X
motor	B-X
function	B-X
of	B-X
the	B-X
thumb	B-X
.	B-X
A	B-X
median	B-X
nerve	B-X
block	B-X
results	B-X
in	B-X
force	B-X
deficits	B-X
in	B-X
all	B-X
directions	B-X
,	B-X
with	B-X
the	B-X
most	B-X
severe	B-X
impairment	B-X
in	B-X
abduction	B-X
and	B-X
flexion	B-X
.	B-X

Motor	O
function	O
was	O
subsequently	O
evaluated	O
by	O
measuring	O
maximal	O
force	O
production	O
in	O
all	O
directions	O
within	O
the	O
transverse	O
plane	O
perpendicular	O
to	O
the	O
longitudinal	O
axis	O
of	O
the	O
thumb	O
.	O

Force	O
envelopes	O
were	O
constructed	O
using	O
these	O
measured	O
multidirectional	O
forces	O
.	O
<EOS>	B-X
Force	B-X
envelopes	B-X
were	B-X
constructed	B-X
using	B-X
these	B-X
measured	B-X
multidirectional	B-X
forces	B-X
.	B-X
RESULTS	B-X
:	B-X
Blockage	B-X
of	B-X
the	B-X
median	B-X
nerve	B-X
resulted	B-X
in	B-X
decreased	B-X
force	B-X
magnitudes	B-X
and	B-X
thus	B-X
smaller	B-X
force	B-X
envelopes	B-X
.	B-X
Areas	B-X
enclosed	B-X
by	B-X
pre-	B-X
and	B-X
post-block	B-X
force	B-X
envelopes	B-X
were	B-X
20628	B-X
+/-	B-X
7747	B-X
N.N	B-X
,	B-X
and	B-X
10700	B-X
+/-	B-X
4474	B-X
N.N	B-X
,	B-X
respectively	B-X
,	B-X
representing	B-X
an	B-X
average	B-X
decrease	B-X
of	B-X
48.1	B-X
%	B-X
.	B-X

Results	O

Blockage	O
of	O
the	O
median	O
nerve	O
resulted	O
in	O
decreased	O
force	O
magnitudes	O
and	O
thus	O
smaller	O
force	O
envelopes	O
.	O
<EOS>	B-X
PURPOSE	B-X
:	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
characterize	B-X
thumb	B-X
motor	B-X
dysfunction	B-X
resulting	B-X
from	B-X
simulated	B-X
lower	B-X
median	B-X
nerve	B-X
lesions	B-X
at	B-X
the	B-X
wrist	B-X
.	B-X
METHODS	B-X
:	B-X
Bupivacaine	B-X
hydrochloride	B-X
was	B-X
injected	B-X
into	B-X
the	B-X
carpal	B-X
tunnel	B-X
of	B-X
six	B-X
healthy	B-X
subjects	B-X
to	B-X
locally	B-X
anesthetize	B-X
the	B-X
median	B-X
nerve	B-X
.	B-X
Motor	B-X
function	B-X
was	B-X
subsequently	B-X
evaluated	B-X
by	B-X
measuring	B-X
maximal	B-X
force	B-X
production	B-X
in	B-X
all	B-X
directions	B-X
within	B-X
the	B-X
transverse	B-X
plane	B-X
perpendicular	B-X
to	B-X
the	B-X
longitudinal	B-X
axis	B-X
of	B-X
the	B-X
thumb	B-X
.	B-X
Force	B-X
envelopes	B-X
were	B-X
constructed	B-X
using	B-X
these	B-X
measured	B-X
multidirectional	B-X
forces	B-X
.	B-X
RESULTS	B-X
:	B-X
Blockage	B-X
of	B-X
the	B-X
median	B-X
nerve	B-X
resulted	B-X
in	B-X
decreased	B-X
force	B-X
magnitudes	B-X
and	B-X
thus	B-X
smaller	B-X
force	B-X
envelopes	B-X
.	B-X
The	B-X
average	B-X
force	B-X
decrease	B-X
around	B-X
the	B-X
force	B-X
envelope	B-X
was	B-X
27.9	B-X
%	B-X
.	B-X
Areas	B-X
enclosed	B-X
by	B-X
pre-	B-X
and	B-X
post-block	B-X
force	B-X
envelopes	B-X
were	B-X
20628	B-X
+/-	B-X
7747	B-X
N.N	B-X
,	B-X
and	B-X
10700	B-X
+/-	B-X
4474	B-X
N.N	B-X
,	B-X
respectively	B-X
,	B-X
representing	B-X
an	B-X
average	B-X
decrease	B-X
of	B-X
48.1	B-X
%	B-X
.	B-X
CONCLUSION	B-X
:	B-X
Lower	B-X
median	B-X
nerve	B-X
lesion	B-X
,	B-X
simulated	B-X
by	B-X
a	B-X
nerve	B-X
block	B-X
at	B-X
the	B-X
wrist	B-X
,	B-X
compromise	B-X
normal	B-X
motor	B-X
function	B-X
of	B-X
the	B-X
thumb	B-X
.	B-X
A	B-X
median	B-X
nerve	B-X
block	B-X
results	B-X
in	B-X
force	B-X
deficits	B-X
in	B-X
all	B-X
directions	B-X
,	B-X
with	B-X
the	B-X
most	B-X
severe	B-X
impairment	B-X
in	B-X
abduction	B-X
and	B-X
flexion	B-X
.	B-X

The	O
average	O
force	O
decrease	O
around	O
the	O
force	O
envelope	O
was	O
27	O
.	O
9	O
%	O
.	O
<EOS>	B-X
Motor	B-X
function	B-X
was	B-X
subsequently	B-X
evaluated	B-X
by	B-X
measuring	B-X
maximal	B-X
force	B-X
production	B-X
in	B-X
all	B-X
directions	B-X
within	B-X
the	B-X
transverse	B-X
plane	B-X
perpendicular	B-X
to	B-X
the	B-X
longitudinal	B-X
axis	B-X
of	B-X
the	B-X
thumb	B-X
.	B-X
Force	B-X
envelopes	B-X
were	B-X
constructed	B-X
using	B-X
these	B-X
measured	B-X
multidirectional	B-X
forces	B-X
.	B-X
RESULTS	B-X
:	B-X
Blockage	B-X
of	B-X
the	B-X
median	B-X
nerve	B-X
resulted	B-X
in	B-X
decreased	B-X
force	B-X
magnitudes	B-X
and	B-X
thus	B-X
smaller	B-X
force	B-X
envelopes	B-X
.	B-X
The	B-X
average	B-X
force	B-X
decrease	B-X
around	B-X
the	B-X
force	B-X
envelope	B-X
was	B-X
27.9	B-X
%	B-X
.	B-X
A	B-X
maximum	B-X
decrease	B-X
of	B-X
42.4	B-X
%	B-X
occurred	B-X
in	B-X
a	B-X
direction	B-X
combining	B-X
abduction	B-X
and	B-X
slight	B-X
flexion	B-X
,	B-X
while	B-X
a	B-X
minimum	B-X
decrease	B-X
of	B-X
10.5	B-X
%	B-X
occurred	B-X
in	B-X
a	B-X
direction	B-X
combining	B-X
adduction	B-X
and	B-X
slight	B-X
flexion	B-X
.	B-X
Relative	B-X
decreases	B-X
in	B-X
adduction	B-X
,	B-X
extension	B-X
,	B-X
abduction	B-X
,	B-X
and	B-X
flexion	B-X
were	B-X
17.3	B-X
%	B-X
,	B-X
21.2	B-X
%	B-X
,	B-X
41.2	B-X
%	B-X
and	B-X
33.5	B-X
%	B-X
,	B-X
respectively	B-X
.	B-X
Areas	B-X
enclosed	B-X
by	B-X
pre-	B-X
and	B-X
post-block	B-X
force	B-X
envelopes	B-X
were	B-X
20628	B-X
+/-	B-X
7747	B-X
N.N	B-X
,	B-X
and	B-X
10700	B-X
+/-	B-X
4474	B-X
N.N	B-X
,	B-X
respectively	B-X
,	B-X
representing	B-X
an	B-X
average	B-X
decrease	B-X
of	B-X
48.1	B-X
%	B-X
.	B-X
Relative	B-X
decreases	B-X
in	B-X
the	B-X
adduction	B-X
,	B-X
extension	B-X
,	B-X
abduction	B-X
,	B-X
and	B-X
flexion	B-X
quadrant	B-X
areas	B-X
were	B-X
31.5	B-X
%	B-X
,	B-X
42.3	B-X
%	B-X
,	B-X
60.9	B-X
%	B-X
,	B-X
and	B-X
52.3	B-X
%	B-X
,	B-X
respectively	B-X
.	B-X
A	B-X
median	B-X
nerve	B-X
block	B-X
results	B-X
in	B-X
force	B-X
deficits	B-X
in	B-X
all	B-X
directions	B-X
,	B-X
with	B-X
the	B-X
most	B-X
severe	B-X
impairment	B-X
in	B-X
abduction	B-X
and	B-X
flexion	B-X
.	B-X

A	O
maximum	O
decrease	O
of	O
42	O
.	O
4	O
%	O
occurred	O
in	O
a	O
direction	O
combining	O
abduction	O
and	O
slight	O
flexion	O
,	O
while	O
a	O
minimum	O
decrease	O
of	O
10	O
.	O
5	O
%	O
occurred	O
in	O
a	O
direction	O
combining	O
adduction	O
and	O
slight	O
flexion	O
.	O

Relative	O
decreases	O
in	O
adduction	O
,	O
extension	O
,	O
abduction	O
,	O
and	O
flexion	O
were	O
17	O
.	O
3	O
%	O
,	O
21	O
.	O
2	O
%	O
,	O
41	O
.	O
2	O
%	O
and	O
33	O
.	O
5	O
%	O
,	O
respectively	O
.	O
<EOS>	B-X
The	B-X
average	B-X
force	B-X
decrease	B-X
around	B-X
the	B-X
force	B-X
envelope	B-X
was	B-X
27.9	B-X
%	B-X
.	B-X
A	B-X
maximum	B-X
decrease	B-X
of	B-X
42.4	B-X
%	B-X
occurred	B-X
in	B-X
a	B-X
direction	B-X
combining	B-X
abduction	B-X
and	B-X
slight	B-X
flexion	B-X
,	B-X
while	B-X
a	B-X
minimum	B-X
decrease	B-X
of	B-X
10.5	B-X
%	B-X
occurred	B-X
in	B-X
a	B-X
direction	B-X
combining	B-X
adduction	B-X
and	B-X
slight	B-X
flexion	B-X
.	B-X
Relative	B-X
decreases	B-X
in	B-X
adduction	B-X
,	B-X
extension	B-X
,	B-X
abduction	B-X
,	B-X
and	B-X
flexion	B-X
were	B-X
17.3	B-X
%	B-X
,	B-X
21.2	B-X
%	B-X
,	B-X
41.2	B-X
%	B-X
and	B-X
33.5	B-X
%	B-X
,	B-X
respectively	B-X
.	B-X
Areas	B-X
enclosed	B-X
by	B-X
pre-	B-X
and	B-X
post-block	B-X
force	B-X
envelopes	B-X
were	B-X
20628	B-X
+/-	B-X
7747	B-X
N.N	B-X
,	B-X
and	B-X
10700	B-X
+/-	B-X
4474	B-X
N.N	B-X
,	B-X
respectively	B-X
,	B-X
representing	B-X
an	B-X
average	B-X
decrease	B-X
of	B-X
48.1	B-X
%	B-X
.	B-X
Relative	B-X
decreases	B-X
in	B-X
the	B-X
adduction	B-X
,	B-X
extension	B-X
,	B-X
abduction	B-X
,	B-X
and	B-X
flexion	B-X
quadrant	B-X
areas	B-X
were	B-X
31.5	B-X
%	B-X
,	B-X
42.3	B-X
%	B-X
,	B-X
60.9	B-X
%	B-X
,	B-X
and	B-X
52.3	B-X
%	B-X
,	B-X
respectively	B-X
.	B-X
A	B-X
median	B-X
nerve	B-X
block	B-X
results	B-X
in	B-X
force	B-X
deficits	B-X
in	B-X
all	B-X
directions	B-X
,	B-X
with	B-X
the	B-X
most	B-X
severe	B-X
impairment	B-X
in	B-X
abduction	B-X
and	B-X
flexion	B-X
.	B-X

Areas	O
enclosed	O
by	O
pre	O
-	O
and	O
post	O
-	O
block	O
force	O
envelopes	O
were	O
20628	O
+/-	O
7747	O
N	O
.	O
N	O
,	O
and	O
10700	O
+/-	O
4474	O
N	O
.	O
N	O
,	O
respectively	O
,	O
representing	O
an	O
average	O
decrease	O
of	O
48	O
.	O
1	O
%	O
.	O

Relative	O
decreases	O
in	O
the	O
adduction	O
,	O
extension	O
,	O
abduction	O
,	O
and	O
flexion	O
quadrant	O
areas	O
were	O
31	O
.	O
5	O
%	O
,	O
42	O
.	O
3	O
%	O
,	O
60	O
.	O
9	O
%	O
,	O
and	O
52	O
.	O
3	O
%	O
,	O
respectively	O
.	O
<EOS>	B-X
The	B-X
average	B-X
force	B-X
decrease	B-X
around	B-X
the	B-X
force	B-X
envelope	B-X
was	B-X
27.9	B-X
%	B-X
.	B-X
A	B-X
maximum	B-X
decrease	B-X
of	B-X
42.4	B-X
%	B-X
occurred	B-X
in	B-X
a	B-X
direction	B-X
combining	B-X
abduction	B-X
and	B-X
slight	B-X
flexion	B-X
,	B-X
while	B-X
a	B-X
minimum	B-X
decrease	B-X
of	B-X
10.5	B-X
%	B-X
occurred	B-X
in	B-X
a	B-X
direction	B-X
combining	B-X
adduction	B-X
and	B-X
slight	B-X
flexion	B-X
.	B-X
Relative	B-X
decreases	B-X
in	B-X
adduction	B-X
,	B-X
extension	B-X
,	B-X
abduction	B-X
,	B-X
and	B-X
flexion	B-X
were	B-X
17.3	B-X
%	B-X
,	B-X
21.2	B-X
%	B-X
,	B-X
41.2	B-X
%	B-X
and	B-X
33.5	B-X
%	B-X
,	B-X
respectively	B-X
.	B-X
Areas	B-X
enclosed	B-X
by	B-X
pre-	B-X
and	B-X
post-block	B-X
force	B-X
envelopes	B-X
were	B-X
20628	B-X
+/-	B-X
7747	B-X
N.N	B-X
,	B-X
and	B-X
10700	B-X
+/-	B-X
4474	B-X
N.N	B-X
,	B-X
respectively	B-X
,	B-X
representing	B-X
an	B-X
average	B-X
decrease	B-X
of	B-X
48.1	B-X
%	B-X
.	B-X
Relative	B-X
decreases	B-X
in	B-X
the	B-X
adduction	B-X
,	B-X
extension	B-X
,	B-X
abduction	B-X
,	B-X
and	B-X
flexion	B-X
quadrant	B-X
areas	B-X
were	B-X
31.5	B-X
%	B-X
,	B-X
42.3	B-X
%	B-X
,	B-X
60.9	B-X
%	B-X
,	B-X
and	B-X
52.3	B-X
%	B-X
,	B-X
respectively	B-X
.	B-X
A	B-X
median	B-X
nerve	B-X
block	B-X
results	B-X
in	B-X
force	B-X
deficits	B-X
in	B-X
all	B-X
directions	B-X
,	B-X
with	B-X
the	B-X
most	B-X
severe	B-X
impairment	B-X
in	B-X
abduction	B-X
and	B-X
flexion	B-X
.	B-X

Conclusion	O
<EOS>	B-X
Conclusion	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X

Lower	O
median	O
nerve	O
lesion	O
,	O
simulated	O
by	O
a	O
nerve	O
block	O
at	O
the	O
wrist	O
,	O
compromise	O
normal	O
motor	O
function	O
of	O
the	O
thumb	O
.	O
<EOS>	B-X
PURPOSE	B-X
:	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
characterize	B-X
thumb	B-X
motor	B-X
dysfunction	B-X
resulting	B-X
from	B-X
simulated	B-X
lower	B-X
median	B-X
nerve	B-X
lesions	B-X
at	B-X
the	B-X
wrist	B-X
.	B-X
METHODS	B-X
:	B-X
Bupivacaine	B-X
hydrochloride	B-X
was	B-X
injected	B-X
into	B-X
the	B-X
carpal	B-X
tunnel	B-X
of	B-X
six	B-X
healthy	B-X
subjects	B-X
to	B-X
locally	B-X
anesthetize	B-X
the	B-X
median	B-X
nerve	B-X
.	B-X
Motor	B-X
function	B-X
was	B-X
subsequently	B-X
evaluated	B-X
by	B-X
measuring	B-X
maximal	B-X
force	B-X
production	B-X
in	B-X
all	B-X
directions	B-X
within	B-X
the	B-X
transverse	B-X
plane	B-X
perpendicular	B-X
to	B-X
the	B-X
longitudinal	B-X
axis	B-X
of	B-X
the	B-X
thumb	B-X
.	B-X
RESULTS	B-X
:	B-X
Blockage	B-X
of	B-X
the	B-X
median	B-X
nerve	B-X
resulted	B-X
in	B-X
decreased	B-X
force	B-X
magnitudes	B-X
and	B-X
thus	B-X
smaller	B-X
force	B-X
envelopes	B-X
.	B-X
Areas	B-X
enclosed	B-X
by	B-X
pre-	B-X
and	B-X
post-block	B-X
force	B-X
envelopes	B-X
were	B-X
20628	B-X
+/-	B-X
7747	B-X
N.N	B-X
,	B-X
and	B-X
10700	B-X
+/-	B-X
4474	B-X
N.N	B-X
,	B-X
respectively	B-X
,	B-X
representing	B-X
an	B-X
average	B-X
decrease	B-X
of	B-X
48.1	B-X
%	B-X
.	B-X
CONCLUSION	B-X
:	B-X
Lower	B-X
median	B-X
nerve	B-X
lesion	B-X
,	B-X
simulated	B-X
by	B-X
a	B-X
nerve	B-X
block	B-X
at	B-X
the	B-X
wrist	B-X
,	B-X
compromise	B-X
normal	B-X
motor	B-X
function	B-X
of	B-X
the	B-X
thumb	B-X
.	B-X
A	B-X
median	B-X
nerve	B-X
block	B-X
results	B-X
in	B-X
force	B-X
deficits	B-X
in	B-X
all	B-X
directions	B-X
,	B-X
with	B-X
the	B-X
most	B-X
severe	B-X
impairment	B-X
in	B-X
abduction	B-X
and	B-X
flexion	B-X
.	B-X
From	B-X
our	B-X
results	B-X
,	B-X
such	B-X
a	B-X
means	B-X
of	B-X
motor	B-X
function	B-X
assessment	B-X
can	B-X
potentially	B-X
be	B-X
applied	B-X
to	B-X
functionally	B-X
evaluate	B-X
peripheral	B-X
neuropathies	B-X
.	B-X

A	O
median	O
nerve	O
block	O
results	O
in	O
force	O
deficits	O
in	O
all	O
directions	O
,	O
with	O
the	O
most	O
severe	O
impairment	O
in	O
abduction	O
and	O
flexion	O
.	O
<EOS>	B-X
PURPOSE	B-X
:	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
characterize	B-X
thumb	B-X
motor	B-X
dysfunction	B-X
resulting	B-X
from	B-X
simulated	B-X
lower	B-X
median	B-X
nerve	B-X
lesions	B-X
at	B-X
the	B-X
wrist	B-X
.	B-X
METHODS	B-X
:	B-X
Bupivacaine	B-X
hydrochloride	B-X
was	B-X
injected	B-X
into	B-X
the	B-X
carpal	B-X
tunnel	B-X
of	B-X
six	B-X
healthy	B-X
subjects	B-X
to	B-X
locally	B-X
anesthetize	B-X
the	B-X
median	B-X
nerve	B-X
.	B-X
Motor	B-X
function	B-X
was	B-X
subsequently	B-X
evaluated	B-X
by	B-X
measuring	B-X
maximal	B-X
force	B-X
production	B-X
in	B-X
all	B-X
directions	B-X
within	B-X
the	B-X
transverse	B-X
plane	B-X
perpendicular	B-X
to	B-X
the	B-X
longitudinal	B-X
axis	B-X
of	B-X
the	B-X
thumb	B-X
.	B-X
Force	B-X
envelopes	B-X
were	B-X
constructed	B-X
using	B-X
these	B-X
measured	B-X
multidirectional	B-X
forces	B-X
.	B-X
RESULTS	B-X
:	B-X
Blockage	B-X
of	B-X
the	B-X
median	B-X
nerve	B-X
resulted	B-X
in	B-X
decreased	B-X
force	B-X
magnitudes	B-X
and	B-X
thus	B-X
smaller	B-X
force	B-X
envelopes	B-X
.	B-X
The	B-X
average	B-X
force	B-X
decrease	B-X
around	B-X
the	B-X
force	B-X
envelope	B-X
was	B-X
27.9	B-X
%	B-X
.	B-X
A	B-X
maximum	B-X
decrease	B-X
of	B-X
42.4	B-X
%	B-X
occurred	B-X
in	B-X
a	B-X
direction	B-X
combining	B-X
abduction	B-X
and	B-X
slight	B-X
flexion	B-X
,	B-X
while	B-X
a	B-X
minimum	B-X
decrease	B-X
of	B-X
10.5	B-X
%	B-X
occurred	B-X
in	B-X
a	B-X
direction	B-X
combining	B-X
adduction	B-X
and	B-X
slight	B-X
flexion	B-X
.	B-X
Relative	B-X
decreases	B-X
in	B-X
adduction	B-X
,	B-X
extension	B-X
,	B-X
abduction	B-X
,	B-X
and	B-X
flexion	B-X
were	B-X
17.3	B-X
%	B-X
,	B-X
21.2	B-X
%	B-X
,	B-X
41.2	B-X
%	B-X
and	B-X
33.5	B-X
%	B-X
,	B-X
respectively	B-X
.	B-X
Areas	B-X
enclosed	B-X
by	B-X
pre-	B-X
and	B-X
post-block	B-X
force	B-X
envelopes	B-X
were	B-X
20628	B-X
+/-	B-X
7747	B-X
N.N	B-X
,	B-X
and	B-X
10700	B-X
+/-	B-X
4474	B-X
N.N	B-X
,	B-X
respectively	B-X
,	B-X
representing	B-X
an	B-X
average	B-X
decrease	B-X
of	B-X
48.1	B-X
%	B-X
.	B-X
Relative	B-X
decreases	B-X
in	B-X
the	B-X
adduction	B-X
,	B-X
extension	B-X
,	B-X
abduction	B-X
,	B-X
and	B-X
flexion	B-X
quadrant	B-X
areas	B-X
were	B-X
31.5	B-X
%	B-X
,	B-X
42.3	B-X
%	B-X
,	B-X
60.9	B-X
%	B-X
,	B-X
and	B-X
52.3	B-X
%	B-X
,	B-X
respectively	B-X
.	B-X
CONCLUSION	B-X
:	B-X
Lower	B-X
median	B-X
nerve	B-X
lesion	B-X
,	B-X
simulated	B-X
by	B-X
a	B-X
nerve	B-X
block	B-X
at	B-X
the	B-X
wrist	B-X
,	B-X
compromise	B-X
normal	B-X
motor	B-X
function	B-X
of	B-X
the	B-X
thumb	B-X
.	B-X
A	B-X
median	B-X
nerve	B-X
block	B-X
results	B-X
in	B-X
force	B-X
deficits	B-X
in	B-X
all	B-X
directions	B-X
,	B-X
with	B-X
the	B-X
most	B-X
severe	B-X
impairment	B-X
in	B-X
abduction	B-X
and	B-X
flexion	B-X
.	B-X
From	B-X
our	B-X
results	B-X
,	B-X
such	B-X
a	B-X
means	B-X
of	B-X
motor	B-X
function	B-X
assessment	B-X
can	B-X
potentially	B-X
be	B-X
applied	B-X
to	B-X
functionally	B-X
evaluate	B-X
peripheral	B-X
neuropathies	B-X
.	B-X

From	O
our	O
results	O
,	O
such	O
a	O
means	O
of	O
motor	O
function	O
assessment	O
can	O
potentially	O
be	O
applied	O
to	O
functionally	O
evaluate	O
peripheral	O
neuropathies	O
.	O
<EOS>	B-X
PURPOSE	B-X
:	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
characterize	B-X
thumb	B-X
motor	B-X
dysfunction	B-X
resulting	B-X
from	B-X
simulated	B-X
lower	B-X
median	B-X
nerve	B-X
lesions	B-X
at	B-X
the	B-X
wrist	B-X
.	B-X
Motor	B-X
function	B-X
was	B-X
subsequently	B-X
evaluated	B-X
by	B-X
measuring	B-X
maximal	B-X
force	B-X
production	B-X
in	B-X
all	B-X
directions	B-X
within	B-X
the	B-X
transverse	B-X
plane	B-X
perpendicular	B-X
to	B-X
the	B-X
longitudinal	B-X
axis	B-X
of	B-X
the	B-X
thumb	B-X
.	B-X
CONCLUSION	B-X
:	B-X
Lower	B-X
median	B-X
nerve	B-X
lesion	B-X
,	B-X
simulated	B-X
by	B-X
a	B-X
nerve	B-X
block	B-X
at	B-X
the	B-X
wrist	B-X
,	B-X
compromise	B-X
normal	B-X
motor	B-X
function	B-X
of	B-X
the	B-X
thumb	B-X
.	B-X
A	B-X
median	B-X
nerve	B-X
block	B-X
results	B-X
in	B-X
force	B-X
deficits	B-X
in	B-X
all	B-X
directions	B-X
,	B-X
with	B-X
the	B-X
most	B-X
severe	B-X
impairment	B-X
in	B-X
abduction	B-X
and	B-X
flexion	B-X
.	B-X
From	B-X
our	B-X
results	B-X
,	B-X
such	B-X
a	B-X
means	B-X
of	B-X
motor	B-X
function	B-X
assessment	B-X
can	B-X
potentially	B-X
be	B-X
applied	B-X
to	B-X
functionally	B-X
evaluate	B-X
peripheral	B-X
neuropathies	B-X
.	B-X

Introduction	O

The	O
thumb	O
has	O
unique	O
anatomical	O
and	O
biomechanical	O
characteristics	O
that	O
are	O
required	O
to	O
perform	O
many	O
manipulative	O
tasks	O
.	O

Thumb	O
motor	O
dysfunction	O
resulting	O
from	O
neuromuscular	O
and	O
musculoskeletal	O
pathologies	O
severely	O
hinders	O
the	O
performance	O
of	O
these	O
daily	O
tasks	O
.	O

Clinical	O
treatment	O
,	O
prevention	O
protocols	O
,	O
and	O
rehabilitation	O
efficacy	O
requires	O
a	O
thorough	O
understanding	O
of	O
thumb	O
motor	O
capabilities	O
,	O
as	O
well	O
as	O
its	O
associated	O
functional	O
deficit	O
.	O

Investigations	O
of	O
underlying	O
pathological	O
mechanism	O
of	O
the	O
thumb	O
help	O
advance	O
clinical	O
treatments	O
such	O
as	O
tendon	O
transfers	O
[	O
1	O
]	O
,	O
functional	O
electrical	O
stimulation	O
[	O
2	O
]	O
and	O
plasticity	O
suppression	O
[	O
3	O
]	O
.	O

Measurement	O
of	O
strength	O
during	O
maximum	O
voluntary	O
contraction	O
is	O
a	O
simple	O
and	O
direct	O
means	O
of	O
assessing	O
neuromuscular	O
function	O
.	O

Popular	O
instruments	O
used	O
for	O
quantitative	O
assessment	O
of	O
thumb	O
strength	O
are	O
pinch	O
dynamometers	O
.	O

The	O
pinch	O
output	O
,	O
however	O
,	O
provides	O
limited	O
information	O
about	O
thumb	O
motor	O
function	O
in	O
that	O
it	O
offers	O
a	O
single	O
generic	O
force	O
in	O
one	O
specific	O
direction	O
.	O

Each	O
muscle	O
/	O
tendon	O
within	O
the	O
thumb	O
has	O
a	O
distinct	O
anatomical	O
origin	O
and	O
insertion	O
,	O
suggesting	O
its	O
external	O
force	O
potential	O
in	O
a	O
particular	O
direction	O
[	O
4	O
-	O
6	O
]	O
.	O

Hence	O
,	O
evaluation	O
of	O
strengths	O
in	O
multiple	O
directions	O
offers	O
insight	O
concerning	O
the	O
motor	O
capacity	O
of	O
individual	O
muscles	O
.	O

Force	O
production	O
of	O
a	O
digit	O
has	O
been	O
measured	O
in	O
various	O
directions	O
such	O
as	O
flexion	O
/	O
extension	O
[	O
7	O
,	O
8	O
]	O
,	O
abduction	O
/	O
adduction	O
[	O
9	O
-	O
14	O
]	O
,	O
or	O
in	O
combined	O
directions	O
[	O
15	O
,	O
16	O
]	O
.	O
<EOS>	B-X
Finally	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
major	B-X
problems	B-X
facing	B-X
therapeutic	B-X
nanomedicine	B-X
for	B-X
cancer	B-X
chemotherapy	B-X
,	B-X
and	B-X
propose	B-X
possible	B-X
future	B-X
directions	B-X
in	B-X
this	B-X
field	B-X
.	B-X
CXCR3	B-X
is	B-X
a	B-X
chemokine	B-X
receptor	B-X
with	B-X
three	B-X
ligands	B-X
;	B-X
CXCL9	B-X
,	B-X
CXCL10	B-X
,	B-X
and	B-X
CXCL11	B-X
.	B-X
Long	B-X
ago	B-X
we	B-X
reported	B-X
that	B-X
one	B-X
of	B-X
these	B-X
chemokines	B-X
,	B-X
CXCL10	B-X
,	B-X
not	B-X
only	B-X
attracts	B-X
CXCR3+	B-X
CD4+	B-X
and	B-X
CD8+	B-X
effector	B-X
T	B-X
cells	B-X
to	B-X
sites	B-X
of	B-X
inflammation	B-X
,	B-X
but	B-X
also	B-X
direct	B-X
their	B-X
polarization	B-X
into	B-X
highly	B-X
potent	B-X
effector	B-X
T	B-X
cells	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
CXCL10	B-X
and	B-X
possibly	B-X
CXCL9	B-X
differ	B-X
from	B-X
other	B-X
chemokines	B-X
by	B-X
their	B-X
ability	B-X
to	B-X
restrain	B-X
tumor	B-X
growth	B-X
and	B-X
enhance	B-X
anti-tumor	B-X
immunity	B-X
.	B-X
Along	B-X
with	B-X
this	B-X
an	B-X
accumulating	B-X
number	B-X
of	B-X
studies	B-X
showed	B-X
in	B-X
various	B-X
human	B-X
cancers	B-X
a	B-X
clear	B-X
association	B-X
between	B-X
poor	B-X
prognosis	B-X
and	B-X
low	B-X
expression	B-X
of	B-X
CXCL10	B-X
at	B-X
tumor	B-X
sites	B-X
,	B-X
and	B-X
vice	B-X
versa	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
possibility	B-X
that	B-X
CXCL9	B-X
and	B-X
CXCL10	B-X
may	B-X
differ	B-X
in	B-X
their	B-X
biological	B-X
function	B-X
via	B-X
biased	B-X
signaling	B-X
and	B-X
its	B-X
possible	B-X
relevance	B-X
to	B-X
cancer	B-X
immunotherapy	B-X
.	B-X
The	B-X
current	B-X
mini	B-X
review	B-X
focuses	B-X
on	B-X
exploring	B-X
the	B-X
role	B-X
of	B-X
CXCR3	B-X
ligands	B-X
in	B-X
directing	B-X
the	B-X
biological	B-X
properties	B-X
of	B-X
CD4+	B-X
and	B-X
CD8+	B-X
T	B-X
cells	B-X
in	B-X
the	B-X
context	B-X
of	B-X
cancer	B-X
and	B-X
autoimmunity	B-X
.	B-X
We	B-X
believe	B-X
that	B-X
the	B-X
combined	B-X
role	B-X
of	B-X
these	B-X
chemokines	B-X
in	B-X
attracting	B-X
T	B-X
cells	B-X
and	B-X
also	B-X
directing	B-X
their	B-X
biological	B-X
properties	B-X
makes	B-X
them	B-X
key	B-X
drivers	B-X
of	B-X
immune	B-X
function	B-X
.	B-X

Bourbonnais	O
et	O
al	O
.	O
developed	O
an	O
apparatus	O
to	O
measure	O
thumb	O
force	O
production	O
in	O
eight	O
directions	O
in	O
the	O
transverse	O
plane	O
of	O
the	O
thumb	O
and	O
investigated	O
force	O
dependence	O
on	O
the	O
direction	O
of	O
effort	O
[	O
15	O
]	O
.	O

Yokogawa	O
and	O
Hara	O
measured	O
index	O
fingertip	O
forces	O
in	O
various	O
directions	O
within	O
the	O
flexion	O
/	O
extension	O
plane	O
[	O
8	O
]	O
.	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
the	B-X
present	B-X
study	B-X
is	B-X
to	B-X
investigate	B-X
whether	B-X
distribution	B-X
patterns	B-X
of	B-X
the	B-X
maximum	B-X
fingertip	B-X
force	B-X
in	B-X
all	B-X
directions	B-X
from	B-X
0	B-X
deg	B-X
to	B-X
360	B-X
deg	B-X
around	B-X
the	B-X
index	B-X
fingertip	B-X
are	B-X
the	B-X
same	B-X
among	B-X
subjects	B-X
.	B-X
Distributions	B-X
of	B-X
the	B-X
maximum	B-X
index	B-X
fingertip	B-X
force	B-X
were	B-X
measured	B-X
at	B-X
four	B-X
finger	B-X
postures	B-X
for	B-X
five	B-X
subjects	B-X
(	B-X
healthy	B-X
males	B-X
,	B-X
ages	B-X
21	B-X
to	B-X
25	B-X
)	B-X
.	B-X
It	B-X
became	B-X
apparent	B-X
that	B-X
distribution	B-X
patterns	B-X
of	B-X
the	B-X
fingertip	B-X
force	B-X
were	B-X
very	B-X
similar	B-X
among	B-X
subjects	B-X
,	B-X
through	B-X
the	B-X
application	B-X
of	B-X
an	B-X
analysis	B-X
of	B-X
variance	B-X
(	B-X
level	B-X
of	B-X
significance	B-X
:	B-X
5	B-X
%	B-X
)	B-X
to	B-X
the	B-X
measurement	B-X
results	B-X
.	B-X
In	B-X
the	B-X
production	B-X
of	B-X
the	B-X
maximum	B-X
fingertip	B-X
force	B-X
,	B-X
Valero-Cuevas	B-X
et	B-X
al	B-X
.	B-X
[	B-X
1998	B-X
,	B-X
2000	B-X
]	B-X
reported	B-X
that	B-X
patterns	B-X
of	B-X
control	B-X
signals	B-X
for	B-X
driving	B-X
muscle	B-X
forces	B-X
were	B-X
common	B-X
among	B-X
subjects	B-X
.	B-X
The	B-X
results	B-X
of	B-X
the	B-X
present	B-X
study	B-X
indicate	B-X
that	B-X
patterns	B-X
of	B-X
maximum	B-X
fingertip	B-X
force	B-X
are	B-X
also	B-X
similar	B-X
among	B-X
subjects	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
possibility	B-X
is	B-X
high	B-X
that	B-X
the	B-X
static	B-X
transfer	B-X
characteristic	B-X
for	B-X
index	B-X
fingers	B-X
from	B-X
input	B-X
(	B-X
i.e.	B-X
,	B-X
control	B-X
signals	B-X
to	B-X
muscles	B-X
)	B-X
to	B-X
output	B-X
(	B-X
ie.	B-X
,	B-X
the	B-X
maximum	B-X
fingertip	B-X
force	B-X
)	B-X
is	B-X
also	B-X
common	B-X
among	B-X
subjects	B-X
.	B-X

Recently	O
,	O
we	O
developed	O
experimental	O
apparatuses	O
to	O
measure	O
multi	O
-	O
directional	O
forces	O
of	O
a	O
digit	O
in	O
its	O
transverse	O
plane	O
[	O
17	O
-	O
19	O
]	O
.	O

From	O
these	O
multi	O
-	O
directional	O
forces	O
we	O
constructed	O
force	O
envelopes	O
representative	O
of	O
the	O
characteristic	O
force	O
output	O
pattern	O
of	O
a	O
digit	O
[	O
17	O
-	O
19	O
]	O
.	O

Disorders	O
resulting	O
from	O
traumatic	O
injuries	O
to	O
and	O
various	O
diseases	O
of	O
these	O
nerves	O
are	O
common	O
in	O
clinical	O
practice	O
.	O
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
review	B-X
is	B-X
to	B-X
identify	B-X
the	B-X
effectiveness	B-X
of	B-X
neural	B-X
mobilization	B-X
techniques	B-X
in	B-X
various	B-X
neuro-musculoskeletal	B-X
conditions	B-X
.	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
establish	B-X
an	B-X
evidence-based	B-X
clinical	B-X
practice	B-X
guideline	B-X
for	B-X
the	B-X
primary	B-X
management	B-X
of	B-X
obstetrical	B-X
brachial	B-X
plexus	B-X
injury	B-X
(	B-X
OBPI	B-X
)	B-X
.	B-X
This	B-X
clinical	B-X
practice	B-X
guideline	B-X
addresses	B-X
4	B-X
existing	B-X
gaps	B-X
:	B-X
(	B-X
1	B-X
)	B-X
historic	B-X
poor	B-X
use	B-X
of	B-X
evidence	B-X
,	B-X
(	B-X
2	B-X
)	B-X
timing	B-X
of	B-X
referral	B-X
to	B-X
multidisciplinary	B-X
care	B-X
,	B-X
(	B-X
3	B-X
)	B-X
Indications	B-X
and	B-X
timing	B-X
of	B-X
operative	B-X
nerve	B-X
repair	B-X
and	B-X
(	B-X
4	B-X
)	B-X
distribution	B-X
of	B-X
expertise	B-X
.	B-X
Iatrogenic	B-X
nerve	B-X
injuries	B-X
are	B-X
an	B-X
undesired	B-X
byproduct	B-X
of	B-X
the	B-X
practice	B-X
of	B-X
medicine	B-X
and	B-X
have	B-X
been	B-X
so	B-X
since	B-X
antiquity	B-X
.	B-X
The	B-X
majority	B-X
of	B-X
such	B-X
injuries	B-X
occur	B-X
perioperatively	B-X
,	B-X
and	B-X
are	B-X
,	B-X
therefore	B-X
,	B-X
attributed	B-X
to	B-X
surgeons	B-X
and	B-X
anesthesiologists	B-X
.	B-X
Nonetheless	B-X
,	B-X
the	B-X
members	B-X
of	B-X
almost	B-X
every	B-X
clinical	B-X
specialty	B-X
are	B-X
at	B-X
risk	B-X
to	B-X
some	B-X
degree	B-X
.	B-X
Iatrogenic	B-X
nerve	B-X
injuries	B-X
can	B-X
affect	B-X
almost	B-X
any	B-X
portion	B-X
of	B-X
the	B-X
peripheral	B-X
nervous	B-X
system	B-X
,	B-X
and	B-X
can	B-X
result	B-X
from	B-X
many	B-X
different	B-X
causes	B-X
.	B-X
This	B-X
article	B-X
reviews	B-X
many	B-X
of	B-X
the	B-X
more	B-X
common	B-X
iatrogenic	B-X
nerve	B-X
lesions	B-X
.	B-X

Clinical	O
manifestations	O
of	O
hand	O
dysfunction	O
are	O
distinctive	O
depending	O
on	O
the	O
nerve	O
involved	O
.	O
<EOS>	B-X
Diagnosis	B-X
of	B-X
ICU-AW	B-X
is	B-X
clinical	B-X
and	B-X
is	B-X
based	B-X
on	B-X
Medical	B-X
Research	B-X
Council	B-X
sum	B-X
score	B-X
and	B-X
handgrip	B-X
dynamometry	B-X
for	B-X
limb	B-X
weakness	B-X
and	B-X
recognition	B-X
of	B-X
a	B-X
patient	B-X
's	B-X
ventilator	B-X
dependency	B-X
or	B-X
difficult	B-X
weaning	B-X
from	B-X
artificial	B-X
ventilation	B-X
for	B-X
diaphragmatic	B-X
weakness	B-X
(	B-X
DW	B-X
)	B-X
.	B-X
Its	B-X
diagnosis	B-X
requires	B-X
both	B-X
clinical	B-X
assessment	B-X
of	B-X
muscle	B-X
strength	B-X
and	B-X
complete	B-X
electrophysiological	B-X
evaluation	B-X
of	B-X
peripheral	B-X
nerves	B-X
and	B-X
muscles	B-X
.	B-X
The	B-X
peroneal	B-X
nerve	B-X
test	B-X
(	B-X
PENT	B-X
)	B-X
is	B-X
a	B-X
quick	B-X
simplified	B-X
electrophysiological	B-X
test	B-X
with	B-X
high	B-X
sensitivity	B-X
and	B-X
good	B-X
specificity	B-X
that	B-X
can	B-X
be	B-X
used	B-X
instead	B-X
of	B-X
complete	B-X
electrophysiological	B-X
evaluation	B-X
as	B-X
a	B-X
screening	B-X
test	B-X
in	B-X
non-cooperative	B-X
patients	B-X
.	B-X
DW	B-X
,	B-X
assessed	B-X
by	B-X
bilateral	B-X
phrenic	B-X
nerve	B-X
magnetic	B-X
stimulation	B-X
or	B-X
diaphragm	B-X
ultrasound	B-X
,	B-X
can	B-X
be	B-X
an	B-X
isolated	B-X
event	B-X
without	B-X
concurrent	B-X
limb	B-X
muscle	B-X
involvement	B-X
.	B-X
Therefore	B-X
,	B-X
it	B-X
remains	B-X
uncertain	B-X
whether	B-X
DW	B-X
and	B-X
limb	B-X
weakness	B-X
are	B-X
different	B-X
manifestations	B-X
of	B-X
the	B-X
same	B-X
syndrome	B-X
or	B-X
are	B-X
two	B-X
distinct	B-X
entities	B-X
.	B-X

For	O
example	O
,	O
thenar	O
atrophy	O
is	O
a	O
major	O
clinical	O
observation	O
affecting	O
thumb	O
function	O
at	O
the	O
later	O
stages	O
of	O
compression	O
neuropathy	O
of	O
the	O
median	O
nerve	O
.	O

Several	O
studies	O
have	O
been	O
conducted	O
to	O
investigate	O
the	O
effects	O
of	O
simulated	O
peripheral	O
neuropathies	O
using	O
local	O
anesthetization	O
[	O
5	O
,	O
16	O
,	O
20	O
,	O
21	O
]	O
.	O

Kozin	O
et	O
al	O
.	O
<EOS>	B-X
Carpal	B-X
instability	B-X
includes	B-X
a	B-X
broad	B-X
spectrum	B-X
of	B-X
osseous	B-X
and	B-X
ligamentous	B-X
injuries	B-X
which	B-X
have	B-X
been	B-X
subclassified	B-X
into	B-X
greater	B-X
and	B-X
lesser	B-X
arc	B-X
injuries	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
combinations	B-X
of	B-X
both	B-X
(	B-X
Mayfield	B-X
et	B-X
al	B-X
.	B-X
J	B-X
Hand	B-X
Surg	B-X
[	B-X
Am	B-X
]	B-X
5:226-241	B-X
,	B-X
1980	B-X
;	B-X
Yaeger	B-X
et	B-X
al	B-X
.	B-X
Skeletal	B-X
Radiol	B-X
13	B-X
(	B-X
2	B-X
)	B-X
:120-30	B-X
,	B-X
1985	B-X
)	B-X
.	B-X
The	B-X
injuries	B-X
typically	B-X
occur	B-X
from	B-X
a	B-X
fall	B-X
on	B-X
the	B-X
outstretched	B-X
hand	B-X
with	B-X
the	B-X
wrist	B-X
in	B-X
ulnar	B-X
deviation	B-X
,	B-X
hyperextension	B-X
,	B-X
and	B-X
intercarpal	B-X
supination	B-X
(	B-X
Yaeger	B-X
et	B-X
al	B-X
.	B-X
The	B-X
force	B-X
classically	B-X
propagates	B-X
from	B-X
the	B-X
radial	B-X
to	B-X
the	B-X
ulnar	B-X
side	B-X
of	B-X
the	B-X
wrist	B-X
resulting	B-X
in	B-X
a	B-X
fracture	B-X
(	B-X
greater	B-X
arc	B-X
)	B-X
or	B-X
dislocation	B-X
(	B-X
lesser	B-X
arc	B-X
)	B-X
pattern	B-X
with	B-X
the	B-X
extent	B-X
of	B-X
the	B-X
injury	B-X
occurring	B-X
in	B-X
an	B-X
orderly	B-X
pattern	B-X
depending	B-X
upon	B-X
the	B-X
degree	B-X
of	B-X
hyperextension	B-X
and	B-X
the	B-X
duration	B-X
and	B-X
magnitude	B-X
of	B-X
the	B-X
force	B-X
(	B-X
Mayfield	B-X
et	B-X
al	B-X
.	B-X
Multiple	B-X
variations	B-X
occur	B-X
,	B-X
including	B-X
transradial	B-X
styloid	B-X
fractures	B-X
as	B-X
well	B-X
as	B-X
fractures	B-X
through	B-X
carpal	B-X
bones	B-X
surrounding	B-X
the	B-X
lunate	B-X
(	B-X
Mayfield	B-X
et	B-X
al	B-X
.	B-X
Skeletal	B-X
Radiol	B-X
13	B-X
(	B-X
2	B-X
)	B-X
:120-30	B-X
,	B-X
1985	B-X
;	B-X
Kozin	B-X
SH	B-X
.	B-X
Although	B-X
carpal	B-X
dislocations	B-X
have	B-X
been	B-X
noted	B-X
for	B-X
many	B-X
years	B-X
,	B-X
the	B-X
mechanisms	B-X
and	B-X
classification	B-X
have	B-X
only	B-X
been	B-X
recently	B-X
clarified	B-X
.	B-X
We	B-X
report	B-X
a	B-X
case	B-X
of	B-X
a	B-X
complex	B-X
dislocation	B-X
involving	B-X
the	B-X
entire	B-X
proximal	B-X
carpal	B-X
row	B-X
without	B-X
an	B-X
associated	B-X
fracture	B-X
.	B-X
While	B-X
this	B-X
type	B-X
of	B-X
complex	B-X
carpal	B-X
dislocation	B-X
has	B-X
been	B-X
previously	B-X
described	B-X
,	B-X
to	B-X
our	B-X
knowledge	B-X
,	B-X
it	B-X
has	B-X
never	B-X
been	B-X
reported	B-X
without	B-X
a	B-X
fracture	B-X
of	B-X
the	B-X
forearm	B-X
,	B-X
wrist	B-X
,	B-X
or	B-X
hand	B-X
.	B-X

[	O
21	O
]	O
studied	O
the	O
effects	O
of	O
median	O
and	O
ulnar	O
nerve	O
blocks	O
on	O
grip	O
and	O
pinch	O
strength	O
and	O
showed	O
significant	O
decreases	O
following	O
nerve	O
blockage	O
[	O
21	O
]	O
.	O

Boatright	O
and	O
Kiebzak	O
[	O
20	O
]	O
investigated	O
the	O
effects	O
of	O
median	O
nerve	O
block	O
on	O
thumb	O
abduction	O
strength	O
.	O

Kaufman	O
et	O
al	O
.	O
<EOS>	B-X
A	B-X
total	B-X
of	B-X
37	B-X
RCTs	B-X
were	B-X
identified	B-X
.	B-X
Results	B-X
indicate	B-X
that	B-X
physical	B-X
exercise	B-X
has	B-X
a	B-X
positive	B-X
impact	B-X
on	B-X
muscle	B-X
mass	B-X
and	B-X
muscle	B-X
function	B-X
in	B-X
subjects	B-X
aged	B-X
65	B-X
years	B-X
and	B-X
older	B-X
.	B-X
However	B-X
,	B-X
any	B-X
interactive	B-X
effect	B-X
of	B-X
dietary	B-X
supplementation	B-X
appears	B-X
to	B-X
be	B-X
limited	B-X
.	B-X
Systemic	B-X
immunoglobulin	B-X
light-chain	B-X
(	B-X
AL	B-X
)	B-X
amyloidosis	B-X
is	B-X
characterized	B-X
by	B-X
deposition	B-X
of	B-X
amyloid	B-X
fibrils	B-X
of	B-X
light	B-X
chains	B-X
produced	B-X
by	B-X
clonal	B-X
CD38+	B-X
plasma	B-X
cells	B-X
.	B-X
Daratumumab	B-X
,	B-X
a	B-X
human	B-X
CD38-targeting	B-X
antibody	B-X
,	B-X
may	B-X
improve	B-X
outcomes	B-X
for	B-X
this	B-X
disease	B-X
.	B-X

[	O
5	O
]	O
measured	O
isometric	O
thumb	O
forces	O
in	O
eight	O
directions	O
together	O
with	O
electromyographic	O
signals	O
of	O
thumb	O
muscles	O
after	O
block	O
of	O
the	O
median	O
nerve	O
.	O

Labosky	O
and	O
Waggy	O
[	O
22	O
]	O
studied	O
the	O
strength	O
related	O
to	O
grip	O
,	O
pinch	O
,	O
thumb	O
adduction	O
,	O
thumb	O
abduction	O
,	O
and	O
finger	O
flexion	O
after	O
radial	O
nerve	O
block	O
[	O
22	O
]	O
.	O

Kuxhaus	O
studied	O
the	O
three	O
dimensional	O
feasible	O
force	O
set	O
at	O
the	O
thumb	O
-	O
tip	O
before	O
and	O
after	O
ulnar	O
nerve	O
block	O
and	O
reported	O
this	O
to	O
be	O
a	O
reproducible	O
and	O
sensitive	O
means	O
to	O
detect	O
impairment	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
utilize	O
our	O
developed	O
apparatus	O
and	O
protocols	O
to	O
investigate	O
the	O
effects	O
of	O
lower	O
median	O
nerve	O
lesion	O
on	O
thumb	O
motor	O
function	O
.	O

The	O
lesion	O
was	O
simulated	O
by	O
blocking	O
the	O
median	O
nerve	O
at	O
the	O
wrist	O
using	O
an	O
anesthetic	O
.	O
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
effects	B-X
of	B-X
a	B-X
simulated	B-X
peripheral	B-X
median	B-X
nerve	B-X
lesion	B-X
on	B-X
precision	B-X
pinch	B-X
movement	B-X
by	B-X
the	B-X
thumb	B-X
and	B-X
index	B-X
finger	B-X
.	B-X
PURPOSE	B-X
:	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
characterize	B-X
thumb	B-X
motor	B-X
dysfunction	B-X
resulting	B-X
from	B-X
simulated	B-X
lower	B-X
median	B-X
nerve	B-X
lesions	B-X
at	B-X
the	B-X
wrist	B-X
.	B-X
METHODS	B-X
:	B-X
Bupivacaine	B-X
hydrochloride	B-X
was	B-X
injected	B-X
into	B-X
the	B-X
carpal	B-X
tunnel	B-X
of	B-X
six	B-X
healthy	B-X
subjects	B-X
to	B-X
locally	B-X
anesthetize	B-X
the	B-X
median	B-X
nerve	B-X
.	B-X
Force	B-X
envelopes	B-X
were	B-X
constructed	B-X
using	B-X
these	B-X
measured	B-X
multidirectional	B-X
forces	B-X
.	B-X
RESULTS	B-X
:	B-X
Blockage	B-X
of	B-X
the	B-X
median	B-X
nerve	B-X
resulted	B-X
in	B-X
decreased	B-X
force	B-X
magnitudes	B-X
and	B-X
thus	B-X
smaller	B-X
force	B-X
envelopes	B-X
.	B-X
CONCLUSION	B-X
:	B-X
Lower	B-X
median	B-X
nerve	B-X
lesion	B-X
,	B-X
simulated	B-X
by	B-X
a	B-X
nerve	B-X
block	B-X
at	B-X
the	B-X
wrist	B-X
,	B-X
compromise	B-X
normal	B-X
motor	B-X
function	B-X
of	B-X
the	B-X
thumb	B-X
.	B-X
A	B-X
median	B-X
nerve	B-X
block	B-X
results	B-X
in	B-X
force	B-X
deficits	B-X
in	B-X
all	B-X
directions	B-X
,	B-X
with	B-X
the	B-X
most	B-X
severe	B-X
impairment	B-X
in	B-X
abduction	B-X
and	B-X
flexion	B-X
.	B-X

We	O
hypothesized	O
that	O
a	O
median	O
nerve	O
block	O
would	O
cause	O
(	O
1	O
)	O
a	O
decrease	O
in	O
force	O
production	O
,	O
which	O
would	O
be	O
direction	O
-	O
dependent	O
with	O
the	O
most	O
severe	O
reduction	O
in	O
the	O
abduction	O
direction	O
,	O
and	O
(	O
2	O
)	O
a	O
decrease	O
in	O
the	O
force	O
envelope	O
area	O
and	O
force	O
quadrant	O
area	O
,	O
with	O
the	O
greatest	O
decrease	O
in	O
the	O
abduction	O
quadrant	O
.	O

Methods	O
<EOS>	B-X
Methods	B-X
to	B-X
calculate	B-X
the	B-X
sample	B-X
size	B-X
are	B-X
explained	B-X
in	B-X
statistical	B-X
textbooks	B-X
,	B-X
but	B-X
because	B-X
there	B-X
are	B-X
many	B-X
different	B-X
formulas	B-X
available	B-X
,	B-X
it	B-X
can	B-X
be	B-X
difficult	B-X
for	B-X
investigators	B-X
to	B-X
decide	B-X
which	B-X
method	B-X
to	B-X
use	B-X
.	B-X

Subjects	O

Six	O
healthy	O
male	O
subjects	O
(	O
mean	O
age	O
:	O
26	O
.	O
9	O
+/-	O
5	O
.	O
1	O
years	O
)	O
participated	O
in	O
this	O
study	O
.	O
<EOS>	B-X
A	B-X
healthy	B-X
overall	B-X
dietary	B-X
pattern	B-X
,	B-X
with	B-X
the	B-X
potential	B-X
to	B-X
reduce	B-X
oxidative	B-X
stress	B-X
,	B-X
has	B-X
been	B-X
suggested	B-X
as	B-X
a	B-X
means	B-X
to	B-X
decrease	B-X
the	B-X
risk	B-X
of	B-X
developing	B-X
cataract	B-X
.	B-X
We	B-X
aimed	B-X
to	B-X
investigate	B-X
the	B-X
hypothesis	B-X
that	B-X
an	B-X
intervention	B-X
with	B-X
a	B-X
Mediterranean	B-X
diet	B-X
(	B-X
MedDiet	B-X
)	B-X
rather	B-X
than	B-X
a	B-X
low-fat	B-X
diet	B-X
could	B-X
decrease	B-X
the	B-X
incidence	B-X
of	B-X
cataract	B-X
surgery	B-X
in	B-X
elderly	B-X
subjects	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
right	B-X
atrial	B-X
and	B-X
ventricular	B-X
strain	B-X
parameters	B-X
on	B-X
cardiac	B-X
magnetic	B-X
resonance	B-X
(	B-X
CMR	B-X
)	B-X
in	B-X
patients	B-X
with	B-X
precapillary	B-X
pulmonary	B-X
hypertension	B-X
(	B-X
PPH	B-X
)	B-X
and	B-X
whether	B-X
they	B-X
can	B-X
aid	B-X
in	B-X
the	B-X
assessment	B-X
of	B-X
PPH	B-X
prognosis	B-X
.	B-X
Is	B-X
ageing	B-X
associated	B-X
with	B-X
a	B-X
decline	B-X
in	B-X
semen	B-X
quality	B-X
and	B-X
molecular	B-X
changes	B-X
to	B-X
human	B-X
sperm	B-X
?	B-X

The	O
subjects	O
had	O
no	O
previous	O
history	O
of	O
neuromuscular	O
or	O
musculoskeletal	O
disorders	O
of	O
the	O
upper	O
extremities	O
.	O
<EOS>	B-X
Occupational	B-X
therapy	B-X
practitioners	B-X
are	B-X
key	B-X
health	B-X
care	B-X
providers	B-X
for	B-X
people	B-X
with	B-X
musculoskeletal	B-X
disorders	B-X
of	B-X
the	B-X
distal	B-X
upper	B-X
extremity	B-X
.	B-X
This	B-X
systematic	B-X
review	B-X
provides	B-X
an	B-X
update	B-X
to	B-X
a	B-X
previous	B-X
review	B-X
by	B-X
summarizing	B-X
articles	B-X
published	B-X
between	B-X
2006	B-X
and	B-X
July	B-X
2014	B-X
related	B-X
to	B-X
the	B-X
focused	B-X
question	B-X
,	B-X
What	B-X
is	B-X
the	B-X
evidence	B-X
for	B-X
the	B-X
effect	B-X
of	B-X
occupational	B-X
therapy	B-X
interventions	B-X
on	B-X
functional	B-X
outcomes	B-X
for	B-X
adults	B-X
with	B-X
musculoskeletal	B-X
disorders	B-X
of	B-X
the	B-X
forearm	B-X
,	B-X
wrist	B-X
,	B-X
and	B-X
hand	B-X
?	B-X
Evidence	B-X
for	B-X
interventions	B-X
was	B-X
synthesized	B-X
by	B-X
condition	B-X
within	B-X
bone	B-X
,	B-X
joint	B-X
,	B-X
and	B-X
general	B-X
hand	B-X
disorders	B-X
;	B-X
peripheral	B-X
nerve	B-X
disorders	B-X
;	B-X
and	B-X
tendon	B-X
disorders	B-X
.	B-X
The	B-X
burden	B-X
of	B-X
disabling	B-X
musculoskeletal	B-X
pain	B-X
and	B-X
injuries	B-X
(	B-X
musculoskeletal	B-X
disorders	B-X
,	B-X
MSDs	B-X
)	B-X
arising	B-X
from	B-X
work-related	B-X
causes	B-X
in	B-X
many	B-X
workplaces	B-X
remains	B-X
substantial	B-X
.	B-X
Our	B-X
objective	B-X
was	B-X
to	B-X
update	B-X
a	B-X
systematic	B-X
review	B-X
of	B-X
workplace-based	B-X
interventions	B-X
for	B-X
preventing	B-X
and	B-X
managing	B-X
upper	B-X
extremity	B-X
MSD	B-X
(	B-X
UEMSD	B-X
)	B-X
.	B-X

Each	O
subject	O
signed	O
an	O
informed	O
consent	O
form	O
approved	O
by	O
the	O
Institutional	O
Review	O
Board	O
prior	O
to	O
participating	O
in	O
the	O
experiment	O
.	O
<EOS>	B-X
We	B-X
demonstrate	B-X
that	B-X
this	B-X
can	B-X
significantly	B-X
improve	B-X
classification	B-X
performance	B-X
as	B-X
compared	B-X
to	B-X
conventional	B-X
techniques	B-X
exclusively	B-X
based	B-X
on	B-X
sEMG	B-X
signals	B-X
.	B-X

Median	O
nerve	O
block	O
<EOS>	B-X
Ultrasound-guided	B-X
median	B-X
nerve	B-X
block	B-X
can	B-X
cause	B-X
arterial	B-X
vasodilation	B-X
,	B-X
which	B-X
may	B-X
improve	B-X
the	B-X
success	B-X
rate	B-X
of	B-X
radial	B-X
artery	B-X
cannulation	B-X
.	B-X
A	B-X
conduction	B-X
block	B-X
at	B-X
a	B-X
noncompressible	B-X
site	B-X
warrants	B-X
further	B-X
investigation	B-X
.	B-X
Median	B-X
nerve	B-X
block	B-X
in	B-X
the	B-X
forearm	B-X
and	B-X
persistent	B-X
median	B-X
artery	B-X
.	B-X
Variations	B-X
in	B-X
the	B-X
Formation	B-X
of	B-X
the	B-X
Median	B-X
Nerve	B-X
and	B-X
Its	B-X
Clinical	B-X
Correlation	B-X
.	B-X

Injections	O
were	O
performed	O
under	O
aseptic	O
conditions	O
while	O
the	O
subjects	O
sat	O
with	O
the	O
forearm	O
supinated	O
and	O
the	O
wrist	O
slightly	O
extended	O
.	O

After	O
the	O
skin	O
at	O
the	O
palmer	O
area	O
of	O
the	O
wrist	O
was	O
cleaned	O
with	O
alcohol	O
,	O
4	O
mL	O
of	O
0	O
.	O
5	O
%	O
bupivacaine	O
hydrochloride	O
(	O
Astra	O
Pharmaceuticals	O
,	O
Westborough	O
,	O
MA	O
,	O
USA	O
)	O
was	O
injected	O
into	O
the	O
carpal	O
tunnel	O
with	O
a	O
sterile	O
25	O
-	O
gauge	O
short	O
-	O
bevel	O
needle	O
.	O

The	O
needle	O
was	O
inserted	O
through	O
the	O
transverse	O
carpal	O
ligament	O
in	O
line	O
with	O
the	O
radial	O
border	O
of	O
the	O
fourth	O
digit	O
slightly	O
ulnar	O
to	O
the	O
palmaris	O
longus	O
tendon	O
at	O
the	O
level	O
of	O
the	O
distal	O
wrist	O
crease	O
.	O

Forty	O
minutes	O
was	O
allowed	O
for	O
the	O
median	O
nerve	O
block	O
to	O
reach	O
complete	O
effectiveness	O
[	O
23	O
]	O
and	O
was	O
verified	O
using	O
the	O
Semmes	O
-	O
Weinstein	O
monofilament	O
test	O
.	O

The	O
average	O
monofilament	O
score	O
was	O
2	O
.	O
85	O
across	O
the	O
five	O
digits	O
before	O
nerve	O
block	O
.	O

About	O
40	O
minutes	O
after	O
nerve	O
injection	O
,	O
little	O
sensory	O
impairment	O
occurred	O
in	O
the	O
ulnar	O
distribution	O
(	O
score	O
=	O
3	O
.	O
22	O
)	O
,	O
while	O
the	O
sensory	O
score	O
in	O
the	O
median	O
distribution	O
was	O
greater	O
than	O
6	O
.	O
15	O
.	O

The	O
effects	O
of	O
nerve	O
block	O
lasted	O
more	O
than	O
6	O
hours	O
with	O
all	O
subjects	O
regaining	O
normal	O
hand	O
function	O
within	O
12	O
hours	O
.	O

Testing	O
apparatus	O
<EOS>	B-X
Urine	B-X
testing	B-X
apparatus	B-X
.	B-X
[	B-X
Recent	B-X
findings	B-X
on	B-X
MRI	B-X
testing	B-X
--	B-X
clinical	B-X
application	B-X
of	B-X
3T	B-X
ultra-high	B-X
magnetic	B-X
apparatus	B-X
]	B-X
.	B-X
Dissolution	B-X
apparatus	B-X
with	B-X
multiple	B-X
testing	B-X
stations	B-X
.	B-X
This	B-X
study	B-X
describes	B-X
the	B-X
rationale	B-X
for	B-X
and	B-X
design	B-X
of	B-X
an	B-X
apparatus	B-X
for	B-X
testing	B-X
maxillofacial	B-X
and	B-X
other	B-X
skin	B-X
adhesives	B-X
.	B-X
The	B-X
apparatus	B-X
provides	B-X
for	B-X
tensile	B-X
,	B-X
torsion	B-X
,	B-X
and	B-X
combined	B-X
tensile-torsion	B-X
tests	B-X
in	B-X
a	B-X
hard	B-X
machine	B-X
test	B-X
.	B-X
The	B-X
results	B-X
of	B-X
the	B-X
calibration	B-X
studies	B-X
of	B-X
the	B-X
apparatus	B-X
are	B-X
discussed	B-X
.	B-X

The	O
experimental	O
apparatus	O
was	O
designed	O
and	O
constructed	O
to	O
measure	O
maximum	O
voluntary	O
contraction	O
forces	O
of	O
any	O
digit	O
at	O
any	O
point	O
along	O
the	O
digit	O
.	O

Force	O
application	O
was	O
possible	O
in	O
any	O
direction	O
within	O
the	O
transverse	O
plane	O
of	O
the	O
longitudinal	O
axis	O
of	O
the	O
digit	O
.	O

The	O
apparatus	O
consisted	O
of	O
position	O
control	O
accessories	O
,	O
a	O
force	O
transducer	O
,	O
and	O
a	O
custom	O
fitted	O
aluminum	O
ring	O
attached	O
to	O
the	O
transducer	O
(	O
Figure	O
1A	O
,	O
1B	O
)	O
.	O

The	O
transducer	O
(	O
Mini40	O
,	O
ATI	O
Industrial	O
Automation	O
,	O
NC	O
,	O
USA	O
)	O
,	O
capable	O
of	O
measuring	O
6	O
degrees	O
of	O
freedom	O
forces	O
and	O
moments	O
,	O
was	O
attached	O
to	O
a	O
mounting	O
clamp	O
via	O
an	O
aluminum	O
adapter	O
plate	O
while	O
the	O
aluminum	O
ring	O
was	O
secured	O
to	O
the	O
tool	O
side	O
of	O
the	O
transducer	O
using	O
a	O
custom	O
adapter	O
.	O

The	O
ring	O
served	O
as	O
a	O
connection	O
anchor	O
for	O
the	O
transducer	O
and	O
the	O
digit	O
.	O

The	O
force	O
transducer	O
and	O
ring	O
attachment	O
were	O
positioned	O
in	O
a	O
desired	O
orientation	O
using	O
an	O
aluminum	O
slide	O
rail	O
,	O
tubing	O
,	O
and	O
lockable	O
mounting	O
clamps	O
(	O
80	O
/	O
20	O
Inc	O
.	O
,	O
Columbia	O
City	O
,	O
IN	O
,	O
USA	O
)	O
.	O

The	O
slide	O
rail	O
was	O
secured	O
to	O
an	O
aluminum	O
base	O
plate	O
.	O

Foam	O
padded	O
wooden	O
blocks	O
with	O
two	O
locking	O
straps	O
secured	O
the	O
arm	O
to	O
the	O
base	O
plate	O
.	O

The	O
analog	O
outputs	O
from	O
the	O
transducer	O
were	O
digitized	O
using	O
a	O
16	O
-	O
bit	O
analog	O
-	O
to	O
-	O
digital	O
converter	O
(	O
PCI	O
-	O
6031	O
,	O
National	O
Instruments	O
,	O
TX	O
,	O
USA	O
)	O
.	O

The	O
X	O
(	O
abduction	O
/	O
adduction	O
)	O
and	O
Y	O
(	O
flexion	O
/	O
extension	O
)	O
force	O
components	O
in	O
the	O
transverse	O
plane	O
were	O
displayed	O
on	O
the	O
screen	O
while	O
the	O
subject	O
performed	O
a	O
force	O
production	O
task	O
.	O

The	O
resolutions	O
of	O
the	O
force	O
transducer	O
in	O
its	O
axial	O
(	O
flexion	O
/	O
extension	O
)	O
and	O
horizontal	O
(	O
abduction	O
/	O
adduction	O
)	O
directions	O
were	O
0	O
.	O
16	O
N	O
and	O
0	O
.	O
08	O
N	O
,	O
respectively	O
.	O

A	O
personal	O
computer	O
equipped	O
with	O
LabVIEW	O
(	O
National	O
Instrument	O
,	O
TX	O
,	O
USA	O
)	O
was	O
used	O
for	O
force	O
data	O
acquisition	O
,	O
display	O
,	O
and	O
processing	O
.	O

Experimental	O
procedures	O
<EOS>	B-X
The	B-X
main	B-X
intention	B-X
of	B-X
these	B-X
contributions	B-X
is	B-X
to	B-X
sensitize	B-X
users	B-X
of	B-X
laboratory	B-X
animals	B-X
for	B-X
the	B-X
proper	B-X
and	B-X
rational	B-X
use	B-X
of	B-X
them	B-X
in	B-X
experimental	B-X
research	B-X
,	B-X
as	B-X
well	B-X
as	B-X
to	B-X
disseminate	B-X
the	B-X
permitted	B-X
and	B-X
unpermitted	B-X
procedures	B-X
in	B-X
laboratory	B-X
animals	B-X
.	B-X
In	B-X
this	B-X
paper	B-X
we	B-X
present	B-X
the	B-X
PREPARE	B-X
guidelines	B-X
:	B-X
Planning	B-X
Research	B-X
and	B-X
Experimental	B-X
Procedures	B-X
on	B-X
Animals	B-X
:	B-X
Recommendations	B-X
for	B-X
Excellence	B-X
.	B-X
Reducing	B-X
sources	B-X
of	B-X
variance	B-X
in	B-X
experimental	B-X
procedures	B-X
in	B-X
in	B-X
vitro	B-X
research	B-X
.	B-X
In	B-X
this	B-X
article	B-X
,	B-X
we	B-X
extend	B-X
the	B-X
single-step	B-X
procedure	B-X
to	B-X
two	B-X
new	B-X
step-up	B-X
procedures	B-X
for	B-X
NI	B-X
trials	B-X
with	B-X
multiple	B-X
new	B-X
treatments	B-X
.	B-X
A	B-X
comparative	B-X
study	B-X
of	B-X
test	B-X
power	B-X
shows	B-X
that	B-X
both	B-X
proposed	B-X
step-up	B-X
procedures	B-X
provide	B-X
a	B-X
significant	B-X
improvement	B-X
of	B-X
power	B-X
when	B-X
compared	B-X
to	B-X
the	B-X
single-step	B-X
procedure	B-X
.	B-X
One	B-X
of	B-X
the	B-X
two	B-X
proposed	B-X
step-up	B-X
procedures	B-X
also	B-X
allows	B-X
the	B-X
flexibility	B-X
of	B-X
allocating	B-X
different	B-X
error	B-X
rates	B-X
between	B-X
the	B-X
sensitivity	B-X
hypothesis	B-X
and	B-X
the	B-X
NI	B-X
hypotheses	B-X
so	B-X
that	B-X
the	B-X
assignment	B-X
of	B-X
fewer	B-X
patients	B-X
to	B-X
the	B-X
placebo	B-X
becomes	B-X
possible	B-X
when	B-X
designing	B-X
NI	B-X
trials	B-X
.	B-X
We	B-X
illustrate	B-X
the	B-X
new	B-X
procedures	B-X
using	B-X
data	B-X
from	B-X
a	B-X
clinical	B-X
trial	B-X
.	B-X

Each	O
subject	O
was	O
tested	O
before	O
and	O
after	O
median	O
nerve	O
block	O
.	O
<EOS>	B-X
Both	B-X
nerve	B-X
demyelination	B-X
and	B-X
increased	B-X
axonal	B-X
branching	B-X
associated	B-X
with	B-X
collateral	B-X
sprouting	B-X
reduce	B-X
the	B-X
safety	B-X
factor	B-X
for	B-X
impulse	B-X
transmission	B-X
and	B-X
could	B-X
cause	B-X
activity-dependent	B-X
hyperpolarization	B-X
and	B-X
conduction	B-X
block	B-X
during	B-X
voluntary	B-X
contraction	B-X
,	B-X
and	B-X
thus	B-X
fatigue	B-X
.	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
investigate	B-X
whether	B-X
activity-dependent	B-X
conduction	B-X
block	B-X
is	B-X
associated	B-X
with	B-X
fatigue	B-X
in	B-X
demyelinating	B-X
neuropathies	B-X
and	B-X
lower	B-X
motor	B-X
neuron	B-X
disorders	B-X
.	B-X
Although	B-X
there	B-X
has	B-X
been	B-X
much	B-X
discussion	B-X
about	B-X
optimal	B-X
patient	B-X
management	B-X
to	B-X
protect	B-X
the	B-X
ulnar	B-X
nerve	B-X
and	B-X
brachial	B-X
plexus	B-X
,	B-X
little	B-X
attention	B-X
has	B-X
been	B-X
paid	B-X
to	B-X
the	B-X
median	B-X
nerve	B-X
during	B-X
wrist	B-X
hyperextension	B-X
.	B-X
The	B-X
authors	B-X
report	B-X
the	B-X
effects	B-X
of	B-X
wrist	B-X
hyperextension	B-X
on	B-X
conduction	B-X
in	B-X
the	B-X
median	B-X
nerve	B-X
.	B-X

The	O
nerve	O
block	O
procedures	O
were	O
performed	O
immediately	O
after	O
the	O
completion	O
of	O
the	O
first	O
testing	O
session	O
.	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
randomized	B-X
controlled	B-X
trial	B-X
is	B-X
to	B-X
identify	B-X
if	B-X
a	B-X
fascia	B-X
iliaca	B-X
block	B-X
reduces	B-X
postoperative	B-X
pain	B-X
and	B-X
narcotic	B-X
consumption	B-X
and	B-X
improves	B-X
early	B-X
functional	B-X
outcomes	B-X
in	B-X
primary	B-X
total	B-X
hip	B-X
arthroplasty	B-X
(	B-X
THA	B-X
)	B-X
performed	B-X
through	B-X
the	B-X
mini-posterior	B-X
approach	B-X
.	B-X

Post	O
-	O
block	O
testing	O
started	O
after	O
the	O
verification	O
of	O
complete	O
median	O
nerve	O
block	O
,	O
approximately	O
40	O
minutes	O
after	O
the	O
injection	O
.	O

During	O
each	O
test	O
,	O
the	O
subject	O
was	O
seated	O
in	O
a	O
chair	O
adjacent	O
to	O
the	O
testing	O
station	O
modified	O
with	O
a	O
wooden	O
board	O
to	O
align	O
their	O
back	O
vertically	O
throughout	O
the	O
trials	O
.	O

The	O
subjects	O
rested	O
their	O
forearm	O
on	O
padded	O
wooden	O
blocks	O
positioning	O
their	O
shoulder	O
in	O
approximately	O
60	O
degrees	O
of	O
frontal	O
plane	O
abduction	O
.	O

Nylon	O
straps	O
fitted	O
with	O
plastic	O
snap	O
locking	O
mechanisms	O
secured	O
the	O
forearm	O
and	O
minimized	O
the	O
intervention	O
of	O
the	O
elbow	O
and	O
shoulder	O
during	O
thumb	O
force	O
application	O
.	O

Subjects	O
grasped	O
a	O
vertical	O
dowel	O
secured	O
to	O
the	O
distal	O
end	O
of	O
the	O
wooden	O
blocks	O
in	O
a	O
midprone	O
position	O
.	O

Formable	O
thermoplastic	O
braces	O
were	O
used	O
to	O
fix	O
the	O
elbow	O
in	O
90	O
degrees	O
of	O
flexion	O
,	O
and	O
the	O
wrist	O
in	O
20	O
degrees	O
of	O
extension	O
and	O
0	O
degrees	O
of	O
ulnar	O
deviation	O
.	O

A	O
metallic	O
brace	O
was	O
used	O
to	O
fix	O
the	O
interphalangeal	O
joint	O
of	O
the	O
thumb	O
in	O
full	O
extension	O
.	O

The	O
aluminum	O
ring	O
was	O
placed	O
around	O
the	O
middle	O
of	O
the	O
proximal	O
phalanx	O
and	O
oriented	O
to	O
accommodate	O
comfortable	O
thumb	O
position	O
with	O
the	O
metacarpophalangeal	O
joint	O
flexed	O
approximately	O
15	O
degrees	O
.	O

Prior	O
to	O
testing	O
,	O
a	O
line	O
was	O
drawn	O
on	O
the	O
proximal	O
phalange	O
at	O
the	O
midpoint	O
between	O
the	O
interphalangeal	O
and	O
metacarpophalangeal	O
joints	O
.	O

The	O
alignment	O
of	O
the	O
ring	O
with	O
the	O
circumferential	O
line	O
standardized	O
the	O
location	O
of	O
force	O
application	O
within	O
and	O
between	O
subjects	O
.	O

As	O
force	O
application	O
was	O
at	O
the	O
middle	O
of	O
the	O
proximal	O
phalanx	O
,	O
mechanical	O
action	O
pertains	O
to	O
both	O
the	O
metacarpophalangeal	O
and	O
carpometacarpal	O
joints	O
.	O

We	O
chose	O
the	O
terminology	O
of	O
flexion	O
/	O
extension	O
and	O
adduction	O
/	O
adduction	O
based	O
on	O
the	O
mechanical	O
action	O
with	O
respect	O
to	O
the	O
metacarpophalangeal	O
joint	O
.	O

With	O
the	O
thumb	O
in	O
the	O
ring	O
(	O
Figure	O
1B	O
)	O
,	O
extension	O
and	O
flexion	O
occurred	O
in	O
parallel	O
with	O
the	O
palm	O
,	O
and	O
abduction	O
and	O
adduction	O
occurred	O
in	O
a	O
plane	O
perpendicular	O
to	O
the	O
palm	O
.	O

Each	O
subject	O
performed	O
15	O
circumferential	O
MVC	O
trials	O
with	O
randomized	O
starting	O
directions	O
(	O
Figure	O
1C	O
)	O
.	O

The	O
subject	O
was	O
allotted	O
15	O
seconds	O
to	O
complete	O
each	O
circumferential	O
trial	O
,	O
and	O
was	O
instructed	O
to	O
use	O
the	O
entire	O
time	O
allotted	O
to	O
traverse	O
the	O
perimeter	O
of	O
the	O
ring	O
once	O
.	O

A	O
dot	O
generated	O
on	O
the	O
computer	O
screen	O
was	O
programmed	O
to	O
traverse	O
a	O
circle	O
within	O
15	O
seconds	O
to	O
provide	O
the	O
subject	O
with	O
directional	O
feedback	O
of	O
their	O
force	O
application	O
.	O

Subjects	O
were	O
given	O
60	O
seconds	O
of	O
rest	O
between	O
each	O
circumferential	O
trial	O
.	O

Each	O
subject	O
was	O
familiarized	O
with	O
the	O
task	O
with	O
a	O
few	O
practice	O
trials	O
.	O
<EOS>	B-X
A	B-X
few	B-X
retrospective	B-X
and	B-X
prospective	B-X
studies	B-X
support	B-X
current	B-X
recommendations	B-X
for	B-X
endoscopic	B-X
surveillance	B-X
in	B-X
FAP	B-X
and	B-X
HNPCC	B-X
,	B-X
the	B-X
main	B-X
subjects	B-X
of	B-X
this	B-X
paper	B-X
.	B-X
Where	B-X
firm	B-X
data	B-X
have	B-X
been	B-X
lacking	B-X
,	B-X
various	B-X
professional	B-X
organizations	B-X
have	B-X
been	B-X
very	B-X
willing	B-X
to	B-X
provide	B-X
consensus	B-X
clinical	B-X
practice	B-X
guidelines	B-X
.	B-X
General	B-X
guidelines	B-X
need	B-X
to	B-X
be	B-X
tailored	B-X
to	B-X
the	B-X
peculiarities	B-X
of	B-X
a	B-X
patient	B-X
's	B-X
circumstances	B-X
,	B-X
a	B-X
task	B-X
best	B-X
accomplished	B-X
in	B-X
the	B-X
hands	B-X
of	B-X
practitioners	B-X
familiar	B-X
with	B-X
the	B-X
natural	B-X
history	B-X
of	B-X
the	B-X
condition	B-X
.	B-X
Surveillance	B-X
,	B-X
chemoprevention	B-X
,	B-X
and	B-X
imaginative	B-X
hybrid	B-X
surveillance/endoscopic	B-X
therapy/chemoprevention	B-X
trials	B-X
may	B-X
gradually	B-X
decrease	B-X
the	B-X
present	B-X
dependence	B-X
on	B-X
prophylactic	B-X
colectomy/proctocolectomy	B-X
.	B-X

Data	O
were	O
collected	O
from	O
each	O
subject	O
at	O
100	O
samples	O
per	O
second	O
producing	O
a	O
total	O
of	O
22	O
,	O
500	O
pairs	O
of	O
force	O
components	O
from	O
the	O
15	O
circumferential	O
trials	O
.	O

Our	O
previous	O
study	O
[	O
19	O
]	O
indicated	O
that	O
the	O
testing	O
protocol	O
did	O
not	O
cause	O
noticeable	O
fatigue	O
.	O
<EOS>	B-X
To	B-X
describe	B-X
study	B-X
design	B-X
considerations	B-X
and	B-X
to	B-X
simulate	B-X
a	B-X
trial	B-X
of	B-X
biomarker-guided	B-X
sepsis	B-X
management	B-X
aimed	B-X
to	B-X
reduce	B-X
acute	B-X
kidney	B-X
injury	B-X
(	B-X
acute	B-X
kidney	B-X
injury	B-X
)	B-X
.	B-X
However	B-X
,	B-X
recent	B-X
publications	B-X
of	B-X
randomized	B-X
controlled	B-X
studies	B-X
and	B-X
case	B-X
series	B-X
studies	B-X
indicated	B-X
the	B-X
positive	B-X
effect	B-X
of	B-X
gait	B-X
retraining	B-X
in	B-X
clinical	B-X
and	B-X
functional	B-X
outcomes	B-X
,	B-X
which	B-X
re-raise	B-X
the	B-X
focus	B-X
of	B-X
gait	B-X
retraining	B-X
.	B-X
Spontaneous	B-X
object	B-X
exploration	B-X
tasks	B-X
do	B-X
not	B-X
require	B-X
training	B-X
,	B-X
and	B-X
allow	B-X
repeated	B-X
testing	B-X
of	B-X
subjects	B-X
,	B-X
provided	B-X
novel	B-X
objects	B-X
are	B-X
used	B-X
on	B-X
each	B-X
trial	B-X
.	B-X
Therefore	B-X
,	B-X
these	B-X
tasks	B-X
are	B-X
ideally	B-X
suited	B-X
for	B-X
the	B-X
study	B-X
of	B-X
the	B-X
ontogeny	B-X
of	B-X
episodic	B-X
memory	B-X
and	B-X
its	B-X
constituents	B-X
(	B-X
e.g.	B-X
,	B-X
object	B-X
,	B-X
spatial	B-X
,	B-X
and	B-X
contextual	B-X
memory	B-X
)	B-X
.	B-X

Force	O
envelope	O
and	O
quadrants	O
<EOS>	B-X
Peak	B-X
forces	B-X
measured	B-X
in	B-X
all	B-X
directions	B-X
were	B-X
used	B-X
to	B-X
create	B-X
polar	B-X
plots	B-X
and	B-X
to	B-X
construct	B-X
force	B-X
envelopes	B-X
using	B-X
cubic	B-X
spline	B-X
interpolation	B-X
.	B-X
The	B-X
areas	B-X
of	B-X
the	B-X
force	B-X
envelope	B-X
and	B-X
force	B-X
quadrants	B-X
were	B-X
then	B-X
calculated	B-X
.	B-X
The	B-X
area	B-X
of	B-X
the	B-X
entire	B-X
force	B-X
envelope	B-X
was	B-X
found	B-X
to	B-X
be	B-X
12,142	B-X
+/-	B-X
3,149	B-X
N-N	B-X
.	B-X
The	B-X
percentage	B-X
quadrant	B-X
areas	B-X
,	B-X
relative	B-X
to	B-X
the	B-X
total	B-X
force	B-X
envelope	B-X
area	B-X
,	B-X
for	B-X
extension-adduction	B-X
,	B-X
extension-abduction	B-X
,	B-X
flexion-abduction	B-X
,	B-X
and	B-X
flexion-adduction	B-X
were	B-X
7.8	B-X
%	B-X
,	B-X
11.4	B-X
%	B-X
,	B-X
39.3	B-X
%	B-X
,	B-X
and	B-X
41.4	B-X
%	B-X
,	B-X
respectively	B-X
.	B-X

Data	O
from	O
multiple	O
circumferential	O
trials	O
were	O
accumulated	O
to	O
construct	O
a	O
force	O
envelope	O
.	O

The	O
procedures	O
to	O
generate	O
a	O
force	O
envelope	O
were	O
as	O
follows	O
:	O
<EOS>	B-X
Bioprosthetic	B-X
aortic	B-X
heart	B-X
valves	B-X
are	B-X
known	B-X
to	B-X
degenerate	B-X
within	B-X
7-15	B-X
years	B-X
of	B-X
implantation	B-X
.	B-X
Repeated	B-X
procedures	B-X
,	B-X
such	B-X
as	B-X
two	B-X
or	B-X
three	B-X
valve-in-valves	B-X
,	B-X
significantly	B-X
reduce	B-X
the	B-X
effective	B-X
valve	B-X
flow	B-X
area	B-X
,	B-X
putting	B-X
a	B-X
limit	B-X
on	B-X
recurrent	B-X
treatments	B-X
.	B-X
With	B-X
increasing	B-X
life	B-X
expectancy	B-X
and	B-X
the	B-X
use	B-X
of	B-X
TAVI	B-X
in	B-X
younger	B-X
,	B-X
lower-risk	B-X
patients	B-X
,	B-X
the	B-X
demand	B-X
for	B-X
multiple	B-X
replacement	B-X
procedures	B-X
will	B-X
inevitably	B-X
increase	B-X
.	B-X
Simulations	B-X
have	B-X
been	B-X
performed	B-X
to	B-X
determine	B-X
the	B-X
forces	B-X
,	B-X
frame	B-X
design	B-X
and	B-X
electromagnetic	B-X
parameters	B-X
required	B-X
to	B-X
crimp	B-X
and	B-X
retrieve	B-X
a	B-X
26	B-X
mm	B-X
diameter	B-X
valve	B-X
.	B-X
A	B-X
force	B-X
of	B-X
2.87	B-X
N	B-X
and	B-X
a	B-X
current	B-X
of	B-X
2.52	B-X
A	B-X
per	B-X
electromagnet	B-X
were	B-X
required	B-X
to	B-X
partially	B-X
crimp	B-X
the	B-X
frame	B-X
to	B-X
an	B-X
envelope	B-X
radius	B-X
of	B-X
11	B-X
mm	B-X
.	B-X
While	B-X
this	B-X
amount	B-X
of	B-X
force	B-X
allowed	B-X
the	B-X
frame	B-X
to	B-X
be	B-X
crimped	B-X
solely	B-X
through	B-X
magnetic	B-X
attraction	B-X
,	B-X
re-sheathing	B-X
of	B-X
the	B-X
frame	B-X
was	B-X
not	B-X
possible	B-X
due	B-X
to	B-X
the	B-X
weaker	B-X
shear	B-X
holding	B-X
force	B-X
of	B-X
the	B-X
magnets	B-X
.	B-X
This	B-X
would	B-X
decrease	B-X
both	B-X
the	B-X
force	B-X
that	B-X
the	B-X
electromagnets	B-X
had	B-X
to	B-X
exert	B-X
during	B-X
crimping	B-X
and	B-X
the	B-X
current	B-X
required	B-X
to	B-X
generate	B-X
this	B-X
force	B-X
.	B-X

Cartesian	O
force	O
coordinates	O
(	O
Xi	O
,	O
Yi	O
)	O
were	O
transformed	O
into	O
polar	O
coordinates	O
(	O
R	O
alpha	O
,	O
alpha	O
)	O
,	O
where	O
R	O
alpha	O
was	O
the	O
force	O
magnitude	O
at	O
an	O
angular	O
position	O
alpha	O
.	O

Each	O
alpha	O
was	O
rounded	O
to	O
the	O
nearest	O
integer	O
ranging	O
from	O
0	O
to	O
359	O
degrees	O
.	O

The	O
maximum	O
,	O
F	O
alpha	O
,	O
was	O
determined	O
from	O
a	O
string	O
of	O
N	O
data	O
points	O
along	O
each	O
radial	O
line	O
defined	O
by	O
alpha	O
.	O

At	O
the	O
completion	O
of	O
the	O
15	O
trials	O
,	O
there	O
were	O
,	O
on	O
average	O
,	O
N	O
=	O
63	O
data	O
points	O
on	O
each	O
radial	O
line	O
of	O
alpha	O
based	O
on	O
the	O
distribution	O
off	O
the	O
22	O
,	O
500	O
data	O
points	O
around	O
360	O
degrees	O
.	O

A	O
moving	O
average	O
with	O
an	O
interval	O
of	O
10	O
degrees	O
was	O
applied	O
to	O
the	O
maximal	O
series	O
data	O
F	O
alpha	O
(	O
alpha	O
=	O
0	O
,	O
1	O
,	O
2	O
,	O
.	O
.	O
.	O
,	O
359	O
)	O
to	O
obtain	O
filtered	O
maximal	O
forces	O
.	O

These	O
forces	O
formed	O
a	O
force	O
envelope	O
.	O
<EOS>	B-X
Analysis	B-X
of	B-X
chromosome	B-X
rearrangements	B-X
that	B-X
separate	B-X
pericentric	B-X
heterochromatin	B-X
and	B-X
centromeres	B-X
indicates	B-X
that	B-X
they	B-X
must	B-X
remain	B-X
associated	B-X
in	B-X
order	B-X
to	B-X
balance	B-X
Cohesin/DNA	B-X
catenation-based	B-X
binding	B-X
forces	B-X
and	B-X
centromere-based	B-X
pulling	B-X
forces	B-X
during	B-X
the	B-X
metaphase-anaphase	B-X
transition	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
a	B-X
centromere	B-X
embedded	B-X
in	B-X
heterochromatin	B-X
facilitates	B-X
nuclear	B-X
envelope	B-X
assembly	B-X
around	B-X
the	B-X
entire	B-X
complement	B-X
of	B-X
segregating	B-X
chromosomes	B-X
.	B-X
Because	B-X
the	B-X
nuclear	B-X
envelope	B-X
initially	B-X
forms	B-X
on	B-X
pericentric	B-X
heterochromatin	B-X
,	B-X
nuclear	B-X
envelope	B-X
formation	B-X
proceeds	B-X
from	B-X
the	B-X
pole	B-X
,	B-X
thus	B-X
providing	B-X
time	B-X
for	B-X
incorporation	B-X
of	B-X
lagging	B-X
and	B-X
trailing	B-X
chromosome	B-X
arms	B-X
into	B-X
the	B-X
newly	B-X
formed	B-X
nucleus	B-X
.	B-X
The	B-X
gastrointestinal	B-X
tract	B-X
is	B-X
enveloped	B-X
by	B-X
concentric	B-X
and	B-X
orthogonally	B-X
aligned	B-X
layers	B-X
of	B-X
smooth	B-X
muscle	B-X
;	B-X
however	B-X
,	B-X
an	B-X
understanding	B-X
of	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
these	B-X
muscles	B-X
become	B-X
patterned	B-X
and	B-X
aligned	B-X
in	B-X
the	B-X
embryo	B-X
has	B-X
been	B-X
lacking	B-X
.	B-X
Differential	B-X
growth	B-X
within	B-X
the	B-X
early	B-X
gut	B-X
tube	B-X
generates	B-X
residual	B-X
strains	B-X
that	B-X
orient	B-X
the	B-X
first	B-X
layer	B-X
circumferentially	B-X
,	B-X
and	B-X
when	B-X
formed	B-X
,	B-X
the	B-X
spontaneous	B-X
contractions	B-X
of	B-X
this	B-X
layer	B-X
align	B-X
the	B-X
second	B-X
layer	B-X
longitudinally	B-X
.	B-X

The	O
area	O
formed	O
by	O
a	O
force	O
envelope	O
was	O
divided	O
into	O
adduction	O
-	O
extension	O
,	O
extension	O
-	O
abduction	O
,	O
abduction	O
-	O
flexion	O
,	O
and	O
flexion	O
-	O
adduction	O
quadrants	O
by	O
radial	O
lines	O
oriented	O
at	O
0	O
degrees	O
,	O
90	O
degrees	O
,	O
180	O
degrees	O
,	O
and	O
270	O
degrees	O
A	O
quadrant	O
force	O
was	O
represented	O
using	O
the	O
mean	O
magnitude	O
of	O
the	O
forces	O
in	O
that	O
quadrant	O
.	O

The	O
areas	O
of	O
the	O
entire	O
envelope	O
and	O
each	O
quadrant	O
were	O
calculated	O
by	O
summing	O
the	O
areas	O
of	O
individual	O
arc	O
sections	O
formed	O
by	O
the	O
polar	O
coordinates	O
of	O
the	O
force	O
envelope	O
.	O

(	O
Figure	O
2	O
)	O
.	O
<EOS>	B-X
and	B-X
Kilic	B-X
F.	B-X
,	B-X
Journal	B-X
of	B-X
Neurochemistry	B-X
101	B-X
(	B-X
4	B-X
)	B-X
937-948	B-X
,	B-X
2007	B-X
(	B-X
https	B-X
:	B-X
//doi.org/10.1111/j.1471-4159.2007.04469.x	B-X
)	B-X
.	B-X
The	B-X
above	B-X
article	B-X
,	B-X
published	B-X
online	B-X
on	B-X
23rd	B-X
January	B-X
2007	B-X
in	B-X
Wiley	B-X
Online	B-X
Library	B-X
(	B-X
wileyonlinelibrary.com	B-X
)	B-X
,	B-X
has	B-X
been	B-X
retracted	B-X
by	B-X
agreement	B-X
between	B-X
the	B-X
Journal	B-X
's	B-X
Editor	B-X
in	B-X
Chief	B-X
,	B-X
JÃ¶rg	B-X
B.	B-X
Schulz	B-X
,	B-X
and	B-X
John	B-X
Wiley	B-X
&	B-X
Sons	B-X
Ltd	B-X
.	B-X
The	B-X
corresponding	B-X
author	B-X
,	B-X
Dr.	B-X
Fusun	B-X
Kilic	B-X
,	B-X
notified	B-X
the	B-X
Journal	B-X
's	B-X
Editorial	B-X
Office	B-X
of	B-X
the	B-X
following	B-X
concerns	B-X
related	B-X
to	B-X
the	B-X
article	B-X
that	B-X
were	B-X
brought	B-X
to	B-X
his	B-X
attention	B-X
:	B-X
Figures	B-X
2C	B-X
and	B-X
2D	B-X
are	B-X
duplicates	B-X
The	B-X
'Lysate	B-X
'	B-X
and	B-X
the	B-X
'Bound	B-X
'	B-X
lanes	B-X
in	B-X
Figure	B-X
7A	B-X
are	B-X
identical	B-X
The	B-X
Myc-SERT	B-X
bands	B-X
in	B-X
Figure	B-X
7B	B-X
,	B-X
lanes	B-X
2	B-X
and	B-X
3	B-X
are	B-X
duplicates	B-X
of	B-X
lanes	B-X
4	B-X
and	B-X
5	B-X
,	B-X
and	B-X
again	B-X
of	B-X
lanes	B-X
6	B-X
and	B-X
7	B-X
The	B-X
45	B-X
kD	B-X
bands	B-X
in	B-X
Figure	B-X
7B	B-X
,	B-X
lanes	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
are	B-X
duplicates	B-X
of	B-X
lanes	B-X
5	B-X
,	B-X
6	B-X
,	B-X
and	B-X
7	B-X
Dr.	B-X
Kilic	B-X
investigated	B-X
the	B-X
concerns	B-X
and	B-X
,	B-X
in	B-X
response	B-X
to	B-X
the	B-X
journal	B-X
,	B-X
concluded	B-X
that	B-X
they	B-X
were	B-X
unjustified	B-X
.	B-X
The	B-X
Journal	B-X
's	B-X
Editorial	B-X
Office	B-X
undertook	B-X
its	B-X
own	B-X
visual	B-X
inspection	B-X
and	B-X
,	B-X
in	B-X
relation	B-X
to	B-X
Figure	B-X
7B	B-X
,	B-X
maintains	B-X
that	B-X
duplication	B-X
is	B-X
present	B-X
.	B-X
They	B-X
concluded	B-X
:	B-X
In	B-X
Figure	B-X
7B	B-X
,	B-X
45	B-X
kD	B-X
,	B-X
lanes	B-X
1	B-X
and	B-X
5	B-X
appear	B-X
identical	B-X
,	B-X
as	B-X
well	B-X
as	B-X
lane	B-X
2	B-X
and	B-X
6	B-X
,	B-X
and	B-X
lanes	B-X
3	B-X
,	B-X
4	B-X
,	B-X
and	B-X
7	B-X
(	B-X
with	B-X
lane	B-X
4	B-X
being	B-X
clipped	B-X
at	B-X
the	B-X
right-hand	B-X
side	B-X
)	B-X
In	B-X
the	B-X
Flag-SERT	B-X
,	B-X
lanes	B-X
2	B-X
and	B-X
6	B-X
appear	B-X
identical	B-X
,	B-X
as	B-X
well	B-X
as	B-X
lanes	B-X
3	B-X
and	B-X
7	B-X
In	B-X
the	B-X
Myc-SERT	B-X
,	B-X
lanes	B-X
2	B-X
and	B-X
6	B-X
appear	B-X
identical	B-X
,	B-X
as	B-X
well	B-X
as	B-X
lanes	B-X
3	B-X
,	B-X
5	B-X
,	B-X
and	B-X
7	B-X
.	B-X
The	B-X
problems	B-X
are	B-X
highlighted	B-X
in	B-X
the	B-X
following	B-X
screenshot	B-X
of	B-X
Figure	B-X
7B	B-X
.	B-X

Statistical	O
Analyses	O
<EOS>	B-X
Analyses	B-X
can	B-X
be	B-X
conducted	B-X
using	B-X
Microsoft	B-X
Excel	B-X
,	B-X
but	B-X
there	B-X
was	B-X
no	B-X
previous	B-X
guide	B-X
available	B-X
.	B-X
Statistical	B-X
methods	B-X
to	B-X
analyse	B-X
threshold	B-X
concentrations	B-X
from	B-X
a	B-X
batch	B-X
of	B-X
serial	B-X
dilution	B-X
assays	B-X
should	B-X
account	B-X
for	B-X
the	B-X
grouping	B-X
of	B-X
the	B-X
data	B-X
.	B-X

One	O
-	O
and	O
two	O
-	O
factor	O
repeated	O
measures	O
analyses	O
of	O
variance	O
(	O
ANOVA	O
)	O
were	O
used	O
to	O
analyze	O
outcome	O
measures	O
.	O
<EOS>	B-X
The	B-X
Children	B-X
with	B-X
Hemiparesis	B-X
Arm	B-X
and	B-X
Movement	B-X
Project	B-X
(	B-X
CHAMP	B-X
)	B-X
addresses	B-X
two	B-X
pressing	B-X
issues	B-X
concerning	B-X
paediatric	B-X
constraint-induced	B-X
movement	B-X
therapy	B-X
(	B-X
CIMT	B-X
)	B-X
:	B-X
effects	B-X
of	B-X
two	B-X
dosages	B-X
and	B-X
two	B-X
types	B-X
of	B-X
constraint	B-X
on	B-X
functional	B-X
outcomes	B-X
.	B-X
Systematic	B-X
reviews	B-X
conclude	B-X
that	B-X
CIMT	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
efficacious	B-X
treatments	B-X
,	B-X
but	B-X
wide	B-X
variations	B-X
in	B-X
treatment	B-X
protocols	B-X
,	B-X
outcome	B-X
measures	B-X
and	B-X
patient	B-X
characteristics	B-X
have	B-X
prevented	B-X
conclusions	B-X
about	B-X
potential	B-X
effects	B-X
of	B-X
dosage	B-X
levels	B-X
and	B-X
constraint	B-X
methods	B-X
.	B-X
A	B-X
common	B-X
feature	B-X
of	B-X
preclinical	B-X
animal	B-X
experiments	B-X
is	B-X
repeated	B-X
measurement	B-X
of	B-X
the	B-X
outcome	B-X
,	B-X
e.g.	B-X
,	B-X
body	B-X
weight	B-X
measured	B-X
in	B-X
mice	B-X
pups	B-X
weekly	B-X
for	B-X
20	B-X
weeks	B-X
.	B-X
Separate	B-X
time	B-X
point	B-X
analysis	B-X
or	B-X
repeated	B-X
measures	B-X
analysis	B-X
approaches	B-X
can	B-X
be	B-X
used	B-X
to	B-X
analyze	B-X
such	B-X
data	B-X
.	B-X
Given	B-X
the	B-X
ethical	B-X
responsibilities	B-X
to	B-X
maximize	B-X
valid	B-X
results	B-X
obtained	B-X
from	B-X
animals	B-X
used	B-X
in	B-X
research	B-X
,	B-X
our	B-X
objective	B-X
was	B-X
to	B-X
evaluate	B-X
approaches	B-X
to	B-X
reporting	B-X
repeated	B-X
measures	B-X
design	B-X
used	B-X
by	B-X
investigators	B-X
and	B-X
to	B-X
assess	B-X
how	B-X
assumptions	B-X
about	B-X
variation	B-X
in	B-X
the	B-X
outcome	B-X
over	B-X
time	B-X
impact	B-X
type	B-X
I	B-X
and	B-X
II	B-X
error	B-X
rates	B-X
and	B-X
precision	B-X
of	B-X
estimates	B-X
.	B-X
We	B-X
assessed	B-X
the	B-X
reporting	B-X
of	B-X
repeated	B-X
measures	B-X
designs	B-X
of	B-X
58	B-X
studies	B-X
in	B-X
preclinical	B-X
animal	B-X
experiments	B-X
.	B-X
We	B-X
used	B-X
simulation	B-X
modelling	B-X
to	B-X
evaluate	B-X
three	B-X
approaches	B-X
to	B-X
statistical	B-X
analysis	B-X
of	B-X
repeated	B-X
measurement	B-X
data	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
we	B-X
assessed	B-X
the	B-X
impact	B-X
of	B-X
(	B-X
a	B-X
)	B-X
repeated	B-X
measure	B-X
analysis	B-X
assuming	B-X
that	B-X
the	B-X
outcome	B-X
had	B-X
non-constant	B-X
variation	B-X
at	B-X
all	B-X
time	B-X
points	B-X
(	B-X
heterogeneous	B-X
variance	B-X
)	B-X
(	B-X
b	B-X
)	B-X
repeated	B-X
measure	B-X
analysis	B-X
assuming	B-X
constant	B-X
variation	B-X
in	B-X
the	B-X
outcome	B-X
(	B-X
homogeneous	B-X
variance	B-X
)	B-X
,	B-X
(	B-X
c	B-X
)	B-X
separate	B-X
ANOVA	B-X
at	B-X
individual	B-X
time	B-X
point	B-X
in	B-X
repeated	B-X
measures	B-X
designs	B-X
.	B-X
Of	B-X
58	B-X
studies	B-X
with	B-X
repeated	B-X
measures	B-X
design	B-X
,	B-X
three	B-X
provided	B-X
a	B-X
rationale	B-X
for	B-X
repeated	B-X
measurement	B-X
and	B-X
23	B-X
studies	B-X
reported	B-X
using	B-X
a	B-X
repeated-measures	B-X
analysis	B-X
approach	B-X
.	B-X
Of	B-X
the	B-X
35	B-X
studies	B-X
that	B-X
did	B-X
not	B-X
use	B-X
repeated-measures	B-X
analysis	B-X
,	B-X
fourteen	B-X
studies	B-X
used	B-X
only	B-X
two	B-X
time	B-X
points	B-X
to	B-X
calculate	B-X
weight	B-X
change	B-X
which	B-X
potentially	B-X
means	B-X
collected	B-X
data	B-X
was	B-X
not	B-X
fully	B-X
utilized	B-X
.	B-X
Simulation	B-X
studies	B-X
showed	B-X
that	B-X
an	B-X
incorrect	B-X
assumption	B-X
about	B-X
the	B-X
variance	B-X
structure	B-X
resulted	B-X
in	B-X
modified	B-X
error	B-X
rates	B-X
and	B-X
precision	B-X
estimates	B-X
.	B-X
The	B-X
reporting	B-X
of	B-X
the	B-X
validity	B-X
of	B-X
assumptions	B-X
for	B-X
repeated	B-X
measurement	B-X
data	B-X
is	B-X
very	B-X
poor	B-X
.	B-X
The	B-X
homogeneous	B-X
variation	B-X
assumption	B-X
,	B-X
which	B-X
is	B-X
often	B-X
invalid	B-X
for	B-X
body	B-X
weight	B-X
measurements	B-X
,	B-X
should	B-X
be	B-X
confirmed	B-X
prior	B-X
to	B-X
conducting	B-X
the	B-X
repeated-measures	B-X
analysis	B-X
using	B-X
homogeneous	B-X
covariance	B-X
structure	B-X
and	B-X
adjusting	B-X
the	B-X
analysis	B-X
using	B-X
corrections	B-X
or	B-X
model	B-X
specifications	B-X
if	B-X
this	B-X
is	B-X
not	B-X
met	B-X
.	B-X

The	O
independent	O
variables	O
were	O
testing	O
SESSION	O
(	O
n	O
=	O
2	O
,	O
i	O
.	O
e	O
.	O
,	O
pre	O
-	O
and	O
post	O
-	O
block	O
)	O
,	O
force	O
DIRECTION	O
(	O
n	O
=	O
16	O
)	O
,	O
and	O
force	O
QUADRANT	O
(	O
n	O
=	O
4	O
)	O
,	O
with	O
SESSION	O
as	O
a	O
repeated	O
variable	O
.	O

Dependent	O
variables	O
were	O
directional	O
force	O
,	O
individual	O
quadrant	O
area	O
and	O
force	O
envelope	O
area	O
.	O

Statistical	O
analyses	O
were	O
performed	O
using	O
SPSS	O
11	O
(	O
SPSS	O
Inc	O
.	O
,	O
Illinois	O
)	O
with	O
statistical	O
significance	O
set	O
at	O
alpha	O
=	O
0	O
.	O
05	O
.	O

Results	O

Force	O
envelope	O
and	O
directional	O
forces	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
biomechanically	B-X
evaluate	B-X
the	B-X
motor	B-X
function	B-X
of	B-X
the	B-X
index	B-X
finger	B-X
based	B-X
on	B-X
multi-directional	B-X
strengths	B-X
.	B-X
Cell-cell	B-X
junctions	B-X
respond	B-X
to	B-X
mechanical	B-X
forces	B-X
by	B-X
changing	B-X
their	B-X
organization	B-X
and	B-X
function	B-X
.	B-X
The	B-X
gastrointestinal	B-X
tract	B-X
is	B-X
enveloped	B-X
by	B-X
concentric	B-X
and	B-X
orthogonally	B-X
aligned	B-X
layers	B-X
of	B-X
smooth	B-X
muscle	B-X
;	B-X
however	B-X
,	B-X
an	B-X
understanding	B-X
of	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
these	B-X
muscles	B-X
become	B-X
patterned	B-X
and	B-X
aligned	B-X
in	B-X
the	B-X
embryo	B-X
has	B-X
been	B-X
lacking	B-X
.	B-X
Ultimately	B-X
,	B-X
combining	B-X
real-time	B-X
nuclear	B-X
deformations	B-X
and	B-X
chromatin	B-X
dynamics	B-X
can	B-X
be	B-X
a	B-X
powerful	B-X
tool	B-X
to	B-X
study	B-X
mechanisms	B-X
of	B-X
how	B-X
forces	B-X
affect	B-X
the	B-X
dynamics	B-X
of	B-X
genome	B-X
function	B-X
.	B-X

Figure	O
3	O
shows	O
the	O
force	O
envelopes	O
produced	O
by	O
each	O
subject	O
(	O
A	O
to	O
F	O
)	O
before	O
and	O
after	O
median	O
nerve	O
block	O
.	O

The	O
post	O
-	O
block	O
force	O
envelope	O
was	O
inside	O
the	O
pre	O
-	O
block	O
envelope	O
for	O
each	O
subject	O
,	O
indicating	O
a	O
decrease	O
in	O
force	O
magnitude	O
in	O
all	O
directions	O
after	O
nerve	O
block	O
.	O

Figure	O
4	O
shows	O
the	O
average	O
pre	O
-	O
and	O
post	O
-	O
block	O
force	O
envelope	O
across	O
all	O
subjects	O
.	O

Force	O
magnitudes	O
were	O
significantly	O
reduced	O
after	O
nerve	O
block	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
resulting	O
in	O
significantly	O
smaller	O
force	O
envelopes	O
.	O

The	O
average	O
decrease	O
across	O
all	O
directions	O
was	O
27	O
.	O
9	O
%	O
.	O
<EOS>	B-X
Legionella	B-X
occurrence	B-X
was	B-X
monitored	B-X
in	B-X
Las	B-X
Vegas	B-X
Valley	B-X
(	B-X
Las	B-X
Vegas	B-X
,	B-X
Nevada	B-X
,	B-X
USA	B-X
)	B-X
drinking	B-X
water	B-X
sources	B-X
,	B-X
including	B-X
non-treated	B-X
surface	B-X
water	B-X
,	B-X
seasonal	B-X
groundwater	B-X
(	B-X
61	B-X
wells	B-X
,	B-X
before	B-X
and	B-X
after	B-X
chlorination	B-X
)	B-X
,	B-X
finished	B-X
water	B-X
(	B-X
after	B-X
treatment	B-X
at	B-X
water	B-X
treatment	B-X
facilities	B-X
)	B-X
,	B-X
and	B-X
chlorinated	B-X
distribution	B-X
system	B-X
water	B-X
(	B-X
at	B-X
9	B-X
reservoirs	B-X
and	B-X
75	B-X
sample	B-X
locations	B-X
throughout	B-X
the	B-X
network	B-X
)	B-X
.	B-X
Legionella	B-X
pneumophila	B-X
was	B-X
detected	B-X
at	B-X
least	B-X
once	B-X
at	B-X
each	B-X
of	B-X
the	B-X
wells	B-X
sampled	B-X
before	B-X
chlorination	B-X
,	B-X
with	B-X
an	B-X
overall	B-X
positivity	B-X
rate	B-X
of	B-X
38	B-X
%	B-X
(	B-X
343/908	B-X
)	B-X
.	B-X
During	B-X
well	B-X
start-up	B-X
(	B-X
time	B-X
<	B-X
2	B-X
hours	B-X
;	B-X
turbidity	B-X
>	B-X
3	B-X
NTU	B-X
)	B-X
,	B-X
L.	B-X
pneumophila	B-X
concentrations	B-X
averaged	B-X
2,792Â±353	B-X
MPN/100	B-X
mL	B-X
,	B-X
with	B-X
a	B-X
median	B-X
of	B-X
105	B-X
MPN/100	B-X
mL	B-X
,	B-X
and	B-X
range	B-X
of	B-X
<	B-X
1	B-X
to	B-X
90,490	B-X
MPN/100	B-X
mL	B-X
across	B-X
61	B-X
seasonally	B-X
operated	B-X
(	B-X
typically	B-X
April-October	B-X
)	B-X
groundwater	B-X
wells	B-X
.	B-X
After	B-X
initial	B-X
flushing	B-X
(	B-X
turbidity	B-X
<	B-X
3	B-X
NTU	B-X
)	B-X
,	B-X
the	B-X
average	B-X
concentration	B-X
decreased	B-X
by	B-X
more	B-X
than	B-X
two	B-X
orders	B-X
of	B-X
magnitude	B-X
to	B-X
24Â±3	B-X
MPN/100	B-X
mL	B-X
but	B-X
ranged	B-X
from	B-X
<	B-X
1	B-X
to	B-X
>	B-X
2,273	B-X
MPN/100	B-X
mL	B-X
.	B-X
This	B-X
trend	B-X
indicates	B-X
that	B-X
stagnation	B-X
(	B-X
up	B-X
to	B-X
391	B-X
days	B-X
)	B-X
contributed	B-X
to	B-X
greater	B-X
initial	B-X
concentrations	B-X
,	B-X
and	B-X
flushing	B-X
alone	B-X
was	B-X
incapable	B-X
of	B-X
complete	B-X
L.	B-X
pneumophila	B-X
elimination	B-X
.	B-X
L.	B-X
pneumophila	B-X
concentration	B-X
was	B-X
significantly	B-X
,	B-X
positively	B-X
correlated	B-X
with	B-X
total	B-X
aqueous	B-X
adenosine	B-X
triphosphate	B-X
(	B-X
ATP	B-X
)	B-X
(	B-X
p	B-X
<	B-X
0.00001	B-X
,	B-X
r=0.41-0.71	B-X
)	B-X
,	B-X
turbidity	B-X
(	B-X
p	B-X
<	B-X
0.00001	B-X
,	B-X
r=0.27-0.51	B-X
)	B-X
,	B-X
orthophosphate	B-X
(	B-X
p=0.35-0.076	B-X
,	B-X
r=0.51-0.59	B-X
)	B-X
,	B-X
and	B-X
pump	B-X
depth	B-X
(	B-X
p=0.032	B-X
,	B-X
r=0.40	B-X
)	B-X
.	B-X

A	O
maximum	O
decrease	O
of	O
42	O
.	O
4	O
%	O
occurred	O
at	O
199	O
degrees	O
,	O
corresponding	O
to	O
a	O
combined	O
direction	O
of	O
abduction	O
and	O
slight	O
flexion	O
,	O
while	O
a	O
minimum	O
decrease	O
of	O
10	O
.	O
5	O
%	O
occurred	O
at	O
328	O
degrees	O
corresponding	O
to	O
a	O
combined	O
direction	O
of	O
adduction	O
and	O
slight	O
flexion	O
.	O

Relative	O
decreases	O
at	O
0	O
degrees	O
(	O
adduction	O
)	O
,	O
90	O
degrees	O
(	O
extension	O
)	O
,	O
180	O
degrees	O
(	O
abduction	O
)	O
,	O
and	O
270	O
degrees	O
(	O
flexion	O
)	O
directions	O
were	O
17	O
.	O
3	O
%	O
,	O
21	O
.	O
2	O
%	O
,	O
41	O
.	O
2	O
%	O
and	O
33	O
.	O
5	O
%	O
,	O
respectively	O
.	O

A	O
single	O
force	O
in	O
each	O
quadrant	O
was	O
represented	O
using	O
the	O
mean	O
magnitude	O
of	O
the	O
forces	O
in	O
that	O
quadrant	O
(	O
see	O
description	O
in	O
the	O
Methods	O
)	O
.	O

The	O
average	O
quadrant	O
forces	O
were	O
significantly	O
decreased	O
after	O
nerve	O
block	O
(	O
p	O
<	O
0	O
.	O
001	O
;	O
Figure	O
5	O
)	O
.	O

The	O
amount	O
of	O
decrease	O
was	O
also	O
different	O
between	O
quadrants	O
(	O
p	O
<	O
0	O
.	O
005	O
)	O
.	O

Relative	O
decreases	O
in	O
mean	O
quadrant	O
forces	O
were	O
24	O
.	O
5	O
%	O
,	O
38	O
.	O
7	O
%	O
,	O
32	O
.	O
1	O
%	O
,	O
and	O
18	O
.	O
1	O
%	O
for	O
extension	O
,	O
abduction	O
,	O
flexion	O
,	O
and	O
adduction	O
,	O
respectively	O
.	O

The	O
maximal	O
decreases	O
in	O
mean	O
quadrant	O
force	O
,	O
38	O
.	O
7	O
%	O
,	O
occurred	O
in	O
the	O
abduction	O
quadrant	O
.	O

Force	O
envelope	O
areas	O
and	O
quadrant	O
areas	O
<EOS>	B-X
Peak	B-X
forces	B-X
measured	B-X
in	B-X
all	B-X
directions	B-X
were	B-X
used	B-X
to	B-X
create	B-X
polar	B-X
plots	B-X
and	B-X
to	B-X
construct	B-X
force	B-X
envelopes	B-X
using	B-X
cubic	B-X
spline	B-X
interpolation	B-X
.	B-X
The	B-X
areas	B-X
of	B-X
the	B-X
force	B-X
envelope	B-X
and	B-X
force	B-X
quadrants	B-X
were	B-X
then	B-X
calculated	B-X
.	B-X
The	B-X
area	B-X
of	B-X
the	B-X
entire	B-X
force	B-X
envelope	B-X
was	B-X
found	B-X
to	B-X
be	B-X
12,142	B-X
+/-	B-X
3,149	B-X
N-N	B-X
.	B-X
The	B-X
percentage	B-X
quadrant	B-X
areas	B-X
,	B-X
relative	B-X
to	B-X
the	B-X
total	B-X
force	B-X
envelope	B-X
area	B-X
,	B-X
for	B-X
extension-adduction	B-X
,	B-X
extension-abduction	B-X
,	B-X
flexion-abduction	B-X
,	B-X
and	B-X
flexion-adduction	B-X
were	B-X
7.8	B-X
%	B-X
,	B-X
11.4	B-X
%	B-X
,	B-X
39.3	B-X
%	B-X
,	B-X
and	B-X
41.4	B-X
%	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
percentage	B-X
quadrant	B-X
areas	B-X
for	B-X
extension	B-X
,	B-X
abduction	B-X
,	B-X
flexion	B-X
,	B-X
and	B-X
adduction	B-X
were	B-X
4.9	B-X
%	B-X
,	B-X
23.6	B-X
%	B-X
,	B-X
52.7	B-X
%	B-X
,	B-X
and	B-X
18.8	B-X
%	B-X
,	B-X
respectively	B-X
.	B-X

Areas	O
enclosed	O
by	O
the	O
post	O
-	O
block	O
envelopes	O
were	O
significantly	O
smaller	O
than	O
the	O
pre	O
-	O
block	O
envelopes	O
(	O
p	O
<	O
0	O
.	O
001	O
;	O
Figure	O
4	O
)	O
.	O

Post	O
-	O
block	O
force	O
envelope	O
area	O
,	O
10700	O
+/-	O
4474	O
N	O
.	O
N	O
,	O
was	O
51	O
.	O
9	O
%	O
of	O
pre	O
-	O
block	O
force	O
envelope	O
area	O
,	O
20628	O
+/-	O
7747	O
N	O
.	O
N	O
.	O

Quadrant	O
area	O
decreased	O
significantly	O
(	O
p	O
<	O
0	O
.	O
001	O
;	O
Figure	O
6	O
)	O
.	O

The	O
maximal	O
percentage	O
decrease	O
in	O
area	O
after	O
nerve	O
block	O
was	O
60	O
.	O
9	O
%	O
in	O
the	O
abduction	O
quadrant	O
,	O
followed	O
by	O
a	O
52	O
.	O
3	O
%	O
area	O
decrease	O
in	O
the	O
flexion	O
quadrant	O
.	O

Discussion	O
<EOS>	B-X
Discussion	B-X
structures	B-X
are	B-X
argumentation-theoretical	B-X
tools	B-X
that	B-X
can	B-X
be	B-X
employed	B-X
to	B-X
tackle	B-X
three	B-X
barriers	B-X
that	B-X
separate	B-X
lay	B-X
stakeholders	B-X
from	B-X
policy	B-X
debates	B-X
:	B-X
difficulty	B-X
,	B-X
magnitude	B-X
,	B-X
and	B-X
complexity	B-X
.	B-X
Discussions	B-X
about	B-X
preventive	B-X
behaviors	B-X
were	B-X
assessed	B-X
before	B-X
testing	B-X
and	B-X
1	B-X
and	B-X
6	B-X
months	B-X
post-testing	B-X
.	B-X
Discussion	B-X
of	B-X
preventive	B-X
behaviors	B-X
declined	B-X
following	B-X
test	B-X
reporting	B-X
,	B-X
with	B-X
more	B-X
rapid	B-X
decline	B-X
reported	B-X
by	B-X
noncarriers	B-X
.	B-X
Discussions	B-X
are	B-X
an	B-X
important	B-X
part	B-X
of	B-X
medical	B-X
education	B-X
research	B-X
papers	B-X
,	B-X
but	B-X
there	B-X
is	B-X
little	B-X
guidance	B-X
on	B-X
how	B-X
to	B-X
write	B-X
up	B-X
the	B-X
discussion	B-X
section	B-X
.	B-X

In	O
this	O
study	O
we	O
simulated	O
a	O
lower	O
median	O
nerve	O
lesion	O
and	O
evaluated	O
the	O
resultant	O
thumb	O
motor	O
function	O
deficit	O
.	O
<EOS>	B-X
PURPOSE	B-X
:	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
characterize	B-X
thumb	B-X
motor	B-X
dysfunction	B-X
resulting	B-X
from	B-X
simulated	B-X
lower	B-X
median	B-X
nerve	B-X
lesions	B-X
at	B-X
the	B-X
wrist	B-X
.	B-X
METHODS	B-X
:	B-X
Bupivacaine	B-X
hydrochloride	B-X
was	B-X
injected	B-X
into	B-X
the	B-X
carpal	B-X
tunnel	B-X
of	B-X
six	B-X
healthy	B-X
subjects	B-X
to	B-X
locally	B-X
anesthetize	B-X
the	B-X
median	B-X
nerve	B-X
.	B-X
Motor	B-X
function	B-X
was	B-X
subsequently	B-X
evaluated	B-X
by	B-X
measuring	B-X
maximal	B-X
force	B-X
production	B-X
in	B-X
all	B-X
directions	B-X
within	B-X
the	B-X
transverse	B-X
plane	B-X
perpendicular	B-X
to	B-X
the	B-X
longitudinal	B-X
axis	B-X
of	B-X
the	B-X
thumb	B-X
.	B-X
RESULTS	B-X
:	B-X
Blockage	B-X
of	B-X
the	B-X
median	B-X
nerve	B-X
resulted	B-X
in	B-X
decreased	B-X
force	B-X
magnitudes	B-X
and	B-X
thus	B-X
smaller	B-X
force	B-X
envelopes	B-X
.	B-X
CONCLUSION	B-X
:	B-X
Lower	B-X
median	B-X
nerve	B-X
lesion	B-X
,	B-X
simulated	B-X
by	B-X
a	B-X
nerve	B-X
block	B-X
at	B-X
the	B-X
wrist	B-X
,	B-X
compromise	B-X
normal	B-X
motor	B-X
function	B-X
of	B-X
the	B-X
thumb	B-X
.	B-X
A	B-X
median	B-X
nerve	B-X
block	B-X
results	B-X
in	B-X
force	B-X
deficits	B-X
in	B-X
all	B-X
directions	B-X
,	B-X
with	B-X
the	B-X
most	B-X
severe	B-X
impairment	B-X
in	B-X
abduction	B-X
and	B-X
flexion	B-X
.	B-X
From	B-X
our	B-X
results	B-X
,	B-X
such	B-X
a	B-X
means	B-X
of	B-X
motor	B-X
function	B-X
assessment	B-X
can	B-X
potentially	B-X
be	B-X
applied	B-X
to	B-X
functionally	B-X
evaluate	B-X
peripheral	B-X
neuropathies	B-X
.	B-X

Our	O
internal	O
control	O
via	O
pre	O
-	O
and	O
post	O
-	O
block	O
design	O
offered	O
a	O
particular	O
advantage	O
of	O
investigating	O
the	O
mechanical	O
role	O
of	O
muscles	O
innervated	O
by	O
a	O
targeted	O
nerve	O
.	O

The	O
testing	O
and	O
analytical	O
methods	O
employed	O
have	O
provided	O
advanced	O
quantification	O
of	O
thumb	O
motor	O
function	O
.	O

The	O
results	O
have	O
confirmed	O
our	O
initial	O
hypotheses	O
that	O
greatest	O
force	O
decreases	O
occurred	O
in	O
directions	O
related	O
to	O
abduction	O
,	O
and	O
that	O
the	O
post	O
-	O
block	O
thumb	O
force	O
envelope	O
area	O
was	O
smaller	O
than	O
the	O
pre	O
-	O
block	O
force	O
envelope	O
area	O
.	O

Preferential	O
force	O
attenuation	O
in	O
the	O
quadrants	O
of	O
abduction	O
and	O
flexion	O
after	O
median	O
nerve	O
block	O
are	O
in	O
agreement	O
with	O
anatomical	O
and	O
neuromuscular	O
features	O
of	O
the	O
thumb	O
.	O

The	O
median	O
nerve	O
innervates	O
the	O
abductor	O
pollicis	O
brevis	O
,	O
the	O
opponens	O
pollicis	O
and	O
superficial	O
head	O
of	O
the	O
flexor	O
pollicis	O
brevis	O
,	O
all	O
of	O
which	O
contribute	O
to	O
the	O
abduction	O
and	O
flexion	O
of	O
the	O
thumb	O
[	O
4	O
]	O
;	O
therefore	O
,	O
denervation	O
of	O
these	O
muscles	O
after	O
median	O
nerve	O
block	O
would	O
cause	O
the	O
greatest	O
force	O
deficit	O
related	O
to	O
median	O
nerve	O
function	O
[	O
5	O
]	O
.	O

Additionally	O
,	O
as	O
force	O
application	O
moved	O
towards	O
adduction	O
,	O
the	O
force	O
deficit	O
decreased	O
as	O
neuromuscular	O
control	O
shifted	O
from	O
the	O
median	O
nerve	O
to	O
the	O
ulnar	O
nerve	O
via	O
the	O
first	O
dorsal	O
interosseous	O
and	O
adductor	O
pollicis	O
brevis	O
.	O

Force	O
deficit	O
in	O
extension	O
was	O
also	O
comparably	O
small	O
as	O
extension	O
forces	O
are	O
mainly	O
produced	O
by	O
the	O
extensors	O
pollicis	O
brevis	O
and	O
longus	O
originating	O
in	O
the	O
forearm	O
.	O

Our	O
reported	O
force	O
decreases	O
following	O
a	O
median	O
nerve	O
block	O
(	O
40	O
.	O
9	O
%	O
in	O
abduction	O
,	O
34	O
.	O
1	O
%	O
in	O
flexion	O
)	O
were	O
smaller	O
than	O
those	O
reported	O
in	O
the	O
literature	O
.	O

Kozin	O
et	O
al	O
.	O
<EOS>	B-X
Carpal	B-X
instability	B-X
includes	B-X
a	B-X
broad	B-X
spectrum	B-X
of	B-X
osseous	B-X
and	B-X
ligamentous	B-X
injuries	B-X
which	B-X
have	B-X
been	B-X
subclassified	B-X
into	B-X
greater	B-X
and	B-X
lesser	B-X
arc	B-X
injuries	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
combinations	B-X
of	B-X
both	B-X
(	B-X
Mayfield	B-X
et	B-X
al	B-X
.	B-X
J	B-X
Hand	B-X
Surg	B-X
[	B-X
Am	B-X
]	B-X
5:226-241	B-X
,	B-X
1980	B-X
;	B-X
Yaeger	B-X
et	B-X
al	B-X
.	B-X
Skeletal	B-X
Radiol	B-X
13	B-X
(	B-X
2	B-X
)	B-X
:120-30	B-X
,	B-X
1985	B-X
)	B-X
.	B-X
The	B-X
injuries	B-X
typically	B-X
occur	B-X
from	B-X
a	B-X
fall	B-X
on	B-X
the	B-X
outstretched	B-X
hand	B-X
with	B-X
the	B-X
wrist	B-X
in	B-X
ulnar	B-X
deviation	B-X
,	B-X
hyperextension	B-X
,	B-X
and	B-X
intercarpal	B-X
supination	B-X
(	B-X
Yaeger	B-X
et	B-X
al	B-X
.	B-X
The	B-X
force	B-X
classically	B-X
propagates	B-X
from	B-X
the	B-X
radial	B-X
to	B-X
the	B-X
ulnar	B-X
side	B-X
of	B-X
the	B-X
wrist	B-X
resulting	B-X
in	B-X
a	B-X
fracture	B-X
(	B-X
greater	B-X
arc	B-X
)	B-X
or	B-X
dislocation	B-X
(	B-X
lesser	B-X
arc	B-X
)	B-X
pattern	B-X
with	B-X
the	B-X
extent	B-X
of	B-X
the	B-X
injury	B-X
occurring	B-X
in	B-X
an	B-X
orderly	B-X
pattern	B-X
depending	B-X
upon	B-X
the	B-X
degree	B-X
of	B-X
hyperextension	B-X
and	B-X
the	B-X
duration	B-X
and	B-X
magnitude	B-X
of	B-X
the	B-X
force	B-X
(	B-X
Mayfield	B-X
et	B-X
al	B-X
.	B-X
Multiple	B-X
variations	B-X
occur	B-X
,	B-X
including	B-X
transradial	B-X
styloid	B-X
fractures	B-X
as	B-X
well	B-X
as	B-X
fractures	B-X
through	B-X
carpal	B-X
bones	B-X
surrounding	B-X
the	B-X
lunate	B-X
(	B-X
Mayfield	B-X
et	B-X
al	B-X
.	B-X
Skeletal	B-X
Radiol	B-X
13	B-X
(	B-X
2	B-X
)	B-X
:120-30	B-X
,	B-X
1985	B-X
;	B-X
Kozin	B-X
SH	B-X
.	B-X
Although	B-X
carpal	B-X
dislocations	B-X
have	B-X
been	B-X
noted	B-X
for	B-X
many	B-X
years	B-X
,	B-X
the	B-X
mechanisms	B-X
and	B-X
classification	B-X
have	B-X
only	B-X
been	B-X
recently	B-X
clarified	B-X
.	B-X
We	B-X
report	B-X
a	B-X
case	B-X
of	B-X
a	B-X
complex	B-X
dislocation	B-X
involving	B-X
the	B-X
entire	B-X
proximal	B-X
carpal	B-X
row	B-X
without	B-X
an	B-X
associated	B-X
fracture	B-X
.	B-X
While	B-X
this	B-X
type	B-X
of	B-X
complex	B-X
carpal	B-X
dislocation	B-X
has	B-X
been	B-X
previously	B-X
described	B-X
,	B-X
to	B-X
our	B-X
knowledge	B-X
,	B-X
it	B-X
has	B-X
never	B-X
been	B-X
reported	B-X
without	B-X
a	B-X
fracture	B-X
of	B-X
the	B-X
forearm	B-X
,	B-X
wrist	B-X
,	B-X
or	B-X
hand	B-X
.	B-X

[	O
21	O
]	O
reported	O
a	O
60	O
%	O
decrease	O
in	O
pinch	O
strength	O
after	O
a	O
median	O
nerve	O
block	O
using	O
mepivicaine	O
hydrochloride	O
[	O
21	O
]	O
.	O

Boatright	O
and	O
Kiebzak	O
[	O
20	O
]	O
reported	O
an	O
approximate	O
70	O
%	O
decrease	O
in	O
thumb	O
abduction	O
strength	O
after	O
median	O
nerve	O
block	O
using	O
Lidocaine	O
[	O
20	O
]	O
.	O

Kaufman	O
et	O
al	O
.	O
<EOS>	B-X
A	B-X
total	B-X
of	B-X
37	B-X
RCTs	B-X
were	B-X
identified	B-X
.	B-X
Results	B-X
indicate	B-X
that	B-X
physical	B-X
exercise	B-X
has	B-X
a	B-X
positive	B-X
impact	B-X
on	B-X
muscle	B-X
mass	B-X
and	B-X
muscle	B-X
function	B-X
in	B-X
subjects	B-X
aged	B-X
65	B-X
years	B-X
and	B-X
older	B-X
.	B-X
However	B-X
,	B-X
any	B-X
interactive	B-X
effect	B-X
of	B-X
dietary	B-X
supplementation	B-X
appears	B-X
to	B-X
be	B-X
limited	B-X
.	B-X
Systemic	B-X
immunoglobulin	B-X
light-chain	B-X
(	B-X
AL	B-X
)	B-X
amyloidosis	B-X
is	B-X
characterized	B-X
by	B-X
deposition	B-X
of	B-X
amyloid	B-X
fibrils	B-X
of	B-X
light	B-X
chains	B-X
produced	B-X
by	B-X
clonal	B-X
CD38+	B-X
plasma	B-X
cells	B-X
.	B-X
Daratumumab	B-X
,	B-X
a	B-X
human	B-X
CD38-targeting	B-X
antibody	B-X
,	B-X
may	B-X
improve	B-X
outcomes	B-X
for	B-X
this	B-X
disease	B-X
.	B-X

[	O
5	O
]	O
stated	O
that	O
a	O
median	O
nerve	O
block	O
with	O
Lidocaine	O
almost	O
completely	O
diminished	O
force	O
production	O
in	O
the	O
abduction	O
direction	O
[	O
5	O
]	O
.	O

The	O
discrepancy	O
may	O
be	O
due	O
to	O
the	O
anesthetic	O
used	O
and	O
strength	O
testing	O
method	O
.	O

Although	O
the	O
sensory	O
block	O
appeared	O
to	O
be	O
complete	O
for	O
each	O
method	O
,	O
the	O
motor	O
capabilities	O
of	O
the	O
muscles	O
associated	O
with	O
the	O
median	O
nerve	O
might	O
or	O
might	O
not	O
be	O
completely	O
eliminated	O
.	O

Such	O
a	O
result	O
is	O
largely	O
dependent	O
on	O
a	O
particular	O
anesthetic	O
,	O
its	O
concentration	O
and	O
dosage	O
,	O
as	O
well	O
as	O
the	O
efficacy	O
of	O
the	O
injection	O
technique	O
at	O
immersing	O
the	O
nerve	O
.	O

The	O
methods	O
of	O
strength	O
testing	O
may	O
also	O
help	O
explain	O
the	O
different	O
magnitudes	O
of	O
strength	O
deficit	O
after	O
the	O
nerve	O
block	O
.	O

All	O
previous	O
results	O
were	O
based	O
on	O
forces	O
obtained	O
in	O
discrete	O
direction	O
(	O
s	O
)	O
,	O
and	O
focused	O
exertions	O
,	O
while	O
the	O
current	O
study	O
utilized	O
a	O
method	O
of	O
force	O
production	O
in	O
a	O
continuous	O
,	O
circumferential	O
and	O
dynamic	O
manner	O
.	O

Furthermore	O
,	O
thumb	O
motor	O
performance	O
can	O
be	O
maintained	O
despite	O
the	O
absence	O
of	O
certain	O
individual	O
muscles	O
.	O

For	O
example	O
,	O
Britto	O
and	O
Elliot	O
reported	O
that	O
the	O
loss	O
of	O
abductor	O
pollicis	O
longus	O
and	O
extensor	O
pollicis	O
brevis	O
in	O
their	O
two	O
patients	B-Species
did	O
not	O
show	O
functional	O
compromise	O
of	O
strength	O
and	O
grip	O
strength	O
[	O
24	O
]	O
.	O

In	O
a	O
broader	O
sense	O
,	O
the	O
neuromuscular	O
system	O
has	O
remarkable	O
capabilities	O
to	O
accomplish	O
the	O
same	O
motor	O
function	O
goal	O
using	O
different	O
effectors	O
and	O
different	O
goals	O
using	O
the	O
same	O
effectors	O
,	O
a	O
phenomenon	O
so	O
called	O
"	O
motor	O
equivalence	O
"	O
[	O
25	O
]	O
.	O

An	O
unexpected	O
finding	O
from	O
this	O
study	O
was	O
that	O
the	O
force	O
deficit	O
occurred	O
in	O
all	O
directions	O
(	O
Figure	O
4	O
)	O
.	O

In	O
other	O
words	O
,	O
the	O
median	O
nerve	O
block	O
caused	O
reduced	O
force	O
production	O
by	O
those	O
muscles	O
not	O
associated	O
with	O
the	O
median	O
nerve	O
.	O

Several	O
potential	O
explanations	O
exist	O
to	O
describe	O
such	O
a	O
phenomenon	O
.	O
<EOS>	B-X
The	B-X
dominant	B-X
discourse	B-X
surrounding	B-X
neurodevelopmental	B-X
conditions	B-X
such	B-X
as	B-X
autism	B-X
and	B-X
ADHD	B-X
emphasizes	B-X
biological	B-X
explanations	B-X
.	B-X
In	B-X
this	B-X
paper	B-X
we	B-X
describe	B-X
the	B-X
concept	B-X
of	B-X
developmental	B-X
diversity	B-X
as	B-X
an	B-X
alternative	B-X
to	B-X
more	B-X
categorical	B-X
approaches	B-X
to	B-X
neurodevelopmental	B-X
conditions	B-X
.	B-X
We	B-X
explore	B-X
how	B-X
dynamic	B-X
models	B-X
of	B-X
life	B-X
offer	B-X
possibilities	B-X
to	B-X
look	B-X
at	B-X
neurodevelopmental	B-X
conditions	B-X
differently	B-X
:	B-X
rather	B-X
than	B-X
seeing	B-X
autistic	B-X
people	B-X
as	B-X
people	B-X
with	B-X
fundamental	B-X
flaws	B-X
in	B-X
their	B-X
genes	B-X
or	B-X
software	B-X
faults	B-X
in	B-X
their	B-X
brains	B-X
that	B-X
have	B-X
to	B-X
be	B-X
explained	B-X
,	B-X
autism	B-X
appears	B-X
as	B-X
a	B-X
phenomenon	B-X
that	B-X
exists	B-X
in	B-X
interaction	B-X
with	B-X
the	B-X
context	B-X
,	B-X
as	B-X
a	B-X
meaningful	B-X
reaction	B-X
to	B-X
the	B-X
environment	B-X
.	B-X
Next	B-X
to	B-X
yielding	B-X
a	B-X
more	B-X
complete	B-X
picture	B-X
on	B-X
the	B-X
phenomenon	B-X
of	B-X
autism	B-X
,	B-X
we	B-X
describe	B-X
how	B-X
an	B-X
approach	B-X
that	B-X
takes	B-X
developmental	B-X
diversity	B-X
as	B-X
a	B-X
starting	B-X
point	B-X
offers	B-X
a	B-X
new	B-X
way	B-X
to	B-X
look	B-X
at	B-X
existing	B-X
challenges	B-X
of	B-X
autism	B-X
research	B-X
,	B-X
such	B-X
as	B-X
how	B-X
to	B-X
deal	B-X
with	B-X
the	B-X
significant	B-X
overlap	B-X
between	B-X
diagnosis	B-X
.	B-X

First	O
,	O
the	O
injection	O
into	O
the	O
carpal	O
tunnel	O
at	O
the	O
wrist	O
,	O
although	O
localized	O
,	O
potentially	O
diffused	O
into	O
the	O
intrinsic	O
fascia	O
of	O
the	O
hand	O
partially	O
compromising	O
function	O
of	O
the	O
ulnar	O
nerve	O
,	O
which	O
innervates	O
the	O
adductor	O
pollicis	O
.	O

Although	O
Semmes	O
-	O
Weinstein	O
monofilament	O
testing	O
confirmed	O
the	O
continued	O
sensation	O
of	O
the	O
digits	O
within	O
the	O
ulnar	O
nerve	O
distribution	O
,	O
it	O
is	O
not	O
inconceivable	O
that	O
the	O
injection	O
could	O
have	O
contaminated	O
the	O
ulnar	O
innervated	O
muscles	O
,	O
the	O
first	O
dorsal	O
interosseous	O
and	O
deep	O
head	O
of	O
the	O
flexor	O
pollicis	O
brevis	O
[	O
20	O
]	O
.	O

Secondly	O
,	O
thumb	O
force	O
in	O
any	O
direction	O
is	O
produced	O
by	O
synergistic	O
activation	O
of	O
the	O
many	O
intrinsic	O
muscles	O
,	O
and	O
as	O
a	O
result	O
,	O
the	O
muscular	O
deficiency	O
associated	O
with	O
one	O
direction	O
may	O
hinder	O
the	O
force	O
production	O
in	O
other	O
directions	O
by	O
other	O
muscles	O
[	O
5	O
,	O
22	O
]	O
.	O

For	O
example	O
,	O
Kaufman	O
et	O
al	O
.	O
demonstrated	O
that	O
thumb	O
muscles	O
not	O
innervated	O
by	O
the	O
median	O
nerve	O
displayed	O
lower	O
electromyographical	O
activation	O
and	O
shifted	O
the	O
direction	O
of	O
maximum	O
activation	O
after	O
a	O
median	O
nerve	O
block	O
[	O
5	O
]	O
.	O

Labosky	O
and	O
Waggy	O
showed	O
that	O
a	O
radial	O
nerve	O
block	O
caused	O
a	O
53	O
%	O
decrease	O
in	O
thumb	O
abduction	O
strength	O
because	O
of	O
the	O
lack	O
of	O
stabilization	O
of	O
the	O
radial	O
innervated	O
extensor	O
muscles	O
[	O
22	O
]	O
.	O

Consequently	O
,	O
deficiency	O
of	O
median	O
innervated	O
muscles	O
inherently	O
limits	O
force	O
production	O
in	O
other	O
directions	O
as	O
neuromuscular	O
switching	O
is	O
necessary	O
to	O
produce	O
force	O
in	O
changing	O
directions	O
.	O

The	O
median	O
innervated	O
muscles	O
are	O
the	O
dominant	O
abductors	O
of	O
the	O
thumb	O
metacarpophalangeal	O
and	O
carpometacarpal	O
joint	O
.	O

The	O
more	O
than	O
50	O
%	O
residual	O
abduction	O
force	O
found	O
in	O
this	O
study	O
suggests	O
that	O
the	O
injection	O
did	O
not	O
totally	O
block	O
the	O
motor	O
function	O
of	O
these	O
muscles	O
,	O
even	O
though	O
a	O
complete	O
sensory	O
loss	O
was	O
verified	O
.	O

This	O
concurs	O
with	O
clinical	O
observations	O
of	O
median	O
compression	O
neuropathy	O
.	O

Individuals	O
with	O
carpal	O
tunnel	O
syndrome	O
complain	O
of	O
sensory	O
dysfunction	O
early	O
in	O
the	O
disease	O
process	O
(	O
at	O
the	O
beginning	O
)	O
,	O
while	O
motor	O
signs	O
of	O
thenar	O
wasting	O
and	O
thumb	O
weakness	O
occur	O
as	O
the	O
disease	O
advances	O
.	O

The	O
concept	O
that	O
the	O
motor	O
deficit	O
is	O
more	O
resistant	O
to	O
peripheral	O
median	O
neuropathy	O
than	O
sensory	O
loss	O
has	O
been	O
well	O
documented	O
[	O
23	O
,	O
26	O
,	O
27	O
]	O
.	O

Butterworth	O
et	O
al	O
.	O
studied	O
the	O
temporal	O
effects	O
on	O
sensory	O
and	O
motor	O
blockade	O
after	O
injection	O
of	O
bupivacaine	O
or	O
mepivacaine	O
,	O
and	O
found	O
that	O
sensory	O
loss	O
was	O
complete	O
but	O
about	O
a	O
20	O
%	O
compound	O
motor	O
action	O
potential	O
remained	O
after	O
40	O
minutes	O
[	O
23	O
]	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
incorporated	O
a	O
method	O
for	O
assessing	O
thumb	O
motor	O
deficit	O
based	O
on	O
strength	O
measurement	O
with	O
a	O
standard	O
local	O
anesthetic	O
to	O
investigate	O
the	O
effects	O
of	O
a	O
simulated	O
median	O
neuropathy	O
on	O
thumb	O
motor	O
function	O
.	O

Median	O
nerve	O
block	O
results	O
in	O
force	O
deficits	O
in	O
all	O
directions	O
,	O
with	O
the	O
most	O
severe	O
impairment	O
in	O
abduction	O
and	O
flexion	O
.	O
<EOS>	B-X
PURPOSE	B-X
:	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
characterize	B-X
thumb	B-X
motor	B-X
dysfunction	B-X
resulting	B-X
from	B-X
simulated	B-X
lower	B-X
median	B-X
nerve	B-X
lesions	B-X
at	B-X
the	B-X
wrist	B-X
.	B-X
METHODS	B-X
:	B-X
Bupivacaine	B-X
hydrochloride	B-X
was	B-X
injected	B-X
into	B-X
the	B-X
carpal	B-X
tunnel	B-X
of	B-X
six	B-X
healthy	B-X
subjects	B-X
to	B-X
locally	B-X
anesthetize	B-X
the	B-X
median	B-X
nerve	B-X
.	B-X
Motor	B-X
function	B-X
was	B-X
subsequently	B-X
evaluated	B-X
by	B-X
measuring	B-X
maximal	B-X
force	B-X
production	B-X
in	B-X
all	B-X
directions	B-X
within	B-X
the	B-X
transverse	B-X
plane	B-X
perpendicular	B-X
to	B-X
the	B-X
longitudinal	B-X
axis	B-X
of	B-X
the	B-X
thumb	B-X
.	B-X
Force	B-X
envelopes	B-X
were	B-X
constructed	B-X
using	B-X
these	B-X
measured	B-X
multidirectional	B-X
forces	B-X
.	B-X
RESULTS	B-X
:	B-X
Blockage	B-X
of	B-X
the	B-X
median	B-X
nerve	B-X
resulted	B-X
in	B-X
decreased	B-X
force	B-X
magnitudes	B-X
and	B-X
thus	B-X
smaller	B-X
force	B-X
envelopes	B-X
.	B-X
The	B-X
average	B-X
force	B-X
decrease	B-X
around	B-X
the	B-X
force	B-X
envelope	B-X
was	B-X
27.9	B-X
%	B-X
.	B-X
A	B-X
maximum	B-X
decrease	B-X
of	B-X
42.4	B-X
%	B-X
occurred	B-X
in	B-X
a	B-X
direction	B-X
combining	B-X
abduction	B-X
and	B-X
slight	B-X
flexion	B-X
,	B-X
while	B-X
a	B-X
minimum	B-X
decrease	B-X
of	B-X
10.5	B-X
%	B-X
occurred	B-X
in	B-X
a	B-X
direction	B-X
combining	B-X
adduction	B-X
and	B-X
slight	B-X
flexion	B-X
.	B-X
Relative	B-X
decreases	B-X
in	B-X
adduction	B-X
,	B-X
extension	B-X
,	B-X
abduction	B-X
,	B-X
and	B-X
flexion	B-X
were	B-X
17.3	B-X
%	B-X
,	B-X
21.2	B-X
%	B-X
,	B-X
41.2	B-X
%	B-X
and	B-X
33.5	B-X
%	B-X
,	B-X
respectively	B-X
.	B-X
Areas	B-X
enclosed	B-X
by	B-X
pre-	B-X
and	B-X
post-block	B-X
force	B-X
envelopes	B-X
were	B-X
20628	B-X
+/-	B-X
7747	B-X
N.N	B-X
,	B-X
and	B-X
10700	B-X
+/-	B-X
4474	B-X
N.N	B-X
,	B-X
respectively	B-X
,	B-X
representing	B-X
an	B-X
average	B-X
decrease	B-X
of	B-X
48.1	B-X
%	B-X
.	B-X
Relative	B-X
decreases	B-X
in	B-X
the	B-X
adduction	B-X
,	B-X
extension	B-X
,	B-X
abduction	B-X
,	B-X
and	B-X
flexion	B-X
quadrant	B-X
areas	B-X
were	B-X
31.5	B-X
%	B-X
,	B-X
42.3	B-X
%	B-X
,	B-X
60.9	B-X
%	B-X
,	B-X
and	B-X
52.3	B-X
%	B-X
,	B-X
respectively	B-X
.	B-X
CONCLUSION	B-X
:	B-X
Lower	B-X
median	B-X
nerve	B-X
lesion	B-X
,	B-X
simulated	B-X
by	B-X
a	B-X
nerve	B-X
block	B-X
at	B-X
the	B-X
wrist	B-X
,	B-X
compromise	B-X
normal	B-X
motor	B-X
function	B-X
of	B-X
the	B-X
thumb	B-X
.	B-X
A	B-X
median	B-X
nerve	B-X
block	B-X
results	B-X
in	B-X
force	B-X
deficits	B-X
in	B-X
all	B-X
directions	B-X
,	B-X
with	B-X
the	B-X
most	B-X
severe	B-X
impairment	B-X
in	B-X
abduction	B-X
and	B-X
flexion	B-X
.	B-X
From	B-X
our	B-X
results	B-X
,	B-X
such	B-X
a	B-X
means	B-X
of	B-X
motor	B-X
function	B-X
assessment	B-X
can	B-X
potentially	B-X
be	B-X
applied	B-X
to	B-X
functionally	B-X
evaluate	B-X
peripheral	B-X
neuropathies	B-X
.	B-X

Future	O
endeavors	O
using	O
this	O
methodology	O
can	O
potentially	O
further	O
elucidate	O
underlying	O
pathomechanisms	O
of	O
peripheral	O
neuropathies	O
in	O
all	O
digits	O
of	O
the	O
hand	O
.	O

